<SEC-DOCUMENT>0000950170-22-003753.txt : 20220315
<SEC-HEADER>0000950170-22-003753.hdr.sgml : 20220315
<ACCEPTANCE-DATETIME>20220315161637
ACCESSION NUMBER:		0000950170-22-003753
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		131
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220315
DATE AS OF CHANGE:		20220315

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Adicet Bio, Inc.
		CENTRAL INDEX KEY:			0001720580
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				813305277
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38359
		FILM NUMBER:		22741300

	BUSINESS ADDRESS:	
		STREET 1:		200 CLARENDON  STREET
		STREET 2:		FLOOR 6
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116
		BUSINESS PHONE:		617-482-2333

	MAIL ADDRESS:	
		STREET 1:		200 CLARENDON  STREET
		STREET 2:		FLOOR 6
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	resTORbio, Inc.
		DATE OF NAME CHANGE:	20171024
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>acet-20211231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="ASCII"?><!-- DFIN New ActiveDisclosure (SM) Inline XBRL Document - http://www.dfinsolutions.com/ --><!-- Creation Date :2022-03-15T16:13:29.6879+00:00 --><!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:nonNumeric="http://www.xbrl.org/dtr/type/non-numeric" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:acet="http://www.adicetbio.com/20211231" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:utr="http://www.xbrl.org/2009/utr">
 <head>
  <title>10-K</title>
  <meta http-equiv="Content-Type" content="text/html" />
 </head>
 <body>
  <div style="display:none;"><ix:header><ix:hidden><ix:nonFraction id="F_8bc0353d-5786-49d3-9a18-9b33edc0a9e9" name="us-gaap:ProceedsFromIssuanceOfCommonStock" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_ba39addf-7250-4185-b821-6a0528ff4070" name="us-gaap:BusinessCombinationAssetsArisingFromContingenciesAmountRecognized" contextRef="C_f72b75a3-3766-46c7-b232-aba9e69a07a2" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_c90c6857-d677-4f9c-addf-13927bc45ed0" name="us-gaap:AccountsReceivableRelatedPartiesCurrent" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_efcea327-b6ef-4d61-b48e-b5bba5b6c3c3" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_88961339-6e41-46f7-b484-e70d789d380b" name="us-gaap:StockIssuedDuringPeriodValueIssuedForServices" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_e03a3503-c022-4462-9b6a-c5859ba7d7b7" name="us-gaap:StockholdersEquity" contextRef="C_859eba6f-9081-481e-ab8c-7b531e2b242e" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_05b13237-3492-4f95-aba3-8ed6a6944362" name="acet:RightOfUseAssetsRecognized" contextRef="C_fd2a51f4-a4e0-4fd4-8b72-384f893e07dc" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_18ae40c3-cc09-44ce-a2f4-2c852da4b4aa" name="us-gaap:CommonStockDividendsPerShareDeclared" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" unitRef="U_USDollarShare" decimals="INF">0</ix:nonFraction><ix:nonFraction id="F_30164a23-1034-41b4-8a87-4e24b682b3f4" name="acet:IssuanceOfRedeemableConvertiblePreferredStockOnExerciseOfWarrantsWithLoanAgreement" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_840dcd2b-2fae-46dc-8023-bd4695fdd5df" name="dei:CurrentFiscalYearEndDate" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c">--12-31</ix:nonNumeric><ix:nonNumeric id="F_c1e55cb3-2170-40e8-895f-7b8d4abd20f6" name="dei:DocumentFiscalPeriodFocus" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c">FY</ix:nonNumeric><ix:nonFraction id="F_fb093abf-4f4f-4827-a9da-293d131e9450" name="us-gaap:PreferredStockValue" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_1ad28aba-0f89-4c1e-b355-7124041766a1" name="us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_8cea713b-4adc-4d3c-bf88-22e31cbfdc99" name="us-gaap:FairValueOfAssetsAcquired" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_dbc0d54f-50e5-4e0d-931c-eb2600eb1f07" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_daaa68b0-d842-4ae0-a584-de681974e221" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_2945645f-2178-4658-b960-77d1100e9bac" name="us-gaap:FairValueAdjustmentOfWarrants" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_ca459d7d-097c-4350-b8c5-17e431b35615" name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="C_e67dfaf7-9162-49e0-8217-ba044cdeed37" unitRef="U_shares" decimals="INF" format="ixt:zerodash">&#x2014;</ix:nonFraction><ix:nonFraction id="F_8f366528-b927-44dd-955d-3902dd5285e6" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_fe50c4e8-749d-4335-ae8f-18aed2ad9940" name="us-gaap:PreferredStockValue" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_45fcbe03-3582-4802-9e09-cb05d0dc0471" name="dei:EntityCentralIndexKey" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c">0001720580</ix:nonNumeric><ix:nonFraction id="F_a0789779-e166-43dd-bd77-089b6487a8c3" name="us-gaap:SubleaseIncome" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_4a6a6b6d-811d-48f1-b09b-f42e96a2fd90" name="us-gaap:CommonStockDividendsPerShareDeclared" contextRef="C_b9e4ebe3-8c57-40bf-bb42-6e19b62ee01c" unitRef="U_USDollarShare" decimals="INF">0</ix:nonFraction><ix:nonNumeric id="F_c0c9a2db-8c34-4a1e-9d4b-7ac4f7464089" name="dei:AmendmentFlag" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c">false</ix:nonNumeric><ix:nonFraction id="F_53469473-0173-4a8a-bfc4-8856f9b34255" name="us-gaap:BusinessCombinationAssetsArisingFromContingenciesAmountRecognized" contextRef="C_fd1ca962-13a9-4d81-ab99-ced7557eb7ab" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_2ae19e7d-b6bf-4828-a15f-80c9a443829c" name="us-gaap:OperatingLossCarryforwardsExpirationDate" contextRef="C_4e76cb9d-4c4a-40ac-b56d-06fc2a5d3fbd">2037-12-31</ix:nonNumeric><ix:nonFraction id="F_fd5f7e8a-5341-4223-a549-e2815d0b8b31" name="us-gaap:GainLossOnDispositionOfAssets1" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_c2c0c022-3bc2-47ee-ac21-0348f3accf14" name="acet:ProceedsFromSalesOfMarketableDebtSecurities" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_57e77e30-6b2f-47ee-bd06-1e77e3f45b01" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="C_e67dfaf7-9162-49e0-8217-ba044cdeed37" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_52b544c5-2e54-4c52-8e46-49be2abe9635" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonNumeric id="F_df7286aa-ef38-49c2-b278-229734179a35" name="us-gaap:OperatingLossCarryforwardsExpirationDate" contextRef="C_3507c3c5-6e58-434e-aad1-74893d0a8f54">2035-12-31</ix:nonNumeric><ix:nonFraction id="F_f39be877-1c11-4604-9a1a-96f74b63b799" name="us-gaap:CashAcquiredFromAcquisition" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_91d06931-2771-4e60-b971-253316eaba0d" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="C_2f0f3de2-b33a-4142-ac46-c01ab9f559d3" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_61e7ff69-16bd-48b2-b350-de1645a65d44" name="us-gaap:ProceedsFromStockPlans" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_d2cce7e8-1134-4bea-822d-f684fe63d39a" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" contextRef="C_aa86a251-e22c-4f99-914b-e9fcfc7e5f73" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_2d04a4ef-82d4-4143-8241-c8043e042c95" name="us-gaap:CommitmentsAndContingencies" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_5fee429c-5b1b-432c-a994-6ed5a5249e6a" name="acet:CommonStockOfferingCostsIncludedInAccruedLiabilitiesAtPeriodEnd" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_9dc969f6-49b9-4163-aafc-0d7ce2a0811a" name="us-gaap:OtherLiabilities" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_78769c32-8afb-4b2d-96fd-6e254cea5840" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_0592c904-f2c4-43cd-af23-a8efec565b99" name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_e34744e6-32c7-4857-bf62-b6bfb9ec543a" name="us-gaap:DebtConversionConvertedInstrumentAmount1" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_60ec8ff2-c4ea-47b4-849f-ad0d9cd49e80" name="us-gaap:ConversionOfStockAmountConverted1" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_7a22c7d2-0058-4f73-9325-35673702fe09" name="us-gaap:TemporaryEquitySharesOutstanding" contextRef="C_aa86a251-e22c-4f99-914b-e9fcfc7e5f73" unitRef="U_shares" decimals="INF" format="ixt:zerodash">&#x2014;</ix:nonFraction><ix:nonNumeric id="F_6bd37428-42c2-4038-b96a-a6cfe4c5c8c5" name="dei:EntityIncorporationDateOfIncorporation" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c">2014-11-30</ix:nonNumeric><ix:nonFraction id="F_0fbb73f0-a2b4-4955-a72c-3389ceca5af9" name="us-gaap:StockholdersEquity" contextRef="C_d33cc417-791a-47d8-87ef-b0d73a0d0b66" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_819eaa0a-0a31-4f5b-b68e-5e64ffc6ff53" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" unitRef="U_USD" xsi:nil="true"></ix:nonFraction><ix:nonFraction id="F_634bc8da-c716-4b7e-bc3c-fdf201cf4001" name="us-gaap:CommitmentsAndContingencies" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" unitRef="U_USD" xsi:nil="true"></ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="acet-20211231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="C_d66319b0-75d0-4205-b25e-8c8321f342f3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_65724930-27ec-4cc0-971f-f08bfefcc88e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c1e72a0b-a7f8-4f4b-bd56-9c13a9000d2b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acet:NationalInstitutesOfHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_269b2bf6-80a4-4772-a84e-435846b50f75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_91052d8c-9e4f-403f-ba68-6576fa344a03"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_76a7c6aa-3344-4804-9a25-aa31c1d6210f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_38799e03-7018-4654-b7db-0fc7800d94e4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">acet:AdicetTherapeuticsIncMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_eb6b17d5-2d48-4838-8382-90249e566d9f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">acet:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_229551d3-2c1b-4ec2-99aa-16652dd7eb75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_97f163d5-9ecd-43f8-8bae-d896a29f9d75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">acet:SeptemberFifteenTwoThousandTwentyWarrantFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_745de059-cb14-4ea1-8c29-12d351f50320"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2c23f818-11c0-4555-af2a-af3a6c3d7db0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acet:TwoThousandFourteenAndTwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4066c921-3deb-4a5c-8fd4-0507b83d109f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_02dd56d4-2777-4e62-8616-7488897fd4d0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2d0f9825-f275-4fef-8d45-4314b18f7073"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a6003cef-f951-463a-a0b1-c940267e5c47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">acet:ResTORbioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f2283cea-c435-437b-958f-019a9a629ca9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acet:NationalInstitutesOfHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-01</xbrli:startDate><xbrli:endDate>2019-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e67dfaf7-9162-49e0-8217-ba044cdeed37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3af201ab-f6bf-43f9-bbd9-545d3f60a016"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5972f862-a654-46cb-b4c6-99346fd20b9c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_81126e27-9bfb-4e06-802d-fc47c6df7727"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_25b4b380-f29f-4199-a59a-67e5d8821aef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_905b1778-abfc-4dfb-825e-88b08dac4474"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c38e333f-e2eb-4d69-906a-0a7b3cfda69b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acet:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_33bee37a-503e-457c-a296-23686ab0bf7a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d3f0bab3-8542-4755-967f-e529938079a8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">acet:RfsOpcoLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_23640616-f433-4b74-849e-d9ad90a3ad0c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_47c45ab3-564a-4faf-b5b3-316708cef184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acet:TwoThousandSeventeenAndTwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d7c1aa19-f30c-49e2-89e6-bd6ca6fed85c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">acet:SeptemberFifteenTwoThousandTwentyWarrantOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e0e2612c-d563-4a7b-9f21-1a5002c22dc4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_2f0f3de2-b33a-4142-ac46-c01ab9f559d3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">acet:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0c05cb34-710a-4fe0-a5ad-4326137cbe67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">acet:SeptemberFifteenTwoThousandTwentyWarrantThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_29c03a6c-7260-483a-ab00-555f1e331404"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acet:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f0f88cdf-2c57-4430-af9d-f7f4ee5dd8be"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9fa0d050-80a6-4eb0-b277-441b2edd40e6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">acet:ResTORbioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_607c7869-0981-4346-b7b5-2e6c06ea1c1b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-10</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d85d1bbc-33b7-4189-abac-0387bd90ab52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acet:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9afec6f3-5050-458f-b651-8d672791f22c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_594a64fe-9232-4c34-a446-273a36865ed4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">acet:FederalAndStateResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_61d94a43-5646-47f3-b305-92ab60efd0b9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">acet:FourthAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acet:PacificWesternBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_aa86a251-e22c-4f99-914b-e9fcfc7e5f73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_38fcd5c7-531b-45fa-b26b-773edcb7ea4a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_57a750f3-8a24-41e7-9a82-33461f5929df"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0e581963-9b5e-4dbd-bb03-47a0e58483c2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">acet:ResTORbioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-15</xbrli:startDate><xbrli:endDate>2020-09-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9b4eb834-de39-4790-9fd5-164fe2bbae7e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2bdce80c-0fa1-4c32-b7bb-48e057af1270"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_36729629-5671-4810-b3a0-0a65b96f4982"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7c105d75-0eff-40e5-a076-0166362fc4d4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-28</xbrli:startDate><xbrli:endDate>2022-01-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d7f61ae5-e6e7-4a2d-b7f8-a2343ab6ffcd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7241f66e-a735-4719-b5b2-0d08cdf5a400"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acet:TwoThousandFourteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bdaaafd2-c90a-4125-9ca9-c8ea735b0f55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_eae66964-012d-43ad-a3b1-27bc081b6037"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">acet:ContractLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f42c98ab-830c-4e22-89f5-e18b91b6cd8e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d9bc8440-92d6-4375-83a6-16f30d5e1156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:UnusualRiskOrUncertaintyByNatureAxis">acet:COVID19Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">acet:ContingentValueRightsAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-30</xbrli:startDate><xbrli:endDate>2020-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9c4e6975-00c5-410c-91ea-8f78158b9eb4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">acet:NovartisLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acet:NovartisInternationalPharmaceuticalLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b79560ec-35d7-487d-96ee-7f96cca3cf73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_41ca3bfc-5bca-4c8e-8757-b6a526d155a4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">acet:ContractLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d75d589d-a181-4cd4-ad70-8e7ae30da242"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">acet:SeptemberFifteenTwoThousandTwentyWarrantThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_33ca374a-c073-4a53-8b64-e82bcfbfe97f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_35b723a6-c5cf-49a4-9335-d4bc407fc9fc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">acet:OptionsAvailableForFutureGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_6ed2f7b8-095e-4a87-ad70-d100496cc258"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9dda731b-43d4-46e4-905f-51b9789cec27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">acet:CommonStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_81494d43-98de-4a2b-a975-25afa4970b74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">acet:ContingentValueRightsAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:ChangeDuringPeriodFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7d366b41-4178-4cf0-85c2-805e8d8b6c0a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acet:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2016-07-29</xbrli:startDate><xbrli:endDate>2016-07-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4e9b72dd-9a34-4bc0-8d92-21bc3dbb099f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:UnusualRiskOrUncertaintyByNatureAxis">acet:COVID19Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">acet:ContingentValueRightsAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-11-01</xbrli:startDate><xbrli:endDate>2020-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3ff20287-8f1c-4d12-b176-b2761961daee"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acet:TwoThousandEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_47329381-5696-4150-b182-6307d7bace64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">acet:SeptemberFifteenTwoThousandTwentyWarrantOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_89d1a790-504a-43c7-8716-b106ad45345d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">acet:CommonStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b2fceb56-058f-472e-a003-7e909e8b6b12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">acet:ResTORbioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e7b49a0d-aba6-4a40-8906-1ce775d20e23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_8d576fd1-c342-4304-8b64-31bfd7e0d001"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acet:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-27</xbrli:startDate><xbrli:endDate>2021-04-27</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4a463e61-a719-45b8-b4f2-fb3e5d6433eb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">acet:MenloParkLeaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_382b6885-27c8-4c22-95fd-15e7dd95382f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acet:TwoThousandEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c66707bf-a227-49f3-9c39-d4e971ab95bd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-31</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_515b257e-b0b9-4013-a431-c4113b38f357"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_7447a494-85e3-4ae0-ad10-48552cb40723"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acet:TwoThousandEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fdcf93e8-6acd-43f5-89f3-9404d1046341"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_baae0ca2-627c-4fcf-80d3-97c07794901d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:UnusualRiskOrUncertaintyByNatureAxis">acet:COVID19Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">acet:ContingentValueRightsAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_39a111ce-846b-4680-8cb9-7243c84bbf71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:UnusualRiskOrUncertaintyByNatureAxis">acet:COVID19Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fc8377ae-c923-40ee-9f57-b8fa6cd9e90b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-24</xbrli:startDate><xbrli:endDate>2021-06-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4e76cb9d-4c4a-40ac-b56d-06fc2a5d3fbd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f72b75a3-3766-46c7-b232-aba9e69a07a2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a9b28221-7291-479e-aade-1c4cce9e9ee2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acet:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_66c6bb36-401e-4afc-b955-ab56bbccb097"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-15</xbrli:startDate><xbrli:endDate>2020-09-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_aab33e86-f1f3-4f74-9094-e2ed14ea13cc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bdd4c9c6-4256-4ee5-b7de-760f8fec3c69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_f7497dd4-b12f-4bd8-b7a8-8dd651b1c575"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fddea6c4-817b-4e77-aea4-89981e10e5a9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_62266203-5d56-4f94-a47f-f581aa528dbf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">acet:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_87ab7035-f594-4fe7-8bcf-c303cd53528e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c3918e4a-2434-4382-9707-ca0c30475b0a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">acet:ContingentValueRightsAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:ChangeDuringPeriodFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8968c75b-77f9-4e93-84f0-e12dc0959c9f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acet:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_32996dbe-7c67-4061-9092-811f3ea449f5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acet:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ecef1783-dbe7-4a31-ab16-82774cd71330"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">acet:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ebfaf6a1-e4c4-4844-90bf-eb7e876fd554"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e39012be-aa0b-44c4-bc70-f388d0297447"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">acet:BostonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1ac06182-fa6d-4612-a577-224903f3d8ec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f0fe55b1-e361-4417-baab-c311c3746c48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5a2b4879-2585-49d1-b0c2-05cb9d882735"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bd372fd7-75a1-4e5a-93b8-53cd9832c95c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acet:TwoThousandEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ee99e6bd-ad45-468e-9fbb-435628a329b5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_93d3a97b-1f9f-4a76-9398-f29f21995887"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4f49ca26-ce78-4bcd-aa4b-b027527c27af"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-29</xbrli:startDate><xbrli:endDate>2021-07-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7c0ad6be-8917-45ec-bfbe-3f58f537064d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_68012e05-ebbc-4f75-b9ec-4a4dfe9d312a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">acet:ContractLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3b4615b0-36e3-4745-a8ee-bb680c1705d1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8b04952a-abb5-4154-8047-1764f9eef410"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">acet:SeptemberFifteenTwoThousandTwentyWarrantFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a3c832c4-7b25-488e-a569-24d85c95e6db"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acet:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_92ecfec8-f8f4-4b99-9099-e1803e6b82f7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:ChangeDuringPeriodFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b25c6402-54af-4bb9-9e89-3b3f8319d96f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_086b3add-2ea8-447d-a2b0-fbfba9fbf32a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">acet:EmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4669da95-189e-49f2-9e8b-0f44bc2c3332"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acet:TwoThousandEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_98e3df4a-7a5c-4af8-b922-80b4bfd6c7c5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acet:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_188057dd-d8a2-49b6-b276-041c6c6962c8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4a46099c-74bf-4057-bccf-7f08136ee114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:ChangeDuringPeriodFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c9838f86-a839-4a13-93ca-c0b2d3b58809"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fd2a51f4-a4e0-4fd4-8b72-384f893e07dc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_e467cca2-7a5b-404b-9e56-feeb98925d23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_54827df2-7ab1-4397-b75e-6c83f7055086"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-09-14</xbrli:startDate><xbrli:endDate>2020-09-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ed6df093-d6d5-4c84-a08c-07bf173fcdb1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">acet:ResTORbioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_6bc5ff1d-cdce-445a-9774-b450949c38dc"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acet:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3507c3c5-6e58-434e-aad1-74893d0a8f54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_75ebf3d9-c86e-4807-98b4-2e10b253829b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_8ebb8127-795c-4f3e-930b-1793c330d85e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d01f7af2-d072-472c-aed6-fdd2ba352899"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3bebb335-7ef4-439f-88ab-b54a40df0583"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acet:TwoThousandSeventeenAndTwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b9512590-14bb-4410-8257-cfe9d48166b8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_61d717f8-651c-4c2c-bbdf-85e091817288"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">acet:NovartisLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acet:NovartisInternationalPharmaceuticalLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-03-23</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_d735ff93-b890-4e3f-88c9-64a20e0a25a7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_4bc22030-2d0d-4a1f-b865-b78ea80ec73c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a904b84b-2c56-4da2-95ba-b90ab8586e15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0e775bc8-410a-49ef-80c8-2b1c45c0da93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b7f956dc-e09b-4592-9b31-a71664b48260"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">acet:ContingentValueRightsAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_0897fc9d-88dd-4a06-87d5-dbac0106894b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">acet:RedeemableConvertiblePreferredStockWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_61c5baba-2674-42bd-b177-79bf4833cac0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">acet:SeptemberFifteenTwoThousandTwentyWarrantTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_23c45869-fbfe-42d5-ad00-b90a165dbcd2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_425adbd0-c74a-4998-835c-069d0757ec60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acet:TwoThousandSeventeenAndTwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b758350f-0170-4fae-8ec9-d587850903ab"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acet:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-04-01</xbrli:startDate><xbrli:endDate>2020-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ab4803e6-aff5-4742-8d52-34995d4eb9b3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:UnusualRiskOrUncertaintyByNatureAxis">acet:COVID19Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">acet:ContingentValueRightsAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5595a158-5264-494e-ab32-6b3d9fad68b5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_03b136b5-e9d4-4893-ab0d-2dc91c51accf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ebf71bd0-6119-4662-9dc2-2e319bd6c751"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:UnusualRiskOrUncertaintyByNatureAxis">acet:COVID19Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5ad68f0f-dc2d-43e8-92c2-f0f53b821bd5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">acet:ResTORbioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-09-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e645c0e4-c8b9-494e-86ea-d249ee6b8de0"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_de3e4a83-2efd-4bdb-9ed1-e22b3ab57037"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">acet:ContractLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_95800697-5c2c-4d5a-aff7-318a343c4784"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fca8dc62-71f2-4995-91e8-1b030e192627"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">acet:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b662f1d9-b03b-4be8-bc81-ab4638821609"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">acet:RedeemableConvertiblePreferredStockWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fdd289b2-efd1-4e91-9b8b-97c14283103e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_dccfe9c7-9db3-41d8-9a49-8d136b5e0bfa"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">acet:OptionsAvailableForFutureGrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_bb96533e-8bc4-44b9-adcb-bbc676d9bb65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">acet:ResTORbioMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b7eaefd8-96b9-433a-a39f-12214b972204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_788e17f6-1175-45bd-816d-ca6c3191ac61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_edd4abe0-f9c0-4ed5-ad3b-408b1b6e6b9e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acet:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-07-31</xbrli:startDate><xbrli:endDate>2019-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_fd1ca962-13a9-4d81-ab99-ced7557eb7ab"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">acet:ContingentValueRightsAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_775ace4d-f0e0-4bb0-b785-08666d208bbb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">acet:CaliforniaResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4d645798-711d-496e-8eb5-907d5667159d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1d137f38-c8f9-4c04-bef7-225e2c879fcf"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b9e4ebe3-8c57-40bf-bb42-6e19b62ee01c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ead71044-8531-48be-a61d-d7cd5c9f9352"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acet:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-01-01</xbrli:startDate><xbrli:endDate>2017-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_19e31569-c13e-46a3-a9e6-a74f0c5c72c6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">acet:MarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_22d1874f-4dce-4f63-bbf4-e46373c23281"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acet:TwoThousandEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_cea994b1-c7e3-4048-aeb0-aab2a8ee080d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">acet:RedwoodCityLeaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3b9411c3-8cc1-4889-996e-5f7080c40edb"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_3606b322-7fbf-4372-8ef9-9fed27772088"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:UnusualRiskOrUncertaintyByNatureAxis">acet:COVID19Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">acet:ContingentValueRightsAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b571f234-c627-4f7d-82fb-c74e7cbd480a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">acet:ResTORbioMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_23d1c211-5416-49b1-b67a-b83adbf5b18b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">acet:RfsOpcoLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-19</xbrli:startDate><xbrli:endDate>2021-07-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3ca7e266-0fdc-4e92-9c8c-d4aea36592ef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">acet:ContractAssetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_5207f624-84b3-469d-bd6b-fe0a7c570cde"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">acet:MarketableSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_cd9014db-0372-4b1d-af87-ae8fac0a18ea"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">acet:ContingentValueRightsAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ed4f0fb0-7a37-45a2-b10b-11e180b401f7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_342b3c71-2aea-451c-ba15-14d5101cb509"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_5e765ceb-b63f-4177-a750-139c07a36c25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-10-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_bc8e068c-61df-4e55-851e-10fa3cd91cf7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acet:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-31</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c620e2d6-dea3-45ea-8e5e-d3a20a684708"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_e474c1ad-c5d1-430f-a989-9a1559ca7832"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-10-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_9c600e1c-0c03-4bf9-8b76-f6fd3c4ce8d6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c5ef6f51-8e27-49fd-b340-0ef1ea2559f1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ce2525a9-10cf-4599-b98b-ee9a7da54cd2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_352e5b4d-b5f5-47ad-a765-412097c40d31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_383a2850-17d4-45d4-93aa-3b9d2268d63a"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acet:TwoThousandEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c416c367-1d15-4743-aa82-f287dc4229d1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acet:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_fe5ab009-8804-4e01-8541-0e9d8aa6c52f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ab272512-6afd-4b7d-821d-0cda8200b065"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">acet:SeptemberFifteenTwoThousandTwentyWarrantTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b1857342-ffb7-45ed-afa1-3915a6f75d31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acet:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_634bf63d-c1b7-40ac-bfb2-44d198c085ab"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acet:NationalInstitutesOfHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ce377847-1500-4676-9ec9-6e92cf9c03dd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-24</xbrli:startDate><xbrli:endDate>2021-06-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_75d47652-161b-4dc3-8594-ce11750f60a2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_99983e52-f2a5-42a0-b031-14f6461609ac"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">acet:FourthAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acet:PacificWesternBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_734e8966-cc1e-4985-a3ff-9c6d800e8bb3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_36830567-b9c7-4c61-a102-2db396446fbd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_316edeb3-e98f-436c-970f-b13de1ce7e93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:UnusualRiskOrUncertaintyByNatureAxis">acet:COVID19Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">acet:ContingentValueRightsAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ccba61f6-d5c4-43f1-bc3d-bdfb92b7ccad"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_a7d83825-c513-40b3-914c-c2f0871374ec"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_996c2c1e-c6b1-4f2c-b4f0-2957fe857977"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acet:TwoThousandEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ae89cac7-0fec-4757-8ed0-2429d1ad7ac5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acet:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-12-31</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_ad66e4cc-7bab-41c5-80c2-e13c75c2e208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_daaa68b0-d842-4ae0-a584-de681974e221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_7071ab79-c6d3-48f5-825b-3abca7958518"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_60060862-7047-426c-9c18-ea7eefd1e40c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_1878c95b-a997-415a-9e16-86e0a1c15a68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_c9ada5f0-e0e5-4266-9e2f-ad21061bf510"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2c5c9f72-4620-4181-b264-9a1444d1f83d"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">acet:SalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">acet:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-12-01</xbrli:startDate><xbrli:endDate>2020-12-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_d33cc417-791a-47d8-87ef-b0d73a0d0b66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_edc51531-f059-4811-b4b9-e22729a4e46c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">acet:FourthAmendmentMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acet:PacificWesternBankMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-10-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ca657af2-2ffc-4ae2-b3b7-1641af2126e2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">acet:ResearchFundingAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acet:NationalInstitutesOfHealthMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_c10c6884-14c3-4600-ae9f-b3a86ebd71ef"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-06-24</xbrli:startDate><xbrli:endDate>2021-06-25</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_677843d2-a967-4c7e-806b-bedb3b76e41f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acet:TwoThousandSeventeenAndTwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-05-01</xbrli:startDate><xbrli:endDate>2021-05-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_da9e6c7e-f0b9-4a9e-9854-806aece05e6c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_21b4de8c-d5dc-46f7-9bc7-44236de1a72c"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">acet:CommonStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ba6aebac-1228-4929-ac87-bcb3b11a0965"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acet:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0d31c0ca-f12c-41d7-9a4f-d658501001c3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">acet:SalesAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">acet:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-03-12</xbrli:startDate><xbrli:endDate>2021-03-12</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_3f1fec59-9c84-4fb5-b910-7eb14b6ef44f"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acet:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_91668149-580c-41d2-a60a-c106cf15c4df"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_b33e9899-16fc-42cc-96d1-97d706c7101b"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-04-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_859eba6f-9081-481e-ab8c-7b531e2b242e"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_9012bab3-6ac1-4389-8e31-ccc520a1ad87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_1fdee497-9bd9-4434-b8dd-50a2c01519cd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">acet:ContractLiabilityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_f7498518-7e9a-4c87-8ba1-fa0ec641d5dd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">acet:CommonStockWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_a5e55134-4c6c-4529-bddd-d3adb88995cd"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_4e6c9fea-07ee-4070-8aba-8ca1ddff8ad6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acet:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-28</xbrli:startDate><xbrli:endDate>2022-01-28</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_0c48ad1d-3ddc-4d42-94e0-eacbdc6debba"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="C_ba86b9b9-6782-4f93-bfa9-5fc357e6e1f8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acet:TwoThousandFourteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="C_2e8c65f5-54e7-412c-9d4a-c7dea4022906"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001720580</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="U_ValueRight"><xbrli:measure>acet:ValueRight</xbrli:measure></xbrli:unit><xbrli:unit id="U_pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="U_sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="U_Lawsuit"><xbrli:measure>acet:Lawsuit</xbrli:measure></xbrli:unit><xbrli:unit id="U_shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="U_Customer"><xbrli:measure>acet:Customer</xbrli:measure></xbrli:unit><xbrli:unit id="U_Segment"><xbrli:measure>acet:Segment</xbrli:measure></xbrli:unit><xbrli:unit id="U_USDollarShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="U_USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_3577aa04-acc2-44f1-903a-a30dd6a3a68b" fromRefs="F_fa98f595-6fe9-482c-a845-5536ac884496 F_02ca4e77-9c2a-4c1c-a9ab-6dcb167902d3 F_41788e52-a9f6-472d-b520-3c5c3a010951 F_803ea030-804d-4af6-ae34-b6185545f97e"></ix:relationship><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_7667a44b-4b7d-46fe-a77a-02f957bfe903" fromRefs="F_0099be2f-edcf-42f8-9783-ee98ff854bed F_e7895ac5-a282-4161-858e-49465cbe531e F_8b9f407e-f217-4fde-baff-1f665d44ddc0 F_305f8387-b718-488f-a8a2-0200819b734c F_286b4dd8-de72-4494-a772-8e314c9d9fb7 F_f92de538-49fa-4f31-8dab-f0d8259d1d68 F_170bf009-3fc4-40d7-bdea-5719513fa678 F_fdec90d6-ca79-4616-84a2-3da07ccd4eb7"></ix:relationship><ix:relationship linkRole="http://www.xbrl.org/2003/role/link" arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" toRefs="FNT_9de3ffc8-0280-4d4d-8e75-e7b828a8e6e2" fromRefs="F_c8d12e80-3ad7-488e-a4d6-720e653a110e F_37a62b6e-7f72-4455-bb60-c81a41a19eec"></ix:relationship></ix:resources></ix:header></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:16.0pt;font-family:Times New Roman;">UNITED STATES</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:16.0pt;font-family:Times New Roman;">SECURITIES AND EXCHANGE COMMISSION</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:16.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Washington, D.C. 20549</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:16.0pt;font-family:Times New Roman;">FORM </span><span style="font-size:16.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_33ed1a9e-33f2-455c-8ba2-bf3543252e9c" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="dei:DocumentType"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:16.0pt;font-family:Times New Roman;">10-K</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:16.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">(Mark One)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:4.0%;"></td>
    <td style="width:96.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:0.9450000000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a3d461ca-ba3d-494a-a6c0-9c0109aef8c2" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">&#9746;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;line-height:0.9450000000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">For the fiscal year ended </span><span style="font-size:7.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cbb26a8c-0451-446a-ab1a-128b9f96dec1" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">December 31, </span><span style="font-size:7.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_078b0eec-320b-4fd2-982c-3ab1c9176bbf" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="dei:DocumentFiscalYearFocus"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">2021</span></ix:nonNumeric></span><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;"></span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">OR</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:4.0%;"></td>
    <td style="width:96.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:0.9450000000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9954755c-0814-47c8-9aa1-cb4af79d93dc" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:2.0pt;line-height:0.9450000000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">For the transition period from </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:7.0pt;font-family:Times New Roman;">                    </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;"> to</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;"> </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">                    </span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Commission File No. </span><span style="font-size:7.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_384eb8e2-9939-4ec9-ad65-507ac8dc2563" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="dei:EntityFileNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">001-38359</span></ix:nonNumeric></span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:20.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c15ec1e6-43e3-42b8-9b21-a9cef8071c6d" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="dei:EntityRegistrantName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:20.0pt;font-family:Times New Roman;">Adicet Bio, Inc.</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(Exact name of registrant as specified in its charter)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:49.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:50.0%;"></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:0.9450000000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:7.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_151e515a-81fd-49cd-8f5c-c925d5483a9d" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Delaware</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:0.9450000000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:0.9450000000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:7.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4a72e133-62f9-4fb2-9852-a4b66dc70669" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="dei:EntityTaxIdentificationNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">81-3305277</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:0.9450000000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(State or other jurisdiction of</span></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:0.9450000000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">incorporation or organization)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:0.9450000000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:0.9450000000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(I.R.S. Employer</span></p><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:0.9450000000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Identification No.)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:7.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7b662327-3147-4592-ac66-7c58e3bd7489" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="dei:EntityAddressAddressLine1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">200 Clarendon Street</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">, </span><span style="font-size:7.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_adc6565f-3e97-47e4-b794-7883367bb66a" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="dei:EntityAddressAddressLine2"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Floor 6</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:7.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_69babf2e-7a0f-4c9c-991e-9579f1cb2ec9" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="dei:EntityAddressCityOrTown"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Boston</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">, </span><span style="font-size:7.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1bc20cea-8afa-42e8-b8f5-84ac4ca19b8a" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="dei:EntityAddressStateOrProvince"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">MA</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;"> </span><span style="font-size:7.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f19ec6e4-57ba-485d-8bd6-7b5ebd376420" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="dei:EntityAddressPostalZipCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">02116</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(</span><span style="font-size:7.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_bc57aad9-a4d9-4f5c-ab0f-14e940143c66" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="dei:CityAreaCode"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">650</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">)</span><span style="font-size:7.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f4f62fed-72f0-4602-b2f2-23143b83839f" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="dei:LocalPhoneNumber"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;"> 503-9095</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(Address, including zip code, and telephone number, including area code, of registrant&#x2019;s principal executive offices)</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Securities registered pursuant to Section 12(b) of the Act:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:40.0%;"></td>
    <td style="width:20.0%;"></td>
    <td style="width:40.0%;"></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="border-top:0.500pt solid;background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;vertical-align:middle;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:0.9450000000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Title of each class</span></p></td>
    <td style="border-top:0.500pt solid;background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:0.9450000000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Trading Symbol(s)</span></p></td>
    <td style="border-top:0.500pt solid;background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:0.9450000000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Name of each exchange on which registered</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;vertical-align:middle;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:0.9450000000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:7.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a4ed1765-af53-49ed-9afc-c6c7657f97ab" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="dei:Security12bTitle"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Common Stock, par value $0.0001 per share</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:0.9450000000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:7.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fa8455b0-48a6-4e23-99d5-4db1b4a20beb" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="dei:TradingSymbol"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">ACET</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:0.9450000000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:7.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_75e6d061-5d75-4685-a9a3-6f7d58bd9735" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">The Nasdaq Global Market</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Securities registered pursuant to Section 12(g) of the Act:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">None</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"> </span></p>
  <p style="margin-left:40.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.500pt solid;margin-right:40.0%;text-align:center;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.    &#9744;  Yes    &#9746;  </span><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_34db2215-f014-4d98-9066-72c0f6016eea" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="dei:EntityWellKnownSeasonedIssuer"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">No</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.    &#9744;  Yes    &#9746;  </span><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a630f4f0-26da-4cbd-9987-45e3ba758417" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="dei:EntityVoluntaryFilers"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">No</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    &#9746;  </span><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c91474a6-e1a0-4c7c-8d88-af8d83ced077" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="dei:EntityCurrentReportingStatus"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Yes</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">    &#9744;   No</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    &#9746;  </span><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_826947de-59bc-4a20-858a-76460c0b4356" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="dei:EntityInteractiveDataCurrent"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Yes</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">   &#9744;  No</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of &#x201c;large accelerated filer,&#x201d; &#x201c;accelerated filer,&#x201d; &#x201c;smaller reporting company,&#x201d; and &#x201c;emerging growth company&#x201d; in Rule 12b-2 of the Exchange Act.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:19.704%;"></td>
    <td style="width:3.139%;"></td>
    <td style="width:52.157%;"></td>
    <td style="width:2.38%;"></td>
    <td style="width:19.037%;"></td>
    <td style="width:3.583%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:0.9450000000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Large accelerated filer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:0.9450000000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9744;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:0.9450000000000001;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:0.9450000000000001;font-family:Times New Roman;margin-bottom:1.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:0.9450000000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Accelerated filer</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:0.9450000000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9744;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:0.9450000000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9c24832d-bd83-470c-9188-049122314e77" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Non-accelerated filer</span></ix:nonNumeric></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:0.9450000000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9746;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:0.9450000000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:0.9450000000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:0.9450000000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Smaller reporting company</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:0.9450000000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3aa408b2-028c-480b-b0be-090cbe514a84" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:0.9450000000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:0.9450000000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:0.9450000000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:0.9450000000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:0.9450000000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Emerging growth company</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:0.9450000000000001;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_71b8ced4-6b90-4225-bcae-64ac80d5923f" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9746;</span></ix:nonNumeric></span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  </span><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ee51350b-8bbc-4899-bfbf-6dd782f1c159" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="dei:EntityExTransitionPeriod" format="ixt-sec:boolballotbox"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#x2019;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. </span><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_99efc04e-7994-4b49-adfb-c36074f5a742" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="dei:IcfrAuditorAttestationFlag" format="ixt:booleanfalse"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.):    </span><span style="font-size:8.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7ad66f56-83bd-4287-8ab0-b33f01207b88" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="dei:EntityShellCompany" format="ixt:booleanfalse"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#9744;</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> Yes    &#9746; No</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">As of June 30, 2021, the aggregate market value of the registrant&#x2019;s voting and non-voting common stock held by non-affiliates was approximately $</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_37976fe4-4154-4e95-a216-10ac6a4b26a1" contextRef="C_5595a158-5264-494e-ab32-6b3d9fad68b5" name="dei:EntityPublicFloat" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">226.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> million based on a closing price of $10.29 per share as quoted by The Nasdaq Global Market as of such date. In determining the market value of non-affiliate common stock, shares of the registrant&#x2019;s common stock beneficially owned by officers, directors and affiliates have been excluded. This determination of affiliate status is not necessarily a conclusive determination for other purposes.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">As of </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">March 10, 2022 there were </span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_be411f2c-89c3-4980-acfd-6c295ecf3b34" contextRef="C_607c7869-0981-4346-b7b5-2e6c06ea1c1b" name="dei:EntityCommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">39,877,109</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> sha</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">res of common stock, $0.0001 par value per share, outstanding.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:3.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">DOCUMENTS INCORPORATED BY REFERENCE</span></p>
  <div><ix:nonNumeric id="F_814e4b24-d434-4598-8649-9f353d4ba288" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="dei:DocumentsIncorporatedByReferenceTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Part III of this Annual Report on Form 10-K incorporates by reference certain information from the registrant&#x2019;s definitive Proxy Statement for its 2022 annual meeting of shareholders, scheduled to be held on June 2, 2022, which the registrant intends to file pursuant to Regulation 14A with the Securities and Exchange Commission not later than 120 days after the registrant&#x2019;s fiscal year end of December 31, 2021. Except with respect to information specifically incorporated by reference in this Form 10-K, the Proxy Statement is not deemed to be filed as part of this Form 10-K.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Summary of the Material and Other Risks Associated with Our Business</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have a limited operating history and face significant challenges and expense as we build our capabilities.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our business is highly dependent on the success of ADI-001. If we are unable to obtain approval for ADI-001 and effectively commercialize ADI-001 for the treatment of patients in our approved indications, our business would be significantly harmed.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our gamma delta T cell candidates represent a novel approach to cancer treatment that creates significant challenges for us.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our product candidates are based on novel technologies, which makes it difficult to predict the likely success of such product candidates and the time and cost of product candidate development and obtaining regulatory approval.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our clinical trials may fail to demonstrate the safety and efficacy of any of our product candidates, which would prevent or delay regulatory approval and commercialization.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may not be able to file investigational new drug (IND) applications to commence additional clinical trials on the timelines we expect, and even if we are able to, the FDA may not permit us to proceed. We may encounter substantial delays in our clinical trials or may not be able to conduct our trials on the timelines we expect.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The market opportunities for our product candidates may be limited to those patients who are ineligible for or have failed prior treatments and may be small.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We do not currently operate our own manufacturing facility and currently depend on the ability of our third-party suppliers and manufacturers with whom we contract to perform adequately, particularly with respect to the timely production and delivery of our product candidates, including ADI-001. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are highly dependent on our key personnel, and if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses. A pandemic, epidemic or outbreak of an infectious disease, such as COVID-19, may materially and adversely affect our business and operations.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Failure to achieve and maintain effective internal control over financial reporting could harm our business and negatively impact the value of our common stock.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If our collaboration agreement with Regeneron Pharmaceuticals, Inc. (Regeneron) is terminated, or if Regeneron materially breaches its obligations thereunder, our business, prospects, operating results, and financial condition would be materially harmed.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The U.S. Food and Drug Administration regulatory approval process is lengthy and time-consuming, and we may experience significant delays in the clinical development and regulatory approval of our product candidates.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If our efforts to protect the proprietary nature of the intellectual property related to our technologies are not adequate, we may not be able to compete effectively in our market.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We depend on intellectual property licensed from third parties and termination of any of these licenses could result in the loss of significant rights, which would harm our business.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We will need substantial additional financing to develop our products and implement our operating plans. If we fail to obtain additional financing, we may be unable to complete the development and commercialization of our product candidates.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">i</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">TABLE OF CONTENTS</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:10.006%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:81.997%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:5.998%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Page</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#explanatory_note_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">EXPLANATORY NOTE</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#special_note_regarding_forwardlooking_st"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#part_i"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">PART I</span></a><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span></p></td>
   </tr>
   <tr style="height:11.5pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 1.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_1_business"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Business</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span></p></td>
   </tr>
   <tr style="height:11.5pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 1A.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#risk_factors"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Risk Factors</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">46</span></p></td>
   </tr>
   <tr style="height:11.5pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 1B.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#unresolved_staff_comments"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Unresolved Staff Comments</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">87</span></p></td>
   </tr>
   <tr style="height:11.5pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 2.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_2_properties"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Properties</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">87</span></p></td>
   </tr>
   <tr style="height:11.5pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 3.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_3_legal_proceedings"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Legal Proceedings</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">87</span></p></td>
   </tr>
   <tr style="height:11.5pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 4.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_4_mine_safety_disclosures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Mine Safety Disclosures</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">87</span></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#part_ii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">PART II</span></a><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">88</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 5.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_5_market_for_registrants_common_equ"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Market for Registrant&#x2019;s Common Equity, Related Stockholder Matters and Issuer Purchases of <br />Equity Securities</span></a><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">88</span></p></td>
   </tr>
   <tr style="height:11.5pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 6.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_6"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Reserved</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">88</span></p></td>
   </tr>
   <tr style="height:11.5pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 7.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_7_managements_discussion_analysis_f"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Management&#x2019;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">89</span></p></td>
   </tr>
   <tr style="height:11.5pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 7A.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_7a_quantitative_qualitative_disclos"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">99</span></p></td>
   </tr>
   <tr style="height:11.5pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 8.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_8_financial_statements_supplementar"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Financial Statements and Supplementary Data</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100</span></p></td>
   </tr>
   <tr style="height:11.5pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 9.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9_changes_in_disagreements_with_acc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100</span></p></td>
   </tr>
   <tr style="height:11.5pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 9A.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9a_controls_procedures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Controls and Procedures</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100</span></p></td>
   </tr>
   <tr style="height:11.5pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 9B.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_9b_or_information"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Other Information</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">102</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 9C.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#disclosure_regarding_foreign"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Disclosure Regarding Foreign Jurisdictions That Prevent Inspections</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">102</span></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#part_iii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">PART III</span></a><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">103</span></p></td>
   </tr>
   <tr style="height:11.5pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 10.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_10_directors_executive_ficers_corpo"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Directors, Executive Officers and Corporate Governance</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">103</span></p></td>
   </tr>
   <tr style="height:11.5pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 11.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_11_executive_compensation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Executive Compensation</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">103</span></p></td>
   </tr>
   <tr style="height:11.5pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 12.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_12_security_ownership_certain_benef"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">103</span></p></td>
   </tr>
   <tr style="height:11.5pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 13.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_13_certain_relationships_related_tr"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Certain Relationships and Related Transactions, and Director Independence</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">103</span></p></td>
   </tr>
   <tr style="height:11.5pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 14.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_14_principal_accountant_fees_servic"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Principal Accountant Fees and Services</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">103</span></p></td>
   </tr>
   <tr style="height:5.75pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:middle;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#part_iv"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">PART IV</span></a><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">104</span></p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 15.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_15_exhibits"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Exhibits and Financial Statement Schedules</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">104</span></p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Item 16.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#item_16_10k_summary"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Form 10-K Summary</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">104</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ii</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="explanatory_note_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">EXPLANATO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">RY NOTE</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:2.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prior to September 15, 2020, we were a clinical-stage biopharmaceutical company known as resTORbio, Inc. (resTORbio) that had historically focused on developing innovative medicines that target the biology of aging, to prevent or treat age-related diseases with the potential to extend healthy lifespans. resTORbio was originally incorporated under the laws of the State of Delaware in July 2016 and commenced research and development operations in March 2017.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On September 15, 2020, we completed our business combination whereby a wholly-owned subsidiary of resTORbio merged with and into Adicet Bio, Inc. (Former Adicet), with Former Adicet surviving as a wholly-owned subsidiary of resTORbio and changing our name to Adicet Therapeutics, Inc. (such transactions, the Merger). In connection with the completion of the Merger, resTORbio was renamed Adicet Bio, Inc. (Adicet Bio).</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Immediately prior to the Effective Time of the Merger, resTORbio effected a reverse stock split of our common stock at a ratio of 1-for-7 (the Reverse Stock Split). At the Effective Time of the Merger, each outstanding share of Former Adicet&#x2019;s capital stock was converted into the right to receive 0.1240 (the Exchange Ratio) shares of Adicet Bio&#x2019;s common stock.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unless otherwise noted, all references to common stock share and per share amounts in this Annual Report on Form 10-K have been retroactively adjusted to reflect the conversion of shares in the Merger based on the Exchange Ratio and Reverse Stock Split. As used herein, the words &#x201c;Adicet Bio,&#x201d; &#x201c;Adicet,&#x201d; &#x201c;the Company,&#x201d; &#x201c;we,&#x201d; &#x201c;us,&#x201d; and &#x201c;our&#x201d; refer to, for periods following the Merger, Adicet Bio (formerly resTORbio, Inc.), together with its direct and indirect subsidiaries, and for periods prior to the Merger, Adicet Therapeutics, Inc. (formerly Adicet Bio, Inc.). </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> In addition, the word &#x201c;resTORbio&#x201d; refers to the Company prior to the completion of the Merger, and we sometimes refer to Adicet Therapeutics, Inc. as &#x201c;Former Adicet.&#x201d;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.0014583333333331;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.0014583333333331;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="special_note_regarding_forwardlooking_st"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">SPECIAL NOTE REGARDING FORWARD-LOO</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">KING STATEMENTS AND INDUSTRY DATA</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This Annual Report on Form 10-K contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this Annual Report on Form 10-K, including statements regarding our strategy, future operations, future financial position, future revenue, projected costs, prospects, plans and objectives of management and expected market growth are forward-looking statements. The words &#x201c;anticipate,&#x201d; &#x201c;believe,&#x201d; &#x201c;continue,&#x201d; &#x201c;could,&#x201d; &#x201c;estimate,&#x201d; &#x201c;expect,&#x201d; &#x201c;intend,&#x201d; &#x201c;may,&#x201d; &#x201c;plan,&#x201d; &#x201c;potential,&#x201d; &#x201c;predict,&#x201d; &#x201c;project,&#x201d; &#x201c;should,&#x201d; &#x201c;target,&#x201d; &#x201c;would&#x201d; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">These forward-looking statements include, among other things, statements about:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to execute our clinical trials for ADI-001 in Non-Hodgkin&#x2019;s lymphoma (NHL), including the ability to successfully complete our Phase 1 clinical trial and the period during which the results of the trial will become available;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the anticipated timing of our submission of Investigational New Drug (IND) applications or equivalent regulatory filings and initiation of future clinical trials, including the timing of the anticipated results;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the impact of the ongoing COVID-19 pandemic on our continuing operations, clinical development plans, including the timing of initiation and completion of studies or trials, financial forecasts and expectations, and other matters related to our business and operations;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the timing of and our ability to obtain and maintain regulatory approvals for our product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the rate and degree of acceptance and clinical utility of any products for which we receive regulatory approval;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our commercialization, marketing and manufacturing capabilities and strategy;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our intellectual property position and strategy;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to identify additional product candidates with significant commercial potential;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our plans to enter into collaborations for the development and commercialization of product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the potential benefits of any future collaboration;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to contract with third-party suppliers and manufacturers and their ability to perform adequately;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the success of competing therapies that are or may become available;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">developments relating to our competitors and our industry;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to retain the continued service of our key professionals and to identify, hire, and retain additional qualified professionals;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our financial performance;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our expectations related to the use of cash, cash equivalents and marketable securities;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our estimates regarding expenses, future revenue, capital requirements and needs for additional financing;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to maintain effective internal control over financial reporting;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the impact of government laws and regulations; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">other risks and uncertainties, including those listed under the caption &#x201c;Risk Factors.&#x201d;</span></div></div>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary statements included in this Annual Report on Form 10-K, particularly in the &#x201c;Risk Factors&#x201d; section, that could cause actual results or events to differ materially from the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, collaborations, joint ventures or investments that we may make or enter into.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">You should read this Annual Report on Form 10-K and the documents that we reference herein and have filed or incorporated by reference as exhibits hereto completely and with the understanding that our actual future results may be materially different from what we expect. We do not assume any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This Annual Report on Form 10-K includes statistical and other industry and market data that we obtained from industry publications and research, surveys and studies conducted by third parties. Industry publications and third-party research, surveys and studies generally indicate that their information has been obtained from sources believed to be reliable, although they do not guarantee the accuracy or completeness of such information. We are responsible for all of the disclosure contained in this Annual Report on Form 10-K, and we believe these industry publications and third-party research, surveys and studies are reliable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="part_i"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PART</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> I</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">All brand names or trademarks appearing in this report are the property of their respective owners. Unless the context requires otherwise, references in this report to &#x201c;Adicet Bio,&#x201d; &#x201c;Adicet,&#x201d; &#x201c; the &#x201c;Company,&#x201d; &#x201c;we,&#x201d; &#x201c;us&#x201d; and &#x201c;our&#x201d; refer to Adicet Bio, Inc. and its subsidiaries, as applicable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="item_1_business"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 1. B</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">usiness.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Overview</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer. We are advancing a pipeline of &#x201c;off-the-shelf&#x201d; gamma delta T cells, engineered with chimeric antigen receptors (CAR) and T cell receptor-like antibodies (TCRL), to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. Our approach to activate, engineer and manufacture allogeneic gamma delta T cell product candidates derived from the peripheral blood cells of unrelated donors allows us to generate new product candidates in a rapid and cost-efficient manner.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is in an ongoing Phase 1 study for the treatment of Non-Hodgkin's Lymphoma (NHL). Our pipeline also includes ADI-002, an allogeneic gamma delta CAR-T cell therapy expressing a GPC3-targeted CAR and a cell intrinsic soluble form of interluiken-15 (IL-15), for the treatment of solid tumors. In addition, we are engaged in discovery and preclinical stage activities directed to expansion of our pipeline of product candidates for both hematological malignancies and solid tumors.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our Approach</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our proprietary engineering and manufacturing process begins with isolating and expanding gamma delta T cells from the blood of unrelated donors, and results in the potential to treat up to 1,000 patients per batch depending on dosing and the CAR target. Gamma delta T cells have unique attributes that we believe make them especially well-suited to be used for cancer therapy. Approximately 95% of T cells in circulation are so-called alpha beta T cells, named after the proteins that make up the cells&#x2019; T cell receptor (TCR). The remaining T cells include a population that makes up between 1% and 5% of all T cells, the gamma delta T cells, along with a few other cell types. Distinct among immune cell populations, we believe gamma delta T cells may have the following combination of attributes:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Can be used in patient irrespective of the tissue-types of the patient i.e., a &#x201c;universal&#x201d; product;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Can be used &#x201c;off-the-shelf&#x201d; after being expanded from unrelated donors; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Are actively cytotoxic to tumor cells;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">May functionally persist in patients for clinically meaningful periods or time;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Can replicate in an appropriate and measured way after manufacture and administration; Can have their reactivity to tumor cells enhanced further by the addition of a CAR;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Express both T cell and natural killer (NK) cell receptors, facilitating both adaptive and innate anti-tumor immune responses; and</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Can be manufactured potentially in large numbers to facilitate the consistent treatment of many patients and avoids the cumbersome nature and expense of isolating cells from each patient.</span></div></div>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">By contrast, approved CAR-T cell therapies, as well as the majority of CAR-T cell therapies in clinical development, are based on a different population of T cells, known as alpha beta T cells, which have the ability to attack unrelated tissues if they are not immunologically matched to the patient. For this reason, the majority of alpha-beta-T-cell-derived CAR-T cell products are custom-generated from cells isolated from each patient, or require significant gene editing to manufacture if the T cells are derived from donors that are unrelated to the patient. Gamma delta T cells, by contrast, do not in principle require immunological matching and therefore cells isolated from unrelated donors can potentially be administered to any patient. This may enable cell therapy products based on gamma delta T cells to be manufactured in bulk and distributed as readily available off-the-shelf products. In animal models and early third-party clinical trials, gamma delta T cells do not expand in healthy tissues, indicating that they may be associated with a lower risk of life-threatening immune responses. In addition to their ability to circulate, gamma delta T cells have an inherent capacity to locate in tissues and recognize and attack cancerous cells.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In comparison to a number of NK cell therapies currently in development, CAR-modified gamma delta T cells functionally persist in non-clinical models for protracted periods of time and are designed to persist after single or repeat dosing of patients for clinically meaningful periods. Our manufacturing process results in highly homogeneous cell populations that we have observed to display potent anti-tumor activity in non-clinical models. Unlike most NK cells, that only exhibit characteristics on innate lymphocytes, gamma delta T cells display features of both innate and adaptive anti-tumor immunity and readily recognize and kill tumor cells with and without expression of CARs. Additionally, we believe that our short proprietary process to manufacturing CAR-modified gamma delta T cells without any &#x201c;feeder&#x201d; cell lines compares favorably to manufacturing alternatives used in expanded allogeneic NK cell-based therapies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our Pipeline</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is in an ongoing Phase 1 study for the treatment of NHL. On December 6, 2021, we reported positive interim clinical data from the initial dose escalation portion of this study that showed complete and near complete responses at low doses along with a generally favorable tolerability profile. We aim to provide a further clinical update for ADI-001 in the first half of 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our pipeline also includes three other product candidates in the discovery or preclinical phases for which we aim to file investigational new drug (IND) applications between 2023 and 2025.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As part of a collaboration with Regeneron Pharmaceuticals, Inc. (Regeneron) pursuant to an agreement signed in 2016, Regeneron has the option to obtain development and commercial rights for a certain number of product candidates, and we have an option to participate in the development and commercialization of these potential products or are entitled to royalty payments by Regeneron. Immunocellular therapy product candidates developed and commercialized by us under our agreement with Regeneron will be subject to payment of royalties to Regeneron. On January 28, 2022, Regeneron exercised its option to license exclusive rights to ADI-002. For additional information on our agreement with Regeneron, please see the section entitled </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">&#x201c;Business&#x2014;Strategic Agreements&#x201d; </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">of this Annual Report on Form 10-K.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img102984888_0.jpg" alt="img102984888_0.jpg" style="width:681px;height:321px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Figure 1. Company Pipeline</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our Strategy</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our objective is to be the leading biotechnology company developing CAR-modified gamma delta T cells for oncology. Key elements of our strategy include our plans to:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Continue to advance clinical development of ADI-001.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> ADI-001, our lead hematologic cancer product candidate, is currently in an ongoing Phase 1 study for the treatment of NHL. CD20 is a well validated target for immunotherapy for NHL. Our goal is to capitalize on our leadership in engineered allogeneic anti-CD20 gamma delta CAR T cell therapy and pursue a broad clinical development plan for multiple subtypes of NHL.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Continue to innovate and invest in the gamma delta T cell platform and pipeline</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. We expect to continue to develop product candidates in oncology based on the gamma delta T cell platform using either previously validated antigens or those that we identify and target using our TCRL technology. We may utilize additional genetic engineering, editing technologies or other technologies with the goal of further improving the activity and tolerability profile of our product candidates. A key strength of our gamma delta T cell therapy platform lies in our ability to target antigens of both known and unknown potential and devote our clinical development resources to those antigens that show the most promise in preclinical </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> analyses and early human trials.</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exploit the potential for outpatient administration</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. While we expect that the initial subjects receiving our gamma delta T cell-based therapies in clinical studies will be hospitalized for a minimum of 24-hour observation after infusion, a favorable tolerability profile may allow administration of such investigational therapies in an outpatient setting. We believe this would represent a significant competitive advantage for our gamma delta T cell-based therapies as compared to existing approved CAR-T cell therapies.</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Expand and protect our intellectual property</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. We will continue to aggressively protect the gamma delta T cell production methodology we have developed as well as specific product candidates based on proprietary antigen-binding domains. For more information on our intellectual property, see &#x201c;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Business&#x2014; Our Intellectual Property</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d; of this Annual Report on Form 10-K.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Background</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Anticancer Immune Cell Therapy</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In recent years, the field of immuno-oncology has advanced numerous therapies for the treatment of cancer. Immuno-oncology deploys the immune system to attack and, in some cases, to eliminate cancer. One of the key breakthroughs in immuno-oncology involved using T cells, a key element of the immune system, and turning them into even more potent, tumor-cell-specific killers. Researchers have achieved this improvement and targeting by loading the T cells with a gene encoding a CAR. These engineered receptors represent a powerful combination of, first, a region that binds to a target on a cancer cell and tethers the T cell to it; and second, a signal that activates the T cell to eliminate the tethered cancer cell. To our knowledge, all marketed CAR-T cells contain predominantly alpha beta T cells. While we believe the use of CAR-T cell therapies is promising, conventional CAR-T cell therapies also have some key flaws that, we believe, can potentially be addressed by using a cell population, specifically, gamma delta T cells rather than alpha beta T cells.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of  December 31, 2021, four CD19-targeting CAR-T cell therapies have been approved by the FDA for the treatment of B cell lymphomas: axicabtagene ciloleucel (Yescarta&#174;) and brexucabtagene autoleucel (Tecartus&#153;) developed by Kite Pharma, now Gilead Sciences, Inc. (Gilead); tisagenlecleucel (Kymriah&#174;), developed by Novartis; and lisocabtagene maraleucel (Breyanzi&#174;) developed by Juno Therapeutics, Inc. (now Bristol Myers Squibb Company). Among the 111 patients with diffuse large B cell lymphoma, (DLBCL), treated with Yescarta&#174; in a clinical trial, an objective response rate of 82% was observed with 54% of patients achieving a complete response. This high efficacy, however, is associated with significant adverse events, with 13% of patients experiencing grade 3 or higher cytokine release syndrome and 28% of patients experiencing grade 3 or higher neurologic events. In the Yescarta&#174; DLBCL clinical trial, three patients died due to adverse events during treatment and ten patients who were enrolled in the trial were not able to be treated due to disease progression or complications that arose during the period of time required to generate the patient-specific therapy or because of the inability to generate the desired CAR-T cells from the patient&#x2019;s cells. We believe that, despite their progress to date, currently available CAR-T cell therapies have not reached their full promise, and our gamma delta CAR-T cell approach has the potential to be a significant improvement.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The current generation of approved CAR-T cell therapies for B cell lymphomas represented by Yescarta&#174;, Tecartus&#153;, Breyanzi&#174;, and Kymriah&#174; are autologous cell therapies, that is, they are based on immune cells isolated from a patient, modified and expanded in a laboratory and then reintroduced into the same patient. One key reason for taking this autologous approach is that the cytotoxic, or, cell-killing, cells are predominantly alpha beta T cells that are used to generate these therapies and are cells that the immune system uses to recognize and attack foreign cells. If these types of T cells were to be introduced into a patient from an unrelated donor, the donor T cells would attack healthy tissues throughout the patient in a process known as graft versus host disease (GvHD) potentially causing multiple organ failure and death.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The T cells used for first-generation CAR-T cell therapies were derived from a highly abundant subclass of T cells known as alpha beta T cells. Alpha beta T cells, which comprise approximately 95% of the T cells in circulation in the body, are able to distinguish whether cells that they encounter are either normal cells that belong in the body or foreign or damaged cells that need to be destroyed. Alpha beta T cells have a receptor on their surface called a TCR which is made up of alpha and beta protein chains. These TCRs recognize targets, also known as antigens, on cells that are presented by antigen-presenting molecules encoded by the major histocompatibility complex (MHC). The MHC contains genes that encode a number of proteins with multiple variants, such that most individuals have a distinct MHC profile. During normal T cell development, those T cells that recognize the combination of the specific MHC profile and antigens that are presented by healthy cells of the specific individual are eliminated, resulting in a population of T cells that circulate throughout the body, vigilantly checking for abnormal antigens or foreign cells, including from another individual.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In one type of cellular immunotherapy known as adoptive cell therapy, naturally occurring immune cells from a patient are isolated and are activated using cytokines and tumor-specific antigens to stimulate the growth and expansion of antitumor T cells that already exist at low abundance in the patient. After activation and expansion in the laboratory, large numbers of T cells that are primed to recognize the tumor are reintroduced into the same patient.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">CAR-T cell therapies are a variant of this adoptive cell therapy in which, instead of trying to activate T cells based on the ability of naturally occurring TCRs to recognize tumor antigens, a CAR designed to recognize a specific tumor antigen is genetically introduced into T cells. These CAR-T cells are then able to destroy any cells expressing the appropriate antigen completely independent of MHC. However, without further genetic engineering, CAR-T cells derived from alpha beta T cells still have endogenous TCRs which restrict their use to the original patient.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Limitations of autologous cell therapies</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Autologous cell therapies, such as those developed by Kite Pharma and Novartis, have a number of limitations, including but not limited to the following:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Treatment delays imposed by individualized manufacturing</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Due to the individualized manufacturing process, patients must wait up to three to four weeks for the individualized products to be manufactured and administered. In the registrational trials for Yescarta&#174; and Kymriah&#174;, up to 31% of intended patients ultimately did not receive treatment primarily due to complications from the underlying disease that occurred during manufacturing or due to manufacturing failures.</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Manufacturing variability and failure</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. It was reported by Novartis in 2018 that variability in product specifications had been observed in the production of Kymriah&#174;. In addition, in approximately 9% of the cases, no product could be shipped to patients at all due to out-of-specification issues or from manufacturing failures.</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">High cost limits patient access</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The high cost of therapy and payer policies can limit access to autologous CAR-T cell therapies. According to a 2019 article published in the journal </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Managed Care</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, treating physicians estimate that the costs of autologous CAR-T cell therapies combined with patient care services are approximately $1 million per patient, generating reluctance of payers to approve these therapies for patients before they have exhausted other options. These therapies are then relegated to the most heavily pretreated patients who may be unable to withstand the severe side effects.</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Scalability.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Because each patient requires a custom manufacturing batch, the production of autologous CAR-T cells at the scale needed to meet commercial demand and anticipated label and geographic expansions may be challenging.</span></div></div>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Autologous cell therapies, such as CAR-T cells derived from alpha beta T cells, have been successful in their initial use in hematological malignancies. Furthermore, they have provided critical data that demonstrates the potential of immunocellular cancer therapies. However, manufacturing of these cells imposes some critical limitations that could be minimized if similar allogeneic cell therapies that can be given to any patient, regardless of the donor of cells, are developed. We believe that allogeneic cell therapies offer great promise for optimizing the access to therapy, overcoming manufacturing-related and cost-related limitations of autologous cell therapies.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Gamma delta T cells and their allogeneic potential</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Gamma delta T cells are a subset of T cells that have TCRs comprising gamma and delta receptor chains. In contrast to alpha beta T cells, gamma delta T cells are not selective for patient-specific MHC molecules. Therefore, gamma delta T cells from an unrelated donor can be administered to a patient without inducing GvHD and may recognize tumor-associated antigens in an MHC-independent manner. Gamma delta T cells primarily reside in tissues and comprise between 1% and 5% of circulating T cells.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Gamma delta T cells correlate with improved outcomes</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">An analysis of the transcriptional profiles of 5,872 patient tumor samples across 25 malignancies published in </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Nature Medicine</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> in 2015 found that gene signatures consistent with gamma delta T cells were the strongest predictors of overall survival.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The association of gamma delta T cells with overall survival in solid tumors had a z-score over three, meaning it was over three standard deviations above the mean, corresponding to a p value less than 0.001.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img102984888_1.jpg" alt="img102984888_1.jpg" style="width:490px;height:380px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Figure 2. Analysis of the immune cell composition of tumor samples that gamma delta T cells were highly predictive of overall survival. Adapted from Gentles et al., Nat Med. 2015; 21(8).</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additionally, high levels of gamma delta T cells have been associated with improved overall survival in acute leukemia patients who received hematopoietic stem cell transplants (HSCT). In a study published by KT Godder et al. in 2007 in the journal </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Bone Marrow Transplantation</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, those patients with high levels of gamma delta T cells after the transplant had a leukemia free survival at five-years of 54.4% and overall survival of 70.8%. Those with low levels of gamma delta T cells had a significantly lower five-year leukemia free survival of 19.1% and a five-year overall survival of 19.6%.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img102984888_2.jpg" alt="img102984888_2.jpg" style="width:311px;height:269px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Figure 3. HSCT patients who develop high levels of gamma delta T cells have improved survival. Adapted from Godder et al., Bone Marrow Transplantation 2007; 39.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The correlation between high levels of gamma delta T cells and disease-free survival extends to patients with </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">solid tumors</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. In a study published by Meraviglia et al in 2017 in the journal </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">OncoImmunology</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, across a cohort of 557 patients with colorectal cancer, those with high gamma delta T cell levels had a five-year disease-free survival rate of over 80%, and revealed that disease-free survival probability was significantly higher in CRC patients with high number of tumor infiltrating gamma delta T cells.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img102984888_3.jpg" alt="img102984888_3.jpg" style="width:343px;height:288px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Figure 4. High levels of gamma delta T cells are correlated with increased disease-free survival in colorectal cancer patients. Adapted from Meraviglia et al., Oncoimmunology 2017; 6 (10).</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We believe that these studies and others point to an important role of gamma delta T cells in disease control and overall survival and indicate that gamma delta T cell-based therapies have the potential to deliver clinically meaningful results.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Advantages of gamma delta T cell-based therapies</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Immunotherapies developed using gamma delta T cells have a number of advantages over other therapies developed using other cell types, including the following:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Lack of GvHD</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> A body of published evidence, mainly in the field of HSCT, supports the safety profile of transfer of allogeneic gamma delta T cells to patient recipients from unrelated donors. HSCT procedures containing significant numbers of gamma delta T cells were able to proceed with no signs of acute or chronic GvHD. In many cases, the presence of gamma delta T cells in the HSCT products correlated with improved clinical outcomes, indicating the antitumor potential of gamma delta T cells. Additionally, a study performed by Martin Wilhelm and colleagues in 2014 indicated that gamma delta T cells from haploidentical donors could be successfully expanded and infused in large numbers (2.17x10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> cells / kg (range, 0.9-3.84)), followed by further expansion (mean, 68-fold) in the patients without any observed GvHD.</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">MHC-independent tumor antigen recognition. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Gamma delta TCR can recognize tumor associated antigens in a MHC-independent manner, facilitating the use of products derived from donors who are unrelated to patients which may avoid the need to match the human leukocyte antigen (HLA)-type of the donor to the patient.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">  </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Tumor localization</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. In addition to being present in the circulation at low frequency, gamma delta T cells have an inherent propensity to home to tissues and tumors. Their ability to be activated in environments with low levels of oxygen such as those found in the tumor microenvironment has the potential to increase the activity of gamma delta T cells in solid tumors.</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Limited cytokine secretion</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Unlike alpha beta T cells, gamma delta T cells can be made to secrete lower levels of certain cytokines such as interleukin 2 (IL-2). This, combined with lack of recognition of normal, non-malignant, cells by of gamma delta T cells, may lower the risk of life-threatening cytokine release syndrome.</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Limited ability for tumors to escape.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Although the initial responses to immunotherapies such as antibodies and CAR-T cells are often impressive, many patients become refractory or relapse. A common mechanism for the relapse to these therapies is loss of the expression of the CAR-targeted antigen such as CD19 from tumor cells. Because gamma delta </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;visibility:hidden;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">T cells also express innate cytotoxic immune receptors, they can recognize and kill tumor cells even in the absence of the CAR-targeted tumor antigen.</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Ability to manufacture more efficiently and cost-effectively.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Unlike alpha beta T cells, therapies based on gamma delta T cells can potentially be manufactured in bulk and used in the allogeneic or off-the-shelf setting, addressing many of the shortcomings of conventional alpha beta T cell therapy.</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Potential for superior cytotoxic activity</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. T cells from some cancer patients, for example those with chronic lymphocytic leukemia, often display an exhausted, or otherwise dysfunctional, phenotype and CAR-T cell products from these cells may perform poorly. Our allogenic cell therapy is manufactured from unrelated donors whose T cells have been proven to generate highly active CAR-T cell product.</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Potential for re-dosing.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Along with increased availability of material due to the ability to utilize off-the-shelf donor-derived starting material from unrelated donors compared to conventional CAR-T cell therapies, the lack of MHC-dependent GvHD also opens up the possibility of being able to re-dose patients to achieve further clinical activity if they do not obtain an adequate clinical response from initial treatment or if they relapse. A number of studies with other CAR-T cell therapies have linked the development of cytokine release syndrome with high numbers of circulating CAR T cells following rapid alpha beta T cell proliferation. Having the option to retreat patients with gamma delta T cells provides the option of starting with a low dose and re-dosing if required.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our CAR gamma delta T cell technology</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Human gamma delta T cells can be divided into three main subsets based on their TCR delta chain usage: V&#x3b4;1, V&#x3b4;2 and V&#x3b4;3. The most abundant subset of gamma delta T cells in the circulatory system, the V&#x3b4;2 cells, is also the most well-studied. However, it is the V&#x3b4;1 subset which primarily resides in tissues and presents a favorable cytotoxic anti-tumor profile that we are activating and manufacturing using our proprietary platform technology.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">V</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x3b4;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">1 gamma delta T cells</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">V&#x3b4;1 cells have properties of both the innate and adaptive immune system, meaning that they can be activated by tumor-specific antigens as well as by general activators common to damaged or otherwise abnormal cells. Similar to other T cells, they express TCRs, but also express cytotoxicity receptors that are found on innate immune cells such as NK cells. These gamma delta T cells can induce tumor cell death through multiple mechanisms including the secretion of cytotoxic proteins such as granzymes and perforin as well as through the secretion of cytokines such as interferon gamma (IFN&#x3b3;), and tumor necrosis factor alpha (TNF&#x3b1;).</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> preclinical cancer models, V&#x3b4;1 cells are more cytotoxic and may have a longer durability than V&#x3b4;2 cells. V&#x3b4;1 cells are also more resistant to activation induced cell death (AICD), which has posed significant problems in clinical trials following chronic stimulation of V&#x3b4;2 cells. V&#x3b4;1 cells normally reside within tissues and they are able to adapt to lower nutrient availability and decreased oxygen levels, conditions which are similar to those in the microenvironments or localized areas associated with certain solid tumors. Incubation of these gamma delta T cells in conditions of low oxygen (hypoxia) that are typical of tumors has been shown to enhance their cytotoxicity.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Anticipated advantages of V</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">&#x3b4;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">1 gamma delta T cells over NK cell based therapies</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">An alternate approach to the development of allogeneic CAR T cells consists of engineered NK cell-based therapy. While both gamma delta T cell and NK cell therapy generally are not expected to cause GvHD, NK cells express a broad repertoire of both inhibitory and activating receptors and have more limited tumor induced secretion of multiple cytokines. We believe that the gamma delta T cell technology we are developing has several advantages over this approach. Unlike engineered NK cells, V&#x3b4;1 gamma delta T cells have the following advantages:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The presence of gamma delta cells in tumors is strongly correlated with positive clinical outcomes; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Can display tumor-induced secretion of multiple cytokines including expressing high levels of interferon-gamma;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Can be produced as highly homogeneous cell populations that display potent non-clinical anti-tumor activity;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Express activating receptors more predominantly; and</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Display features of adaptive immunity including, TCR-mediated, but MHC-independent, tumor antigen recognition, a long lifespan and persistence for protracted periods of time;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We believe these advantages position gamma delta T cell-based therapies to become an attractive alternative to NK based therapies for many oncology indications and lines of therapy.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Anticipated advantages of V</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">&#x3b4;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">1 gamma delta T cells over other approaches to generate allogeneic CAR-T cells</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">An alternative approach to the development of allogeneic gamma delta CAR T cells consists of introducing genetic modifications that disable the TCR in alpha beta T cells derived from donors that are unrelated to the patient. This process prevents these cells from attacking the patient&#x2019;s healthy cells. We believe that the unrelated donor-derived gamma delta T cell technology, which lacks the ability to attack healthy cells from unrelated individuals, has a number of advantages over this approach. In an allogeneic paradigm, unlike alpha beta T cells, V&#x3b4;1 gamma delta T cells have the following advantages:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Do not rely on genetic manipulations to inactivate the alpha beta TCR;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Display properties of both adaptive and innate immune systems and are capable of killing cells even if their specifically targeted CAR antigen is expressed at low levels or not present;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">May not be prone to exhaustion and are likely to persist longer;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">May maintain the capacity to home to tissues and tumors rather than predominantly residing in circulation; and</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">May be less likely to induce cytokine release syndrome due to more limited endogenous IL-2 secretion by activated cells.</span></div></div>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We believe these advantages position gamma delta T cell based therapies to become an attractive alternative to alpha beta T cell based therapies.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Anticipated advantages of V</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">&#x3b4;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">1 gamma delta T cells over bispecific antibody T cell recruitment for tumor immunotherapy</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">An alternative approach to the development of allogeneic CAR T cells consists of bispecific antibodies that are designed to crosslink T cells to specific targets on the tumor. This approach generally requires healthy and functional T cells able to attack the tumor when guided to the tumor expressing the target antigen. We believe that the unrelated donor-derived gamma delta T cell technology has a number of potential advantages over this approach. Unlike bispecific antibodies, V&#x3b4;1 gamma delta T cells have the following advantages:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Do not rely on functional T cells derived from the patient for clinical activity;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Display properties of both adaptive and innate immune systems and are capable of killing cells even if their specifically targeted CAR antigen is not present;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Maintain the capacity to home to tissues and tumors rather than predominantly residing in circulation and can actively distribute into localized tumors; and</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">May be less likely to induce cytokine release syndrome due to more limited endogenous IL-2 secretion by activated cells.</span></div></div>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We believe these advantages position gamma delta T cell-based therapies to become an attractive to bispecific-based therapies for many oncology indications and lines of therapy.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our key anticipated differentiation from gamma delta T cell competitors</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We believe that the gamma delta T cell technology that we are developing has a number of potential advantages over the technology of gamma delta T cell competitor companies, including the following:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Robust and practical proprietary antibody-based manufacturing method for gamma delta T cells</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Large-scale expansion of blood-derived gamma delta T cells</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Ability to selectively expand multiple gamma delta T cell subpopulations including highly potent V&#x3b4;1 cells</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">No potentially pro-tumorigenic Th17-type responses in our V&#x3b4;1 subpopulation</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In-house CAR target identification and verification process</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Ability to effectively target tumor-specific intracellular protein-derived peptides using proprietary TCRL antibodies</span></div></div>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We believe these advantages position our gamma delta T cell based therapies to become an attractive approach to the technologies used by other gamma delta T cell competitor companies.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Production of gamma delta T cells</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To produce gamma delta T cell-based product candidates, we isolate peripheral blood mononuclear cells, from unrelated donors that meet all the safety criteria for human cells, tissues, and cellular and tissue-based products (HCT/P), criteria for donors as outlined by the FDA in Title 21 of the Code of Federal Regulations (CFR), Part 1271. We then activate V&#x3b4;1 gamma delta T cells using a proprietary agonistic antibody and cytokines and expands these cells before introduction of replication-incompetent retroviral vectors containing the coding sequence for CAR constructs. These CAR-modified cells are further expanded, routinely greater than 6,000-fold at clinical scale, resulting in cell cultures that primarily consist of the desired gamma delta T cells. To reduce the chance of a patient developing GvHD, the remaining alpha beta T cells are then depleted using alpha-beta-specific, antibody-based techniques. The resulting gamma delta T cells are then formulated in an infusible solution to form the final drug product, which is filled into vials and then frozen to enable delivery of a post-thaw cell dose from each vial of CAR-T cells.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img102984888_4.jpg" alt="img102984888_4.jpg" style="width:604px;height:166px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Figure 5. Production process for our CAR gamma delta T cell products.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img102984888_5.jpg" alt="img102984888_5.jpg" style="width:263px;height:221px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Figure 6. Fold expansion of gamma delta T cells.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We believe that our manufacturing process, including the generation of the antibodies and retroviral vectors, meets current Good Manufacturing Practices (cGMPs). We expect to be able to produce tens to hundreds of doses from a single donor, greatly increasing the efficiency of manufacturing compared to autologous alpha beta T cell therapies. We have chosen to partner with a number of contract manufacturing organizations (CMOs) in the United States and Europe to access specific capabilities to ensure that the manufacturing process is highly scalable, and fully cGMP-compliant.  We believe this process has the potential to treat up to 1,000 patients per batch.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ADI-001, an anti-CD20 CAR gamma delta T cell therapy targeting NHL</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">B cell NHL overview</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">NHL is the most common cancer of the lymphatic system. An estimated 77,240 new cases are expected to be diagnosed in the United States in 2020, according to the web site of the U.S. National Institutes of Health (NIH). According to the cancer.net web site maintained by the American Society for Clinical Oncology (ASCO), approximately 90% of NHL patients in western countries have B cell lymphomas of various types and DLBCL is the most common and aggressive type of NHL, accounting for 30% of NHL. The second most common type is follicular lymphoma (FL), which occurs in 20% of NHL patients. Mantle cell lymphoma (MCL), is diagnosed in 5% to 7% of NHL cases.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Although B cell NHLs represent a heterogeneous set of lymphomas, many cell surface antigens are shared among them, including CD19 and CD20. First line therapy for patients with aggressive B cell NHLs, such as DLBCL, is chemotherapy in combination with radiation or rituximab, an antibody that targets CD20. According to the rituximab label as published on the FDA web site, the addition of rituximab to chemotherapy results in an approximately 10% to 15% overall increase in survival at one year compared to chemotherapy alone with almost no increase in toxicity. According to an article published by K.T. Godder et al. in the journal </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Bone Marrow Transplantation</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> in 2007, up to 50% of patients become refractory or relapse after treatment. Of those, according to an article published by Andrew R. Rezvani and David G. Maloney in the journal </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Best Practice &amp; Research Clinical Haematology</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> in 2011, approximately 60% percent are resistant to rituximab upon relapse. Subsequent chemotherapy-based therapies typically have limited efficacy in these patients and, at that point, they become candidates for treatment with allogeneic HSCT or anti-CD19 CAR-T cell therapy. Approximately 35% of patients treated with anti-CD19 CAR-T cell therapies relapse within one year, according to the label for Kymriah&#174; published on the Novartis web site.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our solution, ADI-001</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ADI-001 is a gamma delta T cell product candidate that targets malignant B-cells via an anti-CD20 CAR and via the gamma delta T cell endogenous receptors, which we are developing as an allogeneic immunocellular therapy for the treatment of B-cell NHL. ADI-001 is created from V&#x3b4;1 gamma delta T cells isolated from unrelated donors. It is manufactured in bulk under cGMP-compliant conditions and is intended to be supplied as an immediately available off-the-shelf anti-CD20 CAR-T cell therapy.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ADI-001 contains an anti-CD20 CAR that has a proprietary antigen-binding domain that recognizes a region of CD20 distinct from that recognized by rituximab. Similar to other CAR-Ts cells including the one used to create Kymriah&#174;, our CAR-T cells contain the clinically validated costimulatory domain from 4-1BB and the CD3&#x3b6;.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Clinical data</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In October 2020, the FDA cleared our IND application for ADI-001 for the treatment of NHL. The active IND enabled us to initiate the first-in-human clinical trial to assess safety and efficacy of ADI-001 in NHL patients in the first quarter of 2021. The Phase 1 study for ADI-001 will enroll up to 80 late-stage NHL patients at a number of cancer centers across the United States The study includes a dose finding portion followed by dose expansion cohorts to explore the activity of ADI-001 in multiple subtypes of NHL. Included in this trial will be previously treated patients who were not able to receive approved autologous CAR-T cell therapies due to medical, technical, logistical, or financial reasons, as well as patients who relapsed after receiving autologous CAR-T cell therapies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Patients enrolled in the trial will undergo chemotherapy-based lymphodepletion for three days followed by ADI-001 dosing by infusion on day five. Patients will be evaluated at four weeks, twelve weeks and then every three months for the first year and at months 18 and 24 after treatment. Once a recommended dose has been selected, up to 36 patients will be enrolled in indication-specific dose expansion cohorts: DLBCL, MCL, and one for all other B cell malignancies. Select patients experiencing clinical benefit with ADI-001 may be eligible for retreatment.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">An additional cohort in this trial will investigate the potential of IL-2 therapy to boost the activity and durability of ADI-001. Treatment with IL-2 is supported by preclinical data that we have generated demonstrating that IL-2 improves the antitumor</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">activity of our gamma delta T cells both </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Treatment of HSCT patients with IL-2 has also been shown to stimulate the proliferation of gamma delta T cells in the clinic.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img102984888_6.jpg" alt="img102984888_6.jpg" style="width:605px;height:247px;" />&#160;</p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(*)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">	</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Dose escalation study</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Figure 7. Phase 1 ADI-001 study patient flow.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Phase 1 Interim Clinical Data</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On December 6, 2021, we reported positive interim clinical data from the initial dose escalation portion of the Phase 1  study evaluating the safety and tolerability of ADI-001 in NHL that showed complete and near complete responses at low doses along with a generally favorable tolerability profile. We have since completed dosing of subjects in the second lowest dose level of our Phase 1 study and we are currently enrolling subjects in dose level three. We aim to provide a clinical update for ADI-001 in the first half of 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of the November 22, 2021 data cutoff, six patients had been enrolled and received ADI-001. The first two patients enrolled in the lowest dose level tested did not reach the day 28 assessment and were not evaluable for efficacy per protocol.  Three of the four evaluable patients achieved responses, including two complete responses (CR) and one partial response (PR) that investigators characterized as near complete response. Patients were heavily pre-treated, with a median of five lines of prior systemic therapy, including a patient who had received prior autologous CD19 CAR T, and achieved complete response following a single infusion of ADI-001 administered at the lowest dose level.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Of the four efficacy evaluable patients, three received ADI-001 at dose level one (30 million CAR+ cells) and one received ADI-001 at dose level two (100 million CAR+ cells). In dose level one, one patient achieved a CR, one patient achieved a PR that was characterized as near CR and one patient had progressive disease (PD). In dose level two, the first patient achieved a CR.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All evaluable patients had been heavily pre-treated with a median of five lines of prior systemic therapies. Of the three patients who achieved PR or better under Lugano 2014 criteria (ORR=75%, CR=50%), one had FL transformed into a large B-cell tumor with four prior lines of therapy, one had DLBCL with five prior lines of therapy including two cycles of anti-CD19 CAR T cell therapy, and the third had MCL with five prior lines of therapy. These patients achieved two CRs and a near CR.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Overall, ADI-001 infusions were generally well-tolerated. No dose-limiting toxicities GvHD, Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS), Grade 3 or higher Cytokine Release Syndrome (CRS) have been reported to-date, suggesting a potentially wide therapeutic window for ADI-001.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A significant increase in circulating IL-15 was observed during the 28-day window following lymphodepletion, potentially providing cytokine support for the proliferation of ADI-001. Emergence of circulating ADI-001 in the blood was observed by quantitative polymerase chain reaction and by flow cytometry, demonstrating expansion of ADI-001 in patients. Elevations in additional circulating cytokines, primarily IL-2 and IL-8 were observed during the first 14 days from dosing, consistent with the activation profile of ADI-001 and similar to the observed time-to-peak for cytokines previously reported in association with autologous alpha-beta CAR T cells.  Importantly, no meaningful increases in IL-6 were seen in association with ADI-001, except for one patient who experienced COVID-19 infection, suggesting reduced likelihood for ICANS and high-grade CRS.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:2.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Table 1:  Summary of ADI-001 interim data from two dosing cohorts*:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:12.842%;"></td>
    <td style="width:11.463%;"></td>
    <td style="width:22.858%;"></td>
    <td style="width:13.996%;"></td>
    <td style="width:13.996%;"></td>
    <td style="width:24.844%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="border-top:1.000pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;border-left:1.000pt solid rgba(0,0,0,1);vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Dose Level</span></p></td>
    <td style="border-top:1.000pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Age/Sex</span></p></td>
    <td style="border-top:1.000pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">B-cell lymphoma subtypes</span></p></td>
    <td style="border-top:1.000pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"># Prior lines of therapies</span></p></td>
    <td style="border-top:1.000pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prior CAR T?</span></p></td>
    <td style="border-top:1.000pt solid rgba(0,0,0,1);background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Best Response (BOR) by Lugano Criteria (2014)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td rowspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;border-left:1.000pt solid rgba(0,0,0,1);vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30 million CAR+ cells</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">62/F</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Transformed DLBCL&#x200b; (from chronic lymphocytic leukemia)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5 prior lines</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">No</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">PD</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">66/F</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Transformed high grade&#x200b; B cell tumor (from FL)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4 prior lines</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">No</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">PR</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(Near CR)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">75/M</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">DLBCL</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5 prior lines</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Yes (liso-cel)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">CR</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;border-left:1.000pt solid rgba(0,0,0,1);vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100 million CAR+ cells</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">62/M</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">MCL</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5 prior lines</span></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">No</span></p></td>
    <td style="border-top:1.000pt solid rgba(255,255,255,0.01);background-color:rgba(0,0,0,0);padding-top:0.010in;border-right:1.000pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(0,0,0,1);padding-right:0.010in;text-align:right;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">CR</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">*Efficacy evaluable patients as of November 22, 2021 database entry. Data are subject to further review and verification.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Preclinical data</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All preclinical experiments were conducted using anti-CD20 CAR-modified gamma delta T cells, a research version of ADI-001. We evaluated the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> potency of our anti-CD20 CAR gamma delta T cells using human-derived laboratory cell lines, known as Raji and Daudi human Burkitt&#x2019;s lymphoma cell lines, which are known to express high levels of CD20. Mixing the tumor cells with the anti-CD20 CAR gamma delta T cells resulted in apoptosis, or cell death, of the tumor cells after four hours. Increasing the ratio of the number of anti-CD20 CAR gamma delta T cells to tumor cells resulted in a higher percentage of dying tumor cells. Similar potency in the killing of target cells by anti CD20 CAR gamma delta T cells was observed in both Mino cells, a human MCL line that expresses high levels of CD20; and WILL-2 cells, cells derived from a rituximab-resistant patient with B cell lymphoma that expresses low levels of CD20. These results suggest that anti-CD20 CAR gamma delta cells can be</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">highly efficient at recognizing and eliminating tumor cells that express any level of CD20. In all cases, our gamma delta T cells that did not have anti-CD20 CAR expression also caused tumor cell death due to innate cytotoxic receptors.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img102984888_7.jpg" alt="img102984888_7.jpg" style="width:567px;height:505px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Figure 8. Anti-CD20 CAR gamma delta T cells demonstrated potent cell killing activity across multiple human tumor cell lines.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have tested the antitumor activity of our anti-CD20 CAR gamma delta T cells in multiple tumor models in immunocompromised mice including Raji tumor models, a Mino tumor model and a Granta tumor model derived from a mantle cell tumor. Five to seven days after tumors were implanted into these mice, anti-CD20 CAR gamma delta T cells were administered as a single intravenous dose. Human recombinant IL-2 was administered three times a week for the duration of the study to stimulate the gamma delta T cells. In all cases, treatment using our anti-CD20 CAR gamma delta T cells was able to arrest tumor growth. The absolute duration of these studies was not pre-specified, however each of the studies were terminated when the growth of tumors in any of the animals in the no-treatment control group (tumor-only) exceeded a pre-specified limit; in subcutaneous tumor models this limit was generally tumor growth exceeding 4000mm3. This resulted in the individual studies being run for slightly different durations.</span></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img102984888_8.jpg" alt="img102984888_8.jpg" style="width:568px;height:394px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Figure 9. Anti-CD20 CAR gamma delta T cells inhibited tumor growth in multiple animal models.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Treatment of Raji tumors in mice with anti-CD20 CAR gamma delta T cells resulted in the complete elimination of tumors in four out of six mice. Sixty days after the original &#x2014; and only &#x2013; dose of anti-CD20 CAR gamma delta T cells, the four mice with complete responses were re-challenged with Raji tumor cells. Growth of these newly introduced tumors continued to be suppressed at least until the end of the experiment at day 100. We believe that these results suggest that our gamma delta cells</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">had a long persistence </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">in vivo</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and remain active. Other preclinical experiments have shown that they can undergo up to twenty cell doublings and can have antitumor activity that can extend to six months in animal models.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img102984888_9.jpg" alt="img102984888_9.jpg" style="width:253px;height:231px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Figure 10. Gamma delta T cells retained their antitumor activity for at least 90 days in a Raji tumor model. Four of the six mice in the primary tumor challenge exhibited complete responses, and these four mice were given a second tumor challenge without additional gamma delta CAR T cells.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We performed a direct analysis of the ability of our gamma delta CAR-T cells to migrate and proliferate in tumors using a fluorescent dye technology to examine cell division. Gamma delta CAR-T cells were treated with a fluorescent dye that attaches to cellular proteins. As these fluorescent cells divided, the molecules modified with the fluorescent dye were split among the mother and daughter cells. This resulted in a reduction in the average fluorescence signal per cell. Quantification of the amount of fluorescence per cell was then used as a surrogate for the number of divisions that a cell has undergone.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Using this assay, we observed that, within six days, our CAR gamma delta T cells had undergone significant cell divisions in tumors with little replication in blood, spleen, bone marrow or liver. By contrast, in a similar experiment using CAR alpha beta T cells, it was observed that replication occurred in all tissues examined. We believe that this selective replication in tumors by CAR gamma delta T cells, compared to CAR alpha beta T cells, may contribute to increased antitumor activity and a lower risk of developing life-threatening systemic immune responses such as cytokine release syndrome.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img102984888_10.jpg" alt="img102984888_10.jpg" style="width:606px;height:220px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Figure 11. Proliferation of CAR gamma delta T cells was primarily localized in tumors, while the proliferation of CAR alpha beta T cells was observed in all tissues examined.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interleukin 15 (IL-15) is a cytokine that preferentially stimulates T cell and NK cell activation, proliferation and cytolytic activity. These functional activities of IL-15 translate to enhanced antitumor responses in multiple tumor models. IL-15 is closely related to a cytokine that is a known activator of immune responses, IL-2. Both cytokines have the potential to stimulate gamma delta T cells. IL-15 plays a more important role in maintaining T cell responses that are long-lasting and show high affinity for cancer cell targets, while IL-2 has a more significant role in activating cytotoxic responses.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The antitumor activity of our anti-CD20 CAR gamma delta T cells was tested in SRG-15 mice. These are mice that lack much of their mouse immune system but that do express human IL-15. In these studies, potent antitumor activity against Raji tumors in was observed. Furthermore, this activity was not accompanied by the development of GvHD. In contrast, mice treated with anti-CD20 CAR alpha beta T cells had antitumor responses, but subsequently experienced increased mortality due to the development of GvHD.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img102984888_11.jpg" alt="img102984888_11.jpg" style="width:258px;height:217px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Figure 12. Anti-CD20 CAR gamma delta T cells do not induce GvHD, whereas treatment with anti-CD20 CAR alpha beta cells caused GvHD that led to increased mortality.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ADI-002, an anti-GPC3 CAR gamma delta T cell therapy for HCC</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">HCC disease background</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Hepatocellular carcinoma (HCC) is the most prevalent form of liver cancer. The risk of HCC development is increased by a number of environmental and lifestyle factors such as hepatitis B and hepatitis C virus, alcohol drinking, tobacco smoking, aflatoxin exposure, obesity and diabetes. These factors lead to wide disparities in disease incidence across geographies. According to a 2013 publication by Sahil Mittal and Hashem B. El-Serag in the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Journal of Clinical Gastroenterology</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, in the U.S., the incidence is approximately six per 100,000 per year, while in sub-Saharan Africa and Eastern Asia the incidence is over 20 per 100,000 per year.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Patients diagnosed with HCC generally have a poor prognosis. The majority of patients are diagnosed with advanced disease and they have a five-year survival rate of approximately 11%, according to cancer.net, the web site of ASCO. Patients are initially treated with combinations of cytotoxic drugs or radiation. In some cases, they may also receive targeted therapies including kinase inhibitors such as lenvatinib, marketed as Lenvima&#174; by Eisai; and sorafenib, marketed as Nexavar&#174; by Bayer and subsequently cabozantinib, marketed as Cabometyx&#174; by Exelixis. These therapies, however, have significant toxicities and limited clinical benefit with progression free survival of less than eight months. Checkpoint immunotherapies such as pembrolizumab and nivolumab have demonstrated some efficacy in HCC, although response rates are less than 20% according to the label for pembrolizumab, marketed by Merck as Keytruda&#174;. The combination of both nivolumab and ipilimumab, despite increased toxicities, increased this response rate to 33%. We believe these results demonstrate that there is significant unmet need in HCC and that there is potential to treat HCC with immunotherapy.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">GPC3, a tumor-associated antigen</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">GPC3 is a tumor-associated antigen that is expressed in many tumors but in almost no normal tissues other than embryonic liver and kidney or placenta.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Glypican 3 Expression in Tumors*</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:57.188%;"></td>
    <td style="width:1.361%;"></td>
    <td style="width:0.904%;"></td>
    <td style="width:10.826%;"></td>
    <td style="width:0.882%;"></td>
    <td style="width:1.34%;"></td>
    <td style="width:13.145%;"></td>
    <td style="width:1.34%;"></td>
    <td style="width:13.015%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="5" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">No. (%) Staining</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Tumor Entity</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">No. of Cases</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Negative</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Positive</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Hepatocellular carcinoma</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">44</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15 (34)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29 (66)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Squamous cell carcinoma of the lung</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23 (46)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27 (54)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Liposarcoma</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14 (48)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15 (52)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Testicular nonseminomatous germ cell tumor</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">62</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30 (48)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">32 (52)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cervical intraepithelial neoplasia (grade 3)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17 (59)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12 (41)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Malignant melanoma</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">48</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">34 (71)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14 (29)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Adenoma of the adrenal gland</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11 (73)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4 (27)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Schwannoma</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">46</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">34 (74)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12 (26)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Malignant fibrous histiocytoma</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22 (76)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7 (24)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Adenocarcinoma of the stomach (intestinal subtype)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">45</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">36 (80)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9 (20)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Chromophobe renal cell carcinoma</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12 (80)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3 (20)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Invasive lobular carcinoma of the breast</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">46</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">37 (80)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9 (20)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Medullary carcinoma of the breast</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25 (83)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5 (17)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Squamous cell carcinoma of the larynx</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">49</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">41 (84)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8 (16)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Small cell carcinoma of the lung</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">49</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">41 (84)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8 (16)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Invasive transitional cell carcinoma of the urinary bladder</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">43</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">36 (84)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7 (16)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Mucinous carcinoma of the breast</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">26</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22 (85)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4 (15)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Squamous cell carcinoma of the cervix</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">41</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">35 (85)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6 (15)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Figure 13. Screening of a panel of over 4,000 tumor samples found that GPC3 is expressed in numerous cancers. Baumhoer et al., Am. J. Clin. Pathol. 2008;129.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In a trial conducted by David Ho at the University of Hong Kong and colleagues and published in the journal </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">PLOS One</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> in 2012, high levels of GPC3 are detected by immunohistochemistry in a large proportion of HCC tumor tissue samples, but no GPC3 can be detected in adjacent normal cells.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img102984888_12.jpg" alt="img102984888_12.jpg" style="width:562px;height:214px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Figure 14. Immunohistochemistry detected strong signals of GPC3 in liver tumor tissue, but negative staining for GPC3 was detected in the adjacent non-tumorous tissue. Adapted from Ho et al., PLoS One. 2012;7(5).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our solution, ADI-002</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ADI-002 is an anti-GPC3 CAR gamma delta T cell product candidate that we are developing for the treatment of solid tumors. We believe that modification of V&#x3b3;1 gamma delta T cells, which have an inherent tumor homing ability, with a CAR that is specific for GPC3, may result in a therapeutic product able to have potent antitumor activity in patients suffering from multiple solid tumors. On January 28, 2022, Regeneron exercised its option to license the exclusive, worldwide rights to ADI-002 pursuant to our agreement signed in 2016. In conjunction with the exercise of its option, Regeneron paid us an exercise fee of $20.0 million. We elected not to exercise our option to co-fund the further development of ADI-002. Accordingly, Regeneron is responsible, at its sole cost, for all development, manufacturing and commercialization of ADI-002 and we are entitled to royalties of any future sales of such products by Regeneron. See the section titled </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">&#x201c;Business&#x2014;Strategic Agreements&#x201d;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of this Annual Report on Form 10-K.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To enhance the proliferative ability and durability of our anti-GPC3 CAR gamma delta T cells, we engineered these cells to express soluble IL-15. We anticipate that the tumor homing ability of gamma delta T cells will potentially result in expression</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">of IL-15 predominantly in tumors. In combination with the inherent secretion of factors such as interferon gamma from activated gamma delta T cells, the secretion of IL-15 is anticipated to lead to reversal of immunosuppressive effects in the tumor microenvironment and direct stimulation of the gamma delta T cells.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We demonstrated in </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> assays that our anti-GPC3 CAR gamma delta T cells have potent and GPC3-antigen-dependent cell killing activity. When our anti-GPC3 CAR-T cells were added to HepG2 cells, a cell line expressing GPC3 that was derived from a patient with HCC, an increase in tumor cell killing was observed. Gamma delta T cells prepared without the addition of our anti-GPC3 CAR were still able to kill the HepG2 cells, only with less potency at 18 hours. We believe that this CAR-independent killing activity was driven by innate receptors on our gamma delta T cells and that this innate antitumor activity may provide meaningful antitumor clinical activity in cases in which tumors may lose the expression of the targeted GPC3 antigen. Loss of tumor-expressed antigens represents a significant mechanism of escape from antitumor activities from other immunotherapies such as anti-CD19 CAR-T cell therapies. The ability to continue to have antitumor activity driven by the innate immune cell properties of our gamma delta T cells is a distinct advantage compared to alpha beta T cells, which lack this capability. Our gamma delta T cells had no cell killing activity when added to RAT2 normal fibroblasts that do not express GPC3.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img102984888_13.jpg" alt="img102984888_13.jpg" style="width:327px;height:273px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Figure 15. Expression of an anti-GPC3 CAR in gamma delta T cells led to potentiation of killing of HepG2 hepatocellular carcinoma cell line.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Anti-GPC3 CAR gamma delta T cells had dose-dependent antitumor activity in HepG2 tumors in immunodeficient mice. HepG2 tumor cells were inoculated into immunocompromised mice and allowed to grow to a volume of 200 mm3 over a period of approximately eight days. A single dose of anti-GPC3 CAR gamma delta T cells was then administered and tumor growth at day 37 was assessed. High doses of anti-GPC3 gamma delta T cells led to complete suppression of tumor growth.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img102984888_14.jpg" alt="img102984888_14.jpg" style="width:501px;height:194px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Figure 16. Dose-dependent inhibition of HepG2 tumor growth by anti-GPC3 gamma delta T cells</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Future clinical candidates in solid tumors.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition to the product candidates described above, we anticipate many further opportunities for developing product candidates based on our gamma delta T cell technology. We believe that the</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">spectrum of indications that products such as CAR-T cell therapies have been able to address has been limited by two factors: the weak ability of alpha beta T cell-based therapies to penetrate solid tumors, and the scarcity of tumor-specific antigens on the cell surface that can be targeted by antibody-derived binding domains that are an essential component of the CAR constructs. We believe that the tumor homing ability of our gamma delta T cell technology represents a potential solution to the solid tumor localization problem and our TCRL antibody technology can be used to identify and target tumor-specific antigens.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The tumor recognition challenge</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Therapeutics such as antibodies and CARs recognize cell surface molecules. In HCC and select other tumors, there are proteins such as GPC3 which are selectively expressed on the surface of tumors cells that can be used as antigens for immune-targeted therapy. The lack of their expression on normal cells limits the potential of on-target, off-tumor systemic toxicities. Surface-expressed proteins that are strictly expressed only on tumor cells are, however, rare. In most cases surface expressed antigens such as CD19 and CD20 are expressed both on hematopoietic tumor and normal cells. Therapies that target CD19 or CD20 therefore result in killing of both tumor and normal cells. In hematological malignancies these therapies result in systemic depletion of normal B cells. However, this is mechanism-based toxicity can be managed in clinical practice. Challenges arise with antigens such as epidermal growth factor receptor (EGFR) that is overexpressed on some types of tumor cells, but also expressed on normal epithelial cells elsewhere in the body. Dosing with anti-EGFR antibodies has led to significant dermatological and cardiac toxicities.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Intracellular proteins represent nearly half of the proteins found in human cells. These proteins provide an untapped reservoir of potential tumor-specific antigens that are inaccessible to traditional antibody-binding domains. Immune surveillance for these intracellular proteins is normally done by alpha beta T cells. These intracellular proteins are chopped up by a cell component known as the proteasome into short peptides between eight and ten amino acids long. These short peptides are then presented to the T cells by the MHC. TCRs on the T cells are then able to recognize the complex of the peptide and the MHC, triggering creation of T cell populations prepared to attack these specific sequences.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Gamma delta T cells have advantages compared to alpha beta T cells with regard to their potential as allogeneic therapies, their ability to localize to tumors and their retention of innate immune signaling pathways. However, to be most effective they need to be able to be engineered to attack specific tumors.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our solution, TCRLs</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have developed an antibody platform that enables the discovery of TCRL antibodies that recognize peptides that are presented on the cell surface by specific MHC molecules. In effect, our TCRL antibodies have the same antigen recognition properties as TCRs but are highly specific for a single tumor antigen and MHC molecule. They do not recognize other MHC molecules or antigens that may be expressed by healthy cells.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img102984888_15.jpg" alt="img102984888_15.jpg" style="width:273px;height:236px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Figure 17. Schematic diagram of the interaction between our TCRL antibodies and tumor-specific peptides presented by the MHC.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">TCRLs are conventional antibodies with antigen binding domains that specifically recognize peptide-MHC complexes that can be used to create CARs. Introduction of these CARs into our gamma delta T cells enables them to target tumors expressing intracellular tumor antigens when these antigens are selectively presented by MHC on the surface of tumor cells. Gamma delta CAR-T cells generated using TCRLs open up the potential to bring immune cell therapy to tumors that lack tumor-specific surface antigens, a group that includes most solid tumors.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The TCRL discovery process starts by carrying out an analysis of the peptides expressed by MHC receptors in a panel of hundreds of tumor and normal tissues. In searching for candidate peptides, we focus on differentially expressed peptides that are broadly expressed in tumors but that are not found in normal tissues. Candidate peptides are then validated by expression analysis both in other tissues as well as in databases. Those peptides that, based on bioinformatic analysis, are predicted to have minimal cross-reactivity with peptides from normal cells are then further prioritized. This peptide discovery process leads, step-by-step, to the narrowing of the list of potential candidates by approximately one thousand-fold. Once a tractable number of remaining candidates has been identified, a population that includes the most promising ones, antibodies are then created that are specific to the complex of an MHC receptor and the bound peptides. These antibodies mimic key aspects of tumor as recognized by the immune system. By creating CARs that incorporate these antigen-recognition templates in gamma delta T cell-based product candidates, we create a set of candidates designed to specifically attack tumors by virtue of their intracellular proteins.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Tyrosinase is a well-validated tumor-expressed antigen for which we have developed TCRLs. The specificity for a mouse and a humanized version of one of these TCRLs was determined by comparing their binding affinity</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">to that of a series of peptides that contained single amino acid changes. It was learned that changes to any of the internal eight amino acid positions to the amino acid alanine led to reductions in binding of 70% or greater. Substituting any amino acid in a non-anchor position resulted in substantial loss of binding and indicates the high degree of specificity that the TCRL antibody has for the targeted MHC peptide complex.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img102984888_16.jpg" alt="img102984888_16.jpg" style="width:597px;height:209px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Figure 18. Single amino acid changes to the targeted peptide reduced binding by at least 70 percent.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The antigen-binding domain from a tyrosinase TCRL was incorporated into a CAR and introduced into our gamma delta T cells to assess cell killing activity against tumor cell lines. These anti-Tyr CAR gamma delta T cells led to cell killing of WM266.4 human metastatic melanoma tumor cells, which are known to express tyrosinase. Anti-Tyr CAR gamma delta T cells, however, had no cell killing activity when tested against ten other cell lines from tumors such as colon, bladder and pancreatic cancers, B cell leukemia and retinoblastoma &#x2013; all of which do not express tyrosinase. That observation points to a desirable level of specificity for our anti-Tyr CAR gamma delta T cells and to an important </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> proof of concept.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furthermore, these anti-Tyr CAR gamma delta T cells had potent antitumor activity in a WM266.4 tumor model leading to tumor shrinkage within five days of administration and a durable antitumor response through 27 days. Although the TCRL-based</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">CAR that is generated binds to an MHC-peptide complex, it does not induce the GvHD that is seen with alpha beta T cells because it recognizes a single peptide that has been selected to be highly specific for tumor cells.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img102984888_17.jpg" alt="img102984888_17.jpg" style="width:452px;height:213px;" />&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Figure 19. Anti-Tyr CAR gamma delta T cells showed potent antitumor activity in a WM266.4 melanoma model.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have generated TCRLs against a number of solid tumor antigens which are being evaluating in animal models. We believe that the combination of our gamma delta and TCRL technology provides the basis for a new generation of CAR-T cell therapies that have the potential to transform the treatment of solid tumors.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="our_intellectual_property"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Our Intellectual Property</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our gamma delta T cell-based product candidates and substantially all of our intellectual property have been developed by us, with certain antigen binding domains derived from our collaboration with Regeneron. Additional intellectual portfolio assets were acquired in 2016 via acquisition of Applied Immune Technologies Ltd. (AIT), which is now our wholly owned subsidiary, Adicet Bio Israel, Ltd. We strive to protect and enhance the proprietary technology, inventions and improvements that are commercially material to our business, including seeking, maintaining and defending our patent rights.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our policy is to develop and maintain protection of our proprietary position by, among other methods, filing or in-licensing United States and foreign patents and applications related to our technology, inventions, and improvements that are material to the development and implementation of our business. We also rely on trademarks, trade secrets, know-how, continuing technological innovation, confidentiality agreements, and invention assignment agreements to develop and maintain our proprietary position.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our patent portfolio includes protection for our lead product candidates, ADI-001 and ADI-002, as well as our other research-stage candidates. As of February 23, 2022, there are multiple patent families comprising three pending United States non-provisional applications and over 30 corresponding foreign patent applications pending in such jurisdictions as Australia, Canada, China, Europe, Japan, Russia, and South Africa with claims directed to reagents and related protocols for gamma delta T cell expansion and resulting compositions of matter encompassing both ADI-001 and ADI-002, which, if issued, are expected to expire between 2035 and 2038. The first U.S. non-provisional application in our original patent family recently granted as U.S. Patent No. 11,135,245, expiring on May 19, 2038, and the pending U.S. non-provisional application in our second patent family stands allowed.  As of February 23, 2022, there are also two patent families comprising two U.S. non-provisional applications  and over 25 corresponding foreign patent applications pending in such jurisdictions as Australia, Canada, China, Europe, Israel, Japan, South Korea, Mexico, New Zealand, Russia, Singapore and South Africa , with claims directed to CAR constructs and antigen binding domains relating to ADI-001 and ADI-002, as well as their methods of use for certain indications, preconditioning methods, and dosing regimens, where applications claiming the benefit of these PCT applications, if issued, would expire between 2038 and 2039. Additionally, we have one pending U.S. provisional application directed to certain methods of treatment using ADI-001, and another pending U.S. provisional application directed to certain proprietary antibodies to GPC3 and methods of use thereof. With respect to ADI-001, we have a collaboration with Regeneron which grants us access to certain proprietary antigen binding domains covered by Regeneron&#x2019;s patent rights, including in particular the antigen binding domain incorporated into ADI-001.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additionally, there are multiple granted patents and pending patent applications in the United States and internationally directed to our TCRL platform technology, with actual and, in the case of pending applications, anticipated expiration dates between 2021 and 2037. Although certain earlier patents relating to our TCRL platform technology will expire in 2021, other patents covering this technology remain in force, or are expected to issue from pending applications, including three pending patent families directed to certain carcinoma, melanoma and glioblastoma targets, are expected to expire between 2036 and 2037. As a result, we do not expect that the expiration of the earlier patents in our TCRL portfolio, individually or in the aggregate, will have a material adverse effect on our future operations or financial position.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The term of individual patents depends upon the legal term of the patents in the countries in which they are obtained. In most countries in which we file, the patent term is 20 years from the date of filing of the first non-provisional application to which priority is claimed. In the U.S., patent term may be lengthened by patent term adjustment, which compensates a patentee for administrative delays by the United States Patent and Trademark Office in granting a patent or may be shortened if a patent is terminally disclaimed over an earlier-filed patent. In the U.S., the term of a patent that covers an FDA-approved drug may also be eligible for a patent term extension of up to five years under the Hatch-Waxman Act, which is designed to compensate for the patent term lost during the FDA regulatory review process. The length of the patent term extension involves a complex calculation based on the length of time it takes for regulatory review. A patent term extension under the Hatch-Waxman Act cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval and only one patent applicable to an approved drug may be extended. Moreover, a patent can only be extended once, and thus, if a single patent is applicable to multiple products, it can only be extended based on one product. Similar provisions are available in Europe and certain other foreign jurisdictions to extend the term of a patent that covers an approved drug.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our commercial success depends in part on our ability to obtain and maintain proprietary protection for our product candidates, as well as novel discoveries, core technologies, and know-how, as well as our ability to operate without infringing on the proprietary rights of others and to prevent others from infringing our proprietary rights.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The patent positions of companies like us are generally uncertain and involve complex legal, scientific, and factual questions. In addition, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and its scope can be reinterpreted after issuance. Consequently, we do not know whether any of our product candidates will be protectable or remain protected by enforceable patents or will be commercially useful in protecting our commercial products and methods of using and manufacturing the same. We also cannot predict whether the patent applications it is currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient proprietary protection from competitors. Any patents that we hold or control may be challenged, circumvented or invalidated by third parties. In addition, while we have confidence in our agreements and security measures, either may be breached, and we may not have adequate remedies. Further, our trade secrets may otherwise become known or independently discovered by competitors.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have licensed various intellectual property and trade secrets to third parties for purposes of collaboration, product development and research and development.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="strategic_agreements"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Strategic Agreements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">License and Collaboration Agreement with Regeneron</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On July 29, 2016, our wholly owned subsidiary, Adicet Therapeutics, Inc. (Former Adicet), entered into a license and collaboration agreement with Regeneron, which was amended in April 2019, with such amendment becoming effective in connection with Regeneron&#x2019;s investment in Former Adicet's Series B preferred stock financing transaction in July 2019 (as amended, referred to as the Regeneron Agreement) when Former Adicet was an early-stage, privately held company.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Agreement Structure.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The Regeneron Agreement has two principal components: (a) a research collaboration component under which the parties will research, develop, and commercialize next-generation engineered gamma delta immune cell therapeutics (ICPs) namely engineered gamma delta immune cells with CARs and TCRs directed to disease-specific cell surface antigens, which includes the grant of certain licenses to intellectual property between the two parties, and (b) for a certain period following the effective date, a license to us to use certain of Regeneron&#x2019;s proprietary mice to develop and commercialize ICPs generated by us, with certain limitations relating to targets under the Regeneron Agreement.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research Collaboration.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Research activities under the collaboration are governed by research plans, which include the strategy, goals, activities, and responsibilities of the parties with respect to a target. We are primarily responsible for generating, validating, and optimizing ICPs, developing processes for manufacture of ICPs, and certain preclinical and clinical manufacturing activities for ICP&#x2019;s; Regeneron&#x2019;s key responsibility is generating, validating, and optimizing CARs and TCRs that bind to the applicable target. The parties have formed a joint research committee to monitor and govern the research and development efforts during the research program term.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Rights to Research Targets.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Under the terms of the collaboration, the parties will conduct research on mutually agreed upon targets. Regeneron may obtain exclusive rights for the targets that it chooses in accordance with the target selection mechanism set forth in the Regeneron Agreement, and we similarly may obtain exclusive rights for targets it chooses in accordance with such target selection mechanism. We have the right to develop and commercialize ICPs to the first collaboration target to come out of the research program. On January 28, 2022, we received a payment of $20 million from Regeneron for exercise of its option to license exclusive rights to ADI-002 and Regeneron potentially has additional options to other ICP targets under the Regeneron Agreement. For those targets it does not have an option to license, Regeneron has a right of first negotiation for up to two targets. Regeneron has the right to terminate the research program in its entirety (a) for convenience on six months prior written notice given at any time after December 31, 2019, or (b) following a change of control (as defined in the Regeneron Agreement) of us. The parties mutually agreed to their first product declaration criteria for collaboration ICP, CD20, in 2018.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">26</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Rights to Adicet-Developed Targets.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Regeneron has an exclusive license to use targeting moieties generated by us by its use of Regeneron&#x2019;s proprietary mice to develop and commercialize non-ICPs.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Exclusivity</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. During the five-year target selection period that expired in July 2021, we were not permitted to directly or indirectly research, develop, manufacture or commercialize an ICP, or grant a license to do the foregoing, except pursuant to the Regeneron Agreement. For so long as either party is researching or developing an ICP to a target under the research program, neither party may research, develop, manufacture or commercialize any other ICP to such target, or grant a license to do the foregoing. And for so long as a party is researching, developing or commercializing an ICP to target that is licensed to it (and royalty bearing) under the agreement, neither party may research, develop, manufacture or commercialize any other ICP to such target, or grant a license to permit another party to do the foregoing. These exclusivity obligations are limited to engineered gamma delta immune cells to targets reasonably considered to have therapeutic relevance in oncology. The Regeneron Agreement includes certain exceptions to the exclusivity obligations of the parties, including with respect to targets that are rejected by one party in the target selection process, as well as protections in the event of a change of control of a party where the acquirer has a competing program.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Co-Funding and Profit Sharing. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have an option to co-fund specified portions of the future development costs for, and to co-promote, ICPs to a target for which Regeneron has exercised an option, and to participate in the profits for such target. We have the right to exercise this right in various geographic regions, including on a worldwide basis. In the event we exercise such right, the parties will share further development costs and profits proportionally to their co-funding percentages.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Financial Terms.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> We received a non-refundable upfront payment of $25.0 million from Regeneron upon execution of the Regeneron Agreement and received an aggregate of $20.0 million of additional payments for research funding from Regeneron as of December 31, 2021. On January 28, 2022, we received payment of $20.0 million from Regeneron for exercise of its option to license exclusive rights to ADI-002. Regeneron has additional options to other ICP targets under the Regeneron Agreement which may entitle us to exercise fees of up to an aggregate of $80.0 million. For each collaboration ICP, we have a specified period of time to elect to co-fund the future development costs and participate in any potential profits with Regeneron up to a specified co-funding percentage in various geographic regions. If we do not exercise our right to co-fund the development of such collaboration ICPs, Regeneron must also pay us high single digit royalties as a percentage of net sales for ICPs to targets for which it has exclusive rights, and low single digit royalties as a percentage of net sales on any non-ICP product comprising a targeting moiety generated by us through the use of Regeneron&#x2019;s proprietary mice. We elected not to exercise our option to co-fund the development of ADI-002. Additionally, under the Regeneron Agreement, we must pay Regeneron mid-single to low double digit, but less than teens, of royalties as a percentage of net sales of ICPs to targets for which we have exercised exclusive rights, and low to mid-single digit of royalties as a percentage of net sales of targeting moieties generated from our license to use Regeneron&#x2019;s proprietary mice. Royalties are payable until the longer of the expiration or invalidity of the licensed patent rights or twelve (12) years from first commercial sale.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Other Terms</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Regeneron Agreement contains customary representations, warranties and covenants by us and Regeneron and includes (i) an obligation of ours to use commercially reasonable efforts to develop and commercialize at least one product based on a collaboration ICP that is not an optioned collaboration ICP for each collaboration target and (ii) an obligation of Regeneron to use commercially reasonable efforts to develop and commercialize at least one product based on an optioned collaboration ICP for each collaboration target. We and Regeneron are required to indemnify the other party against all losses and expenses related to breaches of the representations, warranties and covenants under the Regeneron Agreement.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Term and Termination.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The term of the Regeneron Agreement expires, on a product-by-product basis, on the expiration of the obligation to pay royalties for such product. The Regeneron Agreement is subject to early termination by either party upon uncured material breach by the other party. The licenses to develop and commercialize an ICP to a target that one party has exclusively licensed may be terminated by such party for convenience.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Equity Investments.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> In connection with the collaboration, Regeneron and we entered into a side letter pursuant to which, among other matters, Regeneron was granted certain stockholder rights and investment rights in connection with our next equity financing that met certain criteria and in connection with an initial public offering by us. Regeneron exercised its investment right and purchased approximately $10.0 million of our Series B preferred stock in a private placement transaction in July 2019.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="license_agreement_with_trdf"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">License Agreement with TRDF</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We and our wholly owned subsidiary, Adicet Bio Israel, Ltd. (formerly AIT), are parties to an Amended and Restated License Agreement dated May 21, 2014, as was amended in June 2015 and January 2016, with Technion Research and Development Foundation Ltd. (TRDF) the technology transfer subsidiary of Technion &#x2013; Israel Institute of Technology (Technion). The license agreement provides us with an exclusive, royalty-bearing, worldwide license, with a right to grant sublicenses, to make use of certain TRDF patents and know-how relating to moieties that recognize and bind to TCRLs, along with certain improvements and research results developed at TRDF and relating to either the licensed patents and know-how of TCRL, in each case for the purposes of research, development, and commercialization of specified products. We further obtained joint ownership rights in improvements, developments, and inventions developed in the laboratory of a specified professor under certain conditions, including where we provided specified amounts of funding for research specific to TCRL compounds. TRDF</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">also grants us an exclusive, worldwide, assignable, sublicensable license to TRDF&#x2019;s rights in such jointly owned improvements, developments, and inventions. Technion further agrees not to enforce against us any TCRL-related technology owned by Technion but not licensed to us under the agreement, and to require its licensees to agree to the same. We are required to meet certain diligence obligations to preserve our exclusive licenses. Either Adicet or Technion may terminate the agreement or a specific license if the other party materially breaches its obligations under the agreement or with respect to a specific license granted under it and fails to cure that breach. We have the right to terminate the agreement at any time by providing notice to TRDF.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In return for the license, We are required to pay TRDF, for ten (10) years after the first commercial sale of a product for which it owes royalties under the agreement, on a licensed-product-by-licensed-product basis, (i) certain royalties in the low single-digit percentages of all net sales by us and any of our controlled affiliates, and (ii) the lesser of (a) a low single-digit percentage of net sales of our sublicensees, or (b) low double-digit percentage of amounts received by us or our controlled affiliates in the form of royalties on net sales from our sublicensees, subject to certain reductions. Furthermore, we agreed to pay for all patent filing and maintenance expenses for the patents included in the licenses granted to us by TRDF, with limited exceptions.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the agreement, TRDF reserves the right, for itself, alone or with other certain academic institutions, to utilize the licensed technology solely for educational and non-commercial research purposes.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The license agreement continues in full force and effect on a product-by-product and country-by-country basis until the expiration of all payment obligations for any licensed product as described above. Upon the expiration, we will have a fully paid-up, worldwide, non-exclusive license (with the right to grant sublicenses) to develop, have developed, manufacture, have manufactured, use, market, offer for sale, sell, have sold, import, export, and otherwise transfer physical possession or title to products for which royalties would have otherwise been due under the agreement.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1260416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Manufacturing</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are developing and enabling scalable and propriety cGMP-compliant manufacturing processes. We have invested resources to optimize our manufacturing process and plans to continue to invest to continuously improve our production and supply chain capabilities over time.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We manufacture cell-based immunotherapy products based on gamma delta T cells obtained from the blood of donors who are unrelated to the patients that will be treated. These products are classed as allogeneic cell therapy products. Donor-derived blood is fractionated and the fractions containing gamma delta T cells are frozen prior to use in future manufacturing campaigns. We believe that our freezing and storing of the donor blood products allows us to efficiently schedule subsequent manufacturing steps. After obtaining blood products from unrelated donors the manufacturing process begins with the activation of a subpopulation of gamma delta T cells using an antibody that is proprietary to us. This antibody, in combination with other factors including the cytokine, IL-2, induces gamma delta T cells to proliferate, whereupon we expose the cells to a viral vector that transfers a gene sequence encoding a CAR, or other gene sequences, to the proliferating cells. This step is referred to as the transduction step. Following the transduction step gamma delta T cells are induced to proliferate further with IL-2 before an enrichment step that increases the proportion of gamma delta T cells, removes unwanted residual alpha beta T cells and results in the CAR-modified gamma delta T cells drug product. CAR-modified gamma delta T cell products are then frozen in single-use vials for long-term storage at cryogenic temperatures. These storage conditions are designed to ensure stability of the cell-based drug products for protracted periods of time. The storage in singe use vials is designed to simplify the handling and treatment administration. Just prior to administration of treatment, the vials will be thawed and then the contents infused into the patient. We believe that the single manufacturing process we are developing will be able to be completed in approximately two weeks and will result in sufficient quantities of drug product to treat numerous patients.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To date, we currently rely, and expects to continue to rely, on third parties for the manufacture of our product candidates and any products that we may develop. We have chosen to partner with a number of CMOs in the United States and Europe to access specific capabilities to ensure that the manufacturing process is highly scalable, closed and fully cGMP compliant. This strategy allows us to maintain a more flexible infrastructure while focusing our expertise on developing our products. In addition to the quality management systems utilized by strategic manufacturing partners, we have established a quality control and quality assurance program, which includes a set of standard operating procedures and specifications designed to ensure that our products are manufactured in accordance with cGMPs, and other applicable domestic and foreign regulations.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For example, we currently engage a single US-based third-party manufacturer to provide the active pharmaceutical ingredient for ADI-001. We also utilize separate third party contractors to manufacture cGMP-compliant starting and critical materials that are used for the manufacturing of our product candidates, such as donor blood products, gamma delta T cell activating antibody and viral vectors that are used to deliver the applicable CAR gene into the T cells. We believe all materials and components utilized in the production of the cell line, viral vector and final gamma delta T cell product are available from qualified suppliers and suitable for pivotal process development in readiness for registration and commercialization. Going forward, we intend to continue to expand our manufacturing capability through agreements with leading cell therapy CMOs.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">28</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If any of our current manufacturers becomes unavailable to us for any reason, we believe that there are a number of potential replacements, although we would likely incur some delay in identifying and qualifying such replacements. We plan to continue to create a robust supply chain with redundant sources of supply comprised of both internal and external infrastructure.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Competition</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The pharmaceutical and biotechnology industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. We face potential competition from many different sources, including existing and novel therapies developed by biopharmaceutical companies, academic research institutions, governmental agencies and public and private research institutions, in addition to standard of care treatments.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Novartis and Kite Pharma (now Gilead) were the first to achieve FDA approval for autologous T cell therapies. In August 2017, Novartis obtained FDA approval to commercialize Kymriah&#174;, for the treatment of children and young adults with B-cell acute lymphoblastic leukemia (ALL) that is refractory or has relapsed at least twice. In May 2018, Kymriah&#174; received FDA approval for adults with relapsed or refractory (R/R) large B-cell lymphoma. In October 2017, Kite Pharma obtained FDA approval to commercialize Yescarta&#174;, the first CAR T cell product candidate for the treatment of adult patients with R/R large B-cell lymphoma. In July 2020, Gilead obtained FDA approval to commercialize Tecartus&#153;, the first CAR T cell product candidate for the treatment of adult patients with R/R MCL. In February 2021, Bristol Myers Squibb obtained FDA approval to commercialize Breyanzi&#174; for the treatment of adults with R/R large B-cell lymphoma.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Due to the promising therapeutic effect of T cell therapies in clinical trials, we anticipate increasing competition from existing and new companies developing these therapies, as well as in the development of allogeneic T cell therapies generally. Potential T cell therapy competitors include, but are not limited to:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Allogeneic T </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">cell therapy competition: Atara Biotherapeutics, Inc., Allogene Therapeutics, Inc., Cellectis, S.A., Celyad S.A., CRISPR Therapeutics AG, Editas Medicine, Inc., Fate Therapeutics Inc., Gilead Sciences, Inc., Intellia Therapeutics, Inc., Poseida Therapeutics, Inc., Precision Biosciences, Inc., Immatics Biotechnologies GmbH, GammaDelta Therapeutics Limited, TC BioPharm Limited, Incysus Therapeutics, Inc. and Gadeta BV.</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Autologous T cell therapy</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> competition</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">: Adaptimmune Therapeutics PLC, Autolus Therapeutics plc, bluebird bio, Inc., Bristol-Myers Squibb Company, Gilead Sciences, Inc., Johnson &amp; Johnson, Iovance Biotherapeutics, Inc., Mustang Bio, Inc., Novartis International AG, TCR&#xb2; Therapeutics Inc. and Tmunity Therapeutics, Inc.</span></div></div>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Although we believe our development of proprietary processes for engineering and manufacturing gamma delta T cells expressing CARs is unique due to what we believe is the enormous potential of these cells, it is likely that additional competition may arise from existing companies currently focusing on development of alpha beta or gamma delta T cell therapies, or from new entrants in the field.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Competition may also arise from non-cell based immune oncology platforms. For instance, we may experience competition from companies, such as Amgen Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG, Genmab A/S, GlaxoSmithKline plc, MacroGenics, Inc., Merus N.V., Regeneron Pharmaceuticals, Inc., and Xencor Inc., that are pursuing bispecific antibodies, which target both the cancer antigen and T cell receptor, thus bringing both cancer cells and T cells in close proximity to maximize the likelihood of an immune response to the cancer cells. Additionally, companies, such as Amgen Inc., AbbVie, Daiichi Sankyo Company, Limited, GlaxoSmithKline plc, ImmunoGen, Inc., Immunomedics, Inc., and Seattle Genetics, Inc., are pursuing antibody drug conjugates, which utilize the targeting ability of antibodies to deliver cell-killing agents directly to cancer cells.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Many of our competitors, either alone or with their collaboration partners, have significantly greater financial resources and expertise in research and development, preclinical testing, clinical trials, manufacturing, and marketing than we do. Future collaborations and mergers and acquisitions may result in further resource concentration among a smaller number of competitors.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our commercial potential could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for our own products, which could result in our competitors establishing a strong market position before we are able to enter the market or make our development more complicated. The key competitive factors affecting the success of all of our programs are likely to be efficacy, safety and tolerability profile, convenience, price, reimbursement and cost of manufacturing.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">These competitors may also vie for a similar pool of qualified scientific and management talent, sites and patient populations for clinical trials, and investor capital, as well as for technologies complementary to, or necessary for, our programs.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Government Regulation and Product Approval</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As a biopharmaceutical company that operates in the United States, we are subject to extensive regulation. Our cell products will be regulated as biologics. With this classification, commercial production of our products will need to occur in registered facilities in compliance with cGMP for biologics. The FDA categorizes human cell- or tissue-based products as either minimally manipulated or more than minimally manipulated and has determined that more than minimally manipulated products require clinical trials to demonstrate product safety and efficacy and the submission of a Biologics License Application (BLA) to the FDA for marketing authorization. Our products are considered more than minimally manipulated and will require evaluation in clinical trials and the submission and approval of a BLA before we can market them. Generally, before a new drug or biologic can be marketed, considerable data demonstrating our quality, safety and efficacy must be obtained, organized into a format specific for each regulatory authority, submitted for review and approved by the regulatory authority.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Government authorities in the United States (at the federal, state, and local level) and in other countries extensively regulate, among other things, the research, development, testing, manufacturing, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of biopharmaceutical products such as those we are developing. Our product candidates must be approved by the FDA before they may be legally marketed in the United States and by the appropriate foreign regulatory agency before they may be legally marketed in foreign countries. Generally, our activities in other countries will be subject to regulation that is similar in nature and scope as that imposed in the U.S., although there can be important differences. Additionally, some significant aspects of regulation in Europe are addressed in a centralized way but country-specific regulation remains essential in many respects. The process for obtaining regulatory marketing approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">United States Product Development Process</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the U.S., the FDA regulates pharmaceutical and biological products under the Federal Food, Drug and Cosmetic Act (the FDCA), the Public Health Service Act (the PHSA), and their implementing regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes and regulations require the expenditure of substantial time and financial resources. Failure to comply with the applicable United States requirements at any time during the product development process, approval process or after approval, may subject an applicant to administrative or judicial sanctions. FDA sanctions could include, among other actions, refusal to approve pending applications, withdrawal of an approval, a clinical hold, warning letters, product recalls or withdrawals from the market, product seizures, total or partial suspension of production or distribution injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us. The process required by the FDA before a biological product may be marketed in the United States generally involves the following:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">completion of nonclinical laboratory tests and key animal studies according to good laboratory practices (GLPs), and applicable requirements for the humane use of laboratory animals or other applicable regulations;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">submission to the FDA of an IND application, which is subject to a waiting period of thirty (30) calendar days, must become effective before human clinical trials may begin;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">approval by an independent Institutional Review Board (IRB) or ethics committee for each clinical site before the trial is commenced;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">performance of adequate and well-controlled human clinical trials according to the FDA&#x2019;s regulations commonly referred to as good clinical practices (GCPs) and any additional requirements for the protection of human research patients and their health information, to establish the safety and efficacy of the proposed biological product for our intended use;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">submission to the FDA of a BLA for marketing approval that includes substantial evidence of safety, purity, and potency from results of nonclinical testing and clinical trials;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">satisfactory completion of an FDA Advisory Committee review, if applicable;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">satisfactory completion of an FDA inspection of the manufacturing facility or facilities where the biological product is produced to assess compliance with cGMP, to assure that the facilities, methods and controls are adequate to preserve the biological product&#x2019;s identity, strength, quality and purity and, if applicable, the FDA&#x2019;s current good tissue practices (GTPs) for the use of human cellular and tissue products;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">potential FDA audit of the nonclinical study and clinical trial sites that generated the data in support of the BLA; and</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">FDA review and approval, or licensure, of the BLA prior to any commercial marketing or sale of the biologic in the U.S.</span></div></div>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Before testing any biological product candidate, including our product candidates, in humans, the product candidate enters the preclinical testing stage. Preclinical tests, also referred to as nonclinical studies, include laboratory evaluations of product chemistry, toxicity and formulation, as well as animal studies to assess the potential safety and activity of the product candidate. The conduct of the key preclinical tests must comply with federal regulations and requirements including GLPs. An IND is a request for authorization from the FDA to administer an investigational product to humans and must become effective before human clinical trials may begin. The clinical trial sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, to the FDA as part of the IND. Some preclinical testing may continue even after the IND is submitted. The IND automatically becomes effective thirty (30) days after receipt by the FDA, unless the FDA raises concerns or questions regarding the proposed clinical trials and requests additional information and or places the trial on a clinical hold within that 30-day time period. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. The FDA may also impose clinical holds on a biological product candidate at any time before or during clinical trials due to safety concerns or non-compliance. If the FDA imposes a clinical hold, trials may not recommence without FDA authorization and then only under terms authorized by the FDA. Accordingly, we cannot be sure that submission of an IND will result in the FDA allowing clinical trials to begin, or that, once begun, issues will not arise that suspend or terminate such trials.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Clinical trials involve the administration of the biological product candidate to patients under the supervision of qualified investigators at independent clinical sites/hospitals, physicians not employed by or under the trial sponsor&#x2019;s control. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria, and the parameters to be used to monitor subject safety, including stopping rules that assure a clinical trial will be stopped if certain adverse events should occur. Each protocol and any amendments to the protocol must be submitted to the FDA as part of the IND. Clinical trials must be conducted and monitored in accordance with the FDA&#x2019;s regulations comprising the GCP requirements, including the requirement that all research patients provide informed consent. Further, each clinical trial must be reviewed and approved by an independent institutional review board (IRB) at or servicing each institution at which the clinical trial will be conducted. An IRB is charged with protecting the welfare and rights of trial participants and considers such items as whether the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the form and content of the informed consent that must be signed by each clinical trial subject or his or her legal representative and must monitor the clinical trial until completed. Some studies also include oversight by an independent group of qualified experts organized by the clinical study sponsor, known as a data safety monitoring board, which provides authorization for whether or not a study may move forward at designated check points based on access to certain data from the study and may halt the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. There are also requirements governing the reporting of ongoing clinical studies and clinical study results to public registries.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A sponsor who wishes to conduct a clinical trial outside of the United States may, but need not, obtain FDA authorization to conduct the clinical trial under an IND. If a foreign clinical trial is not conducted under an IND, the sponsor may submit data from the clinical trial to the FDA in support of a BLA. A clinical trial outside the United States may also be conducted under the authorization of similar regulatory authorities of the country/region. The FDA will accept a well-designed and well-conducted foreign clinical study not conducted under an IND if the study was conducted in accordance with GCP requirements, and the FDA is able to validate the data through an onsite inspection if deemed necessary.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Human clinical trials are typically conducted in three sequential phases that may overlap or be combined:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Phase 1. The biological product is typically introduced into healthy human subjects and tested for safety. However, in the case of some products for severe or life-threatening diseases, such as cancer or the hematological malignancies that we aspire to treat, initial human testing is routinely conducted directly in ill patients with the approval of relevant ethics committee(s) under the supervision of a licensed physician.</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Phase 2. The biological product is evaluated in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance, optimal dosage and dosing schedule.</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Phase 3. Clinical trials are undertaken to further evaluate dosage, clinical efficacy, potency, and safety in an expanded patient population at geographically dispersed clinical trial sites. These clinical trials are intended to establish the overall risk to benefit ratio of the product and provide an adequate basis for product labeling.</span></div></div>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Post-approval clinical trials, sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These clinical trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication, particularly for long-term safety follow-up. In case of an accelerated BLA approval based on limited clinical data, FDA may mandate a Phase 4 clinical trial prior to full approval. During all phases of clinical development, regulatory agencies require extensive monitoring and auditing of all clinical activities, clinical data, and clinical trial investigators. Annual progress</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">reports detailing the results of the clinical trials must be submitted to the FDA. Written IND safety reports must be promptly submitted to the FDA, and the investigators for serious and unexpected adverse events, any findings from other studies, tests in laboratory animals or </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">in vitro</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> testing that suggest a significant risk for human patients, or any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor must submit an IND safety report within fifteen (15) calendar days after the sponsor determines that the information qualifies for reporting. The sponsor also must notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction within seven (7) calendar days after the sponsor&#x2019;s initial receipt of the information.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Phase 1, Phase 2 and Phase 3 clinical trials may not be completed successfully within any specified period, if at all. The FDA or the sponsor or its data safety monitoring board may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research patients are being exposed to an unacceptable health risk, including risks inferred from other unrelated immunotherapy trials. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#x2019;s requirements or if the biological product has been associated with unexpected serious harm to patients.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Concurrently with clinical trials, companies usually complete additional studies and must also develop additional information about the physical characteristics of the biological product as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. To help reduce the risk of the introduction of adventitious agents with use of biological products, the PHSA emphasizes the importance of manufacturing control for products whose attributes cannot be precisely defined. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other things, the sponsor must develop methods for testing the identity, strength, quality, potency and purity of the final biological product according to the requirements of the phase of clinical development. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the biological product candidate does not undergo unacceptable deterioration over its shelf life.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Further, as a result of the ongoing COVID-19 pandemic, the extent and length of which is uncertain, we will be required to develop and implement additional clinical study policies and procedures designed to help protect study participants from the COVID-19 virus, which may include using telemedicine visits and remote monitoring of patients and clinical sites. We will also need to ensure data from our clinical studies that may be disrupted as a result of the pandemic is collected pursuant to the study protocol and is consistent with GCPs, with any material protocol deviation reviewed and approved by the site IRB. Patients who may miss scheduled appointments, any interruption in study drug supply, or other consequence that may result in incomplete data being generated during a study as a result of the pandemic must be adequately documented and justified. For example, on March 18, 2020, the FDA issued a guidance on conducting clinical trials during the pandemic, which describes a number of considerations for sponsors of clinical trials impacted by the pandemic, including the requirement to include in the clinical study report (or as a separate document) contingency measures implemented to manage the study, and any disruption of the study as a result of COVID-19; a list of all study participants affected by COVID-19-related study disruption by unique subject identifier and by investigational site, and a description of how the individual&#x2019;s participation was altered; and analyses and corresponding discussions that address the impact of implemented contingency measures (e.g., participant discontinuation from investigational product and/or study, alternative procedures used to collect critical safety and/or efficacy data) on the safety and efficacy results reported for the study. The FDA has continued to update and revise its guidance for ongoing clinical trials throughout the COVID-19 public health emergency.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">United States Review and Approval Processes</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">After the completion of clinical trials of a biological product, FDA approval of a BLA must be obtained before commercial marketing of the biological product. The BLA submission must include results of product safety, efficacy, development, laboratory and animal studies, human trials, information on the manufacture and composition of the product, proposed labeling and other relevant information. The testing and approval processes require substantial time and effort and there can be no assurance or guarantee that the FDA will accept the BLA for filing and, even if filed, that any approval will be granted on a timely basis, if at all.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the Prescription Drug User Fee Act (PDUFA), as amended, each BLA must be accompanied by a significant user fee. The FDA adjusts the PDUFA user fees on an annual basis. PDUFA also imposes an annual program fee for biological products. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business. Additionally, no user fees are assessed on BLAs for products designated as orphan drugs, unless the product also includes a non-orphan indication.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Within 60 or 74 days following submission of the application, the FDA reviews a BLA submitted to determine if it is substantially complete before the agency accepts it for filing. The FDA may refuse to file any BLA that it deems incomplete or not properly reviewable at the time of submission and may request additional information. In this event, the BLA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing. Under the goals and policies agreed to by the FDA under PDUFA, the FDA has 10 months from the filing date to complete its initial review of an original BLA and respond to the applicant, and six months from the filing date of an original BLA</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">32</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">designated for priority review. The FDA does not always meet its PDUFA goal dates for standard and priority BLAs, and the review process is often extended by FDA requests for additional information or clarification.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Once the submission is accepted for filing, the FDA begins an in-depth substantive review of the BLA. The FDA reviews the BLA to determine, among other things, whether the proposed product is safe, potent, and/or effective for its intended use, and has an acceptable purity profile, and whether the product is being manufactured in accordance with cGMP to assure and preserve the product&#x2019;s identity, safety, strength, quality, potency and purity. The FDA may refer applications for novel biological products or biological products that present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the biological product approval process, the FDA also will determine whether a Risk Evaluation and Mitigation Strategy (REMS) is necessary to assure the safe use of the biological product. A REMS is a safety strategy to manage a known or potential serious risk associated with a medicine and to enable patients to have continued access to such medicines by managing their safe use, and could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. If the FDA concludes a REMS is needed, the sponsor of the BLA must submit a proposed REMS. The FDA will not approve a BLA without a REMS, if required. Both Kymriah&#174; and Yescarta&#174; were approved with a REMS.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Before approving a BLA, the FDA will inspect the facilities at which the product is manufactured. The FDA will not approve the product unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. For cellular immunotherapy products, the FDA also will not approve the product if the manufacturer is not in compliance with current good tissues practices (cGTP), to the extent applicable. These are FDA regulations and guidance documents that in part govern the methods used in, and the facilities and controls used for, the manufacture of human cells, tissue, and HCT/Ps, which are human cells or tissue intended for implantation, transplant, infusion, or transfer into a human recipient. The primary intent of the GTP requirements is to ensure that cell and tissue-based products are manufactured in a manner designed to prevent the introduction, transmission and spread of communicable disease. FDA regulations also require tissue establishments to register and list their HCT/Ps with the FDA and, when applicable, to evaluate donors through screening and testing. Additionally, before approving a BLA, the FDA will typically inspect one or more clinical sites to assure that the clinical trials were conducted in compliance with IND trial requirements and GCP requirements. To assure cGMP, GTP and GCP compliance, an applicant must incur significant expenditure of time, money and effort in the areas of training, record keeping, production, and quality control.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Notwithstanding the submission of relevant data and information, the FDA may ultimately decide that the BLA does not satisfy its regulatory criteria for approval and deny approval. Data obtained from clinical trials are not always conclusive and the FDA may interpret data differently than we interpret the same data. If the agency decides not to approve the BLA in its present form, the FDA will issue a complete response letter that describes all of the specific deficiencies in the BLA identified by the FDA. The deficiencies identified may be minor, for example, requiring labeling changes, or major, for example, requiring additional clinical trials. Additionally, the complete response letter may include recommended actions that the applicant might take to place the application in a condition for approval. If a complete response letter is issued, the applicant may either resubmit the BLA, addressing all of the deficiencies identified in the letter, or withdraw the application.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If a product receives regulatory approval, the approval may be limited to specific diseases and dosages or the indications for use may otherwise be limited, which could restrict the commercial value of the product. Further, the FDA may require that certain contraindications, warnings or precautions be included in the product labeling. The FDA may impose restrictions and conditions on product distribution, prescribing, or dispensing in the form of a risk management plan, or otherwise limit the scope of any approval. In addition, the FDA may require post marketing clinical trials, sometimes referred to as Phase 4 clinical trials, designed to further assess a biological product&#x2019;s safety and effectiveness, and testing and surveillance programs to monitor the safety of approved products that have been commercialized.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Pediatric Information</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, under the Pediatric Research Equity Act, a BLA or supplement to a BLA must contain data to assess the safety and effectiveness of the product for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective. The FDA may grant deferrals for submission of data or full or partial waivers. A sponsor who is planning to submit a marketing application for a drug that includes a new active ingredient, new indication, new dosage form, new dosing regimen or new route of administration must submit an initial Pediatric Study Plan (PSP), within sixty (60) days of an end-of-Phase 2 meeting or, if there is no such meeting, as early as practicable before the initiation of the Phase 3 or Phase 2/3 study. The initial PSP must include an outline of the pediatric study or studies that the sponsor plans to conduct, including study objectives and design, age groups, relevant endpoints and statistical approach, or a justification for not including such detailed information, and any request for a deferral of pediatric assessments or a full or partial waiver of the requirement to provide data from pediatric studies along with supporting information. The FDA and the sponsor must reach an agreement on the PSP. A sponsor can submit amendments to an agreed-upon initial PSP at any</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">33</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">time if changes to the pediatric plan need to be considered based on data collected from preclinical studies, early phase clinical trials and/or other clinical development programs.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Orphan Drug Designation</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the U.S., or more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making available in the United States a drug or biologic for this type of disease or condition will be recovered from sales in the United States for that drug or biologic. Orphan drug designation must be requested before submitting a BLA. After the FDA grants orphan drug designation, the generic identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. The orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review or approval process.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If a product that has orphan drug designation subsequently receives the first FDA approval for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications, including a full BLA, to market the same biologic for the same indication for seven years, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity. Orphan drug exclusivity does not prevent FDA from approving a different drug or biologic for the same disease or condition, or the same drug or biologic for a different disease or condition. Among the other benefits of orphan drug designation are tax credits for certain research and a waiver of the BLA application user fee.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A designated orphan drug may not receive orphan drug exclusivity if it is approved for a use that is broader than the indication for which it received orphan designation. In addition, exclusive marketing rights in the United States may be lost if the FDA later determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1260416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Expedited Development and Review Programs</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">FDA provides programs intended to facilitate and expedite development and review of new products that are intended to address an unmet medical need in the treatment of a serious or life-threatening disease or condition. These programs are referred to as fast track designation, priority review designation, accelerated approval, Regenerative Medicine Advanced Therapy (RMAT) designation, and breakthrough therapy designation.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The fast track program is intended to expedite or facilitate the process for reviewing new products that meet certain criteria. Specifically, new products are eligible for fast track designation if they are intended to treat a serious or life-threatening disease or condition and demonstrate the potential to address unmet medical needs for the disease or condition. Fast track designation applies to the combination of the product and the specific indication for which it is being studied. The FDA may consider for review sections of the BLA on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the BLA, the FDA agrees to accept sections of the BLA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the BLA.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any product submitted to the FDA for approval, including a product with a fast track designation, may also be eligible for other types of FDA programs intended to expedite development and review, such as priority review and accelerated approval. A product is eligible for priority review if it has the potential to provide safe and effective therapy where no satisfactory alternative therapy exists or a significant improvement in the treatment, diagnosis or prevention of a disease compared to marketed products. The FDA will attempt to direct additional resources to the evaluation of an application for a new product designated for priority review in an effort to facilitate the review. Additionally, a product may be eligible for accelerated approval. Products studied for their safety and effectiveness in treating serious or life-threatening diseases or conditions may receive accelerated approval upon a determination that the product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality, that is reasonably likely to predict an effect on irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity, or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require that a sponsor of a drug or biological product receiving accelerated approval perform adequate and well-controlled post-marketing clinical studies. In addition, for products being considered for accelerated approval,  the FDA generally requires, unless otherwise informed by the agency, that all advertising and promotional materials intended for dissemination or publication within 120 days of marketing approval be submitted to the agency for review during the pre-approval review period, which could adversely impact the timing of the commercial launch of the product.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Regenerative Medicine Advanced Therapy (RMAT), designation was established by the FDA in 2017 to facilitate an efficient development program for, and expedite review of, any drug that meets the following criteria: (1) it qualifies as a RMAT, which is defined as a cell therapy, therapeutic tissue engineering product, human cell and tissue product, or any combination product using such therapies or products, with limited exceptions; (2) it is intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition; and (3) preliminary clinical evidence indicates that the drug has the potential to address unmet medical needs for such a disease or condition. RMAT designation provides potential benefits that include more frequent</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">34</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">meetings with FDA to discuss the development plan for the product candidate and eligibility for rolling review and priority review. Products granted RMAT designation may also be eligible for accelerated approval on the basis of a surrogate or intermediate endpoint reasonably likely to predict long-term clinical benefit, or reliance upon data obtained from a meaningful number of sites, including through expansion to additional sites. Once approved, when appropriate, the FDA can permit fulfillment of post-approval requirements under accelerated approval through the submission of clinical evidence, clinical studies, patient registries, or other sources of real world evidence such as electronic health records; through the collection of larger confirmatory datasets; or through post-approval monitoring of all patients treated with the therapy prior to approval.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Breakthrough therapy designation is also intended to expedite the development and review of products that treat serious or life-threatening conditions. The designation by FDA requires preliminary clinical evidence that a product candidate, alone or in combination with other drugs and biologics, demonstrates substantial improvement over currently available therapy on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Breakthrough therapy designation comes with all of the benefits of fast track designation, which means that the sponsor may file sections of the BLA for review on a rolling basis if certain conditions are satisfied, including an agreement with FDA on the proposed schedule for submission of portions of the application and the payment of applicable user fees before the FDA may initiate a review.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Fast Track designation, priority review, RMAT and breakthrough therapy designation do not change the standards for approval but may expedite the development or regulatory approval process for our products.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Post-Approval Requirements</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any products for which we receive FDA approvals are subject to continuing regulation by the FDA, including, among other things, record-keeping requirements, reporting of adverse experiences with the product, providing the FDA with updated safety and efficacy information, product sampling and distribution requirements, and complying with FDA promotion and advertising requirements, which include, among others, standards for direct-to-consumer advertising, restrictions on promoting products for uses or in patient populations that are not described in the product&#x2019;s approved uses (known as off-label use), limitations on industry-sponsored scientific and educational activities, and requirements for promotional activities involving the internet. Although a physician may prescribe a legally available product for an off-label use, if the physician deems such product to be appropriate in his/her professional medical judgment, a manufacturer may not market or promote off-label uses. However, it is permissible to share in certain circumstances truthful and not misleading information that is consistent with the product&#x2019;s approved labeling.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Further, additional FDA limitations on approval or marketing could restrict the commercial promotion, distribution, prescription or dispensing of products. Product approvals may be withdrawn for non-compliance with regulatory standards or if problems occur following initial marketing. Newly discovered or developed safety or effectiveness data may require changes to a product&#x2019;s approved labeling, including the addition of new warnings and contraindications, and may also require the implementation of other risk management measures, including a REMS, or the conduct of post-marketing studies to assess a newly discovered safety issue.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, quality control and manufacturing procedures must continue to conform to applicable manufacturing requirements after approval to ensure the adequate stability of the product. cGMP regulations require among other things, quality control and quality assurance as well as the corresponding maintenance of records and documentation and the obligation to investigate and correct any deviations from cGMP. Manufacturers and other entities involved in the manufacture and distribution of approved products are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP and other laws. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance. Discovery of problems with a product after approval may result in restrictions on a product, manufacturer, or holder of an approved BLA, including, among other things, recall or withdrawal of the product from the market. In addition, changes to the manufacturing process are strictly regulated, and depending on the significance of the change, may require prior FDA approval before being implemented. Other types of changes to the approved product, such as adding new indications and claims, are also subject to further FDA review and approval.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We rely, and expect to continue to rely, on third parties to produce clinical and commercial quantities of our products in accordance with cGMP regulations. These manufacturers must comply with cGMP regulations that require, among other things, quality control and quality assurance, the maintenance of records and documentation and the obligation to investigate and correct any deviations from cGMP. Manufacturers and other entities involved in the manufacture and distribution of approved biologics are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP requirements and other laws.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA also may require post-marketing testing, known as Phase 4 testing, and surveillance to monitor the effects of an approved product. Discovery of previously unknown problems with a product or the failure to comply with applicable FDA requirements can have negative consequences, including adverse publicity, judicial or administrative enforcement, warning letters from the FDA, mandated corrective advertising or communications with doctors, and civil or criminal penalties, among</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">35</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">others. Newly discovered or developed safety or effectiveness data may require changes to a product&#x2019;s approved labeling, including the addition of new warnings and contraindications, and also may require the implementation of other risk management measures. Also, new government requirements, including those resulting from new legislation, may be established, or the FDA&#x2019;s policies may change, which could delay or prevent regulatory approval of our products under development.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">U.S. Marketing Exclusivity</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Biologics Price Competition and Innovation Act of 2009 (BPCIA), amended the PHSA to authorize the FDA to approve similar versions of innovative biologics, commonly known as biosimilars. A competitor seeking approval of a biosimilar must file an application to establish its molecule as highly similar to an approved innovator biologic, among other requirements. BPCIA, however, bars the FDA from approving biosimilar applications for 12 years after an innovator biological product receives initial marketing approval. This 12-year period of data exclusivity may be extended by six months, for a total of 12.5 years, if the FDA requests that the innovator company conduct pediatric clinical investigations of the product.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Depending upon the timing, duration and specifics of the FDA approval of the use of our product candidates, some of our United States patents, if granted, may be eligible for limited patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, commonly referred to as the Hatch-Waxman Act. The Hatch-Waxman Act permits a patent restoration term of up to five years, as compensation for patent term lost during product development and the FDA regulatory review process. However, patent term restoration cannot extend the remaining term of a patent beyond a total of 14 years from the product&#x2019;s approval date. The patent term restoration period is generally one-half the time between the effective date of an IND and the submission date of a BLA plus the time between the submission date of a BLA and the approval of that application. Only one patent applicable to an approved product is eligible for the extension and the application for the extension must be submitted prior to the expiration of the patent. The United States Patent and Trademark Office, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration. In the future, we may intend to apply for restoration of patent term for one of our currently owned or licensed patents to add patent life beyond its current expiration date, depending on the expected length of the clinical trials and other factors involved in the filing of the relevant BLA.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pediatric exclusivity is another type of regulatory market exclusivity in the United States Pediatric exclusivity, if granted, adds six months to existing exclusivity periods and patent terms. This six-month exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary completion of a pediatric trial in accordance with an FDA-issued &#x201c;Written Request&#x201d; for such a trial.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Other U.S. Healthcare Laws and Compliance Requirements</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the United States, our activities are potentially subject to regulation by various federal, state and local authorities in addition to the FDA, including but not limited to, the Centers for Medicare &amp; Medicaid Services (CMS), other divisions of the United States Department of Health and Human Services (HHS) (e.g., the Office of Inspector General, the United States Department of Justice (DOJ), and individual United States Attorney offices within the DOJ, and state and local governments). For example, our business practices, including any of our research and future sales, marketing and scientific/educational grant programs may be required to comply with the anti-fraud and abuse provisions of the Social Security Act, the false claims laws, the patient data privacy and security provisions of the Health Insurance Portability and Accountability Act of 1996 (HIPAA), transparency requirements, and similar state, local and foreign laws, each as amended.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The federal Anti-Kickback Statute prohibits, among other things, any person or entity, from knowingly and willfully offering, paying, soliciting or receiving any remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or in return for purchasing, leasing, ordering or arranging for the purchase, lease or order of any item, good, facility or service reimbursable under Medicare, Medicaid or other federal healthcare programs. The term remuneration has been interpreted broadly to include anything of value. The federal Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on one hand and prescribers, purchasers, formulary managers, and other individuals and entities on the other. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution. The exceptions and safe harbors are drawn narrowly and require strict compliance in order to offer protection. Practices that involve remuneration that may be alleged to be intended to induce prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exception or safe harbor. Failure to meet all of the requirements of a particular applicable statutory exception or regulatory safe harbor does not make the conduct per se illegal under the Anti-Kickback Statute. Instead, the legality of the arrangement will be evaluated on a case-by-case basis based on a cumulative review of all of the facts and circumstances. Our practices may not in all cases meet all of the criteria for protection under a statutory exception or regulatory safe harbor.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additionally, the intent standard under the federal Anti-Kickback Statute was amended by the Patient Protection and Affordable Care Act of 2010, as amended by the Health Care and Education Reconciliation Act of 2010, collectively, the Affordable Care Act (ACA), to a stricter standard such that a person or entity no longer needs to have actual knowledge of the federal Anti-Kickback Statute or specific intent to violate it in order to have committed a violation. Rather, if &#x201c;one purpose&#x201d; of the remuneration is to induce referrals, the federal Anti-Kickback Statute is violated. In addition, the ACA codified case law that</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">36</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a claim that includes items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal civil False Claims Act (discussed below).</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The civil monetary penalties statute imposes penalties against any person or entity who, among other things, is determined to have presented or caused to be presented a claim to, among others, a federal healthcare program that the person knows or should know is for a medical or other item or service that was not provided as claimed or is false or fraudulent.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The federal civil False Claims Act prohibits, among other things, any person or entity from knowingly presenting, or causing to be presented, a false claim for payment to, or approval by, the federal government or knowingly making, using, or causing to be made or used a false record or statement material to a false or fraudulent claim to the federal government. As a result of a modification made by the Fraud Enforcement and Recovery Act of 2009, a claim includes &#x201c;any request or demand&#x201d; for money or property presented to the United States government. For example, pharmaceutical and other healthcare companies have been, and continue to be, investigated or prosecuted under these laws for allegedly providing free product to customers with the expectation that the customers would bill federal programs for the product and for causing false claims to be submitted because of the companies&#x2019; marketing of the product for unapproved, and thus non-reimbursable, uses.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">HIPAA created additional federal criminal statutes that prohibit knowingly and willfully executing, or attempting to execute, a scheme to defraud or to obtain, by means of false or fraudulent pretenses, representations or promises, any money or property owned by, or under the control or custody of, any healthcare benefit program, including private third-party payors and knowingly and willfully falsifying, concealing or covering up by trick, scheme or device, a material fact or making any materially false, fictitious or fraudulent statement in connection with the delivery of or payment for healthcare benefits, items or services.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Also, many states have similar fraud and abuse statutes or regulations, such as state anti-kickback and false claims laws, which may be broader in scope and apply regardless of payor. These laws are enforced by various state agencies and through private actions. Some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#x2019;s voluntary compliance guidelines and the relevant federal government compliance guidance, require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers, and restrict marketing practices or require disclosure of marketing expenditures. In addition, certain state and local laws require the registration of pharmaceutical sales representatives.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may be subject to data privacy and security regulations by both the federal government and the states in which we conduct business. HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act (HITECH) and their implementing regulations, impose requirements on certain types of individuals and entities relating to the privacy, security and transmission of individually identifiable health information. Among other things, HITECH makes HIPAA&#x2019;s privacy and security standards directly applicable to business associates that are independent contractors or agents of covered entities that receive or obtain protected health information in connection with providing a service on behalf of a covered entity. HITECH also created four new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#x2019; fees and costs associated with pursuing federal civil actions. In addition, state laws govern the privacy and security of health information in specified circumstances, many of which differ from each other in significant ways and may not have the same effect, thus complicating compliance efforts.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may also be subject to federal government price reporting laws, which require us to calculate and report complex pricing metrics in an accurate and timely manner to government programs, as well as federal consumer protection and unfair competition laws, which broadly regulate marketplace activities that potentially harm consumers.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additionally, the federal Physician Payments Sunshine Act within the Affordable Care Act, and its implementing regulations, require that certain manufacturers of drugs, devices, biological and medical supplies for which payment is available under Medicare, Medicaid or the Children&#x2019;s Health Insurance Program (with certain exceptions) annually report information to CMS related to certain payments or other transfers of value made or distributed to physicians, as defined by such law, and teaching hospitals, or to entities or individuals at the request of, or designated on behalf of, physicians and teaching hospitals and certain ownership and investment interests held by physicians and their immediate family members. Effective January 1, 2022, these reporting obligations extend to include transfers of value made to certain non-physician providers (physician assistants, nurse practitioners, clinical nurse specialists, certified registered nurse anesthetists and anesthesiologist assistants, and certified nurse midwives).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In order to distribute products commercially, we must comply with state laws that require the registration of manufacturers and wholesale distributors of drug and biological products in a state, including, in certain states, manufacturers and distributors who ship products into the state even if such manufacturers or distributors have no place of business within the state. Some states also impose requirements on manufacturers and distributors to establish the pedigree of product in the chain of distribution, including some states that require manufacturers and others to adopt new technology capable of tracking and tracing product as it moves through the distribution chain. Several states have enacted legislation requiring pharmaceutical and biotechnology companies to establish marketing compliance programs, file periodic reports with the state, make periodic public disclosures on sales, marketing, pricing, clinical trials and other activities, and/or register their sales representatives, as well as to prohibit</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">37</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">pharmacies and other healthcare entities from providing certain physician prescribing data to pharmaceutical and biotechnology companies for use in sales and marketing, and to prohibit certain other sales and marketing practices. All of our activities are potentially subject to federal and state consumer protection and unfair competition laws.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If our operations are found to be in violation of any of the federal and state healthcare laws described above or any other governmental regulations that apply to us, we may be subject to penalties, including without limitation, civil, criminal and administrative penalties, damages, fines, disgorgement, imprisonment, exclusion from participation in government programs, such as Medicare and Medicaid, refusal to allow us to enter into government contracts, contractual damages, reputational harm, administrative burdens, diminished profits and future earnings, additional reporting requirements and/or oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Coverage, Pricing and Reimbursement</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which we obtain regulatory approval. In the United States and markets in other countries, sales of any products for which we receive regulatory approval for commercial sale will depend, in part, on the extent to which third-party payors provide coverage, and establish adequate reimbursement levels for such products. In the U.S., third-party payors include federal and state healthcare programs, private managed care providers, health insurers and other organizations. The process for determining whether a third-party payor will provide coverage for a product may be separate from the process for setting the price of a product or for establishing the reimbursement rate that such a payor will pay for the product. Third-party payors may limit coverage to specific products on an approved list, or also known as a formulary, which might not include all of the FDA-approved products for a particular indication. Third-party payors are increasingly challenging the price, examining the medical necessity and reviewing the cost-effectiveness of medical products, therapies and services, in addition to questioning their safety and efficacy. We may need to conduct expensive pharmaco-economic studies in order to demonstrate the medical necessity and cost-effectiveness of our products, in addition to the costs required to obtain the FDA approvals. Our product candidates may not be considered medically necessary or cost-effective. A payor&#x2019;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Further, one payor&#x2019;s determination to provide coverage for a product does not assure that other payors will also provide coverage for the product. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Different pricing and reimbursement schemes exist in other countries. In the European Union (EU), governments influence the price of pharmaceutical products through their pricing and reimbursement rules and control of national health care systems that fund a large part of the cost of those products to consumers. Some jurisdictions operate positive and negative list systems under which products may only be marketed once a reimbursement price has been agreed. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost-effectiveness of a particular product candidate to currently available therapies. Other member states allow companies to fix their own prices for medicines but monitor and control company profits. The downward pressure on health care costs has become very intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-border imports from low-priced markets exert a commercial pressure on pricing within a country.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The marketability of any product candidates for which we receive regulatory approval for commercial sale may suffer if the government and third-party payors fail to provide adequate coverage and reimbursement. In addition, emphasis on managed care in the United States has increased and we expect will continue to increase the pressure on healthcare pricing. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Healthcare Reform</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the United States and some foreign jurisdictions, there have been, and continue to be, several legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of product candidates, restrict or regulate post-approval activities, and affect the ability to profitably sell product candidates for which marketing approval is obtained. Among policy makers and payors in the United States and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. In the U.S., the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">38</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For example, the ACA has substantially changed healthcare financing and delivery by both governmental and private insurers. Among the ACA provisions of importance to the pharmaceutical and biotechnology industries, in addition to those otherwise described above, are the following:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">created an annual, nondeductible fee on any entity that manufactures or imports certain specified branded prescription drugs and biologic agents apportioned among these entities according to their market share in some government healthcare programs that began in 2011;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">increased the statutory minimum rebates a manufacturer must pay under the Medicaid Drug Rebate Program, retroactive to January 1, 2010, to 23.1% and 13% of the average manufacturer price for most branded and generic drugs, respectively, and capped the total rebate amount for innovator drugs at 100% of the Average Manufacturer Price (AMP);</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">created a new Medicare Part D coverage gap discount program, in which manufacturers must now agree to offer 50% (increase to 70% pursuant to the Bipartisan Budget Act of 2018, effective as of January 1, 2019) point-of-sale discounts, off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturers&#x2019; outpatient drugs to be covered under Medicare Part D;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">extended manufacturers&#x2019; Medicaid rebate liability to covered drugs dispensed to individuals who are enrolled in Medicaid managed care organizations;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">expanded eligibility criteria for Medicaid programs by, among other things, allowing states to offer Medicaid coverage to additional individuals and added new mandatory eligibility categories for individuals with income at or below 133% of the federal poverty level, thereby potentially increasing manufacturers&#x2019; Medicaid rebate liability;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">expanded the entities eligible for discounts under the 340B Drug Discount Program;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">created a Patient-Centered Outcomes Research Institute to oversee, identify priorities in, and conduct comparative clinical effectiveness research, along with funding for such research;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">expanded healthcare fraud and abuse laws, including the Anti-Kickback Statute and the Foreign Corrupt Practices Act (FCPA), created new government investigative powers, and enhanced penalties for noncompliance;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">created a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for drugs that are inhaled, infused, instilled, implanted, or injected;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">required reporting of certain financial arrangements with physicians and teaching hospitals;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">required annual reporting of certain information regarding drug samples that manufacturers and distributors provide to physicians;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">established a Center for Medicare and Medicaid Innovation at CMS to test innovative payment and service delivery models to lower Medicare and Medicaid spending; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">created a licensure framework for follow on biologic products.</span></div></div>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There remain legal and political challenges to certain aspects of the ACA. On June 17, 2021, the Supreme Court dismissed the most recent judicial challenge to the ACA brought by several states without specifically ruling on the constitutionality of the ACA. Prior to the Supreme Court's decision, President Biden issued an executive order to initiate a special enrollment period from February 15, 2021 through August 15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. The executive order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, reexamining Medicaid demonstration projects and waiver programs that include work requirements, and policies that create barriers to unnecessary barriers to obtaining access to health insurance coverage through Medicaid or the ACA. It is unclear how other healthcare reform measures of the Biden administration or other efforts, if any, to challenge, repeal or replace the ACA will impact our business. In addition, other legislative and regulatory changes have been proposed and adopted in the United States since the ACA was enacted.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Further legislation or regulation could be passed that could harm our business, financial condition and results of operations. Other legislative changes have been proposed and adopted since the ACA was enacted:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On August 2, 2011, President Obama signed into law the Budget Control Act of 2011, which, among other things, created the Joint Select Committee on Deficit Reduction to recommend to Congress proposals in spending reductions. The Joint Select Committee on Deficit Reduction did not achieve a targeted deficit reduction of at least $1.2 trillion for fiscal years 2012 through 2021, triggering the legislation&#x2019;s automatic reduction to several government programs. This includes aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, which went into effect beginning on April 1, 2013 and will stay in effect through 2030 unless additional </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">39</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;visibility:hidden;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Congressional action is taken. Pursuant to the Coronavirus Aid, Relief, and Economic Security Act, also known as the CARES Act, as well as subsequent legislation, these reductions have been suspended from May 1, 2020 through March 31, 2022 due to the COVID-19 pandemic. Following the temporary suspension, a 1% payment reduction will occur beginning April 1, 2022 through June 30, 2022, and the 2% payment reduction will resume on July 1, 2022.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(36,36,36,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(36,36,36,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On January 2, 2013, the U.S. American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(36,36,36,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(36,36,36,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On April 13, 2017, CMS published a final rule that gives states greater flexibility in setting benchmarks for insurers in the individual and small group marketplaces, which may have the effect of relaxing the essential health benefits required under the ACA for plans sold through such marketplaces.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(36,36,36,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(36,36,36,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On May 30, 2018, the Right to Try Act, was signed into law. The law, among other things, provides a federal framework for certain patients to access certain investigational new drug products that have completed a Phase 1 clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA permission under the FDA expanded access program. There is no obligation for a pharmaceutical manufacturer to make its drug products available to eligible patients as a result of the Right to Try Act. </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(36,36,36,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(36,36,36,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On&#x202f;May 23, 2019, CMS published a final rule to allow Medicare Advantage Plans the option of using step therapy for Part B drugs beginning January 1, 2020.</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(36,36,36,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(36,36,36,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On December 20, 2019, former President Trump signed into law the Further Consolidated Appropriations Act (H.R. 1865), which repealed the Cadillac tax, the health insurance provider tax, and the medical device excise tax.  It is impossible to determine whether similar taxes could be instated in the future.</span></div></div>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additionally, there has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been several recent United States  Congressional inquiries and federal and state legislative activity designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">At the federal level, President Biden signed an Executive Order on July 9, 2021 affirming the administration&#x2019;s policy to (i) support legislative reforms that would lower the prices of prescription drug and biologics, including by allowing Medicare to negotiate drug prices, by imposing inflation caps, and, by supporting the development and market entry of lower-cost generic drugs and biosimilars; and (ii) support the enactment of a public health insurance option. Among other things, the Executive Order also directs HHS to provide a report on actions to combat excessive pricing of prescription drugs, enhance the domestic drug supply chain, reduce the price that the Federal government pays for drugs, and address price gouging in the industry; and directs the FDA to work with states and Indian Tribes that propose to develop section 804 Importation Programs in accordance with the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, and the FDA&#x2019;s implementing regulations. FDA released such implementing regulations on September 24, 2020, which went into effect on November 30, 2020, providing guidance for states to build and submit importation plans for drugs from Canada. On September 25, 2020, CMS stated drugs imported by states under this rule will not be eligible for federal rebates under Section 1927 of the Social Security Act and manufacturers would not report these drugs for &#x201c;best price&#x201d; or Average Manufacturer Price purposes. Since these drugs are not considered covered outpatient drugs, CMS further stated it will not publish a National Average Drug Acquisition Cost for these drugs. If implemented, importation of drugs from Canada may materially and adversely affect the price we receive for any of our product candidates. Further, on November 20, 2020 CMS issued an Interim Final Rule implementing the Most Favored Nation, or MFN, Model under which Medicare Part B reimbursement rates would have been be calculated for certain drugs and biologicals based on the lowest price drug manufacturers receive in Organization for Economic Cooperation and Development countries with a similar gross domestic product per capita.  However, on December 29, 2021 CMS rescinded the Most Favored Nations rule. Additionally, on November 30, 2020, HHS published a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The rule also creates a new safe harbor for price reductions reflected at the point-of-sale, as well as a safe harbor for certain fixed fee arrangements between pharmacy benefit managers and manufacturers. Pursuant to court order, the removal and addition of the aforementioned safe harbors were delayed and recent legislation imposed a moratorium on implementation of the rule until January 1, 2026. Although a number of these and other proposed measures may require authorization through additional legislation to become effective, and the Biden administration may reverse or otherwise change these measures, both the Biden administration and Congress have indicated that they will continue to seek new legislative measures to control drug costs.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Individual states in the United States have also increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Individual states in the United States  have also been increasingly passing legislation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">40</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We anticipate that these and other healthcare reform efforts will continue to result in additional downward pressure on coverage and the price that we receive for any approved product, and could materially harm our business. Any reduction in reimbursement from Medicare and other government programs may result in a similar reduction in payments from private payors. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our products. Such reforms could have an adverse effect on anticipated revenue from product candidates that we may successfully develop and for which we may obtain regulatory approval and may affect our overall financial condition and ability to develop product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The Foreign Corrupt Practices Act</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FCPA prohibits any United States individual or business from offering, paying, promising to pay, or authorizing payment of money or anything of value, to any person, while knowing that all or a portion of such money or thing of value will be offered, given or promised, directly or indirectly, to any foreign official, political party or candidate to influence the foreign official in his or her official capacity, induce the foreign official to do or omit to do an act in violation of his or her lawful duty, or to secure any improper advantage in order to assist the individual or business in obtaining or retaining business.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FCPA also obligates companies whose securities are listed in the United States to comply with certain accounting provisions requiring us to maintain books and records that accurately and fairly reflect all transactions of the corporation, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls. Compliance with the FCPA is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the FCPA presents particular challenges in the pharmaceutical industry, because, in many countries, hospitals are owned and operated by the government, and doctors and other hospital employees are considered foreign officials for the purposes of the statute. Certain payments made in connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions. Various laws, regulations and executive orders also restrict the use and dissemination outside of the U.S., or the sharing with certain non-United States  nationals, of information classified for national security purposes, as well as certain products and technical data relating to those products.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accordingly, if we expand our presence outside of the U.S., we will need to dedicate additional resources to complying with the laws and regulations in each jurisdiction in which it plans to operate. Therefore, this may preclude us from developing, manufacturing, or selling certain products and product candidates outside of the U.S., which could limit our growth potential and increase our development costs.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Packaging and Distribution in the United States</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If our products are made available to authorized users of the Federal Supply Schedule of the General Services Administration, additional laws and requirements apply. Products must meet applicable child-resistant packaging requirements under the United States  Poison Prevention Packaging Act. Manufacturing, sales, promotion and other activities also are potentially subject to federal and state consumer protection and unfair competition laws.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The distribution of pharmaceutical products is subject to additional requirements and regulations, including extensive record-keeping, licensing, storage and security requirements intended to prevent the unauthorized sale of pharmaceutical products. The failure to comply with any of these laws or regulatory requirements subjects firms to possible legal or regulatory action. Depending on the circumstances, failure to meet applicable regulatory requirements can result in criminal prosecution, fines or other penalties, injunctions, exclusion from federal healthcare programs, requests for recall, seizure of products, total or partial suspension of production, denial or withdrawal of product approvals, or refusal to allow a firm to enter into supply contracts, including government contracts. Any action against us for violation of these laws, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management&#x2019;s attention from the operation of our business. Prohibitions or restrictions on sales or withdrawal of future products marketed by us could materially affect our business in an adverse way.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Changes in regulations, statutes or the interpretation of existing regulations could impact our business in the future by requiring, for example: (i) changes to our manufacturing arrangements; (ii) additions or modifications to product labeling; (iii) the recall or discontinuation of our products; or (iv) additional record-keeping requirements. If any such changes were to be imposed, they could adversely affect the operation of our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Additional Regulation</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition to the foregoing, state and federal laws regarding environmental protection and hazardous substances, including the Occupational Safety and Health Act, the Resource Conservancy and Recovery Act and the Toxic Substances Control Act,</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">41</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">affect our business. These and other laws govern our use, handling and disposal of various biological, chemical and radioactive substances used in, and wastes generated by, our operations.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Even if we contract with third parties for the disposal of these materials and waste products, we cannot completely eliminate the risk of contamination or injury resulting from these materials. If our operations result in contamination of the environment or expose individuals to hazardous substances, we could be liable for damages and governmental fines, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations. We maintain workers&#x2019; compensation insurance to cover costs and expenses it may incur due to injuries to our employees, but this insurance may not provide adequate coverage against potential liabilities. However, we do not maintain insurance for environmental liability or toxic tort claims that may be asserted against it. In addition, we may incur substantial costs in order to comply with current or future environmental, health and safety laws and regulations. Current or future environmental laws and regulations may impair our research, development or production efforts. In addition, failure to comply with these laws and regulations may result in substantial fines, penalties or other sanctions.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We believe that we are in material compliance with applicable environmental laws and that continued compliance therewith will not have a material adverse effect on our business. We cannot predict, however, how changes in these laws may affect our future operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Europe / Rest of World Government Regulation</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition to regulations in the U.S., we will be subject to a variety of regulations in other jurisdictions governing, among other things, clinical trials and any commercial sales and distribution of our products. Whether or not we obtain FDA approval of a product, we must obtain the requisite approvals from regulatory authorities in foreign countries prior to the commencement of clinical trials or marketing of the product in those countries. Certain countries outside of the United States  have a similar process that requires the submission of a clinical trial application much like the IND prior to the commencement of human clinical trials. In the EU, for example, a clinical trial application must be submitted to each country&#x2019;s national health authority and an independent ethics committee, much like the FDA and IRB, respectively. Once the clinical trial application is approved in accordance with a country&#x2019;s requirements, clinical trial development may proceed. Because biologically sourced raw materials are subject to unique contamination risks, their use may be restricted in some countries.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The requirements and process governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, the clinical trials must be conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In April 2014, the EU adopted the new Clinical Trials Regulation (EU) No 536/2014, or Regulation, which replaced the Clinical Trials Directive 2001/20/EC, or Directive, on January 31, 2022. The new Regulation overhauls the current system of approvals for clinical trials in the EU. Specifically, the new Regulation, which is directly applicable in all EU member states (meaning that no national implementing legislation in each EU member state is required), aims at simplifying and streamlining the approval of clinical trials in the EU. The main characteristics of the regulation include: a streamlined application procedure via a single-entry point through the Clinical Trials Information System, or CTIS; a single set of documents to be prepared and submitted for the application as well as simplified reporting procedures for clinical trial sponsors; and a harmonized procedure for the assessment of applications for clinical trials.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To obtain regulatory approval of a medicinal product under EU regulatory systems, we must submit an MAA. The centralized procedure provides for the grant of a single marketing authorization by the European Commission that is valid across all of the EU, and in the additional member states of the European Economic Area (Iceland, Liechtenstein and Norway). The scientific evaluation of MAAs for Advanced Therapy Medicinal Product, or ATMPS (which comprise gene therapy, somatic cell therapy and tissue engineered medicines) is primarily performed by a specialized scientific committee called the Committee for Advanced Therapies, or CAT. The CAT prepares a draft opinion on the quality, safety and efficacy of the ATMP which is the subject of the MAA, which is sent for final approval to the Committee for Medicinal Products for Human Use, or CHMP. The CHMP recommendation is then sent to the European Commission, which adopts a decision binding in all EU Member States. The maximum timeframe for the evaluation of an MAA for an ATMP is 210 days from receipt of a valid MAA, excluding clock stops when additional information or written or oral explanation is to be provided by the applicant in response to questions asked by the CAT and/or CHMP. Clock stops may extend the timeframe of evaluation of an MAA considerably beyond 210 days. Where the CHMP gives a positive opinion, the EMA provides the opinion together with supporting documentation to the European Commission, who make the final decision to grant a marketing authorization, which is issued within 67 days of receipt of the EMA&#x2019;s recommendation. Accelerated assessment may be granted by the CHMP in exceptional cases, when a medicinal product is of major public health interest, particularly from the viewpoint of therapeutic innovation. If the CHMP accepts such a request, the timeframe of 210 days for assessment will be reduced to 150 days (excluding clock stops), but it is possible that the CHMP may revert to the standard time limit for the centralized procedure if it determines that the application is no longer appropriate to conduct an accelerated assessment.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Products with an orphan designation in the EU can receive ten years of market exclusivity, during which time &#x201c;no similar medicinal product&#x201d; for the same indication may be placed on the market. A &#x201c;similar medicinal product&#x201d; is defined as a medicinal</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">42</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">product containing a similar active substance or substances as contained in an authorized orphan medicinal product, and which is intended for the same therapeutic indication. An orphan product can also obtain an additional two years of market exclusivity in the EU where an agreed pediatric investigation plan for pediatric studies has been complied with. The criteria for designating an &#x201c;orphan medicinal product&#x201d; in the EU are similar in principle to those in the United States. Under Article 3 of Regulation (EC) 141/2000, a medicinal product may be designated as an orphan medicinal product if it meets the following criteria: (1) it is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition; and (2) either (i) the prevalence of such condition must not be more than five in 10,000 persons in the EU when the application is made, or (ii) without the benefits derived from orphan status, it must be unlikely that the marketing of the medicine would generate sufficient return in the EU to justify the investment needed for its development; and (3) there exists no satisfactory method of diagnosis, prevention or treatment of such condition authorized for marketing in the EU, or if such a method exists, the product will be of significant benefit to those affected by the condition, as defined in Regulation (EC) 847/2000. Orphan medicinal products are eligible for financial incentives such as reduction of fees or fee waivers and are, upon grant of a marketing authorization, entitled to ten years of market exclusivity for the approved therapeutic indication. The application for orphan designation must be submitted before the application for marketing authorization. The applicant will receive a fee reduction for the MAA if the orphan designation has been granted, but not if the designation is still pending at the time the marketing authorization is submitted. Orphan designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process. The 10-year market exclusivity may be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan designation, for example, if the product is sufficiently profitable not to justify maintenance of market exclusivity. Otherwise, orphan medicine marketing exclusivity may be revoked only in very select cases, such as if: (i) a second applicant can establish that its product, although similar, is safer, more effective or otherwise clinically superior; (ii) the marketing authorization holder of the authorized orphan product consents to a second orphan medicinal product application; or (iii) the marketing authorization holder of the authorized orphan product cannot supply enough orphan medicinal product.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For other countries outside of the EU, such as countries in Eastern Europe, Latin America or Asia, the requirements governing the conduct of clinical trials, product licensing, pricing and reimbursement vary from country to country. In all cases, again, the clinical trials must be conducted in accordance with GCP and the applicable regulatory requirements and the ethical principles that have their origin in the Declaration of Helsinki.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we or our potential collaborators fail to comply with applicable foreign regulatory requirements, we may be subject to, among other things, fines, suspension or withdrawal of regulatory approvals, product recalls, seizure of products, operating restrictions and criminal prosecution.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">European Union General Data Protection Regulation</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition to EU regulations related to the approval and commercialization of our products, we may be subject to the EU&#x2019;s General Data Protection Regulation (GDPR). The GDPR imposes stringent requirements for controllers and processors of personal data of persons in the EU, including, for example, more robust disclosures to individuals and a strengthened individual data rights regime, shortened timelines for data breach notifications, limitations on retention of information, increased requirements pertaining to special categories of data, such as health data, and additional obligations when we contracts with third-party processors in connection with the processing of the personal data. The GDPR also imposes strict rules on the transfer of personal data out of the European Union to the United States and other third countries. In addition, the GDPR provides that EU member states may make their own further laws and regulations limiting the processing of personal data, including genetic, biometric or health data.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The GDPR applies extraterritorially, and we may be subject to the GDPR because of our data processing activities that involve the personal data of individuals located in the European Union, such as in connection with our EU clinical trials. Failure to comply with the requirements of the GDPR and the applicable national data protection laws of the EU member states may result in fines of up to &#x20ac;20,000,000 or up to 4% of the total worldwide annual turnover of the preceding financial year, whichever is higher, and other administrative penalties. GDPR regulations may impose additional responsibility and liability in relation to the personal data that we process and we may be required to put in place additional mechanisms to ensure compliance with the new data protection rules.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, further to the U.K.&#x2019;s exit from the EU on January 31, 2020, the GDPR ceased to apply in the U.K. at the end of the transition period on December 31, 2020. However, as of January 1, 2021, the U.K.&#x2019;s European Union (Withdrawal) Act 2018 incorporated the U.K. GDPR into U.K. law. The U.K. GDPR and the U.K. Data Protection Act 2018 set out the U.K.&#x2019;s data protection regime, which is independent from but aligned to the EU&#x2019;s data protection regime. Non-compliance with the U.K. GDPR may result in monetary penalties of up to &#163;17.5 million or 4% of worldwide revenue, whichever is higher. Although the UK is regarded as a third country under the EU&#x2019;s GDPR, the European Commission (&#x201c;EC&#x201d;) has now issued a decision recognizing the UK as providing adequate protection under the EU GDPR and, therefore, transfers of personal data originating in the EU to the UK remain unrestricted. Like the EU GDPR, the UK GDPR restricts personal data transfers outside the UK to countries not regarded by the UK as providing adequate protection. The UK government has confirmed that personal data transfers from the UK to the EEA remain free flowing.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">43</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To enable the transfer of personal data outside of the EEA or the UK, adequate safeguards must be implemented in compliance with European and UK data protection laws. On June 4, 2021, the EC issued new forms of standard contractual clauses for data transfers from controllers or processors in the EU/EEA (or otherwise subject to the GDPR) to controllers or processors established outside the EU/EEA (and not subject to the GDPR). The new standard contractual clauses replace the standard contractual clauses that were adopted previously under the EU Data Protection Directive. The UK is not subject to the EC&#x2019;s new standard contractual clauses but has published a draft version of a UK-specific transfer mechanism, which, once finalized, will enable transfers from the UK. We will be required to implement these new safeguards when conducting restricted data transfers under the EU and UK GDPR and doing so will require significant effort and cost.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Compliance with these and any other applicable privacy and data security laws and regulations is a rigorous and time-intensive process, and we may be required to put in place additional mechanisms ensuring compliance with the new data protection rules. If we fail to comply with any such laws or regulations, we may face significant fines and penalties that could adversely affect our business, financial condition and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">U.S. Data Privacy Law</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">California recently enacted legislation, effective January 1, 2020, that has been dubbed the first &#x201c;GDPR-like&#x201d; law in the United States. Known as the California Consumer Privacy Act (CCPA), it creates new individual privacy rights for consumers (as that word is broadly defined in the law) and places increased privacy and security obligations on entities handling personal data of consumers or households. The CCPA requires covered companies to provide new disclosures to California consumers, provides such consumers new ways to opt-out of certain sales of personal information, and allows for a new cause of action for data breaches. As our business progresses, the CCPA may impact (possibly significantly) our business activities and exemplifies the vulnerability of our business to the evolving regulatory environment related to personal data and protected health information.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Some observers have noted that the CCPA could mark the beginning of a trend toward more stringent privacy legislation in the United States, which could increase our potential liability and adversely affect our business.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Further, a new California privacy law, the California Privacy Rights Act, or CPRA, was passed by California voters on November 3, 2020. The CPRA will create additional obligations with respect to processing and storing personal information that are scheduled to take effect on January 1, 2023 (with certain provisions having retroactive effect to January 1, 2022). Additionally,  some observers have noted that the CCPA and CPRA could mark the beginning of a trend toward more stringent privacy legislation in the U.S., which could increase our potential liability and adversely affect our business. Already, in the United States, we have witnessed significant developments at the state level. For example, on March 2, 2021, Virginia enacted the Consumer Data Protection Act (the &#x201c;CDPA&#x201d;) and, on July 8, 2021, Colorado&#x2019;s governor signed the Colorado Privacy Act (&#x201c;CPA&#x201d;), into law. The CDPA and the CPA will both become effective January 1, 2023. While the CDPA and CPA incorporate many similar concepts of the CCPA and CPRA, there are also several key differences in the scope, application, and enforcement of the law that will change the operational practices of regulated businesses. The new laws will, among other things, impact how regulated businesses collect and process personal sensitive data, conduct data protection assessments, transfer personal data to affiliates, and respond to consumer rights requests.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A number of other states have proposed new privacy laws, some of which are similar to the above discussed recently passed laws. Such proposed legislation, if enacted, may add additional complexity, variation in requirements, restrictions and potential legal risk, require additional investment of resources in compliance programs, impact strategies and the availability of previously useful data and could result in increased compliance costs and/or changes in business practices and policies. The existence of comprehensive privacy laws in different states in the country would make our compliance obligations more complex and costly and may increase the likelihood that we may be subject to enforcement actions or otherwise incur liability for noncompliance.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Human Capital</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, we had 86 full-time employees and 16 consultants. Of our full-time employees, 24 hold a Ph.D. and 4 hold a M.D. None of our employees are represented by labor unions or covered by collective bargaining agreements. We consider our relationship with our employees to be good.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We offer attractive benefits, including competitive salaries, excellent health insurance, and a 401K match. We are committed to pay equity, regardless of gender, race/ethnicity, or sexual orientation and conduct comprehensive pay equity analyses on a semi-annual basis. In addition to providing strong benefits packages to employees, we believe in fostering individual and organizational effectiveness by offering our employees various professional development opportunities. We believe that investing in our employees&#x2019; career growth provides individuals and the organization with the knowledge and skills to respond effectively to current and future business demands and support to the organization&#x2019;s development efforts. Our culture is one that actively supports the application of new knowledge and skills on the job.</span><span style="background-color:rgba(0,0,0,0);color:rgba(51,51,51,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> In 2022, we plan to continue </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">add to our human capital resources as we grow. We are also monitoring the current landscape of wage inflation and labor shortages in connection with our employees' overall compensation.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">44</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Corporate Information</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prior to September 15, 2020, we were a clinical-stage biopharmaceutical company known as resTORbio, Inc. that had historically focused on developing innovative medicines that target the biology of aging, to prevent or treat age-related diseases with the potential to extend healthy lifespan. resTORbio was originally incorporated under the laws of the State of Delaware in July 2016 and commenced research and development operations in March 2017.<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On September 15, 2020, we completed our business combination whereby a wholly owned subsidiary of resTORbio, Inc. merged with and into Adicet Bio, Inc., with Adicet Bio, Inc. surviving as a wholly-owned subsidiary of resTORbio and changing our name to Adicet Therapeutics, Inc. In connection with the completion of the Merger, resTORbio was renamed Adicet Bio, Inc. (Adicet Bio).<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Immediately prior to the Effective Time of the Merger, resTORbio effected a reverse stock split of our common stock at a ratio of 1-for-7. At the Effective Time of the Merger, each outstanding share of former our capital stock was converted into the right to receive 0.1240 shares of resTORbio common stock.<br /><br />Our website is located at www.adicetbio.com. Our common stock trades on the Nasdaq Global Market under the symbol &#x201c;ACET.&#x201d;<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We own or have rights to various trademarks, service marks and trade names that we use in connection with the operation of our business. This Annual Report on Form 10-K may also contain trademarks, service marks and trade names of third parties, which are the property of their respective owners. Our use or display of third parties&#x2019; trademarks, service marks, trade names or products in this Annual Report on Form 10-K is not intended to, and does not imply a relationship with, or endorsement or sponsorship by us. Solely for convenience, the trademarks, service marks and trade names referred to in this Annual Report on Form 10-K may appear without the &#174;, &#153; or SM symbols, but the omission of such references is not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable law, our rights or the right of the applicable owner of these trademarks, service marks and trade names.<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Available Information</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our Internet address is www.adicetbio.com. Our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K, including exhibits, proxy and information statements and amendments to those reports filed or furnished pursuant to Sections 13(a), 14, and 15(d) of the Securities Exchange Act of 1934, as amended (the Exchange Act), are available through the &#x201c;Investors&#x201d; portion of our website free of charge as soon as reasonably practicable after we electronically file such material with, or furnish it to, the Securities and Exchange Commission (SEC). Information on our website is not part of this Annual Report on Form 10-K or any of our other securities filings unless specifically incorporated herein by reference. In addition, our filings with the SEC may be accessed through the SEC&#x2019;s Interactive Data Electronic Applications system at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">www.sec.gov</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. All statements made in any of our securities filings, including all forward-looking statements or information, are made as of the date of the document in which the statement is included, and we do not assume or undertake any obligation to update any of those statements or documents unless we are required to do so by law.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">45</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="risk_factors"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 1A.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> Risk Factors.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Investing in our common stock involves a high degree of risk. In evaluating the Company and our business, you should carefully consider the following risks and uncertainties, together with all other information in this Annual Report on Form 10-K, including our consolidated financial statements and related notes and &#x201c;Management&#x2019;s Discussion and Analysis of Results of Operations and Financial Condition,&#x201d; as well as our other filings with the Securities and Exchange Commission (SEC), before investing in our common stock. Any of the risk factors we describe below could adversely affect our business, financial condition or results of operations. The market price of our common stock could decline if one or more of these risks or uncertainties actually occur, causing you to lose all or part of your investment in our common stock. The risks and uncertainties we describe below are not the only ones we face. Additional risks and uncertainties that we currently do not know about or that we currently believe to be immaterial may also impair our business. Certain statements below are forward-looking statements. See &#x201c;Special Note Regarding Forward-Looking Statements and Industry Data&#x201d; in this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Our Business and Industry</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Operating History</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We have a limited operating history and face significant challenges and expense as we build our capabilities.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. We began operation in November 2014. We have a limited operating history upon which someone can evaluate our business and prospects and is subject to the risks inherent in any early stage company, including, among other things, risks that we may not be able to hire sufficient qualified personnel and establish operating controls and procedures. We currently do not have complete in-house resources to enable our gamma delta T cell platform. As we build our own capabilities, we expect to encounter risks and uncertainties frequently experienced by growing companies in new and rapidly evolving fields, including the risks and uncertainties described herein. Consequently, any predictions made about our future success or viability may not be as accurate as they could be if we had a history of successfully developing and commercializing biopharmaceutical products.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We have incurred net losses in every period since our inception and anticipate that we will incur substantial net losses in the future.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are an early clinical stage biopharmaceutical company. Investment in biopharmaceutical product development is highly speculative because it entails substantial upfront capital expenditures and significant risk that any potential product candidate will fail to demonstrate adequate effect or an acceptable safety profile, gain regulatory approval and become commercially viable. We have no products approved for commercial sale and have not generated any revenue from product sales to date, and we will continue to incur significant research and development and other expenses related to our ongoing operations. As a result, we are not profitable and have incurred net losses in each period since our inception. To date, we have financed our operations primarily with proceeds from our license and collaboration agreements and the issuance and sale of our capital stock, including a follow-on public offering in December 2021 which raised net proceeds of approximately $94.2 million from the sale of our common stock. For the years ended December 31, 2021 and 2020, we reported net losses of $62.0 million and $36.7 million, respectively. As of December 31, 2021, we had an accumulated deficit of $168.3 million.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We expect to incur significant expenditures for the foreseeable future, and we expect these expenditures to increase as we continue our research and development of, and seek regulatory approvals for, product candidates based on our gamma delta T cell platform, including ADI-001. Even if we succeed in commercializing one or more of our product candidates, we will continue to incur substantial research and development and other expenditures to develop and market additional product candidates. We may encounter unforeseen expenses, difficulties, complications, delays and other unknown factors that may adversely affect our business. The size of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenue. Our prior losses and expected future losses have had and will continue to have an adverse effect on our stockholders&#x2019; equity and working capital. Further, even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would depress the value of our company and could impair our ability to raise capital, expand our business, maintain our research and development efforts, diversify our product candidates or even continue our operations, any of which could have a material adverse effect on our business, financial condition, results of operations, and prospects and cause investors to lose all or part of their investments.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">46</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our history of recurring losses and anticipated expenditures could raise substantial doubts about our ability to continue as a going concern.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In our financial statements for the period ending to December 31, 2020, we concluded that our recurring losses from operations and need for additional financing to fund future operations raised substantial doubt about our ability to continue as a going concern. Similarly, our independent registered public accounting firm included an explanatory paragraph in its report on our financial statements for the period ended December 31, 2020 with respect to this uncertainty. As of December 31, 2021, we believe that with our existing cash and cash equivalents we are able to fund our expenses and capital expenditure requirements beyond twelve months from the issuance of these financial statements and into the second half of 2024. Our ability to continue as a going concern beyond this point will require us to obtain additional funding. If we are unable to obtain sufficient funding, our business, prospects, financial condition and results of operations will be materially and adversely affected, and we may be unable to continue as a going concern. If we are unable to raise capital when needed or on acceptable terms, we would be forced to delay, limit, reduce or terminate our product development or future commercialization efforts of one or more of our product candidates, or may be forced to reduce or terminate our operations. If we are unable to continue as a going concern, we may have to liquidate our assets and may receive less than the value at which those assets are carried on our audited financial statements, and it is likely that investors will lose all or a part of their investment. In our own future required quarterly assessments, we may again conclude that there is substantial doubt about our ability to continue as a going concern, and future reports from our independent registered public accounting firm may also contain statements expressing substantial doubt about our ability to continue as a going concern. If we seek additional financing to fund our business activities in the future and there exists substantial doubt about our ability to continue as a going concern, investors or other financing sources may be unwilling to provide additional funding to us on commercially reasonable terms, if at all.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Our Product Candidates</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our business is highly dependent on the success of ADI-001. If we are unable to obtain approval for ADI-001 and effectively commercialize ADI-001  for the treatment of patients in our approved indications, our business would be significantly harmed.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our business and future success depends on our ability to obtain regulatory approval of, and then successfully commercialize, our most advanced product candidate, ADI-001. ADI-001 is in the early stages of development with an ongoing Phase 1 study to assess the safety and efficacy of ADI-001 in Non-Hodgkin's Lymphoma (NHL) patients that commenced in March 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our preclinical or clinical results to date may not predict results for our planned or ongoing trials or any future studies of ADI-001 or any other allogeneic gamma delta T cell product candidate. Because of the lack of evaluation of allogeneic products and gamma delta T cell therapy products in the clinic to date, any such product&#x2019;s failure, or the failure of other allogeneic T cell therapies or gamma delta T cell therapies, may significantly influence physicians&#x2019; and regulators&#x2019; opinions in regards to the viability of our entire pipeline of allogeneic T cell therapies, which could have a material adverse effect on our reputation. If our gamma delta T cell therapy is viewed as less safe or effective than autologous therapies or other allogeneic T cell therapies, our ability to develop other allogeneic gamma delta T cell therapies may be significantly harmed.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All of our product candidates, including ADI-001 , will require additional clinical and non-clinical development, regulatory review and approval in multiple jurisdictions, substantial investment, access to sufficient commercial manufacturing capacity and significant marketing efforts before we can generate any revenue from product sales. In addition, because ADI-001 is our most advanced product candidate, and because our other product candidates are based on similar technology, if ADI-001 encounters safety or efficacy problems, manufacturing problems, developmental delays, regulatory issues or other problems, our development plans and business would be significantly harmed, which could have a material adverse effect on our business, reputation and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our gamma delta T cell candidates represent a novel approach to cancer treatment that creates significant challenges for us.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are developing a pipeline of gamma delta T cell product candidates and a novel antibody platform that are intended for use in patient with certain cancers. Advancing these novel product candidates creates significant challenges for us, including:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">manufacturing our product candidates to our specifications and in a timely manner to support our future clinical trials, and, if approved, commercialization;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">sourcing future clinical and, if approved, commercial supplies for the raw materials used to manufacture our product candidates;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">understanding and addressing variability in the quality of a donor&#x2019;s T cells, which could ultimately affect our ability to produce product in a reliable and consistent manner;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">inability to achieve efficacy in cancer patients following treatment with our product candidates;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">47</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">achieving a side effect profile, including graft-versus-host disease (GvHD), from our product candidates that makes them commercially attractive for further development;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">educating medical personnel regarding the potential side effect profile of our product candidates, if approved;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">using medicines to manage adverse side effects of our product candidates which may not adequately control the side effects and/or may have a detrimental impact on the efficacy of the treatment;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">conditioning patients with chemotherapy or other lymphodepletion agents in advance of administering our product candidates, which may increase the risk of adverse side effects;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">obtaining regulatory approval, as the U.S. Food and Drug Administration (FDA) and other regulatory authorities have limited experience with development of allogeneic T cell therapies for cancer; and </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">establishing sales and marketing capabilities upon obtaining any regulatory approval to gain market acceptance of a novel therapy.</span></div></div>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The success of our business, including our ability to obtain financing and generate any revenue in the future, will primarily depend on the successful development, manufacturing, positive efficacy and safety profile in our clinical trials, regulatory approval and commercialization of our novel product candidates, which may never occur. We have not yet succeeded and may not succeed in demonstrating efficacy and safety for any of our product candidates in clinical trials or in obtaining marketing approval thereafter. Given our early stage of development, it may be several years, if at all, before we have demonstrated the safety and efficacy of a product candidate sufficient to warrant approval for commercialization. If we are unable to develop, or obtain regulatory approval for, or, if approved, successfully commercialize our product candidates, we may not be able to generate sufficient revenue to continue our business, which could have a material adverse effect on our results of operations and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our product candidates are based on novel technologies, which makes it difficult to predict the likely success of such product candidates and the time and cost of product candidate development and obtaining regulatory approval.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have concentrated our research and development efforts on our allogeneic gamma delta T cell therapy and our future success depends on the successful development of this therapeutic approach. We are in the early stages of developing our platform and product candidates and there can be no assurance that any development problems we have experienced or may experience in the future will not cause significant delays or result in unforeseen issues or unanticipated costs, or that any such development problems or issues can be overcome. We may also experience delays in developing a sustainable, reproducible and scalable manufacturing process or transferring that process to commercial partners, which may prevent us from completing our future clinical studies or commercializing our products on a timely or profitable basis, if at all. In addition, our expectations with regard to the advantages of an allogenic gamma delta T cell therapy platform relative to other therapies may not materialize or materialize to the degree we anticipate. Further, our scalability and costs of manufacturing may vary significantly as we develop our product candidates and understand these critical factors.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, the clinical study requirements of the FDA, European Medicines Agency (EMA) and other regulatory agencies and the criteria these regulators use to determine the safety and efficacy of a product candidate are determined according to the type, complexity, novelty and intended use and market of the potential products. The regulatory approval process for novel product candidates such as ours can be more complex and consequently more expensive and take longer than for other, better known or extensively studied pharmaceutical or other product candidates. Approvals by the EMA and FDA for existing autologous CAR-T therapies, such as Kymriah&#174; and Yescarta&#174;, may not be indicative of what these regulators may require for approval of our therapies. Also, while we expect reduced variability in our products candidates compared to autologous products, we do not have significant clinical data supporting any benefit of lower variability. More generally, approvals by any regulatory agency may not be indicative of what any other regulatory agency may require for approval or what such regulatory agencies may require for approval in connection with new product candidates.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our product candidates may also not perform successfully in clinical trials or may be associated with adverse events that distinguish them from the autologous CAR-T therapies that have previously been approved or alpha beta T cell therapies that may be approved in the future. Unexpected clinical outcomes could materially and adversely affect our business, results of operations and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">48</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our product candidates may cause undesirable side effects or have other properties that could halt our clinical development, prevent our regulatory approval, limit our commercial potential or result in significant negative consequences.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Undesirable or unacceptable side effects caused by our product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign regulatory authorities. Results of our clinical trials could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. Approved autologous CAR-T therapies and those under development have shown frequent rates of cytokine release syndrome and neurotoxicity, and adverse events have resulted in the death of patients. While we believe our gamma delta T cell approach may lessen such results, similar or other adverse events for our allogeneic gamma delta T cell product candidates may occur. In addition, while we anticipate our focus on gamma delta T cells may lessen the likelihood of GvHD relative to therapies relying on unrelated alpha beta T cells, similar or other adverse events for our allogeneic gamma delta T cell product candidates may occur.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If unacceptable toxicities arise in the development of our product candidates, we could suspend or terminate our trials or the FDA or comparable foreign regulatory authorities could order us to cease clinical trials or deny approval of our product candidates for any or all targeted indications. The data safety monitoring board may also suspend or terminate a clinical trial at any time on various grounds, including a finding that the research patients are being exposed to an unacceptable health risk, including risks inferred from other unrelated immunotherapy trials. Treatment-related side effects could also affect patient recruitment or the ability of enrolled subjects to complete the trial or result in potential product liability claims. Novel therapeutic candidates, such as those we are developing, may result in novel side effect profiles that may not be appropriately recognized or managed by the treating medical staff. We anticipate having to train medical personnel using our product candidates to understand the side effect profile of our product candidates for our clinical trials and upon any commercialization of any of our product candidates. Inadequate training in recognizing or managing the potential side effects of our product candidates could result in serious adverse events including patient deaths. Based on available preclinical data and on management&#x2019;s clinical experience with other cell therapy agents, the safety profile of our pipeline product candidates is expected to include cytokine release syndrome, neurotoxicity, and possibly additional adverse events. Any of these occurrences may have a material adverse effect our business, financial condition and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Clinical Trials</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our clinical trials may fail to demonstrate the safety and efficacy of any of our product candidates, which would prevent or delay regulatory approval and commercialization.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Before obtaining regulatory approvals for the commercial sale of our product candidates, including ADI-001 and ADI-002, we must demonstrate through lengthy, complex and expensive preclinical testing and clinical trials that our product candidates are both safe and effective for use in each target indication. Clinical testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. The results of preclinical studies and early clinical trials of our product candidates may not be predictive of the results of later-stage clinical trials.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There is typically an extremely high rate of attrition from the failure of product candidates proceeding through clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy profile despite having progressed through preclinical studies and initial clinical trials. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy, insufficient durability of efficacy or unacceptable safety issues, notwithstanding promising results in earlier trials. Most product candidates that commence clinical trials are never approved as products.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, for ADI-001 and ADI-002 and any future trials that may be completed, we cannot guarantee that the FDA or foreign regulatory authorities will interpret the results as we do, and more trials could be required before we submit our product candidates for approval. To the extent that the results of the trials are not satisfactory to the FDA or foreign regulatory authorities for support of a marketing application, approval of our product candidates may be significantly delayed, or we may be required to expend significant additional resources, which may not be available to us, to conduct additional trials in support of potential approval of our product candidates. Any of the foregoing could have a material adverse effect on our business, prospects and financial condition.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may not be able to file investigational new drug (IND) applications to commence additional clinical trials on the timelines we expect, and even if we are able to, the FDA may not permit us to proceed.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In October 2020, the IND for our lead product candidate, ADI-001, to treat patients with NHL was cleared by the FDA. Even if such regulatory authorities agree with the design and implementation of the clinical trials set forth in an IND or clinical trial application, we cannot guarantee that such regulatory authorities will not change their requirements in the future. Moreover, we cannot be sure that submission of an IND for any of our other product candidates will result in the FDA allowing trials to begin, or that, once begun, issues will not arise that result in a decision by us, by independent Institutional Review Boards (IRBs) or independent ethics committees, or by the FDA or other regulatory authorities to suspend or terminate clinical trials. For</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">49</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">example, we may experience manufacturing delays or other delays with IND-enabling studies or the FDA or other regulatory authorities may require additional preclinical studies that we did not anticipate.  Moreover, we cannot be assured that submission of an IND will result in the FDA allowing clinical trials to begin, or that, once begun, issues will not arise that result in a decision by us, by IRBs, or independent ethics committees or by the FDA or other regulatory authorities to suspend or terminate clinical trials, including as a result of a clinical hold. Additionally, even if such regulatory authorities agree with the design and implementation of the clinical trials set forth in an IND or clinical trial application, we cannot guarantee that such regulatory authorities will not change their requirements in the future. The inability to initiate clinical trials any of our product candidates on the timeline currently anticipated or at all could have a material adverse effect on our business, results of operations and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may encounter substantial delays in our clinical trials, or may not be able to conduct our trials on the timelines we expect.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Clinical testing is expensive, time consuming and subject to uncertainty. We cannot guarantee that any clinical studies will be conducted as planned or completed on schedule, if at all. Even if these trials begin as planned, issues may arise that could suspend or terminate such clinical trials. A failure of one or more clinical studies can occur at any stage of testing, and our future clinical studies may not be successful. Events that may prevent successful or timely completion of clinical development include:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">inability to generate sufficient preclinical, toxicology or other in vivo or in vitro data to support the initiation of clinical studies;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">delays in sufficiently developing, characterizing or controlling a manufacturing process suitable for advanced clinical trials;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">delays in developing suitable assays for screening patients for eligibility for trials with respect to certain product candidates;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">delays in reaching a consensus with regulatory agencies on study design;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">delays in reaching agreement on acceptable terms with prospective contract research organizations (CROs) and clinical study sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and clinical study sites;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">delays in obtaining required IRB approval at each clinical study site;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">imposition of a temporary or permanent clinical hold by regulatory agencies for a number of reasons, including after review of an IND application or amendment, or equivalent application or amendment; as a result of a safety finding that presents unreasonable risk to clinical trial participants; a negative finding from an inspection of our clinical study operations or study sites; developments on trials conducted by competitors for related technology that raises FDA concerns about risk to patients of the technology broadly; or if FDA finds that the investigational protocol or plan is clearly deficient to meet its stated objectives;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">delays in recruiting suitable patients to participate in our clinical studies;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">difficulty collaborating with patient groups and investigators;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">failure by our CROs, other third parties or it to adhere to clinical study requirements;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">failure to perform in accordance with the FDA&#x2019;s Good Clinical Practice (GCP) requirements or applicable regulatory guidelines in other countries;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">transfer of manufacturing processes to any new contract manufacturing organization (CMO) or our own manufacturing facilities or any other development or commercialization partner for the manufacture of product candidates;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">delays in having patients&#x2019; complete participation in a study or return for post-treatment follow-up;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">patients dropping out of a study;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">occurrence of adverse events associated with the product candidate that are viewed to outweigh its potential benefits;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">changes in the standard of care on which a clinical development plan was based, which may require new or additional trials;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the cost of clinical studies of our product candidates being greater than we anticipate;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">clinical studies of our product candidates producing negative or inconclusive results, which may result in us deciding, or regulators requiring us, to conduct additional clinical studies or abandon product development programs;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">delays or failure to secure supply agreements with suitable raw material suppliers, or any failures by suppliers to meet our quantity or quality requirements for necessary raw materials; and</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">delays in manufacturing, testing, releasing, validating, or importing/exporting sufficient stable quantities of our product candidates for use in clinical studies or the inability to do any of the foregoing.</span></div></div>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our timing of filing on these product candidates is dependent on further preclinical and manufacturing success, which we work on with various third parties. We cannot be sure that we will be able to submit our INDs in a timely manner, if at all, or that submission of an IND or IND amendment will result in the FDA allowing testing and clinical trials to begin, or that, once begun, issues will not arise that suspend or terminate such clinical trials. Additionally, even if such regulatory authorities agree with the design and implementation of the clinical trials set forth in an IND or clinical trial application, we cannot guarantee that such regulatory authorities will not change their requirements in the future.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any inability to successfully complete preclinical and clinical development could result in additional costs to us or impair our ability to generate revenue. In addition, if we make manufacturing or formulation changes to our product candidates, we may be required to or we may elect to conduct additional studies to bridge our modified product candidates to earlier versions. Clinical study delays could also shorten any periods during which our products have patent protection and may allow our competitors to bring products to market before we do, which could impair our ability to successfully commercialize our product candidates and may harm our business and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Monitoring safety of patients receiving our product candidates is challenging, which could adversely affect our ability to obtain regulatory approval and commercialize.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In our planned clinical trials of our product candidates, we have contracted with and expect to continue to contract with academic medical centers and hospitals experienced in the assessment and management of toxicities arising during clinical trials. Nonetheless, these centers and hospitals may have difficulty observing patients and treating toxicities, which may be more challenging due to personnel changes, inexperience, shift changes, house staff coverage or related issues. This could lead to more severe or prolonged toxicities or even patient deaths, which could result in us or the FDA delaying, suspending or terminating one or more of our clinical trials, and which could jeopardize regulatory approval. Medicines used at centers to help manage adverse side effects of ADI-001 and ADI-002 may not adequately control the side effects and/or may have a detrimental impact on the efficacy of the treatment. Use of these medicines may increase with new physicians and centers administering our product candidates, any of which could have a material adverse effect on our ability to obtain regulatory approval and commercialize on the timelines anticipated or at all, which could have a material adverse effect on our business and results of operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If we encounter difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise adversely affected.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may experience difficulties in patient enrollment in our clinical trials for a variety of reasons, including, without limitation, the impact of the ongoing COVID-19 pandemic. The timely completion of clinical trials in accordance with the protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the study until the conclusion. The enrollment of patients depends on many factors, including:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the patient eligibility criteria defined in the protocol;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the size of the patient population required for analysis of the trial&#x2019;s primary endpoints;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the proximity of patients to study sites;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the design of the trial;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our ability to recruit clinical trial investigators with the appropriate competencies and experience;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our ability to obtain and maintain patient consents; and</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">51</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the risk that patients enrolled in clinical trials will drop out of the trials before the infusion of our product candidates or trial completion.</span></div></div>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We intend to conduct a number of clinical trials for product candidates in the fields of cancer in different geographies, all of which have been affected to varying extents by the ongoing COVID-19 pandemic. We believe that the coronavirus pandemic will have an impact on various aspects of our future clinical trials. For example, investigators may not want to take the risk of exposing cancer patients to COVID-19 since the dosing of patients is conducted within an in-patient setting. Other potential impacts of the COVID-19 pandemic on our future various clinical trials include patient dosing and study monitoring, which may be paused or delayed due to changes in policies at various clinical sites, federal, state, local or foreign laws, rules and regulations, including quarantines or other travel restrictions, prioritization of healthcare resources toward pandemic efforts, including diminished attention of physicians serving as our clinical trial investigators and reduced availability of site staff supporting the conduct of our clinical trials, interruption or delays in the operations of the government regulators, or other reasons related to the COVID-19 pandemic. It is unknown how long these pauses or disruptions could continue.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, our clinical trials will compete with other clinical trials for product candidates that are in the same therapeutic areas as our product candidates, and this competition will reduce the number and types of patients available to us because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial being conducted by one of our competitors. Since the number of qualified clinical investigators is limited, some of our clinical trial sites are also being used by some of our competitors, which may reduce the number of patients who are available for our clinical trials in that clinical trial site.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Moreover, because our product candidates represent unproven methods for cancer treatment, potential patients and their doctors may be inclined to use conventional therapies, such as chemotherapy and hematopoietic cell transplantation or autologous CAR-T cell therapies, rather than enroll patients in our clinical trial. Patients eligible for allogeneic CAR-T cell therapies but ineligible for autologous CAR-T cell therapies due to aggressive cancer and inability to wait for autologous CAR-T cell therapies may be at greater risk for complications and death from therapy.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Delays in patient enrollment may result in increased costs or may affect the timing or outcome of our ongoing clinical trial and planned clinical trials, which could prevent completion of these trials and adversely affect our ability to advance the development of our product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Clinical trials are expensive, time-consuming and difficult to design and implement.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Human clinical trials are expensive and difficult to design and implement, in part because they are subject to rigorous regulatory requirements. Because our gamma delta T cell product candidates are based on new technologies and will require the creation of inventory of mass-produced, off-the-shelf products, we expect that we will require extensive research and development and have substantial manufacturing and processing costs. In addition, costs to treat patients with NHL cancer and to treat potential side effects that may result from our product candidates can be significant. Accordingly, our clinical trial costs are likely to be significantly higher than for more conventional therapeutic technologies or drug products, which is expected to have a material adverse effect on our financial position and ability to achieve profitability.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">A variety of risks associated with conducting research and clinical trials abroad and marketing our product candidates internationally could materially adversely affect our business.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We plan to globally develop our product candidates. Accordingly, we expect that it will be subject to additional risks related to operating in foreign countries, including:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">differing regulatory requirements in foreign countries;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">unexpected changes in tariffs, trade barriers, price and exchange controls and other regulatory requirements;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">increased difficulties in managing the logistics and transportation of storing and shipping product candidates produced in the United States and shipping the product candidate to the patient abroad;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">import and export requirements and restrictions;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">economic weakness, including inflation, or political instability in particular foreign economies and markets;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">foreign taxes, including withholding of payroll taxes;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">52</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">difficulties staffing and managing foreign operations;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">workforce uncertainty in countries where labor unrest is more common than in the United States; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">differing payor reimbursement regimes, governmental payors or patient self-pay systems, and price controls;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">potential liability under the Foreign Corrupt Practices Act or comparable foreign regulations;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">challenges enforcing our contractual and intellectual property rights, especially in those foreign countries that do not respect and protect intellectual property rights to the same extent as the United States;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">business interruptions resulting from geo-political actions, including war and terrorism.</span></div></div>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">These and other risks associated with our potential international operations may materially adversely affect our ability to attain or maintain profitable operations, which could have a material adverse effect on our business and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Marketing Our Product Candidates</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The market opportunities for our product candidates may be limited to those patients who are ineligible for or have failed prior treatments and may be small.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA often approves new therapies initially only for use in patients who are currently not adequately treated with currently approved therapies. We expect to initially seek approval of ADI-001 and our other product candidates in this setting. Subsequently, for those products that prove to be sufficiently beneficial, if any, we would expect to seek approval in earlier lines of treatment and potentially as a first line therapy. There is no guarantee that our product candidates, even if approved, would be approved for earlier lines of therapy, and, prior to any such approvals, we will have to conduct additional clinical trials, including potentially comparative trials against approved therapies. We are also targeting a similar patient population as autologous CAR-T product candidates, including approved autologous CAR-T products. Our therapies may not be as safe and effective as autologous CAR-T therapies and may only be approved for patients who are ineligible for autologous CAR-T therapy.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our projections of both the number of people who have the cancers we are targeting, as well as the subset of people with these cancers in a position to receive second or later lines of therapy and who have the potential to benefit from treatment with our product candidates, are based on our beliefs and estimates. These estimates have been derived from a variety of sources, including scientific literature, patient foundations, or market research and may prove to be incorrect. Further, new studies may change the estimated incidence or prevalence of these cancers. The number of patients may turn out to be lower than expected. Additionally, the potentially addressable patient population for our product candidates may be limited or may not be amenable to treatment with our product candidates. Even if we obtain significant market share for our product candidates, because the potential target populations are small, we may never achieve profitability without obtaining regulatory approval for additional indications.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If we fail to develop additional product candidates, our commercial opportunity will be limited.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">One of our core strategies is to pursue clinical development of additional product candidates beyond ADI-001. Developing, obtaining regulatory approval and commercializing additional gamma delta T cell product candidates will require substantial additional funding and is prone to the risks of failure inherent in medical product development. We cannot provide you any assurance that it will be able to successfully advance any of these additional product candidates through the development process.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Even if we receive FDA approval to market additional product candidates for the treatment of cancer, we cannot assure you that any such product candidates will be successfully commercialized, widely accepted in the marketplace or more effective than other commercially available alternatives. If we are unable to successfully develop and commercialize additional product candidates, our commercial opportunity will be limited. Moreover, a failure in obtaining regulatory approval of additional product candidates may have a negative effect on the approval process of any other, or result in losing approval of any approved, product candidate which could have a material adverse effect on our business and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">53</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We currently have no marketing and sales organization and as a company have no experience in marketing products. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our product candidates, we may not be able to generate product revenue.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We currently have no sales, marketing or distribution capabilities and as a company have no experience in marketing products. We may develop a marketing organization and sales force, which will require significant capital expenditures, management resources and time. We will have to compete with other pharmaceutical and biotechnology companies to recruit, hire, train and retain marketing and sales personnel.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we are unable or decide not to establish internal sales, marketing and distribution capabilities, we will pursue collaborative arrangements regarding the sales and marketing of our products; however, there can be no assurance that we will be able to establish or maintain such collaborative arrangements, or if we are able to do so, that it will have effective sales forces. Any revenue we receive will depend upon the efforts of such third parties, which may not be successful. We may have little or no control over the marketing and sales efforts of such third parties and our revenue from product sales may be lower than if we had commercialized our product candidates ourselves. We also face competition in our search for third parties to assist us with the sales and marketing efforts of our product candidates.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There can be no assurance that we will be able to develop in-house sales and distribution capabilities or establish or maintain relationships with third-party collaborators to commercialize any product that receives regulatory approval in the United States or overseas. If we are unable to successfully market and distribute our products, our business, results of operations and prospects could be materially adversely affected.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.0925;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The biopharmaceutical industry, and the immuno-oncology industry specifically, is characterized by intense competition and rapid innovation. Our competitors may be able to develop other compounds or drugs that are able to achieve similar or better results. Our potential competitors include major multinational pharmaceutical companies, established biotechnology companies, specialty pharmaceutical companies and universities and other research institutions. Many of our competitors have substantially greater financial, technical and other resources, such as larger research and development staff and experienced marketing and manufacturing organizations and well-established sales forces. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large, established companies. Mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in our competitors. Competition may increase further as a result of advances in the commercial applicability of technologies and greater availability of capital for investment in these industries. Our competitors, either alone or with collaborative partners, may succeed in developing, acquiring or licensing on an exclusive basis drug or biologic products that are more effective, safer, more easily commercialized or less costly than our product candidates or may develop proprietary technologies or secure patent protection that we may need for the development of our technologies and products.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Specifically, engineered T cells face significant competition in both the chimeric antigen receptor (CAR) and T cell receptor (TCR) technology space from multiple companies. Even if we obtain regulatory approval of our product candidates, the availability and price of our competitors&#x2019; products could limit the demand and the price we are able to charge for our product candidates. We may not be able to implement our business plan if the acceptance of our product candidates is affected by price competition or the reluctance of physicians to switch from existing methods of treatment to our product candidates, or if physicians switch to other new drug or biologic products or choose to reserve our product candidates for use in limited circumstances.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Manufacturing</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We do not currently operate our own manufacturing facility and currently depend on the ability of our third-party suppliers and manufacturers with whom we contract to perform adequately, particularly with respect to the timely production and delivery of our product candidates, including ADI-001. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We do not currently own or operate any manufacturing facilities. We rely, and expect to continue to rely, on third parties for the manufacture of our product candidates for preclinical and clinical development. We may not be able to achieve clinical or commercial manufacturing and cell processing on our own or through our contract manufacturing organizations (CMOs), including timely supply of off-the-shelf product to satisfy demands to support clinical trials of any of our product candidates. Very few companies have experience in manufacturing gamma delta T cell therapy derived from blood of unrelated donors and gamma delta T cells require several complex manufacturing steps before being available as a mass-produced, off-the-shelf product. While we believe our manufacturing and processing approaches are appropriate to support our clinical product development, we have limited experience in managing the allogeneic gamma delta T cell engineering process, and our allogeneic</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">54</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">processes may be more difficult or more expensive than the approaches taken by our competitors. We cannot be sure that the manufacturing processes employed by or on our behalf will result in T cells that will be safe and effective.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our operations remain subject to review and oversight by the FDA and the FDA could object to our use of any manufacturing facilities. We must first receive approval from the FDA prior to licensure to manufacture our product candidates, which we may never obtain. Even if approved, we would be subject to ongoing periodic unannounced inspection by the FDA and corresponding state agencies to ensure strict compliance with current Good Manufacturing Practices (cGMPs) and other government regulations. Our license to manufacture product candidates will be subject to continued regulatory review.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our cost of goods development is at an early stage. The actual cost to manufacture and process our product candidates could be greater than we expect and could materially and adversely affect the commercial viability of our product candidates.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The manufacture of biopharmaceutical products is complex and requires significant expertise, including the development of advanced manufacturing techniques and process controls. Manufacturers of cell therapy products often encounter difficulties in production, particularly in scaling out and validating initial production and ensuring the absence of contamination. These problems include difficulties with production costs and yields, quality control, including stability of the product, quality assurance testing, operator error, shortages of qualified personnel, as well as compliance with strictly enforced federal, state and foreign regulations. Furthermore, if contaminants are discovered in our supply of product candidates or in the manufacturing facilities, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination. We cannot assure you that any stability or other issues relating to the manufacture of our product candidates will not occur in the future.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our product candidates and any products that we may develop may compete with other product candidates and approved products for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may fail to manage the logistics of storing and shipping our product candidates. Storage failures and shipment delays and problems caused by us, our vendors or other factors not in our control, such as weather, could result in loss of usable product or prevent or delay the delivery of product candidates to patients.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may also experience manufacturing difficulties due to resource constraints or as a result of labor disputes. If we were to encounter any of these difficulties, our ability to provide our product candidates to patients would be jeopardized, which could have a material adverse effect on our business, results of operations and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Our Operations</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We are highly dependent on our key personnel, and if we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our ability to compete in the highly competitive biotechnology and pharmaceutical industries depends upon our ability to attract and retain highly qualified managerial, scientific and medical personnel. We are highly dependent on our management, scientific and medical personnel. The loss of the services of any of our executive officers, other key employees, and other scientific and medical advisors, and our inability to find suitable replacements could result in delays in product development and harm our business.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We conduct substantially all of our operations at our facilities in the San Francisco Bay Area. This region is headquarters to many other biopharmaceutical companies and many academic and research institutions. Competition for skilled personnel in this market is intense and may limit our ability to hire and retain highly qualified personnel on acceptable terms or at all.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To induce valuable employees to remain at the company, in addition to salary and cash incentives, we have provided stock options and restricted stock units that vest over time. The value to employees of stock options that vest over time may be significantly affected by fluctuations in our stock price that are beyond our control and may at any time be insufficient to counteract more lucrative offers from other companies. Despite our efforts to retain valuable employees, members of our management, scientific and development teams may terminate their employment with us on short notice. Although we have employment agreements with our key employees, these employment agreements provide for at-will employment, which means that any of our employees could leave our employment at any time, with or without notice. We do not maintain &#x201c;key person&#x201d; insurance policies on the lives of these individuals or the lives of any of our other employees. Our success also depends on our ability to continue to attract, retain and motivate highly skilled junior, mid-level and senior managers as well as junior, mid-level and senior scientific and medical personnel.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">55</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We will need substantial additional financing to develop our products and implement our operating plans. If we fail to obtain additional financing, we may be unable to complete the development and commercialization of our product candidates.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We expect to spend a substantial amount of capital in the clinical development of our product candidates, including the ongoing Phase 1 clinical trial for ADI-001. We will need substantial additional financing to develop our products and implement our operating plans. In particular, we will require substantial additional financing to enable commercial production of our products and initiate and complete registration trials for multiple products. Further, if approved, we will require significant additional amounts in order to launch and commercialize our product candidates.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, we believe that with our cash and cash equivalents we are able to fund our expenses and capital expenditure requirements beyond twelve months from the issuance date of the accompanying consolidated financial statements. However, changing circumstances may cause us to consume capital significantly faster than we currently anticipate, and we may need to spend more money than currently expected because of circumstances beyond our control. We may require additional capital for the further development and commercialization of our product candidates, including funding our internal manufacturing capabilities and may need to raise additional funds sooner if we choose to expand more rapidly than we presently anticipate.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We cannot be certain that additional funding will be available on acceptable terms, or at all. Other than the funding agreement and our loan agreement with Pacific Western Bank, we have no committed source of additional capital and if we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back or discontinue the development or commercialization of our product candidates or other research and development initiatives. Our license agreements may also be terminated if we are unable to meet the payment obligations under the agreements. We could be required to seek collaborators for our product candidates at an earlier stage than otherwise would be desirable or on terms that are less favorable than might otherwise be available or relinquish or license on unfavorable terms our rights to our product candidates in markets where we otherwise would seek to pursue development or commercialization themselves. Additionally, we may not be able to incur indebtedness if the ongoing macroeconomic effects of the COVID-19 pandemic, including certain actions taken by U.S. or other governmental authorities, such as decreases in short-term interest rates as announced by the Federal Reserve, cause the closure of banks for an extended period of time or a sudden increase in requests for indebtedness at one time by many potential borrowers, either or both of which could overwhelm the banking industry. Furthermore, the impact of geopolitical tension, such as a deterioration in the bilateral relationship between the United States and China or an escalation in conflict between Russia and Ukraine, including any resulting sanctions, export controls or other restrictive actions, also could lead to disruption, instability and volatility in the global markets, which may have an impact on our ability to obtain additional funding.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any of the above events could significantly harm our business, prospects, financial condition and results of operations and cause the price of our common stock to decline.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We have grown rapidly and will need to continue to grow the size of our organization, and it may experience difficulties in managing this growth.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As our development and commercialization plans and strategies develop, and as we transition into operating as a public company, we have rapidly expanded our employee base and expect to continue to add managerial, operational, sales, research and development, marketing, financial and other personnel. Current and future growth imposes significant added responsibilities on members of management, including:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">identifying, recruiting, integrating, maintaining and motivating additional employees;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">managing our internal development efforts effectively, including the clinical and FDA review process for our product candidates, while complying with our contractual obligations to contractors and other third parties; and</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">improving our operational, financial and management controls, reporting systems and procedures.</span></div></div>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our future financial performance and our ability to commercialize our product candidates will depend, in part, on our ability to effectively manage our growth, and our management may also have to divert a disproportionate amount of our attention away from day-to-day activities in order to devote a substantial amount of time to managing these growth activities.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We currently rely, and for the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors and consultants, pursuant to arrangements which expire after a certain period of time, to provide certain services, including certain research and development as well as general and administrative support. There can be no assurance that the services of independent organizations, advisors and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified replacements. In addition, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by consultants is compromised for any reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval of our product candidates or otherwise</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">56</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">advance our business. There can be no assurance that we will be able to manage our existing consultants or find other competent outside contractors and consultants on economically reasonable terms, or at all.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we are not able to effectively expand our organization by hiring new employees and expanding our groups of consultants and contractors, we may not be able to successfully implement the tasks necessary to further develop and commercialize our product candidates and, accordingly, may not achieve our research, development and commercialization goals, which could have a material adverse effect on our business, results of operations and prospects.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may form or seek strategic alliances or enter into additional licensing arrangements in the future, and we may not realize the benefits of such alliances or licensing arrangements.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may form or seek strategic alliances, create joint ventures or collaborations or enter into additional licensing arrangements with third parties that we believe will complement or augment our development and commercialization efforts with respect to our product candidates and any future product candidates that we may develop. Any of these relationships may require us to incur non-recurring and other charges, increase our near and long-term expenditures, issue securities that dilute our existing stockholders or disrupt our management and business. In addition, we face significant competition in seeking appropriate strategic partners and the negotiation process is time-consuming and complex. Moreover, we may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for our product candidates because they may be deemed to be at too early of a stage of development for collaborative effort and third parties may not view our product candidates as having the requisite potential to demonstrate safety and efficacy. Any delays in entering into new strategic partnership agreements related to our product candidates could delay the development and commercialization of our product candidates in certain geographies for certain indications, which would harm our business prospects, financial condition and results of operations.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we license products or businesses, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations and company culture. For instance, our License and Collaboration Agreement (the Regeneron Agreement) with Regeneron Pharmaceuticals, Inc. (Regeneron) requires significant research and development commitments that may not result in the development and commercialization of product candidates. We cannot be certain that, following a strategic transaction or license, we will achieve the results, revenue or specific net income that justifies such transaction, which could have a material adverse effect on our business and results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Business Disruptions</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our operations, and those of our CMO, CROs and other contractors and consultants, could be subject to earthquakes, power shortages, telecommunications failures, water shortages, floods, hurricanes, typhoons, fires, extreme weather conditions, medical epidemics, such as the COVID-19 pandemic, and other natural or man-made disasters or business interruptions. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our ability to manufacture our product candidates could be disrupted if our operations or those of our suppliers are affected by a man-made or natural disaster, the severity and frequency of which may be amplified by global climate change, or other business interruptions. We have facilities located in California near major earthquake faults and fire zones. The ultimate impact on us, our significant suppliers and our general infrastructure of being located near major earthquake faults and fire zones and being consolidated in certain geographical areas is unknown, but our operations and financial condition could suffer in the event of a major earthquake, fire or other natural disaster.<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">A pandemic, epidemic or outbreak of an infectious disease, such as the ongoing COVID-19 pandemic, may materially and adversely affect our business and operations.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our business, financial position, results of operations or cash flows may be affected by the ongoing global COVID-19 pandemic and the resulting volatility and uncertainty it has caused, and is likely to continue to cause, in the United States and international markets, including as a result of prolonged economic downturn or recession. Since January 2020, the COVID-19 pandemic has spread around the world. The continued spread of COVID-19, despite progress in vaccination efforts, has resulted in significant governmental measures being implemented to control the spread of COVID-19 and its variants, including quarantines, travel restrictions, social distancing and business shutdowns. Such measures have had, and are likely to continue to have, adverse impacts on the United States economy of uncertain severity and duration and may negatively impact our operations and those of third parties on which we rely, including by causing disruptions in the supply of our product candidates and the conduct of current and future clinical trials. In addition, the COVID-19 pandemic has affected and may further affect the operations of the FDA and other health authorities, which could result in delays of reviews and approvals, including with respect to our product candidates. The ongoing COVID-19 pandemic is also likely to directly or indirectly impact the pace of enrollment in our future clinical trials as patients may avoid or may not be able to travel to healthcare facilities and physicians&#x2019; offices unless</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">57</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">due to a health emergency, and clinical trial sites may be less willing to enroll patients in clinical trials that may compromise a person&#x2019;s immune system. Such facilities and offices may also be required to focus limited resources on non-clinical trial matters, including treatment of COVID-19 patients, and may not be available, in whole or in part, for clinical trial services related to ADI-001 or our other product candidates. Additionally, while the ultimate economic impact brought by, and the duration of the COVID-19 pandemic is difficult to assess or predict, the impact of the COVID-19 pandemic on the global financial markets may reduce our ability to access capital, which could negatively impact our short-term and long-term liquidity.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The extent to which the ongoing COVID-19 pandemic may continue to impact our business will depend on future developments, which are highly uncertain and cannot be predicted with confidence, such as the duration and severity of the pandemic, including the continued emergence of new variants, developments or perceptions regarding the safety of vaccines, or any additional preventative and protective actions taken to contain the pandemic or treat its impact. We do not yet know the full extent of potential delays or impacts on our business, financing, or clinical trial activities or on healthcare systems or the global economy as a whole. However, any of the foregoing risks, or other unforeseen risks related to the COVID-19 pandemic, could have a material impact on our liquidity, capital resources, operations, and business and those of the third parties on which it relies.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Inadequate funding for the FDA and other government agencies, or disruptions in their staffing levels related to the COVID-19 global pandemic, could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the approval of our product candidates rely, which would negatively impact our business.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, adequate staffing, furloughs, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory, and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of other government agencies on which our operations may rely, including those that fund research and development activities is subject to the political process, which is inherently fluid and unpredictable.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Disruptions at the FDA and other agencies may also slow the time necessary for new drugs to be reviewed and/or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years, including beginning on December 22, 2018, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA, have had to furlough critical FDA and other government employees and stop critical activities. Since March 2020 when foreign and domestic inspections of facilities were largely placed on hold, the FDA has been working to resume routine surveillance, bioresearch monitoring and pre-approval inspections on a prioritized basis. Since April 2021, the FDA has conducted limited inspections and employed remote interactive evaluations, using risk management methods, to meet user fee commitments and goal dates. Ongoing travel restrictions and other uncertainties continue to impact oversight operations both domestic and abroad and it is unclear when standard operational levels will resume. The FDA is continuing to complete mission-critical work, prioritize other higher-tiered inspectional needs (e.g., for-cause inspections), and carry out surveillance inspections using risk-based approaches for evaluating public health.  Should FDA determine that an inspection is necessary for approval of a marketing application and an inspection cannot be completed during the review cycle due to restrictions on travel, and the FDA does not determine a remote interactive evaluation to be adequate, FDA has stated that it generally intends to issue, depending on the circumstances, a complete response letter or defer action on the application until an inspection can be completed. During the COVID-19 public health emergency, a number of companies announced receipt of complete response letters due to the FDA's inability to complete required inspections for their applications. Regulatory authorities outside the United States may adopt similar restrictions or other policy measures in response to the COVID-19 pandemic and may experience delays in their regulatory activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business, including our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Healthcare Regulation</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our relationships with customers, physicians including clinical investigators, clinical research organizations and third-party payors are subject, directly or indirectly, to federal and state healthcare fraud and abuse laws, false claims laws, health information privacy and security laws, transparency laws, government price reporting and other healthcare laws and regulations. If we or our employees, independent contractors, consultants, commercial partners, vendors, or other agents violate these laws, we could face substantial penalties.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">These laws may impact, among other things, our clinical research program, as well as our proposed and future sales, marketing, and education programs. In particular, the promotion, sales and marketing of healthcare items and services is subject to extensive laws and regulations designed to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive and other business arrangements. We may also be subject to federal, state and foreign laws governing the privacy and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">58</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">security of identifiable patient information. See the section entitled &#x201c;Business &#x2013; Government Regulation and Product Approval - Other United States Healthcare Laws and Compliance Requirements&#x201d; elsewhere in this Annual Report on Form 10-K.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available, it is possible that some of our business activities, or our arrangements with physicians, could be subject to challenge under one or more of such laws. If we or our employees, independent contractors, consultants, commercial partners and vendors violate these laws, we may be subject to investigations, enforcement actions and/or significant penalties.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have adopted a code of business conduct and ethics, but it is not always possible to identify and deter employee misconduct or business noncompliance, and the precautions we take to detect and prevent inappropriate conduct may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. Efforts to ensure that our business arrangements will comply with applicable healthcare laws may involve substantial costs. It is possible that governmental and enforcement authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law interpreting applicable fraud and abuse or other healthcare laws and regulations. If any such actions are instituted against us, and we are not successful in defending themselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of civil, criminal and administrative penalties, damages, disgorgement, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diminished profits and future earnings, additional reporting requirements and/or oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations. In addition, the approval and commercialization of any of our product candidates outside the United States will also likely subject us to foreign equivalents of the healthcare laws mentioned above, among other foreign laws.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Data protection, privacy and similar laws restrict access, use, and disclosure of information, and failure to comply with or adapt to changes in these laws could materially and adversely harm our business.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are subject to federal and state data privacy and security laws and regulations and Laws and expectations relating to privacy continue to evolve. Changes in these laws may limit our data access, use, and disclosure, and may require increased expenditures. In addition, data protection, privacy and similar laws protect more than patient information and, although they vary by jurisdiction, these laws can extend to employee information, business contact information, provider information, and other information relating to identifiable individuals. For example, the California Consumer Privacy Act requires covered businesses to, among other things, provide disclosures to California consumers regarding the collection, use and disclosure of such consumers&#x2019; personal information and afford such consumers new rights with respect to their personal information, including the right to opt out of certain sales of personal information. In addition, the CPRA as well as comprehensive privacy laws in Colorado and Virginia will become effective in 2023. Further, numerous other states have proposed similar privacy laws. We believe that further increased regulation in additional jurisdictions is likely in the area of data privacy. Any of the foregoing may have a material adverse effect on our ability to provide services to patients and, in turn, our results of operations</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The collection and use of personal data in the European Union (EU) are governed by the GDPR. The GDPR imposes stringent requirements for controllers and processors of personal data, including, for example, more robust disclosures to individuals and a strengthened individual data rights regime, shortened timelines for data breach notifications, limitations on retention of information, increased requirements pertaining to special categories of data, such as health data, and additional obligations when we contract with third-party processors in connection with the processing of the personal data. The GDPR also imposes strict rules on the transfer of personal data out of the European Union to the United States and other third countries. In addition, the GDPR provides that EU member states may make their own further laws and regulations limiting the processing of personal data, including genetic, biometric or health data.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The GDPR applies extraterritorially, and we may be subject to the GDPR because of our data processing activities that involve the personal data of individuals located in the European Union, such as in connection with our EU clinical trials. Failure to comply with the requirements of the GDPR and the applicable national data protection laws of the EU member states may result in fines of up to &#x20ac;20,000,000 or up to 4% of the total worldwide annual turnover of the preceding financial year, whichever is higher, and other administrative penalties. GDPR regulations may impose additional responsibility and liability in relation to the personal data that our processes and we may be required to put in place additional mechanisms to ensure compliance with the new data protection rules. This may be onerous and may interrupt or delay our development activities, and adversely affect our business, financial condition, results of operations and prospects.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, many jurisdictions outside of Europe are also considering and/or enacting comprehensive data protection legislation. We also continue to see jurisdictions imposing data localization laws. These regulations may interfere with our intended business activities, inhibit our ability to expand into those markets or prohibit us from continuing to offer services in those markets without significant additional costs. Because the interpretation and application of many privacy and data protection laws (including the GDPR), commercial frameworks, and standards are uncertain, it is possible that these laws, frameworks, and</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">59</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">standards may be interpreted and applied in a manner that is inconsistent with our existing data management practices and policies. If so, in addition to the possibility of fines, lawsuits, breach of contract claims, and other claims and penalties, we could be required to fundamentally change our business activities and practices or modify our solutions, which could have an adverse effect on our business. Any inability to adequately address privacy and security concerns, even if unfounded, or comply with applicable privacy and security or data security laws, regulations, and policies, could result in additional cost and liability to us, damage our reputation, inhibit our ability to conduct trials, and adversely affect our business</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Data protection, privacy and similar laws protect more than patient information and, although they vary by jurisdiction, these laws can extend to employee information, business contact information, provider information, and other information relating to identifiable individuals. Failure to comply with these laws may result in, among other things, civil and criminal liability, negative publicity, damage to our reputation, and liability under contractual provisions. In addition, compliance with such laws may require increased costs to us or may dictate that wet not offer certain types of services in the future.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Litigation</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our product candidates.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We face an inherent risk of product liability as a result of the future clinical testing of our product candidates and will face an even greater risk if we commercialize any products. For example, we may be sued if our product candidates cause or are perceived to cause injury or are found to be otherwise unsuitable during clinical testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product, negligence, strict liability or a breach of warranties. Claims could also be asserted under state consumer protection acts. If we cannot successfully defend themselves against product liability claims, we may incur substantial liabilities or be required to limit commercialization of our product candidates. Even successful defense would require significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">decreased demand for our product candidates;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">injury to our reputation;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">withdrawal of clinical trial participants;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">initiation of investigations by regulators;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">costs to defend the related litigation;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a diversion of management&#x2019;s time and our resources;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">substantial monetary awards to trial participants or patients;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">product recalls, withdrawals or labeling, marketing or promotional restrictions;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">loss of revenue;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">exhaustion of any available insurance and our capital resources; and</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the inability to commercialize any product candidate.</span></div></div>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our inability to obtain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of products we develop, alone or with corporate collaborators. Our insurance policies may also have various exclusions, and we may be subject to a product liability claim for which we have no coverage. Assuming we obtain clinical trial insurance for our clinical trials, we may have to pay amounts awarded by a court or negotiated in a settlement that exceeds our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain, sufficient capital to pay such amounts. Even if our agreements with any future corporate collaborators entitle it to indemnification against losses, such indemnification may not be available or adequate should any claim arise.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">60</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:13.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Our Financial Position</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:0.9pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Raising funds through lending arrangements may restrict our operations or produce other adverse results.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our current Loan and Security Agreement with Pacific Western Bank, as amended on October 21, 2021 (the Loan Agreement), sets the interest rate of the term loans under the Loan Agreement at the greater of (i) 0.25% above the Prime Rate then in effect and (ii) 4.25%. The Loan Agreement contains a variety of affirmative and negative covenants, including required financial reporting, limitations on certain dispositions of assets, limitations on the incurrence of additional debt and other requirements. To secure our performance of our obligations under this Loan Agreement, we granted a security interest in substantially all of our assets, other than certain intellectual property assets, to Pacific Western Bank and issued a warrant to purchase our capital stock. Our failure to comply with the covenants in the Loan Agreement, the occurrence of a material impairment in our prospect of repayment operations, business or financial condition, our ability to repay the loan, or in the value, perfection or priority of Pacific Western Bank&#x2019;s lien on our assets, as determined by Pacific Western Bank, or the occurrence of certain other specified events could result in an event of default that, if not cured or waived, could result in the acceleration of all or a substantial portion of our debt, potential foreclosure on our assets and other adverse results. Additionally, we are bound by certain negative covenants setting forth actions that are not permitted to be taken during the term of the Loan Agreement without consent of Pacific Western Bank, including, without limitation, incurring certain additional indebtedness, making certain asset dispositions, entering into certain mergers, acquisitions or other business combination transactions or incurring any non-permitted lien or other encumbrance on our assets. The foregoing prohibitions and constraints on our operations could result in our inability to: (a) acquire promising intellectual property or other assets on desired timelines or terms; (b) reduce costs by disposing of assets or business segments no longer deemed advantageous to retain; (c) stimulate further corporate growth or development through the assumption of additional debt; or (d) enter into other arrangements that necessitate the imposition of a lien on corporate assets. Moreover, if the conditions set forth in the consent provided by Pacific Western Bank are not satisfied, we would effectively need to terminate the Loan Agreement and repay any outstanding loan funds or refinance the facility with another lender. As of the date of this Annual Report on Form 10-K, no amounts have been drawn under the Loan Agreement.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Failure to achieve and maintain effective internal control over financial reporting could harm our business and negatively impact the value of our common stock.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Effective internal control over financial reporting is necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures, are designed to prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered in their implementation could cause us to fail to meet our reporting obligations. In addition, any testing by us conducted in connection with Section 404, or any subsequent testing by our independent registered public accounting firm, may reveal deficiencies in our internal control over financial reporting that are deemed to be material weaknesses or that may require prospective or retroactive changes to our financial statements, or may identify other areas for further attention or improvement. Inferior internal controls could also cause investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of our stock.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are required to disclose changes made in our internal controls and procedures on a quarterly basis and our management is required to assess the effectiveness of these controls annually. However, for as long as we are an emerging growth company (EGC) or a smaller reporting company (SRC), our independent registered public accounting firm will not be required to attest to the effectiveness of our internal control over financial reporting pursuant to Section 404. We will remain an EGC until the earliest to occur of: (1) the last day of the fiscal year in which we have more than $1.07 billion in annual revenue; (2) the date we qualify as a large accelerated filer, with at least $700.0 million of equity securities held by non-affiliates; (3) the date on which we have issued more than $1.0 billion in non-convertible debt securities during the prior three-year period; or (4) the last day of the fiscal year ending after the fifth anniversary of our initial public offering, which would be December 31, 2023.<br /> We will qualify as a SRC if the market value of our common stock held by non-affiliates is below $250 million (or $700 million if our annual revenue is less than $100 million) as of June 30 in any given year. An independent assessment of the effectiveness of our internal control over financial reporting could detect problems that our management&#x2019;s assessment might not. Undetected material weaknesses in our internal control over financial reporting could lead to financial statement restatements and require us to incur the expense of remediation.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We and our independent registered public accounting firm previously identified material weaknesses in our internal control over financial reporting, which have since been remediated. Nevertheless, if we experience additional material weaknesses or deficiencies in the future or otherwise fail to establish and maintain effective internal controls, we may be unable to produce timely and accurate financial statements, and we may conclude that our internal control over financial reporting is not effective, which could adversely impact our investors&#x2019; confidence and our stock price.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In our Annual Report on Form 10-K for the year ended December 31, 2020, we reported material weaknesses in our internal control over financial reporting related to deficiencies in our controls over the financial statement close process, including over complex accounting issues, expense classification and accrued research and development expenses, as well as the cash disbursement process. During 2021, we took a number of actions to improve our internal control over financial reporting to remediate these material weaknesses, including the hiring key personnel, implementing an Enterprise Resource Planning (ERP) system, and augmenting our controls to enhance our control environment. As a result of these efforts, management has concluded</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">61</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">that the previously disclosed material weaknesses have been remediated as of December 31, 2021.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We expect to continue our efforts to improve our control processes, though there can be no assurance that our efforts will ultimately be successful or avoid potential future material weaknesses, and we expect to continue incurring additional costs as a result of these efforts. If we are unable to successfully remediate any future material weaknesses in our internal control over financial reporting, or if we identify any additional material weaknesses, the accuracy and timing of our financial reporting may be adversely affected, we may be unable to maintain compliance with securities law requirements regarding timely filing of periodic reports in addition to applicable stock exchange listing requirements, investors may lose confidence in our financial reporting, and our stock price may decline as a result. We also could become subject to investigations by Nasdaq, the SEC or other regulatory authorities, which could harm our reputation and our financial condition, or divert financial and management resources from our core business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Taxation</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under Section 382 and Section 383 of the Internal Revenue Code of 1986, as amended, or the IRC, if a corporation undergoes an &#x201c;ownership change&#x201d; (generally defined as a greater than 50 percentage point change (by value) in the ownership of its equity over a three year period), the corporation&#x2019;s ability to use its pre-change net operating loss carryforwards and certain other pre-change tax attributes to offset its post-change income may be limited. We may have experienced such ownership changes in the past, and we may experience ownership changes in the future as a result of subsequent shifts in our stock ownership. As of December 31, 2021, we had federal net operating loss carryforwards of approximately </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$271.6 million</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, and our ability to utilize those net operating loss carryforwards could be limited by an &#x201c;ownership change&#x201d; as described above.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Comprehensive tax reform legislation could adversely affect our business and financial condition.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The rules dealing with U.S. federal, state and local income taxation are constantly under review by persons involved in the legislative process and by the Internal Revenue Service, or IRS, and the U.S. Treasury Department. Changes to tax laws (which changes may have retroactive application) could adversely affect us or holders of our common stock. In recent years, many changes have been made and changes are likely to continue to occur in the future.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additional changes to U.S. federal income tax law are currently being contemplated, and future changes in tax laws could have a material adverse effect on our business, cash flow, financial condition or results of operations. It cannot be predicted whether, when, in what form, or with what effective dates, new tax laws may be enacted, or regulations and rulings may be enacted, promulgated or issued under existing or new tax laws, which could result in an increase in our or our stockholders&#x2019; tax liability or require changes in the manner in which we operate in order to minimize or mitigate any adverse effects of changes in tax law or in the interpretation thereof. You are urged to consult your tax advisor regarding the implications of potential changes in tax laws on an investment in our common stock.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Third Parties</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If our collaboration with Regeneron is terminated, or if Regeneron materially breaches its obligations thereunder, our business, prospects, operating results, and financial condition would be materially harmed.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our financial performance may be significantly affected by our Regeneron collaboration that we have entered into to develop next-generation engineered immune-cell therapeutics with fully human CARs and TCRs directed to disease-specific cell surface antigens in order to enable the precise engagement and killing of tumor cells. Under the Regeneron Agreement, Regeneron paid us a non-refundable upfront payment of $25.0 million and an aggregate of $20.0 million of additional payments for research funding as of December 31, 2021, and we will collaborate with Regeneron to identify and validate targets and develop a pipeline of engineered immune-cell therapeutics for selected targets. Regeneron has the option to obtain development and commercial rights for a certain number of the product candidates developed by the parties, subject to an option payment for each product candidate. On January 28, 2022, we received a payment of $20.0 million from Regeneron for exercise of its option to license exclusive rights to ADI-002. If Regeneron exercises its option on a given product candidate, we then have an option to participate in the development and commercialization for such product. If we do not exercise our option, we will be entitled to royalties on any future sales of such products by Regeneron. We did not exercise our option to participate in the development and commercialization of ADI-002. In addition to developing CARs and TCRs for use in novel immune-cell therapies as part of the collaboration, Regeneron will have the right to use these CARs and TCRs in our other antibody programs outside of the collaboration. Regeneron will also be entitled to royalties on any future sales of products developed and commercialized by us under the agreement. If Regeneron were to terminate our collaboration agreement with us, we may not have the resources or skills to replace those of our collaborator, which could require us to seek additional funding or another collaboration that might not be available on favorable terms or at all, and could cause significant delays in development and/or commercialization efforts and result in substantial additional costs to us. Termination of such collaboration agreement or the loss of rights provided to us under such agreement may create substantial new and additional risks to the successful development and commercialization of our products and could materially harm our financial condition and operating results.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">62</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Regeneron may change its strategic focus or pursue alternative technologies in a manner that results in reduced, delayed or no revenue to us under the agreement. Regeneron has a variety of marketed products and product candidates either by itself or under collaboration with other companies, including some of our competitors, and the corporate objectives of Regeneron may not be consistent with our best interests. Regeneron may change its position regarding its participation and funding of our and Regeneron joint activities, which may impact our ability to successfully pursue the program.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our existing and future collaborations will be important to our business. If we are unable to maintain any of these collaborations, or if these collaborations are not successful, our business could be adversely affected.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have entered, and plan to enter, into collaborations with other companies, including our collaboration agreement with Regeneron, that we believe can provide us with additional capabilities beneficial to our business. The collaboration with Regeneron provides us with important technologies, expertise and funding for our programs and technology, and we expect to receive additional technologies, expertise and funding under this and other collaborations in the future. Our existing therapeutic collaborations, and any future collaborations we enter into, may pose a number of risks, including the following:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">collaborators have significant discretion in determining the efforts and resources that they will apply;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">collaborators may not perform their obligations as expected;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">collaborators may dispute the amounts of payments owed;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">collaborators may not pursue development and commercialization of any product candidates that achieve regulatory approval or may elect not to continue or renew development or commercialization programs or license arrangements based on clinical trial results, changes in the collaborators&#x2019; strategic focus or available funding, or external factors, such as a strategic transaction that may divert resources or create competing priorities;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">collaborators could develop independently, or with third parties, products that compete directly or indirectly with our products and product candidates if the collaborators believe that the competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">product candidates discovered in collaboration with us may be viewed by our collaborators as competitive with our own product candidates or products, which may cause collaborators to cease to devote resources to the development or commercialization of our product candidates;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">collaborators may dispute ownership or rights in jointly developed technologies or intellectual property;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">collaborators may fail to comply with applicable legal and regulatory requirements regarding the development, manufacture, sale, distribution or marketing of a product candidate or product;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">collaborators with sales, marketing, manufacturing and distribution rights to one or more of our product candidates that achieve regulatory approval may not commit sufficient resources to the sale, marketing, manufacturing and distribution of such product or products;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">disagreements with collaborators, including disagreements over proprietary rights, contract interpretation, payment obligations or the preferred course of discovery, development, sales or marketing, might cause delays or terminations of the research, development or commercialization of product candidates, might lead to additional and burdensome responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">collaborators may not properly maintain or defend their or our relevant intellectual property rights or may use our proprietary information in such a way as to invite litigation that could jeopardize or invalidate our intellectual property or proprietary information or expose us to potential litigation and liability;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">if a collaborator of ours is involved in a business combination or cessation, the collaborator might deemphasize or terminate the development or commercialization of any product candidate licensed to it by us; and</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">63</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">collaborations may be terminated by the collaborator, and, if terminated, we could be required to raise additional capital to pursue further development or commercialization of the applicable product candidates, or potentially lose access to the collaborator&#x2019;s intellectual property.</span></div></div>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If</span><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> our therapeutic collaborations do not result in the successful discovery, development and commercialization of products or if one of our collaborators terminates our agreement with us, we may not receive any future research funding or milestone or royalty payments under the collaboration. If we do not receive the funding we expect under these agreements, our development and commercialization of our technology and product candidates could be delayed and we may need additional resources to develop product candidates and our technology. All of the risks relating to product discovery, development, regulatory approval and commercialization described in these risk factors also apply to the activities of our therapeutic collaborators.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition to the Regeneron collaboration described above, for some of our programs, we may in the future determine to collaborate with pharmaceutical and biotechnology companies for discovery, development and potential commercialization of therapeutic products. We face significant competition in seeking appropriate collaborators because, for example, third parties also have rights to allogeneic T cell technologies. For example, in April 2020, Johnson &amp; Johnson entered into a collaboration agreement with Fate Therapeutics, a company that is also using allogeneic T cell technologies, for up to four CAR Natural Killer (NK) and CAR-T cell therapies. Our ability to reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#x2019;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#x2019;s evaluation of a number of factors. If we are unable to reach agreements with suitable collaborators on a timely basis, on acceptable terms, or at all, we may have to curtail discovery efforts or the development of a product candidate, reduce or delay our development program or one or more of our other development programs, delay our potential manufacture or commercialization, or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our expense. If we elect to fund and undertake discovery, development, manufacturing or commercialization activities on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms or at all. If we fail to enter into collaborations and do not have sufficient funds or expertise to undertake the necessary discovery, development, manufacturing and commercialization activities, we may not be able to further develop our product candidates, manufacture the product candidates, bring them to market or continue to develop our technology and our business may be materially and adversely affected.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We are subject to certain exclusivity obligations under our agreement with Regeneron.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the five-year period following the effective date of the Regeneron agreement, with certain limited exceptions, we may not directly or indirectly research, develop, manufacture or commercialize a gamma delta immune cell product (ICP) or grant a license to do the foregoing, except pursuant to the terms of the Regeneron agreement. Both parties also have obligations not to research, develop, manufacture or commercialize an ICP with the same target as one being developed under a research program or commercialized by a party (and royalty bearing under the agreement), for so long as such activities are occurring. These exclusivity obligations are limited to engineered gamma delta immune cells to targets reasonably considered to have therapeutic relevance in oncology. If our collaboration with Regeneron is not successful, including any failure caused by the risks listed in the preceding paragraphs, and the agreement and research programs are not terminated, we may not be able to enter into collaborations with other companies with respect to ICP&#x2019;s and our business could be adversely affected.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The exclusivity obligations under the Regeneron agreement expired on July 29, 2021. Prior to this expiration date, our ability to advance any gamma delta immune cell therapeutics outside of the scope of the research plan agreed on with Regeneron was limited. The restrictions on internal development under the Regeneron agreement could lead to delays in our ability to discover and develop gamma delta immune cell therapeutics for targets not covered by the collaboration with Regeneron and loss of opportunities to obtain additional research funding and advance our own technologies separately from the Regeneron collaboration. If we are delayed in our ability to advance our technologies due to the Regeneron agreement, our business could be harmed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We rely and will continue to rely on third parties to conduct our clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval of or commercialize our product candidates.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We currently depend and will continue to depend upon independent investigators and collaborators, such as universities, medical institutions, CROs and strategic partners to conduct our preclinical and clinical trials under agreements with us.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We negotiate budgets and contracts with CROs and study sites, which may result in delays to our development timelines and increased costs. We will rely heavily on these third parties over the course of our clinical trials, and we control only certain aspects of their activities. Nevertheless, we are responsible for ensuring that each of our studies is conducted in accordance with applicable protocol, legal, regulatory and scientific standards, and our reliance on third parties does not relieve us of our regulatory responsibilities. We and these third parties are required to comply with GCPs, which are regulations and guidelines enforced by the FDA and comparable foreign regulatory authorities for product candidates in clinical development. Regulatory authorities enforce these GCPs through periodic inspections of trial sponsors, principal investigators and trial sites. If we or any of these third parties fail to comply with applicable GCP regulations, the clinical data generated in our clinical trials may be</span><span style="color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">64</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that, upon inspection, such regulatory authorities will determine that any of our clinical trials comply with the GCP regulations. In addition, our clinical trials must be conducted with biologic product produced under cGMPs and will require a large number of test patients. Our failure or any failure by these third parties to comply with these regulations or to recruit a sufficient number of patients may require us to repeat clinical trials, which would delay the regulatory approval process. Moreover, our business may be implicated if any of these third parties violates federal or state fraud and abuse or false claims laws and regulations or healthcare privacy and security laws.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any third parties conducting our clinical trials are and will not be our employees and, except for remedies available to us under our agreements with such third parties, we cannot control whether or not they devote sufficient time and resources to our ongoing preclinical, clinical and nonclinical programs. These third parties may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical studies or other drug development activities, which could affect their performance on our behalf. If these third parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for other reasons, our clinical trials may be extended, delayed or terminated and we may not be able to complete development of, obtain regulatory approval of or successfully commercialize our product candidates. As a result, our financial results and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenue could be delayed.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(35,31,32,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If any of our relationships with trial sites, or any CRO that we may use in the future, terminates, we may not be able to enter into arrangements with alternative trial sites or CROs or do so on commercially reasonable terms. Switching or adding third parties to conduct our clinical trials will involve substantial cost and require extensive management time and focus. In addition, there is a natural transition period when a new third party commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We currently rely on third parties to manufacture our clinical product supplies, and we may have to rely on third parties to produce and process our product candidates, if approved.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We currently utilize, and expect to continue to utilize, third parties to manufacture our product candidates. If the field of cell therapy continues to expand, we may encounter increasing competition and costs for these materials and services. Demand for third-party manufacturing in cell therapy may grow at a faster rate than existing capacity, which could disrupt our ability to find and retain third-party manufacturers capable of producing sufficient quantities of our product candidates at an acceptable cost or at all. We have also not yet caused our product candidates to be manufactured or processed on a commercial scale and may not be able to achieve manufacturing and processing at a commercial scale and therefore may be unable to create an inventory of mass-produced, off-the-shelf product to satisfy demands for any of our product candidates.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We do not yet have sufficient information to reliably estimate the cost of the commercial manufacturing and processing of our product candidates, and the actual cost to manufacture and process our product candidates could materially and adversely affect the commercial viability of our product candidates. As a result, we may never be able to develop a commercially viable product.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, we anticipate reliance on a limited number of third-party manufacturers may adversely affect our operations and exposes us to the following risks:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may be unable to identify manufacturers on acceptable terms or at all because the number of potential manufacturers is limited and the FDA may have questions regarding any replacement contractor. This may require new testing and regulatory interactions. In addition, a new manufacturer would have to be educated in, or develop substantially equivalent processes for, production of our products after receipt of FDA questions, if any.</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our third-party manufacturers might be unable to timely formulate and manufacture our product or produce the quantity and quality required to meet our clinical and commercial needs, if any.</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Contract manufacturers may not be able to execute our manufacturing procedures appropriately.</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our future contract manufacturers may not perform as agreed or may not remain in the contract manufacturing business for the time required to supply our clinical trials or to successfully produce, store and distribute our products.</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Manufacturers are subject to ongoing periodic unannounced inspection by the FDA, the Drug Enforcement Administration and corresponding state agencies to ensure strict compliance with cGMP and other government regulations and corresponding foreign standards. We do not have control over third-party manufacturers&#x2019; compliance with these regulations and standards.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">65</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may not own, or may have to share, the intellectual property rights to any improvements made by our third-party manufacturers in the manufacturing process for our products.</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our third-party manufacturers could breach or terminate their agreement(s) with us.</span></div></div>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If any CMO with whom we contract fails to perform its obligations, we may be forced to manufacture the materials ourselves, for which we may not have the capabilities or resources, or enter into an agreement with a different CMO, which we may not be able to do on reasonable terms, if at all. In either scenario, our clinical trials supply could be delayed significantly as we establish alternative supply sources. In some cases, the technical skills required to manufacture our product candidates may be unique or proprietary to the original CMO and we may have difficulty, or there may be contractual restrictions prohibiting us from, transferring such skills to a back-up or alternate supplier, or we may be unable to transfer such skills at all. In addition, if we are required to change CMOs for any reason, we will be required to verify that the new CMO maintains facilities and procedures that comply with quality standards and with all applicable regulations. We will also need to verify, such as through a manufacturing comparability study, that any new manufacturing process will produce our product candidates according to the specifications previously submitted to the FDA or another regulatory authority. The delays associated with the verification of a new CMO could negatively affect our ability to develop product candidates or commercialize our products in a timely manner or within budget. Furthermore, a CMO may possess technology related to the manufacture of our product candidates that such CMO owns independently. This would increase our reliance on such CMO or require us to obtain a license from such CMO in order to have another CMO manufacture our product candidates. In addition, changes in manufacturers often involve changes in manufacturing procedures and processes, which could require that we conduct bridging studies between our prior clinical supply used in our clinical trials and that of any new manufacturer. We may be unsuccessful in demonstrating the comparability of clinical supplies which could require the conduct of additional clinical trials.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our contract manufacturers would also be subject to the same risks we face in developing our own manufacturing capabilities, as described above. Each of these risks could delay our clinical trials, the approval, if any, of our product candidates by the FDA or the commercialization of our product candidates or result in higher costs or deprive us of potential product revenue. In addition, we will rely on third parties to perform release tests on our product candidates prior to delivery to patients. If these tests are not appropriately done and test data are not reliable, patients could be put at risk of serious harm.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Cell-based therapies rely on the availability of specialty raw materials, which may not be available to us on acceptable terms or at all.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our product candidates require many specialty raw materials, including viral vectors that deliver the targeting moiety and other genes to the product candidate. We currently manufacture through contract manufacturers, some of which have limited resources and experience supporting a commercial product, and such suppliers may not be able to deliver raw materials to our specifications. Those suppliers normally support blood-based hospital businesses and generally do not have the capacity to support commercial products manufactured under cGMP by biopharmaceutical firms. The suppliers may be ill-equipped to support our needs, especially in non-routine circumstances like an FDA inspection or medical crisis, such as widespread contamination. We also do not have contracts with many of these suppliers, and we may not be able to contract with them on acceptable terms or at all. Accordingly, we may experience delays in receiving key raw materials to support clinical or commercial manufacturing. Additionally, since the beginning of the COVID-19 pandemic, three vaccines for COVID-19 have received Emergency Use Authorization by the FDA, and one of those later received marketing approval. Additional vaccines may be authorized or approved in the future.  The resultant demand for vaccines and potential for manufacturing facilities and materials to be commandeered under the Defense Production Act of 1950, or equivalent foreign legislation, may make it more difficult to obtain materials or manufacturing slots for the materials needed for our clinical trials, which could lead to delays in these trials.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, some raw materials utilized in the manufacture of our candidates are currently available from a single supplier, or a small number of suppliers. We cannot be sure that these suppliers will remain in business or that they will not be purchased by one of our competitors or another company that is not interested in continuing to produce these materials for our intended purpose. Further, the lead time needed to establish a relationship with a new supplier can be lengthy, and we may experience delays in meeting demand in the event we must switch to a new supplier. The time and effort to qualify a new supplier could result in additional costs, diversion of resources or reduced manufacturing yields, any of which would negatively impact our operating results. We may be unable to enter into agreements with a new supplier on commercially reasonable terms, which could have a material adverse impact on our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If we or our third-party suppliers use hazardous, non-hazardous, biological or other materials in a manner that causes injury or violates applicable law, we may be liable for damages.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our research and development activities involve the controlled use of potentially hazardous substances, including chemical and biological materials. We and our suppliers are subject to federal, state and local laws and regulations in the United States governing the use, manufacture, storage, handling and disposal of medical and hazardous materials. Although we believe that our and our suppliers&#x2019; procedures for using, handling, storing and disposing of these materials comply with legally prescribed standards, we and our suppliers cannot completely eliminate the risk of contamination or injury resulting from medical or</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">66</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">hazardous materials. As a result of any such contamination or injury, we may incur liability or local, city, state or federal authorities may curtail the use of these materials and interrupt our business operations. In the event of an accident, we could be held liable for damages or penalized with fines, and the liability could exceed our resources. Compliance with applicable environmental laws and regulations is expensive, and current or future environmental regulations may impair our research, development and production efforts, which could harm our business, prospects, financial condition or results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our internal computer systems, or those used by our CROs or other contractors or consultants, may fail or suffer security breaches.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our internal computer systems and the systems of our CROs, contractors and consultants are vulnerable to damage from computer viruses and unauthorized access. Additionally, as a result of the ongoing COVID-19 pandemic, we have transitioned certain of our workforce to a remote working model. As our employees and our business partners&#x2019; employees work from home and access our systems remotely, we may be subject to heightened security and privacy risks, including the risks of cyberattacks and privacy incidents. While we have not experienced any such material system failure or security breach to date, if such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations. For example, the loss of clinical trial data from future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability and the further development and commercialization of our product candidates could be delayed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may not realize the benefits of acquired assets or other strategic transactions.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We actively evaluate various strategic transactions on an ongoing basis. We may acquire other businesses, products or technologies as well as pursue joint ventures or investments in complementary businesses. The success of our strategic transactions, and any future strategic transactions depends on the risks and uncertainties involved including:</span></p>
  <div style="margin-left:2.667%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.424326795639711%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">unanticipated liabilities related to acquired companies or joint ventures;</span></div></div>
  <div style="margin-left:2.667%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.424326795639711%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">difficulties integrating acquired personnel, technologies, and operations into our existing business;</span></div></div>
  <div style="margin-left:2.667%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.424326795639711%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">retention of key employees;</span></div></div>
  <div style="margin-left:2.667%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.424326795639711%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">diversion of management time and focus from operating our business to management of strategic alliances or joint ventures or acquisition integration challenges;</span></div></div>
  <div style="margin-left:2.667%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.424326795639711%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">increases in our expenses and reductions in our cash available for operations and other uses;</span></div></div>
  <div style="margin-left:2.667%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.424326795639711%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">disruption in our relationships with collaborators or suppliers as a result of such a transaction; and possible write-offs or impairment charges relating to acquired businesses or joint ventures.</span></div></div>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If any of these risks or uncertainties occur, we may not realize the anticipated benefit of any acquisition or strategic transaction. Additionally, foreign acquisitions and joint ventures are subject to additional risks, including those related to integration of operations across different cultures and languages, currency risks, potentially adverse tax consequences of overseas operations and the particular economic, political and regulatory risks associated with specific countries.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Future acquisitions or dispositions could result in potentially dilutive issuances of our equity securities, the incurrence of debt, contingent liabilities or amortization expenses or write-offs of goodwill, any of which could have a material adverse effect on our financial condition.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Government Regulation</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Regulatory Approval</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The FDA regulatory approval process is lengthy and time-consuming, and we may experience significant delays in the clinical development and regulatory approval of our product candidates.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The research, testing, manufacturing, labeling, approval, selling, import, export, marketing, and distribution of drug products, including biologics, are subject to extensive regulation by the FDA and other regulatory authorities in the United States. We are not permitted to market any biological drug product in the United States until we receive approval of a biologics license application (BLA) from the FDA. We have not previously submitted a BLA to the FDA, or similar approval filings to comparable</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">67</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">foreign authorities. A BLA must include extensive preclinical and clinical data and sufficient supporting information to establish the product candidate&#x2019;s safety and effectiveness for each desired indication. The BLA must also include significant information regarding the chemistry, manufacturing and controls for the product.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We expect the novel nature of our product candidates to create further challenges in obtaining regulatory approval. For example, the FDA has limited experience with commercial development of allogeneic T cell therapies for cancer. We may also request regulatory approval of future product candidates by target, regardless of cancer type or origin, which the FDA may have difficulty accepting if our clinical trials only involved cancers of certain origins. The FDA may also require a panel of experts, referred to as an Advisory Committee, to deliberate on the adequacy of the safety and efficacy data to support licensure. The opinion of the Advisory Committee, although not binding, may have a significant impact on our ability to obtain licensure of the product candidates based on the completed clinical trials, as the FDA often adheres to the Advisory Committee&#x2019;s recommendations. Accordingly, the regulatory approval pathway for our product candidates may be uncertain, complex, expensive and lengthy, and approval may not be obtained.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may also experience delays in obtaining regulatory approvals, including but not limited to:</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">obtaining regulatory authorization to begin a trial, if applicable;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">redesigning our study protocols and need to conduct additional studies as may be required by a regulator;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">governmental or regulatory delays and changes in regulation or policy relating to the development and commercialization of our product candidate by the FDA or other comparable foreign regulatory authorities;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the outcome, timing and cost of meeting regulatory requirements established by the FDA, and other comparable foreign regulatory authorities;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the availability of financial resources to commence and complete the planned trials;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">negotiating the terms of any collaboration agreements we may choose to initiate or conclude;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">reaching agreement on acceptable terms with prospective CROs and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">failure of third-party contractors, such as CROs, or investigators to comply with regulatory requirements, including GCP standards;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">clinical sites deviating from trial protocol or dropping out of a trial;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">delay or failure in obtaining the necessary approvals from regulators or institutional review boards, or IRBs, in order to commence a clinical trial at a prospective trial site, or their suspension or termination of a clinical trial once commenced;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inability to recruit and enroll suitable patients to participate in a trial;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">having patients complete a trial, including having patients enrolled in clinical trials dropping out of the trial before the product candidate is manufactured and returned to the site, or return for post-treatment follow-up;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">difficulty in having patients complete a trial or return for post-treatment follow-up;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">addressing any patient safety concerns that arise during the course of a trial;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">inability to add new clinical trial sites;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">varying interpretations of the data generated from our preclinical or clinical trials;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the cost of defending intellectual property disputes, including patent infringement actions brought by third parties;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the effect of competing technological and market developments;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">68</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the cost and timing of establishing, expanding and scaling manufacturing capabilities;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">inability to manufacture, or obtain from third parties, sufficient quantities of qualified materials under cGMPs, for the completion in preclinical and clinical studies; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">problems with biopharmaceutical product candidate storage, stability and distribution resulting in global supply chain disruptions;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the cost of establishing sales, marketing and distribution capabilities for any product candidate for which we may receive regulatory approval in regions where we choose to commercialize our products on our own; or</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">potential unforeseen business disruptions or market fluctuations that delay our product development or clinical trials and increase our costs or expenses, such as business or operational disruptions, delays, or system failures due to malware, unauthorized access, terrorism, war, natural disasters, strikes, geopolitical conflicts, restrictions on trade, import or export restrictions, or public health crises, such as the ongoing COVID-19 pandemic.</span></div></div>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We could also encounter delays if physicians encounter unresolved ethical issues associated with enrolling patients in clinical trials of our product candidates in lieu of prescribing existing treatments that have established safety and efficacy profiles. Further, a clinical trial may be suspended or terminated by us, the IRBs for the institutions in which such trials are being conducted or by the FDA or other regulatory authorities due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, safety issues or adverse side effects, failure to demonstrate a benefit from using a product candidate, changes in governmental regulations or administrative actions, lack of adequate funding to continue the clinical trial, or based on a recommendation by the Data Safety Monitoring Committee. If we experience termination of, or delays in the completion of, any clinical trial of our product candidates, the commercial prospects for our product candidates will be harmed, and our ability to generate product revenue will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down our product development and approval process and jeopardize our ability to commence product sales and generate revenue.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may ultimately lead to the denial of regulatory approval of our product candidates.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We expect the product candidates we develop will be regulated as biological products, or biologics, and therefore they may be subject to competition sooner than anticipated.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Biologics Price Competition and Innovation Act (BPCIA) was enacted as part of the Affordable Care Act to establish an abbreviated pathway for the approval of biosimilar and interchangeable biological products. The regulatory pathway establishes legal authority for the FDA to review and approve biosimilar biologics, including the possible designation of a biosimilar as &#x201c;interchangeable&#x201d; based on its similarity to an approved biologic. Under the BPCIA, an application for a biosimilar product cannot be approved by the FDA until 12 years after the reference product was approved under a BLA. The law is complex and is still being interpreted and implemented by the FDA. As a result, its ultimate impact, implementation, and meaning are subject to uncertainty. While it is uncertain when such processes intended to implement the BPCIA may be fully adopted by the FDA, any such processes could have a material adverse effect on the future commercial prospects for our biological products.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We believe that any of the product candidates we develop that are approved in the United States as a biological product under a BLA should qualify for the 12-year period of exclusivity. However, there is a risk that this exclusivity could be shortened due to congressional action or otherwise, potentially creating the opportunity for generic competition sooner than anticipated. Moreover, the extent to which a biosimilar, once approved, will be substituted for any one of the reference products in a way that is similar to traditional generic substitution for non-biological products is not yet clear, and will depend on a number of marketplace and regulatory factors that are still developing.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The regulatory landscape that will govern our product candidates is uncertain; regulations relating to more established cell therapy products are still developing, and changes in regulatory requirements could result in delays or discontinuation of development of our product candidates or unexpected costs in obtaining regulatory approval.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Government authorities in the United States at the federal, state and local level and in other countries regulate, among other things, the research, development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing and export and import of drug and biological products. Generally, before a new drug or biologic can be marketed, considerable data demonstrating its quality, safety and efficacy must be obtained, organized into a format specific for each regulatory authority, submitted for review and approved by the regulatory authority.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">69</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Because we are developing novel allogeneic cell immunotherapy product candidates, the regulatory requirements that we will be subject to are not entirely clear. Even with respect to more established products that fit into the category of cell therapies, the regulatory landscape is still developing. For example, regulatory requirements governing cell therapy products have changed frequently and may continue to change in the future. Moreover, there is substantial, and sometimes uncoordinated, overlap in those responsible for regulation of existing cell therapy products.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Complex regulatory environments exist in other jurisdictions in which we might consider seeking regulatory approvals for our product candidates, further complicating the regulatory landscape. For example, in the EU a special committee called the Committee for Advanced Therapies (CAT) was established within the EMA in accordance with Regulation (EC) No 1394/2007 on advanced-therapy medicinal products (ATMPs) to assess the quality, safety and efficacy of ATMPs, and to follow scientific developments in the field. ATMPs include somatic cell therapy products and tissue engineered products. These various regulatory review committees and advisory groups and new or revised guidelines that they promulgate from time to time may lengthen the regulatory review process, require us to perform additional studies, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of our product candidates or lead to significant post-approval limitations or restrictions. Because the regulatory landscape for our gamma delta CAR-T cell product candidates is new, we may face even more cumbersome and complex regulations than those emerging for cell therapy products. Furthermore, even if our product candidates obtain required regulatory approvals, such approvals may later be withdrawn as a result of changes in regulations or the interpretation of regulations by applicable regulatory agencies.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring a potential product to market could decrease our ability to generate sufficient product revenue to maintain our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The FDA may disagree with our regulatory plan and we may fail to obtain regulatory approval of our product candidates.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The general approach for FDA approval of a new biologic or drug is for the sponsor to provide dispositive data from two well-controlled, Phase 3 clinical studies of the relevant biologic or drug in the relevant patient population. Phase 3 clinical studies typically involve hundreds of patients, have significant costs and take years to complete. We expect registrational trials for our product candidates to be designed to evaluate the efficacy of the product candidate in an open-label, non-comparative, two-stage, pivotal, multicenter, single-arm clinical trial in patients who have exhausted available treatment options. If the results are sufficiently compelling, we intend to discuss with the FDA submission of a BLA for the relevant product candidate. However, we do not have any agreement or guidance from the FDA that its regulatory development plans will be sufficient for submission of a BLA. In addition, the FDA may only allow us to evaluate patients that have failed or who are ineligible for autologous therapy, which are extremely difficult patients to treat and patients with advanced and aggressive cancer, and our product candidates may fail to improve outcomes for such patients.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA may grant accelerated approval for our product candidates and, as a condition for accelerated approval, the FDA may require a sponsor of a drug or biologic receiving accelerated approval to perform post marketing studies to verify and describe the predicted effect on irreversible morbidity or mortality or other clinical endpoint, and the drug or biologic may be subject to withdrawal procedures by the FDA that are more accelerated than those available for regular approvals. In addition, the standard of care may change with the approval of new products in the same indications that we are studying. This may result in the FDA or other regulatory agencies requesting additional studies to show that our product candidate is superior to the new products.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our clinical trial results may also not support approval. In addition, our product candidates could fail to receive regulatory approval for many reasons, including the following:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials; </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that our product candidates are safe and effective for any of their proposed indications;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval, including due to the heterogeneity of patient populations;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we may be unable to demonstrate that our product candidates&#x2019; clinical and other benefits outweigh their safety risks;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the data collected from clinical trials of our product candidates may not be sufficient to the satisfaction of the FDA or comparable foreign regulatory authorities to support the submission of a BLA or other comparable submission in foreign jurisdictions or to obtain regulatory approval in the United States or elsewhere;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">70</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the FDA or comparable foreign regulatory authorities will inspect our commercial manufacturing facility and may not approve our facility; and</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may seek orphan drug designation for some or all of our product candidates across various indications, but we may be unable to obtain such designations or to maintain the benefits associated with orphan drug designation, including market exclusivity, which may cause our revenue, if any, to be reduced.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug or biologic intended to treat a rare disease or condition, defined as a disease or condition with a patient population of fewer than 200,000 in the United States, or a patient population greater than 200,000 in the United States when there is no reasonable expectation that the cost of developing and making available the drug or biologic in the United States will be recovered from sales in the United States for that drug or biologic. In order to obtain orphan drug designation, the request must be made before submitting a BLA. In the U.S., orphan drug designation entitles a party to financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages, and user-fee waivers. After the FDA grants orphan drug designation, the generic identity of the drug and its potential orphan use are disclosed publicly by the FDA. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If a product that has orphan drug designation subsequently receives the first FDA approval of that particular product for the disease for which it has such designation, the product is entitled to orphan product exclusivity, which means that the FDA may not approve any other applications, including a BLA, to market the same biologic (meaning, a product with the same principal molecular structural features) for the same indication for seven years, except in limited circumstances such as a showing of clinical superiority to the product with orphan drug exclusivity or if FDA finds that the holder of the orphan drug exclusivity has not shown that it can assure the availability of sufficient quantities of the orphan drug to meet the needs of patients with the disease or condition for which the drug was designated. As a result, even if one of our product candidates receives orphan exclusivity, the FDA can still approve other biologics that do not have the same principal molecular structural features for use in treating the same indication or disease or the same biologic for a different indication or disease during the exclusivity period. Furthermore, the FDA can waive orphan exclusivity if we are unable to manufacture sufficient supply of our product or if a subsequent applicant demonstrates clinical superiority over our products.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may seek orphan drug designation for some or all of our product candidates in specific orphan indications in which there is a medically plausible basis for the use of these products. Even if we obtain orphan drug designation, exclusive marketing rights in the United States may be limited if we seek approval for an indication broader than the orphan designated indication and may be lost if the FDA later determines that the request for designation was materially defective or if we are unable to assure sufficient quantities of the product to meet the needs of patients with the rare disease or condition, or if a subsequent applicant demonstrates clinical superiority over our products, if approved. In addition, although we may seek orphan drug designation for other product candidates, we may never receive such designations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Regenerative Medicine Advanced Therapy (RMAT) designation, even if granted for any of our product candidates, may not lead to a faster development or regulatory review or approval process and it does not increase the likelihood that our product candidates will receive marketing approval.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may seek RMAT designation for one or more of our product candidates. In 2017, the FDA established the RMAT designation to expedite review of a cell therapy, therapeutic tissue engineering product, human cell and tissue product, or any combination product using such therapies or products, with limited exceptions intended to treat, modify, reverse, or cure a serious or life-threatening disease or condition and for which preliminary clinical evidence indicates that the potential to address unmet medical needs for such a disease or condition. RMAT designation provides potential benefits that include more frequent meetings with FDA to discuss the development plan for the product candidate, and eligibility for rolling review and priority review. Products granted RMAT designation may also be eligible for accelerated approval on the basis of a surrogate or intermediate endpoint reasonably likely to predict long-term clinical benefit, or reliance upon data obtained from a meaningful number of sites, including through expansion to additional sites. There is no assurance that we will be able to obtain RMAT designation for any of our product candidates. RMAT designation does not change the FDA&#x2019;s standards for product approval, and there is no assurance that such designation will result in expedited review or approval or that the approved indication will not be narrower than the indication covered by the designation. Additionally, RMAT designation can be revoked if the criteria for eligibility cease to be met as clinical data emerges.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">71</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Positive results from early preclinical studies and clinical trials are not necessarily predictive of the results of any future clinical trials of our product candidates, and may change as more patient data becomes available and is subject to audit and verification procedures that could result in material changes in the final data. If we cannot replicate the positive results from our earlier preclinical studies and clinical trials of our product candidates in our future clinical trials, we may be unable to successfully develop, obtain regulatory approval for and commercialize our product candidate.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">From time to time, we may publish interim, top-line or preliminary results from our preclinical studies or clinical trials. Such clinical results are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. Preliminary or top-line results also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim and preliminary data should be viewed with caution until the final data are available. Data from clinical trials that we may complete are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to fully and carefully evaluate all data. Preliminary or &#x201c;top line&#x201d; data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously announced. As a result, interim, &#x201c;top-line,&#x201d; and preliminary data should be viewed with caution until the final data are available. Adverse differences between preliminary or interim data and final data could significantly harm our business prospects. It is also difficult to predict the timing of announcing interim results.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accordingly, any positive results from our preclinical studies and ongoing and future clinical trials of our product candidates may not necessarily be predictive of the results from required later clinical trials. Similarly, even if we are able to complete our planned preclinical studies or any future clinical trials according to our current development timeline, the positive results from such preclinical studies and clinical trials may not be replicated in subsequent preclinical studies or clinical trial results.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials after achieving positive results in early-stage development, and we cannot be certain that we will not face similar setbacks. These setbacks have been caused by, among other things, preclinical findings made while clinical trials were underway, or safety or efficacy observations made in preclinical studies and clinical trials, including previously unreported adverse events. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses and many companies that believed their product candidate performed satisfactorily in preclinical studies and clinical trials nonetheless failed to obtain FDA or similar regulatory approval.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If the clinical updates, or the interim, &#34;top-line&#34;, or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for and commercialize our product candidates, our business, operating results, prospects or financial condition may be harmed.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">   </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction, while a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. For example, even if the FDA grants marketing approval of a product candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion of the product candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in the United States, including additional preclinical studies or clinical trials as clinical studies conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may also submit marketing applications in other countries. Regulatory authorities in jurisdictions outside of the United States have requirements for approval of product candidates with which we must comply prior to marketing in those jurisdictions. Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. If we fail to comply with the regulatory requirements in international markets and/or receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additionally, on June 23, 2016, the UK held a referendum in which a majority of voters approved an exit from the EU, or Brexit, and the UK formally left the EU on January 31, 2020. There was a transition period during which EU pharmaceutical laws continued to apply to the UK, which expired on December 31, 2020. However, the EU and the UK have concluded a trade and cooperation agreement, or TCA, which was provisionally applicable since January 1, 2021 and has been formally applicable since May 1, 2021. The TCA includes specific provisions concerning pharmaceuticals, which include the mutual recognition of GMP, inspections of manufacturing facilities for medicinal products and GMP documents issued, but does not foresee wholesale</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">72</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">mutual recognition of UK and EU pharmaceutical regulations. At present, Great Britain has implemented EU legislation on the marketing, promotion and sale of medicinal products through the Human Medicines Regulations 2012 (as amended) (under the Northern Ireland Protocol, the EU regulatory framework will continue to apply in Northern Ireland). The regulatory regime in Great Britain therefore currently aligns in the most part with EU regulations, however it is possible that these regimes will diverge in future now that Great Britain&#x2019;s regulatory system is independent from the EU and the TCA does not provide for mutual recognition of UK and EU pharmaceutical legislation. For example, the new Clinical Trials Regulation, which became effective in the EU on January 31, 2022 and provides for a streamlined clinical trial application and assessment procedure covering multiple EU Member States, has not been implemented into UK law, and a separate application will need to be submitted for clinical trial authorization in the UK. The separate, and potentially diverging, regulatory regimes between Great Britain and the EU may increase our regulatory burden of applying for and obtaining authorization in Great Britain and the EU.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Even if we receive regulatory approval of our product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any regulatory approvals that we receive for our product candidates will require post-market surveillance to monitor the safety and efficacy of the product candidate. The FDA may also require a risk evaluation and mitigation strategy (REMS), in order to approve our product candidates, which could entail requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or a comparable foreign regulatory authority approves our product candidates, the manufacturing processes, labeling, packaging, distribution, adverse event reporting, storage, advertising, promotion, import, export and recordkeeping for our product candidates will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMPs and GCPs for any clinical trials that we conduct post-approval. As such, we and our contract manufacturers will be subject to continual review and inspections to assess compliance with cGMPs and adherence to commitments made in any BLA, other marketing application and previous responses to inspectional observations. Accordingly, we and others with whom we work must continue to expend time, money and effort in all areas of regulatory compliance, including manufacturing, production and quality control. In addition, the FDA could require us to conduct another study to obtain additional safety or biomarker information.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Further, we will be required to comply with FDA's promotion and advertising rules, which include, among others, standards for direct-to-consumer advertising, restrictions on promoting products for uses or in patient populations that are not described in the product&#x2019;s approved uses (known as &#x201c;off-label use&#x201d;), limitations on industry-sponsored scientific and educational activities and requirements for promotional activities involving the internet and social media. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label may be subject to significant liability. However, physicians may, in their independent medical judgment, prescribe legally available products for off-label uses. The FDA does not regulate the behavior of physicians in their choice of treatments, but the FDA does restrict manufacturer&#x2019;s communications on the subject of off-label use of their products. Later discovery of previously unknown problems with our product candidates, including adverse events of unanticipated severity or frequency, or with our third-party suppliers or manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical studies to assess new safety risks; or imposition of distribution restrictions or other restrictions under a REMS program. Other potential consequences include, among other things:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">restrictions on the marketing or manufacturing of our product candidates, withdrawal of the product from the market or voluntary or mandatory product recalls;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">fines, warning letters or holds on clinical trials;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">refusal by the FDA to approve pending applications or supplements to approved applications filed by us or suspension or revocation of license approvals;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">product seizure or detention, or refusal to permit the import or export of our product candidates; and</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">injunctions or the imposition of civil or criminal penalties.</span></div></div>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The FDA&#x2019;s and other regulatory authorities&#x2019; policies may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">73</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Even if we obtain regulatory approval of our product candidates, the products may not gain market acceptance among physicians, patients, hospitals, cancer treatment centers and others in the medical community, adversely affecting our ability to achieve our commercial and financial projections.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The use of engineered gamma delta T cells as a potential cancer treatment is a recent development and may not become broadly accepted by physicians, patients, hospitals, cancer treatment centers and others in the medical community. We expect physicians in the large bone marrow transplant centers to be particularly important to the market acceptance of our products and we may not be able to educate them on the benefits of using our product candidates for many reasons. Additional factors will influence whether our product candidates are accepted in the market, including:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the clinical indications for which our product candidates are approved;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">physicians, hospitals, cancer treatment centers and patients considering our product candidates as a safe and effective treatment;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the potential and perceived advantages of our product candidates over alternative treatments;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the prevalence and severity of any side effects;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">product labeling or product insert requirements of the FDA or other regulatory authorities;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">limitations or warnings contained in the labeling approved by the FDA;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the timing of market introduction of our product candidates as well as competitive products;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the cost of treatment in relation to alternative treatments;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the availability of coverage and adequate reimbursement and pricing by third-party payors and government authorities;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the willingness of patients to pay out-of-pocket in the absence of coverage and adequate reimbursement by third-party payors and government authorities;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">relative convenience and ease of administration, including as compared to alternative treatments and competitive therapies; and</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the effectiveness of our sales and marketing efforts.</span></div></div>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If our product candidates are approved but fail to achieve market acceptance among physicians, patients, hospitals, cancer treatment centers or others in the medical community, we will not be able to generate significant revenue. Even if our products achieve market acceptance, we may not be able to maintain that market acceptance over time if new products or technologies are introduced that are more favorably received than our products, are more cost effective or render our products obsolete.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Coverage and reimbursement may be limited or unavailable in certain market segments for our product candidates, which could make it difficult for us to sell our product candidates, if approved, profitably.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Successful sales of our product candidates, if approved, depend on the availability of coverage and adequate reimbursement from third-party payors including governmental healthcare programs, such as Medicare and Medicaid, managed care organizations and commercial payors, among others. Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which we obtain regulatory approval. In addition, because our product candidates represent new approaches to the treatment of cancer, we cannot accurately estimate the potential revenue from our product candidates. See the section entitled </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">&#x201c;Business &#x2013; Government Regulation and Product Approval &#x2013; Coverage, Pricing and Reimbursement&#x201d;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> elsewhere in this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Patients who are provided medical treatment for their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Obtaining coverage and adequate reimbursement from third-party payors is critical to new product acceptance.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">74</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Third-party payors decide which drugs and treatments they will cover and the amount of reimbursement. Reimbursement by a third-party payor may depend upon a number of factors, including, but not limited to, the third-party payor&#x2019;s determination that use of a product is:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a covered benefit under its health plan;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">safe, effective and medically necessary;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">appropriate for the specific patient;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">cost-effective; and</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">neither experimental nor investigational.</span></div></div>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Obtaining coverage and reimbursement of a product from a government or other third-party payor is a time consuming and costly process that could require us to provide to the payor supporting scientific, clinical and cost-effectiveness data for the use of our products. Even if we obtain coverage for a given product, if the resulting reimbursement rates are insufficient, hospitals may not approve our product for use in their facility or third-party payors may require co-payments that patients find unacceptably high. Patients are unlikely to use our product candidates unless coverage is provided, and reimbursement is adequate to cover a significant portion of the cost of our product candidates. Separate reimbursement for the product itself may or may not be available. Instead, the hospital or administering physician may be reimbursed only for providing the treatment or procedure in which our product is used. Further, from time to time, CMS revises the reimbursement systems used to reimburse health care providers, including the Medicare Physician Fee Schedule and Outpatient Prospective Payment System, which may result in reduced Medicare payments. In some cases, private third-party payers rely on all or portions of Medicare payment systems to determine payment rates. Changes to government healthcare programs that reduce payments under these programs may negatively impact payments from private third-party payers and reduce the willingness of physicians to use our product candidates.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the United States, no uniform policy of coverage and reimbursement for products exists among third-party payors. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. Further, one payor&#x2019;s determination to provide coverage for a product does not assure that other payors will also provide coverage for the product. Adequate third-party reimbursement may not be available to enable us to maintain price levels sufficient to realize an appropriate return on our investment in product development. Because our product candidate may have a higher cost of goods than conventional therapies, and may require long-term follow-up evaluations, the risk that coverage and reimbursement rates may be inadequate for us to achieve profitability may be greater. There is significant uncertainty related to insurance coverage and reimbursement of newly approved products. It is difficult to predict at this time what third-party payors will decide with respect to the coverage and reimbursement for our product candidate. Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. Additional state and federal healthcare reform measures are expected to be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for certain pharmaceutical products or additional pricing pressures. Specifically, there have been several United States Congressional inquiries and federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. We expect to experience pricing pressures in connection with the sale of any of our product candidates due to the trend toward managed healthcare, the increasing influence of health maintenance organizations, cost containment initiatives and additional legislative changes.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We intend to seek approval to market our product candidates in both the United States and in selected foreign jurisdictions. Increased efforts by governmental and third-party payors in the United States and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for our product candidate. If we obtain approval in one or more foreign jurisdictions for our product candidates, we will be subject to rules and regulations in those jurisdictions. In some foreign countries, particularly those in Europe, the pricing of biologics is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after obtaining marketing approval of a product candidate. Some of these countries may require the completion of clinical trials that compare the cost-effectiveness of a particular product candidate to currently available therapies. Other EU member states allow companies to fix their own prices for medicines but monitor and control company profits. The downward pressure on health care costs has become very intense. As a result, increasingly high barriers are being erected to the entry of new products. In addition, in some countries, cross-border imports from low-priced markets exert a commercial pressure on pricing within a country.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The marketability of any product candidates for which we receive regulatory approval for commercial sale may suffer if government and other third-party payors fail to provide coverage and adequate reimbursement. We expect downward pressure on pharmaceutical pricing to continue. Further, coverage policies and third-party reimbursement rates may change at any time.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">75</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Even if favorable coverage and reimbursement status is attained for one or more products for which we receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The advancement of healthcare reform may negatively impact our ability to sell our product candidates, if approved, profitably.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Third-party payors, whether domestic or foreign, or governmental or commercial, are developing increasingly sophisticated methods of controlling healthcare costs. In both the United States and certain foreign jurisdictions, there have been a number of legislative and regulatory changes to the health care system that could impact our ability to sell our product candidates, if approved, profitably. See the section entitled &#x201c;Business &#x2013; Government Regulation and Product Approval &#x2013; Healthcare Reform&#x201d; elsewhere in this Annual Report on Form 10-K.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal and state levels directed at broadening the availability of healthcare and containing or lowering the cost of healthcare. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our products. Such reforms could have an adverse effect on anticipated revenue from product candidates that we may successfully develop and for which we may obtain regulatory approval and may affect our overall financial condition and ability to develop product candidates.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Additionally, there has been heightened governmental scrutiny in the United States of pharmaceutical and biologics pricing practices in light of the rising cost of prescription drugs and biologics. Such scrutiny has resulted in various congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On July 9, 2021, President Biden issued an executive order directing the FDA to, among other things, continue to clarify and improve the approval framework for generic drugs and biosimilars, including the standards for interchangeability of biological products, facilitate the development and approval of biosimilar and interchangeable products, clarify existing requirements and procedures related to the review and submission of BLAs, and identify and address any efforts to impede generic drug and biosimilar competition.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that the U.S. Federal Government will pay for healthcare drugs and services, which could result in reduced demand for our drug candidates or additional pricing pressures. Individual states in the United States have also become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain drug access and marketing cost disclosure and transparency measures, and designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, financial condition, results of operations and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our drugs or put pressure on our drug pricing, which could negatively affect our business, financial condition, results of operations and prospects. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the demand for our product candidates if we obtain regulatory approval;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to set a price that it believes is fair for our products;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to generate revenue and achieve or maintain profitability;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the level of taxes that we are required to pay; and</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the availability of capital.</span></div></div>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors, which may adversely affect our future profitability.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">76</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:13.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Our Intellectual Property</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:13.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Our Intellectual Property</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If our efforts to protect the proprietary nature of the intellectual property related to our technologies are not adequate, we may not be able to compete effectively in our market.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We rely upon a combination of patents, trade secret protection and license agreements to protect the intellectual property related to our technologies. Any disclosure to or misappropriation by third parties of our confidential proprietary information could enable competitors to quickly duplicate or surpass our technological achievements, thus eroding our competitive position in our market.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additional patent applications have been filed, and we anticipate additional patent applications will be filed, both in the United States and in other countries, as appropriate. However, we cannot predict:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">if and when patents will issue;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the degree and range of protection any issued patents will afford us against competitors including whether third parties will find ways to invalidate or otherwise circumvent our patents;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">whether or not others will obtain patents claiming aspects similar to those covered by our patents and patent applications; or</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">whether we will need to initiate litigation or administrative proceedings which may be costly whether we win or lose.</span></div></div>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Composition of matter patents for biological and pharmaceutical products such as CAR-based product candidates often provide a strong form of intellectual property protection for those types of products, as such patents provide protection without regard to any method of use. We cannot be certain that the claims in our pending patent applications covering composition of matter of our product candidates will be considered patentable by the United States Patent and Trademark Office (USPTO), or by patent offices in foreign countries, or that the claims in any of our issued patents will be considered valid and enforceable by courts in the United States or foreign countries. Method of use patents protect the use of a product for the specified method. This type of patent does not prevent a competitor from making and marketing a product that is identical to our product for an indication that is outside the scope of the patented method. Moreover, even if competitors do not actively promote their product for our targeted indications, physicians may prescribe these products &#x201c;off-label.&#x201d; Although off-label prescriptions may infringe or contribute to the infringement of method of use patents, the practice is common and such infringement is difficult to prevent or prosecute.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The strength of patents in the biotechnology and pharmaceutical field involves complex legal and scientific questions and can be uncertain. The patent applications that we own or in-license may fail to result in issued patents with claims that cover our product candidates or uses thereof in the United States or in other foreign countries. Even if the patents do successfully issue, third parties may challenge the patentability, validity, enforceability or scope thereof, for example through inter partes review (IPR) post-grant review or ex parte reexamination before the USPTO or oppositions and other comparable proceedings in foreign jurisdictions, which may result in such patents being cancelled, narrowed, invalidated or held unenforceable. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property or prevent others from designing their products to avoid being covered by our claims. If the breadth or strength of protection provided by the patents and patent applications we hold with respect to our product candidates is threatened, it could dissuade companies from collaborating with us to develop, and threaten our ability to commercialize, our product candidates. Further, if we encounter delays in our clinical trials, the period of time during which we could market our product candidates under patent protection would be reduced. United States patent applications containing or that at any time contained a claim not entitled to a priority date before March 16, 2013 are subject to the &#x201c;first to file&#x201d; system implemented by the America Invents Act (2011).</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This first to file system will require us to be cognizant going forward of the time from invention to filing of a patent application. Since patent applications in the United States and most other countries are confidential for a period of time after filing, we cannot be certain that it was the first to file any patent application related to our product candidates. Furthermore, for United States applications in which all claims are entitled to a priority date before March 16, 2013, an interference proceeding can be provoked by a third-party or instituted by the USPTO, to determine who was the first to invent any of the subject matter covered by the patent claims of our applications. For United States applications containing a claim not entitled to priority before March 16, 2013, there is a greater level of uncertainty in the patent law in view of the passage of the America Invents Act, which brought into effect significant changes to the United States patent laws, including new procedures for challenging patent applications and issued patents.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">77</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may not be successful in obtaining or maintaining necessary rights to product components and processes for our development pipeline through acquisitions and in-licenses.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may require access to additional intellectual property to develop our current or future product candidates. Accordingly, the growth of our business will likely depend in part on our ability to acquire, in-license or use these proprietary rights.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our product candidates may also require specific formulations to work effectively and efficiently and these rights may be held by others. We may be unable to acquire or in-license any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, which would harm our business. Even if we are able to obtain a license, it may be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. In that event, we may be required to expend significant time and resources to develop or license replacement technology. We may need to cease use of the compositions or methods covered by such third-party intellectual property rights.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The licensing and acquisition of third-party intellectual property rights is a competitive area, and companies, which may be more established, or have greater resources than we do, may also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider necessary or attractive in order to commercialize our product candidates. More established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.1020833333333333;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Competitors may infringe our patents or the patents of our licensors. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that one or more of our patents is not valid or is unenforceable or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated, held unenforceable or interpreted narrowly and could put our patent applications at risk of not issuing. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#x2019; fees for willful infringement, obtain one or more licenses from third parties, pay royalties or redesign our infringing products, which may be impossible or require substantial time and monetary expenditure.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interference proceedings provoked by third parties or brought by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications or those of our licensors. An unfavorable outcome could result in a loss of our current patent rights and could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Litigation or interference proceedings may result in a decision adverse to our interests and, even if we are successful, may result in substantial costs and distract our management and other employees. We may not be able to prevent, alone or with our licensors, misappropriation of our trade secrets or confidential information, particularly in countries where the laws may not protect those rights as fully as in the United States.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Periodic maintenance fees on any issued patent are due to be paid to the USPTO and foreign patent agencies in several stages over the lifetime of the patent. The USPTO and various foreign governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. Noncompliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. In such an event, our competitors might be able to enter the market, which would have a material adverse effect on our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">78</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The lives of our patents may not be sufficient to effectively protect our products and business.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years after its first effective filing date. Although various extensions may be available, the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired for a product, we may be open to competition from biosimilar or generic medications. In addition, although upon issuance in the United States a patient&#x2019;s life can be increased based on certain delays caused by the USPTO, this increase can be reduced or eliminated based on certain delays caused by the patent applicant during patent prosecution. If we do not have sufficient patent life to protect our products, our business and results of operations will be adversely affected.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may be subject to claims challenging the inventorship of our patents and other intellectual property.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may in the future be subject to claims that former employees, collaborators, or other third parties have an interest in our patents or other intellectual property as an inventor or co-inventor. For example, we may have inventorship disputes arise from conflicting obligations of consultants or others who are involved in developing our product candidates. Litigation may be necessary to defend against these and other claims challenging inventorship. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Issued patents covering our product candidates could be found unpatentable, invalid or unenforceable if challenged in court or the USPTO.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If we or one of our licensing partners initiate legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim that the patent covering our product candidate, as applicable, is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace, and there are numerous grounds upon which a third party can assert invalidity or unenforceability of a patent. Third parties may also raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include IPR, ex parte re-examination and post grant review in the United States, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). Such proceedings could result in revocation or amendment to our patents in such a way that they no longer cover and protect our product candidates. The outcome following legal assertions of unpatentability, invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior art, of which we, our patent counsel and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of unpatentability, invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product candidates. Such a loss of patent protection could have a material adverse impact on our business.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:13.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Third Party Intellectual Property</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:13.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We depend on intellectual property licensed from third parties and termination of any of these licenses could result in the loss of significant rights, which would harm our business.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are dependent on patents, know-how and proprietary technology, both our own and licensed from others. We depend substantially on our license agreements with Regeneron. These licenses may be terminated upon certain conditions. Any termination of these licenses could result in the loss of significant rights and could harm our ability to commercialize our product candidates. To the extent these licensors fail to meet their obligations under their license agreements, which we are not in control of, we may lose the benefits of our license agreements with these licensors. In the future, we may also enter into additional license agreements that are material to the development of our product candidates.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Disputes may also arise between us and our licensors regarding intellectual property subject to a license agreement, including those related to:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the scope of rights granted under the license agreement and other interpretation-related issues;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our right to sublicense patent and other rights to third parties under collaborative development relationships;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">79</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our product candidates, and what activities satisfy those diligence obligations; and</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners.</span></div></div>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If disputes over intellectual property that we have licensed or license in the future, prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are generally also subject to all of the same risks with respect to protection of intellectual property that we license, as we are for intellectual property that we own, which are described below. If we or our licensors fail to adequately protect this intellectual property, our ability to commercialize products could suffer.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Confidentiality agreements with employees and third parties may not prevent unauthorized disclosure of trade secrets and other proprietary information.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition to the protection afforded by patents, we seek to rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable, processes for which patents are difficult to enforce and any other elements of our product discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents. Trade secrets, however, may be difficult to protect. Although we require all of our employees to assign their inventions to us, and require all of our employees and key consultants who have access to our proprietary know-how, information, or technology to enter into confidentiality agreements, we cannot be certain that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Furthermore, the laws of some foreign countries do not protect proprietary rights to the same extent or in the same manner as the laws of the United States As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United States and abroad. If we are unable to prevent unauthorized material disclosure of our intellectual property to third parties, we will not be able to establish or maintain a competitive advantage in our market, which could materially adversely affect our business, operating results, and financial condition.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Third-party claims of intellectual property infringement may prevent or delay our product discovery and development efforts.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our commercial success depends in part on us avoiding infringement of the patents and proprietary rights of third parties. There is a substantial amount of litigation involving patents and other intellectual property rights in the biotechnology and pharmaceutical industries. Numerous United States and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing our product candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may give rise to claims of infringement of the patent rights of others.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are aware of United States and foreign patents held by a third parties relating to gamma delta T cell expansion protocols and related compositions which, on information and belief, are invalid and/or not infringed. In the event that these patents are successfully asserted against our product candidates, such as ADI-001 and ADI-002, or the use of our precursor cells in manufacture of these product candidates, such litigation may negatively impact our ability to commercialize these product candidates in such jurisdictions. We are also aware of several United States and foreign patents held by third parties relating to certain CAR compositions of matter, methods of making and methods of use which, on information and belief, are invalid and/or not infringed. Nevertheless, third parties may assert that we infringe their patents or are otherwise employing their proprietary technology without authorization and may sue us. Generally, conducting clinical trials and other development activities in the United States is not considered an act of infringement. If and when ADI-001 or ADI-002 or another CAR-based product candidate is approved by the FDA, third parties may then seek to enforce their patents by filing a patent infringement lawsuit against us. Patents issued in the United States by law enjoy a presumption of validity that can be rebutted only with evidence that is &#x201c;clear and convincing,&#x201d; a heightened standard of proof. We may not be able to prove in litigation that any patent enforced against us is invalid and/or not infringed.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Additionally, there may be third-party patents of which we are currently unaware with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that our product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of our product candidates, constructs or molecules used in or formed during the manufacturing process, or any final product itself, the holders of any such patents may be able to block our ability to commercialize the product candidate unless we obtained a license under the applicable patents, or until such patents expire or they are finally determined to be held not infringed, unpatentable, invalid or unenforceable. Similarly, if any third-party patent were held by a court of competent</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">80</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">jurisdiction to cover aspects of our formulations, processes for manufacture or methods of use, including combination therapy or patient selection methods, the holders of any such patent may be able to block our ability to develop and commercialize the product candidate unless we obtained a license or until such patent expires or is finally determined to be held not infringed, unpatentable, invalid or unenforceable. In either case, such a license may not be available on commercially reasonable terms or at all. If we are unable to obtain a necessary license to a third-party patent on commercially reasonable terms, or at all, our ability to commercialize our product candidates may be impaired or delayed, which could in turn significantly harm our business.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Parties making claims against us may seek and obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business and may impact our reputation. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys&#x2019; fees for willful infringement, obtain one or more licenses from third parties, pay royalties, or redesign our infringing products, which may be impossible or require substantial time and monetary expenditure. We cannot predict whether any such license would be available at all or whether it would be available on commercially reasonable terms. Furthermore, even in the absence of litigation, we may need to obtain licenses from third parties to advance our research or allow commercialization of our product candidates. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we would be unable to further develop and commercialize our product candidates, which could harm our business significantly.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Intellectual Property Laws</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Changes in United States patent law could diminish the value of patents in general, thereby impairing our ability to protect our products.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical industry involve both technological and legal complexity, and is therefore costly, time-consuming and inherently uncertain. Recent United States Court of Appeals for the Federal Circuit and Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the United States Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may not be able to protect our intellectual property rights throughout the world.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We may not be able to protect our intellectual property rights outside the United States Filing, prosecuting, and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the U.S., or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biopharmaceutical products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that it develops or licenses.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We may be subject to claims that our employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have received confidential and proprietary information from third parties. In addition, we employ individuals who were previously employed at other biotechnology or pharmaceutical companies. We may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed confidential information of</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">81</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">these third parties or our employees&#x2019; former employers. Litigation may be necessary to defend against these claims. Even if we are successful in defending against these claims, litigation could result in substantial cost and be a distraction to our management and employees.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Ownership of Our Common Stock</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Ownership Generally</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">An active trading market for our common stock may not be sustained. If an active trading market is not sustained, our ability to raise capital in the future may be impaired.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our shares began trading on The Nasdaq Global Select Market on January 26, 2018. Given the limited trading history of our common stock, there is a risk that an active trading market for our shares may not be sustained, which could put downward pressure on the market price of our common stock and thereby affect your ability to sell shares you purchased. An inactive trading market for our common stock may also impair our ability to raise capital to continue to fund our operations by selling shares and impair our ability to acquire other companies or technologies by using our shares as consideration.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The trading price of our common stock highly volatile, which could result in substantial losses for purchasers of our common stock. Securities class action or other litigation involving our company or members of our management team could also substantially harm our business, financial condition and results of operations.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our stock price is highly volatile. The stock market in general and the market for smaller pharmaceutical and biotechnology companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. As a result of this volatility, you may not be able to sell your common stock at or above the purchase price and you may lose some or all of your investment. The market price for our common stock may be influenced by many factors, including:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the success of existing or new competitive products or technologies; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">regulatory actions with respect to our product candidates or our competitors&#x2019; products and product candidates;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">announcements by us or our competitors of significant acquisitions, strategic partnerships, joint ventures, collaborations or capital commitments;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the timing and results of clinical trials of ADI-001 in NHL; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">commencement or termination of collaborations for our development programs;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">failure or discontinuation of any of our development programs;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">results of clinical trials of product candidates of our competitors;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">regulatory or legal developments in the United States and other countries;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">developments or disputes concerning patent applications, issued patents or other proprietary rights;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the recruitment or departure of key personnel;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the level of expenses related to any of our product candidates or clinical development programs;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the results of our efforts to develop additional product candidates or products;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">actual or anticipated changes in estimates as to financial results or development timelines;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">announcement or expectation of additional financing efforts;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">sales of our common stock by us, our insiders or other stockholders;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">variations in our financial results or those of companies that are perceived to be similar to us;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">changes in estimates or recommendations by securities analysts, if any, that cover us;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">changes in the structure of healthcare payment systems;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">market conditions in the pharmaceutical and biotechnology sectors;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">general economic, industry and market conditions; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the other factors described in this &#x201c;Risk Factors&#x201d; section.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">82</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for biopharmaceutical companies, which have experienced significant stock price volatility in recent years.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our principal stockholders and management own a significant percentage of our stock and will be able to exert significant control over matters subject to stockholder approval.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our executive officers, directors, and 5% stockholders beneficially owned, in the aggregate, approximately 42.2% of our outstanding voting common stock. Accordingly, these stockholders will have the ability to influence us through this ownership position and significantly affect the outcome of all matters requiring stockholder approval. For example, these stockholders may be able to significantly affect the outcome of elections of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. This may prevent or discourage unsolicited acquisition proposals or offers for our common stock that you may feel are in your best interest as one of our stockholders.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Risks Related to Market Uncertainties</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The global credit and financial markets have experienced extreme volatility and disruptions in the past several years, including severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. We believe that the state of global economic conditions are particularly volatile and uncertain, not only in light of the COVID-19 pandemic and the potential global recession resulting therefrom, but also due to recent and expected shifts in political, legislative and regulatory conditions concerning, among other matters, international trade and taxation, and that an uneven recovery or a renewed global downturn may negatively impact our ability to conduct clinical trials on the scale and timelines anticipated. There can be no assurance that further deterioration in credit and financial markets and confidence in economic conditions will not occur. Our general business strategy may be adversely affected by any such economic downturn, volatile business or political environment or continued unpredictable and unstable market conditions. If the current equity and credit markets deteriorate, it may make obtaining any necessary debt or equity financing more difficult, more costly and more dilutive. For example, as a result of political, social, and economic instability abroad, including as a result of armed conflict, war or threat of war, in particular, the current conflict between Russia and Ukraine, including resulting sanctions, terrorist activity and other security concerns in general, there could be a significant disruption of global financial markets, impairing our ability to raise capital when needed on acceptable terms, if at all.  Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our growth strategy, financial performance and stock price and could require us to delay or abandon clinical development plans. In addition, there is a risk that one or more of our current service providers, manufacturers and other partners may not survive an economic downturn, which could directly affect our ability to attain our operating goals on schedule and on budget. To the extent that our profitability and strategies are negatively affected by downturns or volatility in general economic conditions, our business and results of operations may be materially adversely affected.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Risks Related to our Charter and Bylaws</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Anti-takeover provisions under our charter documents and Delaware law could delay or prevent a change of control which could limit the market price of our common stock and may prevent or frustrate attempts by our stockholders to replace or remove our current management.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our third amended and restated certificate of incorporation and amended and restated bylaws contain provisions that could delay or prevent a change of control of our company or changes in our board of directors that our stockholders might consider favorable. Some of these provisions include:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a board of directors divided into three classes serving staggered three-year terms, such that not all members of the board will be elected at one time;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a prohibition on stockholder action through written consent, which requires that all stockholder actions be taken at a meeting of our stockholders;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a requirement that special meetings of stockholders be called only by the chairman of the board of directors, the chief executive officer, or by a majority of the total number of authorized directors;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">advance notice requirements for stockholder proposals and nominations for election to our board of directors;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a requirement that no member of our board of directors may be removed from office by our stockholders except for cause and, in addition to any other vote required by law, upon the approval of the holders of not less than 75% of the votes that all our stockholders would be entitled to cast in an annual election of directors;</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">83</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">a requirement of approval of not less than 75% of all outstanding shares of our voting stock to amend any bylaws by stockholder action or to amend specific provisions of our certificate of incorporation; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the authority of the board of directors to issue preferred stock on terms determined by the board of directors without stockholder approval and which preferred stock may include rights superior to the rights of the holders of common stock.</span></div></div>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporate Law, which may prohibit certain business combinations with stockholders owning 15% or more of our outstanding voting stock. These anti-takeover provisions and other provisions in our amended and restated certificate of incorporation and amended and restated bylaws could make it more difficult for stockholders or potential acquirors to obtain control of our board of directors or initiate actions that are opposed by the then-current board of directors and could also delay or impede a merger, tender offer or proxy contest involving our company. These provisions could also discourage proxy contests and make it more difficult for you and other stockholders to elect directors of your choosing or cause us to take other corporate actions you desire. Any delay or prevention of a change of control transaction or changes in our board of directors could cause the market price of our common stock to decline.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Our amended and restated bylaws provides that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for most legal actions between us and our stockholders, which could limit our stockholders&#x2019; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, employees or agents.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our amended and restated bylaws specifies that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for (i) any derivative action or proceeding brought on behalf of the Company, (ii) any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee of the Company to the Company or the Company&#x2019;s stockholders, (iii) any action asserting a claim arising pursuant to any provision of the Delaware General Corporation Law or the restated certificate of incorporation or amended and restated bylaws, or (iv) any action asserting a claim against the Company governed by the internal affairs doctrine. This choice of forum provision contained in our amended and restated bylaws will not apply to any causes of action arising under the Securities Act or the Exchange Act. Any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock shall be deemed to have notice of and to have consented to the provisions of our amended and restated bylaws described above; provided, however, that stockholders cannot and will not be deemed to have waived our compliance with the U.S. federal securities laws and the rules and regulations thereunder.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We believe this provision benefits us by providing increased consistency in the application of Delaware law by chancellors particularly experienced in resolving corporate disputes, efficient administration of cases on a more expedited schedule relative to other forums and protection against the burdens of multi-forum litigation. However, the provision may have the effect of discouraging lawsuits against our directors, officers, employees and agents as it may limit any stockholder&#x2019;s ability to bring a claim in a judicial forum that such stockholder finds favorable for disputes with us or our directors, officers, employees or agents. The enforceability of similar choice of forum provisions in other companies&#x2019; bylaws or certificates of incorporation has been challenged in legal proceedings, and it is possible that, in connection with any applicable action brought against us, a court could find the choice of forum provisions contained in our amended and restated bylaws to be inapplicable or unenforceable in such action. If a court were to find the choice of forum provision contained in our amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business, financial condition or results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">General Risk Factors</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We are an EGC and the reduced disclosure requirements applicable to EGCs may make our common stock less attractive to investors.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are an EGC, and, for as long as we continue to be an EGC, we may choose to take advantage of exemptions from various reporting requirements applicable to other public companies but not to &#x201c;emerging growth companies.&#x201d; We will remain an EGC until the earliest to occur of: (1) the last day of the fiscal year in which we have more than $1.07 billion in annual revenue; (2) the date we qualify as a large accelerated filer, with at least $700.0 million of equity securities held by non-affiliates; (3) the date on which we have issued more than $1.0 billion in non-convertible debt securities during the prior three-year period; and (4) the last day of the fiscal year ending after the fifth anniversary of our initial public offering. For as long as we remain an &#x201c;emerging growth company,&#x201d; we expect to avail ourselves of the exemptions from various reporting requirements applicable to other public companies but not to EGCs, including not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, as amended (Section 404).</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">84</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><br />Assuming we do not surpass one of the thresholds in clauses (1) through (3), our status as an EGC will end on December 31, 2023, which will be the last day of the fiscal year ending after the fifth anniversary of our initial public offering. As such, we will be subject to the disclosure requirements applicable to other public companies that were not applicable to us as an EGC. These requirements include:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">compliance with the auditor attestation requirements of Section 404;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">compliance with any requirement that may be adopted by the Public Company Accounting Oversight Board regarding mandatory audit firm rotation or a supplement to the auditor&#x2019;s report providing additional information about the audit and the financial statements;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">full disclosure obligations regarding executive compensation; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">compliance with the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute payments not previously approved.</span></div></div>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><br />When our independent registered public accounting firm is required to undertake an assessment of our internal control over financial reporting, the cost of our compliance with Section 404 will correspondingly increase. Moreover, if we are not able to comply with the requirements of Section 404 applicable to us in a timely manner, or if we or our independent registered public accounting firm identifies deficiencies in our internal control over financial reporting that are deemed to be material weaknesses, the market price of our stock could decline and we could be subject to sanctions or investigations by the SEC or other regulatory authorities. Additionally, we expect that our loss of EGC status will require additional attention from management and will result in increased costs to us, which could include higher legal fees, accounting fees and fees associated with investor relations activities, among others.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We are also a SRC and the reduced disclosure requirements applicable to SRCs may make our common stock less attractive to investors.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are considered a SRC under Rule 12b-2 of the Exchange Act. We are therefore entitled to rely on certain reduced disclosure requirements, such as an exemption from providing selected financial data and executive compensation information. These exemptions and reduced disclosures in our SEC filings due to our status as a smaller reporting company also mean our auditors are not required to review our internal control over financial reporting and may make it harder for investors to analyze our results of operations and financial prospects. We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our common stock prices may be more volatile. We will remain a smaller reporting company until our public float exceeds $250 million or our annual revenues exceed $100 million with a public float greater than $700 million.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We have broad discretion over the use of our cash, cash equivalents, and marketable securities and may not use them effectively.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our management has broad discretion to use our cash, cash equivalents, and marketable securities to fund our operations and could spend these funds in ways that do not improve our results of operations or enhance the value of our common stock. The failure by our management to apply these funds effectively could result in financial losses that could have a material adverse effect on our business, cause the price of our common stock to decline and delay the development of our product candidates. Pending our use to fund operations, we may invest our cash, cash equivalents, and marketable securities in a manner that does not produce income or that loses value.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">We do not anticipate paying any cash dividends on our capital stock in the foreseeable future. Accordingly, stockholders must rely on capital appreciation, if any, for any return on their investment.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have never declared nor paid cash dividends on our capital stock. We currently plan to retain all of our future earnings, if any, to finance the operation, development and growth of our business. In addition, the terms of any future debt or credit agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock will be your sole source of gain for the foreseeable future.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our share price and trading volume could decline.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The trading market for our common stock will be influenced by the research and reports that industry or securities analysts publish about us or our business. If one or more of the analysts who cover us issues an adverse opinion about our company, our stock price would likely decline. If one or more of these analysts ceases research coverage of us or fails to regularly publish</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">85</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">reports on us, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Sales of a substantial number of shares of our common stock by our existing stockholders in the public market could cause our stock price to fall.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">  </span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the perception in the market that holders of a large number of shares intend to sell shares, could reduce the market price of our common stock. Certain holders of our common stock have rights, subject to conditions, to require us to file registration statements covering their shares or to include their shares in registration statements that we may file for ourselves or other stockholders. Registration of these shares under the Securities Act of 1933, as amended (Securities Act) would result in the shares becoming freely tradable without restriction under the Securities Act, except for shares held by affiliates, as defined in Rule 144 under the Securities Act. Any sales of securities by these stockholders could have a material adverse effect on the trading price of our common stock.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On March 12, 2021, we filed a registration statement on Form S-3 (File No. 333-254193) with the SEC, which was declared effective on March 30, 2021 (Shelf Registration Statement), in relation to the registration of common stock, preferred stock, debt securities, warrants and/or units of any combination thereof for the purposes of selling, from time to time, our common stock, debt securities or other equity securities in one or more offerings. We also simultaneously entered into a Capital On Demand&#153; Sales Agreement (Sales Agreement) with JonesTrading Institutional Services, LLC (Sales Agent), to provide for the offering, issuance and sale of up to an aggregate amount of $75.0 million of our common stock from time to time in &#x201c;at-the-market&#x201d; offerings under the Shelf Registration Statement and subject to the limitations thereof. The Company will pay to the Sales Agent cash commissions of 3% of the aggregate gross proceeds of sales of common stock under the Sales Agreement. Sales of common stock, debt securities or other equity securities by us may represent a significant percentage of our common stock currently outstanding. If we sell, or the market perceives that we intend to sell, substantial amounts of our common stock under the Shelf Registration Statement or otherwise, the market price of our common stock could decline significantly.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We also filed a registration statement on Form S-8 registering the issuance of shares of common stock issued or reserved for future issuance under our equity compensation plans. Shares registered under this registration statement on Form S-8 can be freely sold in the public market upon issuance and once vested, subject to volume limitations applicable to affiliates and the lock-up agreements described above. If any of these additional shares are sold, or if it is perceived that they will be sold, in the public market, the market price of our common stock could decline.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, certain of our employees, executive officers, and directors may enter into Rule 10b5-1 trading plans providing for sales of shares of our common stock from time to time. Under a Rule 10b5-1 trading plan, a broker executes trades pursuant to parameters established by the employee, director, or officer when entering into the plan, without further direction from the employee, officer, or director. A Rule 10b5-1 trading plan may be amended or terminated in some circumstances. Our employees, executive officers, and directors also may buy or sell additional shares outside of a Rule 10b5-1 trading plan when they are not in possession of material, nonpublic information.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">86</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="unresolved_staff_comments"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 1B. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Unresolved Staff Comments.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Not applicable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_2_properties"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 2. Pr</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">operties.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have offices in Boston, Massachusetts, and Menlo Park, California. Our principal executive offices are located at 200 Clarendon, Floor 6, Boston, Massachusetts 02116. The original term of this lease expires on March 31, 2022, and was renewed in February 2022 to expire on July 31, 2022. We also leased office and laboratory space located in Menlo Park, California. The lease expires on June 30, 2022. In addition, in October 2018, we entered a new lease for office and laboratory space in Redwood City, California that expires on February 28, 2030. We expect to complete occupancy in the new facility in the fourth quarter of 2022. We believe that our office and laboratory space is sufficient to meet our current needs and that suitable additional space will be available as and when needed.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_3_legal_proceedings"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 3. Legal </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Proceedings.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are not currently subject to any material legal proceedings. From time to time, we may be subject to various legal proceedings and claims that arise in the ordinary course of our business activities. Although the results of litigation and claims cannot be predicted with certainty, as of the date of this report, we do not believe we are party to any claim or litigation the outcome of which, if determined adversely to us, would individually or in the aggregate be reasonably expected to have a material adverse effect on our business. Regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_4_mine_safety_disclosures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 4. Mine Saf</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ety Disclosures.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Not applicable.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">87</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="part_ii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PART</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> II</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="item_5_market_for_registrants_common_equ"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 5. Market for Registrant&#x2019;s Common Equity, Related Stoc</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">kholder Matters and Issuer Purchases of Equity Securities.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our common stock trades on The Nasdaq Global Market under the symbol &#x201c;ACET&#x201d;. Trading of our common stock commenced on January 26, 2018, in connection with our initial public offering of resTORbio. Prior to that time, there was no established public trading market for our common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of March 10, 2022, we had approximately 24 holders of record of our common stock. The actual number of holders of our common stock is greater than this number of record holders and includes stockholders who are beneficial owners, but whose shares are held in street name by brokers or held by other nominees. This number of holders of record also does not include stockholders whose shares may be held in trust by other entities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Dividends</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have never declared or paid any cash dividends on our common stock. We currently intend to retain all available funds and any future earnings, if any, to fund the development and growth of our business. We do not expect to pay any cash dividends in the foreseeable future. Any future determination to pay dividends will be made at the discretion of our board of directors and will depend on various factors, including applicable laws, our results of operations, financial condition, future prospects, then applicable contractual restrictions and any other factors deemed relevant by our board of directors. Investors should not purchase our common stock with the expectation of receiving cash dividends.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Equity Compensation Plan</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The information required by Item 5 of Form 10&#x2011;K regarding equity compensation plans is incorporated herein by reference to Item 12 of Part III of this Annual Report on Form 10&#x2011;K.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Recent Sales of Unregistered Securities</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Securities Purchase Agreement</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On February 12, 2021, we entered into a stock purchase agreement with certain existing investors for $15.0 million of shares of our common stock, with an initial closing for certain investors held simultaneously with the closing of our February 2021 public offering and a subsequent closing for certain additional investors. Pursuant to the terms of the private placement, we issued 1,153,840 shares of common stock at a price of $13.00 per share, which was the price per share of our February 2021 public offering (the Private Placement Shares). We received the full proceeds from the sale and did not pay any underwriting discounts or commissions with respect to the shares of common stock that sold in the concurrent private placement. Proceeds from the private placement will be used primarily to fund activities related to our internal discovery research, other pipeline candidates and to fund the continued development of our gamma delta T cell platform; the external costs for the development of ADI-001 through the completion of a Phase 1 dose expansion study for ADI-001 in NHL; and the remainder, if any, to fund working capital and other general corporate purposes. The private placement was exempt from registration pursuant to Section 4(a)(2) of the Securities Act as a transaction by an issuer not involving a public offering. Pursuant to the terms of the private placement, we subsequently filed a Registration Statement on Form S-3 (File No. 333-256088), dated May 21, 2021, pursuant to which we registered the Private Placement Shares. We have agreed to maintain the effectiveness of the registration statement until such time as all Private Placement Shares covered by the registration statements have been sold or may be sold under Rule 144 without manner of sale restrictions or volume limitations, subject to certain exceptions.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Purchase of Equity Securities by the Issuer and Affiliated Purchasers</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We did not purchase any of our equity securities during the period covered by this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="item_6"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 6. Reserved</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">88</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="item_7_managements_discussion_analysis_f"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 7. Management&#x2019;s Discussion and Analysis of</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> Financial Condition and Results of Operations.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">You should read the following discussion and analysis of our financial condition and results of operations together with our consolidated financial statements and related notes included elsewhere in this Annual Report on Form 10-K. This discussion and other parts of this Annual Report on Form 10-K contain forward-looking statements that involve risks and uncertainties, such as our plans, objectives, expectations, intentions and beliefs. Our actual results could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those identified below and those discussed in the section entitled &#x201c;Risk Factors&#x201d; included elsewhere in this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer. We are advancing a pipeline of &#x201c;off-the-shelf&#x201d; gamma delta T cells, engineered with chimeric antigen receptors (CAR) and T cell receptor-like antibodies (TCRL), to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. Our approach to activate, engineer and manufacture allogeneic gamma delta T cell product candidates derived from the peripheral blood cells of unrelated donors allows us to generate new product candidates in a rapid and cost-efficient manner.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is in an ongoing Phase 1 study for the treatment of Non-Hodgkin's Lymphoma (NHL). Our pipeline also includes ADI-002, an allogeneic gamma delta CAR-T cell therapy expressing a GPC3-targeted CAR and a cell intrinsic soluble form of interluiken-15 (IL-15), for the treatment of solid tumors In addition, we are engaged in discovery and preclinical stage activities directed to expansion of our pipeline of product candidates for both hematological malignancies and solid tumors.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our proprietary engineering and manufacturing process begins with isolating and expanding gamma delta T cells from the blood of unrelated donors, and results in the potential to treat up to 1,000 patients per batch depending on dosing and the CAR target. The potential to administer product candidates based on gamma delta T cells to patients without inducing a graft versus host immune response could mean that our products can potentially be used as &#x201c;off-the-shelf&#x201d; therapies. This is in contrast to products based on alpha beta T cells, which either must be manufactured for each patient from his or her own T cells, or require significant gene editing to manufacture if the T cells are derived from donors that are unrelated to the patient. Based on what we believe is the unique potential of these cells and associated modifications, we are initially developing product candidates in oncology, both for hematological malignancies and for solid tumors. In October 2020, the U.S. Food and Drug Administration (FDA) cleared our Investigational New Drug (IND) application for ADI-001, our lead product candidate, for the treatment of Non-Hodgkin&#x2019;s Lymphoma (NHL). In March 2021, we initiated the first-in-human clinical trial to assess safety and efficacy of ADI-001 in NHL patients. The Phase 1 study for ADI-001 will enroll up to 80 late-stage NHL patients at a number of cancer centers across the United States. The study includes a dose escalation portion followed by dose expansion cohorts to explore the activity of ADI-001 in multiple subtypes of NHL. In December 2021, we announced positive interim clinical data from the initial dose escalation portion of this study.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Recent Developments</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Public Offerings and Private Placement</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In February 2021, we completed an underwritten public offering of 10,575,513 shares of our common stock, including the exercise in full by the underwriters of their option to purchase up to an additional 1,344,743 shares of common stock at a public offering price of $13.00 per share. The net proceeds from the offering, after deducting underwriting discounts and commissions and offering expenses were approximately $128.8 million.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the February 2021 offering, we also entered into a stock purchase agreement with certain existing investors to purchase 1,153,840 shares of our common stock for $15.0 million at a price per share equal to the public offering price, with an initial closing for certain investors held simultaneously with the closing of the offering and a subsequent closing for certain additional investors. We received the full proceeds from the sale and did not pay any underwriting discounts or commissions with respect to the shares of common stock that sold in the concurrent private placement. Pursuant to the terms of the private placement, we subsequently filed a Registration Statement on Form S-3 (File No. 333-256088), dated May 21, 2021, pursuant to which we registered the Private Placement Shares. We have agreed to maintain the effectiveness of the registration statement until such time as all Private Placement Shares covered by the registration statements have been sold or may be sold under Rule 144 without manner of sale restrictions or volume limitations, subject to certain exceptions.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2021, we completed an underwritten public offering of 7,187,500 shares of our common stock, including the exercise in full by the underwriters of their option to purchase up to an additional 937,500 shares of common stock, at a public offering price of $14.00 per share. The net proceeds from the offering, after deducting underwriting discounts and commissions and offering expenses were approximately $94.2 million.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">89</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">At-the-Market (ATM) Offering</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On March 12, 2021, we entered into a Sales Agreement (the 2021 Sales Agreement) with JonesTrading Institutional Services (the Agent), pursuant to which we could sell, from time to time, at our option, up to an aggregate of $75.0 million of shares of our common stock, through the Agent, as our sales agent. No shares were sold under the 2021 Sales Agreement as of December 31, 2021. In connection with the 2021 Sales Agreement, we terminated a prior ATM program with Evercore Group L.L.C. and H.C. Wainwright &amp; Co., L.L.C.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Loan Agreement</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On October 21, 2021, we amended our Loan and Security Agreement (the Loan Agreement) with Pacific Western Bank  (PacWest)(the Loan Amendment) under which PacWest will provide one or more Term Loans, as well as Non-Formula Ancillary Services which shall not exceed $5.5 million in the aggregate. Non-Formula Ancillary Services are defined as automated clearinghouse transactions, corporate credit card services, letters of credit, or other treasury management services. The aggregate sum of the outstanding Term Loans and Non-Formula Ancillary Services shall at no time exceed $15.0 million, which each Term Loan to be in an amount of not less than $1.0 million. As of December 31, 2021, we had outstanding Non-Formula Ancillary Services of $4.4 million. Accordingly, as of December 31, 2021, the Company has $10.6 million available under the Term Loan. Pursuant to the Loan Amendment, the interest rate for the Term Loans shall be set at an annual rate equal to the greater of (i) 0.25% above the Prime Rate then in effect and (ii) 4.25%.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of the date of this Annual Report on Form 10-K, we were in compliance with such covenants and had no indebtedness outstanding under the Loan Agreement.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Impact of COVID-19 Pandemic</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2019, a novel strain of coronavirus, COVID-19, was reported in China. The spread of COVID-19 from China to other countries has resulted in the World Health Organization (WHO) declaring the outbreak of COVID-19 as a &#x201c;pandemic,&#x201d; or a worldwide spread of a new disease, on March 11, 2020. Since then, COVID-19 has spread globally and new variants of the virus have emerged. Many countries around the world have imposed quarantines and restrictions on travel and mass gatherings to slow the spread of the virus and have closed non-essential businesses. The continued spread of COVID-19, despite progress in vaccination efforts, has resulted in significant governmental measures being implemented to control the spread of COVID-19 and its variants. These measures may result in a period of business, supply, and drug product manufacturing disruption, and in reduced operations, any of which could materially affect our business, financial condition and results of operations.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In response to the COVID-19 pandemic, we tasked members of our Executive Leadership team, Human Resources, Facilities and Operations and Employee Communications to develop guidelines and processes intended to raise awareness of new health and well-being protocols and potentially helpful practices for cross-functional teamwork for our employees. We implemented remote working and shift scheduling, provided our team members practical recommendations based on guidelines from the Centers for Disease Control and Prevention, State of California Department of Health Care Services, State of Massachusetts Department of Public Health, OSHA and other regional government entities. In addition, we are committed to updating these recommendations and communicating new pertinent information when available. While doing so we are sensitive to ensuring any guidance provided may vary by locality based on government orders and regulations.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Thus far we have not experienced a significant disruption or delay in our operations as it relates to the clinical development of our drug candidates. However, we anticipate that the impact of the COVID-19 pandemic may create difficulties in our clinical trials for a variety of reasons, including future regulations regarding, or the inability or unwillingness of patients to, travel to participate in clinical trials, or to participate in clinical trials that are administered in medical facilities that also treat COVID-19, potential delays in the FDA&#x2019;s review and approval processes and/or shortages of medical supplies that may force medical professionals to focus on non-clinical procedures, including treatment of COVID-19. The duration and ultimate impact of the ongoing COVID-19 pandemic on clinical trials generally, and on our trials particularly, is currently unknown.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In addition, the spread of COVID-19, which has caused a broad impact globally, may materially affect us economically. While the potential economic impact brought by, and the duration of, COVID-19 may be difficult to assess or predict, a widespread pandemic could result in significant disruption of global financial markets, reducing our ability to access capital, which could in the future negatively affect our liquidity. In addition, a recession or market correction resulting from the spread of COVID-19 and its variants could materially affect our business. Possible effects may also include absenteeism in our labor workforce, unavailability of products and supplies used in operations, and a decline in value of assets held by us, including property and equipment, and marketable debt securities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">90</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Financial Operations Overview</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Revenue</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have no products approved for commercial sale and do not expect to generate revenue from product sales unless and until we successfully complete development and obtain regulatory approval for our product candidates, which we expect will not be for at least several years, if ever. Our revenues to date are generated from our License and Collaboration Agreement with Regeneron Pharmaceuticals, Inc. (Regeneron) and the agreement referred to as the &#x201c;Regeneron Agreement&#x201d;. The primary purpose of the Regeneron Agreement is to establish a strategic relationship to identify and validate appropriate targets and work together to develop a pipeline of engineered immune cell products (Collaboration ICPs) for the selected targets. The Regeneron Agreement provides for the following: (i) licenses to our technology, (ii) research and development services, (iii) services or obligations in connection with participation in the research committee, (iv) information sharing, and (v) manufacturing services to manufacture of Collaboration ICPs for the research programs. The Regeneron Agreement provides Regeneron an option to obtain an exclusive, royalty-bearing development and commercial license under our intellectual property to develop and commercialize the optioned Collaboration ICPs ready for an IND submission.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We received a non-refundable upfront payment of $25.0 million from Regeneron upon execution of the Regeneron Agreement on July 29, 2016 and have received an aggregate of $20.0 million of additional payments for research funding from Regeneron as of December 31, 2020. In addition, Regeneron may have to pay us additional amounts in the future consisting of up to an aggregate of $80.0 million of option exercise fees for a certain number of Collaboration ICPs. On January 28, 2022, we received a payment of $20.0 million from Regeneron for exercise of its option to license exclusive rights to ADI-002 and Regeneron potentially has additional options to other Collaboration ICP targets under the Regeneron Agreement. We declined to exercise our option to co-fund the development of ADI-002 with Regeneron, and accordingly, Regeneron must also pay us high single digit royalties as a percentage of net sales for ADI-002 or any other optioned ICPs to targets for which it has exclusive rights and low single digit royalties as a percentage of net sales on any non-ICP product comprising a target generated by us through the use of Regeneron&#x2019;s proprietary mice. We must pay Regeneron mid-single to low double digit royalties as a percentage of net sales of Collaboration ICPs to targets for which we have exercised exclusive rights, and low to mid-single digit royalties as a percentage of net sales of targeting moieties generated from our license to use Regeneron&#x2019;s proprietary mice. Royalties are payable until the longer of the expiration or invalidity of the licensed patent rights or 12 years from first commercial sale.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We use a cost-based input method to measure proportional performance and to calculate the corresponding amount of revenue to recognize under the Regeneron Agreement. In applying the cost-based input method of revenue recognition, we use actual costs incurred relative to budgeted costs to fulfill the combined performance obligation. Revenue is recognized based on actual costs incurred as a percentage of total budgeted costs as we complete our performance obligations over the research term of five years. A cost-based input method of revenue recognition requires us to estimate costs to complete our performance obligations, which requires significant judgment to evaluate assumptions related to cost estimates. The cumulative effect of revisions to estimated costs to complete our performance obligations is recorded in the period in which changes are identified and amounts can be reasonably estimated.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Operating Expenses</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research and Development</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development expenses, which consist primarily of costs incurred in connection with the development of our product candidates, are expensed as incurred. Research and development expenses consist primarily of:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">employee related costs, including salaries, benefits and stock-based compensation expenses for research and development employees;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">costs incurred under agreements with consultants, contract manufacturing organizations (CMOs) and contract research organizations (CROs);</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">lab materials, supplies, and maintenance of equipment used for research and development activities; and</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">allocated facility-related costs, such as rent, utilities, insurance, repairs and maintenance, depreciation and amortization, information technology costs and general support services.</span></div></div>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We do not allocate our costs by product candidate, as a significant amount of research and development expenses are not tracked by product candidate, and we believe the allocation of such costs would be arbitrary and would not provide a meaningful assessment as we have used our employee and infrastructure resources across multiple product candidate research and development programs.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">91</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are focusing substantially all of our resources on the development of our product candidates. At this time, we cannot reasonably estimate or know the nature, timing and estimated costs of the efforts that will be necessary to complete the development of our product candidates. We are also unable to predict when, if ever, material net cash inflows will commence from sales of our product candidates. The duration, costs, and timing of clinical trials and development of our product candidates will depend on a variety of factors, including:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the scope, rate of progress and expense of clinical trials and other research and development activities;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">clinical trial results;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">uncertainties in clinical trial enrollment rate or design;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">significant and changing government regulation;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the timing and receipt of any regulatory approvals;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the FDA&#x2019;s or other regulatory authority&#x2019;s influence on clinical trial design;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">establishing commercial manufacturing capabilities or making arrangements with third-party manufacturers;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">commercializing product candidates, if and when approved, whether alone or in collaboration with others;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">obtaining and maintaining patent and trade secret protection and regulatory exclusivity for product candidates;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">continued applicable safety profiles of the products following approval; and</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">retention of key research and development personnel.</span></div></div>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A change in the outcome of any of these variables with respect to the development of a product candidate could significantly change the costs, timing and viability associated with the development of that product candidate. For example, if the FDA, or another regulatory authority, were to require us to conduct clinical trials beyond those that it currently anticipates will be required for the completion of clinical development of a product candidate, or if we experience significant delays in enrollment in any of our clinical trials, we could be required to expend significant additional financial resources and time on the completion of clinical development. Furthermore, we are unable to predict when or if our product candidates will receive regulatory approval with any certainty.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are focusing substantially all of our resources on the development of our product candidates. We expect our research and development expenses to increase substantially during the next few years, as we seek to initiate clinical trials for our product candidates, complete our clinical program, pursue regulatory approval of our product candidates and prepare for a possible commercial launch. Predicting the timing or the cost to complete our clinical program or validation of our commercial manufacturing and supply processes is difficult and delays may occur because of many factors, including factors outside of our control. For example, if the FDA or other regulatory authorities were to require us to conduct clinical trials beyond those that we currently anticipate, or if we experience significant delays in enrollment in any of our clinical trials, we could be required to expend significant additional financial resources and time on the completion of clinical development. Furthermore, we are unable to predict when or if our product candidates will receive regulatory approval with any certainty.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">General and Administrative</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative expenses consist principally of payroll and personnel expenses, including salaries and bonuses, benefits and stock-based compensation expenses, professional fees for legal, consulting, accounting and tax services, allocated overhead expenses, including rent, equipment, depreciation, information technology costs and utilities, and other general operating expenses not otherwise classified as research and development expenses.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We anticipate that our general and administrative expenses will increase for the foreseeable future due to anticipated expenses related to the Merger and future expenses related to operating as a public company, including expenses related to personnel costs, expanded infrastructure and higher consulting, legal and accounting services costs associated with complying with the applicable Nasdaq and SEC requirements, investor relations costs and director and officer insurance premiums.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Interest Income</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest income consists primarily of interest income earned on our cash and cash equivalents and marketable debt securities.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">92</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Interest Expense</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest expense consists primarily of the non-cash amortization of costs incurred in connection with the Loan Agreement entered into with PacWest in April 2020, and subsequently amended in October 2021.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Other Income (Expense), Net</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In 2020, other income (expense), net primarily consists of changes in the fair value of our redeemable convertible preferred stock tranche liability and redeemable convertible preferred stock warrant liability prior to their conversion to warrants to purchase common stock upon closing of the Merger. In 2021, other income (expense), net primarily consists of state franchise and capital taxes not related to income.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Results of Operations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Comparison of the Years Ended December 31, 2021 and 2020</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes our results of operations for the periods indicated (in thousands, except percentages):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:46.395%;"></td>
    <td style="width:1.089%;"></td>
    <td style="width:1.47%;"></td>
    <td style="width:9.649%;"></td>
    <td style="width:0.969%;"></td>
    <td style="width:1.089%;"></td>
    <td style="width:1.47%;"></td>
    <td style="width:9.649%;"></td>
    <td style="width:0.969%;"></td>
    <td style="width:1.089%;"></td>
    <td style="width:1.47%;"></td>
    <td style="width:9.649%;"></td>
    <td style="width:0.969%;"></td>
    <td style="width:1.089%;"></td>
    <td style="width:0.697%;"></td>
    <td style="width:8.876%;"></td>
    <td style="width:3.409%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Change</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">% Change</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Revenue &#x2013; related party</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,730</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17,903</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(8,173</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(46</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating expenses</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">48,943</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">34,334</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14,609</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">43</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22,220</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22,760</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(540</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total operating expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">71,163</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">57,094</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14,069</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Loss from operations</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(61,433</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(39,191</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(22,242</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">57</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest income</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">91</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">785</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(694</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(88</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest expense</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(176</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(134</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(42</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other income (expense), net</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(606</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(953</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">347</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(36</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Loss before income tax benefit</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(62,124</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(39,493</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(22,631</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">57</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Income tax expense (benefit)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(125</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(2,815</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,690</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">*%</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(61,999</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(36,678</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(25,321</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">69</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
   </tr>
  </table>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:2.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:2.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">* Not meaningful</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Revenue</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Revenue decreased by $8.2 million, or 46%, for the year ended December 31, 2021 compared to the year ended December 31, 2020 resulting from the decrease in revenue recognized under the Regeneron Agreement. This decrease in revenue was primarily due to our achievement of a milestone under the Regeneron Agreement in June 2020 relating to the selection of a clinical candidate for ADI-002. This resulted in an increase in the transaction price of $10.0 million and recognition of an additional cumulative catch-up of revenue of $5.0 million in June 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research and development</span></p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:66.889%;"></td>
    <td style="width:1.421%;"></td>
    <td style="width:1.284%;"></td>
    <td style="width:13.213%;"></td>
    <td style="width:0.637%;"></td>
    <td style="width:1.421%;"></td>
    <td style="width:1.284%;"></td>
    <td style="width:13.213%;"></td>
    <td style="width:0.637%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Payroll and personnel expenses</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;">(1)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21,267</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15,490</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Costs incurred under agreements with consultants, CMOs, and CROs</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14,853</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,195</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lab materials, supplies, and maintenance of equipment used for research<br />&#160;&#160;&#160;and development activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,649</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,401</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other research and development expenses</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-4.6899999999999995pt;white-space:pre-wrap;font-weight:normal;font-size:6.7pt;font-family:Times New Roman;position:relative;">(2)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8,174</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,248</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total research and development expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">48,943</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">34,334</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.03pt;font-family:Times New Roman;">(1)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> Employee related costs, including salaries, benefits, bonuses, and stock-based compensation expenses for research and development employees.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.03pt;font-family:Times New Roman;">(2)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> Allocated facility-related costs, such as rent, utilities, insurance, repairs and maintenance, depreciation and amortization, information technology costs and general support services.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">93</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development expenses increased by $14.6 million, or 43%, during the year ended December 31, 2021 compared to the year ended December 31, 2020. The increase in research and development expenses was primarily due to an increase of $5.8 million in personnel expenses, including salaries, benefits, and bonuses due to increases in headcount of employees involved in research and development activities, as well as an increase in stock-based compensation expense of $3.1 million due to higher option grant activity. In addition, there was an increase of $3.7 million in fees incurred for CRO, CMO, consultants, and other externally sponsored research and $4.9 million increase in facility and other expenses. This increase was primarily due to ramping up of clinical development activities related to ADI-001, our leading product candidate.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">General and administrative</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative expenses decreased by $0.5 million, or 2%, during the year ended December 31, 2021 as compared to the same period in 2020. The decrease in general and administrative expenses was primarily due to a decrease of $6.3 million in professional fees primarily related to decreases of $5.1 million in legal fees and $1.7 million in audit fees, due to higher expenses associated with the Merger in 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">These decreases in professional fees were offset by an increase of $0.5 million in other professional fees consisting of investor relations, IT management, and other enterprise solutions. In addition, the decreases in general and administrative expenses were offset by a $3.1 million increase in payroll and personnel expenses, which includes salaries, benefits, bonuses, and temporary contractor fees due to higher stock-based compensation expenses of $4.2 million caused by increased option grant activity and higher salaries and benefits of $1.0 million reduced by lower temporary contractor fees of $2.2 million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Further, there was an increase of $2.8 million in facilities and other expenses, primarily related to rent, depreciation costs, and director and officer liability insurance.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Interest income</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest income decreased by $0.7 million, or 88%, during the year ended December 31, 2021 compared to the year ended December 31, 2020, which was primarily attributable to the decrease in average balance of marketable debt securities in 2021 and decrease in interest rates, which lowered return on investments.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Interest Expense</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest expense increased by less than $0.1 million during the year ended December 31, 2021 as compared to the same period in 2020 due to the non-cash amortization of costs incurred in connection with the Loan Agreement that was entered in April 2020 and subsequently amended in October 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Other income (expense), net</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other income (expense), net decreased by $0.3 million, or 36%, during the year ended December 31, 2021 compared to the year ended December 31, 2020. The decrease was primarily due to a realized gain recognized in 2020 related to a change in fair value of the redeemable preferred stock warrant liability prior to their conversion to warrants to purchase common stock upon closing of the Merger in September 2020 offset by $0.2 million related to the derecognition of fixed assets related to the sublease of the Boston lease in August 2021, $0.6 million of franchise taxes, and less than $0.1 million of realized loss due to foreign exchange.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Income tax expense (benefit)</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We recognized an income tax benefit of $0.1 million during the year ended December 31, 2021 compared to the income tax benefit of $2.8 million for the year ended December 31, 2020. The reduction in benefit relates to the nature of discrete tax benefit during the year ended December 31, 2020, as a result of the recognition of a net operating loss carryback under the CARES Act. Income tax benefit of $0.1 million for the year ended December 31, 2021 was primarily due to the tax effect of the reduction in the deferred tax liability associated with the basis differences from in-process research and development (IPR&amp;D).</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Liquidity and Capital Resources</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, our principal source of liquidity was cash and cash equivalents, which totaled $277.5 million. Our net losses were $62.0 million and $36.7 million for the years ended December 31, 2021 and 2020, respectively.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Sources of Liquidity</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Since our formation in 2014, we have funded our operations with an aggregate of $116.3 million in gross cash proceeds from the sale of redeemable convertible preferred stock and an aggregate of $45.0 million received to date from Regeneron under the Regeneron Agreement. In September 2020, following the closing of the Merger, all outstanding shares of the redeemable</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">94</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">convertible preferred stock converted into 12,048,671 shares of common stock. We also acquired $64.1 million of cash, cash equivalents, and restricted cash owned by resTORbio, as part of the Merger.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In February 2021, we completed an underwritten public offering of 10,575,513 shares of our common stock, including the exercise in full by the underwriters of their option to purchase up to an additional 1,344,743 shares of common stock, at a public offering price of $13.00 per share. The net proceeds from the offering, after deducting underwriting discounts and commissions and offering expenses were approximately $128.8 million. In connection with the offering, we also entered into a stock purchase agreement with certain existing investors to purchase 1,153,840 shares of our common stock for $15.0 million at a price per share equal to the public offering price, with an initial closing for certain investors held simultaneously with the closing of the offering and a subsequent closing for certain additional investors.<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2021, we completed an underwritten public offering of 7,187,500 shares of our common stock, including the exercise in full by the underwriters of their option to purchase up to an additional 937,500 shares of common stock, at a public offering price of $14.00 per share. The net proceeds from the offering, after deducting underwriting discounts and commissions and offering expenses were approximately $94.2 million.<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Loan Agreement</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On October 21, 2021, we amended the Loan Agreement with PacWest (the Loan Amendment) under which PacWest will provide one or more Term Loans, as well as Non-Formula Ancillary Services which shall not exceed $5.5 million in the aggregate. Non-Formula Ancillary Services are defined as automated clearinghouse transactions, corporate credit card services, letters of credit, or other treasury management services. The aggregate sum of the outstanding Term Loans and Non-Formula Ancillary Services shall at no time exceed $15.0 million, which each Term Loan to be in an amount of not less than $1.0 million. As of December 31, 2021, we had outstanding Non-Formula Ancillary Services of $4.4 million. Accordingly, as of December 31, 2021, the Company has $10.6 million available under the Term Loan. Pursuant to the Loan Amendment, the interest rate for the Term Loans shall be set at an annual rate equal to the greater of (i) 0.25% above the Prime Rate then in effect and (ii) 4.25%.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of the date of this Annual Report on Form 10-K, we were in compliance with such covenants and had no indebtedness outstanding under the Loan Agreement.<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">At-the-Market (ATM) Offering</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On March 12, 2021, we entered into the 2021 Sales Agreement with the Agent, pursuant to which we could sell, from time to time, at our option, up to an aggregate of $75.0 million of shares of our common stock, through the Agent, as our sales agent. No shares were sold under the 2021 Sales Agreement as of December 31, 2021.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Future Funding Requirements</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have incurred losses since inception and have incurred losses of $62.0 million and $36.7 million for the years ended December 31, 2021 and 2020, respectively. As of December 31, 2021, we had an accumulated deficit of $168.3 million.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, we had cash and cash equivalents of $277.5 million. We believe that our cash and cash equivalents will be sufficient for us to continue as a going concern for at least 12 months from the issuance date of our consolidated financial statements as of and for the year ended December 31, 2021 included elsewhere in this Annual Report on Form 10-K. We have based these estimates on assumptions that may prove to be wrong, and we could deplete our available capital resources sooner than we expect. Because of the risks and uncertainties associated with research, development, and commercialization of product candidates, we are unable to estimate the exact amount of our working capital requirements.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All of our revenue to date is generated from the Regeneron Agreement, which is a collaboration and license agreement. We do not expect to generate any significant product revenue until we obtain regulatory approval of and commercialize any of our product candidates or enter into additional collaborative agreements with third parties, and we do not know when, or if, either will occur. We expect to continue to incur significant losses for the foreseeable future, and we expect the losses to increase as we continue the development of, and seek regulatory approvals for, our product candidates and begin to commercialize any approved products. We are subject to all of the risks typically related to the development of new product candidates, and we may encounter unforeseen expenses, difficulties, complications, delays, and other unknown factors that may adversely affect our business.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We will continue to require additional capital to develop our product candidates and fund operations for the foreseeable future. We may seek to raise capital through private or public equity or debt financings, collaborative or other arrangements with</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">95</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">corporate sources, or through other sources of financing. We anticipate that we will need to raise substantial additional capital, the requirements for which will depend on many factors, including:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the scope, timing, rate of progress and costs of our drug discovery efforts, preclinical development activities, laboratory testing and clinical trials for our product candidates;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the number and scope of clinical programs we decide to pursue;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the cost, timing and outcome of preparing for and undergoing regulatory review of our product candidates;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the scope and costs of development and commercial manufacturing activities;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the cost and timing associated with commercializing our product candidates, if they receive marketing approval;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the extent to which we acquire or in-license other product candidates and technologies;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the costs of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending intellectual property-related claims;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our ability to establish and maintain collaborations on favorable terms, if at all;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our efforts to enhance operational systems and our ability to attract, hire and retain qualified personnel, including personnel to support the development of our product candidates and, ultimately, the sale of our products, following FDA approval;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">our implementation of operational, financial and management systems;</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the impact of the COVID-19 pandemic on United States and global economic conditions that may impact our ability to access capital on terms anticipated, or at all; and</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the post-merger costs associated with being a public company.</span></div></div>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A change in the outcome of any of these or other variables with respect to the development of any of our product candidates could significantly change the costs and timing associated with the development of that product candidate. Furthermore, our operating plans may change in the future, and we will continue to require additional capital to meet operational needs and capital requirements associated with such operating plans.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Adequate funding may not be available to us on acceptable terms or at all. Our failure to raise capital as and when needed could have a negative impact on our financial condition and our ability to pursue our business strategies. If we are unable to raise additional funds when needed, we may be required to delay, reduce, or terminate some or all of our development programs and clinical trials or we may also be required to sell or license to other rights to our product candidates in certain territories or indications that we would prefer to develop and commercialize ourselves. If we are required to enter into collaborations and other arrangements to supplement our funds, we may have to give up certain rights that limit our ability to develop and commercialize our product candidates or may have other terms that are not favorable to us or our stockholders, which could materially affect our business and financial condition.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">See the section of this Annual Report on Form 10-K titled &#x201c;</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Risk Factors</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d; for additional risks associated with our substantial capital requirements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Summary Statement of Cash Flows</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table sets forth the primary sources and uses of our cash, cash equivalents, and restricted cash for each of the periods presented below (in thousands):</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:62.971%;"></td>
    <td style="width:1.525%;"></td>
    <td style="width:1.503%;"></td>
    <td style="width:14.485%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:1.525%;"></td>
    <td style="width:1.503%;"></td>
    <td style="width:14.485%;"></td>
    <td style="width:1.002%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net cash provided by (used in):</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(51,052</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(41,552</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Investing activities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(2,796</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">115,217</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">242,685</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">303</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net increase in cash, cash equivalents and restricted cash</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">188,837</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">73,968</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">96</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:13.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Cash Flows from Operating Activities</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The use of cash in all periods resulted primarily from our net losses adjusted for non-cash charges and changes in components of working capital. The increases in cash used in operating activities for the years ended December 31, 2021 and 2020 were primarily due to increased external research and development expenses as we continue to develop our product candidates, and increased internal and external expenses related to the initiation of our Phase 1 clinical trial. Higher costs associated with increased employee headcount related to expanded development activities also contributed to the increase in cash used in operating activities.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">These factors were partially offset by lower professional services costs in 2021. Non-cash charges for the year ended December 31, 2021 also include $12.5 million of stock-based compensation expense, compared to $5.3 million for the year ended December 31, 2020. The changes in prepaid expenses and other current assets, accounts payable, and accrued and other liabilities resulted from the timing of payments to our service providers.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We currently lease an office space in Boston, MA under a non-cancellable operating lease (the Boston Lease), with an expiration date of July 31, 2026. The Boston Lease was amended on April 1, 2019, to relocate into a premises in the same building with additional space. The initial annual base rent for this lease was $0.6 million and increases 2% annually. On July 19, 2021, we subleased the office space in Boston, MA. The term of the sublease started on September 1, 2021 and will end on July 30, 2026. The aggregate base rent due to us under the Sublease Agreement is approximately $3.5 million. Pursuant to the Sublease Agreement, we agreed to transfer certain furniture located in the subleased premises to the sublessee for $1.00. We remain liable for the lease payments under the Boston Lease.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We also have an office facility in Menlo Park, CA under a non-cancellable operating lease (the Menlo Park Lease), with an expiration date of March 31, 2022 (subject to any optional extension). This lease was amended on June 25, 2021 to extend the term of lease from March 31, 2022 to June 30, 2022 and replace the previously leased premises (known as 173 and 175-177 Jefferson Drive) with a nearby premises (known as 235 Constitution Drive). The lease commenced on July 15, 2021 and expires on June 30, 2022. In connection with these changes, we incur monthly rent payments ranging from $87,286 to $89,904, increasing over the remaining term of the lease. This lease was amended on September 30, 2019 to include additional office space, with an expiration date of March 31, 2022 (subject to any optional extension). The initial annual base rent for the Menlo Park Lease is an aggregate of $1.0 million, and such amount will increase 3% annually. On October 28, 2018, we executed an additional non-cancelable lease agreement for a new office and laboratory facility in Redwood City, CA (the Redwood City Lease), with an expiration date of February 28, 2030. The initial annual base rent for the Redwood City Lease is an aggregate of $1.3 million, and such amount will increase 3% annually.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On July 30, 2021, we entered a short-term lease agreement with the Boston Properties, Inc. for a temporary office space located at 200 Clarendon Street, Boston, MA. The initial lease term commenced on July 30, 2021 and expire on November 30, 2021. In October 2021, we extended the lease term to March 31, 2022 and most recently, in February 2022, extended the lease term to July 31, 2022. The base rent is less than $0.1 million per month.<br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Cash Flows from Investing Activities</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net cash used in investing activities was $2.8 million for the year ended December 31, 2021, which consisted of purchases of property and equipment of $13.0 million related to the construction of our new building in Redwood City, CA, partially offset by proceeds from sales and maturities of marketable debt securities of $10.3 million.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net cash provided by investing activities was $115.2 million for the year ended December 31, 2020, which consisted of cash and restricted cash acquired in connection with the Merger of $64.1 million, proceeds from maturities of marketable debt securities of $57.8 million, partially offset by purchases of marketable debt securities of $5.7 million and purchases of property and equipment of $1.0 million.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Cash Flows from Financing Activities</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net cash provided by financing activities was $242.7 million for the year ended December 31, 2021, which was related to net cash proceeds received from our public offerings and concurrent private placement in February 2021 and December 2021 of  $238.1 million, and cash proceeds of $4.8 million from exercise of stock options and purchases under our Employee Stock Purchase Plan (ESPP), offset by debt issuance costs of approximately $0.2 million.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><br />Net cash provided by financing activities was $0.3 million for the year ended December 31, 2020, due to cash proceeds of $0.5 million from exercise of stock options partly offset by payment of debt issuance costs of $0.2 million.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">97</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Critical Accounting Policies, Significant Judgments and Use of Estimates</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our discussion and analysis of our financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with GAAP. The preparation of our consolidated financial statements requires us to make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and expenses, and disclosure of contingent assets and liabilities in our consolidated financial statements. Actual results may differ from these estimates under different assumptions or conditions and could have a material impact on our reported results. While our significant accounting policies are more fully described in the Notes to our consolidated financial statements included elsewhere in this Annual Report on Form 10-K, we believe the following accounting policies to be the most critical in understanding the judgments and estimates we use in preparing our consolidated financial statements:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Revenue Recognition</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We earn all of our revenue in connection with our license and collaboration agreement with Regeneron, which allows Regeneron to utilize our technology and know-how to develop product candidates.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For elements of collaboration arrangements that are accounted for pursuant to ASC Topic 606, Revenue from Contracts with Customers, or ASC 606, we identify the performance obligations and allocate the total consideration we expect to receive on a relative standalone selling price basis to each performance obligation. Key assumptions to determine the standalone selling price may include forecasted revenues, development timelines, reimbursement rates for personnel costs, the expected number of targets or indications expected to be pursued, discount rates and probabilities of technical and regulatory success.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We recognize revenue associated with each performance obligation as the control over the promised goods or services transfer to our collaboration partner which occurs either at a point in time or over time. If control transfers over time, revenue is recognized by using a method of measuring progress that best depicts the transfer of goods or services, for example based on actual costs incurred relative to total forecasted costs to be incurred over the period the transfer of goods or services occurs. We evaluate the measure of progress and related inputs each reporting period and any resulting adjustments to revenue are recorded on a cumulative catch-up basis. Revenue to be recognized is equal to the total transaction price multiplied by the ratio of actual expense incurred divided by total forecasted expense.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Accrued CMO, CRO, and Research and Development Expenses</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have entered into various agreements with CMOs and CROs. Our research and development accruals are estimated based on the level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. The estimated costs of research and development provided, but not yet invoiced, are included in accrued and other current liabilities on the consolidated balance sheet. If the actual timing of the performance of services or the level of effort varies from the original estimates, we will adjust the accrual accordingly. Payments made to CMOs and CROs under these arrangements in advance of the performance of the related services are recorded as prepaid expenses and other current assets on the consolidated balance sheets until the services are rendered. To date, our estimated accruals have not differed materially from the actual costs.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock-Based Compensation</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We use a fair value-based method to account for all stock-based compensation arrangements with employees and non-employees, including stock options and restricted stock awards. Our determination of the fair value of stock options on the date of grant utilizes the Black-Scholes option pricing model. The fair value of the option granted is recognized on a straight-line basis over the period during which an optionee is required to provide services in exchange for the option award, known as the requisite service period, which usually is the vesting period. For awards that have a performance condition, the Company recognizes compensation expense based on its assessment of the probability that the performance condition will be achieved, using an accelerated attribution model, over the explicit or implicit service period. We account for forfeitures as they occur. In determining fair value of the stock options granted, we use the Black&#x2013;Scholes option-pricing model, which requires the input of subjective assumptions. These assumptions include estimating the length of time employees will retain their vested stock options before exercising them (expected term), the estimated volatility of our common stock price over the expected term (expected volatility), risk-free interest rate and expected dividends. Changes in the following assumptions can materially affect the estimate of fair value and ultimately how much stock-based compensation expense is recognized; and the resulting change in fair value, if any, is recognized in our consolidated statement of operations and comprehensive loss during the period the related services are rendered. These inputs are subjective and generally require significant analysis and judgment to develop. Changes in the following assumptions can materially affect the estimate of the fair value of stock-based compensation:</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected Term &#x2014; The expected term is calculated using the simplified method which is used when there is insufficient historical data about exercise patterns and post-vesting employment termination behavior. The simplified method is based on the vesting period and the contractual term for each grant, or for each vesting-tranche for awards with graded vesting. The mid-point between the vesting date and the maximum contractual expiration date is used as the expected term under this method. For awards with multiple vesting-tranches, the times from grant until the mid-points for each of the tranches may be averaged to provide an overall expected term.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">98</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected Volatility &#x2014; The Company has limited trading history. As such, the expected volatility was determined by examining the historical volatilities of a peer group of comparable publicly traded companies in biotechnology and pharmaceutical related industries to be representative of our expected future stock price volatility. For purposes of identifying these peer companies, we consider the industry, stage of development, size and financial leverage of potential comparable companies. For each grant, we measure historical volatility over a period equivalent to the expected term. </span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Risk-Free Interest Rate &#x2014; The risk-free interest rate is based on the implied yield currently available on United States Treasury zero-coupon issues with a remaining term equivalent to the expected term of the stock award.</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected Dividend Rate &#x2014; We have not paid and does not anticipate paying dividends in the near future. Accordingly, we estimate the dividend yield to be zero.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Common Stock Valuations</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prior to our Merger, the estimated fair value of the common stock underlying our stock options and stock awards was determined at each grant date by our board of directors, with assistance from management and external appraisers. All options to purchase shares of our common stock were intended to be exercisable at a price per share not less than the per-share fair value of our common stock underlying those options on the date of grant. The approach to estimate the fair value of our common stock was consistent with the methods outlined in the American Institute of Certified Public Accountants&#x2019; Practice Aid, Valuation of Privately-Held-Company Equity Securities Issued as Compensation (Practice Aid). Subsequent to the Merger, the fair value of our common stock is determined based on the closing market price.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Emerging Growth Company and Smaller Reporting</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In April 2012, the Jumpstart Our Business Startups Act of 2012 (the JOBS Act) was enacted. Section 107 of the JOBS Act provides that an emerging growth company (EGC), can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act of 1933, as amended, or the Securities Act, for complying with new or revised accounting standards. Thus, an EGC can delay the adoption of certain accounting standards until those standards would otherwise apply to private companies.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have elected to use the extended transition period for new or revised accounting standards during the period in which we remain an emerging growth company; however, we may adopt certain new or revised accounting standards early. We will remain an emerging growth company until the earliest to occur of: (1) the last day of the fiscal year in which we have more than $1.07 billion in annual revenue; (2) the date we qualify as a large accelerated filer, with at least $700.0 million of equity securities held by non-affiliates; (3) the date on which we have issued more than $1.0 billion in non-convertible debt securities during the prior three-year period; and (4) last day of the fiscal year ending after the fifth anniversary of our initial public offering, which would be December 31, 2023.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We are also a smaller reporting company meaning that the market value of our stock held by non-affiliates is less than $700 million and our annual revenue was less than $100 million during the most recently completed fiscal year. We may continue to be a smaller reporting company if either (i) the market value of our stock held by non-affiliates is less than $250 million or (ii) our annual revenue was less than $100 million during the most recently completed fiscal year and the market value of our stock held by non-affiliates is less than $700 million. If we are a smaller reporting company at the time we cease to be an emerging growth company, we may continue to rely on exemptions from certain disclosure requirements that are available to smaller reporting companies. Specifically, as a smaller reporting company we may choose to present only the two most recent fiscal years of audited financial statements in our Annual Report on Form 10-K and, similar to emerging growth companies, smaller reporting companies have reduced disclosure obligations regarding executive compensation.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Recently Issued and Adopted Accounting Pronouncements</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">See the section titled &#x201c;Summary of Significant Accounting Policies&#x201d; in Note 2 to our financial statements included elsewhere in this Annual Report on Form 10-K for additional information.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="item_7a_quantitative_qualitative_disclos"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 7A. Quantitative and Qualitat</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ive Disclosures About Market Risk.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Interest Rate Risk</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, we had cash and cash equivalents of $277.5 million, which consisted of cash and money market funds. Interest income is sensitive to general level of interest rates; however, due to the nature of these investments, an immediate 10% change in interest rates would not have a material impact on our cash and cash equivalents, financial position, or results of operations.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">99</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Foreign Currency Exchange Risk</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our headquarters are located in the United States, where a majority of our general and administrative expenses and research and development costs are incurred in U.S. Dollars. As we grow our business, our results of operations and cash flows may be subject to fluctuations due to foreign currency exchange rates. To date, we do not believe foreign currency exchange rate fluctuations have had a significant impact on our results of operations for any periods presented herein.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Inflation Risk</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our assets are primarily monetary, consisting of cash and cash equivalents. Because of their liquidity, these assets are not directly affected by inflation. Since we intend to retain and continue to use our equipment, furniture, fixtures and office equipment, computer hardware and software and leasehold improvements, we believe that the incremental inflation related to replacement costs of such items will not materially affect our operations. Inflation generally affects us by increasing our cost of labor, clinical trial and manufacturing costs. We do not believe that inflation had a material effect on our business, financial condition or results of operations during the years ended December 31, 2021 and 2020.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="item_8_financial_statements_supplementar"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 8. Financial Statemen</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ts and Supplementary Data.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All financial statements and supplementary data required to be filed hereunder are filed as listed under Item 15(a) of this Annual Report on Form 10-K and are incorporated herein by this reference.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="item_9_changes_in_disagreements_with_acc"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 9. Changes in and Disagreements with Accou</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ntants on Accounting and Financial Disclosure.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="item_9a_controls_procedures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 9A. Controls</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> and Procedures.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Evaluation of disclosure controls and procedures</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer (our principal executive officer and principal financial officer, respectively), evaluated the effectiveness of our disclosure controls and procedures as of December 31, 2021. The term &#34;disclosure controls and procedures,&#34; as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange act is recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company's management, including its principal executive and principal financial officers, as appropriate to allow timely decisions regarding required disclosure.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. There are inherent limitations to the effectiveness of any system of disclosure controls and procedures. These limitations include the possibility of human error, the circumvention or overriding of the controls and procedures and reasonable resource constraints. In addition, because we have designed our system of controls based on certain assumptions, which we believe are reasonable, about the likelihood of future events, our system of controls may not achieve its desired purpose under all possible future conditions. Accordingly, our disclosure controls and procedures provide reasonable assurance, but not absolute assurance, of achieving their objectives.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Management's Annual Report on Internal Control over Financial Reporting</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) for the Company. Our internal control over financial reporting is designed to provide reasonable assurances regarding the reliability of financial reporting and the preparation of our</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">consolidated financial statements in accordance with U.S. generally accepted accounting principles, or GAAP, and includes those policies and procedures that:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the Company;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the Company are being made only in accordance with authorization of management and directors of the Company; and</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company's assets that could have a material affect on the financial statements.</span></div></div>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree or compliance with the policies or procedures may deteriorate.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our management, with the participation of its Chief Executive Officer and Chief Financial Officer, assessed our internal control over financial reporting as of December 31, 2021. Management based its assessment on criteria established in Internal Control&#x2014;Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission and concluded that our internal control over financial reporting was effective at the reasonable assurance level as of December 31, 2021.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This Annual Report on Form 10-K does not include an attestation report of our independent registered public accounting firm due to a transition period established by rules of the SEC for &#x201c;emerging growth companies&#x201d;.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Remediation of Previously Reported Material Weakness</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">During the preparation of our consolidated financial statements as of and for the year ended December 31, 2020, we identified  material weaknesses in our internal control over financial reporting. The material weaknesses we identified were as follows:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we did not design or maintain an effective control environment commensurate with our financial reporting requirements due to lack of a sufficient number of accounting professionals with the appropriate level of experience and training;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we did not design and maintain formal accounting policies, procedures and controls to achieve complete, accurate and timely financial accounting, reporting and disclosures, and monitoring controls maintained at the corporate level were not at a sufficient level of precision to provide the appropriate level of oversight of activities related to our internal control over financial reporting;</span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we did not design and maintain effective controls over segregation of duties with respect to the preparation and review of account reconciliations as well as creating and posting manual journal entries; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">we did not design and maintain formal accounting policies, processes and controls to analyze, account for and disclose complex transactions. </span></div></div>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We took a number of actions in 2021 to improve our internal control over financial reporting to remediate these material weaknesses. The remediation efforts and progress summarized below are intended to address and remediate the identified material weaknesses:</span></p>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the first quarter of 2021, we engaged a permanent Vice President, Corporate Controller, and a Senior Manager of Finance, together with third-party consultants, to improve and oversee all aspects of accounting operations, financial reporting, and Sarbanes-Oxley Act of 2002, as amended, compliance; </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We also successfully implemented a new Enterprise Resource Planning (ERP) system, Microsoft 365 Business Central, in January 2021, replacing QuickBooks and providing efficiency and financial controls. We provided appropriate training to all key accounting personnel who are responsible for posting and reviewing journal entries; and </span></div></div>
  <div style="margin-left:4.528%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:4.537%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:4.7521786492374725%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the first quarter of 2021, we reevaluated our existing internal controls and, in the second quarter, we implemented additional controls to enhance our internal control environment. Since the third quarter of 2021, we have been performing internal control testing to ensure these controls are operating effectively as designed and implemented. </span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For the year ended December 31, 2021, we completed our testing of the design and operating effectiveness of the implemented controls and determined they were effective. As a result, we have concluded the material weaknesses identified in fiscal year 2020 have been remediated as of December 31, 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We cannot assure you that material weaknesses or significant deficiencies will not occur in the future or that we will be able to remediate such weaknesses or deficiencies in a timely manner, which could impair our ability to accurately and timely report our financial position, results of operations or cash flows. For additional information, see the related risks in the section titled &#34;Risk Factors&#34; of this Annual Report on Form 10-K.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Changes in Internal Control over Financial Reporting</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other than as stated above, no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) occurred during the year ended December 31, 2021 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. As a result of the COVID-19 pandemic, since March 2020, we have requested that our employees work remotely, as appropriate. We have not identified any material changes in our internal control over financial reporting as a result of these changes to the working environment. We are continually monitoring and assessing the COVID-19 situation to determine any potential impacts on the design and operating effectiveness of our internal controls over financial reporting.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="item_9b_or_information"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 9B. Other</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> Information.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">None.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;" id="disclosure_regarding_foreign"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 9C. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Disclosure Regarding Foreign Jurisdictions That Prevent Inspections.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Not applicable.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">102</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_iii"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PART </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">III</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_10_directors_executive_ficers_corpo"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 10. Directors, Executive Of</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ficers and Corporate Governance.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The information required by this item regarding directors, executive officers and corporate governance will be included in our 2022 Proxy Statement, which we intend to file with the SEC within 120 days of the end of our fiscal year pursuant to General Instruction G(3) of Form 10-K, and is incorporated herein by reference.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have adopted a code of business conduct and ethics for directors, officers, and employees, known as the Code of Business Conduct and Ethics. The Code of Business Conduct and Ethics is available on our website at </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">http://www.adicetbio.com</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> under the Corporate Governance section of our Investors page. We will promptly disclose on our website (i) the nature of any amendment to the policy that applies to our principal executive officer, principal financial officer, or controller, or persons performing similar functions and (ii) the nature of any waiver, including an implicit waiver, from a provision of the policy that is granted to one of these specified individuals, the name of such person who is granted the waiver and the date of the waiver. Shareholders may request a free copy of the Code of Business Conduct and Ethics from our Compliance Officer, c/o Adicet Bio, Inc., 200 Clarendon Street, Floor 6, Suite #6041, Boston, MA 02116.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_11_executive_compensation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 11. Executiv</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">e Compensation.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The information required by this item regarding executive compensation will be included in our 2022 Proxy Statement, which we intend to file with the SEC within 120 days of the end of our fiscal year pursuant to General Instruction G(3) of Form 10-K, and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_12_security_ownership_certain_benef"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 12. Security Ownership of Certain Beneficial Ow</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ners and Management and Related Stockholder Matters.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The information required by this item regarding security ownership of certain beneficial owners and management and securities authorized for issuance under equity compensation plans will be included in our 2022 Proxy Statement, which we intend to file with the SEC within 120 days of the end of our fiscal year pursuant to General Instruction G(3) of Form 10-K, and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_13_certain_relationships_related_tr"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 13. Certain Relationships and Related</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> Transactions, and Director Independence.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The information required by this item regarding certain relationships and related transactions and director independence will be included in our 2022 Proxy Statement, which we intend to file with the SEC within 120 days of the end of our fiscal year pursuant to General Instruction G(3) of Form 10-K, and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_14_principal_accountant_fees_servic"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 14. Principal Accoun</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">tant Fees and Services.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our independent public accounting firm is KPMG LLP, Boston Massachusetts (PCAOB Auditor ID: </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3d44cb85-9cad-48b7-8e5e-1d7f493858c9" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="dei:AuditorFirmId"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">185</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">).</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The information required by this item regarding principal accounting fees and services will be included in our 2022 Proxy Statement, which we intend to file with the SEC within 120 days of the end of our fiscal year pursuant to General Instruction G(3) of Form 10-K, and is incorporated herein by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">103</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="part_iv"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">PART</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> IV</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_15_exhibits"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 15. Exhibits and Finan</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">cial Statement Schedules.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(a) The following documents are included in this Annual Report on Form 10-K:</span></p>
  <div style="display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following Report and Consolidated Financial Statements of the Company are included in this Annual Report:</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Report of Independent Registered Public Accounting Firm</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Consolidated Balance Sheets</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Consolidated Statements of Operations and Comprehensive Loss</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders&#x2019; Equity (Deficit)</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Consolidated Statements of Cash Flows</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span></div></div>
  <div style="display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(2)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial Statement Schedules:</span></div></div>
  <div style="margin-left:3.333%;display:flex;margin-top:6.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All financial statement schedules have been omitted because they are not applicable, not required or the information required is shown in the financial statements or the notes thereto.</span></div></div>
  <div style="display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(3)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exhibits. The exhibits filed as part of this Annual Report on Form 10-K are set forth on the Exhibit Index immediately preceding the signature page of this Annual Report on Form 10-K. The Exhibit Index is incorporated herein by reference.</span></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;" id="item_16_10k_summary"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Item 16. 10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">-K Summary</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have elected not to include summary information.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">104</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ADICET BIO, INC.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:91.999%;"></td>
    <td style="width:8.001%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Page</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#report_independent_registered_public"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Report of Independent Registered Public Accounting Firm (KPMG LLP,  Boston, MA, Auditor Firm ID: 185)</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Consolidated Financial Statements</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:24.5pt;word-break:break-word;vertical-align:top;"><p style="margin-left:24.5pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_balance_sheets"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Consolidated Balance Sheets as of December 31, 2021 and 2020</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:24.5pt;word-break:break-word;vertical-align:top;"><p style="margin-left:24.5pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_statements_operations_compr"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Consolidated Statements of Operations and Comprehensive Loss for the years ended December 31, 2021 and 2020</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:24.5pt;word-break:break-word;vertical-align:top;"><p style="margin-left:24.5pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_statements_redeemable_conve"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders&#x2019; Equity (Deficit) for the years ended December 31, 2021 and 2020</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:24.5pt;word-break:break-word;vertical-align:top;"><p style="margin-left:24.5pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#consolidated_statements_cash_flows"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Consolidated Statements of Cash Flows for the years ended December 31, 2021 and 2020</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:24.85pt;word-break:break-word;vertical-align:top;"><p style="margin-left:24.85pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="#notes_to_consolidated_financial_statemen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span></a></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="report_independent_registered_public"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Report of Independent Registered Public Accounting Firm</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Arial;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To the Stockholders and Board of Directors</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Adicet Bio, Inc.:</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Arial;font-style:italic;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Opinion on the Consolidated Financial Statements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:5.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have audited the accompanying consolidated balance sheets of Adicet Bio, Inc. and subsidiaries (the Company) as of December 31, 2021 and 2020, the related consolidated statements of operations and comprehensive loss, redeemable convertible preferred stock and stockholders&#x2019; equity (deficit), and cash flows for the years then ended, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2021 and 2020, and the results of its operations and its cash flows for the years then ended, in conformity with U.S. generally accepted accounting principles.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Basis for Opinion</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">These consolidated financial statements are the responsibility of the Company&#x2019;s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#x2019;s internal control over financial reporting. Accordingly, we express no such opinion.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_00719bb7-3ba3-42e8-9e9f-e32992e9f232" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="dei:AuditorName"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">KPMG LLP</span></ix:nonNumeric></span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We have served as the Company&#x2019;s auditor since 2020.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0ebb31c2-b604-4522-9374-a4244dcdf724" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="dei:AuditorLocation"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Boston, Massachusetts</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 15, 2022</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"><br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </span>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Adicet Bio, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_balance_sheets"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Consolidated B</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">alance Sheets</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(in thousands, except share and per share amounts)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:66.954%;"></td>
    <td style="width:1.96%;"></td>
    <td style="width:1.196%;"></td>
    <td style="width:12.819%;"></td>
    <td style="width:0.804%;"></td>
    <td style="width:1.45%;"></td>
    <td style="width:1.196%;"></td>
    <td style="width:12.819%;"></td>
    <td style="width:0.804%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">Assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">Current assets:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">Cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_ccde0454-71eb-4e96-b4b6-85286ce3eef9" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">277,544</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_f4447c19-14e0-4f83-917b-3c08564dc4d6" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">84,330</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">Short-term marketable debt securities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_79c93f3a-fc1e-4e16-a028-5624683fd282" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,284</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">Accounts Receivable&#x2014;related party</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_39992612-3b4f-4b9f-8f19-59c48094dc2b" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:AccountsReceivableRelatedPartiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">185</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.5pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_c90c6857-d677-4f9c-addf-13927bc45ed0;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">Prepaid expenses and other current assets</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_241001ac-bb8a-4a02-b021-6168f0bbe6b8" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,709</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_44157cd7-702a-437f-a821-cd628185104a" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,722</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">Total current assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_af0defbb-2ab6-4637-a2b9-93fd40f71b88" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">282,438</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_74510a9a-e3da-4c5b-996e-ba82c82c4ec5" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="us-gaap:AssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">100,336</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">Property and equipment, net</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_0f575883-6186-4727-97dd-a4de6b8074fe" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14,643</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_0c043dfe-1422-4201-861e-13047dfc3079" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,790</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">Operating lease right-of-use asset</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_3b480f68-1c76-4ae5-bdc9-f7d890361c66" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">20,358</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_4546b836-1f3f-4a05-8572-373d902298c5" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">23,066</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">Goodwill</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_a391e332-b1f1-450a-b2de-541c77039818" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:Goodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">19,462</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_371714a8-6e44-4a1c-8265-ad8fd46991e2" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="us-gaap:Goodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">20,089</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">In-process research and development</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_c4933828-40f9-4ab1-b1c1-d34a0fea1375" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="us-gaap:DevelopmentInProcess" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,190</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">Restricted cash</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_9e7ef0bf-cf7d-48d9-8cf3-539172a4fe93" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">150</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_790e0540-b043-4a5b-8de5-a490e14ee9d4" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,527</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">Long-term marketable debt securities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_86cff01b-f2f2-448f-9ea5-aec78a62d068" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">Other non-current assets</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_3e7e87ef-56fd-47bb-8316-5107b1c28fed" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,887</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_7d1fd44d-3516-467f-bf72-366f16cf811b" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="us-gaap:OtherAssetsNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,837</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">Total assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_1aec0880-be91-4713-aeb1-b9a94e63315b" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">338,938</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_8b546985-1df6-4298-986f-2905b9874956" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="us-gaap:Assets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">153,835</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">Liabilities, redeemable convertible preferred stock, and stockholders&#x2019; equity (deficit)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">Current liabilities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">Accounts payable</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_deb20859-d9e4-46ab-ba44-34c1fd6a800c" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,263</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_d19515a5-4a70-417f-9567-c3ee6b40233a" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="us-gaap:AccountsPayableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,552</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">Contract liabilities&#x2014;related party, current</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_4c3879f0-9590-413a-b215-4f2c06de0625" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:ContractWithCustomerLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,805</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_a16a5321-1772-4864-b09a-ecbc257a55cb" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="us-gaap:ContractWithCustomerLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,980</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">Accrued and other current liabilities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_06d9a678-6fc6-4251-b6e0-c3cd9ebc0b2a" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,682</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_b1437f02-d35c-45d0-baaf-c5e5c69ff8e4" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,732</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">Operating lease liability</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_7ae51979-4aad-43a9-8364-78a0aa5ef51d" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,567</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_fba12e1e-d927-4c75-b0c0-4ea96effa901" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,215</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">Total current liabilities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_f5108eef-6550-4db8-9456-230d1a4b0b0a" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">16,317</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_dc36b280-c520-41e4-be83-0ea22203ec9d" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="us-gaap:LiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">22,479</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">Operating lease liability, net of current maturities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_6623c94d-43ef-48da-8e31-570f7dfd63f6" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">19,377</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_372daccf-5bc8-4b66-a634-01186dc7c3e7" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">20,424</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">Contingent consideration liability</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.5pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_efcea327-b6ef-4d61-b48e-b5bba5b6c3c3;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_86694194-a5e6-4283-8675-7543fcec76c8" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="us-gaap:BusinessCombinationContingentConsiderationLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">980</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">Deferred tax liability</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.5pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_8f366528-b927-44dd-955d-3902dd5285e6;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_e02df7e3-2abf-470e-9846-da1a6c1633cb" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">125</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">Other non-current liabilities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_b661c1c4-15b4-4ee5-be95-6cbd2c4abbe4" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:OtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">115</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.5pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_9dc969f6-49b9-4163-aafc-0d7ce2a0811a;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">Total liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_c4f94cbf-494a-4da3-bdae-4f750f01d9d5" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">35,809</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_6be5003d-b88e-4e87-b10e-eb078613a432" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="us-gaap:Liabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">44,008</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:9.5pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_2d04a4ef-82d4-4143-8241-c8043e042c95;"><span style="-sec-ix-hidden:F_634bc8da-c716-4b7e-bc3c-fdf201cf4001;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">Commitments and contingencies (Note 12)</span></span></span></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">Stockholders&#x2019; equity:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Preferred stock, $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bf1daf4c-a8fc-4469-82e0-3e70861206e5" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_USDollarShare" scale="0" decimals="4"><ix:nonFraction id="F_f28e5e1f-622c-483d-9a83-db00d44084a6" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="us-gaap:PreferredStockParOrStatedValuePerShare" unitRef="U_USDollarShare" scale="0" decimals="4">0.0001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;par value, </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ef590c62-8720-4b51-baf1-38f5f1271e43" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_2c8c48f0-5ad5-4805-9844-6f9b2286406e" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="us-gaap:PreferredStockSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">10,000,000</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;shares authorized as of December 31, 2021 and December 31, 2020, respectively; </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_da1b5ba9-bc23-497c-a99b-67ebd163ff9d" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="F_901c4ab4-7891-433c-8264-d50bb4a70538" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="F_dff72034-7044-4011-accd-da0216bdd459" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="us-gaap:PreferredStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="F_1454f8a0-1668-4136-a01a-75c35856eff5" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt-sec:numwordsen">none</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;issued and outstanding as of December 31, 2021 and December 31, 2020, respectively</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.5pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_fb093abf-4f4f-4827-a9da-293d131e9450;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.5pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_fe50c4e8-749d-4335-ae8f-18aed2ad9940;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Common stock, $</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_113191bb-7f98-489d-8b48-88b6d518a3a5" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_USDollarShare" scale="0" decimals="4"><ix:nonFraction id="F_ed8f35a3-a7ab-43bc-9355-48f634d2cc12" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="us-gaap:CommonStockParOrStatedValuePerShare" unitRef="U_USDollarShare" scale="0" decimals="4">0.0001</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;par value, </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6e696406-209f-4faf-945f-e8e746e1661b" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_fef8e744-a586-4aff-be34-67b33af908ff" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="us-gaap:CommonStockSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">150,000,000</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;shares authorized as of December 31, 2021 and December 31, 2020, respectively; </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_14da6420-45be-468d-927c-54c1f4d26bee" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_c8cd8ca5-247d-4be0-afa7-a02550609950" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">39,736,914</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;and </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9dbfe1d2-81f3-45b7-ba5d-c21dc19215ca" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal"><ix:nonFraction id="F_1b028396-a420-49a2-a17f-fd2b74da267d" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">19,677,249</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#160;shares issued and outstanding as of December 31, 2021 and December 31, 2020, respectively</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_c3be1a1a-1d72-4e54-a5f6-b57adf36ec35" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_0f489f1c-c25e-413e-9153-bf82678a4547" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="us-gaap:CommonStockValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">Additional paid-in capital</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_96970bb0-4674-4316-8da9-878ff128b9a7" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">471,449</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_8c8f8d4e-bc2d-4342-9e07-2188ddec4967" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="us-gaap:AdditionalPaidInCapitalCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">216,126</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">Accumulated deficit</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">(</span><span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_9db6bc25-baac-49ba-8252-9ddb7e9a6690" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">168,324</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">(</span><span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_479d4aa9-b222-48cd-923b-a7fea23677ac" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">106,325</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">Accumulated other comprehensive income</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.5pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_52b544c5-2e54-4c52-8e46-49be2abe9635;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_bf855a7a-0510-4015-87a4-b8de080cf668" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">24</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">Total stockholders&#x2019; equity</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_4a7f29d0-7aae-4b6c-883e-e5734e439075" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">303,129</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_a1873744-ea4c-422e-89d4-0299eb0749e4" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">109,827</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">Total liabilities, redeemable convertible preferred stock, and stockholders&#x2019; equity</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_dcd0df79-b756-48a4-a988-bb4233081142" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">338,938</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_69cee506-5848-41ce-9b1e-979e86430def" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="us-gaap:LiabilitiesAndStockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">153,835</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The accompanying notes are an integral part of these consolidated financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Adicet Bio, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_statements_operations_compr"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Consolidated Statements of Ope</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">rations and Comprehensive Loss</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(in thousands, except share and per share amounts)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:65.723%;"></td>
    <td style="width:1.46%;"></td>
    <td style="width:1.284%;"></td>
    <td style="width:12.827%;"></td>
    <td style="width:0.843%;"></td>
    <td style="width:1.46%;"></td>
    <td style="width:1.284%;"></td>
    <td style="width:12.817%;"></td>
    <td style="width:0.843%;"></td>
    <td style="width:1.46%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="8" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Revenue&#x2014;related party</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_287db975-ca66-41c8-9677-432f023fab7b" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:RevenueFromRelatedParties" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,730</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8b6e21fb-9bbf-4839-b6ea-edb217833650" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:RevenueFromRelatedParties" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">17,903</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating expenses:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_18f95c57-a34c-42f2-a2a6-f69bda8cf5e3" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">48,943</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ed11340f-dba4-42f4-bdf2-16d370fcfadf" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:ResearchAndDevelopmentExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">34,334</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0052fadf-55ff-405e-8198-0532fd48f92f" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">22,220</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d553d0b6-76c7-4b85-a8b0-6d927902372f" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:GeneralAndAdministrativeExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">22,760</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total operating expenses</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_20f6f23e-2554-485b-8851-a91911eb9726" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">71,163</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_75b17fdb-3f8a-47fc-9857-f4d4b11454d8" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:OperatingExpenses" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">57,094</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Loss from operations</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_565ea8cb-be89-47dc-9a59-c6a0ea98ad7f" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">61,433</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_90809e17-9ca8-4d31-9435-6a84b6a97989" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:OperatingIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">39,191</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest income</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1b3a84f4-90fc-48c6-8fab-565b67b38065" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:InterestAndOtherIncome" unitRef="U_USD" scale="3" decimals="-3">91</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_154867af-fadb-49b6-be29-b8ac41b83ee5" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:InterestAndOtherIncome" unitRef="U_USD" scale="3" decimals="-3">785</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest expense</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c1844478-033b-4c33-8a85-ad51419fe5e2" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3">176</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_73bfc77e-54c6-48df-94a7-2d60a85d7317" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:InterestExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">134</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other income (expense), net</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_91cc23e3-a510-46b4-82cf-8fc987812a65" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-">606</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8cbb41ed-c58c-4bd5-990f-3e502abf7752" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:OtherNonoperatingIncomeExpense" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">953</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Loss before income tax benefit</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6df62586-1ef9-47a7-a6ef-e94a75d5b31c" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">62,124</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d09f233e-9eab-4a1f-a1c6-4ecd2b4a47b3" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">39,493</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Income tax expense (benefit)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ebf7fdcb-9c7f-42e1-8ad9-8a7d6edb2f87" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">125</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b82afb37-14ab-4b6b-b178-85d6d0914af5" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">2,815</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8c34973f-c230-4375-b204-22c0cbd9e61f" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">61,999</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6e5cc7e3-f06b-417d-9ec1-0040106a9133" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">36,678</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss per share attributable to common stockholders, basic and diluted</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e9892d91-4629-4f88-892e-e4e2f5f8fb5f" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:EarningsPerShareBasicAndDiluted" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-">2.00</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e84be55e-9ffb-4357-bd70-f36d8c2e8358" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:EarningsPerShareBasicAndDiluted" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-">5.01</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted-average shares used in computing net loss per share <br />&#160;&#160;&#160;attributable to common stockholders, basic and diluted</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_48592fa8-3f47-43ca-b945-7b5c55761e9e" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">30,952,152</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_be24a2c8-f575-4f4f-a758-1af850fdee72" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">7,319,977</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other comprehensive income (loss):</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unrealized gain (loss) on marketable debt securities, net of tax</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">(</span><span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_66e384a9-eba9-4864-b882-2a55e48d6663" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">24</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_71f41e00-ea4d-44de-abd3-b12fc678ca1d" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" unitRef="U_USD" scale="3" decimals="-3">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total other comprehensive income (loss)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5e263406-0e8a-40c5-84c7-ccd4f70649ac" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">24</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b4969882-f62f-4304-be03-9e2981a3d414" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Comprehensive loss</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f17cdf13-4b0d-4bbe-b963-8c0cee1ee9c6" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">62,023</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_841e0051-c700-4e5a-acc8-60585af9824f" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:ComprehensiveIncomeNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">36,677</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The accompanying notes are an integral part of these consolidated financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Adicet Bio, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_statements_redeemable_conve"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Consolidated Statements of Redeemable Converti</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ble Preferred Stock and Stockholders&#x2019; Equity (Deficit)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">(in thousands, except share amounts)</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:31.61%;"></td>
    <td style="width:1.021%;"></td>
    <td style="width:0.384%;"></td>
    <td style="width:5.996%;"></td>
    <td style="width:0.5%;"></td>
    <td style="width:1.021%;"></td>
    <td style="width:0.739%;"></td>
    <td style="width:5.62%;"></td>
    <td style="width:0.5%;"></td>
    <td style="width:0.558%;"></td>
    <td style="width:0.558%;"></td>
    <td style="width:0.384%;"></td>
    <td style="width:6.119%;"></td>
    <td style="width:0.384%;"></td>
    <td style="width:1.021%;"></td>
    <td style="width:0.739%;"></td>
    <td style="width:5.735%;"></td>
    <td style="width:0.384%;"></td>
    <td style="width:1.021%;"></td>
    <td style="width:0.739%;"></td>
    <td style="width:7.032%;"></td>
    <td style="width:0.384%;"></td>
    <td style="width:1.021%;"></td>
    <td style="width:0.739%;"></td>
    <td style="width:6.923%;"></td>
    <td style="width:0.5%;"></td>
    <td style="width:1.021%;"></td>
    <td style="width:0.739%;"></td>
    <td style="width:6.93%;"></td>
    <td style="width:0.5%;"></td>
    <td style="width:1.021%;"></td>
    <td style="width:0.739%;"></td>
    <td style="width:6.923%;"></td>
    <td style="width:0.5%;"></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Redeemable Convertible<br />Preferred Stock</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Common Stock</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Additional<br />Paid-In</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Accumulated</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Accumulated<br />Other<br />Comprehensive</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Total<br />Stockholders&#x2019;<br />Equity</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Shares</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Amount</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Shares</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Amount</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Capital</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Deficit</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Income (Loss)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">(Deficit)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Balance at December 31, 2019</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8608a419-8eb7-47c8-a068-9bf8c0f8b593" contextRef="C_fe5ab009-8804-4e01-8541-0e9d8aa6c52f" name="us-gaap:TemporaryEquitySharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">97,166,921</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_93e8f042-0de7-4f3c-831a-d4aa33da0155" contextRef="C_fe5ab009-8804-4e01-8541-0e9d8aa6c52f" name="us-gaap:TemporaryEquityCarryingAmountAttributableToParent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">114,083</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3d14b5ee-5b18-4d1a-aaa3-5b431d55eda0" contextRef="C_d33cc417-791a-47d8-87ef-b0d73a0d0b66" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,155,578</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_0fbb73f0-a2b4-4955-a72c-3389ceca5af9;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2a96bec8-a994-4e0d-8eae-65e45f548314" contextRef="C_352e5b4d-b5f5-47ad-a765-412097c40d31" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,258</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">(</span><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e11f198a-bb58-45d1-93b3-54c4bbf02bf8" contextRef="C_ccba61f6-d5c4-43f1-bc3d-bdfb92b7ccad" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">69,647</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0f3e5dc0-6fae-4e28-b842-f6184a11c4e4" contextRef="C_75ebf3d9-c86e-4807-98b4-2e10b253829b" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">23</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">(</span><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_44a414fa-bd6d-4101-9afb-b8ea3ec73cca" contextRef="C_95800697-5c2c-4d5a-aff7-318a343c4784" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">60,366</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Issuance of common stock upon exercise of stock options</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f1e58d6e-0927-44da-9466-b8b2849b2b63" contextRef="C_c9838f86-a839-4a13-93ca-c0b2d3b58809" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">210,752</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cdc6a351-acc8-40bb-9e68-f922dcd14332" contextRef="C_c9838f86-a839-4a13-93ca-c0b2d3b58809" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c00fedca-5431-4f5a-a7ad-4519bec64de4" contextRef="C_229551d3-2c1b-4ec2-99aa-16652dd7eb75" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">459</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_701c04e2-9e52-4d1c-ba27-1c91aafe5cb7" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">460</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Stock-based compensation expense</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e1cbca28-cac8-4c21-b359-50a6f76810ff" contextRef="C_229551d3-2c1b-4ec2-99aa-16652dd7eb75" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,263</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_87fa4fa6-0eb4-434a-88ed-23ed763e950a" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,263</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Conversion of shares of redeemable convertible preferred stock<br />&#160;&#160;&#160;to shares of common stock in connection with the Merger</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">(</span><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_eb7a0b33-0be8-4cae-8987-6536a8b9dc50" contextRef="C_fdd289b2-efd1-4e91-9b8b-97c14283103e" name="acet:TemporaryEquityStockConversionSharesInConnectionWithMerger" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">97,166,921</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">(</span><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_325c33df-e2c7-42f2-8ef8-77f4b6e02882" contextRef="C_fdd289b2-efd1-4e91-9b8b-97c14283103e" name="acet:TemporaryEquityStockConversionInConnectionWithMerger" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">114,083</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8cb079bb-da04-40ec-a0e2-b9b39d85420e" contextRef="C_c9838f86-a839-4a13-93ca-c0b2d3b58809" name="acet:StockIssuedDuringPeriodSharesConversionOfSecurities" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">12,048,671</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e9098fcd-4709-4403-9dc1-564d049fb5f0" contextRef="C_c9838f86-a839-4a13-93ca-c0b2d3b58809" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d3077bde-d9be-4fff-baf6-59166f239c45" contextRef="C_229551d3-2c1b-4ec2-99aa-16652dd7eb75" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">114,082</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e6fb4f03-8cc3-47c0-99ec-87410e7b6ed1" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">114,083</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Exchange of common stock in connection with the Merger</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a304aaa6-6c75-42f7-a1aa-a44b5ea081c6" contextRef="C_c9838f86-a839-4a13-93ca-c0b2d3b58809" name="acet:StockExchangedDuringPeriodSharesInConnectionWithMerger" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,207,695</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f015b4ce-c31f-42d5-9c9f-593b3cc6ff6c" contextRef="C_229551d3-2c1b-4ec2-99aa-16652dd7eb75" name="acet:StockExchangedDuringPeriodValueInConnectionWithMerger" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">83,516</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_46ce823a-0bee-4af4-820c-eb19c561d344" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="acet:StockExchangedDuringPeriodValueInConnectionWithMerger" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">83,516</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Issuance of common stock upon accelerated vesting of restricted stock units in connection with merger</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ee44a1af-8627-48b4-a42b-5380e844ba0a" contextRef="C_c9838f86-a839-4a13-93ca-c0b2d3b58809" name="acet:StockIssuedDuringPeriodSharesUponAcceleratedVestingOfRSUWithMerger" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">54,553</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_845156f0-286c-43a5-8018-15627f40be86" contextRef="C_229551d3-2c1b-4ec2-99aa-16652dd7eb75" name="acet:StockIssuedDuringPeriodValueUponAcceleratedVestingOfRSUWithMerger" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">626</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_55a69b0a-03d7-4a0b-a01b-d3a19f9c7fa3" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="acet:StockIssuedDuringPeriodValueUponAcceleratedVestingOfRSUWithMerger" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">626</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Conversion of redeemable convertible preferred stock<br />&#160;&#160;&#160;warrants to common stock warrants</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_17e07411-9d1c-4a63-8af8-5ddf9d6b5cca" contextRef="C_229551d3-2c1b-4ec2-99aa-16652dd7eb75" name="us-gaap:ConversionOfStockAmountConverted1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,922</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a295df63-6e40-4784-a846-de6066019b83" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:ConversionOfStockAmountConverted1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,922</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Net loss</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">(</span><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_da2138f4-88df-4a3d-a500-e53557ba55fc" contextRef="C_d735ff93-b890-4e3f-88c9-64a20e0a25a7" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">36,678</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">(</span><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_525b3e59-8042-40b6-8640-ce688564e5c5" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">36,678</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Other comprehensive loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4a2dddab-3a9f-47f5-b386-97fe3624c9c2" contextRef="C_9afec6f3-5050-458f-b651-8d672791f22c" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_329fd40c-055c-4fb9-88c4-4c9ecfba8a0b" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Balance at December 31, 2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_7a22c7d2-0058-4f73-9325-35673702fe09;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_d2cce7e8-1134-4bea-822d-f684fe63d39a;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9580616b-63ff-43a9-a305-e4354ed7bf28" contextRef="C_36830567-b9c7-4c61-a102-2db396446fbd" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">19,677,249</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_44bad64c-f6dd-4c87-90b3-61aae861cc0d" contextRef="C_36830567-b9c7-4c61-a102-2db396446fbd" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_85f1e2cf-7dee-4959-b7a8-2f226bf7d360" contextRef="C_f0f88cdf-2c57-4430-af9d-f7f4ee5dd8be" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">216,126</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">(</span><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a04f0070-9ef8-45e1-9c1c-04453439cac8" contextRef="C_02dd56d4-2777-4e62-8616-7488897fd4d0" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">106,325</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f139f065-2f55-4a10-a6d4-c518a7f79dd8" contextRef="C_81126e27-9bfb-4e06-802d-fc47c6df7727" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">24</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a3eb2a56-664b-499a-a3f3-436feddbca5d" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">109,827</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Issuance of common stock upon exercise of stock options</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_30c34bd3-c31a-462b-87ef-aaf47fd1dc80" contextRef="C_9b4eb834-de39-4790-9fd5-164fe2bbae7e" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,125,339</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_89738b03-0415-4eba-a49c-9a27064de9ac" contextRef="C_ce2525a9-10cf-4599-b98b-ee9a7da54cd2" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,688</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_99301ceb-df85-4e1e-b00b-27a0745c38ed" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,688</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Issuance of common stock related to financing, net of issuance costs of $</span><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a28dbe6b-6782-4778-8524-230920c9ff2e" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">823,940</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c0cb8276-d7e9-4d06-af4d-9d6246b6f32f" contextRef="C_9b4eb834-de39-4790-9fd5-164fe2bbae7e" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">18,916,853</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8f4f0b18-1e68-4aa8-88ac-090235aaadca" contextRef="C_9b4eb834-de39-4790-9fd5-164fe2bbae7e" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_934fae98-b141-4d61-ac4a-3b6dca01e76f" contextRef="C_ce2525a9-10cf-4599-b98b-ee9a7da54cd2" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">237,995</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_80b33d97-2a9e-454d-adda-c852ab6e3361" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">237,997</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Issuance of common stock for cashless exercise of warrants</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_866ce8d0-384c-4d9d-962a-dfc54fa489cb" contextRef="C_9b4eb834-de39-4790-9fd5-164fe2bbae7e" name="us-gaap:StockIssuedDuringPeriodSharesIssuedForServices" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,806</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_88961339-6e41-46f7-b484-e70d789d380b;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Issuance of common stock resulting from Employee Stock Purchase Plan</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d03daeda-e7fc-4c97-a60b-956ab24bdced" contextRef="C_9b4eb834-de39-4790-9fd5-164fe2bbae7e" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">15,667</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_396b2e28-1e79-49d3-8b70-bdbe079c1073" contextRef="C_ce2525a9-10cf-4599-b98b-ee9a7da54cd2" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">129</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_00d8d33d-99fe-4eaa-92d2-d43edcb8dac4" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">129</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Stock-based compensation expense</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1b4f8d4c-8096-4209-95eb-b1e679fd044e" contextRef="C_ce2525a9-10cf-4599-b98b-ee9a7da54cd2" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,511</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_db8af69f-ee0c-462d-87d2-435e8aff7c19" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,511</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Net loss</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">(</span><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_93455aa4-df1e-49e0-8bb5-66d13dac6da7" contextRef="C_2e8c65f5-54e7-412c-9d4a-c7dea4022906" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">61,999</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">(</span><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d8f96cc6-3af0-4716-80b0-668a68874b9e" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:NetIncomeLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">61,999</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">Other comprehensive loss</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">(</span><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_07c7440f-3e89-4160-8ebe-94fc123d7aa4" contextRef="C_b79560ec-35d7-487d-96ee-7f96cca3cf73" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">24</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">(</span><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_eed55996-b95a-47c6-8400-3d61303f8972" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">24</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:7.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:7.0pt;font-family:Times New Roman;">Balance at December 31, 2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_ca459d7d-097c-4350-b8c5-17e431b35615;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_57e77e30-6b2f-47ee-bd06-1e77e3f45b01;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid rgba(0,0,0,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_24322b7c-33bb-4312-8c58-e64d3450addb" contextRef="C_4bc22030-2d0d-4a1f-b865-b78ea80ec73c" name="us-gaap:SharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">39,736,914</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0ae40be6-70b0-4cf7-99ff-6ecedf4eea4c" contextRef="C_4bc22030-2d0d-4a1f-b865-b78ea80ec73c" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4054d2e5-8360-4c22-90fe-5fde615a1ecd" contextRef="C_5972f862-a654-46cb-b4c6-99346fd20b9c" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">471,449</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">(</span><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_728e4ee3-8c1c-474d-910d-31380da2441a" contextRef="C_60060862-7047-426c-9c18-ea7eefd1e40c" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">168,324</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_e03a3503-c022-4462-9b6a-c5859ba7d7b7;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:7.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:7.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3f39c728-a2d1-4056-a474-93d453bf7605" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:StockholdersEquity" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">303,129</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:7.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:7.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The accompanying notes are an integral part of these consolidated financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Adicet Bio, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="consolidated_statements_cash_flows"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Consolidated Statem</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ents of Cash Flows</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">(in thousands)</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:69.799%;"></td>
    <td style="width:1.352%;"></td>
    <td style="width:1.019%;"></td>
    <td style="width:12.043%;"></td>
    <td style="width:0.686%;"></td>
    <td style="width:1.352%;"></td>
    <td style="width:1.019%;"></td>
    <td style="width:12.043%;"></td>
    <td style="width:0.686%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Cash flows from operating activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Net loss</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e6a6bab8-96e3-45bb-901a-89cdb119fd34" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">61,999</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7b037bcb-2feb-48ae-873d-2d71bb009ad2" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:ProfitLoss" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">36,678</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Adjustments to reconcile net loss to net cash used in operating activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Depreciation and amortization expense</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a3c13d49-5df1-4eac-942e-f91bfe2cd8a4" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,538</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_106b8815-ab67-4c60-850f-cbf21f3fb72d" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,226</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Noncash lease expense</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_14ecd520-83f3-4659-8358-508ef9194fa7" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:OtherNoncashExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,529</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_af3e395e-2ed6-4e04-b73b-38adfb763f44" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:OtherNoncashExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">725</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Stock-based compensation expense</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3d32fe8a-7cca-4d1b-b161-b9f749d7e2ed" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,511</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e42644ac-fc64-4568-871d-ecfe661f426b" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:ShareBasedCompensation" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,263</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Loss on disposal of assets for lease</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1b1055fb-7cf4-4bfc-b295-a4547aa459b3" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:GainLossOnDispositionOfAssets1" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">31</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_fd5f7e8a-5341-4223-a549-e2815d0b8b31;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Net amortization of premiums and accretion of discounts on investments</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c34b7d34-5012-44a4-b63f-1bc051ec8480" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">10</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_89158fe9-cbbe-470e-92d0-1e1e5bc3a0ec" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">5</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Change in fair value of redeemable convertible preferred stock warrant liability</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_2945645f-2178-4658-b960-77d1100e9bac;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c0b17ab9-7bc8-4dae-9350-eed60156b3ba" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:FairValueAdjustmentOfWarrants" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">897</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Impairment of in-process research and development</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_55a172b0-7f61-4f8d-a61e-76c7fe593df7" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="acet:ImpairmentOfInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,190</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fb81a443-bdaf-4852-a651-94b20981e602" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="acet:ImpairmentOfInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,300</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Gain on remeasurement of contingent consideration liability</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_81ef5e3e-640b-4f22-a923-be78e83c771f" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="acet:GainOnRemeasurementOfContingentConsiderationLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">980</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_feed592a-ee5d-4669-88dc-4a1e80e063d2" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="acet:GainOnRemeasurementOfContingentConsiderationLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,900</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Amortization of deferred debt issuance costs</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1f0b51f2-f722-4237-8bdb-402addde2ba2" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="acet:AmortizationOfDebtIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">175</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_06b9c405-bf26-43a0-90ef-84ee7b7cf54a" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="acet:AmortizationOfDebtIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">134</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Changes in operating assets and liabilities:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Accounts Receivable&#x2014;related party</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_23bb86cb-2cc4-4cd3-bb8b-4f272494b735" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">30</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_1ad28aba-0f89-4c1e-b355-7124041766a1;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Prepaid expenses and other current assets</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c3af6f0f-1fea-43c9-8c91-1ef8e4a87102" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,634</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ca997762-6d8d-47ec-ad5e-ab5d712179eb" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,233</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Other non-current assets</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_411b2e78-1e3d-4952-889c-8c8da64388c9" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">42</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4699ced2-f32f-4725-9157-e8170e541f07" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,260</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Accounts payable</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_87f96fac-a177-4f07-bab3-25d0eb3e3f9b" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,137</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b3d660d1-2fbe-4f32-aead-db51cfa8e5f0" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:IncreaseDecreaseInAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">814</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Contract liabilities&#x2014;related party</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_820f07c5-550a-4bee-97bc-92af46b472f6" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">9,175</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e2022cb1-3a4d-44ac-ae0f-048e681b1dd7" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">7,903</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Operating lease liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0df859d4-ad9b-4f98-b638-003db09d92bf" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="acet:IncreaseDecreaseInOperatingLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">511</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8cc1377f-14fc-472f-8507-bc96231707a2" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="acet:IncreaseDecreaseInOperatingLeaseLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">859</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Accrued and other current liabilities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ce66b0ee-5afa-4fcf-b595-da133944452b" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">855</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f0952468-c4ed-41ff-a100-c8ed80a3ec9d" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">787</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Other non-current liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_60a9e1d9-e81b-43d8-96d6-f9b2b2d700e7" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">9</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4658101f-25d5-49e9-9055-578863d8c280" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">242</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Net cash used in operating activities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bd0b6f97-7908-4f6c-8a3c-d0e878e89032" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">51,052</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_eaccf406-f214-448a-ab65-fa5f0134cae9" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">41,552</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Cash flows from investing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Cash and restricted cash acquired in connection with the Merger</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_f39be877-1c11-4604-9a1a-96f74b63b799;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f84ae42c-b0fd-424d-942f-dd281982e07a" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:CashAcquiredFromAcquisition" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">64,114</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Proceeds from sales of marketable debt securities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bdc70c82-cc8a-4612-bf56-7a6f8b9ec1a9" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="acet:ProceedsFromSalesOfMarketableDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,500</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_c2c0c022-3bc2-47ee-ac21-0348f3accf14;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Purchases of marketable debt securities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_0592c904-f2c4-43cd-af23-a8efec565b99;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6ba8e206-8f80-45db-9868-10015f2f9683" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:PaymentsToAcquireMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,700</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Proceeds from maturities of marketable debt securities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e61164f2-de21-4082-b30e-cc039b45754f" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,750</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_86561105-facf-412a-ac93-cf569e1e3d76" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">57,793</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Purchase of property and equipment</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bbbd9603-24b4-4fac-8973-0a5a79122b7b" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,046</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8fae1af5-f094-43ab-a255-7b83a3d49ea7" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">990</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Net cash provided by (used in) investing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c963fb6d-1149-4683-b170-6fe61dfb5446" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">2,796</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ae2c7e91-8af9-47e0-8754-d8fbb149bdb4" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">115,217</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Cash flows from financing activities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Proceeds from issuance of common stock, net of issuance costs</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_28e52752-d2cc-48f3-af29-406b67f88208" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:ProceedsFromIssuanceOfCommonStock" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">238,129</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_8bc0353d-5786-49d3-9a18-9b33edc0a9e9;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Proceeds from Employee Stock Purchase Plan</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7ea9be40-ddd8-463d-8525-c5ebb3b4eb58" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:ProceedsFromStockPlans" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">129</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_61e7ff69-16bd-48b2-b350-de1645a65d44;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Proceeds from exercise of stock options</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8e470252-0e5f-40a8-af42-0e0582a2a481" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,688</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_228af2b2-db66-494b-ac2f-814c52b2638c" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">460</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Deferred issuance costs</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4e469b14-3d0f-4fbb-869b-c5122de58f8f" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:PaymentsOfDebtIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">261</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">(</span><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c403a97e-9f7b-44f6-89e0-41f2debc35a5" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:PaymentsOfDebtIssuanceCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">157</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">)</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Net cash provided by financing activities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_22a91b01-b728-46b3-b204-e0c115b0f653" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">242,685</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6b1b4fa4-7019-43a8-97a7-dab6be36116e" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">303</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Net change in cash, cash equivalents and restricted cash</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_14e63d0f-df2d-4629-b683-09ce09feda1b" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">188,837</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d1670bcf-98db-4938-80c2-b59646737a6c" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">73,968</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Cash, cash equivalents and restricted cash, at the beginning of the period</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b09eaf75-2727-4c44-ace6-1241d326a381" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">88,857</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a95c7df2-b21d-4321-8f6c-62f2b981830a" contextRef="C_95800697-5c2c-4d5a-aff7-318a343c4784" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14,889</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Cash, cash equivalents and restricted cash, at the end of the period</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dc18f372-2620-4c4d-837c-c8567ef180d0" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">277,694</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ef666f90-1bda-4314-b23b-4d223215f2f7" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">88,857</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Reconciliation of cash, cash equivalents and restricted cash to consolidated balance sheets:</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Cash and cash equivalents</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_de2eefb9-3b2d-4cce-ad02-ec0bb0e4bcea" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">277,544</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0a7650c8-f93d-429e-acb2-96ba662d3080" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">84,330</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Restricted cash</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_25eff3d2-0e7b-4b04-a687-12803a2f47ba" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">150</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_053ba858-9c79-4a2b-85d7-30baa88f19a4" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="us-gaap:RestrictedCashNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,527</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Cash, cash equivalents and restricted cash in consolidated balance sheets</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_73823f37-2989-476f-a0f3-01f6d3858975" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">277,694</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6ec0a199-d905-45ce-b9bb-9046fefde05f" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">88,857</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Supplemental cash flow information</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Cash paid for income taxes</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2d5ef63b-7fea-4214-aea3-f618c5affcc4" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:IncomeTaxesPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">43</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ea93b15f-ca91-4e0d-98e1-37a32e0adb3f" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:IncomeTaxesPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Cash received for income tax refunds</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ad7ffdad-607a-4eb4-963b-f1df9154be95" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:ProceedsFromIncomeTaxRefunds" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,766</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f7de021a-f976-4760-b201-f1bdda5c8dd5" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:ProceedsFromIncomeTaxRefunds" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">664</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Supplemental disclosures of noncash investing and financing activities</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Purchase of property and equipment included in accounts payable and accrued liabilities</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_36371b41-fe8e-4ecc-9d1a-3fb8cca5b0ee" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">651</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ee686fce-aa57-47aa-a7ad-165e05cafaf4" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">115</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Common stock offering costs included in accrued liabilities at period end</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_887752bd-387f-4529-be65-120435cd1ad1" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="acet:CommonStockOfferingCostsIncludedInAccruedLiabilitiesAtPeriodEnd" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">132</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_5fee429c-5b1b-432c-a994-6ed5a5249e6a;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Right-of-use assets recognized upon adoption of Topic 842</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_05b13237-3492-4f95-aba3-8ed6a6944362;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_09e49f66-e304-4bbe-bc68-a4277c49d2b7" contextRef="C_788e17f6-1175-45bd-816d-ca6c3191ac61" name="acet:RightOfUseAssetsRecognized" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,424</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Operating lease right-of-use asset obtained in exchange for operating lease liability</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_78769c32-8afb-4b2d-96fd-6e254cea5840;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e2489b86-51d4-40e5-b8fd-6e8a6871eb3e" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">22,367</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Conversion of redeemable convertible preferred stock into common stock</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_e34744e6-32c7-4857-bf62-b6bfb9ec543a;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_79bea176-473d-4664-a863-bbb018bacc0a" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:DebtConversionConvertedInstrumentAmount1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">114,083</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Conversion of redeemable convertible preferred stock warrants into common stock warrants</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_60ec8ff2-c4ea-47b4-849f-ad0d9cd49e80;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3c489fa2-b00e-4934-9eda-b46688271d37" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:ConversionOfStockAmountConverted1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,922</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Fair value of net assets acquired in Merger</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_8cea713b-4adc-4d3c-bf88-22e31cbfdc99;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6adc8b13-4416-4ccf-8e23-3e0e475b84f9" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:FairValueOfAssetsAcquired" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">84,142</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Adjustment to Goodwill</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_266d7bc7-3bbe-49de-bdd1-a2249a501666" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="acet:AdjustmentToGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">413</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9e3c0038-ae14-4176-b3d6-aabf4b372d01" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="acet:AdjustmentToGoodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">650</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Issuance of redeemable convertible preferred stock warrants in connection with the Loan Agreement</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_30164a23-1034-41b4-8a87-4e24b682b3f4;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">$</span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:8.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9e47242b-8979-4472-9f9f-32c0084e1ef2" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="acet:IssuanceOfRedeemableConvertiblePreferredStockOnExerciseOfWarrantsWithLoanAgreement" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">144</ix:nonFraction></span></p></td>
    <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">The accompanying notes are an integral part of these financial statements.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Adicet Bio, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="notes_to_consolidated_financial_statemen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Financial Statements</span></p>
  <div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_17b1e974-6cf0-452a-a7e9-f64d686da5a0" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="acet:OrganizationAndNatureOfBusinessTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">1. Organization and Nature of the Business</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Adicet Bio, Inc. (formerly resTORbio, Inc. (resTORbio)), together with its subsidiaries, (the Company) is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer. The Company is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs) and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. The Company's approach to activate, engineer, and manufacture allogeneic gamma delta T cell product candidates derived from the peripheral blood cells of unrelated donors allows it to generate new product candidates in a rapid and cost efficient manner.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company was incorporated in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_6bd37428-42c2-4038-b96a-a6cfe4c5c8c5;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">November 2014</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> in Delaware. The principal executive offices are located in Boston, Massachusetts. The Company also has another office in Menlo Park, California.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Adicet Bio, Inc. (when referred to prior to the Merger (as defined below), (Former Adicet)) was incorporated in November 2014 in Delaware and was headquartered in Menlo Park, CA. Adicet Bio Israel Ltd. (formerly Applied Immune Technologies Ltd.) (Adicet Israel) is a wholly owned subsidiary of Former Adicet and is located in Haifa, Israel. Adicet Israel was founded in 2006. During 2019, Former Adicet consolidated its operations, including research and development activities, in the United States and as a result substantially reduced its operations in Israel.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Merger with resTORbio</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prior to September 15, 2020, the Company was a clinical-stage biopharmaceutical company known as resTORbio that had historically focused on developing innovative medicines that target the biology of aging, to prevent or treat age-related diseases with the potential to extend healthy lifespans. On </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d2ca398e-a36f-4a45-8fab-99162c8600f7" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="acet:EntityDateOfMerger" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">April 28, 2020</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, resTORbio entered into a definitive Merger Agreement with Former Adicet. Under the terms of the Merger Agreement, Former Adicet agreed to merge with a wholly owned subsidiary of resTORbio in an all-stock transaction with Former Adicet surviving as a wholly owned subsidiary of resTORbio and changing its name to &#x201c;Adicet Therapeutics, Inc.&#x201d; (such transactions, the Merger). Under the exchange ratio formula in the Merger Agreement, immediately following the Effective Time of the Merger, the securityholders of Former Adicet as of immediately prior to the Effective Time of the Merger owned approximately </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_13e1646c-8b09-417f-8279-87949311080b" contextRef="C_38799e03-7018-4654-b7db-0fc7800d94e4" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" unitRef="U_pure" scale="-2" decimals="2">75</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the outstanding shares of the Company&#x2019;s common stock on a fully-diluted basis and securityholders of resTORbio as of immediately prior to the Effective Time of the Merger owned approximately </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0184ebe0-e70c-48dd-94cf-a2e6dadf71fa" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" unitRef="U_pure" scale="-2" decimals="2">25</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the outstanding shares of the Company&#x2019;s common stock on a fully-diluted basis (in each case excluding equity incentives available for grant).</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company concluded that the transaction represented a business combination pursuant to Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 805, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Business Combinations</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Further, Former Adicet was determined to be the accounting acquirer based upon the terms of the Merger and other factors including: (i) Former Adicet&#x2019;s securityholders own approximately 75% of the voting rights of the combined company (on a fully-diluted basis excluding equity incentives available for grant); (ii) Former Adicet designated a majority (five of seven) of the initial members of the Board of Directors of the combined company; and (iii) the terms of the exchange of equity interests based on the exchange ratio at the announcement of the Merger factored in an implied premium to resTORbio&#x2019;s stockholders. The composition of senior management of the combined company was determined to be a neutral factor in the accounting acquirer determination, as the combined company will leverage the expertise of the senior management of both companies. Accordingly, the reported operating results prior to the business combination are those of Former Adicet.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On September 15, 2020, the Company completed the Merger pursuant to the Merger Agreement (the Effective Time). In connection with the Merger, and immediately prior to the Effective Time, resTORbio effected a reverse stock split of its common stock at a ratio of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6089a786-dac8-450b-bbce-2080af687d65" contextRef="C_54827df2-7ab1-4397-b75e-6c83f7055086" name="us-gaap:StockholdersEquityReverseStockSplit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1-for-7</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (the Reverse Stock Split). Also, in connection with the Merger, the Company changed its name from &#x201c;resTORbio, Inc.&#x201d; to &#x201c;Adicet Bio, Inc.&#x201d; (the Name Change), Former Adicet changed its name from &#x201c;Adicet Bio, Inc.&#x201d; to &#x201c;Adicet Therapeutics, Inc.&#x201d; and the business conducted by the Company became primarily the business, which was previously conducted by Former Adicet, which is a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">At the Effective Time, each outstanding share of Former Adicet capital stock was converted into the right to receive </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_92eb49b6-362a-4d6f-a369-9f58b1214ee5" contextRef="C_54827df2-7ab1-4397-b75e-6c83f7055086" name="acet:ExchangeRatio" unitRef="U_pure" scale="0" decimals="4">0.1240</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exchange Ratio) shares of Company&#x2019;s common stock, as set forth in the Merger Agreement. The Exchange Ratio was determined based on the total number of outstanding shares of Company&#x2019;s common stock and Former Adicet capital stock, each on a fully diluted basis, and the respective valuations of Former Adicet and resTORbio at the time of execution of the Merger Agreement. In connection with the Merger, the Company also assumed certain outstanding Former Adicet warrants and Former Adicet stock options under Former Adicet&#x2019;s 2015 Stock Incentive Plan (the 2015 Adicet Stock Incentive Plan) and Former Adicet&#x2019;s 2014 Share Option Plan (the 2014 Share Option Plan and, together with the 2015 Adicet Stock Incentive Plan, the Former Adicet Plans), with such stock options and warrants henceforth representing the right to purchase a number of shares of Company&#x2019;s common stock equal to the Exchange Ratio multiplied by the number of shares of Former Adicet&#x2019;s</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Adicet Bio, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">capital </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">stock previously represented by such stock options and warrants, as applicable, with a proportionate adjustment in exercise price.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Immediately following the Effective Time, there were approximately </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_600d3f4e-a87c-4e9a-b940-0c892c6cd8b5" contextRef="C_38799e03-7018-4654-b7db-0fc7800d94e4" name="us-gaap:CommonStockSharesOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">19,589,828</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of the Company&#x2019;s common stock outstanding (post Reverse Stock Split), with the former equity holders of Former Adicet holding approximately </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3e226e39-176f-4353-9134-336f00e5b3d5" contextRef="C_38799e03-7018-4654-b7db-0fc7800d94e4" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" unitRef="U_pure" scale="-2" decimals="2">75</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the outstanding shares of Company&#x2019;s common stock on a fully-diluted basis and the former equity holders of resTORbio holding approximately </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6d4bd728-362a-4652-9b06-c018d73096e0" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" unitRef="U_pure" scale="-2" decimals="2">25</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the outstanding shares of Company&#x2019;s common stock on a fully-diluted basis (in each case excluding equity incentives available for grant).</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Please refer to Note 3 &#x201c;Business Combinations&#x201d; for further discussions of the Merger.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Liquidity</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has incurred significant net operating losses and negative cash flows from operations since inception and had an accumulated deficit of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0787f583-a2ff-4dda-a2fe-e32f53e4da56" contextRef="C_38799e03-7018-4654-b7db-0fc7800d94e4" name="us-gaap:RetainedEarningsAccumulatedDeficit" unitRef="U_USD" scale="6" decimals="-5" sign="-" format="ixt:numdotdecimal">168.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as of December 31, 2021. The Company has historically financed its operations primarily through a collaboration and licensing arrangement, the private placement of equity securities and debt, and cash received in the Merger. To date, none of the Company&#x2019;s product candidates have been approved for sale and therefore the Company has not generated any revenue from product sales. Management expects operating losses and negative cash flows to continue for the foreseeable future, until such time, if ever, that it can generate significant sales of its product candidates currently in development.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In February 2021, the Company completed an underwritten public offering of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d78e18d2-a06f-4860-a26f-3fa81e587ab6" contextRef="C_aab33e86-f1f3-4f74-9094-e2ed14ea13cc" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">10,575,513</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of its common stock at a public offering price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0abf2111-73c3-413e-a8ce-06e1f092e8ac" contextRef="C_4066c921-3deb-4a5c-8fd4-0507b83d109f" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_USDollarShare" decimals="INF">13.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share. The Company received net proceeds from the offering, after deducting underwriting discounts and commissions and offering expenses of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_360d3e3f-4a9b-4f46-856b-40b164b3c0d5" contextRef="C_aab33e86-f1f3-4f74-9094-e2ed14ea13cc" name="acet:UnderwritingDiscountsAndCommissionsAndOtherOfferingExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">128.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. In connection with the offering, the Company also entered into a stock purchase agreement </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">with certain existing investors to purchase </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cf5141c0-ebe9-4eb2-9f11-abb31e004e4d" contextRef="C_4066c921-3deb-4a5c-8fd4-0507b83d109f" name="us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">1,153,840</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of its common stock for $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_57d56c2d-080c-4f02-839e-9a9cd451a2a9" contextRef="C_aab33e86-f1f3-4f74-9094-e2ed14ea13cc" name="us-gaap:PaymentsForRepurchaseOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">15.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million at a price per share equal to the public offering price, with an initial closing for certain investors held simultaneously with the closing of the offering and a subsequent closing for certain additional investors.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2021, the Company closed an underwritten public offering, or the December 2021 Follow-On Offering, of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0d586199-37ae-48bb-8919-4387585934b6" contextRef="C_c66707bf-a227-49f3-9c39-d4e971ab95bd" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">7,187,500</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of its common stock at a public offering price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9cbb61a0-3254-4460-8774-c8fdad23c6cc" contextRef="C_0e775bc8-410a-49ef-80c8-2b1c45c0da93" name="us-gaap:SharesIssuedPricePerShare" unitRef="U_USDollarShare" decimals="INF">14.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share. The Company received net proceeds from the offering, after deducting underwriting discounts and commissions and offering expenses of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4b334608-178b-4798-bb55-0308893a033a" contextRef="C_c66707bf-a227-49f3-9c39-d4e971ab95bd" name="acet:UnderwritingDiscountsAndCommissionsAndOtherOfferingExpenses" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">94.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company expects that its cash and cash equivalents balances as of December 31, 2021, including the gross proceeds it received in February 2021 and December 2021 from its underwritten public offerings and the proceeds received from a stock purchase agreement with certain existing investors, will be sufficient to fund its forecasted operating expenses, capital expenditure requirements for at least the next twelve months from the issuance of these annual consolidated financial statements.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All of the Company&#x2019;s revenue to date is generated from the Regeneron Agreement, which is a collaboration and license agreement with Regeneron. The Company does not expect to generate any significant product revenue until it obtains regulatory approval of and commercialize any of the Company&#x2019;s product candidates or enter into additional collaborative agreements with third parties, and it does not know when, or if, either will occur. The Company expects to continue to incur significant losses for the foreseeable future, and it expects the losses to increase as the Company continues the development of, and seek regulatory approvals for, its product candidates and begin to commercialize any approved products. The Company is subject to all of the risks typically related to the development of new product candidates, including, but not limited to, raising additional capital, development by its competitors of new technological innovations, risk of failure in preclinical and clinical studies, safety and efficacy of its product candidates in clinical trials, the risk of relying on external parties such as contract research organizations (CROs) and contract manufacturing organizations (CMOs), the regulatory approval process, market acceptance of the Company&#x2019;s products once approved, lack of marketing and sales history, dependence on key personnel and protection of proprietary technology and it may encounter unforeseen expenses, difficulties, complications, delays, and other unknown factors that may adversely affect its business.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Until such time as the Company can generate significant revenue from product sales, if ever, the Company expects to finance its operations through the sale of equity, debt financings, collaborative or other arrangements with corporate or other sources of financing. Adequate funding may not be available to the Company on acceptable terms or at all. The Company&#x2019;s failure to raise capital as and when needed could have a negative impact on its financial condition and the Company&#x2019;s ability to pursue its business strategies. Although the Company continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Adicet Bio, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2ace3216-cd81-4a78-8492-5f9392403e3b" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:SignificantAccountingPoliciesTextBlock" escape="true" continuedAt="F_2ace3216-cd81-4a78-8492-5f9392403e3b_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2. Summary of Significant Accounting Policies</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_290fb5f0-38ac-4057-98af-efe6d41016ed" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Basis of Presentation</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The consolidated financial statements and related disclosures have been prepared in conformity with accounting principles generally accepted in the United States of America (United States GAAP or GAAP).</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9a958462-6e17-47ca-986b-042968bf1275" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:ConsolidationPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Principles of Consolidation</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. The United States dollar is the functional and reporting currency of the Company and its subsidiaries.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cc694fd8-53aa-4256-a64b-491461b55909" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:UseOfEstimates" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent liabilities at the date of the consolidated financial statements as well as the reported amounts of revenues and expenses during the reporting period. Such estimates include the valuation of the intangible assets acquired in business combinations, redeemable convertible preferred stock warrant liability, redeemable convertible preferred stock tranche liability, the Technion Research and Development Foundation liability (TRDF Liability), contingent consideration liability for contingent value right (CVR), deferred tax assets, useful lives of property and equipment, accruals for research and development activities, revenue recognition and stock-based compensation and the Company&#x2019;s incremental borrowing rate. Actual results could differ from those estimates.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_90daee09-7cfa-42b5-ac48-eb5618acf397" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Contingent Consideration Liability (CVR)</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The estimated fair value of the CVR, initially measured and recorded on the acquisition date, is considered to be a Level 3 instrument. The contingent consideration liability is recorded at fair value at the end of each reporting period with changes in estimated fair values recorded in research and development expenses in the consolidated statements of operations and comprehensive loss. During the second quarter of 2021, the Company performed a re-measurement of the fair value of the CVR liability and adjusted the liability to zero. This resulted in a $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3121ce48-ccd5-43ee-9424-ac8ff7a84150" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="acet:GainLossOnChangeInFairValueOfContingentConsiderationLiability" unitRef="U_USD" scale="6" decimals="-5">1.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million gain in research and development expense in the statements of operations and comprehensive loss for the year ended December 31, 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7363d5fb-7dc7-4acc-9b77-b183f6126c6f" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Goodwill</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Goodwill represents the excess of the purchase price over the fair value of net tangible and identified intangible assets acquired in a business combination. Goodwill is not amortized but is evaluated at least annually for impairment or when a change in facts and circumstances indicate that the fair value of the goodwill may be below the carrying value.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Goodwill is tested for impairment at the reporting unit level annually in the fourth quarter, or more frequently when events or changes in circumstances indicate that the asset might be impaired. Examples of such events or circumstances include, but are not limited to, a significant adverse change in legal or business climate, an adverse regulatory action or unanticipated competition. The Company has determined that it operates in a single operating segment and has a single reporting unit.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prior to performing the impairment test, the Company assesses qualitative factors to determine whether the existence of events or circumstances would indicate that it is more likely than not that the fair value of the reporting unit was less than the carrying amount. If after assessing the totality of events or circumstances, the Company were to determine that it is more likely than not that the fair value of the reporting unit is less than the carrying amount, then the Company would perform a quantitative impairment test.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The quantitative impairment test involves comparing the fair value of the reporting unit to the carrying value. If the fair value of the reporting unit exceeds the carrying value of the net assets, goodwill is not impaired, and no further testing is required. If the fair value of the reporting unit is less than the carrying value, the Company measures the amount of impairment loss, if any, as the excess of the carrying value over the fair value of the reporting unit. The Company performed an annual test for goodwill impairment in the fourth quarter of the fiscal year ended December 31, 2021 and determined that goodwill was </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4b6bf1b6-ec69-4c81-bc28-8081a9323738" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:GoodwillImpairmentLoss" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">t impaired.</span></p></ix:nonNumeric></div><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Adicet Bio, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_eedf67ef-86f1-4a6f-862c-a44e2399c275" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Intangible Assets</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the Merger, the Company acquired certain IPR&amp;D assets, which were classified as indefinite-lived intangible assets. Acquired IPR&amp;D represents the fair value assigned to research and development assets that the Company acquires and have not been completed at the acquisition date. The fair value of IPR&amp;D acquired in a business combination is recorded on the Company&#x2019;s consolidated balance sheets at the acquisition-date fair value and is determined by estimating the costs to develop the technology into commercially viable products, estimating the resulting revenue from the products, and discounting the projected net cash flows to present value. IPR&amp;D is not amortized, but rather is reviewed for impairment on an annual basis or more frequently if indicators of impairment are present, until the project is completed, abandoned, or transferred to a third party. The Company performed a review for impairment of IPR&amp;D during the second quarter of the year ended December 31, 2021 and recognized an impairment charge of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e62eee29-00b0-435f-83e4-a63272161084" contextRef="C_e645c0e4-c8b9-494e-86ea-d249ee6b8de0" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, which was recorded as research and development expenses in the consolidated statement of operations and comprehensive loss.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_14a7f997-0e23-4f5d-b23b-b9f879d43d46" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:SegmentReportingPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Segments</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company operates and manages its business as </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_86602ea6-7991-40ea-ad5e-7ea2d308827a" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:NumberOfOperatingSegments" unitRef="U_Segment" decimals="0" format="ixt-sec:numwordsen"><ix:nonFraction id="F_cf9e6bf4-2751-4584-9ef6-d1e514e24e81" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:NumberOfReportableSegments" unitRef="U_Segment" decimals="0" format="ixt-sec:numwordsen">one</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> reportable and operating segment, which is the business of research and development of allogeneic immunotherapies for cancer and other diseases. The Company&#x2019;s Chief Executive Officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1ce79b71-9d8c-4994-b2cb-5411a5c05547" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:ConcentrationRiskCreditRisk" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Concentration of Credit Risk</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of cash and cash equivalents, and marketable debt securities. The Company&#x2019;s cash and cash equivalents are held at two financial institutions in the United States and one financial institution in Israel and such amounts may, at times, exceed insured limits. The Company invests its cash equivalents and marketable debt securities in money market funds, United States government securities, commercial paper, corporate bonds, and asset-backed securities. The Company limits its credit risk associated with cash equivalents and marketable debt securities by placing them with banks and institutions it believes are highly creditworthy and in highly rated investments. The Company has not experienced any losses on its deposits of cash and cash equivalents and marketable debt securities to date.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a18c5060-237f-4460-859b-daaadf8f79f0" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="acet:NumberOfCustomer" unitRef="U_Customer" decimals="INF" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> customer, Regeneron, which represents </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7f664578-7e7c-4138-8146-286bf26ece07" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="acet:CustomersPercentageOfTotalRevenue" unitRef="U_pure" scale="-2" decimals="2"><ix:nonFraction id="F_6efffd7e-d27f-4121-b177-5a98b18df9c2" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="acet:CustomersPercentageOfTotalRevenue" unitRef="U_pure" scale="-2" decimals="2"><ix:nonFraction id="F_356350f9-8577-47c1-bbed-6efca549f691" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="srt:FinancingReceivableNonaccrualToOutstandingPercent" unitRef="U_pure" scale="-2" decimals="2">100</ix:nonFraction></ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the Company&#x2019;s total revenue during the years ended December 31, 2021 and 2020 and outstanding accounts receivable as of December 31, 2021 (see Note 10).</span></p></ix:nonNumeric></div><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_81c4d2ab-1851-4ff0-9f4c-24beac06b577" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="acet:RisksAndUncertaintiesPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Risks and Uncertainties</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, protection of proprietary technology, dependence on key personnel, compliance with government regulations and the need to obtain additional financing to fund operations. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical studies, clinical trials, and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance and reporting.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#x2019;s product candidates are still in development and, to date, none of the Company&#x2019;s product candidates have been approved for sale and, therefore, the Company has not generated any revenue from product sales.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There can be no assurance that the Company&#x2019;s research and development will be successfully completed, that adequate protection for the Company&#x2019;s intellectual property will be obtained or maintained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company&#x2019;s product development efforts are successful, it is uncertain when, if ever, the Company will generate revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from other pharmaceutical and biotechnology companies.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">current COVID-19 (coronavirus) pandemic, which is impacting worldwide economic activity, poses risk that the Company or its employees, contractors, suppliers, and other partners may be prevented from conducting business activities for an indefinite period of time, including due to shutdowns that may be requested or mandated by governmental authorities. The extent to which the coronavirus impacts the Company&#x2019;s operations will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the outbreak, new information that will emerge concerning the severity of the coronavirus and the actions to contain the coronavirus or treat its impact, among others. COVID-19 may impact the timing of regulatory approval of the INDs for clinical trials, the enrollment of any clinical trials that are</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Adicet Bio, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">approved, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the availability of clinical trial materials and regulatory approval and commercialization of our products. COVID-19 may also impact the Company&#x2019;s ability to access capital, which could negatively impact short-term and long-term liquidity.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ae192d79-4daf-4dc4-a3c8-aa30bf2c34eb" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Cash and Cash Equivalents</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company considers all highly liquid investments purchased with maturities of three months or less from the purchase date to be cash equivalents. As of December 31, 2021 and 2020, cash and cash equivalents consist of cash deposited with banks and investments in money market funds with maturities of three months or less from the date of purchase.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7e1590ad-2547-4626-87b8-4bb32babc899" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:MarketableSecuritiesPolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Marketable Debt Securities</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Marketable debt securities are investments in marketable debt securities with maturities greater than three months at the time of purchase. The Company determines the appropriate classification of its investments in marketable debt securities at the time of purchase and reevaluates such designation at each balance sheet date. The Company has classified and accounted for its marketable debt securities as available-for-sale. The Company classifies highly liquid securities with maturities beyond 12 months as long-term marketable debt securities in the consolidated balance sheet. These securities are carried at fair value as determined based upon quoted market prices or pricing models for similar securities. Unrealized gains and losses, if any, are excluded from earnings and are reported as a component of accumulated other comprehensive income (loss). The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in interest income on the consolidated statements of operations and comprehensive loss. Realized gains and losses, if any, on available-for-sale securities are included in other income (expense), net. The cost of securities sold is based on the specific identification method. Interest and dividends on securities classified as available-for-sale are included in interest income. The Company did not have any outstanding marketable debt securities as of December 31, 2021 and did not identify any of its marketable debt securities as other-than-temporarily impaired as of December 31, 2020.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_24d6e3ae-8384-4a15-ae7e-bc3862156d9e" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Restricted Cash</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Restricted cash is comprised of cash that is restricted as to withdrawal or use under the terms of certain contractual agreements. Restricted cash for years ended December 31, 2021 and 2020 consists of collateral for letters of credit issued in connection with real estate leases (see Note 12).</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_117f2107-3416-42ef-8303-72d28fe5a51f" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Fair Value of Financial Instruments</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The carrying amounts of certain financial instruments of the Company, including cash equivalents, restricted cash, accounts payable and accrued and other current liabilities approximate fair value due to their relatively short maturities. The Company&#x2019;s marketable debt securities and CVR liability are carried at fair value (see Notes 4 and 5).</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b2f95461-204c-4989-9ac1-ffa6d623e9ab" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Property and Equipment, Net</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is computed on a straight-line basis over the estimated useful lives of the related assets, generally three years. Leasehold improvements are amortized using the straight-line method over the shorter of the assets&#x2019; estimated useful lives or the remaining term of the lease. Maintenance and repairs are charged to operations as incurred. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the consolidated balance sheet and any resulting gain or loss is reflected in the consolidated statements of operations and comprehensive loss in the period realized.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2ec753bc-02bc-48d3-9bb7-266674eb3d40" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Impairment of Long-Lived Assets</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. Recoverability is measured by comparison of the carrying amount of the asset or asset group to the future net cash flows which the asset or asset group is expected to generate. If such asset or asset group is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset or asset group exceeds the fair value of the asset or asset group. There has been </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_12003f10-b6c9-4025-a656-b48bcc365dae" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:AssetImpairmentCharges" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen"><ix:nonFraction id="F_d90e2806-24d3-4364-b88a-a51cc7292afa" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:AssetImpairmentCharges" unitRef="U_USD" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> such impairment of long-lived assets during the years ended December 31, 2021 and 2020.</span></p></ix:nonNumeric></div><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7c2bc12d-fa66-4772-9b78-2f1f5ccb4a3e" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:RevenueRecognitionPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Revenue Recognition</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under ASC 606, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Revenue from Contracts with Customers</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (ASC 606), the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Adicet Bio, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps as prescribed by ASC 606:</span></p><div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(i)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">identify the contract(s) with a customer;</span></div></div><div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(ii)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">identify the performance obligations in the contract;</span></div></div><div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(iii)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">determine the transaction price;</span></div></div><div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(iv)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">allocate the transaction price to the performance obligations in the contract; and</span></div></div><div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(v)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">recognize revenue when (or as) the Company satisfies a performance obligation.</span></div></div><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A contract with a customer exists when (i) the Company enters into a legally enforceable contract with a customer that defines each party&#x2019;s rights regarding the products or services to be transferred and identifies the payment terms related to these products or services, (ii) the contract has commercial substance and (iii) the Company determines that collection of substantially all consideration for products or services that are transferred is probable based on the customer&#x2019;s intent and ability to pay the promised consideration.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">At contract inception, once the contract is determined to be within the scope of ASC 606, the Company identifies the goods or services promised and determines the performance obligations by assessing whether each promised good or service is distinct. Goods or services that are not distinct are bundled with other goods or services in the contract until a bundle of goods or services that is distinct is created. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All of the Company&#x2019;s revenues are derived through a license and collaboration agreement (see Note 10).</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For revenue recognition purposes, the Company determines the term of its license or collaboration agreements by evaluating the period during which present and enforceable rights and obligations exist. This determination is impacted by the existence of substantive termination penalties, among other factors.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company recognizes revenue under the Company&#x2019;s license or collaboration agreements that are within the scope of ASC 606. These agreements include promises related to licenses to intellectual property and research and development services. If the license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgement to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. Accordingly, the transaction price is generally comprised of a fixed fee due at contract inception and at specified future dates, variable consideration in the form of milestone payments due upon the achievement of specified events and tiered royalties earned when customers recognize net sales of licensed products. The Company measures the transaction price based on the amount of consideration to which it expects to be entitled in exchange for transferring the promised goods and/or services to the customer. The Company utilizes the &#x201c;most likely amount&#x201d; method to estimate the amount of variable consideration to which it will be entitled for the contract. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. At the inception of each arrangement that includes development and regulatory milestone payments, the Company evaluates whether the associated event is considered most likely to be achieved and estimates the amount to be included in the transaction price.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Payments or reimbursements for the Company&#x2019;s research and development efforts where such efforts are considered part of or a single performance obligation are recognized over time using a measure of progress that best reflects the Company&#x2019;s performance in satisfying the obligation.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Upfront payments are recorded as contract liabilities upon receipt or when due and may require deferral of revenue recognition to a future period until the Company performs its obligation under these arrangements. Amounts payable to the Company are recorded as accounts receivable when the Company&#x2019;s right to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one year or less.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Adicet Bio, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from its collaboration arrangement.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1c6ad6f5-0f53-4280-a4b9-c9bca0c690f1" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:ResearchAndDevelopmentExpensePolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research and Development Expenses</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development expenses include costs directly attributable to the conduct of research and development programs, including payroll and related expenses, costs for CMOs, costs for CROs, materials, supplies, depreciation on and maintenance of research equipment, consulting costs, and the allocated portions of facility costs, such as rent, utilities, insurance, repairs and maintenance, depreciation, information technology costs and general support services. All costs associated with research and development are expensed within the consolidated statements of operations and comprehensive loss as incurred.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Costs incurred in obtaining technology licenses are charged to research and development expense as acquired in-process research and development if the technology licensed has not reached technological feasibility and has no alternative future use.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2469ac9e-4ce6-4576-847f-58a2fe4456f1" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="acet:AccruedResearchAndDevelopmentPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Accrued CRO, CMO, and Research and Development Expenses</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has entered into various agreements with CMOs and CROs. The Company&#x2019;s research and development accruals are estimated based on the level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. The estimated costs of research and development provided, but not yet invoiced are included in accrued and other current liabilities on the consolidated balance sheets. If the actual timing of the performance of services or the level of effort varies from the original estimates, the Company will adjust the accrual accordingly. Payments made to CMOs and CROs under these arrangements in advance of the performance of the related services are recorded as prepaid expenses and other current assets on the consolidated balance sheets until the services are rendered. Through December 31, 2021 there had been no material adjustments to the Company&#x2019;s prior period estimates of accrued research and development expenses.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5d8b7f22-3b3d-4d6b-9e0f-8bd0928d7e4f" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:LesseeLeasesPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Leases</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Effective January 1, 2020, the Company adopted ASU No. 2016-02, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Leases (Topic 842)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (ASU 2016-02), using the modified retrospective approach through a cumulative-effect adjustment as of the adoption date, with prior periods unchanged and presented in accordance with the guidance in Topic 840, Leases (Topic 840).</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Consistent with ASU 2016-02, the Company determines if an arrangement is a lease, or contains a lease, at inception. Leases with a term greater than 12 months are recognized on the balance sheet as Right-of-Use (ROU) assets and current and long-term operating lease liabilities, as applicable. The Company has elected not to recognize on the balance sheet leases with terms of 12 months or less. The Company typically only includes an initial lease term in its assessment of a lease arrangement. Options to renew a lease are not included in the Company&#x2019;s assessment unless there is reasonable certainty that the Company will renew. The Company monitors its plan to renew its leases no less than on a quarterly basis. In addition, the Company&#x2019;s lease agreements generally do not contain any residual value guarantees or restrictive covenants.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In accordance with ASU 2016-02, the ROU assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term. As most of the Company&#x2019;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate (IBR), which is the estimated rate the Company would be required to pay for a fully collateralized borrowing equal to the total lease payments over the term of the lease, to determine the present value of future minimum lease payments. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. For lease agreements entered into or reassessed after the adoption of ASU 2016-02, the Company does not combine lease and non-lease components. Variable lease payments are expenses as incurred.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Assumptions made by the Company at the commencement date are re-evaluated upon occurrence of certain events, including a lease modification. A lease modification results in a separate contract when the modification grants the lessee an additional right of use not included in the original lease and when lease payments increase commensurate with the standalone price for the additional right of use. When a lease modification results in a separate contract, it is accounted for in the same manner as a new lease.</span></p></ix:nonNumeric></div><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_674672a4-f5b9-49a2-a30f-9bb50ef1c43a" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="acet:FairValueOfCommonStockPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Fair Value of Common Stock</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prior to the Merger the fair value of the Company&#x2019;s common stock was determined by its Board of Directors with input from management and third-party valuation specialists. The Company&#x2019;s approach to estimate the fair value of the Company&#x2019;s common stock is consistent with the methods outlined in the American Institute of Certified Public Accountants Practice Aid, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Valuation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Adicet Bio, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">of Privately-Held-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Company</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> Equity Securities Issued as Compensation</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Determining the best estimated fair value of the Company&#x2019;s common stock requires significant judgement and management considers several factors, including the Company&#x2019;s stage of development, equity market conditions affecting comparable public companies, significant milestones and progress of research and development efforts. Subsequent to the Merger, the fair value of the Company&#x2019;s common stock is determined based on its closing market price.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7a42727e-ea20-4e76-a60e-516687ea59c8" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock-Based Compensation</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company accounts for stock-based compensation arrangements with employees and non-employees using a fair value method which requires the recognition of compensation expense for costs related to all stock-based payments including stock options. The fair value method requires the Company to estimate the fair value of stock-based payment awards on the date of grant using an option-pricing model. The Company uses the Black-Scholes option-pricing model to estimate the fair value of options granted that are expensed on a straight-line basis over the requisite service period, which is generally the vesting period. The Company accounts for forfeitures as they occur. Option valuation models, including the Black-Scholes option-pricing model, require the input of several assumptions. Changes in the assumptions used can materially affect the grant-date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend yield, expected volatility and the expected life of the award. For awards that have a performance condition, the Company recognizes compensation expense based on its assessment of the probability that the performance condition will be achieved, using an accelerated attribution model, over the explicit or implicit service period.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b960adb9-a2fa-4cd2-ae6f-4e9e0d179f30" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:IncomeTaxPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Income Taxes</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences attributable to differences between carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax reporting purposes and for operating loss and tax credit carryforwards. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#x2019;s deferred tax assets and liabilities are measured using enacted tax rates expected to apply in the years in which these temporary differences are expected to be recovered or settled. A valuation allowance is recorded to reduce deferred tax assets if it is determined that it is more likely than not that all or a portion of the deferred tax asset will not be realized. The Company considers many factors when assessing the likelihood of future realization of deferred tax assets, including recent earnings results, expectations of future taxable income, carryforward periods available and other relevant factors. The Company records changes in the required valuation allowance in the period that the determination is made.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company assesses its income tax positions and records tax benefits for all years subject to examination based upon management&#x2019;s evaluation of the facts, circumstances and information available as of the reporting date. For those tax positions where it is more likely than not that a tax benefit will be sustained, the Company records the largest amount of tax benefit with a greater than 50% likelihood of being realized upon ultimate settlement with a taxing authority having full knowledge of all relevant information. For those income tax positions where it is not more likely than not that a tax benefit will be sustained, the Company does not recognize a tax benefit in the consolidated financial statements. The Company records interest and penalties related to uncertain tax positions, if applicable, as a component of income tax expense (benefit).</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_062993b7-b646-4141-a29e-3587d3c16d57" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Comprehensive Income (Loss)</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Comprehensive income (loss) is defined as a change in equity of a business enterprise during a period, resulting from transactions from non-owner sources. The other comprehensive loss disclosed in the Company&#x2019;s consolidated statements of operations and comprehensive loss for the years ended December 31, 2021 and 2020 consists of changes in unrealized gains and losses on marketable debt securities.</span></p></ix:nonNumeric></div><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3a55aa8f-d06d-46c3-8057-db694bfd8d8c" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:EarningsPerSharePolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Net Loss per Share Attributable to Common Stockholders</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Basic </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common stock outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common stock and potentially dilutive securities outstanding for the period. The Company&#x2019;s potentially dilutive shares, which include outstanding stock options, Employee Stock Purchase Plan awards, unvested restricted stock units (RSUs), and shares issuable upon conversion of the Convertible Notes, are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive. Basic and diluted net loss per share attributable to common stockholders is presented in conformity with the two-class method required for participating securities. The two-class method determines net income (loss) per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income (loss) available to common</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Adicet Bio, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">stockholders </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">for the period to be allocated between common and participating securities based upon their respective rights to share in undistributed earnings as if all income (loss) for the period had been distributed. The Company&#x2019;s participating securities do not have a contractual obligation to share in the Company&#x2019;s losses. As such, the net loss is attributed entirely to common stockholders. Since the Company has reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for those periods.</span></p></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_7e3a8d1d-ce23-432c-b070-bb413a6a3784" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:SubsequentEventsPolicyPolicyTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Subsequent Events Considerations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the consolidated financial statements to provide additional evidence for certain estimates or to identify matters that require additional disclosure. Subsequent events have been evaluated as required. The Company has evaluated all subsequent events and determined that there are no material recognized or unrecognized subsequent events requiring disclosure, other than as disclosed in these notes to the consolidated financial statements.  See Note 21 for further information.</span></p></ix:nonNumeric></div><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_54552f8d-ea7b-46ea-aeca-15be5ef6deed" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" escape="true" continuedAt="F_54552f8d-ea7b-46ea-aeca-15be5ef6deed_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Recent Accounting Pronouncements</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">From time to time, new accounting pronouncements are issued by the FASB under its ASC or other standard setting bodies and adopted by the Company as of the specified effective date, unless otherwise discussed below.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Recently Adopted Accounting Pronouncements</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In August 2018, the FASB issued ASU No. 2018-15, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Intangibles&#x2013;Goodwill and Other&#x2014;Internal-Use Software (Subtopic 350-40): Customer&#x2019;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That is a Service Contract </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(ASU 2018-15). The amendments in ASU 2018-15 align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). Accordingly, the update requires</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">entities in a hosting arrangement that is a service contract to follow the guidance in ASC 350-40, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Internal-Use Software</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (ASC 350-40) to determine which implementation costs to capitalize as an asset related to the service contract and which costs to expense. Costs to develop or obtain internal-use software that cannot be capitalized under ASC 350-40, such as training costs and certain data conversion costs, also cannot be capitalized for a hosting arrangement that is a service contract. Therefore, an entity in a hosting arrangement that is a service contract determines which project stage an implementation activity relates to. Costs for implementation activities in the application development stage are capitalized depending on the nature of the costs, while costs incurred during the preliminary project and post-implementation stages are expensed as the activities are performed. ASU 2018-15 also requires entities to expense the capitalized implementation costs of a hosting arrangement that is a service contract over the term of the hosting arrangement. ASU 2018-15 was effective for public entities for annual periods beginning after December 15, 2019, including interim periods within those fiscal years. For nonpublic entities, ASU 2018-15 is effective for annual reporting periods beginning after December 15, 2020, and interim periods within annual periods beginning after December 15, 2021. Early adoption is permitted, including adoption in any interim period. The Company adopted ASU 2018-15 beginning January 1, 2021. The adoption of ASU 2018-15 resulted in an immaterial amount of assets recorded on the Company's balance sheet.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In November 2018, the FASB issued ASU No. 2018-18, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Collaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(ASU 2018-18), which is intended to clarify the circumstances under which certain transactions in collaborative arrangements should be accounted for under the revenue recognition standard. Certain transactions between collaboration arrangement participants should be accounted for as revenue under ASC Topic 606 when the collaborative arrangement participant is a customer in the context of a unit of account. For public business entities, this ASU is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. For all other entities, this ASU is effective for fiscal years and interim periods within those years beginning after December 15, 2020. Early adoption is permitted.  The Company adopted ASU 2018-18 beginning January 1, 2021. The adoption of this standard did not have a material impact on the Company's financial statements and related disclosures.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2019, the FASB issued ASU No. 2019-12, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Income Taxes (Topic 740)&#x2014;Simplifying the Accounting for Income Taxes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (ASU 2019-12), which simplify various aspects related to the accounting for income taxes. This ASU removes exceptions to the general principles in Topic 740 related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. For public companies, this ASU is effective for interim and annual reporting periods beginning after December 15, 2020. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2021, and interim periods within fiscal years beginning after December 15, 2022. Early adoption is permitted. The Company adopted ASU 2019-12 beginning January 1, 2021 on a prospective basis. The adoption of this standard did not have a material impact on the Company's financial statements and related disclosures</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Adicet Bio, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In March 2020, the FASB issued ASU No. 2020-04, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Reference Rate Reform (Topic 848)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (ASU 2020-04). The amendments in ASU 2020-04 provide optional expedients and exceptions for applying generally accepted accounting principles to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments in ASU 2020-04 are effective for all entities as of March 12, 2020 through December 31, 2022. An entity may elect to apply the amendments for contract modifications by Topic or Industry Subtopic as of any date from the beginning an interim period that includes or is subsequent to March 12, 2020, or prospectively from the date that the financial statements are available to be issued. Once elected for a Topic or an Industry Subtopic, the amendments must be applied prospectively for all eligible contract modifications for that Topic or Industry Subtopic. The Company may elect to apply ASU 2020-04 as its contracts referenced in London Interbank Offered Rate (LIBOR) are impacted by reference rate reform. The Company adopted ASU 2020-04 beginning January 1, 2021. The adoption of this standard did not have a material impact on the Company's financial statements and related disclosures.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><br /></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Accounting Pronouncements Not Yet Adopted</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Financial Instruments&#x2014;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(ASU 2016-13), which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. This ASU replaces the existing incurred loss impairment model with an expected loss model. It also eliminates the concept of other-than-temporary impairment and requires credit losses related to available-for-sale debt securities to be recorded through an allowance for credit losses rather than as a reduction in the amortized cost basis of the securities. These changes will result in earlier recognition of credit losses. For public business entities that meet the definition of a Securities and Exchange Commission (SEC) filer, excluding entities eligible to be smaller reporting companies as defined by the SEC, adoption is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. For SEC filers that are eligible to be smaller reporting companies and for all other entities, this ASU is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact the adoption of this ASU will have on its consolidated financial statements and related disclosures.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In January 2017, the FASB issued ASU No. 2017-04, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Intangibles &#x2013; Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(ASU 2017-04). The new guidance simplifies the subsequent measurement of goodwill by removing the second step of the two-step impairment test. The amendment requires an entity to perform its annual or interim goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity still has the option to perform the qualitative assessment for a reporting unit to determine if the quantitative impairment test is necessary. The new guidance for accelerated filing companies became effective for annual periods or any interim goodwill impairment tests in fiscal years beginning after December 15, 2019 and all other entities should adopt the amendments in this update for its annual or any interim goodwill impairment tests in fiscal years beginning after December 15, 2022. The amendment should be applied on a prospective basis. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company is currently evaluating the impact the adoption of this ASU will have on its consolidated financial statements and related disclosures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span><ix:continuation id="F_2ace3216-cd81-4a78-8492-5f9392403e3b_1"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:continuation id="F_54552f8d-ea7b-46ea-aeca-15be5ef6deed_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In July 2021, FASB issued ASU No. 2021-05, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Lease (Topic 842), Lessors - Certain Leases with Variable Lease Payments </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(ASU 2021-05). ASU 2021-05 amends the lease classification requirements for lessors when classifying and accounting for a lease with variable lease payments that do not depend on a reference rate index or a rate. The update provides criteria, that if met, the lease would be classified and accounted for as an operating lease. ASU 2021-05 is effective for reporting periods beginning after December 15, 2021, with early adoption permitted. The Company is currently evaluating the impact of the adoption of this ASU on the Company's consolidated financial statements, but does not believe the adoption of this standard will have a material impact on the Company's consolidated financial statements.</span></ix:continuation></span><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"></span></ix:continuation></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p>
  <div><ix:nonNumeric id="F_a209bc5c-0c5c-48ac-b2dd-50cbd1ce2aa4" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:BusinessCombinationDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">3. Business Combination</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On September 15, 2020, Former Adicet completed its merger with resTORbio. Based on the Exchange Ratio of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_01dd02dc-9d68-4cf9-9b1f-b6fc78ec8512" contextRef="C_0e581963-9b5e-4dbd-bb03-47a0e58483c2" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" unitRef="U_pure" scale="0" decimals="4">0.1240</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, immediately following the Merger, resTORbio stockholders and holders of resTORbio restricted stock units and options to acquire resTORbio common stock owned approximately </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_90d9badc-17c5-4080-8e31-a9628a685ca0" contextRef="C_b2fceb56-058f-472e-a003-7e909e8b6b12" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" unitRef="U_pure" scale="-2" decimals="3">25.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the outstanding capital stock of the combined company on a fully diluted basis, and Former Adicet stockholders, holders of options or warrants to acquire Former Adicet capital stock owned approximately </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f907d43b-e0cc-40b9-8ad6-fb7ddaa530cd" contextRef="C_5ad68f0f-dc2d-43e8-92c2-f0f53b821bd5" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" unitRef="U_pure" scale="-2" decimals="3">75.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the outstanding capital stock of the combined company on a fully diluted basis.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">resTORbio&#x2019;s stockholders continued to own and hold their existing shares of the Company&#x2019;s common stock (after giving effect to the </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_676fc392-e01d-4bd9-9d8d-5b43ba011d5c" contextRef="C_66c6bb36-401e-4afc-b955-ab56bbccb097" name="us-gaap:StockholdersEquityReverseStockSplit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1-for-7</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> reverse stock split). Pursuant to the terms of the Merger, the vesting of all outstanding resTORbio stock options was accelerated in full as of immediately prior to the Effective Time. All out-of-the-money resTORbio stock options were cancelled for no consideration. All in-the-money resTORbio stock options remained outstanding after the completion of the Merger in accordance with their terms. For accounting purposes, the Company assumed </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_779b8859-d65f-4267-b281-465650bcf7e4" contextRef="C_0e581963-9b5e-4dbd-bb03-47a0e58483c2" name="acet:NumberOfSharesOfSurvivingStockOptions" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">81,370</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> in-the-money resTORbio stock options after giving effect to reverse stock split. In addition, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ae5d38a5-dff6-43f1-930a-0ba37b6f465a" contextRef="C_5ad68f0f-dc2d-43e8-92c2-f0f53b821bd5" name="acet:UnvestedRestrictedStockUnitsOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">91,309</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> unvested </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">resTORbio restricted stock units outstanding</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Adicet Bio, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">unsettled, after giving effect to reverse stock split, as of immediately prior to the Effective Time of the Merger, were accelerated in full and the holders of such restricted stock units received </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1916a6af-801e-41fa-802f-8c6c3a5404cc" contextRef="C_0e581963-9b5e-4dbd-bb03-47a0e58483c2" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">54,553</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of the Company&#x2019;s common stock (after reduction by the number of shares of resTORbio common stock necessary to satisfy applicable tax withholding obligations at the maximum statutory rate). The fair value of these modified stock options and restricted stock units attributable to pre-combination services was recorded as a component of consideration transferred and the fair value of these modified stock options and restricted stock units attributable to post-combination services was recognized as stock compensation expense in the Company&#x2019;s consolidated statements of operations and comprehensive loss.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">At the closing of the Merger, all shares of Former Adicet common stock and Former Adicet redeemable convertible preferred stock then outstanding were converted to Former Adicet&#x2019;s common stock under their original terms and were then exchanged for the Company&#x2019;s common stock.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the Merger, the Company entered into a Contingent Value Rights Agreement (the CVR Agreement) with Computershare Inc. and Computershare Trust Company, N.A. as joint rights agent. Per the terms of the Merger, each holder of resTORbio common stock as of immediately prior to the completion of the Merger is entitled to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ad4a922f-15f5-4fb6-ad8a-a6f2320bc612" contextRef="C_ed6df093-d6d5-4c84-a08c-07bf173fcdb1" name="acet:ContractualContingentValueRight" unitRef="U_ValueRight" decimals="0" format="ixt-sec:numwordsen">one</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> contractual contingent value right, subject to and in accordance with the terms and conditions of the CVR Agreement, for each share of resTORbio common stock held by such holder as of immediately prior to the Effective Time. The CVR holders were entitled to receive net proceeds from the commercialization, if any, from a third-party commercial partner of RTB101, resTORbio&#x2019;s small molecule product candidate that is a potent inhibitor of target of rapamycin complex 1 (TORC1), for a COVID-19 related indication.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The total purchase price was allocated to the tangible and intangible assets acquired and liabilities assumed of resTORbio based on their fair values as of the completion of the Merger, with the excess allocated to goodwill. The purchase price is calculated based on the fair value of resTORbio common stock that the resTORbio stockholders owned as of the closing date of the Merger because, with no active trading market for shares of Former Adicet, the fair value of the resTORbio&#x2019;s common stock represented a more reliable measure of the fair value of consideration transferred in the Merger. </span><span style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e28b47f9-4961-41bb-b63b-18437209507e" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:BusinessAcquisitionProFormaInformationTextBlock" escape="true" continuedAt="F_e28b47f9-4961-41bb-b63b-18437209507e_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following summarizes the purchase price in the Merger (in thousands, except share and per share amounts):</span></ix:nonNumeric></span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:continuation id="F_e28b47f9-4961-41bb-b63b-18437209507e_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:77.846%;"></td>
        <td style="width:2.091%;"></td>
        <td style="width:1.577%;"></td>
        <td style="width:17.704%;"></td>
        <td style="width:0.782%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Fair value of common stock shares of the combined company <br />&#160;&#160;&#160;owned by resTORbio stockholders (1)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_469a5573-0b9d-46a1-abaf-31cefad89607" contextRef="C_5ad68f0f-dc2d-43e8-92c2-f0f53b821bd5" name="us-gaap:EquityIssuedInBusinessCombinationFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">84,142</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Fair value of contingent consideration liability with respect to CVR (2)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_15ae4ac4-efc7-4068-bf99-1fc7c4c0ed0d" contextRef="C_5ad68f0f-dc2d-43e8-92c2-f0f53b821bd5" name="us-gaap:BusinessCombinationContingentConsiderationLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,880</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Purchase price</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fa974f4a-7a66-4275-a67e-0df37c187ff2" contextRef="C_0e581963-9b5e-4dbd-bb03-47a0e58483c2" name="us-gaap:BusinessCombinationConsiderationTransferred1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">87,022</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="margin-left:3.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9d630a7c-11bc-473e-a37c-e079e575e9e0" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" escape="true"><div style="display:flex;margin-top:0.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Represents the share consideration of the combined company that the resTORbio stockholders own as of the closing of the Merger calculated as follows:</span></div></div><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:77.785%;"></td>
        <td style="width:2.078%;"></td>
        <td style="width:1.565%;"></td>
        <td style="width:17.508%;"></td>
        <td style="width:1.064%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Number of shares of the combined company owned by resTORbio<br />&#160;&#160;&#160;stockholders (a)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_019cfa3b-ff69-4ed2-909d-86357365d5fc" contextRef="C_0e581963-9b5e-4dbd-bb03-47a0e58483c2" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,207,695</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Multiplied by the fair value per share of resTORbio common <br />&#160;&#160;&#160;stock (b)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_88818858-dc62-419f-84b9-73eb33390702" contextRef="C_5ad68f0f-dc2d-43e8-92c2-f0f53b821bd5" name="us-gaap:BusinessAcquisitionSharePrice" unitRef="U_USDollarShare" scale="0" decimals="2">16.59</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Acquisition date fair value of resTORbio</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9c4aab64-401a-4b49-9de6-85197569f157" contextRef="C_0e581963-9b5e-4dbd-bb03-47a0e58483c2" name="us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">86,396</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Estimated fair value of modified stock options and restricted stock units attributable to pre-combination services (3)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1352c10e-e543-4a85-ad06-2588815f253e" contextRef="C_0e581963-9b5e-4dbd-bb03-47a0e58483c2" name="acet:FairValueOfModifiedStockOptionsAndRestrictedStockUnitsAttributableToPreCombinationServices" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">626</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: portion of the fair value to be distributed as CVR (c)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a2ddba6f-0ffc-45b3-94d0-30fe50a46cb1" contextRef="C_0e581963-9b5e-4dbd-bb03-47a0e58483c2" name="acet:LessPortionOfFairValueToBeDistributedAsCVR" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">2,880</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Fair value of shares of the combined company  owned by resTORbio<br />&#160;&#160;&#160;stockholders</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c792468d-5aa0-4ee5-995c-42a1b3ff58d7" contextRef="C_5ad68f0f-dc2d-43e8-92c2-f0f53b821bd5" name="us-gaap:EquityIssuedInBusinessCombinationFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">84,142</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="margin-left:10.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><div style="margin-left:6.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">a.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Represents the number of shares of common stock of the combined company that the resTORbio stockholders owned as of the closing of the Merger. This amount is calculated as </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e2a81716-173c-42b6-8d10-b6c201137a52" contextRef="C_0e581963-9b5e-4dbd-bb03-47a0e58483c2" name="us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,207,695</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> shares (post-reverse stock split) of resTORbio common stock outstanding as of September 15, 2020.</span></div></div><div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">b.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The fair value of shares of the combined company owned by resTORbio stockholders is based on the closing price of resTORbio common stock on September 14, 2020.</span></div></div><div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">c.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The fair value of resTORbio common stock was further adjusted to remove the estimated fair value of the CVR embedded within the closing price, as each holder of resTORbio stock received one contractual CVR immediately prior to the Merger.</span></div></div><div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(2)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Each holder of resTORbio common stock as of immediately prior to the completion of the Merger was entitled to one CVR issued by resTORbio, subject to and in accordance with the terms and conditions of the CVR Agreement, for each share of resTORbio common stock held by such holder as of immediately prior to the Effective Time of the Merger.</span></div></div><div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(3)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Based on the capitalization of resTORbio as of September 15, 2020, </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_35d0533d-2981-4ddf-9068-c799d50444b3" contextRef="C_5ad68f0f-dc2d-43e8-92c2-f0f53b821bd5" name="acet:UnvestedRestrictedStockUnitsOutstanding" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">91,309</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> outstanding unvested resTORbio restricted stock units were accelerated in connection with the Merger and holders of the restricted stock units were issued approximately </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4c3cc4f1-f07b-4d87-b62f-2d14379f867a" contextRef="C_0e581963-9b5e-4dbd-bb03-47a0e58483c2" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">54,553</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> shares </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">of resTORbio </span></div></div><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Adicet Bio, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;visibility:hidden;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;"></span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">common </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">stock on a net settlement basis. Similarly, in connection with the Merger, vesting of outstanding resTORbio stock options was accelerated in full and the stock options that were not in the in-the-money on the close of the Merger were canceled, resulting in approximately </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6b2ca9c3-a4b6-49cd-949c-162e3074e676" contextRef="C_0e581963-9b5e-4dbd-bb03-47a0e58483c2" name="acet:NumberOfSharesOfSurvivingStockOptions" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">81,370</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> surviving stock options. The acquisition date fair value of these modified resTORbio restricted stock units and resTORbio stock options attributable to the pre-combination services is included in the estimated purchase price.</span></div></div><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Merger was accounted for as a business combination which requires that assets acquired, and liabilities assumed be recognized at their fair value as of the acquisition date. While the Company uses its best estimates and assumptions as part of the purchase price allocation process to value the assets acquired and liabilities assumed on the acquisition date, its estimates and assumptions are subject to refinement. Fair value estimates are based on a complex series of judgments about future events and uncertainties and rely heavily on estimates and assumptions. The judgments used to determine the estimated fair value assigned to each class of assets acquired and liabilities assumed, as well as asset lives, can materially impact the Company&#x2019;s results of operations.</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b40c81de-77dc-41ae-bdb2-54b43301049b" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following summarizes the allocation of the purchase price to the net tangible and intangible assets acquired (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.38%;"></td>
        <td style="width:1.14%;"></td>
        <td style="width:1.752%;"></td>
        <td style="width:12.157%;"></td>
        <td style="width:1.164%;"></td>
        <td style="width:1.14%;"></td>
        <td style="width:1.801%;"></td>
        <td style="width:13.051%;"></td>
        <td style="width:1.164%;"></td>
        <td style="width:1.14%;"></td>
        <td style="width:1.752%;"></td>
        <td style="width:12.194%;"></td>
        <td style="width:1.164%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As of <br />December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Measurement Period Adjustments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Final Purchase <br />Price Allocation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net assets acquired:</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash and cash equivalents</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d5f2efcd-6f98-408a-9e6f-c0bf13010753" contextRef="C_9fa0d050-80a6-4eb0-b277-441b2edd40e6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">63,869</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5c467a75-a8c6-4162-bbef-7b2aab498abc" contextRef="C_a6003cef-f951-463a-a0b1-c940267e5c47" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">63,869</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prepaid expenses and other current assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b56b8880-c867-4962-a6b6-157d80afb015" contextRef="C_9fa0d050-80a6-4eb0-b277-441b2edd40e6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,059</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_49edec2a-dbc5-47f2-b82c-c06c4abcc690" contextRef="C_b571f234-c627-4f7d-82fb-c74e7cbd480a" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">615</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b42ccd1e-dc5d-4ca3-bb61-e287975c145d" contextRef="C_a6003cef-f951-463a-a0b1-c940267e5c47" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,674</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_81cc8e5e-4f23-4a92-8241-4dd9114de987" contextRef="C_9fa0d050-80a6-4eb0-b277-441b2edd40e6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3">318</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4211bb21-9b56-428f-9989-8477d2608d50" contextRef="C_a6003cef-f951-463a-a0b1-c940267e5c47" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3">318</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">IPR&amp;D</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7386d844-0726-4b0f-b870-b66a2052067a" contextRef="C_9fa0d050-80a6-4eb0-b277-441b2edd40e6" name="acet:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,490</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5825db38-667d-41f3-b721-cd17e9ca6ffd" contextRef="C_a6003cef-f951-463a-a0b1-c940267e5c47" name="acet:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,490</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Restricted cash</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9a51f29b-e23c-413f-84ee-5f6d238658b3" contextRef="C_9fa0d050-80a6-4eb0-b277-441b2edd40e6" name="acet:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" unitRef="U_USD" scale="3" decimals="-3">245</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0d8dac5d-01d7-4055-9727-faf6ebcb3bc9" contextRef="C_a6003cef-f951-463a-a0b1-c940267e5c47" name="acet:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" unitRef="U_USD" scale="3" decimals="-3">245</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accounts payable</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0305ff9c-da27-44d7-ac58-c459ca8be826" contextRef="C_9fa0d050-80a6-4eb0-b277-441b2edd40e6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,316</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f9fc4753-f074-4999-9c38-1b46aeac041d" contextRef="C_b571f234-c627-4f7d-82fb-c74e7cbd480a" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">12</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8cfb80c3-3975-4a95-b234-2d8625d1ee8a" contextRef="C_a6003cef-f951-463a-a0b1-c940267e5c47" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,304</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued and other current liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_74c1abe9-8575-4861-baff-2c24ab60418e" contextRef="C_9fa0d050-80a6-4eb0-b277-441b2edd40e6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,365</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_21ed1926-f93b-4efe-824d-2394e7d1990d" contextRef="C_a6003cef-f951-463a-a0b1-c940267e5c47" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,365</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b498acd7-c39b-4402-9cd6-d646180effaa" contextRef="C_9fa0d050-80a6-4eb0-b277-441b2edd40e6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax liability</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_35bbdc57-1520-4735-87d2-6b5972619154" contextRef="C_9fa0d050-80a6-4eb0-b277-441b2edd40e6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3">367</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a2ec9caf-32a3-4bbd-8bed-196eeba8cc4e" contextRef="C_a6003cef-f951-463a-a0b1-c940267e5c47" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" unitRef="U_USD" scale="3" decimals="-3">367</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Goodwill</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b19ef29f-5d86-4172-9469-a3a7a0ca8f66" contextRef="C_9fa0d050-80a6-4eb0-b277-441b2edd40e6" name="us-gaap:Goodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">20,089</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7c061d4e-1706-4284-bf32-ed0d3efff414" contextRef="C_b571f234-c627-4f7d-82fb-c74e7cbd480a" name="us-gaap:Goodwill" unitRef="U_USD" scale="3" decimals="-3" sign="-">627</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5bc9db0a-d41f-47c6-968c-b1dfd4fdce80" contextRef="C_a6003cef-f951-463a-a0b1-c940267e5c47" name="us-gaap:Goodwill" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">19,462</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Purchase price</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7373668d-5353-4b19-bcc7-3293264ba20a" contextRef="C_9fa0d050-80a6-4eb0-b277-441b2edd40e6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">87,022</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_65a44cd7-9e0c-4c7c-a1f6-63bbd47a545a" contextRef="C_a6003cef-f951-463a-a0b1-c940267e5c47" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">87,022</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The goodwill of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_34cb9c14-a8c2-46e9-bc3c-aed8ea87fa2b" contextRef="C_a6003cef-f951-463a-a0b1-c940267e5c47" name="us-gaap:Goodwill" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">19.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million is not tax deductible and represents the excess of the consideration paid over the fair value of assets acquired and liabilities assumed. Goodwill is mainly attributable to the enhanced value of the combined company, as reflected in the increase in market value of the resTORbio common shares following the announcement of the Merger with Former Adicet.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The fair value of acquired IPR&amp;D is related to the research and development of RTB101 for a COVID-19 related indication and was conducted pursuant to resTORbio's license agreement with Novartis (see Note 11). The RTB101 compound IPR&amp;D project was valued using an income approach, specifically a projected discounted cash flow method, adjusted for the probability of technical success (PTS). The projected discounted cash flow models used to estimate the Company&#x2019;s IPR&amp;D reflect significant assumptions regarding the estimates a market participant would make in order to evaluate a drug development asset, including the following:</span></p><div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Estimates of potential cash flows to be generated by the project and resulting asset, which was developed utilizing estimates of total patient population, market penetration rates, demand risk adjustment factors, and product pricing; </span></div></div><div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Estimates regarding the timing of and the expected costs of goods sold, research and development expenses, selling, general and administrative expenses to advance the clinical programs to commercialization, cash flow adjustments and partner profit split; </span></div></div><div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The projected cash flows were then adjusted using PTS factors that were selected considering both the current state of clinical development and the nature of the proposed indication, (i.e., respiratory therapeutics); and </span></div></div><div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Finally, the resulting probability adjusted cash flows were discounted to a present value using a risk-adjusted discount rate, developed considering the market risk present in the forecast and the size of the asset. </span></div></div><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">IPR&amp;D intangible asset is not amortized, but rather is reviewed for impairment on an annual basis or more frequently if indicators of impairment are present, until the project is completed, abandoned, or transferred to a third party. Upon the review of impairment indicators of IPR&amp;D during the second quarter of 2021, the Company concluded that the IPR&amp;D was fully</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Adicet Bio, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">impaired </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and recorded an impairment charge within research and development expenses in the consolidated statement of operations and comprehensive loss for the remaining balance of the IPR&amp;D intangible asset June 30, 2021. The Company recognized IPR&amp;D impairment charges of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_774b5fb0-ab54-4f39-9ccc-f5eb5e0661f4" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_00850232-9ccc-4c74-a232-b409e4471904" contextRef="C_7c0ad6be-8917-45ec-bfbe-3f58f537064d" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b81001d3-3ea4-4379-89fa-9c2b617f3836" contextRef="C_bdd4c9c6-4256-4ee5-b7de-760f8fec3c69" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the quarters ended as of December 31, 2020, March 31, 2021, and June 30, 2021. On July 29, 2021, the Company sent Novartis a termination notice. Termination will automatically take effect as of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_138767df-c828-488c-aca6-78d2c413b56b" contextRef="C_4f49ca26-ce78-4bcd-aa4b-b027527c27af" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durday"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">60</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> days from the date of delivery of the termination notice to Novartis, but in no event later than October 1, 2021 without any further notice or action required of either Novartis or the Company.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The contingent consideration for the CVR was valued using an income approach, leveraging the probability adjusted discounted cash flow used in the valuation of the IPR&amp;D and then deducting the administrative fee to be retained by the combined company and other permitted deductions in order to arrive at the net cash expected to be paid out to the CVR holders. The probability adjusted cash flow includes significant estimates and assumptions pertaining to commercialization events and cash consideration received by the Company for the grant of rights to commercialize RTB101 during the term of the CVR Agreement (as discussed above). These cash flows were then discounted to present value using the same discount rate applied in the valuation of the IPR&amp;D.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Transaction costs for the Merger were $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e67e75de-978c-46d2-b6db-898fa01ccb97" contextRef="C_bb96533e-8bc4-44b9-adcb-bbc676d9bb65" name="us-gaap:PaymentsForMergerRelatedCosts" unitRef="U_USD" scale="6" decimals="-5">7.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the year ended December 31, 2020 and were expensed as incurred in general and administrative expenses in the consolidated statements of operations and comprehensive loss.</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d315c5de-67fe-4f36-806b-a14160bdca29" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following tables present changes in the Company's IPR&amp;D and CVR since the Merger (in thousands):</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:27.815%;"></td>
        <td style="width:1.362%;"></td>
        <td style="width:1.196%;"></td>
        <td style="width:11.31%;"></td>
        <td style="width:0.588%;"></td>
        <td style="width:1.362%;"></td>
        <td style="width:1.196%;"></td>
        <td style="width:11.085%;"></td>
        <td style="width:0.794%;"></td>
        <td style="width:1.362%;"></td>
        <td style="width:1.196%;"></td>
        <td style="width:11.281%;"></td>
        <td style="width:0.588%;"></td>
        <td style="width:1.362%;"></td>
        <td style="width:1.196%;"></td>
        <td style="width:11.085%;"></td>
        <td style="width:0.794%;"></td>
        <td style="width:1.362%;"></td>
        <td style="width:1.196%;"></td>
        <td style="width:11.281%;"></td>
        <td style="width:0.588%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Acquisition Date <br />Fair value as of<br />September 15, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Change in <br />Fair value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As of<br />December 31,<br />2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Change in <br />Fair value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As of<br />December 31,<br />2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">In-process research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_aa0bb6f9-43fc-44a0-837f-dd33d9437b16" contextRef="C_f7497dd4-b12f-4bd8-b7a8-8dd651b1c575" name="us-gaap:BusinessCombinationAssetsArisingFromContingenciesAmountRecognized" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,490</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">(</span><span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_5fba530e-5602-4830-aca7-08c553d50653" contextRef="C_4a46099c-74bf-4057-bccf-7f08136ee114" name="us-gaap:BusinessCombinationAssetsArisingFromContingenciesAmountRecognized" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">2,300</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_952d24e0-a208-4f4e-a0f0-579280d112dc" contextRef="C_75d47652-161b-4dc3-8594-ce11750f60a2" name="us-gaap:BusinessCombinationAssetsArisingFromContingenciesAmountRecognized" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,190</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">(</span><span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_69d0ebb1-cf55-44f2-b6fa-d1f876b0be5c" contextRef="C_92ecfec8-f8f4-4b99-9099-e1803e6b82f7" name="us-gaap:BusinessCombinationAssetsArisingFromContingenciesAmountRecognized" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,190</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.5pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_ba39addf-7250-4185-b821-6a0528ff4070;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">Contingent Value Rights</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_e189516b-4868-47b8-b747-cef4095fcc31" contextRef="C_b7f956dc-e09b-4592-9b31-a71664b48260" name="us-gaap:BusinessCombinationAssetsArisingFromContingenciesAmountRecognized" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,880</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">(</span><span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_3bc18483-7802-4562-b01a-b55851f0660c" contextRef="C_81494d43-98de-4a2b-a975-25afa4970b74" name="us-gaap:BusinessCombinationAssetsArisingFromContingenciesAmountRecognized" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">1,900</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_533516fc-11dd-4bd7-bb5b-cd2aef797f18" contextRef="C_cd9014db-0372-4b1d-af87-ae8fac0a18ea" name="us-gaap:BusinessCombinationAssetsArisingFromContingenciesAmountRecognized" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">980</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">(</span><span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"><ix:nonFraction id="F_307b0efe-b77b-42b2-ac84-1751937419e0" contextRef="C_c3918e4a-2434-4382-9707-ca0c30475b0a" name="us-gaap:BusinessCombinationAssetsArisingFromContingenciesAmountRecognized" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">980</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.5pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_53469473-0173-4a8a-bfc4-8856f9b34255;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0224ca9c-a69a-483d-8a44-1804362e0e60" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:FairValueDisclosuresTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">4. Fair Value Measurements</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company determines the fair value of financial and non-financial assets and liabilities using the fair value hierarchy which establishes three level of inputs that may be used to measure fair value, as follows:</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 1 &#x2014; Observable inputs, such as quoted prices in active markets for identical assets or liabilities.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 2 &#x2014; Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 3 &#x2014; Unobservable inputs which reflect management&#x2019;s best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#x2019;s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability.</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_1cd1d79b-a8f3-4cb5-8dba-6d6486bc6498" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following tables present information about the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands):</span></p><p style="text-indent:7.933%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:46.433%;"></td>
        <td style="width:1.005%;"></td>
        <td style="width:1.728%;"></td>
        <td style="width:10.689%;"></td>
        <td style="width:0.735%;"></td>
        <td style="width:1.005%;"></td>
        <td style="width:1.728%;"></td>
        <td style="width:9.157%;"></td>
        <td style="width:0.735%;"></td>
        <td style="width:1.005%;"></td>
        <td style="width:1.728%;"></td>
        <td style="width:9.157%;"></td>
        <td style="width:0.735%;"></td>
        <td style="width:1.005%;"></td>
        <td style="width:1.728%;"></td>
        <td style="width:10.689%;"></td>
        <td style="width:0.735%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level 1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level 2</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level 3</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Money market funds (1)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fa98f595-6fe9-482c-a845-5536ac884496" contextRef="C_ebfaf6a1-e4c4-4844-90bf-eb7e876fd554" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">147,071</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_02ca4e77-9c2a-4c1c-a9ab-6dcb167902d3" contextRef="C_b7eaefd8-96b9-433a-a39f-12214b972204" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">147,071</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total fair value of assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ec2ad17d-b3bc-42e5-821d-d62d7c9015a7" contextRef="C_93d3a97b-1f9f-4a76-9398-f29f21995887" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">147,071</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_adfe03b9-1c0d-4394-9ea3-5b74f08b9451" contextRef="C_23c45869-fbfe-42d5-ad00-b90a165dbcd2" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">147,071</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Adicet Bio, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:48.026%;"></td>
        <td style="width:0.993%;"></td>
        <td style="width:1.594%;"></td>
        <td style="width:9.745%;"></td>
        <td style="width:0.821%;"></td>
        <td style="width:1.017%;"></td>
        <td style="width:1.594%;"></td>
        <td style="width:9.757%;"></td>
        <td style="width:0.821%;"></td>
        <td style="width:1.017%;"></td>
        <td style="width:1.594%;"></td>
        <td style="width:8.973%;"></td>
        <td style="width:0.821%;"></td>
        <td style="width:1.017%;"></td>
        <td style="width:1.594%;"></td>
        <td style="width:9.794%;"></td>
        <td style="width:0.821%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level 1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level 2</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level 3</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Money market funds (1)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_41788e52-a9f6-472d-b520-3c5c3a010951" contextRef="C_515b257e-b0b9-4013-a431-c4113b38f357" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">63,817</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_803ea030-804d-4af6-ae34-b6185545f97e" contextRef="C_ad66e4cc-7bab-41c5-80c2-e13c75c2e208" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">63,817</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Marketable debt securities (2)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Asset-backed securities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e7895ac5-a282-4161-858e-49465cbe531e" contextRef="C_3b9411c3-8cc1-4889-996e-5f7080c40edb" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,522</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fdec90d6-ca79-4616-84a2-3da07ccd4eb7" contextRef="C_a5e55134-4c6c-4529-bddd-d3adb88995cd" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,522</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Corporate debt securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_286b4dd8-de72-4494-a772-8e314c9d9fb7" contextRef="C_33ca374a-c073-4a53-8b64-e82bcfbfe97f" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,762</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0099be2f-edcf-42f8-9783-ee98ff854bed" contextRef="C_d66319b0-75d0-4205-b25e-8c8321f342f3" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,762</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Commercial paper</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f92de538-49fa-4f31-8dab-f0d8259d1d68" contextRef="C_1ac06182-fa6d-4612-a577-224903f3d8ec" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_305f8387-b718-488f-a8a2-0200819b734c" contextRef="C_905b1778-abfc-4dfb-825e-88b08dac4474" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Marketable debt securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8b9f407e-f217-4fde-baff-1f665d44ddc0" contextRef="C_19e31569-c13e-46a3-a9e6-a74f0c5c72c6" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,284</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_170bf009-3fc4-40d7-bdea-5719513fa678" contextRef="C_5207f624-84b3-469d-bd6b-fe0a7c570cde" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,284</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Total fair value of assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1847d241-8c15-4a6c-93a1-ce9a777d57eb" contextRef="C_76a7c6aa-3344-4804-9a25-aa31c1d6210f" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">63,817</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e5d9a433-7264-47d0-af77-b1a49ee296c5" contextRef="C_d01f7af2-d072-472c-aed6-fdd2ba352899" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,284</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_72710344-6071-4d67-80c6-f0c016a88cd8" contextRef="C_745de059-cb14-4ea1-8c29-12d351f50320" name="us-gaap:AssetsFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">74,101</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Liabilities:</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Contingent consideration</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e6260aba-deb5-4dde-bef8-ac7c5fc45244" contextRef="C_b662f1d9-b03b-4be8-bc81-ab4638821609" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">980</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dca09712-74bc-4006-8030-030c2ad1247d" contextRef="C_0897fc9d-88dd-4a06-87d5-dbac0106894b" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">980</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Total fair value of liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e586e468-f626-47cc-b54b-31efb251bd50" contextRef="C_342b3c71-2aea-451c-ba15-14d5101cb509" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">980</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b05189c4-c0cf-42da-8925-93d43be7fca7" contextRef="C_745de059-cb14-4ea1-8c29-12d351f50320" name="us-gaap:LiabilitiesFairValueDisclosure" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">980</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p><div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(1)</span><div style="display:inline;"><ix:footnote id="FNT_3577aa04-acc2-44f1-903a-a30dd6a3a68b" xml:lang="en-US"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Included in cash and cash equivalents in the consolidated balance sheets</span></ix:footnote></div></div><div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(2)</span><div style="display:inline;"><ix:footnote id="FNT_7667a44b-4b7d-46fe-a77a-02f957bfe903" xml:lang="en-US"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Included in short-term marketable debt securities in the consolidated balance sheets.</span></ix:footnote></div></div></ix:nonNumeric></div><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Money market funds are included within Level 1 of the fair value hierarchy because they are valued using quoted market prices. Corporate debt securities, commercial paper and asset-backed securities are classified within Level 2 of the fair value hierarchy as they take into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income-based and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate the fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data and other observable inputs.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As part of the acquisition of resTORbio, the Company entered into a CVR Agreement and recorded the fair value of the CVR as part of consideration transferred. The Company considers the contingent consideration liability a Level 3 instrument (one with significant unobservable inputs) in the fair value hierarchy. In June 2021, the Company determined the possibility of any commercialization events for RTB101 was close to zero (see Note 3). As a result, the fair value of the CVR liability was adjusted to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e09e4deb-2499-4d2f-8180-0db46615321f" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="acet:EstimatedFairValueOfCVRLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">zero</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. On October 27, 2021, the Company provided a Termination Notice under the CVR Agreement to the joint rights agents to terminate its obligations under the CVR Agreement, effective immediately.</span></p></ix:nonNumeric></div>
  <div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_07747e35-46b5-4aba-a510-85df7493db1e" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">5. Marketable Debt Securities</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_848e7ef9-900c-44ff-9f31-c71c0895129a" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:MarketableSecuritiesTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following tables summarize the Company&#x2019;s marketable debt securities (in thousands):</span></p><p style="text-indent:7.933%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:47.571%;"></td>
        <td style="width:1.035%;"></td>
        <td style="width:1.481%;"></td>
        <td style="width:9.946%;"></td>
        <td style="width:0.664%;"></td>
        <td style="width:1.035%;"></td>
        <td style="width:1.481%;"></td>
        <td style="width:9.989%;"></td>
        <td style="width:0.664%;"></td>
        <td style="width:1.035%;"></td>
        <td style="width:1.481%;"></td>
        <td style="width:9.989%;"></td>
        <td style="width:0.664%;"></td>
        <td style="width:1.035%;"></td>
        <td style="width:1.481%;"></td>
        <td style="width:9.782%;"></td>
        <td style="width:0.664%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Amortized<br />Cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Unrealized<br />Losses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Unrealized<br />Gains</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Fair<br />Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Asset-backed securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_619a8c46-a0e8-4bdc-b6a1-5c41c4d18f14" contextRef="C_a904b84b-2c56-4da2-95ba-b90ab8586e15" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,507</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ed9e99c2-f731-4176-b630-487d5d34a011" contextRef="C_a904b84b-2c56-4da2-95ba-b90ab8586e15" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6cff3b91-61bd-4e8e-9c5a-37d95b6e52b0" contextRef="C_a904b84b-2c56-4da2-95ba-b90ab8586e15" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6d9634da-2990-4754-8546-9f2558c6d99e" contextRef="C_a904b84b-2c56-4da2-95ba-b90ab8586e15" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,522</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Corporate debt securities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6244cebe-4c23-4705-be4e-5ca0f5640a56" contextRef="C_c620e2d6-dea3-45ea-8e5e-d3a20a684708" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,754</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_78323ae3-7b40-4866-80c2-42633178419a" contextRef="C_c620e2d6-dea3-45ea-8e5e-d3a20a684708" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ff015ec3-8b1b-4703-bc7e-2ca71120db42" contextRef="C_c620e2d6-dea3-45ea-8e5e-d3a20a684708" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">8</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d579afe1-95bd-48a2-b1a4-af991a8da127" contextRef="C_c620e2d6-dea3-45ea-8e5e-d3a20a684708" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,762</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e0cb6afe-eafd-4824-b31f-3e59e10d479d" contextRef="C_fdcf93e8-6acd-43f5-89f3-9404d1046341" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">999</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_eb34490a-3a57-4ddb-bea5-4b34826ada04" contextRef="C_fdcf93e8-6acd-43f5-89f3-9404d1046341" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e470129a-1581-439b-9cd7-323f1039f3c3" contextRef="C_fdcf93e8-6acd-43f5-89f3-9404d1046341" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_92a4980a-d021-4cad-b32b-b261f09d7c5e" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,260</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dcecd051-6b88-497a-9b51-d06e2c55d569" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f4d1e722-dcea-40f1-8d17-1a488892b5a8" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">24</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_215ba233-6226-49ce-9021-314f116ab0a4" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,284</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:7.933%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_03749ca5-2bbf-46e0-bd68-8047e8a36499" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="acet:MarketableDebtSecuritiesClassificationTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes the classification of the Company&#x2019;s marketable debt securities in the consolidated balance sheets (in thousands):</span></p><p style="text-indent:7.933%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:73.372%;"></td>
        <td style="width:1.089%;"></td>
        <td style="width:1.514%;"></td>
        <td style="width:9.769%;"></td>
        <td style="width:0.708%;"></td>
        <td style="width:1.089%;"></td>
        <td style="width:1.514%;"></td>
        <td style="width:10.237%;"></td>
        <td style="width:0.708%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Short-term marketable debt securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2c3fb7b4-08ea-4d2c-a7d1-cb96cb061ba3" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_52a47c53-67ce-40be-a6eb-b8aa594c0c6c" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,284</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Long-term marketable debt securities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_99f1682d-1947-4818-bbe7-75f7da81302e" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5855a352-ef9a-43cf-a76a-643cc50a9649" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ad30bc17-59c3-410a-af7a-8c18b582a93a" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="us-gaap:MarketableSecurities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,284</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Adicet Bio, Inc.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_246a4b89-9bb6-448b-ab8d-a275ff83c73e" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="acet:PrepaidExpensesAndOtherCurrentAssetsTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">6. Prepaid Expenses and Other Current Assets</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_975a49a1-675b-4ee2-bdc5-7403c4caf776" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="acet:PrepaidExpensesAndOtherCurrentAssetsTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prepaid expenses and other current assets consisted of the following (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:63.509%;"></td>
        <td style="width:1.373%;"></td>
        <td style="width:2.116%;"></td>
        <td style="width:13.901%;"></td>
        <td style="width:0.855%;"></td>
        <td style="width:1.373%;"></td>
        <td style="width:2.116%;"></td>
        <td style="width:13.901%;"></td>
        <td style="width:0.855%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prepaid Insurance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cc9fb909-d08f-4c65-bc1f-a66ef4e8a4a3" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:PrepaidInsurance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,884</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d477784a-924e-40db-9946-87ea8e493264" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="us-gaap:PrepaidInsurance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,443</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prepayments to CRO's</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2ee14c5e-a4fc-48b7-bc7b-9e55efeae3d6" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="acet:PrepaymentsToCros" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,658</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_133ac2b1-2526-469d-8a87-2305fbd0d0a2" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="acet:PrepaymentsToCros" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">420</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prepaid Maintenance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a7d698f5-4430-491d-af75-35cabe6e53f1" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:PrepaidExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,021</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_359563b9-39de-43b8-a283-b90a039cbeae" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="us-gaap:PrepaidExpenseCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">761</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prepayments to CMO's</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d708b07a-765e-4ac4-b9fa-4356c2319fa0" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="acet:PrepaymentsToCmos" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">115</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c77eb321-8d96-489e-ab72-d865661eb25f" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="acet:PrepaymentsToCmos" unitRef="U_USD" scale="3" decimals="-3">135</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other current assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2464bbdb-a912-4273-b531-03b550d8072b" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:OtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c6aba313-7cb9-48e7-89b6-185993d591e9" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="us-gaap:OtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3">229</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Tax receivable</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_35116441-1b04-4b29-a73b-5e936379b6d9" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:IncomeTaxesReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_95b0934e-bb2d-4f63-8f79-182ba6cd6b16" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="us-gaap:IncomeTaxesReceivable" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,711</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest receivable</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_57de9372-7815-41e0-8a30-edc5b70170e0" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:InterestReceivableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">29</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2e47c406-21bc-4597-90e7-55f67eb1dc87" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="us-gaap:InterestReceivableCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">23</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d84340cd-2ca4-4cd8-9868-72c25988ed6d" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,709</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ab60a451-66cc-4ab0-b68b-d65903f6e9ee" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,722</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5c7dce37-3e7a-4a41-8c33-28a46887929a" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:13.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">7. Property and Equipment, net</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e216fc72-da9d-424b-92f3-15e27df004cb" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:PropertyPlantAndEquipmentTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment, net consisted of the following (in thousands):</span></p><p style="text-indent:7.933%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:40.608%;"></td>
        <td style="width:1.47%;"></td>
        <td style="width:20.353%;"></td>
        <td style="width:1.47%;"></td>
        <td style="width:1.752%;"></td>
        <td style="width:14.459%;"></td>
        <td style="width:1.164%;"></td>
        <td style="width:1.47%;"></td>
        <td style="width:1.752%;"></td>
        <td style="width:14.336%;"></td>
        <td style="width:1.164%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As of December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Useful life (years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Laboratory equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_11a57c1e-4aeb-4e5e-ae3e-c72eeee2d94c" contextRef="C_eb6b17d5-2d48-4838-8382-90249e566d9f" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_400633ac-8eee-40e4-8ecf-3562b425dcb3" contextRef="C_fca8dc62-71f2-4995-91e8-1b030e192627" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,502</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a3e8aef4-7779-4ba2-a977-66ab0ada7d9d" contextRef="C_ecef1783-dbe7-4a31-ab16-82774cd71330" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,350</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_436abea9-58ce-4aaa-86b5-c0420be5fa43" contextRef="C_2bdce80c-0fa1-4c32-b7bb-48e057af1270" name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lesser of useful life<br />or lease term</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1a5f191c-14e4-46d7-85d0-3956cfa3d4fa" contextRef="C_e0e2612c-d563-4a7b-9f21-1a5002c22dc4" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,614</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5f7bc290-65a2-4caa-a182-2c7864abda80" contextRef="C_23640616-f433-4b74-849e-d9ad90a3ad0c" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,427</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furniture and fixtures</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_2d9364b5-6b29-40be-939d-5c490d2b69fa" contextRef="C_36729629-5671-4810-b3a0-0a65b96f4982" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_54dbe9ba-1f24-4994-9460-c98d4c263f2f" contextRef="C_c5ef6f51-8e27-49fd-b340-0ef1ea2559f1" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3">303</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7b143184-a5c9-4dff-8b8b-9c3e13101d82" contextRef="C_fddea6c4-817b-4e77-aea4-89981e10e5a9" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">524</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Construction in progress</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8f5cb10f-3046-470d-aa5f-4ae506356d52" contextRef="C_91668149-580c-41d2-a60a-c106cf15c4df" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,014</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ae09dcd4-4ce6-402c-a351-042baa5aea74" contextRef="C_3af201ab-f6bf-43f9-bbd9-545d3f60a016" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,090</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Computer equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_50cba4a6-86cf-4e1a-86ca-075abb84d2ee" contextRef="C_87ab7035-f594-4fe7-8bcf-c303cd53528e" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dbef3a66-1199-4de7-baca-d79cde03e977" contextRef="C_f42c98ab-830c-4e22-89f5-e18b91b6cd8e" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">216</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_01a5dc26-ea7b-4bbd-a610-a61ef8924dfa" contextRef="C_8ebb8127-795c-4f3e-930b-1793c330d85e" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">93</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Software</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_777620ac-f48e-49db-b1c2-5c86cc7c6189" contextRef="C_f0fe55b1-e361-4417-baab-c311c3746c48" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f36910f6-9463-4229-955d-53f58aa21470" contextRef="C_269b2bf6-80a4-4772-a84e-435846b50f75" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">320</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_10ffc444-beb0-4f14-bd3d-f3eb0faa2c56" contextRef="C_3b4615b0-36e3-4745-a8ee-bb680c1705d1" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">170</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">   </span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7ab46b37-4ced-4a03-9fa4-30c34fd1377a" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">20,969</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_15fbf4dd-81f4-4915-ac1e-18d259b64050" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="us-gaap:PropertyPlantAndEquipmentGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,654</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: Accumulated depreciation and<br />&#160;&#160;&#160;amortization</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c60d89c6-dc22-4694-ba75-fe8017b135ec" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,326</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ee72001a-593f-4b93-9082-6686337ce306" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,864</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_985b7d3a-886e-4df7-9a3f-9138f4dfd539" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">14,643</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_efb53457-feef-4632-8e52-dab3e4858ddc" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="us-gaap:PropertyPlantAndEquipmentNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,790</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:7.933%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Depreciation and amortization expense for each of the years ended December 31, 2021 and 2020 was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cfd47156-fb1b-4e53-8f5e-ed3ab77a1249" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d68568c7-8ca8-496b-963c-edb067c9797f" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:DepreciationAndAmortization" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively. All of the Company&#x2019;s property and equipment as of December 31, 2021 and 2020 is located in the U.S. Construction in progress has increased by $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f58b5316-7628-407f-8e84-a81a56295c82" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="acet:IncreaseInConstructionInProgress" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal"><ix:nonFraction id="F_f945639d-33f6-4996-bbf3-3773dfb781b1" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="acet:IncreaseInConstructionInProgress" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">11.9</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million due to building construction related to the Company's leased space in Redwood City. Construction in process will continue to increase through the first half of 2022, until completion of construction.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6467f8c9-3d2d-4cbc-bb73-ca0f3640ca20" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">8. Accrued and Other Current Liabilities</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a90e5860-66bb-43a8-acab-b57d1e11719b" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued and other current liabilities consisted of the following (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:58.84%;"></td>
        <td style="width:2.508%;"></td>
        <td style="width:2.115%;"></td>
        <td style="width:17.974%;"></td>
        <td style="width:0.855%;"></td>
        <td style="width:2.508%;"></td>
        <td style="width:2.115%;"></td>
        <td style="width:12.23%;"></td>
        <td style="width:0.855%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fb891a66-0e72-46b6-9bcb-30db3c311c26" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,020</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1e37e36a-39f5-41dd-99b1-a5a90431c0ed" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,833</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued CMO costs</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_24ba304f-32a0-4d82-b0f6-e123a3b348e5" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="acet:AccruedCmoCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,077</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_de046ddc-ecba-420d-8aa7-809933146bc6" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="acet:AccruedCmoCosts" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">244</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued professional services</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b44dfb8f-e803-4352-857e-cd53f6445495" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">546</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_601d0612-7f2e-46aa-a6a4-3fac3164c341" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">363</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued research and development expenses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1a8dda04-cedc-44c4-b71c-8aeb9c9eead4" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="acet:AccruedResearchAndDevelopmentExpensesCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">504</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d02f492c-1843-47be-96eb-01f55bf018e6" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="acet:AccruedResearchAndDevelopmentExpensesCurrent" unitRef="U_USD" scale="3" decimals="-3">65</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued other liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c95bf824-0e61-4a2c-8d79-03111d6d0064" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3">503</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_358d70f7-60e8-4e4c-ad70-99a36e2482b8" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="us-gaap:OtherAccruedLiabilitiesCurrent" unitRef="U_USD" scale="3" decimals="-3">272</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued CRO costs</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ef0a63c8-93c7-41d6-ab3e-24d732a828bb" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="acet:AccruedCroCosts" unitRef="U_USD" scale="3" decimals="-3">32</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9a12602b-4712-42a2-9dd7-8b9a1c42cd28" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="acet:AccruedCroCosts" unitRef="U_USD" scale="3" decimals="-3">955</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_58452be7-c3e4-48af-9fb7-e9be3126ced6" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,682</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_65afd712-04e9-4ae7-a248-c8d705d8bc2a" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="us-gaap:AccruedLiabilitiesAndOtherLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,732</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_57e5d776-7c4e-4c26-b742-f3994237bb86" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:DebtDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">9. Term Loan</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On April 28, 2020, the Company entered into a Loan and Security Agreement with Pacific Western Bank (PacWest) for a term loan not exceeding $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3bc86f68-d68e-45e1-889f-64240cf58505" contextRef="C_bdaaafd2-c90a-4125-9ca9-c8ea735b0f55" name="acet:TermLoanToFinanceLeaseholdImprovements1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">12.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(the Loan Agreement) to finance leasehold improvements for the facilities in Redwood</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Adicet Bio, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">City, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">CA and other purposes permitted under the Loan Agreement, with an interest rate equal to the greater of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_00901850-3e74-466a-9530-19e3e5f2eb91" contextRef="C_b33e9899-16fc-42cc-96d1-97d706c7101b" name="us-gaap:LoansReceivableBasisSpreadOnVariableRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">0.25</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% above the Prime Rate (as defined in the Loan Agreement) or </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_885f92b4-40db-46c8-b26f-c5f92ee429bf" contextRef="C_57a750f3-8a24-41e7-9a82-33461f5929df" name="us-gaap:LoansReceivableBasisSpreadOnVariableRate" unitRef="U_pure" scale="-2" decimals="4" format="ixt:numdotdecimal">5.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%.  The Loan Agreement granted to Pacific Western Bank a security interest on substantially all of the Company&#x2019;s assets other than intellectual property to secure the performance of the Company&#x2019;s obligations under the Loan Agreement, and contains a variety of affirmative and negative covenants, including required financial reporting, limitations on certain dispositions of assets or distributions, limitations on the incurrence of additional debt or liens and other customary requirements. As of December 31, 2021, the Company was in compliance with such covenants.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the Loan Agreement in April 2020, the Company may request to draw upon the term loan at any time through the date eighteen months after the date of the Loan Agreement (Availability End Date), which was </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0fe58d25-9983-42b7-9cb8-a517674b3961" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:DebtInstrumentMaturityDateRangeEnd1" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">October 28, 2021</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. No amounts were drawn under the Loan Agreement through the Availability End Date.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On October 21, 2021, the Company amended the Loan Agreement with PacWest (the Loan Amendment) under which PacWest will provide one or more Term Loans, as well as Non-Formula Ancillary Services which shall not exceed $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_19a4fb10-4f9f-4889-9bb1-1de52073a733" contextRef="C_edc51531-f059-4811-b4b9-e22729a4e46c" name="acet:LoanAmountDrawn" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">5.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in the aggregate. Non-Formula Ancillary Services are defined as automated clearinghouse transactions, corporate credit card services, letters of credit, or other treasury management services. The aggregate sum of the outstanding Term Loans and Non-Formula Ancillary Services shall at no time exceed $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4a37913f-51c9-417a-88c4-991cbd786b39" contextRef="C_edc51531-f059-4811-b4b9-e22729a4e46c" name="acet:TermLoanAndNonFormulaAncillaryService" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">15.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_71bebc53-02a6-4bd0-a12d-571785019fe3" contextRef="C_99983e52-f2a5-42a0-b031-14f6461609ac" name="us-gaap:LongTermDebtDescription"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">which each Term Loan to be in an amount of not less than $1.0 million. As of December 31, 2021, the Company had outstanding Non-Formula Ancillary Services of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7c2ae940-11d9-4b45-a079-1bec5f7aae4e" contextRef="C_61d94a43-5646-47f3-b305-92ab60efd0b9" name="us-gaap:LoansPayable" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">4.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. Accordingly, as of December 31, 2021, the Company has $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d1e45293-2730-484a-9b92-1345b3531e89" contextRef="C_61d94a43-5646-47f3-b305-92ab60efd0b9" name="us-gaap:DebtInstrumentFaceAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">10.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million available under the Term Loan. Pursuant to the Loan Amendment, the interest rate for the Term Loans shall be set at an annual rate equal to the greater of (i) 0.25% above the Prime Rate then in effect and (ii) 4.25%.</span></ix:nonNumeric></span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, the deferred debt issuance costs were $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3f12bd19-d998-4b07-a6f3-bd6005b6e590" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:DeferredFinanceCostsGross" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and are included in other non-current assets on the Company&#x2019;s consolidated balance sheets.</span></p></ix:nonNumeric></div>
  <div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a1b79e15-0f07-475a-85ce-bf630203a336" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">10. Regeneron License and Collaboration Arrangement</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Agreement Terms</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On July 29, 2016, the Company entered into a license and collaboration agreement with Regeneron, which was amended in April 2019, with such amendment becoming effective in connection with Regeneron&#x2019;s investment in the Company&#x2019;s Series B redeemable convertible preferred stock private placement transaction in July 2019 (as amended, the Regeneron Agreement).</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Agreement Structure</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Regeneron Agreement has two principal components: (a) a research collaboration component under which the parties will research, develop, and commercialize next-generation engineered gamma delta immune cell therapeutics (ICPs), namely engineered gamma delta immune cells with CARs and TCRs directed to disease-specific cell surface antigens, which includes the grant of certain licenses to intellectual property between the two parties, and (b) for a certain period following the effective date, a license to the Company to use certain of Regeneron&#x2019;s proprietary mice to develop and commercialize ICPs generated by the Company, with certain limitations relating to targets under the Regeneron Agreement.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research Collaboration</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Research activities under the collaboration are governed by research plans, which include the strategy, goals, activities, and responsibilities of the parties with respect to a target. The Company is primarily responsible for generating, validating, and optimizing ICPs, developing processes for manufacture of ICPs, and certain preclinical and clinical manufacturing activities for ICPs; Regeneron&#x2019;s key responsibility is generating, validating, and optimizing CARs and TCRs that bind to the applicable target. The parties have formed a joint research committee to monitor and govern the research and development efforts during the research program term.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Rights to Research Targets</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Under the terms of the collaboration, the parties will conduct research on mutually agreed upon targets. Regeneron may obtain exclusive rights for the targets that it chooses in accordance with the target selection mechanism set forth in the Regeneron Agreement, and the Company similarly may obtain exclusive rights for targets it chooses in accordance with such target selection mechanism. The Company has the right to develop and commercialize ICPs to the first collaboration target to come out of the research program. On January 28, 2022, the Company received a payment of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_19b8c498-e7cf-43b0-869e-12b7ace84dfa" contextRef="C_4e6c9fea-07ee-4070-8aba-8ca1ddff8ad6" name="us-gaap:ProceedsFromStockOptionsExercised" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">20.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million from Regeneron for exercise of its option to license exclusive rights to ADI-002 and Regeneron potentially has additional options to other ICP targets under the Regeneron Agreement. Pursuant to the Agreement with Regeneron, the Company had the right to elect to co-fund ADI-002's future development costs. The Company did not elect its option. For those targets it does not have an option to license, Regeneron has a right of first negotiation for up to two targets. Regeneron has the right to terminate the research program in its entirety (a) for convenience on six months prior written notice given at any time after December 31, 2019, or (b) following a change of control (as defined in the Regeneron Agreement) of the Company. The parties mutually agreed to their first product declaration criteria for collaboration ICP, CD20, in 2018.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Rights to Company-Developed Targets</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Regeneron has an exclusive license to use targeting moieties generated by the Company by its use of Regeneron&#x2019;s proprietary mice to develop and commercialize non-ICPs.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Adicet Bio, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Exclusivity</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. During the five-year target selection period that expired in July 2021, the Company may not directly or indirectly research, develop, manufacture or commercialize an ICP, or grant a license to do the foregoing, except pursuant to the agreement. For so long as either party is researching or developing an ICP to a target under the research program, neither party may research, develop, manufacture or commercialize any other ICP to such target, or grant a license to do the foregoing. And for so long as a party is researching, developing or commercializing an ICP to target that is licensed to it (and royalty bearing) under the agreement, neither party may research, develop, manufacture or commercialize any other ICP to such target, or grant a license to permit another party to do the foregoing. These exclusivity obligations are limited to engineered gamma delta immune cells to targets reasonably considered to have therapeutic relevance in oncology. The Regeneron Agreement includes certain exceptions to the exclusivity obligations of the parties, including with respect to targets that are rejected by one party in the target selection process, as well as protections in the event of a change of control of a party where the acquirer has a competing program.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Co-Funding and Profit Sharing</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Company has an option to co-fund specified portions of the future development costs for, and to co-promote, ICPs to a target for which Regeneron has exercised an option, and to participate in the profits for such target. The Company has the right to exercise this right in various geographic regions, including on a worldwide basis. In the event the Company exercises such right, the parties will share further development costs and profits proportionally to their co-funding percentages.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Financial Terms</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Company received a non-refundable upfront payment of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2cfff9f2-2f5e-478e-9b49-3068847d5804" contextRef="C_ae89cac7-0fec-4757-8ed0-2429d1ad7ac5" name="acet:NonRefundableUpfrontPaymentReceived" unitRef="U_USD" scale="6" decimals="-5">25.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million from Regeneron upon execution of the Regeneron Agreement and has received an aggregate of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dde2a3fa-b854-4e12-b3a3-812ffdf31294" contextRef="C_ae89cac7-0fec-4757-8ed0-2429d1ad7ac5" name="acet:LicenseAgreementAdditionalPaymentForResearchFundingReceived" unitRef="U_USD" scale="6" decimals="-5">20.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of additional payments for research funding from Regeneron as of December 31, 2021. In addition, Regeneron may have to pay the Company additional amounts in the future consisting of up to an aggregate of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e68f840e-cee4-4fce-8edb-8fd5b1503ecb" contextRef="C_bc8e068c-61df-4e55-851e-10fa3cd91cf7" name="acet:LicenceAgreementAdditionalAmountPayableOfOptionExerciseFees" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">80.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of option exercise fees for a certain number of collaboration ICPs, as specified in the Regeneron Agreement. Regeneron must also pay the Company high single digit royalties as a percentage of net sales for ICPs to targets for which it has exclusive rights, and low single digit royalties as a percentage of net sales on any non-ICP product comprising a targeting moiety generated by the Company through the use of Regeneron&#x2019;s proprietary mice. The Company must pay Regeneron mid-single to low double digit, but less than teens, of royalties as a percentage of net sales of ICPs to targets for which the Company has exercised exclusive rights, and low to mid-single digit of royalties as a percentage of net sales of targeting moieties generated from the Company&#x2019;s license to use Regeneron&#x2019;s proprietary mice. Royalties are payable until the longer of the expiration or invalidity of the licensed patent rights or </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8a8cf18a-1bcb-4809-a8a8-1999eb6cb0d4" contextRef="C_d85d1bbc-33b7-4189-abac-0387bd90ab52" name="acet:LicenseAgreementTerminationDescription"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">twelve (12) years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> from first commercial sale.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Other Terms</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Regeneron Agreement contains customary representations, warranties and covenants by the Company and Regeneron and includes (i) an obligation of the Company to use commercially reasonable efforts to develop and commercialize at least one product based on a collaboration ICP that is not an optioned collaboration ICP for each collaboration target and (ii) an obligation of Regeneron to use commercially reasonable efforts to develop and commercialize at least one product based on an optioned collaboration ICP for each collaboration target. The Company and Regeneron are required to indemnify the other party against all losses and expenses related to breaches of its representations, warranties and covenants under the Regeneron Agreement.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Term and Termination</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The term of the Regeneron Agreement expires, on a product-by-product basis, on the expiration of the obligation to pay royalties for such product. The Regeneron Agreement is subject to early termination by either party upon uncured material breach by the other party. The licenses to develop and commercialize an ICP to a target that one party has exclusively licensed may be terminated by such party for convenience.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Equity Investments</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. In connection with its collaboration, Regeneron and the Company entered into a side letter pursuant to which, among other matters, Regeneron was granted certain stockholder rights and investment rights in connection with the Company&#x2019;s next equity financing that met certain criteria and in connection with an initial public offering by the Company. Regeneron exercised its investment right and purchased approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_46e9de16-64e8-46c9-bc5b-8de792734606" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="acet:ExercisedInvestmentRightAndPurchased" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">10.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of the Company&#x2019;s Series B redeemable convertible preferred stock in a private placement transaction in July 2019. The remaining obligations under the side letter agreement terminated immediately prior to the Effective Time of the Merger.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Revenue Recognition</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company identified the following material promises under the Regeneron Agreement: (1) a research license, (2) a collaboration invention license, (3) a trademark license, (4) research and development services during the research term, (5) manufacturing services to manufacture collaboration ICPs for the research programs, (6) participation in the joint research committee, and (7) information sharing during the research term. The Company considered that the licenses granted under the Regeneron Agreement are not capable of being distinct and are not distinct from the research and development and manufacturing services within the context of the Regeneron Agreement, because 1) such licenses are for the research and development effort during the research term, unless Regeneron exercises its option under the Regeneron Agreement, 2) the research and development services significantly increase the utility of such licenses, and 3) research and development services require collaboration ICPs being manufactured. Specifically, the Company&#x2019;s granted licenses can only provide benefit to Regeneron in combination with the Company&#x2019;s research and development and manufacturing services to discover the collaboration ICPs. Similarly, the participation in the joint research committee and information sharing are not capable of being distinct and are not distinct from</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Adicet Bio, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the research and development and manufacturing services within the context of the agreement, because the participation in the joint research committee is for monitoring and governing of the research and development efforts and the information sharing is for sharing results of such research and development efforts. Therefore, all of the promises above are combined into a single performance obligation.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company also evaluated whether the option provided to Regeneron represents a material right that would require separate deferral and recognition. The option exercise will provide Regeneron with a development and commercial license to develop and commercialize the optioned collaboration ICPs. The Company concluded that the $25.0 million upfront payment to the Company was not negotiated to provide incremental discount for the future option fees payable upon Regeneron&#x2019;s exercise of the option.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Regeneron could decide not to exercise the option at its own discretion. The exercise of the option by Regeneron is not certain and is dependent on many factors, such as progress made on the specific option-eligible collaboration ICP, Regeneron&#x2019;s overall assessment of commercial feasibility of the further research, development and commercialization of the Option products, availability and cost of alternative programs and products. The option provides Regeneron with a license for intellectual property that will be improved from the inception of the Regeneron Agreement. In addition, the option fee is significant compared to the sum total of the upfront payment and research funding fees in the original Regeneron Agreement. Therefore, the Company determined that the option provided to Regeneron does not represent a material right and that any potential exercise of the option should be accounted as a separate contract. Hence, upon the option exercise by Regeneron the option fee would be allocated to the development and commercial license which would be the only performance obligation in that separate contract and recognized as revenue when control of the license rights is transferred to Regeneron.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For revenue recognition purposes, the Company determined that the duration of the contract is the same as the research term of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_aba04bce-dc29-4d22-926b-5f96946dea2a" contextRef="C_7d366b41-4178-4cf0-85c2-805e8d8b6c0a" name="acet:ContractResearchTermPeriod" format="ixt-sec:durwordsen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">five years</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> beginning on the execution of the Regeneron Agreement on July 29, 2016. The contract duration is defined as the period during which parties to the contract have present and enforceable rights and obligations. For revenue recognition purposes, the five-year term has been extended to the first quarter of 2022 due to additional time required to complete the performance obligation under the Regeneron Agreement. The Company determined that Regeneron faces significant in-substance penalties were it to terminate the Regeneron Agreement prior to the end of the research term.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">At contract inception, the Company determined the transaction price of the Regeneron Agreement to be $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_180adde0-f7cb-413c-87d8-ffb93e084ca7" contextRef="C_7d366b41-4178-4cf0-85c2-805e8d8b6c0a" name="acet:AgreementTransactionPrice" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">55.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, consisting of the $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_142dfea5-f8b1-4b34-aac8-87ec5acc8d6d" contextRef="C_7d366b41-4178-4cf0-85c2-805e8d8b6c0a" name="acet:LicenceAgreementUpfrontPayment" unitRef="U_USD" scale="6" decimals="-5">25.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million upfront payment and the aggregate research funding fees of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c264b4ea-f21a-4efe-b04b-4bff4a688c6f" contextRef="C_7d366b41-4178-4cf0-85c2-805e8d8b6c0a" name="acet:LicenseAgreementAdditionalPaymentForResearchFundingReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">30.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million payable over the research term. In order to determine the transaction price, the Company evaluated all the payments to be received during the duration of the contract. Per the terms of the original Regeneron Agreement prior to the amendment effective from July 2019, the research funding fees of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d86d87c2-d85d-47bf-bfad-abbe1824c1bc" contextRef="C_7d366b41-4178-4cf0-85c2-805e8d8b6c0a" name="acet:ResearchFundingFee" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">30.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million were payable merely due to the passage of time and therefore did not represent a variable consideration. After the amendment became effective in July 2019, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d93d306c-f34a-4a86-a5bd-9ddc8d08e644" contextRef="C_7d366b41-4178-4cf0-85c2-805e8d8b6c0a" name="acet:ContingentConsiderationFees" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">20.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of these fees became contingent upon meeting certain development and regulatory milestones. Therefore, the Company concluded that after the amendment such potential payments became variable consideration. The receipt of the variable consideration was subject to substantial uncertainty and was therefore excluded from the transaction price upon the effective date of the amendment. Accordingly, the transaction price was reduced to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_18c900d4-c08a-47e1-a0ed-9485bb3d1cca" contextRef="C_edd4abe0-f9c0-4ed5-ad3b-408b1b6e6b9e" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">35.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in July 2019. The Company re-evaluates the transaction price if there is a significant change in facts and circumstances at least at the end of each reporting period. The Company increased the transaction price by $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_701ac29a-be2e-41a3-8a88-39f89536f66d" contextRef="C_b758350f-0170-4fae-8ec9-d587850903ab" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" unitRef="U_USD" scale="6" decimals="-5">10.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in June 2020 to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_817c4c91-bd3e-4873-9a77-b919d3aba515" contextRef="C_8968c75b-77f9-4e93-84f0-e12dc0959c9f" name="us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" unitRef="U_USD" scale="3" decimals="-2" format="ixt:numdotdecimal">45.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million when it achieved the milestone for the selection of a clinical candidate to the second collaboration target under the Regeneron Agreement, resulting in the recognition of an additional $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4754997f-ea18-48d3-886a-e3447fff6d96" contextRef="C_b758350f-0170-4fae-8ec9-d587850903ab" name="acet:LicenceAgreementAdditionalRevenueRecognised" unitRef="U_USD" scale="6" decimals="-5">5.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in revenue during the three months ended June 30, 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company also considered the existence of any significant financing component within the Regeneron Agreement given its upfront payment structure. Based upon this assessment, the Company concluded that the up-front payment was provided for valid business reasons and not for the purpose of providing financing. The reason for the initial advance payment at the beginning of the contract is not to provide financing to the Company, but to ensure Regeneron&#x2019;s commitment to the contract and to provide assurance that the customer will perform its obligations under the contract. Accordingly, the Company has concluded that the upfront payment structure of the Regeneron Agreement does not result in the existence of a significant financing component.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The royalty payments will be recognized when the related sales occur as they were determined to relate predominantly to the intellectual property licenses granted to Regeneron and therefore have also been excluded from the transaction price.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has determined that the combined performance obligation is satisfied over time. ASC 606 requires the Company to select a single revenue recognition method for the performance obligation that depicts the Company&#x2019;s performance in transferring control of the services. Accordingly, the Company utilizes a cost-based input method to measure proportional performance and to calculate the corresponding amount of revenue to recognize. The Company believes this is the best measure of progress because it reflects how the Company transfers its performance obligation to Regeneron. In applying the cost-based input method of revenue recognition, the Company uses actual costs incurred relative to budgeted costs to fulfill the combined performance obligation. These costs consist primarily of internal full-time equivalent effort and third-party contract costs. Revenue is recognized based on actual costs incurred as a percentage of total budgeted costs as the Company completes its</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Adicet Bio, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">performance obligations over the research term of five years. A cost-based input method of revenue recognition requires management to make estimates of costs to complete the Company&#x2019;s performance obligations. In making such estimates, significant judgment is required to evaluate assumptions related to cost estimates. The cumulative effect of revisions to estimated costs to complete the Company&#x2019;s performance obligations will be recorded in the period in which changes are identified and amounts can be reasonably estimated. A significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods.</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6fe7e88c-d271-4e8a-ad84-a78688c8b09c" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table presents changes in the Company&#x2019;s contract liabilities (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:47.822%;"></td>
        <td style="width:1.089%;"></td>
        <td style="width:1.492%;"></td>
        <td style="width:9.475%;"></td>
        <td style="width:0.882%;"></td>
        <td style="width:1.089%;"></td>
        <td style="width:1.492%;"></td>
        <td style="width:9.464%;"></td>
        <td style="width:0.882%;"></td>
        <td style="width:1.089%;"></td>
        <td style="width:1.525%;"></td>
        <td style="width:9.802%;"></td>
        <td style="width:0.991%;"></td>
        <td style="width:1.089%;"></td>
        <td style="width:1.492%;"></td>
        <td style="width:9.431%;"></td>
        <td style="width:0.893%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year ended December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Balance at beginning <br />of period</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Additions</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Additions (Deductions) </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;font-family:Times New Roman;position:relative;">(1)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Balance at<br />end of <br />period</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Contract liability</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_29d238c3-7114-44e9-ba1b-fb1de9962295" contextRef="C_1fdee497-9bd9-4434-b8dd-50a2c01519cd" name="acet:ContractAssetsAndLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,980</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_da621f8f-6c57-4c71-8a9a-8583e90b6133" contextRef="C_68012e05-ebbc-4f75-b9ec-4a4dfe9d312a" name="acet:ContractAssetsAndLiabilitiesAdditionsDeductions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">9,175</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7d324ae8-14e2-4dca-be22-c1cf4fe2fe36" contextRef="C_de3e4a83-2efd-4bdb-9ed1-e22b3ab57037" name="acet:ContractAssetsAndLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,805</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">    </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year ended December 31, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Balance at beginning <br />of period</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Additions</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Additions (Deductions) </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;font-family:Times New Roman;position:relative;">(1)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Balance at<br />end of <br />period</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Contract asset</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0e35c73d-ca28-4050-ab28-7b94075d0ba0" contextRef="C_3ca7e266-0fdc-4e92-9c8c-d4aea36592ef" name="acet:ContractAssetsAndLiabilitiesAdditions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_37a62b6e-7f72-4455-bb60-c81a41a19eec" contextRef="C_3ca7e266-0fdc-4e92-9c8c-d4aea36592ef" name="acet:ContractAssetsAndLiabilitiesAdditionsDeductions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Contract liability</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fe2c0d24-a3ad-4b4d-a3be-617ae4b392dc" contextRef="C_41ca3bfc-5bca-4c8e-8757-b6a526d155a4" name="acet:ContractAssetsAndLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">21,883</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_73971250-35cf-4da0-95f3-a2bdeace9412" contextRef="C_eae66964-012d-43ad-a3b1-27bc081b6037" name="acet:ContractAssetsAndLiabilitiesAdditions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,000</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c8d12e80-3ad7-488e-a4d6-720e653a110e" contextRef="C_eae66964-012d-43ad-a3b1-27bc081b6037" name="acet:ContractAssetsAndLiabilitiesAdditionsDeductions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">17,903</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c80a115f-5c99-43aa-81e5-faef3fa3df6f" contextRef="C_1fdee497-9bd9-4434-b8dd-50a2c01519cd" name="acet:ContractAssetsAndLiabilities" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,980</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><ix:footnote id="FNT_9de3ffc8-0280-4d4d-8e75-e7b828a8e6e2" xml:lang="en-US"><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:6.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(1)	Deductions to contract liabilities relate to deferred revenue recognized as revenue during the reporting period.</span></p></ix:footnote></ix:nonNumeric></div><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, contract liabilities related to the Regeneron Agreement of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_109d3cb5-c1c2-44b1-a852-a63cbea69279" contextRef="C_d85d1bbc-33b7-4189-abac-0387bd90ab52" name="acet:ContractLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">4.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million was comprised of the $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9fe87a2f-08fd-4188-9626-a6261b523b2c" contextRef="C_d85d1bbc-33b7-4189-abac-0387bd90ab52" name="acet:LicenceAgreementUpfrontPayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">25.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million upfront payment, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dcd29d9d-b81a-4864-841b-4c4cc39f5ba2" contextRef="C_ead71044-8531-48be-a61d-d7cd5c9f9352" name="acet:LicenseAgreementAdditionalPaymentForResearchFundingReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal"><ix:nonFraction id="F_bf5bddf5-de1e-49e9-a496-f78b676a1ecb" contextRef="C_6bc5ff1d-cdce-445a-9774-b450949c38dc" name="acet:LicenseAgreementAdditionalPaymentForResearchFundingReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">10.0</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in total research funding fees for fiscal years 2017 and 2018, and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_34dd2e68-c012-487e-ba04-b848ce935b2b" contextRef="C_29c03a6c-7260-483a-ab00-555f1e331404" name="acet:LicenceAgreementCumulativeRevenueRecognised" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">10.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for achievement of the milestone for the selection of a clinical candidate for the second collaboration target in June 2020, less $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b237f562-3889-4999-b2b4-f87397eb216a" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="acet:LicenceAgreementCumulativeRevenueRecognised" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">40.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of cumulative license and collaboration revenue recognized from the inception of the Regeneron Agreement as of December 31, 2021 and will be recognized as the combined performance obligation is satisfied.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2020, contract liabilities related to the Regeneron Agreement of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a3b7101e-7edb-445c-8681-cf882a62a06e" contextRef="C_a9b28221-7291-479e-aade-1c4cce9e9ee2" name="acet:ContractLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">14.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million was comprised of the $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fba2cd8a-2a84-4b2e-a4ef-69db4e9f464a" contextRef="C_a9b28221-7291-479e-aade-1c4cce9e9ee2" name="acet:LicenceAgreementUpfrontPayment" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">25.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million upfront payment, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a547e9c7-478b-4ddc-9506-19c677f57d56" contextRef="C_ead71044-8531-48be-a61d-d7cd5c9f9352" name="acet:LicenseAgreementAdditionalPaymentForResearchFundingReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal"><ix:nonFraction id="F_8c7b69d8-eda9-480d-af1e-d5196b4ea220" contextRef="C_6bc5ff1d-cdce-445a-9774-b450949c38dc" name="acet:LicenseAgreementAdditionalPaymentForResearchFundingReceived" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">10.0</ix:nonFraction></ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in total research funding fees for fiscal years 2017 and 2018, and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_30a96b43-3b86-43f9-b27c-1aea724f6ebe" contextRef="C_29c03a6c-7260-483a-ab00-555f1e331404" name="acet:LicenceAgreementCumulativeRevenueRecognised" unitRef="U_USD" scale="6" decimals="-6" format="ixt:numdotdecimal">10</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for achievement of the milestone for the selection of a clinical candidate to the second collaboration target in June 2020, less $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7bcb20a0-53e0-44d7-97a6-97cbfd502d4b" contextRef="C_3f1fec59-9c84-4fb5-b910-7eb14b6ef44f" name="acet:LicenceAgreementCumulativeRevenueRecognised" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">31.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of cumulative license and collaboration revenue recognized from the inception of the Regeneron Agreement as of December 31, 2020.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For the years ended December 31, 2021 and 2020, the Company recognized $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0c7b949d-6a62-4b14-9fe4-ac2e04bc8051" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="acet:LicenseAndCollaborationRevenue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">9.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e6cb4d59-bee4-4768-9d44-f8aaae2eaffa" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="acet:LicenseAndCollaborationRevenue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">17.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of license and collaboration revenue, respectively, from amounts included in the contract liability balances at the beginning of the period. There were no costs to obtain or fulfill the contract that meet the criteria to be capitalized.</span></p></ix:nonNumeric></div>
  <div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e21159c8-4fdb-4eae-98b8-8442ce748c3b" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="acet:LicenseFundingAndOtherAgreementsTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">11. License, Funding and Other Agreements Related to the CVR</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Contingent Value Rights Agreement</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As discussed in Note 3, in connection with the Merger, the Company entered into the CVR Agreement with Computershare Inc. and Computershare Trust Company, N.A. as joint rights agent. The CVR holders are entitled to receive net proceeds from the commercialization, if any, received from a third-party commercial partner of RTB101 for a COVID-19 related indication. The total fees and expenses of the Company&#x2019;s clinical trials for a COVID-19 related indication of RTB101 is limited to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_75a0d90f-d98a-4a73-86b4-5cbf7e1add98" contextRef="C_316edeb3-e98f-436c-970f-b13de1ce7e93" name="acet:FeesAndExpenseIncurredInConnectionWithClinicalTrials" unitRef="U_USD" scale="6" decimals="-5">3.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million under the CVR Agreement. Through October 31, 2020, the Company&#x2019;s total accumulated spend was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7a2497b5-c7fe-41b1-a700-97ec7523f656" contextRef="C_d9bc8440-92d6-4375-83a6-16f30d5e1156" name="acet:FeesAndExpenseIncurredInConnectionWithClinicalTrials" unitRef="U_USD" scale="6" decimals="-5">1.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of expenses. In November 2020, management terminated the nursing home study due to slow enrollment and as a consequence lowered the probability of finding a partner due to the delay in time to commercialization of RTB101.</span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d94c5ba1-5d99-4915-95a5-d2749ffd97d9" contextRef="C_baae0ca2-627c-4fcf-80d3-97c07794901d" name="acet:PostExposureProphylaxisDescription"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> In February 2021, management terminated the National Institute on Aging study of RTB101 for COVID-19 post-exposure prophylaxis in adults age 65 years and older due to poor enrollment</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. In March 2021, management estimated that the probability of finding a partner should be further reduced. As a result, the fair value of the CVR liability was decreased by $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_acff99c1-adde-4c71-822c-ddd57fadd1f5" contextRef="C_4e9b72dd-9a34-4bc0-8d92-21bc3dbb099f" name="acet:IncreaseDecreaseInEstimatedFairValueOfCvrLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e56cd58b-e823-460d-b431-34cb393c10b0" contextRef="C_3606b322-7fbf-4372-8ef9-9fed27772088" name="acet:EstimatedFairValueOfCVRLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. In June 2021, the Company determined the possibility of any commercialization events for RTB101 was close to zero (see Note 3). As a result, the fair value of the CVR liability was adjusted to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c365daf8-7e57-4167-8e34-2a28f0769c7b" contextRef="C_ab4803e6-aff5-4742-8d52-34995d4eb9b3" name="acet:EstimatedFairValueOfCVRLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">zero</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On October 27, 2021, the Company provided a Termination Notice under the CVR Agreement to the joint rights agent to terminate its obligations under the CVR Agreement, effective immediately.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Novartis License Agreement</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On March 23, 2017, resTORbio entered into an exclusive license agreement with Novartis International Pharmaceutical Ltd. (Novartis). Under the agreement, Novartis granted resTORbio an exclusive, field-restricted, worldwide license, to certain</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Adicet Bio, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">intellectual property rights owned or controlled by Novartis, to develop, commercialize and sell one or more therapeutic products comprising RTB101 or RTB101 in combination with everolimus in a fixed dose combination. The exclusive field under the license agreement is for the treatment, prevention and diagnosis of disease and other conditions in all indications in humans and animals.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b3e98ac4-7036-4199-9e9f-8860b2266b95" contextRef="C_9c4e6975-00c5-410c-91ea-8f78158b9eb4" name="acet:LicenseAgreementTerminationDescription"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The agreement may be terminated by either party upon a material breach of obligation by the other party that is not cured with 60 days after written notice. resTORbio may terminate the agreement in its entirety or on a product-by-product or country-by-country basis with or without cause with 60 days&#x2019; prior written notice.</span></ix:nonNumeric></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As consideration for the license, resTORbio is required to pay up to an aggregate of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bdd325f1-a57b-4dd5-a426-f75026b5bed6" contextRef="C_61d717f8-651c-4c2c-bbdf-85e091817288" name="acet:LicenseAgreementMilestonePaymentsUponSatisfactionOfClinicalMilestonesPayable" unitRef="U_USD" scale="6" decimals="-5">4.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million upon the satisfaction of clinical milestones, up to an aggregate of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_43007918-e776-4e28-85f3-392f274fa501" contextRef="C_61d717f8-651c-4c2c-bbdf-85e091817288" name="acet:LicenseAgreementMilestonePaymentsUponSatisfactionOfRegulatoryMilestonesPayableForFirstIndicationApproved" unitRef="U_USD" scale="6" decimals="-6">24</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million upon the satisfaction of regulatory milestones for the first indication approved, and up to an aggregate of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_241b1afe-42a0-4e85-9213-4564460a9542" contextRef="C_61d717f8-651c-4c2c-bbdf-85e091817288" name="acet:LicenseAgreementMilestonePaymentsUponSatisfactionOfRegulatoryMilestonesPayableForSecondIndicationApproved" unitRef="U_USD" scale="6" decimals="-6">18</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million upon the satisfaction of regulatory milestones for the second indication approved. In addition, resTORbio is required to pay up to an aggregate of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f7beff7f-3405-413f-814e-3480c80be908" contextRef="C_61d717f8-651c-4c2c-bbdf-85e091817288" name="acet:LicenseAgreementMilestonePaymentsUponSatisfactionOfCommercialMilestonesPayable" unitRef="U_USD" scale="6" decimals="-6">125</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million upon the satisfaction of commercial milestones, based on the amount of annual net sales. resTORbio is also required to pay tiered royalties ranging from a mid-single digit percentage to a low-teen digit percentage on annual net sales of products. These royalty obligations last on a product-by-product and country-by-country basis until the latest of (i) the expiration of the last valid claim of a Novartis patent covering a subject product, (ii) the expiration of any regulatory exclusivity for the subject product in a country, or (iii) the 10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">th</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> anniversary of the first commercial sale in the country, and are subject to a reduction after the expiration of the last valid claim of a Novartis patent or the introduction of a generic equivalent of a product in a country.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On July 27, 2021, the Company sent Novartis a termination notice. Termination automatically took effect on September 25, 2021, 60 days from the date of delivery of the termination notice to Novartis, without further notice of action required of either Novartis or the Company.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">National Institute of Health</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In May 2019, resTORbio was awarded a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ce09697e-fc17-4e25-b8fe-362b3cddee1d" contextRef="C_f2283cea-c435-437b-958f-019a9a629ca9" name="acet:GrantTerm" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-year grant for up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4beed18f-8934-46f1-84d7-f7981a73ea20" contextRef="C_c1e72a0b-a7f8-4f4b-bd56-9c13a9000d2b" name="us-gaap:GrantsReceivable" unitRef="U_USD" scale="6" decimals="-5">1.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million from the NIH to study RTB101 and the regulation of antiviral immunity in the elderly. resTORbio is entitled to use the award solely to conduct the research and is solely responsible for commencing and conducting the research and will furnish periodic progress updates to the NIH throughout the term of the award. After completing the research, resTORbio must provide the NIH with a formal report describing the work performed and the results of the research.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For funds received under the NIH funding agreement, resTORbio recognizes a reduction in research and development expenses in an amount equal to the qualifying expenses incurred in each period up to the amount funded by the NIH. Qualifying expenses incurred by resTORbio in advance of funding by the NIH are recorded in the consolidated balance sheets as other current assets. For the year ended December 31, 2021, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e2c52228-2f4e-4187-9c8d-facf6e38c620" contextRef="C_ca657af2-2ffc-4ae2-b3b7-1641af2126e2" name="acet:QualifyingExpenses" unitRef="U_USD" scale="6" decimals="-5">0.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million qualifying expenses have been incurred and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ec9ba0a6-6c25-432f-a388-7ba3fdd7f95f" contextRef="C_634bf63d-c1b7-40ac-bfb2-44d198c085ab" name="acet:QualifyingExpenses" unitRef="U_USD" scale="6" decimals="-5">0.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million have been funded by the NIH. The difference in the amount incurred by the Company and funded by the NIH was due to timing of requesting reimbursements from the NIH. On a cumulative basis as of December 31, 2021, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f55c8dd0-ba99-4014-9fea-01e2814c74c6" contextRef="C_ca657af2-2ffc-4ae2-b3b7-1641af2126e2" name="acet:QualifyingExpensesOnCumulativeBasis" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million has been incurred and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_10df9f85-a281-4fb3-8112-8dec96d14400" contextRef="C_634bf63d-c1b7-40ac-bfb2-44d198c085ab" name="acet:QualifyingExpensesOnCumulativeBasis" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million has been funded by the NIH.</span></p></ix:nonNumeric></div>
  <div><ix:nonNumeric id="F_c4f024b9-3967-4030-8a3f-c1f6bb02e210" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">12. Commitments and Contingencies</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Operating Leases</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company leases office and laboratory space in Menlo Park, CA, Redwood City, CA, and Boston, MA. As of December 31, 2021, except as described below, there have been </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_310b480d-3345-4c28-a25a-df579df8572f" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="acet:IncreaseDecreaseInLeaseObligation" unitRef="U_USD" scale="3" decimals="INF" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> material changes in lease obligation from those disclosed in Note 12 to consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2020.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On June 25, 2021, </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d0de40a7-c57c-4a87-93f2-26bee2476d80" contextRef="C_fc8377ae-c923-40ee-9f57-b8fa6cd9e90b" name="acet:AmendedLeaseAgreementDescription"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the Company entered into an amendment to the Menlo Park lease to extend the term of the lease from March 31, 2022 to June 30, 2022 and replace the previously leased premises (known as 173 and 175-177 Jefferson Drive) with another nearby premises (known as 235 Constitution Drive).</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The lease commenced on </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_72df2bc1-ac90-42a7-84c6-ab5c0ba8d2cf" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="acet:OperatingLeasesCommencementDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">July 15, 2021</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and expires on </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_02744409-0fc4-49b3-96f3-1b958020d232" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:LeaseExpirationDate1" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">June 30, 2022</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. In connection with these changes, the Company will incur monthly rent payments ranging from $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_da7fe626-d78c-48b8-ab94-5528a14dcee5" contextRef="C_c10c6884-14c3-4600-ae9f-b3a86ebd71ef" name="us-gaap:LeaseAndRentalExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">87,286</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0c2b255f-7c87-487f-8970-3016a6c4eb39" contextRef="C_ce377847-1500-4676-9ec9-6e92cf9c03dd" name="us-gaap:LeaseAndRentalExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">89,904</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, increasing over the remaining term of the lease. Given the lease is short-term in nature, the Company is using the practical expedient for the lease and has not recorded a right of use asset or lease liability. Therefore, the Company will recognize rent expense on a straight-line basis over the lease term.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On July 19, 2021, the Company entered into a Sublease (the Sublease Agreement) with RFS OPCO LLC (Sublessee), whereby the Company agreed to sublease to Sublessee all of the </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9f76942e-4b84-46cf-bf5d-c36a930775ff" contextRef="C_d3f0bab3-8542-4755-967f-e529938079a8" name="acet:AreaOfSublease" unitRef="U_sqft" decimals="INF" format="ixt:numdotdecimal">9,501</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> rentable square feet of office space in Boston, MA, currently leased by the Company pursuant to the Company&#x2019;s lease with 500 Boylston &amp; 222 Berkeley Owner (DE) LLC, dated January 8, 2018, as amended (the Master Lease). </span><span style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d576b5a4-cf6b-42b1-b4dd-4b3bb81a160f" contextRef="C_23d1c211-5416-49b1-b67a-b83adbf5b18b" name="acet:SubleaseAgreementDescription" continuedAt="F_d576b5a4-cf6b-42b1-b4dd-4b3bb81a160f_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">term of the sublease started on September 1, 2021 and ends on July 30, </span></ix:nonNumeric></span><span style=""></span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">26</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Adicet Bio, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:continuation id="F_d576b5a4-cf6b-42b1-b4dd-4b3bb81a160f_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2026. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The aggregate base rent due to the Company under the Sublease is approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1592afb6-fe61-4f05-9951-42189534de67" contextRef="C_23d1c211-5416-49b1-b67a-b83adbf5b18b" name="us-gaap:OperatingLeasesRentExpenseSubleaseRentals1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million starting October 1, 2021. The Company records sublease income as a reduction of lease expense. </span></ix:continuation></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Upon execution of the Sublease Agreement, the Company received a cash security deposit of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c6774db9-1af1-42bf-9447-aa830c7412ce" contextRef="C_d3f0bab3-8542-4755-967f-e529938079a8" name="us-gaap:SecurityDepositLiability" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million from the Subleasee which is recorded as other non-current liabilities in the consolidated balance sheets. </span><span style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f6453709-3551-453a-91fb-d64ecf8a23f1" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="acet:ScheduleOfSubleaseIncomeTableTextBlock" escape="true" continuedAt="F_f6453709-3551-453a-91fb-d64ecf8a23f1_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The expected undiscounted cash flows to be received from the sublease as of December 31, 2021 is as follows (in thousands):</span></ix:nonNumeric></span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:continuation id="F_f6453709-3551-453a-91fb-d64ecf8a23f1_1"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:74.179%;"></td>
        <td style="width:2.254%;"></td>
        <td style="width:1.284%;"></td>
        <td style="width:21.646%;"></td>
        <td style="width:0.637%;"></td>
       </tr>
       <tr>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4ba6a085-9dd8-4d30-86a9-c35dc39b6147" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="acet:OperatingLeasesFutureMinimumSubleaseIncomeDueCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">657</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2023</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0233bd78-b371-40d9-9175-0ddb5eef3b6d" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="acet:OperatingLeasesFutureMinimumSubleaseIncomeDueInTwoYears" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">671</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2024</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ccb3cddd-6c7e-4ae4-a837-1a5644b552d6" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="acet:OperatingLeasesFutureMinimumSubleaseIncomeDueInThreeYears" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">685</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2025</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c2599745-b094-4404-8317-065f63154c2b" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="acet:OperatingLeasesFutureMinimumSubleaseIncomeDueInFourYears" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">699</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2026</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e50467d0-00a1-4a17-a2e2-4586820bbe07" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="acet:OperatingLeasesFutureMinimumSubleaseIncomeDueInFiveYears" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">416</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1704a651-42b5-485e-b490-3d4945f2e51d" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="acet:OperatingLeasesFutureMinimumSubleaseIncomeDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,128</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:continuation></div><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company recognized rent expense, net of sublease income, of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2c2ffb97-910a-4388-9364-d4600b1b18f4" contextRef="C_fd2a51f4-a4e0-4fd4-8b72-384f893e07dc" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">4.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b14f8e10-ca2a-4f4c-a05d-c840887192b7" contextRef="C_788e17f6-1175-45bd-816d-ca6c3191ac61" name="us-gaap:OperatingLeasePayments" unitRef="U_USD" scale="6" decimals="-5">0.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the years ended December 31, 2021 and 2020, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_57b957d2-c610-402e-bf1b-871fb4daf1a8" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="acet:ScheduleOfWeightedAverageIBRAndRemainingLeaseTermTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The IBR and the remaining lease terms of our facilities and their weighted average IBR and remaining terms are as follows as of December 31, 2021:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:40.659%;"></td>
        <td style="width:2.429%;"></td>
        <td style="width:27.242%;"></td>
        <td style="width:2.429%;"></td>
        <td style="width:27.242%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Lease Locations</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">IBR</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Remaining Terms<br />(in years)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Redwood City, CA</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_85a9c467-5a51-4bc3-9b89-476e095daee4" contextRef="C_cea994b1-c7e3-4048-aeb0-aab2a8ee080d" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="4">6.90</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_25ceb44b-0ed8-4ea6-a1e4-48e5451bf083" contextRef="C_cea994b1-c7e3-4048-aeb0-aab2a8ee080d" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.2</span></ix:nonNumeric></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Boston, MA</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f9e8e442-4306-4edd-be8f-2399027af5f9" contextRef="C_e39012be-aa0b-44c4-bc70-f388d0297447" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="4">9.30</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8bee48ff-060c-443a-9323-72898024ff0d" contextRef="C_e39012be-aa0b-44c4-bc70-f388d0297447" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.6</span></ix:nonNumeric></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Menlo Park, CA</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_75ac86c3-7df3-4fec-afb2-6b27fdc55f4a" contextRef="C_4a463e61-a719-45b8-b4f2-fb3e5d6433eb" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="4">6.80</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b89f66a6-95bc-4906-b432-39bddfe35fd1" contextRef="C_4a463e61-a719-45b8-b4f2-fb3e5d6433eb" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.5</span></ix:nonNumeric></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted Average</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e0576bac-be9f-4c28-8a81-840eb2404c2c" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" unitRef="U_pure" scale="-2" decimals="4">7.20</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a9bfc9e7-96ad-4276-8512-eae756b35f85" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.7</span></ix:nonNumeric></span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:11.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ffb45c7c-e446-488f-90af-48527c4a194f" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:LeaseCostTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table contains a summary of the lease costs recognized under ASC 842 and other information pertaining to the Company&#x2019;s operating leases for the years ended December 31, 2021 and 2020:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.395%;"></td>
        <td style="width:2.168%;"></td>
        <td style="width:1.503%;"></td>
        <td style="width:21.795%;"></td>
        <td style="width:0.991%;"></td>
        <td style="width:1.503%;"></td>
        <td style="width:21.958%;"></td>
        <td style="width:0.686%;"></td>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="5" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Lease Cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fae34b0a-2918-4401-b7b7-7792fb47f98f" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,282</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4d420338-db20-4cda-a801-24678519a2e3" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:OperatingLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">894</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Short-term lease cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f6adc545-fb90-4fb0-b178-850a7b13261f" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:ShortTermLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">235</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_96aee900-b9f2-418d-8f17-24067eef11ba" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:ShortTermLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">56</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Variable lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a1b011b5-1e2e-4432-b27e-132d3ca7375c" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_15422c2a-7574-4d88-baa0-e318ad6a11f8" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:VariableLeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Sublease Income</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ba4ae4fe-bd24-4447-9d05-74c95f5fdf72" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:SubleaseIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">223</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_a0789779-e166-43dd-bd77-089b6487a8c3;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bb58ae8d-d5c6-49c0-b3ba-e56c6a6ac340" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,294</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b7911849-2064-4683-ba86-7b68850532e1" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:LeaseCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">950</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Other Information</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating cash flows used for lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f06e02fd-4739-4588-99cb-a2686896bf18" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:OperatingLeasePaymentsUse" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">511</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9b942133-67a1-4423-b745-bd2edfc39c3e" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:OperatingLeasePaymentsUse" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">859</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease right of use asset obtained in exchange of operating lease liability</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_819eaa0a-0a31-4f5b-b68e-5e64ffc6ff53;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f06281c5-e92a-48ab-9495-ec1f576c66a5" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">22,367</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:nonNumeric></div><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, operating right-of-use assets were $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cba60e86-056f-4403-b911-f890a3636aa4" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:OperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="6" decimals="-5">20.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and operating lease liabilities were $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_573681d3-ecec-4f8c-93d7-e16b301d45f0" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="6" decimals="-5">20.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. The Company has no material finance leases.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_0c6d83b4-62b1-46ec-a998-2f1323fefd8d" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" escape="true" continuedAt="F_0c6d83b4-62b1-46ec-a998-2f1323fefd8d_1"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The maturities of the operating lease liabilities as of December 31, 2021 were as follows (in thousands):</span></ix:nonNumeric></span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:continuation id="F_0c6d83b4-62b1-46ec-a998-2f1323fefd8d_1"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.062%;"></td>
        <td style="width:1.774%;"></td>
        <td style="width:1.277%;"></td>
        <td style="width:16.252%;"></td>
        <td style="width:0.634%;"></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2022</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a4207cff-22cc-4c82-9c2c-b07bf817f054" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,933</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9b628353-ca8f-46f2-887b-1be3394a7db7" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,428</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2024</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_49c7da9c-022f-4421-af26-7a0cd015032a" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,525</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_43c0d771-32cb-4463-a8c8-e951ba9321b8" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,625</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2026 and thereafter</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e32ec52e-20c4-4dc5-9619-7963f9fb5250" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,747</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total undiscounted lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3e310cfd-e782-433f-8135-ac8ca6c9f4c7" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">27,258</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: imputed interest</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_81db5667-02fc-49a7-a4fe-fb877f180561" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,314</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total operating lease liability</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_614f81de-024b-4de3-bf81-da6ece8b203c" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:OperatingLeaseLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">20,944</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: current portion</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_be2d74b0-fa01-484c-bbf6-65e6147bf2df" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:OperatingLeaseLiabilityCurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,567</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease liability, net of current maturities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a37b42b8-14e5-4a38-be85-906207da6e5f" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:OperatingLeaseLiabilityNoncurrent" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">19,377</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Adicet Bio, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:3.333%;font-size:10.0pt;margin-top:2.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></ix:continuation></div><p style="text-indent:3.333%;font-size:10.0pt;margin-top:2.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company maintains letters of credit of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_aaab0699-2f40-4aa8-a28c-1cb871deccf3" contextRef="C_cea994b1-c7e3-4048-aeb0-aab2a8ee080d" name="us-gaap:LettersOfCreditOutstandingAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">4.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a60ef4cf-63a3-4620-8683-c6dea4a166ac" contextRef="C_4a463e61-a719-45b8-b4f2-fb3e5d6433eb" name="us-gaap:LettersOfCreditOutstandingAmount" unitRef="U_USD" scale="6" decimals="-5">0.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b0d8bb15-d480-4694-851e-6609a539a7d2" contextRef="C_e39012be-aa0b-44c4-bc70-f388d0297447" name="us-gaap:LettersOfCreditOutstandingAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in connection with the Company&#x2019;s office leases in Redwood City, CA, Menlo Park, CA, and  Boston, MA, respectively. As of December 31, 2021, the cash amount associated with the Menlo Park Lease is recorded as restricted cash on the consolidated balance sheet. As of December 31, 2020, all cash amounts are recorded as restricted cash on the consolidated balance sheet.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Indemnification Agreements</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third-party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. The Company has never incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. The Company has also entered into indemnification agreements with its directors and officers that require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers to the fullest extent permitted by Delaware corporate law. The Company currently has directors&#x2019; and officers&#x2019; liability insurance.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Legal Proceedings</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the Merger, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fd218832-e845-46cd-a84b-f541fa5c90d9" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="acet:LawsuitsFiledAgainstCompany" unitRef="U_Lawsuit" decimals="INF" format="ixt-sec:numwordsen">seven</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> lawsuits were filed against the Company, its directors, Former Adicet, and/or Merger Sub. which were either dismissed or settled for of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b1ec35e2-d4d8-4133-a9a9-6f992ed9abe9" contextRef="C_5e765ceb-b63f-4177-a750-139c07a36c25" name="us-gaap:LitigationSettlementExpense" unitRef="U_USD" scale="6" decimals="-5">0.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in the fourth quarter of 2020.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8e80afa6-0f81-473f-b7d3-b330c7087f8d" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">13. Stockholders' Equity</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Common Stock</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Common stockholders are entitled to dividends if and when declared by the Board of Directors subject to the prior rights of the preferred stockholders. As of December 31, 2021 and 2020, no dividends on common stock had been declared by the Board of Directors.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In February 2021, the Company completed an underwritten public offering of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bbd77c94-cc34-4886-af3a-9a7c5658c85b" contextRef="C_ee99e6bd-ad45-468e-9fbb-435628a329b5" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">10,575,513</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of its common stock at a public offering price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8cee86d4-0796-48a5-a3e3-31ed1e34c8ff" contextRef="C_a7d83825-c513-40b3-914c-c2f0871374ec" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_USDollarShare" decimals="INF">13.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share. The Company received net proceeds from the offering, after deducting underwriting discounts and commissions and offering expenses of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f70a844e-14f5-4c8a-9172-f158a5ff53eb" contextRef="C_ee99e6bd-ad45-468e-9fbb-435628a329b5" name="us-gaap:SaleOfStockConsiderationReceivedPerTransaction" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">128.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the February 2021 offering, </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_beea17cb-947a-4609-8a6c-57ef3ae78927" contextRef="C_ee99e6bd-ad45-468e-9fbb-435628a329b5" name="us-gaap:SaleOfStockDescriptionOfTransaction"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the Company also entered into a stock purchase agreement with certain existing investors to purchase </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ca92c3a5-9480-45a2-aba3-2083f0b47103" contextRef="C_a7d83825-c513-40b3-914c-c2f0871374ec" name="us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">1,153,840</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of our common stock for  $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d4a81f3b-7610-4cab-bff7-ea081854acef" contextRef="C_ee99e6bd-ad45-468e-9fbb-435628a329b5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">15.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million at a price per share equal to the public offering price, with an initial closing for investors held simultaneously with the closing of the offering and a subsequent closing for certain additional investors.</span></ix:nonNumeric></span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2021, the Company closed an underwritten public offering, or the December 2021 Follow-On Offering, of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_da88dc70-ad54-485b-9f89-ccccd190b41a" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">7,187,500</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of its common stock at a public offering price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f017416e-e4bd-4aea-ac1b-ef3a58f1ae64" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:SaleOfStockPricePerShare" unitRef="U_USDollarShare" decimals="INF">14.00</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share. The Company received net proceeds from the offering, after deducting underwriting discounts and commissions and offering expenses of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e8954169-dd3c-4603-a8ea-57fe435be9ff" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">94.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million.</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b17aadf4-94fc-4587-bbd1-3964770d9eec" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="acet:ScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has the following shares of common stock reserved for future issuance:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:63.237%;"></td>
        <td style="width:1.656%;"></td>
        <td style="width:0.637%;"></td>
        <td style="width:15.452%;"></td>
        <td style="width:0.637%;"></td>
        <td style="width:1.656%;"></td>
        <td style="width:0.637%;"></td>
        <td style="width:15.452%;"></td>
        <td style="width:0.637%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock options available for future grant</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_56f919d6-826b-4f37-95ee-7e80029808aa" contextRef="C_35b723a6-c5cf-49a4-9335-d4bc407fc9fc" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">1,961,338</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_111babca-edd7-4693-8a01-e3af33e0112e" contextRef="C_dccfe9c7-9db3-41d8-9a49-8d136b5e0bfa" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">1,739,621</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock options issued and outstanding</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_630c21fd-f308-4f01-ab79-ebade7060ae0" contextRef="C_91052d8c-9e4f-403f-ba68-6576fa344a03" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">3,875,317</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_84de8b9b-9082-46d8-a6ab-1574098e2e04" contextRef="C_6ed2f7b8-095e-4a87-ad70-d100496cc258" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">3,706,945</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unvested restricted stock units</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5f368eb3-71a2-4a6e-ad2a-560893b003aa" contextRef="C_03b136b5-e9d4-4893-ab0d-2dc91c51accf" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">771,660</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_02e1dd82-8fbe-4d12-aeff-86d8f2c18bf1" contextRef="C_0c48ad1d-3ddc-4d42-94e0-eacbdc6debba" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Common stock warrants issued and outstanding</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_884db404-8667-4df2-9f7c-8d7cf3c6b19d" contextRef="C_21b4de8c-d5dc-46f7-9bc7-44236de1a72c" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">220,890</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e9767764-f83f-4155-8f6e-9b52d22d7b33" contextRef="C_9dda731b-43d4-46e4-905f-51b9789cec27" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">226,191</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total common stock reserved</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_46ae16b9-6a9e-4c00-926a-2360a7c9ff05" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">6,829,205</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_080c033c-5d2a-4817-8668-38db4a65a82b" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">5,672,757</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Warrants to Purchase Shares of Common Stock</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In February 2021, PacWest exercised 5,301 warrants, which resulted in the net issuance was 1,806 shares of common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c185f974-f454-4105-b28a-391430b10667" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following provides a roll forward of outstanding warrants:</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">28</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Adicet Bio, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:53.616%;"></td>
        <td style="width:1.588%;"></td>
        <td style="width:0.578%;"></td>
        <td style="width:12.525%;"></td>
        <td style="width:0.764%;"></td>
        <td style="width:1.588%;"></td>
        <td style="width:1.147%;"></td>
        <td style="width:12.191%;"></td>
        <td style="width:0.568%;"></td>
        <td style="width:1.588%;"></td>
        <td style="width:0.578%;"></td>
        <td style="width:12.701%;"></td>
        <td style="width:0.568%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Number of <br />Warrants</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted<br />Average<br />Exercise<br />Price</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted<br />Average<br />Contractual<br />Term (Years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Outstanding and exercisable warrants to purchase<br />&#160;&#160;&#160;preferred shares as of December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_215b3d8c-559e-4b0d-8123-fa3481e2f39f" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="acet:ClassOfWarrantOutstandingAndExercisableToPurchasePreferredShares" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">226,191</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_86fe3100-32bf-4cea-a559-dae62bcedb1e" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_USDollarShare" scale="0" decimals="4">11.3177</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_455dd06e-a615-4196-b183-7232efc56c85" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="acet:WarrantsOutstandingAndExercisableWeightedAverageRemainingContractualTerm" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">5.66</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Issued</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_39ca1378-7332-4b8d-8718-5ad93afcfcd3" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="acet:ClassOfWarrantOrRightIssued" unitRef="U_shares" decimals="0" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_73daf0d9-358d-48cb-b8a7-5225360dbfe8" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="acet:ClassOfWarrantExercised" unitRef="U_shares" decimals="0" sign="-" format="ixt:numdotdecimal">5,301</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Outstanding and exercisable warrants to purchase<br />&#160;&#160;&#160;common stock as of December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d4435be5-4d70-4dd1-b00b-a4ac105f9cd3" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="acet:ClassOfWarrantOutstandingAndExercisableToPurchaseCommonStock" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">220,890</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d217fa63-2fe7-447f-9c65-ee5d70b943d3" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_USDollarShare" scale="0" decimals="4">11.3177</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4549c81e-d778-41a0-b27b-87ee02065237" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="acet:WarrantsOutstandingAndExercisableWeightedAverageRemainingContractualTerm" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">4.66</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_9d80d234-b478-486d-b0aa-5efdcba02d5b" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="acet:ScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, the Company's outstanding warrants to purchase shares of common stock consisted of the following:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:21.212%;"></td>
        <td style="width:1.5%;"></td>
        <td style="width:0.627%;"></td>
        <td style="width:20.574%;"></td>
        <td style="width:0.627%;"></td>
        <td style="width:1.5%;"></td>
        <td style="width:1.284%;"></td>
        <td style="width:13.782%;"></td>
        <td style="width:0.627%;"></td>
        <td style="width:1.5%;"></td>
        <td style="width:15.419%;"></td>
        <td style="width:1.5%;"></td>
        <td style="width:19.849%;"></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"><br />Issuance Date</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Number of<br />Shares of<br />Common<br />Stock Issuable</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Exercise<br />Price</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Classification</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Expiration Date</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5eb7db5f-9ce3-46c6-81d6-1ccb461b222f" contextRef="C_d7c1aa19-f30c-49e2-89e6-bd6ca6fed85c" name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">September 15, 2020</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e4bda378-71c9-40b0-a47f-0745c07aed62" contextRef="C_47329381-5696-4150-b182-6307d7bace64" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">101,610</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4b47bf2b-2c81-47af-b6a0-807001595453" contextRef="C_47329381-5696-4150-b182-6307d7bace64" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_USDollarShare" scale="0" decimals="4">11.3177</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Equity</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_8d03db82-01fa-47cb-a0ad-2a38761f1377" contextRef="C_d7c1aa19-f30c-49e2-89e6-bd6ca6fed85c" name="acet:ClassOfWarrantOrRightsExpirationDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">July 25, 2026</span></ix:nonNumeric></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_ab00a2b6-aee0-4d95-b162-86b598f24d2a" contextRef="C_ab272512-6afd-4b7d-821d-0cda8200b065" name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">September 15, 2020</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fb06a34c-87c2-492b-a6c0-371fc8f3cb7b" contextRef="C_61c5baba-2674-42bd-b177-79bf4833cac0" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">30,924</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_876bad56-e7e3-4d0b-9398-7de550f275f9" contextRef="C_61c5baba-2674-42bd-b177-79bf4833cac0" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_USDollarShare" scale="0" decimals="4">11.3177</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Equity</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6fb99c30-6ffd-4d92-bc4a-ee760116411a" contextRef="C_ab272512-6afd-4b7d-821d-0cda8200b065" name="acet:ClassOfWarrantOrRightsExpirationDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">August 21, 2026</span></ix:nonNumeric></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d27d1814-e17f-4717-a374-7bbd5868be86" contextRef="C_d75d589d-a181-4cd4-ad70-8e7ae30da242" name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">September 15, 2020</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2d39647a-abc0-4784-afe4-6a756c6cf123" contextRef="C_0c05cb34-710a-4fe0-a5ad-4326137cbe67" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">77,312</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_76a42a81-f508-4995-a714-ffe5b52b0a6c" contextRef="C_0c05cb34-710a-4fe0-a5ad-4326137cbe67" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_USDollarShare" scale="0" decimals="4">11.3177</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Equity</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_aeb5d4c0-ef5d-43d6-918f-212ba1a0b8aa" contextRef="C_d75d589d-a181-4cd4-ad70-8e7ae30da242" name="acet:ClassOfWarrantOrRightsExpirationDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">September 19, 2026</span></ix:nonNumeric></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4b99b1e4-497f-49ca-b060-f41d5fac10be" contextRef="C_8b04952a-abb5-4154-8047-1764f9eef410" name="us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">September 15, 2020</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e4463e26-7218-4041-b78a-9694f4eca669" contextRef="C_97f163d5-9ecd-43f8-8bae-d896a29f9d75" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">11,044</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_02cce1a3-8a0f-48d6-bcf2-b0ee96569a9e" contextRef="C_97f163d5-9ecd-43f8-8bae-d896a29f9d75" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" unitRef="U_USDollarShare" scale="0" decimals="4">11.3177</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Equity</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_fe852265-bc54-4969-96d8-715ded3d761a" contextRef="C_8b04952a-abb5-4154-8047-1764f9eef410" name="acet:ClassOfWarrantOrRightsExpirationDate" format="ixt:datemonthdayyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">September 26, 2026</span></ix:nonNumeric></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_439cfc25-56f5-424c-8c45-dc5eb801df12" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:ClassOfWarrantOrRightOutstanding" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">220,890</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_96751e1b-a987-4937-ae36-f599fcee41cd" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="acet:AtTheMarketOfferingTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">14. At-the-Market (ATM) Offering</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On December 1, 2020, the Company entered into a Sales Agreement (the 2020 Sales Agreement) with Evercore Group L.L.C. and H.C. Wainwright &amp; Co., LLC (collectively, the Agents), pursuant to which the Company may sell, from time to time, at its option, up to an aggregate of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a68f0eba-7be8-454b-b36e-b9daf6c63488" contextRef="C_2c5c9f72-4620-4181-b264-9a1444d1f83d" name="acet:MaximumAggregateValueOfCommonStockAvailableForOfferingAtMarketPriceUnderSalesAgreement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">50.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of shares of the Company&#x2019;s common stock, through the Agents, as its sales agents. No sales of Shares have been made under the 2020 Sales Agreement. The ATM offering was terminated in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_f34210bf-219f-4cdd-a11f-e3cc813cf795" contextRef="C_62266203-5d56-4f94-a47f-f581aa528dbf" name="acet:TerminationAgreementMonthAndYear" format="ixt:datemonthyearen"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">February 2021</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On March 12, 2021, the Company entered into a Sales Agreement (the 2021 Sales Agreement) with</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">JonesTrading Institutional Services (the Agent), pursuant to which the Company could sell, from time to time, at its option, up to an aggregate of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9904eb58-4745-4003-a135-0e79dd225beb" contextRef="C_0d31c0ca-f12c-41d7-9a4f-d658501001c3" name="acet:MaximumAggregateValueOfCommonStockAvailableForOfferingAtMarketPriceUnderSalesAgreement" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">75.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of shares of its common stock, through the Agent, as its sales agent. No shares were sold under the 2021 Sales Agreement as of December 31, 2021.</span></p></ix:nonNumeric></div>
  <div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a802b184-f620-4be0-9367-144f229fce2c" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">15. Stock-Based Compensation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock-based Compensation Expense</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_dde999fd-ece3-4ac9-aaef-3f338988e90e" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" escape="true" continuedAt="F_dde999fd-ece3-4ac9-aaef-3f338988e90e_1"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table presents stock-based compensation expense as reflected in the Company's consolidated statements of operations and comprehensive loss (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.807%;"></td>
        <td style="width:1.49%;"></td>
        <td style="width:1.284%;"></td>
        <td style="width:13.201%;"></td>
        <td style="width:0.627%;"></td>
        <td style="width:1.49%;"></td>
        <td style="width:1.284%;"></td>
        <td style="width:13.191%;"></td>
        <td style="width:0.627%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_969a96ad-9b53-4097-b4cc-e69ef69f6118" contextRef="C_e645c0e4-c8b9-494e-86ea-d249ee6b8de0" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,759</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_976390d7-5288-47f3-bc70-764394782b9e" contextRef="C_38fcd5c7-531b-45fa-b26b-773edcb7ea4a" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,674</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_97d9d53c-fc1e-445d-ba14-2fffc2cec29f" contextRef="C_33bee37a-503e-457c-a296-23686ab0bf7a" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">7,752</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e99c6784-2bf2-4101-8353-221c7ac75f1c" contextRef="C_e7b49a0d-aba6-4a40-8906-1ce775d20e23" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,589</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total stock-based compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_75607dc3-81f6-4296-bee2-132ca07741a5" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,511</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a5257ac4-f46f-46d1-89d6-02a1df4577ee" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,263</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Adicet Bio, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Summary of Plans</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Plans are administered by the Board of Directors or, at the discretion of the Board of Directors, by a committee of the Board of Directors. The exercise prices, vesting and other restrictions are determined at the discretion of the Board of Directors, or its committee if so delegated, except that the exercise price per share of stock options may not be less than 100% of the fair market value of the share of common stock on the date of grant and the term of the stock option may not be greater than ten years. Incentive stock options granted to employees and restricted stock awards granted to employees, officers, members of the Board of Directors, advisors, and consultants of the Company typically vest over four years. Non-statutory options granted to employees, officers, members of the Board of Directors, advisors, and consultants of the Company typically vest over three or four years. Shares that are expired, terminated, surrendered or canceled under the Plans without having been fully exercised will be available for future awards. In addition, shares of common stock that are tendered to the Company by a participant to exercise an award are added to the number of shares of common stock available for the grant of awards.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The 2017 Plan and 2018 Plan</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In 2017, resTORbio adopted the 2017 Plan. In connection with resTORbio&#x2019;s initial public offering completed in January 2018, the resTORbio Board adopted and resTORbio&#x2019;s stockholders approved the 2018 Plan. The 2018 Plan provides that the number of shares reserved and available for issuance under the plan will automatically increase each January 1, beginning on January 1, 2019, by </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b5792576-1160-4cbe-8d2f-40df0e5180dc" contextRef="C_b1857342-ffb7-45ed-afa1-3915a6f75d31" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the outstanding number of shares of resTORbio&#x2019;s common stock on the immediately preceding December 31 or such lesser number of shares as determined by the Board. On April 27, 2021, the stockholders approved an amendment and restatement of the 2018 Stock Option and Incentive Plan, to, among other things, increase the aggregate number of shares authorized for issuance under the 2018 Plan by </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_08e7a1bc-63b5-4e51-b9ba-8cf5374d1f1b" contextRef="C_8d576fd1-c342-4304-8b64-31bfd7e0d001" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,500,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares, plus on January 1, 2022 and each January 1, thereafter, the number of shares authorized for issuance shall be increased by the lesser of 5% of the number of shares of Common Stock issued and outstanding on the immediately preceding December 31, or such lesser number as determined by the compensation committee. On January 1, 2022, the number of shares reserved and available for issuance under the 2018 Plan automatically increased by </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9fb9bc6b-a24a-4cb1-830c-5e7c90865bdd" contextRef="C_ba6aebac-1228-4929-ac87-bcb3b11a0965" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,986,845</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of Common Stock equal to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_527d3b21-b136-4f8f-82c5-53cc04a96f2a" contextRef="C_98e3df4a-7a5c-4af8-b922-80b4bfd6c7c5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the number of shares of Common Stock issued and outstanding on December 31, 2021.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Since the date of effectiveness of the 2018 Plan, resTORbio has not and the Company will not grant any further awards under the 2017 Plan. However, any shares of common stock subject to awards under the 2017 Plan that expire, terminate, or otherwise are surrendered, canceled, forfeited or repurchased without having been fully exercised or resulting in any common stock being issued will become available for issuance under the 2018 Plan. As of December 31, 2021, there are no outstanding options under the 2017 Plan.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, the number of shares of common stock available for grant under the 2017 and 2018 Plan is </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a6f9dc34-4998-457f-9e65-81f6b8e19bd0" contextRef="C_3bebb335-7ef4-439f-88ab-b54a40df0583" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,683,999</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. As of December 31, 2021, an aggregate of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d085a839-afc2-49d7-8eea-81071e8b0281" contextRef="C_3bebb335-7ef4-439f-88ab-b54a40df0583" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,574,170</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock were issuable upon the exercise of outstanding stock options under the 2017 Plan and 2018 Plans at a weighted average exercise price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c6a13906-c008-4d78-9515-8593d428b02c" contextRef="C_425adbd0-c74a-4998-835c-069d0757ec60" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_USDollarShare" decimals="INF">15.10</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share. In addition to this amount, as of December 31, 2021, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5e920b4a-6f21-4be9-8578-8b028a085c9b" contextRef="C_425adbd0-c74a-4998-835c-069d0757ec60" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">771,660</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock were issuable upon the vesting of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a398ad6f-71c6-42e1-b707-10612b1be51a" contextRef="C_677843d2-a967-4c7e-806b-bedb3b76e41f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">6,410</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> performance stock units (PSUs) granted in May 2021, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4e3c434f-f4e4-4c7f-9632-899f8cb01396" contextRef="C_47c45ab3-564a-4faf-b5b3-316708cef184" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">205,250</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> RSUs granted in August 2021, and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_24e358ff-33e7-43a4-a00d-28157d150523" contextRef="C_2d0f9825-f275-4fef-8d45-4314b18f7073" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">560,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> RSUs and PSUs granted in October 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The 2014 Plan and 2015 Plan</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, the number of shares of common stock available for grant under the 2014 and 2015 Plan is </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8a1f2bf4-44e8-4d74-a6f4-0e0578e65251" contextRef="C_2c23f818-11c0-4555-af2a-af3a6c3d7db0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">277,339</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, an aggregate of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2d3ef7c5-c77e-4281-b7a6-8da7d6ba76c9" contextRef="C_c416c367-1d15-4743-aa82-f287dc4229d1" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">915,657</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock were issuable upon the exercise of outstanding stock options under the 2015 plan at a weighted average exercise price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0f342c2d-80a6-43c5-b91e-6a3b4cb44f3a" contextRef="C_a3c832c4-7b25-488e-a569-24d85c95e6db" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2">11.46</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share and an aggregate of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e046ea8b-98fd-45fe-8c14-2c592a3ddb44" contextRef="C_7241f66e-a735-4719-b5b2-0d08cdf5a400" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">22,987</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock were issuable upon the exercise of outstanding stock options under the 2014 Plan at a weighted average exercise price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e35d7f5d-e95a-4192-a844-038748cb0bd4" contextRef="C_ba86b9b9-6782-4f93-bfa9-5fc357e6e1f8" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_USDollarShare" decimals="INF">1.61</ix:nonFraction></span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Since the date of effectiveness of the Merger, the Company has not and will not grant any further awards under the 2014 Plan.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2018 Employee Stock Purchase Plan</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The 2018 ESPP provides that the number of shares reserved and available for issuance will automatically increase each January 1, beginning on January 1, 2019 and increasing each January 1 thereafter through January 1, 2028, by the least of (i) </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_942453d6-4a2b-41f0-a8cd-33a499530b33" contextRef="C_383a2850-17d4-45d4-93aa-3b9d2268d63a" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" unitRef="U_pure" scale="-2" decimals="2" format="ixt:numdotdecimal">1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the outstanding number of shares of the Company&#x2019;s common stock on the immediately preceding December 31; (ii) </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_18e27a8e-4b69-4d3b-93d2-7116e135bca8" contextRef="C_4669da95-189e-49f2-9e8b-0f44bc2c3332" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">77,703</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares or (iii) such number of shares as determined by the ESPP administrator.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> On January 1, 2020, as a result of the foregoing evergreen provision, the number of shares of common stock available for issuance under the 2018 ESPP automatically increased from </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_beab3575-98fb-45f2-9d1f-10a3087ddfa2" contextRef="C_22d1874f-4dce-4f63-bbf4-e46373c23281" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">79,369</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7c388480-1f3e-4459-8b30-0533cf941010" contextRef="C_3ff20287-8f1c-4d12-b176-b2761961daee" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">131,432</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On January 1, 2021, as a result of the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Adicet Bio, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">foregoing </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">evergreen provision, the number of shares of common stock available for issuance under the 2018 ESPP automatically increased from </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f3bb4d76-4437-4e22-b414-c2c115c682ff" contextRef="C_3ff20287-8f1c-4d12-b176-b2761961daee" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">131,432</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_443d05cb-29ef-494b-83b8-884dff8bbb18" contextRef="C_7447a494-85e3-4ae0-ad10-48552cb40723" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">524,775</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. During the 2021 Annual Meeting of the stockholders held on April 27, 2021, the stockholders approved an amendment and restatement of the Company's 2018 ESPP. As a result, the Company increased the shares available for issuance under the 2018 ESPP to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6f1c645a-3c3f-4093-8166-84f3d7c5f1f4" contextRef="C_382b6885-27c8-4c22-95fd-15e7dd95382f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">524,775</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For the year ended December 31, 2021 the Company issued a total of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6131ea67-ef9b-43df-82f9-d7c725cc6380" contextRef="C_382b6885-27c8-4c22-95fd-15e7dd95382f" name="acet:NumberOfSharesAvailableForSaleUnderEmployeeStockPurchasePlan" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">15,667</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares under the 2018 ESPP. Expense related to the issuance of such shares was less than $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0f2de97e-8576-428b-9833-00390359a8f1" contextRef="C_996c2c1e-c6b1-4f2c-b4f0-2957fe857977" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_087af3b1-fee3-4014-9eb6-5ee4ac41d157" contextRef="C_bd372fd7-75a1-4e5a-93b8-53cd9832c95c" name="acet:NumberOfSharesAvailableForSaleUnderEmployeeStockPurchasePlan" unitRef="U_shares" decimals="INF" format="ixt-sec:numwordsen">No</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares were issued under the 2018 ESPP during the year ended December 31, 2020.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock Options</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a78e708c-a8d8-42ce-9ff6-3a876c32a4b0" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A summary of stock option activity is set forth below (in thousands, except share and per share data):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:89.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:40.835%;"></td>
        <td style="width:0.672%;"></td>
        <td style="width:12.503%;"></td>
        <td style="width:0.903%;"></td>
        <td style="width:1.179%;"></td>
        <td style="width:1.344%;"></td>
        <td style="width:12.128%;"></td>
        <td style="width:0.595%;"></td>
        <td style="width:1.179%;"></td>
        <td style="width:0.661%;"></td>
        <td style="width:12.569%;"></td>
        <td style="width:0.595%;"></td>
        <td style="width:1.179%;"></td>
        <td style="width:1.344%;"></td>
        <td style="width:11.721%;"></td>
        <td style="width:0.595%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;">Outstanding Awards</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;">Number of<br />Shares<br />Underlying<br />Outstanding<br />Options</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;">Weighted<br />Average<br />Exercise<br />Price</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;">Weighted<br />Average<br />Remaining<br />Contractual<br />Term (in years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;">Aggregate<br />Intrinsic<br />Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Outstanding, December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4516ba21-89ae-4888-88ef-16a09b47f2da" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,706,945</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f17ab2f7-18e7-433e-bc61-8ad0b121a76c" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2">10.90</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3cff97be-061f-491c-9294-9270362d7556" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">7.98</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a8b9b1a1-e2a5-42d7-ac6f-5f70f026bf8a" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">15,126</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Options authorized</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Options granted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_deb25515-0175-47b2-8e10-4830a4c9796f" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">2,161,472</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b38d173d-8491-45d5-9d50-0afed6d6d7c5" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2">14.37</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Options exercised</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9f138a61-0c7f-4fde-a323-c693d7dfbdf2" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">1,125,339</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_65551013-80af-41d9-8fc8-38241a256863" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2">4.17</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Options forfeited or cancelled</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6e7292f0-947f-428a-8ab3-e4543bc1c4f3" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">867,761</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_13ccb89c-8cbd-4f05-ab0f-52e4ccdfede8" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2">14.06</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Outstanding, December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_447bbea6-8b6f-4912-aca5-a65fe0a2dfaf" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,875,317</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5714f290-fb0a-4d64-80a3-786ad4c0cc06" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2">14.08</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_4155e887-2396-41bf-a2c2-218e37cf671f" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">8.85</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_76ad66d9-c215-425a-8f1d-81edf94f3946" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,212</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Options exercisable December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1cc852c2-ad7f-4086-8cd2-c22897e04b97" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">991,847</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d82de667-4dc7-4e14-91f6-e88d340a9984" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2">13.42</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_5f603be6-fbf1-4431-b62e-e08e2ad829df" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">8.46</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ba98ea63-39db-4683-9bb4-0567dd18c4ed" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,033</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Vested and expected to vest, December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d50c5dc1-6c4d-49d7-b220-8d1980982c06" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,875,317</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6ba7d05a-337f-43b1-acd3-e78897ab6329" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" unitRef="U_USDollarShare" scale="0" decimals="2">14.08</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_12819ae6-9ff5-45b5-b9cf-69c82565bde8" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">8.85</span></ix:nonNumeric></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_60d1ba78-0c54-4fee-81c3-e82c9f3c8da0" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">13,212</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_61efa2cc-42ba-4c5f-bec5-5ef645aa295d" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The fair value of each stock option was estimated at the date of grant using a Black-Scholes option-pricing model using the following assumptions:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:48.693%;"></td>
        <td style="width:1.96%;"></td>
        <td style="width:0.642%;"></td>
        <td style="width:22.409%;"></td>
        <td style="width:0.642%;"></td>
        <td style="width:1.96%;"></td>
        <td style="width:0.642%;"></td>
        <td style="width:22.409%;"></td>
        <td style="width:0.642%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8895e3cd-3aec-4ec4-bce8-335696bcaecf" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">77.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3d78704d-800a-4803-a8a8-d590c054d091" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">79.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f47b6348-f4db-442a-aea9-e5b090f26ec8" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">72.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_68a87a87-6c84-4fc9-9c99-46288c5e6321" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">96.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_60e55daf-6af7-4f12-b791-83197508c20e" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1dd69e9b-158b-4253-bdae-7f9e02c2d00d" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">1.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_897ea6fd-71b0-40ec-b523-65132cdd23a8" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9b0c88d7-37e8-4721-8688-f53eaaf68f1b" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">1.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Dividend yield</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b91d5be9-70a6-43b0-96f1-b72bc7ca804f" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1a7edfc5-8109-4366-aec5-2d2e0c785849" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" unitRef="U_pure" scale="-2" decimals="2" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected term</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_635d51f9-9048-47c9-bef5-6835fddda9aa" contextRef="C_ed4f0fb0-7a37-45a2-b10b-11e180b401f7" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.90 </span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">- </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_3c57dece-9425-483f-8e57-c08975427bac" contextRef="C_7071ab79-c6d3-48f5-825b-3abca7958518" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.08 </span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">years</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d1039ab1-b7b7-40c9-a5cb-9d27a87ee199" contextRef="C_1d137f38-c8f9-4c04-bef7-225e2c879fcf" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.00 </span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">- </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a4452e0f-6e23-460a-9f5e-6b298ea726c7" contextRef="C_734e8966-cc1e-4985-a3ff-9c6d800e8bb3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.08 </span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">years</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The assumptions are as follows:</span></p><div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Expected volatility.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The Company has limited trading history. As such, the expected volatility was determined by examining the historical volatilities for comparable publicly traded companies within the biotechnology and pharmaceutical industry using an average of historical volatilities of the Company&#x2019;s industry peers.</span></div></div><div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Risk-free interest rate.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The risk-free interest rate is based on the United States Treasury yield with a maturity equal to the expected term of the option in effect at the time of grant.</span></div></div><div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Dividend yield.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The expected dividend is assumed to be zero as dividends have never been paid and there are no current plans to pay dividends on common stock.</span></div></div><div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#x2022;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Expected term.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The expected term represents the period that the stock-based awards are expected to be outstanding. The expected term is calculated using the simplified method which is used when there is insufficient historical data about exercise patterns and post-vesting employment termination behavior. The simplified method is based on the vesting period and the contractual term for each grant, or for each vesting-tranche for awards with graded vesting. The mid-point between the vesting date and the maximum contractual expiration date is used as the expected term under this method. For awards with multiple vesting-tranches, the times from grant until the mid-points for each of the tranches may be averaged to provide an overall expected term.</span></div></div><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company will continue to use judgment in evaluating the expected volatility, risk-free interest rates, dividend yield and expected term, utilized for stock-based compensation on a prospective basis.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Adicet Bio, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying stock options and the fair value of the Company&#x2019;s common stock for stock options that were in-the-money at December 31, 2021 and 2020. The aggregate intrinsic value of stock options exercised during the years ended on December 31, 2021 and 2020 was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9e1acc77-6b75-4b9a-a119-f9e36c2ee9bd" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">10.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0ade86ce-dcfe-439b-9268-1597fa0cdf7d" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The total fair value of options that vested during the years ended December 31, 2021 and 2020 was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ba527582-0f59-44f0-85b3-b54dffa3fd55" contextRef="C_d7f61ae5-e6e7-4a2d-b7f8-a2343ab6ffcd" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_96c432af-1299-4c0d-9357-d8eeffcff249" contextRef="C_5a2b4879-2585-49d1-b0c2-05cb9d882735" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.4</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively. The options granted during the years ended December 31, 2021 and 2020 had a weighted-average per share grant-date fair value of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f921fde9-96f0-4ca8-941e-077db0d5ad9e" contextRef="C_d7f61ae5-e6e7-4a2d-b7f8-a2343ab6ffcd" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" decimals="INF">9.68</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share and $9</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_85bef381-c3e2-4afe-a1f9-3fa837aae129" contextRef="C_5a2b4879-2585-49d1-b0c2-05cb9d882735" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" decimals="INF">.96</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, the total unrecognized stock-based compensation expense related to unvested stock options was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0d2de8d1-9457-4710-bfdc-da365ecf6c21" contextRef="C_65724930-27ec-4cc0-971f-f08bfefcc88e" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" unitRef="U_USD" scale="6" decimals="-5">24.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, which is expected to be recognized over the remaining weighted-average vesting period of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_77e65117-ecb8-487c-9f30-99d98212fe84" contextRef="C_c9ada5f0-e0e5-4266-9e2f-ad21061bf510" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.8 </span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">years.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Restricted Stock Units</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c0ebdb29-e657-4737-9344-f6bd66ccec42" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table presents a summary of the Company's RSU activity and related information:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.347%;"></td>
        <td style="width:3.293%;"></td>
        <td style="width:0.578%;"></td>
        <td style="width:19.667%;"></td>
        <td style="width:0.764%;"></td>
        <td style="width:3.293%;"></td>
        <td style="width:1.146%;"></td>
        <td style="width:19.334%;"></td>
        <td style="width:0.578%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Number of Units Outstanding</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted-<br />Average<br />Grant Date Fair Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Outstanding, December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_834ff9cd-fb9d-4d6e-8dac-a85f3b12e884" contextRef="C_0c48ad1d-3ddc-4d42-94e0-eacbdc6debba" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" unitRef="U_shares" decimals="0" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">RSUs granted (including performance-based RSUs)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b6358411-165c-40e2-ac22-0d9efa661d17" contextRef="C_b25c6402-54af-4bb9-9e89-3b3f8319d96f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">777,160</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5d7833c6-bccd-4a7c-9a48-7508735e8ad5" contextRef="C_b25c6402-54af-4bb9-9e89-3b3f8319d96f" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2">7.84</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">RSUs Vested</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ec5fb741-761d-49b6-9d33-9104e7f534c4" contextRef="C_b25c6402-54af-4bb9-9e89-3b3f8319d96f" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" unitRef="U_shares" decimals="INF" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">RSUs forfeited</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a8d8fab2-a380-4fb4-9460-eb356ab219b3" contextRef="C_b25c6402-54af-4bb9-9e89-3b3f8319d96f" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">5,500</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8b6aa3cc-f1a3-4072-8a89-a645a8329d73" contextRef="C_b25c6402-54af-4bb9-9e89-3b3f8319d96f" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2">7.12</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Outstanding, December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fd5c7b4a-41ed-4895-8ef0-1bd29f19a47e" contextRef="C_03b136b5-e9d4-4893-ab0d-2dc91c51accf" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">771,660</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_03ef5a94-9c61-45b9-baec-63e1c3102fde" contextRef="C_03b136b5-e9d4-4893-ab0d-2dc91c51accf" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2">7.85</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In May 2021, the Company granted </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2df57381-2347-4eba-a2f1-e6dd151ca6f0" contextRef="C_b9512590-14bb-4410-8257-cfe9d48166b8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">6,410</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> RSUs with service and performance conditions to an employee, none of which vested during the year ending December 31, 2021. Vesting of these awards is contingent on the occurrence of certain milestone events and fulfilment of any remaining service condition. As a result, the related compensation cost is recognized as an expense when achievement of the milestone is considered probable. The expense recognized for these awards is based on the grant date fair value of the Company's common stock multiplied by the number of units granted. The Company recognized less than $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_78c1ae41-2355-4e47-8624-69481c51bfac" contextRef="C_9c600e1c-0c03-4bf9-8b76-f6fd3c4ce8d6" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of related expense during the year ended December 31, 2021.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In October 2021, the Company granted </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_54359c88-ef4a-4f3a-9612-3dc661c836ff" contextRef="C_e474c1ad-c5d1-430f-a989-9a1559ca7832" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">560,000</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> RSUs with service and performance conditions to certain employees, none of which vested during the year ended December 31, 2021. Vesting of these awards is contingent on the occurrence of certain milestone events and fulfilment of any remaining service condition. As a result, the related compensation cost is recognized as an expense when achievement of the milestone is considered probable. The expense recognized for these awards is based on the grant date fair value of the Company's common stock multiplied by the number of units granted. The Company recognized $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8bc618a2-00f4-4b18-b6bd-27e8dd084304" contextRef="C_e474c1ad-c5d1-430f-a989-9a1559ca7832" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of related expense during the year ended December 31, 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The weighted-average grant date fair value of RSUs granted during the year ended December 31, 2021 was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_79d1ca09-5e8c-4443-a748-c0dd9b6ea646" contextRef="C_9c600e1c-0c03-4bf9-8b76-f6fd3c4ce8d6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" unitRef="U_USDollarShare" scale="0" decimals="2">7.84</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. There was no RSU activity during the year ended December 31, 2020. Additionally, no RSUs vested during the year ended December 31, 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, there was approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ea1b7371-b266-47e7-9014-8f60ec6549a7" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">4.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of unrecognized compensation cost related to unvested RSUs that the Company expects to recognize over a remaining weighted-average period of approximately </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_48a24c53-0b36-4973-afa5-edd47e2e3a4b" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.3 </span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">years.</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:continuation id="F_dde999fd-ece3-4ac9-aaef-3f338988e90e_1"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table presents stock-based compensation expense by type of award (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.091%;"></td>
        <td style="width:1.49%;"></td>
        <td style="width:1.147%;"></td>
        <td style="width:13.24%;"></td>
        <td style="width:0.578%;"></td>
        <td style="width:1.49%;"></td>
        <td style="width:1.147%;"></td>
        <td style="width:13.24%;"></td>
        <td style="width:0.578%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock Options</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_069a0748-00b9-4a60-81b3-3b8a5dbfa30b" contextRef="C_e467cca2-7a5b-404b-9e56-feeb98925d23" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">10,511</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e11b3260-99a6-4ab7-86cb-aabe79c515db" contextRef="C_9012bab3-6ac1-4389-8e31-ccc520a1ad87" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,263</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Restricted stock units (including performance-based RSUs)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_67d34c86-9769-45fc-86ed-83c3324b6bb2" contextRef="C_b25c6402-54af-4bb9-9e89-3b3f8319d96f" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,944</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_dbc0d54f-50e5-4e0d-931c-eb2600eb1f07;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Employee Stock Purchase Plan</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2259fcde-0fe4-4484-af8b-a5f9bd37f7f2" contextRef="C_086b3add-2ea8-447d-a2b0-fbfba9fbf32a" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">56</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_91d06931-2771-4e60-b971-253316eaba0d;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#x2014;</span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6fa32a68-83aa-4480-8ad3-d17735569241" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">12,511</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a6e2309f-6c63-4f66-ae59-0c8fd040486d" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:AllocatedShareBasedCompensationExpense" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,263</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">32</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Adicet Bio, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude></ix:continuation></div></ix:nonNumeric></div>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_18d79349-4837-40ce-8c74-061d9f5d5b37" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:EarningsPerShareTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">16. Net Loss Per Share</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_c5da6339-8d0f-45b2-a1ff-4d1f22754013" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders (in thousands, except share and per share data):</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.812%;"></td>
        <td style="width:1.416%;"></td>
        <td style="width:1.503%;"></td>
        <td style="width:13.777%;"></td>
        <td style="width:0.991%;"></td>
        <td style="width:1.416%;"></td>
        <td style="width:1.503%;"></td>
        <td style="width:13.592%;"></td>
        <td style="width:0.991%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Numerator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss attributable to common stockholders</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bfe67008-df19-4d1d-865a-848a0ef72c26" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">61,999</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b885de10-ec48-4487-a09f-2f1c37da1cd9" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">36,678</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Denominator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted-average shares used in computing net loss<br />&#160;&#160;&#160;per share attributable to common stockholders,<br />&#160;&#160;&#160;basic and diluted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_859e580a-b894-4721-bc8e-9782421d42f6" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">30,952,152</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_88459837-93bf-454c-b033-1fcdd060db6c" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted" unitRef="U_shares" decimals="0" format="ixt:numdotdecimal">7,319,977</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss per share attributable to common stockholders,<br />&#160;&#160;&#160;basic and diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_470110b3-32ec-4345-b579-26b69d7fe09f" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:EarningsPerShareBasicAndDiluted" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-">2.00</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c97c85ec-687d-4c22-a005-315162f6b0bd" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:EarningsPerShareBasicAndDiluted" unitRef="U_USDollarShare" scale="0" decimals="2" sign="-">5.01</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:2.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company's potentially dilutive shares, which include outstanding stock options, unvested RSUs, and unexercised warrants to purchase common stock, are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:2.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b6db3cc8-fc16-4698-b752-3be79659bf1d" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:2.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the period presented because including them would have been antidilutive:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.516%;"></td>
        <td style="width:1.449%;"></td>
        <td style="width:0.697%;"></td>
        <td style="width:14.399%;"></td>
        <td style="width:0.697%;"></td>
        <td style="width:1.449%;"></td>
        <td style="width:0.697%;"></td>
        <td style="width:14.399%;"></td>
        <td style="width:0.697%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Options to purchase common stock</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ef9e0762-d21e-4fad-ac75-83b904f8bfda" contextRef="C_c9ada5f0-e0e5-4266-9e2f-ad21061bf510" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,875,317</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b2b5c4a7-5b78-40e5-97c8-97bffe6026ce" contextRef="C_d7f61ae5-e6e7-4a2d-b7f8-a2343ab6ffcd" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,706,945</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unvested Restricted Stock Awards</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3c38aeae-5dd0-4ba5-81de-284a6f29c303" contextRef="C_b25c6402-54af-4bb9-9e89-3b3f8319d96f" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">771,660</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5fecfb33-895a-4607-9e2d-abe21965e3f6" contextRef="C_daaa68b0-d842-4ae0-a584-de681974e221" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="0" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Common stock warrants</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9dc77fe9-cddc-44d6-a33c-f78374e84146" contextRef="C_89d1a790-504a-43c7-8716-b106ad45345d" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">220,890</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f203d0f0-2fdb-4a99-94cc-d557c38a7b22" contextRef="C_f7498518-7e9a-4c87-8ba1-fa0ec641d5dd" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">226,191</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_64866bbf-f5be-48ac-85b0-cb3282d14e7b" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">4,867,867</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ee5e93d9-0dc7-4821-86be-51ebf2e5738a" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">3,933,136</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_68c772cc-b698-4c31-ae02-aae39951dd00" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:IncomeTaxDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">17. Income Taxes</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_a799ab20-7ecd-4b76-9944-a3d7033bf637" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The components of the provision for (benefit from) income taxes are as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.545%;"></td>
        <td style="width:1.448%;"></td>
        <td style="width:1.514%;"></td>
        <td style="width:13.057%;"></td>
        <td style="width:1.002%;"></td>
        <td style="width:1.448%;"></td>
        <td style="width:1.514%;"></td>
        <td style="width:13.471%;"></td>
        <td style="width:1.002%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Years Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Current:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Federal</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4efb4afa-5d08-4bd9-a7a7-26d5c4ae1e23" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:CurrentFederalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fae80ea5-efa3-4ce6-9501-b29abbae44bb" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:CurrentFederalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">2,678</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">State</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5bf20de0-feeb-44cf-87de-19bc5792c7d6" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_07ead932-b268-45aa-8a62-bb39ff9eb790" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3">105</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Foreign</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_52f84544-5fd7-4250-8aa3-58718a92cb30" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:CurrentForeignTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0f767700-4bb9-46bd-89f6-9849eeb9858f" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:CurrentForeignTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total current</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5822a00d-b7cd-4d33-888b-1ac7e4de8b64" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_62562c48-d708-41a2-a361-50d501db15d2" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:CurrentIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">2,573</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred:</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Federal</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cb27d2d1-b199-45fe-8a4f-b29a1e6c2226" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-">125</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_bac4e86b-c286-446b-ab71-182d5e4592f5" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">242</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">State</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ca487e65-13d5-450e-b5e2-4718e3ee9322" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_86d583cf-37c7-42bc-afbe-4d44447ceb30" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Foreign</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3a4121dc-7dd6-4b80-8a31-4c0a9c84fd9a" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4e3a8c57-d8af-445b-87e4-45cbb5ff7bd8" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total deferred</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_0029867e-c906-4ec1-a2bc-001f5ca140ee" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-">125</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_63f0ab20-89b2-46b1-86c2-0c8693c72680" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:DeferredIncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">242</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Provision for (benefit from) income taxes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_821664a2-86e4-408e-9c72-ed9119cce9aa" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">125</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_85d2f2cf-af75-414d-8b5e-1de5dd4c2f39" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">2,815</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:2.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Income tax benefit of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_135bea61-e36b-415c-8d2f-3eda21311cf5" contextRef="C_ebf71bd0-6119-4662-9dc2-2e319bd6c751" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the year ended December 31, 2021 is primarily due to the adjustment in deferred tax liability arising from the impairment charge of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_727754a5-4fc0-423f-a89c-f3d86ae9b759" contextRef="C_ebf71bd0-6119-4662-9dc2-2e319bd6c751" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of acquired IPR&amp;D. In contrast, the income tax benefit of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5e624383-75c3-4c93-bdc4-0371bd07a3fc" contextRef="C_39a111ce-846b-4680-8cb9-7243c84bbf71" name="us-gaap:IncomeTaxExpenseBenefit" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">2.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the year ended December 31, 2020 was primarily due to a the recognition of a net operating loss carryback under the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) which was enacted on March 27, 2020 in response to the COVID-19 pandemic.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d80a1f5e-6662-4bc3-84d5-27ee37a66f78" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For the rate table below the (provision for) benefit from income taxes differ from the amount expected by applying the federal statutory rate to the loss before taxes as follows:</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">33</span></p>
       <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Adicet Bio, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.102%;"></td>
        <td style="width:1.427%;"></td>
        <td style="width:0.686%;"></td>
        <td style="width:11.84%;"></td>
        <td style="width:3.496%;"></td>
        <td style="width:1.427%;"></td>
        <td style="width:0.686%;"></td>
        <td style="width:11.84%;"></td>
        <td style="width:3.496%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Federal statutory income tax rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_70345b7d-1297-4451-95db-a446297ddfee" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">21.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_20c3af58-1413-40e3-b421-1ff4287fc86c" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">21.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other permanent differences</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9212c52d-8f33-42de-9529-727b74bb8379" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">1.9</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c952809a-8ce5-4cd5-b2b5-1e954f8117c8" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">0.5</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">State income taxes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_73bab7c6-ae18-47bc-9e06-e2910e61783d" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">6.9</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9a4acd21-6765-4939-befd-f6f258273328" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">6.1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Federal benefit from NOL carryback</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_36514535-f1d7-4abf-a36f-f8b86c0aa626" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="acet:EffectiveIncomeTaxRateReconciliationNOLCarryback" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b995385b-17ae-42b6-88d2-0af988686110" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="acet:EffectiveIncomeTaxRateReconciliationNOLCarryback" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">6.7</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5f6ef1ac-6fa0-4e39-a970-a5d766fca187" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">24.8</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5f51bcd0-1b1a-4b29-801c-8921e0e5b24c" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">25.8</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in fair value of redeemable convertible preferred stock tranche liability and TRDF liability</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c301dd70-2c30-4279-99c5-98c8f68f3caf" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="acet:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilityAndTRDFLiability" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_748f4ff7-c0a3-4318-8a76-28fc8cd63fc5" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="acet:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilityAndTRDFLiability" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">0.5</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock-based compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7c0076e0-a4fc-4237-8f3e-999791259553" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" unitRef="U_pure" scale="-2" decimals="3" sign="-" format="ixt:numdotdecimal">1.0</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b03bbe6c-5793-4963-86a9-8463c404e5c3" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Provision for income taxes</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_40d22de7-4f95-45ec-8f7d-275978642d6f" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">0.2</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_102cbfed-cdcd-4ae0-98b5-9c03dd7ad13a" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" unitRef="U_pure" scale="-2" decimals="3" format="ixt:numdotdecimal">7.1</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_e95727ea-47d4-4001-96a2-10b6c64bb56f" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The tax effects of temporary differences and carryforwards of the deferred tax assets are presented below (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.389%;"></td>
        <td style="width:1.438%;"></td>
        <td style="width:1.503%;"></td>
        <td style="width:13.363%;"></td>
        <td style="width:1.002%;"></td>
        <td style="width:1.438%;"></td>
        <td style="width:1.503%;"></td>
        <td style="width:13.363%;"></td>
        <td style="width:1.002%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred Tax Assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net operating loss carryforwards</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_5405a066-1925-4897-9c25-bacf97485e29" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">67,675</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_46c0296a-651a-47e6-a3bd-b8a660a10934" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">51,796</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease right-of-use asset liability</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_be37183d-0225-4477-a617-c97e3cc0c624" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="acet:DeferredTaxOperatingLeaseRightOfUseAssetLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,504</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_22266ef9-7ba1-4b0f-948d-4d4320ad6e69" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="acet:DeferredTaxOperatingLeaseRightOfUseAssetLiability" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,686</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred revenue</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_85d58b2b-1ca8-4f32-afa2-1eed415b6cc6" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:DeferredTaxAssetsDeferredIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,263</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_cb992e4e-7909-4ab1-a2b7-e8f0c8468e61" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="us-gaap:DeferredTaxAssetsDeferredIncome" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">2,857</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock-based compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c39a0849-9ef9-4557-adf3-6680d2a62c69" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,726</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a0ef67e7-ce84-4930-8258-9f15a58450fb" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,750</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Intangible assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_60e5f62f-5a04-427a-b397-a0b674469c2c" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,081</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_863d8501-62c9-4247-9412-b9f883463b9c" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,195</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Fixed assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a94b29b8-1d11-4c1e-bdb5-ed1f23690f34" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="acet:DeferredTaxAssetsFixedAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">196</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a75a1a47-a0f7-41db-bb56-4956ecc43a31" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="acet:DeferredTaxAssetsFixedAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accruals and reserves</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_97888aca-49b5-40a5-bf64-37a662e153e1" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">1,042</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_4eff0d36-b77a-46a5-a188-e97cd6d155c0" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">654</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development credit carryforwards</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a600750c-e5cf-4e39-9b7b-86ba9f071a90" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">26</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_853bad09-546f-4ed6-9187-d39965bdf2e1" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">26</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Gross deferred tax assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ccd892cb-74fb-4e91-bb33-ed734a121e10" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">78,513</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_20db7c87-ef75-4c87-862b-53040814d547" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="us-gaap:DeferredTaxAssetsGross" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">63,964</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: Valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e2df1a08-8da1-4fc3-94a0-d6fdc814505c" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">73,163</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6d2862f5-27a0-4138-91dd-6ededd672948" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="us-gaap:DeferredTaxAssetsValuationAllowance" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">57,715</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax assets, net of valuation allowance</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_22830ece-592b-4f5a-b187-cac9bb650377" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">5,350</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f584c48c-d5ce-4582-a640-5186c8f778cf" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="us-gaap:DeferredTaxAssetsNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">6,249</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax liabilities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Fixed assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_820db54f-0a7a-4252-b729-7bb165a231d4" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="acet:DeferredTaxLiabilitiesFixedAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_8550b4ed-cee7-43e7-bddc-5523985868e2" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="acet:DeferredTaxLiabilitiesFixedAssets" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Basis Difference IPR&amp;D</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_99956645-572e-484d-9e9c-d239fe0c6313" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="acet:DeferredTaxBasisDifferenceIPRD" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_dc3a9a62-3962-4608-a617-e127d7b6cb6d" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="acet:DeferredTaxBasisDifferenceIPRD" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">313</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease right-of-use asset</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_db400933-eed0-4434-92f8-6df42a347dfe" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="acet:DeferredTaxOperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">5,350</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_ce5aad38-3273-48e4-a687-855ceb3ca128" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="acet:DeferredTaxOperatingLeaseRightOfUseAsset" unitRef="U_USD" scale="3" decimals="-3" sign="-" format="ixt:numdotdecimal">6,061</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9b197fdb-cf38-4be1-812c-880fcb2ec27a" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e0ba42a6-e4dd-4060-9bdb-42b2cf1dc333" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">125</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On September 15, 2020 Adicet Bio and resTORbio completed the Merger upon which Adicet Bio became the parent company of the consolidated group. The Merger did not create a step up in basis for tax basis of the asset as it was considered a tax-free merger. The above deferred tax table includes deferred related to resTORbio.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has established a valuation allowance against its deferred tax assets due to the uncertainty surrounding the realization of such assets.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ASC 740 requires that the tax benefit of net operating losses, temporary differences and credit carryforwards be recorded as an asset to the extent that management assesses that realization is &#x201c;more likely than not.&#x201d; Realization of the future tax benefits is dependent on the Company&#x2019;s ability to generate sufficient taxable income within the carryforward period. Because of the Company&#x2019;s recent history of operating losses, management believes that recognition of the deferred tax assets arising from the above-mentioned future tax benefits is currently not likely to be realized and, accordingly, has provided a valuation allowance.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The valuation allowance increased by $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_f1049ba3-f4f7-4ce4-a81b-df91fe16f8d4" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="acet:DeferredTaxAssetsValuationAllowanceIncrease" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">15.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million during 2021 and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6f5a55ac-269c-479c-b193-98f2b9ef1b85" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="acet:DeferredTaxAssetsValuationAllowanceIncrease" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">37.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million during 2020.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, the Company had net operating loss carryforwards of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a482db41-3bb5-4475-a4a5-e23bf9a7cba7" contextRef="C_da9e6c7e-f0b9-4a9e-9854-806aece05e6c" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">271.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_435f8d82-be7e-441c-bb8a-b30a7e70124d" contextRef="C_4d645798-711d-496e-8eb5-907d5667159d" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">143.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_9acf0336-e0ae-4173-a5dd-643e9fa6d891" contextRef="C_1878c95b-a997-415a-9e16-86e0a1c15a68" name="us-gaap:OperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">17.1</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million to reduce future taxable income, if any, for federal, state and foreign income tax purposes, respectively. Of the federal net operating loss carryforwards, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_7fc38b33-afb8-4c4b-a059-870707fef8e5" contextRef="C_da9e6c7e-f0b9-4a9e-9854-806aece05e6c" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">7.6</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million will begin to expire in 2036 if not utilized, and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b15747e6-f8e5-4ed8-beae-902bd7553acf" contextRef="C_da9e6c7e-f0b9-4a9e-9854-806aece05e6c" name="acet:OperatingLossCarryforwardsIndefinitely" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">264.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million can be carried forward indefinitely. The state carryforwards will begin to expire in 2035.</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">34</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Adicet Bio, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company also had approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_738ba14a-9b1d-49e3-b0a1-ed17d2b92f61" contextRef="C_da9e6c7e-f0b9-4a9e-9854-806aece05e6c" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of federal and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a4664222-af4b-4c31-b3ea-e2e4625ea6a3" contextRef="C_775ace4d-f0e0-4bb0-b785-08666d208bbb" name="us-gaap:TaxCreditCarryforwardAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">1.5</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of California research and development tax credit carryforwards available to offset future taxable income as of December 31, 2021. The federal credits begin to expire in 2041 and the California research credits can be carried forward indefinitely.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Utilization of the net operating loss carryforwards and research and development tax credit carryforwards may be subject to an annual limitation under Section 382 of the Internal Revenue Code of 1986, and corresponding provisions of state law, due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_d25255cd-70f3-47bb-a267-259268e67b52" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="acet:OwnershipChangePlanDescription"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain shareholders or public groups in the stock of a corporation by more than 50% over a three-year period</span></ix:nonNumeric></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Company has not conducted a study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception due to the significant complexity and cost associated with such a study. If the Company has experienced a change of control, as defined by Section 382, at any time since inception, utilization of the net operating loss carryforwards or research and development tax credit carryforwards would be subject to an annual limitation under Section 382, which is determined by first multiplying the value of the Company&#x2019;s stock at the time of the ownership change by the applicable long-term tax-exempt rate, and then could be subject to additional adjustments, as required. Any limitation may result in expiration of a portion of the net operating loss carryforwards or research and development tax credit carryforwards before utilization. Further, until a study is completed and any limitation is known, no liability related to uncertain tax positions is recorded in the consolidated financial statements. The Company does not expect its unrecognized tax benefit balance to change materially over the next 12 months.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company files income tax returns in the United States federal jurisdiction, California, Massachusetts, New York and Israel. The tax years 2015 to 2021 remains open to United States federal and state examination to the extent of the utilization of net operating loss and credit carryovers.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, the Company had unrecognized tax benefits of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_098061f1-f53a-48a4-a495-ee2e72ba9ac3" contextRef="C_188057dd-d8a2-49b6-b276-041c6c6962c8" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million related to the transfer of certain intellectual property from its Israeli subsidiary. In addition, as of December 31, 2021, the Company had unrecognized tax benefits of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_3661ff44-ee31-4c32-872c-e72a720bf2d3" contextRef="C_594a64fe-9232-4c34-a446-273a36865ed4" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">3.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million related to the federal and state research and development credits as a result of no formal research credit study performed.</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_78b8f27e-f6e9-4f88-a3ce-0ada280168c3" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" escape="true"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A reconciliation of the beginning and ending unrecognized tax benefit amount is as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.82%;"></td>
        <td style="width:1.489%;"></td>
        <td style="width:1.284%;"></td>
        <td style="width:13.199%;"></td>
        <td style="width:0.627%;"></td>
        <td style="width:1.489%;"></td>
        <td style="width:1.284%;"></td>
        <td style="width:13.18%;"></td>
        <td style="width:0.627%;"></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at the beginning of the year</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e7614a64-f3b8-4622-a5fd-5541890f2be5" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">797</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_2fefc43b-a9ae-4d51-81ce-c09f4e0dc1c1" contextRef="C_95800697-5c2c-4d5a-aff7-318a343c4784" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">797</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Adjustment based on tax positions related to current year</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_30a1fa9f-745f-4dbc-ab2d-95938cc977b0" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">3,243</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_a820f87f-b292-4943-97d5-ac58f1f3dea4" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" unitRef="U_USD" scale="3" decimals="-3" format="ixt:zerodash">&#x2014;</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at the end of the year</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6946feb3-3874-4350-8b9a-b67209729075" contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">4,040</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_1fc9d9ee-50bd-4a40-bc34-046ceda3865f" contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef" name="us-gaap:UnrecognizedTaxBenefits" unitRef="U_USD" scale="3" decimals="-3" format="ixt:numdotdecimal">797</ix:nonFraction></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></ix:nonNumeric></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company recognizes interest expense and penalties related to the above unrecognized tax benefits within income tax expense (benefit). Management determined that no accrual for interest and penalties was required as of December 31, 2021.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_cbda20cc-f366-414e-b695-7e96b8f00e49" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:DefinedContributionPlanTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">18. Defined Contribution Plan</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company maintains a defined contribution plan under Section 401(k) of the Internal Revenue Code covering substantially all full-time United States employees. Employee contributions are voluntary and are determined on an individual basis subject to the maximum allowable under federal tax regulations. During the year ended December 31, 2021 the Company made aggregate matching contributions of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c4ba052a-aa11-44b4-a92d-c2fac1221537" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.3</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. The Company did </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_31ad9f53-ca99-415f-b8d9-40d32262afbf" contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c" name="acet:CompanyContributionToPlanWithRespectToEmployeesContribution" unitRef="U_USD" scale="3" decimals="-3" format="ixt-sec:numwordsen">no</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">t make contributions to the 401(k) plan during 2020.</span></p></ix:nonNumeric></div>
  <div style="font-size:10.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_6f2f4869-61c0-4d89-9f7e-255aa66d09e8" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:RelatedPartyTransactionsDisclosureTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">19. Related Party Transactions</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, Regeneron owned </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_39529796-c96a-4ac8-9d6d-a878b8e47030" contextRef="C_c38e333f-e2eb-4d69-906a-0a7b3cfda69b" name="us-gaap:CommonStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">883,568</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of the Company's common stock. Regeneron became a related party in July 2019 as a result of Series B redeemable convertible preferred stock financing. Upon closing the Merger, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_6d9fea93-71de-4e92-925e-4bb41459658f" contextRef="C_c38e333f-e2eb-4d69-906a-0a7b3cfda69b" name="us-gaap:PreferredStockSharesIssued" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">7,125,552</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of the redeemable convertible preferred stock converted into </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_75ac485c-0a03-4efb-a740-b2d6791037f6" contextRef="C_32996dbe-7c67-4061-9092-811f3ea449f5" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" unitRef="U_shares" decimals="INF" format="ixt:numdotdecimal">883,568</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of the Company&#x2019;s common stock. For the years ended December 31, 2021 and 2020, the Company recorded revenue related to the Regeneron Agreement of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_d61c50cb-82af-419c-8cc4-020ad93d8487" contextRef="C_d85d1bbc-33b7-4189-abac-0387bd90ab52" name="us-gaap:RevenueFromRelatedParties" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">9.7</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_c1d50901-e757-4fe3-9d3e-f3a4052e45ac" contextRef="C_a9b28221-7291-479e-aade-1c4cce9e9ee2" name="us-gaap:RevenueFromRelatedParties" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">17.9</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively. As of December 31, 2021, the Company recorded less than $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_fbd35bc8-e769-4995-96bc-a7fbaf8ad4f6" contextRef="C_32996dbe-7c67-4061-9092-811f3ea449f5" name="us-gaap:AccountsReceivableGrossCurrent" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">0.2</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in accounts receivable and has deferred revenue of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_b829ea69-a159-4831-8cf5-bd7c32eb5a39" contextRef="C_32996dbe-7c67-4061-9092-811f3ea449f5" name="us-gaap:DeferredRevenue" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">4.8</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million related to the Regeneron Agreement (See Note 10).</span></p></ix:nonNumeric></div>
  <div style="font-size:12.0pt;font-family:Times New Roman;"><ix:nonNumeric id="F_b28dc005-4907-45d8-809a-4fe3949f37cc" contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c" name="us-gaap:SubsequentEventsTextBlock" escape="true"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">20. Subsequent Events</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Regeneron Option</span></p><ix:exclude><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">35</span></p>
     <hr style="page-break-after:always;" /><p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Adicet Bio, Inc.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Notes to Consolidated Financial Statements</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></ix:exclude><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On January 28, 2022, Regeneron exercised its option to license the exclusive, worldwide rights to ADI-002, an allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapy directed against Glypican-3, pursuant to the Regeneron Agreement.<br /> In conjunction with the exercise of the Option, Regeneron paid an exercise fee of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><ix:nonFraction id="F_e09963e7-23a7-4957-b51d-2b5c2a898ac8" contextRef="C_7c105d75-0eff-40e5-a076-0166362fc4d4" name="acet:ExerciseFeePaid" unitRef="U_USD" scale="6" decimals="-5" format="ixt:numdotdecimal">20.0</ix:nonFraction></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million to the Company on January 28, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the Regeneron Agreement, upon Regeneron&#x2019;s exercise of the option, the Company had a specified period of time to elect to co-fund ADI-002&#x2019;s future development costs, and to participate in any potential profits with Regeneron up to a specified co-funding percentage in various geographic regions, including on a worldwide basis (Co-Funding Option). Adicet elected not to exercise its Co-Funding Option for ADI-002. Accordingly, Regeneron is responsible, at its sole cost, for all development, manufacturing and commercialization of ADI-002 and must pay the Company high single digit royalties as a percentage of any net sales of ADI-002 for a period commencing on the first commercial sale until the longer of (i) the expiration or invalidity of the licensed patent rights or (ii) a low double digit amount of years from first commercial sale.</span></p></ix:nonNumeric></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">F-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">36</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">EXHIBIT INDEX</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:8.695%;"></td>
    <td style="width:1.144%;"></td>
    <td style="width:90.16%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Exhibit</span></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Number</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:7.2pt;word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="margin-left:7.2pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);text-indent:0.05pt;word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="margin-left:0.05pt;text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Description of Exhibit</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;3.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1720580/000119312518025718/d483880dex31.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Third Amended and Restated Certificate of Incorporation of the Registrant (as currently in effect) (incorporated by reference to Exhibit 3.1 to the Registrant&#x2019;s Current Report on Form 8-K (File No. 001-38359) filed with the SEC on January 30, 2018).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;3.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1720580/000119312520246853/d24517dex31.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Certificate of Amendment of Third Amended and Restated Certificate of Incorporation of resTORbio, Inc. related to the Reverse Stock Split, dated September 15, 2020 (incorporated by reference to Exhibit 3.1 to the Registrant&#x2019;s Current Report on Form 8-K (File No. 001-38359) filed with the SEC on September 16, 2020).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;3.3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1720580/000119312520246853/d24517dex32.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Certificate of Amendment of Third Amended and Restated Certificate of Incorporation of resTORbio, Inc. related to the Name Change, dated September 15, 2020 (incorporated by reference to Exhibit 3.2 to the Registrant&#x2019;s Current Report on Form 8-K (File No. 001-38359) filed with the SEC on September 16, 2020).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;3.4</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1720580/000119312518025718/d483880dex32.htm"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amended and Restated Bylaws of the Registrant (as currently in effect) (incorporated by reference to Exhibit 3.2 to the Registrant&#x2019;s Current Report on Form 8-K (File No. 001-38359) filed with the SEC on January 30, 2018)</span></a><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">.</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;4.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1720580/000156459020010474/torc-ex43_235.htm"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Description of Securities (incorporated by reference to Exhibit 4.3 to the Registrant&#x2019;s Annual Report on Form 10-K (File No. 001-38359) filed with the SEC on March 12, 2020).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;&#160;4.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/0001720580/000119312517383712/d475892dex42.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amended and Restated Investors&#x2019; Rights Agreement, dated as of November 29, 2017, among the Registrant and the other parties thereto (incorporated by reference to Exhibit 4.2 to our Registration Statement on Form S-1 (File No. 333-222373) filed with the SEC on December 29, 2017).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;4.3*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="acet-ex4_3.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Specimen Common Stock Certificate</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;10.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1720580/000119312521044801/d137638dex101.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Stock Purchase Agreement, dated February 12, 2021, by and among the Registrant and the Investors named therein (incorporated by reference to Exhibit 10.1 to the Registrant&#x2019;s Registration Statement on Form 8-K, as amended (File No. 001-38359) filed with the SEC on February 16, 2021).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;10.2</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1720580/000119312520246853/d24517dex1026.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Loan and Security Agreement, dated as of April 28, 2020, by and between Pacific West Bank and Adicet Therapeutics, Inc. (incorporated by reference to Exhibit 10.26 to the Registrant&#x2019;s Current Report on Form 8-K (File No. 001-38359) filed with the SEC on September 16, 2020).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;10.3</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1720580/000119312520246853/d24517dex1032.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">First Amendment to Loan and Security Agreement, dated as of July 8, 2020, by and between Pacific West Bank and Adicet Therapeutics, Inc. (incorporated by reference to Exhibit 10.32 to the Registrant&#x2019;s Current Report on Form 8-K (File No. 001-38359) filed with the SEC on September 16, 2020).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;10.4</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1720580/000119312520246853/d24517dex103.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Second Amendment to Loan and Security Agreement, dated as of September 14, 2020, by and between Pacific West Bank and Adicet Therapeutics, Inc. (incorporated by reference to Exhibit 10.3 to the Registrant&#x2019;s Current Report on Form 8-K (File No. 001-38359) filed with the SEC on September 16, 2020).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;10.5</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1720580/000119312520246853/d24517dex104.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Third Amendment to Loan and Security Agreement, dated as of September 15, 2020, by and between Pacific West Bank and Adicet Therapeutics, Inc. (incorporated by reference to Exhibit 10.4 to the Registrant&#x2019;s Current Report on Form 8-K (File No. 001-38359) filed with the SEC on September 16, 2020).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;10.6+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1720580/000095017021002279/acet-ex10_1.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Fourth Amendment to Loan and Security Agreement, dated as of October 21, 2021, between Adicet Therapeutics, Inc. and Pacific Western Bank (incorporated by reference to Exhibit 10.1 to the Registrant&#x2019;s Current Report on Form 8-K (File No. 001-38359) filed with the SEC on October 25, 2021).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;10.7</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1720580/000119312520246853/d24517dex105.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Form of Warrant to Purchase Common Stock issued to Beech Hill Securities, dated September 15, 2020 (incorporated by reference to Exhibit 10.5 to the Registrant&#x2019;s Current Report on Form 8-K (File No. 001-38359) filed with the SEC on September 16, 2020).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;10.8</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1720580/000119312520246853/d24517dex106.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Warrant to Purchase Common Stock issued to PacWest Bancorp, dated September 15, 2020 (incorporated by reference to Exhibit 10.6 to the Registrant&#x2019;s Current Report on Form 8-K (File No. 001-38359) filed with the SEC on September 16, 2020).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;10.9</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1720580/000119312520246853/d24517dex107.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Unconditional Secured Guaranty, dated September 15, 2020 (incorporated by reference to Exhibit 10.7 to the Registrant&#x2019;s Current Report on Form 8-K (File No. 001-38359) filed with the SEC on September 16, 2020).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">105</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:8.695%;"></td>
    <td style="width:1.144%;"></td>
    <td style="width:90.16%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;10.10+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1720580/000095017021002279/acet-ex10_2.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Affirmation and Amendment of Guaranty, dated as of October 21, 2021, between the Registrant and Pacific Western Bank (incorporated by reference to Exhibit 10.2 to the Registrant&#x2019;s Current Report on Form 8-K (File No. 001-38359) filed with the SEC on October 25, 2021).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;10.11*#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="acet-ex10_11.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amended and Restated 2018 Stock Option and Incentive Plan and forms of award agreements thereunder.</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;10.12#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1720580/000119312517383712/d475892dex101.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">2017 Stock Incentive Plan and forms of award agreements thereunder (incorporated by reference to Exhibit 10.1 to the Registrant&#x2019;s Registration Statement on Form S-1, as amended, (File No. 333-222373) filed with the SEC on January 16, 2018)</span></a><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;10.13#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1720580/000119312520246853/d24517dex1013.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Adicet Therapeutics, Inc. 2015 Stock Incentive Plan and forms of award agreements thereunder (incorporated by reference to Exhibit 10.13 to the Registrant&#x2019;s Current Report on Form 8-K (File No. 001-38359) filed with the SEC on September 16, 2020).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;10.14*#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="acet-ex10_14.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amended and Restated 2018 Employee Stock Purchase Plan.</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;10.15*#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="acet-ex10_15.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Adicet Bio, Inc. 2022 Inducement Plan and forms of award agreements thereunder.</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;10.16*#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="acet-ex10_16.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Form of Employment Agreement.</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;10.17*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="acet-ex10_17.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Form of Indemnification Agreement between the Registrant and each of its directors and executive officers.</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;10.18*#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="acet-ex10_18.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amended and Restated Non-Employee Director Compensation Policy.</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;10.19*#</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="acet-ex10_19.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amended and Restated Senior Executive Cash Incentive Bonus Plan.</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;10.20</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1720580/000119312520246853/d24517dex1023.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Lease Agreement, dated as of October 31, 2018, by and between Adicet Therapeutics, Inc. as Tenant, and Westport Office Park, LLC as Landlord (incorporated by reference to Exhibit 10.23 to the Registrant&#x2019;s Current Report on Form 8-K (File No. 001-38359) filed with the SEC on September 16, 2020).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;10.21</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1720580/000119312521001980/d105716dex101.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">First Amendment to Lease, dated as of December 30, 2020, by and between Adicet Therapeutics, Inc. as Tenant, and Westport Office Park, LLC as Landlord (incorporated by reference to Exhibit 10.1 to the Registrant&#x2019;s Current Report on Form 8-K (File No. 001-38359) filed with the SEC on January 5, 2021).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;10.22</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1720580/000119312518010514/d475892dex1015.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Office Lease Agreement, dated as of January 8, 2018, by and between the Registrant and 500 Boylston and 222 Berkeley Owner (DE) LLC (incorporated by reference to Exhibit 10.15 to the Registrant&#x2019;s Registration Statement on Form S-1, as amended, (File No. 333-222373) filed with the SEC on January 16, 2018).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;10.23</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1720580/000156459019019433/torc-ex102_58.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">First Amendment to Office Lease, dated as of April 1, 2019, by and between the Registrant and 500 Boylston and 222 Berkeley Owner (DE) LLC (incorporated by reference to Exhibit 10.2 to the Registrant&#x2019;s Quarterly Report on Form 10-Q (File No. 001-38359) filed with the SEC on May 15, 2019).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;10.24</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1720580/000156459021037772/acet-ex101_8.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Sublease Agreement, dated as of July 19, 2021, between the Registrant and RFS Opco LLC (incorporated by reference to Exhibit 10.1 to the Registrant&#x2019;s Current Report on Form 8-K (File No. 001-38359) filed with the SEC on July 26, 2021).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;10.25</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1720580/000095017021000417/acet-20210625ex10_1.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Third Amendment to Business Park Lease, dated as of June 25, 2021, between the Registrant and Facebook, Inc. (incorporated by reference to Exhibit 10.1 to the Registrant&#x2019;s Current Report on Form 8-K (File No. 001-38359) filed with the SEC on July 1, 2021).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;10.26</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1720580/000095017021000417/acet-20210625ex10_2.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Second Amendment to Business Park Lease, dated as of October 19, 2020, between the Registrant and Facebook, Inc. (incorporated by reference to Exhibit 10.2 to the Registrant&#x2019;s Current Report on Form 8-K (File No. 001-38359) filed with the SEC on July 1, 2021).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;10.27</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1720580/000119312520246853/d24517dex1025.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amendment to Business Park Lease, dated as of September 2019, between Adicet Therapeutics, Inc. and David D. Bohannon Organization (incorporated by reference to Exhibit 10.25 to the Registrant&#x2019;s Current Report on Form 8-K (File No. 001-38359) filed with the SEC on September 16, 2020)</span></a><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;10.28</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1720580/000119312520246853/d24517dex1024.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Business Park Lease, dated as of September 30, 2015, by and between Adicet Therapeutics, Inc. and David D. Bohannon Organization (incorporated by reference to Exhibit 10.24 to the Registrant&#x2019;s Current Report on Form 8-K (File No. 001-38359) filed with the SEC on September 16, 2020).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;10.29</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1720580/000119312521111629/d44496dex101.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Standard Form of Agreement between Owner and Contractor Where the Basis for Payment is a Stipulated Sum, effective as of April 2, 2021, by and between Adicet Therapeutics, Inc., as Owner, and CP Enterprises, Inc. d/b/a CP Construction, as Contractor (incorporated by reference to Exhibit 10.1 to the Registrant&#x2019;s Current Report on Form 8-K (File No. 001-38359) filed with the SEC on April 9, 2021)</span></a><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">106</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:8.695%;"></td>
    <td style="width:1.144%;"></td>
    <td style="width:90.16%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;10.30+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1720580/000119312520246853/d24517dex1027.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amended and Restated License Agreement, dated as of May 21, 2014, by and between Technion Research and Development Foundation Ltd., acting on behalf of itself and the Technion-Israel Institute of Technology, and Adicet Therapeutics, Inc. as successor in interest to Applied Immune Technology, Ltd. (incorporated by reference to Exhibit 10.27 to the Registrant&#x2019;s Current Report on Form 8-K (File No. 001-38359) filed with the SEC on September 16, 2020).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;10.31+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1720580/000119312520246853/d24517dex1028.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amendment No. 1 to Amended and Restated License Agreement, dated as of June 30, 2015, by and between Technion Research and Development Foundation Ltd., acting on behalf of itself and the Technion-Israel Institute of Technology, and Applied Immune Technology, Ltd. (incorporated by reference to Exhibit 10.28 to the Registrant&#x2019;s Current Report on Form 8-K (File No. 001-38359) filed with the SEC on September 16, 2020).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;10.32+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1720580/000119312520246853/d24517dex1029.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amendment No. 2 to Amended and Restated License Agreement, dated as of January 13, 2016, by and between Technion Research and Development Foundation Ltd., Applied Immune Technology, Ltd., and Adicet Therapeutics, Inc. (incorporated by reference to Exhibit 10.29 to the Registrant&#x2019;s Current Report on Form 8-K (File No. 001-38359) filed with the SEC on September 16, 2020).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;10.33+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1720580/000119312520246853/d24517dex1030.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">License and Collaboration Agreement, dated as of July 29, 2016, by and between Adicet Therapeutics, Inc. and Regeneron Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.30 to the Registrant&#x2019;s Current Report on Form 8-K (File No. 001-38359) filed with the SEC on September 16, 2020).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;10.34+</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="https://www.sec.gov/Archives/edgar/data/1720580/000119312520246853/d24517dex1031.htm" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amendment No. 1 to License and Collaboration Agreement, dated as of April 24, 2019, by and between Adicet Therapeutics, Inc. and Regeneron Pharmaceuticals, Inc. (incorporated by reference to Exhibit 10.31 to the Registrant&#x2019;s Current Report on Form 8-K (File No. 001-38359) filed with the SEC on September 16, 2020).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;21.1</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="/exhibit" style="-sec-extract:exhibit"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Subsidiaries of the Registrant (incorporated by reference to Exhibit 21.1 to the Registrant&#x2019;s Annual Report on Form 10-K (File No. 001-38359) filed with the SEC on March 12, 2021).</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;23.1*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="acet-ex23_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Consent of KPMG LLP, independent registered public accounting firm.</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;31.1*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="acet-ex31_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Certification of Principal Executive Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;31.2*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="acet-ex31_2.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Certification of Principal Financial Officer pursuant to Rule 13a-14(a) and Rule 15d-14(a) of the Securities Exchange Act of 1934, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span><span style="color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;&#160;32.1**</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><a href="acet-ex32_1.htm"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,255,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Certification of Principal Executive Officer and Principal Financial Officer pursuant to 18 U.S.C. &#167;1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101.INS*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inline </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">XBRL Instance Document</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101.SCH*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inline </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">XBRL Taxonomy Extension Schema Document</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101.CAL*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inline </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">XBRL Taxonomy Extension Calculation Linkbase Document</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101.DEF*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inline </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">XBRL Taxonomy Extension Definition Linkbase Document</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101.LAB*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inline </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">XBRL Taxonomy Extension Label Linkbase Document</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:6.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101.PRE*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Inline </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">XBRL Taxonomy Extension Presentation Linkbase Document</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:5.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:5.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">104*</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cover Page Interactive Data File</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;margin-right:73.333%;text-align:left;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">* Filed herewith.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">+ Portions of this exhibit (indicated by asterisks) have been omitted pursuant to Item 601(b)(10) of Regulation S-K.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"># Indicates a management contract or any compensatory plan, contract or arrangement.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">** The certifications furnished in Exhibit 32.1 hereto are deemed to accompany this Annual Report on Form 10-K and will not be deemed &#x201c;filed&#x201d; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. Such certifications will not be deemed to be incorporated by reference into any filings under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that the Registrant specifically incorporates it by reference.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">107</span></p>
  <hr style="page-break-after:always;" />
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="signatures"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">SIGNA</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">TURES</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:51.989%;"></td>
    <td style="width:4.008%;"></td>
    <td style="width:44.002%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Adicet Bio, Inc.</span></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Date: March 15, 2022</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">By:</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Chen Schor</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Chen Schor</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">President, Chief Executive Officer and Director</span></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">(Principal Executive Officer)</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:6.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;" id="powerofattorney"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">POWER OF ATTORNEY</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Each person whose individual signature appears below hereby authorizes and appoints Chen Schor and Nick Harvey, and each of them, with full power of substitution and resubstitution and full power to act without the other, as his or her true and lawful attorney-in-fact and agent to act in his or her name, place and stead and to execute in the name and on behalf of each person, individually and in each capacity stated below, and to file any and all amendments to this annual report on Form 10-K and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing, ratifying and confirming all that said attorneys-in-fact and agents or any of them or their or his substitute or substitutes may lawfully do or cause to be done by virtue thereof.</span></p>
  <p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the requirements of the Securities Act of 1934, this Annual Report on Form 10-K has been signed by the following persons in the capacities and on the dates indicated.</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:22.32%;"></td>
    <td style="width:0.9%;"></td>
    <td style="width:55.781%;"></td>
    <td style="width:0.998%;"></td>
    <td style="width:20.002%;"></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Signature</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Title</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Date</span></p></td>
   </tr>
   <tr style="height:2.9pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:4.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Chen Schor</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Chen Schor</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">President, Chief Executive Officer and Director (principal executive officer)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 15, 2022</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Nick Harvey</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Nick Harvey</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Chief Financial Officer (principal financial officer and principal accounting officer)</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 15, 2022</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Jeffrey Chodakewitz</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:16.55pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Jeffrey Chodakewitz, M.D.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 15, 2022</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Steve Dubin</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:17.3pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Steve Dubin</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 15, 2022</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Carl L. Gordon</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:15.85pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Carl L. Gordon, Ph.D.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 15, 2022</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Aya Jakobovits</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:18.7pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Aya Jakobovits, Ph.D.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 15, 2022</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Michael Kauffman</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Michael Kauffman, M.D., Ph.D</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 15, 2022</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Bastiano Sanna</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:20.9pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Bastiano Sanna, Ph.D.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 15, 2022</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ Andrew Sinclair</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Andrew Sinclair, Ph.D.</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Director</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 15, 2022</span></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">108</span></p>
  <hr style="page-break-after:always;" />
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.3
<SEQUENCE>2
<FILENAME>acet-ex4_3.htm
<DESCRIPTION>EX-4.3
<TEXT>
<html>
 <head>
  <title>EX-4.3</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 4.3</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img128415308_0.jpg" alt="img128415308_0.jpg" style="width:524px;height:849px;">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:4.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(255,255,255,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;">ZQ|CERT#|COY|CLS|RGSTRY|ACCT#|TRANSTYPE|RUN#|TRANS# COMMON STOCK PAR VALUE $0.0001 COMMON STOCK Certificate Number ZQ00000000 Adicet Bio Shares **000000 ****************** ***000000 ***************** **** 000000 **************** ***** 000000 *************** ****** 000000 ************** Adicet Bio, Inc. INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE THIS CERTIFIES THAT ** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Alexander David Sample **** Mr. Sample **** Mr. Sample SEE REVERSE FOR CERTAIN DEFINITIONS CUSIP 007002 10 8 is the owner of **000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares*** *000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares**** 000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****0 00000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****00 0000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000 000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****0000 00**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****00000 0**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000 **Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000* *Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000** Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**Shares****000000**S THIS CERTIFICATE IS TRANSFERABLE IN CITIES DESIGNATED BY THE TRANSFER AGENT, AVAILABLE ONLINE AT www.computershare.com FULLY-PAID AND NON-ASSESSABLE SHARES OF COMMON STOCK OF Adicet Bio, Inc. (hereinafter called the &#x201c;Company&#x201d;), transferable on the books of the Company in person or by duly authorized attorney, upon surrender of this Certificate properly endorsed. This Certificate and the shares represented hereby, are issued and shall be held subject to all of the provisions of the Articles of Incorporation, as amended, and the By-Laws, as amended, of the Company (copies of which are on file with the Company and with the Transfer Agent), to all of which each holder, by acceptance hereof, assents. This Certificate is not valid unless countersigned and registered by the Transfer Agent and Registrar. Witness the facsimile seal of the Company and the facsimile signatures of its duly authorized officers. DATED DD-MMM-YYYY FACSIMILE SIGNATURE TO COME COUNTERSIGNED AND REGISTERED: COMPUTERSHARE TRUST COMPANY, N.A. TRANSFER&#x2008;AGENT AND&#x2008;REGISTRAR, Ad ci et Bio, Inc INCORPORATED SEAL July 5, 2016 DELAWARE FACSIMILE SIGNATURE TO COM Chief Financial Officer By AUTHORIZED&#x2008;SIGNATURE Adicet Bio CUSIP/IDENTIFIER XXXXXX XX X Holder ID XXXXXXXXXX Insurance Value 1,000,000.00 Number of Shares 123456 DTC 12345678 123456789012345 PO BOX 43004, Providence, RI 02940-3004 Certificate Numbers 1234567890/1234567890 1234567890/1234567890 1234567890/1234567890 1234567890/1234567890 1234567890/1234567890 1234567890/1234567890 Transaction Num/No. 1 2 3 4 5 6 Denom. 1 2 3 4 5 6 Total 1 2 3 4 5 6 7MR A SAMPLE DESIGNATION (IF ANY) ADD 1 ADD 2 ADD 3 ADD 4 1234567</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><img src="img128415308_1.jpg" alt="img128415308_1.jpg" style="width:602px;height:759px;">&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(255,255,255,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;">Adicet Bio, Inc. THE COMPANY WILL FURNISH WITHOUT CHARGE TO EACH SHAREHOLDER WHO SO REQUESTS, A SUMMARY OF THE POWERS, DESIGNATIONS, PREFERENCES AND RELATIVE, PARTICIPATING, OPTIONAL OR OTHER SPECIAL RIGHTS OF EACH CLASS OF STOCK OF THE COMPANY AND THE QUALIFICATIONS, LIMITATIONS OR RESTRICTIONS OF SUCH PREFERENCES AND RIGHTS, AND THE VARIATIONS IN RIGHTS, PREFERENCES AND LIMITATIONS DETERMINED FOR EACH SERIES, WHICH ARE FIXED BY THE ARTICLES OF INCORPORATION OF THE COMPANY, AS AMENDED, AND THE RESOLUTIONS OF THE BOARD OF DIRECTORS OF THE COMPANY, AND THE AUTHORITY OF THE BOARD OF DIRECTORS TO DETERMINE VARIATIONS FOR FUTURE SERIES. SUCH REQUEST MAY BE MADE TO THE OFFICE OF THE SECRETARY OF THE COMPANY OR TO THE TRANSFER AGENT. THE BOARD OF DIRECTORS MAY REQUIRE THE OWNER OF A LOST OR DESTROYED STOCK CERTIFICATE, OR HIS LEGAL REPRESENTATIVES, TO GIVE THE COMPANY A BOND TO INDEMNIFY IT AND ITS TRANSFER AGENTS AND REGISTRARS AGAINST ANY CLAIM THAT MAY BE MADE AGAINST THEM ON ACCOUNT OF THE ALLEGED LOSS OR DESTRUCTION OF ANY SUCH CERTIFICATE. The following abbreviations, when used in the inscription on the face of this certificate, shall be construed as though they were written out in full according to applicable laws or regulations: TEN COM - as tenants in common UNIF GIFT MIN ACT -............................................Custodian ................................................ (Cust) (Minor) TEN ENT - as tenants by the entireties under Uniform Gifts to Minors Act ........................................................ (State) JT TEN - as joint tenants with right of survivorship UNIF&#x2008;TRF MIN ACT -............................................Custodian (until age ................................) and not as tenants in common (Cust) .............................under Uniform Transfers to Minors Act ................... (Minor) (State)  Additional abbreviations may also be used though not in the above list. PLEASE INSERT SOCIAL SECURITY OR OTHER IDENTIFYING NUMBER OF ASSIGNEE For value received, hereby sell, assign and transfer unto (PLEASE PRINT OR TYPEWRITE NAME AND ADDRESS, INCLUDING POSTAL ZIP CODE, OF ASSIGNEE) Shares of the common stock represented by the within Certificate, and do hereby irrevocably constitute and appoint Attorney to transfer the said stock on the books of the within-named Company with full power of substitution in the premises Dated: 20 Signature(s) Guaranteed: Medallion Guarantee Stamp THE SIGNATURE(S) SHOULD BE GUARANTEED BY AN ELIGIBLE GUARANTOR INSTITUTION (Banks, Stockbrokers, Savings and Loan Associations and Credit Unions) WITH MEMBERSHIP IN AN APPROVED SIGNATURE GUARANTEE MEDALLION PROGRAM, PURSUANT TO S.E.C. RULE 17Ad-15. Signature: Signature: Notice: The signature to this assignment must correspond with the name as written upon the face of the certificate, in every particular, without alteration or enlargement, or any change whatever The IRS requires that the named transfer agent (&#x201c;we&#x201d;) report the cost basis of certain shares or units acquired after January 1, 2011. If your shares or units are covered by the legislation, and you requested to sell or transfer the shares or units using a specific cost basis calculation method, then we have processed as you requested. If you did not specify a cost basis calculation method, then we have defaulted to the first in, first out (FIFO) method. Please consult your tax advisor if you need additional information about cost basis. If you do not keep in contact with the issuer or do not have any activity in your account for the time period specified by state law, your property may become subject to state unclaimed property laws and transferred to the appropriate state 1234567 SECURITY INSTRUCTIONS THIS IS WATERMARKED PAPER DO NOT ACCEPT WITHOUT NOTHING WATERMARK HOLD TO LIGHT TO VERIFY WATERMARK</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.11
<SEQUENCE>3
<FILENAME>acet-ex10_11.htm
<DESCRIPTION>EX-10.11
<TEXT>
<html>
 <head>
  <title>EX-10.11</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 10.11</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ADICET BIO, INC.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">AMENDED AND RESTATED 2018 STOCK OPTION AND INCENTIVE PLAN</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">SECTION 1.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">GENERAL PURPOSE OF THE PLAN; DEFINITIONS</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The name of the plan is the Adicet Bio, Inc. Amended and Restated 2018 Stock Option and Incentive Plan (the &#x201c;Plan&#x201d;). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of Adicet Bio, Inc. (the &#x201c;Company&#x201d;) and its Affiliates upon whose judgment, initiative and efforts the Company largely depends for the successful conduct of its businesses to acquire a proprietary interest in the Company. It is anticipated that providing such persons with a direct stake in the Company&#x2019;s welfare will assure a closer identification of their interests with those of the Company and its stockholders, thereby stimulating their efforts on the Company&#x2019;s behalf and strengthening their desire to remain with the Company.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following terms shall be defined as set forth below:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">&#x201c;2017 Plan&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> means the Adicet Bio, Inc. 2017 Stock Incentive Plan, as amended.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">&#x201c;Act&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> means the Securities Act of 1933, as amended, and the rules and regulations thereunder.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">&#x201c;Administrator&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> means either the Board or the compensation committee of the Board or a similar committee performing the functions of the compensation committee and which is comprised of not less than two Non-Employee Directors who are independent.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">&#x201c;Affiliates&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> means, at the time of determination, any &#x201c;parent&#x201d; or &#x201c;subsidiary&#x201d; of the Company as such terms are defined in Rule 405 of the Act. The Board will have the authority to determine the time or times at which &#x201c;parent&#x201d; or &#x201c;subsidiary&#x201d; status is determined within the foregoing definition.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">&#x201c;Award&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> or </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">&#x201c;Awards,&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> except where referring to a particular category of grant under the Plan, shall include Incentive Stock Options, Non-Qualified Stock Options, Stock Appreciation Rights, Restricted Stock Units, Restricted Stock Awards, Unrestricted Stock Awards, Cash-Based Awards and Dividend Equivalent Rights.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">&#x201c;Award Certificate&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> means a written or electronic document setting forth the terms and provisions applicable to an Award granted under the Plan. Each Award Certificate is subject to the terms and conditions of the Plan.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">&#x201c;Board&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> means the Board of Directors of the Company.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">&#x201c;Cash-Based Award&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> means an Award entitling the recipient to receive a cash-denominated payment.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">&#x201c;Code&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> means the Internal Revenue Code of 1986, as amended, and any successor Code, and related rules, regulations and interpretations.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">&#x201c;Consultant&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> means a consultant or adviser who provides bona fide services to the Company or an Affiliate as an independent contractor and who qualifies as a consultant or advisor under Instruction A.1.(a)(1) of Form S-8 under the Act.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">&#x201c;Continuous Service&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> means that a Service Relationship is not interrupted or terminated. For this purpose, a Service Relationship shall be deemed to continue without interruption in the event an individual&#x2019;s status changes from full-time employee to part-time employee or Consultant.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">&#x201c;Dividend Equivalent Right&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> means an Award entitling the grantee to receive credits based on cash dividends that would have been paid on the shares of Stock specified in the Dividend Equivalent Right (or other award to which it relates) if such shares had been issued to and held by the grantee.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">&#x201c;Effective Date&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> means the date on which the Plan becomes effective as set forth in Section 19.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">&#x201c;Exchange Act&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> means the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">&#x201c;Fair Market Value&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of the Stock on any given date means the fair market value of the Stock determined in good faith by the Administrator; provided, however, that if the Stock is admitted to quotation on the National Association of Securities Dealers</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/115808348.2</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Automated Quotation System (&#x201c;Nasdaq&#x201d;), Nasdaq Global Market or another national securities exchange, the determination shall be made by reference to market quotations. If there are no market quotations for such date, the determination shall be made by reference to the last date preceding such date for which there are market quotations.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">&#x201c;Incentive Stock Option&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> means any Stock Option designated and qualified as an &#x201c;incentive stock option&#x201d; as defined in Section 422 of the Code.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">&#x201c;Non-Employee Director&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> means a member of the Board who is not also an employee of the Company or any Subsidiary.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">&#x201c;Non-Qualified Stock Option&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> means any Stock Option that is not an Incentive Stock Option.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">&#x201c;Option&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> or </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">&#x201c;Stock Option&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> means any option to purchase shares of Stock granted pursuant to Section 5.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">&#x201c;Restricted Shares&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> means the shares of Stock underlying a Restricted Stock Award that remain subject to a risk of forfeiture or the Company&#x2019;s right of repurchase.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">&#x201c;Restricted Stock Award&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> means an Award of Restricted Shares subject to such restrictions and conditions as the Administrator may determine at the time of grant.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">&#x201c;Restricted Stock Units&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> means an Award of stock units subject to such restrictions and conditions as the Administrator may determine at the time of grant.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">&#x201c;Sale Event&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shall mean (i) the sale of all or substantially all of the assets of the Company on a consolidated basis to an unrelated person or entity, (ii) a merger, reorganization or consolidation pursuant to which the holders of the Company&#x2019;s outstanding voting power and outstanding stock immediately prior to such transaction do not own a majority of the outstanding voting power and outstanding stock or other equity interests of the resulting or successor entity (or its ultimate parent, if applicable) immediately upon completion of such transaction, (iii) the sale of all of the Stock of the Company to an unrelated person, entity or group thereof acting in concert, or (iv) any other transaction in which the owners of the Company&#x2019;s outstanding voting power immediately prior to such transaction do not own at least a majority of the outstanding voting power of the Company or any successor entity immediately upon completion of the transaction other than as a result of the acquisition of securities directly from the Company.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Sale Price</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d; means the value as determined by the Administrator of the consideration payable, or otherwise to be received by stockholders, per share of Stock pursuant to a Sale Event.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">&#x201c;Section 409A&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> means Section 409A of the Code and the regulations and other guidance promulgated thereunder.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">&#x201c;Service Relationship&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> means any relationship as an employee, Non-Employee Director or Consultant of the Company or any Affiliate.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">&#x201c;Stock&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> means the Common Stock, par value $0.0001 per share, of the Company, subject to adjustments pursuant to Section 3.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">&#x201c;Stock Appreciation Right&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> means an Award entitling the recipient to receive shares of Stock (or cash, to the extent explicitly provided for in the applicable Award Certificate) having a value equal to the excess of the Fair Market Value of the Stock on the date of exercise over the exercise price of the Stock Appreciation Right multiplied by the number of shares of Stock with respect to which the Stock Appreciation Right shall have been exercised.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">&#x201c;Subsidiary&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> means any corporation or other entity (other than the Company) in which the Company has at least a 50 percent interest, either directly or indirectly.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">&#x201c;Ten Percent Owner&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> means an employee who owns or is deemed to own (by reason of the attribution rules of Section 424(d) of the Code) more than 10 percent of the combined voting power of all classes of stock of the Company or any parent or subsidiary corporation.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">&#x201c;Unrestricted Stock Award&#x201d;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> means an Award of shares of Stock free of any restrictions.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/115808348.2</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">SECTION 2.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">ADMINISTRATION OF PLAN; ADMINISTRATOR AUTHORITY TO SELECT GRANTEES AND DETERMINE AWARDS</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(a) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Administration of Plan</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Plan shall be administered by the Administrator.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(b) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Powers of Administrator</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Administrator shall have the power and authority to grant Awards consistent with the terms of the Plan, including the power and authority:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(i) to select the individuals to whom Awards may from time to time be granted;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(ii) to determine the time or times of grant, and the extent, if any, of Incentive Stock Options, Non-Qualified Stock Options, Stock Appreciation Rights, Restricted Stock Awards, Restricted Stock Units, Unrestricted Stock Awards, Cash-Based Awards and Dividend Equivalent Rights, or any combination of the foregoing, granted to any one or more grantees;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(iii) to determine the number of shares of Stock to be covered by any Award;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(iv) to determine and modify from time to time the terms and conditions, including restrictions, not inconsistent with the terms of the Plan, of any Award, which terms and conditions may differ among individual Awards and grantees, and to approve the forms of Award Certificates;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(v) to accelerate at any time the exercisability or vesting of all or any portion of any Award;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(vi) subject to the provisions of Section 5(c), to extend at any time the period in which Stock Options may be exercised; and</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(vii) at any time to adopt, alter and repeal such rules, guidelines and practices for administration of the Plan and for its own acts and proceedings as it shall deem advisable; to interpret the terms and provisions of the Plan and any Award (including related written instruments); to make all determinations it deems advisable for the administration of the Plan; to decide all disputes arising in connection with the Plan; and to otherwise supervise the administration of the Plan.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All decisions and interpretations of the Administrator shall be binding on all persons, including the Company and Plan grantees.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(c) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Delegation of Authority to Grant Awards</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Subject to applicable law, the Administrator, in its discretion, may delegate to a committee consisting of one or more officers of the Company, including the Chief Executive Officer of the Company, all or part of the Administrator&#x2019;s authority and duties with respect to the granting of Awards to individuals who are (i) not subject to the reporting and other provisions of Section 16 of the Exchange Act and (ii) not members of the delegated committee. Any such delegation by the Administrator shall include a limitation as to the amount of Stock underlying Awards that may be granted during the period of the delegation and shall contain guidelines as to the determination of the exercise price and the vesting criteria. The Administrator may revoke or amend the terms of a delegation at any time but such action shall not invalidate any prior actions of the Administrator&#x2019;s delegate or delegates that were consistent with the terms of the Plan.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(d) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Award Certificate</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Awards under the Plan shall be evidenced by Award Certificates that set forth the terms, conditions and limitations for each Award which may include, without limitation, the term of an Award and the provisions applicable in the event employment or service terminates.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(e) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Indemnification</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Neither the Board nor the Administrator, nor any member of either or any delegate thereof, shall be liable for any act, omission, interpretation, construction or determination made in good faith in connection with the Plan, and the members of the Board and the Administrator (and any delegate thereof) shall be entitled in all cases to indemnification and reimbursement by the Company in respect of any claim, loss, damage or expense (including, without limitation, reasonable attorneys&#x2019; fees) arising or resulting therefrom to the fullest extent permitted by law and/or under the Company&#x2019;s articles or bylaws or any directors&#x2019; and officers&#x2019; liability insurance coverage which may be in effect from time to time and/or any indemnification agreement between such individual and the Company.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(f) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Foreign Award Recipients</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Notwithstanding any provision of the Plan to the contrary, in order to comply with the laws in other countries in which the Company and its Subsidiaries operate or have employees or other individuals eligible for Awards, the Administrator, in its sole discretion, shall have the power and authority to: (i) determine which Subsidiaries shall be covered by the Plan; (ii) determine which individuals outside the United States are eligible to participate in the Plan; (iii) modify the terms and conditions of any Award granted to individuals outside the United States to comply with applicable foreign laws; (iv) establish</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/115808348.2</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">subplans and modify exercise procedures and other terms and procedures, to the extent the Administrator determines such actions to be necessary or advisable (and such subplans and/or modifications shall be attached to this Plan as appendices); provided, however, that no such subplans and/or modifications shall increase the share limitations contained in Section 3(a) hereof; and (v) take any action, before or after</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">an Award is made, that the Administrator determines to be necessary or advisable to obtain approval or comply with any local governmental regulatory exemptions or approvals. Notwithstanding the foregoing, the Administrator may not take any actions hereunder, and no Awards shall be granted, that would violate the Exchange Act or any other applicable United States securities law, the Code, or any other applicable United States governing statute or law.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">SECTION 3.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">STOCK ISSUABLE UNDER THE PLAN; MERGERS; SUBSTITUTION</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(a) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Stock Issuable</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The maximum number of shares of Stock reserved and available for issuance under the Plan shall be 5,136,003 shares of Stock (the &#x201c;Initial Limit&#x201d;), subject to adjustment as provided in Section 3(c), plus on January 1, 2022 and each January 1 thereafter, the number of shares of Stock reserved and available for issuance under the Plan shall be cumulatively increased by 5% of the number of shares of Stock issued and outstanding on the immediately preceding December 31 (the &#x201c;Annual Increase&#x201d;). Subject to such overall limitation, the maximum aggregate number of shares of Stock that may be issued in the form of Incentive Stock Options shall not exceed the Initial Limit cumulatively increased on January 1, 2022 and on each January 1 thereafter by the lesser of the Annual Increase for such year or 3,150,000 shares of Stock, subject in all cases to adjustment as provided in Section 3(c). For purposes of this limitation, the shares of Stock underlying any Awards that are forfeited, canceled, held back upon exercise of an Option or settlement of an Award to cover the exercise price or tax withholding, reacquired by the Company prior to vesting, satisfied without the issuance of Stock or otherwise terminated (other than by exercise) under each of the Plan and the 2017 Plan shall be added back to the shares of Stock available for issuance under the Plan. In the event the Company repurchases shares of Stock on the open market, such shares shall not be added to the shares of Stock available for issuance under the Plan. Subject to such overall limitations, shares of Stock may be issued up to such maximum number pursuant to any type or types of Award. The shares available for issuance under the Plan may be authorized but unissued shares of Stock or shares of Stock reacquired by the Company.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(b) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Maximum Awards to Non-Employee Directors</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Notwithstanding anything to the contrary in this Plan, the value of all Awards awarded under this Plan and all other cash compensation paid by the Company to any Non-Employee Director in any calendar year shall not exceed $1,000,000. For the purpose of this limitation, the value of any Award shall be its grant date fair value, as determined in accordance with ASC 718 or successor provision but excluding the impact of estimated forfeitures related to service-based vesting provisions.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(c) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Changes in Stock</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Subject to Section 3(d) hereof, if, as a result of any reorganization, recapitalization, reclassification, stock dividend, stock split, reverse stock split or other similar change in the Company&#x2019;s capital stock, the outstanding shares of Stock are increased or decreased or are exchanged for a different number or kind of shares or other securities of the Company, or additional shares or new or different shares or other securities of the Company or other non-cash assets are distributed with respect to such shares of Stock or other securities, or, if, as a result of any merger or consolidation, sale of all or substantially all of the assets of the Company, the outstanding shares of Stock are converted into or exchanged for securities of the Company or any successor entity (or a parent or subsidiary thereof), the Administrator shall make an appropriate or proportionate adjustment in (i) the maximum number of shares reserved for issuance under the Plan, including the maximum number of shares that may be issued in the form of Incentive Stock Options, (ii) the number and kind of shares or other securities subject to any then outstanding Awards under the Plan, (iii) the repurchase price, if any, per share subject to each outstanding Restricted Stock Award, and (iv) the exercise price for each share subject to any then outstanding Stock Options and Stock Appreciation Rights under the Plan, without changing the aggregate exercise price (i.e., the exercise price multiplied by the number of shares subject to Stock Options and Stock Appreciation Rights) as to which such Stock Options and Stock Appreciation Rights remain exercisable. The Administrator shall also make equitable or proportionate adjustments in the number of shares subject to outstanding Awards and the exercise price and the terms of outstanding Awards to take into consideration cash dividends paid other than in the ordinary course or any other extraordinary corporate event. The adjustment by the Administrator shall be final, binding and conclusive. No fractional shares of Stock shall be issued under the Plan resulting from any such adjustment, but the Administrator in its discretion may make a cash payment in lieu of fractional shares.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(d) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Mergers and Other Transactions</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. In the case of and subject to the consummation of a Sale Event, the parties thereto may cause the assumption or continuation of Awards theretofore granted by the successor entity, or the substitution of such Awards with new Awards of the successor entity or parent thereof, with appropriate adjustment as to the number and kind of shares and, if appropriate, the per share exercise prices, as such parties shall agree. To the extent the parties to such Sale Event do not provide for the assumption, continuation or substitution of Awards, upon the effective time of the Sale Event, the Plan and all outstanding Awards granted hereunder shall terminate. In such case, except as may be otherwise provided in the relevant Award Certificate, all Options and Stock Appreciation Rights with time-based vesting conditions or restrictions that are not vested and/or exercisable immediately prior to the effective time of the Sale Event shall become fully vested and exercisable as of the effective time of the Sale Event, all other Awards with time-based vesting, conditions or restrictions shall become fully vested and nonforfeitable as of the effective time of the Sale Event, and all Awards with conditions and restrictions relating to the attainment of performance goals may become vested</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/115808348.2</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and nonforfeitable in connection with a Sale Event in the Administrator&#x2019;s discretion or to the extent specified in the relevant Award Certificate. In the event of such termination, (i) the Company shall have the option (in its sole discretion) to make or provide for a payment, in cash or in kind, to the grantees holding Options and Stock Appreciation Rights, in exchange for the cancellation thereof, in an amount equal to the difference between (A) the Sale Price multiplied by the number of shares of Stock subject to outstanding Options and Stock Appreciation Rights (to the extent then exercisable at prices not in excess of the Sale Price) and (B) the aggregate exercise price of all such outstanding Options and Stock Appreciation Rights (provided that, in the case of an Option or Stock Appreciation Right with an exercise price equal to or greater than the Sale Price, such Option or Stock Appreciation Right shall be cancelled for no consideration); or (ii) each grantee shall be permitted, within a specified period of time prior to the consummation of the Sale Event as determined by the Administrator, to exercise all outstanding Options and Stock Appreciation Rights (to the extent then exercisable) held by such grantee. The Company shall also have the option (in its sole discretion) to make or provide for a payment, in cash or in kind, to the grantees holding other Awards in an amount equal to the Sale Price multiplied by the number of vested shares of Stock under such Awards.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">SECTION 4.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">ELIGIBILITY</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Grantees under the Plan will be such employees, Non-Employee Directors or Consultants of the Company and its Affiliates as are selected from time to time by the Administrator in its sole discretion; provided that Awards may not be granted to employees, Non-Employee Directors or Consultants who are providing services only to any &#x201c;parent&#x201d; of the Company, as such term is defined in Rule 405 of the Act, unless (i) the stock underlying the Awards is treated as &#x201c;service recipient stock&#x201d; under Section 409A or (ii) the Company has determined that such Awards are exempt from or otherwise comply with Section 409A.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">SECTION 5.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">STOCK OPTIONS</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(a) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Award of Stock Options</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Administrator may grant Stock Options under the Plan. Any Stock Option granted under the Plan shall be in such form as the Administrator may from time to time approve.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock Options granted under the Plan may be either Incentive Stock Options or Non-Qualified Stock Options. Incentive Stock Options may be granted only to employees of the Company or any Subsidiary that is a &#x201c;subsidiary corporation&#x201d; within the meaning of Section 424(f) of the Code. To the extent that any Option does not qualify as an Incentive Stock Option, it shall be deemed a Non-Qualified Stock Option.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock Options granted pursuant to this Section 5 shall be subject to the following terms and conditions and shall contain such additional terms and conditions, not inconsistent with the terms of the Plan, as the Administrator shall deem desirable. If the Administrator so determines, Stock Options may be granted in lieu of cash compensation at the optionee&#x2019;s election, subject to such terms and conditions as the Administrator may establish.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(b) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Exercise Price</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The exercise price per share for the Stock covered by a Stock Option granted pursuant to this Section 5 shall be determined by the Administrator at the time of grant but shall not be less than 100 percent of the Fair Market Value on the date of grant. In the case of an Incentive Stock Option that is granted to a Ten Percent Owner, the exercise price of such Incentive Stock Option shall be not less than 110 percent of the Fair Market Value on the grant date. Notwithstanding the foregoing, Stock Options may be granted with an exercise price per share that is less than 100 percent of the Fair Market Value on the date of grant (i) pursuant to a transaction described in, and in a manner consistent with, Section 424(a) of the Code, (ii) to individuals who are not subject to U.S. income tax on the date of grant or (iii) the Stock Option is otherwise compliant with Section 409A.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(c) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Option Term</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The term of each Stock Option shall be fixed by the Administrator, but no Stock Option shall be exercisable more than ten years after the date the Stock Option is granted. In the case of an Incentive Stock Option that is granted to a Ten Percent Owner, the term of such Stock Option shall be no more than five years from the date of grant.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(d) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Exercisability; Rights of a Stockholder</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Stock Options shall become exercisable at such time or times, whether or not in installments, as shall be determined by the Administrator at or after the grant date. The Administrator may at any time accelerate the exercisability of all or any portion of any Stock Option. An optionee shall have the rights of a stockholder only as to shares acquired upon the exercise of a Stock Option and not as to unexercised Stock Options.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(e) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Method of Exercise</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Stock Options may be exercised in whole or in part, by giving written or electronic notice of exercise to the Company, specifying the number of shares to be purchased. Payment of the purchase price may be made by one or more of the following methods except to the extent otherwise provided in the Award Certificate:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/115808348.2</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(i) In cash, by certified or bank check or other instrument acceptable to the Administrator;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(ii) Through the delivery (or attestation to the ownership following such procedures as the Company may prescribe) of shares of Stock that are not then subject to restrictions under any Company plan. Such surrendered shares shall be valued at Fair Market Value on the exercise date;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(iii) By the optionee delivering to the Company a properly executed exercise notice together with irrevocable instructions to a broker to promptly deliver to the Company cash or a check payable and acceptable to the Company for the purchase price; provided that in the event the optionee chooses to pay the purchase price as so provided, the optionee and the broker shall comply with such procedures and enter into such agreements of indemnity and other agreements as the Company shall prescribe as a condition of such payment procedure; or</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(iv) With respect to Stock Options that are not Incentive Stock Options, by a &#x201c;net exercise&#x201d; arrangement pursuant to which the Company will reduce the number of shares of Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate exercise price.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Payment instruments will be received subject to collection. The transfer to the optionee on the records of the Company or of the transfer agent of the shares of Stock to be purchased pursuant to the exercise of a Stock Option will be contingent upon receipt from the optionee (or a purchaser acting in his stead in accordance with the provisions of the Stock Option) by the Company of the full purchase price for such shares and the fulfillment of any other requirements contained in the Award Certificate or applicable provisions of laws (including the satisfaction of any withholding taxes that the Company is obligated to withhold with respect to the optionee). In the event an optionee chooses to pay the purchase price by previously-owned shares of Stock through the attestation method, the number of shares of Stock transferred to the optionee upon the exercise of the Stock Option shall be net of the number of attested shares. In the event that the Company establishes, for itself or using the services of a third party, an automated system for the exercise of Stock Options, such as a system using an internet website or interactive voice response, then the paperless exercise of Stock Options may be permitted through the use of such an automated system.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(f) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Annual Limit on Incentive Stock Options</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. To the extent required for &#x201c;incentive stock option&#x201d; treatment under Section 422 of the Code, the aggregate Fair Market Value (determined as of the time of grant) of the shares of Stock with respect to which Incentive Stock Options granted under this Plan and any other plan of the Company or its parent and subsidiary corporations become exercisable for the first time by an optionee during any calendar year shall not exceed $100,000. To the extent that any Stock Option exceeds this limit, it shall constitute a Non-Qualified Stock Option.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">SECTION 6.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">STOCK APPRECIATION RIGHTS</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(a) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Award of Stock Appreciation Rights</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Administrator may grant Stock Appreciation Rights under the Plan. A Stock Appreciation Right is an Award entitling the recipient to receive shares of Stock (or csh, to the extent explicitly provided for in the applicable Award Certificate) having a value equal to the excess of the Fair Market Value of a share of Stock on the date of exercise over the exercise price of the Stock Appreciation Right multiplied by the number of shares of Stock with respect to which the Stock Appreciation Right shall have been exercised.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(b) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Exercise Price of Stock Appreciation Rights</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The exercise price of a Stock Appreciation Right shall not be less than 100 percent of the Fair Market Value of the Stock on the date of grant.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(c) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Grant and Exercise of Stock Appreciation Rights</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Stock Appreciation Rights may be granted by the Administrator independently of any Stock Option granted pursuant to Section 5 of the Plan.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(d) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Terms and Conditions of Stock Appreciation Rights</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Stock Appreciation Rights shall be subject to such terms and conditions as shall be determined on the date of grant by the Administrator. The term of a Stock Appreciation Right may not exceed ten years. The terms and conditions of each such Award shall be determined by the Administrator, and such terms and conditions may differ among individual Awards and grantees.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">SECTION 7.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">RESTRICTED STOCK AWARDS</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(a) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Nature of Restricted Stock Awards</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Administrator may grant Restricted Stock Awards under the Plan. A Restricted Stock Award is any Award of Restricted Shares subject to such restrictions and conditions as the Administrator may determine at the time of</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/115808348.2</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">grant. Conditions may be based on continuing employment (or other Service Relationship) and/or achievement of pre-established performance goals and objectives.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(b) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Rights as a Stockholder</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Upon the grant of the Restricted Stock Award and payment of any applicable purchase price, a grantee shall have the rights of a stockholder with respect to the voting of the Restricted Shares and receipt of dividends; provided that if the lapse of restrictions with respect to the Restricted Stock Award is tied to the attainment of performance goals, any dividends paid by the Company during the performance period shall accrue and shall not be paid to the grantee until and to the extent the performance goals are met with respect to the Restricted Stock Award. Unless the Administrator shall otherwise determine, (i) uncertificated Restricted Shares shall be accompanied by a notation on the records of the Company or the transfer agent to the effect that they are subject to forfeiture until such Restricted Shares are vested as provided in Section 7(d) below, and (ii) certificated Restricted Shares shall remain in the possession of the Company until such Restricted Shares are vested as provided in Section 7(d) below, and the grantee shall be required, as a condition of the grant, to deliver to the Company such instruments of transfer as the Administrator may prescribe.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(c) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Restrictions</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Restricted Shares may not be sold, assigned, transferred, pledged or otherwise encumbered or disposed of except as specifically provided herein or in the Restricted Stock Award Certificate. Except as may otherwise be provided by the Administrator either in the Award Certificate or, subject to Section 16 below, in writing after the Award is issued, if a grantee&#x2019;s employment (or other Service Relationship) with the Company and its Subsidiaries terminates for any reason, any Restricted Shares that have not vested at the time of termination shall automatically and without any requirement of notice to such grantee from or other action by or on behalf of, the Company be deemed to have been reacquired by the Company at its original purchase price (if any) from such grantee or such grantee&#x2019;s legal representative simultaneously with such termination of employment (or other Service Relationship), and thereafter shall cease to represent any ownership of the Company by the grantee or rights of the grantee as a stockholder. Following such deemed reacquisition of Restricted Shares that are represented by physical certificates, a grantee shall surrender such certificates to the Company upon request without consideration.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(d) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Vesting of Restricted Shares</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Administrator at the time of grant shall specify the date or dates and/or the attainment of pre-established performance goals, objectives and other conditions on which the non-transferability of the Restricted Shares and the Company&#x2019;s right of repurchase or forfeiture shall lapse. Subsequent to such date or dates and/or the attainment of such pre-established performance goals, objectives and other conditions, the shares on which all restrictions have lapsed shall no longer be Restricted Shares and shall be deemed &#x201c;vested.&#x201d;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">SECTION 8.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">RESTRICTED STOCK UNITS</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(a) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Nature of Restricted Stock Units</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Administrator may grant Restricted Stock Units under the Plan. A Restricted Stock Unit is an Award of stock units that may be settled in shares of Stock (or cash, to the extent explicitly provided for in the applicable Award Certificate) upon the satisfaction of such restrictions and conditions at the time of grant. Conditions may be based on continuing employment (or other Service Relationship) and/or achievement of pre-established performance goals and objectives. The terms and conditions of each such Award shall be determined by the Administrator, and such terms and conditions may differ among individual Awards and grantees. Except in the case of Restricted Stock Units with a deferred settlement date that complies with Section 409A, at the end of the vesting period, the Restricted Stock Units, to the extent vested, shall be settled in the form of shares of Stock. Restricted Stock Units with deferred settlement dates are subject to Section 409A and shall contain such additional terms and conditions as the Administrator shall determine in its sole discretion in order to comply with the requirements of Section 409A.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(b) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Election to Receive Restricted Stock Units in Lieu of Compensation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Administrator may, in its sole discretion, permit a grantee to elect to receive a portion of future cash compensation otherwise due to such grantee in the form of an award of Restricted Stock Units. Any such election shall be made in writing and shall be delivered to the Company no later than the date specified by the Administrator and in accordance with Section 409A and such other rules and procedures established by the Administrator. Any such future cash compensation that the grantee elects to defer shall be converted to a fixed number of Restricted Stock Units based on the Fair Market Value of Stock on the date the compensation would otherwise have been paid to the grantee if such payment had not been deferred as provided herein. The Administrator shall have the sole right to determine whether and under what circumstances to permit such elections and to impose such limitations and other terms and conditions thereon as the Administrator deems appropriate. Any Restricted Stock Units that are elected to be received in lieu of cash compensation shall be fully vested, unless otherwise provided in the Award Certificate.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(c) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Rights as a Stockholder</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. A grantee shall have the rights as a stockholder only as to shares of Stock acquired by the grantee upon settlement of Restricted Stock Units; provided, however, that the grantee may be credited with Dividend Equivalent Rights with respect to the stock units underlying his Restricted Stock Units, subject to the provisions of Section 11 and such terms and conditions as the Administrator may determine.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/115808348.2</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(d) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Termination</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Except as may otherwise be provided by the Administrator either in the Award Certificate or, subject to Section 18 below, in writing after the Award is issued, a grantee&#x2019;s right in all Restricted Stock Units that have not vested shall automatically terminate upon the grantee&#x2019;s termination of employment (or cessation of Service Relationship) with the Company and its Subsidiaries for any reason.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">SECTION 9.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">UNRESTRICTED STOCK AWARDS</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Grant or Sale of Unrestricted Stock</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Administrator may grant (or sell at par value or such higher purchase price determined by the Administrator) an Unrestricted Stock Award under the Plan. An Unrestricted Stock Award is an Award pursuant to which the grantee may receive shares of Stock free of any restrictions under the Plan. Unrestricted Stock Awards may be granted in respect of past services or other valid consideration, or in lieu of cash compensation due to such grantee.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">SECTION 10.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">CASH-BASED AWARDS</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Grant of Cash-Based Awards</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Administrator may grant Cash-Based Awards under the Plan. A Cash-Based Award is an Award that entitles the grantee to a payment in cash upon the attainment of specified performance goals. The Administrator shall determine the maximum duration of the Cash-Based Award, the amount of cash to which the Cash-Based Award pertains, the conditions upon which the Cash-Based Award shall become vested or payable, and such other provisions as the Administrator shall determine. Each Cash-Based Award shall specify a cash-denominated payment amount, formula or payment ranges as determined by the Administrator. Payment, if any, with respect to a Cash-Based Award shall be made in accordance with the terms of the Award and may be made in cash.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">SECTION 11.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">DIVIDEND EQUIVALENT RIGHTS</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(a) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Dividend Equivalent Rights</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Administrator may grant Dividend Equivalent Rights under the Plan. A Dividend Equivalent Right is an Award entitling the grantee to receive credits based on cash dividends that would have been paid on the shares of Stock specified in the Dividend Equivalent Right (or other Award to which it relates) if such shares had been issued to the grantee. A Dividend Equivalent Right may be granted hereunder to any grantee as a component of an award of Restricted Stock Units or as a freestanding award. The terms and conditions of Dividend Equivalent Rights shall be specified in the Award Certificate. Dividend equivalents credited to the holder of a Dividend Equivalent Right may be paid currently or may be deemed to be reinvested in additional shares of Stock, which may thereafter accrue additional equivalents. Any such reinvestment shall be at Fair Market Value on the date of reinvestment or such other price as may then apply under a dividend reinvestment plan sponsored by the Company, if any. Dividend Equivalent Rights may be settled in cash or shares of Stock or a combination thereof, in a single installment or installments. A Dividend Equivalent Right granted as a component of an Award of Restricted Stock Units shall provide that such Dividend Equivalent Right shall be settled only upon settlement or payment of, or lapse of restrictions on, such other Award, and that such Dividend Equivalent Right shall expire or be forfeited or annulled under the same conditions as such other Award.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(b) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Termination</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Except as may otherwise be provided by the Administrator either in the Award Certificate or, subject to Section 16 below, in writing after the Award is issued, a grantee&#x2019;s rights in all Dividend Equivalent Rights shall automatically terminate upon the grantee&#x2019;s termination of employment (or cessation of Service Relationship) with the Company and its Subsidiaries for any reason.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">SECTION 12.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">TRANSFERABILITY OF AWARDS</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(a) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Transferability</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Except as provided in Section 12(b) below, during a grantee&#x2019;s lifetime, his or her Awards shall be exercisable only by the grantee, or by the grantee&#x2019;s legal representative or guardian in the event of the grantee&#x2019;s incapacity. No Awards shall be sold, assigned, transferred or otherwise encumbered or disposed of by a grantee other than by will or by the laws of descent and distribution or pursuant to a domestic relations order. No Awards shall be subject, in whole or in part, to attachment, execution, or levy of any kind, and any purported transfer in violation hereof shall be null and void.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(b) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Administrator Action</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Notwithstanding Section 12(a), the Administrator, in its discretion, may provide either in the Award Certificate regarding a given Award or by subsequent written approval that the grantee (who is an employee or director) may transfer his or her Non-Qualified Stock Options to his or her immediate family members, to trusts for the benefit of such family members, or to partnerships in which such family members are the only partners, provided that the transferee agrees in writing with the Company to be bound by all of the terms and conditions of this Plan and the applicable Award. In no event may an Award be transferred by a grantee for value.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/115808348.2</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(c) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Family Member</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. For purposes of Section 12(b), &#x201c;family member&#x201d; shall mean a grantee&#x2019;s child, stepchild, grandchild, parent, stepparent, grandparent, spouse, former spouse, sibling, niece, nephew, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including adoptive relationships, any person sharing the grantee&#x2019;s household (other than a tenant of the grantee), a trust in which these persons (or the grantee) have more than 50 percent of the beneficial interest, a foundation in which these persons (or the grantee) control the management of assets, and any other entity in which these persons (or the grantee) own more than 50 percent of the voting interests.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(d) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Designation of Beneficiary</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. To the extent permitted by the Company, each grantee to whom an Award has been made under the Plan may designate a beneficiary or beneficiaries to exercise any Award or receive any payment under any Award payable on or after the grantee&#x2019;s death. Any such designation shall be on a form provided for that purpose by the Administrator and shall not be effective until received by the Administrator. If no beneficiary has been designated by a deceased grantee, or if the designated beneficiaries have predeceased the grantee, the beneficiary shall be the grantee&#x2019;s estate.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">SECTION 13.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">TAX WITHHOLDING</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(a) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Payment by Grantee</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Each grantee shall, no later than the date as of which the value of an Award or of any Stock or other amounts received thereunder first becomes includable in the gross income of the grantee for Federal income tax purposes, pay to the Company, or make arrangements satisfactory to the Administrator regarding payment of, any Federal, state, or local taxes of any kind required by law to be withheld by the Company with respect to such income. The Company and its Subsidiaries shall, to the extent permitted by law, have the right to deduct any such taxes from any payment of any kind otherwise due to the grantee. The Company&#x2019;s obligation to deliver evidence of book entry (or stock certificates) to any grantee is subject to and conditioned on tax withholding obligations being satisfied by the grantee.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(b) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Payment in Stock</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Administrator may require the Company&#x2019;s tax withholding obligation to be satisfied, in whole or in part, by the Company withholding from shares of Stock to be issued pursuant to any Award a number of shares with an aggregate Fair Market Value (as of the date the withholding is effected) that would satisfy the withholding amount due; provided, however, that the amount withheld does not exceed the maximum statutory tax rate or such lesser amount as is necessary to avoid liability accounting treatment. For purposes of share withholding, the Fair Market Value of withheld shares shall be determined in the same manner as the value of Stock includible in income of the grantees. The Administrator may also require the Company&#x2019;s tax withholding obligation to be satisfied, in whole or in part, by an arrangement whereby a certain number of shares of Stock issued pursuant to any Award are immediately sold and proceeds from such sale are remitted to the Company in an amount that would satisfy the withholding amount due.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">SECTION 14.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">SECTION 409A AWARDS</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Awards are intended to be exempt from Section 409A to the greatest extent possible and to otherwise comply with Section 409A. The Plan and all Awards shall be interpreted in accordance with such intent. To the extent that any Award is determined to constitute &#x201c;nonqualified deferred compensation&#x201d; within the meaning of Section 409A (a &#x201c;409A Award&#x201d;), the Award shall be subject to such additional rules and requirements as specified by the Administrator from time to time in order to comply with Section 409A. In this regard, if any amount under a 409A Award is payable upon a &#x201c;separation from service&#x201d; (within the meaning of Section 409A) to a grantee who is then considered a &#x201c;specified employee&#x201d; (within the meaning of Section 409A), then no such payment shall be made prior to the date that is the earlier of (i) six months and one day after the grantee&#x2019;s separation from service, or (ii) the grantee&#x2019;s death, but only to the extent such delay is necessary to prevent such payment from being subject to interest, penalties and/or additional tax imposed pursuant to Section 409A. Further, the settlement of any such Award may not be accelerated except to the extent permitted by Section 409A.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">SECTION 15.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">TERMINATION OF SERVICE RELATIONSHIP, TRANSFER, LEAVE OF ABSENCE, ETC.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(a) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Termination of Service Relationship</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. If the grantee&#x2019;s Service Relationship is with an Affiliate and such Affiliate ceases to be an Affiliate, the grantee shall be deemed to have terminated his or her Service Relationship for purposes of the Plan.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(b) For purposes of the Plan, the following events shall not be deemed a termination of a Service Relationship:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(i) a transfer to the employment of the Company from an Affiliate or from the Company to an Affiliate, or from one Affiliate to another; or</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/115808348.2</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(ii) an approved leave of absence for military service or sickness, or for any other purpose approved by the Company, if the employee&#x2019;s right to re-employment is guaranteed either by a statute or by contract or under the policy pursuant to which the leave of absence was granted or if the Administrator otherwise so provides in writing.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">SECTION 16.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">AMENDMENTS AND TERMINATION</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Board may, at any time, amend or discontinue the Plan and the Administrator may, at any time, amend or cancel any outstanding Award for the purpose of satisfying changes in law or for any other lawful purpose, but no such action shall materially and adversely affect rights under any outstanding Award without the holder&#x2019;s consent. Except as provided in Section 3(c) or 3(d), without prior stockholder approval, in no event may the Administrator exercise its discretion to reduce the exercise price of outstanding Stock Options or Stock Appreciation Rights or effect repricing through cancellation and re-grants or cancellation of Stock Options or Stock Appreciation Rights in exchange for cash or other Awards. To the extent required under the rules of any securities exchange or market system on which the Stock is listed, to the extent determined by the Administrator to be required by the Code to ensure that Incentive Stock Options granted under the Plan are qualified under Section 422 of the Code, Plan amendments shall be subject to approval by the Company&#x2019;s stockholders. Nothing in this Section 16 shall limit the Administrator&#x2019;s authority to take any action permitted pursuant to Section 3(c) or 3(d).</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">SECTION 17.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">STATUS OF PLAN</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">With respect to the portion of any Award that has not been exercised and any payments in cash, Stock or other consideration not received by a grantee, a grantee shall have no rights greater than those of a general creditor of the Company unless the Administrator shall otherwise expressly determine in connection with any Award or Awards. In its sole discretion, the Administrator may authorize the creation of trusts or other arrangements to meet the Company&#x2019;s obligations to deliver Stock or make payments with respect to Awards hereunder, provided that the existence of such trusts or other arrangements is consistent with the foregoing sentence.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">SECTION 18.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">GENERAL PROVISIONS</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(a) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">No Distribution</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Administrator may require each person acquiring Stock pursuant to an Award to represent to and agree with the Company in writing that such person is acquiring the shares without a view to distribution thereof.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(b) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Issuance</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. To the extent certificated, stock certificates to grantees under this Plan shall be deemed delivered for all purposes when the Company or a stock transfer agent of the Company shall have mailed such certificates in the United States mail, addressed to the grantee, at the grantee&#x2019;s last known address on file with the Company. Uncertificated Stock shall be deemed delivered for all purposes when the Company or a Stock transfer agent of the Company shall have given to the grantee by electronic mail (with proof of receipt) or by United States mail, addressed to the grantee, at the grantee&#x2019;s last known address on file with the Company, notice of issuance and recorded the issuance in its records (which may include electronic &#x201c;book entry&#x201d; records). Notwithstanding anything herein to the contrary, the Company shall not be required to issue or deliver any evidence of book entry or certificates evidencing shares of Stock pursuant to the exercise or settlement of any Award, unless and until the Administrator has determined, with advice of counsel (to the extent the Administrator deems such advice necessary or advisable), that the issuance and delivery is in compliance with all applicable laws, regulations of governmental authorities and, if applicable, the requirements of any exchange on which the shares of Stock are listed, quoted or traded. Any Stock issued pursuant to the Plan shall be subject to any stop-transfer orders and other restrictions as the Administrator deems necessary or advisable to comply with federal, state or foreign jurisdiction, securities or other laws, rules and quotation system on which the Stock is listed, quoted or traded. The Administrator may place legends on any Stock certificate or notations on any book entry to reference restrictions applicable to the Stock. In addition to the terms and conditions provided herein, the Administrator may require that an individual make such reasonable covenants, agreements, and representations as the Administrator, in its discretion, deems necessary or advisable in order to comply with any such laws, regulations, or requirements. The Administrator shall have the right to require any individual to comply with any timing or other restrictions with respect to the settlement or exercise of any Award, including a window-period limitation, as may be imposed in the discretion of the Administrator.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(c) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Stockholder Rights</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Until Stock is deemed delivered in accordance with Section 18(b), no right to vote or receive dividends or any other rights of a stockholder will exist with respect to shares of Stock to be issued in connection with an Award, notwithstanding the exercise of a Stock Option or any other action by the grantee with respect to an Award.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(d) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Other Compensation Arrangements; No Employment Rights</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Nothing contained in this Plan shall prevent the Board from adopting other or additional compensation arrangements, including trusts, and such arrangements may be either generally applicable or applicable only in specific cases. The adoption of this Plan and the grant of Awards do not confer upon any employee any right to continued employment with the Company or any Subsidiary.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/115808348.2</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(e) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Trading Policy Restrictions</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Option exercises and other Awards under the Plan shall be subject to the Company&#x2019;s insider trading policies and procedures, as in effect from time to time.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(f) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Clawback Policy</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Awards under the Plan shall be subject to the Company&#x2019;s clawback policy, as in effect from time to time.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">SECTION 19.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">EFFECTIVE DATE OF PLAN</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This Plan, as amended and restated, shall become effective upon approval by the holders of a majority of the votes cast at a meeting of stockholders at which a quorum is present. No grants of Stock Options and other Awards may be made hereunder after the tenth anniversary of the Effective Date and no grants of Incentive Stock Options may be made hereunder after the tenth anniversary of the date the Plan, as amended and restated, is approved by the Board.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">SECTION 20.  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">GOVERNING LAW</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This Plan and all Awards and actions taken thereunder shall be governed by, and construed in accordance with, the laws of the State of Delaware, applied without regard to conflict of law principles.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">DATE APPROVED BY BOARD OF DIRECTORS: December 21, 2017</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">DATE APPROVED BY STOCKHOLDERS: January 12, 2018</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">AMENDED AND RESTATED BY THE BOARD OF DIRECTORS: March 2, 2021</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">DATE STOCKHOLDERS APPROVED AMENDED AND RESTATED PLAN: April 27, 2021</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/115808348.2</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">INCENTIVE STOCK OPTION AGREEMENT</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">UNDER THE ADICET BIO, INC.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">AMENDED AND RESTATED 2018 STOCK OPTION AND INCENTIVE PLAN</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:30.666%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:32.666%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:32.666%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Name of Optionee:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">No. of Option Shares:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Option Exercise Price per Share:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Grant Date:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expiration Date:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the Adicet Bio, Inc. Amended and Restated 2018 Stock Option and Incentive Plan as amended through the date hereof (the &#x201c;Plan&#x201d;), Adicet Bio, Inc. (the &#x201c;Company&#x201d;) hereby grants to the Optionee named above an option (the &#x201c;Stock Option&#x201d;) to purchase on or prior to the Expiration Date specified above all or part of the number of shares of Common Stock, par value $0.0001 per share (the &#x201c;Stock&#x201d;), of the Company specified above at the Option Exercise Price per Share specified above subject to the terms and conditions set forth herein and in the Plan.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Exercisability Schedule</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. No portion of this Stock Option may be exercised until such portion shall have become exercisable. Except as set forth below, and subject to the discretion of the Administrator (as defined in Section 2 of the Plan) to accelerate the exercisability schedule hereunder, this Stock Option shall be exercisable with respect to the following number of Option Shares on the dates indicated so long as the Optionee remains an employee of the Company or a Subsidiary on such dates:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:68.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:48.778%;"></td>
    <td style="width:27.918%;"></td>
    <td style="width:20.355%;"></td>
    <td style="width:1.474%;"></td>
    <td style="width:1.474%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid rgba(0,0,0,1);text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Incremental Number of<br>Option Shares Exercisable*</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-bottom:0.010in;border-bottom:1.000pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Exercisability Date</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">( %)</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">( %)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">( %)</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">( %)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">( %)</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <table style="border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:1.796%;"></td>
    <td style="width:98.204%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">*</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Max. of $100,000 per yr.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Once exercisable, this Stock Option shall continue to be exercisable at any time or times prior to the close of business on the Expiration Date, subject to the provisions hereof and of the Plan.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Manner of Exercise</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(a) The Optionee may exercise this Stock Option only in the following manner: from time to time on or prior to the Expiration Date of this Stock Option, the Optionee may give written notice to the Administrator of his or her election to purchase some or all of the Option Shares purchasable at the time of such notice. This notice shall specify the number of Option Shares to be purchased.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Payment of the purchase price for the Option Shares may be made by one or more of the following methods: (i) in cash, by certified or bank check or other instrument acceptable to the Administrator; (ii) through the delivery (or attestation to the ownership) of shares of Stock that have been purchased by the Optionee on the open market or that are beneficially owned by the Optionee and are not then subject to any restrictions under any Company plan and that otherwise satisfy any holding periods as may be required by the Administrator; or (iii) by the Optionee delivering to the Company a properly executed exercise notice together with irrevocable instructions to a broker to promptly deliver to the Company cash or a check payable and acceptable to the Company to pay the option purchase price, provided that in the event the Optionee chooses to pay the option purchase price as so provided, the Optionee and the broker shall comply with such procedures and enter into such agreements of indemnity and other agreements as the Administrator shall prescribe as a condition of such payment procedure; or (iv) a combination of (i), (ii) and (iii) above. Payment instruments will be received subject to collection.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/115808348.2</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The transfer to the Optionee on the records of the Company or of the transfer agent of the Option Shares will be contingent upon (i) the Company&#x2019;s receipt from the Optionee of the full purchase price for the Option Shares, as set forth above, (ii) the fulfillment of any other requirements contained herein or in the Plan or in any other agreement or provision of laws, and (iii) the receipt by the Company of any agreement, statement or other evidence that the Company may require to satisfy itself that the issuance of Stock to be purchased pursuant to the exercise of Stock Options under the Plan and any subsequent resale of the shares of Stock will be in compliance with applicable laws and regulations. In the event the Optionee chooses to pay the purchase price by previously-owned shares of Stock through the attestation method, the number of shares of Stock transferred to the Optionee upon the exercise of the Stock Option shall be net of the Shares attested to.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(b) The shares of Stock purchased upon exercise of this Stock Option shall be transferred to the Optionee on the records of the Company or of the transfer agent upon compliance to the satisfaction of the Administrator with all requirements under applicable laws or regulations in connection with such transfer and with the requirements hereof and of the Plan. The determination of the Administrator as to such compliance shall be final and binding on the Optionee. The Optionee shall not be deemed to be the holder of, or to have any of the rights of a holder with respect to, any shares of Stock subject to this Stock Option unless and until this Stock Option shall have been exercised pursuant to the terms hereof, the Company or the transfer agent shall have transferred the shares to the Optionee, and the Optionee&#x2019;s name shall have been entered as the stockholder of record on the books of the Company. Thereupon, the Optionee shall have full voting, dividend and other ownership rights with respect to such shares of Stock.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(c) The minimum number of shares with respect to which this Stock Option may be exercised at any one time shall be 100 shares, unless the number of shares with respect to which this Stock Option is being exercised is the total number of shares subject to exercise under this Stock Option at the time.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(d) Notwithstanding any other provision hereof or of the Plan, no portion of this Stock Option shall be exercisable after the Expiration Date hereof.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Termination of Employment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. If the Optionee&#x2019;s employment by the Company or a Subsidiary (as defined in the Plan) is terminated, the period within which to exercise the Stock Option may be subject to earlier termination as set forth below.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(a) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Termination Due to Death</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. If the Optionee&#x2019;s employment terminates by reason of the Optionee&#x2019;s death, any portion of this Stock Option outstanding on such date, to the extent exercisable on the date of death, may thereafter be exercised by the Optionee&#x2019;s legal representative or legatee for a period of 12 months from the date of death or until the Expiration Date, if earlier. Any portion of this Stock Option that is not exercisable on the date of death shall terminate immediately and be of no further force or effect.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(b) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Termination Due to Disability</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. If the Optionee&#x2019;s employment terminates by reason of the Optionee&#x2019;s disability (as determined by the Administrator), any portion of this Stock Option outstanding on such date, to the extent exercisable on the date of such termination of employment, may thereafter be exercised by the Optionee for a period of 12 months from the date of disability or until the Expiration Date, if earlier. Any portion of this Stock Option that is not exercisable on the date of disability shall terminate immediately and be of no further force or effect.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(c) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Termination for Cause</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. If the Optionee&#x2019;s employment terminates for Cause, any portion of this Stock Option outstanding on such date shall terminate immediately and be of no further force and effect. For purposes hereof, &#x201c;Cause&#x201d; shall mean, unless otherwise provided in an employment agreement between the Company and the Optionee, a determination by the Administrator</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">that the Optionee shall be dismissed as a result of (i) any material breach by the Optionee of any agreement between the Optionee and the Company; (ii) the conviction of, indictment for or plea of nolo contendere by the Optionee to a felony or a crime involving moral turpitude; or (iii) any material misconduct or willful and deliberate non-performance (other than by reason of disability) by the Optionee of the Optionee&#x2019;s duties to the Company.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(d) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Other Termination</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. If the Optionee&#x2019;s employment terminates for any reason other than the Optionee&#x2019;s death, the Optionee&#x2019;s disability, or Cause, and unless otherwise determined by the Administrator, any portion of this Stock Option outstanding on such date may be exercised, to the extent exercisable on the date of termination, for a period of three months from the date of termination or until the Expiration Date, if earlier. Any portion of this Stock Option that is not exercisable on the date of termination shall terminate immediately and be of no further force or effect.  The Administrator&#x2019;s determination of the reason for termination of the Optionee&#x2019;s employment shall be conclusive and binding on the Optionee and his or her representatives or legatees.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Incorporation of Plan</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Notwithstanding anything herein to the contrary, this Stock Option shall be subject to and governed by all the terms and conditions of the Plan, including the powers of the Administrator set forth in Section 2(b) of the Plan. Capitalized terms in this Agreement shall have the meaning specified in the Plan, unless a different meaning is specified herein.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/115808348.2</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Transferability</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. This Agreement is personal to the Optionee, is non-assignable and is not transferable in any manner, by operation of law or otherwise, other than by will or the laws of descent and distribution. This Stock Option is exercisable, during the Optionee&#x2019;s lifetime, only by the Optionee, and thereafter, only by the Optionee&#x2019;s legal representative or legatee.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Status of the Stock Option</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. This Stock Option is intended to qualify as an &#x201c;incentive stock option&#x201d; under Section 422 of the Internal Revenue Code of 1986, as amended (the &#x201c;Code&#x201d;), but the Company does not represent or warrant that this Stock Option qualifies as such. The Optionee should consult with his or her own tax advisors regarding the tax effects of this Stock Option and the requirements necessary to obtain favorable income tax treatment under Section 422 of the Code, including, but not limited to, holding period requirements. To the extent any portion of this Stock Option does not so qualify as an &#x201c;incentive stock option,&#x201d; such portion shall be deemed to be a non-qualified stock option. If the Optionee intends to dispose or does dispose (whether by sale, gift, transfer or otherwise) of any Option Shares within the one-year period beginning on the date after the transfer of such shares to him or her, or within the two-year period beginning on the day after the grant of this Stock Option, he or she will so notify the Company within 30 days after such disposition.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Tax Withholding</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Optionee shall, not later than the date as of which the exercise of this Stock Option becomes a taxable event for Federal income tax purposes, pay to the Company or make arrangements satisfactory to the Administrator for payment of any Federal, state, and local taxes required by law to be withheld on account of such taxable event. The Company shall have the authority to cause the required tax withholding obligation to be satisfied, in whole or in part, by withholding from shares of Stock to be issued to the Optionee a number of shares of Stock with an aggregate Fair Market Value that would satisfy the withholding amount due; provided, however, that the amount withheld does not exceed the maximum statutory tax rate or such lesser amount as is necessary to avoid adverse accounting treatment or as determined by the Administrator.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">No Obligation to Continue Employment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Neither the Company nor any Subsidiary is obligated by or as a result of the Plan or this Agreement to continue the Optionee in employment and neither the Plan nor this Agreement shall interfere in any way with the right of the Company or any Subsidiary to terminate the employment of the Optionee at any time.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Integration</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. This Agreement constitutes the entire agreement between the parties with respect to this Stock Option and supersedes all prior agreements and discussions between the parties concerning such subject matter.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Data Privacy Consent</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. In order to administer the Plan and this Agreement and to implement or structure future equity grants, the Company, its subsidiaries and affiliates and certain agents thereof (together, the &#x201c;Relevant Companies&#x201d;) may process any and all personal or professional data, including but not limited to Social Security or other identification number, home address and telephone number, date of birth and other information that is necessary or desirable for the administration of the Plan and/or this Agreement (the &#x201c;Relevant Information&#x201d;). By entering into this Agreement, the Optionee (i) authorizes the Company to collect, process, register and transfer to the Relevant Companies all Relevant Information; (ii) waives any privacy rights the Optionee may have with respect to the Relevant Information; (iii) authorizes the Relevant Companies to store and transmit such information in electronic form; and (iv) authorizes the transfer of the Relevant Information to any jurisdiction in which the Relevant Companies consider appropriate. The Optionee shall have access to, and the right to change, the Relevant Information. Relevant Information will only be used in accordance with applicable law.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Notices</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Notices hereunder shall be mailed or delivered to the Company at its principal place of business and shall be mailed or delivered to the Optionee at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:41.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:7.406%;"></td>
    <td style="width:2.446%;"></td>
    <td style="width:90.149%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ADICET BIO, NC.</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Name:</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Title:</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned. Electronic acceptance of this Agreement pursuant to the Company&#x2019;s instructions to the Optionee (including through an online acceptance process) is acceptable.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/115808348.2</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:6.011%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:42.987%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:2.996%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:45.0%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Dated:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Optionee&#x2019;s Signature</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Optionee&#x2019;s name and address:</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/115808348.2</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">NON-QUALIFIED STOCK OPTION AGREEMENT</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">FOR NON-EMPLOYEE DIRECTORS</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">UNDER THE ADICET BIO, INC.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2018 STOCK OPTION AND INCENTIVE PLAN</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:24.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:39.343%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:32.657%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Name of Optionee:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">No. of Option Shares:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Option Exercise Price per Share:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Grant Date:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expiration Date:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the Adicet Bio, Inc. Amended and Restated 2018 Stock Option and Incentive Plan as amended through the date hereof (the &#x201c;Plan&#x201d;), Adicet Bio, Inc. (the &#x201c;Company&#x201d;) hereby grants to the Optionee named above, who is a Director of the Company but is not an employee of the Company, an option (the &#x201c;Stock Option&#x201d;) to purchase on or prior to the Expiration Date specified above all or part of the number of shares of Common Stock, par value $0.0001 per share (the &#x201c;Stock&#x201d;), of the Company specified above at the Option Exercise Price per Share specified above subject to the terms and conditions set forth herein and in the Plan. This Stock Option is not intended to be an &#x201c;incentive stock option&#x201d; under Section 422 of the Internal Revenue Code of 1986, as amended.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Exercisability Schedule</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. No portion of this Stock Option may be exercised until such portion shall have become exercisable. Except as set forth below, and subject to the discretion of the Administrator (as defined in Section 2 of the Plan) to accelerate the exercisability schedule hereunder, this Stock Option shall be exercisable with respect to the following number of Option Shares on the dates indicated so long as the Optionee remains in service as a member of the Board on such dates:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:68.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:48.778%;"></td>
    <td style="width:27.918%;"></td>
    <td style="width:20.355%;"></td>
    <td style="width:1.474%;"></td>
    <td style="width:1.474%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid rgba(0,0,0,1);text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Incremental Number of<br>Option Shares Exercisable</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid rgba(0,0,0,1);text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Exercisability Date</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">( %)</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">( %)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">( %)</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">( %)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">( %)</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Once exercisable, this Stock Option shall continue to be exercisable at any time or times prior to the close of business on the Expiration Date, subject to the provisions hereof and of the Plan.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Manner of Exercise</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(a) The Optionee may exercise this Stock Option only in the following manner: from time to time on or prior to the Expiration Date of this Stock Option, the Optionee may give written notice to the Administrator of his or her election to purchase some or all of the Option Shares purchasable at the time of such notice. This notice shall specify the number of Option Shares to be purchased.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Payment of the purchase price for the Option Shares may be made by one or more of the following methods: (i) in cash, by certified or bank check or other instrument acceptable to the Administrator; (ii) through the delivery (or attestation to the ownership) of shares of Stock that have been purchased by the Optionee on the open market or that are beneficially owned by the Optionee and are not then subject to any restrictions under any Company plan and that otherwise satisfy any holding periods as may be required by the Administrator; (iii) by the Optionee delivering to the Company a properly executed exercise notice together with irrevocable instructions to a broker to promptly deliver to the Company cash or a check payable and acceptable to the Company to pay the option purchase price, provided that in the event the Optionee chooses to pay the option purchase price as so provided, the Optionee and the broker shall comply with such procedures and enter into such agreements of indemnity and other agreements as the Administrator shall prescribe as a condition of such payment procedure; (iv) by a &#x201c;net exercise&#x201d; arrangement pursuant to which the Company will reduce the number of shares of Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate exercise price; or (v) a combination of (i), (ii), (iii) and (iv) above. Payment instruments will be received subject to collection.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The transfer to the Optionee on the records of the Company or of the transfer agent of the Option Shares will be contingent upon (i) the Company&#x2019;s receipt from the Optionee of the full purchase price for the Option Shares, as set forth above, (ii) the fulfillment of any other requirements contained herein or in the Plan or in any other agreement or provision of laws, and (iii) the receipt by the Company of any agreement, statement or other evidence that the Company may require to satisfy itself that the issuance of Stock to be</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/115808348.2</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">purchased pursuant to the exercise of Stock Options under the Plan and any subsequent resale of the shares of Stock will be in compliance with applicable laws and regulations. In the event the Optionee chooses to pay the purchase price by previously-owned shares of Stock through the attestation method, the number of shares of Stock transferred to the Optionee upon the exercise of the Stock Option shall be net of the Shares attested to.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(b) The shares of Stock purchased upon exercise of this Stock Option shall be transferred to the Optionee on the records of the Company or of the transfer agent upon compliance to the satisfaction of the Administrator with all requirements under applicable laws or regulations in connection with such transfer and with the requirements hereof and of the Plan. The determination of the Administrator as to such compliance shall be final and binding on the Optionee. The Optionee shall not be deemed to be the holder of, or to have any of the rights of a holder with respect to, any shares of Stock subject to this Stock Option unless and until this Stock Option shall have been exercised pursuant to the terms hereof, the Company or the transfer agent shall have transferred the shares to the Optionee, and the Optionee&#x2019;s name shall have been entered as the stockholder of record on the books of the Company. Thereupon, the Optionee shall have full voting, dividend and other ownership rights with respect to such shares of Stock.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(c) The minimum number of shares with respect to which this Stock Option may be exercised at any one time shall be 100 shares, unless the number of shares with respect to which this Stock Option is being exercised is the total number of shares subject to exercise under this Stock Option at the time.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(d) Notwithstanding any other provision hereof or of the Plan, no portion of this Stock Option shall be exercisable after the Expiration Date hereof.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Termination as Director</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. If the Optionee ceases to be a Director of the Company, the period within which to exercise the Stock Option may be subject to earlier termination as set forth below.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(a) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Termination Due to Death</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. If the Optionee&#x2019;s service as a Director terminates by reason of the Optionee&#x2019;s death, any portion of this Stock Option outstanding on such date, to the extent exercisable on the date of death, may thereafter be exercised by the Optionee&#x2019;s legal representative or legatee for a period of 12 months from the date of death or until the Expiration Date, if earlier. Any portion of this Stock Option that is not exercisable on the date of death shall terminate immediately and be of no further force or effect.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(b) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Other Termination</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. If the Optionee ceases to be a Director for any reason other than the Optionee&#x2019;s death, any portion of this Stock Option outstanding on such date may be exercised, to the extent exercisable on the date the Optionee ceased to be a Director, for a period of six months from the date the Optionee ceased to be a Director or until the Expiration Date, if earlier. Any portion of this Stock Option that is not exercisable on the date the Optionee ceases to be a Director shall terminate immediately and be of no further force or effect.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Incorporation of Plan</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Notwithstanding anything herein to the contrary, this Stock Option shall be subject to and governed by all the terms and conditions of the Plan, including the powers of the Administrator set forth in Section 2(b) of the Plan. Capitalized terms in this Agreement shall have the meaning specified in the Plan, unless a different meaning is specified herein.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Transferability</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. This Agreement is personal to the Optionee, is non-assignable and is not transferable in any manner, by operation of law or otherwise, other than by will or the laws of descent and distribution. This Stock Option is exercisable, during the Optionee&#x2019;s lifetime, only by the Optionee, and thereafter, only by the Optionee&#x2019;s legal representative or legatee.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">No Obligation to Continue as a Director</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Neither the Plan nor this Stock Option confers upon the Optionee any rights with respect to continuance as a Director.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Integration</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. This Agreement constitutes the entire agreement between the parties with respect to this Stock Option and supersedes all prior agreements and discussions between the parties concerning such subject matter.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Data Privacy Consent</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. In order to administer the Plan and this Agreement and to implement or structure future equity grants, the Company, its subsidiaries and affiliates and certain agents thereof (together, the &#x201c;Relevant Companies&#x201d;) may process any and all personal or professional data, including but not limited to Social Security or other identification number, home address and telephone number, date of birth and other information that is necessary or desirable for the administration of the Plan and/or this Agreement (the &#x201c;Relevant Information&#x201d;). By entering into this Agreement, the Optionee (i) authorizes the Company to collect, process, register and transfer to the Relevant Companies all Relevant Information; (ii) waives any privacy rights the Optionee may have with respect to the Relevant Information; (iii) authorizes the Relevant Companies to store and transmit such information in electronic form; and (iv) authorizes the transfer of the Relevant Information to any jurisdiction in which the Relevant Companies consider appropriate. The Optionee shall have access to, and the right to change, the Relevant Information. Relevant Information will only be used in accordance with applicable law.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/115808348.2</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Notices</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Notices hereunder shall be mailed or delivered to the Company at its principal place of business and shall be mailed or delivered to the Optionee at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:41.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:7.406%;"></td>
    <td style="width:2.446%;"></td>
    <td style="width:90.149%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ADICET BIO, NC.</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Name:</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Title:</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned. Electronic acceptance of this Agreement pursuant to the Company&#x2019;s instructions to the Optionee (including through an online acceptance process) is acceptable.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:6.011%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:42.987%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:2.996%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:45.0%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Dated:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Optionee&#x2019;s Signature</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Optionee&#x2019;s name and address:</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/115808348.2</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">NON-QUALIFIED STOCK OPTION AGREEMENT</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">FOR COMPANY EMPLOYEES</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">UNDER THE ADICET BIO, INC.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2018 STOCK OPTION AND INCENTIVE PLAN</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:26.981%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:0.056%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:36.981%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:32.981%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Name of Optionee:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">No. of Option Shares:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Option Exercise Price per Share:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Grant Date:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expiration Date:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the Adicet Bio, Inc. Amended and Restated 2018 Stock Option and Incentive Plan as amended through the date hereof (the &#x201c;Plan&#x201d;), Adicet Bio, Inc. (the &#x201c;Company&#x201d;) hereby grants to the Optionee named above an option (the &#x201c;Stock Option&#x201d;) to purchase on or prior to the Expiration Date specified above all or part of the number of shares of Common Stock, par value $0.0001 per share (the &#x201c;Stock&#x201d;) of the Company specified above at the Option Exercise Price per Share specified above subject to the terms and conditions set forth herein and in the Plan. This Stock Option is not intended to be an &#x201c;incentive stock option&#x201d; under Section 422 of the Internal Revenue Code of 1986, as amended.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Exercisability Schedule</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. No portion of this Stock Option may be exercised until such portion shall have become exercisable. Except as set forth below, and subject to the discretion of the Administrator (as defined in Section 2 of the Plan) to accelerate the exercisability schedule hereunder, this Stock Option shall be exercisable with respect to the following number of Option Shares on the dates indicated so long as Optionee remains an employee of the Company or a Subsidiary on such dates:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:68.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:48.778%;"></td>
    <td style="width:27.918%;"></td>
    <td style="width:20.355%;"></td>
    <td style="width:1.474%;"></td>
    <td style="width:1.474%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid rgba(0,0,0,1);text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Incremental Number of<br>Option Shares Exercisable</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid rgba(0,0,0,1);text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Exercisability Date</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">( %)</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">( %)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">( %)</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">( %)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">( %)</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Once exercisable, this Stock Option shall continue to be exercisable at any time or times prior to the close of business on the Expiration Date, subject to the provisions hereof and of the Plan.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Manner of Exercise</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(a) The Optionee may exercise this Stock Option only in the following manner: from time to time on or prior to the Expiration Date of this Stock Option, the Optionee may give written notice to the Administrator of his or her election to purchase some or all of the Option Shares purchasable at the time of such notice. This notice shall specify the number of Option Shares to be purchased.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Payment of the purchase price for the Option Shares may be made by one or more of the following methods: (i) in cash, by certified or bank check or other instrument acceptable to the Administrator; (ii) through the delivery (or attestation to the ownership) of shares of Stock that have been purchased by the Optionee on the open market or that are beneficially owned by the Optionee and are not then subject to any restrictions under any Company plan and that otherwise satisfy any holding periods as may be required by the Administrator; (iii) by the Optionee delivering to the Company a properly executed exercise notice together with irrevocable instructions to a broker to promptly deliver to the Company cash or a check payable and acceptable to the Company to pay the option purchase price, provided that in the event the Optionee chooses to pay the option purchase price as so provided, the Optionee and the broker shall comply with such procedures and enter into such agreements of indemnity and other agreements as the Administrator shall prescribe as a condition of such payment procedure; (iv) by a &#x201c;net exercise&#x201d; arrangement pursuant to which the Company will reduce the number of shares of Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate exercise price; or (v) a combination of (i), (ii), (iii) and (iv) above. Payment instruments will be received subject to collection.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The transfer to the Optionee on the records of the Company or of the transfer agent of the Option Shares will be contingent upon (i) the Company&#x2019;s receipt from the Optionee of the full purchase price for the Option Shares, as set forth above, (ii) the fulfillment of any other requirements contained herein or in the Plan or in any other agreement or provision of laws, and (iii) the receipt by the Company of any agreement, statement or other evidence that the Company may require to satisfy itself that the issuance of Stock to be purchased pursuant to the exercise of Stock Options under the Plan and any subsequent resale of the shares of Stock will be in</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/115808348.2</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">compliance with applicable laws and regulations. In the event the Optionee chooses to pay the purchase price by previously-owned shares of Stock through the attestation method, the number of shares of Stock transferred to the Optionee upon the exercise of the Stock Option shall be net of the Shares attested to.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(b) The shares of Stock purchased upon exercise of this Stock Option shall be transferred to the Optionee on the records of the Company or of the transfer agent upon compliance to the satisfaction of the Administrator with all requirements under applicable laws or regulations in connection with such transfer and with the requirements hereof and of the Plan. The determination of the Administrator as to such compliance shall be final and binding on the Optionee. The Optionee shall not be deemed to be the holder of, or to have any of the rights of a holder with respect to, any shares of Stock subject to this Stock Option unless and until this Stock Option shall have been exercised pursuant to the terms hereof, the Company or the transfer agent shall have transferred the shares to the Optionee, and the Optionee&#x2019;s name shall have been entered as the stockholder of record on the books of the Company. Thereupon, the Optionee shall have full voting, dividend and other ownership rights with respect to such shares of Stock.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(c) The minimum number of shares with respect to which this Stock Option may be exercised at any one time shall be 100 shares, unless the number of shares with respect to which this Stock Option is being exercised is the total number of shares subject to exercise under this Stock Option at the time.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(d) Notwithstanding any other provision hereof or of the Plan, no portion of this Stock Option shall be exercisable after the Expiration Date hereof.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Termination of Employment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. If the Optionee&#x2019;s employment by the Company or a Subsidiary (as defined in the Plan) is terminated, the period within which to exercise the Stock Option may be subject to earlier termination as set forth below.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(a) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Termination Due to Death</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. If the Optionee&#x2019;s employment terminates by reason of the Optionee&#x2019;s death, any portion of this Stock Option outstanding on such date, to the extent exercisable on the date of death, may thereafter be exercised by the Optionee&#x2019;s legal representative or legatee for a period of 12 months from the date of death or until the Expiration Date, if earlier. Any portion of this Stock Option that is not exercisable on the date of death shall terminate immediately and be of no further force or effect.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(b) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Termination Due to Disability</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. If the Optionee&#x2019;s employment terminates by reason of the Optionee&#x2019;s disability (as determined by the Administrator), any portion of this Stock Option outstanding on such date, to the extent exercisable on the date of such termination of employment, may thereafter be exercised by the Optionee for a period of 12 months from the date of disability or until the Expiration Date, if earlier. Any portion of this Stock Option that is not exercisable on the date of disability shall terminate immediately and be of no further force or effect.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(c) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Termination for Cause</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. If the Optionee&#x2019;s employment terminates for Cause, any portion of this Stock Option outstanding on such date shall terminate immediately and be of no further force and effect. For purposes hereof, &#x201c;Cause&#x201d; shall mean, unless otherwise provided in an employment agreement between the Company and the Optionee, a determination by the Administrator that the Optionee shall be dismissed as a result of (i) any material breach by the Optionee of any agreement between the Optionee and the Company; (ii) the conviction of, indictment for or plea of nolo contendere by the Optionee to a felony or a crime involving moral turpitude; or (iii) any material misconduct or willful and deliberate non-performance (other than by reason of disability) by the Optionee of the Optionee&#x2019;s duties to the Company.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(d) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Other Termination</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. If the Optionee&#x2019;s employment terminates for any reason other than the Optionee&#x2019;s death, the Optionee&#x2019;s disability or Cause, and unless otherwise determined by the Administrator, any portion of this Stock Option outstanding on such date may be exercised, to the extent exercisable on the date of termination, for a period of three months from the date of termination or until the Expiration Date, if earlier. Any portion of this Stock Option that is not exercisable on the date of termination shall terminate immediately and be of no further force or effect.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Administrator&#x2019;s determination of the reason for termination of the Optionee&#x2019;s employment shall be conclusive and binding on the Optionee and his or her representatives or legatees.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Incorporation of Plan</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Notwithstanding anything herein to the contrary, this Stock Option shall be subject to and governed by all the terms and conditions of the Plan, including the powers of the Administrator set forth in Section 2(b) of the Plan. Capitalized terms in this Agreement shall have the meaning specified in the Plan, unless a different meaning is specified herein.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Transferability</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. This Agreement is personal to the Optionee, is non-assignable and is not transferable in any manner, by operation of law or otherwise, other than by will or the laws of descent and distribution. This Stock Option is exercisable, during the Optionee&#x2019;s lifetime, only by the Optionee, and thereafter, only by the Optionee&#x2019;s legal representative or legatee.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/115808348.2</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Tax Withholding</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Optionee shall, not later than the date as of which the exercise of this Stock Option becomes a taxable event for Federal income tax purposes, pay to the Company or make arrangements satisfactory to the Administrator for payment of any Federal, state, and local taxes required by law to be withheld on account of such taxable event. The Company shall have the authority to cause the required tax withholding obligation to be satisfied, in whole or in part, by withholding from shares of Stock to be issued to the Optionee a number of shares of Stock with an aggregate Fair Market Value that would satisfy the withholding amount due; provided, however, that the amount withheld does not exceed the maximum statutory tax rate or such lesser amount as is necessary to avoid adverse accounting treatment or as determined by the Administrator.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">No Obligation to Continue Employment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Neither the Company nor any Subsidiary is obligated by or as a result of the Plan or this Agreement to continue the Optionee in employment and neither the Plan nor this Agreement shall interfere in any way with the right of the Company or any Subsidiary to terminate the employment of the Optionee at any time.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Integration</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. This Agreement constitutes the entire agreement between the parties with respect to this Stock Option and supersedes all prior agreements and discussions between the parties concerning such subject matter.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Data Privacy Consent</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. In order to administer the Plan and this Agreement and to implement or structure future equity grants, the Company, its subsidiaries and affiliates and certain agents thereof (together, the &#x201c;Relevant Companies&#x201d;) may process any and all personal or professional data, including but not limited to Social Security or other identification number, home address and telephone number, date of birth and other information that is necessary or desirable for the administration of the Plan and/or this Agreement (the &#x201c;Relevant Information&#x201d;). By entering into this Agreement, the Optionee (i) authorizes the Company to collect, process, register and transfer to the Relevant Companies all Relevant Information; (ii) waives any privacy rights the Optionee may have with respect to the Relevant Information; (iii) authorizes the Relevant Companies to store and transmit such information in electronic form; and (iv) authorizes the transfer of the Relevant Information to any jurisdiction in which the Relevant</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Companies consider appropriate. The Optionee shall have access to, and the right to change, the Relevant Information. Relevant Information will only be used in accordance with applicable law.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Notices</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Notices hereunder shall be mailed or delivered to the Company at its principal place of business and shall be mailed or delivered to the Optionee at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:40.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:8.279%;"></td>
    <td style="width:2.488%;"></td>
    <td style="width:89.233%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ADICET BIO, NC.</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Name:</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Title:</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned. Electronic acceptance of this Agreement pursuant to the Company&#x2019;s instructions to the Optionee (including through an online acceptance process) is acceptable.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:6.011%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:42.987%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:2.996%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:45.0%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Dated:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Optionee&#x2019;s Signature</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Optionee&#x2019;s name and address:</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(255,255,255,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"><br></font><font style="background-color:rgba(0,0,0,0);color:rgba(255,255,255,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/115808348.2</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">NON-QUALIFIED STOCK OPTION AGREEMENT</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">FOR NON-EMPLOYEE CONSULTANTS</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">UNDER THE ADICET BIO, INC.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2018 STOCK OPTION AND INCENTIVE PLAN</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:32.66%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:32.66%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:30.679%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Name of Optionee:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">No. of Option Shares:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Option Exercise Price per Share:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Grant Date:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expiration Date:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the Adicet Bio, Inc. Amended and Restated 2018 Stock Option and Incentive Plan as amended through the date hereof (the &#x201c;Plan&#x201d;), Adicet Bio, Inc. (the &#x201c;Company&#x201d;) hereby grants to the Optionee named above, who is a Consultant of the Company, an option (the &#x201c;Stock Option&#x201d;) to purchase on or prior to the Expiration Date specified above all or part of the number of shares of Common Stock, par value $0.0001 per share (the &#x201c;Stock&#x201d;), of the Company specified above at the Option Exercise Price per Share specified above subject to the terms and conditions set forth herein and in the Plan. This Stock Option is not intended to be an &#x201c;incentive stock option&#x201d; under Section 422 of the Internal Revenue Code of 1986, as amended.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Exercisability Schedule</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. No portion of this Stock Option may be exercised until such portion shall have become exercisable. Except as set forth below, and subject to the discretion of the Administrator (as defined in Section 2 of the Plan) to accelerate the exercisability schedule hereunder, this Stock Option shall be exercisable with respect to the following number of Option Shares on the dates indicated so long as the Optionee remains in service to the Company or a Subsidiary as a Consultant on such dates:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:68.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:48.778%;"></td>
    <td style="width:27.918%;"></td>
    <td style="width:20.355%;"></td>
    <td style="width:1.474%;"></td>
    <td style="width:1.474%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid rgba(0,0,0,1);text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Incremental Number of<br>Option Shares Exercisable</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-bottom:0.010in;border-bottom:1.000pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Exercisability Date</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:1.000pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">( %)</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">( %)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">( %)</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">( %)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">( %)</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Once exercisable, this Stock Option shall continue to be exercisable at any time or times prior to the close of business on the Expiration Date, subject to the provisions hereof and of the Plan.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Manner of Exercise</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(a) The Optionee may exercise this Stock Option only in the following manner: from time to time on or prior to the Expiration Date of this Stock Option, the Optionee may give written notice to the Administrator of his or her election to purchase some or all of the Option Shares purchasable at the time of such notice. This notice shall specify the number of Option Shares to be purchased.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Payment of the purchase price for the Option Shares may be made by one or more of the following methods: (i) in cash, by certified or bank check or other instrument acceptable to the Administrator; (ii) through the delivery (or attestation to the ownership) of shares of Stock that have been purchased by the Optionee on the open market or that are beneficially owned by the Optionee and are not then subject to any restrictions under any Company plan and that otherwise satisfy any holding periods as may be required by the Administrator; (iii) by the Optionee delivering to the Company a properly executed exercise notice together with irrevocable instructions to a broker to promptly deliver to the Company cash or a check payable and acceptable to the Company to pay the option purchase price, provided that in the event the Optionee chooses to pay the option purchase price as so provided, the Optionee and the broker shall comply with such procedures and enter into such agreements of indemnity and other agreements as the Administrator shall prescribe as a condition of such payment procedure; (iv) by a &#x201c;net exercise&#x201d; arrangement pursuant to which the Company will reduce the number of shares of Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate exercise price; or (v) a combination of (i), (ii), (iii) and (iv) above. Payment instruments will be received subject to collection.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The transfer to the Optionee on the records of the Company or of the transfer agent of the Option Shares will be contingent upon (i) the Company&#x2019;s receipt from the Optionee of the full purchase price for the Option Shares, as set forth above, (ii) the fulfillment of any other requirements contained herein or in the Plan or in any other agreement or provision of laws, and (iii) the receipt by the Company of any agreement, statement or other evidence that the Company may require to satisfy itself that the issuance of Stock to be purchased pursuant to the exercise of Stock Options under the Plan and any subsequent resale of the shares of Stock will be in compliance with applicable laws and regulations. In the event the Optionee chooses to pay the purchase price by previously-owned shares of Stock through the attestation method, the number of shares of Stock transferred to the Optionee upon the exercise of the Stock Option shall be net of the Shares attested to.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/115808348.2</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(b) The shares of Stock purchased upon exercise of this Stock Option shall be transferred to the Optionee on the records of the Company or of the transfer agent upon compliance to the satisfaction of the Administrator with all requirements under applicable laws or regulations in connection with such transfer and with the requirements hereof and of the Plan. The determination of the Administrator as to such compliance shall be final and binding on the Optionee. The Optionee shall not be deemed to be the holder of, or to have any of the rights of a holder with respect to, any shares of Stock subject to this Stock Option unless and until this Stock Option shall have been exercised pursuant to the terms hereof, the Company or the transfer agent shall have transferred the shares to the Optionee, and the Optionee&#x2019;s name shall have been entered as the stockholder of record on the books of the Company. Thereupon, the Optionee shall have full voting, dividend and other ownership rights with respect to such shares of Stock.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(c) The minimum number of shares with respect to which this Stock Option may be exercised at any one time shall be 100 shares, unless the number of shares with respect to which this Stock Option is being exercised is the total number of shares subject to exercise under this Stock Option at the time.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(d) Notwithstanding any other provision hereof or of the Plan, no portion of this Stock Option shall be exercisable after the Expiration Date hereof.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Termination as Consultant</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. If the Optionee ceases to be a Consultant to the Company or a Subsidiary for any reason, any portion of this Stock Option outstanding on such date may be exercised, to the extent exercisable on the date the Optionee ceased to provide services, for a period of three months from the date the Optionee ceased to provide services or until the Expiration Date, if earlier. Any portion of this Stock Option that is not exercisable on the date the Optionee ceases to be a Consultant to the Company or a Subsidiary shall terminate immediately and be of no further force or effect.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Incorporation of Plan</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Notwithstanding anything herein to the contrary, this Stock Option shall be subject to and governed by all the terms and conditions of the Plan, including the powers of the Administrator set forth in Section 2(b) of the Plan. Capitalized terms in this Agreement shall have the meaning specified in the Plan, unless a different meaning is specified herein.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Transferability</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. This Agreement is personal to the Optionee, is non-assignable and is not transferable in any manner, by operation of law or otherwise, other than by will or the laws of descent and distribution. This Stock Option is exercisable, during the Optionee&#x2019;s lifetime, only by the Optionee, and thereafter, only by the Optionee&#x2019;s legal representative or legatee.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">No Obligation to Continue as a Consultant or Service Provider</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Neither the Plan nor this Stock Option confers upon the Optionee any rights with respect to continuance as a Consultant or other service provider to the Company or a Subsidiary.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Integration</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. This Agreement constitutes the entire agreement between the parties with respect to this Stock Option and supersedes all prior agreements and discussions between the parties concerning such subject matter.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Data Privacy Consent</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. In order to administer the Plan and this Agreement and to implement or structure future equity grants, the Company, its subsidiaries and affiliates and certain agents thereof (together, the &#x201c;Relevant Companies&#x201d;) may process any and all personal or professional data, including but not limited to Social Security or other identification number, home address and telephone number, date of birth and other information that is necessary or desirable for the administration of the Plan and/or this Agreement (the &#x201c;Relevant Information&#x201d;). By entering into this Agreement, the Optionee (i) authorizes the Company to collect, process, register and transfer to the Relevant Companies all Relevant Information; (ii) waives any privacy rights the Optionee may have with respect to the Relevant Information; (iii) authorizes the Relevant Companies to store and transmit such information in electronic form; and (iv) authorizes the transfer of the Relevant Information to any jurisdiction in which the Relevant Companies consider appropriate. The Optionee shall have access to, and the right to change, the Relevant Information. Relevant Information will only be used in accordance with applicable law.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Notices</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Notices hereunder shall be mailed or delivered to the Company at its principal place of business and shall be mailed or delivered to the Optionee at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:40.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:8.279%;"></td>
    <td style="width:2.488%;"></td>
    <td style="width:89.233%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ADICET BIO, NC.</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Name:</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Title:</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/115808348.2</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned. Electronic acceptance of this Agreement pursuant to the Company&#x2019;s instructions to the Optionee (including through an online acceptance process) is acceptable.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:6.011%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:42.987%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:2.996%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:45.0%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Dated:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Optionee&#x2019;s Signature</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Optionee&#x2019;s name and address:</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/115808348.2</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">RESTRICTED STOCK AWARD AGREEMENT</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">UNDER THE ADICET BIO, INC.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2018 STOCK OPTION AND INCENTIVE PLAN</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:27.01%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:34.997%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:35.989%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Name of Grantee:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">No. of Shares:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:6.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Grant Date:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the Adicet Bio, Inc. Amended and Restated 2018 Stock Option and Incentive Plan as amended through the date hereof (the &#x201c;Plan&#x201d;), Adicet Bio, Inc. (the &#x201c;Company&#x201d;) hereby grants a Restricted Stock Award (an &#x201c;Award&#x201d;) to the Grantee named above. Upon acceptance of this Award, the Grantee shall receive the number of shares of Common Stock, par value $0.0001 per share (the &#x201c;Stock&#x201d;) of the Company specified above, subject to the restrictions and conditions set forth herein and in the Plan. The Company acknowledges the receipt from the Grantee of consideration with respect to the par value of the Stock in the form of cash, past or future services rendered to the Company by the Grantee or such other form of consideration as is acceptable to the Administrator.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Award</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The shares of Restricted Stock awarded hereunder shall be issued and held by the Company&#x2019;s transfer agent in book entry form, and the Grantee&#x2019;s name shall be entered as the stockholder of record on the books of the Company. Thereupon, the Grantee shall have all the rights of a stockholder with respect to such shares, including voting and dividend rights, subject, however, to the restrictions and conditions specified in Paragraph 2 below. The Grantee shall (i) sign and deliver to the Company a copy of this Award Agreement and (ii) deliver to the Company a stock power endorsed in blank.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Restrictions and Conditions</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(a) Any book entries for the shares of Restricted Stock granted herein shall bear an appropriate legend, as determined by the Administrator in its sole discretion, to the effect that such shares are subject to restrictions as set forth herein and in the Plan.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(b) Shares of Restricted Stock granted herein may not be sold, assigned, transferred, pledged or otherwise encumbered or disposed of by the Grantee prior to vesting.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(c) If the Grantee&#x2019;s employment with the Company and its Subsidiaries is voluntarily or involuntarily terminated for any reason (including death) prior to vesting of shares of Restricted Stock granted herein, all shares of Restricted Stock shall immediately and automatically be forfeited and returned to the Company.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Vesting of Restricted Stock</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The restrictions and conditions in Paragraph 2 of this Agreement shall lapse on the Vesting Date or Dates specified in the following schedule so long as the Grantee remains an employee of the Company or a Subsidiary on such Dates. If a series of Vesting Dates is specified, then the restrictions and conditions in Paragraph 2 shall lapse only with respect to the number of shares of Restricted Stock specified as vested on such date.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:68.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:48.792%;"></td>
    <td style="width:27.918%;"></td>
    <td style="width:20.341%;"></td>
    <td style="width:1.474%;"></td>
    <td style="width:1.474%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid rgba(0,0,0,1);text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Incremental Number<br>of Shares Vested</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid rgba(0,0,0,1);text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Vesting Date</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">( %)</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">( %)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">( %)</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">( %)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">( %)</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Subsequent to such Vesting Date or Dates, the shares of Stock on which all restrictions and conditions have lapsed shall no longer be deemed Restricted Stock. The Administrator may at any time accelerate the vesting schedule specified in this Paragraph 3.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Dividends</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Dividends on shares of Restricted Stock shall be paid currently to the Grantee.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Incorporation of Plan</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Notwithstanding anything herein to the contrary, this Award shall be subject to and governed by all the terms and conditions of the Plan, including the powers of the Administrator set forth in Section 2(b) of the Plan. Capitalized terms in this Agreement shall have the meaning specified in the Plan, unless a different meaning is specified herein.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/115808348.2</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Transferability</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. This Agreement is personal to the Grantee, is non-assignable and is not transferable in any manner, by operation of law or otherwise, other than by will or the laws of descent and distribution.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Tax Withholding</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Grantee shall, not later than the date as of which the receipt of this Award becomes a taxable event for Federal income tax purposes, pay to the Company or make arrangements satisfactory to the Administrator for payment of any Federal, state, and local taxes required by law to be withheld on account of such taxable event. Except in the case where an election is made pursuant to Paragraph 8 below, the Company shall have the authority to cause the required tax withholding obligation to be satisfied, in whole or in part, by withholding from shares of Stock to be issued or released by the transfer agent a number of shares of Stock with an aggregate Fair Market Value that would satisfy the withholding amount due; provided, however, that the amount withheld does not exceed the maximum statutory tax rate or such lesser amount as is necessary to avoid adverse accounting treatment or as determined by the Administrator.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Election Under Section 83(b)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Grantee and the Company hereby agree that the Grantee may, within 30 days following the Grant Date of this Award, file with the Internal Revenue Service and the Company an election under Section 83(b) of the Internal Revenue Code. In the event the Grantee makes such an election, he or she agrees to provide a copy of the election to the Company. The Grantee acknowledges that he or she is responsible for obtaining the advice of his or her tax advisors with regard to the Section 83(b) election and that he or she is relying solely on such advisors and not on any statements or representations of the Company or any of its agents with regard to such election.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">No Obligation to Continue Employment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Neither the Company nor any Subsidiary is obligated by or as a result of the Plan or this Agreement to continue the Grantee in employment and neither the Plan nor this Agreement shall interfere in any way with the right of the Company or any Subsidiary to terminate the employment of the Grantee at any time.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Integration</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. This Agreement constitutes the entire agreement between the parties with respect to this Award and supersedes all prior agreements and discussions between the parties concerning such subject matter.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Data Privacy Consent</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. In order to administer the Plan and this Agreement and to implement or structure future equity grants, the Company, its subsidiaries and affiliates and certain agents thereof (together, the &#x201c;Relevant Companies&#x201d;) may process any and all personal or professional data, including but not limited to Social Security or other identification number, home address and telephone number, date of birth and other information that is necessary or desirable for the administration of the Plan and/or this Agreement (the &#x201c;Relevant Information&#x201d;). By entering into this Agreement, the Grantee (i) authorizes the Company to collect, process, register and transfer to the Relevant Companies all Relevant Information; (ii) waives any privacy rights the Grantee may have with respect to the Relevant Information; (iii) authorizes the Relevant Companies to store and transmit such information in electronic form; and (iv) authorizes the transfer of the Relevant Information to any jurisdiction in which the Relevant Companies consider appropriate. The Grantee shall have access to, and the right to change, the Relevant Information. Relevant Information will only be used in accordance with applicable law.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Notices</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Notices hereunder shall be mailed or delivered to the Company at its principal place of business and shall be mailed or delivered to the Grantee at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:40.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:8.279%;"></td>
    <td style="width:2.488%;"></td>
    <td style="width:89.233%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ADICET BIO, NC.</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Name:</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Title:</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned. Electronic acceptance of this Agreement pursuant to the Company&#x2019;s instructions to the Grantee (including through an online acceptance process) is acceptable.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/115808348.2</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:6.011%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:42.987%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:2.996%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:45.0%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Dated:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Grantee&#x2019;s Signature</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Grantee&#x2019;s name and address:</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/115808348.2</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">RESTRICTED STOCK UNIT AWARD AGREEMENT</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">FOR NON-EMPLOYEE DIRECTORS</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">UNDER THE ADICET BIO, INC.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2018 STOCK OPTION AND INCENTIVE PLAN</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:27.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:35.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:36.0%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Name of Grantee:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">No. of Restricted Stock Units:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Grant Date:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the Adicet Bio, Inc. Amended and Restated 2018 Stock Option and Incentive Plan as amended through the date hereof (the &#x201c;Plan&#x201d;), Adicet Bio, Inc. (the &#x201c;Company&#x201d;) hereby grants an award of the number of Restricted Stock Units listed above (an &#x201c;Award&#x201d;) to the Grantee named above. Each Restricted Stock Unit shall relate to one share of Common Stock, par value $0.0001 per share (the &#x201c;Stock&#x201d;) of the Company.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Restrictions on Transfer of Award</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. This Award may not be sold, transferred, pledged, assigned or otherwise encumbered or disposed of by the Grantee, and any shares of Stock issuable with respect to the Award may not be sold, transferred, pledged, assigned or otherwise encumbered or disposed of until (i) the Restricted Stock Units have vested as provided in Paragraph 2 of this Agreement and (ii) shares of Stock have been issued to the Grantee in accordance with the terms of the Plan and this Agreement.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Vesting of Restricted Stock Units</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The restrictions and conditions of Paragraph 1 of this Agreement shall lapse on the Vesting Date or Dates specified in the following schedule so long as the Grantee remains in service as a member of the Board on such Dates. If a series of Vesting Dates is specified, then the restrictions and conditions in Paragraph 1 shall lapse only with respect to the number of Restricted Stock Units specified as vested on such date.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:68.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:48.792%;"></td>
    <td style="width:27.918%;"></td>
    <td style="width:20.341%;"></td>
    <td style="width:1.474%;"></td>
    <td style="width:1.474%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid rgba(0,0,0,1);text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Incremental Number of<br>Restricted Stock Units Vested</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid rgba(0,0,0,1);text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Vesting Date</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">( %)</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">( %)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">( %)</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">( %)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Administrator may at any time accelerate the vesting schedule specified in this Paragraph 2.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Termination of Service</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. If the Grantee&#x2019;s service with the Company and its Subsidiaries terminates for any reason (including death or disability) prior to the satisfaction of the vesting conditions set forth in Paragraph 2 above, any Restricted Stock Units that have not vested as of such date shall automatically and without notice terminate and be forfeited, and neither the Grantee nor any of his or her successors, heirs, assigns, or personal representatives will thereafter have any further rights or interests in such unvested Restricted Stock Units.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Issuance of Shares of Stock</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. As soon as practicable following each Vesting Date (but in no event later than two and one-half months after the end of the year in which the Vesting Date occurs), the Company shall issue to the Grantee the number of shares of Stock equal to the aggregate number of Restricted Stock Units that have vested pursuant to Paragraph 2 of this Agreement on such date and the Grantee shall thereafter have all the rights of a stockholder of the Company with respect to such shares.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Incorporation of Plan</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Notwithstanding anything herein to the contrary, this Agreement shall be subject to and governed by all the terms and conditions of the Plan, including the powers of the Administrator set forth in Section 2(b) of the Plan. Capitalized terms in this Agreement shall have the meaning specified in the Plan, unless a different meaning is specified herein.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 409A of the Code.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> This Agreement shall be interpreted in such a manner that all provisions relating to the settlement of the Award are exempt from the requirements of Section 409A of the Code as &#x201c;short-term deferrals&#x201d; as described in Section 409A of the Code.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">No Obligation to Continue as a Director</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Neither the Plan nor this Award confers upon the Grantee any rights with respect to continuance as a Director.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Integration</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. This Agreement constitutes the entire agreement between the parties with respect to this Award and supersedes all prior agreements and discussions between the parties concerning such subject matter.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/115808348.2</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Data Privacy Consent</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. In order to administer the Plan and this Agreement and to implement or structure future equity grants, the Company, its subsidiaries and affiliates and certain agents thereof (together, the &#x201c;Relevant Companies&#x201d;) may process any and all personal or professional data, including but not limited to Social Security or other identification number, home address and telephone number, date of birth and other information that is necessary or desirable for the administration of the Plan and/or this Agreement (the &#x201c;Relevant Information&#x201d;). By entering into this Agreement, the Grantee (i) authorizes the Company to collect, process, register and transfer to the Relevant Companies all Relevant Information; (ii) waives any privacy rights the Grantee may have with respect to the Relevant Information; (iii) authorizes the Relevant Companies to store and transmit such information in electronic form; and (iv) authorizes the transfer of the Relevant Information to any jurisdiction in which the Relevant Companies consider appropriate. The Grantee shall have access to, and the right to change, the Relevant Information. Relevant Information will only be used in accordance with applicable law.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Notices</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Notices hereunder shall be mailed or delivered to the Company at its principal place of business and shall be mailed or delivered to the Grantee at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:40.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:21.256%;"></td>
    <td style="width:2.512%;"></td>
    <td style="width:38.116%;"></td>
    <td style="width:38.116%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="4" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ADICET BIO, INC.</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Name:</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Title:</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned. Electronic acceptance of this Agreement pursuant to the Company&#x2019;s instructions to the Grantee (including through an online acceptance process) is acceptable.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:6.011%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:42.987%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:2.996%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:45.0%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Dated:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Grantee&#x2019;s Signature</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Grantee&#x2019;s name and address:</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/115808348.2</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">RESTRICTED STOCK UNIT AWARD AGREEMENT</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">FOR COMPANY EMPLOYEES</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">UNDER THE ADICET BIO, INC.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2018 STOCK OPTION AND INCENTIVE PLAN</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:35.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:32.0%;"></td>
    <td style="width:1.0%;"></td>
    <td style="width:31.0%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Name of Grantee:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">No. of Restricted Stock Units:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Grant Date:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the Adicet Bio, Inc. Amended and Restated 2018 Stock Option and Incentive Plan as amended through the date hereof (the &#x201c;Plan&#x201d;), Adicet Bio, Inc. (the &#x201c;Company&#x201d;) hereby grants an award of the number of Restricted Stock Units listed above (an &#x201c;Award&#x201d;) to the Grantee named above. Each Restricted Stock Unit shall relate to one share of Common Stock, par value $0.0001 per share (the &#x201c;Stock&#x201d;) of the Company.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Restrictions on Transfer of Award</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. This Award may not be sold, transferred, pledged, assigned or otherwise encumbered or disposed of by the Grantee, and any shares of Stock issuable with respect to the Award may not be sold, transferred, pledged, assigned or otherwise encumbered or disposed of until (i) the Restricted Stock Units have vested as provided in Paragraph 2 of this Agreement and (ii) shares of Stock have been issued to the Grantee in accordance with the terms of the Plan and this Agreement.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Vesting of Restricted Stock Units</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The restrictions and conditions of Paragraph 1 of this Agreement shall lapse on the Vesting Date or Dates specified in the following schedule so long as the Grantee remains an employee of the Company or a Subsidiary on such Dates. If a series of Vesting Dates is specified, then the restrictions and conditions in Paragraph 1 shall lapse only with respect to the number of Restricted Stock Units specified as vested on such date.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:68.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:48.792%;"></td>
    <td style="width:27.918%;"></td>
    <td style="width:20.341%;"></td>
    <td style="width:1.474%;"></td>
    <td style="width:1.474%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:8.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Incremental Number of</font></p><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:1.000pt solid rgba(0,0,0,1);text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Restricted Stock Units Vested</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;padding-bottom:0.010in;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Vesting Date</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">( %)</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">( %)</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">( %)</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(204,238,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">( %)</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Administrator may at any time accelerate the vesting schedule specified in this Paragraph 2.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Termination of Employment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. If the Grantee&#x2019;s employment with the Company and its Subsidiaries terminates for any reason (including death or disability) prior to the satisfaction of the vesting conditions set forth in Paragraph 2 above, any Restricted Stock Units that have not vested as of such date shall automatically and without notice terminate and be forfeited, and neither the Grantee nor any of his or her successors, heirs, assigns, or personal representatives will thereafter have any further rights or interests in such unvested Restricted Stock Units.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Issuance of Shares of Stock</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. As soon as practicable following each Vesting Date (but in no event later than two and one-half months after the end of the year in which the Vesting Date occurs), the Company shall issue to the Grantee the number of shares of Stock equal to the aggregate number of Restricted Stock Units that have vested pursuant to Paragraph 2 of this Agreement on such date and the Grantee shall thereafter have all the rights of a stockholder of the Company with respect to such shares.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Incorporation of Plan</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Notwithstanding anything herein to the contrary, this Agreement shall be subject to and governed by all the terms and conditions of the Plan, including the powers of the Administrator set forth in Section 2(b) of the Plan. Capitalized terms in this Agreement shall have the meaning specified in the Plan, unless a different meaning is specified herein.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Tax Withholding</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Grantee shall, not later than the date as of which the receipt of this Award becomes a taxable event for Federal income tax purposes, pay to the Company or make arrangements satisfactory to the Administrator for payment of any Federal, state, and local taxes required by law to be withheld on account of such taxable event. The Company shall have the authority to cause the required tax withholding obligation to be satisfied, in whole or in part, by withholding from shares of Stock to be issued to the Grantee a number of shares of Stock with an aggregate Fair Market Value that would satisfy the withholding amount due; provided, however, that the amount withheld does not exceed the maximum statutory tax rate or such lesser amount as is necessary to avoid adverse accounting treatment or as determined by the Administrator.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/115808348.2</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 409A of the Code.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> This Agreement shall be interpreted in such a manner that all provisions relating to the settlement of the Award are exempt from the requirements of Section 409A of the Code as &#x201c;short-term deferrals&#x201d; as described in Section 409A of the Code.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">No Obligation to Continue Employment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Neither the Company nor any Subsidiary is obligated by or as a result of the Plan or this Agreement to continue the Grantee in employment and neither the Plan nor this Agreement shall interfere in any way with the right of the Company or any Subsidiary to terminate the employment of the Grantee at any time.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Integration</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. This Agreement constitutes the entire agreement between the parties with respect to this Award and supersedes all prior agreements and discussions between the parties concerning such subject matter.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Data Privacy Consent</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. In order to administer the Plan and this Agreement and to implement or structure future equity grants, the Company, its subsidiaries and affiliates and certain agents thereof (together, the &#x201c;Relevant Companies&#x201d;) may process any and all personal or professional data, including but not limited to Social Security or other identification number, home address and telephone number, date of birth and other information that is necessary or desirable for the administration of the Plan and/or this Agreement (the &#x201c;Relevant Information&#x201d;). By entering into this Agreement, the Grantee (i) authorizes the Company to collect, process, register and transfer to the Relevant Companies all Relevant Information; (ii) waives any privacy rights the Grantee may have with respect to the Relevant Information; (iii) authorizes the Relevant Companies to store and transmit such information in electronic form; and (iv) authorizes the transfer of the Relevant Information to any jurisdiction in which the Relevant Companies consider appropriate. The Grantee shall have access to, and the right to change, the Relevant Information. Relevant Information will only be used in accordance with applicable law.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Notices</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Notices hereunder shall be mailed or delivered to the Company at its principal place of business and shall be mailed or delivered to the Grantee at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:40.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:53.987%;"></td>
    <td style="width:2.72%;"></td>
    <td style="width:21.646%;"></td>
    <td style="width:21.646%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="4" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ADICET BIO, INC.</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Name:</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Title:</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned. Electronic acceptance of this Agreement pursuant to the Company&#x2019;s instructions to the Grantee (including through an online acceptance process) is acceptable.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:6.011%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:42.987%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:2.996%;"></td>
    <td style="width:1.002%;"></td>
    <td style="width:45.0%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Dated:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Grantee&#x2019;s Signature</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Grantee&#x2019;s name and address:</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(255,255,255,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;">ADICET BIO, INC. 500 BOYLSTON STREET, 13TH FLOOR BOSTON, MASSACHUSETTS 02116 VOTE BY</font><font style="color:rgba(255,255,255,1);white-space:pre-wrap;font-weight:normal;font-size:1.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/115808348.2</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.14
<SEQUENCE>4
<FILENAME>acet-ex10_14.htm
<DESCRIPTION>EX-10.14
<TEXT>
<html>
 <head>
  <title>EX-10.14</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 10.14</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ADICET BIO, INC.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">AMENDED AND RESTATED 2018 EMPLOYEE STOCK PURCHASE PLAN</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The purpose of the Adicet Bio, Inc. Amended and Restated 2018 Employee Stock Purchase Plan (&#x201c;the Plan&#x201d;) is to provide eligible employees of Adicet Bio, Inc. (the &#x201c;Company&#x201d;) and each Designated Subsidiary (as defined in Section 11) with opportunities to purchase shares of the Company&#x2019;s common stock, par value $0.0001 per share (the &#x201c;Common Stock&#x201d;). 524,775 shares of Common Stock have been approved and reserved for this purpose, plus on January 1, 2022, and each January 1 thereafter through January 1, 2031, the number of shares of Common Stock reserved and available for issuance under the Plan shall be cumulatively increased by the least of (i) 1,262,560 shares of Common Stock, (ii) one percent (1%) of the number of shares of Common Stock issued and outstanding on the immediately preceding December 31st, or (iii) such lesser number of shares of Common Stock as determined by the Administrator. The Plan is intended to constitute an &#x201c;employee stock purchase plan&#x201d; within the meaning of Section 423(b) of the Internal Revenue Code of 1986, as amended (the &#x201c;Code&#x201d;), and shall be interpreted in accordance with that intent.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Administration</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Plan will be administered by the person or persons (the &#x201c;Administrator&#x201d;) appointed by the Company&#x2019;s Board of Directors (the &#x201c;Board&#x201d;) for such purpose. The Administrator has authority at any time to: (i) adopt, alter and repeal such rules, guidelines and practices for the administration of the Plan and for its own acts and proceedings as it shall deem advisable; (ii) interpret the terms and provisions of the Plan; (iii) make all determinations it deems advisable for the administration of the Plan; (iv) decide all disputes arising in connection with the Plan; and (v) otherwise supervise the administration of the Plan. All interpretations and decisions of the Administrator shall be binding on all persons, including the Company and the Participants. No member of the Board or individual exercising administrative authority with respect to the Plan shall be liable for any action or determination made in good faith with respect to the Plan or any option granted hereunder.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Offerings</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Company will make one or more offerings to eligible employees to purchase Common Stock under the Plan (&#x201c;Offerings&#x201d;). Unless otherwise determined by the Administrator, an Offering will begin on the first business day occurring on or after each January 1 and July 1 and will end on the last business day occurring on or before the following June 30 and December 31, respectively. The Administrator may, in its discretion, designate a different period for any Offering, provided that no Offering shall exceed one year in duration or overlap any other Offering.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Eligibility</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. All individuals classified as employees on the payroll records of the Company and each Designated Subsidiary are eligible to participate in any one or more of the Offerings under the Plan, provided that as of the first day of the applicable Offering (the &#x201c;Offering Date&#x201d;) they are customarily employed by the Company or a Designated Subsidiary for more than 20 hours a week and have completed at least three months of employment. Notwithstanding any other provision herein, individuals who are not contemporaneously classified as employees of the Company or a Designated Subsidiary for purposes of the Company&#x2019;s or applicable Designated Subsidiary&#x2019;s payroll system are not considered to be eligible employees of the Company or any Designated Subsidiary and shall not be eligible to participate in the Plan. In the event any such individuals are reclassified as employees of the Company or a Designated Subsidiary for any purpose, including, without limitation, common law or statutory employees, by any action of any third party, including, without limitation, any government agency, or as a result of any private lawsuit, action or administrative proceeding, such individuals shall, notwithstanding such reclassification, remain ineligible for participation. Notwithstanding the foregoing, the exclusive means for individuals who are not contemporaneously classified as employees of the Company or a Designated Subsidiary on the Company&#x2019;s or Designated Subsidiary&#x2019;s payroll system to become eligible to participate in this Plan is through an amendment to this Plan, duly executed by the Company, which specifically renders such individuals eligible to participate herein.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Participation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(a) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Participants</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. An eligible employee who is not a Participant in any prior Offering may participate in a subsequent Offering by submitting an enrollment form to his or her appropriate payroll location at least 15 business days before the Offering Date (or by such other deadline as shall be established by the Administrator for the Offering).</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(b) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Enrollment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The enrollment form will (a) state a whole percentage to be deducted from an eligible employee&#x2019;s Compensation (as defined in Section 11) per pay period, (b) authorize the purchase of Common Stock in each Offering in accordance with the terms of the Plan and (c) specify the exact name or names in which shares of Common Stock purchased for such individual are to be issued pursuant to Section 10. An employee who does not enroll in accordance with these procedures will be deemed to have waived the right to participate. Unless a Participant files a new enrollment form or withdraws from the Plan, such Participant&#x2019;s deductions and purchases will continue at the same percentage of Compensation for future Offerings, provided he or she remains eligible.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/115808347.2</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(c) Notwithstanding the foregoing, participation in the Plan will neither be permitted nor be denied contrary to the requirements of the Code.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Employee Contributions</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Each eligible employee may authorize payroll deductions up to a maximum of fifteen percent of such employee&#x2019;s Compensation for each pay period. The Company will maintain book accounts showing the amount of payroll deductions made by each Participant for each Offering. No interest will accrue or be paid on payroll deductions.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Deduction Changes</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Except as may be determined by the Administrator in advance of an Offering, a Participant may not increase or decrease his or her payroll deduction during any Offering, but may increase or decrease his or her payroll deduction with respect to the next Offering (subject to the limitations of Section 5) by filing a new enrollment form at least 15 business days before the next Offering Date (or by such other deadline as shall be established by the Administrator for the Offering). The Administrator may, in advance of any Offering, establish rules permitting a Participant to increase, decrease or terminate his or her payroll deduction during an Offering.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Withdrawal</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. A Participant may withdraw from participation in the Plan by delivering a written notice of withdrawal to his or her appropriate payroll location. The Participant&#x2019;s withdrawal will be effective as of the next business day. Following a Participant&#x2019;s withdrawal, the Company will promptly refund such individual&#x2019;s entire account balance under the Plan to him or her (after payment for any Common Stock purchased before the effective date of withdrawal). Partial withdrawals are not permitted. Such an employee may not begin participation again during the remainder of the Offering, but may enroll in a subsequent Offering in accordance with Section 4.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Grant of Options</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. On each Offering Date, the Company will grant to each eligible employee who is then a Participant in the Plan an option (&#x201c;Option&#x201d;) to purchase on the last day of such Offering (the &#x201c;Exercise Date&#x201d;), at the Option Price hereinafter provided for, the lowest of (a) a number of shares of Common Stock determined by dividing such Participant&#x2019;s accumulated payroll deductions on such Exercise Date by the lower of (i) 85 percent of the Fair Market Value of the Common Stock on the Offering Date, or (ii) 85 percent of the Fair Market Value of the Common Stock on the Exercise Date, (b) a number of shares determined by dividing $25,000 by the Fair Market of the Common Stock on the Offering Date of such Offering ; or (c) such other lesser maximum number of shares as shall have been established by the Administrator in advance of the Offering; provided, however, that such Option shall be subject to the limitations set forth below. Each Participant&#x2019;s Option shall be exercisable only to the extent of such Participant&#x2019;s accumulated payroll deductions on the Exercise Date. The purchase price for each share purchased under each Option (the &#x201c;Option Price&#x201d;) will be 85 percent of the Fair Market Value of the Common Stock on the Offering Date or the Exercise Date, whichever is less.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Notwithstanding the foregoing, no Participant may be granted an option hereunder if such Participant, immediately after the option was granted, would be treated as owning stock possessing 5 percent or more of the total combined voting power or value of all classes of stock of the Company or any Parent or Subsidiary (as defined in Section 11). For purposes of the preceding sentence, the attribution rules of Section 424(d) of the Code shall apply in determining the stock ownership of a Participant, and all stock which the Participant has a contractual right to purchase shall be treated as stock owned by the Participant. In addition, no Participant may be granted an Option which permits his or her rights to purchase stock under the Plan, and any other employee stock purchase plan of the Company and its Parents and Subsidiaries, to accrue at a rate which exceeds $25,000 of the fair market value of such stock (determined on the option grant date or dates) for each calendar year in which the Option is outstanding at any time. The purpose of the limitation in the preceding sentence is to comply with Section 423(b)(8) of the Code and shall be applied taking Options into account in the order in which they were granted.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Exercise of Option and Purchase of Shares</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Each employee who continues to be a Participant in the Plan on the Exercise Date shall be deemed to have exercised his or her Option on such date and shall acquire from the Company such number of whole shares of Common Stock reserved for the purpose of the Plan as his or her accumulated payroll deductions on such date will purchase at the Option Price, subject to any other limitations contained in the Plan. Any amount remaining in a Participant&#x2019;s account at the end of an Offering solely by reason of the inability to purchase a fractional share will be carried forward to the next Offering; any other balance remaining in a Participant&#x2019;s account at the end of an Offering will be refunded to the Participant promptly.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Issuance of Certificates</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Certificates representing shares of Common Stock purchased under the Plan may be issued only in the name of the employee, in the name of the employee and another person of legal age as joint tenants with rights of survivorship, or in the name of a broker authorized by the employee to be his, her or their, nominee for such purpose.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Definitions</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The term &#x201c;Compensation&#x201d; means the amount of base pay, prior to salary reduction pursuant to Sections 125, 132(f) or 401(k) of the Code, but excluding overtime, commissions, incentive or bonus awards, allowances and reimbursements for expenses such as relocation allowances or travel expenses, income or gains on the exercise of Company stock options, and similar items</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/115808347.2</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The term &#x201c;Designated Subsidiary&#x201d; means any present or future Subsidiary (as defined below) that has been designated by the Board to participate in the Plan. The Board may so designate any Subsidiary, or revoke any such designation, at any time and from time to time, either before or after the Plan is approved by the stockholders. The current list of Designated Companies is attached hereto as </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Appendix A</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The term &#x201c;Fair Market Value of the Common Stock&#x201d; on any given date means the fair market value of the Common Stock determined in good faith by the Administrator; provided, however, that if the Common Stock is admitted to quotation on the National Association of Securities Dealers Automated Quotation System (&#x201c;Nasdaq&#x201d;), Nasdaq Global Market or another national securities exchange, the determination shall be made by reference to the closing price on such date. If there is no closing price for such date, the determination shall be made by reference to the last date preceding such date for which there is a closing price.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The term &#x201c;Initial Public Offering&#x201d; means the first underwritten, firm commitment public offering pursuant to an effective registration statement under the Securities Act of 1933, as amended, covering the offer and sale by the Company of its Common Stock.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The term &#x201c;Parent&#x201d; means a &#x201c;parent corporation&#x201d; with respect to the Company, as defined in Section 424(e) of the Code.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The term &#x201c;Participant&#x201d; means an individual who is eligible as determined in Section 3 and who has complied with the provisions of Section 4.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The term &#x201c;Subsidiary&#x201d; means a &#x201c;subsidiary corporation&#x201d; with respect to the Company, as defined in Section 424(f) of the Code.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Rights on Termination of Employment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. If a Participant&#x2019;s employment terminates for any reason before the Exercise Date for any Offering, no payroll deduction will be taken from any pay due and owing to the Participant and the balance in the Participant&#x2019;s account will be paid to such Participant or, in the case of such Participant&#x2019;s death, to his or her designated beneficiary as if such Participant had withdrawn from the Plan under Section 7. An employee will be deemed to have terminated employment, for this purpose, if the corporation that employs him or her, having been a Designated Subsidiary, ceases to be a Subsidiary, or if the employee is transferred to any corporation other than the Company or a Designated Subsidiary. An employee will not be deemed to have terminated employment for this purpose, if the employee is on an approved leave of absence for military service or sickness or for any other purpose approved by the Company, if the employee&#x2019;s right to reemployment is guaranteed either by a statute or by contract or under the policy pursuant to which the leave of absence was granted or if the Administrator otherwise provides in writing.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Special Rules</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Notwithstanding anything herein to the contrary, the Administrator may adopt special rules applicable to the employees of a particular Designated Subsidiary, whenever the Administrator determines that such rules are necessary or appropriate for the implementation of the Plan in a jurisdiction where such Designated Subsidiary has employees; provided that such rules are consistent with the requirements of Section 423(b) of the Code. Any special rules established pursuant to this Section 13 shall, to the extent possible, result in the employees subject to such rules having substantially the same rights as other Participants in the Plan.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Optionees Not Stockholders</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Neither the granting of an Option to a Participant nor the deductions from his or her pay shall constitute such Participant a holder of the shares of Common Stock covered by an Option under the Plan until such shares have been purchased by and issued to him or her.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Rights Not Transferable</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Rights under the Plan are not transferable by a Participant other than by will or the laws of descent and distribution, and are exercisable during the Participant&#x2019;s lifetime only by the Participant.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Application of Funds</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. All funds received or held by the Company under the Plan may be combined with other corporate funds and may be used for any corporate purpose.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Adjustment in Case of Changes Affecting Common Stock</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. In the event of a subdivision of outstanding shares of Common Stock, the payment of a dividend in Common Stock or any other change affecting the Common Stock, the number of shares approved for the Plan and the share limitation set forth in Section 8 shall be equitably or proportionately adjusted to give proper effect to such event.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amendment of the Plan</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Board may at any time and from time to time amend the Plan in any respect, except that without the approval within 12 months of such Board action by the stockholders, no amendment shall be made increasing the number of shares approved for the Plan or making any other change that would require stockholder approval in order for the Plan, as amended, to qualify as an &#x201c;employee stock purchase plan&#x201d; under Section 423(b) of the Code.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Insufficient Shares</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. If the total number of shares of Common Stock that would otherwise be purchased on any Exercise Date plus the number of shares purchased under previous Offerings under the Plan exceeds the maximum number of shares issuable under the</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/115808347.2</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Plan, the shares then available shall be apportioned among Participants in proportion to the amount of payroll deductions accumulated on behalf of each Participant that would otherwise be used to purchase Common Stock on such Exercise Date.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Termination of the Plan</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Plan may be terminated at any time by the Board. Upon termination of the Plan, all amounts in the accounts of Participants shall be promptly refunded.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Governmental Regulations</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Company&#x2019;s obligation to sell and deliver Common Stock under the Plan is subject to obtaining all governmental approvals required in connection with the authorization, issuance, or sale of such stock.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Governing Law</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. This Plan and all Options and actions taken thereunder shall be governed by, and construed in accordance with, the laws of the State of Delaware, applied without regard to conflict of law principles.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Issuance of Shares</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Shares may be issued upon exercise of an Option from authorized but unissued Common Stock, from shares held in the treasury of the Company, or from any other proper source.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Tax Withholding</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Participation in the Plan is subject to any minimum required tax withholding on income of the Participant in connection with the Plan. Each Participant agrees, by entering the Plan, that the Company and its Subsidiaries shall have the right to deduct any such taxes from any payment of any kind otherwise due to the Participant, including shares issuable under the Plan.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Notification Upon Sale of Shares</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Each Participant agrees, by entering the Plan, to give the Company prompt notice of any disposition of shares purchased under the Plan where such disposition occurs within two years after the date of grant of the Option pursuant to which such shares were purchased or within one year after the date such shares were purchased.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">26. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Effective Date and Approval of Shareholders</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Plan shall take effect on the date immediately preceding the date on which the Company&#x2019;s registration statement on Form S-1 becomes effective following approval by the holders of a majority of the votes cast at a meeting of stockholders at which a quorum is present or by written consent of the stockholders.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">DATE APPROVED BY BOARD OF DIRECTORS: December 21, 2017</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">DATE APPROVED BY STOCKHOLDERS: January 12, 2018</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">AMENDED AND RESTATED BY THE BOARD OF DIRECTORS: March 2, 2021</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">DATE STOCKHOLDERS APPROVED AMENDED AND RESTATED PLAN: April 27, 2021</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/115808347.2</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:24.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">APPENDIX A<br><br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Designated Subsidiaries</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:24.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Adicet Therapeutics, Inc.</font></p>
  <p style="text-indent:11.467%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/115808347.2</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.15
<SEQUENCE>5
<FILENAME>acet-ex10_15.htm
<DESCRIPTION>EX-10.15
<TEXT>
<html>
 <head>
  <title>EX-10.15</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 10.15</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ADICET BIO, INC.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2022 INDUCEMENT PLAN</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:0.003472222222222222in;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:13.0%;"></td>
    <td style="width:87.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">SECTION 1.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">GENERAL PURPOSE OF THE PLAN; DEFINITIONS</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The name of the plan is the Adicet Bio, Inc. 2022 Inducement Plan (the &#x201c;Plan&#x201d;). The purpose of the Plan is to encourage and enable Adicet Bio, Inc. (the &#x201c;Company&#x201d;) to grant equity awards to induce highly-qualified prospective officers and employees to accept employment and provide them with a proprietary interest in the Company. It is anticipated that providing such persons with a direct stake in the Company&#x2019;s welfare will assure a closer identification of their interests with those of the Company and its stockholders, thereby stimulating their efforts on the Company&#x2019;s behalf and strengthening their desire to remain with the Company. The Company intends that the Plan be reserved for persons to whom the Company may issue securities without stockholder approval as an inducement pursuant to Rule 5635(c) of the Marketplace Rules of the NASDAQ Stock Market, Inc.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following terms shall be defined as set forth below:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">&#x201c;Act&#x201d;</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> means the Securities Act of 1933, as amended, and the rules and regulations thereunder.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">&#x201c;Administrator&#x201d;</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> means either the Board or the compensation committee of the Board or a similar committee performing the functions of the compensation committee and which is comprised of not less than two Non-Employee Directors who are independent.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">&#x201c;Award&#x201d;</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> or </font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">&#x201c;Awards,&#x201d;</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> except where referring to a particular category of grant under the Plan, shall include Non-Qualified Stock Options, Stock Appreciation Rights, Restricted Stock Units, Restricted Stock Awards, Unrestricted Stock Awards, and Dividend Equivalent Rights.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">&#x201c;Award Certificate&#x201d;</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> means a written or electronic document setting forth the terms and provisions applicable to an Award granted under the Plan. Each Award Certificate is subject to the terms and conditions of the Plan.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">&#x201c;Board&#x201d;</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> means the Board of Directors of the Company.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">&#x201c;Code&#x201d;</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> means the Internal Revenue Code of 1986, as amended, and any successor Code, and related rules, regulations and interpretations.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">&#x201c;Continuous Service&#x201d;</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> means that a Service Relationship is not interrupted or terminated. For this purpose, a Service Relationship shall be deemed to continue without interruption in the event an individual&#x2019;s status changes from full-time employee to part-time employee or consultant.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">&#x201c;Dividend Equivalent Right&#x201d;</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> means an Award entitling the grantee to receive credits based on cash dividends that would have been paid on the shares of Stock specified in the Dividend Equivalent Right (or other award to which it relates) if such shares had been issued to and held by the grantee.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">&#x201c;Effective Date&#x201d;</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> means the date on which the Plan is approved by the Board as set forth in Section 19.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">&#x201c;Exchange Act&#x201d;</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> means the Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">&#x201c;Fair Market Value&#x201d;</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of the Stock on any given date means the fair market value of the Stock determined in good faith by the Administrator; provided, however, that if the Stock is admitted to quotation on the National Association of Securities Dealers Automated Quotation System (&#x201c;Nasdaq&#x201d;), Nasdaq Global Market or another national securities exchange, the determination shall be made by reference to market quotations. If there are no market quotations for such date, the determination shall be made by reference to the last date preceding such date for which there are market quotations.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">&#x201c;Non-Employee Director&#x201d;</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> means a member of the Board who is not also an employee of the Company or any Subsidiary.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">&#x201c;Non-Qualified Stock Option&#x201d;</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> means any Stock Option that is not an &#x201c;incentive stock option&#x201d; under Section 422 of the Code.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">&#x201c;Option&#x201d;</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> or </font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">&#x201c;Stock Option&#x201d;</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> means any option to purchase shares of Stock granted pursuant to Section 5.</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">&#x201c;Restricted Shares&#x201d;</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> means the shares of Stock underlying a Restricted Stock Award that remain subject to a risk of forfeiture or the Company&#x2019;s right of repurchase.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">&#x201c;Restricted Stock Award&#x201d;</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> means an Award of Restricted Shares subject to such restrictions and conditions as the Administrator may determine at the time of grant.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">&#x201c;Restricted Stock Units&#x201d;</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> means an Award of stock units subject to such restrictions and conditions as the Administrator may determine at the time of grant.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">&#x201c;Sale Event&#x201d;</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shall mean (i) the sale of all or substantially all of the assets of the Company on a consolidated basis to an unrelated person or entity, (ii) a merger, reorganization or consolidation pursuant to which the holders of the Company&#x2019;s outstanding voting power and outstanding stock immediately prior to such transaction do not own a majority of the outstanding voting power and outstanding stock or other equity interests of the resulting or successor entity (or its ultimate parent, if applicable) immediately upon completion of such transaction, (iii) the sale of all of the Stock of the Company to an unrelated person, entity or group thereof acting in concert, or (iv) any other transaction in which the owners of the Company&#x2019;s outstanding voting power immediately prior to such transaction do not own at least a majority of the outstanding voting power of the Company or any successor entity immediately upon completion of the transaction other than as a result of the acquisition of securities directly from the Company.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201c;</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Sale Price</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d; means the value as determined by the Administrator of the consideration payable, or otherwise to be received by stockholders, per share of Stock pursuant to a Sale Event.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">&#x201c;Section 409A&#x201d;</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> means Section 409A of the Code and the regulations and other guidance promulgated thereunder.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">&#x201c;Service Relationship&#x201d;</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> means any relationship as an employee, Non-Employee Director or consultant of the Company or any Affiliate.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">&#x201c;Stock&#x201d;</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> means the Common Stock, par value $0.0001 per share, of the Company, subject to adjustments pursuant to Section 3.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">&#x201c;Stock Appreciation Right&#x201d;</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> means an Award entitling the recipient to receive shares of Stock (or cash, to the extent explicitly provided for in the applicable Award Certificate) having a value equal to the excess of the Fair Market Value of the Stock on the date of exercise over the exercise price of the Stock Appreciation Right multiplied by the number of shares of Stock with respect to which the Stock Appreciation Right shall have been exercised.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">&#x201c;Subsidiary&#x201d;</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> means any corporation or other entity (other than the Company) in which the Company has at least a 50 percent interest, either directly or indirectly.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">&#x201c;Unrestricted Stock Award&#x201d;</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> means an Award of shares of Stock free of any restrictions.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:0.003472222222222222in;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:13.0%;"></td>
    <td style="width:87.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">SECTION 2.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">ADMINISTRATION OF PLAN; ADMINISTRATOR AUTHORITY TO SELECT GRANTEES AND DETERMINE AWARDS</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(a) </font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Administration of Plan</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Plan shall be administered by the Administrator.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(b) </font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Powers of Administrator</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Administrator shall have the power and authority to grant Awards consistent with the terms of the Plan, including the power and authority:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(i) to select the individuals to whom Awards may from time to time be granted;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(ii) to determine the time or times of grant, and the extent, if any, of Non-Qualified Stock Options, Stock Appreciation Rights, Restricted Stock Awards, Restricted Stock Units, Unrestricted Stock Awards, and Dividend Equivalent Rights, or any combination of the foregoing, granted to any one or more grantees;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(iii) to determine the number of shares of Stock to be covered by any Award;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(iv) to determine and modify from time to time the terms and conditions, including restrictions, not inconsistent with the terms of the Plan, of any Award, which terms and conditions may differ among individual Awards and grantees, and to approve the forms of Award Certificates;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(v) to accelerate at any time the exercisability or vesting of all or any portion of any Award;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(vi) subject to the provisions of Section 5(c), to extend at any time the period in which Stock Options may be exercised; and</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(vii) at any time to adopt, alter and repeal such rules, guidelines and practices for administration of the Plan and for its own acts and proceedings as it shall deem advisable; to interpret the terms and provisions of the Plan and any Award (including related written instruments); to make all determinations it deems advisable for the administration of the Plan; to decide all disputes arising in connection with the Plan; and to otherwise supervise the administration of the Plan.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All decisions and interpretations of the Administrator shall be binding on all persons, including the Company and Plan grantees.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(c) </font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Reserved.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(d) </font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Award Certificate</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Awards under the Plan shall be evidenced by Award Certificates that set forth the terms, conditions and limitations for each Award which may include, without limitation, the term of an Award and the provisions applicable in the event employment or service terminates.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(e) </font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Indemnification</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Neither the Board nor the Administrator, nor any member of either or any delegate thereof, shall be liable for any act, omission, interpretation, construction or determination made in good faith in connection with the Plan, and the members of the Board and the Administrator (and any delegate thereof) shall be entitled in all cases to indemnification and reimbursement by the Company in respect of any claim, loss, damage or expense (including, without limitation, reasonable attorneys&#x2019; fees) arising or resulting therefrom to the fullest extent permitted by law and/or under the Company&#x2019;s articles or bylaws or any directors&#x2019; and officers&#x2019; liability insurance coverage which may be in effect from time to time and/or any indemnification agreement between such individual and the Company.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(f) </font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Foreign Award Recipients</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Notwithstanding any provision of the Plan to the contrary, in order to comply with the laws in other countries in which the Company and its Subsidiaries operate or have employees or other individuals eligible for Awards, the Administrator, in its sole discretion, shall have the power and authority to: (i) determine which Subsidiaries shall be covered by the Plan; (ii) determine which individuals outside the United States are eligible to participate in the Plan; (iii) modify the terms and conditions of any Award granted to individuals outside the United States to comply with applicable foreign laws; (iv) establish subplans and modify exercise procedures and other terms and procedures, to the extent the Administrator determines such actions to be necessary or advisable (and such subplans and/or modifications shall be attached to this Plan as appendices); provided, however, that no such subplans and/or modifications shall increase the share limitations contained in Section 3(a) hereof; and (v) take any action, before or after</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">an Award is made, that the Administrator determines to be necessary or advisable to obtain approval or comply with any local governmental regulatory exemptions or approvals. Notwithstanding the foregoing, the Administrator may not take any actions hereunder, and no Awards shall be granted, that would violate the Exchange Act or any other applicable United States securities law, the Code, or any other applicable United States governing statute or law.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:0.003472222222222222in;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:13.0%;"></td>
    <td style="width:87.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">SECTION 3.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">STOCK ISSUABLE UNDER THE PLAN; MERGERS; SUBSTITUTION</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(a) </font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Stock Issuable</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The maximum number of shares of Stock reserved and available for issuance under the Plan shall be 1,000,000 shares of Stock, subject to adjustment as provided in Section 3(c). For purposes of this limitation, the shares of Stock underlying any Awards that are forfeited, canceled, held back upon exercise of an Option or settlement of an Award to cover the exercise price or tax withholding, reacquired by the Company prior to vesting, satisfied without the issuance of Stock or otherwise terminated (other than by exercise) under the Plan shall be added back to the shares of Stock available for issuance under the Plan. In the event the Company repurchases shares of Stock on the open market, such shares shall not be added to the shares of Stock available for issuance under the Plan. Subject to such overall limitations, shares of Stock may be issued up to such maximum number pursuant to any type or types of Award. The shares available for issuance under the Plan may be authorized but unissued shares of Stock or shares of Stock reacquired by the Company.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(b) </font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Reserved.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(c) </font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Changes in Stock</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Subject to Section 3(d) hereof, if, as a result of any reorganization, recapitalization, reclassification, stock dividend, stock split, reverse stock split or other similar change in the Company&#x2019;s capital stock, the outstanding shares of Stock are increased or decreased or are exchanged for a different number or kind of shares or other securities of the Company, or additional shares or new or different shares or other securities of the Company or other non-cash assets are distributed with respect to such shares of Stock or other securities, or, if, as a result of any merger or consolidation, sale of all or substantially all of the assets of the Company, the outstanding shares of Stock are converted into or exchanged for securities of the Company or any successor entity (or a parent or subsidiary thereof), the Administrator shall make an appropriate or proportionate adjustment in (i) the maximum number of shares reserved for issuance under the Plan, (ii) the number and kind of shares or other securities subject to any then outstanding Awards under the Plan, (iii) the repurchase price, if any, per share subject to each outstanding Restricted Stock Award, and (iv) the exercise price for each share subject to any then outstanding Stock Options and Stock Appreciation Rights under the Plan, without changing the aggregate exercise price (i.e., the exercise price multiplied by the number of shares subject to Stock Options and Stock</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Appreciation Rights) as to which such Stock Options and Stock Appreciation Rights remain exercisable. The Administrator shall also make equitable or proportionate adjustments in the number of shares subject to outstanding Awards and the exercise price and the terms of outstanding Awards to take into consideration cash dividends paid other than in the ordinary course or any other extraordinary corporate event. The adjustment by the Administrator shall be final, binding and conclusive. No fractional shares of Stock shall be issued under the Plan resulting from any such adjustment, but the Administrator in its discretion may make a cash payment in lieu of fractional shares.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(d) </font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Mergers and Other Transactions</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. In the case of and subject to the consummation of a Sale Event, the parties thereto may cause the assumption or continuation of Awards theretofore granted by the successor entity, or the substitution of such Awards with new Awards of the successor entity or parent thereof, with appropriate adjustment as to the number and kind of shares and, if appropriate, the per share exercise prices, as such parties shall agree. To the extent the parties to such Sale Event do not provide for the assumption, continuation or substitution of Awards, upon the effective time of the Sale Event, the Plan and all outstanding Awards granted hereunder shall terminate. In such case, except as may be otherwise provided in the relevant Award Certificate, all Options and Stock Appreciation Rights with time-based vesting conditions or restrictions that are not vested and/or exercisable immediately prior to the effective time of the Sale Event shall become fully vested and exercisable as of the effective time of the Sale Event, all other Awards with time-based vesting, conditions or restrictions shall become fully vested and nonforfeitable as of the effective time of the Sale Event, and all Awards with conditions and restrictions relating to the attainment of performance goals may become vested and nonforfeitable in connection with a Sale Event in the Administrator&#x2019;s discretion or to the extent specified in the relevant Award Certificate. In the event of such termination, (i) the Company shall have the option (in its sole discretion) to make or provide for a payment, in cash or in kind, to the grantees holding Options and Stock Appreciation Rights, in exchange for the cancellation thereof, in an amount equal to the difference between (A) the Sale Price multiplied by the number of shares of Stock subject to outstanding Options and Stock Appreciation Rights (to the extent then exercisable at prices not in excess of the Sale Price) and (B) the aggregate exercise price of all such outstanding Options and Stock Appreciation Rights (provided that, in the case of an Option or Stock Appreciation Right with an exercise price equal to or greater than the Sale Price, such Option or Stock Appreciation Right shall be cancelled for no consideration); or (ii) each grantee shall be permitted, within a specified period of time prior to the consummation of the Sale Event as determined by the Administrator, to exercise all outstanding Options and Stock Appreciation Rights (to the extent then exercisable) held by such grantee. The Company shall also have the option (in its sole discretion) to make or provide for a payment, in cash or in kind, to the grantees holding other Awards in an amount equal to the Sale Price multiplied by the number of vested shares of Stock under such Awards.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:0.003472222222222222in;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:13.0%;"></td>
    <td style="width:87.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">SECTION 4.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">ELIGIBILITY</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Grantees under the Plan will be such individuals to whom the Company may issue securities without stockholder approval in accordance with Rule 5635(c)(4) of the Marketplace Rules of the NASDAQ Stock Market, Inc. and related guidance thereunder, as are selected from time to time by the Administrator in its sole discretion.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:0.003472222222222222in;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:13.0%;"></td>
    <td style="width:87.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">SECTION 5.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">STOCK OPTIONS</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(a) </font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Award of Stock Options</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Administrator may grant Stock Options under the Plan. Any Stock Option granted under the Plan shall be a Non-Qualified Stock Option and shall be in such form as the Administrator may from time to time approve.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock Options granted pursuant to this Section 5 shall be subject to the following terms and conditions and shall contain such additional terms and conditions, not inconsistent with the terms of the Plan, as the Administrator shall deem desirable.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(b) </font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Exercise Price</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The exercise price per share for the Stock covered by a Stock Option granted pursuant to this Section 5 shall be determined by the Administrator at the time of grant but shall not be less than 100 percent of the Fair Market Value on the date of grant. Notwithstanding the foregoing, Stock Options may be granted with an exercise price per share that is less than 100 percent of the Fair Market Value on the date of grant (i) to individuals who are not subject to U.S. income tax on the date of grant or (ii) the Stock Option is otherwise compliant with Section 409A.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(c) </font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Option Term</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The term of each Stock Option shall be fixed by the Administrator, but no Stock Option shall be exercisable more than ten years after the date the Stock Option is granted.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(d) </font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Exercisability; Rights of a Stockholder</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Stock Options shall become exercisable at such time or times, whether or not in installments, as shall be determined by the Administrator at or after the grant date. The Administrator may at any time accelerate the exercisability of all or any portion of any Stock Option. An optionee shall have the rights of a stockholder only as to shares acquired upon the exercise of a Stock Option and not as to unexercised Stock Options.</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(e) </font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Method of Exercise</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Stock Options may be exercised in whole or in part, by giving written or electronic notice of exercise to the Company, specifying the number of shares to be purchased. Payment of the purchase price may be made by one or more of the following methods except to the extent otherwise provided in the Award Certificate:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(i) In cash, by certified or bank check or other instrument acceptable to the Administrator;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(ii) Through the delivery (or attestation to the ownership following such procedures as the Company may prescribe) of shares of Stock that are not then subject to restrictions under any Company plan. Such surrendered shares shall be valued at Fair Market Value on the exercise date;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(iii) By the optionee delivering to the Company a properly executed exercise notice together with irrevocable instructions to a broker to promptly deliver to the Company cash or a check payable and acceptable to the Company for the purchase price; provided that in the event the optionee chooses to pay the purchase price as so provided, the optionee and the broker shall comply with such procedures and enter into such agreements of indemnity and other agreements as the Company shall prescribe as a condition of such payment procedure; or</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(iv) By a &#x201c;net exercise&#x201d; arrangement pursuant to which the Company will reduce the number of shares of Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate exercise price.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Payment instruments will be received subject to collection. The transfer to the optionee on the records of the Company or of the transfer agent of the shares of Stock to be purchased pursuant to the exercise of a Stock Option will be contingent upon receipt from the optionee (or a purchaser acting in his stead in accordance with the provisions of the Stock Option) by the Company of the full purchase price for such shares and the fulfillment of any other requirements contained in the Award Certificate or applicable provisions of laws (including the satisfaction of any withholding taxes that the Company is obligated to withhold with respect to the optionee). In the event an optionee chooses to pay the purchase price by previously-owned shares of Stock through the attestation method, the number of shares of Stock transferred to the optionee upon the exercise of the Stock Option shall be net of the number of attested shares. In the event that the Company establishes, for itself or using the services of a third party, an automated system for the exercise of Stock Options, such as a system using an internet website or interactive voice response, then the paperless exercise of Stock Options may be permitted through the use of such an automated system.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:0.003472222222222222in;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:10.101%;"></td>
    <td style="width:1.01%;"></td>
    <td style="width:88.889%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">SECTION 6.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">STOCK APPRECIATION RIGHTS</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(a) </font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Award of Stock Appreciation Rights</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Administrator may grant Stock Appreciation Rights under the Plan. A Stock Appreciation Right is an Award entitling the recipient to receive shares of Stock (or cash, to the extent explicitly provided for in the applicable Award Certificate) having a value equal to the excess of the Fair Market Value of a share of Stock on the date of exercise over the exercise price of the Stock Appreciation Right multiplied by the number of shares of Stock with respect to which the Stock Appreciation Right shall have been exercised.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(b) </font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Exercise Price of Stock Appreciation Rights</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The exercise price of a Stock Appreciation Right shall not be less than 100 percent of the Fair Market Value of the Stock on the date of grant.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(c) </font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Grant and Exercise of Stock Appreciation Rights</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Stock Appreciation Rights may be granted by the Administrator independently of any Stock Option granted pursuant to Section 5 of the Plan.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(d) </font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Terms and Conditions of Stock Appreciation Rights</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Stock Appreciation Rights shall be subject to such terms and conditions as shall be determined on the date of grant by the Administrator. The term of a Stock Appreciation Right may not exceed ten years. The terms and conditions of each such Award shall be determined by the Administrator, and such terms and conditions may differ among individual Awards and grantees.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:0.003472222222222222in;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:13.0%;"></td>
    <td style="width:87.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">SECTION 7.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">RESTRICTED STOCK AWARDS</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(a) </font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Nature of Restricted Stock Awards</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Administrator may grant Restricted Stock Awards under the Plan. A Restricted Stock Award is any Award of Restricted Shares subject to such restrictions and conditions as the Administrator may determine at the time of grant. Conditions may be based on continuing employment (or other Service Relationship) and/or achievement of pre-established performance goals and objectives.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(b) </font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Rights as a Stockholder</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Upon the grant of the Restricted Stock Award and payment of any applicable purchase price, a grantee shall have the rights of a stockholder with respect to the voting of the Restricted Shares and receipt of dividends; provided that if the lapse of restrictions with respect to the Restricted Stock Award is tied to the attainment of performance goals, any dividends paid by</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the Company during the performance period shall accrue and shall not be paid to the grantee until and to the extent the performance goals are met with respect to the Restricted Stock Award. Unless the Administrator shall otherwise determine, (i) uncertificated Restricted Shares shall be accompanied by a notation on the records of the Company or the transfer agent to the effect that they are subject to forfeiture until such Restricted Shares are vested as provided in Section 7(d) below, and (ii) certificated Restricted Shares shall remain in the possession of the Company until such Restricted Shares are vested as provided in Section 7(d) below, and the grantee shall be required, as a condition of the grant, to deliver to the Company such instruments of transfer as the Administrator may prescribe.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(c) </font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Restrictions</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Restricted Shares may not be sold, assigned, transferred, pledged or otherwise encumbered or disposed of except as specifically provided herein or in the Restricted Stock Award Certificate. Except as may otherwise be provided by the Administrator either in the Award Certificate or, subject to Section 16 below, in writing after the Award is issued, if a grantee&#x2019;s employment (or other Service Relationship) with the Company and its Subsidiaries terminates for any reason, any Restricted Shares that have not vested at the time of termination shall automatically and without any requirement of notice to such grantee from or other action by or on behalf of, the Company be deemed to have been reacquired by the Company at its original purchase price (if any) from such grantee or such grantee&#x2019;s legal representative simultaneously with such termination of employment (or other Service Relationship), and thereafter shall cease to represent any ownership of the Company by the grantee or rights of the grantee as a stockholder. Following such deemed reacquisition of Restricted Shares that are represented by physical certificates, a grantee shall surrender such certificates to the Company upon request without consideration.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(d) </font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Vesting of Restricted Shares</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Administrator at the time of grant shall specify the date or dates and/or the attainment of pre-established performance goals, objectives and other conditions on which the non-transferability of the Restricted Shares and the Company&#x2019;s right of repurchase or forfeiture shall lapse. Subsequent to such date or dates and/or the attainment of such pre-established performance goals, objectives and other conditions, the shares on which all restrictions have lapsed shall no longer be Restricted Shares and shall be deemed &#x201c;vested.&#x201d;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:0.003472222222222222in;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:13.0%;"></td>
    <td style="width:87.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">SECTION 8.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">RESTRICTED STOCK UNITS</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(a) </font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Nature of Restricted Stock Units</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Administrator may grant Restricted Stock Units under the Plan. A Restricted Stock Unit is an Award of stock units that may be settled in shares of Stock (or cash, to the extent explicitly provided for in the applicable Award Certificate) upon the satisfaction of such restrictions and conditions at the time of grant. Conditions may be based on continuing employment (or other Service Relationship) and/or achievement of pre-established performance goals and objectives. The terms and conditions of each such Award shall be determined by the Administrator, and such terms and conditions may differ among individual Awards and grantees. Except in the case of Restricted Stock Units with a deferred settlement date that complies with Section 409A, at the end of the vesting period, the Restricted Stock Units, to the extent vested, shall be settled in the form of shares of Stock. Restricted Stock Units with deferred settlement dates are subject to Section 409A and shall contain such additional terms and conditions as the Administrator shall determine in its sole discretion in order to comply with the requirements of Section 409A.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(b) </font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Rights as a Stockholder</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. A grantee shall have the rights as a stockholder only as to shares of Stock acquired by the grantee upon settlement of Restricted Stock Units; provided, however, that the grantee may be credited with Dividend Equivalent Rights with respect to the stock units underlying his Restricted Stock Units, subject to the provisions of Section 11 and such terms and conditions as the Administrator may determine.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(c) </font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Termination</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Except as may otherwise be provided by the Administrator either in the Award Certificate or, subject to Section 16 below, in writing after the Award is issued, a grantee&#x2019;s right in all Restricted Stock Units that have not vested shall automatically terminate upon the grantee&#x2019;s termination of employment (or cessation of Service Relationship) with the Company and its Subsidiaries for any reason.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:0.003472222222222222in;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:13.0%;"></td>
    <td style="width:87.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">SECTION 9.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">UNRESTRICTED STOCK AWARDS</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Grant or Sale of Unrestricted Stock</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Administrator may grant (or sell at par value or such higher purchase price determined by the Administrator) an Unrestricted Stock Award under the Plan. An Unrestricted Stock Award is an Award pursuant to which the grantee may receive shares of Stock free of any restrictions under the Plan. Unrestricted Stock Awards may be granted in respect of past services or other valid consideration, or in lieu of cash compensation due to such grantee.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:0.003472222222222222in;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:13.0%;"></td>
    <td style="width:87.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">SECTION 10.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">RESERVED</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:0.003472222222222222in;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:13.0%;"></td>
    <td style="width:87.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">SECTION 11.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">DIVIDEND EQUIVALENT RIGHTS</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(a) </font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Dividend Equivalent Rights</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Administrator may grant Dividend Equivalent Rights under the Plan. A Dividend Equivalent Right is an Award entitling the grantee to receive credits based on cash dividends that would have been paid on the shares of Stock specified in the Dividend Equivalent Right (or other Award to which it relates) if such shares had been issued to the grantee. A Dividend Equivalent Right may be granted hereunder to any grantee as a component of an award of Restricted Stock Units or as a freestanding award. The terms and conditions of Dividend Equivalent Rights shall be specified in the Award Certificate. Dividend equivalents credited to the holder of a Dividend Equivalent Right may be paid currently or may be deemed to be reinvested in additional shares of Stock, which may thereafter accrue additional equivalents. Any such reinvestment shall be at Fair Market Value on the date of reinvestment or such other price as may then apply under a dividend reinvestment plan sponsored by the Company, if any. Dividend Equivalent Rights may be settled in cash or shares of Stock or a combination thereof, in a single installment or installments. A Dividend Equivalent Right granted as a component of an Award of Restricted Stock Units shall provide that such Dividend Equivalent Right shall be settled only upon settlement or payment of, or lapse of restrictions on, such other Award, and that such Dividend Equivalent Right shall expire or be forfeited or annulled under the same conditions as such other Award.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(b) </font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Termination</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Except as may otherwise be provided by the Administrator either in the Award Certificate or, subject to Section 16 below, in writing after the Award is issued, a grantee&#x2019;s rights in all Dividend Equivalent Rights shall automatically terminate upon the grantee&#x2019;s termination of employment (or cessation of Service Relationship) with the Company and its Subsidiaries for any reason.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:0.003472222222222222in;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:13.0%;"></td>
    <td style="width:87.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">SECTION 12.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">TRANSFERABILITY OF AWARDS</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(a) </font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Transferability</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Except as provided in Section 12(b) below, during a grantee&#x2019;s lifetime, his or her Awards shall be exercisable only by the grantee, or by the grantee&#x2019;s legal representative or guardian in the event of the grantee&#x2019;s incapacity. No Awards shall be sold, assigned, transferred or otherwise encumbered or disposed of by a grantee other than by will or by the laws of descent and distribution or pursuant to a domestic relations order. No Awards shall be subject, in whole or in part, to attachment, execution, or levy of any kind, and any purported transfer in violation hereof shall be null and void.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(b) </font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Administrator Action</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Notwithstanding Section 12(a), the Administrator, in its discretion, may provide either in the Award Certificate regarding a given Award or by subsequent written approval that the grantee (who is an employee or director) may transfer his or her Non-Qualified Stock Options to his or her immediate family members, to trusts for the benefit of such family members, or to partnerships in which such family members are the only partners, provided that the transferee agrees in writing with the Company to be bound by all of the terms and conditions of this Plan and the applicable Award. In no event may an Award be transferred by a grantee for value.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(c) </font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Family Member</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. For purposes of Section 12(b), &#x201c;family member&#x201d; shall mean a grantee&#x2019;s child, stepchild, grandchild, parent, stepparent, grandparent, spouse, former spouse, sibling, niece, nephew, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including adoptive relationships, any person sharing the grantee&#x2019;s household (other than a tenant of the grantee), a trust in which these persons (or the grantee) have more than 50 percent of the beneficial interest, a foundation in which these persons (or the grantee) control the management of assets, and any other entity in which these persons (or the grantee) own more than 50 percent of the voting interests.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(d) </font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Designation of Beneficiary</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. To the extent permitted by the Company, each grantee to whom an Award has been made under the Plan may designate a beneficiary or beneficiaries to exercise any Award or receive any payment under any Award payable on or after the grantee&#x2019;s death. Any such designation shall be on a form provided for that purpose by the Administrator and shall not be effective until received by the Administrator. If no beneficiary has been designated by a deceased grantee, or if the designated beneficiaries have predeceased the grantee, the beneficiary shall be the grantee&#x2019;s estate.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:0.003472222222222222in;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:13.0%;"></td>
    <td style="width:87.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">SECTION 13.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">TAX WITHHOLDING</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(a) </font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Payment by Grantee</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Each grantee shall, no later than the date as of which the value of an Award or of any Stock or other amounts received thereunder first becomes includable in the gross income of the grantee for Federal income tax purposes, pay to the Company, or make arrangements satisfactory to the Administrator regarding payment of, any Federal, state, or local taxes of any kind required by law to be withheld by the Company with respect to such income. The Company and its Subsidiaries shall, to the extent permitted by law, have the right to deduct any such taxes from any payment of any kind otherwise due to the grantee. The Company&#x2019;s obligation to deliver evidence of book entry (or stock certificates) to any grantee is subject to and conditioned on tax withholding obligations being satisfied by the grantee.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(b) </font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Payment in Stock</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Administrator may require the Company&#x2019;s tax withholding obligation to be satisfied, in whole or in part, by the Company withholding from shares of Stock to be issued pursuant to any Award a number of shares with an aggregate Fair Market Value (as of the date the withholding is effected) that would satisfy the withholding amount due; provided, however, that the amount withheld does not exceed the maximum statutory tax rate or such lesser amount as is necessary to avoid liability accounting treatment. For purposes of share withholding, the Fair Market Value of withheld shares shall be determined in the same manner as the value of</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock includible in income of the grantees. The Administrator may also require the Company&#x2019;s tax withholding obligation to be satisfied, in whole or in part, by an arrangement whereby a certain number of shares of Stock issued pursuant to any Award are immediately sold and proceeds from such sale are remitted to the Company in an amount that would satisfy the withholding amount due.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:0.003472222222222222in;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:13.0%;"></td>
    <td style="width:87.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">SECTION 14.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">SECTION 409A AWARDS</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Awards are intended to be exempt from Section 409A to the greatest extent possible and to otherwise comply with Section 409A. The Plan and all Awards shall be interpreted in accordance with such intent. To the extent that any Award is determined to constitute &#x201c;nonqualified deferred compensation&#x201d; within the meaning of Section 409A (a &#x201c;409A Award&#x201d;), the Award shall be subject to such additional rules and requirements as specified by the Administrator from time to time in order to comply with Section 409A. In this regard, if any amount under a 409A Award is payable upon a &#x201c;separation from service&#x201d; (within the meaning of Section 409A) to a grantee who is then considered a &#x201c;specified employee&#x201d; (within the meaning of Section 409A), then no such payment shall be made prior to the date that is the earlier of (i) six months and one day after the grantee&#x2019;s separation from service, or (ii) the grantee&#x2019;s death, but only to the extent such delay is necessary to prevent such payment from being subject to interest, penalties and/or additional tax imposed pursuant to Section 409A. Further, the settlement of any such Award may not be accelerated except to the extent permitted by Section 409A.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:0.003472222222222222in;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:13.0%;"></td>
    <td style="width:87.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">SECTION 15.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">TERMINATION OF SERVICE RELATIONSHIP, TRANSFER, LEAVE OF ABSENCE, ETC.</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(a) </font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Termination of Service Relationship</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. If the grantee&#x2019;s Service Relationship is with an Affiliate and such Affiliate ceases to be an Affiliate, the grantee shall be deemed to have terminated his or her Service Relationship for purposes of the Plan.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(b) For purposes of the Plan, the following events shall not be deemed a termination of a Service Relationship:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(i) a transfer to the employment of the Company from an Affiliate or from the Company to an Affiliate, or from one Affiliate to another; or</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(ii) an approved leave of absence for military service or sickness, or for any other purpose approved by the Company, if the employee&#x2019;s right to re-employment is guaranteed either by a statute or by contract or under the policy pursuant to which the leave of absence was granted or if the Administrator otherwise so provides in writing.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:0.003472222222222222in;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:6.958%;"></td>
    <td style="width:92.883%;"></td>
    <td style="width:0.159%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">SECTION 16.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">AMENDMENTS AND TERMINATION</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Board may, at any time, amend or discontinue the Plan and the Administrator may, at any time, amend or cancel any outstanding Award for the purpose of satisfying changes in law or for any other lawful purpose, but no such action shall materially and adversely affect rights under any outstanding Award without the holder&#x2019;s consent. Except as provided in Section 3(c) or 3(d), without prior stockholder approval, in no event may the Administrator exercise its discretion to reduce the exercise price of outstanding Stock Options or Stock Appreciation Rights or effect repricing through cancellation and re-grants or cancellation of Stock Options or Stock Appreciation Rights in exchange for cash or other Awards. Nothing in this Section 16 shall limit the Administrator&#x2019;s authority to take any action permitted pursuant to Section 3(c) or 3(d).</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:0.003472222222222222in;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:13.0%;"></td>
    <td style="width:87.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">SECTION 17.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">STATUS OF PLAN</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">With respect to the portion of any Award that has not been exercised and any payments in cash, Stock or other consideration not received by a grantee, a grantee shall have no rights greater than those of a general creditor of the Company unless the Administrator shall otherwise expressly determine in connection with any Award or Awards. In its sole discretion, the Administrator may authorize the creation of trusts or other arrangements to meet the Company&#x2019;s obligations to deliver Stock or make payments with respect to Awards hereunder, provided that the existence of such trusts or other arrangements is consistent with the foregoing sentence.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:0.003472222222222222in;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:13.0%;"></td>
    <td style="width:87.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">SECTION 18.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">GENERAL PROVISIONS</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(a) </font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">No Distribution</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Administrator may require each person acquiring Stock pursuant to an Award to represent to and agree with the Company in writing that such person is acquiring the shares without a view to distribution thereof.</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(b) </font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Issuance</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. To the extent certificated, stock certificates to grantees under this Plan shall be deemed delivered for all purposes when the Company or a stock transfer agent of the Company shall have mailed such certificates in the United States mail, addressed to the grantee, at the grantee&#x2019;s last known address on file with the Company. Uncertificated Stock shall be deemed delivered for all purposes when the Company or a Stock transfer agent of the Company shall have given to the grantee by electronic mail (with proof of receipt) or by United States mail, addressed to the grantee, at the grantee&#x2019;s last known address on file with the Company, notice of issuance and recorded the issuance in its records (which may include electronic &#x201c;book entry&#x201d; records). Notwithstanding anything herein to the contrary, the Company shall not be required to issue or deliver any evidence of book entry or certificates evidencing shares of Stock pursuant to the exercise or settlement of any Award, unless and until the Administrator has determined, with advice of counsel (to the extent the Administrator deems such advice necessary or advisable), that the issuance and delivery is in compliance with all applicable laws, regulations of governmental authorities and, if applicable, the requirements of any exchange on which the shares of Stock are listed, quoted or traded. Any Stock issued pursuant to the Plan shall be subject to any stop-transfer orders and other restrictions as the Administrator deems necessary or advisable to comply with federal, state or foreign jurisdiction, securities or other laws, rules and quotation system on which the Stock is listed, quoted or traded. The Administrator may place legends on any Stock certificate or notations on any book entry to reference restrictions applicable to the Stock. In addition to the terms and conditions provided herein, the Administrator may require that an individual make such reasonable covenants, agreements, and representations as the Administrator, in its discretion, deems necessary or advisable in order to comply with any such laws, regulations, or requirements. The Administrator shall have the right to require any individual to comply with any timing or other restrictions with respect to the settlement or exercise of any Award, including a window-period limitation, as may be imposed in the discretion of the Administrator.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(c) </font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Stockholder Rights</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Until Stock is deemed delivered in accordance with Section 18(b), no right to vote or receive dividends or any other rights of a stockholder will exist with respect to shares of Stock to be issued in connection with an Award, notwithstanding the exercise of a Stock Option or any other action by the grantee with respect to an Award.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(d) </font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Other Compensation Arrangements; No Employment Rights</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Nothing contained in this Plan shall prevent the Board from adopting other or additional compensation arrangements, including trusts, and such arrangements may be either generally applicable or applicable only in specific cases. The adoption of this Plan and the grant of Awards do not confer upon any employee any right to continued employment with the Company or any Subsidiary.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(e) </font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Trading Policy Restrictions</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Option exercises and other Awards under the Plan shall be subject to the Company&#x2019;s insider trading policies and procedures, as in effect from time to time.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(f) </font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Clawback Policy</font><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Awards under the Plan shall be subject to the Company&#x2019;s clawback policy, as in effect from time to time.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:0.003472222222222222in;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:13.0%;"></td>
    <td style="width:87.0%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">SECTION 19.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">EFFECTIVE DATE OF PLAN</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This Plan shall become effective upon approval by the Board.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:0.003472222222222222in;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:6.958%;"></td>
    <td style="width:92.714%;"></td>
    <td style="width:0.327%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(255,255,255,1);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">SECTION 20.</font></p></td>
    <td style="background-color:rgba(255,255,255,1);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">GOVERNING LAW</font></p></td>
    <td style="background-color:rgba(255,255,255,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This Plan and all Awards and actions taken thereunder shall be governed by, and construed in accordance with, the laws of the State of Delaware, applied without regard to conflict of law principles.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">DATE APPROVED BY BOARD OF DIRECTORS: JANUARY 27, 2022</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">NON-QUALIFIED STOCK OPTION AGREEMENT</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">FOR COMPANY EMPLOYEES UNDER THE</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ADICET BIO, INC.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2022 INDUCEMENT PLAN</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:24.026%;"></td>
    <td style="width:1.085%;"></td>
    <td style="width:36.902%;"></td>
    <td style="width:1.085%;"></td>
    <td style="width:36.902%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Name of Optionee:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;border-bottom:0.750pt solid rgba(0,0,0,1);text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">No. of Option Shares:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;border-bottom:0.750pt solid rgba(0,0,0,1);text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Option Exercise Price per Share:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;border-bottom:0.750pt solid rgba(0,0,0,1);text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Grant Date:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;border-bottom:0.750pt solid rgba(0,0,0,1);text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expiration Date:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;border-bottom:0.750pt solid rgba(0,0,0,1);text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the Adicet Bio, Inc. 2022 Inducement Plan as amended through the date hereof (the &#x201c;Plan&#x201d;), Adicet Bio, Inc. (the &#x201c;Company&#x201d;) hereby grants to the Optionee named above an option (the &#x201c;Stock Option&#x201d;) to purchase on or prior to the Expiration Date specified above all or part of the number of shares of Common Stock, par value $0.0001 per share (the &#x201c;Stock&#x201d;) of the Company specified above at the Option Exercise Price per Share specified above subject to the terms and conditions set forth herein and in the Plan. This Stock Option has been granted as an inducement pursuant to Rule 5635(c)(4) of the Marketplace Rules of The NASDAQ Stock Market LLC, and consequently is intended to be exempt from the NASDAQ rules regarding stockholder approval of equity compensation plans. This Agreement and the terms and conditions of this Stock Option shall be interpreted in accordance with and consistent with such exemption. This Stock Option is not intended to be an &#x201c;incentive stock option&#x201d; under Section 422 of the Internal Revenue Code of 1986, as amended. The Plan is discretionary in nature and may be amended, cancelled, or terminated at any time.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Exercisability Schedule</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. No portion of this Stock Option may be exercised until such portion shall have become exercisable. Except as set forth below, and subject to the discretion of the Administrator (as defined in Section 2 of the Plan) to accelerate the exercisability schedule hereunder, this Stock Option shall be exercisable with respect to the following number of Option Shares on the dates indicated so long as Optionee remains an employee of the Company or a Subsidiary on such dates:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:6.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Stock Option will vest over a period of four years, with 25% of the shares underlying such option vesting on the first anniversary of the grant and the remaining 75% vesting in thirty-six equal monthly installments thereafter.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Once exercisable, this Stock Option shall continue to be exercisable at any time or times prior to the close of business on the Expiration Date, subject to the provisions hereof and of the Plan.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Manner of Exercise</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(a) The Optionee may exercise this Stock Option only in the following manner: from time to time on or prior to the Expiration Date of this Stock Option, the Optionee may give written notice to the Administrator of his or her election to purchase some or all of the Option Shares purchasable at the time of such notice. This notice shall specify the number of Option Shares to be purchased.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Payment of the purchase price for the Option Shares may be made by one or more of the following methods: (i) in cash, by certified or bank check or other instrument acceptable to the Administrator; (ii) through the delivery (or attestation to the ownership) of shares of Stock that have been purchased by the Optionee on the open market or that are beneficially owned by the Optionee and are not then subject to any restrictions under any Company plan and that otherwise satisfy any holding periods as may be required by the Administrator; (iii) by the Optionee delivering to the Company a properly executed exercise notice together with irrevocable instructions to a broker to promptly deliver to the Company cash or a check payable and acceptable to the Company to pay the option purchase price, provided that in the event the Optionee chooses to pay the option purchase price as so provided, the Optionee and the broker shall comply with such procedures and enter into such agreements of indemnity and other agreements as the Administrator shall prescribe as a condition of such payment procedure; (iv) by a &#x201c;net exercise&#x201d; arrangement pursuant to which the Company will reduce the number of shares of Stock issuable upon exercise by the largest whole number of shares with a Fair Market Value that does not exceed the aggregate exercise price; or (v) a combination of (i), (ii), (iii) and (iv) above. Payment instruments will be received subject to collection.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The transfer to the Optionee on the records of the Company or of the transfer agent of the Option Shares will be contingent upon (i) the Company&#x2019;s receipt from the Optionee of the full purchase price for the Option Shares, as set forth above, (ii) the fulfillment of any other requirements contained herein or in the Plan or in any other agreement or provision of laws, and (iii) the receipt by the Company of any agreement, statement or other evidence that the Company may require to satisfy itself that the issuance of Stock to be</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">purchased pursuant to the exercise of Stock Options under the Plan and any subsequent resale of the shares of Stock will be in compliance with applicable laws and regulations. In the event the Optionee chooses to pay the purchase price by previously-owned shares of Stock through the attestation method, the number of shares of Stock transferred to the Optionee upon the exercise of the Stock Option shall be net of the Shares attested to.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(b) The shares of Stock purchased upon exercise of this Stock Option shall be transferred to the Optionee on the records of the Company or of the transfer agent upon compliance to the satisfaction of the Administrator with all requirements under applicable laws or regulations in connection with such transfer and with the requirements hereof and of the Plan. The determination of the Administrator as to such compliance shall be final and binding on the Optionee. The Optionee shall not be deemed to be the holder of, or to have any of the rights of a holder with respect to, any shares of Stock subject to this Stock Option unless and until this Stock Option shall have been exercised pursuant to the terms hereof, the Company or the transfer agent shall have transferred the shares to the Optionee, and the Optionee&#x2019;s name shall have been entered as the stockholder of record on the books of the Company. Thereupon, the Optionee shall have full voting, dividend and other ownership rights with respect to such shares of Stock.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(c) [Reserved].</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(d) Notwithstanding any other provision hereof or of the Plan, no portion of this Stock Option shall be exercisable after the Expiration Date hereof.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Termination of Employment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. If the Optionee&#x2019;s employment by the Company or a Subsidiary (as defined in the Plan) is terminated, the period within which to exercise the Stock Option may be subject to earlier termination as set forth below.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(a) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Termination Due to Death</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. If the Optionee&#x2019;s employment terminates by reason of the Optionee&#x2019;s death, any portion of this Stock Option outstanding on such date, to the extent exercisable on the date of death, may thereafter be exercised by the Optionee&#x2019;s legal representative or legatee for a period of 12 months from the date of death or until the Expiration Date, if earlier. Any portion of this Stock Option that is not exercisable on the date of death shall terminate immediately and be of no further force or effect.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(b) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Termination Due to Disability</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. If the Optionee&#x2019;s employment terminates by reason of the Optionee&#x2019;s disability (as determined by the Administrator), any portion of this Stock Option outstanding on such date, to the extent exercisable on the date of such termination of employment, may thereafter be exercised by the Optionee for a period of 12 months from the date of disability or until the Expiration Date, if earlier. Any portion of this Stock Option that is not exercisable on the date of disability shall terminate immediately and be of no further force or effect.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(c) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Termination for Cause</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. If the Optionee&#x2019;s employment terminates for Cause, any portion of this Stock Option outstanding on such date shall terminate immediately and be of no further force and effect. For purposes hereof, &#x201c;Cause&#x201d; shall mean, unless otherwise provided in an employment agreement between the Company and the Optionee, a determination by the Administrator that the Optionee shall be dismissed as a result of (i) any material breach by the Optionee of any agreement between the Optionee and the Company; (ii) the conviction of, indictment for or plea of nolo contendere by the Optionee to a felony or a crime involving moral turpitude; or (iii) any material misconduct or willful and deliberate non-performance (other than by reason of disability) by the Optionee of the Optionee&#x2019;s duties to the Company.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(d) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Other Termination</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. If the Optionee&#x2019;s employment terminates for any reason other than the Optionee&#x2019;s death, the Optionee&#x2019;s disability or Cause, and unless otherwise determined by the Administrator, any portion of this Stock Option outstanding on such date may be exercised, to the extent exercisable on the date of termination, for a period of three months from the date of termination or until the Expiration Date, if earlier. Any portion of this Stock Option that is not exercisable on the date of termination shall terminate immediately and be of no further force or effect.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Administrator&#x2019;s determination of the reason for termination of the Optionee&#x2019;s employment shall be conclusive and binding on the Optionee and his or her representatives or legatees.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Incorporation of Plan</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Notwithstanding anything herein to the contrary, this Agreement shall be subject to and governed by all the terms and conditions of the Plan, including the powers of the Administrator set forth in Section 2(b) of the Plan. Capitalized terms in this Agreement shall have the meaning specified in the Plan, unless a different meaning is specified herein.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Transferability</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. This Agreement is personal to the Optionee, is non-assignable and is not transferable in any manner, by operation of law or otherwise, other than by will or the laws of descent and distribution. This Stock Option is exercisable, during the Optionee&#x2019;s lifetime, only by the Optionee, and thereafter, only by the Optionee&#x2019;s legal representative or legatee.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Tax Withholding</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Optionee shall, not later than the date as of which the exercise of this Stock Option becomes a taxable event for Federal income tax purposes, pay to the Company or make arrangements satisfactory to the Administrator for payment of any Federal, state, and local taxes required by law to be withheld on account of such taxable event. The Company shall have the authority to cause the required tax withholding obligation to be satisfied, in whole or in part, by withholding from shares of Stock to be issued to</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the Optionee a number of shares of Stock with an aggregate Fair Market Value that would satisfy the withholding amount due; provided, however, that the amount withheld does not exceed the maximum statutory tax rate or such lesser amount as is necessary to avoid adverse accounting treatment or as determined by the Administrator.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">No Obligation to Continue Employment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Neither the Company nor any Subsidiary is obligated by or as a result of the Plan or this Agreement to continue the Optionee in employment and neither the Plan nor this Agreement shall interfere in any way with the right of the Company or any Subsidiary to terminate the employment of the Optionee at any time.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Integration</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. This Agreement constitutes the entire agreement between the parties with respect to this Stock Option and supersedes all prior agreements and discussions between the parties concerning such subject matter.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Data Privacy Consent</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. In order to administer the Plan and this Agreement and to implement or structure future equity grants, the Company, its subsidiaries and affiliates and certain agents thereof (together, the &#x201c;Relevant Companies&#x201d;) may process any and all personal or professional data, including but not limited to Social Security or other identification number, home address and telephone number, date of birth and other information that is necessary or desirable for the administration of the Plan and/or this Agreement (the &#x201c;Relevant Information&#x201d;). By entering into this Agreement, the Optionee (i) authorizes the Company to collect, process, register and transfer to the Relevant Companies all Relevant Information; (ii) waives any privacy rights the Optionee may have with respect to the Relevant Information; (iii) authorizes the Relevant Companies to store and transmit such information in electronic form; and (iv) authorizes the transfer of the Relevant Information to any jurisdiction in which the Relevant Companies consider appropriate. The Optionee shall have access to, and the right to change, the Relevant Information. Relevant Information will only be used in accordance with applicable law.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10. </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Notices</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Notices hereunder shall be mailed or delivered to the Company at its principal place of business and shall be mailed or delivered to the Optionee at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:40.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:7.254%;"></td>
    <td style="width:2.72%;"></td>
    <td style="width:90.026%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="3" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ADICET BIO, INC.</font></p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;border-bottom:0.750pt solid rgba(0,0,0,1);text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:7.2pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Title:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned. Electronic acceptance of this Agreement pursuant to the Company&#x2019;s instructions to the Optionee (including through an online acceptance process) is acceptable.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <table style="margin-left:0.003472222222222222in;border-spacing:0;table-layout:fixed;width:99.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:5.972%;"></td>
    <td style="width:0.984%;"></td>
    <td style="width:42.496%;"></td>
    <td style="width:0.984%;"></td>
    <td style="width:3.928%;"></td>
    <td style="width:0.487%;"></td>
    <td style="width:0.487%;"></td>
    <td style="width:0.984%;"></td>
    <td style="width:43.677%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Dated:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;border-bottom:0.750pt solid rgba(0,0,0,1);text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;border-bottom:0.750pt solid rgba(0,0,0,1);text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Optionee&#x2019;s Signature</font></p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Optionee&#x2019;s name and address:</font></p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;border-bottom:0.750pt solid rgba(0,0,0,1);text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;border-bottom:0.750pt solid rgba(0,0,0,1);text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;border-bottom:0.750pt solid rgba(0,0,0,1);text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.25pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:middle;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:1.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:1.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:bottom;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.003in;word-break:break-word;padding-left:0.003in;vertical-align:top;padding-bottom:0.003in;padding-right:0.003in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:1.0pt;border-bottom:0.750pt solid rgba(0,0,0,1);text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:24.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">RESTRICTED STOCK UNIT AWARD AGREEMENT<br>FOR COMPANY EMPLOYEES<br>UNDER THE ADICET BIO, INC.<br>2022 INDUCEMENT PLAN</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Name of Grantee:	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">	</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">No. of Restricted Stock Units:	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">	</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Grant Date:	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">	</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expiration Date:	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">	</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:24.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the Adicet Bio, Inc. 2022 Inducement Plan as amended through the date hereof (the &#x201c;Plan&#x201d;), Adicet Bio, Inc. (the &#x201c;Company&#x201d;) hereby grants an award of the number of Restricted Stock Units listed above (an &#x201c;Award&#x201d;) to the Grantee named above.  Each Restricted Stock Unit shall relate to one share of Common Stock, par value $0.0001 per share (the &#x201c;Stock&#x201d;) of the Company. This Award has been granted as an inducement pursuant to Rule 5635(c)(4) of the Marketplace Rules of NASDAQ Stock Market, Inc. and consequently is intended to be exempt from the NASDAQ rules regarding stockholder approval of equity compensation plans.</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Restrictions on Transfer of Award</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.  This Award may not be sold, transferred, pledged, assigned or otherwise encumbered or disposed of by the Grantee, and any shares of Stock issuable with respect to the Award may not be sold, transferred, pledged, assigned or otherwise encumbered or disposed of until (i) the Restricted Stock Units have vested as provided in Paragraph 2 of this Agreement and (ii) shares of Stock have been issued to the Grantee in accordance with the terms of the Plan and this Agreement.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Vesting of Restricted Stock Units</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.  The restrictions and conditions of Paragraph 1 of this Agreement shall lapse on the Vesting Date or Dates specified in the following schedule so long as the Grantee remains an employee of the Company or a Subsidiary on such Dates.  If a series of Vesting Dates is specified, then the restrictions and conditions in Paragraph 1 shall lapse only with respect to the number of Restricted Stock Units specified as vested on such date.  </font></div></div>
  <table style="margin-left:0.5in;border-spacing:0;table-layout:fixed;width:89.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:40.206%;"></td>
    <td style="width:59.794%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="border-top:0.500pt solid;background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Incremental Number of<br>Restricted Stock Units Vested</font></p></td>
    <td style="border-top:0.500pt solid;background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Vesting Date</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">[________] (__%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">[________] (__%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">[________] (__%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;border-left:0.500pt solid;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">[________] (__%)</font></p></td>
    <td style="background-color:rgba(0,0,0,0);border-right:0.500pt solid;word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Administrator may at any time accelerate the vesting schedule specified in this Paragraph 2.</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Termination of Employment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.  If the Grantee&#x2019;s employment terminates for any reason (including death or disability) prior to the satisfaction of the vesting conditions set forth in Paragraph 2 above, any Restricted Stock Units that have not vested as of such date shall automatically and without notice terminate and be forfeited, and neither the Grantee nor any of his or her successors, heirs, assigns, or personal representatives will thereafter have any further rights or interests in such unvested Restricted Stock Units. </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Issuance of Shares of Stock</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.  As soon as practicable following each Vesting Date (but in no event later than two and one-half months after the end of the year in which the Vesting Date occurs), the Company shall issue to the Grantee the number of shares of Stock equal to the aggregate number of Restricted Stock Units that have vested pursuant to Paragraph 2 of this Agreement on such date and the Grantee shall thereafter have all the rights of a stockholder of the Company with respect to such shares. </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Incorporation of Plan</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.  Notwithstanding anything herein to the contrary, this Agreement shall be subject to and governed by all the terms and conditions of the Plan, including the powers of the Administrator set forth in Section 2(b) of the Plan.  Capitalized terms in this Agreement shall have the meaning specified in the Plan, unless a different meaning is specified herein.</font></div></div>
  <hr style="page-break-after:always;">
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">6.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Tax Withholding</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.   The Grantee shall, not later than the date as of which the receipt of this Award becomes a taxable event for Federal income tax purposes, pay to the Company or make arrangements satisfactory to the Administrator for payment of any Federal, state, and local taxes required by law to be withheld on account of such taxable event.  The Company shall have the authority to cause the required tax withholding obligation to be satisfied, in whole or in part, by (i) withholding from shares of Stock to be issued to the Grantee a number of shares of Stock with an aggregate Fair Market Value that would satisfy the withholding amount due; provided, however, that the amount withheld does not exceed the maximum statutory tax rate or such lesser amount as is necessary to avoid adverse accounting treatment or as determined by the Administrator or (ii) causing its transfer agent to sell from the number of shares of Stock to be issued to the Grantee, the number of shares of Stock necessary to satisfy the Federal, state and local taxes required by law to be withheld from the Grantee on account of such transfer.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">7.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 409A of the Code.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  This Agreement shall be interpreted in such a manner that all provisions relating to the settlement of the Award are exempt from the requirements of Section 409A of the Code as &#x201c;short-term deferrals&#x201d; as described in Section 409A of the Code.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">8.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">No Obligation to Continue Employment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.  Neither the Company nor any Subsidiary is obligated by or as a result of the Plan or this Agreement to continue the Grantee in employment and neither the Plan nor this Agreement shall interfere in any way with the right of the Company or any Subsidiary to terminate the employment of the Grantee at any time.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">9.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Integration</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.  This Agreement constitutes the entire agreement between the parties with respect to this Award and supersedes all prior agreements and discussions between the parties concerning such subject matter.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">10.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Data Privacy Consent</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.  In order to administer the Plan and this Agreement and to implement or structure future equity grants, the Company, its subsidiaries and affiliates and certain agents thereof (together, the &#x201c;Relevant Companies&#x201d;) may process any and all personal or professional data, including but not limited to Social Security or other identification number, home address and telephone number, date of birth and other information that is necessary or desirable for the administration of the Plan and/or this Agreement (the &#x201c;Relevant Information&#x201d;).  By entering into this Agreement, the Grantee (i) authorizes the Company to collect, process, register and transfer to the Relevant Companies all Relevant Information; (ii) waives any privacy rights the Grantee may have with respect to the Relevant Information; (iii) authorizes the Relevant Companies to store and transmit such information in electronic form; and (iv) authorizes the transfer of the Relevant Information to any jurisdiction in which the Relevant Companies consider appropriate.  The Grantee shall have access to, and the right to change, the Relevant Information.  Relevant Information will only be used in accordance with applicable law.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">11.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Notices</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.  Notices hereunder shall be mailed or delivered to the Company at its principal place of business and shall be mailed or delivered to the Grantee at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing.</font></div></div>
  <p style="margin-left:43.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:36.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Adicet Bio, Inc.</font></p>
  <p style="margin-left:43.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">By:	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">	</font></p>
  <p style="margin-left:43.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:24.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	Title:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:36.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned.  Electronic acceptance of this Agreement pursuant to the Company&#x2019;s instructions to the Grantee (including through an online acceptance process) is acceptable.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Dated:	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">	</font></p>
  <p style="margin-left:43.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Grantee&#x2019;s Signature</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:43.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Grantee&#x2019;s name and address:</font></p>
  <p style="margin-left:43.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">	</font>&#160;</p>
  <p style="margin-left:43.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">	</font>&#160;</p>
  <p style="margin-left:43.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">	</font>&#160;</p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.16
<SEQUENCE>6
<FILENAME>acet-ex10_16.htm
<DESCRIPTION>EX-10.16
<TEXT>
<html>
 <head>
  <title>EX-10.16</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 10.16</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">EMPLOYMENT AGREEMENT</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This Employment Agreement (&#x201c;Agreement&#x201d;) is made between Adicet Bio, Inc., a Delaware corporation (the &#x201c;Company&#x201d;), and _____________________ (the &#x201c;Executive&#x201d;).</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">WHEREAS, the Company desires to employ the Executive and the Executive desires to be employed by the Company beginning on ______________ (the &#x201c;Effective Date&#x201d;) on the terms contained herein.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">NOW, THEREFORE,</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">in consideration of the mutual covenants and agreements herein contained and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the parties agree as follows:</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Employment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Term</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.   The term of this Agreement shall commence on the Effective Date and continue until terminated in accordance with the provisions hereof (the &#x201c;Term&#x201d;). The Executive&#x2019;s employment with the Company shall be &#x201c;at will,&#x201d; meaning that the Executive&#x2019;s employment may be terminated by the Company or the Executive at any time and for any reason subject to the terms of this Agreement.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Position and Duties</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.  The Executive shall serve as the [</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Title</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">] of the Company and shall have such powers and duties as may from time to time be prescribed by [the Board of Directors of the Company (the &#x201c;Board&#x201d;)]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">[the Chief Executive Officer of the Company (the &#x201c;CEO&#x201d;)]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.  The Executive shall devote [his/her] full working time and efforts to the business and affairs of the Company.  Notwithstanding the foregoing, the Executive may serve on other boards of directors, with the approval of the Nominating and Corporate Governance Committee of the Board [of Directors of the Company (the &#x201c;Board&#x201d;)], or engage in religious, charitable or other community activities as long as such services and activities do not interfere with the Executive&#x2019;s performance of [his/her] duties to the Company as provided in this Agreement.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Compensation and Related Matters</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Base Salary</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.  The Executive&#x2019;s initial base salary shall be paid at the rate of  $[__________] per year.  The Executive&#x2019;s base salary shall be subject to periodic review by</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> the Compensation Committee of the Board (the &#x201c;Compensation Committee&#x201d;). The base salary in effect at any given time is referred to herein as &#x201c;Base Salary.&#x201d;  The Base Salary shall be payable in a manner that is consistent with the Company&#x2019;s usual payroll practices for executive officers. The Executive&#x2019;s salary and any other cash compensation may be provided through TriNet, Inc. or another professional employer organization (a &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">PEO</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;). As a result of the Company&#x2019;s arrangement with the PEO, the PEO will be considered the Executive&#x2019;s employer of record for these purposes for so long as that arrangement exists.  While the PEO will have responsibility for</font></div></div>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;margin-right:66.667%;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> NTD: For the CEO.</font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">2</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> NTD: For non-CEO C-Level Executives.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/115800828.1</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the functions above, the Company retains responsibility for overseeing the Executive&#x2019;s work and reviewing the Executive&#x2019;s performance, among other functions.</font></p>
  <div style="text-indent:13.333%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Incentive Compensation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.  The Executive shall be eligible to receive cash incentive compensation as determined by the Board or the Compensation Committee from time to time.  [Commencing in calendar year _____,]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> [t]he Executive&#x2019;s initial target annual incentive compensation shall be [___] percent of the Executive&#x2019;s Base Salary[; provided that any incentive compensation for calendar year ____ will be prorated based on the Effective Date]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.  The target annual incentive compensation in effect at any given time is referred to herein as &#x201c;Target Bonus.&#x201d;  The actual amount of the Executive&#x2019;s annual incentive compensation, if any, shall be determined in the sole discretion of the Board or the Compensation Committee, subject to the terms of any applicable incentive compensation plan that may be in effect from time to time.  Except [as otherwise provided herein, ]as may be provided by the Board or the Compensation Committee or as may otherwise be set forth in the applicable incentive compensation plan the Executive must be employed by the Company on the day such incentive compensation is paid in order to earn or receive any incentive compensation.  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expenses.  The Executive shall be entitled to receive prompt reimbursement for all reasonable expenses incurred by the Executive during the Term in performing services hereunder, in accordance with the policies and procedures then in effect and established by the Company for its executive officers.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other Benefits.  The Executive shall be eligible to participate in or receive benefits under the Company&#x2019;s employee benefit plans in effect from time to time, subject to the terms of such plans.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(e)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Paid Time Off.  The Company&#x2019;s current paid time off policy for executives is flexible and paid time off may be taken at such times and intervals as the Executive may determine, subject to the business needs of the Company and the terms and conditions of any policies as may be in effect from time to time.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(f)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Equity.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Executive shall be granted an option to purchase approximately [___] percent of issued and outstanding shares of Common Stock at the Closing of the Merger at a per share exercise price determined on the grant date in accordance with the Company&#x2019;s equity grant policies, with [25 percent of the shares underlying the option vesting on the first anniversary] of the Effective Date and the remainder of the shares underlying the option vesting thereafter in [36 equal monthly]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> installments until the fourth anniversary of the Effective Date, subject to the Executive&#x2019;s continued service with the Company through each such vesting date. [This grant will be subject to the terms of a non-shareholder approved equity incentive plan to be approved by the Board pursuant to the &#x201c;inducement exception&#x201d; provided under NASDAQ Listing Rule 5635(c)(4).] </font></div></div>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;margin-right:66.667%;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">3</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> NTD: For a new hire executive who commences employment at the end of a calendar year and will not be eligible for incentive compensation until the following year.</font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">4</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> NTD: For a new hire executive who commences employment part-way through a calendar year and will be eligible for prorated incentive compensation in the year of hire.</font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">5</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> NTD: To be modified for each executive.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/115800828.1</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="text-indent:13.333%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(g)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Indemnification</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Company shall indemnify the Executive to the extent that its officers, directors and employees are entitled to indemnification pursuant to the Company&#x2019;s Certificate of Incorporation and Bylaws for any acts or omissions by reason of being an officer or employee of the Company as of the Effective Date. At all times during the Employment Term, the Company shall maintain in effect a director and officers liability insurance policy with the Executive as a covered officer.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Termination</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.  The Executive&#x2019;s employment hereunder may be terminated without any breach of this Agreement under the following circumstances:</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Death</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.  The Executive&#x2019;s employment hereunder shall terminate upon death.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Disability</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Company may terminate the Executive&#x2019;s employment if the Executive is disabled and unable to perform or expected to be unable to perform the essential functions of the Executive&#x2019;s then existing position or positions under this Agreement with or without reasonable accommodation for a period of 180 days (which need not be consecutive) in any 12-month period.  If any question shall arise as to whether during any period the Executive is disabled so as to be unable to perform the essential functions of the Executive&#x2019;s then existing position or positions with or without reasonable accommodation, the Executive may, and at the request of the Company shall, submit to the Company a certification in reasonable detail by a physician selected by the Company to whom the Executive or the Executive&#x2019;s guardian has no reasonable objection as to whether the Executive is so disabled or how long such disability is expected to continue, and such certification shall for the purposes of this Agreement be conclusive of the issue.  The Executive shall cooperate with any reasonable request of the physician in connection with such certification.  If such question shall arise and the Executive shall fail to submit such certification, the Company&#x2019;s determination of such issue shall be binding on the Executive.  Nothing in this Section 3(b) shall be construed to waive the Executive&#x2019;s rights, if any, under existing law including, without limitation, the Family and Medical Leave Act of 1993, 29 U.S.C. &#167;2601 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">et seq</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. and the Americans with Disabilities Act, 42 U.S.C. &#167;12101 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">et seq.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Termination by the Company for Cause</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Company may terminate the Executive&#x2019;s employment hereunder for Cause.  For purposes of this Agreement, &#x201c;Cause&#x201d; shall mean:  (i) conduct by the Executive constituting a material act of misconduct in connection with the performance of [his/her] duties, including, without limitation, misappropriation of funds or property of the Company or any of its subsidiaries or affiliates other than the occasional, customary and de minimis use of Company property for personal purposes; (ii) the commission by the Executive of acts satisfying the elements of (A) any felony or (B) a misdemeanor involving moral turpitude, deceit, dishonesty or fraud; (iii) any misconduct by the Executive, regardless of whether or not in the course of the Executive&#x2019;s employment, that would reasonably be expected to result in material injury or reputational harm to the Company or any of its subsidiaries or affiliates if the Executive were to continue to be employed in the same position; (iv) continued willful nonperformance by the Executive of [his/her] material duties hereunder (other than by reason of the Executive&#x2019;s physical or mental illness, incapacity or disability) which, to the extent it is curable by the Executive, is not cured within thirty (30) after written notice thereof is given to the Executive by the [Board/CEO]; (v) a breach by the Executive of the Restrictive Covenants Agreement or any of the provisions contained in Section 8 of this Agreement; (vi) a material violation by the Executive of the Company&#x2019;s written employment policies; or (vii) failure to cooperate with a bona fide internal investigation or an investigation by regulatory or law enforcement authorities, after being instructed by the Company to cooperate, or the willful destruction or failure to preserve documents or other materials known to be relevant to such investigation or the inducement of others to fail to cooperate or to produce documents or other materials in connection with such investigation.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Termination by the Company without Cause</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.  The Company may terminate the Executive&#x2019;s employment hereunder at any time without Cause. Any termination by the Company of the Executive&#x2019;s employment under this Agreement which does not constitute a termination for Cause under Section 3(c) and does not result from the death or disability of the Executive under Section 3(a) or (b) shall be deemed a termination without Cause.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(e)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Termination by the Executive</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.  The Executive may terminate [his/her] employment hereunder at any time for any reason, including for Good Reason.  For purposes of this Agreement, &#x201c;Good Reason&#x201d; shall mean that the Executive has complied with the &#x201c;Good Reason Process&#x201d; (hereinafter defined) following the occurrence of any of the following events:  (i) a material diminution in the Executive&#x2019;s responsibilities, authority or </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/115800828.1</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:13.333%;text-align:left;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">duties </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">provided </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">changes to the Executive&#x2019;s responsibilities, authority or duties prior to a Change in Control that are made in the good faith discretion of the Company&#x2019;s CEO as part of the Company&#x2019;s evolving business needs and strategy shall not be a Good Reason occurrence; (ii) a material diminution in the Executive&#x2019;s Base Salary except for across-the-board salary reductions based on the Company&#x2019;s financial performance similarly affecting all or substantially all senior management employees of the Company; (iii) a material change in the geographic location at which the Executive provides services to the Company such that there is an increase of at least thirty (30) miles of driving distance to such location from the Executive&#x2019;s principal residence as of such change; or (iv) the material breach of this Agreement by the Company.  &#x201c;Good Reason Process&#x201d; shall mean that (i) the Executive reasonably determines in good faith that a &#x201c;Good Reason&#x201d; condition has occurred; (ii) the Executive notifies the Company in writing of the first occurrence of the Good Reason condition within 60 days of the first occurrence of such condition; (iii) the Executive cooperates in good faith with the Company&#x2019;s efforts, for a period not less than 30 days following such notice (the &#x201c;Cure Period&#x201d;), to remedy the condition; (iv) notwithstanding such efforts, the Good Reason condition continues to exist; and (v) the Executive terminates [his/her] employment within 180 days after the end of the Cure Period.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Matters Related to Termination</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Notice of Termination</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Except for termination as specified in Section 3(a), any termination of the Executive&#x2019;s employment by the Company or any such termination by the Executive shall be communicated by written Notice of Termination to the other party hereto.  For purposes of this Agreement, a &#x201c;Notice of Termination&#x201d; shall mean a notice which shall indicate the specific termination provision in this Agreement relied upon.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Date of Termination</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.  &#x201c;Date of Termination&#x201d; shall mean:  (i) if the Executive&#x2019;s employment is terminated by death, the date of death; (ii) if the Executive&#x2019;s employment is terminated on account of disability under Section 3(b) or by the Company for Cause under Section 3(c), the date on which Notice of Termination is given; (iii) if the Executive&#x2019;s employment is terminated by the Company without Cause under Section 3(d), the date on which a Notice of Termination is given or the date otherwise specified by the Company in the Notice of Termination; (iv) if the Executive&#x2019;s employment is terminated by the Executive under Section 3(e) other than for Good Reason, 30 days after the date on which a Notice of Termination is given, and (v) if the Executive&#x2019;s employment is terminated by the Executive under Section 3(e) for Good Reason, the date on which a Notice of Termination is given after the end of the Cure Period.  Notwithstanding the foregoing, in the event that the Executive gives a Notice of Termination to the Company, the Company may unilaterally accelerate the Date of Termination and such acceleration shall not result in a termination by the Company for purposes of this Agreement.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Accrued Obligations</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.  If the Executive&#x2019;s employment with the Company is terminated for any reason, the Company shall pay or provide to the Executive (or to the Executive&#x2019;s</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">authorized representative or estate) (i) any Base Salary earned through the Date of Termination; (ii) unpaid expense reimbursements (subject to, and in accordance with, Section 2(c) of this Agreement); and (iii) any vested benefits the Executive may have under any employee benefit plan of the Company through the Date of Termination, which vested benefits shall be paid and/or provided in accordance with the terms of such employee benefit plans (collectively, the &#x201c;Accrued Obligations&#x201d;).</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Resignation of All Other Positions</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.  To the extent applicable, the Executive shall be deemed to have resigned from all officer and board member positions that the Executive holds with the Company or any of its respective subsidiaries and affiliates upon the termination of the Executive&#x2019;s employment for any reason.  The Executive shall execute any documents in reasonable form as may be requested to confirm or effectuate any such resignations.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Severance Pay and Benefits Upon Termination by the Company without Cause or by the Executive for Good Reason Outside the Change in Control Period</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. If the Executive&#x2019;s employment is terminated by the Company without Cause as provided in Section 3(d) or the Executive terminates employment for Good Reason as provided in Section 3(e), in each case outside of the Change in Control Period (as defined below), then, in addition to the</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued Obligations, subject to the Executive signing a separation agreement containing, among other provisions, a general release of claims in favor of the Company and related persons and entities, including the PEO, a reaffirmation of the Executive&#x2019;s Continuing Obligations (as defined below), confidentiality, return of property and non-disparagement, in a form and manner satisfactory to the Company (the &#x201c;Separation Agreement and Release&#x201d;) </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/115800828.1</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and the Separation Agreement and Release becoming irrevocable and fully effective, all within 60 days after the Date of Termination (or such shorter time period provided in the Separation Agreement and Release):</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the Company shall pay the Executive an amount equal to [___] months</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">6</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> of the Executive&#x2019;s Base Salary (the &#x201c;Severance Amount&#x201d;); and</font></div></div>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;margin-right:66.667%;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">6</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> NTD: 12 months for CEO, 9 months for all other executives.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <div style="text-indent:13.333%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the Company shall pay any unpaid bonus earned for the year preceding the date of Executive&#x2019;s employment termination, payable at the time it otherwise would have been paid had the Executive&#x2019;s employment with the Company not terminated; and</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">subject to the Executive&#x2019;s copayment of premium amounts at the applicable active employees&#x2019; rate and the Executive&#x2019;s proper election to receive benefits under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">COBRA</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201d;), the Company shall pay to the Executive a monthly cash payment (including a gross up payment to account for applicable taxes and withholdings) equal to the monthly employer contribution that the Company would have made to provide health insurance to the Executive and covered dependents if the Executive had remained employed by the Company until the earliest of (A) the [__]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">7</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> month anniversary of the Date of Termination; (B) the date that the Executive becomes eligible for group medical plan benefits under any other employer&#x2019;s group medical plan; or (C) the cessation of the Executive&#x2019;s health continuation rights under COBRA.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The amounts payable under Section 5(a) and (c), to the extent taxable, shall be paid out in substantially equal installments in accordance with the Company&#x2019;s payroll practice over [__]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">8</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> months commencing within 60</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">days after the Date of Termination; provided, however, that if the 60-day period begins in one calendar year and ends in a second calendar year, such payments, to the extent they qualify as &#x201c;non-qualified deferred compensation&#x201d; within the meaning of Section 409A of the Internal Revenue Code of 1986, as amended (the &#x201c;Code&#x201d;), shall begin to be paid in the second calendar year by the last day of such 60-day period; provided, further, that the initial payment shall include a catch-up payment to cover amounts retroactive to the day immediately following the Date of Termination.  Each payment pursuant to this Agreement is intended to constitute a separate payment for purposes of Treasury Regulation Section 1.409A-2(b)(2).</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">6.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Severance Pay and Benefits Upon Termination by the Company without Cause or by the Executive for Good Reason within the Change in Control Period</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.  The provisions of this Section 6 shall apply in lieu of, and expressly supersede, the provisions of Section 5 if (i) the Executive&#x2019;s employment is terminated either (a) by the Company without Cause as provided in Section 3(d), or (b) by the Executive for Good Reason as provided in Section 3(e), and (ii) the Date of Termination occurs on or within 12 months after the occurrence of the first event constituting a Change in Control (such period, the &#x201c;Change in Control Period&#x201d;)</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">9</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> following the Effective Date. These provisions shall terminate and be of no further force or effect after the Change in Control Period.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">If the Executive&#x2019;s employment is terminated by the Company without Cause as provided in Section 3(d) or the Executive terminates employment for Good Reason as provided in Section 3(e) and in each case the Date of Termination occurs during the Change in Control Period, then, in addition to the Accrued Obligations, and subject to the signing of the Separation Agreement and Release by the Executive and the Separation Agreement and Release</font></div></div>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;margin-right:66.667%;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">7</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> NTD: 12 months for CEO, 9 months for all other executives.</font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">8</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> NTD: 12 months for CEO, 9 months for all other executives.</font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">9</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> NTD: The CIC Period begins 3 months prior to the CIC for CEO only.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/115800828.1</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">becoming fully effective, all within the time frame set forth in the Separation Agreement and Release but in no event more than 60 days after the Date of Termination:</font></p>
  <div style="margin-left:6.667%;text-indent:14.286%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:14.285408162172008%;">(i)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the Company shall pay the Executive a lump sum in cash in an amount equal to</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">[___] times the sum of (A) the Executive&#x2019;s then-current Base Salary (or the Executive&#x2019;s Base Salary in effect immediately prior to the Change in Control, if higher) plus (B) the Executive&#x2019;s Target Bonus for the then-current year (or the Executive&#x2019;s Target Bonus in effect immediately prior to the Change in Control, if higher) and</font></div></div>
  <div style="margin-left:6.667%;text-indent:14.286%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:14.285408162172008%;">(ii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the Company shall pay any unpaid bonus earned for the year preceding the date of Executive&#x2019;s employment termination, payable at the time it otherwise would have been paid had the Executive&#x2019;s employment with the Company not terminated, and </font></div></div>
  <div style="margin-left:6.667%;text-indent:14.286%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:14.285408162172008%;">(iii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">notwithstanding anything to the contrary in any applicable option agreement or other stock-based award agreement, all stock options and other stock-based awards held by the Executive that are subject solely to time-based vesting (the &#x201c;Time-Based Equity Awards&#x201d;) shall immediately accelerate and become fully vested and exercisable or nonforfeitable as of the later of (i) the Date of Termination or (ii) the effective date of the Separation Agreement and Release (the &#x201c;Accelerated Vesting Date&#x201d;), provided in order to effectuate the accelerated vesting contemplated by this subsection, the unvested portion of the Executive&#x2019;s options that would otherwise be forfeited on the Date of Termination will be delayed until the earlier of (A) the effective date of the Separation Agreement Release (at which time acceleration will occur), or (B) the date that the Separation Agreement and Release can no longer become fully effective (at which time the unvested Time-Based Equity Awards will be terminated or forfeited). Notwithstanding the foregoing, no additional time-based vesting of the Time-Based Equity Awards shall occur during the period between the Date of Termination and the Accelerated Vesting Date; and</font></div></div>
  <div style="margin-left:6.667%;text-indent:14.286%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:14.285408162172008%;">(iv)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">subject to the Executive&#x2019;s copayment of premium amounts at the applicable active employees&#x2019; rate and the Executive&#x2019;s proper election to receive benefits under COBRA, the Company shall pay to the Executive a monthly cash payment (including a gross up payment to account for applicable taxes and withholdings) equal to the monthly employer contribution that the Company would have made to provide health insurance to the Executive and covered dependents if the Executive had remained employed by the Company until the earliest of (A) the [__]  month anniversary of the Date of Termination; (B) the date that the Executive becomes eligible for group medical plan benefits under any other employer&#x2019;s group medical plan; or (C) the cessation of the Executive&#x2019;s health continuation rights under COBRA. </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The amounts payable under this Section 6(a), to the extent taxable, shall be paid or commence to be paid within 60 days after the Date of Termination; provided, however, that if the 60-day period begins in one calendar year and ends in a second calendar year, such payments to the extent they qualify as &#x201c;non-qualified deferred compensation&#x201d; within the meaning of Section 409A of the Code, shall be paid or commence to be paid in the second calendar year by the last day of such 60-day period.</font></p>
  <div style="text-indent:13.333%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Additional Limitation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</font></div></div>
  <div style="margin-left:6.667%;text-indent:14.286%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:14.285408162172008%;">(i)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Anything in this Agreement to the contrary notwithstanding, in the event that the amount of any compensation, payment or distribution by the Company to or for the benefit of the Executive, whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise, calculated in a manner consistent with Section 280G of the Code, and the applicable regulations thereunder (the &#x201c;Aggregate Payments&#x201d;), would be subject to the excise tax imposed by Section 4999 of the Code, then the Aggregate Payments shall be reduced (but not below zero) so that the sum of all of the Aggregate Payments shall be $1.00 less than the amount at which the Executive becomes subject to the excise tax imposed by Section 4999 of the Code; provided that such reduction shall only occur if it would result in the Executive receiving a higher After Tax Amount (as defined below) than the Executive would receive if the Aggregate Payments were not subject to such reduction.  In such event, the Aggregate Payments shall be reduced in the following order, in each case, in reverse chronological order beginning with the Aggregate Payments that are to be paid the furthest in time from consummation of the transaction that is subject to Section 280G of the Code:  (1) cash payments not subject to Section 409A of the Code; (2) </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/115800828.1</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:6.667%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:13.333%;text-align:left;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">cash payments subject to Section 409A of the Code; (3) equity-based payments and acceleration; and (4) non-cash forms of benefits; provided that in the case of all the foregoing Aggregate Payments all amounts or payments that are not subject to calculation under Treas. Reg. &#167;1.280G-1, Q&amp;A-24(b) or (c) shall be reduced before any amounts that are subject to calculation under Treas. Reg. &#167;1.280G-1, Q&amp;A-24(b) or (c).</font></div></div>
  <div style="margin-left:6.667%;text-indent:14.286%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:14.285408162172008%;">(ii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For purposes of this Section 6(b), the &#x201c;After Tax Amount&#x201d; means the amount of the Aggregate Payments less all federal, state, and local income, excise and employment taxes imposed on the Executive as a result of the Executive&#x2019;s receipt of the Aggregate Payments.  For purposes of determining the After Tax Amount, the Executive shall be deemed to pay federal income taxes at the highest marginal rate of federal income taxation applicable to individuals for the calendar year in which the determination is to be made, and state and local income taxes at the highest marginal rates of individual taxation in each applicable state and locality, net of the maximum reduction in federal income taxes which could be obtained from deduction of such state and local taxes. </font></div></div>
  <div style="margin-left:6.667%;text-indent:14.286%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:14.285408162172008%;">(iii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The determination as to whether a reduction in the Aggregate Payments shall be made pursuant to Section 6(b)(i) shall be made by a nationally recognized accounting firm selected by the Company (the &#x201c;Accounting Firm&#x201d;), which shall provide detailed supporting calculations both to the Company and the Executive within 15 business days of the Date of Termination, if applicable, or at such earlier time as is reasonably requested by the Company or the Executive.  Any determination by the Accounting Firm shall be binding upon the Company and the Executive.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Definitions</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.  For purposes of this Section 6, the following terms shall have the following meanings:</font></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#x201c;Change in Control&#x201d; shall mean any of the following:</font></p>
  <div style="margin-left:6.667%;text-indent:14.286%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:14.285408162172008%;">(i)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">any &#x201c;person,&#x201d; as such term is used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended (the &#x201c;Act&#x201d;), any of its subsidiaries, or any trustee, fiduciary or other person or entity holding securities under any employee benefit plan or trust of the Company or any of its subsidiaries), together with all &#x201c;affiliates&#x201d; and &#x201c;associates&#x201d; (as such terms are defined in Rule 12b-2 under the Act) of such person, shall become the &#x201c;beneficial owner&#x201d; (as such term is defined in Rule 13d-3 under the Act), directly or indirectly, of securities of the Company representing 50 percent or more of the combined voting power of the Company&#x2019;s then outstanding securities having the right to vote in an election of the Board (&#x201c;Voting Securities&#x201d;) (in such case other than as a result of an acquisition of securities directly from the Company); or </font></div></div>
  <div style="margin-left:6.667%;text-indent:14.286%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:14.285408162172008%;">(ii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the date a majority of the members of the Board is replaced during any 12-month period by directors whose appointment or election is not endorsed by a majority of the members of the Board before the date of the appointment or election; or </font></div></div>
  <div style="margin-left:6.667%;text-indent:14.286%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:14.285408162172008%;">(iii)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the consummation of (A) any consolidation or merger of the Company where the stockholders of the Company, immediately prior to the consolidation or merger, would not, immediately after the consolidation or merger, beneficially own (as such term is defined in Rule 13d-3 under the Act), directly or indirectly, shares representing in the aggregate more than 50 percent of the voting shares of the Company issuing cash or securities in the consolidation or merger (or of its ultimate parent corporation, if any), or (B) any sale or other transfer (in one transaction or a series of transactions contemplated or arranged by any party as a single plan) of all or substantially all of the assets of the Company. </font></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Notwithstanding the foregoing, a &#x201c;Change in Control&#x201d; shall not be deemed to have occurred for purposes of the foregoing clause (i) solely as the result of an acquisition of securities by the Company which, by reducing the number of shares of Voting Securities outstanding, increases the proportionate number of Voting Securities beneficially owned by any person to 50 percent or more of the combined voting power of all of the then outstanding Voting Securities; provided, however, that if any person referred to in this sentence shall thereafter become the beneficial owner of any additional shares of Voting Securities (other than pursuant to a stock split, stock dividend, or similar transaction or as a result of an acquisition of securities directly from the Company) and immediately</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/115800828.1</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">thereafter beneficially owns 50 percent or more of the combined voting power of all of the then outstanding Voting Securities, then a &#x201c;Change in Control&#x201d; shall be deemed to have occurred for purposes of the foregoing clause (i).</font></p>
  <div style="text-indent:6.667%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">7.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Section 409A</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Anything in this Agreement to the contrary notwithstanding, if at the time of the Executive&#x2019;s separation from service within the meaning of Section 409A of the Code, the Company determines that the Executive is a &#x201c;specified employee&#x201d; within the meaning of Section 409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit that the Executive becomes entitled to under this Agreement or otherwise on account of the Executive&#x2019;s separation from service would be considered deferred compensation otherwise subject to the 20 percent additional tax imposed pursuant to Section 409A(a) of the Code as a result of the application of Section 409A(a)(2)(B)(i) of the Code, such payment shall not be payable and such benefit shall not be provided until the date that is the earlier of (A) six months and one day after the Executive&#x2019;s separation from service, or (B) the Executive&#x2019;s death.  If any such delayed cash payment is otherwise payable on an installment basis, the first payment shall include a catch-up payment covering amounts that would otherwise have been paid during the six-month period but for the application of this provision, and the balance of the installments shall be payable in accordance with their original schedule. </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All in-kind benefits provided and expenses eligible for reimbursement under this Agreement shall be provided by the Company or incurred by the Executive during the time periods set forth in this Agreement.  All reimbursements shall be paid as soon as administratively practicable, but in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred.  The amount of in-kind benefits provided or reimbursable expenses incurred in one taxable year shall not affect the in-kind benefits to be provided or the expenses eligible for reimbursement in any other taxable year (except for any lifetime or other aggregate limitation applicable to medical expenses).  Such right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To the extent that any payment or benefit described in this Agreement constitutes &#x201c;non-qualified deferred compensation&#x201d; under Section 409A of the Code, and to the extent that such payment or benefit is payable upon the Executive&#x2019;s termination of employment, then such payments or benefits shall be payable only upon the Executive&#x2019;s &#x201c;separation from service.&#x201d;  The determination of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in Treasury Regulation Section 1.409A&#x2011;1(h).</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The parties intend that this Agreement will be administered in accordance with Section 409A of the Code.  To the extent that any provision of this Agreement is ambiguous as to its compliance with Section 409A of the Code, the provision shall be read in such a manner so that all payments hereunder comply with Section 409A of the Code.  Each payment pursuant to this Agreement or the Restrictive Covenants Agreement is intended to constitute a separate payment for purposes of Treasury Regulation Section 1.409A&#x2011;2(b)(2).  The parties agree that this Agreement may be amended, as reasonably requested by either party, and as may be necessary to fully comply with Section 409A of the Code and all related rules and regulations in order to preserve the payments and benefits provided hereunder without additional cost to either party.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(e)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company makes no representation or warranty and shall have no liability to the Executive or any other person if any provisions of this Agreement are determined to constitute deferred compensation subject to Section 409A of the Code but do not satisfy an exemption from, or the conditions of, such Section.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">8.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Continuing Obligations</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;"> </font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Restrictive Covenants Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. As a condition of employment, the Executive is required to enter into the Employee Confidentiality, Assignment and Nonsolicitation Agreement, attached hereto as </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Exhibit A</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (the &#x201c;Restrictive Covenants Agreement&#x201d;).</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">  </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For purposes of this Agreement, the obligations in this Section 8 and those that arise in the Restrictive Covenants Agreement and any other agreement relating to confidentiality, assignment of inventions, or other restrictive covenants shall collectively be referred to as the &#x201c;Continuing Obligations.&#x201d;</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/115800828.1</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="text-indent:13.333%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Third-Party Agreements and Rights</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.  The Executive hereby confirms that the Executive is not bound by the terms of any agreement with any previous employer or other party which restricts in any way the Executive&#x2019;s use or disclosure of information, other than confidentiality restrictions (if any), or the Executive&#x2019;s engagement in any business. The Executive represents to the Company that the Executive&#x2019;s execution of this Agreement, the Executive&#x2019;s employment with the Company and the performance of the Executive&#x2019;s proposed duties for the Company will not violate any obligations the Executive may have to any such previous employer or other party.  In the Executive&#x2019;s work for the Company, the Executive will not disclose or make use of any information in violation of any agreements with or rights of any such previous employer or other party, and the Executive will not bring to the premises of the Company any copies or other tangible embodiments of non-public information belonging to or obtained from any such previous employment or other party.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(c)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Litigation and Regulatory Cooperation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.  During and after the Executive&#x2019;s employment, the Executive shall cooperate fully with the Company in (i) the defense or prosecution of any claims or actions now in existence or which may be brought in the future against or on behalf of the Company which relate to events or occurrences that transpired while the Executive was employed by the Company, and (ii) the investigation, whether internal or external, of any matters about which the Company believes the Executive may have knowledge or information.  The Executive&#x2019;s full cooperation in connection with such claims, actions or investigations shall include, but not be limited to, being available to meet with counsel to answer questions or to prepare for discovery or trial and to act as a witness on behalf of the Company at mutually convenient times.  During and after the Executive&#x2019;s employment, the Executive also shall cooperate fully with the Company in connection with any investigation or review of any federal, state or local regulatory authority as any such investigation or review relates to events or occurrences that transpired while the Executive was employed by the Company.  The Company shall reimburse the Executive for any reasonable out&#x2011;of&#x2011;pocket expenses incurred in connection with the Executive&#x2019;s performance of obligations pursuant to this Section 8(c).</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(d)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Relief</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Executive agrees that it would be difficult to measure any damages caused to the Company which might result from any breach by the Executive of the Continuing Obligations, and that in any event money damages would be an inadequate remedy for any such breach. Accordingly</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">,</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> the Executive agrees that if the Executive breaches, or proposes to breach, any portion of the Continuing Obligations, the Company shall be entitled, in addition to all other remedies that it may have, to an injunction or other appropriate equitable relief to restrain any such breach without showing or proving any actual damage to the Company.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">9.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Arbitration of Disputes</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(a)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Arbitration Generally</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.  Any controversy or claim arising out of or relating to this Agreement or the breach thereof or otherwise arising out of the Executive&#x2019;s employment or the termination of that employment (including, without limitation, any claims of unlawful employment discrimination or retaliation, whether based on race, religion, national origin, sex, gender, age, disability, sexual orientation, or any other protected class under applicable law) shall, to the fullest extent permitted by law, be settled by arbitration in any forum and form agreed upon by the parties or, in the absence of such an agreement, under the auspices of JAMS in [Boston, Massachusetts/San Francisco, California] in accordance with the JAMS Employment Arbitration Rules, including, but not limited to, the rules and procedures applicable to the selection of arbitrators.  The Executive understands that the Executive may only bring such claims in the Executive&#x2019;s individual capacity, and not as a plaintiff or class member in any purported class proceeding or any purported representative proceeding.   The Executive further understands that, by signing this Agreement, the Company and the Executive are giving up any right they may have to a jury trial on all claims they may have against each other.  Judgment upon the award rendered by the arbitrator may be entered in any court having jurisdiction thereof.  This Section 9 shall be specifically enforceable. Notwithstanding the foregoing, this Section 9 shall not preclude either party from pursuing a court action for the sole purpose of obtaining a temporary restraining order or a preliminary injunction in circumstances in which such relief is appropriate, including without limitation relief sought under the Restrictive Covenants Agreement; provided that any other relief shall be pursued through an arbitration proceeding pursuant to this Section 9.</font></div></div>
  <div style="text-indent:13.333%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:13.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:13.333%;">(b)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Arbitration Fees and Costs</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.  The Executive shall be required to pay an arbitration fee to initiate any arbitration equal to what the Executive would be charged as a first appearance fee in court. The Company shall advance the remaining fees and costs of the arbitrator.  However, to the extent permissible under the </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/115800828.1</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:13.333%;text-align:left;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">law, and following the arbitrator&#x2019;s ruling on the matter, the arbitrator may rule that the arbitrator&#x2019;s fees and costs be distributed in an alternative manner.  Each party shall pay its own costs and attorneys&#x2019; fees, if any. If, however, any party prevails on a statutory or contractual claim that affords the prevailing party attorneys&#x2019; fees (including pursuant to this Agreement), the arbitrator may award attorneys&#x2019; fees to the prevailing party to the extent permitted by law.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">10.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Consent to Jurisdiction</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.  The parties hereby consent to the jurisdiction of the state and federal courts of the</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">[State/Commonwealth] of [California/Massachusetts].  Accordingly, with respect to any such court action, the Executive (a) submits to the exclusive personal jurisdiction of such courts; (b) consents to service of process; and (c) waives any other requirement (whether imposed by statute, rule of court, or otherwise) with respect to personal jurisdiction or service of process.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">11.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Integration</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.  This Agreement constitutes the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior agreements between the parties concerning such subject matter, provided that, the Restrictive Covenants Agreement remains in full force and effect.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">12.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Withholding; Tax Effect</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.  All payments made by the Company to the Executive under this Agreement shall be net of any tax or other amounts required to be withheld by the Company under applicable law.  Nothing in this Agreement shall be construed to require the Company to make any payments to compensate the Executive for any adverse tax effect associated with any payments or benefits or for any deduction or withholding from any payment or benefit.  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">13.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Successors and Assigns</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.  Neither the Executive nor the Company may make any assignment of this Agreement or any interest in it, by operation of law or otherwise, without the prior written consent of the other; provided, however, that the Company may assign its rights and obligations under this Agreement (including the Restrictive Covenants Agreement) without the Executive&#x2019;s consent to any affiliate or to any person or entity with whom the Company shall hereafter effect a reorganization or consolidation, into which the Company merges or to whom it transfers all or substantially all of its properties or assets; provided further that if the Executive remains employed or becomes employed by the Company, the purchaser or any of their affiliates in connection with any such transaction, then the Executive shall not be entitled to any payments, benefits or vesting pursuant to Section 5 or pursuant to Section 6 of this Agreement solely as a result of such transaction.  This Agreement shall inure to the benefit of and be binding upon the Executive and the Company, and each of the Executive&#x2019;s and the Company&#x2019;s respective successors, executors, administrators, heirs and permitted assigns.  In the event of the Executive&#x2019;s death after the Executive&#x2019;s termination of employment but prior to the completion by the Company of all payments due to the Executive under this Agreement, the Company shall continue such payments to the Executive&#x2019;s beneficiary designated in writing to the Company prior to the Executive&#x2019;s death (or to the Executive&#x2019;s estate, if the Executive fails to make such designation).</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">14.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Enforceability</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.  If any portion or provision of this Agreement (including, without limitation, any portion or provision of any section of this Agreement) shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in circumstances other than those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">15.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Survival</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The provisions of this Agreement shall survive the termination of this Agreement and/or the termination of the Executive&#x2019;s employment to the extent necessary to effectuate the terms contained herein.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">16.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Waiver</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. No waiver of any provision hereof shall be effective unless made in writing and signed by the waiving party. The failure of any party to require the performance of any term or obligation of this Agreement, or the waiver by any party of any breach of this Agreement, shall not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">17.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Notices</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Any notices, requests, demands and other communications provided for by this Agreement shall be sufficient if in writing and delivered in person or sent by a nationally recognized overnight courier service or by registered or certified mail, postage prepaid, return receipt requested, to the Executive at the last address the </font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/115800828.1</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Executive has filed in writing with the Company or, in the case of the Company, at its main offices, attention of the Board.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">18.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Amendment</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.  This Agreement may be amended or modified only by a written instrument signed by the Executive and by a duly authorized representative of the Company.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">19.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Effect on Other Plans and Agreements</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.  An election by the Executive to resign for Good Reason under the provisions of this Agreement shall not be deemed a voluntary termination of employment by the Executive for the purpose of interpreting the provisions of any of the Company's benefit plans, programs or policies.  Nothing in this Agreement shall be construed to limit the rights of the Executive under the Company&#x2019;s benefit plans, programs or policies except as otherwise provided in Section 8 hereof, and except that the Executive shall have no rights to any severance benefits under any Company severance pay plan, offer letter or otherwise.  In the event that the Executive is party to an agreement with the Company providing for payments or benefits under such plan or agreement and under this Agreement, the terms of this Agreement shall govern and the Executive may receive payment under this Agreement only and not both.  Further, Section 5 and Section 6 of this Agreement are mutually exclusive and in no event shall the Executive be entitled to payments or benefits pursuant to both Section 5 and Section 6 of this Agreement.  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">20.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Governing Law</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.  This is a [California/Massachusetts] contract and shall be construed under and be governed in all respects by the laws of the [State/Commonwealth] of [California/Massachusetts], without giving effect to the conflict of laws principles thereof.  With respect to any disputes concerning federal law, such disputes shall be determined in accordance with the law as it would be interpreted and applied by the United States Court of Appeals for the [9</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">th</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/1</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">st</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">]Circuit.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">21.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">[</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Conditions</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.  Notwithstanding anything to the contrary herein, the effectiveness of this Agreement shall be conditioned on (i) the Executive&#x2019;s satisfactory completion of reference and background checks, if so requested by the Company, and (ii) the Executive&#x2019;s submission of satisfactory proof of the Executive&#x2019;s legal authorization to work in the United States.]</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">10</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:0.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">22.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:10.0pt;font-family:Times New Roman;">Counterparts</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.  This Agreement may be executed in any number of counterparts, each of which when so executed and delivered shall be taken to be an original; but such counterparts shall together constitute one and the same document.</font></div></div>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;margin-right:66.667%;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:4.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">10</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> NTD: For new hires only.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">    </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/115800828.1</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">IN WITNESS WHEREOF, the parties have executed this Agreement effective on the Effective Date.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:50.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:20.279%;"></td>
    <td style="width:79.721%;"></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">ADICET BIO, INC.</font></p></td>
   </tr>
   <tr>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Name:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Its:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">[EXECUTIVE]</font></p></td>
   </tr>
   <tr>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td colspan="2" style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:10.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">[Name]</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/115800828.1</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.17
<SEQUENCE>7
<FILENAME>acet-ex10_17.htm
<DESCRIPTION>EX-10.17
<TEXT>
<html>
 <head>
  <title>EX-10.17</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:4.533%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Exhibit 10.17</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:14.0pt;font-family:Times New Roman;">ADICET BIO, INC.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:14.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:14.0pt;font-family:Times New Roman;">FORM OF DIRECTOR INDEMNIFICATION AGREEMENT</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:18.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">This Indemnification Agreement (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) is made as of [________] by and between Adicet Bio, Inc., a Delaware corporation (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Company</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), and [Director] (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Indemnitee</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;).</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">RECITALS</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">WHEREAS, the Company desires to attract and retain the services of highly qualified individuals, such as Indemnitee, to serve the Company;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">WHEREAS, in order to induce Indemnitee to provide or continue to provide services to the Company, the Company wishes to provide for the indemnification of, and advancement of expenses to, Indemnitee to the maximum extent permitted by law;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">WHEREAS, the Third Amended and Restated Certificate of Incorporation (as amended and in effect from time to time, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Charter</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) and the Amended and Restated Bylaws (as amended and in effect from time to time, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Bylaws</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) of the Company require indemnification of the officers and directors of the Company, and Indemnitee may also be entitled to indemnification pursuant to the General Corporation Law of the State of Delaware (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">DGCL</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;);</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">WHEREAS, the Charter, the Bylaws and the DGCL expressly provide that the indemnification provisions set forth therein are not exclusive, and thereby contemplate that contracts may be entered into between the Company and members of the board of directors, officers and other persons with respect to indemnification;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">WHEREAS, the Board of Directors of the Company (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Board</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) has determined that the increased difficulty in attracting and retaining highly qualified persons such as Indemnitee is detrimental to the best interests of the Company&#x2019;s stockholders;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">WHEREAS, it is reasonable and prudent for the Company contractually to obligate itself to indemnify, and to advance expenses on behalf of, such persons to the fullest extent permitted by applicable law, regardless of any amendment or revocation of the Charter or the Bylaws, so that they will serve or continue to serve the Company free from undue concern that they will not be so indemnified;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">WHEREAS, this Agreement is a supplement to and in furtherance of the indemnification provided in the Charter, the Bylaws and any resolutions adopted pursuant thereto, and shall not be deemed a substitute therefor, nor to diminish or abrogate any rights of Indemnitee thereunder; and</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[WHEREAS, Indemnitee has certain rights to indemnification and/or insurance provided by [  ] (&#x201c;[&#149;]&#x201d;) which Indemnitee and [&#149;] intend to be secondary to the primary obligation of the Company to indemnify Indemnitee as provided in this Agreement, with the Company&#x2019;s acknowledgment and agreement to the foregoing being a material condition to Indemnitee&#x2019;s willingness to serve or continue to serve on the Board.]</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">NOW, THEREFORE, in consideration of the premises and the covenants contained herein, the Company and Indemnitee do hereby covenant and agree as follows:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/105004718.3</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:10.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Section 1.        </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Services to the Company</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Indemnitee agrees to [continue to] serve as a director of the Company.  Indemnitee may at any time and for any reason resign from such position (subject to any other contractual obligation or any obligation imposed by law), in which event the Company shall have no obligation under this Agreement to continue Indemnitee in such position.  This Agreement shall not be deemed an employment contract between the Company (or any of its subsidiaries or any Enterprise) and Indemnitee.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Section 2.        </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Definitions</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">As used in this Agreement:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)        &#x201c;Affiliate&#x201d; and &#x201c;Associate&#x201d; shall have the respective meanings ascribed to such terms in Rule 12b-2 of the General Rules and Regulations under the Securities Exchange Act of 1934, as amended, as in effect on the date of this Agreement; provided, however, that no Person who is a director or officer of the Company shall be deemed an Affiliate or an Associate of any other director or officer of the Company solely as a result of his or her position as director or officer of the Company.</font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b)       A Person shall be deemed the &#x201c;Beneficial Owner&#x201d; of, and shall be deemed to &#x201c;Beneficially Own&#x201d; and have &#x201c;Beneficial Ownership&#x201d; of, any securities:</font></p>
  <p style="margin-left:6.667%;text-indent:21.429%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(i)        which such Person or any of such Person&#x2019;s Affiliates or Associates, directly or indirectly, Beneficially Owns (as determined pursuant to Rule 13d-3 of the Rules under the Exchange Act, as in effect on the date of this Agreement);</font></p>
  <p style="margin-left:6.667%;text-indent:21.429%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(ii)       which such Person or any of such Person&#x2019;s Affiliates or Associates, directly or indirectly, has: (A) the legal, equitable or contractual right or obligation to acquire (whether directly or indirectly and whether exercisable immediately or only after the passage of time, compliance with regulatory requirements, satisfaction of one or more conditions (whether or not within the control of such Person) or otherwise) upon the exercise of any conversion rights, exchange rights, rights, warrants or options, or otherwise; (B) the right to vote pursuant to any agreement, arrangement or understanding (whether or not in writing); or (C) the right to dispose of pursuant to any agreement, arrangement or understanding (whether or not in writing) (other than customary arrangements with and between underwriters and selling group members with respect to a bona fide public offering of securities);</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="margin-left:6.667%;text-indent:21.429%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(iii)      which are Beneficially Owned, directly or indirectly, by any other Person (or any Affiliate or Associate thereof) with which such Person or any of such Person&#x2019;s Affiliates or Associates has any agreement, arrangement or understanding (whether or not in writing) (other than customary agreements with and between underwriters and selling group members with respect to a bona fide public offering of securities) for the purpose of acquiring, holding, voting or disposing of any securities of the Company; or</font></p>
  <p style="margin-left:6.667%;text-indent:21.429%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(iv)      that are the subject of a derivative transaction entered into by such Person or any of such Person&#x2019;s Affiliates or Associates, including, for these purposes, any derivative security acquired by such Person or any of such Person&#x2019;s Affiliates or Associates that gives such Person or any of such Person&#x2019;s Affiliates or Associates the economic equivalent of ownership of an amount of securities due to the fact that the value of the derivative security is explicitly determined by reference to the price or value of such securities, or that provides such Person or any of such Person&#x2019;s Affiliates or Associates an opportunity, directly or indirectly, to profit or to share in any profit derived from any change in the value of such securities, in any case without regard to whether (A) such derivative security conveys any voting rights in such securities to such Person or any of such Person&#x2019;s Affiliates or Associates; (B) the derivative</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/105004718.3</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">security is required to be, or capable of being, settled through delivery of such securities; or (C) such Person or any of such Person&#x2019;s Affiliates or Associates may have entered into other transactions that hedge the economic effect of such derivative security;</font></p>
  <p style="margin-left:6.667%;text-indent:7.143%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Notwithstanding the foregoing, no Person engaged in business as an underwriter of securities shall be deemed the Beneficial Owner of any securities acquired through such Person&#x2019;s participation as an underwriter in good faith in a firm commitment underwriting.</font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(c)       A &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Change in Control</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; shall be deemed to occur upon the earliest to occur after the date of this Agreement of any of the following events:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="margin-left:6.667%;text-indent:21.429%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(i)  Acquisition of Stock by Third Party. Any Person is or becomes the Beneficial Owner (as defined above), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the combined voting power of the Company&#x2019;s then outstanding securities unless the change in relative Beneficial Ownership of the Company&#x2019;s securities by any Person results solely from a reduction in the aggregate number of outstanding shares of securities entitled to vote generally in the election of directors [or as a result of conversions of Class B Common Stock], provided that a Change of Control shall be deemed to have occurred if subsequent to such reduction such Person becomes the Beneficial Owner, directly or indirectly, of any additional securities of the Company conferring upon such Person any additional voting power;</font></p>
  <p style="margin-left:6.667%;text-indent:21.429%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(ii) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Change in Board of Directors</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. During any period of two (2) consecutive years (not including any period prior to the execution of this Agreement), individuals who at the beginning of such period constitute the Board, and any new director (other than a director designated by a person who has entered into an agreement with the Company to effect a transaction described in Sections 2(c)(i), 2(c)(iii) or 2(c)(iv) whose election by the Board or nomination for election by the Company&#x2019;s stockholders was approved by a vote of at least two-thirds of the directors then still in office who either were directors at the beginning of the period or whose election or nomination for election was previously so approved, cease for any reason to constitute at least a majority of the members of the Board;</font></p>
  <p style="margin-left:6.667%;text-indent:21.429%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(iii) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Corporate Transactions</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. The effective date of a merger or consolidation of the Company with any other entity, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior to such merger or consolidation continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving or successor entity) more than 50% of the combined voting power of the voting securities of the surviving or successor entity outstanding immediately after such merger or consolidation and with the power to elect at least a majority of the board of directors or other governing body of such surviving or successor entity;</font></p>
  <p style="margin-left:6.667%;text-indent:21.429%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(iv) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Liquidation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. The approval by the stockholders of the Company of a complete liquidation of the Company or an agreement for the sale, lease, exchange or other transfer by the Company, in one or a series of related transactions, of all or substantially all of the Company&#x2019;s assets; and</font></p>
  <p style="margin-left:6.667%;text-indent:21.429%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(v) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Other Events</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. There occurs any other event of a nature that would be required to be reported in response to Item 6(e) of Schedule 14A of Regulation 14A (or a response to any similar item on any similar schedule or form) promulgated under the Securities Exchange Act of 1934, as amended, whether or not the Company is then subject to such reporting requirement.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">3</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/105004718.3</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(d)       &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Corporate Status</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; describes the status of a person as a current or former director of the Company or current or former director, manager, partner, officer, employee, agent or trustee of any other Enterprise which such person is or was serving at the request of the Company.</font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(e)        &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Enforcement Expenses</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; shall include all reasonable attorneys&#x2019; fees, court costs, transcript costs, fees of experts, travel expenses, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees, and all other out-of-pocket disbursements or expenses of the types customarily incurred in connection with an action to enforce indemnification or advancement rights, or an appeal from such action.  Expenses, however, shall not include fees, salaries, wages or benefits owed to Indemnitee.</font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(f)        &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Enterprise</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; shall mean any corporation (other than the Company), partnership, joint venture, trust, employee benefit plan, limited liability company, or other legal entity of which Indemnitee is or was serving at the request of the Company as a director, manager, partner, officer, employee, agent or trustee.</font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(g)       &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Expenses</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; shall include all reasonable attorneys&#x2019; fees, court costs, transcript costs, fees of experts, travel expenses, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees, and all other out-of-pocket disbursements or expenses of the types customarily incurred in connection with prosecuting, defending, preparing to prosecute or defend, investigating, being or preparing to be a witness in, or otherwise participating in, a Proceeding or an appeal resulting from a Proceeding.  Expenses, however, shall not include amounts paid in settlement by Indemnitee, the amount of judgments or fines against Indemnitee or fees, salaries, wages or benefits owed to Indemnitee.</font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(h)       &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Independent Counsel</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means a law firm, or a partner (or, if applicable, member or shareholder) of such a law firm, that is experienced in matters of Delaware corporation law and neither presently is, nor in the past five (5) years has been, retained to represent: (i) the Company, any subsidiary of the Company, any Enterprise or Indemnitee in any matter material to any such party; or (ii) any other party to the Proceeding giving rise to a claim for indemnification hereunder.  Notwithstanding the foregoing, the term &#x201c;Independent Counsel&#x201d; shall not include any person who, under the applicable standards of professional conduct then prevailing, would have a conflict of interest in representing either the Company or Indemnitee in an action to determine Indemnitee&#x2019;s rights under this Agreement.  The Company agrees to pay the reasonable fees and expenses of the Independent Counsel referred to above and to fully indemnify such counsel against any and all expenses, claims, liabilities and damages arising out of or relating to this Agreement or its engagement pursuant hereto.</font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(i)        &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Person</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; shall mean (i) an individual, a corporation, a partnership, a limited liability company, an association, a joint stock company, a trust, a business trust, a government or political subdivision, any unincorporated organization, or any other association or entity including any successor (by merger or otherwise) thereof or thereto, and (ii) a &#x201c;group&#x201d; as that term is used for purposes of Section 13(d)(3) of the Securities Exchange Act of 1934, as amended.</font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(j)        The term &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Proceeding</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; shall include any threatened, pending or completed action, suit, arbitration, alternate dispute resolution mechanism, investigation, inquiry, administrative hearing or any other actual, threatened or completed proceeding, whether brought in the right of the Company or otherwise and whether of a civil, criminal, administrative, regulatory or investigative nature, and whether formal or informal, in which Indemnitee was, is or will be involved as a party or otherwise by reason of the fact that Indemnitee is or was a director of the Company or is or was serving at the request of the Company as a director, manager, partner, officer, employee, agent or trustee of any Enterprise or by reason</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">4</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/105004718.3</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">of any action taken by Indemnitee or of any action taken on his or her part while acting as a director of the Company or while serving at the request of the Company as a director, manager, partner, officer, employee, agent or trustee of any Enterprise, in each case whether or not serving in such capacity at the time any liability or expense is incurred for which indemnification, reimbursement or advancement of expenses can be provided under this Agreement; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">however</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, that the term &#x201c;Proceeding&#x201d; shall not include any action, suit or arbitration, or part thereof, initiated by Indemnitee to enforce Indemnitee&#x2019;s rights under this Agreement as provided for in Section 12(a) of this Agreement.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Section 3.        </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Indemnity in Third-Party Proceedings</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  The Company shall indemnify Indemnitee to the extent set forth in this Section 3 if Indemnitee is, or is threatened to be made, a party to or a participant in any Proceeding, other than a Proceeding by or in the right of the Company to procure a judgment in its favor.  Pursuant to this Section 3, Indemnitee shall be indemnified against all Expenses, judgments, fines, penalties, excise taxes, and amounts paid in settlement actually and reasonably incurred by Indemnitee or on his or her behalf in connection with such Proceeding or any claim, issue or matter therein, if Indemnitee acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the Company and, in the case of a criminal proceeding, had no reasonable cause to believe that his or her conduct was unlawful.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Section 4.        </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Indemnity in Proceedings by or in the Right of the Company</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  The Company shall indemnify Indemnitee to the extent set forth in this Section 4 if Indemnitee is, or is threatened to be made, a party to or a participant in any Proceeding by or in the right of the Company to procure a judgment in its favor.  Pursuant to this Section 4, Indemnitee shall be indemnified against all Expenses actually and reasonably incurred by Indemnitee or on his or her behalf in connection with such Proceeding or any claim, issue or matter therein, if Indemnitee acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the Company. No indemnification for Expenses shall be made under this Section 4 in respect of any claim, issue or matter as to which Indemnitee shall have been finally adjudged by a court to be liable to the Company, unless and only to the extent that the Delaware Court of Chancery (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Delaware Court</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, Indemnitee is fairly and reasonably entitled to indemnification for such expenses as the Delaware Court shall deem proper.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Section 5.        </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Indemnification for Expenses of a Party Who is Wholly or Partly Successful</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. Notwithstanding any other provisions of this Agreement and except as provided in Section 7, to the extent that Indemnitee is a party to or a participant in any Proceeding and is successful in such Proceeding or in defense of any claim, issue or matter therein, the Company shall indemnify Indemnitee against all Expenses actually and reasonably incurred by him or her in connection therewith.  If Indemnitee is not wholly successful in such Proceeding but is successful as to one or more but less than all claims, issues or matters in such Proceeding, the Company shall indemnify Indemnitee against all Expenses actually and reasonably incurred by Indemnitee or on his or her behalf in connection with each successfully resolved claim, issue or matter.  For purposes of this Section and without limitation, the termination of any claim, issue or matter in such a Proceeding by dismissal, with or without prejudice, shall be deemed to be a successful result as to such claim, issue or matter.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Section 6.        </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Reimbursement for Expenses of a Witness or in Response to a Subpoena</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. Notwithstanding any other provision of this Agreement, to the extent that Indemnitee, by reason of his or her Corporate Status, (i) is a witness in any Proceeding to which Indemnitee is not a party and is not threatened to be made a party or (ii) receives a subpoena with respect to any Proceeding to which Indemnitee is not a party and is not threatened to be made a party, the Company shall reimburse Indemnitee for all Expenses actually and reasonably incurred by him or her or on his or her behalf in connection therewith.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">   </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">5</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/105004718.3</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Section 7.        </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Exclusions</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Notwithstanding any provision in this Agreement to the contrary, the Company shall not be obligated under this Agreement:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)        to indemnify for amounts otherwise indemnifiable hereunder (or for which advancement is provided hereunder) if and to the extent that Indemnitee has otherwise actually received such amounts under any insurance policy, contract, agreement or otherwise; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> that the foregoing shall not [i] apply to any personal or umbrella liability insurance maintained by Indemnitee, [or (ii) affect the rights of Indemnitee or the Fund Indemnitors as set forth in Section 13(c)];</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b)       to indemnify for an accounting of profits made from the purchase and sale (or sale and purchase) by Indemnitee of securities of the Company within the meaning of Section 16(b) of the Securities Exchange Act of 1934, as amended, or similar provisions of state statutory law or common law, or from the purchase or sale by Indemnitee of such securities in violation of Section 306 of the Sarbanes Oxley Act of 2002 (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">SOX</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;);</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(c)        to indemnify with respect to any Proceeding, or part thereof, brought by Indemnitee against the Company, any legal entity which it controls, any director or officer thereof or any third party, unless (i) the Board has consented to the initiation of such Proceeding or part thereof and (ii) the Company provides the indemnification, in its sole discretion, pursuant to the powers vested in the Company under applicable law; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">however</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, that this Section 7(c) shall not apply to (A) counterclaims or affirmative defenses asserted by Indemnitee in an action brought against Indemnitee or (B) any action brought by Indemnitee for indemnification or advancement from the Company under this Agreement or under any directors&#x2019; and officers&#x2019; liability insurance policies maintained by the Company in the suit for which indemnification or advancement is being sought as described in Section 12; or</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(d)       to provide any indemnification or advancement of expenses that is prohibited by applicable law (as such law exists at the time payment would otherwise be required pursuant to this Agreement).</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Section 8.        </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Advancement of Expenses</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Subject to Section 9(b), the Company shall advance the Expenses incurred by Indemnitee in connection with any Proceeding, and such advancement shall be made as incurred, and such advancement shall be made within thirty (30) days after the receipt by the Company of a statement or statements requesting such advances (including any invoices received by Indemnitee, which such invoices may be redacted as necessary to avoid the waiver of any privilege accorded by applicable law) from time to time, whether prior to or after final disposition of any Proceeding.  Advances shall be unsecured and interest free.  Advances shall be made without regard to Indemnitee&#x2019;s (i) ability to repay the expenses, (ii) ultimate entitlement to indemnification under the other provisions of this Agreement, and (iii) entitlement to and availability of insurance coverage, including advancement, payment or reimbursement of defense costs, expenses of covered loss under the provisions of any applicable insurance policy (including, without limitation, whether such advancement, payment or reimbursement is withheld, conditioned or delayed by the insurer(s)).  Indemnitee shall qualify for advances upon the execution and delivery to the Company of this Agreement which shall constitute an undertaking providing that Indemnitee undertakes to the fullest extent required by law to repay the advance if and to the extent that it is ultimately determined by a court of competent jurisdiction in a final judgment, not subject to appeal, that Indemnitee is not entitled to be indemnified by the Company.  No other form of undertaking shall be required. The right to advances under this paragraph shall in all events continue until final disposition of any Proceeding, including any appeal therein.  Nothing in this Section 8 shall limit Indemnitee&#x2019;s right to advancement pursuant to Section 12(e) of this Agreement.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">6</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/105004718.3</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:-7.143%;padding-left:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Section 9.       </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Procedure for Notification and Defense of Claim</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)        To obtain indemnification under this Agreement, Indemnitee shall submit to the Company a written request therefor specifying the basis for the claim, the amounts for which Indemnitee is seeking payment under this Agreement, and all documentation related thereto as reasonably requested by the Company.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b)       In the event that the Company shall be obligated hereunder to provide indemnification for or make any advancement of Expenses with respect to any Proceeding, the Company shall be entitled to assume the defense of such Proceeding, or any claim, issue or matter therein, with counsel approved by Indemnitee (which approval shall not be unreasonably withheld or delayed) upon the delivery to Indemnitee of written notice of the Company&#x2019;s election to do so.  After delivery of such notice, approval of such counsel by Indemnitee and the retention of such counsel by the Company, the Company will not be liable to Indemnitee under this Agreement for any fees or expenses of separate counsel subsequently employed by or on behalf of Indemnitee with respect to the same Proceeding; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> that (i) Indemnitee shall have the right to employ separate counsel in any such Proceeding at Indemnitee&#x2019;s expense and (ii) if (A) the employment of separate counsel by Indemnitee has been previously authorized by the Company, (B) Indemnitee shall have reasonably concluded that there may be a conflict of interest between the Company and Indemnitee in the conduct of such defense, (C) the Company shall not continue to retain such counsel to defend such Proceeding, or (D) a Change in Control shall have occurred, then the fees and expenses actually and reasonably incurred by Indemnitee with respect to his or her separate counsel shall be Expenses hereunder.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(c)        In the event that the Company does not assume the defense in a Proceeding pursuant to paragraph (b) above, then the Company will be entitled to participate in the Proceeding at its own expense.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(d)       The Company shall not be liable to indemnify Indemnitee under this Agreement for any amounts paid in settlement of any Proceeding effected without its prior written consent (which consent shall not be unreasonably withheld or delayed). The Company shall not, without the prior written consent of Indemnitee (which consent shall not be unreasonably withheld or delayed), enter into any settlement which (i) includes an admission of fault of Indemnitee, any non-monetary remedy imposed on Indemnitee or any monetary damages for which Indemnitee is not wholly and actually indemnified hereunder or (ii) with respect to any Proceeding with respect to which Indemnitee may be or is made a party or may be otherwise entitled to seek indemnification hereunder, does not include the full release of Indemnitee from all liability in respect of such Proceeding.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Section 10.      </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Procedure Upon Application for Indemnification</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)        Upon written request by Indemnitee for indemnification pursuant to Section 9(a), a determination, if such determination is required by applicable law, with respect to Indemnitee&#x2019;s entitlement to indemnification hereunder shall be made in the specific case by one of the following methods:  (x) if a Change in Control shall have occurred, by Independent Counsel in a written opinion to the Board; or (y) if a Change in Control shall not have occurred: (i) by a majority vote of the disinterested directors, even though less than a quorum; (ii) by a committee of disinterested directors designated by a majority vote of the disinterested directors, even though less than a quorum; or (iii) if there are no disinterested directors or if the disinterested directors so direct, by Independent Counsel in a written opinion to the Board.  For purposes hereof, disinterested directors are those members of the Board who are not parties to the action, suit or proceeding in respect of which indemnification is sought.  In the case that such determination is made by Independent Counsel, a copy of Independent Counsel&#x2019;s written opinion shall be delivered to Indemnitee and, if it is so determined that Indemnitee is entitled to indemnification, payment to Indemnitee shall be made within thirty (30) days after such determination.  Indemnitee shall cooperate with the Independent Counsel or the Company, as applicable, in making such determination with respect to Indemnitee&#x2019;s entitlement to indemnification, including providing to</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">7</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/105004718.3</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">such counsel or the Company, upon reasonable advance request, any documentation or information which is not privileged or otherwise protected from disclosure and which is reasonably available to Indemnitee and reasonably necessary to such determination.  The Company shall likewise cooperate with Indemnitee and Independent Counsel, if applicable, in making such determination with respect to Indemnitee&#x2019;s entitlement to indemnification, including providing to such counsel and Indemnitee, upon reasonable advance request, any documentation or information which is not privileged or otherwise protected from disclosure and which is reasonably available to the Company and reasonably necessary to such determination.  Any out-of-pocket costs or expenses (including reasonable attorneys&#x2019; fees and disbursements) actually and reasonably incurred by Indemnitee in so cooperating with the Independent Counsel or the Company shall be borne by the Company (irrespective of the determination as to Indemnitee&#x2019;s entitlement to indemnification) and the Company hereby indemnifies and agrees to hold Indemnitee harmless therefrom.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b)       If the determination of entitlement to indemnification is to be made by Independent Counsel pursuant to Section 10(a), the Independent Counsel shall be selected by the Board if a Change in Control shall not have occurred or, if a Change in Control shall have occurred, by Indemnitee.  Indemnitee or the Company, as the case may be, may, within ten (10) days after written notice of such selection, deliver to the Company or Indemnitee, as the case may be, a written objection to such selection; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">however</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, that such objection may be asserted only on the ground that the Independent Counsel so selected does not meet the requirements of &#x201c;Independent Counsel&#x201d; as defined in Section 2 of this Agreement, and the objection shall set forth with particularity the factual basis of such assertion.  Absent a proper and timely objection, the person so selected shall act as Independent Counsel.  If such written objection is so made and substantiated, the Independent Counsel so selected may not serve as Independent Counsel unless and until such objection is withdrawn or the Delaware Court has determined that such objection is without merit.  If, within twenty (20) days after the later of (i) submission by Indemnitee of a written request for indemnification pursuant to Section 9(a), and (ii) the final disposition of the Proceeding, including any appeal therein, no Independent Counsel shall have been selected without objection, either Indemnitee or the Company may petition the Delaware Court for resolution of any objection which shall have been made by Indemnitee or the Company to the selection of Independent Counsel and/or for the appointment as Independent Counsel of a person selected by the court or by such other person as the court shall designate.   The person with respect to whom all objections are so resolved or the person so appointed shall act as Independent Counsel under Section 10(a) hereof.  Upon the due commencement of any judicial proceeding or arbitration pursuant to Section 12(a) of this Agreement, Independent Counsel shall be discharged and relieved of any further responsibility in such capacity (subject to the applicable standards of professional conduct then prevailing).</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(c) Notwithstanding anything to the contrary contained in this Agreement, the determination of entitlement to indemnification under this Agreement shall be made without regard to the Indemnitee&#x2019;s entitlement to and availability of insurance coverage, including advancement, payment or reimbursement of defense costs, expenses or covered loss under the provisions of any applicable insurance policy (including, without limitation, whether such advancement, payment or reimbursement is withheld, conditioned or delayed by the insurer(s)).</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Section 11.     </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Presumptions and Effect of Certain Proceedings</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)        To the extent permitted by applicable law, in making a determination with respect to entitlement to indemnification hereunder, it shall be presumed that Indemnitee is entitled to indemnification under this Agreement if Indemnitee has submitted a request for indemnification in accordance with Section 9(a) of this Agreement, and the Company shall have the burden of proof and the burden of persuasion by clear and convincing evidence to overcome that presumption in connection with the making of any determination contrary to that presumption.  Neither (i) the failure of the Company or of Independent Counsel to have made a determination prior to the commencement of any action pursuant to this Agreement that indemnification is proper in the</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">8</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/105004718.3</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">circumstances because Indemnitee has met the applicable standard of conduct, nor (ii) an actual determination by the Company or by Independent Counsel that Indemnitee has not met such applicable standard of conduct, shall be a defense to the action or create a presumption that Indemnitee has not met the applicable standard of conduct.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b)       The termination of any Proceeding or of any claim, issue or matter therein, by judgment, order, settlement or conviction, or upon a plea of guilty, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">nolo</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">contendere</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> or its equivalent, shall not (except as otherwise expressly provided in this Agreement) of itself adversely affect the right of Indemnitee to indemnification or create a presumption that Indemnitee did not act in good faith and in a manner which he or she reasonably believed to be in or not opposed to the best interests of the Company or, with respect to any criminal Proceeding, that Indemnitee had reasonable cause to believe that his or her conduct was unlawful.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(c)        Indemnitee shall be deemed to have acted in good faith if Indemnitee&#x2019;s actions are based on the records or books of account of the Company or any other Enterprise, including financial statements, or on information supplied to Indemnitee by the directors, officers, agents or employees of the Company or any other Enterprise in the course of their duties, or on the advice of legal counsel for the Company or any other Enterprise or on information or records given or reports made to the Company or any other Enterprise by an independent certified public accountant or by an appraiser or other expert selected with reasonable care by the Company or any other Enterprise. The provisions of this Section 11(c) shall not be deemed to be exclusive or to limit in any way the other circumstances in which Indemnitee may be deemed to have met the applicable standard of conduct set forth in this Agreement. In addition, the knowledge and/or actions, or failure to act, of any director, manager, partner, officer, employee, agent or trustee of the Company, any subsidiary of the Company, or any Enterprise shall not be imputed to Indemnitee for purposes of determining the right to indemnification under this Agreement. Whether or not the foregoing provisions of this Section 11(c) are satisfied, it shall in any event be presumed that Indemnitee has at all times acted in good faith and in a manner Indemnitee reasonably believed to be in or not opposed to the best interests of the Company. Anyone seeking to overcome this presumption shall have the burden of proof and the burden of persuasion by clear and convincing evidence.</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Section 12.      </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Remedies of Indemnitee</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)        Subject to Section 12(f), in the event that (i) a determination is made pursuant to Section 10 of this Agreement that Indemnitee is not entitled to indemnification under this Agreement, (ii) advancement of Expenses is not timely made pursuant to Section 8 of this Agreement, (iii) no determination of entitlement to indemnification shall have been made pursuant to Section 10(a) of this Agreement within sixty (60) days after receipt by the Company of the request for indemnification for which a determination is to be made other than by Independent Counsel, (iv) payment of indemnification or reimbursement of expenses is not made pursuant to Section 5 or 6 or the last sentence of Section 10(a) of this Agreement within thirty (30) days after receipt by the Company of a written request therefor (including any invoices received by Indemnitee, which such invoices may be redacted as necessary to avoid the waiver of any privilege accorded by applicable law) or (v) payment of indemnification pursuant to Section 3 or 4 of this Agreement is not made within thirty (30) days after a determination has been made that Indemnitee is entitled to indemnification, Indemnitee shall be entitled to an adjudication by the Delaware Court of his or her entitlement to such indemnification or advancement.  Alternatively, Indemnitee, at his or her option, may seek an award in arbitration to be conducted by a single arbitrator pursuant to the Commercial Arbitration Rules of the American Arbitration Association.  Indemnitee shall commence such proceeding seeking an adjudication or an award in arbitration within 180 days following the date on which Indemnitee first has the right to commence such proceeding pursuant to this Section 12(a); </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">however</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, that the foregoing time limitation shall not apply in respect of a proceeding brought by Indemnitee to enforce his or her rights under Section 5 of this Agreement. The Company shall not oppose Indemnitee&#x2019;s right to seek any such adjudication or award in arbitration.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">9</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/105004718.3</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b)       In the event that a determination shall have been made pursuant to Section 10(a) of this Agreement that Indemnitee is not entitled to indemnification, any judicial proceeding or arbitration commenced pursuant to this Section 12 shall be conducted in all respects as a de novo trial, or arbitration, on the merits and Indemnitee shall not be prejudiced by reason of that adverse determination.  In any judicial proceeding or arbitration commenced pursuant to this Section 12, the Company shall have the burden of proving Indemnitee is not entitled to indemnification or advancement, as the case may be.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(c)        If a determination shall have been made pursuant to Section 10(a) of this Agreement that Indemnitee is entitled to indemnification, the Company shall be bound by such determination in any judicial proceeding or arbitration commenced pursuant to this Section 12, absent (i) a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee&#x2019;s statement not materially misleading, in connection with the request for indemnification, or (ii) a prohibition of such indemnification under applicable law.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(d)       The Company shall be precluded from asserting in any judicial proceeding or arbitration commenced pursuant to this Section 12 that the procedures and presumptions of this Agreement are not valid, binding and enforceable and shall stipulate in any such court or before any such arbitrator that the Company is bound by all the provisions of this Agreement.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(e)        The Company shall indemnify Indemnitee to the fullest extent permitted by law against any and all Enforcement Expenses and, if requested by Indemnitee, shall (within thirty (30) days after receipt by the Company of a written request therefor) advance, to the extent not prohibited by law, such Enforcement Expenses to Indemnitee, which are incurred by Indemnitee in connection with any action brought by Indemnitee for indemnification or advancement from the Company under this Agreement or under any directors&#x2019; and officers&#x2019; liability insurance policies maintained by the Company in the suit for which indemnification or advancement is being sought.  Such written request for advancement shall include invoices received by Indemnitee in connection with such Enforcement Expenses but, in the case of invoices in connection with legal services, any references to legal work performed or to expenditures made that would cause Indemnitee to waive any privilege accorded by applicable law need not be included with the invoice.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(f)        Notwithstanding anything in this Agreement to the contrary, no determination as to entitlement to indemnification under this Agreement shall be required to be made prior to the final disposition of the Proceeding, including any appeal therein.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Section 13.     </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Non-exclusivity; Survival of Rights; Insurance; Primacy of Indemnification; Subrogation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)        The rights of indemnification and to receive advancement as provided by this Agreement shall not be deemed exclusive of any other rights to which Indemnitee may at any time be entitled under applicable law, the Charter, the Bylaws, any agreement, a vote of stockholders or a resolution of directors, or otherwise.  No amendment, alteration or repeal of this Agreement or of any provision hereof shall limit or restrict any right of Indemnitee under this Agreement in respect of any action taken or omitted by such Indemnitee in his or her Corporate Status prior to such amendment, alteration or repeal.  To the extent that a change in Delaware law, whether by statute or judicial decision, permits greater indemnification or advancement than would be afforded currently under the Charter, Bylaws and this Agreement, it is the intent of the parties hereto that Indemnitee shall enjoy by this Agreement the greater benefits so afforded by such change.  No right or remedy herein conferred is intended to be exclusive of any other right or remedy, and every other right and remedy shall be cumulative and in addition to every other right and remedy given hereunder or now or hereafter existing at law or in equity or otherwise.  The assertion or employment of any right or remedy hereunder, or otherwise, shall not prevent the concurrent assertion or employment of any other right or remedy.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">10</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/105004718.3</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b)       To the extent that the Company maintains an insurance policy or policies providing liability insurance for directors, managers, partners, officers, employees, agents or trustees of the Company or of any other Enterprise, Indemnitee shall be covered by such policy or policies in accordance with its or their terms to the maximum extent of the coverage available for any such director, manager, partner, officer, employee, agent or trustee under such policy or policies. If, at the time of the receipt of a notice of a claim pursuant to the terms hereof, the Company has director and officer liability insurance in effect, the Company shall give prompt notice of such claim to the insurers in accordance with the procedures set forth in the respective policies.  The Company shall thereafter take all necessary or desirable action to cause such insurers to pay, on behalf of the Indemnitee, all amounts payable as a result of such Proceeding in accordance with the terms of such policies. Upon request of Indemnitee, the Company shall also promptly provide to Indemnitee: (i) copies of all of the Company&#x2019;s potentially applicable directors&#x2019; and officers&#x2019; liability insurance policies, (ii) copies of such notices delivered to the applicable insurers, and (iii) copies of all subsequent communications and correspondence between the Company and such insurers regarding the Proceeding.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(c)        [The Company hereby acknowledges that Indemnitee has certain rights to indemnification, advancement of expenses and/or insurance provided by [   ] and certain of its affiliates (collectively, the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Secondary Indemnitors</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;).  The Company hereby agrees (i) that it is the indemnitor of first resort (</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">i.e.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, its obligations to Indemnitee are primary and any obligation of the Secondary Indemnitors to advance expenses or to provide indemnification for the same expenses or liabilities incurred by Indemnitee are secondary), (ii) that it shall be required to advance the full amount of expenses incurred by Indemnitee and shall be liable for the full amount of all Expenses, judgments, penalties, fines and amounts paid in settlement to the extent legally permitted and as required by the terms of this Agreement and the Charter and/or Bylaws (or any other agreement between the Company and Indemnitee), without regard to any rights Indemnitee may have against the Secondary Indemnitors, and (iii) that it irrevocably waives, relinquishes and releases the Secondary Indemnitors from any and all claims against the Secondary Indemnitors for contribution, subrogation or any other recovery of any kind in respect thereof.  The Company further agrees that no advancement or payment by the Secondary Indemnitors on behalf of Indemnitee with respect to any claim for which Indemnitee has sought indemnification from the Company shall affect the foregoing and the Secondary Indemnitors shall have a right of contribution and/or be subrogated to the extent of such advancement or payment to all of the rights of recovery of Indemnitee against the Company.  The Company and Indemnitee agree that the Secondary Indemnitors are express third party beneficiaries of the terms of this Section 13(c).]</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(d)       [Except as provided in paragraph (c) above,] in the event of any payment under this Agreement, the Company shall be subrogated to the extent of such payment to all of the rights of recovery of Indemnitee [(other than against the Secondary Indemnitors)], who shall execute all papers required and take all action necessary to secure such rights, including execution of such documents as are necessary to enable the Company to bring suit to enforce such rights.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(e)        [Except as provided in paragraph (c) above,] the Company&#x2019;s obligation to provide indemnification or advancement hereunder to Indemnitee who is or was serving at the request of the Company as a director, manager, partner, officer, employee, agent or trustee of any other Enterprise shall be reduced by any amount Indemnitee has actually received as indemnification or advancement from such other Enterprise.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Section 14.       </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Duration of Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  This Agreement shall continue until and terminate upon the later of: (a) ten (10) years after the date that Indemnitee shall have ceased to serve as a director of the Company or (b) one (1) year after the final termination of any Proceeding, including any appeal, then pending in respect of which Indemnitee is granted rights of indemnification or advancement hereunder and of any proceeding commenced by Indemnitee pursuant to Section 12 of this Agreement relating thereto. This Agreement shall be binding upon the Company and its successors and assigns and shall inure to the benefit of Indemnitee and his or her heirs, executors</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">11</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/105004718.3</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">and administrators.  The Company shall require and cause any successor (whether direct or indirect by purchase, merger, consolidation or otherwise) to all, substantially all or a substantial part, of the business and/or assets of the Company, by written agreement in form and substance satisfactory to Indemnitee, expressly to assume and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform if no such succession had taken place.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Section 15.      </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Severability</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  If any provision or provisions of this Agreement shall be held to be invalid, illegal or unenforceable for any reason whatsoever: (a) the validity, legality and enforceability of the remaining provisions of this Agreement (including, without limitation, each portion of any section of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall not in any way be affected or impaired thereby and shall remain enforceable to the fullest extent permitted by law; (b) such provision or provisions shall be deemed reformed to the extent necessary to conform to applicable law and to give the maximum effect to the intent of the parties hereto; and (c) to the fullest extent possible, the provisions of this Agreement (including, without limitation, each portion of any section of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall be construed so as to give effect to the intent manifested thereby.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Section 16.      </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Enforcement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)        The Company expressly confirms and agrees that it has entered into this Agreement and assumed the obligations imposed on it hereby in order to induce Indemnitee to serve or continue to serve as a director of the Company, and the Company acknowledges that Indemnitee is relying upon this Agreement in serving as a director of the Company.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b)       This Agreement constitutes the entire agreement between the parties hereto with respect to the subject matter hereof and supersedes all prior agreements and understandings, oral, written and implied, between the parties hereto with respect to the subject matter hereof; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">however</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, that this Agreement is a supplement to and in furtherance of the Charter, the Bylaws and applicable law, and shall not be deemed a substitute therefor, nor to diminish or abrogate any rights of Indemnitee thereunder.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Section 17.      </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Modification and Waiver</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  No supplement, modification or amendment, or waiver of any provision, of this Agreement shall be binding unless executed in writing by the parties thereto.  No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provisions of this Agreement nor shall any waiver constitute a continuing waiver. No supplement, modification or amendment of this Agreement or of any provision hereof shall limit or restrict any right of Indemnitee under this Agreement in respect of any action taken or omitted by such Indemnitee prior to such supplement, modification or amendment.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Section 18.      </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Notice by Indemnitee</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Indemnitee agrees promptly to notify the Company in writing upon being served with any summons, citation, subpoena, complaint, indictment, information or other document relating to any Proceeding or matter which may be subject to indemnification, reimbursement or advancement as provided hereunder.  The failure of Indemnitee to so notify the Company or any delay in notification shall not relieve the Company of any obligation which it may have to Indemnitee under this Agreement or otherwise. unless, and then only to the extent that, the Company did not otherwise learn of the Proceeding and such delay is materially prejudicial to the Company&#x2019;s ability to defend such Proceeding or matter; and, provided, further, that notice will be deemed to have been given without any action on the part of Indemnitee in the event the Company is a party to the same Proceeding.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Section 19.      </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Notices</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  All notices, requests, demands and other communications under this Agreement shall be in writing and shall be deemed to have been duly given if (i) delivered by hand and receipted for by the</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">12</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/105004718.3</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">party to whom said notice or other communication shall have been directed, (ii) mailed by certified or registered mail with postage prepaid, on the third business day after the date on which it is so mailed, (iii) mailed by reputable overnight courier and receipted for by the party to whom said notice or other communication shall have been directed or (iv) sent by facsimile transmission, with receipt of oral confirmation that such transmission has been received:</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)        If to Indemnitee, at such address as Indemnitee shall provide to the Company.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b)       If to the Company to:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="margin-left:20.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Adicet Bio, Inc.</font></p>
  <p style="margin-left:20.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">200 Clarendon Street, Floor 6</font></p>
  <p style="margin-left:20.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Boston, MA 02116</font></p>
  <p style="margin-left:20.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Attention: President and CEO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">or to any other address as may have been furnished to Indemnitee by the Company.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Section 20.      </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Contribution</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  To the fullest extent permissible under applicable law, if the indemnification provided for in this Agreement is unavailable to Indemnitee for any reason whatsoever, the Company, in lieu of indemnifying Indemnitee, shall contribute to the amount incurred by Indemnitee, whether for judgments, fines, penalties, excise taxes, amounts paid or to be paid in settlement and/or for Expenses, in connection with any Proceeding in such proportion as is deemed fair and reasonable in light of all of the circumstances in order to reflect (i) the relative benefits received by the Company and Indemnitee in connection with the event(s) and/or transaction(s) giving rise to such Proceeding; and/or (ii) the relative fault of the Company (and its directors, officers, employees and agents) and Indemnitee in connection with such event(s) and/or transactions.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Section 21.      </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Internal Revenue Code Section 409A</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  The Company intends for this Agreement to comply with the Indemnification exception under Section 1.409A-1(b)(10) of the regulations promulgated under the Internal Revenue Code of 1986, as amended (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Code</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), which provides that indemnification of, or the purchase of an insurance policy providing for payments of, all or part of the expenses incurred or damages paid or payable by Indemnitee with respect to a bona fide claim against Indemnitee or the Company do not provide for a deferral of compensation, subject to Section 409A of the Code, where such claim is based on actions or failures to act by Indemnitee in his or her capacity as a service provider of the Company.  The parties intend that this Agreement be interpreted and construed with such intent.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Section 22.      </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Applicable Law and Consent to Jurisdiction</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  This Agreement and the legal relations among the parties shall be governed by, and construed and enforced in accordance with, the laws of the State of Delaware, without regard to its conflict of laws rules. Except with respect to any arbitration commenced by Indemnitee pursuant to Section 12(a) of this Agreement, the Company and Indemnitee hereby irrevocably and unconditionally (i) agree that any action or proceeding arising out of or in connection with this Agreement shall be brought only in the Delaware Court, and not in any other state or federal court in the United States of America or any court in any other country, (ii) consent to submit to the exclusive jurisdiction of the Delaware Court for purposes of any action or proceeding arising out of or in connection with this Agreement, (iii) consent to service of process at the address set forth in Section 19 of this Agreement with the same legal force and validity as if served upon such party personally within the State of Delaware, (iv) waive any objection to the laying of venue of any such action or proceeding in the Delaware Court, and (v) waive, and agree not to plead or to make, any claim that any such action or proceeding brought in the Delaware Court has been brought in an improper or inconvenient forum.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">13</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/105004718.3</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Section 23.      </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Headings</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  The headings of the paragraphs of this Agreement are inserted for convenience only and shall not be deemed to constitute part of this Agreement or to affect the construction thereof.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Section 24.      </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Identical Counterparts</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  This Agreement may be executed in one or more counterparts, each of which shall for all purposes be deemed to be an original but all of which together shall constitute one and the same Agreement.  Only one such counterpart signed by the party against whom enforceability is sought needs to be produced to evidence the existence of this Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Section 25.      </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Monetary Damages Insufficient/Specific Enforcement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. The Company and Indemnitee agree that a monetary remedy for breach of this Agreement may be inadequate, impracticable and difficult of proof, and further agree that such breach may cause Indemnitee irreparable harm. Accordingly, the parties hereto agree that Indemnitee may enforce this Agreement by seeking injunctive relief and/or specific performance hereof, without any necessity of showing actual damage or irreparable harm (having agreed that actual and irreparable harm will result in not forcing the Company to specifically perform its obligations pursuant to this Agreement) and that by seeking injunctive relief and/or specific performance, Indemnitee shall not be precluded from seeking or obtaining any other relief to which he may be entitled. The Company and Indemnitee further agree that Indemnitee shall be entitled to such specific performance and injunctive relief, including temporary restraining orders, preliminary injunctions and permanent injunctions, without the necessity of posting bonds or other undertaking in connection therewith. The Company acknowledges that in the absence of a waiver, a bond or undertaking may be required of Indemnitee by the Court, and the Company hereby waives any such requirement of a bond or undertaking.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[Remainder of Page Intentionally Left Blank]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">14</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/105004718.3</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">IN WITNESS WHEREOF, the parties have caused this Agreement to be signed as of the day and year first above written.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:50.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:14.033%;"></td>
    <td style="width:85.967%;"></td>
   </tr>
   <tr style="height:12.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">ADICET BIO, INC.</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Name:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Title:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:50.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:14.0%;"></td>
    <td style="width:86.0%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[Indemnitee]</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:14.0pt;font-family:Times New Roman;">ADICET BIO, INC.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:14.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:14.0pt;font-family:Times New Roman;">FORM OF OFFICER INDEMNIFICATION AGREEMENT</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">This Indemnification Agreement (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) is made as of [________________] by and between Adicet Bio, Inc., a Delaware corporation (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Company</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), and [Officer] (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Indemnitee</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;).</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:8.040000000000001pt;font-family:Times New Roman;">1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">RECITALS</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">WHEREAS, the Company desires to attract and retain the services of highly qualified individuals, such as Indemnitee, to serve the Company;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">WHEREAS, in order to induce Indemnitee to provide or continue to provide services to the Company, the Company wishes to provide for the indemnification of, and advancement of expenses to, Indemnitee to the maximum extent permitted by law;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">WHEREAS, the Third Amended and Restated Certificate of Incorporation (as amended and in effect from time to time, the &#x201c;Charter&#x201d;) and the Amended and Restated Bylaws (as amended and in effect from time to time, the &#x201c;Bylaws&#x201d;) of the Company require indemnification of the officers and directors of the Company, and Indemnitee may also be entitled to indemnification pursuant to the General Corporation Law of the State of Delaware (the &#x201c;DGCL&#x201d;);</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">WHEREAS, the Charter, the Bylaws and the DGCL expressly provide that the indemnification provisions set forth therein are not exclusive, and thereby contemplate that contracts may be entered into between the Company and members of the board of directors, officers and other persons with respect to indemnification;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">WHEREAS, the Board of Directors of the Company (the &#x201c;Board&#x201d;) has determined that the increased difficulty in attracting and retaining highly qualified persons such as Indemnitee is detrimental to the best interests of the Company&#x2019;s stockholders;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">WHEREAS, it is reasonable and prudent for the Company contractually to obligate itself to indemnify, and to advance expenses on behalf of, such persons to the fullest extent permitted by applicable law, regardless of any amendment or revocation of the Charter or the Bylaws, so that they will serve or continue to serve the Company free from undue concern that they will not be so indemnified; and</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">WHEREAS, this Agreement is a supplement to and in furtherance of the indemnification provided in the Charter, the Bylaws and any resolutions adopted pursuant thereto, and shall not be deemed a substitute therefor, nor to diminish or abrogate any rights of Indemnitee thereunder.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">NOW, THEREFORE, in consideration of the premises and the covenants contained herein, the Company and Indemnitee do hereby covenant and agree as follows:</font></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;margin-right:66.667%;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">1 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">To be entered into with all C-level officers and Section 16 officers.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/105005427.2</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Section 1.        </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Services to the Company</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. Indemnitee agrees to [continue to] serve as [a director and] an officer of the Company.  Indemnitee may at any time and for any reason resign from [any] such position (subject to any other contractual obligation or any obligation imposed by law), in which event the Company shall have no obligation under this Agreement to continue Indemnitee in such position.  This Agreement shall not be deemed an employment contract between the Company (or any of its subsidiaries or any Enterprise) and Indemnitee.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Section 2.        </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Definitions</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">As used in this Agreement:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a) &#x201c;Affiliate&#x201d; and &#x201c;Associate&#x201d; shall have the respective meanings ascribed to such terms in Rule 12b-2 of the General Rules and Regulations under the Securities Exchange Act of 1934, as amended, as in effect on the date of this Agreement; provided, however, that no Person who is a director or officer of the Company shall be deemed an Affiliate or an Associate of any other director or officer of the Company solely as a result of his or her position as director or officer of the Company.</font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b) A Person shall be deemed the &#x201c;Beneficial Owner&#x201d; of, and shall be deemed to &#x201c;Beneficially Own&#x201d; and have &#x201c;Beneficial Ownership&#x201d; of, any securities:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="margin-left:6.667%;text-indent:21.429%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(i) which such Person or any of such Person&#x2019;s Affiliates or Associates, directly or indirectly, Beneficially Owns (as determined pursuant to Rule 13d-3 of the Rules under the Exchange Act, as in effect on the date of this Agreement);</font></p>
  <p style="margin-left:6.667%;text-indent:21.429%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:21.429%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(ii) which such Person or any of such Person&#x2019;s Affiliates or Associates, directly or indirectly, has: (A) the legal, equitable or contractual right or obligation to acquire (whether directly or indirectly and whether exercisable immediately or only after the passage of time, compliance with regulatory requirements, satisfaction of one or more conditions (whether or not within the control of such Person) or otherwise) upon the exercise of any conversion rights, exchange rights, rights, warrants or options, or otherwise; (B) the right to vote pursuant to any agreement, arrangement or understanding (whether or not in writing); or (C) the right to dispose of pursuant to any agreement, arrangement or understanding (whether or not in writing) (other than customary arrangements with and between underwriters and selling group members with respect to a bona fide public offering of securities);</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="margin-left:6.667%;text-indent:21.429%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:21.429%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(iii) which are Beneficially Owned, directly or indirectly, by any other Person (or any Affiliate or Associate thereof) with which such Person or any of such Person&#x2019;s Affiliates or Associates has any agreement, arrangement or understanding (whether or not in writing) (other than customary agreements with and between underwriters and selling group members with respect to a bona fide public offering of securities) for the purpose of acquiring, holding, voting or disposing of any securities of the Company; or</font></p>
  <p style="margin-left:6.667%;text-indent:21.429%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:21.429%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(iv) that are the subject of a derivative transaction entered into by such Person or any of such Person&#x2019;s Affiliates or Associates, including, for these purposes, any derivative security acquired by such Person or any of such Person&#x2019;s Affiliates or Associates that gives such Person or any of such Person&#x2019;s Affiliates or Associates the economic equivalent of ownership of an amount of securities due to the fact that the value of the derivative security is explicitly determined by reference to the price or value of such securities, or that provides such Person or any of such Person&#x2019;s Affiliates or Associates an opportunity, directly or indirectly, to profit or to share in any profit derived from any change in the value of such securities, in any case without regard to whether (A) such derivative security conveys any voting</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/105005427.2</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">rights in such securities to such Person or any of such Person&#x2019;s Affiliates or Associates; (B) the derivative security is required to be, or capable of being, settled through delivery of such securities; or (C) such Person or any of such Person&#x2019;s Affiliates or Associates may have entered into other transactions that hedge the economic effect of such derivative security;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Notwithstanding the foregoing, no Person engaged in business as an underwriter of securities shall be deemed the Beneficial Owner of any securities acquired through such Person&#x2019;s participation as an underwriter in good faith in a firm commitment underwriting.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(c) A &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Change in Control</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; shall be deemed to occur upon the earliest to occur after the date of this Agreement of any of the following events:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="margin-left:6.667%;text-indent:21.429%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(i) Acquisition of Stock by Third Party. Any Person is or becomes the Beneficial Owner (as defined above), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the combined voting power of the Company&#x2019;s then outstanding securities [(other than acquisitions of Class B Common Stock by a Qualified Stockholder (as defined in the Charter))] unless the change in relative Beneficial Ownership of the Company&#x2019;s securities by any Person results solely from a reduction in the aggregate number of outstanding shares of securities entitled to vote generally in the election of directors [or as a result of conversions of Class B Common Stock], provided that a Change of Control shall be deemed to have occurred if subsequent to such reduction such Person becomes the Beneficial Owner, directly or indirectly, of any additional securities of the Company conferring upon such Person any additional voting power;</font></p>
  <p style="margin-left:6.667%;text-indent:21.429%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(ii) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Change in Board of Directors</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. During any period of two (2) consecutive years (not including any period prior to the execution of this Agreement), individuals who at the beginning of such period constitute the Board, and any new director (other than a director designated by a person who has entered into an agreement with the Company to effect a transaction described in Sections 2(c)(i), 2(c)(iii) or 2(c)(iv) whose election by the Board or nomination for election by the Company&#x2019;s stockholders was approved by a vote of at least two-thirds of the directors then still in office who either were directors at the beginning of the period or whose election or nomination for election was previously so approved, cease for any reason to constitute at least a majority of the members of the Board;</font></p>
  <p style="margin-left:6.667%;text-indent:21.429%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(iii) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Corporate Transactions</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. The effective date of a merger or consolidation of the Company with any other entity, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior to such merger or consolidation continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving or successor entity) more than 50% of the combined voting power of the voting securities of the surviving or successor entity outstanding immediately after such merger or consolidation and with the power to elect at least a majority of the board of directors or other governing body of such surviving or successor entity;</font></p>
  <p style="margin-left:6.667%;text-indent:21.429%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(iv) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Liquidation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. The approval by the stockholders of the Company of a complete liquidation of the Company or an agreement for the sale, lease, exchange or other transfer by the Company, in one or a series of related transactions, of all or substantially all of the Company&#x2019;s assets; and</font></p>
  <p style="margin-left:6.667%;text-indent:21.429%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(v) </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Other Events</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. There occurs any other event of a nature that would be required to be reported in response to Item 6(e) of Schedule 14A of Regulation 14A (or a response to any similar item on any similar schedule or form) promulgated under the Securities Exchange Act of 1934, as amended, whether or not the Company is then subject to such reporting requirement.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">3</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/105005427.2</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(d) &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Corporate Status</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; describes the status of a person as a current or former [director or] officer of the Company or current or former director, manager, partner, officer, employee, agent or trustee of any other Enterprise which such person is or was serving at the request of the Company.</font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(e) &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Enforcement Expenses</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; shall include all reasonable attorneys&#x2019; fees, court costs, transcript costs, fees of experts, travel expenses, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees, and all other out-of-pocket disbursements or expenses of the types customarily incurred in connection with an action to enforce indemnification or advancement rights, or an appeal from such action.  Expenses, however, shall not include fees, salaries, wages or benefits owed to Indemnitee.</font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(f) &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Enterprise</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; shall mean any corporation (other than the Company), partnership, joint venture, trust, employee benefit plan, limited liability company, or other legal entity of which Indemnitee is or was serving at the request of the Company as a director, manager, partner, officer, employee, agent or trustee.</font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(g) &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Expenses</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; shall include all reasonable attorneys&#x2019; fees, court costs, transcript costs, fees of experts, travel expenses, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees, and all other out-of-pocket disbursements or expenses of the types customarily incurred in connection with prosecuting, defending, preparing to prosecute or defend, investigating, being or preparing to be a witness in, or otherwise participating in, a Proceeding or an appeal resulting from a Proceeding.  Expenses, however, shall not include amounts paid in settlement by Indemnitee, the amount of judgments or fines against Indemnitee or fees, salaries, wages or benefits owed to Indemnitee.</font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(h) &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Independent Counsel</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; means a law firm, or a partner (or, if applicable, member or shareholder) of such a law firm, that is experienced in matters of Delaware corporation law and neither presently is, nor in the past five (5) years has been, retained to represent: (i) the Company, any subsidiary of the Company, any Enterprise or Indemnitee in any matter material to any such party; or (ii) any other party to the Proceeding giving rise to a claim for indemnification hereunder.  Notwithstanding the foregoing, the term &#x201c;Independent Counsel&#x201d; shall not include any person who, under the applicable standards of professional conduct then prevailing, would have a conflict of interest in representing either the Company or Indemnitee in an action to determine Indemnitee&#x2019;s rights under this Agreement. The Company agrees to pay the reasonable fees and expenses of the Independent Counsel referred to above and to fully indemnify such counsel against any and all expenses, claims, liabilities and damages arising out of or relating to this Agreement or its engagement pursuant hereto.</font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(i) &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Person</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; shall mean (i) an individual, a corporation, a partnership, a limited liability company, an association, a joint stock company, a trust, a business trust, a government or political subdivision, any unincorporated organization, or any other association or entity including any successor (by merger or otherwise) thereof or thereto, and (ii) a &#x201c;group&#x201d; as that term is used for purposes of Section 13(d)(3) of the Securities Exchange Act of 1934, as amended.</font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:14.286%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(j) The term &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Proceeding</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d; shall include any threatened, pending or completed action, suit, arbitration, alternate dispute resolution mechanism, investigation, inquiry, administrative hearing or any other actual, threatened or completed proceeding, whether brought in the right of the Company or otherwise and whether of a civil, criminal, administrative, regulatory or investigative nature, and whether formal or informal, in which Indemnitee was, is or will be involved as a party or otherwise by reason of the fact that Indemnitee is or was [a director or] an officer of the Company or is or was serving at the</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">4</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/105005427.2</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">request of the Company as a director, manager, partner, officer, employee, agent or trustee of any Enterprise or by reason of any action taken by Indemnitee or of any action taken on his or her part while acting as [a director or] an officer of the Company or while serving at the request of the Company as a director, manager, partner, officer, employee, agent or trustee of any Enterprise, in each case whether or not serving in such capacity at the time any liability or expense is incurred for which indemnification, reimbursement or advancement of expenses can be provided under this Agreement; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">however</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, that the term &#x201c;Proceeding&#x201d; shall not include any action, suit or arbitration, or part thereof, initiated by Indemnitee to enforce Indemnitee&#x2019;s rights under this Agreement as provided for in Section 12(a) of this Agreement.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Section 3.        </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Indemnity in Third-Party Proceedings</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  The Company shall indemnify Indemnitee to the extent set forth in this Section 3 if Indemnitee is, or is threatened to be made, a party to or a participant in any Proceeding, other than a Proceeding by or in the right of the Company to procure a judgment in its favor.  Pursuant to this Section 3, Indemnitee shall be indemnified against all Expenses, judgments, fines, penalties, excise taxes, and amounts paid in settlement actually and reasonably incurred by Indemnitee or on his or her behalf in connection with such Proceeding or any claim, issue or matter therein, if Indemnitee acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the Company and, in the case of a criminal proceeding, had no reasonable cause to believe that his or her conduct was unlawful.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Section 4.        </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Indemnity in Proceedings by or in the Right of the Company</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  The Company shall indemnify Indemnitee to the extent set forth in this Section 4 if Indemnitee is, or is threatened to be made, a party to or a participant in any Proceeding by or in the right of the Company to procure a judgment in its favor.  Pursuant to this Section 4, Indemnitee shall be indemnified against all Expenses actually and reasonably incurred by Indemnitee or on his or her behalf in connection with such Proceeding or any claim, issue or matter therein, if Indemnitee acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the Company.  No indemnification for Expenses shall be made under this Section 4 in respect of any claim, issue or matter as to which Indemnitee shall have been finally adjudged by a court to be liable to the Company, unless and only to the extent that the Delaware Court of Chancery (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Delaware Court</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, Indemnitee is fairly and reasonably entitled to indemnification for such expenses as the Delaware Court shall deem proper.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Section 5.        </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Indemnification for Expenses of a Party Who is Wholly or Partly Successful</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Notwithstanding any other provisions of this Agreement and except as provided in Section 7, to the extent that Indemnitee is a party to or a participant in any Proceeding and is successful in such Proceeding or in defense of any claim, issue or matter therein, the Company shall indemnify Indemnitee against all Expenses actually and reasonably incurred by him or her in connection therewith.  If Indemnitee is not wholly successful in such Proceeding but is successful as to one or more but less than all claims, issues or matters in such Proceeding, the Company shall indemnify Indemnitee against all Expenses actually and reasonably incurred by Indemnitee or on his or her behalf in connection with each successfully resolved claim, issue or matter.  For purposes of this Section and without limitation, the termination of any claim, issue or matter in such a Proceeding by dismissal, with or without prejudice, shall be deemed to be a successful result as to such claim, issue or matter.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Section 6.        </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Reimbursement for Expenses of a Witness or in Response to a Subpoena</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. Notwithstanding any other provision of this Agreement, to the extent that Indemnitee, by reason of his or her Corporate Status, (i) is a witness in any Proceeding to which Indemnitee is not a party and is not threatened to be made a party or (ii) receives a subpoena with respect to any Proceeding to which Indemnitee is not a party and is not threatened to be</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">5</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/105005427.2</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">made a party, the Company shall reimburse Indemnitee for all Expenses actually and reasonably incurred by him or her or on his or her behalf in connection therewith.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">   </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Section 7.        </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Exclusions</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Notwithstanding any provision in this Agreement to the contrary, the Company shall not be obligated under this Agreement:</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)       to indemnify for amounts otherwise indemnifiable hereunder (or for which advancement is provided hereunder) if and to the extent that Indemnitee has otherwise actually received such amounts under any insurance policy, contract, agreement or otherwise; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> that the foregoing shall not [i] apply to any personal or umbrella liability insurance maintained by Indemnitee, [or (ii) affect the rights of Indemnitee or the Fund Indemnitors as set forth in Section 13(c)];</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b)       to indemnify for an accounting of profits made from the purchase and sale (or sale and purchase) by Indemnitee of securities of the Company within the meaning of Section 16(b) of the Securities Exchange Act of 1934, as amended, or similar provisions of state statutory law or common law, or from the purchase or sale by Indemnitee of such securities in violation of Section 306 of the Sarbanes-Oxley Act of 2002 (&#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">SOX</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;);</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(c)       to indemnify for any reimbursement of, or payment to, the Company by Indemnitee of any bonus or other incentive-based or equity-based compensation or of any profits realized by Indemnitee from the sale of securities of the Company pursuant to Section 304 of SOX or any formal policy of the Company adopted by the Board (or a committee thereof), or any other remuneration paid to Indemnitee if it shall be determined by a final judgment or other final adjudication that such remuneration was in violation of law;</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:8.040000000000001pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(d)       to indemnify with respect to any Proceeding, or part thereof, brought by Indemnitee against the Company, any legal entity which it controls, any director or officer thereof or any third party, unless (i) the Board has consented to the initiation of such Proceeding or part thereof and (ii) the Company provides the indemnification, in its sole discretion, pursuant to the powers vested in the Company under applicable law; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">however</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, that this Section 7(d) shall not apply to (A) counterclaims or affirmative defenses asserted by Indemnitee in an action brought against Indemnitee or (B) any action brought by Indemnitee for indemnification or advancement from the Company under this Agreement or under any directors&#x2019; and officers&#x2019; liability insurance policies maintained by the Company in the suit for which indemnification or advancement is being sought as described in Section 12; or</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(e)       to provide any indemnification or advancement of expenses that is prohibited by applicable law (as such law exists at the time payment would otherwise be required pursuant to this Agreement).</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Section 8.        </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Advancement of Expenses</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Subject to Section 9(b), the Company shall advance the Expenses incurred by Indemnitee in connection with any Proceeding, and such advancement shall be made as incurred, and such advancement shall be made within thirty (30) days after the receipt by the Company of a statement or statements requesting such advances (including any invoices received by Indemnitee, which such invoices may be redacted as necessary to avoid the waiver of any privilege accorded by applicable law) from time to time, whether prior to or after final disposition of any Proceeding.  Advances shall be unsecured and interest free.  Advances shall be made without regard to Indemnitee&#x2019;s (i) ability to repay the expenses, (ii) ultimate entitlement to indemnification under the other provisions of this Agreement, and (iii) entitlement to and availability of insurance coverage, including advancement, payment or reimbursement of defense costs, expenses of covered loss under the provisions of any applicable insurance policy (including , without limitation, whether such advancement, payment or reimbursement is withheld, conditioned or delayed by the insurer(s)). Indemnitee shall qualify for advances upon the execution and delivery to the Company of this Agreement which shall</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">6</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/105005427.2</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">constitute an undertaking providing that Indemnitee undertakes to the fullest extent required by law to repay the advance if and to the extent that it is ultimately determined by a court of competent jurisdiction in a final judgment, not subject to appeal, that Indemnitee is not entitled to be indemnified by the Company. No other form of undertaking shall be required. The right to advances under this paragraph shall in all events continue until final disposition of any Proceeding, including any appeal therein.  Nothing in this Section 8 shall limit Indemnitee&#x2019;s right to advancement pursuant to Section 12(e) of this Agreement.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Section 9.       </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Procedure for Notification and Defense of Claim</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)       To obtain indemnification under this Agreement, Indemnitee shall submit to the Company a written request therefor specifying the basis for the claim, the amounts for which Indemnitee is seeking payment under this Agreement, and all documentation related thereto as reasonably requested by the Company.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b)       In the event that the Company shall be obligated hereunder to provide indemnification for or make any advancement of Expenses with respect to any Proceeding, the Company shall be entitled to assume the defense of such Proceeding, or any claim, issue or matter therein, with counsel approved by Indemnitee (which approval shall not be unreasonably withheld or delayed) upon the delivery to Indemnitee of written notice of the Company&#x2019;s election to do so.  After delivery of such notice, approval of such counsel by Indemnitee and the retention of such counsel by the Company, the Company will not be liable to Indemnitee under this Agreement for any fees or expenses of separate counsel subsequently employed by or on behalf of Indemnitee with respect to the same Proceeding; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> that (i) Indemnitee shall have the right to employ separate counsel in any such Proceeding at Indemnitee&#x2019;s expense and (ii) if (A) the employment of separate counsel by Indemnitee has been previously authorized by the Company, (B) Indemnitee shall have reasonably concluded that there may be a conflict of interest between the Company and Indemnitee in the conduct of such defense, (C) the Company shall not continue to retain such counsel to defend such Proceeding, or (D) a Change in Control shall have occurred, then the fees and expenses actually and reasonably incurred by Indemnitee with respect to his or her separate counsel shall be Expenses hereunder.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(c)       In the event that the Company does not assume the defense in a Proceeding pursuant to paragraph (b) above, then the Company will be entitled to participate in the Proceeding at its own expense.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(d)       The Company shall not be liable to indemnify Indemnitee under this Agreement for any amounts paid in settlement of any Proceeding effected without its prior written consent (which consent shall not be unreasonably withheld or delayed). The Company shall not, without the prior written consent of Indemnitee (which consent shall not be unreasonably withheld or delayed), enter into any settlement which (i) includes an admission of fault of Indemnitee, any non-monetary remedy imposed on Indemnitee or any monetary damages for which Indemnitee is not wholly and actually indemnified hereunder or (ii) with respect to any Proceeding with respect to which Indemnitee may be or is made a party or may be otherwise entitled to seek indemnification hereunder, does not include the full release of Indemnitee from all liability in respect of such Proceeding.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">7</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/105005427.2</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Section 10.      </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Procedure Upon Application for Indemnification</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:8.040000000000001pt;font-family:Times New Roman;">2</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)        Upon written request by Indemnitee for indemnification pursuant to Section 9(a), a determination, if such determination is required by applicable law, with respect to Indemnitee&#x2019;s entitlement to indemnification hereunder shall be made in the specific case by one of the following methods: [(x) if a Change in Control shall have occurred and indemnification is being requested by Indemnitee hereunder in his or her capacity as a director of the Company, by Independent Counsel in a written opinion to the Board; or (y) in any other case,] (i) by a majority vote of the disinterested directors, even though less than a quorum; (ii) by a committee of disinterested directors designated by a majority vote of the disinterested directors, even though less than a quorum; or (iii) if there are no disinterested directors or if the disinterested directors so direct, by Independent Counsel in a written opinion to the Board.  For purposes hereof, disinterested directors are those members of the Board who are not parties to the action, suit or proceeding in respect of which indemnification is sought.  In the case that such determination is made by Independent Counsel, a copy of Independent Counsel&#x2019;s written opinion shall be delivered to Indemnitee and, if it is so determined that Indemnitee is entitled to indemnification, payment to Indemnitee shall be made within thirty (30) days after such determination. Indemnitee shall cooperate with the Independent Counsel or the Company, as applicable, in making such determination with respect to Indemnitee&#x2019;s entitlement to indemnification, including providing to such counsel or the Company, upon reasonable advance request, any documentation or information which is not privileged or otherwise protected from disclosure and which is reasonably available to Indemnitee and reasonably necessary to such determination.  The Company shall likewise cooperate with Indemnitee and Independent Counsel, if applicable, in making such determination with respect to Indemnitee&#x2019;s entitlement to indemnification, including providing to such counsel and Indemnitee, upon reasonable advance request, any documentation or information which is not privileged or otherwise protected from disclosure and which is reasonably available to the Company and reasonably necessary to such determination. Any out-of-pocket costs or expenses (including reasonable attorneys&#x2019; fees and disbursements) actually and reasonably incurred by Indemnitee in so cooperating with the Independent Counsel or the Company shall be borne by the Company (irrespective of the determination as to Indemnitee&#x2019;s entitlement to indemnification) and the Company hereby indemnifies and agrees to hold Indemnitee harmless therefrom.</font></p>
  <p style="text-indent:0.0%;padding-bottom:1.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;border-bottom:0.750pt solid;margin-right:66.667%;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">2 </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Bracketed portions for CEO Director version only</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">8</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/105005427.2</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b)       If the determination of entitlement to indemnification is to be made by Independent Counsel pursuant to Section 10(a), the Independent Counsel shall be selected by the Board[; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> that, if a Change in Control shall have occurred and indemnification is being requested by Indemnitee hereunder in his or her capacity as a director of the Company, the Independent Counsel shall be selected by Indemnitee].  Indemnitee [or the Company, as the case may be,] may, within ten (10) days after written notice of such selection, deliver to the Company [or Indemnitee, as the case may be,] a written objection to such selection; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">however</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, that such objection may be asserted only on the ground that the Independent Counsel so selected does not meet the requirements of &#x201c;Independent Counsel&#x201d; as defined in Section 2 of this Agreement, and the objection shall set forth with particularity the factual basis of such assertion.  Absent a proper and timely objection, the person so selected shall act as Independent Counsel.  If such written objection is so made and substantiated, the Independent Counsel so selected may not serve as Independent Counsel unless and until such objection is withdrawn or the Delaware Court has determined that such objection is without merit.  If, within twenty (20) days after the later of (i) submission by Indemnitee of a written request for indemnification pursuant to Section 9(a), and (ii) the final disposition of the Proceeding, including any appeal therein, no Independent Counsel shall have been selected without objection, either Indemnitee or the Company may petition the Delaware Court for resolution of any objection which shall have been made by Indemnitee or the Company to the selection of Independent Counsel and/or for the appointment as Independent Counsel of a person selected by the court or by such other person as the court shall designate.  The person with respect to whom all objections are so resolved or the person so appointed shall act as Independent Counsel under Section 10(a) hereof.  Upon the due commencement of any judicial proceeding or arbitration pursuant to Section 12(a) of this Agreement, Independent Counsel shall be discharged and relieved of any further responsibility in such capacity (subject to the applicable standards of professional conduct then prevailing).</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(c)        Notwithstanding anything to the contrary contained in this Agreement, the determination of entitlement to indemnification under this Agreement shall be made without regard to the Indemnitee&#x2019;s entitlement to and availability of insurance coverage, including advancement, payment or reimbursement of defense costs, expenses or covered loss under the provisions of any applicable insurance policy (including, without limitation, whether such advancement, payment or reimbursement is withheld, conditioned or delayed by the insurer(s)).</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Section 11.     </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Presumptions and Effect of Certain Proceedings</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)       To the extent permitted by applicable law, in making a determination with respect to entitlement to indemnification hereunder, it shall be presumed that Indemnitee is entitled to indemnification under this Agreement if Indemnitee has submitted a request for indemnification in accordance with Section 9(a) of this Agreement, and the Company shall have the burden of proof and the burden of persuasion by clear and convincing evidence to overcome that presumption in connection with the making of any determination contrary to that presumption.  Neither (i) the failure of the Company or of Independent Counsel to have made a determination prior to the commencement of any action pursuant to this Agreement that indemnification is proper in the circumstances because Indemnitee has met the applicable standard of conduct, nor (ii) an actual determination by the Company or by Independent Counsel that Indemnitee has not met such applicable standard of conduct, shall be a defense to the action or create a presumption that Indemnitee has not met the applicable standard of conduct.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b)       The termination of any Proceeding or of any claim, issue or matter therein, by judgment, order, settlement or conviction, or upon a plea of guilty, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">nolo</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">contendere</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> or its equivalent, shall not (except as otherwise expressly provided in this Agreement) of itself adversely affect the right of Indemnitee to indemnification or create a presumption that Indemnitee did not act in good faith and in a manner which he or she reasonably believed to be in or not opposed to the best interests of the Company or, with respect to any criminal Proceeding, that Indemnitee had reasonable cause to believe that his or her conduct was unlawful.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">9</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/105005427.2</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(c)        Indemnitee shall be deemed to have acted in good faith if Indemnitee&#x2019;s actions are based on the records or books of account of the Company or any other Enterprise, including financial statements, or on information supplied to Indemnitee by the directors, officers, agents or employees of the Company or any other Enterprise in the course of their duties, or on the advice of legal counsel for the Company or any other Enterprise or on information or records given or reports made to the Company or any other Enterprise by an independent certified public accountant or by an appraiser or other expert selected with reasonable care by the Company or any other Enterprise. The provisions of this Section 11(c) shall not be deemed to be exclusive or to limit in any way the other circumstances in which Indemnitee may be deemed to have met the applicable standard of conduct set forth in this Agreement. In addition, the knowledge and/or actions, or failure to act, of any director, manager, partner, officer, employee, agent or trustee of the Company, any subsidiary of the Company, or any Enterprise shall not be imputed to Indemnitee for purposes of determining the right to indemnification under this Agreement. Whether or not the foregoing provisions of this Section 11(c) are satisfied, it shall in any event be presumed that Indemnitee has at all times acted in good faith and in a manner Indemnitee reasonably believed to be in or not opposed to the best interests of the Company. Anyone seeking to overcome this presumption shall have the burden of proof and the burden of persuasion by clear and convincing evidence.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Section 12.      </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Remedies of Indemnitee</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)        Subject to Section 12(f), in the event that (i) a determination is made pursuant to Section 10 of this Agreement that Indemnitee is not entitled to indemnification under this Agreement, (ii) advancement of Expenses is not timely made pursuant to Section 8 of this Agreement, (iii) no determination of entitlement to indemnification shall have been made pursuant to Section 10(a) of this Agreement within sixty (60) days after receipt by the Company of the request for indemnification for which a determination is to be made other than by Independent Counsel, (iv) payment of indemnification or reimbursement of expenses is not made pursuant to Section 5 or 6 or the last sentence of Section 10(a) of this Agreement within thirty (30) days after receipt by the Company of a written request therefor (including any invoices received by Indemnitee, which such invoices may be redacted as necessary to avoid the waiver of any privilege accorded by applicable law) or (v) payment of indemnification pursuant to Section 3 or 4 of this Agreement is not made within thirty (30) days after a determination has been made that Indemnitee is entitled to indemnification, Indemnitee shall be entitled to an adjudication by the Delaware Court of his or her entitlement to such indemnification or advancement.  Alternatively, Indemnitee, at his or her option, may seek an award in arbitration to be conducted by a single arbitrator pursuant to the Commercial Arbitration Rules of the American Arbitration Association.  Indemnitee shall commence such proceeding seeking an adjudication or an award in arbitration within 180 days following the date on which Indemnitee first has the right to commence such proceeding pursuant to this Section 12(a); </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">however</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, that the foregoing time limitation shall not apply in respect of a proceeding brought by Indemnitee to enforce his or her rights under Section 5 of this Agreement. The Company shall not oppose Indemnitee&#x2019;s right to seek any such adjudication or award in arbitration.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b)       In the event that a determination shall have been made pursuant to Section 10(a) of this Agreement that Indemnitee is not entitled to indemnification, any judicial proceeding or arbitration commenced pursuant to this Section 12 shall be conducted in all respects as a de novo trial, or arbitration, on the merits and Indemnitee shall not be prejudiced by reason of that adverse determination.  In any judicial proceeding or arbitration commenced pursuant to this Section 12, the Company shall have the burden of proving Indemnitee is not entitled to indemnification or advancement, as the case may be.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(c)        If a determination shall have been made pursuant to Section 10(a) of this Agreement that Indemnitee is entitled to indemnification, the Company shall be bound by such determination in any judicial proceeding or arbitration commenced pursuant to this Section 12, absent (i) a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee&#x2019;s statement not materially</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">10</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/105005427.2</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">misleading, in connection with the request for indemnification, or (ii) a prohibition of such indemnification under applicable law.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(d)       The Company shall be precluded from asserting in any judicial proceeding or arbitration commenced pursuant to this Section 12 that the procedures and presumptions of this Agreement are not valid, binding and enforceable and shall stipulate in any such court or before any such arbitrator that the Company is bound by all the provisions of this Agreement.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(e)        The Company shall indemnify Indemnitee to the fullest extent permitted by law against any and all Enforcement Expenses and, if requested by Indemnitee, shall (within thirty (30) days after receipt by the Company of a written request therefor) advance, to the extent not prohibited by law, such Enforcement Expenses to Indemnitee, which are incurred by Indemnitee in connection with any action brought by Indemnitee for indemnification or advancement from the Company under this Agreement or under any directors&#x2019; and officers&#x2019; liability insurance policies maintained by the Company in the suit for which indemnification or advancement is being sought.  Such written request for advancement shall include invoices received by Indemnitee in connection with such Enforcement Expenses but, in the case of invoices in connection with legal services, any references to legal work performed or to expenditures made that would cause Indemnitee to waive any privilege accorded by applicable law need not be included with the invoice.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(f)        Notwithstanding anything in this Agreement to the contrary, no determination as to entitlement to indemnification under this Agreement shall be required to be made prior to the final disposition of the Proceeding, including any appeal therein.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Section 13.     </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Non-exclusivity; Survival of Rights; Insurance; Subrogation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)        The rights of indemnification and to receive advancement as provided by this Agreement shall not be deemed exclusive of any other rights to which Indemnitee may at any time be entitled under applicable law, the Charter, the Bylaws, any agreement, a vote of stockholders or a resolution of directors, or otherwise.  No amendment, alteration or repeal of this Agreement or of any provision hereof shall limit or restrict any right of Indemnitee under this Agreement in respect of any action taken or omitted by such Indemnitee in his or her Corporate Status prior to such amendment, alteration or repeal.  To the extent that a change in Delaware law, whether by statute or judicial decision, permits greater indemnification or advancement than would be afforded currently under the Charter, Bylaws and this Agreement, it is the intent of the parties hereto that Indemnitee shall enjoy by this Agreement the greater benefits so afforded by such change.  No right or remedy herein conferred is intended to be exclusive of any other right or remedy, and every other right and remedy shall be cumulative and in addition to every other right and remedy given hereunder or now or hereafter existing at law or in equity or otherwise.  The assertion or employment of any right or remedy hereunder, or otherwise, shall not prevent the concurrent assertion or employment of any other right or remedy.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b)       To the extent that the Company maintains an insurance policy or policies providing liability insurance for directors, managers, partners, officers, employees, agents or trustees of the Company or of any other Enterprise, Indemnitee shall be covered by such policy or policies in accordance with its or their terms to the maximum extent of the coverage available for any such director, manager, partner, officer, employee, agent or trustee under such policy or policies.  If, at the time of the receipt of a notice of a claim pursuant to the terms hereof, the Company has director and officer liability insurance in effect, the Company shall give prompt notice of such claim to the insurers in accordance with the procedures set forth in the respective policies.  The Company shall thereafter take all necessary or desirable action to cause such insurers to pay, on behalf of the Indemnitee, all amounts payable as a result of such Proceeding in accordance with the terms of such policies. Upon request of Indemnitee, the Company shall also promptly provide to Indemnitee: (i) copies of all of the Company&#x2019;s</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">11</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/105005427.2</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">potentially applicable directors&#x2019; and officers&#x2019; liability insurance policies, (ii) copies of such notices delivered to the applicable insurers, and (iii) copies of all subsequent communications and correspondence between the Company and such insurers regarding the Proceeding.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(c)        In the event of any payment under this Agreement, the Company shall be subrogated to the extent of such payment to all of the rights of recovery of Indemnitee, who shall execute all papers required and take all action necessary to secure such rights, including execution of such documents as are necessary to enable the Company to bring suit to enforce such rights.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(d)       The Company&#x2019;s obligation to provide indemnification or advancement hereunder to Indemnitee who is or was serving at the request of the Company as a director, manager, partner, officer, employee, agent or trustee of any other Enterprise shall be reduced by any amount Indemnitee has actually received as indemnification or advancement from such other Enterprise.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Section 14.       </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Duration of Agreement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  This Agreement shall continue until and terminate upon the later of: (a) ten (10) years after the date that Indemnitee shall have ceased to serve as [both a director and] an officer of the Company or (b) one (1) year after the final termination of any Proceeding, including any appeal, then pending in respect of which Indemnitee is granted rights of indemnification or advancement hereunder and of any proceeding commenced by Indemnitee pursuant to Section 12 of this Agreement relating thereto.  This Agreement shall be binding upon the Company and its successors and assigns and shall inure to the benefit of Indemnitee and his or her heirs, executors and administrators.  The Company shall require and cause any successor (whether direct or indirect by purchase, merger, consolidation or otherwise) to all, substantially all or a substantial part, of the business and/or assets of the Company, by written agreement in form and substance satisfactory to Indemnitee, expressly to assume and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform if no such succession had taken place.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Section 15.      </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Severability</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  If any provision or provisions of this Agreement shall be held to be invalid, illegal or unenforceable for any reason whatsoever: (a) the validity, legality and enforceability of the remaining provisions of this Agreement (including, without limitation, each portion of any section of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall not in any way be affected or impaired thereby and shall remain enforceable to the fullest extent permitted by law; (b) such provision or provisions shall be deemed reformed to the extent necessary to conform to applicable law and to give the maximum effect to the intent of the parties hereto; and (c) to the fullest extent possible, the provisions of this Agreement (including, without limitation, each portion of any section of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall be construed so as to give effect to the intent manifested thereby.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Section 16.      </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Enforcement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)        The Company expressly confirms and agrees that it has entered into this Agreement and assumed the obligations imposed on it hereby in order to induce Indemnitee to serve or continue to serve as [a director and] an officer of the Company, and the Company acknowledges that Indemnitee is relying upon this Agreement in serving as [a director and] an officer of the Company.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b)       This Agreement constitutes the entire agreement between the parties hereto with respect to the subject matter hereof and supersedes all prior agreements and understandings, oral, written and implied, between the parties hereto with respect to the subject matter hereof; </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">provided</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">however</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">, that this Agreement is a supplement to and in furtherance of the Charter, the Bylaws and applicable law, and shall not be deemed a substitute therefor, nor to diminish or abrogate any rights of Indemnitee thereunder.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">12</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/105005427.2</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Section 17.      </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Modification and Waiver</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  No supplement, modification or amendment, or waiver of any provision, of this Agreement shall be binding unless executed in writing by the parties thereto.  No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provisions of this Agreement nor shall any waiver constitute a continuing waiver. No supplement, modification or amendment of this Agreement or of any provision hereof shall limit or restrict any right of Indemnitee under this Agreement in respect of any action taken or omitted by such Indemnitee prior to such supplement, modification or amendment.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Section 18.      </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Notice by Indemnitee</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Indemnitee agrees promptly to notify the Company in writing upon being served with any summons, citation, subpoena, complaint, indictment, information or other document relating to any Proceeding or matter which may be subject to indemnification, reimbursement or advancement as provided hereunder.  The failure of Indemnitee to so notify the Company or any delay in notification shall not relieve the Company of any obligation which it may have to Indemnitee under this Agreement or otherwise. unless, and then only to the extent that, the Company did not otherwise learn of the Proceeding and such delay is materially prejudicial to the Company&#x2019;s ability to defend such Proceeding or matter; and, provided, further, that notice will be deemed to have been given without any action on the part of Indemnitee in the event the Company is a party to the same Proceeding.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Section 19.      </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Notices</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  All notices, requests, demands and other communications under this Agreement shall be in writing and shall be deemed to have been duly given if (i) delivered by hand and receipted for by the party to whom said notice or other communication shall have been directed, (ii) mailed by certified or registered mail with postage prepaid, on the third business day after the date on which it is so mailed, (iii) mailed by reputable overnight courier and receipted for by the party to whom said notice or other communication shall have been directed or (iv) sent by facsimile transmission, with receipt of oral confirmation that such transmission has been received:</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(a)        If to Indemnitee, at such address as Indemnitee shall provide to the Company.</font></p>
  <p style="text-indent:13.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">(b)       If to the Company to:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Adicet Bio, Inc.</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">200 Clarendon Street, Floor 6</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Boston, MA 02116</font></p>
  <p style="text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Attention: President and CEO</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">or to any other address as may have been furnished to Indemnitee by the Company.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Section 20.      </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Contribution</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  To the fullest extent permissible under applicable law, if the indemnification provided for in this Agreement is unavailable to Indemnitee for any reason whatsoever, the Company, in lieu of indemnifying Indemnitee, shall contribute to the amount incurred by Indemnitee, whether for judgments, fines, penalties, excise taxes, amounts paid or to be paid in settlement and/or for Expenses, in connection with any Proceeding in such proportion as is deemed fair and reasonable in light of all of the circumstances in order to reflect (i) the relative benefits received by the Company and Indemnitee in connection with the event(s) and/or transaction(s) giving rise to such Proceeding; and/or (ii) the relative fault of the Company (and its directors, officers, employees and agents) and Indemnitee in connection with such event(s) and/or transactions.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Section 21.      </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Internal Revenue Code Section 409A</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  The Company intends for this Agreement to comply with the Indemnification exception under Section 1.409A-1(b)(10) of the regulations promulgated under the Internal Revenue Code of 1986, as amended (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Code</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), which provides that indemnification of, or the purchase of an insurance policy providing for payments of, all or part of the expenses incurred or damages paid or payable</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">13</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/105005427.2</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">by Indemnitee with respect to a bona fide claim against Indemnitee or the Company do not provide for a deferral of compensation, subject to Section 409A of the Code, where such claim is based on actions or failures to act by Indemnitee in his or her capacity as a service provider of the Company.  The parties intend that this Agreement be interpreted and construed with such intent.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Section 22.      </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Applicable Law and Consent to Jurisdiction</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  This Agreement and the legal relations among the parties shall be governed by, and construed and enforced in accordance with, the laws of the State of Delaware, without regard to its conflict of laws rules. Except with respect to any arbitration commenced by Indemnitee pursuant to Section 12(a) of this Agreement, the Company and Indemnitee hereby irrevocably and unconditionally (i) agree that any action or proceeding arising out of or in connection with this Agreement shall be brought only in the Delaware Court, and not in any other state or federal court in the United States of America or any court in any other country, (ii) consent to submit to the exclusive jurisdiction of the Delaware Court for purposes of any action or proceeding arising out of or in connection with this Agreement, (iii) consent to service of process at the address set forth in Section 19 of this Agreement with the same legal force and validity as if served upon such party personally within the State of Delaware, (iv) waive any objection to the laying of venue of any such action or proceeding in the Delaware Court, and (v) waive, and agree not to plead or to make, any claim that any such action or proceeding brought in the Delaware Court has been brought in an improper or inconvenient forum.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Section 23.      </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Headings</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  The headings of the paragraphs of this Agreement are inserted for convenience only and shall not be deemed to constitute part of this Agreement or to affect the construction thereof.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Section 24.      </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Identical Counterparts</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  This Agreement may be executed in one or more counterparts, each of which shall for all purposes be deemed to be an original but all of which together shall constitute one and the same Agreement.  Only one such counterpart signed by the party against whom enforceability is sought needs to be produced to evidence the existence of this Agreement.</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Section 25.      </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Monetary Damages Insufficient/Specific Enforcement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">. The Company and Indemnitee agree that a monetary remedy for breach of this Agreement may be inadequate, impracticable and difficult of proof, and further agree that such breach may cause Indemnitee irreparable harm. Accordingly, the parties hereto agree that Indemnitee may enforce this Agreement by seeking injunctive relief and/or specific performance hereof, without any necessity of showing actual damage or irreparable harm (having agreed that actual and irreparable harm will result in not forcing the Company to specifically perform its obligations pursuant to this Agreement) and that by seeking injunctive relief and/or specific performance, Indemnitee shall not be precluded from seeking or obtaining any other relief to which he may be entitled. The Company and Indemnitee further agree that Indemnitee shall be entitled to such specific performance and injunctive relief, including temporary restraining orders, preliminary injunctions and permanent injunctions, without the necessity of posting bonds or other undertaking in connection therewith. The Company acknowledges that in the absence of a waiver, a bond or undertaking may be required of Indemnitee by the Court, and the Company hereby waives any such requirement of a bond or undertaking.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[Remainder of Page Intentionally Left Blank]</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">14</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/105005427.2</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">IN WITNESS WHEREOF, the parties have caused this Agreement to be signed as of the day and year first above written.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:50.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:14.033%;"></td>
    <td style="width:85.967%;"></td>
   </tr>
   <tr style="height:12.0pt;">
    <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">ADICET BIO, INC.</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">By:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Name:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Title:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:50.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:14.0%;"></td>
    <td style="width:86.0%;"></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">[Name of Indemnitee]</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/105005427.2</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.18
<SEQUENCE>8
<FILENAME>acet-ex10_18.htm
<DESCRIPTION>EX-10.18
<TEXT>
<html>
 <head>
  <title>EX-10.18</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Exhibit 10.18</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">ADICET BIO, INC.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> AMENDED AND RESTATED NON-EMPLOYEE DIRECTOR COMPENSATION POLICY</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The purpose of this Amended and Restated Non-Employee Director Compensation Policy (the &#x201c;Policy&#x201d;) of Adicet Bio, Inc. (the &#x201c;Company&#x201d;), is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officers of the Company or its subsidiaries.  In furtherance of the purpose stated above, all non-employee directors shall be paid compensation for services provided to the Company asset forth below:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Cash Retainers</font></p>
  <p style="margin-left:1.733%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Annual Retainer for Board Membership</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">:   $35,000 for general availability and participation in meetings and conference calls of our Board of Directors (the &#x201c;Board&#x201d;).  No additional compensation will be paid for attending individual meetings of the Board.</font></p>
  <p style="margin-left:1.733%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Additional Annual Retainer for Non-Executive Chair of the Board</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">:  $30,000</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="margin-left:1.733%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Additional Annual Retainers for Committee Membership</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:97.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:81.342%;"></td>
    <td style="width:1.034%;"></td>
    <td style="width:17.624%;"></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;padding-left:0.030in;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Audit Committee Chair:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;padding-left:0.030in;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;padding-left:0.030in;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">$15,000</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;padding-left:0.030in;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;padding-left:0.030in;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;padding-left:0.030in;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;padding-left:0.030in;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Audit Committee member:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;padding-left:0.030in;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;padding-left:0.030in;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">$7,500</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;padding-left:0.030in;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;padding-left:0.030in;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;padding-left:0.030in;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;padding-left:0.030in;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Compensation Committee Chair:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;padding-left:0.030in;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;padding-left:0.030in;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">$10,000</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;padding-left:0.030in;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;padding-left:0.030in;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;padding-left:0.030in;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;padding-left:0.030in;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Compensation Committee member:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;padding-left:0.030in;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;padding-left:0.030in;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">$5,000</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;padding-left:0.030in;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;padding-left:0.030in;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;padding-left:0.030in;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;padding-left:0.030in;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Nominatingand Corporate Governance Committee Chair:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;padding-left:0.030in;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;padding-left:0.030in;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">$8,000</font></p></td>
   </tr>
   <tr>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;padding-left:0.030in;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;padding-left:0.030in;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;padding-left:0.030in;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
   </tr>
   <tr style="height:12.0pt;">
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;padding-left:0.030in;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Nominatingand Corporate Governance Committee member:</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;padding-left:0.030in;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);padding-top:0.010in;word-break:break-word;padding-left:0.030in;vertical-align:top;padding-right:0.010in;"><p style="text-indent:0.0pt;font-size:12.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">$4,000</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:1.733%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">No additional compensation for attending individual committee meetings.  All cash retainers will be paid quarterly, in arrears, or upon the earlier resignation or removal of the non-employee directors, pro-rated based on the number of actual days served by the director during such calendar quarter.  Chair and committee member retainers are in addition to retainers for members of the Board.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/114637232.2</font></p>
  <hr style="page-break-after:always;">
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Equity Retainers</font></p>
  <p style="margin-left:1.733%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Initial Award</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">: An initial, one-time equity award (the &#x201c;Initial Award&#x201d;) of 37,000 options to each new non-employee director upon his or her election to the Board, which shall vest in thirty-six (36) equal monthly beginning on the date of grant, however, that all vesting shall cease if the director resigns from the Board or otherwise ceases to serve as a director of the Company. This Initial Award applies only to non-employee directors who are first elected to the Board subsequent to the Company&#x2019;s initial public offering.  If the Initial Award is in the form of a stock option, such stock option shall have a per share exercise price equal to the Fair Market Value (as defined in the Company&#x2019;s 2018 Stock Option and Incentive Plan) of the Company&#x2019;s common stock on the date of grant.</font></p>
  <p style="margin-left:1.733%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Annual Award</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">:  On each date of the Company&#x2019;s Annual Meeting of Stockholders following the completion of the Company&#x2019;s initial public offering (the &#x201c;Annual Meeting&#x201d;), each continuing non-employee member of the Board, other than a director receiving an Initial Award, will receive an annual equity award (the &#x201c;Annual Award&#x201d;) of 18,500 options, which shall vest in full upon the earlier to occur of the first anniversary of the date of grant or the date of the next Annual Meeting; provided, however, that all vesting shall cease if the director resigns from the Board or otherwise ceases to serve as a director, unless the Board determines that the circumstances warrant continuation of vesting. If the Annual Award is in the form of a stock option, such stock option shall have a per share exercise price equal to the Fair Market Value (as defined in the Company&#x2019;s 2018 Stock Option and Incentive Plan) of the Company&#x2019;s common stock on the date of grant.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Expenses</font></p>
  <p style="margin-left:1.733%;text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The Company will reimburse all reasonable out-of-pocket expenses incurred by non-employee directors in attending meetings of the Board or any Committee.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Adopted by the Board on December 21, 2017, as amended by the Board on April 30, 2021 and subsequently on January 27, 2022.</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">2</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">ACTIVE/114637232.2</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.19
<SEQUENCE>9
<FILENAME>acet-ex10_19.htm
<DESCRIPTION>EX-10.19
<TEXT>
<html>
 <head>
  <title>EX-10.19</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;">Exhibit 10.19</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:14.0pt;font-family:Times New Roman;">ADICET BIO, INC.<br>AMENDED AND RESTATED</font><font style="text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:14.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);text-transform:uppercase;color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:14.0pt;font-family:Times New Roman;">SENIOR EXECUTIVE CASH INCENTIVE BONUS PLAN</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Purpose</font></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">This Senior Executive Cash Incentive Bonus Plan (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Incentive</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Plan</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) is intended to provide an incentive for superior work and to motivate eligible executives of Adicet Bio, Inc. (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Company</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) and its subsidiaries toward even higher achievement and business results, to tie their goals and interests to those of the Company and its stockholders and to enable the Company to attract and retain highly qualified executives.  The Incentive Plan is for the benefit of Covered Executives (as defined below).</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Covered Executives</font></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">From time to time, the Compensation Committee of the Board of Directors of the Company (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Compensation</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Committee</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) may select certain key executives (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Covered</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Executives</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;) to be eligible to receive bonuses hereunder.  Participation in this Plan does not change the &#x201c;at will&#x201d; nature of a Covered Executive&#x2019;s employment with the Company.</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Administration</font></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The Compensation Committee shall have the sole discretion and authority to administer and interpret the Incentive Plan.</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Bonus Determinations</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">a.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Corporate Performance Goals</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  A Covered Executive may receive a bonus payment under the Incentive Plan based upon the attainment of one or more performance objectives that are established by the Compensation Committee in its sole discretion and relate to financial and/or operational metrics with respect to the Company or any of its subsidiaries (the &#x201c;</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;font-style:italic;">Corporate Performance Goals</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">&#x201d;), including the following:  cash flow (including, but not limited to, operating cash flow and free cash flow); research and development, publication, clinical and/or regulatory milestones; revenue; corporate revenue; earnings before interest, taxes, depreciation and amortization; net income (loss) (either before or after interest, taxes, depreciation and/or amortization); changes in the market price of the Company&#x2019;s common stock; economic value-added; acquisitions or strategic transactions, including licenses, collaborations, joint ventures or promotion arrangements; operating income (loss); return on capital, assets, equity, or investment; total stockholder returns; coverage decisions; return on sales; gross or net profit levels; productivity; expense efficiency; margins; operating efficiency; working capital; earnings (loss) per share of the Company&#x2019;s common stock; sales or market shares; number of prescriptions or prescribing physicians; revenue; corporate revenue; operating income and/or net annual recurring revenue; or any other performance goal selected by the Compensation Committee, any of which may be (A) measured in absolute terms or compared to any incremental increase, (B) measured in terms of growth, (C) compared to another company or companies or to results of a peer group, (D) measured against the market as a whole and/or as compared to applicable market indices and/or (E) measured on a pre-tax or post-tax basis (if applicable).  Further, any Corporate Performance Goals may be used to measure the performance of the Company as a whole or a business unit or other segment of the Company, or one or more product lines or specific markets.  The Corporate Performance Goals may differ from Covered Executive to Covered Executive and from performance period to performance period.</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:12.0pt;font-family:Times New Roman;"> </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">b.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Calculation of Corporate Performance Goals</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  At the beginning of each applicable performance period, the Compensation Committee will determine whether any significant element(s) will be included in or </font></div></div>
  <hr style="page-break-after:always;">
  <div style="font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">excluded from the calculation of any Corporate Performance Goal with respect to any Covered Executive.  In all other respects, Corporate Performance Goals will be calculated in accordance with the Company&#x2019;s financial statements, generally accepted accounting principles, or under a methodology established by the Compensation Committee at the beginning of the performance period and which is consistently applied with respect to a Corporate Performance Goal in the relevant performance period.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">c.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Target; Minimum; Maximum</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Each Corporate Performance Goal shall have a &#x201c;target&#x201d; (100 percent attainment of the Corporate Performance Goal) and may also have a &#x201c;minimum&#x201d; hurdle and/or a &#x201c;maximum&#x201d; amount.  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">d.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Bonus Requirements; Individual Goals</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Except as otherwise set forth in this Section 4(d):  (i) any bonuses paid to Covered Executives under the Incentive Plan shall be based upon objectively determinable bonus formulas that tie such bonuses to one or more performance targets relating to the Corporate Performance Goals, (ii) bonus formulas for Covered Executives shall be adopted in each performance period by the Compensation Committee and communicated to each Covered Executive at the beginning of each performance period and (iii) no bonuses shall be paid to Covered Executives unless and until the Compensation Committee makes a determination with respect to the attainment of the performance targets relating to the Corporate Performance Goals.  Notwithstanding the foregoing, the Compensation Committee may adjust bonuses payable under the Incentive Plan based on achievement of one or more individual performance objectives or pay bonuses (including, without limitation, discretionary bonuses) to Covered Executives under the Incentive Plan based on individual performance goals and/or upon such other terms and conditions as the Compensation Committee may in its discretion determine.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">e.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Individual Target Bonuses</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  The Compensation Committee shall establish a target bonus opportunity for each Covered Executive for each performance period.  For each Covered Executive, the Compensation Committee shall have the authority to apportion the target award so that a portion of the target award shall be tied to attainment of Corporate Performance Goals and a portion of the target award shall be tied to attainment of individual performance objectives. </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">f.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Employment Requirement</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">.  Subject to any additional terms contained in a written agreement between the Covered Executive and the Company, the payment of a bonus to a Covered Executive with respect to a performance period shall be conditioned upon the Covered Executive&#x2019;s employment by the Company on the bonus payment date.  If a Covered Executive was not employed for an entire performance period, the Compensation Committee may pro rate the bonus based on the number of days employed during such period.</font></div></div>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Timing of Payment</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">a.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">With respect to Corporate Performance Goals established and measured on a basis more frequently than annually (e.g., quarterly or semi-annually), the Corporate Performance Goals will be measured at the end of each performance period after the Company&#x2019;s financial reports with respect to such period(s) have been published.  If the Corporate Performance Goals and/or individual goals for such period are met, payments will be made as soon as practicable following the end of such period, but not later than 74 days after the end of the fiscal year in which such performance period ends.</font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">b.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">With respect to Corporate Performance Goals established and measured on an annual or multi-year basis, Corporate Performance Goals will be measured as of the end of each such performance period (e.g., the end of each fiscal year) after the Company&#x2019;s financial reports with respect to such period(s) have been published.  If the Corporate Performance Goals and/or individual goals for any such period are met, bonus payments will be made as soon as practicable, but not later than 74 days, after the end of the relevant fiscal year.  </font></div></div>
  <div style="text-indent:6.667%;font-size:0;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;text-indent:0;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">c.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">For the avoidance of doubt, bonuses earned at any time in a fiscal year must be paid no later than 74 days after the last day of such fiscal year.</font></div></div>
  <hr style="page-break-after:always;">
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:12.0pt;min-width:6.667%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;display:inline-flex;font-size:12.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:6.667%;">6.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Amendment and Termination</font></div></div>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">The Company reserves the right to amend or terminate the Incentive Plan at any time in its sole discretion.</font></p>
  <p style="text-indent:-7.143%;padding-left:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">7.	</font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;text-decoration:underline;font-size:12.0pt;font-family:Times New Roman;">Company Recoupment Rights</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">A Covered Executive&#x2019;s rights with respect to any award granted pursuant to the Incentive Plan shall in all events be subject to reduction, cancellation, forfeiture or recoupment to the extent necessary to comply with (i) any right that the Company may have under any Company clawback, forfeiture or recoupment policy as in effect from time to time or other agreement or arrangement with a Covered Executive, or (ii) applicable law.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:12.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;">Adopted by the Board on December 21, 2017, as amended on January 27, 2022.</font><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>10
<FILENAME>acet-ex23_1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html>
 <head>
  <title>EX-23.1</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:36.0pt;line-height:13.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Arial;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:10.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 23.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Consent of Independent Registered Public Accounting Firm</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">We consent to the incorporation by reference in the registration statements (Nos. 333-258763, 333-254192, 333-250033, 333-249275, 333-237123, 333-230363, and 333-222746) on Form S-8 and (Nos. 333-256088 and 333-254193) on Form S-3 of our report dated March 15, 2022, with respect to the consolidated financial statements of Adicet Bio, Inc. <br><br></font><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">/s/ KPMG LLP</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Boston, Massachusetts</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">March 15, 2022</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </font>&#160;</p>
  <p style="text-indent:-5.337%;padding-left:5.067%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>11
<FILENAME>acet-ex31_1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html>
 <head>
  <title>EX-31.1</title>
 </head>
 <body>
  <p style="margin-left:66.667%;text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Exhibit 31.1</font></p>
  <p style="margin-left:66.667%;text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO RULE 13a-14(a) / RULE 15d-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">I, Chen Schor, certify that:</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">I have reviewed this Annual Report on Form 10-K for the fiscal year ended December 31, 2021 of Adicet Bio, Inc. (the &#x201c;registrant&#x201d;);</font></div></div>
  <p style="margin-left:3.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Calibri;">&#160;</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Calibri;">&#160;</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Calibri;">&#160;</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Calibri;">&#160;</font></p>
  <div style="margin-left:10.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;">a.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Calibri;">&#160;</font></p>
  <div style="margin-left:10.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;">b.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Calibri;">&#160;</font></p>
  <div style="margin-left:10.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;">c.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Calibri;">&#160;</font></p>
  <div style="margin-left:10.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;">d.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The registrant&#x2019;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Calibri;">&#160;</font></p>
  <div style="margin-left:10.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;">a.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></div></div>
  <p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Calibri;">&#160;</font></p>
  <div style="margin-left:10.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;">b.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Calibri;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.0%;"></td>
    <td style="width:50.0%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">/s/ Chen Schor</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Chen Schor</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">President and Chief Executive Officer</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Calibri;">&#160;</font></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Dated: March 15, 2022</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>12
<FILENAME>acet-ex31_2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html>
 <head>
  <title>EX-31.2</title>
 </head>
 <body>
  <p style="margin-left:66.667%;text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Exhibit 31.2</font></p>
  <p style="margin-left:66.667%;text-indent:20.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO RULE 13a-14(a) / RULE 15d-14(a) OF THE SECURITIES EXCHANGE ACT OF 1934, AS AMENDED</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">I, Nick Harvey, certify that:</font></p>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">1.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">I have reviewed this Annual Report on Form 10-K for the fiscal year ended December 31, 2021 of Adicet Bio, Inc. (the &#x201c;registrant&#x201d;);</font></div></div>
  <p style="margin-left:3.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Calibri;">&#160;</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">2.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Calibri;">&#160;</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">3.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Calibri;">&#160;</font></p>
  <div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">4.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The registrant&#x2019;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:8.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Calibri;">&#160;</font></p>
  <div style="margin-left:10.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;">a.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div></div>
  <p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Calibri;">&#160;</font></p>
  <div style="margin-left:10.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;">b.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Calibri;">&#160;</font></p>
  <div style="margin-left:10.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;">c.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Evaluated the effectiveness of the registrant&#x2019;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Calibri;">&#160;</font></p>
  <div style="margin-left:10.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;">d.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Disclosed in this report any change in the registrant&#x2019;s internal control over financial reporting that occurred during the registrant&#x2019;s most recent fiscal quarter (the registrant&#x2019;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#x2019;s internal control over financial reporting; and</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">5.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The registrant&#x2019;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#x2019;s auditors and the audit committee of the registrant&#x2019;s board of directors (or persons performing the equivalent functions):</font></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Calibri;">&#160;</font></p>
  <div style="margin-left:10.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;">a.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">all significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#x2019;s ability to record, process, summarize and report financial information; and</font></div></div>
  <p style="margin-left:13.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Calibri;">&#160;</font></p>
  <div style="margin-left:10.0%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.7033333333333336%;">b.</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#x2019;s internal control over financial reporting.</font></div></div>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
   <tr style="visibility:collapse;">
    <td style="width:50.0%;"></td>
    <td style="width:50.0%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">/s/ Nick Harvey</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Nick Harvey</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Chief Financial Officer</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p></td>
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">(Principal Financial and Accounting Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.2410416666666666;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Dated: March 15, 2022</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>13
<FILENAME>acet-ex32_1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html>
 <head>
  <title>EX-32.1</title>
 </head>
 <body>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Exhibit 32.1</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">CERTIFICATIONS OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="text-indent:6.667%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the Annual Report on Form 10-K of Adicet Bio, Inc. (the &#x201c;Company&#x201d;) for the fiscal year ended December 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the &#x201c;Report&#x201d;), the undersigned hereby certify, pursuant to 18 U.S.C. Section 1350, that, to the best of their knowledge:</font></p>
  <p style="text-indent:5.933%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(1)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended; and</font></div></div>
  <p style="margin-left:6.667%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:12.0pt;font-family:Calibri;">&#160;</font></p>
  <div style="margin-left:3.333%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(2)</font><div style="display:inline;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div></div>
  <p style="text-indent:5.933%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:40.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">/s/ Chen Schor</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Chen Schor</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">President and Chief Executive Officer</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">(Principal Executive Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Dated: March 15, 2022</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <p style="margin-left:46.667%;text-indent:12.5%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</font></p>
  <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:40.0%;border-collapse:separate;">
   <tr style="visibility:collapse;">
    <td style="width:100.0%;"></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;border-bottom:0.500pt solid;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">/s/ Nick Harvey</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Nick Harvey</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Chief Financial Officer</font></p></td>
   </tr>
   <tr style="height:9.0pt;">
    <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">(Principal Financial and Accounting Officer)</font></p></td>
   </tr>
  </table>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Dated:  March 15, 2022</font></p>
  <p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><font style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</font></p>
  <hr style="page-break-after:always;">
 </body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>img102984888_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img102984888_0.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &W Z(# 2(  A$! Q$!_\0
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M3_O\O^-%@-'S9/[[?G1YLG]]OSK._MK2_P#H)6G_ '^7_&C^VM+_ .@E:?\
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M '^7_&BP&CYLG]]OSH\V3^^WYUG?VUI?_02M/^_R_P"-']M:7_T$K3_O\O\
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M\_ZX2?\ H)J6W_X]8?\ KFO\J?0"3)]:,GUHHI &3ZT9/K110 9/K1D^M%%
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M/K1D^M%% !D^M&3ZT44 &3ZT9/K110 9/K1D^M%% "J3N'/>J&BD_P!AV/\
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M -?;?^@K5VJ6G??O_P#K[;_T%:8%VBBBD 4444 %%%% !1110 4444 %%%%
M%;4?^07>?]<)/_034MO_ ,>L/_7-?Y5%J/\ R"[S_KA)_P"@FE2>&WLX&GFC
MB4HH!D<*#Q[T^@%BBFQRQS1B2*1)$/1D8,#^(HWH9#&&7>!DKGD#UQ2 =113
M'FBC)#RHI W$,P&!Z_2@!]%(2 "20 .I-"L&4,I!4\@@Y!H 6BBB@ HHHH *
M*** "BBB@ HHHH HZS_R"+CZ+_Z$*OM]X_6J&L_\@BX^B_\ H0J^WWC]:.@"
M4444 %%%% !1110 4444 4M8_P"0'J'_ %[2?^@FK@Z"J>L?\@/4/^O:3_T$
MU<'04= %HHHH **** "BBB@ HHHH CN/^/6;_KFW\JBT[_D%V?\ UPC_ /01
M4MQ_QZS?]<V_E46G?\@NS_ZX1_\ H(HZ 6:*** "BBB@ HHHH **** %7[P^
MM4-%_P"0'8_]<%_E5]?O#ZU0T7_D!V/_ %P7^5'0"]1110 4444 %%%% !11
M10 =ZHZ1_P @X?\ 7:;_ -&O5[O5'2/^0</^NTW_ *->CH!>HHHH **** "B
MBB@ HHHH *I:9]RZ_P"ON;_T*KM4M,^Y=?\ 7W-_Z%0!=HHHH **C%Q TQA6
M:(R@9,8<;A^'6I* "BBB@ HHHH **0.I<H&4L!DKGD#Z4%U#A"R[B,A<\D?2
M@!:*** *4'_(:OO^N,'\Y*NU2@_Y#5]_UQ@_G)5VA@%%%% !1110 4444 %5
MM1_Y!=Y_UPD_]!-6:K:C_P @N\_ZX2?^@FA 2V__ !ZP_P#7-?Y5)67<:M'I
MZ6$'V:YN9KE,1QP*I/RJ"2=S 4D'B/2Y<K+<I:3B0Q&"Z=4D#C'&,\]1T)ZT
M[,#5HJI%JFGSM.L-];2&#_7!)5/E_P"]SQ^-0CQ!HQA,PU:Q\H$ O]H3 )S@
M9S['\J+,#1HJDNL:8]R;==1M#.%WF,3+NVXSG&<XQ48\0:*PR-7L"-P7BX3J
M>@Z]Z+,#1HHHI %%%% !1110 52T[[]__P!?;?\ H*U=K-M96A349%AEF*W3
M8CBQN;Y4Z9('ZTP-*BL2U\4V5PDLLT-Q96\4C1//>&.- ZG!7.\\_A5[^V-,
MW0+_ &C:;K@9A'G+F0>J\\_A1RL"[15&+6=+G$IAU*SD$2EI"DZG8!P2>>!4
M)\1:5]KL;:.]@E:^+"%HY%96VC)YS^%%F!J4444@"BBB@ HHHH **** *VH_
M\@N\_P"N$G_H)K UZ.26Z\.)%;VT[^8^([DX0_NN^%;^5;^H_P#(+O/^N$G_
M *":@EU&VL(]/CN"0;G$:-@8!";B2>PP#5)V YB2UETG54CU&_73K"],L\GV
M.4Q11R *%0/P1QENV36.+[48?MFH>?,-0ETZW^:21DS'YKJTFW!QA<'('&2>
M]>@Q:KI=Y%*T-_9SQPC=*5E5@@ZY//%5K3Q%I=_=M!:RK,5D$/FHR%"2F_Y3
MGYACTJU)]@.7MI;VZUJPLO[;,EC++)_QY7TDAP(\[3*0"><'C..1GM69]LFD
MMKB_FO)?MC:441FE/S[)V7..A( &>.^>]>AIJ^D^1+,FH67DP-MD=9EVQGT)
MSP:J3^)=%BGMH1=6\IGBDEB:.1"I5.N"3C_]1]*%-WV%8Y+5-;>2^'V>]N L
ML\]O-#-=9.T1OQY0&$&1P3@GWKM/#?\ R+&E?]>D7_H(J9=1TYKI+?[3:BZD
M0.(3(OF$8SG&<FEM-4TZ^D:*SOK6X=!N*0RJQ ]< ]*EO2U@\RY1114#"BBB
M@ HHHH **** "BBB@"CK/_((N/HO_H0J^WWC]:H:S_R"+CZ+_P"A"K[?>/UH
MZ )1534]1BTJQ>[F21T5E7;$ 6)9@H R0.I'>J@\06RM-'<V]S:3Q1^;Y5P$
M4LF0-RG<5(R1GGO[TTFP-:BJJ:G82W4EJE[;-<1#,D0E4N@]QG(J,:UI1M'N
MQJ5F;9&V-,)UV*WH3G&:+,"]15==0LW1G6[@*I&)682# 0YPQ]N#S[4T:G8-
M=?91>VQN-N_RA*N[;C.<9SC%*S M452M=7TR^\S[)J%I<>4NZ3RIE;8/4X/
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MXM'CM8TN?/$75I<EI<#"\8W#DX'/--\+WLU]XFM3/<&<PB]B1VD,AV!TP-Q
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M!Z]:<?#%]]A:-;.,2?V MDN&7_7;LE>OZ]*ZS?JO_/O8_P#?]_\ XBC?JO\
MS[V/_?\ ?_XBESNUA];_ -;W+%LC1VD*/]]8U5N<\@<U+5+?JO\ S[V/_?\
M?_XBC?JO_/O8_P#?]_\ XBI>H+30NT52WZK_ ,^]C_W_ '_^(HWZK_S[V/\
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M5_Y]['_O^_\ \11OU7_GWL?^_P"__P 11SO^O2PK%VBJ6_5?^?>Q_P"_[_\
MQ%&_5?\ GWL?^_[_ /Q%9V&7:*I;]5_Y]['_ +_O_P#$4;]5_P"?>Q_[_O\
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M8W%OYUU,M[%)-+<R[F$:;L 9QP"<X%;&_5?^?>Q_[_O_ /$4;]5_Y]['_O\
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M^]C_ -_W_P#B*IZ<^I[+G;!9'_2I<YG<<[N?X*+ ;-%4M^J_\^]C_P!_W_\
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M6_5?^?>Q_P"_[_\ Q%&_5?\ GWL?^_[_ /Q%/G?]?>*VEB[15+?JO_/O8_\
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M87/;L'THP?2O$?[;U7_H)77_ ']-']MZK_T$KK_OZ:/9L+GMV#Z48/I7B/\
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M_09N_P#ONC_A+O$7_09N_P#ONCZ['L'^K%?^=?B?15%?.O\ PEWB+_H,W?\
MWW1_PEWB+_H,W?\ WW1]=CV#_5BO_.OQ/HJBOG7_ (2[Q%_T&;O_ +[H_P"$
MN\1?]!F[_P"^Z/KL>P?ZL5_YU^)]%45\Z_\ "7>(O^@S=_\ ?='_  EWB+_H
M,W?_ 'W1]=CV#_5BO_.OQ/HJBOG7_A+O$7_09N_^^Z/^$N\1?]!F[_[[H^NQ
M[!_JQ7_G7XGT517SK_PEWB+_ *#-W_WW1_PEWB+_ *#-W_WW1]=CV#_5BO\
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M15',%%%% %*#_D-7W_7&#^<E7:I0?\AJ^_ZXP?SDJ[0P"BBB@ HHHH ****
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MBC"JHP /2A$2.-8XU"HHPJJ, #TIU>M2I*FK(_/,PS"IC:G//;HNP4445J<
M4444 %%%% !1110 4444 %%%% !5+3/N77_7W-_Z%5VJ6F?<NO\ K[F_]"H
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M?_OTO^-'_"M;7_H)S_\ ?I?\:[BBCGD%CA_^%:VO_03G_P"_2_XT?\*UM?\
MH)S_ /?I?\:[BBCGD%CA_P#A6MK_ -!.?_OTO^-'_"M;7_H)S_\ ?I?\:[BB
MCGD%CA_^%:VO_03G_P"_2_XT?\*UM?\ H)S_ /?I?\:[BBCGD%CA_P#A6MK_
M -!.?_OTO^-'_"M;7_H)S_\ ?I?\:[BBCGD%CA_^%:VO_03G_P"_2_XT?\*U
MM?\ H)S_ /?I?\:[BBCGD%CA_P#A6MK_ -!.?_OTO^-'_"M;7_H)S_\ ?I?\
M:[BBCGD%CA_^%:VO_03G_P"_2_XT?\*UM?\ H)S_ /?I?\:[BBCGD%CA_P#A
M6MK_ -!.?_OTO^-'_"M;7_H)S_\ ?I?\:[BBCGD%CA_^%:VO_03G_P"_2_XT
M?\*UM?\ H)S_ /?I?\:[BBCGD%CA_P#A6MK_ -!.?_OTO^-'_"M;7_H)S_\
M?I?\:[BBCGD%CA_^%:VO_03G_P"_2_XT?\*UM?\ H)S_ /?I?\:[BBCGD%CA
M_P#A6MK_ -!.?_OTO^-'_"M;7_H)S_\ ?I?\:[BBCGD%CA_^%:VO_03G_P"_
M2_XT?\*UM?\ H)S_ /?I?\:[BBCGD%CA_P#A6MK_ -!.?_OTO^-'_"M;7_H)
MS_\ ?I?\:[BBCGD%CA_^%:VO_03G_P"_2_XT?\*UM?\ H)S_ /?I?\:[BBCG
MD%CA_P#A6MK_ -!.?_OTO^-'_"M;7_H)S_\ ?I?\:[BBCGD%CA_^%:VO_03G
M_P"_2_XT?\*UM?\ H)S_ /?I?\:[BBCGD%CA_P#A6MK_ -!.?_OTO^-'_"M;
M7_H)S_\ ?I?\:[BBCGD%CA_^%:VO_03G_P"_2_XT?\*UM?\ H)S_ /?I?\:[
MBBCGD%CA_P#A6MK_ -!.?_OTO^-'_"M+3_H)S_\ ?I?\:[BBCGD%C@M4^%UI
MJEVMP^JW$96)(L+$IX50,]?:J?\ PIVQ_P"@S=?]^5_QKTFBN>5"G)W:/1IY
MMC:<%"%2R6BT7^1YM_PIVQ_Z#-U_WY7_ !H_X4[8_P#09NO^_*_XUZ312^K4
MNQ?]M8__ )^?@O\ (\V_X4[8_P#09NO^_*_XT?\ "G;'_H,W7_?E?\:])HH^
MK4NP?VUC_P#GY^"_R/-O^%.V/_09NO\ ORO^-'_"G;'_ *#-U_WY7_&O2:*/
MJU+L']M8_P#Y^?@O\CS;_A3MC_T&;K_ORO\ C1_PIVQ_Z#-U_P!^5_QKTFBC
MZM2[!_;6/_Y^?@O\CS;_ (4[8_\ 09NO^_*_XT?\*=L?^@S=?]^5_P :])HH
M^K4NP?VUC_\ GY^"_P CS;_A3MC_ -!FZ_[\K_C1_P *=L?^@S=?]^5_QKTF
MBCZM2[!_;6/_ .?GX+_(\V_X4[8_]!FZ_P"_*_XT?\*=L?\ H,W7_?E?\:])
MHH^K4NP?VUC_ /GY^"_R/-O^%.V/_09NO^_*_P"-'_"G;'_H,W7_ 'Y7_&O2
M:*/JU+L']M8__GY^"_R/-O\ A3MC_P!!FZ_[\K_C1_PIVQ_Z#-U_WY7_ !KT
MFBCZM2[!_;6/_P"?GX+_ "/-O^%.V/\ T&;K_ORO^-'_  IVQ_Z#-U_WY7_&
MO2:*/JU+L']M8_\ Y^?@O\CS;_A3MC_T&;K_ +\K_C1_PIVQ_P"@S=?]^5_Q
MKTFBCZM2[!_;6/\ ^?GX+_(\V_X4[8_]!FZ_[\K_ (T?\*=L?^@S=?\ ?E?\
M:])HH^K4NP?VUC_^?GX+_(\V_P"%.V/_ $&;K_ORO^-'_"G;'_H,W7_?E?\
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MXL];_P"%P6/_ $";G_OXM'_"X+'_ *!-S_W\6O)**/K57N']@8'^7\6>M_\
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MT2%BD1L3%TV;1C;VQUS^.:YRY\P74WFD&7>V\J003GGI0G<9%1115""BBB@
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MO/\ OT:+H1ET5J?\(WK?_0)O/^_1H_X1O6_^@3>?]^C1= 9=%:G_  C>M_\
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M*P7GKQFJM:G_  C>M_\ 0)O/^_1H_P"$;UO_ *!-Y_WZ-%T!ET5J?\(WK?\
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M9.LVD??9'7I0P,(RDD]>J[LQ:*VO^$0\2?\ 0"O_ /OR:/\ A$/$G_0"O_\
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M% !1110 4444 %%%% !1110!2@_Y#5]_UQ@_G)5VJ4'_ "&K[_KC!_.2KM#
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MO_O@?XT?\+$T?_GE=_\ ? _QHY6!UM%<E_PL31_^>5W_ -\#_&C_ (6)H_\
MSRN_^^!_C1RL#K:*Y+_A8FC_ //*[_[X'^-'_"Q-'_YY7?\ WP/\:.5@=;17
M)?\ "Q-'_P">5W_WP/\ &C_A8FC_ //*[_[X'^-'*P.MHKDO^%B:/_SRN_\
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M."X'S1-PZ_A6G7AVCZ9J>HWB_P!F1R>8ASYJG:$^K=J]IL8YXK"".ZE$MPJ
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M_P"_9H^R7/\ S[3?]^S7N^!Z"C ]!1[3R"QX1]DN?^?:;_OV:/LES_S[3?\
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M]DZE_P! Z\_[\/\ X4?V3J7_ $#KS_OP_P#A7TS11]27</\ 6B?_ #[7W_\
M /F;^R=2_P"@=>?]^'_PH_LG4O\ H'7G_?A_\*^F:*/J2[A_K1/_ )]K[_\
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M0 4444 %%%% !1110 4444 %%%% !5+3/N77_7W-_P"A5=JEIGW+K_K[F_\
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MA<#T^7QOH$;E?MC/CND3$?GBF?\ "=Z!_P _,O\ WY;_  KR:BK]FA7/6?\
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MK)+N6YD$+R&('R6/S  GC'H15/\ X69X6_Y_9?\ P'?_  KS+6?^13M?^O\
MD_\ 1:5R]>9B,1.G4<4?5Y7DN'Q6%C6J-W=]FN_H>Z_\+,\+?\_LO_@._P#A
M1_PLSPM_S^R_^ [_ .%>%45C]<J>1Z'^K6#[R^]?Y'NO_"S/"W_/[+_X#O\
MX4?\+,\+?\_LO_@._P#A7A5%'URIY!_JU@^\OO7^1[K_ ,+,\+?\_LO_ (#O
M_A1_PLSPM_S^R_\ @._^%>%44?7*GD'^K6#[R^]?Y'T9HGBG2/$+2IIUUYDD
M7+(RE6QZX/45L5\R6%_=:7?17EG,T4\1RK#^1]1[5[MX0\7VOBBQ_ABOXA^^
M@S_X\OJ/Y5TT,0JFDMSP\VR:6$_>4KN'XKU\CI:***ZCP0HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *I:9]RZ_Z^YO_ $*KM4M,^Y=?]?<W_H5
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M8^$[7"D_Z?)V_P"F:5R^Q_[C?E7A8S^,S]#R#_<(?/\ -B44NQ_[C?E1L?\
MN-^5<I[-Q**78_\ <;\J-C_W&_*@+B44NQ_[C?E1L?\ N-^5 7$KHO"7A*[\
M47^U<Q649_?3XZ>P]32^$_"-WXGO]H#0V<9'G3D=/8>IKW?3M.M=)L(K*RB$
M4$8PJCO[GU-=6'P_/[TMCP,XSA85>RI:S?X?\$-.TZUTFPBLK*$101C 4=_<
M^IJU117I)6T1\+*3DW*3NV%%%%,04444 %%%% !1110 4444 %%%% !1110
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ML\'_ #PB_P"^!1]G@_YX1?\ ? J2B@"/[/!_SPB_[X%'V>#_ )X1?]\"I**
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M\M/[B_E1Y:?W%_*G44!<0  8  ^E+110(**** "BBB@ HHHH **** "BBB@
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M4?\ "7:__P!!*7_OE?\ "L6BBR VO^$NU_\ Z"4O_?*_X4?\)=K_ /T$I?\
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MTK81=TC3FU74XK02>6K99Y,9V*!DG\JTD\-J->N]/ENF$4$#7"S)'DR( &!
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MH **** "BBB@ HHHH **** "BBB@ JEIGW+K_K[F_P#0JNU2TS[EU_U]S?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?98_5OSH IT5<^RQ^K?G1]EC]6_.@"G15S[+'ZM^=% $U%%%(84444 %%%%
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M.?6F-H44B_O+NZD?:4WLRDXR#TVX[=,8IL7AVTA=&22;C&_.T[\$GDXR.O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M45&V@^7SU/)Z<\>M-75+R"_FFDD8(I)=6+%$!9 3@], FM;^V+__ *%O4_\
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M:G>0:7;Z@LL:/<A=ZR9VK@'[H)P"3[BNAMY#-;12D%2Z!L$8(R/2LS^V+_\
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MW_QZC^V+_P#Z%O4_^_MM_P#'J.5@:]%9']L7_P#T+>I_]_;;_P"/4?VQ?_\
M0MZG_P!_;;_X]1RL#7HK(_MB_P#^A;U/_O[;?_'J/[8O_P#H6]3_ ._MM_\
M'J.5@:]%9']L7_\ T+>I_P#?VV_^/4?VQ?\ _0MZG_W]MO\ X]1RL#7HK(_M
MB_\ ^A;U/_O[;?\ QZC^V+__ *%O4_\ O[;?_'J.5@:]%9']L7__ $+>I_\
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MQ?\ _0MZG_W]MO\ X]1RL#7HK(_MB_\ ^A;U/_O[;?\ QZC^V+__ *%O4_\
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M@:]%9']L7_\ T+>I_P#?VV_^/4?VQ?\ _0MZG_W]MO\ X]1RL#7HK(_MB_\
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M?_'J/[8O_P#H6]3_ ._MM_\ 'J.5@:]%9']L7_\ T+>I_P#?VV_^/4?VQ?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
F*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>img102984888_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img102984888_1.jpg
M_]C_X  02D9)1@ ! 0$#O@.^  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" '6 EX# 1$  A$! Q$!_\0
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M)P5M?0!DE_KEG6Y.67COH[@7:*96ZPD(HS=<.^NC[B_I*<U^)"B$G.\7;WK
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MA.JN.K1IY.?'1H*]3"2*2"9$4$R)))E*1--,A4TR$(4"D(0A  I2E* %*4H
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M[5V?IW2J'6\=QNC'W7U*6?;R4ZFZ[:F<5F>)X8VF9#0J]E4W%02,JM/O5YR
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MTP:?2_K6.;LT9)W[:94@:OVPE\F]H2_@S)RVHD1T-MF3+HK1G.:&U(;<*FI
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M ,BTG)+*\_\ TY;_ #Y/3Y_^ )^)#<A^>([  ?'Y9E??/Q\_+VJWX\_I^_\
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M_P"U_P!<O'NAEW\>V_)/]A;;N:['OQ;(#[=)?O2?B>]''^P.J/P_]>L1\_\
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MG^T&]?X'V7_57+VQ*_*_^8SVUH]RK6^9[2\G-JH4*]?,M"O/P^/QI]E ?N^
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M#Y>/L_;^/-#B Z&<^GA?&QN.-].JY40<YS3Q(N<":, \$-=717K_ #^IF*(
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M(&.L:M]%5WIFPQFYK1X3 ^\"H!H:$Z[[A7"EPP78@0A?Z4I2_;\"@'Q^_P"
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MNT-/TZORL;;WK!LT9Q\A9VCY@NC/2#!HQ8M63V3*Y<,V[!BBU413:I%*1?:
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MH+<UI NHIFCU(](G_@+K^/\ WY)#_+>PY^_N[ES\M/>0/X"XCO?]C]XMDO\
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M6<-Y1=_*"NHJ]!0'!0>J FL0R8%)[!BACL_-3<Y,.CSSGOF7 ->7L##085:
MV\5O\$4P7;F2MF9.V39$"4R4;(-L0.>^7[0FW3<(O<://&.?%SJEMYSW7B^\
MK/O-DLC3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$3A$X1.$5!^0_/Y#\OG
M^Q^GA%H&ZV=@K9Z>V.W[I_>NMG870=TJ&G;M+X67-\BN%SH/8Z&TO1K9H.>S
MS74(2.<TRI.'1[0UB-%_#J:KZ]4=,)*0=^^9 @LK+[N3HZ_-7E4/-B.NZN^.
M"^S'4M/ZZ]_AVWL7A.MRKC0/3IP.A3[[K'AVF:[GD5KT)KFFV>YTR*=U=A/K
M,&\(WF&0,S2KD!<H+(+%4,F<!&IMZ.2[U:%$?0L%UZ4&.[(['F.^Y%B>_P#J
M)WOM'H3;&868<=L>O5#AL$A,MPFP))T!&;O5#6T&7K[A?:2TAG)6"#KEC8UR
M:%)FYG#($ZQY](I>MI/I&4JTT/&=U9+PNBM,CG^SFDW7K_:-O@Y2$W_2<WM,
M75Y"1O>R%GVS&UR\_(Z -QC*U/7*/96R5H435E)1$R2;-4Y!N-6_1Z;[SVDW
M2/\ 54[-Z*]JD^UH4]TRZLU:$N*\8Z2KDO9H#4^P<A.P$=+G2!H[E8=A-Q#R
M39(J&79MI)DJN0I'*0B5T\V/3=OKVK&_J-UEH.Y=+M0UW+;-M'5#,)O8E]8I
M5<SV6UUK!Z-9:C%1V.Z+:\LA8R<D+97ZXX0MD8D\3@Y=.LR\\RDCM4@5!T@Y
MZ;=6U-M_3N*[5J+TW&).$O.)Z"EUWN.$=.I#$MI@<EQ[3^J=E[P(YYH]WW>W
M6U\BXQ9A/MGV)2NS9^]@)*C,7,89I28<WXLP6K2S=1LY;[\JG17T5N\_25\K
M7U.[&PV(S%0+F>X6YZAZ8>!T&#&S5$SBV)RL=W*?7%AFDDT@)2RL$+71\[7C
M"OJRUGYE["0T<D1\^7,W4<'*&MU-8/41MYZ<NU98D<XF*IWO6>T3&[9H%]G.
M^T=I,_G>T]9[*%VK$,_L+1G,=@,?[]YX[KT8QQV%HH'GH3,M'=VUA]3E<XY(
M1AB+(QQ6"8[*FIOON('6!H/2L4>O\FJIW9Z4>X266,'7/L4 D1255.) NN7A
M[1BI%.<"^!\B(AX 1\>?(@ YUP?&F4%Y#:RL>\N '[3!2I(%]<:WTY%Y][)-
MCW<',)K&/?\ Q[9)HQCG&YLR*YK6N- 2VI(HT&I(6I$6#[X@+"0^[_J>^_T?
MG>N<SY2%Y6'[2\$]KS/B\QY"+["I] ?>/'T"0\?_ '@^_P!'Y<]ORD+GBPSY
MW(9>9( [7F*"\? 11YF7\Z"Q?B _[@D/D/\ YWOO]'XSFW?"PKL/A8=W]97B
M)H"G:\Q2A_O$7 XWYB^JK%][P_\ N"0^?GX,'H_/X_,$! ?VQXXQAO;%A@7?
MWV&+P*'^GK"UO@3(>^DO,8XB!%(/]1?/Z"^_L"0_YO??Z/QGM^5A>6A^VM':
M\S2G:\Q3'^0B^PN)F+_[&$A\?_M>^_\ $!^G]/&?"%3$BPRRGA4BPZD:AX6M
M! C5^$EYC--SO@(M3H '@5KSBHK>KEHS9Z-WHR(L9 ")WBJ' #LG8>#J6.+#
MR)?<>T #[(@43 !3>R8"CY*;QPDS&E!*VA2)"KQ$:_C(8<? -,3>-=^-XI1<
M_9T.WHHL.#'EISM&';<AVJPRT>C09R":%O%D@YMP)QJ-A7]"=,!]Y]OP4,/Q
M\_+X>!#S]GQ^8?Y.>:-'_:_]R^K K=L(!^KLVK]G-2U)PB<(G")PB<(G")PB
M<(G")PB<(G")PB<(G")PB<(G")PB<(G")\N$7G"/GW8#2>^GJNU?%\BZEZ)'
M3[[KG7K%-]E369ZI6W$WU_7CVYXJN0-/G$K!#E:N%WLE&N9Z 4?*MR,@6;D6
M!ZD4--^4<^J_1<5>O6/"*EUT[^XQUVW&RQ5_>X?Z9F74[J[8;\U:)1DS.1.D
M3L9V+G*$PF5W;5E:032S)DX:-5W%@C*']6,2.U(PLBHJ0"FH<F Q]?IH%\=A
MOU.8!J%+]-Z;4I-CN7>2/JO8>$H>@4[+I7:[FPQIQ9-,J?42VZ0QM&40^GQK
M*.J\SI014!%C+?45I9IOV=H66E49R_EIW])HKCU[^I2EZS:Y.:KT1[&M;9>=
M,O5SS%/LIE5O/LE3J58U*I2U6K3]VA1KN\SYZ]H=WG:Q$S,<R<:%4S,X^VH'
M:/5XUG)$?I\ITUPOJ*;]%%H?^PZE_@&E--QY3?SKQ1]?VS<V&9&8[=$QC9_6
MO(F2()A$6"?GSY*(CY$/B/Z/B/PYZ7R7SA8-EXT;+0[J$4K#:=&DT!&DUN7R
MUX3 T\(&6M6@N.4MK&I SJ"8NVTIT :EEWZ(T_L5O_>$_P"#S(<XZW?UE@F:
M-3?ZJ?1&G]C-_P"\I_P>,XZW?UDS1J;_ %4^B-/[&;_WE/\ @_IY<XZW=:9F
MG-%-=!KIOTX)]$:?V*W_ +PG_!Y,\ZW?UM_4F8-3?ZN_K3Z*U#P -4!\C]B*
M?S^_Q[/Z/T\T/>ZX GPB0:UJ: FFNG)Z%6M;G-%!4N#=%U03G#70@787]'T%
MNU AD?HZ/@'*BOL^Y)[( *:10,'DOCVC>! ?  /P\@/CR'./@RP@SL6,#3/@
MAA-]2 \$C:+AB*7X8+)(L[*.R9@V7"8..@VP^:<;KV.EHL.M: TSG;,*#33Y
MBU:C\VS<?UHI_P 'G)9U-)',1R:%C69L;_53Z(T_L9O_ 'E/^#RY_P#E._K)
MF?Y+?ZJ?16H (_1FX#^: #[E/S\3%#^I^T!$!_1Y^SACLY[ #4#.Q_Z)U\^'
MGHOUAL $0N:T?!OI6GQ2>GKU+V;>D,4A.AV1E3*4I0D+^ %( %  _#RP" >
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M6WIL@ !]0I_#_P!G>X?Y+9QW7Y6?+QN3M2'^'3KJG>6X&OFZ2O %>Z&=N_\
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M_%M4\LT?0X*=]7@-_P!&;?[%8O\ NZ[K53^H=Z7)#"49FA@(#\@PJ7$/L$/
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M X@;E+*A6C'CF'9(CF=#"ZDL2R*8=6A^:06G'$M-36I6,963>2<E8\2/ED9
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MAPVM8TO<\FC10&E0T777#;CAY_R@['G)3*2W;3MV<M:V(,U:TS$FIB! ?+B
MV(]Q<<RL!SZ"M!GO<;N13 _(3=</'C\:VV_^$4WS^W^"WGF^[Y%K>*2G/QAY
M=.^T+B/>OY&8>[%N$:!G2M,?^HKTZ[]2?D)NN'_&MMO_ (13?XK<'A(M:_\
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M)R?SVFH=VD":TI6KGD=((V+.6181D6$Q<A!9!GM<SB'FI7Z\EHRL1Y635_*
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M=PV&CY%X@P;+J-8]:48'?"B5HV4%PLDF+?>_K3S\FFZ_]K 7[5OKZTW""T#
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MGR?[LY4D_P"@HM3_ /[%4+Z"EN+X,GV>K(F 0$H!D\D >/B'GX7Q81\?'P
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M:.QF^XAF_6W:W/7/&:)U]OWXMG"%CJU*JMFMNN:%(MHUX\O<O+3EK0:5NIV
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MZ5]-&HY;2*Y1*^>14*O(+QE;C&\:W=/W!")$7?.P0%T\5(FF51RNJ8I"E$
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M( '"*T4]%SY4R1$KW35#K*$21(G9X0YE55#@1--(I7PBHH<X@0A" )C'$"E
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M%X )NO\ Z1&E>?\ LCYF-)\&[9B7B18>9;=F-JVM!1DP2(@-0&DYH=G77-U
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M)W]5B:F.NEI=F^N?QEAM0TS\9VDACA]A(N+XNFFQ7\*ARX;D$O\ T0A*#51
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M*/@ $?B'P ?EPBI[PGCS[9?'S\^?A]H_Y!X1<O:#QY\AX^__ &^_[/O^SA$
M0'X@("'W@/GA%7A%Q,<A?'M&*7SY^8@'R^?[7V\(J@8#  E$! ?D(?$!X15X
M11B[B]>$.UO7>_8,XMBU)2NYZN)[*VB$YU>/_!RW05J*5.+5>QY'(NQA 9B)
MG:0(E<"OX4%,$SD6OW1_2.J.@7'O+9VNNV"&1[?9])4JK5E>M-9*"P60O$C6
M;!L]DJS<)=N>;>ZU:*=6+%/MEQBTV3N/5*W67!TN90I3D.&L;0#R=>K7F.Y=
M+MWI^Q:AKW4#L9 X8OO<76D]JJ-_QU+7JL^O5/K[>IQ&Q9^V2N-,=UF_*UEH
MPB)MC*N9^HV,D1!NG<.BZ9.%7K???%4"FFN^^OE6.+EZ:%@;9)E>3YYKE0N5
M=IT!>F&EUOM]C,7V)H^P7/1K"%SGMHE(HL[2YFK:NSM2TNK"NZW/H5AI7IV0
MK(0!&S:+78S7=3;=?MQ\Z@%^F_T[,.JJDOU_]/SKCD.+9?E5OSS.=QG<\IL;
M57&DZCF5(L=NGT&"KE= BKN:BIA]'PD89VHPK5>+).F=<@D&,.T4.BT!0U56
M8-9I%-SWK/L=:HM5KE*J\;D6J'CZU4H*)K4 Q,ZJ-@=NS,8:%9L8]NHY<*K.
M%Q2;E%9=5193VE#G,:.-&N.- 33D&&CK*5I?4@MO!&@CEV57D>Z:^D!V?UGJ
M;URTBM6K&VL!=,?I-BBDIBQ6=M(H,I*';KH(/T&M2=HD=$(( H"3E5,I@$"J
MF^WMVR<O;*DK*D9&-+S(B2\)L-[H3&U<Y@#00[C#5NG01I 7BW+3L>\N,H,J
M\HK;LZT+"@R-KVE%G83(\U-09EC71'EHBNA244 T<:AKBTBE]:TV==+/2F['
M]=>S&9;%>+'E,E5JBO/*R36K3UD>S2P2->DHUM]$;/JO&M52@Y=)@M[UXD!4
MP$Q1$_LE'9Y199V;:EE3,E*0YMD6/F \>&YI:'-)&)(<"*@ :ZZ5R?!EP#Y8
MY(9:V);]K3]CQY"1B3#HC9.>G8T8&++Q832UD:2A0RT.>W.)B @7BO[*]$C,
M#@ "<ABB/M^?:*(?#VS"4/(@'R ?T>?NYU><6TPS16[8+C@ =.&S6O7S2:.!
MK41(E"3B"XT/.*4V+]_"J<(G"+%,?^+P-EG : 4-3_%W!#,> D_(43\(IT((
MOM'\0XE^O?KL0!$/K$/)@7'Z."'DBRMPB<(G")PB<(G")PB<(G")PB<(HI]F
M.J<3V:2JB$IN'9''DZFI-' G7[8)C*0L99LC%-5&VEB6SDL\BQ*Q\1A'10!G
M]+?>R!OI)@ I0'???' *!"/H>]>6V8.L4:]F._#7'WK=XT<YDU[6VQM25&,@
MJJL^B_P?1CB,$X9VJLL9S"II$B5BK+(G8F0643,2FG3KTK;G0:;'9[3*M1XE
M])R,;4:Y"UF/?33I-],.V,%'-XQHYE'B2#8CI^J@V3,Z<%;HE56$YRI)E$"%
M*X*\.$3A$X1.$3A$X1.$3A$X1.$3A$X1>?+U9+KHF7=V.C6W4:TVJ.B^N66;
M_NFA4^&EI%"!O.70VF]:J%K3*Q0C9<K*7_!_*M%NENBCOFZ_T&1KZ"K;V%O9
MX4.KGZ/S]*_#1=.NV\>LDEIE;T";:X]&XUV;ZQY+$-Y%X\HDO*XY!=>;Q>M9
M/6"ND(>=?%TC97U&:/5@,L9#.7K$KI%-0"IDTUNNTZ1O7KZ<\='-6TC'G?JA
MRW9O:;OO!L,[41S9>U1]!EG#QI51ZXX?8B0%"R&@HV%Q&1\>YGG(-H"JL7SJ
M0<'=2[X'4D]D'BA+A6OJ%;M>]=M5"_NWVD>SO<GHMW QVU:=$Y-CN$Z[L6B5
M&P05\S0;5DS'>,ER'6U;;FESCH&6,YJ]5N4S;X=S+P:3IN6O [CE3-'9C*S\
MO3S>GJ0&HNUTVBGZCT'%6%LG:[4HCU$MR[DT)U8[U0\EZP=TLNPK+6<O,JT6
M[O>K%<S26N=Q5@8U4$91=]L]PN-:/*-VRST8>E^[8.O8,0YU!=ACZ//ZE=Z[
MZO2K!2W/M%A6K[IV4:]]++NLE4L8].[1EL]EH;,C8EV&'L):KY&3V5994J]7
M&TC3'AT%SM\DE:9..K@=]]%&^O[R@BDFRJTUH;Z:<-0I<:[#4[*T6S"O^H;V
M /W3-B&BL,@R:IR78*;QJL9/IU,UFD7Z[YTB#YM6=DRSL)(JN,0TZ=M1V[><
M8Y'"1C69^K'3BODEQM$<JFN4-XIH.)%Q%^&PBZM2-=+J+5G_ "11:K=3>XO2
MB4I]EL56F%,![!,S2-7GY:NR@LW%WS,ZK,9"%>L7HMCBB0ZR(K>[.9!+WA?S
M0YAF7<U,R=@/C2LR^5B&:EV%\-Q:\M<7EP8<<YQ%: U):!@%Z>[$RRK-MGA6
M?(6G95FVW+NR<M>*V2M"##CMSFQ)8MC-A1 \9T-@?FN(\%HBD$$$K2 ZWG>P
M:NA#;-F*'T=<0]G6]! X>$C>!( 6,?SOE[/D#?'Y@/@>=+MMJV&N!]U[1KG-
M_:C10TDD?M$T%#2_&[1I7TLB\'.0[H,5O<'DJ!Q40$P[/DN,#<QU["(=0Z^H
M(OTK^B5UK>O'V!8@\D'CI^\>9-G+EP[>.%G;UTZ6JD0L[=O'C@RJ[APX55]X
MLHNH=98XG5.<QCB(^DI0E\K)Q2_C'OE81>ZZA+F--1KJ=/**!?%;*N&(.5.4
M\*%#9!@0;=M&! A!H A,;.1VM8&C ,: T"X #DKG_FY7 IPB<(G"+&,56*LQ
MUBZ6YC-BXN$]4Z1#S\!].9*A&0D$^M:T!(_5R282#491S,S20NG2AFSKZ 4C
M8I#MG'O&^/53#HIZFG?GZ;NA9.X1.$3A$X1.$3A$X1.$3A$X1.$3A$X111[P
M]C774WJQKF]1=<0N%DIL1$L:34W;L\>QLN@72RPM$H,)(ODP%5G%R%PLL*A*
MND@]ZWC3.E4A!0A1 GIW\RC7G]$]2[.KMD-KNV\YEV1K%JL3*'[ Y67**SCL
M9FT%,LESN+CAMPCI%]8YMM1IL6B#JK:$M8Y&W5]1VNTDXJ83("I2E->C'U78
M[.50GRS?_4HT7K%M/=2L=@,>FHW']/[2^ZZUV' 64;"VZ@==-.OE=7JA-9A;
MHULD!9+#5*<=2/LZL-(-&4\NB9Y$/F8*%.5WZN3?7H68>Y_JE6#/^NF5W?J_
M5HBUZ/I%%P[=+0VM:3AS!XE@.F7RA5)2SW1)BY9F=6JV2UP"FYI6!<,W%@D6
M-JM"9%X6C32?"E<-HKOTK9GV/['T+JKA5IW[3T; I2J8%>&;1J<&YL4^8+'8
MXBLM1C(-HH5Y)+%?S+8XM&?O7:J8&(V0<.1(B<-Z;Z-Z(33?SZ@HS0WJ2T!P
MSVYO:\8[%4*^X= YY:Y+(9[,OK/3;K5-<F7M;S&Q4.#J4W8FLJUM5CBY2#<,
MWTC&O:L^CGOX5I0S9JNN0A--[N2N 6([YZAHV.D:,ZKIK;ULT?!=(RFC;+0=
M9RR(TFP-B]BT%*AB\A$$I6D#5W4(]O%EK<]+RD;:GR[2*K-B@'S!B\6*L0F-
M*:[^L>=9S@^^^<0N82$I;C6B8T&@]B:[TWN56BZ>C$VBR=@)&6@:^BYKM34G
MGI&=5MC>:;:7"+JS+A-KGKPLBLX4%JI[15=12?4SQJ\Z)3JNPI6LQV;Z7I<U
MC65=BI:JL6V):5I\&]F8I6N5R:3G%K$@SF)JO3,)3K1-5F,K%TEF(LJ]*O#N
MF9G#??%2M=]]^4*W/4YM';3(.O6P=ENN.^U/+V6#8GH6A2] M.)P^F(7^;K$
M:K.1Q?PCD+/"/*RT.W:FC%T&3)Z)S*B\$WMI@F9^?6JI$=5J[V+@J,-@[![S
M [K+6V/K-CKCJ#Q^'R)O4XU_!INY*(<-XJQSY)XSAVX*NB_=*M%6A$ 1]R<%
M3GX18%JWJDXA99I=ZXINMU;$79-6_ WM%9:81M@M[5Q*%L-CT8\+/LI5_88Z
M'8P%1M,K 6>RUV$KUP;5^2+69"27!JBY*5OIOS^C\EB;3_5+AG^';=(4N@:K
MC&KH=4-A[)=;GFW4./CH#6:UG=;(_&R0+)I/2QDUX=Q,UB8E:)<4ZY;"P4NT
M?KPY6H.S-2O2,;]^75H*Z*D^I;)T68UDFT1[V[/37+J;F&$9_F]?AF-HN6B[
MAUW:ZI.P0R<Y.0U<:(G?,[#,DE+--Q$7"Q#$[(CI==1JBL4.DDUTW\YWY-*F
MBYW!AV ZD;G<6M*T#.'L?0=JJ-DHNHUE:JW*N66N5.::RC!PV!=]%S$<?WB3
MJ'LU;E)BLS\<X;/XB4>(G,*<S0^K'$YK_!):/" -QH-)O)&U"T/&:20"""0<
M*U:3A=2O2.9>:;TR?4Z[-QF>='L :I9F&>_4N09N85:@_&?&N.!81*IQE!L/
MN D?HBAA^DBP!(%0]H4!#VBCVFW(NRSD\VU<Z/VSVBZ8<'O(:'F&'B@(! J0
M T%U=-5Y'C\-^6$#A1BY%L@6<^R(>4[;':\0*S/:YCYCHCGAY!+&EI>[,;2K
M3G8KV2-E"'4.4IO:*'M '@WD0\?,%/A\!^8%^_QY#X<ZL%XJ,"2 <1<:&AKK
MJ#A2E+Z!>N*U)'@$-H/!+:BHK0TY!1?NY54X1.$3A%'R)K-@2[/VVXJ13E.K
M/<3IU;:S)Q2!LO.QMUM\B\C4R@I[\5D&$@S=*&%$J0$<)@50Q_: I2E]::*5
MKMPIZ5(/A5.$3A$X1.$3A$X1.$3A$X1.$4).[.=:O9L^?7K,^R^RX&.4U'0;
MG*PF/5[,)^1TPL57AF6D&[#2*;; :NT#0[AO##$$:"HXE%0>@Y*1$I&'3LZU
M"*Z>05(OUW=?5I6IC.,_[F:#T B.V@^L7H4;9+%BIME2F$:+UU5QJMBO6U;2
M2H3$DM0$YPZ<0F7\')N>.[9OTY%N[?)PB1R$C.7H&&_K Z+E+MO)4UYM.B[7
MR$K=EU"TA[L/6'K_ *I)%L)9'0L=SRW2'X6E9%LRCZ<K$<^=KS81L=$1WT]P
MX5577.PBHUHH97WB#%J0Y42Q:M]ZJ2'")PB<(G")PB<(G")PB<(G")PBXF.0
MGP,8 '[ $?'GR/@/VQ^ ?IX11WT_K/CVPZ##:3?8MU,SD'D>O88FT-)KI03S
M/]O/4OQ@1LE%$_G#MT^+3(9%F^.)5F)/I9$A\N#>R0@[1=N</R6+L(Z#]<.M
MK#K_ !V5P\_$M^M5*UFBYO\ 6%IE)AP:+VN=KMET%[9G#]15Q8YR3E:S&.6\
MK(J'<-"F<))"":A0*.G0-^=*4OY.?ET?IJ"S9EV"9YE%NVZ\4U&62G.P.D,M
M4T11],.I%LXMK"BU//&RL2V6_G40Q_!RF0I#L&GA$SLCAT/YZYPXWWW*:[\=
M]ZJUM2ZEXQLNA_C*T*#?STZ?#=-Z[.F2LP\1@7^8:X_@9&ZQ;V(1$K9=^\6K
MD<1I)CX=,$063;G**IC 18\QGH!UPP(G7M'.X2P,$>M6;Z-EN=)25GDI@'5?
MUB2BYN^O;>:0,NI:K#8)F++*NYN4.H[4>NWRIC&^DF &_(BM3.O2VZ'99ODU
MV2HG7/.X73I+ZC6C7"$*S5K=*F()>;=HV:@5%5 ]=I=G>KSSM5_-0$>S>'.F
MW%LHU$BGO"<MXU'!?(OIOX\&BL+B\OVWRU A=I4[&PG7B7T1:1P^)VT)UQ;D
M+NS@7$:>R W975RXNL;35;4K18RSJA)L:T@9%N1)OOOR*$7'D..%_5SX\JUI
M^IWT\A.[?J:]+\8L%VF\^9)=3>SUQ+/U^,CI=\9S#:!C[4&/T:5\-BMW))50
MRBG_ )*04R GX]KR'%VS8LO;D@^3F2X0.,9$+FTS@YE0VFBXN&FMU-)79'!9
MPE6GP5Y5,RJLR2EIZ:%GS-G.@1W.APG09IK&Q Y[&N<VC6>"6C$D7&A5L./Y
M&\RLZ"Z9>T.I%%1%5,#!1:6)B"=,P>T7RH'DP#X$ \_$WV\PSO;60T5$S.DB
M\ EAJ1@"* 7<U-87I!_9JY5.8Y@R/L.&7M+!$9.S.>S.!&<T&$07-&%Q-PT!
M>A;,ZHQS_/Z)0FL@M(MJ95("J-))XBFW=2*-=BF40F\713*":2[@C0JBR:8^
M[34.8A?)0*/.PX<(P(<& !X,*"QFCP0QK6M! J ::!=J*\9VG:)M:TK0M)X#
M(EI3TS//8+P(DQ&?&>&D@%P:YQ:#0&@O I19(Y^BVB<(G")PBC=56SA/M+LK
MM5LNFT<Y5BJ#9VHW5(V<+MYK53+HHN#$!%99N"J)E4R',=$%4A.4@*$$Q32.
M0^A2)<.VK4AU'3E!LFF43J*+JD133('CR=1102D(7XA^<8P!Y^'GSPJJ-WK-
MVFFLT=-W2*H"9)9NLFLDJ4!\"9-1,QB' !^ B4P@!OAY\_#A%^GA%01 H"8P
M@  'D1'Y '"+A[U,? @<!\_ /'V^0\AX^_S]@_(?D'QX15]XG_5E'X^/@(#\
M?N#[_P!CY\(J"LD7QY.4/(>0\C\_CX^'[/PXKOOOAK15!0@B!?:^(_(! 0^[
M[P#X_$/A\^$7/A$X1.$3A$X11W[8]>J[VLZ[ZEU_M$K+5Z-TBODC6MG@"HFG
M:C88V28S]2N$*1R ME)6J6J)AK"Q1<?[G7<1R:"X@DH<0(H95CK_ .H5I%UQ
MIIV@W#'H?*,-N<+?I$>M++3*C?>R=DJ2#DE5:Z8>;F2Q='HI9,[:TVRB5I>>
M8VV49-H1X\3KGTAHX(:GHIZK]F'Z!1WI'I^=^ZAB.K=18?L!UNJ/7C7-$WF;
ML5[KV<Z1+=@6-"W[1K7=;A7H )NSM\]8V,8>V2-6CY]Q&NVT8FH6628.GB"8
M'E>?DWZ5#7S<UXPNY>?JOKM%Z,>$;)EEW@LFG]*R/0+=!X353OV6R[%&YZXK
MN&2%-CZTTG<VKMN8UB2<QM)K3V+@'!X@_P!4V"2&RM@2DS*NS7???0JIH=G.
MJSW:NI"W6>F6MQ!*-U,F1B;->Y"PW61-'YG?:?:#FGYF0?.['/R\K'5A5LI,
M2<@ZD'4@[*]D'"YQ6.9S?GM4T"FB@OV7=7-S*+G<+H)L.[W_ '[1LUU."J*V
MKY!ULSAG5)(;K#L;(VP[7K]I%OIU^LM(EHFR,,^U6#N"51E5:H[1FF:)'AG!
M'S%TNQ<$T[+ND'].A1OIGI.;#$LNQL<1_P!:,L@.PTYT[O25*QZHWF/KV>V+
MK-J;.UR\&FXE7!WMW);*M'I>_O,H2)G'%G="DYB$(2/9 #??>Y7?'1SZ<=-^
MQ3&F?3^<2_?Y#MD:ZMDLD<M8S0[#B81*_OYCL_6J!)XS5-<&6*J#5NSC,BEW
M4,I'@B*SFPLHF:,(K,T5B-:E#712FVO(=&]-:B%US](*<PW6,J;C7>K#W)\3
MU:6TVN:N;/;--=E;S')SDU9*/3K"WL+MUG=2G*E*2C1&0U&M$<6&<80C16*C
MJQ(OGSH%;N75TXB_GJE.7I._-ALP6U_N1A<QV8ZE]ANO$#.Q]6G=HR&\9O%V
M.69.7\5!R%L@GD4WDG[%B=)XY9,U7(*K(-C%7.0!!,?:'A59MKL I!4:N5=V
MH1V>'K4-7W:R!%$R._J^*;QJZJ1!$5$RN!1,=/R;VDRF+[1A,40$BT\4?TZ.
MS3+#7_1>U[CGT7TFA\YW/,*^O2*=)J[EH-+U.MVFN42O:.[L1G-6@PR0]M5G
MUIFG*E?Z%-5ZOA($A(M2:8/Y7S='-CU'2,5*7WZZZ]%-E.O2L047TA-%;TW2
M:S88;J'G,L\ZIZKUNIMQQ_.K@\LMSLFD5AE5C:O>INYNW<I0(]*+CP&0SG.U
MG+>4D)1ZYD;&]:1\5'IVO5LIUZ4OT;:UTZM=!IUX!9@O'IK:R\@=4914KU[U
M..T*T];YB<R'<\X<V+,[[7,7PM/(IJNSTV+25L=&FG4X1O?*1>*0V&7@7<2T
MC9!)PSD9!/C?"B4KCKT$_DLU85UFOO5GI'V'HE^M$=)KSL)N]U@J56IZ]6BA
M8W5I^D/$XK*<\G],DY>\2E7@!8.))$\NX:-$)*:DF\'#0T,FQCT50+W8"\TQ
M  OIJ-,.G2@#7 M<: BE1J)O)(IHJ;M.R]>?#TR_3C[7/Z7T?W)E4JN;/#1N
M/W\LDI=HH)'\%VAXR67>A#^[%R9P#$# #3VO>>^$$_: 1\<[9A97V++Y,BS&
MNBQ)LV=$EW,<UU ]\)K"&N(\(APSKA<#0KQW-<#F7,?A4?E3#;)0[&.6+K78
M\QH1COD1%9$SC#KG4<T%A!)<#?F9I%?:>W]OV_SB& H^?!C /DPC^</P /!0
M#R(  B)A\?'X@/GJ2[P,VX$.)!%*5O%QOTWZCRKV)4ESZM:T @-I_2H*%VYO
M*_;S4JG")PB<(L&Q=UGE^Q-HSI15L-9C<BJER:H@U3*\+-S%NM40].=X4044
M:F91+(J34Q?825*HJ4?:5/Y*5OILKUK(=VT"C9M7WMKT&WUNDUF.$@/I^TS+
M"#B&QU/@DFJ_D5V[8JJH@())>\%140$"%,(" %5;&8;CC^SL9"4R?3J+HT?%
MN"-)%S3;)%SY(YRK[8I(O@CW*YVAU0(<4@<%3]Y[!_8$WLF\%*C?F]865OG\
MN%5P!0@CX P"(#X'] _</W#^OA%;YKA4B6!.IGL]?):56OTU.MGF8XL\HS'S
MX=$B#. D#-Q !$%@;BF( (@;P'GA%<!U4TR@<YRD*/R,80 !^'GYC^@!']0"
M/RX16O WNDVI>3;5BWUFQN85P+27;P4[&2R\6Y QB"WD$F#EPHT6]LAB>[7*
MF;VBF* >T APE1KWW(7T0NU,=/"1[6VUES(*+F:IL&\]%K/5'13&(9L1JFZ,
MN9P4Y3%,B5,5"F*8HE 2B $5S_/Y<(G")PBLK1KC"YY1;E?[(=1*MT6IV2Y6
M)9% 7*R,%6(=Y.2RJ+<! RZI&#!P*:!1]I4X%('@1X1>2*NX/6]7T6_ZI)^E
MKU*"6M'7J)[YY#@J>JZ>Q)<JF.GPZ4HWUBKL9E' 4-6LM/?+V.";M:$[KJ%R
M.V9V&071%VKPH>@<U!=TTY]&I>J[K[I]2VO%LMUZAH+M:7I= JMUK#-TU39.
M(^%L$0VD&$8NU1 $6Z\<@L5DL@D ))J-Q*D'L '"JS)PB<(G")PB<(G")PB<
M(G")PB<(H(>I]:;+1O3V[BW*FV*;J5KKF!:!*5^RUN1<P\_!2;:'6,WDX>49
MJ(NX^0;&'VF[MNJFJB?\XA@'A+]&XK?OK6J&,[-;G6Z7UPZGZUHEP#L;A_=S
MI=7K#?DY%Y!R'97JMJKBTAGFJ2HLW":<JC;48I_3-7BBF<-$[_5G822)4I:/
M Y:1?C6XU&^.R\ T-]ZQ'UZ[1[+V1L=(Z97"_P"XXMF%O[4=TZ]<>U[Z0FX.
M<V.S9]OMLGJKTTPO27[A1W7W3S-G24E,76*7;.D:[39K.<]=DGXNRFA[JWWW
MOU,*WZ1IJ02.370Z!?@!CO'[;=C)_K)6,0H^14V+OVO;[J->P3%:[<;')1=2
M2GC5>P6>2L5[LY496<"NU2FTZ;F9$&:3ZP3[Q!"/:J"]?&<DBU*#^S>IQO/7
MMQG.,;CG/7C'.QU^M&G@QM>@:I.M.M4IE&:,*:]+JM?F8V(?: NK;I"\1M3A
MZ#)1+"=CIZ%M#R1?'A&#!Y*-N^_*IZ,:UILOPY[Z4P4!^R_J%ZMOF=FUO/;+
M<<<6)Z?7J$FGZ[1;M+&JJ>NXIJ&3TYAH5(L#5*'-8H@Z#EY-9S<OH#.0/7K$
M4/=MG2CM$&^C1OR%7?5C^G-SJ>T;ZF>I1O9Z&Z\J4[%8&+C+ED><DK&R:?+Y
M?OVQPMTK59=RFU8J:X1$9EV@5J+=S3P&M1B[1)7*RJ5V=:-@9S:C&*6*>O4=
M^?"BSRCZMG3YUVK6ZZI;SAHP)<R:V-OH!-2@#INM.<:2>@GR0D;[0)%L1$@"
M2!/Z>+P#&*B9B!!!42.<UC7.<:-:"2=0 QYEI@_D@C4M&R7NOTKM667^V9Q9
MU>O/8:)/8Z7-/8&8&,7N^8JNH\7S!1)Q]$=+-T#KH <"J>Z*/@/'GF'9<3T[
M9MA.F9",^!&[<@,+VNS3F/+@_ TQS:U!P ."]'=BWDU8&5G"K#L;*6SI>U+.
M=D_:4V)6:@MCP#'@-A/@1(D)P\,,H=HSB 14E:@"]Z^ZQQ*4W;?L"("(!X#3
M+: _$?CY$S\2^/'VCY_2'P'G3YRIRBH:6K')P'PS34\@%2OI##X$>"DQ&_V$
MY-T+FBHL)K+B0#0N:6M-#<3<,>7?1Z"/87=]GU/L3%Z[L>DZ?'P-!H+^%:7V
MV2MF;QCU[:)YN\=QJ<@NN1HLY;((H+*I%*91-(A3C[)/AV+P?VK:=HQ;1;:,
MS%F! ;#XO/-<PN(%/ZM>2INJO%_9<9$9*9(65D1W+Y/R%C/FINU&3D:4EH4%
MTRV&UCFM>Z&UI>&@DM#B<V_-I@O4#SLQ>(4X1.$3A%B.,T!U*[%><T-%HI-:
M?3:%:$)<JYU%GRUR?V]FNR5;&*5)%)D6KHJ)J$4,=<71P.4/<DX33OOOHNK!
M>AT*L]YM'VB_[@BZN>*Y=K-KQ+(,A=R$@CG[QWG#E.'N>FVV!:.&K:VV"<LY
MI&,@_KKZ=&PD$P1(S8IO7+A<S#INW&K]5*8UZ-'F5,!SZN8;WOU['\007KF*
M+X#2M%L^>L'S]S3J9J<Q<9&(C%Z_&N5W"%;6LE68J/'D2Q%NS<IHD=E:E("?
ML/RWOZ]/.@H,!T+/EG[FTTU@G*+BU/N_8W0Z[(/(.<@\LB2J56LSS(YD743<
M]3G%(W.ZN\8KE%*08.)UW,M1 0&*45]E$ZGJZ$)U"N'7IY.;TTRFTO6E0V$6
MC1=2J%>JM[KM2N]L>T^MV!:T1;!&!9RTK#1QY\[&/+(/U(UFR+*K-&I60/SN
M4V1E6Y4SF)?YZ;U]7,M54;6)G+NM_6?NLPOF@3&[7R]8+.:S,R]ZM4C!:)6-
MWML+7[%1G]+>2JU08P,*PM[8]1;Q,(Q6@'D&R=,U@.+CWX^@=?5ZM*E]!RZ=
M%#31CMOIIPN6SCLE1+;I6=HTZM:.;,(9U;JXZTRRMI)[ 3)LGBW2K^\PU=LT
M>J@YK4Q.L$6\<,_]);BPCUY,Q7+=4Q5"-.^_7I5(J-(UD?IZEK4J3E6 F^TL
MITK_ !FV;KK%]9+#&M%&DS?+U5I[LP20D&T*K@SZR/YF5G'K6!65);Y.G/'-
M:<2IHL4USRJ*BI2:Z:>BH &]QVX460^K:=)RS6<BJ^BY-V:R?1[S47T?GEGU
MW;;/HE0T6:B:RT>7!@\KY-(MD)4[@=DFXFV<#/Q+9T1 '7U8JBY:KM4R4 IT
M>GT:/6MO0" _+A55X1.$3A$X1.$3A$X1.$3A$X1.$5AZ>VTAW0K,VR&7J,#I
M*T<<E1F+Y"RMBJ$?*BHF)'$]"0<K"2TBR*B"H"W8RK)85#$-[WV2F(8BU4=3
MML]1K7NPV^Y]HM^ZD!1.K.Z5O*]%2J61:G'6>^1<SF%+TQ>0J,C*:C)1M:>%
M;W).'2^MX^71*M''>F3.DY30(WNOWYZ)O?N*K<818GLD ZA/;, CX_I1'P/V
M%'\X  !#Y_>'Q^(>2+D1=(YA(10IC 'D0 ?(^/A_G ?O\?'Y<(H,:]ZB77+%
M=6?Y+;']]>R58=T5CIUPJ.97.X9IBCO37Z4;GS?8[_ 1;NO4)6TN5VZC9.5<
M^U&QSII,3?U9$NF[U1OO^JE?3U=:_(GZCW6E?6DLG0E[VJDIJA<*)KA,NO!L
M!6VP5Q9#DZ>TA$!1CW090#5\C8DD,<-L+^"/UC^$IR18K]F_/=UT5J-[N?DW
MJH>Y/ZHMI<W"JN]S)G='R,E ]0B^Z':V,=8!=P,5U&[!U3+ZDX9D^L9 ZH2E
M6FWCN=:ILG;N3G2-$X=-L"I6:A+]/-R*4Q>X.:]D\;[-56LU_5:-<J?@]IM$
MI2MDRVWY5:'%0N5+MA:G<8=A:8YJE,UN;4BI%L1Y'.%UH]ZU48R[:.> 5%2'
M;2FFNI0T(H;P<;]!%];Q=0]8*UB>@=W?TO9\UQKK98:O28VFY5U8JKN%FH=*
M9+9)!:%5K<&V^LCO))Q'>[7;OUE5P:LT3"NF3V 33*)39A:V3DM(V#9UL0XL
M1T6:,%KV.<US6\;#<]^:&M! !:T7N=HY%TGD=PEVOE%PDY59%S$G(,LVP63[
MH$W"XT3<6)+3LO+L$4.BN80YD5Y<6,:*L!&-!Z3N8@N[4X1.$3A$X18O8UNF
M);!-VYO->\OSW/H*O2->^L69OH]3C[#.OXN8^J2D!\C]*E7\FS^GJ*"V7^C>
MX23*HBJ8Q*7UTX*$F:P%=[)]N.Q=XU%@QM%=ZNVV"Q[':A/I)2->K%@<5*-M
ME]T;ZE>@LP6MTPXG&<)&SKIJ=U&0,89O&';%<.5%YA=6O+BI0$UU7?J*=%=9
MV+K7=4J9?4WS*2R2+B(MY%=8= DMV?55LT9,)BOV&S5QCD#2R_5B:3)](JRC
M"PR5?67!1\6,C7ATS"R GBJ::#E.^N\:!RE9(O/=-4^N63KIAF?#H^TU7Z,C
M/M[E9H;+:57S/VA';1Z:0L2PV6Z,DT5$A6'/:U840.)VZK]NX**92M=5^/-3
MT[+E(O*F^RQE5DG6VSM#G;J[?O))!EG$++0]6K\29HW%G7FRDZ_D)>;7;N4G
M:SF:>F8B\,NFFDP:)(E(,(!/)R7<^.%*X5U4QM^G?U<E_*M,ZF>4N0].6^]M
M74'%*]E5KE>=R;ZV9FV-H<7H5?VF1C8&'96D2'F6D=%0\6PJ"%=1=DBQB"'9
M'9&!97VJM)  )H+KZ^DZ>7$G;@MPVX5-KJN!W&F35\?9BRM])%O8[O%.&L>\
MKD*NV;.K&N5Z\50;1B2\65\R=/%5419LW#A8BJ1TRF"=&V_#?F6HX:J[[-/J
M6O'*Z10+MO\ CVK=/L@:9SBN+4G08"Q:[&UEKGE?WME*5Y&,JU&JC!9M%/[_
M %V+G&1+&OH<LT&%*Z+[R$EWWTE=?EW_ %OWZUIV "[3A0[!0WCEV+%>-9[.
M]3(OKS<^P'4'KPU3F+K4Z?-:Y5G,;9]WI>GZ%*N&T5>+1(A DC)-I*6F5%B\
M/69UZ^@FL@W$'DF1LH<Q  -1VW<MYTZ^8E;W">?9+Y^?LAY_7X#SPM2Y<(G"
M*R=%217H]P0<U9:\-5:I9".:8@FW55MZ!H=V"U5(5V)6ACV)$5(<A')@;G,\
M]E;^=B(@1>1R9K?4>M4NFWG)^^_>5W%Z-GL[UNHOIZ9M%U:S]OFE1BK"1_;^
MI[-9:$>:WF\)3;$B-9G9VQ+LU:7!D1;(70L0#!P<IR[3R74J#LW&*]7. P;.
MLXOE-=CL]#)8Z#SJG13++@<-WHYXV903-NC33OF8BU>+5U-,(IPZ0$4G"[4Z
MI#' P#P@P%=2S!PJG")PB<(G")PB<(G")PB<(G"+"W8K$JQV2PW4\$NKR8CZ
MAK=)G:-8WU?7;M9MI%SK0S5RXC'#ML\;HO$RF\HF6:N$_:_ITQ !X0^KS^E1
MTW3H'B&_Z#U1U2W%L\=?^H%OB+3G-EK,DA&.YMA%(,3#3;R"C%PG8*@_DX6%
MGSQIDT%&,[%MY",<,E5G/O2;[[\JZ.8].7#+)UDL/5^1DKZ>M2&OW?>*M>FD
MTSC]-S+6+?J-@UMG=<^LK6-*6!F*G:+&^2K3DK%8Q84R\5)B^;/7Q5U?RZ]Z
M\VI0"EU3SK+6_=5(+L)G^<5>QWB^5N_9!;*KHV8[;4EH-AH50TJKQ#V#+<&J
M;N&?U=Z:>BY2;CK7 /81>O3D7-R4:HP(W50! JHXJ^FA%-B5BZP'8[?HCLI6
M[=HUO6[/.I"E62^6$VL,:U%WBGS-0L-2>YL3-W$=2Z>WKU(BJM&Q55<5J+DX
M?W4D>3=R!2@-?-HT=.&)Y,*+Z7#TL<9OE/95>XZ3NUJ?DP;<\%F[I:+TC9;G
M9XGL+:8"XZ#:)B6FHEV4MA^N:ZU+76D:WCZM7(I0L+%P#:,:,6[9UG?EZ4IH
MP&RY+[Z:U9T&S_1[1V"W.2PUWIU#V*3Z\S#JFS]2->J!)5J:B35^XV"JR6D4
M>I/YZHP\S*TNH6:(A3O0D4XPD6RDW;0S??S:U:5KMQ4KB]9<R)V&<=D$8\Q[
MDXR1#'U(SZ'#C6DX1O=U+T6829!&E=%L@RYQ1/(?33%!EY(" +![WA2Z^MXT
M@X;>8Z5H^]5GIZ?NSZDO3#&4+Z3.5&_5/LS< L"L -E*H$/?LC:#'FC"R44;
MPZ^LSG,Z!UX1%$I13-[POGA;<L$90V6^4='= AMCLC&( "ZK'4 #26@@\8TZ
MJ"I%5VIP0<)SN"7+(96MLQEK1#9LY9C9)T4P6N$VUN<XQ!#BD!L-CJ4::X M
MK4XJ#^1PWP!\>V$=^K\4:OGX#Y_MW^/P ?AY_1\/LP4\&$MHM*,TC \4#0].
MC'F7J0=FX\%O_P"'<G3.%:VO$KT]IFG.MC_IN>F&MT!N&EVA?74-2+I%>K==
M^AHTP]5-#_@],2,H#U109Z8%Z+@\@5N1$$FX)$(94ZA_Z4,HR9R7;DV^;(G'
M3+YIK:U:  &TP&<30U\(DD5 H+ZGH7AHX<SPQ2.3<F<F)>PS84:=C.C0IQ\<
MQQ'%<TAT*%3-+!0>$7D 5HMQ/,L702<(G")PBQ3&T$(O6KQHX2WOS7"GT:KC
M"%:^P:/_  /?6UV#\7@+'%<LA^% I@B+=+W L1$#K>]$$YS\W)O>F^_0H13/
M3KL!4W^U5O M]KU+R'>;+;KE/U6V4JPR5HSNSZ")U+C*9;=*A<:E(182#U9Q
M+Q[5][7U/)F*=!P8IE?;OHO4IYJ;Z>M9DZ@=<+?U^@]!;:-;V^IWZZW]U897
M77)9,+E>(-K&Q\95ANI9%9PU82==C4#PK2+@%!@$&+=%RV3*\>O3<(+N3>M?
M7N>]O?3G*;'/R5[I#FX8=IDFNJ]?W[$[ M2).;D%CG44=VV";)K4^[&65.*C
MLMLK\L9W\??*B;P<"4U7=-.C5LT:*++]&IMI8YJ%*U6W):G++M)F'F[*M6H^
MKFL<)(K.T&Z4E!12JL6D]"%<),)-9@5!M(.$UWB31J#CZ.FWP]&_.E+J'53?
M:H5TWI3J$6AE&5W7:HFV=:,-N4-<J%3$:,K':+/#37KB1SBL:!<33CF*DH"B
MR1V#Y(\1 1S^PFAHU&3.DBFL5P!WP4(P%U+Z_EC39>*+('8#K/L.[4NTT9YM
M4"S@9C7J[=XR&E,T)*0 YS -"+CDMQCF5CA5;I"2]C11F)EV]>MOK%HD$*[;
M+,S&\M]^6B$$Z;JX<@.S6=-?0OW0^$=D7]2MN?WSL-7&=8EZ4>NU)YBF3?BD
MM%!G&[MBYA9Z$E4;E/M!91B;11J> +'MVCULX,W46(W]XBHWWU\BM#L &%"=
M>G"ZGY@Z/PU'K=M5CU3+=(['ZW3+ZEAQ)]UG$#GV?/Z0VD+38H8];>7>ZN92
MR6)1W+-H)5PWC8F&+&Q+1W(OG0E6_P!SIHDWY#?6]3F  *'@/EPJJ\(G")PB
M<(G")PB<(G")PB<(G")PBUS9[@VL8+.^I;K;9W%R$EV!T)QL..LZT5Y+3;-2
ML]<J308UE+QCF/214G5K=35UF,:Q^LD7359F!E#+*JH$;-]'J4ICMN\]/.H
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MUEKA\U^@SS&09%47<,&9OI)6WOTBI& AP]HY38ME=:TY8UCF=DBP1A'A0ZN
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M\A#HV2);R)XMXL@/N'#B/6649J.$0!)<4O?) !#AQOO^2HWT[[/0LU\(@^?
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MQ(&W!?A-]EKP0Q92:A0(]L,CQ)>/#@NBV+,-AB*^$YK"]S9B(X-SB*D,<?\
M)O)'MMJR2C2$A8]P! <QT5&,7!"'*8I5FK!!!3W:@>R14GMIF,4Y?'M%^90$
M!#G>#6N:R'44!8WF(:VHKIH:@G6%\M9F*V/,S+P"T]LQGD%I!S8CW.8<!0.:
M014DZ" 1175S4OR6"J[4["P[#:C<W4>*5:L.=95"1$D+AN8KR3KTKHB\RV!N
M18SI(S-"<C#B=9%-)4'( @94Q% 3;[[^A33Z>B['8LZ\*IPB<(G")PB<(G")
MPB<(G")PB<(G")PB<(G")PB<(G")PB<(G"+0/W8ZR=C+!VUWKL[CN935GL^,
MY1TPUW OH;N*8EU#2,'U':Y/2L<AW[QX4S&2NV4WJ:IBRC]-K&>;:R476622
M5*4H1I_/5M&% ?->H?6CT_.V:57M#MWE,I>K5=.J>*:5NL.UE(.,:[%JK[OJ
MMVB[%]?6T@ZE$$'D]-49W*U"+:RZB=;EV*$76G\LC%O5#HDI2[8 .;6><==
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MPUTW3,FJLY.UNCWVV2:<JI)LHETQ)*LFD?/2$!7Y.3=1Y&X0$-.<;FMH7$X
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MY>R/W!4-_)"?<<Q3%_%W@0>0^8P%R$/L_J;B!_G]W[?@>4<)=JM<"9*5<!H
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M',0Y:.TOA&*P2KX;7O;4O:USJ&ZMUTN/YH9ZB?\ %AO?_,E0_CAS:=\.P/\
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M1[]"/7W< DB91P=F98BY44R+%5,?<ORSR>$HR9,5W$/B&&V,V X%SLTDL+0
M: -K73A>*%<4WL9>%J8MF-8;I:RW6A E.WHD"+;+WM; ,5L+C,]S'0[WQ
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M-AUWMQ699RLZ-#V:F=B6SV6ZJTTCP7 &?J9?8;OMC0L<Z]XW9)9Y6G"90]E
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M8]U'62^#9<U:;IOB.V0R%+1(4(@0L^'GEXCD4#_!I6AHL)C_ "1O?!_]*U3
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M "@Y-:_YS@^KJQ3\GOWH_N1M_P#W.IW_ $;E[E<H?FB>NQ^ ?=U)W\N"'_E
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M-ROM:R9J'/6=/6IQLI-P2'PHT(2T"'QC'"H+<YCA4'05.TJI3^/ &^/WE$/
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M6D3[4J[@&[D\RVCR'>+L4T$CG*%V^/*H;P1?>#>#0WZCH.HK2SZH_<".Z/\
MJ6=+MEE*0_T%)7J=V9IY:]&S+>#7 \U?\@<_6!W[MJ^2,DW+&B0R/N_>J'63
M,!_93.!N&MZVH-B2#IV/!=&A"*V&6PB \N>' !N=^S>*9U+@2:W479?!/P83
M/"OE6[)F0M.7LJ:@69,6GQ\Y#BQX8@R[V07!W%$.<YQF+KZ^#H"LO^:/*G]O
M5FR_NDP_\7>8/WR+/^;)W[1"]2],^\BRD^F]@?8+1]I/YH\J8?+JS90_[Y,/
M_%WCODV><;-G3_WB$GO(LI/IO8'V"T?:3^:/:G_<M67]TF'_ (O<=\BS_FR=
M^T0O4GO(LI/IO8'V"T?:3^:/:G_<M67]TF'_ (O<=\BS_FR=^T0O4GO(LI/I
MO8'V"T?:3^:/:G_<M67]TF'_ (O<=\BS_FR=^T0O4GO(LI/IO8'V"T?:5#?R
M1U4CA[(]6;+X'[M)A_V/^YT?VO ^>.^3(#"S)ZINNF(0/H/1>GO(LHC0.RXL
M'-J,[-L^T'&A.AI< >D*JO\ )%E93;(OU>J]B,W=.G;)!(NEQ KE69$;G<&7
M,$#[L$%".R @"8B<IDU/>@3^=\WT3+^3;)P9P6=.N@1(AAMSIB%0O%!X;+R;
M\2ZH(OP%_"PNP\MV+;MH6*_+*Q&Q9&!*/C18=G33W!LZ8HEZ4<W-+A!>7G.^
M#&DAUWYP_DCFIIIB1/JO:"?'V@ FEPGM>T/P$?;-7_(CX /(B(B/Z_CS:MX3
M)"H)LV.V@QSX9 '(&WZ;J4UW%<P[L(<H&-(A9<640XWCW/F6NOI6AXUU^-,!
MM!*W+=!NY#?O+BZVSL:*^SMJUNL_2S5^0FFDZL=6"2CG'U@1ZT:LTRI.B2 $
M!#W/MIBEY.8WM (9K8EKP;<DFSTNU\.$7NAYKP [.8!G5H * F@H-N%%YGX5
M>#B;X+,K'9,3D_"M-_N?+3S9J%"=!8YDR8G%T8Y[W-<!"=4%QN=> 2IT\YA=
M;)PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PBH8H&*)3?$!^8>1#R'W?#[
M!^W]'"+H+).050@)NUV%T6.@Z[$R$Y-2)DW"P,HJ(:+2#YV9)L19RJ5LU;JJ
M^[0255,!?823.<P%%Z44=*MW0ZO77JNIW5KFIP\CUC0I5CT-SJ2C"<:1S2JU
M1:1;V)^ZB'\8WL;=U'.XE^T7BUH<LLH\;_1B,U5U$B')S4WP6/[;ZC?1NB4O
M)=!N6]U2NU7;Z$VT[-GDFQLR;F7S1T@P<&O<C#$AE9:K4YF22CR2=AM+"%B8
MI9PDWD'398#)E*#7A7F/.I@O+-5HRJ/[VXDVOX*M()Q:W<XV.=\S4@F4:I*J
M2R!V7T@7C8(U,SM!1D585T (+<% ,F E5&NK]X>IEJZHO^[E;UF$=]7HZJ6&
M^R.IA&V!FP:0%:<NFE@=NH5S%-[.C(,GK)=DK%*0Q9A=Z5-LDR6751(=TW;W
M_IZ$T>C2NVNG<;JO0\,J_8?0=>J%3Q:]5ZKV>J6ZU+N(A&P0EP2BW5=7BX61
M;HSSI9VA+QKI6/2BQ?Q[=87,@V:HH+*)$4A:U8ZO;(>-LE2FXFR5^8:D>Q$[
M R#67AI%FH7PFY82+%5PT<H'* @51!4Y!_.#SY\\;Z?3Z+D6.NPZB:N![@F4
M1,8<@TSP7P8HB(TJ>+X ?S?B/@?9\_/YE\B'D&G\]>O\T-]QP-QUTI?0ZUY[
M_3U[S>DY3NDO5*I:G)9 70:[@^?1-R2E.O\ +STB6P,X1JE(%>R[?.9)*0=)
MK@<JSHCUR54XF."IQ$1'')NV\FI>/&A3<S)-CPGYD41(#BYKC6K2XP:$U%X!
M)N!P7>F3_!CP]VA9=FSN3EF981++GY*%.69$D+>XN6?)1A6'$AP8=HPS":X
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M)PB<(G")PB<(G")PB<(L(=F!\==-X$ ,(_B=TH0]@!$WD*;,B'L@ "(C\/@
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MJ5DYZ%9L>U'1)V)$A2O:\L]L)X<8;7O<_.C-+6AI-1G+X_S1?UP_XA]X\?\
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M+F!XS74!+34:+P5YERWR/M'(+*>T\E+5BP)BT;(BL@S466B&)!+WPVQ*PWN
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MHF4:/T&[E(%DCE41]XD7WJ9@4)Y((&'O[)&%$@Y/R$**TPXC&.#F/N<"8CJ
MC7@::B-87R9[(V:E9WACRPFI&9@3LK,34O%@S,K$$:!$AF4@>$V(VXWU%U14
M&];4A/X#S[)_U 'Q_P ?,D72"K[7_J3?M?\ T^$5?/Q\>!_7X^'[?"*O")PB
M<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(M(7JL6.1J_97TQYN$VS+NO$
MJTV+L6FWUK98B,G,]KHK=:;F@LWF(N9M]$CW*TN10(F.%:S,3(OG:"R*3U4A
M&BI#ZO/S[ZL1C/;>PUX<Y+E=3GO4 Q#4Z+IW</)<IW[?.J9:ME;C#\4ME6N4
MDA#3ME@=/TS\!G&E:!6JW12:"XD8%>-86ARRCU6KQ5"2;%*[D4Y<1?K]-%&N
M_P"AZ V:[UU_Q?MT]ENOU1[?8'2,MM&H=@[A7U=8=SF.V^[;5U"B.Y,%%6J5
MHXQ<U&U.<@[+.2+@YY-^_P N4L9'<NW9M28:[ZGGQTX;-&O&_81TVTY?1>@?
M9B->2NJRK[+W_97-WB>J:34ML?02\'3W#XE7JFY4E9Q#Z_2JVC,EC8*V/W"M
MF1]VXK]J$DY!N$R@:$7@7B\X W' @UOQYZ5!6EX!8:A[@ 20PEKW7$$ BE":
MT!NH2"*$!>#O) 5)D^<F,"HHC48A,"JB(I@<K8!$/!1 0,4#^0'Y"83#XYYH
MRE=".4=L9S\\B<B7-.BINJ;J"A%#K7VWX&Q';P1<',7^$&7.2UG0 R8<Z)"$
M2$PN- PYP-'>"344NH+JW][9?ZA+]I3^%SA\Z!\F?K,]:[&XP_$@_5C>M/;+
M_4)?M*?PN,Z!\F?K,]:<8?B0?JQO6GME_J$OVE/X7&= ^3/UF>M.,/Q(/U8W
MK3VR_P!0E^TI_"XSH'R9^LSUIQA^)!^K&]:K[0#\ *0/B A[)5!]H?ZD? C\
M!#S_ /2^?-#S!(_8<*T_I-ICB<1T_K^;RV)FAS88(<US V'-$N<#^R[,J0TU
M%2;@:+]JKXHLDX_W(>TE)O)(RHF5]V(NFK1H*0)&( @</HOO#*^^$3 <I!('
ML 8-\Z;8ZSX,H8=!#C%X>'C.>"QS:'$4KIN-PQHL>98;8.5TUE&(L-T2:L=M
MFOEB)K-81,0XYB $@ D0P#RT I5?A]LO]0E^TI_"YM,Z!\0_69ZUDO&'XD'Z
ML;UI[9?ZA+]I3^%QG0/DS]9GK3C#\2#]6-ZT]LO]0E^TI_"XSH'R9^LSUIQA
M^)!^K&]:Y%-\Q A?!0$1*0JH^T!@$O@W@WP#R/P'[Q'Y_+FAQA&I#2,T7>&W
M$UO%*[*[*5H+U"]U<\,91E:M9#F7!^<"P->&X-J?VC@:+VT^@:=,>A,>4I"D
M$-AU,/!"F @@1S!%,8!-Y'R)_P"F PA^<)@*(E* CWYP>M+<F9<G-\*8F'7.
M#G&KA0N&@@#-VM#3_2HOE!V7!8>&6> A0H3Q8%AM>R Z*Z&'0Y=['"L0 UK2
M["@:1I6[#F;+S*G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")PB<(G")P
MBXF(4X>#% P?I#C%%Q!%(! 0(7R'R'QY$/AX\@(_'S\/G\_F/S$>$4-.PG=S
M'.MN\]7<!T=K;4K1VNLECJN?3T7%,G=0A9BO(Q0)ENLHO)M74(WFI*=BH.&<
MMV#]->:D&3);W N4C&(NLT;OEA>==P\XZ56!6S%U70\FMVQ%F4(YB- J%0J0
M2*RI[G8'4HV5B'\JVA9QY%MDH]V11C&.';I=J@*9CM&_F3S:;_R4>HOU6\T?
ML833U^O79B#ZDVBS1]:@.XTS3*JQQEX68ET8""O#N$&YFUR*RR?FED&$3HTK
MG;2O.$'C*85,W@7:,J)#T[^C]%LZ"X4M.P)U$;)74[6NT^GI5@9J,+8E8\P"
M(/TX7Z7]9JLS% 3 [3;'1$"B/O/!?/"+OE#LP5!H )'< F"@(E.F*B::@F(1
M4R7M>\*F<Y1(53V!*)P$ 'X&$"+0'ZA_:O+>G?JF=,];UUK:7544Z@]HZL1O
M4(9G/2II27T+&7+0QV3Z3B4?HI4H]R*RWTHQB']T )B!A,7C;5M:5L:4,Y.Y
M_:_&,A5ALSWB(^M  2T4.;>20!SBN<\'G!W;_";E!$R>R9BR<.U8-GQ[3=V_
M,1)66=*2SX<-X,6'!CN,0.CAS6&'0EM<X7*[_P OWT-_M;W3]S*M_P >.8QW
MP<G-4[]GA_BKN[WH/#!XQDI]\S?^[T_+]]#?[6]T_<RK?\>..^#DYJG?L\/\
M1/>@<,/C&2GWS-_[O3\OWT-_M;W3]S*M_P >..^#DYJG?L\/\1/>@<,/C&2G
MWS-_[O3\OWT-_M;W3]S*M_QXX[X.3FJ=^SP_Q$]Z!PP^,9*??,W_ +O3\OWT
M-_M;W3]S*M_QXX[X.3FJ=^SP_P 1/>@<,/C&2GWS-_[O5!]?KH:(> K>ZB/W
M!F=; 1_4(7<1_3\ $?AQWP,G#@)T:R9=A '-$JJWL0.& D Q\ECL;;$V7:[A
M[GW\BQ'!>N#TIC=JT/0G->VP]?M5&SBMQ9"9Y!&?IR-5DKP[ECNV?X8D30;'
M2L,?]&7!8_OC@X()2 B'M3OAY.DEE)P-;>#VLR\G17C*7:J"E;\;M7O/>&#,
M;,%^3#'.<81)MB:SRQIN<^DD6B&22&&@-21>;AEW\OWT-_M;W3]S*M_QXY>^
M#DYJG?L\/\1:/>@<,/C&2GWS-_[O5!]?KH8(" US=0#Q\RYI6RC^P;\. \#^
MD! 0^?D/GQWP<G,*3M^N7AD<_P *GO0.&"_X?)4W&YMLS0<=@)L^@.HE?5/^
M2 .B28A[$%OQ"E\"4H9Y7@*!@\^!*4+O[(#X$?B @/S^ ^>.^#D[2YTX,,)8
M5(J*X1,+O3>GO0.%PM+S%R7+B,TL=;,R26UO))LTM)PNSJGS_H_F@GHO_P #
M=@/W/:__ !XY>^%D[\><^RGVUH]Z#PN:\E_OF/\ [N3^:">B_P#P+V ^0C_V
M/*_\@#R/_=Q]W'?"R=^/.?9B,2!I>-:>] X7#6AR7N!/\\QQ< 2<;.V;B]2
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MNATW3Z6[>/XYM:J)8HNT5]=_%K"WD6:4K$.73-1RQ7#W+I$JHG05\$4*4P@
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M:?0W/]BK?^#K_P#B>.UIKQ68\D_U)VQ*>.RGEV>M<B,G1C> ;+!\!^/N%_L
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MTWQ#X^?E]PB/]+\N!7.;05\( X7#I&D#SZ%" ;B*@W7TI@<:[*K0%Z>WIO\
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M>YEI_-T]]DF/PUS+JF;J 84;Y3%P*)0-[FUUY0"^UY^)Q+)>R4  !$?B)O9
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M^!Q=XV_ZY]I3BX'B\MY*0_!3V _K1/\ D)?P.+O&W_7/M)Q<#Q>6\E(?@I[
M?UHG_(2_@<7>-O\ KGVDXJ ,9:6'^JD/P4]@/ZT3_D)?P.+O&W_7/M)Q<#Q>
M6\E(?@I[ ?UHG_(2_@<7>-O^N?:5XJ!XM+>2D/P4]@/ZT3_D)?P.+O&W_7/M
M*<7 \7EO)2'X*>P']:)_R$OX'%WC;_KGVE>*@>+2WDI#\%?3W1!1 PM2*F(Y
M2$I?9* CY 1$/!"@(@/@//GS\O !Y\>?S?$<P'-G'CP2;GN%75H+ZD75)O\
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M(]3?T?\ 0<9>!^_X_@#\?V//)[HY(5_E+%V^!!J-7]'U)W'=E#\EPC?>T?\
M?%7^6<]#<?\ SPZF_N.,OX@\>Z.1_P K8OU(/LJ]QO91'"%PCG_Q:/\ OB?R
MSGH;_P#"'4W]G'&8?XZ#P+1R/.$6Q?J0?93N-[*+Y+A'^]H_[XN1.SGH;^T
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M*" ]T.P(&>8 >UP:ZL8O+<X-H2[-T4SJJY@]!7T_P_[I-Q#]6J5[^)(<_ Y
M9,_(1Q_WEWI!6]]]IPUG&<L8_P#@4+\55_(*^G_\/Z)=Q']>J5[X?I#S21\#
M^U^OCN R:^1C_:3ZE/?:<-7C=B_<4+\5!]!7T_\ XA^$NY#_ -]2O>/_ )B1
MX[@,FOD8_P!I=ZD]]IPU>-V+]Q0OQ50/05]/\/\ NDW$/U:I7OXDAQW 9,_(
M1Q_WEWI!5/9:<-9QF[%/+84+\55_(*^G_P"?^N7<?UCJE>\_;]])_P H<=P&
M37R,?[2?4I[[/AJ\;L7[BA?BI^03]/\ \> LNX?J_&K70#_YBN.X#)GY"/\
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M=>Q$:OI6'XQT"=ZWGN9W23DI2K7W1ISL);LSF;C<XI=T5'0)#.Z? P<9$-[
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M9<HD[!,9[+33515Q5W]KK[JJV8S'W:J::K:PUQ\[A9E@^2>1TC'K';O&BQ!
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M!8;'5;9<HT@.H1!945%-0N.!V+2_AEX52TM&7F5-:@C/MB.YMQ!%6D"NL5-
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M03WZ/"7\Q9&?=DW^_J_AZ(8@ B ]+_6B 0$0'_H.X<(?#R'S ! 0^T! ? _
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MMYMQZ>52=3*42%$2A\@^8%$?W@_9Y47/V"?U)?\ DA_FX1<3 0H>?8*/D?
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M8'+[GJ,4XF6B],@;2P?2CMU6UC-[*U@U$S?0;(YK:Y%$I]M77DHM#G27!^1
M4%?8)BHU=A_5"Z\YZ[&D9!J^/:GM<=MF1Y-9<P;W= \M%HW;5JQGMU40^JCJ
ME?V2D-9Q9](PK%=VYBEVH$FV[1$JPD;[X5YU#@:=>X6?>YG8:S=:<_SBX5J#
MAK$]NG93KKBK]M.+OD&K2"V75JW09N7:_0!(H:5B8^8</XM)41:'>IID<E%
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M:1_D@"QCE,M*V70LAJU;H4N:D/G\G=X]EU%<)I0E*=J1RJMD1;VLXHG8P O
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M_IOS"_G?+Y_#X_(/G]P?=PBY  !\@ /U!XX1/9+_ %(?M!PBI[)?E[)?'W>
M_5]WW?#A%04TQ\@)""!A 1 2E'R(>  1\A\1    \_+P'"*OL$#S^87XCY'\
MT/B/GS]WW_'A%3W9/(C[!/(AX$?9#R(?<(^/B'Q'X#\.$50(0/D0H>//CP !
=X\CY'Y?>/Q'[^$7+P _, _V\_P"<?VQX1.$7_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>img102984888_2.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img102984888_2.jpg
M_]C_X  02D9)1@ ! 0$#O@.^  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $^ 7 # 1$  A$! Q$!_\0
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MT)N/DCR;W+IVK\@]A\<J#Q\JNI7YB:GB-?GNVP[?M!K9IX)N;GM@5&ZH-*/
M1U?0A8Z#AHMB:=EU; K*R2B4<R:D01O=2U&(.>[>&*U.%TL!:TP1>08?A=;+
M4SM(+ZE]4[&(F11%S(HHJ3>L]]23%G.X1RTU*(Q:7#F8A43'>WI&U-?7T45/
M3O#@V+J/HR22>0,=(YU3&QKF-C<)8HU[S]L^LX&_U/D S1N<UJB)Y,1T1M6
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MIVS$S.8]^4C74Q?+'>.6H;1F(TD=2]A!F9!U$3&!V9AC93O+H&B,>;LG9]:
ML-/TM3&SG:M,;:%KD]2Z#8=<;<O6O[H6BVM6(<6RD3]KJTM&RT_5K.O 0BLS
M%OUC%65BF2[=5LLB!QSD)ED<^0[[9**EP^H@)(IZNEHH6PTD=5"VS9O)VM+H
MWN\]KY)CO$32M=C$.IA=!&2T>7U.)QR9&6GK:N:>>HGIY' F)TKJB5K@,C&6
MMMYC"WCZR[.KC-J-O46M+@K6T;T>1U')5Q-_=I^5%HMH]YLUYKM-95\X57>H
M19]N7))Z5VJL>616CBR*BYX])0=SJF9TD,I+2^"6HGC.XT 25.S5%LG,2T#=
M+78-A]+$&!H8V9CJA@;(\K%T49@?3-8&0/:UIC8Y^C=H)]ILG.<Y^\<7J99G
M.+BYT;A"28V@"2=\<1]6\@9ZO7*?E=FT'858BGE=B]D:6V=<-1WPU4D7B$D_
MJ,E8J9)1SF9K#F1;)/@AY8KQLT>&7=QX-'+EPJKQF-ZN661A<!4-@951![A#
M5,IG3.IVU$8(;(8#4U/4ORDC$\K6/#9'@[7.WXXXWAKQ"^:2G<X OIWU @;4
M.@?K'Y0VFIVSAIW91!#OM<8F%L-7OLR.*E_BH6#?PVQ(&'C=7O-/3493MM[#
MJ[385$=2TU8THS:1(V>(?8[AA:K)8[8SD;:>3?#9)Z7E':[M5^X*?.XZR9X:
MQK)C0.-.UC&TL4N%L9%AT\%,&B&&>C@CCIH)8V!S8(XXS<11[DWG;L0))DB=
M6D5!)-2YF)$NQ"&2>_6/AK93UT\9=9TUY&EI?)OS8XXCZ4>ZTWQJ1_ R3ZD\
MCY&<E=HQSJ=DCN)!_8*96Z(^<1$@58CR"42@JG"'8*1JB*D?*-1E&IR.S]\,
M*EC:NG933C>BBGJJF/=)8YLU9B]5CLLC7-(<TMQ*LFEBL?O;=R-IW6 +93S/
MI9F316WXZ>GI0' .8ZGIJ"+#&1/;HYKZ.%L4M_XR[R[-Q7[C^)&CHM*,9M*J
MH,3$\=D>+#6#7DWJT,.F$3(B%=<,#J"FX='(@1%674$7ZJ0G(=4>^81SK7.Q
M 8NVJ-QCCJ=]>([Q7?2C$1 :<LW33B(8K5[G5;I9>+=MU3+:Z(G#QA8IB6_0
M[YGT3GDR.:^<4 F?,Y^\9W2?1M,7F7>+G"1SKF5Y,,/^S6XSK4?3=!@T]J42
M'TE0'>J:V]USN+8-$L5BUG+.FTA8:/L&QUJ;CY>ZP5FEFB<U/DEW1W;Z8.XD
M0=I.7"QU%4[RVHJ9ZEK)!64=+0U5.1:EGIJ&*2&ABDIQ:-S:**:9E,2+L;-*
MT[S9'M., %+%#% .K\GJZFNIIAG44U362-EJI()W7DC\HD9$Z5H=NN,,)M>*
M/=FSC]Q3U!QE:BRU3&S4:U^I[JW5Q4I>P24Z*=/TW$2<%0V)#R"BA@<1T7+N
MVSM\(F=27[BH\.HJD!QW2U,\PGZU^^ZIK#B$[R!O253J##\-?(2  -^GPVF+
MFM:UG6B20-!D<%J$$3963-;9[*8TC+$[K8#7U^)!@!)ONU6)51:YQ+^K<R,N
M(C:K(YH6Y,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(M7ME[5[2D'
M=MAT>$T/S;V8OK*^6;6UELVH^(NX]ET<;=47@,9Z-C+=4X"2A9(S%T8J2_F[
MD3HF,!5B)FZ@#Q^?GWJ^(]OPMEW]U\[=;[K1K#_1'[2;IXCU]H/R(^ !$?Y(
M_,'KZ>L/GZ2X[_FZ6&>8R[\^[)8'M:=8?!Q&[2<?G#@/R(^?K_)'QZ=!#P]8
MAX=0$!&@@\0.\COMR^SM4RY^QW;V<;<;:A9]UHUA_HD=I-Z^GO!^0_A\?7]Z
M/P#U#^D!Z> @(DRY\^#N'</GU+'NM&L/7[4?M)^G0!]X/R'_ *O"H^L![H?/
MW@Z>HW1EEF,^W/O[O@5;#TAZG\;?R?7W$Z6N#M:=8#TZ<1^TG\>G^8/R'Z^/
M3K_)'_F@("/3KZ^@>(#T=YMVE,KVN./!UO\ N\>'!/=:=8>'\4CM)O'X/:#\
MB.O0! !'[4/GZ]/6/0<>(^>^WSXIE>UQWV=;CV7X<0-1Q3W6C6/3J/$;M)P^
M;VA'(81^'H'4*D(=1 .OK_'UP;#B._/[1PT/LNEA?\(:@7LZV?'\&]AQ[BL^
MZT:PZB'M2.TFZ@(AX<!^1'P"8!_DA\11'^@0 .H^&$RYCAP=Q[V^OEQR3W6C
M6(>OB-VD_P#3[0?D/ZNH  _:CZA^;J/0/$ Z@ KCTAW7SOGE[+>(3+F.ZSNW
M*Y;;AK>VF:Q[K1K#_1'[2;KX]/XA'(?Q$ #H'VH^L1, !\_KZ!XX^?7Q^?!,
MN8]3O@GNM.L.O3VH_:3^H!#^(/R(\>O3I_)'X1$H>/3[(.O0 $0999C/OUY:
M:ZZ7T/9=8>D/4[+37S>WA<9%9]UHUAUZ!Q'[28?'IU]H/R'Z>KKU#]Z/B'B7
MY_K@\/ >CQ'#V^U,N8'@[[!EXVT6/=:=8>'7B-VDX>'4?X@_(?P#UCU_>C\
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MC0\0EAGD,];B^@(X]ZZGZ@^DODBUH'_L16_A]?\ T;_LRW/NX#AHKH+  ?\
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MA$PB81,(F$3")A%4WF5_BPHP_"')7BF(#U$! 0Y$ZV$!#I\/7(?M'O"#4?\
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MR$_M.<@/I&Q]!TGY?%/YXQ3];3[J>T7YIV!_HSZ/_P"S:>U2UW_/+D)_:<Y
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M(VVFL7U>=+5'4J3,D6>L*U?:".Q1G1<>>C*%>D1@87T2# J3$4#&%QYX+M0
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M:N"'Z"//JZM\+L.ZAM/*RLKH:>1TE5'#NT\D,\IEI@X'RJ:\3>KIXR'2,+Y
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MQYO\G([F6-*791&J-9$TDRVR^:,ZPRU](1,HIL:9I!)E="+3L 6Q-JG)RT<
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M2SS4\P:\"2&62-UVN(/I0YH<02@!0Y/Z" "@  'U6J-X  = #_OW\6<C]\.
M_GK"_P#M]-_[JZO[CG2V=>C+;[_5''OU!1GL3='9R[=]$?53VEQ%V*%?<^>0
M@76V:HLPQ+H3$,9:/-,O7AF@J&(F*I4!(184TQ5*<2$Z<"LK-C\0?#)756SU
M9)3'>@DJ9J"=\1)SZMTCG.:#?-H.Z38D&P7U>S&R_P"Z0V*-:=C]G^F+98XE
M#Y/B'[W\,VOP@5T(#@(ZH4,, G#0YX89 YS YX86A[@>1=]Y]G;LJL-J5L';
M/$JZU%D+8S&M6BXZLFX1B=FEY!H=C&2#]=HR.V0$4$#M4D3)(&,@02I&,0;6
MU^R.)1-AQ"LP"MB8[>9'53T,[6.&6]&)'NW'6 &\VQMEHM6S^R'[HK93%I<>
MV9V:Z7MG\;G$HJ,6P?"=K<.Q"I;._K)FU-72P1S5#99+2R-F>]KY0)7 O:'#
MY)[N[.I&FQ>NV^U^)+:A0K^*E8FFMKAJQO68Z4@Y%O,0\BRA$'Z<>V?1LJU;
M23-TDW*NB^02=%4!8@'S/Z2V4ZJG@%?@8AI)8YZ6)M10MCIIH7%\4L#&N#(G
MQN)+', ()/,WR?LE^Z+DQRKVGEV;Z7Y=HZ^EK:*MQV;"=K9<7JZ/$:66AKJ6
MHQ"2!U5+3U=%-+23POE,<E/(^$MZLEJ]-"\H>#%<E;+.0._N-,/,7.1:R]NE
M(W9&O&;^S2K*/;1+22G':$N1:3>MHMFTCT'#LZJJ3-NB@0X)IE*&R#%]F:9T
M[H,3P:$U,[JFH,=92,,U0]D<;YI=V0;\KF11M+W7<6L:+V 75UW1OTY8G283
MA^(["])M=0X%22T."TE5LWM)/38513U4U;-2X?#)1NCI():RHGJ9(H&L8^:5
M\C@7.)7Q#DUP3+<5MA%WWQF+>G%?1JBUO#8VN@LBM8;OUI1"OGF0E@?GAT9)
MPN_3CS+BV*[5.N"8*&[V&XQLRRHFJF8I@[*FICAAJ)VUE()9HJ<RN@CD>) Y
MS83/,8@39AE>0/.*R/1STZ.P1FS3MA^D\[/1XG)C4>"'9W:4X4S%Y:9E')B3
M:$TGDS:Y])''3.J1'USH6-C+]P +SP[L[.OS9RS#;7$X&CR^);2=M_9MK#R+
MG9"+E-XE>UT_27=4MB;I%%P2>. R1%DR*%<@8H"&AE=LC&V-K*S 6-BK),0B
M#*BB:(ZZ4R&2K;9^52\S2[TP\]W6.!-B5V7[T_W18ECG&S72Z)H=G';(0RC!
MMJ^LBV5?$^!VSL;_ ";>9@KH9'Q.PUI%(8WN88MTD*2PYH\0N@?QH-!#_P!K
M5&_WYG._?#@/YYPO_M]-_P"ZOE_N.=+7_!EM]_JCCWZ@GMT>(7^E!H+\[5&_
MWWC]\. _GG"_^WTW_NI]QSI:_P"#+;[_ %1Q[]04.[MW5K7D;2W&C-#7"!VY
M9M@R]9BY64U_((VNKZ^K#2PQ,U8K;=++"G>0D,W8P\>Z)$QKM^E)3TVO'Q3!
MJH*RRS?@XAB%'BT'T=AE1%7S5$U.V1](]L\-+"R=DLLU3-$71Q!K(G"-CG"2
M60M8QIN2/K-C=C]I>CO&H]MMN<'K]D\-P&DQ*II:;:"FDPK$\>Q*7#JNCH,*
MP?#:X0UM9)/55$;JJHBIW4U#1LGJ:B5N[&R2_8!T_K$?ZQZY],O"TPBJ;NSW
MR'"W[]MT_J)N>$5LL(F$3")A%KA[-O[6^87X0CEA^EL;A%L>PB81,(HPUVZ
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MVS4A&Z!E3',D@4J1! A0*!%B4B(N;:@QF(YE*,@<LGH-7[9%VW!W&O$)"/=
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M*<EN(S?DOM9S=+G*6"MTW:CG;TA#(P=&K[Y=6.HD(>"G7M385> 2CVA6>N6
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M6,:;EC;3ANZYSB2TN)SLL'M+\2QBO)N,4KFU@:;E\8%'2TI9(\D]8Z].7!P
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M#_BINM;4&V9?2=RA*)8K038-=A8F;LD?$5>(?3TQ'5TDVDYCHJ9G&4>I$LK
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M, :K'$7R?GN17\K5;@*;78&HU6(80%8J\/&UZNP46W3:1D-"0[-&/BXN/:I
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@J81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>img102984888_3.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img102984888_3.jpg
M_]C_X  02D9)1@ ! 0$#O@.^  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $@ 5<# 1$  A$! Q$!_\0
M'@ !  $$ P$!              @!!@<) @0% PK_Q !C$   !0," P,##0L(
M! 83   ! @,$!0 &!P@1$B$Q"1-!%%'1%187(CA35V%Q=(&1DADC,C64F*&T
MM=3P&"0G4EBQP>$H1Y.60D548I6S)3,T-D-D=G=X@H6BHZ2VPL32T__$ !P!
M 0$  @,! 0             ! @4$!@<#"/_$ %(1  $# P$$!0H"!@<$!@L
M   ! @,$!1$&$B$Q40<306'P%!4B<8&1H;'!T1;Q"",R5)/A%R0S5I72TS5"
M8W-%=I2RML(E-C=&4F)D97>"M?_:  P# 0 "$0,1 #\ _?Q0"@% * 4!@&:S
M]"PVHRR-.2L!++3M[XUNS)32Y$UV(0K%A:<M%Q+F,=(&5\O4>NU9,BR"B"9D
M")I&!0W$8  3MX>WW_;XF8WMQP<;P>J4M&1O>B8$0D9%FP%;A$ ,*172R0J
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MP5.*>M%Y'BS5>N=MNSESMC/%S$7".QR7W\T13>E4,A0"@% * 4 H!0"@% *
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MHII[I1076::X-E="^BM,LS:ZMIHTA=Y54TT,D-*KHVS/8LC$6^*Y1H10"@%
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MTD_]9K5_X8M9^>.F+_V!=%'_ .2^F/\ _J6TP?<^#K^SCK>UPQ%LYUO[",%
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M621N3BUS785')VHJ;O8IV^_3$1 !$1 =N0;_ -WA61\<IG&_/;W+R7DOYGU
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M$-P8!L !L <@Y &P!\6WA0I6@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@%
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M:@Q'IT#&[H=^?QA_'.JGT7Y+@B_5/FAMI*KN?@$HE'8P]0$ V$-@-MT$P#N
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M?@F >@\A >0AN \O 0Z#XT!\1=M2G33,X1*HL)P23,J0JBHI@ J D0P@902
M("?@ W" @([4!\),0&,D! 0$/(7?3YNI0$<]'?N=<>?-IC]O2= 2;H!0"@%
M* 4 H#6[:0[=JAEX1,( 72580B \PV]?"_41Z;<QY#N/C0F[*=Z_'"_1,&R$
M! 0 0$! >@ATH4K0"@% * 4 H!0"@% * 4!01 -@'QZ4!6@% * 4 H!0"@%
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M;.I&XK;O5#(>0\.W];D'.6<:^,6RC2)FYVPKH(0L]9TT9VT=$<QZYTRN62H
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M_LLU4RZ*,9<:I XKARJ(<1R@(A[*EX^ CORZ?I\:<_A[D!L+[]#WY+_:$]-
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MH!0"@% ="0E8V);J/)1^SC6:/ "KM^Y1:-4Q4,!"%.X<'32*8YA "E,<!$1
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MF2(DLB32HDDS<[,LB;<B;2(BX>[+DRC6HN%WHU$7<B%_UB44 H!0"@% * 4
MH!0"@% * 4 H!0'1E/Q;(_,7?ZNI0$<M'7N=<=_-IC]O2= 2;H!0"@% * 4
MH!0"@*".W7IXCRV#Y: K0"@% * 4 H!0"@% * 4 H!0"@% * 4 H!0"@% *
M4 H!0"@% * 4 H!0'1E/Q;(_,7?ZNI0$<M'7N=<>?-IC]O2= 9PO2][1QY N
M+IOFYH2T;;9*(IO9VX9!M%Q38[@X)H$7>NU$D$C+J"":7$<!,<0* "(@% 6'
MB_4'A?,Z%PN\791LR^6MJ/",+D-!3#9<T"Z5 3H)R1#&(HV*X('&V65(5%P3
MVR)SASH,_#GN\>LR>%PP)S%33FXA1500(FF229&.H<?P2$("PF,8W+8H (CO
MR"A,IS3WFOS5KK'SGIF=W'=4;I>>W_@ZQ8Z%EKPR2GD*W(.0%A(*MT90]NVJ
M\XI&67A3K@51'[V=V8ABMRF$0W#?V8\>%^?<3YC+A0E[4C[JCD';EK)P#6X&
M#4411?.&[U@G(M6PH*\)DG:R:J:(I*<(D6-PFV$!V%(DZ4-5]UZC;CS?;%VX
M4N3"\MABZXBVG,?<LK&RCR7"98*R;9T(1HF19'*R!LNJU,JHH0KI+B'J% 77
MK,U*2^D[!5VYLC,5W#EEM9D<^FIV$M^0C8H\7!1C-9](S4@_E%"((LFJ*(E$
MJ9%5E%#D*0FVX@!C^>UQVM;6E+$VI.7MF22G<XPMDABW#Z:Z W;=U]9":(N+
M9L:-4.!4SO%>^[UZ]%,$&C)%=TH  0I3 6YIYU\164W>5;%RSCZX,+YGPE=T
M?:F1[" %+T:,"SD&6YH"<83\&V4:N8B2B./=P<B1$G:9VX&,82T)Z_A]M_U+
M*TJZTKFU/ZLLU6? N(Q/"V/<;6Q)P<8O#OV%W$NF8G7K4ZTXH[22!N+B-9F=
M$C1 #((*MU!YF/L*;10Z!OU\: 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4
M H!0"@% * 4 H!0"@% * Z,I^+9'YB[_ %=2@(Y:._<ZX\^;3'[>DZ @)VM6
M5X&+?:.,(3]E3>2H/*^H%E<]]V%;<>>9EY7'&*&7KAN!SZD(JHKR#%NX=L3N
M&Z9P!8I!3'J&PB^/"<.WPA:F'L"WIG.X]9V;K"Q5#8"LC.UG8^Q=AZT[_B'U
MLKW.TL'[Y)9$O*V+9.@]A49-8QXZ%217+)'9-TU7(<([F#>O%.>4Y[O<OW[<
M9S\,8]GCJ3M#(ECW5.2^G-U$VU<4;,R:$,?*XRQVK)P"JQ8SRZ3.S%V9(H%0
M!V0Z'>;"J!B[T&$3Y>/&XQ1KIGUM=06QB;#N!-1T/J!C,JVF@G/7K&2-GXHM
M*V;/O!"0GYV[E?5%Q!7)!/HIHX]3V(,W+A^+EL/$02<!GC\QW\<93=[-WY\#
M;W,:B@LU+,R4YB?)BL1@YK:B992 M].3#(RLS%(/%BX]C&S@B\DG$*'!F^(I
MW (K 8A!V3$0;_'V]_:%7'CQP[>1!CLH;[OJ]3ZL;DR?B[*&-[WR-J$O#)3=
M'(-N*0[=6Q))PG%V(S8/3J'(Z=MH1@D9VT3+LT!4A1,)^(*!/9[.Q>T]GM?L
MC3:NEZ]]/UIXQRM?MRYLAX^'%UCZU7,]%Q=LDNB*-=19A^@LF+-TK!-WQ6S3
MNSB[!0$^(I3#091..[UF#M5<%.-YKLN=25L8ER3<NG;3E,R+R],:L+944R#:
M!GEBHVU8UU.[-(OWKA>WW+4Y%6I%A.T4634*8O>"-!V=^[FG?R^G<2UT%8<N
M=I<NIO57D*#D[7N;6#DYE>$)9-P-R)7!9&-;4@T;8LF&N%M[=)"7>-&R\N\9
MD.L5J5\F@905 ,!1?&/'\OM/:W\<V9:LU<ER6Y;<+"7!>3AHZNN5C6"+5W/.
M(] 6K%1^LF4IU/)4!,FD7D4H&$=MQ$1 O@.0>?XQZ_30"@% * 4 H!0"@% *
M 4 H!0"@% * 4 H!0"@% * 4 H!0"@% * 4 H"WD[KMM684MU*>AE+A10\I6
M@22C$\TBV_X*ZT65<7J:1O YT +L(#OM0'HR!P4BY Q>@L7@?2""@#0$=-'7
MN=<=_-IC]O2= 7]<>$,;W5E6PLUSEMMI#).,8BY8&R+A555[R$BKM*V)/H((
M<0(B=\FT03.H8HF A>$!VZ@98(0. O$0.( Z#L;;KRWV#?8!V\U ?3A*'0H!
M] 4 X2[B.P;CU'8-Q^4?'Z: IP%V .$NP= V#ERV_NH"O"4=MRE';IR#E\E
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M@(@.X!U'P^OI\OF\: H50AC"4I@$Q=A$ Z@ [;#^D* CSGC3U@W4!'1L1FZ
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MK 4!-W:0'/L CP[!0'= P&#<!W#^/JH"M * 4 H!0"@% * B_EO1KIUSA?\
M$93R18(360H&"6MJ&NMK/7%"RT=!N516<QS1>&E& )(.%!$RXE*!U>0'.)0
M*#''OX_(]*[]*.";XQ_:F-KHLKU4MRQ7!7=EKC+S:=R6N] #E,]AKJ1D"7"R
M<JIG.DNLG(\:Z1A35$Y>$ $5$7Y>/LNXJ]TE:=WN)&6#EL70!,:1;U.6C8%J
M5TV783R2WE1+C9RZ#@DPC<8.A%R,X5]ZHG7,90[@PB-!CCW^/H7KB+"6,L&V
MVO;&,;7;VY&/I!>7EE._=OI6;F'0_P XEIR6D%W,E*R*NVQG3URLIP[%*(%
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M)FF[>@YLZ8HFF8:*E10, @*)I!B@[,F8!Z&**PE'H/+F%!\3W: 4 H!0"@%
M* 4 H!0"@% ?,PJ (\) $/ =P#P^7ST!3B5][#[0>F@'$K[V'V@]- .)7WL/
MM!Z: <2OO8?:#TT XE?>P^T'IH!Q*^]A]H/30#B5][#[0>F@'$K[V'V@]- .
M)7WL/M!Z: <2OO8?:#TT XE?>P^T'IH!Q*^]A]H/30#B5][#[0>F@'$K[V'V
M@]- .)7WL/M!Z: <2OO8?:#TT!:=\VA'9!M"Z;'GT3*05X6[,6O,I)+"DLI%
MSK!>.?E24*.Y%1;.% 3.',IA =PH".TCHOPW*X^TZXT=QLD-M:7;RM&^L5IA
M(J=^TGK)9OF4&I)*_A/$2HR#D%TC; H(E$1#AH3'CGGCGL+>?Z"<#2.,;TQ(
MYB9CUHW[FLF?;A12EE2.EL@DFX^X <(N-^))AZH1K41:%]KW13$#\(1$,>O<
MN[G_ #W;OYEYY!T?X5RG+Y/E[^M8;C'+V/+>QE>D>Z>K%8N[;M5\YDH,6A"'
M*9E),7[HSM%^@)5R+)I&*8.#F+CL3EXYGJX@T\J8B=I+I94RC?;%C#D@86#O
MBY!E8F#BD03(V1:(@D0ZR[9!))NFZ<F56[HG")N>]"(B)XQ\L)\#'N?]/V0K
MNSGIIS_BB9AXFZ\0STQ;=\QDTHLG'W=A^\VZ:-RQ*1D"GX):,<MT92'XR@F9
MUQ@8Y0 -Q5SX_)>)[4[HKPM<&,)'$3Z,E1L^2RT;-*Z24DHF[]>QKC"Z1<D<
M /$#090H#Y-R+W(BGTYT!POG1/@W(UV9GO2[;>>2<SGBRK4L2_.*263;J1-D
MKE=6RYC"$, L).,>)I/$'B0\95T4SAS =Q,?GVY]?N^N4,>_<Z\,RL?D5&_)
MJ_\ )D[DO&Z>():[[SN15_/Q.-4ET');6@%B FE'ME'#9!9TN1,7#M0@&74.
M(FW)GQN\>_>,)X]>?G[NPRI-Z/,-W)?N-LC34,]>3N*\17-A&V4#2"@,#V%=
ML46%F6#]N \+A9>. 4 7,/&'$)N8[" (F/''CQ]JY+8@-#F+8.-Q'#.)B]KA
MA\$7XPO_ !/'3T\H]3M!_%,5(Z-B&B@E!1>$:-%122:+F/P@0@\6Q0 13VEM
M']CL[BS3>=EW+?..[WSQ=-MWA>]UVG.F9R02UK118>,38<9%$DF)VA !RU,0
MZ:QQXC!L&U 1^R#H.E6UD1N,L2SZ7J+EC/%L9+U77I>KY=Y=^0+=@73>5?,F
M8-T2-1D)MW',(]<A2-T$V0K"(B)S[B8[?';SSCBO!>XV7-D 9H)-6R!$V[=)
M)!!,H@!4T44RI))E#D %(F0I2AY@\.04*??B5][#[0>F@'$K[V'V@]- .)7W
ML/M!Z: <2OO8?:#TT XE?>P^T'IH!Q*^]A]H/30#B5][#[0>F@'$K[V'V@]-
D .)7WL/M!Z: <2OO8?:#TT XE?>P^T'IH!Q*^]A]H/30'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>img102984888_4.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img102984888_4.jpg
M_]C_X  02D9)1@ ! 0$#O@.^  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "F EP# 1$  A$! Q$!_\0
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MF88&+'1VFV94Y"4U[Y.$XQ<BBLZR1Q-##X$DDTS".*N=QQ60SL(G/E5;?<D
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M:]G&FG&FJ^?4<WOM_KUIJB[(TP!L]PF >PV@$;5JE!#!K'>2NE#FQ1P>\CP
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MVP60K/+C[-F;+3U*X;G:AB2&)V!F@<H&$4[5V'%N0(V#G?QQAZ>]69'HOK'
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M"OSXK)4C&E2X$!QW"),R/!RTF8Y&;5XR]B-E]G+V&_<I"7,*RG"?UL>@$@D
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MDM5:L3R5Y;-M))Q8D0%)X8J\<D2F*/<QO-),0S\D6(A2^HP%0*6W+'R IXD
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M^PM3;K><I&Y3G*%I4G/C.?&<>,_?G2:UYG575-U=5=3R4;JZAE.Q8$;J0=B
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M-18R6EZ*]0^HK[94XZ"2S5BILLBB2%*\\4QCEA>2M8BD,KUK4+EMV*DA@"H
MVU]9/L?>D'2N.]/:O5]VK@<UE.IJ<M:[/2R=K-XF_CQ=IY2I7S&'R%:.A3SN
M"NPBFT=>.583$\AD>68LE/U(VA>=?FAIFMV DUF 7K1EX-*GSY%=-NU$S&L
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M4M=ZE5ER&01XDAH0W,D&HUW*226")D9YUA:&$+(X=='7L-N0SV"W1L'<=@
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M9Z?5G#E;@"W@WE J$-L*%M%JKU,Z/;+X6@D @:]'2.1DD>Q*\=2)Y+#DPPU
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M"K6:S*=XP%V$0YO(TA"0I$H_3>5G58QN.18;>-]2E4LP4??YV\^![G\-O?\
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M_NA['_\ ?>:T_KTY7_67&?[Y<_Z?79'_ 'NSTY_V0^O?^"].?_*]/YX>C/\
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M'BE3<!F ['K@H5+D2CQ]X9$'JRR^N8QMO)WXZF.FL.K2!X^W&BJ[%WG7C$&
M!*J2>4CL $0,3] ;:BEG WVVW)_9[C5D>ONM/9W8G;#N,:LG7C8^F:SVNIO9
M&K@;O;AT0!2M?$]T63.P-?K*763+C5H@!.S:S'HMN(5D@4P/$V4P3>8S B24
M9L$U^A!C,4D=V"W+C9:3R01L6EF%6/M3E(@"ZNBR=Z$.JDR1H-^1U."LSR'B
M5#@@;^WX>21OOX_ ;G?QXU5-JWKWL+;^]@?7,$@"(OYNX$J3->.V0&-KE>EA
M'IS=F)D;([/P&<&@(HPG/S(@39/U5N&AD-B=(F0VG\DLWH*U)KSAVA6(3+PC
M=I'#;=L",#D"Y95.X 7?=M@NI"*2P7?SOMN? W'[?'M]#^K5MC'7KL=9?4/V
MOL.3U^VY5]7;4@[AUO!VF=!1( >OUC:VG[3H"L[?)6I1'%7D3ERY$>[VP8*.
MS3C,>18XS$9^>TG#F,?&T8\'6@%VK)9KM4L-61R[N]:TEZ2LL84N%VWBC9E"
MGY"3L3M4<6$I^5MN+#D/ V(V#'[_ '^A\G?8_0U"MZ$V2[O3'6IJ" 7M7](2
MM5)A8M=>3556I!'(CWXNJI^*S^'LN8^;P?\ J/T]0S.)6',YS\+F4_'5Q1-\
MF3X?LFP?S<G<[6VY!BV,G,^5X;<N7X>=4_!N?'ZEMM_Y]]]C_#^W5QY?K[V-
MJWJ,ZKV5#Z_;<M&J=1B=):LE[8! X;X6S5_3^D:?U_LVWA5K4236(TI9(=*N
ME1&ECT,^X/9K;<B(S-?PA&*)=H/@K$!NUH[5IK=D5G<\XWM6Y;D=8Q\3)QXD
M12,JD<BY&P]IY5NZIXG90%)]MRH"^6]B?!\>Y!]]AOJGO:'7N_Z>WJ<ZX%L@
M;!?:_<1]%'2JW8@A&N6F45D0XU6+![$F>D0T+LT0@+(QWB<V$H4U/^ =P-E0
MYS4?*JUZ&S22\ ZPO$9F$B.)(BJDR(T>Q<M&0R[*#R(!4G<:D,I#%?!(.V_X
M_K\_]NK5-B=7^T>K.SO3H@ ZYW[<U;ZH57KW7#UUI0N)8J-L,UJBRJV9L&.-
MN42;)KD6O@9Y\C1*B4LQ$.@N"K(LNPPP/F1FF\;KY''V*&462_#5ER4MUTAE
M)CFA2P@@@)B(#EW[8EE6,-Q=V0L7!;4]D8-&0I;B1N??<J=_)\C8>V_T&QV]
MAJN#N)HFT=?.R&Q];V,U"M;TJPR[96[2/+CC&;95+J2F&*R<(.P9DO ZPSXL
MG"+&$(NMD@YYHA$FH\(;D/7[%7H[F/AL(K1!8Q$\3*R]J2-55U4$#= ?[6RC
MBZ>5V]M29%*N02"2?!\>1]/8G8>?J=A[;ZG%OGIAVQK=?Z;ZYK?7VX;=E:1H
MTB9:[/0HD&]T>7;MB;+/[OF:Z>M%;G$Q4,/2@L]FO%C!B0.".V'-P^F2I4",
MB7(L]+*XV23*V)+L586Y5$,<Q,4PCKP)3$W;D )>1UYA$Y,(Q'OL2-ICH_R*
M 6"@[LH/C<\AY^FP)'T\_?\ 2)/J ZR,ZR[4[4DE9PPC!V@?+[KK;P\Z#.$(
ME?V<:*65H!:F01,JT!NE5GR2%7L]?F2<R8I00])CJDC)@^9(NF#LI/C:X"E6
MKHM5]U95,E=%C+Q%E7G%(H61) -F5MCLRD"";]-C_IOF\>??Z>-_(]CX]_P\
MZSUV@ZL;VU[U<ZV DT25>*WJ2L[)VCM+8VOC5:V%4Z.1WO8*N3A4PC,IQDU.
M$PJ:$J85ZQF2D"  ;N-G/0(,^4B$N7(H<=D:<^2OLTO8>S)7K00S+)%+,*<<
MJM*O=159I'D<*@9I.S%&6')MM1,AX)M\P&Y)'D ML?H/'@#W_FU$+K?]RNY?
M'];%OO/_ /4F^7/)>5J$>!\?2WW_ !F &^V_G;S]^VI<9\M_@N/XOYOYM?T,
M_059>8]*KJW\=IQCXXR^26/BH4W\:,]LNWJ8D->_"?>R\CPMIQ/E"TY\I5G'
MWYICJT_^$&0_!H@?(/GL1^-QN/'UV/OXU<(/$2#]?_*)U<)S&]3M:VW\(8_U
M(ZM_]]]H_P"]]0YT]]G#^V=6_P"UX?\ Y=_6@/7']+IK]64_Y>-U0[I+_6%V
MO_N=H?\ Z0NA>=!9K^[^D_\ =(__ .&NH]:5H?VG-_XH3_+W3^OLZ;*RGMWU
M=_N@-29_O7D)GDKK/^\_JK;W_J<S?^3;.IW3IVZBZ;\;_P#T]A?X1DZA'\8&
MIP>LY3&=>]G]>TV/-619!=?:C'1-<93'<D8D7O94[*E,(6XAOVJE*;QA*\^<
M(PK/W5XQKCT#;GT/8<C;?J#(>-]_:IC1OO\ C[_A[:SOU>7AU>BCR!A:'G_^
M9R!&H)B_XHM^_NH=-?Y']\\V9-_?9C?]S.=_ROTWK7B_Z!W?\>X?_)O4FI0>
MD]6$W;N0#IRY68+=JU9N&OKFX93(S$26IDJ%F3AA3C6'LLX>^)AK+B,.>WVY
M6G&?.,)]:FX>GN48>2MO%'ZCVO1'W'W^VLQ],%Y]:XQ=R 8;X/ZC2LCSY'\^
MMCU/IGP$I2G&UI?A.,)QXJS.,>,8\?;'UO[8_L<XF^/'^H#_ 'P__#KJ[X3_
M -)__9__ -:BYV<ZN1^O8^I3F+<_9UV>85B99<$('8BX&M07,+2I$^9E[+V9
MOM]N4H]F&_/E7N\8GP6.^6^3AQ ]F+;[DC[AM_)J3+#VN/GERW\[;;;;?B?Y
M?V:DAU"Z<9D?2]I[9%8^7SAN=5:<09^[OWPN*:/1G/&<-9QX>@#'D8^)C+<F
M6G+>4,KD6;.V\<;?-MLSJ?"GSN%/U/WL/U#R-38(-]G<>/WJGZ_BPV_7X/[?
MNU;!C&$XPE.,8QC'C&,8QC&,8_+&,8^V,8_=CENU6ZZ=L.O3+;1[761Y",)F
M'0),9')2P(VTQH+LN*XRB2_7#"'!9MMOW9RH;/;7$E_Z$\A2%9QFX8FY'C\I
MC[TT+V(ZEN&P\$=N:A)*L;ABB7:Q6>J6VV[\1#Q^ZD'SJS=18V7,8'+XJ"S'
M4FR&/M5([,V/K9:*!YX60228RZK5+ZKON:ME6AF_1=2#MK3SO]'L&N+63J5G
M"FZ\3AY1,8'66"V(-J"D/=("$" I,B3@:^0'J9DNP,R'%0W5KC*5Y:SSZ.8?
M+4\SCX+]&U5N0R;Q/-1E-BK\5#LMJ&&QPC[ZQ3<D64(HE #J#RU\=\[A,AT[
ME+.)RE.]C[<(6=*N4@%3(? V"7HV;57N2_#26:YCED@:1C [F)F8KN<K=7M4
M6?;.W:E  #I3XT18P3Q\Y^"&MB *TJ9)>0#DVVJOR(\6=7YI2,W$)+FNIAPH
M>9)"3_08BL9Q_KSJ"A@.GLA+;FC6:S2MK4J'*-AK=T1HAM)CKZHTD5V*N[20
M"(&6281PH.4@(ROTPZ5R75O5V(K8^"5X*F5Q[9"^N$'4='%-/*PH39C$,\<,
M^-GMQ+!:-EA!#7::Q-^;A.]IG>KO1:]=V=K5.I2@N//#(?18K&(, CXHG!)5
M\[7B]9*C82,&Z?::R>7$*CDQ3$.:P_ BORDNQ'<Q'M"^E7I7CLWCSGNH8)WB
MM,AIT[%:U5L5Y8+=2[6O5YI2:N2H7J@>"<R5I8F261(R)%[B]2^N_KKE^GLN
M.DND;=6*:D'&3R5*[2R%6W7MX[(8R[BK4%=5O87+XK(F*W6$%Z"Q"\$,LH,3
MK!)6>&[6;$)3(4+;A29L^F_%J[)@<;8@E3B M4!F ;,.L3#*7QP(J:B%E8L=
ME9A)LI1YAB=@U'(-ID\VYG_2?I7)4IH\=C:N,OB/*&A/'W8JL%[+2P2O:LQ5
MFCGL)3:'?'U#.*=4.\0KM$Q4:%Z3]>NO.G\G5GR>;R&8Q7=P:Y:K8,5N_:Q6
M KV88\=1L7EL5Z<F12?CEL@:[Y*^RK/)=6PO=:QN[]"F>PFN .UJ#<:S-NTV
MI39LKZ?/B$VK3:&XU7$@:X<M4$R5JL,=3QX<V*FJJP42PX4?2Y&@P&$/Q%Z9
MZ4]3;70%R7I3/PW9\92OP5:LTM'\G/C\2@N2S6HL9\/#<FMWY)JTZR7+,A:
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M;$IQB'CV)^9>8BHRM&%H;4\ZAIM649QE.<-J4E>$^/'ZOCEW<@*6V_1'+_\
MI\_Y_P#.-0*/8>_GZ_KW._MJ<7>5BS(V_LK45='E&=!=/K-%T)1J[#2YFHTY
MH?(*ALV$A$;RB J\;AMM<N5WL]BD,+,GS,J='?EJ'"!D2'8\.8Q6@LRLIN95
M#;E=MN[)R"N$3ZB&M$\4,: \410=N3$F;*#R*CV3QX\ [;;G8#W^\#QY/L"-
M05=]C4=WPVC+;;+BOA93C#>4H0I7LRG&/'MSX\>,8_;R]D;A0/KL/QVV._\
M$/Z#4K;Z#W/M^LZGYW('6@&<A];:(.)M:.ZP:DTO8B8$.EU !VY[4UUK*T[$
MW1=HC*D19]JN>Q]E1ZU&L)-J1-&5R/3:6/>CB1$2/BQ8MD*F],R_&9"S:178
MCF(JTUB.&K"?<1Q00&1D7;DYEE;<L3J=)OX11\JJIV&_N5!W/WGR!^K;SXVU
M =+;>$X;2A"6\^4^Q*4X1X5G/NQ[<8]OC/G/G'CQGSGS^?+_ +#;VWV]OO\
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MDZFW\.K%_7A_CIUO_8%I/_"W8'-;>@']XDW^Z#(_\UQVL^]8?[\5_P 2X_\
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M4=5<H\G,Q(^%#6]$]F9T9YIK"[WK:.K[<CYC(7I'MNM]ZIW^'.39H,<L=:E
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MD&(S%*:U7J37GCFN4Y(X-Z]97G96D"HQ1&*\@Q4(&848_P PCM7_ +:74?\
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M^,;SJ2?[4/\ "'_Y]7/Z:SY_@T':O^QW7KO^$WHK.//[OSQCF+V_[_,>?/\
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M['@C!,7X\F8]*GNRW_A+:MF7SM_-O$UQHPD(810PIPC4MQ#OL2SLS<1N6<[
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MPX^RWF3*PTSA;S2<K]SB,9A6.1P"L;L"ZQ@JK$&1VD5$! (+NT,JJH^9FBD
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M&H1;'U1VB)O=G&:BQLB'M6SS;%,UCMF)M>3&UGG5DDG5'@VM:YK]ZZ1X5:V
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M=))0L156N2*BQK6LW2C2QBP*M2VF/GG^'+"7@EQS /DY,T<SHIC1WU'Y[T<
M!:26:A70("ZF?*4_RA0C+*"H-BF8YE)/$":%&822QHW2X'J"]5)Y\77OTBY'
MNEPS9ADH8!'! **Z[15;-P *%2$!A@7:$Z_3^+':_.PQ/:$J3EQI,E7RV*F3
M"9*&&U,\&PIF<2('1I76I8%.T\,:EFFCK7.52=HPW"Q%-'Y:*3C"K<GK1H&8
MVW@2 J-U8VG*5"6_1"VSP:LQ/&6.:"124GB9^I!^^%8F"^T^P)U6LT3677G7
MM!O@WYVJV.L7RUQ+;53UDRPW7;7'&+R@I@<+;JLMMF/%G-%$+E/)4VYAF9)A
M+BQT(56.3)Y#/38*"H+$7;6R(,%V(;$J\A7L"YEY*]M9#M (E;B1NSREL0O9
M"K)M43"C,362CL.REW.Q3S5P@/Q%;X+$I8KM$&>=Y)$7SQ49%+=E#FGJNQ9N
MSU6K.O$V(@,&48)KZTF=FV.P&9P\@5(5? =-/KLE\W7Q8V81)RA/U(.Y!B3)
M;4MMJ-C+TGX&&><5<=/+;FC$[SO) *\ KUQ&'N+(969:YE=8@)HXI"TL"A3)
M*(Q%&TS1&P\/:@X0D\W!FCEGD"1UY$4<#(VX_M4DBCC*20D9<XDHG>A&S^T5
M(U+K^'5;)J._T\3<J[L"*\728GC2^MS]W86W%>4U%9]LP0R/=8D16Y,="I33
M[;<MK]6I_(SPT\G+;+Q6L?+<C[*F-XW%=^DQ$_-=^231]132*Z,5=(:SH2KN
M6@FG"24E0;BRM7N!P5DAEEFZN@GB*_1X).FXD96\J\TZMY10+%^6/51IQIIQ
MIIQIIQIKJ=]K\BV4:YU6)(:BRK+5;#7XTJ0E:V(SYD3+',R'T-_T13++DE+C
MJ4?KY0E6$_K9QR7,ADBD0'8NI4$_3<;;_L]]5%285[5:PREE@L0S,HV!812*
MY4$^-R%V&_C5=9?T_I]AJ5A$SK978-LF=*=)=7*Y>!@J;]=K9O64J[3+.5@3
M_?&(P*K=DV,<+)1!<V"7DB69\>2_CS%PG)[F>66[>N0P2=NWU>>I):DC@0V:
MJ30314+7$,)"&CDW8I)&IEY!'(*FTX^I)57&QRR*Z8_ V,2C+&IDAM6HI()+
M]<L-PR(87C4NIYP* R<B^L0WKTX=FV744S7]8)Z[J.+>6V@5N]>DVF^64<T?
MNE!IU#K%R$W,@$:/IQ6HM4E2S%!K86@@;<HQ"?+E5F +I<Y&V;KFW'.39D-:
MGVZ=AH((Y896R<N2GB>-)&[L=@NB)+-/)\'/&UF"J5E2""HKQ]I"'BB=FL4V
MEC#R"&:M5K25@G%E80R R\N2(TDE>)*<D_;)?66V^AQQVSV1TRYJ\X MFY^L
MFYK 2)@Y$H^:>TQ0:/1[C3S,*2,?BEQU@ET9NVB"L\H\IPJ=FL%!*'8GU.=)
MDS,;RP.B30I3N]535H(V41B#J"MF5K.>)58[%*QE6C(C0HU:,M&Z2/VQ(KU7
MAJ=F20SSRX/!XN>9]S^>Q&4HVY70MRD>"W5J!65V#).L8(>,#AC\EZ:5C13$
M5NK6VG5&1^';Z/+IJXTM6(UR42[+B-Y4JLV.8$:C3%5.%51LO7<_&437@T(S
M-R#'O#<NCY/L.=97JO.L]H5HNDT"33%QW\'A[N,R-M.X7VL6YK:7H92"[SUX
MVLECL=5311<[;1(L LS]7/NB+NL/44D#U(V4<0ZU1$R3Q\E#QR,D+QDAU^HG
MZ;,DM0["#CXU^"/%].;SJ@/$^=;-A)I&S-MWBKV^)=*_9K/&9*PL#'J^Y*E2
M:\*J[C966F2(%PW$OR9$Q<Z(KT%A'L.L%SIB7FD<=222GA,ED;]NJZPR/R$Z
MWQ!")IYE*Q[/VX.U7AD&%I/TP@!BSRR1EGFC:;)8K&8NC8XOQ3G77'M+-QC0
ML9B>4DYFGFSRSU L;6O.YFMA9NH5)'9"UVRW5B]@!,I!Z&]= HZ.1!W@3%9$
M+)"().!*CNY&V7$HV$-E$)<!SW<OKMIR*]G ;Q-+^0[(D-&4CX*W6@S<V6BA
M((?M=^&;X"=.S(BQ0HRB6-NPE40#;N6/*F[CH:K3J ;->PN%CQ#V(F)^=HY(
MADH':1&^)E8-Q*]U^@CNC1PS9!UTM G2]2=3O#1.RI.L:,#G3M=BQ&F:[: ,
MR6'02$B6G+O=,6)C$\FW7!$>.'!@1$AXHX.^HOW 9J."2(PR7Y^"]1L+-F15
MMJ^=Q2T(ZZ.LCD5ZL\,=Z0\P9K,MF41QN5WI3!SK6X'CKJ9Z.$I#M1[)(<9G
MJ^5GGL!O=I:JSX^!!S:*#A&\LD4CHEGN/MC&,8\8QC'C'[O['\G,<U5:\\::
M<::<::K/[?;"V50NPFM["%+P)%%UIUF[1;UE4-XW=:^FUW'6@VGI"_6'ZU81
M@DL.:0=Q#8@680>$PFIQ<C@:X52(ECKOC.P*'4,LD?.PD6&K5G9862%,A:NI
M,P$L,K1NQJQ@SP\)XT'&)U#2"2-XA-^283(88Y\OQM2*'9^S#5DF'$(T;.$^
M:0P\@LSA%DW0<3P-T[I[IH4<UDZ$TI];UMK'6^U+Q4_JML&F-E1MH&"K(BE:
M.7/F8S//!H(K(91DK!)Q;-=)PX2R%KC$G+K==%AJ4M_X1);SPOU#!TU'.J0\
MH)Y#61\I=C!815"]M98J_,,8*UUOBV: C5O%B4X^&Y^YXFGPMS.*LLC]E(JJ
M22"FTH0<I6$166=5V@[]5S6D$H776;1WKW^.E6J:&I.F?P^/&]L3@1!4M=E&
MT"^I5H:'6!LPB(EN"^1O0MS,4:B$N-&J1%&"DUZR15Y"HIJU#'M5AL6I+O,T
ML3D)EK"#@8<I=^ $41E\]R%G2T)74I* U0Q1GA<U<)(9C;^&KF+9LJ,0KS%P
M5F?%/E%L,BJ 43MFL\ <.P(LK,NQK:R1V@[VDM'JUC)J]>!G6[%4Z7L:Z C*
M\L$H%(N-RJ]0C*@&Y=FK(B'/S).RT0,P(UY(S2,)J&[68<.4T35-QN#%O*6\
M?/,52MDZV&%B,,!\?>GG@JEHQ#8D:/>!I3&$0-&KA[5=@@DM\UOAADRJA5:3
M&Y#*K$S!@U7%X^+(6U#<HT!XRQ0]Z22(H\T;Q5[2"<0<GO\ [E6_5&WIU$ B
M-;I"UJ?UL&%HEV.E1=SNCW8K9I"B,3-=PX2\1),2D1!$V61;EQYRC!!QR&A\
M.T+==(4V*QD=Y5:3XDM/?R>.A^%0.('QF#3--8M!@08+0D6M"$,90P69R\G;
M$)JKC&O4%A.)*T'R+]T\8Y$^.3'I6A8'?OI(PFF+ @)-4B5.5CNIB1WU)R2
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M1I3F1I'#>" _*WVEJS"G899Q,B^?@2<--X>;7A"?'H9@& ) ;B6 ) 8H24+
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MQ<-.-+_I<A"BRF_:M/\ 1&4>?*?*<Q1NT4L,\9X2P316(7'Z4<T$JS0R*?\
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M=XP@E[MA8OGD[A:O.TL\/(S.@]GXS/: &T-R3(2S<]I)4?)X2YAYQ$S#@L<
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MXPHL88; Z['NC2=MO&QM9;.IA:E8*46N;#I,^M[)K<RT5.?7]E2:7+*&X$.
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*-.--.--.--?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>img102984888_5.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img102984888_5.jpg
M_]C_X  02D9)1@ ! 0$#O@.^  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #= 0<# 1$  A$! Q$!_\0
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M6'.%I; 8E!&T#K7-&X,F#'VVKY>15.UWJ++]F0RZ[*E#IJ7&WQK.]T.(V/\
MIJ'?S 4+0=Q_KH1K\B1Z:;+IJ]XB<TKQNM6U)_IIR]5:[BKM"OEIO9*PVN9L
M'4K)1!-4*3B+;L:93(52M]D%(":ALJ<D&2=A?F/6DB0-RZ7DC&F,$8 P-3G.
M.^0$# -=<YSDG708QY#'9=?+\-^=D)W2$$+EUF92^K'K7:+?R]=S9CT)ZQW!
MQ$LB<%LP0T2T!"L$PS%L(*<+M,:2%.PXA" XTJ.VC3G.F@R, '&N!H!VQCR3
ME&NIP221TR>NV=]<9QY+L GB/S^O$H%F&6SJ:;]'(W8J4Z1+NSA&Z6B=?*=7
M:.5<L4L@/E"I#0\)3*/]7H< ..A Y=-"/0HR&U%F"D+B=-,::8T&#DX]=<GS
M/3 0- .<G.O7?3&OD.@VSKNK .\!Y?:K#?[/;*\U:B?2N?!.767ZP;02B[HX
M/5LVR$%QG6M-BFIS]VL4LL]#]M\C)ELN/N[3"A(8!S@  < '.FFNF_?;JG*,
MDG7( UZ 9V[;JB)'@'P^6B/&F%^K31;,$TAT'+Z0:?"3K#9^.G.%6J]SQSFE
M,R+M9^?GYC!DMO28KI[2K/&'13I([.+N<X_AV SCL<@;[9'?;JIR#SZ]=-1@
MGUPI.3\*>(F7[H@JF^30-V:)NR:;OH5IC5&OV(X6 6 W=ZB'@D(NJ_="5BJX
M&Q:.QGU.B3T.66K[0>8=L;IBA[AC;(QK@9TSIZ8)&.VB%C3G.<'.F=,G<^JE
ME(\9Z30SE'LXVR=&*66D?7M"#=BN,HQ(LD3HT>MLV0;8H3T9 A(GWZ;4B(H9
M71M>A""(&/(A,-)G&6R<+B>P&F@';;^9^O94- QC.F?GGO\ 1:*S%9)A$PB8
M1,(F$3")A$PB81,(F$69.3_F&\JOU'C?[>;PH-W>OX"TWA55O>>JU;GDF!$L
M$>VOO$F'I$?ZMT.ZV]I+;"T-K^:D54 8CPG-K<3[;,MUEYU'Q.-MK0E2M=!>
M.)+=8Y(8ZV.YO=.USV&@LUUN;0UI =XC[=1U+(G:C#)'->1KR\I!/Q55PIZ-
MS&S-JB9&N<WW>BK:L ,+0>=U+!,V,Y<.5KRUSADM!#7$91!>?G/S79+!RQ5(
MZ'&@!H3SL>Q,U.RDBDJ9%9BR)+4VB0 3]M#P]MRM)CS)L#2OC2WN7&B-2F'-
M^>TOMCLU1Q-66%UJO+(*:%SXZQMMN$U5)-%@R,?9XJ-UQ@BP?AE?&Y^0#+%"
MQV6ZK3<<T%1>:BTBAN+6P-)%2*2HD<Y[61O<)***%U73LP_#9)8@"0.8,$D9
M=L$S?ZV YX6Z@6>FP:D$I\^\DY$L60AD8E?&!WCLQU\-,CQRD>8R/8<4L=)B
MLSD/)W&<80_K:->MTT[*N""IB$@CJ8HYHQ-%+3RADK0]HEAG9'-"\!P#XY6,
MDC=EKVM<"%N<<K98F3,Y^22-LC0]CXW\KVAPYHY&MD8[!U8]K7M.6N ((68"
MODWU>GT^9?>A^.LBM5:8%J9^LSQO2PUA>8;M5VI50CU?H,1 (<NJ7=N/<T'6
M(-:5?ZK*8!'8*KA&E,P?I#Z>0$X#M?BR"TC8$Z:Z@XQG0C0X.RRYCC)&F <Y
M'7'H<Z]L:;[*3C?,GAKAH/4S5O:AVHR0@PD1P];Z(=K8U%@Z=<.24UX_<MT4
M< K.[1>:47JP_=FD!XLBT-:##99-$L1.*3D=C.-!G)R!J ">IV!SUT^> >TZ
M9U]#WP.G5=A4?+?C%DF5 $_;8:++;@S1IAL*'O1BICV):;*^,CE[S*I88#79
MYF'4;%*"";:Y7#!IH1.6*'36FVGGW*[!.-M-QG7L,Y._1.<:#.I[ D?7&!MU
MPNH@^8_*[/9N<5BAN%[%.O/20M"(1S5<N'/R=?&V;F/5.EUB\,!KS5PA&QU.
MRQN5F!@ X(96"+O;G/0#$A8>9%W>1P#B1C SN#GXFM(T.A!=J#KY=4Y@3@?G
M3()'3KC11[K/E[]FO;HO&8M1K!$FH/5C+,.V=5 <UN/06;01(P%PN&5JTBD!
M.H%JW]'*<L<"1=*DY%>DQ8$7<N6^REP&$C.=R1L2!C'[B-LD@#0J.> <=< X
MZGTZ';N%8TKRSX1%F6X>FV&",^F&M5PC!!\^Z-8)9@Z@V0K,T31HX.I$'.D3
M0UC%$P-B9Y]JS;K9<=.'G_HV5%>;1.5VAQH?,=@===-"#KC0J\[>_E\QN%"X
M7FWQ>6:+(23FR:DBD\IM=1/A 5MLECO)+J!CLXOZH >: ZS-OSUDK#7%;#/.
MB&0LDN/C-EUEA@EJMDWM7D=VUR<@D#& TY.3@#X@G.W77H#UUSGIOT_"LP?W
MRK6"\<8K-1]JS5[M//.E=$ W&%+4S$CCN>R^<1-Q7!LB&B6J045T)&G6Y"X,
ML1(#R8<V'N2XMN-.4X<3IRD CUS_ $^Z<PRT?\P)!],?U4!Z?YK<)YA#Z?J6
M;-V _P N W4J1 5^GW&<@^8H%>79[/2:G96J^NI62[A!"=3S]6"&R!RMC42R
MIX? 'C"<B)0QQQI^[&-1L3@$ZZ ]"<90O:,Z[9&QW&N-O165;N[5.G\IM_6I
MHNX.AZ@-@RW@TBI'Z[83!$P.!S00,*.M\"O*E3R\NQAP;;[BV!T ^_,#%YH\
MB&-1AV(:20T8R3C((.-QGKV\\Z'!!5+@!GIIY;XQ_-4#U'RRZ?PFD&[EU_QV
MD#HHD[SQF-)I'2Q5P $J]<ST\8?<;)3JW5C#-PYZ(&R+&?K:ZTH(4AR1<>N7
M(I*DS6AN88''#79)!T(P<C;J1J=-]^BQ+B-VXVU!SG?;0'.FV/ILOUL_FX#%
M=<OG':Q0BMTL%;;Y2%J4J >&0!][Z#U&485]68TF6QMD0'IH :BSVJTO.SD-
M#6S,8:((%@Z1\^!AP'' WR-<@#J=.NP\_JJ78.!J=,:[Y^VVN<J]>3]6.7,Y
M>*#?JA HG3N=MU@A80 6SN7.N3JW=8Q1ZJV>N69^OU2;.&D90"RA9,<I6PA*
M 9K91I4-X>L:2(8D8P0<@YP=CIC((R<'4?@H#DD'0CIY'8_W]ME=^19)A$PB
M81,(F$7S?KZ;]/Q]/N__ +TW_P!,(O-/B%_\U3O3.O%"(*M7;FPZT68 !BE3
M0ZI"FYE?M$P0N-2S \$6(D-0H\.3$G?3D?41^2VE>R;$M#J'?!N%;U[5JOB#
MB2HFHJ&[6*GK[A1TT-150VRG\:CKY*4,M-3'1SRRB-L3V2"J'(0 Z2=L^0_S
MVRU_&%1<KO+-#25=LCJJJGI&231TK ^EJWP/;2S103RR^&UCHY/>&!CY&C$K
M'!X.C;+Y'E^>!#!_IO#.HUD0!'R2!(V'<IUR -,QFE+4I4T+9M$([3B]):1(
MGAX3#:G$KDKCM:4M._R\8W*AAGENO!/$U.*>&>=[[>VW7J#PZ>-\LCB^@K72
ML8V-A>Y\M/&UC,ODY6M<1W]5Q ^W03U-RLUSIH*:)\LM1%[G5TX:QI<3S051
MF:W3'/+3Q,;N]S&Y*Y_C)Y)5_P EZ<7LX8"2K,ROG701@,2D,S%,NJCM3H,J
M+.8;81)CRX,AI2M*CL.QI;<J-M+K334N3]/!'&5%QS9WWF@I*RC@CK)J%S*M
MK/BFACAE>8I8G.BE:&SLYN5P>PG#VMRTNRX=XCI>(Z>HGIX*BF=2U'N\T-0&
M\P+HVRL>QS"0YCV/QJ&N:YK@6X#7.TCFXK84PB81,(F$69.3_F&\JOU'C?[>
M;PH-W>OX"TWA5,(NG9KP",9EV..$$,6"?%:@SCC(Z&T8F0F%:4S$E$D,IF2(
MS2DI4VPZ\MI&TIVE.MZUZ?(R@HHZN6O91TK*Z:-L,U8R")M5-"PY9%+4!HED
MC80"UCWEK3J "N,0PME=.(HQ,]H8^81M$KV-_:QT@'.YHZ-)('0+Y8J^'MM?
M.56Q0&2@"RAR0 X,D?%[! 08AO#R4%[X%(7[4J'(>8<^!25? YOX5)WZ;U]>
MRY#J".ZR0]X<_3()VLW;R![??:_ "@JW3Q)^=2(4.L!@-OJ%P9=F,UFF $7>
MR/O4D*&W:KRD\6@A=DD"5CR9LZ3)Y\^#D- .I)U.X(ZG0:G3ON3@8PY<C!)(
MV TT (/;4Z;GY87]0?"7GT"#98#=LN;C5GG\K(3%N. OCCN<F\C;WY*A6XWP
MADITV2ME^) 2ONI=6JN0X*(:HI34@B^+R=P/XN^?B8&=^P!]<]T+!G()!T^Q
M)VQY_G=<.G>$H.@OP&*?VCLU8K;@. -MU8KQ:KAX]W*!1EB#@+&6/0ZLBV"Y
MXT?8&6WH5</" Q5VKU5PD.?3!)M&1>3NUI.2<D'KOUQT^6O=4- V)^N_J1KI
MZX\E7G,/X:/(N<%XYB1<+?<7%%*B3.PS(7G(:!:5T_GW;N9QT6%FFTJM.E7S
M=;[G8%V4Q/?E'RY,4)D+*LPT.CU4R./0#?;/4@GKW;MVSONH& '?([''8C?
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M0I88Z5'S!9.!)9E[4ZMIO$C'4'L1L?S]0J#E57R?\P_E7^H\9_;E.1!N[U_
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MU[Q9 =DF>2SHUZ#N_IAP.@DUB'D%+"]SW02;"K+@9JU17RLB\C>@TUP==^?
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M*4Z]$I2G7IK2=:UK6M:UK6M:]-?=FG$DDDG)))).Y).22>I)U)ZE>U
M    8  T  &@ &P7W"J81,(F$3")A$PB81,(F$69.3_F&\JOU'C?[>;PH-W>
MOX"TWA5,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB818P\C>B0P]R!ID,
M.%!7&P#W73 2-Z+>L-Y.2)%#XI3V&]?]Y/.6B:9FQ&-J0I,L4.D?>G7KK7J6
MT2\:>T;A7A6)XCI+4)>)KQ._6"F:R.>FH99R#\+:2 72[/:X$8H(G8)+<:%Q
MIQ!#9(I*V2,U$=BH_P!5-''_ ,6ONM9*ZU\-VR,8.9:^Y22-C:'-<)8X7?MS
MF\.&<\F\VYT*#G9+1&YF9$^W]#,-)]$F>@6J2LQ:IS>_Q^4;(R%CQ3>_348/
M!'Q4I2EA.M>@\3W>*]7BHJ:1CH;;3LBM]GIG;TUHH&"FH(G;?XA@8)IW?QU,
MLTFI>2NQX*L$W#M@IJ2MD947FLEJ+OQ#6,&&UM^NDIJ[I.T[^"VHD=!2M/\
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MU4Y],XTVWZXSV^7X6QN.7^Q7H+9(]R#!05UHMS+T6V1*R4G&JR^3'0Q9B&0
M$B@P,2?@D 1T/*=8GC(T@<1<G#-KFMPFY\K XTQG!&1G0[D:_19 D[XR#@XV
M_O50'D_YAO*K]1XW^WF\B#=WK^ M-X53")A$PB81,(F$3")A$PB81,(F$3")
MA$PB81,(O)[^*9U],#DK_*ZK78UPMDPQ5RY1M<A?K7(VISTH=J'"BRHY R>)
MQX!)S0H:B5(A 69Q<@S%@*9FIZZAX%MWMFXLI/9C6U511V>"G'$?&%YHPT3V
M2VTQ<RV4E-4305-#2W:^UKQ!2NN4,M.R@AN$S8):KW)DGC7MIXM@X>X6GC91
MLN%?-4T3*6E>YS0Z9TCY6\C(Y(ZBH='3P3SU$-(730TK3--X<#P\WM_#BI&J
M=XJ4>9,K!*KV2[3K!=;3',,;CD9Q0H6DQ(,[;"V678P_=='A(P6,\C;K0>-"
MVZ[)>6Y*?W3B?AZR<'7"'@KABI-3PWPC0TMELSG5)K)&PL::RL-35:-J*V>Z
MUE?4UTL;60NK)YA#%!"UD$?;>R 5$W ]MNM=;G6VY7J6KN-?$^$T_B.\=U'1
M31PN DBIG6RDH12LES)[N(WR.D>]TC]UYKB]/3")A$PB81,(F$3")A%5%PXC
MS6],'V+&"EO.64Z$LY(@+LEGK9MJP5T0R $& Q^MF1)NN3XH1GZ)5(KQ 6N4
M.?FQ)FWV)\Y$BY/?N/KNH0#N-U$U^*W ES)LI7.A^FI]0^HT@0@H?;K*:_\
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M+V),(F$3")A$PB81,(F$3")A$PB?AA%\UO6]>NM^NL(LR\G_ ##>5?ZCQO\
M;O"@W/K^ M-X53")A$PB81,(F$3")ZZW^&_7")A$PBX\F9$AH2Y+DL16UN-M
M(7(>;90IUU6D--)4XI*=N.+WI#:-;^):MZ2G6]_=F$DL<0#I9&1M+@T.D<UC
M2YQPUH+B 7$Z!H.3T"CG-:,N<&C(&7$ 9)P!D]2= -R= OVVI*4[4K>M)UKU
MWO>_36M?Z[]<S5VW5.W;R&X9S<^)JU\ZQ0ZI83C#\D8'-V,="G2(L;?PO2E,
MN/>L>-IS>FD2)6V&77O5EI:W=?!F$DL$-OK+K/4TD%NH'^%5UD]730PPRB,2
MF$NEE87SB(B5T,8?*V-S7N8&N!/45=^LU!64MOK+E2T];6@FFII)1XD@!(S@
M9# XM<V,R%@D>US(RYS7 5A+\TN*S=OQ^:NV_NA5E>FMB^*U$K=4Z<5\QI*'
M["EL?38/KN*[Z[(62+I*=)7O?P+2K?!!7T4M.*R62LI:(O<P54ECXBJ&R%IC
M:[P(*"T5E95!KI6-+J6FF:T\P<1X<G)ULW&%G$XI*'WV\UCF%[8+10U-9&1R
M\X+Z\,9:X ]A#V&HKH0]KF.87"2/GP.[VGRO\JNZ'_'G4F7X^4.=)(/V,4Q2
MG=]0K5*&1''D#S]TBV^>*C3K6EZ"S/< 0&(S3DYD4&/R8J'R9/4[7[7HYN,+
MEPAPMP<(KG;Z=QHN-^*7W&IIXIF,IW5-R9P'-9+>V)\9ED;8A?+R8"]M/6W*
M@G?.RUQ>=U-7Q/QA?)N&JJLK;':IGR.N=OHJ*&FKZ>W112EM-4WR&Y5$I;7N
M\!E4^WQ4[W>/X%-4QPMDFF]1^/<'YWQ$(P)IHG7SB846!-L)'VI)TA'AHTEB
M,Y+0TRU$'LJ^)R.)&,0A4=UQUYJ&F0\^\[L%#:(:6KK;I55%9>+]=)73W?B&
M\3^^WFZ3..2ZIJBUC8X6X#8:.ECIZ&F8UL=/3QL: O5++8+58*6*CM=)#311
M0QP,\.-C,0Q#$<3 QK61PLU<V*-K(P]SY.4R/>YUR9VR[E,(F$3")A$PB81,
M(F$3")A$PB814[Y! K19N)]. 4QB=-LA6H%8@X:,(,B29C3C/_;00PI(F#HX
MTD='ZEB($]\B/9AS)K,AV?#;;5):K<9&=@0>_H?D=5'9((&ZAWC#5Y]8Y]8(
MK=.*\UJI.^V@QS;G)Q@?$)T6DS=0$1!#XH62+#@K$T\P?LHX%&(.)$##T,>Z
MP->CN#(5<<D:@Z:D=3_VZ_;M&]?4X]/3HLM\5\6?+JB7[HEM.^0E?'[OJFIA
M<E#%R;_,.E8$C3(J3+#VD<%'@FH(I3\:,@3-=;BL+9&-1]PXS#C7GD%F]H$M
MTXEEK.,XJ:U5-W=4\.4U/::"LEHK6Z6N+*.7WNFC;2^%3R4,7A125@FDADF?
M.R0O=4><6#AOC.AKJBHN7$[98JB!_C!DE17MEK/%C+)HJ2OA;3VZ,1B8F&B<
MV,>*R#D='3Q/&GOLR\D?YG8G]%*C_P#N,^S]!XN_SY/_ /CED_\ X6W>X7C_
M ->?_P!-HOZ+A3>6>3SR6]0O*D?#7I6]N+=X14IB5H^'TTA*4V*(I&_B]%;5
M\:];UKX?AU^.OKH['?&O>;EQG=ZF/E'A,M]LX:M[VR9&72/JK+=FR,+<@,;%
M&X./-XA Y#Q26Z^NQX7$9CWYN:T44F=N7E^)G+CXLYYLY&.7!YNM^R/RO_F[
M$_\ EYJO]X9V'Z-+_F7BK_Z^#?\ X.N/],XB_P SM_Z)1_\ O+XKD?EAM.])
M\NQ.M[]/17^SQ5-_#]^O7?\ Z8Z_'7KK_/\ '\,HLK\CGXEXL+>H;)P<TGYC
M@C([]=M00GZ9Q%UXG;CRLE%_,S'_ +9'FOR^Q_RS_F_$_P#EXJ_]Z9E^B,_S
M%QC_ /=\'_\ P=9_IU__ ,R#_HU'_P"ZGV/^6?\ -^(W_P _'BK[_P#S3_+'
MZ(P;<1\8YUWJ^#\?/_P.H;;?R-.) //]&H]/K+A<+?$O++?W[\RHWK_\/M3_
M +NQ^BM_S+QJ/(5O!>/EGV?DX^97'^E\1=.)F>>;+!G[5C1] !V "_ASB'EF
MI"TI\RH^E*0I*=Z\?JGK>M[UO6M^NK=K>O3>_7UUO6_N^[>M^F\HLS0YI/$G
M&C@' X-;P5@X(.#_ .7^QQJH;5Q&01_M.QN01S"RP9&1C(YJPC(W&01E9_XE
MX?>7'/Y]OD3/*"+5&C\]J<^H4)F].=/S=+D[<*SF[MH+' 35:<0I]8Y!*22]
MW34R6VV.C>_K/#_#'$U*^]_[2\?<2W=E3='5%G]P-EHW4M'_ (G-X_ZM8[\*
M?QQ)&QMJM?N=MH33!\3JGQPRFU7AOA'BNU25SZCB"& 53F/=X<E;>#4R@O,E
M1(VO-&VEF=\'/(SWF6H#W,GDQ!"\W]]@?E#M2MJ\U;$GU5O>DL<:YTTE.M[]
M?A3IW<E7PZU]VM*4I7X[VO?KOUVQMII6L:TW/B>5[?W2S76U\\GF\4O#])"'
M'0$1Q1LP!A@.JVG]%OQ<2>,+@T'4,AM5C:UN<Z-]XHJMY:-,![WO[O742O&;
MR7E>NU>=7365?"O6MQ^:<M8TGW/QWI+(1OXO@_\ 4TYM>T_Z[]=[W]E-3PTO
M-X4E<_G+23554=81R@@!OO--(& YR_D#0\AI(^$!<=1PY<JGDYN,>(X>0$?[
MJRPP<_-RY+\65V2"/@(Y2WF."=,9\[-X#>1O0Q0>-+\L2O5-CBB9#87J 6%6
M XQ+K?M/&!TJC"Y;DLG'1KX40"(Q:)3:UMQC 16W79.G<=\!T/M!H*&@KK[<
M['^GUS*V.HH;9;;BV8.:8JB&2F,MGD;,^(CW2K]^DBHY ]SJ"K;*YK-<O' 5
MQK6T_)Q)=KJ(GOS37NLA;3LYFM#9XC06QCC(US1XC)F2<\3G,AFI7%[Y.^D?
MPZ^AFXD>-<O+[IER2PPRQIDQ%M<.)I#*-(0UJ)6^I@&76$)]6VT2T25::_PK
M6XO:UKV)MAX=:&-EL5#<FQ8$1X@,_$APT@M<^&]RUM&'X:T.$%)!"X-P(6L/
M(-D@X3IF4L4%3<[[5N;!'#-(Z]7*$S%K0US_ /=ZB)S23ES,.RSF(:X<SB:V
M)_P?:>3LX.V;ZNW"GUZ0*F1($/FT24#(RA17Z62_8H-BMY^6;5+7I$.7I92)
MIV$VVWO_ !HTYKTKASCBIX6M=QMMGL/"E$^MCDCAN%#P[;+976\30M@F]S?:
MJ>BC:71M!:98I2QX#FG8#4KQ['>%[S=K5<Y:F^016U\#Y;7'=JJ>WW$TT@D@
M%9'7.JYB&@"%XIYH&R4_^"\.: 1O&%R?R,'1F88_R3KD&&PA+;$2'X_U>-&8
M;3K6DMM,,VU#3:$ZUK24(3I.M:]-:],TJ1[Y7F25[I'N.7/D<7O)[ESB23YD
MY7JD<3(F-CB:V-C1AK(V,8QH[-:UH 'D OVUR_R42XIU/DT!TZO6DK<UP.M:
M<6E/_"E2]6[XE:3_ ):WO>M?Y9ARM#BX !Q !.-2!G )ZXR<9VR<;K+EUSDY
M[X;GZX7Z?9IY,?S/!?Z#5S^[\JN#W/V_HGV:>3'\SP7^@U<_N_"8/<_;^B?9
MIY,?S/!?Z#5S^[\)@]S]OZ)]FGDQ_,\%_H-7/[OPF#W/V_HGV:>3'\SP7^@U
M<_N_"8/<_;^B?9IY,?S/!?Z#5S^[\)@]S]OZ)]FGDQ_,\%_H-7/[OPF#W/V_
MHGV:>3'\SP7^@U<_N_"8/<_;^B?9IY,?S/!?Z#5S^[\)@]S]OZ)]FODQ_,Z%
MW_[OL&KG]WZ_ZX3'F?M_171S\1<P53&"N@W"%?K7%<(Z(6N!6(]/8*,.E)KX
MKXZ_$)%8D.5"$.P!\YZ+*3'(38D@BS$'MRTP(Q53+")A$PB81,(O..'V7JRO
M(^&MWH3CM4)>6%B\8U<4^@ZJD6-J(?QK*=AC7]!9L+N]JN[Y\2P8=DR;,JH;
MH9QD:FL-$VV#^^3#>7('\ =S9)U+N7&^,??UV7&"2X_$/W$<NFP&<YU.?LO1
MS.-<B81,(F$6:/*"7?\ 5,'CN7=,>H-ZERC$\$""KYG$N?2Y .M&":*?5B_6
M89NGA4QY#4:S6:?(JQZ:JK@BL*']$+EJ,0\FXSJ,CKOIJ-="/3?<A8NSC0X^
M0UTVUT'T*G/C_?I'5.&<?Z3+FQR4V]<TI-JGD(8N0$AS2)RN#B!"5$$2I$N0
M-BO37WW(T-V7+W'84VWJ5)2G3[APY7.&,8)&,YQ\U6G(!WR%;V8JIA$PBQ1Y
ME]"ZY6?L)YYQN9,"V7M73SE.DV0<1I@0B*@USE/0>C)C#SW0:M?*L$D%IE/C
M17ILJAW2<L8DC#% 4S)2#0?-@!R7; 9Z]2!L""<9Z$:XZ+%Q(P!N21N!L">N
M>W8JZ/&N^S^H<#Y'?BQ.09+V>B@B!@O*"C*\^3+ZB)C%)S@<(7/@H>Y1!B2]
MK0$V4!/I6F2%FOBWHB]QXPYP&P.F_P"0#]1GNC22T$[G^^BN_,5DF$3")O\
M#?\ ]OQ_^6$7F;XM=ZZQ<.YJI-XL5PLJ+34^Y6JQC2M4I(SG?/S/,^MU*EUH
M3QBWU<;")WJEE@5HFQB)JP%KC(67 --R"]<LK%HJ,#D<T!N1IJ -\D$<V2-0
M"-!I@'.@.,G!I))!.=R=-!@X !Z]3UZ+TRSC6:81,(G_ "PBP19NA=8@=/\
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M.:+/ 5UQ^6R*!J)#[(325.381:7&A-ZC!8<,G,9.A\FX.<@GX7$?)I.O4[:
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>.W7O]RM39BJF$3")A$PB81,(F$3")A$PB81,(O_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>img102984888_6.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img102984888_6.jpg
M_]C_X  02D9)1@ ! 0$#O@.^  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #W ET# 1$  A$! Q$!_\0
M'P !  (" P$! 0$           8'" D$!0H# @$+_\0 5A   00#  $ !08(
M"0D%!0@#!0(#! 8  0<("1$2%!43%AE8E]47&"%55Y.4U#$U4W25EK/1UB(T
M05%45G72UR,D)9&T"C)"4K$F,S<X.4.!N'=YM__$ !T! 0 !!0$! 0
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MEEOP[4HYB$SJD4<^P52#*[>'&TH7O81"[L8AN> 6EC?@$D (8P1SP"20A/L
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MK\RF3J6J5&UG6UTG3P:$G='0EMUXY*KBPD.PD,D<+UR:Z3M5= 4JRNQ3LED
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M_L,EV69?C&,8QC&,8QC&,8QC&,8QC&,8QC&,J^__ .=COYN]_:)R2/X?[O\
M?(Y/@_O_ -LI^V)LZZM944E8=NY*KYE-2<L2Y3=?19U#I.@*SJX$>9.0'25W
M$437#B2I286G]QX[[VD-*R(O"\6/QN_P?$3Q?#X,GA=P\3P^XA>_LY[>X@=W
M') \\B//!XXYX/'/LY^#GCSX^/-6SOH[+O20#M?H_3GNJB+!S;E-?NHSL)]F
MD395YX5UD'TKFUKJ5HY1S/3@HAN4?ZN3.6"\U[IA D?>I#-G&78'')0X_4?9
M#!/())ZPJ/'9M20-2C,RB"]4>M9BEBMVO?KQ'52.*"2LJQ^.8G@D*EH/!('
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M.6'DK987"NB$'EPQ!^ =O'M_+SY?C\OARI*-YY\#O-=O!FTS9%&! >F='YS
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MY"TLCJ;,_$:RV&#32-),X2,RN TLC,H9O?.W/GDG"KSPH'  \E\^%]@X Y/
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M63-$Q3P490(HQ)WMW%I@@\5QYGA6?DJ.?(?%SVB\<_#\9_-SY?LS#0KX7GU
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M1/\ 9H_ZEO\ Y<8Q[I$_V:/^I;_Y<8Q[I$_V:/\ J6_^7&,>Z1/]FC_J6_\
MEQC'ND3_ &:/^I;_ .7&,>Z1/]FC_J6_^7&,UXUN5*7Z5WL8-<E]06/Z/OQT
M*L"%/.*%L$Y?D3Y.Q)1)D?M6XC<^3%APXTB8AE,AZ/%C,N.*;8:2CH)%7[%J
MC]J]YW^Q4MP.XJ-=K"%+>WM!9B!SP"Q(').0#_ZRP^#P(_\ XDF;#O=(G^S1
M_P!2W_RYS^3X]TB?[-'_ %+?_+C&/=(G^S1_U+?_ "XQCW2)_LT?]2W_ ,N,
M8]TB?[-'_4M_\N,8]TB?[-'_ %+?_+C&?5#;;6O9;0AM/K]?LH2E&O7OU:WO
MU)UK7KWK6M>O^'\FL8S]XQC&,8QC&,8QC&,8QC&,_#B-.(6VK:])<0I"MMN+
M:<UI6MIWM#K2D.MKUK?^2XVM*T;]2D*2K6MZ?^?C_P!<9I>\2O1C=O\ '[SV
M\AO)B[^8?9^G<;NC=>=YCS<YTBYDC)Q]@65&0H7<YDZ7IJ[#N0#",VO<S8ER
MBVBD4FR>-[@E!&HD_L=KU)2OZ*AK8=13K6X3)ZS82O"J("Z,S45 YA:VRJ]D
M@+VE#&G*/RN)%6>.>20S.R-QVJ6))\N/?GX>SS"^WD$$GD9NDSCLR\8QC&,8
MQC&,8QC&,8QC&,8QC&,8QC&,8QFHSTJGH]NX^< CBTO@/D_>O'^T\YZE0#]@
M&Q[5:&J 7 UZX#['"O<.K"I28C/7^5E8R+;S\VPD:LK)B[ F"L338 O7^KZ8
MW]+2O<%_60;"*Q5GCC8QQ^.CR0M&T#2N"34M*?"L(>[L!\1$)\1)<6S \P3L
ME:,JRD^9[2 W/=Q_W*?-3Y<\<'X.-H'.J8CG=$J-%19;?<OFH &A'+=T"Q3[
M9=K._!C(9DGK38B2URBALM(2[.GO^IF*A]]3$")"@M1HC'-6)O6)Y9_#BA\6
M1G$4$:Q0Q!B2(XHU\E1!PJCS/ Y8LQ+')4=H Y)X''+'EC^,GX2?A_9P,F>0
MY7&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC*Q[/S=_KW++QS
M:'?+YR\A;0,L6+Z)S&QD*I>Z665I+PNQUPR-?CO-S!9!F-*7!D*=&%XS;X@O
M&EBYTR,[DT[(J6H++006EBD#/7LQK+!,GL>.1&!'#J2 PX="0Z%752+77N4K
MW,O(X#*2&!^ @CXC_<?8?+->OHG_  ,[/X*\9LU3[UY$V[NMXL5TMA >.W:;
M/-Y;1:U-M]A/LKIM9-O(;BV:^E#1&^7XT_"1,6<.;!QW7V!4HP?W_5.\I[NY
M'+1U\5&&.&)6;PHQ9GD6&.,^-(G/,<"HL$" \=B=Y +A(X*T#PH1)(9&))]I
M[5!)/D#\+<]S$^?)X'QG:QG+YDXQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&
M,8QC&,8QC&,8QC&,9I9H7HQ.W53TGMQ\PRGF+VH[X^3J8$36^13NF7:19I)J
M)8K,=A<EMIAZ:KXWP2@&SQFY5.O2"#CY"?9]5DU#DB11J;;.QGZDI2]-0ZA=
M13COK,YDMK7A$01HXHVMQ(![R_.D:0RR!>%6+Q(RK,BPX@K.+)E,SF,J.$+'
MGD$GM)^% 22 ?C[2" 2=TV<=F7C&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8
MQC&,8QFE'TF/-?)OEPB?Y!\#[SVL;2([[:NC<^@]#M;D2IZEO(9:M59:V26X
MQ7')3K;!D,G:FP+CS,X<EL'N5'#?)O2!0Z@UT3[S2[G;1U%8>OT4O62M;N(
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MT?ZI7_5)]&/$D^^/^DWTX_'D\R/K0=T^TRU_>>/K?1_JE?\ 5)]&/$D^^/\
MI-]./QY/,CZT'=/M,M?WGCZWT?ZI7_5)]&/$D^^/^DWTX_'D\R/K0=T^TRU_
M>>/K?1_JE?\ 5)]&/$D^^/\ I-]./QY/,CZT'=/M,M?WGCZWT?ZI7_5)]&/$
MD^^/^DWTX_'D\R/K0=T^TRU_>>/K?1_JE?\ 5)]&/$D^^/\ I-]./QY/,CZT
M'=/M,M?WGCZWT?ZI7_5)]&/$D^^/^DWTX_'D\R/K0=T^TRU_>>/K?1_JE?\
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M/P,!&WBISY=Z(WD0"/T<E$=NKW1LLB2Q++"Z^:L&7OC=3\(8$<$>U3Y>W/\
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MZ7=J6O50L46+9JFVMY>][?>CU\P.BR7];_[24P_O>DJTI"<6C8]:J03G[IT
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M")L^[S4-*>A/MO19HR<0'RH\MR6&=)N[L#@H5Y#H4/#J&1@#Y]K*>1["/,$
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MRX"RUFJ1N>B^N<?\?>AA[=;6[?Q?9/I[U L'<D 92 0CF8+K8$.BW5<O3AI
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M$$<^SWH]G/DH ]A(YY \_,<^SRS[=M[< G#*/2.'R3%,I]=H1RIVF/6W[=6
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M-<,JQMW=ID,'>8U +02+(\I/;P%L5RRJ>.P.H[ &/&4*+VD@\GM[N.X^08$
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M /8 /@ R#/AC&,8QC&,8QC&=V?LART2H4T^1>)2AX,!6X3SR6DJC@ZN'A5\
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M?1^^&/U>.?\ [(0^\,?83TI^ Z7Z,G[S'N6>CWY)ZK]7+^]Q]'[X8_5XY_\
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M_K]6M[UK>_\ 1Z]?Z\ZGW6_23\L-O^LB_=9PGVO?H6_L[Z?_ %5G^)QKP/\
M#[?K]7 :#OU;WK?JB3=^K>OX=;_[_P#PZ_TZ_P!&/=;])/RPV_ZR+]UC[7OT
M+?V=]/\ ZJS_ !.?W\0[P_\ T 4+]DG?OV/=;])/RPV_ZR+]UC[7OT+?V=]/
M_JK/\3C\0[P__0!0OV2=^_8]UOTD_+#;_K(OW6/M>_0M_9WT_P#JK/\ $X_$
M.\/_ - %"_9)W[]CW6_23\L-O^LB_=8^U[]"W]G?3_ZJS_$X_$.\/_T 4+]D
MG?OV/=;])/RPV_ZR+]UC[7OT+?V=]/\ ZJS_ !./Q#O#_P#0!0OV2=^_8]UO
MTD_+#;_K(OW6/M>_0M_9WT_^JL_Q./Q#O#_] %"_9)W[]CW6_23\L-O^LB_=
M8^U[]"W]G?3_ .JL_P 3C\0[P_\ T 4+]DG?OV/=;])/RPV_ZR+]UC[7OT+?
MV=]/_JK/\3C\0[P__0!0OV2=^_8]UOTD_+#;_K(OW6/M>_0M_9WT_P#JK/\
M$X_$.\/_ - %"_9)W[]CW6_23\L-O^LB_=8^U[]"W]G?3_ZJS_$X_$.\/_T
M4+]DG?OV/=;])/RPV_ZR+]UC[7OT+?V=]/\ ZJS_ !./Q#O#_P#0!0OV2=^_
M8]UOTD_+#;_K(OW6/M>_0M_9WT_^JL_Q./Q#O#_] %"_9)W[]CW6_23\L-O^
MLB_=8^U[]"W]G?3_ .JL_P 3C\0[P_\ T 4+]DG?OV/=;])/RPV_ZR+]UC[7
MOT+?V=]/_JK/\3C\0[P__0!0OV2=^_8]UOTD_+#;_K(OW6/M>_0M_9WT_P#J
MK/\ $X_$.\/_ - %"_9)W[]CW6_23\L-O^LB_=8^U[]"W]G?3_ZJS_$X_$.\
M/_T 4+]DG?OV/=;])/RPV_ZR+]UC[7OT+?V=]/\ ZJS_ !./Q#O#_P#0!0OV
M2=^_8]UOTD_+#;_K(OW6/M>_0M_9WT_^JL_Q.?)[P4\.([2WI'!N>L,MZUM;
MKT>6TTC6]Z3K:W%D$I3K:MZUK>]Z]>]ZU_#O65'I:]))/ ZOW!/Q"2(G_P"#
MC[7OT+?V=]/_ *JS_$Y_$^"_ALI[4=/".=J?VSJ1IA+,K;VX^U>SI_3>B'M[
M9VK_ "=.Z3[&U?DTKU_DQ[K7I)XY^R_<<<\<^)%QS\7_ *GV_BQ]KWZ%O[.^
MG_U5G^)S)RJ5*KT6OC:I3*^(J];#L:C# 8*!&&C(3/M;6K3$2*VVTE;KBEO/
MN[3MV0^MQ]];CSBUJX;8;&_MKD^PV=RS?O67[Y[=N9YYY6X !>21F8A5 5%Y
M"H@5$"JH ^I:C3ZK0:ZKJ-)KJ6IU=*/PJE#7UXJM6!.2Q$<,*J@9V+/(Y!>2
M1FDD9G9F./G1O#+Q7ZI:YMXZ?QZJ7.VF5L,2CUFD%YT^3\DCY.'"9<D%?99C
M1VD_)0A\1#4:,TGY.-';1KV<I%>N0H(X9WC1>3VH  .3YD\#VD^TGS)]IS.:
M*-CRR@D_"2?IR&;]'+X.ZUO>_&WG6M:_+O>XI+U:U_KW_P")9?\ 738?UJ7\
MX^C*>!%_V#]OTY_->CF\'-^SO7C=SG>E:]:=ZC$M^UKU>OUI_P#$_P NO5^7
MUZ]?Y/RX^NFP_K4OYQ]&/ B_[!^WZ<_OT<G@]]6SG7[*3^\L?738?UJ7\X^C
M'@1?]@_;]./HY/![ZMG.OV4G]Y8^NFP_K4OYQ]&/ B_[!^WZ<?1R>#WU;.=?
MLI/[RQ]=-A_6I?SCZ,>!%_V#]OTX^CD\'OJV<Z_92?WECZZ;#^M2_G'T8\"+
M_L'[?IQ]')X/?5LYU^RD_O+'UTV']:E_./HQX$7_ &#]OTX^CD\'OJV<Z_92
M?WECZZ;#^M2_G'T8\"+_ +!^WZ<?1R>#WU;.=?LI/[RQ]=-A_6I?SCZ,>!%_
MV#]OTX^CD\'OJV<Z_92?WECZZ;#^M2_G'T8\"+_L'[?IS(_E_'^7<4KFZER>
MAUF@5U4IV<^-K0Q@>W,G/>K3DT@^A.Y1*9M&D,ZE3WY,A$=MF,AQ+#+3:,6:
M>:P_?-(\K<< NQ/ ^(? !\/  '))]I.7JBH.%  ]OEED9%EV,8QC&,8SSN>D
MBXY4+CYF=AL73/#3KODO$L_HWZKS7@-EH'CS<>I1*KY M]<\A"$..)Z>& R0
M7'K6.9/U0L]:B5FK3@2!+'E7YK4?Y%:_H'3UN6+34XZVXJ:TQ=136;\<^PAK
M&6@:FN4EZKR*]R)C',HB6.3O960*3R,P;"*97+0M)S %C(C+</W2'R;CA#]S
MY\CCR/(&06D&?2CN=^Y/PXU:_)>G0H%/$>/_ %&\RZ!-MW*H$]OP&7-:\@@=
MP;\?7:%[GKRMBZEQ[5/[[>[41M$.?7+?4:M5"0<*2EF3IGU"W=2+6RDRO?JP
M"P(;14[WM]0DB-\6.?K4>#$M"&)8F66*:657=:*;/B(A,@][V.W;RG/@<^(#
MX?;_ .N]A\1CSR& ! S/;T;W:O+/R1\<^L>0-\4/8O%A5!YUQOG%Y6R)H0N\
M\-YJ(YSU*R%3=1#3S?S=Z%Y2#.J.3IT"*:D0:6% *"C_ 'E+L-S1]14M5KMA
M5H0=QACYL7+,/+SM!=L/8JQK'*ZQ^)7UC5>%)0-,\G>W'#"6N\LD;2-]T?>H
MK>2AD4*Q) Y(:4-Y^?"@<?%F)%^YIW5[TC'&>M7?C,6_=RF6[QMK=E'0/&&V
MWKQTHW(!#?0)/1>F\=\R3$N-NGG^>K+-&9=8N-=YE:3%T<'UZ#5K\")A;#%V
ML%BD.G[E6&Z8*(BV,D9;910;">VW@"O6MZ= ?&CL=G:)89+,:0]TC30.CQF(
MJ_K"LR]S\Q@@1EHU0=W<R2G[DK\(*J23QPP((]#V<#F?C&,8QC&,8QC&,8QC
M&,8QFL_TM%%G=#\1$5]CE]J[((C^0OBI8KMSJF\_-]2-V+G%6\BN;V#HK&J#
M7A9HK9AS-,'&GRXR.+F)D#6Y3;S*F5+UG1]+3BOMC)ZS%3<Z_:1P6)IXZJ1V
M9=?9CKGQY&1(V,S($8L.&(X/.8]I>Z+CM+CQ(BRA2Q*B12WO0"2.T'D<>S-0
MYX=Y1<BA=OE>%/#_ "J\9O&SMGD S/XI0:7R"U4PM2I-'\7E1K,?F\9C<*[5
M=^64CL/<V0[-;#R*7S&O'3=<DD[M<J+5C*TE^LC;66VI#<W=7LMC2H%;L\]N
M*99Q-L_Z.-;IO4H;4U.B6,C^-:D1) L$,TJ>\Q3XB=YA22.-WY10I7M[8^#[
MP(Y57?C@ ("1R64'SR^\=.T>=MJ\M?'KQ]ZG:KD/&W+@_!?.CJDTM4:_63-9
MKNN!2N3=;\;3H>17ATZK2B?EBNN=%?$2!L4_ !RSX ?.A#AS\2/J-A3TD6JV
M%^M%"S0WKVDJJDTDJ22>OBW5V*.)&60+JO$K!PYC9Q'(RLS Y+&\QECC<D<H
MDS>]"D#L['C(X'']+PW''/'(YX&1^S<FZF]Z4!5M9Y3T^1U9?F[S6[UOO+-$
MN:^<#? (?X3$*E>>>_A?0,W0!8A[MBBL0CR*2=C6 ST0J*N;-<G)TR=1)':K
M?8UX)M5A5&EL0R43/ ++;YMTLL%@5._UAG%+L*VQ&8TK(\!D'FF4*MZQW=K=
MWCJ0_:>/ \'M9>X#M [^25)Y[B&X^'/05G!YG8QC&,8QC&,8QC&,8QC&,8QC
M&,8QC&,8QC&,8QC&,8QC-<7I::,<Z/X#]CI]?Y]9^JS"-I\?9DWG].IQ?H%B
MLM< ^2?(;#;XD&F 1Y4M8FH]4%&IY$?#'2U+%Q)KCK6V&W=ZZ'I6=*^]J326
M(JH6*^JV)ID@CBDDUUN.$M,[*D?,KHJL6'OB.#SQF/:4M X"E^2GO0"Q($BD
M^0YY\@>?Q9J*GAN]\J+=Y-^$W O*/Q<\7^X]NX17J'4J5QBW<R)U0Q2^%]@F
M=<Z*GB+'"NS=$YK0^CWI7&:6@B)Y%48EJM]=;EV.YTVIS#!R?U8>C:2BFYOZ
MS9[.E2O23RSW(;*RI->IBI7]=-ZG7LSUX/79NUK<K10R=L4,TJHBXW#KWF&.
M2*-WC"A4*\=J.781A'9%9NP>2J&(\V4'G+^\9NW>D&L_D3XD<%[!:;X,D];X
M5X^^8?7IA^E5^IV"A ^:<HMW-?(KB%@K,JM"25=E]!\BW>&VJ4V\/C2((^YW
M<=7Y N%#A#HV!LJ6ACU^VO5(H&%2]?U-18YY)8YWLVXK.ONQRB5TE6OKA>B'
M#$,T,#2!BS,;XWG+Q1N3RR)*W*@%0J%9$8$#CND["/A\V^ 9R/*FEOVOTE(4
MK2O';R4%6VB3Z'<IWE")YEW ]!Z*8B\J/ :OXS<:ZL!JLOEG$^($G;%%*^0%
MVM%J;"2+G+F1-U9XL.*64.U<PBZ<=9MAK7BG6>%=6]FE&U=3:CDDV5RJ\RV;
MMU?#*4((XBXA56\4(R1NE7FP"J2 @J3)VN0Q[2!&C %40\\NQ/'<>>.02/IZ
M#3DG5.3;[3$N= OE6 F^0>)J2I*X<2OOCRUON%>K?1H'8JY*J%_1J5UCHXF7
M, N]1\FP&HM?["4D!G8L-K836DTZUMU;?J;0SP2R);VO:L-V#8'U*22LU.03
M0$BI68+(*NLDYDIH'Y/](>5-77O[E8 I%SRA3AP&[AP?NF^Y+2#R8_D&>@C.
M#S.QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8S7IZ57F1_LG@7W/F-
M9I]BOQ6XR.3C%5*J""9T\7$I[;S>984PQ@>/)(OMPZ_&)D9SL=E7N8^)+G/*
M;8C.N(Z#I>S'3WM*S+-' D(MMXLKJB(WJ5D1\LY"@M(5503[YB%')(&065+P
MNH!;GM' ')([UY\O/GRYY_%FA2@\P](A1^FWKOM>Y!VX'V*D^$AWQ%KMQ3S2
M87//43Q^ZSX*T$_<J4-L8>96;#T+H(85Y3=KXQ7WHQ%J]--BYP80=CI>BN]Q
M/9Z?FK04)+=)Z<^ZCVTD/K(1!/?J;R>.&9HV62.O7=M72NN"A@]^'=#PPPE6
M=6=PK]ZP^$&["25C:%25!'!9AXCH/A^ ',OQQKTBG12L:I4_I7FS7> Z-^8<
MWFW6;9Q6O4KR"MM3IG".)V3CD#J(JW</AR:NU/[W,ZI7.=/G:%3;ST.K07H&
MV9#?N1!>H9-!74S35M-)>\/4"Q4BNR3Z^*::]<CMM6:&\PE*T%JR60D\T%>9
MN[D'E<EYG)X#3",&4JQ4"1@(T*!N4Y4>(7"\J"P'LXXRAX_&/,+KG5:B:Z2W
MY<UV]=,[9Z*?L%JLL#E,N$ YZXQXR'1_>[779I/E9"@TJP\SZ,1G5DT%-IDK
MI+LJ.[8*V\M$:9O.:YJ*E:5*WUID@K4^J*D4;6@TE@'9(:$<H6RL\T=FNJRH
MZ<";M/AR#EAE@25V7N,P9FK,3VGA?Z,]Y!*D*58\$'V<^8.;3JS2N[]N]%IT
MZB^0$CN,[M:*QY5U:+)8>M?*.QW6)S_I?7:[Q6018YTQ2"Y-Z^T0!1)4N(-'
M1A'2A9A+TD:3%V-QJ7S,LU&EU-6FH"DM/Q=7*1Q%:IPM8K5)+H4V#.BB">2=
M5+,SUF3@.KQ@C)"N]9@_?W\2@>U7;M9PG/'!]\ OLX# _$<U\]3Y;*+W+T<E
M(*^./DV&Z#3O'GPFG77RD%\/[YT6+P%GE-@#6";QGCXZC5.>!YMUWHI>(1KW
M?[S<BH 56N6KACK# M<IN&&$;^M9"0]13IL=:]>:_N5AUC7J%<WS:1XUN7&G
ME62S4KH5DU\$*R-):[FC:$%I'@92374QR B.(F4([>'VD'L4*/>LQY$A;V+Y
M$'R ],^?-\V&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8SAD1P\P/GB2T&&4%
M%(<H<3&D(S,R 1'S6%QIL&=#D(<CRX<N,ZY'DQGVW&7V7%M.H4A:D[JK,C*Z
M,592&5E)5E93R&4C@@@@$$$$$<C! (((Y!\B#["/B.=-3:73^=U<'1^?U2MT
M:EUF T*KE1J ,96JR &,;5MD>% AHL(6+A-;4K;<6%%881M2MI1K:M[W?---
M8E>>Q+)/-*Q>269VDED8^UG=R69C\)8DY0 * J@  <  < #\0R2Y'E<8QC&,
M8QC&,8QC&,8QC&,8QC&,8QD-%<ZY^#N=JZ,%HU0$=!O40&/NUZ&5H- N%O@5
MB,Y#K<&SV6+#:,GH=?B//1@D4I-E,"V'76H*&$.+3N9K$[PQ5WGF>O 7:&!I
M':&%I2#(T418I&9" 7**"Y +<D90*H)8* S<<L .3Q[.3[3Q\'/LR99#E<8Q
MC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,I?FX[G-BMO0>
MK!N95ZL]%E'S'*[7>]UH)$N]P#\T-SA(ADG:(L)LV6K4=[4F77QQ&<_&@-R%
MKC,MJ<4I4S6+#0QUFGF:O$[R15VE<PQR/P'>.(L8T=P!WLJAFX')/&6@+W,P
M50Q]Z6 '<0OL!/') Y\AR0,MHFDDJ!+T'=@LE-L+]P<)L2),#4G6O6WJ6S%D
M19"F%;U["]LOH<;TKY1*7-H^272 P":,V5E:OWCQA Z),4Y]]X;2)(@<#S 9
M""1P2O/<(;0M&M,*+5TM^&WJ[6HY):PEXY7QDADBE,9/DQ20,H/< W':=*_>
M/2:>0_CGT(ESCI/CQ281:(A,P:1AV\_("6,*^XZW#.@9RQ+.Y8Z4IEUO>G&F
M)<.4S(@SXT6;&?CM^G^D?07T9UKIH-WI.L]I+7D)BG@DUM1+5*TBJTM2W$+#
M>'-&&5@0S1RQLDT+R1.CGPUZ0?JIO23Z,^I+73/4_HVT4%R%1/5LP[G8R4=G
M1D9U@V&OG:HAFK3%'4AD2:"5)*]B**>*2-::^FLZ'^@RF?UL.?=V=/\ :NZ;
MY6;/YNJ_O\XC[>CJ7Y Z/YWO_P -CZ:SH?Z#*9_6PY]W8^U=TWRLV?S=5_?X
M^WHZE^0.C^=[_P##8^FLZ'^@RF?UL.?=V/M7=-\K-G\W5?W^/MZ.I?D#H_G>
M_P#PV/IK.A_H,IG];#GW=C[5W3?*S9_-U7]_C[>CJ7Y Z/YWO_PV/IK.A_H,
MIG];#GW=C[5W3?*S9_-U7]_C[>CJ7Y Z/YWO_P -CZ:SH?Z#*9_6PY]W8^U=
MTWRLV?S=5_?X^WHZE^0.C^=[_P##8^FLZ'^@RF?UL.?=V/M7=-\K-G\W5?W^
M/MZ.I?D#H_G>_P#PV/IK.A_H,IG];#GW=C[5W3?*S9_-U7]_C[>CJ7Y Z/YW
MO_PV/IK.A_H,IG];#GW=C[5W3?*S9_-U7]_C[>CJ7Y Z/YWO_P -CZ:SH?Z#
M*9_6PY]W8^U=TWRLV?S=5_?X^WHZE^0.C^=[_P##8^FLZ'^@RF?UL.?=V/M7
M=-\K-G\W5?W^/MZ.I?D#H_G>_P#PV/IK.A_H,IG];#GW=C[5W3?*S9_-U7]_
MC[>CJ7Y Z/YWO_PV/IK.A_H,IG];#GW=C[5W3?*S9_-U7]_C[>CJ7Y Z/YWO
M_P -CZ:SH?Z#*9_6PY]W8^U=TWRLV?S=5_?X^WHZE^0.C^=[_P##8^FLZ'^@
MRF?UL.?=V/M7=-\K-G\W5?W^/MZ.I?D#H_G>_P#PV75Q+TQ]3M%IBU[M?.T<
M\$$I#<>-=*Z8E6 6*==VE"-V 1(&QR+ _2O:V\4&OD'&-*1IP5\BEZ4WR_57
MU-.QU]"2YTON3NK$",\FKN5HZ=BPJ@D^IV$G>!YN. L$Z0A^#VV.XK&>ZZ$^
MK8T^VVT6NZZZ:'3=.U(L<6\UEV;8U*C.0J_7&E)6CM1UP>2]NK)9:/E0U3L#
MS+NE'D(!:!"*BIL0D,)1(\\<1@2&I<&?!F,HD1)D.5'6XQ)BR6'&WH\AEQ;3
MS2T.-K4A6M[\P30S5YI:]B*2">"1X9H9D:.6*6-BDD4L;@/')&X*NC ,K JP
M!!&>Y*UFO<KP6ZD\-JK:ABL5K->5)J]BO,BR0SP31LT<L4L;*\<B,R.C!E)!
M!SF9'DV,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8Q
MC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8Q
MC&,8QC&,8QC&,8QC&,8QC&,8RE.&36)X.^/,&#QE+7:^SPEO6!I#+\%\=T4_
M ?#CDH*%=+ B78RX -W;L-;HUEAQ8L8M2H;3*#X?RG]GEY?F_/R<NO&5S61Z
M5GC GHOC*5OZ(;6[9QZ?!L8J<EM/O3@ J0@A;0(4[ZM[U"<C2HAQQ&_5OW@!
M']A2=+<2Y]U^I]ZGL:7KJOJ#(WUOZEAEHV(B3X:W((9;5"P%^^B2.2JI_P"R
MV_(/"E?*WU7?0]3J7T66^HE@4[CHJS7V=2PJCQ6UURS7H[:F7]O@-%+#L''M
M\371]I 9@WEFSWWGY,8QC&,9E;QJ=;&>6VJ)QNP)K77EWH%(+2AMF'U"Z$.=
M)"$FV8U7-S"(F8H3#LBE/W,4&G)?EH?K<XE$DC!+K\'Y[U/%KFZ@U\G4U,WN
MFQJ;:5TGHS;'5P[HVH"SWZL4-B(6):/":RQ9A*1E+T4$B3V%27Z[T18W"=)[
M>'HG9#5]9'J#7RW):NTKZ7>6.FA1M)'%J;\UFG.:<.S)DWE2E8#S+)J[%J&6
MK4>2OD'8Z)RRS,Q+>8K]#-[)G2E7[)T>#=E!H-;-U3A7'B=OLU#& [,(K=E(
MZZ4>MDIV=""V<#8K#(8'#X<N+9:Y[7&4=OU!0>36UKFWJB"G!L.F=)+JQ:FO
M5=CU9U+!K:.WGM4+%VC"='4UZ"*6U0MTJB-/-+')2NC/I&TZ?Z2VB0[F[K>G
M]AZWL+>IZVZGK;XTJ^LOZCT?]%6]UM>GZM#:TM7M+/V3[#<S//!1VNOV>QD2
MM6@EAVFLYX5H \KLL!N9# T)\SJNAS-(YM"NY453[:?_  .\&;>:(MM7=B;"
MGL^_7Z9M,4X$,V*PU")79LJ:5>DL3I*%O?T)3'+<W$=;UVS5VN[EU5>QLM=2
M/4W5S(T+-JGBDA<1:>,>)5M5J5/927(HXH%C:+'VNOZ2VE9)H=?T[)>^M=*]
MHNEX-_<J:7<; =%>CU'2RJ;^.>"RGC]13<1;"A>V>RTL.MFFGMR2QV(58*;X
M_#&70D()4I)(X![:1)&6[^>GNT.T4K@-7O5?JU6?AVKX$4&1NNR+-2H1.P0[
M4[<14-F(,GNDM)*N[6GL^LK#BU+;V*04[?2T$%4Z>G"NWH;3J^_JKE^^LNO]
M;@GDZ<2CM)8*<M!=9/*TD\2P<P+HMCI/1U4C>A!0T\MN_K^O+-J\.HMA8;I_
M;:/T=ZG?Z[4:EX-O];[=6'K.7:Z*O;V,.W;=TX8XJMA[7%QYK;>>\EH5=LDZ
MN;J8\NS6>V4R6\-L;1"'8(;=-K[U-.CU$NBW&889L$Y%B=K]GC .=,61K3BX
ME,@(9CM-ZK7;GJ+;WJ$5WZXS5FO]+;.)9Z1ADIRG9W$V=6;P-)K(ZS5(326Y
M0DN;IJ3$"39S%G8[W<]-]'=/ZS9SZSZSU[L>LZ[T<[U=FMF#8PII-=)I-A7-
MKJ;=SW4V-A=D^MVL6NZ9CV:AS#HZPCC1()26.7M<!F<E*6D7'OO2JI:NI--K
M%C7H8VUU>4S-YL"(7)PPUH*3DU>FW47##;@.(?D=FB((R&9,9A,#;[5]\W6$
M?4=?7V'U&BV&OT#,+$Z23Z^_&T6\M0ZP5F]:@2_L]78DM"92B=,RF%&C=C+H
M-"G2B>CJ?HZWMZD?4/5&HV_5B(U2J\-7;ZJ6.QTO0L[MKJ^HVY=3H]Y4@H^K
MLLDG7$ LR)+%&*]LVL\0W;+T]T&XUXSRN4SRE'(A,Z[5BQ*'VR/;N9O(G4X)
M',$"E6A#ZO%NR+1-3#%!="W9(LJM1$B&8<YS7U(?K;J5TVLNUNH8VZA/4=B'
M5WZ0FUS:[>J8MG:>M#7ORS7I-6:$1DL6O6 D]<"&&RXZ_<[&S]=^H7ZCW>MN
M])2Q])+T73GWVJV35MS'N>EG6QI*,5VS;U,%;4Q;U=M.(:E$5'DJ6V-JS1C:
MF ?S2U?>[3^>69^7ULD/Z NC1R(6L!@HH]OL51<4[SZW2;>2:.%R/+/GPN*]
M( UB1%2MV*!62GO07\ZBW]<3I^D8MU16+IN";3C;/#:OVK5FH.F=B NXUT>M
M@:I6AW_UJ$B);OI)PKVQ!$LJ9P] Z8=0]?V>G-I)+UC9K=1-T_':HZFC0J;'
M[-=,Q?IS<R[JTE^Y9Z2&_,3RZ_521!FBU[6K#UWRW;E*INXMEW7I?/\ \'&Z
MCW5'8HXN344Q9?:UT)U-,DB8L=U,V8.5T?=8<YH_6FG +#C=D=![;%)LF]\W
MK$V?B4?78]Q]?/KCTD>F7L1[$R1]++MU.S2Q(ZF*.8:7UX;Q;Q6VX:BMH&QZ
MEG9;J;2&':?6Z;IS[&?K+U^O6L=672K%-UVW3SKI):4,;">>K]DYU+]+R:M&
MUT;+LGH%:@V9.'?930L]7^"3A\.M#I:.-/PC@^L18D&/%*0NR]@C,?$HD9QQ
MQHQ+!MAB$MR<K<V8U+C3U[VS*85OZ9TO5L5+G5\4TMZ>,]3K)4FOR22O)7EZ
M9Z;=O D<*K5H[9LPQB(>%&T<D0]_&XSXMUM>I[#6^CRQ6@U56<=$2P;"OJ88
M*\<5N#KCK6*/UJ&%F9+LVO6C8F:P?'FCFBL-S'+&31F=;G XQC&,9Z*_0[=X
M,VRCWGAECG/3M\XV/L=)=DN;=>CU<[)DQRP5"E;]I,$,:;C2X2=^WM&K _&0
MI$>+&:1XM^J4Z1K:[:ZKJNE$L0W8FI;144*K["HB25[1 'G+:JL\<I' /J:N
M07D=C^E?U%7I!N[C1;_H#9V'L'IGU?9Z)I7+R1ZG82RQ7:*D^8KT;RQ30 EB
MOURDB4K%%$@W2YYASW+C&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC
M&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC
M&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,IKAY'92MV^3NQ'++IKLO<!R
M9A]EQF4/T(ZO;A6Z["2X4+;4#K:H6P8%Y+\9M\1!AO-BQ*%Z&QF4'^Y_URY<
M97,)O2*6X;3_  Z[.^0=;2Z?"0*B+CKWK3DPE9#(\<EIA.__ 'W(T-R:27K7
MY4QH$AW7_P!WGU'T,:Z?9>DKIA(58K4MR[&=Q[(X*-::<LY^!7D6. ?&\J+\
M.?"OJE=S5TOH4ZXDL.H?8T*^FJ1D@-/:VEZM6"1@_=-% T]I@/,15Y''W.>0
MC/T?S\9,8QC&,8QG:;*%)(R!7G)\E8:$4(%((U;BE0XA0U'$P2D]EG_W429\
M4&'8E.)_RG6AL1"O7IE/JQ_5Z\<\UY84%J6O#7EG"@2R5ZKV)J\+/[2D4EJR
M\:GR5IY"/NCF4;=N6K7UK6)6I06K-NO59R8(;=Z.G!;L(GL66Q%0I1S.!RZ5
M80?*-<RQ+>(9$:FZ*9Z$"GHJ=GZ#2F)J Y2"))VKEPZ*1ML%^>37#4)@K<GP
M@E=)O1I+9D\ZZP\P,$,Z-N_.X/23#,=8'TMN$["CI]H\1LUY;$&OWTSPZZ5(
M8%D%B4+%+:NP)(C5:BJRM/98U5^P7/0S9JC>%.I-?8&HVO4FBCG%.W!3M[?I
M.M%9W%>2S:,)IUV>Q!1UEJ2*1;NP=XWCJTT%Y^:6\3Q<NT:#TWHK+\2><GA
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MZ\^1/5W^6]S_  6/P$]O_0WU7[/+=]SX^R[I3Y3]/?/6M_B<>Y_UY\B>KO\
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M'=_ZK4'_ *G8^UFZ]_"G2?SAMOY'C[=ST4?@#T@_-/3O_BO'TRWB]_N1W?\
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M(:Z$3UY(I"8NZ.O9:'LH' >]68=.IUH-/C1]&8MBJ[3#W0JY+0T7KMN<H91
M6L3+@U\*K[MR;(UV3>H<'=4;)P9S3A-U++ZVX9NL.D:$T6SU]5)YMJ^N%W:5
M--=B)K7=<NV@-J_'K&]8N+K#!<34R2_7 P2Q,(%+(&RH/1WZ0=I6GTNWO25:
M^ACW'UMT>PZCUDRI<UNY;IZV*.JGW2>J:U]XMG6R]000'4+:KV%:TXCD9,=#
M]-LM6BC)=@%.BFC#QI@>W*>BZEO+KI5\&8VN A]<V,U$,19@W3\J.RQ)F09[
M$5Q]<&7IGM:>TH["2Q%3L+8:JM5YBBR>&HNUTMUN)2@B=I*TD<_9&[.D<L3R
M*@EC[OFFQTFTU,56;8U'J)=>]'665XA-(VMMO0NEJZR-/$D-V*:KXDL<<<L\
M%B.%I&KS!(QF?FJSTR>AN$%8'C1<B4U+K0\YV [*#H<TK27V(=5IXR9-9]?^
M2IIR=$?A;4G_ />'.IW^5.>&/JE[->;KG6P1%6FJ=-U([)''*O+?V4\43\>8
M989$E /_ $S*1Y'/U+^HFI6Z_HMW=J<.E?8=:;"6DK A9(X-1I:LT\?/D5:Q
M#) 2/^NLX/FN;;,\[9[%QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8
MQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8
MQC&,8QC&,8QC&,8QC&,8QC&4UP'2]<Q';<9KC"G+1TI[;=3D,2@GJ?Z9;WDN
M-/QI4UE<]Y+FGC:=2%+;-N$6G6V'D+CM,#\?X_\ 7R_9ERXQC&,8QC&,8QC&
M,ZHZ="U@.2L-C+#@0(-#?(%C!:8Q &CH,9&W'Y<V9)6VQ'8:1K>UN.K2G7Y-
M>OU[UK>14J6KUF"G2KS6[=F18:]:O&\T\TKGA(XHHPSN['R"J"<Q+^PHZJE:
MV6SN5J&OI0R6;EVY-'7JUH(E+233SRLL<4:*.69V &>3GT@_EA&\H^P,/55R
M1^"_GD6;7Z-N0VY'<,.RY#3I^VN17DI>B[//Q(+$*.\EM] 84+7*CQ9SLQA'
MZ%^AOT>R=!=-N-@$^OVZDBN;4(5<55C1EJ:Y9%Y63U19)7E=2R&S8G$;O$L;
MG\?_ *H[TOQ>ECK1'U#2?8ITW%/KM 9%>-KS32(^PW+0N \/UPDA@C@B<+(M
M*I4::.*P\T:X%9]=SSUF2S?D[;7:?6J69"P+$'K\.IAI TO8[\JMV"NTHO$,
M@PI>F0[9$J?LK?&BH92?"$1)\\<,CZ2]&)2"90APC=!:X;*_M*MJ6E9NR[&T
MDU>CI_7J=W:UY*UNU7V<NNDV/DD]B2O#+9DBAFL2$K) D%>'Z@OI4W#Z75Z.
M]1K[*EK8-/1EJW-GU"=9L=9HKD-VA1N:2'<0Z?AGK5(;=BO2AL6*]2+AXK4E
MNW9F._*YTA 7:;+3*Y8^NM]#IE]9L<I@O 'R;%3 ),:.N9.$'.CX$PZ\^X'V
M6$[&H!&W!:",V/J9))Z):[W/1#,-?1VEVETXVEV>H:E&U::9*6SN03S:N"6S
M4FFCJ*BV?5[ G-JJ)V@B?PDK^!NO=>>Q VWVFCUFSZR'4FCZA39RQW*]:79Z
M.A<K5MY:KTMA6KS;!Y)*1N5/510OM4%J>,3RV_6NJ:\N;BU6AE:16*^J,,9J
M>V=NE+D]!9(5&FG*-'(C:\Y9=UP*\9$6(L2LNA(J(LW9ICQN4]Z_DHC4[>C?
M6->L7C?N![#;$,%KZQ9FAV.RJ;5X)[HI>NVEK6:5:&B;$\@JT8EJQKQW2-BK
MZ9-VFKJZM=5K3%573E"]O=O EG3:2_H(K577-M#K*+WJ>SNVMJ*=2$W]K.]^
M9^>R%.BI'DW::0(&B(=="36Q%:@5B,IXE:X<4G 'FK@<1#MH878(0.Y!),RY
MS53:]81LP6]L>.^3;80LJV4R]KT'0VMF>S+>M1-9OS7Y M?7RR02S5M;5,FN
MLSTY;>LM)%K(A'=ISQSKXTW)8BNU?7Z+TJ;;0TZM.'6Z^=:6JKZJ(O9W$$5J
MM6O;K8+#N:57904-W1DGW<YGUNQJS5']7K=J1JUQ;?SD>2UCFM,O3JG4Y1L0
M/+#:@?5NP-3:FT?H@7GYA<2*R;;&DG'!8-@H-V8AS4BS\J;-:2[%=:@,5CZ%
MI1,Z1;'8QU+,U>?94P*;1;%J>VM;BL))'JM/ JSVVKS^K21&Q3CBB8JZM*UL
MGI1V<ZH]C3Z>6_3K7*NFV)^N*3ZA-CT_1Z<NM#$E]:MIFJ4([=;UV&<5-C+/
M80-$Z5XX5;.OE[H]8-FPP;<6S=*WTPK$B?$&$J(N1)$%\3'=5-><9%O1I+J?
M7O;DU"_96F5^3V=[77=,UM6M,5;5H24-%]8:\DG@L1 )4F2RZB)0UA713Y=L
M3#D&,<^6BW'6=W>ML?7Z5$Q;7J@]4VXH?68P;3PR5Y*<;F=V2H\4KCS+3JW!
M$WEP>N%]3L8JZ7"^-MPGCMU%]#&$UN)D-,Q_PD!S(8S,@IBR([C$F&R;DR!G
MK<6PQ(:8^59?90II<]CIZE8U>LU!:1*FJL::Q !V,S_62S6LUHI?$1PZ2M5C
M2?R#LC/VLK$,,:IU;LZF\W74"K!)L-[4ZDJVV82(D?V3TKU*]/7$,D;1RPI?
MEDJ^^,:2+'WHZ H>31^O6>A,+;%MP9KKG0N?=&=E%4RY;SY/G<*Z#AXJ5K4M
MIN2$,0[R5C'8CR%NRX[4:.U(CL[DHD1[;IJAN&!L-+$JZ;<Z58Z_AQHD&ZEU
MDTUB/^C)CM5I=57DJ2*0L;L[LCMV%)M!UGM>GHRM1*]AVZDZ;ZF>6X)IGDM=
M-0;VM7IS 3*LM"[!O[D6PA<,\T211I)&AE62=+\D[)(?($9U6JLPVV:NYJF%
ME?'V5\_5? D&N$1H&%'-MP)HD((%C6JG#.QR>@<B$T[[<QE;T9S4CH:BB0P1
M;#8156JZJKM*X%-QN!J+4MV&>W*]5I8K%JS8G;825'@]:25EXC8(Z[YO2?LY
M'LV9]1J)KRW]]?T=P_7&,].'J&A7UEJKKH(KZ5YJ=&G4JKIH+\=KZWRUT?NG
M1GB:40O+NTPH)F&U3:RUJPP; /.;@E[N+CF6+5S<5S,VHV/'6F-!..-"16R5
M<299GQ*R7+&9(V+[,J,B%KY?1O0EEJR-M+S>I2TY:GBU=78>JU#=V-Y5%6:>
MB\M16GL""Z:S0R7J]>LDTG,;F7;0>F3;5X+L$>DU:?7*OLJVP,%W?5([T>WZ
M8I]+WS?KU=M%7ONE2H;6L6]'8@U5VY=EJP<2Q+!7H7O%@$=,L'3]"XVC%C';
M'/H#G+75I(M/J$Z][!&ZX='&X$IQL0W$E:=FS(<P;.)P94-QN4A3&ZM=(T[.
MBIZ'UA_5J4YG4V:FOV$=CGUDF.W4NU9JLT8:RTD96**6*:&"6.56C(?FZ/I!
MV-/JG8]5^J1"[LJQK2"E?W&HEJ#BF/&U]_6;"M?K3,M-890\\T$]:Q:KRPLL
MJF.1S_)4@;:-1;%SFAE!U@8M44B+C_.@) W$L?2!W58L.*T'L41R'&!6F"\S
M$U'>0],!D9<$@_(F(A$XN##T+#4:K)2W>WKSTWU\D%AQ0M3"2EI)NGY9)&LT
MY%D>W0E5I"ZE8K4,<L*)&98)-G8]*%F^EZ'9=,]/6ZVP3;Q6:D8VM&OX.TZG
MJ]7101)2V<+0Q:_;5Y$A$;AYJ%J:O9>2=8+</(.^31FWR;1,/U"HLG;?$O%>
M=MD1%EU-K=4Z)T$UTDT.#B6[$T+DO"['8C*P\X@Q)G-BI2A4A^1IJ')B6U.A
M*VM2A'3V6Q:IK9-3=772&CX5[8Z735M)6GLV&IM/&MBE2K"S#"\<)L1BPB)W
M2)))L?2G=W4NVGV.ETR;#<Q;[7/N(5V@GUFHZDZDO=47JM*FNR2I*]79[.\:
M5BS'+86I,:DLD@2"6&$]]Z@WUKHDVR0].I$18$(2*^5A-C')CB-O$[)87AC4
MPBT-EW2[%+1>2 YJ?,:@D;++BM2'6VD+WM.C] W3FEBHRE39DFEL6.V5IUB4
M]L%&DL[10M/'J]77H:J&9HHVEAHQR,BEB,T7I#ZK7K#J6?:0]PIQ5X*=0O M
M5IV7OM;/9/52:RE6;>[VWM=_9K)8F2"UM)XDD=4!,@\;_&+J'D[=XM3H A](
MMF1'W:;G,C/:K51&N*UMV63FZTEMV:MG3BAP6.YLB4=1M,=I+#<F5&Q.M^O-
M#T'JI-CM["FPZ/\ 6_61.OKVQG4>4<$1Y*Q!B!/:=1# I!=B[1QOLO1CZ*NJ
M_2KOH=/T[2D%1)8_KMO)XG&KTU5F'?-:G "O.4#&K1C8V;;J5C41K++%Z_N/
M\LJ_$^:4[EM.96T IPAH9&=>TC4HA)4MR43+SMMZ2VH@9*2)A2<IM*&O>I;N
MF4-M:0A/YO=2;^_U1O-EO]FX:YL[+3R!>?#A0!8X*\0))$-:!(Z\0)+>'&O<
M2W)/[/=%]):GH3I;2=):1&37:2DE6)Y.WQK,I9IK=VP5 4V;UN2>W8*!4\:9
M^Q53M463FDSJ,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8Q
MC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8Q
MC&,8QC&,8QC&,8QE->/[2V>5 D.#*\(6HM=WMP*J7;.@VO>+Y9I&G8Q1H[9&
MY$B7IW4PDA)B3J*4D38?R,#;&QT1E![/+R]O^O\ O[<N7&5QC&,8QC&,8QC&
M1.Z J<=!2F[S61-K!0=?$'AA:L(M[6EQM;4E^.#V.*ORI36MJVWJ)">D_EW\
MFG?Y<V&LM[*I;C;57K&OMR_T*SUKQUS<.0"CVA-76.-CQW&258_9W'-/O-?I
M=AKY4W^JI[C7P?\ I+U+FJ7=)W1 D214/5K<DTR@GL$,$DOF0@/.8*/]X]&1
M&>>C29?CM'D1W7&'V'^8BVGF'FE[;=9>:<IR5MNMK2I#C:TI6A:=I5K6];UG
MUA.DO3I(JND76CHZJZ.F\L,KHP!5E8;(AE8$%6!((((/&>?I/2#]2M$[Q2R^
MC2.2-VCDCDZ3J(\;H2KHZ-I RNK JRL 5(((!&?+\/\ Z,+\X^./V:B/\(9=
M]B'IW^\=;?/=G^8Y;[HGU*7]8]&7^5:?\EQ^'_T87YQ\<?LU$?X0Q]B'IW^\
M=;?/=G^8X]T3ZE+^L>C+_*M/^2X_#_Z,+\X^./V:B/\ "&/L0]._WCK;Y[L_
MS''NB?4I?UCT9?Y5I_R7'X?_ $87YQ\<?LU$?X0Q]B'IW^\=;?/=G^8X]T3Z
ME+^L>C+_ "K3_DN/P_\ HPOSCXX_9J(_PAC[$/3O]XZV^>[/\QQ[HGU*7]8]
M&7^5:?\ )<?A_P#1A?G'QQ^S41_A#'V(>G?[QUM\]V?YCCW1/J4OZQZ,O\JT
M_P"2X_#_ .C"_./CC]FHC_"&/L0]._WCK;Y[L_S''NB?4I?UCT9?Y5I_R7'X
M?_1A?G'QQ^S41_A#'V(>G?[QUM\]V?YCCW1/J4OZQZ,O\JT_Y+C\/_HPOSCX
MX_9J(_PAC[$/3O\ >.MOGNS_ #''NB?4I?UCT9?Y5I_R7'X?_1A?G'QQ^S41
M_A#'V(>G?[QUM\]V?YCCW1/J4OZQZ,O\JT_Y+C\/_HPOSCXX_9J(_P (8^Q#
MT[_>.MOGNS_,<>Z)]2E_6/1E_E6G_)<?A_\ 1A?G'QQ^S41_A#'V(>G?[QUM
M\]V?YCCW1/J4OZQZ,O\ *M/^2X_#_P"C"_./CC]FHC_"&/L0]._WCK;Y[L_S
M''NB?4I?UCT9?Y5I_P EQ^'_ -&%^<?''[-1'^$,?8AZ=_O'6WSW9_F./=$^
MI2_K'HR_RK3_ )+C\/\ Z,+\X^./V:B/\(8^Q#T[_>.MOGNS_,<>Z)]2E_6/
M1E_E6G_)<R3XIW7QEONE4[A=[YM,4.0[);I]2W !2&F-:TY)F0:UJ,,D/14>
MM.Y4R% <CM+4E+[J5JUK?$=4=)]<ZCC9=5ZG>1"=E0[+8B:TC.>0D<MXO.BR
M-P?#BEE5V )12 3GU#H7K_T5]0@Z3H#?]+S&JKRKI=/ZOKY4C'#2S0:OPJDK
MPJ6!EG@KM$C$"1PQ S(G.,SZ7C&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8Q
MC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8Q
MC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QE-^/\ &5$Y+5F5A1U>7MZRO*$"B3I>
M!&W*MAV5M;!%\F8<D>^?+>^NZV1D)9?D.1T:8;:3':90?CRY,97&,8QC&,8Q
MC&,8QC-$OI;_ !0!, F/)^CBF!A..4@!>KQ8+*68Q5@N\B""N3S;>DMMDV2B
MXH(L_K2G"FB@I]SV7H,EZ5ZR^IU](5MKC=![6P\]>2O-9Z>DE8L]>2LIEM:U
M&8EC ]=9+==/9 8)T7WLJ*GY_P#U8WH@U\>O3TK:&G'5MQVZ]'J^*NBI%<CN
M.(*&[=5 46TMM#K[DGFUL6JDC</!*\N@G/7V?G?C&,LWB],%]%ZWS:A&WIT<
M1<+K7*X3?&28D(BU!+E(T*2N#,GQ9T&+*2T\K;,B7#E1F7/9<>8=;2I&]#U1
MM+&DZ<WFWJK"]G6ZN[=@2>.26%I:\#R()8X9(I9(RRCN2.6-V'(5U)!SJNA]
M'4ZEZRZ7Z>OO8CI;K>ZS66I*DL,%E*]VW%!*T$]F&Q7AE".3')-!-$C<,\;J
M"INBU<(ICP@>:KMB&T+X:/LQGH(JU=/J_8VZO71Y>B5ZIV#1WCE20YN1=+)<
MY0"#5'*XZ7@[KTFP392 $S4J'R^OZNV:V9JMRE/N!/-1K::QK]#?Z::_=FK;
M:YL:9J=2[$KX>KI:R.W+L5NK6E%Q*<4;6XNR7M]MZ/\ 2/3K7==LZW3QJU]K
M=ZCJ;?JK4];)J=96N]/:W3[+ZX=$Z=6\7>;3>2ZZOIVUCW8/K;+LIYEUTXF@
M[!/A[9Y<(4T,M @B>;1?"=KABP]XL#(BL54K2Q(4^+BUVG$S1^/:7;U79$".
M+&RY<:&;'2RT<2Q$/K#PGTET(Y;#3T+,-0G40:Z2Q9U5)K-_85]I8M4[$EW9
MP5:;T%U-U97L311O)5FCKO8>2H+.2/0OM)H*:5=M2L[!5Z@M[B&I2WVRCI:K
M47-%3H[&I%K=):O;&/;OU!K)*T=2M--'!?JS7(Z<<.Q:E&#'BS:J]HC'.W2B
M"S,1J^38-??W=%%"X?FPUH]:#,=+=,5%'Q&:VXH]!AG9(HW,88D#OA+)MI0S
M,^MZ0-?=,#U-5M[%61]1#+<3ZUB"M9WDS5*%9^[9B2:1KRBI-+52Q5B=TF]8
M:JPGS57?1+M]:+,=_>=/U;T*=0SP:V0[SUR[2Z8K)L-M>B TABKPIJV;8P0;
M"6G?GBBEKBFE]#4R6V7Q,E,7$W4ZE9HI6*#M'2 V[#J!>#SQ*)2+!4@'L)J%
M6YQ//CIL&5:$),3M+*AGDPR,F/*AQ8@YRP:VAZ1D?6U=AL:$E>2U0TED4_&U
M5-(9-K3V-SD[+8;N*G-'-%0)K0D5[2F2&-TEDDF6GN=IZ'I8]W?T^GVL5R*A
MM^J*'UR%;?[%[46@V.FUQ4:74],6-C6GKR[91=G#7*4@@LRQ2P10U6V,=;\?
MAPKK7C]S"TS2C4KHEP^:'0EB9L%S8V;![Y<>1E_FK*?&+:0A ZLMRX;Y**12
MHBX[)<9W$6W!:SFZRGL=.]9;[7Q5VCTNM&RTPL12CQXIND=9U%7^N$:3AF)F
MO-'(L$D)$(5 PD!E;6KZ.:U3K'T<=*;:Q;27J;=#2]1M3GKL:L\'I$W?1ESZ
MT325&15%75+-!):AL@V7>5D,++72RJ?XAUZSNWF$]:3,!U_I%"K7(B>FH3T(
MU2+3;N>PIURL(_434J6I=/ZU030*$+EC=3)\LC&4X[J-IE.CV7I)N4%U,JZ^
MK,J:3;WNHX.Z59:NUH:[=2Q:RE+XOAQ@;+IW;U;<L\<YCAC@<!3(&/3Z7T,Z
M[;-OH7VUZNTG4_3VKZ,M]D#07M%M]STW!/N]E6\$32EM+UCT[>U]>I-6\>Q-
M:B[G\+PQ5%;IG%.D3B,.H"NKUG80!U$NZX>/5NSPB\>H\>Z+T"N2GB8ZG5QJ
MLDI!NDQ8Q&N+C'TE@LXFH6=&20JY,WH+VTZIT<,,NRL=/7O6K>AKJM.I=H2U
MI-CU+I=/=C2"?9W6O0)5VDDD-T/3->U% )ZDZ6A'%R.JT?0O5%FS7TU3J_5&
MCKNJ[KML-CJ]K!=CTW1?4W4>ME>U6TFL3569+^BABLZUHMB+E&Q:-385):)E
MGIJB4>3>2!6.DP(KHNO )]GL5A.:)K&APT!Z)#V^['"#2Y>6_,)D1@F#%@#9
M3CLXC&^7]VAIDRX_4;?;)J8:[FM8NV+MR&A2IU3 L]FU,LDO8KVIJ]:-(X()
M[$LDTZ*L4+]O?(4C?B.G]#+O[-N,7:>LJ:W76-KLME?%MJU*C7>&$R-%0JW;
MLTDUJS5J015ZLK-8LQ>(8H!+-'?5P\7WQ9.+$K]VK,A)BL R5-@D9!YTCT I
M'XW1^GW-59?B51D?!$)>MFXE45;7:[*)^U&&*V^0BD'T<?K>ODL5Y);NKO(:
MMZU!M)8$J+!IJ\G4VUT.K%Y9-@TTU@KKO$V'UN6Y'!Q)..V%X4/T'=>BB2I:
MABUV]U4@NZJA:TL%F38O9ZCN1=$Z#JO>'5/#ITKP4@^X,.H.X?6S6N8JA\2S
M%9D5OP]Z/\6@BV20N:EZM%[80G#*[THI&AA \NKCG" AJ!1'Y=Z'$"UP"B11
MCGT>TA9,M<R3((0P\-TINONE:7U::PU>Q$5O5M=!#8NZ.N\EJS'?F$-EI=LL
M6HFAKZVU8L5MR]"TD8C1(9+,JP8/H7ZF]=KU$M4YP^JN[BS8J:WJBW%!0HS:
MJJ]BDM?I^2;J"M8N;JA3J7>FXMM1EF::62S#2@>YF/U^I)GG-P.TJP?(**@)
M:(TAV+J6B-(:?CLS84QAHC$'DF&ID&3&EHC$QX\G%2]J.1@0IK3\5KLM/M:V
M[UM3:4PXKW(RZ+(8S(C([Q2QNT,DT#M%+&\9D@FF@D*]\,TL3)(WSKJ+17>F
M=UL-%L?#-O73"*1XA,L4J21I/!-&EF&M:C2>"6*98K5:M:A#^%:KP3I)$D/S
M99I<[4&<-5DP-L%=*D01T/,8("3 F8^/)#IT9>G&)<*;%<:D1I#2]:4AUIQ*
MD[_@WZM[S'MU*MZM/3NUX;=2S&T-BM8C2:":)QP\<L4@9'1AY%6!&9="_>U=
MVKL=;;LT-A2GCLT[M.:2O:K6(F#QS03Q,LD4B, 5=&!!^'/6!Z/7RSE>4?(I
M/SL<C_A1YW)@@[LJ.VW';-QYK#S@"VM16=)9B[--0YT8A&82AALP,(/1F(D&
M3"C-_GKZ9/1XG0/4:#7A_K!N4EMZH.6=JKQ.JV]<TC$M)ZJTD3PNY+M6GA61
MY)4E=OU]^IO],,OI9Z-F^O#1?99TU+7H;TQ*L:7XK$;MKMRL* )";ZP6(K,4
M86-;E2P\4<->6")<^\^0YZ(QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC
M&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC
M&,8QC&,8QC&,8QC&,8QC&,8QC&8M<\<['SOGS55@\*$+>K1/4 /!A]<'.1#
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M_2KTY-6V*/K-ND]G4=0Z&*25:6REGK[/HJATA2V\UJY97ZW;)EUL%W>0:FK
M^WL/XEG:R15XZ<G6I\HPQ&RW\B9AV=H;=NB7RU,[<AUJWMC@%N#P [  G6;/
MK0P[#9@C(<&5"BE:\\RU&'2Q9N%($16W)VZ M0T=/#6EU[3ZO2ZG7OQ+>UIF
MMZZS-9:Y!>H?T]21I9Y)8Y9*]Q69YH[%65+$A&*/2O2M;3J.S=AVR5M]U+U!
MMX^Z#5;M:NOW-."FFOM:K;<5=A D%6""6O%;UKHL5::I>@DIQ(_XL?D;0+9"
M+5EX'?*G72CSDM)D 7;,VN*_#Z 2ND"+\L>+?+RQA31':I\>8>=>$&X((G&D
M&&@3<6?6CT1N==+7OK;U&PNP*L?JURLU;7R)+IX-7-)V5*X2.>OX/$+QU%2Q
M5EMP.E9K;/%39^DSIW<07-4]#J#3ZVV[3"]KKJWMO#)!U';WE>+Q-C<\2:K;
M%KFS'-L'>G?KZ^U%)=37K#8C_0_)9F^JM"U B8IBR\YO=2T%9)(D"!A>Y^2Q
M[O'O<=O:6$.P8< I""..;BL2I!$<U,^20RAE*,W3="OJ!0 MU[#T=WJ=D;30
M%+,];5]#U.DO"=O?%999J\MI5\1XTAF:/N+EB==U+Z48^HFVS'7VJ<>TZ9Z@
MTPHI:62G5M[STH[#TA>-&O"!X((+<%%F,4<LMFLD_:J*BK2CMVA(*\Q=B0I2
M1//((-O;#FV42B,]%@EVRQ2U:;6MC2Y!8I,'#GE[^54&@!T2M(=94TWU"ZJ8
MU]^LDL9L[J6V0Z]QCAA-./74H_-0_"5J\4TRCE1:FLF,E6#'A6WL"W.E7A@E
M%/IN"@IC8HLUFPNRFW&RF/:3'W27+<]:L['O-&M26;M="JVL2\F;0<M]W+EY
M,]RL'X76T :X-C!0; LGT2MGZ\++D&@L(=&)$P\<NRV\3E)E$MQFY+4:2GWE
MS3G/0]"4*NMU->M'"+].7IPW+L\EJVUBOIKU.[8K0M:EG>""R]9F6"/PX/$9
M&D0]@XZ^UZ4MM?W6^N79;#:K8P=8C7ZRK%1H1U+?4FLV.NJ7;,=&"M%:MTX[
MJ+);F$MKPEE2*4>(P:56'R2K%S:-@RH:T54#;Z]%G6DG5'ALHX]U4E<QU\OM
MKC09+XJ&\$MQ08-%Z#*)0W!T.O5(CM^8^"7 GZ^ET-?U;5;=>U0V%S6W9(=?
M7V*SI47I^#5S:C4:]Y8TL2K:UL$\U@V? E$\MS8PA8DM":';[+TGZK>)>H7*
M6VU.OW.MBL;:WJ)*LM^3JZUO*W4/4.WBKRR4X'H;FW5JU12]9@>M#K=-9,D\
MFO:O8[HCY/T:RS3!<[6;- (DFKVTQ'8^$V81&:L768G4!Z9XHK-%![%+E?\
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MGPG_ $4D?M%Z/_BK'N]^E+Y0P_,ND_E^/M3_ $%?)"S_ )EZG_F^/HN?"?\
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M)2@$N8S+2U&BL*/NT(61:%3('S[<]B,-O#Y(.S*9*-Z,1XWLK6.C(:+3;0E
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5,8QC&,8QC&,8QC&,8QC&,8QC&?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>img102984888_7.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img102984888_7.jpg
M_]C_X  02D9)1@ ! 0$#O@.^  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" (: EP# 1$  A$! Q$!_\0
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MSV7/QE%KDRV$ 'T<Q,C/(R+<1] !9LF(C]LN.-ZU=UR;CFHE\A7V&ZHQ72A
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MCB\DEF*>/C_"MYQ:14#J]B;:7VMP6(_)2$BA0^$OD6=F)\4Z'9V7JS3=Y)Y
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M 1!11%(QR$$"@)A]Q@ /0 $1_@ CF>M$LUB")V\$DE1&;V^E68 GW]O8'O\
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MY0B1V=^G0),J2,6C#^/?CUU=<>NV[^LBL7 /5+R('"^'JHC=+)XCV'?]GL=
ME2P]B,M!SS3+S&,8QC&,8QC&,8QC&,8QC&,9$:<Y%K$[VG2NU'%ML*5II6B[
M?HEK1TVT4>KOX:X6.)L;J<=NE&QI<LFT6B2-46Z+DK,Z*QC*$$Q/0W6DJ4QR
M1? 3KR2+2PV5DZ\($TSW'C]-0!Y_,_.,DHD\E"H/%06[&2U(UF'40GJ,:B[>
MNQ.G?G+)>K)597)/2I&J!T\1Y%^NSUV#$C5OB"U!J[H:M;>9[?W-8-5:VV3=
M-U:9Y<G9&N*Z@U1N/8;=^WM=Z@EV\&C;9(RQ)>84B(*9G'<3!NI-=RR2]P
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MQB(*&(!UI&?>QS1-,#>XXJ^A0$<ON,::3D/(-5IX_;YZY%'*WOU'74F2S*Q
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MSJ\FAIH]IUA2:)'\6MM ;1(0>#PH2Q]AKE*^-UM$=:\\5?61S]^L(O:_(5B
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M!$:,TDNF[9NT13;-$$6S=$H$10;I$112('Z$323*4A"A_ I2@'^3-A "@!0
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M0Z:0% 3>N6Q6EULMS5/U&*^QM26(8R?2:^OA4L6"!T'E=*T49D8>1CB12>E
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M=!+:,C.[SF)IXQ#/)4^:F%&6>+_Q<\E/Y>253T?49NXXV)1;*^ Q >(>3!
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M6>G J@,(JTD#57B02!P%:!VC)_M=,2"&Z;,5U1L6L/=)L-:F%BP6^DRS"86
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MPF^"_$_BGN[DGQ)IMR?:<ET5FXK[.#43W(8N*6^75:S>@O(OP])(E-H?B"5
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M.'*IC>PIR(D32)Y]NMYM>17Y-EN+<ERU)[ M],4$8]D@K0J!'7@C7Z4BC55
M^_9))MZU6"G"L%>-8HU[/0^[,?=G=CVSNQ]W=B68^Y)RI7KK=.S2]V<RWRO<
M==:7>H<H36]6-GL5/U4XF(>\I[*URQK4+(:_D47OTDK'MI #&?+OEHWVHD4^
M JRQ12#U7B>GUO\ 0?DU&QS#B=&YRF#1O5KW-H(IJ)UVQDLS1[",Q^<4C1]"
M-8Q+VQ^KQ![RAV%BQ^*4)8]=?FBH-;]62.%"LGS%81H8295\P&/3=A>NO;O[
M9=S"21IF&B)<\?(1!Y6,821XJ70!K*QAGS5)T:/DVP'4!O(,A5%L]0!0X(N4
ME4P.8"^X?&9HQ#-+")(Y1%+)&)86\XI0CE?4B?H>4;]>2-T/)2#T.\V0'L ]
M$=@'H^Q'8[Z(_0C['^.<GF+.<8QG@Q@* F,(%*4!$1$?0  /N(B(_8  ,8 )
M/0'9/L /N3^[('[,[&6FKE(:/Y1K:&[]QH%.UGYYLHH;4&HCJE53)(['N;,3
M,3O&BI04"HP[A>==B3X3%;'.0#:G?Y(TEA]7QVNNVVBD+-(&(UFM\B1ZE^VG
M:^:=%OE(F:P_7B0A(SZ&XK\#TH:*M\0?C'M9/A_P60K-K-=*B_TXYNJ%'>KQ
M70S=6%@F1O [N]%'KH/(2 S*&*\EIWC2-A;8QW5T+;G_ $)T&FF)VEOM"*:=
M/U]\_H=:)U112%"$JC! X%*23^E7GW)B"NJ_2,JHEF76\;2*PFSW%E]QN0#X
MVIP%KT_+HF/6TU AJH/MZ@0V&/;&0%B#&YO\<[>PTMC@7PTTE?X9?#-V"S:/
M3R,^\Y-Z8\4N\SY$Q.PW-EQV33]:/60AO32LX17R5J&NZ UM+B\MJ34D+J[;
ME:NK>C78=.SN6Q!,)&Z\Z1F6351*)S"5,[H2 (B/IE^*=1;#6UJUQ;=0C61#
M&+#(.^D:8+ZA4=GI2W7\,\=DY+R.741\?EW^ZDT,,IFATDFTNOJ(IFZ!ECUS
M3FHDA"CMUB!]A[YF62,I,8QC&,8QC&,8QC&,8QC&,8QC&,T7T%S+H#JRBCK3
MHS4E(W#1PD&\LC7KQ"-9AFSE&@B+>2CSK%^HCWR8"9,'3)9!84CG2,<R9S%'
M!)5KRRP3R0HT]9G>O,1^9"TB&.3TW'3*)$/C(H/BXZ# ]#K-'8GBCGACE=(K
M**D\8/T2JCAT\U/8)1P'C;KR1AY*0??,FT]I?4_/VOH#5&D]?575^N*NBHA
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M]<M(X#] XAY, HB)0Y[U/[1$/01#\F1'H(AZCZ"/\O4?\^4&7>2ZQC&,8QC
M_H/^;&,Z;OD#V!>M,=H;^5LFY*?%R%]V506+*&G]24O;_P"$Z5E(0C=689RL
MVK+O($:@4#E?:\,SA%I59R67;N!(]*MFW_"#BG&^26.?+R+X9WN4W=:NQV,'
M)EMS-2O0Q4:DNLX?4A!].OLE#2$QQDNYG2>5 LL9/TE\3^1\OU?PV_9SL?#_
M .*-;A.@NT8>/S\439'BFQJ<V/(M@F\YWLY%GI2;C16E>@G]))EEU^K%*6A)
M966.6-;$^#;SV5I_DJGSC.Y<GVO3BLA:Y.H2>W]F26O;)'UIS9)!>/9/%8L;
M#4JTT2:G(HPJJ;WY*TV62C70)+)"@GY'K:G+;5S81\4XI!KM.VSN)K.)W[FT
MO[K01QR^F^IM3QU96$M>9)2*\L?JU1(('Z]+K/2_B_!\"9N2UZ_Q0YC\0+/Q
M(J\=XY%S'FW$.*<<BXARO;_A%9I=_KZ5J]K[-N.VC1B3=0R2U]V\9V->22.<
M2-EUF\T9=;S8UZW:RU1L63]Y4T6G.?0T!MJ3>&'U*(-XB+KH+)G%02))I.'2
M:AS>_P!"^@IB?>M;PGXQW6+3_#=ZE7H'YZWO:.MK#V[);\32K*H'\8OT/Z>^
M>*7>._LTS1%M/^T+L*]I4=FU^\^&.^:96!^E!)H;>V64MT>FB0IV4!8=MXZK
MZZ\PFW?[75PZU#RITKI>T[$.:M5C:6S:0$1 PBJJ;E626KJI3.%Y&SA%MW*T
M+[F::38_I( "AFQ"&]3XMP30TM_H8>;<MX?!+<N10KQR'=0W+EZ^\/JPZQ98
M0E>0F4%)?"3\T(8X_(N ?)+NDN;&KRN?@-+?\WH\:T%G>;#=TM#<U%754()8
MHI]K?H[CT=G\G5$A9_2IN22C/X1>3Y2UP5MIA:]T5ZI]4*;EW'ST^N=KVI,Z
M\A6]CO$-;MT.&A)(MGN-2CD7CF^G6434?3+%<KHRBJX23]-1H+PJ_IGQUY;I
MOAKH]??UT=6CR3;/#QW7MKJ?K[F'25X)Y; UD4 ,]>O5CCC1IHD C5U1"&*=
M1?@)\'.5_&R3F$>OM:^#7\1UM;>7+W(MK4TG'I=CLMM5HP4KVUO-%3%NS%)9
MN58)YE5VJ./$M)&#VTH3R.\PMF*4>G#[EJ3:,208,H:1Y\VA#@V9H($(V39,
M6M64009(I%*@BFF"2:94P333*0I<^)?Z=Z>9GEG&Y25W9G-G4;,RR,Q\F=B*
M[EBQ))9CY$^Y[)[/T'8_96^*4!C%>Q\/]C$Z>0FUOQ'X9/ OBQ7TRYV\73@
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MN\C==O(Y9W/NS$Y\:<MYCR?G>\N<DY=NK^]W-YRTUS86'F=$[)2O71B8ZU2
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M$Y4K/7I5Y 6ZF3Y$%&Z<W69U@=-RP>E24$IR'!=DY*4A7;5<J9 +5;;34=U
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MW5"[;&I*_C]TC,JZXTV7<KFP0.[+[(UNT-#OY9@%$J,FGK0"2^Q -$*NAKA
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M,DC*'(8Y"-3FE6]SN;\7H7]SM[\'D']"[M+UN#S7L*_HV+$D?FH)"MX^2@D
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M/3\I'0D)$,W$E+3$L];QT9&Q[-(RSIZ_?.U$6S1HV13,JNX753123*8ZA@*
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MI5ZDZN]E94ZFM['.QL*O:K9))K*Q]:KZ4@Y;GF)UZDW74:Q3$J[U<J*ADT3
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MR\;,Q#EW'O$RJIG2.9!<_L4(=,_M.40#++#- P2:*2)F1)%61&0M'(H>-U#
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M4(+*D6ZVGX5-<Z^S#5K(ZRN>S "\K$CL5?\ D,3U%(;7\WT[N!:J*;WK]8Y
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MO&7<]::VDK!"Z\ZTE[UMVQ5^.9%;UJ!/JRPPC:RVIR*C=8[;ZE5K&I.# Z6
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M]"=H!XL5!8$C-BW[3VKMI2%!E=BT6N7&1U;<&6P-=O9Z/3?.*==8UNX:,+-
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M4  "YDFGFLRO/8EDFFE8M)+*Q=W8_JS,23T  !]@     ,Q0PPUXUA@B2&)
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M#%, "4Q1 2B AZ@("'J @(" @(?80^^/WC]1[$?N/[CC[_;/.,8QC&,8QC/
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M$JI\2+5NZBAOM8\SZ_86+],P6D$=VA?UL_H7*-L)W#(\3%2D\#>E,ODR*OB
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M#2UWI5=J[0V]_9#E<YL1EI&_6CG[G4U195$56DS/5X]00>S$16Q0(FJ#Z7J
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ML0<KGW&@;506&)V5:[5V+3;O8RRLLK?)-4,KR2-(L4R2PJOD.HCW2_US6A[
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M<M1L&]6JL<=A6C:*;LR(QB?Q]I8I@<$TP4$#* 0H*& /0#' H>X0#^ ";U$
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M%0(@!!$@(E3!,"B)?;Z?;.SDR>1D)<L.F\SY>0ZZZ;R[['7MT>_;V^V=5 0
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M7HC6'-MFU[LW9\QKBRZSAKK;9V6;KU^F,&EHA*_)V!]76H%7=F(Q6;QJ229
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M**,@VGQ=UO!^(WG35@<][ E-N:[[.9;8L.K8]*'_ #>E3(ZUS<J,@1%>428
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MQV:9BZ]7X1DXDIB<FW[6*B(J.:IBJY?2,B^509LFC=(IE%G#E9-),A1,8X
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MRN">R.M;11ZA6NZU[-BUIM3M(.)ZVW:D:CKKEJKZ4(AD8M)"S2)75K#.1%!
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MLK([L' F'2,.]=U4SE^ ;==K-9V/*1NUW:%NX+Z5M9#?$BUD'IU&UEV98$8
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M^+,#U4:[H?8M_P##9Y(M::IUY,/IV*[ZW;;(374%!.XY_.TO7V^*?:Y2#JL
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M<DCL,2>U'79 3LGF* A -K/A03>TON$=A;9+^]Z![OW0K8@'J;U'T Q@#U]
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M-;7=:=9.F-7,HW?)D- ,0;++*"<@?(  'O'(6=LMFQC&,8QC&,9X,4#%,40
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M6X( "0)@0 #*J666:9K$LLLEAY?7:=I',YG\_4]?UN_4$PD_,$H82"0!PP8
MY8P(E6..*LB010QB***)5CCCB">GZ2QJ @C]/M#&!X%"5(*DC(?07C1X6K-3
MV+1X+FZA1M8VPS;1M]C4"2XC-Q;.5:SC2)3>*29WT3$-I=DSD$8N%<QS CIJ
M@H#?U13]MY8Y5R&U\C\QM;4OX;9BN5/-D/A;A1XXK,GT]V)T221!)8]5_&20
M=_6W=5!H=36FLV(*4,4]NG8U\TB>2L*5LAK-6'H]5X9F56=(!&"40_ZB=9II
MWA7DG0,9;8K46C*93$KU#/J[:WK-%\]FYBOR3<6KV"6L,L]?SJ,.X1$?=&M9
M%!F"G]W(B5< 4##M>1;K=P+5V>QGM5582"L2L==I%\O&1X8ECCDE7S8+(ZLZ
MJ?$,%]LS:W4Z[4W(]C0JQPWH@JQ6F[FGB5&5@D;S&0QQED5G1/%)"J^88*O6
M&:A\:O#^A[>UO>I^?JK4;.SCIB(0?MI&S/T"QE@9+1TTQ/%R\X_BEF\BQ<+M
MG*:S)0#)*J%#T]PCDF]RWD.RIV=?=V4EBG<CCALP/#7"RQ1313QHQ6%7 2:"
M)QXL#V@]^B08D7'-/!<IWXZI%O7V9+M.8SV&:"U+7L57G0-*5,C5[5B,E@P\
M96]N^B-F:,XUY?YIFK/8M%Z6I6MYZXF,%@EX%@K]>Z;&<&=?AK5R]7=J1<,#
MHPN"0L4+**(L!%",RF(02Q;W(=ULZ<%"_LK5JI797CAED[4R(AC268@!K$R1
MDHLL[22*K, WU'N5#J-;7NS;&"G!'=F5T:=4 9$D<221PJ/H@CDD"O)' L:R
M,JEP2J]<5I_FY]K_ *$Z4Z%M5K:6VR;R=46%K;9")48!0=:T"#59Q-.376=N
MA?F=STC-V&0=)$9H+.GY"@V]4O>/$NT5N.:O010&):NPVVUV,WGV-A>V+00P
M2>GT/36GK:M>FB^3=D2R>WJ$9RU%I-_9W,KJ5&HUNFU\"AP:M:K-;N7)'8L4
M::]>N,[LB)U#6K(Q<IWGJA^$N0(&^; V7$\^ZX:7+:45,PE\DPA2K-K#&6-,
M4K$U<0ZZBL*V"?((A-J,8]JM*B(F?*+F$1'C\>W/X9%IQLK8UT+PR10"5@8V
MKR>K6"3#\Y4JR /6C601P,JM$JE5(2:G72[,;B6I#)LE651:= S=6(5KV&*$
M>D9+$"B&>0H9)8O)'9E9@<6J/CBXKHE7V!2JIHBNQ-5VDVAF5\@RRUI=L9]G
M7I3\9AFJI'TZZ,S;Q\EZ.D4HXS0GN*0AP,D0I ES<KY!8?723;*9Y-5=38T)
M"D(D@O)&L2V2XC#2R!$ _-+@DLQ!9B3CCTFLB%\1U55=G0M:NY&'D$4FONJR
M6JBQ>7IPPRHW@5A5"JA50J% %>WE?N''W/='F]>V12<I]RZIN&M;1MMEKFJH
MW.VWW76J'\4T7;R"-@N-7@Z^UDHR$;5%E*?7'6$ =J(P\@=NZ70WCX:\=Y3R
M;8ZV[1%:?5<3VFPV\";"R]2JN]V4<LXD62"K:FE?YTP7K$7I%&2()ZD7J -1
M\D744Z.XB8&ML>1Z.KQQKD*22SQ:FD3"@BC66)5:M3L6H:S%T'JS^4GJ!3U.
MRD>2GA"6U;3[ZGT3K*EUZ:AT!85VX62*@+?" S]S%6'F:HHZ5EF+^/6;*-3)
MD;K-G!4R.8]P[8KMG2VOW?AWSJ/:W:,G'ME<M13L9;-2M+/3G,A]03PV@@B>
M.0,'[)5E)*R*CJRK<UMKIXZ=9H[M6"L(HTA26:.)U2-0BQE'8.&0*%(Z/N/;
ML=$X?+^6[AYH[2CZUL.V[+?KG,DW:ZQU/LVY"NL'M]J*+AA5BLU5%3&]J7L<
MF*80,/N H>HS(?A3S5T:2SKJNM10"S;/:ZRGXJ>^R5>T7  '9[7L CV[]LY;
M>:P,JI.\Q;V45Z]FQY']P,,3K]O?W(!'VS7>Q_)I<W-)NKS1O#_9]KGV-3L,
MA6K):](K52AH2S*-=JLWTJK*SJ4V[C6:Z:3MVQ819Y-^W*9JP0.Y4 "3M=\-
MZBW::;SFW#:E=[5>.S6J;I;=\Q/*H=(A% T"R.I9%>241H?J=O$=G'-N)?"7
MY75[.=UB=HV:KZ,1<*2H8S/')UV!V%0LP/2*S>V5(>)WR%]L;J[4A-<;&OMB
MVU0[VTMSZ[Q<K%,U&- 3C8:3E6,]$*QK!N%58H3+=C!?0**$C7))%%C\)GXM
M5">L_%;X?<+TO#9-CKJ-?4WZ+U(Z4L4KB38>I-'%)!*)';YIS"[S^H!ZB>F7
M\@GEFK\:WFVO;0U[,AL0/'*\H]-5%8H&*$%%!12X$7C(>R6'N67V[;N?*6>A
MXQC&,8QC&,8QC&,8QC&,8QC/61)),#%333(4QC',!"%*!CF'U,8P%  $QA^Y
MC#]Q']1Q^[^'L/X#]PQ_']?WX3111+[4DDTBB83"5-,I"^XP^IC>A0 /<(_<
M1_41_4<8PFBBE[OB233]YA.?XR%)[CF_OCF]H![C#_$P^HC_ !''[OX#H?P'
M[A^X8_C^I^Y_?E4.Q/\ '2\R_P! OI;_ &M:2QC+8L8QC&,8QC&,8QC&,8QC
M&,8QC&,8QC&,8QC&,8REGSIW#<=2Y#@@U-9)&NM;+M.O56\%KTFK'6F=A)B/
ME4XZ A2,U4Y5^21G",2R4?$@J[7:$#Y$S,P<^GL?P1IZ>WRZ;\6K16&K:NQ:
MH_,1"6K!/#)"TEB;S!B3TX//TWEZ4.1T?,KFM<KDMQ:HFH[(SV(8Y/3)$K1O
MY+X1>/U%F?P[5/K*^77MWD#O%/S;W!NC4UU@=E]"])<[Z(BI]NC6*_'LF\-=
MKA*.RNCV;\$L]R9.K55:Y%J(M$W";)B9C*R3]P9DHDLR>F/O'Q3Y%PK3;>E/
MK./<;Y!O9*Y:U8D=YJ-.-?'Y;UZM)TJVK$@+E3))ZD42*'!5T J^.5-Q/4E2
MY<O5*ZOXPIXJEAB?>0B6='F2(-]*CH$DL5;H#+E]:>,;C[74R6U2&NG>V;N"
MYG2EVW?8I?:5@5=J?O+.A"R+KPZ*JR@BL?Z:)0*54"J$*4Q2B'C^R^)/+MA"
M:J;%-51\0@I:2O%JX @[\5[K*LS!5Z4>4S=CL'V.;-#I]?"XD,/KS#W]>T[V
M9>SUV0TQ8+WUV? *._TR=T5#Q$$R0C82+CX>.:IE1;,(MDVCV3=(GV*F@T:)
MHMTDR^H^TB:92AZCZ &:/)++,[232R32.2S22NTCL3^K.Q+$_P 22<L@
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ME_U9"#V/;++4UGO7J^N%AJT%Z:**U*/(QQUDD6:6:5%/YB5DC:R5Z/O%V/J
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M'>+3V<PL1W!7AU4R&Q$NJBI*55%E5%@="!/,9@RN2!W^E-[X@\I^''QZTWP
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MF1O?#?X8%E FK+8@_P##/E-4MV5;74634T[$8[CN6IE!]FRR$"@4/0   _@
M   '^0 #T  S=<^7,\XQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8Q@1 /N
M(^@?S'&,\ (#^@@/^8?7&,\XQE4W.W^-B\BG_$EQO_U?M/&,M9QC&,8QC&,8
MQC&,8QC&,8QC&,8QC&,8QC*INA!/U)WEHKF-L;ZW6/-+)OU)O9J'_P"A2%R*
M*\/H^GO3D,45%D7[IY<'+!05&KEBDB99$XI%$GI^@ZXSP7>\D;J/:<D=N,:)
MO;U(Z9\9MW=C[_U3$J5%< ,KD]$!B#2VN[FTJTA[PTE&PM=?8R]F.E$W7V/G
MZECK_P#DH>CWEK.>8#_+^[+K&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&
M,8QC&,8QC(J]Q= J<K<B=$]"M31OXIJ?5-MMD"G,%,I&.;*SC5DZVT?)%50,
MLW>3BK!LH@59(RQ5!3*H03>X*G=W9:-'U*[1+:L6]?KZC3@F%;.ROUJ$+2@,
MI*(]@.X##Z5/OEIIJ<-[810V3**J1V;5MH1W*M6E5FN6&3Z7^KTH'\?H;W(]
MLI'Y1\KNXGG,?3W5.W>L.0>H&VCM#L[PZT9H37%UUWL.F; E B3Q;*U/+///
MQFZD#Z3"NO)ROQ*T:I)E.+24]Z!D%+S?+^%ZBS/1KOL[4V_U^DU5U'$=!YK=
MM]?X6X2#8@:Q++!<JK+Z+S5*\S1>?JJR5>@C;<[K7TIYEH0OJMAM+U21?*X(
M*=?YUGKR=>DY@@KV:\X7S$=J>NLH0>S2BXN[?Z])TG5^<^Z4]'J.]X<LDZYU
M3;]2Q,_4X^DP3208I6S6-Y3LLQ*(R#FKQLJS?DMZ:T<W<@@[!= 0$@I3EH0J
MW*]7ZKS;3A=K4QWKBKZ=+:T]K)=IK9K0'R>K)7OT'0Q-+('@F1AT4)-:;D[Q
M<;VJ0>EJ^4KLHX:LA#6]3<HP5[T$-F4,JV4N4;$C,T<8]">OXDE91URQ-R:A
MW%YFN>'VI-JZWVBSA>$^D6DRZUU>:Q=D(ATOMC2AV[>44K4I)DCUG!"'.@F[
M%$ZQ2*"F!@(?VU>66758QC&,8QC&,8QC&,8QC&,8QC&,8QD%O(#T!9M*:6;U
MG5@"]Z WU8X_2VB8A $UG@76W%5;N+09L8JGI&4J&*^L#YXLBHR;.&[!-YZ)
M.?0=UX'HJVZW+6-F0F@T5:3=;V9NPGR50ADJA_8&6[,8X(T!$C*9"GNO8KMG
M:>M7"P=&W:D6K34CON>0'ZR/^9"@>:0_8+&>_N.]S<M<_P!;YAT70M-5L0<E
MK,6"L_-'+_ORSV^3,+^TV>15,)E%WLS,K.G)CJG.=- 4&P&^-!,I:?DV^L\F
MW=_<V1XFS*17A![2M3C'A5JQ@ !4AA"IT  6#/\ =B3GI58Z5:*M'[B-?J8_
MVI)#[R2.?N7D<EF)_4_N R0>462L8QC&,8QFK=V;7K>C=47S;-L6!*#HU<?S
MCA/U_NKYR@G[(V*:E !%1[+R2C2-9)% 3*.G210#[Y VFP@U6OM[&P>H:D#S
M,/U<J.DC7][R.5C0?JS 9MW N';7X@\RXYPS2QE]CR':5M?$W7T5XI'\K5V8
MGV6O1JK-;L.2 D,+DGVR.?".J[33]5R>U-HI*?MMZ,GU]O[/,X]XKQ2DZ3WU
M&F) J'RMF-*JAHV%08&,8&;DCU(IA#*?BE"Q6U[W]@/^-=U,=EL">_)#*/ZK
M4]_=4IU?2@5/;Q8.  ,]._:&Y?I]WS&KP_B#K_0#X7:V/@_$5C\?2N)KFZW>
M_;P^B6QR#="WL)+*@&Q"U=R ?;)O9L^>!XQC&,8QC&,8QC&,8QC&,8QC&,8Q
MC&,8QC&,8QC*T/+C4>@MC<0;$UCS/2K;>MF;)LFNJ<>+I-I1I$^TJ$A=X1Q=
M)%O;U9",&MH)UYF]:.IE%V1:.1>&=% Q4C ,"S"\^QX[$T)FH#?5+&V3YAJJ
MMKZ4-FZ8I+"]M#'9LUZU9W56;QF(4%B,L*<JUZ>_L+9%6\G']I%J7^52X_XE
M=B6A T=60B.:2!+4UI5D*J/0+!T=4840GW$YYIX/[7T9JND;<X_ZNJF]><-7
M;KB++TE<>C7%=K&\[A 5B,O.JMH7"7EOH&TS3'\TS%Q%-XY:)E_5X '729+$
MMP(.1O\ #[5PV9'TFU^($O&-U#%%\E?K6((A?VVN-B,^L]:]#6JK6F$@)J36
M/3$4K.<IK%F3C<7+=G/6BEVFKX#)RC3J\PL5[E<FS2H76@7I8YZ5]K+R1,I_
M.@A$@>$!!/SCW8[/@_??D@Y\--[TV?SCS#K+0F]*967\A>-_;5AG>Q*U*JWR
M#I:+L\W=;*WFY=FC-M8))=X9L[4=BR31;G.0N:M.;V@NRS1QB73<PV.BJ.D2
M1O\ A3:^EL*M24H%]4:^26:*O))Y3&&0)([E0<S7*:T;NEGBEE;\?XS^+7T=
MBR-M*NULT)[T8)ZCDOQ&)[2(%B]6)7C1/)AF:>-KI*F]6^0WR$;=H=6VG3Z^
M]U7R;!IPVXM;V?55S(ZAF>S4W+E2IVYDPF$XU<5R_0R!FX-GH$5% YOC-Z0<
M[Y>[C&,8QC&,8QC&,8QC&,8QC&,8QC&,8S"]CWVN:MH%SV3;WZ475Z)6)JV3
M[]81]C>+@H]>1>&   QE%3(MS)H))E.HLL=-)(AE#E*,O7T;&SO4]=4C,MJ]
M9AJUXQ]WEGD6-!_  L"Q^RJ"3[#,<LJ0Q232,%CB1Y'8_9412S,?X  DY!'Q
MH4*RCJ>X]+[)8J,]K]?WE_NFQMG!?:O"4]RF,;JRJ$+ZB)&D-34FKM%,2I*$
M4EUB+)E5(;-W^(U^M^+4^-ZYP^JXA1CTM9E(*S7%/J;2UV![O-=+(3V05B4J
M>B,K=1&YKR7)E*V-C*;<@/W2-@$K1?P$==8QU_SBQ/U$Y9%GGN6V,8QC&,8Q
MC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&1C[(TA<>C>;-JZ<U]>V.MKI
M<H!-M6[=+U:#NT$PEH^19RS1K8JI8F$E$SE=E56(1<VS79JJ&C7CA1J!7*:0
MY#N1VF^4FIM#\Q1V%'8QQV$+06&HV8['RTQ7\R)9O#Q6Q#^=6E].>,,R>)FT
M9X()9A9CD>"S2O49#"Y2:$7JDU3YF'ZE1Y*YF$RPR]PS^!AF!C=LISC?$_TO
MTW-[]V'V[:=!:^NFQ..W7&]+@N8(BP#70B/S+%W%OM.[/IYE7W#V5)/0L<5A
M4&#,(Z*C_J4&S\H@B0,UR".77[]J4LU;;\@W7']X1(3-1U4W&[#6Z4,7DQFN
MRV)R$M7YO";Y91$H<MVN/5W;%&]QX6(X+.NXW4W=-)57TKNS7D% :RZ\J($@
MJ1056EDJU(S)"+DAL?E@LC[TX\X(ZH;]$0707=-GT=97FF^8S\BZEJ.H&]FD
M8:W4A^[:'M.P]C_G%DT*WF[9'1S&/7J+%"0B6I#O#&>J%,0A[E;T1;E.S: Q
M;;F5C52;*NC>=#65=5+;N)6HR,%FL-8OWII7FE2+TX8XXPKEF*TIIRK'Q[61
MV&DU/&!?DJ32@"[L[-ZO%1CENHH:*!:=*$JJP2/Z\TQD?P$*B3B:WS?SWSEY
ME-!16@M(:LTNQM'#'1TC8FNKZ/6J.UGGK3:VEDFSJ9;UV+8%DW+9-50C5=V9
M0[<BJI$P %3>M9ECEY6,8QC&,8QC&,8QC&,8QC&,8QC/6LLDW15<+JIH(()G
M6666.5-)%%,HG5554.($333(4QSG.(%*4!,80 !$.0"Q"@$EB  !V22>@ ![
MDDD  >Y/L,94]RXB;LSJ.[]N3K99;4>HSV?1W)4<[$JS&2!K(?1;0W2U;JI@
M*#VP2+ :W O$S'$\(1XF?XU4"B;U'DI_H=QBEPJ%E&VVPK;OEDB?3)$7C\]7
MI693[I7B<69T]NIRA]PWM1TO^,;LFS;WKU_5J:X$@JP#!;5L#KV:1T]&-@3^
M4A^WF>[9<\MR\QC&,8QC&,8RNG?<HAT7T]KGDMF@>2H6ND(G>_0RR)@.R (F
M03>:FU])![5$C'L%@9IV*28*BDHK#L&JI ,FH< TK<L-WO\ 7\>0>=.AZ6ZW
M?0[5A$Y.LHR'W'YUA18DC8=M#$I'W)'TY\.:DGPQ^$O*?C//**G(^3RWOAS\
M,4<,M@FY5:#FG)JA[5E&LUD[:JI:3S5+UF9#XLJG+%0            ^P  !
MZ  !^@  !]@#[9NN?,?\_P!_[R?WD_J<\XQC&,8QC&,8QC&,8QC&,8QC&,8Q
MC&,8QC&,8QC&,COU!H%STAJQUKV,W!MO1$^C,PUEK6SM+6E:KW&NST"Z!Y'J
MG 05B[#"*JA\<O6+ S?0<RU$6[YJ<H%$N"2*0ST[,-AX)J<YF0!8YH)U>*2"
M6"W6F5X;$+QRMTKKY1RB.:)DEC5AE1X_2LP30+/%:@,#@O)#-$?-)$FK6(62
M:">-XUZ=&Z9"\;JR.PR$D!XC-,.M&]&:LW)L[:V]MA=3S%<L>W>A+F^@XK9S
MVPT-1FXUK(UI.M14=7JNWUX^8-']=BXZ,!B#LBQWB;@CA0F9IPHIZNKK =0V
MHW)Y)3M56,EH<A>6*67:SRS^IZTDBPI5,+#T5I>55%5'8G' \BWK=Z\4V;7-
M/_1V6O:CC%==!Z=B/\+C2-59$[M3SF?R,QMNMGR]1$ZWWQIP[$<EN]I7.<W!
MLKH?=.YW]96V+N;;'Y?2M,Q$4B*5@Z56VL=6(N)A(N&KL8LNFDBS:%4>.W"[
MUVH=90 ++-D"E'1A@B@B^>N;6TT?EYW=I?$*V;DQ8D+U%7@@KP1]0UH(ECC
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M$QQ$K&>_>9XP._?)SZFUC4M,:UI&JJ)')Q=2H5;BZU!LTP !*SC6Q$?G7,
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MKZ4T]E_!"K1( "S/(ZL$15'N23[G[  $D@ G*OO JQC;_KZ^;KL,]%36PJQ
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MN%8(1D#87?DX5]-/6M6'$%.N#T9IV^W9_P!6*,=R3/\ ZL:L1VQ4&.E>\?\
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MR7F7 %*=[.2SHZC^6>JA[W#U94WH4@$(3Y&W>WO[[:W=MLYO7NVYG>5AV(T
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M*"/U&?5G;,6?DYRIE,<Y@(0@"8QC" %*4 ]1,81^P  ?<1'[ 'W'[8^WWSD
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MOB'P7G\]J-=):G>GR;C/*=KN;$7'X:5^<PQV.(5J\,&MD@E:U/JXX8[1L6)
MP[.]#W=IW:+?ZK76SZ)=4?4"F_+=GB)55,XE*?V+-VKM1PBH!3D$R:J1#E]P
M>XH".:G3V>NV"^=&]4MJ#T37L12D']Q",2#_  (!SQOD? N;\0E]'E'$N1:%
M^NQ^*ZB]31E!(\DEFA6*1>U/3([ ]'HG-H 8!#U 0$/3U]<G?S[_ ,_S_?FI
M9UX]P]4;4B_*9KBQ-.0=ORTI0].[;U=!55K8:&E,; A7MZ:BVV/7A6F 9MJ\
MLU:%=HQTDY;RRS=VBJ1$"H+Y[#KOZ%1\.GX?:^(W&*F\WMW7<BCIS+=]:M'5
MI^$]26,1>33QR-X^2=KVCE?( ' XCSJU0L\^I\(Y!:X?IIVX_>Y!%%6_#X[]
MUTL5E\S/ZAC>&N[&0)X1DHDK1NP1NPV01,4IA 2B(>H@/IZAZ_P'T$0]0_CZ
M"(?R$0SQ[^?;[?X=XS]8QFH=S;YU+S[5TK?MZZQ=-A'3U.-CCO2NG3^7DU0$
MR<=#1,>@[E)9Z8@"H+=@T74(F4RJ@$3 3!7;/:Z_3U_FME:CJPEQ&K/Y,TDC
M?9(XT5I)'/\ S45CU[]=9NG!OAWS/XD[=])PK0V][?AKO<M+ 8H:U&I&>GM7
M[MJ2"G2K@D*);,\:LQ"(68@9\.D>B=.=%P+^QZ?N\;;V,0\".FFZ"+V.EX*0
M,!S$9S<)+-F4M%KJ%34,B#MFD5<J:AD#*%(<2]=7N-;N87GUMI+*1OZ<H =)
M(G]_IEBD5)8R0"5\T'D 2O?1R1S[X9<X^&.QK:OF^@M:2Q>K_-Z^5WKVJ.RJ
M@J&L:_84I;%*Y&A=1(8)W,991(%++WNS+/-#QC&,8S'+9;JQ1:_*6JXST56:
MY"LUWTI-33Q%A',6K=,RJJSARN8B92E(4?0H")SF]")E,<0*.&Q8@J0R6+,T
M<$$2EY)976.-%4=DLS$   ?X_I[Y9Z?3;;D.SIZ;1ZZYMMKL)XZ]+7T()+-J
MS-(P1(XHHE9B2Q )Z"J/=B "<KX<]4;RZ975@.*: 6.I2JBS.0ZBV_%O8FB-
MDP/\*KK6M*<D0G-@/4BF%=D\>I1\"*A"@X*X1,;-0.^VF\)BXQ3\*I+*V_V<
M;QTP/=2]"J?&:\P[)5G$<'8 8L#GTI'\'_A]\*(X]E\>^2M9WZHD];X0<(MU
M[O(I6(+I#ROD$32:[C,#D!)X('L[(*28S$XRN[?G.G66H]ISEFT'$]/[<W#/
MA7T-J[NFV>J9W6FTHURR:N%OP.DOW;!6J/:)[SQ-:9-T19I)MUHY18&1_J5M
M0V.MY1I-C/;X\-]>VMD0)M-K.FKGU^QB**Q,5&5E%=Z?9CKHJ (5:/R"$EOH
MCAG-O@/\4>%:S1?%MOA#Q/@>GDVECA/ -?:YOJN7\+NQSS0CY[DE".8[BMR4
M*MS<322B64R16EB-A!'':9X^=:.=>:=L*]@HNT*=?K?L*?LM^D=PJUD]UN]@
M=-XX@VDS:HNWL)$0)VX$C(*":K"6+;QZJ8BL*@N5][XE4>MKYY+%;807KEV>
MU?EVAK?.7+,BQ^5EEJ.\441 "0P @1(G0'1[;Y1_:-Y)4WW,M/3TN]X=M^*<
M=XIJM)Q6CP./;IQWCFIK26O'2I+O(8-A=V22=VMEL9D\KLUE9#X>/I1SOS:<
M^?L8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QF#;,UI1=QT"VZMV;68RXT"]P;
MZN6RL3* KQLS#2*0HNFC@A3$4((@)5$5T5$W#9PFDX;JI+I)J%C6ZE>] U>R
MGJ1,T;@!F1DDAD66&6-T(>.6&5$EBD0ADD164@C)%6U8I3I9K2-%-&'"NO1[
M61&BD1@05:.6)WCD1@5>-V1@5)&1/Y!\=7-/$LG<;#IR+O,I;;M'Q%>D[KM/
M8ELVE;X^CUP3FK.NJ_/7"1D7L'0JX=596)K; Z35%53Y%A7.D@*5E\Y.:C5&
M<,LUKY^]895-O9[ 1>@M[96>O4MVD@[AC=R%C1G\$5I)&> :T'S"6$C$0@KM
M4IUHV=:="J\OKO7HU?(Q5HY)?%G\%\G\(PS%44#0VQ/\=+S+_0+Z6_VM:2R-
MF?+8L8QC&,8QC&8M=Z= ;"I]GHMJ8)RE;MT')5Z<CE1,4CN,E6JK-VB)TS$4
M(8R*IO8HF<JB9P*<ABF* A@LUH;E>>K802P6(GAFC/V>.12KK^OW!/1_0^^6
MVAW>SXUNM5R'2V6I[;2["KL]=:0!F@N4IDG@D\6!5@LB+Y(P*NO:L""1G7V@
MO#+TX-VAI&\=>U2TT<\=K_7]WKQ-?RS*5N.E:#;D+&QUZ[ETI<CA+Y&R0Q_X
MH5<'BA2-BNW#A!'XS>A;&Y\,[O :W !QCE7X7K[-C94/7Y9/(XV4U8PJ;DPC
M$EO7QMX=4'\8O",*@4@$;+JOBM\0-/\ %79_&'7KP:GS#:BSZLU?B %&A8O-
M/\[MM/0EV<L%#=SI:L_UUOF(8Y9FE2H#T!V*FC1LP;-V3-%-LU:HI-VS=$@$
M21003*DBDF0H 4I$TR%(4H!Z 4H!FAJ H"@ !0  /8  =  ?H !T!^@S2)99
M)Y9)YG:6:9WEED<EGDD=B[N['W9F9BQ)]R23GT9SF/,5N-&I>PX1>M7VI5NZ
M5UT=-5Q!VJ$C)^)752,!TE58^5;.VIU$C@!DU!2]Y#?<H@.1[-6K=B:"Y6@M
M0,06ALPQSQ,1]B8Y59"1^A(['Z9;Z/D&^XSL(]KQS=;70[.$,L6PTVPM:V[&
MKCIT6S3EAF"./9U#^+#V(.>ZITZI4.$:UJD5B J%=8^_Z*"K,/'P<0T^0PG4
M^GCHQNV:)"H<1.<2) )S")C"(CZYVKUJ]2)(*L$-:!.PD->*.&).SV?&.)51
M>S[GQ4>^=-QN]SR'83[;?[;9;O:6?'YC8[:]9V-Z;P7Q02VK<LTSA% 50SD*
M/8=#,DS-E7C&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8Q
MC&,8QC&,8QC&,8QC&,JFYV_QL7D4_P")+C?_ *OVGC&6LXQC&,8QC&,@EY&J
M?1K[S%9*I=-G:STTZE9RN%IFS=HMSKQ%1MS213?M9*&4;2D._:6<(QI*)0[U
MB_35:JJ'652<M2+MU8UD\- B_IW6-KCQEZGACV'X58-CTI35>KL!]=>>.4"0
M,A#.BO'WXNP/J'PCM_%NCROYGX,5=E?Y;'KK?KT*.H;?UKVD=HHME4W.F(,.
MQU$Z21Q6H+ ]/R>)U*RK&PIP\*NK:+2M@79S9N@]&;0GKJXV94(S7CV.-+[5
M?_@5M,Z4N$/+S,LY!*GW&/CI"UO8MK$G4E"OV+]V^6!C][+;_$#X8?$2W%M=
M-I+6NY7'6J<=$FSW\>U>?0<?@DJU5BIE %:PJQ69;2>+SE&DF,KR%SZA\4/A
MG^T1\)^.0\>W+[!OAK5NI\0K%[CG$K'%='1YAS^1=O?I["U7L2B2QQ^_LI^/
MZZO+(L6KBC%&E'!"B1B\&^\%\@;'<GD;#H2A-)DZXNOS!48Y2A6 KO\ >$'7
MXU2%X"046 YA4]5UU2F5 BAR&.0@AJ=SB/&KS%Y]-264MYF:M&:<Y?\ YQFI
MM!*3W[^[GL]$]D9I''/VBOC;Q:%:NK^)'))J"Q"#\-W=I.2:PP?3^3\AR"+9
MUE0JH3\N-&"=HK*K,#J9_P .W^DMS*\[]?\ 0NMA9BL[CZM=+ PW)2SKD^19
MLQ497]H^EV\<*HE16(E-&.#;T(4W[A!"O?BMRJ.]+R;=4/%BZ5[4T>UJ @?2
MGIW4>54['U#UCV/X^^;C7_: XYOY?#XF_!#X8\J6<1PV=QH=99X)OEC/BDMA
M+'&9ZU&6R$!=#)KPIE[9@>SW28Q:\\#HG8DIO-^F'7J$O<E;[*33MVGOYKNQ
MM-R00/Y1(D<DV@D9\E&FK32 ($*>/$@*$.@"P%T:NG%SQJ_+O'A_I@INFY)+
M(Z\@&Z6:5:II $3!"ZPF%*W]7,?^D[ 8Y]9;BU\?Q\<^(4?AE4N']GF6#C*<
M:IZVI6?X33?#:;746WAY'(Z/0>PL$E\;6?9R_BBVP/1*L4#7&:XKGE"G-:4=
M>8VGSC49ES1ZZ+\EBUK=I^X-Y16+;F=+6-4MJ8Q9K$0PA^*E09?0&D0<?&V(
MF $'<Z4//):-4S7M#7F-2OZGJT;DUD2&)?,SD6DB,X)^OQ3T_4\NE\<^8^4[
M/]D?7\KY!'0X?\4MU0BY!M?E7U?+-!K=))42Y*(4U:-I[-P:ME']2,ECYD5#
M'YS,W1S*4=->1UZ*Q97LK4<2F9O[$C5[G./<J_.81 RBAIFR*@7XR#ZI&3_4
MX![DO3US,NMYJQ;U.3:Z,=?3Z&D1CV2/OZLYZ '?7W[/78ZRJDYS^RY!X&G\
M"^:W&$GE)^)_%*S$GI@=A4%'5*3Y'V</T0O?BY.1&Z,TSTEJK:NE-][BMECZ
MXH](C+G6Y M.U3$1,WJ.3L[>.^FO4=3*N9XYL;=U]&I%2$@1)20AFAB+) (B
M3UJ;E/<:C<:C>;>Q/R6E22Y"XJ:R&.?5R640)L(JE9F-COP,4C]>I"I\D[/0
M/I'%^3_#?XC_  U^(_PI^'.MU7P.Y1R6YQW;53O^:["UK>>4-)8L-9XM=Y#M
M4ACU#J)DN5JY9*VPG4Q2GP,@'%:*U_U-L[>VP^C.;FL9S]4W](K=$6<;UUM.
M$+N]\PD7<HM.A44)"#F(=.!(1K%L;,Z(#UTV<+-F_P B!W":/2"+>;??W>0<
M?1-+4>E6HN=QKY4.XDC=I#9:HCPRQ>@I6&.=_P QT)'V+JN;:WOA;\.?A'Q7
MX0_&&[:^*'(*W)=UR>&O\.>6Z^5/AM3NU:]2+4)OIJFPHWCL9/7OVM/7/RM:
MP%D8*ZQO)-HMV\D]4<+EF=+<U;4CT"@*2U*V3:J#+O/3U 3BVMD9-L4CF]"@
M"0+>T!]?542B)BW@L\XKL?5U>AV$8'L:=ZS2D8]?\VVDR D^W7F /OW^F>4M
MHOV5]O$AH\\^*W#[4A^M-_Q73<EI0=]!5]72W-=9=5]RS^F21]E['1UYMKLG
M>-2U'LA[MKB#>E.9H4RT$<S^O;[3+2SC$30[Y(94UDK<DVFJR@T Q7)IU",6
M=1!"_B":)CMP*,/8<EVU;77GV7%-M65:U@-+2NU;*HOI.#)Z\$B35PO8/K+$
MQC';C^SFS<-^!OP^W?->*U^&?M _#O>3R[[3M#K>3<;WVGGMR+>KO\D-3MJD
M]#;/-T8?P^2W'#>8_+&0++Y"G.R:CZ*UIH^$Z*==6;EM*L<A7;K-ZS<[?V)'
MP#FNSKQH+&"87%O9S2+I\Q)(QY7#D6122PHN4&J21UD@S1+7&-[K-!!R9^4[
M.TT:UK\^K>_:CK&O9>/TZ\=Q)_4DDC]:/R/I@2^+*@+$=_5/&_C7\*N<_&/9
M_!*#X&\(TD5JUN^,:KFT7#.+VMK'N-+7L_-[*]QR73)6JT[1I6S#$+4CT \$
MEAG59"EX6NN,)'8LI [:[&V(]Z N!$V4S6M=?"Y@=$Z^.L@"Z"$1KTJYD+1)
M-2KG05G[H,H]=%#^Z-DQ#UST6KQEK[0WN3VSN; *304?$Q:>F>@R"*CWXV)$
M)_Y1;]1VZ7M5*CKXXY-\=:O&*>QX9\#N,5_AKHF:>CM>3F2+9?$7DRQR>G))
M?Y.T8EU%24QB1-;H13@A8GJ5_L+#6S9NS;HM6B"+9LV230;MVZ1$4$$4B@1)
M%%%(I4TDDR !2)D*4A"@!2@   9N( 4!5 "@      #H  >P 'L /8#/F>66
M2:22::1Y997:2665VDDDD<EG>1V)9W9B69F)9B2223GNSG.F,8QC&,8QC&,8
MQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8RBSLC4G2&R_*]S6//^['_/SQGQ=OE.
M1V0&HH+:44BG^U#5IU:RNA9%6L4T>SHF:O&YS/"/$T8-P#9%0B[@Q&/_ '_?
M_/\ P]Q_W9O7^U*\G'_C5$?_ *F^H/\ V[G'0_C_ )G_ +<9J37W-_F3F[EM
M^*V'Y#JU3*95[;&1FG;1$<RZCL$ELJH.*Y'/Y6Q6.&-(-@J<C'V-P_@T(M-=
MV5RU8D?BH K@4.>O[_Y_=[_]F,^&J\Z^:.1V=N>OVOR!52OZNJK>HGTK?6'-
MNII2=V>YDX)=Y;T;-63/4DZ>G7)XB$3'*).WHRK54SXQ4Q(!<8S5=,TOY]Y6
M,YZ<73L'6U8D[O/WQET4QC-*ZJF4=,5^'"3&@S%-<&%$;^\MHMHTLNP6"/"$
M&05%-14&_H9C,"?ZP_LC9&NL'L?TGJ!Y8UZK=I&0A5M7:L;LF5LB=BD@Z-7D
M9'V',O'VG6_RW66E?C(,)-E3KJ:3E,XN2O;^/M_$_;_;V?\ /'^'Z_O_ $_G
M^/V_RS%.:)'S@;.ZTV]RUO?K>$TTIK74=;VM#WNM\TZZNL#:&]KO5AK43"!)
M.3L(=.2) 0S.>D6;1VL\8.Y [)5,4$"KK.AU^O?]Y'L/^W_J]\X_7^?Y_P ^
MLLE_M2O)O_'RJ)>G\?3CC4(#Z?Y!_'<XZ_O_ ,S_ -N<YJ?4?-WF0LT;;%]N
M^1"MZXDXR_VF%J3*O\PZDM:%DU]'/2I52XOUU))H,3,6!B(NI&!*58D4L H%
M<+!^^+K^_P#S.,X0_/7FL-1=S2Y.^JB6]U23N[72U2'G#4WX3M&,AH\%:+)6
M><^L^2FKV^1 6TLT2;O0@43?,0RX@ #SC.">Z%\Y",C#HL^Y:2ZC76AYVY3+
MQ3GS4R+B,WVR"/\ P'4C9M]4)7=2ES+R .KN)R+,@9) #(WU'N(_G^?M_F,X
M/?Z#O^?]_P#L_B,U*^U3_9$Z11^AZ?U([/\ E_3KT 5U3JM /S#:82?>;EAS
M&]HB5EK.;80436GX%$;:VF7#U1-J+(2&=?SV<YST\7,_,ST1.;[IF[^VXK15
MXT/9J%4Y2/AN6];6R!GI6TT1E;)T\)8)%S&-I:.K\FY5@T9&-(J@Z,W.=44E
MO<F''0_C_F?Y_P"W&3E?\G>4%%B\68^4QN\>I-7*K-H?CW4+=-T[31.=LW47
M_&S"BFLL!$E% *82$,)@ 1 ,==?O_P R?]YQFNM.\U>8>T:VKD_N3R+U_6FR
MWZ#Y2RT6M\O:EML)".$I!XBQ08V-23:'D2.HY)F\54,U3^%=RJW # B!AYP/
MY_[^O;_+-:ET3YT_[7Z7NQNW*&'0K9],I0VFPT#J<:?),6US7BH1TZO@NOF:
M+25*(WM#M &!P9R:RD.4ZA4P6,Q_/\_S_L]\_.S=%^=6OFVL&L.VZ'?"5O5-
M=LFIS3F@M3UHVP]L/)220LFO9_V.785BOP\0WC7[&T)_4*2#J06:G;IE:B<[
MKW_7_,C_ +O]F/Y_W?\ ?_EFM+QJC^R)(B1?(4;J+4MK8(V)XP8/);5&JX0[
MNNI:C869G.+))E7^%TYV\K(:X4CR@((U]JVM0J>]P9N5_)_SQG/\4PGEOZ=I
MVUYO8O?*6G['K+=]_P!,FKY.2=:RC:5)1E(M$UI9OY1]'G=LI-TZ>MVJS1)5
M@NBU*X;+G!3T*Z_V_P ?YZQ^O_7_ )]C_#KWR1^SN8O+E7]=W><UAY)X6^[&
MB:Q,R%'I4YRIJ*L0UJM+1DJM#0,I822CL\,QDWI$FCF1*W6,T35,L!#>WTSC
MH?Q_S/\ VXSXVW,WE]4U.C9'7D?@4=MFU\$TMKI/EK49Z^GL0:\+W\FEM8R@
M*'A0L?I##/?2 H++U?@@!O0@.O[_ /,XS5S[1'G.2U1I"R,>WJ0ZVS;[#JYE
MO'7:N@M2(P&J*[8S)!M*9K%I!R)[F\H '4&$8':LRV/X?0YT1. AS_=C/FLF
MC/.PQ>W]&M=M4&:8PNV-;5O7SI]H/4\>M<-2SWX+^TS8<N@1<X0=AHWUDS^"
M58AUD['^%-_>Z;"]]"\==?O_ ,R?]^/Y_G^?;-9VK6']D.0QWJL)U)JJ;C6L
MI=2?5.-0:M9.#U^$OT5%5&5!J3Y3&>V76R\S<WT<4?\ L9/1K:N%.J5Z+@O.
M<=_P_?\ N_3_ !_7_P!_69IPO6_*_P!<<MZPZ!N?D('3UEOR%A5D]=.>/M:.
M5:Z>%M,U7D$S+S,A'R*GUK>*2D0,X:(_NNR@F!DP(<W'7]_^9_[<YS<.[^;O
M,?4=6VZQZ.\B-;VOM6,:,U:?KZT<P:DI4#9':LHQ;OFTC9TI-ZI%)M8I9]()
M+ U5^5PU1;"  N)@=#[>_O\ Q/\ O[]O^O&?7L/FCS!PFJ;-9-=>1FOW/;+"
MHK2=8UW-<NZEK]?G+@1D15&N/K6G(N%(^-4?"HU&6*R4,5(I5OA_>$,Y_G[^
M_P#G_P!>,XBQ\X^9EC(Z51K?D*K$W&6R>(SW<\>\SZECG&KH U2D9,TO5FY7
MZA+D\+;V\=7/H5C,BA&OE9;WB=M\1V/Y_G_W9@;?1OG76=PR+CM:A-&CG<>P
MJK-.D]#ZG<'C],04;)+ZZV@U1^8GU-FNLHA&LIJG&,5*OMGRSE-XX%KZ'?K_
M #_M _[\?X?S^[],B[MV$_LC#76H[%L%YT?K10*YK5&X6UK ZEU<^F(60;0U
M_DKC&5MN1F[4G'< $'220)@9G--.+1(IF;%&'*5=U_?]OY_7_;]\X'O^G7[O
M[OW_ ,/[LO[XBNVPME<=\O[!VRZ?/=GW;0VK;3L!W)1;>$D'-PG*=$2-@7>1
M#1HP;1CE63<.3K,4&31)J<12(W1*4" SG)1XQC&,8QC&,8QC&,8QC&,ZZUFZ
M4Z!T/Y7NZ"Z7XEVKUB2<TYR@C,J:ZO.MZ@6IIQ\5L%1BO)?G>2CU'I)LSQXD
MT*S,J9L:)<BX(0JZ!C,9(TWD>[S(4QS^%_J I"%,8QAW=SYZ%*4!$1'_ +9O
ML   B(_PQC-;ZI\O76&[Z#%;0U;X@^FK71)M281BY]ON/1;%%TK7Y>0@9@@-
M9.<9O4_HI:+?LSBLV3!0S<5$A.B=-0[&:P?^>'<<7H@W3,AXK.DFVCBSI*T-
M\':VG%&@3BEX#6Y& QB<B::]YKJ/X&"OX=\/R_[Z^3Z$0<BSCO\ G]/\_MGM
MNWG;W/KJ:V-7;GXJ^DH68U) ZZL^PV:FV--.35N"VS+JP.O7ZRK.3<(O"6.6
M069H)1ZCIPT.F9202:HB50W/7\1_/\_S[YSFGMK?V0,,:>SU#;_BGW<_3I5B
MO,19(2TW73%C815CU0WKCF[IF;K_ (BQ7=UAM=*ZH9RT!;YBS!"QRK@Q'14L
M,U>"RGIV(89X^PWIS1I*G8[Z;P=67L=GH]=COV_7+'5[G;:2R;NEVNQU%PQ/
M";>KNVM?9]&0CU(C/4EAE]-RH\X_/Q8J/)3T,W#SWY+]H[<J4-NWG7P?[6E*
MU(N[!$PEYJERYHKCI1S!RKZMV!JV7,ZBY9 &TI'OXUR D237% _L%5 Q3&P0
MZ[7UY!+7HTX) "!)#5AB< ^Q =(U8 CV([]Q]\L]CS+E^XJ/0VW*^2;2C*R/
M)2V.\VEVI(\;!XW>M9M2PNR. R,R$JP#*0??-A;G\PO4_/6M[#MW<?B'Z:I>
MNZI^&_C]D=;AT;(H1P2\JRA([WM(B:?2"WU,I(LVA?IVBOL,N4ZGM3*<Y9F:
MWGV[-\NO66G:&ZV;L?Q!],UNCL#0R;^<6W'HIZBU5L,NT@X5,[>/G'3L_P!?
M(R$>@0R2!R)_5IF6%,A%#$8R,-Y[)Z'==S:8V/8/$UM]AM=QJ#8D;4M/R-VT
M2^NEW;0TG R$ELV/MI'R\%'IT5LX;0X-Y24;3IPE@"'34;E<E'4K.G>7F6MV
MPI1O6@TUV"6V4C)CM-8A>NI)'EZGIJ_IR#W12RA@"5;Z$T7Q&JZ_]F_FO #R
M>_6WVR^(G&[^NT,=S81I8XXFJV";@I''(*BTFNM7:W78>-B81,T;E2\>2N?[
M(0V"SJT'=''B^Z.2K-DHFU]FPLI^U'4ADWM&T>X*UVG/$0(\%RFE4W!R)N&B
MR*;]^)O6*:O@ 1#;?\?\/?\ [.O]N?/>8=;/[)0D:++-(*V>-GH>$E7TVRKC
M5HYV;JPXK3<BTJ3]E'@J@NJ@15PTO=25(<ZH(@,RDF90JB#LJ#'\_P _[<G:
M'D>[T, &+X7^H1*8 $HAN[GST$!#U ?^$O\ $/OC&:OG/,+U/6]LT+1<WXB.
MF&&UMGUNY6ZB5$^XM&*.9^NZ^_"?SA))/DIL\6U)##.1('0?/&SET+P@,D7'
MQK?&_P"_^?Y.,_5A\P?5-4VAKS3%A\0_3,;LO:T;;)C7]74W%HU5>Q1U&;,W
MEJ<H/$)M2.:A$-G[155-^[:JKE6 &I%S$4 K..QWU^N:5VAYL=RRVN.FHF=\
M6G1\)#Z95)JO=DRXV)HJ>;Z[L=_C&$?"M7\')/74?9_G+:(A;Z1!M*Q"X.BM
MI$Y$OJ2IX+4 LUK%8L$%B"6$LT:3!?51D\C%(K1RA?+R,<@*. 58$'HV^@VS
M:'>Z7=I"UAM/M=?M%KI;M4'G-"W%:$*WJ3QW*32^EX+;JR)8KEA+"PD1<IC<
M[_W!5I)76=AT;W4^8:6VQ4Z;)ZSFI;G68J4'L%6DOMS5VKJ5UW:9&MO6AJ)"
MR-C:H%9OZ_'((F9 1%^H1DIYNGPXLB&G4DYCNK%"E8CL0:^>"*:DKQ.'C3Y6
M2Q) 8D8'PB:)XH_(^$8^V?9LW[9>B.TW?(JG[.WP_P!;RGD&MNZS9<LU^^VM
M'DL\-ZN:UB5]W4UE?:?-3(5,]M+D5NP5 FL,0K+<#JG^R*K+N'9E'TKKKQJ=
M"V'9.P*X\LM,K)-GZECW4]"QU/87A=\V5?.6;!N7\M2D9(@BX7;J%*^20!(%
MTUD4_3P.NAWW]O?W_N^W7M_<!UGP\Q\F9@.@S$]>1;KLGV+,2Q(^W;$L?N22
M<FI_NCG>W_B7NH?_ #W<^?\ O+C.N:KUMYBNH]O2VT8+7/B+Z7LTMI?83_56
MS&;?<6C6IJO?XN.CI9_7EU'\VV2?*MXV6CG0O(T[R/.5T4B;HRA%"$8SY(KS
M,=,S?[:/POQ'],._[7J7>0.X?;M_1Y/R9+L*LPNSMFY%69($@9&K2D?+"I$B
M^2,FZ*@0YG1%$2\]?Q'WZ_7_ #^WV_G]V<=_S_<>OY_S^V8D;SI;N(UUZ^/X
MINDP:[5U+9]YT%4=LZ9 +#JJFPT=8+);40&3]S5O&P\O&O31[X&TJX([33:L
M5E0.0G&/^[^?^_[?Y'-9)_V1K954H-=/QF]&'2LE=U;:X0X;-U2!7T!NN+EY
MG5[\HF< *1;7&0,NZ;(+@FY8@R.G*(LE5$4U7^/^_P#[/YZ_NSG-G<Z^=#=_
M6<1:YWGGQ4='[)BJ/-1U=M;J.V[I>,&&FI: C[/'L'"$Y*1JYU'$%*Q\@4Z*
M:B9$W1$E#D7*HD1C-YV'R=]OU6 G+18/#5T]'0-;AY.?FY!3=>@%",8B&9+R
M,D\.FC8E%E"MF399<R:*:BIP()4R'.)2BQF+5+RX];WG5T'NBJ^(#IJ6UE9*
M4VV+"6DNY=$MF[ZFO(<)]M-%9.YU"2135B1!V5JNT2>@ @D9N5;^YX_Q_P!_
M_9CO^>C_ '?S_G]LUPT\YF\G^I=4[T:>*7I-;56[YREUO5UL+MG3!6]KFMAR
M0Q%-8MV!Y,LHQ/-R(?3)*2;)DDV,8IWIVZ9@-C^?UQ_/^[^?Y/7LDO._L6MS
M$[6;9XN>KXRSUK<52T'.147==-S:4=MF_13:;I5+4D$[*T:KRUBBW:+UF9F+
MF/32.4KA^DL"B*;'\_;K_?EU?,V\XWI?0FK=\1-8FZ6PV=5VUD2J5D58K3U=
M45<.&CF(EE8U9PP4?,7359!<[1=5 3$$2','WQC-Z8QC&,8QC&,8QC&,K2ZR
M\J7.7(6SOV37*O;DV#9H*H,MC[66TYK.:V%$:,UE(R7X4TV#MN0BA*G6:ZLZ
M YB>P'DB+4@NP8_3F34/'K6H+-BS&9$K5*5FE0O;6V?1UE+9;)0U#7V+1["V
MK2,KJH4I&C*TSH&&9YZT\,%5TB:Q;OPW;6OU=?J397J>NZ%ZY6K$J7K5G/I-
M(64-,&BC\G5@)V_M3U^.L!W.G:HE35_Y*-L8+H1P!X0U)+"C81L17(?8T>,,
M'UX*  F%+[ 7WC[<S[4_@GS_ .)AJAUAG%U74EH36\O54J@8LP*D*$#%ST$\
MBP[CZLC="@=81<&S]#Y(Q>_K_,^(A\>^NO+R'?EUX^_EUT>JZN;/+MS=T=>G
M=,&I;DTTWEM?6G;VH[GNV@.J-3][:CI*@A:MAZPEG#EP:1AH5 4I%RTE$(N5
M-$JA)HLE&I%3D[.K0:_9W;GC1FTE&KM-SK+)"['6ZR^K&EL+$">8^6F9?28Q
MM(\,[QPRHDDB@F8&]0IUR+D6VV-G3ZO85BKT-AMZ?D;.MKS,49K,<:/*.T$;
MQH[(Y"^_T\M^6OGSJC;D/J:OT?=FN#;$@;/;>?KWMC7[FH4/H^H4IV=I:K'J
M2;5=N#236( $GIFLNVB7SJ-5^N9MUT$EC)9X*L\M>T\B"I>H4J>TO:BV1%LJ
MFIV#*E+92P]E16F=T1_%VEKLZ">-/,'.MF2.O-"JO\S5L7K&JBV-96>B^VJ1
MM)9UHF(7NQ&L<WB54Q3>A*8I&"J6VWJGR,\T[RZZV!QSJ*S+;!OVKJ"-XN]L
MK/T,GKR(73GDX!Y3T[(@],21M$:X614E&L:W=LXX3"S=O4I!-5JG@URMM-?L
M]I5!-'6V=;6]=QTEYMFEQXIJ!'?KU8_DI4>S],,C^U=Y0DA7KL95UFPU>KL_
M\NVD&TL"NOO)275-165+RGKT)I?GXFC@[:95!:9(@\9>>.<9ES2'1W0VKN5-
M,7K?.Y)M2 U]K^,+)3+QLR<24@Z6<.4&$7$1$8T*=U)S4U)NFD9%,$"BHZ?.
MD4_4A1,<L6U:%80 136+%NU7HTJE9#)9NWK<@BK5:\8Z#2RN>NV9410TCLJ*
MS"35JR6Y'1&CC2&">W8GF<1PUJM6)I[-B9S]HXHD9B%#.Y 2-'D95,?.-/(#
MK7L>3V%38_7NWM&[=U:C6Y.ZZ7WS3C4C8D;5[HR/)4RXH1Q'DBR?URRL4SJL
MW;1ZHJU5*+600:KB0A[5JC"H;:2PS)!>FU=^.)_*76[2"-)WH7%Z'A*T$B3P
MNADAGB)>*1PC^-?\PGKPP^,H6W379:ZP\;)!LM>TI@-NFS],\<<ZF&9'1)89
M"JR(I8=ZRZU\K&B.1]J.]33U!W9M:>IU,C]G;PDM,Z_<76%Y\U9)NS,V&P-K
M/4W;08R&<BD[=)M(TDE*_0-%WOT(H>PQZRI:K6;%I'F2I3HWJ.KN;:WW'K*N
MUV:*]'72V%#LMF998';\LQPQSQO*ZAO:=-6L1P5FBA:U=O0W+5'5P%3>MT]>
M2MRW"CE(_1A8-&I:16ED1XXPSKUF4=2^4KD7E"FZBMEQOR%N?;X=40VIJ50E
M6,U<KA7=@/HQI%79I$+O&0LZ<V2EFKMW.2:K)H8IBLVIUY!0C4UC#3LS<GI\
M2$3#;V-D-983KRAULW<B^IL)D\DAB+Q,L0!>6P?JKQRHKLD59(VT=GD/J*FM
M@HM=220-'):"Q&805X7 E>;P!,@9%6N018:)BH-BI#>\I3>@@!@ 0 ?U^_\
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M9NT2+MG*"A1$JB*Z*A%4SE$2G(8I@$0',TL<D,DD,J-'+$[QR1N.F21&*NC
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M[QNTBHX]T9H7,<JJP[5FC<%) "2C@JP##K.3]+%&]G")(4/LP24$QN5/N$D
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M&MB12P\F?HRGSR0SOF/5[WIV&ZX70GOVO06I)'2C%P2;7+7 I$I84[.Y25@
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M[ EAU\@D>6HW?K"8,JN\2J9U5@FHV=2.S^'[2Q3@CH[#T%L^@8S_ %J!%/\
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M@XKFRJ!Y%BEE*HSH!D.Z_N[<?9OE=\7#O:\+HVO/6'//1#.1I^@]T1._W4)
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MQ_\ 1Z__ /:1_P#Y.>#>4;L@"F$/$[T&(@ B ?FEU]_0/7T__5M_T??^6/\
M@SX?_P#2KQ__ *,O_M#'XUL?_1Z__@\?_P"3ERU(G9*TTNH6::KSVHS%BJ\!
M.RU4DE 6D:Q)2\2TD']>?K D@"KV%=.%8UTH""('7;*&!),!]A?(+D,=:Y;K
M0V$MPU[5B"&W&"L=J**5XX["*2Q5)D42*/)NE8?4?OFPHQ9$9E*,RJS(3V4)
M )4D>Q*D]$C]1FK.I=O.]!<Z;GW-'1Y)63USKRRVB*CEB**-G<M'QRQXM)X5
M(Z:OT/X@9N9\*9R'*T*L8IBB'N"PX[JQN]]I]0TGI)L=C5J22=@%(YI521E[
M[!<(6\ 006Z]C]L[AD1999 6CKU[-F1%(5G2K!)89%)[ 9UC*J>CT2#T>NLK
MHUS6^O*]S),]:7/LZUWB8N/-5PV?*:U-1Z.TH=9FIW7;RTT]37;IA&HR\*O4
M7B[$JYW[B69S0-UP5:) <@E]"VUKB3<A'$Z?#JU2.CR&IJH=H;]YMA96OL8Z
MUPWE>0UYTMQK*%5%B:'S4JW8RDTB7]@*&RL7V"V>[,FO2&$4Q7D@E:*NOE&+
M*21LT3O(\[DM&T; J23'C7.U>L=":CXAZBLW4=UWK4NE;;J*D[.U%LROU Y8
MXVVR T:2VNIRO1$1,M'5;>JB[6;/UGJ<BV2*5R8I?<7-EV6KXKN][S+B5?C%
M+26=!3VUS6;C6SVPS-JHS,8]A!8FE@DCLH/ F,(8V)\>CT125+>Q30U-^U^6
MPQEJ"U3G2OZ$D-BZ*DBP2101R1S+V'C9VE!/8*]#H[#DMO=.Z=[3MT+!]$V'
MI2BT/1FWMN](TF0J59A:#J)]"UF8GM:U*L/8)F$C$S$R\:1[8D2^FI.85CA<
M/I ZB:QCM*F'5\;VW"(K$_'JW'KMK;:C5<<V"6[4M[;O-8CAV5FPDS^E+!%&
MSR%XX(X4/21_6H\KR;YD<BU=>"[-)'<L3R7:'A!Z='6>4:5G[6(2"5^V1'EE
M=Y955_$12$#%^9M^=4Q6QN#=E[(WY,;5J'>C;8:=JU3)5JMQM=U>^C*[(VRL
MN=?.(:/;2S5G&H,48R43E'KX')3N55!]YTC(3>0Z+B\E'G6HH:*+6V^#0Z^:
MIMX[-B2ULO*:&O:38+,[0MZIE=X?22/Q*H![+TU7'?OLNJVS6?R]GN)=?)K@
MD8K0UF6R(37;H3BQ&:RM(9I92WFX]A]Y2]&WS>VYNU*EQAJ;=$SSM4XO2+[=
M^PK_ %"$@Y38-C,I9"5V$K-8=6=E)Q46S:K_ !/95T1@JJL@HZ;G,/M2 FK<
M;HZ35</V',MKJ(M_9&XATFOU]J>:+7P,T'KSVK:UVCFE)7M(E\P X4]#LG+?
M9SSBUK-96E-9[\=JW8MA$>2.M6;TD@K"17B6:257:1W23QC\?  A@VJ^S]A]
M':RINA>5:1U,VC=^61GLO8-DWM-,Z939*1H6KZ],O:]$RK%Z<*VVE;I9I&J5
M=ZY9HH&?':24DV:HI?4-PL^(4N/[2]ON56N+,^@HIKJD6A@>[<C&RV4\$4SQ
M.O=@PUX$N6TC=F$0:.-F/TD]+*V:M.G0.Q<V]KLFIP;&5*Z2U:2++:FL.HB$
M3O HJUC(L:&02OT%<]Y'WI?NZRW;5'CEV'#] ;)T%2MV([2:[UL^H*VSM5K:
M3]&JM>2=LVL O7K(NZ(PMY7R?L9QRI$XR15D#E401252V'CW!ZU'=_$+7RZ'
M7[VUJ(M?/H:NWLR5:CU[UN5HG>?UZRJ6J%5+.ZDRQ^ (+'NL;9SS:/72FS)7
MLG:P:_8S5XXY)E>*"X+ C3T["_F/'',JI&S$%.AUVIGIP7=-_P"_N*[1*7?8
M\O(6"R26T*_I+<QXR$A[U,T5$SJ*H-^L<,Q36AX^SD>@LX4:*LB*&2:-Q?M?
MJ#J'4T7GU+2:'EM**EK8H1!6UEG>:999I]?!?;J:W1K3.PEDK/$$!99& ]1A
M$_Z"SX_8DL_-F:P]O7I?D@H7)$6*W/354622:/Q")*DQE$?<:?V5\HP  8F:
M]Z]WWNC1/'^EHF^3->Z>L_2%AU+O>R,&L66>CZMSZNZF=IRKY%Q'+L62T_7E
MZDFHY28D27=S#A%K[0,8I=MV'%-#J>0<FWCT(9^*U^,0[W3U9&E:O):W:+6U
MM4%9%D817!9(C+ED2)2Q( )KEMWEU5O723N=T-V./Q65"))V93<>]$"ICD$6
MM0KYE KEBP4,01IXNYK-.=HO^M;%:>A#\DRO0U>T!JC85=V0R@JW5K;73$JL
M_7[-ILR;Z.M.I[G<CR,2C9%VK&TM'#51\93W_&0+6'35H>'1<2@K: <M?0V^
M0;'7VM:]FQ<HV UBK)!MPR/2VM2FJ3) KR5F'BK =GOC;63^(6=@'L-J]2U/
M6V9*]@PBG?218[5B. #QO0-++%%:,JEU=Y%@[1$R?]#OG0<-Y/[)IZ_;C7N.
MMIKG25V= 4.-K$56ZQ4U#;"""@VJ D%_-R\JUB&_K*34E+#]>_>.@08LV*+-
MLCH=FCH+'PR&VHZ@5=E5Y!3UL^PELRV;-KSHF>PW7Y<$,#RGJ*%(>TC56:1Y
M"SFQN26X=YIX_F2*MZOMI#42-%C5:K0)"7D;RFEE/F6=BZQACU'&J]C-Y=*=
M@S6F=FT+2&K=(6?H#<5WJ\[L :; 6: IZ,-K^LOF[&5G7<W8@.S5>N'"CAM"
MQ*9"GD7;4Z!W345414HN.<4AW&OV&XV>ZK:'4:^Q7I/=GK6+C2W;:NT$$=>O
MT_B JM-*6ZC5@P5NCU/NV6JK56.%K%F]--#5@#QPJ_RT<<MAY)Y2$B6..5"O
MTL78E?IZ[R'>^?,YK+1FZ)/5<CJJ8DF%'&G-MJ2K^^U"MVJM2UOC(Z5-$U77
M[XZ\I?G-8;R:"-E/&OV*+-XFY11.NDFFY6W#0_!_9;W4ILTVL,1NR75U2QT+
MEJK:CI32P_,6;L86.C#9>)C7,B2,Z%695)\!5;#?Q4/%&K.UA:<%RU \\%=X
M!8B69*R>JP^8M"-U9HT 4>2 2'MO"*TQM#8*VU[X5IL&[%C5/,EK.JLFZ=JG
MDVJ=(D:M#N#59%O]<5-&M.B*%46@"D)&J&$?D:";US9*>KHKKM0)=?3:0?"?
M?6)":T#,UV&U81;+-X=M8C((2<DRJ!]+= 9CV-EV@Y(\<LBJ'X>T+>;KZ268
MZ3/X#L>FLJMW(J]!_(^8)).6<\]=]?M^Z2VMH1MIB>IT?K65M4*2W3MRK 3K
M][4I%..7<3&LC_2VVO0T^)E758G"EEXR200,59PT6$$P\YWO!3I.,ZOD)W%>
MV^QBJ3FG!3M&&..VA<)'LAY5)K-<@+9KGTI(R3XA^O>P.R/XM+K!6<+"TL;6
M'DBC+O$H?U(:Y;U9JDJG\FRA(;V+1H&[%B6:!EIC&,8QC&,8QC&,8QC&,8QC
M&,8QC&,8QC&,@AN?R3<B: V-.ZIVCL20@KM6R1JDO%MJ9;I=-L66C6LLQ]'\
M7$.F2PJL7C=4P(KG%,3_ !G]JA3%#3]MSOC6DO2Z[979(+<(0R1K4M2@"1%D
M0AXH60]HRD@,2.^C[Y]$<#_97^-GQ*XOK^8\0XO5V/']HUM*5R7?:2B\II6I
MJ5CNM<O0V$"6()4!>-?+Q\E[4@G5W^[%\!_^%N8_\W5]_P#=_*[_ (4.%_\
MG.7_ *!>_P#5\W#_ . Y^TC_ .A5'_\ "GC?_M/,0_MDJ!VG.R\CK.^SLQIJ
MBEB6 PL6>PTE:P7%\59^ZD+* ?A-A=1,6S*V9Q,851I&.G9I!T]+)$!!)M8Z
MO9ZWF$EB>I;FGUE'T8_03UZAFM2!I&>T.HIVBC50L,?DL3N9&</TH&L<WX3S
M3]G'7:;6;[CVOU7/.5_B5M]Q;35<A&KT%)X:L-+2>0OZFO?NSO+8OW6CL78:
MPJPUOE&:623\2&\:GQO)5Z_6JVS4%IJQS*]9O$$]<S]N:L9-[&.G=?LU:8K*
MRLTP=H/8XL9,,8L5(MPP?I.!CVSAO]4;)MKFOXFM;8RSR5M7+.U:Y S6+2+)
M)$[P3UHV,TL;!HRDR1=QLCJ?!""QC< X_P K_:$&[X94U-+=\[U&JCWO&MQ#
M7U.BM34ZUZO6VFEW-J"/7ZZU7F@N?-Z^S=5+L5JI)%\W-#*(5S(/,7P'Z!_W
M6YC_ ,W5]_\ 7 95?\*'"_\ SG+_ - O?^KYN'_P'/VD?_0JC_\ A3QO_P!I
MX'S&<!@ B.VYCT#[C_W.K[_[OX_X4.&?^<Y3_P#V%[_\QC_X#?[2/_H51_\
MPIXW_P"T\L6HUSK^QJ;5K]4WAI&KW. BK-7GYVSAF=Y#33)&0CG)VCM)%TV,
MLU724,@X2362$WL4(4X" ;U5LPW*T%NNWG!9BCGA?IE+1RJ'0E6 925([! (
M/L<^7N0:+9\8WFXXYNH%J[?1;*[J=G666*=8+VOL25;42S0/)#*(YHG421.\
M;@>2L00<RD?T'_,.9\J,@'J[H+9=LV3WY6I9[$FB>?9V(CM:I(1":*[)%SJ\
MEH<?BK@JPFEA/+F!8OR@F8B7N0 WQF*4FEU=Y?ETG,+SM&;&EVW(JE$B/Z5A
MUM.O-661/?U&621R[$]N" >@ <^C.7_#7BVFXK^SAMJ4%U;OQ+UEVWRII+KR
M1SR1<PETT?R493JD%HIX$1^09^I"/+OO3.I_(U^%:*YOE-J4G9&T=Q[JU7:=
MA(1>GZ2RD0E?RG8E8R403C"RS-.*.E'G3?&66%.,*DT<>]TDX7;-E</]-:U6
MKK([-/8W=C8XQJ>0V8]=3]9/0MPJ+<W8D584KS+([J_7Y;(L7J.?$;WS']E\
MW/B'\5*?#]_Q;B/!N!<SU/&)+G.>03U/DAN=:+5.1K;4IVN*]E7KB.,/;9YH
MO&%XHY98Y<4/M7FV_1VJ%V>S(.$G-SP:$[0Z=9%@BK9)H*OI"*5:FBC_ "@F
M\:2\3*1:Z95U$S.V#@K=5=,"'/>P<FT5B2M#%LZS3V]?#M(("Q69Z$]=[<=C
MTV4,J-7C>0ANF"HW8'6>+\B^!'Q3XY8YFECBFPOZ_@>QDUO(]YJXS<TU25:]
M:Y',+@">4$]*[3MQN8PP@LQM(J,2HU!3_)7S_=KC,5*&97@$$8J]RM/M+J%8
M(UO9)=;-))[:VE07"74D <M4(IVHQ&?CX1"3(4IV:RA3 .45?X@Z2S5V-M$N
M+%1U5W=UQ)%&C[764(O6GLZ]3+[](4(BLFO*%D5F0 -X[MO/V5_B5Q_14=W?
MFX]ZDEWCE+>:>'86)-KQ0\KFJP:6;>1FBM;TII+D*V/PVS?DJ,2MB-",^G4?
MD:TUMR<B8I"G[;HT=9=:2^TZ?:;]2QAJ]<:Y6F"4A:RUMPUD)!U(.:\B=4'!
MBM"LWX-U%8EV^1.W.O,K\TU,PV#S1WZ,=#5MNP]VG)";FG0*'V%2,><DD"NP
M0*Z1S,2"(RI!S%S;]F#G7"M?<N2;OA7(;6JY;2X;O-1QO?B_LM#MMK8DK:;\
M5CEJUH:T>S=%]-3.9ZQD1+L->02(FBY7RCT[8M0V\RUC3=OT*;J.E+'M^'V/
M9*-4+'76=:C@,2)G_P O(WYLX>FFG!!0B(F56B3N%Q]CTS4I%/2CL\\BM:S;
M34Z^RU<VLBUD\MFW0K6UCCV%^O7A40)=5)))XGD=5,R&.-6E^IHQ&WH57]D7
M><8WG!YN6;WA'(Z.\Y_J^#W>*ZKD6[U>TGVUGIKNM.S?C<D5==?&P>]>I)>6
M*/IH%F++FT;9Y'M<:M.O6[/1]R7F;INNM;;!V)9J306;BO0M3NT$C)N;M+^R
MPJ)P4;&F-[Y&,.NX>)F6%*++*(M5W!+F[S;5T+NPIS5]BPU5VI3V5N*HTE.E
M\]%!)6GGG#^T,AL)'TJF56#EHP@#G3])^R]RKE\<.UU/(."Z"AON3\KXUQC4
M\@Y)/%M-CNN/[%ZD6@HAM:K;"W:4!:UM8XZ[! ]PTWFCC;GMI^2?GS55U3J#
M]"Z65K'Q-5GKO;JO"-'=9UW#75!JZK+ZSJ/Y2.E%P?LW:#Q5O7XR9=,6QP.\
M11,()YVM<VTM/:S:N4V.JEN'7W;Z1JU&G?LF-8*LSA_5+NTT*L\<+Q1&5?4=
M?&3PK^'?LL_$OF?'VWM630:N6U<W&NX]I-ML)X=MRB]H9)H=M7U*5J=JG&:T
MT+P+)L[="&Q*"M>20#RSW[(\D'/^L]G.-<2R5PE6D(\K$=>-A042P<T:@OKF
M1DI6T+ \<R[27<E>I2#-9PO P\LWCTE@,]51$BI4S<VTR[=M4?F2(]@NHDOB
M(-13;.RQK0:0.9?5]5UA9_1,"RLJ&4=,5Q\4_9=^)7+>(1\KI-HZ<VPK[>WQ
M_C-^[9BY#R2MHFL+M9=9!%2FI1FN]6=(HMC>I2VGC(KI)Y(7Y0?(#J)&R[CA
MY"J[/C*YH52RH;-V4[JJ1]?0CN ;Q3EG'(S363<+R$K9R2J18",:,E7BIT_:
M^29?4-16Z+SC4&ILK\L.PKT=5-9J6;<U7Q@>_7V(UAH5W#L)[4MAXS&J?E^G
M("\B,LBI$'[-_-I=3P6]4V_$;FT^(Z:F7B?%8-RXY+?@V<EV*>U)0FJ1)5IZ
MEZ3_ (C;GL) JN&KO8].81X?7?)WH"8IFQK7,PNQ:;):ZC:U,*T>PP4:K<+7
M&W63&$IJ]19P4W,L))2PS(I1B#1>19NF3ARW&22:(*E6'JO.=2U*Q9,%];=:
M[3US:GY=7V3W=BLK:^"*..1X9#;6&9D<3>"+#,9&0IT;S:?LF_$FCON+:6C>
MXOO:O*;6VI1\AUFQMIH]-:X_4_$-]'NY]CKZ%FFFKH>=R6=*LT-B**45))I$
M*9\W*'2-UWKU'T=&2D=LJETNL:]TT]@-6[-KS.N3M1G)E.R&GW0LD!<J*EF"
MMV*Q'19-\S<)D(+<R8E.7.>*;:WM=ARXV3:2"GM=?#2IW(1!/0B?3UI+%>2,
M#L%K?JRAF:3R5@T;&-ESM\8OA;HOAY\)?A=:IV^*;_>[CDG/8-ER_B6TGVVN
MW>OU[Z<:R);$@A5#1,UF,PFI6GC9V$H?M6SAI+KO8VM;-W=1-B.(=Y9=)U9O
MM;1JB<05@2>HMOA%6E7B'#1-?W3+N)O#9.%=O4S%4>*2":*@D,4H!6GDNRAU
MG,:\[PMO-'M#1UI$*JMB/=+">-NT(;Q=WFL?+N!T&]$LW;>>3ZGP7XORG5_L
M[<BXQ'>@U//]M+P[XA(]XV3K>1:+81S;F]%,Z=4*]WCTQV$%=@PA2M)(OEVV
M19Z#Z+Z6B;-J2#6VQL.OLM7Z2KEWZ\F-':]J\NMK.]VOZ-["3%R8V5D_9RU,
M(R.]4E*E7%T)MI%Q[F7.H<BZ)"5^XW6RAWZ+^,7(-/I*VNK;F]1IUY:-;>6'
M1Y%VJ2*)9*LU=HFD%-E% 6(GD\?('/7?AC\,/A7=T_--@G#N,[.SS#X@;70?
M!*C\0^3[>BG+.-Z8SP7Z&BLZFQ6GI;\V!62GNMM&^OGNV8J*J&CD)ESNCH+>
M=/V[Q6UJ%HUS(Z7WQ?*O5)639PD@\M-S;RE16GGDV@X=.4XJMPKH"(J1;-@@
M[DO<J"KA^"(?1YM-K9;>#F&HUK-173;.#<-%%&LDMQVU]".SZLT[%8HQZ[^G
M'%"K@Q(9))6,HCB\6X'\-OA]O.$?'F;=:GE-7GOPZXYM-S3K3["M7T^CEJ;R
M+60T)888FN;381>4BW)K,D-3Z/"*L7/KY+C?V_Z5SI2FUQN3:?F%9><C:K4Z
MI4HLTU;+G;9DQTXFM5V,!5!->1?G3/[#.7+9JB0AU%UTR@'K9;K>5M+'6,T-
MFU9O3_*T:-*+UK=N?P:5DB3M5 CC1GDDD=$10.V)(!\:^''PXWWQ.W\FCT<N
MMHI2UUO<[K=;JXM#2Z'2T K7MMM+921HJM977R$44TSLRK'$['H1SN_D/U=0
MJE09F:UUN-.Z[!-8S,-/.*FPB-DQ#6GO3L+/(SK*>G(N#9Q\:N4!0<HS;DLN
MFHFI$@\)\IDZG8\TUFL-..:O?DM6J V<M.*!19HT?,Q//=CEDC,7A*KQ>FI>
M1G1BJE!YYZAQ_P#9FY?R3=\DH:_D_!FT'&1K!9YQ'N;-WBMV;=UULZBMKK&N
MU]O83V;<9(DB?7Q&DZ,ETUV\ \6=U]CVBW3-QNNB]E33/6TKX^-E[CIZ*#-@
MV/'WR%LCJ,:SBS=\P<.F\[!J-EHQPT6659I.&ZI#(*B!51U+D')=@O\ 2^UJ
M]E(*D'#>-[C4.BIXQ/L=A=5K<2R1^7=FNL099E;H*H"H00?6>!_!#4Z:KQ_C
M_P 0>+49N4U/VFN*\#WS23V95L\=O:F*W/KDDKV8H9-=L%ECN13QQI/)%+&Z
MR("5R2FO>Y*@QD-!:7L$3LF^;/MNG]26N]VBOUE"0AJNO>JU$*,9VVK)NF+L
M6\S)N5%7CJOP\DSB@5%60^A1 0)OK\EH_P!(I^/1U[LEBNT*6+,5=GI5IK,;
M35H9I59G3U8P.I2GH*S+&\JN>AY;R3]G_>6*7Q'Y]KKO%>/\2TO-N9Z?CNIV
M>UDJ[#<1\>VMU;.OTL;0V(/4U]2-$ABV=ZI/=*!*OS,A'E8> ^H>N;!GS3GG
M&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,B]T5QAS-U<A&EWOJB!NS^&2^GA[
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MO8_$?:[+TYI=1QN+8_,U+5O;5]2D6QV$M*>.Q%\S.)2$5Y(D];Y5*[2*"OD
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M *+!_P#F\U[^FW,__2[D_P#]_P"U_P#6\?L?U+_X+M=?^1-:_P#9F/PW7?\
MD%+_ *+!_P#F\?TVYG_Z7<G_ /O_ &O_ *WF>M&C1@U;L6#5NR9,T4FS1FT1
M3;-6K=$@)HMV[=$I$D$4DRE(DDD0J:9"@4I0* !DM55%"HJJJ@!54!54 =
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J8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QG__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>img102984888_8.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img102984888_8.jpg
M_]C_X  02D9)1@ ! 0$#O@.^  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" &D EX# 1$  A$! Q$!_\0
M'@ !  (" @,!              @)!@<%"@$"! /_Q !4$  !! (" 0,# @,"
M"@8$"0T% @,$!@$'  @)$1(3%!4A%C$*%U$B01@C)%5A<9&4T_ E,C-2@;$9
M)CC1-G)V>)*AMK?!&C1"0U-48G>CLK7A\?_$ !P! 0 " P$! 0
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MQ)^:G5;&-<]H1 R)LAIH:T.HI2EBDF9/.>PJ8Z6-$B$2H4R;:UU+9$F4HO\
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M+,)JR!X! 'E]>$*GI],^EEE"XI51S:[%+NW$:Y!-B%S%^U_\-3L"<B52P_\
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M25VN0(R()WR>2S%F!*@(D3S1801'SXT929'QIYP(:S6:_:@$E6V\ZT=2N/\
MXO:,VJV,KJH59X=98N5RFV(#,573 .D?BD>G*2&[;UY$L;5!EP;PRP.BDJE
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MJ+)"@T#MCV)[#[[B;3W71=S6^L2MDZE*5ROV(S8AP"H!CI\C:4"I3P^EB#6
MQ-S))1:2I#DUJPB[4JVQ6ME8*=+P'L]!0*C5=64NY?WU?9>5 ",W$,H9< [!
MBA/21H$.WT]SG-2=A&Z<WOMM[?Q-H-J\;C@>3$ZK6JUQMX&)4J%KJIE2^XQI
MR(N*1<1+5BB_'WVWIL(;M:JZBJ-SL^D_*9O?MW5M$&KM50L+;6JK\%EUT$1!
M6/YR%:JUQ'9FK/5^+9VXBX<IA7U28;ZFODYNJN!K5>#S,6M+7>!=]X2V"4D(
MMU]G<[*+%>Y7)D@IT5D(%#84R"FI;L+5R8RN>KM.UL7^+% 8*3M-KX3VM)[E
MF:K<Z+6U!MU;"@B7*[]N'2MI@0^:2MQB2RAH\?=?'_W,N0+:G:E.GJA7MX7+
MOCU^[=@^I<+9=;>^*HZ2J).E3:X0V<RU'H[>P[>R:E'9<J.XX$:S!CL/$I$E
MY3;5C7V4:(_"R$-+9)UMSQH_9.4!5EH7XPKF *H*L1!L#7-35ETE"^_#7RE?
M*PED%TOOBMXFJN6-#[RTOAK64'M+S#6N\.;.EL2;;[ _ FR*GUZ@"1FB26;B
M$2.!^,WT:[;6^#W>V=M+JB^:N6].S&B-^ZHI>INS]3H6R]9DZ70SXEFVT;:K
M\95?1>=>&" ]@C&.0QP,VA\HL*Z2BQHSDF%9KHZ_04Z-PHO:O=^.+)[04R*U
M+W]?4K1,57Q,V=3L 1:J7*[)\W *6PZH]8"&2>=[<[386JRPHV_"/@O2!0L3
M)E8G07-^ZX#FUR.:U]<7:KJCD%-?\4TQ8GALY8D&T5V_L/BAV1H?>+X>]=J[
MCI3<%73'@$ZXVX2*VG]1XI >QV>-'!54I:V@\T1!MEI99ABBIY,XDJ0^AU<Z
M1#XA\I:8H=<*I$5:D;,UU'6ILMURK%?=3KN(VUJA&#"17*8D C@0")$!G\./
MFELAM6Y<JJ&PM-K#88-NVBB4$-9=IZ0@;%B(GDF ,_"0B4D0D4P%TOXS>S?4
M&T50WUPI=>.3-R]!B.FMJ%]O7(9LB9U][& :RDH"E5>?=2I@C+U+=+3(<"'Z
M+4?N-48E0HIC[4@;$::<Z6ZVI7/^,Z--_13L;&ANO#U[HZ+-HJ]Z*]S4W2(9
M>TONWN7-7=O]44[QR!' D6<O1UXK5_!EO8!/G];+J6YI+*1K+1:K0P-I3%)A
M7181=6"+RJ4)*S0$05!LZ2",(/J_W'TU.WWVN[GIM=2K>/'/O'2EEMV\>R6J
M-B/IV@5=A2AXFD0:I K<*HZ^M1)1)_7M*8^\R1:?0?(>B3)4.$[S=W9UH>'?
M%].D(]S>N\,'JJ\57-VK?(7-B3ZVPN=QOG[]>NQ1D:U"! 9$MMB>\-?J4 LV
M-WX2(IZ@TU_>NNN EIURU7:5)*K%.K(*FHAS50#99/5/:7W5JA8,?8WX[^O>
MW(&X.G_8F;551-2M^(K1>FW+!)*"F9K6Q6S(&TN ':XY,38&LM@_28HBX-2-
MQG.(WU7U6?AYZ?Q"]:-O]I%9A1#MCXRUUNH,<EW*]#7W:EHRD8D E=A@K@#*
M#*>J1&1B9SS^M(;6I\*-04,"K5W,M*/0>F_90VJ8%/$,%JUR8D'5'3,3,Q$Q
MS*WMYU[VYM'NEXY-N4:LLF*!H._;?.;5-.&PPYRMC+3060@-]H:0FQR)E4TD
ME4?+(>-->C^GRR$-,Y^3GF]*Y5/8[:Q9+H5:\+WM97*(DI.Z^RABU=(Q)#$@
M!3W"B%QQ,$43Q$]/:C-K1II)CJLK\5^']F2Y^&/)40OQ:;!EP$RN7+X7U=P^
MKX!+B>*IMS=#N^;]7[1];J#HJH6C6^SN^%6[?UO=DK;U6$J)U27LBFV(K2(E
M$G8CEX=L M#IT^?.+RH8-X5 DLC7IY:0/B2;'AIE2L_[-6;*P54? VWOS8%:
MI?YVO=?X@<JXN1]0KH5NH6]7$VRL+7"5&DFM"UMV]XO&KJH]]GBSPY7JJ$IE
M44KNOUFNKQ79UCPTK3M4L*[ +LC%KNV&J%4A.V.PGCY[%[!UCY@0P/4X$O9^
MUN[M)6;1^95AH[4FY5&E,:^^]NRB$\FWBOQQKXLZMD;8I YUYU,ER'&6J8E;
M\>I>BO4\!HL3TSI_'>WWFU#@B!6OM[J+%>U/3$BXRI=42M7<<(3VB&)GHS:P
MP3V.TL@4]NSX,IZ=!Q!"17%Z^XIM>?8Q#OL1U',0J3B&<E 1(^W<#QJ]B-Z[
M1[6R]=56FUZL7OJSU%J] =-& T*J7:_Z$VCF[G=9V$0(?=)BP9,./C@U%YHE
M0?#,J.RTMV.TXAO>IL0I,;L"7-U];[4-=XP52(OCV.MKZ,M>]D-9RI=H;#.]
M7BP0S-E"6'$!'<&%:P93JZXG'36_P#XC\*NM(&8G5VMK80=4U@N8)B!$#AL5
MI&14;( NYTB6([UZ8=V>WB.VV]+1UPK?7^Y73I .ZEZQT3%VM1K>;OYK&S@M
MX*6NQ6H$Y I8$"-A"LBJQ!(E,D%,O.*DMPD(;;?@,:M:K:6JQ-]FY\<>"M[9
M4:26%'6^'=E69;=8-I2-K86*\MED($P*NF$=3&' 9E#F2W4+*#J!HM%XOJ+L
M+9!+MW=]IXJ4ZZ$",L"G6>KK7+NU(/L&R0(.HPNRMW7,=LGIH8ZN$FV*1#MF
M@,Z@F)"1XF(U7=G4A%<<6.C0LI@N,"I>?D::CJ3'?0SE+:_8O"N5?$\?>]O;
M.K/Y)^T/84WN%A#+*^P&]2)P3(ME4FE,,7R+.UU!$B7'$/AHBU-?41:5)36I
MUT74K( (X.K"+H@P1,!8<&[I; F,,F#X*/>B5/2;R V;8O2&MG='3*5:.IME
MU'4KCVCH_;&6.TML_0^J7)Z4CH?7F*8C%HEKLT"2.03R4K$ES,^#.B.D<B'8
M[B/24]K2;XAL^(K,E45L5WG[74N5-Z;&PL:MM%$4G<DA-=5QWG!F8KR2QX8)
M.@.:6SJF/AM^@JSY]XD@--L@(:#->J-W4V-ANP@5@=AIZ^LVCVUD\!98!J9$
M8,1D=CQS;QN?43R@::D!:SKW9':3M?L[:6MS! D)GPKQ1ER:*4I<6VD*\_.F
MP0AY8 N$?$E?28)BSY3SPU#4I7S^:!DU]!]G:  +%GPM;5M-AKC*12VQ7\87
M]O*8;/X!OM:V:72^.L((4*<7X,BOM@U1>(_%EQDF-3=:R-/3O*$/,UE/\+*U
M96%#,2P?);%UMZEG$3W)8Y43#((^.%]+.R?<#;)?8G97KY5>K%-K71G8/3P=
M1PNR:IL([L@O>EQ,_J1B73H^!%;H=8^W,+K XP\LTB8MES,&,U'4XNUM.PRC
MXPL4KK';'Q.W3OH(8F1G6OT>PN;>M>NM,^U8V)W&H0,H(EQ65R;!GX)@UKSI
M.\(4C0HJGAB]?LW+L<R-]6PUE;4,I4U1V[*JLU@=8?+A61M.%@N?5L5R(\5O
MDR+:K ["*5D%![.[0:E=/-V,)V+5I,8+TNC:KUUJT!;H)--AR.E%(,NC$KQ*
M CY4@O,FGU(7 PXMYM/:*YI[NQ6%L2#3^)K'_$OBQ<C,G5WZ?%%?=U:JA!13
M:C[LK#IA>$FM:&2'7QS,50*U2K-*HYMB[X56.J\&RZ$C6OZP]1N*%AMQ0P,Q
M++FX&['F90Y;J4,&)@5P=P4'JOO31OD.:V'JS4,.\]<=B=*:'U>E6:%>ZI5I
M6FI6JU$?L\@A4S#K)2SC2T% J#!:K;*U17WWURLL,QE>_@6GEM-3]HU6X7;O
M>)MPSQ-2=TPQ5FV7A\M46M*!F"KM;:_$\PSIK DQZBY@N+=?MT%^!X04M7X=
M2.HMJ,F=\:A;.M;^\N\SJ%PKKBSN)ZBLL:KTZNX,YH70W0/L/0=4>(6OE=6A
M MGZO]@MG; WVF)8:4I^L +8*VDS&*?7P":T6B03D6&O8F1P3Q2<I:VE36L8
MANJ9[ 7ZL;\;O<_P@?9<'AJ"$6?#M_NGPR@J@KB)* \Y0V$R_B*\F)L[G#A(
MZ;0,]7MJWJ3[?CH=VH9](9KU[G9O4\IF9&"51=6A0',-!<"H1$AZ([#7.!EC
M'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,^0@B8N#-0.=CLD%Q)*8#TMI;\
M5F:IE>(KLEEIQIUZ.V_EM;S3;K;CC>%(0XA6<*QHSN=L^U(0WI+MRR)D(/B>
MGK@>"D>>.J(F)XYXF)]<W7*X8N6P1*@QE@A,"9+@HZX I@H$I'F!F1F(GB9B
M8],HBSX[>S.]NV] [!;]KG5;2,K5]>VK73VQ.M'ZTSL+LK%V-49-/8A;"@G!
M@J("K8M#JSSXL@7M\YV<XS#8FX99Q)3;B*<:CQ'54=M+/$>@LZ5FMY!VNJV+
M<B9;5C)[4NL5"@IJ"JO79),)CFE(P.2NN.\]J22$,1I_$>OWM6Z]A#>"IK+!
ML1J! 8-?;N)E2=BR6=$@F(KI6+"&->Z,\;'=ZHF^B5;V.>Z\*U;T3+[J 5N7
M4"5W<N6PZML2C7(*(MQEHJ'2,"DXTX\,'2*M#<E-)9:G&,F5*^G&JNW;M?8,
MWVS<#5[3=^ &^$XK+D2I5;*XU"4MEDC#7+MKU<.8?2'E/10KL$TC7#6A=!*Z
M%7EE)/C"OXE%[N1LFIFQOW[5>5#)J J_G#!4]PO,R8P4UQ3R[QH#QE=T!0OH
MSI'>-HT#&T)TZVN>[ Q['KZ3;YNT+-<)Q:U%PFNY,$L*A F! @G:9<DA<8<I
MATQ ;8@K ,R&79#\\7ZAV0V+(L1=I>#!\(U5K@(KVILZ'7Z6QL727XE?R=>F
M2EUAEL6W0-R65Q*$*IVE$VIL:("$HV_B>-]:)IE#:BJ7B&SNJR$$,?C'<9Y9
MK"GLQ3%CJ8^86N&OW)I7H=W"HG7O<O0>TV30DGJQ8:_OX;2-N#<W-6YR:=QF
M[)9P0VPT_,:-5Q2ZF;M$G!DVP:)N'8,%EF) B//K?:XFQ6K;>':E*R1HVFNT
MFDTE:$0)TGSHAI5ZU]Q'$,3#J5(0;46!E-ETOBQ KD&=6I9C6^)&[BD/<J[#
MQ!L=]>58D^_7^]9LON4ZLP1 V8NV.[6<9+6FL'E^Q,R,AA&D?'MW3E[7ZQV[
ML,;T"&JG7OJ!MCJ)%@ZK(W(L:(#K!3!5/K6P9C]B$P8[TX[B,[/)5Z/B/&KJ
M(C;;1$N[.5B)U=O<I[?_ -H%PH>G8^/=300:O@.IKK"-K<ONK 40+7K7YUQQ
M:+H)G4M$5A[)/;6UI1JJWAO7HCOT_#.\.\II\K?>JS2&L)G$R0(8,5JBX7'=
MZB-[B,8@%1JUSQN>0['3?K-U@<M^I?T[UIM1>JF=?T_=>Z-6 .P^J\PEMU&R
M7B^48(.N=1L-9+NK,+IX59 233A+3Q)M?HC&]O85-EMJ>VN*.&6-*-.ZB9EM
M?4;1*J5=&SHK_#C8_@UG!*K8H[?>X6<Q+"RNE9T:NXI4SB5GN?O'76B6N+5S
M7OL[&U=U-[K%HTNX=JJ,6JI-[DH83%#';&=A=4O%EV!T.CH+$L9_6I%CJ_V?
M[4;>OCXBP6F=F=4MRUBWA*BS7'CPIXL6+LOG8?W=)Z>B4TUAUQXF1DX6MR:-
MJB;:GD+9A?V<!X2F94E9'L0VM&YWH6@5UU5R36.9[0A ',+!71,9N]<%7VJ5
M%P5[Q+K=RKF3( KUJ:UO61--C98+8(%D4E+1&&&0D91&N]U^'G>M_"1;8-+T
M U>*7W([4[P!Z\E[*VAK2OW?6?823$;A0)NT]9,B+S1K@#;A1R+C8MDF(EX0
M\*GYFQ)"\9X>J9]W3IR(9=*?"!^&;H@PE=ED[@MLFW6GI(;(+* 6VM9$0:)2
M0=#4K9'3V5E>P+9+$O+J=NM3O*C"0IQ&RAX?#3/J6 /U3#^ITJL5V0U4P!%)
MK-J2V/2O&-V*Z[Q>K.ZNMXCKX)WAHDQOJ;:M+V2Z[B.ZOMT#L'%#LV!].X+>
MNU[&<NP>0#'2Y-BF!T#SB_J&&Q(YG.,O]4]D"[MD5==FA?\ "^O\,/8:DTFT
MPU>ZL;JE:I5ZX$ORX.LM2RHUA.8!046 CX Y"EG8IL&Z79M+WY;RI*B.R+ 9
MJUZIU2X32"2<25PQ5E,+4LA^*LTB(Y^-KQ?]KJ(/T]OVDV[25L[95/N7MSMY
M>J787K?7M)SY6]*=!HM@I%</P81*U1V*>'&P)(\U,%*=.3FYCCL2&V['9QK3
MN5=8[34J?>;J:'A3;^%K-JR(C>9.VV'WF6T6E<RD118)BQHRSDTRN/,@<&>;
MW8+:5-W%P118N[[P_OJ*JY$Q2H\-UW(K:][61!D5T7F3K8A I*1@:[1#J+"3
M/BM[5.=>MCT4W6NKVV-G7WN!MOL; /S;GMO5\W6D[902OI$7;4E_J$)VUU.R
M58W#+1I@.2U.8L8%4-J639=5(8S7AZE)\+UJ%FWKIT6DVVJ^]EBLKRG6]]9O
MK=V(XKW*-JHP3N:UW0L+79"&.6F2+=)L/;>*=G?57L)WNPT%S[K(9.H^MJO#
ME'4%5,RX95MI?5&:NR5UET UL)2RQ JGGV5Z6[^W-XM9/38KM /M/?9#7^OZ
MM8]I7>02$BKD;KUG ECA<I*;BEBGI*@#I##3\AB1,G.(:=F+0_(><1OL+%&W
MXEUFS34"MJZF_P!9L;%20">JI5@1MP*5Q"8.S,,;Y<>E(2R0$H$8G--3#J5&
MTBRXFV'TMDA;!(V=HK9-*JKN,GN,"JLUUX<?XC!5#"B"*8B.T'QA;SZ_&>TE
M0Z-7/7W7;3O9GKH#A1F@"B0LYJ'M+4HC81-NI;4(4[(:J5X *<09=8+QY@0N
MEPJ.'+D.KPN*W>;>H7J-EC;":OB*GM]$LCE<LU%BQ#=[X>MM"(*O7L0D"IV%
M]UE<;3:X""5+B;52*J;6ENDL1L+U5K5[K\$7 YPK*=3MT QG0ZS4:YPV:[06
M%D06XV&XID:S-H=%-I='M!]WMX]@3FN:RSOWINSULJ-1!;=W+O"V6#=Q6V+>
M$#8MCVC!?.%IMZQ&R2ABA*H8T;.FJ&1!RL1WY[]RQ>KV:T:2@IS;.V\>>#MS
MKZJJM=8HIZLU^>J"2HA]CR*>IT/LR9E76V0A*E@J8*ZFSL]?MK+0&MHO#/BN
MGL[UA[(ES-D-<Z]TEE,UZ@O:LE&I71$.-4E+6.F0O$Z>=5=H:[[+&NQMI0%@
M4Z^=(.I>FQX)4J:FXB[GJX26?M;!T2Z/:B08C"B\>/&<:(R7W)#<AMV.S\>,
MJM;6V@7>,*H'W2V7V@['>UFJF#05(J"=?$]?,<F;4$80(R$IX.3YGICGT1)F
MO\*GTD$Z_P ,^0L P9 X>^RJV/ S'/ A'2R#@"%G,=,^LYL+<W5G8]^\AW3W
MM.$FUAK6^A];;YJ5SA3R$UBSR2NR1PJ)7U Q[8U^%,BMNPWLD79)*$Y'3A.6
MFI&<X3SDZJP%$O$I.@I^]]'KM;5@(ZI%]7<!?83>9&!7*1F!*.N9/TD8CUR]
MLQFYK]%65,0S6^)F[>QU\P)5#T=[7#"ICGJ=YBR$R!0(PN"+KDN!RN6;XR>Y
M4&Q9UB!L.@Y/70)Y&ZGWL"V6:1ND;:YB%(V*/M5EH4X.@3*K@Y=<A)(/#RK9
M"4NP24PX.61C;CTMNWH;U>@OPEYT6RSPKI]IH%#7Z"7:J6*&W33NGUP)*?!W
M5);6'D)ZC?#X[(J;KNUSL"\2S5F(CQ&%&T??B1*K=K'K2=7#MS,-KM95:X'E
MT&M8@F5&3)8O89GQK]@2&B;SK9DMKK%@LGE2&=T![JSI; YO4T/;X.\K@R7T
MUY3K=PR''/(0+0P[!5+RVUDKA&<N8CT]U- _LU)T%,>$M1=H[/HCGN.L:_?U
MAFIU3'<'N;.O)$R%<#!SQR(Q,EZ(LEXT(/ACQ!6KJHQ//P&I>L$O,<<](S--
ML1(]R>"">.>8S\M^^,3L!LS<W9O=U(N.M05H+=H.J7:#KY!LJC!0"<-=?->E
M:D7J6SHD,>Q)"#CSIJ6@>2#O&)$13<>:ME.4Y:Y%J;Y:FMHY!06+&MW?C*Q;
MKD4J4_5>*JR:A0BP,$2;RA"6PR4F$2!*Y*'28RWX3L5;&FXC4C8>']/KAL@
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M2E"$)2E.,)QC&,D1$1$1$1%,D1%,D1%,\R1%,S)%,S,S,S,S,\S/.:"(@(@
MB ","(C$"(B,<"(C'$0,1$1$1$1$1Q'IGZ\QFV.,8XQCC&.,8XQCC&.,8XQC
MC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQD=.UUVVOKK15UN6E)FFH.Q0;,"6%>
MWY:95+U@XW@E%00C';-$QE8I^7!6_'$OO>D7)-R*B2I+*E9Y5M-:GL$N%2$V
M%B\6'T,)!0?6-7GX2M273*@/X3X(9XF8F+5127$X7=Z.*SR425]R >(<J.Q$
M?%%42];!A$F*^9&)F.,BMX_.W6W>SLK9$79P8/%52&@L=DU1J0=SJXN5ENRF
MR;5*W+BRV.F[':'NQU1ID02D26%J2W)GCTQI;"N=0DJ\C%H>\,G;A2@LA-2R
M2(69P^*;.3;7;,1*[2&-K^ZI*&\#G*[K1NC5.%3Q5-K9K%-I"W"U8=@[8< F
MP E,E4>L'D,]T.I8'.1AV%VZ[6:5D;GO.TB)FNQ[BSV$']5*H^WIJUZR(2=?
M3B[U:G'7:3 DWX;,&44,N[NLG[D]#-.-E@L]D//:A0U4*<2ZK1J$TRV>PGPS
M9LE(#UZ[7>(/%7AO06W4R#IIV':QWB>E10I@V@M",7X:P)8(VMI9K4VVKRES
M&NUX;9*T&V?_ 'ALM+X4W&Y.O8,098JUMC8T&P9+HBN^D1IIFF"^*?NG[Y[:
MC]]N=,?Y_P#S6+.)M^C;_=U=04V7-:AZ5(7UJC.U9L?BE*4[;QRT/F/M"2":
MJ[B&A>27H5Q.<]REM=BD5K#PZ?B)+:LD3)VK-8?A,J!V3+XD#VO$C8NA4)!-
M.M6-,UA8P#DJ@-IR*O48,N(\(&QO0,Q6GQ"SQNNW-(>J(DESX5KE4BU%J!BQ
M:A@NZ%R&-47NYV=V-5Q^^$78'7*]KFQ=)J7<-10Z6#E ]CN]AXU$_F-8';)/
MP_9P,N&[>L.46(%(QH450AE)9LHW-=;:Z(UZX;*G)BUE#?;V]J:E62B'ZBK&
MHK6:+B8$B3KBMA:$[Q.ZD%KU$M5<'?XJ;%_6NK+N(&S^/IO#>UWCWPB(F_9T
MFZ\14+2#$B(%U+=/P_\ @=D%N3;M$PFL6 (B?=.\A>E+;V0"=5Y-0WS1]IVE
M>PDU!>RM(WRAU"YLZO99D7"=4;=8AD,-8A\&/*A2&IHM^1'D,SX+B%^V6Q[^
M9'K$3]>)_GZQZ?I[_G],J3'$S$_*9CWB8])F/28R=W&,<8QQC'&,<8QQC'&,
M<8QQC'&,<8QQC'&,^29 @D&VVB$*).::>:DM-S([,EMN0PO#C$AM#R%I0^RO
M&%M.IQAQM6,*0I.?SQ'I,%$S!#/(S$\3$S$Q/$QZQZ3,?I./E,?(HX*/E,>_
M$Q[3'/KQ.?7C&,?C'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<
M8QQC-7[KAV>?J78D:F6Z;0[.JI&G1%M&BX!DD$DQH3LI4H</)I<@.SU,LN,0
MW9+3R(LAUN7AA];"65T=D1A0ML C&55GMGM3TL*%I870!\%*R*8B(.!(A]QC
MJXF.AJNS.RI"](/4RPI1+81"'+2A8F?3,20J(H;*YF!9T=LYZ"+*$'MQ[6=I
M_6,G:=L;+A[9D=:.KUCT,)_6)\3)W)MVU;44&W,U9:]&DQAVPR::DD&T7%V*
M!,CA0Q:>8CL0<I7/C^F[%4?%MJNL1$!WGA>LVJ(2Y5;PQ8U>Q=N+()(F1V88
MIIW-CT]^FZE2CS"Y=T.X7B*'4]-8FDY[+"E>.8$V""X/;T=SJ4^'0\P(J@K3
M09955UHL[%M;7QY5@K&56#[;ZB[/LMI3- #*3<01?M0*W9)E6_;&R*]9*#6X
M=6J0R0_0U,5FX"\VC)D&1Q#&OLQ P<%-DLU^:((DW)8_@:L&4[5 WG^'3M[N
MQ%A,=RT*[UNO9J58%G1W$G N7L"EP.;4_P#=0L.A:L+RUL &VO9R R1W:>GK
MC6:QJZLMI47T[5@Q24P#5]2GZZ86Q2=B(;<T^?J)-F-5#OQN9GR&BNB^TM*T
M>NQ['4;_ 'FNWJJW2['9&:U6$CI===)M&M=UZK/E#P\BAPF,KUJ.2J_*:4U/
M2AMZ.Z[8]XY_./3CZ\S\O3Y?*..?;TCF=_K$<\1[3/K,Q^?S_G[^_OS$6N\Q
MC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,
M<8QQC'&,<8QQC'&,<8QQC'&,<8QQC(*^1-=1QUT1'V+JH+N/69#;.EAFS*<?
MU_8=G0&]?$-F5N+;K&FGU6$2/3IE8"NRC<&0/'SG(,F&W*5%?0VIM4714.[K
MAO1$([UTQ9VS,E7%:?9,UTB8@?8EM\*]:7% @(/*),.J"CIZZ)E6VD+)5V!I
MKS%P+ 7YD@[<S5*#F.\+@@XE \FV8@0B2XC(B^,@_JLML.V,Z:T"*TL <T^#
MEWA([36V-8HS=8^QK:-$!&"6RQ0A)2(BF1Q1A X0W*1!?(.NNR&\/)81;K%<
M;K6,M%(B:/"E@DRQ?P[FYI+3_$:>WUFY@ZZ_"*:W3RN!^$6N*>H?/G*O/5Q%
M(BX;'C%$F*SF/N>GN]<CPU8AL#"5GL]?+KKDB761Q!2M4+Z9GY'Z5=:&"E\)
MJUI#EL['&7(19*\1,V,E36X6QER'=@_IRESB\BK4^7=WY<J3:B%5$AYQN1(?
M>G2'7'G5*KB/15&F$D*5C56DA(H?61197=2K5;4%%BM5I/J5;%2JAH(K6*U9
MZ5@RNH@Z)L(WKLE 2U9F[B0"5-L,6Y#;-FO,=BS9;7LV:SK#UL<VM8>AADIS
M1+$E>/?JJNG2*4Y1+ [%E655MD65W9NSG=BN&7*WFF.*_F:NWYOR1[E.4NJ+
M#IL6!*J\Z\*S"^E=<;5NR9::#. GL1='IZ!A=@=DQ+MB-U8Q 7QO.K5F6QN"
M\7E5JR<3-9,A$$='5TS,>E.%^L\UON[S'D/)SSS3\EYRYY7RLJ[/G;G1,>9=
MUY&_T>ZPO6ZCW1O64:"2UY'H<:MBQ1^T":CG&K651]:R#M)'&HU2M,^A-YQF
MID+(&*S0CK;#T%]IV.RM$H6'A>N;&&D5R\ZU:>TXAG%N[4\A<N) X)=:U:H1
M%)UBN"FG5B$2?;@1C25+*NJK(_@IKIIC$$<,.G7M3>14>Z"[UBLNX1V10]C%
M2YC6$,DUDE 3LA&V,UYI?&\^>)T^1K=_4?<M- &"A9>-<1Y5JD:V_5[UJ*2I
M[X@E!F.*$?I]D7 @OP4,$,$'9>7X^6H?3^/I_+U_<?QR3+K>,8XQCC&.,8XQ
MCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.
M,8XQCC&>,_MG\YQ_IQ^_$_\ 7^6,ZQ?;;N3?-?=I]K4G5'D5*;#)"+(ZT5ZT
MBDZ/T,WIU[V06L5A[?NWZD6U[*>B9=41?:LTM!)^*IV-%;D3$>F8M))6A7$?
M^\DSL205^&J0/$WS6U$5(X;<&DL3K&%#FR\U"(1##(HDVD F"DC^[F34%D5I
M4UY3(U!,72^(D*GFRD7"5N(KJ$R,I)<",]E.IR7IU7K\N6[]3(E@Q,F0^J9!
M)?.]('QGG7ON(UID:0^1U:U_6CV68,KW?/$:;CN-H3=N *[=I8CT@%EX"$K:
MKI$6D(CVG23E<#$1*VD3 _RF1'$S-&D9LIU&&76;*M<R+N*=U&2A(B[J1!+>
MJ9Y[BA%3/\RQ$9B,YQ4:,I32E1V%*8]?@4IIO*F?7'IGXLY3ZM^N/QGV9Q^/
MQ^W*_P ^?GQ,<_/B?>.?I/SCYY:^7'RYYX^7/OS^O/S]\_;C&=>*UL/(_B*-
M7R5+CY9?ZNWAMMM \>Q(2MJNUWWK>(L#6"$Y"\*3AIF<3G(C>W.(S$5"\Y6^
M7\8]O?Y_PX])Y^>8^?Y\?O\ G_7C\L[#O&9QQC'&,<8QQC'&,<8QQC'&,<8Q
MQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&
M,<8R-/;.D;=V!IR>"TF38A72/:*2>>$R+:4H#=VK%>M8HS:]?JO@0>6+4S%T
M!0YH+-A@#)KT%,M6%,_"ZZI,?)+LT;$*&RNM9ES*QL)2VEV'+JM;(Q,/31NG
M6V+:)QVMBNH5!Q NP11.GRY*O(L$:_-:^U64Y0]3$-<'3!!/6LE&Q?<KC9"9
M;3)T7$@QJ  M ].NO_8;5&Q]AVO;UG<(0;E5*_*LC/\ ,6P7F!;]P%3!2R6R
MTUT&9B1(FO:E3X!*'K2K#1R6)-E!A(1<L+%NQ(K3]I4J12=2$I:M-FDNB;$B
M%A@4Z1HVFXM-AC"&QXGOL#8MUD,=7U)5NBNXO-,!=.QWGWTVXZ5 2=@=A(='
M; ;5RN6FU:^A:X:/AS6UBISL>VD]HZZ][4"2X,[%.0Y+CC&.,905O&9JAWSW
M='X=9'7./MB)H[LRYLTB7%7Z+3)X651*=^A6JB5.-(H1.;$;9.XL35(==(07
M'1V+1['7QN,Y]>)^G,?KSZ_+&7Z\QC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8Q
MQC'&,<8QG\?_ .N,9H(3VLZOGK! J8/L;HHS:2A1D&,K8O;5"('B!F1)^CCB
M80B*?=GRB4B7Z16(3$=<EZ3G##3:W<^SC'/],W[QC'&,<8QQC'&,<8QQC'&,
M<8QQC'&,<8QQC/57_5S_ ,_W\Q/^W[_?K]/7&4#[@/=K FQ-IAW>KFZ[[!<L
M794?7KR# ]=IP0I^NPX=CKQ.%%K1?0UDPW5":)WIB9!A3ARUX<^ DCXTXBJ]
M3JJ%P!UK):$:!$W@2^_P\7><;L))),F5'X<@TPV"DN@H"4 V),:%I.P&VQD6
MEMJCO;%_H7,G!:!OA0J=>AT-0,=Q7B&0L2GT'K#K\PP.5'< FU6[5?7$9:SM
M0LE[O-+U8!FG:>"?"9L1VSC:Y 07A-3"!(<":=^Y(DNSY[D]$1B.U*ELXD^Q
MIAZ]XBM5E7MU;UXB=.+FP?3CDE)BI#GL01$P9-:H3 R1$)L$>/@(N!F?PQ2M
M/IZ.CL'0BZ=*@FXUWQE%N*RX</"1(3<Q\$L('I432'J8M7+!@SGR.VXC6]6W
ML'J"O?H^9IW3&Z=Y,EKT1CV2D5S>=QD4FL#:#&AU.6*NA8-/@%"1W)<C5XJQ
MT)+0];TN4TC$_D&#NVZHBZTCM-/H465#'6[:[JJ^TDY4P@$-?7A:0LM[A6?\
M4!*K'*FC&NUL'JM8S86$$!+5XCMD!&!!%;PS>I4[J>I4LF;KHNPQ P/E>4F)
MV8@P/-^EM^[M'E;7$;I=*>B5[M91=/-O(Q<WWI&JK8(K$URTL82.:9FVJ++.
M.MR\I5#JPUEA["IY!Z+E,GC4K'?9J0<!A%W;[_6VY 8CM#K:&RN47*DRB.T\
MJM9;WN@8Y-@(612J2LW>:X;<DR)S3U_AV[3@YG\7[SO:VKL0=TCS+*X6;9UD
MHZ^86AEAJXEPKJ2'[5H&U?XA.@2]>F0-G'UG0.V*J9L .>,F)Q9P P -/5R:
MB/>BQ-B;7IK2HTC$[7]/9^1Q2(QBR81E46WQ\/K'KS']?Y^G,>_,Q_K*/69G
MY>W^_I^YYYC.RAS&9QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC
M'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8S"MA2=@PZJ0DZP&
M4XS<65Q%P!M[-F*Y6Y4?$MG[DB69! K(1A/_ &_ZE4%Q :8SF;AA$G#<=3CJ
M-"DH)4P,$N&CWXZNEG9XGJE'/ $[GIZ :2UES,$P(]<V&!D6Q,S!]IG8].0F
MQTSV8=Q/4*9/B&FL38(\D"V%$#,<NI5WN=K@;$=MHJVNI*[%N=F%6&=;Z+?*
M+#AR3L@,]0:/9JD65/?@4^<&F,*A'JZ&G05/NQG_ )9#3C:+AP'E*' 2LUTJ
MQ3+0D'W5WI=LD7ID28IH36M(2+09 FH$& =)STQLDAMO"8$HZNB95,RI#*:J
MU-R3$Q6U;F.6UY!(3'7+N2'@8+[=@]V^OFLMF;#U-:K3/:MVJ='D^P=]:'A)
MQ.  H TK%#X:>F0\.YD6DA+FQ5"ZQ$9?)RX[[#WL;Q*BX>I+9WE7FH$G31OZ
M75FM?$L?LO$#K%?64:W7( Q[WU^R<D8*0QZ(<T((Y \UUGZ]%DQ1.QI[C8K8
MWD4HU^B"FS97;3..$UT+N R"X(C!-@A'A7Q:R<\C&IV1[L:3K/?<;9C%A> N
MZ*>H07&WDQHU+5L619TBD7%=5<JS-(;=L#A-JX./>C2PJ8:K)[0V9&=*I&98
M!K =@5]Z^HD:F-2RBG8QL#XY$JS-IK8Z:T6BLC?KMIC83W&+D$2,>0&2)@:T
MZBX_YEZ-Q.SC617&>.U-N=-M8&;LU!5-!T6"3))[O*L^1#0$\]3X(./L*Q5.
MU_RA8F;3#5#+FN:25WTQ#?U("O!&:3@V 47N'W$8TTU K1:*$=*#\6:6$;DH
M<Y:"G8/86-=(BMR;=V@DV$/8OW]?0C:6Z=!H2</8JA,6!:0KJODAK5[#;DQ7
MF-LL3758.O8GKIAL7IA1"^EKRNV==-VVL^F 4J]3M5[ *)UBOY=KG)"L$NR'
MO8]6S<^:?QPIL+-&1K#&H^Y"M=NAI)]R].%\TC6WZS3<HTV*W7F!R'<!LUE8
M25)E/(62^ZH8RB)ARK\OW^_IFV77\8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,
M<8QQC'&,<8SHW];/(1W9M?GI+:K*:0I>:P3VJ4T9;]7#]7@Q\W6^HZ.;M1@#
M>,6YJ)B9".5A)B1=YMDD2\-6EF8D7%;2W($(8WZ8Z8GF>?\ 6?Z?G[?US6)G
MJGF/E'M/,>_]_P!.8X^G,YWD.:9MCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQ
MGA6,YQG&/WXQE)6Z/'UNR^WG<9(AG45XJ=BL=]N.NHELN%T#%+)L?:D('3 =
MMV(RR%*Q82>L] CV'^6 FMOSE6(HX,>CKH\R-))/Z4A*O5J*EIKNU8\DB\L1
M85)3=T6_V7B.N$2AT[V["*&EBO#P4%%+C.Z27133FQRQKC&66*[G#>L5''"U
M65U]4W54O#!](-@-&%BU9W3+4<6)NF"XJ$839.WP%3GHNMQ%!L)R?97X])@5
M$Y9)6<,E#[C0%H*2-2%8^7#,\HK#\YU6,N_'(?5GU<],Y58VLHV;MD4(BK6V
M#;DQ65,0-=%HV3"%STQ$0I;.V$P,1$#$Q$>V0ZN':U.NCN]^Q074COL@IES:
MHKCNG!$1SW##K*",BGF8(RGDIB=)\>VD'HVJ1<8ULL97M74VDZ^?K ^TP$!-
MFT[7!]NTTD)M)F17I,JP1P%@2Z1C*%RP#KN94R+*<?A27(V=_--^]';8H K#
MG4K<J*)\NN_K:]FMK]@H!F#&U57:9*YELI(Q2QJ6&A4CF\L=A7;6L1R#BV<&
M4?YIK[FW7N;2G$%)KBK<;52+(A</%8D"GK[AR4Z?:GT]/3_Q],>OK_=G]OWQ
M_=_3E?),Z\ECQ&A_Q#&J1,%F)$B,=9]B$?HX<D*E"99(%7%RY;HF!?S!*)(E
MNHRX].)ZWI.""ORP;M'QJ7$S\I_6/[_]/WQF(]Y_K]/E^?OQQ_KZ<^O8=YC,
MXXQCC&.,8XQCC&:CW[MT5H'2&W-X'!1(Z'U'KFX;%)!0^&\E"T.H IQQ\; R
M[_BD2IJ(68[3COJVTIS#B\92G.,OG],91;X@O/!,\F>^-@Z'MG7UO4AH)19^
MRZB:K]MEV\5+ "C0<,1"V5<H$'R/+MK/#I$&?'5F&1]DQA,.,MEM3FQ#TQ[\
M_O\ 7-8+JYXC]_O]^_'8NYKFV.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8
MXQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,9B5[C4^;3K-"V Z);I4X(1@VG)Z:T
M/#*!3(SD<DV2F//QFX\-V*MQMYQ3[7M0K/HO&?3E>T%<T&%KHE!<=<',",\%
M!#$SS'KU1''$Q,S$<9*@G"T"1U=V)Y#HCDHGB>9B.)^7//IZ1ZY"[HT)Z,ZS
MK%BU/T\V'K6Q-JL1RU64=5;P*LIQPF:)D)ZI,V/'FN2,PQ[;^1@QQF-\#8R%
M&:<=?<;6\OH-9;M:^H/QQ6I5$4:[A7\ DBK7K]]GK,2]_:6]\S(BQQS(B G
MY5*$KNV9*0"W8:;FJDN"XES3A8CSZ+61L6$1$R(Q,<S(S,1#LWBYW:5V-M2P
MN=D@-J ;'Z[[=UZZ1LVMQXRX2MDW[8X/80$M9IP&2E!H (G 1<>5,9E02*1
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M7Q.A%*K;@DNH7AR/#,DI#PY%VIL&0RF)(2[\\533V^N)G?8?;([%6G>BTU,
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M:\Q8:5;1V@8#Y8P=E9UE@[:.0-/E$5;K*&PLU <$0$E3[#JIS5"-H._&KO\
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M0GYH:;&:EL.REMQFGH[CJ7FG)"T,(6A*GE);PK.*&T43]9L$@4"3J-I0D7'
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M^+%<ACS'6T5K*I8!JR5WO-K)<P=,5%';,[,3VQAYI3$SU,<J(ZHT3TDT'O\
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MKFN;5JW6PB63TP_NC>>G)44H1G6AB3-E.:F%OQK+(/0"X<[%9DJ(G8T^@!P
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M3[P(%1MZ1D"(^J0+L7[$FU>U?8.%N;+Y/R=.C6L*K5S(S"JM<UHE0CVH=8*
M^)DC%I(9<)8D8L;#6.'K'PE08#D%P8Y"B*BM9C1%C76F'1ZXS&6V%0G&67(B
MF\QUM-J;RC$KH9#WPUD-;#6=QD-AT,/K*"9#HDA9!E$E!B1"<3U04Q/.0U^W
M*$2E<I3V5]I4JE$J7T#T+E)"))D!X&5$(RN8Z)&)CB.3Y'DV.,9UYK8AG_\
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M'PJWVY;VX78=!]\@X4?P-D1(A]H;UG$_',1>WI'N3UWWA4ZN:K&Y-42; :"
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M)N6=F240(&3.ID<3(=$>I1.<ZCXRKW+2ZY4G(AG5),AO>D>A1,B>VI4F?/1
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MG7ZR%3<=(0[K[?0LV\]OIZN>V)=/'4/OQS\O:<VAU>[9Z8[@4(ELC29DJ6K
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MBJ6[BZ\MEL5_-%JZMN%2!/ >\.LH ];[/F%S4KPM  39F];G-SJXS^V?^?\
MW_\ EGC&4_;)['[^#;VV5:PVR?M^N-1]NNL_6+^2F*I4Y(*X5C= _7F+1<35
MFEBW+W%N$(AL=J96EA+"-K\2%7D1B((MF?)D-V]/5\P6D-YRX?$%KQE5-9Q
M#K@\-:[Q VFRE*H61NL6]&MUV;A6E%5M-3737-:[,XV,SV;:ZL#5;J==J-D;
MSF6_>)7]E6"U7:!ST+0.O>=:G%:$N#8A%AS[*N:6=:OOWYC1NF?,P(W#1>N+
M)8EU;EWK2IPA8[CL$&8V@-O(&L Y4W%,,#E#J?)J66)JZVH*)QF[((-2B$M^
M+@7(Y96G62>N@WW^RU03LC\NH34XF-B?)B39AZ@5VS@VDF6'+ @0@1*8Y(XD
MXZ1YB9@."DHF(&.)+B(XF2ZHGIZH@>)B9GF,NNN?\1=I,/7[98J?U![C64)K
M^9.%7ZVV/6R*11J27$M#WC$&U6!N3:YH-X8R1C2)K4X$B3%CO,.2([>7T)Y;
MG34U.<FUO=8N!3#:SZQ-V"+12$%"9*H##K,@YA9]]81$]1!)B/,NX4P,BLIF
M9X*)F!D8Y]9]9X+TXGB/KQ/&8R]YOMPV*QCJJ-T?4]2&CX698Z\(N6O^W^W;
M23KT%V$S,-1*O2]":^;G083I&"Q.DQCWT4:1*CHS,6F0SE5:5Z,%53FSL[#X
M9Q?K!6KUE0OGCFE<)]F3*8B"CNU 'UF)B)CF74R9..D(&(^$^KJ^7I)#Z<1'
M_P!5Z^^8G*\K1&PUR?<KIWEO^N:<"L,ZKV8SI#QB;*B"@MA'FFP4VM2KEN8S
MM.!%.P3"L 9<696VGVBJ\15PT2?\5F6;.D4R["M39LUW+@*<WMC(V:ARN1)A
MS34E-B)/\0!)0C'H,R43S+AG ]3!$HGXND8F#B9](X*9D>/;F)^<9U52O2B^
MD^Z<^X3+I;B<$GMR9NJ1)=U!V$$[Q(4B1L-9*1:TUT1HV-"&EI"W,MX("5Q1
M(PNZF%!C-(:;;1W?O31SXA3M3VF].J-1+6,\DL-C%U-$4?=X2BRI?D^X$I"X
M';Z*? 2B3YF:T@Z4D,*1UDPA@)9,J[<G,P<E(<R4A,'*Y&?Q/AZY&.N>U,3[
M0>)HQ7V[C<;KY);;4YME;K3)^S'N]V*U*M+]A57FZNU-&'!,)9)ZU-_8DAFE
MX?R8:P*;:2\GX,\2-_;\G%+R6EE8J%4M+2ZPK1]/_G.P=:6RSB(ZCZHF>)DO
M69F;/:"3ZN3ZH]>.X<1^O3!<?SC*(M'=#NIFN.[U;V?<MP;:V!2Z1L/^<5@T
M!(Z7]GY%LFT>>=*/BXAF>2KKD]V ]*0Y&P9)/*Q/FP7_ *B=*<1(4[UV[;PJ
MFQ8V&JH>(*-[L$>O25C6%1I;$EB,/ZH@[#*JV]QBJ\K@A&0 CD0^. %V>D1:
M=<_CF#.!8,FKJ+B("9F(9(],$?5,%/44#'5Q'9-!^13PW0A5(OH71)Y\-<BH
MJL:YNR^EM]+0[6=)/2H@8'4[#/I$O!@K/D19D<;$@2WI#[L=]ME*LMJQSDM\
M4^)7 2CWVW[1<]:POV5++T]>5K8 <?.8Z>(X]OI+Y:MUP?83+!]CE82<<\_^
M:1ZH])GY^TSD'NO4CQ.]:NPS&[J=<^_92\:-D3[>?JEBZY71T-4X-MK5B8C2
M[>/%Z;%E1(AT',*$A;KL^"EU@?\ 4_(['8>2OWOB'[8O$?B/0V]!=U^F55NJ
M0IKJZKL6.$.2X2 FWVKZB)(P<DLO29](],X=+PUKZ-T+ZFVI<!,*!8Q4JY:!
MB42,)&?9DS'!>G$1[1QENC?FQZ-DX%.?:C=AR O9R$M:_>1UAW+*@[ ;DB'S
MB6ZJO%46Q8T2 ,:47PF!F0EP5'D3,XS&;<7CY*/(SR/(E$]42,S$Q,3Z3$QQ
M,%S$<<<3S[>N>B_6/U]OX\^OR^?]\XV-YEN@H]=OGQ*[O>"O6JG&[[-C=3]M
MQE41?VQ)5UNTR&J<A0!7V9U!%Q$]3&?MSJ9*L? O"LR$YYCTFYIC,Q'233(9
MF)B8YB2F)XGB>9C^.8CI^41Z>W'']/;T_P"V9(KS2=-$2ZP/4)[,)GW6/)F4
MZ%GJUNW$JU0X4)DE,E5]G])?(59BCY#$V0Y$PXAJ*\V^M6&UI5F/C]/K[Q_O
M_3WS//\ 3G^F8V2\UG06<*M9LM WO-":W)RP]X*D.K>W9(VBF(S$*3/&665)
MJ*V !"/%FCI$N--5'>;8EPW7$^QYK.=P-JYY6PUS,<3(&03,1[<],QU>OM'K
MQ//SS',3Z3'Y^O']/7U_7V]_7,@8\R/2X64!5*-6^R8TS8AQ(U6JVQU1W/$G
MFQ(U419<J&%M5!#LV! 42@K(2XK2VHZI\53RTYD-Y5J1$9=1D1E/N1E)3/ZR
M4S/R^<^T1'MQF>8B/3Y>G$?7GVSBG?./T18K1VZ/R>P#-/JYJ=6[+:7.M>XD
M5^OV$65; DP1DJJKXACRP\XZT'FP9#J)$8DXB&ZA+^?9C7U]/S_?[YX]/7'/
M^G/R_P!_^GYYSB_-#TV;M<:B.".S*+O,!OV:'3U]6MUILLJMQ9K8V4?C!\U/
M$UX/&(/,P7R#;2HS<MYMA3F'%IQEQ/Y>_'//I'[_ -^)GC$SQS,_+]/]_G\L
MX;'G"Z+KK>;BE?8951P>55LV=/6?<F0/ZF;L&:FNO_=,5;Z7[RFTIS7%#OD^
MJP<QD9EOZO&6N)CGTGY_PS/[_?&:K&>0GQ5A+ZF$&ZU7,3LZN18=]1%&]";O
M!NH*&DBO ^XMIBZX:+#F4EHKN(9QM37L(1EY9D8D-9SCLL\1>(')97=O=RVN
MU1*:ANTNFIB2'I)1K-\@8$$]) 43$CZ3''IE8:E02@QK5Q(2ZA,4J@A+GGJ@
MH&)@N?7F)YYGG-E2_-GT1-5@ 0=QV)DU;9DANL5 NSUHW0D;="!QB6U%$U@B
MU5L-EB!!F/-S#8'N./O8CO+9QGXE*3R!D@,&#Q!K*#"9XGI,9@AGB?2>)B.>
M?3TXGWF,L>_R_*?;T_7B?WSD!-#;*\,G77<F-GZFU;V^&;1T_$G3RF"&F^SA
M[-/@VVLF1RYED!%!$F+$BD:Y++O0G2D?XU,MN3&,Y7&^1'T'>?:AXR\1:NSI
M]K?K.H6Y3+UKU])!%Y=Z["^&J4)ATL2N9D2CJB.)Y&>)XU/P_J:%@+56L2GC
M!B)S8>R.&#(E'2QI#,S$SQ/$S'O$QD]7O-'T!(PZ1+D"=YSH.TWV6-<R'^J^
MVI,;8<EP4^>89J*W*@M%D>6$B23#2!OU*LC(STW&,,,K6GP L:,\BU@S$?\
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M7Q>S;RMS6@2O) )+T.HX(6&8W)K=RR((J//V1!LZSFR%?LQ89AH;]$YX]?\
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M)5UF0213"R.1L-JE*09(L>(N0P"-(,"('JF8&8*=7%"'A69SWF1$\ ),%?*
ML0+V+@EH.4M Q!Q 4]4#$27,9*R%I_50Z#K46/US2H0W366LZF@QJT)9B:VR
MR EU5G-(81%2U6<MUJ?- H4)3%RD3+D04YQ'=6C+-N/Z9Y<U%JM4?9$=S7E+
MS&V^IQS:S2JV)^+8JG0K5==7=49BY39%. 6&@ZU%L2LJ&MHAY_Q*<(XF8B)F
M9XB/69GVB/K...?SY]/W&1*O=TZ9S;+6]X$-A0VW.BUD/:QB0Z.^0F!:Y;-K
M5*L5YO7_ .EZ^*(/6T_*"RJ[!K-<K+,R;&(2FX,>,N7[XK>L%)II6%B;5;*Q
M9JT)4LVE;?38Y=L$+6),/R\UWDTX'H!2'/DNRHSB0E$MC5MD$G7K+MO[S5I%
M%=W4*6.)A""^Z4="P.8-C"6L1DV+$MP:L']7=\:ONQ;7=.H-EUQN2RV"7M,/
M)HK(E%ONL942OVEK:%2/!QY)=OBK!P19R';139AG[;#8E-80RSR=J6)A,G($
M%A(6*[4M6Y#T,ZH%B'*,UM#J$P*0.>AH,6<"P#$88*.MJI@@:AD*<I@&MJC)
M:W +%G F/<0U3US(Q#$M4T)); *=V/4"D2++6;E(J5=>MM,#EZ]4K*Z'@+-U
MD#8,#<' P(GECZP6,+8#"L$(41YJ/+2.AX?;<Q':]L7[_?&;9$3>.H.G>SZU
M9^B]G=KM+>WPZ>VR<U[KAR%4K2>DA+>"OMNO4I8J ^W%F$K(D9..%BC*9)M<
MI[T7(=<6XC4"ADW(7,'Y"JNY<]>(KUVO&NIC9GB!@W% "/,G/J4C 1)1JTH1
MY/N\K^\+#:M*)B>;+TH9:<"XB)YZ$J,S*>!B8Z>KKF!S.-.;3ZV=@MAS=B:U
MKDH[?*;4G:;%VN:T_=*N_(HY ZZ\^ J&R+=4Q$2S5J:<$_<GX59-$![[K<8J
MM"FWX\AR6%,[ 69"5 <A$+='9L1#50\).JR0L@)+(9ZS5 C)0!3!S(YNT938
M96.1EBB8#)40N5!J.%L&'JDT%(GR/ L+JD2D>8$IC<.-(Z>Q3?Y=XU?0OT'^
MI\W7]'8JH7%:_6&;9F^9L_V7Z/[?]]S=<YM62GT_UF3^?NF7LS/\;S3,<1],
MTUN_;_5/0=YBVC;4VM5/8U^ICE5EW"+5"):V1M8##"<R9EML->"DY]5UA7SQ
MYMZ99+1)&4X(3(XD2I\=UQ:N$?XFSY1,@3X\O!09BI:SN,:FBMKF2"5-OO2U
M%!+&"RZY3%5A:8%$;FLQ05F0*51WN.F)-C(KJA]J4I'ESAK(D76B4!C760&Z
M0$PDM/Z;G]&J&_I[H_624&YD]!EH2-4,WROE[7&$7^I!)5IC-5[9Q*NHIDO:
MP"LGIIC P(:3:QP-^9)Q!:BM2E-R)4RP#6*"9%,6)F"_#8P*=GR5UU=;)%EE
M%*Y$U+CD"Q=6S$I>2V#(Y$9  @<F) <59[@%#07-Y?>HB\U]05SN)Z6U =*S
ML+);%08M7)SD:UU0F"]S/LTRL-&]BP!PN_%D!!R2-S&B($L4+@6>9B/\YN&.
M&3ID"%'(+D-1X<J1':2EIU:,QYMFFMI0.L.CZ/K6S[$J-"KM4TD7$#])Q(])
M8+3J599XF33@(74-:""9YEFS3PLV97Q(BF#5E90UZ3"C1EQ</)Q&;($U+X,W
M/,EI4M;',80*8]O2M8D1"FNAUAQ\="4):YI H#*-Q7) YD=(JKKAKVF0K6E9
M-4@"89R(C#+#DH7$SRQ[E)""8P!F(X.]]!Z3+V]LJ 3M.S&/($8FGMA4V+KS
M8>VV3SFK:I7=,VX,5UO7Z08,TN #AY#UJZ K@-BK8.S%P)[++RLQ$6O+OFRJ
MI 01M33L+>) 5*:^PED47S=$IIBFW*W2@S? L%%@HGIKND(P*&5VV/\ ("+)
M4VK=$HM!9 #8:IIN@+7(+&#.83(B#:Y3,181++"1^L-8ISK<E"H-3C/:J$2!
M>JWTUH?%E:[#% T,',&5#"HC4BKQ)8*%!$2X([$-*X$1F%(;RVREM$1#TD0S
MQR)2,\3!1S$\3P43(E'IZ%$S$_*<#,$,%'/!1$QS$C/$QS'(S$3$_6)B)B?2
M8YSB;)J[2,.G[5BVNBZZCT?8JBUGW-'-  35;N:E!HD$V=V W+C8@&E*!!H,
M8@0.?49^WC8[;SGP1D83$UJT+-KC%:EB1F9SP(C'K,S,^T?2/>?:(F?3)%J-
MK 4H"8UI"   R1F93P(C$>LS,SQ$?6<AF[O7HY:[+3.UL6_EVI_7L,2U)4PP
MRO74?)DC=Z)K2 ,<%JW]+HM5VBW*-5QKNMS%6$3A9F#%)/ GB$>-*7&F8IRX
MK2:6P5M]FJ">V<V5V:5?S=VK:JP/F*=FG3XN6T6UI;6ID%IP @Q,HH-<G8'N
M+Z:REN-\L :K$.:*$OJVRF*UQ#[,Q40ZHURW7(FHLCL#*XDSK\%UFWSJ$O.I
M=-U[<=1;@.F[9;0\BF0V!%KN$DQC]4S+O5S N+)S<V+$)RQ9H]E&M'H)P8N.
M499G0UH1LU)I(8/HF&*4]1K8#4N0\(:EZ'*,U.2Y9":VK,@,9Y@I^2"B28'!
M :6FERV :FJ<N>#6Q;!$P,9]9@AB9B8*.1*)G<:Z)2W;@-V$Y5:\N]"*W-IX
MNX*$0<V0?5"4Z&3(5R$9RQ]?%"32(Z!.DC67T1'I4.,^XTIQEM28\VS+.,8X
MQCC&.,8XQCC&.,8XQC/[9_OX_K^_SQE.W>:UF[ZK4\?9XG6>@*-3=HW@@]$[
M57-;%#W"@922(FN9#?RDN.67U+EFGB \%>+'62&9C<.9 !F9$%YB/720#:19
M:L+)MTNU$=/ &S:A>G8Z$T'1X@JS+4TT[&LJ:\W7#%GCRL@PV!/9[BJ=P$6>
MRD-AKQL;/A8ZTJDTMRT@MRX1M*0J\K76G%,4EFNL:YN#UB#;&^MML7>="ZDM
MJ]?$=4X.T*N36M<E4O(FU"-F VW$#K3):CRL,,QFVE0L3(\:;]$N/];&CROE
M91UMDLE77B;2<P^TYI,D):#K"5O=7?VY)?F:C6%5L]LB7WTL[9$OI*>=39W$
MEPN%BJU>JK(>.U854NV*JKU?@C_PNP4D+U3DI+RUA77\7.83W>GWL5T^[,DM
M8O'HVP(&D=CRZE)JR92[+&-,5<BY#D $P4JG?>&%I^4=F$E4M,M#2HZ<O81C
MG+:58649OG"]9][::-NPC-8+TL[:G&Y-C%S!K4.LFW+6!,&"X(AF"B)CK4(?
M-H(J@EMSMV)H+L"LT,V,5FSKUM!WX1K.["!(&_AG$R)_#,Y$CQ[F*(0V]V-B
M]?[)BT=9V*EU^G5*<&L9:U4F/M(E4S[NSHP$L1GD6$&WHZ*K/NT"%(PXP?EY
M>+LM%Y$O&>XY8CJWR4!$CXJW*M=TP,+C3+U?A_M!1(/@;JE[*=E%,TDRJ+BN
M+K'TB0#Q%2J;=61-\W2T%&=PILMB5["+^TA96U-B)3M65(5%L6P-LD+IE9"(
ME)%:WSDY?RF'R,&1==W=3;C;96C;B%H6D;4;J&@-F'=@0+[N&[NVB!/6 TX%
M /BJZ;V";A@!]8K;DAVV%(!$JEI535!)*?>SJID=K8,1.Q9=:\-U*ZJL =^F
MJ+6P\S?3#9X6A9W*UBV8J)#%4!&S;IPH2G>_678UU/J=Y10'N_.V;IM'2FIU
M;6C77=&N),-RH1<[',PT0M/FI6ML(Q"X@!,61!AB#@Z2(<G"X$QP3-PG$P6N
M3%:>4.EX1E2,282EYC/X0K*<.M*]N<X].2V%PJP]4-%\+<U<.#GH= &0PT)G
MUZ6<=8\^O$QE:N<L0EDK)4FE9RHO\RI(!*5E[?$'/3/I[QD9>\@4H9ZG;[^T
MV^X4N2)U7?CV2='+.5\_+P(J1F6R+9.PV\F!$>7*1'7)F )0TSA#&&8A&,EY
M[W^>\0L8C47+*BGKKJEH!S\!L&8A7=B.)-8,D6DF9[3Y"$V!97-JF=O2K%VR
MJUSB.BRT$F<1RP%F42WLS,3 -8J#3#NF6(%I.KDJR"7*IIW3;G6K-8,G;A8H
M6_QVJ/'Q.Z7AU6:QP[(;?,V!+.XI&N0D<@RFU22>/J(FT7&XY*2FOMLXL2F1
M>$.*]\H*<^*&@,*\W'VC;=&V6'NKPM&NH%4&RJ.5ITTE.]8)P 5)NI.3/S*$
MB/DZLR7@[2E>-BM:7@=;:UI<D+C\1]3IB!L#RYNR[HZ!:0,BL0BP<)CM6+13
MV14YSE*<Y_?*<9S_ *_3\_\ U\\Y^G/Y?7_OG6CGB.??B.?U^>5%=FH-R!=E
MMWK$;1L$-RS^/W:1(0BWV&Q1=;4&:Q? (>%.BA:B/EN#$0D.S"!2RQ I>YO-
M2'F_N#L"% APZ"EPY'BRDUH+6<> S*R\N)5%R_XY59Z628#71Y:O742EG72S
MM VVSN<O"S/;':>#;!@Y@S'C=)UJDP!MBNCP,Q10'$]ZUW7M)+70YBI,E51
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MN29*QF)84"OF(.2&[7!1&1.*.VI+GROK@#L$E9&%51S$B+;)P*5D?  1]9S
MC,QUQ-0["#&6YHCMG<]LC](Q>TW>*-<;/V!=M.L8!7:+=4HI/68TC\I.*R%R
M)R]>%TNH)FLCP1F+%@"V'C$2%A<HK2&DI0IA^?3X5\4)\/\ 0V7;!]RI]HVW
M0RV!1$LN[\=<517<6!68D=JJJJ$5WPN+\ =CO/-24$?BKP!:V(G#%:Y&NO?9
M;3=>JN67X531SM%JL=JPSL2MVIM6'=ZZ S?MT=GW4GTZZR$-BR+#,NLO2&N'
M[!-MOUOZJG2UU<=E$^S9)>A)=@G1O@E&G".$D'"3TE<U*)*G4XZ^Y@HV=KNJ
M0BS,J*\BK 161LC0HMFFN*IE0H3L)LK4*IE0@(PN9"(F:R!K!-I=%DMUB]EM
M5:=Q&ULNTBME:7I72U\R]O=U0U&=UTRUL%#&?&197CY*]U;6";AZ\U073^P8
M365,[&=9C,VSZZIIN?5]K'K)L6)#G5$G9 LUM*@=>"_)\U7EX;S9+//AM2&5
M0!6,3.3I^7>)=-W" (G9;'7JKVYA==BG>$]U8=LI(YE;NR_LJ0,P0TUU]A>*
M.XNN2I-R$!X8W4KDR.-;5V+'5.LK"3J^)M*M%">F(E<6@A['2'K9EE&@)P-J
MP.>W3^P0J[V[L@26UIO<%]V?>^Q9RU7C61N_%]G:+$,6J4<! -T1[:\S!" S
M4-0RHU85$KM9Q$G#F&!&; -P[.;LZHN[I%*& 7Y?1ZQMZ]4@)UFPV86$*L5F
M$1$\]N]UNS?@IA9]FE=BS5JR*QQL9:&Q:3GP\YVQTZM!XI7L:>KBG<FG<%2N
MV'W;3KT*VN>T0L]Z[L:KO.,EA==VG(,WQQC'&,<8QQC'&,<8QQC'&,<8QQC'
M&,<8QQC(E=E=1;=V> NXJNVZMG]?G]=&*X1T-9 TNO#[T7F-2D^V=N&MEXUS
MJ,2:TXQ&S]F'NX:6QC+KN6)$C"8#6'2[S%?SRN]KW)0+/+F@JE^I;<X#YD++
M96AG9KV.U7-L@#CA,E,65L"(6(?X<^UL%/=(P\; VJ;JZ5&HQ*$*$V<.<H6O
MA1&:0[P+YQ#IGJF^:Z?VR4+5 GJ#6EN.51_5^A2EIA6Y_6[8.IPQ%Q)((BS-
M@$0&+M9&GC#(D66DM>QK!F<W$+F2$1KI,9U50!EB+;YNW;*F=F$E4U]@*@U]
M:PHB.^:K";MZ2B356C812KL--89BA$1+E$JOY0%:ZO4M!!BP;^S7=V5A^U ^
M>Y MIVM?KQAHK:R-;WF+"61S.3E3)LT%VHU>>W5UQW7J>KR($6QW_7-GK0)X
MHZXR-P7(#G4#VR#S3;SC,%^5AN/*=0R\IIAU;F&G/;[%4[RF-4J5#UFB[KKD
M+ZH"610V-6\2A(OA$VC6E8$4P$&424P/,Q.@@@F@PH +-.]2)DC+(5%ZE8I=
MZ5Q,2P4]_NDN)@C@)")B9B8C_P!4=?[?<W+N_?&U-:KT\W?J/HO7("A3K37;
M4:=7JD+94GK61DU.5/!Q(9$I:5B@#"9[Y.0("M3B,88J4U :[!&@*^SA;):>
MV\4['Q (DH@95JOU&BU%:O9.2(&6V?<[+3H1)I2#TJAS6 R1XJJCPMZUK#CI
MUWA36>'V",]23MU-QOME8=4F9@_)DO:5UK)RD.)H/(D@,!)S]Y3SIXXQE86C
MNNVS*5V81;Q&N(NF*D.L>\CNV3@38A2Y5SL:G9!J05UU(C"3ITE80Y:I2I,@
M^<:-"PX^NDI<D!372 &6K+,FN,$T&):,@$:FG031G@Q3M47*C[.U0T1F#0VL
MJW64][/O%X6^BXK\.63)LF>:MB[@K%B;R;'WEURB1UJ]4ZE&L=6#@&,[Y4BZ
M0&:RXUT6%F+7=O+/>1Y'GJM"7$*;6G"D+3E*TJQC*5)5CT4G.,_C.,XSG&<?
MTSS$Q!1(E$2)1,3$QS$Q,<3$Q\XF/28S,3,3$Q/$Q,3$Q[Q,>L3_  RHV^=4
M]N"RV_K50Z$ GQ6NXG6_L/K.B"S0$%BZ4O4E!H(&T 1_RYCB*X;<FBCK@.,;
M7 @RR4**Y)F0X\W$QN:N[L(\)DSNL/2[CQC8N*5(RV*>^H>(-70)$L):CA(;
M:NYB>X/160Q(3W.A<UKU:+H;Q &E4;/7>&@4YPG(>=TOB'7^(+ M$!)@S;/7
MS7%\ 4"ZS#C$A ^98=,=;;!H=1VU8=E5MJDV+<^_]C[E9HB30^P2J6%M+5?$
MA@A8J'6\%?-O0JX@V7:#2IPZ)/+OQ&I\U;#DEW +76U>BUPM!S=90O+L.4!@
MHW[+Q#O-\:U]V!8850W 4Y:0+[K*QL !481FH+.=IOK\R?:VFPH6*X-X[RTT
MO#>AT90R!-@#W'ZESU")ETH<J#Z608C,3D>6LAMM#2-@.]GM1[5JU;KZ H;7
M>\0-Z-N/L#)TT[;Z_4 U.03S!^$V58^$/(@YF1W5OB8+"4LN,_XC'*<(+KWT
M2(DG8>&#UM=9,,%MO,W.OML!DJ_$4+*M8^NR/QQTB S)0$1L\H(O#YQU=>O\
M1C?LL@5DQ5 -+MJ@0KO?ALD;ET9"N7X<FUC"B(EDEI;IEH#86J]@N$6M79Z]
M:T":E&T"QZV@[#?V'6]C;4@'\S%[3K$R:<-F&@K -#@F$9MB1%U-QIS48Z*;
M2*8>7UX:)5K?4TR58/6?=U!R5 [5>41:"^PVIZDS%Z&T4#70QBIC6^<9"WV)
M'*QA'=K M )97;LV7;BI@U;)%R:?W;6&#A;E_=I(NN+J0L +8%71)I7U99ER
MID^5Q]Z*[N/84JOZKI?7^Q7_ %'?:]-&;YO]"LVL >Q2%(;*1GGM* ?US8ZQ
M+' [^TF4S;[+&)9<& G)$,%&;-DDF T=85GL0FX@)IUVZ^Z ,@&5]A>IV&MI
MCL 'ELT=2^5WY7"VS=9,T^ KLLQ8L$4JIRVLX8V#)MTPDE]1Z^E:0I=VQ6[D
M=H[5Y7-17Q"-4EC=9#C175FF*;UOWG"V_2J2YJ^/7]7TWN3;>V+.VDVVL9'X
MJ5@I!6&)UG$JL"6_94V^"</8K)'&8C=79KHE9&(<FY<CC5V-7_AF:YUJQ#GZ
M;6>-M>PR$F'M;/B?:[E]>W7.>)4@*^X*Y<.T*G1<K2A:60Z'AQKU!;$;!-$1
MJHV>T\$;)%9("I6NK^&*&AJV:-D!* (IG0BJI-7NJ-5L).5=DP*X/D>='(S]
MKS&X@>JED=":<"[GVJS80K=7%GB-9'PJ8])5)BR]CM8M$X7$)D*E!?DR!X.&
M6#SC<N0V,P8%PY,R:S"<L[]8 EJ5--BK=U$**Q3JFED.*NII"+GN^&LL#GLC
M#2=8%JDS7=822Q"R3/Q)%(DNF1,6F^T'I8JM8<N")*!,(L&V ,QE PF!=*V!
M6:5ZB7=W7%99K76.UO;)(T?;P2!M&V;@!@-K:XW]LRW8N!+>UA&TV\R=>_IX
MW9G,6C[A37REYJS@N#7A5>>"J::8MMF9? :]R]1$4?#]2A;4!70UM+3/VW55
MMJL##+=D0O':Z@!B=R^_>#9M3TKYA187+5V]I3=MQ7MME9V%2RU2V;)-U6C\
MN%(HDH"FI>M"@*+;TEK*NLH^02V";,W2TP8;"U&KB+,9_45C%UX*./V#+*8V
M3AJ$-BQ2A?,=']EC[E.:?F_"G\-_/[,?A/IR2XU#KEMU9'EJS;+V5Z_5U=A#
M&D:D]7,]7:7(AS\^GVC*=)5A%.HFV_S5I59"K-GI@/,/6H!<_HCT'NL@F=,>
M@]7'RSTNT0O/I]H@@!E<-&Y=?+QQ(BX)>75"9)Z ^W"'V1$=F3(4#F2%-QRF
M&8TAWZ)Q[V,.J]&U<ZU#20R$K2YO3R"G\PHRB8GI.8@N(F(GB>F>"XF?2)SH
M5Y7#ERTVJ5UQUL3$2T!GTD@B2")*(]>)(>?;F.<I83U@[&(V:]V/!Z4G OL>
MT-#[$-Z*L&T0-PMMQM6NXE^KETG:RO)<\4$5?68ZMW<>QJO7)4W60L.0!)3&
MJW39)AU4ZZDUU6U& VS9KKVGB2V@&P$[&O6WWABSI"9M72WHO; [XTG6&39N
MFC6K)%:RP0537SKBK-Q7E)FFGLZ_2):Q<,C7V+.D\24=VA6KKPN&4*OEDW5"
M4I1WKEE96:_X96RL;Z8ZTO.M-2G&]C!H]7M>P=O;BV],IT<M$.?HR)L_8)RV
MBZO*+#O49-)BQI"*@PX*6^,27<G-0)<V,VW,?2*T4--KP8#YU>IKTG/4!@IM
MB&OLO[,,@62I++)5E&P5DT$"WM*@X6&X 4WMS<F6=&RVSKJ0=T]Y:/+U:JH;
MT&P(,QJ]Z1!AP$-@)(B$IF6G(LL8XQCC&.,8XQCC&.,8XQCC&.,9\DR!!(M8
M8(0HDYC#B'<,S([,IK#K6?<V[AM]"T8<;5^6UX3[D9_*<XSS'$<Q/S&>1GYC
M/MS$^\3Q\XXG'RF/D43!1\IB?>)CYQ/SB?3/JQC&,>F,>F.9QGG.,9_&<>N/
MZ9XQGR0H$$<QB,/AQ8,?"W',,1([,9G"W5Y<=7\3"&T>]Q><K6KV^JU9RI6<
MYSG/'RB/D,0(Q\H&/:(CY1'RB/2,?.9^<SS,_.9GWF9^<S]9]<^OC&?))'P9
MCL5^7#BRGH3OSPG9$=E]R(_C\?/%6ZA:H[WICT^5K*%^GX]W'M/5'H720\_/
MI*."'GWZ2CT*/:8]\<SQ,<^DS$S'RF1YXF8]N8YGB?>.9X]\^OC&>JT(<0I"
MTI6A>,I4E6,*2I.<>F4J3G&<*QG'XSC.,XSC\9QG'$\<3S[?/GVX_/&?*X/@
M/2(TMV%$<E0L+3#D.1F5OQ$N)RAS$9Y2,N,8<3GVN8:4C"T_V5>J?QE[3)1Z
M3,=,S\Y&9YD9GWF.?7CVY]<?*(^43$Q'RB8](F(]HF(](G/LXQGYJ::4K*U-
MH4O+>6LKRA.59;SGU4W[O3W>Q6?SE'K[<Y_.<<Q,1,3$Q$P41!1/M,1SQ$Q\
MXCJ+CGZS]9Q\XGYQSQ/SCGCGCZ<\1S^D?2,_&'!A#F$Q8$2-"C(RK*(T1AF-
M';RM65KRAEA#;:<K4K*U9PG&5*SE6?7.<YSGZ?E'$?E$>T1](CZ1CYS/SF>9
MGYS,^\S/SF?K.>DX</)M88)08A!C"O=AB;&9E,^[VJ3[OB?0XCW>U2D^[V^O
MIG./7TSG&<3$3[Q$_K'/SB?]8B?UB/IC/G;!A&FX;+(@6TT.>S('M-#XB&X+
MZ_7*GX:$,X3%>5E659=8PVO.<YSE7YYMS/,3S/,#(Q//K S'$C$_(9CTF/:8
M].,QQ'$QQ'$S!3'$<24>Q3'M,Q\IGUC.5YC,YQ&:^"S-22R&%9)(6IU!#[=#
M^N2ZK&<*<3*^'YTN9QG/JO"\*SZY]<_G/JCT]O3Y>GIZ3'$QZ?6)F/TG$_%Z
M3ZQ$\Q$^O$Q,3$^OSB8B>?K$3\L^R(/@P,/8@PXL/$A]<F1B+'9CX?DN_P#:
M2'L,H1AQ]S\>]U>,N+],>Y6?3',1Q$",<0(QP(QZ1$?08]HCT]H^F/>9F?69
MXYGYSQZ1S/O/$>D9^SS+,EEV/(:;?8>0IIYEY"7&G6UXRE;;C:\90M"TYRE2
M%8RE2<YQG&<9SCB8B8XF(F)]XF.8G^$YF)F)YB9B8]ICTF/XY\2PXE<6-"<&
M#UPH2VG(<1<.,J-%6QGU87&84UEJ.MGUS\2F4H4WZY]F<>N>;3,R4%,S)1/,
M%/J43QQS$^\3QZ>GR]/;-8B(&1B(@2])&(B!GF>J8F/:?7U]O?USDN8S.?&H
M? 7-017"BJ(-,JCMSE1VLRVXZU>]3").4?,AE2LY4II*\-J5G*E)SG/KQ'IU
M3'I)1$%QZ=41/,07UB)]8B?:?;$^O'/KTS,CSZ\3,<3,?29CTGCWCTSS&'P(
M2Y+D.%$BN37LR)CD:.RPN5(SC"<OR5M(2I][.,>F77<K7G^]7'R@?_+$S,1\
MHDIYF8CVB9GUGZS[XGUF9GUF8B)F?>8CGB)GWXCF>(^7,\9]?&,^&2+&S&51
MY8^%*86\F2MF3%8?:7)2K"TR%-NMK0I]*\87AW*<KPK'N]?7\\1Z2,QZ2$]0
M3'N)>OQ#/_EGUGUCB?6?K./_ %1\BCI+_P"F'B(X+ZQQ$1Q/IQ$9]V,>GXQ^
M,?T_NQQC/S<9:=]N'&T.80M+B<+2E6$N)S[DKQA6,^BTJ_*58],XS^<9X_?]
M./\ 29C])QGSLCX$>1)F1X41B7,RWF7*9CLM2)66D^UK,E]"$NR,MI]<-Y>4
MO*,9SA/IC/IQ'I'$>D3,E,1Z1U3[EQ[<S\Y]YQ/K,3/K,1Q$SZS$?2)^4?E[
M9]G&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC(<
M;>[EUG46R;+KR3JO;ERCZ_H5;VAM&\4H15B%6UQ1;*0LT*,>.QR5N$VDJW!8
MI]@)$XE3KEAGQAT'+C<5]]UF.N1"R?U&<Q6K^<#7!;?/X)WF)KN%$0J&M >+
M=43>U2ZZR=!,8*EM8NPVJ]5:K8 ._P"<\YV*Z9B7E%&:\.X ^@)*8L#V5"9-
M=(D"PEA+ \TC]P^K\FPR:FSO'7JK%#8KTB4+R=8;>:1:B8 *!1\CF$QW'YQ:
MU5L?F*T\Y)B2C@MF<U&5,8PO*T-:XT*63'!;;1E8<$4VD39%R@B)_$E1T[2C
M-?4N'(-'7+HZ)H'92L%,8?0+JT6PZX(9\N2E/@R&8ZES%=R[!+9 L&M)6""$
M@9CRT'M-UV)['B:B';BHD[9<Z>6%QJ;$.1Y!E1,'()1"8YQEK*VX\^/)#&&$
M0I#K4J4X))IB-/Y@2_AT4!OCJ2)-#R_FH,(Z@-'O+%G'PL@1F&' 21 F8<<0
MJ8.9[/\ A.WYF83W6BA?7,1U-,%&*YXF>DBAZ1CJZ8EC 5SW2@,TY;^]5"I.
MU;)KLYKS:#-;IVQ*)JJV;B;@5%>N -YV/$KK]4$RVLW%%YD,S)%KKX^04@4V
M6.@RB&')<AJ%&ERF,TUE<%)\A6&V[:UZ!62@(NMTXV2NBH@[D*Z8I6Y6=KL
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M../E[_7G]?K_ !QGMA",)PG"<83CT]$_W8]/3T],?MCT],>G]/[N9]_X_O\
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MJDZM<U'@%6E5;%WBK4;2\L[AQ9>A.MVVNIA K)A>8MM"\NL*C;"8$FO-PL!
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M/0-<;#LUD&UL2_K<=&#QS6T@D)TX"GV"?+'TI$**5CLC<EY27VV;-&C3OO\
M#T*V(A6\5%:HZ0F(9YENYIQ:!U6V@9E=6GYFA>JKN^889L1)>5$)$CUV$OUZ
M=\3$=VQX>H(W-]:F 2IU#QKL%B6S,$R_V+ N\GVH"!Z8.R,E/1G&Q/+Q9*D7
MVSLFL]4['<NF/7S<F-$[J[$_S(K0.SB[I$,!@5D,4G44N _/M],J!$^-9,E)
M%D!3Y/NDY%#)BF,H5!JJB[T:$K=D* ^*['EO#LR#+/F);8?3IV+\+&/(U+]J
MLY==PS9,0&#>E7,C$UU;*\[%51<WK6HH!L-BD9BO$02 MLI4FOD1M7T5F+EB
MS\O7EI=L;,C'<R0>@>]NT.PW:G=^BJ?UK6QJCK]L8C0[_OZ=LT8R-<S+I0:T
MTI5<I3M?;-&C1F1/E1[ ,1+CP:R,R')_>2;Y1P;#Q6IPS63L[+@JB;MO0KUY
M$G.L;+4;6*5A4=$0"ZGDS"S-LRB?-$5,$,A9V(QLI72OU-?6*;C7:K1[FR<1
M"0J4MW2L64R4D4R;8<GM+6$%+%BUS.STJ%L2^R'9?;NU>S':[643M29Z1=8>
MD-0U'-V?LW7^O1>P-L7N^[:B3"HUB(DU6;DP$I8&#':AR&A-8*%"\^6E:G8T
M=IS+$&NA!:Q^ZMD1][Q':\-:JD,BM7>UU2E8NV[K)@Y.6G?4JJJ.RH 6;6L@
MN(*S:2X+>NUE1"V/?HF^(-A8;)204SLVD5D50ZUK$@"C8?8:<L9ZBI:I@P9G
M)C?([8M7:EZCB=*GY?D[L?:#9.X-8:]V:S]FZ_$YI?7T!\C"AW$=-JT8.RD-
M)9DBK=9$B0&8X^"\:BA24A2(<GINHOL[,:,T$ZMT^'&[^6=\V46UJUY"F6(X
M*RQ ,IV)(%J*P3+B(0*UC9ZD4![%;7;38NO&Y=/?Z?3+J2H)MK=MZ;B"O+(E
M(/:%FK+!(P3$5[@PQG^%(VY%M7RO;6HY'=12F=.">Q]8]/AU=;[G7N#N&M!'
M==V^76!EKNM0U(#* TN[@EZ]&3EK,3GY=)B3U)BH@94J6GV5%(I% W7WIK:2
MYO+>CU&P96([%PJMT-?.QL45F4U-=-MRE$WOO</39,4G"/CGA%LSKZY25MWY
MZ>IN;6N%L15KJN(=914'80)"Z\Y-9YK2*( ?P1<Q1-B!QK<'FQK6I:)VNM3^
MEI!\UH@UH%[556@7)U$[>NO>Q-7&VZE76'C%4?EUAQD0X<62#(@6!49X(\E<
MU*%+<:Q%)BRURK,BJPSQAO/">Z4!0R-/.CZK=C8=TY2%A!:?M;'I*:PA)D@F
MS"R;BO*KG2RJV&5K/A76>)M8\X$(V+-K8'7U]0H!,R&\6U--$ ^(V%8KD*Y)
MP!.H^^_EJ["56L[P1TYU?5"0+25QZK 36\K+<1CL.67WPN >S3!E'(5>=!FN
M/!R  //-MV!2PS%H4;3#5D:AF1:UFK:[::9%T96%SQML?"P4N9@]JS416796
M+QX.BE]UMFE-N :59M(YD#EG 067H#2[6\HY(D_9_9\8S:$)->IK-"S-:R2_
M5>QLUE5YN?=@FN; &L3,!8!'^.Q>UG=77_D&@D@W7TK?;N_XXT[ NW6H7V'A
M#]1:_.B-I9FG+1)MY,,V(-EOLD-8,*1 T209)DB48:]B&(Q+(L0KG75*7CQI
M/)^NU>S\*6"V+:YB^M5^ZMJS85J-698PWFR)="H8A5E5$FN:MD)4=JS69;G[
M.P%@5[FR+QS3&DJ8@M@_S'A@-9;MGR"HJ5>H@8QAM;3+8P%=3H-A#=GU4["U
MWM=UXU+V(J@<K7@>UJA M$8 ;^%14'(>6]%(B)KL=2H\AT:2BRX?U3&<,RD,
MID-I2AW"4MKKRU=YM.7!8"%UWHL ,@+ZMRNJW5=T3,RLF5WJ(US,R!R0\EQS
M/-U]R+U:7=N5,79NTK"IF9[5O7W'T+:Q*1&3 +-9H@SI'K"!/I'GIB07.=EW
M'&,<8QQC'&,<8R',KH-U7F,VAB1K9;C5Q[#ANU5A3^J;:CZ[>=?=AOB;EC*#
M:<QTQ7($57V*-EH [\></#',*5C,]>RZI]S=@H#_ (?+8EJ?2"\K.U5;3>F.
MJ)AO?5=LCPWK@(9ROID1F-;(#<+;%8CK+>5-=1V<\R,V:NJBN-!?P\=KLQ51
M\2>V1]'+)*2+GE;?T>ZQ7YSL2Y<=9Q+!_A60ZI"WFU/,V!QBX-4<<V+JCC3*
M2B&Z_*"QF65Q)==2+DIELM3%.JDHP[BO$2%)&O61KK5ML_>(%9D#$[2R58G6
MUO&8<)D5-$P,,A8P$B(P)G!6ALN"T-N"B7CKYU<R0B2SU\@Y95F**)4Q9@]H
M'U@1&)\24\1Q].J>EW7?2]D!6^ATPA%LM=U QH@:8.7"X6R8K5\>P3+0W72#
MEH.%\E%9-$)<EPH1^J*K:<Q#5,^C::CHM/MNLCM =(&&Z9KF[,.TN MGJJ+-
M=2(P@($974:Q1]$#WY*6/[C9D\H*K*1&OA(RO[K/9,H3!GU5RV]L+UZ0*2DN
M&V5+,!F9% @*T0M0B$:EU;XN>CVE]F57;NMM,XKEXHMDL5IH\Y%VOT\732%K
M&E11V)5JV3L\RN 0<V*:(K4 &"XPAN4^F6W#3(99<;D1L;E>O-93R[94/NPR
M9 N<RC!5B77;8;!O8*?)H%$FPI2(D*Y&&,@IGQ%AMAS8@CM6@O-B(Z%^;%KG
ME8!0=*U-<UYG9-8#-B8"&R8K7 YWKKH!U$U42["E*7I:N0G>U,J7*WQ#(/E#
M@F^8GN%GIL.4(-3YXT:-EOG"LA\:'C0(2WYCCN6?>EK**93)Z>MH2]=53:3Z
MU68C\%DPJ (&Q$.B:\(5Y7AG^%Z(E';GF<E-S3V9;B6%&P)((EXST\K'_-^'
M$0KK=Z>9/HZ[/2/F)9,1F(T'QF=,M:5#9]&JFK"#-<V_1R6M+I%+[#V-99"M
M?%F\M3:=79UBM1.93Z^M.&O8/JSPAIO,:)E&,?2Q_CFNV7["GY"VPG5RM5;K
M>>(=8M4G=^JZS8'A]@D-ZB"',,8[CHZ>&LZHD"%6^O95P!-I";%>O(#$*K(M
MB(655J_$H0#Q!<,A2QZNVOUY >-KO]-^N4RPT2S$-<0BI+7&ESG7JJME21DD
M+C:ALD49"-T\@'FD'AAF*0B"(+#\PO%FD?C;7A,M/RN94LV77&[Y]F1<SQ+-
M6=U)+7TW)IVK-RO\$# )[=FV]L2@5SR<1,\",1BF,:^OJ*M*2KIT3";JH690
M=5AUUU2(63,L.90H _$(XB!YB(F9F==Z+\</37KC8SEMU1IN"*/':V4I>9IZ
MQ6VZI!TDVM*R]+J$6XG3L2G50C\;3<P#66!8^0PPQ'=94PRVVG9]RS:HV==9
M:3ZMT "]#H%CKX*$A4%ZP42^V"X(I 'L,!(B.!ZYYS,# VDVUQVG5FF^KVN5
M*JO.9DWUD!TH0X^9$FJ6)]'P=71R.8OK+Q7=$]06<'<*#HV$)/UG-V9K\J5;
M;P99"B-AU^;6+361<$S9)\&!4I@8D0CQ:Q%CM!1KTV3,'PHTQU3_ #8KULZM
MFH;C--S6QJK<G/6VU2&S7M %AY<N:U3:J(58,Y>I0=E;!41"4L-,7A8#A;5W
MU;-7:$5@FZJ'P+DJ"(4KK*RUC@ (6]G0;A.5*Z-K]<NCO63J@9MMDTAKK-;L
MMWCPA]ALA>SVVZV!\&,>?DBZS",70X>(":N+D27WX%=%OPQ$9UW+B(F%)1E(
M[UIE4:9-F:\-%YCP,'8L N4A8M-B.[:L F94#GFPQ7,B,Q!%S6-*SL^;(>7"
MHTJGF86A+6]YJJR8GM5UM; L8*0"#(0DN>@>,#WQXTNE_9&[$=C;4T^W-NAZ
M'''6P[5K==M?R;R-B-(CQ1U\:HUBK\:YPF(R/I&V+$P12F*MR-_V+BD9@JM9
M2ZQKS J8[S#*QQ#:IV)XY>55D&B7%$1!L[?4<1\4SZY9:UCA7!G/6I?938'\
M.TE,290I5L.FPM<&9&("V!$N)B(Z1XV_3>I'7K7UXF["IVN!H*Q3],U7KX_B
M+,*J"IT_2GYK];I3%=?G.@X\ =DA*;Q(:@)G/QUX8DRG6D)3C>S9?<5MDVV3
M97O+P;':BZ!9YRXNHRB+6243,1Y5IJ( Z5E!=1#)<3E5%=-6--%98UX\/5+=
M'3PGD(I5;MFM<LJ7 S'5!V*==D$SK,)7P!")%$Z(U?XM.CFF[H'V#KK3.0-I
MKF;BW69BKSL$I$K Z^"9(6R@:V(+6B<) UV7!F2\1P0N%%&0),AR9"C,2<X=
MQEEJPZE;U[7&RM?U9Z:[USUNM:XV(9V'V2B;#.W-=0I83>XE8RM1B!G!3'$,
MM(N%$0^KLE;>MT1"U)V*A>,65UPZ4"9Q9;W8A?2Z9&604K"1VI6>C_6BGA^N
M0"O:^7!%=3C)X_H>-FRVB3^BRME@FAIJ2MV27>>/8F0[ 5:^*PN$V6<R?>PA
MM;32D2%?M%==L29$VWZ6/#[6R <%J15KTQ5Z.GHCA>LICW8'O3VIF63+#DHA
M2 U64QB8KMV9;ABXF8ZM@5JS=*Q)?YHYLVWL[<3"_CZ8#H@1C4Q/Q7=&"H?9
MH"3IC+0C;&PH>U[+"@7K8(UD7L6#/(E&;?1$P+1'QKDRL@7)2I,JC_852W9;
MN9.'4X0E%=36IKZRLIA@K3DZ==,%/=K+L)BNVJ+_ /G%2-$0GR9L*M"_2%1[
MY9:PG6;]QO2;]HA-?8$0!(6Q0X+"6N5(]HK0/6MT6^CS/< 3ELS&2"ZZ]4=#
M]4 EMKNAJ1BCB+S9L7&U1OOMA/N&+-]G' W3,F99"I>;F9*@"H?UCB9&/K)2
M7ITG#LN0^\Y/8O6;2JR'&,II^9BJH%J4"!MV66W L5 $"N7,*0#CI6/"UP(#
M Q7%*Q83HB9:::Z6,(B,VC57*U$TC(I-O3,RQI3+&E,FPB*9G/(;JCH0'8.P
M=EB4"%()=I_H<;W04(%BXV^LCZ[(J<>--$DYTH:/B9 2I$!^,)BP&9"'E./H
M6[A*TTSB&:P=0?Q:\;=V\*)^5O8DD[;H9'#8)A(20Q!\*(()4!/KEB&L'9IW
M F0;%%*AKDV1F1D*FL;9=25"X_"_"9;L%)R$FV&=+2,8&(CUK_Q5=%M7+FO4
MK2V1<LAKO8&II<^1>=@EB#FN=F18<"T5!$TO:)TA@-B!!CP@46.MI%:C8<;
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MCWL/H5ZYY1D8ZU-&36Y#(:ARC-3DLB)B&*:LA8!<3,<B4<QZ3S'IEA3F)[D
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M1<8!L6;9F1.(X+2E_P##35[G8-GQQW9W<M3TWL?L."[3?R)%B*3)J ;<\.S
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M:+F:SM-!0[<8L9AH7*U&15"A8^YK6X3DGHT9+V<H0G.))(BDR*2*2*2(I_\
M,9%$D4\>DR4S,S,^\S^F1B,"(@,1 @(B,?\ I$8Z1B/RB(B(^D1^7&=GKFN;
M8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQC
MC&.,8XQCC&.,8XQCC&.,8XQCC&.,8_;C&5\5[R7]<;7N.QZ)KX_;T_8E3O+N
MOSPMS5I\6U#,M$E#%3FEF?MT@A7E+0N8R?'198Z2.0N;&>=:0K.,T8G8)18K
MQ^"^9&&,_#[1#,08V0GEM>0F1ZH: S$$)<<%$RO?^[V-38_YJDK?T*F&]U;0
MZUR@PF5NDHY&( YX9!+G@QF(V-W69W:7U#FI:7H)6]IN97 #9+-<N->I=L&Z
MU?&D9%A352-EEP(&3-ARQ%JN9#4YB>('FIQD:ETC!B-YYFS3YE#J[5FRF=*^
M3Q7,23FC59%.HQ<03#K/LD!7!3$L;64RJ,1-F#&[19"60Y;(7;!U2*I%$0*X
M.RL;-F&%R"WUJO=94EHRJ+<H8V)4HP.B?5.K[S7]%42K;9ZZ;,&W6Y].^N6I
M^N05_7Y6[$J-M*B[BM\XZN4<"C2L/4TY+9.AW.>4LT^OY0'$./3IJI(EV+SO
M,*;%A85'C&Z/8^ ]H[8E'E5SK=?I]<%\/,LZ%#&M.OMANTH*&L\^*$U[3&]L
M8$'KZU92SI=BG4L?:I3E4C%R"G;;/JT@BH):U\W.I(T[7;)834*U+TKD&GXL
M6F[\:I-8I=<TCL9>U-35[M$[VZF,ZX.#5;'K5J[#5"W0@+%NE#80[<$V]UD?
M-/5\57BIQY0>-)A._;7%I'N[5K%"+>LOJ"4:6I5^S*M:4:# %7--N=*[<D>M
M@"=8*@-/<6+MA=5R[*WR0-LE;@3YV\KW;%;9TH85OQ';M>+[.KV"+4 ,:_8^
M&]_4H+#92:E4XLNO>':=>LUM=E9M&8D*ZZ)-&Q#3HGL8Z%[&WOI,#UAJ:DW?
ML)#LU4%=CM5;*JM?*4\7J2O!;<;IVO@<BD6:OO&+P.C(9EF8$.$1:&%Y;4#W
M2(\V164+E:FJBV?5:G9[VVF)L#9-.JN6E'KU%(F<(B6!=L+JE,&E=@),%RR%
MC(TB;M7N60S4'3:"H,"N50-ZHFY%T9@EA+&+6VFICQEBS)?;!A=HIR:71/>M
MV[*]5-2[IV.-K0F\W&!8DV:!3FB3%7:)UVXV&JO.!&3$N<4:@R<!$RFVYTR0
M^C+RDJ7C&,)Q%^G/\??^/&31\_RG^T3_ 'R7'&9QQC'&,<8QQC'&,<8QQC'&
M,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8SK^^5#3L7
M;N]Z:U6NC(7<=Z$4ZO1'^S+6TM<#[)KR*;/E&*]2VM36BY5>3;,E"C3SPJ,<
M<C@K"_(D!FGW58E(13IJ9-Z\U %1[A@@[0)3?C965Z^']DJQF*X.G6F&&#9A
MI("'P$* #F>R] U*ZK#%V>D9;%8WG3FFEUN*W>BP(RR(M/\ P$DOD/,'VQGO
M3(99AX^Z^0J75+6E7,N-J-UW]4ASJ$TW4^O5134&VFF2<*33=)'K-K@!,ART
MNQID(.;G2\2FW7#:FS2YS2.YLF@\Z;E%)J9JM5*F2U[8:'D*XBP#>M7 ',20
M!7#RBXF%U9)(@4\C7#VQN!(BLAV>RABQ6E<K9-QLF!0DSF3B9^,[$Q:,N3L@
M#2(1F.P0@R7Y,6--B2),-:6YD=B0T\]$<6GWH;DM-K4MA:D?VTH=2A2D_P!K
M&,X_/.?'K',>L<D//RY&>"CGZC/O'R^>="?2>)])XB>)]^)]IX^D_*?:<^AQ
MQMI"G'5I;;0G*EK6K"4(2G&<J4I6?3"4XQC.<JSG&,8QZYSQ_>8B/SF9XB/U
MF?2/SQGRNDAS$B-$?GPV9<W"\PXKLEEN1+PVG"G,Q6%K2[(^-.<*7\25^S&?
M57ICB/69&/4HCJF/G _^J8]^/S]N8F.?3'RZOES$<_+F?:.?;F?E'O.)),=#
M3A4R?"B)4^U%2J3*883F2]Z?#&PIU:,9D.^N/C9QGY%^N/:G/KCF.8YB(GF2
MF1&(]9DHB9F(B/69B(F>(]?3'$\3/'H,=13\H'GCF9^4<^G,^G.=?#R61I__
M *1OQKS,[%ZVR!JNVFE&4:O@4D>UVLAR<53;ROU68V#BV.DY6HG4Y5$BUW-,
MC16S*DR<&EK3EES:..)])^?K\O>/EZ?SYX]O2<Q/O[Q\O3Y^_P"X]O?YYV'.
M8S..,8XQCC&.,8XQCC&.,8XQCC&.,96UMJD[?A=OM&5P+VUW^ H^WT;FMIJB
MC(ND%U\.C6L*@$0U< R"FFB5A9 35'B4<FD@<(%GF'&_A*L.M_+EC^/[_?\
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MO-2LQL,.)<R5^,RNI/XK+9M556N.L[+$'VW@@1YEI)9^&V @I6?P'P7IF"^
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M%]W[,ZC:\@,1KQU>QFFLC5Q 7Y5,#N^F EET6P@IUQU.N-_;EZGIM_:N+;I
M5/88CIKH^KI>T1]S>Q7Y#9HHDNWHS*DI*O3T7/$ERYMTK*Y*8BX:[5C K,7E
MC604[E<*Z)NC]K<G<B.)>/AV*'A:1.Z(QWON2$K\1^K_ /W?#HV,24.[N1.*
M(UJ9V,''A\OLZ>")=\50O$4M\019BO S,QM9,_"O:@8BX4^2FK!#'I8/MOHG
M=K--L9O61_55?(6_9]]MY@7:J<2>"H";7TX*U7=9N&P$N([+OD>0.<L TK(P
MF'/<?S#)KPG.7^<>JF*ZK%!AF>OM1LZC92P@LTM=<WFIWB0U<'!J0]+M7"IY
M&%<66N$.YS!W)+_$1L0%@WD_=%I 0\U5K.PUVJV&J:6T[4=RREJMA)JZ2AB&
M5J_3)"L!&KCN5$OVOO(SX]-26WM7MW:PEON7J*XU#2YWK2+JFKZ!5GZ;LH2#
M6,[&AJO'BVZRA6X,J#BI$;5+.RHI!\L0&YS%0\BZYLO=8>40)/:UQ1$^@RUD
MG(Q'_IB2XCX?3T]OE7K(&M7KUQF9&NA"!*9F2(4K%<$4S/J4P/)<S,S,S/KS
MQG:,Y!D^.,8XQCC&.,8XQCC&.,8XQCC&5;^7.6H[UDINB8K,680[1]D^O.A$
MC94AR.B<"L>R0]@NJ/\ %)4XZANE5<^MUE/IEQ'JG.<8SG/,Q_+W_G$>G]<9
M:#%C,0HL:'%:2S%B,,QHS*,>B&6&&TM,M(Q_<EMM"4)Q_=C&.8QG[\8QQC'&
M,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QG\XS_=QC
M*L=N]2TG.QB;OCLQ0ZI>+BY7I(*!9ZTRK::1-6-N2(<"O($;)I@6X#Q3Q'(T
M&_9J)8GA.7V62+YQ*_IW=:$=@W !&;!>-RP5;H"P4S7BJISQ,'H%DJK@/F1K
MA#55X42RD#9.;Q@T$28BL92RE7&P1$GF6>8:I!"2'D$,<3BK>8*1:^3%BQ,1
MBQVC4L;10F1(^1-(2)<V48-FBCJ'BE@L!%272QPDIEMB(W+(R,9><CCXL(=%
MQ[8T"%%B--,(L.=+2'@ 4L!D%*6/2"PDS9(CSR4S)F9D1D1$13,SZY"I7;@I
MDS8QA0;6G,=1G "N)X&! !%8    B B,1 ^\SF/(<EQQC-,]AZYK:W:2V96M
MP'<5K69BJSXEQ.YO!'6V!@E7QK5)S>A)@ 1K6,2$,(^XQ3(]>/?\&7O8\I"W
MM[1S^7_?&0X\/L<?#\<W6V('>^I#PQ%YB!Y.)SA3$H1%VA=V!DG!1UZ2Z4Q(
M@HCO8)NR)#I'W_6N27UOY=4G\_\ M_MF(^?Z_P!HRRWC,XXQCC&.,8XQCC&.
M,8XQCC&.,8XQCC&:=[![+3IW26S]EX8=ERZC3C)(3!885*D$3RHJHM?&QHK>
M<.RY!$W(@0F(K/J](<?2TUC*UIQEB?WSZ9\?6W5N=*Z&U3K!Y?SDZG2@L.Q3
M/J)<K)&V28J2%M)YDSW'9KWW*R2RD["Y;CDC*7\8=6I>,YXQF[N,8XQCC&.,
M8XQCC&.,8XQCC&.,8XQCC&.,8XQE<_D>J6R;7K[6F-7$]TU:PA]F02SEZZ]5
M%RZ;:J8]@211+=K8>99 -24P;;4H$7=NT2R@DC9[_MK\DAB%)BU3AD7:Y RR
MH/+;%9R@%DMI-KB"D6R:4BNL3.EQ$E<V^XD(J6*;9\P-M<AY"^!"@SDZ!K6X
MV#/X5L#-B!1T-.PH(*5Q+@K1,\W$W*_<JLS;QTSUSNIFNVY1,X:+BB%Y 60O
M:X5D%W(I: -ZL(JPD;L'MM@M)H-<9A6+*D642X=GP1Y=R5'$*8$IA1F>UL)4
M?W<ZNI2*UG2::U537,F555GZY!J"LPQ%QI$9X K77;F/2TY[X8T^/3D^O8@P
MWL<G;[1+CLC 6"8NZV)[H@1(B8'I@9J0NF2^@ZJ$():0FYB.QAY<C##.)#C:
M&EOX;1AY;3:EJ;;6[A/O4VA3BU(1E64I4M>4XQE6<YY_UCY3/,_G/'',_GQZ
M<_3+OT_+GC\N??C]>(Y_3/9UEEYM;+S3;K3B<H<:=;2XVXA7XRA:%XRE:<X_
M=*L9QG^_''M,3'I,<<3\XXGF./IQ,1,?2?7&?&^($R9<.?)&#I$X=[_M\Q^%
M&=EP?D3[7/HY#C2GHOO3_97\"T>Y/XSZX_'$>DR4>DD,B4QZ3(S[C,^\C/,\
MQ/IZ^V)B)B!F.1B8*!GV@H](*(]HF(](F/6,Y#TQC]L>G&,ZZ/DKM-47Y,?&
MW3VM\[FF7-GM1I(W)ZWRJH0:T,+!KK&WX[>SAUSS0F1DC84F1Z"WP:=D2Y;8
MQ2Y&:RA/K):S'M/Z?WC'[_?K^O\ K\L[%W,8QQC'&,<8QQC'&,<8QQC'&,<8
MRK+M0TQM#R,>.C3V68,Z+JZ/OSMI8HS[V528*JC4(6IJ&2;B80I.4XL6RRF6
M93BDX;D1<):_QGYP_?\ KS_+T_G^6/W_ -/X_P"^6F\8QQC'&,<8QQC'&,<8
MQQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,<8QQC'&,Z[7="ITVY>2"O"
MY]ZJ])>:1IAJU";85><L5YAG",9 Z)K0H%H=LF45<58*(P_'+%A,EXTM9H.V
M(^X8L#N_ATY#8W"$>Z([JJP4 119\]0'P_N:UEA1*EOHP^A4":!MF7)#85;!
MKJW945;Q/37:UNNE\L7(Z3;I"P,DA$TMD'B31W*_6$2^+D5]O>8-Y0D"#9KR
M '/H& W1]CYEU%ZV=*5+;-3T<*$3X1/8>T;2-B&'ZMKT>A^589%7AEVWJZJT
MR_BBP1TFR1IPN,W)DO\ V^?-3$C.4[#120-<PEU%C8-XI7W+3F^7;%!%=?0R
M3AE^:\/4M9V7(@T5(BPU9AT$+-D$FN@;%ID+77!IF" &6K\T]I 0ERBE%AJ9
M(P0+Q6RT<5@;!5-A.V'<T\ N1HW<(5%E=>].Z_W.Z+(ZU#1)^_JI?]N7H!6I
M=]"%<9(:WG'M74>,2?!59T.1#V:T)D2/I&H*03?1:/E15?M(""G9>&='LM*A
MADNA?VM>I]\=FUUDYC:CMDB*,DUE=3*5E%CSL3WHWBA-@5#7MQ-:W_QA;UNQ
M3 O=;H^'0INU;2$E+1Y>])6U7.BN#65C19JMKD0\XT=[S=J:Q1=?[2Q?:\38
M[0PM[C*=4YU%"MB-$F:)NBMZYI9D;/B.QRUJBQ*\8F3+7"M<J<@A868CD-8N
M EZ$](O7SYW7Z=[S,KU7P%=9L%B"[*_^*MEIJ^QK(1(G6D$U]T(:\F+8T6U8
M;8.Q#I6/+VEZ*]'9[VI7 *NJN>)-?]VVG%Q9+3Z/?WJ=AUD>EP&V[X=;-L$P
M"YK7X6D5'6AS)-D.S5:UU1^Q^H.ZTTYOBKU7:T+4HPX*Z_'-AO7H':]7B=D0
M8%_H&K*C90["A+ZBL1\PX!%A)+30EIUK!)67)-9+%V]:FZ*5H,=GN-4X%L)@
M-+4NKPJWPR9);'HM*%RH*0AR38J 6T5A(PX5LFT1EA@&JTNQZV" S#-D%P7)
M"%Q'X"V4B-1'RR!;T&9]$&6Q/#\X.>\<W6QT-'Q##.A[PZ&AXA.#,0Q#NT;N
ML7$2,=:CNC$QH.6&$C7H\=X?AO$1V.RXTII&F2Q\_P!?[1EEG&9QQC'&,<8Q
MQC'&,<8QQC'&,<8QQC/"O7VY]N<85Z9]N<X]<8SZ?C.<8SC.<8S^^,9QZX_'
MKC]^,92AL.V]F]B=X=7](MG;#T[=J B)0>S%XBTG3IVKFWJ53[3?IXT07)&=
MOVV- @P[W1M=-+G, WI!68<3'2V,8:2[)8_?Z_KZ?Z9=AQC'&,<8QQC'&,<8
MQQC'&,<8QQC'&,<8QQC'&,<8RDKR#'4[,W%C2MIVC5*)1Z@C0,F$&L.NQ-P?
M*7'>=XM&O19^//7M;696$+KOT"%FVOD),(A/KDQX[DIK#:HJ=7SM@6DP(;.Z
MNZ>F$QT^7*KX3'Q+9>Y@G,DNS76VJD25)Q86$#\)]:ZU[<_=:K%;LNE):W57
M[9+@&>9C8>*5^'JJ%K9 P$U+3$V[!"X8FL1<C)# ,LLZP:M':1T33M= S5+M
M<2N12JF#.OJM!I58,O3R\\F[(AA8AZS,M2WY$M:21%\\1E%".9).=(^IDNH3
M>V%HW]#12<2JA40I1,B1(:M1:5"F9!:T5SA8]A0#V:ZB$!(A'JG-.N*9:),"
M>]=M/8P%],B5BP;6=W@S-K@DI[K"+K:<24B,STQ$.D=X-LB]L;;UIMS7-3LA
MC7.DIV]K)3]!&LW.ZZFC1[1"$CM4W=LH0A#+5>CM7EOW81- .AF94<,8%-!G
M/^B2).LME6-5L-@ZT'1JK^EHW;H+:-#N;)5INU(>H"8"?#,5Q9L&=37/IO59
M&K7=(U&7#KV9V5*DE83.S#<'00QD#9:K7M0&K=,E *"-_#X776V5+J7!)!V;
M"!;;3DVQ._F9G4*\]K^M^KS.V:@,%GR]$LA^7"IU*M%:K@.47+;">=FR\V=F
MFQY4&: ',H!)/'[ RS%ACXPF1DZS-Y:P%[35+ A7C:;+4US(V"<IH;/;ZW75
M[(PF&];[];81?UM>>)FM NNE5B>WD"'H=%XA[S!H*MPT07VSF]3K7&6ZG%CM
M\1K[-6:FP?$$ -[@U8MRN><!W;WJV[0K!N&P4^H:\GZOZOTC0EMW' /RCZ;M
M=']W/RG90^@S(*TAZXW2@+4<NF2<B'%66=)4'0P';9R25+5KK;>%+6$-9_C*
M?!:ND>'(L0C3-G:..>5M3#-]10-(! BA5EQ6@_"46ILDZPKK!/WG'A@_%9P[
MTI%5@MJ*:"R#EL/;&BV1-LSU!6DJ8#6L]UIHP;L+VZWYK:3;(<S9VN=9P!^^
MKS7:W;)E =("R5= Z3#;$U[JJ5@^84Q+MFP[+.?"OGH66)\I:5BZT)1.;0\O
MFZ]A/#@U$^_5G<+7K%F('O[U/>ZG7IUU">GOID-=L+%KD.\YI42LG((DDA.Z
M.ESX@.C7$O2,;M"<E0:&G>U.QNV-A>\P0JL"=VG7J#_RDUO.KAG7*Y8<"^X^
M^)FW?(EX\A/WKM;6H]2[F:BKQS4=\Z\3Z9UN;N 6F[+48NU&W88JT(A;[#(=
M)9'#!D*QRPQ,0U+)P8"DQ5/HNO!:WV%I+N*6YH*9/,$:P80"<QS_ .8!@N)C
MF(GZ<1E6JQK*M9KPA3FUT,:J)@H6UB@,UP4>D])E(<_/C.T5R'+&.,8XQCC&
M.,8XQCC&.,8XQCC&5;:8RC9WE:[B;%;4,FB^O_7G0'6D9*CO?--@66UE;?N^
M\#9&,>Y$=7V\]0W7&4J0[GU:4\C./B5S/RC^/\OE_?'[_?\ ++2>8QCC&.,8
MXQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&>,Y],>O
M].8F>(F?IC.NCVX[ Z?A]YPR],;\F2=L&K?I6CVBB4ZRQHM#.E@%[: DJY=K
M)"W=5Q >T0!T@B->9*TLA.CK;B#)4<PVXT.5GP],OV0+1'F*-O<U[3^O_D2F
M:-=%RU3GIL^9)5>L)E62H9N-K>5$1:46 SOI*OK&E8$UVZ>BOKJ@!0#Y:3;=
MS7U[,E*/*H=:L<Q8:V!JIM,MP<+DQ*[O??7/5/9JH"*1M\0:,UT+: =U&Q0=
MQMM+D1[-7'') ,DHC3S0,A(4+EN8FQ(\F2]$;G,Q9OP9DQ8[K>D!$6*UL",+
M%,FG6:!FLDFY+*YF,"41UREK @BB9"#*0D9F9S<6F*+-?@95<4"; $ 'W% U
M;X7U%$D(RQ0=?00]P8D#Z@(AG5<WH5UK*N5!\[7;K8Y=-7&Q%GV/;FU3I"QP
M(%G9N0P#?YQ.X296Q:R(LS#9416KLZ=!BWLN-0H#,9]YERP#27:&X )%XKJ!
M$PA4*EE$7#2MFCH[!["I#VS7V!K*XHRZQ=!B,Q$422I3)LZ>;724-8+5KO @
M+U93A*&JJ7 K)&U468UWP'#%E!%S[M]!NJ:2=^)O:P1._F.&MU?."B5HMQ*N
MB1=^-QK+=6*/6YIU\'KQVSV.%#/F)='@ )DHQ$CD%/XD-)7B!<2JO%=9M"!.
MB:GBUGG$1J[!6M8JO=DIMH1KK!=ZE74X$U3!4I (2J WL%YNV-VR(/<*K"B%
MJP.LZ+E8*=MEFF0S5LOM5 BM9L/2Q[D&Y;&$+W0>01M85+JAI'9"M':KMM^*
M+P9NLVJQK>_8=B[*MDR+#'.OSKQM&R./DBWVZ+#BQY5CL:6(8L6Q!BJ;:988
MS.;C-:53 "I F*EK6M01+6FYS)%8C!N>XS8]QP37'/4PRF(XCZ(ZS;,D;&"I
M9&PR84*0$*0D9.9Z$I7'2I(<+7$ET#$D7,?O$/)D3/'AUVFRX4@7+FP+_-E"
MY:V'98J5+VM>I$@9+<C.O17)0]YQ<.2Y%>>BN/LN+CO/,J0O,4_O]_+,Q\_U
M]?UXC]_+],LFXS..,8XQCC&.,8XQCC&.,8XQCC&.,9Z.84IMS"%_&O*%82OT
MQGV*RG.$K],_C/MSZ9],_C/IZ<8SHF^.+I#Y I7FI+[T+;)G6FATK8NR[OL+
M=TN]OJ@;<TZ6NVRZ"/%U\%F1)G% QBY4XH 9 R(<,&&E51^="<S!BB)DS>9'
MICT]?T^?S_?Z9K$3S/KZ>D<3[_V^?/$^O.=[7FF;8XQCC&.,8XQCC&.,8XQC
MC&.,8XQCC&.,8XQCC&5,>1"W:=U6: [$W;TZZ[;?JS@N$ C;<W1L;5E*E0RC
MDF?):IH^'<ZF?-SFXK*72N'H;OT;"7Y#N4,X:?=S462PMFKM+2ZTQ8HD2"77
MB!01,P #W()/(H'KF9*) !F>L RP0,*K+8(V(J 1V9(9%%)9M@8EC"GH@6EP
M7/I$%',^HR42[Z;V[7^Q^M=#LNL*-2-7T8W#/("U#5YT,>J0-#)TK E_83M=
M$@Q,E3TUF3+>=A#(_P $]U]M:G'FENJZNR0R84MMFPR'ZVB:G3UJ:M%BDHT"
M@B(RZ$J,!KM'@2 0, &)Z8YFO:N>^:T(5VMC=6Q82# 8Y%M@--PB 1#6F$E8
M4420&1+,R*)*=2BNA(\[=(]GWSMJS;V'US7=RU-2QY<.Q4#V:%?IH259XNSK
MI72_WG9QN;&KPX0DFMNK#LC53<2P4V?*^O:B2R%!;,E**Y?7K*]QP!VJK4:B
MZK958'71)5@:V\D'W&%+ ?'764JO4?90^XPVDVM*VFI%'87=I1 2.;%:Y?U]
M_5NZ;4$,S732V#E45=J'5C6BR5EUE"6KW#<>I6LBVA-S]?J'%SJZI;F V41.
M:KC.9(FKRK.'0(FD:Q5I4IL*):REIN:Z(%MCALF?E^8XRF3*D/.8AK>[K&FP
MV_=>VUVT3#2DR+[OW%;<14EI=3!KL=7):PYD:RW'"!$($(C!2US:):Q7-NH^
MJWMQ "4NI-H^9(!X$K':9$M=,=RP2P)YF?)YHW;OC_3M"TVV1!W.;J6N=OU'
M4%/WYKYBF!3$C84#2L^7+K$JN6R43C2:!/+0YB@EI=0)LK9(0Q&0/:$36OKU
M2UK)5[OFI6#$K\2?\65JWJ,JW7EZ%?EK_B)]&8U6L:57MJ9WJLD-D <Q>:,3
M$U 4@SK78TA>'6[ .#-FH([90N$'$K7:5&RVH(L1,@(;!G<KN-23"PQ4"$XV
MVRY$CNM-*;<;0ZRVXE#C6,):<QA:5>CC:<8PAS_KIQC'M5CTY6F9F9*9^+F2
MZHB(F)GWF/?UF>>?UR6!B!@8CX8&!X^72,<1$_6(CVSKO^2LO3U^2[QM!&MI
M=A)%Y;[5:3G2=/30UC;ZQ0:_FL;=0W=1)URFM59_:KTG/T$D>Q>I)9L0IQU8
M%#.%/HS'M/M_?WC\_G[<\3_#UQZ1Z?\ ;_;^_&=BOF,SCC&.,8XQCC&.,8XQ
MCC&.,9X4K"4Y4K.,)3C*E9S^,8QC'KG.<_TQC\YXQE7?BV7FZU/MIV'7(@SV
MNQG=S?=MKI&&UE"GZ'KN>'T;369+F<8^=UF#K"0]AS&,(]DI*$XSA'O5F?[1
M_6.?[YB/G_7]8])_V_A[?6T7F,SCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQC
MC&.,8XQCC&.,8XQCC&.,8XQCC&>%?MG_ %9YB?;Z?G]/S_3Z_EC.O[V+Q+E=
MO1IO:HF3UM67V5J^KZ1VML=VRLU\$5&79F-/5JHQJJ58-8V<QO!AUEC(#=RJ
M588\Z:^,)0RPB/&1R31SQ;K0)P%Y^Q&RVC(05V]KU4UR_P -@+NJF^H\J=E\
MW->YEU"+SGC65>0@H;R)+76!7$^71J;""OQ/73I7;#&>7\1F,=5E-S6#=2F*
M]VL&O:S658BR59]@\[ *,>B<?G.<^F/7U_U?T_;'_AS3]_OG&>W&,<8S6NXE
M[(;U?>%ZA8ITK92:].S4(^P)!>)372OM3Z(L$D!'E&&8/TWU&<J@1W7_ )L-
M8PCV>_.$XR$7B&^XY\=_7;)=,-!?,"_Y+H'+><'H+9VK>?N:1[DA*)#D!,WY
MTPER&VY"XV&U/(0[E2<,Q'S]>?7^T99/QF<<8QQC'KC/[9]>,8XQCC&.,8XQ
MCC&.,8XQD1NWE[LL*IUO26LR+@W</8TO+US3"D;+BI-+KN(?U6R=HK0PI#R8
M] J3DB9$<2['P[9I];'8DL.D&E<9B?;U^?I_/TS7>C.AR=#["KE] ]EMZV!B
MO4*J:N53K! THS5B^O:.[9)=5K))%=U&",H:%$K68)J)CR\$R0EO(R2(2FDY
M;4S.3]XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,94'Y6BP:"%U;_,+
M2C]SU8U+NH\]M%GL1KK1OZ(?NM%L5+EU[,:\Q9C]E<M@PLY$8:$L8EQ)28\R
M+(CR(?N777:.OL@Z6E2;-<9HVQ8DC.]7N5-E5[*#@I[^MN:ZIM4N8)5UMJA+
MP97[X%U*YL7K;L*E=@6.JE<IMK=Q,U5,Z2)[#B5RFPJQ8I-1$$3TV&JB!::3
MB5/C_@XA]7*.3RIMU%I)W:[_ '%.S@&WG3.+A=#MA4>F7:I" =1D3C*IZB,T
M/5!K5>KDF0Z#&N/L0,/N=?8CV)HUI 4Q1T^JJ=D4FA-<:]%(PE1-*66%J'@1
MN,@/,C$.$ 60C'GJ,K9%MR3)P6-A<;W38IC&G+B6PC['X:SA@$$KF2<,CS9*
M;).G-YZ^[ :1VO8+/5=:;4HUYLE,=RU9PE9L0XL1#Y2^J(IV3&BOK6J*B6A<
M-R8QAV(W,2J*MY,A.6\451+JPW%1+*I'"QL#$RJ3(9,!Z^.(E@"1KYX[H"1K
MZA&9BXR839.FV87: 9,ZY_"X1$N@I()X*) ^ 9''*RF!.!F8B<^M=OJU$KAB
MX72PAJI5*]"=)';'82,40%#CV,8R[,(DISK$2)'1ZXQEUYU"?<I*<9RI6,9U
MYCK4OF.MST5DAS'4VQ:<"*R%Q[FU[V+2E8\DQAB 1)%$3( &PI%8D90)G,#$
MS, L"8PYX]@6L"893\( )$4P,3,:[M'8G1-)N52UY;MMT&N7>^1H\RGU<Q91
MD$Q8(DQ[,>!)'Q7WTJ6P1DX5&&NN9;00DI7'A*?>0MM.ZA-UAM10&RTB.75Q
M&9:N>"GI,(^*#Z0,NWQUR R4#(QSD;9A-4+S9A=-A="[)S I,H[?/2R9Z9B.
MZJ"*)Z1E@1,Q)C$_+;NS'7RAQI$NX[FUQ7HT.[HUK,>(VP.TB'L!<!DIFG3,
MIE+S%L+(R0P1E#'\-R8<%UN7+0RPK#G-5<O.LM,2T[I."H(1)>8*NV$/A4QZ
M'V7S"&3$\ Z844PR8'-B$@&R91,#3!#+<S'_ ,.%H>NM+H]U]\)@TP41+ ^,
M(D?7*0?)09*/^2OQL"4V'M$^ _PI](DV*_-I@1'3I,URK[=1@J!V T-2=E[G
M<8S\<JONEGAR0.52TQ4K2A2-N)CJB8XF)F)B?0HF)XXXGVF)]_3ZQSFL3!1!
M#,3$Q$Q,>L3$QS$Q/SB8]8SL7<US..,9I?L-:SE'TW>K56K NKG@PMJ2*,MT
M$SM!<>;F=%:8CIHU?D12YW)!;F!^6X<AI<3$K,Y:\-1E\XN_N6:.M98IG(V1
M?4%(Q0L;'ODRRI<5O+5C6V/,]78E\&(U89-@^0449[K[---0\0>.?#VGVFM'
M;:Z_<--RB7B2AX1%J(K/,V3XBV:GT=;%:!\SW+"F"[L^7$9-PY6WT WMV$O&
MS+I5MN"B]#%2[IMLY&KA8)9KZHV?^]QE& \79V2CX'6\#73RFQD+79.(\4E-
MS<Y9DY2WC"?,^!-EM;J7)VBVU24-]J*C>Y=(X/=6A;8^_.N:UN*C>O6!20M9
MH6@+!?A-4,?J'_Q)?9Y]F?ASPKH=OX(O4_$EQ6C\%:]VUIW]3X<C7:[[M:-"
MZWPEY->R\4V/%"P*Z_Q34<%11HZ6)ZC^*XSGT#/Q)CC&.,8XQCC&:1[+;+BZ
M:Z\;QVQ-?3&CZZU/?KBN0O.,)96 K!,BRM7KG'X2^PWZX]<9S^V/SG'&,TUX
MY=;$-2]%.JE&,J2X?@Z5I1BROXC)B*DVBW#&[?993L=*E_$]).'9[SR5+6O#
MJU>]65^N>,9-/C&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQ
MCC&.,8XQCC&.,8SCUQG']>8GVGCW^7ZXRJ J9Z=:5[?.5K;-"W%;=]W"PA#6
MJ]C["J>T-WB2+MOD27%PM5S( >Q5/6XNBRG5"":!T"O/AAK,>>6FN0&OKD[Z
MLI.7TJ40BTIA(LFR.W:L(\O7=YUVP;/)4VFR43$/"NNS78$I673)9VW2()O7
M)AE5U<#6I,25:L]3WU_)A15$\WI! 7.>RQ[EVQD&'\8!:]C]L?ZL<US&>>,8
MXQFO=L5^QVO6]SKM0NY#6]E+ 9T4/>1(D.=)5N5E&%_<(8@_'E!I[V&T+8PR
M0CNL>UY2\I]Z4\8G(.>(B/(B>/'KQ#F3'24R'"V%%EDGVFF'R<J/M>],R23[
M$=*([#T]]#DIUB.A$=EQU3;"$M)2G#,1\_U]?UXC\Y_?\YLEXS..,9JK>%UG
MZZU/>KN+,4L"0K0&24BEMB22<.EQ'6%-^W-@DAF))5F$[[O@PH?'D2\R'64L
MQWUJPTKD[R^S6:RU>4=0&5X60^>-JZQR3EAVB-"G/ACH*5([:6E+S7';/_+/
MK_ .AK^*/&7AWP_;I;[85MOLDTW4_#"JC]\\&P7,:Q5]BJ9V X[DQ9:I/;!D
MFU<1UC6IT8[H;6W=MVX42]B6*<.(778=A$"]B2K"S<)XEF$+<&T[5495)K0L
MC7J0I+I ],L$MJT8'F8#C]?@X5E[/F?!WB&[MSL5KM=],U>?L C9]Q>U:MFU
M?"B%,(77\C040ZTC!K71:1(M%7$=S]4?^(/["/!WV?\ @O1>(?#EYF]LUM#X
M7UEZWX85K&:.O=-]P+6\\8MC?[:Y5VOB'D*^N1K$GJ)L4;$+V5F8Z(N Y[S/
MQ1CC&.,8XQCC&.,9Z..(:0MUU:6VVT*<<<6K"$(0C&5+6M2LX2E*4XRI2LYQ
MC&,9SG.,8XQD(^N,=_=FT]D=MBZ7':T2Q(U#UQAR/7*(.IZF3<1;+]':4A'P
M3=NW^,0G,O\ HM4FBU>B.H<1]3*;4QDW^,8XQCC&.,8XQCC&.,8XQCC&.,8X
MQCC&.,8XQCC&.,94%W$VGBQ]BXNJ':+V(Q8-(5:D[DUCM;K9K03M8[7CVPD;
M!I%I"W:M6Z(3IZ@Q.O#<QAR9(MTBYF3-DP)P^5":>SI5ZV+O7 .PAM;8NTC.
ME*RJ6Z%G5:K9FN6M$YBVNRT&\)Z)4**Q,[B7O0U-TU./4S%5E6]K*>U,.]/G
M56ZFVOHKL[0P/15D$2(F4G#R9;7$+-*FC,[JE4J=1>N(:"&![6&")JKQ;++&
MW56HP+9Q@]:+&;L5T-V>I H<8:,EV(S.)$X@6O"H0QN#,BQQ0UAG+3/+&V-
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M6OU5GRW@IA,\.4C/IZB;>*>A8*'J.]8,RZ%B =1F1,873U&PC,IDBF9^_?\
MB9J(UGVL[33T^\&LTVE\+:W55&V;%D*&O3X?U[%4JQ6FN8NJDVLE*8/H7!S
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ML&(:R_+O$,1 MDZ@IIP,UV,<3 S)D^L%1/2B]'@Z?%Q7BY:!MDM_"=>5:2$
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MH05<GA<082#;(5&F91 2&A/Z9N,AV3@;@Q5EQXUW"27B8W+4R37(\P64=WT
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M%M1+EK?C"X;;AYQ#,=HBG*,K3'9'IRO/]G"?T;]E6F^SR]X8-^QIZ>W8C;7
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M9*+(;GF,0B)5S$=4Q]I'"?L+]H$KM7;5@*XP"!?8:P4CQ ]*1,YA0],0,"'
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MQ-='H3G,=:DNM\JI?NZ^RN[0MV*-M/7VK51S*]A7<62F=MR2!H=:C-9])1U
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MZ);MMXDJPUU13=K(@D6FJ%8MQMV W:-MA !4#Q%;T-)*3&D23IT=D"HL:]9
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M0DX134]MZT+O%3Q;3VU'*<2V"YL+9&RJKL*61IM4MJC-).[3M=VM,$2.:/M
M2(!5F*0AIX83<CNMJEN,-7']+:&KM@,*!P[%$():1<$T-K<IFTVJ4HK"[!J)
MJ&.&6J7_ (63:-<6%34N4V[B2<MY$-&U)JL.<*_-4U$-=J6D0T["P 6,0F84
MY3D7>D#MD [.[=NC'-61 93;Y333=JN=:KD(N(LCU%DW I,<ER1NLG=BQ(!
MEKJ)?9D-D+,N(5$<Z.C..QPLM@C-C^_EF!L=7!4"YW^+:FB=DZ@7FUM==L"L
MWJ_&@*L*G9FE/)6 H$IP.J%82?27$=BXPRE*EJJ]ZZ*U..@MVSH5I<M#Y[+F
M6)>.M"&1/9*]%E4K>E35T59W?M.R:RO W9?8795"-==NM?9NWZ]/@]KE@$"S
M[KU?N^PUD'EJY,3A[W8:N4NN0:A6ADFU1YS=O23FS;17<G"3C3-[N#"J^WI*
M*[M8J> QKZRQ6%(WF7G[>EM6MTPR:%_\1;/5^7KDL6A%(ZS]6Q/G18=NIJJ1
M6=?J-E;FM4M^(/$Z=@]5\H\KJ8UOA7<:IBMPX%60C34-[9*P[N@L;E>W6N18
M'6S(]D;7!4N=U[1C=@95'/&*?62AIA;66%,%B 6#+),J8SC"F5-S'GD9:5C&
M6_3V9QCTY)LDIK['8(KSS73>MJ1/5U?@K>P%?%S//P0/Q1[^^<#6M:_74'V(
MX>ZE5:Z..GAK$ ;/A_\ +\<SZ?+VRK'OW<[#3=@Q]AT#?MIAVC3\S29RSZ9!
M7R767JWKLW?)2+)8Z]JN# 9A]B+3M8?%FT>#6K<6R+KZ!*I%;Q&L#CC<ROJ"
M'[WHB:XM5KV_1HK;#Y:*#V-.BBGK9KE(HJUAL[!&WO;P!*_4K\BF6)021M;,
MA'4WY*"4VGI-AN:HIZD,<=&+CFWBMCU&\JBZ4UJNEGHIW7LF+LC%A31XKKW:
M;B#[:03UKV9&W;'WULWL16 ,"@;:W,6B:7'Z_)&Y46%?M76&T8UL-'BA( ;2
MG)0K7U>F@;F^WC!<[D]F4O?4J&=?-?B9:?AY?B [["\S6L]S9:H6UZSK,,L)
M98?N";KY2RO Z[7MH'2"4L.==H_N6E6A3Y=0;JII I"+JS5E&COE%MRH@5GW
M(U3+%M3N^#+&PB]6LRL%+RY&2^B+'?DN87EN.TX\YAIIQYW*&DY6O#;+*5NN
MN92G/L;:0MQ:O1*$J5G&,U'-%"6N.#(4K8TA6!L9(K&3F 6N"-AS$3 @ D9E
MP(Q,S$9. 2PP 9&",A 9,A 8DIB(DC.1$1B9^(B*!&.9F8B)G.LCL/N_MC86
MZ>R:X6S]M:UJECTUU[R H$JK;%UH[I2B'^V3.LKU;G9]HK8!H/L$YKHEDX;M
MZ7&UUG)%(@,0D_I.3-;NZ2FF\E2+S(?%SQ;H@O-79[,5*EWPQ=NJTU2TN4M4
MH]FFC3MDMD.N7'V)3*TLKR,]Y[*S4E1KPPZFD\7E74RI#8MV]8S7S&V>$PQ;
MP2F;=JBIA&A51"ILI[S["IN"Z&6,L2!]B*@J[6'8E)U5V8O6N]76RT6J=>S$
MFD#J[3"R1+]W*2B!.TIKMA,G@C9(D2)$&DPOMTN:Z]"5A.Q<,U&@ME('8M5-
MI+W M:O,!4\2[S7TW$M(@KJFA4JJEH /F.UY@Y-C38="5J1L=DA-@VK$M:TD
M&R6^0L6]+KK5JH)')-$9>X[D*:9$GS?:7T(!*ESRY4R;'&,<8QQC'&,<8QQC
M'&,U]LS5.O-QUARG;,J@RW5Y<N,1:A$$OMNP2<)2EPBHHC#>BD@Y:'E2_I2@
MN9#GQ\..I:D(2XYA6A )$!SS!KDI Q(@,>H26<002)=+%D2VAST-61+8) 1#
M.XF0P8QQ(G'28D(F!1$P0S('!#U <":SXZUL$6+(3$2CEJ11JAK:KB:71*^-
MJ]6!Q\QA@84S\,6.A;BWGG594I;TF7*D.NRITZ4Z_-GS'GI<R0_)>==7.UK'
M')LF)+B!B($0 !'T$%K"!6M8QZ"M8B QQ C$1$9 M0*B8 >.HB,YF9(C,IY(
MS,IDC,O_ #&924\1S/I&97R/),Q&^4*F[/J!^@[!K8FW4VT#W!9^NG(B)HPI
M!=4E>6)+"_\ N.(;>9=;4AZ.^VV^PXT\VAQ.C%BR ZN>5L4Y9"1 :W),6I<I
M@2)K:I@BQ3 (3 Q$AF)C-@,@F9&8^(&+,9@2 UM EL6P"B08MBR(# Q("&9@
MHF)S@M5:<UGI"LKI^JZ@,IU?>*3S<R) S*D2"1LFM+A$R7*$9$PL8*S,H;2^
M0*3I<M;33+'RX989;188YK84)ER*5PI00(@"PZB.1$ $1B2,B8PN.IC#-C")
MAD4QP,01GZR9]/6<S)$4+ 5KB2*9GI6L!6L>>D $0"(&(C-E\BS;&<>N,XS_
M 'X]/]O,3$3'$^L?3&:2HO7#1NL[H?V'0]:5JL7"RYF9*&!L=Y&48)RU$"R!
M,%Q]P97FS)!7W VW7X0Q!J>E$PHF7);0XG91$FO%512"($ @(YGA*X"%5Q*9
MDQK)A:X16@O+HA80I00(\&Q#VBYHB;1(C@^D8GNL[G<?,#$05EO=;WK)1-AO
M<9W&%UESNWF,9\ZY<5MU##DEAM]W_LV7'4(=<]<^G]AM2L+7^<9Q_9QG\XSC
M]\9XQFJ;3H33MV;V,W:M>5HWC;@ROAMDKFP<*>MXVIMR6ZPP5D(6A]2Z]]7(
M<#2H[C$H<^YB1%>;?0VXG$QRH4\S"PN3L%B)$$KO2%94V@("$P?VZ=4.X!"7
M2@(B8CTR>++X)1=PIE%9E)4%$&(U',>UM:1*)$D,99L&:C@@*7,YB8*8SG=9
M:JU[INJL4K655%U"LL2YA'(T8AY2I90B]E\B6)SI;LDB7+SW?:N:5*2YA"5E
M#>'Y*\-HPF4VL9"A,N00H4)"(@5I2)&R%J6,0"PEC&-* &.MK&-+EC#(J:TJ
M43C6 B=ALO><>IN=( ON-.>2,H4I2ADIGH2I2@Z5K 1SER7%9=;9>DL-/._A
MIIUUMMQWUS[<?&A:L*7ZJ_&/;C/KG\8_/(\ES&3M#IUG/U"U6"NC"UBH,PJ1
MIAB:QAZ;6YIP1) %Y(MS.?1ATB&F2ALI7HK#D5]QO.,>[UYD9D):0SQ+ZQU'
M>D?B5F-2]B#_ /4LVUT&0SZ22@GY9OW&=HD=<]DW)>:^?A)U;N=AG'R-7=9T
M%\NLOKF!:\ZYZ/U/9CUPUUK:MU.QV/#Z21$9'?3\4>5*S.F00\5Y]Z#7!LV;
MGZV<+KL86/FRTMR945YYII:,K(U(FLLB%,R$R'5,]4*@H2!&4R9+0)D-=1%*
MJX%((!8S,3H[_$/BTZ(98B#X:41UQ+>CO'S$1'=?*PFPWCNO(8)QF4<YN!J?
M!?<^)F;$>=S[O1IJ0RXY_8_Z_P#80M2O[/\ ^E^/[/\ ?Z<UQFD-T]8=$]B)
M--G;EUX,N\_7D\F4HY&7.-#255(F821Q2<$( R8R9!ESAZ?H7Y#3V'E1''XV
M%X9?>0N.%@+_ #0QTV(KLJ]V)F"\LXUFY$\3$2MI*7+ GD2E8<Q/3&22TY05
M:2Y0;TV25,#(S8KPP4-]8F>M4.9VRB?ADY*/7B8Q9'2SJZD[2;*YIVM3#^O8
MHJ%5BI-XR6EQXU?(R"]>06=)$Y?ZF572LN22KKMHP8=!3GE2A*XCV$KQ86UB
MGE96<@\H".X,0,B2ZTTP< Q$ NQ%69KS96(V)3^&39'TR!H ZJ-)P]VJ+&L%
M+.3#E[PM.">J9F4LL+!YUYF42T!/M]4<Y*/'XQC'].1YOF#[*UM1MPT2T:QV
M96Q]PH-T%O!+55RN'LC3@B0I"I Z>B.\PZY%?RA.'FDNI2ZC&6W/<VI:%0O0
MJR$+< L"&)= E',0VNT'I/CF/B4Y:V#SS$$$3QZ9,BP^JR'5VDEL U<&'$%
M/4:'#$S$^C$L-9?/I*>)B>)C0([HKU1%5*1186H1::N[/%$XXY\];YC@:<%@
M2A(R1624VP2"E45'$S)8G*:U-%(D"I+XV2EZ"ZIC-EK&.D":9,-;G/AAS,L-
MECL^8[K/\[UOE"2<EQ,2PU 9K(QB<@2,5X8*(A0-2JN:P]%2I!D:!A4?AC*3
M(B48")KF?@*.(R3-9K%=I@ 55JF%&UVN H;0\.$$1&8(X=#9QG#<>+%82AMM
M&,Y4M6<8]SCJUNN*6ZXM:C&,<<L:<F90,24\?Y0&  1B(@1!8"*U@,0"UB(
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MS, N)F>E<24\"/$1)3/'K,Y "UA+) !"6LEK9$8B6-*!$F',1R9S C$D7)3
MQ$SQ$9I3=W;C16@[*+I>T#-DBES=<DVI<4!K?8%[B#*FS.6)DG[+,IE9/PP
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MK\6Y%Q#*8S"(DVQ182#,X>TB+$9PR]+=CI3&CM^GHRWA.0,E@Y:R):[#.\\
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E.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQCC&.,8XQG__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>img102984888_9.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img102984888_9.jpg
M_]C_X  02D9)1@ ! 0$#O@.^  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #] 14# 1$  A$! Q$!_\0
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M2DJ4=!6LLG*,H\E?F1#"V^W@]<$I 6R,RBJ1:LT94832A3&[=!PK=>V/$._
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M+!&1]4LFWW/GOMG.37N]#5K5:IFTO(SL7\;+T:?8DGHR_25^Q'HC4!%564*
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M48!K 1/^3/\ =DW^[O\ ,;59G=J49WD\78NQ9XTX[R8D\F;\#LA^D\>QIU'
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MEV^>^^F<Z[;9U_IY))( )) ' !/H GD@#\N??'Y^]./?/X^CS^)X' ]_?T.
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M)ZKSU7D\\#DD\#[#DD\?<D^]79XU&GC33QIIXTT\::>-->?:A>O'!B/[0U[
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M+Y?ZF\*HR]CLH6:L 6,6]2-?D#'QC_E8).V>2 F&;2X,)!@&6D2;A B013^
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M:Z1XW UKCN>=W685.X$-:<SSMD4:]A-(3MCXT\48< 1QW6D$'H2=$6:,A'#
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M.NGCQMC28&#;:$23&P\6V=(]<^--5[QIIXTT\::>--/&FGC35O6UR?7:M9+
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M;329FNRE53QM)9ALK I-?Q8OG@\F18 \-;(L!Z"JII:G ] *J@LWV 55'H
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M\'WQ,K%S,G)QW\+EZ8RR:JN>'5>*NRJ>.5<$Q]'U]P&U(E+1>:3>_!_MS_\
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M_"?^'IU]54E9WJEP6I1U#I%(Z6*9SOD'+JF<W84-QHX#K=A*7T_;=Q2W<\>
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MR><J_2U,EV?(>DQ3QLUG=FJ2OULQ+<DG6X2FH55F@"*JIPJCJJ *BJ>.0%
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MR_Z_Z_T\::QLRZ-Q^"^*:2WO/.8>G:8VRCJ3&RUN.]:ZLA-I=\JD1)N'V,,
M8=I-OQ!?D6)%G;/W(=,YP3ZS03^HJI%>GLJB]:L'Z^U5>J4(;@#A7/V!T?Z5
M7O\ 2K%63M]*L26FI7G@$DEI@CGDED'W(U=ZBMUROR,YD*%*DE=L)6KF50K!
M6R-VD^,8F9M-PX(=CV$V,8Q*:7F4F3Y8QO+M_3P/2J@](G;JH]*O8\MU7[+V
M(!;@#DCDZ'@DN?;,!V8^R0/MRWW( )XY/KGUKBL%LJU33,[%:;(AK5?2:Q[.
M7C]N G3J=99(8HMF;)@0.&!K)*2/''DJ:+&^Y$&FOSVFCQM!95X[$*"0 20
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M0_RS\?;T2?XM4BG  )/-:33^A=2?7)'3.]B^!J1EA+OM7*$NC@0,Y=JUZ)4
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MH&)-8BZ:QJVQ>N#(E]F+4)Y]-SG*@<Y;%R)VR<=$\M<7-&#4)SP*F^+CJPY
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M+LV0@G>*;3+%KH?9K*Q&=L?RW(;*Q/V0A\!SEB03/=OK )447JP7Z !XQ'Z
MO F3%1 M/JQB!$DR'73D\*.2>K=AR226[BGU$\EQY%6@5RRBBK0 . VJM3N$
M\AY\;,PI5!0ULHE7&H,V602PQ'B:0Z#;2L1LS;C,69 L4(IKLV&=TP%AA'.8
M$0PQ::0S%T>;'F;A5,R!XPJ32*HL^.B3$YS3QJH0K- 5/1>)Y/97[-W0L5?L
MW?LU'LS%N>S,:TI0,Q+!Z48$&CD_BF<%XYSQ@"VI7.JS7&BR)D.N8+@<:&@!
MMA$R\Q<&3)M),,JPMKJ%6$JAWT7*U2=:L5C!@!P#Z9&E""#1SRO1BS,Q<%TH
M31B2U&9YS9G<L[=$#,0B@.?YA^#.M"/LO=!8(54>D"C(OU50%!M4@<T<FWC?
M5S@##[6I?,*]O$.R8M1A=,L( A9W,!(KD00" Z((5(Y@-.C<5P>"*OM<'&Y8
M+"=BR,R0KL@55/"I+P*O ($1XN(D$'M)/EX"<VY28C,350B@0WULSL27:AL6
MY^KS$45K C@BS"U>]1Q1S1R[$L2?I'JYP J-_ 1R^O2BV>Q;6UV#MLQ_7%62
M6 P0IO"NP=@%>6P7L#E+3*T<2-JD,*2,M"E,\@6V1K4E"U'<HU&!<]S_ !F=
M[!BP)9*O1WJC<I1W9Z*S'G4*H0$(.@9$0A/I'68F)<!>.&D)2$G'#R$T$V7J
M-=FT^N_);G=Q+S:*H Z8#<T8\C@6'" R(X:<QL*:S;P#!_AX(".%:(5VZ\L$
MP;\'2/YCQ:3ZPSPX>5PUQV8ME4Q+UIW84\N$^36#AP0P<5R7JS@]C5(OR&D"
M<PW6<9*J*D/F1,!% Z9<HPM,CC@R:,5EXR.OC>J$%:,-5LOAG)#J_6ZN114F
M4E/+)/K(T.A I"8T[[_[0H1F+/"TQ.\P67I89)39-K%&8;&\_81F$ZRR7<NM
M.Q[*@DO' 414(%CT ">%1.?677QJ9S*J"BD8 =59!_*[^1N?9:G+'R%CRWD^
MIOXG/?ZF';ACS3M?7/A.LU8GUY11]9J:H/05C?5"%KE.F:+F*EBN'QK'C&XQ
MBUPV"(U(Q-F2!HQTVSG!I/W89F=:J[,Z7G.-D8\I24I5A.;+_*56-ZR5>. E
M&0<*>-9*Q0J5/4K5KJ5]$5>TLEJ CWV:\(V)Y]TFK'V.=7X+0Z@$15"Q:^NB
M*HR@M#4",0_.:O)CA%X)BY9)MG;: 8D14M'FTQG/UQA#Z[9SC3'DL[O2M6=C
M2ZNEG)Y:BO5+N&)^_>LIT;G[LBG[C6"HJSG)5 G)E>: <*CI.D491^!65:S7
MC[+1A^.K#U]=N)QN(W\/.D [B%\QLL!XNA8LH[=P1^:YD'U&)BB'!=,<8:ND
MT,>B9PXUT<,UY3330O4K,J!%9@@FT@O/*^-NG,R#SRBB<Q-3R)!%$N@ UD?J
M9F/!9F1V/ Y+S[!7_HY#N'<<-0.XH6#,#^J_Z[\1JK-$YKG,ZLE8UEA^V13+
MP<CZ+6N*PLI432$;23 NS(6I*%]="/F@D+ 4P[AA301E%XGS-JDEC1BQ0SY)
MY/0L[,H/W 8TH&XX+*[J259@8(# *1RH(('V'IS0#@?=10^0*?I% M..Z*1F
C?S5J=/&FGC33QIIXTT\::>--/&FGC33QIIXTT\::>--?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>img102984888_10.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img102984888_10.jpg
M_]C_X  02D9)1@ ! 0$#O@.^  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #< EX# 1$  A$! Q$!_\0
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MCV!4"0JQYJI1Z];#LDY+R31<L'O-W=Y7J]*SOD#'F'\S2<%!UZ7RQCJI)PK
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M,L$S);-Y+.IRJ+Y0CG)(+TNVL38U:-G,>9Y7W@DOAF"\=(/;2:369%F]:US
MNHKI$\B5[+%-0=*TJ"%"BO/3Z-J.5[)6%T4,HKO(8T>H%V,*I&Q:W6>S35BB
M&18GDCE2<AF%9PRQJ@WE$AL1]U"6##U6?NU5PMA&SEKB3:LS9XO$-.SC:QMN
M8\9XAEB4B]HRK^N1>/Z[?I9G*9)O[F'A9"87K$<2)C6C8T6S<64DS,,(M6[5
M\/6YO2S+U%2IJDFC.U6K8OMZ; L+6&>.LK-%4@6Q SV&W=^J16@L&*;IT1RB
M:.FT2GE>JBY )2(8Q"Q*1B69SQ2::1)$CC ;CTF>PT$;0O+D%][1(*[)9;<T
M? MQR3CW!N*,7YUR/D-E;*M6F3/%F3:S+6]J]K\!.&+.S]OC:]!RDN-5\GCF
MSIA'N@7L,;)JQ47)VX-$+-T[ER&G,=?M>'!$4DG<WZRZ86D)B]D5$?4XDGEY
M%XP$>&*R';I5!^:5WA5I1:TI-6A('$&)I+Z&%MR2LK+1#0[*PD:7BYA6,R-D
M>W_<?G'*6[3<KC67H=<3PCCZ,P[*T>U-+>T-.L&%_I,C96#M[ %K:#R4/<02
M3>J(.)= :@#4&(#*>5&63FUIE:KH]>Q+,ZZD=3U:E/"(BT1:B-*!@63J *(1
M:FEZW3)F,G2*KTE9[)L++/2-4=2K:T?3]161CQ8I<M:W&+(!W[/Z#!6%??=!
M&;)?[L8DV#:T69.-,8TQC3&-,8TQC3&-,8TQFOS<\_RS9]S^V#!M SG?<'5J
M_8YW'76VRN.H?&LG/3$EC=UA9K6&BBV2J)?6#6.;DNTZ=PDPCVCARHJ@*CD2
MH$)K::2(>GKUF>M%;] J:0]:&<S+$LER[<@F=NA+ [$QQ(%#2<01OMW.)VZ<
M%0J!RL:@\#M[UC2A8L +[AO)&I)()V&PV&8;2-U^4<>U[=#4,GDJ>3[AM5RW
M6J(]R78+A1,"5.S4&^8TJF4:Q><A3$ZJG6*E*P3.SGJ]J2K$2\1DY)BSEH*N
M-6LDY8Q=Z2I6M1:1<@4TTU1[]::NBS6A#<TZP8F6FF\EB9+<+UI(HY)&:.=Y
MXGGZ40E- 5HYYX.3S*E2I=@8J.L8[+R0R13<5CB!@FKV'ZR\4>L(O8ZY*-D>
M$^T6QUF-UB $ZT>#A,L2>?Z6C<F5PK=RI$9D[;XLQ>SE2CK963N86U1-NIQ;
M->:7;(IVDVD8.IRB+V.CY(JS-HN:+-3CNR,[ 5-+JZRL<]>6K8DT^:TU&R[P
M2[/!-2MM5CDC/-9H[ GAD>%0[TAV+I'PYNVI)I;=)A*BV+%,WJ;*Z@<X[$22
MQ%ME,%I5K2*)) !E5FWEE:;#;QO6BJ,]CF,=B>Z90I%4GW1U7,U$L#RI:!(R
MAH]N5PT8W)BC"6)1JU26?1\5,%; 9=XB(FQI=,FBU.GI+2(MJS8TJG,2I*T[
M6HM5CEB=029&HRV3%, 5YR0NHX@@Y>K/#-),Q+/6@DOD21D V:]#KDRPD@JB
MV4KLT#-NH5T=B5.8KLXRNO9[I9:G>=PN;L@Y3D*5#W9YC7,>!$\"03"+*[3C
MIBY82BI3%% M5AQV6:D&T$HXD[)>5XOO(+SN_1D)1%U)9VJ5%BA<U:51:E6V
M*S7(;XNW%:1;!@AU(16I((9;*5Y9H^%: ,T$R1>S'(JXJ3%VKM(>D]F"2:.%
M$85W$9KF4022)SD-3TB%'^Z%BL\<DB[NC"G&Y3<]F2L;B]U=5QSN4M\=EG%3
M7#([:MI,)0J'<X3-LQ::0PFI:$L,?['\CDD8R<FW"\?*6B*OM:8TV..M8'+E
MHQAG*@Y>B4(+%#3)I]/BM06=<N4]5ORSV*_J[38I-.1K*S).D$)KP3VK*-8B
MF$DD*Q%7YA#>MD1RNCNU>)=&CMPRQJ'DGON^J\8%C?F)C(]:E"(8U1V$IXLK
M,'6Y%KWZN:M[(]L2P;:+!@W!M\C\9YKS"QMM89FK-H34@&UUD*Q0GAQFKC4,
M9O+$S0NTV61B'R8,Y@U7A;2,8H5770:3'.:">FQQ2ZS,8]'B>.1_25>W+1IO
M9DC!6HMZW$U>L>,IY<9;"UJ[++E+NT:3<TWEIU%MW$! 6,>B+>DAA8G[M/'5
M83,FRH>2PI*]CE$OW'WIV.X77<9CS%6*(Z8EL#1UMCWCJRY7J%7LSBSPM6:V
M&&EW6,W+-_;&.,+.9\BSJ^0!0>(S;M!<Z<&E$=,L;&GT_HZ3'J4U@Q"<RA.%
M:6Q'%T++UITEF1EC6["D<EP4&(,E81!IHY)E094"J^HTZ97J"=JK,.8A+QV8
MEFC,18<GB+LE66=1]QG9MDE6*0KY;:MY$>^VT[>LC;O+AA[!M]S)2*?+5M*Q
M95J46ADI>7K%=DEYVOL91&L$8O))_-%[VHQR4LI"BNT;"_<^4(CK9ZSHRPZY
MJ&FZ-';O"I8G1H(Z\LLM<)8>%$+(9&F795^[\8PS'B$W'?64K$DE 7;(5(%5
M2ULD1PM]S,CLV_LP\0DGLM(Q*1M)OQ\HNAM[V:*-7-_&3<S8?C7.-]K&0K.Q
MK05"]QC^QR,/!4K&\^UJA8H:Q'E<OY!K:'5E)/.I$XI+2*=8%DH,<G(KV/5M
M:6OX92&P_IVMV*].2,PMTUEMZ]:TGFK=3RJ%(X> 5?21$9P8C+P7,E+K;NQH
MJ&"K0:X&9^)VBTE=0 ;LQ!M;,=QN*W(*>J%W/?9?[1ME@YQ0*ED[&M4QSEK(
M=>L]^CZ'E+<1BG&T/#XZ@)!A',7\UD&QKIU]2\3[R21C&5"KR-@\EE6<N+VQ
MI5^.](UU?13::T:]A[<-&.#TN2E3L67-F=K"I7J0J%>RA6M+,+$IJQ]'CR"R
MND30')3J%2BRV##5ZA"M)&L,,LEFPJEC5CC:9(2GW:=I"#'$Z"1H_5DCM-*'
M3,#XMW*PU5KDAB7)>/%,C-I"^9QQ7B:Q+-V:#AS*4JDUVRRCM3(>0F"3-V5.
M+B7K"LRBX-4HNWNO+$C!4-"E74;.FRRR]>!JW$5:-NY))%:57CLM J1S00)%
M)%),)5%I.?36J\J.BQ"[6(5DC50YFLUY$DEC2*&:K(87C>T"\)YS),D4D;/"
MPB:1Y(XV1V[;'^[#,UTW890I[''D'(;=8/;EA7-%9L1K>SCK2UC\B,LHRZ4^
MZKZM9,_>+V8U7CH :VM+H!6 B3S(NGPS"K)M1=TZMI^AW[=J5UU+3]:U;3I8
MHT,D+MIU>D_HZR!U4;B5['I!0\NJ*_#[CU'IAD-NUH\=8$0ZG0KV=Y0%=?2;
M3Q&5@"Q'1V6'H#[\@R]0!@BXO1.T9O\ D5#!H5S9[?QD-SN)Y'+>"&K_ "AC
M=JVFH&LL*N_N"E^>^4J&H#)DVN$$]KCM!I:I"R,)!J+F%@)0SJ(9W[>A0TY=
M4AEU2 OHS1MJ"K7LDK!.\L<)K[*5GM&2,12UB8XXY) 19>)))513&6&O/TV$
M=B9ZH(*DI90<B"NXWKE%F=; .Y6!]HBTD"S?7<NU&Q/6\=;?[:A$04/9]P<'
M?9Z#JV7\M8]PI U-OBF995;(K.U9"M3YU!*RL3;W[>L0<;6&MA=69X*TFT3;
MUUE)3+&VF@6)+ERO&[3P4ZFG77GJUI[$LM?5ZZV]-$-1564RV*S-*ZRF&. 1
M2K+,LG326M')@,LB-%)Z79I=(E'VFJ231V':1&*"NC1#:4%I&$T/&$L9%C[2
MO]HLEE$N!6N L&63+$UG[$>5LK0;,U^HU6AZLWPU>JKCVZ1=FM"CN;B'3<ED
ML@QL-/4\UICYQTBQ<1I%X&3//,*9-%-9]5]+M+7ATJ/1;$DAKV.K/!KE>]:J
M"*LZQRQVA%3^Z5K/0X,\BR2Q-"5>(Y.:5V( ::W?HLJNDBQ6*+0HS&13Q>L_
M4=Q-'R8(B$1.TRH.DQWO7R]F?<;MVBL98MCE<"YCVU6C+,MZ2W&+A+I7Y>%R
M)0ZA/N7<>C7Y<%W5 =3,G *0$?-"QMCAZ:5:RK-&,0([OG1JU:GK;V[1](HV
M=%6H\,+O%-6U2AJEVN_%GC8&\M>(_=%Y4Q%[0D,Q$=N:615H\(BLKVM:J6HG
M=01/I=G3ZEB,,.044WEG;F-_2C(J 1]+D^T?7.9D8TQC3&-,8TQC3&-,8TQC
M3&-,9KDS<YS/D/>W1\$4C<-D3!E*3VP6K+;\N.J_BF6>3MMCLJ5NIL1EULE8
M]O0C&(14DN0646,6*J@B918PB EW6G+6CTS5KTU."Y+7N:+6@6P]@11K=AUV
M2=N-:>NS,QH5P.3D  \0"2<HG?BVGQ*.(L^MFE<?SG^B+I A"EN2 *;DS'V"
M22NYV&V8Y2MZ&1ZGA/)4QE&'QQ9KI@?<1?-O%[O]CR=2]ON,9A*ILHB>KF0)
M68N*\@V@']JK5EKS9[68"/FRH7 \FBU2CH!,CEJ>E5LRZ5+5ZT$.K:;+=6LD
M4MR:*U6U&YI=FG60$2SHUBC8GK/*R!*O$33-*%,MQHGAEN0L_6%:2L8G"D.]
M>Y0K7TDL;(D<9KBRM:8IN)'"RQ1\)&6++\6=HQC'(["E61_7)*F4>]8!RYG*
M(NDE.P,Q F4P!=1IF9J:E)P*[V&E'-5*XBK-#V*&EY"%MM8?+2T69-LR,=:U
M?TJ:BFH$EI9**:18%?HR0V9JFM57L4YNA*%FAECD6*I;KRH'KV;->,L_4W%,
M/*:6K".'*S?NZ9R5PZ1W*;J O4'L/%:B%BQ5E! >&I88JO [=[FW=O8J)L3-
MNI84ES4;;:*CC9U5J996[ZRKUFPYFME4I5,-9(VO-TI29+"/KI$S$W!PK<)1
MZFU=P\<51\HB)Y&E$Z_7T/TA69]02E//$!LHB#27S#S/!GABAM"%F(CDECC+
M;1N=J*LZ2U9KK(>C#3NW40MPZ\=>*:6J"VV\0N%(021O LQ+$],MGOV=9):6
M66R53IK<!G#*V1(-.KV"P4W/V%6."+-3HN>-.M&,_3:A[%>,)MYCNW/XF21A
MY"2&UI-%X!:.+,D>IOTU[FIU^,$$T-"G7K"::N)ZE[T]FE"0R"M=D6U/$EJ*
M)ED]F*OU1*[*K(H6.E6/5 =F#RP]1$Z;)#(J/PDEK%UYNB.RQR NY0F/GQ,@
M+Z_FFZ?.#_<!EN&HFXZV7S+53WSLL.PVSM&BT*9IP[=?23'T=;[A,2D)0&=_
MIR53ITU;;87($YD0L.WDH5C&O&4@,LWC'FTK4*QT[199]/A%.[I=^QJ6LO//
M#)3LPSZTM<Q[SBL[\Z=&%*IKN]GK-&OW1A)'%B0![ZF1H'KBF-/2-!+Z;-)2
MT^4PO&0SLLTT]A998WC%5%-ABL,+JUXJSOV+/OL;VQUA.U0FW;,65S89QIG)
MW:JTY5F+6\FI>L5.:FL<(#Y_@:+?[/#JP=0G_.$E+++R$,\GJU 1L@+UOJET
M@G:NUE$U)M-?55H&*1O]&CHG5)(7L+O&EU--5KC0%3'P5H?2/2@(#7-(D0G<
M,'BJV$J32 E=YGN)IY,*L 9HH[DB0/*./+O-"LM<"8QS:M^]_NFV?>%E["N+
MX5B_P1C_ "X]JSRQ9.ISZPQMMQR$^QD6^3L9M6;R>QY.Q24*[N494)]-Z:Q0
MS5K&R+^O/Y,$6\'3(XO4SV+#!-4?3Y"4KRM"*UU$DW@LDI'9EA+QUK<<97H3
MNZH\XA<YEU46;5!0X&4):-60<^BSRI,L04!ASC@L@L]:T5/.("7I /&'LWCO
M=#66=*P^SW%6S$>%\TY7@XES5\:S&7:JO+W-S)BT9QCBJ)OD*R\F5IUX[:E+
M&1,,Y-'/WI(DBKQ9,JBD:CIK+J&IU])AM7XJ$LXDX5Y":X22<".8H9B%586V
MG;8.J._$<2,UE&=Y-/JW;96**:.$^DMLD<I>&"1WV)"1ORF&\'-B@9!R(=<I
MMC/?YGF$Q9D2_P"9\!A9'3;>C:]LF/83&U]KCZ<E9)[FZ?QA7:N9I)PE9BR>
MB*C2+CG%JD95!*T$46FG"4,FDL0,N;2:<DFA5Z=OC-J>D27I9+,3Q5T]&T_4
MM1ELNZO.Z1NE$Q-&D3M$ 95$G\V<ERZV-6]C:OIWH+$!@\O&Q'HRLBKL!)(W
MK%K:CD@WVJ[@@2YDV;^U-I&WVQR5&R/3Z9"7['V/H'(N9JE+[A<6U>1KC"PE
MDGC*MXM0N"U?DLUW 8.*<3P1</%UN.,T=1,<>93GY1M$#11T)]0#S5Y9Y*GI
MB4(9X]/LSN]@PUIII)H*_5:O5K"U$LLQ:21R7]'@FZ<G&&:1(X>48$\\<\R1
M=6)4$,4\L$1>=V6-);31.8HNXC"DV9(4:)Y9$S?VAU+P7:L?(62O5<^/\B#C
M8\!8'>:,=P>2I^/R;(0D7%SU)P5).@O-L@X-]8&!+(IWL1,-VZ,DZB86919@
M9>*&@6+UFQ15G6[7M6*;Q1UI[$$4T".P]+M0@QU8YI(WACDVE"L \W2A/5%M
M[*"DFH1@O6:H+O-B(@8CNS)%U".K.L7&4Q^RK!UC21IMXQ@$IO:S9C2^=H/,
MY%Q%%3.%]IC"$GZ\XKE\BRVIS'*8M@+FWBO-*U9;B_?7,)!S- Y>2Q254YTZ
M^)90$P?FH@TZI/I^BN+,B7M5UGU64Z#/&CS6M*IHO(2#<5C>,Q=4WL<^EQB:
M/D<B=9%MI#"BE/4)U1N<@4NT4_B+E*"%;@)O5<5,1-VBZ1MEF69HT[Z=[0')
M$!.Y%J+S9WD MMQMB2)W$S<9[*&,ACTL%2Y[2BWEG$PF_531R<+NEV:-+C9J
MUD(T[^.ZO3TL8NG)ZCU756)IWU6 007QI=MUKV7:.ZT<,J&NG!3:JF*5I'GW
MAD18G KM(\"2T*9)/1Q'"S&["TM,,\:=1D8I)%/R;:LP9JX4L75_28SN.G9Z
M'79[[5+"V%IR(@FK:M3KI;"=1W"3:5QS#C7#;XN.[R686J\;1XS(<JQ=Y!R-
M+,Z_,/DJA'EC8]DB@R1F+1%O9F':/KM?P];E>^)3(B:?J<FD2O5J6=0;TZ (
MUC[E60N*U=)89)9CL[K,BUH;#K,L<1R":"I)$/NEV 6(8I&2(+$>(3KS%C'&
MTKEXXP"Z\H96E:*()(^4W;M%8*LN+=+5S!N4,BXSQ[BG$N<[]DRLOJ3'Q=4Q
M1EF'G)UC8G,%:K% V"7DX:*@GTF^K%<93,RI'-'J_<H.$V#.3M0Z-(\\M:S;
MK4YX]<G\/(DO6DZNHPIIQ4*8(I"L#2:C%&\\@6.+8.2RLPCJY<J]:Q$K2^E:
M:=3CC4*&Z*2W$DC9V81"55J,R(7WD9^ V",^9%CG=#F.Z[V<N8$'#2BN&*AB
M["MY@<F-K-2TUVB&1RY<6+9):*/9CV&1AK8XI,; UZ&85Y*:K[R+F).Q%3BY
M6*5 VF5X]&:[+:Z5^/5K^GM5,4K*QJ0::XA$BH4651;>R\Q?HM$\4"[3I(#:
MDG'6HB "6&WIT5WGN Q66Q:BZR@D'I*(4AZ94R-('D!Z17+]ZTN7\:8QIC&F
M,:8QIC*,9$VOYID=P]YSOAO</#XE')F*L;8LM\1)8<89$EFS7&DYDF9BK!4Y
MJ2NL+%1<JL.2I!,4)JK62/(O'LUU6SE$RK0VSJ7*L>G2:=;J268VU*QJ4;Q6
M?1F62Q2T^D\3_<9BR<-/1PRF-P9' (.S"EU#2PSJ!U8JYK;2 O$R>D26 616
MC;?E*RL!(-U"]QWWBRX]FK6EH7!43C3("%>'"]8RQ5%E<H8WJN<&=J4S?/0U
MKR/DA:%M2T?%169Y&T13N7C[TDV>,6J=BL$.ZK;^%>),6]\:RS2Z@TL!$%ZG
MI]%(:D\M1Z572T>*C6JV$YRK5Z+(EN)N3VFKU9VE2S LIA5(1.3&29;T^HR2
M2>TEBU9YF5[$(XA]F=O1^#1M61Y(8R(I&3(YR9L%=.&O9K85B/2.TU7;O*N(
M++62$"PT!'3N&:768>TI4:W0R;DZKEMD7,="PU*H0T21=BW+3Y-1?N&I2HKY
MM+7 NIZYJCI% ;6E/Z/6<RS%M32Q3ATZ:.1P7ZVG0SZE:AFF)*<I$#F2<EJ+
M$*/0:L S/)J4;QNI"-!6G2^;^X4!3#8JOZ!,B<2[SUY H6'9;_;GL+67<%AN
MRXEK.5[#AI:V&CV<S;JQ$1\Q)NJT1VFK/U44'SAD9O&VM@56%F7<<_CY4L4Z
M=H,7S91<52\_4ECKVJ]B:O'<C@D$C59B>C.55N"S ;\XUD*2F-@R2]/IRJ\3
MNC9*OP64+R61XF2*9&*25W9E/7B/<"14#*C$;QLXE0K(B,O.W?$E\PU3@I=Q
MRE&Y(BHE&+BZ2UA<5U'$T32ZU$QZ4>UKD;!4YPO'K,D2(I"V.<J)FJ29&R9!
M3 !UDZC<BO2]=*[PS.\LEF62U-:>P\A5@[-,-U*D/OQ^^Y['8*HS&BBZ.ZJP
MZ01%CB"*!&5+EV##NW4Y+N&W(*<MR7;/MP?@Z-PDGEE*.G9">#*^;<AYL>FD
M&K5L,-)9"<L'+N!9 V$07CXT[ H-7*X%<+ H<5B@(!JQ8M-8@T^!T 73Z(HH
M=R>J@M6K/-@>P.]IDXCML@/<DG+G'[K/+OWG>)R/<IBJUZNP^9A7#G?R9R!V
M RL]5V!,:W+4^MNLTW>?VZ8TRL.:L;;?'\!448VN7MK:9.\5Y!_D%!@%TL5-
MIEREE['4JL^<(^1/6<.WE).9C8MNRUL%UA@B2&K$VI1:<=*BU(O('6FU!M+9
MFK BN]LZ:S4_2"OWC&7I^D[3K1-$LIL!3THK=H7+42]Q)-Z6E]PC-N\,4UV-
M;$T2'8]X(VBJL\#?'.]GPPR/+9TF\U9ELN0Y7,N$;IM[0E8BB8YQM,5W'-T?
MM9-P,O)4R#:'R!:(1U'1GHY,VA(\;"(HOTXN 9GG9Q60MQ:HU6M7AI0+6EAO
MZ7J<DS2S6$ENZ0\DE6=:TS&"N9)99'MF(![ Z:=1(X8T6]N#825@'B2*] L!
M [P:C&D-J$S#:;IF%.$:AAP+-*QDE$;I<7'6/9*NU6K,,C61EEB^5UIY.ODB
M2IE<K,I(G3=KKM%F\3"I'90H-$%$6Y$V*WNS(BZ4.9=941Q+5A)IYI:\)IQS
M$%H(YI9%Y%0)#S<AB)&Y-Q/90W ;@;FS%&8XEB9VE"$A"X7<(&WC4\0 60!0
M7(Y,5Y'8]A4]IL02;U.8QRMF:UO\<%W15#=!1:RYK%6(ZHLS YU'<#.TY.P-
MT49.QP5DN2KEFB\F1-(0,&=!HV,Z70.Y7SH]8:.32[!JQ/:TW3IM+Z_-U%BH
MVB6-!JB2+<QI)5J6.9DB"FQ)&O-5!;>98Q*VI;$HFIE99HQ[02T;L%Z>PC-N
MX$TT"_<>73C#-PV'$+EF6-H,A<LO2F:,9Y?D\16JXUJKU')#<V.<=9/AK;$T
MUQ,*UJ381V0H>3)5K;%-9V2C$YM@9W'/8X[5&7K\D=BU42M4M16K6>G/66W6
M-I[L:=::M+#:DKP5I626!U+1315:PDA=6'*!'C:-BY>J51*8W!XS10-623[Y
M3 99)U22+<*_3GEEDC<%7'5D1F92H6/<C]GTWO64KID!CFRT5J'R;+8=LN1Z
MLE0L:S+^QV3":-89U@T=>)2 /9JG5I)C4XP)ZGUY5G'*R*DC)0Z\*,O,-I#(
MJ:P*T<4;4XYA5OV;],>D6XTADMNCRK*JRGTK@8P*\DY=XUXI*9XXXT2F1&DB
M"&5N1T\Z;)(5C)> BP>:J$5(I7>S(TIC"HX^]2.0F0]S>MB:5SCMW522S':H
M;&^[M4]ALM)2K-6?C3<B/8"CUB9N%=LCA%.9=-).&H$,0*O)**1S*0=2CU%<
MY%VK9E:JZL:PT,M6CFFT'4*]NG*9)$Y5X-6FUIJ4J+O&RR79Y?\ 2./42%EC
M"DJ6:9E,LEF4-TS<TZ:A9"@,)&?35TJ"T.6Y26O32- B$1RL@=UY$DRA>MJD
M'>;9GNVN;9,Q[G/.VB VTRC1NQCUD:]"P#G+#E&T1RBIBJ/)5P;*SXJC)WTL
MTPB&G28?*%NG#2VZ56J]-2KZRNM%]R#U5K4ZX@V\NF135B_=]W8;; '+J-PD
MI2; ^@UYJZ*?*19I4F9F^!!3B-O,'<^0&19-[%W36T05TQ5FJ9QE8AQ;C'$>
M0%'>-L;Y*B[S XF924?4[ TBKY$R;>H71JSF9-DM+Q9G46^8JLFTK R0QC%9
M'9^NS(][TFHD]>YJEO6%A6>>!Z]RZL,4_">)E>2"2*O622*0$_Z.CPO"SR]3
M%6NJ5ZT2,1+5J)2CF/M!H(RSH)(23&S)+)+(CKQ8&5T<R)P5,XM6SN#MB6[1
M-[>)Y-3=IARG8>LCDL9#==69T^D7:DI3\2BW3:-'<A(M[L[D7+)5NU8(.F2"
M+5-%LH9,F!'?:):J)$@6KKEG7$'*0@R64T:/T;=F=^E&-&B(=G>1NL_(L0&.
M7'(R-79F,C0:>NG\B%5I%66_*9F"*L:R,U]]U2-8QP7BH!('=8[VOKXPSC.9
M=JN3[ A!W7'6.:5D'&[R!KSR*LLUBF!?5BF7%G8#MPGJ^Z1A)!PWF(9@LI'2
MSA".<]33R9TF_OV=4:W7LP3UXV,NHW-3K2!W5J4VH&IZ9&%!X3QNM*$1B4$Q
M%IG!8M&(\*&JL$.F11NP.G:?6TMI"%)LTZ9NRUT==MHW2Q?GF:2/8N.$9'%3
MO;'6JS*QIC&F,:8QIC&F,:8QIC&F,J1N!VW77*^3,19>QKFU_A6]8DKV3JHR
M?HX_K&0X^:@LIJT5>;0=1=F=-4&CMHM08HS%Z@<Y@*X=IJ)F*8HAG:?;CI>L
M%FK"W#J,-*&6+JO 5]!L3V(F21 3NSSL&!''8#MYY,FTD4,9&Q@LM:C<'^FU
M>2NRLODRE)&/F"&V(.199^S[K4UCQI#,LHVLN7"9\C]S4WFVTURDW25NF7X^
MLN:0VE+E19"%9422KD=25FE8K54C8F&CJDSA*\[KYV,G%%>KY,6KO#8K20UX
MXJE6E<TZ*DDDX5*NH223766<R-.+D]B62=[A9G)=H2IJ'T?+2H2MKK2/+);-
M8RR#C&0*;1&K"BHO%:T0B -<@I(7DFD+69&F-?L_=G]8&^TM;!% M%[R#D6\
M;KXG*J>54V].J-@Q\IDVV@RS+;01@FL'!Q\$UQ5.9&K)8Z!C6SA=E9D8=FU
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MV-4&J%N1W61:R5A"HV(X%4Y%CNVYV\O-&W3:BP )HI*B;_ZP2R5Y#R/NV,
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ML16&5=Q\?D"1QU%@+;N%4<=QK23D2R2BCA-5HI,$<KM:^4J*WG-]&OVJ?2=
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MC&F,:8QIC&F,:8QIC&F,TK;SY=.?W<N&13@HCCS"%'B.D0 !2DL@7*ZSLNF
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M$@3X$TI:?)=6Y2A\!3-K8BH !X%%00#PXUVW@EB='DC/;H:E?CV\AL\WI [
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M:[$W4 LJTH\<Y;Q?HG6US,%IQPW?35E9KL%H>.2\LUS7'U>4P5WEBTQ-@49
MAONI1UFDWWD6NA Z,1X&0[R2J045>5N6WON57=:"]-HU\FM.K<^I(I&XA4JA
MB3<%_::12I5<B(0 W(' #E-R!BFX$#%'],4P" @(& 1 0$!Y ?'G6C.VQ^&Q
M^KZ!W^K+7Z_J^KW#Z_RYL*V:9[QM0=L.(:SDN]056EV%YMN#8)M,O01<2$Q7
M+7*-ZY&%(4AS-NNINZPOY2[%%B@C)18KNR&D68+=_P"&M6I5M"TZ*Y:B@D2>
M;3$$LG=Y()F$2^7L[P/ Q+!54.@9O:7?;:;;@AH5DL3)&1+)4CYML6:.5UB7
M8]QO%TSN=@ RDD<AOL>UV7GFZQIC*T;?/UW[KOMEWGS&X,U)\_R+^P9 \ORM
M^TY[]S&2,OXKJ]/MF(L3SV:5$<B5QCD&C5,:JC;5<;OVTLA8)JM/;M>J!6&D
MG!._-4F(24LX!\R;NXMNT3<ODI%A:Y;6(%=7:&3KK*\83E"RUI6KN>;*3&;*
MQ12*H9BLNXV"G>X%4PSGEM,JQ- "2$<^D0B9&V1SOZ,9F0[J!(J\B02,S'#6
M4+#E6O/IVQX7RG@YVTEEHQ"L9;#'@6"2;)-&;DLXP'&V0LC0PQ"ZCM1FB+R6
M9R0NF3OKCB-@;.7-YE"JC<U8MRY(.7*/B=ASY*J^UMN.#/V(Y<3N,LJY+NO!
MU"\=G/'A)R&YX<6+>SY-S5.^W'D.^4:[7;WJ]+^V\V6_])K&FJ<KRU>\;WM.
M5/WJB/PG@],99G3&-,8TQC3&-,8TQC3&-,8TQC3&-,8TQC3&-,9ULS+Q\!$2
MD[+.4F45"QSV5DWBYRIHM(^/;J.WCE8YA I$D&Z2BIS&$ *4@B(@ <ZHDD2)
M'DD8*B*SNQ[ *BEF)/P !.4LRHK.Q 5%+,3V 50223[@ "3GYEXRSRCZOH6]
M5 6DED2T7+)[]JNF;K;L[Q:)J]*L3D4 %$ET&D^Q8CU@"B!TSE-[HG&OE3QO
MXFO:+#IUBFR"?4-4NZE:ZD8DY:959KMZ%5._%YA9KPI(K<HP6(/NSS/4=1EJ
M05I8]U>W:EL."@+=%Y#,R$.#L2)T4D;,I4@-[\VB]F[,$[G<;4P.)C1^3ZS<
MD2#X<,[IC2JQI3E+R/N#R%+DP 0]R)TSAR)@/Q[GX&G22OJ<<>_3]+@M(?<R
MVZ<)# [;'?H^8[$[^?;.QT20,+B ]NM%.@/GPFKQ $_2T3[?-DTT+W_&YG[6
M7:-\X&[37=YO1Y-_Q+_TY<S3&-,9$60,\8EQ99:G4+_<V5:L%V(HK7&;ME++
MHN6Z<[7JN9Z_DF4>ZBX&/&R6VL0*<C/O8Q@M+ST7').#NWB*1B?=':-!R=1&
M2HV!WF,H@0;D!I9VAE2")=Y)I$*1*[]L-[*EV[*%E<GX) @DGD('<1P1D232
M$<(8]Y)&5 2,BH^3*/D:I05XI]A9RE:LE<9VV)?*=['*JUV02%9I*N8^339R
M,>V53 QNI^U;"3I,"@$,4P!+*4 +#8%(I-]P1PFB6:(D@D#G&ZL 3N =B 00
M'])T_I)-- R^_JUYG@F4?A<)8W3==U)&ZD@@GPM.4*)3%Z4VL-B:,U\AV>*I
M].22*N_/-STTW>NHULW!@DY%-LX1CW1O.;@$8Q(2$(L[3.LB4Y%:2585!,K)
M/($[ A*\$MF8DD@#C##*X!.[<"J\F(!'M&\IVZ<?2Y-N-AUIX:T>WO;E-/$G
ML@[<^3;*"1GVHQC3&:IMS_\ 74^R[^QUOO\ P!Q5J?<?I'[&QEO)+WY50^UJ
MR!\YV.M4GS7Z?[CD>\?0?VKEG=3DXTQC3&-,8TQC3&-,8TQC3&-,8TQC3&-,
M95+>)N(3V[8D<S$.BUE<F71Z%*Q+6G*AR)R]RD6KA?S@^[K\]2K]1B6TA;;*
MZ+T]$1#K-$5 D'S!);7ZE<%*L\@V,K;I"A_I2'R8_P#IC^_8_,!N-\T'B/6/
M4^GF2%5EOVG]%TVNQ($MIU9N;D=U@K1+)9L/[HHF5=Y'C5OSI.J:S&G+T-Y)
MNGK%.$=UN6F7IB@[DGUE;.E+19I "@"8R$E)S*LVY./7T/C+*@<3B)M?,7B'
M5W/BR&X]EX*/AZ[0H3,9#'%QU"..35[4I+!>(CU"H SEA"*;N6 +$>!7>*6H
M=/>1Y(((O199'/M2M84FY9D&^W6G>25Y2/OB0>Y&^?I-VF9-'+&WO%MI>N4%
MK,G486#N[9%RFY-'7:!C6L;9VBQR&$0,:305=H]?!U&CMLKXE4 =?2/AW6Z&
MOZ57U#3[*V8B#!(X5T9;$("RHZ2 .C>4BAA[43I(I9'5C[_X:U2/6-%HW$D2
M27HK!;"/SZ=RN!%9C8^>XE5B.0#%2K$ G;)[F?U'E?WM??XJKK>9O<JGV?\
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M(_4#C+&27ORJA]K5?_G.QUJD^[Z?[C]HR/>/H/[1EG!$"@)C" % !$1$0
M Y$1$?   /$1'P -3DYC3RZTV/=F8/[;66+\@MP.R>3T4V=D%V(%:]39=T18
M/*3"!6_) [XP\)]0^&K1FA4\6EC5AMV:1 >^VW8G?ON-OC[O=EEK%=&X//"K
M=O9:5%;VCL.Q8'N>P[=SV&9&FJFJ7J24(H7D0ZDSE.7D/6')1$.0Y#D.>0U<
M!!\B#]'?+H(/<$$?$'?//4Y.-,8TQG@HHFD43JJ$3( @ F4.4A>1'@ ZC"
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M7@JJ1R(U.I7Q#$T%=U:W*."A2&Z ;LT\@&^PC&Y53L9'XH-MR1IQ2B6$"+*
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M_P"/'L:UCZ+:/ES=?Q_IZ!7_ -X_MES]_CI+\9/STO\ CSD,;5D!Y!6T<_\
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MWATMM,-UG*".VW(*B947\@P,!QR;CCD14CG310X>Y#W)S&* AR !R/-F2-)
M%<%ARWVY,ON/X)'S>>6I8HYN*R LHW( 9U[]AO[++O\ EW^;)HD,,8WEF3J-
MDX!P^CWR"C5XS=6&S+-G398HD6;N$3S(D506((IJI' R:J9C$.4Q#" V6IUG
M4JT996!!!DE((/F".?<'W@]B.Q[9CMI]-U9'BY(X*NIDEV93YJPY]P?>#V/O
MSJU-NN!%2/2+8;QHL61[OR_OZ9 +&>]RD1%$71U6)SKBBDDFFD*AC"F1,A2=
M(%+Q3ZNH$,#3K'E]]O!&>7EY[KW\A]64>J=+V8'3J1#D%]ZT)Y$  %MT)8@
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M/)QM^P6[:D9.L/8U<,TR]*356EU\Z")? >$4C,!(CX@ \I 0>0 >>0U)H42
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M*$)*K*6E4%AQ)XR,R[D$C<CMN=MMSGDTP3A6/0(U88GQXR:I@4"-FE0@FR!
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M9"0=F4'=3[F .QVR?5NG[$"I$I((Y =Q\"#L=B#W&WO_ "9=O".-\/W_ !M
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M;IL9K-J-(]FIZE9A(/F!NK=__P Q8?DSI*%[_C<S]K+M&^<#=IKUO-F/)O\
MB7_IRYFF,:8QIC&F,:8QIC&F,U3;G_ZZGV7?V.M]WX!8JU/N/TC]C8RWDE[\
MJH?:U9 ^<['6J3YK]/\ <<CWCZ#^U<L[J<G&F,:8QIC&F,:8QIC&F,:8QIC&
MF,:8QIC*L;I[\UBZ6[QO'*"M:<@Q[B/%)$Y!"$K!U2(SD_)\F Z+=1MW\1$E
M*!E7TPZ331+W#1^NU\^^4'54CTJ7P_7;EJ.N020$*>U/32ZQWKM@C=HT,1DJ
MU0%+3W)$51TXYY(N<\27DAJ-00EK-Z-DV4C[C6)VFGD[@JI7>*(#O),X"]E<
MK0IRZ73=J';&X81G<-W+8A"F,H"I!46,7@!/RP;"S52*F)>\(JX Y#""73\Z
MZUXMMZ;XC%>!AZGTD5(-5@2!999FM)U[$L;C[H'TZK)3ECC0J'YVDD1R8BG1
M:%X1TR]X8B%N+CKNOK>M:'<>R\,-2+3Y14H5Y$[0M'K-V+4ZL\LZ,T#5]/DB
MDA1K//OHV7)#6&DV1%0ITX&^5-^JH0Q3 5FM,(0TF(\&Z1%.-E'AC%$0 !*(
MF$./#O4U&L)=(U:I8@MUZ6N:9*9ZTT<\)C:['1MD21LR$QU[4Q8<@5(V8 C;
M/-7@MZ7>JBY6L5)Z]RG*\%F&2"58I75"[1RJK\&AE+(3V9?:4D=\VV3/ZCRO
M[VOO\55U]'9Z7E4^S_\ >1;5/L$XX_!MCIC+?:8R$<KYYJ6(;+BRI3\9/24S
MEVSK5:L$BAKS-DB\:I(.':TA)VFPUJ/5520<%7:UV$<35UFT47RM<J\PG&29
MFD1D23FN.SBM-;9F#<%A@:))#NJLS$-*FX1&Z:<I93'"CR++*4A-@[=,3Q5]
MN2ANI,DLB]F( 7C#)NS,H9^$2<Y9(T:*7>^S;82<ID;$Y%KUAAK6K8_+[?%3
M$;Z.5%G TJ0O#25GG#QRU=*1-G81CN.J[^(:R3:9F4'$>T44<-'1$;B(SJS
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M3NGZ=1O_ .8R>A'\9#_^M+_<XSGT3BOHLS\H9W\8ZGU96_#N?I"__F<="/\
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M!=^X<N.@I"% "BJ(!P(^L3"/J56K#3A6O )!$@ 42SSV&4*H55$EB263B%4
M#GMVW\R2>3CC6-2J[\05 !9GV''ML7+']??W^67?UD97C3&8_8JI6K:R0CK-
M Q$\Q:R\!8&S27CVL@W0G*K,LK'6I9))RFH0DA S\;'S,2[* +,)-DV>-CIK
MHIG*'LLKCLZ%BC#LREHWB8J1W!:-W0[>:,RGL3D[G9AN=F5D8>YD;[Y2/>I]
MX/8YWG=)#T\ID'I$!+R0H](@'2 AR'@(!X (>(!X>K3(SGNDPYX3('4(F'W!
M?$QO PCX>(B   B/B/'CI_'\?6?KQGGIC&F,U([IMU^Z#&/:7;#-O&-L4N['
M@K,==S"\RA-)SE,:.YPT(QAA>2,(SEK(QDVZ.&6[B(M$Z1PR;N++'VAU'5="
M<D8QPU2D#<,=_+;8?'?\G;R/V^[&7!L46SE-XU-2>$.H0FVO(!B@FX<-QY]D
M['7K,V61,(> > F$/W-6)H8Y@JRJ6 .XV=TV.Q/]!EWWV\CN/A[][;QI(5Y
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MNFZ*:"?4/ ";H3*4O4(  "/'(\!SZM51Q10KPABCA0DL4B18T)( WXH%7?8
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M1MMB-"]_QN9^UEVC?.!NTU[-GE0\F_XE_P"G);W*98DL&X-R1E>'AF]AE*7
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M\F.K(L.H>')I LU2Q+J.F(WL]73+SB69(=^S>A:@UE)43?I16*G( ."?0/E
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M9)N9A%8HQ=Y"R55=5D0H\EH+%I\L;&,O$$,M>SKD;+P!AOP46"FLR-2YD"J
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ME\=Z_?\ +YYUY:#3 [D35N*5,W2[A$Z[8KA1-(0*4Q2G7%0X=8$+UCU=2@E
M3B80#6&/"OAS[GRT:A)TD,<9E@68HA"@@-+S.[<5Y-OR;8<B<R3XCUW9P-5N
M()'ZCK%*8E9P202L7 >SR;B-MEW(4 '/!3'U(54*JI58,RA.CI.,>AR'=B8R
M?AT<#W9CG,GU /08QC%X$1'4-X3\,LX=M"TLLNVQ]#A_HEBI("[$J68J2"5)
M)78]\D>)-?52BZQJ 5N6X%J7OR 5N_+<<@ &V(Y  '<#/I3I-11*!$JY$)D
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M"!2)(I%,HH<P@!2%$PB  (ZJ1'ED2*-6>25UCC1 69W<A415&Y+,Q"J!W)(
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M)I0R%(K$=93N>4DCZ=I^I2 * >!@AU.M',LI1TL=6(*W2+FTX9#"K*09H&L
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M *XCVZ5,2CYM6-*5 K>>F)5VJ@1\X<''SF60:I+>N3[GUE+8X<NSK0+-!2C
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M):NUB=J[3EJ\BPJZ%%=9MJ6K.1C3&0%NL\=KVXX  1$<$9<X  Y$?Z09_P
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M^E-8KIO-805HXYXD?IB.7[[CM:^0?Y.O%QU*#PG0U7PIXGU&.>QH-8:U'?\
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M(\ZU9.Y)/F3N?=Y_,.P_)G0@;  >0  W))[?$G<GZ2=S[\M_J,G&F,XZ2_\
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MYRS-]\WS*/O(E\HXE2,=ES[4MRU6:"MIU?T'1]-K1:;HFG*1PT_2ZI85H.P
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M=!D3Q'H\:$&2W5A@GA\1:="A[O/+02KJD2)N\@T:2*,,\JJ=N(#R #\8 /\
M#KT+/C'.=,96C;Y^N_==]LN\^8W!FI/G^1?V#('E^5OVG++ZC)QIC-77:[B
M;5Z8(_!N\V6_WMS6-1TQEJMY)RI[9\K'.8I"%B8@QC&$"E*4+/!\F,81  *
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M)CS62HQ( 89*/9^F*?9!M2.0Q3D/@?&QR'*(&*<AJRP,4Q3 (@8IBB!BF 1
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MXZ=*4><<@_\ R-]F/3Z/^V5OS\?^+.?9*QT/B%^I(A\86RO\?\XZ=*3\6_\
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M^M3BOU69K+6R6)NNTAG%ND'*[YM(-'TLK'P+=XKYMB@8.)90QWW;N/<[J.X
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MBUY!4:@BZ9NF5523;MHAJ@U1(CJ>FOQ?;OVZLOOWW_I_/V(V*_T2.VULWIR
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MI1RV?%=6"=7D*##$3R,49.^^Y12=_CY>?S_3\3OF+J.H(O%+MI5XE.*S2*O
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MQY5U([S= O9J0C@0AU(P\4T=E=6"3,YD&K-)\]24;H/'"Z+)FF@]'@[#HQ;
M[@=-//X^7\;# UK5PY<:G>#LH0MZ5-R*J20N_/?8%F('D"S'S)WPA+L\MF[?
MT,1;X"QRA'T:AV7'41&!58)5NZKUI:UQD]5FG;F.7EI:<9MJPQ)%3[N2/*L#
MKR"Y')G#LZH3T(>_W&+N=S]S3N1Y'R\Q[CYC*1J^J */6%S9$,:#TB798VVY
M(HY;!&V 90 I  (V&V=3)=FIL<EFBC%YMRQX+96')!'*WC56:GF]/'C_ !<4
MA5V:[==-P%0DW;<7R:I7PRXHV87 V-NWE$G0A_%1^>_\VGGOO\/CW^GOYY0=
M3U(C8W[A&VW_ )F7R*&/;?GOQZ9,?'?CPW0#B2#@F)=E&TO9GM<C:_DFB8@N
M\1AVNVR9L>2;3BBC-I23CUI^=M2BSPCED^$JC-&53BFI#OU .5NW HI%.5,D
M&O QW,,1/EN47W?DRY'K&JPH(XM1NQHNY5$LRJHW))V4, -R2>VW<[YFN)<#
M;*MQ^.,(;@8#;;B1K&3U;9Y#J#-2B44BL<%RJSF-=QUB;5M)Y79IW'L)=ZP<
MM5W$Q',99$7;%0';1NZ(]&K[$="+8^8Z:=]O+?M[O=\,DZUJ[,C'4[Q9"60F
MU+NI(*DJ>?8D$@['N.QW&9O+;#MGDVWOK1_MSQ,9#)44E#6HK>FPS(RC%&&4
M@2%AE&;5%2LKC&K*$.\KIHQTHYZ'JBQWA"+@]'@]T,7;R^YIV/Q';MOL-]MO
M+XY2=7U5NH&U&ZPE $@-F4AP!L X+>T -P =P 2/([9BDIV<&RR<7EUYC &/
MGP2UT+>^X+ QT<C'S 4NK40S5@$.UC3EA#P]2CW9X=V=VT--.Y:5Z0<R"HA/
M0A_%1?DC3N/AY'L<I.JZF3N=0N$\@^YL2GVE4*&[L=VXJJ[G<D*H.X50(XQO
MV6&TO%.?++F"L8MQV-6L.%Z1BLV,IVCQ%EB6$O3)R4>!>V\K8SRKA.2E*^K!
M5UVR2:H)F"#&66=.'\H_,H,$) 4Q1D [[%%.Q(V)';8$]MR!W_+B/5-2A8O%
M?MQN5"%DGD5BB_>JS!@S*O?B"2!OV]VW<U3 FR[-.6KW#N=I6.(V6VZS@U^/
MD)K&5.C8*W)7F%,E)SD5")1I49V!:OX&2K[&5EF:B(3D%+GB#%,U66&/1Z^V
MW0BV/<_<U]WQ[?/V^L9=]=ZQN&.I7"R[A6:=V(WVWXEB=M^P.VVX['MF8.>S
M<V..EC+J[9\2F4->Y'(O2-,@10"P2E1?4IRW\F,P,W-7"0T@X5;54Z1J\VF"
MH3B,<64;I.BPU:NP(:"(@C;8QKY;[[>78;^8'8^_*HM>UJ&198M3NQR))UE9
M9V!67B5Z@V_I[=N7GML =L@?(79I=GCBS"EJF+CA5)]4,=4M:S3KIJ^EAL;^
M-H-(;1QCM_-#F.%22<0=>1_H:/19(.I119T"*:SI4XU"&-0 .8'N^ZS$CS[
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MP'U[?W')S]KSVK/[9#@_^(;%_P X+3M\#]8^S([_  'UG[,>UY[5G]LAP?\
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M_P#406^<C;8GXD;#;?X#X9XC%Q@E=%&.8"5]WOEI1:-^EYWW K>5!W?#CO1
M.][[K[S@.OGC3W >X>0]P[ENP]WM,S?22?,G'OW]^VV_OVV VW^&P ^@ >0&
M>1XZ/4 I5&+,Y2N4WA0.V1,!7B73W3HH&(( Y3Z"=VN'"I.DO2<.D.'O!]XW
MV/O&^^^Q]V_)M_CN=_,X^(]QVW'QVV W^.P  ^@9Y^1L^OO/)6W>=^+KO.X2
MZ_*12\G%QU='5WXH?G(J\]X*7YWU='N=!V\NW8CM\"=R/H)))^).YQ_?MO\
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M#[QV'S#??8?#OW^G/,K-H10%2-6Q%0.=0%"H)%4 ZJ9$E#@<"@8#J))IIG,
M\G33(0PB4I0!\?G\_GW;D=__ ,WM?\7?SQ\![AML/AL-AM] ) ^ .WEG@E'1
MZ %!!@S1 CA5X0$FJ"8%=K@<%G10(0 *X6!10%5PX54!0X',/6;D.P '8 ;
M#L -]]@/<-^^P[;X^)][;%C^$1ML3\=MAMOY;#/$(R- KH@1[$"/>]\L*#1N
M!7??B)E_*B]WPX[XQA,KWH'[P1$3\B(Z>[;W=NWN[$L.WS%B1\"2?,G'OW]_
MQ]_D%_Z55?H4#R SE2,C54P25CV2B0.".P24:('3!TD)13<@0R8E!PF)2B1;
MCO""4HE, @'#R(([$$D'W@MN20?,$DDDCSW._F<?$>X@ CX@   _$   #R
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8\<6W!)7:15#$G) TR<:8QIC&F,:8S__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>img102984888_11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img102984888_11.jpg
M_]C_X  02D9)1@ ! 0$#O@.^  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $0 40# 1$  A$! Q$!_\0
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MG["0QI_;K*_V+B4J^S-[:]]=E78A:#,@=%M-Y,R-SPZAU4LAX]&'*D@@'TS
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MLHAUHI/&F#0Z<4T'BC0X0H_ D[AT)=/K%_$VM3;O?9U+PUCJ:'4(ZE.K(?G
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MC%O_ #D(?V3S'W>?*!^:G?\ KV/]FX^[;Q=^;[J7^OO_ &?C]=]Y;_XC%O\
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MGZ5D?W>8^X#Y//SK]-^J_P"\<?/'6_WMW_38_9X_&*^HQ_!'],_2LC^[S'W
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ML_MO:=Z5KW]B6M^WOK[?;>OLS(^1;Y/P0?FS;/!!X/5-_@\?0?P_PP/DU\(
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MA?\ W.+_ .CXG_R<^U]DU/W-K_ZF?]7/I_+G_P#33_[5_P##'T&%_P#<XO\
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M.2&5)BE669ZA[R_XY6^\"O'D@Y<5W$E- !)-AA4JQ3N;U^W6\00L%.H]FO\
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M\8QC&,8QC&,CN\Z_"6P>7,KG$H+<:"%1385R#NCNET U?Q@"3<6PB(G6^;L
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M5'%"2X=Y5K)V!Y:='0DJS QA$$S$*HDRHID !,K.B512@X4JE9SHJD<*Z(X
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MWG3X"W3)7EOUKK'*A$,C99W028Y,'GC]'!F9$R+7=3+&S**QOFH]>XBFK&E
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M)R4["EF^+W7M7*;8?F025;)46O\ 0ZMRP18[,,@[BS I(W8[4P6%U!Z:N;(
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M&M&2=9;FP1V\B<-'J'4NG;#.02Q?S.G&LT16[I5X)%%"M*(7IO#1B@J['41
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MQZ?#/H!Z<<>G'PX]../AQ^+C,&.I^GQP2]T&]U"J")7.2UU#GJ^FQB3%I(L
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MV5N1^$*@!.%&>]Q7SP["WX'BBDJR^SRG&/:5X[3.<D"E>#RO<26))L] \/>
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MMP1L2&/CQHC,UJM:AH_Q[)3'JQX2,DA(%G+4HPG- ]:.]:L&I5WHS,8T0(&
<^+TM5SP%!I>KVJP50J(#2C%415FBD(BJB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>img102984888_12.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img102984888_12.jpg
M_]C_X  02D9)1@ ! 0$#O@.^  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #F ET# 1$  A$! Q$!_\0
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M"&%J\_S1:T;6QG0NU69^[G4K%;X6$G#9!@E)T=27/>6_%76]9T?!<MY,\?\
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M/1T='HZ.CT='1Z.CH]'1T>CHZ/1T='HZ.CT='1Z.CH]'1T>CHZX#_EC_ /E
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MHZ/1T='HZ.CT='1Z.CH]'1T>CHZ/1T='HZ.CT='29_([_P#%Z\\?_L9\H?\
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MRL_0C&V-X"/_ '!J\I:Q+6U\S_>)DE)>CKS'O]O_ !_KU_EC[]]:BT/]-_\
M%5W"_B'XSP>,T.'X/\(/)G/^6/ O,<7LOQ\[+ZWG,?>QJKNCEBKEGI:]Y?2Z
M]_9_?L?NZVO;9IW+K++&FPZ]ZW='_P#O_P#G/HZ.CT='1Z.CH]'1T>CHZ/1T
M='HZ.CT='1Z.CH]'1T>CHZ/1T='HZ.CT='1Z.CH]'1T>CHZ/1T=1&]HGD8VE
MIA]$'1J-LQ-J3&O'UQ\IEQ+_ +X"(]Y+X_W?^W\^N6)"DJ-B!Z7^Y_8>L_\
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MRB;;I@)!=87DL[#)@O>02+"B(C^(]_>',,]B9)&2M(XB!+M$C2*H!]$CT<$
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M&D<*KL2TBR.V4*JFP55"J=P"HC16#$$N=@ORR;3Y*\S;W!]CR&%1Q+NF'1W
M79;40^V"I8^$I F0/M'O$R9RZ!6/L,24S_/KCB>-2[4O6)IUAEK1[(DD@^11
M2Z*&]EQH& 7]W!QGX@-C"C1QKIMEL,Z$G#?I7(!/B))RSR$8(&"=@>FW:RN=
MJ;;=ZGA4<W6V_H_JVFFDN+U]@A,@3W>WR* &9&0.?[B@2@O;V]V<UJ6W!'!)
M))+! C"&/.5B1O3Z!@0BR956V'M?L8;TE#%X?*B,I+.'.N%#,B-&C2,BL6
M;0%E*EB0!D[63J<P.FY2[S<N.L-^B2X-$>[%1,Q\6$43\2%90(S)%"HB8]IB
M2'TC#.:SP,%4LA+*I(7)C*K\6&R*5"KH"5*_I)QCIJBZR,[*R[X5\$G4DY(
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MPBX>,2>16B+^D(8!I' V^("N/T,[(<ZE134F(!E<AF)F7N/XD/L)M*(F0&"
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MJ9,@K.J88*@9L*K@2_%2]\3\3RU>W3XNSW'QZTYN&IWZM63E'X>O([7(:E=
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MMO.P<3R<?>?'7>-Y'E:]>&G&8%@?0%A"H0R?:,R;1G5@N'#!O6V.J7SW'/\
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MN4YJTC5[,$M=UQB.6(Q3;$9>1ED0.P/Q'T4)'WD=*I@*'5TD7Y,LD;QRQO\
M%20Q@DUS&21@:X)!USUF71_&2S>\^X7FP.U5GY."P=>]CS0:>BX\Z@=1%*GJ
M_?!U\8@8RQ:H@F2:XV%,29?;ZL=+GD3MZ3@&I[S3OI!9\J&*,23"8EHM,/(#
MJH9)3JN I558!S.5>0S.69\(CQ% =F6(PAEF)_IQJ"9)%13O(TBY+.&Z?GA_
MSKP_G1?2+Y!NB[_9.O8Q-.MK9]K-LN9,B86J:;8?*QF68 A7:4) 1J)9?%D?
M&6/+]O6^">J;XCULU3*DJ2QNN"RY1BA*Q.!@L"XV&N 5P1& H%D=59<RA3Y5
M",& 5E.AR2C"37Y$2)*CQNB.I42'7]IP_*;^1S#MJO7Z39^,KS6H>3/G9)@*
M4ZV('4KN>(,_519<A]LHF4@4E$2Q_E\\E9K:5WDJQJ3+*'C#I[ 4C;#,J>E+
M1; 89F8@=.J;O,SQD$_(NGC9FR 02<ZLD>S'*ARBNQ^.3@"TIYW,NV*E^5"U
MT^[$-.)L2)"?_<#CF?KD#F8$H_Q_;'^(CTV0*@95D?:34[!R@)4OE5*DQY&<
M$'"_0RQ(/7;V)51U 4(GIE& V,$!""H/I<#TW[#UE<&?UJUBM49:#-LW'5Z)
M6*]:F(6+UMBED4+J)<U*FO<7NI?V,3!%(C+@$9D56S],"00X&0NOK+JNI)$C
M9_<$>P 0%."PCE3)1F_2V/FX4* &(+ @A#C(+'78'&WOK^0N$E%\"K64NH-^
MFS%FJY<V&,JUW+&FR8)3TQ]L"SZBF!L U4E,I]I[:%DT)]JRM[+AS&I!0;;9
M*J^/8)).-B<$*.@ \D8#J(W($1!7  R-F5&#*=L@$X#*5"Y)(ZS-X.MV?(7:
M]SU/8^.'<?T-'I+G+9UMTF4[F#6$0B^<N]_K-QB E]7P2:_I+V(@/WG>7KP4
MJM&E4Y-.0KR0)<G1-,1SR@ 097;81JBZHQ$C8)VPF.G322PUI5EA6,K*P&0=
M957]! D4$Y^1;4M&ZXU<D,0].Q\;<5V+,.YIY%=O^RME>YAPP1(ZNBKV"'!_
M/O\ V2,E\1CV&0$HDICU%U>2LT!8,+O";4)KRY]>:(D%DRRD,_HD ?8/IEVR
M6T3281)/Z@D?R+XRRJK@,N< '"@,< G3.3C/5,S> Y3J_)]?R[7TYL:E)3LI
MU95JM;RUVE(.F+7PJ"_6<I1?&$D2V?8R99$^T3#K^9VH^-;BI8(EB=Q(SNH5
M]20Z%"2!XR%P#\CGT<:MTO(I@C<+N6 &!O$1]8< :LVP'VQ((]K[R>FETVO5
MY#G=;I]HU4,O!1&A<:YDP+E"T0^M; %S( B^ F(+9\?E\0 B]H&+BKRVY(JD
M,3"65M(D]&0;,691AE0)JDFV2JD8.RY'357C9EC!=M\ NN"L0."K.J#T0QQ]
M98$^@,GI*:&+X\_&S@O*OFOG:#MI.B5OL=FCF)O7>CZ'4N"'ZE);7P?ZE$'6
M%S +4%:JHK%@H"2F(EJQY/N2[QO#R7XXH8S^!"9RJ1PA<ERP907E4)LP!8RA
M5 ()!Z[FL;%H%J&)RS/,1CQER^6<,"S*K'!5" L>6?ZVZ3OA/5Z;\BL^CY>Z
MKEM#Q=8J7SK8^:%P[):V:N NCH(,THM5E-^\J[QE4#9@2^MD@,^TAST%;MF2
M3AJER+DEF0222E1&T,S;QE ,R+(5"DH 1JK $ G/3Z/6.-=4&[*49<JZLJ^-
MDPQ59%4&0J03\P6"Y /6C>@\I^*N$V\#D>KWLW"Z7HJPVLQ5R+9'=IS?5GC<
ML.I*=4R:+=!BZ<7=1].J=QH)6UC"&(KM#A>1NPS7*5.6:"LS1V)XG0*)2KRE
M$5V#RN(P9F6(O\,/Z .6A:1GT60D*0RP:EBAQXBTC@879L(F<!VR%'IL>SRI
MW&7PG.]-V^E9NV:52K5$,R&-9-0(@*S%9L@!2H7?/W.?@8S[L.1DX:<(4Z4O
M)7:].LRK+/\ "-I/TQJP+'_J?3!3[SG /Z>NZT;"((T8+QEW>13L96,ND8?)
M 7V5]G!&"#C'5"\:>7\3RCRV=VG, S)S-.(4:+WQ!BG59FL8DMA0@#)OPA30
M^"#%)0/O'S^1S=&UP]UN/G,320%5+QH'W4HS)\D3R*=&PZA]B1@Y'KITD 94
MDD)9BIU5<909;8KAB6/IOD"5PP.?W+#$[:V+I+8YPVA"2&9^##D#B)ED!/P+
M[BDF% Q\8G_'O$!$,O*&R< C5(P,9+J-F U()!^P!C8>PQ!)'7*HH42!FR@+
M*,MLH] ,[8+#5G0-@_N,D^R$AR?GKQSW7E#R#XNP+FY;W_'5/5=KS8S-%.58
MT,2U%?8H9FD1MJN9CP2BLY[(JO\ K9^S76Y$RT+!<[9Y/CN.H<Q9_'6MR+(M
M>/S(]J))P7A:2,!2L,JD^.1794*.KX8 =$=Q=74>5663_B'7Q%2S0NJ-^L.)
M!^B0*)!JP!3#B&\:>6</S%?Z''5A:&8.-]T-7IPE]32K-L'65:(/\?1;^)?I
M@PCAJUO,1B$%+$.8X27B4B>61+"V\D*@>,(8P20#]N5#N)&]E#]DY #F&=X%
M21&".DBY*NADC#^C[!8 E?6OV-B2/2%G;SE8%W1N,>@4BX42 $M=24$N5S#"
M.0&7$4"E(*&9,?<8*)&(B%"Z$QE#&I.I$BC9?>=3E%<%2WQ!Q\68Y&%/7%E]
MHM5(<J@T]$/G)^\(2S'8D@'W@  LN.KE<77TZQU*]A290G256,ZX*=7=<JLI
M0Q)!'_*:U.8"Y&)]X*?F4^\_'OXQNK 8.Z K@;:AT(*J=@7=_I@"F,'./ILC
ME5+3(P21%20$G+!2SLAV "8U5F^.0&48R.H#Q]Q3>#X_,Q66%WR0=FV%AX21
M(BQ8F?97VB<"2Q$6&*R OD1$N0@(F)._8_.GEE*:K)&BZ*RY'B&H\K)A"TBD
M!F.$."VK-KTWDD4RO$&"C !8!AY)--\M[V:-2  ,^FV)(7!Z5W;^(=.WYJY3
MRCRG1[\YD5]:AW7+*?5G%VZS?U+.=HI99-?Z&EB:E=5FJY7R<5:YLH"9_=:/
MI26Y#:X6?BK%6-9A+7L4+T:Z6:LM=B)ZS%03)#;@=8BI'_$2#!RB@+49Q$DO
M_!V:-@ V"SC<%<QY#/$ 74@-H@=2"IR3T.YBTF]@95NN) E]46 )1$%'N107
MR]OXF9."F9C_ +IGY>\^_OZ2@_X4?[87&/[8)&#]9(^B?W.3U2;BLMJ=6;9A
M(06]C/\ ;T??U_?J=]*]-NCT='1Z.CH]'1T>CHZ/1T='HZ.CT='2R\SJA_BG
MOU39=3$^8U!*U7,5O0/T3)-4PXD0,!B9$BB8B?\ ,>WI&P',,@20PN5(60 $
MIG_$ WKZ_OZZ?\45')4B\8E468B8F) ?##XD@@^_\B#UQ,ZWJ_&]/GZU3L_*
MB>/-'0T6U+U_H\&OF6A9I@.0NY5LM%[*S(CZ;"#,ZM_YM%ZPKC)3F7+"'SHD
M_+@RM94JS%&BE5G)C$D;'.B@9*[@/JQ&OK&W\4EYGWI<*LZ&K(/&D,TDRMX7
M\C0A(RC2#.RN%#QLN020!U?_ !9RN7Y#J=WS9]EEZ%1M!6@U7/JR*6FB[3TZ
M%Z<ZDQ0L@6:(K;9"Q7$7H1(_2<I7!E?.0XGB[G%5(8^4BG,ABB;Q+!LJ@!I9
M!XV,@=2,J225(]$E3U5'Y*]QMU+,G&6(RA=%-M[#1NC*\:D^34:*IP8\,"P!
M8#/38?P>STG]<U5!>IUZ5.Y6570%V+C/V:S:@HDE-EK6*"8^)K,),0+XA,^T
M^I_F'@K<$>*@59))8-5E4C*'[5B% (/UD^R/63CJ%HS_ /[E#:E9/<ZR2!]0
MC$,#[V!7!P<9]#8#X@=9=\K\NW'NXG2+REYFOTEG,X[54BTFKG;E38TET$L.
M6K--^^L?F51#_K;6M*(UF,J*8R'N6E%6J5I:E58K]N.&G.J/'K9F=PHE;8$>
M4DX.RJPT)&0 1IO;]U[,UNM/.LM6H)^0@D:-S+7$46QC0KAU23TDBXU9&^L:
MDM3P]6Y7=R-'A?/>[HV_(6/5L[-!>M4JYE LQFO=KX&OB6,U((U6E5557;M2
MUUZM<$TV/KDH^3.DTN&K=SWK YFHF\,,Q"P1Q"5T@>N\6XM%@H+R&0N&)08Q
MZ0Y>1Z\BW^UJ<<?#W7\,TD3M+,\SPHUBO.LH'AT;?1-<&, @L/96?ASQ[<[0
M>S?Y,O=[2V.7K]+ALZ3*W]GF;'2\Q9T=-O/10N93ZZNBIQD%46=2Z,S3NIL&
MY"?N^36_;G%\AW/R<ZWI;%9L1UF_'FD@CD5R2FSKJ):S+AV3 R<C(^C+=R\I
M3[>JTAQ5;BYZ\S5KD=6U!#<:K=6O%^4&68-)3E_)\I#*%5XRF-PA @.A_%_B
MNZO4ZRN&SM/Q_P \=O\ =Y6JNFC)?;JIJ7,_:T^>IBNMLW:K%FNJBP+1HLEC
M$19:WV7=.2['J5;]"/D*D:<9#$=C!LAD*IJLA R_C!)#Q?XLL3E6ZB^,[_Y2
M&K=LU.5L)SEDQB.>PKRRPI)(PL4X+<G_  %=&0&7*!QA0(L8+&X#FJG9\STN
M/D[A<U9H]+8'5VZM.]+G7:$9.OA6?HBK=3=&GE/RZMFZTBKJ6L:0E\%2A?53
MB^*Y+B.4X;C*$<]BI.4CY.(PH%8N+%:2-YAM,ZPB)/'\E 5D)R2.H[D.2N\9
MRG$\IR,C-7L4D9..=OB8Y!+7N1A8RJP@VXYY@QPS28D"$D%DM^>?DOKL.>9\
M8<_K>)^<SMK@WZ/E/,Z%>B'4)P+=ZMD8^GR9(3'-M_9O#9^=M[?L0L(L0GXK
M^4T+O3E9>*XP<1%^(HEC@B"V(U#JXD13&J[J-PZJ5\8+8+-[ )ZNW\.N$JWK
M,_<-J'G;35>2\'&2T41ZMFP8))G@N2DM91%B*%T"!) 0C,,X$;S?)Z'D6]P'
MF3+XBW8S7<.YN=;U.@B KT;*45:O/K4R@],5[0UW:4Z\KJ@"K2:WP<)E*U^W
M+-[N"Z.4DXV"X)N/C@K/*8$$*(@C6&,3:EPTI=V+!6<L3]'!YYE:? \=R/;S
M\M^$R\PDMJ"O7G9GF4[R69'CE5R8%=(17Q)B2-W)0@91S?QE\ <[Y>V_)OF/
MP[.1JVMI^?P6=9A6[Q&70T_ON6+/TT:DCCVC?\RE=MJ\HK5J;6?4&]9LF:/:
M?:<7'<U=F[HH&OQUFW(OB\H:H7US'YT1A&-M7 9B%8LBY;10MBYCO[N*WVS4
MXGM+G(;MD4H9.2NQPM5YJ40A4$(FLNK3J0%4O'FR418I6>)% J7YEN\+%WWX
M[8_6\35ZGQ/EV^LI]7P_,L?3JX^%T&#05S5W4Q,]:6]#S5"S3N13X]46+&GH
M?IW:U2S--7M+=^<KV9'>XOCD6*.M&J".6G PUD\JN8DFA7_=FE;1FF'C0%6&
MZKN2S_AM1[ZFH]R\C4M2)S=K\9JEODY4;SVJ\DILQQM:9XC<EAE"&W*!!7B9
M_+(BL'6[?[9[3M>^Y*EXGK^5..\,^.?&.EK9WCSR'S=!E/;UZ6@[!YZK@YG5
M6AW<AM7/N7UIG?;4KU*X8[SI_7$QZI/<4-V[)#0X:UR!I01+/!YXK$XA4*PD
M, FC56&' $B^5@0X1B">IKCYJ''<9R-[N6#@;'<G+\Q'3L7^$Y#22".6-+=R
M2])QR346$DL4>YI[F7R3JK[%2W^>39O(\<\WQ%FKT/CS5W^ASLFU>ZG%;OV\
MNU=S+43F8]+E,EU#7P:3[,4K=K+N:6<,P5FZ8!6^Y57Y#C]Z,'%0)=K_ )$@
MBENWYMX8E4G!" '"MJ0!@$$C*%ACJ2X96;E[W*+^%S%6E4L6(*_%3B%+(CE7
M$\UB_/%+7LNL8EB6Q#4L2*0B#:35EWXO;Y&_'JGC^"\71ZKIYQ;>,ZEY4\9P
MW1Y#^A[TNU;7^[>.)MJ[S[:5R+5.Y;OU4(O$M%_[U+<$%=>!GL=M9XJC+)+9
MN3"U-9JL\M6*&4Z?/R)ZTU&FRK\6'O)/2/<M3B^^+<W=MJM0J598K$<_;W.@
MU>9-ND%@C''WPL,%M+$?AGA2*:1T8O"8V93KU(Y[H"T\X$4;P:W,NF56^IJI
MKVK$>PN*\QWZ2C0]I#*@B:B(( ,2;*Y7_=>ZG(V!8:C2?\JO.?+=MQ*TKURX
MS*YT#$MM_B*_'& ?K.,6^/C""Q;A:E?A&*O&/(T:RZ!/"J"<K*BD[$"1E+8;
M!.QZA=S!Y'/_ *RY.USW3XMB19N+UJ5/H-')1>.O/[O_ $0,)&57K*$65K2%
M_KS$N)P_\GQ97^'X2C:18+,-V&YJMOS8L-65V +#"C*_?Q. ,,0?B</>.Y#E
M[\,8DJ7N,LU0QI?B/)4@MO I'A!E8#\EG;XE6;=2$"'1"_K_ -A556,DZO0?
M+B[UR?V<VK>MTLO3BRDK5>:T)NC4;1D?[?UUKA!P:_<C(A'T\GXY>,GXZ%.?
M%C@[LH66I'-B-(P6!357?6,X&,-Z4%6 (QTWBY@7(^0FDX80\]4@(BN3UTEL
M(Z,$=F9XDD$ZDY5WV*G(7# MU6_(?&\['2>/^8S-O.XCDM;6N6NN16^JJ>IG
MT*;KB\BD]8E^E%O4"J[5:M3(;GK8@UQ!M:*O<?&=H?E<9QL4U>K6L[2S&!HT
M&L8!"^0K\5DSAL'[7[ZZ[<Y;GQ3YWEK-2WR?(4ZT<7'B3R.L5B:5(/R)8P5\
MPKUS(:ZY4).R,6^(4V+QYT_(<S1ZKGG<[J7_ ![SVLX>>TJN8_0STY5@HB*E
M>I*HNV*]9IN,;@UC"*Q_.#-<0PO. K\-5CY95HM:XNO*17LF(3PK%J'?5L,?
MU%ODH.1@C/[)=PQ<W>DX:RO(Q5N=OU4:[3DL+5M265V*2.S/XXWD@$:Z,^2R
M?)5)TZD;O U^BYG8TKYERG)/I6FFO1MJB[%:NXGU'%"P&M7K17]Y6MS?V0%G
MUP 2<S,=>[.K<C3N6Q.*'&31O+"C,J,4"G#:_$HFP8J&R<>BO]NX^Z&XJ_1I
MZIR?+QRQQL:R.8A+* DJ*Q,C2REL;&)6C9EV#%5ZQY^._(<#@EW^SKY^W:J;
MW37E)?8S=6QF/P:KX3C6J@@+!;6;7E# -U<32PH9,P C(YCV-Q';L%SD)>4B
M9JV\QBD8,R$!L)L2I] #V!DY']_9T[OWEN?L1<14XUZR6JM6!IE2>LEJ*>2,
MO8C<,ZLC(WQ*A_TC']P;MPZ^?K>0NGYK!I[F]G7\(+F9^SS&DDU.3>9:U/V[
M.C375(:B74Y396*1-<* &G847SE46O0Y2Y#QM.7\&\&:I&\;QIL_S/C5D"JK
M8#>_8)& !]QMY;UGA./Y#D9Z]*U7MF.T1R%7!0QZUF5(9FES*XE#QY<[;$H%
M('29Y/3_ "/\C^7_ "KXQPJ.MX:#G-T*]CR&SH:Q4SPM$YN4#QLF@Y$WM2,J
M7!2:?TU:=B2JV;DP (<V[?H<I:Y^?CC:AH)*))G&K*T<9=@4 &%.2WPU9CZ)
MV7/4KS)[-X;MCA>=MRP=R_D5QIQ$=63\E[,4:+-^59EW_%K^?3SY#/,H#QQ-
ML&$[XN\K^./!'Y ^7.3Z[S3L]A@JY3G*NMM[U^QJMO\ ?&RY1V<J\*?V[ANJ
MY2LJZ=(%Q3)]YYK27N0KN= \-P/.W*UBQ8Y)FA9OZD<LHB92"REU3QX!:0*0
M1I[0_I5FA.9X?N3N_LO@.0X?M:'B;#\I<_'J<= 82.' CDK7(TPJ,LMDV(1.
MQ:3QUTV8+_4>:\-^;NMY;S9_OGPMX_NEC6-3I;G=R^^GG<C7P810KYE&\C9"
MMH/U6 A%K.$*1GEUF*4R5L<Z)9=N<[9M\YRJ<:@DXZ-Y!#N6CCC=<,9(2V %
M+%BZC!DV##.2>D^ZN"JCM>M3[IYF""\E>C%07Q/=MBT7F:QK^*TD(A3=TF<S
M(9Y4Q&KI&C'O!X$\^<YYUY_4OYL5L[=Y[39C]+SR])%^UD70 &I%WU?!H18J
M&MH_-0?$S),R1+*9U+BN8@Y-'9&7R1LR.IR&!1M7&&]G#*1Z^\#]LGKY[[C[
M<L]O3UXY&>:O<@2S4L^)XDL1-D%D#%LZ."AP?V!]9&7T7M[?YF?_ *$?S,_Q
M/M'\1_F/>(G^?>)_]O;U,^R/V]$9'UZQD>A_;^_V02<^NJYZ'[Y]'Z_8Y(_?
M_P!_N/[ ]?*2")^'S]C*9D8CV]R@9]RB/XF)_CVB??\ F!]_:8]O> D XP!^
MP_?[_L<@$^_62??U]$=>@>B<$@?N?0R?K./_ +9P?W/['_9]Y*9]_P"(]O;W
M_CV_B8C_ -X]XCV_\>T^_P#CUX!_;_+[(!]?7O/OT!^_^7UUY]_8R#^P]?O_
M ./?K]B"#CK^E_\ >,>X^_RCVGV]OX^7_;,1_B?_ *,Q$>_^?Y_SZ/6"1[!!
M)]_7^OH]# X^P00<?^,?V_Z?]_OJP>E^FW1Z.CH]'1T>CHZY_+TJI7NH_J-%
M#E*Z;54%=\+F2:.C:@'_ !:)1/Q^$?$QB8 Y_B??^/4= Z*SO!Y87B:1&U;3
M9B-G)<#3#%QD-Z_P_(GK0T6:**J(V8;UH<L'9"JM$K XQ[4E21D 8R<,/80>
MGW'3['D"S@)Y[ZL$H@UZ@&'P@!/V8D?Y$/X'W^7N1#_$>T>WQB)/\6HO'&WY
MD:R\AS6/MC&<:N<[*WRRN5"Y  ^EP7L$<BR!64^+Q'Y;'9\JI&0=0 ,L6"@Y
M'R7)(Z9U/V2F3A:('VDI8?P ?9<_'Y1\I_CV_CY3$_&)CWB9C^?48"P63QX(
M<J2JJ%5Y,'XD+GV% 94PQ56^1QG [%U&&E+ZD-&DB_I]^C[#X+D#T"?2EO\
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M\]S-ONGEEO6EA_(LE(Q'&NJ E0B!2S%@P! /O 12V<@Y>M,%CB@A0*$9QG5
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MOV(*T3B*.8^-I&U+)AO"Q;.?\.2N#[?!&<])R*(F#,&,D:CW& B>PN2(R"Q
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MBLI=)$"B-NEAI(I39SJK^BR;AHUV4,WM?TJ2/(P5CXP@V+@](?Q%\EZGF/\
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MV@L,%U,@7Y!E"Y0G74 @>^WY?QLNYR:;CLX,S=V[7*UTB]2]L=B;9H95=69
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M5%Z,S1J85F^_/N-'^5*N2D7_ "$:S'%\H#4/_P!1>WVFB@BNL)W(5JT\3P.
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M]A1UCH*AS)DU.=]215\!$ 4"_A[1!2<',SZM7*P48JO&S4HX7F2(-.RLIW&
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M6U#O\SN4@$2.UF6JXB?_ &E+5R'Q*?:?:)]_:9]I]O?W]I_QZX=BJ,RC)49
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MG1CC:8UU17J-P[)LE5>G=E*[(TQLV;#6>[26N2'X[3VE;XSC.W*#T>Y:U;D
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M4.T,:NSE&!#'#G!958,?IF. .K5RG\1ZU7@)8DEJ7.X>3BBCY"UPLL-*G/\
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M9"&N,(-9(;[?)AB8E!@)3\?B<2,B?OZCUC<Q!\EHW8@E5D5B2RCY:%7R5Q]
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M,S Y]%VR6U4EBV_IAGVX!X^BD]_'T47:3C+Y7%$1US^J!DUQ/\_&%_'Y^_\
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M!/QX@'8J779R<L/(5 T0_%F3ZV4#4M@]2WE3Q_R/D?-#(ZSGD;:!L38K2\G
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M"6./;G7&H)'T>DC9$C+'DAF&N&(;5F/L +CR$ALX4XQ[S[/6#?S"_(^]^/\
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M-B_ +8RN]Z:[F@< 92I4MEHH&0Z>]<L4(Z$MJ9J<4PL0U#(WBBD".OE5'^!
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MV]2SIZO+C-$*.F Y%,4?&Y=BK#/WKB:#SHR %3)3A84]9KQ_Q!YUX^,_%XM
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M0F",@G+GG^)%]><DHV*%,4[S<94NS2!'BEO12*[O-\E(66.17B(5M9$4,I(
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M=V\MFGO1:0J(6UKM!GS)C!+WG]11?%JTA'_SQB%0?\2 3/O\9&Y%5:5%J8;
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MDJ@:1:3JZO\ G=$I)_#[D5B%KD>?KW7M0;F*2VNZ*BC!1Y,%E48UP/1)V/L
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MKJP5WAAY)HXIYU1%*"U-:F1?R9)5C;1WC6.$-XT5Y")2R_*^%SOCS@--_/\
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MP!&;*+(D@E4JJREF",P109),@>U7":AM?@KZ_,,T)^00=3S/%YJ?%GCK'?\
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M)0P1^)3'RG^"F?45RO+W.2BA:Y.7-2(10R,3LB:A,;!2Q ] %@S;#8C/2*S
M/J4B#N2[J2S.V/9+*S#XEB<$%2"2 2!U/;'*[U^G37S^Q%,4M56JMFPRS<T5
MC_<]]EKC^9^Q_*5,'YK+Y$N"F1]O43QLT=9CY8FL+JT"AL/+(P75I1J(S\9
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M60)"O88MYP-B(F8XIN6AL/:XM+#F"-C/)"/-XHW.,21LQ5E9@V5*LS-&VB?
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M/9EGLLBJ%0K&L<:@"21V92H .% 8L2%QTW465B#.&8I+'I&'B4JHV9V,CG5
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MSP22BP@&S+5G)&)'7T,!_>0!@^GG'T*J5^0?D>.C6W^(WXUJ"PD?XLGI%>U
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M"5E) #$]1'A_\A> \Q;6WA<NUJW<_HMJ/"T,PM[4P,-;7.))<^\L7 @4D?\
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M@OL9!?\ 9"Q@??Y'/\2L8F(B??W_ (F9:,N$4(!C8.25/O[/[@'(P<^AK^P
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MQ^+'+!$EA#-*K_J/B"@:E2S.0 =<*Q!!/74'$YDZ697I:M^-306TV';)2U_
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M)5,G\63!'4>,I7^?G@X6HL*L3)/'),0%0!6+,X&&957XA(D9PYC/^'(Y@/C
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M%>TE&?1(S-Y5'P1@65E]+\B!Z(R2OHG .1]]4YJYE0$MD1Y/D8%003\LJ"<
M'"^AG)'T>H#8X?DO*?$[7+Z&=_N>JFJ5/2Q!;H9-/?\ F/S9EVEH=7B]4@($
M FY'Z["5\'Q]<R'J#Y6!;K3#P21 DN8$<QF3.=@2C 9.=O1'R]$Y)ZFN,NVN
M)GJV8YHUD#!HK,L4-@P$>UE'D5PA4_IRI93@C!&1S@\R?B_P?0XVIBX:M7(T
MG9=GG*W.%M:0XN2JB)W<Z/Z2ZPT:8PY06#;EPMI'[P'N$R94CN;L+C5[?6YQ
MUR>K<,2:P^4B NS,&58\%HG34$$,2#G;T1C3^V>_^5AYI/SH*TL"6#:DNK40
M6I%D^#9F542="'("2 *"5."4QU65\+9_%OA,SK?)/D3E.G\;] A;&-Z;2H\E
MOX@4\VQ )86OIA0Z"X(J73SDYPJNVW.@CKNL_-DP7&V>2[=XU(ID3FX+->0.
M8ED::)8T9FDT)?1U^]D9!G(]#'4AR-OC>[>9*<9%9X;EH+"K%"B_E5;<LLZJ
MJQ-!$)88Y9&RR3!TCP5201Z :Z+H?+OD#P5A<_C\URK\?:A.3DD'3M;LZ_"B
M9U*5S[Z]1F?F;?Z:QINE%FXD;=8REX?:4!+RQ\YS?;@-6K :[J-V$^;+0*22
M\3$:>; !8JQ)(8J?K-86+M[B.Z7DL\A.+*YF=!2)K5N0_6\+9<//5\GR0Z(3
M&<:^L%><31N</A6ZM3CV9N(P;=D5W 19U*EFQ)5W Y*R8+ULMA/VVSF/VW?;
M8)(#8CV>=DPOQ7&6XQQN]65G*,RH97>7&$898CYDG9@JMMG']U^Z77EKU:1^
M5!N((D98BZU_&C!Q(C?TRI$?L( 6B4!"6T]9:\R[W2>*J".]U<Q-BGRE]SJF
M7FZ16-?2;9MU@IV4Y\.KT[-BO>E<!F5)6PC:4-8,!+64CN>UW'VO<H<A9 DA
MAE=$JO.WCTL2$HVH.H5 X)"AB"'&N1U=^UZ?$=TFSPM.1H[/)5XXI+,U=411
M"K>56F8&0>2-2?/("I"[8^AUB[NO->UWO6]TOSK0Z;QQW.#A;5CQIS[]1V5D
MZ5O*H5WV+5I=:\!W-IUFY"HH 5FI3%CP65IAN9ZRKG><N]P6^0Y#DGFK63%&
M%K0)(B0-&71(B<$@X'Q;*EF.#@H5.J\'VS3[<X[B*_;+4.;XZY;@CYB[X4M6
M85GF<+##'XWTB"QLSSIB635/A'& .F-H^4.BN>%JMCJIZ;R71Y2A4T7\MS>4
MW/R)R,>O&C5NZ=5*V7;SK+U+KTLFRZH9E'[+ZLDGX1+RVK[<'4A5[%U4F@CL
M54&M:$;!3)*PSJ%/IE9B!@G(QD0U?B*D'==AJD%3AYK<DJQ7N0F_(MBS88P/
M7K*62)&5"Q>6-)0H!C6;9@3H?%_.GBO(_&X7"XGBKMPWNMK4*?)A.%7KQH+T
M\]%Z+-&U<BHC/FA7=^M+K!!*&K]P60^[ T"O_$_C+_&1=N4>,D/,LHI1+$%\
M:RAO$TD4F57(PQ#HY5@ P.HSU1IOX1<[Q/+6^>M\_P 9_+*4TUCD2U\M)"(I
MF0Q7(4\QE:1AL8XU9BN5.I!!J?8^,_-' *S5+UJO ^/-%M6EK=5:O+TNMY#'
M?52S4=>@8.A?'4VQ D.<ZY&8Z_+72T& P*_9[6[IX6>*2W8GI4N1E$4MF6<R
MRQK,5V$S12 *A))U9OC]!AMDSM'N+L_G?R2D+<QRU&.>Q7XJ&"2"CR%A&(K1
M5&;2: PUVQ*$B1IA$OB ;T%M^8V9^,/C3\9[/*VO)/3=)J[K*I<O2J[]_J-[
MH.].Q6I4;V=G29Q<MJM2N=('(IY>>D6$]=:)4#9/O/@>W*/$Q1<??AFY<1BW
M(DCE*QBC&TT\NN3"K@E Q=F8.=<E5Z\_AUS_ 'MSG>J6AVY6HU8V>M((J*U8
MZM-B7>!Y7SXT*"1Q*\CSNS%W=SY&ZR3S7*=CY*PN.X+C7=9Y#Z+F,9+;L:M&
MW&IR>M%*LY,Q9T69E,5,N?&G8M9KFN49&+++*?W^V _@V.6$,'&Q2RV)&DDD
MK0+-X8X6D9'BC#(VD: >A)@8 ; )4G9K-VIPEWE.2Y2&EPW'V[&(G2:'P<E
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M_P#EKF^NE?WUV&R%&P_5\N]U<I<L)P34:]2I<5HS>E_J(N21J@*A2S8. 7#
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M"G<L+8L.5C,E*Z\B1I!&+$8FBE@1=8S 0HTD!+4ZW#[@J]#6TMF]_MI&B?\
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MRXA.(TF&9,MN2S!"?2@?1?'^"U3Y#CN'2G9YAN0GELT;$$+R7*))*+#^2/\
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M8!Z4DDQ)L&!?7*A1&HTS@%6+ *H."!DQD%0&]^K]SMF:ZYJ$A5I!)]P"(F2
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M, 6F  F_0L5_!QE\AL1O\ESZ<?P$%:*>:6Q%7J1*0)+$ZH88U#NX1-@6+C8
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MQK%-9>N#5A>+"=9849-NU1^25_64H4PE, @_N(>*G+U[5GA5YM89JE M#O'
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M06; !T )?$XF(F(B)E%[AY./A3PJSDT6<RM J9=<C$BABQ?$C!0R>\C)^7Q
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MC4+7SH%372!5#D!]%T!;?Y%B?0('4:DA>0$$,L:EE!5I']EF>1\,"KAV9B
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M)LKL?L&<M-:X%,(MO(]Y<G>O4KZQ5:S4:2T(X0K2P20.Z22>79T8DR*!&JL
MOHECA@W9>,A$" A4^LMERX*[@X1<E!C.$+#*D$,,7_H/&G+V?%X^$N>UD\A7
MLYU.MD).RLKS4YUX-#[3HP*F:"RL 3[) DA?89\F(E:Y HF'E[<?+?SR:&2U
M)'.[RDQZJ&F01$B7VL> S"$%U**#_4!<$^3:3NKE?@B *(R&96 8:@9"@*0&
M7;YY!;)8#-W\9<7:X'QYA< Z\W8/(D&/VK=1"67#=::^X[Z?N$JRFN9+%K]V
MK]R^,0O_ +09<ER7\QY&QR#0QPF8EUCC<MJ%58UA#Z"1G5<@F0KE0WKY8Z5
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M)4Q:M/.L@5_8(2L:RI,0_P#DP,F1C-WH=Z58(C^751)WC1PL1V;!PJLWY B
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M:555O$LP80G)90$. %.0  < ' &<=0W>MSN\#CX>TEDC\DT1FFJP5YO"@+)
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M WO.N,@9R<Y&:/4SRKUK6+HWKFQ7FQ9/0'86#UW*[B]P1:AXL5:KI'V6(',
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MGX#*R'WF(=BR K'DH00RA@I ^0Q)DY;Y;EFP?T+EL:@^_EK#F$;XD8B4*"0
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M[$;Q++6!1&%>1XEDRJKU_O*[.,C3UO#'D3,YC7YP:TESW60*E5B=/O TK;[
MLK5MBJ2S96TT65#;A?R^E;#7#%>)YOA*2V.UN7K1SM'"5CL"-</D#4/L"?("
MN25.QQ] @$M>2I<C*E;N[M[D+U2R\RF]QS-*)%09)EA"%?-3F5M'@>,M#L59
MY!L4P5Y]\?\ 2\YU3]7Q[U*,!%'<+3KWZ.6BCT .=3T,^=([I*.ELBFF]=>8
MD4D,UI,4E)3)8ER,=WB.X)KW#Y$<38CL>5E('D5@I9"'5$12&U;WN<C].-I[
M9Y+B^3XM:G/TYK(LU&KM5DG:Q1*[PSBO$B$252\ZF0,6(/EU)74];;_$?O*P
M]%WO'>0.HI=+V%F:6BKI[WZU<.@7&>JC<IDA;GU&6<B(%!RKXD[W=,)]H@9V
M+L3NJE+;Y*+GITLWYXXV69F9@%5"OA4,"RZ94X5\>\Y!&#D?\1. E''<)?[<
MH3<9P\)L0&A&7F:M(;+2QS>0)')I;9B\?D0E1JI9F&>G'>Z>/$WRK[NA89A;
M!N9H]!F9X/;B90_:Q+;*ZL?U$*[$NJ!]BJ[A6S^X2!9% SM?FXN*LV(IY$2E
M8>1_+DDK&Q8HK$ L <^F  'K/5>L<2_<$<,E. O<I+&B4IY=!<LL%#"+R@0/
M(K+*0IEV**0V6'O&_!^?;6BSR^_F59]WQ[F]\>3S6[_2K=RW:KL30S7K.C33
M^UH59N2RP-N9AD3^R%PBA$L]4RMW/##R/*U^)A%JM._E:>0DAQ*6U9 0')9?
MV9<D8; #=:!RW9CFKVP>3>U7YF7BC/;XU)(H1$?+/.I$\\GAKN(@$>')4'3Q
MC+A0Z>9VNGS:FZ=C.;5T,33O:+L2P>=2T=/)JM*;.FJNG1M(31E#&NIS[_M?
M%!@Q,&<P9%;Y"K<,[0D-')N(R&.54[/\#D*H)P,?WR/OU$V:O&6$K1QV5:*U
M6CB2UF::&M8F75('F-:)I)PX42  PJSG5@ I#LY[\C.,Z&_XBQ>:HS=M]=TV
M(JLS6HWLP*]9&BL77:5/3J5779,TN"N"8^,??+OLD1"&:W-WAPG*U..HA1';
ML6((P)$_IHZNC./)@+D@?#!9F.%^)!ZSZ7L3N'A['<%V_(T=7C:=AY5KS16)
M)BZ82&1H))8H<"0/,\N2N@51EG9?T!>M#ZP/H]'1T>CHZ/1T=<N>H\F9K_)>
MAPQU+W[H:.K8-X!(I^D-&S,0+8'XS$Q$>W]_O,E/\S[Q$O/Y<W\O-L.BHTNI
M^:[;,Y]8))0^]F9@?C@@8;?JYU'(\,8#EC"KHQ1=%4*H=A@Y)UPN6&Y)PI"J
M#UZ3<:[#R3]LR,A\3B/^61 AF9B/;V_[2F/_ )<O^Z??VDO:(?S+G9B0&1MO
MB6D8MH4&Q 8%5!!8*,Y(8XZD8Q&50L$"G8:%%UQ\0&8DJ-A@DD!L IDX'I8>
M./R,X+J_)>OXHIV+<;F>%UOO8&)_<5G.-%XE(DCL E;P(!<X04R5G\2+W&?5
MCG[<Y&EQ<'*R,DU2P45ESDQR2*7B0DY$CL,/A,^B",@^V4DD;2RQ*C;J'.3J
MB,B,8W(4$MA96U#% ,!2V-UWGORA\Q97XZ>*=OS%=PM'H,[GHH(+'SE_9?O6
M-.T%6JL!D60*/D423?C\%",E$3[_ ,<]N=O2]Q\M4XJ.2.!K <_D6"HC1$C\
MA/K4;855"?J.0"/1Z\_($=>:1U$@B*XB60(Y\FHUW(90H9B1J% 4XC'V.H=/
MF&UN^&>>\K8O,:(V-C"I[:N><L/WD3>4#@KV!]QF&5Q. (3 )DIB8'V&(]<S
M\:M+F['&36HD2O9DKO94J 2CG,D94L"K@'/S/U[V.I+RL!)720+L[K%8$>Q=
M@K %E=5"@M&26VP%<J JJ01TQ_%/4='W'*YFYV.7&,VXQT!4()@VKB8!)"LB
M]_FT($BDX&)]OX^,^WNTOU%I3R013QS*A;QS1,5)C9UU*X]L2A(D.J@YP%^\
M$FBJC9Q(P_J'0D, 3[ ^3A2!LBDDID>_W+6KY-G][.HH)5B;%4V+=\"$%%/S
MAE<RB#6)K8/U&H?<HB0(X]R^,L \GF"O\V9F4%W;50&(T4*OME"%FR1^Z @D
M'IOOO'Y)';+A!C&!J,@8+$DA06(  4?%P2<Y1/C'\FO$_G31\H\[R1GK=+X2
MUG\_TM)]!A%7T$0V(72?"_BPV$IM:$!,M"?X./X_BR\KVURO#P<9<MH@@YJ)
M9Z;[(&,) !DE!<'48P2%*L?TY]90AES))##)(41UCFV.<C#M&JNKZGYHP>)_
MZB,K%U&#HV.4U-?<P\C=_0O\X=\2?:R;LPNS7(6N4L;(RM7]\C'N$S$%(M%9
MK'XQ,Q,\<%>>>!)S:$1U22-08I%.I#HPR&"Y (!)RAPQ4Y*P^17==7*H61LZ
M1@D*H=@#AG56P"1AO1P2.JYN>9>'X'M>4Y3I^JIXO0]K<FO@Y[H>;=!@OBN4
M>X P4+=8:NJM]IB5L>SZ@+YQ_"U/B+]^M;NU:CRUJ2LUN<E5\2@%B-6*.7")
MY&"!U! SZ!Z&,3$*20SJ/BJY#$,J;;X)4LX52'."WP5@!L)]/G#E5]DO@SW*
M7^X#'[2SA4WWB6?RA9-F96-IZY(Q21_(I&8#Y1'O"*<9R3T6Y):IDJAB#*&5
M 4 4,WL ,B (FWMMF8 $!1TFT,"-XR[*S(!J4SHQRVA93(JRNAV125+']/[C
MIP6W)@Z"DU2)U],&U3#A,Q$,@C-DQ[Q[_P#>8B/]TLGV]H'W]F$AV*G_ .DL
M2#[!+@+J,J?08G#%2#C)SD=<JO\ 2=#H="%7/VV,8;;)()/ZLKZ)!^CGJCZV
MCDIU-<*]M5]N6T*=U*2F/TW.J)OI^^3CVEDUWJ>:_E[R+E_,1F1B>&*%PA.T
MBJ@;T-?F6U .X"N6*, WLAB1]X#N 3>..1UT23VI:-P&U!#L"0?D255AA\!"
M21_AQCXM_(;RYUWY!]CXZU.)FIXRQ:VJM?1/H6*E%E<($\QM+2,I5IONN^0/
MJ0M3*Y$N/Y #]77D>"X:KVOQW)Q7PW)V?&&IEP),,S>99(L!HS#EFCDR8W#$
M']29!'962SLH,:./')K@$:@HJE&?=F1CL'5==]A]. _*GY(<#<\DV_#F>'1E
MU=>M<K5-0LEJN;;LY]<GOPZNK!$I=U24.F5^WPD$FP3@2"2C'[<OUN'3ER85
MJL8R(!.'L)#(P2.5H -S&,@'7+;?2G5BK0*[R:NK)AV+2%%\32A6>5!\MF(\
M.?>/E@ C(REOQL\G_D=WG2>7<WSQXT_V#G8G3KH<-I*K0J-K(_Z@G2J/V'S?
MKTP73D-2) ;;7V5C\@#V&2[JXSMFE5X=^ Y)K]B:HTE^+5G\<HT8,6*J8WD/
MD#1@_!0@!SG*J13(I,VF!(IC395R,/E B*V44NIB9RY+F4;%1\=9Z6/'35,J
MDG;MX]G'W,[=0RM*/NT?T623Z+%-F!_7N(F$L84DQ'O\I&?F/M6:EDUVL%HD
ME26"6#61)!JT@.DA88'P;)P/B3J"1^Z[A5;<J^<ELKK\%/\ PP<@*,X(89/O
M(&!@CU-YS(#4NZM.C4SK^D7QMM564N[9<'O)@UTP,.@A$?=H1(B,1!_(A]_3
M2=YY%BC#S/'![R7)C0DLI55]@''R)+#&2/U$ \PRR(FKC+%6;5@3L2RY]C&5
M! "ZL1J?9&/>,^>_*6W;_+?I/QYGQEUE.O@XDZ"NYMDQ.-89%6E8EBZP5H^&
M2T; TL^]-J?VKJWJ^@1'Y>K?8[2CK]IU>YEY.K)+8G"'CH]1+$K.R29=GV\B
M"-I955%T5LEGR.NP9GW!KD1!5=)G8*VWQ E9<(#"1Z&'+;G5A@,W3AZ#RUXF
MWO)'_I'LWL^[W>;27N5\:S6,U55V#:*'E8))U8M*6LF0D'#8%9+.0F/>9B%X
MGEHN*',UTFCH.TM8V4L&/R2Y*E3&&5Y(F8D!V^(8>V]YZ3B^+R(2",;;-&S(
M0!LK([IXQ-JNP$9!*C(!Q@M:B&P728;T[E5F!FYC:UK.FM,.+2;, M@V8]_I
M!*@*!&)&&%/\_+_$,=JQJ.DD;-9:<-%.S8"1J"'55 &QD( V!(P P#'KDJRK
M+(,(6 1H6 U))+J_V/:KD@:G;&0<DYR[^4/E/R[X\[#FZ'C/FD;]377!F5JG
M9MKU+P:2Z]G%=?J@U>3^KF/#349K%UKY,4BQ, 4#9>W.)X:_7O2\I>:OX250
M(Z(8HA!N)UCE.9_),'B8HNBZC8!BHZ]022@"('.2S,JM(I=0&/D95RJ_; 93
M8$!6!) N7E+Q%P7F/'Y^.ZR&7D\OH1HUY5;.F:[#XIV2JB:Y8;:L/K+^PH]I
M8U$_60^[)F XON'E>$-K^7S!&L(89BX4J0$8(Z_J(^,AP6 *;ZG)  >Z*S@N
M6E5E98_ZC#89 )D5"$1&*J^GZ21^M2V.ELSA.!;^1N/U^1Y(B>WQ.7*W_P"F
M%#2KS;T:-:JNO5T7YA6"LG61\EK(/HE?R=]GS4)D)38Y+E(^UFH/Q>W'V+:H
M.6EA9X4=VW,:2?I+LQ8*H(;*X(;((Y4U6GD5P6GC4>E*HH8H8@6Q\8WT95#$
M L-!JH=PWO\ Q^_)?M_*O4]WF]!RF5A9V.JGH4;&-=L/?7EUJY3;C;E-Z_A1
MW*#*D-_Z=RY,2>!4P!(M9QW)VW5X6MQTE:Y-9:P62598T7T#"5FKRHQ9H)-R
MIWSK_3P[$LJHQ1B6.0-N"C!54AX]&.VZY?XNP&,$Z#!?"8U/6A?('"<SY3X+
M4Y;JLR-S#W*\UY0=BS1?)LD3:,OKL59KC\9,U2MTC#8'[!B?C,5_C^0M\;>@
MNUG\-FJ24D,0ET(!56 <-DD%02%4NC$(<#(Y *2_/5MF0/$R?%D"N"28F8-H
MH8:[G5M0#C[6?C?PWXQ_'5HQS_1=)3K=,5?(15WMI^W31<6Q+3I R4"VLE;'
M"NO8L3'Q$D@9R'QF9KE>X.5[C0?DQ5I#45I9#6KK$QRF-V)8AL8)50< C;T=
M@/62-P72 *0?UEW+!=LCXLKZ@ALD>RP))+$@*V>WX#"[K!UN8V$*L8VY1FEJ
M9^@";U2:+"ADA9I@#SL*^X18$$N)6V4E[C)?**Y5LV*%F"[6FUGK,LD4L;LK
MA@2 JL@PH<,S%B?0!&/:]<K.B_(1&1589 !#@88%E5P?D=B,@@C.1@@*U/\
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MP1DQE,Q[*2, -TM X:-)4=)$.HV63.&!6,8^+*X'R).55@48'1E;KH=XD_\
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M 9+X"Z@-^GJ!L\.6ER?:XN%6I/SV:%RI%>B+!&PR;!6-.P@X*0.[^TURCM3
M NU'S)8PN1*MU>QTY"GS:TW!BAE_&41$J6G"!W);V2R[(IT'H@@( ,=34O=)
MI7>%FMEEF>!9PTPV"QK_ $H$8'.L)5 X498HQ&26SUS(Q?(_D#_>/>9%[KZ.
M!6\2:M*V/';HEG]1JULQWS6M%J@F].P3*K$6BO9UH_ZA!L6*X&&?7CL+\]Q3
M<G*_*K0FX2676!Y$$ME8W>-0610P)'K5F)R5(&A!&W6N+X*:CPMB/B)[Y[GA
M>!;]=38XNK-.GLF.0P+"JR>2)8Y(U\389VVU5LV]OYNYS\C^L\@T\2_T=?H=
MZXI>!@TZ=L\N_2K_ *JJP6;BZ8E??E/K,LTVZ$_3#Y<U857DD6U[E)>1_)E[
M@N1S)8L7(K**TD=B5@"H2&4HPD#"+ 9574JWHD; 7/A^V[7;=/B89*E.6A4A
M?\FW(P22N6+F1X8V;6..8*B3"OM*P102\; CJ==\J8_1^"\7J^OXQO->8^*Y
M6OI]3FZ-8J"+>A6KIBXRMN0B,IU<WM.R*)=_Q2[X6 6Y-@!V+D>Y.V;G:U.S
M7I,G-\?#'$4:LT+S:@+Y@S* 5?99"C,&&=&SJ2,'@[5YJAW?<H5N0%SMGE;T
MD5.Q%/\ D%(I6/A22N&\\<B+B(L$T.A9"VQ'67/]G>:?*',L\T<CQ_.ZO'8A
M:.73QKW8+1M]2->I;1IMHX]6&XMEZ #VIT-'5HLNJK+(94KZY+.&XKENXHHN
MY$A"UZP94CU \GCW+EP"DH]9)"1R$Z@(L@8@Z$M[MGMNS_LSR/,35^4N>"9Y
M4XUI(./RT30)+<9Q+'N6'ED@KV%B9V+-MZ&HOQ"\R>/W]:K6=UU6W19XWM8E
M+"NH_1=C%F:U:&U[-*X?[KFIE3);:8KY(*W:^Z%08N;??X8]T<74YCD6Y.:.
MIY./6,)+@(LB,K@!QNF94)8,K%69F(..J#_%#M?FUX:.O!QLPE7G!9DM1'R+
M.MBK*J.CH%A$1. 55OGXTT+%2.E SLO(53L%Z7*W.3[-7;^1K5SF$Z>@L<_G
MLK=#[591JK*)M_%T+M-?ZK)%D,"]-E352V:PT\<I/+W9)?X^I!R$=CF)/Q("
MVL<Z23$K%(LI98U=7&JA0F54_'<,+9%QG#MP:5>2EY#BVXS@$3E)88&-FU-6
M]&S$TKA8;$:2N7C.GN,(5=LR,W/RI[&ITG!::?*W@^_XK[W&H _D^H-&=K4M
M1ZQ3%4<?I.?4PWU1/^^QE7Y0Y:S5^U6BM-@)T?\ BIRT9XFJMCA;'#\@FLD=
MOQHH!SJL23UV.06+?H;*Z_:@["H_POXBY4YH'A.\:W<_#W)6BN<?#)8KRP([
M9EEM4;VJQ3 9*S1&0,VVKET#!!?D#^'O?^6/#WB3R]E]SM^1>BXZK2V_]H;H
MXR NGHJRPL:U-5:M2HVMVB%-M"I2MTEV65+-B:[UVGQ\XBQVMRESLE>=K73,
MUV".2U7'EP\?C8+'"[2NZ#:3>38_-E*N&'Q-H[8[_P"W.#[TYKMNQQ4?#QV6
ML4ZO*UY+,@@\;2@0RB57DABL;K*UB.0I$P560J-@L^JU_(WEKQ_Q",_Q%OEY
M&\>=94ZC#Z2V$T!S:U$J5?3PVZ#:J:Y*M+_<IW<];&5A0V%OEA$XO5(>Y>L\
M93C/$31&O+)%-R*QK'%-2$?I&3^ELHF$,D!"JT?C)"^P#9.,XKC.!YKE?R>X
M^./"\I1EIV>/5FE:::0L8+$42N\@D1_'(DQ =G!T"@>M^4/-_BK?XCDLVAPO
M48O6<S9J/V4T>?@FUPO6'4] /ZK42]=NP<_;:;0;*7 ""L6AKRL6>M"D[J[:
MM]N\9!%5\'*51%Y?%7 D4@$2$RA03A@2-2=CA@,$GK*6[0[JI<]R5FUR%&WQ
M%^.1:KR<@ICD*1)-"JU9&BDB1053S",1$OHCR,PS0_-OG3CO''%YW?:&FW-R
M_P!RERN[:M.A'09R-6U!*8_(%CK%I+9+]I2*B7%*&DM4$0K FO+]R)<>G)29
MQ/+6>M(L>5E=E#/NT6?2XV<.257Y!R 1E[V[VGR%^W9X;P)+*6DY"C%^JI-X
MHPHCCN'1(Y"Q$9DDD11(H#H,DFK>/O.'XV]=X;ZGQ#Y*7<UZ.J=K#YWJ*E;3
MUA[5&Q"69LIMU:Q7<S79;M?*<[6FMK(N+;9KA-90.E3M[NKLZ?@.2XCFV5.0
MCD=TE>LXG8[N86B;Q_$IHJZC".ITSDLH=]P]I?Q!H=T\7W%VV@B\4<4MSCC/
M#5;AY*P>.RD\$LB)+6\,9/Y54R5FC8!I!(Q4X7\3?CWY-\!UM/&N/T.RY2UT
MRSP\$;XD[CY'97]VK81]Q#6T+F;2FII7JS98-TW.;"DF9MRZ_:N7>1@M1<<D
M8KOK+F0$V-3&4D,8U13&JLD2L-E0H-B5 78>3[C[?YU:TT,JU.0%/%FW+$NM
MZ,56\=**8Y::.&Q*LL*2@[Q!"H:0''=WFOR S^[QNB97PM%^S0O6.>_HNC\:
M^45G$4.7<77FN+%FLK<D%=4@Y1J!Q$]<^TA]-\%WBG-\$.+AIAYX:QBD#(&)
M) U^PWR4%AZ(PRJ?:^F^0>4[(DX/E:EJ2_$M6VL-^*S7+23)%9+21^1?B4+1
MXE)V4HSH0&5E!Y2];'/<C^0[P\C:UM?/ZFQ9:56P4SS[4Z%;Z:F=4S@!E6AA
MUZ@/J)02EWH>R&V28TX?/S?S0FH=W25>1L-' 6#2*F-1&27#;,?)C+X;_E(U
M4:X'7TIQ,]CD^R18X*JLMV&N(U:-2;JO#,7FEEG 1YKKMXIGU<US$KK HA1D
MZUA>\+:ODSQQHL\<=1IYM'0T[ T<O0SURW!S_>O:+-S$:'TW(K5/^I:DZM9D
MLH:3$F[Z$)(+P_;-GF^(FM<7EJBN8"Y7*!#_ ,[@X$BEL;D'8%?OT30$[GH\
M'S]2/GJE8WHX$DG\,[)^?,BR1^9_#O$6=?&'VD3$U<.D9>0@KG!\<<]P^@MV
MMR%1?09/6&UNJ>C#4H.O#[!:U1ZY3] . [5443$&%P4_: N6<C#UN)I<%-%%
M;1C;\^&<N?2!@002 H7*[89OFO[C/N5M<YR?+QR_A<D6H3<<56L(/ZD@D*Q_
MBM&V[EAJCLQ.!$TAC;1QEB7>L["S?T.OMLHWN/P8OK%3ZK]!5F@JLI@_.O4&
M&Z$*F9"324DLR& 7#(()?<[;VD6U!XY85761"/@P((&PV*YV*Y]+@')'[]0U
M&A42N..Q/%R-M89(W#+$8[#2,AU:8GQY #'R$9*L=RH#=)/\<>UK7\1%WBN5
M?-SHM+4W]JE076_V\5W6U+C08&<-JOI4I<9+ C&I\I@B8-<Q)A>F?;=NJXL-
M4JO)R+V77\?1FD7QE8Q&'565@!@ ;L-1KG/KJQ][<5;2[X>4NHM2C6KU*\\S
M2?F:0UXMMG*M5E9<,VOG!!R!)]#K5?-[//4Y9C>0CK<]T8V-<+5/5TTNO6:N
MT9B!4GV?H<VHCY+3*VKC]420KXE PPM.XRS!!<@K\Y *UF3? L1E0[.",9PW
MH!3@#.<?1]8S7DZMDP26. 8W:+I6,;4J[)"&JD%Q,JM(4E9LL65V$K;,&7VO
M7CVM//J]MX=Y$JQ'7#L>:_V[J*^MS[OZ.O2!;*[5K-*_I:V(MDSZA-"Y8!P
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MK'$JLYV9F8[-L2=*YGMF?G.-/<'<\$S\T$IQI'"\%?R5TB8&::*(Y9XPH'P
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M8_B!QEB&#C16CA-F.$.LK(U5(XE!$:JZZ!0L842$EUD*L5P#UU6YW\6=G?\
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M<CVW<X+@Y)^':Q,([$E1::F62!U+JZ2%&5"&CD*,2K!EWP?A[Z:'C?\ );P
MO![SQOUO8V+'.XN_J9-K^JYVALUJF6U"T6\>O<JTI_28IDOB4G,%0-L ,?\
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MK&BM\P][,1H6H %_(H]BF!B!(#@9]X_B('V)I8"B*5D5Y?9*JK ;,&.0#@*
M"KZCUALC!SD:'4_X549 \D*(2QP$S&I4_N&V  8 ^A]+G=A0]OR?ROC/CG=Q
MV^@W R 9]CRM W[UBYLB"!K@$D1+(IGW ?C 3\I.)@O2W!5K?-30I2CE:>QL
M0DN8BK*SA4D0C8'UXT+D X4?+!ZXOD0QL)"%$65W*F0,WV""I)QJ&;('Q*D
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M0B(HNE9%!&X_L*)&8"1CY1Z95;7\XBBH<Q;-:"K"5K3%%9X_397?WE8U&%R
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MR(A ^,"S?!&.H#%#E0/W+:L?GD:G<G]+#'L'I9)<1^.2,LBNWL*7/Q"ELLX
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M,H<O!Y!+:IP321SD1+(DH1F1988YBRL-<3)&^RKB,%V+[+P:QE41R:K)L#D
MZE@?^& BAF1"'^0D!("G0 KM4_#7,][RG-V<[NGJ3JNN%<K4*FKI;J<U3*Z
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M200G\3E? O,>1O"OE!'$U_&E?D^DG_>]O<YB]BYX<DC"U*=;/Z8*X!F]"X=
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M'-69"&E77.&DP=U^G,+(-1(L@71)>WZUGE>/Y6E8O3TX#8:6G%7"0V34+&S
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M9,2*H4@XU,9;8-[?&0.FRLTDDQU<LK(A9=6DA+!"H;+;1C4C0,%3+$ACG/2
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M%(9@,DZ>G;! ZFO,GD'4\9LXFESW$[7>1U77Y7-#7R6UX9CIOU6'8V;]IBG
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MT)RQV"J""PP2/7V?_P"?WU+4.\.X>,"I4Y&Q'&IR(O+*8L^CDH7*YR 3@#)
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M%^8'M0021[)SC]BH>9GU*K%$N<@'+DC/_5OO/LD8S[]>^IJQX.Q;" 06[LC
M?/V8(T/G_P GO\O;WK2(^_O/O\1B)]_YC_'LD96+[D#(.0/8 ^\9P06/T<D_
MMZQDYXCY62,DK!"21C)WSC.0 59?0^O[_?O))ZI?.?BUSO.6=>PCM.RMCK_*
M&U[;\Z4(&3^< @%45^PC_,1!_+^)F/?^9].I[[3PUX!7K0I74*OB0KL/W##8
M@@GWC& <G]SD3EIU<N420[;+NTAT."#K\AZ/K_/ QG!.9NA^.^+2B9+J>@L,
M^?S!C%982J(F9$ %=.!B(B8B9]IDO:/>?\^[1I Q0A%4(,$99@WWG.6]9S]+
MJ ?8]]*_SRQH4:*$YSE@&4DG&3@'7.  " " 6R3GU:V^'L1E6K6C3U%S6^S_
M )X_4)K/LGY3\I)$B$0?]_Q"!'W_ /'M[>WA<DY(!/KV<EL#/K))_N?9R<=(
MCE9@VPBBQ^R8;4$  ']6?1&P]XV]G/UU]:?B?.H_5-?<V )?R]RG].?M^7^(
M;_TW]PC,R0C[Q[%,S_C^("^?M5/PT (R ,YR/_J(^)/[C[]^^O).4ED#*T46
MK$$J/(!D>LC#XS@ >P1@?62Q,=I>%LO3L'9;T&T#"(2'XAGF ^PB)Q\6U3@H
M,1F)]_Y@C,H_F?XZ\S!=5 4%MC@9R??['T/O]L#T/7KKN/EI8T">"%@!@'^H
MI&""""L@((*J<@_8)_?KS?\ H7BS(D6[KS(JE41"LX1B)CV^0A^K(B4?Q,3$
M?Y_G_P S'H\K $# R023DDL,X;).<^R#DG(P/6.NOYQ+DG\>#8L&V^>?0 Q^
MK'[?>/0P/[D_ROP-S@'89_5=29L"P9CZLZ 7+1@3-8Q4CXE_'O'M,1'^)B8B
M/7)<?'"("""<@ML0=LG8G]\_Y#/KWG/K\U8D&&BA(]#ZDSJ/H$[^SGV"<GZ_
MSS!ZWXT<GN9-_%T]WH'T=*E<S[0B=)3"JW5,2T 8%6/K* :7P,8]Q+V*/Y]_
M=:"U)7F@GB"AZ\B2QALL@:-E=/@21JK(I &, 8&/>0\S(P936KE6]%3Y"-??
MQ WS@Y]C."23CWTH.?\ P#\:<SQV_P ;E]AW*ZW0VSMV] [68=Q<S_"UJ$J$
MUX6L))?L2B^8S$3$0 0,Y9[HO6[U6]-#6+U4T6)5=8F!+$[#?.=CL#G8$#V3
MDGE>8G6(PK%" 7,A(#C+' .0'QC'V%USZ_Y1U9N7_"KQ[S?)T.0+I.MV*%"P
MNVNSI/H?ND]+OOKG]U:FF%BEG\ "Q&)7)+/Y1/O$?<Y:>W<FNF*"%YUT>.)&
M,>I34KAV8D'V3G[.#Z(!"HYVQH(S! 5 P1_4&V6+$G$@!/L ''H =7B[^.&5
M;R[-!?;=;3LOT)T U:\Y,7:W]PR-5 EGS7FN, (?%R6D0>\$4^_O#6.T$E21
MH(9552K1/Y DF<Y9M74[>_14@C53]CVDW,3%6410H"21J&!&<8 ]_2@''K)R
M<D]25?\ 'WGT0!EN[3[(J4L[3E9A&PEQ$2V0BG"@-A?(R@ $(DR^(Q'M$-@S
M L1@!FSJ!@#_ "]>S@8&2<D  Y'2AYVRR:&*(C__ *EQ[!'UN<#!P!^W5/I?
MBQ41TNONW_)W;Z^;J5Y0KE[2>?7CYA0P358HG6RU78:N((2^^RT&_/Y&'R )
MA])>B:I%6BHUX)(V#-:1YS++Z(9)$>1HBC>B%"#0CX_9Z37F;*LS:QL&&"K
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')R3DY/7_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>img102984888_13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img102984888_13.jpg
M_]C_X  02D9)1@ ! 0$#O@.^  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" %5 9D# 1$  A$! Q$!_\0
M'@ !  (" P$! 0            @)!@<$!0H! @/_Q !-$   !@(" 0," P0'
M P<)"0 ! @,$!08 !P@1$@D3(10Q%2)!%CE1=PH7(S)A<;4D@;08&24S0E)3
M-55BD967H=/4)S9#1'2"AY+P_\0 '0$!  $% 0$!              $#! 4&
M!P(("?_$ $H1  $$ 0(#!04&!0$%!P$)  $  @,$$04A!A(Q!Q-!4? B87&!
MD0@4(Z&QP14RT>'Q0A87)#-2&"53@I*3TC1#1U155V-D<M/_V@ , P$  A$#
M$0 _ /?QA$PB81,(F$3")A$PB81,(M <H>26N>(^C;YR#VRM(MZ#KJ-+*V!6
M)9F?R!6RBZ;8@-6A!*990RRI"@4!#[]]X3UZ\EB^KN7^I-N\6V/+NHN)974K
M^EO[X@X=L#MY;\#C4%7#HQF)A$Y7!$T5.DN_D0 .P[[PGQ]WYKIN%'-S2W/7
M4:FZ-%.9EU3DI^1KASSL<>,>A(Q:ADG)1;',803 Q>R&[_, @/7SA%+XIR&$
MP%.4PE'HP%, B41^P& !$0$?X#UA%\]Q/\WYR?D_O_F+^7O[>7S^7O\ QZPB
MXLA(Q\3'O)64>M8^,CVJSU](/5TVS-FS;IF67=.7"IB)(H(I%,HHJH8I"$*)
MA$ #"*C3<?\ 2)O3BU)>9JB-+C>-HN:RZ496*?U;2Y.VU:*=(F\5T59QD LU
M11$!!04CF*42B'8]83?T?[*Q+0G/?BOR3T#)\E=5;5@9K5M>B7LM;9%5<C62
MIY(UL=T^:6:*4-]9%/D$B"/T[A,IE/CVO+O"C/KS]X]VZ@7K3^D >G[LO9,!
M0$)_8M2B+A83U:E[1N]!F*YJZUS970LTVD1;WQ"1RPN' >V@;W.CB)?L AA3
MOOT^O^/W5VJ"Z+E%%RW537;N$DUD%DCE.DLBJ4#IJIG*(E.10ABF(8HB!BB
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M/E[C^>?0X7I-<P=+<@ME<Q..+[A#1^)TOK==24WI7F4E$3-;G9-T8R$J,O\
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MHOFG.7W&7D%-S%;TQNNA;#GH+S&2BJ[.-W;U)-,W@HNB@(D.[;$/^4SEH"R
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M[!VCJM5>7GM--Z\6S.UY)1T[:5BU&<H-624<Z7,H5NI,MA7%PR(8A% :@X\
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MV\+ K:_4)Y)3^THCR,O&Z:UO)R%3HC-58PG.C*N(]..5?MD \4T46R*2I@*
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M"'@EX( 4YQ OD'>;!HG"W$'$3B-'TNU;C#@UUAL9;6C)_P#$G=RQMP-W NR
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M5-!.%82S[+CK#=A!9-E0*(4]OMKUZF @FQ_#H;ZDK)==7Q23^O5;% P]B(
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M*O,!)%3:P Y?$=C+)S<W,X8#<<OB5KFMW[%9\4,+C&'L+R\=3OC /D/$+4O
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MDDGX 9)( )50=ON&Q_4DN#6F:8EY2F<3ZK.I--FW905XJ3V2LV4*HZ@($B8
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M2$#Y,(!A%Y7K57>$._>3>_MY<*_4[=\-MHO+ G4]Y,XZSUA.A[$E&J!2DL\
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M9O0*LR6>LG &8FEFS4Q0,0$3K%=F.NX4%4I")ZOH?#6JZCJQXGXLDCFFY?\
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MZWU"HAV#8"B!@Y['QSJ&OW7T>$-(?;KL<6NUZ]SPZ6W!P3%['//T..78Y!Z
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M[C@%VQ?,3G )('DK X?U;. ,8V(T@K?(134A"@5K'Z[F(Y A"!XE*"+=BBF
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MOJK\+WQ_!GL&7<B/P04:G.*$4_P34*V$AQ_3X$?GOOKK,H>TC@[(:-6:YQ.
MUL%@DD>&.[Z[]%JL7V4.W"0./^RD<36C+GS:II\;<>!!=-@CX97;E]3KB,<W
M@6XV$3#]B_L;.@(_^MN'W^P?IGO_ 'A\*[8OR')Q@5;'7_V\?FO7_90[:<$G
M0=.  SDZWIV/J)3\_'&^%VIO4=XQ%()_QNXB'CY!XT:>$3!UV'C_ &'SV'VR
MM_MWP[_^(L'X4YR=_P#R*U_[+_:US<O\/T,'FY3GB'31@^_\4KJ9_P!33BS5
M(A2PV>9N=?KZ14#'FY:DR[&+*+H"_3$,[7*1(IUS'*1,IC (G'Q_O=A@\=:
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M7HD.K8KQ;K_3J\W.FFXG;'K*TQ<4@HJ/BD19XNV!,AE#=%(4?DPCT'>$_O\
MEZ_)=A#^L+PLL,4QG:_.;,G(.40(ZC)F*U7:WD;(M5 [3<LG2;82+HG#Y*H3
MX$/D,(N>?U<.(*2:BRKG;2:*)#JK*GU';BII))E$QU#F%KT4A"@)C#^@!V/Q
MA%B=1]:_@+L%.16H-^N=V1AW0L9=:KZYLTLE%OBCT9F_.W;"5NY*/8"D<0,
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MM8;^8;*9<5CA8%&Z9R&CBK^$7XI@#0$TO$.R_+_9?AP!P&AZ:&O)Y@*L>^0
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M!WRIFHEO&7B6<*S#5NK38Z!?)M0CG:+10RP/G#9-,Q3 F41Z#(_Q\OW^?O\
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8F$3")A$PB81,(F$3")A$PB81,(F$7__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>img102984888_14.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img102984888_14.jpg
M_]C_X  02D9)1@ ! 0$#O@.^  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #J ET# 1$  A$! Q$!_\0
M'P !  (" @,! 0            @)!@<%"@$"! ,+_\0 5!    8#  $" P0&
M! @*!0T  0(#! 4&  <("1$2$Q05%A@A,2)!45F8U@H7(V$D.55Q>)&UTQDE
M-CA3@9*5T? H,H:6L28I,S="15)6EZ&VP?'_Q  = 0$  @(# 0$
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MB^@NY-@P-BXKV;7-8REL@K+24X2$:5NM(;"9-W$/JPFBTV(IN&LO(P)9)*+
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M5"%2 G5O-_'P]C:?'O\ #K['7$ZPZ,[WAY?E?LC8NY*A9^=NQ-\,=5RO*?V
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M,T;$PN,<8&[$3D_,,18Y7U?07E(W$68!=@9A:37AH,)O%3P$8?3U-S!JX1]
M] ]1@$/R /P /V 'X!^08?I\F^K,ZK;]7_-U9AD*5KG;VJJ=O'6-YU#L%M(/
M*3L6N255L[6*EI"!DEX>51%!XFRF8E=K)1K@R9A!-VR<(KI&_2(<!PBJ #^C
MO^,L   H^Z/0  /^<;N/]7_M7A%U^NZ)O^CW\*]&S',]JT]V)M.YTM:,;;+E
MM8[YO;VO49](M2O5(-PYF]IPSJ5L<6U<,G$I%L&IDFA7!FRCSZ@B9F)/O[^/
M3P5E1_#SXLMGO^$[[IR"VU/:HZ4EK#/,Y=;?6WA<RM3<Z7L]R@E&XO;*=W#N
MRO6;(7A6YF[D/AN&+A0Z)U$S%&OU=V^6O[*;I?Z/#XS"F*8*/N?U*(&#UZ,W
M&(>H#ZAZ@-K_ !_$,*5Y'^CQ>,P1$1H^Y_41$?\ G%[B_7_[58139XW\<_,'
M![F]N^=X*ZPR^QTH-"T&MVR;G?BKIUT[]2,*Q):Y:2)&BF>2=BL9F5(SCW$!
M83 F0 (ITX1,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$P
MB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3
M")A$PB81,(F$3")A%"GM[[":WUJIUE8JS<[1:>68JRWBIPU$E!C96T)S$>2$
MF*),)JD5C9&I6HJS)&>0E43LV*31&8]Z*D>4XE#_ '\>GS\OEXJ%VCE>W=Q=
M8Z2V5TAQ+K#6%$US4;1$U*9J'75=V/ ZY=3D(Z(-HKVL8O7L$O)V>:8F;4X\
ME]<,RB*ZLN+%F03K*J2^G@_S;^_W^31N]O+1O<KIP_(/_P"_S_Z\A2GH'[/S
M_/")A$PB815?>8;H?5'/W ^^QVG.OX,NUM>7G5E*%A79ZP#(W2?ID\YC(]R$
M''OPBFJR3!R965E!:1K?V%!=T0QR%,1<CX:"B3Q4\!E-^9>8-7 /H/K^(0"'
MK^(?@/\ U?ADOU^3?1F90WZO^;JS#(4IA$PBZ3OE3_HYJG1_<-\W]ISKC1>L
M8C=]G;W3;]*W18E65KIECEB-$YN8I[.-05)-0\HS;C)Q\3,+PRR#]46Q'ZS!
M0'*!1W=&;HS=.OT\_BKSZ73-!<G17BXYPHFX:98JGHJ5N%(1L4C<ZL#V2+&Z
M%O2+F:DRH2IV[):7DUUW8MR'%%!1V1JB8P%3]Q/+QT?5^[R=4P]_?TIJV\T=
MF[!T!HG0^M]I:MT_;F],M=XGK7-DEKC+QP-@MA:DI"!](CF<:^4=Q$>]=!+I
MOEV1GAB)H*D3 I^_O5=L3F_H#7?5&B=6]$:G?.Y'7FW*C&W"KN'[4[&0(R?E
M.19E(M#B86\A&O474<^2*=5(KMJL"*RR/L5.4-U^_O5O:MVX4IA$PB81,(F$
M3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB8
M1,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$40^
M^*A?K_QQT32]7OEXZ]6764]$P3IO/P]5'W.DTROT%[+/+-XN!8NXSYQK(2[E
M=$8]BLX<H*$<IHCDMIKU?1E#]WNZ_+JJ9?'=3.,(3I/5*FK>6:'K78["%G6\
M=:ZYY":-O=2).2JNT)1%AKN*VS89>RMW+4%VA7(5Y4[%!0))PFU*B<Z<OKHW
M=U?7NTU][Z=>_P '[_>C:^+_ 'Y_'Q;Y>WLK!^0?JS%2F$3")A$PBA+Y(V[9
MQP3UX+ANW<"AS[M%9'YA!)<$5BU.3*59,%2' BI0,8"J% #E]1]I@PBU/X9O
M\5/P#_HOZM_V ADOW_!OR90WZO\ FZLRR%*81,(M+7'G'0FPK [M=YT]KNVV
M5^DU1>SM@JD1*2CI%D@5LT37>NVJJZA&S<A$42F.()IE*0OH4 #":+%AXZY3
M,8AC<[Z>,9,1,F8U"KIC)F$!*)DS"Q$4S"41*8Q!*)BB)1$2B(84::^?S=OR
M=4&]C?T6[E/J'IIUOZF;9N.@Z[;Y=A-;-U13JM"2D%,R*"S?ZJ[IDB[>LCTA
M2>:(&(]0"/FFC:065DV:"7N%H)/[_?=]^WP['NH-2Z_T/J^B:;U576=2UUK:
MM1=1I]=8^\6\7"1#<K9HA\14QUG"Q@**SITN<Z[MTJLY7.=54YA*6Z+8^$3"
M)A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,
M(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$
MPB81,(H,>3 L(?@WJ(+'!V"QPP:JFSOHBL2C>&EG)$U&QTC_ %%T8$$(UHX*
MB\G"J$6*O"MW[?X"XJ@D=]_?U1_9]_?V[=ZB1QG&;'-LO6,M-4?Q6MH1Q75G
M"EHYEG))SM-P#BM'%%Y3FBM>:MOD7ZI@&1)\\!48A5<"**^P/=+^/GKW-W?/
M7K]]7[E#=WC\=-=/O17/!^0?YO\ S^>0I3")A$PB8151>:!GU&[X*W0/,DWJ
M:&%M3;JXW.&U8N8DRR6G24FPA8X^DC$JIE9715V:.-&.Y$JC$B9%P4*!Q)ZD
M66^&CV_\%3P'[/4"?=@U=[0-_P"L!?H*'H!OS]1 /3U']8Y+^WR;\FT^BAOU
M?\W5F&0I3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$
M3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB8
M1,(F$3")A$PB81,(F$3")A$PB81,(F$4>.D:/MR]45>,U(]U6]DC$<(2] W9
M5WEBUEL"+<D(52'L2\0;ZY#"B8OQVC]@VDD16]$WT:Z0$0*3[_T^*AG4N?.E
MV5JKS^F\^\(<S*,!5;2FR:9'3>Q+ZR8.4B-GRE"BTZ1K^(BWSAH=RBD%@DI!
MDDF<I5VKL@&2,Z=?I_=O[J.O3NZ>?Z=?+7S5I#!NNU8LVSIVI(.6[5NBX?K$
M226>K))$35=JIH$(BFHX.4RIR)$*F0QQ*F4I  H%*^O")A$PB810<\EDM%1?
M!/6I925C(L9#0FSV##ZE(-(\'KY6I2ATF30SM9$KAVJ5,XI-D1.NH!#>PAA#
M"+6'AF_Q4_ /^B_JW\_P_P#N!#)?O^#?DRAN[XE^;JS+(4IA$PB818+:=H:U
MHTG#0MUV#2:C,6)3X4#%6:TPD%(S2@G^&!(ME)OFKA\(J?V0?+)J>JGHF'Z8
M@7":_?[^7<LZ 0$ $! 0$/4!#\0$!_(0']8#A$PB81,(F$3")A%X]0_:'^O"
M+SA$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81
M,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"+0
MG4.]&7-&@-J;T?P3NS(:XJKN>3@F:Q&QY1[\5!E'-%WJA3)Q[!1^[;#)22A#
MIQT>#EZ9-0$!()0_LT^*K+X:\E.\=Z3FE('?>N]1P+G<-MZ2U4BIIRP66=5A
M]F<]7";:O7QV5@3!1QJ^;I\6 MKB"J:Q+8*$>K'HM9-H8A->O<^GF_3_ $?V
M/\^G6Z_"E,(F$3")A%6CY=-$:?WEP-T63;E!A;XGKG5E\V)24IHS\I*]=8*K
M2AX>PLACWK(XO8]0XJH%7,LV^(!3*(*>T #(3,6,1)V:06 V;N(&,)&%_-F.
M,"]XL_@MB&U8KQVX8)CBBO5QJW !]!L5PM5KHPRM_P 0#;IU;#-_S((R\%Z>
M&@QC>*C@(QA$QC<P:N$1'\Q$8!#U$?3]8Y#_ *-]69:S?J_YNK,<A2F$3")A
M%_+@\XW,_D%E/)KO69V9K?>&QV5TV&^5YYLM>K]IMU8=ZQ7<)K4B!H;N#:O&
M4*2$;J)LGD,F+-ZQF472STIW"@NE"AOU?7W^?Q\/8OZ('C8JN^:1P?RS4^G7
M$JXWM!:AK+#8@S[T)*?;RJ:*@M&$\_ RGS4W&Q!H]A+*F46.+]LX!1990#JG
M*?MO<IOX1,(F$3")A%7IY0+GN.B\D7*<TJM/,;#]6K[.<F:PFX/.PE2=/#$F
MY!BHT34<M"B -VKMZB!5&;)RX7!1'V_%)T?TBV\O2X5OSX7G#;$H6.6NSE/#
M6*1FGDB9F(M=N@D3-J $9,[.VYOI;^$K!<#\1>FG X[CV/'6<7V/)3X^CEBC
M''7\W# Q8^M9&8@BF?5Y)H*YNXSV(8HW"3785)OB'V]T-,=5,*NULUUNFN9F
M"GE]EMIV4F;%#PK1M&.G4+-G=2+AV2(DE)])DP;+IJ)J/BO'#0Q%2G$R7C'H
MBS7$EKB1ZQV;MW&R5ISR':)))HH'82*";<;DT4A2L,;=1YC&3.SZ:M]\?QL\
M$>C&CZ'K&7FQ. P/%-'(XV/A.7'4Z.,O7YI;<,60Q[158H2NU QISV9@(2&L
M\$4S$#BPGV3>A^@]=<R:PF=J[,>ND(*+409M(^,22<S<_+O#&*QA85HNNU2<
M/W0D4.'QG"#=!!)9RX7212.</H?/9W'\.XV?*9*1XZT.C;09BEED-](XH0<A
M8Y#?N9R%F9G)R9F=V_+#T9^C7BCTL<6T.#N$Z\4N1N#)--9M&<5#&T8&9[%^
M_/'',<5:%B$7Y<4LLDAQQ11G(8LHD<9^3'4W8%LD==Q]7LVO]@-6$G.,(6=6
MCY*.FX..<D3.O&R[ R1ADF[5=NZD8UU'MRMRF5!H\D$T3K9U;A#TC8?BZS+2
MK0V:=V,))A@L<LAE@ M-\4L9.Q&PN!21.(N&K[2D%G)>T>G3^%'C3T(X:KQ-
M:R^)XEX;GLU,?8OXX+-2UC\A9A(ACMT;(DW999HY8:UJ&S*\CL'.@K%((*R?
M/05\L)A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$
MPB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB8119[<
MN$U0>3-_VZ UW7=L2,)K6Q.0U];@]U5L;,[;X$FWLB8*(J+P;6,6>2$HV052
M<.6319!LJFN=,X/O[]RA_FJP_'ASMSGI+<,#9=([?X&EW]RKDN1S7M*PMV6V
M%(PLTU+8WC.E/+;T;L1.O1:LFDUFIM&/JA59)!J(O@14+\1*7=]?<S,_3\^[
MQ\^O=\77IK]>]N_QU\&T;Y^:OB_\_LR%*81,(F$3"*KWS#= 4/0O!&_!O3*\
M/"[/UW>=9UP:31[!=C-K'.T^:58.+ 2 :N1@( GRIP?3TD*,>Q*(*.%2D QB
MRS.[._3U6U?5V9]-6'HSNSD^KMT'5]-2TVB3M8$9&,I"\;-#&TAL<L49.+RQ
MQ,T02&)SR;Y1=XH1DE:)I)G!H899 Y+PT%$GBIX#*;T]2\P:N ?0?4/4(!#U
M]!#\!#^\/P'#]?DWT9F53=WQ+\W5F&0I3")A$PB]#)IG$HG3(<2#ZE$Q2F$H
M_M*(@(@/]X>F$7OA$PB81,(F$3"+\U4DETSHK)D524*8BB2A0.FH0Y1*<BA#
M )3D,41*8I@$I@$0$!#(=F?H[,[>3]>_H_TZ+(2("$P(@,28A(7<2$A?42$F
MT=B9V9V=G9V=M6ZK#:=K;7VO4WR5$I-6IZ<HZ.]DBUJ"CH8'SI0YU#+.Q8-T
M!7,!U#B0%!,5/WF!,"@(AFM6HTZ3&U.K7JM(6^1J\,<.\NO4^6([GZOHY:Z:
MOIT7-YSBCB3B8ZQ\19[+YPZ<(P5"RN1M7WK0@(BP0]IED:-MHBQ.&CGM9R=W
M9G6B>QN5:OU]IQ_J^P2CBO2+>0;6"I69LB#L\#8V*:R+=RNQ,J@1^Q<MG+ED
M^:BLBH9NX.H@NDNFF;.$XKX9J<5X>;%6I"@<C":O8 6,H+$>NP]CN+&+B1 8
M.[:B3Z.SZ.O0_0?Z8<QZ$^.:W%V,J19.M)6EQF9Q,TCP#D<79*,Y8H[#!(5>
MS%+%%8K3;#$98V&0#C,Q4'/'YXNI?D_8[S<.QM@Q%KN*$3-URNPM3:/DH!A'
M2YD$G$J]D)1%H_>2+EF@*)&!&"#1C\90WS;X_P ,4^E<!>C'_"5^7*W;\=RZ
M\4M:O'6 PKQ0R.S/(1R:&<I@.CCL$(]7]:1WU;Z"_B4_BZJ>F;A>#@?A?AF[
MAL$=VAE,I?S4U<\E9LTAD**G6K4SFK058IY.85E[,DUCE@/(KCN8[C\]:7PZ
MF$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(GJ'Y>OX_
MLPB81,(GJ ?F.$3")A$PB81,(O4QRE] ,8I1,/M* B "8?V!Z_F/I^/H'ZOQ
M_+&OAYHO;")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(HB=ZZX=;<X]W_KA
MA&2DQ(6W7\E%QS"&CY:6DE7YEVJS)1K$P:B4G*F;ND47!XQLH4'Z22C5<#-U
M52C+=_DC^[7[]J@9R=OS;KK?^JM0[/YKUMK>:F*C/2A[7$\[WW64P]:UJ(!M
M)2D++3@*P<:FO(+-&[V)"0<.TFS\B:1#I'(MA_%]=?CU]W5M7^^[N4,_ATU\
MM?[=?%]?/XJZ[U_#U'\/P]1_N_U^G_[Y"E1_UMU#I#;NS]VZAUS>(ZTW/G5[
M6XK;R$:!U8RI35IC7<O'PCB7] 8N)5M'-#N)9JV55&*%5)!X=-S\5%(BT=I[
MR.\R[QV/3]<4B6NA5-GH75UIF\6"C3D#K3=K?7:ZK>XJ:JNCU((^SA#_ "[E
MT)1(Q4?QS9>2C"/6) 7,1?'2/)?RG?\ ;U5T[!V.W)2&Q+E=]=:LO<K1;#&Z
MIVM?=;FD$[S4M>W]=M](GIBNKQ$NV<D'Y5J\<1;Y.*=2'P?<8HUT[_T\=6\_
MOYZ?$AY0N0W.W(W4J%PLJPS.XW/.\/M!.ESRFE93?;-(ZCO4#'99&YH1Q=6R
MB:C)9JGZQQ9)):."3%Z@LBF37[[_ '/TU[UF_D<,8O!/8!BB)3!SSM/T$HB
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MZ:WVGT=$5/>=>Z2N6PZW7^B]P04(^F:/&4-_6 AH^-MB"-9CHMQ.R@IQ5?\
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M<IK>,T-J:?V+-V0DBP?S]9OU#I$MK\B**2K2;:DV!$S,+-*KJ_%0*V59*)H
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M/0 )\90_M_5Z81>Z,3%-W[J5;QD>A*/2)I/9)%FV2?NTT0 J2;IX1,KAP1(
M $R*J'*0  "@ !A$")BPDC3 1L>$N=N#0\J#-L$D9H!O<#4SX$_FC-P-^D"(
MJBF!OQ OKA%7QY7=MZMU3P3TJ79VPZ=K_P"WFHMB4>EC;[!'0(6FXR=.F7$;
M5X'Z@NB,I.OT6CE1I&LP5=+%14,1,2D,($7"^&<!#Q4<! (" AR_JX! 0]!
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MWCT8?]F3T:_^+<1_^NOJ1XKZ$25:'/Y!]^*E;KD56(:LT< =$(J144E!%N8
M*8""GZ@40]IA]Q3>GH,CPGGA,2+CO.F+$SN#UL>S.S/J[:M%KH7<^N[IT[M5
M4?IU]&A!,(_PT^C<"DC( )LMQ#K"1 0[P_G,[NSNQ,Q/WMT(>]6+(D,DDDF=
M0RQTTR$,J<"@=4Q2@45# 4 *!CB F,!0 OJ/X  ?AG>FZ,S.[N[,VKOWO[7T
MZ:^Y?,ADQ$1,+ Q$Y, ZN(L[N["+OU=A[FUZZ-UZK],E8IA$PB81=5;NS:&[
M"=6;%2L<]:*N>M3Q6="CXV2DXIFVJC00&N2L2D@X337-*I>C]S()$$[E\LX3
M-[ 2^ G\M<;9#,'Q3D7MRV:YU;9QT8P.2,8JH%_E)(-KMH\T6R8I ?UY)#[N
M@M\,^E3B#B>+CS,1V[V0QK4IXPP\%>Q/6B:@ L56S  2,,I6"<C.9A<CD<HW
M9F!Q;L4<KV#8MJY]U9/[7:.6E]DJPV6GBOFOR+]P8%5DV#^09>Q/Y1](QA&;
MUVC\-,067.84TQ,*9?H3A2QD;7#V+L98""_)7=YMX[)#$99!@ED'1M))H!BE
M/5F=R-W<6=]&^ON"K>8O<*8&WGXSBR]C'0271DCY,KR.SL,DL6C<J66-@ED#
M1MI&[:-W-('.PKM"81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F
M$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB8108[ALW-T?6:
M95M_\_VKHUW;9A\WU]0Z3J"2VC9_K3%LDN\D(M^Q010HYVS=1,ZEA>3]=(FF
M4P$?"9,2A+>/5NG7OT?X??@BC1R=HSL.H]"&ML2O9-#\<_3I SG0.Z-JN>@M
MDV"7=-URQ:M><>]TRTO%1:ZK9PXCDK_L960*U48BFR36^.F?333O?SZ_3]=6
M]RQ9G[^[OZ>/Q[V=^C:/K\7\;?LA9)A$PB81,(JQO+[SSI3?W!6_C;FUU ["
M_JHUM?=HZ["<-(%^RNP(2ESK2)M$::.?,3A(L$'[M-$%SK-A!8WQ6ZGX>A%]
M'AG,)O%1P$8P^IC<P:N,81_,1&!0$1'T] _$1]?PR7_1OJS*&_5_H[JS'(4I
MA$PB81,(F$3")A$PB81,(L,V!=V6NZI)6Z0A+786D6+0%8FDUR0MED<_-NT6
M9!8046FJ^>@B=<JSD42#\!JFLX/_ &:1LU;ML*-:2S)%8F&/;K'4@DLSEN)@
M;9#$Q&>CDSEHW06<GZ,ZYSAO V.)LS4PM:_A\;-<YVR[G\I5PV*AY$$E@NTY
M&X05X',8GCA8R9Y9BCB'UC95I=?^0^2UQH2X675>KMUUZ\ >*C(:P[+TI:Z]
M4($TI(H-%Y21D)INWC1<(-SJ%C&KDYTG4FHT25152%1,?/N*^/"Q>!O7,;C<
MO'=!HP@EOX>Y!4A*64(WEF.4 !F$2?EB[^O*X"[.SNOJOT*?PR5N*?2/@L3Q
MAQ=P%DN'W&[;OXSA7CW#9/-Y)J=62:.G5K4)9+31R2B!7)8A$HJ@3F$@2,)-
M6;XQ?(%M2K; G-5;!C+CM2C6I6Y7P"TFF.;3=J_;YB24L4[,$CJZR^<?PD])
M/'JDB@JF",:^>(N6BB*'Q&RGFOHQX_RK7K.*R4-O)5;#W,@TE2D=FW7M32O/
M.91U@<C@FED+=J+<J0VVNP/M'ZN_BT_AJX/RW#>/XRX9MX+@[B##C@N''?/9
MZ+#X#)X2E5'&8ZB]G*6.SULACJD%<:I@>^W7@.*<9)&"4.PQJWH* VO./(&*
MH&YZHNRCC21W^Q=5VBCPZZ15TD!;-92::HM7#X3*E.5F0WQC)%45*42IG$/?
M<=FH,G+)#%3RM8HPWN5_&VJ49-N8= DG 1(M7UVL[OHSOW,OS/XO]&N2X-Q]
M?(W.(^!<S'8M-4&OPOQAA^(+T9/&<G-FJ4)CFBK,P.+SD.QI" '=B,==]9S"
M\Z3")A$PB81,(L&L.LM=VV8C;!:*/5+%.0_PPBY>:@(N2D8\J2IET2M7CMJJ
MNB1%<YUDB%4 B:QC*$*!Q$PZ%G%8RY-%9MX^G9L0:<F:>M%++'M=W':9@1,P
MN[NS:Z,[N[=>JXZUB,5>GAM7<;0MV:^WD6+-2">:%A)R%HY)(R,&$G<F879F
M)]S=>JS@   ] _+-]<BO.$3")A$PB81,(F$3")A$PB81,(F$3")A$PBX2Q.I
MUG"R#BLQ;&:GDFYSQ<7)R:D.P>N@$OM1=2B3&249)"43"98K%T)1  ^$/KZA
M7,\HQF4(#)*S:@!F\8D6O<1L)N+:>.TM/)UO8V+'S7ZL65MV*...5AMVZE0;
MUF"'1]9(:AV*HV#9]-(WL1,^O];+KH^57ISLK7.Q]2U^/%[IV!&%+9HI37-E
MD+ TM5I),NVJC65G#P$&5T:,0;M"DJXM7" I/_GG/S0/D$VW@GI1XEXPQ=_#
MP4Q/&5S!K#'2E.RUNTTI!R9)'@B9^6(@[5]K[VDW$[ZBP_I[_!WZ)?09Q3PO
MQID[7(XXR+7WQ%P>*,56QDV&Q!489AFIX]LED7A&W)+,[Y?GQR-)7>O"T+UY
M"ENOY]O/0-QJ&O97:^M:I5OK=&A)><D6-R>.IHDT[BVK@Q%ZHM56!(Y1V=0R
MKMH,RX-&*&,V S@4Q-GL>%M9FU4HRY.A7JG-2@EGY=HY)!G.("('@*O'L]9W
MW"\CO&^H^MIJ_P $>DK >C?!YSB6EP9Q5F,PU#B&_2Q]:S@H(:!8^"Y-%OCS
M,>7L%;:(!$(9NP1M<C9IM(M^BDUG.+RM4TVO=%SW?NGL,MFV+OO6>C./KKK[
M4T-4.6XA],;8OE\G:G%7BS7NSA!U>UV=Y5VC"UP<)#5N*BD(U%.+EYV2?/!5
M(DUHKD(X6+.6Y)&.]G\]BZ<0 14Z&/P#00RV;NT2&2Q=N#;DWSD$-2J%6$8R
MEM$;WVV9LC'AJX"[P\/XC.7;$FT+%FSF[.1AKT:3$>K04ZU6"0CB#F6;=F<7
MDY=+8HT[3ZWIUMVSR0R==R[NHG/&Q.5=U7J#OL.#'6]WV+M"J[(K=7K2=DA#
MZ^7?/)Z+;*S$6-:^B12<D\;'4=-5G"@IGME"?M_%D8,Q9*MPUP9D\!CJ3#<K
MSR9J3B*:6Y7JBYM:&Y7K8TFB*4HA FC 1(WD"Z2&&.AAG8'ABDXIS^*RDMF4
MHYJU?'4:#M4ELGH\;UK!V-T^QI==2(W8=I9_H?=O872-QY<Y3W;<+CH>TR/+
M%QZ.WI;:A$1],VS>V3;:CG6FK:^U,_BGS/7#^1ADFU[OZ45&C))/G3.";%C6
MB[L,Y$ZT-FWFISTA'"XK@MI\?1L;JX<2\24;]O*B\^LDDV,Q,F)LU*T(R:3V
M+)\Z4PJ"$F@+2P8NG/&X3!E>)N*Z%*W99RL-PYP^=5\?.\+Q0".0RL63IR'-
M)&S15ZTI11/)9YD4D^QHJTZ$T.1ZZW[V_:G-;A;B>FK:5J,7;KN_L36-&3KK
MO9UDKVOGB2\%#BU,V5>V8L-"22+E=297<+HIG+P.4N3QQ33U^RPY *K%5DL"
MU?"12QV)6>;(L3A6&!PL50M,4H<NK2FL0@TTDIK;Q]6.2=H[,DQ8^:V#6(XA
M*;)!!+%$SQ8UX@.T4@/7M20[(Y3*>W' 9\H(@64I=7[#UQXK6G75JDJ1M?:=
M=YH8;"F).E/FSJBVF\#!H)G<M7L2!F@Q@3*Q#RX1Q2H)&0?HM02(0@%Y;C$?
MPZ_9JXL!K/:R>)QM(I1D."N>9N4:(W &0N;+1B.X5NIO/=/4:!BDU-S6MPP(
M9#DO=*0X8FRD]@-T<=MZ^,:[8>I.[-RX<DU>JU6XVW;!=:9MGJ;5LGGK3FR:
MO7*/N?974VV;W9INF1ELVG"S+BII:@D'$G7/J;]*HU!*MH*T2%AW;DBT6K&3
M:CY1E'IIR;MX+IT8UN4>EA9LQ6$2GH4!N0-/?+F7A*C,.[('+$T0M+($%CF5
M0C:H+6=@1MR8C6AC#MYBKB[AN$-J\U>VU>B+#48+H;XZ #)S3FBB::*(+)GV
MF0H6F*1GED!ZY>0>YMA73K=K)WC>45<-+]OUK<LQSAK-O+5*16TQ,Z)LJS"'
MA2$A"?5TAVAKE-S>%AGCKE^HQRB#<Z8&*CFK##(&"R]*82+.5.&\7QR-O<Q\
MNOF0ECR&%A(1&(HL -GAV:/<+SD>0O[N8-<R;E,@4+9&G:J!&&,@S]O@RU'$
M<A-:GIQ!)1SD@&[E 61O4N(L?,(:PB-?%[3<IV9]$\-=2;WV)LWCR)A]Z="7
M#9>T;]OM_P!"U??402*TA8=)4.>N,:I):0E)"GU]G+6ZLRZ=+91K;7\O,J?3
M5996PHECTE'2?(8N**1HF< /'Q<!8K,9-Y]WXQ'F\E3QP8RW6!W"7L-O(S7F
MO$<34!K]E8#"<J[2Z>3)X_Q5Q(XK@\<SX?#M78"QLE"I>NR9"E=DT,!FAPT!
MR5QY@WBO0;&8HFL\NZG;G841I+HFF:1OE15BJOL32^S]H4[:RL\@2&<V34"2
M$Q<->RL2K&$-%O I[I.SQDU]5=).V[24;&C4#,RK+<"5R,*W$TQ.PR\.86KG
MV@<F;\1QLUF:A9*&33^7-0O_ (?#+%LEW19&&;<+QO&?)C2ED_ ^2QS-F<X>
M /8#/V&Y)4:YCRD;?NDBOQ0WP$V$&BFJ#&3EV@7"HO>_1]Y[.F>8+O2=0[+G
MZUKKG]_U)TOSM%[6EZ VA=>[(,LRUE8('8M.>UF7L>ZHME6IZW46CR<6G4YN
M$%^66<1L@>-7#DCICA\WF[^1*23&X6GBL/9M1LQ3X3B2T-7-67I4',XLEV"C
M*];B-[#AV:HU8Z#33S35CIKS09'&T<? 8!D<ME<G=Q0C&$\&9PN(GM8@!OV>
MT5RQM#+VY*\V(L5^U22V0DCLURJ@5N#<O2LD_LLEX[-D:$ZNZ@A=8]=;HH-$
MEFD'LABU8/M9R&G+C96IV+25J<F^@[*\D:[%.IR1(\,^,_3D4%#%^84]FQ#C
MYHN+K.$ON)#)BN,<O*T3MRFLXZE5NT"I&#"X4&>?F5XQTC. PU9QT9:,EN"7
MA.[F:@.$]+(\*X^(2UW1M?XFKX?*0VHR>5BM1QR6*QN[N\,\>HEJ#N]J-LVY
MICDN@4MENK<ZD+%*B6M0UQVM-GDK':))DU4=JC*2S6.1"1E1:E,NX7!FW(8I
M?7V@(  Z4]J.:TX[88998WE&" .6'*A:*(Y #<71B*/>^O4Y->YWTV(X3&(C
M_F'&,C"4AOKM.9Y) C<M&\ -@;P$--7T7V:?ZGYYZ"?S43I;;-3V-(UYFWD)
MMG77:[A:-9.UQ;MW+DJS=#VI*K%,D0Q?=^F'H/IF;PRO7.RP%R!E&!Y=/4:8
MXSD"-W\#((S-F\A=_!5//$TPUWD'GE$<XQ:^N\0&$9R,W_RB<@"[^9,JD>1N
MO[]1JQ8M35:JS.^M^;E[?[=C=;5^Y[#>5FK0-&U3=&[V?DK5>Y&+N<E7*K7F
M4E'1<#%P=7G55I%^T8-(UHT%=T@I;[F"X,@KA&4M;T>UL[F;4LG+<()N)<OC
M*LDA-'));OW[3A7K >T7BJSG-8B"",)%QFK<0<<SS<YJS\;8O"8V""-I&Y\W
M 7#F2E$!>2**K3KQPV;-J1GW/-./+AFEL$329IOE AI2\TF@WO3TQKR6>7S?
M.E]J/'=M8R\3K?=NC:+#[+^R,>\0A&87* V#1W[^?IUI(%?<*-HM5!]76[PR
MK=O4!Q3P3VZQR%6+A:YQ-C7GC""S<+$9YN'\[B9X.9(%2YC+4M67F!-:KV()
MVD V$2=7&$D4O9Y6!YX>(<1@[KQ&QUZU?/XB?+X?+M,;1')3LC#V.8"ABDJV
MY "1W XR/E=&^2EGO,>9XJ(TK8H&Z;]V#M>I6.FR]HCS2.I:UJ>M?:>3N\\J
MWB!"692S*8HJ<='()1Q@6NC(BCX3M#$<<BV/D:S%7D+E.W"A\2WW=F)\=:CR
M-/#%@IV B%[S9>Q9J.6\?4Q]J?E,S;!PLF,$-RQ'NF@#B2I@,5.S"T.:@N5+
MF2BS-.0#E%L=+BJ-B]6DUD&P')!C!YA=N?Z@ZVOL9<]Q<]:(TZKM2V:XY_>;
M5V[/.-BM]<ITBNW%C;HRG,:<J:O3Y[5L&37K,S*MH9T[J,:RCF*;I6RI.G#=
MN;JF6.2?A_BJX)%7H8R&SBI+T,FMILO+B6R+QU:[/$Y18^E8J6[UGM,<D/:J
MT=6&S(9-'S&/BY&6X9B,&EL92TUR"O*+#5*C2R-2K(5JP3'L.Y8EDKTXA@F"
M7LUHK,E:, >2)_&7:&VC<W<MZ8U%J5YT+N:"X\UMO;<,OL+:RU#CH:LV=65B
M8%B-N>UB_P O:MCV=]!39X^)=Q[&,!M%KNI*SM051(?NG$[A%E^([D</_1&#
MGQ-*Y+6$&L36;.%#(/#C*6D<=B2*I&UJUS[-,0*W4C8Y)9SY?!5(Q&*M7*<6
MR67O\2R8ZI*1%%#7Q^>*G))DK0\PJ=8)[D52MR*]LY>SV7BB:*L[ON^I^4ZN
M;1NG/=;U=K %8W=FNT-CN9#:U_C-3OVS8MN?46=I.O6S^#G(+96RZ;8XYV-H
MJOVGJI$8H6;V+DI-1^@VS3AIO+?O5AE"6I5KX6U!9@8I+-ZIQ!CSRF.R-?'F
MT4A8L*8B]VT$LDM:P10-5D>-R)8EDK5!EEA>.TU[.XRU!(3#7I9+AVY'0O8V
MQ=;<,=VQ8,WQPG",-J*-Y#F@9W8<:?\ E_U@EOS^JV&JD59*:UW5]WN4E8>\
MK/-P([").DK;R>C=--*<Z;26KXF95!G+6M383&99HM).1^RJC)D"B^IA!'-%
M2:,VB'+17)<9(S/+$S4FNOIE3?E-C1M?AUAJAMVMB.6B,_(:T[PW9MI,*UIY
MQ'=C8JD^2BE<H91CN159@CQPL,OXA9BCO5))8?\ +B4?:7KR3E P2W#@/J #
MZ>GKF*E><(F$3"+0W3NQ[YJ#0VS-G:PHA]FWVF5U2:KE"10E7+FTO$'34JD4
MT;PB#F37=K-3+F:(MDO[1R1(JITD154*^7Q1:ATUW)2MS6^N4>/TOU%1YJPL
MG#HKW9FAK?3*U%G:,%'[AM+65^0\4T6'X1VK?^W43=.Q310.<5"CA^GM[^[V
M?OX>"AGU_MU4U\*4PB81,(F$58'F$W!*ZCX)WY]+TWMK<'V]US>J,])JB$C)
MI6BLY6H3*BMYN19*6BOD*=#_   ^JOV@/72)5"BFT4$0 99M6)]6;:VNCOU+
MUA'0>G5^N[1]/58GUZ:/8$;&,Q/)&#Q1M(PFY,4SO-%%RX6828I&:5YG$G >
M3%*3$Y"(%]WAH#V^*C@(ON*;TY@U<'N*/J4WI (?B41_$0'\P_NP_P"C?DWY
MJIOU?\W5F.0I3")A$PB81,(F$3")A$PB818_:;76Z17Y6UVZ;C*Y6X-HJ_EY
MJ8>(,(Z.:(E]QUW3IP<B29?R*4!-[U#F*FF4ZABD-38L0589+%F6.""$'DEF
ME-@CC 6U<B(G9F9O?[&ZKD<3B,IGLE3P^%Q]O*97(3A6I8^C!)9M6IS?08X8
M8A(R?Q)]-HBSF3B+.[1;UMT=R=W#7KQKNJV""V5$D:*,[;2;!%O8]R]B#KD3
M3D214L@T=.XLSD$A;R;,!^6<@@;XC=Q\+.MX[B#ACC"&[2IVJV3B!BCMU)0(
M=\6NW>\,P"YPN3,XRBSBS[78F?1>N\5>B_TR_P /^2X?XGS&,R7"=TIAGPN?
MQMR"S'7O"!$55[M*2:&&XT6]I*D[MSHGD;9+$QK0NQ8;E7Q4Z=N.W-=:K0;6
M"S/T(")8$EY-]-VB:?J*O(ZOJ6":<2CJ)KC+Y99^Z(V3.FB@U$Y6SET*0#PU
M^/A?T98:[EJ.+&(IC&(0C,RGM32.Y15WGF*0HX <7)V;U $=6%RT7HG#%WTQ
M?QA\<X+@KBCC&2;'8JO)DKEDJ52O0P]"L(06LD&-H1TX;N4L/-'7A>4F.227
M:\L4/,=:[X'\I#GK;9C_ %%=]:L*-:E824L=<DJ[,.Y6&DV409$[^-?-I!JD
M[8/F[58'"3HCIRW> FJ06[,Q2?%XO@7TFQ\77Y<79QXT;@PG8@**8IH9@C<6
MD!V*,2C,!)B9]2$V8F;:[=>T?Q'?PAAZ%N%:W&N XLL<0X8<A4Q>5JY2C!2O
MU)[K2-6M5Y:LIP6:\LL;Q'"44,L&Z,N9.SELN"SU=?$J81,(F$3"+T,HF4?0
MRA"B'Y@8Y0$/7\OP$0R-6\V^::MW:]?)>/C(_P#2I_\ ;+_XXU;S;YLHU;S;
MIW^Q/BI?](G_ -LO_CC5O-OFFK>;+] $!#U 0$!_(0_$!_Z\E2F$3")A$PB8
M1,(F$3")A$PB81,(F$3")A$PBXB4K\#.?*?6X6)F/I[HCYA]5CF<A\D]2$13
M>- =HK V=)^OZ#A'V+%#\ .&5R112[>9&$FPF,-X"6PV[B'<S[2;P)M';P=;
ME/(Y#'O,]"]<HO9A*O8>G:GK/8KG_7!/R9 YL)?\44FX"T;47T7+@  'H'X
M&6+33'>BA-LOC!M8=HVW<^FMT;&YNV+LN%@J]MF4UY&T.QP^RXRL(/6M>=3]
M6V/5;;!-+-$,Y!S'-K;"M(Z=6B_EXYZZ=-63--"@*XC6MX_<;XR_9GN6J#NS
M1O<M5H*=FS7F%FL59;5:O!'::&48YWABE(.<',?8DL%*528Q%[E"$*M2YJ_-
M"G'//:CJ2 [O%/!#:L33P#+&10G-,P$P3&+\=ICQ_P"H=$W72%RI,]>%AT5I
M:]:4KL-/2,7*L9J)V'=8N_V&RV!R>(3D5[&>PQIEFQF+MC%MT'BZ)([T30,G
MR3VRY^5F&**,<IC>&<3R1W\NG1X4&_'BPKN1%(1O#D#BL23G*4C11NVTW,BU
MY'DGKU(9Y"EDK9?+9N2P[",EJ]FH(H;I3" M$,;E%SHXX0C8#)VU<&86SO?/
M)\#N2\T3<58OUTTIO;6L-8*Q4=N:_)7GTL2H6I1JO8:=8JW<H6QU"UUM^[8L
MI)%A-PSA2,EFB$E&.&K@IQ4T(1DK6+=BK*\+Y"I6HY&/9')#=JT[!VJ@G'()
M-'/5GEG*M:A>.>(+%B+>44Q@K3,)J\5:Q$,P5;,EVB3D824KDL'9IIH3!VU&
M>OI%8@D8X9A"-R#?&!-B-BY.VK+UZ,BXKMKHJNSBK.287FRI1NGIH;NWE4RI
MN!)79[6S^M4EPW*!RQR])C8469%3E %1]#!-B*"R\L)PZ8^>L-6:BTLKN0--
M8EE,;KGVT))QM2P2D,S#V<*P1C&58#>B%Y8=TH3$]QK)V8++B+A7<H:L,<0U
M'9ZLD,#TXYHQFCD)YY;9R&8V3!MG43E+2FON:(_DF(JPR&DF=%D=>.ZY//W4
MJYFX"92=DG#3,DJ8KIW(S*[]Z^?/2&0.#UR=9L5N!4B)V9=QS0R1W(P&$H:E
M:&&ONA"K7H0P04(ZSB6^)Z<5:!H)-Y2"<0R$9'J[YXTY<7.UNO*96WN6<A+8
MF8)#L7;MB6W<GF#:T1=IGGE*2(8QAVR/&,8QZ"T=F_ 5A1UK.:4/V-TFIJ!2
MAR&N:/3R*:P0D:)6GT YK"+8UU3U]]K;P:*@W2C2+->9.;%%9)H_7%P]:(KE
M7B_%8K8Y9AR%B^<+W;,@C 5F,+E>W8$X:PQ5VEO-7&M:L!$,I036MCA).1ME
M0)L5/!+C8PJ0UCDDK5!9Y8:YD)<@82F>2:.O4D+F5JS2O$(A' ;20 P+G+'X
MV^9'=5TG!4"F0VF+#H2TT*T4;8VKJG1X"_'/18\T*:'G9X]9=*341;()=[$V
MMN]344DD7JS@BB+L$ET[K-F6SEBRQ.T9REF&LTX?Y-&U7S=&W1MTYH T_P N
M VAGK")"4-BK5D$GY>A:D%<8,3)B=Q3#)!CXAN6&&:[%/C;U/(U[P3&+LULK
M%-N<;BXRA/8 @<9'9?+7O'5JRKZVYIU_#7;831]RMN"5W#K6]D<5P+:>1L4I
M:GEIJTTH2ODBG=4LL;;Y2ORS%"-;.%8Q-DH1T1\W*ZR8K,D-_%7P87/&</?X
M8*%]>5D,6^+KXUX[K?U$;24Z61 XGBY=ZK&<;!&Y1E;*'-K9VL3^KG,R^>,W
M9G.CD6RWXK'+2=VT#E$4]06E:7=4L31R;R+<L/\ )5QU+=@1W+4)&0[V4C*!
MTI5['L@\79R5.2)IR3KUB@MD1J<D!DW+N/GF#MC$S,*S'YB6C7"[8H%()S%U
M*$44?$F(R-H DI5:&=AMQR"TD-F2:G%9Q<%JOH[6JK9FCC[)0DVQI:\1F^P3
M$MBQ/)^!9BE!TN69</-0D9F&6M/7R QVK5:=W9ZMF/%6<C'%.+[AYQ,+$3LR
MV'L_@NIW"_O=BZSVEL7GR6M>LJ_I79T=K!O35H/8>IZL:1+7:J[C+?6;$C5W
MT(SF9B+BK33_ *+8&4;)+-DW@@DV,CD^^1\I':,[=+-9 ,KE*<ID+6LB,#53
MMM9CV6X3M51C@NQQ3-%:CBBWBQ@QK"/E0QXWLT$5>UAJDE#$W(ATDI49)H['
M9>2[O7GBALQ#8J\Z,SK2O*\9,,T@EFMKXLU-/Q/)M<A5IVD5?CJ^5^]:NKE:
M78"P='K-)GJ+&0-@5EV$F]=1(1<^X<N5FCEG*.)!!)=1^('7*KNO>L'G2X@E
M(9;IT,UCB!Q8(.3FZT52=QCCV['KPPQC4 ":.-A8"$P9F;4&K$&#L8&-B"K8
MM8BY)+N<[+S8C+0YD#*0]6,[EN%WN2&)'*TLI"02$QM+=1LW7*4JZ"*P%_$I
M54R*E*/X_B4#E$ 'T$0]0#U]!]/7-+1N_P =--?'3W]ZV5X3:-D?7X#=! 3?
MF**1$O=^SW>PI?<'^?U]/U?CDOU9V\U&G77Q\_'3R]RK60\9&OJ\G#3NN-P[
M:UWMBI;HWGNBC[;B#TJ3GJV_Z'?(.]D4Q>MSE3?TJRTI^FU9H,XZQ0$@^8J,
MVK]&2!^B"XQ7WU(<5#6D>)L;PV'"D[[0/\4Q$64L9B +HF+@UBMD+#SUK-88
M)(-" 'V33C)-A@M3YF>P&]\OGJ7$C"QF#8_*4L)1X?&2F0DQ<F?'4WCM0V'G
M"8K$A>KRX&B73Q=:8O.@GVE):][/3L,]N<.@[7O!M)P9-J67;3Y L99[,Y=&
M@AKL:C9:T9S4'$+"P4=%1E:<?3HALT^$FIF1#7Y^ >.L$='AWM$57&<R:2O;
MI72N2Y"CDII3.U<AR%F[);MR%,,\EB. ^8(P@#;%>U+#)F)I6BMSYD*HV))X
MA$89,>]-\7+5BK\D("QG8*S51%MCZ2\\9GGGYFWM6\-:NU/TY?NH(";MCNQ7
M6B0=#C:3)+Q!Z-0VD>A"M9V7I[)M$MI-G+W1"L5=.S+.Y)V@X" 9?+(-@%4#
M65YI*];+5Q?>69RKY2U.>KRMK/>N=CC=G86J]OR=^Z[&)R///J\FT!%M"2K7
M(\04<;PMB,<^/BCC,N3/MAJ5(+4\9:MVFMCZ4&/A*-XXQK"3/&YR&;\9NWAN
M!VSM:Q[>K&X=K:4LFQM8-],[C2UNXJIFNT-<QKB9=P<:_&U5NPKU>=@5[%.$
MC;;4%8>>*SDUV2SI5$J/PN.*E%)4S6.E(SQN=?M%VFQ<L6R04FQ\>2AE#28)
M7IC#7LP;WJW(Z]<;$)\KKR0W) EQ=H! ;V&>8<?;=G(HJUFQ!;GK20FY03!V
MFN$]>0XWFJR',\,@M,0K5$!XQ*EKF.UO_4?O[=>F;72-%5OFVR72NC09^3V=
MJ2I/'TA7HVVQ=PILY7F-DAW<K*JQEPJ\5"3K0LD\2!PHDH4A.4OV3R-G,R6!
M9J7$$E&QE,="1PP2VJ%%\;%9KS _:Z4LE%WJV'KV!:6(8=1:2"$PU(F:**GM
M$2NXV7*28[(2"Q3UQR]T,A<@DCT:"W ]R&&>*.S%)RI (F)^=,Q\I;O&3JVR
M4/66DXW9.RZUSOKQG44'>E6P4R:BK2_I-A^U<18SW6Q524V)4[0^L !(V2>I
M5H@G\Z<#$<*)$.I[\QN2?BU;+21PR28^:G9Q,(@\$6+FQ\$-6B%8H'CF.C7K
M5XH6Q\\DE:0.8TPR#-.,F! Q8V_CV(V/+196#+72+F6<C%G"L'E"L#(Q0-:L
MR6K$@6XH@FKG()0.!0P%%L^G<6L];[-L%KUSNK:5)UE;K[)[4LVBX5*D'J$A
ML6=72=V&;:VF1JCS8T-%V%\@E(356B+6T@G;P7BI6J)9!ZFMJ4M*=>&J0C:@
MIQV(L;'-N$:$-B>6R4(\EXWLP136;)5XK;S# TS".HP0"%EPI+DS6-[PSR1U
MX[T@"!E>:K4"E!)(\PR/#8&O!5C.S6>&:5JL>\G<YGDFT >@>G[,*$PB81,(
MHP=I+;R;\K[R5YK*]'>!:%*_U>FBTF"\PE+B*)5EX-"3*>.<3R$:9ZM"(/2B
MW6E$VB:GH!O7'O\ O[_MJH?[[_TZJN;FNV!,]+Z5:\M6/JJP:^0KMS0ZR1Z0
M#:I:\B7Z 4U2D(P^UTBG1VE]MVR:+EA1O9&'@E98[[T:-60"Z=>_V>_XJ&?\
MN[IW/IW=>[IXMKY>2NXPLDPB81,(F$4*_(]_S".P?]'G:7_\4D<(M0^&;_%3
M\ _Z+^K?]@(9+]_P'\F4-W?$OS=699"E,(F$3")A$PB81,(F$3")A%!+R,\]
M7_ICF6Q:ZUHZ:EM:,W V5E%/G8L&EB2@W*BR\(J['^P15<$4!PS%UZ-3O6K=
M-8Z)3?'3Z9Q[@;O$?#5S&8Z00MF<,T8&?+CFY,C$4)'U8=[=1=VV[Q9BT9W=
MOH7^&#TF<-^BCTLXKBCBN"4L,=#(XJQ<KP=IGQ99"$8X\@$#?S) B(>5.T/\
MYH)9"C$W'EG43XPN".G-;=,0FW=GTV5U;5*-&V!%PC,NFH/[:[F8EW#(1+)E
M'/7'Q6"*CL)-R[>>UJ'R: (E4<'(='R?T8\!<28CB$<KE:Y8^K5@GCV&8.=H
MY@*)@$8S+6,=>81'T]46%GUU;[5_BV_B.]$O%?HHO\%<(YRIQ?F>(+F,DBDH
MP3/6PL-"[!>ENSSVH(MEF0(>R100:ROSY'D((Q)COAZ<YRHO4NI)_5%[(J@T
MD0*^A)QFF523K%C:$4^EST<4QTRJK-#J'(NT44*B^:*N&:QBD6$Y?<.(<#1X
MEQ5G$WQ?E3BSQRBS/)7G'K%/'KTW1EUVOZIBY 70G7YW>B?TH<1>B'C3&\9\
M.$$D]3=!?QTY.-3+XR<@[7C;3L)D 3B#/'. O)7F&.>/4@VE#7AOQA5#CZZS
M&S)2_OMEWQS%O("#>#!IUN'K\-('2%^="/+)2SAW+/R-TT5G:[TB"#4RB"#3
MWG.Y/U#@KT;8_@^U/D.V29&]+$4$<QP#6C@A-V<V")I)2>23:+$9&[,+;1%M
M7=>Y?Q!?Q:9STX8&CPI5X;K\*<.07(,ED(.WGE;V3O5A-J[262JTHX*=8I#D
MCAC@*22;;+),XB,36F9Z4OD1,(F$7Y++HMTCK.%DD$4RB91590B21"A^9CJ'
M$I2E#U#U$P@'XY!$(LY$["+=7<G9F9O-W?HRAW86<B=A%FU=W=F9F\W=^C-[
MUQ?VCKW^78;_ +T8_P"_RKM-?_GP_P#W0_\ ,JNTU_\ GP__ '0_\RBMMNN\
MBO[DA*[6M5686VRE9M6Q'VSI2!5>IMTA;M!2CF%C9-4DO:F*0.?ET4E5 ]IU
M3*C^ETW-T>"I[PS9JU4"]:8 !I,O/5<Q%M@?RH;448!ZNF]P$7)NI.3OKT_-
M0\$E?"3-7J,-ZVT<<8S9B6J4K SB&R&.W$+-WMO8&9WZ.3N_75]_Y_Y^C;QI
M&.A6XIQ-GN<\PGR(;%M2R+^-;Z]M$NT264^TY_:B219,':9TS$]5$T_TA(<Q
M3<+D^&.&(,AP[#7CT@NY"U%:8<K>(9( Q5VP D3W7VBT\44C$.CN[,VKB3L_
M%Y+AOAN/(</QP@XPV;]J.=@RMYQEB'%W9A$G[8_JM+'&;.SMU9GU5'76-\E*
M]T-LBK4!U,TRHTJPK5N&AX^S6!ZW?(PXD35EWCEY*N57AII<%'@ *HI)LUD6
MR8>B?O-XUQ,80Y[*5J!6*=.K:DJ0P17K<H.-8GB>9SDF(C*<F*;J^@B0@VH@
MSO\ +?I"SU^IQCEZ&*ELXNAB;+5*M>*W:,9QA$"*S,1SD\K63=R$==C0N CH
M[.Z[)G,^T8Z^:"U+;90L35WTS28=9Q"&E2F(S4;HBR$4#/W*CT6K@&P.VGS:
MJKD&RZ0+*J* 8YOI/A?*1W^'\3:EY-:22G&)0\S1AY+E"Q"TDAR-'*T?-C8S
M,F Q8C-]2?[$X/S0Y?A; 9.>.&C+=Q52:2KSM6A)XA9Q%Y2YC@^FX'D?>X..
M[4M5O]I(Q[_W_(OV3WX?I\3Y1T@Y]GN#U+[_ (*A_;ZA^(>[T]0_$,[ $L4F
MO+D ]._88EI[]KOI\5V<)(Y->7(!Z=^PA+37NUT=]%]F6+-,(F$3")A$PB81
M,(F$3")A$PB81,(F$3'W]_-$_/")A$PB81,(F$3")A$PB81,(O B ?F.$7G"
M)A$PB81,(@B ?GCN1> $!]?3]7X#C5O-%YPB81,(F$3")A$PBA!Y)I@('A+J
M"4&XV6A?+ZHGTRV>G-G+NSM3NO@-"1\*1DLV>(O)XZQ8(CUJZ;+QX21GR3A$
M[<%2&[V_7N^*AWT^G?[U55P%S/0J'T;JZZQOB@Z@YHG&41.*%W#L7K*8VC4*
M@N_JSM%TA(U!YM>R)R9I<%E(AHJ,*X%JX<INQ*@*0')+MIXL_N][]_1F_-]-
M$\O'W=&^'LZ_;LNQH'Y!^O\ O_;D*4PB81,(F$58'F#U[M._\%;\_JPWO,Z,
M^RNN+W9[FK#T:JW<^Q*<QI\T62UX\3M/]G ,YPZJ(+S\7[I5BFD?Y0GQ3D52
MEG9F)G%GU;1G=WU%]PON;1V9W=F<="8FT)WTW,)-8!B S"4,<KR1L &;RL5<
MFFBD>:'ER@!2.$9P.,X31<J>0FC&<89HON\- @/BIX"$I0( \P:N$"@(B!0^
M@H>A0$?Q$ _(!'\</^C?DWY*IOU?\W5F.0I3")A$PB81,(F$3")A$PB81,(G
MH'[ PB81,(F$3")A%A6Q:!7-I4JPT"VHNW%<L[ T=*HL7KB.>';&435]&[YH
M=-PW.!TB#[TS (@ E, E$0'2R./K92E8H6V,J]D-DC 91GHQ,3;3'1V=B%G\
MGTT=G9W9^/RV+IYK'7,5? SIWH2@L!'+) 91EIJPRQ$,@/T;UA)G;S4(P\7?
M*   ?1[T(!^K^L"P  _]0+A^ _W9TG_9APM_R[__ 'T_RV:?I[%YJWH3X 9M
M.Q9/3_ZWE/\ \E4E]1\=;2U1NJRU6I:\N]KI4A(_-:]EX:%G;.DZ@WI?CM(I
M>0;MGAOJT48%6;Y)RH10YD/G #X"Y3!XSQ'PCD\1E[%2O2N6JDDQE0GBAEF:
M6"1R.*)S '8IH09X91?UG*)Y--A@3_,_'?HYSF#XGO4L=@\ID<7.828>S5K7
M,B+U919QK23[9B&Q!*T@RC*8ZLS3:[#=QL&I/CUU>PJ_+;/9\):F]\O\A*-M
MEM4K9,-0;+A1K396\>BW17,C&NHY=C&MG0M!*)U&SA,QC)*G*/=:O -"&'A"
M/)1VPNY.U:#)1M-LY8?AN0N11"+ _*DAY5>,W!W=W Q=WU7L>)]$& BQW!D>
M>IWFR^2WCFQ#*7HVYWX9<N<H0CG8(2ADBB$^3LU(#%]1(A>42GBWY",?U5@[
M>*AA]1%6]2XG4_5Z&,J<3F_#\ ]!]?3\/RSMQ>B_A/75POL[OJ^ETNK^UMG>
M[^/>[^.K]>Y/Z$?1X[ZOCKK[M.IY6\3EX,SD<SD[>77R9NB^LOBZY/ H 2&O
M)2@  4I+_/E*!0_  *!5@ "A^H   #\@  S-O1APJS,S1WV9N[_.FW_]-?FL
M_P#8GP!X4<DWL;-906;3HS,S669F;N9F;1F[NBD%H?E34?.#FPNM9,I]HM:$
MF*,L::L4G. =./,L=L5 CY4Q&X@=PH)SIE]ZGJ!3&$I0 .?P7"F(X=.Q)C@L
M,=H8PE>>P<S;(B(@81?01T(G=RT<G?QTZ+MG"_!'#_![W'P<%J%[W*[1VB]:
MN;N3NV;6LRR,&F\M7'1RZ:N^BDAG9%VY,(F$3")A$PB81,(F$3")A$PB81,(
MN,F7,FTC'CF&C4I>421$S*-7?%C4G:WJ  DH^.BX*V*("(BH*"GIZ>GM_'U"
MF<I@BD*"(9IF%WCB*3E"9-IH+R.),#/YNSZ>3JJ8I0B,H8VFE87<(BD:)C+P
M%Y'$F!O;M?W*BSR2=!]/4C8&M(:)&9U9 %B4;#'#59D\DE8;0G*O6RJ#^8:L
M69'I6#=%F0*TLDJ@8KKYQRDX*[0*EX;Z1.(.)JF1Q\#<[#UQKA9A[):>0;%K
MG2C(YSA'&TG)$8F:L3$(B;&8NTPLWS+Z:.+>-<1E,'7HE8PU-X6N1E2E>9KE
M\)S#E33A&(R#&&S_ "3BXGS&.1C8@9K;-)7+;MKJ%&D=BT!C774M3XB3FI%*
MPIJ.2RSB.;K*$/7?IJ*[ SDYQ45:G=G,Q.8R ^[V9ZK@+V;NTL?-E<='5.:C
M!+/*-EG/GE$!/K4Y;%%S')R('D=XGU M=-5[]@+V9NX_&S97'1U)K%"O-9(;
M#.0V3B C%ZW*$HMSN[N+F[QOZCZNRWUG8UV%4\WOH6^;=V]U>S=;PV5S/S_Q
M[<*%J]W+Z2HL+?\ :.Q]G62L1]RL4E,MYC76U3LJ%#1-GK,3'14'4$9)P_)+
MR\C/HLDT&I*:SBV*BS=N8HVNYS-XG'5-FM6.I@6@BM7LA(P%(4MFX-T86YU6
M&M5K"TC2S60(+K>@7@P]:)Y)8L%C,WD+;OI(TF9L7H:F/I1$0CK6KU8K-B4H
MK!3RW(XXFC"I/OC[MKL(+!MCE:OQ_D6D-6Z'V'RSN'9K;=<#!:BH[C:VPJ??
MZU6JTV>Q.TZ'9O5VW:.Y5G(U*N,H*1E)!LX411:#[4$K)FF&]Q7ZC!=QO#O"
M64PV(A;MD%J3,S<0R6+,5>$RNW(+%>ECRABBLERX9-HES9&D5I0Q#0PKB,KM
M:XES>)R-B8VBLUJ^/Q]&08)93".M!/#8EFYEB2L D7]0; <7RK1'4G7W5,US
M#S7;;))<X; M?,UOZ/WILFKTR(8[#EZ[&[/=ZQUDPHU:V!%62N4-_>$6R5]M
M1IRNV!:*CUF\)',&QGPNVG(34X[%O+RNTM"'#XK@Z6QC:T\<SQ\2<44;MV]C
M9[4H3$6.PHXRW#MC8+5BS-"!6@&I-S]&(I(L55L@T=K\2XFXGQ="]8?7F</\
M.G ,.5&&#D@=[+-D<<<1.+5(H1LS# ?-@$)!]@RNQ><M#MI>U]F=!QCVMQ%N
M4K$_K?0]*N.P;]98^.&4K;+8;B+UG:ZBC%MR-E6DLY:5?74?*"Z%P>8B?EO8
M/!Y.]-"TL]6&LV0"L,E2I(Y0X:68;,@$]X[,V^*O(-BC%(_XI7* (+-H2/FN
M,&YCZ@32/#9GD"A-9$+%H1YF1IP2Q1=*7)C-I)(R@NRANQ]LI'G@K.VL0E/L
M8O65^UQXR6/86SHVIVO9L#S?&;.LL91Y-L[ITY<G$"W5*A&R<:[D6A(ES+.4
M#/CL'CQ!F07:3594J*8CRO%PCB[]NIBP83FR>.Q=%K+RE!%9RMRG0C,B/9-+
M2KV+?,C-]LEBK&!L[%(Q+6X;!LDU=[<DG)$<C8F,6C"R=+'-;L:&&G+AO2U*
MK#/$XL,%LI <1:-Q;,>>=;="1<52MQ[>ZLM-VD+34XZT;&UHO2]<QNGX=:6@
M/J:\?K7Z578R^UQC!/'")49*S7:YKR+%DI\TV16>_%:VY'L.&DRM5WDN5:#6
MH6R%UVCNO+2D%I;SM6:*K'#*,-@GHO ;Q#+&(VB>NYS:-"6UF*^-NL 5)[O*
MLC1J:R5QANAOAHD4V^:>6 9(0[8)Q/-+'+*\ A,,44&^4^V-U7/JM5?9M\CI
M'GGL*M[@GN/ZQ])KS1W1'N@K.K NX=>7C6Q)&:<;,IWOV(U3G'3T6Z<>NDP4
M(B)DLU(0,<#E:]@2;B&IP]B^-QD)P;EXK.C8"7$A&#-%*W#[G@)Y+!#SI'S9
MA/N:%G;D[_*'(TYZ@LV*BSMO@RZ\<ISQV,G1ACL09AR(&DJ#D[5?B'&]FU>(
M"Q58A?F6'91GX@[2Z'V?L[E&'C.E=C;JV+M>^[N#HO36S=<TNHZYI.E:+/7"
M,2O6J;7$ZSU_)24S7)AI3(%)M%6C8C:33F79)9!F=()%#D,9!%,,0D(SX\."
M,9G,C?E(H\E4SF0HT"QL<, E$QT\GD)K\4PR4WA""L,D%N,HV"UJ90CB;*$!
M/6N0<:38;$U(PYM*[C*^0MC?BLSDTC16J6'A:X!M9&P5D B*M($\G(NJV1UU
M4M3]#5/05WK4S$EOFFMB;:INQ5GL:2IS+K52C9S=J,J514CV/L$=77K6S-W#
M@AF+R-!Z!%"*,50-PA6HPK<2V"]4N&L15SD\).S'<QEB>Q4FGJD[Z.=.Y%6K
MV(B9G_S]602VD[-R#5)2_!.4)RMF\S)@@>.,C[+?[,URI'89NNV_!'<>N8L[
M-)2DC/0I(]U1G0G8%OZCF>5KEJ6H]#O-<0VD9SICIC2.M;V\U=>J3K"W'/&Z
MOV/]O*I+,AMEQB5H&?L5=TTLL:)NU?*^D'Q5%6;-FOOM4?&9O+6,G(8XS%4,
M1CY[;,118/B3(]GRKQRT'8ARS18XRKYQI!,,-7".U %B2R<2J:4;>-HTZD41
MY/)YO)G2B<V_Z8PF$DLXVRX61.,\?!<R!TSQ5B,@/(3F5:0X8XWF';W3=HVJ
MO/<#7;G[N;H*/U7UYN*B:Z<)Q4=H:3CC:_D]06VU(V. <672,O-,[1,R%=C7
MTHYE'SY!)PO)-D(UF4Z:3>Z*C8'BNQ@[S[&/&\89>0(MC#7FQ-2O;I5J<@"X
MOCA*9WC<GEDF@(-;!MHZU);,!<+V\W4%VDI7>%J$0'NT+\5XCKXC(=LCD(I.
MUQ13RQ.+&')LPLY 1"8G/N(Z]Y)U''(ZSV!VKJB?NE%*>NVJ6V7M35L9?74S
M'&,F^4ML? I56(9315/T7C9C78=!(Y0*5DD/KZZQ68;A=JKA7C@F$7B&J4AU
M]!%HW*,I)9B+<8D1/S";>Y,.T686NY,E=RBF>1Y1(G)I183'F.\@@XL(:,(&
M+ SMNV,+DY.[D_(]+]BT[GG5&N-MQ58G-U0FUME:XUI26>L)"!>KSC_9[A=K
M7)F-?R$@UB7L**B:2R[E!\(?)*F=H_%(D)33R+/XQC\&]>2/(9&:[7BCG9X1
M@EI8ZWDI.U.;;X8VAJ2;SV$\;>ML+31YA.K-BLIF6MQ/1Q6/#(R21?SNTQ29
M"EC@CK/&[C)*<UV/E,Y,)DVS>SDSJ);SRJK0 ;>-<>4MM5Q#F?8%2HO34B2S
M4F7B=<DOQX8:E/5!XR>@MM)FLRGXV3GVL0SAW->CSKJ*_.JI BI91BCO?A$H
M3C#4S.;DX8K6)A(7'B&*>&J522%MQM2>S:I0CD6=P(KD!-#L:8HJ[CS4GOQ'
M#OM4, W%90#+$S2\.M#>L'<&4B81M-'B\DP439BEDHSQA-KRW/VV1YA^>==[
M<M.O%6S"7KNN]DPVI-BV9/8]$C;C#W>;5A6Z257TX_DBWR]P$6XL<,E.ST,@
MB5G\60.S9R)8IV(8XF)\K)2CC=@_%+MG&XPPTL-/<K6Y:)/::!S?'U9K=>Q#
M#9GUU*+?-%# 8S/.0,<?!;GD(7;'XF+-W6-^2P49*CW]E8Y69K=T:6V=ZD;,
MY;QABDDL/RFT1V_WC?[SJUXYT)1=G5S6M9[)TKI!WTA7KA"P[22L<+N2IP^P
M85*LM'1+.>A._C/JBXLGQ#LY:2,M&'C@:G,YS+!AVK.< 366Y-+/9<K5."1N
M;'D\2.,SP@5L1T& ;5BGSJD$S'SHXHYW<'V,^.;)J.!XX"!^TWL5PS8>R]=W
MCGQ&1L_AEB%X2)MTEBE5NPS7#CY95AF(1YA!(P2-IG7M!U;LO8T(1GO*Y/ME
M^0%MS$NG=KI#3T#3+C*:PBK421H3%0&ZM=U>BQ:I%)6B&<R99ET^>E_LU_;F
M.,;MU;ARE$(Q_B,''UZ&S-N.RX\,Y7+/<CN2[GYC2'2D@Q8QB(UJG9XI=7$B
M?9R,O\W.67BA!^':'!%2S%4$XXK/X[#BVK6F"0B9KC#FH2R4K.(3E7<HXQ/7
M=D^QO)=5J)-WRLQ^E=CW:Q4OK2C<AM8BNR%9(YLMUOU!8WN)L<>:1D&R+2N-
M$'Z3&5^>43?-2HN7Z:"Z*0)GIHM)D&PS5X]9,W+Q;#6$R$(X#X1>QVL[<NKM
M%!:&L90RB$CQNXC(&KLL;@A1_$BL2,T6,QW#V1F,!(RDCXAM#5KPPQZ#NL12
M$S.!$(2NXB!MJ[CA*'E0^2"].KARUM>HPVCMTU;1?1D^XLE*E(O6MMO3^"85
M)]5C,7HN=H0#@;37'D\^AFT2M7V,LDLHT>J)*HEV:$(9 \*\4O+KY^Y<Q&-F
MGB.,WSF/*>.U1LP,Q%7JO8@*M7R3D<%B<HQ:,!<C"JUS*OXK&X-+8Q&,CSMJ
M&$F)GPLL':QM1RNPB=D:HSSRT=-\85IMTNO+YDONC^H6NBYC4-!K=!F=M;AW
MO8IJ UCKB$F8BM_4T:M K6>W6&<LLX)HZOURNPJ1#NY!9NZ.O(/HR-;MS+/2
MF)JP\RQ>*C#'N.OCK&7O&1, U,;5MTJ,LY:_[R8[F1J5JU8/7GEE?0@".0VO
MV1A1DR$TS10=JJX^MH!&=O)7HK5BK4B%NYRK4;MJ:4] AK59I'8G80*L;DSN
MV]5V-WQ'W:E[5V1NK:?D,WEJ/2&BIFS1)IJO-*C2ZQ:)6N.K5(OG-<JE"ID2
MVEI8\FW,[8E3>M09LCKR1$R[-0>U87A"&H+6K=C!<2YF];F_RQ1XW'<792D]
MF^1L1M/$]C&XJ"#220K!PUP)HP>0=6V1Q9OBZ:P!UJF/N<&XVO5BUG8[N4X2
MPLS-1 & 'AN2M>RLLY/&W9VL69&>3U#D?/\ E-I]=@T8F5U%:(7>#??)^<K'
MJBU6ZI5:!JVQRT[[?M!E]OR*HTI*M62JBFYI,R8J2UJDUT(9M'MGPJ%3KA$;
MDF*;'D]J+*PYF4"<.18B/AVS%4S-)JLA;[.4KR3PRP4:YD]JF?; E&$)""R9
MVJ1Y0[Q!6?&-A")F)IXYH>(GD;$VQDCZ0TI3AGKV;,[1C5MP%5(3DDAYOP[]
M\M6HM"VI6BS-43-=:KK2K[7VM5+9M/6&N9NDUJUIRBT?#UYK9)T4]F7CX,'+
M./LS55O@G009C]7(M*,4%:N=6:;(D]ACQ^,R XNQ<KQG9G*X5:&X318P-+A1
M5J]FL=N0A!XRG:.$+)QRM'L=EL?]'PN,87<G!8LU8I)6CI\BO9['S)LB;-7B
M&S8:0:CNSM)'#++-V<!%RLQUU?:[M.@TS950<.'56OM8@[?77+MJJR=+PUAC
MF\I'*.&:WHLU7,U<I"LW4_314]Q#>HE]1W;]*?&W;6/M,(V:4\M:=A)C%I(B
M<#VDVC$.K='9FU;O9GU9N-H78,C2K7ZSD\%N$)XMXN![)&U9B%^XF[G;5VU;
MH[MU6ENS=:K[AY<W9K%O8*95E+M1Y&!&>V&YFFE)CDWAT"K*V5Q79RMS246=
M(IT5S1\W'K_VA0!<"B8A]5GT?7]OU9V^CK;_ ';Z/K]_JJ&.0-1[6YN[KY@I
M5PZ?TKN*!O,/LMLPJ>HME=$W65B4ZQ27RR#B:K5PW3<ZO'58A1*@C89B)<MV
MTF1I&MDTWKMJY3ER9V=F%F]O37O]S?1-?J_R[_9^WZ+M!YBB81,(F$3"*M+R
MY;VT_H_@GH<-M[!KE!_K,U??]<4+[0O/E!M-ZF:;-N8JL1!0(<SF5?(,G2B#
M<H![BHG$3  84.^GGWZ=/U]B_/PSE$OBHX"*8/02\P:N 0_8(0* "'_4.2_Z
M-]&9&_5_S=68Y"E,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(HY[$
MYRTY?+0XM%Q<6YO.S)&C8Q(S;.PJHR<?)($;($9PL':XN,34!(A"J"S9$46/
MZJ+"HH<QAZYD.',-?M%9NE;:Q/M;0,KD*H%L$8Q:.&"U%$S[6%G8 ;4M2=MQ
M$[]4RW".!RMTKU\LD-F<8X_\OQ!FL?$31#M!@K4\C7KB3,^A/'$Q'KJ;D^BP
M]3ASGQ=1LNO&["769*J+L5UMR[:569+JH*-E5VBA[D)VRRK955NHJB)#G054
M1,84SF*.D7 O#QN!%%?(HW<HR++Y4GC)Q<'('>YJ+N!.#NSL[B[CKH^BXY_1
MMPJ11D4.7(HG<HR+B;B-RC(A('*-WRNH$X$0.0;7<2(7=Q=V?KI=9#>=:=#[
M+I3>9OE>AJY:'25)CWMOML@JE65?:I!/V$A+RSU^Y)(-3IN?F =*"9PHJD0Q
M13%,OSUQ-#:QV?R=/F7(HZUV9J836;,IA5<W*J<<DTAR.QP.$C&QOKO?JVFC
M?('I"DR^$XQS>,"[F:-6I;8<3 66RDK]A,![-+#-8M2RR<[5R<M[OS'*,>HZ
M+LT<J+WAQSIIU38[=^UN?V%A23:4L5<LK\1)$R+164*Z,9R$BXCDV;A\#@?C
M_-JK?& JGN*'TIPH]Y^',/\ B(R#<:E&,C2[GE<0<A@.7?ZW-D@:*23<S%O(
MMS,^K-]I<$GE#X1X<+,QRQ91\13:Z$[$T[3#"(ZSB;D33$+"4S$3DTCEJ^NN
MD@<["NTIA$PB81,(H-^13>E_YWY7O6QM9)J)7!)U 04;-@Q:R+>K!/2S=@XL
M+IJ\*HV4!HB<S9G\=!P@62>,C+H*(@<![-PABZF8SU2C=?\ RQ#-+)$Q$!3\
MF,C&$2%V)G-VU+:[$X">TF=M5V7A/&U<IF8:US:4 QS3%"Y$+V'C!W&)G%Q+
MO=C)F(7< )F=M=6J+\6'=?3>S.CVVH=GW"<VM4K=7;)**.IAG'&>4N0B6YI5
M*:+(QT:U7"*>*E&%48/%ODDEY!D+($#I%07] X[X5P=##/D:%:.A8KSPQL,9
MR;;02.X/'RSD-N8/27>#.3B!;F)WW-W;C#A[$5L1)=JUH:5BM)"PO%N$9A,F
MA>)P<MKDS$QB3"QOL+<[ZNZ[*JBA4DSJJ#[2)D,<X_\ X2E 3&']?X  "(_G
M^ 9XSY>UV9O:[]S,O)69W=F;O=]&][JARP><[7\5MUQ6X[3LY*:HCY1W".[L
M-@;-K(Y5;21F9I^.K9F)V@PQ44CKILG4JE(N2"13XC41^ /J</HOO28X9SR,
M(9 XQE"IR2>)F(-_)DFWL[3/JS:C&0"^K/JO2XO1U*=)C/(B%\A8^3R=:X:@
MS\DI'-C(]S[>8P,+=?4)O6>]*#F8VQPL38(9VC(1$Y&L9>*?-S@=!Y'239)X
MR=(G 1 Z2[99-4A@$0$I@$!],\ODC.*0XI!<)(S(# FT(3!W$A=O!V=G9_:O
M-Y8I()9(91<)(C..07Z.)@3B3/[G9V7*9@JTPB81,(F$3"+AY>O0,^#()R&B
MI<(UZE(Q_P!3CVC\&+] ?5%ZT!TDJ#=TEZC\-=+VJD_4;*)JU>SR^T00SM%(
MTL331!)RY!UVR!O$MICKT(=";P=4S5J]CE]H@AGY4@RQ<V,).7(/],@;Q+:;
M>!#H3>#LN8] #\@],O5R8104O_&]B#;>P-V<Z;PE>?+KN2*K\5N=D-%KVRZ9
M?U*JS=QD!:/LU//(H\!>640[&%7L<9*?"DHEI'-9&*=*,&[@-8:[C3N8MY2+
M%7K=J_+4T9I(+MZM!4O3T;'4JW;8*T#V8BCFB*>(+$012/+S=B6QS9*=HXQ>
M_0K14J]K5_7HU[%BW7IVHOZ;$5:U:L2UR$H9HVL3Q%(<1@$>+:6\<>LM*7;0
M%KB[78+6ST%I+86G(J$N,579<EB5V/?8S8DS<Y)]\DDHQEVTVP728,XUNBU1
M9O12$PB@!E.4:WMM92Q%"$8Y#$\*8:&,2+6C3X1#(Q4'CE?62:6>#(-'9,R%
MG* 9 %GD(6HG.6U7JQ63:2:'-9K.V)Q!@:W<SD$45L7@9WCBA$XGEB =SCO<
M')V;5]I[ZY/':&SZ#O[66RYK2._]<5FPT6%O\7 Q5QA)R@6ITTD)FEW>D3:S
M5A8H<LJP9S40HB_BI*'ET =-7PI*N6RVC#SJL]Z:M((CE:M.GDX98^=%9AQ]
MB:U1F!MX%!=J26;00V8R?^1;LPS13 8-'9(83U:]6Q&YM1MS7L?+'(\4M2U9
MKC5L]68@FK6H B"Q7E!V(H*\L9Q2Q,;X_9N<.G)>N,(Z'[=M<9./V$M&WR0E
MM+ZOL,#.(2R1$3*5*M"C%GI*S!/XQ(\7$W:$BD6,#Y%^8I3!C:@KVFL5C"7\
M/LU1K30/*)6W9YK4D\@76 1$YX;79"9ZI!'#6J%$(RQRR3TP%- ;V!EUMA:.
MS7)P9JD+<FK'#"547:26*&6KVG5[8RR36KFZ1HC@CKYOK_CG2]"Y,C^,$XN2
ML.F&^O9/6\FRL$B=S,3L/.)O!G'C^1:D:?!D9%[(/) %(Y)F@Q<*D+'H-D4$
M4R7YIPSC$%@.3$,%&M6"N9@5.+%Q5X<;R)C(Y>;3&I6()Y"DD.6)I)'-R)GS
MQ<DN+L=LBD:6U)>NY&S+-&!!9MY*S/;OE) S-$T-B6S.Q5Q%HQA/E,VUM5HI
MIQ-O)OJZ7T@MVYLE75K?7S[7%%:)ZXU^C>86 <UY>K,B7*^G(N]O:T5#N/\
M!73>.J<BM(M63][(.3I+).61)LS'<;,!'<GR1Q/?EC%ZD5@'NU[5TFKPEI%9
MOQ025)I0DY$<=RU)'5:0HGALQ,D6$M4I<?6A:I0E:6M0LO)/'$,3.]6J$S21
MS-3K'M80<BLE!''#VH2%YGXB0\4W+L) Z&)I2GUK1&PN?[51K%5ML4.E5A*Z
M2[.JQ:L!8*_9'BK1+ZK&[!@7<@PM(KG,JNN\^I%]SQ!,^76+,D^6/) PUX;
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MQF,64T_M-KWU>;Q:IOL&C=C3LU)UFJQH.K?2Z&VHY*>Q81*;9K&U-V@W^9:
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M_''K3^0\NZ^;?)_W5J??1\O'[H"O_P <>L_Y#QU\V^3_ +HGWT?+Q^Z K_\
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M=J4(H7KZ1C&TA-HUCFDQB#-H);-3T9W9M7=I$YQ:X-5$[(ZFO>P]J].Q4=T
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M)RCVL#Z<[SU5>KCLJ9MO<_1<%8F=SJ\=9KIIN/U74XBC48TO!_5 B]=W"/\
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MM,FH<1%UN#MU,8ZRLS:G;':6"-M]E@"2-GI]C<@QD*;4W%@LKI%%:1CH]S'
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M]65*A><(H#W'D/8E=W%M/=7+^X:]J2;WXRKJ&ZZC?]<.-H4.RSE6C%X*(V#
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MO:%KYMAIJG WET"MP5H$%%WJ!G(52-2,NFU0NUKV&U=D7'ZBFY$I?3"[6KW
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M-6FR# XV:V5G89LO#+5<9C*8:[UHY& ,G*5WR5@G@FNY>[D+EX;-<)<9*=^
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#B__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>img102984888_15.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img102984888_15.jpg
M_]C_X  02D9)1@ ! 0$#O@.^  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $M 5P# 1$  A$! Q$!_\0
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M/3FCMA; 5^\^VI]1V359RP/?V<B=R_\ V=',9)9Q)?9MTU7#D&!7(HH)*K*
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MC9$&G:5A')&##DF6:20--M[YT>\1DQO<::-I<T7M!W3/DDC$<=ASWN#=]4T
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M@(\"06DM<"' D$$$$$&B"#R"#P0>05E+LY1$PB81,(F$3")A$PB^"(  B/X
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M(F$3")A$PB81,(F$3")A$PB81<2X'%%0$R@=3X")""<4P,</R4HJ 4XD 1
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M>O$\K<UQCE!5JY8Z%U$U<-ETSHKMUTJ# %61724*51)9)0#$43.4IR'*(&*
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M8U)VB\V=9JOJBP6'7CX]HL!)%HP;V.1/K1_)09DH1NVA0EF;=TV<F:JG5?\
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M315R@L4PS08'CR69 )[O!DRX7QO!8\- ,;KHVQQ)!:0UU@@[2"%0R<,+2.9
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M59E5C%$P"5((V@J$.(?'\^E/7Y#\^A 1KL<?X3_+^?S"6/4?B%2LCY6J6_\
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M[.?_ !#V;[)U\0#]1'Z"GH/]8_C"+7QUJO\ L[_D]&R',@<K4$].=8KOE5C
M0C<JV\]O*.3+J&'XD*D58YE3"/P*4IS?+XA[PJ=!QY?KW*SZTI=HZIU3<L%T
M73%Q6H%=FY;J%5;N&BT4T4;+MU2")%$5D3$424((E.0P&*(@(#A5^2J;")A$
MPB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$
M3")A$PB81,(F$3")A$PB81,(N-9,JJ2J1O?Q53.D;XCZ'TH42#Z'^0^C?@?Y
M?KA%K2635E+AJY9N3(SKCJ0O"3YIM^%O44VT'1['",D9/9:4K:Z&PVL&NU;(
MZJRKZ;OZ4C:/@[<1K5B9JC)^FZ)U_*-0^W7['=)[3R=B]3^T;LU@]K(=2BT>
M7L_D94S=19JDXQS#@&,8[HSDRC*QBR,2&Q/$; >"M@S2=3DQOC&8&2_%[LR_
M$-B=W7=M+@Z3=TV-+'AQO@M<.:*V28-C&Q,-$14,@FVAHV,CX^(0;@4&Z$6S
M:)-H]% "@  DDT22(0H!_"0H>@ OK/6"""011!((]#YA:]>K[_4/0_C_  _[
MA_0?^\/YY1%]PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3
M")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$7PP^BF'^@"/^P/>$6O*FX^
MXY?V"Z'WZ=#OIQ[]_K]U>;@I[]A^OL5!'\?D??XS\%?M9)E_MO:FT>(.^W'1
MH^?/8[LBSW_NUSSU]5[)IU#L:R__  ?+)/I<V;QP?+<;KU!]%L&11/IQ<:G^
MGP8,R>O_ %6Z9?T_U9^]LG^\?_C=_P#V*\;7?RQ$PB81,(F$3")A$PB81,(F
M$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB
M81,(F$7"X'XH+F]^OBBJ/O\ IZ(8?>5'4?,?S1:Z<$J+CCZ>7_47,-M5;V'K
MT/W5NL)_?^0@K[_X]9^"OVA5/_;AS1=AWV]83>?_ ,O,[-,KSY\%6;Y]NGL6
M(0WL8W_](G^=.FR/4^GE[4%L5-"_%HU+_P"BW1+_ +$RAG[UO^\[_$?YE>.K
ML9:B81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(
MF$3")A$PB81,(F$3")A$PB81,(F$3"+HR3YA&,73^4?,XV.9HG</GT@X1:,F
MK5,HF66=.7!TT$$2$ PJ**G*0I0$3"  (X186:0VX6V%UG:=25ZVN9FE3%;B
M7E7J,/?+XQU6]V4WLMAE[W!13%*::UN4)+LG\ ]+"L$W%==F92+9B0[C[MNK
MY=E?8I]D^;VG/;3*[ =FINU9U-NLG7WX#3J1U1O=;<XSAP)R088B)2-UQLN]
MK:S6ZGGMQ_A6YF0W&+#'W(D<(BQUDMVW0:23QQR3YGG-F'KT'K\!Z#T ?@/7
M\OQ_+/45A+[A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$
M3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$6%WR]:9V[::7 ;/I<_:Y;
M7M2:.FVQ]?,I-8L+'M062787<D(U(F,D5N8RS2>5>'=_LYHDQ?-D4$"2"H$6
MNQ&23^&>QDQ$/%XZ4B91.2C'[-047+%^P,Q<LW;94@@*:S9PDFJD8/\ JG(
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MR6W.:98"8G@,#"26$/9*\B04/]F98Y(JW6\T["S70AD T;!639Y'17J[8D!
M.QD",63M9HHZF8\#KEK_ *.F45DY%V5% YRIE=N"F365\8U;2<[0\^?3=1B$
M63CEH=L<7Q2->T/CDAD+6=Y'(UP+7;6D&V.:U[7-'IVG:EB:KB19N')OAEW
M!VT2,>QQ8^.1K7.#7L<T@AKG-(IS'.8YKCLG^+#G#;6I*0?8L[LV#>Z[VM",
MK%$:T@T59=JW>.T&1X^TN; NHT+%S01Y%(R6A&,<Y2,*:*;Q\==B0B>M6;R>
M?+ZW^'%?G]%EXPJK %'>+'<MS\;/2?)5RL-6I.U;UU5MSHK5<PPDU;%52NU]
MK-=DZT:6X46C94L;-&CT8ZR-4VCY2(1>"[(VD5VA6BO;_P#:7$@[0Z=JD<4D
MV+!IN-@9+"!'*&_"NQ\AT1)(+V;BYETUY ;8!+ECF)SHG,--<7;O46*('L#7
M6B1UJ^%>7;]0\CW5?'O0_->U><M"ZML5TYIM]&BKC6NA'EQC[OM629QD;#)1
ME>/K:&-2Z@[1"7?R+R<FY=^Q5+'QS=N\3.O($Q,670--U7"U#%S\W)CAU&*8
MPR8(B=#BM<]SB^3XA_?2M.P ,8T.&YQHTU5(D<S:Y@' L[@;<""*Z^A)L]:Y
M5MM%>,;9W,W8G/.[]:&BIS7,URZKI#H9O=;O*W'8.G[O&UGZC"[:&M%X3L4D
MRB9V?5&)E:W#.8:*09MS/!CW39PBT:9&=VCQ]2TG.P\G>S(;J0S,$P01PX^7
M Z2G0YT4'=M<YC '-D>'OW$ .!#B;&0%CV.'(V;76;+374$\CGH1Y6"*JK@=
ME\#[_L>A-=5?3VV-C].7RA=@Z!Z-!ATYL^M1 A7=2/)=[*5:MVFLZV8-8<LP
MLZ:>_OX24,54ZSLAS?0!FXQM(UK"BSLB3+QH=/@GTG.T_=I^,]]2988ULDD4
MF1;]@::VO;?0U8(DDC<64"7&VFG&AP>:H>?O^*R9Z,MF\;K4Y1_OW3=8TE:T
MIQRQC:Q5-LI[?8R%?*Q8JMYM:QHTJB P=KO5W[,T0$6X,BDR2=_?'^\!!#G\
MV+#BE:W"RI,N(L!=))C?"N:^W6SNS+-;:#2'[A>ZMHJU(TN(\0 -] ;XH?ZA
M8K.7>?\ OG@&0W-HS3NG])]": O>]K?MS5FS;5NV2U;=**SV>^:2EGAMCU;^
MSVY*W :T\*L6-?P,JT?S22/M=1F#Y-&)Z74\_1-<;A9N5E9N!G0846+DXT6&
MS)AG.,'-C=CRG(B[GO&UN#VEK'&Z=M)?"QLL9<T!KFN<7!UT1==02;X]/0GS
M 5A-A>(3I+IZM]A;)W%OAGJS;O4=]_>P-852J4*\U:!CM++J1W,44&T)B%)<
MHE>%B8J(?6!Q6%8U-&1EIDR*2JBJYW&=!VJP--DTG'P\'XG%TR 1'(FEG@DE
M?EC=J3_AXY.[<)'O>&-E#[:UG0  6&![VR%S@'242TC<!M^Z+%<>7 Y%$B^%
MU+!XPNINL>O-%[YZZ2BZ7$L^"5M#;CGM-[EG82Y1V]6TK<D4[/4W5;:PCE]
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MV["X DV1TLAD<X/$NUKV&C7 H]#R?Z^8\U<KM#N.,UKH:GS7,-UU9LC<6_\
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MIG5QJ[E"PKLDJ@:+K%CCK2^3M58D9('+]]SFKC)Q,N%_Q4DDAC)C>6L:8P"
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M]/('\%CNR\=@LR6 0#M!?1/J6V!]2%&38?DCZ0KYCH6]YXY>3D54G8I!NCL
M-L[!;JM?0JHCK;6=9@&[QZ@0P"LQ9W!T8%A!#ZH"8#9(,,V0^6-E&C=V#Y_>
M# ?8AU'R/2XSF-X,<<D@-46@&[JK#2YPOW (XX/(4=%>SM];);MR17>.T-A
MY.NV58<+^,;:%F;J+*?Q$*PO]Z:WB'^FDD()INP=D(=?^\]E]?' AQ6_?R+X
M'W1?-_\ (V3@@&^>..EH9LMWW,<-%CESAT]PXL-V>>/(^7*I1/3VY]D3#YTZ
MJ7G>VPH[:%4+^_&_];<P4I=<H$*!$HJ.V11Y>*'^'T*0P92_$QC FH8 '*W@
MMOB1XXVUNN_<ES;!\S0/''5*S30+H663?%\>=>$\DGSOZKLS?CVW9=Z3<*DT
M\;T8:3N-1L=>:W;IGR,VG94A!R$W$NF#&P/8>+B-AMWSN,<N4Y S=,0,HX0
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MZ8VMTU*8Y/[[XG*88712,Y=&\#U+3MYZ'=T(]P5,V6-W#9&./F X$CYCJ/J
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MZ9Z7;4.X:%O>V9!)ML9FG)M;)%71E$L&D6[&N'3:0J#%ZHD#$S9903$1,#D
M3,0^Z9)&=.DR#B8G>LR8X0>Z-;'1DDD;^7$B[L5SZBL<@]Z&=X\-+7//B'!#
MAP.+V^H-^YY5253OJ[R/-.DMQ+4RK#.[%Z?A^?9"'4EI59LT@G%KF*VM8D'1
M@*\=3I6<6@]425(#,SAPH8Q2I"0,M?ID;<O(Q^]?MBPW9(< .7B$2!E60&DN
MJQ9(%\JYLI+6NV_>DV5?EN+0[IUZ&J'T5([$\@^_*HGU#<8/4NKI/6G+&YV>
MO;2M(V^RLKA;(64DH:,9?N['MXAU%,IAL9^L[?O9-[^SU"+-6[1DH=N[4/)#
MIF,_X*-^1,V;-@,K*8SNXW .)WDN#BTU0#6WP39L!4=*X![@P5&X-/B-GD70
MV\4#=D_U5U8CMS9]-LNZ87>>M*@P)1.;$.HJBCK>RRLTNZJ*SE^U/3K(ZF(M
MBD%F;.$F;=23B69XI00>.443(_0(:!VGQ2,QW8TLA[W+^"<9FM8!)32)&[2?
M!R>"=W'(!("KWC@7A[1;6;_";Z78-@>W/3J/*S^J9V)O".L^@&^XM>ZQ:UCJ
M2J6:>UHIK:TSTU/5"2@:F6[MXN](R\:T82;!W!JHH.)VNJD192GU$U6@M0*L
M5)@XY;DG'EF+L-[&R]ZP-;(US^[+H]IMI#@::\66\@@V$$CK9N#:D;;:)-&B
M[GCI5"QY^5*L>%>EMY=74IGMRW4C6E-UG(I6&#CT(">L<G<75NK=@-&/'BK)
M]'(Q+&LKH%<MVZ1I!S+?>,#.E"D:OD4D;-1P\?"E,$<LTDS2USM[6",1O9N:
M 0XN+QP7$@#F@32K$\R .VAK3=<V;#B#Y#CA>E*]%[NN/0.TM3:/I6KGE?T+
M^XZ.R9;:%ML%<EK!)7./;3WV%*;PD/+MV32-@7)3&FYU$S-W+E,R11!(HN,H
M,7'CQH9LB28.R1(86PQL>UK8R67(7.;9+Q6QI!#?$3T"%SRYS6!I#:#MQ(-D
M7Q0/%5R>MFNEJ/3CR);7L.Q=B,]9:)D[C1-6;B6U+,PL14=L6:_6A*%FT8BV
M6>'L58J#W6%85BT5QE(ZKVJPHR3]BT5.Z=1ZCIDDID_LN%D<)FR1%)/C]^US
MWPLB9N:71L<U\@F>'5M+V-V@GH0'589G6:98:_90W$FN"13:%<&B>1Z<*'&Y
M]G[)967R8I,M@79FE6>@.2H^M(MK---RUV.E[Y'MI:/A$TWA0BVDFU_T>1;,
M001>(^TG!%"?C,_'AA+=()BC)?BY[GDL:=Y;&_:76/$6]03='D*QY<.^IQ!#
MXP.3Q\N?Y=5L<$_ZI?\ U0_[@SEEEK]81,(F$3")A$PB81,(F$3")A$PB81,
M(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"*@76KZ$]V3%;?=5M
MDMLB$JLA28JUF,Y_:#.JRL@A*2$,F0%P:"V<OVZ+DQCMSKE.7T14I#&*,@ED
M$3H0\B)SVR.9Q1>T$!Q/6P"0.:5-HW!U#< 0#YT39'Y*QB'#/*#:S*6]#2U7
M1GC6MG>&[A)683:1ML8R*<NE-P\423+%Q#M222([=#',VQ'A_D1T15(YDQR/
MVAFEG=G(>6[#&1X;,9:6EKG;=Q&TU1)KR\E9W4=WM%@@CKP1YCG@^XJ_-5K*
M\NZ$FX/:5:E-;0CN#W79&UOVC''6DRHW"R,UVKEM+2(IOB*).$G#)JJ ,CM4
MA.D'R3$!, V-S,EKH7MF<'8[2R$BKC:;MHXY')ZVJ[&^(58>;<#Y_K^?/55,
MXT?J=W8I&UO*-"/)Z7URGJ.4?/$EG02&MTW"CDE1=M7"RC->+^LJH<Y5&XKJ
M?(2G6,3^'+!D3!@8)'!C9>^:!0VRU6\$"P:]#73C@*NUI)) )(VDD78]#[>R
MH/6_(7.>I9H]BH6L(B'F2Q3V!8/G#Z;F3P4%) )7\+6B3<G(I5J,=E$Q5VD&
MFP34(8R9P,D/PR27-RIF[9)G.:7!Y%-;N<+IS]H:7D6:+R2J-C8TV&@$"@>3
M0XZ6370?@KEZJU'KK2-.::_U75F%-IS%[)R+2"C3NU&J#V8>K2,DX*=ZX=.!
M.[>+JKJ 98Q0,80(4A?10BFFER)#+,\R2$-!<:LAH#6B@ .  .G/G95S6AHV
MM% 6:'N23^9*H*_<J<_[.O;/9=VUO$S%V:-V#16<([EHQ:5:Q2OUHIM8&\3(
M,6=A0C50*=DG--WQ6X$33( ))D3+)'F9,49ACE<V,V=A#7 %PHENX$L)'4M(
MZD]3:M+&$[BT7QSSY=+]?JNG)<C\^2EX?;$/KY"/M4O-M;+/NH&<LM<C[+8&
M3HKUM,6:"@IB.@[!($=D*X.YE8]THX4]BY%8#& :C-R1&(N])8&EC0]K'EC"
M*+6.>USF-KBFD >0"KL;>ZJ-V2"19]2 :/U7:F.4>>Y]SL=W,:P@GSC;L]5;
M/L=55:4 UJGJ0]3DJK)/P3D" FO#/DDW+8&@-TSJ%'ZY%2B(91N9DM$36S.
M@:]D7#3L;(*>&\?Q#K^5*AC82XEH\5$^Y;R/]?7S\U(8     _0 ]!_D&8RO
)3")A$PB81?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>img102984888_16.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img102984888_16.jpg
M_]C_X  02D9)1@ ! 0$#O@.^  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #4 ET# 1$  A$! Q$!_\0
M'@ !   & P$               4&!P@)"@$#! +_Q !J$   !@$! @<,!@(*
M#@4&#P ! @,$!08 !P@1$A,5%B%5U0D4,4%45I*4E9;3U")14Z31UCAA%R,R
M<79W@9&VP20T-C=$171UH;&SM+7P&"8S0G@E*$9RLN$U.4-25V)C96:"DZ.E
MIO'_Q  > 0$  00# 0$             " $&!PD" P4$"O_$ %T1  $# P$#
M" 4%"0P'!@0'  $  @,$!1$&!Q(A"!,Q05%AD=$4<:&Q\!4B,C:!%R,W<G1U
MM+7!"18D)28S-4)S=K+A-$-%562CLV-EE+;"\4145I(G4V*6I<75_]H # ,!
M  (1 Q$ /P#?XPB81,(F$3")A%2?6'4.;TT@*_/0]3):T9'4"@5*;(><1A @
MH6Z6V(JSJQD%1C(JRKB*4ET%6\*W11/(*F*FJ_CVY5G:1%9)(;?-M=WQE0J9
MI'7IA_<JWK)>=,7T]J'(UYI,5'9_L\Y4-2"W J5$EEJE8W4S%QYZ:P;%GHR5
M83(+RDM#*1+] 2*I2^VFV7L&EQX*B*/J%=T-G0MBFY&<&+M%<>;4\A)P^EH1
M=;+$O(ZQM&,M'HH710+)%N(EJ^!Y'-I<&3E(2*]YZ]1CVJCQ<K@Z27 X96C1
MT^7'C#E3+P&K-%=RIN,<!.*:1N 0#*'X)"F,!%+XW*' !$4)\  !$1&JV4
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MA#DZ\-I5.1T_(=W'V%M./VE9TY3(!V85'=?+-UD?UZD]7J"S^\SJYU=][?\
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MY/;;;F/LYNSGW\5)6S>DFOM :+HJEX2:NIU+(<N\Q>$4T^Q 0X11*8-X>,!
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M X,LXZR#X ]!&5)FSBDY1U^T85!HNJ*>IM+."1"E*902SS$0(4RIDTRB80W
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M^#'D=3'=))'0>HE:>9>@N_\ ?']?1_7_ #9/)WTF_9[U!W!WVCK^:.[/#H[
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MQD=_@?)$Y<4ZBGO56GSV,CO\#Y(L0W=&]BN3VH+%IVII/1I:$U$FY1R%_O\
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M3:7U!+=IJF]W!]DJZ!]>-7-=.8ZF*\P4\TN89IW0U'-^E-K'/])@S,@ !X
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M F,HJ<P^,<GCLUN%;==!:4N-QJ9:RNK+/33555.XOFGF=O;TDCCTO=CB> [
M%KXVI6VAM&T/5]LME+#0T%%>ZJ"DI*=NY#3P-+=R*)N3NL:#P!)QVJN'($AY
MWV3T*Y^7\OA6$K7=L+4J^: Z)2NH]+L2S^>8S]9BT6]D8Q3Z*,WF95%BZ,HW
MCF,2Z,L1%0PH&*\*0BFXRA%"AP1O#0VGZ+4VH8+5<'U$=-)35DSG4KXXYM^G
M@=+& Z6&=@:7#YXYLDC@TM/%6GK6^5FG;#-<Z!E/)41U-)$&U3))(=R>=L<A
M+(IH'EP:268D #L$@C@L=FA6W[M#:F:QZ;:?6!Y46T+<+9&P4FXB:\=O)HM'
M@J%548KNI)\W1<%X("119HX('2 I&W]&4]1[*M-6FPW>Y4M5>7U%!135$+)Z
MFC?"9(QP$C&6^)SF=.0V1IZ.*QGI_:??[K?+7;:BFM#8:RMBIYC#2UC91&\D
M/+'27"1C7 ?1)8\9ZBK5MH"X72/USU=8M[I;B(-=2+@W2(G8Y9N0B2,X\3(4
MB#1TW:HE*4  J;=!%$@ !2)E -V:3=H-YO,6NM81Q7>ZPQ1ZBNS8H8KE6QQ1
M,;6S!L<;&5 :V-@&&MZAPR1A;PMG%BLTN@-&RS6BUS2NTQ97R32VZB?+*\T$
M)=)*]T!+WO=ESG.)))XE9H]A9&;GMF6@R;ZX6<SI=W<2J&4<1K]001N,XD7A
M.I:,D'RFXI"@ *NU (  1,")E*0LU-AM1456S+3\U5--43ODNP?-/*^:5^[=
MZYK=^21SGNW6@,;O..&M Z%!G;[3T]+M4U%#2P0TT#8;+N04\4<$+-ZRT#G%
MD436,:7.<7.(:-YQ+CDDE7=\@2'G?9/0KGY?S+:PVG($AYWV3T*Y^7\(G($A
MYWV3T*Y^7\(G($AYWV3T*Y^7\(G($AYWV3T*Y^7\(G($AYWV3T*Y^7\(OD\#
M(%(8W.VQFX(;^"9.NB4V[Q& *^ B ^, $!W> 0\.%0\ >O@>!Z#ZUI[ONAZ]
MZ=_]G.@WCNWC_92@;QW  ;_'T  ;_%D\8^B+^RC_ .DWA^SM[\\5!YPS/)GA
M]\D/ ]A<<>SC]JOVVIT%4M)MC,ZCQPZ!;0A!0B:Y6P$:%$E=_:&W>[9 XI!O
M#I<'<*]&[C?" Z9>6MC[I%#C_P#,U*<\<D&Y4Y&<]G''K.<K<]R'L#9Y<NG.
M]IIN#T<;559/;D@<<D\1P XYJ_W+YFL]U5U'20DGT88-/$#F68%8BJ<.<T:'
M -W\R>I\'HW_ $4RGW^$V[< 6;R7S_*[4HP#G3D>"<Y'\9TI../7T'.1@\ #
MQ5Y\J_CI'3/$C&I9. Z#_%55TY!/#.>!''IRLVO($AYWV3T*Y^7\FVH()R!(
M!_Z7V3T*Y^7\'H*+59VDR&3V@M:4SJJ+F)J9<"F65!,%%!":=[SG!)-)(#&\
M(@FF0OU% .C)H:3&-+Z>XY_B:W\> _\ AV=G!0WU8<ZGO_0/XWKN SP_A#^T
MDJ[;5ALJ38(V8')GSM5)6Z6@A&*A68-6X@>Y"*B1DVB;L5#;A >.=+$W&-N(
M @42ZRN77_IU'_>>+_R^\>'#/K)ZL+9]R#?YNX?W8>#_ /N&(]_'H'#'0."D
MO8*;J.=J+3Q))VX8J&;7,"N6@-C+I_\ 4F?$1(#QNZ0^D "41.@<0*(\'<;<
M(14V"?A4T_U_P>\^VSUXZNSI'>..1D&6G*(_!/J7B1]\L?1W7^VG'J.,'NZ,
M'BMB3D"0\[[)Z%<_+^;$%K53D"0\[K)Z%<_+^$6LYMR(*-]JW6!)5RN\.23K
MA3.7(-P75$:363;U :H-D $H"!0XM!,."4.$!C;S#+S9S]1[ ..>9JLY_+ZS
MKZ^OPXJ)^T7ZX7K'1S]/GUFWT6/8HQ3D3CL2:BK"Y7!,NT742"T $.]SF&CK
M""QC&0%R"H /! ".2H[@Z4A'>(PIY?OU5L';Z;;,=(Z9;MV'!!/3D9X#!'7-
MO]S]R-8WK'0;;<N'5G<M!SU]QZL@D'CC$E;-Y#*;0&BZ9%5$#'U-I92K) F*
MJ0C/L0!1,%4U4A.7PEXQ-0F_PE$,UN;.#C:!HHX! U1920<X(].AX'!!P>O!
M!QT$'BMF6U $[.=<@$C^2M\XC&1_%U1T9!&1T\01PPMH#D"0\[K)Z%<_+^;/
M5JB4PHIBDDFF951<Q"%*9=;BP56,4H *J@))I) <XAPC<6DF3A"/!(4-P 1=
MN$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"+@>@!_KPBLZE-JF9-
M>M2]+JII.ZG=0:5JS6]*ZY&2MUB:_!W):=T9:ZX*V)>?2C)M2LQS*J#)-",U
MXF4DG4JR:HB@U1?G79$7DG=L5A%QVFEHC]/Y*3I-QK.DMKMLPM/L8Z;H\9K9
M=&>GU)[VKO>3U&UN$;,[$MD1;3<5R9$MU)"./-N#)1QR*\=Z^:QS91X]5!%L
MEP.,4$BA^#QARID^@D4YQWG.4OT2CNW[QW  B!%+#NY5M1JX3)) )SH*E*'>
MCX-YA(8 #>+7<&\?&(@'UB 9R:0'-)Z X>\+A(,L>.UCA["M/4O23ZN@=^_Q
M;]_AR>3N+V_9["2H.Y^>TXZVD=_0L@.T ];.-F;8L;(J\-9IIY:$W). H7BS
MF=P0E#A&(!3[P 1WIB8/UYI]Y<WUUH.^X7\<>'$"TD^&1TXZ5N&Y"?U*O _X
M/3A^P_+(''HZ6GP46[G2_:1NTDP=/5@00+2K<4R@D44W&,E'\$."D10_3N'_
M +N[]?@S"')VX[2Z< 9/R'>">X!M/D\?_?L"SIRF2!LPJ,]=\LPSWE]2 /MR
ML_?/6L]9AZH_^5R?JUU(-UK/68?JWM'_ ,KA#T'*P)Z[;<FTU4=:-4ZO4]3>
M\*Q7[W9(F 9<T:0Y[UBF,DN@R;]\2%8</E^*1(4O&NUE7)]W"64.<1,,FM,[
M/M'W#3MDKJRTF6JK+925-1**ZXQ\Y--"U\C]QE6R-F\XD[K&-:,X  X*-VI-
M?:JM]_O%#370Q4U+<:J"",4=O?N112N8QN_)3.>[= QO/<7'I))XGLU%V@M5
MM2MDFB6RU7Z97N8:ZV6(7DH44JHNI!LJ@99FT6+56L(T712<+G4$#D.J8YBF
M4$_%I\""G+>HX](QZ:I=,RUEF@EKZ=\K:.OK62/,MONCG!TSJATKFET,;MQT
MFXTL!:-XJ>?(9J3JVJU/4:DAHKS+%;)FQ^G6^AF9&R.Y6P-<R(T_,LD E<T2
M-;SA:\@NW<@R;L=ZAV]SM+Z3)3]XM[Z)-+SG?S21LU@D6*R9*?8U$RN&*[YP
MDX*5<B:A"'14 JA"*% #%*8(A['+Y?:K:;I2EJ;U=JJGFJJT2P5-RK)X9 RT
MW"0!\<LSF. <UK@'-/S@#TA3$VVV&PT.RS6%32V2S4L\5%;S%44]KH()XG.O
MEKC)BFAIV2QES7EA+'#+7$.RW*V&N>M9ZS#U1_\ *YL-6ME.>M9ZS#U1_P#*
MX14 O6VELXZ;6=_3KC?%HNP1B3)9XR)5[8^*DG(LT7[00<L81RV/QK5PBH($
M5,).'P#@4Y3%"[K3H75%\H(;E;;<*BBG=*V*8U='%O&&5\,@YN6=DC=V1CF_
M.8W.,MR"";4NFMM-V:MEMUQKWP5<#8G21"CK90T31MEC^^0T\D9S&]KL!Q(S
M@X/!2C:]MK3)UH[J-J;H])MKT^T_/ (N8N4B[) -%'$Y+L&*:2BSZ+:+" -'
M+AR4[<JA041(FH)>'N''NUPZ@V5Z4N-_KK7"^JI:>&HI:2:JB?%4,?<:*AE+
MWTDDKV"/TQK@,!SG 8#F[RR+LA@L&U;5]LTY1W6HBI:N>H@JJR"CE;-3NBME
M;<8Q'%61PMDYP49:2"6AI/S@["LKC.ZEWY_)QS$^E5.23>OV3-14L[-F.D1T
MY20.H4@MOI&3*H)P ?")0 0Z<B32<IR_U%724[M+6=K:BI@@<YM=6ES6S2M8
M7 &/!+0XD \"1A3!K.2KIZEI*JI&K;RXT]-43M::"A#7&&%\@:7"4D-<6@$@
M$@$D G@LP!;I6]VX\D '#?P@!H^Z-V\1#>#7<.X \7A\63*.1P/2,@X[1T^[
MAV]2A("",CB#Q'J/0N>>M9ZS#U1_\KA$YZUGK,/5'_RN$3GK6>LP]4?_ "N$
M3GK6>LP]4?\ RN$3GK6>LP]4?_*X1.>M9ZS#U1_\KA%B<[JU.1<O3='@CG7?
M I6NR"IN1<)<$!AFNX?VY)/?XOW._P (;\S?L3_T^_8Z10TI[\&>0 ]G2.W*
MPOME_P! LIZO2JH?;S41Z.X \59WW.5\UC]J:LN'BO$HEJUT*)^ HI](\.8"
MAP4B'.._</3P=P>,<OW:L"[1=6,Y)K[: /75, XGO(\>XJQ-EN!JVE)Z!27$
MGKP!3$D^"M;LA@-9)\Q1WE-/3!@'I#>!I-T8!W" "&\! =P@ AXP <_/;<?Z
M0N0_X^M'A42#]F?4OT56LYM= ?\ N^B_1(5LB;)=I@6&S7HLT=OP2<(T.'*J
MGWL\/P3<!3HX2;<Y!_\ RF$,V1;)..S319ZC8J4CU'?6L+;&0=J.N<=6H*P?
M:-Q7#\]:SUF'JC_Y7,B+&JL.[I%8X:4V6K"V8/0<+A;J*IQ?$.DMY2V%MO'A
M+()DZ-__ ,[?]0#F2]DA_EK2#MH+G^B/6.MJ?U0JCU>G6X9]=4S"PR;)ZZ3;
M:7T/<+GX"*.HD&=0^XQN"4#JAOX) ,8?"'04HC^K) :V.-(:F)Z!:JDGMZ,K
M NB^.KK!@=-S@^SB>GW+U[1"R:^O.L2Z)N&BKJ7<E4S@!@ Q#SSTP#N,!3!T
M;AW" #T^#/SZ;1?KYK0=!&I+RT@XR"*Z?L)[5^AW9H0[9YHMP/ Z6LA'J-OA
M(/VYZUF\V"K+"1NR[I\U>O@0<)O;H)TQ;NU-P'NDZ<H\)) Y!WE$!Z##NW[A
MZ=X!.#8/G[EVG3VR7CV7FOS\>"@7RA"/NLZD'6(;)G[;';B/9Q5XO/6L]9AZ
MH_\ E<S L*ISUK/68>J/_E<(G/6L]9AZH_\ E<(K#MH7;^0T.U&5HC'3<EQ;
M)P41,A-\ZE8+A&E!=@9KR>K6GYP[W[V+^W"XW*\8.XA.#TQ_VC[<G: U,_3H
MTR+J6T%'7>E&[>A9%7SV(^9^3ZKZ'-'YW.#.?HA2*V8[!!M&TLS4G[Z3:2ZX
M5M :/Y']-P:/F<R<_P#*5+G?,P&YS?S=W@]V54[9BVO8[:%B[?)2=4+1.;$A
M%,$D0F'-BY1"2:NW!E>,1@XT&O$"UX'%F*J*G#X0&*!=QKJV6;3';2J2\51L
MWR-\DU5)3&,5PKQ-Z5#+*'A_HE(8RWFL;NZ\'.<A6GM;V6#9=666D%\^6S>*
M6LJ=_P"3_D_T?T2:&+<W?3*SG=_G@[>WF;N,8.<BZ/GK6>LP]4?_ "N966(5
M\GN=:.4Q"R8"8P<$H=Z/@WB/0 ;Q:@ ;QZ.D0#'0J$$@@=)&!ZRM/I[N%X]$
M.D!?.A ?K#OI3Z]WXY/&/AS8[(XQ_P IJ@\XXGDR/Z\@QV9+A[,J_7:F>-G6
MDVQHF@J"AVFA#=!P4"*%XI4"5SZ B<A0,/0/203%Z/W6:9>6J#]TBA/5OZD'
MK(N< .%N>Y#X'W/;F,\0[3+B#G@/DJKQQ[^I5?[E_*,(G574=>0< W2/IVW3
M*;BU5=Y^<T:.[@HIJ&#H'PB4 _7TY9O)@!.KM2'' :=CR?7<J0#VJ\N5@0-(
MZ9!Z7:EDW>!XXM543QZ.@'I[%FSYZUGK,/5'_P KDVU!%<#=*R("'*8=(#_@
MC_Y7"+5=VDEDW&T%K2LB;AI*ZF7 Y#;C%X1333L0'<8"F#>'U@ _6&31TF<Z
M7TZ1T&RV\CU>CL\O7VJ&^JQC4]__ #O7?]=X_8KM=6'[178)V8&":P&=M[G9
MUED> H D3.>Y%*;AB0$AWB8 W%.)@W](>'-9/+K'\.H_[SQ>/[WW'W$>*V?<
M@W^;N']V'G[#J&(>\'PRI+V"WK:/VH=/'3M3BFZ;6YBHIP3GX(#29\H?13*<
MX[S& .@H[M^\>C(J[! 3M4T^!_\ +7D_8+-7D^ !*EGRB"!LGU*2<#G+'XF_
MVT >U;$7/6L]9AZH_P#E<V'K6LG/6L]9AZH_^5PBUGMN-V@]VK-7W+4_&H+2
M==,FIP#DX0%I59(/T5"D.'TBF#Z10\&\-X=.2\V<\=$6$CKAJ?9<*WS43]HO
MUPO8_P"(I?U=1^[AXJ,4]T@&Q)J*T%3<X/M%5%4J?!..],M'6*)N$!> &XP"
M&X3 ;>'@W" C"KE^_573_P"6VL?\V[]O$^L9"FW^Y^D?ORO(Z_DZY'';][LX
M^,XSU94E;."R;?7_ $876-P$D=3:6HH?<8W!(6?8B8W!*!C#N -^XH"/U!FM
MO9R"=H&B6@9+M464#UFNBPMF6U ANSG7)/0-*WTD]@%MJ"3[%L_<]:SUF'JC
M_P"5S9ZM42F1!9)RBDNB;AI+)D53/N,7A$.4#$-P3 4Q>$40'<8 ,&_I !Z,
M(NW")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$$-X;A\?\G^D.G"
M*W"8V3-!9R>O-IDJC*GL6HT[$V>US374#4>-D'%C@XTL)%3D0YC;:T4JTJTK
MY1K)7M5&%<*591>LK'4@5UHY0BBP;,FA17]4D H# IJ0Z!U6X\)2?"!8G0F>
M<<6W<5L);F_*1]9L %FZ;%R\8^C:3+)I2%2:0SI%)4A%7G"+ROO[3=?J;K?[
M,P?UYR9]-OXS?>%PD_FW_B.]Q6F<'[C^0?Z\GD[Z;?L]Y4'A_.-_&;^Q9"]H
M;]%_8C_BYM7^^0.:?N7,/Y;4/?7W_P!]J6X7D)_4J\?DFG?=>%&.YM_I-1W\
M";A_LH[,'\G;\)5/^9+O_AIEG7E,?@PJ?SY9O\=4MAC)^K72N!Z $?J <(M4
M+:F$1VDM=1'_ .E.Y_\ &7.3-T=PTGIL=EFH/^@Q0[UC]:M0?G:M_P"N]5:>
M?H*:?_\ B0N0_P#]()FNO]T"_G-)_EM)^J[PMCG[GM]+5/Y#/^M;4N=B#]*G
M1O\ SW/_ -";-D(]B_X4](?E=;^J;BIR;=OP4:T_(;=^OK4MF/-D:UAIA%K0
M=T0_2VU(_P @I/\ 0V%R6>S'ZD6C^UN7Z?.HJ;3?KG<_[*A_0XE-VSW^A/MA
M_P"?-*A_EY>C_P  _FR,G+<_!S5?FMG_ )CLP4H.0_QVEV_\XU/_ );O!]ZL
M^J_]TE?_ ,_0O_$FV:@K?_25L_.-#^DQK<C=_P"C+C^;Z[]&D6W@3]P7_P!4
M/]6;8V_1'QUK3T>D^L^]?6<E1,(F$3")A$PBQ$=UL_N,T:_A991__A6P?UYF
M_8I_IU^_(J;_ *TBPMME_P!!LG=551_Y40_;[ K,>YL_I6U?^"EV\?\ ]S#_
M ,[LOO:O]2JS\NMWZ2Q6-LL^MU'^2W#]'*M1LO\ =-8/US\S_P 4=!GY[[C_
M $A<_P NK3XSR%?HJMG]%T'YOH_;20K9CV0/T8M$?X P_P#[*F;(MDOX-=&?
MF.E_]:UA;8_PHZX_/]7_ .A7(9D18T5@'=,?T5+#_#&A_P!(6V9,V2?72D_(
M;E^B/6.MJ?U0J?RVW?I3%A.V2/TG="OXQH+_ -I7) :U^J.I?S74^Y8%T9];
M;#^<X/8XE>O:._O_ .LO\9]U_P"/O<_/EM$&->:SQ_\ 45X_3:@?L7Z'MFOX
M/=&?W6LOZ!$LZG<_/T5=//\ +;M_3:>R<.P?\%VG?[2[_KFO4"N4+^%C4G]C
M9/U';E>CF8%A52)J?J!$Z5:?VW46=:OWL/3H1W.R+2+305D7#5D4#*ILTW*[
M9 ZY@'Z!57")!'H%0N>C:+9/>;I0VJF=''/7U#*:*28N;$Q\AP#(6->\-[2U
MCCW+S[K<8;1;:VYU#))(:&GDJ98X0TRO9&W>+8P]S&EQZMYS1WJPJ-[J5H9*
M24;%H4[4XB\I(L8Q ZL9702(O(.T6:1U1+9#F!,BBQ3*"4IC 0#"4IAW .29
M]CVH8(9IG5]H(@ADF<T25>\6QL,C@,TF,[K3C) S@9"Q[%M:T_++%"VBN@=+
M+'$W,=(<&1[6!S@*LNW1O!SL D-!.,\%8UW27IVF'H_70::/AW[MYYC-4_**
M_"9/^8[/[JU;9.3+^#*'^\%Y_P %&KK>Y2?W*:R?PBJ7_"YC,I\EO^C-8_G&
MT_HE4L3\K3^E]&?FV[?I5&LM&2K415UJ_P#9G_\ 5'"H[H/J/N6FF^_MU]^M
M\Z'^=TH.3QCZ(O[*+_I-4'W?Z1)^/+_ZU?\ [5HB.D6Q9^K0-ON]"N9IDY:O
MX2:+O?J,_:;E!\?^Y6YWD/G_ /#RY#L?IGVVJK59.Y7?WV]2?XN&_P#2>.#^
MK+-Y,'UNU'_=UGZRI#^U7GRK_JAIKNU*_P#5=4LYN3<4$%P/0 C]0#A%J<;3
M'Z0^MO\ &=<?^-.P_P!09-'2GU8T]^9K?^CL4-M5_6:_]UWKO^N]7>ZN?_%^
M[+7A_NWM/1XOW5S\/_/CS63RZ_\ 3J/^\\7Z@>MG_(._FZ_^[+__ #!$I)[G
M_P#I4:<_Y-=/Z#V'(J;!?PIZ?_)[Q^IZ]2TY0_X*-2_VED_7UN6R#FQ!:U4P
MBU?MN[]+363_ #I6P_D"CUC\1R7FSKZDV'^QJO;<*SR'QA1/VB_7"]'_ +>F
M'_\ '42B]._0<U'\/1M'U ?"/AYBJ_\ /\WU!D*N7[C]ZM@X#C6VS/VRW=3;
M_<_?KC>N XVVYCH_[.T>W)/%2/LT_I":)_QH4G^D##-;>SGZ_P"BN[4]F_3H
M@MF>T_\ !SKC^ZM\_5U0%M19L]6J%,(F$3")A$PB81,(F$3")A$PB81,(F$3
M")A$PB81,(F$3")A%:KM74BWWRK5N'KL?J!+1*<A:G5@C],;U(:=VT[O]CRV
MMZ4[;6*,MU+>$:L+LO!N5&Q9<R /2Q[YVT7:L5@ BMR4H>UE.WW12QS2=T0L
M5-5V=HN8FX^[LH>B&90LG:66U6YMU2B[.G#W)O?X 8]6A+O:G(R#1\XK\@P+
M5GL8X%J19+'I'IVJA(YPV;/!X'%+NVJKUN3<<HJ<8V2=LE%.$F!REW.4^ <Q
M3CPP*)#$4OJ,+@JFHD><KW!4(8AMU:D '@G 2CN'G..X=P] ^(< D$'(X'(X
M'I';QZ/#UJA <"TYP00<=.",''3Q^PK&H'<GM(@#=^R1J*(?KYM>/]Z##,L_
M=FU9_P#(Z=_\'<?_ /56+/N0Z8X'TV^Y&./I5OSPZ\_)?2JQ7'8-J%XHFEVG
MLO>;&A":1PK^"K+F.9QB,H]9R*C15=2=7=)/&CIR4S-+BCL&,8D4#* =$_"*
M)8Y[4]"V;:_<X;MJF:XTE5#-5SL98IZ:D@WJT0<\TLN%%='EK?1X^;^^APR_
M><_(W9'[*-H=\V.VRIM.EZ:UUM-51444C[_!5U<X;0^D<T6/MU;:8PYPJI.<
MS$0<,W!'@[WIT5V%ZKH->$=0*9>+ _FT(N2B"-[*QC7L9WM*%1*X.9O%DAG0
MKD! G$G!Z"9=YN&DI]'@VMHW8MI/0U[9?[/6ZAGK64M12".Y5MNGIN:J0P2$
MQTMHHI><&XW<=SVZ..6.SPNO7&W/6&O[$_3UZH-.4]#)54U8Z6V4=S@JA+2%
MYC:)*N\5T7-NYQW.#F-XX&Z]O'-X?>ERZ]KONU(?FC,M\>T>!\UAE.]+D/\
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M55!*("<V\B^"5*J)S+>QIUFO)V%FC)-VD\2%C2S+5"9<@\ET&\H5L#Y!&5>
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MJU;,FZ#-FW0:-&J*3=LU:HIMV[=NB0J2*"""12)(HI)E*FDDF4I$R%*0A0*
M !%WX1,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(
MF$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$P
MB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3
M")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81
M,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A
M$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F
M$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB
M81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3"
M)A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,
M(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$
MPB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$3")A$PB81,(F$
M3")A$PB81,(F$3")A$PB81,(F$3")A$PB8149UGU=5T<KCBTNJ58;+!M6YCO
M9.$6B>(B7"B@(-0E4'K]J]39++J(IF>LV[PB(J;E2D'@\-Q^#_DBIMLR[04W
MK768T[VGS/?L4V)'6VY :':5=:?0;D462BVY7YI-95RFHW<G;I1Q4&8.."HN
M4O% H13S?-HG3C3C53332"RNI-&TZI)RRD*Z;,"N(&&".8R#QD%KE!<I#"#9
ME(F5C:L)F[@LO*QCQB!D%2)\9],%)-4PUL\88(Z" 3S.D<&[X)+GQP#_ %LL
M4#)JN9@W0RE@EE+N !H\\V(20YW/SB!C6#><'%T48>X#B(S/44M,'\?O]5 S
M&'ES>B)VIMG:?B&4]!ZQ467B9.:C:]&.XZ:1>!(RTQ$I6"+18)( HX>-WT L
MG/H2+=)2-/!B>8[["-25<D[7VNY1OYI]%4,E,<TG-OC+7!L#FLFW\X##'))'
M&YKRUW.2PL WIH@_K,\(9)(9&AD.[SC\_-;OEX:<_P!8$Q2C+<C,,X/\S+N2
M'ISMN[/5]TRBM2WE]@J<W?"Q1?URPR34+%"R$D2779QKJ/8G=*/'"C. FWIU
M8LKUJBVA9M1=9((65[S[ZBS5\$S(6PNF$D+)V31C[SN.I:>JD+WNPV$0QU,/
M.&8L;]\C<TEDL3GC-&V2JB<=V2DJ:FFD9@E[C35D]$'QL +Y!-+3OYIK&N>X
M_,W><!:*II;1&AJT7>9U'56DJP&F;1J^O]@3G&AZ_46KUBVDVJTY/%.,0R*K
M&/64F */>$2.?,GZ@%:/&RRORNH*UI@:ZEG:ZJJ'4E.QT;FR35+*AU(^".,@
M2/D;5-?3%H:<3L?"?OC7-!L\+][<EC>&0>DO+7!S6TYA%0)G.!+1&8")@XG!
MC.^/F\5Y&VTMH"[7KK5OJ[0E'-KD7,37VW.2-(XD)-I-#6W##B#KE5:.B6(
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MG8<235-XBHWQM+9&O=/!3U GGB:6 4U+([(#GS0P=/;NU2KL4\-):0M7D*P
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3PB81,(F$3")A$PB81,(F$7__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>img102984888_17.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img102984888_17.jpg
M_]C_X  02D9)1@ ! 0$#O@.^  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" $< EL# 1$  A$! Q$!_\0
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M,DE57!B*AZ)^XIRE@/UU^L=);Z=A3-BQRJ*S4<,M'7L'4>*@X[R\5A9K9/;
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MBW%-R]=U'JX)KT],[7HGI;3+YEBCI4-W8VUJUKRY*;==GWD NLAW"$UNV2B
MF<D?UUU\TZ0[=-JGH/5'7\3Q;S??(E>%I>MN8]K71ETOM6!E2$).W*?BX9)B
MQUM495N16&9$,\2G3 >3^7X3)BEYOHO536H+ZG!VN+J6[+4:*O>NUZR>G:CQ
M)$[9L&12S:65G/8)P,44F,%/=Y1+T?4WEK5YT54XBF^D%GJ._4/RON*-:[(Z
M*GXY@@KDJ>+C1F2:X#3(1*UD-L^_>;*G&=3=8W_:')^^=X.^IM5ZVD>++EJJ
MDVB>;Z]W!$P2<2=C/&@#D#6UIBEDXQZ2R6)%)%&)(Z8)+ 8RB0\NFK&T5I6Z
M'3[:EJ.IM5UO;V3[MJPM5:QHKC:Q.?7OLB4-1#%7%VZRS@G3*&3W#VE'6R^E
M:M=/[K8!-CI2>C8U&PU<H([@7D-MV*T6=;'%@X8BVD:D0)#7>#8(1+NY^_3W
M+;ZD;'TMMOOKG#</4T'<^$:=IN45U15[!LN3K/3U71=_;EK;&58Y7Y'KE-ZW
M"&N3XJD;$RZ3QTHJ4XBL$L]BFQ=^TG6](W*NIV.UZCI[KI2XXHJ59J)I12NQ
M6>P853-=I:[!++L-U$H$9F"((K=/%\-)]G+MTR"IZ!&XH=5TS,7VVU[]Y=ZB
M;E#V,MUU58;6>I<SY+, 3!Y4LLR\\-WS=.C.4.5>;=SUC9S_ *:N^J;_ "-6
M=3=<G[%5ZDG7%9*1IM8VYL9LW=Q=8F&D"[@8HJ$NX%PZ7:JM4A451$!I^MQ'
M=;?J:QHGZ\GZO3ZFQ=LR85:FQVCTIU]Y^L[H@;IGLEOL-!$24IF;,CV'!3#Z
M<\.MKZTMFJXK5;;JK;4]?64!/NT-1+[6QI19KQ/DI5!UH@M!.@009*I20L$1
MS#-0-">2G3'<W![S9?,NII2ZN=H[]OUZVS5]AVFVL[P]V,2.->K3LVR-ZP6/
MI+RNUDK1AK:MG65CY'[>E#-#(E3/GJ=5=Z792W].K?O5-?3Z+T>F^#:D "NB
MM=LO.Q2,B&=EL]ALV/L[#OB&]C_,9]L#,2=V-XZ%N]"E6K>PZMK[%1=W:8LK
MU)JZO7&D3**VIHZ]:Z\6!+A9K\GC8Y[!+:;Z?9/I+F[?,?',G<C(OM0;$:,H
M^/;+O7SUVXJDJD@U9M&Q%7#IRNJ8J2"""9U5E#%(F0QC  _%]F)%4F!&3F&U
MYXB)*9XLI*9XB)GU$3,SQQ$1S/J,]5T^8!O-2;#%8#L*I$9E  (PT>2(BF($
M8_&9GCCG,*=JTSMBY_P]-*U96-=VR3V>SYSUJN;79H5\PN2B]8LL-.2L8$"_
M0;2))=*.CW*B<<JW([5.0J1$A.<I1^I]4;.E4^UNIO3<+M9K^KM=?LV*TQ8&
M*H5@ VCXI*&"!''?V<]L04SZ&<I>DE2=#84F$%=U[7=644S8*5!-BY]Z+K"9
M3' PYA@(%/REWC//;/.6NK.V+1U!V=1]E5;GKHZA4&M^-_<M#0L>U]06JD$G
M;BJC&).8.+;OVAE170<M#-FA'8-'4LM[S1K1PB4JIJKJ'6QK^EOM:[K]"Q9W
M#-0ZC4I60L6&U!;;8M\+&.[O;#BB*X]SE"'>T0[AB=]1:$B^RJG*6B6HZIM?
M>3RB(K5F_=%=)KET3(R"Y3/?9CBO,G"Q83!,1C9J+C.N?\-GA=)+<R+EGW'3
M,D^W65_J>02G?LSD]R<JJ[2%:"+(HP:ZS:+$X6OV1ATB-DA 41( ^WL;:0^T
M3J"0V7;KZ_V771H2-L?@5;,-=JC2*9\GP_QXV#LD C_:):3.V._NY\NR'3T?
MMS[)F[8^T#7!,PLILLU\[Y]-I*B(\LUHUP !,"?$*8AA3VQSE?;%Y;VS+:P\
MH=)U/I6SGIT;W=J79:FH(&M/JK';;TY5!@)V_5F@QIVD?%3[.89-70&8Q *L
MI1=,6)A,=0J>>7U.VJ5==]CVQW;9LIU=WK"=EYN;EK7G8MV4:G8V4%++'CHO
M--I4$,S"QDU"4!.>A-+&]1=>5M>]=&UM>B>GJ-"Y$>*NR[-.Q%BK%D(\:G6E
M0=1KAGN3+A\DCW1.7'IL,VZ&Z%W'T-R[RMM3G+1E2X$W7J'8*-PTU(:8?;7V
M5+PQSU*K0= %BS?69Y4BM5R$FT8]8%5#)MF:RWU"/OX;0+.MZ4ZL1M]O7VKN
MH-UHK.BKHO%L6C%)I%>VTJGN*@#ULA,+* -LE)D,2)=MAHGTV=1_9S732^'M
M:+>&_;7SA:44M<^*Z5ZH[,E"[4,LB-PC$S!((@BD?EYRB>(;2=:U!P7SL5OK
M)EKV]3FMHEW?OJJ>2JW*1FE'+QVL%M!PP8SCAXDLX4.1*6 RJ ']"%( @ [_
M &A7RM=2WT)M_$4*OPJZ@*?Y:@P-*L!$D0.4P93$PP@CF2B8*9F)SSVH67CN
M/<!Q8L;7<-,W 4.D6;*Q(1R<=_B\8J\<?W)6(2/R]N0PVA/[&X%ZC[<N-NUO
MOV:T;VG&5.QT3>W->N)';UUU)L: J:U3?15@IT.W>2:"H'<EFJY)J-%XKW-?
MIUP 3JB2KU@*W'2-'I4;J]=M]'O-SL*,V9%-;:T-Y;7?;"K)<K79J&B$.2WL
M[U'+ +YAYNWUUIZBJ]5I0O8HLZ?5ZK=T7N%?PS='+E426GO$F4[BK7#6*_BP
M_P!2':N2B)$37NXMA^/+R:CN6;ZFW'K2XU2J1W+P] T5O ;ILT&!$CVM^&KJ
MTT<2T2F\>.42M6RS<73EJV(L9ND<BY2WVV#3KM?9VKX;3U-VOK*FW=KU%F;5
M6OKXV%4:GQ-WCPP4(%['?.0IDSB2[>WF+K[!?>6S;5;9.@GIG9Q!V52A9[3X
M:Y)KK"R?(X @!6!SQY)(1&"F?4C^J>>&&H]:^,;9L;S/*[&YIY^<(6?HW2&L
M];HS4\ZF9W5T'#5O8LSJ]@Q27NLK49M%XO)-W3%U*)+.#&.F903@7([E0]==
M8'<O]A[+7;C4=-;9AD^KJ[3-KY"4EP2<5$[.I"ZRW)B%C"X*2X@<K]75=:Z&
MK5ZX@F\VQT]M=K19Q6L;2I64UEM!N;VE)U&MEQ5FG'Q'/9Q/9ZL-&\XW;?.J
M?)=T#I70U\T;JJ]SNE-P<IZJLU&=:]MLWM+04>E,V"^1.L!;HO:L>YO600C=
M'Z%L\E_54YT3'#T'B_8MZ6UW0GWA<1M-UH.J]QMK((MEL8H].[LQH-H.LC)P
MTF4[%JW\&)G%?@ F(B1RV4JAU#N;VO6@ZNOVW10]+;;8&44%[+;19MVZ+8(N
MTUAJ&Q63-D@\;)GO RF6P$2XWG'JJYSNG+D^UMM*.6\M=R^NZK9KP-C(EIV%
MHFX(RU0;.P(KQB7V!L]UXT7@@+,D8%7;**E$3_A(_I-?]QZO8IZ8.U3L:KH2
MKK.L];9[U2.TW8Z_;6-@H&^20AL[2]K'B@"8<.3,0$G)2-->MW+VIV75 ]@[
MFTW9] (K$@^!TVPIZO2HLQ3@8(H2S5;*S-_B%R-H&R0J,9G++&4J+T]Y6>I6
M4AHBV?;]Y<M4EMIK9=>U&ZE*8TEZ14IB,ML<_OL=%JM*W-O$0CVAB+ND'<R<
MC9H8JPIM@'P$67W_ +,^K:0W('85NJMMN+%5KS4RUK=EK:L*&HJ9XMP6P^(9
M-=4%/EEKI'OEA9833BGU;T)L8X+5+TM#0=@S#/AME4W;&JL60CGX=:M="U#<
M9VPI4+3W0OLC(.ZYY>_ECA;Q76B)Y\EH7<C+LNF6'8,XUUC+L]DQ<>_V%9/O
M4I;WA(8EDC84[ &WU"\T9",08@@/J1N*8C[4=IV_:+JJ\; 8U ?9WM*I!%J!
MH18_X-K>-+($XKS9FY)QVLGSS9[AB);W#E'U"IK>EOM((5L9;?UXAM7Y9.RZ
MHOK@/&RK'$M*L-(1*)1RKX?ED\A,EF6[RV5:T6BL\8)U>L6*S*1'=W/DU+)U
MV#E)P\3"L)61.^F9,L6U=FCXEB42F>23L$638IBF773 P"/C>AFK1UBASS!2
M8Z7ZO5+FE"U0QVK$5!Y"F!@V%\JQDH(YY@>9CC/2;&)+I;J=01W-96UL+4,=
MS&2.WIF7C".2.1$2(NV)F!B2GU$SF/C9O,L7='WGBNMGT&M:KE,0Q6NIK#-:
MT>3$W+E9Z=!9H76KUU#+NY%9&<33$BM5.NO]Q313]XKD(4,T;K:G0_0%>M:9
M6;'V@[.Q=2EQ*=%>.KJ9*;; "AGPTUSL&).CP$DFE'<LBG)->?/]HTQ9D6ZY
M?1?3RE2<B5876-=?7>5!S,A%B957%H<^09A7(C/;$Y6JA!V,/%+"5MU"3X6L
MO$+2'7KKF+DOYE";#3I6AHE:&50^Z_=_K %J:/.V^N^J_P @4?F_HRN^TLP?
MO^KF59%ZV[V\:#KE#@8!;*2 U$ON@PD>"@AY&1]Q/&<.@A^'GIP71"/%-<3%
MD0H50/(]LP7 @,>HB/0Q'''KC-:KJ7CO?VN.!.8-T:+UU=70[QTSI#2_7&H(
MVF6)S9?JZW-1LM2-DKU%E'GF6T_ O6'V:;=.(TJJ;%PF=\HFB4PA]3C9ZYGV
MJNU-^RH]+/5VJZLT>P!P%6UVXHUJZ[Z(?)>%=/:56&3>3B)LHD8COG/'Z:NY
MOV8V[2U,5O=1TUUCIY08&#MAH-K:V!_#DHH@G,H6/%8I1$24(<1*$HCWD4\C
MD!KR4W#K'_BMX]Z"D]61&G*T3477O'+38\SO:K746(#-ZXND10V82T5"&4#Z
MMF945FJJO]*XI_(J"?CM*Q@W>J6ZK;+UV\9LWR&OM>+[GWNLAA2-J7,GP%:J
MR4!PV1D@Y@)D.SGT]<"'ISI5/A1?HS1"-DF[ A=TNP!*9K,JJ./+*[*UR#2&
M.Y32D9")@IFA:1H7O+=?CPC;)9H7:=]N?//7U5Z&Y;HN^U21>[=B:5UK*G7C
M*K> D#BNULTG%.7AX!"84^K.=)HV4.3Y4S987=GKM'U-T?M;"=?-[[FV&KZX
M^X)AM.L6Y0ZJVWKX 14VQ6":YN%7$=GD+B6#(SI2!%VIUSIJ#K-?5;FE7J]-
MV=IWPM-JJ^I<_C=_]H+7L96E/+HC^(9&/"Q$X]/;/3/676/3.FY'CF2\A^J9
M-A<-=1.Z]#W[1 :RT'5*G%RBBFP9F9V1:F932TBY2,>/10@%9%M(%;%.V,0J
MR9C.GM1K-4][MP[I_;]//;<MALW7.;P)G7]FOIT-:(C8,G6EBXQ= $DGG!'$
MB$9"WMI[-'8KUTVJ/4@4%HHHHA\0#[Y;!?GLV[?<==*$56G MB.#%2_X?),@
M<FWF3K5GM? 6R8.IUN?ML^O;=0K-X.LPLE89ATFSV=5G3Q1"*B6KQZX2;-TE
M7#DR;<Q$6Z:BJHD2(8P>-Z;E0]8=&&Z0"LOJ:D5AC)$4JK^"V)FXRF 6N!+M
M(SF!CF(F9F8Y])7F8U/58]W#6=&]2*3'/!LL'KF0M:HCYF-,^/&L(DR+U$?E
M@%W7R?O0EK[XUTOK6[/]*\_:,V-M+G=I&4VQOT;'>^H!HJL['P14HM5*6EZX
M,/.)DCH+ZEXQ(X<&<I(B?T'V^LV57[GUM]S0G>#U7H^B6--@P8]/Z/J.]N?B
M1CN[YJ-5;J+^(*(5(*$>Z8#F--6I)=2]-J6Q(4[^J=UILN\( Z^[K=%LZ9K5
M)9/ +<YPM<U9S#W.YB!GW.3^V#IS<-UZ1T'#TJIW"+F93P][,US%V9:$G(J(
M@MAS$3%,XB E+$=FDQ@IXSLQ0*P=NFTBB)3* @'L,(5FT:DZ/VQ=K%-&SUIT
MM;2D&*,MC2K;"\^XNJ/=$60;7@EE*^Y<PR(*>"CF)T^R*VK^RDWS*/@MEN"M
M'*R(J$LU&K6I]A,1)K$6K*0@XCR$LA&"(9B*1X+'6QZ[S+SE'>.3<%2ZTT30
M+M5+_ORR:C'6]:U);7L(_CY*X%VD^39(;-3N\B8JC5*'<S"OHL#@X)^WUR9U
MC-G<!U9N=+U%4J:7;:,:M&M\3*WV0!20KZ$=7'\1)UVB<%8\8*7V=_?\\\0J
M,1J64*>XJEL;(]4AL2!8Q:!BYOV+);LK_P PHA51RYBN9@UGEFL*Y\<#, .(
M>/MF,N@.;]4[#1[ICMV:3WQ+WN\Q">C-?5W0]&38S\G(N+JGT-)LVTKL.M7!
M@[2 8YC,R4TZ/(N4@:%^-+W>DC=T&5BW.N#4#JXZ1G5B=ZTZM>6;**ZIZ M(
MJ!X=Y8*$O!1J2"UDQD<EVP]Y5L@&VIV^76-MU NVAU#BS]X+F_%A6]AS)+X2
M*_B[W+?"#DP.%!,$ GNZ@4 ]/7\C_<1_O_U]/SZ9\6XB/I'&7>?K&,8QC&,8
MQC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QD#.FMN26M
MNF^-89UL!*DT*Z2^WFET:R4O'PT!/C$TA%]!-Y5S(F21.9I(&%=DF#A(PK&'
MT XB!<WU_:S8;9+>"%?2UNU6 I]#<7LJ"Q< \QRP$L://O@"+UG:X!#HHL*"
M8='4^AJFX1Y(*EBOMI<HBXF!4UBD=_TY,5\3SQS!N,Z]M5OT;JU^AO.)>7^6
M\AB>N5D:_9( D[*:O;[MEX%I *1S)<[IW!N:V@T:JJD0_P":9"1451]_OR=J
MZT-V'V="2B:.QZ0=L=RLA(@;>+H?<WF.M!'I9)V((=V3VPMP+_\ 3Q,/>&%>
MOUUXF0F-?M:"-84$,$E![_0(D$SZ[X97?:64QW3*C.(G\<SKY79VQC&,8S$3
MWS6]BP4^VLFJ.F-XI])W:7K$+S+H.ES44PH3-\Q>LQM,S?*6R9)_S;048\7D
MK=;)='AFL,Q!)A$K%D',>S<XUB[,[6BNI"K1QM*MK?NV$RS7TNEHLJG8J-4<
M+IV"HC;1JGJB;]O9MK",DM3"7)M@I^IOL;$TD5=1=3295.%7;G4;%/+52ES(
M,GL.W-0&TX&:B:";3WA 2UD4SV[!==V7;.M58"$VJKI366BIRX;AG-2=&LN>
MX^0NRK^(5DCMU6<?8+19GM>A82;=0D YC(B%=DEQ%:?370^+([+=.A=ZJVEX
M;2M)0C3EJ&=\/<-6&[E^T(=<,@NTWPCJEL-]FN8]L@@7>5DJY*K7[.NZ;U]=
ME1VWV);)>U3"93'QJT:A&K'[R+F:=6Q9M;.8"NBS)$I;'^ 4AY//OFTWW4^T
M^.M2:YVWO#6FD-I\G;&Z';6VGVA>G[&L<O5E:5"U!C9K1\;B36"/2L+R7G(\
MIP1F'J::CLZC<! UAN:-NELNOW66J1=Z2U-"S2J5Q$-<5[:7;\'<*K,1#ZU9
M-%: JOCP+^)^:/+ 2.=:5:>F^FF FRV=MU/&ENNM,!UI=*CJ;-AU,K8&?9<L
MVUP7QE<C)H4W2!R!R16V:]$[MW'S%X^*;/;"O-9E.B]_V[3VU=HT!^E6;F_K
M.L[%=(5NNUL*:1U8"7NJ%88*/I.*1*X.NH[,S^(BWJ$JW459ZLT%$NY%/8?9
MY9ZQL(J&5=9[4.E-#M5I#MY,:(7MI9=\+W=I+!2B*0"8FC98L:WIK=V4V%6K
M-#[0-;TDBQ96+V3J;W4^TUSBX+D"O(HTU5IM%[AL&[MAA>IG<(7[;$MJ[IFB
MREHE-IV/G_H+<&I-:66^R)W4_9(2N-(R5I["Z3Z1$E)5\R<2P0[^;,0CIPS0
M35<>JY#";5I19TG2VT-*46]GIV'>\"X2BQ9I;38:WXQ21GM5\2FHDVB$>.70
MPQB.^8BYN:Z-/M]CKEVGV:TJU.TK18/RMIAN=54V#-?YI^=JZUAKI039E@H:
MI13(K$BQ3;5\E/F>Y7V;S-'=7\I<<535O071^O-$HSE#V/=[1968W.Q,8]P[
M08_6D;HN4(I==PW5<D4;B[(F15(4Q.!8&:_RY_KZ_P /KZ_IFT!C&,8QC&,8
MQC&! !_4 '_O^<8QZ!Z>GH'I^W]L8SCT#]@_T#&,>@?L'^F,8]I?V#_0,8QZ
M!^P?[]/T_;] QC.?0!_4 '&,X] _8/\ 3&," "("( (A^@^GY#^_X'&,YQC.
M/0/V#_3''[CU_IC'M+^P?Z!_O^V,8]I?V#_0,8QZ!^P?Z!C&/0/V#_3&,YQC
M./0/V#_3'[_?^&,>@?L'Y]/_ )?IC&<^@?L&,9Q[0_'X#\?I^/\ O_\ <<8Q
M[0_8/],8QZ!^OH'K_L,8QZ!Z>GH'I^WH'IF.(_U_S^N./W^_IG(@ _J #_WS
M.,X]I?V#_0,8SGT#]/3\?MC&<>TOH >@>@?IC&/0/V#_ $#''^7K]_X8QZ!^
MP?Z?^G_T_&,9SZ!^P8QG @ _J #_ -P]<8Q[2_L'Z>GZ?V_Z_O\ ^N(CCZ8Q
MZ!^P?C]/P'XQC'H'[!^?U_'ZXQCVA^P?[_&./]_\\9SC&,8QC&,8QC&,8QC&
M,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&8Y>WV50O^S^5=&7
M'6.G+U%[&N=QF)&:W14RVR'K4%1JV28FVM8:&?1I6MOL#94K2.>*NS-VJ*#A
MPNS>D2^ RE 'LK;''"JVIT-S;62#M&T\?B:]1:4,+D5H4;?B+YR#.$@L8&)+
MN'N^6JT[6)87EM[G4ZM22DOAO)8"]8BP\!_YK%C5)554$!$Y_,'$1,%CXU76
M>3HIWKGLFI<W4*KU.P],LM#:FUI!TG5JR;]TEL!Q2H/=U7F4*@PMK64!ZR6L
MAV3::>D;1R2[HC@Y$T_9<:<KP-Z>J$YE?8]6:"QMY[R:#-%5+17MM-*260>5
M5O7UA3:\JX$3NBKB(@>ZNW->L4=1PSP,J=(WT5'G$K:G=7%["A3.#\G?"GU=
MC;\-05D)&ZE$3'>10.Q"'Z!Z_ME/DK&,8QC(';&\=6@]E;KLW0;^Q;ZJFT;?
M$PT!/S>NM^[0H;9W!P/H:-ATXJNV!G'LXY)7W.%6K)!NFX<'.NN"B@^X-=>/
MW9+HK$<KL[$=K82\I>BQ= 1 &.4V2!@ D80"BB5 GE8A$3.;VCFY-8G0$G3J
M32JL ! TUB8336)!$3,L:9-,RY,CGGNRX6U^,=*[DG*Y9;8.P6,_ 03.JNY:
MH;,NE/>W.IL3_*G5=A*0$NR"[5]94RRKJ.GBNTG1W3L5A,#E4#.Q<V[5DU*:
M%Z>ZY0:L6:RR8P0K-^N.)JL)(&2TS*X\:Y\<?+Q&(:V*E>I#6#%.3FG9$R&]
M5EH@+IKW(F+"Y?*DFZ1/YV)4ST01.-U<6:&WI#Z_A[+#6.I_X7,7L-19?55R
MLFKK%7ZY*1J<1+55I.4R0BI *Q*QZ*#>0@SK&8. ;H',E[TR&#6PN+5VQL+)
ML=9N5F4[\L89+V%1KUV3JWU3/CM(\Z@:(-$H HGLX@BB58YIT%ZVL(*J(=7M
M5 $![J-NLIJ$VZ3..^K:!#W)\ZB$R4TP*9@ISM7/C705WTQ2=#/*M(0-#UHX
M@G^NU:=8INIVND3-<$XQD_6KA#/&U@C)XIE7"CJ61??6/E73I5VHLHNH8>UL
MV7+Z=FQK%7:X,2EU4RK2JJZL-)E !3(#% Z8+JG3XE!(6M4AV ,1%JUJ]2DS
M7@A3JC60]JK01:AEN+17AOLEW<17QND=L;DS\1%DS;#.\RF;AZ+T/K;G.@-=
M;ZNBGL=7TI27GGSN9F).R6.P6*?>J2$Y8[/99MR\F+!.RKM057LI)NEW2WM3
M3$X)))D)WLVVV8J@<+6FC430IUD*!%:K4KQ/C0A*X%:P@B-A0,<FUC&%,F93
M)-9:#M-&6&Z[:9<MO<PFNL6&P $QC#F9GM6M:EC' K4M:P@0"(C /YA.P>%+
M1U+Q7QYLNR[1F^@M9]D<]7AI2-<QZT,G7Y&ROX20J4W:+'9JVXK4U6CI/V"L
MC%5^6"<!-8Z9114(H!(V=I]\\?Z?XQ$^HY_TGZYLM8S.,8QC&,8QC&,8QC&,
M8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,
M8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,
M8QC&,8QC&,8QC&,8QC&,8QC&62WMSMJ'I.J-Z9N&J%LT,QD$Y6,5;RDO 3,/
M(ID.B+R'L%??1DW%++-U%6KDS%^A]2U65;K@HD<Q1YRI<O58D8EJA8L9GV))
M?$"]#@GY'UWC BY#1-3($>X9XCCJ#V+6U0E'C;*R,"$2CO2?>EH]T3V.2?SI
M<':Q9<R!1S/-M*YRAR]&[#H$S7JU&#8>>ZJQK&OJ8WL#YS6]9L72:YV<NSHW
MUZD0RLKYLHN1*SOX]695;F5%%X G5.>PB];.QLME#).SLHBC;N2 RP%*4H3U
M]9L#$4T2GPPVM7\4&J0$QE9=LPSJHBK2UI+@:U9Q;--:2G^T/8XYB]:[IEEP
MQL@PU-L2R LB;0F'1)1+C(>=\8QC&,8QC&,8QC&,8QFN'Y\:;5&EL\9-U:U:
M!0MLEY&N?(V4M:$,Q2L#YBA.1R;5@]FDFY7SEJDFD4B#9=P=(A$BE3(!2>@,
M9L>8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8Q
MC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8Q
MC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QEB-Z3_0M:CH*6T'
M0M?[)6;/G!K=4[C;)"F3$A%?  MB4^:2CI*&2E1< 8%BSR:3,4?3V*E/ZCFD
M'(/'R*-E:5'$R@PBP#NX>PNQO:HT]O=WQW@SNX@9]SG802==W\656X-4H[UR
M=4E\EYX:03Y@9QV>&1 @Y[O)Q$1S"?3.Y8>G]&WNT;<T=T/I/8_0SG7]659V
M.LQUXU2VE:JR6A89M#;)H"\JQ]TH#SWKKS32-;I&+[CJHD*;TL** 95L:RC9
M6XF[&[O27:$J=GNG6U$V%IAO\!@+3KX8,"WR&9$ "<\<UUXS"U7V5M)#%;6U
MM&+*IQ91*?O2[:2YHCPU;#?L267\+M!8#)3$04QE/R%DO&,8QC&,8QC&,8QC
M&,9J;><_E=*K=@\!]8%W/N284V1W5S'1CZ3F+6H[TO52U^2@61;'5:D*94HR
MP2/T7SR+T%#BNX=NU  HJB&,?I^O/Z_XYMDXQC&,8QC&,8QC&,8QC&,8QC&,
M8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,
M8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,
M8QC&,8QC&,8QC&,8QE!;-4V4E1YX^H4*<YV(5LG_ "VA?U)=*I'="X1!4)A2
M"$LJ5 &HKF)](/R"N"0#_0)LY-EL>.5]G'E#S=_=SX??D\?;_P"9].SNX'Z]
MV=4^'OGS^7L\;.WQ=G=Y>PO%SW^NSR=ODX^;L[NWB>,QR>-F4[*DF&S/\?F>
MO I26XMW)-%T'.P%;T2?0V \(@VBT[2H>.#7+=#ZI*KJ)A]4:,(P,43%%01M
M8BC.@Z>*(=%N=!J"3Q*I(ER#O.6UX^>-I,P$M[>!B>Z"B.8B(EF;$;K;#$+\
M(W^&]LEXHF*%3L^!B)[81)>S@HB89+./?.96,K\[8QC&,8QC&,8QC&,8QC-3
MKSG["ZF?]>\"ZZM&D*=#\HPO=O,4OK?>K.YNGMSM=V>2,$K/UJ4I0MDVL0PC
MGJSYNB_^==1PFS14)[/F. /W^_W./]?Y?A_/\_7N./\ WVQ<8QC&,8QC&,8Q
MC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8Q
MC&,8QC&,8QC&,8QC&,8S5!\T/D'\O/$O7&HJ9SR?GMKH+IJS5/5N@S7"M-;!
M:W^S54X-C:4+2X4EV1X6&":LL25B^61.B5L=<_H()#ZL9L <*K=C+\UTI3O1
MOKQKTT,A:@NJ.K02"FEC2V63+4QCP0561!<U9",,_P#C4$/JQ5$0 _N#&,E]
MC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8Q
MC&,8RR&\=WL-+0D8Y3I5ZV5;;*\4C*?K_7D(:7L-DDDD@652^I<*LX2#8-D1
M!9Y,6"3CHULG^!7.L8B1^?+6.&O73+7$LW%)&"4)2N8@W6'LD0 !DHB 'O>V
M>82EDB7'45AXCL.:*4+-:R/M-IDUW="E*2H3:PV2,QS PL/1-8L/FR*K?J?L
M2 4+/7[@*T,J$8QEG:NO]NT>\[ B6/J)S/'M)!"%1>G01]5G3.)G';L#$,DU
M3>*B4II0C47\MJWXIB/;U5VOJ+F.>988<6(7''$D%<Y_&1B(XR.4N9'=53+)
MY^5-AJZ]AG,\0(]Q$B&%]8$W@'N!ED3[R=5"O$#LBH0=VK)GXPM@9$>LBRL6
M_A91 HF,FJVD8F40:R$<];+$40=-':":J*R9R&*/H CFQ7.LTDF2RF! Q-1B
MQ3%L 6+8LQF8(# A*/I,1/!0)1,1HAPO7WB)AP;%F#!D#6Q1DIJR&?Q!@$,R
M,R)<=P$0S$S5^<,[8Q],9C]Z;[ V[SD\MMS<<S2<_P \:P3@7FQ]KN]AP$-.
MN8R:<MF[Q]K'7R#&8?W/^7!=I!*M9:3JCMRL51O$I/C 0Q^5=P39I*O%%1.S
MW%+0T2""LV9O[&VBA1?:KB( C76+EE"O.#WV07+GLJ@"IY[64D%5S:?%VQ6U
M5_<VDQ,(4NIKD6+5FL-AD_-L/A:CG HEA6GNKKFW!NF%^;O3O"6U[=#4C4&C
MIC>$I6M+,>B-G 2Z0U!/3]42:SE*,=QK>9CI)Q9K9)$CI5=K644X[^B.4(K(
MI'4(&8LMF@>[?L%G7U/3ENM0VVQ5$62"[8AS)54J+F&6AK5D%9M,\B_&MB86
M+C.8':O6.[0T5JG(LL=2Q=/356S"(:N@FBQQVWES%3O9LJ:$1*V>1A.YD!04
MSV=B=XG3;:(CN=]2/M\W??NKY?=M9K+BY1.N&4;JVO,H9S+S<G.R["6($K]5
M8(N*CH5%B=1Z_54*=RV21.KDK9HM:G9[RA:1,IZ9J_&;RVHH*$*.RRM6743_
M 'KEFS*+#5H@E1"4D<L[I$"X:Z5[+2:S=+.4AN=BC4ZZN\)!DWFTWWFC;F9B
M:J*JD$%AL@R1:2UPN>Z9CY37D#@GNA=#[7U9K>8V!=^C[:37NM=5OI^,J+DM
MW9/)..M459K0^;NV$.PJ+^#EVTI*(L7X+&;$,T:JE7+[<VJ[U;>AJ*L#99L=
M.WJ*NXR^'7]Q)U=/<E<*"AI"XZ5^I"ZDQ)$]DJE@=A3D)=Y(ZNYM+HNJA1W*
M>G'I%?G9&[L;2SJ$51F)6$H9:J/.+<R(?#"+H">\1R\7./5,)O+5]ZO=DK#W
M54_J&XW?7^X:?+R3>>"DVG7WM6GTV\]&MD&T_#GCEFTK'2K-FA]6S<E#Z5-8
MATP[/KK&IJMA6=-BCN=>.PJ--<H<,0]]2Q7L(DC\5BM;JV$F,&8E "P2D3B(
M[!-M=F[2OU"IVZ3EB0>07*L5K-=-RC>K-&!\E>W4L*8/< &MD-28\K[BUHO*
MCY-^%^V+_P"-S7',/0=8VO=JGY#=$6">K\+%6EDZ8PR-KC6*\@=::@HUH9%%
MT8B)BIN#J&,H42$,4!$(G$_E^_W$YVXGZ\3_ +9N%XQC&,8QC&,8QC&,8QC&
M,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&
M,8QC&,8QC&,8QFJ3_$E__F$\*O\ _-Q#_P#M.FL9C\9_E'^I9M;8S.,8QC&,
M8QC&,8QC&?E10B1#J*G(FFF4QU%%# 0A"% 3&.<YA I2E* B8QA   !$1  Q
MC*;K=TI]R3=JU&U5VSI1ZXM7RE?F8Z7(S<AZ^J#HS!PX!!7\#_0J)3?@?Q^!
MQCF/SRIL8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&8^.\=E[2
MI1M$52C;!>:2K.U-E!2KKO..J#*Z/J,L\9?_  =#HQTHT?Q,<%VLIVL$::E6
M:S)G[RI&^)5PDJ3%)+KFY12 X$IU>SNTJY#'CVFSI"EB-<ULS'C5\--NVQ8$
M#K UY4E@%SSV<2ZVGO7O'YV(MZ]+XB3DJ6MM$\+VT%81/D*J05U1)=RTS8\S
M%F"YC(=J2W8VD-@<\3>U^CK3?>A=P[E1I,GS1!P-=-J&;TJRG%HZ?N\1%Q$4
MYDZK)5NIBRN,I9GEE^(LD*D8JU*DX*V"UU$T;6QKZX:_>BQH;6WZB;889GT]
M=^[+-BN-*S'C6-,-TI6HJH8+BO+:1]QM 3BKV4/30NVYL>$J6SK:[IZ5 ,GO
MU1?JH/XZO\QG:NZT[%^P:O"&M)<'$>$"$LY)2E* @4H% 1$1  ]/41$1$?T#
M\B(B(C^X_P!\J\G?Y9^L8QC&8G.HM/=R[?W]'*(4#GO9W*U*6K\_1]96O;%S
MH#F=O\>J1T-MVTSC-<6Y&W1];= #BHU-H\8P[:201FI9.3?-X_Z';2.*K<;=
MO*7\6%T@U=M,0^-3KC7X'6ZU5T+$]XX#= W#; 5J[)KU14PV63[W#[JT4Z3)
M75MTI5MQ8OML7&RTCFH%D#GQ:DUPH+-<5>:V0S#G36(JI=GHGE;IB4W7:]W\
M^HZ65G=W\U,>=-K0^RINUQK.F(QLC*R,7;::Z@(*2&RE8!9)QJ>#D6L 5Y]/
M'+"_;^Y5(D)]8[-;J30,L2&CZAV&NV1715!;*H^I7;K;916(O!8*YKI1(05E
M<5[")Y\P,*<[C=A2.G;JZRYV_34;445NZ5TKRMG.OLK0VS RVL%*]KX[276;
M+TVV<BLDAW=2V\4;HU*_Y5O?+CC6ENO7/?/EEYJE8G<$M8JS!SU0LK.N. LS
M.7K418'3>5BK#66KO[4I&BB_8.W#<7S91--3+3=7[6UV_6%D!37H]9T55+<>
MS?K[%*W8=0M+"?EM@->[<0ZL3*\$PEM%ORD)5VK4NET_H]99,K-[0;@=RFP(
M"M=\WT7U-C39Q,?"+>QB;*G@MY*E'C\,P<D/G2' >S*5SWR+"ZPF:%8MY\I;
M0D=PM"7)>=AJ!;K!=Y.PS&Q:^G)Q;23F(&-<.[*^0K\D>(DUVS=JV%TS.=10
M S;NF/4.JV])<.1K>EG]&^.P?P[7:MVBUFE"_)*%X#;66IKVYK<>)DL:F&C
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M+,.(DYF!G-M/<NKM(UPELVS=X&BP"CM&/0D)MT9(';]Q_P"4S8-42+OG[@P
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M]2BME2'+'CVUA*]W=<B*C!S Z]<BKI_63H1.B>2VCLID5>)8M8M4H*2$:Q=
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M,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8QC&,8$0 !$1   /41'\  !^HB/\
M8 QC-?KO+R<6O;%_M/CD\:='BNE>F[;#2U3W%L 7 KZ/YFJ\XV<0TW,;#M"
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M3M:GGD?%R$C5Y"&>,Y5FM(1;&00 Z[9TT*HA[C]'IKS1TVSIL:=3=:T;REV
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MF?D<U2K5RNU-F86R&@WN@@(3AZX54])JM:Z"L6=)NHWE-\"M2K-AU2U4OU+
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M'FBM=U<QS5%Z2/;XJ0/=[A)R,&XF*F6EIF^YPPP[M5ZU^XN" FX^A^5(_M5
M,9CZ_7]?7[_?O-L+&9QC&,8QC&,8QC&,8QC&>/,V& KC11_89N(@F*13'4>3
M$BSC6I"$$H',==XLBD4I1.4#")O0!,4!_)@]<Q$S$S$3,#QS,1/$<^HYGZ1S
M/J.?KCF/SSZ1,Y"SS5-]!R\9,LEDTU4G<4_:R#91)4!,DH1=HJJD8BA0$2&
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M:-O:.M-4:_8F6P?GAG=,& =D#*P]SW\QQ,_3Z?EG.*8I@ Q3%,40 0,40$!
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M<6/2HTK88BRP<@E?N380C)GV",3,P #)F7': QW&0Q[SH"F&+#$9D$AY&ES
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MV[P+*Y4L5JXGQ,S+;!J\:PB!F9,I[?UYF,DMV%)266"LI)2@EARM@LF!CWS
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M5*@5G!*^Q%T50YA$OL*!F/7Y1']9_'W/X_O\,P<>6?P5^263Z7BI+6DKT+Y
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MM<M[F7KL5(+V> AW:C^*AIY1RU4-*1D<^55=LF3P5F[=PH=5),ICF$<KF4Q
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M$5Y82U+6"P\KB@WO.%B/EL.D0\KV2;60M8D<B Q$959:6-:/D(W2/=+&L;V
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M*GS#$LJ.K!93$V5=R)N17:%B*4$4MD6H%OE60Q,"$QM8H<LLKK;R-#LB0/\
M%KW L36L=B"F&MJJL#*66@C@((7PLDE!34' >W=O=.\AUZ[[?8R=+N-M0M3
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M)%TJ_&)A R\2HSDBK& 73!9R>/51<';F<'VW=E%_7?:*FN1R_J_<ZC;T%L"
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M=HU34>?(W^J*4GSCTJVZZNHND-D<G%32],%J;LP$$V+9='3HXA(<\,5%Z?\
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..&,8QC&,8QC&,8QC/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>img128415308_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img128415308_0.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" ,I ?,# 2(  A$! Q$!_\0
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ME%)"X B5N5/"[=RDA3M)W%3!)J_BZ&:::#7-2OK6$,GGV>IO<*%'4/L<XZ@
MG!&5SS7TJR?#7MRK[V?//-<1;27X(^PI/VP+..ZGA/PR\;'R?,S(-.7:VS.=
MIW<Y]?>HF_;%M%@27_A5WCCYG9"@TY2PV@$G&[IS^AKY0M]6\6WEY;01ZOJ%
MS/@%H+6^>5XF[!D5LCH1C QSD97CH(8]<NIK>*ZU_599'E\HZ?IU[)<74KN
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ML 9 5"G<02/E.[ /3(-?([ZQXKMM*GU6;6]2^PQM(=LNH-$S@*3L4L^ >#G
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MDJVPD'PB\<,QD*"/[!SPH()] <U\CV^H>)9[&9)O$&LW=Z"R_P!GZ=?O*QV
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M_;&LY5F(^%WCD&-0X4Z:H+98+@?-[U\UV>L:X;I](U*^UR6_"&<R:?J!>2U
M1W!,09F< (&.[@EUSR,&-F\3&RQ::]J&H[4#D6M](9XE;<0LD+$.H(1B-RY
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MS7<9)185Z,^Y=N%!PK-NP.:\]T719-+N+_3+E<VOAY$GE6=79#>?=*NCK\R
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M [MF4900WLFKZ/<S:?J/B34KV'2]#6+[2NH$![9;<;=IC8;A(,$*NPGJ ,G
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M]:N56V95"@^3. $1V93G=LSG:&!/S<M2CRZR5_16_)_UWL=$*KDK1?XW_/\
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MGD]5<EA^))KYC_8I\%S^&I_$U\IUJ;3;^UL7MKO6+:\B^U'$K-*GVAV&TE^
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MDD2PO@ARRKF925&SY6&W;6(=:L=%T&]T[3K1(=P0S3S%?,NI%0(-Q4#:" 7
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MD-Q"ITQXI98E1I(?,E9(OWC*FYI2J\G:<5ZVRAL@C(JIH:A;G4P!@?:1P/\
MKFE<]:I4J0Y92;]=3:G3ITY<T(V]#PW]D56MM4\4PQ^"M.\)6<EO9W<*Z?97
M-N\22&9H[:?SF8/*L7E2$IM \[:0"*^B_"<?DZ#9Q[I'*I@F:-XWZGJKDL/Q
M)-3+TKCOA']D\G4_LHL?O1[OL*W [-C=YOZ =.<U'Q1?E8]*E2YL/5GV<7MI
MU6_3^D=+X;U!UUS5;!K._7=.]P+F: K!CY5VJQ=LYZC  Z\#'-/5-<DL/B!;
MV<=S9H+J*-7BE6X:8@%R-N/W8[\\>_:L[PK]D_X65J_EBP^T;)=WDK<"?[Z9
MW;OW?IG;UXQQFG>(-:\CXG:;8[]0'F(AVQWA6 YW]8]ASTYYYXSC%:1C[R]#
MUE03K27*W[E^W3?6Y7^*WV3SM'^TBPSF3;]M6X)ZIG;Y7X9#=>,=ZO\ Q*\G
M_A&+C[1]F\OS(\_:A+L^\,?ZOY@?3MZU#\2+B6&;2_+GFAR7SY.JI99Y7J&'
MS?AT_&M#QM#<SZ)*EH)VG+I@6UTML_WAT<@C\._2I6T/7]3*$N6.$;>S?5?S
M?A\_4@\*^7_PC.G>3Y/E^2-OV<.(_P#@._YL?7FN)_X4KX+\6W-]JVJZ!:WV
MI7-PXEN) =S;)&"9P><"N]T6&>WT6TCNEF2X6,!UGF$S@_[3@?,?>JOA]2EA
M(Z?\_,^5]?WK?K3C4E";<'8\/%1A5J2YE=7?F<5!^SM\.DC;;X5LPX.2/FSG
MT)SR.GY"IX_V>_AX8WV>&;55D R!N'OG@]<]^M;OCCXD^%OAK9VNH^*/$&G^
M'[2ZD\B*;4+A85D;!.T%CR0 3],UQ\?[5GP=1F7_ (69X9VYR/\ B91]_P :
MU^LUOYW][./ZM1_D7W&M'^SY\/X9C*GARV64G=N!;KQSC.,_*.>N!CI2']G?
MX>E2/^$:M!N'S%0RECQ\QP>O'7K5?3?VGOA+K&H6MA9?$7PY=7MU*D$$$6HQ
MEY)&(5549Y)) 'UKU&CZQ6_G?WL/J]'^1?<>=R?L_P#@*XFN)+CPY:7$DTC2
MN90SAF8Y)()P>_7IVJ.3]GGX?3+ME\.6T@X7!+8(&" 1GG!&>??U->D44?6*
MW\[^]A]7H_R+[CSJ3]GOX?7"N)/#5K(KG++)N8'V.3R/8TQ_V<?AW-'L;PU:
M,>1N;<3SU[_3\A7I*TY>M'UFNOMO[V'U>C_(ON1Y@W[,OPWD4!_#%FW &3NS
MP"N<YZX)&?>I&_9L^',BN&\+V+,V,/M.Y><X!SP,]A7;6_BK3;G7I-&22<:C
M'&96BDM94&P'&[>5"D9Z$'GMFK>GZUI^K9^PWUM>[5#G[/,LF%)(!X/0E6'_
M  $^E+ZSB=W-_>S>67QIJ\J5O^W>^WWGG_\ PS;\/6DED/ARU+2C#'+<C.<=
M>*4_LU?#@Y \*V*C=N"JI50>^ #CG^I]37IM*O6CZU7_ )W][,?JU'^1?<CR
M\?LR_#A8T5?"]HH10JXW< #  ^:G_P##-GP[QC_A&;+;_=VG;G YQG';/UYZ
MUZ?11]:K_P [^]A]6H?R+[D>8_\ #.'P^:'RV\-VKJ!M 8,1M/\ #UY%.7]G
M;P!P'\.6LW))\X,^3DG)R>3DDY/]!7IE-I?6*W\[^]A]6H_R+[CS=?V>? *1
MNB>'X$5HQ"0K.!Y8<.%Z\C<!^7I38OV=_A_;[6A\-VD4J\"50P;IC&<]/;MQ
M7I5,I?6:W\[^]C^KT?Y%]QYHO[.7P^BY3P[;+A/+&"^0OH#G@>W3  IK?LY?
M#U@,^&K/?TW88''/'7IR:]-I&IK%5_YW][)^KT?Y%]R/,O\ AG#X=!UD/A>S
M+KD;L-DYZYYY_&F+^S;\-XM[)X7M%9T\LX+?=P!Z]<*HSUP!7IS=*;5_6:_\
M[^]B^KT?Y%]R/-/^&</ARN#'X7LXFV;-T89>,Y['UII_9O\ ARRA3X6LW4#
M#*3CW&3P?<=*]-HI?6*_\[^]A]7H_P B^Y'F3?LY?#EIO-/A>S,^_>)"&X.-
MOKZ<?@/04U?V</AO$JD^%K(A<DD[O3KUZ^]>FMUJ&;YF1/4Y/T'^11]8K_SO
M[V'U>C_(ON1YU_PS_P##Y$5_^$8M1-D8(+;N"2!G/8D_F:&_9]^'R;)/^$<M
M4D1A)O!;D@@\\\C*@XZ$@5Z&N&9I&^ZO _J?\^E"QF0[W'NJ^G_UZ/K%;^=_
M>Q_5Z/\ (ON1YVGP#\!;TD3PO9ED8,LC@[N.G.<D#T/%/;X!> C#%&_AZWD$
M> NYG. "Q Z^K-^=>@^<O(4%S_L_XU&TC_\ /,X^HS1]8K?SO[V'U>C_ "+[
MCS__ (4)X"2-8QX6LQ$K^9MB+(-VTKT!QT)&.A!/J:;'\!OAZL2PKX:M4V[B
M%;=QGKQG!^M>@^<%^\&0>IZ?F*CVB[4$C,74#U]ZKZQ6_G?WL?U>C_(ON1Y^
M/@#\/F5?*\+6BJN-IRW)&,'K[#FH/^&>_AML:(^$[/!8MY)W'KP>,],<>E>B
M-(Z$JGSJ.K8Y7_&E*QJH?=@]1)U)I_6*W\[^]B^K4?Y%]R//5_9\^'BK&LGA
M.R.UBRL^7.XG.3D]<\Y]:D'[/OP[^7/A:U(5MV-SX)YYZ]>:[WS'N%9"-GKN
M_F!21QC.R0F0]BW.1_C1]8K?SO[V'U>C_(ON1P#_  !^&^)!_P (Q8!Y%*2-
MD[G4]0QSD^G/;BF-^SY\-9$9!X8LPLA!==[?.?4\\GO]:]( QP!BG;0RX(R*
M/K%;^=_>Q?5J'\B^Y'GB_L__  ^60NOABS#$Y.-W88'?M35^ ?P^B3R!X7M$
M1DV':6 8#H",]J] \DH<Q';_ +/;_P"M2_+<1D8((Z^H-'UBM_._O8?5Z/\
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MA_>7\Z+A8A;K5=F*M*PZC"CZ_P"2*N-;L>1S_ND&JGEG" @Y9B_X=OYBBX#
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MI;/F1#ZOG]:@+=&/3:S_ )G/^-6+1=K0COD5?074[->@IU-7H*=7&6%%%%,
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M5XU^SG)9:9J6M6NE_P!FRAX&N))[6S$!C92JJC$$_(<LP' !W'N:R37-*_\
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MUD,;O+(KL(A&&.2I8AG.!(,=>,OP//HZZ3XE&K6S6&E20V<%VCVD=IB1LJS
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M<T3)Y2A7?S&WAF\W Z@1*Q)\P4WX3_!_6?AMK-U?7UWI:)'IWV%I=/$Q?4I
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MA6^F+)#JJF.+#/)Y1D?>PVL\<B",(-WW221UGRO:WZK^K?Y#?PW_ *Z_U?\
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MVH1Z+^OU(>TGW?\ P?T/HFZA*,V =I"J,]N>GZU'M/F CG,A_12/Z5.LA3S
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M\FE7!L$M6'D30I=M&H D=I ,'"* @W;=S'<<\<GPRE+R_1_U\_N\^6L$O/\
M5?U\CSW]FOPG#I/Q"\;73RWFH[[;[*^I:EHMSICVT@8.8?+8>1EE>-CY>S[B
MD)R373_ _1XK/Q:^R]T=FBTT@KI\,Z&X5EM<.7>)%8#9OX9B/M(SC=D\=^RC
MXIT_Q!XTUJ.#1M#L1=:6US-'I]Q+-('62.)A(6N)58._F@84$+$IR0^!Z/\
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MO(M+/_$VL_\ KNG_ *$*4MA]3Z1[TZF]Z=6!84444""BBB@ KDM2_P"/^?\
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MF=F!!R<TVGR1JR_,H;ZBH?)C_N+^54(4S+T!W-_=7DT>6TF"_"_W?\:< %&
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M(6MU=-Z/M8EIXGY5@OF\G' Z']E.PMM'O/$FGQ'3WN98+:_W:=-%=((9&F*
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MV6DXCL[6*WVQQQ,R+\S!%VJ&;J<#@9K"\6?$:S\/S6EM;6=QJVM7D1GMM)A
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M-\+? _B;Q-XQMI=.U_Q==QW+6$Z[)8H8PY1I$P-CLTTAV]AMS@Y A;FA];N
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M'[1X1N)9&FPS2;IEA+N[-SDG("G!KO? [:FWPE']K)JEA?3-80-)<1D2[H@
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MPZY_QUINJ:QX2U:PT9K!=1N;=X8_[4C=[<[A@APA#8()Z?K705Y_\;/'&H>
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M?LX^'Y_AKX=\)IK&EK)(NGZI#;+=I;AW)+PRAPJJ6);$R\%CD#I7T#_P3_\
M@RGPA\+>*QJ>OZ=K'CC4KR*36[33[U+HZ>55S%#*RDCS<O*S'_:P,XR?C+XT
M?M+?';XQ7&@6>LM>> _"WB>X^S:=:64,EI#=)N168R']Y,H\Q,\[#G@5^AG[
M)G[+=C^R_P"&=2TZ#6Y]>U#5)8[F]N)(A#$&C4A5C0$D#D\ECGVZ5"-'L>ZR
M+NN F> =OY=:DMW+S2''4;A]1TJ&)MH=SV'\^*56,<.X'!+<?A_D4R#C_C%)
MJT?P=\:?V'IL6LZNVF3K:Z?- )UG?8<J8SP^1GY/XNG>O!/V1=-T&Q^(VN0^
M!?#TUCX6ET.V:_O[OPX^ER?VFC[6C5Y &=64NY095" %ZUW7[8$>H:9X!3Q#
M8Z-!JUEI-O=7%ZLVN7.F&.&2+8VTP [V(.!NQM."".M<+^RGIUUX1^+VI:3J
M6@VVC7MQX>74X3;^,+O7%DA,Z+@K*2J$''S=3GC(SB*?\5^GZ2_#KZKR+J?P
MU_76/_ ^3\ST+5/#-KJ'QY6[B@NI[6WFCEN)8=.N)(DN4\AD1I%D\L9"HY8K
MQL3/05ZUXNL;?5?"MS:7C!8;AHXI&(!^5I%7NC#J?[OITZCS2.Z\.0_&2\LK
M7PY>WNN75^MRVHR74:0)LBMPYV^8&PJR1  J2S$XX!(].\82RV?AO5KBW2%Y
M8X&:#S\; 0,ACD$<8!Y'455/2G#^OZ[?(WH7^LQMO=',Z]>6]G'K6A1P74$(
MTQ)C<PK%+(\2XC*+&,,QVJ.3ZG'85X+??$+4&\-R:<\.N6<__"#PV<UQ+H%[
MYKZA\@8,_DG.0NT/]W(^]T->[7#:G>#5;RXADLX9="BCEN9@1&#D%]C*&YVN
MQX!Y'3BO'[WQ%KWCYM>\.6<'AR[8Z1#I,\EGXB\U89&D"HS#[(Q#;B 1@8R?
MF!&1Z5%;W5_GZH_2LDA%)\\$TG%M\T5;97]Y.]^W?U/0?$VS3? -[J'BVRD\
M2>'8;>R5-+>Q%S(TH6,L2K0]"Q&3\V.>5/ \UD_X1"/QAINH^"/",5O<F422
M"Y\)-;VL5N;28Y\QXUQF3R^05)Z#(SGM_B@=0T'P%JGA^QMM4>7?I_VR;3!)
M)*T9\M)!&(U\S;LB&2.?F/([<UX/\3P1V'BO2KJXUZ-V5H=-&IZ=?;TMQATW
MS3Q *,F109'S\JCT)VAM.<?/;;9=/G^9T9;"4<'.M!2=VU9/W>5J"NXI/76]
M[IO6[/6]0L=16[UB[AU.WMKB\MK*W@@B?RS;MO49.U"P!+<#/0GE>H]$M[/S
M+6(,5\Q4"[EZ$@>E>?RQKHNGZWKD37EU=VYMED@@F2/?Y:1.%)*J,G=\V2V0
M<9_A'=Z;>17UC!<H-BRHLFU6##!&<@C^8KS*E['YYCG*4(OHM+Z+[,?ZOU!H
MS&<,,&O+-:U"ZL9O$LD$YB,-Y!(F45U#?-D@," 3@<CG@<]Z]=C829W?ODZ>
MX^HKR_Q%X>,L?B&:SNI9YKW48;9+66-$"..@5@>0=XZ^E%%KFL_+\T5E?(JD
MN?;3?_$OTON?,GB#6OAGXNUK5M+T[5K7P[I4=^/M/B"ZU68W$BYP4M[=I/FP
M03YK@@9X5J]MT>UTJR^'^LIH>HQ^(-(G-O:6LT-V+J=D4D[G?)R3S@'OGH,5
MD^)/"GCN#_A)I6\86S1BYB4^9H8VR,-W&1)QC(S@]ZN:!XFNO%W@G6M6N(TM
M[Z:2%91:,0GF(TB,T9/(4E21GL1UKTZDN:FN5W2MUOV\E_7J?IN/KK$X>FZ-
M1RA&4+WFY:OE:;YH0=WKL[*UK*YY[_PB+>*-!U3Q/HO@'X?0:->S6TUEI]U
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M=F\6+ EZ(=46.W\[>SA&\UD.<LC9(#$8&1R,^6?LLZ"L>KSZO!<02V$VG_\
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MGS%06!8]E#$X S6'XJ^(5CH-C<M:-#J%^EI=744+S>3;-]G*K*LER5,<)5G
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M J(5(<@E6)W?> 7ITI:W'=-'O6-MOC^\V?R__72NN[RHQUP/S/-))EFBC'7
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M_P#'&_X7/!/$WA"]TGQA<>']2TK1Y%D+:C+--XIU7R$B!B!5U+G(/FC^')Y
M[5[9I_@V.W\'W>FSO:Z-?M=06IM]!5;B"V4#$85'PP')ZX/'3UX;Q9\%"NH>
M(O$%]XM\1/>!DL[>YCEM'+J2I=)56'/ 1#S@X 'U[N\M;CPWIWC!4UB^U"ZL
MXK/;J5Q,J3,PSGS&C5>@//'3'%>C4J<T(I2OMW\C]!S#&_6J-"-*MS25K_$U
MS7AMS75O>5_3;<^=)+'Q)I.H:OK]WJ.LW-]<7N#J^H>!IF>-07W(F)R(E]45
M><<]*]NT_4#<>&;W4I]9M]6CN[ZWE6^AC6"&7<LA#(NXE0>H!9B/7K69)\3O
M&-D+^)+GP#''97XF,IU>:<EY03\@\A=P!D[%2,$9[UV?@3P?I&A^!=&T*/4Y
M;]_MJQ2W42*OG%5D*LHW$*AY((SD8X]+J5&XIS7;:VVG9>AOFV,E*E&>*BDT
MU;E47[J2>\8*UDHV5[.^VAUO@YYSK'B2)MYC2[)5#G:I)8G [9KJOF_NU@^#
M;/[+J&O7JW%Q,MW>./+EC51$4=@0".HYZGGBNH\QMP.^/\S7DS>OW?D?E>,<
M77?+Y?DK_B5O+D_N&OD?XK>&;^^\>>+7M;;5+8I).TUL1>&&[BDBMD$$91E4
MO=. H*Y""!BP)SCZ_:8^CD^W KYC^+GB#7M/\;:KI@\37'VZYF+Z/I>BZM<-
M>-,\<2P&2VA4E(80ES(P;*2[E+=/ERC_ !%_75?UV?4Y/L/^NC_KNOO/I@6I
MQEF"_K65XN:[LO".MSZ5#Y^J1V4SVBR)N5IA&Q0%<C(W8X)%:ZM\O#,H_O-_
M^NN8^)-B^I_#OQ3:6\7VFXGTJZB2*0'#L8F 4X(.#G'!!]Q65:_LY/R9=*SJ
M13[H^?OV5?B%X@NO&6JZ;?Z7K^H65[:VLDNJZA8:3";:Z5)!*DC6;C]SA46/
M<K,,,,@4MUK6GZA\8KB[U8:7;16NJ6MI:6UAXAL4:W(*+M>%4WNQ=MV,Y^?;
MQBF?L+:QHVK:+KITJ:.X:VCM;:XD@T+2[!5E57RN^RE?S2/^FF,9R/O&NKL?
MB/>>'?B-)HWB'P=X:MM4FOX4;5+&];#>8%"2.?LY"2-T5)'5C@ 9X)ZI+][&
MW]?TCFC=PE?^M"3]I6UTZ.XT759M%O-1N[&17;>9XK*>)A(@ADEB<;#O=7'R
MMDJ 1SQJ:%!IVE_L[P1:W;:C=:;-$QFAL8)9+B&.6X)!4%GD*QAQALEBB;O:
MJ/[4S:;J'AS1=(:\CM]=N[X_8EGN+=(U)@F#/*)B!MV;PI'S;RN.]=W\)-/;
M2_AMID!:,32":5Y(9(I5\R25W=E,8V;=S' 7@# [5SV;IS2[_H;WM*+\OU.%
M^ /A_P"'UE-%J'@^77;J^;3402ZO%=)B!BASF1%0L2$Z9/!QQFN3^-"Z[#XZ
MU'S5+:6UG%_;(TIYO*_L[?+Y?VOCT\[/D_-MW9^7%=_\)_A3JW@?6I+^_?34
M061M)9+"6=Y-5FWJWVNY$G D 5AQN/[QOFQ@5QGQ,TF^\;?%!I;CP_KUMIEC
M##"EY:Z-Y\=\ZRR%DE)E"O$OR%0RD?,Y]JV;YIP_KO\ U\R-HS_KM_7R.]_:
M*A^T?#&>%K*.[M)+JW%RK6XG:*$R /(JLZ L!ZL!@G@]#=^!ILE\ BXLIWN1
M/=SR-)-;) [.6RQ*HS#K[] !P.*SOCU:V&N>';;1Y["YU^X>Z@NY-,L51YFM
MEE5)9!&X(<*)!D<8R"#D"KOP)\,CPUX(6T"WJ!KF65DOK!+)QDCI"I(4'&2<
M\L6;C.*FGM-_U]G^O7\'4^Q_7<]&M28X0#PSY(_,"O#OB4WPZ_X3>^.O_#[5
MM=UE;(R37=MICW"/:J!SPV" 3CID[2!G!KVP2"6X<YPBKC(KP/\ :7@M[KQ-
MH:ZIY]GI1L[A3?V-JLLKMO0F"0F5 8BO.PA@Q'.,#,2^)?/\G_7GL5'9_P!=
M5_7EN>X:/<6LVAZ=<V"(EE)#&T*H %$14%0 .@QZ>E69(_+MY4SR3G\!_G]*
MKZ08Y]-M?+($+6T;IA @"[1T4<#C/ XJQN\VXC/0.-N/;I_*MY?$S&'PH8S&
M.&-Q]YN/R_S^E,/_ !]%1T;I^(X_G2R/YB2#'"$%?8=,?RIDA/[M^AQC\O\
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MZ-ZI*Z?-%JW5+17O*_*CTSXJ:YJ7AOPSK\T!MK&&>VT^&2XFMD(M%D9%>5R
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M]ZD8MW?]?K^.IDO@E)+3^OZ]-#VCXV>)_#?@?1[36M9\.6NOSS3?9H5NUA7
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M9QBD!]AK*AMI,G'S $'\::%?="OS+#C_ ($,D_I^M4=$COKCP[I<^KHL6K-
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MF6;>%19&W1B/R/F]2PRW6L'QCG4/CE<Z;)J"Z38-?6$MSITTERT>JR*L;)*
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M<\#6GQ:MM:M?%\&@^-8[F*21;J);RWWM$8DCE+ -"&23Y8UEC!+!MI)YB/\
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MCK@9Q47G _O'5@!TRO3WI6*!MN52-3SV'TI/.CD;)=0@Z<]?>@9-:R*_F.Q
MPA(5N"/>A8?-A=P?+&X87'#<'DBB!4N-S2 &,*2H/\Z14=H)"IS%E?E;J>O?
MTJ0'-,9HXT V<$;NH/)Z>M/^2QO 1_JV/(ZGD=O6F-(MQ;HB#E20<_PT_<+6
MZC:5L\+B1N_ XI -7S&65D&T;03GDMSZ?C3C"LENDH+.5.#SU4^U"LT5PR(N
M(VRH+<8/T^M$$;*71G(5N0%  #?YS0!XCX@W-\8$TBTM/MUC=:C:ZI??9X[=
MY;:2-$V2/*7!BC/EK\A4R,-^P[2<>N>-[-KOPAJ_V8M',UK(O[L=]IQQWST_
MPK!F^$NB:AXU7Q!*T_\ : D2=,)#MW(  ,F,MV_O5M>*(I?^$8U:!79MUNR,
M/-2([",'#NI5>,\L#THAI%+^NB_0Z\._]I@UW7YG';9KR^ET^6[6.*?0[6%I
M&C/#M(!DY=1G!^[NYR.O0Z'B*UO;2^U+2(KB\NH?[*A6/[+$LGEMYFW?Y1)R
M3R<XQCZ57O+S3HH]5"6:/<V>DP323SS]TVL@<*0%"D YX)YP,8S7\07,>N6N
MI:@)K2&]ETB+%S9H[3^465L!F!C9=Y;& 376[W\CZJGS2J1NM-.B>ONZZ#_$
M$TJ6_B!5B2 BP@(GDMU61I, $-M&>2!P2>1TK1FM;BUTGQ)JD.HM'<-##"/)
M 5D(1"6!WG!(?H0N..#U;+U"\TRWN_$$M]917\2V5FEPS-Y3S9(P"P(YY& !
MSR!GI6AJ^H6DO_"2:0\5@L#PP7,B71DEW[@BEF1#NVA0F,8Y'/K2=]D2E+W%
M&.GNWT6J_=W\_P"O6QJD]VL>OWAAN7!L;?$-W:QM%YB[3NWD$,<MSUZ''05Z
M)8R/]AMLG9F-2%7@#@=!7F.N6L+MXH^9;J%]+M0+&011P=@"&<KQ_O/G]*]/
MTV../3K6,[D"Q* N!\O XX-95/A/+S!+V,.__P!K'^OU)_\ 6Y/\6.??WKR_
MQ18_:K7Q@=0:&WLKZ2WMEF29R?W9S@B,,P;'.,<[L'BO4,K&W1LCWQ7D^O:H
M^E3^*;K[;Y2PWUM-$LVS9$^6Y7/K@=<]!4T;N6GE^:%E,9.H^3?W?7XX[?.W
M0R!X7T/P'9_$-- B6U@GDM7>*W#?ZQG.56-< ==HV@<+@G"\=;K6IS:5<>*&
MBN;4BQFL[N.V:UD9P[X#;F(PV[ P4)*[<<&JNI:DUO)XB4R36T*WT#RS63&.
M=D;(90P]AQ[DU)KVDR7EKXG6SN!>W%]=0V[6MTRQ[ .0 =W\0P!TZ' -;WYF
MG+R_]M/;E4]M-2Q#;;Y;MZW_ (6[:[)]>MO6W=6FD73W.GWMG!*J:OYEU)?[
M8Q\ZR.A1@_S$ C'?!/ [4]0\,?:X[][*\LK>[U+6#\SPOM+(9<J2,$MUYZ<'
MD\56UB2.:'Q>5^0OJ%F@610"S(RJ=I/7[A_+M5[6M3GTVX\22VSA#9:A:-""
MB,J^8 '.&& 278YSG/?L5&^EGV_]M_5_@9156-N25F[:/:_N>OVI+Y(WO!<#
MKK/B25D*Q/>$+(5.UL,X.#CG!KK?,"\;<^_>N>\,ZLT^J:]IS0L!976[SF14
M63S!YF %_N@@$GDFNB\H'G/OCO7+/?[OR/F<8VZS<ET7W65OP$VEON_-_.OF
MKXM:/XH\/WGBBW;6-.TKPGXDN_G^VW]O%)*TD4<;+&'B+%L(,*"3Z5])^8>@
M^45\PZ\NBZA^T5)?0:C8>&=5MKUXTU&]O8[LSSQ6R K+;R(KQ1-'.P417"@L
MN2F36<?XB_K2Z_X'^3.1_ _ZUU/IY6\SJ-Q_6N/^+W@^P\:_#W6].NM&L?$4
MJV\EQ:V&I#,$EPB$Q!N1QNQSD?6NQVC&$/'?UK(\4:/9Z[X9UC3M2E:VTV[M
M)K>YF#B,I&Z%6(8]" 3SVK.HN:#2+INTTV?-?[%OA'4_"^L>,X+[1=/TR)H+
M)Q<:=IL%I')N\YU \N60O^Z:)LD@ LP&<9.OXPN'TCXW:CJ5G]C.FC4=,AU(
M74%J]T)I%BCC, <&1EP4R0RX.[8&(;/H'P?^#Y^&M[J&J3^))O$=Y>V=I813
M_8[>TCCM+</Y*A8% =L2-ESU& , 8KR[XO:M<:;\;8KT6T=UKUO=6$6BSO>I
M D<3E!+ R-$0QD)D 8MGYQ@KMR>B4E[6%N_]?U^?7&*?+-OM_E_7^73V'XQ?
M#>[^)7ANWTVUU/\ LYDF>5@6D59,PR(A;RV4G:[HX!R#LZ="-'X;>$;WPCX%
MLM$N9XA=0B8EK5W=(@\KNJJTGS,$#!=S<G;D]:\Y_:*L]/;1?#OB74M,WZQ!
M. VEFXGV7">3*SQ,\)^54YDWX(/EXP<BNX^#:0Z;\+=.@AEDN'A-R&5ED7RY
M!/)N@_>$OB-LQY8DG9GO63LHSO\ UH7JW&QROPC^"NJ?#?Q==:E=:G#?VTUC
MY#2>=<2332GR=S,)78*-T4CY!R3.0>$!.7XQ\?>/? OB[5;62^T[5]#BCCO)
M)TT:5WTRUDEEP9V690<*N 4#-B,L5'4GP3^(FH?%CQD=6U;3]'DCL+)TBEM8
M!]ILIOW2O&S^<^-[>?\ )@$+"A)_> 5E?$3XA>%M6\>26^K>"_[2O+.X%F;E
MM4:)9T63*B6-5 D4$DA'W 9/J:M7O!?U:XGM._\ 3.L_:.CU?5/ DFF:-I.I
MZG<7DR1L-/CW1A1SMFQ(C!#GJ,].01P=+X":3K=GX!BAUZVGT^\GNYI1;3/N
MV1DCA/G8[2<GDCEB<*, 9W[2MT4^'T\89K.U%W!(E['*BE9_,147:RMN)R2O
MHRJ>N*J_LQZMX<7P1?:?HDUO'):W4C2:;!(I^R(6(4!0!@':03CEE<GDFE2^
MW_7;^O\ APJ;0\O^">P7-P$Q#",J.<9Z^YKP+]H[2EO-:\.S/XFT_3Y8XY@N
MG7QN?ND;6G1;?+$@. =V.P#+SGWJ*,1IYDIVKG);U/H*\)\=_#;Q=XN^)E]K
M'AOQQ;:5%]F^R+;+<3--;GY2RLB.%VYPV#SENV:&KRC_ %T&G9-W_JY[)X?M
M1'I=D&NIKT06Z*+J1F#3-M WGGJ>OYU;CC9D>4.=OW4##(^OZ5#:6,]GIEG8
MS7;7-Q'$JSS[0N]@H!..<9//7N:FN%DV)$"K+]YN,?09_P ]:VD[R;,H+W4A
MGF,T*&1<1[B5*\@].:_.CPCI.JR?M-:;XSN;Z34_#-YXWDT:UFU.\LKV_BF$
M[J D4L+20Q;EP-CAE7!!K]&;B8_NXB#&%7YF[<\XS^-?%.B_$/P5/\?=*U6Q
M\(>#;?XB77C:YT2[LHXI3JD%H"T:WA3[HD^5I&?&"C  YR:SA_'@_P"OBBO^
M!Y;]#27\&:_K:7]?*W4^U5F6-G1U&2I"A1PU1K&T=NWF-F+</E!^[P>OJ*DA
M*1QS"7AF7G=_%R.G^%,#2I;D$[8BXPQY;H>OYU9(Z8+:Q(PP(N<CTYZU!YR1
MMN#J4/WL'I[U*\*VRQ$C*$$Y;DKS_+^5-_U;!3]QN![>U,!P9) 0"K#\Z\#_
M &V/M?\ PI46&GZA?V%[J6JV=C;/97RV8,DDFT++,P(6+J6R#T [\>\! &V,
M/]UN_P!,UY)^U/XFT_PO\*6_MS1]+UK1;[4;.PO/[:1FL[>&290\TNT9&P<@
MCHQ4]JSJ+F27FOS7]7Z%P=G?R?Y'GW[#.DWGAGP[XW\,:HEFFM:3JB1W+6"V
MC0.S0HZL)K>*/S#AN=X+ \9[5].-\^[!SO3(^O\ DBO!_P!D[7_#EYIWC'2?
M!^D:%9>%]&UMK>PU#PZ'^S7T;Q(X9F;EY5RJLP)' QP*]W3/R?5E_P _E6\G
M?E?DOR1C%6NO-_F+(VZ-B.A&?TKR/2_^0M9_]=T_]"%>M?\ +#'HN*\ETO\
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ML.I(YQE1G(R*K?"'X?ZA\/?!PTG4[BUDN?M$T@%L\C(N[! !D)<]"W/3=M'
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M:686]\LBMM4KL+$<A3R3]<Y_*F2:#;48Y_>N#EB3QN_H!3(EDO&)W$1GJ^,
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M:%7A!^OO7.:*UU;Z3I[22))=_9XA<>7(6CF;:,LK'J"<D'W]S6];S1W:%@V
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MI/AHY$CXX8D<_A2 D\T6_P A'SGH?7ZT>2(\R;L2=@.GT IJW4"+LRI<]5W
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M+U71=#GM8[6XN$U35]"U+5"C!XP(0MDRE589)\PE3LQBOI]O+8L 2WF*",<
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MG)'[TX)YI;_PW\0+SXC7NMVNAS:5Y]]9K%<V^L0K#]D0HLWGP!/WQ*A\%B2
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MM[J.W8X8'.^0%1CZ5D_!OPUJG@_P>+'5(OL[_;9WAA:9)I(H6;Y%=T159O\
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M1M:W7Z_U]YGU2_K;^ON.[UG6O"NA_#%_&YG_ +0FOIUMX]+NXW1H[UCA8I7
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M/E%B!&,_3/[/UWI'A+P#]B?4(XXDNYW5IF R"Y.1CC&<X]J\G-$G0BH^5O\
M/\-/F>GEC:KR<O._^7^9[<E7(?NURT?CG0"RK_:UIN9MH'F#)/H/>ID^('AQ
M2JG6K/<1D#S1S7RG++L?3\R[F/XY\/>)O$7B^QCTRZBBTB+3I9);;4+5+BQN
MI_-CVQS*?F&5WD,I!&,\\J9/A_>ZW<>+=<MK_0+CPYIEII]E%!9C:UGY_F7)
MF:W=0 ZE3#DX4],J#Q6]_P +!\.0S".36;..3LK2@'\JDN/B'X:B?RWUJS23
MCY6E //3BM5*7)R<O]7O_P  ]9YE?#/#2A&UK)[-:IW\V]M=;;-:WUY/O55F
M^]61)\0?#>T,-:L\$;@?-'(SC/Y\5&_C?07Y&JVI^DE9<K['E<R[FA-7QE\7
M/&-YIOC7Q3I5U:MJ&CS.T3VMSF2%XW"AT"G[H+;>5P<@G.:^L9O'&@#(.KVB
M\$\R#MUKXI^+7BK4[/XJ^(A)?V)T4W44MD^J1M<11,T:A3"B[7.7).T,4)+$
MC((/N913YJTKKI^JV\SQLTJ<M%6?7]&9EGX;N_#^J:/%I/C*Q\.^?\L&G>*+
M$7&Y(T=U8RJ'8HBL C%4&"@!8#-:GA+PE8Q6^EZ]/J\?C^[BF-PGV*T^S6-M
M,"%5IE &Z12K%-ZJ/OD;\\<1;ZCX0O8WU2^T[6]=&H2;[K5=3M_L\3R,QF8%
MHI'5$.\94 ME .,;1J0ZQH/ANZAOK5]7\.7-Y&=LM_IGF6T]NS([F96FW[L0
M,Y>+C)!4#J?JIPJ25M;^BU^:][^M3YF$H)WTMZO3]#TKQEX@G\0>$_$4VNS/
M+IRPM#;[Y"QANG!"-$Y_U;98L74@%4;((XKSW0M7DU2:_P!:NMQM-?2.SN)W
MW_+=CYO->23)VX!;Y,#][G^'"V?[/U_XB:A+-JC2+H5JJ%#8-Y]K#&QPJPC;
MC+Y1B[%G*J>@(S7N-2E\9>'9;R8?8?#NF3[K&W67S6:5EA(!,AE5ML,:%CNR
M6FDW)\]94Z<8+D7S\O\ -W1=2<I/F_I_\ 9<:@DVC:+*MLYT_2%74[A&#-ND
MD13'%OB(=2IRC8.T9(Q\A8=S\._$UQ_PAMOJFEW4AN9KJ4ZO<"0F:>21G<!W
MZNOSX5#A04;C.2>)LM7U+2+/4_%%A<P73ZA/LU2!Y@T)+21LK_)Y>Y#*@0EG
M4$2/DDODR-8ZOX=>S\0^$EO(=,U,A\3N=BLT8D\B9V#+,C"15!8YS&2&W$54
MX*:Y'_P/-/[_ ,A4YN+YU_79HZOQCX7M?%=UJ7B"2\'@[4Y@IFU:2 75E=/'
MM*-*AP//VA@"H8E=V4/+#EDT/5-=OK:WNO'VEZJ9-/BG@LO#>F!+FY!1XPR.
MRIB8 X.W>5+#Y<#BMJ&O:+XRU#RKU[KQ!<6XD:"RTC3V;3X8WV;P6$HFFP8)
M5W# .T8^7"G'N9O!.I07$@TCQ!;PI(&DU6TB,LD;NIC^=G=$5AD%U]48JP'-
M.G"<8V=_N3M]^O\ 6@JDXR?-I][U^[3^M3J=/\37EE8V?ASPY:RZ;9V\AM8[
M6WPV2S@NK\'S0[;2V[<".",5R%]=MXIUNXTG0I$GAMM3_M33(X5DD@$@"K.D
M<9^549H3(@<X 3G"FK,WBG7O&R);:1J,5\NJS1QWDUE:O:WDXE&YOM"!FQE3
M\WE%4;<V3CDV;>"?0;^W\/Z*DL6LS6S)>ZM,SPFV65%#E$P2D<:L_)C'$9SS
MC'1&*IW=O>_K5W_X?4RE)STO[O\ 6B,>.Q.LI=V^EVEYOU5#'8?:(@XVLGFO
MO48Q\BLK;22&/RG YUO"WB)KN]U%;&XDDOM/M(K3269Y'D2VA),CPAES%))Y
M@D)QE5W[2,$5-H^GVL%]8OX<O;C^V-+WS:?"_E*MVWG!Q#\B%AO560+\V[?@
M;0<',_LN7Q5HK:QH,5]9:SIH;?'9F60/M0%9D=2[1R ,C'IR'."2152<974M
MO/\ 7R=OS,XJ4=5O_6WG_P  Z^[OA\2+ZQ%_;W2:IIT;S0ZA:J'F@C9OW@<$
MXEB8EBRLW"Y.Y1NK/L=&O[JP73I_BIX;@TTWXLWEDT@&X!\GA#\FS8 Y7>),
M!B?GP,C%N_&<5W;?8_%&HGR[C8UY;Z#8I)>781A(BRR,ZQ(&$385%RV%)!R!
M5B"W\*2W3Z0/#.J17S#RC&UM/N"E=S2>3YH8)D;MV\_,,XVFLN24%:SMY)/Y
MZ_H:\ZEK?7U:_(]5T-1\.UU>#1[:ZAGNI%N)]6NV:.ZN\$^6P Z0@ ;$4G (
MY/)/*_$[68;/6M-L[IV&J:C8/::HR-(AE61E>!Y!&<R2HT8<L>2K#=NX6L;3
M_''V"PFL?"^H2+-;)*+:SUNUCAO;3.Z:;RY0S))M,H^5UW*6<@#:139+>[\"
M64.LZK!>'7KX!8C>/(A0'EY68O&TDK8D(R?[F%R,#FA2Y9\\M_Q>GX+^EL=$
MJG-#ECM^"_X)8ANTMH]!M-4C>*[TF/R)E&(]T:0M,AC0#)&P)&N3N9BH8_-F
MJ;:U'I?B2.35UDBMM:U1-0NHLR1[K:.0M'"P4B-_F^\%"EBBX.&!)XAMY;?4
M+Z/5+O=J>O(IU2-7B^1I)=[1Q[XPVY,QK@XQL[%0PT;Z26]OE\':SYE[;K:[
M]-NK61G<QJ+B6/Y,A75P)8BHC(XA^;='6VF_1[V^^Z^?Y&.K^7]6?R/1]4UG
M4(;?4M"U"WCU32)(S"MC,Q$#VYVX5$& BD %50# YR" :X&Y\$MX;UJRM]&\
M<:;H$LEO(AT?Q7I_FSQCRN T@5F8A2NP%4W!4^5@<M0;7/$O@F#4-'U:^AT^
M*S=X+6;48FN6BE4+L-K"=I(D SM=C&O7/#"LB\F\%M9S:C<:;K=YIUW+*XU"
M[A,#3M(Q8KOC=D P\95=OW]A+;0Q7&G1<-M4^RNG]^GZFU2JI?%NN[M;[M?T
M+]CIT.DV&F>*+[4O^$RF@G66*ZBLUAL[>XVA4,D8YDD41_*&5<!6.TY#5-XJ
M\57>M>']3NM6GFB1 L%DSL1)#=,Q9&@;'[MRP9G4$*5'() K"_MW1/#]W+)9
MQW_AFYU"+;=:?K&FDV%Q$$WY(\[S4/[J-MZYP67[@)!+73M6\77EUJFOR7(T
M/2(MZIIZL8MODM,Z0E5"IN\I8RY._P"8;FSP>KD5^>?3[_1):?<<W.[<D.O]
M7;W^\I74TNM-JFN2133+KKBX/V>-S_IJJ\CKYD@R P:1D51CYT#8!!HDN+C0
M9(]?M_M5L-+CDL;:0J\;_:Y 2SB1!R!'*3AQ]^->@;!V+*^77+>QO+]VTG0[
M*^8V%I:2JPEF,N'E7S ZY14V[MSXWH,'YB(&OXO#.B0W B;5O"UY<F:YM9)?
M*:UG"S;D0IL4,8W8JV1EH(R%&P+6MW\-O*WZ7VV,K=;_ -=_O.B\+>+KSPQI
M.C3Z)(W]G/ FYH\D&=#MDDFXQ++N!8EBV$*[0!@5F7NA11Z+-K>DZO\ \(1%
M=2-.!=V2W-I*V=KF%<$H68#<BH_(4X0$ T+C2]:\ ZDPL;ESH5Z'+-JD;16D
MF'5&$@(QN !<,C!@K#!*Y-0-K7A_Q$\MWJ$6L>);F&W$173--\FTL[=&+ P#
MSC(I_>1$/(,<DL#G(QY%?GAL^VOR:>E_4UYG;EGT_K1K7[CM8/ T?B+5-;.N
M^+K'Q5+:*(VT/PM9>1F$^66 EPKF':H#8#$!2-R[@3Z!9^)+_4#!8O#;V>B6
M]MNGLL;[-;>-> \1&THH!XZ\#&.#7BL=]X5TV.'7+6RUK1TLG+VVJ:;;&=(Y
M!B5<--(JR*K*@"E5.Y\9.,5L3WWB/QQ]FTK2[BWU#2F,KR_V5&Z0SRQJI=IK
M?!8%7(_=E@@PI4'.*Y:M%S^+1+NK6^[3]3IIU5'X=WV=[_?K^AG:-K2W6K6N
MHV:75S9Z!-=%(V\RXG_L]_,D$8WL8PZ+)(I/)VNHR6QBY-(;G1]<TC3</<ZA
M<B R;A/&D2/$S,> 0"655(Y)5B2JIFK,#&YGU'PAICRP:!;X34KN>8^=,B,7
M<D;F13)M10"B#,B@-C)-+PV][<:E;:AI-RIU;1;=/LL3,F)?GS)&P2/<<D [
M1CC?@J6YWTE>7;_AU?YF&JLN_P#3M\CH_AGX@CU2\U^33&EBU>QCACLF,DAE
MM[2)/+ B+DM$Q)+2'J=S#. 0>@\1V4'Q&FLGU:"2&YL89&37+7]X;:-LEA."
M0&@).2&9<9W97YJ\[AAO/$FBKXO\/17L>JV,6VY-K([GY4C'G)*&D*,R3?.,
MD,8F.WYF EU[Q9:ZP1H_B?4I"9FQ<Z?X?M$DEEF1U(DGF+A03&9&*1*1]\G&
M1C"5+FJ<\-'^*T_%?AJ;QJ6AR2V_!_\ !_$2;1=2>RL[*3XI^&[FPDN[BW\R
M'1PES*N "CAD1$0_,5)=<[R2W'RW[;59?AY>:MIVG6EY!J%RZW%W>70\NZN&
M(!B?>,&,+N^1!C 9>IR3SUY'X1DOKBUN_"^LM>[6%Y9P02[[6,@*[+$TAV8P
M7#%W&1+D$,F:B>-IQ9"V\.ZJUT]G$\-NNIV@AU.W0*'=(W5GCD'F%E!(+J20
M,':#U>S<]+:>:27K[OZ_(Y^=1UOKY-O\_P!"QXJUCS-6?29+C9=:IIZ6^I@&
M2/=*S">WDE1 ,S JGF-P"K-DEN:HQH^FW5G+=V=ZTVFQ+#<(D"QAI(A&J (P
MQA@4(+X(PVX949N1Z9+X%M["[O;.XU'Q+J=PDT4-YYJ1QL3#(<Y*M+(SSI&3
MASMBD Y8A;%SI.G-<36>K:O<OJM[=V]Q=73M$XBEQ(26)3>Q3[A88QEQAN-V
ML7%*RV_/H_E_DC.2;=WN4/#LP\/ZMI'A;4982L<\MU)%=+*EL][,GEQ>9"PP
MRJ%C.,$!FDW# Q75:AXBNO%6FQ^&M=L[S55FN%1(YGQ=B8$B-U<\Q.N2 !@<
M@8(R#B3:;/XZU"^T'5HI;;Q)%Y86^1FF\["PQ$S)GD,LD,VX(!N\T@X<D5+7
MQMJ^CVR_\)#J8TN:',8EFMFN=3AC+E)4C#,F,(,[I22H/!Y4F)153WK>]_3N
MK="HR<-+^[_6CN;LNCZIIEWJMM:?$71;&..T>1K?6=)!N;?+#?MVJX,K98%6
M8'#-E5(^7L/"OAZS\#WEEK5E<'Q3J%Q;/'#X@6 06HW$F1;9%)"NVX;R2&_A
MP@5EKR^U7P790V<;Z%KF"I^SW5W"\;W; YDSY;E96WA@%7:-HD!)9E+;5GXD
MTSPG=7-EIKW.CS3,UQ<:/X@L=MI+)D>6J2B5I(2)))%!.5/S@L:QJ0E-<JOK
MY)7^:U^_YFT)QB[NWWMV^_3^M#L?B-XNGL/#NFZ[?W#-K"W\<NF7$LKA]L3;
MG4R??,!4E3'SRV5 (.:'PLDCT[Q%HMCY,B64_B"WO[!F5H_D,D"M&S.2[RC=
M%D$XVH<'<I!Q5L-5F>Z\6>+$O+M+.5TA:1ODF9)%54WKL5(E:1V*1E0?+(W=
M2-SP+>:AJGCKP!XCU.Y"W,FH6EI9VOFA@L!927.\,?F8J-RN<E6P0" <)0C&
MDX+S^^VR_P _-FL9N512?E]U]V?H3'3Z8G:GU^?GW04444 %-W#<%YSC/0X_
M.G44 (U?GG\9M \6I\:_$U_HFA:J#-?R>7<V\#A2P4!2& [XZ],9K]#&&:\6
M\5_LA?#GQIXRO/%.IV-[)K%W,MQ++'>R(I8  ?*#C@ =J]?+<53PE24JFS5M
MK_JCR\PPT\53C&&Z?>WZ,^(+?P7XJM[V6]_X1_Q%&;P 75G963VL4OW "TD1
M7Y<@DY!/+;1P35>Y\)^.[R:4?\(_JUM:R!I?L\6GM#'D\$N$4 L2OU.!DU]E
MQ?L(?":&WE@&F:AY4@4,IU&7H#D <\<\TDW[!_PFGCBC?3M198UV+_Q,902-
MQ;GGGDGK7T?]M8:]]?\ P'_[8\#^R,1:VG_@7_VI\B+X/\;_ &ZVD.@:HD\(
MR;B.R=)68<Y>0*&/?DY]\$X;H(['Q9#-:O=>&]:=ED:3[99VLUM>Q2* ,F6/
M!D 51]X/P,#D@U]02_L+_"B:XN)WTR_:2XW&3-_)@EOO-C/!^E1M^P?\)F@2
M$Z;J)C5V?']HRY)8 -DYR<[1^59RS;"2WO\ ^ __ &Q<<KQ,7I;_ ,"_^U/E
M6W\'>*M#VVFD:)JS6$IC:XDDL/)FEP %1UC!W8PQSD\NQR05I8?"?B=;>WF7
MP[JHNC=7 V?8Y"D>$AVRDXYW_,.@SL')KZN'[#/PI%['=?V;?M-&%";M0D*K
MM4*.,XZ "HH_V$?A/':R6Z:?J2QNZR'_ (F,N=RA@ISGL&(I?VMANK?_ (#_
M /;#_LO$=E_X%_\ :GRJ/#OB747LKG6=-UBTDT_;);75K9E[I57E4R5WQX8$
MC:<Y+8R6%6&MO%1$BV7A_4-/;?)LF>"62[(X#,]PVY^2%PJE5X'RC.*^IQ^P
MK\(_*AC?1KR00C:F[49QA=Q;;PPXW$G\:G;]B'X3--<RG0[HM<!A+_Q,9\-N
M8%C]_@D@=*7]K83K?_P'_P"V#^R\3;I_X%_]J?%C^%?%IAN@NBZD#,,>>;,^
M:1P&42;=P!!8$9&0>< Y,=CX<\:1WD*S:!J5Y;+\J17%JQ"94@[6*[H\J#\T
M>&'7M7VB?V%OA"UNL+:'>&-69U_XF=Q\I8 ''S^B@?A4O_##WPD,ZS'0KII%
M01Y.HSXVA-@!&_'"\5M_;6%M;7_P'_[8S_LC$;W7_@3_ /D3XNA\-^)QJ*:M
M!I&O37L86.TCU.R\Q[=25=<3,6.X'D$8'<8*FI(?"_B*:ZNI;_0]7N9;AY(@
MTEF\Q92?O'(^7)!Y]NE?9"_L+?"%;=X1H=YL9D=O^)G<9)4$+SO[!B/QIX_8
M<^$:M;L-#NP;< 1#^TKC"X8L/X^<$G\Z7]LX7S_\!7_R0_[(Q'E_X%_]J?&+
M^'?%\FEWFEW&B:H^FR2N'$EGYVS@J)51EQN^8\C'<=Z>OA?Q<MB]M;^'->U
MQ;8(YKZR=XHU!^5(X6WHI4@$N,8P-F V:^RU_8<^$B_:"-$O 9P5<_VE<="P
M8@?/P,@&BZ_8?^%-SI<.GC2KZ&UAFDN%6/49L^8ZHK-DL3DB-?RI?VSA?/\
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M+\[2*NTR\<'<2ZG&.I!=%X7\6:/I-SI^FZ'JB6+'+E;(0O+)EC\P0<JH;CG
MX..:^T&_8?\ A))<7$S:%=%[C<9/^)C<8);[QQOZFF/^PS\(Y+98#H=YY:NS
MK_Q,[C*L0 2#O]% _"C^VL+?K_X"O_D@_LC$>7_@7_VI\93>#_$,:1+;Z%JJ
MW<$>X2)9.N27W$;@/FR"",8]J?=>&O%NH:A%JEUINMVVKQ#RDN[.QW22JZJO
M,JE6!V#:#G&",_*IK[-7]A_X2+<).-#NA(BJB?\ $QGP %"]-_H #ZU&O[#/
MPB2W>$:%>!'9&;_B9W&25R%YW]@Q_.G_ &UAO/\ \!7_ ,D']D8CR_\  O\
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M(-SC&1RO'4<G HB\9:1,L!2Y<B>X^R1_N)!F3CC[O'4<GCWK:HK:]+^5_?\
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M]E^V_P"HD_U.,[ON]?\ 9Z^U;-%%Z7\K^_\ X <M?^9?^ O_ .2,9?%^DLR
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M-XRTB-79KEP$NOL;?N)/];S\OW>G!YZ>];5%%Z7\K^__ ( <M?\ F7_@+_\
MDC%F\9:1;K<%[EP+>X%K)^XD.)#GC[O/0\CCWHN/&6D6BWAEN746DJPS?N)#
MM<YP!A>>AY&16U11>E_*_O\ ^ '+7_F7_@+\_P"]Z?CWTQ;KQAI-G]N\ZY=?
ML+(D^()#M+9VXPOS=.V:6Z\7Z39_;A+<NOV((9\02';OQMQA>>HZ9QWK9HHO
M2ZQ?W^GEZ_AVU'&OTDO_  %^?][T^Y]],:X\7Z3;->"2Y=3:1I+-^XD.U7QM
M/"\_>'3.*)/%^E0M<*]PX,$"W$G[B0XC;&#]WG[PX'-;-%%Z7\K^_P#X'K_6
MYRU^DE_X"_/^]Z?CWTR_^$FT[:C>>V'177]T_P!U@"#T]"**U**5Z?9_?_P"
MN6K_ #+[G_F%%%%9&X4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M/6EQ7EOUFO3I5XP4Z3C[14F_>Y[Q4HM:VC=+2VMG>R9[SXJ_Y%C6/^O.;_T
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MH<D=-+WZ=_/<****@Y@HHHH **** "BBB@ HHHH **** "BBB@ I",C!&17
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MX6ZU'P3I+7<<O@9;80WL4LH_LRV7YG9UCN2-W4D. #^\.X84[AGII)6UC?\
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MX\RRF"QS-)(C2.X<HNQH\&#<6ZD.5P3IQ^./">GZ# T/@YTT2ZM+H$VT%DT
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M7-HL:+<2)&T\ET%F-LD,19G0%U!,KX(^7**,A1C6ZY?C_K\SU95:7(KXQO\
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M****S.,**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*C!>=UKJ_*WW?GMRJZAK+>3=Z;'XKEG_ +50V]C?Q7D8DC5XED,KNH5=XW,
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>=W:QHZDG!4V]$V_F[7_)!1112,PHHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>img128415308_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 img128415308_1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" +W EH# 2(  A$! Q$!_\0
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M/%?#_P <] O]<\80:G;PZ9I&BH\]E?))YAOH(Y##,X0="LH"@#J'4]ZK:?\
M'S19-;U:WU339M%M+&:6!8[N"07DK+';L%$8!&XM<*H&><C'>DT_X+_!SQ19
MZ9I6B7UJMS91269N-+N8UN;K<AW"9@N7;*^9[,F?:B;X4?#S4-:9-1\<7VJ>
M(;^5IX[B:^@\_P YO)".BI&%!4VT948QD-D'--;I/M][[KY [:M=_N7;[S:U
M+XX>"=%^RIJ2ZAIUQ(K23VMW9&.6SC5]ADF4GA-QQE=V>HXI8/B?!?\ PH\6
M^,[?0YK?^PS?*EK??()S;EANR,_*VWKVJCXJ^"_@V77--D\0^,M0/B"X3[.]
MQ?7=N9[V(R;Q'AH\1J&X7R@F,D Y-;*Z%X%L_"?C/P=)XL4:?>FZFOHY+V$2
M6"SD^8%.WY5#,?O[L$X/I2=W%VWL_OT_3^MAJW,K[77W:_K_ %N<-X._:"M]
M6^U+JR:#'';2V0DO].FG:W"W&\E2)$5PZB,G.-I!Z]J].\$^-O#_ (^N+BWT
M^*\MKB*&.Z6&_MC \UO(2(YT!^\C%3@]>.0*XO6/A'X L9';Q=XSO-6NECM8
MR^JWEM$ZVZES'%MBBC&QR6YQN..&XK:\,^!M'\.WEE?Z3XYGOKH6L#">\N;>
M8_V5 S'RDVH!Y9+<R<MG'S<5>G7^OZ_*^^EXUM_7]?\ !L2^+/B3I7@GQ=J&
MEZK9N+&UT^SNUN+9&EFDEN+EX$B$8'/S*O/^U4-I\9/"-\UK';VVJSW,C,+F
MUBT]WFL LOE,;A1DH _'&?7IS6MX@\'^#_%WBJUU6XUG_B87L-@;>.WNXPLR
M6]P]S"R#!W;FW9(/*J<8QFLF'X3^%H-7EUG2?%FI:3/J=Q.]S+87T2B\'FF5
MXMVPD!&#<H0P!8$^D1NK<WG_ ,#_ ()3ZV\ORU_X!Z3_ &)#_<'Y4?V)#_<'
MY5GZ;XGT33=-M8Y?$MO?"2+[1'=7-S%NEC8E@V5 !7' ('0=^M;BW]L]Y]E6
M>,W/E^;Y(8;]A.-V/3/>F(I_V)#_ '!^5']B0_W!^55[[QQX>TW5FTR[UJRM
M]05=[6TDZAU!&<D9XXYI=6\;:!H:JVH:Q968;:5\Z=5SN!*XY[A6(^A]* )_
M[$A_N#\J/[$A_N#\J;;^+=$NHGD@U>QFCCCCE=H[A&"HYPC'!Z,> >]12>-_
M#T-U:6SZW8)<7>?(C:X0-)@D''//((^H(H G_L2'^X/RH_L2'^X/RJ>WUJPO
M&A6"]@F::'[1&$D!+Q<?./5>1S[U6_X2S1=I;^UK+ @2Y_X^%_U3':LG7[I/
M /0F@!W]B0_W!^5']B0_W!^59\GQ(\*PW\=D_B'3ENY%WI";E=S+_> ST]ZO
M:AXLT72[>2>\U6SMH8XTE9Y9E4!')"-UZ,0<>N.* '?V)#_<'Y4?V)#_ '!^
M5);^+-%NK-KJ'5K.6V6$7)F2=2HB)(#YS]W((S[&H-'\<>'_ !!J4VGZ;K-G
M?7T()EMX)@SI@XY Z4>0>98_L2'^X/RH_L2'^X/RJ"/QMX?DO+FT36K!KJV(
M6:$7";HR6VX(S_>('UXJW-X@TRWDV2ZA:QO]H6TVO*H/G, 5CZ_>((.WKS0!
M'_8D/]P?E1_8D/\ <'Y5!!XV\/W6L3:5%K5B^I0EEDM1.OF*5&6&,]0.3Z56
M7XD^%&L9[U?$6FM:02"*29;I"JL?N@G/?!QZXXH T/[$A_N#\J/[$A_N#\JK
M7GCKP]I^BP:Q<ZS9V^E3'$=Y),%B8\]&/'8TV/Q]X;FNK&V37=/:XOE#6T7V
MA=TP.<%1GG.#CUP<4>0%O^Q(?[@_*C^Q(?[@_*H=3\::%HNJ0Z;?:O9VNH3!
M3':RR@2,&) (7KR01^%69/$6E0Q7\KZE:)'8-LNW:=0+=L X<Y^4X(//J*/,
M!G]B0_W!^5']B0_W!^5,L?%VB:I;?:+35K.Y@\IIC)'.I 13AF// !X/I2ZM
MXLT70;>VGU+5K.QANB!#)<3JBR<9X)/(P>M #O[$A_N#\J/[$A_N#\JF77-.
M8J%OK<EI_LPQ*.9<9V=?O8YQ6??>/?#>FV<-W=:[I\-K-(\4<S7"[7="0Z@Y
MY*D'/IB@"U_8D/\ <'Y4?V)#_<'Y53_X6!X:_M%; :]I[7C()%A6X4L5*[@>
M#T*\_2K=WXJT:PM6N;G5;."!8%N3)).H7RF.%?.>A/ /<T +_8D/]P?E1_8D
M/]P?E3M-\2Z3K$<,ECJ5K>)-$9XVAF5]T8."PP>@/!]#67#\3/"=QI]Q?1>)
M-+DM+<JLLRW2%4+'"YYXSV]: -+^Q(?[@_*C^Q(?[@_*LX_$KPHK6H;Q#IJ&
MZ&Z'=<J-XW;<C)Z;@1]:U=0\0:9I/G?;=0M;3R4623SI538K-M4G)X!88'J:
M (_[$A_N#\J/[$A_N#\J4^)M)#7JG4[7=9*6N1YR_N0"02_/ R#U]*9;^+=$
MNM:DT>'5K.758UW/9I.IE '7Y<YXX^F10 [^Q(?[@_*C^Q(?[@_*FR>+-%AU
MH:1)JMFFJ;-_V-IU$NW&<[<YZ<_3FET/Q5HWB99VTG5+34A VR7[+,LFP]LX
M/?MZT +_ &)#_<'Y4?V)#_<'Y5FQ_$SPG-;W,Z>(],:&V&9G%TF$!;:">>F>
M/K4DOQ%\+P6-I>2^(-.BM;MS'!-)<JJR,#@@$GG!Z^F: +W]B0_W!^5']B0_
MW!^52-X@TR.,NVH6RH)6@+&5<>8%+%.O4 $X]!61'\3_  E-8R7J>(]-:TC=
M4:;[2NS<>0,Y[CF@#3_L2'^X/RH_L2'^X/RJB?B)X774QIQ\0:<+XIY@@^TI
MN*;=V[KTQSGI6CH?B+2_$UH;K2=0MM1MU;8TEM*' 8=CCH>GYT ,_L2'^X/R
MH_L2'^X/RJW#J=I<WMS9PW4,MW;;3/ D@+Q;AE=R]1D=,]:S;?QMX?O+JYMX
M-:L)9[9UCFC2X0LC,VU01GJ6.WZ\=: )_P"Q(?[@_*C^Q(?[@_*G+XDTF34C
MIRZE:-?@.?LHF7S,)C>=N<\;ESZ9%58/''AVZL[JZAUW3I;:UB6:>9+I"D4;
M9VNQS@ X.">N* +']B0_W!^5']B0_P!P?E3;SQ9HNG1WLEUJMG EDB27)DG4
M>2K_ '"_/ ;MGK4>G^-- U2)I+/6;&Y18WE9H[A3M1" ['G@*2,^F1F@";^Q
M(?[@_*C^Q(?[@_*H]5\8:'H=C;7FHZM9V-K<X\B:XF5%DR,@J2>1@Y^E-7QI
MH+:TFD+K%F^J2!66T693(05W X![CGZ4 3?V)#_<'Y4?V)#_ '!^549OB)X8
MM]6ETR77M/CU&$XDMFN%$B=N1GCJ*FUGQSX>\.R>7J>M6-C)NV;)YU5MVW=C
M&?3GZ4!Y%C^Q(?[@_*C^Q(?[@_*HM8\9:%X?M+6ZU/5[.PM[K_42W$RHLG&>
M"3SQS]*:WCCP]'J,=@VN:>+V2+SD@^TIN9,;@P&>1MY^G- $_P#8D/\ <'Y4
M?V)#_<'Y4UO%FB*LK'5[(")(I7_TA?E63_5L>> W8]^U9:_%3P>]K]H7Q+II
M@WB,2"Y7:6(S@'//'- &M_8D/]P?E1_8D/\ <'Y5 OC;P_)?6=DFMZ>]U>()
M+:%;E"TRGH5YYSSC'7!Q4^O>*-(\+6\4^L:E:Z9#*_EQO=2B,,V"<#/? )_"
M@ _L2'^X/RH_L2'^X/RJK<>//#EK?6MG+KE@MU=(LD$7VA2TBM]UEYY!['O4
MFG^-?#^JM(MGK5A=-'*('$5PC$2'.%X/4X./7!H F_L2'^X/RH_L2'^X/RJI
M:^/O#5[YY@U_391!(L4I6Z0A&9MJ@\]VX'J>*O3>(M+MW5)=1M8W:<VH5IE!
M,P7=Y8Y^]CG'7% #/[$A_N#\J/[$A_N#\JI:3\0O#.NW#6^GZ]I]Y.K;#'#<
M*Q#?W<9Z\=*?8^//#>I%Q:Z]IUP4G6V;R[I#^\8X1.O5CD#UQQ0!:_L2'^X/
MRH_L2'^X/RJ&Z\;>'[&Z@MKC6K""XGD,,<<EPH9G!P5 SUSQ]>*VJ/,#+_L2
M'^X/RH_L2'^X/RK4HH *1E#*01D'@@TM5M2\S^S[KR=WF^4VS;UW8.,>^:F3
MY8ME17,TCRB3X&375]9.UW'8P0^([W6'DTN:2UG,4T4B(@= #N!<9&<8SR:Y
M[X>? 7Q'X"\36=V9K/4+.-($9QJUQ$X",Y):/R2)3AA]YADY^M<QI_P[^*#:
M#X7G?4;U9+Z6);S3)[RZ8!@DK&6=^&BR=BE5XSC.:=X3M_&<?BO15\0/XD,,
M%G"CB>QOY%$XGE\Q5>([" -@#R9W+M/K5KW7;L[?<B9>\F^ZO][_ ,SU?Q)\
M/]<D\;:KJFFVNAZE::Q#;0S/K&\O9>43S&@0AP0=P&Y,,,YKA?$'[.>M^)O#
M=GX:NO[$BTW3Y)F6_1I#<:@DD@8I,NSY 5)W89MS =.V%<^%?'>F> -'OKV?
M5GOK[65-XD"7T\T=M_I!_>QQL6"Y\K_5A1]W/%6]1T7QW-KZZEIKZS'HMHNE
M+YBI=I<*N]_M#102',G\(=9,L%.>U2DOA?>W]>A5VG==K_H7+/\ 9F\13:_9
MZGJ>OVKW*36PFNK?=YQAM]R1*NY",[-I.>-S/]:NR?LTZGIFJ3ZCHFLPVYC5
M["UL;G+QFQ>)UD$DFS?O,DCR8'RYV^E<GH&E^/M0T.UAM;WQ!IWB235+=I;B
M>POD6.-9G9A*TW[IHR H;R\?*:UM'U+Q=J4MQ=>,].\9:=%+)='3[+14E=X[
MD74G#,@(V[/*\MG(3:6YIKWE9^?XI???;_AQ/35>2_KTW-&Q_9EU/3=%UK28
M-3LQ8MHMG9Z)AI$ETRZB9W8I(!D1AWRF.0"1C%=]\0_A.VO^ ]*T'PZ]MI$V
MFS1_9Y'!VI$5:*8# )W&.23'JV,^M>6>3XK;5/'37,OB:UO)+B\6QDMM.O9)
M(XB1L:-MP@8!<X"'<?X3FNO\*ZMXLLO@]KPL]-U.XUQKE[72S="==_F%464+
M,OFQ1(6+'?G 4\D4-\ROOL_77^O4?VNVZ_#_ (']7.>U+]F/6/[*O[6PO=+^
M6ZF73UF,BK#9^6PAA)"'!#.V< C &,UW^F^'/&UOX]M?$,^GZ L<FG+IUU#'
MJ4Y:,++OWH3;C?QG@[>1UKRV3_A;FFVL2QPZQ<7OAW2[VWN+8.98M74N/*>.
M4JN^=4(*G )9&!'S5H> 5\6GQ-IKR+XK36CJZ_;?[0BG6P.G?9TW9+#RRV[.
M IW;L^]5'66^WZ^[^6K^;W)EI'^O\7YZ+[CO-:^"K:YXA\<:K+J#1/KELMO:
MQQR-Y28M_*+2IC!.[D8/2N8F^!/B3Q7K6F:GK=]9Z++:""#_ (DUR[R".&VN
M(ED5WC7YB\X.TC 5>I-4/&FC_$!?B)K>KV3:HFC+JT441LVF>40_8TX2$'8T
M32DAFP2IR>U9_@/4/$OA[1_#=Y?P^)KB:/4(#JL::5J+2>7Y$P;<L@;>-Y7/
MEC'3VJ(I26O6W]?CJ5*Z^Y_\-^&A-#^R_KEK8F6SU'2[#5E6SLV>,RM%=VL4
MFZ5905R&8_O%QG:V1T)K3;X"^);6;2Q9R:0DL(59K[[1*/D%S)*4> QLDWRO
MA6^1D.<$]:-=F\<>*/'&H:A_9VM6_@J\1]*AMX9)8+B-EC\R.Z\G8&4&4,N[
M/1ER.*ATW2?&GAK3=)O+4>(+IM-T*PU*>TG>25KNY\P_:H#GDR%"?D]0M'Q+
MWN]_OO\ \/;S%W2_K;_AOD=9\+?@G=?#W6]$OI=3EOEM?#XTJXCN+R:<"4.C
M9A5^$C^4\#';BN9LOV:]2MM<M;M]1LGMH]2=)(</\^D(=]M:]/O+* Q[8)P:
MS=#L?%T/Q/MKC7Y-<:VN(;.\$9M+Z6&*61Y7DA5H?W:^6#&A\S^Z#7H/Q8;5
M_&GAGPP_A7[5-%>:I \QC>6V_P!'PVXR,HWHO3/'I3E>5F][V]+O^OE<.KMV
MO^']?,S(/@??IHFEVLDNFM=6OAF\T5YMK<S2M$5<';G: C<]>1@5EP_L^ZMH
M.OZ7K.G7T6LR:?;6:"QUR^GFCFDBCFC<;V5BB@3!DP#@KT'6N:AM?BWX=N-0
M:<ZIK&EQVEQH<4D3R-*9"A>.Z6(KN8"7]V)2V2F#BDM?!/CG_A$?$5EJDVOI
MJ$=KI\^GIIUS<%'8X$S!V);S,E@\?0;0W?-->\VUY/\ &3_6_P Q/31^?Z+_
M (!N'X#^*K6/Q EM)HGE^*()(+^/S9$CTX-,7Q !&?,4*3P=GS<]#7JGA7P.
M?#WBSQ3JI6U$>JR0-#Y";9%"1;&W<#J>>":\HU6RU[2?%NH6>K?\):_@J*:1
M+5M)$\L[2>5'Y9)0%RF=^#]W?U/2J-_X=^(?BK7H+."36[&T:XNBEQJ%Q+;^
M2OV6W$3LT7#,'\PX!P6#<U*V27;\-[?U]Y36NO?_ (%S<F^"/B.^\(P^%I8]
M!M;*SVK%K-O)*M_<J)UDW%@@\IB 2Q#/EL<CK577/V:]:UC4-4CB\3/:Z:+R
M35=.DEE:ZNOMAABCC:5Y5) 41O@J20'XQBL"+3?B=J&C^(8]=CUR:+5+![C3
M)[.:1)[>XM_DC#1JH,1E3YRI)RW%:>J:+\0]'\962^'9=:?3].2.Y6"\=Y(+
MS%H3) [MW9R0#V?%/X5S?UK_ )<H:R=OZ_IWM]Y:N?V;=:U.2YO+O6;=;V^O
M;^XN+>.60V]N;B(H)H1M!\Q22,'Y2KMWP:=K7P5\:^(E:6<:#8B&6Q,&GV%V
M\*8@,FXK,MN'C!#C"D/C!YKG=-U#QRNFZ9=ZKIGBR;Q PLWTZT4SQ1I$>9EF
M9$:,2ALAA+@%<8.*]D^(VK7FN>!8[O0&U![5KZ)+XZ?$ZWGV59=L_E+C=NX/
M09(SCM0URV]4ONV^[J)._P!S_'?[^@NM> K[Q#\([GPS<1V<6HRVQA4S7#W<
M2-NR"9&16;COM!KF?$GP=UC4;[7;2S31QIFMW-I<R:A,66[L?)$8*1($(8?N
M\K\RX+M7"CPGX^\5>*I;+1;O7--\+BWN#I=]J\]S;RV[$H [# =BK;BB28R
M>U='X@\&^)M'UKQ9=Z7<Z_=W*1Z7]CD\^5H9)'F/VID3IC 4L!]T&CJI=PZ<
MO8Z3Q1\--?N_BQ_PE6G+:7-HUE:VWE3:I-:,&BDE8ED2%UD4B0=2.AKE;?\
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MCR2JH&^,AU&"#_%QS72>'O@_K>EZIHEK-_9(TS2=7FU9-5A9_M]UO$G[IUV
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MC9@ [R<[3@8K @^-O@31K?3;OPWX$L(+N]MK.]=AIQM!%),[!02(=S[3N.Y
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ML8%W-#B0^< IVQ _+NY)KN?B%\2]1\$^(#I@M[9VU*U3^QFD)'F77FA)$?\
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M_KGGK53P_P#&31] \.W^N:1\/K"VM[.X$,5II,(BN&WSB)B/W2J3@;L*QSM
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MCXXTG3;Y;&/2IWM;62X\K<QGE3<4?9(QADR1M5E*D'[W-1?$+]H"7PCX^O\
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M_P @UO?K_P -K\V:.I77PAUSPWH5V;I;BP6SA&E2V%S<K*8EG C6(QL'W>:
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M3INJ-QB3<DN5#!2=OS09P0N1MK4\,7WBN\\=6$NLCQ!9V8L;+R8+N"^EW/\
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MV4=G'M/V>Y:-%#'D KC/TKK;'XP0W'P];Q/_ &:LL[7:6$5I:7*R">9Y%CC
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M+;^O\OS-2P\;>(]>\/?#GS91I-]X@:>*[D2 9&VVE='56^[DHK8/8XKSN_\
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M7\DPCLEZ_P"7YG.:W\9-3TC6)3-XB6)K:YM;>UTF"""=[Z&2-"USG<&D5F)
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MEK=![G;Z]H-CXFTN73M1A\^SE9&>/<5R5<.O((/WE!_"LC4OAKX=U>"]AN[
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M_A:7B/\ Z)9XH_[_ .G_ /R31TL+K<L+\#/"06X5K:]E,B".)I=1G=K51()
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M_P#3_P#Y)H ]'HKSC_A:7B/_ *)9XH_[_P"G_P#R31_PM+Q'_P!$L\4?]_\
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M_P#I_P#\DT?\+2\1_P#1+/%'_?\ T_\ ^2: /1Z*\X_X6EXC_P"B6>*/^_\
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M3"66)5B1PK2Y:)LX (!'!Z5ZW=>&](OK**SN=+LKBTA3RH[>6W1HT3&-H4C
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M1,\S!Y&DL8F+L 0"<KR<$CGU-//@?PXUQ%.?#^E^?$XDCE^QQ[D8  ,#MR"
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ML^A::UO,H26)K2,HZABP##&" Q)Y[DFB?P7X?NK%+.;0M-ELT<2K;O9QF-7
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MD,K#(8'((KS?X0_\C!\2O^QDD_\ 2>"@#TJBBB@ KB_C5_R2'QG_ -@BZ_\
M135VE<7\:O\ DD/C/_L$77_HIJ -[PE_R*NC?]>4/_HM:UJR?"7_ "*NC?\
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M/2E&2E9=]2I1:_+[M/Z_ ^G_ .Q[#;M^PVVW^[Y*XZ8]/3BE_LFQ/)LK?/\
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MEGENM:C\J$P.HDA0"$L-YRT8Y/,3$CM0']?U^![U_P (_I7[P?V99XD01/\
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MY=P:_K[O\SUVBOE'1?$'Q$\?>*)Y=+U35)3HUE<2RM&EN(OMS1Y6!<'#1EE
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MY?$CL6']C:F,$#F)><MMS][MU^E &U16'_PDTGEJ_P#8NJ<C[ODID?*I_O\
M^UCZ@TK>)I%7/]BZHW!/$*=BP_O_ .S_ ./+0!MT5C?\)$_G"/\ L?4NH&_R
MEV\[>?O?[7_CK>G+%\3R$9_L351\I;F%.RDX^_UXQ]2* -RO-?A#_P C!\2O
M^QDD_P#2>"M/X;W5U<:AXMW&1M-756%IYN<KE%,JCV$A8>G6LSX0_P#(P?$K
M_L9)/_2>"CHGZ!W/2J*** "N+^-7_)(?&?\ V"+K_P!%-7:5Q?QJ_P"20^,_
M^P1=?^BFH WO"7_(JZ-_UY0_^BUK6K)\)?\ (JZ-_P!>4/\ Z+6M:@ HHHH
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M][V. #J:*P+?Q-<7=P\4&DRS;-I=H[F [0VT@D;\XP6^NP^V91K6I[<GP_=
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M@'Q=82W;6-_J\TD%@+X>;]CLD8B")@K8. 7/#9^<>E-];"CK:YZDFOZ;)</
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M.,^'WPY3P"TRQW\U_&;:*V1[C'F$(TCEFP ,DRD<#@ 5V=%%4W<D*\U^$/\
MR,'Q*_[&23_TG@KTJO-?A#_R,'Q*_P"QDD_])X*0STJBBB@ K-\2:#:>*O#^
MI:-?AS9:A;R6LPC;:VQU*G!['!ZUI44 >8VOP+2SM8;>'QWXU2&%%C11JJ\*
MHP!_J_05+_PI4_\ 0^^-?_!JO_QNO2:* /-O^%*G_H??&O\ X-5_^-T?\*5/
M_0^^-?\ P:K_ /&Z])HH \V_X4J?^A]\:_\ @U7_ .-T?\*5/_0^^-?_  :K
M_P#&Z])HH \V_P"%*G_H??&O_@U7_P"-T?\ "E3_ -#[XU_\&J__ !NO2:*
M/-O^%*G_ *'WQK_X-5_^-T?\*5/_ $/OC7_P:K_\;KTFB@#S;_A2I_Z'WQK_
M .#5?_C='_"E3_T/OC7_ ,&J_P#QNO2:* /-O^%*G_H??&O_ (-5_P#C='_"
ME3_T/OC7_P &J_\ QNO2:* /-O\ A2I_Z'WQK_X-5_\ C='_  I4_P#0^^-?
M_!JO_P ;KTFB@#S;_A2I_P"A]\:_^#5?_C='_"E3_P!#[XU_\&J__&Z])HH
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MN^[ZXT=/^)GAW5-06RMM0$ETQA CV'/[U6:/MW"-],4 <_\ \*5/_0^^-?\
MP:K_ /&Z/^%*G_H??&O_ (-5_P#C=:_B+XL^'_#.J7>G7;W,EW;+&9$M[=I
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MZK'(0(RY ^7>Q"C/4FC=7#9V,3_A2I_Z'WQK_P"#5?\ XW1_PI4_]#[XU_\
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MU^T2M%;/<6[HESM5FW1L1A@0C8]<>XH>FX:F9_PI4_\ 0^^-?_!JO_QNNA\
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ML_\ OS-_\17K]% 'D'_#7'PB_P"AUL_^_,W_ ,11_P -<?"+_H=;/_OS-_\
M$5Z_10!Y!_PUQ\(O^AUL_P#OS-_\11_PUQ\(O^AUL_\ OS-_\17K]% 'D'_#
M7'PB_P"AUL_^_,W_ ,11_P -<?"+_H=;/_OS-_\ $5Z_10!Y!_PUQ\(O^AUL
M_P#OS-_\11_PUQ\(O^AUL_\ OS-_\17K]% 'D'_#7'PB_P"AUL_^_,W_ ,11
M_P -<?"+_H=;/_OS-_\ $5Z_10!Y!_PUQ\(O^AUL_P#OS-_\11_PUQ\(O^AU
ML_\ OS-_\17K]% 'D'_#7'PB_P"AUL_^_,W_ ,11_P -<?"+_H=;/_OS-_\
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M_P#BZPX_@K%=:?I=GJ>K-<P6-_)>K':6R6RG<@54 !. I&[=G<2>M4%^ O\
MQ,+&Y;6E(M9DD*?8^)0"<EP9"#(P;#.0> , 8H ZK_A8C[B/^$4\2<=_L2?_
M !=+_P +$?\ Z%3Q'_X!I_\ %URNF_ F;0=0LKO2O$LMI]E**MJUH&MRBOO
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MZ^BN1_X17Q+_ -#O>?\ @OM?_B*3_A$_$N[/_"<7F,=/[/M?_B*!'7T5R/\
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M_$4 =?17(?\ ")^)=P/_  G%X!W']GVO/_CE+_PBOB3_ *':\_\ !?:__$4
M==17(+X3\2C.?'%X>?\ H'VO'_CE#>%/$I4@>-[P'U_L^U_^(H Z^BN0_P"$
M4\2_]#O>?^"^U_\ B*/^$3\2[@?^$XO .X_L^UY_\<H Z^BN1_X17Q)_T.UY
M_P""^U_^(I%\)^)1G/CB\//_ $#[7_XB@#KZ*Y!O"GB4J0/&]X#Z_P!GVO\
M\11_PBGB7_H=[S_P7VO_ ,10!U]%<A_PB?B7<#_PG%X!Z?V?:\_^.4O_  BO
MB3_H=KS_ ,%]K_\ $4 ==17(-X3\2E<#QQ> ^O\ 9]K_ /$4O_"*^)/^AVO/
M_!?:_P#Q% '745R'_")^)=V?^$XO,8Z?V?:__$4O_"*^)?\ H=[S_P %]K_\
M10!UU%<@OA/Q*!SXXO&/_8/M?_B*&\)^)2O'CB\!]?[/M?\ XB@#KZ*Y'_A%
M?$G_ $.UY_X+[7_XBD_X1/Q+NS_PG%YC'3^S[7_XB@#KZ*Y'_A%?$O\ T.]Y
M_P""^U_^(I%\)^)0.?'%X3Z_V?:__$4 =?17(-X3\2D<>.+P'U_L^U_^(I?^
M$5\2?]#M>?\ @OM?_B* .NHKD/\ A$_$N[/_  G%YC'3^S[7_P"(I?\ A%?$
MO_0[WG_@OM?_ (B@#KJ*Y&/PKXD52&\;7CG'!_L^U&/_ !RM[1;&\T^R\J^U
M*359]Q/VB2)(SCL,( .* -"BBB@ HHHH **P[SQUX;T^ZDMKKQ!I5M<QG:\,
MU[$CJ?0@MD5 WQ(\)*,GQ1HH'J=0A_\ BJ .CHKG?^%C>$_^AHT;_P &$/\
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M&$7_ ,52?\+(\)9(_P"$HT7([?VA#_\ %4 ='17._P#"QO"?_0T:-_X,(?\
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M (F$/_Q5 '1T5SI^(_A-02?%&B@?]A"'_P"*H_X6-X3_ .AHT7_P80__ !5
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M38_\^=O_ -^E_P *MT4 5/[*LO\ GSM_^_2_X4?V38_\^=O_ -^E_P *MT4
M5/[*LO\ GSM_^_2_X4?V39?\^=O_ -^E_P *MT4 5/[*LO\ GSM_^_2_X4?V
M38_\^=O_ -^E_P *MT4 5/[)LO\ GSM_^_2_X4?V38_\^=O_ -^E_P *MT4
M5/[)L?\ GSM_^_2_X4?V59?\^=O_ -^E_P *MT4 5/[)L?\ GSM_^_2_X4?V
M39?\^=O_ -^E_P *MT4 5/[)L?\ GSM_^_2_X4?V38_\^=O_ -^E_P *MT4
M5/[*LO\ GSM_^_2_X4?V38_\^=O_ -^E_P *MT4 5/[)LO\ GSM_^_2_X4?V
M38_\^=O_ -^E_P *MT4 5/[)L?\ GSM_^_2_X4?V59?\^=O_ -^E_P *MT4
M5/[)L?\ GSM_^_2_X4?V39?\^=O_ -^E_P *MT4 5/[)L?\ GSM_^_2_X4?V
M38_\^=O_ -^E_P *MT4 5/[*LO\ GSM_^_2_X4?V38_\^=O_ -^E_P *MT4
M5/[)LO\ GSM_^_2_X4?V38_\^=O_ -^E_P *MT4 5/[*LO\ GSM_^_2_X4?V
M38_\^=O_ -^E_P *MT4 5/[)LO\ GSM_^_2_X4?V38_\^=O_ -^E_P *MT4
M5/[)L?\ GSM_^_2_X4O]E67_ #YV_P#WZ7_"K5% %3^R;'_GSM_^_2_X4?V3
M8_\ /G;_ /?I?\*MT4 5/[)L?^?.W_[]+_A1_9-C_P ^=O\ ]^E_PJW10!5_
MLJR_Y\[?_OTO^%)_9-C_ ,^=O_WZ7_"K=% %3^R;'_GSM_\ OTO^%']DV/\
MSYV__?I?\*MT4 5/[)L?^?.W_P"_2_X4O]E67_/G;_\ ?I?\*M44 5/[)L?^
M?.W_ ._2_P"%']DV/_/G;_\ ?I?\*MT4 5/[)LO^?.W_ ._2_P"%']DV/_/G
M;_\ ?I?\*MT4 5?[*LO^?.W_ ._2_P"%)_9-C_SYV_\ WZ7_  JW10!4_LFQ
M_P"?.W_[]+_A1_9-E_SYV_\ WZ7_  JW10!4_LFQ_P"?.W_[]+_A2_V59?\
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MSN7).,#ZT=-?+];_ *!UL=FVO>+XHWDET#1(T4%BQUM\!1U)_P!&XQ6?I/Q
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MI>L;:>:>X>)9(B%^:,!"2>O:O<_L<!;<8(\^NP?Y[G\Z6.VAB4*D2(J]%50
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M_>/[G@>])OJPL>KT5XW<>._B39V^F7$T7@..'4YH[:RD;5+K$\K@LB+^YZD
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MN1T_XE\/'_CM+_PKGPG_ -"OHO\ X+X?_B: -C^U;+_G\M_^_J_XT?VK9?\
M/Y;_ /?U?\:QA\-_"2Y(\+:*">O_ !+X?_B:#\-_"1&#X7T4C_L'P_\ Q- &
MS_:ME_S^6_\ W]7_ !H_M6R_Y_+?_OZO^-8W_"M_"0Z>%M%'_</A_P#B:/\
MA6_A+(/_  BVBY'3_B7P\?\ CM &S_:EE_S^6_\ W]7_ !H_M6R_Y_+?_OZO
M^-8__"N?"?\ T*^B_P#@OA_^)I!\-_"0R1X6T49Z_P#$OA_^)H V?[5LO^?R
MW_[^K_C1_:ME_P _EO\ ]_5_QK&/PW\)$8/A?12/^P?#_P#$T?\ "M_"0Z>%
MM%'_ '#X?_B: -G^U;+_ )_+?_OZO^-']J67_/Y;_P#?U?\ &L;_ (5OX2R#
M_P (MHN1T_XE\/'_ ([2_P#"N?"?_0KZ+_X+X?\ XF@"UKFL6<>BW[K>,&6!
MR/L)$D_W3_JU&=S^@QR<5\Y6NH>-+C2X+NTF\7Q13F:33+&YMK@3076Z 1QW
M3/&,JR^:QS\@+,,\"OH:'X?^%K>9)8O#6D12QL&1TL(@RD=""%X-;]$=)<P=
M+%5M2M$)5KJ!6'!!D''ZT?VK9?\ /Y;_ /?U?\:RI_A_X7NII)IO#>D2S2,6
M>22QB9F)ZDDKR:C'PW\)+T\+:*.<_P#(/A_^)H V?[5LO^?RW_[^K_C1_:EE
M_P _EO\ ]_5_QK&;X;^$F&#X6T4CT.GP_P#Q-+_PKGPG_P!"OHO_ (+X?_B:
M -C^U;+_ )_+?_OZO^-']J67_/Y!_P!_5_QK&_X5OX2W9_X1;1<],_V?#_\
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MY! !J*[^%>EZI-J.[QGOEN;JWMKKR;6+'VB)5^S* .%*C&1_%GG%-;W:W_X
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M]/K4E !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/*&,<3, S@8R0.IQD9^M2T %%%% !1110 4444 %%%% !1110 4444 %%%%
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MTOS+N^4YB6+)' +>O%%[[#<7&Z?2_P"!Z-_PL=/^A:\2?^"UO\:!\2$9B/\
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MNN;2YX([&O4J\R^,W_(<^&'_ &-<7_I)<UZ;2#H%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M>7?!C_D9/BC_ -C/)_Z305ZC7EWP8_Y&3XH_]C/)_P"DT% 'J-%%% !1110
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MH!4')7'44-XS^$TENL831Y8Y&6]\A=,W$R%F4,4$>?,+*PQC=\IXX-"V2?\
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M<=/_ /'_ /XFC_AI3X9?]#CI_P#X_P#_ !->E;1Z"C:/04"/-?\ AI3X9?\
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M_P"/_P#Q-'_#2GPR_P"AQT__ ,?_ /B:]*VCT%&T>@H \U_X:4^&7_0XZ?\
M^/\ _P 31_PTI\,O^AQT_P#\?_\ B:]*VCT%&T>@H \U_P"&E/AE_P!#CI__
M (__ /$T?\-*?#+_ *''3_\ Q_\ ^)KTK:/04;1Z"@#S7_AI3X9?]#CI_P#X
M_P#_ !-'_#2GPR_Z''3_ /Q__P")KTK:/04;1Z"@#S7_ (:4^&7_ $..G_\
MC_\ \31_PTI\,O\ H<=/_P#'_P#XFO2MH]!1M'H* /-?^&E/AE_T..G_ /C_
M /\ $T?\-*?#+_H<=/\ _'__ (FO2MH]!1M'H* /-?\ AI3X9?\ 0XZ?_P"/
M_P#Q-'_#2GPR_P"AQT__ ,?_ /B:]*VCT%&T>@H \U_X:4^&7_0XZ?\ ^/\
M_P 31_PTI\,O^AQT_P#\?_\ B:]*VCT%&T>@H \U_P"&E/AE_P!#CI__ (__
M /$UE?L]ZY9>)KSXCZMID_VO3KKQ-*T%RJD)*HMX02N0,C((S[5Z_M'H*6@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M]+TZRN7!$I>=VC"_*H92N&.X-D]/3FI]E.W-;2UR/[,Q?L_:\GNVYKW6V_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MUW#'UIHGC;&)%.>GS"@"2BFLZJNXL OJ3Q1O7KN&/K0 ZBD5@Z@J0P]0:6@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HJ.29(=N]U0,
M=HW-C)]*>* %HHHH *X#QYX@\8:;JGD>'],6ZB,0*,UN9$9CNW%G#KMVX7Y<
M?-GJ*[^N'\8V?C.YUI6T*^^R:>L2@JJ0-N?;(2?G!/41#\36E.W-K;YGIY?R
M^V]_EM;[=[?AU*_BB_\ &.GZ]9II:_:[1K1/.86>Y/,#,7(^<88@  $X&[O6
M)I?BSXCWD;2SZ-% D3D;)+)E:52!@X\P[=N3GKG'%9^H:+\5-:C*75TUN!=
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M2=HS]D/E7,8"[$),@)8\_,!@>]:Z?\)S9^&]31KN"YUM5AFM!/Y*AN%\Y#M
M 4'< 3[<UG^'6^),^K:)-?W-K-I3Y-RUNL+*Z#(#$Y!^8 .-F<;\'I25KW]W
M^M?^ 8QY/>JVHZ*V[UTO=*V[O;IKII8J6_C#XDWC7S)H,<"0JTL2W%H5:3Y3
MB/B3J#CD=>E:GA/Q1XWO=:M(-6TA4LY+5W:2.U>(+("VW<6?Y=P"_* 2":SM
M9L_B)IHU.+0[@W+SRS311R/;DVV93Y>-XY4KU!/';%27<?Q4,,'E2VRLMP(W
M\M(69XP,^8=Q &2VT@'(V9'6G:,EIRJYK.G1J0:C[%7VU::TW_R_R-7PCKOC
M/5M<@BU.Q2RTU4D>:62T:-F<!-L:YD/ +/\ /SNV]!67=^+OB!<^>MGH8@:W
MMYG8SVC$32KG;&A\P<,-OS5/KFH>-=4\4:I:^'[ADLK<QQ>:4@,2$Q9?&X;B
MX<C@_*!GO4%M-\1/MK0/.T\<)(E\LV@EWDGRR!C A*@$Y&_.<<4DEO[IE&G&
M_M6J*ND[-O3KJK;N_P"17TO5O'$NM6MAJNDM>Z/=2QBXCEL]WE(4&?G+XP&!
M)SD]L&KOBCQCXWL=3N;;2M >:"WE.)?LC.)8]R[0AW@%B"W)P!BLNUN/BG<6
MZ.MQ#<.MPRR+$MJ%"[>S9.5!.0,;CT)'6IX?^%L,UKN,**L3!]XMVWMEN6P1
MM/W=H7('.[-597N^4Z)4J?M%.3H:*UN9VOWM;?\ X LWBWQWI=K<75S8106*
MW+Q$S6Y9XHL;A,3YGS<G:%X^M/UCQ1XDUKP+X<NK;08]8FO_ -Y=PR6):/:&
M&,H7RA(Y!^;&*?>V?CNS\#PQ6B22:G)?7$MRU[);,5@+NRAP?D((P,*1@?2K
M>DZIXOM?"/B*ZO9(GN[9BU@R")E?;UBVQYP,C;DDGG/%+3=):,AJG:-2$:3:
MG;1[_9VWM=WO?97L0^-O&/BWP[XD>TT_3=VC-Y$4%Q%8--M9F4$<.NX\G  X
MQR?6K!XP^(KWDZW.A1VMLOECS(K1YG12H)=1O D)/!0$%?4XJ2&\^(JW0#B.
M\D4">2U!MD_=LZ[%0'#!@/,#%N"5&VK^K3>-[[3;<:3?0)J5OI\7VN!/(?-T
M77>#G@83>1@@9I)**2:1,8TZ<84W&DWMS7?EJ]-/5JVOJ8$>I?$*'4A?O97#
MP/"8VMV@9UA&]\N(Q)\[8V_+[\&NH\1>(O%EE;:4VFZ<UP\MH9)0;,DF;Y<(
MPWCRA@L>2W(Q6$M_\2K+4-.CN(I+II S2)%';B)T4(=I.<K*?GSSL/&*KK_P
MMY[6\=VBCG\N-H8HTMB,_+E0Q;@_>!)! [9IN-VG[II.E&K.,Y.@DO[VCOIV
MZ?UJ.U#Q5\1KB)X;?2Y$5[>0QW,>GE9-X+;696DPN0  O)/MGC0U?5/%7AW7
MM231M*FN=.DB66.%++Y QB8LZMO'S>9MRAY.2<UFK'\3[76)[>WN8S&YEG2*
MX:WD."['KD,% *!<#&<Y&*[OX?VVL6>FW,6LQW/GR7,TZR74D3/L9SM4^6=H
M(&.!QS2E:*OH8XF=/#PYTJ4EVB[MW>[]+=.[.(LO%WQ%O)K*.YT(QJ\2/(T=
MJZ!'$F#N)?H5YV@'OFM:/Q%XNO/!EK->:/MU"2Z:&Y3[ 9!Y0!(98?,R03@9
M)XZXIMIH>OZ+?>(=8OK]K6&.RN/LLDSK)' ?-=P^WK]T+G/;BL^36/B%Y.GW
MC-% ;U872U<P*@W99H?F^<R@;0#]W[V:>DMDOZZ&DHTJTOW4:22:UU739;WW
MU]-?.%O%?Q#N-4F<:+-;V=O,PC_T0\QE6&2@?]X00I !&<U-?>+O'<T=NL.A
MWF^W=I9GCM/+\Y0ZB, &0]5+%ESP1C-:7BAO&5UX/MR-UC=2S3BY6.6!7CC+
MMY WL=N,% Q4Y]*K>&=/\;)?:=-?OFVMM/95\N6$P&0PH!G!W,WF!N3\N,4E
MRVNTM/T&I473]JXTERW5K[VNOG?I\F9EGXF^),MT+FXTI]ODL!$+0JBD-*-^
MW?DL1L.PGTP173>"]<\9ZCK*#6;".WTQO,0?Z,8Y/E"E)#ESC=EAMQQCK6+_
M ,7%FCCAAU!+M)HU>.X0VRY)5/,WX .Q27 *#.<9[5W_ (<FFTWP[HUOK%P5
MU+R(XI?M$B%Y)0 #RO!)/IZTJC26RU[')CJD(TWRPI-RT]V[:WU\K?\ #FW1
M117$?)A1110 AKRSQEI?P=D\=6>E^)M.\)W'B_66 @MK^V@DO+H@<<%2QX!Y
M/I7J9YKYQUCPC\1OAW\7O&'B+PQX%T3QW!XDD@GM]2OM36SN=-9(A'Y3[D8M
M$"-PV$'YCQ0!UGBKP_\  SX8ZAI7]O:-X-\/WUW<1I8+<6<$<TDI8!/+ 7=G
M=C!'?%>P\U\Q>-OV:]9U3X;ZEJ%Z+;Q3\4=8U/3[N_U)L(D$45U'(;>VW_ZN
M&-%; '+$$G)-?3U Q:***!!7.^+-+N-0$!@B:8Q[OERI&2!C(/;W'(KHJJW5
M]#9LHE?87.%X)S0!QL/A_4@MVLELS,[[S\R!77<I*!OO<@$<U))H]_\ Z<MM
MIGV2*\541!,#Y6&!)(SQD=A77&^@"LQE7"J'//0'H:='>121HZL-K-M&>.?2
M@9Q^D^&;_3]4TV5@IA1%,I7"[6P<@C/S'WK7N/#L5UJ6H2M"H2:!5613AM^6
MR?8]*UX]0ADDD17!:,$MP>,=?K33JUHK*IG0,S! ,_Q$9 _*@"OX<L9=/TN-
M;DEKN0F2=B<EG/4UF3Z'=W&BQ6NYHY1=F4LK\JNXD'/Y<5L_VQ;'.')^;9]Q
MOO>G2E_MBU#[#,JMNV@-D9.<8_6@#CM-\.ZFNI":\ME=GG+2%F#1[><D?Q*?
M;IS5J7PG<-9VD4420LBSF3(# L<[/Z<]JZ?^V+3=*OGH6C^^ <D<X_G0-6MM
MF[SEQ^O?M^!H$<<-"U:33[6T:U;_ $>5II"9N)5;_EF#USSWK3M= #7T5R-,
M6S0"7]V7W$$@!3P<#H>E;O\ ;%K\N9-N[IN4C^8J:XOHK7:97V;NG!H P9M+
MN?[*TJ.2W^U"W/[^WW#YN"!UX.#7/'PCJXM)%56"379E>W$W*( =NTGZX(KN
M6UBT4']^I&2IVY.",9_F*;_;-HH#>;P<\[3CCJ>E&PRIX7LKBQLW2>,1'S"4
M& #MP.2 < _2MNFJP90P.0>AJHVL6JLRF894[=N#DG., =_PH$7:*K-J$"P1
MS&51%(P56)X))P!^=02:Y90DAYU&#M) )&?3ZT :%%0M<HL)E+!8PNXL>.*K
MOK%I'C=.@! 8'G&#TY]Z +U%9XURS;?B7[GWOE/R_7CBI(=5MYIEB23=(V2%
MVGMP>U %RBJUQJ%O:MB654/^T?;/]#3&U:V4Q@R?ZQ=Z'!P1CKF@"Y15*;5K
M6W.))E4[=QZG"^I]!3FU2W66.,R O( 5 !.0>E %NBJ\UY%"X1Y%1F!8!NX'
M4U777;-F51,"6^[A3\WTXYH T**K&_A'EYD4>9G9D_>QUQ26VI07;8BD#G&>
M <'Z'O0!:JKJ.HP:79R7-P^R)!D^OT'O5GM7-:NMQ)KD<CZ6U]8PQ$')4C<2
M.54]2.10,M6OB@7"P326<MO:3/M2>0@#VR.HS[U?U#4?L?E(D37$TQQ'&A S
M@9)R> *98W4&L6C@QX )CD@F )4CJ"*RK[PB%A!L)I$=3D132%D/L#U4^A%
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M502%W!\YR4(+*N"2!5:S^%?P]T&_TJUUOQ<UOK=I;6]W*KQPP0NLBK'&$78
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M\%6<OC"QMX]'+V<%T( YGDED108@L@*NK8 .6QGD5M-^S#X8DP6N;PR_)^_
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?*** /4(;>.WA2*&-8HD&U4C&U5 [ #I3]HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>34
<FILENAME>acet-20211231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-03-15T16:13:41.2822+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:href="acet-20211231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" xlink:href="acet-20211231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:href="acet-20211231.xsd#Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="acet-20211231.xsd#Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:href="acet-20211231.xsd#Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:href="acet-20211231.xsd#Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" xlink:href="acet-20211231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusiness" xlink:href="acet-20211231.xsd#Role_DisclosureOrganizationAndNatureOfBusiness" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:href="acet-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombination" xlink:href="acet-20211231.xsd#Role_DisclosureBusinessCombination" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:href="acet-20211231.xsd#Role_DisclosureFairValueMeasurements" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureMarketableDebtSecurities" xlink:href="acet-20211231.xsd#Role_DisclosureMarketableDebtSecurities" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets" xlink:href="acet-20211231.xsd#Role_DisclosurePrepaidExpensesAndOtherCurrentAssets" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet" xlink:href="acet-20211231.xsd#Role_DisclosurePropertyAndEquipmentNet" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilities" xlink:href="acet-20211231.xsd#Role_DisclosureAccruedAndOtherCurrentLiabilities" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureTermLoan" xlink:href="acet-20211231.xsd#Role_DisclosureTermLoan" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRegeneronLicenseAndCollaborationArrangement" xlink:href="acet-20211231.xsd#Role_DisclosureRegeneronLicenseAndCollaborationArrangement" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureLicenseFundingAndOtherAgreementsRelatedToCVR" xlink:href="acet-20211231.xsd#Role_DisclosureLicenseFundingAndOtherAgreementsRelatedToCVR" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingences" xlink:href="acet-20211231.xsd#Role_DisclosureCommitmentsAndContingences" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockholdersEquity" xlink:href="acet-20211231.xsd#DisclosureStockholdersEquity" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureAtMarketATMOffering" xlink:href="acet-20211231.xsd#Role_DisclosureAtMarketATMOffering" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensation" xlink:href="acet-20211231.xsd#Role_DisclosureStockBasedCompensation" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShare" xlink:href="acet-20211231.xsd#Role_DisclosureNetLossPerShare" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:href="acet-20211231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureDefinedContributionPlan" xlink:href="acet-20211231.xsd#Role_DisclosureDefinedContributionPlan" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" xlink:href="acet-20211231.xsd#Role_DisclosureRelatedPartyTransactions" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSubsequentEvents" xlink:href="acet-20211231.xsd#Role_DisclosureSubsequentEvents" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="acet-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationTables" xlink:href="acet-20211231.xsd#Role_DisclosureBusinessCombinationTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" xlink:href="acet-20211231.xsd#Role_DisclosureFairValueMeasurementsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureMarketableDebtSecuritiesTables" xlink:href="acet-20211231.xsd#Role_DisclosureMarketableDebtSecuritiesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" xlink:href="acet-20211231.xsd#Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables" xlink:href="acet-20211231.xsd#Role_DisclosurePropertyAndEquipmentNetTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesTables" xlink:href="acet-20211231.xsd#Role_DisclosureAccruedAndOtherCurrentLiabilitiesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRegeneronLicenseAndCollaborationArrangementTables" xlink:href="acet-20211231.xsd#Role_DisclosureRegeneronLicenseAndCollaborationArrangementTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencesTables" xlink:href="acet-20211231.xsd#Role_DisclosureCommitmentsAndContingencesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockholdersEquityTables" xlink:href="acet-20211231.xsd#DisclosureStockholdersEquityTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" xlink:href="acet-20211231.xsd#Role_DisclosureStockBasedCompensationTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareTables" xlink:href="acet-20211231.xsd#Role_DisclosureNetLossPerShareTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:href="acet-20211231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails" xlink:href="acet-20211231.xsd#Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="acet-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails" xlink:href="acet-20211231.xsd#Role_DisclosureBusinessCombinationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesPurchasePriceInMergerDetails" xlink:href="acet-20211231.xsd#Role_DisclosureBusinessCombinationScheduleOfSummarizesPurchasePriceInMergerDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfEstimatedShareConsiderationOfCombinedCompanyDetails" xlink:href="acet-20211231.xsd#Role_DisclosureBusinessCombinationScheduleOfEstimatedShareConsiderationOfCombinedCompanyDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfEstimatedShareConsiderationOfCombinedCompanyParentheticalDetails" xlink:href="acet-20211231.xsd#Role_DisclosureBusinessCombinationScheduleOfEstimatedShareConsiderationOfCombinedCompanyParentheticalDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesPurchasePriceInMergerParentheticalDetails" xlink:href="acet-20211231.xsd#Role_DisclosureBusinessCombinationScheduleOfSummarizesPurchasePriceInMergerParentheticalDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsAcquiredDetails" xlink:href="acet-20211231.xsd#Role_DisclosureBusinessCombinationScheduleOfSummarizesAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsAcquiredDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/DisclosureBusinessCombinationScheduleOfChangesInTheCompanysIprdAndCvrSinceTheMergerDetails" xlink:href="acet-20211231.xsd#DisclosureBusinessCombinationScheduleOfChangesInTheCompanysIprdAndCvrSinceTheMergerDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSupplementalUnauditedProFormaInformationDetails" xlink:href="acet-20211231.xsd#Role_DisclosureBusinessCombinationScheduleOfSupplementalUnauditedProFormaInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:href="acet-20211231.xsd#Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfLevel3FinancialInstrumentsDetails" xlink:href="acet-20211231.xsd#Role_DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfLevel3FinancialInstrumentsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:href="acet-20211231.xsd#Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureMarketableDebtSecuritiesScheduleOfMarketableDebtSecuritiesDetails" xlink:href="acet-20211231.xsd#Role_DisclosureMarketableDebtSecuritiesScheduleOfMarketableDebtSecuritiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureMarketableDebtSecuritiesSummaryOfClassificationOfMarketableDebtSecuritiesInConsolidatedBalanceSheetsDetails" xlink:href="acet-20211231.xsd#Role_DisclosureMarketableDebtSecuritiesSummaryOfClassificationOfMarketableDebtSecuritiesInConsolidatedBalanceSheetsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="acet-20211231.xsd#Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails" xlink:href="acet-20211231.xsd#Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:href="acet-20211231.xsd#Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesSummaryOfAccruedAndOtherCurrentLiabilitiesDetails" xlink:href="acet-20211231.xsd#Role_DisclosureAccruedAndOtherCurrentLiabilitiesSummaryOfAccruedAndOtherCurrentLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails" xlink:href="acet-20211231.xsd#Role_DisclosureTermLoanAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRegeneronLicenseAndCollaborationArrangementAdditionalInformationDetails" xlink:href="acet-20211231.xsd#Role_DisclosureRegeneronLicenseAndCollaborationArrangementAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRegeneronLicenseAndCollaborationArrangementSummaryOfChangeInCompanySContractLiabilitiesDetails" xlink:href="acet-20211231.xsd#Role_DisclosureRegeneronLicenseAndCollaborationArrangementSummaryOfChangeInCompanySContractLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureLicenseFundingAndOtherAgreementsRelatedToCVRAdditionalInformationDetails" xlink:href="acet-20211231.xsd#Role_DisclosureLicenseFundingAndOtherAgreementsRelatedToCVRAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails" xlink:href="acet-20211231.xsd#Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSubleaseIncomeDetails" xlink:href="acet-20211231.xsd#DisclosureCommitmentsAndContingenciesScheduleOfSubleaseIncomeDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfWeightedAverageIBRAndRemainingLeaseTermDetails" xlink:href="acet-20211231.xsd#Role_DisclosureCommitmentAndContingenciesScheduleOfWeightedAverageIBRAndRemainingLeaseTermDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesSummaryOfLeaseCostsAndOtherInformationDetails" xlink:href="acet-20211231.xsd#Role_DisclosureCommitmentAndContingenciesSummaryOfLeaseCostsAndOtherInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:href="acet-20211231.xsd#Role_DisclosureCommitmentAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails" xlink:href="acet-20211231.xsd#Role_DisclosureCommitmentAndContingenciesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" xlink:href="acet-20211231.xsd#DisclosureStockholdersEquityAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceDetails" xlink:href="acet-20211231.xsd#DisclosureStockholdersEquityScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfOutstandingWarrantsDetails" xlink:href="acet-20211231.xsd#DisclosureStockholdersEquityScheduleOfOutstandingWarrantsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockDetails" xlink:href="acet-20211231.xsd#DisclosureStockholdersEquityScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureAtTheMarketATMOfferingAdditionalInformationDetails" xlink:href="acet-20211231.xsd#Role_DisclosureAtTheMarketATMOfferingAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" xlink:href="acet-20211231.xsd#Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:href="acet-20211231.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" xlink:href="acet-20211231.xsd#Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsToEstimateFairValueOfStockOptionsUsingBlackScholesOptionPricingModelDetails" xlink:href="acet-20211231.xsd#Role_DisclosureStockBasedCompensationScheduleOfAssumptionsToEstimateFairValueOfStockOptionsUsingBlackScholesOptionPricingModelDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails" xlink:href="acet-20211231.xsd#DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:href="acet-20211231.xsd#Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails" xlink:href="acet-20211231.xsd#Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="acet-20211231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForBenefitFromIncomeTaxesDetail" xlink:href="acet-20211231.xsd#Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForBenefitFromIncomeTaxesDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDiffersFromFederalStatutoryRateToLossBeforeTaxesDetail" xlink:href="acet-20211231.xsd#Role_DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDiffersFromFederalStatutoryRateToLossBeforeTaxesDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="acet-20211231.xsd#Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetail" xlink:href="acet-20211231.xsd#Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetails" xlink:href="acet-20211231.xsd#Role_DisclosureDefinedContributionPlanAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="acet-20211231.xsd#Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" xlink:href="acet-20211231.xsd#Role_DisclosureSubsequentEventsAdditionalInformationDetails" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine2" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory" order="33" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag" order="34" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId" order="35" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName" order="36" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation" order="37" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock" order="38" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:label="us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopmentInProcess" xlink:label="us-gaap_DevelopmentInProcess"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_RedeemableConvertiblePreferredStockWarrantLiability" xlink:label="acet_RedeemableConvertiblePreferredStockWarrantLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilities" xlink:label="us-gaap_OtherLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsReceivableRelatedPartiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Goodwill" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DevelopmentInProcess" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedCashNoncurrent" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAssetsNoncurrent" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Assets" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsPayableCurrent" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrent" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredRentCreditNoncurrent" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acet_RedeemableConvertiblePreferredStockWarrantLiability" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherLiabilities" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Liabilities" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommitmentsAndContingencies" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" order="31" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockValue" order="32" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockValue" order="33" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="34" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="35" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="36" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="37" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="38" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockLiquidationPreferenceValue" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromRelatedParties" xlink:label="us-gaap_RevenueFromRelatedParties"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RevenueFromRelatedParties" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossBeforeTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InterestAndOtherIncome" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InterestExpense" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_TemporaryEquityStockConversionSharesInConnectionWithMerger" xlink:label="acet_TemporaryEquityStockConversionSharesInConnectionWithMerger"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_TemporaryEquityStockConversionInConnectionWithMerger" xlink:label="acet_TemporaryEquityStockConversionInConnectionWithMerger"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_StockIssuedDuringPeriodSharesConversionOfSecurities" xlink:label="acet_StockIssuedDuringPeriodSharesConversionOfSecurities"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_StockExchangedDuringPeriodValueInConnectionWithMerger" xlink:label="acet_StockExchangedDuringPeriodValueInConnectionWithMerger"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_StockExchangedDuringPeriodSharesInConnectionWithMerger" xlink:label="acet_StockExchangedDuringPeriodSharesInConnectionWithMerger"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_StockIssuedDuringPeriodValueUponAcceleratedVestingOfRSUWithMerger" xlink:label="acet_StockIssuedDuringPeriodValueUponAcceleratedVestingOfRSUWithMerger"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_StockIssuedDuringPeriodSharesUponAcceleratedVestingOfRSUWithMerger" xlink:label="acet_StockIssuedDuringPeriodSharesUponAcceleratedVestingOfRSUWithMerger"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_24"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_25"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_26"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding_27"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acet_TemporaryEquityStockConversionSharesInConnectionWithMerger" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acet_TemporaryEquityStockConversionInConnectionWithMerger" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acet_StockIssuedDuringPeriodSharesConversionOfSecurities" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acet_StockExchangedDuringPeriodValueInConnectionWithMerger" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acet_StockExchangedDuringPeriodSharesInConnectionWithMerger" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acet_StockIssuedDuringPeriodValueUponAcceleratedVestingOfRSUWithMerger" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="acet_StockIssuedDuringPeriodSharesUponAcceleratedVestingOfRSUWithMerger" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockAmountConverted1" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_24" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_25" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_26" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding_27" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="acet_SeriesBRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="acet_SeriesBRedeemableConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="acet_SeriesBRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_CommonStockOfferingCostsIncludedInAccruedLiabilitiesAtPeriodEnd" xlink:label="acet_CommonStockOfferingCostsIncludedInAccruedLiabilitiesAtPeriodEnd"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIncomeTaxRefunds" xlink:label="us-gaap_ProceedsFromIncomeTaxRefunds"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ProceedsFromSalesOfMarketableDebtSecurities" xlink:label="acet_ProceedsFromSalesOfMarketableDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashExpense" xlink:label="us-gaap_OtherNoncashExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_RightOfUseAssetsRecognized" xlink:label="acet_RightOfUseAssetsRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="acet_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ImpairmentOfInProcessResearchAndDevelopment" xlink:label="acet_ImpairmentOfInProcessResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_GainOnRemeasurementOfContingentConsiderationLiability" xlink:label="acet_GainOnRemeasurementOfContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfAssetsAcquired" xlink:label="us-gaap_FairValueOfAssetsAcquired"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_AmortizationOfDebtIssuanceCosts" xlink:label="acet_AmortizationOfDebtIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_GoodwillMeasurementPeriodAdjustments" xlink:label="acet_GoodwillMeasurementPeriodAdjustments"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_AdjustmentToGoodwill" xlink:label="acet_AdjustmentToGoodwill"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_IssuanceOfRedeemableConvertiblePreferredStockOnExerciseOfWarrantsWithLoanAgreement" xlink:label="acet_IssuanceOfRedeemableConvertiblePreferredStockOnExerciseOfWarrantsWithLoanAgreement"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_VestingOfEarlyExercisedStockOptions" xlink:label="acet_VestingOfEarlyExercisedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ExerciseOfRedeemableConvertiblePreferredStockTrancheLiabilities" xlink:label="acet_ExerciseOfRedeemableConvertiblePreferredStockTrancheLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_TerminationOfRedeemableConvertiblePreferredStockTrancheLiability" xlink:label="acet_TerminationOfRedeemableConvertiblePreferredStockTrancheLiability"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_SettlementOfTRDFLiability" xlink:label="acet_SettlementOfTRDFLiability"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="acet_SeriesBRedeemableConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaid" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_CashAcquiredFromAcquisition" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="acet_CommonStockOfferingCostsIncludedInAccruedLiabilitiesAtPeriodEnd" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_ProceedsFromIncomeTaxRefunds" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockPlans" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="acet_ProceedsFromSalesOfMarketableDebtSecurities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashExpense" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="acet_RightOfUseAssetsRecognized" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnDispositionOfAssets1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="acet_IncreaseDecreaseInOperatingLeaseLiabilities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="acet_ImpairmentOfInProcessResearchAndDevelopment" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_ConversionOfStockAmountConverted1" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="acet_GainOnRemeasurementOfContingentConsiderationLiability" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_FairValueOfAssetsAcquired" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="acet_AmortizationOfDebtIssuanceCosts" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="acet_GoodwillMeasurementPeriodAdjustments" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="acet_AdjustmentToGoodwill" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="acet_IssuanceOfRedeemableConvertiblePreferredStockOnExerciseOfWarrantsWithLoanAgreement" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="acet_VestingOfEarlyExercisedStockOptions" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="acet_ExerciseOfRedeemableConvertiblePreferredStockTrancheLiabilities" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="acet_TerminationOfRedeemableConvertiblePreferredStockTrancheLiability" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="acet_SettlementOfTRDFLiability" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusiness" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_OrganizationAndNatureOfBusinessTextBlock" xlink:label="acet_OrganizationAndNatureOfBusinessTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="acet_OrganizationAndNatureOfBusinessTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombination" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurements" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureMarketableDebtSecurities" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:label="acet_PrepaidExpensesAndOtherCurrentAssetsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="acet_PrepaidExpensesAndOtherCurrentAssetsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilities" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureTermLoan" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_TermLoanAbstract" xlink:label="acet_TermLoanAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acet_TermLoanAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRegeneronLicenseAndCollaborationArrangement" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureLicenseFundingAndOtherAgreementsRelatedToCVR" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_LicenseFundingAndOtherAgreementsAbstract" xlink:label="acet_LicenseFundingAndOtherAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_LicenseFundingAndOtherAgreementsTextBlock" xlink:label="acet_LicenseFundingAndOtherAgreementsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acet_LicenseFundingAndOtherAgreementsAbstract" xlink:to="acet_LicenseFundingAndOtherAgreementsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingences" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockholdersEquity" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureAtMarketATMOffering" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_AtTheMarketOfferingTextBlock" xlink:label="acet_AtTheMarketOfferingTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="acet_AtTheMarketOfferingTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensation" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShare" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureDefinedContributionPlan" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_DefinedContributionPlanAbstract" xlink:label="acet_DefinedContributionPlanAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanTextBlock" xlink:label="us-gaap_DefinedContributionPlanTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acet_DefinedContributionPlanAbstract" xlink:to="us-gaap_DefinedContributionPlanTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSubsequentEvents" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityPolicyTextBlock" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="us-gaap_BusinessCombinationsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_RisksAndUncertaintiesPolicyTextBlock" xlink:label="acet_RisksAndUncertaintiesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_RedeemableConvertiblePreferredStockPolicyTextBlock" xlink:label="acet_RedeemableConvertiblePreferredStockPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_RedeemableConvertiblePreferredStockTrancheLiabilityPolicyTextBlock" xlink:label="acet_RedeemableConvertiblePreferredStockTrancheLiabilityPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_RedeemableConvertiblePreferredStockWarrantLiabilityPolicyTextBlock" xlink:label="acet_RedeemableConvertiblePreferredStockWarrantLiabilityPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_AccruedResearchAndDevelopmentPolicyTextBlock" xlink:label="acet_AccruedResearchAndDevelopmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_FairValueOfCommonStockPolicyTextBlock" xlink:label="acet_FairValueOfCommonStockPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConsolidationPolicyTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StockholdersEquityPolicyTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BusinessCombinationsPolicy" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="acet_RisksAndUncertaintiesPolicyTextBlock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="acet_RedeemableConvertiblePreferredStockPolicyTextBlock" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="acet_RedeemableConvertiblePreferredStockTrancheLiabilityPolicyTextBlock" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="acet_RedeemableConvertiblePreferredStockWarrantLiabilityPolicyTextBlock" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="acet_AccruedResearchAndDevelopmentPolicyTextBlock" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="acet_FairValueOfCommonStockPolicyTextBlock" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SubsequentEventsPolicyPolicyTextBlock" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentsTableTextBlock" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentsTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessAcquisitionProFormaInformationTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentsTableTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ScheduleOfChangesInFairValueOfUnobservableFinancialInstrumentsTableTextBlock" xlink:label="acet_ScheduleOfChangesInFairValueOfUnobservableFinancialInstrumentsTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="acet_ScheduleOfChangesInFairValueOfUnobservableFinancialInstrumentsTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureMarketableDebtSecuritiesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="us-gaap_MarketableSecuritiesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_MarketableDebtSecuritiesClassificationTableTextBlock" xlink:label="acet_MarketableDebtSecuritiesClassificationTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_MarketableSecuritiesTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="acet_MarketableDebtSecuritiesClassificationTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:label="acet_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="acet_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRegeneronLicenseAndCollaborationArrangementTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ScheduleOfSubleaseIncomeTableTextBlock" xlink:label="acet_ScheduleOfSubleaseIncomeTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ScheduleOfWeightedAverageIBRAndRemainingLeaseTermTableTextBlock" xlink:label="acet_ScheduleOfWeightedAverageIBRAndRemainingLeaseTermTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="acet_ScheduleOfSubleaseIncomeTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="acet_ScheduleOfWeightedAverageIBRAndRemainingLeaseTermTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LeaseCostTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockholdersEquityTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceTextBlock" xlink:label="acet_ScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockTableTextBlock" xlink:label="acet_ScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="acet_ScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="acet_ScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_OrganizationAndNatureOfBusinessAbstract" xlink:label="acet_OrganizationAndNatureOfBusinessAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_AdicetTherapeuticsIncMember" xlink:label="acet_AdicetTherapeuticsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="dei_EntityIncorporationDateOfIncorporation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_EntityDateOfMerger" xlink:label="acet_EntityDateOfMerger"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ExchangeRatio" xlink:label="acet_ExchangeRatio"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_OptionToPurchaseOfCommonStockAtPublicOfferingPrice" xlink:label="acet_OptionToPurchaseOfCommonStockAtPublicOfferingPrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:label="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_UnderwritingDiscountsAndCommissionsAndOtherOfferingExpenses" xlink:label="acet_UnderwritingDiscountsAndCommissionsAndOtherOfferingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acet_OrganizationAndNatureOfBusinessAbstract" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="acet_AdicetTherapeuticsIncMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="dei_EntityIncorporationDateOfIncorporation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="acet_EntityDateOfMerger" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="acet_ExchangeRatio" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="acet_OptionToPurchaseOfCommonStockAtPublicOfferingPrice" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="acet_UnderwritingDiscountsAndCommissionsAndOtherOfferingExpenses" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="acet_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ExchangeRatio" xlink:label="acet_ExchangeRatio"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_SummaryOfSignificantAccountingPoliciesTable" xlink:label="acet_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_GainLossOnChangeInFairValueOfContingentConsiderationLiability" xlink:label="acet_GainLossOnChangeInFairValueOfContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_NumberOfCustomer" xlink:label="acet_NumberOfCustomer"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_CustomersPercentageOfTotalRevenue" xlink:label="acet_CustomersPercentageOfTotalRevenue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_FinancingReceivableNonaccrualToOutstandingPercent" xlink:label="srt_FinancingReceivableNonaccrualToOutstandingPercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDeferredLiabilities"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acet_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="acet_ExchangeRatio" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="acet_SummaryOfSignificantAccountingPoliciesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acet_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acet_SummaryOfSignificantAccountingPoliciesTable" xlink:to="acet_SummaryOfSignificantAccountingPoliciesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acet_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="acet_GainLossOnChangeInFairValueOfContingentConsiderationLiability" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acet_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acet_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acet_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="acet_NumberOfCustomer" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acet_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="acet_CustomersPercentageOfTotalRevenue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acet_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="srt_FinancingReceivableNonaccrualToOutstandingPercent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acet_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AssetImpairmentCharges" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acet_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acet_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfReportableSegments" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acet_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acet_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acet_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_IncreaseDecreaseInDeferredLiabilities" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_TransitionAgreementMember" xlink:label="acet_TransitionAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ResTORbioMember" xlink:label="acet_ResTORbioMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:label="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_NumberOfSharesOfSurvivingStockOptions" xlink:label="acet_NumberOfSharesOfSurvivingStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_UnvestedRestrictedStockUnitsOutstanding" xlink:label="acet_UnvestedRestrictedStockUnitsOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentTangibleAndIntangiblesAssets" xlink:label="acet_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentTangibleAndIntangiblesAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForMergerRelatedCosts" xlink:label="us-gaap_PaymentsForMergerRelatedCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedBonusesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedBonusesCurrentAndNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_LumpSumCompensationPayment" xlink:label="acet_LumpSumCompensationPayment"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_AmountPayableUponClosingOfMerger" xlink:label="acet_AmountPayableUponClosingOfMerger"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LegalFees" xlink:label="us-gaap_LegalFees"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_AdvisoryServicesAnnualFee" xlink:label="acet_AdvisoryServicesAnnualFee"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ContractualContingentValueRight" xlink:label="acet_ContractualContingentValueRight"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="acet_TransitionAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="acet_ResTORbioMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="acet_NumberOfSharesOfSurvivingStockOptions" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="acet_UnvestedRestrictedStockUnitsOutstanding" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="acet_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentTangibleAndIntangiblesAssets" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_Goodwill" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_PaymentsForMergerRelatedCosts" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationAcquisitionRelatedCosts" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_Cash" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_AccruedBonusesCurrentAndNoncurrent" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="acet_LumpSumCompensationPayment" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="acet_AmountPayableUponClosingOfMerger" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_LegalFees" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="acet_AdvisoryServicesAnnualFee" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="acet_ContractualContingentValueRight" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesPurchasePriceInMergerDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure" xlink:label="us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ResTORbioMember" xlink:label="acet_ResTORbioMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="acet_ResTORbioMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfEstimatedShareConsiderationOfCombinedCompanyDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ResTORbioMember" xlink:label="acet_ResTORbioMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="us-gaap_BusinessAcquisitionSharePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:label="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_BusinessCombinationAccelerationOfRestrictedStockUnitsUponMerger" xlink:label="acet_BusinessCombinationAccelerationOfRestrictedStockUnitsUponMerger"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_FairValueOfModifiedStockOptionsAndRestrictedStockUnitsAttributableToPreCombinationServices" xlink:label="acet_FairValueOfModifiedStockOptionsAndRestrictedStockUnitsAttributableToPreCombinationServices"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_LessPortionOfFairValueToBeDistributedAsCVR" xlink:label="acet_LessPortionOfFairValueToBeDistributedAsCVR"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure" xlink:label="us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="acet_ResTORbioMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionSharePrice" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="acet_BusinessCombinationAccelerationOfRestrictedStockUnitsUponMerger" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="acet_FairValueOfModifiedStockOptionsAndRestrictedStockUnitsAttributableToPreCombinationServices" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="acet_LessPortionOfFairValueToBeDistributedAsCVR" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfEstimatedShareConsiderationOfCombinedCompanyParentheticalDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ResTORbioMember" xlink:label="acet_ResTORbioMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="acet_ResTORbioMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesPurchasePriceInMergerParentheticalDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_UnvestedRestrictedStockUnitsOutstanding" xlink:label="acet_UnvestedRestrictedStockUnitsOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ResTORbioMember" xlink:label="acet_ResTORbioMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_NumberOfSharesOfSurvivingStockOptions" xlink:label="acet_NumberOfSharesOfSurvivingStockOptions"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="acet_UnvestedRestrictedStockUnitsOutstanding" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="acet_ResTORbioMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="acet_NumberOfSharesOfSurvivingStockOptions" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsAcquiredDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ResTORbioMember" xlink:label="acet_ResTORbioMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementAdjustmentMember" xlink:label="srt_RestatementAdjustmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment" xlink:label="acet_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" xlink:label="acet_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="acet_ResTORbioMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementDomain" xlink:to="srt_ScenarioPreviouslyReportedMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RestatementDomain" xlink:to="srt_RestatementAdjustmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="srt_RestatementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="acet_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="acet_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_Goodwill" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/DisclosureBusinessCombinationScheduleOfChangesInTheCompanysIprdAndCvrSinceTheMergerDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAssetsArisingFromContingenciesAmountRecognized" xlink:label="us-gaap_BusinessCombinationAssetsArisingFromContingenciesAmountRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeDuringPeriodFairValueDisclosureMember" xlink:label="us-gaap_ChangeDuringPeriodFairValueDisclosureMember"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ContingentValueRightsAgreementMember" xlink:label="acet_ContingentValueRightsAgreementMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember" order="0" priority="2" use="optional" preferredLabel="http://fasb.org/us-gaap/role/label/axisDefault"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_InProcessResearchAndDevelopmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_FairValueDisclosureItemAmountsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_BusinessCombinationAssetsArisingFromContingenciesAmountRecognized" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_ChangeDuringPeriodFairValueDisclosureMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByMeasurementBasisAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="acet_ContingentValueRightsAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSupplementalUnauditedProFormaInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_BusinessAcquisitionsProFormaRevenue1" xlink:label="acet_BusinessAcquisitionsProFormaRevenue1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="acet_BusinessAcquisitionsProFormaRevenue1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_MarketableSecuritiesMember" xlink:label="acet_MarketableSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="us-gaap_AssetBackedSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ContingentConsiderationMember" xlink:label="acet_ContingentConsiderationMember"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_RedeemableConvertiblePreferredStockWarrantsMember" xlink:label="acet_RedeemableConvertiblePreferredStockWarrantsMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="acet_MarketableSecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_AssetBackedSecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CommercialPaperMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="acet_ContingentConsiderationMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="acet_RedeemableConvertiblePreferredStockWarrantsMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfLevel3FinancialInstrumentsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_RedeemableConvertiblePreferredStockTrancheLiabilityMember" xlink:label="acet_RedeemableConvertiblePreferredStockTrancheLiabilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeDuringPeriodFairValueDisclosureMember" xlink:label="us-gaap_ChangeDuringPeriodFairValueDisclosureMember"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_RecognitionOfPreferredStockWarrantLiabilities" xlink:label="acet_RecognitionOfPreferredStockWarrantLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_TRDFLiabilityMember" xlink:label="acet_TRDFLiabilityMember"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_RedeemableConvertiblePreferredStockWarrantLiabilityMember" xlink:label="acet_RedeemableConvertiblePreferredStockWarrantLiabilityMember"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_RecognitionOfContingentConsiderationLiability" xlink:label="acet_RecognitionOfContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ContingentConsiderationLiabilityMember" xlink:label="acet_ContingentConsiderationLiabilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="us-gaap_LiabilitiesFairValueAdjustment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_LiabilitiesFairValueExercised" xlink:label="acet_LiabilitiesFairValueExercised"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_LiabilitiesFairValueSettled" xlink:label="acet_LiabilitiesFairValueSettled"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ChangeInFairValueIncludedInResearchAndDevelopmentExpense" xlink:label="acet_ChangeInFairValueIncludedInResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ConversionOfConvertiblePreferredStockWarrantsIntoCommonStockWarrantsInConnectionWithMerger" xlink:label="acet_ConversionOfConvertiblePreferredStockWarrantsIntoCommonStockWarrantsInConnectionWithMerger"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_9"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="acet_RedeemableConvertiblePreferredStockTrancheLiabilityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember" order="0" priority="2" use="optional" preferredLabel="http://fasb.org/us-gaap/role/label/axisDefault"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_FairValueDisclosureItemAmountsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_ChangeDuringPeriodFairValueDisclosureMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="acet_RecognitionOfPreferredStockWarrantLiabilities" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="acet_TRDFLiabilityMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="acet_RedeemableConvertiblePreferredStockWarrantLiabilityMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementBasisAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="acet_RecognitionOfContingentConsiderationLiability" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="acet_ContingentConsiderationLiabilityMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueAdjustment" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="acet_LiabilitiesFairValueExercised" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="acet_LiabilitiesFairValueSettled" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="acet_ChangeInFairValueIncludedInResearchAndDevelopmentExpense" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="acet_ConversionOfConvertiblePreferredStockWarrantsIntoCommonStockWarrantsInConnectionWithMerger" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure_9" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_MilestoneClosingLiability" xlink:label="acet_MilestoneClosingLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_RedeemableConvertiblePreferredStockWarrantLiabilityMember" xlink:label="acet_RedeemableConvertiblePreferredStockWarrantLiabilityMember"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_AdditionalClosingLiability" xlink:label="acet_AdditionalClosingLiability"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_GainLossFromTheRemeasurementOfRedeemableConvertiblePreferredStock" xlink:label="acet_GainLossFromTheRemeasurementOfRedeemableConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_IncreaseDecreaseInEstimatedFairValueOfCvrLiability" xlink:label="acet_IncreaseDecreaseInEstimatedFairValueOfCvrLiability"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_EstimatedFairValueOfCVRLiability" xlink:label="acet_EstimatedFairValueOfCVRLiability"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="acet_MilestoneClosingLiability" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="acet_RedeemableConvertiblePreferredStockWarrantLiabilityMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="acet_AdditionalClosingLiability" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="acet_GainLossFromTheRemeasurementOfRedeemableConvertiblePreferredStock" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="acet_IncreaseDecreaseInEstimatedFairValueOfCvrLiability" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="acet_EstimatedFairValueOfCVRLiability" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureMarketableDebtSecuritiesScheduleOfMarketableDebtSecuritiesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:label="us-gaap_MarketableSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="us-gaap_MarketableSecuritiesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="us-gaap_AssetBackedSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_MarketableSecuritiesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_FinancialInstrumentAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_AssetBackedSecuritiesMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_MarketableSecuritiesLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureMarketableDebtSecuritiesSummaryOfClassificationOfMarketableDebtSecuritiesInConsolidatedBalanceSheetsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecurities" xlink:label="us-gaap_MarketableSecurities"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_MarketableSecurities" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_PrepaymentsToCros" xlink:label="acet_PrepaymentsToCros"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_PrepaymentsToCmos" xlink:label="acet_PrepaymentsToCmos"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="us-gaap_IncomeTaxesReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidInsurance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="acet_PrepaymentsToCros" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseCurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="acet_PrepaymentsToCmos" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_IncomeTaxesReceivable" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_InterestReceivableCurrent" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_LaboratoryEquipmentMember" xlink:label="acet_LaboratoryEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="acet_LaboratoryEquipmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_IncreaseInConstructionInProgress" xlink:label="acet_IncreaseInConstructionInProgress"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_DepreciationAndAmortization" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="acet_IncreaseInConstructionInProgress" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesSummaryOfAccruedAndOtherCurrentLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_AccruedCmoCosts" xlink:label="acet_AccruedCmoCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_AccruedResearchAndDevelopmentExpensesCurrent" xlink:label="acet_AccruedResearchAndDevelopmentExpensesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_AccruedCroCosts" xlink:label="acet_AccruedCroCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="acet_AccruedCmoCosts" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="acet_AccruedResearchAndDevelopmentExpensesCurrent" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="acet_AccruedCroCosts" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_TermLoanToFinanceLeaseholdImprovements1" xlink:label="acet_TermLoanToFinanceLeaseholdImprovements1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_PacificWesternBankMember" xlink:label="acet_PacificWesternBankMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_FourthAmendmentMember" xlink:label="acet_FourthAmendmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_TermLoanAbstract" xlink:label="acet_TermLoanAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrimeRateMember" xlink:label="us-gaap_PrimeRateMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansReceivableBasisSpreadOnVariableRate" xlink:label="us-gaap_LoansReceivableBasisSpreadOnVariableRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDateRangeEnd1" xlink:label="us-gaap_DebtInstrumentMaturityDateRangeEnd1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_LoanAmountDrawn" xlink:label="acet_LoanAmountDrawn"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="us-gaap_DeferredFinanceCostsGross"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_TermLoanAndNonFormulaAncillaryService" xlink:label="acet_TermLoanAndNonFormulaAncillaryService"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtDescription" xlink:label="us-gaap_LongTermDebtDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayable" xlink:label="us-gaap_LoansPayable"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="acet_TermLoanToFinanceLeaseholdImprovements1" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="acet_PacificWesternBankMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="acet_FourthAmendmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acet_TermLoanAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="srt_RangeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_PrimeRateMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_VariableRateAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_LoansReceivableBasisSpreadOnVariableRate" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDateRangeEnd1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="acet_LoanAmountDrawn" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_LongtermDebtTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_DeferredFinanceCostsGross" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="acet_TermLoanAndNonFormulaAncillaryService" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_LongTermDebtDescription" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_LoansPayable" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRegeneronLicenseAndCollaborationArrangementAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_RegeneronPharmaceuticalsIncorporationMember" xlink:label="acet_RegeneronPharmaceuticalsIncorporationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_NonRefundableUpfrontPaymentReceived" xlink:label="acet_NonRefundableUpfrontPaymentReceived"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_LicenseAgreementAdditionalPaymentForResearchFundingReceived" xlink:label="acet_LicenseAgreementAdditionalPaymentForResearchFundingReceived"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_LicenceAgreementAdditionalAmountPayableOfOptionExerciseFees" xlink:label="acet_LicenceAgreementAdditionalAmountPayableOfOptionExerciseFees"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ContractResearchTermPeriod" xlink:label="acet_ContractResearchTermPeriod"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_LicenceAgreementUpfrontPayment" xlink:label="acet_LicenceAgreementUpfrontPayment"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_LicenceAgreementAdditionalRevenueRecognised" xlink:label="acet_LicenceAgreementAdditionalRevenueRecognised"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ContingentConsiderationFees" xlink:label="acet_ContingentConsiderationFees"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_AgreementTransactionPrice" xlink:label="acet_AgreementTransactionPrice"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ResearchFundingFee" xlink:label="acet_ResearchFundingFee"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_LicenseAgreementCumulativeRevenueReductionRecognised" xlink:label="acet_LicenseAgreementCumulativeRevenueReductionRecognised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:label="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_LicenseAgreementTerminationDescription" xlink:label="acet_LicenseAgreementTerminationDescription"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ExercisedInvestmentRightAndPurchased" xlink:label="acet_ExercisedInvestmentRightAndPurchased"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_LicenceAgreementCumulativeRevenueRecognised" xlink:label="acet_LicenceAgreementCumulativeRevenueRecognised"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ContractLiability" xlink:label="acet_ContractLiability"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_LicenseAndCollaborationRevenue" xlink:label="acet_LicenseAndCollaborationRevenue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="acet_RegeneronPharmaceuticalsIncorporationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="acet_NonRefundableUpfrontPaymentReceived" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="acet_LicenseAgreementAdditionalPaymentForResearchFundingReceived" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="acet_LicenceAgreementAdditionalAmountPayableOfOptionExerciseFees" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="acet_ContractResearchTermPeriod" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="acet_LicenceAgreementUpfrontPayment" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="acet_LicenceAgreementAdditionalRevenueRecognised" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="acet_ContingentConsiderationFees" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="acet_AgreementTransactionPrice" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="acet_ResearchFundingFee" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="acet_LicenseAgreementCumulativeRevenueReductionRecognised" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="acet_LicenseAgreementTerminationDescription" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="acet_ExercisedInvestmentRightAndPurchased" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="acet_LicenceAgreementCumulativeRevenueRecognised" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="acet_ContractLiability" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="acet_LicenseAndCollaborationRevenue" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRegeneronLicenseAndCollaborationArrangementSummaryOfChangeInCompanySContractLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ContractAssetsAndLiabilities" xlink:label="acet_ContractAssetsAndLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ContractAssetMember" xlink:label="acet_ContractAssetMember"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ContractLiabilityMember" xlink:label="acet_ContractLiabilityMember"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ContractAssetsAndLiabilitiesAdditions" xlink:label="acet_ContractAssetsAndLiabilitiesAdditions"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ContractAssetsAndLiabilitiesAdditionsDeductions" xlink:label="acet_ContractAssetsAndLiabilitiesAdditionsDeductions"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ContractAssetsAndLiabilities" xlink:label="acet_ContractAssetsAndLiabilities_3"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="acet_ContractAssetsAndLiabilities" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="acet_ContractAssetMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_BalanceSheetLocationAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="acet_ContractLiabilityMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="acet_ContractAssetsAndLiabilitiesAdditions" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="acet_ContractAssetsAndLiabilitiesAdditionsDeductions" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="acet_ContractAssetsAndLiabilities_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureLicenseFundingAndOtherAgreementsRelatedToCVRAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_FeesAndExpenseIncurredInConnectionWithClinicalTrials" xlink:label="acet_FeesAndExpenseIncurredInConnectionWithClinicalTrials"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ContingentValueRightsAgreementMember" xlink:label="acet_ContingentValueRightsAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualRiskOrUncertaintyByNatureAxis" xlink:label="us-gaap_UnusualRiskOrUncertaintyByNatureAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualRiskOrUncertaintyNatureDomain" xlink:label="us-gaap_UnusualRiskOrUncertaintyNatureDomain"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_COVID19Member" xlink:label="acet_COVID19Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_NovartisInternationalPharmaceuticalLimitedMember" xlink:label="acet_NovartisInternationalPharmaceuticalLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ResearchFundingAgreementMember" xlink:label="acet_ResearchFundingAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_LicenseFundingAndOtherAgreementsAbstract" xlink:label="acet_LicenseFundingAndOtherAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_IncreaseDecreaseInEstimatedFairValueOfCvrLiability" xlink:label="acet_IncreaseDecreaseInEstimatedFairValueOfCvrLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_NationalInstitutesOfHealthMember" xlink:label="acet_NationalInstitutesOfHealthMember"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_NovartisLicenseAgreementMember" xlink:label="acet_NovartisLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_EstimatedFairValueOfCVRLiability" xlink:label="acet_EstimatedFairValueOfCVRLiability"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_LicenseAgreementTerminationDescription" xlink:label="acet_LicenseAgreementTerminationDescription"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfClinicalMilestonesPayable" xlink:label="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfClinicalMilestonesPayable"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfRegulatoryMilestonesPayableForFirstIndicationApproved" xlink:label="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfRegulatoryMilestonesPayableForFirstIndicationApproved"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfRegulatoryMilestonesPayableForSecondIndicationApproved" xlink:label="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfRegulatoryMilestonesPayableForSecondIndicationApproved"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfCommercialMilestonesPayable" xlink:label="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfCommercialMilestonesPayable"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_GrantTerm" xlink:label="acet_GrantTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantsReceivable" xlink:label="us-gaap_GrantsReceivable"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_QualifyingExpenses" xlink:label="acet_QualifyingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_PostExposureProphylaxisDescription" xlink:label="acet_PostExposureProphylaxisDescription"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_QualifyingExpensesOnCumulativeBasis" xlink:label="acet_QualifyingExpensesOnCumulativeBasis"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="acet_FeesAndExpenseIncurredInConnectionWithClinicalTrials" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:to="acet_ContingentValueRightsAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UnusualRiskOrUncertaintyByNatureAxis" xlink:to="us-gaap_UnusualRiskOrUncertaintyNatureDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UnusualRiskOrUncertaintyNatureDomain" xlink:to="acet_COVID19Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="acet_NovartisInternationalPharmaceuticalLimitedMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="acet_ResearchFundingAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acet_LicenseFundingAndOtherAgreementsAbstract" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:to="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="acet_IncreaseDecreaseInEstimatedFairValueOfCvrLiability" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="acet_NationalInstitutesOfHealthMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_UnusualRiskOrUncertaintyByNatureAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:to="acet_NovartisLicenseAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="acet_EstimatedFairValueOfCVRLiability" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="acet_LicenseAgreementTerminationDescription" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="srt_RangeAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfClinicalMilestonesPayable" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfRegulatoryMilestonesPayableForFirstIndicationApproved" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfRegulatoryMilestonesPayableForSecondIndicationApproved" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfCommercialMilestonesPayable" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="acet_GrantTerm" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_GrantsReceivable" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="acet_QualifyingExpenses" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="acet_PostExposureProphylaxisDescription" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="acet_QualifyingExpensesOnCumulativeBasis" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermPurchaseCommitmentLineItems" xlink:label="us-gaap_LongTermPurchaseCommitmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_IncreaseDecreaseInLeaseObligation" xlink:label="acet_IncreaseDecreaseInLeaseObligation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermPurchaseCommitmentTable" xlink:label="us-gaap_LongTermPurchaseCommitmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_MenloParkLeaseAgreementMember" xlink:label="acet_MenloParkLeaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_RfsOpcoLlcMember" xlink:label="acet_RfsOpcoLlcMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_RedwoodCityLeaseAgreementMember" xlink:label="acet_RedwoodCityLeaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_AreaOfSublease" xlink:label="acet_AreaOfSublease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_BostonMember" xlink:label="acet_BostonMember"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_SubleaseAgreementDescription" xlink:label="acet_SubleaseAgreementDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" xlink:label="us-gaap_OperatingLeasesRentExpenseSubleaseRentals1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecurityDepositLiability" xlink:label="us-gaap_SecurityDepositLiability"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_AmendedLeaseAgreementDescription" xlink:label="acet_AmendedLeaseAgreementDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LandSubjectToGroundLeases" xlink:label="us-gaap_LandSubjectToGroundLeases"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TenantImprovements" xlink:label="us-gaap_TenantImprovements"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_OperatingLeasesCommencementDate" xlink:label="acet_OperatingLeasesCommencementDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_16"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_LawsuitsFiledAgainstCompany" xlink:label="acet_LawsuitsFiledAgainstCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:label="us-gaap_LitigationSettlementExpense"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="acet_IncreaseDecreaseInLeaseObligation" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LongTermPurchaseCommitmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentTable" xlink:to="us-gaap_LeaseContractualTermAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="acet_MenloParkLeaseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="acet_RfsOpcoLlcMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="acet_RedwoodCityLeaseAgreementMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentTable" xlink:to="srt_CounterpartyNameAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="acet_AreaOfSublease" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="acet_BostonMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="acet_SubleaseAgreementDescription" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentTable" xlink:to="us-gaap_LongTermPurchaseCommitmentLineItems" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_SecurityDepositLiability" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="acet_AmendedLeaseAgreementDescription" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_LeaseAndRentalExpense" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_LandSubjectToGroundLeases" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_OperatingLeasePayments" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_TenantImprovements" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="acet_OperatingLeasesCommencementDate" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_OperatingLeaseLiability" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_FinanceLeaseLiability" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_16" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_LettersOfCreditOutstandingAmount" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="acet_LawsuitsFiledAgainstCompany" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_LitigationSettlementExpense" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSubleaseIncomeDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_OperatingLeasesFutureMinimumSubleaseIncomeDueCurrent" xlink:label="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueCurrent"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInTwoYears" xlink:label="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInTwoYears"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInThreeYears" xlink:label="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInThreeYears"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInFourYears" xlink:label="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInFourYears"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInFiveYears" xlink:label="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInFiveYears"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_OperatingLeasesFutureMinimumSubleaseIncomeDue" xlink:label="acet_OperatingLeasesFutureMinimumSubleaseIncomeDue"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInTwoYears" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInThreeYears" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInFourYears" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInFiveYears" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="acet_OperatingLeasesFutureMinimumSubleaseIncomeDue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfWeightedAverageIBRAndRemainingLeaseTermDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermPurchaseCommitmentTable" xlink:label="us-gaap_LongTermPurchaseCommitmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermPurchaseCommitmentLineItems" xlink:label="us-gaap_LongTermPurchaseCommitmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_RedwoodCityLeaseAgreementMember" xlink:label="acet_RedwoodCityLeaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_BostonMember" xlink:label="acet_BostonMember"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_MenloParkLeaseAgreementMember" xlink:label="acet_MenloParkLeaseAgreementMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LongTermPurchaseCommitmentTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="acet_RedwoodCityLeaseAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentTable" xlink:to="us-gaap_LeaseContractualTermAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="acet_BostonMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LongTermPurchaseCommitmentTable" xlink:to="us-gaap_LongTermPurchaseCommitmentLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="acet_MenloParkLeaseAgreementMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesSummaryOfLeaseCostsAndOtherInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_LeaseCostOtherInformationAbstract" xlink:label="acet_LeaseCostOtherInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePaymentsUse" xlink:label="us-gaap_OperatingLeasePaymentsUse"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acet_LeaseCostOtherInformationAbstract" xlink:to="us-gaap_OperatingLeasePayments" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LeaseCostAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_OperatingLeaseCost" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="acet_LeaseCostOtherInformationAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_ShortTermLeaseCost" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acet_LeaseCostOtherInformationAbstract" xlink:to="us-gaap_OperatingLeasePaymentsUse" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acet_LeaseCostOtherInformationAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_VariableLeaseCost" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_SubleaseIncome" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCost" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiability" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="us-gaap_SaleOfStockDescriptionOfTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:label="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ClassOfWarrantExercised" xlink:label="acet_ClassOfWarrantExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared" xlink:label="us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_SaleOfStockPricePerShare" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_SaleOfStockDescriptionOfTransaction" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="acet_ClassOfWarrantExercised" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_CommonStockDividendsPerShareDeclared" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_OptionsAvailableForFutureGrantsMember" xlink:label="acet_OptionsAvailableForFutureGrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_AdditionalAuthorizedAndUnissuedRedeemableConvertiblePreferredStockMember" xlink:label="acet_AdditionalAuthorizedAndUnissuedRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_RedeemableConvertiblePreferredStockWarrantsMember" xlink:label="acet_RedeemableConvertiblePreferredStockWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_CommonStockWarrantsMember" xlink:label="acet_CommonStockWarrantsMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="acet_OptionsAvailableForFutureGrantsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="acet_AdditionalAuthorizedAndUnissuedRedeemableConvertiblePreferredStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="acet_RedeemableConvertiblePreferredStockWarrantsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="acet_CommonStockWarrantsMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfOutstandingWarrantsDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ClassOfWarrantOutstandingAndExercisableToPurchasePreferredShares" xlink:label="acet_ClassOfWarrantOutstandingAndExercisableToPurchasePreferredShares"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ClassOfWarrantOrRightIssued" xlink:label="acet_ClassOfWarrantOrRightIssued"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ClassOfWarrantExercised" xlink:label="acet_ClassOfWarrantExercised"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_NumberOfSecuritiesConvertedToWarrantsToPurchaseCommonStock" xlink:label="acet_NumberOfSecuritiesConvertedToWarrantsToPurchaseCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ClassOfWarrantOutstandingAndExercisableToPurchaseCommonStock" xlink:label="acet_ClassOfWarrantOutstandingAndExercisableToPurchaseCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_WarrantsOutstandingAndExercisableWeightedAverageRemainingContractualTerm" xlink:label="acet_WarrantsOutstandingAndExercisableWeightedAverageRemainingContractualTerm"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="acet_ClassOfWarrantOutstandingAndExercisableToPurchasePreferredShares" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="acet_ClassOfWarrantOrRightIssued" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="acet_ClassOfWarrantExercised" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="acet_NumberOfSecuritiesConvertedToWarrantsToPurchaseCommonStock" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="acet_ClassOfWarrantOutstandingAndExercisableToPurchaseCommonStock" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="acet_WarrantsOutstandingAndExercisableWeightedAverageRemainingContractualTerm" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_SeptemberFifteenTwoThousandTwentyWarrantOneMember" xlink:label="acet_SeptemberFifteenTwoThousandTwentyWarrantOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_SeptemberFifteenTwoThousandTwentyWarrantTwoMember" xlink:label="acet_SeptemberFifteenTwoThousandTwentyWarrantTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_SeptemberFifteenTwoThousandTwentyWarrantThreeMember" xlink:label="acet_SeptemberFifteenTwoThousandTwentyWarrantThreeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ClassOfWarrantOrRightsExpirationDate" xlink:label="acet_ClassOfWarrantOrRightsExpirationDate"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_SeptemberFifteenTwoThousandTwentyWarrantFourMember" xlink:label="acet_SeptemberFifteenTwoThousandTwentyWarrantFourMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="acet_SeptemberFifteenTwoThousandTwentyWarrantOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="acet_SeptemberFifteenTwoThousandTwentyWarrantTwoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="acet_SeptemberFifteenTwoThousandTwentyWarrantThreeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="acet_ClassOfWarrantOrRightsExpirationDate" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="acet_SeptemberFifteenTwoThousandTwentyWarrantFourMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureAtTheMarketATMOfferingAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_MaximumAggregateValueOfCommonStockAvailableForOfferingAtMarketPriceUnderSalesAgreement" xlink:label="acet_MaximumAggregateValueOfCommonStockAvailableForOfferingAtMarketPriceUnderSalesAgreement"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_AtTheMarketOfferingMember" xlink:label="acet_AtTheMarketOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_SalesAgreementMember" xlink:label="acet_SalesAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_TerminationAgreementMonthAndYear" xlink:label="acet_TerminationAgreementMonthAndYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="acet_MaximumAggregateValueOfCommonStockAvailableForOfferingAtMarketPriceUnderSalesAgreement" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="acet_AtTheMarketOfferingMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="acet_SalesAgreementMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_ScheduleOfStockByClassTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="acet_TerminationAgreementMonthAndYear" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_TypeOfArrangementAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ClassOfStockLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="us-gaap_ShareBasedCompensationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_EmployeeStockPurchasePlanMember" xlink:label="acet_EmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_StockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="acet_EmployeeStockPurchasePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="us-gaap_ShareBasedCompensationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_TwoThousandEighteenStockIncentivePlanMember" xlink:label="acet_TwoThousandEighteenStockIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_TwoThousandSeventeenAndTwoThousandEighteenStockIncentivePlanMember" xlink:label="acet_TwoThousandSeventeenAndTwoThousandEighteenStockIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_TwoThousandFourteenStockIncentivePlanMember" xlink:label="acet_TwoThousandFourteenStockIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_TwoThousandFifteenStockIncentivePlanMember" xlink:label="acet_TwoThousandFifteenStockIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_TwoThousandFourteenAndTwoThousandFifteenStockIncentivePlanMember" xlink:label="acet_TwoThousandFourteenAndTwoThousandFifteenStockIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_TwoThousandEighteenEmployeeStockPurchasePlanMember" xlink:label="acet_TwoThousandEighteenEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_NumberOfSharesAvailableForSaleUnderEmployeeStockPurchasePlan" xlink:label="acet_NumberOfSharesAvailableForSaleUnderEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_InducementGrantsMember" xlink:label="acet_InducementGrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_TerminationAgreementMonthAndYear" xlink:label="acet_TerminationAgreementMonthAndYear"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_MergerMember" xlink:label="acet_MergerMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="acet_TwoThousandEighteenStockIncentivePlanMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="acet_TwoThousandSeventeenAndTwoThousandEighteenStockIncentivePlanMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="acet_TwoThousandFourteenStockIncentivePlanMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="acet_TwoThousandFifteenStockIncentivePlanMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_StatementScenarioAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="acet_TwoThousandFourteenAndTwoThousandFifteenStockIncentivePlanMember" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="acet_TwoThousandEighteenEmployeeStockPurchasePlanMember" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="acet_NumberOfSharesAvailableForSaleUnderEmployeeStockPurchasePlan" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="acet_InducementGrantsMember" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="acet_TerminationAgreementMonthAndYear" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="acet_MergerMember" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="us-gaap_ShareBasedCompensationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesAuthorized" xlink:label="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAsPartOfMerger" xlink:label="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAsPartOfMerger"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesGranted" xlink:label="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesGranted"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesExercised" xlink:label="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesExercised"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesCancelled" xlink:label="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesCancelled"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_6"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAuthorized" xlink:label="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedAsPartOfMerger" xlink:label="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedAsPartOfMerger"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_13"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAuthorizedInPeriodWeightedAverageExercisePrice" xlink:label="acet_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAuthorizedInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumedAsPartOfMergerInPeriodWeightedAverageExercisePrice" xlink:label="acet_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumedAsPartOfMergerInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_22"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesAuthorized" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAsPartOfMerger" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesGranted" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesExercised" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesCancelled" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_6" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAuthorized" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedAsPartOfMerger" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_13" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="14" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="15" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="16" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="acet_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAuthorizedInPeriodWeightedAverageExercisePrice" order="17" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="acet_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumedAsPartOfMergerInPeriodWeightedAverageExercisePrice" order="18" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="19" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="20" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" order="21" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_22" order="22" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="23" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="24" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="25" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="26" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="27" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="28" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="29" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="30" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsToEstimateFairValueOfStockOptionsUsingBlackScholesOptionPricingModelDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="us-gaap_ShareBasedCompensationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_4"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_4" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_RedeemableConvertiblePreferredStockWarrantsMember" xlink:label="acet_RedeemableConvertiblePreferredStockWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_CommonStockWarrantsMember" xlink:label="acet_CommonStockWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_UnvestedCommonStockFromEarlyExerciseOfOptionsMember" xlink:label="acet_UnvestedCommonStockFromEarlyExerciseOfOptionsMember"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_RedeemableConvertiblePreferredStockTrancheLiabilityAndTRDFObligationMember" xlink:label="acet_RedeemableConvertiblePreferredStockTrancheLiabilityAndTRDFObligationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AwardTypeAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="acet_RedeemableConvertiblePreferredStockWarrantsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="acet_CommonStockWarrantsMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="acet_UnvestedCommonStockFromEarlyExerciseOfOptionsMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="acet_RedeemableConvertiblePreferredStockTrancheLiabilityAndTRDFObligationMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_IncomeTaxesTable" xlink:label="acet_IncomeTaxesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualRiskOrUncertaintyByNatureAxis" xlink:label="us-gaap_UnusualRiskOrUncertaintyByNatureAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_CaliforniaResearchAndDevelopmentMember" xlink:label="acet_CaliforniaResearchAndDevelopmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualRiskOrUncertaintyNatureDomain" xlink:label="us-gaap_UnusualRiskOrUncertaintyNatureDomain"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_COVID19Member" xlink:label="acet_COVID19Member"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_IncomeTaxesDisclosureLineItems" xlink:label="acet_IncomeTaxesDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntellectualPropertyMember" xlink:label="us-gaap_IntellectualPropertyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_FederalAndStateResearchAndDevelopmentMember" xlink:label="acet_FederalAndStateResearchAndDevelopmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit" xlink:label="us-gaap_TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_OperatingLossCarrybackDurationUnderCARESAct" xlink:label="acet_OperatingLossCarrybackDurationUnderCARESAct"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_PercentageOfNetOperatingLossCarryforwards" xlink:label="acet_PercentageOfNetOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_DeferredTaxAssetsValuationAllowanceIncrease" xlink:label="acet_DeferredTaxAssetsValuationAllowanceIncrease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:label="us-gaap_OperatingLossCarryforwardsExpirationDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_OperatingLossCarryforwardsIndefinitely" xlink:label="acet_OperatingLossCarryforwardsIndefinitely"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_OwnershipChangePlanDescription" xlink:label="acet_OwnershipChangePlanDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acet_IncomeTaxesTable" xlink:to="us-gaap_UnusualRiskOrUncertaintyByNatureAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="acet_CaliforniaResearchAndDevelopmentMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UnusualRiskOrUncertaintyByNatureAxis" xlink:to="us-gaap_UnusualRiskOrUncertaintyNatureDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_UnusualRiskOrUncertaintyNatureDomain" xlink:to="acet_COVID19Member" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acet_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="acet_IncomeTaxesTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_IntellectualPropertyMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="acet_FederalAndStateResearchAndDevelopmentMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acet_IncomeTaxesTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acet_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acet_IncomeTaxesDisclosureLineItems" xlink:to="acet_OperatingLossCarrybackDurationUnderCARESAct" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acet_IncomeTaxesTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acet_IncomeTaxesTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acet_IncomeTaxesDisclosureLineItems" xlink:to="acet_PercentageOfNetOperatingLossCarryforwards" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acet_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acet_IncomeTaxesTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acet_IncomeTaxesTable" xlink:to="acet_IncomeTaxesDisclosureLineItems" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acet_IncomeTaxesDisclosureLineItems" xlink:to="acet_DeferredTaxAssetsValuationAllowanceIncrease" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acet_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acet_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsExpirationDate" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acet_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acet_IncomeTaxesDisclosureLineItems" xlink:to="acet_OperatingLossCarryforwardsIndefinitely" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acet_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" order="10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acet_IncomeTaxesDisclosureLineItems" xlink:to="acet_OwnershipChangePlanDescription" order="11" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acet_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acet_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" order="13" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForBenefitFromIncomeTaxesDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDiffersFromFederalStatutoryRateToLossBeforeTaxesDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_EffectiveIncomeTaxRateReconciliationNOLCarryback" xlink:label="acet_EffectiveIncomeTaxRateReconciliationNOLCarryback"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilityAndTRDFLiability" xlink:label="acet_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilityAndTRDFLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="acet_EffectiveIncomeTaxRateReconciliationNOLCarryback" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="acet_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilityAndTRDFLiability" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" order="9" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_DeferredTaxLiabilitiesFixedAssets" xlink:label="acet_DeferredTaxLiabilitiesFixedAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_DeferredTaxOperatingLeaseRightOfUseAssetLiability" xlink:label="acet_DeferredTaxOperatingLeaseRightOfUseAssetLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_DeferredTaxBasisDifferenceIPRD" xlink:label="acet_DeferredTaxBasisDifferenceIPRD"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_DeferredTaxOperatingLeaseRightOfUseAsset" xlink:label="acet_DeferredTaxOperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_DeferredTaxAssetsFixedAssets" xlink:label="acet_DeferredTaxAssetsFixedAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="acet_DeferredTaxLiabilitiesFixedAssets" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="acet_DeferredTaxOperatingLeaseRightOfUseAssetLiability" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="acet_DeferredTaxBasisDifferenceIPRD" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="acet_DeferredTaxOperatingLeaseRightOfUseAsset" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="acet_DeferredTaxAssetsFixedAssets" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" order="6" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="7" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="8" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetail" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_3"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits_3" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_DefinedContributionPlanAbstract" xlink:label="acet_DefinedContributionPlanAbstract"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_CompanyContributionToPlanWithRespectToEmployeesContribution" xlink:label="acet_CompanyContributionToPlanWithRespectToEmployeesContribution"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acet_DefinedContributionPlanAbstract" xlink:to="acet_CompanyContributionToPlanWithRespectToEmployeesContribution" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="acet_DefinedContributionPlanAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_RegeneronPharmaceuticalsIncorporationMember" xlink:label="acet_RegeneronPharmaceuticalsIncorporationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromRelatedParties" xlink:label="us-gaap_RevenueFromRelatedParties"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:label="us-gaap_AccountsReceivableGrossCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="acet_RegeneronPharmaceuticalsIncorporationMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_StatementClassOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionLineItems" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RevenueFromRelatedParties" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AccountsReceivableGrossCurrent" order="4" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DeferredRevenue" order="5" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" xlink:title="presentationLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ExerciseFeePaid" xlink:label="acet_ExerciseFeePaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="acet_ExerciseFeePaid" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" order="0" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" order="1" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_RangeAxis" order="2" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="3" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>35
<FILENAME>acet-20211231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Schema Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-03-15T16:13:37.1971+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<xsd:schema targetNamespace="http://www.adicetbio.com/20211231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:acet="http://www.adicetbio.com/20211231" xmlns:xlink="http://www.w3.org/1999/xlink">
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase"/>
  <xsd:import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" namespace="http://fasb.org/srt/2021-01-31"/>
  <xsd:import schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" namespace="http://fasb.org/us-gaap/2021-01-31"/>
  <xsd:import schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" namespace="http://xbrl.sec.gov/dei/2021q4"/>
  <xsd:import schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" namespace="http://www.xbrl.org/dtr/type/2020-01-21"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="acet-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Labels link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="acet-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="acet-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition link" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="acet-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation link" xlink:type="simple"/>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" id="Role_StatementConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" id="Role_StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>100020 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" id="Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>100030 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" id="Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit">
        <link:definition>100040 - Statement - Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" id="Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical">
        <link:definition>100050 - Statement - Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" id="Role_StatementConsolidatedStatementsOfCashFlows">
        <link:definition>100060 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusiness" id="Role_DisclosureOrganizationAndNatureOfBusiness">
        <link:definition>100070 - Disclosure - Organization and Nature of Business</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>100080 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombination" id="Role_DisclosureBusinessCombination">
        <link:definition>100090 - Disclosure - Business Combination</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurements" id="Role_DisclosureFairValueMeasurements">
        <link:definition>100100 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureMarketableDebtSecurities" id="Role_DisclosureMarketableDebtSecurities">
        <link:definition>100110 - Disclosure - Marketable Debt Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets" id="Role_DisclosurePrepaidExpensesAndOtherCurrentAssets">
        <link:definition>100120 - Disclosure - Prepaid Expenses and Other Current Assets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet" id="Role_DisclosurePropertyAndEquipmentNet">
        <link:definition>100130 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilities" id="Role_DisclosureAccruedAndOtherCurrentLiabilities">
        <link:definition>100140 - Disclosure - Accrued and Other Current Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureTermLoan" id="Role_DisclosureTermLoan">
        <link:definition>100150 - Disclosure - Term Loan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRegeneronLicenseAndCollaborationArrangement" id="Role_DisclosureRegeneronLicenseAndCollaborationArrangement">
        <link:definition>100160 - Disclosure - Regeneron License and Collaboration Arrangement</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureLicenseFundingAndOtherAgreementsRelatedToCVR" id="Role_DisclosureLicenseFundingAndOtherAgreementsRelatedToCVR">
        <link:definition>100170 - Disclosure - License Funding and Other Agreements Related to the CVR</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingences" id="Role_DisclosureCommitmentsAndContingences">
        <link:definition>100180 - Disclosure - Commitments and Contingences</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockholdersEquity" id="DisclosureStockholdersEquity">
        <link:definition>100190 - Disclosure - Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureAtMarketATMOffering" id="Role_DisclosureAtMarketATMOffering">
        <link:definition>100200 - Disclosure - At-the-Market (ATM) Offering</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensation" id="Role_DisclosureStockBasedCompensation">
        <link:definition>100210 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShare" id="Role_DisclosureNetLossPerShare">
        <link:definition>100220 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100230 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureDefinedContributionPlan" id="Role_DisclosureDefinedContributionPlan">
        <link:definition>100240 - Disclosure - Defined Contribution Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactions" id="Role_DisclosureRelatedPartyTransactions">
        <link:definition>100250 - Disclosure - Related Party Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSubsequentEvents" id="Role_DisclosureSubsequentEvents">
        <link:definition>100260 - Disclosure - Subsequent Events</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100270 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationTables" id="Role_DisclosureBusinessCombinationTables">
        <link:definition>100280 - Disclosure - Business Combination (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables" id="Role_DisclosureFairValueMeasurementsTables">
        <link:definition>100290 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureMarketableDebtSecuritiesTables" id="Role_DisclosureMarketableDebtSecuritiesTables">
        <link:definition>100300 - Disclosure - Marketable Debt Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" id="Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables">
        <link:definition>100310 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables" id="Role_DisclosurePropertyAndEquipmentNetTables">
        <link:definition>100320 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesTables" id="Role_DisclosureAccruedAndOtherCurrentLiabilitiesTables">
        <link:definition>100330 - Disclosure - Accrued and Other Current Liabilities  (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRegeneronLicenseAndCollaborationArrangementTables" id="Role_DisclosureRegeneronLicenseAndCollaborationArrangementTables">
        <link:definition>100340 - Disclosure - Regeneron License and Collaboration Arrangement (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencesTables" id="Role_DisclosureCommitmentsAndContingencesTables">
        <link:definition>100350 - Disclosure - Commitments and Contingences (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockholdersEquityTables" id="DisclosureStockholdersEquityTables">
        <link:definition>100360 - Disclosure - Stockholders' Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationTables" id="Role_DisclosureStockBasedCompensationTables">
        <link:definition>100370 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareTables" id="Role_DisclosureNetLossPerShareTables">
        <link:definition>100380 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>100390 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails" id="Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails">
        <link:definition>100400 - Disclosure - Organization and Nature of the Business - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>100410 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails" id="Role_DisclosureBusinessCombinationAdditionalInformationDetails">
        <link:definition>100420 - Disclosure - Business Combination - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesPurchasePriceInMergerDetails" id="Role_DisclosureBusinessCombinationScheduleOfSummarizesPurchasePriceInMergerDetails">
        <link:definition>100430 - Disclosure - Business Combination - Schedule of Summarizes the Purchase Price in the Merger (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfEstimatedShareConsiderationOfCombinedCompanyDetails" id="Role_DisclosureBusinessCombinationScheduleOfEstimatedShareConsiderationOfCombinedCompanyDetails">
        <link:definition>100440 - Disclosure - Business Combination - Schedule of Estimated Share Consideration of Combined Company (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfEstimatedShareConsiderationOfCombinedCompanyParentheticalDetails" id="Role_DisclosureBusinessCombinationScheduleOfEstimatedShareConsiderationOfCombinedCompanyParentheticalDetails">
        <link:definition>100450 - Disclosure - Business Combination - Schedule of Estimated Share Consideration of Combined Company (Parenthetical) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesPurchasePriceInMergerParentheticalDetails" id="Role_DisclosureBusinessCombinationScheduleOfSummarizesPurchasePriceInMergerParentheticalDetails">
        <link:definition>100460 - Disclosure - Business Combination - Schedule of Summarizes the Purchase Price in the Merger (Parenthetical) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsAcquiredDetails" id="Role_DisclosureBusinessCombinationScheduleOfSummarizesAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsAcquiredDetails">
        <link:definition>100470 - Disclosure - Business Combination - Schedule of Summarizes the Allocation of the Purchase Price to the Net Tangible and Intangible Assets Acquired (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/DisclosureBusinessCombinationScheduleOfChangesInTheCompanysIprdAndCvrSinceTheMergerDetails" id="DisclosureBusinessCombinationScheduleOfChangesInTheCompanysIprdAndCvrSinceTheMergerDetails">
        <link:definition>100480 - Disclosure - Business Combination - Schedule of changes in the Company's IPR&amp;D and CVR since the Merger (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSupplementalUnauditedProFormaInformationDetails" id="Role_DisclosureBusinessCombinationScheduleOfSupplementalUnauditedProFormaInformationDetails">
        <link:definition>100490 - Disclosure - Business Combination - Schedule of Supplemental Unaudited Pro Forma Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" id="Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails">
        <link:definition>100500 - Disclosure - Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured on Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfLevel3FinancialInstrumentsDetails" id="Role_DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfLevel3FinancialInstrumentsDetails">
        <link:definition>100510 - Disclosure - Fair Value Measurements - Schedule of Changes in Fair Value of Level 3 Financial Instruments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" id="Role_DisclosureFairValueMeasurementsAdditionalInformationDetails">
        <link:definition>100520 - Disclosure - Fair Value Measurements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureMarketableDebtSecuritiesScheduleOfMarketableDebtSecuritiesDetails" id="Role_DisclosureMarketableDebtSecuritiesScheduleOfMarketableDebtSecuritiesDetails">
        <link:definition>100530 - Disclosure - Marketable Debt Securities - Schedule of Marketable Debt Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureMarketableDebtSecuritiesSummaryOfClassificationOfMarketableDebtSecuritiesInConsolidatedBalanceSheetsDetails" id="Role_DisclosureMarketableDebtSecuritiesSummaryOfClassificationOfMarketableDebtSecuritiesInConsolidatedBalanceSheetsDetails">
        <link:definition>100540 - Disclosure - Marketable Debt Securities - Summary of Classification of Marketable Debt Securities in Consolidated Balance Sheets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" id="Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails">
        <link:definition>100550 - Disclosure - Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails" id="Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails">
        <link:definition>100560 - Disclosure - Property and Equipment, Net - Summary of Property and Equipment, Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails" id="Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails">
        <link:definition>100570 - Disclosure - Property and Equipment, Net - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesSummaryOfAccruedAndOtherCurrentLiabilitiesDetails" id="Role_DisclosureAccruedAndOtherCurrentLiabilitiesSummaryOfAccruedAndOtherCurrentLiabilitiesDetails">
        <link:definition>100580 - Disclosure - Accrued and Other Current Liabilities - Summary of Accrued and Other Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails" id="Role_DisclosureTermLoanAdditionalInformationDetails">
        <link:definition>100590 - Disclosure - Term Loan - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRegeneronLicenseAndCollaborationArrangementAdditionalInformationDetails" id="Role_DisclosureRegeneronLicenseAndCollaborationArrangementAdditionalInformationDetails">
        <link:definition>100600 - Disclosure - Regeneron License and Collaboration Arrangement - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRegeneronLicenseAndCollaborationArrangementSummaryOfChangeInCompanySContractLiabilitiesDetails" id="Role_DisclosureRegeneronLicenseAndCollaborationArrangementSummaryOfChangeInCompanySContractLiabilitiesDetails">
        <link:definition>100610 - Disclosure - Regeneron License and Collaboration Arrangement - Summary of Change in Company's Contract Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureLicenseFundingAndOtherAgreementsRelatedToCVRAdditionalInformationDetails" id="Role_DisclosureLicenseFundingAndOtherAgreementsRelatedToCVRAdditionalInformationDetails">
        <link:definition>100620 - Disclosure - License Funding and Other Agreements Related to the CVR - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails" id="Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails">
        <link:definition>100630 - Disclosure - Commitment and Contingencies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSubleaseIncomeDetails" id="DisclosureCommitmentsAndContingenciesScheduleOfSubleaseIncomeDetails">
        <link:definition>100640 - Disclosure - Commitments And Contingencies - Schedule of Sublease Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfWeightedAverageIBRAndRemainingLeaseTermDetails" id="Role_DisclosureCommitmentAndContingenciesScheduleOfWeightedAverageIBRAndRemainingLeaseTermDetails">
        <link:definition>100650 - Disclosure - Commitment and Contingencies - Schedule of Weighted Average IBR and Remaining Lease Term (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesSummaryOfLeaseCostsAndOtherInformationDetails" id="Role_DisclosureCommitmentAndContingenciesSummaryOfLeaseCostsAndOtherInformationDetails">
        <link:definition>100660 - Disclosure - Commitment and Contingencies - Summary of Lease Costs and Other Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" id="Role_DisclosureCommitmentAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails">
        <link:definition>100670 - Disclosure - Commitment and Contingencies - Schedule Of Maturities Of Operating Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails" id="Role_DisclosureCommitmentAndContingenciesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails">
        <link:definition>100680 - Disclosure - Commitment and Contingencies - Schedule Of Future Minimum Rental Payments For Operating Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails" id="DisclosureStockholdersEquityAdditionalInformationDetails">
        <link:definition>100690 - Disclosure - Stockholders' Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceDetails" id="DisclosureStockholdersEquityScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceDetails">
        <link:definition>100700 - Disclosure - Stockholders' Equity - Schedule of Number of Shares of Common Stock Reserved for Future Issuance (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfOutstandingWarrantsDetails" id="DisclosureStockholdersEquityScheduleOfOutstandingWarrantsDetails">
        <link:definition>100710 - Disclosure - Stockholders' Equity - Schedule of Outstanding Warrants (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockDetails" id="DisclosureStockholdersEquityScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockDetails">
        <link:definition>100720 - Disclosure - Stockholders' Equity - Schedule Of Outstanding Warrants To Purchase Shares of Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureAtTheMarketATMOfferingAdditionalInformationDetails" id="Role_DisclosureAtTheMarketATMOfferingAdditionalInformationDetails">
        <link:definition>100730 - Disclosure - At-The-Market (ATM) Offering - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails2" id="Role_DisclosureCommitmentAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails2">
        <link:definition>100740 - Disclosure - Commitment and Contingencies - Schedule Of Maturities Of Operating Lease Liabilities (Details)2</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" id="Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails">
        <link:definition>100750 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" id="Role_DisclosureStockBasedCompensationAdditionalInformationDetails">
        <link:definition>100760 - Disclosure - Stock-Based Compensation - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails" id="Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails">
        <link:definition>100770 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsToEstimateFairValueOfStockOptionsUsingBlackScholesOptionPricingModelDetails" id="Role_DisclosureStockBasedCompensationScheduleOfAssumptionsToEstimateFairValueOfStockOptionsUsingBlackScholesOptionPricingModelDetails">
        <link:definition>100780 - Disclosure - Stock-Based Compensation - Schedule of Assumptions to Estimate Fair Value of Stock Options Using Black-Scholes Option Pricing Model (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails" id="DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails">
        <link:definition>100790 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Unit Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails" id="Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails">
        <link:definition>100800 - Disclosure - Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails" id="Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails">
        <link:definition>100810 - Disclosure - Net Loss Per Share - Schedule of Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" id="Role_DisclosureIncomeTaxesAdditionalInformationDetails">
        <link:definition>100820 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForBenefitFromIncomeTaxesDetail" id="Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForBenefitFromIncomeTaxesDetail">
        <link:definition>100830 - Disclosure - Income Taxes - Schedule of Components of Provision for (benefit from) Income Taxes (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDiffersFromFederalStatutoryRateToLossBeforeTaxesDetail" id="Role_DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDiffersFromFederalStatutoryRateToLossBeforeTaxesDetail">
        <link:definition>100840 - Disclosure - Income Taxes - Schedule of (Provision for) Benefit from Income Taxes Differs from Federal Statutory Rate to the Loss Before Taxes (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" id="Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
        <link:definition>100850 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetail" id="Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetail">
        <link:definition>100860 - Disclosure - Income Taxes - Schedule of Reconciliation of Unrecognized Tax Benefits (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetails" id="Role_DisclosureDefinedContributionPlanAdditionalInformationDetails">
        <link:definition>100870 - Disclosure - Defined Contribution Plan - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" id="Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
        <link:definition>100880 - Disclosure - Related Party Transactions - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" id="Role_DisclosureSubsequentEventsAdditionalInformationDetails">
        <link:definition>100890 - Disclosure - Subsequent Events - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="acet_DefinedContributionPlanAbstract" name="DefinedContributionPlanAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_LeaseCostOtherInformationAbstract" name="LeaseCostOtherInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_LicenseFundingAndOtherAgreementsAbstract" name="LicenseFundingAndOtherAgreementsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_OrganizationAndNatureOfBusinessAbstract" name="OrganizationAndNatureOfBusinessAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_TermLoanAbstract" name="TermLoanAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_AccruedCmoCosts" name="AccruedCmoCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_AccruedCroCosts" name="AccruedCroCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_AccruedResearchAndDevelopmentExpensesCurrent" name="AccruedResearchAndDevelopmentExpensesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_AdditionalClosingLiability" name="AdditionalClosingLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_AdjustmentToGoodwill" name="AdjustmentToGoodwill" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_AdvisoryServicesAnnualFee" name="AdvisoryServicesAnnualFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_AgreementTransactionPrice" name="AgreementTransactionPrice" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_AmendedLeaseAgreementDescription" name="AmendedLeaseAgreementDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_AmortizationOfDebtIssuanceCosts" name="AmortizationOfDebtIssuanceCosts" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_AmountPayableUponClosingOfMerger" name="AmountPayableUponClosingOfMerger" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_AreaOfSublease" name="AreaOfSublease" type="dtr-types:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="acet_BusinessAcquisitionsProFormaRevenue1" name="BusinessAcquisitionsProFormaRevenue1" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_BusinessCombinationAccelerationOfRestrictedStockUnitsUponMerger" name="BusinessCombinationAccelerationOfRestrictedStockUnitsUponMerger" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentTangibleAndIntangiblesAssets" name="BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentTangibleAndIntangiblesAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" name="BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_ChangeInFairValueIncludedInResearchAndDevelopmentExpense" name="ChangeInFairValueIncludedInResearchAndDevelopmentExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_ClassOfWarrantExercised" name="ClassOfWarrantExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_ClassOfWarrantOrRightIssued" name="ClassOfWarrantOrRightIssued" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_ClassOfWarrantOrRightsExpirationDate" name="ClassOfWarrantOrRightsExpirationDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_ClassOfWarrantOutstandingAndExercisableToPurchaseCommonStock" name="ClassOfWarrantOutstandingAndExercisableToPurchaseCommonStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="acet_ClassOfWarrantOutstandingAndExercisableToPurchasePreferredShares" name="ClassOfWarrantOutstandingAndExercisableToPurchasePreferredShares" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="acet_CommonStockOfferingCostsIncludedInAccruedLiabilitiesAtPeriodEnd" name="CommonStockOfferingCostsIncludedInAccruedLiabilitiesAtPeriodEnd" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_CompanyContributionToPlanWithRespectToEmployeesContribution" name="CompanyContributionToPlanWithRespectToEmployeesContribution" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_ContingentConsiderationFees" name="ContingentConsiderationFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_ContractAssetsAndLiabilities" name="ContractAssetsAndLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_ContractAssetsAndLiabilitiesAdditions" name="ContractAssetsAndLiabilitiesAdditions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_ContractAssetsAndLiabilitiesAdditionsDeductions" name="ContractAssetsAndLiabilitiesAdditionsDeductions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_ContractLiability" name="ContractLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_ContractResearchTermPeriod" name="ContractResearchTermPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_ContractualContingentValueRight" name="ContractualContingentValueRight" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_ConversionOfConvertiblePreferredStockWarrantsIntoCommonStockWarrantsInConnectionWithMerger" name="ConversionOfConvertiblePreferredStockWarrantsIntoCommonStockWarrantsInConnectionWithMerger" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_CustomersPercentageOfTotalRevenue" name="CustomersPercentageOfTotalRevenue" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_DeferredTaxAssetsFixedAssets" name="DeferredTaxAssetsFixedAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_DeferredTaxAssetsValuationAllowanceIncrease" name="DeferredTaxAssetsValuationAllowanceIncrease" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_DeferredTaxBasisDifferenceIPRD" name="DeferredTaxBasisDifferenceIPRD" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_DeferredTaxLiabilitiesFixedAssets" name="DeferredTaxLiabilitiesFixedAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_DeferredTaxOperatingLeaseRightOfUseAsset" name="DeferredTaxOperatingLeaseRightOfUseAsset" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_DeferredTaxOperatingLeaseRightOfUseAssetLiability" name="DeferredTaxOperatingLeaseRightOfUseAssetLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilityAndTRDFLiability" name="EffectiveIncomeTaxRateReconciliationChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilityAndTRDFLiability" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_EffectiveIncomeTaxRateReconciliationNOLCarryback" name="EffectiveIncomeTaxRateReconciliationNOLCarryback" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_EntityDateOfMerger" name="EntityDateOfMerger" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_EstimatedFairValueOfCVRLiability" name="EstimatedFairValueOfCVRLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_ExchangeRatio" name="ExchangeRatio" type="xbrli:pureItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_ExercisedInvestmentRightAndPurchased" name="ExercisedInvestmentRightAndPurchased" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_ExerciseFeePaid" name="ExerciseFeePaid" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_ExerciseOfRedeemableConvertiblePreferredStockTrancheLiabilities" name="ExerciseOfRedeemableConvertiblePreferredStockTrancheLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_FairValueOfModifiedStockOptionsAndRestrictedStockUnitsAttributableToPreCombinationServices" name="FairValueOfModifiedStockOptionsAndRestrictedStockUnitsAttributableToPreCombinationServices" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_FeesAndExpenseIncurredInConnectionWithClinicalTrials" name="FeesAndExpenseIncurredInConnectionWithClinicalTrials" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_GainLossFromTheRemeasurementOfRedeemableConvertiblePreferredStock" name="GainLossFromTheRemeasurementOfRedeemableConvertiblePreferredStock" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_GainLossOnChangeInFairValueOfContingentConsiderationLiability" name="GainLossOnChangeInFairValueOfContingentConsiderationLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_GainOnRemeasurementOfContingentConsiderationLiability" name="GainOnRemeasurementOfContingentConsiderationLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_GoodwillMeasurementPeriodAdjustments" name="GoodwillMeasurementPeriodAdjustments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_GrantTerm" name="GrantTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_ImpairmentOfInProcessResearchAndDevelopment" name="ImpairmentOfInProcessResearchAndDevelopment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_IncreaseDecreaseInEstimatedFairValueOfCvrLiability" name="IncreaseDecreaseInEstimatedFairValueOfCvrLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_IncreaseDecreaseInLeaseObligation" name="IncreaseDecreaseInLeaseObligation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_IncreaseDecreaseInOperatingLeaseLiabilities" name="IncreaseDecreaseInOperatingLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_IncreaseInConstructionInProgress" name="IncreaseInConstructionInProgress" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_IssuanceOfRedeemableConvertiblePreferredStockOnExerciseOfWarrantsWithLoanAgreement" name="IssuanceOfRedeemableConvertiblePreferredStockOnExerciseOfWarrantsWithLoanAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_LawsuitsFiledAgainstCompany" name="LawsuitsFiledAgainstCompany" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_LessPortionOfFairValueToBeDistributedAsCVR" name="LessPortionOfFairValueToBeDistributedAsCVR" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_LiabilitiesFairValueExercised" name="LiabilitiesFairValueExercised" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_LiabilitiesFairValueSettled" name="LiabilitiesFairValueSettled" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_LicenceAgreementAdditionalAmountPayableOfOptionExerciseFees" name="LicenceAgreementAdditionalAmountPayableOfOptionExerciseFees" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_LicenceAgreementAdditionalRevenueRecognised" name="LicenceAgreementAdditionalRevenueRecognised" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_LicenceAgreementCumulativeRevenueRecognised" name="LicenceAgreementCumulativeRevenueRecognised" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_LicenceAgreementUpfrontPayment" name="LicenceAgreementUpfrontPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_LicenseAgreementAdditionalPaymentForResearchFundingReceived" name="LicenseAgreementAdditionalPaymentForResearchFundingReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_LicenseAgreementCumulativeRevenueReductionRecognised" name="LicenseAgreementCumulativeRevenueReductionRecognised" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfClinicalMilestonesPayable" name="LicenseAgreementMilestonePaymentsUponSatisfactionOfClinicalMilestonesPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfCommercialMilestonesPayable" name="LicenseAgreementMilestonePaymentsUponSatisfactionOfCommercialMilestonesPayable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfRegulatoryMilestonesPayableForFirstIndicationApproved" name="LicenseAgreementMilestonePaymentsUponSatisfactionOfRegulatoryMilestonesPayableForFirstIndicationApproved" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfRegulatoryMilestonesPayableForSecondIndicationApproved" name="LicenseAgreementMilestonePaymentsUponSatisfactionOfRegulatoryMilestonesPayableForSecondIndicationApproved" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_LicenseAgreementTerminationDescription" name="LicenseAgreementTerminationDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_LicenseAndCollaborationRevenue" name="LicenseAndCollaborationRevenue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_LoanAmountDrawn" name="LoanAmountDrawn" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="acet_LumpSumCompensationPayment" name="LumpSumCompensationPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_MaximumAggregateValueOfCommonStockAvailableForOfferingAtMarketPriceUnderSalesAgreement" name="MaximumAggregateValueOfCommonStockAvailableForOfferingAtMarketPriceUnderSalesAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_MilestoneClosingLiability" name="MilestoneClosingLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_NonRefundableUpfrontPaymentReceived" name="NonRefundableUpfrontPaymentReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_NumberOfCustomer" name="NumberOfCustomer" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="acet_NumberOfSecuritiesConvertedToWarrantsToPurchaseCommonStock" name="NumberOfSecuritiesConvertedToWarrantsToPurchaseCommonStock" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_NumberOfSharesAvailableForSaleUnderEmployeeStockPurchasePlan" name="NumberOfSharesAvailableForSaleUnderEmployeeStockPurchasePlan" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_NumberOfSharesOfSurvivingStockOptions" name="NumberOfSharesOfSurvivingStockOptions" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_OperatingLeasesCommencementDate" name="OperatingLeasesCommencementDate" type="xbrli:dateItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_OperatingLeasesFutureMinimumSubleaseIncomeDue" name="OperatingLeasesFutureMinimumSubleaseIncomeDue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueCurrent" name="OperatingLeasesFutureMinimumSubleaseIncomeDueCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInFiveYears" name="OperatingLeasesFutureMinimumSubleaseIncomeDueInFiveYears" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInFourYears" name="OperatingLeasesFutureMinimumSubleaseIncomeDueInFourYears" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInThreeYears" name="OperatingLeasesFutureMinimumSubleaseIncomeDueInThreeYears" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInTwoYears" name="OperatingLeasesFutureMinimumSubleaseIncomeDueInTwoYears" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_OperatingLossCarrybackDurationUnderCARESAct" name="OperatingLossCarrybackDurationUnderCARESAct" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_OperatingLossCarryforwardsIndefinitely" name="OperatingLossCarryforwardsIndefinitely" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_OptionToPurchaseOfCommonStockAtPublicOfferingPrice" name="OptionToPurchaseOfCommonStockAtPublicOfferingPrice" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_OwnershipChangePlanDescription" name="OwnershipChangePlanDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_PercentageOfNetOperatingLossCarryforwards" name="PercentageOfNetOperatingLossCarryforwards" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_PostExposureProphylaxisDescription" name="PostExposureProphylaxisDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_PrepaymentsToCmos" name="PrepaymentsToCmos" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_PrepaymentsToCros" name="PrepaymentsToCros" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_ProceedsFromSalesOfMarketableDebtSecurities" name="ProceedsFromSalesOfMarketableDebtSecurities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_QualifyingExpenses" name="QualifyingExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_QualifyingExpensesOnCumulativeBasis" name="QualifyingExpensesOnCumulativeBasis" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_RecognitionOfContingentConsiderationLiability" name="RecognitionOfContingentConsiderationLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_RecognitionOfPreferredStockWarrantLiabilities" name="RecognitionOfPreferredStockWarrantLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_RedeemableConvertiblePreferredStockWarrantLiability" name="RedeemableConvertiblePreferredStockWarrantLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_ResearchFundingFee" name="ResearchFundingFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_RightOfUseAssetsRecognized" name="RightOfUseAssetsRecognized" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_SettlementOfTRDFLiability" name="SettlementOfTRDFLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAsPartOfMerger" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAsPartOfMerger" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesAuthorized" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesAuthorized" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesCancelled" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesCancelled" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesExercised" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesExercised" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesGranted" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesGranted" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedAsPartOfMerger" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedAsPartOfMerger" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAuthorized" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAuthorized" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumedAsPartOfMergerInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumedAsPartOfMergerInPeriodWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAuthorizedInPeriodWeightedAverageExercisePrice" name="ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAuthorizedInPeriodWeightedAverageExercisePrice" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_StockExchangedDuringPeriodSharesInConnectionWithMerger" name="StockExchangedDuringPeriodSharesInConnectionWithMerger" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_StockExchangedDuringPeriodValueInConnectionWithMerger" name="StockExchangedDuringPeriodValueInConnectionWithMerger" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_StockIssuedDuringPeriodSharesConversionOfSecurities" name="StockIssuedDuringPeriodSharesConversionOfSecurities" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_StockIssuedDuringPeriodSharesUponAcceleratedVestingOfRSUWithMerger" name="StockIssuedDuringPeriodSharesUponAcceleratedVestingOfRSUWithMerger" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_StockIssuedDuringPeriodValueUponAcceleratedVestingOfRSUWithMerger" name="StockIssuedDuringPeriodValueUponAcceleratedVestingOfRSUWithMerger" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_SubleaseAgreementDescription" name="SubleaseAgreementDescription" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_TemporaryEquityStockConversionInConnectionWithMerger" name="TemporaryEquityStockConversionInConnectionWithMerger" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_TemporaryEquityStockConversionSharesInConnectionWithMerger" name="TemporaryEquityStockConversionSharesInConnectionWithMerger" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_TerminationAgreementMonthAndYear" name="TerminationAgreementMonthAndYear" type="xbrli:gYearMonthItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_TerminationOfRedeemableConvertiblePreferredStockTrancheLiability" name="TerminationOfRedeemableConvertiblePreferredStockTrancheLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_TermLoanAndNonFormulaAncillaryService" name="TermLoanAndNonFormulaAncillaryService" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_TermLoanToFinanceLeaseholdImprovements1" name="TermLoanToFinanceLeaseholdImprovements1" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_UnderwritingDiscountsAndCommissionsAndOtherOfferingExpenses" name="UnderwritingDiscountsAndCommissionsAndOtherOfferingExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit"/>
  <xsd:element id="acet_UnvestedRestrictedStockUnitsOutstanding" name="UnvestedRestrictedStockUnitsOutstanding" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false"/>
  <xsd:element id="acet_VestingOfEarlyExercisedStockOptions" name="VestingOfEarlyExercisedStockOptions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit"/>
  <xsd:element id="acet_WarrantsOutstandingAndExercisableWeightedAverageRemainingContractualTerm" name="WarrantsOutstandingAndExercisableWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_IncomeTaxesDisclosureLineItems" name="IncomeTaxesDisclosureLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_SummaryOfSignificantAccountingPoliciesLineItems" name="SummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_AdditionalAuthorizedAndUnissuedRedeemableConvertiblePreferredStockMember" name="AdditionalAuthorizedAndUnissuedRedeemableConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_AdicetTherapeuticsIncMember" name="AdicetTherapeuticsIncMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_AtTheMarketOfferingMember" name="AtTheMarketOfferingMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_BostonMember" name="BostonMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_CaliforniaResearchAndDevelopmentMember" name="CaliforniaResearchAndDevelopmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_CommonStockWarrantsMember" name="CommonStockWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_ContingentConsiderationLiabilityMember" name="ContingentConsiderationLiabilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_ContingentConsiderationMember" name="ContingentConsiderationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_ContingentValueRightsAgreementMember" name="ContingentValueRightsAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_ContractAssetMember" name="ContractAssetMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_ContractLiabilityMember" name="ContractLiabilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_COVID19Member" name="COVID19Member" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_EmployeeStockPurchasePlanMember" name="EmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_FederalAndStateResearchAndDevelopmentMember" name="FederalAndStateResearchAndDevelopmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_FourthAmendmentMember" name="FourthAmendmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_InducementGrantsMember" name="InducementGrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_LaboratoryEquipmentMember" name="LaboratoryEquipmentMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_MarketableSecuritiesMember" name="MarketableSecuritiesMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_MenloParkLeaseAgreementMember" name="MenloParkLeaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_MergerMember" name="MergerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_NationalInstitutesOfHealthMember" name="NationalInstitutesOfHealthMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_NovartisInternationalPharmaceuticalLimitedMember" name="NovartisInternationalPharmaceuticalLimitedMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_NovartisLicenseAgreementMember" name="NovartisLicenseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_OptionsAvailableForFutureGrantsMember" name="OptionsAvailableForFutureGrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_PacificWesternBankMember" name="PacificWesternBankMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_RedeemableConvertiblePreferredStockTrancheLiabilityAndTRDFObligationMember" name="RedeemableConvertiblePreferredStockTrancheLiabilityAndTRDFObligationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_RedeemableConvertiblePreferredStockTrancheLiabilityMember" name="RedeemableConvertiblePreferredStockTrancheLiabilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_RedeemableConvertiblePreferredStockWarrantLiabilityMember" name="RedeemableConvertiblePreferredStockWarrantLiabilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_RedeemableConvertiblePreferredStockWarrantsMember" name="RedeemableConvertiblePreferredStockWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_RedwoodCityLeaseAgreementMember" name="RedwoodCityLeaseAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_RegeneronPharmaceuticalsIncorporationMember" name="RegeneronPharmaceuticalsIncorporationMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_ResearchFundingAgreementMember" name="ResearchFundingAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_ResTORbioMember" name="ResTORbioMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_RfsOpcoLlcMember" name="RfsOpcoLlcMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_SalesAgreementMember" name="SalesAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_SeptemberFifteenTwoThousandTwentyWarrantFourMember" name="SeptemberFifteenTwoThousandTwentyWarrantFourMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_SeptemberFifteenTwoThousandTwentyWarrantOneMember" name="SeptemberFifteenTwoThousandTwentyWarrantOneMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_SeptemberFifteenTwoThousandTwentyWarrantThreeMember" name="SeptemberFifteenTwoThousandTwentyWarrantThreeMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_SeptemberFifteenTwoThousandTwentyWarrantTwoMember" name="SeptemberFifteenTwoThousandTwentyWarrantTwoMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_SeriesBRedeemableConvertiblePreferredStockMember" name="SeriesBRedeemableConvertiblePreferredStockMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_TransitionAgreementMember" name="TransitionAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_TRDFLiabilityMember" name="TRDFLiabilityMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_TwoThousandEighteenEmployeeStockPurchasePlanMember" name="TwoThousandEighteenEmployeeStockPurchasePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_TwoThousandEighteenStockIncentivePlanMember" name="TwoThousandEighteenStockIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_TwoThousandFifteenStockIncentivePlanMember" name="TwoThousandFifteenStockIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_TwoThousandFourteenAndTwoThousandFifteenStockIncentivePlanMember" name="TwoThousandFourteenAndTwoThousandFifteenStockIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_TwoThousandFourteenStockIncentivePlanMember" name="TwoThousandFourteenStockIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_TwoThousandSeventeenAndTwoThousandEighteenStockIncentivePlanMember" name="TwoThousandSeventeenAndTwoThousandEighteenStockIncentivePlanMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_UnvestedCommonStockFromEarlyExerciseOfOptionsMember" name="UnvestedCommonStockFromEarlyExerciseOfOptionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_AccruedResearchAndDevelopmentPolicyTextBlock" name="AccruedResearchAndDevelopmentPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_FairValueOfCommonStockPolicyTextBlock" name="FairValueOfCommonStockPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_RedeemableConvertiblePreferredStockPolicyTextBlock" name="RedeemableConvertiblePreferredStockPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_RedeemableConvertiblePreferredStockTrancheLiabilityPolicyTextBlock" name="RedeemableConvertiblePreferredStockTrancheLiabilityPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_RedeemableConvertiblePreferredStockWarrantLiabilityPolicyTextBlock" name="RedeemableConvertiblePreferredStockWarrantLiabilityPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_RisksAndUncertaintiesPolicyTextBlock" name="RisksAndUncertaintiesPolicyTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_IncomeTaxesTable" name="IncomeTaxesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_SummaryOfSignificantAccountingPoliciesTable" name="SummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true"/>
  <xsd:element id="acet_MarketableDebtSecuritiesClassificationTableTextBlock" name="MarketableDebtSecuritiesClassificationTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock" name="PrepaidExpensesAndOtherCurrentAssetsTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_ScheduleOfChangesInFairValueOfUnobservableFinancialInstrumentsTableTextBlock" name="ScheduleOfChangesInFairValueOfUnobservableFinancialInstrumentsTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_ScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockTableTextBlock" name="ScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_ScheduleOfWeightedAverageIBRAndRemainingLeaseTermTableTextBlock" name="ScheduleOfWeightedAverageIBRAndRemainingLeaseTermTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_AtTheMarketOfferingTextBlock" name="AtTheMarketOfferingTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_LicenseFundingAndOtherAgreementsTextBlock" name="LicenseFundingAndOtherAgreementsTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_OrganizationAndNatureOfBusinessTextBlock" name="OrganizationAndNatureOfBusinessTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_PrepaidExpensesAndOtherCurrentAssetsTextBlock" name="PrepaidExpensesAndOtherCurrentAssetsTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_ScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceTextBlock" name="ScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
  <xsd:element id="acet_ScheduleOfSubleaseIncomeTableTextBlock" name="ScheduleOfSubleaseIncomeTableTextBlock" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>36
<FILENAME>acet-20211231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-03-15T16:13:41.5075+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" xlink:href="acet-20211231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:href="acet-20211231.xsd#Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:href="acet-20211231.xsd#Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:href="acet-20211231.xsd#Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" xlink:href="acet-20211231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails" xlink:href="acet-20211231.xsd#Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="acet-20211231.xsd#Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails" xlink:href="acet-20211231.xsd#Role_DisclosureBusinessCombinationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesPurchasePriceInMergerDetails" xlink:href="acet-20211231.xsd#Role_DisclosureBusinessCombinationScheduleOfSummarizesPurchasePriceInMergerDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfEstimatedShareConsiderationOfCombinedCompanyDetails" xlink:href="acet-20211231.xsd#Role_DisclosureBusinessCombinationScheduleOfEstimatedShareConsiderationOfCombinedCompanyDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfEstimatedShareConsiderationOfCombinedCompanyParentheticalDetails" xlink:href="acet-20211231.xsd#Role_DisclosureBusinessCombinationScheduleOfEstimatedShareConsiderationOfCombinedCompanyParentheticalDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesPurchasePriceInMergerParentheticalDetails" xlink:href="acet-20211231.xsd#Role_DisclosureBusinessCombinationScheduleOfSummarizesPurchasePriceInMergerParentheticalDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsAcquiredDetails" xlink:href="acet-20211231.xsd#Role_DisclosureBusinessCombinationScheduleOfSummarizesAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsAcquiredDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/DisclosureBusinessCombinationScheduleOfChangesInTheCompanysIprdAndCvrSinceTheMergerDetails" xlink:href="acet-20211231.xsd#DisclosureBusinessCombinationScheduleOfChangesInTheCompanysIprdAndCvrSinceTheMergerDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:href="acet-20211231.xsd#Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfLevel3FinancialInstrumentsDetails" xlink:href="acet-20211231.xsd#Role_DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfLevel3FinancialInstrumentsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:href="acet-20211231.xsd#Role_DisclosureFairValueMeasurementsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureMarketableDebtSecuritiesScheduleOfMarketableDebtSecuritiesDetails" xlink:href="acet-20211231.xsd#Role_DisclosureMarketableDebtSecuritiesScheduleOfMarketableDebtSecuritiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails" xlink:href="acet-20211231.xsd#Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails" xlink:href="acet-20211231.xsd#Role_DisclosureTermLoanAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRegeneronLicenseAndCollaborationArrangementAdditionalInformationDetails" xlink:href="acet-20211231.xsd#Role_DisclosureRegeneronLicenseAndCollaborationArrangementAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRegeneronLicenseAndCollaborationArrangementSummaryOfChangeInCompanySContractLiabilitiesDetails" xlink:href="acet-20211231.xsd#Role_DisclosureRegeneronLicenseAndCollaborationArrangementSummaryOfChangeInCompanySContractLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureLicenseFundingAndOtherAgreementsRelatedToCVRAdditionalInformationDetails" xlink:href="acet-20211231.xsd#Role_DisclosureLicenseFundingAndOtherAgreementsRelatedToCVRAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails" xlink:href="acet-20211231.xsd#Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfWeightedAverageIBRAndRemainingLeaseTermDetails" xlink:href="acet-20211231.xsd#Role_DisclosureCommitmentAndContingenciesScheduleOfWeightedAverageIBRAndRemainingLeaseTermDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceDetails" xlink:href="acet-20211231.xsd#DisclosureStockholdersEquityScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockDetails" xlink:href="acet-20211231.xsd#DisclosureStockholdersEquityScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureAtTheMarketATMOfferingAdditionalInformationDetails" xlink:href="acet-20211231.xsd#Role_DisclosureAtTheMarketATMOfferingAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" xlink:href="acet-20211231.xsd#Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:href="acet-20211231.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsToEstimateFairValueOfStockOptionsUsingBlackScholesOptionPricingModelDetails" xlink:href="acet-20211231.xsd#Role_DisclosureStockBasedCompensationScheduleOfAssumptionsToEstimateFairValueOfStockOptionsUsingBlackScholesOptionPricingModelDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails" xlink:href="acet-20211231.xsd#DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails" xlink:href="acet-20211231.xsd#Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:href="acet-20211231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:href="acet-20211231.xsd#Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails" xlink:href="acet-20211231.xsd#Role_DisclosureSubsequentEventsAdditionalInformationDetails" xlink:type="simple"/>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:label="us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopmentInProcess" xlink:label="us-gaap_DevelopmentInProcess"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_RedeemableConvertiblePreferredStockWarrantLiability" xlink:label="acet_RedeemableConvertiblePreferredStockWarrantLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilities" xlink:label="us-gaap_OtherLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsReceivableRelatedPartiesCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Goodwill" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DevelopmentInProcess" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RestrictedCashNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAssetsNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Assets" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccountsPayableCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredRentCreditNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="24" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="25" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acet_RedeemableConvertiblePreferredStockWarrantLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="26" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="27" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="28" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherLiabilities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="29" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_Liabilities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="30" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommitmentsAndContingencies" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="31" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="32" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="33" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="34" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="35" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="36" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="37" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="38" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PreferredStockLiquidationPreferenceValue" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_TemporaryEquityStockConversionSharesInConnectionWithMerger" xlink:label="acet_TemporaryEquityStockConversionSharesInConnectionWithMerger"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_TemporaryEquityStockConversionInConnectionWithMerger" xlink:label="acet_TemporaryEquityStockConversionInConnectionWithMerger"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_StockIssuedDuringPeriodSharesConversionOfSecurities" xlink:label="acet_StockIssuedDuringPeriodSharesConversionOfSecurities"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_StockExchangedDuringPeriodValueInConnectionWithMerger" xlink:label="acet_StockExchangedDuringPeriodValueInConnectionWithMerger"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_StockExchangedDuringPeriodSharesInConnectionWithMerger" xlink:label="acet_StockExchangedDuringPeriodSharesInConnectionWithMerger"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_StockIssuedDuringPeriodValueUponAcceleratedVestingOfRSUWithMerger" xlink:label="acet_StockIssuedDuringPeriodValueUponAcceleratedVestingOfRSUWithMerger"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_StockIssuedDuringPeriodSharesUponAcceleratedVestingOfRSUWithMerger" xlink:label="acet_StockIssuedDuringPeriodSharesUponAcceleratedVestingOfRSUWithMerger"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquitySharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acet_TemporaryEquityStockConversionSharesInConnectionWithMerger" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acet_TemporaryEquityStockConversionInConnectionWithMerger" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acet_StockIssuedDuringPeriodSharesConversionOfSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acet_StockExchangedDuringPeriodValueInConnectionWithMerger" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acet_StockExchangedDuringPeriodSharesInConnectionWithMerger" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acet_StockIssuedDuringPeriodValueUponAcceleratedVestingOfRSUWithMerger" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="acet_StockIssuedDuringPeriodSharesUponAcceleratedVestingOfRSUWithMerger" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="21" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ConversionOfStockAmountConverted1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="22" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="23" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="acet_SeriesBRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="acet_SeriesBRedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="acet_SeriesBRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_CommonStockOfferingCostsIncludedInAccruedLiabilitiesAtPeriodEnd" xlink:label="acet_CommonStockOfferingCostsIncludedInAccruedLiabilitiesAtPeriodEnd"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ProceedsFromSalesOfMarketableDebtSecurities" xlink:label="acet_ProceedsFromSalesOfMarketableDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashExpense" xlink:label="us-gaap_OtherNoncashExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIncomeTaxRefunds" xlink:label="us-gaap_ProceedsFromIncomeTaxRefunds"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_RightOfUseAssetsRecognized" xlink:label="acet_RightOfUseAssetsRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="acet_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ImpairmentOfInProcessResearchAndDevelopment" xlink:label="acet_ImpairmentOfInProcessResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_GainOnRemeasurementOfContingentConsiderationLiability" xlink:label="acet_GainOnRemeasurementOfContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfAssetsAcquired" xlink:label="us-gaap_FairValueOfAssetsAcquired"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_AmortizationOfDebtIssuanceCosts" xlink:label="acet_AmortizationOfDebtIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_GoodwillMeasurementPeriodAdjustments" xlink:label="acet_GoodwillMeasurementPeriodAdjustments"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_AdjustmentToGoodwill" xlink:label="acet_AdjustmentToGoodwill"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_IssuanceOfRedeemableConvertiblePreferredStockOnExerciseOfWarrantsWithLoanAgreement" xlink:label="acet_IssuanceOfRedeemableConvertiblePreferredStockOnExerciseOfWarrantsWithLoanAgreement"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_VestingOfEarlyExercisedStockOptions" xlink:label="acet_VestingOfEarlyExercisedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ExerciseOfRedeemableConvertiblePreferredStockTrancheLiabilities" xlink:label="acet_ExerciseOfRedeemableConvertiblePreferredStockTrancheLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_TerminationOfRedeemableConvertiblePreferredStockTrancheLiability" xlink:label="acet_TerminationOfRedeemableConvertiblePreferredStockTrancheLiability"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_SettlementOfTRDFLiability" xlink:label="acet_SettlementOfTRDFLiability"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="acet_SeriesBRedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ProfitLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationAndAmortization" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_CashAcquiredFromAcquisition" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_IncomeTaxesPaid" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="acet_CommonStockOfferingCostsIncludedInAccruedLiabilitiesAtPeriodEnd" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockPlans" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="acet_ProceedsFromSalesOfMarketableDebtSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_RestrictedCashNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_ProceedsFromIncomeTaxRefunds" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="acet_RightOfUseAssetsRecognized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnDispositionOfAssets1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="acet_IncreaseDecreaseInOperatingLeaseLiabilities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_ConversionOfStockAmountConverted1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="acet_ImpairmentOfInProcessResearchAndDevelopment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="acet_GainOnRemeasurementOfContingentConsiderationLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_FairValueOfAssetsAcquired" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="acet_AmortizationOfDebtIssuanceCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="acet_GoodwillMeasurementPeriodAdjustments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="acet_AdjustmentToGoodwill" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="acet_IssuanceOfRedeemableConvertiblePreferredStockOnExerciseOfWarrantsWithLoanAgreement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="acet_VestingOfEarlyExercisedStockOptions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="acet_ExerciseOfRedeemableConvertiblePreferredStockTrancheLiabilities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="acet_TerminationOfRedeemableConvertiblePreferredStockTrancheLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="acet_SettlementOfTRDFLiability" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_AdicetTherapeuticsIncMember" xlink:label="acet_AdicetTherapeuticsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="dei_EntityIncorporationDateOfIncorporation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_EntityDateOfMerger" xlink:label="acet_EntityDateOfMerger"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ExchangeRatio" xlink:label="acet_ExchangeRatio"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_OptionToPurchaseOfCommonStockAtPublicOfferingPrice" xlink:label="acet_OptionToPurchaseOfCommonStockAtPublicOfferingPrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:label="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_UnderwritingDiscountsAndCommissionsAndOtherOfferingExpenses" xlink:label="acet_UnderwritingDiscountsAndCommissionsAndOtherOfferingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="acet_AdicetTherapeuticsIncMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="dei_EntityIncorporationDateOfIncorporation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="acet_EntityDateOfMerger" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="acet_ExchangeRatio" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="acet_OptionToPurchaseOfCommonStockAtPublicOfferingPrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="acet_UnderwritingDiscountsAndCommissionsAndOtherOfferingExpenses" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="acet_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_SummaryOfSignificantAccountingPoliciesTable" xlink:label="acet_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ExchangeRatio" xlink:label="acet_ExchangeRatio"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_GainLossOnChangeInFairValueOfContingentConsiderationLiability" xlink:label="acet_GainLossOnChangeInFairValueOfContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_NumberOfCustomer" xlink:label="acet_NumberOfCustomer"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_CustomersPercentageOfTotalRevenue" xlink:label="acet_CustomersPercentageOfTotalRevenue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_FinancingReceivableNonaccrualToOutstandingPercent" xlink:label="srt_FinancingReceivableNonaccrualToOutstandingPercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDeferredLiabilities"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acet_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="acet_SummaryOfSignificantAccountingPoliciesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acet_SummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acet_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="acet_ExchangeRatio" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acet_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="acet_GainLossOnChangeInFairValueOfContingentConsiderationLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acet_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acet_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acet_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="acet_NumberOfCustomer" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acet_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="acet_CustomersPercentageOfTotalRevenue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acet_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="srt_FinancingReceivableNonaccrualToOutstandingPercent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acet_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_AssetImpairmentCharges" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acet_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acet_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfReportableSegments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acet_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acet_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acet_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_IncreaseDecreaseInDeferredLiabilities" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ResTORbioMember" xlink:label="acet_ResTORbioMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_TransitionAgreementMember" xlink:label="acet_TransitionAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:label="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_NumberOfSharesOfSurvivingStockOptions" xlink:label="acet_NumberOfSharesOfSurvivingStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_UnvestedRestrictedStockUnitsOutstanding" xlink:label="acet_UnvestedRestrictedStockUnitsOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentTangibleAndIntangiblesAssets" xlink:label="acet_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentTangibleAndIntangiblesAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForMergerRelatedCosts" xlink:label="us-gaap_PaymentsForMergerRelatedCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedBonusesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedBonusesCurrentAndNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_LumpSumCompensationPayment" xlink:label="acet_LumpSumCompensationPayment"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_AmountPayableUponClosingOfMerger" xlink:label="acet_AmountPayableUponClosingOfMerger"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LegalFees" xlink:label="us-gaap_LegalFees"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_AdvisoryServicesAnnualFee" xlink:label="acet_AdvisoryServicesAnnualFee"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ContractualContingentValueRight" xlink:label="acet_ContractualContingentValueRight"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="acet_ResTORbioMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="acet_TransitionAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_RelatedPartyTransactionAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_StockholdersEquityReverseStockSplit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="acet_NumberOfSharesOfSurvivingStockOptions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="acet_UnvestedRestrictedStockUnitsOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="acet_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentTangibleAndIntangiblesAssets" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_Goodwill" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_PaymentsForMergerRelatedCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationAcquisitionRelatedCosts" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_Cash" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_AccruedBonusesCurrentAndNoncurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="acet_LumpSumCompensationPayment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="acet_AmountPayableUponClosingOfMerger" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_LegalFees" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="acet_AdvisoryServicesAnnualFee" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="acet_ContractualContingentValueRight" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesPurchasePriceInMergerDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ResTORbioMember" xlink:label="acet_ResTORbioMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure" xlink:label="us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="acet_ResTORbioMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfEstimatedShareConsiderationOfCombinedCompanyDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ResTORbioMember" xlink:label="acet_ResTORbioMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="us-gaap_BusinessAcquisitionSharePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:label="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_BusinessCombinationAccelerationOfRestrictedStockUnitsUponMerger" xlink:label="acet_BusinessCombinationAccelerationOfRestrictedStockUnitsUponMerger"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_FairValueOfModifiedStockOptionsAndRestrictedStockUnitsAttributableToPreCombinationServices" xlink:label="acet_FairValueOfModifiedStockOptionsAndRestrictedStockUnitsAttributableToPreCombinationServices"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_LessPortionOfFairValueToBeDistributedAsCVR" xlink:label="acet_LessPortionOfFairValueToBeDistributedAsCVR"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure" xlink:label="us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="acet_ResTORbioMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionSharePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="acet_BusinessCombinationAccelerationOfRestrictedStockUnitsUponMerger" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="acet_FairValueOfModifiedStockOptionsAndRestrictedStockUnitsAttributableToPreCombinationServices" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="acet_LessPortionOfFairValueToBeDistributedAsCVR" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfEstimatedShareConsiderationOfCombinedCompanyParentheticalDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ResTORbioMember" xlink:label="acet_ResTORbioMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="acet_ResTORbioMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesPurchasePriceInMergerParentheticalDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ResTORbioMember" xlink:label="acet_ResTORbioMember"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_UnvestedRestrictedStockUnitsOutstanding" xlink:label="acet_UnvestedRestrictedStockUnitsOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_NumberOfSharesOfSurvivingStockOptions" xlink:label="acet_NumberOfSharesOfSurvivingStockOptions"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="acet_ResTORbioMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="acet_UnvestedRestrictedStockUnitsOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="acet_NumberOfSharesOfSurvivingStockOptions" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsAcquiredDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ResTORbioMember" xlink:label="acet_ResTORbioMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementAdjustmentMember" xlink:label="srt_RestatementAdjustmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment" xlink:label="acet_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" xlink:label="acet_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="acet_ResTORbioMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RestatementDomain" xlink:to="srt_ScenarioPreviouslyReportedMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="srt_RestatementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RestatementDomain" xlink:to="srt_RestatementAdjustmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="acet_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="acet_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_Goodwill" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/DisclosureBusinessCombinationScheduleOfChangesInTheCompanysIprdAndCvrSinceTheMergerDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAssetsArisingFromContingenciesAmountRecognized" xlink:label="us-gaap_BusinessCombinationAssetsArisingFromContingenciesAmountRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeDuringPeriodFairValueDisclosureMember" xlink:label="us-gaap_ChangeDuringPeriodFairValueDisclosureMember"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ContingentValueRightsAgreementMember" xlink:label="acet_ContingentValueRightsAgreementMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_FairValueDisclosureItemAmountsDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_BusinessCombinationAssetsArisingFromContingenciesAmountRecognized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_InProcessResearchAndDevelopmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_ChangeDuringPeriodFairValueDisclosureMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByMeasurementBasisAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="acet_ContingentValueRightsAgreementMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_MarketableSecuritiesMember" xlink:label="acet_MarketableSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="us-gaap_AssetBackedSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ContingentConsiderationMember" xlink:label="acet_ContingentConsiderationMember"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_RedeemableConvertiblePreferredStockWarrantsMember" xlink:label="acet_RedeemableConvertiblePreferredStockWarrantsMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="acet_MarketableSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_AssetBackedSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CommercialPaperMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueDisclosure" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="acet_ContingentConsiderationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="acet_RedeemableConvertiblePreferredStockWarrantsMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfLevel3FinancialInstrumentsDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_RedeemableConvertiblePreferredStockTrancheLiabilityMember" xlink:label="acet_RedeemableConvertiblePreferredStockTrancheLiabilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_TRDFLiabilityMember" xlink:label="acet_TRDFLiabilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeDuringPeriodFairValueDisclosureMember" xlink:label="us-gaap_ChangeDuringPeriodFairValueDisclosureMember"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_RecognitionOfPreferredStockWarrantLiabilities" xlink:label="acet_RecognitionOfPreferredStockWarrantLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_RedeemableConvertiblePreferredStockWarrantLiabilityMember" xlink:label="acet_RedeemableConvertiblePreferredStockWarrantLiabilityMember"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_RecognitionOfContingentConsiderationLiability" xlink:label="acet_RecognitionOfContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ContingentConsiderationLiabilityMember" xlink:label="acet_ContingentConsiderationLiabilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="us-gaap_LiabilitiesFairValueAdjustment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_LiabilitiesFairValueExercised" xlink:label="acet_LiabilitiesFairValueExercised"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_LiabilitiesFairValueSettled" xlink:label="acet_LiabilitiesFairValueSettled"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ChangeInFairValueIncludedInResearchAndDevelopmentExpense" xlink:label="acet_ChangeInFairValueIncludedInResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ConversionOfConvertiblePreferredStockWarrantsIntoCommonStockWarrantsInConnectionWithMerger" xlink:label="acet_ConversionOfConvertiblePreferredStockWarrantsIntoCommonStockWarrantsInConnectionWithMerger"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="acet_RedeemableConvertiblePreferredStockTrancheLiabilityMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_FairValueDisclosureItemAmountsDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="acet_TRDFLiabilityMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_ChangeDuringPeriodFairValueDisclosureMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="acet_RecognitionOfPreferredStockWarrantLiabilities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="acet_RedeemableConvertiblePreferredStockWarrantLiabilityMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementBasisAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="acet_RecognitionOfContingentConsiderationLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="acet_ContingentConsiderationLiabilityMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_LiabilitiesFairValueAdjustment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="acet_LiabilitiesFairValueExercised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="acet_LiabilitiesFairValueSettled" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="acet_ChangeInFairValueIncludedInResearchAndDevelopmentExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="acet_ConversionOfConvertiblePreferredStockWarrantsIntoCommonStockWarrantsInConnectionWithMerger" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_RedeemableConvertiblePreferredStockWarrantLiabilityMember" xlink:label="acet_RedeemableConvertiblePreferredStockWarrantLiabilityMember"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_MilestoneClosingLiability" xlink:label="acet_MilestoneClosingLiability"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_AdditionalClosingLiability" xlink:label="acet_AdditionalClosingLiability"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_GainLossFromTheRemeasurementOfRedeemableConvertiblePreferredStock" xlink:label="acet_GainLossFromTheRemeasurementOfRedeemableConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_IncreaseDecreaseInEstimatedFairValueOfCvrLiability" xlink:label="acet_IncreaseDecreaseInEstimatedFairValueOfCvrLiability"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_EstimatedFairValueOfCVRLiability" xlink:label="acet_EstimatedFairValueOfCVRLiability"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="acet_RedeemableConvertiblePreferredStockWarrantLiabilityMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="acet_MilestoneClosingLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="acet_AdditionalClosingLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="acet_GainLossFromTheRemeasurementOfRedeemableConvertiblePreferredStock" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="acet_IncreaseDecreaseInEstimatedFairValueOfCvrLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="acet_EstimatedFairValueOfCVRLiability" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureMarketableDebtSecuritiesScheduleOfMarketableDebtSecuritiesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:label="us-gaap_MarketableSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="us-gaap_MarketableSecuritiesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="us-gaap_AssetBackedSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_MarketableSecuritiesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_FinancialInstrumentAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_AssetBackedSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CommercialPaperMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_LaboratoryEquipmentMember" xlink:label="acet_LaboratoryEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="acet_LaboratoryEquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_PacificWesternBankMember" xlink:label="acet_PacificWesternBankMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_FourthAmendmentMember" xlink:label="acet_FourthAmendmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrimeRateMember" xlink:label="us-gaap_PrimeRateMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_TermLoanToFinanceLeaseholdImprovements1" xlink:label="acet_TermLoanToFinanceLeaseholdImprovements1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansReceivableBasisSpreadOnVariableRate" xlink:label="us-gaap_LoansReceivableBasisSpreadOnVariableRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDateRangeEnd1" xlink:label="us-gaap_DebtInstrumentMaturityDateRangeEnd1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_LoanAmountDrawn" xlink:label="acet_LoanAmountDrawn"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="us-gaap_DeferredFinanceCostsGross"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_TermLoanAndNonFormulaAncillaryService" xlink:label="acet_TermLoanAndNonFormulaAncillaryService"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtDescription" xlink:label="us-gaap_LongTermDebtDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayable" xlink:label="us-gaap_LoansPayable"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="acet_PacificWesternBankMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="acet_FourthAmendmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_PrimeRateMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="acet_TermLoanToFinanceLeaseholdImprovements1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_VariableRateAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_LoansReceivableBasisSpreadOnVariableRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_DebtInstrumentMaturityDateRangeEnd1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_DebtInstrumentFaceAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="acet_LoanAmountDrawn" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_LongtermDebtTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_DeferredFinanceCostsGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="acet_TermLoanAndNonFormulaAncillaryService" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_LongTermDebtDescription" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_LoansPayable" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRegeneronLicenseAndCollaborationArrangementAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_RegeneronPharmaceuticalsIncorporationMember" xlink:label="acet_RegeneronPharmaceuticalsIncorporationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_NonRefundableUpfrontPaymentReceived" xlink:label="acet_NonRefundableUpfrontPaymentReceived"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_LicenseAgreementAdditionalPaymentForResearchFundingReceived" xlink:label="acet_LicenseAgreementAdditionalPaymentForResearchFundingReceived"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_LicenceAgreementAdditionalAmountPayableOfOptionExerciseFees" xlink:label="acet_LicenceAgreementAdditionalAmountPayableOfOptionExerciseFees"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ContractResearchTermPeriod" xlink:label="acet_ContractResearchTermPeriod"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_LicenceAgreementUpfrontPayment" xlink:label="acet_LicenceAgreementUpfrontPayment"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_LicenceAgreementAdditionalRevenueRecognised" xlink:label="acet_LicenceAgreementAdditionalRevenueRecognised"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ContingentConsiderationFees" xlink:label="acet_ContingentConsiderationFees"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_AgreementTransactionPrice" xlink:label="acet_AgreementTransactionPrice"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ResearchFundingFee" xlink:label="acet_ResearchFundingFee"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_LicenseAgreementCumulativeRevenueReductionRecognised" xlink:label="acet_LicenseAgreementCumulativeRevenueReductionRecognised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:label="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_LicenseAgreementTerminationDescription" xlink:label="acet_LicenseAgreementTerminationDescription"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ExercisedInvestmentRightAndPurchased" xlink:label="acet_ExercisedInvestmentRightAndPurchased"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_LicenceAgreementCumulativeRevenueRecognised" xlink:label="acet_LicenceAgreementCumulativeRevenueRecognised"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ContractLiability" xlink:label="acet_ContractLiability"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_LicenseAndCollaborationRevenue" xlink:label="acet_LicenseAndCollaborationRevenue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="acet_RegeneronPharmaceuticalsIncorporationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="acet_NonRefundableUpfrontPaymentReceived" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="acet_LicenseAgreementAdditionalPaymentForResearchFundingReceived" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="acet_LicenceAgreementAdditionalAmountPayableOfOptionExerciseFees" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="acet_ContractResearchTermPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="acet_LicenceAgreementUpfrontPayment" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="acet_LicenceAgreementAdditionalRevenueRecognised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="acet_ContingentConsiderationFees" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="acet_AgreementTransactionPrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="acet_ResearchFundingFee" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="acet_LicenseAgreementCumulativeRevenueReductionRecognised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="acet_LicenseAgreementTerminationDescription" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="acet_ExercisedInvestmentRightAndPurchased" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="acet_LicenceAgreementCumulativeRevenueRecognised" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="acet_ContractLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="acet_LicenseAndCollaborationRevenue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRegeneronLicenseAndCollaborationArrangementSummaryOfChangeInCompanySContractLiabilitiesDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ContractAssetMember" xlink:label="acet_ContractAssetMember"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ContractAssetsAndLiabilities" xlink:label="acet_ContractAssetsAndLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ContractLiabilityMember" xlink:label="acet_ContractLiabilityMember"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ContractAssetsAndLiabilitiesAdditions" xlink:label="acet_ContractAssetsAndLiabilitiesAdditions"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ContractAssetsAndLiabilitiesAdditionsDeductions" xlink:label="acet_ContractAssetsAndLiabilitiesAdditionsDeductions"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_BalanceSheetLocationAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="acet_ContractAssetMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="acet_ContractAssetsAndLiabilities" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="acet_ContractLiabilityMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="acet_ContractAssetsAndLiabilitiesAdditions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="acet_ContractAssetsAndLiabilitiesAdditionsDeductions" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureLicenseFundingAndOtherAgreementsRelatedToCVRAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ContingentValueRightsAgreementMember" xlink:label="acet_ContingentValueRightsAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualRiskOrUncertaintyByNatureAxis" xlink:label="us-gaap_UnusualRiskOrUncertaintyByNatureAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualRiskOrUncertaintyNatureDomain" xlink:label="us-gaap_UnusualRiskOrUncertaintyNatureDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualRiskOrUncertaintyNatureDomain" xlink:label="us-gaap_UnusualRiskOrUncertaintyNatureDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_COVID19Member" xlink:label="acet_COVID19Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_NovartisInternationalPharmaceuticalLimitedMember" xlink:label="acet_NovartisInternationalPharmaceuticalLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ResearchFundingAgreementMember" xlink:label="acet_ResearchFundingAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_FeesAndExpenseIncurredInConnectionWithClinicalTrials" xlink:label="acet_FeesAndExpenseIncurredInConnectionWithClinicalTrials"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_NovartisLicenseAgreementMember" xlink:label="acet_NovartisLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_NationalInstitutesOfHealthMember" xlink:label="acet_NationalInstitutesOfHealthMember"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_IncreaseDecreaseInEstimatedFairValueOfCvrLiability" xlink:label="acet_IncreaseDecreaseInEstimatedFairValueOfCvrLiability"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_EstimatedFairValueOfCVRLiability" xlink:label="acet_EstimatedFairValueOfCVRLiability"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_LicenseAgreementTerminationDescription" xlink:label="acet_LicenseAgreementTerminationDescription"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfClinicalMilestonesPayable" xlink:label="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfClinicalMilestonesPayable"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfRegulatoryMilestonesPayableForFirstIndicationApproved" xlink:label="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfRegulatoryMilestonesPayableForFirstIndicationApproved"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfRegulatoryMilestonesPayableForSecondIndicationApproved" xlink:label="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfRegulatoryMilestonesPayableForSecondIndicationApproved"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfCommercialMilestonesPayable" xlink:label="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfCommercialMilestonesPayable"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_GrantTerm" xlink:label="acet_GrantTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantsReceivable" xlink:label="us-gaap_GrantsReceivable"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_QualifyingExpenses" xlink:label="acet_QualifyingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_PostExposureProphylaxisDescription" xlink:label="acet_PostExposureProphylaxisDescription"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_QualifyingExpensesOnCumulativeBasis" xlink:label="acet_QualifyingExpensesOnCumulativeBasis"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:to="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:to="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:to="acet_ContingentValueRightsAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_UnusualRiskOrUncertaintyByNatureAxis" xlink:to="us-gaap_UnusualRiskOrUncertaintyNatureDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_UnusualRiskOrUncertaintyByNatureAxis" xlink:to="us-gaap_UnusualRiskOrUncertaintyNatureDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_UnusualRiskOrUncertaintyNatureDomain" xlink:to="acet_COVID19Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="acet_NovartisInternationalPharmaceuticalLimitedMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="acet_ResearchFundingAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="acet_FeesAndExpenseIncurredInConnectionWithClinicalTrials" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_UnusualRiskOrUncertaintyByNatureAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:to="acet_NovartisLicenseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="acet_NationalInstitutesOfHealthMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="acet_IncreaseDecreaseInEstimatedFairValueOfCvrLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="acet_EstimatedFairValueOfCVRLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="acet_LicenseAgreementTerminationDescription" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfClinicalMilestonesPayable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfRegulatoryMilestonesPayableForFirstIndicationApproved" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfRegulatoryMilestonesPayableForSecondIndicationApproved" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfCommercialMilestonesPayable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="acet_GrantTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_GrantsReceivable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="acet_QualifyingExpenses" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="acet_PostExposureProphylaxisDescription" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="acet_QualifyingExpensesOnCumulativeBasis" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermPurchaseCommitmentLineItems" xlink:label="us-gaap_LongTermPurchaseCommitmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermPurchaseCommitmentTable" xlink:label="us-gaap_LongTermPurchaseCommitmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_RfsOpcoLlcMember" xlink:label="acet_RfsOpcoLlcMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_IncreaseDecreaseInLeaseObligation" xlink:label="acet_IncreaseDecreaseInLeaseObligation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_MenloParkLeaseAgreementMember" xlink:label="acet_MenloParkLeaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_AreaOfSublease" xlink:label="acet_AreaOfSublease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_RedwoodCityLeaseAgreementMember" xlink:label="acet_RedwoodCityLeaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_SubleaseAgreementDescription" xlink:label="acet_SubleaseAgreementDescription"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_BostonMember" xlink:label="acet_BostonMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" xlink:label="us-gaap_OperatingLeasesRentExpenseSubleaseRentals1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecurityDepositLiability" xlink:label="us-gaap_SecurityDepositLiability"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_AmendedLeaseAgreementDescription" xlink:label="acet_AmendedLeaseAgreementDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LandSubjectToGroundLeases" xlink:label="us-gaap_LandSubjectToGroundLeases"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TenantImprovements" xlink:label="us-gaap_TenantImprovements"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_OperatingLeasesCommencementDate" xlink:label="acet_OperatingLeasesCommencementDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_LawsuitsFiledAgainstCompany" xlink:label="acet_LawsuitsFiledAgainstCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:label="us-gaap_LitigationSettlementExpense"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_LongTermPurchaseCommitmentTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="acet_RfsOpcoLlcMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="acet_IncreaseDecreaseInLeaseObligation" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LongTermPurchaseCommitmentTable" xlink:to="us-gaap_LeaseContractualTermAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="acet_MenloParkLeaseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201602Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="acet_AreaOfSublease" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LongTermPurchaseCommitmentTable" xlink:to="srt_CounterpartyNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="acet_RedwoodCityLeaseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="acet_SubleaseAgreementDescription" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LongTermPurchaseCommitmentTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="acet_BostonMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LongTermPurchaseCommitmentTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_SecurityDepositLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="acet_AmendedLeaseAgreementDescription" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_LeaseAndRentalExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_LandSubjectToGroundLeases" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_OperatingLeasePayments" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_TenantImprovements" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_LeaseExpirationDate1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="acet_OperatingLeasesCommencementDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_OperatingLeaseLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_FinanceLeaseLiability" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_LettersOfCreditOutstandingAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="acet_LawsuitsFiledAgainstCompany" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_LitigationSettlementExpense" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfWeightedAverageIBRAndRemainingLeaseTermDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermPurchaseCommitmentLineItems" xlink:label="us-gaap_LongTermPurchaseCommitmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermPurchaseCommitmentTable" xlink:label="us-gaap_LongTermPurchaseCommitmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_RedwoodCityLeaseAgreementMember" xlink:label="acet_RedwoodCityLeaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_BostonMember" xlink:label="acet_BostonMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_MenloParkLeaseAgreementMember" xlink:label="acet_MenloParkLeaseAgreementMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_LongTermPurchaseCommitmentTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_LongTermPurchaseCommitmentTable" xlink:to="us-gaap_LeaseContractualTermAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="acet_RedwoodCityLeaseAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="acet_BostonMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="acet_MenloParkLeaseAgreementMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_OptionsAvailableForFutureGrantsMember" xlink:label="acet_OptionsAvailableForFutureGrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_AdditionalAuthorizedAndUnissuedRedeemableConvertiblePreferredStockMember" xlink:label="acet_AdditionalAuthorizedAndUnissuedRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_RedeemableConvertiblePreferredStockWarrantsMember" xlink:label="acet_RedeemableConvertiblePreferredStockWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_CommonStockWarrantsMember" xlink:label="acet_CommonStockWarrantsMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="acet_OptionsAvailableForFutureGrantsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="acet_AdditionalAuthorizedAndUnissuedRedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="acet_RedeemableConvertiblePreferredStockWarrantsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="acet_CommonStockWarrantsMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_SeptemberFifteenTwoThousandTwentyWarrantOneMember" xlink:label="acet_SeptemberFifteenTwoThousandTwentyWarrantOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_SeptemberFifteenTwoThousandTwentyWarrantTwoMember" xlink:label="acet_SeptemberFifteenTwoThousandTwentyWarrantTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_SeptemberFifteenTwoThousandTwentyWarrantThreeMember" xlink:label="acet_SeptemberFifteenTwoThousandTwentyWarrantThreeMember"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ClassOfWarrantOrRightsExpirationDate" xlink:label="acet_ClassOfWarrantOrRightsExpirationDate"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_SeptemberFifteenTwoThousandTwentyWarrantFourMember" xlink:label="acet_SeptemberFifteenTwoThousandTwentyWarrantFourMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="acet_SeptemberFifteenTwoThousandTwentyWarrantOneMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_StatementEquityComponentsAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="acet_SeptemberFifteenTwoThousandTwentyWarrantTwoMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="acet_SeptemberFifteenTwoThousandTwentyWarrantThreeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="acet_ClassOfWarrantOrRightsExpirationDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="acet_SeptemberFifteenTwoThousandTwentyWarrantFourMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureAtTheMarketATMOfferingAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_AtTheMarketOfferingMember" xlink:label="acet_AtTheMarketOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_SalesAgreementMember" xlink:label="acet_SalesAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_MaximumAggregateValueOfCommonStockAvailableForOfferingAtMarketPriceUnderSalesAgreement" xlink:label="acet_MaximumAggregateValueOfCommonStockAvailableForOfferingAtMarketPriceUnderSalesAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_TerminationAgreementMonthAndYear" xlink:label="acet_TerminationAgreementMonthAndYear"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ScheduleOfStockByClassTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="acet_AtTheMarketOfferingMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="acet_SalesAgreementMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="acet_MaximumAggregateValueOfCommonStockAvailableForOfferingAtMarketPriceUnderSalesAgreement" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_TypeOfArrangementAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="acet_TerminationAgreementMonthAndYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_EmployeeStockPurchasePlanMember" xlink:label="acet_EmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_StockOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeContractTypeDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_DerivativeInstrumentRiskAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="acet_EmployeeStockPurchasePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_IncomeStatementLocationAxis" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_TwoThousandEighteenStockIncentivePlanMember" xlink:label="acet_TwoThousandEighteenStockIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_TwoThousandSeventeenAndTwoThousandEighteenStockIncentivePlanMember" xlink:label="acet_TwoThousandSeventeenAndTwoThousandEighteenStockIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_TwoThousandFourteenStockIncentivePlanMember" xlink:label="acet_TwoThousandFourteenStockIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_TwoThousandFifteenStockIncentivePlanMember" xlink:label="acet_TwoThousandFifteenStockIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_TwoThousandFourteenAndTwoThousandFifteenStockIncentivePlanMember" xlink:label="acet_TwoThousandFourteenAndTwoThousandFifteenStockIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_TwoThousandEighteenEmployeeStockPurchasePlanMember" xlink:label="acet_TwoThousandEighteenEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_NumberOfSharesAvailableForSaleUnderEmployeeStockPurchasePlan" xlink:label="acet_NumberOfSharesAvailableForSaleUnderEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_InducementGrantsMember" xlink:label="acet_InducementGrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_MergerMember" xlink:label="acet_MergerMember"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_TerminationAgreementMonthAndYear" xlink:label="acet_TerminationAgreementMonthAndYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="acet_TwoThousandEighteenStockIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_ScenarioUnspecifiedDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioForecastMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="acet_TwoThousandSeventeenAndTwoThousandEighteenStockIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="acet_TwoThousandFourteenStockIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="acet_TwoThousandFifteenStockIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_StatementScenarioAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="acet_TwoThousandFourteenAndTwoThousandFifteenStockIncentivePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="acet_TwoThousandEighteenEmployeeStockPurchasePlanMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="acet_NumberOfSharesAvailableForSaleUnderEmployeeStockPurchasePlan" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="acet_InducementGrantsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="acet_MergerMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="acet_TerminationAgreementMonthAndYear" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="14" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="15" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="16" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="17" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="18" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="19" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="20" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsToEstimateFairValueOfStockOptionsUsingBlackScholesOptionPricingModelDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_RedeemableConvertiblePreferredStockWarrantsMember" xlink:label="acet_RedeemableConvertiblePreferredStockWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_CommonStockWarrantsMember" xlink:label="acet_CommonStockWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_RedeemableConvertiblePreferredStockTrancheLiabilityAndTRDFObligationMember" xlink:label="acet_RedeemableConvertiblePreferredStockTrancheLiabilityAndTRDFObligationMember"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_UnvestedCommonStockFromEarlyExerciseOfOptionsMember" xlink:label="acet_UnvestedCommonStockFromEarlyExerciseOfOptionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="acet_RedeemableConvertiblePreferredStockWarrantsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AwardTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="acet_CommonStockWarrantsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="acet_RedeemableConvertiblePreferredStockTrancheLiabilityAndTRDFObligationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="acet_UnvestedCommonStockFromEarlyExerciseOfOptionsMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_IncomeTaxesDisclosureLineItems" xlink:label="acet_IncomeTaxesDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_IncomeTaxesTable" xlink:label="acet_IncomeTaxesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualRiskOrUncertaintyByNatureAxis" xlink:label="us-gaap_UnusualRiskOrUncertaintyByNatureAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualRiskOrUncertaintyNatureDomain" xlink:label="us-gaap_UnusualRiskOrUncertaintyNatureDomain"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_COVID19Member" xlink:label="acet_COVID19Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_default"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_CaliforniaResearchAndDevelopmentMember" xlink:label="acet_CaliforniaResearchAndDevelopmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntellectualPropertyMember" xlink:label="us-gaap_IntellectualPropertyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_FederalAndStateResearchAndDevelopmentMember" xlink:label="acet_FederalAndStateResearchAndDevelopmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit" xlink:label="us-gaap_TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_OperatingLossCarrybackDurationUnderCARESAct" xlink:label="acet_OperatingLossCarrybackDurationUnderCARESAct"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_PercentageOfNetOperatingLossCarryforwards" xlink:label="acet_PercentageOfNetOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_DeferredTaxAssetsValuationAllowanceIncrease" xlink:label="acet_DeferredTaxAssetsValuationAllowanceIncrease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:label="us-gaap_OperatingLossCarryforwardsExpirationDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_OperatingLossCarryforwardsIndefinitely" xlink:label="acet_OperatingLossCarryforwardsIndefinitely"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_OwnershipChangePlanDescription" xlink:label="acet_OwnershipChangePlanDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="acet_IncomeTaxesDisclosureLineItems" xlink:to="acet_IncomeTaxesTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acet_IncomeTaxesTable" xlink:to="us-gaap_UnusualRiskOrUncertaintyByNatureAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_UnusualRiskOrUncertaintyByNatureAxis" xlink:to="us-gaap_UnusualRiskOrUncertaintyNatureDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_UnusualRiskOrUncertaintyNatureDomain" xlink:to="acet_COVID19Member" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_default" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="acet_CaliforniaResearchAndDevelopmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_IntellectualPropertyMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acet_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="acet_FederalAndStateResearchAndDevelopmentMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acet_IncomeTaxesTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acet_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_ForeignCountryMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acet_IncomeTaxesTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acet_IncomeTaxesDisclosureLineItems" xlink:to="acet_OperatingLossCarrybackDurationUnderCARESAct" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acet_IncomeTaxesTable" xlink:to="us-gaap_TaxCreditCarryforwardAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acet_IncomeTaxesDisclosureLineItems" xlink:to="acet_PercentageOfNetOperatingLossCarryforwards" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="acet_IncomeTaxesTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acet_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acet_IncomeTaxesDisclosureLineItems" xlink:to="acet_DeferredTaxAssetsValuationAllowanceIncrease" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="6" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acet_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="7" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acet_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_OperatingLossCarryforwardsExpirationDate" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="8" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acet_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="9" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acet_IncomeTaxesDisclosureLineItems" xlink:to="acet_OperatingLossCarryforwardsIndefinitely" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="10" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acet_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_TaxCreditCarryforwardAmount" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="11" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acet_IncomeTaxesDisclosureLineItems" xlink:to="acet_OwnershipChangePlanDescription" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="12" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acet_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefits" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="13" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="acet_IncomeTaxesDisclosureLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_RegeneronPharmaceuticalsIncorporationMember" xlink:label="acet_RegeneronPharmaceuticalsIncorporationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromRelatedParties" xlink:label="us-gaap_RevenueFromRelatedParties"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:label="us-gaap_AccountsReceivableGrossCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="acet_RegeneronPharmaceuticalsIncorporationMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_ClassOfStockDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_SeriesBPreferredStockMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_CommonStockSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_StatementClassOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_PreferredStockSharesIssued" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="3" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RevenueFromRelatedParties" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="4" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_AccountsReceivableGrossCurrent" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="5" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_DeferredRevenue" priority="2" use="optional"/>
  </link:definitionLink>
  <link:definitionLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ExerciseFeePaid" xlink:label="acet_ExerciseFeePaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="acet_ExerciseFeePaid" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="0" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="1" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" priority="2" use="optional"/>
    <link:definitionArc xlink:type="arc" order="2" xbrldt:closed="false" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="srt_RangeAxis" priority="2" use="optional"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>37
<FILENAME>acet-20211231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-03-15T16:13:41.6761+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets" xlink:href="acet-20211231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:href="acet-20211231.xsd#Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows" xlink:href="acet-20211231.xsd#Role_StatementConsolidatedStatementsOfCashFlows" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsAcquiredDetails" xlink:href="acet-20211231.xsd#Role_DisclosureBusinessCombinationScheduleOfSummarizesAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsAcquiredDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureMarketableDebtSecuritiesScheduleOfMarketableDebtSecuritiesDetails" xlink:href="acet-20211231.xsd#Role_DisclosureMarketableDebtSecuritiesScheduleOfMarketableDebtSecuritiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureMarketableDebtSecuritiesSummaryOfClassificationOfMarketableDebtSecuritiesInConsolidatedBalanceSheetsDetails" xlink:href="acet-20211231.xsd#Role_DisclosureMarketableDebtSecuritiesSummaryOfClassificationOfMarketableDebtSecuritiesInConsolidatedBalanceSheetsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:href="acet-20211231.xsd#Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails" xlink:href="acet-20211231.xsd#Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesSummaryOfAccruedAndOtherCurrentLiabilitiesDetails" xlink:href="acet-20211231.xsd#Role_DisclosureAccruedAndOtherCurrentLiabilitiesSummaryOfAccruedAndOtherCurrentLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSubleaseIncomeDetails" xlink:href="acet-20211231.xsd#DisclosureCommitmentsAndContingenciesScheduleOfSubleaseIncomeDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesSummaryOfLeaseCostsAndOtherInformationDetails" xlink:href="acet-20211231.xsd#Role_DisclosureCommitmentAndContingenciesSummaryOfLeaseCostsAndOtherInformationDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:href="acet-20211231.xsd#Role_DisclosureCommitmentAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails" xlink:href="acet-20211231.xsd#Role_DisclosureCommitmentAndContingenciesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails2" xlink:href="acet-20211231.xsd#Role_DisclosureCommitmentAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails2" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForBenefitFromIncomeTaxesDetail" xlink:href="acet-20211231.xsd#Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForBenefitFromIncomeTaxesDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDiffersFromFederalStatutoryRateToLossBeforeTaxesDetail" xlink:href="acet-20211231.xsd#Role_DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDiffersFromFederalStatutoryRateToLossBeforeTaxesDetail" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:href="acet-20211231.xsd#Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails" xlink:type="simple"/>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredRentCreditNoncurrent" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableRelatedPartiesCurrent" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="3" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="3" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="3" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Goodwill" order="3" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="3" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="3" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="4" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="acet_RedeemableConvertiblePreferredStockWarrantLiability" order="4" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DevelopmentInProcess" order="4" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_RestrictedCashNoncurrent" order="5" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" order="5" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" order="6" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet" order="6" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="7" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilities" order="7" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:label="us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_RedeemableConvertiblePreferredStockWarrantLiability" xlink:label="acet_RedeemableConvertiblePreferredStockWarrantLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopmentInProcess" xlink:label="us-gaap_DevelopmentInProcess"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilities" xlink:label="us-gaap_OtherLiabilities"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_RevenueFromRelatedParties" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossBeforeTax" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="1" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="1" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_InterestAndOtherIncome" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_InterestExpense" order="2" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="3" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromRelatedParties" xlink:label="us-gaap_RevenueFromRelatedParties"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ProfitLoss" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_CashAcquiredFromAcquisition" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockPlans" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="acet_ProceedsFromSalesOfMarketableDebtSecurities" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationAndAmortization" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="2" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OtherNoncashExpense" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts" order="3" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnDispositionOfAssets1" order="4" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="4" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="5" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_FairValueAdjustmentOfWarrants" order="6" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="acet_ImpairmentOfInProcessResearchAndDevelopment" order="7" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="acet_GainOnRemeasurementOfContingentConsiderationLiability" order="8" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="acet_AmortizationOfDebtIssuanceCosts" order="10" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" order="11" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="12" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="13" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="14" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" order="15" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="acet_IncreaseDecreaseInOperatingLeaseLiabilities" order="16" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" order="17" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" order="18" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ProceedsFromSalesOfMarketableDebtSecurities" xlink:label="acet_ProceedsFromSalesOfMarketableDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashExpense" xlink:label="us-gaap_OtherNoncashExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ImpairmentOfInProcessResearchAndDevelopment" xlink:label="acet_ImpairmentOfInProcessResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_GainOnRemeasurementOfContingentConsiderationLiability" xlink:label="acet_GainOnRemeasurementOfContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_AmortizationOfDebtIssuanceCosts" xlink:label="acet_AmortizationOfDebtIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="acet_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsAcquiredDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="acet_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment" order="3" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="acet_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" order="4" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" order="5" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" order="6" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" order="7" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" order="8" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="us-gaap_Goodwill" order="9" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment" xlink:label="acet_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" xlink:label="acet_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureMarketableDebtSecuritiesScheduleOfMarketableDebtSecuritiesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" order="1" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="2" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureMarketableDebtSecuritiesSummaryOfClassificationOfMarketableDebtSecuritiesInConsolidatedBalanceSheetsDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_MarketableSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_MarketableSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" order="1" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecurities" xlink:label="us-gaap_MarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidInsurance" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="acet_PrepaymentsToCros" order="2" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="acet_PrepaymentsToCmos" order="3" weight="-1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_IncomeTaxesReceivable" order="4" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_InterestReceivableCurrent" order="5" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent" order="6" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_PrepaymentsToCros" xlink:label="acet_PrepaymentsToCros"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_PrepaymentsToCmos" xlink:label="acet_PrepaymentsToCmos"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="us-gaap_IncomeTaxesReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="1" weight="-1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesSummaryOfAccruedAndOtherCurrentLiabilitiesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="acet_AccruedCmoCosts" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="acet_AccruedResearchAndDevelopmentExpensesCurrent" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" order="3" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" order="4" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="acet_AccruedCroCosts" order="5" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_AccruedCmoCosts" xlink:label="acet_AccruedCmoCosts"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_AccruedResearchAndDevelopmentExpensesCurrent" xlink:label="acet_AccruedResearchAndDevelopmentExpensesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_AccruedCroCosts" xlink:label="acet_AccruedCroCosts"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSubleaseIncomeDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="acet_OperatingLeasesFutureMinimumSubleaseIncomeDue" xlink:to="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueCurrent" order="0" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="acet_OperatingLeasesFutureMinimumSubleaseIncomeDue" xlink:to="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInTwoYears" order="1" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="acet_OperatingLeasesFutureMinimumSubleaseIncomeDue" xlink:to="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInThreeYears" order="2" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="acet_OperatingLeasesFutureMinimumSubleaseIncomeDue" xlink:to="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInFourYears" order="3" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="acet_OperatingLeasesFutureMinimumSubleaseIncomeDue" xlink:to="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInFiveYears" order="4" weight="1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_OperatingLeasesFutureMinimumSubleaseIncomeDue" xlink:label="acet_OperatingLeasesFutureMinimumSubleaseIncomeDue"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_OperatingLeasesFutureMinimumSubleaseIncomeDueCurrent" xlink:label="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueCurrent"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInTwoYears" xlink:label="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInTwoYears"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInThreeYears" xlink:label="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInThreeYears"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInFourYears" xlink:label="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInFourYears"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInFiveYears" xlink:label="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInFiveYears"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesSummaryOfLeaseCostsAndOtherInformationDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_OperatingLeaseCost" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_ShortTermLeaseCost" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_VariableLeaseCost" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_SubleaseIncome" order="3" weight="-1" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" order="3" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" order="4" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="3" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" order="4" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" order="5" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails2">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_OperatingLeaseLiability" order="1" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForBenefitFromIncomeTaxesDetail">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" order="2" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDiffersFromFederalStatutoryRateToLossBeforeTaxesDetail">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" order="3" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" order="4" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="acet_EffectiveIncomeTaxRateReconciliationNOLCarryback" order="5" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="6" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="acet_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilityAndTRDFLiability" order="7" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" order="8" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_EffectiveIncomeTaxRateReconciliationNOLCarryback" xlink:label="acet_EffectiveIncomeTaxRateReconciliationNOLCarryback"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilityAndTRDFLiability" xlink:label="acet_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilityAndTRDFLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
  </link:calculationLink>
  <link:calculationLink xlink:type="extended" xlink:role="http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails">
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="0" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="1" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="acet_DeferredTaxLiabilitiesFixedAssets" order="1" weight="-1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="acet_DeferredTaxOperatingLeaseRightOfUseAssetLiability" order="1" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="acet_DeferredTaxBasisDifferenceIPRD" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="2" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="3" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="acet_DeferredTaxOperatingLeaseRightOfUseAsset" order="3" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" order="4" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="acet_DeferredTaxAssetsFixedAssets" order="5" weight="1" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" order="6" weight="1.00" use="optional"/>
    <link:calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" order="7" weight="1.00" use="optional"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_DeferredTaxLiabilitiesFixedAssets" xlink:label="acet_DeferredTaxLiabilitiesFixedAssets"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_DeferredTaxOperatingLeaseRightOfUseAssetLiability" xlink:label="acet_DeferredTaxOperatingLeaseRightOfUseAssetLiability"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_DeferredTaxBasisDifferenceIPRD" xlink:label="acet_DeferredTaxBasisDifferenceIPRD"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_DeferredTaxOperatingLeaseRightOfUseAsset" xlink:label="acet_DeferredTaxOperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_DeferredTaxAssetsFixedAssets" xlink:label="acet_DeferredTaxAssetsFixedAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>38
<FILENAME>acet-20211231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!-- DFIN New ActiveDisclosure (SM) XBRL Linkbase Document - http://www.dfinsolutions.com/ -->
<!-- Creation Date :2022-03-15T16:13:40.7620+00:00 -->
<!-- Copyright (c) 2022 Donnelly Financial Solutions, Inc. All Rights Reserved. -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/label/axisDefault" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd#axisDefault" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:title="labelLink" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_COVID19Member" xlink:label="acet_COVID19Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioForecastMember" xlink:label="srt_ScenarioForecastMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostAbstract" xlink:label="us-gaap_LeaseCostAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_OptionToPurchaseOfCommonStockAtPublicOfferingPrice" xlink:label="acet_OptionToPurchaseOfCommonStockAtPublicOfferingPrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRevenue" xlink:label="us-gaap_DeferredRevenue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_RisksAndUncertaintiesPolicyTextBlock" xlink:label="acet_RisksAndUncertaintiesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfReportableSegments" xlink:label="us-gaap_NumberOfReportableSegments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment" xlink:label="acet_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesLineItems" xlink:label="us-gaap_MarketableSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_SeriesBRedeemableConvertiblePreferredStockMember" xlink:label="acet_SeriesBRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Goodwill" xlink:label="us-gaap_Goodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityReverseStockSplit" xlink:label="us-gaap_StockholdersEquityReverseStockSplit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:label="us-gaap_AccountsReceivableRelatedPartiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_CommonStockWarrantsMember" xlink:label="acet_CommonStockWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedAsPartOfMerger" xlink:label="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedAsPartOfMerger"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubleaseIncome" xlink:label="us-gaap_SubleaseIncome"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_IncomeTaxesDisclosureLineItems" xlink:label="acet_IncomeTaxesDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_GainLossOnChangeInFairValueOfContingentConsiderationLiability" xlink:label="acet_GainLossOnChangeInFairValueOfContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:label="us-gaap_BusinessCombinationsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RedeemableConvertiblePreferredStockMember" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:label="acet_IncreaseDecreaseInOperatingLeaseLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_LiabilitiesFairValueSettled" xlink:label="acet_LiabilitiesFairValueSettled"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="us-gaap_BusinessAcquisitionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIncomeTaxRefunds" xlink:label="us-gaap_ProceedsFromIncomeTaxRefunds"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueFromRelatedParties" xlink:label="us-gaap_RevenueFromRelatedParties"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInTwoYears" xlink:label="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInTwoYears"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_TemporaryEquityStockConversionSharesInConnectionWithMerger" xlink:label="acet_TemporaryEquityStockConversionSharesInConnectionWithMerger"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherLiabilities" xlink:label="us-gaap_OtherLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SeriesBPreferredStockMember" xlink:label="us-gaap_SeriesBPreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_LawsuitsFiledAgainstCompany" xlink:label="acet_LawsuitsFiledAgainstCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAssetsArisingFromContingenciesAmountRecognized" xlink:label="us-gaap_BusinessCombinationAssetsArisingFromContingenciesAmountRecognized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ClassOfWarrantOrRightsExpirationDate" xlink:label="acet_ClassOfWarrantOrRightsExpirationDate"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_LicenseFundingAndOtherAgreementsAbstract" xlink:label="acet_LicenseFundingAndOtherAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" xlink:label="acet_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_AreaOfSublease" xlink:label="acet_AreaOfSublease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockLiquidationPreferenceValue" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ExerciseFeePaid" xlink:label="acet_ExerciseFeePaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TenantImprovements" xlink:label="us-gaap_TenantImprovements"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAsPartOfMerger" xlink:label="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAsPartOfMerger"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueDisclosure" xlink:label="us-gaap_LiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_QualifyingExpenses" xlink:label="acet_QualifyingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_RedeemableConvertiblePreferredStockWarrantLiabilityMember" xlink:label="acet_RedeemableConvertiblePreferredStockWarrantLiabilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_SeptemberFifteenTwoThousandTwentyWarrantThreeMember" xlink:label="acet_SeptemberFifteenTwoThousandTwentyWarrantThreeMember"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_LicenceAgreementUpfrontPayment" xlink:label="acet_LicenceAgreementUpfrontPayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ResearchFundingFee" xlink:label="acet_ResearchFundingFee"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_LeaseCostOtherInformationAbstract" xlink:label="acet_LeaseCostOtherInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_RedeemableConvertiblePreferredStockWarrantLiabilityPolicyTextBlock" xlink:label="acet_RedeemableConvertiblePreferredStockWarrantLiabilityPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_TwoThousandFourteenAndTwoThousandFifteenStockIncentivePlanMember" xlink:label="acet_TwoThousandFourteenAndTwoThousandFifteenStockIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_FairValueOfCommonStockPolicyTextBlock" xlink:label="acet_FairValueOfCommonStockPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_TwoThousandFifteenStockIncentivePlanMember" xlink:label="acet_TwoThousandFifteenStockIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashNoncurrent" xlink:label="us-gaap_RestrictedCashNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementDomain" xlink:label="srt_RestatementDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFinanceCostsGross" xlink:label="us-gaap_DeferredFinanceCostsGross"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ContractAssetsAndLiabilitiesAdditions" xlink:label="acet_ContractAssetsAndLiabilitiesAdditions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="us-gaap_DerivativeContractTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_LicenceAgreementCumulativeRevenueRecognised" xlink:label="acet_LicenceAgreementCumulativeRevenueRecognised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ChangeDuringPeriodFairValueDisclosureMember" xlink:label="us-gaap_ChangeDuringPeriodFairValueDisclosureMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_AtTheMarketOfferingTextBlock" xlink:label="acet_AtTheMarketOfferingTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_OperatingLossCarrybackDurationUnderCARESAct" xlink:label="acet_OperatingLossCarrybackDurationUnderCARESAct"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_GainOnRemeasurementOfContingentConsiderationLiability" xlink:label="acet_GainOnRemeasurementOfContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ContractualContingentValueRight" xlink:label="acet_ContractualContingentValueRight"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingAxis" xlink:label="us-gaap_VestingAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="us-gaap_GainLossOnDispositionOfAssets1"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_FairValueOfModifiedStockOptionsAndRestrictedStockUnitsAttributableToPreCombinationServices" xlink:label="acet_FairValueOfModifiedStockOptionsAndRestrictedStockUnitsAttributableToPreCombinationServices"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_TermLoanAndNonFormulaAncillaryService" xlink:label="acet_TermLoanAndNonFormulaAncillaryService"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_BostonMember" xlink:label="acet_BostonMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_DeferredTaxBasisDifferenceIPRD" xlink:label="acet_DeferredTaxBasisDifferenceIPRD"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ContingentConsiderationFees" xlink:label="acet_ContingentConsiderationFees"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_LicenseAndCollaborationRevenue" xlink:label="acet_LicenseAndCollaborationRevenue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="us-gaap_OperatingLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ResTORbioMember" xlink:label="acet_ResTORbioMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:label="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_EmployeeStockPurchasePlanMember" xlink:label="acet_EmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_BusinessAcquisitionsProFormaRevenue1" xlink:label="acet_BusinessAcquisitionsProFormaRevenue1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_RecognitionOfPreferredStockWarrantLiabilities" xlink:label="acet_RecognitionOfPreferredStockWarrantLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IntellectualPropertyMember" xlink:label="us-gaap_IntellectualPropertyMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInFiveYears" xlink:label="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInFiveYears"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAuthorized" xlink:label="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePaymentsUse" xlink:label="us-gaap_OperatingLeasePaymentsUse"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_NumberOfSecuritiesConvertedToWarrantsToPurchaseCommonStock" xlink:label="acet_NumberOfSecuritiesConvertedToWarrantsToPurchaseCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestReceivableCurrent" xlink:label="us-gaap_InterestReceivableCurrent"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_InducementGrantsMember" xlink:label="acet_InducementGrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockTableTextBlock" xlink:label="acet_ScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteAbstract" xlink:label="us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_TemporaryEquityStockConversionInConnectionWithMerger" xlink:label="acet_TemporaryEquityStockConversionInConnectionWithMerger"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VestingDomain" xlink:label="us-gaap_VestingDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementAxis" xlink:label="srt_RestatementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_NovartisLicenseAgreementMember" xlink:label="acet_NovartisLicenseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_RedeemableConvertiblePreferredStockTrancheLiabilityMember" xlink:label="acet_RedeemableConvertiblePreferredStockTrancheLiabilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="us-gaap_LongtermDebtTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_NumberOfSharesOfSurvivingStockOptions" xlink:label="acet_NumberOfSharesOfSurvivingStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesReceivable" xlink:label="us-gaap_IncomeTaxesReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_RedeemableConvertiblePreferredStockTrancheLiabilityAndTRDFObligationMember" xlink:label="acet_RedeemableConvertiblePreferredStockTrancheLiabilityAndTRDFObligationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ContractResearchTermPeriod" xlink:label="acet_ContractResearchTermPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="us-gaap_OtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationDateOfIncorporation" xlink:label="dei_EntityIncorporationDateOfIncorporation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNoncashExpense" xlink:label="us-gaap_OtherNoncashExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="us-gaap_ConsolidationPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_DeferredTaxOperatingLeaseRightOfUseAssetLiability" xlink:label="acet_DeferredTaxOperatingLeaseRightOfUseAssetLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SecurityDepositLiability" xlink:label="us-gaap_SecurityDepositLiability"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesCancelled" xlink:label="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesCancelled"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidInsurance" xlink:label="us-gaap_PrepaidInsurance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_AccruedCroCosts" xlink:label="acet_AccruedCroCosts"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_SummaryOfSignificantAccountingPoliciesLineItems" xlink:label="acet_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfClinicalMilestonesPayable" xlink:label="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfClinicalMilestonesPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ExerciseOfRedeemableConvertiblePreferredStockTrancheLiabilities" xlink:label="acet_ExerciseOfRedeemableConvertiblePreferredStockTrancheLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_IncreaseInConstructionInProgress" xlink:label="acet_IncreaseInConstructionInProgress"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_RedeemableConvertiblePreferredStockPolicyTextBlock" xlink:label="acet_RedeemableConvertiblePreferredStockPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCost" xlink:label="us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_GoodwillMeasurementPeriodAdjustments" xlink:label="acet_GoodwillMeasurementPeriodAdjustments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInFourYears" xlink:label="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInFourYears"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="us-gaap_MarketableSecuritiesTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_CompanyContributionToPlanWithRespectToEmployeesContribution" xlink:label="acet_CompanyContributionToPlanWithRespectToEmployeesContribution"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_SeptemberFifteenTwoThousandTwentyWarrantTwoMember" xlink:label="acet_SeptemberFifteenTwoThousandTwentyWarrantTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit" xlink:label="us-gaap_TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockDescriptionOfTransaction" xlink:label="us-gaap_SaleOfStockDescriptionOfTransaction"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_LicenseAgreementAdditionalPaymentForResearchFundingReceived" xlink:label="acet_LicenseAgreementAdditionalPaymentForResearchFundingReceived"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesGranted" xlink:label="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesGranted"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GrantsReceivable" xlink:label="us-gaap_GrantsReceivable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetBackedSecuritiesMember" xlink:label="us-gaap_AssetBackedSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="us-gaap_CommercialPaperMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_StockExchangedDuringPeriodSharesInConnectionWithMerger" xlink:label="acet_StockExchangedDuringPeriodSharesInConnectionWithMerger"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_LicenseFundingAndOtherAgreementsTextBlock" xlink:label="acet_LicenseFundingAndOtherAgreementsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ExercisedInvestmentRightAndPurchased" xlink:label="acet_ExercisedInvestmentRightAndPurchased"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_UnderwritingDiscountsAndCommissionsAndOtherOfferingExpenses" xlink:label="acet_UnderwritingDiscountsAndCommissionsAndOtherOfferingExpenses"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_TerminationOfRedeemableConvertiblePreferredStockTrancheLiability" xlink:label="acet_TerminationOfRedeemableConvertiblePreferredStockTrancheLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared" xlink:label="us-gaap_CommonStockDividendsPerShareDeclared"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="us-gaap_BusinessAcquisitionSharePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermDebtDescription" xlink:label="us-gaap_LongTermDebtDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_QualifyingExpensesOnCumulativeBasis" xlink:label="acet_QualifyingExpensesOnCumulativeBasis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualRiskOrUncertaintyByNatureAxis" xlink:label="us-gaap_UnusualRiskOrUncertaintyByNatureAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="us-gaap_LeaseCostTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="us-gaap_VariableLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ContractAssetMember" xlink:label="acet_ContractAssetMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_MilestoneClosingLiability" xlink:label="acet_MilestoneClosingLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioPreviouslyReportedMember" xlink:label="srt_ScenarioPreviouslyReportedMember"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_AccruedResearchAndDevelopmentExpensesCurrent" xlink:label="acet_AccruedResearchAndDevelopmentExpensesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_NumberOfSharesAvailableForSaleUnderEmployeeStockPurchasePlan" xlink:label="acet_NumberOfSharesAvailableForSaleUnderEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FinanceLeaseLiability" xlink:label="us-gaap_FinanceLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_FeesAndExpenseIncurredInConnectionWithClinicalTrials" xlink:label="acet_FeesAndExpenseIncurredInConnectionWithClinicalTrials"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrimeRateMember" xlink:label="us-gaap_PrimeRateMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_NationalInstitutesOfHealthMember" xlink:label="acet_NationalInstitutesOfHealthMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ScheduleOfChangesInFairValueOfUnobservableFinancialInstrumentsTableTextBlock" xlink:label="acet_ScheduleOfChangesInFairValueOfUnobservableFinancialInstrumentsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:label="acet_PrepaidExpensesAndOtherCurrentAssetsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_SeptemberFifteenTwoThousandTwentyWarrantOneMember" xlink:label="acet_SeptemberFifteenTwoThousandTwentyWarrantOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ForeignCountryMember" xlink:label="us-gaap_ForeignCountryMember"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_OperatingLeasesFutureMinimumSubleaseIncomeDue" xlink:label="acet_OperatingLeasesFutureMinimumSubleaseIncomeDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="us-gaap_AccountingStandardsUpdate201602Member"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ContingentValueRightsAgreementMember" xlink:label="acet_ContingentValueRightsAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfDebtIssuanceCosts" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_CaliforniaResearchAndDevelopmentMember" xlink:label="acet_CaliforniaResearchAndDevelopmentMember"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ClassOfWarrantOrRightIssued" xlink:label="acet_ClassOfWarrantOrRightIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:label="us-gaap_LitigationSettlementExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:label="us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_AdvisoryServicesAnnualFee" xlink:label="acet_AdvisoryServicesAnnualFee"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_AccruedCmoCosts" xlink:label="acet_AccruedCmoCosts"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_MergerMember" xlink:label="acet_MergerMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInThreeYears" xlink:label="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInThreeYears"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:label="us-gaap_OtherComprehensiveIncomeLossBeforeTax"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_MarketableDebtSecuritiesClassificationTableTextBlock" xlink:label="acet_MarketableDebtSecuritiesClassificationTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="us-gaap_BusinessAcquisitionAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="us-gaap_BalanceSheetLocationAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_TwoThousandFourteenStockIncentivePlanMember" xlink:label="acet_TwoThousandFourteenStockIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_PrepaymentsToCros" xlink:label="acet_PrepaymentsToCros"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_LicenseAgreementTerminationDescription" xlink:label="acet_LicenseAgreementTerminationDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanTextBlock" xlink:label="us-gaap_DefinedContributionPlanTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentsTableTextBlock" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ClassOfWarrantOutstandingAndExercisableToPurchasePreferredShares" xlink:label="acet_ClassOfWarrantOutstandingAndExercisableToPurchasePreferredShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ResearchFundingAgreementMember" xlink:label="acet_ResearchFundingAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_MarketableSecuritiesMember" xlink:label="acet_MarketableSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ContingentConsiderationMember" xlink:label="acet_ContingentConsiderationMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LandSubjectToGroundLeases" xlink:label="us-gaap_LandSubjectToGroundLeases"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_EstimatedFairValueOfCVRLiability" xlink:label="acet_EstimatedFairValueOfCVRLiability"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ScheduleOfSubleaseIncomeTableTextBlock" xlink:label="acet_ScheduleOfSubleaseIncomeTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_EntityDateOfMerger" xlink:label="acet_EntityDateOfMerger"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:label="us-gaap_OperatingLossCarryforwardsExpirationDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_NovartisInternationalPharmaceuticalLimitedMember" xlink:label="acet_NovartisInternationalPharmaceuticalLimitedMember"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfCommercialMilestonesPayable" xlink:label="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfCommercialMilestonesPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityPolicyTextBlock" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_IncreaseDecreaseInEstimatedFairValueOfCvrLiability" xlink:label="acet_IncreaseDecreaseInEstimatedFairValueOfCvrLiability"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_StockIssuedDuringPeriodSharesUponAcceleratedVestingOfRSUWithMerger" xlink:label="acet_StockIssuedDuringPeriodSharesUponAcceleratedVestingOfRSUWithMerger"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ClassOfWarrantExercised" xlink:label="acet_ClassOfWarrantExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_FederalAndStateResearchAndDevelopmentMember" xlink:label="acet_FederalAndStateResearchAndDevelopmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAcquiredFromAcquisition" xlink:label="us-gaap_CashAcquiredFromAcquisition"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="us-gaap_BusinessCombinationsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_StockExchangedDuringPeriodValueInConnectionWithMerger" xlink:label="acet_StockExchangedDuringPeriodValueInConnectionWithMerger"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_OperatingLeasesFutureMinimumSubleaseIncomeDueCurrent" xlink:label="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_AdditionalClosingLiability" xlink:label="acet_AdditionalClosingLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:label="us-gaap_InterestAndOtherIncome"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_UnvestedRestrictedStockUnitsOutstanding" xlink:label="acet_UnvestedRestrictedStockUnitsOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_NonRefundableUpfrontPaymentReceived" xlink:label="acet_NonRefundableUpfrontPaymentReceived"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_FinancingReceivableNonaccrualToOutstandingPercent" xlink:label="srt_FinancingReceivableNonaccrualToOutstandingPercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumedAsPartOfMergerInPeriodWeightedAverageExercisePrice" xlink:label="acet_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumedAsPartOfMergerInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" xlink:label="us-gaap_OperatingLeasesRentExpenseSubleaseRentals1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_StockIssuedDuringPeriodValueUponAcceleratedVestingOfRSUWithMerger" xlink:label="acet_StockIssuedDuringPeriodValueUponAcceleratedVestingOfRSUWithMerger"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansPayable" xlink:label="us-gaap_LoansPayable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_OrganizationAndNatureOfBusinessTextBlock" xlink:label="acet_OrganizationAndNatureOfBusinessTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ImpairmentOfInProcessResearchAndDevelopment" xlink:label="acet_ImpairmentOfInProcessResearchAndDevelopment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure" xlink:label="us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:label="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="us-gaap_BalanceSheetLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_OrganizationAndNatureOfBusinessAbstract" xlink:label="acet_OrganizationAndNatureOfBusinessAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ContractLiabilityMember" xlink:label="acet_ContractLiabilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermPurchaseCommitmentTable" xlink:label="us-gaap_LongTermPurchaseCommitmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="us-gaap_FairValueInputsLevel3Member"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesExercised" xlink:label="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesExercised"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ProceedsFromSalesOfMarketableDebtSecurities" xlink:label="acet_ProceedsFromSalesOfMarketableDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_RedeemableConvertiblePreferredStockWarrantLiability" xlink:label="acet_RedeemableConvertiblePreferredStockWarrantLiability"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_AccruedResearchAndDevelopmentPolicyTextBlock" xlink:label="acet_AccruedResearchAndDevelopmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesFairValueAdjustment" xlink:label="us-gaap_LiabilitiesFairValueAdjustment"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_BusinessCombinationAccelerationOfRestrictedStockUnitsUponMerger" xlink:label="acet_BusinessCombinationAccelerationOfRestrictedStockUnitsUponMerger"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesAuthorized" xlink:label="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfRegulatoryMilestonesPayableForFirstIndicationApproved" xlink:label="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfRegulatoryMilestonesPayableForFirstIndicationApproved"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:label="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_GrantTerm" xlink:label="acet_GrantTerm"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:label="acet_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_MenloParkLeaseAgreementMember" xlink:label="acet_MenloParkLeaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockMember" xlink:label="us-gaap_RestrictedStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_NumberOfCustomer" xlink:label="acet_NumberOfCustomer"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecuritiesTable" xlink:label="us-gaap_MarketableSecuritiesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ClassOfWarrantOutstandingAndExercisableToPurchaseCommonStock" xlink:label="acet_ClassOfWarrantOutstandingAndExercisableToPurchaseCommonStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_RightOfUseAssetsRecognized" xlink:label="acet_RightOfUseAssetsRecognized"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_PostExposureProphylaxisDescription" xlink:label="acet_PostExposureProphylaxisDescription"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ContractLiability" xlink:label="acet_ContractLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsReceivableGrossCurrent" xlink:label="us-gaap_AccountsReceivableGrossCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxesPaid" xlink:label="us-gaap_IncomeTaxesPaid"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="us-gaap_LongtermDebtTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentTangibleAndIntangiblesAssets" xlink:label="acet_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentTangibleAndIntangiblesAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_AdicetTherapeuticsIncMember" xlink:label="acet_AdicetTherapeuticsIncMember"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_VestingOfEarlyExercisedStockOptions" xlink:label="acet_VestingOfEarlyExercisedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DevelopmentInProcess" xlink:label="us-gaap_DevelopmentInProcess"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_MaximumAggregateValueOfCommonStockAvailableForOfferingAtMarketPriceUnderSalesAgreement" xlink:label="acet_MaximumAggregateValueOfCommonStockAvailableForOfferingAtMarketPriceUnderSalesAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_LoanAmountDrawn" xlink:label="acet_LoanAmountDrawn"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_SeptemberFifteenTwoThousandTwentyWarrantFourMember" xlink:label="acet_SeptemberFifteenTwoThousandTwentyWarrantFourMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_AtTheMarketOfferingMember" xlink:label="acet_AtTheMarketOfferingMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_SubleaseAgreementDescription" xlink:label="acet_SubleaseAgreementDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnusualRiskOrUncertaintyNatureDomain" xlink:label="us-gaap_UnusualRiskOrUncertaintyNatureDomain"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_LiabilitiesFairValueExercised" xlink:label="acet_LiabilitiesFairValueExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ContingentConsiderationLiabilityMember" xlink:label="acet_ContingentConsiderationLiabilityMember"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilityAndTRDFLiability" xlink:label="acet_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilityAndTRDFLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ScheduleOfWeightedAverageIBRAndRemainingLeaseTermTableTextBlock" xlink:label="acet_ScheduleOfWeightedAverageIBRAndRemainingLeaseTermTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_FourthAmendmentMember" xlink:label="acet_FourthAmendmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_IncreaseDecreaseInLeaseObligation" xlink:label="acet_IncreaseDecreaseInLeaseObligation"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:label="us-gaap_GoodwillImpairmentLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LoansReceivableBasisSpreadOnVariableRate" xlink:label="us-gaap_LoansReceivableBasisSpreadOnVariableRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DebtInstrumentMaturityDateRangeEnd1" xlink:label="us-gaap_DebtInstrumentMaturityDateRangeEnd1"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_RedwoodCityLeaseAgreementMember" xlink:label="acet_RedwoodCityLeaseAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="us-gaap_LettersOfCreditOutstandingAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_EffectiveIncomeTaxRateReconciliationNOLCarryback" xlink:label="acet_EffectiveIncomeTaxRateReconciliationNOLCarryback"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShortTermLeaseCost" xlink:label="us-gaap_ShortTermLeaseCost"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_LaboratoryEquipmentMember" xlink:label="acet_LaboratoryEquipmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_IncomeTaxesTable" xlink:label="acet_IncomeTaxesTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_DeferredTaxAssetsValuationAllowanceIncrease" xlink:label="acet_DeferredTaxAssetsValuationAllowanceIncrease"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_RfsOpcoLlcMember" xlink:label="acet_RfsOpcoLlcMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_IssuanceOfRedeemableConvertiblePreferredStockOnExerciseOfWarrantsWithLoanAgreement" xlink:label="acet_IssuanceOfRedeemableConvertiblePreferredStockOnExerciseOfWarrantsWithLoanAgreement"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ContractAssetsAndLiabilities" xlink:label="acet_ContractAssetsAndLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_AmountPayableUponClosingOfMerger" xlink:label="acet_AmountPayableUponClosingOfMerger"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_PercentageOfNetOperatingLossCarryforwards" xlink:label="acet_PercentageOfNetOperatingLossCarryforwards"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsForMergerRelatedCosts" xlink:label="us-gaap_PaymentsForMergerRelatedCosts"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_AmendedLeaseAgreementDescription" xlink:label="acet_AmendedLeaseAgreementDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_WarrantsOutstandingAndExercisableWeightedAverageRemainingContractualTerm" xlink:label="acet_WarrantsOutstandingAndExercisableWeightedAverageRemainingContractualTerm"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_OperatingLossCarryforwardsIndefinitely" xlink:label="acet_OperatingLossCarryforwardsIndefinitely"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_RedeemableConvertiblePreferredStockTrancheLiabilityPolicyTextBlock" xlink:label="acet_RedeemableConvertiblePreferredStockTrancheLiabilityPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_TransitionAgreementMember" xlink:label="acet_TransitionAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_RegeneronPharmaceuticalsIncorporationMember" xlink:label="acet_RegeneronPharmaceuticalsIncorporationMember"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ExchangeRatio" xlink:label="acet_ExchangeRatio"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAuthorizedInPeriodWeightedAverageExercisePrice" xlink:label="acet_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAuthorizedInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_StockIssuedDuringPeriodSharesConversionOfSecurities" xlink:label="acet_StockIssuedDuringPeriodSharesConversionOfSecurities"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_DefinedContributionPlanAbstract" xlink:label="acet_DefinedContributionPlanAbstract"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_LicenceAgreementAdditionalAmountPayableOfOptionExerciseFees" xlink:label="acet_LicenceAgreementAdditionalAmountPayableOfOptionExerciseFees"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ChangeInFairValueIncludedInResearchAndDevelopmentExpense" xlink:label="acet_ChangeInFairValueIncludedInResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_LicenceAgreementAdditionalRevenueRecognised" xlink:label="acet_LicenceAgreementAdditionalRevenueRecognised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="us-gaap_RelatedPartyTransactionDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TemporaryEquitySharesOutstanding" xlink:label="us-gaap_TemporaryEquitySharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:label="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_CustomersPercentageOfTotalRevenue" xlink:label="acet_CustomersPercentageOfTotalRevenue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_TerminationAgreementMonthAndYear" xlink:label="acet_TerminationAgreementMonthAndYear"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_DeferredTaxAssetsFixedAssets" xlink:label="acet_DeferredTaxAssetsFixedAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_GainLossFromTheRemeasurementOfRedeemableConvertiblePreferredStock" xlink:label="acet_GainLossFromTheRemeasurementOfRedeemableConvertiblePreferredStock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ContractAssetsAndLiabilitiesAdditionsDeductions" xlink:label="acet_ContractAssetsAndLiabilitiesAdditionsDeductions"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_SalesAgreementMember" xlink:label="acet_SalesAgreementMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_OptionsAvailableForFutureGrantsMember" xlink:label="acet_OptionsAvailableForFutureGrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationAbstract" xlink:label="us-gaap_ShareBasedCompensationAbstract"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_RedeemableConvertiblePreferredStockWarrantsMember" xlink:label="acet_RedeemableConvertiblePreferredStockWarrantsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_TermLoanToFinanceLeaseholdImprovements1" xlink:label="acet_TermLoanToFinanceLeaseholdImprovements1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfAssetsAcquired" xlink:label="us-gaap_FairValueOfAssetsAcquired"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_AdjustmentToGoodwill" xlink:label="acet_AdjustmentToGoodwill"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_AmortizationOfDebtIssuanceCosts" xlink:label="acet_AmortizationOfDebtIssuanceCosts"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RestatementAdjustmentMember" xlink:label="srt_RestatementAdjustmentMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedBonusesCurrentAndNoncurrent" xlink:label="us-gaap_AccruedBonusesCurrentAndNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_UnvestedCommonStockFromEarlyExerciseOfOptionsMember" xlink:label="acet_UnvestedCommonStockFromEarlyExerciseOfOptionsMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermAxis" xlink:label="us-gaap_LeaseContractualTermAxis"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_RecognitionOfContingentConsiderationLiability" xlink:label="acet_RecognitionOfContingentConsiderationLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_TwoThousandEighteenStockIncentivePlanMember" xlink:label="acet_TwoThousandEighteenStockIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ConversionOfConvertiblePreferredStockWarrantsIntoCommonStockWarrantsInConnectionWithMerger" xlink:label="acet_ConversionOfConvertiblePreferredStockWarrantsIntoCommonStockWarrantsInConnectionWithMerger"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_ScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceTextBlock" xlink:label="acet_ScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LeaseContractualTermDomain" xlink:label="us-gaap_LeaseContractualTermDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:label="us-gaap_IncreaseDecreaseInDeferredLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_TwoThousandSeventeenAndTwoThousandEighteenStockIncentivePlanMember" xlink:label="acet_TwoThousandSeventeenAndTwoThousandEighteenStockIncentivePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_AgreementTransactionPrice" xlink:label="acet_AgreementTransactionPrice"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_LessPortionOfFairValueToBeDistributedAsCVR" xlink:label="acet_LessPortionOfFairValueToBeDistributedAsCVR"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_SummaryOfSignificantAccountingPoliciesTable" xlink:label="acet_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_LicenseAgreementCumulativeRevenueReductionRecognised" xlink:label="acet_LicenseAgreementCumulativeRevenueReductionRecognised"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_SettlementOfTRDFLiability" xlink:label="acet_SettlementOfTRDFLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_DeferredTaxOperatingLeaseRightOfUseAsset" xlink:label="acet_DeferredTaxOperatingLeaseRightOfUseAsset"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_LumpSumCompensationPayment" xlink:label="acet_LumpSumCompensationPayment"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_TRDFLiabilityMember" xlink:label="acet_TRDFLiabilityMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_MarketableSecurities" xlink:label="us-gaap_MarketableSecurities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_PrepaymentsToCmos" xlink:label="acet_PrepaymentsToCmos"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_TwoThousandEighteenEmployeeStockPurchasePlanMember" xlink:label="acet_TwoThousandEighteenEmployeeStockPurchasePlanMember"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_OwnershipChangePlanDescription" xlink:label="acet_OwnershipChangePlanDescription"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConversionOfStockAmountConverted1" xlink:label="us-gaap_ConversionOfStockAmountConverted1"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_AdditionalAuthorizedAndUnissuedRedeemableConvertiblePreferredStockMember" xlink:label="acet_AdditionalAuthorizedAndUnissuedRedeemableConvertiblePreferredStockMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LongTermPurchaseCommitmentLineItems" xlink:label="us-gaap_LongTermPurchaseCommitmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TaxCreditCarryforwardAmount" xlink:label="us-gaap_TaxCreditCarryforwardAmount"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_OperatingLeasesCommencementDate" xlink:label="acet_OperatingLeasesCommencementDate"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_DeferredTaxLiabilitiesFixedAssets" xlink:label="acet_DeferredTaxLiabilitiesFixedAssets"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfRegulatoryMilestonesPayableForSecondIndicationApproved" xlink:label="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfRegulatoryMilestonesPayableForSecondIndicationApproved"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LegalFees" xlink:label="us-gaap_LegalFees"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_TermLoanAbstract" xlink:label="acet_TermLoanAbstract"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_CommonStockOfferingCostsIncludedInAccruedLiabilitiesAtPeriodEnd" xlink:label="acet_CommonStockOfferingCostsIncludedInAccruedLiabilitiesAtPeriodEnd"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock"/>
    <link:loc xlink:type="locator" xlink:href="acet-20211231.xsd#acet_PacificWesternBankMember" xlink:label="acet_PacificWesternBankMember"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions"/>
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expiration date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_COVID19Member_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">COVID 19.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_COVID19Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">C O V I D19 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_COVID19Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">C O V I D19</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_COVID19Member_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">COVID-19</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Loss Carryforwards, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases, Future Minimum Payments, Due in Four Years</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioForecastMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Forecast [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioForecastMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Forecast</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rent expense recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases, Rent Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Operating Leases, Rent Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorLocation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_OptionToPurchaseOfCommonStockAtPublicOfferingPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Option to purchase of common stock at public offering price.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_OptionToPurchaseOfCommonStockAtPublicOfferingPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Option To Purchase Of Common Stock At Public Offering Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_OptionToPurchaseOfCommonStockAtPublicOfferingPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option to purchase of common stock at public offering price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Revenue, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Cash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Cash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Cash_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Cash_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets by Major Class</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income (Loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net assets acquired:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RisksAndUncertaintiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Risks and uncertainties policy text block.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RisksAndUncertaintiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Risks And Uncertainties Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RisksAndUncertaintiesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risks and Uncertainties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Emerging Growth Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instrument [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instrument</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Plans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Prepaid Expense and Other Assets, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfReportableSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Reportable Segments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Shares Available for Grant, Ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Shares Available for Grant, Beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares of common stock available for grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchase of property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.0001 par value, 150,000,000 shares authorized as of December 31, 2021 and December 31, 2020, respectively; 39,736,914 and 19,677,249 shares issued and outstanding as of December 31, 2021 and December 31, 2020, respectively</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Value, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Value, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Value, Issued, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Value, Issued, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressStateOrProvince_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, State or Province</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business combination recognized identifiable assets acquired and liabilities assumed in process research and development.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed In Process Research And Development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">IPR&amp;D</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Liabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_SeriesBRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Series B redeemable convertible preferred stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_SeriesBRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_SeriesBRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Redeemable Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_SeriesBRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Series B Redeemable Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases, Future Minimum Payments, Due in Three Years</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Goodwill, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Goodwill, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Goodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Goodwill, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity, Reverse Stock Split</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityReverseStockSplit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse stock split</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableRelatedPartiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts Receivable - related party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableRelatedPartiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable, Related Parties, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_CommonStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock warrants.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_CommonStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Warrants [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_CommonStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Future Minimum Rental Payments For Operating Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedAsPartOfMerger_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options assumed as part of merger.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedAsPartOfMerger_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Assumed As Part Of Merger</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedAsPartOfMerger_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares Underlying Outstanding Options, Assumed as part of the Merger</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubleaseIncome_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Sublease Income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubleaseIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sublease Income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_IncomeTaxesDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income taxes disclosure.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_IncomeTaxesDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_IncomeTaxesDisclosureLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes Disclosure [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock Issued Upon Conversion (1)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of common stock shares issued upon conversion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_GainLossOnChangeInFairValueOfContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gain loss on change in fair value of contingent consideration liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_GainLossOnChangeInFairValueOfContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain Loss On Change In Fair Value Of Contingent Consideration Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_GainLossOnChangeInFairValueOfContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gain (loss) on change in fair value of CVR</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized gain (loss) on marketable debt securities, net of tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number of Shares Outstanding, Basic and Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combinations [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Estimated Useful Lives</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Useful life (in years)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Outstanding Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Lease Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_IncreaseDecreaseInOperatingLeaseLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LiabilitiesFairValueSettled_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Liabilities, fair value, settled.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LiabilitiesFairValueSettled_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Fair Value Settled</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LiabilitiesFairValueSettled_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Termination</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Acquisition [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Company contribution in the plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIncomeTaxRefunds_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Income Tax Refunds</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIncomeTaxRefunds_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash received for income tax refunds</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue from Related Parties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueFromRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue&#8212;related party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInTwoYears_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInTwoYears_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating Leases Future Minimum Sublease Income Due In Two Years</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInTwoYears_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Sublease Income Due In Two Years</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TemporaryEquityStockConversionSharesInConnectionWithMerger_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary Equity Stock Conversion Shares In Connection With Merger.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TemporaryEquityStockConversionSharesInConnectionWithMerger_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Conversion Shares In Connection With Merger</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TemporaryEquityStockConversionSharesInConnectionWithMerger_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Conversion of shares of redeemable convertible preferred stock to shares of common stock in connection with the Merger, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and Administrative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock for cashless exercise of warrants, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Issued for Services</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other non-current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Liabilities, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Purchase price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Remaining Contract Term, Shares exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Series B Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SeriesBPreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Series B Convertible Preferred Stock [ Member ]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LawsuitsFiledAgainstCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lawsuits filed against company.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LawsuitsFiledAgainstCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lawsuits Filed Against Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LawsuitsFiledAgainstCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lawsuits Filed Against Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-sale, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term marketable debt securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-sale, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationAssetsArisingFromContingenciesAmountRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationAssetsArisingFromContingenciesAmountRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Assets Arising from Contingencies, Amount Recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued professional services</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable convertible preferred stock warrants issued in connection with issuance of Series B redeemable convertible preferred stock, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Significant Accounting Policies [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Significant Accounting Policies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Related Party Transactions By Related Party [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CityAreaCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">City Area Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ClassOfWarrantOrRightsExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Rights Expiration Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ClassOfWarrantOrRightsExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expiration Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ClassOfWarrantOrRightsExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Class Of Warrant Or Rights Expiration Date.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LicenseFundingAndOtherAgreementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License funding and other agreements.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LicenseFundingAndOtherAgreementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Funding And Other Agreements [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Assumptions to Estimate Fair Value of Stock Options Using Black-Scholes Option Pricing Model</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gross deferred tax assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred tax assets, net of valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Vested Restricted Stock Units</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Unvested Restricted Stock Units Roll Forward [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income (Expense) [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Income (Expense) [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Liabilities, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Income Tax Liabilities, Net, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Recognition and Deferred Revenue [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from the offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Consideration Received Per Transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reconciliation of cash, cash equivalents and restricted cash to consolidated balance sheets:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies (Note 12)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Warrant Or Right [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business combination recognized identifiable assets acquired and liabilities assumed restricted cash.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Restricted Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AreaOfSublease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Area of Sublease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AreaOfSublease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Area of Sublease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AreaOfSublease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Area of Sublease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock related to financing, net of issuance costs of $823,940, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of common stock shares sold</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-sale</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total, Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Debt Securities, Available-for-sale, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementScenarioAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_StatementScenarioAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Combination</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Liquidation Preference, Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockLiquidationPreferenceValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, liquidation preference, value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ExerciseFeePaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise Fee Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ExerciseFeePaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exercise Fee Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ExerciseFeePaid_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Exercise fee paid.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TenantImprovements_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tenant Improvements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TenantImprovements_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tenant improvements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock resulting from Employee Stock Purchase Plan, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAsPartOfMerger_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award number of shares available for grant as part of merger.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAsPartOfMerger_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant As Part Of Merger</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAsPartOfMerger_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares Available for Grant, Assumed as part of the Merger</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial and Nonfinancial Liabilities, Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total fair value of liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash, cash equivalents and restricted cash, at the end of the period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash, cash equivalents and restricted cash, at the beginning of the period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_QualifyingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Qualifying expenses.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_QualifyingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Qualifying Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_QualifyingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Qualifying expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Conversion, Converted Instrument, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of redeemable convertible preferred stock into common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of shares of redeemable convertible preferred stock to shares of common stock in connection with the Merger</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RedeemableConvertiblePreferredStockWarrantLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Redeemable convertible preferred stock warrant liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RedeemableConvertiblePreferredStockWarrantLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Redeemable Convertible Preferred Stock Warrant Liability [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RedeemableConvertiblePreferredStockWarrantLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable Convertible Preferred Stock Warrant Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_SeptemberFifteenTwoThousandTwentyWarrantThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">September Fifteen Two Thousand Twenty Warrant Three [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_SeptemberFifteenTwoThousandTwentyWarrantThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">September 15, 2020 Warrant Three</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_SeptemberFifteenTwoThousandTwentyWarrantThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">September Fifteen Two Thousand Twenty Warrant Three.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LicenceAgreementUpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront payment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LicenceAgreementUpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Licence Agreement Upfront Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LicenceAgreementUpfrontPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by (used in) investing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term Loan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase of property and equipment included in accounts payable and accrued liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent Consideration Liability (CVR)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of additional shares added on outstanding shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax Credit Carryforward, Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee-related Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Employee-related Liabilities, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">General and Administrative Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">General and Administrative Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Liabilities Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Fair value, ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Fair value, beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Financial Liabilities Fair Value Disclosure, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property and equipment, net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Net, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Net, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract liabilities&#8212;related party, current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Common Stock, Shares, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ResearchFundingFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research funding fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ResearchFundingFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research funding fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Rent Credit, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred rent, net of current portion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net deferred tax liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Liabilities, Gross, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Right-of-Use Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating lease right-of-use asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LeaseCostOtherInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lease cost other information.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LeaseCostOtherInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Cost Other Information [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LeaseCostOtherInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Information</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RedeemableConvertiblePreferredStockWarrantLiabilityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Redeemable convertible preferred stock warrants.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RedeemableConvertiblePreferredStockWarrantLiabilityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Redeemable Convertible Preferred Stock Warrant Liability Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RedeemableConvertiblePreferredStockWarrantLiabilityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable Convertible Preferred Stock Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_SecurityExchangeName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Security Exchange Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Furniture and Fixtures [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and Fixtures</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TwoThousandFourteenAndTwoThousandFifteenStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand fourteen and two thousand fifteen stock incentive plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TwoThousandFourteenAndTwoThousandFifteenStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Fourteen And Two Thousand Fifteen Stock Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TwoThousandFourteenAndTwoThousandFifteenStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2014 and 2015 Stock Incentive Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss attributable to common stockholders</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss) Available to Common Stockholders, Basic, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_FairValueOfCommonStockPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value of common stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_FairValueOfCommonStockPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Of Common Stock Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_FairValueOfCommonStockPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Tranche Three [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Payment Arrangement, Tranche Three</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TwoThousandFifteenStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand Fifteen Stock Incentive Plan Member.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TwoThousandFifteenStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Fifteen Stock Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TwoThousandFifteenStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2015 Stock Incentive Plan Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Payments, Due Next Rolling Twelve Months</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Cash, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RestatementDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revision of Prior Period [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RestatementDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revision of Prior Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFinanceCostsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Issuance Costs, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFinanceCostsGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt issuance costs, gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ContractAssetsAndLiabilitiesAdditions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract assets and liabilities additions.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ContractAssetsAndLiabilitiesAdditions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract Assets And Liabilities Additions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ContractAssetsAndLiabilitiesAdditions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Reconciliation of Unrecognized Tax Benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Deferred Income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Less: current portion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net amortization of premiums and accretion of discounts on investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeContractTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Contract [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental cash flow information</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LicenceAgreementCumulativeRevenueRecognised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Cumulative revenue recognised.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LicenceAgreementCumulativeRevenueRecognised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Licence Agreement Cumulative Revenue Recognised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LicenceAgreementCumulativeRevenueRecognised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Licence agreement cumulative revenue recognised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementClassOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeDuringPeriodFairValueDisclosureMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Changes Measurement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ChangeDuringPeriodFairValueDisclosureMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measure of Changes in Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash used in operating activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AtTheMarketOfferingTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">At the market offering.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AtTheMarketOfferingTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">At The Market Offering [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AtTheMarketOfferingTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">At-the-Market (ATM) Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive securities excluded from computation of earnings per share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_OperatingLossCarrybackDurationUnderCARESAct_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryback duration under CARES act.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_OperatingLossCarrybackDurationUnderCARESAct_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryback Duration Under C A R E S Act</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_OperatingLossCarrybackDurationUnderCARESAct_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryback duration under CARES Act</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_GainOnRemeasurementOfContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gain on remeasurement of contingent consideration liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_GainOnRemeasurementOfContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain on Remeasurement of Contingent Consideration Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_GainOnRemeasurementOfContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gain on remeasurement of contingent consideration liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ContractualContingentValueRight_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contractual Contingent Value Right</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ContractualContingentValueRight_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contractual Contingent Value Right</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ContractualContingentValueRight_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contractual Contingent Value Right</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Loss on disposal of assets for lease</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain (Loss) on Disposition of Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GainLossOnDispositionOfAssets1_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Gain (Loss) on Disposition of Assets, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_FairValueOfModifiedStockOptionsAndRestrictedStockUnitsAttributableToPreCombinationServices_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fair value of modified stock options and restricted stock units attributable to pre-combination services.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_FairValueOfModifiedStockOptionsAndRestrictedStockUnitsAttributableToPreCombinationServices_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Of Modified Stock Options And Restricted Stock Units Attributable To Pre Combination Services</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_FairValueOfModifiedStockOptionsAndRestrictedStockUnitsAttributableToPreCombinationServices_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated fair value of modified stock options and restricted stock units attributable to pre-combination services</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TermLoanAndNonFormulaAncillaryService_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term loan and non formula ancillary service</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TermLoanAndNonFormulaAncillaryService_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Term loan and non formula ancillary service</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TermLoanAndNonFormulaAncillaryService_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Term loan and non formula ancillary service</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_BostonMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Boston [member].</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_BostonMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Boston [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_BostonMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Boston, Massachusetts [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_BostonMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Boston, MA</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities, Net [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_DeferredTaxBasisDifferenceIPRD_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax basis difference IPR&amp;D.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_DeferredTaxBasisDifferenceIPRD_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Basis Difference I P R D</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_DeferredTaxBasisDifferenceIPRD_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis Difference IPR&amp;D</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Provision for income taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Financial Assets and Liabilities Measured on Recurring Basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred Tax Assets:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ContingentConsiderationFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent Consideration, fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ContingentConsiderationFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ContingentConsiderationFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent Consideration fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LicenseAndCollaborationRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License and collaboration revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LicenseAndCollaborationRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License and collaboration revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LicenseAndCollaborationRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License and collaboration revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net change in cash, cash equivalents and restricted cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Portion at Fair Value Measurement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Disclosure Item Amounts [Default]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember_lbl" xlink:role="http://fasb.org/us-gaap/role/label/axisDefault">Portion at Fair Value Measurement [Member] [Default]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ResTORbioMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">resTORbio.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ResTORbioMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Res T O Rbio [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ResTORbioMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">resTORbio</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquisition date fair value of resTORbio common shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Method Investment, Ownership Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity method investment, Ownership percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_CounterpartyNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_EmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_EmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Purchase Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_EmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_BusinessAcquisitionsProFormaRevenue1_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">The pro forma revenues for a period as if the business combination or combinations had been completed at the beginning of the period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_BusinessAcquisitionsProFormaRevenue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisitions Pro Forma Revenue1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_BusinessAcquisitionsProFormaRevenue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue - related party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accounts Payable, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">US Government Agencies Debt Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">US Government Agency Bonds</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RecognitionOfPreferredStockWarrantLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Recognition of preferred stock warrant liabilities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RecognitionOfPreferredStockWarrantLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Recognition Of Preferred Stock Warrant Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RecognitionOfPreferredStockWarrantLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recognition of preferred stock warrant liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Available Loan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Face Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntellectualPropertyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Intellectual Property [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IntellectualPropertyMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intellectual Property</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Par or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock shares issued, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, in Process Research and Development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development credit carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInFiveYears_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInFiveYears_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Sublease Income Due In Five Years</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInFiveYears_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating Leases Future Minimum Sublease Income Due In Five Years</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Components of Provision for (Benefit from) Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options authorized.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares Underlying Outstanding Options, Options authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">State and Local Jurisdiction [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePaymentsUse_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Payments, Use</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePaymentsUse_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating cash flows used for lease liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid in Capital, Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Additional Paid in Capital, Common Stock, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Additional Paid in Capital, Common Stock, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_NumberOfSecuritiesConvertedToWarrantsToPurchaseCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number Of Securities Converted To Warrants To Purchase Common Stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_NumberOfSecuritiesConvertedToWarrantsToPurchaseCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Securities Converted To Warrants To Purchase Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_NumberOfSecuritiesConvertedToWarrantsToPurchaseCommonStock_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of warrants, Impact of converting to warrants for the purchase of common stock and adjusted for the Exchange Ratio and Reverse Stock Split</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestReceivableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Receivable, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestReceivableCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_InducementGrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Inducement grants member.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_InducementGrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Inducement Grants [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_InducementGrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2018 Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of outstanding warrants to purchase shares of common stock .</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Outstanding Warrants To Purchase Shares Of Common Stock Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Outstanding Warrants to Purchase Shares of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Income Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TemporaryEquityStockConversionInConnectionWithMerger_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Temporary equity stock conversion in connection with merger.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TemporaryEquityStockConversionInConnectionWithMerger_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity Stock Conversion In Connection With Merger</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TemporaryEquityStockConversionInConnectionWithMerger_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of shares of redeemable convertible preferred stock to shares of common stock in connection with the Merger</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Software and Software Development Costs [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Software</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss before income tax benefit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentType_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VestingDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Debt Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RestatementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revision of Prior Period [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RestatementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revision of Prior Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Tax Authority [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Domestic Tax Authority</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_NovartisLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Novartis license agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_NovartisLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Novartis License Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_NovartisLicenseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Novartis License Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Consideration Transferred</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Business Combination, Consideration Transferred, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock, $0.0001 par value, 10,000,000 shares authorized as of December 31, 2021 and December 31, 2020, respectively; none issued and outstanding as of December 31, 2021 and December 31, 2020, respectively</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Value, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Value, Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Value, Issued, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Value, Issued, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability, net of current portion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating lease liability, net of current maturities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Accrued and Other Current Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RedeemableConvertiblePreferredStockTrancheLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Redeemable convertible preferred stock tranche liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RedeemableConvertiblePreferredStockTrancheLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Redeemable Convertible Preferred Stock Tranche Liability [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RedeemableConvertiblePreferredStockTrancheLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable Convertible Preferred Stock Tranche Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Issued and Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Options To Purchase Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-term Debt, Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_NumberOfSharesOfSurvivingStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of shares of surviving stock options.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_NumberOfSharesOfSurvivingStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Shares Of Surviving Stock Options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_NumberOfSharesOfSurvivingStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares of surviving stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes Receivable, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement, Contract to Perform for Others, Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Remaining Contract Term, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RedeemableConvertiblePreferredStockTrancheLiabilityAndTRDFObligationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Redeemable convertible preferred stock tranche liability and TRDF obligation.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RedeemableConvertiblePreferredStockTrancheLiabilityAndTRDFObligationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Redeemable Convertible Preferred Stock Tranche Liability And T R D F Obligation [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RedeemableConvertiblePreferredStockTrancheLiabilityAndTRDFObligationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable Convertible Preferred Stock Tranche Liability And TRDF Obligation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Sale and Maturity of Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from maturities of marketable debt securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Proceeds from Sale and Maturity of Marketable Securities, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ContractResearchTermPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract research term period.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ContractResearchTermPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract Research Term Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ContractResearchTermPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract research term period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income tax expense (benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Provision for (benefit from) income taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosures of noncash investing and financing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationDateOfIncorporation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, Date of Incorporation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationDateOfIncorporation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity incorporation date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Basic and Diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss per share attributable to common stockholders, basic and diluted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Earnings Per Share, Basic and Diluted, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncashExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Noncash Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNoncashExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Noncash lease expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average Grant Date Fair Value, RSUs forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Consolidation, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConsolidationPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Principles of Consolidation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementBasisAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Basis [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementBasisAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_DeferredTaxOperatingLeaseRightOfUseAssetLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax operating lease right of use asset liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_DeferredTaxOperatingLeaseRightOfUseAssetLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Operating Lease Right Of Use Asset Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_DeferredTaxOperatingLeaseRightOfUseAssetLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use asset liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SecurityDepositLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash security deposit received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SecurityDepositLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Security Deposit Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesCancelled_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award number of shares available for grant shares cancelled.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesCancelled_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Shares Cancelled</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesCancelled_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares Available for Grant, Options forfeited or cancelled</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidInsurance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Insurance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidInsurance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid insurance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Business Acquisitions, by Acquisition [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Summarizes the Allocation of the Purchase Price to the Net Tangible and Intangible Assets Acquired</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AccruedCroCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued CRO costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AccruedCroCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued CRO costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AccruedCroCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued CRO costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_SummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Vested and expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfClinicalMilestonesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement milestone payments upon satisfaction of clinical milestones payable.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfClinicalMilestonesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Milestone Payments Upon Satisfaction Of Clinical Milestones Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfClinicalMilestonesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate amount payable upon satisfaction of clinical milestones</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Operating Loss Carryforwards, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Five</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Shares, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Common Stock, Shares, Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Common Stock, Shares, Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current State and Local Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Accumulated depreciation and amortization</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ExerciseOfRedeemableConvertiblePreferredStockTrancheLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Exercise of redeemable convertible preferred stock tranche liabilities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ExerciseOfRedeemableConvertiblePreferredStockTrancheLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exercise Of Redeemable Convertible Preferred Stock Tranche Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ExerciseOfRedeemableConvertiblePreferredStockTrancheLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise of redeemable convertible preferred stock tranche liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_IncreaseInConstructionInProgress_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in construction in progress</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_IncreaseInConstructionInProgress_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase in construction in progress</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_IncreaseInConstructionInProgress_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase in construction in progress</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds from the offering, after deducting expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revenue [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RedeemableConvertiblePreferredStockPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Disclosure of accounting policy for redeemable convertible preferred stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RedeemableConvertiblePreferredStockPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Redeemable Convertible Preferred Stock Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RedeemableConvertiblePreferredStockPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">IPO [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IPOMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total lease cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financial Instruments [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financial Instruments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock issuance cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_GoodwillMeasurementPeriodAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Goodwill measurement period adjustments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_GoodwillMeasurementPeriodAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill Measurement Period Adjustments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_GoodwillMeasurementPeriodAdjustments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement period adjustment to goodwill</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Unrealized Losses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Weighted-Average Exercise Price, Outstanding ending</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Weighted-Average Exercise Price, Outstanding beginning</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from operating activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturities Of Operating Lease Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrant exercise price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrants outstanding and exercisable, Weighted average exercise price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrealized Gains</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInFourYears_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInFourYears_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating Leases Future Minimum Sublease Income Due In Four Years</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInFourYears_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Sublease Income Due In Four Years</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Marketable Debt Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss) Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of (Provision for) Benefit from Income Taxes Differs from Federal Statutory Rate to the Loss Before Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued and Other Current Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration of Credit Risk</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted Average IBR</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research And Development Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_CompanyContributionToPlanWithRespectToEmployeesContribution_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Company contribution to plan with respect to employees contribution.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_CompanyContributionToPlanWithRespectToEmployeesContribution_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Company Contribution To Plan With Respect To Employees Contribution</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_CompanyContributionToPlanWithRespectToEmployeesContribution_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined contribution plan for employees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Foreign Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentForeignTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_SeptemberFifteenTwoThousandTwentyWarrantTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">September Fifteen Two Thousand Twenty Warrant Two [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_SeptemberFifteenTwoThousandTwentyWarrantTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">September 15, 2020 Warrant Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_SeptemberFifteenTwoThousandTwentyWarrantTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">September Fifteen Two Thousand Twenty Warrant Two.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Accumulated Other Comprehensive Income (Loss), Net of Tax, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Cuts and Jobs Act, Change in Tax Rate, Income Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax cuts and jobs act of 2017 change in tax rate income tax expense benefit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Tax Cuts and Jobs Act, Change in Tax Rate, Income Tax Expense (Benefit), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressAddressLine1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Address Line One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate intrinsic value of options exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of Shares Underlying Outstanding Options, Ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of Shares Underlying Outstanding Options, Beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockDescriptionOfTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Description of stock purchase agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockDescriptionOfTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Description of Transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LicenseAgreementAdditionalPaymentForResearchFundingReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional payment for research funding received.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LicenseAgreementAdditionalPaymentForResearchFundingReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Additional Payment For Research Funding Received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LicenseAgreementAdditionalPaymentForResearchFundingReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional payment for research funding received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesGranted_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award number of shares available for grant, shares granted.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesGranted_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Shares Granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesGranted_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares Available for Grant, Options granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GrantsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Grants Receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GrantsReceivable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grants receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetBackedSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset-backed Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetBackedSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Asset Backed Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProfitLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Paper [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial Paper</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressPostalZipCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, Postal Zip Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_StockExchangedDuringPeriodSharesInConnectionWithMerger_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock exchanged during period shares in connection with merger.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_StockExchangedDuringPeriodSharesInConnectionWithMerger_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Exchanged During Period Shares In Connection With Merger</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_StockExchangedDuringPeriodSharesInConnectionWithMerger_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exchange of common stock in connection with the Merger, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, maximum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LicenseFundingAndOtherAgreementsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License funding and other agreements.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LicenseFundingAndOtherAgreementsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Funding And Other Agreements [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LicenseFundingAndOtherAgreementsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License, Funding and Other Agreements Related to the CVR</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total undiscounted lease payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ExercisedInvestmentRightAndPurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercised Investment Right and Purchased</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ExercisedInvestmentRightAndPurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Exercised Investment Right and Purchased</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ExercisedInvestmentRightAndPurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exercised Investment Right and Purchased</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_UnderwritingDiscountsAndCommissionsAndOtherOfferingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Underwriting discounts and commissions and other offering expenses.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_UnderwritingDiscountsAndCommissionsAndOtherOfferingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Underwriting Discounts And Commissions And Other Offering Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_UnderwritingDiscountsAndCommissionsAndOtherOfferingExpenses_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Underwriting discounts and commissions and other offering expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Liabilities and Other Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued and other current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Carrying Amount, Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance, temporary equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance, temporary equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Carrying Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TerminationOfRedeemableConvertiblePreferredStockTrancheLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Termination of redeemable convertible preferred stock tranche liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TerminationOfRedeemableConvertiblePreferredStockTrancheLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Termination Of Redeemable Convertible Preferred Stock Tranche Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TerminationOfRedeemableConvertiblePreferredStockTrancheLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Termination of redeemable convertible preferred stock tranche liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance Initial Public Offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net proceeds received from offering</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of additional shares reserved for issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Research And Development Arrangement Contract To Perform For Others [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash used in operating activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payments for repurchase of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for Repurchase of Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockDividendsPerShareDeclared_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockDividendsPerShareDeclared_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock dividends declared | $ / shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionSharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Share Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionSharePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Multiplied by the fair value per share of resTORbio common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term Debt, Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermDebtDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-term Debt, Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other non-current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Noncurrent Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_QualifyingExpensesOnCumulativeBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">qualifying expenses on cumulative basis.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_QualifyingExpensesOnCumulativeBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Qualifying Expenses On Cumulative Basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_QualifyingExpensesOnCumulativeBasis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Qualifying expenses on cumulative basis</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnusualRiskOrUncertaintyByNatureAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unusual Risk or Uncertainty, Nature [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnusualRiskOrUncertaintyByNatureAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unusual Risk or Uncertainty, Nature</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Option</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockOptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Option [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Components [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease, Cost [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseCostTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Lease Costs and Other Information</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Lease, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable lease cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ContractAssetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract Asset.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ContractAssetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract Asset [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ContractAssetMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityRegistrantName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_MilestoneClosingLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone closing liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_MilestoneClosingLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Closing Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_MilestoneClosingLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone closing liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other comprehensive income (loss):</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioPreviouslyReportedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Previously Reported [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioPreviouslyReportedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preliminary</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AccruedResearchAndDevelopmentExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development expenses current.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AccruedResearchAndDevelopmentExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Expenses Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AccruedResearchAndDevelopmentExpensesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued research and development expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_NumberOfSharesAvailableForSaleUnderEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of shares available for sale under employee stock purchase plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_NumberOfSharesAvailableForSaleUnderEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Shares Available For Sale Under Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_NumberOfSharesAvailableForSaleUnderEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares available for sale under employee stock purchase plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finance Lease, Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finance lease liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FinanceLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Finance Lease, Liability, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Interactive Data Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_FeesAndExpenseIncurredInConnectionWithClinicalTrials_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fees and expense incurred in connection with clinical trials.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_FeesAndExpenseIncurredInConnectionWithClinicalTrials_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fees And Expense Incurred In Connection With Clinical Trials</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_FeesAndExpenseIncurredInConnectionWithClinicalTrials_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total fees and expenses related to clinical trials</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrimeRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prime Rate [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrimeRateMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prime Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityAddressCityOrTown_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Address, City or Town</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_NationalInstitutesOfHealthMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">National Institutes of Health.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_NationalInstitutesOfHealthMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">National Institutes Of Health [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_NationalInstitutesOfHealthMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">National Institute of Health</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility, minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Federal, State and Local, Tax Expense (Benefit) [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ScheduleOfChangesInFairValueOfUnobservableFinancialInstrumentsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tabular disclosure of changes in the fair value of the unobservable financial instruments.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ScheduleOfChangesInFairValueOfUnobservableFinancialInstrumentsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Changes In Fair Value Of Unobservable Financial Instruments Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ScheduleOfChangesInFairValueOfUnobservableFinancialInstrumentsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Changes in Fair Value of Level 3 Financial Instruments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepaid expenses and other current assets.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expenses And Other Current Assets [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid Expenses and Other Current Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Expected term (in years)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_TradingSymbol_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transactions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from investing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less: imputed interest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Restricted Stock Unit Activity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_SeptemberFifteenTwoThousandTwentyWarrantOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">September Fifteen Two Thousand Twenty Warrant One [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_SeptemberFifteenTwoThousandTwentyWarrantOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">September 15, 2020 Warrant One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_SeptemberFifteenTwoThousandTwentyWarrantOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">September Fifteen Two Thousand Twenty Warrant One.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Foreign Tax Authority [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ForeignCountryMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign Tax Authority</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_OperatingLeasesFutureMinimumSubleaseIncomeDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_OperatingLeasesFutureMinimumSubleaseIncomeDue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_OperatingLeasesFutureMinimumSubleaseIncomeDue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating Leases Future Minimum Sublease Income Due</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_OperatingLeasesFutureMinimumSubleaseIncomeDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Sublease Income Due</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_LocalPhoneNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Local Phone Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update 2016-02 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountingStandardsUpdate201602Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Topic 842</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ContingentValueRightsAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent value rights agreement [member].</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ContingentValueRightsAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Value Rights Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ContingentValueRightsAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent Value Rights Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders' equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Deferred issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsOfDebtIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments of Debt Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_CaliforniaResearchAndDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">California research and development.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_CaliforniaResearchAndDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">California Research And Development [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_CaliforniaResearchAndDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">California Research And Development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ClassOfWarrantOrRightIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Or Right Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ClassOfWarrantOrRightIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of warrants, Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at the end of the year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at the beginning of the year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized tax benefits</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasePayments_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating cash flows used for lease payments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive Income (Loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock shares issued</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Preferred Stock, Shares Issued, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LitigationSettlementExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Litigation Settlement, Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LitigationSettlementExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Litigation settlement expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets, Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total fair value of assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Three</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AdvisoryServicesAnnualFee_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Advisory services annual fee.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AdvisoryServicesAnnualFee_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Advisory Services Annual Fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AdvisoryServicesAnnualFee_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Advisory services annual fee</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statistical Measurement [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RangeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statistical Measurement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AccruedCmoCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued CMO costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AccruedCmoCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued CMO costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AccruedCmoCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued CMO costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_MergerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Merger.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_MergerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Merger [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_MergerMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Merger</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntitySmallBusiness_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Small Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Preferred Stock, Shares Outstanding, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Preferred Stock, Shares Outstanding, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInThreeYears_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInThreeYears_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating Leases Future Minimum Sublease Income Due In Three Years</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInThreeYears_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Sublease Income Due In Three Years</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Leases [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeLeasesPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">APIC, Share-based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Estimated Share Consideration of Combined Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableRateAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Rate [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableRateAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income (Loss), before Tax</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherComprehensiveIncomeLossBeforeTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total other comprehensive income (loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment charges</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of Long-Lived Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Payment Arrangement, Tranche Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableRateDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Variable Rate [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_VariableRateDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Variable Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Useful Life</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Useful life (in years)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_MarketableDebtSecuritiesClassificationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of classification of company marketable debt securities in condensed consolidated balance sheets.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_MarketableDebtSecuritiesClassificationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Debt Securities Classification Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_MarketableDebtSecuritiesClassificationTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Classification of Marketable Debt Securities in Consolidated Balance Sheets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases, Future Minimum Payments Due</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Acquisition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value of Financial Instruments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Adjustment of Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of redeemable convertible preferred stock warrant liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TwoThousandFourteenStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two Thousand Fourteen Stock Incentive Plan Member.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TwoThousandFourteenStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Fourteen Stock Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TwoThousandFourteenStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2014 Stock Incentive Plan Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_PrepaymentsToCros_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepayments to CRO's</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_PrepaymentsToCros_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepayments to CRO's</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_PrepaymentsToCros_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepayments to CRO's</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LicenseAgreementTerminationDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement termination description.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LicenseAgreementTerminationDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Termination Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LicenseAgreementTerminationDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License agreement termination description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DefinedContributionPlanTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined Contribution Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Number of Shares of Common Stock Issuable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Pro Forma Information, Nonrecurring Adjustments [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Supplemental Unaudited Pro Forma Information</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ClassOfWarrantOutstandingAndExercisableToPurchasePreferredShares_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Number of warrants, Outstanding and exercisable to purchase preferred shares as of December 31, 2020</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ClassOfWarrantOutstandingAndExercisableToPurchasePreferredShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Outstanding And Exercisable To Purchase Preferred Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ClassOfWarrantOutstandingAndExercisableToPurchasePreferredShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of warrants, Outstanding and exercisable to purchase preferred shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price, Options granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted average exercise price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ResearchFundingAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Research funding agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ResearchFundingAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research Funding Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ResearchFundingAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research Funding Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_MarketableSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Marketable securities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_MarketableSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_MarketableSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ContingentConsiderationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent Consideration</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ContingentConsiderationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ContingentConsiderationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent Consideration [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price, Options forfeited or cancelled</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LandSubjectToGroundLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Land Subject to Ground Leases</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LandSubjectToGroundLeases_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Office lease space</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_EstimatedFairValueOfCVRLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Estimated fair value of CVR liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_EstimatedFairValueOfCVRLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Estimated Fair Value Of C V R Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_EstimatedFairValueOfCVRLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated fair value of the CVR liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ScheduleOfSubleaseIncomeTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Sublease Income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ScheduleOfSubleaseIncomeTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule Of Sublease Income.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ScheduleOfSubleaseIncomeTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Sublease Income Table Text Block</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases, Future Minimum Payments Due, Next Twelve Months</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Stock [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Stock [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Derivative Instrument [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_EntityDateOfMerger_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Entity date of merger.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_EntityDateOfMerger_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Date Of Merger</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_EntityDateOfMerger_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity date of merger</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases, Future Minimum Payments, Due Thereafter</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025 and thereafter</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards, Expiration Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLossCarryforwardsExpirationDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards, expiration date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid maintenance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Prepaid Expense, Current, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State income taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_NovartisInternationalPharmaceuticalLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Novartis International Pharmaceutical Ltd. (&#8220;Novartis&#8221;).</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_NovartisInternationalPharmaceuticalLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Novartis International Pharmaceutical Limited [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_NovartisInternationalPharmaceuticalLimitedMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Novartis International Pharmaceutical Ltd.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfCommercialMilestonesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement milestone payments upon satisfaction of commercial milestones payable.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfCommercialMilestonesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Milestone Payments Upon Satisfaction Of Commercial Milestones Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfCommercialMilestonesPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate amount payable upon satisfaction of commercial milestones</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse Stock Split</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock related to financing, net of issuance costs of $823,940</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, New Issues</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_IncreaseDecreaseInEstimatedFairValueOfCvrLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase decrease in estimated fair value of cvr liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_IncreaseDecreaseInEstimatedFairValueOfCvrLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Estimated Fair Value Of Cvr Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_IncreaseDecreaseInEstimatedFairValueOfCvrLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase decrease in estimated fair value of CVR liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_StockIssuedDuringPeriodSharesUponAcceleratedVestingOfRSUWithMerger_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares upon accelerated vesting of rsu with merger.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_StockIssuedDuringPeriodSharesUponAcceleratedVestingOfRSUWithMerger_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Upon Accelerated Vesting Of R S U With Merger</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_StockIssuedDuringPeriodSharesUponAcceleratedVestingOfRSUWithMerger_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon accelerated vesting of restricted stock units in connection with the Merger (Shares)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ClassOfWarrantExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Warrant exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ClassOfWarrantExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of warrants, Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ClassOfWarrantExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ClassOfWarrantExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of warrants, exercised.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Securities, Available-for-sale, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-term marketable debt securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Separately Recognized Transactions [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Combination, Separately Recognized Transactions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_FederalAndStateResearchAndDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Federal and state research and development [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_FederalAndStateResearchAndDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Federal and state research and development [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAcquiredFromAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash Acquired from Acquisition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAcquiredFromAcquisition_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and restricted cash acquired in connection with the Merger</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combinations Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Combination</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_StockExchangedDuringPeriodValueInConnectionWithMerger_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Exchanged During Period Value In Connection With Merger</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_StockExchangedDuringPeriodValueInConnectionWithMerger_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exchange of common stock in connection with the Merger</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_StockExchangedDuringPeriodValueInConnectionWithMerger_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock exchanged during period value in connection with merger.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock for cashless exercise of warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Issued for Services</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Share-based Payment Arrangement, Noncash Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense and Other Assets, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total prepaid expenses and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Option Activity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transactions [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating Leases Future Minimum Sublease Income Due Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Sublease Income Due Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Current Federal Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AdditionalClosingLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional closing liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AdditionalClosingLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Closing Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AdditionalClosingLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional closing liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestAndOtherIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Interest and Other Income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestAndOtherIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest income</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InterestAndOtherIncome_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Interest and Other Income, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Payments, Due after Rolling Year Five</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2026 and thereafter</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_UnvestedRestrictedStockUnitsOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unvested restricted stock units outstanding.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_UnvestedRestrictedStockUnitsOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unvested Restricted Stock Units Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_UnvestedRestrictedStockUnitsOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested restricted stock units outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2025</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Four</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_NonRefundableUpfrontPaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Non refundable upfront payment received.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_NonRefundableUpfrontPaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Non Refundable Upfront Payment Received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_NonRefundableUpfrontPaymentReceived_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non refundable upfront payment received</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_FinancingReceivableNonaccrualToOutstandingPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding accounts receivable percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_FinancingReceivableNonaccrualToOutstandingPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Financing Receivable, Nonaccrual to Outstanding, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Equity Interest Issued or Issuable, Number of Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares of the combined company owned by resTORbio stockholders</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumedAsPartOfMergerInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangements by share based payment award options assumed as part of merger in period weighted average exercise price.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumedAsPartOfMergerInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Assumed As Part Of Merger In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumedAsPartOfMergerInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price, Assumed as part the Merger</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Date from which Warrants or Rights Exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Contingent Consideration, Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent consideration liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Business Combination, Contingent Consideration, Liability, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesRentExpenseSubleaseRentals1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Leases, Rent Expense, Sublease Rentals</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesRentExpenseSubleaseRentals1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases, Rent Expense, Sublease Rentals</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares Underlying Outstanding Options, Shares exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use asset obtained in exchange for operating lease liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Operating lease right of use asset obtained in exchange of operating lease liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_StockIssuedDuringPeriodValueUponAcceleratedVestingOfRSUWithMerger_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period value upon accelerated vesting of rsu with merger.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_StockIssuedDuringPeriodValueUponAcceleratedVestingOfRSUWithMerger_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Upon Accelerated Vesting Of R S U With Merger</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_StockIssuedDuringPeriodValueUponAcceleratedVestingOfRSUWithMerger_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon accelerated vesting ofrestricted stock units in connection with the Merger</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LoansPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding balance under the loan agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LoansPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loans Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LoansPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loans Payable, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_Assets_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_OrganizationAndNatureOfBusinessTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization and nature of business.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_OrganizationAndNatureOfBusinessTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization And Nature Of Business [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_OrganizationAndNatureOfBusinessTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization and Nature of Business</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ImpairmentOfInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Impairment of in process research and development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ImpairmentOfInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Of In Process Research And Development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ImpairmentOfInProcessResearchAndDevelopment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Impairment of in-process research and development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Level 2</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Issued in Business Combination, Fair Value Disclosure</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of common stock shares of the combined company owned by resTORbio stockholders</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of common stock upon exercise of stock options, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares Underlying Outstanding Options, Options exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of outstanding capital stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Equity Method Investments [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Equity Method Investments [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities, redeemable convertible preferred stock, and stockholders' equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Balance Sheet Location [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BalanceSheetLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Balance Sheet Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Cash Flows [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid-in Capital [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_Security12bTitle_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Title of 12(b) Security</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_OrganizationAndNatureOfBusinessAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization and Nature of Business.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_OrganizationAndNatureOfBusinessAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Organization And Nature Of Business [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Separately Recognized Transactions [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Combination, Separately Recognized Transactions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ContractLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ContractLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract Liability [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ContractLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermPurchaseCommitmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-term Purchase Commitment [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermPurchaseCommitmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long Term Purchase Commitment [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Level 3</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award number of shares available for grant shares exercised.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Shares Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares Available for Grant, Options exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesExercised_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Options exercised, Number of Shares Available for Grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ProceedsFromSalesOfMarketableDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from sales of marketable debt securities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ProceedsFromSalesOfMarketableDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Sales Of Marketable Debt Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ProceedsFromSalesOfMarketableDebtSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from sales of marketable debt securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well-known Seasoned Issuer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RedeemableConvertiblePreferredStockWarrantLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Redeemable convertible preferred stock warrant liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RedeemableConvertiblePreferredStockWarrantLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Redeemable Convertible Preferred Stock Warrant Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RedeemableConvertiblePreferredStockWarrantLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable convertible preferred stock warrant liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AccruedResearchAndDevelopmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AccruedResearchAndDevelopmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AccruedResearchAndDevelopmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued CRO, CMO, and Research and Development Expenses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Option vested percentage</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy and NAV</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expiration period closing of the merger</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Fair Value Adjustment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesFairValueAdjustment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Settlement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_BusinessCombinationAccelerationOfRestrictedStockUnitsUponMerger_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business combination acceleration of restricted stock units upon merger.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_BusinessCombinationAccelerationOfRestrictedStockUnitsUponMerger_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Acceleration Of Restricted Stock Units Upon Merger</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_BusinessCombinationAccelerationOfRestrictedStockUnitsUponMerger_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acceleration of restricted stock units upon merger</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Nonvested Restricted Stock Shares Activity [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Restricted Stock Activity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Property and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Level 1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement, Contract to Perform for Others, Type [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Arrangement, Contract to Perform for Others, Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award number of shares available for grant shares authorized.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares Available for Grant, Options authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfRegulatoryMilestonesPayableForFirstIndicationApproved_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement milestone payments upon satisfaction of regulatory milestones payable for first indication approved.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfRegulatoryMilestonesPayableForFirstIndicationApproved_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Milestone Payments Upon Satisfaction Of Regulatory Milestones Payable For First Indication Approved</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfRegulatoryMilestonesPayableForFirstIndicationApproved_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate amount payable upon satisfaction of regulatory milestones for first indication approved</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in estimated transaction price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_GrantTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Grant term.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_GrantTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Grant Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_GrantTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Tabular disclosure of the summary of Prepaid expenses and other current assets.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expenses And Other Current Assets Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Prepaid Expenses and Other Current Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_MenloParkLeaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Menlo Park lease agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_MenloParkLeaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Menlo Park Lease Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_MenloParkLeaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Menlo Park Lease Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_MenloParkLeaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Menlo Park, CA</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, by Balance Sheet Grouping [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Debt Securities [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate Debt Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price, Vested and expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">RSUs granted (includes PSUs)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares Underlying Outstanding Options, Options granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_NumberOfCustomer_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of customer.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_NumberOfCustomer_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Customer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_NumberOfCustomer_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of customer</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Regeneron License and Collaboration Arrangement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments to Acquire Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of marketable debt securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Payments to Acquire Marketable Securities, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecuritiesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate, minimum</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Scenario [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_ScenarioUnspecifiedDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ClassOfWarrantOutstandingAndExercisableToPurchaseCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Number of warrants, Outstanding and exercisable to purchase common stock as of December 31, 2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ClassOfWarrantOutstandingAndExercisableToPurchaseCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class Of Warrant Outstanding And Exercisable To Purchase Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money Market Funds</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Documents Incorporated by Reference [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Documents Incorporated by Reference</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RightOfUseAssetsRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Right-of-use assets recognized upon adoption of Topic 842</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RightOfUseAssetsRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Right-of-use assets recognized in noncash investing or financing activities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RightOfUseAssetsRecognized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Right Of Use Assets Recognized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_PostExposureProphylaxisDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Post Exposure Prophylaxis in adults</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_PostExposureProphylaxisDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Post Exposure Prophylaxis Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_PostExposureProphylaxisDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Post Exposure Prophylaxis in adults</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ContractLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ContractLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ContractLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss per Share Attributable to Common Stockholders</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableGrossCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable, before Allowance for Credit Loss, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccountsReceivableGrossCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes Paid</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxesPaid_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash paid for income taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Computer Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Computer Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases, Future Minimum Payments, Due in Two Years</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">AOCI Attributable to Parent [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Firm ID</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorFirmId_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Firm ID</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongtermDebtTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-term Debt, Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentTangibleAndIntangiblesAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Business combination provisional information initial accounting incomplete adjustment tangible and intangibles assets.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentTangibleAndIntangiblesAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Provisional Information Initial Accounting Incomplete Adjustment Tangible And Intangibles Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentTangibleAndIntangiblesAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement prior adjustment in tangible and intangible assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AdicetTherapeuticsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Adicet Therapeutics, Inc Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AdicetTherapeuticsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adicet Therapeutics Inc [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AdicetTherapeuticsIncMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adicet Therapeutics [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_VestingOfEarlyExercisedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Vesting of early exercised stock options.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_VestingOfEarlyExercisedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Vesting Of Early Exercised Stock Options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_VestingOfEarlyExercisedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting of early exercised stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Tranche One [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Payment Arrangement, Tranche One</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Acquisition Related Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationAcquisitionRelatedCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction cost for business acquisition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DevelopmentInProcess_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Development in Process</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DevelopmentInProcess_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">In-process research and development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Class Of Warrant Or Right [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_MaximumAggregateValueOfCommonStockAvailableForOfferingAtMarketPriceUnderSalesAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Maximum aggregate value of common stock available for offering at-the-market price under sales agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_MaximumAggregateValueOfCommonStockAvailableForOfferingAtMarketPriceUnderSalesAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum Aggregate Value Of Common Stock Available For Offering At Market Price Under Sales Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_MaximumAggregateValueOfCommonStockAvailableForOfferingAtMarketPriceUnderSalesAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum aggregate value of common stock available for offering at-the-market price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Auditor Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AuditorName_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Auditor Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LoanAmountDrawn_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Loan amount drawn</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LoanAmountDrawn_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loan Amount Drawn</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LoanAmountDrawn_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan amount drawn</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_SeptemberFifteenTwoThousandTwentyWarrantFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">September Fifteen Two Thousand Twenty Warrant Four [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_SeptemberFifteenTwoThousandTwentyWarrantFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">September 15, 2020 Warrant Four</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_SeptemberFifteenTwoThousandTwentyWarrantFourMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">September Fifteen Two Thousand Twenty Warrant Four.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred stock shares authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price, Shares exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AtTheMarketOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">At the market offering Member.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AtTheMarketOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">At The Market Offering [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AtTheMarketOfferingMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">At The Market Offering [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MinimumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Remaining Contract Term, Vested and expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_SubleaseAgreementDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sublease Agreement Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_SubleaseAgreementDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sublease Agreement Description.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_SubleaseAgreementDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sublease Agreement Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon exercise of stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnusualRiskOrUncertaintyNatureDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unusual Risk or Uncertainty, Nature [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnusualRiskOrUncertaintyNatureDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unusual Risk or Uncertainty, Nature</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LiabilitiesFairValueExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Liabilities, fair value, exercised.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LiabilitiesFairValueExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Fair Value Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LiabilitiesFairValueExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2023</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Two</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ContingentConsiderationLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent Consideration Liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ContingentConsiderationLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration Liability [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ContingentConsiderationLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent Consideration Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilityAndTRDFLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation change in fair value of redeemable convertible preferred stock tranche liability and TRDF liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilityAndTRDFLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation Change In Fair Value Of Redeemable Convertible Preferred Stock Tranche Liability And T R D F Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilityAndTRDFLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of redeemable convertible preferred stock tranche liability and TRDF liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Pro Forma Information [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionProFormaInformationTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Summarizes the Purchase Price in the Merger</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Issuance of shares of common stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of securities called</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Business Acquisitions By Acquisition [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ScheduleOfWeightedAverageIBRAndRemainingLeaseTermTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of weighted average ibr and remaining lease term table text block.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ScheduleOfWeightedAverageIBRAndRemainingLeaseTermTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Weighted Average I B R And Remaining Lease Term Table [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ScheduleOfWeightedAverageIBRAndRemainingLeaseTermTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Weighted Average IBR and Remaining Lease Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Annual Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentAnnualReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Annual Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Asset Impairment Charges</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Asset impairment charges</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Asset Impairment Charges, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_FourthAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fourth Amendment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_FourthAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Fourth Amendment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_FourthAmendmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fourth Amendment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less: Valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Valuation Allowance, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_IncreaseDecreaseInLeaseObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in lease Obligation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_IncreaseDecreaseInLeaseObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Increase Decrease in Lease Obligation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_IncreaseDecreaseInLeaseObligation_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease in Lease Obligation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash flows from financing activities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill, Impairment Loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill impairment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFilerCategory_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of Shares Underlying Outstanding Options, Vested and expected to vest</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Construction in Progress [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Construction In Progress</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted- Average Grant Date Fair Value, RSUs granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">RSUs forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">RSUs forfeited</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings (Accumulated Deficit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accumulated deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Retained Earnings (Accumulated Deficit), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Retained Earnings (Accumulated Deficit), Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Retained Earnings (Accumulated Deficit), Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LoansReceivableBasisSpreadOnVariableRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Loans Receivable, Basis Spread on Variable Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LoansReceivableBasisSpreadOnVariableRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest rate for term loan to finance leasehold improvements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentMaturityDateRangeEnd1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Debt Instrument, Maturity Date Range, End</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DebtInstrumentMaturityDateRangeEnd1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Loan availability end date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RedwoodCityLeaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Redwood City lease agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RedwoodCityLeaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Redwood City Lease Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RedwoodCityLeaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redwood City Lease Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RedwoodCityLeaseAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Redwood City, CA</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Depreciation, Depletion and Amortization, Nonproduction, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LettersOfCreditOutstandingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Letters of Credit Outstanding, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LettersOfCreditOutstandingAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Letters of Credit issued amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Outstanding, December 31,2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Outstanding, December 31, 2020</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Outstanding, December 31,2021</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Outstanding December 31, 2020</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityExTransitionPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Ex Transition Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_EffectiveIncomeTaxRateReconciliationNOLCarryback_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Effective income tax rate reconciliation NOL carryback.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_EffectiveIncomeTaxRateReconciliationNOLCarryback_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation N O L Carryback</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_EffectiveIncomeTaxRateReconciliationNOLCarryback_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal benefit from NOL carryback</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Short-term Lease, Cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShortTermLeaseCost_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Short-term lease cost</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_MaximumMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Change in Company's Contract Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Laboratory Equipment Member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Laboratory Equipment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LaboratoryEquipmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory Equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Cash</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">RSUs Vested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Acquisition, Acquiree</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payables and Accruals [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_IncomeTaxesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Income taxes.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_IncomeTaxesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_IncomeTaxesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Company&#8217;s Marketable Debt Securities by Contractual Maturity</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Tax Identification Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred Stock, par value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_DeferredTaxAssetsValuationAllowanceIncrease_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred Tax Assets Valuation Allowance Increase.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_DeferredTaxAssetsValuationAllowanceIncrease_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Valuation Allowance Increase</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_DeferredTaxAssetsValuationAllowanceIncrease_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase in valuation allowance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment, Net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Note, Stock Split, Conversion Ratio</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reverse stock split exchange ratio</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RfsOpcoLlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">RFS OPCO LLC [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RfsOpcoLlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">RFS OPCO LLC [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RfsOpcoLlcMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">RFS OPCO LLC [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign rate differential</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_IssuanceOfRedeemableConvertiblePreferredStockOnExerciseOfWarrantsWithLoanAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Issuance of redeemable convertible preferred stock on exercise of warrants with loan agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_IssuanceOfRedeemableConvertiblePreferredStockOnExerciseOfWarrantsWithLoanAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Issuance Of Redeemable Convertible Preferred Stock On Exercise Of Warrants With Loan Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_IssuanceOfRedeemableConvertiblePreferredStockOnExerciseOfWarrantsWithLoanAgreement_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of redeemable convertible preferred stock warrants in connection with the Loan Agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Deferred tax liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation expense, estimated weighted-average period for recognition</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accruals and reserves</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">In Process Research and Development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_InProcessResearchAndDevelopmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">In Process Research and Development [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustment based on tax positions related to current year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Decrease Resulting from Current Period Tax Positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold Improvements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares reserved for issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ContractAssetsAndLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract assets and liabilities.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ContractAssetsAndLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract Assets And Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ContractAssetsAndLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance at end of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ContractAssetsAndLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance at beginning of period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AmountPayableUponClosingOfMerger_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amount payable upon closing of merger.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AmountPayableUponClosingOfMerger_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amount Payable Upon Closing Of Merger</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AmountPayableUponClosingOfMerger_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Payable upon closing of merger</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_PercentageOfNetOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">percentage of net operating loss carryforwards.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_PercentageOfNetOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Net Operating Loss Carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_PercentageOfNetOperatingLossCarryforwards_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of net operating loss carryforwards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForMergerRelatedCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Payments for Merger Related Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PaymentsForMergerRelatedCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transaction cost for merger</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AmendedLeaseAgreementDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amended lease Agreement Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AmendedLeaseAgreementDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amended lease Agreement Details</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AmendedLeaseAgreementDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amended lease Agreement Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Remaining Terms (in years)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityFileNumber_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity File Number</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_WarrantsOutstandingAndExercisableWeightedAverageRemainingContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Warrants Outstanding And Exercisable Weighted Average Remaining Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_WarrantsOutstandingAndExercisableWeightedAverageRemainingContractualTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Warrants outstanding and exercisable, Weighted average remaining contractual term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_OperatingLossCarryforwardsIndefinitely_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards indefinitely.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_OperatingLossCarryforwardsIndefinitely_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Indefinitely</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_OperatingLossCarryforwardsIndefinitely_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Loss Carryforwards Indefinitely</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Other Noncurrent Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other non-current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued, Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance price per shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounting Standards Update</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RedeemableConvertiblePreferredStockTrancheLiabilityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Redeemable convertible preferred stock tranche liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RedeemableConvertiblePreferredStockTrancheLiabilityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Redeemable Convertible Preferred Stock Tranche Liability Policy [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RedeemableConvertiblePreferredStockTrancheLiabilityPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable Convertible Preferred Stock Tranche Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Accounts Payable, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TransitionAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Transition agreement.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TransitionAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Transition Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TransitionAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Transition Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RegeneronPharmaceuticalsIncorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Regeneron Pharmaceuticals Incorporation [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RegeneronPharmaceuticalsIncorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Regeneron Pharmaceuticals, Inc.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RegeneronPharmaceuticalsIncorporationMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Regeneron Pharmaceuticals Incorporation.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ExchangeRatio_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Exchange ratio.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ExchangeRatio_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Exchange Ratio</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ExchangeRatio_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exchange ratio</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities, Current [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events Considerations</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAuthorizedInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangements by share based payment award options authorized in period weighted average exercise price.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAuthorizedInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Authorized In Period Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAuthorizedInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Exercise Price, Options, authorized</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingences</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Lease, Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating lease liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_StockIssuedDuringPeriodSharesConversionOfSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Conversion of sharesaof redeemable convertible preferred stock to shares of common stock in connection with the Merger, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_StockIssuedDuringPeriodSharesConversionOfSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Conversion Of Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_StockIssuedDuringPeriodSharesConversionOfSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of shares of redeemable convertible preferred stock to shares of common stock in connection with the Merger, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_DefinedContributionPlanAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Defined contribution plan abstract.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_DefinedContributionPlanAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LicenceAgreementAdditionalAmountPayableOfOptionExerciseFees_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional amount payable of option exercise fees.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LicenceAgreementAdditionalAmountPayableOfOptionExerciseFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Licence Agreement Additional Amount Payable Of Option Exercise Fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LicenceAgreementAdditionalAmountPayableOfOptionExerciseFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Licence agreement additional amount payable of option exercise fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment, Gross</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total property and equipment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Property, Plant and Equipment, Gross, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Property, Plant and Equipment, Gross, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Property, Plant and Equipment, Gross, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ChangeInFairValueIncludedInResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Change in fair value included in research and development expense.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ChangeInFairValueIncludedInResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Change In Fair Value Included In Research And Development Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ChangeInFairValueIncludedInResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in the fair value included in research and development expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityPublicFloat_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Number of Shares Underlying Outstanding Options, Options forfeited or cancelled</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LicenceAgreementAdditionalRevenueRecognised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Licence agreement additional revenue recognised.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LicenceAgreementAdditionalRevenueRecognised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Licence Agreement Additional Revenue Recognised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LicenceAgreementAdditionalRevenueRecognised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Licence agreement additional revenue recognised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_CoverAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cover [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Related Party Transaction [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RelatedPartyTransactionDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Related Party Transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Temporary Equity, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Balance, temporary equity, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Balance, temporary equity, shares</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TemporaryEquitySharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares repurchased under stock purchase agreement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Repurchase Program, Number of Shares Authorized to be Repurchased</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of changes in the Company's IPR&amp;D and CVR since the Merger</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Separately Recognized Transactions [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Number of Operating Segments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_CustomersPercentageOfTotalRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Customers percentage of total revenue.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_CustomersPercentageOfTotalRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Customers Percentage Of Total Revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_CustomersPercentageOfTotalRevenue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customers percentage of total revenue</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TerminationAgreementMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Termination Agreement, month and year.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TerminationAgreementMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Termination Agreement Month And Year</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TerminationAgreementMonthAndYear_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Agreement terminated</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Arrangement, Contract to Perform for Others [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research And Development Arrangement Contract To Perform For Others [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_DeferredTaxAssetsFixedAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Fixed Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_DeferredTaxAssetsFixedAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Fixed Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_DeferredTaxAssetsFixedAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred Tax Assets Fixed Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Restricted Stock Units (RSUs)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested Restricted Stock Awards</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash, Cash Equivalents, and Short-term Investments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash, cash equivalents and marketable securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash, Cash Equivalents, and Short-term Investments, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_GainLossFromTheRemeasurementOfRedeemableConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Gain (loss) from the remeasurement of the redeemable convertible preferred stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_GainLossFromTheRemeasurementOfRedeemableConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Gain Loss From The Remeasurement Of Redeemable Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_GainLossFromTheRemeasurementOfRedeemableConvertiblePreferredStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gain from the remeasurement of the redeemable convertible preferred stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long-Lived Tangible Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Accrued Liabilities, Current</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued other liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_DocumentTransitionReport_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Transition Report</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average grant date fair value of options granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ContractAssetsAndLiabilitiesAdditionsDeductions_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Contract assets and liabilities additions (deductions).</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ContractAssetsAndLiabilitiesAdditionsDeductions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract Assets And Liabilities Additions Deductions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ContractAssetsAndLiabilitiesAdditionsDeductions_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Additions (Deductions)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_SalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Sales agreement member.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_SalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sales Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_SalesAgreementMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sales Agreement [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Payment from Regeneron for exercise of its option to license exclusive rights</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Stock Options Exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from exercise of stock options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lessee, Operating Lease, Renewal Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amended lease term from the date of relocation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_OptionsAvailableForFutureGrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Options available for future grants.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_OptionsAvailableForFutureGrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Options Available For Future Grants [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_OptionsAvailableForFutureGrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock Options Available for Future Grant</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Foreign</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Noncash Expense [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RedeemableConvertiblePreferredStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Redeemable convertible preferred stock warrants member</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RedeemableConvertiblePreferredStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Redeemable Convertible Preferred Stock Warrants [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RedeemableConvertiblePreferredStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Redeemable Convertible Preferred Stock Warrant Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RedeemableConvertiblePreferredStockWarrantsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Redeemable Convertible Preferred Stock Warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Research and Development Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Research and Development Expense, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TermLoanToFinanceLeaseholdImprovements1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">term loan to finance leasehold improvements 1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TermLoanToFinanceLeaseholdImprovements1_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">term loan to finance leasehold improvements 1</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TermLoanToFinanceLeaseholdImprovements1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Term loan to finance leasehold improvements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Contract with Customer, Liability, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract liabilities&#8212;related party, net of current portion</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfAssetsAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value of Assets Acquired</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueOfAssetsAcquired_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of net assets acquired in Merger</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AdjustmentToGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustment to Goodwill</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AdjustmentToGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Adjustment to goodwill</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AdjustmentToGoodwill_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Adjustment To Goodwill</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases, Future Minimum Payments, Due in Five Years</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2024</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AmortizationOfDebtIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Amortization of deferred debt issuance costs.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AmortizationOfDebtIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amortization Of Debt Issuance Costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AmortizationOfDebtIssuanceCosts_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amortization of deferred debt issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition, Pro Forma Net Income (Loss)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expense related to options granted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Total stock-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RestatementAdjustmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Revision of Prior Period, Adjustment [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RestatementAdjustmentMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Period Adjustments</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedBonusesCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Bonuses</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AccruedBonusesCurrentAndNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount equal to pro-rated bonus</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_UnvestedCommonStockFromEarlyExerciseOfOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Unvested common stock from early exercise of options.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_UnvestedCommonStockFromEarlyExerciseOfOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unvested Common Stock From Early Exercise Of Options [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_UnvestedCommonStockFromEarlyExerciseOfOptionsMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unvested Early Exercised Common Stock Options</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Statement of Financial Position [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dividend yield</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Contractual Term [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseContractualTermAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RecognitionOfContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Recognition of contingent consideration liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RecognitionOfContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Recognition Of Contingent Consideration Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_RecognitionOfContingentConsiderationLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recognition of contingent consideration liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal statutory income tax rate, percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders' Equity Attributable to Parent [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&#8217; equity (deficit):</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accounts Receivable-related party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accounts Receivable, Related Parties</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TwoThousandEighteenStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand eighteen stock incentive plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TwoThousandEighteenStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Eighteen Stock Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TwoThousandEighteenStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2018 Stock Incentive Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustment based on tax positions related to prior years</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Adjustment based on tax positions related to prior years</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ConversionOfConvertiblePreferredStockWarrantsIntoCommonStockWarrantsInConnectionWithMerger_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Conversion of convertible preferred stock warrants into common stock warrants in connection with merger.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ConversionOfConvertiblePreferredStockWarrantsIntoCommonStockWarrantsInConnectionWithMerger_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion Of Convertible Preferred Stock Warrants Into Common Stock Warrants In Connection With Merger</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ConversionOfConvertiblePreferredStockWarrantsIntoCommonStockWarrantsInConnectionWithMerger_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of convertible preferred stock warrant into common stock warrant in connection with Merger</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of number of shares of common stock reserved for future issuance.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Number Of Shares Of Common Stock Reserved For Future Issuance [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_ScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Number of Shares of Common Stock Reserved for Future Issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseContractualTermDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lease Contractual Term [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LeaseContractualTermDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Contractual Term</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDeferredLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Deferred Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDeferredLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred rent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInDeferredLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Increase (Decrease) in Deferred Liabilities, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted- Average Grant Date Fair Value, ending balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted- Average Grant Date Fair Value, beginning balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price, Ending Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in the fair value included in other income (expense), net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TwoThousandSeventeenAndTwoThousandEighteenStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand seventeen and two thousand eighteen stock incentive plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TwoThousandSeventeenAndTwoThousandEighteenStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Seventeen And Two Thousand Eighteen Stock Incentive Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TwoThousandSeventeenAndTwoThousandEighteenStockIncentivePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2017 and 2018 Stock Incentive Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AgreementTransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Agreement transaction price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AgreementTransactionPrice_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Agreement transaction price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LessPortionOfFairValueToBeDistributedAsCVR_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Less portion of the fair value to be distributed as CVR.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LessPortionOfFairValueToBeDistributedAsCVR_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Less Portion Of Fair Value To Be Distributed As C V R</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LessPortionOfFairValueToBeDistributedAsCVR_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Less: portion of the fair value to be distributed as CVR</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted average exercise price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Weighted-Average Exercise Price, Options exercised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Summary of significant accounting policies.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_SummaryOfSignificantAccountingPoliciesTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LicenseAgreementCumulativeRevenueReductionRecognised_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement cumulative revenue reduction recognised.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LicenseAgreementCumulativeRevenueReductionRecognised_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Cumulative Revenue Reduction Recognised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LicenseAgreementCumulativeRevenueReductionRecognised_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License agreement cumulative revenue reduction recognised</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Changes in operating assets and liabilities:</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_SettlementOfTRDFLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Settlement of trdf liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_SettlementOfTRDFLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Settlement Of T R D F Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_SettlementOfTRDFLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Settlement of TRDF liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of shares of common stock reserved for future issuance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_DeferredTaxOperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating lease right-of-use asset.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_DeferredTaxOperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Operating Lease Right Of Use Asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_DeferredTaxOperatingLeaseRightOfUseAsset_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease right-of-use asset</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Measurement Frequency [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityShellCompany_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Shell Company</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Public offering price</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Price Per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities and Equity [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities, redeemable convertible preferred stock, and stockholders&#8217; equity (deficit)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LumpSumCompensationPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Lump sum compensation payment.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LumpSumCompensationPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Lump Sum Compensation Payment</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LumpSumCompensationPayment_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lump sum payable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">ICFR Auditor Attestation Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ICFR Auditor Attestation Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Incorporation, State or Country Code</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TRDFLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">TRDF Liability.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TRDFLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">T R D F Liability [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TRDFLiabilityMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">TRDF Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock resulting from Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_MarketableSecurities_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Marketable debt securities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss per Share</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Equity Method Investments [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_PrepaymentsToCmos_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepayments to CMO's</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_PrepaymentsToCmos_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Prepayments to CMO's</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_PrepaymentsToCmos_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Prepayments to CMO's</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosureItemAmountsDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurement</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TwoThousandEighteenEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand eighteen employee stock purchase plan.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TwoThousandEighteenEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Eighteen Employee Stock Purchase Plan [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TwoThousandEighteenEmployeeStockPurchasePlanMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2018 Employee Stock Purchase Plan</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_OwnershipChangePlanDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Ownership change plan description.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_OwnershipChangePlanDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Ownership Change Plan Description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_OwnershipChangePlanDescription_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ownership change plan description</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accrued and other current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="dei_AmendmentFlag_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Schedule of Stock by Class [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Stock By Class [Table]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Conversion of Stock, Amount Converted</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ConversionOfStockAmountConverted1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of redeemable convertible preferred stock warrants to common stock warrants</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AdditionalAuthorizedAndUnissuedRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional authorized and unissued redeemable convertible preferred stock.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AdditionalAuthorizedAndUnissuedRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Additional Authorized And Unissued Redeemable Convertible Preferred Stock [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_AdditionalAuthorizedAndUnissuedRedeemableConvertiblePreferredStockMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Conversion of Additional Authorized and Unissued Redeemable Convertible Preferred Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Nonoperating Income (Expense)</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other income (expense), net</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Nonoperating Income (Expense), Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total fair value of options vested</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermPurchaseCommitmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Long-term Purchase Commitment [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LongTermPurchaseCommitmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Long Term Purchase Commitment [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contract liabilities&#8212;related party</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of common stock shares sold</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and Cash Equivalents, at Carrying Value, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and Cash Equivalents, at Carrying Value, Beginning Balance</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recent Accounting Pronouncements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Tax Credit Carryforward, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TaxCreditCarryforwardAmount_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforward, amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_OperatingLeasesCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating leases commencement date.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_OperatingLeasesCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Commencement Date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_OperatingLeasesCommencementDate_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating leases commencement date</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value, Recurring [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Recurring [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Events</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued and other current liabilities</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation, Tax Credit, Other, Percent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other permanent differences</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_DeferredTaxLiabilitiesFixedAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax liabilities fixed assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_DeferredTaxLiabilitiesFixedAssets_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Fixed Assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_DeferredTaxLiabilitiesFixedAssets_lbl" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Fixed assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfRegulatoryMilestonesPayableForSecondIndicationApproved_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">License agreement milestone payments upon satisfaction of regulatory milestones payable for second indication approved.</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfRegulatoryMilestonesPayableForSecondIndicationApproved_lbl" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Milestone Payments Upon Satisfaction Of Regulatory Milestones Payable For Second Indication Approved</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfRegulatoryMilestonesPayableForSecondIndicationApproved_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate amount payable upon satisfaction of regulatory milestones for second indication approved</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LegalFees_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Legal Fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_LegalFees_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Legal fees</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TermLoanAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Term loan abstract [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_TermLoanAbstract_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Term Loan [Abstract]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Antidilutive Securities, Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Antidilutive Securities, Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Property, Plant and Equipment [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Plant And Equipment [Line Items]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets, Noncurrent</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other non-current assets</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Other Assets, Noncurrent, Total</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaborative Arrangement and Arrangement Other than Collaborative</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate Intrinsic Value, Shares exercisable</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Sale of Stock [Axis]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets, Major Class Name</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_CommonStockOfferingCostsIncludedInAccruedLiabilitiesAtPeriodEnd_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock offering costs included in accrued liabilities at period end</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_CommonStockOfferingCostsIncludedInAccruedLiabilitiesAtPeriodEnd_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Offering Costs Included In Accrued Liabilities At Period End</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_CommonStockOfferingCostsIncludedInAccruedLiabilitiesAtPeriodEnd_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Common Stock Offering Costs Included In Accrued Liabilities At Period End</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Cost by Plan [Table Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock-Based Compensation Expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_PacificWesternBankMember_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pacific western bank</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_PacificWesternBankMember_lbl" xlink:role="http://www.xbrl.org/2003/role/documentation">Pacific western bank [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="acet_PacificWesternBankMember_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Pacific western bank [Member]</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Unrecognized stock-based compensation expense</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock, net of issuance costs</link:label>
    <link:label xml:lang="en-US" xlink:type="resource" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds from Issuance of Common Stock</link:label>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_COVID19Member" xlink:to="acet_COVID19Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioForecastMember" xlink:to="srt_ScenarioForecastMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostAbstract" xlink:to="us-gaap_LeaseCostAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_OptionToPurchaseOfCommonStockAtPublicOfferingPrice" xlink:to="acet_OptionToPurchaseOfCommonStockAtPublicOfferingPrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_RisksAndUncertaintiesPolicyTextBlock" xlink:to="acet_RisksAndUncertaintiesPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockPlans" xlink:to="us-gaap_ProceedsFromStockPlans_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfReportableSegments" xlink:to="us-gaap_NumberOfReportableSegments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment" xlink:to="acet_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:to="us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesLineItems" xlink:to="us-gaap_MarketableSecuritiesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_SeriesBRedeemableConvertiblePreferredStockMember" xlink:to="acet_SeriesBRedeemableConvertiblePreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityReverseStockSplit" xlink:to="us-gaap_StockholdersEquityReverseStockSplit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableRelatedPartiesCurrent" xlink:to="us-gaap_AccountsReceivableRelatedPartiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_CommonStockWarrantsMember" xlink:to="acet_CommonStockWarrantsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockDomain" xlink:to="us-gaap_ClassOfStockDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedAsPartOfMerger" xlink:to="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedAsPartOfMerger_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubleaseIncome" xlink:to="us-gaap_SubleaseIncome_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_IncomeTaxesDisclosureLineItems" xlink:to="acet_IncomeTaxesDisclosureLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:to="us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_GainLossOnChangeInFairValueOfContingentConsiderationLiability" xlink:to="acet_GainLossOnChangeInFairValueOfContingentConsiderationLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RedeemableConvertiblePreferredStockMember" xlink:to="us-gaap_RedeemableConvertiblePreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_IncreaseDecreaseInOperatingLeaseLiabilities" xlink:to="acet_IncreaseDecreaseInOperatingLeaseLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_LiabilitiesFairValueSettled" xlink:to="acet_LiabilitiesFairValueSettled_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIncomeTaxRefunds" xlink:to="us-gaap_ProceedsFromIncomeTaxRefunds_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromRelatedParties" xlink:to="us-gaap_RevenueFromRelatedParties_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInTwoYears" xlink:to="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInTwoYears_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_TemporaryEquityStockConversionSharesInConnectionWithMerger" xlink:to="acet_TemporaryEquityStockConversionSharesInConnectionWithMerger_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodSharesIssuedForServices_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilities" xlink:to="us-gaap_OtherLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeriesBPreferredStockMember" xlink:to="us-gaap_SeriesBPreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_LawsuitsFiledAgainstCompany" xlink:to="acet_LawsuitsFiledAgainstCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationAssetsArisingFromContingenciesAmountRecognized" xlink:to="us-gaap_BusinessCombinationAssetsArisingFromContingenciesAmountRecognized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants" xlink:to="us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ClassOfWarrantOrRightsExpirationDate" xlink:to="acet_ClassOfWarrantOrRightsExpirationDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_LicenseFundingAndOtherAgreementsAbstract" xlink:to="acet_LicenseFundingAndOtherAgreementsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:to="us-gaap_OtherNonoperatingIncomeExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:to="us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedPerTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedPerTransaction_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash" xlink:to="acet_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_AreaOfSublease" xlink:to="acet_AreaOfSublease_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementScenarioAxis" xlink:to="srt_StatementScenarioAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockLiquidationPreferenceValue" xlink:to="us-gaap_PreferredStockLiquidationPreferenceValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ExerciseFeePaid" xlink:to="acet_ExerciseFeePaid_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TenantImprovements" xlink:to="us-gaap_TenantImprovements_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAsPartOfMerger" xlink:to="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAsPartOfMerger_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueDisclosure" xlink:to="us-gaap_LiabilitiesFairValueDisclosure_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyDomain" xlink:to="us-gaap_RelatedPartyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_QualifyingExpenses" xlink:to="acet_QualifyingExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:to="us-gaap_DebtConversionConvertedInstrumentAmount1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_RedeemableConvertiblePreferredStockWarrantLiabilityMember" xlink:to="acet_RedeemableConvertiblePreferredStockWarrantLiabilityMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_SeptemberFifteenTwoThousandTwentyWarrantThreeMember" xlink:to="acet_SeptemberFifteenTwoThousandTwentyWarrantThreeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_LicenceAgreementUpfrontPayment" xlink:to="acet_LicenceAgreementUpfrontPayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="us-gaap_TaxCreditCarryforwardNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialLiabilitiesFairValueDisclosure" xlink:to="us-gaap_FinancialLiabilitiesFairValueDisclosure_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ResearchFundingFee" xlink:to="acet_ResearchFundingFee_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditNoncurrent" xlink:to="us-gaap_DeferredRentCreditNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_LeaseCostOtherInformationAbstract" xlink:to="acet_LeaseCostOtherInformationAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_RedeemableConvertiblePreferredStockWarrantLiabilityPolicyTextBlock" xlink:to="acet_RedeemableConvertiblePreferredStockWarrantLiabilityPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_TwoThousandFourteenAndTwoThousandFifteenStockIncentivePlanMember" xlink:to="acet_TwoThousandFourteenAndTwoThousandFifteenStockIncentivePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_FairValueOfCommonStockPolicyTextBlock" xlink:to="acet_FairValueOfCommonStockPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_TwoThousandFifteenStockIncentivePlanMember" xlink:to="acet_TwoThousandFifteenStockIncentivePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashNoncurrent" xlink:to="us-gaap_RestrictedCashNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementDomain" xlink:to="srt_RestatementDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFinanceCostsGross" xlink:to="us-gaap_DeferredFinanceCostsGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ContractAssetsAndLiabilitiesAdditions" xlink:to="acet_ContractAssetsAndLiabilitiesAdditions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeContractTypeDomain" xlink:to="us-gaap_DerivativeContractTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_LicenceAgreementCumulativeRevenueRecognised" xlink:to="acet_LicenceAgreementCumulativeRevenueRecognised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeDuringPeriodFairValueDisclosureMember" xlink:to="us-gaap_ChangeDuringPeriodFairValueDisclosureMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_AtTheMarketOfferingTextBlock" xlink:to="acet_AtTheMarketOfferingTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_OperatingLossCarrybackDurationUnderCARESAct" xlink:to="acet_OperatingLossCarrybackDurationUnderCARESAct_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_GainOnRemeasurementOfContingentConsiderationLiability" xlink:to="acet_GainOnRemeasurementOfContingentConsiderationLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ContractualContingentValueRight" xlink:to="acet_ContractualContingentValueRight_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnDispositionOfAssets1" xlink:to="us-gaap_GainLossOnDispositionOfAssets1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_FairValueOfModifiedStockOptionsAndRestrictedStockUnitsAttributableToPreCombinationServices" xlink:to="acet_FairValueOfModifiedStockOptionsAndRestrictedStockUnitsAttributableToPreCombinationServices_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_TermLoanAndNonFormulaAncillaryService" xlink:to="acet_TermLoanAndNonFormulaAncillaryService_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_BostonMember" xlink:to="acet_BostonMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_DeferredTaxBasisDifferenceIPRD" xlink:to="acet_DeferredTaxBasisDifferenceIPRD_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ContingentConsiderationFees" xlink:to="acet_ContingentConsiderationFees_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_LicenseAndCollaborationRevenue" xlink:to="acet_LicenseAndCollaborationRevenue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseCost" xlink:to="us-gaap_OperatingLeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ResTORbioMember" xlink:to="acet_ResTORbioMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1" xlink:to="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="us-gaap_EquityMethodInvestmentOwnershipPercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_EmployeeStockPurchasePlanMember" xlink:to="acet_EmployeeStockPurchasePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_BusinessAcquisitionsProFormaRevenue1" xlink:to="acet_BusinessAcquisitionsProFormaRevenue1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_RecognitionOfPreferredStockWarrantLiabilities" xlink:to="acet_RecognitionOfPreferredStockWarrantLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntellectualPropertyMember" xlink:to="us-gaap_IntellectualPropertyMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInFiveYears" xlink:to="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInFiveYears_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAuthorized" xlink:to="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePaymentsUse" xlink:to="us-gaap_OperatingLeasePaymentsUse_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_NumberOfSecuritiesConvertedToWarrantsToPurchaseCommonStock" xlink:to="acet_NumberOfSecuritiesConvertedToWarrantsToPurchaseCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestReceivableCurrent" xlink:to="us-gaap_InterestReceivableCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_InducementGrantsMember" xlink:to="acet_InducementGrantsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockTableTextBlock" xlink:to="acet_ScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteAbstract" xlink:to="us-gaap_StockholdersEquityNoteAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_TemporaryEquityStockConversionInConnectionWithMerger" xlink:to="acet_TemporaryEquityStockConversionInConnectionWithMerger_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember" xlink:to="us-gaap_SoftwareAndSoftwareDevelopmentCostsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAxis" xlink:to="srt_RestatementAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_NovartisLicenseAgreementMember" xlink:to="acet_NovartisLicenseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_RedeemableConvertiblePreferredStockTrancheLiabilityMember" xlink:to="acet_RedeemableConvertiblePreferredStockTrancheLiabilityMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeDomain" xlink:to="us-gaap_LongtermDebtTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_NumberOfSharesOfSurvivingStockOptions" xlink:to="acet_NumberOfSharesOfSurvivingStockOptions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesReceivable" xlink:to="us-gaap_IncomeTaxesReceivable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_RedeemableConvertiblePreferredStockTrancheLiabilityAndTRDFObligationMember" xlink:to="acet_RedeemableConvertiblePreferredStockTrancheLiabilityAndTRDFObligationMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ContractResearchTermPeriod" xlink:to="acet_ContractResearchTermPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsCurrent" xlink:to="us-gaap_OtherAssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationDateOfIncorporation" xlink:to="dei_EntityIncorporationDateOfIncorporation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashExpense" xlink:to="us-gaap_OtherNoncashExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConsolidationPolicyTextBlock" xlink:to="us-gaap_ConsolidationPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_FairValueByMeasurementBasisAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_DeferredTaxOperatingLeaseRightOfUseAssetLiability" xlink:to="acet_DeferredTaxOperatingLeaseRightOfUseAssetLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SecurityDepositLiability" xlink:to="us-gaap_SecurityDepositLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesCancelled" xlink:to="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesCancelled_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidInsurance" xlink:to="us-gaap_PrepaidInsurance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_AccruedCroCosts" xlink:to="acet_AccruedCroCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="acet_SummaryOfSignificantAccountingPoliciesLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfClinicalMilestonesPayable" xlink:to="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfClinicalMilestonesPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ExerciseOfRedeemableConvertiblePreferredStockTrancheLiabilities" xlink:to="acet_ExerciseOfRedeemableConvertiblePreferredStockTrancheLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_IncreaseInConstructionInProgress" xlink:to="acet_IncreaseInConstructionInProgress_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_RedeemableConvertiblePreferredStockPolicyTextBlock" xlink:to="acet_RedeemableConvertiblePreferredStockPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCost" xlink:to="us-gaap_LeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_GoodwillMeasurementPeriodAdjustments" xlink:to="acet_GoodwillMeasurementPeriodAdjustments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInFourYears" xlink:to="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInFourYears_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesTextBlock" xlink:to="us-gaap_MarketableSecuritiesTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_CompanyContributionToPlanWithRespectToEmployeesContribution" xlink:to="acet_CompanyContributionToPlanWithRespectToEmployeesContribution_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentForeignTaxExpenseBenefit" xlink:to="us-gaap_CurrentForeignTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_SeptemberFifteenTwoThousandTwentyWarrantTwoMember" xlink:to="acet_SeptemberFifteenTwoThousandTwentyWarrantTwoMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit" xlink:to="us-gaap_TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockDescriptionOfTransaction" xlink:to="us-gaap_SaleOfStockDescriptionOfTransaction_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_LicenseAgreementAdditionalPaymentForResearchFundingReceived" xlink:to="acet_LicenseAgreementAdditionalPaymentForResearchFundingReceived_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesGranted" xlink:to="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesGranted_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GrantsReceivable" xlink:to="us-gaap_GrantsReceivable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetBackedSecuritiesMember" xlink:to="us-gaap_AssetBackedSecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_StockExchangedDuringPeriodSharesInConnectionWithMerger" xlink:to="acet_StockExchangedDuringPeriodSharesInConnectionWithMerger_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_LicenseFundingAndOtherAgreementsTextBlock" xlink:to="acet_LicenseFundingAndOtherAgreementsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ExercisedInvestmentRightAndPurchased" xlink:to="acet_ExercisedInvestmentRightAndPurchased_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_UnderwritingDiscountsAndCommissionsAndOtherOfferingExpenses" xlink:to="acet_UnderwritingDiscountsAndCommissionsAndOtherOfferingExpenses_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesAndOtherLiabilities" xlink:to="us-gaap_AccruedLiabilitiesAndOtherLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquityCarryingAmountAttributableToParent" xlink:to="us-gaap_TemporaryEquityCarryingAmountAttributableToParent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_TerminationOfRedeemableConvertiblePreferredStockTrancheLiability" xlink:to="acet_TerminationOfRedeemableConvertiblePreferredStockTrancheLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="us-gaap_CommonStockDividendsPerShareDeclared_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionSharePrice" xlink:to="us-gaap_BusinessAcquisitionSharePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebtDescription" xlink:to="us-gaap_LongTermDebtDescription_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_QualifyingExpensesOnCumulativeBasis" xlink:to="acet_QualifyingExpensesOnCumulativeBasis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnusualRiskOrUncertaintyByNatureAxis" xlink:to="us-gaap_UnusualRiskOrUncertaintyByNatureAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseCostTableTextBlock" xlink:to="us-gaap_LeaseCostTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableLeaseCost" xlink:to="us-gaap_VariableLeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ContractAssetMember" xlink:to="acet_ContractAssetMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_MilestoneClosingLiability" xlink:to="acet_MilestoneClosingLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioPreviouslyReportedMember" xlink:to="srt_ScenarioPreviouslyReportedMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_AccruedResearchAndDevelopmentExpensesCurrent" xlink:to="acet_AccruedResearchAndDevelopmentExpensesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_NumberOfSharesAvailableForSaleUnderEmployeeStockPurchasePlan" xlink:to="acet_NumberOfSharesAvailableForSaleUnderEmployeeStockPurchasePlan_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinanceLeaseLiability" xlink:to="us-gaap_FinanceLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_FeesAndExpenseIncurredInConnectionWithClinicalTrials" xlink:to="acet_FeesAndExpenseIncurredInConnectionWithClinicalTrials_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrimeRateMember" xlink:to="us-gaap_PrimeRateMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_NationalInstitutesOfHealthMember" xlink:to="acet_NationalInstitutesOfHealthMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ScheduleOfChangesInFairValueOfUnobservableFinancialInstrumentsTableTextBlock" xlink:to="acet_ScheduleOfChangesInFairValueOfUnobservableFinancialInstrumentsTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_PrepaidExpensesAndOtherCurrentAssetsTextBlock" xlink:to="acet_PrepaidExpensesAndOtherCurrentAssetsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_SeptemberFifteenTwoThousandTwentyWarrantOneMember" xlink:to="acet_SeptemberFifteenTwoThousandTwentyWarrantOneMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCountryMember" xlink:to="us-gaap_ForeignCountryMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_OperatingLeasesFutureMinimumSubleaseIncomeDue" xlink:to="acet_OperatingLeasesFutureMinimumSubleaseIncomeDue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201602Member" xlink:to="us-gaap_AccountingStandardsUpdate201602Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ContingentValueRightsAgreementMember" xlink:to="acet_ContingentValueRightsAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="us-gaap_PaymentsOfDebtIssuanceCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_CaliforniaResearchAndDevelopmentMember" xlink:to="acet_CaliforniaResearchAndDevelopmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ClassOfWarrantOrRightIssued" xlink:to="acet_ClassOfWarrantOrRightIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationSettlementExpense" xlink:to="us-gaap_LitigationSettlementExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_AdvisoryServicesAnnualFee" xlink:to="acet_AdvisoryServicesAnnualFee_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_AccruedCmoCosts" xlink:to="acet_AccruedCmoCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_MergerMember" xlink:to="acet_MergerMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInThreeYears" xlink:to="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInThreeYears_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="us-gaap_LesseeLeasesPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateAxis" xlink:to="us-gaap_VariableRateAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:to="us-gaap_OtherComprehensiveIncomeLossBeforeTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VariableRateDomain" xlink:to="us-gaap_VariableRateDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_MarketableDebtSecuritiesClassificationTableTextBlock" xlink:to="acet_MarketableDebtSecuritiesClassificationTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationAxis" xlink:to="us-gaap_BalanceSheetLocationAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_TwoThousandFourteenStockIncentivePlanMember" xlink:to="acet_TwoThousandFourteenStockIncentivePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_PrepaymentsToCros" xlink:to="acet_PrepaymentsToCros_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_LicenseAgreementTerminationDescription" xlink:to="acet_LicenseAgreementTerminationDescription_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanTextBlock" xlink:to="us-gaap_DefinedContributionPlanTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentsTableTextBlock" xlink:to="us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentsTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ClassOfWarrantOutstandingAndExercisableToPurchasePreferredShares" xlink:to="acet_ClassOfWarrantOutstandingAndExercisableToPurchasePreferredShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ResearchFundingAgreementMember" xlink:to="acet_ResearchFundingAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_MarketableSecuritiesMember" xlink:to="acet_MarketableSecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ContingentConsiderationMember" xlink:to="acet_ContingentConsiderationMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LandSubjectToGroundLeases" xlink:to="us-gaap_LandSubjectToGroundLeases_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_EstimatedFairValueOfCVRLiability" xlink:to="acet_EstimatedFairValueOfCVRLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ScheduleOfSubleaseIncomeTableTextBlock" xlink:to="acet_ScheduleOfSubleaseIncomeTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_EntityDateOfMerger" xlink:to="acet_EntityDateOfMerger_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwardsExpirationDate" xlink:to="us-gaap_OperatingLossCarryforwardsExpirationDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_NovartisInternationalPharmaceuticalLimitedMember" xlink:to="acet_NovartisInternationalPharmaceuticalLimitedMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfCommercialMilestonesPayable" xlink:to="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfCommercialMilestonesPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityPolicyTextBlock" xlink:to="us-gaap_StockholdersEquityPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_IncreaseDecreaseInEstimatedFairValueOfCvrLiability" xlink:to="acet_IncreaseDecreaseInEstimatedFairValueOfCvrLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_StockIssuedDuringPeriodSharesUponAcceleratedVestingOfRSUWithMerger" xlink:to="acet_StockIssuedDuringPeriodSharesUponAcceleratedVestingOfRSUWithMerger_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ClassOfWarrantExercised" xlink:to="acet_ClassOfWarrantExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis" xlink:to="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_FederalAndStateResearchAndDevelopmentMember" xlink:to="acet_FederalAndStateResearchAndDevelopmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAcquiredFromAcquisition" xlink:to="us-gaap_CashAcquiredFromAcquisition_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsPolicy" xlink:to="us-gaap_BusinessCombinationsPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_StockExchangedDuringPeriodValueInConnectionWithMerger" xlink:to="acet_StockExchangedDuringPeriodValueInConnectionWithMerger_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueIssuedForServices" xlink:to="us-gaap_StockIssuedDuringPeriodValueIssuedForServices_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueCurrent" xlink:to="acet_OperatingLeasesFutureMinimumSubleaseIncomeDueCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_AdditionalClosingLiability" xlink:to="acet_AdditionalClosingLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndOtherIncome" xlink:to="us-gaap_InterestAndOtherIncome_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_UnvestedRestrictedStockUnitsOutstanding" xlink:to="acet_UnvestedRestrictedStockUnitsOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_NonRefundableUpfrontPaymentReceived" xlink:to="acet_NonRefundableUpfrontPaymentReceived_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_FinancingReceivableNonaccrualToOutstandingPercent" xlink:to="srt_FinancingReceivableNonaccrualToOutstandingPercent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumedAsPartOfMergerInPeriodWeightedAverageExercisePrice" xlink:to="acet_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumedAsPartOfMergerInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesRentExpenseSubleaseRentals1" xlink:to="us-gaap_OperatingLeasesRentExpenseSubleaseRentals1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_StockIssuedDuringPeriodValueUponAcceleratedVestingOfRSUWithMerger" xlink:to="acet_StockIssuedDuringPeriodValueUponAcceleratedVestingOfRSUWithMerger_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansPayable" xlink:to="us-gaap_LoansPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_OrganizationAndNatureOfBusinessTextBlock" xlink:to="acet_OrganizationAndNatureOfBusinessTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ImpairmentOfInProcessResearchAndDevelopment" xlink:to="acet_ImpairmentOfInProcessResearchAndDevelopment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure" xlink:to="us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage" xlink:to="us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BalanceSheetLocationDomain" xlink:to="us-gaap_BalanceSheetLocationDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_OrganizationAndNatureOfBusinessAbstract" xlink:to="acet_OrganizationAndNatureOfBusinessAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain" xlink:to="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ContractLiabilityMember" xlink:to="acet_ContractLiabilityMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermPurchaseCommitmentTable" xlink:to="us-gaap_LongTermPurchaseCommitmentTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesExercised" xlink:to="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ProceedsFromSalesOfMarketableDebtSecurities" xlink:to="acet_ProceedsFromSalesOfMarketableDebtSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_RedeemableConvertiblePreferredStockWarrantLiability" xlink:to="acet_RedeemableConvertiblePreferredStockWarrantLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_AccruedResearchAndDevelopmentPolicyTextBlock" xlink:to="acet_AccruedResearchAndDevelopmentPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesFairValueAdjustment" xlink:to="us-gaap_LiabilitiesFairValueAdjustment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_BusinessCombinationAccelerationOfRestrictedStockUnitsUponMerger" xlink:to="acet_BusinessCombinationAccelerationOfRestrictedStockUnitsUponMerger_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:to="us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesAuthorized" xlink:to="acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfRegulatoryMilestonesPayableForFirstIndicationApproved" xlink:to="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfRegulatoryMilestonesPayableForFirstIndicationApproved_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice" xlink:to="us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_GrantTerm" xlink:to="acet_GrantTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:to="acet_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_MenloParkLeaseAgreementMember" xlink:to="acet_MenloParkLeaseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockMember" xlink:to="us-gaap_RestrictedStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_NumberOfCustomer" xlink:to="acet_NumberOfCustomer_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesTable" xlink:to="us-gaap_MarketableSecuritiesTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ScenarioUnspecifiedDomain" xlink:to="srt_ScenarioUnspecifiedDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ClassOfWarrantOutstandingAndExercisableToPurchaseCommonStock" xlink:to="acet_ClassOfWarrantOutstandingAndExercisableToPurchaseCommonStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_RightOfUseAssetsRecognized" xlink:to="acet_RightOfUseAssetsRecognized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_PostExposureProphylaxisDescription" xlink:to="acet_PostExposureProphylaxisDescription_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ContractLiability" xlink:to="acet_ContractLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableGrossCurrent" xlink:to="us-gaap_AccountsReceivableGrossCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxesPaid" xlink:to="us-gaap_IncomeTaxesPaid_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongtermDebtTypeAxis" xlink:to="us-gaap_LongtermDebtTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentTangibleAndIntangiblesAssets" xlink:to="acet_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentTangibleAndIntangiblesAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_AdicetTherapeuticsIncMember" xlink:to="acet_AdicetTherapeuticsIncMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_VestingOfEarlyExercisedStockOptions" xlink:to="acet_VestingOfEarlyExercisedStockOptions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationAcquisitionRelatedCosts" xlink:to="us-gaap_BusinessCombinationAcquisitionRelatedCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DevelopmentInProcess" xlink:to="us-gaap_DevelopmentInProcess_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_MaximumAggregateValueOfCommonStockAvailableForOfferingAtMarketPriceUnderSalesAgreement" xlink:to="acet_MaximumAggregateValueOfCommonStockAvailableForOfferingAtMarketPriceUnderSalesAgreement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_LoanAmountDrawn" xlink:to="acet_LoanAmountDrawn_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_SeptemberFifteenTwoThousandTwentyWarrantFourMember" xlink:to="acet_SeptemberFifteenTwoThousandTwentyWarrantFourMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_AtTheMarketOfferingMember" xlink:to="acet_AtTheMarketOfferingMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_SubleaseAgreementDescription" xlink:to="acet_SubleaseAgreementDescription_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnusualRiskOrUncertaintyNatureDomain" xlink:to="us-gaap_UnusualRiskOrUncertaintyNatureDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_LiabilitiesFairValueExercised" xlink:to="acet_LiabilitiesFairValueExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ContingentConsiderationLiabilityMember" xlink:to="acet_ContingentConsiderationLiabilityMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilityAndTRDFLiability" xlink:to="acet_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilityAndTRDFLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionProFormaInformationTextBlock" xlink:to="us-gaap_BusinessAcquisitionProFormaInformationTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ScheduleOfWeightedAverageIBRAndRemainingLeaseTermTableTextBlock" xlink:to="acet_ScheduleOfWeightedAverageIBRAndRemainingLeaseTermTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_FourthAmendmentMember" xlink:to="acet_FourthAmendmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_IncreaseDecreaseInLeaseObligation" xlink:to="acet_IncreaseDecreaseInLeaseObligation_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LoansReceivableBasisSpreadOnVariableRate" xlink:to="us-gaap_LoansReceivableBasisSpreadOnVariableRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentMaturityDateRangeEnd1" xlink:to="us-gaap_DebtInstrumentMaturityDateRangeEnd1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_RedwoodCityLeaseAgreementMember" xlink:to="acet_RedwoodCityLeaseAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LettersOfCreditOutstandingAmount" xlink:to="us-gaap_LettersOfCreditOutstandingAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_EffectiveIncomeTaxRateReconciliationNOLCarryback" xlink:to="acet_EffectiveIncomeTaxRateReconciliationNOLCarryback_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShortTermLeaseCost" xlink:to="us-gaap_ShortTermLeaseCost_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_LaboratoryEquipmentMember" xlink:to="acet_LaboratoryEquipmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_IncomeTaxesTable" xlink:to="acet_IncomeTaxesTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_DeferredTaxAssetsValuationAllowanceIncrease" xlink:to="acet_DeferredTaxAssetsValuationAllowanceIncrease_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_RfsOpcoLlcMember" xlink:to="acet_RfsOpcoLlcMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_IssuanceOfRedeemableConvertiblePreferredStockOnExerciseOfWarrantsWithLoanAgreement" xlink:to="acet_IssuanceOfRedeemableConvertiblePreferredStockOnExerciseOfWarrantsWithLoanAgreement_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InProcessResearchAndDevelopmentMember" xlink:to="us-gaap_InProcessResearchAndDevelopmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ContractAssetsAndLiabilities" xlink:to="acet_ContractAssetsAndLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_AmountPayableUponClosingOfMerger" xlink:to="acet_AmountPayableUponClosingOfMerger_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_PercentageOfNetOperatingLossCarryforwards" xlink:to="acet_PercentageOfNetOperatingLossCarryforwards_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForMergerRelatedCosts" xlink:to="us-gaap_PaymentsForMergerRelatedCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_AmendedLeaseAgreementDescription" xlink:to="acet_AmendedLeaseAgreementDescription_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_WarrantsOutstandingAndExercisableWeightedAverageRemainingContractualTerm" xlink:to="acet_WarrantsOutstandingAndExercisableWeightedAverageRemainingContractualTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_OperatingLossCarryforwardsIndefinitely" xlink:to="acet_OperatingLossCarryforwardsIndefinitely_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_RedeemableConvertiblePreferredStockTrancheLiabilityPolicyTextBlock" xlink:to="acet_RedeemableConvertiblePreferredStockTrancheLiabilityPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_TransitionAgreementMember" xlink:to="acet_TransitionAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_RegeneronPharmaceuticalsIncorporationMember" xlink:to="acet_RegeneronPharmaceuticalsIncorporationMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ExchangeRatio" xlink:to="acet_ExchangeRatio_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsPolicyPolicyTextBlock" xlink:to="us-gaap_SubsequentEventsPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAuthorizedInPeriodWeightedAverageExercisePrice" xlink:to="acet_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAuthorizedInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_StockIssuedDuringPeriodSharesConversionOfSecurities" xlink:to="acet_StockIssuedDuringPeriodSharesConversionOfSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_DefinedContributionPlanAbstract" xlink:to="acet_DefinedContributionPlanAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_LicenceAgreementAdditionalAmountPayableOfOptionExerciseFees" xlink:to="acet_LicenceAgreementAdditionalAmountPayableOfOptionExerciseFees_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ChangeInFairValueIncludedInResearchAndDevelopmentExpense" xlink:to="acet_ChangeInFairValueIncludedInResearchAndDevelopmentExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_LicenceAgreementAdditionalRevenueRecognised" xlink:to="acet_LicenceAgreementAdditionalRevenueRecognised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDomain" xlink:to="us-gaap_RelatedPartyTransactionDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TemporaryEquitySharesOutstanding" xlink:to="us-gaap_TemporaryEquitySharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased" xlink:to="us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock" xlink:to="us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_CustomersPercentageOfTotalRevenue" xlink:to="acet_CustomersPercentageOfTotalRevenue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_TerminationAgreementMonthAndYear" xlink:to="acet_TerminationAgreementMonthAndYear_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_DeferredTaxAssetsFixedAssets" xlink:to="acet_DeferredTaxAssetsFixedAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsAndShortTermInvestments" xlink:to="us-gaap_CashCashEquivalentsAndShortTermInvestments_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_GainLossFromTheRemeasurementOfRedeemableConvertiblePreferredStock" xlink:to="acet_GainLossFromTheRemeasurementOfRedeemableConvertiblePreferredStock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ContractAssetsAndLiabilitiesAdditionsDeductions" xlink:to="acet_ContractAssetsAndLiabilitiesAdditionsDeductions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_SalesAgreementMember" xlink:to="acet_SalesAgreementMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_OptionsAvailableForFutureGrantsMember" xlink:to="acet_OptionsAvailableForFutureGrantsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredForeignIncomeTaxExpenseBenefit_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAbstract" xlink:to="us-gaap_ShareBasedCompensationAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_RedeemableConvertiblePreferredStockWarrantsMember" xlink:to="acet_RedeemableConvertiblePreferredStockWarrantsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_TermLoanToFinanceLeaseholdImprovements1" xlink:to="acet_TermLoanToFinanceLeaseholdImprovements1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfAssetsAcquired" xlink:to="us-gaap_FairValueOfAssetsAcquired_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_AdjustmentToGoodwill" xlink:to="acet_AdjustmentToGoodwill_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_AmortizationOfDebtIssuanceCosts" xlink:to="acet_AmortizationOfDebtIssuanceCosts_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss" xlink:to="us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RestatementAdjustmentMember" xlink:to="srt_RestatementAdjustmentMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedBonusesCurrentAndNoncurrent" xlink:to="us-gaap_AccruedBonusesCurrentAndNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_UnvestedCommonStockFromEarlyExerciseOfOptionsMember" xlink:to="acet_UnvestedCommonStockFromEarlyExerciseOfOptionsMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermAxis" xlink:to="us-gaap_LeaseContractualTermAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_RecognitionOfContingentConsiderationLiability" xlink:to="acet_RecognitionOfContingentConsiderationLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_TwoThousandEighteenStockIncentivePlanMember" xlink:to="acet_TwoThousandEighteenStockIncentivePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ConversionOfConvertiblePreferredStockWarrantsIntoCommonStockWarrantsInConnectionWithMerger" xlink:to="acet_ConversionOfConvertiblePreferredStockWarrantsIntoCommonStockWarrantsInConnectionWithMerger_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_ScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceTextBlock" xlink:to="acet_ScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseContractualTermDomain" xlink:to="us-gaap_LeaseContractualTermDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredLiabilities" xlink:to="us-gaap_IncreaseDecreaseInDeferredLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_TwoThousandSeventeenAndTwoThousandEighteenStockIncentivePlanMember" xlink:to="acet_TwoThousandSeventeenAndTwoThousandEighteenStockIncentivePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_AgreementTransactionPrice" xlink:to="acet_AgreementTransactionPrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_LessPortionOfFairValueToBeDistributedAsCVR" xlink:to="acet_LessPortionOfFairValueToBeDistributedAsCVR_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_SummaryOfSignificantAccountingPoliciesTable" xlink:to="acet_SummaryOfSignificantAccountingPoliciesTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_LicenseAgreementCumulativeRevenueReductionRecognised" xlink:to="acet_LicenseAgreementCumulativeRevenueReductionRecognised_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_SettlementOfTRDFLiability" xlink:to="acet_SettlementOfTRDFLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_DeferredTaxOperatingLeaseRightOfUseAsset" xlink:to="acet_DeferredTaxOperatingLeaseRightOfUseAsset_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_LumpSumCompensationPayment" xlink:to="acet_LumpSumCompensationPayment_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_TRDFLiabilityMember" xlink:to="acet_TRDFLiabilityMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecurities" xlink:to="us-gaap_MarketableSecurities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_PrepaymentsToCmos" xlink:to="acet_PrepaymentsToCmos_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosureItemAmountsDomain" xlink:to="us-gaap_FairValueDisclosureItemAmountsDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_TwoThousandEighteenEmployeeStockPurchasePlanMember" xlink:to="acet_TwoThousandEighteenEmployeeStockPurchasePlanMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_OwnershipChangePlanDescription" xlink:to="acet_OwnershipChangePlanDescription_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther" xlink:to="us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConversionOfStockAmountConverted1" xlink:to="us-gaap_ConversionOfStockAmountConverted1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_AdditionalAuthorizedAndUnissuedRedeemableConvertiblePreferredStockMember" xlink:to="acet_AdditionalAuthorizedAndUnissuedRedeemableConvertiblePreferredStockMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermPurchaseCommitmentLineItems" xlink:to="us-gaap_LongTermPurchaseCommitmentLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAmount" xlink:to="us-gaap_TaxCreditCarryforwardAmount_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_OperatingLeasesCommencementDate" xlink:to="acet_OperatingLeasesCommencementDate_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_DeferredTaxLiabilitiesFixedAssets" xlink:to="acet_DeferredTaxLiabilitiesFixedAssets_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfRegulatoryMilestonesPayableForSecondIndicationApproved" xlink:to="acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfRegulatoryMilestonesPayableForSecondIndicationApproved_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalFees" xlink:to="us-gaap_LegalFees_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_TermLoanAbstract" xlink:to="acet_TermLoanAbstract_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_CommonStockOfferingCostsIncludedInAccruedLiabilitiesAtPeriodEnd" xlink:to="acet_CommonStockOfferingCostsIncludedInAccruedLiabilitiesAtPeriodEnd_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock" xlink:to="us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="acet_PacificWesternBankMember" xlink:to="acet_PacificWesternBankMember_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_lbl"/>
    <link:labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139685485763608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 10, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Adicet Bio, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001720580<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ACET<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 226.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,877,109<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">81-3305277<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.0001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">200 Clarendon Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Floor 6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Boston<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text"> 503-9095<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">02116<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">KPMG LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Boston, Massachusetts<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;">Part III of this Annual Report on Form 10-K incorporates by reference certain information from the registrant&#8217;s definitive Proxy Statement for its 2022 annual meeting of shareholders, scheduled to be held on June 2, 2022, which the registrant intends to file pursuant to Regulation 14A with the Securities and Exchange Commission not later than 120 days after the registrant&#8217;s fiscal year end of December 31, 2021. Except with respect to information specifically incorporated by reference in this Form 10-K, the Proxy Statement is not deemed to be filed as part of this Form 10-K.</span></p><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139685483553160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 277,544<span></span>
</td>
<td class="nump">$ 84,330<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term marketable debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,284<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableRelatedPartiesCurrent', window );">Accounts Receivable - related party</a></td>
<td class="nump">185<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">4,709<span></span>
</td>
<td class="nump">5,722<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">282,438<span></span>
</td>
<td class="nump">100,336<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">14,643<span></span>
</td>
<td class="nump">2,790<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="nump">20,358<span></span>
</td>
<td class="nump">23,066<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">19,462<span></span>
</td>
<td class="nump">20,089<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DevelopmentInProcess', window );">In-process research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,190<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">150<span></span>
</td>
<td class="nump">4,527<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Long-term marketable debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">1,887<span></span>
</td>
<td class="nump">1,837<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">338,938<span></span>
</td>
<td class="nump">153,835<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">3,263<span></span>
</td>
<td class="nump">1,552<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Contract liabilities&#8212;related party, current</a></td>
<td class="nump">4,805<span></span>
</td>
<td class="nump">13,980<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Accrued and other current liabilities</a></td>
<td class="nump">6,682<span></span>
</td>
<td class="nump">5,732<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Operating lease liability</a></td>
<td class="nump">1,567<span></span>
</td>
<td class="nump">1,215<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">16,317<span></span>
</td>
<td class="nump">22,479<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current portion</a></td>
<td class="nump">19,377<span></span>
</td>
<td class="nump">20,424<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liability</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">980<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred tax liability</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">125<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilities', window );">Other non-current liabilities</a></td>
<td class="nump">115<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">35,809<span></span>
</td>
<td class="nump">44,008<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 12)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders&#8217; equity (deficit):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.0001 par value, 10,000,000 shares authorized as of December 31, 2021 and December 31, 2020, respectively; none issued and outstanding as of December 31, 2021 and December 31, 2020, respectively</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value, 150,000,000 shares authorized as of December 31, 2021 and December 31, 2020, respectively; 39,736,914 and 19,677,249 shares issued and outstanding as of December 31, 2021 and December 31, 2020, respectively</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">471,449<span></span>
</td>
<td class="nump">216,126<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(168,324)<span></span>
</td>
<td class="num">(106,325)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">303,129<span></span>
</td>
<td class="nump">109,827<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities, redeemable convertible preferred stock, and stockholders' equity</a></td>
<td class="nump">$ 338,938<span></span>
</td>
<td class="nump">$ 153,835<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableRelatedPartiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39603-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableRelatedPartiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130531-203044<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123360276&amp;loc=SL49130532-203044<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current amount of expenditures for a real estate project that has not yet been completed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139685667268632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">39,736,914<span></span>
</td>
<td class="nump">19,677,249<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">39,736,914<span></span>
</td>
<td class="nump">19,677,249<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred Stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139685483437896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromRelatedParties', window );">Revenue&#8212;related party</a></td>
<td class="nump">$ 9,730<span></span>
</td>
<td class="nump">$ 17,903<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">48,943<span></span>
</td>
<td class="nump">34,334<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">22,220<span></span>
</td>
<td class="nump">22,760<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">71,163<span></span>
</td>
<td class="nump">57,094<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(61,433)<span></span>
</td>
<td class="num">(39,191)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestAndOtherIncome', window );">Interest income</a></td>
<td class="nump">91<span></span>
</td>
<td class="nump">785<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="num">(176)<span></span>
</td>
<td class="num">(134)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income (expense), net</a></td>
<td class="num">(606)<span></span>
</td>
<td class="num">(953)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income tax benefit</a></td>
<td class="num">(62,124)<span></span>
</td>
<td class="num">(39,493)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="num">(125)<span></span>
</td>
<td class="num">(2,815)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (61,999)<span></span>
</td>
<td class="num">$ (36,678)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share attributable to common stockholders, basic and diluted</a></td>
<td class="num">$ (2.00)<span></span>
</td>
<td class="num">$ (5.01)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted</a></td>
<td class="nump">30,952,152<span></span>
</td>
<td class="nump">7,319,977<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive income (loss):</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized gain (loss) on marketable debt securities, net of tax</a></td>
<td class="num">$ (24)<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeTax', window );">Total other comprehensive income (loss)</a></td>
<td class="num">(24)<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (62,023)<span></span>
</td>
<td class="num">$ (36,677)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndOtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndOtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax, after reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33775-111570<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139685480297624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Redeemable Convertible Preferred Stock</div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2019</a></td>
<td class="num">$ (60,366)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 9,258<span></span>
</td>
<td class="num">$ (69,647)<span></span>
</td>
<td class="nump">$ 23<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Balance, temporary equity, shares at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97,166,921<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Balance, temporary equity at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 114,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,155,578<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">210,752<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">5,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Conversion of shares of redeemable convertible preferred stock to shares of common stock in connection with the Merger</a></td>
<td class="nump">114,083<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">114,082<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_TemporaryEquityStockConversionSharesInConnectionWithMerger', window );">Conversion of shares of redeemable convertible preferred stock to shares of common stock in connection with the Merger, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(97,166,921)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_TemporaryEquityStockConversionInConnectionWithMerger', window );">Conversion of shares of redeemable convertible preferred stock to shares of common stock in connection with the Merger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (114,083)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_StockIssuedDuringPeriodSharesConversionOfSecurities', window );">Conversion of shares of redeemable convertible preferred stock to shares of common stock in connection with the Merger, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,048,671<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_StockExchangedDuringPeriodValueInConnectionWithMerger', window );">Exchange of common stock in connection with the Merger</a></td>
<td class="nump">83,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">83,516<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_StockExchangedDuringPeriodSharesInConnectionWithMerger', window );">Exchange of common stock in connection with the Merger, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,207,695<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_StockIssuedDuringPeriodValueUponAcceleratedVestingOfRSUWithMerger', window );">Issuance of common stock upon accelerated vesting ofrestricted stock units in connection with the Merger</a></td>
<td class="nump">626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">626<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_StockIssuedDuringPeriodSharesUponAcceleratedVestingOfRSUWithMerger', window );">Issuance of common stock upon accelerated vesting of restricted stock units in connection with the Merger (Shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of redeemable convertible preferred stock warrants to common stock warrants</a></td>
<td class="nump">2,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,922<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(36,678)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(36,678)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">109,827<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">216,126<span></span>
</td>
<td class="num">(106,325)<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Balance, temporary equity, shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Balance, temporary equity at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,677,249<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">$ 4,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options, shares</a></td>
<td class="nump">1,125,339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,125,339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock related to financing, net of issuance costs of $823,940</a></td>
<td class="nump">$ 237,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">237,995<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock related to financing, net of issuance costs of $823,940, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,916,853<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices', window );">Issuance of common stock for cashless exercise of warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices', window );">Issuance of common stock for cashless exercise of warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,806<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock resulting from Employee Stock Purchase Plan</a></td>
<td class="nump">129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock resulting from Employee Stock Purchase Plan, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,667<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">12,511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of redeemable convertible preferred stock warrants to common stock warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(61,999)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(61,999)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive loss</a></td>
<td class="num">(24)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(24)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 303,129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 471,449<span></span>
</td>
<td class="num">$ (168,324)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquitySharesOutstanding', window );">Balance, temporary equity, shares at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent', window );">Balance, temporary equity at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,736,914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_StockExchangedDuringPeriodSharesInConnectionWithMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock exchanged during period shares in connection with merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_StockExchangedDuringPeriodSharesInConnectionWithMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_StockExchangedDuringPeriodValueInConnectionWithMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock exchanged during period value in connection with merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_StockExchangedDuringPeriodValueInConnectionWithMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_StockIssuedDuringPeriodSharesConversionOfSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Conversion of sharesaof redeemable convertible preferred stock to shares of common stock in connection with the Merger, shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_StockIssuedDuringPeriodSharesConversionOfSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_StockIssuedDuringPeriodSharesUponAcceleratedVestingOfRSUWithMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period shares upon accelerated vesting of rsu with merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_StockIssuedDuringPeriodSharesUponAcceleratedVestingOfRSUWithMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_StockIssuedDuringPeriodValueUponAcceleratedVestingOfRSUWithMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued during period value upon accelerated vesting of rsu with merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_StockIssuedDuringPeriodValueUponAcceleratedVestingOfRSUWithMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_TemporaryEquityStockConversionInConnectionWithMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary equity stock conversion in connection with merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_TemporaryEquityStockConversionInConnectionWithMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_TemporaryEquityStockConversionSharesInConnectionWithMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Temporary Equity Stock Conversion Shares In Connection With Merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_TemporaryEquityStockConversionSharesInConnectionWithMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442407-227067<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=124507222&amp;loc=d3e1436-108581<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueIssuedForServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueIssuedForServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquityCarryingAmountAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquityCarryingAmountAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TemporaryEquitySharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TemporaryEquitySharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139685484524424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Stock issuance cost</a></td>
<td class="nump">$ 823,940<span></span>
</td>
</tr>
</table>
<div style="display: none;"><table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table></div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139685483063064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (61,999)<span></span>
</td>
<td class="num">$ (36,678)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">1,538<span></span>
</td>
<td class="nump">1,226<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashExpense', window );">Noncash lease expense</a></td>
<td class="nump">2,529<span></span>
</td>
<td class="nump">725<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">12,511<span></span>
</td>
<td class="nump">5,263<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Loss on disposal of assets for lease</a></td>
<td class="nump">31<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Net amortization of premiums and accretion of discounts on investments</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Change in fair value of redeemable convertible preferred stock warrant liability</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">897<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_ImpairmentOfInProcessResearchAndDevelopment', window );">Impairment of in-process research and development</a></td>
<td class="nump">1,190<span></span>
</td>
<td class="nump">2,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_GainOnRemeasurementOfContingentConsiderationLiability', window );">Gain on remeasurement of contingent consideration liability</a></td>
<td class="num">(980)<span></span>
</td>
<td class="num">(1,900)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_AmortizationOfDebtIssuanceCosts', window );">Amortization of deferred debt issuance costs</a></td>
<td class="nump">175<span></span>
</td>
<td class="nump">134<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties', window );">Accounts Receivable-related party</a></td>
<td class="num">(30)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,634<span></span>
</td>
<td class="num">(3,233)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Other non-current assets</a></td>
<td class="nump">42<span></span>
</td>
<td class="num">(1,260)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">1,137<span></span>
</td>
<td class="num">(814)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Contract liabilities&#8212;related party</a></td>
<td class="num">(9,175)<span></span>
</td>
<td class="num">(7,903)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_IncreaseDecreaseInOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="num">(511)<span></span>
</td>
<td class="num">(859)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities', window );">Accrued and other current liabilities</a></td>
<td class="nump">855<span></span>
</td>
<td class="nump">787<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other non-current liabilities</a></td>
<td class="num">(9)<span></span>
</td>
<td class="num">(242)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(51,052)<span></span>
</td>
<td class="num">(41,552)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAcquiredFromAcquisition', window );">Cash and restricted cash acquired in connection with the Merger</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">64,114<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_ProceedsFromSalesOfMarketableDebtSecurities', window );">Proceeds from sales of marketable debt securities</a></td>
<td class="nump">7,500<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable debt securities</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(5,700)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Proceeds from maturities of marketable debt securities</a></td>
<td class="nump">2,750<span></span>
</td>
<td class="nump">57,793<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property and equipment</a></td>
<td class="num">(13,046)<span></span>
</td>
<td class="num">(990)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="num">(2,796)<span></span>
</td>
<td class="nump">115,217<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock, net of issuance costs</a></td>
<td class="nump">238,129<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from Employee Stock Purchase Plan</a></td>
<td class="nump">129<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">4,688<span></span>
</td>
<td class="nump">460<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Deferred issuance costs</a></td>
<td class="num">(261)<span></span>
</td>
<td class="num">(157)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">242,685<span></span>
</td>
<td class="nump">303<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash, cash equivalents and restricted cash</a></td>
<td class="nump">188,837<span></span>
</td>
<td class="nump">73,968<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, at the beginning of the period</a></td>
<td class="nump">88,857<span></span>
</td>
<td class="nump">14,889<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, at the end of the period</a></td>
<td class="nump">277,694<span></span>
</td>
<td class="nump">88,857<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Reconciliation of cash, cash equivalents and restricted cash to consolidated balance sheets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">277,544<span></span>
</td>
<td class="nump">84,330<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashNoncurrent', window );">Restricted cash</a></td>
<td class="nump">150<span></span>
</td>
<td class="nump">4,527<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, at the end of the period</a></td>
<td class="nump">277,694<span></span>
</td>
<td class="nump">88,857<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental cash flow information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaid', window );">Cash paid for income taxes</a></td>
<td class="nump">43<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIncomeTaxRefunds', window );">Cash received for income tax refunds</a></td>
<td class="nump">2,766<span></span>
</td>
<td class="nump">664<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosures of noncash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchase of property and equipment included in accounts payable and accrued liabilities</a></td>
<td class="nump">651<span></span>
</td>
<td class="nump">115<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_CommonStockOfferingCostsIncludedInAccruedLiabilitiesAtPeriodEnd', window );">Common stock offering costs included in accrued liabilities at period end</a></td>
<td class="nump">132<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease right-of-use asset obtained in exchange for operating lease liability</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">22,367<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Conversion of redeemable convertible preferred stock into common stock</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">114,083<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConversionOfStockAmountConverted1', window );">Conversion of redeemable convertible preferred stock warrants to common stock warrants</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">2,922<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfAssetsAcquired', window );">Fair value of net assets acquired in Merger</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">84,142<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_AdjustmentToGoodwill', window );">Adjustment to Goodwill</a></td>
<td class="nump">413<span></span>
</td>
<td class="nump">650<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_IssuanceOfRedeemableConvertiblePreferredStockOnExerciseOfWarrantsWithLoanAgreement', window );">Issuance of redeemable convertible preferred stock warrants in connection with the Loan Agreement</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">144<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Topic 842</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosures of noncash investing and financing activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_RightOfUseAssetsRecognized', window );">Right-of-use assets recognized upon adoption of Topic 842</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,424<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_AdjustmentToGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Adjustment to goodwill</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_AdjustmentToGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_AmortizationOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortization of deferred debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_AmortizationOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_CommonStockOfferingCostsIncludedInAccruedLiabilitiesAtPeriodEnd">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common Stock Offering Costs Included In Accrued Liabilities At Period End</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_CommonStockOfferingCostsIncludedInAccruedLiabilitiesAtPeriodEnd</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_GainOnRemeasurementOfContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain on remeasurement of contingent consideration liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_GainOnRemeasurementOfContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_ImpairmentOfInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Impairment of in process research and development</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_ImpairmentOfInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_IncreaseDecreaseInOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in operating lease liabilities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_IncreaseDecreaseInOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_IssuanceOfRedeemableConvertiblePreferredStockOnExerciseOfWarrantsWithLoanAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Issuance of redeemable convertible preferred stock on exercise of warrants with loan agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_IssuanceOfRedeemableConvertiblePreferredStockOnExerciseOfWarrantsWithLoanAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_ProceedsFromSalesOfMarketableDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from sales of marketable debt securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_ProceedsFromSalesOfMarketableDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_RightOfUseAssetsRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Right-of-use assets recognized in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_RightOfUseAssetsRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAcquiredFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAcquiredFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConversionOfStockAmountConverted1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConversionOfStockAmountConverted1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfAssetsAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of assets acquired in noncash investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4313-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfAssetsAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due to the reporting entity for good and services provided to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management, an entity and its principal owners, management, member of their immediate families, affiliates, or other parties with the ability to exert significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in accrued expenses, and obligations classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 310<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123371682&amp;loc=d3e55415-109406<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense or loss included in net income that result in no cash flow, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIncomeTaxRefunds">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash received during the period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIncomeTaxRefunds</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6812-107765<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 210<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120413173&amp;loc=SL116631458-115580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139685484634024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Nature of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_OrganizationAndNatureOfBusinessTextBlock', window );">Organization and Nature of Business</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">1. Organization and Nature of the Business</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Adicet Bio, Inc. (formerly resTORbio, Inc. (resTORbio)), together with its subsidiaries, (the Company) is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer. The Company is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs) and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. The Company's approach to activate, engineer, and manufacture allogeneic gamma delta T cell product candidates derived from the peripheral blood cells of unrelated donors allows it to generate new product candidates in a rapid and cost efficient manner.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company was incorporated in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_6bd37428-42c2-4038-b96a-a6cfe4c5c8c5;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">November 2014</span></span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> in Delaware. The principal executive offices are located in Boston, Massachusetts. The Company also has another office in Menlo Park, California.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Adicet Bio, Inc. (when referred to prior to the Merger (as defined below), (Former Adicet)) was incorporated in November 2014 in Delaware and was headquartered in Menlo Park, CA. Adicet Bio Israel Ltd. (formerly Applied Immune Technologies Ltd.) (Adicet Israel) is a wholly owned subsidiary of Former Adicet and is located in Haifa, Israel. Adicet Israel was founded in 2006. During 2019, Former Adicet consolidated its operations, including research and development activities, in the United States and as a result substantially reduced its operations in Israel.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Merger with resTORbio</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prior to September 15, 2020, the Company was a clinical-stage biopharmaceutical company known as resTORbio that had historically focused on developing innovative medicines that target the biology of aging, to prevent or treat age-related diseases with the potential to extend healthy lifespans. On </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">April 28, 2020</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, resTORbio entered into a definitive Merger Agreement with Former Adicet. Under the terms of the Merger Agreement, Former Adicet agreed to merge with a wholly owned subsidiary of resTORbio in an all-stock transaction with Former Adicet surviving as a wholly owned subsidiary of resTORbio and changing its name to &#8220;Adicet Therapeutics, Inc.&#8221; (such transactions, the Merger). Under the exchange ratio formula in the Merger Agreement, immediately following the Effective Time of the Merger, the securityholders of Former Adicet as of immediately prior to the Effective Time of the Merger owned approximately </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">75</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the outstanding shares of the Company&#8217;s common stock on a fully-diluted basis and securityholders of resTORbio as of immediately prior to the Effective Time of the Merger owned approximately </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the outstanding shares of the Company&#8217;s common stock on a fully-diluted basis (in each case excluding equity incentives available for grant).</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company concluded that the transaction represented a business combination pursuant to Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 805, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Business Combinations</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Further, Former Adicet was determined to be the accounting acquirer based upon the terms of the Merger and other factors including: (i) Former Adicet&#8217;s securityholders own approximately 75% of the voting rights of the combined company (on a fully-diluted basis excluding equity incentives available for grant); (ii) Former Adicet designated a majority (five of seven) of the initial members of the Board of Directors of the combined company; and (iii) the terms of the exchange of equity interests based on the exchange ratio at the announcement of the Merger factored in an implied premium to resTORbio&#8217;s stockholders. The composition of senior management of the combined company was determined to be a neutral factor in the accounting acquirer determination, as the combined company will leverage the expertise of the senior management of both companies. Accordingly, the reported operating results prior to the business combination are those of Former Adicet.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On September 15, 2020, the Company completed the Merger pursuant to the Merger Agreement (the Effective Time). In connection with the Merger, and immediately prior to the Effective Time, resTORbio effected a reverse stock split of its common stock at a ratio of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1-for-7</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (the Reverse Stock Split). Also, in connection with the Merger, the Company changed its name from &#8220;resTORbio, Inc.&#8221; to &#8220;Adicet Bio, Inc.&#8221; (the Name Change), Former Adicet changed its name from &#8220;Adicet Bio, Inc.&#8221; to &#8220;Adicet Therapeutics, Inc.&#8221; and the business conducted by the Company became primarily the business, which was previously conducted by Former Adicet, which is a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">At the Effective Time, each outstanding share of Former Adicet capital stock was converted into the right to receive </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1240</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (the </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Exchange Ratio) shares of Company&#8217;s common stock, as set forth in the Merger Agreement. The Exchange Ratio was determined based on the total number of outstanding shares of Company&#8217;s common stock and Former Adicet capital stock, each on a fully diluted basis, and the respective valuations of Former Adicet and resTORbio at the time of execution of the Merger Agreement. In connection with the Merger, the Company also assumed certain outstanding Former Adicet warrants and Former Adicet stock options under Former Adicet&#8217;s 2015 Stock Incentive Plan (the 2015 Adicet Stock Incentive Plan) and Former Adicet&#8217;s 2014 Share Option Plan (the 2014 Share Option Plan and, together with the 2015 Adicet Stock Incentive Plan, the Former Adicet Plans), with such stock options and warrants henceforth representing the right to purchase a number of shares of Company&#8217;s common stock equal to the Exchange Ratio multiplied by the number of shares of Former Adicet&#8217;s</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">capital </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">stock previously represented by such stock options and warrants, as applicable, with a proportionate adjustment in exercise price.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Immediately following the Effective Time, there were approximately </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19,589,828</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of the Company&#8217;s common stock outstanding (post Reverse Stock Split), with the former equity holders of Former Adicet holding approximately </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">75</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the outstanding shares of Company&#8217;s common stock on a fully-diluted basis and the former equity holders of resTORbio holding approximately </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the outstanding shares of Company&#8217;s common stock on a fully-diluted basis (in each case excluding equity incentives available for grant).</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Please refer to Note 3 &#8220;Business Combinations&#8221; for further discussions of the Merger.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Liquidity</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has incurred significant net operating losses and negative cash flows from operations since inception and had an accumulated deficit of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">168.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million as of December 31, 2021. The Company has historically financed its operations primarily through a collaboration and licensing arrangement, the private placement of equity securities and debt, and cash received in the Merger. To date, none of the Company&#8217;s product candidates have been approved for sale and therefore the Company has not generated any revenue from product sales. Management expects operating losses and negative cash flows to continue for the foreseeable future, until such time, if ever, that it can generate significant sales of its product candidates currently in development.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In February 2021, the Company completed an underwritten public offering of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,575,513</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of its common stock at a public offering price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share. The Company received net proceeds from the offering, after deducting underwriting discounts and commissions and offering expenses of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">128.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. In connection with the offering, the Company also entered into a stock purchase agreement </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">with certain existing investors to purchase </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,153,840</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of its common stock for $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million at a price per share equal to the public offering price, with an initial closing for certain investors held simultaneously with the closing of the offering and a subsequent closing for certain additional investors.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2021, the Company closed an underwritten public offering, or the December 2021 Follow-On Offering, of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,187,500</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of its common stock at a public offering price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share. The Company received net proceeds from the offering, after deducting underwriting discounts and commissions and offering expenses of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">94.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company expects that its cash and cash equivalents balances as of December 31, 2021, including the gross proceeds it received in February 2021 and December 2021 from its underwritten public offerings and the proceeds received from a stock purchase agreement with certain existing investors, will be sufficient to fund its forecasted operating expenses, capital expenditure requirements for at least the next twelve months from the issuance of these annual consolidated financial statements.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All of the Company&#8217;s revenue to date is generated from the Regeneron Agreement, which is a collaboration and license agreement with Regeneron. The Company does not expect to generate any significant product revenue until it obtains regulatory approval of and commercialize any of the Company&#8217;s product candidates or enter into additional collaborative agreements with third parties, and it does not know when, or if, either will occur. The Company expects to continue to incur significant losses for the foreseeable future, and it expects the losses to increase as the Company continues the development of, and seek regulatory approvals for, its product candidates and begin to commercialize any approved products. The Company is subject to all of the risks typically related to the development of new product candidates, including, but not limited to, raising additional capital, development by its competitors of new technological innovations, risk of failure in preclinical and clinical studies, safety and efficacy of its product candidates in clinical trials, the risk of relying on external parties such as contract research organizations (CROs) and contract manufacturing organizations (CMOs), the regulatory approval process, market acceptance of the Company&#8217;s products once approved, lack of marketing and sales history, dependence on key personnel and protection of proprietary technology and it may encounter unforeseen expenses, difficulties, complications, delays, and other unknown factors that may adversely affect its business.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Until such time as the Company can generate significant revenue from product sales, if ever, the Company expects to finance its operations through the sale of equity, debt financings, collaborative or other arrangements with corporate or other sources of financing. Adequate funding may not be available to the Company on acceptable terms or at all. The Company&#8217;s failure to raise capital as and when needed could have a negative impact on its financial condition and the Company&#8217;s ability to pursue its business strategies. Although the Company continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_OrganizationAndNatureOfBusinessTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization and nature of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_OrganizationAndNatureOfBusinessTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139685483903336">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2. Summary of Significant Accounting Policies</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Basis of Presentation</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The consolidated financial statements and related disclosures have been prepared in conformity with accounting principles generally accepted in the United States of America (United States GAAP or GAAP).</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Principles of Consolidation</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. The United States dollar is the functional and reporting currency of the Company and its subsidiaries.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent liabilities at the date of the consolidated financial statements as well as the reported amounts of revenues and expenses during the reporting period. Such estimates include the valuation of the intangible assets acquired in business combinations, redeemable convertible preferred stock warrant liability, redeemable convertible preferred stock tranche liability, the Technion Research and Development Foundation liability (TRDF Liability), contingent consideration liability for contingent value right (CVR), deferred tax assets, useful lives of property and equipment, accruals for research and development activities, revenue recognition and stock-based compensation and the Company&#8217;s incremental borrowing rate. Actual results could differ from those estimates.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Contingent Consideration Liability (CVR)</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The estimated fair value of the CVR, initially measured and recorded on the acquisition date, is considered to be a Level 3 instrument. The contingent consideration liability is recorded at fair value at the end of each reporting period with changes in estimated fair values recorded in research and development expenses in the consolidated statements of operations and comprehensive loss. During the second quarter of 2021, the Company performed a re-measurement of the fair value of the CVR liability and adjusted the liability to zero. This resulted in a $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million gain in research and development expense in the statements of operations and comprehensive loss for the year ended December 31, 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Goodwill</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Goodwill represents the excess of the purchase price over the fair value of net tangible and identified intangible assets acquired in a business combination. Goodwill is not amortized but is evaluated at least annually for impairment or when a change in facts and circumstances indicate that the fair value of the goodwill may be below the carrying value.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Goodwill is tested for impairment at the reporting unit level annually in the fourth quarter, or more frequently when events or changes in circumstances indicate that the asset might be impaired. Examples of such events or circumstances include, but are not limited to, a significant adverse change in legal or business climate, an adverse regulatory action or unanticipated competition. The Company has determined that it operates in a single operating segment and has a single reporting unit.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prior to performing the impairment test, the Company assesses qualitative factors to determine whether the existence of events or circumstances would indicate that it is more likely than not that the fair value of the reporting unit was less than the carrying amount. If after assessing the totality of events or circumstances, the Company were to determine that it is more likely than not that the fair value of the reporting unit is less than the carrying amount, then the Company would perform a quantitative impairment test.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The quantitative impairment test involves comparing the fair value of the reporting unit to the carrying value. If the fair value of the reporting unit exceeds the carrying value of the net assets, goodwill is not impaired, and no further testing is required. If the fair value of the reporting unit is less than the carrying value, the Company measures the amount of impairment loss, if any, as the excess of the carrying value over the fair value of the reporting unit. The Company performed an annual test for goodwill impairment in the fourth quarter of the fiscal year ended December 31, 2021 and determined that goodwill was </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">t impaired.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Intangible Assets</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the Merger, the Company acquired certain IPR&amp;D assets, which were classified as indefinite-lived intangible assets. Acquired IPR&amp;D represents the fair value assigned to research and development assets that the Company acquires and have not been completed at the acquisition date. The fair value of IPR&amp;D acquired in a business combination is recorded on the Company&#8217;s consolidated balance sheets at the acquisition-date fair value and is determined by estimating the costs to develop the technology into commercially viable products, estimating the resulting revenue from the products, and discounting the projected net cash flows to present value. IPR&amp;D is not amortized, but rather is reviewed for impairment on an annual basis or more frequently if indicators of impairment are present, until the project is completed, abandoned, or transferred to a third party. The Company performed a review for impairment of IPR&amp;D during the second quarter of the year ended December 31, 2021 and recognized an impairment charge of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, which was recorded as research and development expenses in the consolidated statement of operations and comprehensive loss.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Segments</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company operates and manages its business as </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> reportable and operating segment, which is the business of research and development of allogeneic immunotherapies for cancer and other diseases. The Company&#8217;s Chief Executive Officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Concentration of Credit Risk</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of cash and cash equivalents, and marketable debt securities. The Company&#8217;s cash and cash equivalents are held at two financial institutions in the United States and one financial institution in Israel and such amounts may, at times, exceed insured limits. The Company invests its cash equivalents and marketable debt securities in money market funds, United States government securities, commercial paper, corporate bonds, and asset-backed securities. The Company limits its credit risk associated with cash equivalents and marketable debt securities by placing them with banks and institutions it believes are highly creditworthy and in highly rated investments. The Company has not experienced any losses on its deposits of cash and cash equivalents and marketable debt securities to date.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> customer, Regeneron, which represents </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the Company&#8217;s total revenue during the years ended December 31, 2021 and 2020 and outstanding accounts receivable as of December 31, 2021 (see Note 10).</span></p></div><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Risks and Uncertainties</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, protection of proprietary technology, dependence on key personnel, compliance with government regulations and the need to obtain additional financing to fund operations. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical studies, clinical trials, and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance and reporting.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#8217;s product candidates are still in development and, to date, none of the Company&#8217;s product candidates have been approved for sale and, therefore, the Company has not generated any revenue from product sales.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There can be no assurance that the Company&#8217;s research and development will be successfully completed, that adequate protection for the Company&#8217;s intellectual property will be obtained or maintained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will generate revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from other pharmaceutical and biotechnology companies.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">current COVID-19 (coronavirus) pandemic, which is impacting worldwide economic activity, poses risk that the Company or its employees, contractors, suppliers, and other partners may be prevented from conducting business activities for an indefinite period of time, including due to shutdowns that may be requested or mandated by governmental authorities. The extent to which the coronavirus impacts the Company&#8217;s operations will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the outbreak, new information that will emerge concerning the severity of the coronavirus and the actions to contain the coronavirus or treat its impact, among others. COVID-19 may impact the timing of regulatory approval of the INDs for clinical trials, the enrollment of any clinical trials that are</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">approved, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the availability of clinical trial materials and regulatory approval and commercialization of our products. COVID-19 may also impact the Company&#8217;s ability to access capital, which could negatively impact short-term and long-term liquidity.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Cash and Cash Equivalents</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company considers all highly liquid investments purchased with maturities of three months or less from the purchase date to be cash equivalents. As of December 31, 2021 and 2020, cash and cash equivalents consist of cash deposited with banks and investments in money market funds with maturities of three months or less from the date of purchase.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Marketable Debt Securities</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Marketable debt securities are investments in marketable debt securities with maturities greater than three months at the time of purchase. The Company determines the appropriate classification of its investments in marketable debt securities at the time of purchase and reevaluates such designation at each balance sheet date. The Company has classified and accounted for its marketable debt securities as available-for-sale. The Company classifies highly liquid securities with maturities beyond 12 months as long-term marketable debt securities in the consolidated balance sheet. These securities are carried at fair value as determined based upon quoted market prices or pricing models for similar securities. Unrealized gains and losses, if any, are excluded from earnings and are reported as a component of accumulated other comprehensive income (loss). The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in interest income on the consolidated statements of operations and comprehensive loss. Realized gains and losses, if any, on available-for-sale securities are included in other income (expense), net. The cost of securities sold is based on the specific identification method. Interest and dividends on securities classified as available-for-sale are included in interest income. The Company did not have any outstanding marketable debt securities as of December 31, 2021 and did not identify any of its marketable debt securities as other-than-temporarily impaired as of December 31, 2020.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Restricted Cash</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Restricted cash is comprised of cash that is restricted as to withdrawal or use under the terms of certain contractual agreements. Restricted cash for years ended December 31, 2021 and 2020 consists of collateral for letters of credit issued in connection with real estate leases (see Note 12).</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Fair Value of Financial Instruments</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The carrying amounts of certain financial instruments of the Company, including cash equivalents, restricted cash, accounts payable and accrued and other current liabilities approximate fair value due to their relatively short maturities. The Company&#8217;s marketable debt securities and CVR liability are carried at fair value (see Notes 4 and 5).</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Property and Equipment, Net</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is computed on a straight-line basis over the estimated useful lives of the related assets, generally three years. Leasehold improvements are amortized using the straight-line method over the shorter of the assets&#8217; estimated useful lives or the remaining term of the lease. Maintenance and repairs are charged to operations as incurred. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the consolidated balance sheet and any resulting gain or loss is reflected in the consolidated statements of operations and comprehensive loss in the period realized.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Impairment of Long-Lived Assets</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. Recoverability is measured by comparison of the carrying amount of the asset or asset group to the future net cash flows which the asset or asset group is expected to generate. If such asset or asset group is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset or asset group exceeds the fair value of the asset or asset group. There has been </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> such impairment of long-lived assets during the years ended December 31, 2021 and 2020.</span></p></div><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Revenue Recognition</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under ASC 606, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Revenue from Contracts with Customers</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (ASC 606), the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps as prescribed by ASC 606:</span></p><div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(i)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">identify the contract(s) with a customer;</span></div></div><div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(ii)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">identify the performance obligations in the contract;</span></div></div><div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(iii)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">determine the transaction price;</span></div></div><div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(iv)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">allocate the transaction price to the performance obligations in the contract; and</span></div></div><div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(v)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">recognize revenue when (or as) the Company satisfies a performance obligation.</span></div></div><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A contract with a customer exists when (i) the Company enters into a legally enforceable contract with a customer that defines each party&#8217;s rights regarding the products or services to be transferred and identifies the payment terms related to these products or services, (ii) the contract has commercial substance and (iii) the Company determines that collection of substantially all consideration for products or services that are transferred is probable based on the customer&#8217;s intent and ability to pay the promised consideration.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">At contract inception, once the contract is determined to be within the scope of ASC 606, the Company identifies the goods or services promised and determines the performance obligations by assessing whether each promised good or service is distinct. Goods or services that are not distinct are bundled with other goods or services in the contract until a bundle of goods or services that is distinct is created. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All of the Company&#8217;s revenues are derived through a license and collaboration agreement (see Note 10).</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For revenue recognition purposes, the Company determines the term of its license or collaboration agreements by evaluating the period during which present and enforceable rights and obligations exist. This determination is impacted by the existence of substantive termination penalties, among other factors.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company recognizes revenue under the Company&#8217;s license or collaboration agreements that are within the scope of ASC 606. These agreements include promises related to licenses to intellectual property and research and development services. If the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgement to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. Accordingly, the transaction price is generally comprised of a fixed fee due at contract inception and at specified future dates, variable consideration in the form of milestone payments due upon the achievement of specified events and tiered royalties earned when customers recognize net sales of licensed products. The Company measures the transaction price based on the amount of consideration to which it expects to be entitled in exchange for transferring the promised goods and/or services to the customer. The Company utilizes the &#8220;most likely amount&#8221; method to estimate the amount of variable consideration to which it will be entitled for the contract. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. At the inception of each arrangement that includes development and regulatory milestone payments, the Company evaluates whether the associated event is considered most likely to be achieved and estimates the amount to be included in the transaction price.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Payments or reimbursements for the Company&#8217;s research and development efforts where such efforts are considered part of or a single performance obligation are recognized over time using a measure of progress that best reflects the Company&#8217;s performance in satisfying the obligation.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Upfront payments are recorded as contract liabilities upon receipt or when due and may require deferral of revenue recognition to a future period until the Company performs its obligation under these arrangements. Amounts payable to the Company are recorded as accounts receivable when the Company&#8217;s right to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one year or less.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from its collaboration arrangement.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research and Development Expenses</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development expenses include costs directly attributable to the conduct of research and development programs, including payroll and related expenses, costs for CMOs, costs for CROs, materials, supplies, depreciation on and maintenance of research equipment, consulting costs, and the allocated portions of facility costs, such as rent, utilities, insurance, repairs and maintenance, depreciation, information technology costs and general support services. All costs associated with research and development are expensed within the consolidated statements of operations and comprehensive loss as incurred.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Costs incurred in obtaining technology licenses are charged to research and development expense as acquired in-process research and development if the technology licensed has not reached technological feasibility and has no alternative future use.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Accrued CRO, CMO, and Research and Development Expenses</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has entered into various agreements with CMOs and CROs. The Company&#8217;s research and development accruals are estimated based on the level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. The estimated costs of research and development provided, but not yet invoiced are included in accrued and other current liabilities on the consolidated balance sheets. If the actual timing of the performance of services or the level of effort varies from the original estimates, the Company will adjust the accrual accordingly. Payments made to CMOs and CROs under these arrangements in advance of the performance of the related services are recorded as prepaid expenses and other current assets on the consolidated balance sheets until the services are rendered. Through December 31, 2021 there had been no material adjustments to the Company&#8217;s prior period estimates of accrued research and development expenses.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Leases</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Effective January 1, 2020, the Company adopted ASU No. 2016-02, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Leases (Topic 842)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (ASU 2016-02), using the modified retrospective approach through a cumulative-effect adjustment as of the adoption date, with prior periods unchanged and presented in accordance with the guidance in Topic 840, Leases (Topic 840).</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Consistent with ASU 2016-02, the Company determines if an arrangement is a lease, or contains a lease, at inception. Leases with a term greater than 12 months are recognized on the balance sheet as Right-of-Use (ROU) assets and current and long-term operating lease liabilities, as applicable. The Company has elected not to recognize on the balance sheet leases with terms of 12 months or less. The Company typically only includes an initial lease term in its assessment of a lease arrangement. Options to renew a lease are not included in the Company&#8217;s assessment unless there is reasonable certainty that the Company will renew. The Company monitors its plan to renew its leases no less than on a quarterly basis. In addition, the Company&#8217;s lease agreements generally do not contain any residual value guarantees or restrictive covenants.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In accordance with ASU 2016-02, the ROU assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term. As most of the Company&#8217;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate (IBR), which is the estimated rate the Company would be required to pay for a fully collateralized borrowing equal to the total lease payments over the term of the lease, to determine the present value of future minimum lease payments. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. For lease agreements entered into or reassessed after the adoption of ASU 2016-02, the Company does not combine lease and non-lease components. Variable lease payments are expenses as incurred.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Assumptions made by the Company at the commencement date are re-evaluated upon occurrence of certain events, including a lease modification. A lease modification results in a separate contract when the modification grants the lessee an additional right of use not included in the original lease and when lease payments increase commensurate with the standalone price for the additional right of use. When a lease modification results in a separate contract, it is accounted for in the same manner as a new lease.</span></p></div><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Fair Value of Common Stock</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prior to the Merger the fair value of the Company&#8217;s common stock was determined by its Board of Directors with input from management and third-party valuation specialists. The Company&#8217;s approach to estimate the fair value of the Company&#8217;s common stock is consistent with the methods outlined in the American Institute of Certified Public Accountants Practice Aid, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Valuation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">of Privately-Held-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Company</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> Equity Securities Issued as Compensation</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Determining the best estimated fair value of the Company&#8217;s common stock requires significant judgement and management considers several factors, including the Company&#8217;s stage of development, equity market conditions affecting comparable public companies, significant milestones and progress of research and development efforts. Subsequent to the Merger, the fair value of the Company&#8217;s common stock is determined based on its closing market price.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock-Based Compensation</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company accounts for stock-based compensation arrangements with employees and non-employees using a fair value method which requires the recognition of compensation expense for costs related to all stock-based payments including stock options. The fair value method requires the Company to estimate the fair value of stock-based payment awards on the date of grant using an option-pricing model. The Company uses the Black-Scholes option-pricing model to estimate the fair value of options granted that are expensed on a straight-line basis over the requisite service period, which is generally the vesting period. The Company accounts for forfeitures as they occur. Option valuation models, including the Black-Scholes option-pricing model, require the input of several assumptions. Changes in the assumptions used can materially affect the grant-date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend yield, expected volatility and the expected life of the award. For awards that have a performance condition, the Company recognizes compensation expense based on its assessment of the probability that the performance condition will be achieved, using an accelerated attribution model, over the explicit or implicit service period.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Income Taxes</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences attributable to differences between carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax reporting purposes and for operating loss and tax credit carryforwards. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#8217;s deferred tax assets and liabilities are measured using enacted tax rates expected to apply in the years in which these temporary differences are expected to be recovered or settled. A valuation allowance is recorded to reduce deferred tax assets if it is determined that it is more likely than not that all or a portion of the deferred tax asset will not be realized. The Company considers many factors when assessing the likelihood of future realization of deferred tax assets, including recent earnings results, expectations of future taxable income, carryforward periods available and other relevant factors. The Company records changes in the required valuation allowance in the period that the determination is made.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company assesses its income tax positions and records tax benefits for all years subject to examination based upon management&#8217;s evaluation of the facts, circumstances and information available as of the reporting date. For those tax positions where it is more likely than not that a tax benefit will be sustained, the Company records the largest amount of tax benefit with a greater than 50% likelihood of being realized upon ultimate settlement with a taxing authority having full knowledge of all relevant information. For those income tax positions where it is not more likely than not that a tax benefit will be sustained, the Company does not recognize a tax benefit in the consolidated financial statements. The Company records interest and penalties related to uncertain tax positions, if applicable, as a component of income tax expense (benefit).</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Comprehensive Income (Loss)</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Comprehensive income (loss) is defined as a change in equity of a business enterprise during a period, resulting from transactions from non-owner sources. The other comprehensive loss disclosed in the Company&#8217;s consolidated statements of operations and comprehensive loss for the years ended December 31, 2021 and 2020 consists of changes in unrealized gains and losses on marketable debt securities.</span></p></div><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Net Loss per Share Attributable to Common Stockholders</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Basic </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common stock outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common stock and potentially dilutive securities outstanding for the period. The Company&#8217;s potentially dilutive shares, which include outstanding stock options, Employee Stock Purchase Plan awards, unvested restricted stock units (RSUs), and shares issuable upon conversion of the Convertible Notes, are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive. Basic and diluted net loss per share attributable to common stockholders is presented in conformity with the two-class method required for participating securities. The two-class method determines net income (loss) per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income (loss) available to common</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">stockholders </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">for the period to be allocated between common and participating securities based upon their respective rights to share in undistributed earnings as if all income (loss) for the period had been distributed. The Company&#8217;s participating securities do not have a contractual obligation to share in the Company&#8217;s losses. As such, the net loss is attributed entirely to common stockholders. Since the Company has reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for those periods.</span></p></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Subsequent Events Considerations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the consolidated financial statements to provide additional evidence for certain estimates or to identify matters that require additional disclosure. Subsequent events have been evaluated as required. The Company has evaluated all subsequent events and determined that there are no material recognized or unrecognized subsequent events requiring disclosure, other than as disclosed in these notes to the consolidated financial statements.  See Note 21 for further information.</span></p></div><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Recent Accounting Pronouncements</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">From time to time, new accounting pronouncements are issued by the FASB under its ASC or other standard setting bodies and adopted by the Company as of the specified effective date, unless otherwise discussed below.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Recently Adopted Accounting Pronouncements</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In August 2018, the FASB issued ASU No. 2018-15, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Intangibles&#8211;Goodwill and Other&#8212;Internal-Use Software (Subtopic 350-40): Customer&#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That is a Service Contract </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(ASU 2018-15). The amendments in ASU 2018-15 align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). Accordingly, the update requires</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">entities in a hosting arrangement that is a service contract to follow the guidance in ASC 350-40, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Internal-Use Software</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (ASC 350-40) to determine which implementation costs to capitalize as an asset related to the service contract and which costs to expense. Costs to develop or obtain internal-use software that cannot be capitalized under ASC 350-40, such as training costs and certain data conversion costs, also cannot be capitalized for a hosting arrangement that is a service contract. Therefore, an entity in a hosting arrangement that is a service contract determines which project stage an implementation activity relates to. Costs for implementation activities in the application development stage are capitalized depending on the nature of the costs, while costs incurred during the preliminary project and post-implementation stages are expensed as the activities are performed. ASU 2018-15 also requires entities to expense the capitalized implementation costs of a hosting arrangement that is a service contract over the term of the hosting arrangement. ASU 2018-15 was effective for public entities for annual periods beginning after December 15, 2019, including interim periods within those fiscal years. For nonpublic entities, ASU 2018-15 is effective for annual reporting periods beginning after December 15, 2020, and interim periods within annual periods beginning after December 15, 2021. Early adoption is permitted, including adoption in any interim period. The Company adopted ASU 2018-15 beginning January 1, 2021. The adoption of ASU 2018-15 resulted in an immaterial amount of assets recorded on the Company's balance sheet.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In November 2018, the FASB issued ASU No. 2018-18, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Collaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(ASU 2018-18), which is intended to clarify the circumstances under which certain transactions in collaborative arrangements should be accounted for under the revenue recognition standard. Certain transactions between collaboration arrangement participants should be accounted for as revenue under ASC Topic 606 when the collaborative arrangement participant is a customer in the context of a unit of account. For public business entities, this ASU is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. For all other entities, this ASU is effective for fiscal years and interim periods within those years beginning after December 15, 2020. Early adoption is permitted.  The Company adopted ASU 2018-18 beginning January 1, 2021. The adoption of this standard did not have a material impact on the Company's financial statements and related disclosures.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2019, the FASB issued ASU No. 2019-12, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Income Taxes (Topic 740)&#8212;Simplifying the Accounting for Income Taxes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (ASU 2019-12), which simplify various aspects related to the accounting for income taxes. This ASU removes exceptions to the general principles in Topic 740 related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. For public companies, this ASU is effective for interim and annual reporting periods beginning after December 15, 2020. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2021, and interim periods within fiscal years beginning after December 15, 2022. Early adoption is permitted. The Company adopted ASU 2019-12 beginning January 1, 2021 on a prospective basis. The adoption of this standard did not have a material impact on the Company's financial statements and related disclosures</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In March 2020, the FASB issued ASU No. 2020-04, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Reference Rate Reform (Topic 848)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (ASU 2020-04). The amendments in ASU 2020-04 provide optional expedients and exceptions for applying generally accepted accounting principles to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments in ASU 2020-04 are effective for all entities as of March 12, 2020 through December 31, 2022. An entity may elect to apply the amendments for contract modifications by Topic or Industry Subtopic as of any date from the beginning an interim period that includes or is subsequent to March 12, 2020, or prospectively from the date that the financial statements are available to be issued. Once elected for a Topic or an Industry Subtopic, the amendments must be applied prospectively for all eligible contract modifications for that Topic or Industry Subtopic. The Company may elect to apply ASU 2020-04 as its contracts referenced in London Interbank Offered Rate (LIBOR) are impacted by reference rate reform. The Company adopted ASU 2020-04 beginning January 1, 2021. The adoption of this standard did not have a material impact on the Company's financial statements and related disclosures.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><br/></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Accounting Pronouncements Not Yet Adopted</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(ASU 2016-13), which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. This ASU replaces the existing incurred loss impairment model with an expected loss model. It also eliminates the concept of other-than-temporary impairment and requires credit losses related to available-for-sale debt securities to be recorded through an allowance for credit losses rather than as a reduction in the amortized cost basis of the securities. These changes will result in earlier recognition of credit losses. For public business entities that meet the definition of a Securities and Exchange Commission (SEC) filer, excluding entities eligible to be smaller reporting companies as defined by the SEC, adoption is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. For SEC filers that are eligible to be smaller reporting companies and for all other entities, this ASU is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact the adoption of this ASU will have on its consolidated financial statements and related disclosures.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In January 2017, the FASB issued ASU No. 2017-04, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Intangibles &#8211; Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(ASU 2017-04). The new guidance simplifies the subsequent measurement of goodwill by removing the second step of the two-step impairment test. The amendment requires an entity to perform its annual or interim goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity still has the option to perform the qualitative assessment for a reporting unit to determine if the quantitative impairment test is necessary. The new guidance for accelerated filing companies became effective for annual periods or any interim goodwill impairment tests in fiscal years beginning after December 15, 2019 and all other entities should adopt the amendments in this update for its annual or any interim goodwill impairment tests in fiscal years beginning after December 15, 2022. The amendment should be applied on a prospective basis. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company is currently evaluating the impact the adoption of this ASU will have on its consolidated financial statements and related disclosures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p></div><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In July 2021, FASB issued ASU No. 2021-05, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Lease (Topic 842), Lessors - Certain Leases with Variable Lease Payments </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(ASU 2021-05). ASU 2021-05 amends the lease classification requirements for lessors when classifying and accounting for a lease with variable lease payments that do not depend on a reference rate index or a rate. The update provides criteria, that if met, the lease would be classified and accounted for as an operating lease. ASU 2021-05 is effective for reporting periods beginning after December 15, 2021, with early adoption permitted. The Company is currently evaluating the impact of the adoption of this ASU on the Company's consolidated financial statements, but does not believe the adoption of this standard will have a material impact on the Company's consolidated financial statements.</span></span><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"/><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139685484546776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combination<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Business Combination</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">3. Business Combination</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On September 15, 2020, Former Adicet completed its merger with resTORbio. Based on the Exchange Ratio of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1240</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, immediately following the Merger, resTORbio stockholders and holders of resTORbio restricted stock units and options to acquire resTORbio common stock owned approximately </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the outstanding capital stock of the combined company on a fully diluted basis, and Former Adicet stockholders, holders of options or warrants to acquire Former Adicet capital stock owned approximately </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">75.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the outstanding capital stock of the combined company on a fully diluted basis.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">resTORbio&#8217;s stockholders continued to own and hold their existing shares of the Company&#8217;s common stock (after giving effect to the </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1-for-7</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> reverse stock split). Pursuant to the terms of the Merger, the vesting of all outstanding resTORbio stock options was accelerated in full as of immediately prior to the Effective Time. All out-of-the-money resTORbio stock options were cancelled for no consideration. All in-the-money resTORbio stock options remained outstanding after the completion of the Merger in accordance with their terms. For accounting purposes, the Company assumed </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">81,370</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> in-the-money resTORbio stock options after giving effect to reverse stock split. In addition, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">91,309</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> unvested </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">resTORbio restricted stock units outstanding</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">unsettled, after giving effect to reverse stock split, as of immediately prior to the Effective Time of the Merger, were accelerated in full and the holders of such restricted stock units received </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">54,553</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of the Company&#8217;s common stock (after reduction by the number of shares of resTORbio common stock necessary to satisfy applicable tax withholding obligations at the maximum statutory rate). The fair value of these modified stock options and restricted stock units attributable to pre-combination services was recorded as a component of consideration transferred and the fair value of these modified stock options and restricted stock units attributable to post-combination services was recognized as stock compensation expense in the Company&#8217;s consolidated statements of operations and comprehensive loss.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">At the closing of the Merger, all shares of Former Adicet common stock and Former Adicet redeemable convertible preferred stock then outstanding were converted to Former Adicet&#8217;s common stock under their original terms and were then exchanged for the Company&#8217;s common stock.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the Merger, the Company entered into a Contingent Value Rights Agreement (the CVR Agreement) with Computershare Inc. and Computershare Trust Company, N.A. as joint rights agent. Per the terms of the Merger, each holder of resTORbio common stock as of immediately prior to the completion of the Merger is entitled to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> contractual contingent value right, subject to and in accordance with the terms and conditions of the CVR Agreement, for each share of resTORbio common stock held by such holder as of immediately prior to the Effective Time. The CVR holders were entitled to receive net proceeds from the commercialization, if any, from a third-party commercial partner of RTB101, resTORbio&#8217;s small molecule product candidate that is a potent inhibitor of target of rapamycin complex 1 (TORC1), for a COVID-19 related indication.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The total purchase price was allocated to the tangible and intangible assets acquired and liabilities assumed of resTORbio based on their fair values as of the completion of the Merger, with the excess allocated to goodwill. The purchase price is calculated based on the fair value of resTORbio common stock that the resTORbio stockholders owned as of the closing date of the Merger because, with no active trading market for shares of Former Adicet, the fair value of the resTORbio&#8217;s common stock represented a more reliable measure of the fair value of consideration transferred in the Merger. </span><span style="font-size:12.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following summarizes the purchase price in the Merger (in thousands, except share and per share amounts):</span></span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:77.846%;"/>
        <td style="width:2.091%;"/>
        <td style="width:1.577%;"/>
        <td style="width:17.704%;"/>
        <td style="width:0.782%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Fair value of common stock shares of the combined company <br/>&#160;&#160;&#160;owned by resTORbio stockholders (1)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">84,142</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Fair value of contingent consideration liability with respect to CVR (2)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,880</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Purchase price</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">87,022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="margin-left:3.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><div style="display:flex;margin-top:0.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Represents the share consideration of the combined company that the resTORbio stockholders own as of the closing of the Merger calculated as follows:</span></div></div><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:77.785%;"/>
        <td style="width:2.078%;"/>
        <td style="width:1.565%;"/>
        <td style="width:17.508%;"/>
        <td style="width:1.064%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Number of shares of the combined company owned by resTORbio<br/>&#160;&#160;&#160;stockholders (a)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,207,695</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Multiplied by the fair value per share of resTORbio common <br/>&#160;&#160;&#160;stock (b)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16.59</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Acquisition date fair value of resTORbio</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">86,396</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Estimated fair value of modified stock options and restricted stock units attributable to pre-combination services (3)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">626</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: portion of the fair value to be distributed as CVR (c)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,880</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Fair value of shares of the combined company  owned by resTORbio<br/>&#160;&#160;&#160;stockholders</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">84,142</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="margin-left:10.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><div style="margin-left:6.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">a.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Represents the number of shares of common stock of the combined company that the resTORbio stockholders owned as of the closing of the Merger. This amount is calculated as </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">5,207,695</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> shares (post-reverse stock split) of resTORbio common stock outstanding as of September 15, 2020.</span></div></div><div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">b.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The fair value of shares of the combined company owned by resTORbio stockholders is based on the closing price of resTORbio common stock on September 14, 2020.</span></div></div><div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;">c.</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">The fair value of resTORbio common stock was further adjusted to remove the estimated fair value of the CVR embedded within the closing price, as each holder of resTORbio stock received one contractual CVR immediately prior to the Merger.</span></div></div><div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(2)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Each holder of resTORbio common stock as of immediately prior to the completion of the Merger was entitled to one CVR issued by resTORbio, subject to and in accordance with the terms and conditions of the CVR Agreement, for each share of resTORbio common stock held by such holder as of immediately prior to the Effective Time of the Merger.</span></div></div><div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(3)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Based on the capitalization of resTORbio as of September 15, 2020, </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">91,309</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> outstanding unvested resTORbio restricted stock units were accelerated in connection with the Merger and holders of the restricted stock units were issued approximately </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">54,553</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> shares </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">of resTORbio </span></div></div><div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;visibility:hidden;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;"/><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">common </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">stock on a net settlement basis. Similarly, in connection with the Merger, vesting of outstanding resTORbio stock options was accelerated in full and the stock options that were not in the in-the-money on the close of the Merger were canceled, resulting in approximately </span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">81,370</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> surviving stock options. The acquisition date fair value of these modified resTORbio restricted stock units and resTORbio stock options attributable to the pre-combination services is included in the estimated purchase price.</span></div></div><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Merger was accounted for as a business combination which requires that assets acquired, and liabilities assumed be recognized at their fair value as of the acquisition date. While the Company uses its best estimates and assumptions as part of the purchase price allocation process to value the assets acquired and liabilities assumed on the acquisition date, its estimates and assumptions are subject to refinement. Fair value estimates are based on a complex series of judgments about future events and uncertainties and rely heavily on estimates and assumptions. The judgments used to determine the estimated fair value assigned to each class of assets acquired and liabilities assumed, as well as asset lives, can materially impact the Company&#8217;s results of operations.</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following summarizes the allocation of the purchase price to the net tangible and intangible assets acquired (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.38%;"/>
        <td style="width:1.14%;"/>
        <td style="width:1.752%;"/>
        <td style="width:12.157%;"/>
        <td style="width:1.164%;"/>
        <td style="width:1.14%;"/>
        <td style="width:1.801%;"/>
        <td style="width:13.051%;"/>
        <td style="width:1.164%;"/>
        <td style="width:1.14%;"/>
        <td style="width:1.752%;"/>
        <td style="width:12.194%;"/>
        <td style="width:1.164%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As of <br/>December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Measurement Period Adjustments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Final Purchase <br/>Price Allocation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net assets acquired:</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash and cash equivalents</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">63,869</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">63,869</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prepaid expenses and other current assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,059</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">615</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,674</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">318</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">318</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">IPR&amp;D</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,490</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,490</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Restricted cash</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">245</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">245</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accounts payable</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,316</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,304</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued and other current liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,365</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,365</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax liability</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">367</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">367</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Goodwill</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20,089</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">627</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19,462</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Purchase price</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">87,022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">87,022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The goodwill of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million is not tax deductible and represents the excess of the consideration paid over the fair value of assets acquired and liabilities assumed. Goodwill is mainly attributable to the enhanced value of the combined company, as reflected in the increase in market value of the resTORbio common shares following the announcement of the Merger with Former Adicet.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The fair value of acquired IPR&amp;D is related to the research and development of RTB101 for a COVID-19 related indication and was conducted pursuant to resTORbio's license agreement with Novartis (see Note 11). The RTB101 compound IPR&amp;D project was valued using an income approach, specifically a projected discounted cash flow method, adjusted for the probability of technical success (PTS). The projected discounted cash flow models used to estimate the Company&#8217;s IPR&amp;D reflect significant assumptions regarding the estimates a market participant would make in order to evaluate a drug development asset, including the following:</span></p><div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Estimates of potential cash flows to be generated by the project and resulting asset, which was developed utilizing estimates of total patient population, market penetration rates, demand risk adjustment factors, and product pricing; </span></div></div><div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Estimates regarding the timing of and the expected costs of goods sold, research and development expenses, selling, general and administrative expenses to advance the clinical programs to commercialization, cash flow adjustments and partner profit split; </span></div></div><div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The projected cash flows were then adjusted using PTS factors that were selected considering both the current state of clinical development and the nature of the proposed indication, (i.e., respiratory therapeutics); and </span></div></div><div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Finally, the resulting probability adjusted cash flows were discounted to a present value using a risk-adjusted discount rate, developed considering the market risk present in the forecast and the size of the asset. </span></div></div><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">This </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">IPR&amp;D intangible asset is not amortized, but rather is reviewed for impairment on an annual basis or more frequently if indicators of impairment are present, until the project is completed, abandoned, or transferred to a third party. Upon the review of impairment indicators of IPR&amp;D during the second quarter of 2021, the Company concluded that the IPR&amp;D was fully</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">impaired </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">and recorded an impairment charge within research and development expenses in the consolidated statement of operations and comprehensive loss for the remaining balance of the IPR&amp;D intangible asset June 30, 2021. The Company recognized IPR&amp;D impairment charges of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the quarters ended as of December 31, 2020, March 31, 2021, and June 30, 2021. On July 29, 2021, the Company sent Novartis a termination notice. Termination will automatically take effect as of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">60</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> days from the date of delivery of the termination notice to Novartis, but in no event later than October 1, 2021 without any further notice or action required of either Novartis or the Company.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The contingent consideration for the CVR was valued using an income approach, leveraging the probability adjusted discounted cash flow used in the valuation of the IPR&amp;D and then deducting the administrative fee to be retained by the combined company and other permitted deductions in order to arrive at the net cash expected to be paid out to the CVR holders. The probability adjusted cash flow includes significant estimates and assumptions pertaining to commercialization events and cash consideration received by the Company for the grant of rights to commercialize RTB101 during the term of the CVR Agreement (as discussed above). These cash flows were then discounted to present value using the same discount rate applied in the valuation of the IPR&amp;D.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Transaction costs for the Merger were $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the year ended December 31, 2020 and were expensed as incurred in general and administrative expenses in the consolidated statements of operations and comprehensive loss.</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following tables present changes in the Company's IPR&amp;D and CVR since the Merger (in thousands):</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:27.815%;"/>
        <td style="width:1.362%;"/>
        <td style="width:1.196%;"/>
        <td style="width:11.31%;"/>
        <td style="width:0.588%;"/>
        <td style="width:1.362%;"/>
        <td style="width:1.196%;"/>
        <td style="width:11.085%;"/>
        <td style="width:0.794%;"/>
        <td style="width:1.362%;"/>
        <td style="width:1.196%;"/>
        <td style="width:11.281%;"/>
        <td style="width:0.588%;"/>
        <td style="width:1.362%;"/>
        <td style="width:1.196%;"/>
        <td style="width:11.085%;"/>
        <td style="width:0.794%;"/>
        <td style="width:1.362%;"/>
        <td style="width:1.196%;"/>
        <td style="width:11.281%;"/>
        <td style="width:0.588%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Acquisition Date <br/>Fair value as of<br/>September 15, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Change in <br/>Fair value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As of<br/>December 31,<br/>2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Change in <br/>Fair value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As of<br/>December 31,<br/>2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">In-process research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">3,490</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">(</span><span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">2,300</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">1,190</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">(</span><span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">1,190</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.5pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_ba39addf-7250-4185-b821-6a0528ff4070;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">&#8212;</span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">Contingent Value Rights</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">2,880</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">(</span><span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">1,900</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">980</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">(</span><span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">980</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.5pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_53469473-0173-4a8a-bfc4-8856f9b34255;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">&#8212;</span></span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139685484574824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">4. Fair Value Measurements</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company determines the fair value of financial and non-financial assets and liabilities using the fair value hierarchy which establishes three level of inputs that may be used to measure fair value, as follows:</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 1 &#8212; Observable inputs, such as quoted prices in active markets for identical assets or liabilities.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 2 &#8212; Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Level 3 &#8212; Unobservable inputs which reflect management&#8217;s best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#8217;s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability.</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following tables present information about the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands):</span></p><p style="text-indent:7.933%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:46.433%;"/>
        <td style="width:1.005%;"/>
        <td style="width:1.728%;"/>
        <td style="width:10.689%;"/>
        <td style="width:0.735%;"/>
        <td style="width:1.005%;"/>
        <td style="width:1.728%;"/>
        <td style="width:9.157%;"/>
        <td style="width:0.735%;"/>
        <td style="width:1.005%;"/>
        <td style="width:1.728%;"/>
        <td style="width:9.157%;"/>
        <td style="width:0.735%;"/>
        <td style="width:1.005%;"/>
        <td style="width:1.728%;"/>
        <td style="width:10.689%;"/>
        <td style="width:0.735%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level 1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level 2</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level 3</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Money market funds (1)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">147,071</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">147,071</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total fair value of assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">147,071</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">147,071</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:48.026%;"/>
        <td style="width:0.993%;"/>
        <td style="width:1.594%;"/>
        <td style="width:9.745%;"/>
        <td style="width:0.821%;"/>
        <td style="width:1.017%;"/>
        <td style="width:1.594%;"/>
        <td style="width:9.757%;"/>
        <td style="width:0.821%;"/>
        <td style="width:1.017%;"/>
        <td style="width:1.594%;"/>
        <td style="width:8.973%;"/>
        <td style="width:0.821%;"/>
        <td style="width:1.017%;"/>
        <td style="width:1.594%;"/>
        <td style="width:9.794%;"/>
        <td style="width:0.821%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level 1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level 2</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level 3</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Money market funds (1)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">63,817</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">63,817</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Marketable debt securities (2)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Asset-backed securities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">7,522</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">7,522</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Corporate debt securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,762</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,762</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Commercial paper</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,000</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,000</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Marketable debt securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10,284</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10,284</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Total fair value of assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">63,817</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10,284</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">74,101</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Liabilities:</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Contingent consideration</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">980</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">980</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Total fair value of liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">980</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">980</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p><div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Included in cash and cash equivalents in the consolidated balance sheets</span></div></div><div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(2)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Included in short-term marketable debt securities in the consolidated balance sheets.</span></div></div></div><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Money market funds are included within Level 1 of the fair value hierarchy because they are valued using quoted market prices. Corporate debt securities, commercial paper and asset-backed securities are classified within Level 2 of the fair value hierarchy as they take into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income-based and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate the fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data and other observable inputs.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As part of the acquisition of resTORbio, the Company entered into a CVR Agreement and recorded the fair value of the CVR as part of consideration transferred. The Company considers the contingent consideration liability a Level 3 instrument (one with significant unobservable inputs) in the fair value hierarchy. In June 2021, the Company determined the possibility of any commercialization events for RTB101 was close to zero (see Note 3). As a result, the fair value of the CVR liability was adjusted to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">zero</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. On October 27, 2021, the Company provided a Termination Notice under the CVR Agreement to the joint rights agents to terminate its obligations under the CVR Agreement, effective immediately.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139685484610184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Debt Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Marketable Debt Securities</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">5. Marketable Debt Securities</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following tables summarize the Company&#8217;s marketable debt securities (in thousands):</span></p><p style="text-indent:7.933%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:47.571%;"/>
        <td style="width:1.035%;"/>
        <td style="width:1.481%;"/>
        <td style="width:9.946%;"/>
        <td style="width:0.664%;"/>
        <td style="width:1.035%;"/>
        <td style="width:1.481%;"/>
        <td style="width:9.989%;"/>
        <td style="width:0.664%;"/>
        <td style="width:1.035%;"/>
        <td style="width:1.481%;"/>
        <td style="width:9.989%;"/>
        <td style="width:0.664%;"/>
        <td style="width:1.035%;"/>
        <td style="width:1.481%;"/>
        <td style="width:9.782%;"/>
        <td style="width:0.664%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Amortized<br/>Cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Unrealized<br/>Losses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Unrealized<br/>Gains</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Fair<br/>Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Asset-backed securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,507</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,522</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Corporate debt securities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,754</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,762</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">999</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,260</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,284</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:7.933%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes the classification of the Company&#8217;s marketable debt securities in the consolidated balance sheets (in thousands):</span></p><p style="text-indent:7.933%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:73.372%;"/>
        <td style="width:1.089%;"/>
        <td style="width:1.514%;"/>
        <td style="width:9.769%;"/>
        <td style="width:0.708%;"/>
        <td style="width:1.089%;"/>
        <td style="width:1.514%;"/>
        <td style="width:10.237%;"/>
        <td style="width:0.708%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Short-term marketable debt securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,284</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Long-term marketable debt securities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,284</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139685484684696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expense and Other Assets, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_PrepaidExpensesAndOtherCurrentAssetsTextBlock', window );">Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">6. Prepaid Expenses and Other Current Assets</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prepaid expenses and other current assets consisted of the following (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:63.509%;"/>
        <td style="width:1.373%;"/>
        <td style="width:2.116%;"/>
        <td style="width:13.901%;"/>
        <td style="width:0.855%;"/>
        <td style="width:1.373%;"/>
        <td style="width:2.116%;"/>
        <td style="width:13.901%;"/>
        <td style="width:0.855%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prepaid Insurance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,884</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,443</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prepayments to CRO's</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,658</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">420</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prepaid Maintenance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">761</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prepayments to CMO's</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">115</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">135</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other current assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">229</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Tax receivable</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,711</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest receivable</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,709</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,722</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_PrepaidExpensesAndOtherCurrentAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepaid expenses and other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_PrepaidExpensesAndOtherCurrentAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139685484521960">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:13.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">7. Property and Equipment, net</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment, net consisted of the following (in thousands):</span></p><p style="text-indent:7.933%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:40.608%;"/>
        <td style="width:1.47%;"/>
        <td style="width:20.353%;"/>
        <td style="width:1.47%;"/>
        <td style="width:1.752%;"/>
        <td style="width:14.459%;"/>
        <td style="width:1.164%;"/>
        <td style="width:1.47%;"/>
        <td style="width:1.752%;"/>
        <td style="width:14.336%;"/>
        <td style="width:1.164%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As of December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Useful life (years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Laboratory equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,502</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,350</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lesser of useful life<br/>or lease term</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,614</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,427</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furniture and fixtures</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">303</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">524</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Construction in progress</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13,014</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,090</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Computer equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">216</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">93</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Software</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">320</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">170</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">   </span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20,969</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,654</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: Accumulated depreciation and<br/>&#160;&#160;&#160;amortization</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,326</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,864</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14,643</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,790</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:7.933%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Depreciation and amortization expense for each of the years ended December 31, 2021 and 2020 was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively. All of the Company&#8217;s property and equipment as of December 31, 2021 and 2020 is located in the U.S. Construction in progress has increased by $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million due to building construction related to the Company's leased space in Redwood City. Construction in process will continue to increase through the first half of 2022, until completion of construction.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139685484706232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accrued and Other Current Liabilities</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">8. Accrued and Other Current Liabilities</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued and other current liabilities consisted of the following (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:58.84%;"/>
        <td style="width:2.508%;"/>
        <td style="width:2.115%;"/>
        <td style="width:17.974%;"/>
        <td style="width:0.855%;"/>
        <td style="width:2.508%;"/>
        <td style="width:2.115%;"/>
        <td style="width:12.23%;"/>
        <td style="width:0.855%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,833</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued CMO costs</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,077</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">244</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued professional services</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">546</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">363</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued research and development expenses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">504</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">65</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued other liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">503</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">272</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued CRO costs</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">32</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">955</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,682</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,732</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139685484704568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Term Loan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_TermLoanAbstract', window );"><strong>Term Loan [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Term Loan</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">9. Term Loan</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On April 28, 2020, the Company entered into a Loan and Security Agreement with Pacific Western Bank (PacWest) for a term loan not exceeding $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(the Loan Agreement) to finance leasehold improvements for the facilities in Redwood</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">City, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">CA and other purposes permitted under the Loan Agreement, with an interest rate equal to the greater of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.25</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% above the Prime Rate (as defined in the Loan Agreement) or </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%.  The Loan Agreement granted to Pacific Western Bank a security interest on substantially all of the Company&#8217;s assets other than intellectual property to secure the performance of the Company&#8217;s obligations under the Loan Agreement, and contains a variety of affirmative and negative covenants, including required financial reporting, limitations on certain dispositions of assets or distributions, limitations on the incurrence of additional debt or liens and other customary requirements. As of December 31, 2021, the Company was in compliance with such covenants.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the Loan Agreement in April 2020, the Company may request to draw upon the term loan at any time through the date eighteen months after the date of the Loan Agreement (Availability End Date), which was </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">October 28, 2021</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. No amounts were drawn under the Loan Agreement through the Availability End Date.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On October 21, 2021, the Company amended the Loan Agreement with PacWest (the Loan Amendment) under which PacWest will provide one or more Term Loans, as well as Non-Formula Ancillary Services which shall not exceed $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in the aggregate. Non-Formula Ancillary Services are defined as automated clearinghouse transactions, corporate credit card services, letters of credit, or other treasury management services. The aggregate sum of the outstanding Term Loans and Non-Formula Ancillary Services shall at no time exceed $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">which each Term Loan to be in an amount of not less than $1.0 million. As of December 31, 2021, the Company had outstanding Non-Formula Ancillary Services of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. Accordingly, as of December 31, 2021, the Company has $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million available under the Term Loan. Pursuant to the Loan Amendment, the interest rate for the Term Loans shall be set at an annual rate equal to the greater of (i) 0.25% above the Prime Rate then in effect and (ii) 4.25%.</span></span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, the deferred debt issuance costs were $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and are included in other non-current assets on the Company&#8217;s consolidated balance sheets.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_TermLoanAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term loan abstract [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_TermLoanAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139685491162680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Regeneron License and Collaboration Arrangement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract', window );"><strong>Revenue Recognition and Deferred Revenue [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Regeneron License and Collaboration Arrangement</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">10. Regeneron License and Collaboration Arrangement</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Agreement Terms</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On July 29, 2016, the Company entered into a license and collaboration agreement with Regeneron, which was amended in April 2019, with such amendment becoming effective in connection with Regeneron&#8217;s investment in the Company&#8217;s Series B redeemable convertible preferred stock private placement transaction in July 2019 (as amended, the Regeneron Agreement).</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Agreement Structure</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Regeneron Agreement has two principal components: (a) a research collaboration component under which the parties will research, develop, and commercialize next-generation engineered gamma delta immune cell therapeutics (ICPs), namely engineered gamma delta immune cells with CARs and TCRs directed to disease-specific cell surface antigens, which includes the grant of certain licenses to intellectual property between the two parties, and (b) for a certain period following the effective date, a license to the Company to use certain of Regeneron&#8217;s proprietary mice to develop and commercialize ICPs generated by the Company, with certain limitations relating to targets under the Regeneron Agreement.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research Collaboration</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Research activities under the collaboration are governed by research plans, which include the strategy, goals, activities, and responsibilities of the parties with respect to a target. The Company is primarily responsible for generating, validating, and optimizing ICPs, developing processes for manufacture of ICPs, and certain preclinical and clinical manufacturing activities for ICPs; Regeneron&#8217;s key responsibility is generating, validating, and optimizing CARs and TCRs that bind to the applicable target. The parties have formed a joint research committee to monitor and govern the research and development efforts during the research program term.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Rights to Research Targets</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Under the terms of the collaboration, the parties will conduct research on mutually agreed upon targets. Regeneron may obtain exclusive rights for the targets that it chooses in accordance with the target selection mechanism set forth in the Regeneron Agreement, and the Company similarly may obtain exclusive rights for targets it chooses in accordance with such target selection mechanism. The Company has the right to develop and commercialize ICPs to the first collaboration target to come out of the research program. On January 28, 2022, the Company received a payment of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million from Regeneron for exercise of its option to license exclusive rights to ADI-002 and Regeneron potentially has additional options to other ICP targets under the Regeneron Agreement. Pursuant to the Agreement with Regeneron, the Company had the right to elect to co-fund ADI-002's future development costs. The Company did not elect its option. For those targets it does not have an option to license, Regeneron has a right of first negotiation for up to two targets. Regeneron has the right to terminate the research program in its entirety (a) for convenience on six months prior written notice given at any time after December 31, 2019, or (b) following a change of control (as defined in the Regeneron Agreement) of the Company. The parties mutually agreed to their first product declaration criteria for collaboration ICP, CD20, in 2018.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Rights to Company-Developed Targets</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Regeneron has an exclusive license to use targeting moieties generated by the Company by its use of Regeneron&#8217;s proprietary mice to develop and commercialize non-ICPs.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Exclusivity</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. During the five-year target selection period that expired in July 2021, the Company may not directly or indirectly research, develop, manufacture or commercialize an ICP, or grant a license to do the foregoing, except pursuant to the agreement. For so long as either party is researching or developing an ICP to a target under the research program, neither party may research, develop, manufacture or commercialize any other ICP to such target, or grant a license to do the foregoing. And for so long as a party is researching, developing or commercializing an ICP to target that is licensed to it (and royalty bearing) under the agreement, neither party may research, develop, manufacture or commercialize any other ICP to such target, or grant a license to permit another party to do the foregoing. These exclusivity obligations are limited to engineered gamma delta immune cells to targets reasonably considered to have therapeutic relevance in oncology. The Regeneron Agreement includes certain exceptions to the exclusivity obligations of the parties, including with respect to targets that are rejected by one party in the target selection process, as well as protections in the event of a change of control of a party where the acquirer has a competing program.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Co-Funding and Profit Sharing</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Company has an option to co-fund specified portions of the future development costs for, and to co-promote, ICPs to a target for which Regeneron has exercised an option, and to participate in the profits for such target. The Company has the right to exercise this right in various geographic regions, including on a worldwide basis. In the event the Company exercises such right, the parties will share further development costs and profits proportionally to their co-funding percentages.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Financial Terms</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Company received a non-refundable upfront payment of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million from Regeneron upon execution of the Regeneron Agreement and has received an aggregate of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of additional payments for research funding from Regeneron as of December 31, 2021. In addition, Regeneron may have to pay the Company additional amounts in the future consisting of up to an aggregate of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">80.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of option exercise fees for a certain number of collaboration ICPs, as specified in the Regeneron Agreement. Regeneron must also pay the Company high single digit royalties as a percentage of net sales for ICPs to targets for which it has exclusive rights, and low single digit royalties as a percentage of net sales on any non-ICP product comprising a targeting moiety generated by the Company through the use of Regeneron&#8217;s proprietary mice. The Company must pay Regeneron mid-single to low double digit, but less than teens, of royalties as a percentage of net sales of ICPs to targets for which the Company has exercised exclusive rights, and low to mid-single digit of royalties as a percentage of net sales of targeting moieties generated from the Company&#8217;s license to use Regeneron&#8217;s proprietary mice. Royalties are payable until the longer of the expiration or invalidity of the licensed patent rights or </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">twelve (12) years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> from first commercial sale.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Other Terms</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Regeneron Agreement contains customary representations, warranties and covenants by the Company and Regeneron and includes (i) an obligation of the Company to use commercially reasonable efforts to develop and commercialize at least one product based on a collaboration ICP that is not an optioned collaboration ICP for each collaboration target and (ii) an obligation of Regeneron to use commercially reasonable efforts to develop and commercialize at least one product based on an optioned collaboration ICP for each collaboration target. The Company and Regeneron are required to indemnify the other party against all losses and expenses related to breaches of its representations, warranties and covenants under the Regeneron Agreement.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Term and Termination</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The term of the Regeneron Agreement expires, on a product-by-product basis, on the expiration of the obligation to pay royalties for such product. The Regeneron Agreement is subject to early termination by either party upon uncured material breach by the other party. The licenses to develop and commercialize an ICP to a target that one party has exclusively licensed may be terminated by such party for convenience.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Equity Investments</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. In connection with its collaboration, Regeneron and the Company entered into a side letter pursuant to which, among other matters, Regeneron was granted certain stockholder rights and investment rights in connection with the Company&#8217;s next equity financing that met certain criteria and in connection with an initial public offering by the Company. Regeneron exercised its investment right and purchased approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of the Company&#8217;s Series B redeemable convertible preferred stock in a private placement transaction in July 2019. The remaining obligations under the side letter agreement terminated immediately prior to the Effective Time of the Merger.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Revenue Recognition</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company identified the following material promises under the Regeneron Agreement: (1) a research license, (2) a collaboration invention license, (3) a trademark license, (4) research and development services during the research term, (5) manufacturing services to manufacture collaboration ICPs for the research programs, (6) participation in the joint research committee, and (7) information sharing during the research term. The Company considered that the licenses granted under the Regeneron Agreement are not capable of being distinct and are not distinct from the research and development and manufacturing services within the context of the Regeneron Agreement, because 1) such licenses are for the research and development effort during the research term, unless Regeneron exercises its option under the Regeneron Agreement, 2) the research and development services significantly increase the utility of such licenses, and 3) research and development services require collaboration ICPs being manufactured. Specifically, the Company&#8217;s granted licenses can only provide benefit to Regeneron in combination with the Company&#8217;s research and development and manufacturing services to discover the collaboration ICPs. Similarly, the participation in the joint research committee and information sharing are not capable of being distinct and are not distinct from</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the research and development and manufacturing services within the context of the agreement, because the participation in the joint research committee is for monitoring and governing of the research and development efforts and the information sharing is for sharing results of such research and development efforts. Therefore, all of the promises above are combined into a single performance obligation.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company also evaluated whether the option provided to Regeneron represents a material right that would require separate deferral and recognition. The option exercise will provide Regeneron with a development and commercial license to develop and commercialize the optioned collaboration ICPs. The Company concluded that the $25.0 million upfront payment to the Company was not negotiated to provide incremental discount for the future option fees payable upon Regeneron&#8217;s exercise of the option.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Regeneron could decide not to exercise the option at its own discretion. The exercise of the option by Regeneron is not certain and is dependent on many factors, such as progress made on the specific option-eligible collaboration ICP, Regeneron&#8217;s overall assessment of commercial feasibility of the further research, development and commercialization of the Option products, availability and cost of alternative programs and products. The option provides Regeneron with a license for intellectual property that will be improved from the inception of the Regeneron Agreement. In addition, the option fee is significant compared to the sum total of the upfront payment and research funding fees in the original Regeneron Agreement. Therefore, the Company determined that the option provided to Regeneron does not represent a material right and that any potential exercise of the option should be accounted as a separate contract. Hence, upon the option exercise by Regeneron the option fee would be allocated to the development and commercial license which would be the only performance obligation in that separate contract and recognized as revenue when control of the license rights is transferred to Regeneron.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For revenue recognition purposes, the Company determined that the duration of the contract is the same as the research term of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">five years</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> beginning on the execution of the Regeneron Agreement on July 29, 2016. The contract duration is defined as the period during which parties to the contract have present and enforceable rights and obligations. For revenue recognition purposes, the five-year term has been extended to the first quarter of 2022 due to additional time required to complete the performance obligation under the Regeneron Agreement. The Company determined that Regeneron faces significant in-substance penalties were it to terminate the Regeneron Agreement prior to the end of the research term.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">At contract inception, the Company determined the transaction price of the Regeneron Agreement to be $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">55.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, consisting of the $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million upfront payment and the aggregate research funding fees of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million payable over the research term. In order to determine the transaction price, the Company evaluated all the payments to be received during the duration of the contract. Per the terms of the original Regeneron Agreement prior to the amendment effective from July 2019, the research funding fees of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million were payable merely due to the passage of time and therefore did not represent a variable consideration. After the amendment became effective in July 2019, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of these fees became contingent upon meeting certain development and regulatory milestones. Therefore, the Company concluded that after the amendment such potential payments became variable consideration. The receipt of the variable consideration was subject to substantial uncertainty and was therefore excluded from the transaction price upon the effective date of the amendment. Accordingly, the transaction price was reduced to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">35.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in July 2019. The Company re-evaluates the transaction price if there is a significant change in facts and circumstances at least at the end of each reporting period. The Company increased the transaction price by $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in June 2020 to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">45.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million when it achieved the milestone for the selection of a clinical candidate to the second collaboration target under the Regeneron Agreement, resulting in the recognition of an additional $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in revenue during the three months ended June 30, 2020.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company also considered the existence of any significant financing component within the Regeneron Agreement given its upfront payment structure. Based upon this assessment, the Company concluded that the up-front payment was provided for valid business reasons and not for the purpose of providing financing. The reason for the initial advance payment at the beginning of the contract is not to provide financing to the Company, but to ensure Regeneron&#8217;s commitment to the contract and to provide assurance that the customer will perform its obligations under the contract. Accordingly, the Company has concluded that the upfront payment structure of the Regeneron Agreement does not result in the existence of a significant financing component.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The royalty payments will be recognized when the related sales occur as they were determined to relate predominantly to the intellectual property licenses granted to Regeneron and therefore have also been excluded from the transaction price.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has determined that the combined performance obligation is satisfied over time. ASC 606 requires the Company to select a single revenue recognition method for the performance obligation that depicts the Company&#8217;s performance in transferring control of the services. Accordingly, the Company utilizes a cost-based input method to measure proportional performance and to calculate the corresponding amount of revenue to recognize. The Company believes this is the best measure of progress because it reflects how the Company transfers its performance obligation to Regeneron. In applying the cost-based input method of revenue recognition, the Company uses actual costs incurred relative to budgeted costs to fulfill the combined performance obligation. These costs consist primarily of internal full-time equivalent effort and third-party contract costs. Revenue is recognized based on actual costs incurred as a percentage of total budgeted costs as the Company completes its</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">performance obligations over the research term of five years. A cost-based input method of revenue recognition requires management to make estimates of costs to complete the Company&#8217;s performance obligations. In making such estimates, significant judgment is required to evaluate assumptions related to cost estimates. The cumulative effect of revisions to estimated costs to complete the Company&#8217;s performance obligations will be recorded in the period in which changes are identified and amounts can be reasonably estimated. A significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods.</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table presents changes in the Company&#8217;s contract liabilities (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:47.822%;"/>
        <td style="width:1.089%;"/>
        <td style="width:1.492%;"/>
        <td style="width:9.475%;"/>
        <td style="width:0.882%;"/>
        <td style="width:1.089%;"/>
        <td style="width:1.492%;"/>
        <td style="width:9.464%;"/>
        <td style="width:0.882%;"/>
        <td style="width:1.089%;"/>
        <td style="width:1.525%;"/>
        <td style="width:9.802%;"/>
        <td style="width:0.991%;"/>
        <td style="width:1.089%;"/>
        <td style="width:1.492%;"/>
        <td style="width:9.431%;"/>
        <td style="width:0.893%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year ended December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Balance at beginning <br/>of period</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Additions</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Additions (Deductions) </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;font-family:Times New Roman;position:relative;">(1)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Balance at<br/>end of <br/>period</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Contract liability</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13,980</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,175</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,805</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">    </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year ended December 31, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Balance at beginning <br/>of period</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Additions</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Additions (Deductions) </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;font-family:Times New Roman;position:relative;">(1)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Balance at<br/>end of <br/>period</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Contract asset</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,000</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,000</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Contract liability</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21,883</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17,903</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13,980</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:6.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(1)	Deductions to contract liabilities relate to deferred revenue recognized as revenue during the reporting period.</span></p></div><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, contract liabilities related to the Regeneron Agreement of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million was comprised of the $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million upfront payment, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in total research funding fees for fiscal years 2017 and 2018, and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for achievement of the milestone for the selection of a clinical candidate for the second collaboration target in June 2020, less $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">40.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of cumulative license and collaboration revenue recognized from the inception of the Regeneron Agreement as of December 31, 2021 and will be recognized as the combined performance obligation is satisfied.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2020, contract liabilities related to the Regeneron Agreement of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million was comprised of the $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million upfront payment, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in total research funding fees for fiscal years 2017 and 2018, and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for achievement of the milestone for the selection of a clinical candidate to the second collaboration target in June 2020, less $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">31.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of cumulative license and collaboration revenue recognized from the inception of the Regeneron Agreement as of December 31, 2020.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For the years ended December 31, 2021 and 2020, the Company recognized $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of license and collaboration revenue, respectively, from amounts included in the contract liability balances at the beginning of the period. There were no costs to obtain or fulfill the contract that meet the criteria to be capitalized.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionAndDeferredRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139685491197784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Funding and Other Agreements Related to the CVR<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_LicenseFundingAndOtherAgreementsAbstract', window );"><strong>License Funding And Other Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_LicenseFundingAndOtherAgreementsTextBlock', window );">License, Funding and Other Agreements Related to the CVR</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">11. License, Funding and Other Agreements Related to the CVR</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Contingent Value Rights Agreement</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As discussed in Note 3, in connection with the Merger, the Company entered into the CVR Agreement with Computershare Inc. and Computershare Trust Company, N.A. as joint rights agent. The CVR holders are entitled to receive net proceeds from the commercialization, if any, received from a third-party commercial partner of RTB101 for a COVID-19 related indication. The total fees and expenses of the Company&#8217;s clinical trials for a COVID-19 related indication of RTB101 is limited to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million under the CVR Agreement. Through October 31, 2020, the Company&#8217;s total accumulated spend was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of expenses. In November 2020, management terminated the nursing home study due to slow enrollment and as a consequence lowered the probability of finding a partner due to the delay in time to commercialization of RTB101.</span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> In February 2021, management terminated the National Institute on Aging study of RTB101 for COVID-19 post-exposure prophylaxis in adults age 65 years and older due to poor enrollment</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. In March 2021, management estimated that the probability of finding a partner should be further reduced. As a result, the fair value of the CVR liability was decreased by $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. In June 2021, the Company determined the possibility of any commercialization events for RTB101 was close to zero (see Note 3). As a result, the fair value of the CVR liability was adjusted to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">zero</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On October 27, 2021, the Company provided a Termination Notice under the CVR Agreement to the joint rights agent to terminate its obligations under the CVR Agreement, effective immediately.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Novartis License Agreement</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On March 23, 2017, resTORbio entered into an exclusive license agreement with Novartis International Pharmaceutical Ltd. (Novartis). Under the agreement, Novartis granted resTORbio an exclusive, field-restricted, worldwide license, to certain</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">intellectual property rights owned or controlled by Novartis, to develop, commercialize and sell one or more therapeutic products comprising RTB101 or RTB101 in combination with everolimus in a fixed dose combination. The exclusive field under the license agreement is for the treatment, prevention and diagnosis of disease and other conditions in all indications in humans and animals.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The agreement may be terminated by either party upon a material breach of obligation by the other party that is not cured with 60 days after written notice. resTORbio may terminate the agreement in its entirety or on a product-by-product or country-by-country basis with or without cause with 60 days&#8217; prior written notice.</span></span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As consideration for the license, resTORbio is required to pay up to an aggregate of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million upon the satisfaction of clinical milestones, up to an aggregate of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million upon the satisfaction of regulatory milestones for the first indication approved, and up to an aggregate of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">18</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million upon the satisfaction of regulatory milestones for the second indication approved. In addition, resTORbio is required to pay up to an aggregate of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">125</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million upon the satisfaction of commercial milestones, based on the amount of annual net sales. resTORbio is also required to pay tiered royalties ranging from a mid-single digit percentage to a low-teen digit percentage on annual net sales of products. These royalty obligations last on a product-by-product and country-by-country basis until the latest of (i) the expiration of the last valid claim of a Novartis patent covering a subject product, (ii) the expiration of any regulatory exclusivity for the subject product in a country, or (iii) the 10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;">th</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> anniversary of the first commercial sale in the country, and are subject to a reduction after the expiration of the last valid claim of a Novartis patent or the introduction of a generic equivalent of a product in a country.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On July 27, 2021, the Company sent Novartis a termination notice. Termination automatically took effect on September 25, 2021, 60 days from the date of delivery of the termination notice to Novartis, without further notice of action required of either Novartis or the Company.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">National Institute of Health</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In May 2019, resTORbio was awarded a </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">-year grant for up to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million from the NIH to study RTB101 and the regulation of antiviral immunity in the elderly. resTORbio is entitled to use the award solely to conduct the research and is solely responsible for commencing and conducting the research and will furnish periodic progress updates to the NIH throughout the term of the award. After completing the research, resTORbio must provide the NIH with a formal report describing the work performed and the results of the research.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For funds received under the NIH funding agreement, resTORbio recognizes a reduction in research and development expenses in an amount equal to the qualifying expenses incurred in each period up to the amount funded by the NIH. Qualifying expenses incurred by resTORbio in advance of funding by the NIH are recorded in the consolidated balance sheets as other current assets. For the year ended December 31, 2021, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million qualifying expenses have been incurred and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million have been funded by the NIH. The difference in the amount incurred by the Company and funded by the NIH was due to timing of requesting reimbursements from the NIH. On a cumulative basis as of December 31, 2021, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million has been incurred and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million has been funded by the NIH.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_LicenseFundingAndOtherAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License funding and other agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_LicenseFundingAndOtherAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_LicenseFundingAndOtherAgreementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License funding and other agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_LicenseFundingAndOtherAgreementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139685484659304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingences<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingences</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">12. Commitments and Contingencies</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Operating Leases</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company leases office and laboratory space in Menlo Park, CA, Redwood City, CA, and Boston, MA. As of December 31, 2021, except as described below, there have been </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> material changes in lease obligation from those disclosed in Note 12 to consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2020.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On June 25, 2021, </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the Company entered into an amendment to the Menlo Park lease to extend the term of the lease from March 31, 2022 to June 30, 2022 and replace the previously leased premises (known as 173 and 175-177 Jefferson Drive) with another nearby premises (known as 235 Constitution Drive).</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The lease commenced on </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">July 15, 2021</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> and expires on </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">June 30, 2022</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. In connection with these changes, the Company will incur monthly rent payments ranging from $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">87,286</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">89,904</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">, increasing over the remaining term of the lease. Given the lease is short-term in nature, the Company is using the practical expedient for the lease and has not recorded a right of use asset or lease liability. Therefore, the Company will recognize rent expense on a straight-line basis over the lease term.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On July 19, 2021, the Company entered into a Sublease (the Sublease Agreement) with RFS OPCO LLC (Sublessee), whereby the Company agreed to sublease to Sublessee all of the </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,501</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> rentable square feet of office space in Boston, MA, currently leased by the Company pursuant to the Company&#8217;s lease with 500 Boylston &amp; 222 Berkeley Owner (DE) LLC, dated January 8, 2018, as amended (the Master Lease). </span><span style="font-size:12.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">term of the sublease started on September 1, 2021 and ends on July 30, </span></span><span style=""/></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2026. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The aggregate base rent due to the Company under the Sublease is approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million starting October 1, 2021. The Company records sublease income as a reduction of lease expense. </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Upon execution of the Sublease Agreement, the Company received a cash security deposit of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million from the Subleasee which is recorded as other non-current liabilities in the consolidated balance sheets. </span><span style="font-size:12.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The expected undiscounted cash flows to be received from the sublease as of December 31, 2021 is as follows (in thousands):</span></span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:74.179%;"/>
        <td style="width:2.254%;"/>
        <td style="width:1.284%;"/>
        <td style="width:21.646%;"/>
        <td style="width:0.637%;"/>
       </tr>
       <tr>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">657</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2023</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">671</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2024</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">685</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2025</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">699</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2026</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">416</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,128</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company recognized rent expense, net of sublease income, of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the years ended December 31, 2021 and 2020, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The IBR and the remaining lease terms of our facilities and their weighted average IBR and remaining terms are as follows as of December 31, 2021:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:40.659%;"/>
        <td style="width:2.429%;"/>
        <td style="width:27.242%;"/>
        <td style="width:2.429%;"/>
        <td style="width:27.242%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Lease Locations</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">IBR</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Remaining Terms<br/>(in years)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Redwood City, CA</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.90</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.2</span></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Boston, MA</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.30</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.6</span></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Menlo Park, CA</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.80</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.5</span></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted Average</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.20</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.7</span></span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:11.0pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table contains a summary of the lease costs recognized under ASC 842 and other information pertaining to the Company&#8217;s operating leases for the years ended December 31, 2021 and 2020:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.395%;"/>
        <td style="width:2.168%;"/>
        <td style="width:1.503%;"/>
        <td style="width:21.795%;"/>
        <td style="width:0.991%;"/>
        <td style="width:1.503%;"/>
        <td style="width:21.958%;"/>
        <td style="width:0.686%;"/>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="5" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Lease Cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,282</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">894</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Short-term lease cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">235</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">56</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Variable lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Sublease Income</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">223</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_a0789779-e166-43dd-bd77-089b6487a8c3;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,294</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">950</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Other Information</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating cash flows used for lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">511</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">859</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease right of use asset obtained in exchange of operating lease liability</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_819eaa0a-0a31-4f5b-b68e-5e64ffc6ff53;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22,367</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></div><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, operating right-of-use assets were $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and operating lease liabilities were $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. The Company has no material finance leases.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The maturities of the operating lease liabilities as of December 31, 2021 were as follows (in thousands):</span></span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.062%;"/>
        <td style="width:1.774%;"/>
        <td style="width:1.277%;"/>
        <td style="width:16.252%;"/>
        <td style="width:0.634%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2022</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,933</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,428</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2024</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,525</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,625</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2026 and thereafter</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13,747</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total undiscounted lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27,258</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: imputed interest</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,314</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total operating lease liability</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20,944</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: current portion</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,567</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease liability, net of current maturities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19,377</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:2.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></div><p style="text-indent:3.333%;font-size:10.0pt;margin-top:2.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company maintains letters of credit of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in connection with the Company&#8217;s office leases in Redwood City, CA, Menlo Park, CA, and  Boston, MA, respectively. As of December 31, 2021, the cash amount associated with the Menlo Park Lease is recorded as restricted cash on the consolidated balance sheet. As of December 31, 2020, all cash amounts are recorded as restricted cash on the consolidated balance sheet.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Indemnification Agreements</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third-party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. The Company has never incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. The Company has also entered into indemnification agreements with its directors and officers that require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers to the fullest extent permitted by Delaware corporate law. The Company currently has directors&#8217; and officers&#8217; liability insurance.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Legal Proceedings</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the Merger, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">seven</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> lawsuits were filed against the Company, its directors, Former Adicet, and/or Merger Sub. which were either dismissed or settled for of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in the fourth quarter of 2020.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139685484666072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Common Stock</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">13. Stockholders' Equity</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Common Stock</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Common stockholders are entitled to dividends if and when declared by the Board of Directors subject to the prior rights of the preferred stockholders. As of December 31, 2021 and 2020, no dividends on common stock had been declared by the Board of Directors.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In February 2021, the Company completed an underwritten public offering of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,575,513</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of its common stock at a public offering price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share. The Company received net proceeds from the offering, after deducting underwriting discounts and commissions and offering expenses of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">128.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the February 2021 offering, </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the Company also entered into a stock purchase agreement with certain existing investors to purchase </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,153,840</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of our common stock for  $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million at a price per share equal to the public offering price, with an initial closing for investors held simultaneously with the closing of the offering and a subsequent closing for certain additional investors.</span></span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2021, the Company closed an underwritten public offering, or the December 2021 Follow-On Offering, of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,187,500</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of its common stock at a public offering price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14.00</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share. The Company received net proceeds from the offering, after deducting underwriting discounts and commissions and offering expenses of approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">94.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million.</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has the following shares of common stock reserved for future issuance:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:63.237%;"/>
        <td style="width:1.656%;"/>
        <td style="width:0.637%;"/>
        <td style="width:15.452%;"/>
        <td style="width:0.637%;"/>
        <td style="width:1.656%;"/>
        <td style="width:0.637%;"/>
        <td style="width:15.452%;"/>
        <td style="width:0.637%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock options available for future grant</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,961,338</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,739,621</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock options issued and outstanding</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,875,317</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,706,945</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unvested restricted stock units</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">771,660</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Common stock warrants issued and outstanding</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">220,890</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">226,191</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total common stock reserved</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,829,205</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,672,757</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Warrants to Purchase Shares of Common Stock</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In February 2021, PacWest exercised 5,301 warrants, which resulted in the net issuance was 1,806 shares of common stock.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following provides a roll forward of outstanding warrants:</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:53.616%;"/>
        <td style="width:1.588%;"/>
        <td style="width:0.578%;"/>
        <td style="width:12.525%;"/>
        <td style="width:0.764%;"/>
        <td style="width:1.588%;"/>
        <td style="width:1.147%;"/>
        <td style="width:12.191%;"/>
        <td style="width:0.568%;"/>
        <td style="width:1.588%;"/>
        <td style="width:0.578%;"/>
        <td style="width:12.701%;"/>
        <td style="width:0.568%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Number of <br/>Warrants</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted<br/>Average<br/>Exercise<br/>Price</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted<br/>Average<br/>Contractual<br/>Term (Years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Outstanding and exercisable warrants to purchase<br/>&#160;&#160;&#160;preferred shares as of December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">226,191</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">11.3177</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">5.66</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Issued</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">5,301</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Outstanding and exercisable warrants to purchase<br/>&#160;&#160;&#160;common stock as of December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">220,890</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">11.3177</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">4.66</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, the Company's outstanding warrants to purchase shares of common stock consisted of the following:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:21.212%;"/>
        <td style="width:1.5%;"/>
        <td style="width:0.627%;"/>
        <td style="width:20.574%;"/>
        <td style="width:0.627%;"/>
        <td style="width:1.5%;"/>
        <td style="width:1.284%;"/>
        <td style="width:13.782%;"/>
        <td style="width:0.627%;"/>
        <td style="width:1.5%;"/>
        <td style="width:15.419%;"/>
        <td style="width:1.5%;"/>
        <td style="width:19.849%;"/>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"><br/>Issuance Date</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Number of<br/>Shares of<br/>Common<br/>Stock Issuable</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Exercise<br/>Price</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Classification</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Expiration Date</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">September 15, 2020</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101,610</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11.3177</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Equity</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">July 25, 2026</span></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">September 15, 2020</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30,924</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11.3177</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Equity</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">August 21, 2026</span></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">September 15, 2020</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">77,312</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11.3177</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Equity</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">September 19, 2026</span></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">September 15, 2020</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,044</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11.3177</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Equity</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">September 26, 2026</span></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">220,890</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139685484722968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>At-the-Market (ATM) Offering<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_AtTheMarketOfferingTextBlock', window );">At-the-Market (ATM) Offering</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">14. At-the-Market (ATM) Offering</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On December 1, 2020, the Company entered into a Sales Agreement (the 2020 Sales Agreement) with Evercore Group L.L.C. and H.C. Wainwright &amp; Co., LLC (collectively, the Agents), pursuant to which the Company may sell, from time to time, at its option, up to an aggregate of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">50.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of shares of the Company&#8217;s common stock, through the Agents, as its sales agents. No sales of Shares have been made under the 2020 Sales Agreement. The ATM offering was terminated in </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">February 2021</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On March 12, 2021, the Company entered into a Sales Agreement (the 2021 Sales Agreement) with</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">JonesTrading Institutional Services (the Agent), pursuant to which the Company could sell, from time to time, at its option, up to an aggregate of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">75.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of shares of its common stock, through the Agent, as its sales agent. No shares were sold under the 2021 Sales Agreement as of December 31, 2021.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_AtTheMarketOfferingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>At the market offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_AtTheMarketOfferingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139685484680248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">15. Stock-Based Compensation</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock-based Compensation Expense</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table presents stock-based compensation expense as reflected in the Company's consolidated statements of operations and comprehensive loss (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.807%;"/>
        <td style="width:1.49%;"/>
        <td style="width:1.284%;"/>
        <td style="width:13.201%;"/>
        <td style="width:0.627%;"/>
        <td style="width:1.49%;"/>
        <td style="width:1.284%;"/>
        <td style="width:13.191%;"/>
        <td style="width:0.627%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,759</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,674</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,752</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,589</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total stock-based compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12,511</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,263</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Summary of Plans</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Plans are administered by the Board of Directors or, at the discretion of the Board of Directors, by a committee of the Board of Directors. The exercise prices, vesting and other restrictions are determined at the discretion of the Board of Directors, or its committee if so delegated, except that the exercise price per share of stock options may not be less than 100% of the fair market value of the share of common stock on the date of grant and the term of the stock option may not be greater than ten years. Incentive stock options granted to employees and restricted stock awards granted to employees, officers, members of the Board of Directors, advisors, and consultants of the Company typically vest over four years. Non-statutory options granted to employees, officers, members of the Board of Directors, advisors, and consultants of the Company typically vest over three or four years. Shares that are expired, terminated, surrendered or canceled under the Plans without having been fully exercised will be available for future awards. In addition, shares of common stock that are tendered to the Company by a participant to exercise an award are added to the number of shares of common stock available for the grant of awards.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The 2017 Plan and 2018 Plan</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In 2017, resTORbio adopted the 2017 Plan. In connection with resTORbio&#8217;s initial public offering completed in January 2018, the resTORbio Board adopted and resTORbio&#8217;s stockholders approved the 2018 Plan. The 2018 Plan provides that the number of shares reserved and available for issuance under the plan will automatically increase each January 1, beginning on January 1, 2019, by </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the outstanding number of shares of resTORbio&#8217;s common stock on the immediately preceding December 31 or such lesser number of shares as determined by the Board. On April 27, 2021, the stockholders approved an amendment and restatement of the 2018 Stock Option and Incentive Plan, to, among other things, increase the aggregate number of shares authorized for issuance under the 2018 Plan by </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,500,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares, plus on January 1, 2022 and each January 1, thereafter, the number of shares authorized for issuance shall be increased by the lesser of 5% of the number of shares of Common Stock issued and outstanding on the immediately preceding December 31, or such lesser number as determined by the compensation committee. On January 1, 2022, the number of shares reserved and available for issuance under the 2018 Plan automatically increased by </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,986,845</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of Common Stock equal to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the number of shares of Common Stock issued and outstanding on December 31, 2021.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Since the date of effectiveness of the 2018 Plan, resTORbio has not and the Company will not grant any further awards under the 2017 Plan. However, any shares of common stock subject to awards under the 2017 Plan that expire, terminate, or otherwise are surrendered, canceled, forfeited or repurchased without having been fully exercised or resulting in any common stock being issued will become available for issuance under the 2018 Plan. As of December 31, 2021, there are no outstanding options under the 2017 Plan.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, the number of shares of common stock available for grant under the 2017 and 2018 Plan is </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,683,999</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. As of December 31, 2021, an aggregate of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,574,170</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock were issuable upon the exercise of outstanding stock options under the 2017 Plan and 2018 Plans at a weighted average exercise price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15.10</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share. In addition to this amount, as of December 31, 2021, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">771,660</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock were issuable upon the vesting of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,410</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> performance stock units (PSUs) granted in May 2021, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">205,250</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> RSUs granted in August 2021, and </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">560,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> RSUs and PSUs granted in October 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">The 2014 Plan and 2015 Plan</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, the number of shares of common stock available for grant under the 2014 and 2015 Plan is </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">277,339</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, an aggregate of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">915,657</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock were issuable upon the exercise of outstanding stock options under the 2015 plan at a weighted average exercise price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11.46</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share and an aggregate of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22,987</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of common stock were issuable upon the exercise of outstanding stock options under the 2014 Plan at a weighted average exercise price of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.61</span><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Since the date of effectiveness of the Merger, the Company has not and will not grant any further awards under the 2014 Plan.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">2018 Employee Stock Purchase Plan</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The 2018 ESPP provides that the number of shares reserved and available for issuance will automatically increase each January 1, beginning on January 1, 2019 and increasing each January 1 thereafter through January 1, 2028, by the least of (i) </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the outstanding number of shares of the Company&#8217;s common stock on the immediately preceding December 31; (ii) </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">77,703</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares or (iii) such number of shares as determined by the ESPP administrator.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> On January 1, 2020, as a result of the foregoing evergreen provision, the number of shares of common stock available for issuance under the 2018 ESPP automatically increased from </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">79,369</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">131,432</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares. </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On January 1, 2021, as a result of the</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">foregoing </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">evergreen provision, the number of shares of common stock available for issuance under the 2018 ESPP automatically increased from </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">131,432</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">524,775</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. During the 2021 Annual Meeting of the stockholders held on April 27, 2021, the stockholders approved an amendment and restatement of the Company's 2018 ESPP. As a result, the Company increased the shares available for issuance under the 2018 ESPP to </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">524,775</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For the year ended December 31, 2021 the Company issued a total of </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15,667</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares under the 2018 ESPP. Expense related to the issuance of such shares was less than $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">No</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares were issued under the 2018 ESPP during the year ended December 31, 2020.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock Options</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A summary of stock option activity is set forth below (in thousands, except share and per share data):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:89.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:40.835%;"/>
        <td style="width:0.672%;"/>
        <td style="width:12.503%;"/>
        <td style="width:0.903%;"/>
        <td style="width:1.179%;"/>
        <td style="width:1.344%;"/>
        <td style="width:12.128%;"/>
        <td style="width:0.595%;"/>
        <td style="width:1.179%;"/>
        <td style="width:0.661%;"/>
        <td style="width:12.569%;"/>
        <td style="width:0.595%;"/>
        <td style="width:1.179%;"/>
        <td style="width:1.344%;"/>
        <td style="width:11.721%;"/>
        <td style="width:0.595%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;">Outstanding Awards</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;">Number of<br/>Shares<br/>Underlying<br/>Outstanding<br/>Options</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;">Weighted<br/>Average<br/>Exercise<br/>Price</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term (in years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;">Aggregate<br/>Intrinsic<br/>Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Outstanding, December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">3,706,945</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.90</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">7.98</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">15,126</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Options authorized</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Options granted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">2,161,472</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">14.37</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Options exercised</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,125,339</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">4.17</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Options forfeited or cancelled</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">867,761</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">14.06</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Outstanding, December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">3,875,317</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">14.08</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">8.85</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">13,212</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Options exercisable December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">991,847</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">13.42</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">8.46</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">4,033</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Vested and expected to vest, December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">3,875,317</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">14.08</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">8.85</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">13,212</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The fair value of each stock option was estimated at the date of grant using a Black-Scholes option-pricing model using the following assumptions:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:48.693%;"/>
        <td style="width:1.96%;"/>
        <td style="width:0.642%;"/>
        <td style="width:22.409%;"/>
        <td style="width:0.642%;"/>
        <td style="width:1.96%;"/>
        <td style="width:0.642%;"/>
        <td style="width:22.409%;"/>
        <td style="width:0.642%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">77.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">79.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">72.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">96.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Dividend yield</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected term</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.90 </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">- </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.08 </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">years</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.00 </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">- </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.08 </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">years</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The assumptions are as follows:</span></p><div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Expected volatility.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The Company has limited trading history. As such, the expected volatility was determined by examining the historical volatilities for comparable publicly traded companies within the biotechnology and pharmaceutical industry using an average of historical volatilities of the Company&#8217;s industry peers.</span></div></div><div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Risk-free interest rate.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The risk-free interest rate is based on the United States Treasury yield with a maturity equal to the expected term of the option in effect at the time of grant.</span></div></div><div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Dividend yield.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The expected dividend is assumed to be zero as dividends have never been paid and there are no current plans to pay dividends on common stock.</span></div></div><div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">&#8226;</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Expected term.</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> The expected term represents the period that the stock-based awards are expected to be outstanding. The expected term is calculated using the simplified method which is used when there is insufficient historical data about exercise patterns and post-vesting employment termination behavior. The simplified method is based on the vesting period and the contractual term for each grant, or for each vesting-tranche for awards with graded vesting. The mid-point between the vesting date and the maximum contractual expiration date is used as the expected term under this method. For awards with multiple vesting-tranches, the times from grant until the mid-points for each of the tranches may be averaged to provide an overall expected term.</span></div></div><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company will continue to use judgment in evaluating the expected volatility, risk-free interest rates, dividend yield and expected term, utilized for stock-based compensation on a prospective basis.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying stock options and the fair value of the Company&#8217;s common stock for stock options that were in-the-money at December 31, 2021 and 2020. The aggregate intrinsic value of stock options exercised during the years ended on December 31, 2021 and 2020 was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The total fair value of options that vested during the years ended December 31, 2021 and 2020 was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively. The options granted during the years ended December 31, 2021 and 2020 had a weighted-average per share grant-date fair value of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.68</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share and $9</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">.96</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> per share, respectively.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, the total unrecognized stock-based compensation expense related to unvested stock options was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, which is expected to be recognized over the remaining weighted-average vesting period of </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.8 </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">years.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Restricted Stock Units</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table presents a summary of the Company's RSU activity and related information:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.347%;"/>
        <td style="width:3.293%;"/>
        <td style="width:0.578%;"/>
        <td style="width:19.667%;"/>
        <td style="width:0.764%;"/>
        <td style="width:3.293%;"/>
        <td style="width:1.146%;"/>
        <td style="width:19.334%;"/>
        <td style="width:0.578%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Number of Units Outstanding</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted-<br/>Average<br/>Grant Date Fair Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Outstanding, December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">RSUs granted (including performance-based RSUs)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">777,160</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">7.84</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">RSUs Vested</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">RSUs forfeited</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">5,500</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">7.12</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Outstanding, December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">771,660</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">7.85</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In May 2021, the Company granted </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,410</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> RSUs with service and performance conditions to an employee, none of which vested during the year ending December 31, 2021. Vesting of these awards is contingent on the occurrence of certain milestone events and fulfilment of any remaining service condition. As a result, the related compensation cost is recognized as an expense when achievement of the milestone is considered probable. The expense recognized for these awards is based on the grant date fair value of the Company's common stock multiplied by the number of units granted. The Company recognized less than $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of related expense during the year ended December 31, 2021.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In October 2021, the Company granted </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">560,000</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> RSUs with service and performance conditions to certain employees, none of which vested during the year ended December 31, 2021. Vesting of these awards is contingent on the occurrence of certain milestone events and fulfilment of any remaining service condition. As a result, the related compensation cost is recognized as an expense when achievement of the milestone is considered probable. The expense recognized for these awards is based on the grant date fair value of the Company's common stock multiplied by the number of units granted. The Company recognized $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of related expense during the year ended December 31, 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The weighted-average grant date fair value of RSUs granted during the year ended December 31, 2021 was $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.84</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. There was no RSU activity during the year ended December 31, 2020. Additionally, no RSUs vested during the year ended December 31, 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, there was approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of unrecognized compensation cost related to unvested RSUs that the Company expects to recognize over a remaining weighted-average period of approximately </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.3 </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">years.</span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table presents stock-based compensation expense by type of award (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.091%;"/>
        <td style="width:1.49%;"/>
        <td style="width:1.147%;"/>
        <td style="width:13.24%;"/>
        <td style="width:0.578%;"/>
        <td style="width:1.49%;"/>
        <td style="width:1.147%;"/>
        <td style="width:13.24%;"/>
        <td style="width:0.578%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock Options</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10,511</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">5,263</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Restricted stock units (including performance-based RSUs)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,944</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_dbc0d54f-50e5-4e0d-931c-eb2600eb1f07;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Employee Stock Purchase Plan</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">56</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_91d06931-2771-4e60-b971-253316eaba0d;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">12,511</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">5,263</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139685484643688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">16. Net Loss Per Share</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders (in thousands, except share and per share data):</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.812%;"/>
        <td style="width:1.416%;"/>
        <td style="width:1.503%;"/>
        <td style="width:13.777%;"/>
        <td style="width:0.991%;"/>
        <td style="width:1.416%;"/>
        <td style="width:1.503%;"/>
        <td style="width:13.592%;"/>
        <td style="width:0.991%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Numerator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss attributable to common stockholders</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">61,999</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">36,678</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Denominator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted-average shares used in computing net loss<br/>&#160;&#160;&#160;per share attributable to common stockholders,<br/>&#160;&#160;&#160;basic and diluted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30,952,152</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,319,977</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss per share attributable to common stockholders,<br/>&#160;&#160;&#160;basic and diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.00</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.01</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:2.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company's potentially dilutive shares, which include outstanding stock options, unvested RSUs, and unexercised warrants to purchase common stock, are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:2.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:2.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the period presented because including them would have been antidilutive:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.516%;"/>
        <td style="width:1.449%;"/>
        <td style="width:0.697%;"/>
        <td style="width:14.399%;"/>
        <td style="width:0.697%;"/>
        <td style="width:1.449%;"/>
        <td style="width:0.697%;"/>
        <td style="width:14.399%;"/>
        <td style="width:0.697%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Options to purchase common stock</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,875,317</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,706,945</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unvested Restricted Stock Awards</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">771,660</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Common stock warrants</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">220,890</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">226,191</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,867,867</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,933,136</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139685484674664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">17. Income Taxes</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The components of the provision for (benefit from) income taxes are as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.545%;"/>
        <td style="width:1.448%;"/>
        <td style="width:1.514%;"/>
        <td style="width:13.057%;"/>
        <td style="width:1.002%;"/>
        <td style="width:1.448%;"/>
        <td style="width:1.514%;"/>
        <td style="width:13.471%;"/>
        <td style="width:1.002%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Years Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Current:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Federal</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,678</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">State</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">105</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Foreign</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total current</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,573</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred:</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Federal</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">125</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">242</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">State</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Foreign</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total deferred</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">125</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">242</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Provision for (benefit from) income taxes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">125</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,815</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:2.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Income tax benefit of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the year ended December 31, 2021 is primarily due to the adjustment in deferred tax liability arising from the impairment charge of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of acquired IPR&amp;D. In contrast, the income tax benefit of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million for the year ended December 31, 2020 was primarily due to a the recognition of a net operating loss carryback under the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) which was enacted on March 27, 2020 in response to the COVID-19 pandemic.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><div style="font-size:12.0pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For the rate table below the (provision for) benefit from income taxes differ from the amount expected by applying the federal statutory rate to the loss before taxes as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.102%;"/>
        <td style="width:1.427%;"/>
        <td style="width:0.686%;"/>
        <td style="width:11.84%;"/>
        <td style="width:3.496%;"/>
        <td style="width:1.427%;"/>
        <td style="width:0.686%;"/>
        <td style="width:11.84%;"/>
        <td style="width:3.496%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Federal statutory income tax rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other permanent differences</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.9</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.5</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">State income taxes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.9</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Federal benefit from NOL carryback</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.0</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.7</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24.8</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25.8</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in fair value of redeemable convertible preferred stock tranche liability and TRDF liability</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.0</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.5</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock-based compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Provision for income taxes</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.2</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The tax effects of temporary differences and carryforwards of the deferred tax assets are presented below (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.389%;"/>
        <td style="width:1.438%;"/>
        <td style="width:1.503%;"/>
        <td style="width:13.363%;"/>
        <td style="width:1.002%;"/>
        <td style="width:1.438%;"/>
        <td style="width:1.503%;"/>
        <td style="width:13.363%;"/>
        <td style="width:1.002%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred Tax Assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net operating loss carryforwards</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">67,675</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">51,796</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease right-of-use asset liability</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,504</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,686</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred revenue</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,263</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,857</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock-based compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,726</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,750</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Intangible assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,081</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,195</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Fixed assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">196</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accruals and reserves</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,042</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">654</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development credit carryforwards</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">26</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">26</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Gross deferred tax assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">78,513</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">63,964</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: Valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">73,163</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">57,715</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax assets, net of valuation allowance</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,350</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,249</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax liabilities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Fixed assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Basis Difference IPR&amp;D</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">313</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease right-of-use asset</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,350</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,061</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">125</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On September 15, 2020 Adicet Bio and resTORbio completed the Merger upon which Adicet Bio became the parent company of the consolidated group. The Merger did not create a step up in basis for tax basis of the asset as it was considered a tax-free merger. The above deferred tax table includes deferred related to resTORbio.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has established a valuation allowance against its deferred tax assets due to the uncertainty surrounding the realization of such assets.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">ASC 740 requires that the tax benefit of net operating losses, temporary differences and credit carryforwards be recorded as an asset to the extent that management assesses that realization is &#8220;more likely than not.&#8221; Realization of the future tax benefits is dependent on the Company&#8217;s ability to generate sufficient taxable income within the carryforward period. Because of the Company&#8217;s recent history of operating losses, management believes that recognition of the deferred tax assets arising from the above-mentioned future tax benefits is currently not likely to be realized and, accordingly, has provided a valuation allowance.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The valuation allowance increased by $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million during 2021 and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">37.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million during 2020.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, the Company had net operating loss carryforwards of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">271.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">143.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million to reduce future taxable income, if any, for federal, state and foreign income tax purposes, respectively. Of the federal net operating loss carryforwards, $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million will begin to expire in 2036 if not utilized, and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">264.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million can be carried forward indefinitely. The state carryforwards will begin to expire in 2035.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company also had approximately $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of federal and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.5</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million of California research and development tax credit carryforwards available to offset future taxable income as of December 31, 2021. The federal credits begin to expire in 2041 and the California research credits can be carried forward indefinitely.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Utilization of the net operating loss carryforwards and research and development tax credit carryforwards may be subject to an annual limitation under Section 382 of the Internal Revenue Code of 1986, and corresponding provisions of state law, due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income. </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain shareholders or public groups in the stock of a corporation by more than 50% over a three-year period</span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. The Company has not conducted a study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception due to the significant complexity and cost associated with such a study. If the Company has experienced a change of control, as defined by Section 382, at any time since inception, utilization of the net operating loss carryforwards or research and development tax credit carryforwards would be subject to an annual limitation under Section 382, which is determined by first multiplying the value of the Company&#8217;s stock at the time of the ownership change by the applicable long-term tax-exempt rate, and then could be subject to additional adjustments, as required. Any limitation may result in expiration of a portion of the net operating loss carryforwards or research and development tax credit carryforwards before utilization. Further, until a study is completed and any limitation is known, no liability related to uncertain tax positions is recorded in the consolidated financial statements. The Company does not expect its unrecognized tax benefit balance to change materially over the next 12 months.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company files income tax returns in the United States federal jurisdiction, California, Massachusetts, New York and Israel. The tax years 2015 to 2021 remains open to United States federal and state examination to the extent of the utilization of net operating loss and credit carryovers.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, the Company had unrecognized tax benefits of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million related to the transfer of certain intellectual property from its Israeli subsidiary. In addition, as of December 31, 2021, the Company had unrecognized tax benefits of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million related to the federal and state research and development credits as a result of no formal research credit study performed.</span></p><div style="font-size:10.0pt;font-family:Times New Roman;"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A reconciliation of the beginning and ending unrecognized tax benefit amount is as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.82%;"/>
        <td style="width:1.489%;"/>
        <td style="width:1.284%;"/>
        <td style="width:13.199%;"/>
        <td style="width:0.627%;"/>
        <td style="width:1.489%;"/>
        <td style="width:1.284%;"/>
        <td style="width:13.18%;"/>
        <td style="width:0.627%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at the beginning of the year</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">797</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">797</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Adjustment based on tax positions related to current year</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,243</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at the end of the year</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,040</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">797</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table></div><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company recognizes interest expense and penalties related to the above unrecognized tax benefits within income tax expense (benefit). Management determined that no accrual for interest and penalties was required as of December 31, 2021.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139685484689560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Defined Contribution Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_DefinedContributionPlanAbstract', window );"><strong>Defined Contribution Plan [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanTextBlock', window );">Defined Contribution Plan</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">18. Defined Contribution Plan</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company maintains a defined contribution plan under Section 401(k) of the Internal Revenue Code covering substantially all full-time United States employees. Employee contributions are voluntary and are determined on an individual basis subject to the maximum allowable under federal tax regulations. During the year ended December 31, 2021 the Company made aggregate matching contributions of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million. The Company did </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">t make contributions to the 401(k) plan during 2020.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_DefinedContributionPlanAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined contribution plan abstract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_DefinedContributionPlanAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -URI http://asc.fasb.org/subtopic&amp;trid=2235116<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139685491196680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">19. Related Party Transactions</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, Regeneron owned </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">883,568</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of the Company's common stock. Regeneron became a related party in July 2019 as a result of Series B redeemable convertible preferred stock financing. Upon closing the Merger, </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,125,552</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of the redeemable convertible preferred stock converted into </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">883,568</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> shares of the Company&#8217;s common stock. For the years ended December 31, 2021 and 2020, the Company recorded revenue related to the Regeneron Agreement of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million and $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17.9</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, respectively. As of December 31, 2021, the Company recorded less than $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million in accounts receivable and has deferred revenue of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million related to the Regeneron Agreement (See Note 10).</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39549-107864<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6457730&amp;loc=d3e39691-107864<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139685484721288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">20. Subsequent Events</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Regeneron Option</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">On January 28, 2022, Regeneron exercised its option to license the exclusive, worldwide rights to ADI-002, an allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapy directed against Glypican-3, pursuant to the Regeneron Agreement.<br/> In conjunction with the exercise of the Option, Regeneron paid an exercise fee of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million to the Company on January 28, 2022.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Pursuant to the Regeneron Agreement, upon Regeneron&#8217;s exercise of the option, the Company had a specified period of time to elect to co-fund ADI-002&#8217;s future development costs, and to participate in any potential profits with Regeneron up to a specified co-funding percentage in various geographic regions, including on a worldwide basis (Co-Funding Option). Adicet elected not to exercise its Co-Funding Option for ADI-002. Accordingly, Regeneron is responsible, at its sole cost, for all development, manufacturing and commercialization of ADI-002 and must pay the Company high single digit royalties as a percentage of any net sales of ADI-002 for a period commencing on the first commercial sale until the longer of (i) the expiration or invalidity of the licensed patent rights or (ii) a low double digit amount of years from first commercial sale.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6842918&amp;loc=SL6314017-165662<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139685483438280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Basis of Presentation</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The consolidated financial statements and related disclosures have been prepared in conformity with accounting principles generally accepted in the United States of America (United States GAAP or GAAP).</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Principles of Consolidation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Principles of Consolidation</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. The United States dollar is the functional and reporting currency of the Company and its subsidiaries.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Use of Estimates</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent liabilities at the date of the consolidated financial statements as well as the reported amounts of revenues and expenses during the reporting period. Such estimates include the valuation of the intangible assets acquired in business combinations, redeemable convertible preferred stock warrant liability, redeemable convertible preferred stock tranche liability, the Technion Research and Development Foundation liability (TRDF Liability), contingent consideration liability for contingent value right (CVR), deferred tax assets, useful lives of property and equipment, accruals for research and development activities, revenue recognition and stock-based compensation and the Company&#8217;s incremental borrowing rate. Actual results could differ from those estimates.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Contingent Consideration Liability (CVR)</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Contingent Consideration Liability (CVR)</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The estimated fair value of the CVR, initially measured and recorded on the acquisition date, is considered to be a Level 3 instrument. The contingent consideration liability is recorded at fair value at the end of each reporting period with changes in estimated fair values recorded in research and development expenses in the consolidated statements of operations and comprehensive loss. During the second quarter of 2021, the Company performed a re-measurement of the fair value of the CVR liability and adjusted the liability to zero. This resulted in a $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.0</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million gain in research and development expense in the statements of operations and comprehensive loss for the year ended December 31, 2021.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Goodwill</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Goodwill represents the excess of the purchase price over the fair value of net tangible and identified intangible assets acquired in a business combination. Goodwill is not amortized but is evaluated at least annually for impairment or when a change in facts and circumstances indicate that the fair value of the goodwill may be below the carrying value.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Goodwill is tested for impairment at the reporting unit level annually in the fourth quarter, or more frequently when events or changes in circumstances indicate that the asset might be impaired. Examples of such events or circumstances include, but are not limited to, a significant adverse change in legal or business climate, an adverse regulatory action or unanticipated competition. The Company has determined that it operates in a single operating segment and has a single reporting unit.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prior to performing the impairment test, the Company assesses qualitative factors to determine whether the existence of events or circumstances would indicate that it is more likely than not that the fair value of the reporting unit was less than the carrying amount. If after assessing the totality of events or circumstances, the Company were to determine that it is more likely than not that the fair value of the reporting unit is less than the carrying amount, then the Company would perform a quantitative impairment test.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The quantitative impairment test involves comparing the fair value of the reporting unit to the carrying value. If the fair value of the reporting unit exceeds the carrying value of the net assets, goodwill is not impaired, and no further testing is required. If the fair value of the reporting unit is less than the carrying value, the Company measures the amount of impairment loss, if any, as the excess of the carrying value over the fair value of the reporting unit. The Company performed an annual test for goodwill impairment in the fourth quarter of the fiscal year ended December 31, 2021 and determined that goodwill was </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">t impaired.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy', window );">Intangible Assets</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Intangible Assets</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In connection with the Merger, the Company acquired certain IPR&amp;D assets, which were classified as indefinite-lived intangible assets. Acquired IPR&amp;D represents the fair value assigned to research and development assets that the Company acquires and have not been completed at the acquisition date. The fair value of IPR&amp;D acquired in a business combination is recorded on the Company&#8217;s consolidated balance sheets at the acquisition-date fair value and is determined by estimating the costs to develop the technology into commercially viable products, estimating the resulting revenue from the products, and discounting the projected net cash flows to present value. IPR&amp;D is not amortized, but rather is reviewed for impairment on an annual basis or more frequently if indicators of impairment are present, until the project is completed, abandoned, or transferred to a third party. The Company performed a review for impairment of IPR&amp;D during the second quarter of the year ended December 31, 2021 and recognized an impairment charge of $</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> million, which was recorded as research and development expenses in the consolidated statement of operations and comprehensive loss.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">  </span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Segments</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company operates and manages its business as </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> reportable and operating segment, which is the business of research and development of allogeneic immunotherapies for cancer and other diseases. The Company&#8217;s Chief Executive Officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Concentration of Credit Risk</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of cash and cash equivalents, and marketable debt securities. The Company&#8217;s cash and cash equivalents are held at two financial institutions in the United States and one financial institution in Israel and such amounts may, at times, exceed insured limits. The Company invests its cash equivalents and marketable debt securities in money market funds, United States government securities, commercial paper, corporate bonds, and asset-backed securities. The Company limits its credit risk associated with cash equivalents and marketable debt securities by placing them with banks and institutions it believes are highly creditworthy and in highly rated investments. The Company has not experienced any losses on its deposits of cash and cash equivalents and marketable debt securities to date.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">one</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> customer, Regeneron, which represents </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">100</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% of the Company&#8217;s total revenue during the years ended December 31, 2021 and 2020 and outstanding accounts receivable as of December 31, 2021 (see Note 10).</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_RisksAndUncertaintiesPolicyTextBlock', window );">Risks and Uncertainties</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Risks and Uncertainties</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, protection of proprietary technology, dependence on key personnel, compliance with government regulations and the need to obtain additional financing to fund operations. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical studies, clinical trials, and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance and reporting.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#8217;s product candidates are still in development and, to date, none of the Company&#8217;s product candidates have been approved for sale and, therefore, the Company has not generated any revenue from product sales.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">There can be no assurance that the Company&#8217;s research and development will be successfully completed, that adequate protection for the Company&#8217;s intellectual property will be obtained or maintained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company&#8217;s product development efforts are successful, it is uncertain when, if ever, the Company will generate revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from other pharmaceutical and biotechnology companies.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">current COVID-19 (coronavirus) pandemic, which is impacting worldwide economic activity, poses risk that the Company or its employees, contractors, suppliers, and other partners may be prevented from conducting business activities for an indefinite period of time, including due to shutdowns that may be requested or mandated by governmental authorities. The extent to which the coronavirus impacts the Company&#8217;s operations will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the outbreak, new information that will emerge concerning the severity of the coronavirus and the actions to contain the coronavirus or treat its impact, among others. COVID-19 may impact the timing of regulatory approval of the INDs for clinical trials, the enrollment of any clinical trials that are</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">approved, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">the availability of clinical trial materials and regulatory approval and commercialization of our products. COVID-19 may also impact the Company&#8217;s ability to access capital, which could negatively impact short-term and long-term liquidity.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Cash and Cash Equivalents</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company considers all highly liquid investments purchased with maturities of three months or less from the purchase date to be cash equivalents. As of December 31, 2021 and 2020, cash and cash equivalents consist of cash deposited with banks and investments in money market funds with maturities of three months or less from the date of purchase.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Marketable Debt Securities</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Marketable debt securities are investments in marketable debt securities with maturities greater than three months at the time of purchase. The Company determines the appropriate classification of its investments in marketable debt securities at the time of purchase and reevaluates such designation at each balance sheet date. The Company has classified and accounted for its marketable debt securities as available-for-sale. The Company classifies highly liquid securities with maturities beyond 12 months as long-term marketable debt securities in the consolidated balance sheet. These securities are carried at fair value as determined based upon quoted market prices or pricing models for similar securities. Unrealized gains and losses, if any, are excluded from earnings and are reported as a component of accumulated other comprehensive income (loss). The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in interest income on the consolidated statements of operations and comprehensive loss. Realized gains and losses, if any, on available-for-sale securities are included in other income (expense), net. The cost of securities sold is based on the specific identification method. Interest and dividends on securities classified as available-for-sale are included in interest income. The Company did not have any outstanding marketable debt securities as of December 31, 2021 and did not identify any of its marketable debt securities as other-than-temporarily impaired as of December 31, 2020.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Restricted Cash</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Restricted cash is comprised of cash that is restricted as to withdrawal or use under the terms of certain contractual agreements. Restricted cash for years ended December 31, 2021 and 2020 consists of collateral for letters of credit issued in connection with real estate leases (see Note 12).</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Fair Value of Financial Instruments</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The carrying amounts of certain financial instruments of the Company, including cash equivalents, restricted cash, accounts payable and accrued and other current liabilities approximate fair value due to their relatively short maturities. The Company&#8217;s marketable debt securities and CVR liability are carried at fair value (see Notes 4 and 5).</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Property and Equipment, Net</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is computed on a straight-line basis over the estimated useful lives of the related assets, generally three years. Leasehold improvements are amortized using the straight-line method over the shorter of the assets&#8217; estimated useful lives or the remaining term of the lease. Maintenance and repairs are charged to operations as incurred. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the consolidated balance sheet and any resulting gain or loss is reflected in the consolidated statements of operations and comprehensive loss in the period realized.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Impairment of Long-Lived Assets</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. Recoverability is measured by comparison of the carrying amount of the asset or asset group to the future net cash flows which the asset or asset group is expected to generate. If such asset or asset group is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset or asset group exceeds the fair value of the asset or asset group. There has been </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">no</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> such impairment of long-lived assets during the years ended December 31, 2021 and 2020.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Revenue Recognition</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Under ASC 606, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Revenue from Contracts with Customers</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (ASC 606), the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps as prescribed by ASC 606:</span></p><div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(i)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">identify the contract(s) with a customer;</span></div></div><div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(ii)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">identify the performance obligations in the contract;</span></div></div><div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(iii)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">determine the transaction price;</span></div></div><div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(iv)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">allocate the transaction price to the performance obligations in the contract; and</span></div></div><div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;">(v)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">recognize revenue when (or as) the Company satisfies a performance obligation.</span></div></div><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A contract with a customer exists when (i) the Company enters into a legally enforceable contract with a customer that defines each party&#8217;s rights regarding the products or services to be transferred and identifies the payment terms related to these products or services, (ii) the contract has commercial substance and (iii) the Company determines that collection of substantially all consideration for products or services that are transferred is probable based on the customer&#8217;s intent and ability to pay the promised consideration.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">At contract inception, once the contract is determined to be within the scope of ASC 606, the Company identifies the goods or services promised and determines the performance obligations by assessing whether each promised good or service is distinct. Goods or services that are not distinct are bundled with other goods or services in the contract until a bundle of goods or services that is distinct is created. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">All of the Company&#8217;s revenues are derived through a license and collaboration agreement (see Note 10).</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For revenue recognition purposes, the Company determines the term of its license or collaboration agreements by evaluating the period during which present and enforceable rights and obligations exist. This determination is impacted by the existence of substantive termination penalties, among other factors.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company recognizes revenue under the Company&#8217;s license or collaboration agreements that are within the scope of ASC 606. These agreements include promises related to licenses to intellectual property and research and development services. If the license to the Company&#8217;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgement to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. Accordingly, the transaction price is generally comprised of a fixed fee due at contract inception and at specified future dates, variable consideration in the form of milestone payments due upon the achievement of specified events and tiered royalties earned when customers recognize net sales of licensed products. The Company measures the transaction price based on the amount of consideration to which it expects to be entitled in exchange for transferring the promised goods and/or services to the customer. The Company utilizes the &#8220;most likely amount&#8221; method to estimate the amount of variable consideration to which it will be entitled for the contract. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. At the inception of each arrangement that includes development and regulatory milestone payments, the Company evaluates whether the associated event is considered most likely to be achieved and estimates the amount to be included in the transaction price.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Payments or reimbursements for the Company&#8217;s research and development efforts where such efforts are considered part of or a single performance obligation are recognized over time using a measure of progress that best reflects the Company&#8217;s performance in satisfying the obligation.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Upfront payments are recorded as contract liabilities upon receipt or when due and may require deferral of revenue recognition to a future period until the Company performs its obligation under these arrangements. Amounts payable to the Company are recorded as accounts receivable when the Company&#8217;s right to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one year or less.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from its collaboration arrangement.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Research and Development Expenses</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development expenses include costs directly attributable to the conduct of research and development programs, including payroll and related expenses, costs for CMOs, costs for CROs, materials, supplies, depreciation on and maintenance of research equipment, consulting costs, and the allocated portions of facility costs, such as rent, utilities, insurance, repairs and maintenance, depreciation, information technology costs and general support services. All costs associated with research and development are expensed within the consolidated statements of operations and comprehensive loss as incurred.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Costs incurred in obtaining technology licenses are charged to research and development expense as acquired in-process research and development if the technology licensed has not reached technological feasibility and has no alternative future use.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_AccruedResearchAndDevelopmentPolicyTextBlock', window );">Accrued CRO, CMO, and Research and Development Expenses</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Accrued CRO, CMO, and Research and Development Expenses</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has entered into various agreements with CMOs and CROs. The Company&#8217;s research and development accruals are estimated based on the level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. The estimated costs of research and development provided, but not yet invoiced are included in accrued and other current liabilities on the consolidated balance sheets. If the actual timing of the performance of services or the level of effort varies from the original estimates, the Company will adjust the accrual accordingly. Payments made to CMOs and CROs under these arrangements in advance of the performance of the related services are recorded as prepaid expenses and other current assets on the consolidated balance sheets until the services are rendered. Through December 31, 2021 there had been no material adjustments to the Company&#8217;s prior period estimates of accrued research and development expenses.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Leases</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> Effective January 1, 2020, the Company adopted ASU No. 2016-02, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Leases (Topic 842)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (ASU 2016-02), using the modified retrospective approach through a cumulative-effect adjustment as of the adoption date, with prior periods unchanged and presented in accordance with the guidance in Topic 840, Leases (Topic 840).</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Consistent with ASU 2016-02, the Company determines if an arrangement is a lease, or contains a lease, at inception. Leases with a term greater than 12 months are recognized on the balance sheet as Right-of-Use (ROU) assets and current and long-term operating lease liabilities, as applicable. The Company has elected not to recognize on the balance sheet leases with terms of 12 months or less. The Company typically only includes an initial lease term in its assessment of a lease arrangement. Options to renew a lease are not included in the Company&#8217;s assessment unless there is reasonable certainty that the Company will renew. The Company monitors its plan to renew its leases no less than on a quarterly basis. In addition, the Company&#8217;s lease agreements generally do not contain any residual value guarantees or restrictive covenants.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In accordance with ASU 2016-02, the ROU assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term. As most of the Company&#8217;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate (IBR), which is the estimated rate the Company would be required to pay for a fully collateralized borrowing equal to the total lease payments over the term of the lease, to determine the present value of future minimum lease payments. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. For lease agreements entered into or reassessed after the adoption of ASU 2016-02, the Company does not combine lease and non-lease components. Variable lease payments are expenses as incurred.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Assumptions made by the Company at the commencement date are re-evaluated upon occurrence of certain events, including a lease modification. A lease modification results in a separate contract when the modification grants the lessee an additional right of use not included in the original lease and when lease payments increase commensurate with the standalone price for the additional right of use. When a lease modification results in a separate contract, it is accounted for in the same manner as a new lease.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_FairValueOfCommonStockPolicyTextBlock', window );">Fair Value of Common Stock</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Fair Value of Common Stock</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prior to the Merger the fair value of the Company&#8217;s common stock was determined by its Board of Directors with input from management and third-party valuation specialists. The Company&#8217;s approach to estimate the fair value of the Company&#8217;s common stock is consistent with the methods outlined in the American Institute of Certified Public Accountants Practice Aid, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Valuation</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">of Privately-Held-</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Company</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> Equity Securities Issued as Compensation</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">. Determining the best estimated fair value of the Company&#8217;s common stock requires significant judgement and management considers several factors, including the Company&#8217;s stage of development, equity market conditions affecting comparable public companies, significant milestones and progress of research and development efforts. Subsequent to the Merger, the fair value of the Company&#8217;s common stock is determined based on its closing market price.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Stock-Based Compensation</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company accounts for stock-based compensation arrangements with employees and non-employees using a fair value method which requires the recognition of compensation expense for costs related to all stock-based payments including stock options. The fair value method requires the Company to estimate the fair value of stock-based payment awards on the date of grant using an option-pricing model. The Company uses the Black-Scholes option-pricing model to estimate the fair value of options granted that are expensed on a straight-line basis over the requisite service period, which is generally the vesting period. The Company accounts for forfeitures as they occur. Option valuation models, including the Black-Scholes option-pricing model, require the input of several assumptions. Changes in the assumptions used can materially affect the grant-date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend yield, expected volatility and the expected life of the award. For awards that have a performance condition, the Company recognizes compensation expense based on its assessment of the probability that the performance condition will be achieved, using an accelerated attribution model, over the explicit or implicit service period.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Income Taxes</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences attributable to differences between carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax reporting purposes and for operating loss and tax credit carryforwards. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company&#8217;s deferred tax assets and liabilities are measured using enacted tax rates expected to apply in the years in which these temporary differences are expected to be recovered or settled. A valuation allowance is recorded to reduce deferred tax assets if it is determined that it is more likely than not that all or a portion of the deferred tax asset will not be realized. The Company considers many factors when assessing the likelihood of future realization of deferred tax assets, including recent earnings results, expectations of future taxable income, carryforward periods available and other relevant factors. The Company records changes in the required valuation allowance in the period that the determination is made.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company assesses its income tax positions and records tax benefits for all years subject to examination based upon management&#8217;s evaluation of the facts, circumstances and information available as of the reporting date. For those tax positions where it is more likely than not that a tax benefit will be sustained, the Company records the largest amount of tax benefit with a greater than 50% likelihood of being realized upon ultimate settlement with a taxing authority having full knowledge of all relevant information. For those income tax positions where it is not more likely than not that a tax benefit will be sustained, the Company does not recognize a tax benefit in the consolidated financial statements. The Company records interest and penalties related to uncertain tax positions, if applicable, as a component of income tax expense (benefit).</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income (Loss)</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Comprehensive Income (Loss)</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Comprehensive income (loss) is defined as a change in equity of a business enterprise during a period, resulting from transactions from non-owner sources. The other comprehensive loss disclosed in the Company&#8217;s consolidated statements of operations and comprehensive loss for the years ended December 31, 2021 and 2020 consists of changes in unrealized gains and losses on marketable debt securities.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share Attributable to Common Stockholders</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Net Loss per Share Attributable to Common Stockholders</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Basic </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common stock outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common stock and potentially dilutive securities outstanding for the period. The Company&#8217;s potentially dilutive shares, which include outstanding stock options, Employee Stock Purchase Plan awards, unvested restricted stock units (RSUs), and shares issuable upon conversion of the Convertible Notes, are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive. Basic and diluted net loss per share attributable to common stockholders is presented in conformity with the two-class method required for participating securities. The two-class method determines net income (loss) per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income (loss) available to common</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">stockholders </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">for the period to be allocated between common and participating securities based upon their respective rights to share in undistributed earnings as if all income (loss) for the period had been distributed. The Company&#8217;s participating securities do not have a contractual obligation to share in the Company&#8217;s losses. As such, the net loss is attributed entirely to common stockholders. Since the Company has reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for those periods.</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock', window );">Subsequent Events Considerations</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Subsequent Events Considerations</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the consolidated financial statements to provide additional evidence for certain estimates or to identify matters that require additional disclosure. Subsequent events have been evaluated as required. The Company has evaluated all subsequent events and determined that there are no material recognized or unrecognized subsequent events requiring disclosure, other than as disclosed in these notes to the consolidated financial statements.  See Note 21 for further information.</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Recent Accounting Pronouncements</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">From time to time, new accounting pronouncements are issued by the FASB under its ASC or other standard setting bodies and adopted by the Company as of the specified effective date, unless otherwise discussed below.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Recently Adopted Accounting Pronouncements</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In August 2018, the FASB issued ASU No. 2018-15, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Intangibles&#8211;Goodwill and Other&#8212;Internal-Use Software (Subtopic 350-40): Customer&#8217;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That is a Service Contract </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(ASU 2018-15). The amendments in ASU 2018-15 align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). Accordingly, the update requires</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"> </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">entities in a hosting arrangement that is a service contract to follow the guidance in ASC 350-40, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Internal-Use Software</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (ASC 350-40) to determine which implementation costs to capitalize as an asset related to the service contract and which costs to expense. Costs to develop or obtain internal-use software that cannot be capitalized under ASC 350-40, such as training costs and certain data conversion costs, also cannot be capitalized for a hosting arrangement that is a service contract. Therefore, an entity in a hosting arrangement that is a service contract determines which project stage an implementation activity relates to. Costs for implementation activities in the application development stage are capitalized depending on the nature of the costs, while costs incurred during the preliminary project and post-implementation stages are expensed as the activities are performed. ASU 2018-15 also requires entities to expense the capitalized implementation costs of a hosting arrangement that is a service contract over the term of the hosting arrangement. ASU 2018-15 was effective for public entities for annual periods beginning after December 15, 2019, including interim periods within those fiscal years. For nonpublic entities, ASU 2018-15 is effective for annual reporting periods beginning after December 15, 2020, and interim periods within annual periods beginning after December 15, 2021. Early adoption is permitted, including adoption in any interim period. The Company adopted ASU 2018-15 beginning January 1, 2021. The adoption of ASU 2018-15 resulted in an immaterial amount of assets recorded on the Company's balance sheet.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In November 2018, the FASB issued ASU No. 2018-18, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Collaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606 </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(ASU 2018-18), which is intended to clarify the circumstances under which certain transactions in collaborative arrangements should be accounted for under the revenue recognition standard. Certain transactions between collaboration arrangement participants should be accounted for as revenue under ASC Topic 606 when the collaborative arrangement participant is a customer in the context of a unit of account. For public business entities, this ASU is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. For all other entities, this ASU is effective for fiscal years and interim periods within those years beginning after December 15, 2020. Early adoption is permitted.  The Company adopted ASU 2018-18 beginning January 1, 2021. The adoption of this standard did not have a material impact on the Company's financial statements and related disclosures.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In December 2019, the FASB issued ASU No. 2019-12, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Income Taxes (Topic 740)&#8212;Simplifying the Accounting for Income Taxes</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (ASU 2019-12), which simplify various aspects related to the accounting for income taxes. This ASU removes exceptions to the general principles in Topic 740 related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. For public companies, this ASU is effective for interim and annual reporting periods beginning after December 15, 2020. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2021, and interim periods within fiscal years beginning after December 15, 2022. Early adoption is permitted. The Company adopted ASU 2019-12 beginning January 1, 2021 on a prospective basis. The adoption of this standard did not have a material impact on the Company's financial statements and related disclosures</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In March 2020, the FASB issued ASU No. 2020-04, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Reference Rate Reform (Topic 848)</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> (ASU 2020-04). The amendments in ASU 2020-04 provide optional expedients and exceptions for applying generally accepted accounting principles to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments in ASU 2020-04 are effective for all entities as of March 12, 2020 through December 31, 2022. An entity may elect to apply the amendments for contract modifications by Topic or Industry Subtopic as of any date from the beginning an interim period that includes or is subsequent to March 12, 2020, or prospectively from the date that the financial statements are available to be issued. Once elected for a Topic or an Industry Subtopic, the amendments must be applied prospectively for all eligible contract modifications for that Topic or Industry Subtopic. The Company may elect to apply ASU 2020-04 as its contracts referenced in London Interbank Offered Rate (LIBOR) are impacted by reference rate reform. The Company adopted ASU 2020-04 beginning January 1, 2021. The adoption of this standard did not have a material impact on the Company's financial statements and related disclosures.</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"><br/></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Accounting Pronouncements Not Yet Adopted</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In June 2016, the FASB issued ASU No. 2016-13, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Financial Instruments&#8212;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(ASU 2016-13), which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. This ASU replaces the existing incurred loss impairment model with an expected loss model. It also eliminates the concept of other-than-temporary impairment and requires credit losses related to available-for-sale debt securities to be recorded through an allowance for credit losses rather than as a reduction in the amortized cost basis of the securities. These changes will result in earlier recognition of credit losses. For public business entities that meet the definition of a Securities and Exchange Commission (SEC) filer, excluding entities eligible to be smaller reporting companies as defined by the SEC, adoption is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. For SEC filers that are eligible to be smaller reporting companies and for all other entities, this ASU is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact the adoption of this ASU will have on its consolidated financial statements and related disclosures.</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In January 2017, the FASB issued ASU No. 2017-04, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Intangibles &#8211; Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(ASU 2017-04). The new guidance simplifies the subsequent measurement of goodwill by removing the second step of the two-step impairment test. The amendment requires an entity to perform its annual or interim goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity still has the option to perform the qualitative assessment for a reporting unit to determine if the quantitative impairment test is necessary. The new guidance for accelerated filing companies became effective for annual periods or any interim goodwill impairment tests in fiscal years beginning after December 15, 2019 and all other entities should adopt the amendments in this update for its annual or any interim goodwill impairment tests in fiscal years beginning after December 15, 2022. The amendment should be applied on a prospective basis. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company is currently evaluating the impact the adoption of this ASU will have on its consolidated financial statements and related disclosures.</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">In July 2021, FASB issued ASU No. 2021-05, </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;">Lease (Topic 842), Lessors - Certain Leases with Variable Lease Payments </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(ASU 2021-05). ASU 2021-05 amends the lease classification requirements for lessors when classifying and accounting for a lease with variable lease payments that do not depend on a reference rate index or a rate. The update provides criteria, that if met, the lease would be classified and accounted for as an operating lease. ASU 2021-05 is effective for reporting periods beginning after December 15, 2021, with early adoption permitted. The Company is currently evaluating the impact of the adoption of this ASU on the Company's consolidated financial statements, but does not believe the adoption of this standard will have a material impact on the Company's consolidated financial statements.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_AccruedResearchAndDevelopmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_AccruedResearchAndDevelopmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_FairValueOfCommonStockPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_FairValueOfCommonStockPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_RisksAndUncertaintiesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Risks and uncertainties policy text block.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_RisksAndUncertaintiesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123368208&amp;loc=d3e12565-110249<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6049-115624<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123599081&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18823-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e9038-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 29<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8864-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reporting subsequent events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139685486932280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combination (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock', window );">Schedule of Summarizes the Purchase Price in the Merger</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following summarizes the purchase price in the Merger (in thousands, except share and per share amounts):</span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:77.846%;"/>
        <td style="width:2.091%;"/>
        <td style="width:1.577%;"/>
        <td style="width:17.704%;"/>
        <td style="width:0.782%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Fair value of common stock shares of the combined company <br/>&#160;&#160;&#160;owned by resTORbio stockholders (1)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">84,142</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Fair value of contingent consideration liability with respect to CVR (2)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,880</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Purchase price</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">87,022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock', window );">Schedule of Estimated Share Consideration of Combined Company</a></td>
<td class="text"><div style="display:flex;margin-top:0.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Represents the share consideration of the combined company that the resTORbio stockholders own as of the closing of the Merger calculated as follows:</span></div></div><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:77.785%;"/>
        <td style="width:2.078%;"/>
        <td style="width:1.565%;"/>
        <td style="width:17.508%;"/>
        <td style="width:1.064%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Number of shares of the combined company owned by resTORbio<br/>&#160;&#160;&#160;stockholders (a)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,207,695</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Multiplied by the fair value per share of resTORbio common <br/>&#160;&#160;&#160;stock (b)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">16.59</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Acquisition date fair value of resTORbio</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">86,396</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Estimated fair value of modified stock options and restricted stock units attributable to pre-combination services (3)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">626</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: portion of the fair value to be distributed as CVR (c)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,880</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Fair value of shares of the combined company  owned by resTORbio<br/>&#160;&#160;&#160;stockholders</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">84,142</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock', window );">Schedule of Summarizes the Allocation of the Purchase Price to the Net Tangible and Intangible Assets Acquired</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following summarizes the allocation of the purchase price to the net tangible and intangible assets acquired (in thousands):</span><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"> </span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:50.38%;"/>
        <td style="width:1.14%;"/>
        <td style="width:1.752%;"/>
        <td style="width:12.157%;"/>
        <td style="width:1.164%;"/>
        <td style="width:1.14%;"/>
        <td style="width:1.801%;"/>
        <td style="width:13.051%;"/>
        <td style="width:1.164%;"/>
        <td style="width:1.14%;"/>
        <td style="width:1.752%;"/>
        <td style="width:12.194%;"/>
        <td style="width:1.164%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As of <br/>December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Measurement Period Adjustments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Final Purchase <br/>Price Allocation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net assets acquired:</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Cash and cash equivalents</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">63,869</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">63,869</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prepaid expenses and other current assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,059</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">615</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,674</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">318</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">318</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">IPR&amp;D</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,490</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,490</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Restricted cash</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">245</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">245</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accounts payable</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,316</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,304</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued and other current liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,365</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,365</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax liability</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">367</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">367</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Goodwill</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20,089</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">627</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19,462</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Purchase price</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">87,022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">87,022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock', window );">Schedule of changes in the Company's IPR&amp;D and CVR since the Merger</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following tables present changes in the Company's IPR&amp;D and CVR since the Merger (in thousands):</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:27.815%;"/>
        <td style="width:1.362%;"/>
        <td style="width:1.196%;"/>
        <td style="width:11.31%;"/>
        <td style="width:0.588%;"/>
        <td style="width:1.362%;"/>
        <td style="width:1.196%;"/>
        <td style="width:11.085%;"/>
        <td style="width:0.794%;"/>
        <td style="width:1.362%;"/>
        <td style="width:1.196%;"/>
        <td style="width:11.281%;"/>
        <td style="width:0.588%;"/>
        <td style="width:1.362%;"/>
        <td style="width:1.196%;"/>
        <td style="width:11.085%;"/>
        <td style="width:0.794%;"/>
        <td style="width:1.362%;"/>
        <td style="width:1.196%;"/>
        <td style="width:11.281%;"/>
        <td style="width:0.588%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Acquisition Date <br/>Fair value as of<br/>September 15, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Change in <br/>Fair value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As of<br/>December 31,<br/>2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Change in <br/>Fair value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As of<br/>December 31,<br/>2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">In-process research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">3,490</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">(</span><span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">2,300</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">1,190</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">(</span><span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">1,190</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.5pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_ba39addf-7250-4185-b821-6a0528ff4070;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">&#8212;</span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">Contingent Value Rights</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">2,880</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">(</span><span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">1,900</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">980</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">(</span><span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">980</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.5pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_53469473-0173-4a8a-bfc4-8856f9b34255;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;">&#8212;</span></span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionProFormaInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionProFormaInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table  does not include leveraged buyouts.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1486-128463<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139685484690392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Financial Assets and Liabilities Measured on Recurring Basis</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following tables present information about the Company&#8217;s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands):</span></p><p style="text-indent:7.933%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:46.433%;"/>
        <td style="width:1.005%;"/>
        <td style="width:1.728%;"/>
        <td style="width:10.689%;"/>
        <td style="width:0.735%;"/>
        <td style="width:1.005%;"/>
        <td style="width:1.728%;"/>
        <td style="width:9.157%;"/>
        <td style="width:0.735%;"/>
        <td style="width:1.005%;"/>
        <td style="width:1.728%;"/>
        <td style="width:9.157%;"/>
        <td style="width:0.735%;"/>
        <td style="width:1.005%;"/>
        <td style="width:1.728%;"/>
        <td style="width:10.689%;"/>
        <td style="width:0.735%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level 1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level 2</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level 3</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Money market funds (1)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">147,071</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">147,071</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total fair value of assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">147,071</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">147,071</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:48.026%;"/>
        <td style="width:0.993%;"/>
        <td style="width:1.594%;"/>
        <td style="width:9.745%;"/>
        <td style="width:0.821%;"/>
        <td style="width:1.017%;"/>
        <td style="width:1.594%;"/>
        <td style="width:9.757%;"/>
        <td style="width:0.821%;"/>
        <td style="width:1.017%;"/>
        <td style="width:1.594%;"/>
        <td style="width:8.973%;"/>
        <td style="width:0.821%;"/>
        <td style="width:1.017%;"/>
        <td style="width:1.594%;"/>
        <td style="width:9.794%;"/>
        <td style="width:0.821%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level 1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level 2</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Level 3</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Money market funds (1)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">63,817</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">63,817</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Marketable debt securities (2)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Asset-backed securities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">7,522</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">7,522</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Corporate debt securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,762</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,762</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Commercial paper</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,000</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,000</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Marketable debt securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10,284</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10,284</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Total fair value of assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">63,817</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10,284</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">74,101</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Liabilities:</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:bottom;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Contingent consideration</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">980</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">980</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Total fair value of liabilities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">980</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">980</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p><div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(1)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Included in cash and cash equivalents in the consolidated balance sheets</span></div></div><div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;">(2)</span><div style="display:inline;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Included in short-term marketable debt securities in the consolidated balance sheets.</span></div></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139685577259496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Debt Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Schedule of Marketable Debt Securities</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following tables summarize the Company&#8217;s marketable debt securities (in thousands):</span></p><p style="text-indent:7.933%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:47.571%;"/>
        <td style="width:1.035%;"/>
        <td style="width:1.481%;"/>
        <td style="width:9.946%;"/>
        <td style="width:0.664%;"/>
        <td style="width:1.035%;"/>
        <td style="width:1.481%;"/>
        <td style="width:9.989%;"/>
        <td style="width:0.664%;"/>
        <td style="width:1.035%;"/>
        <td style="width:1.481%;"/>
        <td style="width:9.989%;"/>
        <td style="width:0.664%;"/>
        <td style="width:1.035%;"/>
        <td style="width:1.481%;"/>
        <td style="width:9.782%;"/>
        <td style="width:0.664%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Amortized<br/>Cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Unrealized<br/>Losses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Unrealized<br/>Gains</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Fair<br/>Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Asset-backed securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,507</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">15</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,522</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Corporate debt securities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,754</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,762</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Commercial paper</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">999</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,260</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,284</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_MarketableDebtSecuritiesClassificationTableTextBlock', window );">Summary of Classification of Marketable Debt Securities in Consolidated Balance Sheets</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table summarizes the classification of the Company&#8217;s marketable debt securities in the consolidated balance sheets (in thousands):</span></p><p style="text-indent:7.933%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:73.372%;"/>
        <td style="width:1.089%;"/>
        <td style="width:1.514%;"/>
        <td style="width:9.769%;"/>
        <td style="width:0.708%;"/>
        <td style="width:1.089%;"/>
        <td style="width:1.514%;"/>
        <td style="width:10.237%;"/>
        <td style="width:0.708%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Short-term marketable debt securities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,284</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Long-term marketable debt securities</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,284</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_MarketableDebtSecuritiesClassificationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of classification of company marketable debt securities in condensed consolidated balance sheets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_MarketableDebtSecuritiesClassificationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139685484745176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expense and Other Assets, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock', window );">Summary of Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prepaid expenses and other current assets consisted of the following (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:63.509%;"/>
        <td style="width:1.373%;"/>
        <td style="width:2.116%;"/>
        <td style="width:13.901%;"/>
        <td style="width:0.855%;"/>
        <td style="width:1.373%;"/>
        <td style="width:2.116%;"/>
        <td style="width:13.901%;"/>
        <td style="width:0.855%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prepaid Insurance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,884</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,443</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prepayments to CRO's</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,658</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">420</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prepaid Maintenance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">761</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Prepayments to CMO's</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">115</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">135</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other current assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">229</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Tax receivable</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,711</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Interest receivable</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">29</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">23</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,709</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,722</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the summary of Prepaid expenses and other current assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139685484650072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of Property and Equipment, Net</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment, net consisted of the following (in thousands):</span></p><p style="text-indent:7.933%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:40.608%;"/>
        <td style="width:1.47%;"/>
        <td style="width:20.353%;"/>
        <td style="width:1.47%;"/>
        <td style="width:1.752%;"/>
        <td style="width:14.459%;"/>
        <td style="width:1.164%;"/>
        <td style="width:1.47%;"/>
        <td style="width:1.752%;"/>
        <td style="width:14.336%;"/>
        <td style="width:1.164%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">As of December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Useful life (years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Laboratory equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,502</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,350</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Leasehold improvements</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Lesser of useful life<br/>or lease term</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,614</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,427</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Furniture and fixtures</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">303</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">524</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Construction in progress</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13,014</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,090</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Computer equipment</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">216</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">93</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Software</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">320</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">170</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">   </span>&#160;</p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20,969</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,654</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: Accumulated depreciation and<br/>&#160;&#160;&#160;amortization</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,326</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,864</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Property and equipment, net</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">14,643</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,790</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139685491183800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued and Other Current Liabilities  (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Summary of Accrued and Other Current Liabilities</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued and other current liabilities consisted of the following (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:58.84%;"/>
        <td style="width:2.508%;"/>
        <td style="width:2.115%;"/>
        <td style="width:17.974%;"/>
        <td style="width:0.855%;"/>
        <td style="width:2.508%;"/>
        <td style="width:2.115%;"/>
        <td style="width:12.23%;"/>
        <td style="width:0.855%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,833</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued CMO costs</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,077</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">244</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued professional services</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">546</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">363</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued research and development expenses</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">504</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">65</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued other liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">503</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">272</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accrued CRO costs</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">32</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">955</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,682</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,732</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139685484734488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Regeneron License and Collaboration Arrangement (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Summary of Change in Company's Contract Liabilities</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table presents changes in the Company&#8217;s contract liabilities (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:47.822%;"/>
        <td style="width:1.089%;"/>
        <td style="width:1.492%;"/>
        <td style="width:9.475%;"/>
        <td style="width:0.882%;"/>
        <td style="width:1.089%;"/>
        <td style="width:1.492%;"/>
        <td style="width:9.464%;"/>
        <td style="width:0.882%;"/>
        <td style="width:1.089%;"/>
        <td style="width:1.525%;"/>
        <td style="width:9.802%;"/>
        <td style="width:0.991%;"/>
        <td style="width:1.089%;"/>
        <td style="width:1.492%;"/>
        <td style="width:9.431%;"/>
        <td style="width:0.893%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year ended December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Balance at beginning <br/>of period</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Additions</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Additions (Deductions) </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;font-family:Times New Roman;position:relative;">(1)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Balance at<br/>end of <br/>period</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Contract liability</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13,980</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9,175</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,805</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">    </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year ended December 31, 2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Balance at beginning <br/>of period</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Additions</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Additions (Deductions) </span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;font-family:Times New Roman;position:relative;">(1)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Balance at<br/>end of <br/>period</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Contract asset</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,000</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,000</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Contract liability</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21,883</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">10,000</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">17,903</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13,980</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:6.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(1)	Deductions to contract liabilities relate to deferred revenue recognized as revenue during the reporting period.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139685490299896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingences (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_ScheduleOfSubleaseIncomeTableTextBlock', window );">Schedule Of Sublease Income</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The expected undiscounted cash flows to be received from the sublease as of December 31, 2021 is as follows (in thousands):</span><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:74.179%;"/>
        <td style="width:2.254%;"/>
        <td style="width:1.284%;"/>
        <td style="width:21.646%;"/>
        <td style="width:0.637%;"/>
       </tr>
       <tr>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2022</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">657</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2023</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">671</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2024</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">685</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2025</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">699</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2026</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">416</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,128</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_ScheduleOfWeightedAverageIBRAndRemainingLeaseTermTableTextBlock', window );">Schedule of Weighted Average IBR and Remaining Lease Term</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The IBR and the remaining lease terms of our facilities and their weighted average IBR and remaining terms are as follows as of December 31, 2021:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:40.659%;"/>
        <td style="width:2.429%;"/>
        <td style="width:27.242%;"/>
        <td style="width:2.429%;"/>
        <td style="width:27.242%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Lease Locations</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">IBR</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Remaining Terms<br/>(in years)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Redwood City, CA</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.90</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">8.2</span></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Boston, MA</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">9.30</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4.6</span></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Menlo Park, CA</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.80</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.5</span></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted Average</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.20</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.7</span></span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Summary of Lease Costs and Other Information</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table contains a summary of the lease costs recognized under ASC 842 and other information pertaining to the Company&#8217;s operating leases for the years ended December 31, 2021 and 2020:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:49.395%;"/>
        <td style="width:2.168%;"/>
        <td style="width:1.503%;"/>
        <td style="width:21.795%;"/>
        <td style="width:0.991%;"/>
        <td style="width:1.503%;"/>
        <td style="width:21.958%;"/>
        <td style="width:0.686%;"/>
       </tr>
       <tr style="height:11.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;"> </span>&#160;</p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="5" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">December 31</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Lease Cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(in thousands)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,282</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">894</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Short-term lease cost</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">235</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">56</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Variable lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Sublease Income</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">223</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_a0789779-e166-43dd-bd77-089b6487a8c3;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total lease cost</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,294</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">950</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;">Other Information</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating cash flows used for lease liabilities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">511</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">859</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease right of use asset obtained in exchange of operating lease liability</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_819eaa0a-0a31-4f5b-b68e-5e64ffc6ff53;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">22,367</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Maturities Of Operating Lease Liabilities</a></td>
<td class="text"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The maturities of the operating lease liabilities as of December 31, 2021 were as follows (in thousands):</span><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:80.062%;"/>
        <td style="width:1.774%;"/>
        <td style="width:1.277%;"/>
        <td style="width:16.252%;"/>
        <td style="width:0.634%;"/>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2022</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,933</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2023</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,428</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2024</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,525</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2025</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,625</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2026 and thereafter</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">13,747</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total undiscounted lease payments</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">27,258</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: imputed interest</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,314</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total operating lease liability</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">20,944</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: current portion</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,567</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease liability, net of current maturities</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">19,377</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:2.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_ScheduleOfSubleaseIncomeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule Of Sublease Income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_ScheduleOfSubleaseIncomeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_ScheduleOfWeightedAverageIBRAndRemainingLeaseTermTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of weighted average ibr and remaining lease term table text block.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_ScheduleOfWeightedAverageIBRAndRemainingLeaseTermTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139685570507320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_ScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceTextBlock', window );">Schedule of Number of Shares of Common Stock Reserved for Future Issuance</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The Company has the following shares of common stock reserved for future issuance:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:63.237%;"/>
        <td style="width:1.656%;"/>
        <td style="width:0.637%;"/>
        <td style="width:15.452%;"/>
        <td style="width:0.637%;"/>
        <td style="width:1.656%;"/>
        <td style="width:0.637%;"/>
        <td style="width:15.452%;"/>
        <td style="width:0.637%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock options available for future grant</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,961,338</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,739,621</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock options issued and outstanding</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,875,317</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,706,945</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unvested restricted stock units</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">771,660</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Common stock warrants issued and outstanding</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">220,890</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">226,191</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total common stock reserved</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,829,205</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,672,757</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Outstanding Warrants</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following provides a roll forward of outstanding warrants:</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:53.616%;"/>
        <td style="width:1.588%;"/>
        <td style="width:0.578%;"/>
        <td style="width:12.525%;"/>
        <td style="width:0.764%;"/>
        <td style="width:1.588%;"/>
        <td style="width:1.147%;"/>
        <td style="width:12.191%;"/>
        <td style="width:0.568%;"/>
        <td style="width:1.588%;"/>
        <td style="width:0.578%;"/>
        <td style="width:12.701%;"/>
        <td style="width:0.568%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Number of <br/>Warrants</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted<br/>Average<br/>Exercise<br/>Price</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted<br/>Average<br/>Contractual<br/>Term (Years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Outstanding and exercisable warrants to purchase<br/>&#160;&#160;&#160;preferred shares as of December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">226,191</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">11.3177</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">5.66</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Issued</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Exercised</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">5,301</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Outstanding and exercisable warrants to purchase<br/>&#160;&#160;&#160;common stock as of December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">220,890</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">11.3177</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">4.66</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_ScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockTableTextBlock', window );">Schedule of Outstanding Warrants to Purchase Shares of Common Stock</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">As of December 31, 2021, the Company's outstanding warrants to purchase shares of common stock consisted of the following:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:21.212%;"/>
        <td style="width:1.5%;"/>
        <td style="width:0.627%;"/>
        <td style="width:20.574%;"/>
        <td style="width:0.627%;"/>
        <td style="width:1.5%;"/>
        <td style="width:1.284%;"/>
        <td style="width:13.782%;"/>
        <td style="width:0.627%;"/>
        <td style="width:1.5%;"/>
        <td style="width:15.419%;"/>
        <td style="width:1.5%;"/>
        <td style="width:19.849%;"/>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"><br/>Issuance Date</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Number of<br/>Shares of<br/>Common<br/>Stock Issuable</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Exercise<br/>Price</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Classification</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Expiration Date</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">September 15, 2020</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">101,610</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11.3177</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Equity</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">July 25, 2026</span></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">September 15, 2020</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30,924</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11.3177</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Equity</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">August 21, 2026</span></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">September 15, 2020</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">77,312</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11.3177</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Equity</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">September 19, 2026</span></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">September 15, 2020</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11,044</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">11.3177</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Equity</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">September 26, 2026</span></span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">220,890</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_ScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of number of shares of common stock reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_ScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_ScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of outstanding warrants to purchase shares of common stock .</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_ScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139685484548216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock', window );">Summary of Stock-Based Compensation Expense</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table presents stock-based compensation expense as reflected in the Company's consolidated statements of operations and comprehensive loss (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.807%;"/>
        <td style="width:1.49%;"/>
        <td style="width:1.284%;"/>
        <td style="width:13.201%;"/>
        <td style="width:0.627%;"/>
        <td style="width:1.49%;"/>
        <td style="width:1.284%;"/>
        <td style="width:13.191%;"/>
        <td style="width:0.627%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,759</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,674</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">General and administrative</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,752</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,589</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total stock-based compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">12,511</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,263</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table presents stock-based compensation expense by type of award (in thousands):</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:67.091%;"/>
        <td style="width:1.49%;"/>
        <td style="width:1.147%;"/>
        <td style="width:13.24%;"/>
        <td style="width:0.578%;"/>
        <td style="width:1.49%;"/>
        <td style="width:1.147%;"/>
        <td style="width:13.24%;"/>
        <td style="width:0.578%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock Options</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10,511</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">5,263</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Restricted stock units (including performance-based RSUs)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,944</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_dbc0d54f-50e5-4e0d-931c-eb2600eb1f07;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Employee Stock Purchase Plan</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">56</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;"><span style="-sec-ix-hidden:F_91d06931-2771-4e60-b971-253316eaba0d;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">12,511</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">5,263</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A summary of stock option activity is set forth below (in thousands, except share and per share data):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:89.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:40.835%;"/>
        <td style="width:0.672%;"/>
        <td style="width:12.503%;"/>
        <td style="width:0.903%;"/>
        <td style="width:1.179%;"/>
        <td style="width:1.344%;"/>
        <td style="width:12.128%;"/>
        <td style="width:0.595%;"/>
        <td style="width:1.179%;"/>
        <td style="width:0.661%;"/>
        <td style="width:12.569%;"/>
        <td style="width:0.595%;"/>
        <td style="width:1.179%;"/>
        <td style="width:1.344%;"/>
        <td style="width:11.721%;"/>
        <td style="width:0.595%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;">Outstanding Awards</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;">Number of<br/>Shares<br/>Underlying<br/>Outstanding<br/>Options</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;">Weighted<br/>Average<br/>Exercise<br/>Price</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;">Weighted<br/>Average<br/>Remaining<br/>Contractual<br/>Term (in years)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;">Aggregate<br/>Intrinsic<br/>Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Outstanding, December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">3,706,945</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">10.90</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">7.98</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">15,126</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Options authorized</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Options granted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">2,161,472</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">14.37</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Options exercised</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">1,125,339</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">4.17</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Options forfeited or cancelled</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">867,761</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">14.06</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Outstanding, December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">3,875,317</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">14.08</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">8.85</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">13,212</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Options exercisable December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">991,847</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">13.42</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">8.46</span></span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">4,033</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:5.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Vested and expected to vest, December 31, 2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">3,875,317</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">14.08</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">8.85</span></span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">13,212</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Assumptions to Estimate Fair Value of Stock Options Using Black-Scholes Option Pricing Model</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The fair value of each stock option was estimated at the date of grant using a Black-Scholes option-pricing model using the following assumptions:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:48.693%;"/>
        <td style="width:1.96%;"/>
        <td style="width:0.642%;"/>
        <td style="width:22.409%;"/>
        <td style="width:0.642%;"/>
        <td style="width:1.96%;"/>
        <td style="width:0.642%;"/>
        <td style="width:22.409%;"/>
        <td style="width:0.642%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected volatility</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">77.2</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">79.8</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">72.6</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">96.3</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Risk-free interest rate</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.4</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">% - </span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.7</span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Dividend yield</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Expected term</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.90 </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">- </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.08 </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">years</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.00 </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">- </span><span style="font-size:10.0pt;font-family:Times New Roman;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.08 </span></span><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">years</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Summary of Restricted Stock Unit Activity</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table presents a summary of the Company's RSU activity and related information:</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:51.347%;"/>
        <td style="width:3.293%;"/>
        <td style="width:0.578%;"/>
        <td style="width:19.667%;"/>
        <td style="width:0.764%;"/>
        <td style="width:3.293%;"/>
        <td style="width:1.146%;"/>
        <td style="width:19.334%;"/>
        <td style="width:0.578%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Number of Units Outstanding</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Weighted-<br/>Average<br/>Grant Date Fair Value</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Outstanding, December 31, 2020</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">RSUs granted (including performance-based RSUs)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">777,160</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">7.84</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">RSUs Vested</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">RSUs forfeited</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(</span><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">5,500</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">7.12</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:9.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;">Outstanding, December 31, 2021</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">771,660</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">7.85</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139685485698264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders (in thousands, except share and per share data):</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:64.812%;"/>
        <td style="width:1.416%;"/>
        <td style="width:1.503%;"/>
        <td style="width:13.777%;"/>
        <td style="width:0.991%;"/>
        <td style="width:1.416%;"/>
        <td style="width:1.503%;"/>
        <td style="width:13.592%;"/>
        <td style="width:0.991%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Numerator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss attributable to common stockholders</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">61,999</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">36,678</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Denominator:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Weighted-average shares used in computing net loss<br/>&#160;&#160;&#160;per share attributable to common stockholders,<br/>&#160;&#160;&#160;basic and diluted</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">30,952,152</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7,319,977</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net loss per share attributable to common stockholders,<br/>&#160;&#160;&#160;basic and diluted</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2.00</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5.01</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:2.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the period presented because including them would have been antidilutive:</span></p><p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.516%;"/>
        <td style="width:1.449%;"/>
        <td style="width:0.697%;"/>
        <td style="width:14.399%;"/>
        <td style="width:0.697%;"/>
        <td style="width:1.449%;"/>
        <td style="width:0.697%;"/>
        <td style="width:14.399%;"/>
        <td style="width:0.697%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Options to purchase common stock</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,875,317</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,706,945</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Unvested Restricted Stock Awards</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">771,660</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Common stock warrants</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">220,890</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">226,191</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,867,867</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,933,136</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139685490410968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Components of Provision for (Benefit from) Income Taxes</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The components of the provision for (benefit from) income taxes are as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.545%;"/>
        <td style="width:1.448%;"/>
        <td style="width:1.514%;"/>
        <td style="width:13.057%;"/>
        <td style="width:1.002%;"/>
        <td style="width:1.448%;"/>
        <td style="width:1.514%;"/>
        <td style="width:13.471%;"/>
        <td style="width:1.002%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Years Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Current:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Federal</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,678</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">State</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">105</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Foreign</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total current</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,573</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred:</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Federal</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">125</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">242</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">State</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Foreign</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Total deferred</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">125</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">242</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Provision for (benefit from) income taxes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">125</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,815</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of (Provision for) Benefit from Income Taxes Differs from Federal Statutory Rate to the Loss Before Taxes</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">For the rate table below the (provision for) benefit from income taxes differ from the amount expected by applying the federal statutory rate to the loss before taxes as follows:</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.102%;"/>
        <td style="width:1.427%;"/>
        <td style="width:0.686%;"/>
        <td style="width:11.84%;"/>
        <td style="width:3.496%;"/>
        <td style="width:1.427%;"/>
        <td style="width:0.686%;"/>
        <td style="width:11.84%;"/>
        <td style="width:3.496%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Federal statutory income tax rate</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">21.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Other permanent differences</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.9</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.5</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">State income taxes</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.9</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Federal benefit from NOL carryback</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.0</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6.7</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">24.8</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">25.8</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Change in fair value of redeemable convertible preferred stock tranche liability and TRDF liability</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.0</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.5</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock-based compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1.0</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)%</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.1</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Provision for income taxes</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">0.2</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">7.1</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">%</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">The tax effects of temporary differences and carryforwards of the deferred tax assets are presented below (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:65.389%;"/>
        <td style="width:1.438%;"/>
        <td style="width:1.503%;"/>
        <td style="width:13.363%;"/>
        <td style="width:1.002%;"/>
        <td style="width:1.438%;"/>
        <td style="width:1.503%;"/>
        <td style="width:13.363%;"/>
        <td style="width:1.002%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred Tax Assets:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net operating loss carryforwards</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">67,675</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">51,796</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease right-of-use asset liability</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,504</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,686</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred revenue</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,263</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">2,857</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Stock-based compensation</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,726</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,750</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Intangible assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,081</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,195</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Fixed assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">196</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Accruals and reserves</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">1,042</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">654</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Research and development credit carryforwards</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">26</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">26</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Gross deferred tax assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">78,513</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">63,964</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Less: Valuation allowance</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">73,163</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">57,715</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax assets, net of valuation allowance</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,350</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,249</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Deferred tax liabilities:</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Fixed assets</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Basis Difference IPR&amp;D</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">313</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Operating lease right-of-use asset</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">5,350</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">6,061</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Net deferred tax assets</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">(</span><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">125</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">)</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Reconciliation of Unrecognized Tax Benefits</a></td>
<td class="text"><p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">A reconciliation of the beginning and ending unrecognized tax benefit amount is as follows (in thousands):</span></p><p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p>
      <table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;">
       <tr style="visibility:collapse;">
        <td style="width:66.82%;"/>
        <td style="width:1.489%;"/>
        <td style="width:1.284%;"/>
        <td style="width:13.199%;"/>
        <td style="width:0.627%;"/>
        <td style="width:1.489%;"/>
        <td style="width:1.284%;"/>
        <td style="width:13.18%;"/>
        <td style="width:0.627%;"/>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">Year Ended December 31,</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:8.0pt;">
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2021</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;">2020</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"><p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"><span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at the beginning of the year</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">797</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">797</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"><p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Adjustment based on tax positions related to current year</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">3,243</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">&#8212;</span></p></td>
        <td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
       <tr style="height:10.0pt;">
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">Balance at the end of the year</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">4,040</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">$</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"><span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;">797</span></p></td>
        <td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"><p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"><span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;">&#160;</span></p></td>
       </tr>
      </table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=124434304&amp;loc=d3e36027-109320<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139685479885240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Nature of the Business - Additional Information (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>Sep. 15, 2020</div></th>
<th class="th"><div>Sep. 15, 2020</div></th>
<th class="th">
<div>Feb. 28, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule Of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationDateOfIncorporation', window );">Entity incorporation date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Nov. 30,  2014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_EntityDateOfMerger', window );">Entity date of merger</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Apr. 28,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, Ownership percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1-for-7<span></span>
</td>
<td class="text">1-for-7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_ExchangeRatio', window );">Exchange ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding | shares</a></td>
<td class="nump">39,736,914<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,736,914<span></span>
</td>
<td class="nump">19,677,249<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit | $</a></td>
<td class="nump">$ 168,324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 168,324<span></span>
</td>
<td class="nump">$ 106,325<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased', window );">Common stock, shares repurchased under stock purchase agreement | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,153,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=acet_AdicetTherapeuticsIncMember', window );">Adicet Therapeutics [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule Of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, Ownership percentage</a></td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding | shares</a></td>
<td class="nump">19,589,828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19,589,828<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit | $</a></td>
<td class="nump">$ 168,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 168,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">Initial Public Offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule Of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of common stock shares sold | shares</a></td>
<td class="nump">7,187,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,575,513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased', window );">Common stock, shares repurchased under stock purchase agreement | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,153,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Issuance price per shares | $ / shares</a></td>
<td class="nump">$ 14.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13.00<span></span>
</td>
<td class="nump">$ 14.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_UnderwritingDiscountsAndCommissionsAndOtherOfferingExpenses', window );">Underwriting discounts and commissions and other offering expenses | $</a></td>
<td class="nump">$ 94,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 128,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_EntityDateOfMerger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Entity date of merger.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_EntityDateOfMerger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_ExchangeRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exchange ratio.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_ExchangeRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_UnderwritingDiscountsAndCommissionsAndOtherOfferingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Underwriting discounts and commissions and other offering expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_UnderwritingDiscountsAndCommissionsAndOtherOfferingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationDateOfIncorporation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date when an entity was incorporated</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationDateOfIncorporation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=acet_AdicetTherapeuticsIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=acet_AdicetTherapeuticsIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139685479857816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 15, 2020</div></th>
<th class="th">
<div>Mar. 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>Customer </div>
<div>Segment</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_ExchangeRatio', window );">Exchange ratio</a></td>
<td class="nump">0.1240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_GainLossOnChangeInFairValueOfContingentConsiderationLiability', window );">Gain (loss) on change in fair value of CVR</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_NumberOfCustomer', window );">Number of customer | Customer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_CustomersPercentageOfTotalRevenue', window );">Customers percentage of total revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_FinancingReceivableNonaccrualToOutstandingPercent', window );">Outstanding accounts receivable percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Asset impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of Operating Segments | Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of Reportable Segments | Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,358,000<span></span>
</td>
<td class="nump">$ 23,066,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,944,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research And Development Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_CustomersPercentageOfTotalRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Customers percentage of total revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_CustomersPercentageOfTotalRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_ExchangeRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exchange ratio.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_ExchangeRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_GainLossOnChangeInFairValueOfContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain loss on change in fair value of contingent consideration liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_GainLossOnChangeInFairValueOfContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_NumberOfCustomer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_NumberOfCustomer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_FinancingReceivableNonaccrualToOutstandingPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of nonaccrual to total financing receivable outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1405<br> -Paragraph (a)<br> -Subparagraph (2)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_FinancingReceivableNonaccrualToOutstandingPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123351718&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13854-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13777-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139685480048024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Business Combination - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 29, 2021</div></th>
<th class="th">
<div>Sep. 15, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 15, 2020 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>ValueRight </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityReverseStockSplit', window );">Reverse stock split</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1-for-7<span></span>
</td>
<td class="text">1-for-7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,462<span></span>
</td>
<td class="nump">$ 20,089<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period closing of the merger</a></td>
<td class="text">60 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of common stock shares sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,916,853<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=acet_ResTORbioMember', window );">resTORbio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split exchange ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage', window );">Percentage of outstanding capital stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_NumberOfSharesOfSurvivingStockOptions', window );">Number of shares of surviving stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">81,370<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_UnvestedRestrictedStockUnitsOutstanding', window );">Unvested restricted stock units outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">91,309<span></span>
</td>
<td class="nump">91,309<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of common stock shares sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54,553<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 19,462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForMergerRelatedCosts', window );">Transaction cost for merger | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_ContractualContingentValueRight', window );">Contractual Contingent Value Right | ValueRight</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=acet_ResTORbioMember', window );">resTORbio | Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage', window );">Percentage of outstanding capital stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_ContractualContingentValueRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual Contingent Value Right</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_ContractualContingentValueRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_NumberOfSharesOfSurvivingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of surviving stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_NumberOfSharesOfSurvivingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_UnvestedRestrictedStockUnitsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unvested restricted stock units outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_UnvestedRestrictedStockUnitsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of equity in the acquiree held by the acquirer immediately before the acquisition date in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForMergerRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the reporting period for charges associated with the mergers.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForMergerRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityReverseStockSplit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB Topic 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityReverseStockSplit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=acet_ResTORbioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=acet_ResTORbioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139685480674920">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Business Combination - Schedule of Summarizes the Purchase Price in the Merger (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Sep. 15, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 980<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=acet_ResTORbioMember', window );">resTORbio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure', window );">Fair value of common stock shares of the combined company owned by resTORbio stockholders</a></td>
<td class="nump">$ 84,142<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Contingent consideration liability</a></td>
<td class="nump">2,880<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Purchase price</a></td>
<td class="nump">$ 87,022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of equity issued in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=acet_ResTORbioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=acet_ResTORbioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139685484864472">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Business Combination - Schedule of Estimated Share Consideration of Combined Company (Details) - resTORbio<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th">
<div>Sep. 15, 2020 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Number of shares of the combined company owned by resTORbio stockholders | shares</a></td>
<td class="nump">5,207,695<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Multiplied by the fair value per share of resTORbio common stock | $ / shares</a></td>
<td class="nump">$ 16.59<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1', window );">Acquisition date fair value of resTORbio common shares</a></td>
<td class="nump">$ 86,396<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_FairValueOfModifiedStockOptionsAndRestrictedStockUnitsAttributableToPreCombinationServices', window );">Estimated fair value of modified stock options and restricted stock units attributable to pre-combination services</a></td>
<td class="nump">626<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_LessPortionOfFairValueToBeDistributedAsCVR', window );">Less: portion of the fair value to be distributed as CVR</a></td>
<td class="num">(2,880)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure', window );">Fair value of common stock shares of the combined company owned by resTORbio stockholders</a></td>
<td class="nump">$ 84,142<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_FairValueOfModifiedStockOptionsAndRestrictedStockUnitsAttributableToPreCombinationServices">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of modified stock options and restricted stock units attributable to pre-combination services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_FairValueOfModifiedStockOptionsAndRestrictedStockUnitsAttributableToPreCombinationServices</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_LessPortionOfFairValueToBeDistributedAsCVR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Less portion of the fair value to be distributed as CVR.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_LessPortionOfFairValueToBeDistributedAsCVR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value at acquisition-date of the equity interest in the acquiree held by the acquirer, immediately before the acquisition date for businesses combined in stages.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of equity issued in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=acet_ResTORbioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=acet_ResTORbioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139685570513176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Business Combination - Schedule of Estimated Share Consideration of Combined Company (Parenthetical) (Details) - resTORbio<br></strong></div></th>
<th class="th">
<div>Sep. 15, 2020 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Number of shares of the combined company owned by resTORbio stockholders</a></td>
<td class="nump">5,207,695<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of common stock shares sold</a></td>
<td class="nump">54,553<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120321790&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=acet_ResTORbioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=acet_ResTORbioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139685479844264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Business Combination - Schedule of Summarizes the Purchase Price in the Merger (Parenthetical) (Details) - resTORbio<br></strong></div></th>
<th class="th">
<div>Sep. 15, 2020 </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_UnvestedRestrictedStockUnitsOutstanding', window );">Unvested restricted stock units outstanding</a></td>
<td class="nump">91,309<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Number of common stock shares sold</a></td>
<td class="nump">54,553<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_NumberOfSharesOfSurvivingStockOptions', window );">Number of shares of surviving stock options</a></td>
<td class="nump">81,370<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_NumberOfSharesOfSurvivingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of surviving stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_NumberOfSharesOfSurvivingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_UnvestedRestrictedStockUnitsOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unvested restricted stock units outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_UnvestedRestrictedStockUnitsOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=acet_ResTORbioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=acet_ResTORbioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139685479989384">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Business Combination - Schedule of Summarizes the Allocation of the Purchase Price to the Net Tangible and Intangible Assets Acquired (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract', window );"><strong>Net assets acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 19,462<span></span>
</td>
<td class="nump">$ 20,089<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=acet_ResTORbioMember', window );">resTORbio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract', window );"><strong>Net assets acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">63,869<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">3,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="nump">318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment', window );">IPR&amp;D</a></td>
<td class="nump">3,490<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash', window );">Restricted cash</a></td>
<td class="nump">245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts payable</a></td>
<td class="num">(1,304)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther', window );">Accrued and other current liabilities</a></td>
<td class="num">(2,365)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred tax liability</a></td>
<td class="num">(367)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">19,462<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Purchase price</a></td>
<td class="nump">87,022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=acet_ResTORbioMember', window );">resTORbio | Preliminary</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract', window );"><strong>Net assets acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,869<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,059<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment', window );">Property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">318<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment', window );">IPR&amp;D</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">245<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,316)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther', window );">Accrued and other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,365)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther', window );">Other liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Deferred tax liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(367)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,089<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet', window );">Purchase price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 87,022<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=acet_ResTORbioMember', window );">resTORbio | Measurement Period Adjustments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract', window );"><strong>Net assets acquired:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">615<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="num">$ (627)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business combination recognized identifiable assets acquired and liabilities assumed in process research and development.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business combination recognized identifiable assets acquired and liabilities assumed restricted cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of property, plant, and equipment recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=123455525&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=120320667&amp;loc=SL49117168-202975<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=acet_ResTORbioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=acet_ResTORbioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_ScenarioPreviouslyReportedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RestatementAxis=srt_RestatementAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RestatementAxis=srt_RestatementAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139685480214456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Business Combination - Schedule of changes in the Company's IPR&amp;D and CVR since the Merger (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Sep. 15, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In Process Research and Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAssetsArisingFromContingenciesAmountRecognized', window );">Fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,190<span></span>
</td>
<td class="nump">$ 3,490<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In Process Research and Development | Measure of Changes in Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAssetsArisingFromContingenciesAmountRecognized', window );">Fair value</a></td>
<td class="num">(1,190)<span></span>
</td>
<td class="num">(2,300)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=acet_ContingentValueRightsAgreementMember', window );">Contingent Value Rights Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAssetsArisingFromContingenciesAmountRecognized', window );">Fair value</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">980<span></span>
</td>
<td class="nump">$ 2,880<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=acet_ContingentValueRightsAgreementMember', window );">Contingent Value Rights Agreement | Measure of Changes in Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems', window );"><strong>Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationAssetsArisingFromContingenciesAmountRecognized', window );">Fair value</a></td>
<td class="num">$ (980)<span></span>
</td>
<td class="num">$ (1,900)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationAssetsArisingFromContingenciesAmountRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount, measured at acquisition-date fair value, of all the assets acquired that arise from contingencies and were recognized by the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123413009&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationAssetsArisingFromContingenciesAmountRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_ChangeDuringPeriodFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_ChangeDuringPeriodFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=acet_ContingentValueRightsAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=acet_ContingentValueRightsAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139685480415880">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured on Recurring Basis (Details) - Fair Value Recurring [Member] - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total fair value of assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 147,071<span></span>
</td>
<td class="nump">$ 74,101<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total fair value of liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">980<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Money Market Funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total fair value of assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">147,071<span></span>
</td>
<td class="nump">63,817<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Commercial Paper</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total fair value of assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Marketable Securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total fair value of assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,284<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Asset Backed Securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total fair value of assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,522<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Corporate Debt Securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total fair value of assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,762<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Redeemable Convertible Preferred Stock Warrant Liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total fair value of liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">980<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Level 1</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total fair value of assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">147,071<span></span>
</td>
<td class="nump">63,817<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Level 1 | Money Market Funds</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total fair value of assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 147,071<span></span>
</td>
<td class="nump">63,817<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Level 2</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total fair value of assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,284<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Level 2 | Commercial Paper</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total fair value of assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Level 2 | Marketable Securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total fair value of assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,284<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Level 2 | Asset Backed Securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total fair value of assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,522<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Level 2 | Corporate Debt Securities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total fair value of assets</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[2]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,762<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Level 3</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total fair value of liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">980<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Level 3 | Redeemable Convertible Preferred Stock Warrant Liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesFairValueDisclosure', window );">Total fair value of liabilities</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 980<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%">
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Included in cash and cash equivalents in the consolidated balance sheets</span></td>
</tr>
<tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[2]</td>
<td style="vertical-align: top;" valign="top"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Included in short-term marketable debt securities in the consolidated balance sheets.</span></td>
</tr>
</table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of financial and nonfinancial obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=acet_MarketableSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=acet_MarketableSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=acet_RedeemableConvertiblePreferredStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=acet_RedeemableConvertiblePreferredStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139685486442984">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurements - Additional Information (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Warrants outstanding | shares</a></td>
<td class="nump">220,890<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_EstimatedFairValueOfCVRLiability', window );">Estimated fair value of the CVR liability | $</a></td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_EstimatedFairValueOfCVRLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated fair value of CVR liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_EstimatedFairValueOfCVRLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139685480158328">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Debt Securities - Schedule of Marketable Debt Securities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 10,260<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">10,284<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember', window );">Asset Backed Securities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">7,507<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">7,522<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate Debt Securities</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">1,754<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">1,762<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesLineItems', window );"><strong>Marketable Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">999<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26610-111562<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=123581744&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_AssetBackedSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139685484793112">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Debt Securities - Summary of Classification of Marketable Debt Securities in Consolidated Balance Sheets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Short-term marketable debt securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 10,284<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Long-term marketable debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable debt securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 10,284<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139685485647160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract', window );"><strong>Prepaid Expense and Other Assets, Current [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidInsurance', window );">Prepaid insurance</a></td>
<td class="nump">$ 1,884<span></span>
</td>
<td class="nump">$ 1,443<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_PrepaymentsToCros', window );">Prepayments to CRO's</a></td>
<td class="nump">1,658<span></span>
</td>
<td class="nump">420<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid maintenance</a></td>
<td class="nump">1,021<span></span>
</td>
<td class="nump">761<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_PrepaymentsToCmos', window );">Prepayments to CMO's</a></td>
<td class="nump">115<span></span>
</td>
<td class="nump">135<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">229<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesReceivable', window );">Tax receivable</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,711<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Interest receivable</a></td>
<td class="nump">29<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total prepaid expenses and other current assets</a></td>
<td class="nump">$ 4,709<span></span>
</td>
<td class="nump">$ 5,722<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_PrepaymentsToCmos">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepayments to CMO's</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_PrepaymentsToCmos</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_PrepaymentsToCros">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepayments to CRO's</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_PrepaymentsToCros</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.5(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.3(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=123349782&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidInsurance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6387103&amp;loc=d3e6435-108320<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123349782&amp;loc=d3e5879-108316<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6787-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidInsurance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139685480365256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net - Summary of Property and Equipment, Net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 20,969<span></span>
</td>
<td class="nump">$ 7,654<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation and amortization</a></td>
<td class="num">(6,326)<span></span>
</td>
<td class="num">(4,864)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">14,643<span></span>
</td>
<td class="nump">2,790<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=acet_LaboratoryEquipmentMember', window );">Laboratory Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 5,502<span></span>
</td>
<td class="nump">4,350<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life (in years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 1,614<span></span>
</td>
<td class="nump">1,427<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Useful life (in years)</a></td>
<td class="text">Lesser of useful lifeor lease term<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and Fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 303<span></span>
</td>
<td class="nump">524<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life (in years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction In Progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 13,014<span></span>
</td>
<td class="nump">1,090<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 216<span></span>
</td>
<td class="nump">93<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life (in years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember', window );">Software</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 320<span></span>
</td>
<td class="nump">$ 170<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful life (in years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123364984&amp;loc=d3e1205-110223<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=acet_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=acet_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_SoftwareAndSoftwareDevelopmentCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139685484868984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">$ 1,538<span></span>
</td>
<td class="nump">$ 1,226<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_IncreaseInConstructionInProgress', window );">Increase in construction in progress</a></td>
<td class="nump">$ 11,900<span></span>
</td>
<td class="nump">$ 11,900<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_IncreaseInConstructionInProgress">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase in construction in progress</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_IncreaseInConstructionInProgress</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139685480047848">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued and Other Current Liabilities - Summary of Accrued and Other Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">$ 4,020<span></span>
</td>
<td class="nump">$ 3,833<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_AccruedCmoCosts', window );">Accrued CMO costs</a></td>
<td class="nump">1,077<span></span>
</td>
<td class="nump">244<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent', window );">Accrued professional services</a></td>
<td class="nump">546<span></span>
</td>
<td class="nump">363<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_AccruedResearchAndDevelopmentExpensesCurrent', window );">Accrued research and development expenses</a></td>
<td class="nump">504<span></span>
</td>
<td class="nump">65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued other liabilities</a></td>
<td class="nump">503<span></span>
</td>
<td class="nump">272<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_AccruedCroCosts', window );">Accrued CRO costs</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">955<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities', window );">Total</a></td>
<td class="nump">$ 6,682<span></span>
</td>
<td class="nump">$ 5,732<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_AccruedCmoCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued CMO costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_AccruedCmoCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_AccruedCroCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued CRO costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_AccruedCroCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_AccruedResearchAndDevelopmentExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development expenses current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_AccruedResearchAndDevelopmentExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesAndOtherLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesAndOtherLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.15(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139685480099896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Term Loan - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Oct. 21, 2021</div></th>
<th class="th"><div>Apr. 28, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class Of Warrant Or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansReceivableBasisSpreadOnVariableRate', window );">Interest rate for term loan to finance leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentMaturityDateRangeEnd1', window );">Loan availability end date</a></td>
<td class="text">Oct. 28,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFinanceCostsGross', window );">Debt issuance costs, gross</a></td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=acet_FourthAmendmentMember', window );">Fourth Amendment | Pacific western bank</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class Of Warrant Or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Available Loan</a></td>
<td class="nump">$ 10.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_LoanAmountDrawn', window );">Loan amount drawn</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_TermLoanAndNonFormulaAncillaryService', window );">Term loan and non formula ancillary service</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtDescription', window );">Long-term Debt, Description</a></td>
<td class="text">which each Term Loan to be in an amount of not less than $1.0 million. As of December 31, 2021, the Company had outstanding Non-Formula Ancillary Services of $4.4 million. Accordingly, as of December 31, 2021, the Company has $10.6 million available under the Term Loan. Pursuant to the Loan Amendment, the interest rate for the Term Loans shall be set at an annual rate equal to the greater of (i) 0.25% above the Prime Rate then in effect and (ii) 4.25%.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansPayable', window );">Outstanding balance under the loan agreement</a></td>
<td class="nump">$ 4.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class Of Warrant Or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_TermLoanToFinanceLeaseholdImprovements1', window );">Term loan to finance leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Prime Rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class Of Warrant Or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LoansReceivableBasisSpreadOnVariableRate', window );">Interest rate for term loan to finance leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.25%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_LoanAmountDrawn">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loan amount drawn</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_LoanAmountDrawn</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_TermLoanAndNonFormulaAncillaryService">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term loan and non formula ancillary service</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_TermLoanAndNonFormulaAncillaryService</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_TermLoanToFinanceLeaseholdImprovements1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>term loan to finance leasehold improvements 1</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_TermLoanToFinanceLeaseholdImprovements1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI http://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentMaturityDateRangeEnd1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Latest date the outstanding debt instruments are required to be repaid, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentMaturityDateRangeEnd1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFinanceCostsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFinanceCostsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16)(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LoansReceivableBasisSpreadOnVariableRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage added to reference rate used to compute variable rate on loan receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LoansReceivableBasisSpreadOnVariableRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of long-term debt arrangements, which are debt arrangements that originally require full repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer, and disclosures pertaining to the underlying arrangements, including repayment terms, conversion features, interest rates, restrictions on assets and activities, debt covenants, and other matters important to users of the financial statements. Types of long-term debt arrangements include borrowing under notes payable, bonds payable, debentures, term loans, and other contractual obligations for payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=acet_FourthAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=acet_FourthAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=acet_PacificWesternBankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=acet_PacificWesternBankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableRateAxis=us-gaap_PrimeRateMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableRateAxis=us-gaap_PrimeRateMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139685479297512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Regeneron License and Collaboration Arrangement - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 28, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Jul. 31, 2019</div></th>
<th class="th"><div>Jul. 29, 2016</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Jun. 30, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_ExercisedInvestmentRightAndPurchased', window );">Exercised Investment Right and Purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_LicenceAgreementCumulativeRevenueRecognised', window );">Licence agreement cumulative revenue recognised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_LicenseAndCollaborationRevenue', window );">License and collaboration revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,200,000<span></span>
</td>
<td class="nump">$ 17,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Payment from Regeneron for exercise of its option to license exclusive rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,688,000<span></span>
</td>
<td class="nump">460,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=acet_RegeneronPharmaceuticalsIncorporationMember', window );">Regeneron Pharmaceuticals, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_NonRefundableUpfrontPaymentReceived', window );">Non refundable upfront payment received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_LicenseAgreementAdditionalPaymentForResearchFundingReceived', window );">Additional payment for research funding received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_ContractResearchTermPeriod', window );">Contract research term period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_LicenceAgreementUpfrontPayment', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,000,000.0<span></span>
</td>
<td class="nump">25,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_LicenceAgreementAdditionalRevenueRecognised', window );">Licence agreement additional revenue recognised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_ContingentConsiderationFees', window );">Contingent Consideration fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_AgreementTransactionPrice', window );">Agreement transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">55,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_ResearchFundingFee', window );">Research funding fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice', window );">Increase in estimated transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_LicenseAgreementTerminationDescription', window );">License agreement termination description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">twelve (12) years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_LicenceAgreementCumulativeRevenueRecognised', window );">Licence agreement cumulative revenue recognised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_ContractLiability', window );">Contract liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,800,000<span></span>
</td>
<td class="nump">14,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Payment from Regeneron for exercise of its option to license exclusive rights</a></td>
<td class="nump">$ 20,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=acet_RegeneronPharmaceuticalsIncorporationMember', window );">Regeneron Pharmaceuticals, Inc. | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_LicenceAgreementAdditionalAmountPayableOfOptionExerciseFees', window );">Licence agreement additional amount payable of option exercise fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice', window );">Increase in estimated transaction price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=acet_RegeneronPharmaceuticalsIncorporationMember', window );">Regeneron Pharmaceuticals, Inc. | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_LicenceAgreementCumulativeRevenueRecognised', window );">Licence agreement cumulative revenue recognised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_AgreementTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Agreement transaction price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_AgreementTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_ContingentConsiderationFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent Consideration fees</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_ContingentConsiderationFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_ContractLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_ContractLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_ContractResearchTermPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract research term period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_ContractResearchTermPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_ExercisedInvestmentRightAndPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercised Investment Right and Purchased</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_ExercisedInvestmentRightAndPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_LicenceAgreementAdditionalAmountPayableOfOptionExerciseFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional amount payable of option exercise fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_LicenceAgreementAdditionalAmountPayableOfOptionExerciseFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_LicenceAgreementAdditionalRevenueRecognised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Licence agreement additional revenue recognised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_LicenceAgreementAdditionalRevenueRecognised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_LicenceAgreementCumulativeRevenueRecognised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cumulative revenue recognised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_LicenceAgreementCumulativeRevenueRecognised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_LicenceAgreementUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_LicenceAgreementUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_LicenseAgreementAdditionalPaymentForResearchFundingReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional payment for research funding received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_LicenseAgreementAdditionalPaymentForResearchFundingReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_LicenseAgreementTerminationDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreement termination description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_LicenseAgreementTerminationDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_LicenseAndCollaborationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License and collaboration revenue</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_LicenseAndCollaborationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_NonRefundableUpfrontPaymentReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Non refundable upfront payment received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_NonRefundableUpfrontPaymentReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_ResearchFundingFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research funding fee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_ResearchFundingFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123351226&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=acet_RegeneronPharmaceuticalsIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=acet_RegeneronPharmaceuticalsIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139685479812072">
<tr>
<th class="tl" colspan="2" rowspan="2"><div style="width: 200px;"><strong>Regeneron License and Collaboration Arrangement - Summary of Change in Company's Contract Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th" colspan="2"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=acet_ContractAssetMember', window );">Contract Asset</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_ContractAssetsAndLiabilitiesAdditions', window );">Additions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_ContractAssetsAndLiabilitiesAdditionsDeductions', window );">Additions (Deductions)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,000)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=acet_ContractLiabilityMember', window );">Contract Liability</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_ContractAssetsAndLiabilities', window );">Balance at beginning of period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 13,980<span></span>
</td>
<td class="nump">21,883<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_ContractAssetsAndLiabilitiesAdditions', window );">Additions</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_ContractAssetsAndLiabilitiesAdditionsDeductions', window );">Additions (Deductions)</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(9,175)<span></span>
</td>
<td class="num">(17,903)<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"><sup>[1]</sup></td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_ContractAssetsAndLiabilities', window );">Balance at end of period</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 4,805<span></span>
</td>
<td class="nump">$ 13,980<span></span>
</td>
<td class="fn" style="border-bottom: 0px;"></td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:6.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(1)	Deductions to contract liabilities relate to deferred revenue recognized as revenue during the reporting period.</span></p></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_ContractAssetsAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_ContractAssetsAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_ContractAssetsAndLiabilitiesAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract assets and liabilities additions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_ContractAssetsAndLiabilitiesAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_ContractAssetsAndLiabilitiesAdditionsDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contract assets and liabilities additions (deductions).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_ContractAssetsAndLiabilitiesAdditionsDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=acet_ContractAssetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=acet_ContractAssetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=acet_ContractLiabilityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=acet_ContractLiabilityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139685479161672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Funding and Other Agreements Related to the CVR - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2020</div></th>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Nov. 30, 2020</div></th>
<th class="th"><div>May 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 23, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_EstimatedFairValueOfCVRLiability', window );">Estimated fair value of the CVR liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=acet_NationalInstitutesOfHealthMember', window );">National Institute of Health</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_GrantTerm', window );">Grant term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GrantsReceivable', window );">Grants receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_QualifyingExpenses', window );">Qualifying expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_QualifyingExpensesOnCumulativeBasis', window );">Qualifying Expenses On Cumulative Basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=acet_NationalInstitutesOfHealthMember', window );">National Institute of Health | Research Funding Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_QualifyingExpenses', window );">Qualifying expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_QualifyingExpensesOnCumulativeBasis', window );">Qualifying Expenses On Cumulative Basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=acet_ContingentValueRightsAgreementMember', window );">Contingent Value Rights Agreement | C O V I D19</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_FeesAndExpenseIncurredInConnectionWithClinicalTrials', window );">Total fees and expenses related to clinical trials</a></td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_IncreaseDecreaseInEstimatedFairValueOfCvrLiability', window );">Increase decrease in estimated fair value of CVR liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_EstimatedFairValueOfCVRLiability', window );">Estimated fair value of the CVR liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_PostExposureProphylaxisDescription', window );">Post Exposure Prophylaxis Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> In February 2021, management terminated the National Institute on Aging study of RTB101 for COVID-19 post-exposure prophylaxis in adults age 65 years and older due to poor enrollment<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=acet_NovartisLicenseAgreementMember', window );">Novartis License Agreement | Novartis International Pharmaceutical Ltd.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_LicenseAgreementTerminationDescription', window );">License agreement termination description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The agreement may be terminated by either party upon a material breach of obligation by the other party that is not cured with 60 days after written notice. resTORbio may terminate the agreement in its entirety or on a product-by-product or country-by-country basis with or without cause with 60 days&#8217; prior written notice.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=acet_NovartisLicenseAgreementMember', window );">Novartis License Agreement | Novartis International Pharmaceutical Ltd. | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research And Development Arrangement Contract To Perform For Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfClinicalMilestonesPayable', window );">Aggregate amount payable upon satisfaction of clinical milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfRegulatoryMilestonesPayableForFirstIndicationApproved', window );">Aggregate amount payable upon satisfaction of regulatory milestones for first indication approved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfRegulatoryMilestonesPayableForSecondIndicationApproved', window );">Aggregate amount payable upon satisfaction of regulatory milestones for second indication approved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfCommercialMilestonesPayable', window );">Aggregate amount payable upon satisfaction of commercial milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_EstimatedFairValueOfCVRLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated fair value of CVR liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_EstimatedFairValueOfCVRLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_FeesAndExpenseIncurredInConnectionWithClinicalTrials">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fees and expense incurred in connection with clinical trials.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_FeesAndExpenseIncurredInConnectionWithClinicalTrials</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_GrantTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Grant term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_GrantTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_IncreaseDecreaseInEstimatedFairValueOfCvrLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase decrease in estimated fair value of cvr liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_IncreaseDecreaseInEstimatedFairValueOfCvrLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfClinicalMilestonesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreement milestone payments upon satisfaction of clinical milestones payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfClinicalMilestonesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfCommercialMilestonesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreement milestone payments upon satisfaction of commercial milestones payable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfCommercialMilestonesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfRegulatoryMilestonesPayableForFirstIndicationApproved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreement milestone payments upon satisfaction of regulatory milestones payable for first indication approved.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfRegulatoryMilestonesPayableForFirstIndicationApproved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfRegulatoryMilestonesPayableForSecondIndicationApproved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreement milestone payments upon satisfaction of regulatory milestones payable for second indication approved.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfRegulatoryMilestonesPayableForSecondIndicationApproved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_LicenseAgreementTerminationDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License agreement termination description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_LicenseAgreementTerminationDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_PostExposureProphylaxisDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Post Exposure Prophylaxis in adults</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_PostExposureProphylaxisDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_QualifyingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Qualifying expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_QualifyingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_QualifyingExpensesOnCumulativeBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>qualifying expenses on cumulative basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_QualifyingExpensesOnCumulativeBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrantsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrantsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=acet_NationalInstitutesOfHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=acet_NationalInstitutesOfHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=acet_ResearchFundingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=acet_ResearchFundingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=acet_ContingentValueRightsAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=acet_ContingentValueRightsAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnusualRiskOrUncertaintyByNatureAxis=acet_COVID19Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnusualRiskOrUncertaintyByNatureAxis=acet_COVID19Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=acet_NovartisLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis=acet_NovartisLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=acet_NovartisInternationalPharmaceuticalLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=acet_NovartisInternationalPharmaceuticalLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139685479468632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies - Additional Information (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jul. 19, 2021 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Jun. 25, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($) </div>
<div>Lawsuit</div>
</th>
<th class="th">
<div>Dec. 31, 2020 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Long Term Purchase Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_IncreaseDecreaseInLeaseObligation', window );">Change in lease Obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_AmendedLeaseAgreementDescription', window );">Amended lease Agreement Description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">the Company entered into an amendment to the Menlo Park lease to extend the term of the lease from March 31, 2022 to June 30, 2022 and replace the previously leased premises (known as 173 and 175-177 Jefferson Drive) with another nearby premises (known as 235 Constitution Drive).<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jun. 30,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_OperatingLeasesCommencementDate', window );">Operating leases commencement date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 15,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 23,066,000<span></span>
</td>
<td class="nump">$ 20,358,000<span></span>
</td>
<td class="nump">$ 23,066,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,944,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">23,066,000<span></span>
</td>
<td class="nump">$ 20,358,000<span></span>
</td>
<td class="nump">23,066,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_LawsuitsFiledAgainstCompany', window );">Lawsuits Filed Against Company | Lawsuit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation settlement expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Topic 842</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Long Term Purchase Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,300,000<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Long Term Purchase Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Rent expense recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 87,286,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Long Term Purchase Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Rent expense recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 89,904,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=acet_RfsOpcoLlcMember', window );">RFS OPCO LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Long Term Purchase Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_AreaOfSublease', window );">Area of Sublease | ft&#178;</a></td>
<td class="nump">9,501<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_SubleaseAgreementDescription', window );">Sublease Agreement Description</a></td>
<td class="text">The term of the sublease started on September 1, 2021 and ends on July 30, 2026. The aggregate base rent due to the Company under the Sublease is approximately $3.5 million starting October 1, 2021. The Company records sublease income as a reduction of lease expense. <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1', window );">Operating Leases, Rent Expense, Sublease Rentals</a></td>
<td class="nump">$ 3,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecurityDepositLiability', window );">Cash security deposit received</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=acet_MenloParkLeaseAgreementMember', window );">Menlo Park Lease Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Long Term Purchase Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letters of Credit issued amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=acet_RedwoodCityLeaseAgreementMember', window );">Redwood City Lease Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Long Term Purchase Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letters of Credit issued amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=acet_BostonMember', window );">Boston, Massachusetts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Long Term Purchase Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letters of Credit issued amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_AmendedLeaseAgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amended lease Agreement Details</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_AmendedLeaseAgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_AreaOfSublease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of Sublease</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_AreaOfSublease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_IncreaseDecreaseInLeaseObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase Decrease in Lease Obligation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_IncreaseDecreaseInLeaseObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_LawsuitsFiledAgainstCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lawsuits filed against company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_LawsuitsFiledAgainstCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_OperatingLeasesCommencementDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating leases commencement date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_OperatingLeasesCommencementDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_SubleaseAgreementDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sublease Agreement Description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_SubleaseAgreementDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseSubleaseRentals1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of sublease rental income recognized during the period that reduces the entity's rent expense incurred under operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123403562&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseSubleaseRentals1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecurityDepositLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents money paid in advance to protect the provider of a product or service, such as a lessor, against damage or nonpayment by the buyer or tenant (lessee) during the term of the agreement. Such damages may include physical damage to the property, theft of property, and other contractual breaches. Security deposits held may be interest or noninterest bearing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.15(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecurityDepositLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=acet_RfsOpcoLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=acet_RfsOpcoLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=acet_MenloParkLeaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=acet_MenloParkLeaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=acet_RedwoodCityLeaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=acet_RedwoodCityLeaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=acet_BostonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=acet_BostonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139685485525624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments And Contingencies - Schedule of Sublease Income (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_OperatingLeasesFutureMinimumSubleaseIncomeDueCurrent', window );">2022</a></td>
<td class="nump">$ 657<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInTwoYears', window );">2023</a></td>
<td class="nump">671<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInThreeYears', window );">2024</a></td>
<td class="nump">685<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInFourYears', window );">2025</a></td>
<td class="nump">699<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInFiveYears', window );">2026</a></td>
<td class="nump">416<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_OperatingLeasesFutureMinimumSubleaseIncomeDue', window );">Total</a></td>
<td class="nump">$ 3,128<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_OperatingLeasesFutureMinimumSubleaseIncomeDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Leases Future Minimum Sublease Income Due</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_OperatingLeasesFutureMinimumSubleaseIncomeDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_OperatingLeasesFutureMinimumSubleaseIncomeDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Leases Future Minimum Sublease Income Due Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_OperatingLeasesFutureMinimumSubleaseIncomeDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Leases Future Minimum Sublease Income Due In Five Years</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Leases Future Minimum Sublease Income Due In Four Years</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Leases Future Minimum Sublease Income Due In Three Years</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating Leases Future Minimum Sublease Income Due In Two Years</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139685485764056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitment and Contingencies - Schedule of Weighted Average IBR and Remaining Lease Term (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Long Term Purchase Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted Average IBR</a></td>
<td class="nump">7.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Remaining Terms (in years)</a></td>
<td class="text">7 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=acet_RedwoodCityLeaseAgreementMember', window );">Redwood City, CA</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Long Term Purchase Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted Average IBR</a></td>
<td class="nump">6.90%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Remaining Terms (in years)</a></td>
<td class="text">8 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=acet_BostonMember', window );">Boston, MA</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Long Term Purchase Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted Average IBR</a></td>
<td class="nump">9.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Remaining Terms (in years)</a></td>
<td class="text">4 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseContractualTermAxis=acet_MenloParkLeaseAgreementMember', window );">Menlo Park, CA</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentLineItems', window );"><strong>Long Term Purchase Commitment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted Average IBR</a></td>
<td class="nump">6.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Remaining Terms (in years)</a></td>
<td class="text">6 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=acet_RedwoodCityLeaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=acet_RedwoodCityLeaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=acet_BostonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=acet_BostonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseContractualTermAxis=acet_MenloParkLeaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseContractualTermAxis=acet_MenloParkLeaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139685479972248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitment and Contingencies - Summary of Lease Costs and Other Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostAbstract', window );"><strong>Lease Cost</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 4,282<span></span>
</td>
<td class="nump">$ 894<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermLeaseCost', window );">Short-term lease cost</a></td>
<td class="nump">235<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease Income</a></td>
<td class="num">(223)<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">4,294<span></span>
</td>
<td class="nump">950<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_LeaseCostOtherInformationAbstract', window );"><strong>Other Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePaymentsUse', window );">Operating cash flows used for lease liabilities</a></td>
<td class="nump">511<span></span>
</td>
<td class="nump">859<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Operating lease right of use asset obtained in exchange of operating lease liability</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 22,367<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_LeaseCostOtherInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease cost other information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_LeaseCostOtherInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePaymentsUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePaymentsUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term lease cost, excluding expense for lease with term of one month or less.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139685480047224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitment and Contingencies - Schedule Of Maturities Of Operating Lease Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths', window );">2022</a></td>
<td class="nump">$ 2,933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo', window );">2023</a></td>
<td class="nump">3,428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree', window );">2024</a></td>
<td class="nump">3,525<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour', window );">2025</a></td>
<td class="nump">3,625<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive', window );">2026 and thereafter</a></td>
<td class="nump">13,747<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payments</a></td>
<td class="nump">27,258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="nump">6,314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total operating lease liability</a></td>
<td class="nump">20,944<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: current portion</a></td>
<td class="nump">1,567<span></span>
</td>
<td class="nump">$ 1,215<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability, net of current maturities</a></td>
<td class="nump">$ 19,377<span></span>
</td>
<td class="nump">$ 20,424<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139685486465208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of common stock shares sold</a></td>
<td class="nump">10,575,513<span></span>
</td>
<td class="nump">7,187,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Public offering price</a></td>
<td class="nump">$ 13.00<span></span>
</td>
<td class="nump">$ 14.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction', window );">Proceeds from the offering</a></td>
<td class="nump">$ 128.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockDescriptionOfTransaction', window );">Description of stock purchase agreement</a></td>
<td class="text">the Company also entered into a stock purchase agreement with certain existing investors to purchase 1,153,840 shares of our common stock for  $15.0 million at a price per share equal to the public offering price, with an initial closing for investors held simultaneously with the closing of the offering and a subsequent closing for certain additional investors.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased', window );">Common stock, shares repurchased under stock purchase agreement</a></td>
<td class="nump">1,153,840<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Payments for repurchase of common stock</a></td>
<td class="nump">$ 15.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from the offering, after deducting expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 94.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_ClassOfWarrantExercised', window );">Warrant exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,301)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Common stock dividends declared | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_ClassOfWarrantExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants, exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_ClassOfWarrantExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedPerTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedPerTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockDescriptionOfTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of stock transaction which may include details of the offering (IPO, private placement), a description of the stock sold, percentage of subsidiary's or equity investee's stock sold, a description of the investors and whether the stock was issued in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4569655-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockDescriptionOfTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139685480103496">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Stockholders' Equity - Schedule of Number of Shares of Common Stock Reserved for Future Issuance (Details) - shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares of common stock reserved for future issuance</a></td>
<td class="nump">6,829,205<span></span>
</td>
<td class="nump">5,672,757<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Options Issued and Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares of common stock reserved for future issuance</a></td>
<td class="nump">3,875,317<span></span>
</td>
<td class="nump">3,706,945<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=acet_OptionsAvailableForFutureGrantsMember', window );">Stock Options Available for Future Grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares of common stock reserved for future issuance</a></td>
<td class="nump">1,961,338<span></span>
</td>
<td class="nump">1,739,621<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested Restricted Stock Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares of common stock reserved for future issuance</a></td>
<td class="nump">771,660<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=acet_CommonStockWarrantsMember', window );">Common Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares of common stock reserved for future issuance</a></td>
<td class="nump">220,890<span></span>
</td>
<td class="nump">226,191<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=acet_OptionsAvailableForFutureGrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=acet_OptionsAvailableForFutureGrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=acet_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=acet_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139685480230872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Schedule of Outstanding Warrants (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>Liabilities and Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_ClassOfWarrantOutstandingAndExercisableToPurchasePreferredShares', window );">Number of warrants, Outstanding and exercisable to purchase preferred shares as of December 31, 2020</a></td>
<td class="nump">226,191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_ClassOfWarrantOrRightIssued', window );">Number of warrants, Issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_ClassOfWarrantExercised', window );">Number of warrants, Exercised</a></td>
<td class="num">(5,301)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_ClassOfWarrantOutstandingAndExercisableToPurchaseCommonStock', window );">Number of warrants, Outstanding and exercisable to purchase common stock as of December 31, 2021</a></td>
<td class="nump">220,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="nump">$ 11.3177<span></span>
</td>
<td class="nump">$ 11.3177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_WarrantsOutstandingAndExercisableWeightedAverageRemainingContractualTerm', window );">Warrants outstanding and exercisable, Weighted average remaining contractual term</a></td>
<td class="text">4 years 7 months 28 days<span></span>
</td>
<td class="text">5 years 7 months 28 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_ClassOfWarrantExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants, exercised.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_ClassOfWarrantExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_ClassOfWarrantOrRightIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_ClassOfWarrantOrRightIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_ClassOfWarrantOutstandingAndExercisableToPurchaseCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_ClassOfWarrantOutstandingAndExercisableToPurchaseCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_ClassOfWarrantOutstandingAndExercisableToPurchasePreferredShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_ClassOfWarrantOutstandingAndExercisableToPurchasePreferredShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_WarrantsOutstandingAndExercisableWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_WarrantsOutstandingAndExercisableWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139685479438584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Schedule Of Outstanding Warrants To Purchase Shares of Common Stock (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares of Common Stock Issuable</a></td>
<td class="nump">220,890<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="nump">$ 11.3177<span></span>
</td>
<td class="nump">$ 11.3177<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=acet_SeptemberFifteenTwoThousandTwentyWarrantOneMember', window );">September 15, 2020 Warrant One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Issuance Date</a></td>
<td class="text">Sep. 15,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares of Common Stock Issuable</a></td>
<td class="nump">101,610<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="nump">$ 11.3177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_ClassOfWarrantOrRightsExpirationDate', window );">Expiration Date</a></td>
<td class="text">Jul. 25,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=acet_SeptemberFifteenTwoThousandTwentyWarrantTwoMember', window );">September 15, 2020 Warrant Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Issuance Date</a></td>
<td class="text">Sep. 15,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares of Common Stock Issuable</a></td>
<td class="nump">30,924<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="nump">$ 11.3177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_ClassOfWarrantOrRightsExpirationDate', window );">Expiration Date</a></td>
<td class="text">Aug. 21,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=acet_SeptemberFifteenTwoThousandTwentyWarrantThreeMember', window );">September 15, 2020 Warrant Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Issuance Date</a></td>
<td class="text">Sep. 15,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares of Common Stock Issuable</a></td>
<td class="nump">77,312<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="nump">$ 11.3177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_ClassOfWarrantOrRightsExpirationDate', window );">Expiration Date</a></td>
<td class="text">Sep. 19,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=acet_SeptemberFifteenTwoThousandTwentyWarrantFourMember', window );">September 15, 2020 Warrant Four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Issuance Date</a></td>
<td class="text">Sep. 15,  2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Number of Shares of Common Stock Issuable</a></td>
<td class="nump">11,044<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price</a></td>
<td class="nump">$ 11.3177<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_ClassOfWarrantOrRightsExpirationDate', window );">Expiration Date</a></td>
<td class="text">Sep. 26,  2026<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_ClassOfWarrantOrRightsExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Class Of Warrant Or Rights Expiration Date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_ClassOfWarrantOrRightsExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the warrants or rights are exercisable, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=acet_SeptemberFifteenTwoThousandTwentyWarrantOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=acet_SeptemberFifteenTwoThousandTwentyWarrantOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=acet_SeptemberFifteenTwoThousandTwentyWarrantTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=acet_SeptemberFifteenTwoThousandTwentyWarrantTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=acet_SeptemberFifteenTwoThousandTwentyWarrantThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=acet_SeptemberFifteenTwoThousandTwentyWarrantThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=acet_SeptemberFifteenTwoThousandTwentyWarrantFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=acet_SeptemberFifteenTwoThousandTwentyWarrantFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139685483459944">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>At-The-Market (ATM) Offering - Additional Information (Details) - At The Market Offering [Member] - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Mar. 12, 2021</div></th>
<th class="th"><div>Dec. 01, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_TerminationAgreementMonthAndYear', window );">Agreement terminated</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2021-02<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=acet_AtTheMarketOfferingMember', window );">Sales Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class Of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_MaximumAggregateValueOfCommonStockAvailableForOfferingAtMarketPriceUnderSalesAgreement', window );">Maximum aggregate value of common stock available for offering at-the-market price</a></td>
<td class="nump">$ 75.0<span></span>
</td>
<td class="nump">$ 50.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_MaximumAggregateValueOfCommonStockAvailableForOfferingAtMarketPriceUnderSalesAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum aggregate value of common stock available for offering at-the-market price under sales agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_MaximumAggregateValueOfCommonStockAvailableForOfferingAtMarketPriceUnderSalesAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_TerminationAgreementMonthAndYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Termination Agreement, month and year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_TerminationAgreementMonthAndYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearMonthItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=acet_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=acet_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=acet_SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=acet_SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139685484804312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 12,511<span></span>
</td>
<td class="nump">$ 5,263<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research And Development Expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">4,759<span></span>
</td>
<td class="nump">1,674<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">7,752<span></span>
</td>
<td class="nump">3,589<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">10,511<span></span>
</td>
<td class="nump">5,263<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=acet_EmployeeStockPurchasePlanMember', window );">Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">56<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 1,944<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=acet_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=acet_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139685477067432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2022</div></th>
<th class="th"><div>May 01, 2021</div></th>
<th class="th"><div>Apr. 27, 2021</div></th>
<th class="th"><div>Jan. 01, 2021</div></th>
<th class="th"><div>Jan. 01, 2020</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
<th class="th"><div>Oct. 31, 2021</div></th>
<th class="th"><div>Aug. 31, 2021</div></th>
<th class="th"><div>May 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Expense related to options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,511<span></span>
</td>
<td class="nump">$ 5,263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,100<span></span>
</td>
<td class="nump">2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense, estimated weighted-average period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">RSUs granted (includes PSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">560,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,161,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Stock issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 823,940<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options Issued and Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Total fair value of options vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="nump">$ 2,400<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Weighted-average grant date fair value of options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.68<span></span>
</td>
<td class="nump">$ 0.96<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 24,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Unrecognized compensation expense, estimated weighted-average period for recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 9 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Expense related to options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted- Average Grant Date Fair Value, RSUs granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.84<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">RSUs granted (includes PSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">560,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=acet_TwoThousandEighteenStockIncentivePlanMember', window );">2018 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage of additional shares added on outstanding shares</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=acet_TwoThousandEighteenStockIncentivePlanMember', window );">2018 Stock Incentive Plan | Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares reserved for issuance</a></td>
<td class="nump">1,986,845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=acet_TwoThousandSeventeenAndTwoThousandEighteenStockIncentivePlanMember', window );">2017 and 2018 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares of common stock available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,683,999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,574,170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">RSUs granted (includes PSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,410<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">205,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">771,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=acet_TwoThousandFourteenStockIncentivePlanMember', window );">2014 Stock Incentive Plan Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,987<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=acet_TwoThousandFifteenStockIncentivePlanMember', window );">2015 Stock Incentive Plan Member</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">915,657<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted average exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.46<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=acet_TwoThousandFourteenAndTwoThousandFifteenStockIncentivePlanMember', window );">2014 and 2015 Stock Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Number of shares of common stock available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">277,339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=acet_TwoThousandEighteenEmployeeStockPurchasePlanMember', window );">2018 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage of additional shares added on outstanding shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">524,775<span></span>
</td>
<td class="nump">131,432<span></span>
</td>
<td class="nump">79,369<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">524,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_NumberOfSharesAvailableForSaleUnderEmployeeStockPurchasePlan', window );">Number of shares available for sale under employee stock purchase plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,667<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=acet_TwoThousandEighteenEmployeeStockPurchasePlanMember', window );">2018 Employee Stock Purchase Plan | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares reserved for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">77,703<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=acet_TwoThousandEighteenEmployeeStockPurchasePlanMember', window );">2018 Employee Stock Purchase Plan | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Stock issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_NumberOfSharesAvailableForSaleUnderEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares available for sale under employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_NumberOfSharesAvailableForSaleUnderEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=acet_TwoThousandEighteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=acet_TwoThousandEighteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=acet_TwoThousandSeventeenAndTwoThousandEighteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=acet_TwoThousandSeventeenAndTwoThousandEighteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=acet_TwoThousandFourteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=acet_TwoThousandFourteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=acet_TwoThousandFifteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=acet_TwoThousandFifteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=acet_TwoThousandFourteenAndTwoThousandFifteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=acet_TwoThousandFourteenAndTwoThousandFifteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=acet_TwoThousandEighteenEmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=acet_TwoThousandEighteenEmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139685480006936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Stock Option Activity (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationAbstract', window );"><strong>Share-based Payment Arrangement, Noncash Expense [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares Underlying Outstanding Options, Beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,706,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Number of Shares Underlying Outstanding Options, Options granted</a></td>
<td class="nump">560,000<span></span>
</td>
<td class="nump">2,161,472<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Number of Shares Underlying Outstanding Options, Options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,125,339)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Number of Shares Underlying Outstanding Options, Options forfeited or cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(867,761)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Number of Shares Underlying Outstanding Options, Ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,875,317<span></span>
</td>
<td class="nump">3,706,945<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Number of Shares Underlying Outstanding Options, Shares exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">991,847<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Number of Shares Underlying Outstanding Options, Vested and expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,875,317<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Outstanding beginning</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Options forfeited or cancelled</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Outstanding ending</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14.08<span></span>
</td>
<td class="nump">$ 10.90<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Shares exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Weighted-Average Exercise Price, Vested and expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted-Average Remaining Contract Term, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 10 months 6 days<span></span>
</td>
<td class="text">7 years 11 months 23 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Remaining Contract Term, Shares exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 5 months 15 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Weighted-Average Remaining Contract Term, Vested and expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years 10 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Aggregate Intrinsic Value, Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,212<span></span>
</td>
<td class="nump">$ 15,126<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Aggregate Intrinsic Value, Shares exercisable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Aggregate Intrinsic Value, Vested and expected to vest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139685480600472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Schedule of Assumptions to Estimate Fair Value of Stock Options Using Black-Scholes Option Pricing Model (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum</a></td>
<td class="nump">77.20%<span></span>
</td>
<td class="nump">72.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum</a></td>
<td class="nump">79.80%<span></span>
</td>
<td class="nump">96.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk-free interest rate, minimum</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk-free interest rate, maximum</a></td>
<td class="nump">1.40%<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">10 months 24 days<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 29 days<span></span>
</td>
<td class="text">6 years 29 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139685480600472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Summary of Restricted Stock Unit Activity (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">RSUs granted (includes PSUs)</a></td>
<td class="nump">560,000<span></span>
</td>
<td class="nump">2,161,472<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Outstanding, December 31, 2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">RSUs granted (includes PSUs)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">777,160<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">RSUs Vested</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares', window );">RSUs forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,500)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Outstanding, December 31,2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">771,660<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted- Average Grant Date Fair Value, RSUs granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.84<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue', window );">Weighted Average Grant Date Fair Value, RSUs forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted- Average Grant Date Fair Value, ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.85<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139685491371816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss attributable to common stockholders</a></td>
<td class="num">$ (61,999)<span></span>
</td>
<td class="num">$ (36,678)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted</a></td>
<td class="nump">30,952,152<span></span>
</td>
<td class="nump">7,319,977<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share attributable to common stockholders, basic and diluted</a></td>
<td class="num">$ (2.00)<span></span>
</td>
<td class="num">$ (5.01)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139685491396664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">4,867,867<span></span>
</td>
<td class="nump">3,933,136<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Options To Purchase Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">3,875,317<span></span>
</td>
<td class="nump">3,706,945<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=acet_CommonStockWarrantsMember', window );">Common Stock Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">220,890<span></span>
</td>
<td class="nump">226,191<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Unvested Restricted Stock Awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of earnings per share</a></td>
<td class="nump">771,660<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=acet_CommonStockWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=acet_CommonStockWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139685479743784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Mar. 31, 2021</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory income tax rate, percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (125)<span></span>
</td>
<td class="num">$ (2,815)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_DeferredTaxAssetsValuationAllowanceIncrease', window );">Increase in valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,500<span></span>
</td>
<td class="nump">37,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,675<span></span>
</td>
<td class="nump">$ 51,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_OwnershipChangePlanDescription', window );">Ownership change plan description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain shareholders or public groups in the stock of a corporation by more than 50% over a three-year period<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,040<span></span>
</td>
<td class="nump">$ 797<span></span>
</td>
<td class="nump">$ 797<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment charges</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember', window );">Intellectual Property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=acet_CaliforniaResearchAndDevelopmentMember', window );">California Research And Development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=acet_FederalAndStateResearchAndDevelopmentMember', window );">Federal and state research and development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">271,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsExpirationDate', window );">Operating loss carryforwards, expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2037<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_OperatingLossCarryforwardsIndefinitely', window );">Operating Loss Carryforwards Indefinitely</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">264,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforward, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">143,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsExpirationDate', window );">Operating loss carryforwards, expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2035<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember', window );">Foreign Tax Authority</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnusualRiskOrUncertaintyByNatureAxis=acet_COVID19Member', window );">C O V I D19</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_IncomeTaxesDisclosureLineItems', window );"><strong>Income Taxes Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense (benefit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
<td class="nump">$ 2,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_DeferredTaxAssetsValuationAllowanceIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets Valuation Allowance Increase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_DeferredTaxAssetsValuationAllowanceIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_IncomeTaxesDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income taxes disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_IncomeTaxesDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_OperatingLossCarryforwardsIndefinitely">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards indefinitely.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_OperatingLossCarryforwardsIndefinitely</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_OwnershipChangePlanDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ownership change plan description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_OwnershipChangePlanDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsExpirationDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiration date of each operating loss carryforward included in operating loss carryforward, in YYYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsExpirationDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=acet_CaliforniaResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=acet_CaliforniaResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=acet_FederalAndStateResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=acet_FederalAndStateResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnusualRiskOrUncertaintyByNatureAxis=acet_COVID19Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnusualRiskOrUncertaintyByNatureAxis=acet_COVID19Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139685483453272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Components of Provision for (benefit from) Income Taxes (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (2,678)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">105<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,573)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">(125)<span></span>
</td>
<td class="num">(242)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Foreign</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred</a></td>
<td class="num">(125)<span></span>
</td>
<td class="num">(242)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision for (benefit from) income taxes</a></td>
<td class="num">$ (125)<span></span>
</td>
<td class="num">$ (2,815)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139685479890312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of (Provision for) Benefit from Income Taxes Differs from Federal Statutory Rate to the Loss Before Taxes (Detail)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory income tax rate, percent</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther', window );">Other permanent differences</a></td>
<td class="num">(1.90%)<span></span>
</td>
<td class="num">(0.50%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State income taxes</a></td>
<td class="nump">6.90%<span></span>
</td>
<td class="nump">6.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_EffectiveIncomeTaxRateReconciliationNOLCarryback', window );">Federal benefit from NOL carryback</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">6.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(24.80%)<span></span>
</td>
<td class="num">(25.80%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilityAndTRDFLiability', window );">Change in fair value of redeemable convertible preferred stock tranche liability and TRDF liability</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(0.50%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent', window );">Stock-based compensation</a></td>
<td class="num">(1.00%)<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Provision for income taxes</a></td>
<td class="nump">0.20%<span></span>
</td>
<td class="nump">7.10%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilityAndTRDFLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation change in fair value of redeemable convertible preferred stock tranche liability and TRDF liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilityAndTRDFLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_EffectiveIncomeTaxRateReconciliationNOLCarryback">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective income tax rate reconciliation NOL carryback.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_EffectiveIncomeTaxRateReconciliationNOLCarryback</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 740<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120384911&amp;loc=d3e23163-113944<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139685480055752">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred Tax Assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 67,675<span></span>
</td>
<td class="nump">$ 51,796<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_DeferredTaxOperatingLeaseRightOfUseAssetLiability', window );">Operating lease right-of-use asset liability</a></td>
<td class="nump">5,504<span></span>
</td>
<td class="nump">5,686<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">1,263<span></span>
</td>
<td class="nump">2,857<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">1,726<span></span>
</td>
<td class="nump">1,750<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangible assets</a></td>
<td class="nump">1,081<span></span>
</td>
<td class="nump">1,195<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_DeferredTaxAssetsFixedAssets', window );">Fixed Assets</a></td>
<td class="nump">196<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Accruals and reserves</a></td>
<td class="nump">1,042<span></span>
</td>
<td class="nump">654<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Research and development credit carryforwards</a></td>
<td class="nump">26<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">78,513<span></span>
</td>
<td class="nump">63,964<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: Valuation allowance</a></td>
<td class="num">(73,163)<span></span>
</td>
<td class="num">(57,715)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets, net of valuation allowance</a></td>
<td class="nump">5,350<span></span>
</td>
<td class="nump">6,249<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_DeferredTaxLiabilitiesFixedAssets', window );">Fixed assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_DeferredTaxBasisDifferenceIPRD', window );">Basis Difference IPR&amp;D</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(313)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_DeferredTaxOperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use asset</a></td>
<td class="num">(5,350)<span></span>
</td>
<td class="num">(6,061)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax asset</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 125<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_DeferredTaxAssetsFixedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets Fixed Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_DeferredTaxAssetsFixedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_DeferredTaxBasisDifferenceIPRD">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax basis difference IPR&amp;D.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_DeferredTaxBasisDifferenceIPRD</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_DeferredTaxLiabilitiesFixedAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax liabilities fixed assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_DeferredTaxLiabilitiesFixedAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_DeferredTaxOperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating lease right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_DeferredTaxOperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_DeferredTaxOperatingLeaseRightOfUseAssetLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax operating lease right of use asset liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_DeferredTaxOperatingLeaseRightOfUseAssetLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139685485585400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Reconciliation of Unrecognized Tax Benefits (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at the beginning of the year</a></td>
<td class="nump">$ 797<span></span>
</td>
<td class="nump">$ 797<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions', window );">Adjustment based on tax positions related to current year</a></td>
<td class="nump">3,243<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance at the end of the year</a></td>
<td class="nump">$ 4,040<span></span>
</td>
<td class="nump">$ 797<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139685491301416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Defined Contribution Plan - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_DefinedContributionPlanAbstract', window );"><strong>Defined Contribution Plan [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_CompanyContributionToPlanWithRespectToEmployeesContribution', window );">Defined contribution plan for employees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Company contribution in the plan</a></td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_CompanyContributionToPlanWithRespectToEmployeesContribution">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Company contribution to plan with respect to employees contribution.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_CompanyContributionToPlanWithRespectToEmployeesContribution</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_DefinedContributionPlanAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined contribution plan abstract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_DefinedContributionPlanAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139685480636504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">39,736,914<span></span>
</td>
<td class="nump">19,677,249<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromRelatedParties', window );">Revenue&#8212;related party</a></td>
<td class="nump">$ 9,730<span></span>
</td>
<td class="nump">$ 17,903<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=acet_RegeneronPharmaceuticalsIncorporationMember', window );">Regeneron Pharmaceuticals, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Convertible Preferred Stock, Shares Issued upon Conversion</a></td>
<td class="nump">883,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromRelatedParties', window );">Revenue&#8212;related party</a></td>
<td class="nump">$ 9,700<span></span>
</td>
<td class="nump">$ 17,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableGrossCurrent', window );">Accounts receivable</a></td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred Revenue</a></td>
<td class="nump">$ 4,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=acet_RegeneronPharmaceuticalsIncorporationMember', window );">Regeneron Pharmaceuticals, Inc. | Series B Convertible Preferred Stock [ Member ]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">883,568<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred Stock, Shares Issued</a></td>
<td class="nump">7,125,552<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableGrossCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4428-111522<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124259787&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableGrossCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=120401555&amp;loc=SL114874292-224272<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(C))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=acet_RegeneronPharmaceuticalsIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=acet_RegeneronPharmaceuticalsIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_SeriesBPreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm139685484730200">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Subsequent Events - Additional Information (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jan. 28, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_acet_ExerciseFeePaid', window );">Exercise Fee Paid</a></td>
<td class="nump">$ 20.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_acet_ExerciseFeePaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise fee paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">acet_ExerciseFeePaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>acet_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>acet-20211231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:acet="http://www.adicetbio.com/20211231"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="acet-20211231.xsd" xlink:type="simple"/>
    <context id="C_d66319b0-75d0-4205-b25e-8c8321f342f3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_65724930-27ec-4cc0-971f-f08bfefcc88e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_c1e72a0b-a7f8-4f4b-bd56-9c13a9000d2b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acet:NationalInstitutesOfHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-31</instant>
        </period>
    </context>
    <context id="C_269b2bf6-80a4-4772-a84e-435846b50f75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_91052d8c-9e4f-403f-ba68-6576fa344a03">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_76a7c6aa-3344-4804-9a25-aa31c1d6210f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_38799e03-7018-4654-b7db-0fc7800d94e4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">acet:AdicetTherapeuticsIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_eb6b17d5-2d48-4838-8382-90249e566d9f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">acet:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_229551d3-2c1b-4ec2-99aa-16652dd7eb75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_97f163d5-9ecd-43f8-8bae-d896a29f9d75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">acet:SeptemberFifteenTwoThousandTwentyWarrantFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_745de059-cb14-4ea1-8c29-12d351f50320">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_2c23f818-11c0-4555-af2a-af3a6c3d7db0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acet:TwoThousandFourteenAndTwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_4066c921-3deb-4a5c-8fd4-0507b83d109f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="C_02dd56d4-2777-4e62-8616-7488897fd4d0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_2d0f9825-f275-4fef-8d45-4314b18f7073">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="C_a6003cef-f951-463a-a0b1-c940267e5c47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">acet:ResTORbioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_f2283cea-c435-437b-958f-019a9a629ca9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acet:NationalInstitutesOfHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-01</startDate>
            <endDate>2019-05-31</endDate>
        </period>
    </context>
    <context id="C_e67dfaf7-9162-49e0-8217-ba044cdeed37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_3af201ab-f6bf-43f9-bbd9-545d3f60a016">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_5972f862-a654-46cb-b4c6-99346fd20b9c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_81126e27-9bfb-4e06-802d-fc47c6df7727">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_25b4b380-f29f-4199-a59a-67e5d8821aef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_905b1778-abfc-4dfb-825e-88b08dac4474">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_c38e333f-e2eb-4d69-906a-0a7b3cfda69b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acet:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:SeriesBPreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_33bee37a-503e-457c-a296-23686ab0bf7a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_d3f0bab3-8542-4755-967f-e529938079a8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">acet:RfsOpcoLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-19</instant>
        </period>
    </context>
    <context id="C_23640616-f433-4b74-849e-d9ad90a3ad0c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_47c45ab3-564a-4faf-b5b3-316708cef184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acet:TwoThousandSeventeenAndTwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="C_d7c1aa19-f30c-49e2-89e6-bd6ca6fed85c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">acet:SeptemberFifteenTwoThousandTwentyWarrantOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_e0e2612c-d563-4a7b-9f21-1a5002c22dc4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_2f0f3de2-b33a-4142-ac46-c01ab9f559d3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">acet:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_0c05cb34-710a-4fe0-a5ad-4326137cbe67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">acet:SeptemberFifteenTwoThousandTwentyWarrantThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_29c03a6c-7260-483a-ab00-555f1e331404">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acet:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_f0f88cdf-2c57-4430-af9d-f7f4ee5dd8be">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_9fa0d050-80a6-4eb0-b277-441b2edd40e6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:ScenarioPreviouslyReportedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">acet:ResTORbioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_607c7869-0981-4346-b7b5-2e6c06ea1c1b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
        </entity>
        <period>
            <instant>2022-03-10</instant>
        </period>
    </context>
    <context id="C_d85d1bbc-33b7-4189-abac-0387bd90ab52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acet:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_9afec6f3-5050-458f-b651-8d672791f22c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_594a64fe-9232-4c34-a446-273a36865ed4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">acet:FederalAndStateResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_61d94a43-5646-47f3-b305-92ab60efd0b9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">acet:FourthAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acet:PacificWesternBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_aa86a251-e22c-4f99-914b-e9fcfc7e5f73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_38fcd5c7-531b-45fa-b26b-773edcb7ea4a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_57a750f3-8a24-41e7-9a82-33461f5929df">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
        </entity>
        <period>
            <instant>2020-04-28</instant>
        </period>
    </context>
    <context id="C_0e581963-9b5e-4dbd-bb03-47a0e58483c2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">acet:ResTORbioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-09-15</startDate>
            <endDate>2020-09-15</endDate>
        </period>
    </context>
    <context id="C_9b4eb834-de39-4790-9fd5-164fe2bbae7e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_2bdce80c-0fa1-4c32-b7bb-48e057af1270">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_36729629-5671-4810-b3a0-0a65b96f4982">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_7c105d75-0eff-40e5-a076-0166362fc4d4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-28</startDate>
            <endDate>2022-01-28</endDate>
        </period>
    </context>
    <context id="C_d7f61ae5-e6e7-4a2d-b7f8-a2343ab6ffcd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_7241f66e-a735-4719-b5b2-0d08cdf5a400">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acet:TwoThousandFourteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_bdaaafd2-c90a-4125-9ca9-c8ea735b0f55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-28</instant>
        </period>
    </context>
    <context id="C_eae66964-012d-43ad-a3b1-27bc081b6037">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">acet:ContractLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_f42c98ab-830c-4e22-89f5-e18b91b6cd8e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_d9bc8440-92d6-4375-83a6-16f30d5e1156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">acet:ContingentValueRightsAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:UnusualRiskOrUncertaintyByNatureAxis">acet:COVID19Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-10-30</startDate>
            <endDate>2020-10-31</endDate>
        </period>
    </context>
    <context id="C_9c4e6975-00c5-410c-91ea-8f78158b9eb4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">acet:NovartisLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acet:NovartisInternationalPharmaceuticalLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_b79560ec-35d7-487d-96ee-7f96cca3cf73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_41ca3bfc-5bca-4c8e-8757-b6a526d155a4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">acet:ContractLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_d75d589d-a181-4cd4-ad70-8e7ae30da242">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">acet:SeptemberFifteenTwoThousandTwentyWarrantThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_33ca374a-c073-4a53-8b64-e82bcfbfe97f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_35b723a6-c5cf-49a4-9335-d4bc407fc9fc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">acet:OptionsAvailableForFutureGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_6ed2f7b8-095e-4a87-ad70-d100496cc258">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_9dda731b-43d4-46e4-905f-51b9789cec27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">acet:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_81494d43-98de-4a2b-a975-25afa4970b74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:ChangeDuringPeriodFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">acet:ContingentValueRightsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_7d366b41-4178-4cf0-85c2-805e8d8b6c0a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acet:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-07-29</startDate>
            <endDate>2016-07-29</endDate>
        </period>
    </context>
    <context id="C_4e9b72dd-9a34-4bc0-8d92-21bc3dbb099f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">acet:ContingentValueRightsAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:UnusualRiskOrUncertaintyByNatureAxis">acet:COVID19Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-11-01</startDate>
            <endDate>2020-11-30</endDate>
        </period>
    </context>
    <context id="C_3ff20287-8f1c-4d12-b176-b2761961daee">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acet:TwoThousandEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-01</endDate>
        </period>
    </context>
    <context id="C_47329381-5696-4150-b182-6307d7bace64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">acet:SeptemberFifteenTwoThousandTwentyWarrantOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_89d1a790-504a-43c7-8716-b106ad45345d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">acet:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_b2fceb56-058f-472e-a003-7e909e8b6b12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">acet:ResTORbioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-15</instant>
        </period>
    </context>
    <context id="C_e7b49a0d-aba6-4a40-8906-1ce775d20e23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_8d576fd1-c342-4304-8b64-31bfd7e0d001">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acet:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-27</startDate>
            <endDate>2021-04-27</endDate>
        </period>
    </context>
    <context id="C_4a463e61-a719-45b8-b4f2-fb3e5d6433eb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">acet:MenloParkLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_382b6885-27c8-4c22-95fd-15e7dd95382f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acet:TwoThousandEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_c66707bf-a227-49f3-9c39-d4e971ab95bd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-31</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_515b257e-b0b9-4013-a431-c4113b38f357">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_7447a494-85e3-4ae0-ad10-48552cb40723">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acet:TwoThousandEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-01-01</endDate>
        </period>
    </context>
    <context id="C_fdcf93e8-6acd-43f5-89f3-9404d1046341">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_baae0ca2-627c-4fcf-80d3-97c07794901d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">acet:ContingentValueRightsAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:UnusualRiskOrUncertaintyByNatureAxis">acet:COVID19Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="C_39a111ce-846b-4680-8cb9-7243c84bbf71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:UnusualRiskOrUncertaintyByNatureAxis">acet:COVID19Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_fc8377ae-c923-40ee-9f57-b8fa6cd9e90b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
        </entity>
        <period>
            <startDate>2021-06-24</startDate>
            <endDate>2021-06-25</endDate>
        </period>
    </context>
    <context id="C_4e76cb9d-4c4a-40ac-b56d-06fc2a5d3fbd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_f72b75a3-3766-46c7-b232-aba9e69a07a2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_a9b28221-7291-479e-aade-1c4cce9e9ee2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acet:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_66c6bb36-401e-4afc-b955-ab56bbccb097">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
        </entity>
        <period>
            <startDate>2020-09-15</startDate>
            <endDate>2020-09-15</endDate>
        </period>
    </context>
    <context id="C_3f32af84-ec12-4ae0-9cc1-f2521512740c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_aab33e86-f1f3-4f74-9094-e2ed14ea13cc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="C_bdd4c9c6-4256-4ee5-b7de-760f8fec3c69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-06-30</endDate>
        </period>
    </context>
    <context id="C_f7497dd4-b12f-4bd8-b7a8-8dd651b1c575">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-15</instant>
        </period>
    </context>
    <context id="C_fddea6c4-817b-4e77-aea4-89981e10e5a9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_62266203-5d56-4f94-a47f-f581aa528dbf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">acet:AtTheMarketOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-01</endDate>
        </period>
    </context>
    <context id="C_87ab7035-f594-4fe7-8bcf-c303cd53528e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_c3918e4a-2434-4382-9707-ca0c30475b0a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:ChangeDuringPeriodFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">acet:ContingentValueRightsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_8968c75b-77f9-4e93-84f0-e12dc0959c9f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acet:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_32996dbe-7c67-4061-9092-811f3ea449f5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acet:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_ecef1783-dbe7-4a31-ab16-82774cd71330">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">acet:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_ebfaf6a1-e4c4-4844-90bf-eb7e876fd554">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_e39012be-aa0b-44c4-bc70-f388d0297447">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">acet:BostonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_1ac06182-fa6d-4612-a577-224903f3d8ec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_f0fe55b1-e361-4417-baab-c311c3746c48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_5a2b4879-2585-49d1-b0c2-05cb9d882735">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_bd372fd7-75a1-4e5a-93b8-53cd9832c95c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acet:TwoThousandEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_ee99e6bd-ad45-468e-9fbb-435628a329b5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="C_93d3a97b-1f9f-4a76-9398-f29f21995887">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_4f49ca26-ce78-4bcd-aa4b-b027527c27af">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
        </entity>
        <period>
            <startDate>2021-07-29</startDate>
            <endDate>2021-07-29</endDate>
        </period>
    </context>
    <context id="C_7c0ad6be-8917-45ec-bfbe-3f58f537064d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="C_68012e05-ebbc-4f75-b9ec-4a4dfe9d312a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">acet:ContractLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_3b4615b0-36e3-4745-a8ee-bb680c1705d1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:SoftwareAndSoftwareDevelopmentCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_8b04952a-abb5-4154-8047-1764f9eef410">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">acet:SeptemberFifteenTwoThousandTwentyWarrantFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_a3c832c4-7b25-488e-a569-24d85c95e6db">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acet:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_92ecfec8-f8f4-4b99-9099-e1803e6b82f7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:ChangeDuringPeriodFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_b25c6402-54af-4bb9-9e89-3b3f8319d96f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_086b3add-2ea8-447d-a2b0-fbfba9fbf32a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">acet:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_4669da95-189e-49f2-9e8b-0f44bc2c3332">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acet:TwoThousandEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_98e3df4a-7a5c-4af8-b922-80b4bfd6c7c5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acet:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="C_188057dd-d8a2-49b6-b276-041c6c6962c8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_4a46099c-74bf-4057-bccf-7f08136ee114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:ChangeDuringPeriodFairValueDisclosureMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_c9838f86-a839-4a13-93ca-c0b2d3b58809">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_fd2a51f4-a4e0-4fd4-8b72-384f893e07dc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_e467cca2-7a5b-404b-9e56-feeb98925d23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_54827df2-7ab1-4397-b75e-6c83f7055086">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
        </entity>
        <period>
            <startDate>2020-09-14</startDate>
            <endDate>2020-09-15</endDate>
        </period>
    </context>
    <context id="C_ed6df093-d6d5-4c84-a08c-07bf173fcdb1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">acet:ResTORbioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_6bc5ff1d-cdce-445a-9774-b450949c38dc">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acet:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_3507c3c5-6e58-434e-aad1-74893d0a8f54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_75ebf3d9-c86e-4807-98b4-2e10b253829b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_8ebb8127-795c-4f3e-930b-1793c330d85e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_d01f7af2-d072-472c-aed6-fdd2ba352899">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_3bebb335-7ef4-439f-88ab-b54a40df0583">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acet:TwoThousandSeventeenAndTwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_b9512590-14bb-4410-8257-cfe9d48166b8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-31</endDate>
        </period>
    </context>
    <context id="C_61d717f8-651c-4c2c-bbdf-85e091817288">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">acet:NovartisLicenseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acet:NovartisInternationalPharmaceuticalLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-03-23</instant>
        </period>
    </context>
    <context id="C_d735ff93-b890-4e3f-88c9-64a20e0a25a7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_4bc22030-2d0d-4a1f-b865-b78ea80ec73c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_a904b84b-2c56-4da2-95ba-b90ab8586e15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_0e775bc8-410a-49ef-80c8-2b1c45c0da93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_b7f956dc-e09b-4592-9b31-a71664b48260">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">acet:ContingentValueRightsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-15</instant>
        </period>
    </context>
    <context id="C_0897fc9d-88dd-4a06-87d5-dbac0106894b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">acet:RedeemableConvertiblePreferredStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_61c5baba-2674-42bd-b177-79bf4833cac0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">acet:SeptemberFifteenTwoThousandTwentyWarrantTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_23c45869-fbfe-42d5-ad00-b90a165dbcd2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_425adbd0-c74a-4998-835c-069d0757ec60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acet:TwoThousandSeventeenAndTwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_b758350f-0170-4fae-8ec9-d587850903ab">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acet:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-04-01</startDate>
            <endDate>2020-06-30</endDate>
        </period>
    </context>
    <context id="C_ab4803e6-aff5-4742-8d52-34995d4eb9b3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">acet:ContingentValueRightsAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:UnusualRiskOrUncertaintyByNatureAxis">acet:COVID19Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_5595a158-5264-494e-ab32-6b3d9fad68b5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="C_03b136b5-e9d4-4893-ab0d-2dc91c51accf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_ebf71bd0-6119-4662-9dc2-2e319bd6c751">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:UnusualRiskOrUncertaintyByNatureAxis">acet:COVID19Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_5ad68f0f-dc2d-43e8-92c2-f0f53b821bd5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">acet:ResTORbioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-09-15</instant>
        </period>
    </context>
    <context id="C_e645c0e4-c8b9-494e-86ea-d249ee6b8de0">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_de3e4a83-2efd-4bdb-9ed1-e22b3ab57037">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">acet:ContractLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_95800697-5c2c-4d5a-aff7-318a343c4784">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_fca8dc62-71f2-4995-91e8-1b030e192627">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">acet:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_b662f1d9-b03b-4be8-bc81-ab4638821609">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">acet:RedeemableConvertiblePreferredStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_fdd289b2-efd1-4e91-9b8b-97c14283103e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_dccfe9c7-9db3-41d8-9a49-8d136b5e0bfa">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">acet:OptionsAvailableForFutureGrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_bb96533e-8bc4-44b9-adcb-bbc676d9bb65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">acet:ResTORbioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_b7eaefd8-96b9-433a-a39f-12214b972204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_788e17f6-1175-45bd-816d-ca6c3191ac61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_edd4abe0-f9c0-4ed5-ad3b-408b1b6e6b9e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acet:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-31</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="C_fd1ca962-13a9-4d81-ab99-ced7557eb7ab">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">acet:ContingentValueRightsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_775ace4d-f0e0-4bb0-b785-08666d208bbb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">acet:CaliforniaResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_4d645798-711d-496e-8eb5-907d5667159d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_1d137f38-c8f9-4c04-bef7-225e2c879fcf">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_b9e4ebe3-8c57-40bf-bb42-6e19b62ee01c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="C_ead71044-8531-48be-a61d-d7cd5c9f9352">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acet:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="C_19e31569-c13e-46a3-a9e6-a74f0c5c72c6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">acet:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_22d1874f-4dce-4f63-bbf4-e46373c23281">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acet:TwoThousandEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-01-01</endDate>
        </period>
    </context>
    <context id="C_cea994b1-c7e3-4048-aeb0-aab2a8ee080d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseContractualTermAxis">acet:RedwoodCityLeaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_3b9411c3-8cc1-4889-996e-5f7080c40edb">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_3606b322-7fbf-4372-8ef9-9fed27772088">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">acet:ContingentValueRightsAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:UnusualRiskOrUncertaintyByNatureAxis">acet:COVID19Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-11-30</instant>
        </period>
    </context>
    <context id="C_b571f234-c627-4f7d-82fb-c74e7cbd480a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RestatementAxis">srt:RestatementAdjustmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">acet:ResTORbioMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_23d1c211-5416-49b1-b67a-b83adbf5b18b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">acet:RfsOpcoLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-19</startDate>
            <endDate>2021-07-19</endDate>
        </period>
    </context>
    <context id="C_3ca7e266-0fdc-4e92-9c8c-d4aea36592ef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">acet:ContractAssetMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_5207f624-84b3-469d-bd6b-fe0a7c570cde">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">acet:MarketableSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_cd9014db-0372-4b1d-af87-ae8fac0a18ea">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">acet:ContingentValueRightsAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_ed4f0fb0-7a37-45a2-b10b-11e180b401f7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_342b3c71-2aea-451c-ba15-14d5101cb509">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_5e765ceb-b63f-4177-a750-139c07a36c25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
        </entity>
        <period>
            <startDate>2020-10-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_bc8e068c-61df-4e55-851e-10fa3cd91cf7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acet:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-31</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_c620e2d6-dea3-45ea-8e5e-d3a20a684708">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_e474c1ad-c5d1-430f-a989-9a1559ca7832">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-10-31</endDate>
        </period>
    </context>
    <context id="C_9c600e1c-0c03-4bf9-8b76-f6fd3c4ce8d6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_c5ef6f51-8e27-49fd-b340-0ef1ea2559f1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_ce2525a9-10cf-4599-b98b-ee9a7da54cd2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_352e5b4d-b5f5-47ad-a765-412097c40d31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_383a2850-17d4-45d4-93aa-3b9d2268d63a">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acet:TwoThousandEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="C_c416c367-1d15-4743-aa82-f287dc4229d1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acet:TwoThousandFifteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_fe5ab009-8804-4e01-8541-0e9d8aa6c52f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:RedeemableConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_ab272512-6afd-4b7d-821d-0cda8200b065">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">acet:SeptemberFifteenTwoThousandTwentyWarrantTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_b1857342-ffb7-45ed-afa1-3915a6f75d31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acet:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_634bf63d-c1b7-40ac-bfb2-44d198c085ab">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acet:NationalInstitutesOfHealthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_ce377847-1500-4676-9ec9-6e92cf9c03dd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-24</startDate>
            <endDate>2021-06-25</endDate>
        </period>
    </context>
    <context id="C_75d47652-161b-4dc3-8594-ce11750f60a2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_99983e52-f2a5-42a0-b031-14f6461609ac">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">acet:FourthAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acet:PacificWesternBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_734e8966-cc1e-4985-a3ff-9c6d800e8bb3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_36830567-b9c7-4c61-a102-2db396446fbd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_316edeb3-e98f-436c-970f-b13de1ce7e93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsAxis">acet:ContingentValueRightsAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:UnusualRiskOrUncertaintyByNatureAxis">acet:COVID19Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_ccba61f6-d5c4-43f1-bc3d-bdfb92b7ccad">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_a7d83825-c513-40b3-914c-c2f0871374ec">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="C_996c2c1e-c6b1-4f2c-b4f0-2957fe857977">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acet:TwoThousandEighteenEmployeeStockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_ae89cac7-0fec-4757-8ed0-2429d1ad7ac5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acet:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-12-31</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_ad66e4cc-7bab-41c5-80c2-e13c75c2e208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_daaa68b0-d842-4ae0-a584-de681974e221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_7071ab79-c6d3-48f5-825b-3abca7958518">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_60060862-7047-426c-9c18-ea7eefd1e40c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_1878c95b-a997-415a-9e16-86e0a1c15a68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_c9ada5f0-e0e5-4266-9e2f-ad21061bf510">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_2c5c9f72-4620-4181-b264-9a1444d1f83d">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">acet:AtTheMarketOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">acet:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-01</startDate>
            <endDate>2020-12-01</endDate>
        </period>
    </context>
    <context id="C_d33cc417-791a-47d8-87ef-b0d73a0d0b66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="C_edc51531-f059-4811-b4b9-e22729a4e46c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">acet:FourthAmendmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acet:PacificWesternBankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-10-21</instant>
        </period>
    </context>
    <context id="C_ca657af2-2ffc-4ae2-b3b7-1641af2126e2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acet:NationalInstitutesOfHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">acet:ResearchFundingAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_c10c6884-14c3-4600-ae9f-b3a86ebd71ef">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-06-24</startDate>
            <endDate>2021-06-25</endDate>
        </period>
    </context>
    <context id="C_677843d2-a967-4c7e-806b-bedb3b76e41f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acet:TwoThousandSeventeenAndTwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-05-01</startDate>
            <endDate>2021-05-01</endDate>
        </period>
    </context>
    <context id="C_da9e6c7e-f0b9-4a9e-9854-806aece05e6c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_21b4de8c-d5dc-46f7-9bc7-44236de1a72c">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">acet:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_ba6aebac-1228-4929-ac87-bcb3b11a0965">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acet:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="C_0d31c0ca-f12c-41d7-9a4f-d658501001c3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">acet:AtTheMarketOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">acet:SalesAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-03-12</startDate>
            <endDate>2021-03-12</endDate>
        </period>
    </context>
    <context id="C_3f1fec59-9c84-4fb5-b910-7eb14b6ef44f">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acet:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_91668149-580c-41d2-a60a-c106cf15c4df">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_b33e9899-16fc-42cc-96d1-97d706c7101b">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">us-gaap:PrimeRateMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-04-28</instant>
        </period>
    </context>
    <context id="C_859eba6f-9081-481e-ab8c-7b531e2b242e">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="C_9012bab3-6ac1-4389-8e31-ccc520a1ad87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_1fdee497-9bd9-4434-b8dd-50a2c01519cd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">acet:ContractLiabilityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_f7498518-7e9a-4c87-8ba1-fa0ec641d5dd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">acet:CommonStockWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="C_a5e55134-4c6c-4529-bddd-d3adb88995cd">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:AssetBackedSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_4e6c9fea-07ee-4070-8aba-8ca1ddff8ad6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">acet:RegeneronPharmaceuticalsIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-28</startDate>
            <endDate>2022-01-28</endDate>
        </period>
    </context>
    <context id="C_0c48ad1d-3ddc-4d42-94e0-eacbdc6debba">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="C_ba86b9b9-6782-4f93-bfa9-5fc357e6e1f8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">acet:TwoThousandFourteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="C_2e8c65f5-54e7-412c-9d4a-c7dea4022906">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001720580</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <unit id="U_ValueRight">
        <measure>acet:ValueRight</measure>
    </unit>
    <unit id="U_pure">
        <measure>pure</measure>
    </unit>
    <unit id="U_sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="U_Lawsuit">
        <measure>acet:Lawsuit</measure>
    </unit>
    <unit id="U_shares">
        <measure>shares</measure>
    </unit>
    <unit id="U_Customer">
        <measure>acet:Customer</measure>
    </unit>
    <unit id="U_Segment">
        <measure>acet:Segment</measure>
    </unit>
    <unit id="U_USDollarShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="U_USD">
        <measure>iso4217:USD</measure>
    </unit>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      id="F_8bc0353d-5786-49d3-9a18-9b33edc0a9e9"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:BusinessCombinationAssetsArisingFromContingenciesAmountRecognized
      contextRef="C_f72b75a3-3766-46c7-b232-aba9e69a07a2"
      id="F_ba39addf-7250-4185-b821-6a0528ff4070"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:AccountsReceivableRelatedPartiesCurrent
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      id="F_c90c6857-d677-4f9c-addf-13927bc45ed0"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      id="F_efcea327-b6ef-4d61-b48e-b5bba5b6c3c3"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:StockIssuedDuringPeriodValueIssuedForServices
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_88961339-6e41-46f7-b484-e70d789d380b"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:StockholdersEquity
      contextRef="C_859eba6f-9081-481e-ab8c-7b531e2b242e"
      id="F_e03a3503-c022-4462-9b6a-c5859ba7d7b7"
      unitRef="U_USD"
      xsi:nil="true"/>
    <acet:RightOfUseAssetsRecognized
      contextRef="C_fd2a51f4-a4e0-4fd4-8b72-384f893e07dc"
      id="F_05b13237-3492-4f95-aba3-8ed6a6944362"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="INF"
      id="F_18ae40c3-cc09-44ce-a2f4-2c852da4b4aa"
      unitRef="U_USDollarShare">0</us-gaap:CommonStockDividendsPerShareDeclared>
    <acet:IssuanceOfRedeemableConvertiblePreferredStockOnExerciseOfWarrantsWithLoanAgreement
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_30164a23-1034-41b4-8a87-4e24b682b3f4"
      unitRef="U_USD"
      xsi:nil="true"/>
    <dei:CurrentFiscalYearEndDate
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_840dcd2b-2fae-46dc-8023-bd4695fdd5df">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_c1e55cb3-2170-40e8-895f-7b8d4abd20f6">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:PreferredStockValue
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      id="F_fb093abf-4f4f-4827-a9da-293d131e9450"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      id="F_1ad28aba-0f89-4c1e-b355-7124041766a1"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:FairValueOfAssetsAcquired
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_8cea713b-4adc-4d3c-bf88-22e31cbfdc99"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_daaa68b0-d842-4ae0-a584-de681974e221"
      id="F_dbc0d54f-50e5-4e0d-931c-eb2600eb1f07"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_2945645f-2178-4658-b960-77d1100e9bac"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_e67dfaf7-9162-49e0-8217-ba044cdeed37"
      decimals="INF"
      id="F_ca459d7d-097c-4350-b8c5-17e431b35615"
      unitRef="U_shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      id="F_8f366528-b927-44dd-955d-3902dd5285e6"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      id="F_fe50c4e8-749d-4335-ae8f-18aed2ad9940"
      unitRef="U_USD"
      xsi:nil="true"/>
    <dei:EntityCentralIndexKey
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_45fcbe03-3582-4802-9e09-cb05d0dc0471">0001720580</dei:EntityCentralIndexKey>
    <us-gaap:SubleaseIncome
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      id="F_a0789779-e166-43dd-bd77-089b6487a8c3"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="C_b9e4ebe3-8c57-40bf-bb42-6e19b62ee01c"
      decimals="INF"
      id="F_4a6a6b6d-811d-48f1-b09b-f42e96a2fd90"
      unitRef="U_USDollarShare">0</us-gaap:CommonStockDividendsPerShareDeclared>
    <dei:AmendmentFlag
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_c0c9a2db-8c34-4a1e-9d4b-7ac4f7464089">false</dei:AmendmentFlag>
    <us-gaap:BusinessCombinationAssetsArisingFromContingenciesAmountRecognized
      contextRef="C_fd1ca962-13a9-4d81-ab99-ced7557eb7ab"
      id="F_53469473-0173-4a8a-bfc4-8856f9b34255"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLossCarryforwardsExpirationDate
      contextRef="C_4e76cb9d-4c4a-40ac-b56d-06fc2a5d3fbd"
      id="F_2ae19e7d-b6bf-4828-a15f-80c9a443829c">2037-12-31</us-gaap:OperatingLossCarryforwardsExpirationDate>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      id="F_fd5f7e8a-5341-4223-a549-e2815d0b8b31"
      unitRef="U_USD"
      xsi:nil="true"/>
    <acet:ProceedsFromSalesOfMarketableDebtSecurities
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      id="F_c2c0c022-3bc2-47ee-ac21-0348f3accf14"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_e67dfaf7-9162-49e0-8217-ba044cdeed37"
      id="F_57e77e30-6b2f-47ee-bd06-1e77e3f45b01"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      id="F_52b544c5-2e54-4c52-8e46-49be2abe9635"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:OperatingLossCarryforwardsExpirationDate
      contextRef="C_3507c3c5-6e58-434e-aad1-74893d0a8f54"
      id="F_df7286aa-ef38-49c2-b278-229734179a35">2035-12-31</us-gaap:OperatingLossCarryforwardsExpirationDate>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_f39be877-1c11-4604-9a1a-96f74b63b799"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_2f0f3de2-b33a-4142-ac46-c01ab9f559d3"
      id="F_91d06931-2771-4e60-b971-253316eaba0d"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:ProceedsFromStockPlans
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      id="F_61e7ff69-16bd-48b2-b350-de1645a65d44"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_aa86a251-e22c-4f99-914b-e9fcfc7e5f73"
      id="F_d2cce7e8-1134-4bea-822d-f684fe63d39a"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      id="F_2d04a4ef-82d4-4143-8241-c8043e042c95"
      unitRef="U_USD"
      xsi:nil="true"/>
    <acet:CommonStockOfferingCostsIncludedInAccruedLiabilitiesAtPeriodEnd
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      id="F_5fee429c-5b1b-432c-a994-6ed5a5249e6a"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:OtherLiabilities
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      id="F_9dc969f6-49b9-4163-aafc-0d7ce2a0811a"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_78769c32-8afb-4b2d-96fd-6e254cea5840"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_0592c904-f2c4-43cd-af23-a8efec565b99"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_e34744e6-32c7-4857-bf62-b6bfb9ec543a"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_60ec8ff2-c4ea-47b4-849f-ad0d9cd49e80"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_aa86a251-e22c-4f99-914b-e9fcfc7e5f73"
      decimals="INF"
      id="F_7a22c7d2-0058-4f73-9325-35673702fe09"
      unitRef="U_shares">0</us-gaap:TemporaryEquitySharesOutstanding>
    <dei:EntityIncorporationDateOfIncorporation
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_6bd37428-42c2-4038-b96a-a6cfe4c5c8c5">2014-11-30</dei:EntityIncorporationDateOfIncorporation>
    <us-gaap:StockholdersEquity
      contextRef="C_d33cc417-791a-47d8-87ef-b0d73a0d0b66"
      id="F_0fbb73f0-a2b4-4955-a72c-3389ceca5af9"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_819eaa0a-0a31-4f5b-b68e-5e64ffc6ff53"
      unitRef="U_USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      id="F_634bc8da-c716-4b7e-bc3c-fdf201cf4001"
      unitRef="U_USD"
      xsi:nil="true"/>
    <dei:DocumentType
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_33ed1a9e-33f2-455c-8ba2-bf3543252e9c">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_a3d461ca-ba3d-494a-a6c0-9c0109aef8c2">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_cbb26a8c-0451-446a-ab1a-128b9f96dec1">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_078b0eec-320b-4fd2-982c-3ab1c9176bbf">2021</dei:DocumentFiscalYearFocus>
    <dei:DocumentTransitionReport
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_9954755c-0814-47c8-9aa1-cb4af79d93dc">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_384eb8e2-9939-4ec9-ad65-507ac8dc2563">001-38359</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_c15ec1e6-43e3-42b8-9b21-a9cef8071c6d">Adicet Bio, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_151e515a-81fd-49cd-8f5c-c925d5483a9d">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_4a72e133-62f9-4fb2-9852-a4b66dc70669">81-3305277</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_7b662327-3147-4592-ac66-7c58e3bd7489">200 Clarendon Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_adc6565f-3e97-47e4-b794-7883367bb66a">Floor 6</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_69babf2e-7a0f-4c9c-991e-9579f1cb2ec9">Boston</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_1bc20cea-8afa-42e8-b8f5-84ac4ca19b8a">MA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_f19ec6e4-57ba-485d-8bd6-7b5ebd376420">02116</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_bc57aad9-a4d9-4f5c-ab0f-14e940143c66">650</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_f4f62fed-72f0-4602-b2f2-23143b83839f"> 503-9095</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_a4ed1765-af53-49ed-9afc-c6c7657f97ab">Common Stock, par value $0.0001 per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_fa8455b0-48a6-4e23-99d5-4db1b4a20beb">ACET</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_75e6d061-5d75-4685-a9a3-6f7d58bd9735">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_34db2215-f014-4d98-9066-72c0f6016eea">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_a630f4f0-26da-4cbd-9987-45e3ba758417">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_c91474a6-e1a0-4c7c-8d88-af8d83ced077">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_826947de-59bc-4a20-858a-76460c0b4356">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_9c24832d-bd83-470c-9188-049122314e77">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_3aa408b2-028c-480b-b0be-090cbe514a84">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_71b8ced4-6b90-4225-bcae-64ac80d5923f">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_ee51350b-8bbc-4899-bfbf-6dd782f1c159">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_99efc04e-7994-4b49-adfb-c36074f5a742">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_7ad66f56-83bd-4287-8ab0-b33f01207b88">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="C_5595a158-5264-494e-ab32-6b3d9fad68b5"
      decimals="-5"
      id="F_37976fe4-4154-4e95-a216-10ac6a4b26a1"
      unitRef="U_USD">226000000.0</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="C_607c7869-0981-4346-b7b5-2e6c06ea1c1b"
      decimals="0"
      id="F_be411f2c-89c3-4980-acfd-6c295ecf3b34"
      unitRef="U_shares">39877109</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_814e4b24-d434-4598-8649-9f353d4ba288">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:3.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt;Part III of this Annual Report on Form 10-K incorporates by reference certain information from the registrant&#x2019;s definitive Proxy Statement for its 2022 annual meeting of shareholders, scheduled to be held on June 2, 2022, which the registrant intends to file pursuant to Regulation 14A with the Securities and Exchange Commission not later than 120 days after the registrant&#x2019;s fiscal year end of December 31, 2021. Except with respect to information specifically incorporated by reference in this Form 10-K, the Proxy Statement is not deemed to be filed as part of this Form 10-K.&lt;/span&gt;&lt;/p&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <dei:AuditorFirmId
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_3d44cb85-9cad-48b7-8e5e-1d7f493858c9">185</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_00719bb7-3ba3-42e8-9e9f-e32992e9f232">KPMG LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_0ebb31c2-b604-4522-9374-a4244dcdf724">Boston, Massachusetts</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-3"
      id="F_ccde0454-71eb-4e96-b4b6-85286ce3eef9"
      unitRef="U_USD">277544000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="-3"
      id="F_f4447c19-14e0-4f83-917b-3c08564dc4d6"
      unitRef="U_USD">84330000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="-3"
      id="F_79c93f3a-fc1e-4e16-a028-5624683fd282"
      unitRef="U_USD">10284000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AccountsReceivableRelatedPartiesCurrent
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-3"
      id="F_39992612-3b4f-4b9f-8f19-59c48094dc2b"
      unitRef="U_USD">185000</us-gaap:AccountsReceivableRelatedPartiesCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-3"
      id="F_241001ac-bb8a-4a02-b021-6168f0bbe6b8"
      unitRef="U_USD">4709000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="-3"
      id="F_44157cd7-702a-437f-a821-cd628185104a"
      unitRef="U_USD">5722000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-3"
      id="F_af0defbb-2ab6-4637-a2b9-93fd40f71b88"
      unitRef="U_USD">282438000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="-3"
      id="F_74510a9a-e3da-4c5b-996e-ba82c82c4ec5"
      unitRef="U_USD">100336000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-3"
      id="F_0f575883-6186-4727-97dd-a4de6b8074fe"
      unitRef="U_USD">14643000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="-3"
      id="F_0c043dfe-1422-4201-861e-13047dfc3079"
      unitRef="U_USD">2790000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-3"
      id="F_3b480f68-1c76-4ae5-bdc9-f7d890361c66"
      unitRef="U_USD">20358000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="-3"
      id="F_4546b836-1f3f-4a05-8572-373d902298c5"
      unitRef="U_USD">23066000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Goodwill
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-3"
      id="F_a391e332-b1f1-450a-b2de-541c77039818"
      unitRef="U_USD">19462000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="-3"
      id="F_371714a8-6e44-4a1c-8265-ad8fd46991e2"
      unitRef="U_USD">20089000</us-gaap:Goodwill>
    <us-gaap:DevelopmentInProcess
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="-3"
      id="F_c4933828-40f9-4ab1-b1c1-d34a0fea1375"
      unitRef="U_USD">1190000</us-gaap:DevelopmentInProcess>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-3"
      id="F_9e7ef0bf-cf7d-48d9-8cf3-539172a4fe93"
      unitRef="U_USD">150000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="-3"
      id="F_790e0540-b043-4a5b-8de5-a490e14ee9d4"
      unitRef="U_USD">4527000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="-3"
      id="F_86cff01b-f2f2-448f-9ea5-aec78a62d068"
      unitRef="U_USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-3"
      id="F_3e7e87ef-56fd-47bb-8316-5107b1c28fed"
      unitRef="U_USD">1887000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="-3"
      id="F_7d1fd44d-3516-467f-bf72-366f16cf811b"
      unitRef="U_USD">1837000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-3"
      id="F_1aec0880-be91-4713-aeb1-b9a94e63315b"
      unitRef="U_USD">338938000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="-3"
      id="F_8b546985-1df6-4298-986f-2905b9874956"
      unitRef="U_USD">153835000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-3"
      id="F_deb20859-d9e4-46ab-ba44-34c1fd6a800c"
      unitRef="U_USD">3263000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="-3"
      id="F_d19515a5-4a70-417f-9567-c3ee6b40233a"
      unitRef="U_USD">1552000</us-gaap:AccountsPayableCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-3"
      id="F_4c3879f0-9590-413a-b215-4f2c06de0625"
      unitRef="U_USD">4805000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="-3"
      id="F_a16a5321-1772-4864-b09a-ecbc257a55cb"
      unitRef="U_USD">13980000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-3"
      id="F_06d9a678-6fc6-4251-b6e0-c3cd9ebc0b2a"
      unitRef="U_USD">6682000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="-3"
      id="F_b1437f02-d35c-45d0-baaf-c5e5c69ff8e4"
      unitRef="U_USD">5732000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-3"
      id="F_7ae51979-4aad-43a9-8364-78a0aa5ef51d"
      unitRef="U_USD">1567000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="-3"
      id="F_fba12e1e-d927-4c75-b0c0-4ea96effa901"
      unitRef="U_USD">1215000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-3"
      id="F_f5108eef-6550-4db8-9456-230d1a4b0b0a"
      unitRef="U_USD">16317000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="-3"
      id="F_dc36b280-c520-41e4-be83-0ea22203ec9d"
      unitRef="U_USD">22479000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-3"
      id="F_6623c94d-43ef-48da-8e31-570f7dfd63f6"
      unitRef="U_USD">19377000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="-3"
      id="F_372daccf-5bc8-4b66-a634-01186dc7c3e7"
      unitRef="U_USD">20424000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="-3"
      id="F_86694194-a5e6-4283-8675-7543fcec76c8"
      unitRef="U_USD">980000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="-3"
      id="F_e02df7e3-2abf-470e-9846-da1a6c1633cb"
      unitRef="U_USD">125000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OtherLiabilities
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-3"
      id="F_b661c1c4-15b4-4ee5-be95-6cbd2c4abbe4"
      unitRef="U_USD">115000</us-gaap:OtherLiabilities>
    <us-gaap:Liabilities
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-3"
      id="F_c4f94cbf-494a-4da3-bdae-4f750f01d9d5"
      unitRef="U_USD">35809000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="-3"
      id="F_6be5003d-b88e-4e87-b10e-eb078613a432"
      unitRef="U_USD">44008000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="4"
      id="F_bf1daf4c-a8fc-4469-82e0-3e70861206e5"
      unitRef="U_USDollarShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="4"
      id="F_f28e5e1f-622c-483d-9a83-db00d44084a6"
      unitRef="U_USDollarShare">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="0"
      id="F_ef590c62-8720-4b51-baf1-38f5f1271e43"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="0"
      id="F_2c8c48f0-5ad5-4805-9844-6f9b2286406e"
      unitRef="U_shares">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="0"
      id="F_da1b5ba9-bc23-497c-a99b-67ebd163ff9d"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="0"
      id="F_901c4ab4-7891-433c-8264-d50bb4a70538"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="0"
      id="F_dff72034-7044-4011-accd-da0216bdd459"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="0"
      id="F_1454f8a0-1668-4136-a01a-75c35856eff5"
      unitRef="U_shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="4"
      id="F_113191bb-7f98-489d-8b48-88b6d518a3a5"
      unitRef="U_USDollarShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="4"
      id="F_ed8f35a3-a7ab-43bc-9355-48f634d2cc12"
      unitRef="U_USDollarShare">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="0"
      id="F_6e696406-209f-4faf-945f-e8e746e1661b"
      unitRef="U_shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="0"
      id="F_fef8e744-a586-4aff-be34-67b33af908ff"
      unitRef="U_shares">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="0"
      id="F_14da6420-45be-468d-927c-54c1f4d26bee"
      unitRef="U_shares">39736914</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="0"
      id="F_c8cd8ca5-247d-4be0-afa7-a02550609950"
      unitRef="U_shares">39736914</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="0"
      id="F_9dbfe1d2-81f3-45b7-ba5d-c21dc19215ca"
      unitRef="U_shares">19677249</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="0"
      id="F_1b028396-a420-49a2-a17f-fd2b74da267d"
      unitRef="U_shares">19677249</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-3"
      id="F_c3be1a1a-1d72-4e54-a5f6-b57adf36ec35"
      unitRef="U_USD">4000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="-3"
      id="F_0f489f1c-c25e-413e-9153-bf82678a4547"
      unitRef="U_USD">2000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-3"
      id="F_96970bb0-4674-4316-8da9-878ff128b9a7"
      unitRef="U_USD">471449000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="-3"
      id="F_8c8f8d4e-bc2d-4342-9e07-2188ddec4967"
      unitRef="U_USD">216126000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-3"
      id="F_9db6bc25-baac-49ba-8252-9ddb7e9a6690"
      unitRef="U_USD">-168324000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="-3"
      id="F_479d4aa9-b222-48cd-923b-a7fea23677ac"
      unitRef="U_USD">-106325000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="-3"
      id="F_bf855a7a-0510-4015-87a4-b8de080cf668"
      unitRef="U_USD">24000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-3"
      id="F_4a7f29d0-7aae-4b6c-883e-e5734e439075"
      unitRef="U_USD">303129000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="-3"
      id="F_a1873744-ea4c-422e-89d4-0299eb0749e4"
      unitRef="U_USD">109827000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-3"
      id="F_dcd0df79-b756-48a4-a988-bb4233081142"
      unitRef="U_USD">338938000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="-3"
      id="F_69cee506-5848-41ce-9b1e-979e86430def"
      unitRef="U_USD">153835000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromRelatedParties
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="-3"
      id="F_287db975-ca66-41c8-9677-432f023fab7b"
      unitRef="U_USD">9730000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RevenueFromRelatedParties
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="-3"
      id="F_8b6e21fb-9bbf-4839-b6ea-edb217833650"
      unitRef="U_USD">17903000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="-3"
      id="F_18f95c57-a34c-42f2-a2a6-f69bda8cf5e3"
      unitRef="U_USD">48943000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="-3"
      id="F_ed11340f-dba4-42f4-bdf2-16d370fcfadf"
      unitRef="U_USD">34334000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="-3"
      id="F_0052fadf-55ff-405e-8198-0532fd48f92f"
      unitRef="U_USD">22220000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="-3"
      id="F_d553d0b6-76c7-4b85-a8b0-6d927902372f"
      unitRef="U_USD">22760000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="-3"
      id="F_20f6f23e-2554-485b-8851-a91911eb9726"
      unitRef="U_USD">71163000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="-3"
      id="F_75b17fdb-3f8a-47fc-9857-f4d4b11454d8"
      unitRef="U_USD">57094000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="-3"
      id="F_565ea8cb-be89-47dc-9a59-c6a0ea98ad7f"
      unitRef="U_USD">-61433000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="-3"
      id="F_90809e17-9ca8-4d31-9435-6a84b6a97989"
      unitRef="U_USD">-39191000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestAndOtherIncome
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="-3"
      id="F_1b3a84f4-90fc-48c6-8fab-565b67b38065"
      unitRef="U_USD">91000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestAndOtherIncome
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="-3"
      id="F_154867af-fadb-49b6-be29-b8ac41b83ee5"
      unitRef="U_USD">785000</us-gaap:InterestAndOtherIncome>
    <us-gaap:InterestExpense
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="-3"
      id="F_c1844478-033b-4c33-8a85-ad51419fe5e2"
      unitRef="U_USD">176000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="-3"
      id="F_73bfc77e-54c6-48df-94a7-2d60a85d7317"
      unitRef="U_USD">134000</us-gaap:InterestExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="-3"
      id="F_91cc23e3-a510-46b4-82cf-8fc987812a65"
      unitRef="U_USD">-606000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="-3"
      id="F_8cbb41ed-c58c-4bd5-990f-3e502abf7752"
      unitRef="U_USD">-953000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="-3"
      id="F_6df62586-1ef9-47a7-a6ef-e94a75d5b31c"
      unitRef="U_USD">-62124000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="-3"
      id="F_d09f233e-9eab-4a1f-a1c6-4ecd2b4a47b3"
      unitRef="U_USD">-39493000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="-3"
      id="F_ebf7fdcb-9c7f-42e1-8ad9-8a7d6edb2f87"
      unitRef="U_USD">-125000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="-3"
      id="F_b82afb37-14ab-4b6b-b178-85d6d0914af5"
      unitRef="U_USD">-2815000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="-3"
      id="F_8c34973f-c230-4375-b204-22c0cbd9e61f"
      unitRef="U_USD">-61999000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="-3"
      id="F_6e5cc7e3-f06b-417d-9ec1-0040106a9133"
      unitRef="U_USD">-36678000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="2"
      id="F_e9892d91-4629-4f88-892e-e4e2f5f8fb5f"
      unitRef="U_USDollarShare">-2.00</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="2"
      id="F_e84be55e-9ffb-4357-bd70-f36d8c2e8358"
      unitRef="U_USDollarShare">-5.01</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="0"
      id="F_48592fa8-3f47-43ca-b945-7b5c55761e9e"
      unitRef="U_shares">30952152</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="0"
      id="F_be24a2c8-f575-4f4f-a758-1af850fdee72"
      unitRef="U_shares">7319977</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="-3"
      id="F_66e384a9-eba9-4864-b882-2a55e48d6663"
      unitRef="U_USD">-24000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="-3"
      id="F_71f41e00-ea4d-44de-abd3-b12fc678ca1d"
      unitRef="U_USD">1000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="-3"
      id="F_5e263406-0e8a-40c5-84c7-ccd4f70649ac"
      unitRef="U_USD">-24000</us-gaap:OtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="-3"
      id="F_b4969882-f62f-4304-be03-9e2981a3d414"
      unitRef="U_USD">1000</us-gaap:OtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="-3"
      id="F_f17cdf13-4b0d-4bbe-b963-8c0cee1ee9c6"
      unitRef="U_USD">-62023000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="-3"
      id="F_841e0051-c700-4e5a-acc8-60585af9824f"
      unitRef="U_USD">-36677000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:TemporaryEquitySharesOutstanding
      contextRef="C_fe5ab009-8804-4e01-8541-0e9d8aa6c52f"
      decimals="INF"
      id="F_8608a419-8eb7-47c8-a068-9bf8c0f8b593"
      unitRef="U_shares">97166921</us-gaap:TemporaryEquitySharesOutstanding>
    <us-gaap:TemporaryEquityCarryingAmountAttributableToParent
      contextRef="C_fe5ab009-8804-4e01-8541-0e9d8aa6c52f"
      decimals="-3"
      id="F_93e8f042-0de7-4f3c-831a-d4aa33da0155"
      unitRef="U_USD">114083000</us-gaap:TemporaryEquityCarryingAmountAttributableToParent>
    <us-gaap:SharesOutstanding
      contextRef="C_d33cc417-791a-47d8-87ef-b0d73a0d0b66"
      decimals="INF"
      id="F_3d14b5ee-5b18-4d1a-aaa3-5b431d55eda0"
      unitRef="U_shares">2155578</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_352e5b4d-b5f5-47ad-a765-412097c40d31"
      decimals="-3"
      id="F_2a96bec8-a994-4e0d-8eae-65e45f548314"
      unitRef="U_USD">9258000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_ccba61f6-d5c4-43f1-bc3d-bdfb92b7ccad"
      decimals="-3"
      id="F_e11f198a-bb58-45d1-93b3-54c4bbf02bf8"
      unitRef="U_USD">-69647000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_75ebf3d9-c86e-4807-98b4-2e10b253829b"
      decimals="-3"
      id="F_0f3e5dc0-6fae-4e28-b842-f6184a11c4e4"
      unitRef="U_USD">23000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_95800697-5c2c-4d5a-aff7-318a343c4784"
      decimals="-3"
      id="F_44a414fa-bd6d-4101-9afb-b8ea3ec73cca"
      unitRef="U_USD">-60366000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_c9838f86-a839-4a13-93ca-c0b2d3b58809"
      decimals="INF"
      id="F_f1e58d6e-0927-44da-9466-b8b2849b2b63"
      unitRef="U_shares">210752</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_c9838f86-a839-4a13-93ca-c0b2d3b58809"
      decimals="-3"
      id="F_cdc6a351-acc8-40bb-9e68-f922dcd14332"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_229551d3-2c1b-4ec2-99aa-16652dd7eb75"
      decimals="-3"
      id="F_c00fedca-5431-4f5a-a7ad-4519bec64de4"
      unitRef="U_USD">459000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="-3"
      id="F_701c04e2-9e52-4d1c-ba27-1c91aafe5cb7"
      unitRef="U_USD">460000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_229551d3-2c1b-4ec2-99aa-16652dd7eb75"
      decimals="-3"
      id="F_e1cbca28-cac8-4c21-b359-50a6f76810ff"
      unitRef="U_USD">5263000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="-3"
      id="F_87fa4fa6-0eb4-434a-88ed-23ed763e950a"
      unitRef="U_USD">5263000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <acet:TemporaryEquityStockConversionSharesInConnectionWithMerger
      contextRef="C_fdd289b2-efd1-4e91-9b8b-97c14283103e"
      decimals="INF"
      id="F_eb7a0b33-0be8-4cae-8987-6536a8b9dc50"
      unitRef="U_shares">97166921</acet:TemporaryEquityStockConversionSharesInConnectionWithMerger>
    <acet:TemporaryEquityStockConversionInConnectionWithMerger
      contextRef="C_fdd289b2-efd1-4e91-9b8b-97c14283103e"
      decimals="-3"
      id="F_325c33df-e2c7-42f2-8ef8-77f4b6e02882"
      unitRef="U_USD">-114083000</acet:TemporaryEquityStockConversionInConnectionWithMerger>
    <acet:StockIssuedDuringPeriodSharesConversionOfSecurities
      contextRef="C_c9838f86-a839-4a13-93ca-c0b2d3b58809"
      decimals="INF"
      id="F_8cb079bb-da04-40ec-a0e2-b9b39d85420e"
      unitRef="U_shares">12048671</acet:StockIssuedDuringPeriodSharesConversionOfSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_c9838f86-a839-4a13-93ca-c0b2d3b58809"
      decimals="-3"
      id="F_e9098fcd-4709-4403-9dc1-564d049fb5f0"
      unitRef="U_USD">1000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_229551d3-2c1b-4ec2-99aa-16652dd7eb75"
      decimals="-3"
      id="F_d3077bde-d9be-4fff-baf6-59166f239c45"
      unitRef="U_USD">114082000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="-3"
      id="F_e6fb4f03-8cc3-47c0-99ec-87410e7b6ed1"
      unitRef="U_USD">114083000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <acet:StockExchangedDuringPeriodSharesInConnectionWithMerger
      contextRef="C_c9838f86-a839-4a13-93ca-c0b2d3b58809"
      decimals="INF"
      id="F_a304aaa6-6c75-42f7-a1aa-a44b5ea081c6"
      unitRef="U_shares">5207695</acet:StockExchangedDuringPeriodSharesInConnectionWithMerger>
    <acet:StockExchangedDuringPeriodValueInConnectionWithMerger
      contextRef="C_229551d3-2c1b-4ec2-99aa-16652dd7eb75"
      decimals="-3"
      id="F_f015b4ce-c31f-42d5-9c9f-593b3cc6ff6c"
      unitRef="U_USD">83516000</acet:StockExchangedDuringPeriodValueInConnectionWithMerger>
    <acet:StockExchangedDuringPeriodValueInConnectionWithMerger
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="-3"
      id="F_46ce823a-0bee-4af4-820c-eb19c561d344"
      unitRef="U_USD">83516000</acet:StockExchangedDuringPeriodValueInConnectionWithMerger>
    <acet:StockIssuedDuringPeriodSharesUponAcceleratedVestingOfRSUWithMerger
      contextRef="C_c9838f86-a839-4a13-93ca-c0b2d3b58809"
      decimals="INF"
      id="F_ee44a1af-8627-48b4-a42b-5380e844ba0a"
      unitRef="U_shares">54553</acet:StockIssuedDuringPeriodSharesUponAcceleratedVestingOfRSUWithMerger>
    <acet:StockIssuedDuringPeriodValueUponAcceleratedVestingOfRSUWithMerger
      contextRef="C_229551d3-2c1b-4ec2-99aa-16652dd7eb75"
      decimals="-3"
      id="F_845156f0-286c-43a5-8018-15627f40be86"
      unitRef="U_USD">626000</acet:StockIssuedDuringPeriodValueUponAcceleratedVestingOfRSUWithMerger>
    <acet:StockIssuedDuringPeriodValueUponAcceleratedVestingOfRSUWithMerger
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="-3"
      id="F_55a69b0a-03d7-4a0b-a01b-d3a19f9c7fa3"
      unitRef="U_USD">626000</acet:StockIssuedDuringPeriodValueUponAcceleratedVestingOfRSUWithMerger>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="C_229551d3-2c1b-4ec2-99aa-16652dd7eb75"
      decimals="-3"
      id="F_17e07411-9d1c-4a63-8af8-5ddf9d6b5cca"
      unitRef="U_USD">2922000</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="-3"
      id="F_a295df63-6e40-4784-a846-de6066019b83"
      unitRef="U_USD">2922000</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:NetIncomeLoss
      contextRef="C_d735ff93-b890-4e3f-88c9-64a20e0a25a7"
      decimals="-3"
      id="F_da2138f4-88df-4a3d-a500-e53557ba55fc"
      unitRef="U_USD">-36678000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="-3"
      id="F_525b3e59-8042-40b6-8640-ce688564e5c5"
      unitRef="U_USD">-36678000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_9afec6f3-5050-458f-b651-8d672791f22c"
      decimals="-3"
      id="F_4a2dddab-3a9f-47f5-b386-97fe3624c9c2"
      unitRef="U_USD">1000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="-3"
      id="F_329fd40c-055c-4fb9-88c4-4c9ecfba8a0b"
      unitRef="U_USD">1000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="C_36830567-b9c7-4c61-a102-2db396446fbd"
      decimals="INF"
      id="F_9580616b-63ff-43a9-a305-e4354ed7bf28"
      unitRef="U_shares">19677249</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_36830567-b9c7-4c61-a102-2db396446fbd"
      decimals="-3"
      id="F_44bad64c-f6dd-4c87-90b3-61aae861cc0d"
      unitRef="U_USD">2000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_f0f88cdf-2c57-4430-af9d-f7f4ee5dd8be"
      decimals="-3"
      id="F_85f1e2cf-7dee-4959-b7a8-2f226bf7d360"
      unitRef="U_USD">216126000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_02dd56d4-2777-4e62-8616-7488897fd4d0"
      decimals="-3"
      id="F_a04f0070-9ef8-45e1-9c1c-04453439cac8"
      unitRef="U_USD">-106325000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_81126e27-9bfb-4e06-802d-fc47c6df7727"
      decimals="-3"
      id="F_f139f065-2f55-4a10-a6d4-c518a7f79dd8"
      unitRef="U_USD">24000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="-3"
      id="F_a3eb2a56-664b-499a-a3f3-436feddbca5d"
      unitRef="U_USD">109827000</us-gaap:StockholdersEquity>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_9b4eb834-de39-4790-9fd5-164fe2bbae7e"
      decimals="INF"
      id="F_30c34bd3-c31a-462b-87ef-aaf47fd1dc80"
      unitRef="U_shares">1125339</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_ce2525a9-10cf-4599-b98b-ee9a7da54cd2"
      decimals="-3"
      id="F_89738b03-0415-4eba-a49c-9a27064de9ac"
      unitRef="U_USD">4688000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="-3"
      id="F_99301ceb-df85-4e1e-b00b-27a0745c38ed"
      unitRef="U_USD">4688000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="-3"
      id="F_a28dbe6b-6782-4778-8524-230920c9ff2e"
      unitRef="U_USD">823940000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_9b4eb834-de39-4790-9fd5-164fe2bbae7e"
      decimals="INF"
      id="F_c0cb8276-d7e9-4d06-af4d-9d6246b6f32f"
      unitRef="U_shares">18916853</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_9b4eb834-de39-4790-9fd5-164fe2bbae7e"
      decimals="-3"
      id="F_8f4f0b18-1e68-4aa8-88ac-090235aaadca"
      unitRef="U_USD">2000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_ce2525a9-10cf-4599-b98b-ee9a7da54cd2"
      decimals="-3"
      id="F_934fae98-b141-4d61-ac4a-3b6dca01e76f"
      unitRef="U_USD">237995000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="-3"
      id="F_80b33d97-2a9e-454d-adda-c852ab6e3361"
      unitRef="U_USD">237997000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesIssuedForServices
      contextRef="C_9b4eb834-de39-4790-9fd5-164fe2bbae7e"
      decimals="INF"
      id="F_866ce8d0-384c-4d9d-962a-dfc54fa489cb"
      unitRef="U_shares">1806</us-gaap:StockIssuedDuringPeriodSharesIssuedForServices>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="C_9b4eb834-de39-4790-9fd5-164fe2bbae7e"
      decimals="INF"
      id="F_d03daeda-e7fc-4c97-a60b-956ab24bdced"
      unitRef="U_shares">15667</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_ce2525a9-10cf-4599-b98b-ee9a7da54cd2"
      decimals="-3"
      id="F_396b2e28-1e79-49d3-8b70-bdbe079c1073"
      unitRef="U_USD">129000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="-3"
      id="F_00d8d33d-99fe-4eaa-92d2-d43edcb8dac4"
      unitRef="U_USD">129000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_ce2525a9-10cf-4599-b98b-ee9a7da54cd2"
      decimals="-3"
      id="F_1b4f8d4c-8096-4209-95eb-b1e679fd044e"
      unitRef="U_USD">12511000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="-3"
      id="F_db8af69f-ee0c-462d-87d2-435e8aff7c19"
      unitRef="U_USD">12511000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="C_2e8c65f5-54e7-412c-9d4a-c7dea4022906"
      decimals="-3"
      id="F_93455aa4-df1e-49e0-8bb5-66d13dac6da7"
      unitRef="U_USD">-61999000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="-3"
      id="F_d8f96cc6-3af0-4716-80b0-668a68874b9e"
      unitRef="U_USD">-61999000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_b79560ec-35d7-487d-96ee-7f96cca3cf73"
      decimals="-3"
      id="F_07c7440f-3e89-4160-8ebe-94fc123d7aa4"
      unitRef="U_USD">-24000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="-3"
      id="F_eed55996-b95a-47c6-8400-3d61303f8972"
      unitRef="U_USD">-24000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:SharesOutstanding
      contextRef="C_4bc22030-2d0d-4a1f-b865-b78ea80ec73c"
      decimals="INF"
      id="F_24322b7c-33bb-4312-8c58-e64d3450addb"
      unitRef="U_shares">39736914</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="C_4bc22030-2d0d-4a1f-b865-b78ea80ec73c"
      decimals="-3"
      id="F_0ae40be6-70b0-4cf7-99ff-6ecedf4eea4c"
      unitRef="U_USD">4000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_5972f862-a654-46cb-b4c6-99346fd20b9c"
      decimals="-3"
      id="F_4054d2e5-8360-4c22-90fe-5fde615a1ecd"
      unitRef="U_USD">471449000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_60060862-7047-426c-9c18-ea7eefd1e40c"
      decimals="-3"
      id="F_728e4ee3-8c1c-474d-910d-31380da2441a"
      unitRef="U_USD">-168324000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-3"
      id="F_3f39c728-a2d1-4056-a474-93d453bf7605"
      unitRef="U_USD">303129000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="-3"
      id="F_e6a6bab8-96e3-45bb-901a-89cdb119fd34"
      unitRef="U_USD">-61999000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="-3"
      id="F_7b037bcb-2feb-48ae-873d-2d71bb009ad2"
      unitRef="U_USD">-36678000</us-gaap:ProfitLoss>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="-3"
      id="F_a3c13d49-5df1-4eac-942e-f91bfe2cd8a4"
      unitRef="U_USD">1538000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="-3"
      id="F_106b8815-ab67-4c60-850f-cbf21f3fb72d"
      unitRef="U_USD">1226000</us-gaap:DepreciationAndAmortization>
    <us-gaap:OtherNoncashExpense
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="-3"
      id="F_14ecd520-83f3-4659-8358-508ef9194fa7"
      unitRef="U_USD">2529000</us-gaap:OtherNoncashExpense>
    <us-gaap:OtherNoncashExpense
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="-3"
      id="F_af3e395e-2ed6-4e04-b73b-38adfb763f44"
      unitRef="U_USD">725000</us-gaap:OtherNoncashExpense>
    <us-gaap:ShareBasedCompensation
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="-3"
      id="F_3d32fe8a-7cca-4d1b-b161-b9f749d7e2ed"
      unitRef="U_USD">12511000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="-3"
      id="F_e42644ac-fc64-4568-871d-ecfe661f426b"
      unitRef="U_USD">5263000</us-gaap:ShareBasedCompensation>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="-3"
      id="F_1b1055fb-7cf4-4bfc-b295-a4547aa459b3"
      unitRef="U_USD">-31000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="-3"
      id="F_c34b7d34-5012-44a4-b63f-1bc051ec8480"
      unitRef="U_USD">-10000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="-3"
      id="F_89158fe9-cbbe-470e-92d0-1e1e5bc3a0ec"
      unitRef="U_USD">-5000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:FairValueAdjustmentOfWarrants
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="-3"
      id="F_c0b17ab9-7bc8-4dae-9350-eed60156b3ba"
      unitRef="U_USD">897000</us-gaap:FairValueAdjustmentOfWarrants>
    <acet:ImpairmentOfInProcessResearchAndDevelopment
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="-3"
      id="F_55a172b0-7f61-4f8d-a61e-76c7fe593df7"
      unitRef="U_USD">1190000</acet:ImpairmentOfInProcessResearchAndDevelopment>
    <acet:ImpairmentOfInProcessResearchAndDevelopment
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="-3"
      id="F_fb81a443-bdaf-4852-a651-94b20981e602"
      unitRef="U_USD">2300000</acet:ImpairmentOfInProcessResearchAndDevelopment>
    <acet:GainOnRemeasurementOfContingentConsiderationLiability
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="-3"
      id="F_81ef5e3e-640b-4f22-a923-be78e83c771f"
      unitRef="U_USD">-980000</acet:GainOnRemeasurementOfContingentConsiderationLiability>
    <acet:GainOnRemeasurementOfContingentConsiderationLiability
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="-3"
      id="F_feed592a-ee5d-4669-88dc-4a1e80e063d2"
      unitRef="U_USD">-1900000</acet:GainOnRemeasurementOfContingentConsiderationLiability>
    <acet:AmortizationOfDebtIssuanceCosts
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="-3"
      id="F_1f0b51f2-f722-4237-8bdb-402addde2ba2"
      unitRef="U_USD">175000</acet:AmortizationOfDebtIssuanceCosts>
    <acet:AmortizationOfDebtIssuanceCosts
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="-3"
      id="F_06b9c405-bf26-43a0-90ef-84ee7b7cf54a"
      unitRef="U_USD">134000</acet:AmortizationOfDebtIssuanceCosts>
    <us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="-3"
      id="F_23bb86cb-2cc4-4cd3-bb8b-4f272494b735"
      unitRef="U_USD">30000</us-gaap:IncreaseDecreaseInAccountsReceivableRelatedParties>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="-3"
      id="F_c3af6f0f-1fea-43c9-8c91-1ef8e4a87102"
      unitRef="U_USD">-1634000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="-3"
      id="F_ca997762-6d8d-47ec-ad5e-ab5d712179eb"
      unitRef="U_USD">3233000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="-3"
      id="F_411b2e78-1e3d-4952-889c-8c8da64388c9"
      unitRef="U_USD">-42000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="-3"
      id="F_4699ced2-f32f-4725-9157-e8170e541f07"
      unitRef="U_USD">1260000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="-3"
      id="F_87f96fac-a177-4f07-bab3-25d0eb3e3f9b"
      unitRef="U_USD">1137000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="-3"
      id="F_b3d660d1-2fbe-4f32-aead-db51cfa8e5f0"
      unitRef="U_USD">-814000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="-3"
      id="F_820f07c5-550a-4bee-97bc-92af46b472f6"
      unitRef="U_USD">-9175000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="-3"
      id="F_e2022cb1-3a4d-44ac-ae0f-048e681b1dd7"
      unitRef="U_USD">-7903000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <acet:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="-3"
      id="F_0df859d4-ad9b-4f98-b638-003db09d92bf"
      unitRef="U_USD">-511000</acet:IncreaseDecreaseInOperatingLeaseLiabilities>
    <acet:IncreaseDecreaseInOperatingLeaseLiabilities
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="-3"
      id="F_8cc1377f-14fc-472f-8507-bc96231707a2"
      unitRef="U_USD">-859000</acet:IncreaseDecreaseInOperatingLeaseLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="-3"
      id="F_ce66b0ee-5afa-4fcf-b595-da133944452b"
      unitRef="U_USD">855000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="-3"
      id="F_f0952468-c4ed-41ff-a100-c8ed80a3ec9d"
      unitRef="U_USD">787000</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="-3"
      id="F_60a9e1d9-e81b-43d8-96d6-f9b2b2d700e7"
      unitRef="U_USD">-9000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="-3"
      id="F_4658101f-25d5-49e9-9055-578863d8c280"
      unitRef="U_USD">-242000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="-3"
      id="F_bd0b6f97-7908-4f6c-8a3c-d0e878e89032"
      unitRef="U_USD">-51052000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="-3"
      id="F_eaccf406-f214-448a-ab65-fa5f0134cae9"
      unitRef="U_USD">-41552000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:CashAcquiredFromAcquisition
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="-3"
      id="F_f84ae42c-b0fd-424d-942f-dd281982e07a"
      unitRef="U_USD">64114000</us-gaap:CashAcquiredFromAcquisition>
    <acet:ProceedsFromSalesOfMarketableDebtSecurities
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="-3"
      id="F_bdc70c82-cc8a-4612-bf56-7a6f8b9ec1a9"
      unitRef="U_USD">7500000</acet:ProceedsFromSalesOfMarketableDebtSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="-3"
      id="F_6ba8e206-8f80-45db-9868-10015f2f9683"
      unitRef="U_USD">5700000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="-3"
      id="F_e61164f2-de21-4082-b30e-cc039b45754f"
      unitRef="U_USD">2750000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="-3"
      id="F_86561105-facf-412a-ac93-cf569e1e3d76"
      unitRef="U_USD">57793000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="-3"
      id="F_bbbd9603-24b4-4fac-8973-0a5a79122b7b"
      unitRef="U_USD">13046000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="-3"
      id="F_8fae1af5-f094-43ab-a255-7b83a3d49ea7"
      unitRef="U_USD">990000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="-3"
      id="F_c963fb6d-1149-4683-b170-6fe61dfb5446"
      unitRef="U_USD">-2796000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="-3"
      id="F_ae2c7e91-8af9-47e0-8754-d8fbb149bdb4"
      unitRef="U_USD">115217000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="-3"
      id="F_28e52752-d2cc-48f3-af29-406b67f88208"
      unitRef="U_USD">238129000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromStockPlans
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="-3"
      id="F_7ea9be40-ddd8-463d-8525-c5ebb3b4eb58"
      unitRef="U_USD">129000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="-3"
      id="F_8e470252-0e5f-40a8-af42-0e0582a2a481"
      unitRef="U_USD">4688000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="-3"
      id="F_228af2b2-db66-494b-ac2f-814c52b2638c"
      unitRef="U_USD">460000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="-3"
      id="F_4e469b14-3d0f-4fbb-869b-c5122de58f8f"
      unitRef="U_USD">261000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="-3"
      id="F_c403a97e-9f7b-44f6-89e0-41f2debc35a5"
      unitRef="U_USD">157000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="-3"
      id="F_22a91b01-b728-46b3-b204-e0c115b0f653"
      unitRef="U_USD">242685000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="-3"
      id="F_6b1b4fa4-7019-43a8-97a7-dab6be36116e"
      unitRef="U_USD">303000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="-3"
      id="F_14e63d0f-df2d-4629-b683-09ce09feda1b"
      unitRef="U_USD">188837000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="-3"
      id="F_d1670bcf-98db-4938-80c2-b59646737a6c"
      unitRef="U_USD">73968000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="-3"
      id="F_b09eaf75-2727-4c44-ace6-1241d326a381"
      unitRef="U_USD">88857000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_95800697-5c2c-4d5a-aff7-318a343c4784"
      decimals="-3"
      id="F_a95c7df2-b21d-4321-8f6c-62f2b981830a"
      unitRef="U_USD">14889000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-3"
      id="F_dc18f372-2620-4c4d-837c-c8567ef180d0"
      unitRef="U_USD">277694000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="-3"
      id="F_ef666f90-1bda-4314-b23b-4d223215f2f7"
      unitRef="U_USD">88857000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-3"
      id="F_de2eefb9-3b2d-4cce-ad02-ec0bb0e4bcea"
      unitRef="U_USD">277544000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="-3"
      id="F_0a7650c8-f93d-429e-acb2-96ba662d3080"
      unitRef="U_USD">84330000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-3"
      id="F_25eff3d2-0e7b-4b04-a687-12803a2f47ba"
      unitRef="U_USD">150000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:RestrictedCashNoncurrent
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="-3"
      id="F_053ba858-9c79-4a2b-85d7-30baa88f19a4"
      unitRef="U_USD">4527000</us-gaap:RestrictedCashNoncurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-3"
      id="F_73823f37-2989-476f-a0f3-01f6d3858975"
      unitRef="U_USD">277694000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="-3"
      id="F_6ec0a199-d905-45ce-b9bb-9046fefde05f"
      unitRef="U_USD">88857000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:IncomeTaxesPaid
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="-3"
      id="F_2d5ef63b-7fea-4214-aea3-f618c5affcc4"
      unitRef="U_USD">43000</us-gaap:IncomeTaxesPaid>
    <us-gaap:IncomeTaxesPaid
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="-3"
      id="F_ea93b15f-ca91-4e0d-98e1-37a32e0adb3f"
      unitRef="U_USD">3000</us-gaap:IncomeTaxesPaid>
    <us-gaap:ProceedsFromIncomeTaxRefunds
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="-3"
      id="F_ad7ffdad-607a-4eb4-963b-f1df9154be95"
      unitRef="U_USD">2766000</us-gaap:ProceedsFromIncomeTaxRefunds>
    <us-gaap:ProceedsFromIncomeTaxRefunds
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="-3"
      id="F_f7de021a-f976-4760-b201-f1bdda5c8dd5"
      unitRef="U_USD">664000</us-gaap:ProceedsFromIncomeTaxRefunds>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="-3"
      id="F_36371b41-fe8e-4ecc-9d1a-3fb8cca5b0ee"
      unitRef="U_USD">651000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="-3"
      id="F_ee686fce-aa57-47aa-a7ad-165e05cafaf4"
      unitRef="U_USD">115000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <acet:CommonStockOfferingCostsIncludedInAccruedLiabilitiesAtPeriodEnd
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="-3"
      id="F_887752bd-387f-4529-be65-120435cd1ad1"
      unitRef="U_USD">132000</acet:CommonStockOfferingCostsIncludedInAccruedLiabilitiesAtPeriodEnd>
    <acet:RightOfUseAssetsRecognized
      contextRef="C_788e17f6-1175-45bd-816d-ca6c3191ac61"
      decimals="-3"
      id="F_09e49f66-e304-4bbe-bc68-a4277c49d2b7"
      unitRef="U_USD">1424000</acet:RightOfUseAssetsRecognized>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="-3"
      id="F_e2489b86-51d4-40e5-b8fd-6e8a6871eb3e"
      unitRef="U_USD">22367000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="-3"
      id="F_79bea176-473d-4664-a863-bbb018bacc0a"
      unitRef="U_USD">114083000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:ConversionOfStockAmountConverted1
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="-3"
      id="F_3c489fa2-b00e-4934-9eda-b46688271d37"
      unitRef="U_USD">2922000</us-gaap:ConversionOfStockAmountConverted1>
    <us-gaap:FairValueOfAssetsAcquired
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="-3"
      id="F_6adc8b13-4416-4ccf-8e23-3e0e475b84f9"
      unitRef="U_USD">84142000</us-gaap:FairValueOfAssetsAcquired>
    <acet:AdjustmentToGoodwill
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="-3"
      id="F_266d7bc7-3bbe-49de-bdd1-a2249a501666"
      unitRef="U_USD">413000</acet:AdjustmentToGoodwill>
    <acet:AdjustmentToGoodwill
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="-3"
      id="F_9e3c0038-ae14-4176-b3d6-aabf4b372d01"
      unitRef="U_USD">650000</acet:AdjustmentToGoodwill>
    <acet:IssuanceOfRedeemableConvertiblePreferredStockOnExerciseOfWarrantsWithLoanAgreement
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="-3"
      id="F_9e47242b-8979-4472-9f9f-32c0084e1ef2"
      unitRef="U_USD">144000</acet:IssuanceOfRedeemableConvertiblePreferredStockOnExerciseOfWarrantsWithLoanAgreement>
    <acet:OrganizationAndNatureOfBusinessTextBlock
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_17b1e974-6cf0-452a-a7e9-f64d686da5a0">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;1. Organization and Nature of the Business&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Adicet Bio, Inc. (formerly resTORbio, Inc. (resTORbio)), together with its subsidiaries, (the Company) is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer. The Company is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs) and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. The Company's approach to activate, engineer, and manufacture allogeneic gamma delta T cell product candidates derived from the peripheral blood cells of unrelated donors allows it to generate new product candidates in a rapid and cost efficient manner.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company was incorporated in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_6bd37428-42c2-4038-b96a-a6cfe4c5c8c5;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;November 2014&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; in Delaware. The principal executive offices are located in Boston, Massachusetts. The Company also has another office in Menlo Park, California.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Adicet Bio, Inc. (when referred to prior to the Merger (as defined below), (Former Adicet)) was incorporated in November 2014 in Delaware and was headquartered in Menlo Park, CA. Adicet Bio Israel Ltd. (formerly Applied Immune Technologies Ltd.) (Adicet Israel) is a wholly owned subsidiary of Former Adicet and is located in Haifa, Israel. Adicet Israel was founded in 2006. During 2019, Former Adicet consolidated its operations, including research and development activities, in the United States and as a result substantially reduced its operations in Israel.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Merger with resTORbio&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Prior to September 15, 2020, the Company was a clinical-stage biopharmaceutical company known as resTORbio that had historically focused on developing innovative medicines that target the biology of aging, to prevent or treat age-related diseases with the potential to extend healthy lifespans. On &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;April 28, 2020&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, resTORbio entered into a definitive Merger Agreement with Former Adicet. Under the terms of the Merger Agreement, Former Adicet agreed to merge with a wholly owned subsidiary of resTORbio in an all-stock transaction with Former Adicet surviving as a wholly owned subsidiary of resTORbio and changing its name to &#x201c;Adicet Therapeutics, Inc.&#x201d; (such transactions, the Merger). Under the exchange ratio formula in the Merger Agreement, immediately following the Effective Time of the Merger, the securityholders of Former Adicet as of immediately prior to the Effective Time of the Merger owned approximately &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;75&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of the outstanding shares of the Company&#x2019;s common stock on a fully-diluted basis and securityholders of resTORbio as of immediately prior to the Effective Time of the Merger owned approximately &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;25&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of the outstanding shares of the Company&#x2019;s common stock on a fully-diluted basis (in each case excluding equity incentives available for grant).&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company concluded that the transaction represented a business combination pursuant to Financial Accounting Standards Board (FASB) Accounting Standards Codification (ASC) Topic 805, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Business Combinations&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. Further, Former Adicet was determined to be the accounting acquirer based upon the terms of the Merger and other factors including: (i) Former Adicet&#x2019;s securityholders own approximately 75% of the voting rights of the combined company (on a fully-diluted basis excluding equity incentives available for grant); (ii) Former Adicet designated a majority (five of seven) of the initial members of the Board of Directors of the combined company; and (iii) the terms of the exchange of equity interests based on the exchange ratio at the announcement of the Merger factored in an implied premium to resTORbio&#x2019;s stockholders. The composition of senior management of the combined company was determined to be a neutral factor in the accounting acquirer determination, as the combined company will leverage the expertise of the senior management of both companies. Accordingly, the reported operating results prior to the business combination are those of Former Adicet.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On September 15, 2020, the Company completed the Merger pursuant to the Merger Agreement (the Effective Time). In connection with the Merger, and immediately prior to the Effective Time, resTORbio effected a reverse stock split of its common stock at a ratio of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1-for-7&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; (the Reverse Stock Split). Also, in connection with the Merger, the Company changed its name from &#x201c;resTORbio, Inc.&#x201d; to &#x201c;Adicet Bio, Inc.&#x201d; (the Name Change), Former Adicet changed its name from &#x201c;Adicet Bio, Inc.&#x201d; to &#x201c;Adicet Therapeutics, Inc.&#x201d; and the business conducted by the Company became primarily the business, which was previously conducted by Former Adicet, which is a biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;At the Effective Time, each outstanding share of Former Adicet capital stock was converted into the right to receive &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1240&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; (the &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Exchange Ratio) shares of Company&#x2019;s common stock, as set forth in the Merger Agreement. The Exchange Ratio was determined based on the total number of outstanding shares of Company&#x2019;s common stock and Former Adicet capital stock, each on a fully diluted basis, and the respective valuations of Former Adicet and resTORbio at the time of execution of the Merger Agreement. In connection with the Merger, the Company also assumed certain outstanding Former Adicet warrants and Former Adicet stock options under Former Adicet&#x2019;s 2015 Stock Incentive Plan (the 2015 Adicet Stock Incentive Plan) and Former Adicet&#x2019;s 2014 Share Option Plan (the 2014 Share Option Plan and, together with the 2015 Adicet Stock Incentive Plan, the Former Adicet Plans), with such stock options and warrants henceforth representing the right to purchase a number of shares of Company&#x2019;s common stock equal to the Exchange Ratio multiplied by the number of shares of Former Adicet&#x2019;s&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;capital &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;stock previously represented by such stock options and warrants, as applicable, with a proportionate adjustment in exercise price.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Immediately following the Effective Time, there were approximately &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;19,589,828&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of the Company&#x2019;s common stock outstanding (post Reverse Stock Split), with the former equity holders of Former Adicet holding approximately &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;75&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of the outstanding shares of Company&#x2019;s common stock on a fully-diluted basis and the former equity holders of resTORbio holding approximately &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;25&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of the outstanding shares of Company&#x2019;s common stock on a fully-diluted basis (in each case excluding equity incentives available for grant).&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Please refer to Note 3 &#x201c;Business Combinations&#x201d; for further discussions of the Merger.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Liquidity&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company has incurred significant net operating losses and negative cash flows from operations since inception and had an accumulated deficit of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;168.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million as of December 31, 2021. The Company has historically financed its operations primarily through a collaboration and licensing arrangement, the private placement of equity securities and debt, and cash received in the Merger. To date, none of the Company&#x2019;s product candidates have been approved for sale and therefore the Company has not generated any revenue from product sales. Management expects operating losses and negative cash flows to continue for the foreseeable future, until such time, if ever, that it can generate significant sales of its product candidates currently in development.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In February 2021, the Company completed an underwritten public offering of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,575,513&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of its common stock at a public offering price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;13.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share. The Company received net proceeds from the offering, after deducting underwriting discounts and commissions and offering expenses of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;128.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million. In connection with the offering, the Company also entered into a stock purchase agreement &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;with certain existing investors to purchase &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,153,840&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of its common stock for $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;15.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million at a price per share equal to the public offering price, with an initial closing for certain investors held simultaneously with the closing of the offering and a subsequent closing for certain additional investors.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In December 2021, the Company closed an underwritten public offering, or the December 2021 Follow-On Offering, of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,187,500&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of its common stock at a public offering price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;14.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share. The Company received net proceeds from the offering, after deducting underwriting discounts and commissions and offering expenses of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;94.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company expects that its cash and cash equivalents balances as of December 31, 2021, including the gross proceeds it received in February 2021 and December 2021 from its underwritten public offerings and the proceeds received from a stock purchase agreement with certain existing investors, will be sufficient to fund its forecasted operating expenses, capital expenditure requirements for at least the next twelve months from the issuance of these annual consolidated financial statements.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;All of the Company&#x2019;s revenue to date is generated from the Regeneron Agreement, which is a collaboration and license agreement with Regeneron. The Company does not expect to generate any significant product revenue until it obtains regulatory approval of and commercialize any of the Company&#x2019;s product candidates or enter into additional collaborative agreements with third parties, and it does not know when, or if, either will occur. The Company expects to continue to incur significant losses for the foreseeable future, and it expects the losses to increase as the Company continues the development of, and seek regulatory approvals for, its product candidates and begin to commercialize any approved products. The Company is subject to all of the risks typically related to the development of new product candidates, including, but not limited to, raising additional capital, development by its competitors of new technological innovations, risk of failure in preclinical and clinical studies, safety and efficacy of its product candidates in clinical trials, the risk of relying on external parties such as contract research organizations (CROs) and contract manufacturing organizations (CMOs), the regulatory approval process, market acceptance of the Company&#x2019;s products once approved, lack of marketing and sales history, dependence on key personnel and protection of proprietary technology and it may encounter unforeseen expenses, difficulties, complications, delays, and other unknown factors that may adversely affect its business.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Until such time as the Company can generate significant revenue from product sales, if ever, the Company expects to finance its operations through the sale of equity, debt financings, collaborative or other arrangements with corporate or other sources of financing. Adequate funding may not be available to the Company on acceptable terms or at all. The Company&#x2019;s failure to raise capital as and when needed could have a negative impact on its financial condition and the Company&#x2019;s ability to pursue its business strategies. Although the Company continues to pursue these plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company to fund continuing operations, if at all.&lt;/span&gt;&lt;/p&gt;</acet:OrganizationAndNatureOfBusinessTextBlock>
    <acet:EntityDateOfMerger
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_d2ca398e-a36f-4a45-8fab-99162c8600f7">2020-04-28</acet:EntityDateOfMerger>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="C_38799e03-7018-4654-b7db-0fc7800d94e4"
      decimals="2"
      id="F_13e1646c-8b09-417f-8279-87949311080b"
      unitRef="U_pure">0.75</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="2"
      id="F_0184ebe0-e70c-48dd-94cf-a2e6dadf71fa"
      unitRef="U_pure">0.25</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:StockholdersEquityReverseStockSplit
      contextRef="C_54827df2-7ab1-4397-b75e-6c83f7055086"
      id="F_6089a786-dac8-450b-bbce-2080af687d65">1-for-7</us-gaap:StockholdersEquityReverseStockSplit>
    <acet:ExchangeRatio
      contextRef="C_54827df2-7ab1-4397-b75e-6c83f7055086"
      decimals="4"
      id="F_92eb49b6-362a-4d6f-a369-9f58b1214ee5"
      unitRef="U_pure">0.1240</acet:ExchangeRatio>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="C_38799e03-7018-4654-b7db-0fc7800d94e4"
      decimals="INF"
      id="F_600d3f4e-a87c-4e9a-b940-0c892c6cd8b5"
      unitRef="U_shares">19589828</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="C_38799e03-7018-4654-b7db-0fc7800d94e4"
      decimals="2"
      id="F_3e226e39-176f-4353-9134-336f00e5b3d5"
      unitRef="U_pure">0.75</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="2"
      id="F_6d4bd728-362a-4652-9b06-c018d73096e0"
      unitRef="U_pure">0.25</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="C_38799e03-7018-4654-b7db-0fc7800d94e4"
      decimals="-5"
      id="F_0787f583-a2ff-4dda-a2fe-e32f53e4da56"
      unitRef="U_USD">-168300000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_aab33e86-f1f3-4f74-9094-e2ed14ea13cc"
      decimals="INF"
      id="F_d78e18d2-a06f-4860-a26f-3fa81e587ab6"
      unitRef="U_shares">10575513</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_4066c921-3deb-4a5c-8fd4-0507b83d109f"
      decimals="INF"
      id="F_0abf2111-73c3-413e-a8ce-06e1f092e8ac"
      unitRef="U_USDollarShare">13.00</us-gaap:SharesIssuedPricePerShare>
    <acet:UnderwritingDiscountsAndCommissionsAndOtherOfferingExpenses
      contextRef="C_aab33e86-f1f3-4f74-9094-e2ed14ea13cc"
      decimals="-5"
      id="F_360d3e3f-4a9b-4f46-856b-40b164b3c0d5"
      unitRef="U_USD">128800000</acet:UnderwritingDiscountsAndCommissionsAndOtherOfferingExpenses>
    <us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
      contextRef="C_4066c921-3deb-4a5c-8fd4-0507b83d109f"
      decimals="0"
      id="F_cf5141c0-ebe9-4eb2-9f11-abb31e004e4d"
      unitRef="U_shares">1153840</us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="C_aab33e86-f1f3-4f74-9094-e2ed14ea13cc"
      decimals="-5"
      id="F_57d56c2d-080c-4f02-839e-9a9cd451a2a9"
      unitRef="U_USD">15000000.0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_c66707bf-a227-49f3-9c39-d4e971ab95bd"
      decimals="INF"
      id="F_0d586199-37ae-48bb-8919-4387585934b6"
      unitRef="U_shares">7187500</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="C_0e775bc8-410a-49ef-80c8-2b1c45c0da93"
      decimals="INF"
      id="F_9cbb61a0-3254-4460-8774-c8fdad23c6cc"
      unitRef="U_USDollarShare">14.00</us-gaap:SharesIssuedPricePerShare>
    <acet:UnderwritingDiscountsAndCommissionsAndOtherOfferingExpenses
      contextRef="C_c66707bf-a227-49f3-9c39-d4e971ab95bd"
      decimals="-5"
      id="F_4b334608-178b-4798-bb55-0308893a033a"
      unitRef="U_USD">94200000</acet:UnderwritingDiscountsAndCommissionsAndOtherOfferingExpenses>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_2ace3216-cd81-4a78-8492-5f9392403e3b">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2. Summary of Significant Accounting Policies&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The consolidated financial statements and related disclosures have been prepared in conformity with accounting principles generally accepted in the United States of America (United States GAAP or GAAP).&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Principles of Consolidation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. The United States dollar is the functional and reporting currency of the Company and its subsidiaries.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent liabilities at the date of the consolidated financial statements as well as the reported amounts of revenues and expenses during the reporting period. Such estimates include the valuation of the intangible assets acquired in business combinations, redeemable convertible preferred stock warrant liability, redeemable convertible preferred stock tranche liability, the Technion Research and Development Foundation liability (TRDF Liability), contingent consideration liability for contingent value right (CVR), deferred tax assets, useful lives of property and equipment, accruals for research and development activities, revenue recognition and stock-based compensation and the Company&#x2019;s incremental borrowing rate. Actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Contingent Consideration Liability (CVR)&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The estimated fair value of the CVR, initially measured and recorded on the acquisition date, is considered to be a Level 3 instrument. The contingent consideration liability is recorded at fair value at the end of each reporting period with changes in estimated fair values recorded in research and development expenses in the consolidated statements of operations and comprehensive loss. During the second quarter of 2021, the Company performed a re-measurement of the fair value of the CVR liability and adjusted the liability to zero. This resulted in a $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million gain in research and development expense in the statements of operations and comprehensive loss for the year ended December 31, 2021.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Goodwill&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Goodwill represents the excess of the purchase price over the fair value of net tangible and identified intangible assets acquired in a business combination. Goodwill is not amortized but is evaluated at least annually for impairment or when a change in facts and circumstances indicate that the fair value of the goodwill may be below the carrying value.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Goodwill is tested for impairment at the reporting unit level annually in the fourth quarter, or more frequently when events or changes in circumstances indicate that the asset might be impaired. Examples of such events or circumstances include, but are not limited to, a significant adverse change in legal or business climate, an adverse regulatory action or unanticipated competition. The Company has determined that it operates in a single operating segment and has a single reporting unit.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Prior to performing the impairment test, the Company assesses qualitative factors to determine whether the existence of events or circumstances would indicate that it is more likely than not that the fair value of the reporting unit was less than the carrying amount. If after assessing the totality of events or circumstances, the Company were to determine that it is more likely than not that the fair value of the reporting unit is less than the carrying amount, then the Company would perform a quantitative impairment test.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The quantitative impairment test involves comparing the fair value of the reporting unit to the carrying value. If the fair value of the reporting unit exceeds the carrying value of the net assets, goodwill is not impaired, and no further testing is required. If the fair value of the reporting unit is less than the carrying value, the Company measures the amount of impairment loss, if any, as the excess of the carrying value over the fair value of the reporting unit. The Company performed an annual test for goodwill impairment in the fourth quarter of the fiscal year ended December 31, 2021 and determined that goodwill was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;t impaired.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Intangible Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In connection with the Merger, the Company acquired certain IPR&amp;amp;D assets, which were classified as indefinite-lived intangible assets. Acquired IPR&amp;amp;D represents the fair value assigned to research and development assets that the Company acquires and have not been completed at the acquisition date. The fair value of IPR&amp;amp;D acquired in a business combination is recorded on the Company&#x2019;s consolidated balance sheets at the acquisition-date fair value and is determined by estimating the costs to develop the technology into commercially viable products, estimating the resulting revenue from the products, and discounting the projected net cash flows to present value. IPR&amp;amp;D is not amortized, but rather is reviewed for impairment on an annual basis or more frequently if indicators of impairment are present, until the project is completed, abandoned, or transferred to a third party. The Company performed a review for impairment of IPR&amp;amp;D during the second quarter of the year ended December 31, 2021 and recognized an impairment charge of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, which was recorded as research and development expenses in the consolidated statement of operations and comprehensive loss.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Segments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company operates and manages its business as &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;one&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; reportable and operating segment, which is the business of research and development of allogeneic immunotherapies for cancer and other diseases. The Company&#x2019;s Chief Executive Officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of cash and cash equivalents, and marketable debt securities. The Company&#x2019;s cash and cash equivalents are held at two financial institutions in the United States and one financial institution in Israel and such amounts may, at times, exceed insured limits. The Company invests its cash equivalents and marketable debt securities in money market funds, United States government securities, commercial paper, corporate bonds, and asset-backed securities. The Company limits its credit risk associated with cash equivalents and marketable debt securities by placing them with banks and institutions it believes are highly creditworthy and in highly rated investments. The Company has not experienced any losses on its deposits of cash and cash equivalents and marketable debt securities to date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company has &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;one&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; customer, Regeneron, which represents &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;100&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of the Company&#x2019;s total revenue during the years ended December 31, 2021 and 2020 and outstanding accounts receivable as of December 31, 2021 (see Note 10).&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, protection of proprietary technology, dependence on key personnel, compliance with government regulations and the need to obtain additional financing to fund operations. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical studies, clinical trials, and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance and reporting.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company&#x2019;s product candidates are still in development and, to date, none of the Company&#x2019;s product candidates have been approved for sale and, therefore, the Company has not generated any revenue from product sales.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;There can be no assurance that the Company&#x2019;s research and development will be successfully completed, that adequate protection for the Company&#x2019;s intellectual property will be obtained or maintained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company&#x2019;s product development efforts are successful, it is uncertain when, if ever, the Company will generate revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from other pharmaceutical and biotechnology companies.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;current COVID-19 (coronavirus) pandemic, which is impacting worldwide economic activity, poses risk that the Company or its employees, contractors, suppliers, and other partners may be prevented from conducting business activities for an indefinite period of time, including due to shutdowns that may be requested or mandated by governmental authorities. The extent to which the coronavirus impacts the Company&#x2019;s operations will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the outbreak, new information that will emerge concerning the severity of the coronavirus and the actions to contain the coronavirus or treat its impact, among others. COVID-19 may impact the timing of regulatory approval of the INDs for clinical trials, the enrollment of any clinical trials that are&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;approved, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;the availability of clinical trial materials and regulatory approval and commercialization of our products. COVID-19 may also impact the Company&#x2019;s ability to access capital, which could negatively impact short-term and long-term liquidity.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company considers all highly liquid investments purchased with maturities of three months or less from the purchase date to be cash equivalents. As of December 31, 2021 and 2020, cash and cash equivalents consist of cash deposited with banks and investments in money market funds with maturities of three months or less from the date of purchase.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Marketable Debt Securities&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Marketable debt securities are investments in marketable debt securities with maturities greater than three months at the time of purchase. The Company determines the appropriate classification of its investments in marketable debt securities at the time of purchase and reevaluates such designation at each balance sheet date. The Company has classified and accounted for its marketable debt securities as available-for-sale. The Company classifies highly liquid securities with maturities beyond 12 months as long-term marketable debt securities in the consolidated balance sheet. These securities are carried at fair value as determined based upon quoted market prices or pricing models for similar securities. Unrealized gains and losses, if any, are excluded from earnings and are reported as a component of accumulated other comprehensive income (loss). The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in interest income on the consolidated statements of operations and comprehensive loss. Realized gains and losses, if any, on available-for-sale securities are included in other income (expense), net. The cost of securities sold is based on the specific identification method. Interest and dividends on securities classified as available-for-sale are included in interest income. The Company did not have any outstanding marketable debt securities as of December 31, 2021 and did not identify any of its marketable debt securities as other-than-temporarily impaired as of December 31, 2020.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Restricted Cash&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Restricted cash is comprised of cash that is restricted as to withdrawal or use under the terms of certain contractual agreements. Restricted cash for years ended December 31, 2021 and 2020 consists of collateral for letters of credit issued in connection with real estate leases (see Note 12).&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The carrying amounts of certain financial instruments of the Company, including cash equivalents, restricted cash, accounts payable and accrued and other current liabilities approximate fair value due to their relatively short maturities. The Company&#x2019;s marketable debt securities and CVR liability are carried at fair value (see Notes 4 and 5).&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is computed on a straight-line basis over the estimated useful lives of the related assets, generally three years. Leasehold improvements are amortized using the straight-line method over the shorter of the assets&#x2019; estimated useful lives or the remaining term of the lease. Maintenance and repairs are charged to operations as incurred. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the consolidated balance sheet and any resulting gain or loss is reflected in the consolidated statements of operations and comprehensive loss in the period realized.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. Recoverability is measured by comparison of the carrying amount of the asset or asset group to the future net cash flows which the asset or asset group is expected to generate. If such asset or asset group is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset or asset group exceeds the fair value of the asset or asset group. There has been &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; such impairment of long-lived assets during the years ended December 31, 2021 and 2020.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Under ASC 606, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; (ASC 606), the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps as prescribed by ASC 606:&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;"&gt;(i)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;identify the contract(s) with a customer;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;"&gt;(ii)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;identify the performance obligations in the contract;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;"&gt;(iii)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;determine the transaction price;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;"&gt;(iv)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;allocate the transaction price to the performance obligations in the contract; and&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;"&gt;(v)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;recognize revenue when (or as) the Company satisfies a performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;A contract with a customer exists when (i) the Company enters into a legally enforceable contract with a customer that defines each party&#x2019;s rights regarding the products or services to be transferred and identifies the payment terms related to these products or services, (ii) the contract has commercial substance and (iii) the Company determines that collection of substantially all consideration for products or services that are transferred is probable based on the customer&#x2019;s intent and ability to pay the promised consideration.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;At contract inception, once the contract is determined to be within the scope of ASC 606, the Company identifies the goods or services promised and determines the performance obligations by assessing whether each promised good or service is distinct. Goods or services that are not distinct are bundled with other goods or services in the contract until a bundle of goods or services that is distinct is created. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;All of the Company&#x2019;s revenues are derived through a license and collaboration agreement (see Note 10).&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;For revenue recognition purposes, the Company determines the term of its license or collaboration agreements by evaluating the period during which present and enforceable rights and obligations exist. This determination is impacted by the existence of substantive termination penalties, among other factors.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company recognizes revenue under the Company&#x2019;s license or collaboration agreements that are within the scope of ASC 606. These agreements include promises related to licenses to intellectual property and research and development services. If the license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgement to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. Accordingly, the transaction price is generally comprised of a fixed fee due at contract inception and at specified future dates, variable consideration in the form of milestone payments due upon the achievement of specified events and tiered royalties earned when customers recognize net sales of licensed products. The Company measures the transaction price based on the amount of consideration to which it expects to be entitled in exchange for transferring the promised goods and/or services to the customer. The Company utilizes the &#x201c;most likely amount&#x201d; method to estimate the amount of variable consideration to which it will be entitled for the contract. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. At the inception of each arrangement that includes development and regulatory milestone payments, the Company evaluates whether the associated event is considered most likely to be achieved and estimates the amount to be included in the transaction price.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Payments or reimbursements for the Company&#x2019;s research and development efforts where such efforts are considered part of or a single performance obligation are recognized over time using a measure of progress that best reflects the Company&#x2019;s performance in satisfying the obligation.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Upfront payments are recorded as contract liabilities upon receipt or when due and may require deferral of revenue recognition to a future period until the Company performs its obligation under these arrangements. Amounts payable to the Company are recorded as accounts receivable when the Company&#x2019;s right to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one year or less.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from its collaboration arrangement.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Research and Development Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development expenses include costs directly attributable to the conduct of research and development programs, including payroll and related expenses, costs for CMOs, costs for CROs, materials, supplies, depreciation on and maintenance of research equipment, consulting costs, and the allocated portions of facility costs, such as rent, utilities, insurance, repairs and maintenance, depreciation, information technology costs and general support services. All costs associated with research and development are expensed within the consolidated statements of operations and comprehensive loss as incurred.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Costs incurred in obtaining technology licenses are charged to research and development expense as acquired in-process research and development if the technology licensed has not reached technological feasibility and has no alternative future use.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Accrued CRO, CMO, and Research and Development Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company has entered into various agreements with CMOs and CROs. The Company&#x2019;s research and development accruals are estimated based on the level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. The estimated costs of research and development provided, but not yet invoiced are included in accrued and other current liabilities on the consolidated balance sheets. If the actual timing of the performance of services or the level of effort varies from the original estimates, the Company will adjust the accrual accordingly. Payments made to CMOs and CROs under these arrangements in advance of the performance of the related services are recorded as prepaid expenses and other current assets on the consolidated balance sheets until the services are rendered. Through December 31, 2021 there had been no material adjustments to the Company&#x2019;s prior period estimates of accrued research and development expenses.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; Effective January 1, 2020, the Company adopted ASU No. 2016-02, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Leases (Topic 842)&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; (ASU 2016-02), using the modified retrospective approach through a cumulative-effect adjustment as of the adoption date, with prior periods unchanged and presented in accordance with the guidance in Topic 840, Leases (Topic 840).&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Consistent with ASU 2016-02, the Company determines if an arrangement is a lease, or contains a lease, at inception. Leases with a term greater than 12 months are recognized on the balance sheet as Right-of-Use (ROU) assets and current and long-term operating lease liabilities, as applicable. The Company has elected not to recognize on the balance sheet leases with terms of 12 months or less. The Company typically only includes an initial lease term in its assessment of a lease arrangement. Options to renew a lease are not included in the Company&#x2019;s assessment unless there is reasonable certainty that the Company will renew. The Company monitors its plan to renew its leases no less than on a quarterly basis. In addition, the Company&#x2019;s lease agreements generally do not contain any residual value guarantees or restrictive covenants.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In accordance with ASU 2016-02, the ROU assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term. As most of the Company&#x2019;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate (IBR), which is the estimated rate the Company would be required to pay for a fully collateralized borrowing equal to the total lease payments over the term of the lease, to determine the present value of future minimum lease payments. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. For lease agreements entered into or reassessed after the adoption of ASU 2016-02, the Company does not combine lease and non-lease components. Variable lease payments are expenses as incurred.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Assumptions made by the Company at the commencement date are re-evaluated upon occurrence of certain events, including a lease modification. A lease modification results in a separate contract when the modification grants the lessee an additional right of use not included in the original lease and when lease payments increase commensurate with the standalone price for the additional right of use. When a lease modification results in a separate contract, it is accounted for in the same manner as a new lease.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Fair Value of Common Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Prior to the Merger the fair value of the Company&#x2019;s common stock was determined by its Board of Directors with input from management and third-party valuation specialists. The Company&#x2019;s approach to estimate the fair value of the Company&#x2019;s common stock is consistent with the methods outlined in the American Institute of Certified Public Accountants Practice Aid, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Valuation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;of Privately-Held-&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Company&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; Equity Securities Issued as Compensation&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. Determining the best estimated fair value of the Company&#x2019;s common stock requires significant judgement and management considers several factors, including the Company&#x2019;s stage of development, equity market conditions affecting comparable public companies, significant milestones and progress of research and development efforts. Subsequent to the Merger, the fair value of the Company&#x2019;s common stock is determined based on its closing market price.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company accounts for stock-based compensation arrangements with employees and non-employees using a fair value method which requires the recognition of compensation expense for costs related to all stock-based payments including stock options. The fair value method requires the Company to estimate the fair value of stock-based payment awards on the date of grant using an option-pricing model. The Company uses the Black-Scholes option-pricing model to estimate the fair value of options granted that are expensed on a straight-line basis over the requisite service period, which is generally the vesting period. The Company accounts for forfeitures as they occur. Option valuation models, including the Black-Scholes option-pricing model, require the input of several assumptions. Changes in the assumptions used can materially affect the grant-date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend yield, expected volatility and the expected life of the award. For awards that have a performance condition, the Company recognizes compensation expense based on its assessment of the probability that the performance condition will be achieved, using an accelerated attribution model, over the explicit or implicit service period.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences attributable to differences between carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax reporting purposes and for operating loss and tax credit carryforwards. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company&#x2019;s deferred tax assets and liabilities are measured using enacted tax rates expected to apply in the years in which these temporary differences are expected to be recovered or settled. A valuation allowance is recorded to reduce deferred tax assets if it is determined that it is more likely than not that all or a portion of the deferred tax asset will not be realized. The Company considers many factors when assessing the likelihood of future realization of deferred tax assets, including recent earnings results, expectations of future taxable income, carryforward periods available and other relevant factors. The Company records changes in the required valuation allowance in the period that the determination is made.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company assesses its income tax positions and records tax benefits for all years subject to examination based upon management&#x2019;s evaluation of the facts, circumstances and information available as of the reporting date. For those tax positions where it is more likely than not that a tax benefit will be sustained, the Company records the largest amount of tax benefit with a greater than 50% likelihood of being realized upon ultimate settlement with a taxing authority having full knowledge of all relevant information. For those income tax positions where it is not more likely than not that a tax benefit will be sustained, the Company does not recognize a tax benefit in the consolidated financial statements. The Company records interest and penalties related to uncertain tax positions, if applicable, as a component of income tax expense (benefit).&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Comprehensive Income (Loss)&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Comprehensive income (loss) is defined as a change in equity of a business enterprise during a period, resulting from transactions from non-owner sources. The other comprehensive loss disclosed in the Company&#x2019;s consolidated statements of operations and comprehensive loss for the years ended December 31, 2021 and 2020 consists of changes in unrealized gains and losses on marketable debt securities.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Net Loss per Share Attributable to Common Stockholders&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Basic &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common stock outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common stock and potentially dilutive securities outstanding for the period. The Company&#x2019;s potentially dilutive shares, which include outstanding stock options, Employee Stock Purchase Plan awards, unvested restricted stock units (RSUs), and shares issuable upon conversion of the Convertible Notes, are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive. Basic and diluted net loss per share attributable to common stockholders is presented in conformity with the two-class method required for participating securities. The two-class method determines net income (loss) per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income (loss) available to common&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;stockholders &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;for the period to be allocated between common and participating securities based upon their respective rights to share in undistributed earnings as if all income (loss) for the period had been distributed. The Company&#x2019;s participating securities do not have a contractual obligation to share in the Company&#x2019;s losses. As such, the net loss is attributed entirely to common stockholders. Since the Company has reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for those periods.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Subsequent Events Considerations&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the consolidated financial statements to provide additional evidence for certain estimates or to identify matters that require additional disclosure. Subsequent events have been evaluated as required. The Company has evaluated all subsequent events and determined that there are no material recognized or unrecognized subsequent events requiring disclosure, other than as disclosed in these notes to the consolidated financial statements.  See Note 21 for further information.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;From time to time, new accounting pronouncements are issued by the FASB under its ASC or other standard setting bodies and adopted by the Company as of the specified effective date, unless otherwise discussed below.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In August 2018, the FASB issued ASU No. 2018-15, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Intangibles&#x2013;Goodwill and Other&#x2014;Internal-Use Software (Subtopic 350-40): Customer&#x2019;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That is a Service Contract &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(ASU 2018-15). The amendments in ASU 2018-15 align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). Accordingly, the update requires&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;entities in a hosting arrangement that is a service contract to follow the guidance in ASC 350-40, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Internal-Use Software&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; (ASC 350-40) to determine which implementation costs to capitalize as an asset related to the service contract and which costs to expense. Costs to develop or obtain internal-use software that cannot be capitalized under ASC 350-40, such as training costs and certain data conversion costs, also cannot be capitalized for a hosting arrangement that is a service contract. Therefore, an entity in a hosting arrangement that is a service contract determines which project stage an implementation activity relates to. Costs for implementation activities in the application development stage are capitalized depending on the nature of the costs, while costs incurred during the preliminary project and post-implementation stages are expensed as the activities are performed. ASU 2018-15 also requires entities to expense the capitalized implementation costs of a hosting arrangement that is a service contract over the term of the hosting arrangement. ASU 2018-15 was effective for public entities for annual periods beginning after December 15, 2019, including interim periods within those fiscal years. For nonpublic entities, ASU 2018-15 is effective for annual reporting periods beginning after December 15, 2020, and interim periods within annual periods beginning after December 15, 2021. Early adoption is permitted, including adoption in any interim period. The Company adopted ASU 2018-15 beginning January 1, 2021. The adoption of ASU 2018-15 resulted in an immaterial amount of assets recorded on the Company's balance sheet.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In November 2018, the FASB issued ASU No. 2018-18, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Collaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606 &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(ASU 2018-18), which is intended to clarify the circumstances under which certain transactions in collaborative arrangements should be accounted for under the revenue recognition standard. Certain transactions between collaboration arrangement participants should be accounted for as revenue under ASC Topic 606 when the collaborative arrangement participant is a customer in the context of a unit of account. For public business entities, this ASU is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. For all other entities, this ASU is effective for fiscal years and interim periods within those years beginning after December 15, 2020. Early adoption is permitted.  The Company adopted ASU 2018-18 beginning January 1, 2021. The adoption of this standard did not have a material impact on the Company's financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In December 2019, the FASB issued ASU No. 2019-12, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Income Taxes (Topic 740)&#x2014;Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; (ASU 2019-12), which simplify various aspects related to the accounting for income taxes. This ASU removes exceptions to the general principles in Topic 740 related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. For public companies, this ASU is effective for interim and annual reporting periods beginning after December 15, 2020. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2021, and interim periods within fiscal years beginning after December 15, 2022. Early adoption is permitted. The Company adopted ASU 2019-12 beginning January 1, 2021 on a prospective basis. The adoption of this standard did not have a material impact on the Company's financial statements and related disclosures&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In March 2020, the FASB issued ASU No. 2020-04, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Reference Rate Reform (Topic 848)&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; (ASU 2020-04). The amendments in ASU 2020-04 provide optional expedients and exceptions for applying generally accepted accounting principles to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments in ASU 2020-04 are effective for all entities as of March 12, 2020 through December 31, 2022. An entity may elect to apply the amendments for contract modifications by Topic or Industry Subtopic as of any date from the beginning an interim period that includes or is subsequent to March 12, 2020, or prospectively from the date that the financial statements are available to be issued. Once elected for a Topic or an Industry Subtopic, the amendments must be applied prospectively for all eligible contract modifications for that Topic or Industry Subtopic. The Company may elect to apply ASU 2020-04 as its contracts referenced in London Interbank Offered Rate (LIBOR) are impacted by reference rate reform. The Company adopted ASU 2020-04 beginning January 1, 2021. The adoption of this standard did not have a material impact on the Company's financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In June 2016, the FASB issued ASU No. 2016-13, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Financial Instruments&#x2014;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(ASU 2016-13), which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. This ASU replaces the existing incurred loss impairment model with an expected loss model. It also eliminates the concept of other-than-temporary impairment and requires credit losses related to available-for-sale debt securities to be recorded through an allowance for credit losses rather than as a reduction in the amortized cost basis of the securities. These changes will result in earlier recognition of credit losses. For public business entities that meet the definition of a Securities and Exchange Commission (SEC) filer, excluding entities eligible to be smaller reporting companies as defined by the SEC, adoption is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. For SEC filers that are eligible to be smaller reporting companies and for all other entities, this ASU is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact the adoption of this ASU will have on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In January 2017, the FASB issued ASU No. 2017-04, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Intangibles &#x2013; Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(ASU 2017-04). The new guidance simplifies the subsequent measurement of goodwill by removing the second step of the two-step impairment test. The amendment requires an entity to perform its annual or interim goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity still has the option to perform the qualitative assessment for a reporting unit to determine if the quantitative impairment test is necessary. The new guidance for accelerated filing companies became effective for annual periods or any interim goodwill impairment tests in fiscal years beginning after December 15, 2019 and all other entities should adopt the amendments in this update for its annual or any interim goodwill impairment tests in fiscal years beginning after December 15, 2022. The amendment should be applied on a prospective basis. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company is currently evaluating the impact the adoption of this ASU will have on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In July 2021, FASB issued ASU No. 2021-05, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Lease (Topic 842), Lessors - Certain Leases with Variable Lease Payments &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(ASU 2021-05). ASU 2021-05 amends the lease classification requirements for lessors when classifying and accounting for a lease with variable lease payments that do not depend on a reference rate index or a rate. The update provides criteria, that if met, the lease would be classified and accounted for as an operating lease. ASU 2021-05 is effective for reporting periods beginning after December 15, 2021, with early adoption permitted. The Company is currently evaluating the impact of the adoption of this ASU on the Company's consolidated financial statements, but does not believe the adoption of this standard will have a material impact on the Company's consolidated financial statements.&lt;/span&gt;&lt;/span&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"/&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_290fb5f0-38ac-4057-98af-efe6d41016ed">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Basis of Presentation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The consolidated financial statements and related disclosures have been prepared in conformity with accounting principles generally accepted in the United States of America (United States GAAP or GAAP).&lt;/span&gt;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_9a958462-6e17-47ca-986b-042968bf1275">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Principles of Consolidation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany accounts and transactions have been eliminated in consolidation. The United States dollar is the functional and reporting currency of the Company and its subsidiaries.&lt;/span&gt;&lt;/p&gt;</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_cc694fd8-53aa-4256-a64b-491461b55909">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Use of Estimates&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent liabilities at the date of the consolidated financial statements as well as the reported amounts of revenues and expenses during the reporting period. Such estimates include the valuation of the intangible assets acquired in business combinations, redeemable convertible preferred stock warrant liability, redeemable convertible preferred stock tranche liability, the Technion Research and Development Foundation liability (TRDF Liability), contingent consideration liability for contingent value right (CVR), deferred tax assets, useful lives of property and equipment, accruals for research and development activities, revenue recognition and stock-based compensation and the Company&#x2019;s incremental borrowing rate. Actual results could differ from those estimates.&lt;/span&gt;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_90daee09-7cfa-42b5-ac48-eb5618acf397">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Contingent Consideration Liability (CVR)&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The estimated fair value of the CVR, initially measured and recorded on the acquisition date, is considered to be a Level 3 instrument. The contingent consideration liability is recorded at fair value at the end of each reporting period with changes in estimated fair values recorded in research and development expenses in the consolidated statements of operations and comprehensive loss. During the second quarter of 2021, the Company performed a re-measurement of the fair value of the CVR liability and adjusted the liability to zero. This resulted in a $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million gain in research and development expense in the statements of operations and comprehensive loss for the year ended December 31, 2021.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <acet:GainLossOnChangeInFairValueOfContingentConsiderationLiability
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="-5"
      id="F_3121ce48-ccd5-43ee-9424-ac8ff7a84150"
      unitRef="U_USD">1000000.0</acet:GainLossOnChangeInFairValueOfContingentConsiderationLiability>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_7363d5fb-7dc7-4acc-9b77-b183f6126c6f">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Goodwill&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Goodwill represents the excess of the purchase price over the fair value of net tangible and identified intangible assets acquired in a business combination. Goodwill is not amortized but is evaluated at least annually for impairment or when a change in facts and circumstances indicate that the fair value of the goodwill may be below the carrying value.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Goodwill is tested for impairment at the reporting unit level annually in the fourth quarter, or more frequently when events or changes in circumstances indicate that the asset might be impaired. Examples of such events or circumstances include, but are not limited to, a significant adverse change in legal or business climate, an adverse regulatory action or unanticipated competition. The Company has determined that it operates in a single operating segment and has a single reporting unit.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Prior to performing the impairment test, the Company assesses qualitative factors to determine whether the existence of events or circumstances would indicate that it is more likely than not that the fair value of the reporting unit was less than the carrying amount. If after assessing the totality of events or circumstances, the Company were to determine that it is more likely than not that the fair value of the reporting unit is less than the carrying amount, then the Company would perform a quantitative impairment test.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The quantitative impairment test involves comparing the fair value of the reporting unit to the carrying value. If the fair value of the reporting unit exceeds the carrying value of the net assets, goodwill is not impaired, and no further testing is required. If the fair value of the reporting unit is less than the carrying value, the Company measures the amount of impairment loss, if any, as the excess of the carrying value over the fair value of the reporting unit. The Company performed an annual test for goodwill impairment in the fourth quarter of the fiscal year ended December 31, 2021 and determined that goodwill was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;t impaired.&lt;/span&gt;&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:GoodwillImpairmentLoss
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="INF"
      id="F_4b6bf1b6-ec69-4c81-bc28-8081a9323738"
      unitRef="U_USD">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_eedf67ef-86f1-4a6f-862c-a44e2399c275">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Intangible Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In connection with the Merger, the Company acquired certain IPR&amp;amp;D assets, which were classified as indefinite-lived intangible assets. Acquired IPR&amp;amp;D represents the fair value assigned to research and development assets that the Company acquires and have not been completed at the acquisition date. The fair value of IPR&amp;amp;D acquired in a business combination is recorded on the Company&#x2019;s consolidated balance sheets at the acquisition-date fair value and is determined by estimating the costs to develop the technology into commercially viable products, estimating the resulting revenue from the products, and discounting the projected net cash flows to present value. IPR&amp;amp;D is not amortized, but rather is reviewed for impairment on an annual basis or more frequently if indicators of impairment are present, until the project is completed, abandoned, or transferred to a third party. The Company performed a review for impairment of IPR&amp;amp;D during the second quarter of the year ended December 31, 2021 and recognized an impairment charge of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, which was recorded as research and development expenses in the consolidated statement of operations and comprehensive loss.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;  &lt;/span&gt;&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="C_e645c0e4-c8b9-494e-86ea-d249ee6b8de0"
      decimals="-5"
      id="F_e62eee29-00b0-435f-83e4-a63272161084"
      unitRef="U_USD">1200000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_14a7f997-0e23-4f5d-b23b-b9f879d43d46">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Segments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company operates and manages its business as &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;one&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; reportable and operating segment, which is the business of research and development of allogeneic immunotherapies for cancer and other diseases. The Company&#x2019;s Chief Executive Officer, who is the chief operating decision maker, reviews financial information on an aggregate basis for purposes of allocating resources and evaluating financial performance.&lt;/span&gt;&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="0"
      id="F_86602ea6-7991-40ea-ad5e-7ea2d308827a"
      unitRef="U_Segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="0"
      id="F_cf9e6bf4-2751-4584-9ef6-d1e514e24e81"
      unitRef="U_Segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_1ce79b71-9d8c-4994-b2cb-5411a5c05547">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Concentration of Credit Risk&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Financial instruments, which potentially subject the Company to concentrations of credit risk, consist principally of cash and cash equivalents, and marketable debt securities. The Company&#x2019;s cash and cash equivalents are held at two financial institutions in the United States and one financial institution in Israel and such amounts may, at times, exceed insured limits. The Company invests its cash equivalents and marketable debt securities in money market funds, United States government securities, commercial paper, corporate bonds, and asset-backed securities. The Company limits its credit risk associated with cash equivalents and marketable debt securities by placing them with banks and institutions it believes are highly creditworthy and in highly rated investments. The Company has not experienced any losses on its deposits of cash and cash equivalents and marketable debt securities to date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company has &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;one&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; customer, Regeneron, which represents &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;100&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of the Company&#x2019;s total revenue during the years ended December 31, 2021 and 2020 and outstanding accounts receivable as of December 31, 2021 (see Note 10).&lt;/span&gt;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <acet:NumberOfCustomer
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="INF"
      id="F_a18c5060-237f-4460-859b-daaadf8f79f0"
      unitRef="U_Customer">1</acet:NumberOfCustomer>
    <acet:CustomersPercentageOfTotalRevenue
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="2"
      id="F_7f664578-7e7c-4138-8146-286bf26ece07"
      unitRef="U_pure">1</acet:CustomersPercentageOfTotalRevenue>
    <acet:CustomersPercentageOfTotalRevenue
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="2"
      id="F_6efffd7e-d27f-4121-b177-5a98b18df9c2"
      unitRef="U_pure">1</acet:CustomersPercentageOfTotalRevenue>
    <srt:FinancingReceivableNonaccrualToOutstandingPercent
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="2"
      id="F_356350f9-8577-47c1-bbed-6efca549f691"
      unitRef="U_pure">1</srt:FinancingReceivableNonaccrualToOutstandingPercent>
    <acet:RisksAndUncertaintiesPolicyTextBlock
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_81c4d2ab-1851-4ff0-9f4c-24beac06b577">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Risks and Uncertainties&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company is subject to risks and uncertainties common to early-stage companies in the biotechnology industry, including, but not limited to, development by competitors of new technological innovations, protection of proprietary technology, dependence on key personnel, compliance with government regulations and the need to obtain additional financing to fund operations. Product candidates currently under development will require significant additional research and development efforts, including extensive preclinical studies, clinical trials, and regulatory approval, prior to commercialization. These efforts require significant amounts of additional capital, adequate personnel infrastructure and extensive compliance and reporting.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company&#x2019;s product candidates are still in development and, to date, none of the Company&#x2019;s product candidates have been approved for sale and, therefore, the Company has not generated any revenue from product sales.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;There can be no assurance that the Company&#x2019;s research and development will be successfully completed, that adequate protection for the Company&#x2019;s intellectual property will be obtained or maintained, that any products developed will obtain necessary government regulatory approval or that any approved products will be commercially viable. Even if the Company&#x2019;s product development efforts are successful, it is uncertain when, if ever, the Company will generate revenue from product sales. The Company operates in an environment of rapid change in technology and substantial competition from other pharmaceutical and biotechnology companies.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;current COVID-19 (coronavirus) pandemic, which is impacting worldwide economic activity, poses risk that the Company or its employees, contractors, suppliers, and other partners may be prevented from conducting business activities for an indefinite period of time, including due to shutdowns that may be requested or mandated by governmental authorities. The extent to which the coronavirus impacts the Company&#x2019;s operations will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the outbreak, new information that will emerge concerning the severity of the coronavirus and the actions to contain the coronavirus or treat its impact, among others. COVID-19 may impact the timing of regulatory approval of the INDs for clinical trials, the enrollment of any clinical trials that are&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;approved, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;the availability of clinical trial materials and regulatory approval and commercialization of our products. COVID-19 may also impact the Company&#x2019;s ability to access capital, which could negatively impact short-term and long-term liquidity.&lt;/span&gt;&lt;/p&gt;</acet:RisksAndUncertaintiesPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_ae192d79-4daf-4dc4-a3c8-aa30bf2c34eb">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Cash and Cash Equivalents&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company considers all highly liquid investments purchased with maturities of three months or less from the purchase date to be cash equivalents. As of December 31, 2021 and 2020, cash and cash equivalents consist of cash deposited with banks and investments in money market funds with maturities of three months or less from the date of purchase.&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_7e1590ad-2547-4626-87b8-4bb32babc899">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Marketable Debt Securities&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Marketable debt securities are investments in marketable debt securities with maturities greater than three months at the time of purchase. The Company determines the appropriate classification of its investments in marketable debt securities at the time of purchase and reevaluates such designation at each balance sheet date. The Company has classified and accounted for its marketable debt securities as available-for-sale. The Company classifies highly liquid securities with maturities beyond 12 months as long-term marketable debt securities in the consolidated balance sheet. These securities are carried at fair value as determined based upon quoted market prices or pricing models for similar securities. Unrealized gains and losses, if any, are excluded from earnings and are reported as a component of accumulated other comprehensive income (loss). The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity, which is included in interest income on the consolidated statements of operations and comprehensive loss. Realized gains and losses, if any, on available-for-sale securities are included in other income (expense), net. The cost of securities sold is based on the specific identification method. Interest and dividends on securities classified as available-for-sale are included in interest income. The Company did not have any outstanding marketable debt securities as of December 31, 2021 and did not identify any of its marketable debt securities as other-than-temporarily impaired as of December 31, 2020.&lt;/span&gt;&lt;/p&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_24d6e3ae-8384-4a15-ae7e-bc3862156d9e">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Restricted Cash&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Restricted cash is comprised of cash that is restricted as to withdrawal or use under the terms of certain contractual agreements. Restricted cash for years ended December 31, 2021 and 2020 consists of collateral for letters of credit issued in connection with real estate leases (see Note 12).&lt;/span&gt;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_117f2107-3416-42ef-8303-72d28fe5a51f">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Fair Value of Financial Instruments&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The carrying amounts of certain financial instruments of the Company, including cash equivalents, restricted cash, accounts payable and accrued and other current liabilities approximate fair value due to their relatively short maturities. The Company&#x2019;s marketable debt securities and CVR liability are carried at fair value (see Notes 4 and 5).&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_b2f95461-204c-4989-9ac1-ffa6d623e9ab">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Property and Equipment, Net&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Property and equipment are stated at cost less accumulated depreciation and amortization. Depreciation is computed on a straight-line basis over the estimated useful lives of the related assets, generally three years. Leasehold improvements are amortized using the straight-line method over the shorter of the assets&#x2019; estimated useful lives or the remaining term of the lease. Maintenance and repairs are charged to operations as incurred. When assets are retired or otherwise disposed of, the cost and accumulated depreciation are removed from the consolidated balance sheet and any resulting gain or loss is reflected in the consolidated statements of operations and comprehensive loss in the period realized.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_2ec753bc-02bc-48d3-9bb7-266674eb3d40">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Impairment of Long-Lived Assets&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. Recoverability is measured by comparison of the carrying amount of the asset or asset group to the future net cash flows which the asset or asset group is expected to generate. If such asset or asset group is considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset or asset group exceeds the fair value of the asset or asset group. There has been &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; such impairment of long-lived assets during the years ended December 31, 2021 and 2020.&lt;/span&gt;&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:AssetImpairmentCharges
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="INF"
      id="F_12003f10-b6c9-4025-a656-b48bcc365dae"
      unitRef="U_USD">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="INF"
      id="F_d90e2806-24d3-4364-b88a-a51cc7292afa"
      unitRef="U_USD">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:RevenueRecognitionPolicyTextBlock
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_7c2bc12d-fa66-4772-9b78-2f1f5ccb4a3e">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Under ASC 606, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; (ASC 606), the Company recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the Company expects to receive&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;in exchange for those goods or services. To determine revenue recognition for arrangements that the Company determines are within the scope of ASC 606, the Company performs the following five steps as prescribed by ASC 606:&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;"&gt;(i)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;identify the contract(s) with a customer;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;"&gt;(ii)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;identify the performance obligations in the contract;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;"&gt;(iii)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;determine the transaction price;&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;"&gt;(iv)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;allocate the transaction price to the performance obligations in the contract; and&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;"&gt;(v)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;recognize revenue when (or as) the Company satisfies a performance obligation.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;A contract with a customer exists when (i) the Company enters into a legally enforceable contract with a customer that defines each party&#x2019;s rights regarding the products or services to be transferred and identifies the payment terms related to these products or services, (ii) the contract has commercial substance and (iii) the Company determines that collection of substantially all consideration for products or services that are transferred is probable based on the customer&#x2019;s intent and ability to pay the promised consideration.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;At contract inception, once the contract is determined to be within the scope of ASC 606, the Company identifies the goods or services promised and determines the performance obligations by assessing whether each promised good or service is distinct. Goods or services that are not distinct are bundled with other goods or services in the contract until a bundle of goods or services that is distinct is created. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;All of the Company&#x2019;s revenues are derived through a license and collaboration agreement (see Note 10).&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;For revenue recognition purposes, the Company determines the term of its license or collaboration agreements by evaluating the period during which present and enforceable rights and obligations exist. This determination is impacted by the existence of substantive termination penalties, among other factors.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company recognizes revenue under the Company&#x2019;s license or collaboration agreements that are within the scope of ASC 606. These agreements include promises related to licenses to intellectual property and research and development services. If the license to the Company&#x2019;s intellectual property is determined to be distinct from the other performance obligations identified in the arrangement, the Company recognizes revenue from non-refundable, up-front fees allocated to the license when the license is transferred to the licensee and the licensee is able to use and benefit from the license. For licenses that are bundled with other promises, the Company utilizes judgement to assess the nature of the combined performance obligation to determine whether the combined performance obligation is satisfied over time or at a point in time and, if over time, the appropriate method of measuring progress for purposes of recognizing revenue from non-refundable, up-front fees. Accordingly, the transaction price is generally comprised of a fixed fee due at contract inception and at specified future dates, variable consideration in the form of milestone payments due upon the achievement of specified events and tiered royalties earned when customers recognize net sales of licensed products. The Company measures the transaction price based on the amount of consideration to which it expects to be entitled in exchange for transferring the promised goods and/or services to the customer. The Company utilizes the &#x201c;most likely amount&#x201d; method to estimate the amount of variable consideration to which it will be entitled for the contract. Amounts of variable consideration are included in the transaction price to the extent that it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved. At the inception of each arrangement that includes development and regulatory milestone payments, the Company evaluates whether the associated event is considered most likely to be achieved and estimates the amount to be included in the transaction price.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Payments or reimbursements for the Company&#x2019;s research and development efforts where such efforts are considered part of or a single performance obligation are recognized over time using a measure of progress that best reflects the Company&#x2019;s performance in satisfying the obligation.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Upfront payments are recorded as contract liabilities upon receipt or when due and may require deferral of revenue recognition to a future period until the Company performs its obligation under these arrangements. Amounts payable to the Company are recorded as accounts receivable when the Company&#x2019;s right to consideration is unconditional. The Company does not assess whether a contract has a significant financing component if the expectation at contract inception is such that the period between payment by the customer and the transfer of the promised goods or services to the customer will be one year or less.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;For arrangements that include sales-based royalties, including milestone payments based on the level of sales, and the license is deemed to be the predominant item to which the royalties relate, the Company recognizes revenue at the later of (i) when the related sales occur, or (ii) when the performance obligation to which some or all of the royalty has been allocated has been satisfied (or partially satisfied). To date, the Company has not recognized any royalty revenue resulting from its collaboration arrangement.&lt;/span&gt;&lt;/p&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_1c6ad6f5-0f53-4280-a4b9-c9bca0c690f1">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Research and Development Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development expenses include costs directly attributable to the conduct of research and development programs, including payroll and related expenses, costs for CMOs, costs for CROs, materials, supplies, depreciation on and maintenance of research equipment, consulting costs, and the allocated portions of facility costs, such as rent, utilities, insurance, repairs and maintenance, depreciation, information technology costs and general support services. All costs associated with research and development are expensed within the consolidated statements of operations and comprehensive loss as incurred.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Costs incurred in obtaining technology licenses are charged to research and development expense as acquired in-process research and development if the technology licensed has not reached technological feasibility and has no alternative future use.&lt;/span&gt;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <acet:AccruedResearchAndDevelopmentPolicyTextBlock
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_2469ac9e-4ce6-4576-847f-58a2fe4456f1">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Accrued CRO, CMO, and Research and Development Expenses&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company has entered into various agreements with CMOs and CROs. The Company&#x2019;s research and development accruals are estimated based on the level of services performed, progress of the studies, including the phase or completion of events, and contracted costs. The estimated costs of research and development provided, but not yet invoiced are included in accrued and other current liabilities on the consolidated balance sheets. If the actual timing of the performance of services or the level of effort varies from the original estimates, the Company will adjust the accrual accordingly. Payments made to CMOs and CROs under these arrangements in advance of the performance of the related services are recorded as prepaid expenses and other current assets on the consolidated balance sheets until the services are rendered. Through December 31, 2021 there had been no material adjustments to the Company&#x2019;s prior period estimates of accrued research and development expenses.&lt;/span&gt;&lt;/p&gt;</acet:AccruedResearchAndDevelopmentPolicyTextBlock>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_5d8b7f22-3b3d-4d6b-9e0f-8bd0928d7e4f">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; Effective January 1, 2020, the Company adopted ASU No. 2016-02, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Leases (Topic 842)&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; (ASU 2016-02), using the modified retrospective approach through a cumulative-effect adjustment as of the adoption date, with prior periods unchanged and presented in accordance with the guidance in Topic 840, Leases (Topic 840).&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Consistent with ASU 2016-02, the Company determines if an arrangement is a lease, or contains a lease, at inception. Leases with a term greater than 12 months are recognized on the balance sheet as Right-of-Use (ROU) assets and current and long-term operating lease liabilities, as applicable. The Company has elected not to recognize on the balance sheet leases with terms of 12 months or less. The Company typically only includes an initial lease term in its assessment of a lease arrangement. Options to renew a lease are not included in the Company&#x2019;s assessment unless there is reasonable certainty that the Company will renew. The Company monitors its plan to renew its leases no less than on a quarterly basis. In addition, the Company&#x2019;s lease agreements generally do not contain any residual value guarantees or restrictive covenants.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In accordance with ASU 2016-02, the ROU assets and lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term. As most of the Company&#x2019;s leases do not provide an implicit rate, the Company uses its incremental borrowing rate (IBR), which is the estimated rate the Company would be required to pay for a fully collateralized borrowing equal to the total lease payments over the term of the lease, to determine the present value of future minimum lease payments. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. For lease agreements entered into or reassessed after the adoption of ASU 2016-02, the Company does not combine lease and non-lease components. Variable lease payments are expenses as incurred.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Assumptions made by the Company at the commencement date are re-evaluated upon occurrence of certain events, including a lease modification. A lease modification results in a separate contract when the modification grants the lessee an additional right of use not included in the original lease and when lease payments increase commensurate with the standalone price for the additional right of use. When a lease modification results in a separate contract, it is accounted for in the same manner as a new lease.&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <acet:FairValueOfCommonStockPolicyTextBlock
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_674672a4-f5b9-49a2-a30f-9bb50ef1c43a">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Fair Value of Common Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Prior to the Merger the fair value of the Company&#x2019;s common stock was determined by its Board of Directors with input from management and third-party valuation specialists. The Company&#x2019;s approach to estimate the fair value of the Company&#x2019;s common stock is consistent with the methods outlined in the American Institute of Certified Public Accountants Practice Aid, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Valuation&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;of Privately-Held-&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Company&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; Equity Securities Issued as Compensation&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. Determining the best estimated fair value of the Company&#x2019;s common stock requires significant judgement and management considers several factors, including the Company&#x2019;s stage of development, equity market conditions affecting comparable public companies, significant milestones and progress of research and development efforts. Subsequent to the Merger, the fair value of the Company&#x2019;s common stock is determined based on its closing market price.&lt;/span&gt;&lt;/p&gt;</acet:FairValueOfCommonStockPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_7a42727e-ea20-4e76-a60e-516687ea59c8">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company accounts for stock-based compensation arrangements with employees and non-employees using a fair value method which requires the recognition of compensation expense for costs related to all stock-based payments including stock options. The fair value method requires the Company to estimate the fair value of stock-based payment awards on the date of grant using an option-pricing model. The Company uses the Black-Scholes option-pricing model to estimate the fair value of options granted that are expensed on a straight-line basis over the requisite service period, which is generally the vesting period. The Company accounts for forfeitures as they occur. Option valuation models, including the Black-Scholes option-pricing model, require the input of several assumptions. Changes in the assumptions used can materially affect the grant-date fair value of an award. These assumptions include the risk-free rate of interest, expected dividend yield, expected volatility and the expected life of the award. For awards that have a performance condition, the Company recognizes compensation expense based on its assessment of the probability that the performance condition will be achieved, using an accelerated attribution model, over the explicit or implicit service period.&lt;/span&gt;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_b960adb9-a2fa-4cd2-ae6f-4e9e0d179f30">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company accounts for income taxes using the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences attributable to differences between carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax reporting purposes and for operating loss and tax credit carryforwards. Changes in deferred tax assets and liabilities are recorded in the provision for income taxes.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company&#x2019;s deferred tax assets and liabilities are measured using enacted tax rates expected to apply in the years in which these temporary differences are expected to be recovered or settled. A valuation allowance is recorded to reduce deferred tax assets if it is determined that it is more likely than not that all or a portion of the deferred tax asset will not be realized. The Company considers many factors when assessing the likelihood of future realization of deferred tax assets, including recent earnings results, expectations of future taxable income, carryforward periods available and other relevant factors. The Company records changes in the required valuation allowance in the period that the determination is made.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company assesses its income tax positions and records tax benefits for all years subject to examination based upon management&#x2019;s evaluation of the facts, circumstances and information available as of the reporting date. For those tax positions where it is more likely than not that a tax benefit will be sustained, the Company records the largest amount of tax benefit with a greater than 50% likelihood of being realized upon ultimate settlement with a taxing authority having full knowledge of all relevant information. For those income tax positions where it is not more likely than not that a tax benefit will be sustained, the Company does not recognize a tax benefit in the consolidated financial statements. The Company records interest and penalties related to uncertain tax positions, if applicable, as a component of income tax expense (benefit).&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_062993b7-b646-4141-a29e-3587d3c16d57">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Comprehensive Income (Loss)&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Comprehensive income (loss) is defined as a change in equity of a business enterprise during a period, resulting from transactions from non-owner sources. The other comprehensive loss disclosed in the Company&#x2019;s consolidated statements of operations and comprehensive loss for the years ended December 31, 2021 and 2020 consists of changes in unrealized gains and losses on marketable debt securities.&lt;/span&gt;&lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_3a55aa8f-d06d-46c3-8057-db694bfd8d8c">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Net Loss per Share Attributable to Common Stockholders&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Basic &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;net loss per common share is calculated by dividing the net loss attributable to common stockholders by the weighted-average number of common stock outstanding during the period, without consideration of potentially dilutive securities. Diluted net loss per share is computed by dividing the net loss attributable to common stockholders by the weighted-average number of common stock and potentially dilutive securities outstanding for the period. The Company&#x2019;s potentially dilutive shares, which include outstanding stock options, Employee Stock Purchase Plan awards, unvested restricted stock units (RSUs), and shares issuable upon conversion of the Convertible Notes, are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive. Basic and diluted net loss per share attributable to common stockholders is presented in conformity with the two-class method required for participating securities. The two-class method determines net income (loss) per share for each class of common and participating securities according to dividends declared or accumulated and participation rights in undistributed earnings. The two-class method requires income (loss) available to common&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;stockholders &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;for the period to be allocated between common and participating securities based upon their respective rights to share in undistributed earnings as if all income (loss) for the period had been distributed. The Company&#x2019;s participating securities do not have a contractual obligation to share in the Company&#x2019;s losses. As such, the net loss is attributed entirely to common stockholders. Since the Company has reported a net loss for all periods presented, diluted net loss per common share is the same as basic net loss per common share for those periods.&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:SubsequentEventsPolicyPolicyTextBlock
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_7e3a8d1d-ce23-432c-b070-bb413a6a3784">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Subsequent Events Considerations&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company considers events or transactions that occur after the balance sheet date but prior to the issuance of the consolidated financial statements to provide additional evidence for certain estimates or to identify matters that require additional disclosure. Subsequent events have been evaluated as required. The Company has evaluated all subsequent events and determined that there are no material recognized or unrecognized subsequent events requiring disclosure, other than as disclosed in these notes to the consolidated financial statements.  See Note 21 for further information.&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsPolicyPolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_54552f8d-ea7b-46ea-aeca-15be5ef6deed">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Recent Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;From time to time, new accounting pronouncements are issued by the FASB under its ASC or other standard setting bodies and adopted by the Company as of the specified effective date, unless otherwise discussed below.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Recently Adopted Accounting Pronouncements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In August 2018, the FASB issued ASU No. 2018-15, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Intangibles&#x2013;Goodwill and Other&#x2014;Internal-Use Software (Subtopic 350-40): Customer&#x2019;s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That is a Service Contract &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(ASU 2018-15). The amendments in ASU 2018-15 align the requirements for capitalizing implementation costs incurred in a hosting arrangement that is a service contract with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software (and hosting arrangements that include an internal-use software license). Accordingly, the update requires&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:8.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;entities in a hosting arrangement that is a service contract to follow the guidance in ASC 350-40, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Internal-Use Software&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; (ASC 350-40) to determine which implementation costs to capitalize as an asset related to the service contract and which costs to expense. Costs to develop or obtain internal-use software that cannot be capitalized under ASC 350-40, such as training costs and certain data conversion costs, also cannot be capitalized for a hosting arrangement that is a service contract. Therefore, an entity in a hosting arrangement that is a service contract determines which project stage an implementation activity relates to. Costs for implementation activities in the application development stage are capitalized depending on the nature of the costs, while costs incurred during the preliminary project and post-implementation stages are expensed as the activities are performed. ASU 2018-15 also requires entities to expense the capitalized implementation costs of a hosting arrangement that is a service contract over the term of the hosting arrangement. ASU 2018-15 was effective for public entities for annual periods beginning after December 15, 2019, including interim periods within those fiscal years. For nonpublic entities, ASU 2018-15 is effective for annual reporting periods beginning after December 15, 2020, and interim periods within annual periods beginning after December 15, 2021. Early adoption is permitted, including adoption in any interim period. The Company adopted ASU 2018-15 beginning January 1, 2021. The adoption of ASU 2018-15 resulted in an immaterial amount of assets recorded on the Company's balance sheet.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In November 2018, the FASB issued ASU No. 2018-18, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Collaborative Arrangements (Topic 808): Clarifying the Interaction Between Topic 808 and Topic 606 &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(ASU 2018-18), which is intended to clarify the circumstances under which certain transactions in collaborative arrangements should be accounted for under the revenue recognition standard. Certain transactions between collaboration arrangement participants should be accounted for as revenue under ASC Topic 606 when the collaborative arrangement participant is a customer in the context of a unit of account. For public business entities, this ASU is effective for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. For all other entities, this ASU is effective for fiscal years and interim periods within those years beginning after December 15, 2020. Early adoption is permitted.  The Company adopted ASU 2018-18 beginning January 1, 2021. The adoption of this standard did not have a material impact on the Company's financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In December 2019, the FASB issued ASU No. 2019-12, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Income Taxes (Topic 740)&#x2014;Simplifying the Accounting for Income Taxes&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; (ASU 2019-12), which simplify various aspects related to the accounting for income taxes. This ASU removes exceptions to the general principles in Topic 740 related to the approach for intra-period tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. For public companies, this ASU is effective for interim and annual reporting periods beginning after December 15, 2020. For all other entities, the amendments are effective for fiscal years beginning after December 15, 2021, and interim periods within fiscal years beginning after December 15, 2022. Early adoption is permitted. The Company adopted ASU 2019-12 beginning January 1, 2021 on a prospective basis. The adoption of this standard did not have a material impact on the Company's financial statements and related disclosures&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In March 2020, the FASB issued ASU No. 2020-04, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Reference Rate Reform (Topic 848)&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; (ASU 2020-04). The amendments in ASU 2020-04 provide optional expedients and exceptions for applying generally accepted accounting principles to contracts, hedging relationships, and other transactions affected by reference rate reform if certain criteria are met. The amendments in ASU 2020-04 are effective for all entities as of March 12, 2020 through December 31, 2022. An entity may elect to apply the amendments for contract modifications by Topic or Industry Subtopic as of any date from the beginning an interim period that includes or is subsequent to March 12, 2020, or prospectively from the date that the financial statements are available to be issued. Once elected for a Topic or an Industry Subtopic, the amendments must be applied prospectively for all eligible contract modifications for that Topic or Industry Subtopic. The Company may elect to apply ASU 2020-04 as its contracts referenced in London Interbank Offered Rate (LIBOR) are impacted by reference rate reform. The Company adopted ASU 2020-04 beginning January 1, 2021. The adoption of this standard did not have a material impact on the Company's financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In June 2016, the FASB issued ASU No. 2016-13, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Financial Instruments&#x2014;Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(ASU 2016-13), which requires the measurement and recognition of expected credit losses for financial assets held at amortized cost. This ASU replaces the existing incurred loss impairment model with an expected loss model. It also eliminates the concept of other-than-temporary impairment and requires credit losses related to available-for-sale debt securities to be recorded through an allowance for credit losses rather than as a reduction in the amortized cost basis of the securities. These changes will result in earlier recognition of credit losses. For public business entities that meet the definition of a Securities and Exchange Commission (SEC) filer, excluding entities eligible to be smaller reporting companies as defined by the SEC, adoption is effective for fiscal years beginning after December 15, 2019, including interim periods within those fiscal years. For SEC filers that are eligible to be smaller reporting companies and for all other entities, this ASU is effective for fiscal years beginning after December 15, 2022, and interim periods within those fiscal years. Early adoption is permitted. The Company is currently evaluating the impact the adoption of this ASU will have on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In January 2017, the FASB issued ASU No. 2017-04, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Intangibles &#x2013; Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(ASU 2017-04). The new guidance simplifies the subsequent measurement of goodwill by removing the second step of the two-step impairment test. The amendment requires an entity to perform its annual or interim goodwill impairment test by comparing the fair value of a reporting unit with its carrying amount. An entity still has the option to perform the qualitative assessment for a reporting unit to determine if the quantitative impairment test is necessary. The new guidance for accelerated filing companies became effective for annual periods or any interim goodwill impairment tests in fiscal years beginning after December 15, 2019 and all other entities should adopt the amendments in this update for its annual or any interim goodwill impairment tests in fiscal years beginning after December 15, 2022. The amendment should be applied on a prospective basis. Early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The Company is currently evaluating the impact the adoption of this ASU will have on its consolidated financial statements and related disclosures.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In July 2021, FASB issued ASU No. 2021-05, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Lease (Topic 842), Lessors - Certain Leases with Variable Lease Payments &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(ASU 2021-05). ASU 2021-05 amends the lease classification requirements for lessors when classifying and accounting for a lease with variable lease payments that do not depend on a reference rate index or a rate. The update provides criteria, that if met, the lease would be classified and accounted for as an operating lease. ASU 2021-05 is effective for reporting periods beginning after December 15, 2021, with early adoption permitted. The Company is currently evaluating the impact of the adoption of this ASU on the Company's consolidated financial statements, but does not believe the adoption of this standard will have a material impact on the Company's consolidated financial statements.&lt;/span&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:BusinessCombinationDisclosureTextBlock
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_a209bc5c-0c5c-48ac-b2dd-50cbd1ce2aa4">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;3. Business Combination&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On September 15, 2020, Former Adicet completed its merger with resTORbio. Based on the Exchange Ratio of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1240&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, immediately following the Merger, resTORbio stockholders and holders of resTORbio restricted stock units and options to acquire resTORbio common stock owned approximately &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;25.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of the outstanding capital stock of the combined company on a fully diluted basis, and Former Adicet stockholders, holders of options or warrants to acquire Former Adicet capital stock owned approximately &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;75.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of the outstanding capital stock of the combined company on a fully diluted basis.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;resTORbio&#x2019;s stockholders continued to own and hold their existing shares of the Company&#x2019;s common stock (after giving effect to the &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1-for-7&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; reverse stock split). Pursuant to the terms of the Merger, the vesting of all outstanding resTORbio stock options was accelerated in full as of immediately prior to the Effective Time. All out-of-the-money resTORbio stock options were cancelled for no consideration. All in-the-money resTORbio stock options remained outstanding after the completion of the Merger in accordance with their terms. For accounting purposes, the Company assumed &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;81,370&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; in-the-money resTORbio stock options after giving effect to reverse stock split. In addition, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;91,309&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; unvested &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;resTORbio restricted stock units outstanding&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;and &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;unsettled, after giving effect to reverse stock split, as of immediately prior to the Effective Time of the Merger, were accelerated in full and the holders of such restricted stock units received &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;54,553&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of the Company&#x2019;s common stock (after reduction by the number of shares of resTORbio common stock necessary to satisfy applicable tax withholding obligations at the maximum statutory rate). The fair value of these modified stock options and restricted stock units attributable to pre-combination services was recorded as a component of consideration transferred and the fair value of these modified stock options and restricted stock units attributable to post-combination services was recognized as stock compensation expense in the Company&#x2019;s consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;At the closing of the Merger, all shares of Former Adicet common stock and Former Adicet redeemable convertible preferred stock then outstanding were converted to Former Adicet&#x2019;s common stock under their original terms and were then exchanged for the Company&#x2019;s common stock.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In connection with the Merger, the Company entered into a Contingent Value Rights Agreement (the CVR Agreement) with Computershare Inc. and Computershare Trust Company, N.A. as joint rights agent. Per the terms of the Merger, each holder of resTORbio common stock as of immediately prior to the completion of the Merger is entitled to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;one&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; contractual contingent value right, subject to and in accordance with the terms and conditions of the CVR Agreement, for each share of resTORbio common stock held by such holder as of immediately prior to the Effective Time. The CVR holders were entitled to receive net proceeds from the commercialization, if any, from a third-party commercial partner of RTB101, resTORbio&#x2019;s small molecule product candidate that is a potent inhibitor of target of rapamycin complex 1 (TORC1), for a COVID-19 related indication.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The total purchase price was allocated to the tangible and intangible assets acquired and liabilities assumed of resTORbio based on their fair values as of the completion of the Merger, with the excess allocated to goodwill. The purchase price is calculated based on the fair value of resTORbio common stock that the resTORbio stockholders owned as of the closing date of the Merger because, with no active trading market for shares of Former Adicet, the fair value of the resTORbio&#x2019;s common stock represented a more reliable measure of the fair value of consideration transferred in the Merger. &lt;/span&gt;&lt;span style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following summarizes the purchase price in the Merger (in thousands, except share and per share amounts):&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:77.846%;"/&gt;
        &lt;td style="width:2.091%;"/&gt;
        &lt;td style="width:1.577%;"/&gt;
        &lt;td style="width:17.704%;"/&gt;
        &lt;td style="width:0.782%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Fair value of common stock shares of the combined company &lt;br/&gt;&#160;&#160;&#160;owned by resTORbio stockholders (1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;84,142&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Fair value of contingent consideration liability with respect to CVR (2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,880&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Purchase price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;87,022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="margin-left:3.333%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;div style="display:flex;margin-top:0.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;"&gt;(1)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Represents the share consideration of the combined company that the resTORbio stockholders own as of the closing of the Merger calculated as follows:&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:77.785%;"/&gt;
        &lt;td style="width:2.078%;"/&gt;
        &lt;td style="width:1.565%;"/&gt;
        &lt;td style="width:17.508%;"/&gt;
        &lt;td style="width:1.064%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Number of shares of the combined company owned by resTORbio&lt;br/&gt;&#160;&#160;&#160;stockholders (a)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,207,695&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Multiplied by the fair value per share of resTORbio common &lt;br/&gt;&#160;&#160;&#160;stock (b)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;16.59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Acquisition date fair value of resTORbio&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;86,396&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Estimated fair value of modified stock options and restricted stock units attributable to pre-combination services (3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;626&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Less: portion of the fair value to be distributed as CVR (c)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,880&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Fair value of shares of the combined company  owned by resTORbio&lt;br/&gt;&#160;&#160;&#160;stockholders&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;84,142&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="margin-left:10.0%;text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:6.667%;display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;"&gt;a.&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Represents the number of shares of common stock of the combined company that the resTORbio stockholders owned as of the closing of the Merger. This amount is calculated as &lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;5,207,695&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt; shares (post-reverse stock split) of resTORbio common stock outstanding as of September 15, 2020.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;"&gt;b.&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;The fair value of shares of the combined company owned by resTORbio stockholders is based on the closing price of resTORbio common stock on September 14, 2020.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:6.667%;display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.571084182443509%;"&gt;c.&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;The fair value of resTORbio common stock was further adjusted to remove the estimated fair value of the CVR embedded within the closing price, as each holder of resTORbio stock received one contractual CVR immediately prior to the Merger.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;"&gt;(2)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Each holder of resTORbio common stock as of immediately prior to the completion of the Merger was entitled to one CVR issued by resTORbio, subject to and in accordance with the terms and conditions of the CVR Agreement, for each share of resTORbio common stock held by such holder as of immediately prior to the Effective Time of the Merger.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;"&gt;(3)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Based on the capitalization of resTORbio as of September 15, 2020, &lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;91,309&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt; outstanding unvested resTORbio restricted stock units were accelerated in connection with the Merger and holders of the restricted stock units were issued approximately &lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;54,553&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt; shares &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;of resTORbio &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:flex;margin-top:6.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;visibility:hidden;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;"/&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;common &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;stock on a net settlement basis. Similarly, in connection with the Merger, vesting of outstanding resTORbio stock options was accelerated in full and the stock options that were not in the in-the-money on the close of the Merger were canceled, resulting in approximately &lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;81,370&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt; surviving stock options. The acquisition date fair value of these modified resTORbio restricted stock units and resTORbio stock options attributable to the pre-combination services is included in the estimated purchase price.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Merger was accounted for as a business combination which requires that assets acquired, and liabilities assumed be recognized at their fair value as of the acquisition date. While the Company uses its best estimates and assumptions as part of the purchase price allocation process to value the assets acquired and liabilities assumed on the acquisition date, its estimates and assumptions are subject to refinement. Fair value estimates are based on a complex series of judgments about future events and uncertainties and rely heavily on estimates and assumptions. The judgments used to determine the estimated fair value assigned to each class of assets acquired and liabilities assumed, as well as asset lives, can materially impact the Company&#x2019;s results of operations.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following summarizes the allocation of the purchase price to the net tangible and intangible assets acquired (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.38%;"/&gt;
        &lt;td style="width:1.14%;"/&gt;
        &lt;td style="width:1.752%;"/&gt;
        &lt;td style="width:12.157%;"/&gt;
        &lt;td style="width:1.164%;"/&gt;
        &lt;td style="width:1.14%;"/&gt;
        &lt;td style="width:1.801%;"/&gt;
        &lt;td style="width:13.051%;"/&gt;
        &lt;td style="width:1.164%;"/&gt;
        &lt;td style="width:1.14%;"/&gt;
        &lt;td style="width:1.752%;"/&gt;
        &lt;td style="width:12.194%;"/&gt;
        &lt;td style="width:1.164%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;As of &lt;br/&gt;December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Measurement Period Adjustments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Final Purchase &lt;br/&gt;Price Allocation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net assets acquired:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;63,869&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;63,869&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,059&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;615&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,674&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;318&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;318&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,490&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,490&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;245&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;245&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accounts payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,316&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,304&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,365&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,365&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Other liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred tax liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;367&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;367&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Goodwill&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;20,089&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;627&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;19,462&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Purchase price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;87,022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;87,022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The goodwill of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;19.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million is not tax deductible and represents the excess of the consideration paid over the fair value of assets acquired and liabilities assumed. Goodwill is mainly attributable to the enhanced value of the combined company, as reflected in the increase in market value of the resTORbio common shares following the announcement of the Merger with Former Adicet.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The fair value of acquired IPR&amp;amp;D is related to the research and development of RTB101 for a COVID-19 related indication and was conducted pursuant to resTORbio's license agreement with Novartis (see Note 11). The RTB101 compound IPR&amp;amp;D project was valued using an income approach, specifically a projected discounted cash flow method, adjusted for the probability of technical success (PTS). The projected discounted cash flow models used to estimate the Company&#x2019;s IPR&amp;amp;D reflect significant assumptions regarding the estimates a market participant would make in order to evaluate a drug development asset, including the following:&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Estimates of potential cash flows to be generated by the project and resulting asset, which was developed utilizing estimates of total patient population, market penetration rates, demand risk adjustment factors, and product pricing; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Estimates regarding the timing of and the expected costs of goods sold, research and development expenses, selling, general and administrative expenses to advance the clinical programs to commercialization, cash flow adjustments and partner profit split; &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The projected cash flows were then adjusted using PTS factors that were selected considering both the current state of clinical development and the nature of the proposed indication, (i.e., respiratory therapeutics); and &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Finally, the resulting probability adjusted cash flows were discounted to a present value using a risk-adjusted discount rate, developed considering the market risk present in the forecast and the size of the asset. &lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;This &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;IPR&amp;amp;D intangible asset is not amortized, but rather is reviewed for impairment on an annual basis or more frequently if indicators of impairment are present, until the project is completed, abandoned, or transferred to a third party. Upon the review of impairment indicators of IPR&amp;amp;D during the second quarter of 2021, the Company concluded that the IPR&amp;amp;D was fully&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;impaired &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;and recorded an impairment charge within research and development expenses in the consolidated statement of operations and comprehensive loss for the remaining balance of the IPR&amp;amp;D intangible asset June 30, 2021. The Company recognized IPR&amp;amp;D impairment charges of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million for the quarters ended as of December 31, 2020, March 31, 2021, and June 30, 2021. On July 29, 2021, the Company sent Novartis a termination notice. Termination will automatically take effect as of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;60&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; days from the date of delivery of the termination notice to Novartis, but in no event later than October 1, 2021 without any further notice or action required of either Novartis or the Company.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The contingent consideration for the CVR was valued using an income approach, leveraging the probability adjusted discounted cash flow used in the valuation of the IPR&amp;amp;D and then deducting the administrative fee to be retained by the combined company and other permitted deductions in order to arrive at the net cash expected to be paid out to the CVR holders. The probability adjusted cash flow includes significant estimates and assumptions pertaining to commercialization events and cash consideration received by the Company for the grant of rights to commercialize RTB101 during the term of the CVR Agreement (as discussed above). These cash flows were then discounted to present value using the same discount rate applied in the valuation of the IPR&amp;amp;D.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Transaction costs for the Merger were $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million for the year ended December 31, 2020 and were expensed as incurred in general and administrative expenses in the consolidated statements of operations and comprehensive loss.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following tables present changes in the Company's IPR&amp;amp;D and CVR since the Merger (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:27.815%;"/&gt;
        &lt;td style="width:1.362%;"/&gt;
        &lt;td style="width:1.196%;"/&gt;
        &lt;td style="width:11.31%;"/&gt;
        &lt;td style="width:0.588%;"/&gt;
        &lt;td style="width:1.362%;"/&gt;
        &lt;td style="width:1.196%;"/&gt;
        &lt;td style="width:11.085%;"/&gt;
        &lt;td style="width:0.794%;"/&gt;
        &lt;td style="width:1.362%;"/&gt;
        &lt;td style="width:1.196%;"/&gt;
        &lt;td style="width:11.281%;"/&gt;
        &lt;td style="width:0.588%;"/&gt;
        &lt;td style="width:1.362%;"/&gt;
        &lt;td style="width:1.196%;"/&gt;
        &lt;td style="width:11.085%;"/&gt;
        &lt;td style="width:0.794%;"/&gt;
        &lt;td style="width:1.362%;"/&gt;
        &lt;td style="width:1.196%;"/&gt;
        &lt;td style="width:11.281%;"/&gt;
        &lt;td style="width:0.588%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Acquisition Date &lt;br/&gt;Fair value as of&lt;br/&gt;September 15, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Change in &lt;br/&gt;Fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;As of&lt;br/&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Change in &lt;br/&gt;Fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;As of&lt;br/&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"&gt;In-process research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"&gt;3,490&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"&gt;2,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"&gt;1,190&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"&gt;1,190&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.5pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_ba39addf-7250-4185-b821-6a0528ff4070;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"&gt;Contingent Value Rights&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"&gt;2,880&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"&gt;1,900&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"&gt;980&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"&gt;980&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.5pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_53469473-0173-4a8a-bfc4-8856f9b34255;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="C_0e581963-9b5e-4dbd-bb03-47a0e58483c2"
      decimals="4"
      id="F_01dd02dc-9d68-4cf9-9b1f-b6fc78ec8512"
      unitRef="U_pure">0.1240</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage
      contextRef="C_b2fceb56-058f-472e-a003-7e909e8b6b12"
      decimals="3"
      id="F_90d9badc-17c5-4080-8e31-a9628a685ca0"
      unitRef="U_pure">0.250</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage
      contextRef="C_5ad68f0f-dc2d-43e8-92c2-f0f53b821bd5"
      decimals="3"
      id="F_f907d43b-e0cc-40b9-8ad6-fb7ddaa530cd"
      unitRef="U_pure">0.750</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage>
    <us-gaap:StockholdersEquityReverseStockSplit
      contextRef="C_66c6bb36-401e-4afc-b955-ab56bbccb097"
      id="F_676fc392-e01d-4bd9-9d8d-5b43ba011d5c">1-for-7</us-gaap:StockholdersEquityReverseStockSplit>
    <acet:NumberOfSharesOfSurvivingStockOptions
      contextRef="C_0e581963-9b5e-4dbd-bb03-47a0e58483c2"
      decimals="INF"
      id="F_779b8859-d65f-4267-b281-465650bcf7e4"
      unitRef="U_shares">81370</acet:NumberOfSharesOfSurvivingStockOptions>
    <acet:UnvestedRestrictedStockUnitsOutstanding
      contextRef="C_5ad68f0f-dc2d-43e8-92c2-f0f53b821bd5"
      decimals="INF"
      id="F_ae5d38a5-dff6-43f1-930a-0ba37b6f465a"
      unitRef="U_shares">91309</acet:UnvestedRestrictedStockUnitsOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0e581963-9b5e-4dbd-bb03-47a0e58483c2"
      decimals="INF"
      id="F_1916a6af-801e-41fa-802f-8c6c3a5404cc"
      unitRef="U_shares">54553</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <acet:ContractualContingentValueRight
      contextRef="C_ed6df093-d6d5-4c84-a08c-07bf173fcdb1"
      decimals="0"
      id="F_ad4a922f-15f5-4fb6-ad8a-a6f2320bc612"
      unitRef="U_ValueRight">1</acet:ContractualContingentValueRight>
    <us-gaap:BusinessAcquisitionProFormaInformationTextBlock
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_e28b47f9-4961-41bb-b63b-18437209507e">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following summarizes the purchase price in the Merger (in thousands, except share and per share amounts):&lt;/span&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:77.846%;"/&gt;
        &lt;td style="width:2.091%;"/&gt;
        &lt;td style="width:1.577%;"/&gt;
        &lt;td style="width:17.704%;"/&gt;
        &lt;td style="width:0.782%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Fair value of common stock shares of the combined company &lt;br/&gt;&#160;&#160;&#160;owned by resTORbio stockholders (1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;84,142&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Fair value of contingent consideration liability with respect to CVR (2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,880&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Purchase price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;87,022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:BusinessAcquisitionProFormaInformationTextBlock>
    <us-gaap:EquityIssuedInBusinessCombinationFairValueDisclosure
      contextRef="C_5ad68f0f-dc2d-43e8-92c2-f0f53b821bd5"
      decimals="-3"
      id="F_469a5573-0b9d-46a1-abaf-31cefad89607"
      unitRef="U_USD">84142000</us-gaap:EquityIssuedInBusinessCombinationFairValueDisclosure>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="C_5ad68f0f-dc2d-43e8-92c2-f0f53b821bd5"
      decimals="-3"
      id="F_15ae4ac4-efc7-4068-bf99-1fc7c4c0ed0d"
      unitRef="U_USD">2880000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="C_0e581963-9b5e-4dbd-bb03-47a0e58483c2"
      decimals="-3"
      id="F_fa974f4a-7a66-4275-a67e-0df37c187ff2"
      unitRef="U_USD">87022000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_9d630a7c-11bc-473e-a37c-e079e575e9e0">&lt;div style="display:flex;margin-top:0.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;"&gt;(1)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Represents the share consideration of the combined company that the resTORbio stockholders own as of the closing of the Merger calculated as follows:&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:77.785%;"/&gt;
        &lt;td style="width:2.078%;"/&gt;
        &lt;td style="width:1.565%;"/&gt;
        &lt;td style="width:17.508%;"/&gt;
        &lt;td style="width:1.064%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Number of shares of the combined company owned by resTORbio&lt;br/&gt;&#160;&#160;&#160;stockholders (a)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,207,695&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Multiplied by the fair value per share of resTORbio common &lt;br/&gt;&#160;&#160;&#160;stock (b)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;16.59&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Acquisition date fair value of resTORbio&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;86,396&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Estimated fair value of modified stock options and restricted stock units attributable to pre-combination services (3)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;626&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Less: portion of the fair value to be distributed as CVR (c)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,880&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Fair value of shares of the combined company  owned by resTORbio&lt;br/&gt;&#160;&#160;&#160;stockholders&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;84,142&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="C_0e581963-9b5e-4dbd-bb03-47a0e58483c2"
      decimals="INF"
      id="F_019cfa3b-ff69-4ed2-909d-86357365d5fc"
      unitRef="U_shares">5207695</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="C_5ad68f0f-dc2d-43e8-92c2-f0f53b821bd5"
      decimals="2"
      id="F_88818858-dc62-419f-84b9-73eb33390702"
      unitRef="U_USDollarShare">16.59</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1
      contextRef="C_0e581963-9b5e-4dbd-bb03-47a0e58483c2"
      decimals="-3"
      id="F_9c4aab64-401a-4b49-9de6-85197569f157"
      unitRef="U_USD">86396000</us-gaap:BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1>
    <acet:FairValueOfModifiedStockOptionsAndRestrictedStockUnitsAttributableToPreCombinationServices
      contextRef="C_0e581963-9b5e-4dbd-bb03-47a0e58483c2"
      decimals="-3"
      id="F_1352c10e-e543-4a85-ad06-2588815f253e"
      unitRef="U_USD">626000</acet:FairValueOfModifiedStockOptionsAndRestrictedStockUnitsAttributableToPreCombinationServices>
    <acet:LessPortionOfFairValueToBeDistributedAsCVR
      contextRef="C_0e581963-9b5e-4dbd-bb03-47a0e58483c2"
      decimals="-3"
      id="F_a2ddba6f-0ffc-45b3-94d0-30fe50a46cb1"
      unitRef="U_USD">-2880000</acet:LessPortionOfFairValueToBeDistributedAsCVR>
    <us-gaap:EquityIssuedInBusinessCombinationFairValueDisclosure
      contextRef="C_5ad68f0f-dc2d-43e8-92c2-f0f53b821bd5"
      decimals="-3"
      id="F_c792468d-5aa0-4ee5-995c-42a1b3ff58d7"
      unitRef="U_USD">84142000</us-gaap:EquityIssuedInBusinessCombinationFairValueDisclosure>
    <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued
      contextRef="C_0e581963-9b5e-4dbd-bb03-47a0e58483c2"
      decimals="INF"
      id="F_e2a81716-173c-42b6-8d10-b6c201137a52"
      unitRef="U_shares">5207695</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
    <acet:UnvestedRestrictedStockUnitsOutstanding
      contextRef="C_5ad68f0f-dc2d-43e8-92c2-f0f53b821bd5"
      decimals="INF"
      id="F_35d0533d-2981-4ddf-9068-c799d50444b3"
      unitRef="U_shares">91309</acet:UnvestedRestrictedStockUnitsOutstanding>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="C_0e581963-9b5e-4dbd-bb03-47a0e58483c2"
      decimals="INF"
      id="F_4c3cc4f1-f07b-4d87-b62f-2d14379f867a"
      unitRef="U_shares">54553</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <acet:NumberOfSharesOfSurvivingStockOptions
      contextRef="C_0e581963-9b5e-4dbd-bb03-47a0e58483c2"
      decimals="INF"
      id="F_6b2ca9c3-a4b6-49cd-949c-162e3074e676"
      unitRef="U_shares">81370</acet:NumberOfSharesOfSurvivingStockOptions>
    <us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_b40c81de-77dc-41ae-bdb2-54b43301049b">&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following summarizes the allocation of the purchase price to the net tangible and intangible assets acquired (in thousands):&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:50.38%;"/&gt;
        &lt;td style="width:1.14%;"/&gt;
        &lt;td style="width:1.752%;"/&gt;
        &lt;td style="width:12.157%;"/&gt;
        &lt;td style="width:1.164%;"/&gt;
        &lt;td style="width:1.14%;"/&gt;
        &lt;td style="width:1.801%;"/&gt;
        &lt;td style="width:13.051%;"/&gt;
        &lt;td style="width:1.164%;"/&gt;
        &lt;td style="width:1.14%;"/&gt;
        &lt;td style="width:1.752%;"/&gt;
        &lt;td style="width:12.194%;"/&gt;
        &lt;td style="width:1.164%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;As of &lt;br/&gt;December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Measurement Period Adjustments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Final Purchase &lt;br/&gt;Price Allocation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:middle;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net assets acquired:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;63,869&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;63,869&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Prepaid expenses and other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,059&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;615&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,674&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Property and equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;318&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;318&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,490&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,490&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Restricted cash&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;245&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;245&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accounts payable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,316&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,304&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accrued and other current liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,365&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,365&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Other liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred tax liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;367&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;367&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Goodwill&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;20,089&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;627&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;19,462&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Purchase price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;87,022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;87,022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="C_9fa0d050-80a6-4eb0-b277-441b2edd40e6"
      decimals="-3"
      id="F_d5f2efcd-6f98-408a-9e6f-c0bf13010753"
      unitRef="U_USD">63869000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents
      contextRef="C_a6003cef-f951-463a-a0b1-c940267e5c47"
      decimals="-3"
      id="F_5c467a75-a8c6-4162-bbef-7b2aab498abc"
      unitRef="U_USD">63869000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
      contextRef="C_9fa0d050-80a6-4eb0-b277-441b2edd40e6"
      decimals="-3"
      id="F_b56b8880-c867-4962-a6b6-157d80afb015"
      unitRef="U_USD">3059000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
      contextRef="C_b571f234-c627-4f7d-82fb-c74e7cbd480a"
      decimals="-3"
      id="F_49edec2a-dbc5-47f2-b82c-c06c4abcc690"
      unitRef="U_USD">615000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets
      contextRef="C_a6003cef-f951-463a-a0b1-c940267e5c47"
      decimals="-3"
      id="F_b42ccd1e-dc5d-4ca3-bb61-e287975c145d"
      unitRef="U_USD">3674000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="C_9fa0d050-80a6-4eb0-b277-441b2edd40e6"
      decimals="-3"
      id="F_81cc8e5e-4f23-4a92-8241-4dd9114de987"
      unitRef="U_USD">318000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment
      contextRef="C_a6003cef-f951-463a-a0b1-c940267e5c47"
      decimals="-3"
      id="F_4211bb21-9b56-428f-9989-8477d2608d50"
      unitRef="U_USD">318000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment>
    <acet:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment
      contextRef="C_9fa0d050-80a6-4eb0-b277-441b2edd40e6"
      decimals="-3"
      id="F_7386d844-0726-4b0f-b870-b66a2052067a"
      unitRef="U_USD">3490000</acet:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment>
    <acet:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment
      contextRef="C_a6003cef-f951-463a-a0b1-c940267e5c47"
      decimals="-3"
      id="F_5825db38-667d-41f3-b721-cd17e9ca6ffd"
      unitRef="U_USD">3490000</acet:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment>
    <acet:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash
      contextRef="C_9fa0d050-80a6-4eb0-b277-441b2edd40e6"
      decimals="-3"
      id="F_9a51f29b-e23c-413f-84ee-5f6d238658b3"
      unitRef="U_USD">245000</acet:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash>
    <acet:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash
      contextRef="C_a6003cef-f951-463a-a0b1-c940267e5c47"
      decimals="-3"
      id="F_0d8dac5d-01d7-4055-9727-faf6ebcb3bc9"
      unitRef="U_USD">245000</acet:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="C_9fa0d050-80a6-4eb0-b277-441b2edd40e6"
      decimals="-3"
      id="F_0305ff9c-da27-44d7-ac58-c459ca8be826"
      unitRef="U_USD">1316000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="C_b571f234-c627-4f7d-82fb-c74e7cbd480a"
      decimals="-3"
      id="F_f9fc4753-f074-4999-9c38-1b46aeac041d"
      unitRef="U_USD">-12000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable
      contextRef="C_a6003cef-f951-463a-a0b1-c940267e5c47"
      decimals="-3"
      id="F_8cfb80c3-3975-4a95-b234-2d8625d1ee8a"
      unitRef="U_USD">1304000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther
      contextRef="C_9fa0d050-80a6-4eb0-b277-441b2edd40e6"
      decimals="-3"
      id="F_74c1abe9-8575-4861-baff-2c24ab60418e"
      unitRef="U_USD">2365000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther
      contextRef="C_a6003cef-f951-463a-a0b1-c940267e5c47"
      decimals="-3"
      id="F_21ed1926-f93b-4efe-824d-2394e7d1990d"
      unitRef="U_USD">2365000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther
      contextRef="C_9fa0d050-80a6-4eb0-b277-441b2edd40e6"
      decimals="-3"
      id="F_b498acd7-c39b-4402-9cd6-d646180effaa"
      unitRef="U_USD">0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="C_9fa0d050-80a6-4eb0-b277-441b2edd40e6"
      decimals="-3"
      id="F_35bbdc57-1520-4735-87d2-6b5972619154"
      unitRef="U_USD">367000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="C_a6003cef-f951-463a-a0b1-c940267e5c47"
      decimals="-3"
      id="F_a2ec9caf-32a3-4bbd-8bed-196eeba8cc4e"
      unitRef="U_USD">367000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:Goodwill
      contextRef="C_9fa0d050-80a6-4eb0-b277-441b2edd40e6"
      decimals="-3"
      id="F_b19ef29f-5d86-4172-9469-a3a7a0ca8f66"
      unitRef="U_USD">20089000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="C_b571f234-c627-4f7d-82fb-c74e7cbd480a"
      decimals="-3"
      id="F_7c061d4e-1706-4284-bf32-ed0d3efff414"
      unitRef="U_USD">-627000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="C_a6003cef-f951-463a-a0b1-c940267e5c47"
      decimals="-3"
      id="F_5bc9db0a-d41f-47c6-968c-b1dfd4fdce80"
      unitRef="U_USD">19462000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="C_9fa0d050-80a6-4eb0-b277-441b2edd40e6"
      decimals="-3"
      id="F_7373668d-5353-4b19-bcc7-3293264ba20a"
      unitRef="U_USD">87022000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet
      contextRef="C_a6003cef-f951-463a-a0b1-c940267e5c47"
      decimals="-3"
      id="F_65a44cd7-9e0c-4c7c-a1f6-63bbd47a545a"
      unitRef="U_USD">87022000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet>
    <us-gaap:Goodwill
      contextRef="C_a6003cef-f951-463a-a0b1-c940267e5c47"
      decimals="-5"
      id="F_34cb9c14-a8c2-46e9-bc3c-aed8ea87fa2b"
      unitRef="U_USD">19500000</us-gaap:Goodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="-5"
      id="F_774b5fb0-ab54-4f39-9ccc-f5eb5e0661f4"
      unitRef="U_USD">2300000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="C_7c0ad6be-8917-45ec-bfbe-3f58f537064d"
      decimals="-5"
      id="F_00850232-9ccc-4c74-a232-b409e4471904"
      unitRef="U_USD">500000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="C_bdd4c9c6-4256-4ee5-b7de-760f8fec3c69"
      decimals="-5"
      id="F_b81001d3-3ea4-4379-89fa-9c2b617f3836"
      unitRef="U_USD">700000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="C_4f49ca26-ce78-4bcd-aa4b-b027527c27af"
      id="F_138767df-c828-488c-aca6-78d2c413b56b">P60D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:PaymentsForMergerRelatedCosts
      contextRef="C_bb96533e-8bc4-44b9-adcb-bbc676d9bb65"
      decimals="-5"
      id="F_e67e75de-978c-46d2-b6db-898fa01ccb97"
      unitRef="U_USD">7100000</us-gaap:PaymentsForMergerRelatedCosts>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_d315c5de-67fe-4f36-806b-a14160bdca29">&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following tables present changes in the Company's IPR&amp;amp;D and CVR since the Merger (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:27.815%;"/&gt;
        &lt;td style="width:1.362%;"/&gt;
        &lt;td style="width:1.196%;"/&gt;
        &lt;td style="width:11.31%;"/&gt;
        &lt;td style="width:0.588%;"/&gt;
        &lt;td style="width:1.362%;"/&gt;
        &lt;td style="width:1.196%;"/&gt;
        &lt;td style="width:11.085%;"/&gt;
        &lt;td style="width:0.794%;"/&gt;
        &lt;td style="width:1.362%;"/&gt;
        &lt;td style="width:1.196%;"/&gt;
        &lt;td style="width:11.281%;"/&gt;
        &lt;td style="width:0.588%;"/&gt;
        &lt;td style="width:1.362%;"/&gt;
        &lt;td style="width:1.196%;"/&gt;
        &lt;td style="width:11.085%;"/&gt;
        &lt;td style="width:0.794%;"/&gt;
        &lt;td style="width:1.362%;"/&gt;
        &lt;td style="width:1.196%;"/&gt;
        &lt;td style="width:11.281%;"/&gt;
        &lt;td style="width:0.588%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Acquisition Date &lt;br/&gt;Fair value as of&lt;br/&gt;September 15, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Change in &lt;br/&gt;Fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;As of&lt;br/&gt;December 31,&lt;br/&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Change in &lt;br/&gt;Fair value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;As of&lt;br/&gt;December 31,&lt;br/&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"&gt;In-process research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"&gt;3,490&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"&gt;2,300&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"&gt;1,190&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"&gt;1,190&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.5pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_ba39addf-7250-4185-b821-6a0528ff4070;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"&gt;Contingent Value Rights&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"&gt;2,880&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"&gt;1,900&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"&gt;980&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.5pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"&gt;980&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.5pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_53469473-0173-4a8a-bfc4-8856f9b34255;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.5pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock>
    <us-gaap:BusinessCombinationAssetsArisingFromContingenciesAmountRecognized
      contextRef="C_f7497dd4-b12f-4bd8-b7a8-8dd651b1c575"
      decimals="-3"
      id="F_aa0bb6f9-43fc-44a0-837f-dd33d9437b16"
      unitRef="U_USD">3490000</us-gaap:BusinessCombinationAssetsArisingFromContingenciesAmountRecognized>
    <us-gaap:BusinessCombinationAssetsArisingFromContingenciesAmountRecognized
      contextRef="C_4a46099c-74bf-4057-bccf-7f08136ee114"
      decimals="-3"
      id="F_5fba530e-5602-4830-aca7-08c553d50653"
      unitRef="U_USD">-2300000</us-gaap:BusinessCombinationAssetsArisingFromContingenciesAmountRecognized>
    <us-gaap:BusinessCombinationAssetsArisingFromContingenciesAmountRecognized
      contextRef="C_75d47652-161b-4dc3-8594-ce11750f60a2"
      decimals="-3"
      id="F_952d24e0-a208-4f4e-a0f0-579280d112dc"
      unitRef="U_USD">1190000</us-gaap:BusinessCombinationAssetsArisingFromContingenciesAmountRecognized>
    <us-gaap:BusinessCombinationAssetsArisingFromContingenciesAmountRecognized
      contextRef="C_92ecfec8-f8f4-4b99-9099-e1803e6b82f7"
      decimals="-3"
      id="F_69d0ebb1-cf55-44f2-b6fa-d1f876b0be5c"
      unitRef="U_USD">-1190000</us-gaap:BusinessCombinationAssetsArisingFromContingenciesAmountRecognized>
    <us-gaap:BusinessCombinationAssetsArisingFromContingenciesAmountRecognized
      contextRef="C_b7f956dc-e09b-4592-9b31-a71664b48260"
      decimals="-3"
      id="F_e189516b-4868-47b8-b747-cef4095fcc31"
      unitRef="U_USD">2880000</us-gaap:BusinessCombinationAssetsArisingFromContingenciesAmountRecognized>
    <us-gaap:BusinessCombinationAssetsArisingFromContingenciesAmountRecognized
      contextRef="C_81494d43-98de-4a2b-a975-25afa4970b74"
      decimals="-3"
      id="F_3bc18483-7802-4562-b01a-b55851f0660c"
      unitRef="U_USD">-1900000</us-gaap:BusinessCombinationAssetsArisingFromContingenciesAmountRecognized>
    <us-gaap:BusinessCombinationAssetsArisingFromContingenciesAmountRecognized
      contextRef="C_cd9014db-0372-4b1d-af87-ae8fac0a18ea"
      decimals="-3"
      id="F_533516fc-11dd-4bd7-bb5b-cd2aef797f18"
      unitRef="U_USD">980000</us-gaap:BusinessCombinationAssetsArisingFromContingenciesAmountRecognized>
    <us-gaap:BusinessCombinationAssetsArisingFromContingenciesAmountRecognized
      contextRef="C_c3918e4a-2434-4382-9707-ca0c30475b0a"
      decimals="-3"
      id="F_307b0efe-b77b-42b2-ac84-1751937419e0"
      unitRef="U_USD">-980000</us-gaap:BusinessCombinationAssetsArisingFromContingenciesAmountRecognized>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_0224ca9c-a69a-483d-8a44-1804362e0e60">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;4. Fair Value Measurements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company determines the fair value of financial and non-financial assets and liabilities using the fair value hierarchy which establishes three level of inputs that may be used to measure fair value, as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Level 1 &#x2014; Observable inputs, such as quoted prices in active markets for identical assets or liabilities.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Level 2 &#x2014; Observable inputs other than Level 1 prices such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Level 3 &#x2014; Unobservable inputs which reflect management&#x2019;s best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Assets and liabilities measured at fair value are classified in their entirety based on the lowest level of input that is significant to the fair value measurement. The Company&#x2019;s assessment of the significance of a particular input to the fair value measurement in its entirety requires management to make judgments and consider factors specific to the asset or liability.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following tables present information about the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:7.933%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:46.433%;"/&gt;
        &lt;td style="width:1.005%;"/&gt;
        &lt;td style="width:1.728%;"/&gt;
        &lt;td style="width:10.689%;"/&gt;
        &lt;td style="width:0.735%;"/&gt;
        &lt;td style="width:1.005%;"/&gt;
        &lt;td style="width:1.728%;"/&gt;
        &lt;td style="width:9.157%;"/&gt;
        &lt;td style="width:0.735%;"/&gt;
        &lt;td style="width:1.005%;"/&gt;
        &lt;td style="width:1.728%;"/&gt;
        &lt;td style="width:9.157%;"/&gt;
        &lt;td style="width:0.735%;"/&gt;
        &lt;td style="width:1.005%;"/&gt;
        &lt;td style="width:1.728%;"/&gt;
        &lt;td style="width:10.689%;"/&gt;
        &lt;td style="width:0.735%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Money market funds (1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;147,071&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;147,071&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total fair value of assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;147,071&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;147,071&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:48.026%;"/&gt;
        &lt;td style="width:0.993%;"/&gt;
        &lt;td style="width:1.594%;"/&gt;
        &lt;td style="width:9.745%;"/&gt;
        &lt;td style="width:0.821%;"/&gt;
        &lt;td style="width:1.017%;"/&gt;
        &lt;td style="width:1.594%;"/&gt;
        &lt;td style="width:9.757%;"/&gt;
        &lt;td style="width:0.821%;"/&gt;
        &lt;td style="width:1.017%;"/&gt;
        &lt;td style="width:1.594%;"/&gt;
        &lt;td style="width:8.973%;"/&gt;
        &lt;td style="width:0.821%;"/&gt;
        &lt;td style="width:1.017%;"/&gt;
        &lt;td style="width:1.594%;"/&gt;
        &lt;td style="width:9.794%;"/&gt;
        &lt;td style="width:0.821%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Money market funds (1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;63,817&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;63,817&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Marketable debt securities (2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Asset-backed securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;7,522&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;7,522&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;1,762&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;1,762&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;1,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;1,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Marketable debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;10,284&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;10,284&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Total fair value of assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;63,817&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;10,284&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;74,101&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Contingent consideration&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;980&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;980&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Total fair value of liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;980&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;980&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;"&gt;(1)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Included in cash and cash equivalents in the consolidated balance sheets&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;"&gt;(2)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Included in short-term marketable debt securities in the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Money market funds are included within Level 1 of the fair value hierarchy because they are valued using quoted market prices. Corporate debt securities, commercial paper and asset-backed securities are classified within Level 2 of the fair value hierarchy as they take into consideration valuations obtained from third-party pricing services. The pricing services utilize industry standard valuation models, including both income-based and market-based approaches, for which all significant inputs are observable, either directly or indirectly, to estimate the fair value. These inputs include reported trades of and broker/dealer quotes on the same or similar securities, issuer credit spreads, benchmark securities, prepayment/default projections based on historical data and other observable inputs.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As part of the acquisition of resTORbio, the Company entered into a CVR Agreement and recorded the fair value of the CVR as part of consideration transferred. The Company considers the contingent consideration liability a Level 3 instrument (one with significant unobservable inputs) in the fair value hierarchy. In June 2021, the Company determined the possibility of any commercialization events for RTB101 was close to zero (see Note 3). As a result, the fair value of the CVR liability was adjusted to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;zero&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. On October 27, 2021, the Company provided a Termination Notice under the CVR Agreement to the joint rights agents to terminate its obligations under the CVR Agreement, effective immediately.&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_1cd1d79b-a8f3-4cb5-8dba-6d6486bc6498">&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following tables present information about the Company&#x2019;s financial assets and liabilities measured at fair value on a recurring basis and indicate the level of the fair value hierarchy utilized to determine such fair values (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:7.933%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:46.433%;"/&gt;
        &lt;td style="width:1.005%;"/&gt;
        &lt;td style="width:1.728%;"/&gt;
        &lt;td style="width:10.689%;"/&gt;
        &lt;td style="width:0.735%;"/&gt;
        &lt;td style="width:1.005%;"/&gt;
        &lt;td style="width:1.728%;"/&gt;
        &lt;td style="width:9.157%;"/&gt;
        &lt;td style="width:0.735%;"/&gt;
        &lt;td style="width:1.005%;"/&gt;
        &lt;td style="width:1.728%;"/&gt;
        &lt;td style="width:9.157%;"/&gt;
        &lt;td style="width:0.735%;"/&gt;
        &lt;td style="width:1.005%;"/&gt;
        &lt;td style="width:1.728%;"/&gt;
        &lt;td style="width:10.689%;"/&gt;
        &lt;td style="width:0.735%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:20.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:20.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Money market funds (1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;147,071&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;147,071&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total fair value of assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;147,071&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;147,071&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:48.026%;"/&gt;
        &lt;td style="width:0.993%;"/&gt;
        &lt;td style="width:1.594%;"/&gt;
        &lt;td style="width:9.745%;"/&gt;
        &lt;td style="width:0.821%;"/&gt;
        &lt;td style="width:1.017%;"/&gt;
        &lt;td style="width:1.594%;"/&gt;
        &lt;td style="width:9.757%;"/&gt;
        &lt;td style="width:0.821%;"/&gt;
        &lt;td style="width:1.017%;"/&gt;
        &lt;td style="width:1.594%;"/&gt;
        &lt;td style="width:8.973%;"/&gt;
        &lt;td style="width:0.821%;"/&gt;
        &lt;td style="width:1.017%;"/&gt;
        &lt;td style="width:1.594%;"/&gt;
        &lt;td style="width:9.794%;"/&gt;
        &lt;td style="width:0.821%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Level 1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Level 2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Level 3&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Money market funds (1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;63,817&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;63,817&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Marketable debt securities (2)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Asset-backed securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;7,522&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;7,522&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;1,762&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;1,762&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;1,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;1,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Marketable debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;10,284&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;10,284&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Total fair value of assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;63,817&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;10,284&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;74,101&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Contingent consideration&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;980&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;980&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Total fair value of liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;980&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;980&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;"&gt;(1)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Included in cash and cash equivalents in the consolidated balance sheets&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="display:flex;margin-top:0.0pt;line-height:1.15;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;display:inline-flex;font-size:9.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.333%;"&gt;(2)&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Included in short-term marketable debt securities in the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_ebfaf6a1-e4c4-4844-90bf-eb7e876fd554"
      decimals="-3"
      id="F_fa98f595-6fe9-482c-a845-5536ac884496"
      unitRef="U_USD">147071000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_b7eaefd8-96b9-433a-a39f-12214b972204"
      decimals="-3"
      id="F_02ca4e77-9c2a-4c1c-a9ab-6dcb167902d3"
      unitRef="U_USD">147071000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_93d3a97b-1f9f-4a76-9398-f29f21995887"
      decimals="-3"
      id="F_ec2ad17d-b3bc-42e5-821d-d62d7c9015a7"
      unitRef="U_USD">147071000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_23c45869-fbfe-42d5-ad00-b90a165dbcd2"
      decimals="-3"
      id="F_adfe03b9-1c0d-4394-9ea3-5b74f08b9451"
      unitRef="U_USD">147071000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_515b257e-b0b9-4013-a431-c4113b38f357"
      decimals="-3"
      id="F_41788e52-a9f6-472d-b520-3c5c3a010951"
      unitRef="U_USD">63817000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_ad66e4cc-7bab-41c5-80c2-e13c75c2e208"
      decimals="-3"
      id="F_803ea030-804d-4af6-ae34-b6185545f97e"
      unitRef="U_USD">63817000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_3b9411c3-8cc1-4889-996e-5f7080c40edb"
      decimals="-3"
      id="F_e7895ac5-a282-4161-858e-49465cbe531e"
      unitRef="U_USD">7522000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_a5e55134-4c6c-4529-bddd-d3adb88995cd"
      decimals="-3"
      id="F_fdec90d6-ca79-4616-84a2-3da07ccd4eb7"
      unitRef="U_USD">7522000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_33ca374a-c073-4a53-8b64-e82bcfbfe97f"
      decimals="-3"
      id="F_286b4dd8-de72-4494-a772-8e314c9d9fb7"
      unitRef="U_USD">1762000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_d66319b0-75d0-4205-b25e-8c8321f342f3"
      decimals="-3"
      id="F_0099be2f-edcf-42f8-9783-ee98ff854bed"
      unitRef="U_USD">1762000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_1ac06182-fa6d-4612-a577-224903f3d8ec"
      decimals="-3"
      id="F_f92de538-49fa-4f31-8dab-f0d8259d1d68"
      unitRef="U_USD">1000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_905b1778-abfc-4dfb-825e-88b08dac4474"
      decimals="-3"
      id="F_305f8387-b718-488f-a8a2-0200819b734c"
      unitRef="U_USD">1000000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_19e31569-c13e-46a3-a9e6-a74f0c5c72c6"
      decimals="-3"
      id="F_8b9f407e-f217-4fde-baff-1f665d44ddc0"
      unitRef="U_USD">10284000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_5207f624-84b3-469d-bd6b-fe0a7c570cde"
      decimals="-3"
      id="F_170bf009-3fc4-40d7-bdea-5719513fa678"
      unitRef="U_USD">10284000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_76a7c6aa-3344-4804-9a25-aa31c1d6210f"
      decimals="-3"
      id="F_1847d241-8c15-4a6c-93a1-ce9a777d57eb"
      unitRef="U_USD">63817000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_d01f7af2-d072-472c-aed6-fdd2ba352899"
      decimals="-3"
      id="F_e5d9a433-7264-47d0-af77-b1a49ee296c5"
      unitRef="U_USD">10284000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure
      contextRef="C_745de059-cb14-4ea1-8c29-12d351f50320"
      decimals="-3"
      id="F_72710344-6071-4d67-80c6-f0c016a88cd8"
      unitRef="U_USD">74101000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_b662f1d9-b03b-4be8-bc81-ab4638821609"
      decimals="-3"
      id="F_e6260aba-deb5-4dde-bef8-ac7c5fc45244"
      unitRef="U_USD">980000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_0897fc9d-88dd-4a06-87d5-dbac0106894b"
      decimals="-3"
      id="F_dca09712-74bc-4006-8030-030c2ad1247d"
      unitRef="U_USD">980000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_342b3c71-2aea-451c-ba15-14d5101cb509"
      decimals="-3"
      id="F_e586e468-f626-47cc-b54b-31efb251bd50"
      unitRef="U_USD">980000</us-gaap:LiabilitiesFairValueDisclosure>
    <us-gaap:LiabilitiesFairValueDisclosure
      contextRef="C_745de059-cb14-4ea1-8c29-12d351f50320"
      decimals="-3"
      id="F_b05189c4-c0cf-42da-8925-93d43be7fca7"
      unitRef="U_USD">980000</us-gaap:LiabilitiesFairValueDisclosure>
    <acet:EstimatedFairValueOfCVRLiability
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-3"
      id="F_e09e4deb-2499-4d2f-8180-0db46615321f"
      unitRef="U_USD">0</acet:EstimatedFairValueOfCVRLiability>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_07747e35-46b5-4aba-a510-85df7493db1e">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;5. Marketable Debt Securities&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following tables summarize the Company&#x2019;s marketable debt securities (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:7.933%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:47.571%;"/&gt;
        &lt;td style="width:1.035%;"/&gt;
        &lt;td style="width:1.481%;"/&gt;
        &lt;td style="width:9.946%;"/&gt;
        &lt;td style="width:0.664%;"/&gt;
        &lt;td style="width:1.035%;"/&gt;
        &lt;td style="width:1.481%;"/&gt;
        &lt;td style="width:9.989%;"/&gt;
        &lt;td style="width:0.664%;"/&gt;
        &lt;td style="width:1.035%;"/&gt;
        &lt;td style="width:1.481%;"/&gt;
        &lt;td style="width:9.989%;"/&gt;
        &lt;td style="width:0.664%;"/&gt;
        &lt;td style="width:1.035%;"/&gt;
        &lt;td style="width:1.481%;"/&gt;
        &lt;td style="width:9.782%;"/&gt;
        &lt;td style="width:0.664%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Asset-backed securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,507&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,522&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,754&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,762&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;999&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,260&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,284&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:7.933%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table summarizes the classification of the Company&#x2019;s marketable debt securities in the consolidated balance sheets (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:7.933%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:73.372%;"/&gt;
        &lt;td style="width:1.089%;"/&gt;
        &lt;td style="width:1.514%;"/&gt;
        &lt;td style="width:9.769%;"/&gt;
        &lt;td style="width:0.708%;"/&gt;
        &lt;td style="width:1.089%;"/&gt;
        &lt;td style="width:1.514%;"/&gt;
        &lt;td style="width:10.237%;"/&gt;
        &lt;td style="width:0.708%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Short-term marketable debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,284&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Long-term marketable debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,284&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:MarketableSecuritiesTextBlock
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_848e7ef9-900c-44ff-9f31-c71c0895129a">&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following tables summarize the Company&#x2019;s marketable debt securities (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:7.933%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:47.571%;"/&gt;
        &lt;td style="width:1.035%;"/&gt;
        &lt;td style="width:1.481%;"/&gt;
        &lt;td style="width:9.946%;"/&gt;
        &lt;td style="width:0.664%;"/&gt;
        &lt;td style="width:1.035%;"/&gt;
        &lt;td style="width:1.481%;"/&gt;
        &lt;td style="width:9.989%;"/&gt;
        &lt;td style="width:0.664%;"/&gt;
        &lt;td style="width:1.035%;"/&gt;
        &lt;td style="width:1.481%;"/&gt;
        &lt;td style="width:9.989%;"/&gt;
        &lt;td style="width:0.664%;"/&gt;
        &lt;td style="width:1.035%;"/&gt;
        &lt;td style="width:1.481%;"/&gt;
        &lt;td style="width:9.782%;"/&gt;
        &lt;td style="width:0.664%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="14" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Amortized&lt;br/&gt;Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Unrealized&lt;br/&gt;Losses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Unrealized&lt;br/&gt;Gains&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Fair&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Asset-backed securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,507&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;15&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,522&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Corporate debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,754&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,762&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Commercial paper&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;999&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,260&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;24&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,284&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_a904b84b-2c56-4da2-95ba-b90ab8586e15"
      decimals="-3"
      id="F_619a8c46-a0e8-4bdc-b6a1-5c41c4d18f14"
      unitRef="U_USD">7507000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_a904b84b-2c56-4da2-95ba-b90ab8586e15"
      decimals="-3"
      id="F_ed9e99c2-f731-4176-b630-487d5d34a011"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_a904b84b-2c56-4da2-95ba-b90ab8586e15"
      decimals="-3"
      id="F_6cff3b91-61bd-4e8e-9c5a-37d95b6e52b0"
      unitRef="U_USD">15000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_a904b84b-2c56-4da2-95ba-b90ab8586e15"
      decimals="-3"
      id="F_6d9634da-2990-4754-8546-9f2558c6d99e"
      unitRef="U_USD">7522000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_c620e2d6-dea3-45ea-8e5e-d3a20a684708"
      decimals="-3"
      id="F_6244cebe-4c23-4705-be4e-5ca0f5640a56"
      unitRef="U_USD">1754000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_c620e2d6-dea3-45ea-8e5e-d3a20a684708"
      decimals="-3"
      id="F_78323ae3-7b40-4866-80c2-42633178419a"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_c620e2d6-dea3-45ea-8e5e-d3a20a684708"
      decimals="-3"
      id="F_ff015ec3-8b1b-4703-bc7e-2ca71120db42"
      unitRef="U_USD">8000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_c620e2d6-dea3-45ea-8e5e-d3a20a684708"
      decimals="-3"
      id="F_d579afe1-95bd-48a2-b1a4-af991a8da127"
      unitRef="U_USD">1762000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_fdcf93e8-6acd-43f5-89f3-9404d1046341"
      decimals="-3"
      id="F_e0cb6afe-eafd-4824-b31f-3e59e10d479d"
      unitRef="U_USD">999000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_fdcf93e8-6acd-43f5-89f3-9404d1046341"
      decimals="-3"
      id="F_eb34490a-3a57-4ddb-bea5-4b34826ada04"
      unitRef="U_USD">1000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_fdcf93e8-6acd-43f5-89f3-9404d1046341"
      decimals="-3"
      id="F_e470129a-1581-439b-9cd7-323f1039f3c3"
      unitRef="U_USD">1000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="-3"
      id="F_92a4980a-d021-4cad-b32b-b261f09d7c5e"
      unitRef="U_USD">10260000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="-3"
      id="F_dcecd051-6b88-497a-9b51-d06e2c55d569"
      unitRef="U_USD">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="-3"
      id="F_f4d1e722-dcea-40f1-8d17-1a488892b5a8"
      unitRef="U_USD">24000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="-3"
      id="F_215ba233-6226-49ce-9021-314f116ab0a4"
      unitRef="U_USD">10284000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <acet:MarketableDebtSecuritiesClassificationTableTextBlock
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_03749ca5-2bbf-46e0-bd68-8047e8a36499">&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table summarizes the classification of the Company&#x2019;s marketable debt securities in the consolidated balance sheets (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:7.933%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:73.372%;"/&gt;
        &lt;td style="width:1.089%;"/&gt;
        &lt;td style="width:1.514%;"/&gt;
        &lt;td style="width:9.769%;"/&gt;
        &lt;td style="width:0.708%;"/&gt;
        &lt;td style="width:1.089%;"/&gt;
        &lt;td style="width:1.514%;"/&gt;
        &lt;td style="width:10.237%;"/&gt;
        &lt;td style="width:0.708%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Short-term marketable debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,284&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Long-term marketable debt securities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,284&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</acet:MarketableDebtSecuritiesClassificationTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-3"
      id="F_2c3fb7b4-08ea-4d2c-a7d1-cb96cb061ba3"
      unitRef="U_USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="-3"
      id="F_52a47c53-67ce-40be-a6eb-b8aa594c0c6c"
      unitRef="U_USD">10284000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="-3"
      id="F_99f1682d-1947-4818-bbe7-75f7da81302e"
      unitRef="U_USD">0</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:MarketableSecurities
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-3"
      id="F_5855a352-ef9a-43cf-a76a-643cc50a9649"
      unitRef="U_USD">0</us-gaap:MarketableSecurities>
    <us-gaap:MarketableSecurities
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="-3"
      id="F_ad30bc17-59c3-410a-af7a-8c18b582a93a"
      unitRef="U_USD">10284000</us-gaap:MarketableSecurities>
    <acet:PrepaidExpensesAndOtherCurrentAssetsTextBlock
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_246a4b89-9bb6-448b-ab8d-a275ff83c73e">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;6. Prepaid Expenses and Other Current Assets&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Prepaid expenses and other current assets consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:63.509%;"/&gt;
        &lt;td style="width:1.373%;"/&gt;
        &lt;td style="width:2.116%;"/&gt;
        &lt;td style="width:13.901%;"/&gt;
        &lt;td style="width:0.855%;"/&gt;
        &lt;td style="width:1.373%;"/&gt;
        &lt;td style="width:2.116%;"/&gt;
        &lt;td style="width:13.901%;"/&gt;
        &lt;td style="width:0.855%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Prepaid Insurance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,884&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,443&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Prepayments to CRO's&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,658&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;420&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Prepaid Maintenance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;761&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Prepayments to CMO's&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;115&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;135&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;229&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Tax receivable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,711&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Interest receivable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;29&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,709&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</acet:PrepaidExpensesAndOtherCurrentAssetsTextBlock>
    <acet:PrepaidExpensesAndOtherCurrentAssetsTableTextBlock
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_975a49a1-675b-4ee2-bdc5-7403c4caf776">&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Prepaid expenses and other current assets consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:63.509%;"/&gt;
        &lt;td style="width:1.373%;"/&gt;
        &lt;td style="width:2.116%;"/&gt;
        &lt;td style="width:13.901%;"/&gt;
        &lt;td style="width:0.855%;"/&gt;
        &lt;td style="width:1.373%;"/&gt;
        &lt;td style="width:2.116%;"/&gt;
        &lt;td style="width:13.901%;"/&gt;
        &lt;td style="width:0.855%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Prepaid Insurance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,884&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,443&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Prepayments to CRO's&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,658&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;420&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Prepaid Maintenance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;761&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Prepayments to CMO's&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;115&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;135&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Other current assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;229&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Tax receivable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,711&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Interest receivable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;29&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;23&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,709&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,722&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</acet:PrepaidExpensesAndOtherCurrentAssetsTableTextBlock>
    <us-gaap:PrepaidInsurance
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-3"
      id="F_cc9fb909-d08f-4c65-bc1f-a66ef4e8a4a3"
      unitRef="U_USD">1884000</us-gaap:PrepaidInsurance>
    <us-gaap:PrepaidInsurance
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="-3"
      id="F_d477784a-924e-40db-9946-87ea8e493264"
      unitRef="U_USD">1443000</us-gaap:PrepaidInsurance>
    <acet:PrepaymentsToCros
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-3"
      id="F_2ee14c5e-a4fc-48b7-bc7b-9e55efeae3d6"
      unitRef="U_USD">1658000</acet:PrepaymentsToCros>
    <acet:PrepaymentsToCros
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="-3"
      id="F_133ac2b1-2526-469d-8a87-2305fbd0d0a2"
      unitRef="U_USD">420000</acet:PrepaymentsToCros>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-3"
      id="F_a7d698f5-4430-491d-af75-35cabe6e53f1"
      unitRef="U_USD">1021000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="-3"
      id="F_359563b9-39de-43b8-a283-b90a039cbeae"
      unitRef="U_USD">761000</us-gaap:PrepaidExpenseCurrent>
    <acet:PrepaymentsToCmos
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-3"
      id="F_d708b07a-765e-4ac4-b9fa-4356c2319fa0"
      unitRef="U_USD">115000</acet:PrepaymentsToCmos>
    <acet:PrepaymentsToCmos
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="-3"
      id="F_c77eb321-8d96-489e-ab72-d865661eb25f"
      unitRef="U_USD">135000</acet:PrepaymentsToCmos>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-3"
      id="F_2464bbdb-a912-4273-b531-03b550d8072b"
      unitRef="U_USD">2000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="-3"
      id="F_c6aba313-7cb9-48e7-89b6-185993d591e9"
      unitRef="U_USD">229000</us-gaap:OtherAssetsCurrent>
    <us-gaap:IncomeTaxesReceivable
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-3"
      id="F_35116441-1b04-4b29-a73b-5e936379b6d9"
      unitRef="U_USD">0</us-gaap:IncomeTaxesReceivable>
    <us-gaap:IncomeTaxesReceivable
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="-3"
      id="F_95b0934e-bb2d-4f63-8f79-182ba6cd6b16"
      unitRef="U_USD">2711000</us-gaap:IncomeTaxesReceivable>
    <us-gaap:InterestReceivableCurrent
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-3"
      id="F_57de9372-7815-41e0-8a30-edc5b70170e0"
      unitRef="U_USD">29000</us-gaap:InterestReceivableCurrent>
    <us-gaap:InterestReceivableCurrent
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="-3"
      id="F_2e47c406-21bc-4597-90e7-55f67eb1dc87"
      unitRef="U_USD">23000</us-gaap:InterestReceivableCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-3"
      id="F_d84340cd-2ca4-4cd8-9868-72c25988ed6d"
      unitRef="U_USD">4709000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="-3"
      id="F_ab60a451-66cc-4ab0-b68b-d65903f6e9ee"
      unitRef="U_USD">5722000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_5c7dce37-3e7a-4a41-8c33-28a46887929a">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:13.0pt;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;7. Property and Equipment, net&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Property and equipment, net consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:7.933%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:40.608%;"/&gt;
        &lt;td style="width:1.47%;"/&gt;
        &lt;td style="width:20.353%;"/&gt;
        &lt;td style="width:1.47%;"/&gt;
        &lt;td style="width:1.752%;"/&gt;
        &lt;td style="width:14.459%;"/&gt;
        &lt;td style="width:1.164%;"/&gt;
        &lt;td style="width:1.47%;"/&gt;
        &lt;td style="width:1.752%;"/&gt;
        &lt;td style="width:14.336%;"/&gt;
        &lt;td style="width:1.164%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Useful life (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,502&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,350&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Lesser of useful life&lt;br/&gt;or lease term&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,614&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,427&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;303&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;524&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Construction in progress&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;13,014&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,090&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;216&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;320&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;170&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;   &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;20,969&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,654&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Less: Accumulated depreciation and&lt;br/&gt;&#160;&#160;&#160;amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,326&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,864&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;14,643&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,790&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:7.933%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Depreciation and amortization expense for each of the years ended December 31, 2021 and 2020 was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, respectively. All of the Company&#x2019;s property and equipment as of December 31, 2021 and 2020 is located in the U.S. Construction in progress has increased by $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million due to building construction related to the Company's leased space in Redwood City. Construction in process will continue to increase through the first half of 2022, until completion of construction.&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_e216fc72-da9d-424b-92f3-15e27df004cb">&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Property and equipment, net consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:7.933%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:80.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:40.608%;"/&gt;
        &lt;td style="width:1.47%;"/&gt;
        &lt;td style="width:20.353%;"/&gt;
        &lt;td style="width:1.47%;"/&gt;
        &lt;td style="width:1.752%;"/&gt;
        &lt;td style="width:14.459%;"/&gt;
        &lt;td style="width:1.164%;"/&gt;
        &lt;td style="width:1.47%;"/&gt;
        &lt;td style="width:1.752%;"/&gt;
        &lt;td style="width:14.336%;"/&gt;
        &lt;td style="width:1.164%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;As of December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Useful life (years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Laboratory equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,502&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,350&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Leasehold improvements&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Lesser of useful life&lt;br/&gt;or lease term&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,614&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,427&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Furniture and fixtures&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;303&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;524&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Construction in progress&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;13,014&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,090&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Computer equipment&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;216&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;93&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Software&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;320&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;170&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;   &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;20,969&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,654&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Less: Accumulated depreciation and&lt;br/&gt;&#160;&#160;&#160;amortization&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,326&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,864&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Property and equipment, net&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;14,643&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,790&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_eb6b17d5-2d48-4838-8382-90249e566d9f"
      id="F_11a57c1e-4aeb-4e5e-ae3e-c72eeee2d94c">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_fca8dc62-71f2-4995-91e8-1b030e192627"
      decimals="-3"
      id="F_400633ac-8eee-40e4-8ecf-3562b425dcb3"
      unitRef="U_USD">5502000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_ecef1783-dbe7-4a31-ab16-82774cd71330"
      decimals="-3"
      id="F_a3e8aef4-7779-4ba2-a977-66ab0ada7d9d"
      unitRef="U_USD">4350000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives
      contextRef="C_2bdce80c-0fa1-4c32-b7bb-48e057af1270"
      id="F_436abea9-58ce-4aaa-86b5-c0420be5fa43">Lesser of useful lifeor lease term</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_e0e2612c-d563-4a7b-9f21-1a5002c22dc4"
      decimals="-3"
      id="F_1a5f191c-14e4-46d7-85d0-3956cfa3d4fa"
      unitRef="U_USD">1614000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_23640616-f433-4b74-849e-d9ad90a3ad0c"
      decimals="-3"
      id="F_5f7bc290-65a2-4caa-a182-2c7864abda80"
      unitRef="U_USD">1427000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_36729629-5671-4810-b3a0-0a65b96f4982"
      id="F_2d9364b5-6b29-40be-939d-5c490d2b69fa">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_c5ef6f51-8e27-49fd-b340-0ef1ea2559f1"
      decimals="-3"
      id="F_54dbe9ba-1f24-4994-9460-c98d4c263f2f"
      unitRef="U_USD">303000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_fddea6c4-817b-4e77-aea4-89981e10e5a9"
      decimals="-3"
      id="F_7b143184-a5c9-4dff-8b8b-9c3e13101d82"
      unitRef="U_USD">524000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_91668149-580c-41d2-a60a-c106cf15c4df"
      decimals="-3"
      id="F_8f5cb10f-3046-470d-aa5f-4ae506356d52"
      unitRef="U_USD">13014000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_3af201ab-f6bf-43f9-bbd9-545d3f60a016"
      decimals="-3"
      id="F_ae09dcd4-4ce6-402c-a351-042baa5aea74"
      unitRef="U_USD">1090000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_87ab7035-f594-4fe7-8bcf-c303cd53528e"
      id="F_50cba4a6-86cf-4e1a-86ca-075abb84d2ee">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_f42c98ab-830c-4e22-89f5-e18b91b6cd8e"
      decimals="-3"
      id="F_dbef3a66-1199-4de7-baca-d79cde03e977"
      unitRef="U_USD">216000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_8ebb8127-795c-4f3e-930b-1793c330d85e"
      decimals="-3"
      id="F_01a5dc26-ea7b-4bbd-a610-a61ef8924dfa"
      unitRef="U_USD">93000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="C_f0fe55b1-e361-4417-baab-c311c3746c48"
      id="F_777620ac-f48e-49db-b1c2-5c86cc7c6189">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_269b2bf6-80a4-4772-a84e-435846b50f75"
      decimals="-3"
      id="F_f36910f6-9463-4229-955d-53f58aa21470"
      unitRef="U_USD">320000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_3b4615b0-36e3-4745-a8ee-bb680c1705d1"
      decimals="-3"
      id="F_10ffc444-beb0-4f14-bd3d-f3eb0faa2c56"
      unitRef="U_USD">170000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-3"
      id="F_7ab46b37-4ced-4a03-9fa4-30c34fd1377a"
      unitRef="U_USD">20969000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="-3"
      id="F_15fbf4dd-81f4-4915-ac1e-18d259b64050"
      unitRef="U_USD">7654000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-3"
      id="F_c60d89c6-dc22-4694-ba75-fe8017b135ec"
      unitRef="U_USD">6326000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="-3"
      id="F_ee72001a-593f-4b93-9082-6686337ce306"
      unitRef="U_USD">4864000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-3"
      id="F_985b7d3a-886e-4df7-9a3f-9138f4dfd539"
      unitRef="U_USD">14643000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="-3"
      id="F_efb53457-feef-4632-8e52-dab3e4858ddc"
      unitRef="U_USD">2790000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="-5"
      id="F_cfd47156-fb1b-4e53-8f5e-ed3ab77a1249"
      unitRef="U_USD">1500000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="-5"
      id="F_d68568c7-8ca8-496b-963c-edb067c9797f"
      unitRef="U_USD">1200000</us-gaap:DepreciationAndAmortization>
    <acet:IncreaseInConstructionInProgress
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="-5"
      id="F_f58b5316-7628-407f-8e84-a81a56295c82"
      unitRef="U_USD">11900000</acet:IncreaseInConstructionInProgress>
    <acet:IncreaseInConstructionInProgress
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="-5"
      id="F_f945639d-33f6-4996-bbf3-3773dfb781b1"
      unitRef="U_USD">11900000</acet:IncreaseInConstructionInProgress>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_6467f8c9-3d2d-4cbc-bb73-ca0f3640ca20">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;8. Accrued and Other Current Liabilities&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accrued and other current liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:58.84%;"/&gt;
        &lt;td style="width:2.508%;"/&gt;
        &lt;td style="width:2.115%;"/&gt;
        &lt;td style="width:17.974%;"/&gt;
        &lt;td style="width:0.855%;"/&gt;
        &lt;td style="width:2.508%;"/&gt;
        &lt;td style="width:2.115%;"/&gt;
        &lt;td style="width:12.23%;"/&gt;
        &lt;td style="width:0.855%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accrued compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,833&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accrued CMO costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,077&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;244&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accrued professional services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;546&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;363&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accrued research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;504&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;65&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accrued other liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;503&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;272&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accrued CRO costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;32&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;955&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,682&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,732&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_a90e5860-66bb-43a8-acab-b57d1e11719b">&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accrued and other current liabilities consisted of the following (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:70.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:58.84%;"/&gt;
        &lt;td style="width:2.508%;"/&gt;
        &lt;td style="width:2.115%;"/&gt;
        &lt;td style="width:17.974%;"/&gt;
        &lt;td style="width:0.855%;"/&gt;
        &lt;td style="width:2.508%;"/&gt;
        &lt;td style="width:2.115%;"/&gt;
        &lt;td style="width:12.23%;"/&gt;
        &lt;td style="width:0.855%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accrued compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,833&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accrued CMO costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,077&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;244&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accrued professional services&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;546&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;363&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accrued research and development expenses&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;504&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;65&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accrued other liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;503&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;272&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accrued CRO costs&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;32&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;955&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,682&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,732&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-3"
      id="F_fb891a66-0e72-46b6-9bcb-30db3c311c26"
      unitRef="U_USD">4020000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="-3"
      id="F_1e37e36a-39f5-41dd-99b1-a5a90431c0ed"
      unitRef="U_USD">3833000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <acet:AccruedCmoCosts
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-3"
      id="F_24ba304f-32a0-4d82-b0f6-e123a3b348e5"
      unitRef="U_USD">1077000</acet:AccruedCmoCosts>
    <acet:AccruedCmoCosts
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="-3"
      id="F_de046ddc-ecba-420d-8aa7-809933146bc6"
      unitRef="U_USD">244000</acet:AccruedCmoCosts>
    <us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-3"
      id="F_b44dfb8f-e803-4352-857e-cd53f6445495"
      unitRef="U_USD">546000</us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent>
    <us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="-3"
      id="F_601d0612-7f2e-46aa-a6a4-3fac3164c341"
      unitRef="U_USD">363000</us-gaap:AccruedProfessionalFeesCurrentAndNoncurrent>
    <acet:AccruedResearchAndDevelopmentExpensesCurrent
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-3"
      id="F_1a8dda04-cedc-44c4-b71c-8aeb9c9eead4"
      unitRef="U_USD">504000</acet:AccruedResearchAndDevelopmentExpensesCurrent>
    <acet:AccruedResearchAndDevelopmentExpensesCurrent
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="-3"
      id="F_d02f492c-1843-47be-96eb-01f55bf018e6"
      unitRef="U_USD">65000</acet:AccruedResearchAndDevelopmentExpensesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-3"
      id="F_c95bf824-0e61-4a2c-8d79-03111d6d0064"
      unitRef="U_USD">503000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="-3"
      id="F_358d70f7-60e8-4e4c-ad70-99a36e2482b8"
      unitRef="U_USD">272000</us-gaap:OtherAccruedLiabilitiesCurrent>
    <acet:AccruedCroCosts
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-3"
      id="F_ef0a63c8-93c7-41d6-ab3e-24d732a828bb"
      unitRef="U_USD">32000</acet:AccruedCroCosts>
    <acet:AccruedCroCosts
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="-3"
      id="F_9a12602b-4712-42a2-9dd7-8b9a1c42cd28"
      unitRef="U_USD">955000</acet:AccruedCroCosts>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-3"
      id="F_58452be7-c3e4-48af-9fb7-e9be3126ced6"
      unitRef="U_USD">6682000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:AccruedLiabilitiesAndOtherLiabilities
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="-3"
      id="F_65afd712-04e9-4ae7-a248-c8d705d8bc2a"
      unitRef="U_USD">5732000</us-gaap:AccruedLiabilitiesAndOtherLiabilities>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_57e5d776-7c4e-4c26-b742-f3994237bb86">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;9. Term Loan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On April 28, 2020, the Company entered into a Loan and Security Agreement with Pacific Western Bank (PacWest) for a term loan not exceeding $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;12.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(the Loan Agreement) to finance leasehold improvements for the facilities in Redwood&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;City, &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;CA and other purposes permitted under the Loan Agreement, with an interest rate equal to the greater of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.25&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% above the Prime Rate (as defined in the Loan Agreement) or &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%.  The Loan Agreement granted to Pacific Western Bank a security interest on substantially all of the Company&#x2019;s assets other than intellectual property to secure the performance of the Company&#x2019;s obligations under the Loan Agreement, and contains a variety of affirmative and negative covenants, including required financial reporting, limitations on certain dispositions of assets or distributions, limitations on the incurrence of additional debt or liens and other customary requirements. As of December 31, 2021, the Company was in compliance with such covenants.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Pursuant to the Loan Agreement in April 2020, the Company may request to draw upon the term loan at any time through the date eighteen months after the date of the Loan Agreement (Availability End Date), which was &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;October 28, 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. No amounts were drawn under the Loan Agreement through the Availability End Date.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On October 21, 2021, the Company amended the Loan Agreement with PacWest (the Loan Amendment) under which PacWest will provide one or more Term Loans, as well as Non-Formula Ancillary Services which shall not exceed $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in the aggregate. Non-Formula Ancillary Services are defined as automated clearinghouse transactions, corporate credit card services, letters of credit, or other treasury management services. The aggregate sum of the outstanding Term Loans and Non-Formula Ancillary Services shall at no time exceed $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;15.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;which each Term Loan to be in an amount of not less than $1.0 million. As of December 31, 2021, the Company had outstanding Non-Formula Ancillary Services of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million. Accordingly, as of December 31, 2021, the Company has $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million available under the Term Loan. Pursuant to the Loan Amendment, the interest rate for the Term Loans shall be set at an annual rate equal to the greater of (i) 0.25% above the Prime Rate then in effect and (ii) 4.25%.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2021, the deferred debt issuance costs were $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and are included in other non-current assets on the Company&#x2019;s consolidated balance sheets.&lt;/span&gt;&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <acet:TermLoanToFinanceLeaseholdImprovements1
      contextRef="C_bdaaafd2-c90a-4125-9ca9-c8ea735b0f55"
      decimals="-5"
      id="F_3bc86f68-d68e-45e1-889f-64240cf58505"
      unitRef="U_USD">12000000.0</acet:TermLoanToFinanceLeaseholdImprovements1>
    <us-gaap:LoansReceivableBasisSpreadOnVariableRate
      contextRef="C_b33e9899-16fc-42cc-96d1-97d706c7101b"
      decimals="4"
      id="F_00901850-3e74-466a-9530-19e3e5f2eb91"
      unitRef="U_pure">0.0025</us-gaap:LoansReceivableBasisSpreadOnVariableRate>
    <us-gaap:LoansReceivableBasisSpreadOnVariableRate
      contextRef="C_57a750f3-8a24-41e7-9a82-33461f5929df"
      decimals="4"
      id="F_885f92b4-40db-46c8-b26f-c5f92ee429bf"
      unitRef="U_pure">0.0500</us-gaap:LoansReceivableBasisSpreadOnVariableRate>
    <us-gaap:DebtInstrumentMaturityDateRangeEnd1
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_0fe58d25-9983-42b7-9cb8-a517674b3961">2021-10-28</us-gaap:DebtInstrumentMaturityDateRangeEnd1>
    <acet:LoanAmountDrawn
      contextRef="C_edc51531-f059-4811-b4b9-e22729a4e46c"
      decimals="-5"
      id="F_19a4fb10-4f9f-4889-9bb1-1de52073a733"
      unitRef="U_USD">5500000</acet:LoanAmountDrawn>
    <acet:TermLoanAndNonFormulaAncillaryService
      contextRef="C_edc51531-f059-4811-b4b9-e22729a4e46c"
      decimals="-5"
      id="F_4a37913f-51c9-417a-88c4-991cbd786b39"
      unitRef="U_USD">15000000.0</acet:TermLoanAndNonFormulaAncillaryService>
    <us-gaap:LongTermDebtDescription
      contextRef="C_99983e52-f2a5-42a0-b031-14f6461609ac"
      id="F_71bebc53-02a6-4bd0-a12d-571785019fe3">which each Term Loan to be in an amount of not less than $1.0 million. As of December 31, 2021, the Company had outstanding Non-Formula Ancillary Services of $4.4 million. Accordingly, as of December 31, 2021, the Company has $10.6 million available under the Term Loan. Pursuant to the Loan Amendment, the interest rate for the Term Loans shall be set at an annual rate equal to the greater of (i) 0.25% above the Prime Rate then in effect and (ii) 4.25%.</us-gaap:LongTermDebtDescription>
    <us-gaap:LoansPayable
      contextRef="C_61d94a43-5646-47f3-b305-92ab60efd0b9"
      decimals="-5"
      id="F_7c2ae940-11d9-4b45-a079-1bec5f7aae4e"
      unitRef="U_USD">4400000</us-gaap:LoansPayable>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="C_61d94a43-5646-47f3-b305-92ab60efd0b9"
      decimals="-5"
      id="F_d1e45293-2730-484a-9b92-1345b3531e89"
      unitRef="U_USD">10600000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DeferredFinanceCostsGross
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-5"
      id="F_3f12bd19-d998-4b07-a6f3-bd6005b6e590"
      unitRef="U_USD">100000</us-gaap:DeferredFinanceCostsGross>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_a1b79e15-0f07-475a-85ce-bf630203a336">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;10. Regeneron License and Collaboration Arrangement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Agreement Terms&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On July 29, 2016, the Company entered into a license and collaboration agreement with Regeneron, which was amended in April 2019, with such amendment becoming effective in connection with Regeneron&#x2019;s investment in the Company&#x2019;s Series B redeemable convertible preferred stock private placement transaction in July 2019 (as amended, the Regeneron Agreement).&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Agreement Structure&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. The Regeneron Agreement has two principal components: (a) a research collaboration component under which the parties will research, develop, and commercialize next-generation engineered gamma delta immune cell therapeutics (ICPs), namely engineered gamma delta immune cells with CARs and TCRs directed to disease-specific cell surface antigens, which includes the grant of certain licenses to intellectual property between the two parties, and (b) for a certain period following the effective date, a license to the Company to use certain of Regeneron&#x2019;s proprietary mice to develop and commercialize ICPs generated by the Company, with certain limitations relating to targets under the Regeneron Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Research Collaboration&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. Research activities under the collaboration are governed by research plans, which include the strategy, goals, activities, and responsibilities of the parties with respect to a target. The Company is primarily responsible for generating, validating, and optimizing ICPs, developing processes for manufacture of ICPs, and certain preclinical and clinical manufacturing activities for ICPs; Regeneron&#x2019;s key responsibility is generating, validating, and optimizing CARs and TCRs that bind to the applicable target. The parties have formed a joint research committee to monitor and govern the research and development efforts during the research program term.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Rights to Research Targets&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. Under the terms of the collaboration, the parties will conduct research on mutually agreed upon targets. Regeneron may obtain exclusive rights for the targets that it chooses in accordance with the target selection mechanism set forth in the Regeneron Agreement, and the Company similarly may obtain exclusive rights for targets it chooses in accordance with such target selection mechanism. The Company has the right to develop and commercialize ICPs to the first collaboration target to come out of the research program. On January 28, 2022, the Company received a payment of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;20.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million from Regeneron for exercise of its option to license exclusive rights to ADI-002 and Regeneron potentially has additional options to other ICP targets under the Regeneron Agreement. Pursuant to the Agreement with Regeneron, the Company had the right to elect to co-fund ADI-002's future development costs. The Company did not elect its option. For those targets it does not have an option to license, Regeneron has a right of first negotiation for up to two targets. Regeneron has the right to terminate the research program in its entirety (a) for convenience on six months prior written notice given at any time after December 31, 2019, or (b) following a change of control (as defined in the Regeneron Agreement) of the Company. The parties mutually agreed to their first product declaration criteria for collaboration ICP, CD20, in 2018.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Rights to Company-Developed Targets&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. Regeneron has an exclusive license to use targeting moieties generated by the Company by its use of Regeneron&#x2019;s proprietary mice to develop and commercialize non-ICPs.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Exclusivity&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. During the five-year target selection period that expired in July 2021, the Company may not directly or indirectly research, develop, manufacture or commercialize an ICP, or grant a license to do the foregoing, except pursuant to the agreement. For so long as either party is researching or developing an ICP to a target under the research program, neither party may research, develop, manufacture or commercialize any other ICP to such target, or grant a license to do the foregoing. And for so long as a party is researching, developing or commercializing an ICP to target that is licensed to it (and royalty bearing) under the agreement, neither party may research, develop, manufacture or commercialize any other ICP to such target, or grant a license to permit another party to do the foregoing. These exclusivity obligations are limited to engineered gamma delta immune cells to targets reasonably considered to have therapeutic relevance in oncology. The Regeneron Agreement includes certain exceptions to the exclusivity obligations of the parties, including with respect to targets that are rejected by one party in the target selection process, as well as protections in the event of a change of control of a party where the acquirer has a competing program.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Co-Funding and Profit Sharing&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. The Company has an option to co-fund specified portions of the future development costs for, and to co-promote, ICPs to a target for which Regeneron has exercised an option, and to participate in the profits for such target. The Company has the right to exercise this right in various geographic regions, including on a worldwide basis. In the event the Company exercises such right, the parties will share further development costs and profits proportionally to their co-funding percentages.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Financial Terms&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. The Company received a non-refundable upfront payment of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;25.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million from Regeneron upon execution of the Regeneron Agreement and has received an aggregate of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;20.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million of additional payments for research funding from Regeneron as of December 31, 2021. In addition, Regeneron may have to pay the Company additional amounts in the future consisting of up to an aggregate of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;80.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million of option exercise fees for a certain number of collaboration ICPs, as specified in the Regeneron Agreement. Regeneron must also pay the Company high single digit royalties as a percentage of net sales for ICPs to targets for which it has exclusive rights, and low single digit royalties as a percentage of net sales on any non-ICP product comprising a targeting moiety generated by the Company through the use of Regeneron&#x2019;s proprietary mice. The Company must pay Regeneron mid-single to low double digit, but less than teens, of royalties as a percentage of net sales of ICPs to targets for which the Company has exercised exclusive rights, and low to mid-single digit of royalties as a percentage of net sales of targeting moieties generated from the Company&#x2019;s license to use Regeneron&#x2019;s proprietary mice. Royalties are payable until the longer of the expiration or invalidity of the licensed patent rights or &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;twelve (12) years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; from first commercial sale.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Other Terms&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. The Regeneron Agreement contains customary representations, warranties and covenants by the Company and Regeneron and includes (i) an obligation of the Company to use commercially reasonable efforts to develop and commercialize at least one product based on a collaboration ICP that is not an optioned collaboration ICP for each collaboration target and (ii) an obligation of Regeneron to use commercially reasonable efforts to develop and commercialize at least one product based on an optioned collaboration ICP for each collaboration target. The Company and Regeneron are required to indemnify the other party against all losses and expenses related to breaches of its representations, warranties and covenants under the Regeneron Agreement.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Term and Termination&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. The term of the Regeneron Agreement expires, on a product-by-product basis, on the expiration of the obligation to pay royalties for such product. The Regeneron Agreement is subject to early termination by either party upon uncured material breach by the other party. The licenses to develop and commercialize an ICP to a target that one party has exclusively licensed may be terminated by such party for convenience.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Equity Investments&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. In connection with its collaboration, Regeneron and the Company entered into a side letter pursuant to which, among other matters, Regeneron was granted certain stockholder rights and investment rights in connection with the Company&#x2019;s next equity financing that met certain criteria and in connection with an initial public offering by the Company. Regeneron exercised its investment right and purchased approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million of the Company&#x2019;s Series B redeemable convertible preferred stock in a private placement transaction in July 2019. The remaining obligations under the side letter agreement terminated immediately prior to the Effective Time of the Merger.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Revenue Recognition&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company identified the following material promises under the Regeneron Agreement: (1) a research license, (2) a collaboration invention license, (3) a trademark license, (4) research and development services during the research term, (5) manufacturing services to manufacture collaboration ICPs for the research programs, (6) participation in the joint research committee, and (7) information sharing during the research term. The Company considered that the licenses granted under the Regeneron Agreement are not capable of being distinct and are not distinct from the research and development and manufacturing services within the context of the Regeneron Agreement, because 1) such licenses are for the research and development effort during the research term, unless Regeneron exercises its option under the Regeneron Agreement, 2) the research and development services significantly increase the utility of such licenses, and 3) research and development services require collaboration ICPs being manufactured. Specifically, the Company&#x2019;s granted licenses can only provide benefit to Regeneron in combination with the Company&#x2019;s research and development and manufacturing services to discover the collaboration ICPs. Similarly, the participation in the joint research committee and information sharing are not capable of being distinct and are not distinct from&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;the research and development and manufacturing services within the context of the agreement, because the participation in the joint research committee is for monitoring and governing of the research and development efforts and the information sharing is for sharing results of such research and development efforts. Therefore, all of the promises above are combined into a single performance obligation.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company also evaluated whether the option provided to Regeneron represents a material right that would require separate deferral and recognition. The option exercise will provide Regeneron with a development and commercial license to develop and commercialize the optioned collaboration ICPs. The Company concluded that the $25.0 million upfront payment to the Company was not negotiated to provide incremental discount for the future option fees payable upon Regeneron&#x2019;s exercise of the option.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Regeneron could decide not to exercise the option at its own discretion. The exercise of the option by Regeneron is not certain and is dependent on many factors, such as progress made on the specific option-eligible collaboration ICP, Regeneron&#x2019;s overall assessment of commercial feasibility of the further research, development and commercialization of the Option products, availability and cost of alternative programs and products. The option provides Regeneron with a license for intellectual property that will be improved from the inception of the Regeneron Agreement. In addition, the option fee is significant compared to the sum total of the upfront payment and research funding fees in the original Regeneron Agreement. Therefore, the Company determined that the option provided to Regeneron does not represent a material right and that any potential exercise of the option should be accounted as a separate contract. Hence, upon the option exercise by Regeneron the option fee would be allocated to the development and commercial license which would be the only performance obligation in that separate contract and recognized as revenue when control of the license rights is transferred to Regeneron.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;For revenue recognition purposes, the Company determined that the duration of the contract is the same as the research term of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;five years&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; beginning on the execution of the Regeneron Agreement on July 29, 2016. The contract duration is defined as the period during which parties to the contract have present and enforceable rights and obligations. For revenue recognition purposes, the five-year term has been extended to the first quarter of 2022 due to additional time required to complete the performance obligation under the Regeneron Agreement. The Company determined that Regeneron faces significant in-substance penalties were it to terminate the Regeneron Agreement prior to the end of the research term.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;At contract inception, the Company determined the transaction price of the Regeneron Agreement to be $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;55.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, consisting of the $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;25.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million upfront payment and the aggregate research funding fees of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;30.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million payable over the research term. In order to determine the transaction price, the Company evaluated all the payments to be received during the duration of the contract. Per the terms of the original Regeneron Agreement prior to the amendment effective from July 2019, the research funding fees of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;30.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million were payable merely due to the passage of time and therefore did not represent a variable consideration. After the amendment became effective in July 2019, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;20.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million of these fees became contingent upon meeting certain development and regulatory milestones. Therefore, the Company concluded that after the amendment such potential payments became variable consideration. The receipt of the variable consideration was subject to substantial uncertainty and was therefore excluded from the transaction price upon the effective date of the amendment. Accordingly, the transaction price was reduced to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;35.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in July 2019. The Company re-evaluates the transaction price if there is a significant change in facts and circumstances at least at the end of each reporting period. The Company increased the transaction price by $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in June 2020 to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;45.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million when it achieved the milestone for the selection of a clinical candidate to the second collaboration target under the Regeneron Agreement, resulting in the recognition of an additional $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in revenue during the three months ended June 30, 2020.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company also considered the existence of any significant financing component within the Regeneron Agreement given its upfront payment structure. Based upon this assessment, the Company concluded that the up-front payment was provided for valid business reasons and not for the purpose of providing financing. The reason for the initial advance payment at the beginning of the contract is not to provide financing to the Company, but to ensure Regeneron&#x2019;s commitment to the contract and to provide assurance that the customer will perform its obligations under the contract. Accordingly, the Company has concluded that the upfront payment structure of the Regeneron Agreement does not result in the existence of a significant financing component.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The royalty payments will be recognized when the related sales occur as they were determined to relate predominantly to the intellectual property licenses granted to Regeneron and therefore have also been excluded from the transaction price.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company has determined that the combined performance obligation is satisfied over time. ASC 606 requires the Company to select a single revenue recognition method for the performance obligation that depicts the Company&#x2019;s performance in transferring control of the services. Accordingly, the Company utilizes a cost-based input method to measure proportional performance and to calculate the corresponding amount of revenue to recognize. The Company believes this is the best measure of progress because it reflects how the Company transfers its performance obligation to Regeneron. In applying the cost-based input method of revenue recognition, the Company uses actual costs incurred relative to budgeted costs to fulfill the combined performance obligation. These costs consist primarily of internal full-time equivalent effort and third-party contract costs. Revenue is recognized based on actual costs incurred as a percentage of total budgeted costs as the Company completes its&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;performance obligations over the research term of five years. A cost-based input method of revenue recognition requires management to make estimates of costs to complete the Company&#x2019;s performance obligations. In making such estimates, significant judgment is required to evaluate assumptions related to cost estimates. The cumulative effect of revisions to estimated costs to complete the Company&#x2019;s performance obligations will be recorded in the period in which changes are identified and amounts can be reasonably estimated. A significant change in these assumptions and estimates could have a material impact on the timing and amount of revenue recognized in future periods.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table presents changes in the Company&#x2019;s contract liabilities (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:47.822%;"/&gt;
        &lt;td style="width:1.089%;"/&gt;
        &lt;td style="width:1.492%;"/&gt;
        &lt;td style="width:9.475%;"/&gt;
        &lt;td style="width:0.882%;"/&gt;
        &lt;td style="width:1.089%;"/&gt;
        &lt;td style="width:1.492%;"/&gt;
        &lt;td style="width:9.464%;"/&gt;
        &lt;td style="width:0.882%;"/&gt;
        &lt;td style="width:1.089%;"/&gt;
        &lt;td style="width:1.525%;"/&gt;
        &lt;td style="width:9.802%;"/&gt;
        &lt;td style="width:0.991%;"/&gt;
        &lt;td style="width:1.089%;"/&gt;
        &lt;td style="width:1.492%;"/&gt;
        &lt;td style="width:9.431%;"/&gt;
        &lt;td style="width:0.893%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year ended December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Balance at beginning &lt;br/&gt;of period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Additions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Additions (Deductions) &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;font-family:Times New Roman;position:relative;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Balance at&lt;br/&gt;end of &lt;br/&gt;period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Contract liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;13,980&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9,175&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,805&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;    &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year ended December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Balance at beginning &lt;br/&gt;of period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Additions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Additions (Deductions) &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;font-family:Times New Roman;position:relative;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Balance at&lt;br/&gt;end of &lt;br/&gt;period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Contract asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Contract liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;21,883&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;17,903&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;13,980&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:6.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;(1)	Deductions to contract liabilities relate to deferred revenue recognized as revenue during the reporting period.&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2021, contract liabilities related to the Regeneron Agreement of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million was comprised of the $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;25.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million upfront payment, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in total research funding fees for fiscal years 2017 and 2018, and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million for achievement of the milestone for the selection of a clinical candidate for the second collaboration target in June 2020, less $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;40.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million of cumulative license and collaboration revenue recognized from the inception of the Regeneron Agreement as of December 31, 2021 and will be recognized as the combined performance obligation is satisfied.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2020, contract liabilities related to the Regeneron Agreement of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;14.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million was comprised of the $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;25.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million upfront payment, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in total research funding fees for fiscal years 2017 and 2018, and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million for achievement of the milestone for the selection of a clinical candidate to the second collaboration target in June 2020, less $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;31.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million of cumulative license and collaboration revenue recognized from the inception of the Regeneron Agreement as of December 31, 2020.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;For the years ended December 31, 2021 and 2020, the Company recognized $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;17.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million of license and collaboration revenue, respectively, from amounts included in the contract liability balances at the beginning of the period. There were no costs to obtain or fulfill the contract that meet the criteria to be capitalized.&lt;/span&gt;&lt;/p&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="C_4e6c9fea-07ee-4070-8aba-8ca1ddff8ad6"
      decimals="-5"
      id="F_19b8c498-e7cf-43b0-869e-12b7ace84dfa"
      unitRef="U_USD">20000000.0</us-gaap:ProceedsFromStockOptionsExercised>
    <acet:NonRefundableUpfrontPaymentReceived
      contextRef="C_ae89cac7-0fec-4757-8ed0-2429d1ad7ac5"
      decimals="-5"
      id="F_2cfff9f2-2f5e-478e-9b49-3068847d5804"
      unitRef="U_USD">25000000.0</acet:NonRefundableUpfrontPaymentReceived>
    <acet:LicenseAgreementAdditionalPaymentForResearchFundingReceived
      contextRef="C_ae89cac7-0fec-4757-8ed0-2429d1ad7ac5"
      decimals="-5"
      id="F_dde2a3fa-b854-4e12-b3a3-812ffdf31294"
      unitRef="U_USD">20000000.0</acet:LicenseAgreementAdditionalPaymentForResearchFundingReceived>
    <acet:LicenceAgreementAdditionalAmountPayableOfOptionExerciseFees
      contextRef="C_bc8e068c-61df-4e55-851e-10fa3cd91cf7"
      decimals="-5"
      id="F_e68f840e-cee4-4fce-8edb-8fd5b1503ecb"
      unitRef="U_USD">80000000.0</acet:LicenceAgreementAdditionalAmountPayableOfOptionExerciseFees>
    <acet:LicenseAgreementTerminationDescription
      contextRef="C_d85d1bbc-33b7-4189-abac-0387bd90ab52"
      id="F_8a8cf18a-1bcb-4809-a8a8-1999eb6cb0d4">twelve (12) years</acet:LicenseAgreementTerminationDescription>
    <acet:ExercisedInvestmentRightAndPurchased
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="-5"
      id="F_46e9de16-64e8-46c9-bc5b-8de792734606"
      unitRef="U_USD">10000000.0</acet:ExercisedInvestmentRightAndPurchased>
    <acet:ContractResearchTermPeriod
      contextRef="C_7d366b41-4178-4cf0-85c2-805e8d8b6c0a"
      id="F_aba04bce-dc29-4d22-926b-5f96946dea2a">P5Y</acet:ContractResearchTermPeriod>
    <acet:AgreementTransactionPrice
      contextRef="C_7d366b41-4178-4cf0-85c2-805e8d8b6c0a"
      decimals="-5"
      id="F_180adde0-f7cb-413c-87d8-ffb93e084ca7"
      unitRef="U_USD">55000000.0</acet:AgreementTransactionPrice>
    <acet:LicenceAgreementUpfrontPayment
      contextRef="C_7d366b41-4178-4cf0-85c2-805e8d8b6c0a"
      decimals="-5"
      id="F_142dfea5-f8b1-4b34-aac8-87ec5acc8d6d"
      unitRef="U_USD">25000000.0</acet:LicenceAgreementUpfrontPayment>
    <acet:LicenseAgreementAdditionalPaymentForResearchFundingReceived
      contextRef="C_7d366b41-4178-4cf0-85c2-805e8d8b6c0a"
      decimals="-5"
      id="F_c264b4ea-f21a-4efe-b04b-4bff4a688c6f"
      unitRef="U_USD">30000000.0</acet:LicenseAgreementAdditionalPaymentForResearchFundingReceived>
    <acet:ResearchFundingFee
      contextRef="C_7d366b41-4178-4cf0-85c2-805e8d8b6c0a"
      decimals="-5"
      id="F_d86d87c2-d85d-47bf-bfad-abbe1824c1bc"
      unitRef="U_USD">30000000.0</acet:ResearchFundingFee>
    <acet:ContingentConsiderationFees
      contextRef="C_7d366b41-4178-4cf0-85c2-805e8d8b6c0a"
      decimals="-5"
      id="F_d93d306c-f34a-4a86-a5bd-9ddc8d08e644"
      unitRef="U_USD">20000000.0</acet:ContingentConsiderationFees>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
      contextRef="C_edd4abe0-f9c0-4ed5-ad3b-408b1b6e6b9e"
      decimals="-5"
      id="F_18c900d4-c08a-47e1-a0ed-9485bb3d1cca"
      unitRef="U_USD">35000000.0</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
      contextRef="C_b758350f-0170-4fae-8ec9-d587850903ab"
      decimals="-5"
      id="F_701ac29a-be2e-41a3-8a88-39f89536f66d"
      unitRef="U_USD">10000000.0</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice>
    <us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice
      contextRef="C_8968c75b-77f9-4e93-84f0-e12dc0959c9f"
      decimals="-2"
      id="F_817c4c91-bd3e-4873-9a77-b919d3aba515"
      unitRef="U_USD">45000.0</us-gaap:ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice>
    <acet:LicenceAgreementAdditionalRevenueRecognised
      contextRef="C_b758350f-0170-4fae-8ec9-d587850903ab"
      decimals="-5"
      id="F_4754997f-ea18-48d3-886a-e3447fff6d96"
      unitRef="U_USD">5000000.0</acet:LicenceAgreementAdditionalRevenueRecognised>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_6fe7e88c-d271-4e8a-ad84-a78688c8b09c">&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table presents changes in the Company&#x2019;s contract liabilities (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:47.822%;"/&gt;
        &lt;td style="width:1.089%;"/&gt;
        &lt;td style="width:1.492%;"/&gt;
        &lt;td style="width:9.475%;"/&gt;
        &lt;td style="width:0.882%;"/&gt;
        &lt;td style="width:1.089%;"/&gt;
        &lt;td style="width:1.492%;"/&gt;
        &lt;td style="width:9.464%;"/&gt;
        &lt;td style="width:0.882%;"/&gt;
        &lt;td style="width:1.089%;"/&gt;
        &lt;td style="width:1.525%;"/&gt;
        &lt;td style="width:9.802%;"/&gt;
        &lt;td style="width:0.991%;"/&gt;
        &lt;td style="width:1.089%;"/&gt;
        &lt;td style="width:1.492%;"/&gt;
        &lt;td style="width:9.431%;"/&gt;
        &lt;td style="width:0.893%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year ended December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Balance at beginning &lt;br/&gt;of period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Additions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Additions (Deductions) &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;font-family:Times New Roman;position:relative;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Balance at&lt;br/&gt;end of &lt;br/&gt;period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Contract liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;13,980&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9,175&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,805&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;    &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year ended December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Balance at beginning &lt;br/&gt;of period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Additions&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Additions (Deductions) &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);top:-3.752pt;white-space:pre-wrap;font-weight:bold;font-size:5.36pt;font-family:Times New Roman;position:relative;"&gt;(1)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Balance at&lt;br/&gt;end of &lt;br/&gt;period&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Contract asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Contract liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;21,883&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,000&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;17,903&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;13,980&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:6.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;(1)	Deductions to contract liabilities relate to deferred revenue recognized as revenue during the reporting period.&lt;/span&gt;&lt;/p&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <acet:ContractAssetsAndLiabilities
      contextRef="C_1fdee497-9bd9-4434-b8dd-50a2c01519cd"
      decimals="-3"
      id="F_29d238c3-7114-44e9-ba1b-fb1de9962295"
      unitRef="U_USD">13980000</acet:ContractAssetsAndLiabilities>
    <acet:ContractAssetsAndLiabilitiesAdditionsDeductions
      contextRef="C_68012e05-ebbc-4f75-b9ec-4a4dfe9d312a"
      decimals="-3"
      id="F_da621f8f-6c57-4c71-8a9a-8583e90b6133"
      unitRef="U_USD">9175000</acet:ContractAssetsAndLiabilitiesAdditionsDeductions>
    <acet:ContractAssetsAndLiabilities
      contextRef="C_de3e4a83-2efd-4bdb-9ed1-e22b3ab57037"
      decimals="-3"
      id="F_7d324ae8-14e2-4dca-be22-c1cf4fe2fe36"
      unitRef="U_USD">4805000</acet:ContractAssetsAndLiabilities>
    <acet:ContractAssetsAndLiabilitiesAdditions
      contextRef="C_3ca7e266-0fdc-4e92-9c8c-d4aea36592ef"
      decimals="-3"
      id="F_0e35c73d-ca28-4050-ab28-7b94075d0ba0"
      unitRef="U_USD">10000000</acet:ContractAssetsAndLiabilitiesAdditions>
    <acet:ContractAssetsAndLiabilitiesAdditionsDeductions
      contextRef="C_3ca7e266-0fdc-4e92-9c8c-d4aea36592ef"
      decimals="-3"
      id="F_37a62b6e-7f72-4455-bb60-c81a41a19eec"
      unitRef="U_USD">10000000</acet:ContractAssetsAndLiabilitiesAdditionsDeductions>
    <acet:ContractAssetsAndLiabilities
      contextRef="C_41ca3bfc-5bca-4c8e-8757-b6a526d155a4"
      decimals="-3"
      id="F_fe2c0d24-a3ad-4b4d-a3be-617ae4b392dc"
      unitRef="U_USD">21883000</acet:ContractAssetsAndLiabilities>
    <acet:ContractAssetsAndLiabilitiesAdditions
      contextRef="C_eae66964-012d-43ad-a3b1-27bc081b6037"
      decimals="-3"
      id="F_73971250-35cf-4da0-95f3-a2bdeace9412"
      unitRef="U_USD">10000000</acet:ContractAssetsAndLiabilitiesAdditions>
    <acet:ContractAssetsAndLiabilitiesAdditionsDeductions
      contextRef="C_eae66964-012d-43ad-a3b1-27bc081b6037"
      decimals="-3"
      id="F_c8d12e80-3ad7-488e-a4d6-720e653a110e"
      unitRef="U_USD">17903000</acet:ContractAssetsAndLiabilitiesAdditionsDeductions>
    <acet:ContractAssetsAndLiabilities
      contextRef="C_1fdee497-9bd9-4434-b8dd-50a2c01519cd"
      decimals="-3"
      id="F_c80a115f-5c99-43aa-81e5-faef3fa3df6f"
      unitRef="U_USD">13980000</acet:ContractAssetsAndLiabilities>
    <acet:ContractLiability
      contextRef="C_d85d1bbc-33b7-4189-abac-0387bd90ab52"
      decimals="-5"
      id="F_109d3cb5-c1c2-44b1-a852-a63cbea69279"
      unitRef="U_USD">4800000</acet:ContractLiability>
    <acet:LicenceAgreementUpfrontPayment
      contextRef="C_d85d1bbc-33b7-4189-abac-0387bd90ab52"
      decimals="-5"
      id="F_9fe87a2f-08fd-4188-9626-a6261b523b2c"
      unitRef="U_USD">25000000.0</acet:LicenceAgreementUpfrontPayment>
    <acet:LicenseAgreementAdditionalPaymentForResearchFundingReceived
      contextRef="C_ead71044-8531-48be-a61d-d7cd5c9f9352"
      decimals="-5"
      id="F_dcd29d9d-b81a-4864-841b-4c4cc39f5ba2"
      unitRef="U_USD">10000000.0</acet:LicenseAgreementAdditionalPaymentForResearchFundingReceived>
    <acet:LicenseAgreementAdditionalPaymentForResearchFundingReceived
      contextRef="C_6bc5ff1d-cdce-445a-9774-b450949c38dc"
      decimals="-5"
      id="F_bf5bddf5-de1e-49e9-a496-f78b676a1ecb"
      unitRef="U_USD">10000000.0</acet:LicenseAgreementAdditionalPaymentForResearchFundingReceived>
    <acet:LicenceAgreementCumulativeRevenueRecognised
      contextRef="C_29c03a6c-7260-483a-ab00-555f1e331404"
      decimals="-5"
      id="F_34dd2e68-c012-487e-ba04-b848ce935b2b"
      unitRef="U_USD">10000000.0</acet:LicenceAgreementCumulativeRevenueRecognised>
    <acet:LicenceAgreementCumulativeRevenueRecognised
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="-5"
      id="F_b237f562-3889-4999-b2b4-f87397eb216a"
      unitRef="U_USD">40200000</acet:LicenceAgreementCumulativeRevenueRecognised>
    <acet:ContractLiability
      contextRef="C_a9b28221-7291-479e-aade-1c4cce9e9ee2"
      decimals="-5"
      id="F_a3b7101e-7edb-445c-8681-cf882a62a06e"
      unitRef="U_USD">14000000.0</acet:ContractLiability>
    <acet:LicenceAgreementUpfrontPayment
      contextRef="C_a9b28221-7291-479e-aade-1c4cce9e9ee2"
      decimals="-5"
      id="F_fba2cd8a-2a84-4b2e-a4ef-69db4e9f464a"
      unitRef="U_USD">25000000.0</acet:LicenceAgreementUpfrontPayment>
    <acet:LicenseAgreementAdditionalPaymentForResearchFundingReceived
      contextRef="C_ead71044-8531-48be-a61d-d7cd5c9f9352"
      decimals="-5"
      id="F_a547e9c7-478b-4ddc-9506-19c677f57d56"
      unitRef="U_USD">10000000.0</acet:LicenseAgreementAdditionalPaymentForResearchFundingReceived>
    <acet:LicenseAgreementAdditionalPaymentForResearchFundingReceived
      contextRef="C_6bc5ff1d-cdce-445a-9774-b450949c38dc"
      decimals="-5"
      id="F_8c7b69d8-eda9-480d-af1e-d5196b4ea220"
      unitRef="U_USD">10000000.0</acet:LicenseAgreementAdditionalPaymentForResearchFundingReceived>
    <acet:LicenceAgreementCumulativeRevenueRecognised
      contextRef="C_29c03a6c-7260-483a-ab00-555f1e331404"
      decimals="-6"
      id="F_30a96b43-3b86-43f9-b27c-1aea724f6ebe"
      unitRef="U_USD">10000000</acet:LicenceAgreementCumulativeRevenueRecognised>
    <acet:LicenceAgreementCumulativeRevenueRecognised
      contextRef="C_3f1fec59-9c84-4fb5-b910-7eb14b6ef44f"
      decimals="-5"
      id="F_7bcb20a0-53e0-44d7-97a6-97cbfd502d4b"
      unitRef="U_USD">31000000.0</acet:LicenceAgreementCumulativeRevenueRecognised>
    <acet:LicenseAndCollaborationRevenue
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="-5"
      id="F_0c7b949d-6a62-4b14-9fe4-ac2e04bc8051"
      unitRef="U_USD">9200000</acet:LicenseAndCollaborationRevenue>
    <acet:LicenseAndCollaborationRevenue
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="-5"
      id="F_e6cb4d59-bee4-4768-9d44-f8aaae2eaffa"
      unitRef="U_USD">17900000</acet:LicenseAndCollaborationRevenue>
    <acet:LicenseFundingAndOtherAgreementsTextBlock
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_e21159c8-4fdb-4eae-98b8-8442ce748c3b">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;11. License, Funding and Other Agreements Related to the CVR&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Contingent Value Rights Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As discussed in Note 3, in connection with the Merger, the Company entered into the CVR Agreement with Computershare Inc. and Computershare Trust Company, N.A. as joint rights agent. The CVR holders are entitled to receive net proceeds from the commercialization, if any, received from a third-party commercial partner of RTB101 for a COVID-19 related indication. The total fees and expenses of the Company&#x2019;s clinical trials for a COVID-19 related indication of RTB101 is limited to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million under the CVR Agreement. Through October 31, 2020, the Company&#x2019;s total accumulated spend was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million of expenses. In November 2020, management terminated the nursing home study due to slow enrollment and as a consequence lowered the probability of finding a partner due to the delay in time to commercialization of RTB101.&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; In February 2021, management terminated the National Institute on Aging study of RTB101 for COVID-19 post-exposure prophylaxis in adults age 65 years and older due to poor enrollment&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. In March 2021, management estimated that the probability of finding a partner should be further reduced. As a result, the fair value of the CVR liability was decreased by $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million. In June 2021, the Company determined the possibility of any commercialization events for RTB101 was close to zero (see Note 3). As a result, the fair value of the CVR liability was adjusted to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;zero&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On October 27, 2021, the Company provided a Termination Notice under the CVR Agreement to the joint rights agent to terminate its obligations under the CVR Agreement, effective immediately.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Novartis License Agreement&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On March 23, 2017, resTORbio entered into an exclusive license agreement with Novartis International Pharmaceutical Ltd. (Novartis). Under the agreement, Novartis granted resTORbio an exclusive, field-restricted, worldwide license, to certain&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;intellectual property rights owned or controlled by Novartis, to develop, commercialize and sell one or more therapeutic products comprising RTB101 or RTB101 in combination with everolimus in a fixed dose combination. The exclusive field under the license agreement is for the treatment, prevention and diagnosis of disease and other conditions in all indications in humans and animals.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The agreement may be terminated by either party upon a material breach of obligation by the other party that is not cured with 60 days after written notice. resTORbio may terminate the agreement in its entirety or on a product-by-product or country-by-country basis with or without cause with 60 days&#x2019; prior written notice.&lt;/span&gt;&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As consideration for the license, resTORbio is required to pay up to an aggregate of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million upon the satisfaction of clinical milestones, up to an aggregate of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;24&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million upon the satisfaction of regulatory milestones for the first indication approved, and up to an aggregate of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;18&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million upon the satisfaction of regulatory milestones for the second indication approved. In addition, resTORbio is required to pay up to an aggregate of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;125&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million upon the satisfaction of commercial milestones, based on the amount of annual net sales. resTORbio is also required to pay tiered royalties ranging from a mid-single digit percentage to a low-teen digit percentage on annual net sales of products. These royalty obligations last on a product-by-product and country-by-country basis until the latest of (i) the expiration of the last valid claim of a Novartis patent covering a subject product, (ii) the expiration of any regulatory exclusivity for the subject product in a country, or (iii) the 10&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;vertical-align:top;font-size:6.7pt;font-family:Times New Roman;"&gt;th&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; anniversary of the first commercial sale in the country, and are subject to a reduction after the expiration of the last valid claim of a Novartis patent or the introduction of a generic equivalent of a product in a country.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On July 27, 2021, the Company sent Novartis a termination notice. Termination automatically took effect on September 25, 2021, 60 days from the date of delivery of the termination notice to Novartis, without further notice of action required of either Novartis or the Company.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;National Institute of Health&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In May 2019, resTORbio was awarded a &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;-year grant for up to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million from the NIH to study RTB101 and the regulation of antiviral immunity in the elderly. resTORbio is entitled to use the award solely to conduct the research and is solely responsible for commencing and conducting the research and will furnish periodic progress updates to the NIH throughout the term of the award. After completing the research, resTORbio must provide the NIH with a formal report describing the work performed and the results of the research.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;For funds received under the NIH funding agreement, resTORbio recognizes a reduction in research and development expenses in an amount equal to the qualifying expenses incurred in each period up to the amount funded by the NIH. Qualifying expenses incurred by resTORbio in advance of funding by the NIH are recorded in the consolidated balance sheets as other current assets. For the year ended December 31, 2021, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million qualifying expenses have been incurred and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million have been funded by the NIH. The difference in the amount incurred by the Company and funded by the NIH was due to timing of requesting reimbursements from the NIH. On a cumulative basis as of December 31, 2021, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million has been incurred and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million has been funded by the NIH.&lt;/span&gt;&lt;/p&gt;</acet:LicenseFundingAndOtherAgreementsTextBlock>
    <acet:FeesAndExpenseIncurredInConnectionWithClinicalTrials
      contextRef="C_316edeb3-e98f-436c-970f-b13de1ce7e93"
      decimals="-5"
      id="F_75a0d90f-d98a-4a73-86b4-5cbf7e1add98"
      unitRef="U_USD">3000000.0</acet:FeesAndExpenseIncurredInConnectionWithClinicalTrials>
    <acet:FeesAndExpenseIncurredInConnectionWithClinicalTrials
      contextRef="C_d9bc8440-92d6-4375-83a6-16f30d5e1156"
      decimals="-5"
      id="F_7a2497b5-c7fe-41b1-a700-97ec7523f656"
      unitRef="U_USD">1100000</acet:FeesAndExpenseIncurredInConnectionWithClinicalTrials>
    <acet:PostExposureProphylaxisDescription
      contextRef="C_baae0ca2-627c-4fcf-80d3-97c07794901d"
      id="F_d94c5ba1-5d99-4915-95a5-d2749ffd97d9"> In February 2021, management terminated the National Institute on Aging study of RTB101 for COVID-19 post-exposure prophylaxis in adults age 65 years and older due to poor enrollment</acet:PostExposureProphylaxisDescription>
    <acet:IncreaseDecreaseInEstimatedFairValueOfCvrLiability
      contextRef="C_4e9b72dd-9a34-4bc0-8d92-21bc3dbb099f"
      decimals="-5"
      id="F_acff99c1-adde-4c71-822c-ddd57fadd1f5"
      unitRef="U_USD">400000</acet:IncreaseDecreaseInEstimatedFairValueOfCvrLiability>
    <acet:EstimatedFairValueOfCVRLiability
      contextRef="C_3606b322-7fbf-4372-8ef9-9fed27772088"
      decimals="-5"
      id="F_e56cd58b-e823-460d-b431-34cb393c10b0"
      unitRef="U_USD">600000</acet:EstimatedFairValueOfCVRLiability>
    <acet:EstimatedFairValueOfCVRLiability
      contextRef="C_ab4803e6-aff5-4742-8d52-34995d4eb9b3"
      decimals="-3"
      id="F_c365daf8-7e57-4167-8e34-2a28f0769c7b"
      unitRef="U_USD">0</acet:EstimatedFairValueOfCVRLiability>
    <acet:LicenseAgreementTerminationDescription
      contextRef="C_9c4e6975-00c5-410c-91ea-8f78158b9eb4"
      id="F_b3e98ac4-7036-4199-9e9f-8860b2266b95">The agreement may be terminated by either party upon a material breach of obligation by the other party that is not cured with 60 days after written notice. resTORbio may terminate the agreement in its entirety or on a product-by-product or country-by-country basis with or without cause with 60 days&#x2019; prior written notice.</acet:LicenseAgreementTerminationDescription>
    <acet:LicenseAgreementMilestonePaymentsUponSatisfactionOfClinicalMilestonesPayable
      contextRef="C_61d717f8-651c-4c2c-bbdf-85e091817288"
      decimals="-5"
      id="F_bdd325f1-a57b-4dd5-a426-f75026b5bed6"
      unitRef="U_USD">4300000</acet:LicenseAgreementMilestonePaymentsUponSatisfactionOfClinicalMilestonesPayable>
    <acet:LicenseAgreementMilestonePaymentsUponSatisfactionOfRegulatoryMilestonesPayableForFirstIndicationApproved
      contextRef="C_61d717f8-651c-4c2c-bbdf-85e091817288"
      decimals="-6"
      id="F_43007918-e776-4e28-85f3-392f274fa501"
      unitRef="U_USD">24000000</acet:LicenseAgreementMilestonePaymentsUponSatisfactionOfRegulatoryMilestonesPayableForFirstIndicationApproved>
    <acet:LicenseAgreementMilestonePaymentsUponSatisfactionOfRegulatoryMilestonesPayableForSecondIndicationApproved
      contextRef="C_61d717f8-651c-4c2c-bbdf-85e091817288"
      decimals="-6"
      id="F_241b1afe-42a0-4e85-9213-4564460a9542"
      unitRef="U_USD">18000000</acet:LicenseAgreementMilestonePaymentsUponSatisfactionOfRegulatoryMilestonesPayableForSecondIndicationApproved>
    <acet:LicenseAgreementMilestonePaymentsUponSatisfactionOfCommercialMilestonesPayable
      contextRef="C_61d717f8-651c-4c2c-bbdf-85e091817288"
      decimals="-6"
      id="F_f7beff7f-3405-413f-814e-3480c80be908"
      unitRef="U_USD">125000000</acet:LicenseAgreementMilestonePaymentsUponSatisfactionOfCommercialMilestonesPayable>
    <acet:GrantTerm
      contextRef="C_f2283cea-c435-437b-958f-019a9a629ca9"
      id="F_ce09697e-fc17-4e25-b8fe-362b3cddee1d">P5Y</acet:GrantTerm>
    <us-gaap:GrantsReceivable
      contextRef="C_c1e72a0b-a7f8-4f4b-bd56-9c13a9000d2b"
      decimals="-5"
      id="F_4beed18f-8934-46f1-84d7-f7981a73ea20"
      unitRef="U_USD">1500000</us-gaap:GrantsReceivable>
    <acet:QualifyingExpenses
      contextRef="C_ca657af2-2ffc-4ae2-b3b7-1641af2126e2"
      decimals="-5"
      id="F_e2c52228-2f4e-4187-9c8d-facf6e38c620"
      unitRef="U_USD">400000</acet:QualifyingExpenses>
    <acet:QualifyingExpenses
      contextRef="C_634bf63d-c1b7-40ac-bfb2-44d198c085ab"
      decimals="-5"
      id="F_ec9ba0a6-6c25-432f-a388-7ba3fdd7f95f"
      unitRef="U_USD">500000</acet:QualifyingExpenses>
    <acet:QualifyingExpensesOnCumulativeBasis
      contextRef="C_ca657af2-2ffc-4ae2-b3b7-1641af2126e2"
      decimals="-5"
      id="F_f55c8dd0-ba99-4014-9fea-01e2814c74c6"
      unitRef="U_USD">1300000</acet:QualifyingExpensesOnCumulativeBasis>
    <acet:QualifyingExpensesOnCumulativeBasis
      contextRef="C_634bf63d-c1b7-40ac-bfb2-44d198c085ab"
      decimals="-5"
      id="F_10df9f85-a281-4fb3-8112-8dec96d14400"
      unitRef="U_USD">1300000</acet:QualifyingExpensesOnCumulativeBasis>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_c4f024b9-3967-4030-8a3f-c1f6bb02e210">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;12. Commitments and Contingencies&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Operating Leases&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company leases office and laboratory space in Menlo Park, CA, Redwood City, CA, and Boston, MA. As of December 31, 2021, except as described below, there have been &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; material changes in lease obligation from those disclosed in Note 12 to consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2020.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On June 25, 2021, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;the Company entered into an amendment to the Menlo Park lease to extend the term of the lease from March 31, 2022 to June 30, 2022 and replace the previously leased premises (known as 173 and 175-177 Jefferson Drive) with another nearby premises (known as 235 Constitution Drive).&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; The lease commenced on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;July 15, 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; and expires on &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;June 30, 2022&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. In connection with these changes, the Company will incur monthly rent payments ranging from $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;87,286&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; to $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;89,904&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;, increasing over the remaining term of the lease. Given the lease is short-term in nature, the Company is using the practical expedient for the lease and has not recorded a right of use asset or lease liability. Therefore, the Company will recognize rent expense on a straight-line basis over the lease term.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On July 19, 2021, the Company entered into a Sublease (the Sublease Agreement) with RFS OPCO LLC (Sublessee), whereby the Company agreed to sublease to Sublessee all of the &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9,501&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; rentable square feet of office space in Boston, MA, currently leased by the Company pursuant to the Company&#x2019;s lease with 500 Boylston &amp;amp; 222 Berkeley Owner (DE) LLC, dated January 8, 2018, as amended (the Master Lease). &lt;/span&gt;&lt;span style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;term of the sublease started on September 1, 2021 and ends on July 30, &lt;/span&gt;&lt;/span&gt;&lt;span style=""/&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2026. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The aggregate base rent due to the Company under the Sublease is approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million starting October 1, 2021. The Company records sublease income as a reduction of lease expense. &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Upon execution of the Sublease Agreement, the Company received a cash security deposit of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million from the Subleasee which is recorded as other non-current liabilities in the consolidated balance sheets. &lt;/span&gt;&lt;span style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The expected undiscounted cash flows to be received from the sublease as of December 31, 2021 is as follows (in thousands):&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:74.179%;"/&gt;
        &lt;td style="width:2.254%;"/&gt;
        &lt;td style="width:1.284%;"/&gt;
        &lt;td style="width:21.646%;"/&gt;
        &lt;td style="width:0.637%;"/&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;657&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;671&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;685&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;699&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;416&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,128&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company recognized rent expense, net of sublease income, of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million for the years ended December 31, 2021 and 2020, respectively.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;  &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The IBR and the remaining lease terms of our facilities and their weighted average IBR and remaining terms are as follows as of December 31, 2021:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:40.659%;"/&gt;
        &lt;td style="width:2.429%;"/&gt;
        &lt;td style="width:27.242%;"/&gt;
        &lt;td style="width:2.429%;"/&gt;
        &lt;td style="width:27.242%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Lease Locations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;IBR&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Remaining Terms&lt;br/&gt;(in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Redwood City, CA&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.90&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8.2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Boston, MA&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9.30&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4.6&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Menlo Park, CA&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.80&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Weighted Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.20&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.7&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:11.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table contains a summary of the lease costs recognized under ASC 842 and other information pertaining to the Company&#x2019;s operating leases for the years ended December 31, 2021 and 2020:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.395%;"/&gt;
        &lt;td style="width:2.168%;"/&gt;
        &lt;td style="width:1.503%;"/&gt;
        &lt;td style="width:21.795%;"/&gt;
        &lt;td style="width:0.991%;"/&gt;
        &lt;td style="width:1.503%;"/&gt;
        &lt;td style="width:21.958%;"/&gt;
        &lt;td style="width:0.686%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="5" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Lease Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,282&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;894&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Short-term lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;235&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;56&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Variable lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Sublease Income&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;223&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_a0789779-e166-43dd-bd77-089b6487a8c3;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,294&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;950&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Other Information&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating cash flows used for lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;511&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;859&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating lease right of use asset obtained in exchange of operating lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_819eaa0a-0a31-4f5b-b68e-5e64ffc6ff53;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;22,367&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2021, operating right-of-use assets were $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;20.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and operating lease liabilities were $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;20.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million. The Company has no material finance leases.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The maturities of the operating lease liabilities as of December 31, 2021 were as follows (in thousands):&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.062%;"/&gt;
        &lt;td style="width:1.774%;"/&gt;
        &lt;td style="width:1.277%;"/&gt;
        &lt;td style="width:16.252%;"/&gt;
        &lt;td style="width:0.634%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,933&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,428&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,525&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,625&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2026 and thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;13,747&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;27,258&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Less: imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,314&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total operating lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;20,944&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Less: current portion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,567&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating lease liability, net of current maturities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;19,377&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:2.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:2.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company maintains letters of credit of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in connection with the Company&#x2019;s office leases in Redwood City, CA, Menlo Park, CA, and  Boston, MA, respectively. As of December 31, 2021, the cash amount associated with the Menlo Park Lease is recorded as restricted cash on the consolidated balance sheet. As of December 31, 2020, all cash amounts are recorded as restricted cash on the consolidated balance sheet.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Indemnification Agreements&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In the ordinary course of business, the Company enters into agreements that may include indemnification provisions. Pursuant to such agreements, the Company may indemnify, hold harmless and defend an indemnified party for losses suffered or incurred by the indemnified party. Some of the provisions will limit losses to those arising from third-party actions. In some cases, the indemnification will continue after the termination of the agreement. The maximum potential amount of future payments the Company could be required to make under these provisions is not determinable. The Company has never incurred material costs to defend lawsuits or settle claims related to these indemnification provisions. The Company has also entered into indemnification agreements with its directors and officers that require the Company, among other things, to indemnify them against certain liabilities that may arise by reason of their status or service as directors or officers to the fullest extent permitted by Delaware corporate law. The Company currently has directors&#x2019; and officers&#x2019; liability insurance.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Legal Proceedings&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In connection with the Merger, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;seven&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; lawsuits were filed against the Company, its directors, Former Adicet, and/or Merger Sub. which were either dismissed or settled for of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in the fourth quarter of 2020.&lt;/span&gt;&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <acet:IncreaseDecreaseInLeaseObligation
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="INF"
      id="F_310b480d-3345-4c28-a25a-df579df8572f"
      unitRef="U_USD">0</acet:IncreaseDecreaseInLeaseObligation>
    <acet:AmendedLeaseAgreementDescription
      contextRef="C_fc8377ae-c923-40ee-9f57-b8fa6cd9e90b"
      id="F_d0de40a7-c57c-4a87-93f2-26bee2476d80">the Company entered into an amendment to the Menlo Park lease to extend the term of the lease from March 31, 2022 to June 30, 2022 and replace the previously leased premises (known as 173 and 175-177 Jefferson Drive) with another nearby premises (known as 235 Constitution Drive).</acet:AmendedLeaseAgreementDescription>
    <acet:OperatingLeasesCommencementDate
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_72df2bc1-ac90-42a7-84c6-ab5c0ba8d2cf">2021-07-15</acet:OperatingLeasesCommencementDate>
    <us-gaap:LeaseExpirationDate1
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_02744409-0fc4-49b3-96f3-1b958020d232">2022-06-30</us-gaap:LeaseExpirationDate1>
    <us-gaap:LeaseAndRentalExpense
      contextRef="C_c10c6884-14c3-4600-ae9f-b3a86ebd71ef"
      decimals="-3"
      id="F_da7fe626-d78c-48b8-ab94-5528a14dcee5"
      unitRef="U_USD">87286000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense
      contextRef="C_ce377847-1500-4676-9ec9-6e92cf9c03dd"
      decimals="-3"
      id="F_0c2b255f-7c87-487f-8970-3016a6c4eb39"
      unitRef="U_USD">89904000</us-gaap:LeaseAndRentalExpense>
    <acet:AreaOfSublease
      contextRef="C_d3f0bab3-8542-4755-967f-e529938079a8"
      decimals="INF"
      id="F_9f76942e-4b84-46cf-bf5d-c36a930775ff"
      unitRef="U_sqft">9501</acet:AreaOfSublease>
    <acet:SubleaseAgreementDescription
      contextRef="C_23d1c211-5416-49b1-b67a-b83adbf5b18b"
      id="F_d576b5a4-cf6b-42b1-b4dd-4b3bb81a160f">The term of the sublease started on September 1, 2021 and ends on July 30, 2026. The aggregate base rent due to the Company under the Sublease is approximately $3.5 million starting October 1, 2021. The Company records sublease income as a reduction of lease expense. </acet:SubleaseAgreementDescription>
    <us-gaap:OperatingLeasesRentExpenseSubleaseRentals1
      contextRef="C_23d1c211-5416-49b1-b67a-b83adbf5b18b"
      decimals="-5"
      id="F_1592afb6-fe61-4f05-9951-42189534de67"
      unitRef="U_USD">3500000</us-gaap:OperatingLeasesRentExpenseSubleaseRentals1>
    <us-gaap:SecurityDepositLiability
      contextRef="C_d3f0bab3-8542-4755-967f-e529938079a8"
      decimals="-5"
      id="F_c6774db9-1af1-42bf-9447-aa830c7412ce"
      unitRef="U_USD">100000</us-gaap:SecurityDepositLiability>
    <acet:ScheduleOfSubleaseIncomeTableTextBlock
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_f6453709-3551-453a-91fb-d64ecf8a23f1">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The expected undiscounted cash flows to be received from the sublease as of December 31, 2021 is as follows (in thousands):&lt;/span&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:74.179%;"/&gt;
        &lt;td style="width:2.254%;"/&gt;
        &lt;td style="width:1.284%;"/&gt;
        &lt;td style="width:21.646%;"/&gt;
        &lt;td style="width:0.637%;"/&gt;
       &lt;/tr&gt;
       &lt;tr&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;657&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;671&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;685&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;699&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2026&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;416&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,128&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</acet:ScheduleOfSubleaseIncomeTableTextBlock>
    <acet:OperatingLeasesFutureMinimumSubleaseIncomeDueCurrent
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-3"
      id="F_4ba6a085-9dd8-4d30-86a9-c35dc39b6147"
      unitRef="U_USD">657000</acet:OperatingLeasesFutureMinimumSubleaseIncomeDueCurrent>
    <acet:OperatingLeasesFutureMinimumSubleaseIncomeDueInTwoYears
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-3"
      id="F_0233bd78-b371-40d9-9175-0ddb5eef3b6d"
      unitRef="U_USD">671000</acet:OperatingLeasesFutureMinimumSubleaseIncomeDueInTwoYears>
    <acet:OperatingLeasesFutureMinimumSubleaseIncomeDueInThreeYears
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-3"
      id="F_ccb3cddd-6c7e-4ae4-a837-1a5644b552d6"
      unitRef="U_USD">685000</acet:OperatingLeasesFutureMinimumSubleaseIncomeDueInThreeYears>
    <acet:OperatingLeasesFutureMinimumSubleaseIncomeDueInFourYears
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-3"
      id="F_c2599745-b094-4404-8317-065f63154c2b"
      unitRef="U_USD">699000</acet:OperatingLeasesFutureMinimumSubleaseIncomeDueInFourYears>
    <acet:OperatingLeasesFutureMinimumSubleaseIncomeDueInFiveYears
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-3"
      id="F_e50467d0-00a1-4a17-a2e2-4586820bbe07"
      unitRef="U_USD">416000</acet:OperatingLeasesFutureMinimumSubleaseIncomeDueInFiveYears>
    <acet:OperatingLeasesFutureMinimumSubleaseIncomeDue
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-3"
      id="F_1704a651-42b5-485e-b490-3d4945f2e51d"
      unitRef="U_USD">3128000</acet:OperatingLeasesFutureMinimumSubleaseIncomeDue>
    <us-gaap:OperatingLeasePayments
      contextRef="C_fd2a51f4-a4e0-4fd4-8b72-384f893e07dc"
      decimals="-5"
      id="F_2c2ffb97-910a-4388-9364-d4600b1b18f4"
      unitRef="U_USD">4300000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments
      contextRef="C_788e17f6-1175-45bd-816d-ca6c3191ac61"
      decimals="-5"
      id="F_b14f8e10-ca2a-4f4c-a05d-c840887192b7"
      unitRef="U_USD">900000</us-gaap:OperatingLeasePayments>
    <acet:ScheduleOfWeightedAverageIBRAndRemainingLeaseTermTableTextBlock
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_57b957d2-c610-402e-bf1b-871fb4daf1a8">&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The IBR and the remaining lease terms of our facilities and their weighted average IBR and remaining terms are as follows as of December 31, 2021:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:60.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:40.659%;"/&gt;
        &lt;td style="width:2.429%;"/&gt;
        &lt;td style="width:27.242%;"/&gt;
        &lt;td style="width:2.429%;"/&gt;
        &lt;td style="width:27.242%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Lease Locations&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;IBR&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Remaining Terms&lt;br/&gt;(in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Redwood City, CA&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.90&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;8.2&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Boston, MA&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9.30&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4.6&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Menlo Park, CA&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.80&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.5&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Weighted Average&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.20&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.7&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</acet:ScheduleOfWeightedAverageIBRAndRemainingLeaseTermTableTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_cea994b1-c7e3-4048-aeb0-aab2a8ee080d"
      decimals="4"
      id="F_85a9c467-5a51-4bc3-9b89-476e095daee4"
      unitRef="U_pure">0.0690</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_cea994b1-c7e3-4048-aeb0-aab2a8ee080d"
      id="F_25ceb44b-0ed8-4ea6-a1e4-48e5451bf083">P8Y2M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_e39012be-aa0b-44c4-bc70-f388d0297447"
      decimals="4"
      id="F_f9e8e442-4306-4edd-be8f-2399027af5f9"
      unitRef="U_pure">0.0930</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_e39012be-aa0b-44c4-bc70-f388d0297447"
      id="F_8bee48ff-060c-443a-9323-72898024ff0d">P4Y7M6D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_4a463e61-a719-45b8-b4f2-fb3e5d6433eb"
      decimals="4"
      id="F_75ac86c3-7df3-4fec-afb2-6b27fdc55f4a"
      unitRef="U_pure">0.0680</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_4a463e61-a719-45b8-b4f2-fb3e5d6433eb"
      id="F_b89f66a6-95bc-4906-b432-39bddfe35fd1">P0Y6M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="4"
      id="F_e0576bac-be9f-4c28-8a81-840eb2404c2c"
      unitRef="U_pure">0.0720</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      id="F_a9bfc9e7-96ad-4276-8512-eae756b35f85">P7Y8M12D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_ffb45c7c-e446-488f-90af-48527c4a194f">&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table contains a summary of the lease costs recognized under ASC 842 and other information pertaining to the Company&#x2019;s operating leases for the years ended December 31, 2021 and 2020:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:49.395%;"/&gt;
        &lt;td style="width:2.168%;"/&gt;
        &lt;td style="width:1.503%;"/&gt;
        &lt;td style="width:21.795%;"/&gt;
        &lt;td style="width:0.991%;"/&gt;
        &lt;td style="width:1.503%;"/&gt;
        &lt;td style="width:21.958%;"/&gt;
        &lt;td style="width:0.686%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:11.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:11.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&#160;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="5" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;December 31&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Lease Cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:11.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:11.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(in thousands)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,282&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;894&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Short-term lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;235&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;56&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Variable lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Sublease Income&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;223&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_a0789779-e166-43dd-bd77-089b6487a8c3;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total lease cost&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,294&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;950&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;Other Information&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating cash flows used for lease liabilities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;511&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;859&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating lease right of use asset obtained in exchange of operating lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_819eaa0a-0a31-4f5b-b68e-5e64ffc6ff53;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;22,367&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="-3"
      id="F_fae34b0a-2918-4401-b7b7-7792fb47f98f"
      unitRef="U_USD">4282000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="-3"
      id="F_4d420338-db20-4cda-a801-24678519a2e3"
      unitRef="U_USD">894000</us-gaap:OperatingLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="-3"
      id="F_f6adc545-fb90-4fb0-b178-850a7b13261f"
      unitRef="U_USD">235000</us-gaap:ShortTermLeaseCost>
    <us-gaap:ShortTermLeaseCost
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="-3"
      id="F_96aee900-b9f2-418d-8f17-24067eef11ba"
      unitRef="U_USD">56000</us-gaap:ShortTermLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="-3"
      id="F_a1b011b5-1e2e-4432-b27e-132d3ca7375c"
      unitRef="U_USD">0</us-gaap:VariableLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="-3"
      id="F_15422c2a-7574-4d88-baa0-e318ad6a11f8"
      unitRef="U_USD">0</us-gaap:VariableLeaseCost>
    <us-gaap:SubleaseIncome
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="-3"
      id="F_ba4ae4fe-bd24-4447-9d05-74c95f5fdf72"
      unitRef="U_USD">223000</us-gaap:SubleaseIncome>
    <us-gaap:LeaseCost
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="-3"
      id="F_bb58ae8d-d5c6-49c0-b3ba-e56c6a6ac340"
      unitRef="U_USD">4294000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="-3"
      id="F_b7911849-2064-4683-ba86-7b68850532e1"
      unitRef="U_USD">950000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePaymentsUse
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="-3"
      id="F_f06e02fd-4739-4588-99cb-a2686896bf18"
      unitRef="U_USD">511000</us-gaap:OperatingLeasePaymentsUse>
    <us-gaap:OperatingLeasePaymentsUse
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="-3"
      id="F_9b942133-67a1-4423-b745-bd2edfc39c3e"
      unitRef="U_USD">859000</us-gaap:OperatingLeasePaymentsUse>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="-3"
      id="F_f06281c5-e92a-48ab-9495-ec1f576c66a5"
      unitRef="U_USD">22367000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-5"
      id="F_cba60e86-056f-4403-b911-f890a3636aa4"
      unitRef="U_USD">20400000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-5"
      id="F_573681d3-ecec-4f8c-93d7-e16b301d45f0"
      unitRef="U_USD">20900000</us-gaap:OperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_0c6d83b4-62b1-46ec-a998-2f1323fefd8d">&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The maturities of the operating lease liabilities as of December 31, 2021 were as follows (in thousands):&lt;/span&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:80.062%;"/&gt;
        &lt;td style="width:1.774%;"/&gt;
        &lt;td style="width:1.277%;"/&gt;
        &lt;td style="width:16.252%;"/&gt;
        &lt;td style="width:0.634%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2022&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,933&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2023&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,428&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,525&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2025&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,625&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2026 and thereafter&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;13,747&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;27,258&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Less: imputed interest&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,314&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total operating lease liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;20,944&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Less: current portion&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,567&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating lease liability, net of current maturities&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;19,377&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:2.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-3"
      id="F_a4207cff-22cc-4c82-9c2c-b07bf817f054"
      unitRef="U_USD">2933000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-3"
      id="F_9b628353-ca8f-46f2-887b-1be3394a7db7"
      unitRef="U_USD">3428000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-3"
      id="F_49c7da9c-022f-4421-af26-7a0cd015032a"
      unitRef="U_USD">3525000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-3"
      id="F_43c0d771-32cb-4463-a8c8-e951ba9321b8"
      unitRef="U_USD">3625000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-3"
      id="F_e32ec52e-20c4-4dc5-9619-7963f9fb5250"
      unitRef="U_USD">13747000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-3"
      id="F_3e310cfd-e782-433f-8135-ac8ca6c9f4c7"
      unitRef="U_USD">27258000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-3"
      id="F_81db5667-02fc-49a7-a4fe-fb877f180561"
      unitRef="U_USD">6314000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-3"
      id="F_614f81de-024b-4de3-bf81-da6ece8b203c"
      unitRef="U_USD">20944000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-3"
      id="F_be2d74b0-fa01-484c-bbf6-65e6147bf2df"
      unitRef="U_USD">1567000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-3"
      id="F_a37b42b8-14e5-4a38-be85-906207da6e5f"
      unitRef="U_USD">19377000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="C_cea994b1-c7e3-4048-aeb0-aab2a8ee080d"
      decimals="-5"
      id="F_aaab0699-2f40-4aa8-a28c-1cb871deccf3"
      unitRef="U_USD">4100000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="C_4a463e61-a719-45b8-b4f2-fb3e5d6433eb"
      decimals="-5"
      id="F_a60ef4cf-63a3-4620-8683-c6dea4a166ac"
      unitRef="U_USD">200000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LettersOfCreditOutstandingAmount
      contextRef="C_e39012be-aa0b-44c4-bc70-f388d0297447"
      decimals="-5"
      id="F_b0d8bb15-d480-4694-851e-6609a539a7d2"
      unitRef="U_USD">200000</us-gaap:LettersOfCreditOutstandingAmount>
    <acet:LawsuitsFiledAgainstCompany
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="INF"
      id="F_fd218832-e845-46cd-a84b-f541fa5c90d9"
      unitRef="U_Lawsuit">7</acet:LawsuitsFiledAgainstCompany>
    <us-gaap:LitigationSettlementExpense
      contextRef="C_5e765ceb-b63f-4177-a750-139c07a36c25"
      decimals="-5"
      id="F_b1ec35e2-d4d8-4133-a9a9-6f992ed9abe9"
      unitRef="U_USD">200000</us-gaap:LitigationSettlementExpense>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_8e80afa6-0f81-473f-b7d3-b330c7087f8d">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;13. Stockholders' Equity&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Common Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Common stockholders are entitled to dividends if and when declared by the Board of Directors subject to the prior rights of the preferred stockholders. As of December 31, 2021 and 2020, no dividends on common stock had been declared by the Board of Directors.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In February 2021, the Company completed an underwritten public offering of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10,575,513&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of its common stock at a public offering price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;13.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share. The Company received net proceeds from the offering, after deducting underwriting discounts and commissions and offering expenses of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;128.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In connection with the February 2021 offering, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;the Company also entered into a stock purchase agreement with certain existing investors to purchase &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,153,840&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of our common stock for  $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;15.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million at a price per share equal to the public offering price, with an initial closing for investors held simultaneously with the closing of the offering and a subsequent closing for certain additional investors.&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In December 2021, the Company closed an underwritten public offering, or the December 2021 Follow-On Offering, of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,187,500&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of its common stock at a public offering price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;14.00&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share. The Company received net proceeds from the offering, after deducting underwriting discounts and commissions and offering expenses of approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;94.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company has the following shares of common stock reserved for future issuance:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:63.237%;"/&gt;
        &lt;td style="width:1.656%;"/&gt;
        &lt;td style="width:0.637%;"/&gt;
        &lt;td style="width:15.452%;"/&gt;
        &lt;td style="width:0.637%;"/&gt;
        &lt;td style="width:1.656%;"/&gt;
        &lt;td style="width:0.637%;"/&gt;
        &lt;td style="width:15.452%;"/&gt;
        &lt;td style="width:0.637%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Stock options available for future grant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,961,338&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,739,621&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Stock options issued and outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,875,317&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,706,945&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Unvested restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;771,660&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Common stock warrants issued and outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;220,890&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;226,191&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total common stock reserved&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,829,205&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,672,757&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Warrants to Purchase Shares of Common Stock&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In February 2021, PacWest exercised 5,301 warrants, which resulted in the net issuance was 1,806 shares of common stock.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following provides a roll forward of outstanding warrants:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:53.616%;"/&gt;
        &lt;td style="width:1.588%;"/&gt;
        &lt;td style="width:0.578%;"/&gt;
        &lt;td style="width:12.525%;"/&gt;
        &lt;td style="width:0.764%;"/&gt;
        &lt;td style="width:1.588%;"/&gt;
        &lt;td style="width:1.147%;"/&gt;
        &lt;td style="width:12.191%;"/&gt;
        &lt;td style="width:0.568%;"/&gt;
        &lt;td style="width:1.588%;"/&gt;
        &lt;td style="width:0.578%;"/&gt;
        &lt;td style="width:12.701%;"/&gt;
        &lt;td style="width:0.568%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Number of &lt;br/&gt;Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Contractual&lt;br/&gt;Term (Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Outstanding and exercisable warrants to purchase&lt;br/&gt;&#160;&#160;&#160;preferred shares as of December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;226,191&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;11.3177&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;5.66&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Issued&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;5,301&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Outstanding and exercisable warrants to purchase&lt;br/&gt;&#160;&#160;&#160;common stock as of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;220,890&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;11.3177&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;4.66&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2021, the Company's outstanding warrants to purchase shares of common stock consisted of the following:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:21.212%;"/&gt;
        &lt;td style="width:1.5%;"/&gt;
        &lt;td style="width:0.627%;"/&gt;
        &lt;td style="width:20.574%;"/&gt;
        &lt;td style="width:0.627%;"/&gt;
        &lt;td style="width:1.5%;"/&gt;
        &lt;td style="width:1.284%;"/&gt;
        &lt;td style="width:13.782%;"/&gt;
        &lt;td style="width:0.627%;"/&gt;
        &lt;td style="width:1.5%;"/&gt;
        &lt;td style="width:15.419%;"/&gt;
        &lt;td style="width:1.5%;"/&gt;
        &lt;td style="width:19.849%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"&gt;&lt;br/&gt;Issuance Date&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"&gt;Number of&lt;br/&gt;Shares of&lt;br/&gt;Common&lt;br/&gt;Stock Issuable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"&gt;Classification&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"&gt;Expiration Date&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;September 15, 2020&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;101,610&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11.3177&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Equity&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;July 25, 2026&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;September 15, 2020&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;30,924&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11.3177&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Equity&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;August 21, 2026&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;September 15, 2020&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;77,312&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11.3177&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Equity&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;September 19, 2026&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;September 15, 2020&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11,044&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11.3177&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Equity&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;September 26, 2026&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;220,890&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="C_ee99e6bd-ad45-468e-9fbb-435628a329b5"
      decimals="INF"
      id="F_bbd77c94-cc34-4886-af3a-9a7c5658c85b"
      unitRef="U_shares">10575513</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_a7d83825-c513-40b3-914c-c2f0871374ec"
      decimals="INF"
      id="F_8cee86d4-0796-48a5-a3e3-31ed1e34c8ff"
      unitRef="U_USDollarShare">13.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedPerTransaction
      contextRef="C_ee99e6bd-ad45-468e-9fbb-435628a329b5"
      decimals="-5"
      id="F_f70a844e-14f5-4c8a-9172-f158a5ff53eb"
      unitRef="U_USD">128800000</us-gaap:SaleOfStockConsiderationReceivedPerTransaction>
    <us-gaap:SaleOfStockDescriptionOfTransaction
      contextRef="C_ee99e6bd-ad45-468e-9fbb-435628a329b5"
      id="F_beea17cb-947a-4609-8a6c-57ef3ae78927">the Company also entered into a stock purchase agreement with certain existing investors to purchase 1,153,840 shares of our common stock for  $15.0 million at a price per share equal to the public offering price, with an initial closing for investors held simultaneously with the closing of the offering and a subsequent closing for certain additional investors.</us-gaap:SaleOfStockDescriptionOfTransaction>
    <us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased
      contextRef="C_a7d83825-c513-40b3-914c-c2f0871374ec"
      decimals="0"
      id="F_ca92c3a5-9480-45a2-aba3-2083f0b47103"
      unitRef="U_shares">1153840</us-gaap:StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="C_ee99e6bd-ad45-468e-9fbb-435628a329b5"
      decimals="-5"
      id="F_d4a81f3b-7610-4cab-bff7-ea081854acef"
      unitRef="U_USD">15000000.0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="INF"
      id="F_da88dc70-ad54-485b-9f89-ccccd190b41a"
      unitRef="U_shares">7187500</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="INF"
      id="F_f017416e-e4bd-4aea-ac1b-ef3a58f1ae64"
      unitRef="U_USDollarShare">14.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="-5"
      id="F_e8954169-dd3c-4603-a8ea-57fe435be9ff"
      unitRef="U_USD">94200000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <acet:ScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceTextBlock
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_b17aadf4-94fc-4587-bbd1-3964770d9eec">&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company has the following shares of common stock reserved for future issuance:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:63.237%;"/&gt;
        &lt;td style="width:1.656%;"/&gt;
        &lt;td style="width:0.637%;"/&gt;
        &lt;td style="width:15.452%;"/&gt;
        &lt;td style="width:0.637%;"/&gt;
        &lt;td style="width:1.656%;"/&gt;
        &lt;td style="width:0.637%;"/&gt;
        &lt;td style="width:15.452%;"/&gt;
        &lt;td style="width:0.637%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Stock options available for future grant&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,961,338&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,739,621&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Stock options issued and outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,875,317&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,706,945&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Unvested restricted stock units&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;771,660&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Common stock warrants issued and outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;220,890&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;226,191&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total common stock reserved&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,829,205&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,672,757&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</acet:ScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_35b723a6-c5cf-49a4-9335-d4bc407fc9fc"
      decimals="0"
      id="F_56f919d6-826b-4f37-95ee-7e80029808aa"
      unitRef="U_shares">1961338</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_dccfe9c7-9db3-41d8-9a49-8d136b5e0bfa"
      decimals="0"
      id="F_111babca-edd7-4693-8a01-e3af33e0112e"
      unitRef="U_shares">1739621</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_91052d8c-9e4f-403f-ba68-6576fa344a03"
      decimals="0"
      id="F_630c21fd-f308-4f01-ab79-ebade7060ae0"
      unitRef="U_shares">3875317</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_6ed2f7b8-095e-4a87-ad70-d100496cc258"
      decimals="0"
      id="F_84de8b9b-9082-46d8-a6ab-1574098e2e04"
      unitRef="U_shares">3706945</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_03b136b5-e9d4-4893-ab0d-2dc91c51accf"
      decimals="0"
      id="F_5f368eb3-71a2-4a6e-ad2a-560893b003aa"
      unitRef="U_shares">771660</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_0c48ad1d-3ddc-4d42-94e0-eacbdc6debba"
      decimals="0"
      id="F_02e1dd82-8fbe-4d12-aeff-86d8f2c18bf1"
      unitRef="U_shares">0</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_21b4de8c-d5dc-46f7-9bc7-44236de1a72c"
      decimals="0"
      id="F_884db404-8667-4df2-9f7c-8d7cf3c6b19d"
      unitRef="U_shares">220890</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_9dda731b-43d4-46e4-905f-51b9789cec27"
      decimals="0"
      id="F_e9767764-f83f-4155-8f6e-9b52d22d7b33"
      unitRef="U_shares">226191</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="0"
      id="F_46ae16b9-6a9e-4c00-926a-2360a7c9ff05"
      unitRef="U_shares">6829205</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="0"
      id="F_080c033c-5d2a-4817-8668-38db4a65a82b"
      unitRef="U_shares">5672757</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_c185f974-f454-4105-b28a-391430b10667">&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following provides a roll forward of outstanding warrants:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:53.616%;"/&gt;
        &lt;td style="width:1.588%;"/&gt;
        &lt;td style="width:0.578%;"/&gt;
        &lt;td style="width:12.525%;"/&gt;
        &lt;td style="width:0.764%;"/&gt;
        &lt;td style="width:1.588%;"/&gt;
        &lt;td style="width:1.147%;"/&gt;
        &lt;td style="width:12.191%;"/&gt;
        &lt;td style="width:0.568%;"/&gt;
        &lt;td style="width:1.588%;"/&gt;
        &lt;td style="width:0.578%;"/&gt;
        &lt;td style="width:12.701%;"/&gt;
        &lt;td style="width:0.568%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Number of &lt;br/&gt;Warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Contractual&lt;br/&gt;Term (Years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Outstanding and exercisable warrants to purchase&lt;br/&gt;&#160;&#160;&#160;preferred shares as of December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;226,191&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;11.3177&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;5.66&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Issued&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;5,301&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Outstanding and exercisable warrants to purchase&lt;br/&gt;&#160;&#160;&#160;common stock as of December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;220,890&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;11.3177&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;4.66&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <acet:ClassOfWarrantOutstandingAndExercisableToPurchasePreferredShares
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="0"
      id="F_215b3d8c-559e-4b0d-8123-fa3481e2f39f"
      unitRef="U_shares">226191</acet:ClassOfWarrantOutstandingAndExercisableToPurchasePreferredShares>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="4"
      id="F_86fe3100-32bf-4cea-a559-dae62bcedb1e"
      unitRef="U_USDollarShare">11.3177</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <acet:WarrantsOutstandingAndExercisableWeightedAverageRemainingContractualTerm
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      id="F_455dd06e-a615-4196-b183-7232efc56c85">P5Y7M28D</acet:WarrantsOutstandingAndExercisableWeightedAverageRemainingContractualTerm>
    <acet:ClassOfWarrantOrRightIssued
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="0"
      id="F_39ca1378-7332-4b8d-8718-5ad93afcfcd3"
      unitRef="U_shares">0</acet:ClassOfWarrantOrRightIssued>
    <acet:ClassOfWarrantExercised
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="0"
      id="F_73daf0d9-358d-48cb-b8a7-5225360dbfe8"
      unitRef="U_shares">-5301</acet:ClassOfWarrantExercised>
    <acet:ClassOfWarrantOutstandingAndExercisableToPurchaseCommonStock
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="0"
      id="F_d4435be5-4d70-4dd1-b00b-a4ac105f9cd3"
      unitRef="U_shares">220890</acet:ClassOfWarrantOutstandingAndExercisableToPurchaseCommonStock>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="4"
      id="F_d217fa63-2fe7-447f-9c65-ee5d70b943d3"
      unitRef="U_USDollarShare">11.3177</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <acet:WarrantsOutstandingAndExercisableWeightedAverageRemainingContractualTerm
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_4549c81e-d778-41a0-b27b-87ee02065237">P4Y7M28D</acet:WarrantsOutstandingAndExercisableWeightedAverageRemainingContractualTerm>
    <acet:ScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockTableTextBlock
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_9d80d234-b478-486d-b0aa-5efdcba02d5b">&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2021, the Company's outstanding warrants to purchase shares of common stock consisted of the following:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:21.212%;"/&gt;
        &lt;td style="width:1.5%;"/&gt;
        &lt;td style="width:0.627%;"/&gt;
        &lt;td style="width:20.574%;"/&gt;
        &lt;td style="width:0.627%;"/&gt;
        &lt;td style="width:1.5%;"/&gt;
        &lt;td style="width:1.284%;"/&gt;
        &lt;td style="width:13.782%;"/&gt;
        &lt;td style="width:0.627%;"/&gt;
        &lt;td style="width:1.5%;"/&gt;
        &lt;td style="width:15.419%;"/&gt;
        &lt;td style="width:1.5%;"/&gt;
        &lt;td style="width:19.849%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"&gt;&lt;br/&gt;Issuance Date&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"&gt;Number of&lt;br/&gt;Shares of&lt;br/&gt;Common&lt;br/&gt;Stock Issuable&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"&gt;Classification&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"&gt;Expiration Date&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;September 15, 2020&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;101,610&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11.3177&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Equity&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;July 25, 2026&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;September 15, 2020&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;30,924&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11.3177&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Equity&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;August 21, 2026&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;September 15, 2020&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;77,312&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11.3177&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Equity&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;September 19, 2026&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;September 15, 2020&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11,044&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11.3177&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Equity&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;September 26, 2026&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;220,890&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</acet:ScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockTableTextBlock>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="C_d7c1aa19-f30c-49e2-89e6-bd6ca6fed85c"
      id="F_5eb7db5f-9ce3-46c6-81d6-1ccb461b222f">2020-09-15</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_47329381-5696-4150-b182-6307d7bace64"
      decimals="0"
      id="F_e4bda378-71c9-40b0-a47f-0745c07aed62"
      unitRef="U_shares">101610</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_47329381-5696-4150-b182-6307d7bace64"
      decimals="4"
      id="F_4b47bf2b-2c81-47af-b6a0-807001595453"
      unitRef="U_USDollarShare">11.3177</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <acet:ClassOfWarrantOrRightsExpirationDate
      contextRef="C_d7c1aa19-f30c-49e2-89e6-bd6ca6fed85c"
      id="F_8d03db82-01fa-47cb-a0ad-2a38761f1377">2026-07-25</acet:ClassOfWarrantOrRightsExpirationDate>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="C_ab272512-6afd-4b7d-821d-0cda8200b065"
      id="F_ab00a2b6-aee0-4d95-b162-86b598f24d2a">2020-09-15</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_61c5baba-2674-42bd-b177-79bf4833cac0"
      decimals="0"
      id="F_fb06a34c-87c2-492b-a6c0-371fc8f3cb7b"
      unitRef="U_shares">30924</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_61c5baba-2674-42bd-b177-79bf4833cac0"
      decimals="4"
      id="F_876bad56-e7e3-4d0b-9398-7de550f275f9"
      unitRef="U_USDollarShare">11.3177</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <acet:ClassOfWarrantOrRightsExpirationDate
      contextRef="C_ab272512-6afd-4b7d-821d-0cda8200b065"
      id="F_6fb99c30-6ffd-4d92-bc4a-ee760116411a">2026-08-21</acet:ClassOfWarrantOrRightsExpirationDate>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="C_d75d589d-a181-4cd4-ad70-8e7ae30da242"
      id="F_d27d1814-e17f-4717-a374-7bbd5868be86">2020-09-15</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_0c05cb34-710a-4fe0-a5ad-4326137cbe67"
      decimals="0"
      id="F_2d39647a-abc0-4784-afe4-6a756c6cf123"
      unitRef="U_shares">77312</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_0c05cb34-710a-4fe0-a5ad-4326137cbe67"
      decimals="4"
      id="F_76a42a81-f508-4995-a714-ffe5b52b0a6c"
      unitRef="U_USDollarShare">11.3177</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <acet:ClassOfWarrantOrRightsExpirationDate
      contextRef="C_d75d589d-a181-4cd4-ad70-8e7ae30da242"
      id="F_aeb5d4c0-ef5d-43d6-918f-212ba1a0b8aa">2026-09-19</acet:ClassOfWarrantOrRightsExpirationDate>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable
      contextRef="C_8b04952a-abb5-4154-8047-1764f9eef410"
      id="F_4b99b1e4-497f-49ca-b060-f41d5fac10be">2020-09-15</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_97f163d5-9ecd-43f8-8bae-d896a29f9d75"
      decimals="0"
      id="F_e4463e26-7218-4041-b78a-9694f4eca669"
      unitRef="U_shares">11044</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="C_97f163d5-9ecd-43f8-8bae-d896a29f9d75"
      decimals="4"
      id="F_02cce1a3-8a0f-48d6-bcf2-b0ee96569a9e"
      unitRef="U_USDollarShare">11.3177</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <acet:ClassOfWarrantOrRightsExpirationDate
      contextRef="C_8b04952a-abb5-4154-8047-1764f9eef410"
      id="F_fe852265-bc54-4969-96d8-715ded3d761a">2026-09-26</acet:ClassOfWarrantOrRightsExpirationDate>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="0"
      id="F_439cfc25-56f5-424c-8c45-dc5eb801df12"
      unitRef="U_shares">220890</us-gaap:ClassOfWarrantOrRightOutstanding>
    <acet:AtTheMarketOfferingTextBlock
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_96751e1b-a987-4937-ae36-f599fcee41cd">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;14. At-the-Market (ATM) Offering&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On December 1, 2020, the Company entered into a Sales Agreement (the 2020 Sales Agreement) with Evercore Group L.L.C. and H.C. Wainwright &amp;amp; Co., LLC (collectively, the Agents), pursuant to which the Company may sell, from time to time, at its option, up to an aggregate of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;50.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million of shares of the Company&#x2019;s common stock, through the Agents, as its sales agents. No sales of Shares have been made under the 2020 Sales Agreement. The ATM offering was terminated in &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;February 2021&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On March 12, 2021, the Company entered into a Sales Agreement (the 2021 Sales Agreement) with&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;JonesTrading Institutional Services (the Agent), pursuant to which the Company could sell, from time to time, at its option, up to an aggregate of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;75.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million of shares of its common stock, through the Agent, as its sales agent. No shares were sold under the 2021 Sales Agreement as of December 31, 2021.&lt;/span&gt;&lt;/p&gt;</acet:AtTheMarketOfferingTextBlock>
    <acet:MaximumAggregateValueOfCommonStockAvailableForOfferingAtMarketPriceUnderSalesAgreement
      contextRef="C_2c5c9f72-4620-4181-b264-9a1444d1f83d"
      decimals="-5"
      id="F_a68f0eba-7be8-454b-b36e-b9daf6c63488"
      unitRef="U_USD">50000000.0</acet:MaximumAggregateValueOfCommonStockAvailableForOfferingAtMarketPriceUnderSalesAgreement>
    <acet:TerminationAgreementMonthAndYear
      contextRef="C_62266203-5d56-4f94-a47f-f581aa528dbf"
      id="F_f34210bf-219f-4cdd-a11f-e3cc813cf795">2021-02</acet:TerminationAgreementMonthAndYear>
    <acet:MaximumAggregateValueOfCommonStockAvailableForOfferingAtMarketPriceUnderSalesAgreement
      contextRef="C_0d31c0ca-f12c-41d7-9a4f-d658501001c3"
      decimals="-5"
      id="F_9904eb58-4745-4003-a135-0e79dd225beb"
      unitRef="U_USD">75000000.0</acet:MaximumAggregateValueOfCommonStockAvailableForOfferingAtMarketPriceUnderSalesAgreement>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_a802b184-f620-4be0-9367-144f229fce2c">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;15. Stock-Based Compensation&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Stock-based Compensation Expense&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table presents stock-based compensation expense as reflected in the Company's consolidated statements of operations and comprehensive loss (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.807%;"/&gt;
        &lt;td style="width:1.49%;"/&gt;
        &lt;td style="width:1.284%;"/&gt;
        &lt;td style="width:13.201%;"/&gt;
        &lt;td style="width:0.627%;"/&gt;
        &lt;td style="width:1.49%;"/&gt;
        &lt;td style="width:1.284%;"/&gt;
        &lt;td style="width:13.191%;"/&gt;
        &lt;td style="width:0.627%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,759&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,674&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,752&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,589&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;12,511&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,263&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Summary of Plans&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Plans are administered by the Board of Directors or, at the discretion of the Board of Directors, by a committee of the Board of Directors. The exercise prices, vesting and other restrictions are determined at the discretion of the Board of Directors, or its committee if so delegated, except that the exercise price per share of stock options may not be less than 100% of the fair market value of the share of common stock on the date of grant and the term of the stock option may not be greater than ten years. Incentive stock options granted to employees and restricted stock awards granted to employees, officers, members of the Board of Directors, advisors, and consultants of the Company typically vest over four years. Non-statutory options granted to employees, officers, members of the Board of Directors, advisors, and consultants of the Company typically vest over three or four years. Shares that are expired, terminated, surrendered or canceled under the Plans without having been fully exercised will be available for future awards. In addition, shares of common stock that are tendered to the Company by a participant to exercise an award are added to the number of shares of common stock available for the grant of awards.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;The 2017 Plan and 2018 Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In 2017, resTORbio adopted the 2017 Plan. In connection with resTORbio&#x2019;s initial public offering completed in January 2018, the resTORbio Board adopted and resTORbio&#x2019;s stockholders approved the 2018 Plan. The 2018 Plan provides that the number of shares reserved and available for issuance under the plan will automatically increase each January 1, beginning on January 1, 2019, by &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of the outstanding number of shares of resTORbio&#x2019;s common stock on the immediately preceding December 31 or such lesser number of shares as determined by the Board. On April 27, 2021, the stockholders approved an amendment and restatement of the 2018 Stock Option and Incentive Plan, to, among other things, increase the aggregate number of shares authorized for issuance under the 2018 Plan by &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,500,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares, plus on January 1, 2022 and each January 1, thereafter, the number of shares authorized for issuance shall be increased by the lesser of 5% of the number of shares of Common Stock issued and outstanding on the immediately preceding December 31, or such lesser number as determined by the compensation committee. On January 1, 2022, the number of shares reserved and available for issuance under the 2018 Plan automatically increased by &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,986,845&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of Common Stock equal to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of the number of shares of Common Stock issued and outstanding on December 31, 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Since the date of effectiveness of the 2018 Plan, resTORbio has not and the Company will not grant any further awards under the 2017 Plan. However, any shares of common stock subject to awards under the 2017 Plan that expire, terminate, or otherwise are surrendered, canceled, forfeited or repurchased without having been fully exercised or resulting in any common stock being issued will become available for issuance under the 2018 Plan. As of December 31, 2021, there are no outstanding options under the 2017 Plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2021, the number of shares of common stock available for grant under the 2017 and 2018 Plan is &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,683,999&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. As of December 31, 2021, an aggregate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,574,170&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock were issuable upon the exercise of outstanding stock options under the 2017 Plan and 2018 Plans at a weighted average exercise price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;15.10&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share. In addition to this amount, as of December 31, 2021, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;771,660&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock were issuable upon the vesting of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,410&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; performance stock units (PSUs) granted in May 2021, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;205,250&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; RSUs granted in August 2021, and &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;560,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; RSUs and PSUs granted in October 2021.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;The 2014 Plan and 2015 Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2021, the number of shares of common stock available for grant under the 2014 and 2015 Plan is &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;277,339&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:12.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2021, an aggregate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;915,657&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock were issuable upon the exercise of outstanding stock options under the 2015 plan at a weighted average exercise price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;11.46&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share and an aggregate of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;22,987&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of common stock were issuable upon the exercise of outstanding stock options under the 2014 Plan at a weighted average exercise price of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.61&lt;/span&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Since the date of effectiveness of the Merger, the Company has not and will not grant any further awards under the 2014 Plan.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(255,255,255,1);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;2018 Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The 2018 ESPP provides that the number of shares reserved and available for issuance will automatically increase each January 1, beginning on January 1, 2019 and increasing each January 1 thereafter through January 1, 2028, by the least of (i) &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% of the outstanding number of shares of the Company&#x2019;s common stock on the immediately preceding December 31; (ii) &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;77,703&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares or (iii) such number of shares as determined by the ESPP administrator.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; On January 1, 2020, as a result of the foregoing evergreen provision, the number of shares of common stock available for issuance under the 2018 ESPP automatically increased from &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;79,369&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;131,432&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares. &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On January 1, 2021, as a result of the&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;foregoing &lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;evergreen provision, the number of shares of common stock available for issuance under the 2018 ESPP automatically increased from &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;131,432&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;524,775&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. During the 2021 Annual Meeting of the stockholders held on April 27, 2021, the stockholders approved an amendment and restatement of the Company's 2018 ESPP. As a result, the Company increased the shares available for issuance under the 2018 ESPP to &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;524,775&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;For the year ended December 31, 2021 the Company issued a total of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;15,667&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares under the 2018 ESPP. Expense related to the issuance of such shares was less than $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;No&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares were issued under the 2018 ESPP during the year ended December 31, 2020.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:6.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Stock Options&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;A summary of stock option activity is set forth below (in thousands, except share and per share data):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:89.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:40.835%;"/&gt;
        &lt;td style="width:0.672%;"/&gt;
        &lt;td style="width:12.503%;"/&gt;
        &lt;td style="width:0.903%;"/&gt;
        &lt;td style="width:1.179%;"/&gt;
        &lt;td style="width:1.344%;"/&gt;
        &lt;td style="width:12.128%;"/&gt;
        &lt;td style="width:0.595%;"/&gt;
        &lt;td style="width:1.179%;"/&gt;
        &lt;td style="width:0.661%;"/&gt;
        &lt;td style="width:12.569%;"/&gt;
        &lt;td style="width:0.595%;"/&gt;
        &lt;td style="width:1.179%;"/&gt;
        &lt;td style="width:1.344%;"/&gt;
        &lt;td style="width:11.721%;"/&gt;
        &lt;td style="width:0.595%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;"&gt;Outstanding Awards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;"&gt;Number of&lt;br/&gt;Shares&lt;br/&gt;Underlying&lt;br/&gt;Outstanding&lt;br/&gt;Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"&gt;Outstanding, December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;3,706,945&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;10.90&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;7.98&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;15,126&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Options authorized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Options granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;2,161,472&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;14.37&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Options exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;1,125,339&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;4.17&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Options forfeited or cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;867,761&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;14.06&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"&gt;Outstanding, December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;3,875,317&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;14.08&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;8.85&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;13,212&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Options exercisable December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;991,847&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;13.42&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;8.46&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;4,033&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Vested and expected to vest, December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;3,875,317&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;14.08&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;8.85&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;13,212&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The fair value of each stock option was estimated at the date of grant using a Black-Scholes option-pricing model using the following assumptions:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:48.693%;"/&gt;
        &lt;td style="width:1.96%;"/&gt;
        &lt;td style="width:0.642%;"/&gt;
        &lt;td style="width:22.409%;"/&gt;
        &lt;td style="width:0.642%;"/&gt;
        &lt;td style="width:1.96%;"/&gt;
        &lt;td style="width:0.642%;"/&gt;
        &lt;td style="width:22.409%;"/&gt;
        &lt;td style="width:0.642%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;77.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;79.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;72.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;96.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.90 &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.08 &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.00 &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.08 &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The assumptions are as follows:&lt;/span&gt;&lt;/p&gt;&lt;div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Expected volatility.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; The Company has limited trading history. As such, the expected volatility was determined by examining the historical volatilities for comparable publicly traded companies within the biotechnology and pharmaceutical industry using an average of historical volatilities of the Company&#x2019;s industry peers.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Risk-free interest rate.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; The risk-free interest rate is based on the United States Treasury yield with a maturity equal to the expected term of the option in effect at the time of grant.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Dividend yield.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; The expected dividend is assumed to be zero as dividends have never been paid and there are no current plans to pay dividends on common stock.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="margin-left:3.333%;display:flex;margin-top:12.0pt;line-height:1.035;justify-content:flex-start;align-items:baseline;margin-bottom:0.0pt;min-width:3.333%;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;display:inline-flex;font-size:10.0pt;font-family:Times New Roman;justify-content:flex-start;min-width:3.447919145106397%;"&gt;&#x2022;&lt;/span&gt;&lt;div style="display:inline;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Expected term.&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; The expected term represents the period that the stock-based awards are expected to be outstanding. The expected term is calculated using the simplified method which is used when there is insufficient historical data about exercise patterns and post-vesting employment termination behavior. The simplified method is based on the vesting period and the contractual term for each grant, or for each vesting-tranche for awards with graded vesting. The mid-point between the vesting date and the maximum contractual expiration date is used as the expected term under this method. For awards with multiple vesting-tranches, the times from grant until the mid-points for each of the tranches may be averaged to provide an overall expected term.&lt;/span&gt;&lt;/div&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company will continue to use judgment in evaluating the expected volatility, risk-free interest rates, dividend yield and expected term, utilized for stock-based compensation on a prospective basis.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying stock options and the fair value of the Company&#x2019;s common stock for stock options that were in-the-money at December 31, 2021 and 2020. The aggregate intrinsic value of stock options exercised during the years ended on December 31, 2021 and 2020 was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;10.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, respectively.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The total fair value of options that vested during the years ended December 31, 2021 and 2020 was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, respectively. The options granted during the years ended December 31, 2021 and 2020 had a weighted-average per share grant-date fair value of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9.68&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share and $9&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;.96&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; per share, respectively.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2021, the total unrecognized stock-based compensation expense related to unvested stock options was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;24.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, which is expected to be recognized over the remaining weighted-average vesting period of &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.8 &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;years.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Restricted Stock Units&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table presents a summary of the Company's RSU activity and related information:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.347%;"/&gt;
        &lt;td style="width:3.293%;"/&gt;
        &lt;td style="width:0.578%;"/&gt;
        &lt;td style="width:19.667%;"/&gt;
        &lt;td style="width:0.764%;"/&gt;
        &lt;td style="width:3.293%;"/&gt;
        &lt;td style="width:1.146%;"/&gt;
        &lt;td style="width:19.334%;"/&gt;
        &lt;td style="width:0.578%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Number of Units Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant Date Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"&gt;Outstanding, December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;RSUs granted (including performance-based RSUs)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;777,160&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;7.84&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;RSUs Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;RSUs forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;5,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;7.12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"&gt;Outstanding, December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;771,660&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;7.85&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In May 2021, the Company granted &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,410&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; RSUs with service and performance conditions to an employee, none of which vested during the year ending December 31, 2021. Vesting of these awards is contingent on the occurrence of certain milestone events and fulfilment of any remaining service condition. As a result, the related compensation cost is recognized as an expense when achievement of the milestone is considered probable. The expense recognized for these awards is based on the grant date fair value of the Company's common stock multiplied by the number of units granted. The Company recognized less than $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million of related expense during the year ended December 31, 2021.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In October 2021, the Company granted &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;560,000&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; RSUs with service and performance conditions to certain employees, none of which vested during the year ended December 31, 2021. Vesting of these awards is contingent on the occurrence of certain milestone events and fulfilment of any remaining service condition. As a result, the related compensation cost is recognized as an expense when achievement of the milestone is considered probable. The expense recognized for these awards is based on the grant date fair value of the Company's common stock multiplied by the number of units granted. The Company recognized $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million of related expense during the year ended December 31, 2021.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The weighted-average grant date fair value of RSUs granted during the year ended December 31, 2021 was $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.84&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. There was no RSU activity during the year ended December 31, 2020. Additionally, no RSUs vested during the year ended December 31, 2021.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2021, there was approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million of unrecognized compensation cost related to unvested RSUs that the Company expects to recognize over a remaining weighted-average period of approximately &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.3 &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;years.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table presents stock-based compensation expense by type of award (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.091%;"/&gt;
        &lt;td style="width:1.49%;"/&gt;
        &lt;td style="width:1.147%;"/&gt;
        &lt;td style="width:13.24%;"/&gt;
        &lt;td style="width:0.578%;"/&gt;
        &lt;td style="width:1.49%;"/&gt;
        &lt;td style="width:1.147%;"/&gt;
        &lt;td style="width:13.24%;"/&gt;
        &lt;td style="width:0.578%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Stock Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;10,511&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;5,263&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Restricted stock units (including performance-based RSUs)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;1,944&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_dbc0d54f-50e5-4e0d-931c-eb2600eb1f07;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;56&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_91d06931-2771-4e60-b971-253316eaba0d;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;12,511&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;5,263&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_dde999fd-ece3-4ac9-aaef-3f338988e90e">&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table presents stock-based compensation expense as reflected in the Company's consolidated statements of operations and comprehensive loss (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.807%;"/&gt;
        &lt;td style="width:1.49%;"/&gt;
        &lt;td style="width:1.284%;"/&gt;
        &lt;td style="width:13.201%;"/&gt;
        &lt;td style="width:0.627%;"/&gt;
        &lt;td style="width:1.49%;"/&gt;
        &lt;td style="width:1.284%;"/&gt;
        &lt;td style="width:13.191%;"/&gt;
        &lt;td style="width:0.627%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,759&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,674&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;General and administrative&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,752&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,589&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;12,511&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,263&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:12.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table presents stock-based compensation expense by type of award (in thousands):&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:67.091%;"/&gt;
        &lt;td style="width:1.49%;"/&gt;
        &lt;td style="width:1.147%;"/&gt;
        &lt;td style="width:13.24%;"/&gt;
        &lt;td style="width:0.578%;"/&gt;
        &lt;td style="width:1.49%;"/&gt;
        &lt;td style="width:1.147%;"/&gt;
        &lt;td style="width:13.24%;"/&gt;
        &lt;td style="width:0.578%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Stock Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;10,511&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;5,263&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Restricted stock units (including performance-based RSUs)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;1,944&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_dbc0d54f-50e5-4e0d-931c-eb2600eb1f07;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Employee Stock Purchase Plan&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;56&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;"&gt;&lt;span style="-sec-ix-hidden:F_91d06931-2771-4e60-b971-253316eaba0d;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;12,511&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;5,263&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_e645c0e4-c8b9-494e-86ea-d249ee6b8de0"
      decimals="-3"
      id="F_969a96ad-9b53-4097-b4cc-e69ef69f6118"
      unitRef="U_USD">4759000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_38fcd5c7-531b-45fa-b26b-773edcb7ea4a"
      decimals="-3"
      id="F_976390d7-5288-47f3-bc70-764394782b9e"
      unitRef="U_USD">1674000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_33bee37a-503e-457c-a296-23686ab0bf7a"
      decimals="-3"
      id="F_97d9d53c-fc1e-445d-ba14-2fffc2cec29f"
      unitRef="U_USD">7752000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_e7b49a0d-aba6-4a40-8906-1ce775d20e23"
      decimals="-3"
      id="F_e99c6784-2bf2-4101-8353-221c7ac75f1c"
      unitRef="U_USD">3589000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="-3"
      id="F_75607dc3-81f6-4296-bee2-132ca07741a5"
      unitRef="U_USD">12511000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="-3"
      id="F_a5257ac4-f46f-46d1-89d6-02a1df4577ee"
      unitRef="U_USD">5263000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="C_b1857342-ffb7-45ed-afa1-3915a6f75d31"
      decimals="2"
      id="F_b5792576-1160-4cbe-8d2f-40df0e5180dc"
      unitRef="U_pure">0.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_8d576fd1-c342-4304-8b64-31bfd7e0d001"
      decimals="INF"
      id="F_08e7a1bc-63b5-4e51-b9ba-8cf5374d1f1b"
      unitRef="U_shares">1500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_ba6aebac-1228-4929-ac87-bcb3b11a0965"
      decimals="INF"
      id="F_9fb9bc6b-a24a-4cb1-830c-5e7c90865bdd"
      unitRef="U_shares">1986845</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="C_98e3df4a-7a5c-4af8-b922-80b4bfd6c7c5"
      decimals="2"
      id="F_527d3b21-b136-4f8f-82c5-53cc04a96f2a"
      unitRef="U_pure">0.05</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_3bebb335-7ef4-439f-88ab-b54a40df0583"
      decimals="INF"
      id="F_a6f9dc34-4998-457f-9e65-81f6b8e19bd0"
      unitRef="U_shares">1683999</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_3bebb335-7ef4-439f-88ab-b54a40df0583"
      decimals="INF"
      id="F_d085a839-afc2-49d7-8eea-81071e8b0281"
      unitRef="U_shares">2574170</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_425adbd0-c74a-4998-835c-069d0757ec60"
      decimals="INF"
      id="F_c6a13906-c008-4d78-9515-8593d428b02c"
      unitRef="U_USDollarShare">15.10</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_425adbd0-c74a-4998-835c-069d0757ec60"
      decimals="INF"
      id="F_5e920b4a-6f21-4be9-8578-8b028a085c9b"
      unitRef="U_shares">771660</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_677843d2-a967-4c7e-806b-bedb3b76e41f"
      decimals="0"
      id="F_a398ad6f-71c6-42e1-b707-10612b1be51a"
      unitRef="U_shares">6410</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_47c45ab3-564a-4faf-b5b3-316708cef184"
      decimals="INF"
      id="F_4e3c434f-f4e4-4c7f-9632-899f8cb01396"
      unitRef="U_shares">205250</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_2d0f9825-f275-4fef-8d45-4314b18f7073"
      decimals="INF"
      id="F_24e358ff-33e7-43a4-a00d-28157d150523"
      unitRef="U_shares">560000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="C_2c23f818-11c0-4555-af2a-af3a6c3d7db0"
      decimals="INF"
      id="F_8a1f2bf4-44e8-4d74-a6f4-0e0578e65251"
      unitRef="U_shares">277339</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_c416c367-1d15-4743-aa82-f287dc4229d1"
      decimals="INF"
      id="F_2d3ef7c5-c77e-4281-b7a6-8da7d6ba76c9"
      unitRef="U_shares">915657</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_a3c832c4-7b25-488e-a569-24d85c95e6db"
      decimals="2"
      id="F_0f342c2d-80a6-43c5-b91e-6a3b4cb44f3a"
      unitRef="U_USDollarShare">11.46</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="C_7241f66e-a735-4719-b5b2-0d08cdf5a400"
      decimals="INF"
      id="F_e046ea8b-98fd-45fe-8c14-2c592a3ddb44"
      unitRef="U_shares">22987</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_ba86b9b9-6782-4f93-bfa9-5fc357e6e1f8"
      decimals="INF"
      id="F_e35d7f5d-e95a-4192-a844-038748cb0bd4"
      unitRef="U_USDollarShare">1.61</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum
      contextRef="C_383a2850-17d4-45d4-93aa-3b9d2268d63a"
      decimals="2"
      id="F_942453d6-4a2b-41f0-a8cd-33a499530b33"
      unitRef="U_pure">0.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_4669da95-189e-49f2-9e8b-0f44bc2c3332"
      decimals="INF"
      id="F_18e27a8e-4b69-4d3b-93d2-7116e135bca8"
      unitRef="U_shares">77703</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_22d1874f-4dce-4f63-bbf4-e46373c23281"
      decimals="INF"
      id="F_beab3575-98fb-45f2-9d1f-10a3087ddfa2"
      unitRef="U_shares">79369</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_3ff20287-8f1c-4d12-b176-b2761961daee"
      decimals="INF"
      id="F_7c388480-1f3e-4459-8b30-0533cf941010"
      unitRef="U_shares">131432</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_3ff20287-8f1c-4d12-b176-b2761961daee"
      decimals="INF"
      id="F_f3bb4d76-4437-4e22-b414-c2c115c682ff"
      unitRef="U_shares">131432</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_7447a494-85e3-4ae0-ad10-48552cb40723"
      decimals="0"
      id="F_443d05cb-29ef-494b-83b8-884dff8bbb18"
      unitRef="U_shares">524775</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="C_382b6885-27c8-4c22-95fd-15e7dd95382f"
      decimals="INF"
      id="F_6f1c645a-3c3f-4093-8166-84f3d7c5f1f4"
      unitRef="U_shares">524775</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <acet:NumberOfSharesAvailableForSaleUnderEmployeeStockPurchasePlan
      contextRef="C_382b6885-27c8-4c22-95fd-15e7dd95382f"
      decimals="0"
      id="F_6131ea67-ef9b-43df-82f9-d7c725cc6380"
      unitRef="U_shares">15667</acet:NumberOfSharesAvailableForSaleUnderEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
      contextRef="C_996c2c1e-c6b1-4f2c-b4f0-2957fe857977"
      decimals="-5"
      id="F_0f2de97e-8576-428b-9833-00390359a8f1"
      unitRef="U_USD">100000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <acet:NumberOfSharesAvailableForSaleUnderEmployeeStockPurchasePlan
      contextRef="C_bd372fd7-75a1-4e5a-93b8-53cd9832c95c"
      decimals="INF"
      id="F_087af3b1-fee3-4014-9eb6-5ee4ac41d157"
      unitRef="U_shares">0</acet:NumberOfSharesAvailableForSaleUnderEmployeeStockPurchasePlan>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_a78e708c-a8d8-42ce-9ff6-3a876c32a4b0">&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;A summary of stock option activity is set forth below (in thousands, except share and per share data):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:89.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:40.835%;"/&gt;
        &lt;td style="width:0.672%;"/&gt;
        &lt;td style="width:12.503%;"/&gt;
        &lt;td style="width:0.903%;"/&gt;
        &lt;td style="width:1.179%;"/&gt;
        &lt;td style="width:1.344%;"/&gt;
        &lt;td style="width:12.128%;"/&gt;
        &lt;td style="width:0.595%;"/&gt;
        &lt;td style="width:1.179%;"/&gt;
        &lt;td style="width:0.661%;"/&gt;
        &lt;td style="width:12.569%;"/&gt;
        &lt;td style="width:0.595%;"/&gt;
        &lt;td style="width:1.179%;"/&gt;
        &lt;td style="width:1.344%;"/&gt;
        &lt;td style="width:11.721%;"/&gt;
        &lt;td style="width:0.595%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;"&gt;Outstanding Awards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;"&gt;Number of&lt;br/&gt;Shares&lt;br/&gt;Underlying&lt;br/&gt;Outstanding&lt;br/&gt;Options&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Exercise&lt;br/&gt;Price&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;"&gt;Weighted&lt;br/&gt;Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual&lt;br/&gt;Term (in years)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;"&gt;Aggregate&lt;br/&gt;Intrinsic&lt;br/&gt;Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.5pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.5pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"&gt;Outstanding, December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;3,706,945&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;10.90&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;7.98&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;15,126&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Options authorized&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Options granted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;2,161,472&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;14.37&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Options exercised&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;1,125,339&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;4.17&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Options forfeited or cancelled&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;867,761&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;14.06&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"&gt;Outstanding, December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;3,875,317&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;14.08&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;8.85&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;13,212&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Options exercisable December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;991,847&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;13.42&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;8.46&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;4,033&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:5.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:5.0pt;text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;Vested and expected to vest, December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;3,875,317&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;14.08&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;8.85&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;13,212&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="INF"
      id="F_4516ba21-89ae-4888-88ef-16a09b47f2da"
      unitRef="U_shares">3706945</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="2"
      id="F_f17ab2f7-18e7-433e-bc61-8ad0b121a76c"
      unitRef="U_USDollarShare">10.90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      id="F_3cff97be-061f-491c-9294-9270362d7556">P7Y11M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="-3"
      id="F_a8b9b1a1-e2a5-42d7-ac6f-5f70f026bf8a"
      unitRef="U_USD">15126000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="INF"
      id="F_deb25515-0175-47b2-8e10-4830a4c9796f"
      unitRef="U_shares">2161472</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="2"
      id="F_b38d173d-8491-45d5-9d50-0afed6d6d7c5"
      unitRef="U_USDollarShare">14.37</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="INF"
      id="F_9f138a61-0c7f-4fde-a323-c693d7dfbdf2"
      unitRef="U_shares">1125339</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="2"
      id="F_65551013-80af-41d9-8fc8-38241a256863"
      unitRef="U_USDollarShare">4.17</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="INF"
      id="F_6e7292f0-947f-428a-8ab3-e4543bc1c4f3"
      unitRef="U_shares">867761</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="2"
      id="F_13ccb89c-8cbd-4f05-ab0f-52e4ccdfede8"
      unitRef="U_USDollarShare">14.06</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="INF"
      id="F_447bbea6-8b6f-4912-aca5-a65fe0a2dfaf"
      unitRef="U_shares">3875317</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="2"
      id="F_5714f290-fb0a-4d64-80a3-786ad4c0cc06"
      unitRef="U_USDollarShare">14.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_4155e887-2396-41bf-a2c2-218e37cf671f">P8Y10M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-3"
      id="F_76ad66d9-c215-425a-8f1d-81edf94f3946"
      unitRef="U_USD">13212000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="INF"
      id="F_1cc852c2-ad7f-4086-8cd2-c22897e04b97"
      unitRef="U_shares">991847</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="2"
      id="F_d82de667-4dc7-4e14-91f6-e88d340a9984"
      unitRef="U_USDollarShare">13.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_5f603be6-fbf1-4431-b62e-e08e2ad829df">P8Y5M15D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-3"
      id="F_ba98ea63-39db-4683-9bb4-0567dd18c4ed"
      unitRef="U_USD">4033000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="INF"
      id="F_d50c5dc1-6c4d-49d7-b220-8d1980982c06"
      unitRef="U_shares">3875317</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="2"
      id="F_6ba7d05a-337f-43b1-acd3-e78897ab6329"
      unitRef="U_USDollarShare">14.08</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_12819ae6-9ff5-45b5-b9cf-69c82565bde8">P8Y10M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-3"
      id="F_60d1ba78-0c54-4fee-81c3-e82c9f3c8da0"
      unitRef="U_USD">13212000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_61efa2cc-42ba-4c5f-bec5-5ef645aa295d">&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The fair value of each stock option was estimated at the date of grant using a Black-Scholes option-pricing model using the following assumptions:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:48.693%;"/&gt;
        &lt;td style="width:1.96%;"/&gt;
        &lt;td style="width:0.642%;"/&gt;
        &lt;td style="width:22.409%;"/&gt;
        &lt;td style="width:0.642%;"/&gt;
        &lt;td style="width:1.96%;"/&gt;
        &lt;td style="width:0.642%;"/&gt;
        &lt;td style="width:22.409%;"/&gt;
        &lt;td style="width:0.642%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected volatility&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;77.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;79.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;72.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;96.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Risk-free interest rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.4&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;% - &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Dividend yield&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Expected term&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.90 &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.08 &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.00 &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;- &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.08 &lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;years&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="3"
      id="F_8895e3cd-3aec-4ec4-bce8-335696bcaecf"
      unitRef="U_pure">0.772</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="3"
      id="F_3d78704d-800a-4803-a8a8-d590c054d091"
      unitRef="U_pure">0.798</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="3"
      id="F_f47b6348-f4db-442a-aea9-e5b090f26ec8"
      unitRef="U_pure">0.726</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="3"
      id="F_68a87a87-6c84-4fc9-9c99-46288c5e6321"
      unitRef="U_pure">0.963</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="3"
      id="F_60e55daf-6af7-4f12-b791-83197508c20e"
      unitRef="U_pure">0.001</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="3"
      id="F_1dd69e9b-158b-4253-bdae-7f9e02c2d00d"
      unitRef="U_pure">0.014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="3"
      id="F_897ea6fd-71b0-40ec-b523-65132cdd23a8"
      unitRef="U_pure">0.001</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="3"
      id="F_9b0c88d7-37e8-4721-8688-f53eaaf68f1b"
      unitRef="U_pure">0.017</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="2"
      id="F_b91d5be9-70a6-43b0-96f1-b72bc7ca804f"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="2"
      id="F_1a7edfc5-8109-4366-aec5-2d2e0c785849"
      unitRef="U_pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_ed4f0fb0-7a37-45a2-b10b-11e180b401f7"
      id="F_635d51f9-9048-47c9-bef5-6835fddda9aa">P0Y10M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_7071ab79-c6d3-48f5-825b-3abca7958518"
      id="F_3c57dece-9425-483f-8e57-c08975427bac">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_1d137f38-c8f9-4c04-bef7-225e2c879fcf"
      id="F_d1039ab1-b7b7-40c9-a5cb-9d27a87ee199">P1Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="C_734e8966-cc1e-4985-a3ff-9c6d800e8bb3"
      id="F_a4452e0f-6e23-460a-9f5e-6b298ea726c7">P6Y29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="-5"
      id="F_9e1acc77-6b75-4b9a-a119-f9e36c2ee9bd"
      unitRef="U_USD">10100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="-5"
      id="F_0ade86ce-dcfe-439b-9268-1597fa0cdf7d"
      unitRef="U_USD">2500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_d7f61ae5-e6e7-4a2d-b7f8-a2343ab6ffcd"
      decimals="-5"
      id="F_ba527582-0f59-44f0-85b3-b54dffa3fd55"
      unitRef="U_USD">2300000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="C_5a2b4879-2585-49d1-b0c2-05cb9d882735"
      decimals="-5"
      id="F_96c432af-1299-4c0d-9357-d8eeffcff249"
      unitRef="U_USD">2400000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="C_d7f61ae5-e6e7-4a2d-b7f8-a2343ab6ffcd"
      decimals="INF"
      id="F_f921fde9-96f0-4ca8-941e-077db0d5ad9e"
      unitRef="U_USDollarShare">9.68</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue
      contextRef="C_5a2b4879-2585-49d1-b0c2-05cb9d882735"
      decimals="INF"
      id="F_85bef381-c3e2-4afe-a1f9-3fa837aae129"
      unitRef="U_USDollarShare">0.96</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_65724930-27ec-4cc0-971f-f08bfefcc88e"
      decimals="-5"
      id="F_0d2de8d1-9457-4710-bfdc-da365ecf6c21"
      unitRef="U_USD">24800000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_c9ada5f0-e0e5-4266-9e2f-ad21061bf510"
      id="F_77e65117-ecb8-487c-9f30-99d98212fe84">P2Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_c0ebdb29-e657-4737-9344-f6bd66ccec42">&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:10.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table presents a summary of the Company's RSU activity and related information:&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:51.347%;"/&gt;
        &lt;td style="width:3.293%;"/&gt;
        &lt;td style="width:0.578%;"/&gt;
        &lt;td style="width:19.667%;"/&gt;
        &lt;td style="width:0.764%;"/&gt;
        &lt;td style="width:3.293%;"/&gt;
        &lt;td style="width:1.146%;"/&gt;
        &lt;td style="width:19.334%;"/&gt;
        &lt;td style="width:0.578%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Number of Units Outstanding&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Weighted-&lt;br/&gt;Average&lt;br/&gt;Grant Date Fair Value&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"&gt;Outstanding, December 31, 2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;RSUs granted (including performance-based RSUs)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;777,160&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;7.84&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;RSUs Vested&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;RSUs forfeited&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;5,500&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;7.12&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:9.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:9.0pt;font-family:Times New Roman;"&gt;Outstanding, December 31, 2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;771,660&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:9.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;"&gt;7.85&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:9.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:9.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="C_0c48ad1d-3ddc-4d42-94e0-eacbdc6debba"
      decimals="0"
      id="F_834ff9cd-fb9d-4d6e-8dac-a85f3b12e884"
      unitRef="U_shares">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_b25c6402-54af-4bb9-9e89-3b3f8319d96f"
      decimals="INF"
      id="F_b6358411-165c-40e2-ac22-0d9efa661d17"
      unitRef="U_shares">777160</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_b25c6402-54af-4bb9-9e89-3b3f8319d96f"
      decimals="2"
      id="F_5d7833c6-bccd-4a7c-9a48-7508735e8ad5"
      unitRef="U_USDollarShare">7.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares
      contextRef="C_b25c6402-54af-4bb9-9e89-3b3f8319d96f"
      decimals="INF"
      id="F_ec5fb741-761d-49b6-9d33-9104e7f534c4"
      unitRef="U_shares">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares
      contextRef="C_b25c6402-54af-4bb9-9e89-3b3f8319d96f"
      decimals="INF"
      id="F_a8d8fab2-a380-4fb4-9460-eb356ab219b3"
      unitRef="U_shares">5500</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue
      contextRef="C_b25c6402-54af-4bb9-9e89-3b3f8319d96f"
      decimals="2"
      id="F_8b6aa3cc-f1a3-4072-8a89-a645a8329d73"
      unitRef="U_USDollarShare">7.12</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
      contextRef="C_03b136b5-e9d4-4893-ab0d-2dc91c51accf"
      decimals="INF"
      id="F_fd5c7b4a-41ed-4895-8ef0-1bd29f19a47e"
      unitRef="U_shares">771660</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="C_03b136b5-e9d4-4893-ab0d-2dc91c51accf"
      decimals="2"
      id="F_03ef5a94-9c61-45b9-baec-63e1c3102fde"
      unitRef="U_USDollarShare">7.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_b9512590-14bb-4410-8257-cfe9d48166b8"
      decimals="INF"
      id="F_2df57381-2347-4eba-a2f1-e6dd151ca6f0"
      unitRef="U_shares">6410</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_9c600e1c-0c03-4bf9-8b76-f6fd3c4ce8d6"
      decimals="-5"
      id="F_78c1ae41-2355-4e47-8624-69481c51bfac"
      unitRef="U_USD">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="C_e474c1ad-c5d1-430f-a989-9a1559ca7832"
      decimals="INF"
      id="F_54359c88-ef4a-4f3a-9612-3dc661c836ff"
      unitRef="U_shares">560000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_e474c1ad-c5d1-430f-a989-9a1559ca7832"
      decimals="-5"
      id="F_8bc618a2-00f4-4b18-b6bd-27e8dd084304"
      unitRef="U_USD">1600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="C_9c600e1c-0c03-4bf9-8b76-f6fd3c4ce8d6"
      decimals="2"
      id="F_79d1ca09-5e8c-4443-a748-c0dd9b6ea646"
      unitRef="U_USDollarShare">7.84</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-5"
      id="F_ea1b7371-b266-47e7-9014-8f60ec6549a7"
      unitRef="U_USD">4100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_48a24c53-0b36-4973-afa5-edd47e2e3a4b">P1Y3M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_e467cca2-7a5b-404b-9e56-feeb98925d23"
      decimals="-3"
      id="F_069a0748-00b9-4a60-81b3-3b8a5dbfa30b"
      unitRef="U_USD">10511000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_9012bab3-6ac1-4389-8e31-ccc520a1ad87"
      decimals="-3"
      id="F_e11b3260-99a6-4ab7-86cb-aabe79c515db"
      unitRef="U_USD">5263000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_b25c6402-54af-4bb9-9e89-3b3f8319d96f"
      decimals="-3"
      id="F_67d34c86-9769-45fc-86ed-83c3324b6bb2"
      unitRef="U_USD">1944000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_086b3add-2ea8-447d-a2b0-fbfba9fbf32a"
      decimals="-3"
      id="F_2259fcde-0fe4-4484-af8b-a5f9bd37f7f2"
      unitRef="U_USD">56000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="-3"
      id="F_6fa32a68-83aa-4480-8ad3-d17735569241"
      unitRef="U_USD">12511000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="-3"
      id="F_a6e2309f-6c63-4f66-ae59-0c8fd040486d"
      unitRef="U_USD">5263000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_18d79349-4837-40ce-8c74-061d9f5d5b37">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;16. Net Loss Per Share&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders (in thousands, except share and per share data):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:64.812%;"/&gt;
        &lt;td style="width:1.416%;"/&gt;
        &lt;td style="width:1.503%;"/&gt;
        &lt;td style="width:13.777%;"/&gt;
        &lt;td style="width:0.991%;"/&gt;
        &lt;td style="width:1.416%;"/&gt;
        &lt;td style="width:1.503%;"/&gt;
        &lt;td style="width:13.592%;"/&gt;
        &lt;td style="width:0.991%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net loss attributable to common stockholders&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;61,999&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;36,678&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Weighted-average shares used in computing net loss&lt;br/&gt;&#160;&#160;&#160;per share attributable to common stockholders,&lt;br/&gt;&#160;&#160;&#160;basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;30,952,152&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,319,977&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net loss per share attributable to common stockholders,&lt;br/&gt;&#160;&#160;&#160;basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.01&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:2.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company's potentially dilutive shares, which include outstanding stock options, unvested RSUs, and unexercised warrants to purchase common stock, are considered to be common stock equivalents and are only included in the calculation of diluted net loss per share when their effect is dilutive.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:2.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:2.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the period presented because including them would have been antidilutive:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.516%;"/&gt;
        &lt;td style="width:1.449%;"/&gt;
        &lt;td style="width:0.697%;"/&gt;
        &lt;td style="width:14.399%;"/&gt;
        &lt;td style="width:0.697%;"/&gt;
        &lt;td style="width:1.449%;"/&gt;
        &lt;td style="width:0.697%;"/&gt;
        &lt;td style="width:14.399%;"/&gt;
        &lt;td style="width:0.697%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,875,317&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,706,945&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Unvested Restricted Stock Awards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;771,660&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Common stock warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;220,890&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;226,191&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,867,867&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,933,136&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_c5da6339-8d0f-45b2-a1ff-4d1f22754013">&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following table sets forth the computation of basic and diluted net loss per share attributable to common stockholders (in thousands, except share and per share data):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:64.812%;"/&gt;
        &lt;td style="width:1.416%;"/&gt;
        &lt;td style="width:1.503%;"/&gt;
        &lt;td style="width:13.777%;"/&gt;
        &lt;td style="width:0.991%;"/&gt;
        &lt;td style="width:1.416%;"/&gt;
        &lt;td style="width:1.503%;"/&gt;
        &lt;td style="width:13.592%;"/&gt;
        &lt;td style="width:0.991%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Numerator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net loss attributable to common stockholders&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;61,999&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;36,678&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Denominator:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Weighted-average shares used in computing net loss&lt;br/&gt;&#160;&#160;&#160;per share attributable to common stockholders,&lt;br/&gt;&#160;&#160;&#160;basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;30,952,152&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,319,977&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net loss per share attributable to common stockholders,&lt;br/&gt;&#160;&#160;&#160;basic and diluted&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.00&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5.01&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="-3"
      id="F_bfe67008-df19-4d1d-865a-848a0ef72c26"
      unitRef="U_USD">-61999000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="-3"
      id="F_b885de10-ec48-4487-a09f-2f1c37da1cd9"
      unitRef="U_USD">-36678000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="0"
      id="F_859e580a-b894-4721-bc8e-9782421d42f6"
      unitRef="U_shares">30952152</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="0"
      id="F_88459837-93bf-454c-b033-1fcdd060db6c"
      unitRef="U_shares">7319977</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="2"
      id="F_470110b3-32ec-4345-b579-26b69d7fe09f"
      unitRef="U_USDollarShare">-2.00</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="2"
      id="F_c97c85ec-687d-4c22-a005-315162f6b0bd"
      unitRef="U_USDollarShare">-5.01</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_b6db3cc8-fc16-4698-b752-3be79659bf1d">&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:2.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share attributable to common stockholders for the period presented because including them would have been antidilutive:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:4.533%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.516%;"/&gt;
        &lt;td style="width:1.449%;"/&gt;
        &lt;td style="width:0.697%;"/&gt;
        &lt;td style="width:14.399%;"/&gt;
        &lt;td style="width:0.697%;"/&gt;
        &lt;td style="width:1.449%;"/&gt;
        &lt;td style="width:0.697%;"/&gt;
        &lt;td style="width:14.399%;"/&gt;
        &lt;td style="width:0.697%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Options to purchase common stock&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,875,317&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,706,945&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Unvested Restricted Stock Awards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;771,660&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Common stock warrants&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;220,890&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;226,191&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,867,867&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,933,136&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_c9ada5f0-e0e5-4266-9e2f-ad21061bf510"
      decimals="INF"
      id="F_ef9e0762-d21e-4fad-ac75-83b904f8bfda"
      unitRef="U_shares">3875317</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_d7f61ae5-e6e7-4a2d-b7f8-a2343ab6ffcd"
      decimals="INF"
      id="F_b2b5c4a7-5b78-40e5-97c8-97bffe6026ce"
      unitRef="U_shares">3706945</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_b25c6402-54af-4bb9-9e89-3b3f8319d96f"
      decimals="INF"
      id="F_3c38aeae-5dd0-4ba5-81de-284a6f29c303"
      unitRef="U_shares">771660</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_daaa68b0-d842-4ae0-a584-de681974e221"
      decimals="0"
      id="F_5fecfb33-895a-4607-9e2d-abe21965e3f6"
      unitRef="U_shares">0</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_89d1a790-504a-43c7-8716-b106ad45345d"
      decimals="INF"
      id="F_9dc77fe9-cddc-44d6-a33c-f78374e84146"
      unitRef="U_shares">220890</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_f7498518-7e9a-4c87-8ba1-fa0ec641d5dd"
      decimals="INF"
      id="F_f203d0f0-2fdb-4a99-94cc-d557c38a7b22"
      unitRef="U_shares">226191</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="INF"
      id="F_64866bbf-f5be-48ac-85b0-cb3282d14e7b"
      unitRef="U_shares">4867867</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="INF"
      id="F_ee5e93d9-0dc7-4821-86be-51ebf2e5738a"
      unitRef="U_shares">3933136</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_68c772cc-b698-4c31-ae02-aae39951dd00">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:2.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;17. Income Taxes&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The components of the provision for (benefit from) income taxes are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.545%;"/&gt;
        &lt;td style="width:1.448%;"/&gt;
        &lt;td style="width:1.514%;"/&gt;
        &lt;td style="width:13.057%;"/&gt;
        &lt;td style="width:1.002%;"/&gt;
        &lt;td style="width:1.448%;"/&gt;
        &lt;td style="width:1.514%;"/&gt;
        &lt;td style="width:13.471%;"/&gt;
        &lt;td style="width:1.002%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Current:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,678&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;105&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,573&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;125&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;242&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total deferred&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;125&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;242&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Provision for (benefit from) income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;125&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,815&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:2.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Income tax benefit of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million for the year ended December 31, 2021 is primarily due to the adjustment in deferred tax liability arising from the impairment charge of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million of acquired IPR&amp;amp;D. In contrast, the income tax benefit of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million for the year ended December 31, 2020 was primarily due to a the recognition of a net operating loss carryback under the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) which was enacted on March 27, 2020 in response to the COVID-19 pandemic.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:12.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;For the rate table below the (provision for) benefit from income taxes differ from the amount expected by applying the federal statutory rate to the loss before taxes as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.102%;"/&gt;
        &lt;td style="width:1.427%;"/&gt;
        &lt;td style="width:0.686%;"/&gt;
        &lt;td style="width:11.84%;"/&gt;
        &lt;td style="width:3.496%;"/&gt;
        &lt;td style="width:1.427%;"/&gt;
        &lt;td style="width:0.686%;"/&gt;
        &lt;td style="width:11.84%;"/&gt;
        &lt;td style="width:3.496%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Federal statutory income tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Other permanent differences&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;State income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Federal benefit from NOL carryback&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;24.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;25.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Change in fair value of redeemable convertible preferred stock tranche liability and TRDF liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Provision for income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The tax effects of temporary differences and carryforwards of the deferred tax assets are presented below (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.389%;"/&gt;
        &lt;td style="width:1.438%;"/&gt;
        &lt;td style="width:1.503%;"/&gt;
        &lt;td style="width:13.363%;"/&gt;
        &lt;td style="width:1.002%;"/&gt;
        &lt;td style="width:1.438%;"/&gt;
        &lt;td style="width:1.503%;"/&gt;
        &lt;td style="width:13.363%;"/&gt;
        &lt;td style="width:1.002%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred Tax Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;67,675&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;51,796&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating lease right-of-use asset liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,504&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,686&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,263&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,857&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,726&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,750&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Intangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,081&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,195&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Fixed assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;196&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accruals and reserves&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,042&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;654&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development credit carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;78,513&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;63,964&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Less: Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;73,163&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;57,715&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred tax assets, net of valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,350&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,249&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Fixed assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Basis Difference IPR&amp;amp;D&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;313&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating lease right-of-use asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,350&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,061&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;125&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On September 15, 2020 Adicet Bio and resTORbio completed the Merger upon which Adicet Bio became the parent company of the consolidated group. The Merger did not create a step up in basis for tax basis of the asset as it was considered a tax-free merger. The above deferred tax table includes deferred related to resTORbio.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company has established a valuation allowance against its deferred tax assets due to the uncertainty surrounding the realization of such assets.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;ASC 740 requires that the tax benefit of net operating losses, temporary differences and credit carryforwards be recorded as an asset to the extent that management assesses that realization is &#x201c;more likely than not.&#x201d; Realization of the future tax benefits is dependent on the Company&#x2019;s ability to generate sufficient taxable income within the carryforward period. Because of the Company&#x2019;s recent history of operating losses, management believes that recognition of the deferred tax assets arising from the above-mentioned future tax benefits is currently not likely to be realized and, accordingly, has provided a valuation allowance.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The valuation allowance increased by $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;15.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million during 2021 and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;37.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million during 2020.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2021, the Company had net operating loss carryforwards of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;271.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;143.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;17.1&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million to reduce future taxable income, if any, for federal, state and foreign income tax purposes, respectively. Of the federal net operating loss carryforwards, $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.6&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million will begin to expire in 2036 if not utilized, and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;264.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million can be carried forward indefinitely. The state carryforwards will begin to expire in 2035.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company also had approximately $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million of federal and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.5&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million of California research and development tax credit carryforwards available to offset future taxable income as of December 31, 2021. The federal credits begin to expire in 2041 and the California research credits can be carried forward indefinitely.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Utilization of the net operating loss carryforwards and research and development tax credit carryforwards may be subject to an annual limitation under Section 382 of the Internal Revenue Code of 1986, and corresponding provisions of state law, due to ownership changes that have occurred previously or that could occur in the future. These ownership changes may limit the amount of carryforwards that can be utilized annually to offset future taxable income. &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain shareholders or public groups in the stock of a corporation by more than 50% over a three-year period&lt;/span&gt;&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;. The Company has not conducted a study to assess whether a change of control has occurred or whether there have been multiple changes of control since inception due to the significant complexity and cost associated with such a study. If the Company has experienced a change of control, as defined by Section 382, at any time since inception, utilization of the net operating loss carryforwards or research and development tax credit carryforwards would be subject to an annual limitation under Section 382, which is determined by first multiplying the value of the Company&#x2019;s stock at the time of the ownership change by the applicable long-term tax-exempt rate, and then could be subject to additional adjustments, as required. Any limitation may result in expiration of a portion of the net operating loss carryforwards or research and development tax credit carryforwards before utilization. Further, until a study is completed and any limitation is known, no liability related to uncertain tax positions is recorded in the consolidated financial statements. The Company does not expect its unrecognized tax benefit balance to change materially over the next 12 months.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company files income tax returns in the United States federal jurisdiction, California, Massachusetts, New York and Israel. The tax years 2015 to 2021 remains open to United States federal and state examination to the extent of the utilization of net operating loss and credit carryovers.&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2021, the Company had unrecognized tax benefits of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million related to the transfer of certain intellectual property from its Israeli subsidiary. In addition, as of December 31, 2021, the Company had unrecognized tax benefits of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million related to the federal and state research and development credits as a result of no formal research credit study performed.&lt;/span&gt;&lt;/p&gt;&lt;div style="font-size:10.0pt;font-family:Times New Roman;"&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;A reconciliation of the beginning and ending unrecognized tax benefit amount is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.82%;"/&gt;
        &lt;td style="width:1.489%;"/&gt;
        &lt;td style="width:1.284%;"/&gt;
        &lt;td style="width:13.199%;"/&gt;
        &lt;td style="width:0.627%;"/&gt;
        &lt;td style="width:1.489%;"/&gt;
        &lt;td style="width:1.284%;"/&gt;
        &lt;td style="width:13.18%;"/&gt;
        &lt;td style="width:0.627%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Balance at the beginning of the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;797&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;797&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Adjustment based on tax positions related to current year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,243&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Balance at the end of the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,040&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;797&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;&lt;/div&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:12.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company recognizes interest expense and penalties related to the above unrecognized tax benefits within income tax expense (benefit). Management determined that no accrual for interest and penalties was required as of December 31, 2021.&lt;/span&gt;&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_a799ab20-7ecd-4b76-9944-a3d7033bf637">&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The components of the provision for (benefit from) income taxes are as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.545%;"/&gt;
        &lt;td style="width:1.448%;"/&gt;
        &lt;td style="width:1.514%;"/&gt;
        &lt;td style="width:13.057%;"/&gt;
        &lt;td style="width:1.002%;"/&gt;
        &lt;td style="width:1.448%;"/&gt;
        &lt;td style="width:1.514%;"/&gt;
        &lt;td style="width:13.471%;"/&gt;
        &lt;td style="width:1.002%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Years Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Current:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,678&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;105&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total current&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,573&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Federal&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;125&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;242&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;State&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Foreign&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Total deferred&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;125&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;242&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Provision for (benefit from) income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;125&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,815&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="-3"
      id="F_4efb4afa-5d08-4bd9-a7a7-26d5c4ae1e23"
      unitRef="U_USD">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="-3"
      id="F_fae80ea5-efa3-4ce6-9501-b29abbae44bb"
      unitRef="U_USD">-2678000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="-3"
      id="F_5bf20de0-feeb-44cf-87de-19bc5792c7d6"
      unitRef="U_USD">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="-3"
      id="F_07ead932-b268-45aa-8a62-bb39ff9eb790"
      unitRef="U_USD">105000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="-3"
      id="F_52f84544-5fd7-4250-8aa3-58718a92cb30"
      unitRef="U_USD">0</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="-3"
      id="F_0f767700-4bb9-46bd-89f6-9849eeb9858f"
      unitRef="U_USD">0</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="-3"
      id="F_5822a00d-b7cd-4d33-888b-1ac7e4de8b64"
      unitRef="U_USD">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="-3"
      id="F_62562c48-d708-41a2-a361-50d501db15d2"
      unitRef="U_USD">-2573000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="-3"
      id="F_cb27d2d1-b199-45fe-8a4f-b29a1e6c2226"
      unitRef="U_USD">-125000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="-3"
      id="F_bac4e86b-c286-446b-ab71-182d5e4592f5"
      unitRef="U_USD">-242000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="-3"
      id="F_ca487e65-13d5-450e-b5e2-4718e3ee9322"
      unitRef="U_USD">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="-3"
      id="F_86d583cf-37c7-42bc-afbe-4d44447ceb30"
      unitRef="U_USD">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="-3"
      id="F_3a4121dc-7dd6-4b80-8a31-4c0a9c84fd9a"
      unitRef="U_USD">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="-3"
      id="F_4e3a8c57-d8af-445b-87e4-45cbb5ff7bd8"
      unitRef="U_USD">0</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="-3"
      id="F_0029867e-c906-4ec1-a2bc-001f5ca140ee"
      unitRef="U_USD">-125000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="-3"
      id="F_63f0ab20-89b2-46b1-86c2-0c8693c72680"
      unitRef="U_USD">-242000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="-3"
      id="F_821664a2-86e4-408e-9c72-ed9119cce9aa"
      unitRef="U_USD">-125000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="-3"
      id="F_85d2f2cf-af75-414d-8b5e-1de5dd4c2f39"
      unitRef="U_USD">-2815000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_ebf71bd0-6119-4662-9dc2-2e319bd6c751"
      decimals="-5"
      id="F_135bea61-e36b-415c-8d2f-3eda21311cf5"
      unitRef="U_USD">100000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="C_ebf71bd0-6119-4662-9dc2-2e319bd6c751"
      decimals="-5"
      id="F_727754a5-4fc0-423f-a89c-f3d86ae9b759"
      unitRef="U_USD">1200000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="C_39a111ce-846b-4680-8cb9-7243c84bbf71"
      decimals="-5"
      id="F_5e624383-75c3-4c93-bdc4-0371bd07a3fc"
      unitRef="U_USD">2800000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_d80a1f5e-6662-4bc3-84d5-27ee37a66f78">&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;For the rate table below the (provision for) benefit from income taxes differ from the amount expected by applying the federal statutory rate to the loss before taxes as follows:&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.102%;"/&gt;
        &lt;td style="width:1.427%;"/&gt;
        &lt;td style="width:0.686%;"/&gt;
        &lt;td style="width:11.84%;"/&gt;
        &lt;td style="width:3.496%;"/&gt;
        &lt;td style="width:1.427%;"/&gt;
        &lt;td style="width:0.686%;"/&gt;
        &lt;td style="width:11.84%;"/&gt;
        &lt;td style="width:3.496%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Federal statutory income tax rate&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;21.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Other permanent differences&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;State income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.9&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Federal benefit from NOL carryback&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6.7&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Change in valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;24.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;25.8&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Change in fair value of redeemable convertible preferred stock tranche liability and TRDF liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.5&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1.0&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Provision for income taxes&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.2&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7.1&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;%&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="3"
      id="F_70345b7d-1297-4451-95db-a446297ddfee"
      unitRef="U_pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="3"
      id="F_20c3af58-1413-40e3-b421-1ff4287fc86c"
      unitRef="U_pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="3"
      id="F_9212c52d-8f33-42de-9529-727b74bb8379"
      unitRef="U_pure">-0.019</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="3"
      id="F_c952809a-8ce5-4cd5-b2b5-1e954f8117c8"
      unitRef="U_pure">-0.005</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="3"
      id="F_73bab7c6-ae18-47bc-9e06-e2910e61783d"
      unitRef="U_pure">0.069</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="3"
      id="F_9a4acd21-6765-4939-befd-f6f258273328"
      unitRef="U_pure">0.061</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <acet:EffectiveIncomeTaxRateReconciliationNOLCarryback
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="3"
      id="F_36514535-f1d7-4abf-a36f-f8b86c0aa626"
      unitRef="U_pure">0.000</acet:EffectiveIncomeTaxRateReconciliationNOLCarryback>
    <acet:EffectiveIncomeTaxRateReconciliationNOLCarryback
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="3"
      id="F_b995385b-17ae-42b6-88d2-0af988686110"
      unitRef="U_pure">0.067</acet:EffectiveIncomeTaxRateReconciliationNOLCarryback>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="3"
      id="F_5f6ef1ac-6fa0-4e39-a970-a5d766fca187"
      unitRef="U_pure">-0.248</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="3"
      id="F_5f51bcd0-1b1a-4b29-801c-8921e0e5b24c"
      unitRef="U_pure">-0.258</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <acet:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilityAndTRDFLiability
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="3"
      id="F_c301dd70-2c30-4279-99c5-98c8f68f3caf"
      unitRef="U_pure">0.000</acet:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilityAndTRDFLiability>
    <acet:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilityAndTRDFLiability
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="3"
      id="F_748f4ff7-c0a3-4318-8a76-28fc8cd63fc5"
      unitRef="U_pure">-0.005</acet:EffectiveIncomeTaxRateReconciliationChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilityAndTRDFLiability>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="3"
      id="F_7c0076e0-a4fc-4237-8f3e-999791259553"
      unitRef="U_pure">-0.010</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="3"
      id="F_b03bbe6c-5793-4963-86a9-8463c404e5c3"
      unitRef="U_pure">0.001</us-gaap:EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="3"
      id="F_40d22de7-4f95-45ec-8f7d-275978642d6f"
      unitRef="U_pure">0.002</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="3"
      id="F_102cbfed-cdcd-4ae0-98b5-9c03dd7ad13a"
      unitRef="U_pure">0.071</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_e95727ea-47d4-4001-96a2-10b6c64bb56f">&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:0.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The tax effects of temporary differences and carryforwards of the deferred tax assets are presented below (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:90.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:65.389%;"/&gt;
        &lt;td style="width:1.438%;"/&gt;
        &lt;td style="width:1.503%;"/&gt;
        &lt;td style="width:13.363%;"/&gt;
        &lt;td style="width:1.002%;"/&gt;
        &lt;td style="width:1.438%;"/&gt;
        &lt;td style="width:1.503%;"/&gt;
        &lt;td style="width:13.363%;"/&gt;
        &lt;td style="width:1.002%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred Tax Assets:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;67,675&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;51,796&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating lease right-of-use asset liability&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,504&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,686&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred revenue&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,263&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;2,857&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Stock-based compensation&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,726&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,750&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Intangible assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,081&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,195&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Fixed assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;196&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Accruals and reserves&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;1,042&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;654&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Research and development credit carryforwards&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;26&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;78,513&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;63,964&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Less: Valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;73,163&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;57,715&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred tax assets, net of valuation allowance&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,350&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,249&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Fixed assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Basis Difference IPR&amp;amp;D&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;313&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Operating lease right-of-use asset&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;5,350&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;6,061&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Net deferred tax assets&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;(&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;125&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;)&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-3"
      id="F_5405a066-1925-4897-9c25-bacf97485e29"
      unitRef="U_USD">67675000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="-3"
      id="F_46c0296a-651a-47e6-a3bd-b8a660a10934"
      unitRef="U_USD">51796000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <acet:DeferredTaxOperatingLeaseRightOfUseAssetLiability
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-3"
      id="F_be37183d-0225-4477-a617-c97e3cc0c624"
      unitRef="U_USD">5504000</acet:DeferredTaxOperatingLeaseRightOfUseAssetLiability>
    <acet:DeferredTaxOperatingLeaseRightOfUseAssetLiability
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="-3"
      id="F_22266ef9-7ba1-4b0f-948d-4d4320ad6e69"
      unitRef="U_USD">5686000</acet:DeferredTaxOperatingLeaseRightOfUseAssetLiability>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-3"
      id="F_85d58b2b-1ca8-4f32-afa2-1eed415b6cc6"
      unitRef="U_USD">1263000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="-3"
      id="F_cb992e4e-7909-4ab1-a2b7-e8f0c8468e61"
      unitRef="U_USD">2857000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-3"
      id="F_c39a0849-9ef9-4557-adf3-6680d2a62c69"
      unitRef="U_USD">1726000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="-3"
      id="F_a0ef67e7-ce84-4930-8258-9f15a58450fb"
      unitRef="U_USD">1750000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-3"
      id="F_60e5f62f-5a04-427a-b397-a0b674469c2c"
      unitRef="U_USD">1081000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="-3"
      id="F_863d8501-62c9-4247-9412-b9f883463b9c"
      unitRef="U_USD">1195000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <acet:DeferredTaxAssetsFixedAssets
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-3"
      id="F_a94b29b8-1d11-4c1e-bdb5-ed1f23690f34"
      unitRef="U_USD">196000</acet:DeferredTaxAssetsFixedAssets>
    <acet:DeferredTaxAssetsFixedAssets
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="-3"
      id="F_a75a1a47-a0f7-41db-bb56-4956ecc43a31"
      unitRef="U_USD">0</acet:DeferredTaxAssetsFixedAssets>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-3"
      id="F_97888aca-49b5-40a5-bf64-37a662e153e1"
      unitRef="U_USD">1042000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="-3"
      id="F_4eff0d36-b77a-46a5-a188-e97cd6d155c0"
      unitRef="U_USD">654000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-3"
      id="F_a600750c-e5cf-4e39-9b7b-86ba9f071a90"
      unitRef="U_USD">26000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="-3"
      id="F_853bad09-546f-4ed6-9187-d39965bdf2e1"
      unitRef="U_USD">26000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-3"
      id="F_ccd892cb-74fb-4e91-bb33-ed734a121e10"
      unitRef="U_USD">78513000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="-3"
      id="F_20db7c87-ef75-4c87-862b-53040814d547"
      unitRef="U_USD">63964000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-3"
      id="F_e2df1a08-8da1-4fc3-94a0-d6fdc814505c"
      unitRef="U_USD">73163000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="-3"
      id="F_6d2862f5-27a0-4138-91dd-6ededd672948"
      unitRef="U_USD">57715000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-3"
      id="F_22830ece-592b-4f5a-b187-cac9bb650377"
      unitRef="U_USD">5350000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="-3"
      id="F_f584c48c-d5ce-4582-a640-5186c8f778cf"
      unitRef="U_USD">6249000</us-gaap:DeferredTaxAssetsNet>
    <acet:DeferredTaxLiabilitiesFixedAssets
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-3"
      id="F_820db54f-0a7a-4252-b729-7bb165a231d4"
      unitRef="U_USD">0</acet:DeferredTaxLiabilitiesFixedAssets>
    <acet:DeferredTaxLiabilitiesFixedAssets
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="-3"
      id="F_8550b4ed-cee7-43e7-bddc-5523985868e2"
      unitRef="U_USD">0</acet:DeferredTaxLiabilitiesFixedAssets>
    <acet:DeferredTaxBasisDifferenceIPRD
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-3"
      id="F_99956645-572e-484d-9e9c-d239fe0c6313"
      unitRef="U_USD">0</acet:DeferredTaxBasisDifferenceIPRD>
    <acet:DeferredTaxBasisDifferenceIPRD
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="-3"
      id="F_dc3a9a62-3962-4608-a617-e127d7b6cb6d"
      unitRef="U_USD">-313000</acet:DeferredTaxBasisDifferenceIPRD>
    <acet:DeferredTaxOperatingLeaseRightOfUseAsset
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-3"
      id="F_db400933-eed0-4434-92f8-6df42a347dfe"
      unitRef="U_USD">-5350000</acet:DeferredTaxOperatingLeaseRightOfUseAsset>
    <acet:DeferredTaxOperatingLeaseRightOfUseAsset
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="-3"
      id="F_ce5aad38-3273-48e4-a687-855ceb3ca128"
      unitRef="U_USD">-6061000</acet:DeferredTaxOperatingLeaseRightOfUseAsset>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-3"
      id="F_9b197fdb-cf38-4be1-812c-880fcb2ec27a"
      unitRef="U_USD">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="-3"
      id="F_e0ba42a6-e4dd-4060-9bdb-42b2cf1dc333"
      unitRef="U_USD">125000</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <acet:DeferredTaxAssetsValuationAllowanceIncrease
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="-5"
      id="F_f1049ba3-f4f7-4ce4-a81b-df91fe16f8d4"
      unitRef="U_USD">15500000</acet:DeferredTaxAssetsValuationAllowanceIncrease>
    <acet:DeferredTaxAssetsValuationAllowanceIncrease
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="-5"
      id="F_6f5a55ac-269c-479c-b193-98f2b9ef1b85"
      unitRef="U_USD">37900000</acet:DeferredTaxAssetsValuationAllowanceIncrease>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_da9e6c7e-f0b9-4a9e-9854-806aece05e6c"
      decimals="-5"
      id="F_a482db41-3bb5-4475-a4a5-e23bf9a7cba7"
      unitRef="U_USD">271600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_4d645798-711d-496e-8eb5-907d5667159d"
      decimals="-5"
      id="F_435f8d82-be7e-441c-bb8a-b30a7e70124d"
      unitRef="U_USD">143500000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="C_1878c95b-a997-415a-9e16-86e0a1c15a68"
      decimals="-5"
      id="F_9acf0336-e0ae-4173-a5dd-643e9fa6d891"
      unitRef="U_USD">17100000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="C_da9e6c7e-f0b9-4a9e-9854-806aece05e6c"
      decimals="-5"
      id="F_7fc38b33-afb8-4c4b-a059-870707fef8e5"
      unitRef="U_USD">7600000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <acet:OperatingLossCarryforwardsIndefinitely
      contextRef="C_da9e6c7e-f0b9-4a9e-9854-806aece05e6c"
      decimals="-5"
      id="F_b15747e6-f8e5-4ed8-beae-902bd7553acf"
      unitRef="U_USD">264000000.0</acet:OperatingLossCarryforwardsIndefinitely>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_da9e6c7e-f0b9-4a9e-9854-806aece05e6c"
      decimals="-5"
      id="F_738ba14a-9b1d-49e3-b0a1-ed17d2b92f61"
      unitRef="U_USD">1800000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount
      contextRef="C_775ace4d-f0e0-4bb0-b785-08666d208bbb"
      decimals="-5"
      id="F_a4664222-af4b-4c31-b3ea-e2e4625ea6a3"
      unitRef="U_USD">1500000</us-gaap:TaxCreditCarryforwardAmount>
    <acet:OwnershipChangePlanDescription
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      id="F_d25255cd-70f3-47bb-a267-259268e67b52">In general, an ownership change, as defined by Section 382, results from transactions increasing the ownership of certain shareholders or public groups in the stock of a corporation by more than 50% over a three-year period</acet:OwnershipChangePlanDescription>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_188057dd-d8a2-49b6-b276-041c6c6962c8"
      decimals="-5"
      id="F_098061f1-f53a-48a4-a495-ee2e72ba9ac3"
      unitRef="U_USD">800000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_594a64fe-9232-4c34-a446-273a36865ed4"
      decimals="-5"
      id="F_3661ff44-ee31-4c32-872c-e72a720bf2d3"
      unitRef="U_USD">3200000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_78b8f27e-f6e9-4f88-a3ce-0ada280168c3">&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;A reconciliation of the beginning and ending unrecognized tax benefit amount is as follows (in thousands):&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:0.0pt;line-height:1.15;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;
      &lt;table style="margin-left:auto;border-spacing:0;table-layout:fixed;width:100.0%;border-collapse:separate;margin-right:auto;"&gt;
       &lt;tr style="visibility:collapse;"&gt;
        &lt;td style="width:66.82%;"/&gt;
        &lt;td style="width:1.489%;"/&gt;
        &lt;td style="width:1.284%;"/&gt;
        &lt;td style="width:13.199%;"/&gt;
        &lt;td style="width:0.627%;"/&gt;
        &lt;td style="width:1.489%;"/&gt;
        &lt;td style="width:1.284%;"/&gt;
        &lt;td style="width:13.18%;"/&gt;
        &lt;td style="width:0.627%;"/&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="6" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:8.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2021&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td colspan="2" style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:8.0pt;font-family:Times New Roman;"&gt;2020&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);text-align:left;"&gt;&lt;p style="text-indent:0.0pt;font-size:8.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:center;"&gt;&lt;span style="white-space:pre-wrap;font-size:8.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Balance at the beginning of the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;797&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;797&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(0,0,0,0);text-indent:10.0pt;word-break:break-word;vertical-align:top;"&gt;&lt;p style="margin-left:10.0pt;text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Adjustment based on tax positions related to current year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;3,243&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;&#x2014;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(0,0,0,0);word-break:break-word;vertical-align:bottom;border-bottom:0.500pt solid rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
       &lt;tr style="height:10.0pt;"&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:top;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Balance at the end of the year&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4,040&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;$&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(0,0,0,1);text-align:center;"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:right;"&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;797&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
        &lt;td style="background-color:rgba(207,240,252,1);word-break:break-word;vertical-align:bottom;border-bottom:2.250pt double rgba(255,255,255,0.01);"&gt;&lt;p style="text-indent:0.0pt;font-size:10.0pt;margin-top:0.0pt;line-height:1.05;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="white-space:pre-wrap;font-size:10.0pt;font-family:Times New Roman;"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;
       &lt;/tr&gt;
      &lt;/table&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="-3"
      id="F_e7614a64-f3b8-4622-a5fd-5541890f2be5"
      unitRef="U_USD">797000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_95800697-5c2c-4d5a-aff7-318a343c4784"
      decimals="-3"
      id="F_2fefc43b-a9ae-4d51-81ce-c09f4e0dc1c1"
      unitRef="U_USD">797000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="-3"
      id="F_30a1fa9f-745f-4dbc-ab2d-95938cc977b0"
      unitRef="U_USD">3243000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="-3"
      id="F_a820f87f-b292-4943-97d5-ac58f1f3dea4"
      unitRef="U_USD">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b"
      decimals="-3"
      id="F_6946feb3-3874-4350-8b9a-b67209729075"
      unitRef="U_USD">4040000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="C_25b4b380-f29f-4199-a59a-67e5d8821aef"
      decimals="-3"
      id="F_1fc9d9ee-50bd-4a40-bc34-046ceda3865f"
      unitRef="U_USD">797000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:DefinedContributionPlanTextBlock
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_cbda20cc-f366-414e-b695-7e96b8f00e49">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;18. Defined Contribution Plan&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:left;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;The Company maintains a defined contribution plan under Section 401(k) of the Internal Revenue Code covering substantially all full-time United States employees. Employee contributions are voluntary and are determined on an individual basis subject to the maximum allowable under federal tax regulations. During the year ended December 31, 2021 the Company made aggregate matching contributions of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.3&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million. The Company did &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;no&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;t make contributions to the 401(k) plan during 2020.&lt;/span&gt;&lt;/p&gt;</us-gaap:DefinedContributionPlanTextBlock>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      decimals="-5"
      id="F_c4ba052a-aa11-44b4-a92d-c2fac1221537"
      unitRef="U_USD">300000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <acet:CompanyContributionToPlanWithRespectToEmployeesContribution
      contextRef="C_3f32af84-ec12-4ae0-9cc1-f2521512740c"
      decimals="-3"
      id="F_31ad9f53-ca99-415f-b8d9-40d32262afbf"
      unitRef="U_USD">0</acet:CompanyContributionToPlanWithRespectToEmployeesContribution>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_6f2f4869-61c0-4d89-9f7e-255aa66d09e8">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;19. Related Party Transactions&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;As of December 31, 2021, Regeneron owned &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;883,568&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of the Company's common stock. Regeneron became a related party in July 2019 as a result of Series B redeemable convertible preferred stock financing. Upon closing the Merger, &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;7,125,552&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of the redeemable convertible preferred stock converted into &lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;883,568&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; shares of the Company&#x2019;s common stock. For the years ended December 31, 2021 and 2020, the Company recorded revenue related to the Regeneron Agreement of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;9.7&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million and $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;17.9&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million, respectively. As of December 31, 2021, the Company recorded less than $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;0.2&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million in accounts receivable and has deferred revenue of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;4.8&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million related to the Regeneron Agreement (See Note 10).&lt;/span&gt;&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:CommonStockSharesIssued
      contextRef="C_c38e333f-e2eb-4d69-906a-0a7b3cfda69b"
      decimals="INF"
      id="F_39529796-c96a-4ac8-9d6d-a878b8e47030"
      unitRef="U_shares">883568</us-gaap:CommonStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="C_c38e333f-e2eb-4d69-906a-0a7b3cfda69b"
      decimals="INF"
      id="F_6d9fea93-71de-4e92-925e-4bb41459658f"
      unitRef="U_shares">7125552</us-gaap:PreferredStockSharesIssued>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="C_32996dbe-7c67-4061-9092-811f3ea449f5"
      decimals="INF"
      id="F_75ac485c-0a03-4efb-a740-b2d6791037f6"
      unitRef="U_shares">883568</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:RevenueFromRelatedParties
      contextRef="C_d85d1bbc-33b7-4189-abac-0387bd90ab52"
      decimals="-5"
      id="F_d61c50cb-82af-419c-8cc4-020ad93d8487"
      unitRef="U_USD">9700000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RevenueFromRelatedParties
      contextRef="C_a9b28221-7291-479e-aade-1c4cce9e9ee2"
      decimals="-5"
      id="F_c1d50901-e757-4fe3-9d3e-f3a4052e45ac"
      unitRef="U_USD">17900000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:AccountsReceivableGrossCurrent
      contextRef="C_32996dbe-7c67-4061-9092-811f3ea449f5"
      decimals="-5"
      id="F_fbd35bc8-e769-4995-96bc-a7fbaf8ad4f6"
      unitRef="U_USD">200000</us-gaap:AccountsReceivableGrossCurrent>
    <us-gaap:DeferredRevenue
      contextRef="C_32996dbe-7c67-4061-9092-811f3ea449f5"
      decimals="-5"
      id="F_b829ea69-a159-4831-8cf5-bd7c32eb5a39"
      unitRef="U_USD">4800000</us-gaap:DeferredRevenue>
    <us-gaap:SubsequentEventsTextBlock
      contextRef="C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c"
      id="F_b28dc005-4907-45d8-809a-4fe3949f37cc">&lt;p style="text-indent:0.0%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:bold;font-size:10.0pt;font-family:Times New Roman;"&gt;20. Subsequent Events&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;font-style:italic;"&gt;Regeneron Option&lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;On January 28, 2022, Regeneron exercised its option to license the exclusive, worldwide rights to ADI-002, an allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapy directed against Glypican-3, pursuant to the Regeneron Agreement.&lt;br/&gt; In conjunction with the exercise of the Option, Regeneron paid an exercise fee of $&lt;/span&gt;&lt;span style="font-size:10.0pt;font-family:Times New Roman;background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;20.0&lt;/span&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; million to the Company on January 28, 2022.&lt;/span&gt;&lt;span style="color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt; &lt;/span&gt;&lt;/p&gt;&lt;p style="text-indent:3.333%;font-size:10.0pt;margin-top:12.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"&gt;&lt;span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:10.0pt;font-family:Times New Roman;"&gt;Pursuant to the Regeneron Agreement, upon Regeneron&#x2019;s exercise of the option, the Company had a specified period of time to elect to co-fund ADI-002&#x2019;s future development costs, and to participate in any potential profits with Regeneron up to a specified co-funding percentage in various geographic regions, including on a worldwide basis (Co-Funding Option). Adicet elected not to exercise its Co-Funding Option for ADI-002. Accordingly, Regeneron is responsible, at its sole cost, for all development, manufacturing and commercialization of ADI-002 and must pay the Company high single digit royalties as a percentage of any net sales of ADI-002 for a period commencing on the first commercial sale until the longer of (i) the expiration or invalidity of the licensed patent rights or (ii) a low double digit amount of years from first commercial sale.&lt;/span&gt;&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <acet:ExerciseFeePaid
      contextRef="C_7c105d75-0eff-40e5-a076-0166362fc4d4"
      decimals="-5"
      id="F_e09963e7-23a7-4957-b51d-2b5c2a898ac8"
      unitRef="U_USD">20000000.0</acet:ExerciseFeePaid>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#F_02ca4e77-9c2a-4c1c-a9ab-6dcb167902d3"
          xlink:label="F_02ca4e77-9c2a-4c1c-a9ab-6dcb167902d3"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_41788e52-a9f6-472d-b520-3c5c3a010951"
          xlink:label="F_41788e52-a9f6-472d-b520-3c5c3a010951"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_803ea030-804d-4af6-ae34-b6185545f97e"
          xlink:label="F_803ea030-804d-4af6-ae34-b6185545f97e"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_fa98f595-6fe9-482c-a845-5536ac884496"
          xlink:label="F_fa98f595-6fe9-482c-a845-5536ac884496"
          xlink:type="locator"/>
        <link:footnote id="FNT_3577aa04-acc2-44f1-903a-a30dd6a3a68b" xlink:label="FNT_3577aa04-acc2-44f1-903a-a30dd6a3a68b" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Included in cash and cash equivalents in the consolidated balance sheets</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_02ca4e77-9c2a-4c1c-a9ab-6dcb167902d3"
          xlink:to="FNT_3577aa04-acc2-44f1-903a-a30dd6a3a68b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_41788e52-a9f6-472d-b520-3c5c3a010951"
          xlink:to="FNT_3577aa04-acc2-44f1-903a-a30dd6a3a68b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_803ea030-804d-4af6-ae34-b6185545f97e"
          xlink:to="FNT_3577aa04-acc2-44f1-903a-a30dd6a3a68b"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_fa98f595-6fe9-482c-a845-5536ac884496"
          xlink:to="FNT_3577aa04-acc2-44f1-903a-a30dd6a3a68b"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_f92de538-49fa-4f31-8dab-f0d8259d1d68"
          xlink:label="F_f92de538-49fa-4f31-8dab-f0d8259d1d68"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_286b4dd8-de72-4494-a772-8e314c9d9fb7"
          xlink:label="F_286b4dd8-de72-4494-a772-8e314c9d9fb7"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_8b9f407e-f217-4fde-baff-1f665d44ddc0"
          xlink:label="F_8b9f407e-f217-4fde-baff-1f665d44ddc0"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_170bf009-3fc4-40d7-bdea-5719513fa678"
          xlink:label="F_170bf009-3fc4-40d7-bdea-5719513fa678"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_305f8387-b718-488f-a8a2-0200819b734c"
          xlink:label="F_305f8387-b718-488f-a8a2-0200819b734c"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_fdec90d6-ca79-4616-84a2-3da07ccd4eb7"
          xlink:label="F_fdec90d6-ca79-4616-84a2-3da07ccd4eb7"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_e7895ac5-a282-4161-858e-49465cbe531e"
          xlink:label="F_e7895ac5-a282-4161-858e-49465cbe531e"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_0099be2f-edcf-42f8-9783-ee98ff854bed"
          xlink:label="F_0099be2f-edcf-42f8-9783-ee98ff854bed"
          xlink:type="locator"/>
        <link:footnote id="FNT_7667a44b-4b7d-46fe-a77a-02f957bfe903" xlink:label="FNT_7667a44b-4b7d-46fe-a77a-02f957bfe903" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">Included in short-term marketable debt securities in the consolidated balance sheets.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_f92de538-49fa-4f31-8dab-f0d8259d1d68"
          xlink:to="FNT_7667a44b-4b7d-46fe-a77a-02f957bfe903"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_286b4dd8-de72-4494-a772-8e314c9d9fb7"
          xlink:to="FNT_7667a44b-4b7d-46fe-a77a-02f957bfe903"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_8b9f407e-f217-4fde-baff-1f665d44ddc0"
          xlink:to="FNT_7667a44b-4b7d-46fe-a77a-02f957bfe903"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_170bf009-3fc4-40d7-bdea-5719513fa678"
          xlink:to="FNT_7667a44b-4b7d-46fe-a77a-02f957bfe903"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_305f8387-b718-488f-a8a2-0200819b734c"
          xlink:to="FNT_7667a44b-4b7d-46fe-a77a-02f957bfe903"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_fdec90d6-ca79-4616-84a2-3da07ccd4eb7"
          xlink:to="FNT_7667a44b-4b7d-46fe-a77a-02f957bfe903"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_e7895ac5-a282-4161-858e-49465cbe531e"
          xlink:to="FNT_7667a44b-4b7d-46fe-a77a-02f957bfe903"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_0099be2f-edcf-42f8-9783-ee98ff854bed"
          xlink:to="FNT_7667a44b-4b7d-46fe-a77a-02f957bfe903"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#F_37a62b6e-7f72-4455-bb60-c81a41a19eec"
          xlink:label="F_37a62b6e-7f72-4455-bb60-c81a41a19eec"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#F_c8d12e80-3ad7-488e-a4d6-720e653a110e"
          xlink:label="F_c8d12e80-3ad7-488e-a4d6-720e653a110e"
          xlink:type="locator"/>
        <link:footnote id="FNT_9de3ffc8-0280-4d4d-8e75-e7b828a8e6e2" xlink:label="FNT_9de3ffc8-0280-4d4d-8e75-e7b828a8e6e2" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:p style="text-indent:-3.448%;padding-left:3.333%;font-size:10.0pt;margin-top:6.0pt;line-height:1.035;font-family:Times New Roman;margin-bottom:0.0pt;text-align:justify;"><xhtml:span style="background-color:rgba(0,0,0,0);color:rgba(0,0,0,1);white-space:pre-wrap;font-weight:normal;font-size:9.0pt;font-family:Times New Roman;">(1)	Deductions to contract liabilities relate to deferred revenue recognized as revenue during the reporting period.</xhtml:span></xhtml:p></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_37a62b6e-7f72-4455-bb60-c81a41a19eec"
          xlink:to="FNT_9de3ffc8-0280-4d4d-8e75-e7b828a8e6e2"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="F_c8d12e80-3ad7-488e-a4d6-720e653a110e"
          xlink:to="FNT_9de3ffc8-0280-4d4d-8e75-e7b828a8e6e2"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>126
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M%P,(@ZJ\BBP?C-RXR[F%-$9F[N>:,U@MM@%\7TII]@^V@_I"^/;_4$L#!!0
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M'-_V3B?=G&;@X?6C]Y_;X"&8:Z;XF2C_*G*]/IVD$Y3S%6M*?2GN?N7[@%J
MF2A5^S^ZV]L&$Y0U2HMJ/Q@05$6]^\ON]XDX&(##D0%D/X"\= #=#Z!MH#MD
M;5CG3+/EB11W2!IK\&8NVMRTHR&:HC:O\4I+^+6 <7IY)FHERB)GFN?H(RM9
MG7%T9=PI-$-?K\[1VS?OT!M4U.C+6C2*U;DZF6N8V8R?9_M9/NYF(2.SG//L
M"%$\120@V#'\[.7#@Z?#YQ!O%S3I@B:M/SH6=",EKS5B2D&<QQZ/M/-(6X_A
MF$>FU@AR@S)SP;\UQ9:5,(4S5SM74>O*;+/MDB1)%(8G\^UA3FRS-*0TZ*R>
M  T[H*$7Z-5:2#W37%:PBN0MU^RZY+#NKS52/&MDH0ON!+US&Q^@"09X;0L<
MD#1TXXTZO)$7[X<L$PWD$5WRC$-2#=H9U(^R7; ;)O6#"VUD8TFC 5[OQ*9\
M'JL-R_CI!.JCXG++)TOD62IQ%U'LC>A"\@TK<L3OH10KKMIE(_2:2]COA^O2
M%5=LQ14FP6(0F&T4)82XWT/2H4Z\J+\(S<H7 $RLN4E*0IH.(-IF. @HC=T@
MTPYD^DQJ@=Y@1;0I-9MP X2CIZCFVH4UM4&$<4@'4&TKDBQ&=N&B [KP OT,
M,)DNZAM4<N @) W9S,1JUL!-FUP7WH6-)*#1,+4.*QK$(YG%0<\3@1?R+T+D
M=T59.HM_8&=R$<9D@,QA!FHC78Q .Z P[(7VJ9YMI,BX4LCL5":S72W.^19D
M2KL&G)R#;=1X[,WBGELP\:*YY$K+(C/ER9"!,U_$GCD:EE.'41B19 1>3U38
MSU2_B?KF7]3_L[U;-P$\Q=)S$?:3T>>VZM6BGCU?6+"#7M(T&2;-947'DM:3
M$/:ST*[Z><#9?$-INK#*GL,.1S2ET0C GE-P_")%4Q;LNBC;E^B3-;@O^]A?
M]SO^W; 'LU2<T=O5G))X6$<=5CB*1F@)]R4?^VL^"%@MH1DX#/W''U*"R?LG
M*F'Z2%[.".PB'Z;!4# XK#!=I&/;H"<#[&<#R+%L *<M! YB<L*V:WT<IU;9
MM:VBA(XDGO2$0/R$,.2P1ZQ./48<#!'%P]WKLB)X9'.0GA^(GQ^>:I=G<DH<
MK!!3;$&US0@)DQ$N(P>=B9\]1K/:JA@D5ET<&Q#RT @[8W#PRX(F5@RV&0E"
M,J+824\QY)EF"+8D1&! 9M!>%GD;$O3L_B7B=?HB/;X/RV:JT4U*>JXB?JXZ
MYRL.B<^19O?/!.)U])I '&1&QG9#SV7$SV4VZ3ZW(QRDA8>UT3_IZ[LITE,?
M\?=3N]W]7 QV3P3*V>J<'&9A"!)U).<]BQ(_BYZ)JBJT$:*[=B][W"$9X$5O
M_Q":(TS>.9%[/;]F-7V_HZ?1]Q1-4J\XN=(BNUV+$NK CIJ3]VUW!HW:VYRO
MBJS0[WQJA?1,2OQ,"KWU?I<J,^<4O0F.@B# 1@*@+2L;/D4XF,(C\P^I-9.F
M 6_T6LCB;T/!RI38<Y[QZAIVR>.15?O2AD^#J6DW-KP]B"P?WIL]Q5&A5,?E
MC58:+DPU_P['SE7AS<-K5L7W.WIZ8-;K!^K7#V9/ "=X7E3TG[TINI@F-)XN
M<-C:X\4T3I(I"1>/$_T_;Y':>L<Z!'3TS.YJ1'L]1/UZZ$.>%X:/H6R:DZA9
M44.GNBF@C#I!VDHG3' 8#FNGPX[@&).1DP?:2R+JET0@CYNJV4GY?;EPXK35
MS S'*2562EV&04S'J)4>' +[A<\ATKV0%Q7LF[7Y[+&%VE##O;.%\CM^Q7ZF
MMO@9$W2TUS[4KWUV%*L.ROA/^P+NC,66+32@F%@+QG5@O$C'CCAHKW#H2[KU
M T5@=F+.>=6>=0#W;CE(9W.]&?*%V<@OCC.R#NB=3;_#SMGTSP^^XIA/:+\S
M>5/4"AJ!%0P,CA+P('=?I78W6FS:#SO70FM1M9=KS@"V,8#?5P)TQ?[&?"OJ
MO@TN_P%02P,$%     @ #H)O5+C\&,Z3 @  U@@  !@   !X;"]W;W)K<VAE
M971S+W-H965T,RYX;6R=EEUOFS 4AO^*A7:Q25WX#(0J05I33=O%I*C1MFL7
M3H)58S/;)-U^_6Q#4=*0A#87X(_S'C^O<\#,]UP\R1) H>>*,KEP2J7J6]>5
M>0D5EA-> ],S&RXJK'17;%U9"\"%%574#3PO=BM,F)/-[=A*9'/>*$H8K 22
M355A\?<.*-\O'-]Y&7@@VU*9 3>;UW@+:U _ZY70/;?/4I *F"2<(0&;A?/%
MOUVF)MX&_"*PEP=M9)P\<OYD.M^+A>,9(*"0*Y,!Z]L.ED"I2:0Q_G0YG7Y)
M(SQLOV3_:KUK+X]8PI+3WZ10Y<*9.:B #6ZH>N#[;]#YF9I\.:?27M&^C9TF
M#LH;J7C5B35!15A[Q\_=/AP(_.B,(.@$P5A!V E":[0EL[;NL<+97/ ]$B9:
M9S,-NS=6K=T09O[%M1)ZEFB=RI:<24Y)@144Z Y3S') :Y-.HH\K+("I$A3)
M,?V$/J,/R$6RU*-R[BJ]NLGAYMU*=^U*P9F5[B&?H-"_08$7^ /RY7BY=RQW
MM>?>>- ;#VR^Z*SQJM)EI#<X?[I!-19HAVD#0[[:1(E-9)Z*7>9-/,_3)G:'
M_%?#CCC#GC-\ V>[^0@WJN2"_(-BB+=-&!^ ^%.O_;U"'A-Y1!WUU-';J8F4
MS3!Q=,(1IDD8IW[T"O@TT$_C) FB=)AWVO-.W\ZK7WI28580MAV"GHZ%/@V\
M#!WWT/%%Z)5^XX$0^L%=CZCB>%P57PT[0DUZU&0DJMWB<76<G.[;<!F/"#RB
MGO74L_=0GZ_CV0G(:]1+$4>,:<^8OH?Q2NVF5T$O1;2@[L&I8T[\'UAL"9.(
MPD9KO$FBZUZTIVC;4;RV!]$C5_I8L\U2?WB , %Z?L.Y>NF8LZW_E,G^ U!+
M P04    "  .@F]4X0'4[<$$  !\$   &    'AL+W=O<FMS:&5E=',O<VAE
M970T+GAM;+68W7.C-A# _Q6->]-)9I(8@3$F=3R3Y/J1F5XODUQZ#YT^R&9M
MF !R)6'G^M=W)3#8(,B]- \QX-WEMRMI/SS?<_$J8P!%WK(TES>C6*GM]7@L
M5S%D3%[Q+>3XS9J+C"F\%9NQW I@D5'*TK'K.--QQI)\M)B;9X]B,>>%2I,<
M'@61198Q\>T.4KZ_&='1X<%3LHF5?C!>S+=L \^@7K:/ N_&M94HR2"7"<^)
M@/7-Z)9>W[M&P4C\F<!>'ET3[<J2\U=]\Q#=C!Q-!"FLE#;!\&,']Y"FVA)R
M_%,9'=7OU(K'UP?KOQCGT9DEDW#/TZ])I.*;T6Q$(EBS(E5/?/\;5 [YVMZ*
MI]+\)_M*UAF152$5SRIE),B2O/QD;U4@CA3HM$?!K13<ML*D1\&K%#SC:$EF
MW/K(%%O,!=\3H:71FKXPL3':Z$V2ZV5\5@*_35!/+>YY+GF:1$Q!1)X5?N :
M*4GXFGS>@F ZUI*P/"+W/,.-$NL5W 'YG4M)+LG+\T=R]N&<?"!)3K[$O) H
M*N=CA6CZ!>-5A7%78K@]&-0EGWBN8DE^SB.(3@V,T:?:,??@V)T[:/$CK*Z(
M1R^(Z[C4 G3__>K. (Y7Q]DS]KP>>P_YBF?01)C\=;N42N N_GO ^J2V/C'6
M)SW6GV '>0$__C!SJ?N3@-0LYY8)]<VV%J4QWQC3YWRW" ,/O=P=QZ<K1(/0
M\6JI$U"_!O4'PU#MJ7Q#X TSD01Y/>#^M+8Z?<=]"4RL8K-/(XQ%RK<ZR#;?
M2TO3([<FLW#BM9SO2GD3SYO8G0]JS& 0\U?(T?O44+((#W.B=X!.8S;0H(/@
MXE][E6Q2P=2Q@\YJT-D@Z!>N$)-WULJ&.>L !)1.V_'L2OF!$_;$,ZPQPT%,
MDX/6@F<'5$Q5-L2P\_++*<7E;#%:Q+R0AM0.29TFPSJ#F ^Y @%288K4.<":
M')W.NX_>6^)99(*9WP-WE/[I]\%5:VREH]W(T&#:YK-)]1T9ZC: [B#@9Q6#
MJ$)'SBK*\PN2@_5X5]9.%]OIL%JD0K\GM]$FQU/O_0VY!&RNX$"LV!L^R6&=
MV'$]"R[F\$D;V"+GA9.P#[DI''2X<CPTF%5LR5G%>VX%GEA6V?7;N!8I=T;[
M=FM3/:@_2/L']K4I!ME*YG<*%A[S, S;;!8Y;SH-9CUP31&BPU7H $<P&1$9
M,]P$3"F1+ O%EBG&F!.,=8:]*W9UJ]>8IQ$(>:&[T&15EJXD+52[^ZF\FW:I
MW;9GI<SL6,:_<OH26%.VZ'#=^FIZ88@NV0[3[ 9*YR0I)#89V/>A5]O"%(K\
M?PU!M]9Y3NB[U.\$HBL9>+@5@J G%$UAI+/A_L5DH]5)*WS(3=KQ\Z%VAC:%
MC0Y7MI<<1[(T^1?CN\%1K+)-,&XX:[U"&<P(EHI(6!4B40E(DQ)UWXYGV1J^
MT+*#.GFF*]2S?=RF_KG#]:_J)MZ+G(W9[=:\+K-%J(^Y*8ON<%D\'7;Z4DYE
MY#3EX,#0[BQL<CKEM+?C^&B.RT!LS'@K,6A%KLK)IWY:C]"W9G!L/;_#T;H<
MA!LSY5S^B8E-@A-="FLTZ5P%""7*4;>\47QKIL4E5SA[FLL8&!Y3+8#?KSE7
MAQO]@OH'A\5_4$L#!!0    (  Z";U2[\XHY[P8  * C   8    >&PO=V]R
M:W-H965T<R]S:&5E=#4N>&ULS5IM;]LV$/XKA%%@"1#7(JG7(C'0V$D78-V"
MIMT^,S(="Y5$EZ3M]-^/>HEDB13MN-W0+XULWU'/W9'W/*?J<L?X5[&B5(+G
M+,W%U6@EY?K=9"+B%<V(>,O6-%>_+!G/B%0?^=-$K#DEB](I2R?(<?Q)1I)\
M-+TLO[OGTTNVD6F2TWL.Q";+"/]^35.VNQK!T<L7GY*GE2R^F$POU^2)/E#Y
M97W/U:=)L\HBR6@N$I8#3I=7H_?PW0<<%0ZEQ=\)W8F]:U"$\LC8U^+#W>)J
MY!2(:$IC62Q!U)\MG=$T+592.+[5BXZ:>Q:.^]<OJ]^6P:M@'HF@,Y;^DRSD
MZFH4CL""+LDFE9_8[G=:!^05Z\4L%>6_8%?;.B,0;X1D6>VL$&1)7OTESW4B
M]AP@'G! M0/J.:C,F!UP[8"/O8-;.[@]!Q0,.'BU@]=W& K:KQW\GH/K#S@$
MM4-0%JO*;EF:.9%D>LG9#O#"6JU67)3U+;U519*\V(H/DJM?$^4GIS.6"Y8F
M"R+I CQ(]4?M,RD 6X)/=$'5OG],*5!66\IE4ES?J[U".2_-6?P5D+R^6K%T
M0;GX#=Q\VR3R.SB;TV42)_(<C,&7ASDX>W,.WH D!Y]7;".4F[B<2!5" 602
MUW"O*[AH .YG)DEJ<)O9W8X+Q;#NW+[NC&69.D]#WC=V[_>+15*<1Y*">Y(L
MQBHU,[).S!'>'E@KCC?9)BW+6.?=L,B'XQ?Y2ZXH5]G*5(=;%:UG2\%='K.,
M@K,_F!#GW>4G:M\UFP\UFP^5]W,'[G=-4I+'%!"I,,=O 887 #DP,NV+:B6O
M7*GHK]OIV'>P[U].MOOULMZPZ.OOQ)K$]&JDPA*4;^EH"DR5TV\7(2_LWNS6
MA"GRW:!K]D$W0[@QZ20.-XG#QR3N JCCNF9<<0B@Y:&[ &)%5&3'I'16W</?
MCS& OA\A:$;G-NC<T] =A<K5L@6AZX0#&?,:3-YQF([/S]S3\H.@YWE!:(;B
M-U!\*Y0[(3;EME<]-JX:B"@[Z6:M+NDSY7$BRE^KK]FZ:!+&9NEK"%W?Z9T(
M7\]GU^+&L(H7F6,,FAB#_R+&E_*8JA$8JN$$'C(##1N@H15HV;K'A9A9%$"5
MPA.DU$CTN;BFIJR'&A(/^;B7U -&';!1 S:R@JVXJU2!1>:JG:RN>$MO\1Z]
MK1MZJY(LV9Y/IRJ*>91C7LO#72)70+5_\)'R)\I-*8BTZ'J'M*I9='#O#2PT
M4%7HM++&^0539=F_LQKP?JAC>[^%>R(._H+1&J.$.B?:^C=LM0*TBX5?KJ+S
M&G!G\R+'#?U@J* MOT,[P=\\QRN2/^G]\]4G%>HL'V(/]G33S4&S;B"M%(!V
M+7!:(-:LNX;.Z@1^Y U@;24"M&L$.VF1.%8#-"_%\98*F>1/RE"!E#R)9;//
M-GFBQJ?7ETD7&S[2BF0WZH;=RA'X(WK$'#8X)6YP]E!6]=Q85EV%>*[G#;6-
M5HA NQ+IMHTCF\6.<$Z*,5AUC4Y*7GXPEM"@4"*$^C4\8-4-LY4QT*YC_J02
MI&HL,P+3M<A834Y!?YPY;-<%U\H6:-<MU2P9=V;)0; &1=";IZPFW4&TU0O(
MKA?,HRARC*.HSN30B4(4]&=11Q_\>KO!L!2"/NR?_%N#W1@Z/D9>?]8T+.@.
M)*>5%\@N+UX[;AK3-JMOL@_-&4"V]P#AJ"<(!T?- 40__K2@B[OE=W3D ']\
M_N9(IV@8^4& W(%A#;4LC>PL_1-'4J3/[ZX?AOU]KY-XQZH;1\O@Z$<8_)2Q
M\QKIG LA\C".^J?]L&$WJI:@T8D$S6GUK$ZQU#+)E8DBYPN0*RI0ELF+5\Q$
M]4#W38CP1>2:>YK^F #A((JTGF:PZ]=69_)RJ0%]AEHJ1R<^5#@Q#S:5B72:
MAF$$_7!(D:"6JI&=J@?#6#)%DD2L4BI$9[/:5(?]9B?TL);5D9W53X_#FG@#
MN8?.@,C%+;]C.[];]H[8I*6J77*6@9MLG;+OE-;_N7&_X6I^4>CO5;\VI1\;
MM #JM8:; T;=D%I6QG96_ADAV2J!=;Z&GI*# [A;SL9VSC[ED1LVC=H>[#]-
M.FC6A;SWN-U.U__?$&$'\OKCC%L-@.T:P#9!8)VNQSZ,HMY&OSULUP77$CNV
M$_MK)@BL$_%X3P-7.OF 41=FR]38SM0#4P0TPM29%#M8:QYS@YW;W_8&DP"Z
MKE8>W6ZL* WKV;&&><(N;#D>VSG^U:.&*;<SK+/WP*B!6]K&=MH^>M0P(_K)
M-(U;FL9VFCXP:IC0SK%.PC@*L!_!_A&9[+UZ4+R[\I'PIR07(*5+Y>J\#=1F
MX]7K(-4'R=;EVPB/3$J6E9<K2A:4%P;J]R5C\N5#\8)#\U+.]%]02P,$%
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M:'T GU?&T,GQ"8:_2/X&4$L#!!0    (  Z";U3.%8]:X@D  /(M   8
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MP)P^>%/SC?J%\=YL^)]TIU%9>@"_+PV@)'Z@!=K_8O'VOP%02P,$%     @
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MK8<>OW0L!1BQ*[A2>*:N!R([A(2'N_<M7W(+6HK#M1B9<=T-<"6!I&^+80O
MK@O"SQ(TK-ZQO)W'C7O=VS8_((FNT:)CM 9A<4#4I.?34P"C(=))]Y;W(_DW
M /. \R#)A_,(0FR:H06*%%Q?X;D *O ]:A0P&3Q)YT0>BTC36N)]ZIAT-X"K
M*!O@3+Q%!X+XW9=\J\ID1T(Y3C^:DT3TBFX(=&"Z-]3FB&@:$!=99W3SO 1<
M L2*=U*Y>V#;,&]$B8H8#@RMP_.MNQ]  V_:0\;:(XX80"_I0;_?$4:0!.E]
MU!F5$P F \4!\$#%)$J&PP.XF;883KC)^AZ050@.KJ1S]WQ7@"TX0W@DO372
MO)$&&^4XRJ3,?2,6I-P) 8__PWL%CI*C<4[HV;0=SA7VBY<+ UNA4@_H5!>$
ME$LWLB?)E]ZU)^HAO*G\9P<X U_7=%='4'Z$GWN 0H471&,3S&>M[SS[ .KH
M!EDRGT]!T3=]3GQS>=LI>/8@"U,P_/V.X9\X!>VD3K=#()7[!4R 2P/$DUL;
MW3/CWK$GX&X>FPJU+#*1@E1[<N< D#E^\V%)G(V&(X]W93<SAPY CJ[JX/V(
M%RMO6!%%U V872TC)FH(,!,)0N;QS]_3\F70J!0K1(;S"?BR<%H#7A2)H%$!
M%M:@>.=SLFU\\GG9-MUJRE.,=E$+R^:[14X?01=W-LO-@R8"=AI,<$R&B]Z0
M<K&P$)(F7$EO./B'*(&O60)_(-.T%H<@Z7FX^"^NO4?!DK G%=8%6 "HP7SX
M>/O/(!%^?!OP8__@02P0H185?,ER/R<IXS:H#;LSM"5F= %4UF7^..]((;%:
M:X<2A'7C97N#SQC8P.@DG?#Q1Q90Y'1 ZJN<*!-SNCE?>8H8!A!/*C2))MXD
M+"68-(E.O,XK9(89.32[F6V=D9%N88-J5R+>U@=5V96O%$W7BU A>#%+1H.T
MJ9I[5#3@-]CVUK4%6S"//F?;MBF' B][-",KO&1[B6DG%I8=HPX(]7[)KW\!
M_(-M(JLI\NXAVX :1;N3ZP]<+0!ZK RRK@%B&KD/@?C1N_U4RR)#4HESS0[
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M24@M1,E8DB+0270.53!X&&6D@82X*$G!'OF/PH++ZL<&Y!*R^0!ZH*U>E I
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M;'-PK'G5E,H#PF0%Q]P!LW"M<#<Y&%B. .M.@QH[@CA%+/#T:%X.O*UH6(7
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M@(:U]%5A63MTU":,,S( 65>(P8Q23U/F;R/F0-Y^.AM  Q75!K.MHT^&8V5
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M0A><P![-?O%V/V N+>6L$'/E;.L/)MLZSVZJ9N PUT##KDT>W&_:=P#0ACW
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M/K@<& X^ +]O&N"#\@$7V#?M9]K>Z_\!4$L#!!0    (  Z";U2Q/T"-_1
M $0U   9    >&PO=V]R:W-H965T<R]S:&5E=#$P+GAM;-5;27,;.9:^\U<@
M-)YN*2)%<9$HR5N$O-2,.\9EA>QV'R;F &:"),JY%9 I6?7K^WL/0"Y4IBQW
M1QWF(B63P-MW@"_O"O/-[I2JQ/<LS>VK@UU5E<]/3FR\4YFTTZ)4.;[9%":3
M%3Z:[8DMC9();\K2D\5LMCK)I,X/7K_D=]?F]<NBKE*=JVLC;)UETMR_46EQ
M]^I@?A!>W.CMKJ(7)Z]?EG*K/JOJ[^6UP:>3!DJB,Y5;7>3"J,VK@ZOY\S>G
MM)X7?-7JSG:>!7&R+HIO].%#\NI@1@2I5,4509#X=ZO>JC0E0"#C=P_SH$%)
M&[O/ ?HOS#MX64NKWA;I/W12[5X=7!R(1&UDG58WQ=U_*\_/&<&+B]3R7W'G
MUBZ7!R*N;55D?C,HR'3N_LOO7@Z=#1>SD0T+OV'!=#M$3.4[6<G7+TUQ)PRM
M!C1Z8%9Y-XC3.2GE<V7PK<:^ZO6;VN*-M>)MD:UU+DE4+T\J0*;O3V(/Y8V#
MLAB!,E^(CT5>[:QXGR<JZ0,X 4D-78M UYO%HQ#?J7@JEO-(+&:+^2/PE@V?
M2X:W_ D^K?C?J[6M#"SC_QY!<=J@.&44I_^F*!^%0D[XW)8R5J\.X&56F5MU
M\'HY%4/0Q:=<?%9EI;*U,F)^QM*:18+L%2^N$AW#K>,B*U-5J43HR@I\L<5W
M=[K:P:GLET\W:UT /"P[$0!9[91X_SW>R7RKQ VA$<5&S*;SQ>E,1$)GF4JT
MK%1Z+S9%"I_6^98W?63 40M4P'CC;[LB392Q0N:)",\ V*["4V5T3/3Q!E'G
M1">M+TJGIJJ ]_Y>:Z,Z^\!6!GK=GN(NQWY9EJ;XKC-'WN)L.A/_2<B(/ 0D
M6P$HD1O+4E<R#7O=@ICE"B@D+YG?DS"DV-0I0"4ZK8E ^+^V$=/6EW&7U:C+
M9V"A@,BE,3*O>NSL::I/UP!/YW\23]-6L'_YCXO%_/R%[:LOAGOKO,9Z4 _*
M&GT2'FV$^JYM1738G02H0,!;A[>!V5/:H=Q48'ZK;VFCVFP0J0D\;9P?(^$<
MGX.L6Z!7?H<M4UT=3<5U;6P-68;5 ),U.(,ATO.M<E3A*YFF/8'MV6FCJ3L)
MXXMCY TCV6ER%IB0C*!K_Z714*LGX3V3CPPCOB!I3<650W=<;([Q]3&X5O?C
M.!5L(98YL*9 "=9%3A:.W)<0&5CD(.K\"=",HFQ,[MQAU\G:&P7% XH?/8D1
MIV"\, D1XB*$4RZ+=TK&R@OJG&5:UJ8LK+)15],0$_([<%_,H^7Y[&D$C]C!
M@.ZGX@.(3!)-&R-Q"22S2T0,TC.0_C"J]"0""ZYSJZH*,H]^@HCHYVQAWRY9
MV8,6EK,W=<.'K>/=&"]&Q0HX$G%V&IV=+?\%SS,JJ5UQM+[G37G-F800-\!&
M(FX.[-:BCB.F+4S4;NXI6*4ZENL4+BF_LPD1,^R!ZU1O?=J5%6-#&:.S.@-
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M!<8IT/U<:]PPSD'S,QS_!E!+ P04    "  .@F]49V VF;@"   :!@  &0
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M]UE@*+FW% 1>#8T71%K<U5)].\U,D'WP<K_K4(5;H/!=XH)M_5+[O9!AKAB
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MG<\Y$O$,3NEL4]_"@$U'*^;RH=G.J#VMPZR4=*.2#@R=?&[Y4O"]L,'BVKH
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M%+B\[U7@ZGPT"CRV]8V&+G+*(!I/IJ^BJ2:NP7]+U[+O/O68P^FTXR-"0@]
MN; 0TQD877RV+<^CICQ'KE@DS>NV?M1+%+IO#!VOX<=WB@%[0/1ZDMZ=M;N3
M]6[E>3?L72- V<H+\AC%N\+,2VZII6M-EE^WS5:[VR#?:9G6S8'Z7G_QGCPH
MF-1,M^3QA>Q_/.P*:%V4$B;U\%^W8X:&0)=3.D/NH;8@;+5QJ+*@&0HA]L:\
M8<*XT;"Q*TZA]+*]'L#_[I'H3)\D74HBK6];K;RIT+PUC+J'>8:>$;R^4CE-
M:KJ@N</Y.Q-+&N]YV9Q' SE:W1</N<I0_)B*QF]JR;4?874S7[PBC-D]%8,
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M5>$>5X(C?6D#OB\54"&\T 'U3U>G_P502P,$%     @ #H)O5%XIK#JT!0
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M^"]TO>ST,H"L-5;5@S(QJ+GL_^S+$(<#A:OXB$(Z**2>=V_(LWS#+%O.M>I
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MD;X"R'I %G1W@8+*&^;8?&KT%HSW)C:_"*D&-(GCRA_*RAGZR@GGYC=8DJ6
M:ZV<X>LVE&HIF)HFCNB]4Y+W5(N.*GN%:I3!/;'4%FY5@<4Q04*Z!G'97MPB
M.\EX@WD,X]%[R-)L=()O/"0[#GSC?TT6OE^MK3-T17Z<"#,9PDQ"F,G_J.EI
MJM%%#*^K_E(C667#U Y\ SKZ66#^5@9$?HAH/**EDS&PZEMBDH[>/KT#78(C
MICOET"@FX $WJ%I/72!Q;-!P55';4HF8<IP)L0-Z0-D*\<%1B\*CXH[BK1QS
M: %E(_0.T<9PVR^/I)!$@[#1HB7%AKA4$2P%D@ 9E/M^5<!5P3>\:$D3=1ZW
M7L-/T@Y.!\74!URVTHO16[86V.=7(CT)Y-@S#8ZJ%2R$I5*V(16/W2$S@/ZB
M4H%SE&O"[:]:<'@I+%6!514147:T=7GM28XSHAJ^@30>4X\*09;XZ' *7H B
MS81^^K,6?2[]6813*CJ9)"6-_W8?DX-^EVBJ,-4L\5)!N]8?K,/@O.KFQ8M[
M-W7OF:G\I1%8$C2-S\\B,-TDZS9.-V%ZK+6C6126-0U_--Z!OI=:N_W&!QC^
M3N:_ 5!+ P04    "  .@F]4IIDFD T#   _!P  &0   'AL+W=O<FMS:&5E
M=',O<VAE970R-BYX;6RM5=MN&C$0_971-NI%0GL# J2 !&FKME(J%)KVH>J#
MV1U8*UY[:QL(?]^Q%S8T35 J]04\GCEGSLS:X^%6Z5M3(%JX*X4THZ"PMKJ(
M(I,56#(3J@HE>99*E\R2J5>1J32RW(-*$:5Q?!Z5C,M@//1[,ST>JK457.),
M@UF7)=.[*0JU'05)<-BXYJO"NHUH/*S8"N=H;ZJ9)BMJ6')>HC1<2="X' 63
MY&+:<?$^X!O'K3E:@ZMDH=2M,S[EHR!V@E!@9AT#H[\-7J(0CHAD_-IS!DU*
M!SQ>']@_^-JIE@4S>*G$=Y[;8A3T \AQR=;"7JOM1]S7TW5\F1+&_\*VCFU3
M<+8V5I5[,"DHN:S_V=V^#T> ?OP$(-T#4J^[3N15OF.6C8=:;4&[:&)S"U^J
M1Y,X+MU'F5M-7DXX.[Y&P2SF,&/:[N"K9M(PWR\SC"SQNZ@HVW--:Z[T":XD
MA2LE;6'@O<PQ_Y,@(F&-NO2@;IJ>9'R'60CMI 5IG"8G^-I-M6W/U_[G:N''
M9&&L)NOGB3R=)D_'Y^G\EZZ>YDH&(9S0/3&@ED"-PG*!NFE6BS KE*CIY*NM
M)&R_WVYUS_M@"J;1@VR!<*G*BLG=*P.9*DL*IA.7W89'Z 5FK$1@= 5K$947
MP25\7HL=)4L&P(SW&[H*CGB.FE.**6WE2$-D(9#HY0:UY6Y-XV.)FIQU-EAR
MR63&Y2J$FXI29D(9LKS *]0KU"WHM9*TV^IVTP<%/#/%WD<VEU:=;L;+%_TT
MZ;U]V!*: CYJATP;0'?$_^X[,)F[1=PZ9B25F=(.H'&#<HU-,TF+B[MO]V2E
MJ1Z4OI%G, A[=.V%\!.,J,\@Z86#PU;+-;U"/]G$+GSZ,#RJ1: QY&&26.,P
M;?)P-RPSM9;6N&#D&]]>E[Z@+YT?.GNHQ0OMA/V&X!G%O9XCPA=E$9+X3?C8
ME8N.AEKI#H$;W>Z;D*YZOC6[S>LPJ8?B?7C]M%PQO>)T5P0N"1J'O6X NA[7
MM6%5Y4?D0ED:N'Y9T N'V@60?ZE(Z=YP"9HW<_P;4$L#!!0    (  Z";U2V
M4X-Z#@0  .\(   9    >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;*56;6_;
M-A#^*P<-&!K L6PE7;/.,> D;=<!18-D+Q^&?:"EDT24(E62LN/]^CVD9%5!
MVFS  $,FQ;OGGGNE5GMC/[F:V=-#H[2[3&KOV]=IZO*:&^'FIF6-D]+81GAL
M;96ZUK(HHE*CTFRQ^"%MA-3)>A7?W=KURG1>2<VWEES7-,(>KEB9_66R3(XO
M[F15^_ B7:]:4?$]^]_:6XM=.J(4LF'MI-%DN;Q,-LO75^=!/@K\+GGO)FL*
MGFR-^10V[XO+9!$(L>+<!P2!OQU?LU(!"#0^#YC):#(H3M=']+?1=_BR%8ZO
MC?I#%KZ^3"X2*K@4G?)W9O\S#_Z\#'BY42X^:=_+9C\FE'?.FV90!H-&ZOY?
M/ QQF"A<++ZAD T*6>3=&XHL;X07ZY4U>[)!&FAA$5V-VB G=4C*O;<XE=#S
MZ_MNZ_ASQ]K3FQV>;I5ZP(;#-!\@KGJ([!L0RXP^&.UK1V]TP<5C@!1\1E+9
MD=15]BSB#>=S.EO.*%MDRV?PSD8GSR+>V7]UDO[<;)VW*(F_GH$_'^'/(_SY
M_XGA\Q#98DY/6=YQQ9HMBO=C&VOXHZ9?A.[0/91=Q/!DLXD4/[#-I>.")+1-
MK^,-*9FCC9A\S9#)5>?0";/0+ZI N3'94+LNB&YNWI\N%D 5Z!BE3("6.54"
M/8MJ5UY07J,K+5X*[27.T9LYM]Y8>G&]N3NA7RE'DP5C5K0'*B3./3B)"C/"
M>7JG#JW,A3X]FU';6=<!)Y@.[+[XLJDL,[K?S^'F?(':5VIP)PA>FZ85^D#F
M:43F=/OOJ#/J6NS'D^^_N\B6KWYR8PS)E%&WC^+LD=%:P!MR+>>RE/"L13A,
M$340FF U3IVPR,UIV>GB&-?13-GYSC(BNL-<; ,CB#KO0N"+H-@*ZV4N6^&9
M)'(!LZWQD)-"46M-&5*\E[Z>>->U07/*;# O=15(H@H\)FW VPE0[AQ5;"JD
MJ48Z+5?P% RD1HE$G3 V)V6"\2<=LFQ.WPZ@?5V>S&E3H,9\[S?L:A.]'X,9
MR#Y1(]PIQ\  (<^-#:?J,*UI&+3LD"LGMPI%*WP$<T9QC-@LHJ!4I[&<843J
MKD1_=S;8"S'-3=,$-D+)OT4TCWP-UJ- @VF+L!\>IQJ=02ZP0K)D)3U9<Q#*
M2W8D\)N&%7A!12,.3B@(3 Q$DL="B51T/D0XF"NE=7Y",0)0AVS'1B)E=,4V
M +Z0)T,?M](.?EBD; >_"ND/Q[H=>A[%*4+5'%L\=*D$A #DG@K3;4?'1&-@
M,.@?6%B4J#7-UXG-OS8TT\DE!.$J7K4.J@#M[Z/Q[7B;;_I+[(MX_RGP0=@*
MHX(4EU!=S%^]3'K^QXTW;;S2ML;C@HS+&E\D;(, SDN#5ADVP<#XC;/^!U!+
M P04    "  .@F]4]>W9*H$Q  !@M   &0   'AL+W=O<FMS:&5E=',O<VAE
M970R."YX;6S-?6EOW$B6X%\AO#.S$I"2I739Y3H!67;U:."J,J1R#0:+_< D
M(R6VF60V#\GJ7S_OC'C!2Y+=O3M 5UN92<;QXMU7_'A7-Y_:&^>ZY/.NK-J?
MGMUTW?[[Y\_;[,;MTO:XWKL*?MG6S2[MX&-S_;S=-R[-Z:5=^7Q]<O+J^2XM
MJF<__TC??6A^_K'NN[*HW(<F:?O=+FWNW[BROOOIV>DS_>*RN+[I\(OG/_^X
M3Z_=E>L^[C\T\.FY'R4O=JYJB[I*&K?]Z=G9Z?=OUM_A"_3$GX6[:\W?"6YE
M4]>?\,-%_M.S$UR1*UW6X1 I_'/KSEU9XDBPCK_)H,_\G/BB_5M'_X4V#YO9
MI*T[K\O_+/+NYJ=GKY\EN=NF?=E=UG?_[F1#+W&\K"Y;^O_DCI]]^>I9DO5M
M5^_D95C!KJCXW_2S ,*\\/IDYH6UO+"F=?-$M,JW:9?^_&-3WR4-/@VCX1^T
M57H;%E=4>"I770._%O!>]_,5GT92;Y.KXKHJMD665EUREF5U7W5%=9U\J,LB
M*UR;'.A?AS\^[V!J'.!Y)M.\X6G6,].<KI-?ZZJ[:9-W5>[R>(#GL&:_\+4N
M_,UZ<<2W+CM.7IRNDO7)^G1AO!<>$"]HO!<SXTWM^/^<;=JN <3YOPL3?.,G
M^(8F^&9F@C=I6[0(YP^-:UW5I8B54Y#\@F&2/VY<DM55"RO/T\[ER;:HTBHK
MTC)IX1$'=-2U25KE0$DE/9 7;5;6;0^C)#?IK4LVSE4)4/8^;>#GHL+QD.J+
M[AYPLKL! O(0VC<%#+XOX=UK5[DF+<M[_-WM.WZW@_5\K K\=(7STXK/=JX!
M]$H.XE_^<G;V(:D;^O?P> '2+SVD7RZ"Z$-8'<QZ[L$R ^\O'NR14(?WRSYW
M!!.!(8V%G\_KW3ZM[NED"OCZ[J9&4-9W%8S6]INVR(NT 5P\3L[*$H;J7)/I
M.SH6O@QH6K4I<3I[GJXL@&FDG3_1L/IC6GY\%#G,GC8)(!@N;MM7-"!LAS%G
M7S=T_%G?-*[*[N=V$2U\X4!?^0-]M7@&'UN'4[UKNV*'ZYPZQ:>-0'MG9.>C
MA!\?<Y(CHB#D;=S?^@():9=6(,KPX:2KX=,GES@_)4(G;4'\[?F4NINT2]+M
M%N0309'A"W.G.X\C\+R3$RZ+=%.415?(4): >?5X-CAU]"2/C9O2TWH$GP!$
M!#F)_\XMK'&WKNIE*>XS* DMXD_?('Z$EXA9 -77^7%RU6<W!AR6+&[3LO?G
M@%\ HJ?5=;$IG0=!1C F/-[T+9QOV\)6=AM$;X3G"J;,'>@L^!+L\=;!]/@W
M'//6-?@J2-/L4W*7-DUJP'3_Z#>1R$ MLF_B8O]PV4V%B[\$CIPVL$L$REN
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MWFZ_UAQ^I#6\P&)/3T(DZF21R5ZQFCG)6Q_Y:G1F7JO%5;-GMB7WM&<# !_
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MMX>@E '#VQ69L<[03,[( @&%ILSOBAPX":C9-3RF20O RMF6(0ULY(I"HQZ
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MOD\.BL-@G0F,Z!@/VD-I@>!/XP=X>OBX27:#PRJ+ZS3*H-+1Z%5XUU9T.%O
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ML]C:.X/O.>YT:P\VDI64C_9PDXZ]P#J$!2;&,G!:GG".16&)R(W?!TZOD;3
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MM@4-8E36@>RYE.9PL 3=:)__ U!+ P04    "  .@F]46385OQ<#   #!P
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MN*(WJ!ENZ=&/0A^@_37GJIMH!?W?B/F_4$L#!!0    (  Z";U13]U$$_0,
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M,<>W'BBK@-_7$J_*;F$#]*_'Y5]02P,$%     @ #H)O5!GGT"J.!0  2PX
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M4IJ7#X0#>?G,^L#5.D$($;!"5M<)<9"J\NE2;HS,[7-A*0T^/NQR@Z\]4$2
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M)]#[C23#=!V[0/^5L_P74$L#!!0    (  Z";U3\S-H,X@4  $4/   9
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M)O;HB%BHOQX^Q2!H#H5BH>Y>UY#.0=@Z%VY;%W9_7</$;5/"W^A*/US\OS&
MO[?Z?P=PV\FVP6%[)_FA"E9S;Q<<+Q@')-C)]T,LMSUH.QBV-Y%G%*>::;?L
M;"1NK?:;=MM:VRZ%[6WJ2G\>,/TI<5/,$Q;J>%Z T)-L6\FV%>'@%V9)VQJP
MO3>\+TRB/ZF<=21)GD3V$!H_"0P?![ZWNR:S#D/L>+[G8;=[54C;#<A/[0;D
M6=V M-V _'_=@#RS&Y"-CQM[-[B2LJ!9""@7S%R-PDKZUXUOY:Y0J(FWYG%G
M0S#KLG%WLM?.L^U6VX.(_:/GSLSU6NCTU34Q8C+DA8D8<W9@8H1)<TI5/7,5
MEPE1Y3:"^QPR6?G?Z;;[1.YX2)[$?X<9)D'P),P&&Z<BYECMFHHET\H26&B@
MT_<U@ZA.JJH'Q?/RH&3.E>)I>1L#U=X: _W_@G/U^&#.7IKSPNE_4$L#!!0
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MF<FG7NR1#-:TXN9.[KY D\_0\J62:_<ENV9OX)&TTD86#1@C*)BH__2YT>$
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MR@;@?B&E.3KV5@S_M.0'4$L#!!0    (  Z";U0U;J2#:@(  $X%   9
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M3 ?]?,NY>KDQ!QO-0=;\'U!+ P04    "  .@F]46MHU+S0#   T"P  &0
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M>L.E 8$%Y43]"TK63><T$ZNV_K:NE:6[[X<E/3:H70#M%TK9P\0U0/=\I?\
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M'-#[:\[5Z\2TO,47R^0?4$L#!!0    (  Z";U1#T]*49 (  !8&   9
M>&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;)U5T4[;,!3]%2OB 20@:=HRA-I(
MD&X:TI J,K:':0]N<M-8.':Q;UKX^UT[(2JB[=A>&MNYY]QSCAUWLM'FT58
MR)YKJ>PTJ!!75V%H\PIJ;L_U"A2]*;6I.=+4+$.[,L +#ZIE&$?115ASH8)D
MXM?F)IGH!J50,#?,-G7-S<L-2+V9!H/@=>%>+"MT"V$R6?$E9( /J[FA6=BS
M%*(&9856S$ Y#:X'5^G8U?N"'P(V=FO,G).%UH]N<EM,@\@) @DY.@9.CS6D
M(*4C(AE/'6?0MW3 [?$K^Q?OG;PLN(54RY^BP&H:7 :L@)(W$N_UYBMT?KS
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M?,=LF>1<[O@+Z>I<AS(<K+JUJ!J"KLL/_Q<J!,W*QQ7!,6'*0+Y?4"JV#35
M<W<T^1]02P,$%     @ #H)O5#)5NA9^ @  ^04  !D   !X;"]W;W)K<VAE
M971S+W-H965T-38N>&ULC51+;]LP#/XK@M%#"W3U*^FZPC&01X?UT"%HU^TP
M[*#83"Q4EEQ);MK]^E&2XZ5=DNYBBQ3Y\2-%,EM+]: K $.>:R[T**B,:2[#
M4!<5U%2?R08$WBREJJE!4:U"W2B@I7.J>9A$T7E84R:"/'.ZN<HSV1K.!,P5
MT6U=4_4R 2[7HR .-HI;MJJ,581YUM 5W(&Y;^8*I;!'*5D-0C,IB(+E*!C'
ME].AM7<&WQFL]=:9V$P64CY8X;H<!9$E!!P*8Q$H_IY@"IQ;(*3QV&$&?4CK
MN'W>H']VN6,N"ZIA*OD/5IIJ%%P$I(0E;;FYE>LOT.7C"!:2:_<EZ\XV"DC1
M:B/KSAD9U$SX/WWNZK#E$)_O<4@ZA^2MPV"/0]HYI"Y1S\RE-:.&YIF2:Z*L
M-:+9@ZN-\\9LF+"O>&<4WC+T,_E<84,H\T*H*,G58\L:?")S2KYB WT@X[)D
MMMJ4DVOA6\;6_G@&AC*N3]#D_FY&CH].R!%A@GRK9*L126>A07(V1%AT1":>
M2+*'2)R0&RE,I<F5**%\#1!B5GUJR2:U27(0<0;%&4GC4Y)$2;R#T/3_W:,#
M=-*^TJG#2]^I]"F9<RK,ZX*3G^.%-@J;^M>!4(,^U,"%&NRECA-=,/]8-@ZM
MI3+LMU? ,ZX #;N>R,,.':R=_Z<\'J876?BT7;8=1DERWAN]8CSL&0\/,KX6
M!>X@#;:)"BFP%*T?<Y0;)5<*],Z>&O[+)?X416\8OV?E*8=;4U2#6KGEHI%.
M*XSONE[;[Z^Q&]LW^@GN-;^&_L+XI7A#U8H)33@L$3(Z^XB<E%\T7C"R<;.Z
MD 8GWQTKW,V@K '>+Z4T&\$&Z+=]_@=02P,$%     @ #H)O5._.14_0 @
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M""C$4D? ZK:#!5"J RF,/TU,JQU2&X_;;]&_F-Q5+ALL8,'H3Y+(;&:-+91
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M@T.*>TQQ\*3*;L#O2RG-;F$55*/LZ!]02P,$%     @ #H)O5.\R"MA5!0
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M$ZR*";'8&+ER(]!<&ARHW#+%J1J45<#SA91FM[$75'/ZZ =02P,$%     @
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M\T'0#2##.5T5>B;6W[!*J&WY4E$H]POKZFP40+I26I05V"@H&=]^Z5MU$0>
MN'T"$%> V.G>!G(J[ZBFP[X4:Y#VM&&S Y>J0QMQC%M7'K4TN\S@]' LRI)I
M<\T:*,]@++AF?($\9:C@"SR:5Y"M"@0QAR>7(69P^XK2. ;WHYD#S=#:;V#P
M@.:"X#O*$J[N4%-6J,_]4!N=-EJ85II&6TWQ"4UWF#:@2:XACF+R+SPTZ=4Y
MQG6.L>-KGN![$$::$S5=R32W$@_2_O5@CL.]QE+]]@1KUL&:+ECK1+!CMW3L
M"OPLG48<??*H:=5J6EZ>O34V?P57C,,&J3QNBY^KLT5"%TKS2G(%)(:,;I1'
M9KN6V3XC,UL+89X?TYMK&-]Z*).:,OEXTSMUL,Y%3/>S)(V>U_1NK:9[0=/]
M7-W*]/C]IO=JF3TO]4B8ZL:O8>*SFT3[0A9]O.'DH&Z2BUA^AJ;7:'H])_LB
M1^(+NGZ&K%79WMG9GIQSG>P+)/'7M@GR0L"4RI<S?W6RKW*D]1^\WU<KXB]7
M[_;>3Y,TNG[O][6.))?TWD^65)X?4Q8>=!JV:YM0N6!<08%SPQ4U.B9CN6V$
MMA,MEJ[Y>!;:M#)NF)OF$:4]8/;G0NC=Q/8S=3LZ_ M02P,$%     @ #H)O
M5,@D77U! P  W0D  !D   !X;"]W;W)K<VAE971S+W-H965T-C4N>&ULE99M
M;]HP$,>_BA7M12NMS0,0H *D IM6:56KTG:O37(0JXG-; ?:;[^S$]*40-J]
M@=BY^_MW9^?.HYV0+RH!T.0U2[D:.XG6FRO755$"&5678@,<WZR$S*C&H5R[
M:B.!QM8I2]W \T(WHXP[DY&=NY>3D<AURCC<2Z+R+*/R;0JIV(T=W]E//+!U
MHLV$.QEMZ!H6H)\V]Q)';J42LPRX8H(3":NQ<^U?S7SK8"V>&>Q4[9F84)9"
MO)C!33QV/$,$*43:2%#\V\(,TM0H(<??4M2IUC2.]>>]^D\;/ :SI IF(OW#
M8IV,G8%#8EC1/-4/8O<+RH!Z1B\2J;*_9%?:>@Z)<J5%5CHC0<9X\4]?RT34
M'/SPA$-0.@2'#MT3#IW2H6,#+<AL6'.JZ60DQ8Y(8XUJYL'FQGIC-(R;;5QH
MB6\9^NG)3&09T[@OFE >DYG@FO$U\(B!(A=D4>PN$2OR&S!;:*"TLJ9W.@%)
M;GAQE,R6G,U!4Y:J<W1\6LS)V;=S\HTP3AX3D2OT42-7([-9V8U*OFG!%YS@
M\P-RBTR)(C]X#/%' 1>#K2(.]A%/@U;%.427I.-_)X$7^$> 9E]W]UIP.M4&
M=*Q>YX3>>UI;Q+J56->*=4^(W6U 4K.!)+6R44.VR%"ATK,JYD/?3KK!(!BY
MVWH>FD:#8;>R^<#7J_AZK7R+1$A]H4%FGP 6,F%M[:#3.^!KVO3"XWAAA1>V
MXCU3R>@RA4_@PL;"W@%:F\4'LGY%UF]/7+XLF&YX)#(X1M5OK'D1!)T#L-95
M3,NX4AL:P=C!GJ! ;L&9D)9S.:CP!ZWXCT+3]).L#AK\W:!VW@K^IM&P=R*U
MPXIMV/H!-NI82[R^]UY6O2]^B1%5"5EANU0D5Q 37*?,1(J'C:5,8ZD]6AB]
MY@'W_8.$'#$:](;',^+7FH+_7W5$FF9HF@!&0*A2>+T02ZSU'./!^@ZO44*Q
M:Q@+<>"Z#_+M:(BM&%\ZCV4:_$:QPL,?]@\2X=8:909R;>\/"H]DSG710:K9
MZHYR;3OSP?S4W%UL WZ7*2X^MU2N&5<8_0HEO<L^,LGB+E$,M-C8=KP4&IN[
M?4SP_@72&.#[E1!Z/S +5#>ZR3]02P,$%     @ #H)O5-?[?DT6 P  1PD
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M-6F8OA6[K] EE-EXA6#*_:)=MS8*4-$H+:I.;!Q4E+?_Y*DKQ)X@3@\(<"?
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MM&19 EQ\0%__E52^H"]HICZ7I,P L13]*O,Y<+V:+0D'H5=3EN=*!(-&]R"
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MEDLUMP+7!NH\94QN-WHR:B;AR7]02P,$%     @ #H)O5&,I<24= P  \@@
M !D   !X;"]W;W)K<VAE971S+W-H965T-CDN>&ULM5;?;]HP$/Y7K&C2-JDE
MOX! !4B%=EJE=:N*MCY,>S#)0:PF,;4=*/_]SG;(:)LP]K"7Q';NOON^.]N7
MT9:+1YD"*/*<9X4<.ZE2ZPO7E7$*.94=OH8"ORRYR*G"J5BY<BV )L8IS]S
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M4P)"&^#W)>=J/]$!ZM^<R6]02P,$%     @ #H)O5 G(3*+Q P  V!$  !D
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MHNXUH775JJJ)55O_VE?*4N_PPS5U=]0N@/9SI>QQXAI(\W^1_ )02P,$%
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M"/K0#5![1GZ5D?]G,B)OA(4);U^0_@G8:PB1YSC#=K1!A3;X,VBE1"Y)(F<
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MC1E)4=H+YOE*"'W86 /ED#OY#5!+ P04    "  .@F]4$!PM;N "  !L!P
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M[#Y#K:=G^&*1*?M+=G6LYY"X5%KD-1@SR!FO_NEK[4,+X$<G $$-" X!W1.
ML :$5FB5F94UIYJ.AU+LB#31R&8&UAN+1C6,FRHNM<2O#'%Z_ T/RE>A%%F
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M+; _?O#^P26/R=PP#4LI?O+,Y'-OXI$,-JP6YEKN/D*;T-CZ2Z70[I_L6MO
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MZ6L="!.@GZ><JVW'O*"Y*([_ U!+ P04    "  .@F]4P!2BNGT#  "+"P
M&0   'AL+W=O<FMS:&5E=',O<VAE970X,2YX;6R55MMNVS@0_15"0 $7:'7S
M+2EL [&]P19HMT'2[CXL]H&61A81BO225)S\_0XI6[%;F<J^V+SH',Z9&7)F
MMI?J49< ACQ77.AY4!JS^Q1%.BNAHCJ4.Q"X4TA548-3M8WT3@'-':CB41K'
MDZBB3 2+F5N[4XN9K UG NX4T7554?6R!"[W\R )C@OW;%L:NQ M9CNZA0<P
M/W9W"F=1RY*S"H1F4A %Q3RX23ZM$@=P7_S)8*]/QL1*V4CY:">?\WD06XN
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M#@OUY5Z=YS#7 O4\9TR^#?2)H3LAKOX'4$L#!!0    (  Z";U0Z;N8IL0(
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M9?&%^F6),Q2T"\#]E5)V;[@$W51.7P%02P,$%     @ #H)O5/V)V/Z! P
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M<D3(?T,"F0+(]&B0%]*N"60&(#->R!MS)VO]:S@PI*#/LNV,ZB'?=U83R F
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MHXH"  "Y,@  &@   'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSS=I-;J-
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M62N*K!5%UHHB:T61M?J?LOX8Q\,_CE^>:6_:X3D_6_X\<?,+4$L! A0#%
M  @ #H)O5 =!36*!    L0   !               ( !     &1O8U!R;W!S
M+V%P<"YX;6Q02P$"% ,4    "  .@F]4F')(Y.X    K @  $0
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M=#(N>&UL4$L! A0#%     @ #H)O5+C\&,Z3 @  U@@  !@
M ("!LA8  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    (  Z"
M;U3A =3MP00  'P0   8              " @7L9  !X;"]W;W)K<VAE971S
M+W-H965T-"YX;6Q02P$"% ,4    "  .@F]4N_.*.>\&  "@(P  &
M        @(%R'@  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%
M  @ #H)O5,L.] 4I @  400  !@              ("!ER4  'AL+W=O<FMS
M:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    (  Z";U3.%8]:X@D  /(M   8
M              " @?8G  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"
M% ,4    "  .@F]4FKV#3:L0  !N,0  &               @($.,@  >&PO
M=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @ #H)O5(^>9*$M*
MCX4  !@              ("![T(  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM
M;%!+ 0(4 Q0    (  Z";U2Q/T"-_1   $0U   9              " @5)K
M  !X;"]W;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ #H)O5#!/
M#7S1!P  ^Q0  !D              ("!AGP  'AL+W=O<FMS:&5E=',O<VAE
M970Q,2YX;6Q02P$"% ,4    "  .@F]4'&G%ZO\"   8!P  &0
M    @(&.A   >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    (
M  Z";U1G8#:9N (  !H&   9              " @<2'  !X;"]W;W)K<VAE
M971S+W-H965T,3,N>&UL4$L! A0#%     @ #H)O5$;O"Q/$ P  0 @  !D
M             ("!LXH  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"
M% ,4    "  .@F]4]S^2X+0"  #Z!0  &0              @(&NC@  >&PO
M=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    (  Z";U15\E97NP4
M /$-   9              " @9F1  !X;"]W;W)K<VAE971S+W-H965T,38N
M>&UL4$L! A0#%     @ #H)O5-FB>0UT%P  W$\  !D              ("!
MBY<  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    "  .@F]4
MU?Z-.0$*  !-&@  &0              @($VKP  >&PO=V]R:W-H965T<R]S
M:&5E=#$X+GAM;%!+ 0(4 Q0    (  Z";U3E<CU1G@H  ,8:   9
M      " @6ZY  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%
M  @ #H)O5%XIK#JT!0  IPX  !D              ("!0\0  'AL+W=O<FMS
M:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    "  .@F]4;>4@I&8#   !"
M&0              @($NR@  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+
M 0(4 Q0    (  Z";U3(=2*_X0\  /DT   9              " @<O-  !X
M;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ #H)O5,L[';0&
M!   $ D  !D              ("!X]T  'AL+W=O<FMS:&5E=',O<VAE970R
M,RYX;6Q02P$"% ,4    "  .@F]4<-1I;WX,  "1(0  &0
M@($@X@  >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    (  Z"
M;U2T>$QEV (  %H&   9              " @=7N  !X;"]W;W)K<VAE971S
M+W-H965T,C4N>&UL4$L! A0#%     @ #H)O5*:9)I - P  /P<  !D
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M=#,P+GAM;%!+ 0(4 Q0    (  Z";U3[P/28*@,  .\'   9
M  " @= T 0!X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @
M#H)O5!+"G3+" @   08  !D              ("!,3@! 'AL+W=O<FMS:&5E
M=',O<VAE970S,BYX;6Q02P$"% ,4    "  .@F]4V!_1/@\#  !0!@  &0
M            @($J.P$ >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4
M Q0    (  Z";U0/[P(.P (  .8%   9              " @7 ^ 0!X;"]W
M;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @ #H)O5%DV%;\7 P
M P<  !D              ("!9T$! 'AL+W=O<FMS:&5E=',O<VAE970S-2YX
M;6Q02P$"% ,4    "  .@F]4OI\16? $  !2#   &0              @(&U
M1 $ >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4 Q0    (  Z";U13
M]U$$_0,  $D*   9              " @=Q) 0!X;"]W;W)K<VAE971S+W-H
M965T,S<N>&UL4$L! A0#%     @ #H)O5!GGT"J.!0  2PX  !D
M     ("!$$X! 'AL+W=O<FMS:&5E=',O<VAE970S."YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    (  Z";U0F=*T*,@0  -0/   9              "
M@6=G 0!X;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L! A0#%     @ #H)O
M5/Y,S>#0 @  M@<  !D              ("!T&L! 'AL+W=O<FMS:&5E=',O
M<VAE970T-"YX;6Q02P$"% ,4    "  .@F]4T:HMN"@#   3"   &0
M        @('7;@$ >&PO=V]R:W-H965T<R]S:&5E=#0U+GAM;%!+ 0(4 Q0
M   (  Z";U2#BES<2@(  -\$   9              " @39R 0!X;"]W;W)K
M<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ #H)O5#5NI(-J @  3@4
M !D              ("!MW0! 'AL+W=O<FMS:&5E=',O<VAE970T-RYX;6Q0
M2P$"% ,4    "  .@F]4($JD1HL$  #4$@  &0              @(%8=P$
M>&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0    (  Z";U1:VC4O
M- ,  #0+   9              " @1I\ 0!X;"]W;W)K<VAE971S+W-H965T
M-#DN>&UL4$L! A0#%     @ #H)O5/>Y<(".!0  P2$  !D
M ("!A7\! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q02P$"% ,4    "  .
M@F]4UG2]XU "  #*!   &0              @(%*A0$ >&PO=V]R:W-H965T
M<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    (  Z";U09RP;++P,  +T,   9
M          " @=&' 0!X;"]W;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#
M%     @ #H)O5$/3TI1D @  %@8  !D              ("!-XL! 'AL+W=O
M<FMS:&5E=',O<VAE970U,RYX;6Q02P$"% ,4    "  .@F]4M9)W^^H"   U
M"0  &0              @('2C0$ >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM
M;%!+ 0(4 Q0    (  Z";U1(<I#E-00  $<2   9              " @?.0
M 0!X;"]W;W)K<VAE971S+W-H965T-34N>&UL4$L! A0#%     @ #H)O5#)5
MNA9^ @  ^04  !D              ("!7Y4! 'AL+W=O<FMS:&5E=',O<VAE
M970U-BYX;6Q02P$"% ,4    "  .@F]4[\Y%3] "  !U"   &0
M    @($4F $ >&PO=V]R:W-H965T<R]S:&5E=#4W+GAM;%!+ 0(4 Q0    (
M  Z";U2,G6V6JP0  -8.   9              " @1N; 0!X;"]W;W)K<VAE
M971S+W-H965T-3@N>&UL4$L! A0#%     @ #H)O5.\R"MA5!0  ,A@  !D
M             ("!_9\! 'AL+W=O<FMS:&5E=',O<VAE970U.2YX;6Q02P$"
M% ,4    "  .@F]4]M'X])H#  "S"P  &0              @(&)I0$ >&PO
M=V]R:W-H965T<R]S:&5E=#8P+GAM;%!+ 0(4 Q0    (  Z";U3P,.]4,P8
M &(7   9              " @5JI 0!X;"]W;W)K<VAE971S+W-H965T-C$N
M>&UL4$L! A0#%     @ #H)O5 :P9A-%!@  =!@  !D              ("!
MQ*\! 'AL+W=O<FMS:&5E=',O<VAE970V,BYX;6Q02P$"% ,4    "  .@F]4
M'?)G550"   2!@  &0              @(% M@$ >&PO=V]R:W-H965T<R]S
M:&5E=#8S+GAM;%!+ 0(4 Q0    (  Z";U0OPR:HR@(  )H*   9
M      " @<NX 0!X;"]W;W)K<VAE971S+W-H965T-C0N>&UL4$L! A0#%
M  @ #H)O5,@D77U! P  W0D  !D              ("!S+L! 'AL+W=O<FMS
M:&5E=',O<VAE970V-2YX;6Q02P$"% ,4    "  .@F]4U_M^318#  !'"0
M&0              @(%$OP$ >&PO=V]R:W-H965T<R]S:&5E=#8V+GAM;%!+
M 0(4 Q0    (  Z";U3$]*3O.@0  *P,   9              " @9'" 0!X
M;"]W;W)K<VAE971S+W-H965T-C<N>&UL4$L! A0#%     @ #H)O5*.#E)P>
M P  %0L  !D              ("! L<! 'AL+W=O<FMS:&5E=',O<VAE970V
M."YX;6Q02P$"% ,4    "  .@F]48REQ)1T#  #R"   &0
M@(%7R@$ >&PO=V]R:W-H965T<R]S:&5E=#8Y+GAM;%!+ 0(4 Q0    (  Z"
M;U0)R$RB\0,  -@1   9              " @:O- 0!X;"]W;W)K<VAE971S
M+W-H965T-S N>&UL4$L! A0#%     @ #H)O5(MBW921 @  .P8  !D
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M=#<U+GAM;%!+ 0(4 Q0    (  Z";U19C.4P6@,  / *   9
M  " @;+H 0!X;"]W;W)K<VAE971S+W-H965T-S8N>&UL4$L! A0#%     @
M#H)O5! <+6[@ @  ; <  !D              ("!0^P! 'AL+W=O<FMS:&5E
M=',O<VAE970W-RYX;6Q02P$"% ,4    "  .@F]4@^$*"B@#  !#"P  &0
M            @(%:[P$ >&PO=V]R:W-H965T<R]S:&5E=#<X+GAM;%!+ 0(4
M Q0    (  Z";U1<6.H<[ 4   H9   9              " @;GR 0!X;"]W
M;W)K<VAE971S+W-H965T-SDN>&UL4$L! A0#%     @ #H)O5)'<HI@" P
M- H  !D              ("!W/@! 'AL+W=O<FMS:&5E=',O<VAE970X,"YX
M;6Q02P$"% ,4    "  .@F]4P!2BNGT#  "+"P  &0              @($5
M_ $ >&PO=V]R:W-H965T<R]S:&5E=#@Q+GAM;%!+ 0(4 Q0    (  Z";U2*
M_,A" P0  "T.   9              " @<G_ 0!X;"]W;W)K<VAE971S+W-H
M965T.#(N>&UL4$L! A0#%     @ #H)O5#INYBFQ @  N08  !D
M     ("! P0" 'AL+W=O<FMS:&5E=',O<VAE970X,RYX;6Q02P$"% ,4
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M   4$P  #0              @ %<#P( >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0
M   (  Z";U27BKL<P    !,"   +              "  ;$2 @!?<F5L<R\N
M<F5L<U!+ 0(4 Q0    (  Z";U3*<7ZP.08   8Y   /              "
M 9H3 @!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  .@F]44C7&HXH"  "Y
M,@  &@              @ $ &@( >&PO7W)E;',O=V]R:V)O;VLN>&UL+G)E
M;'-02P$"% ,4    "  .@F]4@]&L 2X"  !$,0  $P              @ '"
L' ( 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     7@!> ,D9   A'P(    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>227</ContextCount>
  <ElementCount>563</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>80</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="acet-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="acet-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="acet-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="acet-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="acet-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit</Role>
      <ShortName>Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="acet-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical</Role>
      <ShortName>Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="acet-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="acet-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070 - Disclosure - Organization and Nature of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusiness</Role>
      <ShortName>Organization and Nature of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="acet-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="acet-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Business Combination</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombination</Role>
      <ShortName>Business Combination</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="acet-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="acet-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Marketable Debt Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureMarketableDebtSecurities</Role>
      <ShortName>Marketable Debt Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="acet-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Prepaid Expenses and Other Current Assets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets</Role>
      <ShortName>Prepaid Expenses and Other Current Assets</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="acet-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="acet-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Accrued and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilities</Role>
      <ShortName>Accrued and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="acet-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Term Loan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureTermLoan</Role>
      <ShortName>Term Loan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="acet-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Regeneron License and Collaboration Arrangement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRegeneronLicenseAndCollaborationArrangement</Role>
      <ShortName>Regeneron License and Collaboration Arrangement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="acet-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100170 - Disclosure - License Funding and Other Agreements Related to the CVR</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureLicenseFundingAndOtherAgreementsRelatedToCVR</Role>
      <ShortName>License Funding and Other Agreements Related to the CVR</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="acet-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Commitments and Contingences</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingences</Role>
      <ShortName>Commitments and Contingences</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="acet-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="acet-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100200 - Disclosure - At-the-Market (ATM) Offering</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureAtMarketATMOffering</Role>
      <ShortName>At-the-Market (ATM) Offering</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="acet-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="acet-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="acet-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="acet-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Defined Contribution Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureDefinedContributionPlan</Role>
      <ShortName>Defined Contribution Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="acet-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="acet-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="acet-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="acet-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Business Combination (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationTables</Role>
      <ShortName>Business Combination (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombination</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="acet-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurements</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="acet-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Marketable Debt Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureMarketableDebtSecuritiesTables</Role>
      <ShortName>Marketable Debt Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureMarketableDebtSecurities</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="acet-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables</Role>
      <ShortName>Prepaid Expenses and Other Current Assets (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="acet-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="acet-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Accrued and Other Current Liabilities  (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesTables</Role>
      <ShortName>Accrued and Other Current Liabilities  (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilities</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="acet-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Regeneron License and Collaboration Arrangement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRegeneronLicenseAndCollaborationArrangementTables</Role>
      <ShortName>Regeneron License and Collaboration Arrangement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRegeneronLicenseAndCollaborationArrangement</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="acet-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Commitments and Contingences (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencesTables</Role>
      <ShortName>Commitments and Contingences (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingences</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="acet-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockholdersEquity</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="acet-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensation</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="acet-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShare</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="acet-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="acet-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Organization and Nature of the Business - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails</Role>
      <ShortName>Organization and Nature of the Business - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="acet-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="acet-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Business Combination - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails</Role>
      <ShortName>Business Combination - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="acet-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Business Combination - Schedule of Summarizes the Purchase Price in the Merger (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesPurchasePriceInMergerDetails</Role>
      <ShortName>Business Combination - Schedule of Summarizes the Purchase Price in the Merger (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="acet-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Business Combination - Schedule of Estimated Share Consideration of Combined Company (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfEstimatedShareConsiderationOfCombinedCompanyDetails</Role>
      <ShortName>Business Combination - Schedule of Estimated Share Consideration of Combined Company (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="acet-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Business Combination - Schedule of Estimated Share Consideration of Combined Company (Parenthetical) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfEstimatedShareConsiderationOfCombinedCompanyParentheticalDetails</Role>
      <ShortName>Business Combination - Schedule of Estimated Share Consideration of Combined Company (Parenthetical) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="acet-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Business Combination - Schedule of Summarizes the Purchase Price in the Merger (Parenthetical) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesPurchasePriceInMergerParentheticalDetails</Role>
      <ShortName>Business Combination - Schedule of Summarizes the Purchase Price in the Merger (Parenthetical) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="acet-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Business Combination - Schedule of Summarizes the Allocation of the Purchase Price to the Net Tangible and Intangible Assets Acquired (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsAcquiredDetails</Role>
      <ShortName>Business Combination - Schedule of Summarizes the Allocation of the Purchase Price to the Net Tangible and Intangible Assets Acquired (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="acet-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100480 - Disclosure - Business Combination - Schedule of changes in the Company's IPR&amp;D and CVR since the Merger (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20211231/taxonomy/role/DisclosureBusinessCombinationScheduleOfChangesInTheCompanysIprdAndCvrSinceTheMergerDetails</Role>
      <ShortName>Business Combination - Schedule of changes in the Company's IPR&amp;D and CVR since the Merger (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="acet-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured on Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails</Role>
      <ShortName>Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured on Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="acet-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100520 - Disclosure - Fair Value Measurements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails</Role>
      <ShortName>Fair Value Measurements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="acet-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>100530 - Disclosure - Marketable Debt Securities - Schedule of Marketable Debt Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureMarketableDebtSecuritiesScheduleOfMarketableDebtSecuritiesDetails</Role>
      <ShortName>Marketable Debt Securities - Schedule of Marketable Debt Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="acet-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>100540 - Disclosure - Marketable Debt Securities - Summary of Classification of Marketable Debt Securities in Consolidated Balance Sheets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureMarketableDebtSecuritiesSummaryOfClassificationOfMarketableDebtSecuritiesInConsolidatedBalanceSheetsDetails</Role>
      <ShortName>Marketable Debt Securities - Summary of Classification of Marketable Debt Securities in Consolidated Balance Sheets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="acet-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>100550 - Disclosure - Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails</Role>
      <ShortName>Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="acet-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>100560 - Disclosure - Property and Equipment, Net - Summary of Property and Equipment, Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails</Role>
      <ShortName>Property and Equipment, Net - Summary of Property and Equipment, Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="acet-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>100570 - Disclosure - Property and Equipment, Net - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails</Role>
      <ShortName>Property and Equipment, Net - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="acet-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>100580 - Disclosure - Accrued and Other Current Liabilities - Summary of Accrued and Other Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesSummaryOfAccruedAndOtherCurrentLiabilitiesDetails</Role>
      <ShortName>Accrued and Other Current Liabilities - Summary of Accrued and Other Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="acet-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>100590 - Disclosure - Term Loan - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails</Role>
      <ShortName>Term Loan - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="acet-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>100600 - Disclosure - Regeneron License and Collaboration Arrangement - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRegeneronLicenseAndCollaborationArrangementAdditionalInformationDetails</Role>
      <ShortName>Regeneron License and Collaboration Arrangement - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="acet-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>100610 - Disclosure - Regeneron License and Collaboration Arrangement - Summary of Change in Company's Contract Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRegeneronLicenseAndCollaborationArrangementSummaryOfChangeInCompanySContractLiabilitiesDetails</Role>
      <ShortName>Regeneron License and Collaboration Arrangement - Summary of Change in Company's Contract Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="acet-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>100620 - Disclosure - License Funding and Other Agreements Related to the CVR - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureLicenseFundingAndOtherAgreementsRelatedToCVRAdditionalInformationDetails</Role>
      <ShortName>License Funding and Other Agreements Related to the CVR - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="acet-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>100630 - Disclosure - Commitment and Contingencies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails</Role>
      <ShortName>Commitment and Contingencies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="acet-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>100640 - Disclosure - Commitments And Contingencies - Schedule of Sublease Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSubleaseIncomeDetails</Role>
      <ShortName>Commitments And Contingencies - Schedule of Sublease Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="acet-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>100650 - Disclosure - Commitment and Contingencies - Schedule of Weighted Average IBR and Remaining Lease Term (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfWeightedAverageIBRAndRemainingLeaseTermDetails</Role>
      <ShortName>Commitment and Contingencies - Schedule of Weighted Average IBR and Remaining Lease Term (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="acet-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>100660 - Disclosure - Commitment and Contingencies - Summary of Lease Costs and Other Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesSummaryOfLeaseCostsAndOtherInformationDetails</Role>
      <ShortName>Commitment and Contingencies - Summary of Lease Costs and Other Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="acet-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>100670 - Disclosure - Commitment and Contingencies - Schedule Of Maturities Of Operating Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails</Role>
      <ShortName>Commitment and Contingencies - Schedule Of Maturities Of Operating Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="acet-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>100690 - Disclosure - Stockholders' Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails</Role>
      <ShortName>Stockholders' Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="acet-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>100700 - Disclosure - Stockholders' Equity - Schedule of Number of Shares of Common Stock Reserved for Future Issuance (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceDetails</Role>
      <ShortName>Stockholders' Equity - Schedule of Number of Shares of Common Stock Reserved for Future Issuance (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="acet-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>100710 - Disclosure - Stockholders' Equity - Schedule of Outstanding Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfOutstandingWarrantsDetails</Role>
      <ShortName>Stockholders' Equity - Schedule of Outstanding Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="acet-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>100720 - Disclosure - Stockholders' Equity - Schedule Of Outstanding Warrants To Purchase Shares of Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockDetails</Role>
      <ShortName>Stockholders' Equity - Schedule Of Outstanding Warrants To Purchase Shares of Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="acet-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>100730 - Disclosure - At-The-Market (ATM) Offering - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureAtTheMarketATMOfferingAdditionalInformationDetails</Role>
      <ShortName>At-The-Market (ATM) Offering - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="acet-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>100750 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="acet-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>100760 - Disclosure - Stock-Based Compensation - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="acet-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>100770 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>74</Position>
    </Report>
    <Report instance="acet-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>100780 - Disclosure - Stock-Based Compensation - Schedule of Assumptions to Estimate Fair Value of Stock Options Using Black-Scholes Option Pricing Model (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsToEstimateFairValueOfStockOptionsUsingBlackScholesOptionPricingModelDetails</Role>
      <ShortName>Stock-Based Compensation - Schedule of Assumptions to Estimate Fair Value of Stock Options Using Black-Scholes Option Pricing Model (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>75</Position>
    </Report>
    <Report instance="acet-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>100790 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Unit Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails</Role>
      <ShortName>Stock-Based Compensation - Summary of Restricted Stock Unit Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="acet-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>100800 - Disclosure - Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails</Role>
      <ShortName>Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="acet-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>100810 - Disclosure - Net Loss Per Share - Schedule of Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share - Schedule of Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="acet-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>100820 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="acet-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>100830 - Disclosure - Income Taxes - Schedule of Components of Provision for (benefit from) Income Taxes (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForBenefitFromIncomeTaxesDetail</Role>
      <ShortName>Income Taxes - Schedule of Components of Provision for (benefit from) Income Taxes (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="acet-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>100840 - Disclosure - Income Taxes - Schedule of (Provision for) Benefit from Income Taxes Differs from Federal Statutory Rate to the Loss Before Taxes (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDiffersFromFederalStatutoryRateToLossBeforeTaxesDetail</Role>
      <ShortName>Income Taxes - Schedule of (Provision for) Benefit from Income Taxes Differs from Federal Statutory Rate to the Loss Before Taxes (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="acet-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>100850 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="acet-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>100860 - Disclosure - Income Taxes - Schedule of Reconciliation of Unrecognized Tax Benefits (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetail</Role>
      <ShortName>Income Taxes - Schedule of Reconciliation of Unrecognized Tax Benefits (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="acet-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>100870 - Disclosure - Defined Contribution Plan - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetails</Role>
      <ShortName>Defined Contribution Plan - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="acet-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>100880 - Disclosure - Related Party Transactions - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails</Role>
      <ShortName>Related Party Transactions - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="acet-20211231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>100890 - Disclosure - Subsequent Events - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails</Role>
      <ShortName>Subsequent Events - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="acet-20211231.htm">acet-20211231.htm</File>
    <File>acet-20211231.xsd</File>
    <File>acet-20211231_cal.xml</File>
    <File>acet-20211231_def.xml</File>
    <File>acet-20211231_lab.xml</File>
    <File>acet-20211231_pre.xml</File>
    <File>acet-ex10_11.htm</File>
    <File>acet-ex10_14.htm</File>
    <File>acet-ex10_15.htm</File>
    <File>acet-ex10_16.htm</File>
    <File>acet-ex10_17.htm</File>
    <File>acet-ex10_18.htm</File>
    <File>acet-ex10_19.htm</File>
    <File>acet-ex23_1.htm</File>
    <File>acet-ex31_1.htm</File>
    <File>acet-ex31_2.htm</File>
    <File>acet-ex32_1.htm</File>
    <File>acet-ex4_3.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>img102984888_0.jpg</File>
    <File>img102984888_1.jpg</File>
    <File>img102984888_10.jpg</File>
    <File>img102984888_11.jpg</File>
    <File>img102984888_12.jpg</File>
    <File>img102984888_13.jpg</File>
    <File>img102984888_14.jpg</File>
    <File>img102984888_15.jpg</File>
    <File>img102984888_16.jpg</File>
    <File>img102984888_17.jpg</File>
    <File>img102984888_2.jpg</File>
    <File>img102984888_3.jpg</File>
    <File>img102984888_4.jpg</File>
    <File>img102984888_5.jpg</File>
    <File>img102984888_6.jpg</File>
    <File>img102984888_7.jpg</File>
    <File>img102984888_8.jpg</File>
    <File>img102984888_9.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1">http://fasb.org/srt/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="738">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="40">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>132
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "acet-20211231.htm": {
   "axisCustom": 0,
   "axisStandard": 32,
   "contextCount": 227,
   "dts": {
    "calculationLink": {
     "local": [
      "acet-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "acet-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "acet-20211231.htm"
     ]
    },
    "labelLink": {
     "local": [
      "acet-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "acet-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "acet-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 812,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 37,
    "http://www.adicetbio.com/20211231": 4,
    "http://xbrl.sec.gov/dei/2021q4": 5,
    "total": 46
   },
   "keyCustom": 112,
   "keyStandard": 451,
   "memberCustom": 37,
   "memberStandard": 39,
   "nsprefix": "acet",
   "nsuri": "http://www.adicetbio.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "100000 - Document - Document and Entity Information",
     "role": "http://www.adicetbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100090 - Disclosure - Business Combination",
     "role": "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombination",
     "shortName": "Business Combination",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessCombinationDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100100 - Disclosure - Fair Value Measurements",
     "role": "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100110 - Disclosure - Marketable Debt Securities",
     "role": "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureMarketableDebtSecurities",
     "shortName": "Marketable Debt Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "acet:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100120 - Disclosure - Prepaid Expenses and Other Current Assets",
     "role": "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets",
     "shortName": "Prepaid Expenses and Other Current Assets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "acet:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100130 - Disclosure - Property and Equipment, Net",
     "role": "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet",
     "shortName": "Property and Equipment, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100140 - Disclosure - Accrued and Other Current Liabilities",
     "role": "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilities",
     "shortName": "Accrued and Other Current Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100150 - Disclosure - Term Loan",
     "role": "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureTermLoan",
     "shortName": "Term Loan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100160 - Disclosure - Regeneron License and Collaboration Arrangement",
     "role": "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRegeneronLicenseAndCollaborationArrangement",
     "shortName": "Regeneron License and Collaboration Arrangement",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "acet:LicenseFundingAndOtherAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100170 - Disclosure - License Funding and Other Agreements Related to the CVR",
     "role": "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureLicenseFundingAndOtherAgreementsRelatedToCVR",
     "shortName": "License Funding and Other Agreements Related to the CVR",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "acet:LicenseFundingAndOtherAgreementsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100180 - Disclosure - Commitments and Contingences",
     "role": "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingences",
     "shortName": "Commitments and Contingences",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100010 - Statement - Consolidated Balance Sheets",
     "role": "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AccountsReceivableRelatedPartiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100190 - Disclosure - Stockholders' Equity",
     "role": "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockholdersEquity",
     "shortName": "Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "acet:AtTheMarketOfferingTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100200 - Disclosure - At-the-Market (ATM) Offering",
     "role": "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureAtMarketATMOffering",
     "shortName": "At-the-Market (ATM) Offering",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "acet:AtTheMarketOfferingTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100210 - Disclosure - Stock-Based Compensation",
     "role": "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100220 - Disclosure - Net Loss Per Share",
     "role": "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShare",
     "shortName": "Net Loss Per Share",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100230 - Disclosure - Income Taxes",
     "role": "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100240 - Disclosure - Defined Contribution Plan",
     "role": "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureDefinedContributionPlan",
     "shortName": "Defined Contribution Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DefinedContributionPlanTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100250 - Disclosure - Related Party Transactions",
     "role": "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactions",
     "shortName": "Related Party Transactions",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100260 - Disclosure - Subsequent Events",
     "role": "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSubsequentEvents",
     "shortName": "Subsequent Events",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SubsequentEventsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100270 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "role": "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionProFormaInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100280 - Disclosure - Business Combination (Tables)",
     "role": "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationTables",
     "shortName": "Business Combination (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BusinessAcquisitionProFormaInformationTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USDollarShare",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100020 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USDollarShare",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100290 - Disclosure - Fair Value Measurements (Tables)",
     "role": "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100300 - Disclosure - Marketable Debt Securities (Tables)",
     "role": "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureMarketableDebtSecuritiesTables",
     "shortName": "Marketable Debt Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:MarketableSecuritiesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "acet:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "acet:PrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100310 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)",
     "role": "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables",
     "shortName": "Prepaid Expenses and Other Current Assets (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "acet:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "acet:PrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100320 - Disclosure - Property and Equipment, Net (Tables)",
     "role": "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables",
     "shortName": "Property and Equipment, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100330 - Disclosure - Accrued and Other Current Liabilities  (Tables)",
     "role": "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesTables",
     "shortName": "Accrued and Other Current Liabilities  (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100340 - Disclosure - Regeneron License and Collaboration Arrangement (Tables)",
     "role": "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRegeneronLicenseAndCollaborationArrangementTables",
     "shortName": "Regeneron License and Collaboration Arrangement (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "acet:ScheduleOfSubleaseIncomeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100350 - Disclosure - Commitments and Contingences (Tables)",
     "role": "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencesTables",
     "shortName": "Commitments and Contingences (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "acet:ScheduleOfSubleaseIncomeTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "acet:ScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100360 - Disclosure - Stockholders' Equity (Tables)",
     "role": "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockholdersEquityTables",
     "shortName": "Stockholders' Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "acet:ScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100370 - Disclosure - Stock-Based Compensation (Tables)",
     "role": "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100380 - Disclosure - Net Loss Per Share (Tables)",
     "role": "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareTables",
     "shortName": "Net Loss Per Share (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromRelatedParties",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100030 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "role": "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100390 - Disclosure - Income Taxes (Tables)",
     "role": "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "acet:OrganizationAndNatureOfBusinessTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "acet:EntityDateOfMerger",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100400 - Disclosure - Organization and Nature of the Business - Additional Information (Details)",
     "role": "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails",
     "shortName": "Organization and Nature of the Business - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "acet:OrganizationAndNatureOfBusinessTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "acet:EntityDateOfMerger",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "acet:OrganizationAndNatureOfBusinessTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_54827df2-7ab1-4397-b75e-6c83f7055086",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "acet:ExchangeRatio",
      "reportCount": 1,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100410 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "role": "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesPolicyTextBlock",
       "div",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": "-5",
      "lang": null,
      "name": "acet:GainLossOnChangeInFairValueOfContingentConsiderationLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "acet:OrganizationAndNatureOfBusinessTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_54827df2-7ab1-4397-b75e-6c83f7055086",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityReverseStockSplit",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100420 - Disclosure - Business Combination - Additional Information (Details)",
     "role": "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails",
     "shortName": "Business Combination - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_4f49ca26-ce78-4bcd-aa4b-b027527c27af",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_25b4b380-f29f-4199-a59a-67e5d8821aef",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100430 - Disclosure - Business Combination - Schedule of Summarizes the Purchase Price in the Merger (Details)",
     "role": "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesPurchasePriceInMergerDetails",
     "shortName": "Business Combination - Schedule of Summarizes the Purchase Price in the Merger (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_5ad68f0f-dc2d-43e8-92c2-f0f53b821bd5",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
       "div",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_0e581963-9b5e-4dbd-bb03-47a0e58483c2",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100440 - Disclosure - Business Combination - Schedule of Estimated Share Consideration of Combined Company (Details)",
     "role": "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfEstimatedShareConsiderationOfCombinedCompanyDetails",
     "shortName": "Business Combination - Schedule of Estimated Share Consideration of Combined Company (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
       "div",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_5ad68f0f-dc2d-43e8-92c2-f0f53b821bd5",
      "decimals": "2",
      "lang": null,
      "name": "us-gaap:BusinessAcquisitionSharePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USDollarShare",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
       "div",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_0e581963-9b5e-4dbd-bb03-47a0e58483c2",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100450 - Disclosure - Business Combination - Schedule of Estimated Share Consideration of Combined Company (Parenthetical) (Details)",
     "role": "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfEstimatedShareConsiderationOfCombinedCompanyParentheticalDetails",
     "shortName": "Business Combination - Schedule of Estimated Share Consideration of Combined Company (Parenthetical) (Details)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_5ad68f0f-dc2d-43e8-92c2-f0f53b821bd5",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "acet:UnvestedRestrictedStockUnitsOutstanding",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100460 - Disclosure - Business Combination - Schedule of Summarizes the Purchase Price in the Merger (Parenthetical) (Details)",
     "role": "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesPurchasePriceInMergerParentheticalDetails",
     "shortName": "Business Combination - Schedule of Summarizes the Purchase Price in the Merger (Parenthetical) (Details)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100470 - Disclosure - Business Combination - Schedule of Summarizes the Allocation of the Purchase Price to the Net Tangible and Intangible Assets Acquired (Details)",
     "role": "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsAcquiredDetails",
     "shortName": "Business Combination - Schedule of Summarizes the Allocation of the Purchase Price to the Net Tangible and Intangible Assets Acquired (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
       "div",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_a6003cef-f951-463a-a0b1-c940267e5c47",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock",
       "div",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_75d47652-161b-4dc3-8594-ce11750f60a2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationAssetsArisingFromContingenciesAmountRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100480 - Disclosure - Business Combination - Schedule of changes in the Company's IPR&D and CVR since the Merger (Details)",
     "role": "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureBusinessCombinationScheduleOfChangesInTheCompanysIprdAndCvrSinceTheMergerDetails",
     "shortName": "Business Combination - Schedule of changes in the Company's IPR&D and CVR since the Merger (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock",
       "div",
       "us-gaap:BusinessCombinationDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_75d47652-161b-4dc3-8594-ce11750f60a2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationAssetsArisingFromContingenciesAmountRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_95800697-5c2c-4d5a-aff7-318a343c4784",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100040 - Statement - Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)",
     "role": "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
     "shortName": "Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit)",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_95800697-5c2c-4d5a-aff7-318a343c4784",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_23c45869-fbfe-42d5-ad00-b90a165dbcd2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100500 - Disclosure - Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured on Recurring Basis (Details)",
     "role": "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails",
     "shortName": "Fair Value Measurements - Schedule of Financial Assets and Liabilities Measured on Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_23c45869-fbfe-42d5-ad00-b90a165dbcd2",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "acet:ScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100520 - Disclosure - Fair Value Measurements - Additional Information (Details)",
     "role": "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
     "shortName": "Fair Value Measurements - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:MarketableSecuritiesTextBlock",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_25b4b380-f29f-4199-a59a-67e5d8821aef",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100530 - Disclosure - Marketable Debt Securities - Schedule of Marketable Debt Securities (Details)",
     "role": "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureMarketableDebtSecuritiesScheduleOfMarketableDebtSecuritiesDetails",
     "shortName": "Marketable Debt Securities - Schedule of Marketable Debt Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:MarketableSecuritiesTextBlock",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_25b4b380-f29f-4199-a59a-67e5d8821aef",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "acet:MarketableDebtSecuritiesClassificationTableTextBlock",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100540 - Disclosure - Marketable Debt Securities - Summary of Classification of Marketable Debt Securities in Consolidated Balance Sheets (Details)",
     "role": "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureMarketableDebtSecuritiesSummaryOfClassificationOfMarketableDebtSecuritiesInConsolidatedBalanceSheetsDetails",
     "shortName": "Marketable Debt Securities - Summary of Classification of Marketable Debt Securities in Consolidated Balance Sheets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "acet:MarketableDebtSecuritiesClassificationTableTextBlock",
       "div",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:MarketableSecurities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "acet:PrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
       "div",
       "acet:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PrepaidInsurance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100550 - Disclosure - Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details)",
     "role": "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails",
     "shortName": "Prepaid Expenses and Other Current Assets - Summary of Prepaid Expenses and Other Current Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "acet:PrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
       "div",
       "acet:PrepaidExpensesAndOtherCurrentAssetsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PrepaidInsurance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100560 - Disclosure - Property and Equipment, Net - Summary of Property and Equipment, Net (Details)",
     "role": "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails",
     "shortName": "Property and Equipment, Net - Summary of Property and Equipment, Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DepreciationAndAmortization",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100570 - Disclosure - Property and Equipment, Net - Additional Information (Details)",
     "role": "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
     "shortName": "Property and Equipment, Net - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": "-5",
      "lang": null,
      "name": "acet:IncreaseInConstructionInProgress",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100580 - Disclosure - Accrued and Other Current Liabilities - Summary of Accrued and Other Current Liabilities (Details)",
     "role": "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesSummaryOfAccruedAndOtherCurrentLiabilitiesDetails",
     "shortName": "Accrued and Other Current Liabilities - Summary of Accrued and Other Current Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "div",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_57a750f3-8a24-41e7-9a82-33461f5929df",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:LoansReceivableBasisSpreadOnVariableRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100590 - Disclosure - Term Loan - Additional Information (Details)",
     "role": "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails",
     "shortName": "Term Loan - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_57a750f3-8a24-41e7-9a82-33461f5929df",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:LoansReceivableBasisSpreadOnVariableRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "acet:ExercisedInvestmentRightAndPurchased",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100600 - Disclosure - Regeneron License and Collaboration Arrangement - Additional Information (Details)",
     "role": "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRegeneronLicenseAndCollaborationArrangementAdditionalInformationDetails",
     "shortName": "Regeneron License and Collaboration Arrangement - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "acet:ExercisedInvestmentRightAndPurchased",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100050 - Statement - Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)",
     "role": "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical",
     "shortName": "Consolidated Statements of Redeemable Convertible Preferred Stock and Stockholders' Equity (Deficit) (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "div",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_3ca7e266-0fdc-4e92-9c8c-d4aea36592ef",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "acet:ContractAssetsAndLiabilitiesAdditions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100610 - Disclosure - Regeneron License and Collaboration Arrangement - Summary of Change in Company's Contract Liabilities (Details)",
     "role": "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRegeneronLicenseAndCollaborationArrangementSummaryOfChangeInCompanySContractLiabilitiesDetails",
     "shortName": "Regeneron License and Collaboration Arrangement - Summary of Change in Company's Contract Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "div",
       "us-gaap:CollaborativeArrangementDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_3ca7e266-0fdc-4e92-9c8c-d4aea36592ef",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "acet:ContractAssetsAndLiabilitiesAdditions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "acet:EstimatedFairValueOfCVRLiability",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100620 - Disclosure - License Funding and Other Agreements Related to the CVR - Additional Information (Details)",
     "role": "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureLicenseFundingAndOtherAgreementsRelatedToCVRAdditionalInformationDetails",
     "shortName": "License Funding and Other Agreements Related to the CVR - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "acet:LicenseFundingAndOtherAgreementsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_f2283cea-c435-437b-958f-019a9a629ca9",
      "decimals": null,
      "lang": "en-US",
      "name": "acet:GrantTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "acet:IncreaseDecreaseInLeaseObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100630 - Disclosure - Commitment and Contingencies - Additional Information (Details)",
     "role": "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails",
     "shortName": "Commitment and Contingencies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "acet:IncreaseDecreaseInLeaseObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "acet:OperatingLeasesFutureMinimumSubleaseIncomeDueCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100640 - Disclosure - Commitments And Contingencies - Schedule of Sublease Income (Details)",
     "role": "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSubleaseIncomeDetails",
     "shortName": "Commitments And Contingencies - Schedule of Sublease Income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "acet:OperatingLeasesFutureMinimumSubleaseIncomeDueCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "acet:ScheduleOfWeightedAverageIBRAndRemainingLeaseTermTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100650 - Disclosure - Commitment and Contingencies - Schedule of Weighted Average IBR and Remaining Lease Term (Details)",
     "role": "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfWeightedAverageIBRAndRemainingLeaseTermDetails",
     "shortName": "Commitment and Contingencies - Schedule of Weighted Average IBR and Remaining Lease Term (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "acet:ScheduleOfWeightedAverageIBRAndRemainingLeaseTermTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100660 - Disclosure - Commitment and Contingencies - Summary of Lease Costs and Other Information (Details)",
     "role": "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesSummaryOfLeaseCostsAndOtherInformationDetails",
     "shortName": "Commitment and Contingencies - Summary of Lease Costs and Other Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LeaseCostTableTextBlock",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100670 - Disclosure - Commitment and Contingencies - Schedule Of Maturities Of Operating Lease Liabilities (Details)",
     "role": "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails",
     "shortName": "Commitment and Contingencies - Schedule Of Maturities Of Operating Lease Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_ee99e6bd-ad45-468e-9fbb-435628a329b5",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100690 - Disclosure - Stockholders' Equity - Additional Information (Details)",
     "role": "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
     "shortName": "Stockholders' Equity - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_ee99e6bd-ad45-468e-9fbb-435628a329b5",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "acet:ScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100700 - Disclosure - Stockholders' Equity - Schedule of Number of Shares of Common Stock Reserved for Future Issuance (Details)",
     "role": "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceDetails",
     "shortName": "Stockholders' Equity - Schedule of Number of Shares of Common Stock Reserved for Future Issuance (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "acet:ScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockCapitalSharesReservedForFutureIssuance",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_25b4b380-f29f-4199-a59a-67e5d8821aef",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "acet:ClassOfWarrantOutstandingAndExercisableToPurchasePreferredShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100710 - Disclosure - Stockholders' Equity - Schedule of Outstanding Warrants (Details)",
     "role": "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfOutstandingWarrantsDetails",
     "shortName": "Stockholders' Equity - Schedule of Outstanding Warrants (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_25b4b380-f29f-4199-a59a-67e5d8821aef",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "acet:ClassOfWarrantOutstandingAndExercisableToPurchasePreferredShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "100060 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "acet:ScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100720 - Disclosure - Stockholders' Equity - Schedule Of Outstanding Warrants To Purchase Shares of Common Stock (Details)",
     "role": "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockDetails",
     "shortName": "Stockholders' Equity - Schedule Of Outstanding Warrants To Purchase Shares of Common Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "acet:ScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockTableTextBlock",
       "div",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_d7c1aa19-f30c-49e2-89e6-bd6ca6fed85c",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "acet:AtTheMarketOfferingTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_62266203-5d56-4f94-a47f-f581aa528dbf",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "acet:TerminationAgreementMonthAndYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100730 - Disclosure - At-The-Market (ATM) Offering - Additional Information (Details)",
     "role": "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureAtTheMarketATMOfferingAdditionalInformationDetails",
     "shortName": "At-The-Market (ATM) Offering - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "acet:AtTheMarketOfferingTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_62266203-5d56-4f94-a47f-f581aa528dbf",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "acet:TerminationAgreementMonthAndYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100750 - Disclosure - Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details)",
     "role": "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails",
     "shortName": "Stock-Based Compensation - Summary of Stock-Based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_e645c0e4-c8b9-494e-86ea-d249ee6b8de0",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
      "reportCount": 1,
      "unitRef": "U_USDollarShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100760 - Disclosure - Stock-Based Compensation - Additional Information (Details)",
     "role": "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
     "shortName": "Stock-Based Compensation - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": "-5",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_25b4b380-f29f-4199-a59a-67e5d8821aef",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100770 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Details)",
     "role": "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails",
     "shortName": "Stock-Based Compensation - Summary of Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100780 - Disclosure - Stock-Based Compensation - Schedule of Assumptions to Estimate Fair Value of Stock Options Using Black-Scholes Option Pricing Model (Details)",
     "role": "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsToEstimateFairValueOfStockOptionsUsingBlackScholesOptionPricingModelDetails",
     "shortName": "Stock-Based Compensation - Schedule of Assumptions to Estimate Fair Value of Stock Options Using Black-Scholes Option Pricing Model (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_2d0f9825-f275-4fef-8d45-4314b18f7073",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100790 - Disclosure - Stock-Based Compensation - Summary of Restricted Stock Unit Activity (Details)",
     "role": "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails",
     "shortName": "Stock-Based Compensation - Summary of Restricted Stock Unit Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "div",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_0c48ad1d-3ddc-4d42-94e0-eacbdc6debba",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100800 - Disclosure - Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders (Details)",
     "role": "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
     "shortName": "Net Loss Per Share - Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100810 - Disclosure - Net Loss Per Share - Schedule of Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details)",
     "role": "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails",
     "shortName": "Net Loss Per Share - Schedule of Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "div",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100820 - Disclosure - Income Taxes - Additional Information (Details)",
     "role": "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
     "shortName": "Income Taxes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": "-5",
      "lang": null,
      "name": "acet:DeferredTaxAssetsValuationAllowanceIncrease",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "acet:OrganizationAndNatureOfBusinessTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100070 - Disclosure - Organization and Nature of Business",
     "role": "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusiness",
     "shortName": "Organization and Nature of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "acet:OrganizationAndNatureOfBusinessTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100830 - Disclosure - Income Taxes - Schedule of Components of Provision for (benefit from) Income Taxes (Detail)",
     "role": "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForBenefitFromIncomeTaxesDetail",
     "shortName": "Income Taxes - Schedule of Components of Provision for (benefit from) Income Taxes (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unitRef": "U_pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100840 - Disclosure - Income Taxes - Schedule of (Provision for) Benefit from Income Taxes Differs from Federal Statutory Rate to the Loss Before Taxes (Detail)",
     "role": "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDiffersFromFederalStatutoryRateToLossBeforeTaxesDetail",
     "shortName": "Income Taxes - Schedule of (Provision for) Benefit from Income Taxes Differs from Federal Statutory Rate to the Loss Before Taxes (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": "3",
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsOther",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_pure",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100850 - Disclosure - Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "role": "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails",
     "shortName": "Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b",
      "decimals": "-3",
      "lang": null,
      "name": "acet:DeferredTaxOperatingLeaseRightOfUseAssetLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_25b4b380-f29f-4199-a59a-67e5d8821aef",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100860 - Disclosure - Income Taxes - Schedule of Reconciliation of Unrecognized Tax Benefits (Detail)",
     "role": "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetail",
     "shortName": "Income Taxes - Schedule of Reconciliation of Unrecognized Tax Benefits (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "div",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DefinedContributionPlanTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_3f32af84-ec12-4ae0-9cc1-f2521512740c",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "acet:CompanyContributionToPlanWithRespectToEmployeesContribution",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100870 - Disclosure - Defined Contribution Plan - Additional Information (Details)",
     "role": "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetails",
     "shortName": "Defined Contribution Plan - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:DefinedContributionPlanTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_3f32af84-ec12-4ae0-9cc1-f2521512740c",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "acet:CompanyContributionToPlanWithRespectToEmployeesContribution",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "td",
       "tr",
       "table",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_6cfa408b-e056-4df9-b6a5-ce56ac19cd7b",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesIssued",
      "reportCount": 1,
      "unitRef": "U_shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100880 - Disclosure - Related Party Transactions - Additional Information (Details)",
     "role": "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
     "shortName": "Related Party Transactions - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:RelatedPartyTransactionsDisclosureTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_32996dbe-7c67-4061-9092-811f3ea449f5",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_shares",
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_7c105d75-0eff-40e5-a076-0166362fc4d4",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "acet:ExerciseFeePaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100890 - Disclosure - Subsequent Events - Additional Information (Details)",
     "role": "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails",
     "shortName": "Subsequent Events - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "p",
       "us-gaap:SubsequentEventsTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_7c105d75-0eff-40e5-a076-0166362fc4d4",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "acet:ExerciseFeePaid",
      "reportCount": 1,
      "unique": true,
      "unitRef": "U_USD",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "100080 - Disclosure - Summary of Significant Accounting Policies",
     "role": "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "acet-20211231.htm",
      "contextRef": "C_b8cc7f17-491b-4f8b-ad3b-a4917a1b996c",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 80,
   "tag": {
    "acet_AccruedCmoCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesSummaryOfAccruedAndOtherCurrentLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued CMO costs",
        "label": "Accrued CMO costs",
        "terseLabel": "Accrued CMO costs"
       }
      }
     },
     "localname": "AccruedCmoCosts",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesSummaryOfAccruedAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_AccruedCroCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesSummaryOfAccruedAndOtherCurrentLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued CRO costs",
        "label": "Accrued CRO costs",
        "terseLabel": "Accrued CRO costs"
       }
      }
     },
     "localname": "AccruedCroCosts",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesSummaryOfAccruedAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_AccruedResearchAndDevelopmentExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesSummaryOfAccruedAndOtherCurrentLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development expenses current.",
        "label": "Accrued Research And Development Expenses Current",
        "terseLabel": "Accrued research and development expenses"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentExpensesCurrent",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesSummaryOfAccruedAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_AccruedResearchAndDevelopmentPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accrued research and development.",
        "label": "Accrued Research And Development Policy [Text Block]",
        "terseLabel": "Accrued CRO, CMO, and Research and Development Expenses"
       }
      }
     },
     "localname": "AccruedResearchAndDevelopmentPolicyTextBlock",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "acet_AdditionalAuthorizedAndUnissuedRedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional authorized and unissued redeemable convertible preferred stock.",
        "label": "Additional Authorized And Unissued Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Conversion of Additional Authorized and Unissued Redeemable Convertible Preferred Stock"
       }
      }
     },
     "localname": "AdditionalAuthorizedAndUnissuedRedeemableConvertiblePreferredStockMember",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "acet_AdditionalClosingLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional closing liability.",
        "label": "Additional Closing Liability",
        "terseLabel": "Additional closing liability"
       }
      }
     },
     "localname": "AdditionalClosingLiability",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_AdicetTherapeuticsIncMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adicet Therapeutics, Inc Member",
        "label": "Adicet Therapeutics Inc [Member]",
        "terseLabel": "Adicet Therapeutics [Member]"
       }
      }
     },
     "localname": "AdicetTherapeuticsIncMember",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "acet_AdjustmentToGoodwill": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustment to goodwill",
        "label": "Adjustment To Goodwill",
        "terseLabel": "Adjustment to Goodwill"
       }
      }
     },
     "localname": "AdjustmentToGoodwill",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_AdvisoryServicesAnnualFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Advisory services annual fee.",
        "label": "Advisory Services Annual Fee",
        "terseLabel": "Advisory services annual fee"
       }
      }
     },
     "localname": "AdvisoryServicesAnnualFee",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_AgreementTransactionPrice": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agreement transaction price",
        "label": "Agreement transaction price"
       }
      }
     },
     "localname": "AgreementTransactionPrice",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRegeneronLicenseAndCollaborationArrangementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_AmendedLeaseAgreementDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amended lease Agreement Details",
        "label": "Amended lease Agreement Description",
        "terseLabel": "Amended lease Agreement Description"
       }
      }
     },
     "localname": "AmendedLeaseAgreementDescription",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "acet_AmortizationOfDebtIssuanceCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortization of deferred debt issuance costs.",
        "label": "Amortization Of Debt Issuance Costs",
        "terseLabel": "Amortization of deferred debt issuance costs"
       }
      }
     },
     "localname": "AmortizationOfDebtIssuanceCosts",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_AmountPayableUponClosingOfMerger": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount payable upon closing of merger.",
        "label": "Amount Payable Upon Closing Of Merger",
        "terseLabel": "Payable upon closing of merger"
       }
      }
     },
     "localname": "AmountPayableUponClosingOfMerger",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_AreaOfSublease": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of Sublease",
        "label": "Area of Sublease",
        "terseLabel": "Area of Sublease"
       }
      }
     },
     "localname": "AreaOfSublease",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "acet_AtTheMarketOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At the market offering Member.",
        "label": "At The Market Offering [Member]",
        "terseLabel": "At The Market Offering [Member]"
       }
      }
     },
     "localname": "AtTheMarketOfferingMember",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureAtTheMarketATMOfferingAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "acet_AtTheMarketOfferingTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "At the market offering.",
        "label": "At The Market Offering [Text Block]",
        "terseLabel": "At-the-Market (ATM) Offering"
       }
      }
     },
     "localname": "AtTheMarketOfferingTextBlock",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureAtMarketATMOffering"
     ],
     "xbrltype": "textBlockItemType"
    },
    "acet_BostonMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boston [member].",
        "label": "Boston [Member]",
        "terseLabel": "Boston, Massachusetts [Member]",
        "verboseLabel": "Boston, MA"
       }
      }
     },
     "localname": "BostonMember",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfWeightedAverageIBRAndRemainingLeaseTermDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "acet_BusinessAcquisitionsProFormaRevenue1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma revenues for a period as if the business combination or combinations had been completed at the beginning of the period.",
        "label": "Business Acquisitions Pro Forma Revenue1",
        "terseLabel": "Revenue - related party"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaRevenue1",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSupplementalUnauditedProFormaInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_BusinessCombinationAccelerationOfRestrictedStockUnitsUponMerger": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business combination acceleration of restricted stock units upon merger.",
        "label": "Business Combination Acceleration Of Restricted Stock Units Upon Merger",
        "terseLabel": "Acceleration of restricted stock units upon merger"
       }
      }
     },
     "localname": "BusinessCombinationAccelerationOfRestrictedStockUnitsUponMerger",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfEstimatedShareConsiderationOfCombinedCompanyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentTangibleAndIntangiblesAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business combination provisional information initial accounting incomplete adjustment tangible and intangibles assets.",
        "label": "Business Combination Provisional Information Initial Accounting Incomplete Adjustment Tangible And Intangibles Assets",
        "terseLabel": "Measurement prior adjustment in tangible and intangible assets"
       }
      }
     },
     "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentTangibleAndIntangiblesAssets",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsAcquiredDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business combination recognized identifiable assets acquired and liabilities assumed in process research and development.",
        "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed In Process Research And Development",
        "terseLabel": "IPR&amp;D"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedInProcessResearchAndDevelopment",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsAcquiredDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash": {
     "auth_ref": [],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsAcquiredDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Business combination recognized identifiable assets acquired and liabilities assumed restricted cash.",
        "label": "Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Restricted Cash",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedRestrictedCash",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsAcquiredDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_COVID19Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "COVID 19.",
        "label": "C O V I D19 [Member]",
        "terseLabel": "C O V I D19",
        "verboseLabel": "COVID-19"
       }
      }
     },
     "localname": "COVID19Member",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureLicenseFundingAndOtherAgreementsRelatedToCVRAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "acet_CaliforniaResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "California research and development.",
        "label": "California Research And Development [Member]",
        "terseLabel": "California Research And Development"
       }
      }
     },
     "localname": "CaliforniaResearchAndDevelopmentMember",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "acet_ChangeInFairValueIncludedInResearchAndDevelopmentExpense": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change in fair value included in research and development expense.",
        "label": "Change In Fair Value Included In Research And Development Expense",
        "terseLabel": "Change in the fair value included in research and development expense"
       }
      }
     },
     "localname": "ChangeInFairValueIncludedInResearchAndDevelopmentExpense",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_ClassOfWarrantExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants, exercised.",
        "label": "Class Of Warrant Exercised",
        "terseLabel": "Number of warrants, Exercised",
        "verboseLabel": "Warrant exercised"
       }
      }
     },
     "localname": "ClassOfWarrantExercised",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfOutstandingWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "acet_ClassOfWarrantOrRightIssued": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class Of Warrant Or Right Issued",
        "terseLabel": "Number of warrants, Issued"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightIssued",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfOutstandingWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "acet_ClassOfWarrantOrRightsExpirationDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Class Of Warrant Or Rights Expiration Date.",
        "label": "Class Of Warrant Or Rights Expiration Date",
        "terseLabel": "Expiration Date"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightsExpirationDate",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "acet_ClassOfWarrantOutstandingAndExercisableToPurchaseCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class Of Warrant Outstanding And Exercisable To Purchase Common Stock",
        "periodEndLabel": "Number of warrants, Outstanding and exercisable to purchase common stock as of December 31, 2021"
       }
      }
     },
     "localname": "ClassOfWarrantOutstandingAndExercisableToPurchaseCommonStock",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfOutstandingWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "acet_ClassOfWarrantOutstandingAndExercisableToPurchasePreferredShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Class Of Warrant Outstanding And Exercisable To Purchase Preferred Shares",
        "periodStartLabel": "Number of warrants, Outstanding and exercisable to purchase preferred shares as of December 31, 2020",
        "terseLabel": "Number of warrants, Outstanding and exercisable to purchase preferred shares"
       }
      }
     },
     "localname": "ClassOfWarrantOutstandingAndExercisableToPurchasePreferredShares",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfOutstandingWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "acet_CommonStockOfferingCostsIncludedInAccruedLiabilitiesAtPeriodEnd": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common Stock Offering Costs Included In Accrued Liabilities At Period End",
        "label": "Common Stock Offering Costs Included In Accrued Liabilities At Period End",
        "terseLabel": "Common stock offering costs included in accrued liabilities at period end"
       }
      }
     },
     "localname": "CommonStockOfferingCostsIncludedInAccruedLiabilitiesAtPeriodEnd",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_CommonStockWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Common stock warrants.",
        "label": "Common Stock Warrants [Member]",
        "terseLabel": "Common Stock Warrants"
       }
      }
     },
     "localname": "CommonStockWarrantsMember",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "acet_CompanyContributionToPlanWithRespectToEmployeesContribution": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Company contribution to plan with respect to employees contribution.",
        "label": "Company Contribution To Plan With Respect To Employees Contribution",
        "terseLabel": "Defined contribution plan for employees"
       }
      }
     },
     "localname": "CompanyContributionToPlanWithRespectToEmployeesContribution",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_ContingentConsiderationFees": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Consideration fees",
        "label": "Contingent Consideration fees",
        "terseLabel": "Contingent Consideration, fees"
       }
      }
     },
     "localname": "ContingentConsiderationFees",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRegeneronLicenseAndCollaborationArrangementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_ContingentConsiderationLiabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Consideration Liability.",
        "label": "Contingent Consideration Liability [Member]",
        "terseLabel": "Contingent Consideration Liability"
       }
      }
     },
     "localname": "ContingentConsiderationLiabilityMember",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "acet_ContingentConsiderationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent Consideration",
        "label": "Contingent Consideration [Member]",
        "terseLabel": "Contingent Consideration [Member]"
       }
      }
     },
     "localname": "ContingentConsiderationMember",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "acet_ContingentValueRightsAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contingent value rights agreement [member].",
        "label": "Contingent Value Rights Agreement [Member]",
        "terseLabel": "Contingent Value Rights Agreement"
       }
      }
     },
     "localname": "ContingentValueRightsAgreementMember",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureBusinessCombinationScheduleOfChangesInTheCompanysIprdAndCvrSinceTheMergerDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureLicenseFundingAndOtherAgreementsRelatedToCVRAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "acet_ContractAssetMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract Asset.",
        "label": "Contract Asset [Member]",
        "terseLabel": "Contract Asset"
       }
      }
     },
     "localname": "ContractAssetMember",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRegeneronLicenseAndCollaborationArrangementSummaryOfChangeInCompanySContractLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "acet_ContractAssetsAndLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract assets and liabilities.",
        "label": "Contract Assets And Liabilities",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period"
       }
      }
     },
     "localname": "ContractAssetsAndLiabilities",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRegeneronLicenseAndCollaborationArrangementSummaryOfChangeInCompanySContractLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_ContractAssetsAndLiabilitiesAdditions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract assets and liabilities additions.",
        "label": "Contract Assets And Liabilities Additions",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "ContractAssetsAndLiabilitiesAdditions",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRegeneronLicenseAndCollaborationArrangementSummaryOfChangeInCompanySContractLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_ContractAssetsAndLiabilitiesAdditionsDeductions": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract assets and liabilities additions (deductions).",
        "label": "Contract Assets And Liabilities Additions Deductions",
        "negatedLabel": "Additions (Deductions)"
       }
      }
     },
     "localname": "ContractAssetsAndLiabilitiesAdditionsDeductions",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRegeneronLicenseAndCollaborationArrangementSummaryOfChangeInCompanySContractLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_ContractLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract liability.",
        "label": "Contract Liability",
        "terseLabel": "Contract liability"
       }
      }
     },
     "localname": "ContractLiability",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRegeneronLicenseAndCollaborationArrangementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_ContractLiabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract liability.",
        "label": "Contract Liability [Member]",
        "terseLabel": "Contract Liability"
       }
      }
     },
     "localname": "ContractLiabilityMember",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRegeneronLicenseAndCollaborationArrangementSummaryOfChangeInCompanySContractLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "acet_ContractResearchTermPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contract research term period.",
        "label": "Contract Research Term Period",
        "terseLabel": "Contract research term period"
       }
      }
     },
     "localname": "ContractResearchTermPeriod",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRegeneronLicenseAndCollaborationArrangementAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "acet_ContractualContingentValueRight": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual Contingent Value Right",
        "label": "Contractual Contingent Value Right",
        "terseLabel": "Contractual Contingent Value Right"
       }
      }
     },
     "localname": "ContractualContingentValueRight",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "acet_ConversionOfConvertiblePreferredStockWarrantsIntoCommonStockWarrantsInConnectionWithMerger": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion of convertible preferred stock warrants into common stock warrants in connection with merger.",
        "label": "Conversion Of Convertible Preferred Stock Warrants Into Common Stock Warrants In Connection With Merger",
        "terseLabel": "Conversion of convertible preferred stock warrant into common stock warrant in connection with Merger"
       }
      }
     },
     "localname": "ConversionOfConvertiblePreferredStockWarrantsIntoCommonStockWarrantsInConnectionWithMerger",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_CustomersPercentageOfTotalRevenue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Customers percentage of total revenue.",
        "label": "Customers Percentage Of Total Revenue",
        "terseLabel": "Customers percentage of total revenue"
       }
      }
     },
     "localname": "CustomersPercentageOfTotalRevenue",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "acet_DeferredTaxAssetsFixedAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets Fixed Assets",
        "label": "Deferred Tax Assets Fixed Assets",
        "verboseLabel": "Fixed Assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsFixedAssets",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_DeferredTaxAssetsValuationAllowanceIncrease": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred Tax Assets Valuation Allowance Increase.",
        "label": "Deferred Tax Assets Valuation Allowance Increase",
        "terseLabel": "Increase in valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowanceIncrease",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_DeferredTaxBasisDifferenceIPRD": {
     "auth_ref": [],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax basis difference IPR&amp;D.",
        "label": "Deferred Tax Basis Difference I P R D",
        "terseLabel": "Basis Difference IPR&amp;D"
       }
      }
     },
     "localname": "DeferredTaxBasisDifferenceIPRD",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_DeferredTaxLiabilitiesFixedAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax liabilities fixed assets",
        "label": "Deferred Tax Liabilities Fixed Assets",
        "negatedLabel": "Fixed assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesFixedAssets",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_DeferredTaxOperatingLeaseRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating lease right-of-use asset.",
        "label": "Deferred Tax Operating Lease Right Of Use Asset",
        "terseLabel": "Operating lease right-of-use asset"
       }
      }
     },
     "localname": "DeferredTaxOperatingLeaseRightOfUseAsset",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_DeferredTaxOperatingLeaseRightOfUseAssetLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax operating lease right of use asset liability.",
        "label": "Deferred Tax Operating Lease Right Of Use Asset Liability",
        "terseLabel": "Operating lease right-of-use asset liability"
       }
      }
     },
     "localname": "DeferredTaxOperatingLeaseRightOfUseAssetLiability",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_DefinedContributionPlanAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Defined contribution plan abstract.",
        "label": "Defined Contribution Plan [Abstract]"
       }
      }
     },
     "localname": "DefinedContributionPlanAbstract",
     "nsuri": "http://www.adicetbio.com/20211231",
     "xbrltype": "stringItemType"
    },
    "acet_EffectiveIncomeTaxRateReconciliationChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilityAndTRDFLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDiffersFromFederalStatutoryRateToLossBeforeTaxesDetail": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation change in fair value of redeemable convertible preferred stock tranche liability and TRDF liability.",
        "label": "Effective Income Tax Rate Reconciliation Change In Fair Value Of Redeemable Convertible Preferred Stock Tranche Liability And T R D F Liability",
        "terseLabel": "Change in fair value of redeemable convertible preferred stock tranche liability and TRDF liability"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInFairValueOfRedeemableConvertiblePreferredStockTrancheLiabilityAndTRDFLiability",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDiffersFromFederalStatutoryRateToLossBeforeTaxesDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "acet_EffectiveIncomeTaxRateReconciliationNOLCarryback": {
     "auth_ref": [],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDiffersFromFederalStatutoryRateToLossBeforeTaxesDetail": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Effective income tax rate reconciliation NOL carryback.",
        "label": "Effective Income Tax Rate Reconciliation N O L Carryback",
        "terseLabel": "Federal benefit from NOL carryback"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNOLCarryback",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDiffersFromFederalStatutoryRateToLossBeforeTaxesDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "acet_EmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Employee Stock Purchase Plan",
        "label": "Employee Stock Purchase Plan [Member]",
        "terseLabel": "Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "EmployeeStockPurchasePlanMember",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "acet_EntityDateOfMerger": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity date of merger.",
        "label": "Entity Date Of Merger",
        "terseLabel": "Entity date of merger"
       }
      }
     },
     "localname": "EntityDateOfMerger",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "acet_EstimatedFairValueOfCVRLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Estimated fair value of CVR liability.",
        "label": "Estimated Fair Value Of C V R Liability",
        "terseLabel": "Estimated fair value of the CVR liability"
       }
      }
     },
     "localname": "EstimatedFairValueOfCVRLiability",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureLicenseFundingAndOtherAgreementsRelatedToCVRAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_ExchangeRatio": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exchange ratio.",
        "label": "Exchange Ratio",
        "terseLabel": "Exchange ratio"
       }
      }
     },
     "localname": "ExchangeRatio",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "acet_ExerciseFeePaid": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise fee paid.",
        "label": "Exercise Fee Paid",
        "terseLabel": "Exercise Fee Paid"
       }
      }
     },
     "localname": "ExerciseFeePaid",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_ExerciseOfRedeemableConvertiblePreferredStockTrancheLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise of redeemable convertible preferred stock tranche liabilities.",
        "label": "Exercise Of Redeemable Convertible Preferred Stock Tranche Liabilities",
        "terseLabel": "Exercise of redeemable convertible preferred stock tranche liability"
       }
      }
     },
     "localname": "ExerciseOfRedeemableConvertiblePreferredStockTrancheLiabilities",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_ExercisedInvestmentRightAndPurchased": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercised Investment Right and Purchased",
        "label": "Exercised Investment Right and Purchased",
        "terseLabel": "Exercised Investment Right and Purchased"
       }
      }
     },
     "localname": "ExercisedInvestmentRightAndPurchased",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRegeneronLicenseAndCollaborationArrangementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_FairValueOfCommonStockPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of common stock.",
        "label": "Fair Value Of Common Stock Policy [Text Block]",
        "terseLabel": "Fair Value of Common Stock"
       }
      }
     },
     "localname": "FairValueOfCommonStockPolicyTextBlock",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "acet_FairValueOfModifiedStockOptionsAndRestrictedStockUnitsAttributableToPreCombinationServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of modified stock options and restricted stock units attributable to pre-combination services.",
        "label": "Fair Value Of Modified Stock Options And Restricted Stock Units Attributable To Pre Combination Services",
        "terseLabel": "Estimated fair value of modified stock options and restricted stock units attributable to pre-combination services"
       }
      }
     },
     "localname": "FairValueOfModifiedStockOptionsAndRestrictedStockUnitsAttributableToPreCombinationServices",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfEstimatedShareConsiderationOfCombinedCompanyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_FederalAndStateResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Federal and state research and development [Member]",
        "label": "Federal and state research and development [Member]"
       }
      }
     },
     "localname": "FederalAndStateResearchAndDevelopmentMember",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "acet_FeesAndExpenseIncurredInConnectionWithClinicalTrials": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fees and expense incurred in connection with clinical trials.",
        "label": "Fees And Expense Incurred In Connection With Clinical Trials",
        "terseLabel": "Total fees and expenses related to clinical trials"
       }
      }
     },
     "localname": "FeesAndExpenseIncurredInConnectionWithClinicalTrials",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureLicenseFundingAndOtherAgreementsRelatedToCVRAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_FourthAmendmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fourth Amendment [Member]",
        "label": "Fourth Amendment [Member]",
        "terseLabel": "Fourth Amendment"
       }
      }
     },
     "localname": "FourthAmendmentMember",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "acet_GainLossFromTheRemeasurementOfRedeemableConvertiblePreferredStock": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain (loss) from the remeasurement of the redeemable convertible preferred stock.",
        "label": "Gain Loss From The Remeasurement Of Redeemable Convertible Preferred Stock",
        "terseLabel": "Gain from the remeasurement of the redeemable convertible preferred stock"
       }
      }
     },
     "localname": "GainLossFromTheRemeasurementOfRedeemableConvertiblePreferredStock",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_GainLossOnChangeInFairValueOfContingentConsiderationLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain loss on change in fair value of contingent consideration liability.",
        "label": "Gain Loss On Change In Fair Value Of Contingent Consideration Liability",
        "terseLabel": "Gain (loss) on change in fair value of CVR"
       }
      }
     },
     "localname": "GainLossOnChangeInFairValueOfContingentConsiderationLiability",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_GainOnRemeasurementOfContingentConsiderationLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gain on remeasurement of contingent consideration liability.",
        "label": "Gain on Remeasurement of Contingent Consideration Liability",
        "terseLabel": "Gain on remeasurement of contingent consideration liability"
       }
      }
     },
     "localname": "GainOnRemeasurementOfContingentConsiderationLiability",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_GoodwillMeasurementPeriodAdjustments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Goodwill measurement period adjustments",
        "label": "Goodwill Measurement Period Adjustments",
        "terseLabel": "Measurement period adjustment to goodwill"
       }
      }
     },
     "localname": "GoodwillMeasurementPeriodAdjustments",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_GrantTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Grant term.",
        "label": "Grant Term",
        "terseLabel": "Grant term"
       }
      }
     },
     "localname": "GrantTerm",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureLicenseFundingAndOtherAgreementsRelatedToCVRAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "acet_ImpairmentOfInProcessResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Impairment of in process research and development",
        "label": "Impairment Of In Process Research And Development",
        "terseLabel": "Impairment of in-process research and development"
       }
      }
     },
     "localname": "ImpairmentOfInProcessResearchAndDevelopment",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_IncomeTaxesDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income taxes disclosure.",
        "label": "Income Taxes Disclosure [Line Items]",
        "terseLabel": "Income Taxes Disclosure [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxesDisclosureLineItems",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "acet_IncomeTaxesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Income taxes.",
        "label": "Income Taxes [Table]",
        "terseLabel": "Income Taxes [Table]"
       }
      }
     },
     "localname": "IncomeTaxesTable",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "acet_IncreaseDecreaseInEstimatedFairValueOfCvrLiability": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in estimated fair value of cvr liability.",
        "label": "Increase Decrease In Estimated Fair Value Of Cvr Liability",
        "terseLabel": "Increase decrease in estimated fair value of CVR liability"
       }
      }
     },
     "localname": "IncreaseDecreaseInEstimatedFairValueOfCvrLiability",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureLicenseFundingAndOtherAgreementsRelatedToCVRAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_IncreaseDecreaseInLeaseObligation": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase Decrease in Lease Obligation",
        "label": "Increase Decrease in Lease Obligation",
        "terseLabel": "Change in lease Obligation"
       }
      }
     },
     "localname": "IncreaseDecreaseInLeaseObligation",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_IncreaseDecreaseInOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 16.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase decrease in operating lease liabilities",
        "label": "Increase Decrease In Operating Lease Liabilities",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingLeaseLiabilities",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_IncreaseInConstructionInProgress": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Increase in construction in progress",
        "label": "Increase in construction in progress",
        "terseLabel": "Increase in construction in progress"
       }
      }
     },
     "localname": "IncreaseInConstructionInProgress",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_InducementGrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inducement grants member.",
        "label": "Inducement Grants [Member]",
        "terseLabel": "2018 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "InducementGrantsMember",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "acet_IssuanceOfRedeemableConvertiblePreferredStockOnExerciseOfWarrantsWithLoanAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Issuance of redeemable convertible preferred stock on exercise of warrants with loan agreement.",
        "label": "Issuance Of Redeemable Convertible Preferred Stock On Exercise Of Warrants With Loan Agreement",
        "terseLabel": "Issuance of redeemable convertible preferred stock warrants in connection with the Loan Agreement"
       }
      }
     },
     "localname": "IssuanceOfRedeemableConvertiblePreferredStockOnExerciseOfWarrantsWithLoanAgreement",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_LaboratoryEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Laboratory Equipment Member",
        "label": "Laboratory Equipment [Member]",
        "terseLabel": "Laboratory Equipment"
       }
      }
     },
     "localname": "LaboratoryEquipmentMember",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "acet_LawsuitsFiledAgainstCompany": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lawsuits filed against company.",
        "label": "Lawsuits Filed Against Company",
        "terseLabel": "Lawsuits Filed Against Company"
       }
      }
     },
     "localname": "LawsuitsFiledAgainstCompany",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "acet_LeaseCostOtherInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lease cost other information.",
        "label": "Lease Cost Other Information [Abstract]",
        "terseLabel": "Other Information"
       }
      }
     },
     "localname": "LeaseCostOtherInformationAbstract",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesSummaryOfLeaseCostsAndOtherInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "acet_LessPortionOfFairValueToBeDistributedAsCVR": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Less portion of the fair value to be distributed as CVR.",
        "label": "Less Portion Of Fair Value To Be Distributed As C V R",
        "terseLabel": "Less: portion of the fair value to be distributed as CVR"
       }
      }
     },
     "localname": "LessPortionOfFairValueToBeDistributedAsCVR",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfEstimatedShareConsiderationOfCombinedCompanyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_LiabilitiesFairValueExercised": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liabilities, fair value, exercised.",
        "label": "Liabilities Fair Value Exercised",
        "terseLabel": "Exercise"
       }
      }
     },
     "localname": "LiabilitiesFairValueExercised",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_LiabilitiesFairValueSettled": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Liabilities, fair value, settled.",
        "label": "Liabilities Fair Value Settled",
        "verboseLabel": "Termination"
       }
      }
     },
     "localname": "LiabilitiesFairValueSettled",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_LicenceAgreementAdditionalAmountPayableOfOptionExerciseFees": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional amount payable of option exercise fees.",
        "label": "Licence Agreement Additional Amount Payable Of Option Exercise Fees",
        "terseLabel": "Licence agreement additional amount payable of option exercise fees"
       }
      }
     },
     "localname": "LicenceAgreementAdditionalAmountPayableOfOptionExerciseFees",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRegeneronLicenseAndCollaborationArrangementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_LicenceAgreementAdditionalRevenueRecognised": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Licence agreement additional revenue recognised.",
        "label": "Licence Agreement Additional Revenue Recognised",
        "terseLabel": "Licence agreement additional revenue recognised"
       }
      }
     },
     "localname": "LicenceAgreementAdditionalRevenueRecognised",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRegeneronLicenseAndCollaborationArrangementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_LicenceAgreementCumulativeRevenueRecognised": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cumulative revenue recognised.",
        "label": "Licence Agreement Cumulative Revenue Recognised",
        "terseLabel": "Licence agreement cumulative revenue recognised"
       }
      }
     },
     "localname": "LicenceAgreementCumulativeRevenueRecognised",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRegeneronLicenseAndCollaborationArrangementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_LicenceAgreementUpfrontPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upfront payment.",
        "label": "Licence Agreement Upfront Payment",
        "terseLabel": "Upfront payment"
       }
      }
     },
     "localname": "LicenceAgreementUpfrontPayment",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRegeneronLicenseAndCollaborationArrangementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_LicenseAgreementAdditionalPaymentForResearchFundingReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additional payment for research funding received.",
        "label": "License Agreement Additional Payment For Research Funding Received",
        "terseLabel": "Additional payment for research funding received"
       }
      }
     },
     "localname": "LicenseAgreementAdditionalPaymentForResearchFundingReceived",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRegeneronLicenseAndCollaborationArrangementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_LicenseAgreementCumulativeRevenueReductionRecognised": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement cumulative revenue reduction recognised.",
        "label": "License Agreement Cumulative Revenue Reduction Recognised",
        "terseLabel": "License agreement cumulative revenue reduction recognised"
       }
      }
     },
     "localname": "LicenseAgreementCumulativeRevenueReductionRecognised",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRegeneronLicenseAndCollaborationArrangementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfClinicalMilestonesPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement milestone payments upon satisfaction of clinical milestones payable.",
        "label": "License Agreement Milestone Payments Upon Satisfaction Of Clinical Milestones Payable",
        "terseLabel": "Aggregate amount payable upon satisfaction of clinical milestones"
       }
      }
     },
     "localname": "LicenseAgreementMilestonePaymentsUponSatisfactionOfClinicalMilestonesPayable",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureLicenseFundingAndOtherAgreementsRelatedToCVRAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfCommercialMilestonesPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement milestone payments upon satisfaction of commercial milestones payable.",
        "label": "License Agreement Milestone Payments Upon Satisfaction Of Commercial Milestones Payable",
        "terseLabel": "Aggregate amount payable upon satisfaction of commercial milestones"
       }
      }
     },
     "localname": "LicenseAgreementMilestonePaymentsUponSatisfactionOfCommercialMilestonesPayable",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureLicenseFundingAndOtherAgreementsRelatedToCVRAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfRegulatoryMilestonesPayableForFirstIndicationApproved": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement milestone payments upon satisfaction of regulatory milestones payable for first indication approved.",
        "label": "License Agreement Milestone Payments Upon Satisfaction Of Regulatory Milestones Payable For First Indication Approved",
        "terseLabel": "Aggregate amount payable upon satisfaction of regulatory milestones for first indication approved"
       }
      }
     },
     "localname": "LicenseAgreementMilestonePaymentsUponSatisfactionOfRegulatoryMilestonesPayableForFirstIndicationApproved",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureLicenseFundingAndOtherAgreementsRelatedToCVRAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_LicenseAgreementMilestonePaymentsUponSatisfactionOfRegulatoryMilestonesPayableForSecondIndicationApproved": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement milestone payments upon satisfaction of regulatory milestones payable for second indication approved.",
        "label": "License Agreement Milestone Payments Upon Satisfaction Of Regulatory Milestones Payable For Second Indication Approved",
        "terseLabel": "Aggregate amount payable upon satisfaction of regulatory milestones for second indication approved"
       }
      }
     },
     "localname": "LicenseAgreementMilestonePaymentsUponSatisfactionOfRegulatoryMilestonesPayableForSecondIndicationApproved",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureLicenseFundingAndOtherAgreementsRelatedToCVRAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_LicenseAgreementTerminationDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License agreement termination description.",
        "label": "License Agreement Termination Description",
        "terseLabel": "License agreement termination description"
       }
      }
     },
     "localname": "LicenseAgreementTerminationDescription",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureLicenseFundingAndOtherAgreementsRelatedToCVRAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRegeneronLicenseAndCollaborationArrangementAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "acet_LicenseAndCollaborationRevenue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License and collaboration revenue",
        "label": "License and collaboration revenue",
        "terseLabel": "License and collaboration revenue"
       }
      }
     },
     "localname": "LicenseAndCollaborationRevenue",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRegeneronLicenseAndCollaborationArrangementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_LicenseFundingAndOtherAgreementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License funding and other agreements.",
        "label": "License Funding And Other Agreements [Abstract]"
       }
      }
     },
     "localname": "LicenseFundingAndOtherAgreementsAbstract",
     "nsuri": "http://www.adicetbio.com/20211231",
     "xbrltype": "stringItemType"
    },
    "acet_LicenseFundingAndOtherAgreementsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "License funding and other agreements.",
        "label": "License Funding And Other Agreements [Text Block]",
        "terseLabel": "License, Funding and Other Agreements Related to the CVR"
       }
      }
     },
     "localname": "LicenseFundingAndOtherAgreementsTextBlock",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureLicenseFundingAndOtherAgreementsRelatedToCVR"
     ],
     "xbrltype": "textBlockItemType"
    },
    "acet_LoanAmountDrawn": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Loan amount drawn",
        "label": "Loan Amount Drawn",
        "terseLabel": "Loan amount drawn"
       }
      }
     },
     "localname": "LoanAmountDrawn",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_LumpSumCompensationPayment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lump sum compensation payment.",
        "label": "Lump Sum Compensation Payment",
        "terseLabel": "Lump sum payable"
       }
      }
     },
     "localname": "LumpSumCompensationPayment",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_MarketableDebtSecuritiesClassificationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of classification of company marketable debt securities in condensed consolidated balance sheets.",
        "label": "Marketable Debt Securities Classification Table [Text Block]",
        "terseLabel": "Summary of Classification of Marketable Debt Securities in Consolidated Balance Sheets"
       }
      }
     },
     "localname": "MarketableDebtSecuritiesClassificationTableTextBlock",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureMarketableDebtSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "acet_MarketableSecuritiesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Marketable securities.",
        "label": "Marketable Securities [Member]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesMember",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "acet_MaximumAggregateValueOfCommonStockAvailableForOfferingAtMarketPriceUnderSalesAgreement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum aggregate value of common stock available for offering at-the-market price under sales agreement.",
        "label": "Maximum Aggregate Value Of Common Stock Available For Offering At Market Price Under Sales Agreement",
        "terseLabel": "Maximum aggregate value of common stock available for offering at-the-market price"
       }
      }
     },
     "localname": "MaximumAggregateValueOfCommonStockAvailableForOfferingAtMarketPriceUnderSalesAgreement",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureAtTheMarketATMOfferingAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_MenloParkLeaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Menlo Park lease agreement.",
        "label": "Menlo Park Lease Agreement [Member]",
        "terseLabel": "Menlo Park Lease Agreement [Member]",
        "verboseLabel": "Menlo Park, CA"
       }
      }
     },
     "localname": "MenloParkLeaseAgreementMember",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfWeightedAverageIBRAndRemainingLeaseTermDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "acet_MergerMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Merger.",
        "label": "Merger [Member]",
        "terseLabel": "Merger"
       }
      }
     },
     "localname": "MergerMember",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "acet_MilestoneClosingLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Milestone closing liability.",
        "label": "Milestone Closing Liability",
        "terseLabel": "Milestone closing liability"
       }
      }
     },
     "localname": "MilestoneClosingLiability",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_NationalInstitutesOfHealthMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "National Institutes of Health.",
        "label": "National Institutes Of Health [Member]",
        "terseLabel": "National Institute of Health"
       }
      }
     },
     "localname": "NationalInstitutesOfHealthMember",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureLicenseFundingAndOtherAgreementsRelatedToCVRAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "acet_NonRefundableUpfrontPaymentReceived": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Non refundable upfront payment received.",
        "label": "Non Refundable Upfront Payment Received",
        "terseLabel": "Non refundable upfront payment received"
       }
      }
     },
     "localname": "NonRefundableUpfrontPaymentReceived",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRegeneronLicenseAndCollaborationArrangementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_NovartisInternationalPharmaceuticalLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Novartis International Pharmaceutical Ltd. (\u201cNovartis\u201d).",
        "label": "Novartis International Pharmaceutical Limited [Member]",
        "terseLabel": "Novartis International Pharmaceutical Ltd."
       }
      }
     },
     "localname": "NovartisInternationalPharmaceuticalLimitedMember",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureLicenseFundingAndOtherAgreementsRelatedToCVRAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "acet_NovartisLicenseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Novartis license agreement.",
        "label": "Novartis License Agreement [Member]",
        "terseLabel": "Novartis License Agreement"
       }
      }
     },
     "localname": "NovartisLicenseAgreementMember",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureLicenseFundingAndOtherAgreementsRelatedToCVRAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "acet_NumberOfCustomer": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of customer.",
        "label": "Number Of Customer",
        "terseLabel": "Number of customer"
       }
      }
     },
     "localname": "NumberOfCustomer",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "acet_NumberOfSecuritiesConvertedToWarrantsToPurchaseCommonStock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number Of Securities Converted To Warrants To Purchase Common Stock.",
        "label": "Number Of Securities Converted To Warrants To Purchase Common Stock",
        "negatedLabel": "Number of warrants, Impact of converting to warrants for the purchase of common stock and adjusted for the Exchange Ratio and Reverse Stock Split"
       }
      }
     },
     "localname": "NumberOfSecuritiesConvertedToWarrantsToPurchaseCommonStock",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfOutstandingWarrantsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "acet_NumberOfSharesAvailableForSaleUnderEmployeeStockPurchasePlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares available for sale under employee stock purchase plan.",
        "label": "Number Of Shares Available For Sale Under Employee Stock Purchase Plan",
        "terseLabel": "Number of shares available for sale under employee stock purchase plan"
       }
      }
     },
     "localname": "NumberOfSharesAvailableForSaleUnderEmployeeStockPurchasePlan",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "acet_NumberOfSharesOfSurvivingStockOptions": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of surviving stock options.",
        "label": "Number Of Shares Of Surviving Stock Options",
        "terseLabel": "Number of shares of surviving stock options"
       }
      }
     },
     "localname": "NumberOfSharesOfSurvivingStockOptions",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesPurchasePriceInMergerParentheticalDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "acet_OperatingLeasesCommencementDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating leases commencement date.",
        "label": "Operating Leases Commencement Date",
        "terseLabel": "Operating leases commencement date"
       }
      }
     },
     "localname": "OperatingLeasesCommencementDate",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "acet_OperatingLeasesFutureMinimumSubleaseIncomeDue": {
     "auth_ref": [],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSubleaseIncomeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Leases Future Minimum Sublease Income Due",
        "label": "Operating Leases Future Minimum Sublease Income Due",
        "terseLabel": "Total",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumSubleaseIncomeDue",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSubleaseIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_OperatingLeasesFutureMinimumSubleaseIncomeDueCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSubleaseIncomeDetails": {
       "order": 0.0,
       "parentTag": "acet_OperatingLeasesFutureMinimumSubleaseIncomeDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Leases Future Minimum Sublease Income Due Current",
        "label": "Operating Leases Future Minimum Sublease Income Due Current",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumSubleaseIncomeDueCurrent",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSubleaseIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInFiveYears": {
     "auth_ref": [],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSubleaseIncomeDetails": {
       "order": 4.0,
       "parentTag": "acet_OperatingLeasesFutureMinimumSubleaseIncomeDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Leases Future Minimum Sublease Income Due In Five Years",
        "label": "Operating Leases Future Minimum Sublease Income Due In Five Years",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumSubleaseIncomeDueInFiveYears",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSubleaseIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInFourYears": {
     "auth_ref": [],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSubleaseIncomeDetails": {
       "order": 3.0,
       "parentTag": "acet_OperatingLeasesFutureMinimumSubleaseIncomeDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Leases Future Minimum Sublease Income Due In Four Years",
        "label": "Operating Leases Future Minimum Sublease Income Due In Four Years",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumSubleaseIncomeDueInFourYears",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSubleaseIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInThreeYears": {
     "auth_ref": [],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSubleaseIncomeDetails": {
       "order": 2.0,
       "parentTag": "acet_OperatingLeasesFutureMinimumSubleaseIncomeDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Leases Future Minimum Sublease Income Due In Three Years",
        "label": "Operating Leases Future Minimum Sublease Income Due In Three Years",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumSubleaseIncomeDueInThreeYears",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSubleaseIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_OperatingLeasesFutureMinimumSubleaseIncomeDueInTwoYears": {
     "auth_ref": [],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSubleaseIncomeDetails": {
       "order": 1.0,
       "parentTag": "acet_OperatingLeasesFutureMinimumSubleaseIncomeDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating Leases Future Minimum Sublease Income Due In Two Years",
        "label": "Operating Leases Future Minimum Sublease Income Due In Two Years",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumSubleaseIncomeDueInTwoYears",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureCommitmentsAndContingenciesScheduleOfSubleaseIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_OperatingLossCarrybackDurationUnderCARESAct": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryback duration under CARES act.",
        "label": "Operating Loss Carryback Duration Under C A R E S Act",
        "terseLabel": "Operating loss carryback duration under CARES Act"
       }
      }
     },
     "localname": "OperatingLossCarrybackDurationUnderCARESAct",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "acet_OperatingLossCarryforwardsIndefinitely": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Operating loss carryforwards indefinitely.",
        "label": "Operating Loss Carryforwards Indefinitely",
        "terseLabel": "Operating Loss Carryforwards Indefinitely"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsIndefinitely",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_OptionToPurchaseOfCommonStockAtPublicOfferingPrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Option to purchase of common stock at public offering price.",
        "label": "Option To Purchase Of Common Stock At Public Offering Price",
        "terseLabel": "Option to purchase of common stock at public offering price"
       }
      }
     },
     "localname": "OptionToPurchaseOfCommonStockAtPublicOfferingPrice",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "acet_OptionsAvailableForFutureGrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Options available for future grants.",
        "label": "Options Available For Future Grants [Member]",
        "terseLabel": "Stock Options Available for Future Grant"
       }
      }
     },
     "localname": "OptionsAvailableForFutureGrantsMember",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "acet_OrganizationAndNatureOfBusinessAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization and Nature of Business.",
        "label": "Organization And Nature Of Business [Abstract]"
       }
      }
     },
     "localname": "OrganizationAndNatureOfBusinessAbstract",
     "nsuri": "http://www.adicetbio.com/20211231",
     "xbrltype": "stringItemType"
    },
    "acet_OrganizationAndNatureOfBusinessTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Organization and nature of business.",
        "label": "Organization And Nature Of Business [Text Block]",
        "terseLabel": "Organization and Nature of Business"
       }
      }
     },
     "localname": "OrganizationAndNatureOfBusinessTextBlock",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusiness"
     ],
     "xbrltype": "textBlockItemType"
    },
    "acet_OwnershipChangePlanDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ownership change plan description.",
        "label": "Ownership Change Plan Description",
        "terseLabel": "Ownership change plan description"
       }
      }
     },
     "localname": "OwnershipChangePlanDescription",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "acet_PacificWesternBankMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Pacific western bank [Member]",
        "label": "Pacific western bank [Member]",
        "terseLabel": "Pacific western bank"
       }
      }
     },
     "localname": "PacificWesternBankMember",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "acet_PercentageOfNetOperatingLossCarryforwards": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "percentage of net operating loss carryforwards.",
        "label": "Percentage Of Net Operating Loss Carryforwards",
        "terseLabel": "Percentage of net operating loss carryforwards"
       }
      }
     },
     "localname": "PercentageOfNetOperatingLossCarryforwards",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "acet_PostExposureProphylaxisDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Post Exposure Prophylaxis in adults",
        "label": "Post Exposure Prophylaxis Description",
        "terseLabel": "Post Exposure Prophylaxis in adults"
       }
      }
     },
     "localname": "PostExposureProphylaxisDescription",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureLicenseFundingAndOtherAgreementsRelatedToCVRAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "acet_PrepaidExpensesAndOtherCurrentAssetsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the summary of Prepaid expenses and other current assets.",
        "label": "Prepaid Expenses And Other Current Assets Table [Text Block]",
        "terseLabel": "Summary of Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "acet_PrepaidExpensesAndOtherCurrentAssetsTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepaid expenses and other current assets.",
        "label": "Prepaid Expenses And Other Current Assets [Text Block]",
        "terseLabel": "Prepaid Expenses and Other Current Assets"
       }
      }
     },
     "localname": "PrepaidExpensesAndOtherCurrentAssetsTextBlock",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssets"
     ],
     "xbrltype": "textBlockItemType"
    },
    "acet_PrepaymentsToCmos": {
     "auth_ref": [],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepayments to CMO's",
        "label": "Prepayments to CMO's",
        "terseLabel": "Prepayments to CMO's"
       }
      }
     },
     "localname": "PrepaymentsToCmos",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_PrepaymentsToCros": {
     "auth_ref": [],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Prepayments to CRO's",
        "label": "Prepayments to CRO's",
        "terseLabel": "Prepayments to CRO's"
       }
      }
     },
     "localname": "PrepaymentsToCros",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_ProceedsFromSalesOfMarketableDebtSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from sales of marketable debt securities.",
        "label": "Proceeds From Sales Of Marketable Debt Securities",
        "terseLabel": "Proceeds from sales of marketable debt securities"
       }
      }
     },
     "localname": "ProceedsFromSalesOfMarketableDebtSecurities",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_QualifyingExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Qualifying expenses.",
        "label": "Qualifying Expenses",
        "terseLabel": "Qualifying expenses"
       }
      }
     },
     "localname": "QualifyingExpenses",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureLicenseFundingAndOtherAgreementsRelatedToCVRAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_QualifyingExpensesOnCumulativeBasis": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "qualifying expenses on cumulative basis.",
        "label": "Qualifying Expenses On Cumulative Basis",
        "terseLabel": "Qualifying expenses on cumulative basis"
       }
      }
     },
     "localname": "QualifyingExpensesOnCumulativeBasis",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureLicenseFundingAndOtherAgreementsRelatedToCVRAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_RecognitionOfContingentConsiderationLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recognition of contingent consideration liability.",
        "label": "Recognition Of Contingent Consideration Liability",
        "terseLabel": "Recognition of contingent consideration liability"
       }
      }
     },
     "localname": "RecognitionOfContingentConsiderationLiability",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_RecognitionOfPreferredStockWarrantLiabilities": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Recognition of preferred stock warrant liabilities.",
        "label": "Recognition Of Preferred Stock Warrant Liabilities",
        "terseLabel": "Recognition of preferred stock warrant liabilities"
       }
      }
     },
     "localname": "RecognitionOfPreferredStockWarrantLiabilities",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_RedeemableConvertiblePreferredStockPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for redeemable convertible preferred stock.",
        "label": "Redeemable Convertible Preferred Stock Policy [Text Block]",
        "terseLabel": "Redeemable Convertible Preferred Stock"
       }
      }
     },
     "localname": "RedeemableConvertiblePreferredStockPolicyTextBlock",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "acet_RedeemableConvertiblePreferredStockTrancheLiabilityAndTRDFObligationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redeemable convertible preferred stock tranche liability and TRDF obligation.",
        "label": "Redeemable Convertible Preferred Stock Tranche Liability And T R D F Obligation [Member]",
        "terseLabel": "Redeemable Convertible Preferred Stock Tranche Liability And TRDF Obligation"
       }
      }
     },
     "localname": "RedeemableConvertiblePreferredStockTrancheLiabilityAndTRDFObligationMember",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "acet_RedeemableConvertiblePreferredStockTrancheLiabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redeemable convertible preferred stock tranche liability.",
        "label": "Redeemable Convertible Preferred Stock Tranche Liability [Member]",
        "terseLabel": "Redeemable Convertible Preferred Stock Tranche Liability"
       }
      }
     },
     "localname": "RedeemableConvertiblePreferredStockTrancheLiabilityMember",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "acet_RedeemableConvertiblePreferredStockTrancheLiabilityPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redeemable convertible preferred stock tranche liability.",
        "label": "Redeemable Convertible Preferred Stock Tranche Liability Policy [Text Block]",
        "terseLabel": "Redeemable Convertible Preferred Stock Tranche Liability"
       }
      }
     },
     "localname": "RedeemableConvertiblePreferredStockTrancheLiabilityPolicyTextBlock",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "acet_RedeemableConvertiblePreferredStockWarrantLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redeemable convertible preferred stock warrant liability.",
        "label": "Redeemable Convertible Preferred Stock Warrant Liability",
        "terseLabel": "Redeemable convertible preferred stock warrant liability"
       }
      }
     },
     "localname": "RedeemableConvertiblePreferredStockWarrantLiability",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_RedeemableConvertiblePreferredStockWarrantLiabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redeemable convertible preferred stock warrant liability.",
        "label": "Redeemable Convertible Preferred Stock Warrant Liability [Member]",
        "terseLabel": "Redeemable Convertible Preferred Stock Warrant Liability"
       }
      }
     },
     "localname": "RedeemableConvertiblePreferredStockWarrantLiabilityMember",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "acet_RedeemableConvertiblePreferredStockWarrantLiabilityPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redeemable convertible preferred stock warrants.",
        "label": "Redeemable Convertible Preferred Stock Warrant Liability Policy [Text Block]",
        "terseLabel": "Redeemable Convertible Preferred Stock Warrants"
       }
      }
     },
     "localname": "RedeemableConvertiblePreferredStockWarrantLiabilityPolicyTextBlock",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "acet_RedeemableConvertiblePreferredStockWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redeemable convertible preferred stock warrants member",
        "label": "Redeemable Convertible Preferred Stock Warrants [Member]",
        "terseLabel": "Redeemable Convertible Preferred Stock Warrant Liability",
        "verboseLabel": "Redeemable Convertible Preferred Stock Warrants"
       }
      }
     },
     "localname": "RedeemableConvertiblePreferredStockWarrantsMember",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "acet_RedwoodCityLeaseAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Redwood City lease agreement.",
        "label": "Redwood City Lease Agreement [Member]",
        "terseLabel": "Redwood City Lease Agreement [Member]",
        "verboseLabel": "Redwood City, CA"
       }
      }
     },
     "localname": "RedwoodCityLeaseAgreementMember",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfWeightedAverageIBRAndRemainingLeaseTermDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "acet_RegeneronPharmaceuticalsIncorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Regeneron Pharmaceuticals Incorporation.",
        "label": "Regeneron Pharmaceuticals Incorporation [Member]",
        "terseLabel": "Regeneron Pharmaceuticals, Inc."
       }
      }
     },
     "localname": "RegeneronPharmaceuticalsIncorporationMember",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRegeneronLicenseAndCollaborationArrangementAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "acet_ResTORbioMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "resTORbio.",
        "label": "Res T O Rbio [Member]",
        "terseLabel": "resTORbio"
       }
      }
     },
     "localname": "ResTORbioMember",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfEstimatedShareConsiderationOfCombinedCompanyDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfEstimatedShareConsiderationOfCombinedCompanyParentheticalDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsAcquiredDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesPurchasePriceInMergerDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesPurchasePriceInMergerParentheticalDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "acet_ResearchFundingAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research funding agreement.",
        "label": "Research Funding Agreement [Member]",
        "terseLabel": "Research Funding Agreement"
       }
      }
     },
     "localname": "ResearchFundingAgreementMember",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureLicenseFundingAndOtherAgreementsRelatedToCVRAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "acet_ResearchFundingFee": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research funding fee",
        "label": "Research funding fee"
       }
      }
     },
     "localname": "ResearchFundingFee",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRegeneronLicenseAndCollaborationArrangementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_RfsOpcoLlcMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "RFS OPCO LLC [Member]",
        "label": "RFS OPCO LLC [Member]",
        "terseLabel": "RFS OPCO LLC [Member]"
       }
      }
     },
     "localname": "RfsOpcoLlcMember",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "acet_RightOfUseAssetsRecognized": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Right-of-use assets recognized in noncash investing or financing activities.",
        "label": "Right Of Use Assets Recognized",
        "terseLabel": "Right-of-use assets recognized upon adoption of Topic 842"
       }
      }
     },
     "localname": "RightOfUseAssetsRecognized",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_RisksAndUncertaintiesPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Risks and uncertainties policy text block.",
        "label": "Risks And Uncertainties Policy [Text Block]",
        "terseLabel": "Risks and Uncertainties"
       }
      }
     },
     "localname": "RisksAndUncertaintiesPolicyTextBlock",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "acet_SalesAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sales agreement member.",
        "label": "Sales Agreement [Member]",
        "terseLabel": "Sales Agreement [Member]"
       }
      }
     },
     "localname": "SalesAgreementMember",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureAtTheMarketATMOfferingAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "acet_ScheduleOfChangesInFairValueOfUnobservableFinancialInstrumentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of changes in the fair value of the unobservable financial instruments.",
        "label": "Schedule Of Changes In Fair Value Of Unobservable Financial Instruments Table [Text Block]",
        "terseLabel": "Schedule of Changes in Fair Value of Level 3 Financial Instruments"
       }
      }
     },
     "localname": "ScheduleOfChangesInFairValueOfUnobservableFinancialInstrumentsTableTextBlock",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "acet_ScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of number of shares of common stock reserved for future issuance.",
        "label": "Schedule Of Number Of Shares Of Common Stock Reserved For Future Issuance [Text Block]",
        "terseLabel": "Schedule of Number of Shares of Common Stock Reserved for Future Issuance"
       }
      }
     },
     "localname": "ScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceTextBlock",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "acet_ScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of outstanding warrants to purchase shares of common stock .",
        "label": "Schedule Of Outstanding Warrants To Purchase Shares Of Common Stock Table [Text Block]",
        "terseLabel": "Schedule of Outstanding Warrants to Purchase Shares of Common Stock"
       }
      }
     },
     "localname": "ScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockTableTextBlock",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "acet_ScheduleOfSubleaseIncomeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule Of Sublease Income.",
        "label": "Schedule Of Sublease Income Table Text Block",
        "terseLabel": "Schedule Of Sublease Income"
       }
      }
     },
     "localname": "ScheduleOfSubleaseIncomeTableTextBlock",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "acet_ScheduleOfWeightedAverageIBRAndRemainingLeaseTermTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of weighted average ibr and remaining lease term table text block.",
        "label": "Schedule Of Weighted Average I B R And Remaining Lease Term Table [Text Block]",
        "terseLabel": "Schedule of Weighted Average IBR and Remaining Lease Term"
       }
      }
     },
     "localname": "ScheduleOfWeightedAverageIBRAndRemainingLeaseTermTableTextBlock",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "acet_SeptemberFifteenTwoThousandTwentyWarrantFourMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "September Fifteen Two Thousand Twenty Warrant Four.",
        "label": "September Fifteen Two Thousand Twenty Warrant Four [Member]",
        "terseLabel": "September 15, 2020 Warrant Four"
       }
      }
     },
     "localname": "SeptemberFifteenTwoThousandTwentyWarrantFourMember",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "acet_SeptemberFifteenTwoThousandTwentyWarrantOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "September Fifteen Two Thousand Twenty Warrant One.",
        "label": "September Fifteen Two Thousand Twenty Warrant One [Member]",
        "terseLabel": "September 15, 2020 Warrant One"
       }
      }
     },
     "localname": "SeptemberFifteenTwoThousandTwentyWarrantOneMember",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "acet_SeptemberFifteenTwoThousandTwentyWarrantThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "September Fifteen Two Thousand Twenty Warrant Three.",
        "label": "September Fifteen Two Thousand Twenty Warrant Three [Member]",
        "terseLabel": "September 15, 2020 Warrant Three"
       }
      }
     },
     "localname": "SeptemberFifteenTwoThousandTwentyWarrantThreeMember",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "acet_SeptemberFifteenTwoThousandTwentyWarrantTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "September Fifteen Two Thousand Twenty Warrant Two.",
        "label": "September Fifteen Two Thousand Twenty Warrant Two [Member]",
        "terseLabel": "September 15, 2020 Warrant Two"
       }
      }
     },
     "localname": "SeptemberFifteenTwoThousandTwentyWarrantTwoMember",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "acet_SeriesBRedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Series B redeemable convertible preferred stock.",
        "label": "Series B Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Series B Redeemable Convertible Preferred Stock",
        "verboseLabel": "Series B Redeemable Convertible Preferred Stock"
       }
      }
     },
     "localname": "SeriesBRedeemableConvertiblePreferredStockMember",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "acet_SettlementOfTRDFLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Settlement of trdf liability.",
        "label": "Settlement Of T R D F Liability",
        "terseLabel": "Settlement of TRDF liability"
       }
      }
     },
     "localname": "SettlementOfTRDFLiability",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAsPartOfMerger": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award number of shares available for grant as part of merger.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant As Part Of Merger",
        "terseLabel": "Number of Shares Available for Grant, Assumed as part of the Merger"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantAsPartOfMerger",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award number of shares available for grant shares authorized.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Shares Authorized",
        "terseLabel": "Number of Shares Available for Grant, Options authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesAuthorized",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesCancelled": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award number of shares available for grant shares cancelled.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Shares Cancelled",
        "terseLabel": "Number of Shares Available for Grant, Options forfeited or cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesCancelled",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesExercised": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award number of shares available for grant shares exercised.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Shares Exercised",
        "negatedLabel": "Options exercised, Number of Shares Available for Grant",
        "terseLabel": "Number of Shares Available for Grant, Options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesExercised",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesGranted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award number of shares available for grant, shares granted.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant Shares Granted",
        "negatedLabel": "Number of Shares Available for Grant, Options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrantSharesGranted",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedAsPartOfMerger": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options assumed as part of merger.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Assumed As Part Of Merger",
        "terseLabel": "Number of Shares Underlying Outstanding Options, Assumed as part of the Merger"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAssumedAsPartOfMerger",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "acet_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangement by share based payment award options authorized.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Options Authorized",
        "terseLabel": "Number of Shares Underlying Outstanding Options, Options authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAuthorized",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "acet_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumedAsPartOfMergerInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangements by share based payment award options assumed as part of merger in period weighted average exercise price.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Assumed As Part Of Merger In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price, Assumed as part the Merger"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAssumedAsPartOfMergerInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "acet_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAuthorizedInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share based compensation arrangements by share based payment award options authorized in period weighted average exercise price.",
        "label": "Share Based Compensation Arrangements By Share Based Payment Award Options Authorized In Period Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price, Options, authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsAuthorizedInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "acet_StockExchangedDuringPeriodSharesInConnectionWithMerger": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock exchanged during period shares in connection with merger.",
        "label": "Stock Exchanged During Period Shares In Connection With Merger",
        "terseLabel": "Exchange of common stock in connection with the Merger, shares"
       }
      }
     },
     "localname": "StockExchangedDuringPeriodSharesInConnectionWithMerger",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "acet_StockExchangedDuringPeriodValueInConnectionWithMerger": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock exchanged during period value in connection with merger.",
        "label": "Stock Exchanged During Period Value In Connection With Merger",
        "terseLabel": "Exchange of common stock in connection with the Merger"
       }
      }
     },
     "localname": "StockExchangedDuringPeriodValueInConnectionWithMerger",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_StockIssuedDuringPeriodSharesConversionOfSecurities": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Conversion of sharesaof redeemable convertible preferred stock to shares of common stock in connection with the Merger, shares",
        "label": "Stock Issued During Period Shares Conversion Of Securities",
        "terseLabel": "Conversion of shares of redeemable convertible preferred stock to shares of common stock in connection with the Merger, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfSecurities",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "acet_StockIssuedDuringPeriodSharesUponAcceleratedVestingOfRSUWithMerger": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period shares upon accelerated vesting of rsu with merger.",
        "label": "Stock Issued During Period Shares Upon Accelerated Vesting Of R S U With Merger",
        "terseLabel": "Issuance of common stock upon accelerated vesting of restricted stock units in connection with the Merger (Shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesUponAcceleratedVestingOfRSUWithMerger",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "acet_StockIssuedDuringPeriodValueUponAcceleratedVestingOfRSUWithMerger": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock issued during period value upon accelerated vesting of rsu with merger.",
        "label": "Stock Issued During Period Value Upon Accelerated Vesting Of R S U With Merger",
        "terseLabel": "Issuance of common stock upon accelerated vesting ofrestricted stock units in connection with the Merger"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueUponAcceleratedVestingOfRSUWithMerger",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_SubleaseAgreementDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sublease Agreement Description.",
        "label": "Sublease Agreement Description",
        "terseLabel": "Sublease Agreement Description"
       }
      }
     },
     "localname": "SubleaseAgreementDescription",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "acet_SummaryOfSignificantAccountingPoliciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policies.",
        "label": "Summary Of Significant Accounting Policies [Line Items]",
        "terseLabel": "Summary Of Significant Accounting Policies [Line Items]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "acet_SummaryOfSignificantAccountingPoliciesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summary of significant accounting policies.",
        "label": "Summary Of Significant Accounting Policies [Table]",
        "terseLabel": "Summary Of Significant Accounting Policies [Table]"
       }
      }
     },
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "acet_TRDFLiabilityMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "TRDF Liability.",
        "label": "T R D F Liability [Member]",
        "terseLabel": "TRDF Liability"
       }
      }
     },
     "localname": "TRDFLiabilityMember",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "acet_TemporaryEquityStockConversionInConnectionWithMerger": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary equity stock conversion in connection with merger.",
        "label": "Temporary Equity Stock Conversion In Connection With Merger",
        "terseLabel": "Conversion of shares of redeemable convertible preferred stock to shares of common stock in connection with the Merger"
       }
      }
     },
     "localname": "TemporaryEquityStockConversionInConnectionWithMerger",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_TemporaryEquityStockConversionSharesInConnectionWithMerger": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Temporary Equity Stock Conversion Shares In Connection With Merger.",
        "label": "Temporary Equity Stock Conversion Shares In Connection With Merger",
        "negatedLabel": "Conversion of shares of redeemable convertible preferred stock to shares of common stock in connection with the Merger, shares"
       }
      }
     },
     "localname": "TemporaryEquityStockConversionSharesInConnectionWithMerger",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "acet_TermLoanAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term loan abstract [Abstract]",
        "label": "Term Loan [Abstract]"
       }
      }
     },
     "localname": "TermLoanAbstract",
     "nsuri": "http://www.adicetbio.com/20211231",
     "xbrltype": "stringItemType"
    },
    "acet_TermLoanAndNonFormulaAncillaryService": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term loan and non formula ancillary service",
        "label": "Term loan and non formula ancillary service",
        "terseLabel": "Term loan and non formula ancillary service"
       }
      }
     },
     "localname": "TermLoanAndNonFormulaAncillaryService",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_TermLoanToFinanceLeaseholdImprovements1": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "term loan to finance leasehold improvements 1",
        "label": "term loan to finance leasehold improvements 1",
        "terseLabel": "Term loan to finance leasehold improvements"
       }
      }
     },
     "localname": "TermLoanToFinanceLeaseholdImprovements1",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_TerminationAgreementMonthAndYear": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Termination Agreement, month and year.",
        "label": "Termination Agreement Month And Year",
        "terseLabel": "Agreement terminated"
       }
      }
     },
     "localname": "TerminationAgreementMonthAndYear",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureAtTheMarketATMOfferingAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "gYearMonthItemType"
    },
    "acet_TerminationOfRedeemableConvertiblePreferredStockTrancheLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Termination of redeemable convertible preferred stock tranche liability.",
        "label": "Termination Of Redeemable Convertible Preferred Stock Tranche Liability",
        "terseLabel": "Termination of redeemable convertible preferred stock tranche liability"
       }
      }
     },
     "localname": "TerminationOfRedeemableConvertiblePreferredStockTrancheLiability",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_TransitionAgreementMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transition agreement.",
        "label": "Transition Agreement [Member]",
        "terseLabel": "Transition Agreement [Member]"
       }
      }
     },
     "localname": "TransitionAgreementMember",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "acet_TwoThousandEighteenEmployeeStockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand eighteen employee stock purchase plan.",
        "label": "Two Thousand Eighteen Employee Stock Purchase Plan [Member]",
        "terseLabel": "2018 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "TwoThousandEighteenEmployeeStockPurchasePlanMember",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "acet_TwoThousandEighteenStockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand eighteen stock incentive plan.",
        "label": "Two Thousand Eighteen Stock Incentive Plan [Member]",
        "terseLabel": "2018 Stock Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandEighteenStockIncentivePlanMember",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "acet_TwoThousandFifteenStockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Fifteen Stock Incentive Plan Member.",
        "label": "Two Thousand Fifteen Stock Incentive Plan [Member]",
        "terseLabel": "2015 Stock Incentive Plan Member"
       }
      }
     },
     "localname": "TwoThousandFifteenStockIncentivePlanMember",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "acet_TwoThousandFourteenAndTwoThousandFifteenStockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand fourteen and two thousand fifteen stock incentive plan.",
        "label": "Two Thousand Fourteen And Two Thousand Fifteen Stock Incentive Plan [Member]",
        "terseLabel": "2014 and 2015 Stock Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandFourteenAndTwoThousandFifteenStockIncentivePlanMember",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "acet_TwoThousandFourteenStockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two Thousand Fourteen Stock Incentive Plan Member.",
        "label": "Two Thousand Fourteen Stock Incentive Plan [Member]",
        "terseLabel": "2014 Stock Incentive Plan Member"
       }
      }
     },
     "localname": "TwoThousandFourteenStockIncentivePlanMember",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "acet_TwoThousandSeventeenAndTwoThousandEighteenStockIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two thousand seventeen and two thousand eighteen stock incentive plan.",
        "label": "Two Thousand Seventeen And Two Thousand Eighteen Stock Incentive Plan [Member]",
        "terseLabel": "2017 and 2018 Stock Incentive Plan"
       }
      }
     },
     "localname": "TwoThousandSeventeenAndTwoThousandEighteenStockIncentivePlanMember",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "acet_UnderwritingDiscountsAndCommissionsAndOtherOfferingExpenses": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Underwriting discounts and commissions and other offering expenses.",
        "label": "Underwriting Discounts And Commissions And Other Offering Expenses",
        "terseLabel": "Underwriting discounts and commissions and other offering expenses"
       }
      }
     },
     "localname": "UnderwritingDiscountsAndCommissionsAndOtherOfferingExpenses",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_UnvestedCommonStockFromEarlyExerciseOfOptionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unvested common stock from early exercise of options.",
        "label": "Unvested Common Stock From Early Exercise Of Options [Member]",
        "terseLabel": "Unvested Early Exercised Common Stock Options"
       }
      }
     },
     "localname": "UnvestedCommonStockFromEarlyExerciseOfOptionsMember",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "acet_UnvestedRestrictedStockUnitsOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unvested restricted stock units outstanding.",
        "label": "Unvested Restricted Stock Units Outstanding",
        "terseLabel": "Unvested restricted stock units outstanding"
       }
      }
     },
     "localname": "UnvestedRestrictedStockUnitsOutstanding",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesPurchasePriceInMergerParentheticalDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "acet_VestingOfEarlyExercisedStockOptions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting of early exercised stock options.",
        "label": "Vesting Of Early Exercised Stock Options",
        "terseLabel": "Vesting of early exercised stock options"
       }
      }
     },
     "localname": "VestingOfEarlyExercisedStockOptions",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "acet_WarrantsOutstandingAndExercisableWeightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Warrants Outstanding And Exercisable Weighted Average Remaining Contractual Term",
        "terseLabel": "Warrants outstanding and exercisable, Weighted average remaining contractual term"
       }
      }
     },
     "localname": "WarrantsOutstandingAndExercisableWeightedAverageRemainingContractualTerm",
     "nsuri": "http://www.adicetbio.com/20211231",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfOutstandingWarrantsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r698",
      "r699",
      "r700"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID",
        "terseLabel": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r698",
      "r699",
      "r700"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location",
        "terseLabel": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r698",
      "r699",
      "r700"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name",
        "terseLabel": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r698",
      "r699",
      "r700"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r701"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r696"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two",
        "terseLabel": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r715"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period",
        "terseLabel": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationDateOfIncorporation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date when an entity was incorporated",
        "label": "Entity Incorporation, Date of Incorporation",
        "terseLabel": "Entity incorporation date"
       }
      }
     },
     "localname": "EntityIncorporationDateOfIncorporation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r711"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r695"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r714"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r698",
      "r699",
      "r700"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag",
        "terseLabel": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r694"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r697"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r56",
      "r58",
      "r118",
      "r119",
      "r274",
      "r299",
      "r713"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.",
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_FinancingReceivableNonaccrualToOutstandingPercent": {
     "auth_ref": [
      "r710"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of nonaccrual to total financing receivable outstanding.",
        "label": "Financing Receivable, Nonaccrual to Outstanding, Percent",
        "terseLabel": "Outstanding accounts receivable percentage"
       }
      }
     },
     "localname": "FinancingReceivableNonaccrualToOutstandingPercent",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r273",
      "r298",
      "r344",
      "r347",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r603",
      "r666",
      "r667",
      "r691",
      "r692"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Upper limit of the provided range.",
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureAtTheMarketATMOfferingAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureLicenseFundingAndOtherAgreementsRelatedToCVRAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRegeneronLicenseAndCollaborationArrangementAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsToEstimateFairValueOfStockOptionsUsingBlackScholesOptionPricingModelDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r273",
      "r298",
      "r344",
      "r347",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r603",
      "r666",
      "r667",
      "r691",
      "r692"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Lower limit of the provided range.",
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureAtTheMarketATMOfferingAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureLicenseFundingAndOtherAgreementsRelatedToCVRAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRegeneronLicenseAndCollaborationArrangementAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsToEstimateFairValueOfStockOptionsUsingBlackScholesOptionPricingModelDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r273",
      "r298",
      "r331",
      "r344",
      "r347",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r603",
      "r666",
      "r667",
      "r691",
      "r692"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureAtTheMarketATMOfferingAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureLicenseFundingAndOtherAgreementsRelatedToCVRAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRegeneronLicenseAndCollaborationArrangementAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsToEstimateFairValueOfStockOptionsUsingBlackScholesOptionPricingModelDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r273",
      "r298",
      "r331",
      "r344",
      "r347",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r603",
      "r666",
      "r667",
      "r691",
      "r692"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median.",
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureAtTheMarketATMOfferingAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureLicenseFundingAndOtherAgreementsRelatedToCVRAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRegeneronLicenseAndCollaborationArrangementAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsToEstimateFairValueOfStockOptionsUsingBlackScholesOptionPricingModelDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r57",
      "r58",
      "r118",
      "r119",
      "r274",
      "r299"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution.",
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAdjustmentMember": {
     "auth_ref": [
      "r121",
      "r122",
      "r123",
      "r124",
      "r125",
      "r128",
      "r129",
      "r131",
      "r133",
      "r134",
      "r136",
      "r137",
      "r152",
      "r494",
      "r495"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cumulative increase (decrease) for adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision.",
        "label": "Revision of Prior Period, Adjustment [Member]",
        "terseLabel": "Measurement Period Adjustments"
       }
      }
     },
     "localname": "RestatementAdjustmentMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsAcquiredDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RestatementAxis": {
     "auth_ref": [
      "r3",
      "r121",
      "r122",
      "r123",
      "r124",
      "r125",
      "r128",
      "r129",
      "r130",
      "r131",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r152",
      "r210",
      "r211",
      "r386",
      "r428",
      "r490",
      "r494",
      "r495",
      "r496",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r719",
      "r720"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision.",
        "label": "Revision of Prior Period [Axis]",
        "terseLabel": "Revision of Prior Period"
       }
      }
     },
     "localname": "RestatementAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsAcquiredDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RestatementDomain": {
     "auth_ref": [
      "r3",
      "r121",
      "r122",
      "r123",
      "r124",
      "r125",
      "r128",
      "r129",
      "r130",
      "r131",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r152",
      "r210",
      "r211",
      "r386",
      "r428",
      "r490",
      "r494",
      "r495",
      "r496",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r719",
      "r720"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustment to previously issued financial statements. Includes, but is not limited to, adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision.",
        "label": "Revision of Prior Period [Domain]",
        "terseLabel": "Revision of Prior Period"
       }
      }
     },
     "localname": "RestatementDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsAcquiredDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [
      "r132",
      "r345",
      "r712"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information reported for future period. Excludes information expected to be reported in future period for effect on historical fact.",
        "label": "Forecast [Member]",
        "terseLabel": "Forecast"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioPreviouslyReportedMember": {
     "auth_ref": [
      "r3",
      "r121",
      "r123",
      "r124",
      "r125",
      "r128",
      "r129",
      "r130",
      "r131",
      "r133",
      "r134",
      "r136",
      "r137",
      "r152",
      "r210",
      "r211",
      "r386",
      "r428",
      "r490",
      "r494",
      "r495",
      "r496",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r719",
      "r720"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents amount as previously reported before adjustment for retrospective application of amendment to accounting standards, other change in accounting principle, correction of error, and other revision.",
        "label": "Previously Reported [Member]",
        "terseLabel": "Preliminary"
       }
      }
     },
     "localname": "ScenarioPreviouslyReportedMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsAcquiredDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [
      "r132",
      "r138",
      "r345"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.",
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r132",
      "r138",
      "r253",
      "r345",
      "r571"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by scenario reported, distinguishing information from actual fact. Includes, but is not limited to, pro forma and forecast. Excludes actual facts.",
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r538"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "Accounting Standards Update 2016-02 [Member]",
        "terseLabel": "Topic 842"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]",
        "terseLabel": "Accrued and Other Current Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r42",
      "r568"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable",
        "totalLabel": "Accounts Payable, Current, Total"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableGrossCurrent": {
     "auth_ref": [
      "r184",
      "r185"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, before Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable"
       }
      }
     },
     "localname": "AccountsReceivableGrossCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableRelatedPartiesCurrent": {
     "auth_ref": [
      "r52",
      "r116",
      "r561",
      "r563"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of receivables arising from transactions with related parties due within one year or the normal operating cycle, if longer.",
        "label": "Accounts Receivable, Related Parties, Current",
        "terseLabel": "Accounts Receivable - related party"
       }
      }
     },
     "localname": "AccountsReceivableRelatedPartiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Net amortization of premiums and accretion of discounts on investments"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedBonusesCurrentAndNoncurrent": {
     "auth_ref": [
      "r634",
      "r659"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for incentive compensation awarded to employees and directors or earned by them based on the terms of one or more relevant arrangements.",
        "label": "Accrued Bonuses",
        "terseLabel": "Amount equal to pro-rated bonus"
       }
      }
     },
     "localname": "AccruedBonusesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesAndOtherLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesSummaryOfAccruedAndOtherCurrentLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid nor invoiced, and liabilities classified as other.",
        "label": "Accrued Liabilities and Other Liabilities",
        "terseLabel": "Accrued and other current liabilities",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "AccruedLiabilitiesAndOtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesSummaryOfAccruedAndOtherCurrentLiabilitiesDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrentAndNoncurrent": {
     "auth_ref": [
      "r634",
      "r659"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesSummaryOfAccruedAndOtherCurrentLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received.",
        "label": "Accrued Professional Fees",
        "terseLabel": "Accrued professional services"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrentAndNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesSummaryOfAccruedAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r40",
      "r243"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: Accumulated depreciation and amortization",
        "periodEndLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Ending Balance",
        "periodStartLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Beginning Balance",
        "totalLabel": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment, Total"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r30",
      "r61",
      "r62",
      "r63",
      "r652",
      "r675",
      "r679"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive income",
        "totalLabel": "Accumulated Other Comprehensive Income (Loss), Net of Tax, Total"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r60",
      "r63",
      "r71",
      "r72",
      "r73",
      "r121",
      "r122",
      "r123",
      "r472",
      "r670",
      "r671",
      "r720"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "verboseLabel": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r28"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional Paid in Capital, Common Stock",
        "periodEndLabel": "Additional Paid in Capital, Common Stock, Ending Balance",
        "periodStartLabel": "Additional Paid in Capital, Common Stock, Beginning Balance",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r121",
      "r122",
      "r123",
      "r383",
      "r384",
      "r385",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r124",
      "r125",
      "r126",
      "r127",
      "r138",
      "r187",
      "r188",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r258",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r425",
      "r426",
      "r427",
      "r428",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r557",
      "r608",
      "r609",
      "r610",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by amendment to accounting standards.",
        "label": "Accounting Standards Update [Axis]",
        "terseLabel": "Accounting Standards Update"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r348",
      "r350",
      "r389",
      "r390"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition",
        "terseLabel": "Stock-based compensation expense",
        "totalLabel": "APIC, Share-based Payment Arrangement, Increase for Cost Recognition, Total"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "auth_ref": [
      "r313",
      "r321"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "terseLabel": "Stock issuance cost"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r350",
      "r375",
      "r388"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Expense related to options granted",
        "verboseLabel": "Total stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of earnings per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureAtTheMarketATMOfferingAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetBackedSecuritiesMember": {
     "auth_ref": [
      "r196",
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities that are primarily serviced by the cash flows of a discrete pool of receivables or other financial assets for example, but not limited to, credit card receivables, car loans, recreational vehicle loans, and mobile home loans.",
        "label": "Asset-backed Securities [Member]",
        "terseLabel": "Asset Backed Securities"
       }
      }
     },
     "localname": "AssetBackedSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureMarketableDebtSecuritiesScheduleOfMarketableDebtSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r96",
      "r240"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "totalLabel": "Asset Impairment Charges, Total",
        "verboseLabel": "Asset impairment charges"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r112",
      "r169",
      "r177",
      "r181",
      "r205",
      "r259",
      "r260",
      "r261",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r270",
      "r271",
      "r467",
      "r475",
      "r510",
      "r566",
      "r568",
      "r628",
      "r651"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r9",
      "r11",
      "r55",
      "r112",
      "r205",
      "r259",
      "r260",
      "r261",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r270",
      "r271",
      "r467",
      "r475",
      "r510",
      "r566",
      "r568"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "auth_ref": [
      "r497"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Fair Value Disclosure",
        "terseLabel": "Total fair value of assets"
       }
      }
     },
     "localname": "AssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r194"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureMarketableDebtSecuritiesScheduleOfMarketableDebtSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Unrealized Gains"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureMarketableDebtSecuritiesScheduleOfMarketableDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r195"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureMarketableDebtSecuritiesScheduleOfMarketableDebtSecuritiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Unrealized Losses"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureMarketableDebtSecuritiesScheduleOfMarketableDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r192",
      "r217"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureMarketableDebtSecuritiesScheduleOfMarketableDebtSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureMarketableDebtSecuritiesScheduleOfMarketableDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r189",
      "r193",
      "r217",
      "r632"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureMarketableDebtSecuritiesScheduleOfMarketableDebtSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Fair Value",
        "totalLabel": "Debt Securities, Available-for-sale, Total",
        "verboseLabel": "Total, Fair Value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureMarketableDebtSecuritiesScheduleOfMarketableDebtSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r191",
      "r217"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureMarketableDebtSecuritiesSummaryOfClassificationOfMarketableDebtSecuritiesInConsolidatedBalanceSheetsDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_MarketableSecurities",
       "weight": 1.0
      },
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Short-term marketable debt securities",
        "totalLabel": "Debt Securities, Available-for-sale, Current, Total"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureMarketableDebtSecuritiesSummaryOfClassificationOfMarketableDebtSecuritiesInConsolidatedBalanceSheetsDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r191",
      "r217"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureMarketableDebtSecuritiesSummaryOfClassificationOfMarketableDebtSecuritiesInConsolidatedBalanceSheetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_MarketableSecurities",
       "weight": 1.0
      },
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-sale, Noncurrent",
        "terseLabel": "Long-term marketable debt securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureMarketableDebtSecuritiesSummaryOfClassificationOfMarketableDebtSecuritiesInConsolidatedBalanceSheetsDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r351",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsToEstimateFairValueOfStockOptionsUsingBlackScholesOptionPricingModelDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRegeneronLicenseAndCollaborationArrangementSummaryOfChangeInCompanySContractLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r479",
      "r482"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRegeneronLicenseAndCollaborationArrangementSummaryOfChangeInCompanySContractLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [
      "r343",
      "r346"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfEstimatedShareConsiderationOfCombinedCompanyDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfEstimatedShareConsiderationOfCombinedCompanyParentheticalDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsAcquiredDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesPurchasePriceInMergerDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesPurchasePriceInMergerParentheticalDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r343",
      "r346",
      "r447",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfEstimatedShareConsiderationOfCombinedCompanyDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfEstimatedShareConsiderationOfCombinedCompanyParentheticalDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsAcquiredDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesPurchasePriceInMergerDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesPurchasePriceInMergerParentheticalDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued": {
     "auth_ref": [
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of equity interests issued or issuable to acquire entity.",
        "label": "Business Acquisition, Equity Interest Issued or Issuable, Number of Shares",
        "terseLabel": "Number of shares of the combined company owned by resTORbio stockholders"
       }
      }
     },
     "localname": "BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfEstimatedShareConsiderationOfCombinedCompanyDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfEstimatedShareConsiderationOfCombinedCompanyParentheticalDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfEstimatedShareConsiderationOfCombinedCompanyDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfEstimatedShareConsiderationOfCombinedCompanyParentheticalDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsAcquiredDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesPurchasePriceInMergerDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesPurchasePriceInMergerParentheticalDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaInformationNonrecurringAdjustmentsTableTextBlock": {
     "auth_ref": [
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the nature and amount of any material, nonrecurring adjustments directly attributable to the business combination(s) included in the reported pro forma revenue and earnings (supplemental pro forma information).",
        "label": "Business Acquisition, Pro Forma Information, Nonrecurring Adjustments [Table Text Block]",
        "terseLabel": "Schedule of Supplemental Unaudited Pro Forma Information"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaInformationNonrecurringAdjustmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionProFormaInformationTextBlock": {
     "auth_ref": [
      "r444",
      "r445"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of pro forma results of operations for a material business acquisition or series of individually immaterial business acquisitions that are material in the aggregate.",
        "label": "Business Acquisition, Pro Forma Information [Table Text Block]",
        "terseLabel": "Schedule of Summarizes the Purchase Price in the Merger"
       }
      }
     },
     "localname": "BusinessAcquisitionProFormaInformationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessAcquisitionSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.",
        "label": "Business Acquisition, Share Price",
        "terseLabel": "Multiplied by the fair value per share of resTORbio common stock"
       }
      }
     },
     "localname": "BusinessAcquisitionSharePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfEstimatedShareConsiderationOfCombinedCompanyDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessAcquisitionsProFormaNetIncomeLoss": {
     "auth_ref": [
      "r444",
      "r445"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The pro forma net Income or Loss for the period as if the business combination or combinations had been completed at the beginning of a period.",
        "label": "Business Acquisition, Pro Forma Net Income (Loss)",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "BusinessAcquisitionsProFormaNetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSupplementalUnauditedProFormaInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAcquisitionRelatedCosts": {
     "auth_ref": [
      "r441"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents acquisition-related costs incurred to effect a business combination which costs have been expensed during the period. Such costs include finder's fees; advisory, legal, accounting, valuation, and other professional or consulting fees; general administrative costs, including the costs of maintaining an internal acquisitions department; and may include costs of registering and issuing debt and equity securities.",
        "label": "Business Combination, Acquisition Related Costs",
        "terseLabel": "Transaction cost for business acquisition"
       }
      }
     },
     "localname": "BusinessCombinationAcquisitionRelatedCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationAssetsArisingFromContingenciesAmountRecognized": {
     "auth_ref": [
      "r451"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount, measured at acquisition-date fair value, of all the assets acquired that arise from contingencies and were recognized by the entity.",
        "label": "Business Combination, Assets Arising from Contingencies, Amount Recognized",
        "terseLabel": "Fair value"
       }
      }
     },
     "localname": "BusinessCombinationAssetsArisingFromContingenciesAmountRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureBusinessCombinationScheduleOfChangesInTheCompanysIprdAndCvrSinceTheMergerDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r454",
      "r455",
      "r457"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Purchase price",
        "totalLabel": "Business Combination, Consideration Transferred, Total"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesPurchasePriceInMergerDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r453",
      "r456",
      "r459"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Contingent consideration liability",
        "totalLabel": "Business Combination, Contingent Consideration, Liability, Total"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesPurchasePriceInMergerDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationDisclosureTextBlock": {
     "auth_ref": [
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).",
        "label": "Business Combination Disclosure [Text Block]",
        "terseLabel": "Business Combination"
       }
      }
     },
     "localname": "BusinessCombinationDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombination"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents": {
     "auth_ref": [
      "r450"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsAcquiredDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions, acquired at the acquisition date. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Cash and Equivalents",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCashAndEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsAcquiredDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets": {
     "auth_ref": [
      "r450"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsAcquiredDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Prepaid Expense and Other Assets",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsPrepaidExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsAcquiredDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable": {
     "auth_ref": [
      "r450"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsAcquiredDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities incurred for goods and services received that are used in an entity's business and related party payables, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Accounts Payable",
        "negatedLabel": "Accounts payable"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsAcquiredDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther": {
     "auth_ref": [
      "r450"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsAcquiredDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other liabilities due within one year or within the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Liabilities, Other",
        "negatedLabel": "Accrued and other current liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsAcquiredDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "auth_ref": [
      "r450"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsAcquiredDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "negatedLabel": "Deferred tax liability"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsAcquiredDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Net [Abstract]",
        "terseLabel": "Net assets acquired:"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsAcquiredDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther": {
     "auth_ref": [
      "r450"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsAcquiredDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of other liabilities due after one year or the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Other",
        "negatedLabel": "Other liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsAcquiredDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment": {
     "auth_ref": [
      "r449",
      "r450"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsAcquiredDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of property, plant, and equipment recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment",
        "terseLabel": "Property and equipment",
        "totalLabel": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Property, Plant, and Equipment, Total"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsAcquiredDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet": {
     "auth_ref": [
      "r450"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsAcquiredDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount recognized for assets, including goodwill, in excess of (less than) the aggregate liabilities assumed.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired, Goodwill, and Liabilities Assumed, Net",
        "totalLabel": "Purchase price"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsAcquiredDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsAxis": {
     "auth_ref": [
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosures related to transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination by type of transaction.",
        "label": "Business Combination, Separately Recognized Transactions [Axis]",
        "terseLabel": "Business Combination, Separately Recognized Transactions"
       }
      }
     },
     "localname": "BusinessCombinationSeparatelyRecognizedTransactionsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureLicenseFundingAndOtherAgreementsRelatedToCVRAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsDomain": {
     "auth_ref": [
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of transaction that is recognized separately from the acquisition of assets and assumptions of liabilities in a business combination by transaction.",
        "label": "Business Combination, Separately Recognized Transactions [Domain]",
        "terseLabel": "Business Combination, Separately Recognized Transactions"
       }
      }
     },
     "localname": "BusinessCombinationSeparatelyRecognizedTransactionsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureLicenseFundingAndOtherAgreementsRelatedToCVRAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock": {
     "auth_ref": [
      "r442"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of transactions that are recognized separately from the acquisition of assets and assumptions of liabilities in the business combination.",
        "label": "Business Combination, Separately Recognized Transactions [Table Text Block]",
        "terseLabel": "Schedule of changes in the Company's IPR&amp;D and CVR since the Merger"
       }
      }
     },
     "localname": "BusinessCombinationSeparatelyRecognizedTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1": {
     "auth_ref": [
      "r443"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value at acquisition-date of the equity interest in the acquiree held by the acquirer, immediately before the acquisition date for businesses combined in stages.",
        "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Fair Value",
        "terseLabel": "Acquisition date fair value of resTORbio common shares"
       }
      }
     },
     "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireeFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfEstimatedShareConsiderationOfCombinedCompanyDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of equity in the acquiree held by the acquirer immediately before the acquisition date in a business combination.",
        "label": "Business Combination, Step Acquisition, Equity Interest in Acquiree, Percentage",
        "terseLabel": "Percentage of outstanding capital stock"
       }
      }
     },
     "localname": "BusinessCombinationStepAcquisitionEquityInterestInAcquireePercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_BusinessCombinationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Business Combinations [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Business Combination"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "auth_ref": [
      "r101",
      "r102",
      "r103"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred.",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "terseLabel": "Purchase of property and equipment included in accounts payable and accrued liabilities"
       }
      }
     },
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Cash": {
     "auth_ref": [
      "r37",
      "r568",
      "r681",
      "r682"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash",
        "periodEndLabel": "Cash, Ending Balance",
        "periodStartLabel": "Cash, Beginning Balance",
        "terseLabel": "Cash payment"
       }
      }
     },
     "localname": "Cash",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAcquiredFromAcquisition": {
     "auth_ref": [
      "r85"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the acquisition of business during the period (for example, cash that was held by the acquired business).",
        "label": "Cash Acquired from Acquisition",
        "terseLabel": "Cash and restricted cash acquired in connection with the Merger"
       }
      }
     },
     "localname": "CashAcquiredFromAcquisition",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r6",
      "r37",
      "r98"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "periodEndLabel": "Cash and cash equivalents",
        "periodStartLabel": "Cash and Cash Equivalents, at Carrying Value, Beginning Balance",
        "terseLabel": "Cash and cash equivalents",
        "totalLabel": "Cash and Cash Equivalents, at Carrying Value, Total"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r16",
      "r99"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r16",
      "r99",
      "r626"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances.  Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsAndShortTermInvestments": {
     "auth_ref": [
      "r37"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash includes currency on hand as well as demand deposits with banks or financial institutions. It also includes other kinds of accounts that have the general characteristics of demand deposits in that the customer may deposit additional funds at any time and effectively may withdraw funds at any time without prior notice or penalty. Cash equivalents, excluding items classified as marketable securities, include short-term, highly liquid Investments that are both readily convertible to known amounts of cash, and so near their maturity that they present minimal risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify under that definition. Original maturity means original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three years ago does not become a cash equivalent when its remaining maturity is three months. Short-term investments, exclusive of cash equivalents, generally consist of marketable securities intended to be sold within one year (or the normal operating cycle if longer) and may include trading securities, available-for-sale securities, or held-to-maturity securities (if maturing within one year), as applicable.",
        "label": "Cash, Cash Equivalents, and Short-term Investments",
        "terseLabel": "Cash, cash equivalents and marketable securities",
        "totalLabel": "Cash, Cash Equivalents, and Short-term Investments, Total"
       }
      }
     },
     "localname": "CashCashEquivalentsAndShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r91",
      "r98",
      "r104"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, at the end of the period",
        "periodStartLabel": "Cash, cash equivalents and restricted cash, at the beginning of the period",
        "totalLabel": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Total"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]",
        "terseLabel": "Reconciliation of cash, cash equivalents and restricted cash to consolidated balance sheets:"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r91",
      "r520"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net change in cash, cash equivalents and restricted cash"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash Flow, Noncash Investing and Financing Activities Disclosure [Abstract]",
        "terseLabel": "Supplemental disclosures of noncash investing and financing activities"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ChangeDuringPeriodFairValueDisclosureMember": {
     "auth_ref": [
      "r511"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measure of change in fair value.",
        "label": "Changes Measurement [Member]",
        "terseLabel": "Measure of Changes in Fair Value"
       }
      }
     },
     "localname": "ChangeDuringPeriodFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureBusinessCombinationScheduleOfChangesInTheCompanysIprdAndCvrSinceTheMergerDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [
      "r110",
      "r112",
      "r141",
      "r142",
      "r143",
      "r146",
      "r148",
      "r155",
      "r156",
      "r157",
      "r205",
      "r259",
      "r264",
      "r265",
      "r266",
      "r270",
      "r271",
      "r296",
      "r297",
      "r301",
      "r305",
      "r510",
      "r702"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfLevel3FinancialInstrumentsDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Stock [Line Items]",
        "terseLabel": "Class Of Stock [Line Items]"
       }
      }
     },
     "localname": "ClassOfStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureAtTheMarketATMOfferingAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date the warrants or rights are exercisable, in YYYY-MM-DD format.",
        "label": "Class of Warrant or Right, Date from which Warrants or Rights Exercisable",
        "terseLabel": "Issuance Date"
       }
      }
     },
     "localname": "ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Warrant exercise price",
        "verboseLabel": "Warrants outstanding and exercisable, Weighted average exercise price"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfOutstandingWarrantsDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Class of Warrant or Right [Line Items]",
        "terseLabel": "Class Of Warrant Or Right [Line Items]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "terseLabel": "Number of securities called",
        "verboseLabel": "Issuance of shares of common stock"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Class of Warrant or Right, Outstanding",
        "terseLabel": "Warrants outstanding",
        "verboseLabel": "Number of Shares of Common Stock Issuable"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightTable": {
     "auth_ref": [
      "r324",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure for warrants or rights issued, which includes the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Class of Warrant or Right [Table]",
        "terseLabel": "Class Of Warrant Or Right [Table]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "auth_ref": [
      "r461",
      "r462",
      "r464"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "terseLabel": "Regeneron License and Collaboration Arrangement"
       }
      }
     },
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRegeneronLicenseAndCollaborationArrangement"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRegeneronLicenseAndCollaborationArrangementAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRegeneronLicenseAndCollaborationArrangementSummaryOfChangeInCompanySContractLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial Paper"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureMarketableDebtSecuritiesScheduleOfMarketableDebtSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r48",
      "r252",
      "r636",
      "r656"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and contingencies (Note 12)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r249",
      "r250",
      "r251",
      "r254",
      "r686"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingences"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingences"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "auth_ref": [
      "r255",
      "r687"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.",
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "terseLabel": "Contingent Consideration Liability (CVR)"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r50"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Number of shares of common stock reserved for future issuance"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "terseLabel": "Common stock dividends declared | $ / shares"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareDeclared",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r121",
      "r122",
      "r494"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value",
        "verboseLabel": "Common stock shares issued, par value"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r27"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued",
        "totalLabel": "Common Stock, Shares, Issued, Total"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r27",
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Common Stock, Shares, Outstanding, Ending Balance",
        "periodStartLabel": "Common Stock, Shares, Outstanding, Beginning Balance",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r27",
      "r568"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "periodEndLabel": "Common Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Common Stock, Value, Issued, Beginning Balance",
        "terseLabel": "Common stock, $0.0001 par value, 150,000,000 shares authorized as of December 31, 2021 and December 31, 2020, respectively; 39,736,914 and 19,677,249 shares issued and outstanding as of December 31, 2021 and December 31, 2020, respectively",
        "totalLabel": "Common Stock, Value, Issued, Total"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r66",
      "r68",
      "r69",
      "r79",
      "r641",
      "r663"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer Equipment [Member]",
        "terseLabel": "Computer Equipment"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r160",
      "r648"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r106",
      "r469"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Principles of Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction In Progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "auth_ref": [
      "r329"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "terseLabel": "Summary of Change in Company's Contract Liabilities"
       }
      }
     },
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRegeneronLicenseAndCollaborationArrangementTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice": {
     "auth_ref": [
      "r328"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in revenue recognized for cumulative catch-up adjustment from change in estimate of transaction price which (increases) decreases obligation to transfer good or service to customer for which consideration from customer has been received or is due. Includes, but is not limited to, change in assessment of whether estimate of variable consideration is constrained.",
        "label": "Contract with Customer, Liability, Cumulative Catch-up Adjustment to Revenue, Change in Estimate of Transaction Price",
        "terseLabel": "Increase in estimated transaction price"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCumulativeCatchUpAdjustmentToRevenueChangeInEstimateOfTransactionPrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRegeneronLicenseAndCollaborationArrangementAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "auth_ref": [
      "r326",
      "r327",
      "r330"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.",
        "label": "Contract with Customer, Liability, Current",
        "terseLabel": "Contract liabilities\u2014related party, current"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "auth_ref": [
      "r326",
      "r327",
      "r330"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.",
        "label": "Contract with Customer, Liability, Noncurrent",
        "terseLabel": "Contract liabilities\u2014related party, net of current portion"
       }
      }
     },
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConversionOfStockAmountConverted1": {
     "auth_ref": [
      "r101",
      "r102",
      "r103"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the stock converted in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Conversion of Stock, Amount Converted",
        "terseLabel": "Conversion of redeemable convertible preferred stock warrants to common stock warrants"
       }
      }
     },
     "localname": "ConversionOfStockAmountConverted1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "auth_ref": [
      "r25",
      "r26",
      "r308",
      "r314",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.",
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "terseLabel": "Common Stock Issued Upon Conversion (1)",
        "verboseLabel": "Number of common stock shares issued upon conversion"
       }
      }
     },
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r332",
      "r340",
      "r680"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate Debt Securities"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureMarketableDebtSecuritiesScheduleOfMarketableDebtSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Federal, State and Local, Tax Expense (Benefit) [Abstract]",
        "terseLabel": "Current:"
       }
      }
     },
     "localname": "CurrentFederalStateAndLocalTaxExpenseBenefitAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForBenefitFromIncomeTaxesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r113",
      "r421",
      "r431"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForBenefitFromIncomeTaxesDetail": {
       "order": 0.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForBenefitFromIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r113",
      "r421"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForBenefitFromIncomeTaxesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForBenefitFromIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r113",
      "r421",
      "r431",
      "r433"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForBenefitFromIncomeTaxesDetail": {
       "order": 0.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.",
        "label": "Current Income Tax Expense (Benefit)",
        "totalLabel": "Total current"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForBenefitFromIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r113",
      "r421",
      "r431"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForBenefitFromIncomeTaxesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForBenefitFromIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "auth_ref": [
      "r101",
      "r103"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Amount",
        "terseLabel": "Conversion of redeemable convertible preferred stock into common stock"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r109",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r283",
      "r284",
      "r285",
      "r287",
      "r290"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Term Loan"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureTermLoan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r272",
      "r288",
      "r289",
      "r530",
      "r532",
      "r533"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Available Loan"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentMaturityDateRangeEnd1": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Latest date the outstanding debt instruments are required to be repaid, in YYYY-MM-DD format.",
        "label": "Debt Instrument, Maturity Date Range, End",
        "terseLabel": "Loan availability end date"
       }
      }
     },
     "localname": "DebtInstrumentMaturityDateRangeEnd1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r113",
      "r422",
      "r431"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForBenefitFromIncomeTaxesDetail": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "terseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForBenefitFromIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]",
        "terseLabel": "Deferred:"
       }
      }
     },
     "localname": "DeferredFederalStateAndLocalTaxExpenseBenefitAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForBenefitFromIncomeTaxesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredFinanceCostsGross": {
     "auth_ref": [
      "r531"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before accumulated amortization, of debt issuance costs. Includes, but is not limited to, legal, accounting, underwriting, printing, and registration costs.",
        "label": "Debt Issuance Costs, Gross",
        "terseLabel": "Debt issuance costs, gross"
       }
      }
     },
     "localname": "DeferredFinanceCostsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r113",
      "r422",
      "r431"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForBenefitFromIncomeTaxesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "terseLabel": "Foreign"
       }
      }
     },
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForBenefitFromIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r96",
      "r113",
      "r422",
      "r431",
      "r432",
      "r433"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForBenefitFromIncomeTaxesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "totalLabel": "Total deferred"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForBenefitFromIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r21",
      "r22",
      "r411",
      "r629",
      "r649"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedLabel": "Net deferred tax liabilities",
        "totalLabel": "Deferred Tax Liabilities, Gross, Total"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r399",
      "r400"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Deferred tax liability",
        "totalLabel": "Deferred Income Tax Liabilities, Net, Total"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRentCreditNoncurrent": {
     "auth_ref": [
      "r23",
      "r535",
      "r556"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of rental payment required by lease over rental income recognized, classified as noncurrent.",
        "label": "Deferred Rent Credit, Noncurrent",
        "terseLabel": "Deferred rent, net of current portion"
       }
      }
     },
     "localname": "DeferredRentCreditNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredRevenue": {
     "auth_ref": [
      "r34"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable.",
        "label": "Deferred Revenue",
        "terseLabel": "Deferred Revenue",
        "totalLabel": "Deferred Revenue, Total"
       }
      }
     },
     "localname": "DeferredRevenue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r113",
      "r422",
      "r431"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForBenefitFromIncomeTaxesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "terseLabel": "State"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForBenefitFromIncomeTaxesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "auth_ref": [
      "r419",
      "r420"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.",
        "label": "Deferred Tax Assets, Deferred Income",
        "terseLabel": "Deferred revenue"
       }
      }
     },
     "localname": "DeferredTaxAssetsDeferredIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r412"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Gross deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "auth_ref": [
      "r419",
      "r420"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from in-process research and development costs expensed in connection with a business combination.",
        "label": "Deferred Tax Assets, in Process Research and Development",
        "terseLabel": "Research and development credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r414"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax asset"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r414"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Deferred tax assets, net of valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]",
        "terseLabel": "Deferred Tax Assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r419",
      "r420"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Net operating loss carryforwards",
        "totalLabel": "Deferred Tax Assets, Operating Loss Carryforwards, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r419",
      "r420"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "auth_ref": [
      "r419",
      "r420"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals",
        "terseLabel": "Accruals and reserves",
        "totalLabel": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r413"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less: Valuation allowance",
        "totalLabel": "Deferred Tax Assets, Valuation Allowance, Total"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Net [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfDeferredTaxAssetsAndLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "Company contribution in the plan"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureDefinedContributionPlanAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanTextBlock": {
     "auth_ref": [
      "r341",
      "r342"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for defined contribution plan.",
        "label": "Defined Contribution Plan [Text Block]",
        "terseLabel": "Defined Contribution Plan"
       }
      }
     },
     "localname": "DefinedContributionPlanTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureDefinedContributionPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DepreciationAndAmortization": {
     "auth_ref": [
      "r96",
      "r241"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "terseLabel": "Depreciation and amortization expense",
        "totalLabel": "Depreciation, Depletion and Amortization, Nonproduction, Total"
       }
      }
     },
     "localname": "DepreciationAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r58",
      "r480",
      "r481",
      "r483",
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DevelopmentInProcess": {
     "auth_ref": [
      "r658"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The current amount of expenditures for a real estate project that has not yet been completed.",
        "label": "Development in Process",
        "terseLabel": "In-process research and development"
       }
      }
     },
     "localname": "DevelopmentInProcess",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r392"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]",
        "terseLabel": "Domestic Tax Authority"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasicAndDiluted": {
     "auth_ref": [
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic and Diluted",
        "terseLabel": "Net loss per share attributable to common stockholders, basic and diluted",
        "totalLabel": "Earnings Per Share, Basic and Diluted, Total"
       }
      }
     },
     "localname": "EarningsPerShareBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r149",
      "r150"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss per Share Attributable to Common Stockholders"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r149",
      "r150",
      "r151",
      "r153"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss per Share"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShare"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r402"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDiffersFromFederalStatutoryRateToLossBeforeTaxesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Provision for income taxes"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDiffersFromFederalStatutoryRateToLossBeforeTaxesDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r114",
      "r402",
      "r434"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDiffersFromFederalStatutoryRateToLossBeforeTaxesDetail": {
       "order": 0.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "Federal statutory income tax rate, percent"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDiffersFromFederalStatutoryRateToLossBeforeTaxesDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r402",
      "r434"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDiffersFromFederalStatutoryRateToLossBeforeTaxesDetail": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDiffersFromFederalStatutoryRateToLossBeforeTaxesDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r402",
      "r434"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDiffersFromFederalStatutoryRateToLossBeforeTaxesDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "terseLabel": "Foreign rate differential"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDiffersFromFederalStatutoryRateToLossBeforeTaxesDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent": {
     "auth_ref": [
      "r391",
      "r402"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDiffersFromFederalStatutoryRateToLossBeforeTaxesDetail": {
       "order": 8.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to expense for award under share-based payment arrangement. Excludes expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Expense (Benefit), Share-based Payment Arrangement, Percent",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationShareBasedCompensationExcessTaxBenefitPercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDiffersFromFederalStatutoryRateToLossBeforeTaxesDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r402",
      "r434"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDiffersFromFederalStatutoryRateToLossBeforeTaxesDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State income taxes"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDiffersFromFederalStatutoryRateToLossBeforeTaxesDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign": {
     "auth_ref": [
      "r402",
      "r434"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDiffersFromFederalStatutoryRateToLossBeforeTaxesDetail": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Foreign, Percent",
        "terseLabel": "Foreign loss"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsForeign",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDiffersFromFederalStatutoryRateToLossBeforeTaxesDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsOther": {
     "auth_ref": [
      "r402",
      "r434"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDiffersFromFederalStatutoryRateToLossBeforeTaxesDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Other, Percent",
        "terseLabel": "Other permanent differences"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsOther",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfProvisionForBenefitFromIncomeTaxesDiffersFromFederalStatutoryRateToLossBeforeTaxesDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r44"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesSummaryOfAccruedAndOtherCurrentLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation",
        "totalLabel": "Employee-related Liabilities, Current, Total"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesSummaryOfAccruedAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r376"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Unrecognized compensation expense, estimated weighted-average period for recognition"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r376"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized stock-based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": {
     "auth_ref": [
      "r376"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost to be recognized for option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Unrecognized compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r373"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Options Issued and Outstanding",
        "verboseLabel": "Options To Purchase Common Stock"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsToEstimateFairValueOfStockOptionsUsingBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r2",
      "r71",
      "r72",
      "r73",
      "r121",
      "r122",
      "r123",
      "r125",
      "r134",
      "r137",
      "r154",
      "r209",
      "r313",
      "r321",
      "r383",
      "r384",
      "r385",
      "r427",
      "r428",
      "r494",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r527",
      "r670",
      "r671",
      "r672",
      "r720"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityIssuedInBusinessCombinationFairValueDisclosure": {
     "auth_ref": [
      "r497"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of equity issued in a business combination.",
        "label": "Equity Issued in Business Combination, Fair Value Disclosure",
        "terseLabel": "Fair value of common stock shares of the combined company owned by resTORbio stockholders"
       }
      }
     },
     "localname": "EquityIssuedInBusinessCombinationFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfEstimatedShareConsiderationOfCombinedCompanyDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesPurchasePriceInMergerDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Equity method investment, Ownership percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_FairValueAdjustmentOfWarrants": {
     "auth_ref": [
      "r96",
      "r291"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.",
        "label": "Fair Value Adjustment of Warrants",
        "terseLabel": "Change in fair value of redeemable convertible preferred stock warrant liability"
       }
      }
     },
     "localname": "FairValueAdjustmentOfWarrants",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfLevel3FinancialInstrumentsDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r497",
      "r498",
      "r499",
      "r504"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfLevel3FinancialInstrumentsDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]",
        "terseLabel": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureBusinessCombinationScheduleOfChangesInTheCompanysIprdAndCvrSinceTheMergerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r497",
      "r508",
      "r509"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureBusinessCombinationScheduleOfChangesInTheCompanysIprdAndCvrSinceTheMergerDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r282",
      "r288",
      "r289",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r340",
      "r498",
      "r576",
      "r577",
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfLevel3FinancialInstrumentsDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r282",
      "r288",
      "r289",
      "r497",
      "r505"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Measurement Basis [Axis]",
        "terseLabel": "Measurement Basis"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureBusinessCombinationScheduleOfChangesInTheCompanysIprdAndCvrSinceTheMergerDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r497",
      "r498",
      "r500",
      "r501",
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "auth_ref": [
      "r282",
      "r288",
      "r289"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
        "label": "Fair Value Measurement [Domain]",
        "terseLabel": "Fair Value Measurement"
       }
      }
     },
     "localname": "FairValueDisclosureItemAmountsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureBusinessCombinationScheduleOfChangesInTheCompanysIprdAndCvrSinceTheMergerDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r503"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r282",
      "r332",
      "r333",
      "r338",
      "r340",
      "r498",
      "r576"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Fair Value Level 1"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r282",
      "r288",
      "r289",
      "r332",
      "r333",
      "r338",
      "r340",
      "r498",
      "r577"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Fair Value Level 2"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r282",
      "r288",
      "r289",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r340",
      "r498",
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Fair Value Level 3"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfLevel3FinancialInstrumentsDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": {
     "auth_ref": [
      "r502"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Gain (Loss) Included in Earnings",
        "terseLabel": "Change in the fair value included in other income (expense), net"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r282",
      "r288",
      "r289",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r340",
      "r576",
      "r577",
      "r578"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfLevel3FinancialInstrumentsDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r503",
      "r506"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Fair Value Recurring [Member]"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfAssetsAcquired": {
     "auth_ref": [
      "r101",
      "r102",
      "r103"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The fair value of assets acquired in noncash investing or financing activities.",
        "label": "Fair Value of Assets Acquired",
        "terseLabel": "Fair value of net assets acquired in Merger"
       }
      }
     },
     "localname": "FairValueOfAssetsAcquired",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinanceLeaseLiability": {
     "auth_ref": [
      "r540",
      "r554"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from finance lease.",
        "label": "Finance Lease, Liability",
        "terseLabel": "Finance lease liability",
        "totalLabel": "Finance Lease, Liability, Total"
       }
      }
     },
     "localname": "FinanceLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r196",
      "r197",
      "r199",
      "r200",
      "r201",
      "r212",
      "r213",
      "r214",
      "r215",
      "r216",
      "r218",
      "r219",
      "r220",
      "r221",
      "r286",
      "r311",
      "r485",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureMarketableDebtSecuritiesScheduleOfMarketableDebtSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialLiabilitiesFairValueDisclosure": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial obligations, including, but not limited to, debt instruments, derivative liabilities, federal funds purchased and sold under agreements to repurchase, securities loaned or sold under agreements to repurchase, financial instruments sold not yet purchased, guarantees, line of credit, loans and notes payable, servicing liability, and trading liabilities.",
        "label": "Financial Liabilities Fair Value Disclosure",
        "periodEndLabel": "Fair value, ending balance",
        "periodStartLabel": "Fair value, beginning balance",
        "totalLabel": "Financial Liabilities Fair Value Disclosure, Total"
       }
      }
     },
     "localname": "FinancialLiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r231",
      "r232",
      "r235",
      "r236",
      "r607",
      "r611"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureBusinessCombinationScheduleOfChangesInTheCompanysIprdAndCvrSinceTheMergerDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r231",
      "r234"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureBusinessCombinationScheduleOfChangesInTheCompanysIprdAndCvrSinceTheMergerDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax departments of governments entitled to levy and collect income taxes from the entity outside the entity's country of domicile.",
        "label": "Foreign Tax Authority [Member]",
        "terseLabel": "Foreign Tax Authority"
       }
      }
     },
     "localname": "ForeignCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture and Fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "auth_ref": [
      "r96"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.",
        "label": "Gain (Loss) on Disposition of Assets",
        "negatedLabel": "Loss on disposal of assets for lease",
        "totalLabel": "Gain (Loss) on Disposition of Assets, Total"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r83"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative",
        "totalLabel": "General and Administrative Expense, Total"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]",
        "terseLabel": "General and Administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r225",
      "r227",
      "r568",
      "r627"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsAcquiredDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredGoodwillAndLiabilitiesAssumedNet",
       "weight": 1.0
      },
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Goodwill, Ending Balance",
        "periodStartLabel": "Goodwill, Beginning Balance",
        "terseLabel": "Goodwill",
        "totalLabel": "Goodwill, Total"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsAcquiredDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": {
     "auth_ref": [
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.",
        "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Intangible Assets"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r229",
      "r233"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "auth_ref": [
      "r96",
      "r226",
      "r228",
      "r230"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Impairment Loss",
        "terseLabel": "Goodwill impairment"
       }
      }
     },
     "localname": "GoodwillImpairmentLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GrantsReceivable": {
     "auth_ref": [
      "r54"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of amounts due under the terms of governmental, corporate, or foundation grants.",
        "label": "Grants Receivable",
        "terseLabel": "Grants receivable"
       }
      }
     },
     "localname": "GrantsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureLicenseFundingAndOtherAgreementsRelatedToCVRAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO [Member]",
        "terseLabel": "Initial Public Offering"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": {
     "auth_ref": [
      "r96",
      "r237"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.",
        "label": "Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)",
        "terseLabel": "Impairment charges"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "auth_ref": [
      "r238",
      "r246"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "terseLabel": "Impairment of Long-Lived Assets"
       }
      }
     },
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "In Process Research and Development"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureBusinessCombinationScheduleOfChangesInTheCompanysIprdAndCvrSinceTheMergerDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r76",
      "r169",
      "r176",
      "r179",
      "r180",
      "r182",
      "r624",
      "r638",
      "r643",
      "r664"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "totalLabel": "Loss before income tax benefit"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r245",
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r404"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]",
        "terseLabel": "Income Tax Authority"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r114",
      "r403",
      "r409",
      "r416",
      "r429",
      "r435",
      "r437",
      "r438",
      "r439"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r115",
      "r136",
      "r137",
      "r168",
      "r401",
      "r430",
      "r436",
      "r665"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForBenefitFromIncomeTaxesDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Income tax expense (benefit)",
        "totalLabel": "Provision for (benefit from) income taxes"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfComponentsOfProvisionForBenefitFromIncomeTaxesDetail",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r70",
      "r397",
      "r398",
      "r409",
      "r410",
      "r415",
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxesPaid": {
     "auth_ref": [
      "r92",
      "r100"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income.",
        "label": "Income Taxes Paid",
        "terseLabel": "Cash paid for income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaid",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesReceivable": {
     "auth_ref": [
      "r53",
      "r633",
      "r660"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount due within one year of the balance sheet date (or one operating cycle, if longer) from tax authorities as of the balance sheet date representing refunds of overpayments or recoveries based on agreed-upon resolutions of disputes.",
        "label": "Income Taxes Receivable, Current",
        "terseLabel": "Tax receivable"
       }
      }
     },
     "localname": "IncomeTaxesReceivable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable",
        "totalLabel": "Increase (Decrease) in Accounts Payable, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivableRelatedParties": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amount due to the reporting entity for good and services provided to the following types of related parties: a parent company and its subsidiaries; subsidiaries of a common parent; an entity and trust for the benefit of employees, such as pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management, an entity and its principal owners, management, member of their immediate families, affiliates, or other parties with the ability to exert significant influence.",
        "label": "Increase (Decrease) in Accounts Receivable, Related Parties",
        "negatedLabel": "Accounts Receivable-related party"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivableRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 17.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in accrued expenses, and obligations classified as other.",
        "label": "Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities",
        "terseLabel": "Accrued and other current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "auth_ref": [
      "r95",
      "r604"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "terseLabel": "Contract liabilities\u2014related party"
       }
      }
     },
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInDeferredLiabilities": {
     "auth_ref": [
      "r95"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Change during the period in carrying value for all deferred liabilities due within one year or operating cycle.",
        "label": "Increase (Decrease) in Deferred Liabilities",
        "terseLabel": "Deferred rent",
        "totalLabel": "Increase (Decrease) in Deferred Liabilities, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInDeferredLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssets": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent assets classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Assets",
        "negatedLabel": "Other non-current assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 18.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Other non-current liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Increase (Decrease) in Prepaid Expense and Other Assets, Total"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntellectualPropertyMember": {
     "auth_ref": [
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Intangible asset arising from original creative thought. Include, but is not limited to, trademarks, patents, and copyrights.",
        "label": "Intellectual Property [Member]",
        "terseLabel": "Intellectual Property"
       }
      }
     },
     "localname": "IntellectualPropertyMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestAndOtherIncome": {
     "auth_ref": [],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).",
        "label": "Interest and Other Income",
        "terseLabel": "Interest income",
        "totalLabel": "Interest and Other Income, Total"
       }
      }
     },
     "localname": "InterestAndOtherIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r75",
      "r167",
      "r529",
      "r531",
      "r642"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "negatedLabel": "Interest expense",
        "totalLabel": "Interest Expense, Total"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestReceivableCurrent": {
     "auth_ref": [
      "r54"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.",
        "label": "Interest Receivable, Current",
        "terseLabel": "Interest receivable"
       }
      }
     },
     "localname": "InterestReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Schedule of Company\u2019s Marketable Debt Securities by Contractual Maturity"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureMarketableDebtSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r198",
      "r625",
      "r646",
      "r684",
      "r709"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for  investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "terseLabel": "Marketable Debt Securities"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureMarketableDebtSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LandSubjectToGroundLeases": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area of land subject to a ground lease.",
        "label": "Land Subject to Ground Leases",
        "terseLabel": "Office lease space"
       }
      }
     },
     "localname": "LandSubjectToGroundLeases",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "areaItemType"
    },
    "us-gaap_LeaseAndRentalExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "Operating Leases, Rent Expense",
        "terseLabel": "Rent expense recognized",
        "totalLabel": "Operating Leases, Rent Expense, Total"
       }
      }
     },
     "localname": "LeaseAndRentalExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseContractualTermAxis": {
     "auth_ref": [
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Axis]",
        "terseLabel": "Lease Contractual Term"
       }
      }
     },
     "localname": "LeaseContractualTermAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfWeightedAverageIBRAndRemainingLeaseTermDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseContractualTermDomain": {
     "auth_ref": [
      "r544"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contractual term of lease arrangement.",
        "label": "Lease Contractual Term [Domain]",
        "terseLabel": "Lease Contractual Term"
       }
      }
     },
     "localname": "LeaseContractualTermDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfWeightedAverageIBRAndRemainingLeaseTermDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r553",
      "r555"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesSummaryOfLeaseCostsAndOtherInformationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesSummaryOfLeaseCostsAndOtherInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lease, Cost [Abstract]",
        "terseLabel": "Lease Cost"
       }
      }
     },
     "localname": "LeaseCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesSummaryOfLeaseCostsAndOtherInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r553"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Summary of Lease Costs and Other Information"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeaseExpirationDate1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date which lease or group of leases is set to expire, in YYYY-MM-DD format.",
        "label": "Lease Expiration Date",
        "terseLabel": "Lease expiration date"
       }
      }
     },
     "localname": "LeaseExpirationDate1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold Improvements [Member]",
        "terseLabel": "Leasehold Improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LegalFees": {
     "auth_ref": [
      "r82"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.",
        "label": "Legal Fees",
        "terseLabel": "Legal fees"
       }
      }
     },
     "localname": "LegalFees",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r542"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r554"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Maturities Of Operating Lease Liabilities"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r554"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total undiscounted lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive": {
     "auth_ref": [
      "r554"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due after Rolling Year Five",
        "terseLabel": "2026 and thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive": {
     "auth_ref": [
      "r554"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Five",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour": {
     "auth_ref": [
      "r554"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Four",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree": {
     "auth_ref": [
      "r554"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Three",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo": {
     "auth_ref": [
      "r554"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Two",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths": {
     "auth_ref": [
      "r554"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Next Rolling Twelve Months",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r554"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails2": {
       "order": 0.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less: imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r543"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Amended lease term from the date of relocation"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LettersOfCreditOutstandingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.",
        "label": "Letters of Credit Outstanding, Amount",
        "terseLabel": "Letters of Credit issued amount"
       }
      }
     },
     "localname": "LettersOfCreditOutstandingAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r43",
      "r112",
      "r178",
      "r205",
      "r259",
      "r260",
      "r261",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r270",
      "r271",
      "r468",
      "r475",
      "r476",
      "r510",
      "r566",
      "r567"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r33",
      "r112",
      "r205",
      "r510",
      "r568",
      "r631",
      "r654"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities, redeemable convertible preferred stock, and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities, redeemable convertible preferred stock, and stockholders\u2019 equity (deficit)"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r45",
      "r112",
      "r205",
      "r259",
      "r260",
      "r261",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r270",
      "r271",
      "r468",
      "r475",
      "r476",
      "r510",
      "r566",
      "r567",
      "r568"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 0.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesFairValueAdjustment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of addition (reduction) to the amount at which a liability could be incurred (settled) in a current transaction between willing parties.",
        "label": "Liabilities, Fair Value Adjustment",
        "terseLabel": "Settlement"
       }
      }
     },
     "localname": "LiabilitiesFairValueAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesFairValueDisclosure": {
     "auth_ref": [
      "r497"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of financial and nonfinancial obligations.",
        "label": "Financial and Nonfinancial Liabilities, Fair Value Disclosure",
        "terseLabel": "Total fair value of liabilities"
       }
      }
     },
     "localname": "LiabilitiesFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationSettlementExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.",
        "label": "Litigation Settlement, Expense",
        "terseLabel": "Litigation settlement expense"
       }
      }
     },
     "localname": "LitigationSettlementExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LoansPayable": {
     "auth_ref": [
      "r20",
      "r630",
      "r650"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Including the current and noncurrent portions, aggregate carrying value as of the balance sheet date of loans payable (with maturities initially due after one year or beyond the operating cycle if longer).",
        "label": "Loans Payable",
        "terseLabel": "Outstanding balance under the loan agreement",
        "totalLabel": "Loans Payable, Total"
       }
      }
     },
     "localname": "LoansPayable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LoansReceivableBasisSpreadOnVariableRate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage added to reference rate used to compute variable rate on loan receivable.",
        "label": "Loans Receivable, Basis Spread on Variable Rate",
        "terseLabel": "Interest rate for term loan to finance leasehold improvements"
       }
      }
     },
     "localname": "LoansReceivableBasisSpreadOnVariableRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_LongTermDebtDescription": {
     "auth_ref": [
      "r47",
      "r314"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of long-term debt arrangements, which are debt arrangements that originally require full repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer, and disclosures pertaining to the underlying arrangements, including repayment terms, conversion features, interest rates, restrictions on assets and activities, debt covenants, and other matters important to users of the financial statements. Types of long-term debt arrangements include borrowing under notes payable, bonds payable, debentures, term loans, and other contractual obligations for payment.",
        "label": "Long-term Debt, Description",
        "terseLabel": "Long-term Debt, Description"
       }
      }
     },
     "localname": "LongTermDebtDescription",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermPurchaseCommitmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Long-term Purchase Commitment [Line Items]",
        "terseLabel": "Long Term Purchase Commitment [Line Items]"
       }
      }
     },
     "localname": "LongTermPurchaseCommitmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfWeightedAverageIBRAndRemainingLeaseTermDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermPurchaseCommitmentTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule setting forth key provisions of an arrangement under which the entity has agreed to purchase goods or services over a period of time greater than one year or the normal operating cycle, if longer, including the item for which expenditures will be made, minimum quantities, milestones, time period and committed amount.",
        "label": "Long-term Purchase Commitment [Table]",
        "terseLabel": "Long Term Purchase Commitment [Table]"
       }
      }
     },
     "localname": "LongTermPurchaseCommitmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfWeightedAverageIBRAndRemainingLeaseTermDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r47"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r47",
      "r257"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecurities": {
     "auth_ref": [
      "r637"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureMarketableDebtSecuritiesSummaryOfClassificationOfMarketableDebtSecuritiesInConsolidatedBalanceSheetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in marketable security.",
        "label": "Marketable Securities",
        "totalLabel": "Marketable debt securities"
       }
      }
     },
     "localname": "MarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureMarketableDebtSecuritiesSummaryOfClassificationOfMarketableDebtSecuritiesInConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Marketable Securities [Line Items]",
        "terseLabel": "Marketable Securities [Line Items]"
       }
      }
     },
     "localname": "MarketableSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureMarketableDebtSecuritiesScheduleOfMarketableDebtSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r645"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MarketableSecuritiesTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in marketable security.",
        "label": "Marketable Securities [Table]",
        "terseLabel": "Marketable Securities [Table]"
       }
      }
     },
     "localname": "MarketableSecuritiesTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureMarketableDebtSecuritiesScheduleOfMarketableDebtSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.",
        "label": "Marketable Securities [Table Text Block]",
        "terseLabel": "Schedule of Marketable Debt Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureMarketableDebtSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r332"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money Market Funds"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r91"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by (used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r91",
      "r94",
      "r97"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r5",
      "r64",
      "r67",
      "r73",
      "r77",
      "r97",
      "r112",
      "r124",
      "r128",
      "r129",
      "r131",
      "r132",
      "r136",
      "r137",
      "r144",
      "r169",
      "r176",
      "r179",
      "r180",
      "r182",
      "r205",
      "r259",
      "r260",
      "r261",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r270",
      "r271",
      "r496",
      "r510",
      "r639",
      "r661"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r128",
      "r129",
      "r131",
      "r132",
      "r139",
      "r140",
      "r145",
      "r148",
      "r169",
      "r176",
      "r179",
      "r180",
      "r182"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "terseLabel": "Net loss attributable to common stockholders",
        "totalLabel": "Net Income (Loss) Available to Common Stockholders, Basic, Total"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recent Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": {
     "auth_ref": [
      "r357"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares.",
        "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]",
        "terseLabel": "Summary of Restricted Stock Activity"
       }
      }
     },
     "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_NumberOfReportableSegments": {
     "auth_ref": [
      "r166"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.",
        "label": "Number of Reportable Segments"
       }
      }
     },
     "localname": "NumberOfReportableSegments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r169",
      "r176",
      "r179",
      "r180",
      "r182"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r545",
      "r555"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesSummaryOfLeaseCostsAndOtherInformationDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesSummaryOfLeaseCostsAndOtherInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r540"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails2": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "terseLabel": "Operating lease liability",
        "totalLabel": "Total operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r540"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Operating lease liability",
        "verboseLabel": "Less: current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r540"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      },
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Operating lease liability, net of current portion",
        "verboseLabel": "Operating lease liability, net of current maturities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfMaturitiesOfOperatingLeaseLiabilitiesDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r541",
      "r549"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Lease payments",
        "verboseLabel": "Operating cash flows used for lease payments"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesSummaryOfLeaseCostsAndOtherInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePaymentsUse": {
     "auth_ref": [
      "r541",
      "r549"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments, Use",
        "terseLabel": "Operating cash flows used for lease liabilities"
       }
      }
     },
     "localname": "OperatingLeasePaymentsUse",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesSummaryOfLeaseCostsAndOtherInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r539"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Operating lease right-of-use asset",
        "verboseLabel": "Operating lease right-of-use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r552",
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted Average IBR"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfWeightedAverageIBRAndRemainingLeaseTermDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r551",
      "r555"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Remaining Terms (in years)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfWeightedAverageIBRAndRemainingLeaseTermDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": {
     "auth_ref": [
      "r534",
      "r536"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.",
        "label": "Operating Leases, Future Minimum Payments Due",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": {
     "auth_ref": [
      "r534",
      "r536"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments Due, Next Twelve Months",
        "terseLabel": "2020"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears": {
     "auth_ref": [
      "r534",
      "r536"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Five Years",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFiveYears",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": {
     "auth_ref": [
      "r534",
      "r536"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Four Years",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": {
     "auth_ref": [
      "r534",
      "r536"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Three Years",
        "terseLabel": "2022"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": {
     "auth_ref": [
      "r534",
      "r536"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Two Years",
        "terseLabel": "2021"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter": {
     "auth_ref": [
      "r534",
      "r536"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_OperatingLeasesFutureMinimumPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due Thereafter",
        "terseLabel": "2025 and thereafter"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueThereafter",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesRentExpenseSubleaseRentals1": {
     "auth_ref": [
      "r534"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The total amount of sublease rental income recognized during the period that reduces the entity's rent expense incurred under operating leases.",
        "label": "Operating Leases, Rent Expense, Sublease Rentals",
        "terseLabel": "Operating Leases, Rent Expense, Sublease Rentals"
       }
      }
     },
     "localname": "OperatingLeasesRentExpenseSubleaseRentals1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r417"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating Loss Carryforwards",
        "terseLabel": "Operating loss carryforwards",
        "totalLabel": "Operating Loss Carryforwards, Total"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwardsExpirationDate": {
     "auth_ref": [
      "r417"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expiration date of each operating loss carryforward included in operating loss carryforward, in YYYY-MM-DD format.",
        "label": "Operating Loss Carryforwards, Expiration Date",
        "terseLabel": "Operating loss carryforwards, expiration date"
       }
      }
     },
     "localname": "OperatingLossCarryforwardsExpirationDate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "dateItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r13",
      "r14",
      "r15",
      "r44"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesSummaryOfAccruedAndOtherCurrentLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AccruedLiabilitiesAndOtherLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Accrued Liabilities, Current",
        "terseLabel": "Accrued other liabilities"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesSummaryOfAccruedAndOtherCurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r54",
      "r568"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r41"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other non-current assets",
        "totalLabel": "Other Assets, Noncurrent, Total"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeTax": {
     "auth_ref": [
      "r71",
      "r72",
      "r78",
      "r202",
      "r521",
      "r526",
      "r527",
      "r640",
      "r662"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before tax, after reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), before Tax",
        "totalLabel": "Total other comprehensive income (loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r65",
      "r68",
      "r71",
      "r72",
      "r74",
      "r78",
      "r313",
      "r521",
      "r526",
      "r527",
      "r640",
      "r662"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive loss",
        "totalLabel": "Other Comprehensive Income (Loss), Net of Tax, Total"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Other comprehensive income (loss):"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r59",
      "r61"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "terseLabel": "Unrealized gain (loss) on marketable debt securities, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilities": {
     "auth_ref": [
      "r635"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other.",
        "label": "Other Liabilities",
        "terseLabel": "Other non-current liabilities",
        "totalLabel": "Other Liabilities, Total"
       }
      }
     },
     "localname": "OtherLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashExpense": {
     "auth_ref": [
      "r97"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense or loss included in net income that result in no cash flow, classified as other.",
        "label": "Other Noncash Expense",
        "terseLabel": "Noncash lease expense"
       }
      }
     },
     "localname": "OtherNoncashExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r84"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income (expense), net",
        "totalLabel": "Other Nonoperating Income (Expense), Total"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other nonoperating income (expense).",
        "label": "Other Nonoperating Income (Expense) [Member]",
        "terseLabel": "Other Income (Expense) [Member]"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "localname": "PayablesAndAccrualsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PaymentsForMergerRelatedCosts": {
     "auth_ref": [
      "r93"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash paid during the reporting period for charges associated with the mergers.",
        "label": "Payments for Merger Related Costs",
        "terseLabel": "Transaction cost for merger"
       }
      }
     },
     "localname": "PaymentsForMergerRelatedCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r88"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "terseLabel": "Payments for repurchase of common stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.",
        "label": "Payments of Debt Issuance Costs",
        "negatedLabel": "Deferred issuance costs"
       }
      }
     },
     "localname": "PaymentsOfDebtIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r190"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of marketable debt securities",
        "totalLabel": "Payments to Acquire Marketable Securities, Total"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r86"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchase of property and equipment",
        "totalLabel": "Payments to Acquire Property, Plant, and Equipment, Total"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r351",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-us": {
       "role": {
        "axisDefault": "Portion at Fair Value Measurement [Member] [Default]",
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion at Fair Value Measurement [Member]",
        "terseLabel": "Fair Value Disclosure Item Amounts [Default]"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureBusinessCombinationScheduleOfChangesInTheCompanysIprdAndCvrSinceTheMergerDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfLevel3FinancialInstrumentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockLiquidationPreferenceValue": {
     "auth_ref": [
      "r110",
      "r301"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of the difference between preference in liquidation and the par or stated values of the preferred shares.",
        "label": "Preferred Stock, Liquidation Preference, Value",
        "terseLabel": "Preferred stock, liquidation preference, value"
       }
      }
     },
     "localname": "PreferredStockLiquidationPreferenceValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r26",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred Stock, par value"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r26",
      "r296"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock shares issued",
        "totalLabel": "Preferred Stock, Shares Issued, Total"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r26"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "periodEndLabel": "Preferred Stock, Shares Outstanding, Ending Balance",
        "periodStartLabel": "Preferred Stock, Shares Outstanding, Beginning Balance",
        "terseLabel": "Preferred stock shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r26",
      "r568"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "periodEndLabel": "Preferred Stock, Value, Issued, Ending Balance",
        "periodStartLabel": "Preferred Stock, Value, Issued, Beginning Balance",
        "terseLabel": "Preferred stock, $0.0001 par value, 10,000,000 shares authorized as of December 31, 2021 and December 31, 2020, respectively; none issued and outstanding as of December 31, 2021 and December 31, 2020, respectively",
        "totalLabel": "Preferred Stock, Value, Issued, Total"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r9",
      "r35",
      "r36"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Total prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Prepaid Expense and Other Assets, Current [Abstract]"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "auth_ref": [
      "r7",
      "r10",
      "r223",
      "r224"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense, Current",
        "terseLabel": "Prepaid maintenance",
        "totalLabel": "Prepaid Expense, Current, Total"
       }
      }
     },
     "localname": "PrepaidExpenseCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidInsurance": {
     "auth_ref": [
      "r8",
      "r10",
      "r222",
      "r224"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer.",
        "label": "Prepaid Insurance",
        "terseLabel": "Prepaid insurance"
       }
      }
     },
     "localname": "PrepaidInsurance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosurePrepaidExpensesAndOtherCurrentAssetsSummaryOfPrepaidExpensesAndOtherCurrentAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrimeRateMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate charged by financial institutions to their most creditworthy borrowers.",
        "label": "Prime Rate [Member]",
        "terseLabel": "Prime Rate"
       }
      }
     },
     "localname": "PrimeRateMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProceedsFromIncomeTaxRefunds": {
     "auth_ref": [
      "r94",
      "r100"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of cash received during the period as refunds for the overpayment of taxes.",
        "label": "Proceeds from Income Tax Refunds",
        "terseLabel": "Cash received for income tax refunds"
       }
      }
     },
     "localname": "ProceedsFromIncomeTaxRefunds",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r87"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Net proceeds received from offering"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from Issuance of Common Stock",
        "terseLabel": "Proceeds from issuance of common stock, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Proceeds from maturities of marketable debt securities",
        "totalLabel": "Proceeds from Sale and Maturity of Marketable Securities, Total"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r87",
      "r378"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options",
        "verboseLabel": "Payment from Regeneron for exercise of its option to license exclusive rights"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRegeneronLicenseAndCollaborationArrangementAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r5",
      "r64",
      "r67",
      "r73",
      "r90",
      "r112",
      "r124",
      "r136",
      "r137",
      "r169",
      "r176",
      "r179",
      "r180",
      "r182",
      "r205",
      "r259",
      "r260",
      "r261",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r270",
      "r271",
      "r465",
      "r470",
      "r471",
      "r477",
      "r478",
      "r496",
      "r510",
      "r643"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss",
        "totalLabel": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest, Total"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r40",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Long-Lived Tangible Asset [Axis]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r247",
      "r688",
      "r689",
      "r690"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": {
     "auth_ref": [
      "r239"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).",
        "label": "Property, Plant and Equipment, Estimated Useful Lives",
        "terseLabel": "Useful life (in years)"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r39",
      "r242"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails": {
       "order": 0.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "periodEndLabel": "Property, Plant and Equipment, Gross, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Gross, Beginning Balance",
        "terseLabel": "Total property and equipment",
        "totalLabel": "Property, Plant and Equipment, Gross, Total"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property Plant And Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r17",
      "r18",
      "r244",
      "r568",
      "r647",
      "r655"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "periodEndLabel": "Property, Plant and Equipment, Net, Ending Balance",
        "periodStartLabel": "Property, Plant and Equipment, Net, Beginning Balance",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r38",
      "r244",
      "r688",
      "r689"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r17",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Summary of Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r17",
      "r242"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Long-Lived Tangible Asset [Domain]",
        "terseLabel": "Long-Lived Tangible Asset"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Useful life (in years)"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_RedeemableConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of type or class of redeemable convertible preferred stock. Convertible redeemable preferred stock possess conversion and redemption features. The stock has redemption features that are outside the control of the issuer.",
        "label": "Redeemable Convertible Preferred Stock [Member]",
        "terseLabel": "Redeemable Convertible Preferred Stock"
       }
      }
     },
     "localname": "RedeemableConvertiblePreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyDomain": {
     "auth_ref": [
      "r339",
      "r560",
      "r561"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Domain]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureLicenseFundingAndOtherAgreementsRelatedToCVRAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRegeneronLicenseAndCollaborationArrangementAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionAxis": {
     "auth_ref": [
      "r339",
      "r560",
      "r561",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party transaction.",
        "label": "Related Party Transaction [Axis]",
        "terseLabel": "Related Party Transaction"
       }
      }
     },
     "localname": "RelatedPartyTransactionAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionDomain": {
     "auth_ref": [
      "r339"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Transaction between related party.",
        "label": "Related Party Transaction [Domain]",
        "terseLabel": "Related Party Transaction"
       }
      }
     },
     "localname": "RelatedPartyTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RelatedPartyTransactionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Related Party Transaction [Line Items]",
        "terseLabel": "Related Party Transaction [Line Items]"
       }
      }
     },
     "localname": "RelatedPartyTransactionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Related Party Transactions [Abstract]"
       }
      }
     },
     "localname": "RelatedPartyTransactionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": {
     "auth_ref": [
      "r339",
      "r560",
      "r563",
      "r612",
      "r613",
      "r614",
      "r615",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r621",
      "r622",
      "r623"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.",
        "label": "Related Party [Axis]",
        "terseLabel": "Related Party"
       }
      }
     },
     "localname": "RelatedPartyTransactionsByRelatedPartyAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureLicenseFundingAndOtherAgreementsRelatedToCVRAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRegeneronLicenseAndCollaborationArrangementAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RelatedPartyTransactionsDisclosureTextBlock": {
     "auth_ref": [
      "r558",
      "r559",
      "r561",
      "r564",
      "r565"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Related Party Transactions Disclosure [Text Block]",
        "terseLabel": "Related Party Transactions"
       }
      }
     },
     "localname": "RelatedPartyTransactionsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactions"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis": {
     "auth_ref": [
      "r394",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by form of arrangement related to research and development.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Axis]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureLicenseFundingAndOtherAgreementsRelatedToCVRAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Research and Development Arrangement, Contract to Perform for Others [Line Items]",
        "terseLabel": "Research And Development Arrangement Contract To Perform For Others [Line Items]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureLicenseFundingAndOtherAgreementsRelatedToCVRAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain": {
     "auth_ref": [
      "r394",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others.",
        "label": "Research and Development Arrangement, Contract to Perform for Others, Type [Domain]",
        "terseLabel": "Research and Development Arrangement, Contract to Perform for Others, Type"
       }
      }
     },
     "localname": "ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureLicenseFundingAndOtherAgreementsRelatedToCVRAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r393",
      "r605",
      "r693"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development",
        "totalLabel": "Research and Development Expense, Total"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research And Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r393"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedCashNoncurrent": {
     "auth_ref": [
      "r12",
      "r19",
      "r104",
      "r685"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as noncurrent. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.",
        "label": "Restricted Cash, Noncurrent",
        "periodEndLabel": "Restricted cash",
        "terseLabel": "Restricted cash"
       }
      }
     },
     "localname": "RestrictedCashNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockMember": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met.",
        "label": "Restricted Stock [Member]",
        "terseLabel": "Restricted Stock"
       }
      }
     },
     "localname": "RestrictedStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Unvested Restricted Stock Awards",
        "verboseLabel": "Restricted Stock Units (RSUs)"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r29",
      "r321",
      "r386",
      "r568",
      "r653",
      "r674",
      "r679"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "negatedLabel": "Accumulated deficit",
        "periodEndLabel": "Retained Earnings (Accumulated Deficit), Ending Balance",
        "periodStartLabel": "Retained Earnings (Accumulated Deficit), Beginning Balance",
        "terseLabel": "Accumulated deficit",
        "totalLabel": "Retained Earnings (Accumulated Deficit), Total"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r2",
      "r121",
      "r122",
      "r123",
      "r125",
      "r134",
      "r137",
      "r209",
      "r383",
      "r384",
      "r385",
      "r427",
      "r428",
      "r494",
      "r670",
      "r672"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromRelatedParties": {
     "auth_ref": [
      "r81",
      "r262",
      "r264",
      "r265",
      "r269",
      "r270",
      "r271",
      "r683"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.",
        "label": "Revenue from Related Parties",
        "terseLabel": "Revenue\u2014related party"
       }
      }
     },
     "localname": "RevenueFromRelatedParties",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueRecognitionAndDeferredRevenueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Recognition and Deferred Revenue [Abstract]"
       }
      }
     },
     "localname": "RevenueRecognitionAndDeferredRevenueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "auth_ref": [
      "r107",
      "r108"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.",
        "label": "Revenue [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueRecognitionPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r550",
      "r555"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Operating lease right-of-use asset obtained in exchange for operating lease liability",
        "verboseLabel": "Operating lease right of use asset obtained in exchange of operating lease liability"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesSummaryOfLeaseCostsAndOtherInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cash received on stock transaction after deduction of issuance costs.",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "terseLabel": "Net proceeds from the offering, after deducting expenses"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockConsiderationReceivedPerTransaction": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of consideration received by subsidiary or equity investee in exchange for shares of stock issued or sold. Includes amount of cash received, fair value of noncash assets received, and fair value of liabilities assumed by the investor.",
        "label": "Sale of Stock, Consideration Received Per Transaction",
        "terseLabel": "Proceeds from the offering"
       }
      }
     },
     "localname": "SaleOfStockConsiderationReceivedPerTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockDescriptionOfTransaction": {
     "auth_ref": [
      "r466",
      "r473",
      "r474"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of stock transaction which may include details of the offering (IPO, private placement), a description of the stock sold, percentage of subsidiary's or equity investee's stock sold, a description of the investors and whether the stock was issued in a business combination.",
        "label": "Sale of Stock, Description of Transaction",
        "terseLabel": "Description of stock purchase agreement"
       }
      }
     },
     "localname": "SaleOfStockDescriptionOfTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureAtTheMarketATMOfferingAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "terseLabel": "Number of common stock shares sold"
       }
      }
     },
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.",
        "label": "Sale of Stock, Price Per Share",
        "terseLabel": "Public offering price"
       }
      }
     },
     "localname": "SaleOfStockPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Summary of Accrued and Other Current Liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureAccruedAndOtherCurrentLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r149"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Schedule of Potentially Dilutive Securities Excluded from Computation of Diluted Net Loss Per Share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of contingent payment arrangements including the terms that will result in payment and the accounting treatment that will be followed if such contingencies occur, including the potential impact on earnings per share if contingencies are to be settled in common stock of the entity. The description also may include the period over which amounts are expected to be paid, and changes in the amount since the previous reporting period. This also includes contingent options and commitments.",
        "label": "Schedule of Business Acquisitions by Acquisition, Contingent Consideration [Table Text Block]",
        "terseLabel": "Schedule of Estimated Share Consideration of Combined Company"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionContingentConsiderationTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r447",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule Of Business Acquisitions By Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfEstimatedShareConsiderationOfCombinedCompanyDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfEstimatedShareConsiderationOfCombinedCompanyParentheticalDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesAllocationOfPurchasePriceToNetTangibleAndIntangibleAssetsAcquiredDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesPurchasePriceInMergerDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesPurchasePriceInMergerParentheticalDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock": {
     "auth_ref": [
      "r447",
      "r448"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of a material business combination completed during the period, including background, timing, and recognized assets and liabilities. This table  does not include leveraged buyouts.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table Text Block]",
        "terseLabel": "Schedule of Summarizes the Allocation of the Purchase Price to the Net Tangible and Intangible Assets Acquired"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRegeneronLicenseAndCollaborationArrangementAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRegeneronLicenseAndCollaborationArrangementSummaryOfChangeInCompanySContractLiabilitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of cost recognized for award under share-based payment arrangement by plan. Includes, but is not limited to, related tax benefit.",
        "label": "Share-based Payment Arrangement, Cost by Plan [Table Text Block]",
        "terseLabel": "Summary of Stock-Based Compensation Expense"
       }
      }
     },
     "localname": "ScheduleOfCompensationCostForShareBasedPaymentArrangementsAllocationOfShareBasedCompensationCostsByPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r423"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Components of Provision for (Benefit from) Income Taxes"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r414"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r148"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Basic and Diluted Net Loss Per Share Attributable to Common Stockholders"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r402"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of (Provision for) Benefit from Income Taxes Differs from Federal Statutory Rate to the Loss Before Taxes"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Equity Method Investments [Line Items]",
        "terseLabel": "Schedule Of Equity Method Investments [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "auth_ref": [
      "r5",
      "r112",
      "r204",
      "r205",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.",
        "label": "Schedule of Equity Method Investments [Table]",
        "terseLabel": "Schedule Of Equity Method Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r497",
      "r498"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Financial Assets and Liabilities Measured on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": {
     "auth_ref": [
      "r537"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.",
        "label": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]",
        "terseLabel": "Schedule Of Future Minimum Rental Payments For Operating Leases"
       }
      }
     },
     "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentsAndContingencesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r40",
      "r244"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable": {
     "auth_ref": [
      "r562",
      "r563"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule of quantitative and qualitative information pertaining to related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.",
        "label": "Schedule of Related Party Transactions, by Related Party [Table]",
        "terseLabel": "Schedule Of Related Party Transactions By Related Party [Table]"
       }
      }
     },
     "localname": "ScheduleOfRelatedPartyTransactionsByRelatedPartyTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable": {
     "auth_ref": [
      "r394",
      "r395"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A schedule reflecting the terms of significant agreements under research and development arrangements accounted for as a contract to perform research and development for others (including royalty arrangements, purchase provisions, license agreements, and commitments to provide additional funding), aggregated by similar arrangements or individually if necessary to understand the effects on the financial statements.",
        "label": "Schedule of Research and Development Arrangement, Contract to Perform for Others [Table]",
        "terseLabel": "Schedule Of Research And Development Arrangement Contract To Perform For Others [Table]"
       }
      }
     },
     "localname": "ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureLicenseFundingAndOtherAgreementsRelatedToCVRAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r351",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsToEstimateFairValueOfStockOptionsUsingBlackScholesOptionPricingModelDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r358"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]",
        "terseLabel": "Summary of Restricted Stock Unit Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r358",
      "r365",
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Summary of Stock Option Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r370"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Assumptions to Estimate Fair Value of Stock Options Using Black-Scholes Option Pricing Model"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "auth_ref": [
      "r49",
      "r110",
      "r155",
      "r156",
      "r292",
      "r293",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r301",
      "r305",
      "r311",
      "r314",
      "r315",
      "r316",
      "r318",
      "r319",
      "r320",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule detailing information related to equity by class of stock. Class of stock includes common, convertible, and preferred stocks which are not redeemable or redeemable solely at the option of the issuer. It also includes preferred stock with redemption features that are solely within the control of the issuer and mandatorily redeemable stock if redemption is required to occur only upon liquidation or termination of the reporting entity.",
        "label": "Schedule of Stock by Class [Table]",
        "terseLabel": "Schedule Of Stock By Class [Table]"
       }
      }
     },
     "localname": "ScheduleOfStockByClassTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureAtTheMarketATMOfferingAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r324",
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]",
        "terseLabel": "Schedule of Outstanding Warrants"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockholdersEquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r408",
      "r424"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Schedule of Reconciliation of Unrecognized Tax Benefits"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the change in restricted stock units (RSUs).",
        "label": "Schedule of Unvested Restricted Stock Units Roll Forward [Table Text Block]",
        "terseLabel": "Schedule of Vested Restricted Stock Units"
       }
      }
     },
     "localname": "ScheduleOfUnvestedRestrictedStockUnitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecurityDepositLiability": {
     "auth_ref": [
      "r659"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This element represents money paid in advance to protect the provider of a product or service, such as a lessor, against damage or nonpayment by the buyer or tenant (lessee) during the term of the agreement. Such damages may include physical damage to the property, theft of property, and other contractual breaches. Security deposits held may be interest or noninterest bearing.",
        "label": "Security Deposit Liability",
        "terseLabel": "Cash security deposit received"
       }
      }
     },
     "localname": "SecurityDepositLiability",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SegmentReportingPolicyPolicyTextBlock": {
     "auth_ref": [
      "r170",
      "r171",
      "r172",
      "r173",
      "r174",
      "r175",
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for segment reporting.",
        "label": "Segment Reporting, Policy [Policy Text Block]",
        "terseLabel": "Segments"
       }
      }
     },
     "localname": "SegmentReportingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeriesBPreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Outstanding nonredeemable series B preferred stock or outstanding series B preferred stock. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Series B Preferred Stock [Member]",
        "terseLabel": "Series B Convertible Preferred Stock [ Member ]"
       }
      }
     },
     "localname": "SeriesBPreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r95"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Stock-based compensation expense",
        "totalLabel": "Share-based Payment Arrangement, Noncash Expense, Total"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Noncash Expense [Abstract]"
       }
      }
     },
     "localname": "ShareBasedCompensationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of service or performance condition required to be met for earning right to award under share-based payment arrangement. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights",
        "terseLabel": "Vesting rights"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r372"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsToEstimateFairValueOfStockOptionsUsingBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "terseLabel": "Expected volatility, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsToEstimateFairValueOfStockOptionsUsingBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "terseLabel": "Expected volatility, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsToEstimateFairValueOfStockOptionsUsingBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "terseLabel": "Risk-free interest rate, maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsToEstimateFairValueOfStockOptionsUsingBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "terseLabel": "Risk-free interest rate, minimum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsToEstimateFairValueOfStockOptionsUsingBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsToEstimateFairValueOfStockOptionsUsingBlackScholesOptionPricingModelDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Number of additional shares reserved for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "auth_ref": [
      "r354"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized",
        "terseLabel": "Number of shares reserved for issuance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "periodEndLabel": "Number of Shares Available for Grant, Ending balance",
        "periodStartLabel": "Number of Shares Available for Grant, Beginning balance",
        "terseLabel": "Number of shares of common stock available for grant"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number",
        "terseLabel": "Number of Shares Underlying Outstanding Options, Shares exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r361"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price, Shares exercisable"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r367"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r364"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Number of Shares Underlying Outstanding Options, Options forfeited or cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod": {
     "auth_ref": [
      "r362"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Net number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures",
        "terseLabel": "Option granted",
        "totalLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures, Total"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Number of Shares Underlying Outstanding Options, Options granted",
        "verboseLabel": "RSUs granted (includes PSUs)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted- Average Grant Date Fair Value, RSUs granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r377"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Outstanding"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r360",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Number of Shares Underlying Outstanding Options, Ending balance",
        "periodStartLabel": "Number of Shares Underlying Outstanding Options, Beginning balance"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r359"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Weighted-Average Exercise Price, Outstanding ending",
        "periodStartLabel": "Weighted-Average Exercise Price, Outstanding beginning"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r368"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Number of Shares Underlying Outstanding Options, Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price, Vested and expected to vest"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Percentage of Outstanding Stock Maximum",
        "terseLabel": "Percentage of additional shares added on outstanding shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r349",
      "r355"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutedNetLossPerShareDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsToEstimateFairValueOfStockOptionsUsingBlackScholesOptionPricingModelDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted average exercise price",
        "verboseLabel": "Weighted-Average Exercise Price, Options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price, Options forfeited or cancelled"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Weighted-Average Exercise Price, Options granted",
        "verboseLabel": "Weighted average exercise price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche One [Member]",
        "terseLabel": "Share-based Payment Arrangement, Tranche One"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche Three [Member]",
        "terseLabel": "Share-based Payment Arrangement, Tranche Three"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheThreeMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period.",
        "label": "Share-based Payment Arrangement, Tranche Two [Member]",
        "terseLabel": "Share-based Payment Arrangement, Tranche Two"
       }
      }
     },
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r351",
      "r356"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "auth_ref": [
      "r352"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of vesting of award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage",
        "terseLabel": "Option vested percentage"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r353"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Expiration period closing of the merger"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r371",
      "r387"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Term",
        "verboseLabel": "Expected term (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationScheduleOfAssumptionsToEstimateFairValueOfStockOptionsUsingBlackScholesOptionPricingModelDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "auth_ref": [
      "r377"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value",
        "terseLabel": "Aggregate Intrinsic Value, Shares exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-Average Remaining Contract Term, Shares exercisable"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-vested options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares",
        "periodEndLabel": "Outstanding, December 31,2021",
        "periodStartLabel": "Outstanding, December 31, 2020",
        "terseLabel": "Outstanding December 31, 2020",
        "totalLabel": "Outstanding, December 31,2021"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of non-vested options forfeited.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares",
        "negatedLabel": "RSUs forfeited",
        "terseLabel": "RSUs forfeited"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of non-vested options forfeited.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted Average Grant Date Fair Value, RSUs forfeited"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of non-vested options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price",
        "periodEndLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price, Ending Balance",
        "periodStartLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price, Beginning Balance",
        "terseLabel": "Weighted- Average Grant Date Fair Value, beginning balance",
        "verboseLabel": "Weighted- Average Grant Date Fair Value, ending balance"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-Average Remaining Contract Term, Outstanding"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r369"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Weighted-Average Remaining Contract Term, Vested and expected to vest"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r357"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Total fair value of options vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options vested.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares",
        "terseLabel": "RSUs Vested"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockbasedCompensationSummaryOfRestrictedStockUnitActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average grant-date fair value of options vested.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant date fair value of options granted"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "Shares Issued, Price Per Share",
        "terseLabel": "Issuance price per shares"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "Shares, Outstanding",
        "periodEndLabel": "Balance, shares",
        "periodStartLabel": "Balance, shares"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermLeaseCost": {
     "auth_ref": [
      "r546",
      "r555"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesSummaryOfLeaseCostsAndOtherInformationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of short-term lease cost, excluding expense for lease with term of one month or less.",
        "label": "Short-term Lease, Cost",
        "terseLabel": "Short-term lease cost"
       }
      }
     },
     "localname": "ShortTermLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesSummaryOfLeaseCostsAndOtherInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r105",
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SoftwareAndSoftwareDevelopmentCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Purchased software applications and internally developed software for sale, licensing or long-term internal use.",
        "label": "Software and Software Development Costs [Member]",
        "terseLabel": "Software"
       }
      }
     },
     "localname": "SoftwareAndSoftwareDevelopmentCostsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosurePropertyAndEquipmentNetSummaryOfPropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]",
        "terseLabel": "State"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r25",
      "r26",
      "r27",
      "r110",
      "r112",
      "r141",
      "r142",
      "r143",
      "r146",
      "r148",
      "r155",
      "r156",
      "r157",
      "r205",
      "r259",
      "r264",
      "r265",
      "r266",
      "r270",
      "r271",
      "r296",
      "r297",
      "r301",
      "r305",
      "r313",
      "r510",
      "r702"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfNumberOfSharesOfCommonStockReservedForFutureIssuanceDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfChangesInFairValueOfLevel3FinancialInstrumentsDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureRelatedPartyTransactionsAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r2",
      "r51",
      "r71",
      "r72",
      "r73",
      "r121",
      "r122",
      "r123",
      "r125",
      "r134",
      "r137",
      "r154",
      "r209",
      "r313",
      "r321",
      "r383",
      "r384",
      "r385",
      "r427",
      "r428",
      "r494",
      "r521",
      "r522",
      "r523",
      "r524",
      "r525",
      "r527",
      "r670",
      "r671",
      "r672",
      "r720"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockholdersEquityScheduleOfOutstandingWarrantsToPurchaseSharesOfCommonStockDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r121",
      "r122",
      "r123",
      "r154",
      "r606"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheetsParenthetical",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficitParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of preferred stock and warrants for common stock issued.",
        "label": "Stock and Warrants Issued During Period, Value, Preferred Stock and Warrants",
        "terseLabel": "Redeemable convertible preferred stock warrants issued in connection with issuance of Series B redeemable convertible preferred stock, net of issuance costs"
       }
      }
     },
     "localname": "StockAndWarrantsIssuedDuringPeriodValuePreferredStockAndWarrants",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r26",
      "r27",
      "r313",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of common stock resulting from Employee Stock Purchase Plan, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesIssuedForServices": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued in lieu of cash for services contributed to the entity. Number of shares includes, but is not limited to, shares issued for services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Shares, Issued for Services",
        "terseLabel": "Issuance of common stock for cashless exercise of warrants, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r26",
      "r27",
      "r313",
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Number of common stock shares sold",
        "verboseLabel": "Issuance of common stock related to financing, net of issuance costs of $823,940, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfEstimatedShareConsiderationOfCombinedCompanyParentheticalDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationScheduleOfSummarizesPurchasePriceInMergerParentheticalDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r26",
      "r27",
      "r313",
      "r321",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Number of Shares Underlying Outstanding Options, Options exercised",
        "verboseLabel": "Issuance of common stock upon exercise of stock options, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r51",
      "r313",
      "r321"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "terseLabel": "Conversion of shares of redeemable convertible preferred stock to shares of common stock in connection with the Merger"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r26",
      "r27",
      "r313",
      "r321"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of common stock resulting from Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueIssuedForServices": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued in lieu of cash for services contributed to the entity. Value of the stock issued includes, but is not limited to, services contributed by vendors and founders.",
        "label": "Stock Issued During Period, Value, Issued for Services",
        "terseLabel": "Issuance of common stock for cashless exercise of warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueIssuedForServices",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r26",
      "r27",
      "r313",
      "r321"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock related to financing, net of issuance costs of $823,940"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r51",
      "r313",
      "r321"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Issuance of common stock upon exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]",
        "terseLabel": "Stock Option"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationSummaryOfStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares authorized to be repurchased by an entity's Board of Directors under a stock repurchase plan.",
        "label": "Stock Repurchase Program, Number of Shares Authorized to be Repurchased",
        "terseLabel": "Common stock, shares repurchased under stock purchase agreement"
       }
      }
     },
     "localname": "StockRepurchaseProgramNumberOfSharesAuthorizedToBeRepurchased",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r27",
      "r31",
      "r32",
      "r112",
      "r186",
      "r205",
      "r510",
      "r568"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders\u2019 equity (deficit):"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "localname": "StockholdersEquityNoteAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r111",
      "r297",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r309",
      "r310",
      "r312",
      "r321",
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/DisclosureStockholdersEquity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r322"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Reverse stock split exchange ratio"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_StockholdersEquityPolicyTextBlock": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for its capital stock transactions, including dividends and accumulated other comprehensive income.",
        "label": "Stockholders' Equity, Policy [Policy Text Block]",
        "terseLabel": "Reverse Stock Split"
       }
      }
     },
     "localname": "StockholdersEquityPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityReverseStockSplit": {
     "auth_ref": [
      "r323"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of the reverse stock split arrangement. Also provide the retroactive effect given by the reverse split that occurs after the balance sheet date but before the release of financial statements.",
        "label": "Stockholders' Equity, Reverse Stock Split",
        "terseLabel": "Reverse stock split"
       }
      }
     },
     "localname": "StockholdersEquityReverseStockSplit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureBusinessCombinationAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r548",
      "r555"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesSummaryOfLeaseCostsAndOtherInformationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "Sublease Income",
        "negatedLabel": "Sublease Income"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesSummaryOfLeaseCostsAndOtherInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "terseLabel": "Subsequent Event [Line Items]"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r528",
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r528",
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]",
        "terseLabel": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r528",
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r528",
      "r570"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Subsequent Events [Abstract]"
       }
      }
     },
     "localname": "SubsequentEventsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for reporting subsequent events.",
        "label": "Subsequent Events, Policy [Policy Text Block]",
        "terseLabel": "Subsequent Events Considerations"
       }
      }
     },
     "localname": "SubsequentEventsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventsTextBlock": {
     "auth_ref": [
      "r569",
      "r572"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.",
        "label": "Subsequent Events [Text Block]",
        "terseLabel": "Subsequent Events"
       }
      }
     },
     "localname": "SubsequentEventsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSubsequentEvents"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]",
        "terseLabel": "Sale of Stock"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureAtTheMarketATMOfferingAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureOrganizationAndNatureOfBusinessAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSubsequentEventsAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental cash flow information"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "auth_ref": [
      "r417"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Tax Credit Carryforward, Amount",
        "terseLabel": "Tax credit carryforward, amount"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by specific tax credit related to an unused tax credit.",
        "label": "Tax Credit Carryforward [Axis]",
        "terseLabel": "Tax Credit Carryforward"
       }
      }
     },
     "localname": "TaxCreditCarryforwardAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "auth_ref": [
      "r418"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The name of the tax credit carryforward.",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "terseLabel": "Tax Credit Carryforward, Name"
       }
      }
     },
     "localname": "TaxCreditCarryforwardNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r423"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income tax expense (benefit) for remeasurement of deferred tax from change in tax rate pursuant to Tax Cuts and Jobs Act.",
        "label": "Tax Cuts and Jobs Act, Change in Tax Rate, Income Tax Expense (Benefit)",
        "terseLabel": "Tax cuts and jobs act of 2017 change in tax rate income tax expense benefit",
        "totalLabel": "Tax Cuts and Jobs Act, Change in Tax Rate, Income Tax Expense (Benefit), Total"
       }
      }
     },
     "localname": "TaxCutsAndJobsActOf2017ChangeInTaxRateIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquityCarryingAmountAttributableToParent": {
     "auth_ref": [
      "r259",
      "r264",
      "r265",
      "r266",
      "r270",
      "r271"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount, attributable to parent, of an entity's issued and outstanding stock which is not included within permanent equity. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. Includes stock with a put option held by an ESOP and stock redeemable by a holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Carrying Amount, Attributable to Parent",
        "periodEndLabel": "Balance, temporary equity",
        "periodStartLabel": "Balance, temporary equity",
        "terseLabel": "Carrying Value"
       }
      }
     },
     "localname": "TemporaryEquityCarryingAmountAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TemporaryEquitySharesOutstanding": {
     "auth_ref": [
      "r24"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of securities classified as temporary equity that have been issued and are held by the entity's shareholders. Securities outstanding equals securities issued minus securities held in treasury. Temporary equity is a security with redemption features that are outside the control of the issuer, is not classified as an asset or liability in conformity with GAAP, and is not mandatorily redeemable. Includes any type of security that is redeemable at a fixed or determinable price or on a fixed or determinable date or dates, is redeemable at the option of the holder, or has conditions for redemption which are not solely within the control of the issuer. If convertible, the issuer does not control the actions or events necessary to issue the maximum number of shares that could be required to be delivered under the conversion option if the holder exercises the option to convert the stock to another class of equity. If the security is a warrant or a rights issue, the warrant or rights issue is considered to be temporary equity if the issuer cannot demonstrate that it would be able to deliver upon the exercise of the option by the holder in all cases. Includes stock with put option held by ESOP and stock redeemable by holder only in the event of a change in control of the issuer.",
        "label": "Temporary Equity, Shares Outstanding",
        "periodEndLabel": "Balance, temporary equity, shares",
        "periodStartLabel": "Balance, temporary equity, shares",
        "terseLabel": "Number of shares outstanding"
       }
      }
     },
     "localname": "TemporaryEquitySharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfRedeemableConvertiblePreferredStockAndStockholdersEquityDeficit"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TenantImprovements": {
     "auth_ref": [
      "r657"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of improvements having a life longer than one year that were made for the benefit of one or more tenants.",
        "label": "Tenant Improvements",
        "terseLabel": "Tenant improvements"
       }
      }
     },
     "localname": "TenantImprovements",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r196",
      "r197",
      "r199",
      "r200",
      "r201",
      "r286",
      "r311",
      "r485",
      "r573",
      "r574",
      "r575",
      "r576",
      "r577",
      "r578",
      "r579",
      "r580",
      "r581",
      "r582",
      "r583",
      "r584",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r595",
      "r596",
      "r597",
      "r598",
      "r599",
      "r600",
      "r601",
      "r602",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureMarketableDebtSecuritiesScheduleOfMarketableDebtSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [
      "r0",
      "r1",
      "r2",
      "r3",
      "r4",
      "r124",
      "r125",
      "r126",
      "r127",
      "r138",
      "r187",
      "r188",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r258",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r425",
      "r426",
      "r427",
      "r428",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r512",
      "r513",
      "r514",
      "r515",
      "r516",
      "r517",
      "r518",
      "r519",
      "r557",
      "r608",
      "r609",
      "r610",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amendment to accounting standards.",
        "label": "Accounting Standards Update [Domain]",
        "terseLabel": "Accounting Standards Update"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r463"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureAtTheMarketATMOfferingAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r117",
      "r332",
      "r644"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "US Government Agency Bonds"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureFairValueMeasurementsScheduleOfFinancialAssetsAndLiabilitiesMeasuredOnRecurringBasisDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureMarketableDebtSecuritiesScheduleOfMarketableDebtSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r396",
      "r405"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "periodEndLabel": "Balance at the end of the year",
        "periodStartLabel": "Balance at the beginning of the year",
        "terseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r407"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Current Period Tax Positions",
        "terseLabel": "Adjustment based on tax positions related to current year"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r406"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "negatedLabel": "Adjustment based on tax positions related to prior years",
        "terseLabel": "Adjustment based on tax positions related to prior years"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesScheduleOfReconciliationOfUnrecognizedTaxBenefitsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnusualRiskOrUncertaintyByNatureAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by nature of risk and uncertainty, for example, but not limited to, threat of expropriation of its assets by a foreign government, rapid technological obsolescence in the industry, risk of natural disaster from earthquake or weather events, and availability of or continuation of a labor force at a reasonable cost.",
        "label": "Unusual Risk or Uncertainty, Nature [Axis]",
        "terseLabel": "Unusual Risk or Uncertainty, Nature"
       }
      }
     },
     "localname": "UnusualRiskOrUncertaintyByNatureAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureLicenseFundingAndOtherAgreementsRelatedToCVRAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UnusualRiskOrUncertaintyNatureDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the nature of the unusual risk or uncertainty, such as the threat of expropriation of its assets by a foreign government, rapid technological obsolescence in the industry, risk of natural disaster from earthquake or weather events, and availability of or continuation of a labor force at a reasonable cost.",
        "label": "Unusual Risk or Uncertainty, Nature [Domain]",
        "terseLabel": "Unusual Risk or Uncertainty, Nature"
       }
      }
     },
     "localname": "UnusualRiskOrUncertaintyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureIncomeTaxesAdditionalInformationDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureLicenseFundingAndOtherAgreementsRelatedToCVRAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r158",
      "r159",
      "r161",
      "r162",
      "r163",
      "r164",
      "r165"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r547",
      "r555"
     ],
     "calculation": {
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesSummaryOfLeaseCostsAndOtherInformationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureCommitmentAndContingenciesSummaryOfLeaseCostsAndOtherInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_VariableRateAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of variable rate.",
        "label": "Variable Rate [Axis]",
        "terseLabel": "Variable Rate"
       }
      }
     },
     "localname": "VariableRateAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VariableRateDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Interest rate that fluctuates over time as a result of an underlying benchmark interest rate or index.",
        "label": "Variable Rate [Domain]",
        "terseLabel": "Variable Rate"
       }
      }
     },
     "localname": "VariableRateDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureTermLoanAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_VestingAxis": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Axis]",
        "terseLabel": "Vesting"
       }
      }
     },
     "localname": "VestingAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_VestingDomain": {
     "auth_ref": [
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Vesting schedule of award under share-based payment arrangement.",
        "label": "Vesting [Domain]",
        "terseLabel": "Vesting"
       }
      }
     },
     "localname": "VestingDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureStockBasedCompensationAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).",
        "label": "Weighted Average Number of Shares Outstanding, Basic and Diluted",
        "terseLabel": "Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted",
        "totalLabel": "Weighted-average shares used in computing net loss per share attributable to common stockholders, basic and diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfShareOutstandingBasicAndDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_DisclosureNetLossPerShareScheduleOfBasicAndDilutedNetLossPerShareAttributableToCommonStockholdersDetails",
      "http://www.adicetbio.com/20211231/taxonomy/role/Role_StatementConsolidatedStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 9
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6787-107765"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4297-108586"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4304-108586"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4313-108586"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4332-108586"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18823-107790"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(d))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(k)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6812-107765"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(4)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=SL124452830-107794"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=122038215&loc=d3e31137-122693"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1278-109256"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "55",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e2626-109256"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70229-108054"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70434-108055"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=6373374&loc=d3e70478-108055"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8672-108599"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8864-108599"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e9038-108599"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4428-111522"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4531-111522"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124402435&loc=SL124402458-218513"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26610-111562"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=124260329&loc=d3e26626-111562"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27161-111563"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=d3e27232-111563"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=123581744&loc=SL120269820-111563"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=123583765&loc=SL75117539-209714"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33775-111570"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(b)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)(4)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=123349782&loc=d3e5879-108316"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "340",
   "URI": "http://asc.fasb.org/extlink&oid=6387103&loc=d3e6435-108320"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13777-109266"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=120320667&loc=SL49117168-202975"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13854-109267"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226317&loc=d3e202-110218"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123364984&loc=d3e1205-110223"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=123351718&loc=d3e2420-110228"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=27011434&loc=d3e125687-122742"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14615-108349"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=123368208&loc=d3e12565-110249"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123465755&loc=SL6230698-112601"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S65",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359872&loc=SL124427846-239511"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(C))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "http://asc.fasb.org/topic&trid=2208564"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(CFRR 211.02)",
   "Topic": "480",
   "URI": "http://asc.fasb.org/extlink&oid=122040564&loc=d3e177068-122764"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=65888546&loc=d3e21300-112643"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21459-112644"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21553-112644"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21484-112644"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21488-112644"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21506-112644"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21521-112644"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21538-112644"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.C)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130531-203044"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123360276&loc=SL49130532-203044"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130551-203045"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=123351226&loc=SL49130549-203045"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/subtopic&trid=2235116"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450702-114947"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(f)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450673-114947"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(8))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=SL79508275-113901"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "740",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120384911&loc=d3e23163-113944"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23199-108380"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420387&loc=d3e23221-108380"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=124434304&loc=d3e36027-109320"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123586518&loc=d3e1043-128460"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(4)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123455525&loc=d3e2207-128464"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123413009&loc=d3e4845-128472"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "44",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=123410050&loc=d3e5558-128473"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(4)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=120321790&loc=d3e6927-128479"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "805",
   "URI": "http://asc.fasb.org/topic&trid=2303972"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "808",
   "URI": "http://asc.fasb.org/topic&trid=5833765"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569616-111683"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4569655-111683"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5618551-113959"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624163-113959"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624171-113959"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=125515794&loc=SL5624177-113959"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123477628&loc=d3e90205-114008"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.28,29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19279-110258"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=SL6742756-110258"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14172-108612"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL120254526-165497"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL121967933-165497"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123597120&loc=SL122642865-165497"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3(a)(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.3(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124435984&loc=d3e28555-108399"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(Note 3)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123403562&loc=d3e38371-112697"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123415192&loc=d3e39927-112707"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123406913&loc=d3e41502-112717"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=123406913&loc=d3e41502-112717"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123341672&loc=SL77916155-209984"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918666-209980"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918673-209980"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918701-209980"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408481&loc=SL77919140-209958"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848",
   "URI": "http://asc.fasb.org/extlink&oid=122150657&loc=SL122150809-237846"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39549-107864"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39603-107864"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39691-107864"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "850",
   "URI": "http://asc.fasb.org/topic&trid=2122745"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "855",
   "URI": "http://asc.fasb.org/topic&trid=2122774"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122625-111746"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669646-108580"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=125521744&loc=d3e122739-111746"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=123371682&loc=d3e55415-109406"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154696&loc=d3e54445-107959"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e637-108580"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "926",
   "URI": "http://asc.fasb.org/extlink&oid=120154821&loc=SL120154904-197079"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61929-109447"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62059-109447"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62395-109447"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "33",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e62479-109447"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e681-108580"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(a)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "35A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(b)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=SL6807758-109447"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(1)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "235",
   "Subparagraph": "(c)(2)",
   "Topic": "932",
   "URI": "http://asc.fasb.org/extlink&oid=123377692&loc=d3e61872-109447"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "http://asc.fasb.org/subtopic&trid=2176304"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669686-108580"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.10)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.15)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.4)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62557-112803"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123599081&loc=d3e62652-112803"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "http://asc.fasb.org/subtopic&trid=2209399"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16)(a)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.1(f))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.10)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.15(a))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.5(c))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iii)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(iv)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.6-07.1(c))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=120401555&loc=SL114874292-224272"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "http://asc.fasb.org/subtopic&trid=2324412"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "210",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=120413173&loc=SL116631458-115580"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "450",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=d3e557-108580"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=SL120174063-112916"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r694": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r695": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r696": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r697": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r698": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r699": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r700": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r701": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r702": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402"
  },
  "r703": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)"
  },
  "r704": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)"
  },
  "r705": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)"
  },
  "r706": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)"
  },
  "r707": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)"
  },
  "r708": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)"
  },
  "r709": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r710": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1405",
   "Subparagraph": "(2)"
  },
  "r711": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r712": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Publisher": "SEC",
   "Section": "11",
   "Subsection": "03"
  },
  "r713": {
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Paragraph": "(m)",
   "Publisher": "SEC",
   "Section": "4",
   "Subparagraph": "(1)(iii)",
   "Subsection": "08"
  },
  "r714": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r715": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "848"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "848"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "848"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(01)",
   "Topic": "848"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124507222&loc=d3e1436-108581"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)(1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.1(e))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3213-108585"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3000-108585"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>133
<FILENAME>0000950170-22-003753-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000950170-22-003753-xbrl.zip
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M/G]W>/_LX_C3M=>Q1+#3)6JJJQ8(EI,]_]]?W^['PWSDR44ZI'QA*\QO#5_
M;SG[EYP/G3;DH_?'I\.+;T)[B]D7[7!"V<(S5<U8<F:^M2^Z$:>/,ZD)KG9S
M#3'@5A1OQ4]OY6,^3PR?*O@H5..6:?'9&#][LJ:>7)X(?'C%)*:3^JL3<,_A
MVR<__\?@Q\/L$_P[^'%238;Y9T;)7WY\WKW&3X_RQ+=BA>1_3:M//SUY.1Y-
M0-B0 YC.DT'LWOWT9)*_3)YW[/H<+_M\=MT?PSB=M%=*U:=!,SD9YI^>I*HY
M'OH3W,/YAR<__UA]>8'#<]V]K%+*H_8E#-BM?6R%595^>K+[#QLB%4HDHHS5
M1+HDB//,$A>$R"E2[[)[,ACY([C-C+XOWM?CF'-J=NOQT9NFF>(^VBLOQT='
MX]'^9!Q_G\WCR^1#+C##?X@BN"]6DAP9)])G2ER,C!2N.%.,&TF!EZ:CJOO!
M;__X;?\5K'I3O1A50UB+>IIA5L_/3^ K$PI>.)]2(88K2B2SB@0+I-2>*FY+
MD=30BQ/Z9=H >S4-3"& Y,6K[31-GC0[=07??,2)(IW@):B7*C<[1^/I"!XV
MCC^.JG_G=''"Q?!@E!=$& VKJJ,A@0M.?(#UU,Y3X_FJ)AP=C=HJ0Y(VALCB
M(FGGSX3C)D2I<KHTX9T8<0(-S"!7GWP8Y@]Y",HKO??U!.;W<EK7L TO3HNK
M((.P% CG"JRM<\0KYXDV624+J^QS6=6T<HG9"PX+IS/<*VE&@K29!!6"5T%'
M$<42=#PEVP1>-17P1/OQV\J':EA-3BY.4<?B);6!9*J <JDX> "O2,Q*^\A<
M3":L:HK6.LV$<$1GR6"7%(-3!"XQ-!D+K&AIN#C%EK^0Z7)Z-:UA9N]!$8W3
M7_UPFKN/=\?U/N "$'K-Q<D%&Z,I#':)8P&V"DS3)P%_X+WQ+#BG5\:'F0HO
M%,"@B'!(2LU!IFA/HK+*!6]@'<V5DSL<#X%*S6L0CY?) [_-P>M"'+6P9)9E
MX"D;B0E*L,P#ESRO:@94!2:X,$1(QY&Q%/*O(#8G[;634F@^GP%JG1<M+MLK
MOS6YDQ[?D ^)>\6*A)4'62A+DL0&PXFP0!0G,C5I981@UF>0KT"(2!T0(L*2
M<;@UCU;QY&60WE\DQ((L?U5] JX9I08VVOZAK_.K'(?PSZ4YW4;(CX=PJ?:J
M3P8IQ^K(#T'COWFW^^1GNN3T!&5:>@YPFPH),BG 4GH+6SQS&;3E011YCDIG
M&NM#3AFP$$@_D U@14PJ>/F^SB6#]$OM[/=&K[_D.E8-#/^;KP%[39J_59/#
MMV,_VOE8P\^O$)-K9;,92)V+$$E33#P07GP&$9(BL106(R2IG2HIJ53FLP<D
M]V(FV'?!_/'#OV=?OQXEM%IN-86?"0%*"S9_U-FC7?VDD66E8A  U0QL>9HM
ML?"$P+DV21\2IT4O/NG<"NL>M9-RN_#9[83:S[M__\I37MA.)5 G? "-4R3\
ML:" O$N><"<2 Q'CI+JD3<]OF584/Z1:83YQ"Y**4) E1,+"DR"4(H9Q224#
M1.+9Q2F ;0E&;(/,W?[[9G0=1'A(C&<!&A@&-)8>-KQ,(I)0K"6<9\%B*"FZ
M2Z!UUU=U2YJ],L-V$33,%7+L/I5D O2=%&PT1;,"D443<3 #D@/7E.; "KVD
M)'>&PW%$0K1R\Q<@5@)Q?9Q'38ML7G_!EY<V8/+>:QLH25;.R.,54"ME;9DS
M("W1A%K-K#@PB9; V\#J%H22LB0X38DQB3&8%JC_^%7R[*1_3IL)<OZ9Q'U(
M$D4OE4LF$>H,[#6 -&!/1$68R5(P8"S-U,7)'.2CXW'MZY,.Q+2$:O:F$S2Y
MT3=U<3Y9FU0\P#_' "9)!\0!, UHT%/0UZ"DDC#GYM.T5[RH,P>=6^"G)]67
MR8M_YWJ<?'/XY.?_^<\OG#+YP[+,58368"H!S4#X29E@3RJ5B'"4@S[A5F5]
M<<*O9@(0Q,CX*!_X+W-\#8+B7;ZD(.]3&I:L:)2@;0P8MT _ 2@N6S"/ !8!
M"DO.R=L(]+6:0N<U)W!2# "GB5 6=@?H=P([Q)$8J$J@_JDT;%%SO@:+9W+R
M$CBH]L,WHY2__"5? M++:4U**3.<*DN7TYY@V%IGC".9H=TK8.^$!%8IM8#]
MI37>7C;:]J>@6UJ5@WOG(=6*](#K@T[$,@9;Q18P.:D+I(!1X32 YN0N;97;
M(.7@LLPA@R41P6R7%-!&"""5=6:P3#QGRE:"E"\ ,!J=YRG 71$H>X %+LE
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MD#E8@=U9A -J.4I<28HP!((\!)_-IKN4%DJZ/DJ+C(<4LZ5@:1?/$+9S]#J
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M'+<D_'^0/N3K:6-M<PB6<4.,0X=;$1F,-1H(,V"S"4&35=LL\P<UIQ-EQ7B
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M$0TC')0ED(A%$CQ3!%A-,<IB4#T.R=Y&0#\H>ZMLM(HY $ 68%UC.11O%-Q
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M--O0OX+=#R:@'R9(3F@KJ-*&!"Q,):-FQ#/*"4]!."VE+J%W.K2GK=)6F5S
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MO.$HMX;C)AJ.!Q]VWNV_:2W$K?&X!3O?-!XGI])JT(4%MR%'5YHK:WOR=LW
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MU@_N"E4!/)Y<<LZ=K4>IT,0:G&00]/!4.-%7@)NQ=]Y L,[>?H;WR\>3[G%
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M$%AS8:3AZK];RGY!:'-*VP6BGG^LOB[>DY__ECOGHA\,JZ,*V75\C-F?B/,
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MR-* R!!8)HC^*',D&**040STJ64<4E*N99RF"WJ/(5@Q#+1-LTI)NA%UA16
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M1YD%DX:*40PTQ3D\2;P&_DBS?!5@ZPXI'0\(T7!+_Y:4*R-,#BH#16C <((
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M,HAE(;.X!%&6=/M[8NOL'?SG6:=Y?_!E8#:22A2Y= 9&7;.,!C$2C#E.9Y0
M!U=AI4NJ0TLHE)P\D(O#CK"I(#$PN:E[9(TX";10H/")F(#_4: >HG=,B<91
M7QB@*'?MWI*ZGR4%UW&BU8<7; \3;.@%@W=78%;:*-]FS#/X)#7B#N48)^?P
M3#L@Y\!BI!'/4 *MP=JI%#%KWP:]:QIP.,NFT]NU<<8\_[B<X<_]SO;VMC4J
M:$[B,"C H(CD3/(R< )SFIOET7PX*V)[XDW#(BFU6";JSQ(D0P'2:E@6LDI'
MFF ^)8OA>5,A]02M> %_C^-N7JK")BYH]F%E0AJ)V6/J_4*EOO#%H[VG>!QF
M#;#Q4&6A+OLB>9:G79PMC6-+X]DD@&>[9B3/G:6XK8EL%!+OB)9-:\4CPQ@&
M?L' [2];DF0Y/N/!.YG$LDL\N6I5I"30Z$UG9FWV!3F^ 59UC4F=_E,Z;]X5
MIE+L2G$-C99P$./@$1XF+$9 HYP88SVSF&&&ZB7FS1*<GDA#2K0YRN:?75'>
M<:^IB0PQ>4NWS-4,9KRC.PD95VWO_OF2A%E3::=ES+I*N[7RY7%K[?0J-D<(
M?9]RNYW>[N[!4?^HO[O7W][?.3KX2:KM3F%11LQ4#I90F1O)U ,M5)Z7LDN\
M9'YG/]^3/;1@;>@P43C+-8BM]ZH-GJ\LI_8\X7GBA_+$S2$95IA#J9ML AIL
M1E;*LF%R+#SA>\)O.>&?9-J919,R7!1I 19F2%8SQ>_(_/$2W!-RVPGY?8 U
MOTG(?8M S#JX[,:0V:O2D1SXR%0&Z*V,RMA.3L?($3S;4[RG^+93/-HLF>19
M6U+'>RD_,LN42<D A6,18B2N@3W8=*GE1RAK T>E"+L;@2X%/M:XNE3>8+,Q
M=:5@\D1@_909^=U4'RIM7)4\8HR=>&;RS-1V9GK%Z0B.QNL0%Q<) :,$L?BL
MXAA(?.O#[\_J\:_<R8:B3T /<#*A494A79<4O4^/IF<2SR0_RDMV-$A41=JY
MMRS&,+E(RND0$65!8SBE KH>CE/^13T[-Z4A0<9.([TT3U6DB^CX<0C12?PH
M;1=>PJ@N54;!R1I(K!/0C^QM0/=GRUGGR6\O%AI8."\Z>DX39VN[RQ4P5/5W
M33*4;W :_)%F>AQ4TQ<H?=$PQK!#B0R41A'F90*G9\I)*%1ID([XG*37"14=
M-N0\>/"4#>0[>!%!4< Y.S$<#GW"PD;<-H+KP+X1DMTF4XL^!&:/*I@A0V_8
MTV%*.H.<>RGKQT#KZ^+ZNI==7%_7%)\X!V3'9N'K0R"0=-HUI24Z[*03+<0!
MYG<NZ7?0I]'EI[7Y%?@<(=%68XQ'US#D7=OT![Z]5AJC2UXLCJYS;DOGT) O
MZZ"E6%&2;LA!/RU32:AFL;3KK9TVG[63F,LD#J-L/(&5ZAS8<DU6#:6U?*F4
M"FF@$D&8SU*<]I$)U235BA?LM5C*;$H:<3JO)BUAD\,R_LR%96AT4[HHXK:Z
M(%+886A B$4M &G?R;4+B9KB@:3P1MV33-V];C_0R@#=IC7JP^=()BYO(K%=
M:F'HOV.ZLFR'(W&#;F8,\CP-%1VSSL+%Z;5NY4<:C]5(PA90T$O*"RY;/K5"
M#$T[=?QQD]24S>LG7H:K5<F$Q0(.V0KU=^/4N$:&FSE5'*; !7]I]X<9GW.M
M:9GS<UM;9-'V9J$]WRSTX&8A;W^LJ7=/N$@7I L+BT ;FE2^]ONR21&6&4H$
MMDMK-@4J6!"=#,_:6'6R)I"8I%BHI\6J%KX84\3:"9RW@/:P"22.*)#(,H;4
M)^I>5C3FB1R0P5*36+*6GF&EBJX^P9*Q.P<NN4*ON?;&J8V9P/'#]R?IE,KT
MC+QS:R%LV0J)UG2(L+B\;.VF:#7J.K1NP6[#&5%'#!8<3U/8M;ZI7,-+I$F\
M,!WW(IP$=(X9M3OGJ%FU^QQ306*X*.0Z3:97-Y*!AFT8L3-^EPIE7#OK!E;"
M=1V!SG\M],7*3D,!I&5AJQG9& 7Z0M01BZ(7+SKUIEX-%)!/L-G'+:8R5U8S
MQZBN\S:2-2M!(\9D,$=2@M5F4Y=TTR@R<LU'6($(;A8672]67PEV .*EX7GE
MMEK ICR=2D]]H5TVABP#;D3Y\L_>-G??2LE/NG#5ZZM?J03\[3O0(XEX*4-)
M>G6_(P;;@WZ'056P-9$B/@B<8P 5U=1QW!%]PE9LPB^I C-"S"Z9PP?86R>4
M11:4Y"#S@D@H@D"\EI%%8-"PI$&%R5!Y#F"XH[-!3\_KE8 5HH21;K#/-(;?
M:;<"$=E5S#!, 6P 57*6SA45*IIL1C7)FD%6\,3TK5FD)[PYT)/@G<%F,+JW
M$3+/\^L-E<W-/0[HPTI=7MK<S6-0/[AK@&S"JFE@AKRW-/M<$QX2HH:7TL ^
M\'EL&HJR<BRVSCZ\?&;Z9]D\,_6R0&X[Q"#PPYZGNPVFNY.<$'4X7UK#(F.)
M=BY)HL$_08;#"T)9$A90KONNM^P'GHE9F>4E1O<HGB6",= MB7?M?2@DG#[(
M]>JA$QVC36<F",/X.C=,_Q09;E>#10L-UN@X8ZLL8I%M3,"F>AO#TZF9"=7<
M=>XH8^-4E?XV*(>+HG:>0A4QNRY9N@!S%L-["X8*&RZJ$^B),PHSHH)%E+SE
M,%^]09!6)J.5=3% $CA4C$M)0&#V])?N\1H=BB&.*1O^04!VJ5D9;HP72W/*
M4G>5H)G_ 18Z^@F#0]+, _<>Y1=<"MGI> CV?$%T4)Y$?@%AEJ/BUK>'/?S<
MN\7A:@?VVX5=T@"+ZS;3$:"9T;3(-9:21@^LSO][M:<_%D2$<9]>Z-YU_O?N
M\07/-P?#[,2<1067T.9-/OG-V%KKH:>\!KE+T%5-QR+/PK\_@1_ZVX.CP]W#
MP\.K[=X?L_$3=)B;_V"BB)0<WC_LS[X<ZZ7M#/ ?& (UX<%?-MY\'T_UM1IC
MMJK?$QKEY*O\UA8U2;8,Y>P;HE&UDY#0]-?B?=%B0=1Z4Q;/,26;A@($)@>*
M9@%&0JA JAEUHT+9N#TZC\BD24@/Z(G?Y4+(6 ,$Z[;K7%^E[3]TY][[WCQ?
M8=5.*72:\BQ"<MX(,$8V5L4@F>M05*/9UA9: *O.QCE3$PQUH Y,AW-#?%0M
MY>_N$<C$."@^)^!*I#FP3\0E*A0JI6]R?8GQ]_ W' .%Q8Y3](-(@NF129@.
MTLX0[D1F^43-*"E2(?(XT5O*,=$BEJ PEF.Y!#&!?CN&'X=9"H?4>.LHP&B-
MTQ+<0RR3 ?_1]F;BPOW8ZH>1Z[ZO7GB$L=5><WK-^0,UITJ2=&XR_AQ9-W'%
M)A"P."@(3XBD\)+WV$8R>?(;Y:UX2@!I)V?O6EVLR5$8H[DJ6[SM4$K*,$JE
M$Q]RKM(R!XU<*5,-.L>=<S2>Q]2/F#G)7*W).I>?AQH4\>9$Y0C0GK"JL"P4
M*5HG&(GZM "%ZB#-=*K"5?,():N1!?7?VGD-I-)!59H4'^/0<66C@SK'<YY7
M\X46U&GE<'OBA.9%@]\!BX2WZ4_>D,"U1QSK\N>E 7;ZP*KCU=4LNKZ9IB3Q
MSU4$7,,5PK]Y8'N3$9%)@Y=/U99X8?8=-@?+Q<I8K -[G2J"H*\EM-K,($TA
M75C^7,W3-B\;C.4 J'V12[>@=U+"WW0%[SKSSJMAKX;;H89??9G%J5H>S$3Q
MFK(PP#'UAM-VLR2HI0E*_NM*X>H:>%O>HG-X.74$JKG1;ZNB?[D^KM;S8L9T
MF,P@"&;C<T8ZS8JG-BT)^'"PVYVD%&K#ZDR-^#7B$52C,B=0P^"6ZA?2MH19
MNG0CSLR3>E5";>7HD%=WFLL"M3%I\:K,$;SG:SW/":N5Z/)K+2@8_0/5SB69
M&/ @<$6FESL=86!+&37^(L%]C6_N3O)RU,O1ULM1*E<F[%$,EW.],!;<Q0C*
M7'*Y TTB:+T E2S47#<E&(^I>I%09\P.U_DB;&VC8)I*,%@C=F%,*8E3D%&U
M'!*\(LB8)C_(^CYNW;4V@;M#Q1B048I(ACG714RQR:RA(J+Q.CI4!V%*"-I\
M.4UV\G+) T5"S]Q]?MH(LK-E&5]1^-#6H&G+4Z<O[#HV+.?>C@-LXL*3!.O[
M*#5RQ@V3IRC8+CETX//3#VHA0S,=3,\%^-<:6W:D9$S0PIP-ZMHP&59&ZCQ<
MA-6-W"!:G_.PDGLR@Q_.EAX62?"-%EQJJ=M@\T6.(URJ]G/04MAP*PCJ(,2:
M89[($*NIHB8F\_"/B<7HQ+@3)2:*2893#LDZ7]X)F/)IC/8P!^ J!%WZNDZ?
MFR?65L>%FT69)3I.-J4QMS0DE#4C.WH=;I#B3G:K?QDV!?3HN1Y.B*@07 +*
MDZ/UF%<]$<(6?%;=##AD- TB$Z2[K'5@Z1YVV&5D.R$(BCB7;E*N&HCA.B(S
M;%7&%KHZBF^'R_H[-"IU;/&*T3+(N>E0A^8(CT"SJ<6+*6C2:NZLE4+2!<]3
MRB5.T^QH+XA<JJ"P@RR6OU5=.Q$9/1F[(ZI7PEY3,D4P$AC+:$S3+F,]#;3F
M_N1F$"7&\<"\@0=3;G45)L'Q>9TQE-@!MAZ](=>!0@K-PHOF/"X;=MCX>2JN
M)S(@2D<:',7!-4<@W5ZY3G/??H36HRFXY9M?:F/L6!N0V^^:ZDC W:58\80&
M%ZP<@Y>S#RII!UJI&HEV^J:3:(3D>OJR?]1U.I:::(3(@\:]6F=> XR]?GG2
M+'I?Z!9'/;LB?RZ"+SAW#*,*B/JMXC26)7Q&;/T/-B1E1?"?_]$_V#WF&3D@
M1;^4U<>#LK ?OY3X:9R.UM_;@8]77@>LZ7<X0EV:WQ' B.*-HDJ'"QSF$DI;
MIL^_?G:,: 3X"C"IS?-_7TPS%4ST:CKUYW](YU@BSS!1(E9Y6BT2""4P#WF1
MR460_*7,GFH/^0?H VU!4/N 714N^ 7VVZ:Q>+] V77Q9ZF&0U-2^:PG3@@[
M'8^[W^]73<DD@Q&0!44# _\LW4!';+U\]^*4!@L1"(3&B:B?/@_#J<-5T#21
MJI+,M'T)FJD#5WTX>"JN03W;_F1Z[M[NTUK;-"L9+2"66\@TQ@>V1 L:O1.$
M("BP VTN,ZI 68:W<$-78!? 69EAV1W^0'^G_GZ,&69(!#3> ,<,BAU,4N$[
M480O"AS638-YN81^D419JKO&!X=?];!$EIDNJ^$U$;8&7MK2:=.-K!PW=SC9
MET58?!?94B1GJSBEB;2QY3S6>P[,YO4D!1E.+1BPI-B,/I;\+OX3S37GV"15
M"&KRT*^,5$X' HP_MHW5N@W0=D)I]!E,89DUZ8E-/"F"^N_MM')W*).#4%/9
M*B8SAS-9@-VUON-0KY.8JST$N_JS)3U;S8[B-YC)";E5K_56<.1V#/8:Q$6S
M9SH'*H:J*J$J<)CU,A-/%E$;)QPIA2>"D1.;3![;<\OA5>=I=L26Z0NJS=)
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M]\ ASQLP_, 878OKA]9!AL4J0=.@)#=ZL#0L25LGPS1:,."@,4PB3B>6*I_
M.Z2=+E2QYX*B#R66M7+3*9=*\5&[GP6-GYJQTOPJ-#0,Q^+PRV!*T^><[R32
M#H4"$P'X="&CI@/0$95J)A-7=H'FS\ML%& 5N9X#A657^K0(WBZB(4\&C9"]
M('RP'@:%>#R4!N&0"GPY=R0/.W TAPG<^>K2=#E1!Y>Q) 1K:LDD7?0OB9/!
MXX)KD3D'=2J?CY 3@7C 3:&$;Z&T1<9F_1>Q]?[MJ1Y#!3^98$=.XE8O@!]9
M0XVR0Z_(?+=R!/PM%9!93XEP'EB54AUAI.8J*H/JT",S80I?:Y$E7K)!JNE
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MJ&N$/8E[$M\$$L=N6:J#IF95T 3AK2CJ.-F9)]XA"I2;:.(:<>HR3UQ<=Y^
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MK,8+YUEFL(#7+T_00[Q412S%H*_SL.(TC:A.[+6,:*/G<FRC*5NGK\_A!9]
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MP/0O# "A^W$RZJRJ!^T.:IH8(-7EMG3YN:';6A8,]1S5YA*$*A)_7:MU3&6
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MEK86 ;S %+, -3V&E!*5F1GA6ZDUT.3UX!H]#%Z.?B0LAAD5=ARZ-J/%BJ.
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MZ:,' N"-/Z9]O<%#-V%;TAEIJP!8N,83FU5>Z%:\3GJ+);R(1[X__9YOSYN
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M:0]C_VVU-&,;<5X-1F?EJQ,$0W(@^&VB[>%"P8K$]J'@?#X$9H0VC>,RFA5
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M>38C+0M"<UH=N:PZ,E![#G9-XO-R)SNSKD]*'(2$=SI$(OVWV/<Z06AE75S
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MKQ*"I/5*(H374RF+Q'%/38PRZD-G87C;XH:=X:_24.(\_]L\;D^WO!]/%Q0
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MUAJ.F;V@3E!U 92L !D1KO>$^NA(3K*JT;K1& 3.:-42%A$FF]15Y5FRLF@
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MC3LX6FKF;Y+\$K(D$7VE-QX5%X":_%J0K%QNCO+)23[CR%!2_HFF]HJ3D7L
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M9QY5+ITM(G^:"G2?R?8Y/C;9Z"YGZZX<5V+.78Q"7#I9Q5<MY^Q>!3*)8G-
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MG/FM2D?RVV;XI,-O4U&;L:U:Y2'M(2MC<MOR9GE^G:PJPS:^4%OQ15IAMO8
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MQLH9":&SQ_'>4EE[*G$XBF6:Q*"BM"S%XH[I]^@=\(AG+DGI&Q '1NZ]]ZN
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MWMF-P<K[;X]F=S0H'\<IFX;#P ^CX[\=1^>I?%=M(H)*]LI^J\&CY"B:J0N
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MBAEH;B#F/RBW:_2X?*E!:6%8V(AZ;=5%TX+P3[L%5^41(274<S"#T,\U?6#
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MT!AW<A4-C9268[&,1D0/43:1%1?EP8:.L'7^%_GFV=V=J./=6^_UW@,JGXZ
MRG\1C=Z_=5AT%O*'B9# Z#C>A;O5-*%>E^N-AD@GGSE2 ?IBS+R&KK>CCA1(
MYU6SAB:"# 8,5)8D0D;WK2,1Q+*_^?F5?' JKVIV[*B'^>2R8GU$"7 6S8S:
MP2!=TF-?_1KE.+Z*)&I.^BO371IC&]63F.8I+MB83%>/?&:!S&P"8^/UYGG5
M(?W1)2VU(44%!U#YMM4%WI'F#N_L.#X**TO6%;%DQU#2E!.AAVG''NL-&H'*
MKTV!D9E\\78^C[WC))UW94X%P64>85#*K4*QX=')%\?_SWDK9O-^'_XC@ORN
M,_AS?6A[ND3S/ =BR*_/71Z,;)N41;B^;+!J98.6E$_I)"A"V4:3KMEN796R
MS^:.6)QK;>A4MJ)LOF_]4U/]>__7<NGVJF)=DHU2>MNC&V^K&P$)5H^7:G*3
MAIN^B7QWG=WF^7";O$U)%=6C7^!AVFEO'XL;6:#W9V_X#^)O'HX;['_$!GN^
M6I%BMB1C7:*2^%VH<>)+AQ=4Z4R5A;+=HW%A0Z)\"40WGO:#I6]J^PL.IPFM
M.OY\<B3NS-$7QY/3S2UN3/8+]#8 [,_$QF6AI#V40='4G\=8>KMK;7B[4H%K
M[F>VJ&/6-+)7XL9'QR>/GS[2"W;Y'DV'[QN#_XO@_+H\IR1G%7OL456XOCXN
MN)WD L=R 8ODTXG8M,4\4E/\5'3SXA^3'Y;-N8S]A;("QK.UVZW$;PR5\M.S
M[]X<>PU[W*O_$_8J4IW7;.AEY=1JU+*"/:_&]02,"NFLY"B:*9NAY;SP5YXN
MH3N'HID'2%>"Y]4'.Z+&)VO]5!./KR@LAC7\O3P4*#W_IJ54I#",N?L#!L;M
MCO9BBH-$Q%QA#*VHXY;MQN6$JC91.^7YWEK*C"C2%I[O>EGL]JX;$H8'AS;-
MQQ4)C;1$>?,,6,=28)HF?1D;<:R9MV)?1+%?I6!^6+[4.#$?DCDFRH;/G*.@
M>SQYW2S+Y<X!RN+Y5R63UM9H=\O9;LM%V7HGTON?BN]UO09E:\H@+3O[BZ??
M3/'?SYZ03//U"S-7G?+8<CTE\KV$$?/FAE_9FRZG]BVG2OJ^ \YX&M9MD%I'
MH;_=3/W40H4*"MV,:-QZ)KTV1-2Q.J2;Q]H,]2QP9L_X<2XH^WWW 1/[;^8\
M_;NK&OR>?,RI BZ68S[F8X5ZLBN?([=;B]M3S.= ],,P''"D,C/5979J.OG?
M6['R)62E!O[^OZ>3,\NE]__Z);X<:X;EN\OJG'5$L?WO=A8/1D0K(2N1H[2
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MG<U(&"Z:3+!6WE4K10G_QU=/CQ\'=9' <9V-*4L=?6\@*Q7O5GC"'BL!GRN
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MK!Q[835:(]UI6W]D$,Z=YV8$X=Q-IE2!RP,X$_?H+:(NM6=3%L>>?J@U=1L
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M%0=-'NE%*+2<RB(5C_C!=R\.)J#PB2HY[_$NL?1<Y"ZTY;*MA-ZO,BJ5'^J
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M>-E<3P"#\A8'K!^^*CD^;7B.!7!0VUCIOQOR,.*VA\KWM*"6!M <@9'%WN[
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MT3U*(M+K6X1P*>YW[X)2@D@CQ+6E^H2!&;IQERV!4MLFU"1\P(EH^HQQ^4&
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M@4=+9!RH3,XG$;8("8^-= +AT$@/16WQ73@<841N$W::A4!K$N3!3J%8$S,
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ML"??F-L'JGAV$ZE[X^3K48Y#>O-&8U2A V7+4-SPL$0?(&UHLE[)JR:6.[(
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M4O@\20H2$94T..FKY.>\ X[4;EC>FC2Q$Z2 CZ";@)I?_-BT!!$Q7-.6)GU
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M#P<\?A!!H(7 GJI=[U^T6%9&586'(%86?1+KFM@Q1=U!<E/0WND/L>/D7%2
M.#I'(]W%JNCZ(+@^%4('A:L/N.JL*6ZCUPQZTXJAC44N2IP2;PE3 ,S<RP64
M-#R+71&U*HU+*QG70']C_5><];4_Z/W"K#;9#U;/O)+FUPUR"Y%4DI8D*+#
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MO7/1H9=P8,QAU96<5%J/@W5;?!3;0AG'MA2S,L0V,M K(X!PJ1CX^LGUO5*
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MU7.^475ZPKA-)"B#+:M4,LHM6#!:8LB#PW_ SB^[XKKA/*FD+G#0+ZDQ]5E
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M7HU_M6> CB@)]C);0%?([593?T]3KZOJLBN(!LG'!$(8%FS]#6;)_RMGOQW
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MF]:#F$50@!\[5$\M_R-M-]+@WG+/T;9$X\>@9A[%CI*T@1C[5E5X)0DDC0<
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MOIA$(51ITKX7-K&B11Y$] MC0+6L@-L$2REP)49?\T73X(OI,1LEJ51BE)4
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M/5;LO#.H!^<<W_1;O6D431V"](3E]1%X'G:08%NQ)ME-&)[7]-'+8MT;#.I
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MLO*N<V%/8@Q1A"?'%G4 (&RBS*]>OCU9@J%N HI7;SHALA?*-IJ.AGMOT%9
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MXS3[H6Z X@>1JC8K(&K6>'F8M+PN03F*M,<LJX"AR9T47_"!4\J?$[#DV@F
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M?KOP>5:D"F]#@'B:O=):<'37T1,CSR#TM(L8!Q.KYL*9C"6/N:%684#*[!&
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M*((PYNA6WNSJULR^+(',1":1]W ,C_Z[&!GM: P14^&()X#A*TG8+CV4@N@
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M."B$7K$6Y%^(RYR:L&#3,]H,CL)K.E:WW=?+)FM(+1PU3;!4YI"B@6V=WC?
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M"&#LO>>Y/[FCG\6YR&IAR4[CHS=-FCMU5=Z-ZG:YM7M*L,>XR)THZ<$C,_<
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M4@D,UUPC%:?ZR\2JW"X_#$!P5/2QO<9VFXT'99FCA@TOHWY!")7?1'$*SVB
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MM0>L8FT^Z^U:OB;_JI-(N]:/@Q6R9NNS*'/0!CKEC,R#[PC:(PHI7"%LF>(
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M2H=+@5:HKF#4P%"NX0!MO,;DQO-=Y,4W0H?F=*W$.(C\3^9%6W@1)O?(.RX
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MSMVYZX_=X60TG_Z)B/L[&.Y>0][&Q79WU5?8O?@+E7*$H!G8Z$JGG*-"^3A
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MGI(0#D7@].>Z7HY=>SCVF*!Z>T.O6+*P9&%"8,ER:)+%=^TQ2Y8>W]!&R?(
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M"VX/[$8LOLD-X4#G#J0RHY@P;F8%%@1=,=F,B&-D*,H+4-9@"] H:?RM5VY
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MCU_9%,6LL(*64NZTWT(:*IKU8HZT3)%0OH2FPT22-9N9O@Q>O?1>O?SEE5[
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M4J7ZK.1LXLW]D7Y?:##HAE$$>AH=(KW1FR9J<>?*\!2=5JSOY[2YG\9KGNC
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MF#OS41SYPWCJ+F9[<2GL7]OQ9I[MCV8<M'^VG($!RX ]+,"R+'O21'P?3/8
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M\O;<4VXO\M3W[>%PQO+TP'B.Z9/@KNX]9OT<U]@%I ! _.3/+X!G]JEV[1$
MOE%0'B(2,Y2953"K8"1F*#]]ANE.^MU3FXR;^,D^@\A>-/0#7\3.S(M\,+_\
M$?SDNTXX&_HC,?2]<#Z^<9')R%^$V& SG+H3QU],A;,(1Z$31[$W=,/8'P[=
MWH;"CO/E,JF6<,&E%601F:=4VQV">6F]_#VOA.5ZK[8$JEG&L8Q[AMR79=P!
M0_G_9^]-F]LXLJSAOX+P=$_8$;CJW!=Y9B)D+?,HPF,I;$]/S"='+C=%3(,
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MJWA9ITF]1LP#QPTMU<8,*CQQT?U$,;QFF(= ;074 1IT[3#,^+-MB3NEE'7
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M'_[SHTMNO-H<]Z(\N63)1XO\\H)+G[\GRW[]:LXH<S JZB!("=+V(26!.Z3
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M/-$S03I@2)MA1U*\8U$\#%Y&K@NDX#DH9!F\0P[2!BF0A1SEC:(C6:0(Q2G
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M"R?CUP]R94^-HB<^TGU)9.3594OKHOI@LP#)O*(T[OR+@^+IK@()+/-Z=^E
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M23)5I<SJ]ZAA#X>,7#MB%/[PDWOJ^>%AY)OC9%,I7H][C?H\'#J0$RNH=6U
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MX/=+8DR2SK^(0E;L!1Y5['ECX B\(^/^7(J![C>TVR4VL,]SC/7 KD WM]V
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MM+F&62*M-?D/IZJ]?ZNFJIF/#A/'Z.D[G__]+<(-2&R)_3M-:A)AC$ X_X7
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MR=:W#JWM\/M>W&\X5@E"/0(T.&14Y%=4Q=%3N3.( &HPD;?53B!:[Z%-@,2
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M.Q!T0)2B%4P&&TR<PP;3FXBCC$(32S3J*8*"3UKL1O9D7!/>K&.:4GV+LL5
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M%>ECU 9]N."=^!GW;U\QF=L[:TJP402!OKU;\J:?NX >.^1"T15&])^4<7/
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MU,!;ERIHV+3C87CRB2C4;GQ:)U8T>GJTW0%O7/FEUG0V23'JR"6</<IR:K!
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M$,7)N.^DU7&+22"3GM&7J<P['M_CXSAU@/'_;4-9NY8B\MS)5>V-8Q\6K*;
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M7C7TL-DT27VD$]].)V>-7RSF;5CV/-HL9JOGF![[:80+G=]A]3Q5SN%;^ "
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M\^6.,)Z$8D51P>D+[Y$J#QAEF!N.3T*>>P;S'LGYRU%%LVZM3=-A1>$+QU0
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M!B,^J8UT%<7^+;N\N>[:9IIYAB:M;;V8^P1O#>C7!P[SV9]Y_I>402;G*W.
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M*G>O"S(M=_)\0NA'/]\7!ISL,X\WW2S!WX25]XIS[?.'N1<)YP,<WPZUYV1
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M"39V[IFRTV1@57>$UYU?+Y&#OP#/?BG!SYWT[N*%$2X!6J\NVL$';?9RK?.
MU?$@C"4Y^.+YVJO@5@0+%##PE &/7*XO.?-1KU8/8OG?5^&<2/>W*\A;+$%\
M_A=%!F6N4ZKX!8BL,C7J&;P*T&L%N@J-$SZC/]I);JM$0-F!".#L _]]^V%]
M)EZU1V:\+%[GQWT*XP]SN4D<]Y8W?)=-/;P\$P#&0)Y;S246"V!9AYGZU&QI
M?B:^.LJ=8X8[^'L).K9OM,Y=!X#38.?EO%BB*H5K>\9PU^\.QN_U>M-.U*EE
M!3I)>UIL' OD!DU_[DKE1K5T1+6$5W.VLA/US]XT#%TU_:U30\@3G6K8T$F3
M780$;H &%+GF+-!<YRL$"%@!C99/-X69G@Q]YQ^+.$OIY-DU-M5H_RM/P3:"
MWAI6)U98RG%6NMX8S)*Z=-*Z*G=]>%";6>/UG!MU)N9%?>[B[B@09ZV;L\="
M>]GNXXT:I'PFJMGE]4_;/.G5#^F\ML-/N:EI'< ]:^YR Q#3:!Q;5/5RRYHT
MMX0CX#Q7K]*N\+9.F ;HX((:1?34U$G&FSYNY3H*G,):B$NG;%Y$UCCBDBG*
M&3&YLH0F,B0LXX9$L<SA 1C5=F=J$369XM8($N;&$!KF<(Z0@C E(JVM90+'
M%6X&(C^@,32Z?EN5YY_0HW[OJAGJ7[_A@M=&'R7,'8<G6[ 26*!,3X!1_DQ#
M'&3% J/;"\_X9>=*[(@M_/;ZEW<D#&,G4>OK+<JE:=LX4 A[?0;^LNY<'U@'
MR;LA_-]))+X^& +:KM_8T ).;7A1)A9NV;[$OX B6CG,U(<!+@&UJ5=TH7VM
MI[O0FEC3X*U3NV5M^NI,E[ ,>+S#*L 7.Z2=]-[7T:MY6%@*KXSFYDL)]'2G
MX6*M%HX&%^4^N["C]M B%?,FW[D+8D#-XCO@BE78Q8*>/][$A:CFA6\6 6XN
MOK6E_H!?X?>+"K&5&WJ"3N(7X(S-E@'?$;"5[\, ')SL'=O6AP7W]@S#U<YS
MAGM4Y6Q?K]N^X-96)\\F.MPVI9YQBJHA*U# 65^0:3!236@#W@I<;-&0H&\$
M@%4GP9M?L)D"'@A>A8W8[R&P7[.4Y!<OAK!N)P("MZ2XCW1Z\9A5IQZ0]<_+
MPCA>/11"P8\HGRNOF^\=K\%,)L*=#=X=IY<\Q^DE\3B]Y$&3L>/TDOM2<)Q>
M<JSI)2/0N"G0^+4QRL7R<MCZ>QK\LHX]6D 1!-M#=\,?34K(Q7C,MT7A\^=M
MEGB[*!@#,>B-^(P7' (X%WBH_;0G9[<13JZVX(1H<#$&KUWR:R/WI)N02EF!
M!^.BO]B?LUCBE)8-7TZLW3QTHFKPC4IT#, O*?Q8%U'YL'+[@$@8['E?!\']
MH_0C[SV/<MOMF8!3U;^R;XF^[;M?]KW8LA^>NBE%IL'KN7;.1N^=Q=[7W8CX
M;SW,YONWX2H7]:O;VSO_!QS2[UTRH[P4,Y=^=(U@/_1()=;QO*>AD9_< Z>6
MO9OOI1TX>[W(!"8>^@,<, ?D4H[^U6^2&NXE([&5K9P+"4*!)7V%=F?" <Z/
M[^6@,95IOKH@)>94YZ@BOEP>3KQW&>,V'>-EHHV+N(3N@3?:S#CU1TEL)Y\V
M(K](B,K\W6>XP9_ OM>&P^;[ []-0FFC%1:^6_J?Z_8\8 $?O=SGP;NO_6TN
MSDPSA$,H-T:B:@(=6$G@':$V?CJZU$>S=&]*\G;ENY90Y#]4I06Q^G3F)'[H
MMF\[DK\1.&M#=TV)!G"UFYK2$Y%#H3S4'DV>PET&V.Z\Q)J)-@70V0[4R3Y+
MO.G7MY%2O7ZD[H).,+&89FE:$5DXJOLD1T_W79.JZ,*QRS,T NYKN"!.FBE7
M&"Q 85F<.>7SQ??MKG4!IK^#B[*:Z0OL<I<XMV@*'DI/9#=J[II[U?[YW,WV
MY*KJ,U0C=E4YI;Q+6"1!^[(8DO +XL)O7=RM63<G[W!3.!F\T'$$S!%E?NT[
M;92I#O'QMZ6\EQ?#(%5ED%5\7]'"@O0M7U:Z+%;66FYC$MO4$)HS0[BDG"1A
MQAC-=<I"NITN$X9Q)51.0FL4UOKGA!D=DIC&7$="YT)M#M?^O9Q_[.C\-T_F
M#Y[*'YOEN'&V[*?X='NXMU-B+ND.BE&Y85JM4=F'YE#MH?I><^^\-^3@17"J
MUB86B15$LI02:J*8R$0DA$6QM=HF4<SOSZE-KT-'^-==4K'A5_ ;VZJ1!O7<
M@8-/.*F[.="M494>=W3.;VM\M[C]0#>QPPSM-2=;I2?>"T+(LYFNZ#U#.V2I
M04(-)'/.5.TP/]S4IS)?GLR8C%E&0T.4P7T8K3+(_Y(PJU,9I6%BE-SIRE+,
M@/)7)(NT!3E+4\+2R) HM")1FD?*YKLRH_;)C&]=;EKKWUM?(=$62+PU5^SJ
M=)L:"7;:XM3X&QT6MZ:IA%R78\,+2]]JO),K]L[SVD,YG,3>J.H"R!D ;7<%
MZPS>*JBQ_Q_<FN(+>'(^AH, W<>,.D3M!E^@/P\KMJ[=[(<%ULY-L6R\FLWJ
M#N_2S,J+.]W2]5)>MKG&+M&.WGY5U#[EOY4#O3R< >T/8+MY&G037#JZ(DE[
MI"XT:5X.:S'@59M-OMRK3@*YZH\.P5F'0!6X]TUI8*^@^O:8AK53>7@AL(AU
M_<A^/6[U.%=FG9U)V-N_M)6[OA'I/ZX?JD(_\K*9#[ L7/N&BW1ZN?'AKD71
M"(Z+1KMRX<)/5'5'MP%,=*RQPM?7"AQCUO&!IEDFF+(1$R222A+*0DX$?$<B
MSKF1F9*AWH$TFJ4ZDE*1))$YH1&#<T"QD3!AN=0\%#*-KX0TGYM"':##*4SA
M65Z8&;#I]U'\0X"9B76.[I3&07K&;XL^V]"U$YHQ+G&\N(3;-?)T8A+[/+UN
MXG-_*/("L?6\:6J:!!<"&Z^]XG.E-\V4XVV3MEDPB9^ZK #.+,'(8A?VWRIQ
MZYJX.F9U:;LF66&ZQH4KJX#$TNVXM/2I@,8\2X$ZUD4/=]!,ETS"W&$7^#3;
M;;EXI"LG%3M-@TU8M1NRLO..:WH\PAO>_0TV<<760KI$2S/4V[7\:7,^!U'U
M8PY[Z2SQ!5EIZ<:<STK7NH.7 DOH^P5=>YR_"!;IJ#-OP@N7F+HITXW]=(^D
MW=RD(M?$M#;AIZ#FW*SO*X);OIP 82\JA4:*B+PD/8$J_,_;.*Z9[+F6\"96
ML(:K74:DN=@5&5-,3<B_-ZE-XQI*EFM*HW+=2%2[Z-T*9]V#!.'$TPI-NI>C
M5A/WA-'?N-^J>X5:V2TR<)IQG5+=\*;@03OPBE$3:=;EV,[/\01P)VX578_R
M><2:'U#)0.%WW;"&P8.0=[O3)U#W;S64;4*(*P9I8/E",[EWH_;&>:,3C-1A
M.,Z)!,@+SO?M7QR':;2;>K21#S>K C=LA%,:?\S#F&X>1O/MGCD:>]U,' 2
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MCZ,V  !Q_4],4L:D_ETI]W[>113B?+)'P0"X^UI@>DH$GQN0C5P/JJ$ E^M
MN*+UK':#CNZ7%JP'!7R];BFI#UUN$AAK??HL*$";Z0).GEU>O^IC7N F>0'P
MSP&H@X_3Y&>>64(@3M-)^[_HL86K\:*2B2LX=8G@S^\_RJ+<#/C#.YAO:K:J
M-XJB-J/_W3*]PS/GK8O[X4S LRFS<H.4@K\NP:OZOCT6;/??.ID2:WGJKO6E
M$O.EFTK3/E?_42;@S)F9)O#K$MQ6.' 2@)V8Z0M0">US3ES(Q%288W[J/K ^
MPX(%<R^BS5&U0W0OSEU/:!NF/7A+AFWIX[2WQ'Y UE_.NHVK%F!C_) QP%1
MYU=B=B$NZQ^_"_Y\5Q[8-]OJ5%C@+GGZUQJD>AG\7)03EV&\OXW=-Y/M.5,0
MO297=O,&($TY<_79.G@+B&?NLIZ?EO"%*W48(FWO,N_N)L4]>^;=/9""?AG8
M F"#F6%7P H3Z56Y,)A<;Z!V>8$! ?#O78U7.9OY4&EK]2=^(-U7,RL7DXT
M@2]BJ^'* ?8?P!7.R\H@>H"G=A #[X5C[[I&3 SU-F&$=4#!%3Y@_[A85S[
M_>!1BO.5#Z8#M/@&CZ4QZM [UB?XUV#( 9">8[ +CHJZZY-8@NI?>H2S<+5W
MR[88%%R&+_.R+ER-@"YJ#''ZX+V+1V/7A)]C[9X-7G]="^"^.EL!V7VX7\R=
M(WUJ/N<QDE0R,9P)14D>)AFA$>>$&VX)8UDHXSC+)-^)1'-%3<;SE(2A2N&<
M4!$>&4&8S5F4,LF-W-,_U&N+Z[F=IY"H^MQ'VL&YN,2\1R\_!7)H"L=TOAYF
MM4 6#3"N@RGB .$+N S IKUA"W 2\G?9.\^E7X"?Y^4R4"OT))R496&@ ?($
M#O\$%U6Q7)HY'@14G?9@/C[8VA'?< ^0W]$S1_&I#$82J\ ]8R/Z1%Z2YD^O
M8U:@9"[QV^;/0 J4-/<\< #^6Z[@*<4*A*[_E&V] ERY*'>>]A:YLZ?R,4Y
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MK]9=\S/[7*2'<1&N<Y-N0J4=-\G'.(*_-+%G?Z?F^=!7>X7CH7Z4J$$J=V_
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MWDU_SY*J/\3"1W:(0.H&_]CE=/)I&. MMIK"B]GVPT8)+1WXJDQLM7DVN,=
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MBKBD&/'<T^.HY,A8PCD/)&D6-I#P[_;+\&)^\78IVO^THWE\EV"=+B;C]S/
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M#<@XP1#'1B''O4=1FIBD29*0K1+I*+GP.'+DM3.(&QZ1EM&B0+F)43H=XM8
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MN%:?N>8' I,]RZ[WY=S!HEVS]>3BAE%<S/7]#SM>D,(0W9*"7'][BW++>U@
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M[_< ZW8XSK0V<)%\&_%32PX =Y_FHS0<730?3E7>?==$-LNG7#W56?4V4PK
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MF_II(IZI8(D/YA!=_$=U4)@<2*6+@W+*$'RK@U*RN?U;S!_C>'(Q')=\;DG
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M@I&IB[Z.4F0@Y2'[W0N6= E+BF"+8/LEV&+]CFO]1(H^.<:0-L(B+K'*T>R
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M8LY *EV,>%\@\9NC9>%*9.1(2_Y^9F>Q1-8[Z@(6\795O#WTYD[*71(N41S
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M1T-?A$D0A"+92(!@70;-!_<]0H.V;?6 N2,#=\ZSE,=IEM:IJ@YP;6=[)A;
MU+_^^ROV:F-0#]#H]H'@(.(#0KQ/^*(Z0>%&Q(='07%EJ.^=R]!;ZU,P!X'%
M*-E.1LE"O<O*<Q-B<UT3%BPVB0,6D2".J>]QYE"YUCYE7ZZ<\7XW<$$UT2<U
M@< BL,,"%@W;MFN">7;L*G@ZI0+B.O!/+*4@GL><*/1"/U1LG4W)T+#MMIK
M9:#A>>+O>956UH<T@5FJ<J&LS]]__!]^.GWW 0.W/;6U"&]?X45"L^6&95'D
M^;[K$2]@BKBA*TFD(D$D\)E$V<)WJ+-.3]THSRO=":KS0P_9#.J+ONH+A!?A
M'2Z\ [1V_3%@N[_[5 J'1]QGQ(G@']>W0\)]&A!%60 VU1>Q+]<977B6,:Y
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M44RC()$Q$0GP/3=6E(24"1*&=B)BI@0+^$9JK2TD*:]<I::OZ3P/R__P"-[
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M=J4&>+.X4O\S@Y?^>*;[/V.$_-EA:&:/K2M8K097#$VO-&V;@_4S':0U/+&
M![V:L-^F6N\L0@M325V(;";56@7V>?F$+U<J?C7-^(GT6W,[WE)7PS]-YMMS
MI_Q$-2F\A"> \P'/SOEE]>Z5]795&? '+ *K:*Q#F0I56^_38F1]SL7#K=.W
MD)3;;P0U5S!K[T=%;K;9&X;QJ5E$X%F3N77Z*$.PTPG/;Q]4T&@';\?R6V[]
ME><SG<_'0N/=L\7E676A2I'JPH"F\;@QC%H>P62:#&:S.UX#7Z5G:F2=%V4F
MSU.I++,)QHCNX8?/Q+;AJO#Z.N-/7QKXZ D_/=4ICUG-+3%)&Y*J\Q3A=^/+
M3>NBM%X?'?YX8_VTA,HR?3-X:9T<!;_KB<!/=.9D;?TENYRF@N?$&5G365G-
MX#KW\/#QG^(2M+CNRPY,]Y^SO/&>=)YV^T+-2W<1YX8/+,(RY:G4[S,_,E%[
MXEPJ&^B^HP+"'*X] B\@L4<E8;$G& ^CD(NEI)M 4-N3@4=LE23@7"J/<#OP
MB4U]W_%9(MRKMNPF9^MC"^LGI;X#TFOQ+($^W[U+MY]S<^Y:MJ+<!=R*Y3D[
M7EN&S(J/BH[(BLA]?UA?C:R9SA68_W*U]'534Q6MIEJ4E@D'567IJ&Z:I#JI
MP90G,F?H''"XK<K:Y&Q1D 0@Z53VU7V263TSF=YG*BNF)I8ABJJN1B;4!F?J
M3(E4I%.=:JV#<G#?*7 7DW9N3<MBOA%FX?UF4WWFXJ.U]]<)$?"4FIH!"=?7
M.^/PS+/*.E'%"< ^ 5-1JA.=&3;2^VK [IO..'#C!1/4Y)Z_/BK(I_:BC2)_
M,[9:9FI>'.Z;%^;UYVCJAUTZS6R^:9&!*P@=](9?L\M%PY!6)H(.#Z:7=4>Z
M@(R^&' W91 ;F:OH+/P%+$<6B,(L 9W49%1J3/6BIGX:D.)_S;O9MW<W!YR"
M8 /LE]?'&@31T@DE<#N9GJ2U51:7[08AD[FR "M<3Y^2 PX5:--J\0;F(3M)
M,8]BDE9,=6"X79*65;WPB.8"H*3KU!AI*ROR$U7J"[Y.W[0F=9J6[7OH+4QG
M\%XRK2\[P6WYA$ZYT5+3T0?- %*X!(=+GG=[(IL7XR9I7)_?K/0F97%Z^X,]
M+M"&;OVNN/7^=;?^D3[]ZC(P8,>I3R_=;T_\XW_]Q^?WGW]:G[]^^/A?/45P
M!;'Q5Y4:L^/ZMK+[?%87W9YV?5LP&P?V.W,XR?AE,:L/DO1"R7=@H^L)X&*
M:D^ X<SXM%('E0)& ::@>V5C#YIK-Y7R%@KIG:5@;-,,K,E!=WY73F]AWWYS
MNW#L1]XO&J3Y9O*E8V 87/>!8R)[3/UKQ\PWI#_0BOS%*S,^NEC EEK/]J2W
MZ<>+"4A1_9@X&J)V%:"<Z<206XLTK-;](QBSZ1.:?SQ6[A<U5'.+/2R;L=J(
MP$V]QP[)([31+1#<.DKM;;<\]7K=COF#JD293COO\!8-=IMQVH@9>DIY6;^7
MDVLE)K3*W$(\$<\7Q_,>=GJ] /46<<?">\WX+?[KC&G?IH?7R^GA#5;=O*38
M<VM2ZF6T25U/JX.W;\_/S\>5$N.3XNSM82DFZ9FJWBIYPLNWDM?\+0V8[87V
M6]NV*8T<RCP:VLP+:/A6NJ$3AK94%PX=3^K39TTJ7=GN"=/*O)G4:><FI'Q@
MRL=HO)XZX7Y.TE):AZ?--B$=5O^AJMHD61SI$4U@3&L3*O^<P]VF13F/Q;=K
M-6E5EWKUYC6ONOYXF=DRJI)$B?J-]3J=GPE7C76Z?*+@,&&67EK.9L$\7U@
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MGM0F_^\I@<]?.3!.KWE79)S(D!!/Q!,9YXXP3K=O4P,9YW!%_OF,DU';"8*
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M0L:V-0>8*Y=JILV?N2"?U9.BA'>60Z)>&U-T)E;0W:5],/T !X!3T7GK^KY
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MIUN=D(.  $!P!?,6)ZI9"=1?I/GB^3D_52.=]B2:RU2UXM)\@L.54?H:/O,
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M3?F):B8UX0F\Q0'/SOEE]>Z5]1:._-/;N)"7?_Y??WH[J4^S/_]_4$L#!!0
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MYEV5J!]Q 9#K\Z>Q&".F#H&I*QJZ&Y[@!<;ZD)_%=9)L9;-E7"*>&5K^KC/
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MF#"\4"H.XO+$T\81>[UC3PR?N94O AJFBQU[=VGM>&M0IH:Z=2C+1N Q@K@
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M'B#6P/$N+,90>'J-(16X=\^L&(4!V<W9U&X10*-_CIG3NL'P8!)HH*HN&=1
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M;6SM75MSX[BQ?L^O4)R7I!*-+<_N3'9J9U.^SE&5UW99GDWRE*(IR$*&(GU
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M%%TY)I_D)S]N9L([\FV9J_D-7*IG[E51UU+.5RB.$1* *=Z":L31766O0?E
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M\*-M&/1*[4^V42N.J-)+_-]M(UX2A:67^I]MH[X,W-(LZ5@GV;$CP#13;9V
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MM6T_T5GEZC")CEBL*JIQ67BIQ9&2CZGM%9IC[8O,JOQ\P=1(#G$,?+(2I.C
M9P"?3H3HKJ,-1)$N6OJF0LATJON#N]%:#Z.7ALMOF"7&3RS!0'DIV@TT !U-
MST?+D?K>513%AVT28PT81*1   B^ $32B!>KY=V# E&=!AWFU.@FL,FH)A^L
M*\\XM9U3PTUQJX#@(]=E(.MGC*0;D);)CISIU]N8?2FKW4,IS5]'F8*"QQ 4
MS/8)VTE_P\!@D;N[B@7',VL]!DI/='0"800O=0C=[IQH2<OCHJ?P^"D\WJFJ
M!@-&PRL?=XDCW$X 7,P*LBX50AXWX&P^A/+NYX4:.$MYJZ57"5)P-D=$G1.J
MAS$X"X;B3?CJLF1:!$N,/&&F32S%R)-H%",M1IY/HQJ4,?*TFH;A&R-_YZEI
MA,?87X-J&00R]N>B6@>(C/XUJ=Y#1\;^]E3'6)&QOE'5.=ADK(]:=8A9&>OK
M5NT#8,;ZYE67<)JQOH?5*31GK,]CZ8KR&>N[6=JBA,;^L)9"W-#8W]DZBC,:
M^VM:>DK*OXK:'%-I\E=6J&,J5M M+!??KP"=M:U!T&X,N]-O2A&$_#]Y]> \
M02EO8W4:<@H2'5V0Z%0Y]C6$QK7DG<ZBH=%$S66OXY!?SSVTOHJ2%S0)GZ,5
M/K'.19;Y%B;/(=Y69[L'1)XPO0ICO)U)D)2?AL_Y.U"'!P^9!+48R& U_<0'
M($!7F#'L3R[QE51>NF/2*.]GC"2L14/R0O,%R/\[CP\O-Q?<2K)^#0:PB,B9
M[Q.#$5H"'X3/Y"@M 8UIP\JS("VZQ4 V"/I7";P!+\54B4418IZ>X4VXD=1U
M;#:&N6I2^ N+U2S(+TMA%25F4U<G;K[&8[D?[D@0I <#]+ E L&G#Q]__/!)
M5M!*H:_YZW@RKTSFE:YRT>%.["H7B08R*1>MPE20\%QI8,-]>)^0R!\L7D:@
MYD:Y3_2L72^?,@;<!=A"X(<TCFH6![--@@_>7_2O'/I%/6P[F7/,2)".DRD:
MR-P-@"<Z\__,0LP?B?9!_XQ"P=J)>A@E@_R/^+F>O0A0@1MC&_I8TJ8SCH/Z
M/U1:2I93S]AF5S@^F5>ZSU82U<12ZVM. LNVV]R([T5[F](\7B5PDW,6\;JJ
M]C:IE>++X-[[!A Q#_)5SEHKHQN-8'B#;S/\QY+=Q0'#6',1(F*1S2!0.'Z=
MAC4("#5O7'[;@C@(TXP&=/D9$47/LO0F2?\'I(*%5>ZN31*O&)P6*RPS$Q,-
ML3OCST990.XPK)+!# 355]S3//SH,CZF0\N05ICR\E!Z08U%3F-M"U,;'S-A
MK(I]]N!70)-++\!C*BZCUJ2[138XK+AM\?Z^*-0W>A 0P.>>QOK,$ )<CW/+
MP<Q66BHX7#$U#F6LE@9+S%?%'C(KPIZXQ=BYS:TXY8>+= E661RHG/63+E80
MTJ1$M[R?10SAL/?S;=.0 [![FZV%?W:<A\235=F-S6TW;[=W8>>J8'F?2$O'
MJO5U4Y7L0X74)T8LPZ=UNE@]X'N/;OXBO>WT)7E9:^/[;K$B8HM*[)FHAT6L
M;>\FQ-,5./?E_8R1])L7QL1NN8BQ"K9-<H/08I5O'5Z93DDGVTR!#.MK9^.\
M)2(#9C68!WWV4L)_=U7]0,[/&X_C)F_/E=+3(T@46;RD^S2NI9>"2ZSJ]F-/
M;#X)<\I!_?Y8/.8UHN;Q?I)7"3P<B&M"QMX&P'OYK,N(MO$2ANVJ<P"4X2<&
M\+[]W8/0P]N4D[YWDJ.R;\]UF7<<UJ(;_CR)J3V2I.&=9RC%BB.4;?BFHY@,
M\X" 6LTKKCPL<H4H%T_PFN!%VH39!N4&W(U 6FXYF'&A]*#0X*.*N5"Z(U;
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M50(W].:8<A"F'(3QY"!@%IILP,%.=TT^1=@?/]!3U,,V,H3!QN(^QDA9I&L
M\39)ME2/BI_R>19WF3"*4JGKE%\P_OP"I\(_/X<10&D2@W-\%>--*PSUY#?6
M-I_RUE>9D*"UMAGMM5+RM/;]&BSQJ3@(*8N5PA*R)MY]4-/'L-B8"TA?&EU@
M'3_UX@ O@?A0\KMI6S#,=R%&$UR _+_S^!*E(98?0>D#P2+W,Q1NK1:C:*.
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M_[*TLM+)WK.-IUYYDKZRSOL5O$]N 233ODH@)5)J#M,RM 5FL YTJ)F_.G_
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M(Q7[E0[G<1]+2)%=GKS6QJ9_%<;D"0^ER;/;&CP3:0H@6JS.(0C"=)&EB"A
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M-8O5W=J#Y!$6LF.2F/8@%3'A,PA(8>V,/$PT1R@C=D33%H'SR$-XJG22,AL
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M:1//*DDU^))$>)@("R9+?($7E.J^RYI/8'K"R,SZ]_,L5_,)C /D98B^7D$
MYG$*(-:"!SYBHL^/&.#A]K#H\^, >']*+\+G,,!:)J%P2.Y0^ZY[!8I%I)$
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M.DQ?YH_6-KP%7NF.M*BYIK5\Q)QSK=OLSW;L 42NNAZ_:!F,4I^SM)M!_W$
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M?,E#N;LY&\WQ5FJ\;$U&Z)''[K\QCPM_"(AV:NR5V=,N%5D8L2[JH0_PEQA
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MS&8)PO/U&HOVH(V@];RU]3B]D+1: :@NH ?[XUC']!224D5":I)?6]O;@U3
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M4#.@M+V)K+D!CH+#QAGQBKY[IC&6PP@2<PW32B-_LF  HC8O(M8'QM+4? J
M;9!\=*B+IG=W>\+8=KUA4J"^985TVRARF5N/LJ&OEZMLO@TC1FM>%!BX Z6E
MXJ!)UFAI/.+IJ^ 88G3$.8C7&1."POJ^[MO+GCE#EW1:[!,-S?SZ/?>AJO Y
M5=6"\$J0Z -Q8#)-'T?+&^N?@^PW6H V9D3S:FWJ[YVN&4^ZS"[F]B,'$DI0
MBE+)A&-(LPT KGP)ULU5B _K.P53&;XNGVGQG(9:HNRG+ICY_@3LU>S(Z$8B
M7J;GZ[2Y-L=>(_]*0@E8 "O"X=[R5L=9KZXN7?K&*_ @SWX7%7O98:\)DY2>
MHPT'18,A.BJ*=/3P'G5NHRZB"(_5?H&9R1WQZBY''D7ZPF(QJ%4W2X?5WT_@
M#L;C<;;# MW]('7V>_C,;RHA0F%:_)(2\1TT-!61Z>YG,2%(06TJY"FV;1^2
M".6_'CE\YEO/&FV_$ =?TB25IC9NZ6A/_NCH=++1 SQW7WIRU#-LK$#M:CA_
M9HPT>8(P'?E:E^#,72)AGYX3\L&T9E;V=L2T4YF"-:T::\8UWNM$\]IW6]BZ
M24PMFJO *DKL6FH+].G7UQ\\G;D6S"%U% XFXP\Z-'@[9X]B5.@EL+A48."M
MK8<_BX>KNM4Z8(C)>C+*V!9!/2JIRO!B4+$Y+_9S-WIU\:_M:VZ]7,6KM>*R
M]>HZE?(4G35,S.TG]/KOHW.QEP"%VG*#'1%)>R#927M/U>7::C4XAI*+( -M
M6?OC.1HZ.8MW^AS%[.)-$RIQ&*#&\1U;HWS%!2D ^7N"4*8TVZG&LI#859K=
MP;HRV2N,EES3V"#&2:\@*7>#>TQ(> KBAH(;^[^W#E735J)DKXV_@ XF]840
MILH.:.D-,GHO>G>;'LQDEW;:HZ-GD$F\>SH!$)K;^I/9=UB0LS1XM$0.-;<]
M65.15FOX&FH1)7FT=&HL:AG0JW#(KHH@VVGV@I8]8&[O3W#'^LJ?V%6WET#\
M.?ASFJ&1O?/*/)2*Q11.%>.Y8+)8AB6N\T++A6D02@MN<+Q,&B6'H20GX%*I
MZ[,@ONP%\6LQ_@+,B'LC&K5F7($S?#\.S!\9<R[^U=_28]VI*;;WL1<W$"PA
MP>%7L'EDR5F0M+ASC&V_0G.2HL0[H61Q_QPDODQ,7?.9!-JOC)2O)&V;9<Z.
M?E66H#=Y6\?L;\G3OWY#DW</=]]4N&0')-UFQ^<R'0,V]$L*J37@SP#-_G/P
M!D""_QT_*DS%+(TI7VNVU*^OK]_C<L-*?WS__L<?X-<_X$2_^3<<_1T*.$2?
M(M'F2!YW1&\GYDEPHC,"4R4X5Z)-=D;D=$DY7P(3GA$QY7_YH5RRW\NRLTLL
MIY_XVJL%>E&49V3M>FW03%O6K ,;[8<C-P^2(B4M L2F/7-]_?GT:3G]T.GT
M17$B#N4O4_KJSIYCCS&G313Q&>&$R9_$GS "P2'^WQ-C4?]DLL"3?1:XG+WX
MY?KBPT]<PCATGJ&HVH![Z9M_0UKDPT_?3W&N8MN<DP7YA5P31H?\B5-RL#N&
M3U?? MJ<ISC5%YH]IN5D@=0[%S,=_-3A_R#<A9U33./+_8D0^ <1DR%\-E_E
MDND;6;*;.6:W='2E>:[[Y8_]X(H@ 8JD0O(4V- _0LE+#+PL3XX74.3V>-G_
M+C."*M\8+'6!G#,J"'(^?/?A2$P!P;&(&$S>+>P7;#P2)01&)#CD*;.O[UJF
M%O]HGQ=(E;E;TB3((@!%I\L@+P:)%Y*(0]G"WISU]964'.LR8'21+LDA*MB,
M "7R)TG+H80_>-[["AA0<SSA>1+>@F0>BW#H(9,&0J T AU20D=.G /CY8GL
M"*(3Y\'PUC4PXNRUPVP5GL?\2;@$ANPE08I(6I.<<#S67"L>=1#-,_K,OJ8*
M90*IY@L%4)C@;9#,!_3)4A\ I;_3XBC6F:G0)IPX^1;(?S<C; 22K@@;X[0X
MK)SW0]AT=ORU^G7WJ4RKJ#@0YL7-]C&.EM)-BU@8 RU)?$!2I$2F,0.?2QR4
MY# J"0KV.QB7_88/3#8PLBOCD_LU4 \6\GZ?$CD46:P('XS@:&1>$#X>D0,2
M'/%D6:_JIT=_>W>'709L"FRW(S^MI$($F<G.5_\>IS-I[?*L3]JY,0 R>(XU
M2;.NTYI8Q?C,^A,!9S"M66XPV.>N"+)"F^N,G-&G* $ #W(6Q.#OGN*T+Y.P
M,NE+A!]T/V.E10B](1^HC9=:B20XBE)NC8UFRZA0=O,_NN.@)5CO;%>&ZT%<
MXK&V*!SA'0Y!RC$('P3\$S@,P7'85V,C.?QB#OFMV+$.87J$_5GJ!(,/6$7X
MG_34]9<8#?.K+%T3D:>?)@[7W2: "-.N!EZ.<C9$FPZ8;>2$B#XCN47EG$B0
MA$2;%1'3XFK?&)?L1!93/][ >L#7*1##.;BC>7VR*/\M1QB-)<V*($J FX&!
M'34U%X? [[S5!R$;'L!20 #+(XSC2JEUP:/8^YPW1IM4B*L@':?1.<Z8JYC%
MU=>KC.#&HLF!&2_7-&/"[=//6?I:/ O U",_$*=()$G":1)!=/)<5,(*1V9%
M2[[E^:9E\/C %T.\\8PD*6F.<MFK>JG7"1MK*W.CCI<].352DAM#Q+3!0DV<
MW./#'0-ZL#;'JV.4!LU?4N02F(R;%V9$95^$8:;.5=S$D. #Z#D]Y;44>P1X
MC$)I9!(ZJ$RSY]+0\1< #D*^E<-]!P$=8D2I9..KPQT$?+23Y?XGSGU"GZ!2
MI-JUG%NIAB.[*?=A\6Q3(02>+-L-BM*17]ZY95,B+_$09X[IRT.2C]SBG" 8
M]4N2Q%V8\^ 8R"KTU/PEB&*!1H#EU/S%D)8+R:=&U-S(*LT(SN[K7\^Z/;7/
MJBA[ZZ-K>^NT5DDWEO=;I]*8_KM9JHJ]02U2SA=ISQ596;0GMT>N"5:=*[1'
M7D(E05)2])-(8X\W_?LU,NA0U%6PW\(89H3\.%;\%0. >UP,0>08,Q2$V9D%
M$4$-=%+,-DN#6AC 1@R!/-*3Y+%!]#O\J[KW9Y<1'I@=.LB%K%V8,_*W[[]_
M__[]![(),O("I&?DPS^\G[&?P7_RG@T4DC$3]>'+,Z$8@YS)CQ]F!)*D<4'J
M/WT_(ZSWAL.!Q;M_)C_^-/O''_\P^^G#WV/[#S_-_O"/_SC[^/<_R8$X1C+7
M,,HZ<$,&G>Y'B2O?XXY_CU_X-^"0JM.=NWY>6AB8_,%HB%IHXV;,8 8KG&F!
M#6U\N8YW**W-\S!D;7(L8[3(V+7Z$B5'!^<)2[.@.2-(E3#)3]*=/B<-AO,Q
MV4'7C$W/(EAF4BAS!Q4E R8J0%EDRB[B]*AWN>:B4R[<93E5+0>"1+H'M^:9
MQ,<BUCRX 9\QF'4V?,[P<."DL6U83MN5QV_"*R^.6)/3O+?/?-[L,R?78$CC
M*RXGBVVUZ?[^%ER_":YO;O\N6&_^^<)A1DS)S[&I7R6%24Y3EU%0#-%/O\N'
M.V8_P7)]+[2"XI6$ -!H^+4&GE^6RCI:I-3&J)@PX5[3_\UMU\5SD)!JIS_!
M' A.PJ&9P>=:574BPX+QF(GZ5"I+J$]FI&5KLLX,W3.-MIE3Y*?3X.28*5%"
M/&,CG?4N]C-0+N+#D3,FP,@!F8BD1F3RC8S 1[7?E3CCFFOIK)'<E@,1;22B
MAA(>:<?(,JZYKN(/'<3ZB7)<Q;#QSO/!& OWSQFEXV),X)"3 9DX?@%J*!,?
MW3'S<YJ&KU$<'_F)9/?I35!?P@G/4I/.)0WGYL)C)[MO)BRG/*)-<-CT2UM@
M.?FQ$IWVR]=#*B#;I_B+NPU3RHX5!C3*_Y-PVC,BJ L! .F?%'-5P _."W=Q
MYVYY$97!H-@0C5[@K;VE,;C_;MC>9\^PJ.,Z"'1"#$'*,<@[)KGB, 0K8I\<
M?[&1-=B+G#,QPHR(,5RA!Y:.@U\#T%.+W Z>I!YH\2HH.P.7M,6$LHAH"?N2
MHG/(25M,-+AOJYPXO-L4:'U%VN,X.E+FNTJSFFA8!:$_]FH78X/OMR;_\O&5
M&(SA/G6AF?P)9S$2\JR/=:IHAG*Q%IV+==6P6 YM?)#;*>IZ\%(7QYYAS(R%
M"#FNU7-B+JV3@V=>.;B5Z;O2S(^-VA.0^L*U,<_AL5JL/M/L:;AQ"@8D/&9V
MJ<?6!M78VEQK)R .2(# K"F?G/+8!3F*";"8:YRA,X/6%)93WH:X/&?M(<IG
M(D19M*N$*!,Q*>6&F^<HD\"-P6?V-:]B<QRI"+9]2)CL'D.)7[+0PHX6LI3
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M#RRC8V.CL[R5+$>*Y6 $EL%.9B^6&8U_H\<N6^*A&IB5K<FG-'"*[;&)V*9
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MKS=09)D7-8$YP.DH4M4"7S2,U)0+A$TUZSU6"<>Z?>+]@]9ZZFR4BH3<%[B
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M0FKSKX+Y2F3$<=_>6<P$WA+RS9.".3Q]/*IVX).B'M-,BOQH/');U,X>-^+
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MW&B>OG*)=([0A&(+N56%"*URH$8^LP-(K$G</<P89V1> PWT=V1A,HIGAW5
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M6F7&OP-D3^'1]QJ:N<VS69:O@GFZA/_ K[YF@,:UR7.@NG**)KN('-=%<B;
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M!5?SU3E;ZKE&E0?[L?\'JP\&@_H[3]?"3;F!,3^W@Y8RH,83)H5.&(IEGWO
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M*&'0C5I6TDII+C!4#R6TG9C@'S=5.^C47ZP1*2Y]QK:18K8!%E,5PM<ITRM
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MB#G 5J9*VA7_>"4N/Z8<L)/^5I-71?D,!F N6?3=_6/!GN%O8\81(9XY H=
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M=7%S&>3Y]BEHW9Y^,/R3&).%>M A@9K:&*^7YJ'P2E_9@MTP,]R96NVU;'*
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M4JI1*)W8^K28L_0U$.9#)O::99:O9EF.L''%34LPVKLF>D2/=M?PY@C/7FF
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MC780ID=1?AM9$0"=J9YW-A9[;R1?C;DA7&Y6FR2 J]H=7!TWXC^* THU9YW
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M::G6<'W50^/'AP;FY"6X;0A\%_'H8OM8P/D[Q^0OK+NPC%\;S['#OST")^7
ML%'#1P=W[=>Q)H6(8NBF G99J,N,+C:*1:T:8#GVNT-')X)OET*EN'3Y89I
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MZ[8@B?_\] 8D=5;B3T:&$WZ>GV,9:H<)D>^WR?IWEH:,SO*(4]>BND25AXO
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MH:EK3!JMZ\WW7F3A+Y,J6A3"]%^$"[];*8H-55YT@._I$:?.5K:^2F_\3^?
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M-DI22/( ^D&STQ2,PJA1_V@]OFF'PFD?62W: :+M>\8!*C7MR]!+$J)JYV(
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MBQ=$>%7+Z)0<OX!!@GZZ0O\9;9%,%<1K02W4WCYGONQ^41I(]%@IN[W)AZ@
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MN6DJ(;H";$L4IZF5: OC+:WLT]9/),)_2Z"FK8G0:]A]FK;:(!>^7&(U3>V
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M;R:A3O/Z7($MB #$ _N%8G$9AVA?8UCL$,3%^O*XQ3%=I"OP!J(,%.6MBVB
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MK_A_>&??D("8)_@^OL8PQ4GWE7N.M2SY 8PM<H6U]@BL2\?=PO>S74:B3Z[
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MY@"T5$D%7E57+;=BY?+TR)J*RN<X;%*J8=WW)Z& 31,T5J:$ &-'P6IK79%
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M:&:-@!\P4N(T=0E>+I"E1*M7L=ZV;->3<2U/*P[^ ,G#\<F6 #_BD#.D46;
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MX3CAI_@"F_CRB8#U(KG\=45;H4+OV5DW,G6KJV ZFU)FL_!L%I[-PK-9>#0
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MIP[G@78\>:7?NU+@]AXB4V52V!Y=]P6R/^M$%@GP+_$TL&T?@E  _]>9I-O
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MX@RFKPMT=M;\Y#=Z0VM Y- $M:EVCL:P*M+;F(O:I_%Y7J8IIX.N120PK2P
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M)5A)D[9.]"<H\*\VAK&ELNF$EU(LZF5N.8#,)N>GB$7B27(2@9G-K5H MXH
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MB_-YB/[RXOF_7V602'?/$3H'EXO5]>/B[/93[FZ.K<80!-M(1A:A-M4&]@.
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M,KZ<XYU5N7YELU*J78POY(@POG^+OQ512U4M \F"968]70VYC!/IXZ/C4_8
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M7C64%QF7<\S2*.C<*^3JZ& L&N\[>):UQQ$9?ZUO#!K><#%<YH-V5R8SD5_
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M%';SA([)!Z]$-SKP A7OL%''V.5%;@9/,!D(:/<(A\31MOI-O69M,Y\X&YY
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M<3%+BWK]!#FF0_QF=8I?7Y'YL_U]>"N[G-N:K5OAG9CNG7BIH\4/8*A>*[7
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MS=<Y\,TT+0T06 T37LP03,<\8M(B)XJP,RVRE<HI7;V=66D-5'0,RTJQJ]V
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MY@+-@?B\ML=8*-H3Y?+]J#SP7#/N\+"XS-)%G,"<-#6[K,Q%\/+Q\?"DE9V
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MO1P[<+(,(%9V\//A_+GP&XH1W6G%\K2LN4!S(#ZO!9W_I3A@5)@N>5E>S?=
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M#NJ^Y5Q;G'@D#FVPRY<&#Y(YD6D58J%&#=T1@>[NFF0XFA1@=L":"^GH%:C
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MP H-)&X&VJY:.]3:IA)#KUF85D,N^%,COH)>1XY,@Z&VLI7;W).DPJ+-TEP
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M&<F<_,@3!GJ3>*9(U,#G (:QNHLUM>>Q1*B7>/(*^WX9^QJ>!#<FHYAL?LN
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MM23(4N"KNONLGB]F&U\ZOO%(+D%>Q;OZQ8V6#_$&J$.(=9J%BZFV@W?Y4J^
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M]WR4Q:OW?WKW?%K,DO?_#U!+ P04    "  .@F]4LJX]T E?  "4^ , $
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MKIN1#9.TW[BE^I+5$&>!#=3\74##!T+#'"ZLIFBJZ$R6ERH9)U**&NYFO0%
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MA'BF$,\4PEKN*Y[I=8AG&C?@[^V>G+Q[ATCQ^R0Z.CR?A'#V!TW)[+K<J=6
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M^/WJCK]0Q>$C40<U\4\GXB"I!C5Q(R :B&\TH!H3\6T G(*:N($@#1I' %H
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M$E9IEI9>F61%1>Q]VE1PMI6]*3H*9]R]*%$-414I$%K'IO[9[A9\'+3VW<G
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MW,<%_$+OV^@2BR5LW)GQX>5$I@TB++Y #9'0;E_PS\*X& B?D>\M<K1OD2Y
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MC0-.@:1& ZI'1U*;XP'MMR,ZPTY-6& T5(/HH<MF4O77$W6H!A& %H 6@!:
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MNQ=&AD$7D[V#TN'D](B!Z1:7NS8G)"_0>9=K L+D*BLMUL:=7\41>+AG\L*
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M&R1P&8QAC-W66UT8 QK<2[7U(L^TY"/R]\#:W@F=U;K2/.S?#@5/9,UY8)1
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M@M *8H(W4@GI+/)8$5FE3];M(DS."]=,@O56'66?WS8>I]MF=#Z.;LE@-0K
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M,=4+!=>C(T];Q.P7V0WSKBAP0\1<=;5:%2"<<:R@N5(8^SD<.;B<=@TI!71
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M*B)"@IC6,8^/LLG18]M6_@9 C5$V[5@V_6EET_N^$7&P0LJ:6P<EJ'QKK%V
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M\ F4Q ^#0TUF@TYC%/14!>:]7Z$J5:ZUWH;I'IHR&]7X_2L%<Q:>';P:?QM
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M6T\\Q_3ZT>.'DR13ZT8Z_C(MQ4PC>WA/51 ^@]QJHZ3L'XVALB"EX#T?K>V
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M54R'7\44^LC4L\X!:0<]<D/*&^4?EG@#6X)/P?WA='DRC(Y>TX/U/XVT;=I
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M0?%A[&QF76'HK/(YU=@ZUH IBK\RD^(XXLM [O>J%FM[!$@>*$#RT9ZF*4>
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M^2*[_G&,+>8^VUE8I\YT8UJ\YH) W?J IA0V-4Y]L/67PX7+T88MMH<M]NS
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M?C(IT]4W__KZR553S+_Y/U!+ P04    "  .@F]4_@?G4CL)  !6:@  $
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M' );6$M-FEXE9+/0M_4-)2O+J.9#VJ53H3YP#*>>=.(0XG%^"*4A74$:$T=
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M;/KE@O"6;J%:!G9(AF0%</$O$20HRH?67@926M9_"+"$#^K4<W A?*JHN#A
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M_(6&S OB_G*+"OV51IR8=-%JUL3!HI1O=D!> U4ZE1HBW_-W)YG10)WZ)J,
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MGQI'[--]__5BI_ONB\G^#U!+ P04    "  .@F]4^.Y/TLX(  "22P  #P
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M.8TJ!*2'$L,UU,5J)05W7M'82B&YD=0!&=)1'WCF5%-I*47TA+<^G_1AF;:
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M3(>K"9]:SZS3_?"-6J?[_KNX_@]02P,$%     @ #H)O5'J3U$XJ!0  %"8
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M^ZBP'PG+=$,5.5Z0LM@MG&@B7<Q6>*T*UABTR]]T#=K%K\'^ 5!+ P04
M"  .@F]4F3<HJ)T,  !/+P  #@   &%C970M97@T7S,N:'1M[5IM<]I($OY^
MOZ(KN=NR4X#!L3=9[$V5# )K%R0B"3OLEZM!## ;(7&2@'@K/_Z>'DF\Q/9N
M<E=[Y]R%.%CS_G3/3'<_+5_.LT7XYB]T.9=B@M]TF:DLE&_,=]6SVLO+D[R$
M]I.BP^4XGMSICDM*L[M0_O@LDQ^RJHHF,LJ:]5K];Q?3.,JJJ?I--ALH+[.+
MA4AF*JIF\;*95X0JDM6Y5+-YUFS4&N?YD*E8J/"NZ:N%3,F6&W+CA8C*T>,X
MR^)%,8%>4X1J%C43GN7BV9M+GJ/$-!;!^UD2KZ))-8C#.&DFL[$XJE?TO^.+
M>W6-XXO-7&6RFBY%()O+1%8WB5CFN#8YT'$<3N[+]GO(G[TQ/\S56&6DE<E=
MWUR>+)^4^@*L*Y-/]?>X,CY?]N^>-[ZO7SQYL=5B1FD2_/@,#XW3UV>-\Y?U
MUW^OUWY=SIZ1"+.'&TH]J4DV;YZ?GBT_7!3(7I_]@,)._*<E=RBG]R[+'VSV
MV=>^UP_)_/D&XO3\O%+^_QPS$<7)0H3[(GZ&_GYY^[%ENO[SCRUG]+'5\SZZ
M7<]W1Q^-5@N5OFO8GC\:F!_=H5T4GU/+Z?<=FSS?:?U, \.E&Z,W-.FOD+]>
M;QPVMV22J:D*1";)7BW&,J%?WM:+#QD3%<B,KE1,WEPDP/;B1='TXMZ'JQYK
MU#7T2&M>\4AK47ZX=0]@A:PHJ)%EMQQWX+B&;[9I:+=-E_QKDWK&K4=.1S][
M/AJYT#91;;@F:BV/6,U6QS(]% T?"U$_J9$1R@\"!S2AMEBK"7EBL0QE+LZW
M]F_MW]J_M7]K_];^9[4_4O9,DUSSQG0]DSJ.JYV78=EP:1W+MGS+L>'0AIXU
M@-]\5:^?4J-.KTFEE,TEQ9L(Z\73K3-_\2+W[KS*?[6&GAJ@,NYX.H#J]-0
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M$.#M81KSD=>7ICCJ#+RX/V(<KW&*59K5"%3(\#BC!DOIPZUJ-P?[-\QM;^D
M"_8Z@G\D>]B_*HR8IWD]W 9NPUI3U40&4JTY&Y.GARB58:B3(0A5\LQ#F<6
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M955U8U-S2VM;>T=G_\#@T/#(Z/>QV;GYA<6EY975M9W=O?V#PZ/CD],?<J$
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M/_%?]<2;7GQD'JF!LO084E?P;N^?HCP*LGW:QO5(.DWFVKZ9<0."*G3%C#W
M8,8LWP-MA."Y"X':;<M4&L&LM*O-G"B^T/V/F'W2TD"D*%HV%Q.&<J>86COE
M AF@2__7&7^NT$-%=K$J3^\A7C*>><\?_(EW_YW8*/^+\V9#*7;1?G?O+[TJ
MO9=2@NB!<P55(/SX(!Y15;&;5;IU<ND[J#,L)+!_774"TO9I^J"[/EHB$]+^
M-Y^^CV(>1/\1]5RY9%0K7"8N 8Y[*QS^Q&A1:V0++T^Y#[* :0H:B/@$]/=!
M%0F X%RYM186@00H9Y& 0082Z"O0JAFZ18T0:T+4*""!5,.PYX9_QR20HVLQ
M40VN_U7U^XPUZJ4]52Y(P,@)LJ*.XOH;&R'ZH@,DFI8A'\U:R>TI7NE&_J%'
M!K3LI[Y1A:1,B:*GR@;B+YEK7K?K[TKU/R<">UY1AK1;GR$JO\ 6<LMD\4ZN
M&D%&2$0^1+L&H$B D^GW<C[L:EJ7IX+,U_2<SM(A_"Q%Y1R0P.U"4&W<" W:
MQQ/6?:NK)IC?\^W-J^2ER*^DP7(NTSFAR&"^WJ]Z6CR1GC8G?MUO=8@&E[V5
MLT>E-[%TO6$H)4<BQVJO%'KUH#0 [^ +K1JX=M7U4(0^$!1+)9%OTBS:]07J
MQ_"!#S,6PFV[X(I*QA@))3.=B'<9M,.9=7O7W%5CS_G!@J]%4E LI;!]:!UK
M@CCXY9HG;MU*"9ID$'W:W^10+]VJAX":LP--F6?P:5Q'EV#03/OQN[R!1WQ%
M59_55R,QH?)7&9ENC+3P:%UF+A%W?.Q $(K?XVX:BI;]17]+$$'H=68J/XF*
M!"S'["M)7WITO<?,V>N9E6)"W2"49+&0^R!K,OAIX3J#U17%3&/R&QXSZG3-
MNEICZW:I=7Z:GYGO6"YH:HYQ>/3,@GE.E(H$Y7EW9[(6V<6N!0/F#=!W"[E7
M%F*@38&$=:5;2\+457SB9_G'F@B-^@O3T<] <JQ12%C 3ZRJV7*4!/WNG,PZ
MVU555[1WD<,&=!K2!S</!C[=DR_I..275Y&BO$*(MBU%:O^=.^Q>&8G/]RR/
MO:L/#.Y/+T5*RK<M59?&/W'T_]).;I9XL,)N76VPH%K*>^C4AC7)H*/AAULE
MN*.1)RB1/CU92E3\J<7LVDE6NW)D/$(MZ9UI?Y[,(5IL><PA5+>P&#'.H=W%
MG+2SZ$WS"E5P@^/-Y67,D/F(Q*'WAQUIY97U<;M&Y3Q1*J3I(L(=WYW"7C['
M<-\"1[3*715^6'(W^?%"P[B9RWO75N_+/1@Y2G,&1 P;R<2:N^_G(K7C^*]E
MJT/]%$7@4OW^O-[^II%#W!61Q]Z)AS/,)3T.7)P&9AO7ZV\KDXA%?.&CFZI1
MN@HJJR@=,I)F=(J5':LR$+?*@ABP9DT3G<.G.GEIRM_ZU,J.6^'^J630M]/A
MV5Y[!IR<9CQ]M/[T.A;C/585"4*T_T%,TN 6DF1A;-E<DKE%&.W:C/)(Q^\Y
MA^B:E&>6H)AM'I<;SQ'/VQ:*^$5]=-6.-[P,$^HA$8E>9P,RA=Q9.=G9HW(N
MM#F&X]S-XAP/:557A%J?,K+G64GV;;:FF]M%E',UNHSFK2@ZQC$WU$EH&3SH
M[DNPGV&,"-1Y^0(%]TG;^(N>,BYKUZLNARI>MO8\6[LO<_\Z.9C86%34\UR\
M.<Z^GMU-MG)<9%T5S(XNQU-[T9!KN<IL0V.;'X+&Q-!.N4\5S'5)P10AZOD*
M[O6;EU7>OY+Y"=*.IPQ&("LP!&AABDF)$@5E9J^Q6[E"K&+XS2X-<TL_9_[:
M!N"\N9^DF_.9NE#F<=!Q>3RS,;O<\,-V_B_H[)C)6W%6/!AEA*I":DIQBW8I
MG\N] D2A-SK3@R+>B'YSU-@4%,O02XUP(^\FS\8)1,LMYN3I>X-'WF>.D4#X
M@7N#'@LV?J9M*.XO8R':%ED7N":6V9$[*OI6J'N09Z?I7E0/5U:J*TJKTU;O
MS)F*^:4UQO=#I8O584-EV"J.E)>H.%F7,#,PGEJ-V2=CY)K<VBA' HSR&U-L
M[C2WA5."V>Y6(H'PWW,8,)8;),&?A(/Y,2%+&\P37/7UQT_4==U@?NO@,OH2
M<HJ5WHO-]2.:JQ-7.(YJ][CQ;#%BC4F-<3S!4&3TSWR]#YU4M>-A(#>00%54
M&;D9$2!VNW)+\>M5:Z8K% 3C!J]#$P*279;T\MHV4Y6B2=YPQI)ONY/FV3"-
M<F/S;>8E/>/ R6[%JZ0N2F[):T@$(QAJP12%;G(*Z,VX;8C*>[NYT*-7PUF6
M];MH16"\P(9EK5Q:^^&@C(GI62WI8]B!IC&B9MI#5$ ))SG (0K=TMD]+E J
M2S#^'+34:>ZL$'LE%:4D@(;]IH_:-ZNTJ09[%>4O;G8NMJQVFU0QJ!RTH4T,
MMZO(U<E<<VUR\IIT.3F^L/N_RT<Q1FD_(#'I)C(V2 EB -QR[DO!7KR"N\8C
M <DZPRUUY_ 33+S3#5Y$J.=]%,_?%J9F"/ZXU.$K+X$^&P?V +V\P,5L=%2?
MP_6G_"TZA2/[D[(6?MA9+8W2*\9NJ.*E,V^JOO%!E:)]TR7,UF[?*1VPB.%_
M5.7B2R072!5"X*OTH(WR4 AE5;%Z9(,E7Z$P;,XK)"?MR4?:+M114LHG*'0T
M*N88Z82ZC:=793N9:LSO,F#>#,#Z\@7=\X6F%;?QE?0,[ZZ"TS.0W0>Y97+R
M9[%&!T>\"']18FNF9(;2=V*(FBZ[I"W3\.'T%-_4X(&EWA&9 ?Q.'>Z7C,^R
MCBOQ(=>?/1O]YI3(KD,<U[VN2S:ANW:D:B3SF"NV8PG_T (PWD ",6:\@&.2
M3]FJF#J[<:KCFF.WYB#KQGZW\-RI\UWZM\]\"8BH3X<_G*[3.&H-&&DKY=1Z
MYIUA,["0T48^;>)@P[TY2+XOB#N:M6YXNK+J8UZ0-;=[LS76[@O%6D]'^.;\
M>,&S$2UXO7V)AY8FKVM8'U?VH7_(9=3=)^(1$6VJC /6IV9.-'A>-N3KR3%$
MT>*SU<86]5#QM^730Y^P9C;*$AZ=//)PD6:Y>T9;&]/J%1LBJ_.T>S$G@E51
M[%9=]5!S=0V1D77ET+T;I&6!+/F/]T:9K^7RH!Z*O4EUT[]=UGLOF(N?RX.;
MN_IE&_I=\]?%)UF?H8F7\[!<[%B7I#?FZTH]S,6H&FE5OZ99\/5P392-&N#>
MM],EN9=/K:"Z.=<W7Q;*^FR'6#.6-KVA<2>TZ:UO#]<T]E2W]YR-FM"7#XWW
M'DE9X;PR=FZ8$&7YLN8YXJ."]46B3?Y1%&-8$&:OZK*!;[)E2M#7QQ<2Z'1,
M6$!!/32$XIMLC?C%G.E<]IS+33@HZ<4_JXH2R2.J9.M'CT:LW+\\>*]4QC32
M,MF7O(/YQLO'G8 (I\9TDZ%B%4YYUI1*::6./>U;I_=F3'Y.'7R8F>DV;?!<
M<NE$B<"QCQ8]/DWP3A^X%L)[';)U!D)/0BTOE)8U,MJS5:)@H4]$#!DZ[\QB
M9&(??YE(HJ?<?F7_='1A?TNQN"))9\>L8GN41EG<RX'FHW1H:!$?':/LV\BZ
MRQL&P;=4HG+UM#DB_' V0<C0QE!T-QG]$9_M_DJOLWITE(\88]7TP5'0F/;B
MO5([U\/-JX=FS,1.,N\6 JE&V]?2U6\U[W+H81;H.FZW'(WJ<I>$R,"?E\L%
M&!V,%VL50/NKNT\+8&<@HIH^0@)S]-,Y2*"G+AP.PGH$5:Q V:MA)#!\Q*Q'
M+65U161:>TCOPRXF-XOJA6:AYRDP&GXL[:V1^$4+!FWL4@V6GX\:C.*:;34-
MO?=7;)+JDXL$A ]%CL"GQT%^4RR:DYG"&L$>Q>\A(Y6MHB1GB8,-+0J\VB4O
M/7AJ? <S$V 9(9W4MAOT^C,NRQ_F2KAZ<-8TRWG]#FZ,N,8[ >_3M4:[F?CX
MR>>M,/GR!RX05[@@2%7"IUN0_",^?A9[03&?CL>6;\KJ0LL?<B;?6(]U[5V3
M)D4+V1N@U-R("7=S^*1K?=G4-3F?Q@K1YQHI$Q!"[_2BU'DE+?&@BL!MFT';
MMG34E_\.[6/TT^WHN^<<A&!BJEV3M4^]8JU^;PN$!A 0GKV^*/&WIE\_9[XT
MQAASGJ3#$&1YJ@V!!.J1P'6)Y[^T!7WAC?/Y9=%!-P]4N:)?X9,)+/+KB3$;
M#G-J016ASRRW7K!.\JZMUM?0M\)>'\Q,19XF4!Q^<J3R(**S]N])A-?/$'SA
MC$IJ/'T[MAIXJ]9T?<R,78[4Y<HNS>LESH,K'JO=]PTP-0:YF6J2"KW][5GE
M0CK]HVZ:ASN.*0F\7C4P_RG_FDO3!Q-$22/18>ZZ:ZL9WR5P7Y'?T/-@[Z*J
M96$.^OAB<=GW16\1YMN&3^W/!/*D<-(_O8_3_$S"V2I]X^5H\P)NCEB;4B;W
MV 6:DN='<ZH3LWRZLW(_3C>![SO#M&<LQ&Z/& L#ESUA/( G!,>T3J>/2V"<
M>'LU<M*4*&8@O778*#H>W5EPX503\5.NI000=<Q,Q)8Y>@=&)T?@:EP/(NUF
ME7H-))#D17$&MH))6)C$_O(Y$0@>Y"Y8FO>\$Z0T&*1D_URL?S3'@+B+*:H-
MX^XMS<U^:1Q-AGH*WL1E$DHDX#26>2\G4NG[[S0;\N;D](*[;TCGF7#*TP8V
MF_C%8%,5?7F$*>H9US:\WZUDZ,$J$3QVHMF-HR+'2!R1T!OI6J0,*.E'VB3_
M(ARTE!+S,_7@KL5B>U@\MATNE*^X&;+;QNSQQ",D/$$.OYT2M\[F@9S" [UN
M 16#2X]X%-W& Q_MT7[U$L=UA=5AZ/'19<I._H+^'AO?R3.67 ]-/ZSY4/OT
M2(&58;'7'ST$&S"S2:C#M\A**%ZQ1B+<,\IKXC@]CU3D*ZS?/'>J8#JJP*L)
M,0X[&-CZN>\(:./R>!-M=BEL+Z91\3FD/[<Z<L0@W7T]\95]Q'Z@YTQCFC&'
M*@7(^0A@&C/ZDD6\D;;CVJ,DP3&W]5U-B()?L$_4!W_C89$%S"S(2.F/Q>G%
MQT]=[65Z-4S!IH1!)WVE7K5'?.W4(DY3&7@YOB"Z_MTK(J)A4ID]V5:!#@Z5
M(F,F3U4:BW,J:?R\?-6Y*:ZBN9@Z.BP;R%<4R7!5<&R:D-DWD+:!F%FS]:>^
MJ\!3CIG]M66V*WTP(\S=@3:T(&Z3R;]&/="I-^IL_)6\*;I;QMW0[ 3<+OG[
M#ZVXXQO)MKK#.?RCV,>G2;K(9Y:+\C-_[K49&2!:H/3\\-*09- _\5.X9:+9
MJ>FX1*Q:+(=T@\M\@%I<$5%@]IBU519W^%@,_^+=">GX=X+2-0%SF)>D^?F_
M</_*&H7\ AM,^C4FUP8T26)V+_<+6%%I1Q/DBZU\G<<L)'_BI24U&W\S5$"T
MO*Q:].T=[TX2\L>C85)%A!8_YS>YH\R$R%YD?MCA=&FZ,V6@?H'8 DPRJ)%
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M0 @)FKI>#L$%:2PK U/O#TC@:!726A-$O_Q&^[]$_DOD_T<B<DI_1P1;_=C
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M!(0[67#734X\>) OM?EN&6L*YE/6JC-J7S](-[A_U55FT^&VA(T5CN6U1,X
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M$K26J<@U%#$S[SCD&.V=KA2Y#J:IEHY_^MVM_XUHK77R&7]A59#\&G&C1TB
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M$_FJ.\'I67#FW>59=IZ#TKE%=)WT+[J)P0:@=-X..7L5?FV6W=1CA-6!"S7
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MG*^0H.^:)UTE8H9T#T[5?MP+T47+2L0<O-(TO4:>%/"/:Q_B_/=UGNR37-E
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M-6K&M]LP0M5&8WE("Z$2KK#/25''@1#WX$:EZ"><9T7Y?'0X;A/&^;(+^\G
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M H3^^?J_:O\X^;_U ?;9#4"&!5L$UX$ 0P: (X-!((-]]@/P &  ,$B(O_V
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M(8+=(((]PL"67HR\"_C@ OB8>0%X2( G+V[$?F[O+EQD)5@Y9"0*?K&I.
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M"1LLIPRMB21!_@C[WEJC]IPJ7+U'W5%!NRI53ID(P9RZ02BE ]5FH$;DO7]
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M9B]>+U4ZM8:2,0I-BR5F1QCL[^W]>0):,G<X:G]PC*G%T$N\TLXR'W,N/JJ
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M.VK .:PIV(_J=4TY\C,V25KUC4(XCI<Z >LZ/7OE+5DDH7Q<^RG(3*^>3R1
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MS),<!1K:,!XF1:7R-8),!V)WZBIFR!M]62I24 PJG7@0IF)UT9QCI#[E^NV
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M9KZ0SM/.OF+_H]V[(,V?<..>Z1FMHW>D#W,4J>V?ZE[9@^VX &74$5=^<7"
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MAJ+A&W,Q2 <K<,-#:\"AEUYE/&,6G'M!&10#H *U'Z*BMFNUV<R+W(M(Z4T
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MYEVV>^/<A!9Z%.4#"Y(#=K0)-V.5W2XJU])83#?/_N]]+2H7[&B7WW>;6\(
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M&;P!0"* !" A@8"\(HZ.@?E.@Y9FPGM67.B[@@.*#GU\X(CN"2+0Q(]V1?Q
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MGH13?.-E"#OY!'3V=";95'I;_D:@%*\J:CX03?MR?8# 4AH,W_NU6CC4.PU
M,)."9*JJBO$9:+8F0E+G3(%"R8XQNJW/H8'M9Y[A;-S;X^X?GS"E"OTRG)F6
M[X\2<[.1N#/L!)8Z6#JRS,DE:Z$TX6#\WBVB*BF477/#E]RXK_]#.!(+.I$<
ML3)$B[B?>P# &)JF];,N=Y:69%^6R23S%)W:0ZXV3]G8)N[,:ME!@:F"&80A
M)8^+470YK?ZE(%B@P\$H9;I*95 8I(":O0-R@HS/8UEVEXRLCTWZF^]7=+;
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M]V8-<FQ@< LV+:INRM %#2FZFBA;;)KDU*.CDE7CM51EF4@YU8Y?BWHN_6%
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M*AC#TZ6FO/^J\&#(1)452:%5457"9(5P\YUPPRE2#CEE0)71AI'!T 0$!$3
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M6(-S-V7-WNZ\"YI#AL*!].LCA43:^7QUGH;;A1HVRQ)!U;S;>>"FXF"RVU\
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MR++Z.6S@+#AJVC9]^3YL)/C>+C_:^7;N//"L ;,4UDT"1CQM")"[ \">*_]
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ME$3W]T^'=[H[%'A]&&!9D4):8@T'+O!.0+&&:\#3T"E"H^,.@SU'PH 3K&,
MP+J3/!]V/8&/SU$/SU&[?CMD!\'J4+#"%&F'% \?$+L4'X,#+ $D;"JB,MPQ
MZNI@HIAC>Q2T@(1(H,00W5 ?7/8P>2 I<?^4:E9_-(#2L&B39G:#94K\F.3;
M*\J58U1D%'FBA;:&F@)FN!F6AGAR!'4&/ WODO( )!FL" ;N""J=+#@Y*=@
M U 01TA]'(UAFU.\N@!=(F)]#]E,0WE78E&ZQ(>\\!_Y#RL&2!]%I1.1$.$!
MKIRMNWLT+QR[Y$@V8'@4:4E/):5$%,\TZV68'.)/LL+0%5?*9ITN,&;RDZ*I
M_A04%;89%U]'9SB-()4(Z9 7(2V%A/S$Z5>[NPP0R16 $Q*"A(2$F0UXNXU$
M 'WQO1/DV?P%Q+X_H^5J/I:ZS-PP&O@*Z;6\/Q5J;_3*=ZRZG#1%SEFOT,RF
MZ8TT]FL<F$Z3=EX4W]9A*Y^0=X45Y "Y%NP'"(@#A,IMC%@JY7WMS!C!.^&E
M4R =)I7A>/2>=#> =,@YP[(-U6:NJKUP+-409WK!<QASR7-\W ]&!3:ZW3E^
MXQ\4YRV+\C?&>"A]]X\G+>Q_ENR"G]K(F(@*C4];T!)I@KR)KQ[R,05>A5NN
M4!*31GGEJ!>RFZCYC24PV+0S^[2,X4\X1ZIQ_TPCC4HB8$P*I-8[CPQQ,:N$
M$3!33O&&I8[:-K6OD<V8FQHCFP0X?>7!!\]%@WQHBF D]8K5RA!*&"-#Z"(+
M=7P*([+#2'%#R<+#DX]X)4IIDR40P<&)Q3,@Y7LFI%HI:893BX(*ABS3+!V1
MJ_1H:45QKJ"[-+4&+AUW6Q+(Y,636GX?IP)#3S8>6$)O!P@7Q)LRT%(*F,BF
M';D#D3YT8F-M\.>CO9T)"49;[(?K21ZB05<+,ITRV;_'8-,KBI4L#[Z^^;\!
M7CT'Y:*R7S+1'[)_R% NIG9:N]<^A<#%&_6'(**.>]H%(&J^(X(5?C);0H"%
M1@U<\^*<_PM,&'6Q8_WPM^<]F_S/I"I4U-KB*Z5QAZO*R&SP/7.HQ,\'P'[G
M3N].C9Z9@Z,L"N<$&>UQ[Y28,?^_.<-_L1/KWPPQUY@70)G-D(SFYM7CJMB<
M5GI)Q^7F+9OR463=!.,<#.9 YMA*H'JIO#J9[YY$[IQCE!J>9@EAMU=(N#$!
MB[.[W6SU*_WZ9J<?' UPM)Q3%R$Z8LDGU79'HF'A[(I9DQ9_:4E X(X4.\]T
MP5B'+G"Q@'R>2KL&;+T)S9W YPNK,'ES,N;%LI; YX+U7!^]E\1PD;.VWKWS
M95E*]V:9YO=%O3H^=A*,?8/X8)&64<DBVB\.]?610L[6:2-BK8S@)<1*%<<Z
MRO/80RVL@=6ZHGOX;;^8M[>4&LO')49)J]2C;O>MD\9*/]^\#78Y+"6%? U^
MC-QS1F;VX*8UAU4=HMM+"D);^QJ8E'0E,<L]-H97<7X""C :S+LJD-W+#FAI
MOOK1R^>#1?6A3E]IO/,I_*@]F(-=SD=26R&J;&2M-OZ6+947='?$&WL/=-W?
M;)8 .3>>M\;$6L_04S4LQ$29+P>!3JF!+O;S:/$Y/S;6A[Y9X/8C1BFRNZ-=
M$32:;RG)Y2GO;E>9+@!)^<)8IR!) =DG//[I^^34_MGV@UHXBU5BH4$#'+<^
M]#F8T'^,- X?BO_$Z!KT+QFT6CEV06OC8'F,G&%+OXYK>>LT(NK*#'+KQ>A7
M3N7N 54AP!1-?1/AONHLQOVHK^2X@ZWXA682F[8IL&8#(%EO; K\'Q"AE_.3
M*C_/$^9^Q:3DQ#S_5CYB5C:#3%71OD>]JI)D/ W#UA'P$&<E?L'F;4:DA'#9
MV/.DD*%7)I@+^TG[@Z@-%^6KF6D-XOG3Q8=',4%X%X,;/@\9MBLG"I\H<EU=
MZ<7"]$%;)0[D!I[_CGKS%P! ZL+_O"$EU]*MCXMK%A%,N"<YNKL[O,FA)AQ@
M? OR<T/(-Z#+G[.!49RKXL=F*ZDS<M=>I^H8Y$%@XZF2)(6?6TGNR<ZON#G;
M/"LK?SPQ;SSC5L /LX_.+N"MH"+2C&E@]TEJ*:4P3?)L3!P/A+:':U1A1V/W
M[E,^)"%7YHZVH'<>,:2E*I@82(X"M+)3G PQTO2;K.D@<'A*^#OH-_330(!V
M8$"'3U669I@Y%4SL5/BJA,7-1;O8G926K'A8,Q%JNUP8F3H+HC/X@=LXWX"G
MIGO8R%'%2FV7P#Q)#:X [:2QRN252(@\EFE.-(<6N2ZZ]0#AG!8&.E"@%+2R
M[_X(GQFM=Q-L<LG3NF*O4H$%\7\0T',Z%'*L^CE1'%,A+A>T5EHW=?O9^3.J
MJ"3?],NG)+N<$Z\VI"7!>Q5-STRQ9+I2S^@KK?]154,&=O9$KY<H\M?E9AVK
M]FP[&N.I413XJV"Q,]3CF]01WH_QY.CX8?I[5S]TXM3 T/3_A$E7%)=3NQ&-
MMX"Q123]5-VBT>P:A%KS9DIC:#WTJM/[ ).N$#&HQ2T=AEW.WM1QB]F8;U@Y
MGT[$N@PQ/]+DZ/) O1@?$J*_-$/CIZ-&!-T:H"D:_/L62JL#3'3C1S_:K 4U
M/I#RGJVKP,K4O$Y6[+N4GFYH>]@4G4,36MYJ-.]:*@KD$Z'R+6R/4ZLT*\P:
M>N/\CGOQ^QKNSED%HHIXC)GY'PF]ZM9*<W4>M]OFWX85^_8$@98?U?KZDY28
MBPVX>9J9+192 W;FJO/I1Q@KC QB[6L-E5&\M$N9B>'3EU'\LJZ[/WEQ5#/2
M?R#W&6>QB9%%%=EM= X@.M&@-1$'2D*NBHWARU\+GWEO?7#D&9ZB%+!&",6<
MZRK>K-HF1 >5L^F?XF,Q-T3J5G'@WI1]*]]HEDJUP:)6!%&S1LEXCCE/3E$>
MULMVT.GSN#S>S&ATGPFOA?._N'OG_IYMD[;N/.[->EJ43[--QGJF3M)-BXOH
M05\7G];2OFB TSQ=+\*3[08AFOK%T3CQ<X-*D/^(*2H38-@G1:PT25GR,VRG
M7]DLD<725)IJ7WLL$.)P;17L7?%<Q$#W%TW*6N!X7W[1N^O9.R+M5K&%+R&N
M);%&8^=]OSHG 2K'9-%+*>C>]!1_OO3Z:?A[6YV;K//I^154[C^_GBBON;/&
M6#T+A!:M3%*7:9NPNA9+G*9Z_048O71$$2DBL%"L69F?:> JIV35#XE7;DP+
M+<A,1<$"9?3),SD>[+[<&!(O:F;VO%X<7RZ;.*>-<9^:%,^#6Y,['=7B[-"W
M?:Y,+!%ZK04/J[+PHQ?28QM+M!8W%+C#Q<^?,3T21*;PI)F=VW:43DL+.5?+
M$+UH70DJ@.]/<:K$4SU-B0R,2J>NO@^M.JUDJUW=_!CQFS6W/[@U769++S8X
M%-"%!N%3(_@+K<8G5^FL^;U6NG6J184:&&?<2,GIZ62W%7YF5AGKPZZV](P<
MX%>3F%G9RPG*+EZ]T2]BRY^^.;5,P*>,P95'Z5U+4?";N4@D)D2V,.DU@G+&
MJI<GQ\+8[L8XP])-QYL0EH9L"%;:''S[103J\KNI',Z;UG0P_*KWPA=.M\7.
M0P/DJVER-:/@M'[)7!#<HV./\=P4?*$+_3CGW'AG-MTLEE+$"(DBC\2MC@=G
M*/ZC^>1L/9?%Y6J]8>/K,-^BI+ACXVWKOKU"7.7VOJ,S<;4=PMQED[MJIS[R
MCJMVYCF%B%A<K:":^JR(3FZ\;9/0#.2T/;>ZOYM+0*3<_@*]N:&^\^KQM3HT
MV#0!KU\\R)LGTD ZVPS(C^<&2HX+'-.C-41V.9>7&E>#3(D'R7-&R=,J[0/L
MDY#3UO94+<=[W*9N"#8JP[(MI$,UL9?PAJO+JZ=/@\R3E_B*!UC>RYPZSNNM
M"5:/2^=#,;_3YSVDV<.:FVYVEITO)+GX3VJUI*29A[5AGYE_"\0;$=[]LCFQ
MU[3O#*,SA$_!.5UT4^(2V#5N)?8[=2^MVY*PV7AJ): ;/N$7?\TL$)7]SL8U
MQ2 Y?4CU$]*Z=J_+1;)%$4KM9VX>.F"A6>?*^M?*7.+;9BB<(+]5"\&[Q\5"
MC9M)R#N#$\Z/FY%V)I^?E(@T+"Z=.JJ,G4#D5G>>0M-5;2Q!__9C(7@S=%ZD
MMWUE^A ,0%P V#VI(=X.3/W1@1E"\!#I<ZNBT95CG] N"XX_7.=?P!E:R8^_
M@$8A<XX\Z*OTM AL8K,V<ZZ:&BB\;]+A2")6O 7KJWK;(BQR.=(\5<M_?N6(
M>TL1VG!@I,M3HZ'T\_2:RCNAL493W1V.L$8[D)O AC]@M:ZMZ#PGD:&N1*SM
M(BI:1MH_G(X$65_YA$;AFU"PJ0HX&V(S!9AW#\6="2EB9-MC0K?=KVJI2F4[
M3R3]=P;SLU;S1-M='-34$>D>X^7"/;9/7HI))IIT1JOM2Z1MKC #@Y'A#CLY
M2KN+*)8<XNX?$'?XIU]!8'3^7!7B_\\9TOE\DEMJB;8H)#@."=V*RKU ^_:4
M_@Y<ET[O&+I@Q];MMF[,'DA@5S"0%)+)9#NO+$3.HA5'+44/4 =/K]&]F?N!
MR7_3#:K\"#I76:<6RL9-R<.I;YKEM_BN^-FS39]-2'AZ8N<5^X,K)U6OOG&*
M6(+B5=P[*+Q@@-X=D*3<^\UK")G*5B.B\DMKH2?:RZETW,$P]1+&TZ-VO@_T
M(5SN%O2/1%@HB=1(-[[MV$B].&X_$*RQ7.7_$\)9L,A\UE4^%#* C-P ##=!
M(CSC4E/%<##,.)#0QL)%^EQU96C=V;[JK9C+\>QO@_?%\;Y*34$J$83CZPE3
MZ7>1ZW9ASK @>I5<&"X*1+5MOO#1NS+:<^91_\WP-)B%WW"/5!4_\!!MT_/!
M7$A7IW&U0D*E6J%HB5.92V+3""*K3OQA/NA<IOKH955*X'T_M,%0=])]P5TS
M T^)0%EXF1OO?Q85LDF?&0C<M%DYC[FI_B!*33&OV[*):V22QYU9/BXZ*<B-
MLO;YT 3:T& >+=* ;[LNV7>H:!W+&!.Q?]!CBI ! I$A47\@TXF=<^;C"!S[
M2P.2'"%SS/TO^=*B[$N]TCR4^"^P(:1+;9'VSI=M<W-@(/ Y\"$.V"*-T .9
M4/E'GU:1LW,X)I2QLAD+C]^RC]\>.JIM8^NO$.@ES3EZ7(<L$7U4*88!'=.0
M6ZN ^9@^8PY]0QBS&Z0M\K4WH^14IA0;&1GI=:[JH6*47><D-$@N"4<3PY&^
M:!D.3B>\Y<YF!$M]A"?DJS_KFXAEK(N<IK:N46+/F*4%DU)%$AGS6JNF>:WH
MTN(BC?'VM!VVF3VZG7*_,:$X(8>^^5\Y)U%41W&-9F>G^!\/^Z^\2E):P//V
MEQ92E#MPX-CIM4%^?COZHV:V'&>TZ;X$M\GG.<7%B.O,YGPS&P8UC[N'C9@-
MX\_N8.\):</C%6A+ZF#1[QM/)^(G)"*U 7@+6R,EN[L[&#TC=H-UN+=0D^98
M%]6# IOC-'1^WNN8L><M]3_E4Q)=UCUGQ?G38Z/R7W7F%=ZHQ+1!X"9Q/[-4
MS39DE8H]%XH)3/HQ3M ](7B8 4"'BCP:I'V.43HRDE:U5X(+B*1&3^$LC01U
M61>SP)?]KWZ3H:[L2R(3DF7&9TMN[,AI&_8YFDNW4C/E&\9ORD\RVG">U/[A
M@;TRZ7&VYYRHTK)UK8=0[)A'M%&@'15@(7.;<K?8 W%MG[MN7:VO .NO%35&
MF];^Q_>\0/G^E5DI%P.F'JX"[K4UW:H?8:"GJMRSKLFJRN)@535SC8G+%>/T
M,'B;D_,N2>[34> &M](J0PA)/6^HPH9EI)S.Y9_AF 4+]!]4N$/,*BFZ!-3/
MK8^KBV;624\'%*8[U8<QOF?:])?R7UQ'*LK"<&U9=8NKSHD 8HC1[=N]?^_!
MA3GXLW.RAZERB2+;^;&>L5'2JU"[KKM#>V5J8MTIY%)HV*B 3HZL=U;%I,NT
MRM:H8?%[Q52/4DK19D')0,*7(\0G22(7IA<]^4$M+<V72FOQ=U8W?_U^LD$/
M_R11PY2+]YPU%K3&Q9\8K99O"[':\;X_/0I7:Q(R$9<'C.00-R,F$9<SQ53-
MII+"T)GU*BE9X40[^-PN3K0)ZKJY+F8U-9I[1^B0\ZMQ7$:1!DZ,6[>:^:]2
M8%U798GYC)\*E3;L[ L*PH]&EU&#F+7"%]N=FR1E&/?,D#7,8.5M!&JM=*"[
MD2 9'P5EZ=/@O.J_C"@[3DQ<1NZGZ:YF^@=;3/ 0Q:W&)2:J7;@BNW#$BA;;
M-2@5LVJP"OB7MX0F_@)^)&>64-_]!9B?WOT8V=HU.U$A:.'#;N%6B0G7X*!,
MDB4DT+Q4O=N]!^-IF\":8ZQ*(20/'$^08M@I"9-Q36LUNUH/_EBK:I'M4NQ2
M2S]_G\*"/AW(TW20*Y?3M9S3U#KO#ET'U; ;$<#8)4>[?#>W'$O;_;Q74;DA
M0+-X)2[]OKR6HXI50GNS;O?XWH*@38 4.&GNYE6E9F5STO+Z-MJTB(Z\K-T"
MG PO0Z>MCHX.6!$(>E$T_<4/3?#>J09EHN@J7*6Z%JJ]^K,/AW-K%I6#(=NN
M6^S J4SW@8[^0],6=UJ-0_;PT>R9V JDJBI?<H36@+?T(*/-U526X$!ZQ G;
M>(P39)IC7^C'[(P+H<D0.26_?@3ZR<MKV;!NQX5#?N^W;M>V85IJA]W%T;F?
MD3>C155,4IZ(A)]BS&X]W\FBF?7T.T(6HT[V<O].?H'&H,6!-1Y*7*-+A1ZO
M)G-%&XX3,ZED[IBQ:=G2*%9EKY  FPVT\]T9>8,5^)!7YIUFKPGL<EUP)F_N
M@EC1LVB<3[&<ML?77\R4_PO8X\2?5._0;:J:YO(%V0QWQ5<9E*NY39K2CH_P
M&;#I5_&ZKDW4:YXN(&532_C'O.S(,F)PGI4M\LKF^BK$SE*?3C7A,A#IU+&G
MG_/Y67FH-KFE@/K=_9L,Z;AAY7(6F$^,W?<GS66WN3E^V%",LE]CXUG0_V+E
MQ=JAFU/,GY8H QR0!-M!I\I)]F\,#DZNDQYH'_VHF6>"3U,Q7B$W2U1 "VDK
M3!Y=H06C)BDW=*,A?>J(S8A4!N6K_>2[$*;YJ1%1$=NIHY]UD3>B92<N_VEA
M119+8D2^_]IIU6 X4# 9>HC^%S /*XND+L)$JJO4_DE&9NJ?_N.NA'=4=N6E
M'$:;MKOI2>FL53M?1GO?9F?";<,;E[^"WWA"F43*TG/2%9YA;&2BX-$DX?W/
M;>YN)>YN?(HR"I4PG:E.$[:$9Y)J?VVX42?J+&0S3$?'3J..(GC:%O ":3([
MLN'^?02/WPZ8%4)O?G32&S",NH_;.'P=2GC">C7%.SL#U4,$@$3=N/X+X"L>
M,F_6 7E#=YU\:]:9(E*DFTH,UA$=A,4]GH_1\"N$)8V<41=M--=6CP>2J2L:
M4XN]DGF^A=]1EQ9-2P"$^+=>5)-GO)MB."*S3EU7M;6)TBSDM+'-\LPFTDL-
MIE,"J  ":?R1 4CU!2=\_GPQX,7^#+X37U!JW_S!)L@I=@$P8^%OM\+-PF G
M)^^U(O&L'$=G#P8]_XW6]4-8&_9*;O,/)^2SMWY5$M.,3M^SG!CFXUND=_ G
M@M+("P) ^RGN/+K%<*@J/(Q&O%\G@<F+4UX5%U^NYO\AY/Z7R"4E8;T;8"9U
M1LF#IGT%H+V&]<$<#=![#W@^7*6-SL[FA6T('Q*C.3\'C>:1'=S\!3CT7G[\
MF4$#B/B1DI*]^+_M87D"AT;)?+PEZ7S>WL)A)D\^#!U@*Z$A ' 2D#"'9'=@
M_W4"MRMJ-9A?=]7[&7%_K86*H>-\WYO!,OA$,^Z3L$U4)U)]?]F;6(K\T@@L
M/2*G&#:EKVY/5!Z#%[O7]:?T>6R TPU33FW7]U"IMO7'%/H:;8/F%5D$J/A?
MTBNV!(*)U5M4F[EVURV692!&M:LTW.9U_CCUFA4](F8S>+7XO6H[P+W;^6KZ
MM3[S]MD'=D&=&T1#/(_QQY:^E6!ET<]1U=7*V3KU]P^O;,GAO%;9 WD/[5X&
M;<L!<KOHJHSWF.@$5/N<P<*SI!"#MAT?#?!,FY[W-Q!/AY>E%H%IAH%2KDT*
M0HI[#IB74<G*AV_T\#-U7+W>HPVLWDEKA'3AS,*Q]487O^K"^4!7S6R!EI5!
M3GQU,!@!5Y1^]*H;U[;?EL\YF%_6%_^W\\K$KY^/GQ>QXE%F;QJ] C,>>%OW
M600:3L7GO"GDH_9YHH&UFB*179F1Z;XD<+@6UM]J-*,HSW*<X:"_76'R,8&)
M:X"^KUAA;KW\0^&LHS1J52OO.K#+/=^79>&I6P!#,Y5<,/93(_A86;C/Y[R.
ME3,XF%G)('T-;+4-Y1/6HAC\@Q@PCD-<RPLZ'4-5! =(2XHT,\V$Z\QW$?>?
MVN<.>LV1RU4$-F"NHV=<M,6EC"#W!5JVQ##[3EAAT1J9#4I7,5AP_Z04-3I_
MD<JLJZM-&A;;"@9Z24F.7V,1+'#UOT_E[?2. 7/B[8.@LSG)>)PHY\6&&V:V
M(/K[R,VF&@1XQ)@Z*V!.\-B#FK*YUJK$#\O(4U45$0ZG<ILHZ9*G&BZWA5E9
M^W^H8A->ZK!GPQ&;AG7DP\0X9Y62-O$T(SKG&>W*CH3M>QW^LFI0FDS@[Z=]
M$?4^>16,#RJB7!6SG"QK;34VU?CC=6RA[P*>]E:6+C*XB82PY0";VI3Q6[,^
M(:W#4)VUU*\:89/1^(2(;Z<Q2;DY,;BXC7=&'"T)Q07B3,C>+A'AL#B1?R8>
MI:>0 >#.N(5".WF6A20HM@/*]Z0DI"3S)]<GFMFZ\NQ ^S5F'H#K7I/.TX-,
M44"-A'0RY3Y"# I/"1?+SD#%/Y7<(/]S_Y9+N\\2"DGIS@.2G1A<:4Q%&+9,
M#+9G_E,\PJ_[_5($#:5:?#S Z9V'[#"*X3^,?A;FF?.58:P75X;+VA,EC"95
M5' XTABVPD47,YIE46 N2VYHI<[("42A-]SA2@$!%H]MO\<(SJ@!="(>.SZ.
M\) 4I]ZKJ>M!U2IUYORWJR1>VP=2O$D&*YL$JNHFI)550E&?))(\T1BA[I63
M>%/T5NA4QM6--,:FV"KLZ)FN%PNM)Z*EHQ;-$RW$5(_9T7:2'0C:<;X<9]R+
MR&O]4MS1EL<J^])<%&7G^>OL?(Z@TQ2-X!-ZF621$(; 7_]1X_VX?S+M/,WP
M<.?C;%.IX2H_[>DPR_IS5J"V5U*L'/#K:&[#0:=<9Y$!D\)L8L+P]B?]O'WJ
M:5&/?>^<J<TI_>::[OJ>>%5>T<-CW2!PL79SM#I1Q\Q!),LF3O+@GQ^)6 [U
M-_!@@O)7+2_4:M;PA;;@]]KXL!P??0HS7TG+I^]L(^*\7D.U"0HB]*:+NK6+
MQ0[_H.[=_+2N]&C.>\&DNX-5UPWT(+\*X;JWNB^T]N!(BLI%+(DQ)10"67Z1
MD1,>"?'QCS$N_\H&GW/1_FVY'AA5)5-B6KD0FW.L+H.G30V$C[8-J:;N\=,V
M1]9-4 Y&DDF[8E>#90H!)-8#!P%(?M1SW)G(3M?>RB4V()4]LQMTQ.X0YL("
MG51Z5 ?1?B0_OQY=_=DM\#NW&+KPRG6#[CU.=%A+E\:FA39.A6FR@X,&Q+^,
M0G4!X]IXR<!DP<)6@WW]4H4UM:!SX@2"YE265/'8%!PXT!$H<I\4Q/4R[/I^
ML<:*[ :U9G+Z\)[RN^O\L0J*:;99"U37Z:Y2Y\O859TBA_MX/9\Z:U;01&&L
M'TH\H%.7D+0.TE:MTR207B0F@IK9H4PI5>1K)WJ9EWS_<Q](1SU1PUG0D^FX
M1.=4.ZC6V*S[K>X]]!GPM<A%5E@_QF:=G?:]]*YR1*E,C3,3^'Z30XZ2!7*7
M;ZI/I&\?XCC;5-ELRS9)&)#DS'AO6(Q\HQJ9)ZRT2>:.M.1)<,+9JX^J4N5<
M.&?2_@N@5+%N4_..6HB0]4T=!J6K@5UBL$LOGQQ5-09.#^^P\U6/B&%=X!2N
M[4<@-Y*W=?'&R_W&>1!/-]>?EA]?0XEA8'O3"K76#[G=TKE?Q4F#)G3)!EHB
MR5CB0IU=#TW23[=Z@GQ"RLRT6[>Z&IU7(]<9Q!!YKF9L98S7ID-0!2S$O_O9
MA-_JD,>+0M:0\OWVJ+<^%;==CR21TA-?7WE$Y?&4_@WIC\WZ>9/6=(AT]^;_
M2NS:95=E5 NS[2W9,?U5/B\N0^DWSX')T4O0;&4H1W[K$G\=A-7=?UA.J"XB
MSR\D%XTTY79)3B1>5T[^Q?!.Y59S,;J&37HO>E!V0VRZ/IF&_)M'>W-5,;52
M@O%J<S06L?*:D$?#T+,QJMPME2='+7N$)_Q=5CEM8GR8Y8#X30MXW1G<$<.)
M?^YZ'PEUITN_%\ZKEGQ;(&Z*BVJW*0D)*YH/*V][Z-X24 08\9]C!B#+GORQ
MUP3_=V!G@J55Q;K"G'K,;KR_)ZA6+#[;Y\N;6( '!_F^T@P9MSQ.C8XDJ3(U
MM2!VMA!J>W$*16$<?Y7M/?+ZI(8<Z97I<7+656!Z_9\]'2#Q[3/GJII70ZV#
MBML0,[:LK80<OH+"9M-H0^,ICAPC$WH0'/G;-RSMX3$]QOIRV4YIP0O/13X-
M,BA8%7 OCP?:U;QY0;FFJE9QFRX'WC13&^PJ#%J_OB.S"0:>2W,[*+9QE_;V
MO3;8,YP5WM8EJP;+H,K6X)98R6U#E8TKROU2#%)ZU>35(A*-M<LCY3S&G2]9
M#H,&.\&E:G<(XLR8T<<_"Q^U+6N.V"KUK><P^AP71VY>!9SIND6ZE%")@^IE
M1-(??/4+2'A*S!&Y$D+F\)A''N>'.P8AZ=YYYRG?9]_/4K;?>T'A+:?O0!SD
M;2:D&BL>%YB([WQF]R&JJK.N,E&IYF[6K7)ZX%F9(*A!;FPX;*XJ,5,#[!B.
M/'A-I,*NQYJ,9^&&1^;*/5#.AY)D7PE].M9>EF09]/&PT/>&M7T&)DDVI,*0
M'Y0-AE.M/,T6-_J5Z;@Q\8Z'TA&#7@Y%7F0<.[/EM--(YW(BCK/V#C8C_%AB
M/7MSO$>U<F2Y4SU-B_8M"LYF5PZL#<J[YVKNU(TU=O]P&FENQ!WID>XJH5CO
M5U RNWE5K1B&PO5A+9@Q_TFYY=H9/GOE64VW[?RM/@5=D6TSD05C^((M4M1:
M,V:Y\3T:9(D5A*8;[/.=6<VLW(3D1A[S GV3L;]/?]1P9 -<#%WMGX83[1F4
MGK<A9B,R.GO.0A/1_&?JKD7O%!WFW&B%PO$U.#Q+_'=FFQ9.FMR$'-#:;ZO6
M--C.)F8,F]Q?C)$SF-B5WD!-%9DG]I$Z/BJ^VH&4ZE'S=X,TSA@S_<C4R@:[
M""L='X+U]!*;E/'B$^P&TAECZVYV.,5F!9 ) XZ,.?E$-_WM=4;&H.^=:LN.
M[YM8FZ"B'5'S&-]3O;MN+?^5$HM9D+$7=@B+2/.^X[LQSEOGD'53PO G17S3
M@$!U,[][:;0^M'QNQ%3Y+PQOJT!S/U_K"K1EZQOCW?+![Y?$#Q"=D[HF%UQ\
M!^4"?B3D#FHQ/Z&S.FC#D/:K70YSV</LX3M9MNGG0<$B:"\T4(I^:-]UVBH5
MR<PR]2\B[=M 0_I)H$^D*ZS4=,DUIBL]6>Q!D_DX!*$)C:]0/J)H*,E%!C"+
MQE4CAE7HY3?R%5/*-.CR#CK=LU[AHGNM+*4GN="?878+F)W05='6IV[B1I=I
MNKEV2SROITCF+3DK8Y^V\8R92G)XG'M;\BO45)9IF!>I _URS7Z_>'6"FC@9
M%EA[_?1UX$\KA$H:7;5C3+,DO#>;%O4ZL]*-\/XX&(::6'98=H7I;YPGU8O3
M\/(BZ5E&[+#73R6J3G.CX2"@#EV&G[DM64<.(R<JN.[,>!PNE$;E](=]YTOH
MV-)9:$;<N_2%L2Y?I^V,,;.NF>@PJU4_SISXYKB&XXO#2OC3,ZG<F]->U;A)
MF'"OZ35"*CQ[('L:I8I0T>8374> %&DD2.970@N"^(@5)3@L)2$#*"EDJ4[Z
MV,"JF\U7L8L;+]?5&V"=:HYWL]0!;6\$RO^T&&G?U9*H=$HF0&F'(RFD-7J7
MKH<,4'X. 4.Q+-JP&^MB/'RPTSO]:MI@3G?T'K/\$4I,"PL)'P\AZN:Z_(-8
M&.G-""($MP-[#-OE,OR'XB91'2H#^\:QD$DA[]XA^DAJ6A=K<Y6B.\,ZA1FL
M&[)JU@:MMP@QTJ'XZ!3FJP_,,=3'YP^4,+YZ _IOE/Y../CX^!?E/*K)/0%>
M^RV4GI!<0?U,Y>4U2+Q0.-='_Y[F5[FG;OHNU_2\&9F@J%8E.'2VW-I$@QG0
M^-#0INL3-;8T >]]IPV-CKA-:R11 49(#:4\^NQ?0N=K59A2NT5WIHKR'SQT
M,<7+$YWN+"%?KZD/EL9=D^0E5X+L:FI!@RF:0]>!8<U0LV*"^@6ZUC[K*PCQ
M=@=$5DA+>IYD=>*@Q 3TA##%F1;8VEQ15995#T-02D7T@?"U>= <;.P&2K5!
M"(%I@W'INFJZ9-2JAE/E6ITN:$$V>"AQ"?($.5O,[),P*Y>_U6$QP?[JWC&"
M,#CZZ!37X0*B\(AY<US-P(Z/>75,=CM-N3FL"T7+ZR^@4@9[0)L(@6B6:8$D
MI,14ERVNC %M-J>."ZUA'FU'R7%/0U/ODKQ(A];,=Q]1)_Y(HL%ZQZN"[#^L
M1-DWB<^#P 7X]:'=G8R]HFR2^/OEHDGY"E>_/@_F#UIQK[6IL<?_(.X.I9Y;
ML"F!?!#>G%7]_"XY#L1X&VQ3BI(/!68=1(",E4H2R.YW?X_#\@,WLX6IHNIC
M@YX&:ZKY_@*(4@9GA]HN-!BT"X__ K1TS*@)\5EL<FK777%:+5"6-(9CG15!
M3;A'OZHCPQSG2AT3Q>#*E6G/YKA/9%7_*/KIDY3F-YGK!UID +OL?ZFII,JZ
MU/.),ZE)J#P.5F#/,%73M@C<-38PI?YQ0QV]=<Z %Z^WVL/@IP@3?[O(YMGQ
MG;#I)7JI;&EA+CD@8 Y[G9C+WYE5S$-:]+H\2VQ"00OXF6X3MVMJW^!@C(;>
MJO\Q7)4P9$4M1/1- ENA8X(^O0\8QYKK[S8(3F,P/[/'B(AV 7(H,NM84 7]
MH/-W,URA+#R^J;,[CF<[UZGF@DMOG.C*2N:+7?*ZNB]E[4G\#OT97B-_L;!9
ML&[^QKE.3Z/WT*[/)W?.6:1'!C^MLTUO#/>CS7*]' M+6= ]S<+KUT.+X;2(
M5).G2^F6+NV2=-DO&J8#E7Z?J+/>..C(@?W[K[9)93+W%'X"N-4(7S0K0B$:
M.[A5[$/FRUT]R=PQI'5]O?;.D46-%@9@=%,ENJV--![VH4S/QSTM<#3^(.1+
M[_6^QNH]Y_$>H\NOM)MEA!''ZM=;HK["Y=-0T]/KV)G'B M2OLF5:-Q\B0\7
M@P=EBO($W5] 8KP:*<W!QCVA?I/QY&8B2E(&,RK/B 2S'7M0AO*&97N[5<W2
M@J:IH_: 1EF_@08[??4XG=59@<74^DP T4P8W)QYYL@0LC?^"5>,1: .*Z6>
MI4;]P1O!5/4I<X:W> 6F.E"]KQ]8$A%.(]]_A3,1<-@G! DQ.[3C\&WF>44<
M*#%U1GX+9U2!"TX+M;6T@E-,LEZ5HFB2SB8T&&JPT(^6U,1[.0-IP8$K@<-A
MY,2-!.:%/74>[?+Y)T+,AK0YRMI,%;Q\06:?KLV-/,:=+EG, 0?(%FC%O!L#
M7SA>*G3%B6R,,RY2-#,8!ML7!@T@1J1E-(^#9*VQ$07/Q[?$L688<<\IM+.1
MG6O.A2#745MDG_W^"S8)+0]OK]A?#_\$.TC$D@4\69LBKW#CW\.HW!JZ/$K-
M70PMNLQ94KP@^B +:V[UF&SFWS8:;*>%NT.0(.UV^H@4^3#6>2A5C&3_ LAA
MCECQ4U6JP=8::3<B7M%&JV3%PJA*"37Y@(/Q)151.EC#<#^G:+"3O9-9^$IN
MK^D-J^KY10_I2G#35/M&&\H*$1^X)!5VW#  B7^$/"GTZX^'VSV<LSTL2)%\
MZF_^ )@$M#> 8U18M[P/+"',;)^ ;X_XF.?'YU?0/4F\CR?0T#/OR8PD+L[?
M_]-O]^,OP.1D@!Y^'&<T*5D@+/Y>6#@N+NSRDZ?VXR:T60,*EASJN8?B'@P,
MI>L&\/HIOO>PAR/T/_ IY;?V=-ZU,=-UKO^S6792L\@U\HU"9WT7/J+,F@MW
MG9K]B2&8CM"_515481T16M\ '/W(\4 ;SV\/E"44B<0#_0,7YUC%^DZE.?E;
MK*<^14@= SO%4C6,S1,Q+XWNLHG(,AHVI<3VI@VN7G2F,QN+MH6@M%P3NV33
M#;2#H8L\:<O=T++"W*IGHW<HHC/BO)R/<F.^-A6C#["5\S@#SFF,'UD-!A?K
M,PE,:]@<3!^2+=OV6*> K*:V6:VU$>)U"E!<GA/^5;.Q-;8V-7(N:3JQ9EZ2
M7PJ2S]9J-//1R7E/%_!T--@VP^PW G7>0J,@^#9,\++B5^ID@^1)+4.[:0B7
M4/."!U?M9OH*9?;(@HV2\2XA,>E?@/H:9>C$&GH26^VTQXXO?$7!^DR5X$9G
M?)OV66H;JBRW&K4D];1W?/VVJ0))QH[5<U"FG[GH0Q?AYZ]J-R/0A+S,&%^\
M&^EEG2DALY/6L8N?M_H<76'@5YJ;BPMMQQ9SH"U_]U^ WWR3OB)\86M=O%L3
MCX5Z(D$U/P&%+;]!KQ7VN]O[I'1J1..WV18M_D -/ WKV/E,\PABO'X25M<N
M',C%QNOXGXHA!&>Y25F(<LPCHVA_ 3IL8\B#BJ[7CRD,Q.6_32[6KZ*J-[+X
M]7[AVU/I$5UMI4XT>QG\>:"5SAC%]A!+2@\FHU@'<.]XI^P0$;X[+?H-LY;Z
M"F?+O;PAK^.?KS,F3&I-(P]&!,O^^6/2]%0)F<NNO@JM51D$NCQ@H_-0GI *
M)&_*0J#-*(*MGL8*7RE!<E7-LAES=5"P)G.;78!W05IA*SW0/Q_<RL-8+FG>
M.*ZU?9[F7->=<G9) LD*\@W\'KA:\5#-KI"5Y9 45ZE!&PYU"J8 &A=5H;/D
M\4'9'RTOAO?F5B@:)/5R$7S3-;R6Q&%=CRUY)JA#96]XLMHN(OME?N?.:ZYH
M."PZIDN:"^1.]!N.6/ \2N+4"ZPB71O6.P2#'-T@QM)N[0(48^%W:+H7$.42
MMR 9NC="JK#QO_?0_;(^+Q9%4V%KQY1W_<S:D"]E:39BE8",4L+\J1@[S39H
M^&BPVGXR[TL=-N,A,-#339Y#77N4O_#$MUW:(5%G>7TIZ0(*0HQ_7K98R2BC
MUWS'7/;J08<,CE*U"GHSY);B$I22'I8U].N\F%=(OEAH@,)9P  Z*"S8<.':
M%YRPS?*553YU9CF-/E0%33+-C!>#\#1BJGZ77MMO3RA3+$3%@<7/N+1DMR7'
M)WL=2XX\%?NH>[EWZ]*MEK#,M[8L5NE#YWA"I;,09VY,CA&I)*O7&3SQ7,$O
MKKQ%3(6YS!"N-?%?N> ,+(Z55C4M&B^ 1B4SW7@D7R: ^_%K9KOZ0\TQ\3*#
MO'B0KSOP5 RQW9!_Y#B-],U[GBR*?<,*#6O0%FQF!NQ?M.@UK+V>+ M,W*S>
MQ8?V&[/O?\HGI?V2U=B%"HJ@5&+>*Y*@+"W.ZA\4%Z<>$<02Z5Y#F&8%()R5
M+R+GT$+H(>A9PI9(%CI01EI6="E.KN:AR/<J"JT*ESS^=#93K<H2X+ 7_LF8
MF&:9G_")8^DY;O8[6+@+A]H14:0/2;#NQTTPQK._U"B_.;;F6N,;&^-()Z-,
MDX5$F@OAJK+@;>8 _KX .2%[+0Z$V"\/SKYCO=$]E3<UI$;E2Y-4YI:U!WRT
MV#<TK 3V:+X3E6FH8'0]I+>,8LT-[Y\.FY_[N/!"/KA]0O(4;X.W@%ME%'(
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M-D\AE_*1LVIX1Q*]X.[%)#]$$FPEI,&E,=X]?T'@EF>$HXJJ4&2O<,XX%>G
MT2A#$)N5HAP&<C(14%WWREYIF_U9S]9>OI@U*E0R*9D6#$C'';Y^BZPM&GZ
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MX-/QH)<@\"O^'N%3[27SMN9 B^6EV&%K\:T@MS!@)/3E&\"J)A2+[S%4+[1
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MHH9$.>;^U%>2RA0J2Z?#JA+\?.LAOG>MZ7K:H_?QB)GYF/A9#"Y^8W?QA"J
M!_:4_85,EBE7*?MI)BA.RH@2A<EJK^X6?<<I[MA8#*"+*XQ0!NVZ>:<QN/]O
M"N;8I"W5=;P+2=U?1GZD'4I=K2! ^9<>Q9T&Q[L/VFWK*W0XMVGGJ@E&@DJ^
M8#JJC975B?,3%4[TLFC!H&NYRI#_W+1]HG'0Q!6/PXHH/\NH#?OC/_LB46;G
M0D&^=B^[C^ "U:*]UF8N3,JB 7[CH-SPL:=@3K/E;(=*2I<P_Z/$<;/ G7NN
M'*&N&6LZ@.NB1Z;$V@]'9+K9_]B2R4":?Z9>W1667Z"1#[.&/UH=2Z-GU-$<
M&E@,LQWL1EDX(YV5\95%@X!^5MN]3=A<)^]06[G/L:T@8NFH<M*0TS'XWABB
MYG8AU^Q;LS>=Y1TC4R33<::9A:LD#RHR1(8F.6=(OY+&W+(B0WKL[]A@H#:,
M,L4JY/F[=A-%I=VA_6?BR;G!PCL_HH]YPGKFC,A9,_L3[68GA\1# 1S]^*S<
MC![F_D*"=IZ72 F;;U+YRS-<(;(<]H2DK&2[,I<3JS0'A<?Y0SFPQ3MYSB(+
MH3)"IDRE#GV\ S$LM<598O#U=)V$+ZQT=I'\.*N","J4KKEN4*(IJYIQQJ0M
M17DO\G%_2Y59@-:@C^NXA(!M":P*"YC,G#F:>/:T-Y.[*Q7LW4/Y@/>C3:^<
MRCMG(T-FB;Q*GJTKI+:ZV+10U9%CDSTZ2-RX! 5<387G+^FNWUWG8?F0'_\[
M+[,J\P4EV/7P#KQS>%B_F*#_W+"O)P@*$0"4F.RO_]Z>^G'0\EP[IF#">^QC
MEWGU0GY=8I2;21,'404]:R(+/)H=A]]X#O5K;9$.CZZF/4M$?#B.D'N!AE"S
M<WHQLR..M+U@?Y,>_X3_>K6GDASKY>[F7&\GM;8 7&L[QM\%)#@<NZWJD1+<
MJ4#$B:P6$P7AT/$&[ D+D;#,-8<B7?W7@G0]I8M?%(:*QS'N!D) .YRP5SN;
M;P#6<J_0W,/=LTM=U^G86T:?E=,WX(! 0'95_YX^;SZ-\V1;1;).0"B3<]U_
MMNF8:*^G[F7L?#?N,HS@D6SW4V$:02BXBX!HY^D2O])GO!JI#//J)8!#&M8.
MV+3LU?$?P_HZBIC?_-)L?GH!C9X<WC[]LCW^Q#VP^2]<QQV.R7]&Q@[BY[V[
MV%]]T2;V)0UUV3<3'<:T*B&%:;.!(+^^XM54B\Z=W1&<C/V;[W-V,N ]S)^P
MQM"@,*W<![H:7D)7I_3 HT-%CV@21*^+)PWI.-9=^#5.J_&&F,AL8_-C]\8Q
MH&WSX&!J5X0C(&/S.<R?J$@AI&Q',>D;(%\S[?3"*(M$,W=:N>]P&.MN! *X
M8-2[!;D[OK(#>3@8FR8+%AW_!(B.A^7JO]W%[!PRJQUL(A(;5#%K9!=E6 48
M"?S"OF==V2JWB7LPC>\&%7\[C-RB!2%]F,CSQCF?\+F\<:_"L.K.3%$G:$1/
MP0DQMFU:0/R+?83Q8==+\^FMF$6IGISEQGL55+R=P!X>9."]+5IM@LZJ T4_
MTL0":="" S,ONW$N)!253UEL_BJ^?^<YW;]TL,A/]<PQZ>AA8F:O--1V57'*
M*4>?R>EB,C400L=[(4)L>NJBS5: 8X*LWL\^@O/K!(#OQ^["HZ_Q/Y7T$L?B
M"]J,+BKVC+XQ=!^QC7G8.%S6AY7W+@9MM4K>WK3 Z9>H3!9U2] R+^_RSJS3
M( &67DE5YF<6*E'A/RIEVM5=E"5H 5-O[&&6><UIO!<M2O$'W>'D"HXRO*R9
M=X,93TX>V>'O,>60I5UA-YK7?Y5^Z5M>$$ RK-@;F(GKD8/N%NB]JW7"K 7O
MIN)824"D8Y[STFOEM,%0:)<:T>10CFU"R1!#@E!7BXD+V>Q=>1&BF8E[>:V"
M:54-.S(@<6!*&FX/#5A[7,G\Q67G+KU:*S03_F$[+Y+!I0#>>]09PFJ#'P8"
M< C+T^15L\%U/1\K<%19U9(ANPW4@:=5$CRL%>S24(YT_/I[C(H14#W;SO)"
MR>U#H;G[ <GUBR98<@RZHTX(5"/8?5]; %.6Y+$XE_:NDV')EO!T5UIZ,!*#
MC N@A09[R%T,H<[F8PA%'4'+<1"Z/$T@!BN_\FY,&C6$05F9,2"7>,*=7DQ*
MQ1(<69Z?W/^#.OV$2) _/"[1U<WJX2L+G>]2T^VTQW/QX=+.=\QME3V',<NY
M3].Z/=0;*P/<VE5+YI CTE@7(R-,_#>#J1US3=+G$;JRI+XO2 "[X9 "5?EN
MGS@:PM/>Q1K3@$&/Q16EQ49E3.K$#SO77VYB77+'[QQP4A7C\\VZSQ^@VT$G
M3UEV&E)A3H0OYV_<'>Z,.AV>@S*T\M%!4+%XM:I@?GPYO!S6<AZ;L5\M>1%<
M.OKRGJXE)G/,RPV$O)'R]Y1)MO.JGN*+J8#R+N'.LGLU+'54<A<?<:E]8F(,
M =C!)7=>0H/TL\[DQP;]E8;SD,P;#QFH+;D9R:&E_)VY*6*IUEG5GV;^=<8=
M6<P_KU(=\S&$*, B^E-.QA8XSW:JB$R %1/N$W"?=MH2RIDXT91Z0M8!EG$4
M_CS-]@,2#@6+:3+"BP7"PI\$SL+IM(6_)'M8=/#5;F'QTQQ6_]3V;$_;IND_
MIS4H;/18O^ MK%K?%?WFL3S"H&'[+;[9+G9.W&@.0IUB&NT< 34A)_@G?! $
MG:-D_T!.C;@=LPT+%(JF'.N^3J W+[<A!V.B4WQ9;N6R-I0S4P$C;Z6:/&Y*
M3ZJ%OEN-S'UVH#J"(('+$D4%OT2WY%D#  ;5=+)^3,>1BL-'P8:KP6],2<P_
M% G>X//SKR_GU\ L1S=/:=JJG@!"$C"&G]$,(\),YUFM)]WV0E\&HX#\1/M8
MWYB\>7PN^*69_<ZP6:D^4;CFW.A+]QN@$->G IS0#RAU<=A>D?-<%!R\,7+^
M>F+$;;BR$0+F"Q UYJ4)+1;=+/4Y:^:=97NX)1&RS]5WK2EZIR'H,UA\ YJA
MUA6G\LX6#P/X5( @K\4>M]^ AUF^SHD 7(LUO5>K&Y6]NI'+;\!S\ ?-FPN0
M5Q H^T+A]94QYJ'%<B#W =<3_%)QN[J_$O AXI?\V?&5 TIRZ$8$$/3G(9M+
M][H5@LKUWTT;AMH[Y$'4.QS-^/47DE3J%X_U_$P%E'$<@@6,#O\.TLL/ITV)
M^_WJUV^ KD(6RWS)2:B-M"B]FW)X:'BL71)U= '3Y3%%GF*[;D6E9)^(@-\6
MJ%2&))2Y67B'LEP4ABJ1\V?3Q![U1!+&EN@^MEWT&B+$[ QY?3/ $LQ&CUN?
M6A-]9U0?LY0A?06OI+I-&YF"SYL<NG5J9Z6?10<N>LZ% /%E&  0O>%2,F#I
M'#O/61;<M+8\>+T 0LS,>W_.9+!?)FO&HQAA@3* O,V0=I6HTOV&.]Z/!$V/
MW)$#&'\(>G4T.F>.M9)U:HNP;>/$3XNLBKK0CL8CP)23:Z:F%(ZQOOSR1V[G
M;LAP,../R4.<\=VB$>24\6I2,/4<&,7TY5^)'TM-#8.-OQ2G;57( !9YW1**
M_2(E.3FY)?KE%_BVZS V[M_'@QDMP4[FWZ,.5UHI6B[.84>&\?*?;EF+6^V4
M5-ZJPXDMKYLSG-4O=YS9V$2(339K8X2?EBE2K22*'2ISI%.A1@UU2XLMD<9$
M5L"+@@07BA]J\:<**H3VQLF<A57B$<EEI,8R4D[0ZBU:H6EDCN%'+M2>&+T/
M5C<\KEUV*H!(HE&;*W7JJES;,,HLP[[39&#2;+SS<"[AKK2Y4O\8_97UYD6G
M+*-+)^(>=7&!AI$]2[_.:6,T]E6)7VH=II8T*X'0SA;.0'-(QE%%(]$$FHS+
M)H-_A29>UZC*">I3!-6L"CTB 6)&^%_?1N@XU[50^?9) MP^HC:P1ZU46[X'
M-CU )\J?=S)16B5G2JR5(Z6F6# T(D+-XBG8?U\D],BJ'=5Z#SU5%3GY#^;F
MJ_%2Z^N^T@C"?ET*&2Z-'M(H\C9YG+VX6'/'B&CH&E,YRT^U3"GM:C^</BIL
M3SD?LKI7:MUP+*O>:@>GY,Z@:QS'8"^A4,EO;:W%+2K0\1L1YG$A)L^Z@8F<
MQP;(U?(Z))WD^-T@2F*98=.FAH .XC>&;!?L=,DOL&UB&N37&+TXUT4FQWPE
MN65&!E#=&-D<VNYT[?K'=E*\[DYX"#[--U<_K6^5U:?8;Q_Y#0\TGC(\+G_U
MGNEYM)BII+UV;UACM^&5B'R ^%>N6:Q)";>++:@[U>KN+V.R2H8X#HJP2)Z/
MY0JHJ+QOST]=/%QH7\^_(VT^;[CN3/IVU%Q/=#Y-"<TQKK]H\:FZGQ,:)5MS
M\,1@RC_*=?L2S6O\:>A(9F?6UK JE-'Y!L!HZ5!J:TCII)..ET 3![HG"!MP
MEU S:[KVE4K<H+!@8,F$YQ<IUZP"F>CN:+C:%7$*H9^8Y+(;S\\DOC [<IIS
M:1D)'IR7)$:X*-BXTU&:QHI=,R-AK'5I! BO3/P')"1^G#QL>TQ3<%XY+_?.
M6 !S\[(OGE.R]++U](*?22)G>=+GO;\!G7KX6B8EA]4=,U$""G&6</A9.%:E
M3,B&I\V+/X=7D_((%;25X#D#Y4[=)<5;-1F=O+ELR _/[R]+TR4WNOS6X=RL
M#EIA?X\7\&C6G[$B:T OPQN8;<D-027,J:!(+YJIHE"G%/[SPB\>HLX_YCR]
MM:1&3S48<#?B=/G0V*LAS"H5BJ51)Q]2N=P_5;3<#R&O5ERW*>1O!/)Y)Y)A
M20V/25+=78]*C 55)&#BF,_*F9 ';!0QMSX/-)$9.W_AO5N=QH["UTULA>^Q
MFJ]/9JE ))@-3T2\8<J/(;FR<>"::]WNH2#4.C*9X N70%IIYWQFY "_#K?#
MODS,OII.5#SPDOLXAN_C>TH>V7;A^L<6-^G.Y;Y0_>5FO[X!SO9#WP"6QF^
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M@AA58>QB)CTLW?%U-:D^&P.9!IW.%+1TL]P(MSK(/W8=-.CA--O=,'/2\K/
M?'E"+.TU+4(<MX#NK9U>OR-IPLGQ_E.,%I)6I:=>.3Y).D\)1YO W&?5E5H&
M)OON4!O-*?EGM<SE[&(]M>%MQ#U()3KALDB;/M;?3R!6M&AUN:SRR@X.K^2B
MBJ?-O&-Z>/\^AO1TG+%&15"&4^](6+S H+#QMR6M=%=N$ %N6X^U%0+)V  @
MC#OA%U;2E/P,=3>U:22Y7!,O<64\=O.K"C1LR/,OF:7<'Z)S+7\!_<2DA.""
M(OP/]BI#D78?ZEMJ(@1<&#.D>.,,B*0MH*%=C(>=?=;<.!FI'A#\A"KF^D44
MMNT4I6Q@&Z]*OWQT%_[N9>HRD69IB+Y4!.C)?NP)A<S"<5)-B-_;/S%.'^1_
M-A/1(6TH>J8]+?7UEGTRLAG[)AM0'OY_Z/"-!T#UR(Z'>WYY*L9=X<U=>3Z\
M %>C(AU#T.1M$%9_\2!FVJTUB\7 ,8=*!(X&_,"^#5%D=.?M..^"(*BU/)2^
M*K7L3W(MM$"EA'C_<Z63,FD@!>8C@=I,9P(K0CB._M?Q[M#WA@#156K(* A;
M%GIDFB2XN8_UXU>-I9O*[S9&3+1+48>1K# .Q@OU%1O#:?9V*$XH_#$DZ*XH
MQSF$;GUICG:,]CKAD 0D)>S&CP7H6+9RI$95]$%BY9KT70#*&P#Z:XS-'I%D
M&'-Z:IJK)2;>3S;S1R\[,<OF&3>H9K8/<U$_/[J(80S,G+OR>C%+G,V6J YV
M9FCBCY(G+KW:J,T+$T Z &K\MR'8^]0EX#/@9]C50^=8\:/&=<G]^FXSY_(0
M/+6?D?^LVO\9)/DY9!E:^=-9CQ?R=>0S!=>!KVM8CZPPWO%<&2@CTT(^.SK)
M4,5*?3>=5.Z62SH &9$S.3L;:0FH-$[6>7^O1/':K#_;+A[E-=)TP3OG6WCD
M%1+(82TTVT[+F;A&[2E)G,T1R^P#4Z_^DW]Y5*K?]O.5!?:"<_J\Q)73'%"]
M+7H!RF^;857COBM;X9_#Q[&(5^7FL;JT$<,8LC)-F9$]MF%<[E:=&(2D9.1I
M>10RTPTF<X Z&M(0U$AY%!(^$\(VW:P;K-X=L55H3$D."F*]JY* _W\G+_VO
M\@%$1'5C0R^OXM7577TJ+TS*-=^ (@UO,M@E2A?%VEFS3E;6"QX=R7JJGQ4Z
M[#)-:R-9"=VV(?JX3SHIQAI1Y18--H*.AD)_EM!W4S^>:)1/=_W2JXU6XC1H
M)9IL;VQ+JP>;XO_ZR?<M_U-B?0FG@V4WVNU8D3%M,U-Z;7G%*^Z&S2J%PC.E
MEL=#4WH*']PDR-D< 7MQF0H-PD(@"Z-Q;/^+6XWHO&(^UR0!7UY<0__,T%D<
MF=XT2\%/:]3;Z:OE3=UL&[;.R.#,(.-WI:A&2!@>OF=QW<BM8N]"5T6QY@4K
M=<9^S4/ZEPL8J_IY>\.K.ZB8;OJK TAVOLP'C&<&MH^MH;67&$.K- ]D3.GE
M^1<GY=KI0OUUC!>TW=SB63NAR6\ 5L,@[R)ZTX2R5N-[:W^*ONJ/4-/BZ%8O
MA (&Y!Q0BQ_1QD%EK.CM771=9")-WN)%,E5<-*7BJTH"HIT.%09%+K20)S^;
MMLRNX.9-TL<X<C 9'>1QMPWXBE.]+(OS91TLQ_C;NEVT^#/,E6S0U5/,Q7:9
MV0KI#V#:+58M>P)GO8SCV@2&+S%IQ<^Z0%PU;MLVCJQ9YTG4G1^O)K<UIXN.
M]Q&(Z=5<-62Z,:NPXY#U.LWHXL[:-YIGXKS+G@M].,_##)_@':K/#P3*.@Z;
M7\]+I9NU3WS 5#EGJ*6L#S-.T9;9L;7@]-V[/%:AQS/0M\=^E- P)IZWQC@:
M^OL)U6G ^,_*=[=M5QYU$,S5K[WH6%W=\ G,Y_#V?EF%6&,KS*J8FT^8I_*6
M1-6H5SG"E]!K^,#_(MZ3J*]G<4:E)=T>/'*XUJET3OG)JKCD4*KLY4=D(+@-
M0R8_?T2/[-JHN6>G(6N[-<-CP7 ]+VWQ!UE%L[6N_(+--6>YZ?S C-9<3,2W
MX6O!V)GZ8#U/M;VZ4-!].790U=T;U(^B_?D^SSFVE?ZGC1;=R_D,+R=$4_EQ
M'"J];I+5D0$3L6C4:&PF$$;"*AL#E&LWS9M&V7U#M31'1J%JU[]*TB9A#7VE
M"WE*/2$]L)P.V[**M"5]ZBF3IKF9T(.F@ J>G;KK<H@K1CVB3/KGAI8!D"52
M2H)Z[\ UV:$O*T/OJ8;[O=4#4K68L%B >;V@O.$=;?F];CWRUX])!=Y?UFJ4
M-^MX)::!#Q*HM!D2?>KQP=8,_>@O7^(J/H0( V8(;=<8V1:>@<S@[B+T<],<
MGFY,'&7!?V@A+.45X%JX\?Z.=#.8136:;$MJ,069S6C;9^WSF;*B-TLIA2,W
M[9VDA1\J"0V46%K6IW\#R!U\B8!T:OW?@%ZU/TCQ;]^ K7P7L)ML?\NS3,)P
M23^ZY=Z[=3F?WH MI<_M'C6BPUBF !#$&E7^\%<B7K757\"X :&[7_Y]<00/
M<3-05Z*W0*@<U34^FL>W]X!AYF^ /]_%CR^I_9?#']XM<J^^HJ,I' ] H3]Y
M<42-0E6Q;V/R"?X3!0KM;L+_Q@0\^WX#VHW>+<+4U84R>7K"YJK8YX'::G-G
MWX"5?[8F?<Z^[9XF"MV(SL.7=;LKY&U_7%1M8?I_5GW.CSQ\I%;D=:K-Q1']
MS9M[#C#YQRV>L,@N@#SI,V8FF"=TC>WIUT40\3D_<PL0^V<+$4 0P%Y1%S<V
M%A>B!+5/5/;\]6>//4G1F5'HH4"_7<S@UUB"E4 P:GRFL8<?W@!&,1\LME<W
M %?NMJ"VZ7?#FO?G9I$KGT)TVL]\&#K[&K7S&YVJ$AEP48T4*$ZJ:2QS4VL(
M1PO9S-F_=>%%81!RY<TO5F1'BIX>, W<23BM2LRR4R0KW%314!PO=W:4^S3:
M(%[@9PL[@[("#TFH]GN0]OA+T*QW)B<_;_,0X7E*AWV[)<,U@G9<'@CU<1?N
MA)5<O8W/CJ^_ 4TYMN-<$3*+VDE7E(U:+^HK*K13'&$&9S?8<&KD&M8C%A%X
MI[DON]3+9&^J_4G]7B?F6HNYIU*3LY!.?@TP";)TNEO/JYQ==+&9AJ!W^KJ'
M3?=T=';3*1&LZ_\TIS:)S<XHE"RT(0$/G3D-\Z3EBIT\=0=&Q2=K.?)_<'EZ
MS:5"'PZA#@[& Z-!B<%.QA+#D0+?H+T^_Z)0OX'<#=*"TH3% 4@.YN*@A/JA
MCD'>=@%$S6!_R>Z0'T8_[DGW&1)0??I,_>($5YNN\L9:3N::2:Y\Q>3?AE[2
MQ23'P^\4-:C\?96=P561XI&FQH9/B,*V[Y@_!?4%_P( ;U#0O1;"S$BV^<;9
M_)XL"H[, $\D4Z@-)(A70$1 "<H]J3(*$7EM#"SV$<'S!>6RXJ7= 7]W9WK4
M>4DM4&YKC0:*>M*_C"NS+=[+Z!O@B9\OC<-]@G!@4 5&.4"1.1/$!<.F=L&E
MQ3[>4*;KQIBZ?,W[F6K$Q89FTW>8$>?:B@ GG]XIU>F18M70BODV?7AU(9V:
MQ$X/X0[;P#C*&[O]Z,L!2="19(<[7)O*>^#.QWNK9'5TRBN^[;E3(JG?!9/[
M;,,=O>I\VUR3]U-?JDRM7IMV41U4U]AD.Z?(QLU:T*^+A@;7]Z41\4(#Q3R(
MYW6Q@ (?CL4Q\;Q"09>SLHF%4**\\8RR488QX5<M=.8O,U3N9/ 2M1+N#++T
M4##T,E#LOZ2.(" H>YB,&YR?NQ#3U9VS$>1'*83YW;1H<<8F._+MUM7 6,HJ
M_$SEN[^%Y]D/JDZGU6*3I.L8B$=*I%;I_2I%,ZMA.6X=0H:LP.1,K3,VQNVB
M>.M47>/+ZFR?-6>)75JID1H6PGDMT*+'8RLJUF'D)%L7+D]*%F66$39G CT"
M3^O2G@*0Q1".V*Y'Y^JUC*QRXTC_/W%-5\F^Y0" (<@]*-E?\",B8I [9.KP
MSZ 1=6.%(7*E <X[&C$%VR!Y:J16!T%YZ:S7-Y17:$_ /S@  " &X&>=;V04
M#+-OK>*OXELB#"\JDC[4_).,<Y>SM*S'I,ID/90J,R9U>B:AP.;PO_;F81?E
MKYRG0F"RB2#.XQ&:)/UZE(T1M8)J8.ER9-,*+K3WYMKF[-5+&A'A* 2(U*QQ
M$9G'62-B7&!>M8[E'%AU8J;? ( O]V8J1HKMVNT^'N%"0A"?.909.8T[KXJI
MQ6#XA/\:XF_\>07ZEI)V%$>5;\!]I[?L-\"0ZQNPO__RVC33Y_9&=O^G=_@;
M,*@[U]/6"#<R]J$VM_/;7U-1VN$2\AOPJ:O_#<#TO.XC]]?&6LM[E;ZQN_Q]
MY_2US/;2_%GKG_@-6&/HDP0R,OE^S3VR??TXZ/Q,>/MI8!2P1_6/#FID=/>R
M(L=@L(="B*ZLN.T9+."+D2D@BM_#(%&( >Y2\9/\I?59V+/]&V"=\;&1_][Q
M_A_FM=T]?P,6_K[Z!WA"6!Q]$/4=Q!_Y2WTVTZK<;2@4#![<JEW $HY>CZ-X
MI5*FO>*H+$ALEEZ7)LHC8L&FA&>\%WD;MVW;IE&!V[)7P#<V:,=:O0;YNH1D
MLBZ;I:0X,A<9?#F*BD^,D*-*_BAQ-<ZHP&#)S&'U#Z)WENNW.C R=PJ-O9)$
MTS;4QMZGB;$$J>#0,5D[&UK+83U6H*/DCF7O65< TX/OJ2&"-I=CM1;.OWW:
M M$:I%KA6ICMO;G AHK+-Q7&P ,:007*C0B!8]VJQT,YW<IO@=*!B.X4PWXT
M?5"@)?<KG9QLY\JR#8:PKTFTI4Z*&Y$IDV(OBM!5'M6:-*2%191+H&_G(9K#
M9=,A<JI,C9I)DQ0WT@]8$F\1R)R3V/41+%EMZCO(K+"]V.<MW#P=<UH/G4P3
MB NX(9$JL8GK20K0$#3_/)(;=,6B4:/JAU<Z-F @Q)^&9D/6RX-EYQP./<<\
M8>G'S$2&+B<]4! _J7(?:69U7FNVQ=- ,]3FE)N6YFF7"Q^?"</%N<U<JZ:H
MPUB J9SX!*ZB_Y\26TAD2_ "R<O91+%L9=\\Q!XK,_PA%; V?+,_4&PB$8,O
MP1_H(N4[P2G-1NI<-<N;)M0IW:!3'K% @\6<--/[L7W<F!>_=@HLS;SJL6CP
M#Z=JFQR;Z(DMGCIM[=B:#?/-\)?F8VQ)T2QFA..8OL&\(XEQ3:PH'J$CW6>-
M!4:(Z_$YRVO:#1%HTSE!R6_\?BK*D)-6G*=9=%%)D9ZH\*Z&3^Z>07';7C K
MUA\C/CI,$=],V6IWT_;<4\<796P*6=;Z';.DK(Y(R9SX427'[G#28[#UOU<7
M+L04UA^P>8W\#<!VC/J1DW.ZZG#XQ+CT+%K;D$+.1=X%EG3J9^K&9VU%@,.E
MEGYA8M]Y%6.A0?SQ*E0P.B.4%VMY.<)>W"((/_$-X$,'%B;CMMZ_KR#W><O9
MMQAULDW\[- N2MT4X+G6"K;3D;7)TW=;$=">ND*/4>#EW5)#I\!]WU<8/S[X
MF9OK\.3;TY%ETN,\014UT4++>;.BH3K[CM YM6WU_MEK9?O;@V:GM_LR-7QF
MKIXH-L;.M@QM\E&F$'/JLB%'H(3$U$[(TGBG3;.T/<E[!2+9^EZ5,3=?+ ,=
M[^8=09;6P%N@1V[>!PP%1:V&AB'_O<FXISZ0Y-(I_/^B[9W"-'N>=-&OT,4N
M5W79MFW;=G79MFW;MNTNV[9MFZ=_<_;,GO_9LV>N3MZLFS?>E9&1&1FQGI61
M/[-IQ>;K*(D6UI]%R/P1+_+)DU$T>MGINN0T"E?AP.Q#(5D_.4SKG"A+N>MI
M- ,=51SP(@(+]+.&(RY KRW739E=X),[S_):U5U,59G3$QR^Z-;/GU'CXQPK
M&-7%CNP0HK34B;LA#M;*5POR&_M+I&4B+1JDW5.T&WXC;6H]9'"D4Y:3N'0_
MOM?^^EHT,+33BZ*4%.D'7\FP+A(HJ4O0)W9AUELQLX]F7):O*^O,<-]:.^/2
MK#8^DBHLSN):LRDA6,V1J-7D$9R'H, N+:NI.8%'S>)4=RP++.]:=8%$7[]<
MB,$NEY.W'YA>C=$P/1QNS+>CBSM)'2*TA\.)UIUY0_)15?X58V<CS?T8HOLV
M'"S\YK;WQ^Z"1Q(_MNKW]8=*7CK,7>=5D&ED0J<VQ<CQ37<D] __<\"<3*>:
M>)HC 8G&-+>5A;;IMK?_(8M?Q>_C Y36JNEG18+EXH>N?&=<TL*2ZE&G",&N
MR94[0G5\BCGGL:<4/@\1!_W2,;7HK4;))F('O"_RPH[6XNM](A.-ED2]7:&1
M.N7J2<HR[(XZ"_80J\*ZM/;(@R!=UZ+UVJ[4JUJVY AIF[S3.M1VYKE1[U@N
M(TFQUE5"O#61J^LT\4;"-O]^[A#(I=@*Z/CTA^OQLV.*L09W_2>Y5LLFFB*A
M*E&I50Z4E9^3&\#IZ^?F\IK&TRLGERDWVA9%C8CQF012&Z/DM!;2F5Y.9@=;
MD5*>G@[)THKX]_ NZ\()-'_$+Q-]C*@<7)\,K"<-J?\D3S.5C4_@K&HV/"P+
M3N$?E\M>)'^Z5+635RK^9)U3QM,12#>@K5G.$M=)4[FR6RJ&C)LIE ;>L\V=
MDPF_7,H3O>-+8REH=-$M4I9*#K"8JX)\7*Z=&ZY1U,>:DB)%7KM-SCU]36LD
M7_P5E6B_$5$-(,9/D>(AX.J_6Q,PGZG[V9B(.AQMO"NTMP+ID#[QS)'!!Y9N
M6_2@$W.A,18!0L0FF]94G[R84%=YDD;/2[#:MI+_DV8UBI'B2(#&J>=/I;<9
MV\RF_8+JP?.UZ#/A/U4H%Z[?6#D\VBSSAC?"UBSV<,]TA3U>;06_ 63LS#6O
M4W 5%<@?V9\G7P=6WX!GCJQO@,CAE2J9MVEV!ZZOUZ;X]K@_[BO?:$WGSEO"
MG<=SP7O</X4RSUP^,1/^<K[F>XSP+F1]M.+_4P S_7T*KOS+\/]#M_]O.)>_
MN!H?' B?0W 2[_N ,]G1ZZV8*Y'M;X!#V?:#-6?R&$)4' ?OPC]LKOB\7WH'
MTUNVHIEX;Y[/F;D$W"+; 8_'C/FX=.\9X#'+[[@VX,3UX2$O^>Z-K^ !%6(=
M2>"P7 @9:2FO=%IBN4XEH""NI41S*6:'F**+,E'/[,:FRW)G4V>=!Q8I=_5V
MD,<)0YY]+(918?"?8SC[:^*=\;,*Y R\PUNE@R-_ UWN:AT>R762X;B4$*/)
MIWECG9>F8$&,.0!*F-8:D-31R<#<V6ZSST]/M'&C8B69R*[1E_CDP* X*$BO
M(@A!V"0DJU28*D\\G8VY]6QQX NOAC=3Q:JV9>'V?;%NE>+3%JA+M,J2\U]L
MC_G'^-F_S)5[FN)B;'^HEW\="B6!+@)PG?-@O@&66%><4*#B%B0"&G0P46 :
M6&R150Y:2[XBF:B3V>C4%AP;NZR4EQ8DYEB/6=SF=O4)MF*>9#.!C1">!E@4
MT ZINW*.*)P29;+[/9C[SXF"/5[[QP<@3U[? #BLPV7U$W"H$U:<2-7Y__:&
M02UD>."8G$8^'J#C/0*@;\ B;BV;\$'<$GWY 3?GYGM:C +U7+/C@XU\I6*#
M.A419>/Q$TZGM@=,"TZ&0W@ IU#FY*8=)]8=*T;"M&/]G?K#Y!Q"^#G!&U<A
MP8?%@Z[FY>1M%46W5_V1V"(W*3=72:IB\=DHQQB+ET(88:ZTTKW5('GK/(8/
M_6]*G ;.)\]-)>\&*WW+*RO"9.((YI#9\:Z(9FI",8Q1O/W:_5EG;%(O5UX#
MZLWXT\7R;?&I@]NK_L4SU(T]#YPZ$7*L?;H+;!+(#_9R,91UXXO"L\G*$WHG
MA1S#M'Q2\^J]PG4L!-M\0\H3M!]YX?G(@+/ CNC886<C684A;I1YT=K[IH<'
MD26"LVF"BL+NYHO6:71216X_[DK+:MNABZD_O9$)RD/-#1JSFF$9U^':P>$8
MRZJG06+KFJ=1&LKK(_I>)3])%G/6[YLXO@&!HINGFS:3G&!KP<]2H@UI@N4;
MDT^ZZBWJ0--Z!15B6G$=M>'A"GM7"/JCIO9X#1 *F9E=UA(P)$U]X9^+YO*#
MFJH\:0;5QTD*[MG.;Q-CI/6K46?3\U74<VV#0)$_14:>*NA!R#5SE"+&Q@U^
M)2%E^"J8$PR$TCE0/^K6JGKI%#5$QU=MG7>KV8M[D@A"##8DWR+-W"A=GC7\
MN60QH<ZG45&1NF2& =85SELQK-?D$K"S;U.D5-9."B=);-0$+V<7)YF"E;P^
M:^]LZG1T6!98(0Y+GL5>A GK>M2;NEA#M_]TG4-<M3(?5"JEZ%EDGQ<B&OLU
M:] TGGL)IC-FDZ)B>,)F#\X!@9?J)U3*A)=QPG\$UGC2X4Y[E)= %N^FXPQ%
MX_>#(Y%!%$B==U(N2H($+Z3I$I R/3P"<#M.OTNK01>T  QW<)@3KHNPI; 4
MFNA1NA*F>97MN&>=MG*%:V$,'30E 4T[!&$B8L%!%C*U]4"%L_G2]Z13^3TD
M=Z]*?P.Z$CX^=EU;<XB1SJH'IX/N;F(^"RY*YC2^ 4:L7V^R]S>_!V:A_GJS
M.ED)D[Y74UVU=XH<<:LG3HNW/Z>@/B:]W2-8QL*O9#G*C#L?G;B57A+=XE:?
MB=OOIS[3PZA(!_E>2G])9[KJGE0)VJU!+I+6]<.SD1">1S\ ?2!W2(#/'),!
M3PC/SCL.9(5E!63!=.@H-6LTE;-M;S00R44$82DR1;J5DQT!6M#,I=:%C)Z9
M><V;'\[14",$F".?](Q4;FUH#61&(Q#A5"MUC@JQ.<M0%4E"PT\#H,&RNP=2
MUO8B DA4J8RQ@0Z_B'J#7XR1TC'86MCD3ID[ #1%*K2P&QD1R4@JR*K]3CG$
M!BSZ6/N]9I[3EOV!OYD7V"=_TA)%J1YC+JNECY3;.,:?D.5]"5.,OM[HAL8,
M]-[< //6O0VPC?A-6D$3_#SWFV"-%YXBR(4MT&XQHGI1B_0##9W5;X5?,6ZK
M"KF)=AC-M6#DQY0-**0],3B-U,_)W12GEP(&ZR\; OK;X K(CWM"8N^ \8!Q
MO$%N7E^/BR]8DE>>+,3R+!,[Q%@Q0JVV)5[J^C'[7Y3&2P .VHE(B43FMECK
M3 @",&=N#DG:YO\:RE=9Y(<6J-96[@%I:CKN&,OL50:HQ*@VX(D=@VNT!Y">
M$0V>S9LESH8Q>>9;;I2>E+*SR\OM@>K8L\2.,7]$7V<)?P,(U^L;LYJ52'Z;
M7\D&/%KP<A$G2Y [)[T2:N-3CX@O?)4EJ1<,FJ!14(K$M67&,??2BXE+  6]
M6TCL-U])F+;9)%0H2T-%+'.Q9%12PQ]+EA\L0%T^NB*GMP0IK,.H1__FH#>E
M%^Y 7D5Y@T: -_:'D0*0\A,0Z2="P>F*1!?EL/WGVFL]7KU]- 0"&=.Q<*&N
M")\XGB&7$("0LUWX0GR07@F%D!, 7,J[3TJ@5B#7!WB@%O<J#VXZ+EQ*_]7]
M_H?!5P\6P9*N_7M4QAYWZ2FMUB.6.<,[T$H%=]&#<PI;)E$D#[U=Z8CB>2+Z
M8YXQ@2$LW(6J-C!4 <KO2!=L?- O,Q0DN5%VS5[6;>^@14N<DK1L\@U,734K
MYE4B\[0:9>O/M,4GQX,9+F%J#;\T,=+,0$@,BBN%64(%[ZGY2Y0S(?[,0@90
M88,_Y*&"+@<U4ZW/Q0Y:BY0O5RW+42#5K-2$!(IN0^L;%P\=^AB_3*<D"%BL
M6*'G#7%(%;H78_2K.NKGC/[L7:3*,MHN\=]F=%$JV$A+[J_B? -ZG*;;O*3.
MHN*#2/'1UT18_%/D+&CB$=(^-BP;F=U+L%EAJ:8JBELHB=:AWL41NRTSV$DM
MXS@DH'WII#FWPRG=9\_812I<I@R*[A[]#+2*'K_Z6TX].O]$55J)1'^U]D8E
M;9+PQT=V9W.;B*4$MTCR<H5##HM(,:"LIY[#RPRHW,[K*B_,3X8GH6[1;#^L
M.U,BSGB9ME_:KA<UJ+N#768?E1A%L!<_03TF:^0R:F)T#!0%X[+9L;C$C8X=
M/WITO*B4RE$OL\3%-B\2_?&GQ"'SK5 N72K)Y^X[ZXQ>V*^Z9)7:M-HDE=&/
M2B,U,/T5FV:&Q4BS(V]SZ0^EIB'TKE"]@]G&-6YZA[UWH<A/F)GG_')7:@.J
MZ\H:(.A=D'M&*<E3^MD3??(-*#.1;%:7$/S\0>R>M9KN9C';0+VS##*I>P?.
MJX;]WEP3SR ]CD'$P'.]5>J40(>[*K5CC;'5G+L2#YL5\V,V#Z(J6!/"]^XX
M!("9]<X:;J*P(UZUH)W2RPN&Q$5YJ%EO+#"?4E^<JY[P*P>7'9;*5?]GQ^J/
MW@UY6(=,8YJN+EC?RNZC& H?&Q7+[G8IWEN75%[/"-ZCT>U&@4=:J?>1^H33
M/WY/T*)KLG]1O^_.)A-YKQ/@/K3WNZ2S[1I,9#_W$#W^!63NL]%D]#GW^QL0
ML>$RTO!EF?4N1*OP_P-&B?5.5)DPI)Y;O?X%MT,\Y#/F/0MW[8;']3H!CZZ!
MM-RZ71^>)V#6_:](Z PG#1766N3%.L^,71X'AA;0*53Y-X!(75VZGG;Q[$_H
MY":'\RAH1-$ U*%Z'&96;PH=WWLMOP G'AYD:&:QM*P[Z)?+Y(-4=X)E)GJO
MB4P[J%@PID,QOERGG*ME9\8M32G!QX\/*IK^<6?J#E.UFG%*A#I#/0D>)C5G
MQ_D-3 [],'?YR4D:>!T=AZZ?9OC+WK9?8D?%Z?I";S6FI,-K )(4R$L/P1N$
MI[]6)]P!&0D-C3E_N3??0B*B@&PP: [ >C$$&L'TSBB3=D&9X*P-(4.;PS<:
M3!2,VM]X36Y_4PF)<GJ9!VI$;*&>L3Y@O::A:9X:"G_G-%\ZYY5D]A8P*SP;
M5H$D.\950S@7J9RGD G# P7EGFY.+3HX8FT$1J\*L^AM(<K@IEGN#]0Y<:L!
M<++[FJCX0@&;DK'L"A]YH[BR9>PT4&(G("7<5+&^YU!SK9;*9?V(-AP-&YR-
M]MA8!H)<_#%TK -$X7B?JFWYWQV!+-7W"R=F'0 _PA'B"MF\>0>__,0B.*%*
MB%6&@.S0#IHUR#VO8T!*4""1[NL9H\#/GX/+2B,94!\KLEQL+W]O1%16!/(*
M3&"?^(%:A.Q8X2)8L:Q34;:I<50"1[C$1*["#3-56  Y%#=)T21<J+F2TQ[J
M@[8UM+G@T)IRB1JA@54_QF7SH,^H[(2(/SHI?:/VM7[&.MM.3$L\8ZVYJ="A
MO'XBW7BQ>I"!R6!M="\J1F=KL1%)CY^47*&8%B_!%>^,*0FAEEJ42;3%/V_D
M.YJ8NQSD%L.12DNU:#I6\+X>QM+M7X67J;$YQ<*^S:@ F6@>7RZ)YZPKAAKE
MS\S(R2\BK*;*!T'=R\>@1ZQD4?$<4I9<7=I]=6BC'NBR>')6%/Q.6!9HY9<!
M%HM20I.NAMT>Y("\-1490%J98EBI$#N8JGVJ:)E G**,B#WO_/R5'3A[,M=A
M46+77B/83_$9,N-T%B3[ZX]J^9-[4?M"1VB@)7P*:/ZFJFI$4)QUY'U15AXM
MQJG:0_[@AX=3T$2 <6EN?1B"F,9B=(UE2%2]4O&>9=)K<*$' B<(WI(.AG!Z
MT$U&,B*5LNWL&#@9!(H0"COX?<!T#I=-R?Q)VR^."XZP"K\KR$2A(:P J1M=
M,++0* K7+H /ZQX/^.K]_6O*2$BLV<?C^<?,MEW/AM-<RLRYCL<GM\?D*;O,
M*:U2N49F,I\V6$? \2PK4='?.)N6FT 3A$VD3 SEHL/S2)P<7+P:G&(J]'%4
MF2UUIVQ 2!0KH_G.7(?+5-&!03H&\C5.2 R6QB+*?&X?+'!!!XADQU;[-.$#
M[>;95-W9\DI&/>TWXGA.?!"[L5!L2VN;R:@(2@@B%IIS)"-D-0!^;L0H/VV2
MY)&)ETPV?_O)F?0;,)CM\PW(TV7Y,V,8$ZV^)8*[4QGP!]7P>9+=ZVM&Y!O@
M7G((\:#Y-37P#7AIF/X&/%#NM_^,NQWG'.G_0+X67N6^E]'U:43HWBI[%>#^
M]0UHL./]^N<XXR?4RU4(D:?]U!W=-^ 'YZRSK.=\RO8EJ,USN;=<C'#WQ87L
M7Q?']0WX!@AT<>:.XF(U=$;R]LH\:"=L,QT^O_-C?IYUF;\%NM.\ %$%$\D#
M/85,JY<$@H(<?[*H '!Y<V(_/5U$XZEK;MI Y(0Q:2 /"O 013HZQP5?<"\R
M7=&71+1?P-G0DM]/YGY0,%Z:@WA1T':E*^>O=^A$4M<PH#I1I[D'^F@8*%/;
M;CID870H#HQV)W-UB  EO$-.M5'E6^&V_Y R0FO22TWD7I6R63&"E;2#L4U+
M, 0^HVO7GC1VXC4$Y_]9:CI#*46#:@4.JAU/E>.!:6348MVNRWX98I,BM"<Y
MJ/5<O^A0JJ6ITK:R)<+4OOP(_O";M>&JT([!%_-UUR<IW9/O\(8WXQN@G_?B
M=L.+B\.CQVO"BY_(CN]RT\&2?R/U:[%$K9 RFB!73Z:^I<0?=G08_E@=W4=E
M<9)@.TSK@I:F"1(0'I#.W_=&]9SDGN_NHDZ5*!5!N;P;1FV:$E8D;W:SFO75
M@<5@;RTV1X/#SEP69ULG';W+)\V0.HF>2X*$-9HP<N]!G=C\<\"5(;[A1G\H
M\F)$;I<%O\*WBL8(C8R&9A*#7LVIN\?G)XM24E$BNWA\<V5C9B'$_5)0GNGD
M&/=AK(8N!F7V:6M<P8 %/W'5/D$''P>+OF 2WU,XX?Z#KV_(Y7UV-2<,ZZDV
M1]M=_G_VB753;?CV81..XEQGS.Q18!Q!]CY"X5J^QG,N+,JKJ,JFQP " #E/
MEGB 8JPW.$$Q;?]T-H+KTY0S;*$(L5ORS/MG;<\)ABY?FM83=%1*;7-KU5/%
MYMG4'VB.+)R&=/84"9$4CYHU-+:@R('S)I7+(XNJ<:A.ID+&A%;U,@JS*3NP
M-X?PD_D:J!JU3ZGZ,Q?8QMU?5EWTKE;N'D2YDJ?TUFF?.J=)4P+-O1-O-/N^
MN0C3/VX7Y=?A0F8V2BML<*<ZPUC_B$7_5U\C-#P>$4Z?,M:PV\/_2*"=+N>W
M^ZR%5SKMX(JT$(LZ>7B?1R?XET.PN4;<TZ!R59+$N:^VK3%2871+VVYO$T$E
M>'ULG '$W]R<GVL3G2[3!TEXPCJ>"C"N.[>.G([SC'89+GEE@\^5D6I>UT]9
MK!?L:*&2,*'##%WD"]T'XR(8"F(*H/L*RPM2IOGG3U>+S$!^HR(<S4%V8SYE
MN[F)3+WC;_Q-+AEF'BIC3$^IC"$7I7$QG:R9 WA%!9/664A7SWZ)ID&GFK28
M%ITJF7J^FB LIY7N,>>X_#;=XB'SKHJ51UPL6)X-*=/(*GFXW;!YPV; ^6,[
MRQQXLDFZO4/A\=2D7S:ZF>K,U!'-6;<[.LX6^EN-?(,Q/=_?L@BMI]EX[!>3
M1I<K="F86F;GNPI:^9N3S?I"E,[P*H=E%/#T.I=#E\V[*C40-Q##/E['$SY7
M7U7"C%IEQCW&$)/G5(1N-;/](*N=",;Y@'9UN'7@.5?/]<ERF32;HGS[^Q3;
M?'R[>9?8 ^8"IL%*R\>TE>R/<@/W(>%YSPJQ+7)92YLB)@H;'5+K^/C20[?Y
MHQ&<%/?6W-, ]>L^-U5;1V(B!"=U)QLV2#3$6\E2$7"^.79;K-:*>D+PBR*3
MYMB)!BG:WV7+VB[!JF8S%>GT]=06A2%%$YI$QQ?:@6-7+&"7S5S]EG4#W)!L
M8T7J<D[0!:-B@[2_S-.K"Z>V9;ZBW 7,3NZS#$^&C3$ P3FC2/)7[> .',K@
M L4:UXIAC]>U-DJ!Q<M&ETC$^DGK]-(FV\I]C)[O)U8+R@0TQQM0$&F&/<=D
MF>Q!AP.9 X?!KVZF](3"C+8$QH(6F7M#QRGP/Y[!8GWH_C"N9%FMHO/V%0Y\
MMIA*J,?+V^O,)EA.' R0FQ+H$TU4[-;-&K#'KF>B[3%F4J8+S.7<53H'7)SK
MZOG81>&^M$RE_"*NE.:>R@#_RB?-*_*BXB(T_.N@SZ62W]\F'B9*_D&_I[^#
MO$>:_MTYNK@'F[JL,Q;@$!#O2UUYXUV&1N"*TZA'KQ[3G+<O$[^4HV=\'/Z=
M>K@UN65RWL,;F'A=UC_K]@ZX\6J9N.NK@8.WN6(N9ZQN#>[*X@+NBK[@&_#K
MU:N_J<LFXP[!*_$Z)I97ZD[W^ISVN?!?"4>OB&ON'8]CPRXJMC'Q>-(/6F@[
MFDU$G\9\*)9-Q5^WQY97:(E?0B(-1.\/0'D?6Y[=]C<XM?O\)S.96SU!I:37
MFJIH=DGQ?OL_'19+HK+<_.@P3H_=H4,B>L06HAD<5G]G*W10NW/*J,W&Y/&^
M/P4;:O0!1SVI(X\']O[Y2I;K[(\SD^I5J_IX[_E.L^J41DUVSN!4$X!][62T
M=W2DA2F *2 M3M $+N(7W3,."VMDG[W9O'/8)2UD54=IT M,W&02 $N4FKI?
M3=]KBF4@J+6??H:!H%'=ZMZP!@#Z!A15U KP"!Y&G.SQVN0 4+IY3;V767#V
MUAY*&XI?74/F)^I);Q)Z[]&..:D9M/P$S*S5"^<:69TG90B!\C^AE_]NZ=HT
MI]F.?1*PWP"I%GGCZ88M75(8QRHIY:*I06/E@UAWL=4A2QWTC(#"/,UV4*^Q
M/L'WAHQ5UNCS$3/Q,$K(6)+< 3]D*1&W$(2BFDDW,S-J@OP"-324>];ZXI7Z
MRRT47%8#V;$U^\I:RU;8M+@8*'.@"% INRA+-5H/[(SLM9E-1:=QQYT\(0"?
MM\%%2$Y(W">NS_;$J%MS(Q,KMBCV,W3.?ULKC0I_U>]V67J'[R?A2]9<(+<O
M FML\42H!QZ @/#F!8#<1[C?8Z?AL!$Q9LVL4U<4=X"3,=HKE4%RT>RT'/U5
M?!)W%:-I%:5"YVJQ_;N41KLX3 TO**>^;=(S!A^%]X\+=E77EVT]7KXQ>:'N
M9(T7UXK9Z!^453N9IKF^[75H;O<PH 9W(<<U5K2D[LH$$0TA%(JHO+K%!BB(
M$3__80M,Y6R@@R@PM&I+Q.Y NFI(^)/R0OM$8'__]XKR%H7]YNPLR=^;UN7/
M 2PG)*P9VQ3LH"JL*B<<=JI%E0W/ ^](0-9F(1. Y1AMB"*S+OQ#GHHPM1KB
M\%LP,4Z*T:0[(B&)DXZ4^>#VDS:S=80R3?CS*<[3KRQGO=;MWS>5K O^VF-V
MUXK5#9,-4VV_QEOE4IS)/F'J3#QDA89UVD*4!:H?HS/8' C(@:+3)!8PL-VM
MT;;E:#[*PC\V(_+%%]^<I%>>L"AV:^1LO#,^(0J<UI7\\MCG=]\^S2LVR._6
MB3FLT2O<R+$.MVH'-PB?EIUOHU8UH']%T1_DZ92@XUR4$F107'+*'BG%=<Z:
ME+U^ANM%)YP\:[)&/[)T[7-[74!G8=:\L@2IA_<J1S4M.:WS6!'"D"Y!6 4(
MZ1]+YBT>"Q>HCSL9I2,Y)6FO1.'H.]C?F_=<=J0N):T.2UQ/.LI*2UO="UGM
M8FI&7J*0$%^6J&DZA<9&5Y68FV\>:39P1(;%S]'W 8>+'*N@JYR/)N-PS=)L
M=W.I:V%@*)0 C9=&H9[.-$$I-_6S84ZN1;-"MZ4$8$4J_2SA%-Q"_AJ4P0H6
M"R$+@\T0ZNDC$'2#_]BY(>#%Y:7U=9ADEV-D\%]RV.U@OI?'ZKLX"D>%AR!2
MA+<^G^%9N6$[3=U M'6#15:D&W&C-^ICN,D0K;O! ^SI"]AZI,[=_!"WB([P
M']$9[:X"O\QX\=QI7=$EV:YZI1FX%.]&2GN;Y_%F2-6M3BFIMSGG_P:,?>%B
M6=(FV"Q])#09/XQ.!)2VF]R2SV3_N[A=;9=TM^:=S$)&]PO6]')J]S> ,?V-
M]!_A=^/_D$U"3##Y@#4YEWIW/,P_$,B8CBEXG[;H]02*!( </^#NW[UZ"NZ^
M<\TB$D*@%PHR=_K#B%0,U7,T54DEI\)2>V7AT+E.P#B*)Q\ER$(5'6@QS?D7
M+@M<+LH5Z)AO= $IJ!\J_=IZ'AU)'1@D4?Z9BKO^!#KX!)47L$KO*P&&! AA
M'QD"L1171?,GG)@OW]B!P-(6[\$FE(8YU&.(3]@/E!2^N6@;4>@G38,0<BB.
MP$9MP>.D#XBDSK6V*RUCPJ!HMS'L_0:D^7J/?@-"IC C ^V"Y[\!IN[)SD8D
M0PP.O!H6Z^<*XWGY^BXF9</L?$4P?Z,6VCBZ$#_NN%17.-,O;_P#\)Z/+I ;
M'$-VHB.L@OH(=0DIJ*,7M;H=+;"&,.W?_4IL<Q](MGZ_J"I%&@\&2R"+CBBC
M/4U_1$U:;)W-%4U1FU'#E.'1GG2M<,?1>P/ /F[@@$%V $6XOKZN-[QPN";K
MT^) 86A(6N316$=)NBCGBMY$P&"Q !"YN6Y5BG^YYO&C6HN)KPC<&IZO! '8
MXU LI1$/%YXL<_ .#^3 T[-K.P0B#\["P5*E(=YFT[?:6&V75<*8OG2CW#TA
M\BN"W".L>8G,P3YIM?@)'<(DWKPK,E9_MM\)5=MGBI\!K9@T/DS0MOU\6/V/
MT5;^>F4ZN.K;HU?K:+;YJN.@ R5WNI%2++^Z^FE[H%)DHW_4&DD DY+KZ]C4
M3Y')&:%\.P(S>%\^X'+AF__*S_IEQ5X[NRQ=S3R25CZ[-^6-7ZUQ= XL.T+<
M#W]!R!^6AZN@]S>TQO6==DJE<*(4_ZH"/2R7*$:R_YE6LZ-3""QL:IY=J.;,
MOHZ>7;F)-EVKD;+X7F/6Z"4&M:HA#%LCZYJ*44:5;IZNO=@L\U.EOBE:?U$A
MGF@"]&MM3@PUW.;LA)-#H9VF(T&&U2'BME__\X_;]:&/Y<)9&W8#8,O]TF+.
M01PF!>7#J7].LVZYH=1%'N:H4&]#_FI9<+FRUJH2Y=0MG7N6X[(N4&J>M7R8
M K)+.@W5I>MYG*W'PV.QNGBCXE>1L8?4T(;YX*=?091,Q?BR]E!M4$!#D@E1
MO/#DD()0''RT9JZS 9'QI!:63+LAL.EJ28VW1'6[PP((:< U^QO3'I@1)S(+
M''VG5A.KS%ZJ"5,PO<#J[5G#]!:'=)_BF IV<Q.[6N[/5$%NP\/3><K""2*U
M N;'T%.>M):VP;Q+5K)@FKF),/X5:O2BMZ8H,P7WAG,L)PZ*&I_TZOI084JD
ML;.HTV1*X%OF+'R3$4*^U/K2#'\2A58#'U6:')5T\J?@YP">^4Q]:J>)T:&1
MV;)"+"-R[7/264T62L.MM+&%>O&H* *B4:7M4H-A0.' @+LMI0&"?* 20I7&
M]G+05K71WV!*86M;L5W\S&>>.OY6M6D#7^6,U^2,.*24_&=F+G?ZC-VP6 ?;
M9%>T,34BD;EO&?](U64:(4F<;_$QNL7:73-16%86 C:HD"%&G[4G/\)C$888
MZES@L9X;JIZM26]335^Q8C=))7N9.ON)BJ6'_"RIOE 0Y=K=M"5I")J5Q\;'
MR22UJ1DS^OC^QZR/%N\>KNOM-^#VOH:W'C=(=P_AB'P;H[_DCK'U(X'R&W"G
MD&4QHW/7!=_E->I#R_U>7W,O_&G[#0B-VG]_<OJPV.]B#O'IF=J]DSI[D7*S
MEG73A=#E.>A.R?Y<Y4VG/0_Y$++!W6ZHV=?%OKW@[ )SP8TW<OOZE7CP1]?-
MY!]DRQIIM[/2EVEW->\M7,<WP&?J&Q"E]>?V@C8N\T[P5G%+O0]U.HWZ*>P;
ML#G_FO_5^@T8X+G^!@2:^ QE<^ZOZ!*R'X3LE70V!-+F,&A>(GT#.LJ_ 4S:
MRR!N<'^!.WS>UHSU7]T@+\KWMW>O']Y3@GW<@;1T)GQS0O#NK?W=VC:_32"4
MO[Q&?X<13<C.^:I\ W;>N54K@$F76Z"CYJS:+3(][!7^V%4HF<_<X#TETQ@8
MGEQ3Q1@;JHA;\(D@H!M2VX7A&9NGS>7WRCD+H+!TN=#;OXT$ 2.;"*32Y2>D
MJO]$"W[#NI5/G[&MB,[P^V$;[Q7:YL1L-;WR=6[X03ZJCH8T2R#"6)421HT^
M98D/I2=0*'H,GO"3CKV1M0/(YQ]5EF[OC\$V)W!-H2-/N+YBWL[O)^MV<?I1
M"'Y>DR+^=<^=CZ\IS-=4NS]_6Q]TDUK*1M)] \"6_^;0Z=VCR(^=V]EH+%>*
M[SS33=<->4J0!^"]TB]*Q#=@N'C O BW!^PE7<)1Z690]OF%3+V@2%(^%O#T
M'=HO*M%]4_ 1/P43T>E&&JFI#<7[]N;X +Q-@L+2L)$;YI3*;3)%SA)MZU(4
M:>T+>E3,J9@.90/H?6NR:&Y#P?Z97F G.CCXZROWP-%H9.7  4F\F:5\O %^
MX>A1::8"38:YT[T6&5!L-'JNDTY U,P8M#_<4JCO>&9'J$H:[Q06(X#U9^L)
MZG\NJ)L&$R$^]UM*]'OXTJ#7F#(#$C03,X_QZO[/J\O_TQ'[>V6B)?P$I4!Y
M1O  ^$,0^!Y>(!#D'CP\/ +@?QI^'^V 6F@]E+[8D1"R/*.A4)0\6>'*$'[T
M*CTP>.W&7KJ^(_0NX7N]AS"N7A=$^_+#6V:M<+)* Q")FB@D5Q!5H)#'7'^'
MM1P!;'[X87M0M+T? "+\HA=%$0](S!8 V$5U=SXAB\W-%^(@O$&>DJ/_"4Q
M $;>Z>L;&M,C.+P!M,.%(!+=ZQQ2L2D;4SKJ#"U:9A19;0]WUIB78?QI9*(S
M-!2YD<E$B>:ZBEI!-$2>.LHM3-(S"Q85U)>O-(N S_5"L<-=?$YJ3DAEX'="
MAZ$D3&TZ<HXA;SMOJ3Y 210^19!!MN:.059.4BZEPH&WR!PK>G)(/LCHD1_A
M(YI%N6@_K7#C5 &"BH!T$Y=0)\L'<46CS]Q8Z9 KYE4?$ RG8+NJAQ^N"*\D
MU*,(Q.T'8F_PYWUSQ#EP]<_[5IWQ-38ZPK)V5J D6-T$QCZ'I'.DP3K>;('(
MJ/RQ6#R,!BN!:6ZX$6V'.#*$ #P7D!C0<?(='UJ",$S?4=O*"Q7Z%-L&IGRF
M>"N0&]&/X_OYL]>3B?Y";46SFIP2_!+6OH8#ZUWS4A5L];ZA3$S]L4_WW0F"
M*=4$<)U5';+V$+5Q0'@XFEO,Y*3A,#8BUOE% CW,:YWKTWAJE%W9I$?VQ,6%
M-'2%-#)TYP57SD5(E.%J32W1B_ OHH%,]@C*C97F0G;64:0,R+L-(><^0U3
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MN=TX$IL_[,C:N"/H!XH!+SPF7W(6='JG:RC:G/K<XZO[MLOVX8V+RRL$QPN
MBUGC\3'QVH0)B6FO5]UA>])>UDD*@P5YT4)UZ1SS%TDP%BX#NZ%LT'\'+R<M
M&?$-=9[&O0$Z\,D'^0#PS'X#[#_:RIH_0^\PUE5$"F= &&$*L]*F4(Z4;G#[
M3BRRMNXI&-48,[TF(^28YY$F(!4"\#88O)Y*-9>8W?UFS<K%>,)DQC5<'E:2
MB/9_X,7JB>*,@FHQ/5].U'G%F*QJ,R(/@;C!"N@8ZUBC8E/C(+NJ7QM[DH:T
ML >"_]QUXF<B: *%MU4C_I/0?"4EFT%+9EDV3N I.3[I7'E!#\6*P+3, 2HP
ML:>!L\0VV\.F$ @BQU##Z]3_O_]SIC5WIUVB.2V0%*Q[K7='5+^;IUP8*XJ>
MUX5HLH2LE5#J?6&F1Z3I2LPT8'AQI?3G.1[#X^?(GD5FTYSQF3MU3!*V;FB0
M1TG@D"@L#BO#9D:2XTZ(/60>X!M@%^T-YTW7N_OKDO&(-)7RY\Y?%P5J!,M$
MXPG*I&H&EBCER2GJ3T7X>^M$6.C]+=CD3:#B*EA&\J%HRLM+?X!@*V*.W.DV
MP'8K4+8D_5?;0%&,0E>%.7;<%J.1:9.;T5SE(WAC^&)-:&[*(@KU&[3,.6R9
M/[/MRSE! 3N[1;0>93WH1"I[3&22=4&@@KRNV:O-T4=I'@JA2<Y#C<P/(:UI
MKDLKZT/MZ^B0A?&B M.E!IEW"PT51&,[!849QCOE['IC;)>>XVR/Q[0LMW(=
M/I-)3&#S9HH[YZ!0?W.L$ZQT:>$%U'T=2S>:I88<)?/TZ.G<%4?JN!H[<NSQ
MQOW[18RN2^?S2A$O7Z=D8.D/HL)%I)H'\5,+4'HL\9$6PXC3]=X+E8XQN9%L
M$?% "Q$[F(QKI67OC\?M(LVL[E-2$R9L36Y^2ND.NPX3;/(MHC(O_ZQ*90JS
ME'H4JV\ \@K="NM$>=E0;_]8NT9ZHR ALW$<MD!SO/S:7OD58-#))O?:O9?.
M"^E"U.2"?MDK.\1^R#IK:^!O0$;>*MYJ.2<\!$)9-V28=@27I9YD?"/O0*HQ
M3A;[4R7&-!?O<5X2$BJ?HKIL0O$1[/.J0V5,WEO0"7J!UG&Y R[LE U'-V&6
MV=*D$)WXO=9VC6QJ!EW%_=2H0V)JM3;=7SE9A1RS**NV >-3OZ<043UB6 I[
M0FH"?&9>*V595GAY"W93U5UY\T>\.0K.81_#M&V6@K#HYE/.*BUZ]NGRB:3Q
M;XGJ%2LDFHO-["&/86TK#29 1]4?C6G5\6.CJR?# R.5\1P5S#HRJM&W!W)O
MDB2L5FUMC;H9VK*N.MY7PA<SMZT=QZ)"(JG*^3X];G^E2?R][7$."O)-1CF.
M(0NLS;E#H6!$^',HOC38?#V'1"FL/H8[':XIV2XL"'E"MLF>L#3(HJM)H(,.
M)MV=B$G*7%KY)WS9$?4-Z@F11A/B0CWA44H5$$+I04,T$5I<2H3*:3<86 >U
MB[6,D6)*(?[L$WT>7M1T@,\-P?Q7V3< ]?J^B'NBT5/$8D3H277>^MQ>]Q0F
MZCFR9*]D[UGP]OC6+=>[IB="]JWDLPO+(\WT)7(Y-NRBQ*F-]B%XZ'U(\5:.
M<1-N_QL@. FR^PVH])!]U1?\*'AC>V:8O46OP4=:E?G?C.7>M(Z\+YTSO#T>
MJF\E,0[4N CI=PC<B5<MQ%^Q*]NN8]X4_S/B*-LC-ZR;EVL&T 4^$H2S0( +
M=,,#3#KMBPO,PS,].TG;8 6_C#.7UFKF?\,A:=K$2,D@/349EJC"J";HQW,J
M :5<^%,_$@;JDS#'%(I93%JLDRP7V]#/W_&</Y.1 M3LLM-V^ZP.6<Y3D"1"
M% Q 6811F>Z]TBP'V>:59-'K!QV5D+JWUYK,1#_E2@L6V ]<U:DCS>1P,Y?F
M$%=W&=;!0MQD)-!$=+%*]3+DK%Q+T..[I\]<][+&?3F% T-+%$]&\^$3L0GW
M1<L$=X/SUP+'NU=&!7N,.@*D]6W>_VFHOF@=Z1#@!H_\=CS!8PLT)O='?%^?
MQ&$=X&)PX<FE>%VR_Y?1.IUBP27F/FI&19H&7\7U!:V '+;-)(*;<OVUS.#C
M 2AXP$[ ?Z;<&>GC0A]>!@P.]XGV=$F^ 4)R%X<&6R)<4A';%Q3Y1AB\_!V)
M?H;1R@C/8:A;Q7IRV6)XOZ\OXH(0865'!,+G80G1=HYXCH'U.7RC7#',"=5T
M23P(C8M,7 W&(<O04Y'J&Y 4;O4FQ@80<H6"C?!<I4/7HQY1E90PEQ8"OT"F
MZWT6@/XF?+@,PG-07<M?A=M-WX#Y713/#T]7W.7]W7=/@IK_H7#T'&KY8+1(
MS:JNE%NK= /-^4"%=$2=6<M2LUKHZ,13.Z53\9'_Y!'!D=6#V#.E9!Q?6#1*
MY814Q+$I5;BL,CX&A>#9_?UU!4+DTU:_#M9!F[:,QP((_,))NXOMG5:)]S9'
ML4:SRC[<('6216(\_'RS&C:OU >879$I2ODF<CIT&!K*OIH&5GV,<L6@7+RE
M0D><C);PVR>3?/4W(.\$)OU:VV?PW?%)LV819UO/,;)YMM09=E=75<V%/7K]
M:EU5+I\SX0>*>5)!I-:"E8P][#@[P<YQ@O<W@$9A2-3^<K6)!..Z['A8!I/)
M8N@ST'%=1E?X!->84$?BK+ZF_ODS:7*+M-R,F;KN ?'&\1DN3+7<6BDI4_#\
MH7R-D3C*OYG7MBH-UWFOVQQ1AK]5*M=4>$>'E@W$KB= \_:XB%]#!^AWJ8<O
M:&R?QK,6/R!<+GT&LU2,(/#'SC71#_&$8Q(Z"K(H$7PZBGR"5*PJ7R$N9#Z^
M09!7H%?(P/[];-,Q50%V44L37JZPD12FD[+VXC,H!,$JKY8=2U$;4"VLP2]X
MHRE)]1D0$JR3V$ Q*1JFG^P]LUN0S,CM_F?;6ZL^I9)/B5^H;)XGN"3>#=P6
M=:W]MWB?:EN-3^.? KJ-)3>M4WYW)N>,2YF_7V*]*VTT/(R^\FC7%%^T3/A>
M&1_3SF7H/L1X55BKN.N_ 7(IE^0?-(RYGFEO$X\E:-Y$N!682Q67@ ] (5PH
MA >QG%?>5Z$GQ <HUS?@H<MSYAXT9L6VBK=PS2!LP/&K.V-<WSB$!0U_T@'D
M]R3B,<@[S409##,*R8YIMWE-.%5"S#/^)3')G=A86-*S/DUZHRDYL @>!!9/
MQ/7/FBX$.JQ"1/!:,)C[XI5SGI]Y(?RP]*ZNKE.N5 ZF=LC5&5']&%1NR9AZ
MAXY+\J&UFXCFPU;IK_HD#6I" VQ'>*"^D/ ]7(W 2;HAZ[2/D-YS.7U'\QS@
M [SJV4WQMR%[_&]U?\PN4]X"N\UD=^VR0 ZFETRJV/Z'H3I0]!R T/T!A$ .
M5?K.IX?XPAK@"3+R 7Z-\/K1EC>$4 9#R*2]VX*D.4A9WT&N\7=W='+H1Q=1
MJ3)D3P$_!NY9#MY9RUECPZ"UXO$KD7)'PE&(+81?<:*[$4B%P!.E$Z;WE3[P
M#/L&%(- >-NF0A$H^,9XV[K/;:2ED++VI:8Z3<':501!!_L#)M=FYC\I:!.Q
M4WZ$!*OOX L$WNJI67G@<5#FA0BF>&!1PH-HS%V088@D=< :CT^4_=^7^7_<
M=Q$6JA@2@/P3MY!M$!5>& \>'M\S9,33#?[%]0Z8%Y<7+F?ZB)<>!T%0IL_%
M >O<^GYQ US4PDIB=NV<.+HB1U9XD,%%+BBUAA 9,OF<K#-#52[JJ+!$/W<W
MLT7OD_FH$)U!<P,Z,5*?ID'D.ADURP6.[5393Y/>21N.I,52.$V /72& @4J
M5JRR[,H97"$J*=2'8NV7W8&F8<%FG A]-':[=CEP6O1L=QK7FLU'HGO$H^8D
M;EW@_/+YLC'>6X)I@^A2+F<4HU1YW9#.+WUM- C*_E;^M@RM\''2HV3^0)DH
MRJS&&C;^??(@J:T?:PSY@O/=!0^:'-!!U)S 3@CUJHI-U?.GIRI@YG3-Q 83
MP'B?;+I%G\85C,B@/9<LPT)\^3SWO9XW$5UR%[URIH"X#6"]7 +%8@J2=']]
M!$7B2X^^8H=$,65N/[),4( W&#S!#&ZIC_G=5M9;L>.TYK+&FK8R\AF<Z=F
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M*86'[R)!_V$M^0,2U#=WCTH\'CI)Y=3 (&YE0Y3!U)A),U5V_Q5SY.].^PT
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M^_#]" 1_<A4.=5;KI':?%Y>^(J3W48C."C;L/2K#5/<!'AHV2332\+->U)2
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M+3^L<) SF$!,>4N8?T3G6XI-*I((E(/Q7KWS$K8FAPC6 ^!*7]3P&R>9F*>
MB[O1-D,U60Z7#7VLA*B:6@4<K2EB HF.LI^"DQ>'T)(<UF@!7+5T&,S51!C&
M< .R>:V^/JWMFN\8VC[3Y_<OZK>?=9]<Z^\9<=V(P^WW:C-T=_Z9%2Z;VX9M
M0[.[N%A>$]EY'!5KS&=MBK<()S:?(7.SWX N+;C;EH\/CXRX$K"5%<]&D.F/
M\G^&V:R13>2]V?LS9PW5Z4[;RP<!)_@;L.)%_3FWPSO^CQD_MWBXH%D)'9N'
MF;X!W #'#]HRG:L.XI"7_D"[BI=FUX7/+52D79W@0[B/HKF_2>G:J=/-_3/@
M&R"<=WQX\P)W?E2\VH:QGXJ_,D6#"LL!1)(ZOTM!7U9RT-1"PTFRI\3B$V@/
MF"+<&.UULNL2@U))8CZ::\9<9*.I5W$PTGM+1Z]WTY1$;A\6I,KZK5>%;^H)
M@R7E7X,F-DJ4F5_XAE&=D=5#(301%BF0>'@?*]8?&P#@;_#0DA1TR,B@X@]>
M7JI& 0V/-Y<V;_>@K**J;JI*;6BS?%<@;CV1VQ7RJOG9ETGW&Q7B]X0CFPR,
M&6V1YH@T<L;1K0'D_QQ3__-H]#L+6_H$J<ORZ]TIDW/(D8@\Q[4A,F])MHM>
M"BZV7'SEHGF-J"*DBR>Q^/5YN)4\<!M:62\Y0C+[1H:@@&)OF^XR&Y-)[36L
M]R?J<B@HQ9GB/4FG_I.V3:IC$8AF:58[WO@:,F_82;_*=R]I?*RT!5!-2&H8
MUKY5H&AKW'>KV9_0B+) 5U[&[UW=Z;C?A5<VG_BLOPJTQ"5;@6Q=;J[ O5RD
MR+!!XP SP\!YP<.MF%14[U>F2;ODE:DG2NT6*\H_,**Y:YQ+K3!](:4<$A$9
MHV&TTBB6F>YLL1S<GL56:F==T%GNLB5A7Y$F8\XAG=+E9%&8K5SMU"$<M71.
M=[Y">1O37,G8V;909AIU@X:A :6Y>Z^-[V(E5]V4.%E"*!_K*/:PGO6 WV'T
ME25P)\O]?*+(DI'H'M?T2-BL7N)T@>W*^-A!:<1J*UCM+DAA><F<O.KN?>6G
MH^P5-@[QR5PI,-;FQE&PBLP308Q6=UZ6OR)S.I9B68IVL8%2OGV0H,"1U7+*
MSU>.Y@.?\0*!7$ZE!]?/M0"0OAIS< -Z@0SDCD5"'?D03*6%H J]R)D(@252
M15^U1X<I&O(=L',""_9SFW6N_2.[XD9/3=OWX,#("*S>@$YL/M[KZ1)JZ6F
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M]UMKUII_;^P\$6?ODS=VW+@9V1Z== BN+42L^F.'KJ:T49UKSS],$;?\+M]
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M8'QUA!GBV: /P/K+I-B]XG'<H[5Z5N.HW.S$3#5)G?N+NOOC-EDX-!Z;LM1
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M+=88\/&:O1_?AUD,1UA)\>MJ<SB0)SW5JSK^1M@#4HNFW5@A;N#</R<1Z]3
MS \ 7/SE->@+,#95?HO%;(_L/7\C/_KUW-7J>A3O@LL@K!DZJ[+P _ PV@Q]
M,D^WV1>UV_0U^1GF V#QNUC!JQ#!F]/PO1_^6@UZ2F/V _!JO 9]?^*\100R
MA)X\NUZ#DGWS=QQEN12">SWGLL*66\K] (#[\SRM/L\+$A?^*^YPD_=)_.6.
M)$&7\>20Y*M,N]1E_7;E(+UMT[8W2_8[I)?@>V9 J#UWASCU2?S5#3&A4 <0
M7 P@0(1$3%3&=0%-Z=OR]0?;@D67R@D7@2J=Z"N]JX6'[M?^8-23@Y9N?]L9
MV_"@CK^!>#T-4W<*=X>.=EZIJ(L=[QYHX ,7V]%W00Y5Y-:KAU%R&Y17YEM3
MEQC.,/L4.BC">N2Q<BK(J*I^D^O+&+&5?Y9_,5*A#R;YAB>[>-M#-@]D/9'K
M"0O!8$'6VYI(PI=ELH:%QEX5&E 3\T^=P> < #QT<4\&F!@F$+(9QZ=E3TJ3
M^#\SZ04=<R*_:^=[/,7@OR$*_2MAHL=$=V&=S4\BS7!&L3\ 6XJ=&!HW<"_
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M/%_2,.SW)PQ1P5*E[]J3O]=\65V*)Q?NG;9C3*"3=C#?=-=MX/W/A^JTV$(
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M"B\=^JH/<H>#+3K[[]H90*OE9^\, :1=D6-@0R&FI_[O$<DW]G%F%E.(/U:
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M+/NY8D%8>CH_$:/#$(XS8)K0:Z!%J,ACHC)3B?%+Y6'&0%A'B%&3>G&6G+B
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MMY8_4X.2?VADQIT*3%WS[GC *(5<Y25Q$[>)K\S3FCK'6;Y> [(0MJ*ODYR
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MX&%"&YH'A VI63+L&O!P[UOT,T05A]4-!=^B$Y;,#*$?%4+B-G^3..(@-='
MVKC"/RW\!1@P,#!( -GK$*M!!@;(B4)4ME,RG"'' FDE>M8"X5]EK7@M+P*>
M0;[EWXY7%U.64\_GO%\R-/;VK7:XQ-RF.;XF]4K*'31KC>U%KXCM1! L?U6\
M=L^GDN[87NP%AO8\'-%E<L.FM!?J<9\#3IS2%N4)&_-5N-J&G=H<2?F@FL',
M%S;5?R[,H7\!"L<\\]?^2@69DY\$]/R=E!X=*VTI#:6!NMW-N3Z:&4U^G=(1
MWXV5QA] #KHBJH7CCJZ&A:N-4<8FOE0KTNVS"MVGF6?5JDL@(K'X:L^:<B\:
M0Z4T(OW:32YB,G5C/8,%_=5,2,K0NRB4+:BW>BT.U7*&HEF(HO-JL2-154J]
M;L4[+R-_HX_5.[4KH%:'U6:R:4A3:PR'ON5";>U^ZH.ZY65EI:)M,<+#&Q8V
M>11<G*NWU81M]$VT=A-(E10>-T+DZ[R&AYO7<J8&4NP_%?=/,VV)&(FGA>(G
MSKKOVY:N+#<"/H!\"YM]4@KM"CO*#)B/'X2-G#^]U4WQ);$XV%&M+VN4_7+7
MG$TG&\2L79:R(EN*8SSJ?ZZ*5]%^4XFL(!?,34H85G)L%#QG($-?/S;E5']L
M?BMPN+'95:6\DABJ)A!B6U,?'^'3:>^1C-%/TZCQ ?T4CHM/3[:&Z,KG&D<%
MDUBS-4R5'H8>*-D!0RJYX5?,JFU<OJZ*I=D$@_R^\9:G*4QD4:)9ILVTM L4
ML[BOV+GM>R%O#ZA-6F0MK8Q2TN*'=G!B&M%I&\NPU2CVQ,,9_N)ZIER4?#"=
MM5IWG1]=-4"I7S>@F]1X0WBM>?D((G:O(5=;V_>@K'S!D-5V!@M5=6+XO<VU
ME3?'D)E%'.445QSE_(!Q#<OAPG#+!3>OTC82_WJO"4U:T([V'9WY/EC-?(&+
MIZ3[0]R3+(&2F^<(=7]"TQ$'BR1Q<L\BC<JA:)FF$FQ?O/1-.^9VXQG];/;A
M 9]I[L+[O2WY;A"+>?*HW+('R[=J_0+YS/C[IYP-X315 [ID6L:5A)%*"ZGN
MJC_?E_HP^I1\UPL+@-F9%I3B JW7[@3WM>G<.] XN94;&;'X8F6)Z[36.?*:
M0J9)"AWKU%5MK2.<>1ZM<BO7\:F*JNZA?,^R498QB$*3H0:.FEA[=QAHQ\"^
M<(MW 4275)C_85W-SGZTL*M30P@R@"R]-CK[L_9R$3B@8.=O/^_^J'E6>R*0
MH3ZB!VMQ%JQ>,G=>B,%S3ZL1K\O)UR/TID>TAE4J?AMLH'>)37)*!O<D>2XE
M+R''G,Y+N6B>I?IM%ON;%3*+)D_F6/I?KYC<YD0^+S!/%-'.W4)T;O3]F16J
M#MB@NW)SS048W&Z5;TND>!LUF(96!D9;*2YP$]K9N*?U;)ZKOYWJ-V-<%(ZM
M?RQS$ @W>3P@4CH.-+^,4DH]J]0+^U3/ZU2KQ>C>R>.M56A@ZY[HDESI%(@G
M&UM=;J)9;(\K%&L>J)JMKRL3K4Q*$3(_Z'][J&%LP%:;-PEV9ATY/=FTI$_K
MZ;OVW#$]%K)DBE$-5FY<'_D*.2TW[X7()%C,_\P>1="G'@-7@OBA7.ZA\U/7
MA\WFZ7,9M3!:QO<8'#G"H8Q*?JX(EYM*W)/K;\:9-)S.;Z1>^-,F#H0]$X[R
M)*D:$'-5JJYUOD9'N??T>&%&80AI6"3R,/PJ-5_7,R]1QR!F1!/5Z\\@[^2/
M/?QU5FELJ(D_/>):_7"[6._D^R^#NI[)<=@\6_Y#BF:G/UB3_9(4-/.01KO8
M21<C5KCJD=RP3E8-;NE9'/U2HTKIP!,!6?^-]%1D \7[8HU3;;FM-/Q0SG#1
M'IIU5C0^UWRPK&./XEEEV'X,(R*;L_2Y#W _&EZ,A&/3!?WN%*[[-.;[V?<%
M# J?=/CHX 27,2"SOCK *L*/\F'X7'J2C^*-+\$"1L]?0 Y7-?<2LYYV:8I0
MJ[H4J#QDX[1T^(RT:+:L*5,]0JME4SX'O4"K]:=FFK-^])P=L1]!(W44UT^&
MRU^)5KAF_$W))/R+S/M57_O'LIY)!LD4'S3YHCEJUCBN/QQVINDGM7M9>SR
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MI&'BY&+F%N/AY5.YP2^N;>A Z'%RAH5&1><7=*^L"DA(JFIHNL"](G"%RVM
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M@<>4SG+_;3NY)(FGCR'?<)RE_!DO;J@Z'@>=^-5[D@Q;&'QW(]/![G<83D8
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M679*.\G!W<M7]=4WAJ9[*S!5/(I;2^"D,B/9 ,2K&&>IL%]J+?77>6%RZ*P
MG:FHZ4\Q4O^TUS=@ /(^G#PR<(%X8]Y"'AO2?R%N1K2B-O2:A50K6TIY-AJ]
M\VMBOB>;P$I93B5>X]_4@@V$S%E5^EFMK-7&RLS,9(%.YX$D970+3WO$(W#&
MF6YDK'!DW*GCT!HB3)R9Y+]\3&PK,P_)Q;B%7],8#D[/^B19B&@%F&=,A#6Y
M4X4R07.OE'_*)<;X^*R+)P#1"IS!:*^-6_UWARG[<;M.XE+/&B9K+"_\X<N
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MT'PZP9=B[K!0GF6]P:4?("[SRE:1MNB#+V].#U_]"M8E.8\5 0L^C"W-5>^
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M_\+*3$:I#;DB1EYJ:0+A06[ 2A_:#C?PEGPLRR"@N1K3Y"K^@!?7;BL!;*]
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M1LG!;W=;1D7K78"':9-ZQ9Y.D<"TK8!MQ5QW->O,BRN$XGW(GP=R$G/?UFZ
MJH></U%WW4V)\FHWI?/KL.6MO.:5YMK$A[._O)I<,[WC,CR0^5R!35_T4H#M
M4Q9+B;8HBPJ.!75T])1:C_327W=@HIB4J/3NQQ=&IF*8=2)GO%!)$)>.^W[
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MH]IQ*U68Z&'D_P6\7K0KQ*@]*&QR&;EC>ADY$ZL&5D!\W7A:>UZA)+#/3WV
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M>K!V@7[F0T'UVZWQ\NKQ&:Q!&RJ-C-_!T$'[B!?T]2@S1VB)]+\!V4#HJSI
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M]87I.F!?H$*; ]-*M7&N7P@4FL!A-6/Q#.%S<H>3(S\([HZLY"93C9OM/2>
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MMFVS=*/TJ30\*S8KWIPESL,?F L^HJKE]BK#!=J-P$:1Y**XJ<?"!P 2G X
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MG\B"ERRJYDU7G74*QKT.&W^\Y7VKH5QSM_6THZ<VG.5.>!ZWU>(JRJTI/=2
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M44LWAQ&#3MO]LU.EA77H2"<5_G:=H@ G;C.A2;CV>)6UB*[[]PCPN4#)0G@
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M$IK^![<7\@]._KFOZ$+2[A_<WD*FJQPFHA4Z@M3?/:0  %(J/OX/ . *GP:
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MLYY^YL?EZ4PR'2=[(361O;%%JOG)[3;/Q."+(J;#I'IUT>BM[_=\C_)^1[J
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ML;UW*XU<"[N2,X=N5&F/,44UA6A+A2)9I&_?/EWAU#N*6637EL>/K;OH[+-
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M7X\^*WG"BZ==(E9,,>YB4(!"TJ[?I1_?ZI-AO6R_ 6^MNE0,)R_GJZ=DL3,
MYG.H\TNVHU$#:6'U9?&Q&I$TN(]S030KVUW]5*2\[!GA6ES9QAEA*[D8/9[P
MA:3K)O-P1*07N&?:K!9[_#ZIKW!-2>0ZIJ5D?@=RCR^"8/:2,,GY<0)Q*%RB
MM@WSV1Y/>,>^J83A!<([WFP+$S$GMB20^S-U>,)</+T,T[E%E%5^] T&<%M\
M.WS13DI+TW*J_/?-U.S/PQ;E=CO;98/:KLX=?:N8?82QINR)=P"#')1?U9I&
MP&O7AVU=1IP[.>D;J)]9:&E5,N>O%+5YU5GEI(DQ-L0;CR%4! -TL6I?^WCQ
M#O@V>F/ZR?=G"Z;9.O!38Z]K=G[<BA-*9,K':S0T)-*L.%YL-=X920RR7<'A
M,9. < J8H1L+F6D1_![C4=\V]N?X3<B-YQ[4),Z!B8*YT E@:?@:]C;*\D]T
M^&?11J*QQ>YE\,4F!7S_*WB-\L5C?"YLK,%2,94>8G&.+3 $T2"@B+(I^LYN
M4V**M<>&1L&EFV.I5D5D;B2**"M#\13$^X"TCFG"3[84M^S+K2D=G<C#>&R6
M9J&^7_E?$-.+B2K%]DU)F=MHXTZK.C/O7Y\OCA)0B2Z<(-@2!D!-.K[M*%G:
M3+$?,0P0=KP<"K4KY8HRK.Z92D_?^TLI3T_/\ZZ7\+EDKU+YI< 9*-;NQ_5&
M.@@ H.="$P$ *.W:"1$MLOWF:::_B,54_X8B^U'DZ<1#EBC=0KX3L2H#]8<Q
M$=44Y"._ICU$56,EX3@%OE^5-[@"_(EQ^!=R$*) A)2+V@K,+WRCCH1")R3?
M%L'KIADHI5,"L\]*%O+2E+PC>*^'D)X&++J(/K1Z+LN[Z(VGZN,OMO$83EXM
M+_)"(41>*$1&058%/JSU@_-S^EIZ^6:<\A?_6W]>^$W]/ZEHG_">ON =8++Q
M4MSHQS<S9?1"\'+Z:V?HEOA7M'#VOW+T?P\>S)][T7G9_;4ST2Z-;+*48"5;
M7L!AQ>XF?;8T+CL^.IBR;<T<I807EYCDU/\[ N**@/U]3452E7$8AH#*AB"U
M&'R/B?4=DZ)ZXJ3UFD8G*I'[K)6?;.>GRE][(IX[ILI DLS*6.I2"I0@U=5"
M+,*S8:7!91(LY&/EYO%?P (%^3"V O0$JZU@)\Y2T7I^"X?,C*2P,TVK<?P5
MV@9Q(K@@%%JJ/(2#;I[2N5F>4+P3 (P*/#T7O)T(I2A)<(M]?7"1M:2'5WN"
M2C% =XH!N3>:,45% __4C?K.<H$F@/5VF7E%><KD-*9PV@ 1<F^)XR;3-^,T
M.Z8%)Z4DG!"O/<+!MD(DN4)?ZE00 @>@+U5M_.N )X!*E4^IJ79-#^\H--K
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M*0(;'G^0-Q([XZ_;Y,;1VE#FL:(9F Q<LS6<;HS"Z'#0(?L93PJI.X7#Z7
M7+S)>D0MKPU0E)3N^*,<%5VT,*Y]QI9F77T'2$[E[R+91R"M=3TO@R ?2_2V
MO9[4&!] IR$'?96G=2K-G$HPEWCGNV;(JIBAN(#'9->[^*&[OCRQ>:;P7:.%
M4[T8W XOH0:IL#J2O #K\Z5_2K#;"4^'+*+*Y5CJ)>BQIC'%4V![B_\[@,WX
MB:/H/[ T[SJ7_G.ZUT: ]O\:VVNDKMW[1KM=K_,;:7Z5]1#;.74_2$D46:YG
MCHHCZ=HG'2/:E<3]"IN&GDAK!B-)$><!G;QZ8?*GBJM&O%Q:[]U*:F&U* B>
MX4Q9D:5NO<,H=IF3C8AQ#D9>V4D"#.0Y2&1Q[DM+)(X5_6#+76BV)/,<:^*6
MZ<D?5*[E40#7F<2#NJ1?A>)TY+)6YC:P%6+Y?6W4!*N$/0"*(!EC"% >1?P]
MKA&5GM9)50W890TR$.8[,?S44O(8HQ48#KV%J*%KP@>:IUHTYGCC#.R<!]X>
MUZNG\OPI\W-+E' R89BR,L2>^>QA0NG PG?^LZ7*RIULM!==IO%)4@Y_5^E/
MH]?X8A-?PR@?A\C<[1-5(IZMP//ADI.XMC67A ;#3.!/C8WR'VCJ,#I5K"&<
MZ?&(1]A*7*I;,:I8 )R(=/%XC+LOQ+\-J#6A)JBN1[:99B5>,]("M%P=0!(S
M61)V7*"W.@%IH!J7$?**P-QF2_%Z.8MFG9K7 \/(I4Z8#(UVL:O8&6EY3<^/
MY'K<I;1E-6F?%;/)8X&:"]N+*[#KK9N7(5CH/WPU3Q_U+6'''GG:+XZP:ZTO
M%B82I.%(LSL!5\!'$=]PR73:)&( JRCIK&OG"^? (%)\MZ9%:5PMG495GRJG
M&M9LLXQ,"3-9WFI^GJHOS1;H/<:!!;(8QY5CXG)9(5)'I0SF;+_CJ4899!2#
M6Q24\7W;Z!V*AIFCER)@/'II3\=^Y(7(3NA02T497#38AV272/7MZMZ%$<]7
MQ8^>7:EC_XS3T.F>+OJ,3F.9+> T-PWA<L..VRF_V"8>YLK($.WSEL3[/C6%
MW1HQ4=F-50!M(-H>7UB?3U+CH0*C79@X5TZG(O].XF0?N+H^$0'Q,"R^/M8=
MGF<%F#(A%G-.R\BB0!;NP$.5;,+?4[EUQ&Z+&=*%UFD7=HB;?&FR'7=MZ<!/
MT3S\D%S)('3*D[-3EI+9%-4I'&:FQSY&KCDRL=%HHD9YC88[Z1O#=$2-%".9
M%=]4NE6L$4VS,)DH]L1ZY[A^3Y&8-JQ)M#%X->HFBN!!^P<+%]3^8&=IJR4=
MY-W2\BJ4,+CD[M^=1?=.I@6[* [R@:B"!+WDYL$W,45\\86S*J*-C=1[A33;
MZRT&G 9UD%B_-8M)PBY1)!EZY4D<V/0@:S-7%!TWC,[DIR X=F!\/Y",]^-%
M80HH\O<P21FBFC;L!S'\Y@>'\F/IUDI(NSQN[+1V+J^I1>Q4G&FYDQ/LFI5_
ME;=C[V48\F@V9D7\T;^Q%\E/',X^;KT#=')Q[A[_ULY]AWL$ . >X/X3]C*;
M7G]*,5^.99,0#W8C/%IE?1!U=]:0#G,;#AT":U0TO1@51*0$E]XI&2 A\J5\
MX0N/BP&)QEPEJ[;+FM#: IW?6SSJ4#E/D#P_O22 @+D;(#O*9:%[MY_S\YZP
M*.'E!:]Y0Y;:^& U9D[1,_/J4E41^"%TB0A4L<5Z;2KL.MJRS_H.V""<_*@O
MT;MM3/9C)Q=NSY>]8W8&JI5PP:X56XDC2SO6,6D>C86**U"/TP>[<NY]@(M2
M+Q&UX=O'D;MR\\WZ.?8=4*3T^N8O</XE$V/)>90CVQI2XJB_<E!)Q,"MDZL=
MQYS2J"GZ\?<K"'F-8?EO]9S#4+VE)"A+EM5KJT*'$\>A5L#FJC9C_J0WE[)C
M2V]FJ4)_?>;+!_CVZC122+]Y99$8YZS+0JZ,+:H]L31Z^3U-$*ICD=J''[DX
M=F8S+30,P!2%A#'13 H1!R-'G+Y!X[$RL(L;^#L,1F7'EYT:"V9;*TV&2L6!
M#[(,R2,6*B>_1"N'*DW:V-);H_7[W.8EV2Q.HP8K,PRPSE(Q3KN5I%<Y+P@?
M+36\(.KS95\JRDM0U+3C2-:D<)(,Y9S8)_&+#I7(.@K&2H@$@_ @TY)>10-?
MXOHD=TDJS0.2_)XK* 52!@D09-!;!3O,4N8-/8XQ_%I]]-\!P5L+BC_--]%4
M[PB1!N-A9OS=V.95'L7?>@<*':\()W4GL!P2*UIU0-BB'(SUHZ104*($??9Q
M^8^^(D5VO +3,E,8%!5<0A&X'+5S2*$L=;E4U,3Y+B,5!<W24C,8#$AE%@'@
MN %V<0"@! !\HE(WS&JBLA'@AE>9PV)'5XK/5'<@52-[K @S;T*FE]6>9PV/
MF%-"IZ_>YXK&".SQM+(?YN8RYV*U#R4DQ4?0DD$Z> >D**>T-DH7%SUJ@0^@
MK"U.9YEX6[/_5![(H5Y8VO7Q)4152RTP.7-[-@E2^Z(D0UGW0AC1_[3_AG-?
M=)U.L*VCI5+D6!4%L":A-F1)[!_LM3R&L.8+>1GK0S53N9)J%V=GSW >K,/O
M;4.B/4D2N]@<HA)!=NN\,4ZR*8@JBO #JIVZ>]HTI*0%=&YOHK\GX/.1\\/3
MK83H&K9G:&NJ_RGT^TX-8\M,V?I2M@KJ0A59?KBE\G'T,VO1.O[2G(.&Q#8Z
M]I-C[PAC*A;;U/@1VLD6'8./UF=.4SR-H(;3/'?J2ZC=XU*GW#9LD$0]*3C;
M )T4K88%R6PW3OC@U@&?PQ'^$@&Q/=B.>2?6&V:[;S,V9TMZ<IS13)SFRQU&
MX!=(]\\:[!7JZP#Z'R-SHCSE2S"?@@7:J:N[2AO_+!=[_2RUDN3\S9\PHTW=
MA=844D"$GL-@6>D;YS *=S&!W!QP <=\Q5$QR#BVR8MRG.6*G^3W:82B^Q[^
M_J*5Q#Y1\$:'"ZTHO5(:+:_)X:K@* +%ELLE\J.H&C)R $0BF7*$@@I6'?%G
M78V IE'8N">!-K,DZ9^14M=$!A4!A])U("&KT*5SBZ86V)6_HLR<>J@"O><E
M_R+/HL9<YW^LRD&__E/O5A>%*QIE797$+"B&>7AT[+2#WV&#E!)QROW,D,NO
M%X^:Z".^*7L(@DZFV.S:"4$Q1U(_C]T=?K1QW#5T#6PDL,<N)5U[-9+?RX\O
M:=3KJ>.5;7H/5"^K26NU)SAH2T_? 4,^[)'\'I\+<7**(67V:47R'?EXU![Q
MW$ U+-)E6CF>0._)_AF4NY)=JM%:I;9R-V/O<=SF7#-KG6)MQ:@IT,F3F*(5
M8DPTM&)GK336DMKV,X=ASN*J(A7]1A\?*HFME_][+:+84TTS0:<%5&V"_+%4
MO7S"2 U3-=,65@=^T$YDM5KWH#:3$PH?4=NH[Z7RC41N#%-W*G*.QD&_((AO
M+I.G#X6$^8RI7P>7[6R_2GW@BRQJ;&S<7G.-DSLN<06>/J5VX4$[3<D"J_,0
MOUE <TA-_Z\D%[%*2R31NI$E_'D<D"V1-VW.#N;?9:?\^/!##>DM"4(? :]_
M*NG_L3)4O&;Z4,=G,\(7=]G45+ 3L?F*^4[YE22/I]EXZ AC*=EXN>CYA!I3
M;WAT *S"$E5'"PHHBI;':9WU"NB/?NAVSA'6Q:FF.<T0_.#]-[E.N% KU._Q
MM+="(.M[C2&O94HBSU(8\$1>K3,1AR\$/Y3[ C3&)0GW1H5*3J.BG8#X!&T8
M@*,CL[R Z2F$UF'_;HE &6U3TZY.XP[P+I5K0)C%ON*-G?V&!?3YN(/,QY=-
M[.%7D_^HIUPRX49:FNFK7$5Y5FO=KCHR&+&:,^D[X(49$%[Q0EXX,MCQ./)R
MZAVT(SOSPD5M^@Y :['#\NW/^L;1E+O<WY1CL9JMGQ348IG(.#<_=5).A>P%
MUG)X=:KG[8:'MF4$0[Y;[*OT4X771*NP5C>8)?_%W776"5=N*.FU$2458KS<
M#T6W]!L]R:'*/K=ML*\?]5>NHY::$.NPMF 1DXXTV_J2BR=@OYT9XU&TO%]!
MZGT/LSG[J?YS-Q%EPM6Y<,;*>-BU ;SGQL]]":$2@\*7S?.9KPI[6_]N6-^F
M5/ ;-_79@> *Q7Y*E3[]M>WVH9>$.)W]CTVV+1;N%\5X.CKGY"MC\VI\+?M=
M)[S8S!K:\:(<VBV]:,.?J\:?V%BRA:/ZY.HE!CB35Y$;1OIMBS"*36-1XE\6
M$P@R.Y]=*:E6N:AK\.-2EO!]PT5>-+.G.>5X%9GO-EL<-+>UW@&,5^*DV),?
MG/&;=:][0,T4Z"&SWB(-MEE94DS&2/,$G@0/J$! ]"C8+T>S\C=;R=;LGNYL
M%<%]BOM'+7<=U.)P"E4BQB6=I_)=TSYBB61HN4SE>HRY-<,>46:G6PD:=P/Q
M(FL2W +Z<,D,?.Q1>?00 LP\NZR"Q6[!:B356.W8W8\/+7(6H367&19"OP?]
MI[;B&OA=GEI1KMV.O:?.F$;/H6HM+LWU;F@[%$[FPU8Z^C'C_3F5+)^+!=HF
M9DHH&+_?MQ'/*ZD0IL(0[[41;_<E)=FT+4<I3D3'> TU$ >N4DWB>^;\<=6@
MR6I'9Z7Z9L) 1C!OR<&0(@?DD_P>RQ2U<#I@_#'&+O$O#921@BXPI3!8.\5\
M9UT4[V=EX(Y#WL>P:SZ.]-^CK8C'08=4M7C]".I4 >KAB/2D^49P2-0] 4C!
M2-0[DQ''J89H(S(T.LD)[O!!HA1YK+[K!EU+UH1\U $BKIJ V @T&$"\(\D#
M.>G]<78%_839RMS;P\^<M'-BDK'@^.\TN"Y8'TVZ$L$?:E-'4X[QP#*7D%";
M J</L'-+8L.5A<V_QZFI3+ =->1T-NK(@;\T'X>I9#S6P0)("V<V0V35TG-)
MC@O"A,=)YT_Q#]BO3V17M^3+0F,-RPY"_F6O&3PSCC>OTJ<#G*L^[P#59[98
M;G+A6;\Q4\7!R3OR!L+_!/4O/1:VX)C;H-X&'@'$YV&-8-XP/-\!+><VO)^W
M,&L>W[@>8V('^WP$7O\)OKO*NRR7N(YPQ3^25)&S.N9)LJ A,BK3LA]18GAP
M\[18Z&K3?5$3UU)E^:D6KF 5@5$V"H#@;DX]*F.0/#W 098"( 1*JB57DM(B
MG8L]LB>%4EK$)R3*!*]J;693LPF=.=.B4*W1[\LQEM/JHXDRA1?,99KQ,'8D
M0^#HB065^XG)TD@R:GHYC[GD--8^K26*_4CDK$+E@'X?$1^=B11'2I107+0]
M.YYE*"1BIAX2ND?6L<@9)@G5_I/(Z\!EN1WLNQ1T[JR?=/_!-J6@QZ,6JZKH
M8%XB0CI%C3D;WX^UO!@)43+"6!:L1U41?BT/,@5USB8G1I".A_Y2CANUZ']>
MN,N10+9;-W[ V9I1GCF^P8.ZPFPJL#6F?I*)4:U::C0U18YW@+4NZ;+18V<X
M67*5"/5MP).16ZCNP+0.IYK02)@>IB2I(>TW":ZJ6R.YG5RM?I3P@5?7?EU1
M/=J5Z*R7K8WP\(BX)KVIR>NBFR?X?.R-U5[RP^;6.-Q15WI+ =A-9Z.Z .P6
MC!#LF72?^\%I&!9'2*YBK>%BN;-WY%K(89-%[G'7GR,>N1H$V%DQ$M*J'#OB
M+4N>T%#\3%A?.2'PYO((S6BO0"*K/E*7KIFDH/H18P2#!705PH84^7J+LL,3
MIU"7J5ZC M-GIEAX'IB8A/*,[+@M=+ZN44[(#W+VOP,PK763C;*([>XY^>O/
M5K4:X_W%F:7394WGMN!?CR7AC:[ <#8NMH7R;PPQ3=Q\OJ<YVOL0._7 27+6
M8#C*S\2;@ &\[+H$Q5Y7-9[ $="N>"#,PJ(0^9SI?*,!OYIBL$X%=AW!5F97
MDTASA0R,@'F0:R*=^BK[RP[ST7SJ&>/\/SDR$BV*:XT&P%S6NSJT"45J7:'\
MC_UT"V]6ZK."&6\&:ZPZ3Y^D5G7-J;%!7'ILAC<<)M5:C&NH=B37/[=RB:@F
MRUI)EBS/P#<2X6!W5+[9(R"7T]D?IR.:HYU&R%B'*Z5K)H9IHK0)'8ZH,+#G
M$UIY-5:+D@B:,PB"$[(^JR[A_D% K><S#CCSPXY5:?1W-U1.I:FZE4S$ ]RB
M0 /K)O7Z$QCN_+GR-EJYO20[_&,?&D$]_>S?D% UOC:DS]A?;?$1 ]HM2?!U
M704_\QK&N36V+8]TPB1ZLPQW6%BMLS</8<'3IP 20A/%OW!/F4?U?E2+I1K-
MMS[O3/B!RIIBYHW;V4(FE6B]9R(W+E1('Y$TP--$,U?08""78I0H6KD:):46
MM](WE1["1F5Y \SAM\^5LV8@]'0DX>).&N!RS?#B(-AV(E/C6L&I;/$FTK+Z
M<@++7,/EDNBHB#)K\O,[79J$ !/A=5-$D94%KO1I_3+4%8^ ,=4ZB@$WS(*=
MO9'/G@<4)DN&2VHX9G4Z8;6[:JSF2:@FDY*A[HP[^BD.02QBEB9R/X>,4U8B
MD=>:2!O:S,GLJ#MPN)Q017O%KE]#H!#*O5<]Z\&H?29?L*\C]3L?T&QACJ4\
MO(RG(+4'PZ! P9=/QB:)_#RDF!B\+LAR5R5F/_G+FYN.Z9$>C&1.A'XF<YTH
M/]0T%_?:7*'41"A"=E8Q%T(>C6BZ%F>9:4II,/Q[5/O^+-?V#]O$W@'=]WFE
ML+!(H\ALH:24I&)%]OAXLT!>OO/U#@."\2GZ#\DZ8E@_:='9( 03Q_-\7-WW
MX_*MOV4UJYH^E6S;K.5VL"Y)J?WA0M971 !^QJ0=5T'0_17KM^;FL%(&*&#!
M5N4(("P@3EK-*WK5NW_50=_U"WYFEUC6ZM*R)S="X[WQ-)@UVPO"!F!(OVVL
MWAW%%#UG#7VR)&WLNZQ&;K<W&-#^%I<HK/LIJ_Z[5@+8]&H8[5[GV64/A(V-
M;?F1.-,A$2;#RMXC;\3A%T:A@!!6,9VJ469)Z3:1J9$:_6:R<NGA68NIX-*V
MGIOI?0Q>!>-8\$P^7<Z\7:0._4!WJ%GFC&= V6I!\-:(-.GJM_9!0C2AXS9]
M>$]L[+OXB)/)10[@_:O1?BEQ:;"/L/:S8W;:/+F^<"\4I3MN_>J"W(%COAVY
MDI9QF#8?+GD5255$HJ)%NX);OP33!3RE$:**'V6DRI%<0AEE="!;($L8226M
MRBC'#><(4JHA#?;;VH& IP;&*O,KT&M%A$Q](X23@3U(O[Y[!PG$.^;4J]^'
MC0NL3V\YFO6I2WZFL;5,5PBE0LDQ"Z3!.))&#PCG"9<WAS!&PF!IE%.));"G
MGD-)A>(Q:JJT@J,HHH"ZFV#MM2*EK,9Q9GV=B&4ZD2$";G3B\BH3G=^7>@3X
M +BH<0H26)G%5&;^/$=R3):E<T?K]IKULH^C]9\QH!\5KS6E-QM<9^![J(M6
ME=A*J'RGX/58>BS*P[59@O++\[V*9YO:P),U38<'%AC-IG-TQQ([X00R2YE0
MC<T.<1KWP'M!F8VL"UIO).<C37$<9$<.#)!]'>K+TC4P"E_P <DYC^2HP@RB
ME+0ROC2JQ8*R+YO8S%UB2^^RP%^4Y)1'0<^M.!R5WQS+@7A<E&G_45:S^%R:
MK#]6=Z%!J*M&@%VN?KERN6@ -::^<2B)=K-(GA)]JFRN$()O.U*O!10H+LYY
MP+0890*N>8WW/Z>2Q!\&**^7 D0 08A+X8I=(F69E.KR\BP%<C+8T= ,+70E
M!(:L AU\X!"00[K<F&"X5N^7@UD2F[J%F=ZE$D=?^RLZC>!7 ?<FIL3^3XM0
MP1.G!0JD,+@R>8M%=24=T4 FUAP%QUK=8FJB.0_OWUQ?%D-7-#7#(LD*#7.R
MU#NO1SGJ(^TDE2KE0:FY7>*S"3+496$RU(EFGCOJL0TF;H-(J)W?KZ:R(+@Y
MZF].:73LHRD%%&I/?"BMO,GP7G$:0QH0BA3.")6K@<39Z0_G!@UNW=%%H%Q-
MUTABJ4SM$\HWBX\92_,4'@67L?BJ^-(U>AW@S5L@M_R/HJ-A^]-^!!YXM=$!
M4 6X1JY2<SSJCEH[ID=EE%I1(+ D4]K! -:*/SH)%HO DKZO5!]0K*'+KS5^
M4L0(@.EG23,J2U" /U9 HQP"A!EF6?YI\J5Z7"+^6:Q(FPP@G6VB^Z$4L_*M
M6]H2HB9#ZFG?NJJ*,^PO>X48,2US^?5/$V]^I4$F3)GUGUC=RJ,/- A!?ST#
MS<''^!D)B44QD%?=OZ2%#M[>D]U^-9L^_):3A+/?OX6?_!-2$,SOAB+P!:X!
M(MV(,#!4  HC,A$1$0\LK"N8.=]V8VVXCI_';HM!$5S\]Q07=<!G[[IGC)VS
MUS:[^V&(Z0":H\OH;I:R)M[7J<:U2GC./5%7I4:KP:C@WG LH)S8+S-(W%:A
M6PP9?8:>D$COL3"M$&6 FA!N!Y^DOQR[5S'-=XP?/SH:YFSZ3D%)BKO+ONE8
MG0F2"-9KFDRJ'-\XO>5G;AD(/QC1%7=@MFN!DAF5,Z*?2E7;5,K['(U3_R#E
M82U46=S\7R2IWK;^!@R1K_OK\*(YW%CKA#O-__6.8'X'?%3M<WT$)]1M5D@)
MY32J7.-#9!%(J;D]-(N3'(O6,BD+,?:"-*RA2+<+4HP3Q=N@L3I<J57; ?=,
MR3C'WS1!O$G9KFMH8;(AYNUJHW0@E)E!BA#)3E&#T;T%WTV9PL^H-RFEJ71,
MH*OZ >KP=%@9TYC*XG9VRJPR K6A0/24'@V?R+@CZSDG_'@2;8TH_5BF#]N=
MVLU4Y=W@%7:S=2&8+K!\U1I51N)0.Y^#3E>\%3K8;HI^-A2:YN@GC?/=XICS
MYX*F=,(O=N6&6@K\[7R&M3S?#@1@ Q%V0NT:G^&D+#Y/,L#;)PN".=SUH[YD
M73HM PHL?5YKLQ.' 5_G"O=QQ4Q:U^\K&,=C5RY4-#18<4<T+"U]R3&X23=3
MRG:I;'3WU"HLN#-[N?+.K1YH$3TLJW#,1Y]8-XB\V%O$/7AB/U<BJ4R6ZVT<
M?9E&+RY,R"[7+,8Q9^FYQ=O!,SM@FAB:5OMT;%^T5:Q'VTKQ5W!;<4.Z@ZHJ
MFS8I1$GLSPA0A\2/N;+4@M'-2&HK.4R->Q6?(G@5RWL7>PC+'1 ;UQ=<=W->
MA.7WW=L\$B59V[^=SK_#-/?%>/+RILJ_O,*/_>&(Z1VPSSY<';[Q>3?SZY6E
M4&3_*QOO=9SW55QN>=7CZ$;1MW= ^F#AX*/:F]?7JTU&1]$30[N-QWF&J7?
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M6L?+GY/NX&9N9GQN]NVGFN"Q[^8][[J[+*8R0X*7!'QG0N$T!9""<L@#&2D
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M@+^6O>T)\RZ?J#7(7W\I0<T'NV@2\3BD?+<*TS)9^?'-&7N_._]V'1<XTIV
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MLB@,FP<"-/J:"-A&8IC= 5Q;G\,/ZT?]@"D=ZL#$WOYWJ:H)=YAN$E)"3MA
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M;7V;]$S?(U2UO"*BG&54.M8F5Z@_]CE<#!%Z*(FD4^2HK"RWYFH<3S^I;5B
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M1A'/.MQBZ/*@B+28M_B%04/U:@X?SO)^,%?GM33Q3+E]<V%968EJ<-Q/:8T
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M%+=]58K4R_057=JRG">OZD2S.-43KVSLJCI05%Z8X\(&TIO(!BFT;OW9R6G
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MRIYYY?VY;KZ?GUO" O_Y*D,#6A!%3,C^9XS\'EQ@PUS[5AHYT)W]*L Z$(J
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MV&%>]8FY^XM5_FK\/33:S!/:(.C8<>YG97+<[&:>D,%Y>E&(DRUI=.#*)K=
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MO_6 (]A)C((RF#T+^>]A5DV/C.P='/P8F81%KAH99=M))OL/E"9;I8_SBM%
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M*]?XY?K#3D(Y_"+J2=7(!"6A5 T9L%6NBW&&#TM];'QU/(<.\M)^EX7V7DY
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ME%(HZNF=G^R>W^/^&[022^2K'#E CK1YD/#'_8YZN\DT;/)0W1ARJS@%4]G
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M VC$F]WE+<:28U(8RA%!%.RT22&H (9R)#ZLO^&/Q(X'5^GCU_;@+[PMYA,
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M1'GJ!=  4  HZ&@H*(#_>6%C8KW 04''0$5['C<G^,\P  45!1,##QOCU4O
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M\"LF)\_BB-\G!L4B_/>#X[&=JD+[2_>[]L0@3I!Y;A%V99_ M>^$IJGNR$[
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MG#UJ,OR#T*AVA\@';(84TO@QIY77NC&K>S!81F!C+-P)/2L%7D3$J=-/&2@
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M?%3][N8/A7_<UL)_^!8?_?7"Q^ 22YT6_=I4JY*DJ_4#7>&%LG;;2 8!-IG
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M G2%E ,WPC&"4=9$6U0TU8TJ=3:^R:TC^).%E!6X86V?A80_3U?>R Q%VE[
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MA;C0;4Z9'$GE>XI3&IU0%BY8Y#*]\N44M,CB]49U6\L:["E:O?%;SMGBI*%
MJB/;>SI^.SZWLW3+[27?@_78[H\:KPA"0GMI#&R*SR3&RBJ2 _>N'CO[^"6?
M^C(Q'^H&U*Z9)G?#8!@G$L\$_"U^0X)D'%M]SI^:;#/9&T+=AF" 5_HS$"UA
M!:%AG-4I+MEW9HJ)+$[*WZIE7EYQL6LWP.I/Z083AS[]@39=VQLD29!;W^1+
M@T%@DZ/XFP"\2MQ%I7BW0=Y7@WFT(EYC_OUA[6Z(Y]"R:2U%U?H#-W(D$MIT
MUW1$1$)H&483JQ%W\QE/[*L(?6=<?]_J76%YB$W+W8>"T8NS/XIW+UK0E@^
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MQ-RA7P+952UFK^M/<=3@0X]Q0E/_,4=)<J\KHW?H_N[G2J&VH*?\:4 WM')
M"MG"9Z=?U(RHD'<G3U!LTF^D&^1:#!83Y"NTU7!UDBDX:"V1I&!"4_6:D,2-
M^_#CNQ!Q&Q8__G_MSX+G.Y__7&%_  A=*-UG>G/:",G^)V\.L)JGCCDAK'/,
M(WV^,ONXK([<)\42>1?!6DXI:P<4+IEE/,#/@_B*ZQJ#<G,N)_.+S%'ZZ X#
MXYT%VE>H-@D6\.A>61.!$5$\LY4HDT&T#&7PF;;_M01?M ZJ-=]">5D*Z&IF
M<A[P):W4\,I;&422^AKV(D;#^84B>P!&7%T>J-L<MX]+?:FB,84W09S/,K+9
M^(?EID:V.I#_A+""B4DI%D2RJ> ;W:&Q13V;EL9A;(RXM_@6E'.ITAVX#?9&
MX#%/Q+\ROA&<T^ NHWP 8&OK-*>]Y,5.-)<(5B0N]>?OOL-W.3P[,!ZW*O[#
M98: 1ISL#.R+0V93,1I^1N%1^M._QPA/D9*.?  LK?]%G,O"V[P;"]OINU'8
M?7GHS#CH9/L!,*5Q/_, Z*;[WYX*9 8=NH:B^>^KQ5L> &=3#X#:T#\#9W_H
M<=RV?S\F2"O".:Q/B: 75=9.:W=74M:!.BNI-T*=C6?_&O.%6?_M08*GTQU:
M,^_PQ$UJ_O'O]^HYP*,= .TG_'?\X^+8*,3&&TDZ;X,'0*=+\NUY^YG+/SL#
M?:[CJ6$S.Z:M*^C8^MFCM) PSXLQYH\9(B:9>D/E)XMW8>?9W.>6?3M*U?S#
MOY8VJ:(4&,HS7<OEOLKVE/6Y>_"\#C2;R#82])//C7"HCDQHJA[E+E,STT9.
M\Q5T"I^.5$)ZLK?MM(._3.GIF1ZX["AP+ TK+@L?3;^O87#H*:-*JR4TY$H?
M/"(.BCHN[CL&]HX\>I'ZLQ6\$CKQ7"?11%0SY"/)S50N!<&MPT2)YQ!"IO)7
M5$3ARTUR7\H27)WQ/F[H4&(#PS))1*HOP^.;FBV5#* #FFL4K^VBGH<Y9W1^
M*U*6CK,NENJS@@M%"N674N^F=,-7^P6'"1U+T[Z?OD?6')%P_LB_BQ@835"T
M%>'^E\LX7:(BL?#=R%0SIN%KS']<QOFUZV,Y&QC!ZP&Y4R>IONN/;W';3GS'
M)JF[L*2$\?()L[1A<5GI=U05G-!CT4TV2TKQ^ $@?7G?2?N?[.#YS]&9E^:8
MH=OP+(NME= ;K^SU3L;"#:FTQ-,V^[O#WP'CGQX ET=_(S;/A.[B($6L8*8@
M_I\OAAWIOECD(I==<D.K13IM^K@%RNXD!RP=4;?Y&>>OQL]5S7Z#4T%M()Y]
MDZL4PGH@'%T/!:M6%$AET<A(J!0IR&IZ)RC'U0"R3ZG;!0+-8FAYH*#&M\\[
M*ML8";6J<W59]!X9:ZC8Z6/LOQ_S=59XN2>5;NSHMH]7CYTOA'Y4G?#YR\N1
M16M^R<D16AZS0,6:KNS2BQY4$)8!#<EJO-Y58X<93FU%TB^B,O.=GE6![$I_
M%)_L]7M+.%&/DGJ 9_G\,UYN:?!33^6!$8N^WU7S5?<ZT^'+]%N8_'BI)-\.
MC$;.A_\4Q^DT*MDY):F)+>1%($>,PH>:23CI4E9,;X(O:"^- AS*5-@9JM(^
M2\X,"KH#9R]@ZS</@$SZ04_1BKO801P$!"%7O]3\ %#>$E"FDZX=CE6N) 7S
M]AZ1GM2L;-\.]*O7F)1%[-B[I,7G"D_,%NEI=,WSVI *_WZ\_WK>\\6V>2JB
M1E9R"<0\#6/X.#_'M^2Z;#@6*2]X!I%0*M\SM@(K*W]JKD2-;D'0:EP?GB6U
M?79,.G)T%GR5L\AYJL\67+?X0A##*2@]G]E?SW6<I2MD>Q.ZT#+;%?#FQ]<+
M]H]4BC(T[R@UBG44A#5W+*M2'(^_+S@&ZU3J[WM4*3H)22?;DW&2?"]];J=E
MA1NE3 )O%8A+->3CUT[:%4,(.Z7IIV/U57=JS!MUM)@/ID+;GH?9&U>X1B&M
M8;!1-CS^_13 >Q<G62]MRYACJE4W^?@N[4WQH&HJ'0R5,9GAD'G%!P!@/W^J
M ;BN_?PBE-35G)66')4]BXT-7KC6D$*E5(4A-T,YTM;F>J[V6VSZ:T;@+VDK
MO#*RG3W2)=."8GY"9_ZY'08["S_?TEW?B\_54^;]=S'F7PW?VW:\!\"X^YO.
MX?8'P/DV?V^(DE1?*!O=MF__S?+(:>&C!\#Q"O\#X"WL 1 R_[KEP&AG[E]>
M[6_J_(?>?;N"0",";T+I-OOX*0)@D?=<'GN(^I)3=3;5BF5W%Z,-4_7X>%YW
MPXWE9PQ=+@Y51JE,^*D0W/+)]TTSQ"NV96_A?@C1W^F5[..Z*%;:@8F,-N<D
M*@7"9_7)BH=83M5#!"=OK7%>%?C:^W4VU LWX.7&8G%(^[ZDBM+& 0$ &RL
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MS[J/]8J5\K@R634#M>"2-+=4QHW2^I/YD$7EE13HGOG-++RSGF+8N1_!&ZS
M=/HS\2+1,)'SB0_I@ @$Y]"ZGXU?V8X=/TW>0^:]X556-[[XG15](7>VYJ(L
M5MZK'GFQY\V'T+A+Q-]T&%_KNL7EE6@8R@&:V%S A2^4FRQL:7*&@<$P L,
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M<R*J)F#1V1Y6_JSQSBBY(6#F13W8!XG8G]"4@%4>H909BQ7N[$N"^AMI$AX
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MT>&VL.KJG?0X*TS_Z4R&!07Y3^7GQ1\)$7@5,F"JB9EWCYW$G=W5\MM<E!\
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M-;ZYJ+3/(,&G2W44&PKX'C(GU#MES]RL4#4]((&=?8IG9K?K.21:_60P)2S
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M:8AKRFW-:?9"&Z&3AD_#;+>> )1]T?M[7(V,I@YL,5Z'BJU7M=!R7IO;LYU
MED? ZF+?,#&OJ4]JMC>P+.F.$> 5NXI?>)I_OC_^XTKM@8KR$@2_!T\Y**NA
M =]Y+=U?\JB'"\F\TO1',Z*TPL$]_+6I>/B:"[H0LTC>[O85RCAH<X*0NMC+
M9FSLEAX_3;.#E7+)UR]3,WWZ"G3:GY@MJ>72_2"KQ(8\G@3'#:2[_,B_;W'+
M V"ENF<?')< '"%NHGOMBRD?1>:1Q&Z.RI5*T4MY.(>QM"X37$%]<;U**Q7C
MO@VPJI(V#J>/\[[ZI/.2J9M^:4,+W;/.AG(H9+!P/G&BRR%:5D@F9&9*=T/!
M19Z@K]S1/,=:";_U+YZ0+EJ>NA\'8:0.2^8(46F*YL$58ZZ47& .9;"3$H(^
M 50VW9*N.WFA?5?!,#P\Y>%J8^?"H6%["41!*9?V$A?.R($T MMKSX 0]WO-
M [UN82'F$9K"8&XBNJT!Z8T_,[8=FM/6W$3!!G]27:G.!7X/E9P#%?+?E6?_
MY:Y1BEG>"AWA%E3K&WWB!0ONC?IG2ZJR;* D+Q>0H:.F'<O0M/[CY:FL+!(8
M&[ZQ820W$%JJ0S.*;S)C(U3P-GQ8QF8ICZ.J%1_.]A36<CP%6C"^."4U#/$Z
MM>.J37JMKSD-,I ,V$N-6K<I$R6RS'P&?&OY6,U 8#GX43)&*0!(0R!<Z.C>
ML )5(GQCS;Y53PPTC2ERX=Z9*WI %15FT7).5[;?EU4W5KY,JII:75U;ZW2K
MQFX=6Z]1LIB*($$?NJ%[MX#P?.FOJ6?#663<\LBA0>AD;NZA[9^0Z>JQE^.P
MXH>&QS/4QI0GV6&AY+3U:# YT/VR4.>X."N?CA\]#;9J>L#H(/C:1+T&H[NY
M7 ,TYZ@7+.47*RF'6^OH[-M\.H1P45ZHFL7Q<>**W64):CHP1)S*M.>+I$(,
MLL!W:(K7' /IM2!["HQY<_T=Z(Z.D\.Y$40@^O ZSW^W<DEKZ6(!7('8E!\5
M_C.\LAZ2W?*VWN!3,7RSDMWHA.>]LM8\D9+E!UG3?4.)<_T7XZ:B9FR4W9+[
M!*^W8W%9A?,TDR*Y6/O4IN$R%<M52VMA^CF5]H58IVE5-R 43HS1J\7U2J?T
M3^BAI.>+M'X#SH;CYDF=H4#=4GEQ#]U,<0;)NCO'0H^>XD./.)63"[$=^^$,
MXJ%F."3NHB5>H"3?#1JE;?^K^V?,?(2Z^OMUJND2Z_9C.&3;Y'K&_G@@"!/6
MB.&H8K7='S$R5V$2%G]VE#)0P4@FJ*)"Y3I3@#N*/A=W58%59+X_TB\D$Q1X
MV\YK*(F)E5ZQ5$DIEX\.?*NO:)R?$%$>!7A>_#]02P,$%     @ #H)O5.ET
M?.)K_@( $@$# !,   !I;6<Q,#(Y.#0X.#A?,3(N:G!GK+IE4%Q1\R8^2(*[
M$QP2@@1WF^ :(+B[!'>":X#@[A:"NP67 8)K<'=W&&R 869Y:[>V]L-N_65_
MY\.M.M7G=I_;Y^GNIV\=^!)\"X"K(",O T! 0$#J1NH& ."K ,G_S/ZOQG^4
M_-_J0(#W /!0 0>(AD@(> !$/ 0D/ 1X/X : $!$^A\K /]]H+QYBXJ&C(2.
MB(#QND .]S\+  C(B A(2$B("(!WKU/D-V]1 'CX!*B$M$1TG&C$] Q<XB1?
MT;DE>"1-74C)WC,F?N 7$%)3-_ON%5Q0W]0\??6JB?)5RYO_Q<[K0/J/(D0$
M5+17,?!U5XB(_[&#B(R$BH"$B(* B(2,A_\&\): EHZ3D$L<A8C^JX3I%3$#
MMYI+<&)!KUG]-,E[R>V0:QY>5_@* /-UFXAX2'@ (. %ZB,D)$I)2147%R\K
M*UM86#@]/7UT='3K[O[_2J PQ;=P\QY$\* 92'4G@&G,"T+;WHTU9K:ZL(.
MX^59-18"];,G=$L[W&C4<<)+N698D]'46(-#(H6$H"?>[\#9+QZ=-H\%D$N(
M;/4>SNUBUR9,%O(P*B:]_S1*Q7ASZ^HEV,U2U2'TAU_\9<N.\ES<XJV+:L73
MEH2Z0U0D&7TA;/D)MGFZ:-@.=3_K/.\%B\3C/9[NUPX\P&0><6I/F)S)\D@=
MI[!"5W8L#A;GM%08Q[RI70^U9]R7ED_^S1Q%4-14-/LM_I&3""YE- H\A .H
M8:*!]W  :'F&KS-V]\1P H=T[<+KJ5M^_K#&8SE K'%FE[YY9I^[.@P+.RN"
M>:RPPRF_T#M8X6#"!VNR^MM@1Q62]?;1Z4;R=R /$*>QUB4S'0Y@!E'8?'LD
MNK>%P&)K^;WFB9]]>5K.P>EX(]I."I^.LK7+ID 32YB)S?(;A6X4.SS,W>V3
MG<.#@4YW,-#QY6EEF,KPY5 '3+MM*TK,_>IND]_Z5]7FU8O*>Y=FD7QI!$.M
MB68(SUG^5QW$PNEO^\NFUU7[.NR6')AQ7:>[^Y<C3D/&0]/#["+>AW^-B.."
ML@2 3]5[&^Q#C2T?X8 ].&#&O&IE))=4!>(^%R%1"A$DNW7WL)R_(8GD:&-S
M ZV X^/  D9]L+?:C"LV]VOS5"JELR<;1&U^%]]_-Q55Q7:L4R8CF\Q-M%D^
M7= : KR59 MKN5 :8:#3%]#E8O) M]M5;8ZM.SD5"?@RIK---F7U.^^<X76^
M]]B#A^!D5*ND<5B;><;<G)96>XK$[%3GMR8,6NMY6@ZCN*[CTO\/6/Q_$,R3
MC(HZU* ,!DA?E,W5%GR/WA:Z:,[%4#*K6&^:='MZ1W2B:VNFUWZOKX1_P/P^
MJ)$.]5'J5<M>[1,7'% 9[O14X!5?'.C=;PDQ!_,/#:76+D%^YW;)?)V_!ED;
M\71Z[!LQ/"SD.ACQ%Y6IC'ILVK&4MV6:R%^K*S*<49^^!-:>PP%NU5\A]8_^
M\X_/X(B;YY[5SGC1X A(X+X3F==SRL9(1[&Y=DWANE<+?7='P;_?>[!B87?'
M8R+RRHE@^04# I-L? MWCW)O.$#$"UAUP>=G.>:=/.#/GB0XC'@D$AB\QZ9H
MWOR7&$GG3>WHH=WRVD0(LL".X[3L/5,8#-&?DE+9DTKM.C_>[;NG\":=<Z>R
M"KM$=ZUBZ:)'*\5&H&BF\U)[EO!W/G<FK=%"FTC74_WN?MHS=00E+L2?0D)I
M>\)BP&&*>R?]WCN_3;O1,QH'"_?.M MC^:D3+8$0#+)5@86:0T/Q2#0,.UW;
M _0/Z&;FT],Y=TF@.9P;]2PH*M1EY>9!<H+$WOUID^HZXS7M4&PX;@SF)_CF
M!49]203][J!&)U7O>N=+H!9[*IXMO_?'=VI<.:ZI1,5R]%Q9H5'(\;O$PH&N
MO:7FU.I$^POK ,6'P7#7RF5S=M5:\XV.F@7B1?W?6O8$L$U96:.9H\>MCN(L
MW];>PEAI'Y];#+6?ZZ,3W^I2"XJUC'$*I4-*DLY7]!+,FN4:3-!-CDY^;@IY
M?:',%]U-?PP=& 'C&&;IBY1B;M*XFBZY+^V@FMK>0*?M9!8&W=GFK0(N/%B(
MNHGQG9??HLE/SZ6+[H.(/+JL97M=-Y2NX0#%M=>'\7-+S.&SF)MUY8'8,:W&
MK<B]9VRLGXXI&JIRJM F'3[>0V)&*!Q@2"GCN>%Y%1_KP_8] <R>T:G;<Y?K
M>]#"..Z9)[[W&!!16@]02KF!K&;-N7N^PT 2-/*W>W.-F.^T\WJ:1G?MRM\1
M-*L<+\UV?I]B\:Q7E\OR:JVT3[8.:%D.%5'UE!O>QQ#*2.IB>TLQR4BX>V#U
M>E,/=6L<)BY"_G;L^L6.K'A$S?O$$93VG[:=\ME25,R[.[@]N'/K/57!QM -
MD\R4373H@4.%ORCNW/Z+0O!_+ZA!@NG  8^?\X^-X8 +T..K9^Y'-^+BJ@-/
MY*FI[\3@ $FMG,^U<(!1X,?Y^_S[VG/VH4^!(3"W,Z#I<PS %QIE84;GO_L:
MX6ZC>IEI@9!H$!57Y7K%B\C4;=^-I'M9=8AG.:/DV.UH\(I!H&OXTD*=W*.O
M?T+)\'._TI/0E7_^$QQPA0('4+JB7#=>V5T#*^" [4/HT,V#[M8%2L6-YZ#V
M(;]C/*N[WX764$);=2WIH^*([II0:W?[N<P%6)"49<^-57NXMTLAFEUGJ?6.
M<Y5D9",?A@+K.=WX4YL-(H8B;5/WJMQ^@_ZX3H_V9M,'8Y1 R^$ Y<GDAIL)
MS(KI \?3[Q.ZIO^\M54ZP#95'52#4R[U;<6^KCZ4_@@-BS_\I%A^:1^*DS($
MYNN97^5?3UU?WA"\B /G+T> :;!/UU/Y?O4[M:,B*@B04Y3QUK7+Q!/(U/4#
MSJ!?R2*1;-R>CZT/89M?3:6LHKGK9"[Y1U%#8D-B7<NB(P+ESN=7N,* +C#9
MF@\P9>><2>J=_*<? >1>&R\W4.EK]J<U&)O78=_RXQ.)O:7704L2\)?=H^]
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MH->-RS!AR*%3+E\+9KG+9('>@WCFSQMUY^NGW-B8L]H%";O?=KU%DYU(U'"
M4Z#WO?]KKW_Y?#?MZ'9-TB_2LE^: .)Q39Z.R!+)WL'F[J,4IFRVWV<,W[J_
M_7Y%E#\):ZU(R[KE.?^2O6NQ?Y2H/8<K!HN+,0>^:MFLK0T/Q(=^V8KG"E#R
MGOV!G>!;.T;5D7#>6:?W'%$<-]'-F&Y,^]/@P$9;=4<S)JQ?OP:[GIC5E_\
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M]G5>-8;%1IR@<Y&>C<HAO8D*X<SQ)3WQ<<0SCR)+TDYEP&A5+4[,"-+^FA\
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MI2^EC@&R"@5,81!8!\8-#GZR;_XFK9=^_LY@C)BTLSV5;AJED30H?4T8'[$
M[>D';-YW#>+XQ3O+Y8L!>T[0 LG^5G"@J\%;1D;RX)R8O1C,^4?80FAXEV/#
M2IH.329ME)846!"O4GDR,J&BRD-"; RP1-ON=A,0N-_4SISC69U%1JEYLN]9
MH['R_+-",MW0P1QICSF:S:*F@$_[&5-_H3ZYYHCD\J/\N/#@'HU?)1&#7W!?
M*U;J(@/ &941$#K'D/,IOY]_*\J;J>@WF34GI7E*>2 9/50<P8ITV%!G2VB_
MJ]17^XXU3N!?+*INP)^CL-^E]\//M1=1@\U9+W! R%/\/O4N)%]^A'6)CE#&
M1-11APFXA <'Q#_=]I'^ M/F%G&<WUP=[Z$#M8J#OX#VIW[+G?*I@8?R)3W6
M)M.CZS9+90H_+<V,6?6X9:&][>MS\W#B =@+8<I];*;8A^I^XJ2^()5[5-:?
M8%57K;UV.OZCIB"N<K&,LG^Z\;:0YI!2OWC+UZ8R.K6M?*:C-4;60AO:NE;N
M8!'.FE19OO+U=TZLQM:=''AJ[R&UTRHJ,I[8TFAVFL:0?66V0Y']@LYX1(M-
M"8\UK<TE$*#ZUWA 3?)BRLC58(K60!;B3I]:1"?*F/BOJHB"Z2/JXNGF!<YY
MXFP<R1^(H_P!GV ;70BNX0HIOGS,9SY*,W;PFY"8,\YFE46%:N#D%(V;>J%Y
MV19D13"3-1'DVIQW.F !!T".9B)3G@/NHAG:3_$(HM^:HJ$FW4?5TFX:U)+M
M$[=FC9J]PV=,*42*>>,0,.FL\D^LZVDBO/1J-V+/+++,=?$@K:<?M\MG>')4
M-DG)&^VJ(JD_. 60/H>T.!L'W0<[!8XOK^Y#S2?:]PU6M:L/;8Y.K4"\3>A]
M^5I@,E;[>K8:DQ&E<3\+?:H>R??6VX]YLID[#'O,BT766*SR:&D>DER<&&1B
M7.+."/<:L"78M-^0I7,G-9O Z5I7 ?8USDB(T +^MSWTC6^&AB02562>9/2+
MS6]\H@(/#[TS$Z>.3YS7Y&(/%LMK^D].*[KT%P$23;;X.];G7 [I,^*?[@7B
M(3K6'-QDOFUM611^_):[%0GC(2;D/1J8SG)F7(C-"$N8<$!ZIU@M5'2G>J-#
M#40_;/4^2:'B7\^,(J']0)XJ+WHX[1YV(<#7$B-T-KQT/]!"8&V@2TP[4ROO
M/L2.TEUG235,2_# 45J1DV1K7AI_)H)]RR$D+!F1<7E ^:#%93N*>3ZF(8=H
M0^GC'7AJFFKJ\A*).N!WU;TU)>9#*ML:AT:-Y7H2XOCV5XGT+[^99\7:9!C8
M^-#[=W9 (X;)Z(A^]UQ5JVNE$1^S%Y3E[\^KS?I]E91B%C[PF":\Q_H:+(7L
M5V( !A?U%?;DIUAHHE*<?*W[3O;.!WDOT-D?MBZ5MUQ;.<ZF8%=LPTIR7=-#
ME\."\TOQI/6=I0ZN_Y;=:SWO4F__GVV<SD7Z'M!59:ZX<,R-J4W2R5S4U.@^
M&2'ER$:W^NL0.#YAV5^::=*XI8=""3>3E-K]DTZ<(&]%G\X5$@\(L09EG*\#
M(1SYH]APK\"4UG"'3Z,L6M)<P;Z4VV]::9QR:@O^@OJ7$<@3M<Q$_*%1J RZ
M86A<?$S&<%AVDH0X<)R">Q<)'[A.=4, 5;F&B<[&]<>)#G)I1L7L6DF&?SU[
M\8$#.!-04024AY"0D8")3$^#FC*]/]$U*##Q P\&Q=7$43 <XH>!HO%)KO7>
M< "Y<YK(MQ4XP'/(IO2?[8<7;E1@KL]C!1XQ3_0I4?('(@)&5LX,R%-FZ*.D
M:IHB<34CW3L\S3B&:Z*>>W"]V%QH<R$ILXS_;NH6/1N2#BWO^W6%-!GRVA@9
M#3*RW*NJ"/%*%M.73YOUT,SB 3.CS65E9FXNIMQUNT;;619-'25Q@#_'(.]?
M!MH[U)%L3'%G::B2!3#9K)_7[N]^WM\?86]ESK2%P@6T3$_M*0!N.1YS_MTQ
MM?037%*_FC=X&$H"7OA<?P7UL"F:(*0AE07(@LM\-YQ8*O; C>[7S6K*A58J
MTD!. II$WB83.P':#!H+-&0XP$9*24G6L[!-N;^IJH<^"[_@7\Y60[@EMACK
M6-UD&[6Y(.EITQ9S4BFXY".$N8\# R=M"9OPM5?F4./8>C;^'G2C#)DG6>D?
M+;-WG:E-M/G#D.%,3X"!D_+<_PQ]&3"G DO#WNK#Y P<2Y=5VT-OV)P+W,Z0
M[M&H;F(LJ+HHNQ#LO:OXD+A-S9#IS,W$Q;KP0L\"^I%BGJ?&]<H%U=VXT$(R
M[%_X\HQNZ*0X,9*>_:.D"O>O,\A^DN6G]/M@)6"8O'9(H?F)DT2@/4%DO_I+
MZC5+VIZ^7EWK'!;,D.N/KZ!",5%D$Y,TUB439;X&L=S>BX1/8AF8A6AJ-N,H
M?-+A%6?]+58;WV/&\#NPV>*WE44 /7!<*J&2'7P'VOM1*3=]A&'-S)V#RX'2
M9'[7RBP:@F+=8JXJJ>.\Q$@C,\JKP8JZQ-]5ES$B,(F^]0<.\-B_Y%Y<V5??
M[;8;(G&A=#]LL-8O_C>_6)H"Q+$C)6J8LZFW8MQKP#@H'B$?1TV_?#_/O_O%
MU]45RU,06<$F@%EBFF>@B<6FA/DKAR:,6M25,T'HL[.<#E/NOPAAQQ_V80$?
M1%A\P6^5AK_J,ZOF>X/^@3=B(VF:LC-U^@>!Z<L04L)Q\4@XP%UV"!+ZZ!?
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M3.)K@86M7T*S%=,K<X1JXXMR@-A)V*!LL+BM)[MC02<6GBP\X<TX369YVK4
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M-.OI"4E\(WV[V8XDT;.(WCFM4I'@GL)VNN<_3@]8O:!&FR/R_L+_A[O.PH?
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MX]$_$Q$)[8;HW<F;\0)< D6K=FS_Y5VI;9\:==NE*[?*\E GV*P@A]6.VDW
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M-6D__D64KC2(##/45@H3)D7+:&A=Q4YLU!FX4_Q.R*6?KD) U3"J3JU"(V2
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M" EHW>"%-<_;PL#[WOXQ56]Q\$BY39\$AS*\"(($EKJRBSCC",P%1Q&X2'!
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MG#OEF3BW-1T5"\UO7!)ZYWB'139OL: ] 6>-SCW/&S76>P0E"3?2^2-&9IU
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MT>9S-3C&J/'C,:A7G9,=BMSZU=K%'SF"5P_2PB "$ Q5+I%M+P[QT4=1G75
MP:2E9H%\S:YY0]Y+G@BFLK;Z5R1*M$4'3,X-@W+97X!E+AKYQ$% L\.Q)8E5
MZ)0BQ2ERDH"MF8/P\O.L$#N.U9B0YIFWOK^9**[7->G9>E%62*UCN9B-UL[,
M1*V*=Q/;+:5A[J1>>BJ <V"TW)_/*<;6Q16X&<@ CZ!)@_$B-U@NN=3C$U\B
M3Q$TF0+M%]U3RVQV('T7NUJA]O!,>N_5-K_4?@KL[UJ82_2BBHIQ#F,RA=9)
MQM5>PPD_AWH)'?GI<V2[U7H(E_BO"]1WL_8(]7OLX&):P9;+7FQ@NTRTEC,/
M(G\INQB]I.H\R 3\!EY7IV0_Y-4E6J'#(]T\'E0ET&W0]!!>TEQ2+8SFB%_'
M)9<QLOD5 CSS:]=UA&NQ J\*8/O-3KLVQAUS\\*O>ZWC9S_;JE9@1U$.Q4K$
M4(Z)\R=;R.($&C+<+J!-^+P:@F[3=+;FC\^MYQ8&SEKNF!\,/.Y8^^RU>\I/
MB0HG!IHQ2>=-%L\[WA'6Y) U$QTH4R[3VY$>66Y59[GQ0(W8]7]I"N7X)D,V
MP3Y0/Q]N>0E1J^-_NL<BQ97U_Z0A&*JE$L LJ:'.Z7@WX(MQSZ ,51Y&M>PH
M[CW(SY0(IJ AGRR_HGGU_Y1U]9/BZ\(O7&#ZE,O9:/['E27]&CJMAQI5U>5^
M0@5:!I.V<MG5!;0MJZ&2]B!/FE\H[55[5/TPL^^RK71+Y54-!B?*?R;=O3'*
M/+*MS.P,,__I%9O\25E%47T4RX'CQ#^L,^?+ )?IV]EE* A4<XTN>Z=R6:AX
M>@S^ F!A75Y^FA=2!W3XE>UL]L[VMKYD/.4%!#@PO&$*K^Q\2/E9G9^O]/J9
MM3V=/S[*?/3V?@KW^#U\1DNW30T-^8;]9^:G GP#V$A);]]'[X7Q_P/W=Q]O
MN$)!J]6WV2<XX=[>-_==8:PW;V%ITIWKMX]],%P9,??_+ 5,+(4IU9V,W9A*
MIL&-5;B68+'11G&QOF;IA[0F] XY9)K#VW2J*;^D2Y1U.D@?%,)4(*NT]"!F
MW\4J8U54=(V@>389LN-M\%ZHE#XI),Q =&!"P1WF,$B&#,?4&0':OV1:LU5P
M!<W)Z:>>UL4APUP5_G/S<@!K,YMPH^EX/WST&[987^_8%X#C&H,#M8PSMUA%
M4F<ZQ0F8V.Z@;24BF$@@):/BRHX ?1";+7:;'Y\?]]K#6AXIQ')98I'AK <1
MSUPE0IZ,9IQE=*+5:MI(CE.YDBI:D@!!8V%!!<UDC'<#ZR*\085U%_&Y$^'S
M&O[#M4"</N3GS'!=7Y!!(+X(K&!0%12**,FHH5</'&^2I3T#G0N6-U)>/8$Q
M<=TP*2^]'U%QYQ< 9A34W?"TTVV$I$YQ*+P$.U8L>YY2746:+-OW)O%+0>'M
M"Q 7<+R^(9\NY\[@6;FTW32GB$'_*U(*J6+-6=0^.ZX@ODKV?/7@-X= %+D-
MN6?0]\!?!QN;_N/T.",XRJ4PL3*&I0+*8V;/3J/:79R710(="Q]TN([0%1[$
MA:J(Y23[F $N"O",$CW.U"X?21]5[;FB[=M*=O5#1[)BG8/:?O2)KNY4VB.$
MQ_%R5N+!\0)#[GO!I(7H&(3_:J;ZDRO+%:"W0&:(LHBH[.Q6[^Z[2AQ#?'Y2
M<:11'^PK(.M'=V3">]BN'F$Z@X"K;W^-*(2MOP"'1\!2P4^5G>1CEKL*-?Z&
M<49?7TO:E#^-]"8R8AU)28%KY!$K<#P/*V]M=_ASH&+C!ORX4I,4$2Y[BGPO
M_')RU%$@FD5<Q+S*_/+" +UBD"15EF*E.7D-:[ .><\.-7YZ,CZ"\NB>"R6%
M_V?1,C<;W+CU5CB5IJ2I/.V+->A.BU0$LM.;2O"%T1['@)#FX>"\0'.=,2$I
MD=."9P41_?71NS2@C7#N9^8GU0FKW>JAT_WCKZF&),QNJ251O735"SK3+"Y"
M3<S>:STM9 K,N/ 9<9F5?;#KT@5V,TZRNX1((;68")4X[D1,@,[+ 9H<GV()
MO?P;\APXWQ+E2$L!Q57&W53FMD:/7O:9'<+CR#=@V-,NUHAM8D&)E#2TL*Y)
M'E^N]HF(?2'WGM>F\9"2VHT*YA8#X1$ML.& NGMJRX=+YW*COC!1#,Y8"=H8
M!D)L5V;$K7:GJ!5#L:[_5@J+OMB$#<S!P<K[SZ!!#T05Y70:ZM<&%U>8M#,Z
M)[FNQ/ZBKXJQ(EP)J^@B/#N"=_OR7WJE!V?$>7X!FL']IK"<QU(Q@7P2.DK#
MXP,O^$'YX6-+=<YLT2U(P?0'(6I&!K(D#?!P/ 26^FR4H-&6<9+;'('=%Z>(
MW2\ _MF+>,0QDQ<4/U+I%\#>G;04EWYYG"Z<G]O(Y\29RHP5 50!7\U(B\<N
MV">W-. 1$JMVYY)*8\AEA_-M*8 5=0%WH!+H0\<\9+]#W(2,(>7'Q1OOJ,$N
MS7UN(T & [KCYU4K94<L2X(E.Q!RYEO.#I/4:]WG=1R)[K!Y2-<AAOFVC$J^
MER/'655CV)YG;4[WI]'<)\*79I_C\C;S,-RPN(5!-H*Z^OM2"8@,\E;FY M0
M'ET B!>JD_F0+EU5V2?%T5X:C-="8&\*M(*F&T0SJN^?X4O8G#L1+]QK; !K
ME(Q_^/Q:).Y=0ENUGZ\E(*UT_%6/&_JO*^R$-DBE\_HI0E\$Q@AYQ )6Q=3V
MRE\$AG&!_; ! (WQVOUA]B1&/^&[C#Q\J'XKP2M<X6NK#C.!@Y8H!?Y/_'_+
M M5#[L1P&%;<,1N(/F(A. ZP_9BHDO,C6IX2/C+Q[/[LO:YQ=VZL0C?[48G-
M-OFIFXJ"[CI0(V5J_0T3_BLP>N]WHBLG"0N13QH3NX$AVRJP&J155F2A?"UE
M%OV$OT+&B45<T@FUWYN)IL'@^F:E)L4LU?M'.^$.Y75+1']TU=N@C(AG48G9
M=ED%AWWH%:MZN+<N2"F+*&$6# "7BJ,L%#!'9NR#7&1H:J&H@XWQ1"HD&(<2
MY9S7_L/[V6P9%3O[1\J[QT4O>>M;'KG%BUHR'+FDZ3M<JO[AQ[?3/[:EI;S1
M^.?[J?I0 W?IUR^%V%*,+F%@(TXXQUKB46$DKL<,K9D*+O$!RC$;E2#3>+DI
M9$_5()<32.VU2F,FAIJR^9AX6,:AJTJ1I2)>.%-M6EJWQ+]" L-S&W_;IGM:
M4AUBZHL,F6*^V=J1C%$S25J,U\ 9)^C+P0_+FQ%"/93[6PB!F\IIR%V[M9)%
M4HF.U,,?Z ,M!'I"^ZRY'=BR0WC.(Q5J&[A 18A1V8G#,@.A!"\8%QA/MX W
M_27/_(!L7YLOP$XLRHQKRX,\IUV[LC']G83X9V'>-H1I[_( A=I5V.Q1!>M+
M012[KH8C1R("5$0(W=*^:?G$5*0^&&5+'U+&$A\TKFP/I^PHQ_.".'1*R8XV
M%H$V0YSSH,:1X@>21X>"W-DY4QXE0;D-BT:-F2+R_7 L8@^ITOV(C0'4+X"Y
M#@OJ X1:,FBN:@T7EM'EP0\5^5",J8"AP1KES -><OI94U'#07"S-90_;0K6
M,%$HF5QC!9!!2 _9)03P@'\W25$(_>X9Z$%OX.'J.CBF@8+^KI-T;@&EMBHH
M[Z4^^AZ7<"].676<T/*KGHM!?KS//9/RGR""=XQ:KS.%GB8-I=6V"9CVUW-]
MM?<*,>6DV%#*07QEJFH*7SR( /&[U?6<J3LEY=N_L^@87-07\1MWUPD"O_0=
MRE54"#AD02ZT@N#TSNVPQMNXGU/5;$9Y-S5<!GQH] ,MJ@J0H<T*KR_8B[J:
MM7Y_ZDHSY=GQX=/U68[$V:1Z22=N6TS9_95=UC(.5*[OXA.)#^Q8JC#R"1-G
M3H/C\_,BO$*9J.()1RKEDU76+.$0*6DF+@AZZ"/U2/H6V;2J3&\-[7>Q?U98
M>!#E-H),1#TZ_9/X4)[T4!M'NB=6*K8PXX+%NB>J"1!^I2?0XN/%[U9/@"[4
M>A6CC>;-#D _ ,'T4(2#%!CWBBEADX<G), 4,[I04B"TA3S#81W$C A?<,IL
MZ5,TLCM"K9%XPF[:K.=RBAQ';A:(M\O6VJ2"4%/(RM"(+BU3:C _PW(Y2@O6
MDK'N!%<BK7#J)R_BO>O"I"F=14R5/#E$ET4FMP4C]JY&@0@$(FM"OGV(YK=3
M\IPF(]9?Z8S!BR;X8[!:4 [I=8@<H4)17-/B$W=X9B,W_Y%>=LQ+B+*J-61D
MT!9>L%3E<L8W%:@;BR.B14)J=@9(NQE(P1&Q'6*E)[(4'R\2F74B'N-3_!]4
M#=7T$4((%2EB!T0X&W/G"Y#Y!@065,FE)03-3C+PJ#/:.?V\$V TZN+<HMY_
M3J-"1E?O_[D.7;R+-/Y_J]J:KF'<%CJ.GM2YZ8F;#PTA:=IA*%JB&2QG;,D2
MV-5H+!,W^@%4?8K(;,6'*=&5V];+JHT"B@U@KP0(62HQD1>8-6=/+XQP,=*I
MF[0X-4&<"6#F[Z=]I]/LAM2QI]^#-F?9GS@YP!\(E05_9&LJ=5OI+/O^Z\_?
M3GSCL4@P&)_BS!""M<?')204 [R DC$6R2.L(TR#M$PIR="\1@D(]Q9C0GU0
M<XX+LHC^'/M28L03/8AY&!.^00RXBOTOW&,=/OWGY#=?@+1VXK@#:?&_#D:D
MEZ;"S*UVR&L?B2$CK81F;-Z<S%J1_;11*0^V/?5)$>:D(N.-E_B$5@QK<2./
MAXZ[CE((2[GQG$5(N)@7;LG6^JE:YIX*%G('5O20Y1OIT V'9B"$?1TU33(Z
M) 'K_ J3.\L4N8Y7^ ;SH"H\A<WJ''2</UG?K8X<7MY1AE9M/]7.Y9]K8'7N
M,$G#?XEDOZ&-6/JIF0VV,?I&Q=FJ0X?!]):R=C;$(Q'!(+W%.\_*I*RVTVK3
M#-$]!Q9;B$QRO $#+RX;('M^T7<?>5?%YMF558341[5GC;/3V>/X4*(IU64C
M+_AY]*5M MGSXIFU&.$C7/#*TGA.;0;5[##&H5/WL"0:J-5DLI,.%0W2ML'U
MJ]R3C+!%Q&#F&)8%F8GPESNB8]-8SF\AJO&H[-N_R.K.H@Z%SGL:]SX'1B/<
M$(A;>2OR$$4M.21'=:[8.@B:R,@]:NN%K::^&8EE[G277$"+TPPNY;/,&SJ,
M_M6+6$V)IY:33D_UPLE9I@*&]#T>NFM:+'(E0@'!)Y5X2/40;O%LH8^ ?Q#)
M-0#CXD ]'$.GKKO6'-M[@G>M!*W^BYNKT8JC7%U6&)]O4+X87+/9:PW@LG@Y
M_'FY+<,DB6K$="W;EH[/<0Z]N+^I-KPD=+72[M2.B"N'P)0][:B4]_2$/5D1
M==R^-GL.R! +"PVK:B(W^<8)'*)LF#\R/XS1:^0]UV3X H7">LV(A6ZEJ/S=
M1KMFF R8+KW_T:_!6/]8]^#Z:0_U@UE(N/Q,]['1I3)U G<E8/P?DYCAG=!G
MH7GZJAM;*#Q2R!1GH;:Q(D@+8RA= HX0/9_.5 9 Y*YXP/'2PEY9/*94+ON?
MFK#R1#Z?QZ0&K!\N"T+_^Y=(YJ[V&AXAMJN6R 4Z5"W."L_J\F(=?3LMZB21
M4&J)(%A+1 I_X:. \']>^;4?/M(X>X,3,DPW<#LEX\(;4-?G9<D,D[:7NG_*
M$G6.9/:5C6C, GO&2&:?*&LLW7)5JJLK8X@%,%IQ*;"Y_FF'6JXI%N CR;CM
M,23EQN-V[CF[L0G=LAM-06K%7$\\@3GE7.ELU=87)>GKA'%F- 0BD>P:6NOC
MC+R1'TI#@TKD52?YXNVI7(\L:)WG.OZ;>GWOD2G09G#$HEYOF;=I>+_ 2[K(
M3VYWFDPVPT$5_FE";W4);Y&+@X:(!J6TE?3YJXVHO\))2U@-"]JS0.6WUQKA
M 8@_/77' 9\4"KOL5]K9CON#KWE (NN"CM3+Y8-VPAOX3(MVO&@@6YA4RQRE
M+PXKA(?:Q.= PX42 J^$,Q$+C%G+PM:QP_[3AL^VT,BW%K7=)IA4=J5&9S!*
M:HQ:PW+?.A*-:H-(2(@Q=O9KW.[S%5?OCU'&UOFGM,AHB7NY!?9AM&:ZQGK%
M"$ C1-*O0%>)%::Q.\6-+T#4,X?S.1P'3RX+0.H^L1+",D+VMIPDR26F0694
M4YCFKD>W16.M[\+2'):9P=9PO#<G-9OK?"O=CP%MM>IQ)[U"[T3C: ZWH6MH
MK<D%BXVY1GK*\+!*?"-AZ2=#1'1],#0OOT,'Z]H#1)-B.AOAKW/X6X\W[VYL
MQSV]>89UJ2!/1KD%?,IO,Q%*$K<<,@KIB9H@I-]QJ[Q'3KG"^,)<ON?S>D<W
M 1M- B[K]QG9J0](A"7S&S-E*96=>*]B'6:\(/NM9@W9\&J=%@>X)5UUPRZ_
MB)'V[;FKTN-B/>?FTT29;0*31M*[YQ00/L*?\DP"W8D7?9$3%3:-'>0RMXO/
MZT]BYRX-///<G:.Y3!_GY!(J[KH12F1./&9#"9EQXSN*H6*'>J>(*B_U#QZX
MX8J;7EZCVW>[9W!FF;35S*?(WZ[ZB"D[=_TC88%7/S..MA,#@RVAWP^9@NP)
M>%EN_T0:3H7V#6DCMLV:"GZOY#[(%F;":]HPCYL*B213?0/%W<DSN8L4!PRX
MP[M&%J,6M0GOZ3\9I;PS.T6G7*SE"J%%= [HBBI-1^B<%B>M_%ZRWH+L9^ ?
M(7%MH?*M\9[SU4IQ?R,)ZWEWW;\-@QOLV*;%>RZ:67]/G64RP':O5S>B$E22
MMUDJD-IGV-&[_S'%3FEKE[%=(MD2./T%(-VL$Y4:M=,J3>J#$B<>W[<VO64/
MM<J(=B *>ZA-8RNP!!G\&@LZY%?]<[MU.[Z5]-)P]_=>L!.GW$DOUI,Q-6"P
MF;!1EF0._2%9D4HPA<L)RT3^F.7[<^=M4O\VZVU:>&</]ZR_S+O3F8#[V,.[
MS#F%;T3)U/R0!6KF(M?L>-?2]:D22Y&*@VZ-5BJ/>\FC?4U=VY'7-F0<PN"P
MOE;0H6S)S;8YAN3Q4 ..&:J^9%-A.T,*:%F*OKX.\?$+X/#$XO:3U'6G<=0U
MN2UW;_]".\;=1(E2L!P%+U.:#B6XR]"%1*(QQ"80<;BCP-G_QWO(&=]V<%IN
MT0AIE('1S_BKL-\G L'IN85? *=16SO\NY>'^XN>F*GIZ,W7+\#FAHGE&Y,1
MWI+*8M7=@]PE;SNJQ\-Q5EH)R''%QE)VB3XDPTQ%K3J.@U#&PHIUII-!DL R
M(LI\@S\L^+*&,J:$8OZHLZ,6RY$^#7RCIEA+X,VSNI&Y/A2+J 1;R#Z."#]C
M:2-@MP05.\4OR%46=&EK[Y4V/2K"\G/%UZ?F@K^Y,0"LWYVRAF?VIG&NSM6S
M]"./H2 X?]V[(;%0:9;'6<+PD@?3IQG%1^T.;4P6R"*;:5UE1Z16+K,U[66*
M&)%$20]9#*=%AC!)M#I?QI.P\O?-GU;]INCX'"&42A1KWIN=<F8&4F9NJ]:+
M,A79X5M#W;FZ<Z['SJ%W[GWVW8K@NMKT[37[QCO5S-$QMY5TKB)CRDK*#_(0
MW:+OW-6Z'U$$G;.O&Y;=0V19=U^ BA]? *AW225<K[:>B]"+Q#]@H.\//+S^
MO7J2[S;T?)5P6<;U8XDR>//[A[T@DK\7V(<G+KYI-GJ[T>_7%.1'^WN2C[@"
MR[I21#Z;C";E"6?V(!"?(E%LU1@D4VW2[<I>6!*/+6%ZUB?KA< O>40^YKS&
MF0M7L)/3U3RAD6.>@3+JMGL8\+OD@_U,C/M0BQ ;V7!@2 )/[MSAFU_U6@4.
M_R<_\\*L8&3XS'#IP&AED)!Y^02Q"N#_ 4I M;\<$.8;D^>[\X+N&>A(O,4>
M&:RE2AQLO'2R14J;E$6&G+>5B'\2Y01-)ZSZ*[=<^NF?SGX7\E28M7+][TNQ
M^MY&R[V?K9RNAP.WV+[-BT=2;6DR[MIQK*V4DT=,+D(H*JU8NUW6(=.225FK
M<C#7>/CN0:Q4@FI7Z[;P\:BQHD-:SXS(5;X$R-JJRR/+(8TWU78J+V.^IK(K
M2\EQG'TC8XJ[5EK2RQ7^.C7#E1' 4K2V6<3"6"2%3(WM9$CU757E3SCM^4\W
M\;^9[CE?&'CO=ZWIEW*VDGN.:V*MCH8YYSWH^BCF/LY;KN<;06 VGUZFH[Z'
MZS_C]DSW<O="=Q5.+K5^-KT33->>Y9B%=8Y(T=8Q*C!E,43S,A3RJ,; ,!@C
MJF]K=K0=L7^[[E;G>7YRK%3GK1UVXWD:\_A_*#)Y%EE$4WBT+/JXV@C=XHB&
M4'?FGW-.E5Q,M?BC2Q,IUZNK0[KHWT3Q5%3KI'/W;/0H<VNY=BTE8*=#06)L
MDB:N9%AWVCS7'QR\>_\ LW;L5ED46+EE!)'MH0K/9+,AU;"KJV <8P!CK,&X
M2_8CO/\ [3TORFB<UN+X\2_DA9929:L5$(DJXC+;!T9V QH^2H>&G';<ORC.
MLQ.]H;E=&A3NZO/WL>EJ9^;E394O8',;GOK:9VJ%*6WJZ+S[J?MB(@91\5#I
M?(Q6Y>WVLU.0AEK$*[52$D6& X(B,X<%_#Z4[J,X.QP1U1>._E-GG8N-N\-;
MJ6&CFABOPV9J[V;HC<P/+!/&\$:V90L3-$%9000 V.LN^2L[@.3MAN^6Q[/K
MN)V;Q0NMS5-K@R[%8AU9T;W.\C12UU F 139$I;GBP":+$$+EYW9X'M'@+$-
MGG;9Y070LD,5=62*M,5W8-#%LS*Q(U?;T<'UG/6A\/R7=7,Q25NU*U'B^3HQ
MD>3D98VDN1R$5A%7N\E-X4L889B8:3:D(4<:LJ/.'F#RC6\=T?+/B>_Q?/<E
MSU_##GJW07BZ3ILW8 65*'1-:G772YA,0:\QV%HQ<_9_?"];&N'Q2&>=T\W+
MXQR7%-+^#5LA:J/80VD2)L O&ZNV- 1K(R%L)A"3L;GVEVYP_P#-).W>XA>G
MY2[#..2_EL I49H6"S34\/!Y;<K8:=+4"QB(1M%&)&^1LOAWR;Y8[?F['=]S
MYDX7)YNYES8+.?0YG(MW+=\$39>NQ:M0O-%3&O+V*LU;O836(?!A#/\ "]X=
MP=S<)+#R5^@M8HL04^);,C(P70+L<L&&0Q!8L,!3]]0/<';/:/ \PE/B^ YN
M3D1895F_)MV88HU=RF8XH2\NZZ@J)49=G+$@J>K3R'5Z.EM[?%\;^0&#2XRW
M0+0RSK5N59M7&W7$R[&=?L7640H5S*;'VT:A^P,='PK_ %@J/. YGE#8M=O0
M\K'#3:4K'-,@22(R)LT05F'I')!"@#V674YSQSG$<=#7K\]RW:7(2\K'*()T
M\EZ.LH@0>-[,:P"9IWP%(DE1O29+L-A1]_\ %Q'C,=S;J>>@T\OJZ.@G4YSJ
M<_DTUM*Q;K,#:77N?JC"IL98L3_T]53C41PQS(9\O2G-=C+V[4GY7C^="V;>
MRS";Q2*[2G+?CB1FT8DE]ODQ;!P,]+T/XB5NZ)*G'6.T?Q9>-EA>O=XV[R):
M&.%@*GEB1\F-)M<"21D#!-5&N#E+R!X&YCQ]X=R.G\.[M/=\<J74?^OO]@OY
M9%2U;LE8LQJA8>>GGCIBO..O0.T]8L&L+(-0.C/.[.QIJ?%5^XJO(068[^K6
MH5CA2U"VN'!C1XXU*A<9"IL3ED()VT/M_O6;F^Z+O"\YQ\O%\Q!NBO6XUY([
M3Q1QB%1 X1HY?QV:8-/JAPS/[)'7DXO@OR"H>&?( ^.[%6]UNIS-\>:[SQKO
M3@;66>H-4[.7C?[FTP)]6Q0)GRV6-K$W3CVI-6E"I-+M4<S74W>,_)GHQR1R
ML]R>.1$*HZR[K"%1HTDQZ1'U4:@[*<K=Q<GVE:YGC*_-2-7JQ7$6_P 7RU,-
M%8%9YO#/.W'PL('2;4"H-T\.'FB)E=%J_P"/7Y2?D]DVHPJG8ZODQ&9D:2>B
M1Y6"WEQ'6K4%9-+DKAT W2L9_N=#;38_JN*ID@=?0J7/B+K'-W_R4*1<>98I
M9F<F-*MB.:1AN^5L0B7Q%=<&*0>)\$LT;@CICR_\/>TK!EY&;B5[=5[,*U&X
M>)+)DH,6DDLW(!8_"CBE&CU98GAFE&R>*:,$+T7U?R9\O<L[GLFYP7*KZSI:
MR[E\+?7VG@%D%A%D[1V[-5BZR)^0Q*DNEOU!7']:61\+C4_B/R/;%>."Q0K&
MS=R6,LR;(0"%!4$JN <^G( !/^$XR]_X?]M\_+;L1=Q71Q_',T<8BXE(\Q%S
MXPFK2(\DAP<-(,;AV,H4YYP_GI^5'6[5;FH9UG4= [BY:GI>'\#;O^T*O/TV
M6+%L+NWM6Z^O=T0L&G]6V)/4I4?%-.%L^?O4^X^<YGN+D:^MNG26>&5XI9Z\
MSUGG.JF.,I-'O*H;:, LH 9G!.<:M_#OLJKQ-*_+!V_YDLF(U.3[EK&X]K10
M'6G3BGJ087]:A=Y9@1N2 HZ_G\9..\A_E%R&UUNAR&AD\S85<I7:W0=2^Y8U
MNCME"RO3_4;=5M)=+&8ICH4F*UVV;2-1PTIBGGMWFN7Y"2&.R.2BXV0H98L1
ML[_\1(W<RMY'1F9M@?0"#/WB1YSE>'[,- F:"#D9Q!9CBBXM:C4J*J916FCB
MCD+SR6\(F[L\,2J ^%/70.LWO^K1RWBQ.WA^)^+^FIGV-*A9F=[?;3JK3:QJ
M-T!J9^+=.H).BPVS>)V8V6Y9!8!K:^T\)>O7:E+MAX1PR+$:\[R%52<ILK%C
MLHQ)@,B9^3YVW!TZQF_5X/BI>4[NM1W>Z;WG>Q!5,8%"@)W=HK-D&266Q75R
MJ:1I OF#).QC*B2!2WC? /FSQG3\?;6-S/9SVF%EF[+OKO6MC"TV>^GD] =F
M\ZR"FUDLE+7F9-:Y!&(1\S)I)2X[L_N.E3IWDEELJV\0D7."V Q56(_NRMZ_
MQ@@D#IY4N\KWSVYS,_*U9[/&QTKDZB2+PUX+5=#X9JB1QJA".RDB,?%0RG)P
M!^F>B^+-2K8'^8?74W_NCXQ+ ^4P/M/N43/O[>W^?XG_ .GN\#^2*-L@[*IV
MS_K ).?\AC^_KY/E3Q.Z>_@6&/W]'4^C@G./KU]_]>O6,1\X]IG^"&/X_P ?
M]WM'_M_[_P#B8_S'_GV]+^@0<Y/OZ^A]8QD'/^7_ *_S28^C_P!"!_TP<_\
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MRF21 DH9O'\W55(W5MB/AJH4)J"RC#$;:#(/2%Z3R[Y.H>=,[B<_@6/Y'0U
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M*@<V4V[:Z'Q]N?\ F]>\OXY6*03049ZGXT<%B-=(DX^.0;B1QB5T*!C'NTC
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M7HCC7ANO=ED2VL+/26*-3$)%;Y!F8MJ7&N48Y(+,"".EA A4J2HV?)+'5@I
M])]EB<E2![V()PNQ+.T.<S=K>R-MH7)OP@IKVHD?UC:<%(UC@9^<.]A)@S]?
MU^T1 E[_ .&RW&2$P@+BPH.S%=<_J5 P(R25!^))95 ]X]MTG$490+&4B)P
MWR",&!."1\1Z/^1)^60%ZJOD"UA<[DQN]#DQ?#!F;J)8F'L6T&1"X1[01?W$
M0A[#!?.1DICV&/92E!-+82O#(8VL,$$AD*QC!);8Y'LKMC (R"/3.<.ZY+[,
MC_J12?\ $"X*@8V"KL2Y/IAZP?>!U_/C?O,WR/SE#JL6LRI7L6;:7HN*,&I_
M7.%2,*+V]Q^:Y()_B?:8,IDO8I[Y&A)QEPU[+J[!=BR%BC+(2RN?DP4 %,Y
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M$P+(%DP^%$P_<V?"(,8_L$S8?M'^8]-J4562Q$MF9H8& !=1G)8@H2N03\@
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M(OFZW=? K80"0#ZO%_G)NWJ4E;CK%26O>$V/(%L2*K%F9A(K.T9QLASC4_$
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MRL$?&C=K*6+H);#4TB8D0&5@;;UQ%^=9Q0MJ(YXP#C92I3"X*LIQ[;XD$##
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MZ3;TSKZ2J-E'VNIO3ENCY3*K\(.*A-B/<OBJR2R(1'YP,2/M_P"9]AE!<&8
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MD[Q74>4/&.ISG"=K=Y^ZN]5W%Z./7;8;=PZ43:?ETHI%+;)6US'T0@#8TX6
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M,*J*,SKW_7^O]>NNN/FC0#*\4>0=%A$ 4N6U;!&*C>0?77*?E"5Q)MD9]B^
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M5$UV$N@EP)HG7@X<5KV7+OB;W=7<,%?GN2Y*O%_+97LUH#$) NBY4,[8V.C
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M7?9DU-:NQ6M0MHN0,P=RAII-\Y[8S@>[CV1?M5^.@DO-9=HY/,I9S8(+%9I
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M\D>7MWQSJ<[K_1R=*I_6KZ&4,_!T:U^JQE*K3N?O1;<QTOF]>A:BFU\ 4J(
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M%V$?WEB"R<^;Q0382*5F=9\/(\C+#JD<B+*F%#MAV^:B0AF "H5=GG'SK_Z
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M5P#HD_GCS37=?:9]H693["M IF9(F>P!\9F?E/O,_*1&/5;E>N8'>1R'>1@
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MD2OL,!M"N8_EDA7QH&]E3ML6"?%=)RA))*  !6P6!!&0&R!JRJQ&[*OR]X
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M7D:U)+$P9T8-]>7Z^0)5DR,:Y+%3CJ'XCNSFJG;E[D+-)+!5(>.B^:0)9K"
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M/NM71LV5!355!I BNP_B L-C0KPE4R?Q9,$=1XRE?Y^>#A:BPJQ,D\<DQ 5
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M\M;YZWS_ !G\LI336.1+7RTD(BF9#%<A3S&5I&&QCC5F*Y4ZD$&I]CXS\T<
MK-4O6J\#X\T6U:6MU5J\O2ZWD,=]5+-1UZ!@Z%\=3;$"0YSKD9CK\M=+08#
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M$RUX0;GA)2YU@O>; D11,P,D'P*)@4YJ_+R+<C)::.T\B;V$PC#<!FV ('C
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MDJJL-=I,R>*,DM@G39/:C?9B#['^71Y99%T9ET#.2I36=YD 78D$+D*?0P2
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MN6#]EV3+V43!]_BL(F2"8*1DC4<C\_</E.Q<E)/#Y)82Q!^,JK\=6.R^_8)
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M8XZRJ\DQ  \@#222;.[ GK;OXV^&>NV?&%7R(O3Z/Q&[R9UNEY&X#Q45+,+
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M=2Y2T&V9*RJ^N3*7UF>FM7M:KP/*33WO!M>:26 J?4##+ZC  !U* *I.74D
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MP?0*84@ *  2#EW)"%74*Q)'D*G#LC_011@@AA\E*@AMQ^YZL?/^4,7HHR]
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MJ+!%>RUQG[,<0"@5L:R!].N(XJ7N"Z(A.(E2N\\LU@-,RI&R(N4#F1W9GC!
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M[R7RCWGWB?575-I5C!(\A&V2PP1E0?\ %JI?&N5U8#](!)Z:(\P+ZA%9F.$
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M[*/T,Q496[KXG^'8FK<P_'3<*MI#)^+&9Y9H+"$AI N)(9X7=!XP1",9#@J
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M<**:=3FUT[&8AVSR4GVY3DVU[EFRSAII6)ZD+)0GC/IS*E_&A-O^0AKVAD*
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MXFP* 2HFQ7AO_ . M&D439-'9+YU;.V.SKBJ;C=SCI.H9F&.)PA>$&11'QB
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M-#>,.F:)%@U8/B%K\@8$&S_-L+CJ[(H\;GOF*??;:M:OYK9.WES-0K$>SLW
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M_[:0DCM-6["NII8+0;+55//8__E)9AW,E]CDDTRM7K6EV?)[>Z^Z4I%]QX]
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M'8J++K/@$WIYHP2QR/8$!,C'Y;T[>7V4PVL5*>JUS^;W;Z4QM7A0'I32O:.
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MR$KZIE- Y@6D$Q3]&5.[.%\'?A3\B_;;U,@3M/PCRI2\B#Q^7T'*F(=E/4-
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MR3*MG$[^UY3FOZ!?;^4.ZKE";35-Z]N'^E6__6;(QLP;%5NTTJ8"- +C>KK
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MKD3VFR0$505=D 1]G*WX^^!91U'F81IT0=&91.(Q5!PI,&18@.VRB=;R&O<
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MYY5FX#0))->_M0Y?Y3V=1,2/.!B_Q Z$O,ZQ-FIX%S=-=,:A^B9!7&'B]JP
MF1<(,28688+5"WP.;B.#Q[W.3GMI3,HFG+_ )"EFMSV4AH,$/5QVW\Y?_+>W
M89!/U'3Q;"M?O@&MQ5R[U55R*!H&'&\P 7R3KZ3^[P?]BD!1M?WX Z/XN,.
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M<'&L=XV=W ^R6NE YE <KT4>;7$"N"^7E-6*YJAJFK"0>SYH#MOK=-R+XCB
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MH<%I9:X&+P3(UFRM JTB#3/#GW3<"6BA3";"<R=N3[)#8RP]) -ANLAHH49
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M/QJ:<+#?Q(91K)FP!DDL4E+-J@%"R!;(?Z1_=TL5\Q]8@4#9O_G/F!"19+7
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M[$U&X$FU?PT]ZJP25[5^<K$%N]!5E/.AX',.;D$N%T31O*MA2S=TW_T<6ZD
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MUS8[W*VDX5BMRXX%1E/!K<,+-F)\Z''J,%=DI6QL W0+#,&O5':25CCXL.0
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MY_S)WH& OJ1BJ*F7#I_*BX=E#QGV<O$=ZJ6VDJE:]?E+A5W]ZHIF9^:20E/
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M_B&V!P2'1K%%JIY^$H%0[C5V^("^-NRJ+@1R;(3<2Z/6+3(#C<$"B><=.Y4
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MT_^@9=96&[FCTL;CMM)?.1T#0SF]?:*I KM@$O:.]30."Z'9O@NZSPDZ >%
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M7,QQ7STQ:E >?UYT&Y@>KK6JV.GADE\!D$"%+=AUU.[B^^Y[>*I\K/1+)-X
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M5D7%4-_36US11EL.QB!/Q*9>9Q?N@SCRFK-Y]8D[WP_R"99HG2O C)KT[/\
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ML*4U_9L^3SJ]!>JF-P&J, B55CCTX#A/SWT>:</Y;X/R!^6#EF3ZAG:B(&5
MRRQ3M$ML"($R5G4G[F_TJZ?X8[?Z:6K+[Q/2'B&*P;:>CZ,R5 UE4765:!"-
M&GU1T2C#OM!&&SJ@8P14>KIC@[E+?/8OI=#3N\HNI0MS-UV;DF%9/,(1B&QC
MI[[-XC>=:^43^HH.A014L6/++P0K3/77ZRD&//WR"9 @L^=(?]MNP62;([/0
M8!RLSV01#G<X?8+B9,>V<4../NRY&N89S6V5KMCIJG.(+N<G^XYUU")Y>$O4
M"R'GA TD5&UB"41!)GU-/\+^DE"9=]$>GJTX$_@+W80PSLSV>()!:>5AHYG?
MHGP>L;%36^P[>S\&5H5H[XNIVZ8/^D2OB549%DXG,=1\AUFU4R;6QFZ5.6PI
M36-[7PIX.M_\SO*?;S*G@5*EI IE5;:[5YX<]XTG_D<0S%;'[YB>>9R)C>3=
M0*M0&G])#YL@J9L'+]5"*73A%2>8RHR>&>SH90!6=JPF<A$*-E7%(V2+#&:,
M(?.,HH->TJ9DZZA#O\[4!@$.9: &C.,?  CG(."-@5FT8L19WWJ34CGB$KUK
M^0]#U[X$\6W!$3P$FT]O^I*@-U/K0EJ3K0W@S84!;O39H>L^S^<G424]X??:
M6_G4V,<N;^K-=R;//PZC.SHKT>1GVF3?F%U#/BV3[HZ2M^'.6'A\[^%U>+?U
M1$7![0V-#FZ?W6W]$10\O9.NM)\634$YB/7I*^,2.^\L<K1!JQGY+9Z+(AU;
M*N?%C#C.4C4LA O;J)<D/1F!Z$M#.WE G>+",K'6W-.R_N<CW-4/FJ3&)"H<
MI:V8?E*4",AO**&I!P>'%@YUDE16_#0)C&OS,I5$EMIJ5K(U%K6MCJB\%3:X
MN71'_G<P<)[A/T"^HI5GUR0%!LP?^RYLS,_ZJVU<+,,MHP9Y ? +A,H2YW+D
M=2/G\8.&I/4#U]BM]_N#N]#&1L?23'<T"8;YDJ].'I^U1J&U@;7R18OB;^^%
MPTD/Y_2%7O6MA,+KA!\+_@G )XRCKS^8UJCY+?%3:&IM74U5.97(D&F<URLG
M_D8.]NX" ]E"Z+$*T!TJNN4/E4'C/(G"O8:%KQY&Z-K<LJPW8<FA!LK#X[\(
M%W_@)@^T0O5NW6G,<^R:WMAW*6TO')SE-XQ<*=8=_J1LE W,#=9-"Z[JPG>L
MJM]Y6'FL,M!>/U7N?FIVOGUUIYB%1*-Q#^BDM@M[*V28U/EE2;<29-FF)8^B
MS=9+WHA!KI(E>_J]LEO'/'EO:>)4P/ZD>YU&[.3-Z4Q%-8VVOS3T=@S8[L?9
M"EJUT]L(>R_9]/9A-UNZYQ_U_WL(13/(W_7Y4;Q-!<TY<K;[O-$TX*23N%_V
MRS5Q-H#(J-;'M/M[$"5O]J[VFCNTA$,M^[R8/#M5M.)0,^.L,HZ4S);\8L=.
M$(FMZQ=J5#OPE[]V8NUN^FVS4YF\"<.R+O'E%CX&F=9$OSQWD;!],ZUBA!CZ
MCD^UF]FUR%"]N+QQZL2UP_'I;Z_@^SGG7_7-T]L;%20NRS/*NBJ^7NH_^YW:
MW-[KMN[-&GT<VQQS U47_LMV6* <!WE4W'.AWDQ-,\;UU5'E8R?=D?X9&FR^
MJ--YUYB]Z5JC2.V<G/_4Z8_#+&+!NP&W:I@G4';2WEG/97"?@ASP"IH)QLZ$
M0U::)WZ[0^8E!5:.7F/FO',Z/SI]%B7FQ66;";6#&$-?_C9*:UK],E2>^4/&
MCO&TS4KSBT*MP\W04*3I9ZQYLR>MVIE@5CNK!#=EE%5)\6K,BDTJSYH;M1&$
MBO7!IT@V&BY\R3N-K*.,O+0=]R=+*2:>"-7VU=O6?$H;;D6K[I7V#T N)CFE
M 2R?YA?3.V#HK5URMMX\O4?)(V\>J5G6X"\HWG^+7TD&0QS2FY8<OG=X3%69
ME$7/T3CN7.^)4FN''!K:LZTT,N:2CV8)6>G*TQ(H0GQM68+'SIH0C^J[;Q"+
M0[UBPLRP;HV3 B"N(9^E.IT3O";:C-/G4AL"55Q4Z:,@:DLEZ*,V* $A(61/
MBYGO,>M&H2F&N4;_ &DO6)/M,2:_#VSL?W2;;@$:[1I<B@>MC9)\5E7KEEHP
M\61&%,Y?17])<*"Q"-TZ:QA6TP_&61)T\!2D(=B9E-5^B/P01N;U%L7^6+L]
MT%L<V_SZ3L;8/'+S15E[;CA)/-_2[C7&"3:!R(A</E\_BYN8!=J[_VVZ]RAQ
MMC>UZXN3>W:@O^T 5KK4[<N*S334TY:O$ \Y!MBTV.#/;O+<$#@H>18,N^Z^
M6QK?6#/-SA,X-.D&<D343*H(LP *0UT0+HHG;X(W=)=[M565OFL\)M[ [N$*
MB:EX/>F",F!!),M.3 H1P,$/B1@<5F&_W>TG?_\WTZ'U9@%3AGS?A<\OP/7&
MO"2-*\'BJ\]"?3#Q6B";"P;W92"VK<!C9]''RH8@GO7^)PPU-CHGJ*:AK$BH
M'$%12W"0HE&YLJ.+/ T3^[QXLH#PEMOTP/=))P'/>QM8!#-/KBY#76]:IB.9
M!5F')%*W>[28 8.ED AU6]Z?^C^R;,&8#T9IF!V5'8!+/.%IX$;9QJ3UL_:4
MTM;+F "UQ-NO'PT7R5U^EVG^R.GI002D8:Q4AN'3 $NE61OXT=Z7F=7J707^
MUZ_U,U^62>VJ*B?:RH88<[,\DZ, Z3JHT7I;F8AY/NJ'_GW!DEK9L]X/SLUI
MLZ6ERY.'G>CLQJ(4V<=JE4'3GAA:/0V12.@(Z99(:/CWG=?;WF(1KYWN'1J4
M=JJ6<7H>DULM%33+12VDIXR"?"OO[AGMXS?K_D98#*:M'"$"EKH$]&O)'<:Y
M)2A#<@J$H@=AVB&WP3^ 9D0OL:>=@6I'&^1IC0O+WW1W_0S2$@3D7(-T=5SM
MG-/Q63I(F-L^/@69W@;9BO1^K ,/$J6N2C,R(C\1B49-B^(!/2=X'KPRN@+L
MI\S@5@<&:;431OBJ7(?[^=CT2848<3E3Y%*$@*:YNLKX%FW>S>Z.\\<?7'PK
M9\^[//.USF<G%Q<JF:OX.OT!B%3N_P"%PN=J/)!BQ!Z'<6PU)OF+M,G%G=<4
M7_5N+;HZ!J-#6;)XP4+TK3#-,]-P375N*38PY9$R46!TL>V\06S/@\O4/&Q>
MBSGU,Z7V1EA;A=-DE5QF&F6-["?WFE4R8#JUVO77#C%SD9L][OGZWEDG:_7@
MSSO-BG_81 E5=L\:+OEEZ!P6R2VR:!,>_I#:T'/;(D-[GEAK[CQ7#LI5.XF
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MHP)(?!N29]3Z?9O[;B=>9B>ND 9Q@+FN8(,MFJ3155/BD- 8:U'BGA#"HP\
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MW^ODV@H>1<RB+O_H,C!$;MIE]DL#?$,_ $^C*+"\?'\N=P.\#[Y^K[9O,I.
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MZWI^/U7K+#P03^X;0-BB-]@QH&DJG)GY3X8O0ZJI.4XA;R7)MAVUY!"&MF*
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M<I.VUZ6!A1T[/&F$?4[*\UDFF2]T+J4*3H]#@-C-7+[NGHF1EG@2F"->HZ6
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MK4DT16"UZ@$.!I3[5$L$]XG*43\U.MCOCD/U;'QZ+Z"8A\B\92!NP<T08 $
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ME&M.QE5B()*>ZR-U&])25&4H,L0/@E4.$VHX#S"F.3'5\_ 1V7-4">?A[D>
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M)P;+/X/UHL(?OA$%DU;%.0!%B,>0" '!!%(CKEASU),#[T.[Y5[4M-^&6O\
MW^K!TO.1^:O&8KNU!P0^*CK4=OU3D00CB$-A GM!G.(% H<JR,P=090EB;CS
M"PY873\^*APJ)4$A>]@;1)[ZL,]@9^%P)SI$YX7E9<SK_$,3(NX</F>;&X %
MXA9ZIXH A!X'JQF!7@A?5K6-H%&1CV)'6I>TCZPS!OJ9D]T7@A!NJ>14C ?:
M[7R:)X;%?K#/0:4%,PEODQ(980WM#N6M<WI8GW(,:PN2N?HF[18WE FI?M2)
MR,^GF]S<R4LK(BZ,&DG%R*+*XB!+?*SE"@WW1U&^ /7Y9CZ^5IC]:9F9T_JS
MXW8>W3UFH=_<>XF1_$3M:UZ714U/SEA0ARDGZ$>^L[MK"G.4I,SL7ISQ'?8
M@2CQ]O#LGJ;4[N"ZERTK,U_#(WW8,P?MHQL\IX<MFY#".V<Z1\:<],>Z>">&
M>?*P Q/"WU(Z^4(D*!TT82;;.34YM_<[ [)=L8>XU:?/X]L&]!4M91$5Q#1S
M'U2.5Y[#H&^OHO"P'=GM'[5&QH^/.C68V]3$!NW])OE1!]%MOO,].FLX4[.V
M*8^E0#SH,<^4P /X[5ZWX3#.8!LL[IA,%]$KQHP]I9&L$I1.,=%[_WAA6?/<
M)/KL2"]%;<=55\OO;#9C9><$HM%-YN]U%K]0$/(]WIV"*7Z6*#-09$4$GI3A
MUH%#:$ =Q",](9\.?+SAEE\O>^*_)[4?NYV\XF[\JL90H['%'Z$X*],P7N ,
M4VP4IT@DMX"GN\[30!=G*SV 45/J\WT#.LF""<PWCX_/7\<:;RBN^P/W-V^$
M;4)67=>QVZ[5'A-7=LS5,,5_WA<1!AH>PA(PS2BH1HAQHZ@"23^F_?UCT"51
M.#TI)0_TM48N5_P2>47M-LX>-S1"&XC6DJ0H*QG-EHLG/-(.7;<9P3%KX50?
MX\2\=1"]%/.8_04$WH"2NPO%:0"^1B>A*67J&KO^)&>HJ3%5D!N7<I!>=^3+
MQP^.*[\%YE\<?<P7B8FJVL79I/*PR%?$Y/C$PJ^5:&XNE:]?_@+2)C9#V^=#
M^%+.LZ:= 2N=S>I.GZ5GE1 ;Z +7"71GB3'="-M "V*6PT5:WZ:@AF)Z;C$Y
M)=:(4GX$@DK/FY?$Q3<@Y_[PCPYGP$861S5!9]L)O<9LQR6RWTG1<->QO34U
MI8KXBC2 37/_=??)!J/WVWGC# GE.S#54ZR9X'R. 0GVAF>A XU']D_^BE(3
M378?!PH'&W;6#E)$$8@>NM^'"'.2I"17TV]M"B2WDT(D,1?'$#$"-$5AR("-
M+[*N-:<^[:%;*E+A"]TFLFQHV4J%JP2RY'!M=D63#-%],F4/:Q6N<DWWS \_
MNA'"8A!:'X/B0*SB(P2_Y8Z!LX ^ZEO>%-WI;I.\D*!EAG4N$B*2I.%2+W]U
MPC>6" <N[Z1UGVZ@X-GC]%P=TO "6-4PKG+H<UV.N5P4R-F%#V&NUL@I;U!Y
MOF3OW,14UFS%H#@G1RK(E=,D!F+!%\900./UX+V\ 4,')0+GD*F_&!D]VK'!
M?Q"!BM\X 2UAA7 E,>NRX%,( T9*0]E36TV2:QB*"!#"=K_YD>RXI\QDKBZ*
M<!=\K<9K<3BC9W,DR'1$\.1!9X557".I]=KWPFJ$E2BF)([:+U!1IS861@&]
M\T<)_1ZUQ_1:PW_Z-<:%B,AQWZ<M9B$K0Y S_\LVY0JW80)E,>6GST+U42C*
M;X UCX1K7AC=S;*,"L*S6VRJ?L^ZQ&NG7TG-]\<=" GY"V.7(,E11N2JPLIK
MZ=$=K;OBS_RHHPG3E$3EG5LY_,$F$#8.[\*<V#?J7C28S1)-E?R[7 B!&V/Z
M3LC4REI .6^AC8*"K:S"6G+Y*!IF9FBX[Z\#$7)FA7%GO=+IW-P6)9_YOV/V
M=\5[0=</^1=7:/]N^ H5@="ADF!\MP& _-48M+2%>_RO"-2_-,3_%-&*YOMC
M"?H#@%_.T/&S)$+WUK\U\F:1,41C!OG[_B*%@GXUY!(# !1_'N )\ GZCT9_
M/6E^.WL#9!8Y/+RJ?S3^F"N/^[CHQ\!OE&"%^V&DPA$IHK0AU;(PS5DE+  0
MVR<)3!+S[&/0G$O6]? HBM\5\?J2D9)B/S]%8"VI^EX;0D2JBN?_9>JS4K#N
M$6&^F(KBB+H<$5H@EWC? E_GCL1IF8(^1\Q!WHH51TBQEUF\!=<"4-,(-BY;
M&R<].> R7"N$1IUG3%<F#D;*C>'W?,Q_*.'V&=07EA_7N!X\SK/F/F!B28BH
MGN1TO:&8XPR,S/</1SFM0WV0V\O]Z(_:F\4<(?7_OV#_2T.7^E+Y0E[-A^8E
MRXI""-;<;IUTHEY($*!C_'58*/0W_LA#36ZGK&.D=?$)2,C7&[0(=.]R@K01
M!4FS>6KZ31MUYU0$0A.,Z$:$T<B'(=&;'%RI9[#V"^(JS*%'@ /:BZ-IA*:^
M%KNCV,5" LNX^WU3+_JUD/ :82QSQ[OB_Q@+7=Z-QS9QU>XF=C/?[4)\6P5N
M&<?-Y"JR5LTRR8\?,I,M$6HGV9H9=3Q^D> 9$2QEZ]8(4K )7O$3(GSE&^#3
M95=_93!L&N-W</GGD]1)H9X2*>=&AT]M?+CXT&R!BKF)O?I\DGP;'QP_Q=C*
M;\?T>&97,P')3NJ8^TLBOJYU3^^+*^V&##;LXS> VD>H*DO2,:HY57&N0SVE
M_TDQ2:DX^2)CD($J<E8('6'Z.YQQ+3](\5CH]8!.0(2;V(?_#5B'#Y'8?9KT
MO+XCNFA=M4GZN=/YFM+A-#73F,7OHN^ZTC7@]K,]8;%(N"Z-5"*"XH(H2K.>
M^DS*EP+I 0;2NCN*&B^9]R[KWO//:QZ<O5.6N75T^^DNC_N94WW7J\L5=5JG
M1)5-59?V#C^\T4'79QV.](5ODWT>Z%\33)>Z[4:3A#4_!DK8ZG>*J3$3G+_B
MR7=YOP'\[;X1#@XF;K@)WBYS7@=Q0=J,2[F]>H' I$"EL1_!U\\&(HS>B.=/
MQ/H"YP'>C^?] KWB/?;_M2#Z:^!"R:A\(DH,QS<_*2!?H7#)%HASCOP4/2/'
MEZ3NQHB2(8WV[0&3L!<@X;_YOA,CK;^4'WTY? E-'AWCM:9@_V$Q<%N!!Y!Q
M/NH,\UQZ#*I;PY'2%_S:,2U[[)E0(= SI9[=]M'YIF%8V09%2R,"FY;F/C@B
M+TI-P3625[,/*C=7&;6"]\,OZD/UWY"F=KW) NM//&C:5G)QZO@.2?U;$X2)
M7(&LT$':<,N;ZHLW*-X:@8IFA7>3)K%7?D7I\/#]V<\L^]$!+\03+>T&)T0%
MY0OZ^E[RG#4XXZ<>E$2\%II-^*/OM2@)#YUH-([DFK$'?H+Q@I4^!,4"+'(F
M2[=W15]G9N9<A,"AFI\$3@8'/PQI58SN"W9:V>N2N2)XX,,N3:+ *I!DN-U=
MM+9--\+#<R6.7MH+48_;Q6;<^.0P,:3_!\#-+5G]:6[EEEF/X*[LQ%JEW"G*
MWRA&:O0=&('E6&F5\L425T%(VB4) /5]A.(5/SSHLM3CFM*9EZV0F=$@$]7
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M?*!R^?M>>)5V\M5R'7E1A@6A[@.%PUC6/F&"M"!9[;)9QO3TAVEH;0"P!@@
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MV(6^.U/]A/%+?"?CQZ@MC^,Q>\\_(0GDYZPO)OD49>^4F/R@R 7T6QX]O-Z
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MC%$D840P5'N&.S::7#BM/F ?T$>J?7GDY_*=L$1Y-#5[*@6ZSFR)>-)JK=E
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M0TQN?<.)7"PNS(J=#Z'&=Q#=0RG&WT^6)D-\"$!6SBQ-/!_;>[@.Z?L X"Q
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M'N4]-W7>ZN^[>VUG8'K7:Z5W@Z2F#(W=ZQY_]3@>*% CWNQB&<&VC<O*Y\N
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M;1(4C*D:]][):HV9/2);"=@(- T1SOD@\>Y9@]54K76-M7X\:5T_1ZM6]54
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M6$3LT,_0YG\Q5.Z%I[4.,"V3#7&>Q96C ^$'\)/J74LEA63+@;_;G)0&V/!
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M?DKP%.UV4C#@![<=M%.@U\8J(2NMY#>7)#EAP2%')&%$@6(#"W1OG2SI4+I
MQY1I'H7P;1)HK:L-6^1,;,9--I5%?V4*?G=E1S4@ )YJ=0#0;C?&<";=TW T
M^-(D$"@.KM>KSK1-:X:2-5>A?@!'VJ;(ZP?E4"/81D.>]]R%M]:<^F'2GA(M
MR,R0MR1*-U<$-=IJ7<HRE']S7:'%,A 5\]W.>%TN?ASP-*DK_ CAB<18?.Z&
MGK>P"G_4/,SOAZ@U;YKM0U5_L] :XI\L62GHE*PNI+@:'^E@DLBR@51EXDA6
M)_;^ZO]==40-DV.Y_[GB8ZZY1 &N,JDIV::9!LG[&OJ2[CZ.'NS:T<5OJ+3
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MY)X?C+W)]G*E8] ?^BS2OF>*_4M7//H0 WTAF6GB*50Z6&>-Z_!_@'X3@G^
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M)S4U10PJ*W;0C*K%2(K'4.F\W4*3+?DV%L* QG\];U]"9;T<)M#R\&6.E_Q
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M:E]CXFW'X(BU2:?/>SQ(*38]K\![0"]#@>?]ALB_=AD+FV-R^GE*U\E<USS
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MZUT7 /"V"A#[J_7?*G\9^>_:@'K[ 4!' !Q!Z[^#0@= HT.]0X=ZZP>0 J
MT-#0[Z"@ /\N"._AX&$1H:!AWGWX,T -#0" >P> @GX' P>#@ B+_*\J+!P
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MP^84X^YB6N&)[;+?K=,:9'K S%G)ZCT>)1:86.B2/'B,0>(>9<A)7=7I5'$
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MO1_K./)M(B%=M#5NYM<F*BJ9G%>)G6Y!0%D2DMXATXUZWLXXI>U*6+U1[OM
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M"JI%.SMO9Y$HH)E57OK(,R\L>:[EP<7@<V"7Q>*F-:KG"DQ]T1AP=B%KTE,
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M1;9@]R^@ \^81*+UZDIPVI?.'Y1G8J."TH2TB3_)^.0>E"@L.*@"S4L&T%7
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M'\I)_:*O9[:$CM$K$=;)U4B[!&2QZV*3FVO+>#DO? (]>@;^1^]^,9U6N,?
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MA;NOQ"/BI2U1QL9*M@LU]4S.W7J?@B%NP 05DE-G0CU4UMB@;J9EL6?!P1A
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M,UDKA)_^MD#@&0E,4JINWB6*N>S"EGT:V]QL;)>@/Y>77W*W])5MG:E7SEN
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MJZZ%9S^Y):PY9&2]IH6>M5I6%4X2.W$_[]40S^&N%Z]'8E>22[/W&TG;=[_
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M$59\C$Z1)2G7'I]095IG%SCH.2IN"=_?3"8;HGVL,V[C"O7TS?DXCU#N%-)
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M/[LNI3K[6/LG*!=.43OHP[X#>I&1L>'W)^,42Z"K5'CC,"+WQV[/SVE=#NL
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MD4-(AW>JX4TKT$M2_=/S+L?C_-#' Z"&TE1**O^MT7TFM^"4T="C,*?5LKA
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M/;=KP#>"Y>8+KG)475G?'5=45\^&VT&B(H<^XAB.&@$CKU]XKK>_E#9OUAO
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M\A6@8G?7&!@>I:R;4C; ZB56)5 H#P.<_I>;\W\6PM\+_P!02P,$%     @
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M:66:!I$UW1?WZ7CY+>X(9+536Y90&+32OEAZ?2MM7OZ[!4"#^_<R-APV0!(
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M.9#IQC/$UA2V&561?(U9;7S3Z.O=Z/C!$^CL1:I&M3B=[7 ]@GY>84L^@ O
MI[U%LKO@6&)JR.X7WPZ5'8X51X7!-CTZ+[,.CKV<-?\:FVL5FYS/PR"'+]ZC
M:Z':C3I,SI^_(-T2SRNW>8^4<_5(8\:&"/]6GW5X <GRZ=TU6OT8XF5DI"0
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M-KQ?<DHE&#)> 4UM^$DOJZ;A0E&H^-E'S=03Z%APN7G%H6M01U8E5_)'2\/
M9+C3PR@&>17?&I,L=YQ]W?M.+D6HZS'US. &E[)^.F-&7.CX+'7_<#0VZ:PD
MP]V*"I@@47 ]0"@4*H6ZKVF7)Q>@6M@N]= 97_SK_A?<JH&],\K%N:-N09K
MJKK2CR9SA[O J\?9N*IPM8ACILFQ>@1Z3,'[<.F2AMSPR%KE46R>/#D)4SB
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M2FE;NY=H>K/1K(+_R+3X- @)?S'!V$0B-H_5E@EX9BH+;+%U0BL&C,'F:;X
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M!]F^,Y9!"@;O^S(2X]N84ZK1'&WAUY675YMD"GCB%%%<W,\VQ<F$@Y8."Q?
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MJE=2)-/B6=#5%(15+ DR5X9U*3%)8SBW7V.YDJ+7"(^_C@K#&^90A3>[V6"
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M")]5D=KNG)R,5[>X9PWP?514&%= 65<K<8ES;6YBE*VM>A'<JF?V<E0HL"Y
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MZ2!_T_ZIIC\Y+CG$'\\5BJ[/[GEII2+.O-8"Z2SDQVPL)R>^8*W 6!2G: E
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MH,"*[Y1C>J*6*KY":*Q%C1^MAF9=N76^H&>!=NF^13]F$R>/'N'M"0]/TU<
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M8=<X M=6,]B7Q>%M<22S$0PY>!W#M##MUW$VVQU3;,A#J1EMBF.H&6VI4RP
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MY^%/Q<5++N<-A4I5;D\=)89EB^2YIER4\4G.+B%;#9:D2XF)T8:S(AQU$U-
M\3BM<MKXU5RUY3 U7!ZS0#K- TBZ1:X9AR/DH)F8&S3=2S1LC#3L.F5G0>TO
M1PA'+XP"R.I'5:@^>2_?WON\]S]^L"V02+]G3+XO$'%^  9 4>>W^H\_2:@_
M "?2'3+U@I>Z"E<*'X!RM</Q\DUF8YDSLW1V0U>F74^:-Q3#ON35R0$GK+#R
M1L>3UL(54B=":7UYHF8P6M@O :-<+$$JY#TOD44^>NPJG(/:,8N]U<S'E6G1
M;"DBT*TNO+4PJ$4(B1JOP2M5$D"BW##W@]&F#NG$I^>7@^&21IJ'U_J[Q_2
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M8L>(_VR<)J6=,KR*T[('4<8:8IUS0A:+4$X2D[6_R^RL!0W.-:S%+Q*=YGP
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MH7'=2$ 1Y6*IU,-(/"JA D],UC39U47>$!-OA_P">%"5X"U%\4Z=S(@&)L<
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M2I"6,(VIP^[G7VVBRW%J'9!-,'2%VI5,A[<D$VYQI23P]T_LW=W-C3(>  "
MN07<DNQ]C:K^O[?-'\O_!5!+ P04    "  .@F]4O&H!&ZJE  !GN@  $P
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MA@&5*F9(KY=;Y"729AU+!(UCO[Z@Y:BG/]%STT\-MWTVE+7^(AB2D72[VS>
M0=D=./M"VN<IF4;O14.C^H='08V.E.3J#?>,94;_#VB\]).'VG[!([O;&/\T
M(3C]Q*&RY, KF?DM\O8;H/4:>?O%M]7K*FI,PY%OX@Q;D 0V)\WB>W5/G^GU
M_Q7^GX2&?W=D]*>3DZ7*!7H9#_RK#C:YH0;$3US5DGP< ^TP4O7VN,E"DLQ!
MJVD99/CE\SS2%3_BLT(W .+R'MZV%6*63%KUVH::ZN5$C1X+E@MW\&W0+EN-
M>V9IB4X& KOFZ3A2W-"GGR++@P?5E;>2R--@+"V'/_!_J37]8Y:Q5/]<[?F
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M(UYHC AC0C^/OX%U4B"L1/<VJTY!]Z2DL*9K!J@NI+.2GZZ_0L%L:F;EZCS
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M(0WRD$-,[,7L-YC%(D#4A?EM:Y^H5:'(3*Y%/E5L@KL"G *'A,8 L&"I$(Z
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M9TJE7X*&))I3$Q5TY#NA(Z7&J4>3CL<^2$,"/7XF'=,WV,E<NY1OX94V5+1
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M&)8TF =MIJLJKJ5R25_;L2;8BM[*YH2VDB(S6>SAL#3M:H)@^2=OG>VNJ][
M]RQAF$AZ[K]:Z=P0^[]A-?ZKG\3_%7VWZS=Z]G\.?='3@6NL$=2H15#L/B]/
M)W.$>9'3YK6U>JQ>%%E^#*IJT_+\) 2EKD!%"R;;E@\%Y]V8AT_>ST]6^6*L
M!=/V!OBLI@AZMX2P\@9H+7W1E[R^NZ<=$FB',=$7=Z/6PZ2>Y<0,#-S_RH6.
M'_\E,K- ';I,#=('AT]""Z&MA <S'^SWJW]JP)>>7-M?'IW?\_3L>'L-;@J:
M^O#"_\6EZ_-SRQ[KPL_UHL&M'TE),YAIC<'BAH8_C#$R19+TY4M*3<DK(^E5
MLOPB84L;J,DK" 4ORC-'71*DY2"R5E?Z**SP:6.=%K!5@\%@'MP$2/?0\GA(
M0V:$(6LR[84L+?GVS +=:NYY* D)W(5X2(-1B"$)0P:9/C_^V8!O@ 6F;(';
M'[>[16<Z!2-U@X\549C1P72%HK0FE"*EJHR5,9549$(E6-A:A]JJD=#?RRNF
M"B:[1E@^B3E5=OXIV\=)V\5689J:$\[6G%1#QSW/XY8&NF:R!T=].JH5+34F
M&U=-%"NDXA4:6B.%"#5(_.,_)Y"^ H@  + 9 -@6(OGAGQ),+PDVCCGI;UD"
M4:5H)DTF*H6S;6-4^-O]R#F2I0^JEX6L^D"-*0TK=>&.6H+\>B!;9*E)DI=)
M%58;C<IT <.,TZ7EYYOBT]'R=+2+TN*'6HI4\QP.A^B&=P])F+[GVXO.0R@X
MPTY\+-&\_RZI-0[&OZSSR6@"X@_*X->7\I$4/FV\)!U8J\G*N5I;-FKL[^<N
M-B.#]YK:&GQAR>)X'VJR%,43DV: 7%<..R9[_.*S6,Q<(8EFX28F%/P!;<WX
M*N'T"B7"<^&I%1K-I ?8'%_/!:+?S;=[IR.K8LS^3EM5\19_78F_1?U3&.CD
M>Q6\HO:@34IDC X]/]"JHXO_>*6;[PM2NLB,<5E[7*29:QJR_Z;FXYWG(^VW
MX16<):4G,I?J,>LO''DU9R],O@6>*6.9,;%332==!FE:MJG:Z7<6M:2432^:
MBA;C"WM$::MEE/98'*DVXMJ+_ &6CU?J#P_'VJPN;2U"IU@PR&(Y1*/-9&IZ
M/RDP>X7*^,R)80G"[0^1ANA"N>.WT&D1VDN0%_J\D9UR*+&0T;*:P3/N&MT^
M"1]%8KXW;?.$B72I%N3M0H&!F)'PBH_=C=ZFP?ZW;R?NG-YKY)H?D\(L0KPF
M$>8Y/)EV$M_"N'X'^;P:7P-^(J<E"N1G8'&9+9=\('/K8^)K"J0O@%=+W[A!
M."8WR1EF%?WZGBWQ(T'@1QV__8E;4$CD:U)O" B:B>9#H2**,NXI?_@>94"2
M9] @BB@P0D#/7QOF''?L-@S[PJ6-W;Z$8H'!DCF43N-J1R<Q0DM()>$8O+Q0
M?(U8X/ ZT.%X U<TI7QJKN(A*(9HZ_ITP+H-T6SOUG?1;9_-N1$^'H^$6=N'
MSZNG&*4QBJ:-*?#16:$P[U;CLT#*=XK>KX],[C3,=/.J&Y5+A\Z?#8-NIA.6
M8PHFHS0F<WC@]Y.^YD=707A\RRS?]J<-%T0/0B(5(3+G>0\9Z0X+S1NMS.*X
M@>GZ98F'<VH=\J+IXZ&1)1(R$V1>02+[G,AY,"O'3+]Y-!IC=>0D?\XH^::3
M(R][UE)[/3O_'&^UMZTP?QD"9G+WP@M] LB'6SYV1"FI&$I&HI<;^U"^6MJ
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M!^:3D^).^7Z$O0_5> .0-'5;W^7SU%%.^5D-[:ZPQ3GD0&QG"923M,N?0HS
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M[^*LI<I@ABA<1"L?2>C>YZP7'WJ#%"T;8C+D"QP:G,U3<P24M=T2-U7?ECH
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M#4UP,8#9]_951#74O.V<*4VH/4];DBBMLH>%DBA,-83'Z_04O!OF3(\7WRT
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MZMJB.^TH8V(U$,.SU6/(ZAT#*.=T/GC@7&BS"B%?.KMK9F;Z5%=;5A61;U*
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MU#/A5?BN5S?4A=7#>?E"NTKR37-@5R-'^A\K1R/[K\:3/G*2JLY*+P#:HA>
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M9"RS]N H;N%W2.'O>^E=BY*M8</)/'FZW.2I4/Z=X2,L7:,.?8#S8%R0,HY
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M]^U*[QO34NKLS:WDAGW8HM.1F/&:M8UKOV_I#-?/4>;2A_"W%1./KRX#=1F
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MVS3W(^SOB!='-0&L9-;B2)M:\!KSS<5AVEO''T1NW9QFD8)#[YU':4D%EV:
MD:SVMAPU_  ILYX;G+%3U8E"P=MV;.J02><YVZBN[[JC(K%/6U\@R^_!,.10
ME[:)3"\8T237>"P.O[=+4RVBT@AN-')"^9+'SP@BQTT6_FSS<LE?+Q4\%D?]
MC<(4]$DIHQ>6MFUL(:\:,?*!TKXY'6".*YXGC/IHH $__ZAU;HB>C[V:1URI
MJ2P+;$7[],TYRZE<@&EV-DQS9L3][@+M:>7@0_IO:B!OR2QY+$^C,HM%Y9X
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M"X\?'2&T(@N[LM*:V*Z,D=WCK*L.A#\B%$B^!!V?W8J<GUQ.ZL4_B)/GT)"
MY.)3F)F(<FKVZGTWA6C[B!,#=Y._T7RCV=W69+O>E5&IR#RJJJJQ),XFG*S[
M9V6]_Y/%UD"&\/E&;X!.V/DG]=X(97]Z[FWJ3P+9V:36PSFZ_R$8T$_9="X]
M8:*^27VE2HTAQNB\X4K8$WOSV'$4"ULXVQ\0(!L+N(6&,!O1!FA^5V7_:6:F
M.T&<KLM8F$@JDT\R3DQ&\L'\*O\Q-Q'A0$0(+5 NXOKDY/(6M5\UD'HEL&E
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M67'U(].7Y86)01YMJ1IRYBLL:S10BGMRF\A[P(/T(''GQ8.\SO &# FF9=*
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MA.WM<@=IG;-6L+Z>D1TWO8P<T\)GPZ%8S8<8?1E/WK&Q##6UY_WB7',I@Y3
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MG<)!PMC0H-Q!\P\ND70=_B%%X5< XYH=]%WW-R^MAC0U:)I;^1D.C S='C7
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MU/A[SA,77YF@[^[DZLOAM0_D()IXNZ8X"?$>WI)U[&:^CPMVXD2P/R2YP\$
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MDWLOV/'7%Z5C8V!5Y9/3YWS.P@[=D:PS& ^EDU?U*7C5FZ\=)2B;8\.4>,2
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ME$\'-'975Y^&-QC,4M8< 6EFEGWPT(\VST.D((7CHE#L&<X<8;;%_5T#O\L
MFL*52[ .]<5I=N6)#5Y0?M+RF[^4I!-Q*VTK8\P,+3(+1>19_ MI;X_3FLQB
M"],WW>$6[5K9[AGQPH0NF2UQ_=GFHAWS\580_@*6#C(E,3F)L:US)_\#CG@>
MRZ255+_[_1 &YV]LJ2\(DG?S)\?W%F9UC?<M<I<6TA02I/O6R&FYQG[+3V2$
M[D@*7(>NW)W,D,_<.9R]LA(5G?'9/_]P?SO^^*FXB4^8^]\.4.OAP3 B7J/%
MLF2'Y6:&#K==3^1D1(HHU.))IJJA4B6:%/KXXF]L.&%TF0, :+Z1KRQ_ 5SQ
M5'[GXY,][3-G"I-GI..02O\ ^4UMZ,J\3[/M55']JTREE0+H;C-GB1,;Q23\
M7L&*R2$UWQ!QX-Q2IT!?"SBO7_X"6GVC'O_$?D1^"/.K'6/=]$8=$3+:-F!M
MU!?J1L6P01_84K+<OX[;4L1(S<?N?I?4<5ZVQ0LI1E!*IGN-%L>DU!TO^#]L
MJ&#^\U+WT<2OT+UJ5@<AYG*[X4'>CN"O_<XT95[\:LB1%.^;/&W$JRH,*UMM
M!9U;JMK[C5(1U<+TR EJ/U\@N57)W3BHR"ZK.SG$'G4+FS>^W+C8/$V275K;
M\B(WS%\M38E;!9MHM]1L68Y6<4Y3CA.?DU-4+^OCRWAXYH@&OD 8[4L#MTHS
M\-V&$8:6^F A)BNK?HQN68TNL\[J?';OJ$0+D\Z7+S[1[E?1&9PF (0@J=L,
MCU*0VI^T >+<:@XAL[ "FF?&2P>J)TAA8[/G82U*4L8DA4;2Q?^"1X?GH!TC
M2)RMR@>:)Q68L[-C9SH?;V/6EW0-MN74]RYF1!Q_RX[PT]8Y;%^Y3HP,<KM-
M$C1-%=/K[>MRI-G0E@OU-*;D",MQ#PX("4[&!MIBM@1\BG-61:Q:/7?VW?B>
M@Y,5L;RB7?0;$HUDT007EP,-AY*"Y%#@D0GU*=USK+-W]31:MRN#*T_8++$<
M8HE7Y\B*XB#.U)]WB'O>CTH"%7V Z$>T)OAN=%W#M%.T]YY>WA;F=%[U #O,
M8463CC_!6]X6%_9]$DN"?[XDNK1Y(KLX!"@^P30FT:/YHS":!D[P9R4W3QMD
M;]Q4YZ0N02O&PD]V6\&HK >GV[3;S(&Y*JR]2U8*6I4D]Z9885+^L#,>N5U3
M^_3&4(7-OJFCLS:'P] =%:.6)1PD.TX(FU&9U<(E2AE@X!=[S+_B?U.-$7WF
M$P.1-,389/&?M><A,K,T)O.]-3G<*[9+C04QA2X9]),.O3"DX4WPL*>].7-9
M,:416N-]W8U^UV-.*HA0PM+NN%#W #T?G7)::VDIB6D=Q$8--<'D3H?JRYB9
MN8RLK-Q+Q6?:S-KH-9ZT!Y;Y56)EJ182RDXL;*C.$B11CT_LV0=X'Q [.L/,
MW>>7+'$5_EPX<X1XP0CF]>JU-92#;">K3CBQIH%45(;K0.S6-3C8<R5H9GQ$
M7HY)>7\IR64EJD8A^'<-^F5TE5/>N,\N^$*;B\U=V6F 1YHZU+F.(Z$U[N(.
MILYK!UB;Q6PGB/0;R$%C"?\/O1$X5!+!1")^^E42*,9F&QZ01O/T0^[0L;2#
M[$>ZM3KKF/+)VJ.2:!5$)*N(NI7Y@71??KVV#6W'J,XMW'X>9802S*09YT8D
MM1Q-9+.@E!KFH7VY%:*\F;4!RZ&,J#A?7W,9(V^.(#N3M7@OGV_*[FMWT:[=
M.K.:#(J2]&VQXRM\2]$]E!+^#=^9Y]R4"E5)@7>AL:1X>H=;\*!2($]<[8=H
MAMC%V-L-C:3>)S#632,884W[%R#E5%=0;7Z*J+GW9U..F-TXW6JRG4< PA!+
M??(0MX6J:6AHC]]V+CF.B^.&IH1-9K'.8\="$\A1+3:QQ_Z4 _T91K^+T((V
M4<-N#&KL 3H%GN'FFSG)T6R(8#<@]@B!EMF=._@;K!?2N#AT1QB#HD5<^=&#
M-[K+Q%)B OM4_]@/)$5P-.M84WTWM8Q'62KMN>8&3_[Y4!LM49YU6G+Y)I-^
M\3 <_(Y^;VBS%"W7@I9;FOY@YTGZ@J):()@I^S,<R$&S(0+ML/HDH'/3(T/6
M<$FME1'%IJ?]S'P%#OR<F2I4BUHTJ^8B^Z!!?3M2IZ;'0+1GQYC?WL!#]+JZ
MRA1]46)0<N58=LP!O2=&L;(HWH^X;C(Y]8-D_#WJ ,'?1KZ;__*NY,3EJHVE
MM-=A6Y)<N4=>P9]C2;_#T.A\.[GF*:+<C.<(5_.#/GK>HFCX5MG +W2>NB!B
MV$SQ80EK'M*Z^ 9#O#FFUALCV)6M("-506;*H-S,G-E<-JA!)<[.!F8V2;!^
MY!Z[U5IV<GPCR-E#OL<3-3(W$V]+[$PCND1S4POW:HJT9G.EWM!X(*=Z1=!&
MY@A@K*J&9-^79!Z]6"6V02!RZQ8I<75-D=Z,TA!:=GRB=6+H?9ZAI&9,ALY8
MS2/5Z%=0B,-E<WV=JR>S"GV?^:(?J1(U(CFIP>3695YI[5!CN7YS@X\:WF[-
M_C#-TN,-#+NGU7NNQW"B_K),%?AL9<""^+0WHIS7 0CXC5;__J4GBH+.M G<
M%CD^-%HW^2%-?K4]JK+L)7!(NLMCI Y>U<]:QL+/@>:RI,SB2=%O@."U:!;J
MRDQV6QPH$'^&OSQ0&)W:X:0,"H2IHN).@6F3:^^:R;-U9P)XG3^@"&HHS8OE
M4%M/&C6W3>07 K4MN+Y0LD4>^G]9U<5(JFOU7]'R<A=$+M?2<V1N90QIH ,O
MV5%K* R#85$Z=.&RM">^-_YO(++UWD*S6RSUVG8Z%B37J5(^STE52IYDVF[I
M6$.4^8V^*:?88_=[R&[WN[D4KF\QRR?-5 8JR4@<D$2?#0.#\NU:=@AL^G!B
MO&XZ[;E=9H'&X&XA.3HUK,NI8:WL+VD'3U2W-@\]X^^;+KJ&]>V<&,_'46J*
M7^=<.3[/UH^SG 8?N2/F#O9^FC@ONY\B3W[OA-0H6=5H548?M!-]CTOHEBRL
M9EH;ZEBSK&YWFN!_50=N"Q+P*T9Q/_"_)-CXAYXO'JV9-+_JS[EO:]]G4+8!
MHV+ -?K:ND!3U7MR'B4X3!:'+Z] 97C_X4PM(M/JE:,N+:LNS654DV"8-I3H
M\\L(I-*(0!)B+-6T*7(/,7'I@4[Q]+5_P8_ESS-Y#36DGLX)&VD5FO8V,_+Q
MURR67^N\MAR7%[?SS+XWT,*6A2#[)IM2RV9Z.2\%ALH<P'W:Q:M+@P-H\YFS
M/[^#O[+P)XS^;!@]/<_=V/S_0$1672**+PJ.7O$?L3=0@VVX:[H.=<2*WM(/
M00+1+7/96IY8^*EMMY>CISG&5],S5C*F6I,4H3)(7/2(WLK!GZ\?_P%E_Z'7
MCQ02F3[WZ_-G4(#/6X K=B+"= &?7:!<ZF_FV2[YYH6J>LA/T]$AT&@;I;AW
M387E(KD)+\LO9&19I2D!F-[41$/%E@P&Q,P?$N4234^SMPGW3%LM_Q?CR.>^
MMK$G=<5->YYIKYS4E1J@?N^.CT/V]2+ 5UIO-X,.E^ZA-E2BRV".UHD)&&Z-
MKN$3;,E4TPR#!:"<9V/U9\.<'H'2M!UX<^!Y4"##@G.UZ"!7TF(DHL$]OBC^
ME/SG_/F9TOV\,J-&19@S>\C&/0)I/WM=B]U"KJK&Q=2E;.8+(<8G49+(>V?"
M?J/4^8M<C\"1C!7#7;\6PWN\%N-V=8<9>F(ARPC^*>;H@>T.A0V-N ^PUQ=;
MA)_8(_2)Q"_54IH\BCG2ZWZ7B.M]YF7U?W)89AD+@MN-P]4:Z3[A\.+E^4K%
M[4/>4!-1$Z8GP+!,Q=^_,.AMS__,!EJ6\IX9!SS\$$XYB%XQ,4OYE>\O]!>
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M4]-$@/>J].O*CNC]98&,IAF_.GYW9[*.T;551K.LP>6JM1L;P\Q*Z8GI-N=
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M_1?*XS28%?ZCKT%<$=M]SA!@5K9G,M8G/*Q@N"DF562;'&O+3Y B>XH"K:3
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M  E'N_);G2,9AF&-%&=82$2<=:*J32_G6WZ27_!&AT3,S#>K-)FR"7EJ^
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MH>@Q.J4R@^==FOJ 7DKIG3H',* WSLOZ64<&]Z#$2 Q0OV-KZ,72MK"43.8
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MR9&+C4?$HU+O&0CYDGTGVHD.-=UC5)D5&%V_QZ(22:S08%(4XU\B84<[]R]
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MF*7*([+*)3AYM9_Q^ RH.<C:6SCB'G6E]W,H>H&C6S- (U67\!%8N0W2X54
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MO_;!%]:$^[6<Y&<5.+)L4]&N8J8[X/77T?85C,6URK] >V^&W,OCAX%V@LI
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MLMH&XJ(4)&:0P>&1\4XB<8:=VLU-S2=%0W:*BDZA76H,V3+<L?6+:V1S9BU
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M1]^$1,C^3W_A6=7W30]@>IE+^=9.626F9EJ#VRS+E6X9+QD?:=QHVJOEW%
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MAD*T'   MF<7Y1#- K.#18O54JK5$JK#)X 0%.H6!BL$8 W0-),#@(!'"4
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M[D]#<0'C/7,HKL/W2V-QB=<F;Y247_685R"2BA-CLVIV(95O24P[)6U;U()
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MEID*#6?/!]V\4#B4]LM^?K\V*9A.1I1W_P)@J^#O#T]?!TX4OC;V3WUFJ4]
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MH."0A[OPW.+BM)",]-764FMT/DF<&R@N<:8"-M8!"RND?J3'Y"I/W9^NN6?
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M%ADT_[2D%%]9\YE\IX1AM'?D9V!4FFB>JZ67IB>+OI-KES@GJDJ$Y<22[JK
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MPB6=:RN #4DV,LL6JU-=HYM1[$+*K[!2LK3)P_6$#8+<IHK A-?FJ\-Y'?-
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M;E#)Y-=S*S)'ZO!GZEO[]+V1X->],T3U,<3^"3T('1Y4V2,@("!T")0 '.H
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M6MT84H)]/#5$N]<H0W=B#506AKHV,%Y0H=JVYN^8'YX?Q/@X!]"Q%:MS[;\
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M[_Y)9N7/[0DQI]W]LE<36]J'FE:2,A="->10VVJWRYNYVMI@;8Y_*-*K?FV
MHB/D/DKO2 K&Z,U7!7+;&=*>+\I^TY?S;W<E7$KLZ#OE3Y3N'K?6AFWB_XJG
M7#<XQ5^\HH@14<@0WNB=O!CII]SBE!/O(CHPUN02+ZIBTX9&,<PNR\OQXHUW
M@"7T"[ /O1^KCZ3PRA!]]?P+4 +=S/NW85<8R5*OKX;8M$:%(H<'=QB,>&GY
MD!7_O'-?A &IB2ZY293!$07A-6^OTQV+CS0A,0Z8(&\OX'2-"P[9,Y -JOE1
M#$WLQ/N,S\1%!&';0BY)FR,*I]AK4LHXO@(=S6Z=K;P C+8T4 J]1%$$^P1)
M&;_/$ 77>2D5+I9 C8/J.C; _M[Y\N*\9WVJ?17"9DOS$@XU)F*]MTG.:U T
M+*LW[D"PHE1R#K_,4Y%&WBEI&-05&0P;X'CZF.DX?SKVXDYY?#?R4YN3Z<&%
ML(GPITX;CHJMNNXZ(ZB%T0YE:C:Y++"D7!-?9 G+I6Z!%F,V2FMJ+==U)Z,)
M#&/NMH"0$A2?IQYOB0\$*F!BC5?$ ,")FR N2"L$]16@MY7#M;%89RRY95\4
MWHI9_Z"P%E(E24,<60K78*K)(P>:C&N:/!,C9$RXK:@1'$D"I,T,C<B'H=8K
M%D/E/H&ISA;>FIZ5;/C*B1,5%$[EMN<'4\O]/0#*LT4'P0[BO*M]9]J9&'4Q
M$S]VM:O*V5:YLAX5Q79-4DP@RFA6;)9#LF5A#HZJHLUNW054%S/;*2.2S2DM
MB_!9TB0&$AGY.$#HMRMR-O@#2MM"D(RO4I#/A3@S13-0<J/I.^+Y2!LB8'5G
M:?JJ_=PZ$S/+VIN%"(IK=+>5V[BO2Q2#U(QMAUQ,M IP0-TE*.UPP6V]K\#=
M,4@:2,XIDX.\710.#N: E"$OCTFZ9X*H%8A&?V9O;!R/LXQG!G'NC<K(Y(W*
MIK?Y]PY*V2;<4_MC1%)7@[*O25@#XLA>R/U&-+Z("!WT!BVGW48.D*PBLD5U
M+L_I!J*@<7?ML^Q([M'(UVF[" ,E4*3.;0U*?)]#0RYC"P+J$6DQ.3D)C:',
M%(ZYD(NV*?+&UN]GM=XRU_1&G9E12FU-7XOWK[]*R$AKDHWR&]?(Z^ #;G4@
MJF'8R*D([]BM#:5LVR]2%IAYE0PBJ)CJ2>[OY3D>J<4"I,M,&*)V%+/<8)-D
M57TZ=I\%60+>MYCO)1[3-N')!^%#/:_%W<D<NRX..";=/ \0K;D%7@ZZ];OY
M R %OO!/ C0@VY9(^TF,X\;%F VQDL+R9T\?9.2&8$NT0YKUOJ 6S4YBP>#V
M>:UZ0%I)_, =95RH_W(P"?]#55,L*C&4]$=YJ-V\DN00\5# $'8:)YG+K HV
M\*!V7GH92+\?.,DFN6QDO4?F>Q[]=2 D /$VF]P]B\S(AL&[P2,XQGL%V7%"
M?'B4+*/77>NP,P N^IUGI+!=FK3>1)5"TF1>2CCIN#1]C((;4020M,<M*FV4
M!EY,'08-C2CQB;^H&M#4&PH* HYB!,T)CNP,198WMJT@21PH!(XL5 =N!DW&
M+#1=6J-[Y$M6:D*OM%KRY93 DL;>Q;RYC!8#L4;!W\3#^5FD/<L=!(MP1]69
MYC4OV2?_$ .J9ZEK-SV4N[8^J]JA)"J5%2 97DT*G(PBZ#TU=6"$%%PQT%J2
M//X.5NRP[E(-&-'VODC-X8H\M%Y]/FFM\_&8=LC$N=@*F?7*IK*1PA"6M!E9
M]U0R]O-1C:#0(- &BE((]*10IV%@$*6I@&$C4H)A0XK*POLXH,$[;5::2%08
M7]B)K(Y#@0UMK1U66XV!#W'*/2Z)O6DF_J1?NI*IUG+FCKK53:J.GW/.LX&I
M4JXV[7OFUV_2[9-/U?'!@F.7C3]>J.1P<,8O*2D^M1P83(!54I[*'L3DCM>H
M#F 7A-&0]?VBMO.3LLS75N P<UYUM)V\/&1S4$42N_<YO8,L"!>N<KK>^?M'
M;=?@D)6B"(TC^;CH'%VF! G5SR+KXK0P H^O*<(XA^T?)VZ@B#-0#)KU ^(:
M= TS-8:'Q,5I38EA:>'Q=@6:T*.2AV7TDZ]05:JJ'<TQ\:H=W]!YI(N=L <)
M[(W)#8U7E^KZIJP#G'5 NL(XP4T'3?$3A!_&T3;1HQR<R:,'8XU#8JPS1#(D
M0*%I^=J/=$GJ+6M?3@TMWXT]E^X/KL^)+3%?*/2&E8.M4=<QXVUWK&]1[$D+
MXF.LUB$G$LP64-F%T.-%"^58T3FD9>>>90?&E1<%]*GC4G\N2LH4)E:Y;G;?
M2'FW5.^FMR\A(XL2?X,V@+<&9_&,AV36C$)IGD0PP+0 G<2!@R!>.JW%X-)8
MW==")6W1#[5*Q$[CPEYT1+Z.BD<\D2/;-9ZQF\PTZ>\-XQ3[-+J[3NTZ]M@M
M@37R./*(UW;IZ!P+XHXJ50N OP$@@$8;:TPOLE=:S%2!Y+J#&'1$#9K\)?3Y
M1_8A%L:-=?GHCESLWEKY0I_M_"4,;V0663+98R^XS+J"M-T5(-S+%4"8)O;V
MZ.9PAIN=9UL2N#H[*)VXR ,9.B@O+,&UY-8G73,N%SU:XN"ZV'"A)5A>.+<"
M<XB9"08,379'9%9_X%C!<2F@X#NKO+!/]=A-WQ\F;^I@)[]J7=SEM1R6DP*L
M^SU51F?:KW,[-GN U7XB+.KLCE_ C=4ZK5CL[)$44O%X+F=\5;VM:.X/EJ(]
MZWO%<]:M>@P?25+UJHBX-XD+8H:5Y%,)9[#STM%[\_-!!R> YCXT]M8.)4))
M:5G0T1OEZ(!)R=XKD*NC4\U:L7U>&OM4@_;)XQ@ZXEM66'/IM-]-!Q9]0S@E
MBE5..S6[U[8[C N+?'TV%);K.;"F3A]XFZNM_$^ST;OY"PW.K8K@J%(2UF"A
M5"2 8ET'*7*?\GPBLY($,?+7_MTUV:]+>2(4H<218QI-Z[BKU]QP[&JHCC<,
M$9-42K)*3O6VTGD+=$[X6Z0P&*HJ"M"$ .,T7^- )I\U1GIWG8--?=$84V&0
M>>K4U1GI:%U+W,A4#.[IQA*SJ'2C(6Y@&"OEX#AR4,3OP$P,VI NL>I@" (<
M\^7B*B#,E#Q+)D:"]%#K>3G>9X1RYTVU:7*J9:-;A!<9,?W$B1/R05?TAWL7
MS%H\-K? T#>OAY@HE<J"H])T2#A"F\DSE).ANE '*'/JR.;2;-G=11;P!??I
M?4F85/JJ^+JN"[$S=]NL^Z:++V&C(GXX>^RD2[A'3(?N>(Q3IVX;4=:L=JO6
M7&FIT,GQB7Y3)ZN.?:"6F%)E>SNC@/0L%-&8<BL7%C'T)"S"1AY<4Y^U+>"5
M[;J])E3T7;-N.>B.LP4._F.(?%T+_."Y<XKZF5ZNK7?+AUU!C0O@"F6%051N
MAYAH=.?NA #<Z^X*Y?K2PX3XBDRD=->G)FU[Y/5&=^4Y2-F(J/_:_D!?^](K
M)%5 J\=M(X:"D8:ABC2'<J@WT2U:9QUOJ 1W[8JYNG.RH$$0NT%N8K\_E3">
M1@F4L;R2MPL79.+S*'DFWGHSR-+8(G?S@'D\Q[G*)8COM!U"YW8IZ"] I+?>
M P>1U;W>V*.Y(E(9AO_2UF>5XBP>=S^BC4?]^JM[K] :663G.H)47/?#W9HS
M5/M$IY_\%Z^F'</$GN;+M9A=P*5AQ:5>OL]C,O(%\SZ"X'0;!& E>KD"!2XH
M5R=3S_%;7*;9YEV,SK>L;2W93'9$X=:G/N=%K<%+X\!'+Q8EJT15X69%ZL=R
MROWF'S;7?;"4*R*4'6Y^P_[M\[);L.3S7K"'3 F$@0[CV9HQ:QT=WN_&?-'[
MZT? QO:'$9WE3XX;M3UT\1DW=]X;3WZ3J[&N$S[UW^0[B=T7FVM!P[_/YVZT
MLTIFHXAP0=GK<,5I%%_@<H^7(.]N8%\KG-M:KZZV:F1)MD)-$FN@%-UQE[N'
M EQV;5HS ^QS#';:&CA]3Z*S,V88;-%'H4Y^)L][N6->9HR!:3A7K]682NFC
M]H%)$. W<P?\("Y1$X9@3NIW:IO:I=,PK_;*LBWQL])]A'(G20=LO#%T=9@M
M UD1;@'XJ94/FNTOL5<B8*>(0??2YEN$_%ZA=1_YQ 3\>F#3OKHB5&'W^CD6
M9]U^L+H? >],OP _(19DI&S+!E8H*$J,YLE=.GWFF*V;Q;Z&O5#,$-2Q#ALC
M+U_$T8[&36&WLE82(D- 1:L+#I%D<_Y,KM_>G83Q#4Y#,GNO^AA]7G#[8;,N
MD#MW97@%=94RG.NS.]LS+\AO?!5[MRUXS/3=M@5/*N=]X#>^H+<XH5C]2-/Z
MJVLBD%,]Q(*YCI.KTZ6#X>CG?</MG"XE_1_1G^_/?P$*#\_.%?$7AS9+<>?V
MRJ@_0;HUXC32>:J0R__(*X.1).1ND61-T*S+>99"3KLD32=,JS6[!L-GO75J
M(Z,_8^><QML_./36VXK>H&*&:6$K;;U'@)FW8JAJI)!B;B%8:Z07'CM),Z^H
M0<.OK\%8AM^-V7=-)\Z/K.Y=N.:E0%<9XJGBR9R<( W#7I^ZVH(AW=.XQN\J
MV5 C[PD".7"OIPHGM#W?S)!=X_1BOCFE*,_3+(\R"2SC$?^8N3F/R627SSBJ
MA_T=W4:2YHF.-EU!28#/G:1AKTC +=_.ZV_NYM!1K(\X3'UT8W7=C?/;?5*T
M$1_< [W->(:P_/T,Z>S)MTAVTTQ6<=VMKZ\W2DA(\&0Z'LYWM'%=.H%^ %K7
MXP!MZ[4#IQ$3)FO\<[^-LYJ$MC5@BD@.I]Z*-E_-L#RMR8-F!Y]_(#:2>H"O
M4OK+FP_48[< (05A=P\8E/L %*' 3[\*O)[IWW$V;T^MF]<KNKGS,MYU4N)\
MVK3F(*4T1H88Q]EA?)9L[.KG4+G"-ETJ<$'-5_0EEPR,V7N^,DR>/6Z(V@!]
MCI7O+0$<W0_GT>,>>@\ _)^@#%D=K2W=0P_=WTRS*NT8LM6X,3;E=%O*4>>_
MH2S.V"KY,MY#E1;8V[WCF"A5R79(=2P9ZB,)DB(A6QW5J- ,BLV2.P#@:I$#
M5]:R^&:%%G\!HFUM-B8FGU:T6P_PK!TVP+/Q W"#JMO<:G!M(WOZ1A4MSQA
MB5\._6,=!DP5V*0X%$?;/KDXKP@%@HE\B@3_*LXF(+N?0R.M(!G"#!*R>.C
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M-_N/7X@R,7C@"BO': Q9)S*]T):XJ!ERI(GRWP&5_R<R(;VR#VOPXPA4_0*
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MLW;%TA:6C\8=M'J%\$!#C.J,9!YB'NS6N9A2W"'+""1H6A_)$E;7!^=]*40
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M = P,=#0 /\:.&B/L''1,;$P\/ZL6Q,# %@8Z!@8&(3X.)B/R   -'0,3"S
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M:DYC]13$@AR?XQ^O-19[7"IU:@L%TSL(L&[]5(T>[+'3"#[JFVGF(Q=G%ZR
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M$]R[R10#1NAY[!!]0U?MP*#;B.\C9G>+;3\? ':H'SMW\8JOZ$05HB*XC,T
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M1]3L >!5?$\;W&.1[*]J>"AE; %I;2T-"CA;WNOSZ\YU$-,.PL:?>UOE"?A
MU.%4="\2N/C\IH"QRX'L#XT)$C*C%1+:KNO!X^VT^5]N.BE_V\L.\KZ+DN'&
M&\=R29:W6UXBL#XNXVA^+-[@CT3>KZ8\>W7'?9X8$RS8Y@[N2ZK$6D^?'_U!
MHS7U\<-]YR4_L5O#W0?"AL64K@[@&\3R3?*?V/U'#ZXG?60[=USG43%\%:U
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M;0[^1./U.^ C+?[)^*_-C@6R*7FI<YDK_LOWY^-$=X^#->X^RPAC=*BL)CP
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M[Y@5^[6Y-MKQ3,Y@8"&,,##9BNJ@%#G1=.;4;=<G#_&>EFI(_K:E9OPIJ;3
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M ]<'UP< _(4")/\E_;?H7T;^NS9@_@X L)$ 9; &<##8 %AL&#ALF+\C  H
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M=UNJPG!VK:>Y3"?TIED D":9PHO9XUNCKG%"4=&[ML*D S8NS$1=ZG)/%<O
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M8 ]9;O5=58[/MK7325)YS?--&C0@K'XTZEF<)?+T@NA:?#6-+X')54/-EX]
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M:]G&FG&FJ^?4<WOM_KUIJB[(TP!L]PF >PV@$;5JE!#!K'>2NE#FQ1P>\CP
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MVP60K/+C[-F;+3U*X;G:AB2&)V!F@<H&$4[5V'%N0(V#G?QQAZ>]69'HOK'
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M"OSXK)4C&E2X$!QW"),R/!RTF8Y&;5XR]B-E]G+V&_<I"7,*RG"?UL>@$@D
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MDM5:L3R5Y;-M))Q8D0%)X8J\<D2F*/<QO-),0S\D6(A2^HP%0*6W+'R IXD
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M^PM3;K><I&Y3G*%I4G/C.?&<>,_?G2:UYG575-U=5=3R4;JZAE.Q8$;J0=B
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M-18R6EZ*]0^HK[94XZ"2S5BILLBB2%*\\4QCEA>2M8BD,KUK4+EMV*DA@"H
MVU]9/L?>D'2N.]/:O5]VK@<UE.IJ<M:[/2R=K-XF_CQ=IY2I7S&'R%:.A3SN
M"NPBFT=>.583$\AD>68LE/U(VA>=?FAIFMV DUF 7K1EX-*GSY%=-NU$S&L
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M4M=ZE5ER&01XDAH0W,D&HUW*226")D9YUA:&$+(X=='7L-N0SV"W1L'<=@
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MMQJ0-G>!-FD5"S*"-QYU]/9?4#HB#$Q9RQU5@X</+4P=\9"7(0QPK0ZEG%;
M79 S"2"KEISVJ<TZ1I(ZR -M%(5M?J@&+TKZ]5-^P5=%U)7+?.BX&Z)M:$;B
MM;X;5^R&H"XDYFBI="1A&RJ7/L;%5(X @R<MO!(4@QB40E0@KG4GI9T:^-H3
MFP8DNWL?-:KRI:GCCL 01688K->P$B@FB9I4?B@<QQDLRJ7!^.OVNO6FEZI]
M<18C#SS-A.DI+]!ZMS&8-9JV;IWKF-MV,=U!C9+%W+87(5X8;U=9[GPJ33$Q
M1,5#IR1H''[=ZTWGK.'71].E:J['&*#JBSVVM;AJQ E)H6HM8O[<+N5;"GWK
M#936Q8=GI]6<.5N +>#>4"H0VPH6T6JO4SH]LOA:"0"!KT=(Y&21[$KQU(GD
ML.3##4!2>::""JJQRK(4+RM&^Y.K']E;UAJ^D?J [Y.>[^1NI8*N)LT*%/"L
M<AE&M1U<:;^5RYBFQ&)I?'7+EN:E:A$DL-9+2/$A*5%DM$[F#GH]8*ZPNL"P
MRET9I F2#F(DM2=F--O4&'.5[,LC9UL0[C >$1=B2Y#R'XZF&WX\AMKE"7#9
M6&<5Y*%I9B:B\#$P(:\H:HK'V1K /YM'*NWGY001K[3U.ONBKF.DRM/JK!6L
M;$,Z3=AR$#0O'TP[Q9^6$ABUB'$21L+LT"RQ0KQ?FR.C-:5U1T*4T12;#;[[
M!C#-D;#$3 (>O3'[Z*M--#Q+':*==!%NJ<AL72Y[1%(ALM73DS-@D0Y*HLL)
M&97E!F+O3TNZ1M8XOFK\/;>19HH%,MF&S7FBEEK3P6:A"12QLF\B._+B_$QC
M=2P^9WVV/7C"]5PU_3?I7)"[4JV,=D<Q.F.P63P^7Q]['T<UB,EA.H$DM9/'
MW()9$JVJD/P;2US.EG9&6*7.W-TZ^<^N6!'3%9,#CX C*$F1,IJ:.(PG5,R8
MLEE7N0XVM/\ *E:%84VXVI3;B5MK4G/A 8%2 01L0?J#KT$@@@[$'<'\=7H]
M6>U8?=HMJN6-<01LH;'\RX2<X9BV)AI/EPH';5G]5S&,97.')RI4;/EYGW1L
MY^#:K%8Q?,OE#_"I/T)^HW]CL/Q\ZKX9Q)\K;!OXC^K_ #:F,XCWMK1G/C"T
M*1G.,><X]R<X\^/V^//Y<I=5&M4;L-Z?ECOQ#7 "^_IQHUFT_KMK4SZJ7ULN
M6ZZ9<A8"VVHJ!O59N5(-M0VH=A$'HKLFOEXL,Z!GLR8$UA24-2'\9ZW].UZT
MS/Y:JYRG4CDK11FO/VQ-&X9W8,))X3X9RORAE(4.&^8JO8GV?OM85O1#HJWT
MA:Z(L]0M8SMO,)>@S,>/51:JTZY@:%\=<W*&GS$@E7D).)0%=VBQ8/3=I54;
MC/6?;>^P#,QQQJ(X8Z0[<&HDNM(PMQMA<NQ-8=6A&<*4E'NRE.<9SC&/OS$!
MZ&V&WVZDQQV^F]?_ *YK>3?]T4Q:C<^E=\?<3U17V^G_ / _QUW73>@==Z"-
MW"Z5&_[3V?:3>J=FZV 54GU[LVJ@>2.RJK.J+9FP7JW61\0&" &23Y>?AN-,
M*341401<*7-D-,+R?I#TLDZ7SM7,V,Y3L150Q:*(1M(^Y4\46*Q*S.0I"CCL
M6(Y%5W.M0^N'VR:/J]Z=Y/H:OT+8P3Y&[C;)R,V<CO+$F/LBR5%:/&5BS2LJ
MH"TH"J7;8D '(MLIX2V4K:VM++9R=/"['HFF@H>_#Z#;MBCQ5@T_L:]VF2.L
MM8HT0I:AD*TAKQ'4!.-CI0IH@')BR;\*2X+^H9IUAT_-U=TY+B*EFM5L_E!K
M>]EU1.U+\/\ HN[1HY5H65E5N0#(_$KR*\^?9]]4L?Z.^H]#K;)XNUF*=6AD
MZ,M.I/'7L'\H57A62.25'C/;8C=& W7<AMP%,0/YA+7']=4W_P"*OV=_Y"\T
MW_6+S?\ KSB?]^@_ZWKO[_OA_0W_ )@=2_\ M7&?]%I_,):WSYQ_-5MX\XSC
M.?YE?L]G[9^V?MBB_?.,9\XQ]O/[\<]'H7F]P?RSB?!!_MU<?7\;>A_[H?T,
M0=^@.I?8_P#[4QOW>WB$ZL#+E(IZT7$^-CEF A8M5HM=4>%O@31(#1]0:NU9
M&L!*NS%*(UQ=FGT F?'@2^&38X&0%?6(L(B_(A1M^15Q3I8VB94FDH4(ZLLD
M9Y1F02RR,$8;AN(D5692R<PP5F #'Y8=395,[U%G,U'$T"9?+9'*+ S=QH%O
MW)K8B:0*@<QB8)SX+RVY<5]A\G/=6/7:*9<[+K^R"[;4BCX@X(D)?BRF,XRE
M6,9\.QI+*O+<F');]S,J*\E33[2E(6G[XSB%E5P58;J?<?T^H^GT!\['7H)4
M@@[$>QU?9UM[*5S?5>2A68XB]"8S6;%7?B^/=G'A"BHGXF?B2!CZ_"LXQ[W8
M*W$QY"E>6W7;1- T1/N4WV#?S-]Q_B(\C[A<89A*/(V8>X\[?K&_T_IY]]2<
MY(U.UJ4_PE#KBO9IOIW5M5UZC4\W;#_8F^[(NTV,,J5;$@:?2:,2M.T=I6*'
M"2ZZ)J5>A./S2TYLD5?;1%!B&)Q,B.'2-B=#WEJQY26P\LJQI2@KQ M)([R2
MS".O70GB&E?V4<5'ESLH8BEL+N4 'C=BQ ^[CY)_H?N!UKY;WJ76SM=LBOT7
MK3V8/RS5/J-6U3UST]LG3,_66L2PNMAXL7--H&QY.PK$_ O.S+?@Y;FIE]H5
M)B7R[6A4,B6%$YHUE>8TY<AC8'GR&/18YI7LW;4%I9[,;2-OW9X>Q&&AKQ\8
MB(9Y6ACC4A652=2&".0JL=P/ 8; D#Z'<[D^?<#WW^_>N_6&H+UMS8X[553@
M1HEKFO&TD56:4BOAJ@-JH\@8N5DNQ*=A+==KE("""QJUSY:,J&P!<M.&7I?P
M8SM_LVX*M9K,IWC 781#F\C2$)"D2C]-Y6=5C&XY%AMXWU*52S!1]_G;SX'N
M?PV]_P!FI_[JKW4K>IG6NJ-/]N2@Q>LM?4W5FHJU?M(%*5H0C:TC(+]^)1MK
M9O) \');>VQ.LUI<OUUU,!@26"U?%V*>(#@H$B)8JDF3HBQ:M8U7%B:6S9DA
MMK-<6(L>ROP_:5&6K6"1B&*RQ)5B@8MJ:P1]E5R"  !Q^4G]\!Y^_?W \$C<
M;;ZK^"Z<V4=VTQHJ%4R#&UG;I,U\_4">61<P5:QD^4.,P3<B4ZW#$QP#T A(
M/$YDA X4.'3R4N2F#%=>Q?'N0+5-LNIJ]I9NZN[!XR%*F, ;L6!4(@!9F*H!
MR.VI/!N7';SOMMY&Q_'V^OZOX=6!;8@=/+W3='=>JWW!+U3]#5'0!6Z_HPQ+
MZU6/?%F*$#.U-G$-HP[NQ>)$"SG)@VJBMAR],2HXG7E0J\=EC(.)F0Y8ZIRL
M,MR])C$D%J7N?W8JWTIQJJ5JZP&$P HB]QH19'.>20D]PD:GMP;C&K;;>!\O
M@GQY)W!WWV&^Q&VPV&PW@"?TQLVM;>EZ&(U$@YMB+<8E#:IXQ4<I+*64G*BQ
M0L8))ANN02\*P)G#IU?+0I#@TN((CRT22N!*:?S?8[M:2H+JR**QB,_<8%0L
M:J2S."-U9""K*?F5P5.Q!VD%6#<3Y.X'C?SO]V_WG5@6PPO4T9IS5/4\[VP.
M4FUZT)70_N630]%3=F:-/=@K!9B4.28L&R1>P:[:+<(US2(%5UL*,U36UP""
M70]L.TQ\["LSK\FQ0MDC;LY./'1S16$ACJB:V*]M*21@A8X&ADCB:Q*TT[++
M/$S<XTE$;1\=3ODV5"Y! \[+N-S]-_<C;;;8$??]^J^MIZCN>G]B$=96B)"G
M6"+@%*$2ZM,38P5S VX8/.TFUT@I!;]MBK=WKY<0;JT^,PA\A!)14.Q(L[#\
M)B^U[<5JN)X]Q&2ZN)/S;Q21DI+',K;]N2)E9) 20&4_,5V)E,I5BOU\;?B#
M[?7V.^X_7JQ2V4SKGJ+08/J#MWL;9M7;I;V79KSV5$ZITOC<M28M;4,*%UIK
MK95VC['H;Q!_2T*-9'C]7I8F^#0EXM)QZ*_/.C,--V".6_:NOE*U%+-3L1P4
M'LW/A93%R9YYX(C!*%^*)0(\[0,\,: A58;32$"B-FV8_I> ?/L5/D; ;G?\
M203M[5Y[DU&=TM:8]?,% -E#FZ\)NU&O=2E/D*?L&A6!IUX#<*U+DQHDWY.9
MB/+@D!9.%!-UTZ.+5TZ/@EQ4R,W?ZEN.W$75'1T=X9890!+#.AVDBDV)7=05
M(=24=&5T)4C4EE*GSL=P""-]OX_J#^KZ?=J?$H)UTTQUQ_F7-Q;NV)0=SWG8
ML'9'8 =IS44#9H\.'@58+C4>H]E&S^R-:8ES]<DB=KN=OI568L$.%<3HV*1G
MILE,;88L8>_;OG(5:M>:I#"8:1M6FKEW+M\39@1()QM. D<4LG$F)"541S'>
M:0J(48GF3N>.QV&PV#>1Y]]P/_TP8W3IJ?IXS7L,60+?Z%?:ZW<M7;-K+!"+
M7K]4G"$T0].CCRS$8L .@S0TC7K=4S#*"U8/P),"5F1'7"GS+U2N+<5]XS#/
M"YALP2%6>*4*K<2R_*Z,K*\<B[K)&0PV(*B6RE2-O*D;AO/D?3W'D^//W'?7
M0*M3CUS?.1Z_%:E/5FJ6&]%<.S&(68U>J41)$S.8<>6WEV5$C^UV/&CYS+><
MQC$9.7,8\3IYHXN'<W'<D2(?*2"TAXH&V!W4D[$GP-O.PU#Y^GZ_YS]WG7]-
M[T:]NWC=_IK=6;WL4S+L5O52B%8)V D\N43--4JS&ZF+(DY3F?BRB3P@/ 3/
MEO*<?F2D.RI#KC[SBU:$ZEK15<YD(8$"1"8.J+X5>ZBR,JCZ*&9N(^@V&KG"
MQ:-23N=B/X"1_-J:78_4>-]Z%V[IC!;Z$[LN@62H1C66<R6Q4TN-?CP9[T;"
MD*D1HTQ3#LEA"T./1TNMMN-K4E:73&9_J=ZAPV<[/Q"XO(5KCP A3+'%(#+&
MK'PKM'R",00KE200"-6OJ'%'.8/*8@2]AK]*>NDI')8Y'0]IG7W*"0*7 V8K
MN 0=CK3)[8]4-R=0]%:TH&Z!@,>:.;RVA803]>.QSXTL"8HFN1&"3+[+;#\1
M#TR(]AJ*1C1)R6\84]';SG&.=O=(=7X/K+.9/(8*:>:"O@L37L+8KO6DAL/?
MRDW:97W5R(V7=HGDBW_1<^^N3NH^FLMTQCZ-/+PQ0S3Y._/ 89TL1RP1UL9"
M9 Z;%07!V$BH^VVZ [Z@.+KQLW#L4\2,DSX52")L=EDQ\(RT&!+-"*ZDI-RI
M:<IBJ-GPPW&6\.+^9(Q\91AO*UHS^6Q!"]>.65(WMS&M65CL9IQ!/9,48 .[
M]BM/+MX^2)SOX\XFJ.XE9$9E@B$\Q4;B*(S0UQ(Y^BF>>&('ZO(B^[ &7/5]
MD1M:@[:ZF/6 =4;MNVU:CM6GCA[YE%8,;,U\0L8J%KFP3HD>6^%_'0F[D(]?
M..1UP(=A@08I%2&9R,YQ#JEYL1?Q'5PKRW*&$IYFIFJ]?B;4&*R,=2Q)DZT;
M,BSG'SXV)K-<,)7J2RO"&>/8WW"+'D*U[I_NI7M92UC+.+FF++7ER-1K=5,?
M.ZJYA^-AR<HK3E#&MF*))F6.3D/5W(U=;M+.=;M9WQD5'ME8ZZQFBS(4T.L0
MQ.2.Z]TEXF8AD4\_ FI7"(1EK7'=6EIQ2V',X>:<3B'HC-8_J&/J/,8J5YZ%
MWJ-VKRR12P,PAPF#KR;Q3*LB[2Q.H#*-]MQ\I&IG4N+NX6?%8W(QK#<KX9#+
M$LD<H039;+SI^<C9D8F.1">+$#<#WWU$M%?-N5Z5;6QDM=:A'1]8EFTHQF!&
ML!8<4+C1#SGN]R9LX6$+SXS?LRAR..EJ]^,M^W.8FQ"+"U#*@LO!)92 G\XU
M>&2&&695^L<<MB"-V^C2H/WVL>X/VFFX-V5ECA:3;Y!-*DLD<1(W^=XX)G5?
M<K$Y]E.TGNFE+L.QMB;*H-2BQIMHN'6[>P$!#F$8(B)))2ZDE3+4DH3?BCA[
M.4M.*<ESI+$9I*?<ZZC'WYBO6V1J8G%X_*7Y>Q1H=18*U;F"22F*".ZO-Q'$
MKR.02/E168[^!J^=.4;63OVL?1B[UNYB,I7KQ<T3N2O4E(7G(R(O@,=W91X]
M]R ;-]2ZME=>.O8_3-AL5=LE_L&U3&W+FU42;!ZO4U+M1#TL!446*)Y@'#BH
MPZ<8.OC%O#AZI<(<Q(DK:>?<Y7]4NKL=UCU%7N8E)A0QV.7'0SV(VADMN;,U
MJ6<0OL\4(,J11"0"1N#R,J!PB]"^G?35[IG"V(,D8Q=OWVNR0PR+*M:,015X
MXGE0F.28]MI).T61>2H&<J6/)\UOK/=/_7]L?V\_EC^7C35HW3?J),DR@VW]
ME1I<"+$>CE*77,N/PY<MYO*7H9XIEE;,AF&A?L>@0?<G,WVX=EIS#4EJ30V;
M/'>-#Y(V8^" "-BHV^NWO]V_\%7!!OM(WL""H^_;R"3^O8C;[M6JG#(JN!R1
MPV0@"A(F'(GD")29''CH<6,VIQV1-G25-QHD=O&/+LAY26FD^5*SC&.4E6M/
M=LP5*L,UBQ8E2&&"")YYI9'(54BAC!>1R3X11NQ\#45^]4QE*UD+]FO3ITX)
M+%FU;GCK5H(8E+O+/8F98H8E W>21@B#RQ &M;[>OJ);OM]XDN44Q(H==!64
M :$AF)(8TL8?K ^:(,0V#X=B- MM*/SGG2>89N.58GX3&?97'BY;C8[0Z4]&
M>E\=BT7*5TRMRW2N5;-EXK-43T[TT5FO(U2R\DV.RE2)5@[M62"2$F17#R<G
MU\W.NOM$=<YK.-)A+TW3^/H9/'WZ5"*:G=-/)8NI/1N0+D:20U\W@;]B1[@@
MO16X;.T4B,L'"$97Z6=\]A,7.L:MV@5D6FO&&T@!94L;$"/I4J<=(V"P7*X6
MRR/K(SW1HAQ^$'%P)L6.\RQ'&Q8.)JXCV,>]3O2;#-B[^<P5=,?<KDVYZ]:K
M:L&Q%#4AI4\9C:%$+#"); 26Q8DB:169YWE[8D767>BGKYU'6SF*Z9ZFMOEL
M9:"T*=B]=HU12FL9&QDLCFLWE\LTEBU\+3:2"G3BL10RQI'3CK]\Q.>D=LO0
M^1L'8#UWT':!U4$V6R5"%/ &I=ALC\$;/P6D[$V38[+:[.3,V0\\2?@2!X89
M(B-S8^7$+PB3[Y3GSNS_ *:)>N&UC9EJB:>NLL3F65E1NX;MNQ)8F>26?F5X
M1QE-Q\I *DG]"_I+]N+\@].IA^O<9/EK6.QF6LU<C1AQ^/AM687IIT[TWC,=
MA\96IXW'BFD\<UVRDO9<(5)B81IC'5/IO*Z5-:VVWM=T1;=DVD_6@@@)@]8J
MS%UO8VSAAJQK59ZI:(8D_5;/27HXXG&.C";"<S)3<R(H8B=$G7;HKT\BQ5F/
M(Y"5I+D,*SPB"22.2I;BF<_FW@E$=BM-!P$L4BL7)*'Y2P.'?:'^V%-U_ALA
MT9T72^#P&0M6L=DK62IX^_5ZAZ=O8RN-I:64QK7<3E\=E!-)1MTYXEA[:6E#
M3K"\,?NQ+\Y_<EV5.0[A3,V'#@2I%1?H\H@''C8D /.D@9:WIN7'!T>/';,S
M9,F4?BQ8Q9Q_*92&VOJKT%!4K])X6&F8Q E4[PQ93\M0UY7D=Y8(KXV1XTD+
M$0HJK6=W@"@H2?S/^J-F]<Z^ZGM9$3-:FR'S3V,%_4W8N110QPP6[&(**\,L
MD,<:?$.SO=BCBM,[=P!<-Q<N_-1<LQT3'L2H^68;K&);,MWXR/AQ'8BDJ3+9
MEK\1WHBDJ3+;=7&4E27<XSEDH7MR<G,2F-PTJN8VC7@W*19 08VC7=TDW!C9
M0X(*[ZP2/?FG&))V[D7&%T$B3/W%X0O$01*DS;1-"01*KF,JP;8VA'K))KZR
ME[M)UV%7*VQ6B\49-K=G@QW]KD*E9C=;;"UXB-M$_2\R28CD1B)K3PP@&:GN
MM!IT=@M'3&X:@Z(CZLZVM82G5@DK4LK'>?GE,?E;-6B+$4,^2J7I#%#E[426
MGM,R*[1K(T;J[(=_J6?6"_Z:^EE;J:7+Y&CD,_TS9Z>X5L+F^G*.3M2U9;4/
M3^6QE82VL'BK<^.@J]J5DCF>"*:+@D@XQ\D]K!4QZ %<U*!9UV-(M_)5J%*B
M#)L*M/5]YDH$@X$B(%9C&Y=VES[K'NS-?:/0U3IH-M7TN6ZUC=%;[/W3E+$)
M2JVY8;L>/GK1V8HY8Z:Y"7(O;7*"DEGY>-5VJ/0#"I)(3<9!.=]<TYC[8/J'
MG^J)\]FD_*=:WF*61MP7K4-O*V,54P$&(.!DRTM0M)RMP17HLLZ'(011)CT<
MU=N'82C57+ PESI,EUP"5BB!Y4>\P>4FOW7\/#REEKL(T:$"F;'%%2I2V\S1
M^968N'(S4Q?],Q'9&B^L.D[W2&5DH6V1H99;;XUVL5'NV,=#.88+ENK5DD^$
M^) #1*Y42 /LJO'(-=2^FWJ'C?47!1Y.DDB7:L%"/.)'4R$>,JYBS5$]K'XZ
M_>@B7(BFWR6&B9S 7BYDI-$S=8YBFMAZ\XQG.<8QC.<YSC&,8QYSG.?MC&,8
M^^<YS^6.--6T],NI$P-(#[AV1'E02;>$3Z;65./17XJ7$>639I+:VW,.N-J]
MT$6Y^JEM>'IS>5J0PBWVK'O%&0?!5VV!]_=1N/V$C]0^_59!!Y$C[@@[JO\
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MX*S/(>)4."!O[?AY)&^_C\!N=_'C54VK>O>PMO[V!]<P2 (B_F[@2I,UX[9
M8VN5Z6$>G-V8F1LCL_ 9P: BC"<_,B!-D_56X:&0V)TB9#:?R2S>@K4FO.':
M%8A,O"-VD<-MVP(P.0+EE4[@!=]VV"ZD(I+!=_.^VY\#<?M\>WT/ZM6V,=>N
MQUE]0_:^PY/7[;E7U=M2#N'6\':9T%$@!Z_6-K:?M.@*SM\E:E$<5>1.7+D1
M[O;!@H[-.,QY%CC,1GY[2<.8Q\;1CP=: 7:LEFNU2PU9'+N[UK27I*RQA2X7
M;>*-F4*?D).Q.U1Q82GY6VXL.0\#8C8,?O\ ?Z'R=]C]#4*WH39+N],=:FH(
M!>U?TA*U4F%BUUY-55:D$<B/?BZJGXK/X>RYCYO!_P"H_3U#,XE8<SG/PN93
M\=7%$WR9/A^R;!_-R=SM;;D&+8R<SY7AMRY?AYU3\&Y\?J6VW_GWWV/\/[=7
M'E^OO8VK>HSJO94/K]MRT:IU&)TEJR7M@$#AOA;-7]/Z1I_7^S;>%6M1)-8C
M2EDATJZ5$:6/0S[@]FMMR(C,U_"$8HEV@^"L0&[6CM6FMV16=SSC>U;EN1UC
M'Q,G'B1%(RJ1R+D;#VGE6[JGB=E 4GVW*@+Y;V)\'Q[D'WV&^J>]H=>[_I[>
MISK@6R!L%]K]Q'T4=*K=B"$:Y:9161#C58L'L29Z1#0NS1" LC'>)S82A34_
MX!W V5#G-1\JK7H;-)+P#K"\1F82(XDB*J3(C1[%RT9#+LH/(@%2=QJ0RD,5
M\$@[;_C^OS_VZM4V)U?[1ZL[.].B #KG?MS5OJA5>O=</76E"XEBHVPS6J+*
MK9FP8XVY1)LFN1:^!GGR-$J)2S$0Z"X*LBR[## ^9&:;QNOD<?8H919+\-67
M)2W72&4F.:%+""" F(@.7?MB658PW%W9"Q<%M3V1@T9"EN)&Y]]RIW\GR-A[
M;_0;';V&JX.XFB;1U\[(;'UO8S4*UO2K#+ME;M(\N.,9ME4NI*88K)P@[!F2
M\#K#/BR<(L80BZV2#GFB$2:CPAN0]?L5>CN8^&PBM$%C$3Q,K+VI(U57500-
MT!_M;*.+IY7;VU)D4JY!())\'QY'T]B=AY^IV'MOJ<6^>F';&MU_IOKFM]?;
MAMV5I&C2)EKL]"B0;W1Y=NV)LL_N^9KIZT5N<3%0P]*"SV:\6,&) X([8<W#
MZ9*E0(R)<BSTLKC9),K8DNQ5A;E40QS$Q3".O E,3=N0 EY'7F$3DPC$>^Q(
MVF.C_(H!8*#NR@^-SR'GZ; D?3S]_P!(D^H#K(SK+M3M225G#",':!\ONNMO
M#SH,X0B5_9QHI96@%J9!$RK0&Z56?)(5>SU^9)S)BE!#TF.J2,F#YDBZ8.RD
M^-K@*5:NBU7W5E4R5T6,O$65><4BA9$D V96V.S*0()OTV/^F^;QY]_IXW\C
MV/CW_#SK/7:#JQO;7O5SK8"31)5XK>I*SLG:.TMC:^-5K853HY'>]@JY.%3"
M,RG&34X3"IH2IA7K&9*0( !NXV<] @SY2(2Y<BAQV1ISY*^S2]A[,E>M!#,L
MD4LPIQRJTJ]U%5FD>1PJ!FD[,498<FVU$R'@FWS ;DD>0"VQ^@\> /?^;40N
MM_W*[E\?UL6^\_\ ]2;Y<\EY6H1X'Q]+??\ &8 ;[;^=O/W[:EQGRW^"X_B_
MF_FU_0S]!5EYCTJNK?QVG&/CC+Y)8^*A3?QHSVR[>IB0U[\)][+R/"VG$^4+
M3GRE6<??FF.K3_X09#\&B!\@^>Q'XW&X\?78^_C5P@\1(/U_\HG5PG,;U.UK
M;?PAC_4CJW_WWVC_ +WU#G3WV</[9U;_ +7A_P#EW]: ]<?TNFOU93_EXW5#
MNDO]87:_^YVA_P#I"Z%YT%FO[OZ3_P!TC_\ X:ZCUI6A_:<W_BA/\O=/Z^SI
MLK*>W?5W^Z U)G^]>0F>2NL_[S^JMO?^IS-_Y-LZG=.G;J+IOQO_ /3V%_A&
M3J$?Q@:G!ZSE,9U[V?U[38\U9%D%U]J,=$UQE,=R1B1>]E3LJ4PA;B&_:J4I
MO&$KSYPC"L_=7C&N/0-N?0]AR-M^H,AXWW]JF-&^_P"/O^'MK._5Y>'5Z*/(
M&%H>?_YG($:@F+_BBW[^ZATU_D?WSS9DW]]F-_W,YW_*_3>M>+_H'=_Q[A_\
MF]2:E!Z3U83=NY .G+E9@MVK5FX:^N;AE,C,1):F2H69.&%.-8>RSA[XF&LN
M(PY[?;E:<9\XPGUJ;AZ>Y1AY*V\4?J/:]$?<??[:S'TP7GUKC%W(!AO@_J-*
MR//D?SZV/4^F? 2E*<;6E^$XPG'BK,XQXQCQ]L?6_MC^QSB;X\?Z@/\ ?#_\
M.NKOA/\ TG_]G_\ UJ+G9SJY'Z]CZE.8MS]G79YA6)EEP0@=B+@:U!<PM*D3
MYF7LO9F^WVY2CV8;\^5>[QB?!8[Y;Y.'$#V8MON2/N&W\FI,L/:X^>7+?SMM
MMMM^)_E_9J2'4+IQF1]+VGMD5CY?.&YU5IQ!G[N_?"XIH]&<\9PUG'AZ ,>1
MCXF,MR9:<MY0RN19L[;QQM\VVS.I\*?.X4_4_>P_4/(U-@@WV=QX_>J?K^+#
M;]?@_M^[5L&,83C"4XQC&,>,8QC&,8QC\L8QC[8QC]V.6[5;KIVPZ],MM'M=
M9'D(PF8= DQD<E+ C;3&@NRXKC*)+]<,(<%FVV_=G*AL]M<27_H3R%(5G&;A
MB;D>/RF/O30O8CJ6X;#P1VYJ$DJQN&*)=K%9ZI;;;OQ$/'[J0?.K-U%C9<Q@
M<OBH+,=2;(8^U4CLS8^MEHH'GA9!))C+JM4OJN^YJV5:&;]%U(.VM/._T>P:
MXM9.I6<*;KQ.'E$Q@=98+8@VH*0]T@(0("DR).!KY >IF2[ S(<5#=6N,I7E
MK//HYA\M3S./@OT;56Y#)O$\U&4V*OQ4.RVH8;'"/OK%-R190BB4 .H/+7QW
MSN$R'3N4LXG*4[V/MPA9TJY2 5,A\#8)>C9M5>Y+\-)9KF.62!I&,#N8F9BN
MYRMU>U19]L[=J4  .E/C1%C!/'SGX(:V( K2IDEY .3;:J_(CQ9U?FE(S<0D
MN:ZF'"AYDD)/]!B*QG'^O.H*& Z>R$MN:-9K-*VM2H<HV&MW1&B&TF.OJC21
M78J[M) (@99)A'"@Y2 C*_3#I7)=6]78BMCX)7@J97'MD+ZX0=1T<4T\K"A-
MF,0SQPSXV>W$L%HV6$$-=IK$WYN$[VF=ZN]%KUW9VM4ZE*"X\\,A]%BL8@P"
M/BB<$E7SM>+UDJ-A(P;I]IK)Y<0J.3%,0YK#\"*_*2[$=S$>T+Z5>E>.S>/.
M>ZA@G>*TR&G3L5K56Q7E@MU+M:]7FE)JY*A>J!X)S)6EB9)9$C(D7N+U+Z[^
MNN7Z>RXZ2Z1MU8IJ0<9/)4KM+(5;=>WCLAC+N*M05U6]A<OBLB8K=807H+$+
MP0RR@Q.L$E9X;M9L0E,A0MN%)FSZ;\6KLF!QMB"5.("U0&8!LPZQ,,I?' BI
MJ(65BQV5F$FRE'F&)V#4<@VF3S;F?])^E<E2FCQV-JXR^(\H:$\?=BJP7LM+
M!*]JS%6:.>PE-H=\?4,XIU0[Q"NT3%1H7I/UZZ\Z?R=6?)YO(9C%=W!KEJM@
MQ6[]K%8"O9ACQU&Q>6Q7IR9%)^.6R!KODK[*L\EU;"]UK&[OT*9[":X [6H-
MQK,V[3:E-FROI\^(3:M-H;C5<2!KARU03)6JPQU/'AS8J:JK!1+#A1]+D:#
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M&,>[*O&.>X)^^&/'CQV&V_+???S[#VV_9[G\.QI8NUM\W+??Z;'W ]O/U.P
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MI4E"CMW0M"J\"!:S>:L,OSN[,896GKZK/L:&ODG>WQ$ILEJQ"ME_Z8J<1;]
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M\K3FJ%P,UE0(^"J!&)]5NX$[\LY7ML:FW"BB<XJ)7#J:CY;G(&K*%&AO\F\
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MAT"1G^=->4JV3B@#Q)*8T6]-G"%;3)-9%N=;@@.B^X2#&X.Y34*!IBX!;W
MY5OW\@OE*Q^#OJZF 7]3'L>3_YP&FB[R4<_?2^$5,A1IA"O'0]:EE5UPUOYN
MU,^V_L_?A.RW9.G#(,B.>?53.Y(!"T9%C7A*2A?\DL.73 R$4- 8S::!_&2*
M;$0ZD:5D5:*K%55P G:*YO!WI^;<ZS>DI3B0*$5 HU\ 8,K/*ZC&XDDTIZLZ
M?295L6N8@4,GDWS8+Y'%GT%"8KFB1)S?WCB.$Y.IB3>&C%C22)$JYE?<4?J
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M,(2H?6#J+ ,<L%=S1?O*!P>@!"7;U>[,@]Y8,-V?G^T@[M&PJ\EL<Y77[I3
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M])NFN=<:BYNAM [?#]G\=W1>\2FRR>G@R _]!-.5OTJKM!P;@T:N-BH#  I
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M/:6H3G CZLXR1S5Q*3IG6]2RPCOR0>3\SN9$(3Q?:H;P;"%RW%_(*+FIYHN
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MA2BF2;2;6<C.&+_-"MH*IX I*&U 619^M*C0YB9S_B(M'CJ41^_<Y=KQ;Z<
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M+-(ZCR54ZU1 V<(4=:=("@!N:WA8 $VM?P"[ND7$FRU%,X.\B9,'U4C]*XG
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M-@,23^]Z#/V?@]4E/AXD.L/"+_<M1\X'TX1%PW+BT/^,UJZGGX//C0N<,VU
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M,/QQV@1OWR^O9-;?MV8&RW/6*YU&Q9^^=XF7,[/+19>'.#X<+CA4'=F^"7=
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MO<CG@[#YJ4.(:)_0NNSOU\K+W%X<)1-&VI6P &\>X=A?X^"?-#6V!'PX> V
MQ^8^#4-[+0("_5F>P.Z#AD=<=K[W0?NB<Q_AVDA22 =C\7 +8H-M=I@+NX6[
M_)W?7YJ&K#!3+\ ?,0%E@>+LF2V=/Q?*@)>EF4ZDWQG>E@>628^1,'%]J11F
MSS[4U2)@B:2,@ \GSF[[A]WJ^EUY7\R^5>XT%;"C9+,@[ ,4=YZ1FH@ L$F!
M+Z)>KA+7S]TC5Y].^:2*.#1-'?D-KI>KTK#@4=1ZDM38=AZ,KY4R%LM"-><&
MJ#(=2VJ],E16>=>Y% 6#C=E%^VM'3Y1"L]=\B=!*O*T=Q_29>Q6XF_IJ^"1M
MDQQ NKJ^.0\IP?<0%IRS=]_R(4T*BV9^2\W4VUOYU<LGY..F:J[ZMVE<(F8M
M*(KN+^6O<=QJN%NMA_)F%-[JC>JY6>; +=]R?00:)*D7R$L)8V.'#9JU-#+T
MP8!(CFO24YP</\XU*/YWS(SVU"[),B3."G:CJPYO"9\0/&F@,<L+J27TX=.3
MHGO88%G<&8%]_GXJ^30I)4F;+;[CSRXRMVF#&O$K84;T5SIASB<J^9^M&RCS
M)$-U20-?:[SK8K[QOK*V(V1ETYH/[W@%&G55<ZU<'I\-?D5Y1.HQ-^[F,'@A
M,0JH!]2;*M'MCMC:&1\:&GW*%2WEYL(F&65+4*16GZ%^\\8)GR!MLB]7S#X%
MY+VO2(.;V/YW 10G.J:"1>D5RY;_0VGZC)1)]^3>VX2EI'=N<+VF"XUS:-;*
M=_9A_7DCLHWT0(BTT*4/-]D[EM DC18[?>ZLC;M^H>HIX7)N=-RE&X*\7D]N
M+!=)'/(YYB.^,?L#FKDEF>4L(?T8U53$<6Z,58'%S"S;WM@2$-H'!69".SNQ
M=CE_^8*.VU,SNFLFQ=O2M;G>9TKI_]\)H,Y56\[7W.G.^1!05/%8XX*+T/UL
M*;.SE<"APCC-1/3WK5^*_.-PW;TJY9,#+ CQPPJ*>2(*7"H#>ULF*ZTQO/9W
M.DA?/]NPQ7B W39L4( _,=22).Y ]IT($$9]O^"=]>MOH665D<)4JZ'%&LO'
M"A5OSPY?"@[W)6>[V_2:YG$Q(^+GJYAOU1MIUC1<Z;)>%EEPYIRK_=YDO@]Y
M!8=^MEW^^[PJ:VT+1U7,54RA>+E5@L2*<DL$_7)48B)6<*5R<UF:L/*YY"IF
M@V$45]QQ\K?EP1(N)YNHA<K2,+7;<;P!1@ISH;<5>=CHK(P/@R+UFK2?;>?U
MA)XM"KHJ=S=-'$B[EDI7W3-U)ND[M1WGQ8=&-"8^*257D%:VJ.A.:#M;.C"X
MCO%A71] +'#*II16.@_7O=+LY(T+W?*CPC /HB"CX_ "UD20VRD,IQC4I,7:
M-TT-#:N"ZF)R<*)6Y>C8\G.'A#-YKS'M:B'-&6$>MI:XG\;'X4PJS+[PO+2[
MT2#;U@<:CS6IU+FW3C>?N#\7(C[G?@-GBQ$EYP:H:SO\"DB4G&!GHH\S]0XS
MH^QR"&L:DZS SL_MDV6#L<X?J:0)4(^C%VM@ZW4MZ$'"A'4HPBLY[2!-!<P0
M"1*$K3$_DURB,?],)_@9R=AC&%5AIX)[,Q[>MWN4\UNZ8-"6;2WC>QL['8ZW
MTTM;&&X:PB(Z 9_B*:L\(Y%D$/)S<=5;27EG[<?U<4TBMU&BI\[;\9A-_>K)
M) NE$G4#35)]EQX?:4J%I7 Y 1$&5+?(V^2T4[%%P^H;Q%VD0Z<&F@:?QU;?
MSOD>O_!<^WMGLL/6K*+TL LIW]51:^2"GB*YA"L1%]K$L^EC\=N3-SHJZ/.)
MZ1[X+0KJ::A1>103B(<2N/23];@)U(+?C_].Z)YIZ-?A337ZX)_%R8A<I8DU
MG[B>K\RSO79-PS8(+ES_K_M5NL[]U>?"$&.;&'*\P5X6A:&IF'I92[H!!+FX
ME;DCC3<(7D#,G-KK5H/@EP:*;Q'(L138<M)-KX6WF%.^(DO[U0^PFN9*S?0K
M<6PT0MB]34SB&1);,@U0$Z'XCLPNT-6T*W"YGM;F<G6>.G2VM/M)"H+)+;FT
M07@L,,9D?[B;H24E*=!NJT,4N%)B0-NJ2>=**QYLR_*V!%DOIGUXZE8].5>^
MN1.K_<$?29E)3PYK,\9=7W$H8H@^\]GYO,VJ.1&#E$LH-EIKR%! =SM(YG#[
M?S#VUE]1,%R_-R(BW5T20PP]E)1<U !#@\S 4,+0*2$EH'0,##'D4-(Y-$,C
MW27=**FT@""B7)[[7>^]SG/.;V?_"7NOM6/MO3_?O:+JA4K"Z6#2Z&2J6V[$
M._\DK1CMIR[4'_E@Y$/U?O=$YR@V27OV-RW$\S?\+[NE]"?2L,Y]7_57$$,N
M.6>%9..VG[2T,O.ZMD (.]KQ-DMJ#EDO&W6MP)+(C\4/?8XE$5J)$J\^1-RP
MDLK80UOK\X=%B$Y*L$G@M\V#[$>4XH[-(AAU[PZK(UVV$XOPO;KRM[+::CB.
M<:X1IYH#IX*^U_Z9U;/)X4]ED!34W4U@GF+XN=+J""B9:02T]ZSK][/Q*5^H
M^?7_GV6J9\]N!]9,1 ?<@HF,OP.,_"K@7> >!\/MYW[UY2O>RY$N1Z0WL2<P
MZ@@="I>GWN1Q#+9/HP9<O7UD679,XC+E+Q)/2=C5A%.O&U)M:V#^9G NW>B:
M*LE'PA(MGB-8FUE*XCV5$7[#>6*>P*C/:%L))KL/8B.+2/8/S>1P/C95*?<=
M)1<RQ8BI'0:]3]Z*Y N=P>71;,OZ4?,?+);71RW.=(8-CEO[RV5,/ IM:KB!
MYG*^AW:2LX010ESI]E@:;_<5R&!4$T/[4%[GUALS5^//=^J9UP,/:D_U-.5+
M%0L+U.#/@/[B9F##'ERFX)]!)B&KUPF.82B+X7A])=8/';LNW]LDD4UC#^G(
M:@AG^7P46YDM-=P)ND[Q8"I=2A.] F\)J'^?E.&:PY)6_IXRF76#-IS*!+>F
M\4FL"A83:\8J'A?O2;K_6G5SRJ@RJGVN6MTH(LVZ"6RM6IR#(PN&Q@Q7B5Y+
M-<H19S9$AL<" [X0&#&'_.1RTE$U-4:'+9$9%3!*>Z&94;TQ=8BUIA*J>I 7
MS&E8R<A=0C#,2,&QN8]- 5\8.]E8BTU=I[A%SQTO2[C>?'&R:#0Y"F;Y1C1Q
MU2] EX":J#=,K"0\6*OAYIJ=2FN:>RS.8ZTUS4-<Z;EL.Y@^)ZTW\F6XNZP[
MY)I>>TU^U18AWA<2>O0UHLIY2 ;@_#.\#!2E/%<3B[.*(!:YMMB)T:V.AJ6Q
MIDQ@=?LCH<-[NV,6AILERH&3="^. '$ETZS#UO/$0VP%?_'.H;TF'D>+RMS2
MG:K+%3<-MLY9=F7@S?-D?R''E&*0I-5@5+=Z&DTJE?J:O446AT\BE?>8<XB"
MZM:;:!DA9O8#6-JNCL%[_J38'4/9\,MLJ6GI!)5P0E)5<"V1&K/:$\SD^ 95
M3DVBVR(#;;R0RI78EJ)=JI(<Z,B<X>F[>ZT!EP1\?#UC7GV80E4\^PT_(&RW
MF1.*YQ$7D\[E7P B("K(L%J]"J:B5(-6':@WF,@7#?&*UYQ_["*N;H%-C%@0
M8)7!HWD:4M\:RD?^XE',3W!89])_1L8=)CR/G#J\>F)O0X43\%8'-PJ/37?[
MZB*B#]O-2M^D7)IA_=X8^_!:(8Y.8R100"V2<_#%!-M&HN=SDR_J#ON6!!]W
MMEI[DF';,SBIYT-8N*",O)X! B[D!USN?!_RHZX0W"E?^5,")5]&^<ZBFO4N
M9Y10EYO@6!V9@Z<<Z2MJB/A2+_5]8,"A[;FF@;D%%?8"+F%FW5HP9<M?2]*I
MF+ZGT.,<54/N<D?,&3],'V]/#[@0+)F/Q=*,OKY&O(],+CVH(QT5'N&/%]6J
MOIR:5^.9'2Z6@##=+/_F;Y*RB=A GB\^]+_F;^SZ XVS?6TAH%Q*OIA+4:^*
MSP>5W3K%41[A?0$]VU%*C; Q<2OAHXK;(!Q?TT_/8-<254.6/-;4<SSZ-S?3
M@H&[GO,N<<0Z2F(M*,IHIO#%J+_G98 1NSI:?HBS.D.F*]4),$P!Y4X2B(RE
M-CEBR[3 L<1X&HC9M?+L#NC0XF*33&.:P"FW3D$!0_E@EWKV9Y5^?J7#DDT
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MJ!,A+)V(NY'6?XAHJTA*EI325:4I/+CFV"[8;U,BXTP39H#R%P9$+*9X@=4
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M0RMM/5:BZY#N)\-(Z;J]T"H##KG<]..FJ10DR3K^ >K-/0!"L;4\0E+: 4M
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M+;FDC"_.&M^P<X:G#K6<V'Q.LUN99PJ<K@S<96!;#J.?L!U'0"KF?Y/8:L^
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M<Y8?AK.\_2(O.JPD?R;M GHT_+:;ZMN2IM=@*7L.9A%DV/V(V2$S!*5+=%=
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MT2HP(;+Y?1&6"9+1&1WFV*2\AM*DY_%B$ !00@@@>D+7E&3$4^H9_D7P2[;
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M]GYQ7/C/%P>V)['\[1PZEW_QRF,$0\QFVF=_.'=,_&.1OJL _>U_9Q:9G@:
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M/&-@X4X6PJLW ?EF"VQ#'@48R)Q1 E"7ZFHZN'ZAMW.$!.)?CPY!;D0_@'C
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M?Z 0FL9O>IC*.YOT.@Q_EO!$!>HC%/=B0]1YIQ(0K7?<^JB!O5O^FN2(Z;O
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M(CHXGP+)/\5B"9M87HC3 2R;UX&3""= Z9*2,\VI+RR<N@F#<8JNM()3GL>
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M:_@&4&EW16O\-H&,"/DP+^;S+6.-/DWR^#G%?CWP#< &Z\XD!1^0ZYP5<L"
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MF% Y49/MAATX4,3%H=1>=@8,86(Y(#'%,1L/H2QF5HCIKRMN8>*=A2KSL*E
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MSQ_Q#A>%I_T,F_FHF?W\];/Q>-P)TGF]Y ;I;T[DE<G5$?)-_YI>%)06%9P
M=RH\P5X3WN?0OE1++KT2@/3&R,M<7'Z+;6?1E36EA_P[;>'TAJ+1PZF0N&F,
MHFS@5DRI>#FD>V_+#,,P&D=N"9T;$+*J47*X'_I;_#(U5RS$(G"]_F!7V_NU
M\OM@Z];'&*&LS)'5S81\ ]!EF(+;,K/%8QQ.]XF1_L^XK0+B@J2YX(\_1M<P
M=RYR(X.R7P#^KNNH""[(B"IU]/;>?SP-!3V_YQU][/V2NR+$\Z5YBQ_683[J
MRK;5Z\$E2$8W)+ N102C\H=)VZ[L$I'#D5;_+UA\CQHMI[A#"%RFC/3>^4)B
M@HLXM,?0[<EN776:EQ[:4TY\#(VE-7;%W"X<:>OS.J Q9'UXCZ=>H'3*1>D]
M8DV0#'EZ<#QPGC&US%2H$M2Z<>\^-#%*&GC8_\"FI)J.RC3!+2BB.;([C7X_
MI8X,7>_P +^4$<)L4M<-?^'K%?F6T5!CC*_)VD^O+N7&?/<!] $##?UG%)QM
MDF64E!?>"\MY\]ELL67]35O1-ITP+A?#7V?^[H^QMH77?Z ;I/L++8%&Y1A+
MT#4TV/WXDE7KT,SH++*AW?VL71'?)X:S_CY RC8]E/F<+-J=R7_'XJ!C:OH,
M"811QW#6^?MD@5A+MXI.%WK)M6!'<WPZ>(S<+&(\)XZV6(3IB'!'\2$8DX&>
MD.:07@FV.YS,YZ*[3"^GE QARQ;H!^ZH.)>]K-_^J/&S"3^W#NB82A!/GLDT
MK+U/,-,W+\6U$8'A8D0W/!7ANHL.Q-\3 ??PHK57F/SZ\:Y3IHT4.2@BJX+6
M0QYB>*B#=IA:)O '.Z1;GI[)RTP9F#:T!*&QB7;_%,T\I!)1B4343W6]T>"P
MM]<JS0F5 A@W*>^Y&/#BO/X6= @_UI\80YSK2S"FE2>0X+35&MM#BI'+&K!F
ME7)O)LYZ W2D6:4%NW_JS\UI6VSOS&U!),T+NGGQ3S)Y P3-0?4KG5BZ5$J3
MRK+BY^WC&!GG";#TAQ7.DCIXJ(O<3!HH(<2U@DJ-S$U+92=/A? 5IJ#5R=$(
M?#421#@&X9@00;OJ28J@GCC$5ECSO45UN;E=Y9$^(0]ZX%X5CE7L8/OUBRS3
M<4J(9VUS[56($LVM:G(AEEX,&O\;(!OOMZ%U"26^^/;7-5,L)7=AEF/T L1Z
M=J\E#F<PAMB0J#\P)VWZ@>2\?D@<+C&G'?9^J,LU5./KP%RN,TY[J3V4S,<.
MD>$[%=U*A5R>\_?IZ'$!/+H*O(Q0XY*;>WD-(\=UBSBB54HYD.0'M(BZN*7@
MK+:Z!K'I!WHUT"@XFV<:6I'5)D"3V[SJL*A1_5>T7R)F: :A$@L^S,[YX5M6
MT* _[> O5A?8SYV'.!T%M:-R[6GO8:1;/DL<R"$C#4IC5>.6\T;=7B90C&9%
M?L2Z)Q08622DAOO:8ORT*/3%!>-0.5;5!>CC.5PZ;PW6&%&;W%]ED:GV$$V>
M_JB"L%[Q8A>I3ZINO3+'MZUM5PL_![,HAE0#D-J9W1*+X%O7DRQ%GDQETZ/7
M*0,Z 7I)T($OV3[)DD[R:]E3<<N&WE&C_PYC>=D2>\,BAZE"/X\?1*MU(N-!
M'XPS#7^Q#NE+]]H(;73SC6 ;ZBI1&]PY'ZY*^&M6V0D&4+;SCIJUKQL*@-#1
MI:X:B#C!2R.EWS&J,UQ)E<D,+]\/._UT@$<W,FO"NY2G-IB_L%,))Y'5&:>T
MMR<SW!*L1B0KZ9EZ\J<JY)GL5E4.P(@95^_F =<IR<X2,$(_[Q2#!9C\BIE]
M-QY:_#T[=[9_&%0NH"HW*UN5%D;,]RB-&K%S+2K(P;*E5.L5T;L8)<C/.Z^4
MDXD[%!3%KUWWJY!8Q27LTHJ3WN'@R-.,"A5Y"ZRO6%=\ID2:[!E_ORMM=%94
MJHK/J:+ -$OLZ[;!'BXJ,24RT)Y*8MTUHVA$5Y%*HOW'TD8#O=0:<.\3BSH+
M4=68OW*8I5.4M8FOU2\[((HY&^!D'Y57.LBF*6II#"AT=O0VPG-2[] ?JJ(&
M06W/FS2%82RS+W6NX#Z6=R_^DHTTVV8PQS9D"EKLK^KHS!0IVDUO4-;2_P7?
MM6?0V9'@VOU1QS%[DNG2=BN14H.&B\BE>))6Q+Z!R#PZE9K*U$PJF8!;-U=4
MV[Y-/AR'AELPK<ZL?B$%SM[.+ Q%7Y=H:EM]1AVB.M-+$W_=U7CKYBRN"%P<
MITEHB^LG,:+>N$;-DM]PN%\A,>(OSBMU$*9<&T 4E:?QABF1+TF^5A8.K;)3
M2I1[2&FJ8NL7(Q!]O];]]7+SM>6[,=L\@T@4:3_CR5QU@T.I2@\"ZYZ&"9P[
M P++=89578RYN[ ?ZK&[VU@'+V-6Q3K- Q\*>EKR0OYBRE@?W'.\Z@%M*6D1
M;)FCMW.P^"ADFW]DL0S\/<$K4 A+#@Q\.N'H[L+(] OVSWUBC^MPE,.8>["7
M%D1AN0^K1&QF;\&7_9$G&7=8P%*5(ZUF)'U^'IGPI0GYGO5,?^FCB[Q<WFA>
M](%!2=7^*#]%P+G_)8+S>% U#*S]4<W@-&E0-S /O:&ZZ- 0!]/]J"9:@AZA
M8(DZCZ>B2=$W3V_O>F5^^2\\;WG?9)"O,9@CZJW[#-&Q))[I1@5C."B#\8VH
MJ#"V0:9A,OV['B_!SE?8;P!>H#O)[A>?Y$0/0>SJP/NGZO?TK_W>6L^Q)+\[
M-[Z4_=O:Q7\G)\ J9[-HA47X6[(-.907NF=G$=JCY6-;.HXS_TNVH^C"0 .7
M54EC4##4IQDJ1>80T+YQEZ%"@/O9J)]4&$'/M9-WVYB;8I4%[3TC\:7X(UTK
M[[+2;ATNP=Y[@ ]S+SZ7?M5W5]Z*MF2-Z-8O*0L&^O*LU++:G%%4R/V9C'#8
M<95_8@-@QH]Y4>>3#PWPWF'L,4:<G3T-E'1"G>%#WQ.)_DPQ7!; AHL* SFX
M1"A%_PIX$'$_)O#5,CH_E+4ML%.6-B]@?\C1S0=5N27.@6^*-.=J.16B(LF*
MG(8>R%+IL3Y;>]E..G6M&5XIBL/$#>-ZGS!9^F;BLY*QF.E50&W-HQ)2"%[5
MYY1)S728#H.G,0%XCF^ Z4P[?[,*\)=)=P52I12HLX&9_8+WUJC@2Q)Q#.TD
MNLSJG:-S*HCH3N/[8N<Y?PE47D=-T:918#-/]XL_?D-Z9UBS++]@^PV7H.8Z
M$TS:H6YYIK)RX!+ "!%.%WID8_>UY;[A=\5.9&'KAJ0AC4,[76W]<O_M;*!
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M$,39)\Y]=N/$25,>*S;CW%C)Y-0V_@SXLIQS_**L3_K58S2<6B]E\PE5R35
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M$W*ITRM,QP-=>LT^ &M^9BCGI)/$1;Y'Z_2PE4 R$_)JOD4)[G\MNBM,>\7
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M^34UP=HV)]8Y)^ S<<NZ[<VU9W_V/!(+N^+=M1<EM_!J\A_%L9H**_+4&,C
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M851_LN,M\U^7TG32MW@Y]4O]DY& TSO*3UKE#69<QSR<R(O#[\6+[;=24P^
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MY/B_.VJRV\$N"2_8]Z-F7J9(Y&8X2T9G40O&7Z8;P<-2#*U:+04$.'R'"/;
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M"A_X*]';/OA U@5=!XL2$D48)2]Z 08E3>A%_V[>^GY/</YBB8F?DJ>CM,#
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M3*B>&TBLM%5N#[@U89$)>&0*KNM*5BHT+RK5M=J;K0P[,&4\*D]_VOLS>Y'
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MRYYZ%[46&B8!K8GR<5[3UI'&#DDTXK)%]^@?9T2/P>K'^Q8^<,;V=#)>.B/
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M<BPU1QC!4DK=8:W: #DA6C&QO2=6'R^N2OHVJ:;;")?VU(V.?YY&<%F>@8%
M?Q6!RGY/J+$2FD4LS";-B$96$Q 5V5OW,C?]D5E6B9V7)$YPBG88BZ"SW NT
M?3K8*5W=(S#'(-@4.O5DK1LJ=SM/9U+A,28,//,#1V,RLA1$;K^3<FW-C@3-
MD?[X.9+553!5V:6;KFLSJ-T&!%.01'KJ\IK)Q22;U8.BK/%JU-/SHP34'/3-
M;<[=B?M+K 5E>N?-XV5H+A;ZV$!Y*&D?W_;2=U&F(<KQ4X"V4)1]>ZAK+H=(
M8*X=Z)N6D94WZ^93T>3GW-S/H5?-V5X[XV/?ZN V"2T'G2U#S_X'QJ=P^.FS
MH=FC[QPZLHL(D0P2=7KPL9%XWIHFBR*QB(VL].=KVR.XI40N.?Q%/38V&4IG
MSM$(]CQN_^K%XVN+NI-G1GIN?C3\%Z^<@<%C3C.Z0RU5"%A.'"]VARQAI.3B
M,@!V/E'>V4!LCQF"3?^B7Q=\<QD<"''WQ61I6WP.V/2O*5S0J!DJ[EA@(,#(
MH^36NG270NNCCH0P!TKT3FJ[R<8/2-LF-RP4^_D*)>&<D%NTH9HV(GF>SVCY
MT<9*RIJ6_6;W\Z1)A@HM&$PBI#F_4/UQ'NZEQ(Z5JXVB/=O%74?W?AF^B_,F
M"T3N]^[IC)Z6==,\9H_*M<U [/@BGZ=",)LXB</FU&0((825G$C&I0(7S\*(
M@_NP5R18IP?%5& > E#2M86JQOY<H=^R^+U!O7D%K L2!K*"*%MBLK2IC-*
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MP5WZM6(8PBZ6Z'XP9L(=5J"#3N,Y+5D9/ZDZ3'C\3:-\B\",=XQ4H=LVXW5
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M=]Y.@)'W.;P^:FE-$1L\Y;]F34!F38-VLG^SB &^"I-U&"VV++5O6"XE%Y>
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MX!^CI"2J0K^LB[^O" U5T;X)-_.$U,W'_H)FJ0&/B/RD!7C-%;*39L8JW:R
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MFJA3U,Y8-BT<M#/LY3J<P20;ZW=#1.VFY+:[[N7H!C,&96[%@A:@D(!U[^^
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M[%UM@R%(]\<KFG]GBN?RY4S^9WA0?'[G8)MMT4:J?\W\Z-UJ($WWZP=3D2?
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MLPG)^/_:#TE%:3^.(;:B#^GYZ_K_?5O'DG;N@[/<E/[L&X.C#+[IZ; N329
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MX7P\E/%V:,7 N0)W?,UTU%(IQ*AATH4UTTUP\E9X =ZE1*&E5:@_]"A00<B
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M)MJNQ?(@1:A%VBB>%'/O+(]@!1G?IKA(KTFB)V2A/QJ6+'KMAO>\KI,D7C.
MTJS?<D:9.&"]EHU3^^/XLI-'S^^/_\DKNP_V5 41)6^&IM_K%]O(/'./Q4[&
M=I?78 O59\%9=?^.ITX]H=YX>N)Q,)PIF_$?^TM+R4WKD8=%\P5U%46V'D2"
M5/.<LAH6L&;'H-SU78I?2%@Q$KA,]]-IR6'.IXG)Y),;V>3 Y]6(:C[.BGY6
M+8$X7!RO'+^<3K4S.9,2#QQWJ6?KPG&OIU>?K8\4Y(8,BUM_X_9XJX,3"/^
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MNX#>3EULR.[?QAW$05O\9T$'%!)18:I:RI; F3E=94+CF=4&6:>6,C]*5X1
MJWUNY>TH+I>P=SN'X1B7&0.G^?>#E-V7BHMZ1+H3<M=S0=#9SZP@]=X;Z7#3
MQ+?"*3T$X:6_QQTHB+XHU#]F=F^4-,^89@5301#6W];Z46D9@BJ8*WO4[5P
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M[%7%![_J[&\_<R_@=S<%^,MH[0D=^TRY*T5Y$!5T@H"_QC%MYM+X4VN2:F-
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M5Q(S/8$2DI0<I<Y%^:4&NUL:E,D9F'REZ#ZNU1-3BGS.QI+!MZ'L\CTGOE&
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M4J0XEDD3<M-%&C%$P('(:N]OG;JAOIJ4#UG\0]G9/.@-F(W;EP"U+_PSQ44
MP?<B*C5(PO$.G;:Q!(P#[FC5UR\F /7C+7@Q=#JNH;R$]C+AH>_UH\Q7UM)>
MZ3OC?&%5D5Q,(D%%?"8=<R#ZK#5W_!-5GL,;1)A:"#)-W@WD'W,7"K#9N+DU
M<TA?/.-<Z?=V.^F.SOIT'#$:S@V/\P N;G=*7H8OIH'JKZ.IU(X$I^H*0%IT
MHAYM[4JP;L[627'>(9#[*1H]I<;KW_>EFWZD$]*$11\M%V_D/W1C7FL&:@$K
MO&*W;BPU(4[$&S_,OR(B2#Q+!GS<>)=FQ(1@UGGEK](QZ 7/SI+1*A=K:5:V
MJ06'AIIU!WML/2^@VR%& G@WF_W6AHI8D6)RZ=0=3R..]M:)=O+G&M0G2^9\
MJX@(CT)KPM!-EQ@ABRHCW^S 31TL$ _:42N-ALD#S2 <=Y.62?GY=1*EK$5X
MQJCT)YVU<?S[)(U5V@#"3)X)T +/O"='(F'J;[.-# MS(H8,>Z@(EQ[?'T0"
MDG\MW\\HH9&-23#G<!2VM+S<_/VD9I#!!-K?BV":EC&!ZM&A5 $#!S4< E$L
MBKOPK7;"4MZ3O("@WG+WPZWU]4K^HW.+_+#6T^OL5B_^3K[68TV.,3IK2U!W
MA%=VJ73G3$_ZKAD66]XIDDN/]Q_&BH!IG3N*/9\&JBQ/VBRN64U%3MUI66;-
M>EUJM$W)X.BP&=V9HWR?@Y".)]L*M6K#M=>W\Q:S$#EZ -G6;UT?FS8>$U74
MKK]+2C2\0UM:<*;CF@Y.>_*7653^DHJ?6V)+=OAIH=SZ<E,551".! 1%(VK"
MP;H5K=UO9!9+,&(#J&X%(<WV1T@##W&<D,4B^%3<;OR6.Y3?I?L#OJS&'Q)6
M],!:(E:IZ4S_P06K_]Y8^4R25)9N$,;D=)E-O5S;]Q],;@\ P^+WSV[S4W>K
M;UPPJH^?XR8]3X[XNDD!'M24S'Z21HAJ]N#!/_^,<B3>KP42Y!A+M'M(B-FZ
MQ'N7B>)N/:Y3$B4*\=T4T,ASH#W831YR+!KK%QJ5YUUT7EZ8PZL;%W*JCKM=
M6M52;%_T2Q($J+/G;T;R)XF'YM[LWT-TN=FB<=$*;ZFDL8*T:M]\<,H:,\0P
M?K=DW=C*EG'<?+QLQI]E3RG_I7$ZR1B>QBR*ISA?NFRWXEQ'2 848O$'HT(#
MRJ!+!>CD$2."911V>],QZ%2>-_6$9<4#E?1(_TR>VVD%]+U(VBZ/Z61QAWS"
M<6F6,R''_$$5$=&X<&QWD]G<(0IJV22# #OY;B6H@NB1J\?N[D]&K@X""EM3
M[M\00',X_-9(XAUOZ E,B%A,?J\L"SJ;[#LS?BTS%>?F>Q-A8K4$WK8@D_[>
M^J[I,&OM-GK2FWU_H7U&FSC^HER<?Y"DZ0JS"L&'T( #U@IDD:?SVQ7R!68/
M,>=U:)_5SP+ZZ0+P]9@A-8UX,G:PMF"20S,;FQY9)/MU).(F["%<N/!)$[IJ
M4@$PFI?IAVUZ'.EQ,-8:!?YM!O)H-TQ_G+XRM"0#,%I6'[$'\0M)(E&R@_J?
MIH2XQ6:N13Y+F*D K0%J_>H.!.\U6NB@9'RG6A6 5TQ)^"TG,I=V4M=^#96B
M,7&GHOZ\UK+S @*C4'5W"H <LQ5A@7Q*S7IPYHU)")B$8R3%G4$2/+]EX4UK
MPA3BZ#";/%GLBF)*-<2GV,S^DK*8)9"DD:A>20V_X @\!*1ZL,5:9;CM-P(4
M7\!^H!).V4V^Y5%ZD0D&-\%L]%^)7 94HV-MZNE<ND.Q^#*77Q#SV1WI[^0I
MY\@DH.>L7LLM6%T;&&=F2@SA<'+3<E\^S^674620NMG$]ERL)U[1!)^:MD/:
MF?4WBD*OKPV['3JFXMI?02E=-LSK[))]/?OEVQBY8#9.L0I>B KGBD:XH](L
M* A1MNQS<Q484U<!"A.LCI0=7Y\2 ]F#;H6X=!;;!*9,4%DUF0*J @ $[X1+
M!KWAD7SD5LX+E":5F&L6,2@E <;]3DH__N4L]] RPZL1K$_0H:]KL9PJ;HU8
M1-KJK&*5&=2>9= "Q[(CF+O%N:(-#'<OWG#XAT2[<V1[Z\W@6N')1B\[N[:A
M)CM<.LW)841W9]!TX48=Z!UELK3:'@;B%VO)O(F *N$*6+YD;7$L,961.=66
M?(DB'WXI[A$'?(G+PMW09#)8RD[^Y:TF+IJBK9C4,K6")7<J3<F&FF79=-YP
MPZ$1M9'FTW[R6D$,]H92M_4G97<Y=8V%!A,]:5L3^Z^WV:+3L^2M9,8BG%IG
MA&!2_]G1VO3G=FIN,)#00OJD*<]J/"0WW*F%/#K>LSJT23;SF0."GA_NY$TU
MI)NN8DU#,>]B:K>_TTTP\U(/?-RXNEZ,'9P.^4FW#+^4Y1X>:?GX:/L/@V3<
M@STJ'[3\UZP9T5T\=NJ:'P'9JPO5J]KL#'</36QE=@V&]K0>-2,'UW]RZ)[)
MM9\>?)\!/2G7>X:^/5Z9[:U&J(NM8A4->LMO0=RI[F6'1&U/#F:BN)BL#LKY
M+P0CON[\5UY6_I^-ZQZW$KB[@D<75>\5IA4$@T6,&YP*A2[#M&Y)H\,L;\Y7
MM8S0-US !=J*-X"JC+XA _.+TEJ=^%:H53_G Y\?$Z"C'O5\S*G/;B%SK?<$
MOUBP;SX^H<)K'ROIMZ8V1Y0^8\#B&Z-B)6!S:T1[+Y9J_;*J0UU>N6%/>\2
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MZ3\GQ\\'V*/@'P<\D<>? \QYY9/*[+VH@8AF[\,VNI782-+@H4%VI(:I\D]
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MV?$/;Y#D^9RSLBR[&,8QC&,8QC&,8QC&,8QC&,8QC&,9_]E02P,$%     @
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MWOH7X-]C"/U_XKM%>HN<C/PV.24EY?W_X)-0W/X7G/<.$Y\4,[\&)<CE-PM
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MT+&8]SK 2=&68[ZUS\RV25Q[V >Y*CTL^WHPJ][LU:MJ)LZQRF>@(V"C3O@
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M@9"EC18"9\[%.6I&Y5N/B'!I/XK,N%?8X9&P?H>KP%/?^4^<[\9IM4<RO5@
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MQ-5G;=ZW/*?YZ )/20V_&+A$CM/A6&J9UVIJA[2<9??]%+D_1N;TH?$8#+I
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M <T10(DX\SE@DOMAAAZ;[\7.ZZ==(64%WOL&T\1IXT4E2!"J2[P[8UD7,B^
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M@(%P^)<DD=''O0(;K+1\>MI5W->'8D_V.V\UDA8W%1OANU!FV=.'F8D^FM0
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MVJG>BZ?L%3'\[C^ = ^QYQJL9T<!;;\LN,O;T8O6:)&N8'?%?&!V[>E<@@M
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M0%A9J>W@?"DR3\:P:#]),67P'3+AW?GOG0V"Y[ZG4)>/H4. ]PC!E"CH;I.
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MF')?WCBUQ-P*MXH%A[&&Y$T\=B"Q:B""[L,%,@"=+'IDX=Z?P!_+<NHB;Y,
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MXCY8_]4_L $'3VIG[1+%.^;P7B4?W[V63)NK;GF'KP6[P9PE*SO5YRV<HX#
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MZ?IHGA_<\^DZCA^R9DW0SL8WKR_UZ)$,T'Z)<F62.\!9.T%./:AH>/]%I+9
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M+5Z %YVR3\-T6C4C"'#^TO(53.$B\+7^"_)S9,?;J<@T]WC6_]ZLZ!\'ZK\
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M-WUJ-U4R*$H&=B1GROED]0<7VG>)2E%0/*?]LN5H#S460)VMWCO:4FT,4K5
M7*(,K9/05DQ 8$+2"OFVXJ[9=8#HMS^_=L(GM1^IZ/WS*DY:\@^W>WX4[6[_
MZ D(\+\AH\AX9.H1WKW)92.8]'0C6/YCI#7P3@SNF>R=[ 70TB;AVO"?@UFE
M;GW1WS51\8^JC5I/H<T<,6TL_WZ":V2HZ"%U)YD.O-O'FXLX)X<T:SZNZQ=O
MR)[TX*\J]V#D^*?A%G-@11;GF_DW? <HM25*?3&-''F_W4URFM<R:K9BJ.*>
MY5*5(UG'^AJOH)M3Y#D*N\_X744<[^(;+[FR;[BC):^$1E]!0"Z@@G6/8=%)
M-'P5Q:9F%. $W>ZI^_$4K-MK,ZE5PZ-D@TV%6,.X>!+CK$ZECJ@:'.,X,)7,
MB*KV<@F6EHU31,2 ])UDB2'T9\2MFXELV]2NZ0"G:]M,-[(3O6WV;83@@*\,
MA-1QKREBKYR^F$6>ID$<<Y+$4L%_ >51N &UED-C+^/_FU/Q?[!VH_/M/YRG
MRD?+G0&KV9E$O<\!47\!G58H/T5_B8X:S9ZJ_P6400BG7 S^_59K[.K:O<Y>
MT] 8LM2(-Y4S<YSIIY5Y]X?F>;S@V:KGA7>8CA%ST/GVRFV@\@N>RP::I1U1
M^0&&M3=&GB_/LE;3*'35Z!]1=2RJEJX]\Z/E@3PU%9S%4S Z9IS@M=^HG A?
M5S@S%]&%X2Q&U\O*P-]?^;#^NKQ'*LV_LP!ZR(;[D:8_E1C\/!&VD5R\\QAM
MK)FQ_:H)*E1G2.Y1^$ >C%U.24W-Q,=)][4NAMJLO&S"! N+=+XY\P.)0\IY
M=C&;Z6O9^=@ S/<04DC3L]$MKG7/ +"(X0!BR:(9,TE%$\/!4 ,9_@*,)_X"
M*"T5_^6V&8([''3[V-ILSKPEP'@7C;+2^5055(>O<W>V=\=V"@<P+Q\6'//-
MX,_7SC8--BBL["-G,1H:<NW'9+0(0LM>3@I('-59V;_\OLX]GNS65_'PL65*
MVRO8XNH(&6H#0+2I7!0),,JRZ=9NW*-NNK,>R^R);7AF!V97@H?DQ<?%2>;B
MCH3SUGH;RB35FMES%CE])<.<WN*Z1JC,F,Y5 C>DO3ZX\\68BW+"+?F@R8R&
M8,+5XVFL/1*:FLCQ1YFEJF 3VD![-'MM+)VQD*,$+_$9 =-QU*J,7U!#'I$/
M,1P#DZ=;G#>?6.0S3_NA6A$PCB#;A,:,AV__*1$ZO?L+(,5"THO[[CWT67ZT
M.3[.EWS)5ZH%?#]4Y42^/CQM%3<IZ /BX=R.^D(AF;0&W4>/?76P*F<1'.<^
MQ8I18DZL=&CX7/G(]B\0FOKDT$8F,=ZD)JX=LC'8(W9=RI3Q80C+LKS8!E=+
M&Q$7;/Z>@+&R%-4FFSKK%RW#GETIL,21M_YV\?1+K.-G[;UR8KKW?:#7 B'
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M_R/"+VGW)A^&[H42-O/MD\(ZV#ILB4^.>.^$XT8@Y^=K 1?/<>JY!=4><M0
MS<@J_DB';2T9$@KF'N8H;\6HVL"B!4>ZL2M)6J&.&8L ?9\4+9G?VXGWJ\BO
MF%BT8TO<#/;?P*-2-^OMU1=EZU_L]TC5PZU'<;U(_(;O* PI]^IN 7>'5<HP
M  #P%] X$C\#/P,0'2$*YMIK_W?-V'3R93J=&99LK#H_TLR 8$B$:7Q)37Z4
M66"R'P+2C)A(_VEV4!U9J*FH)T+\S2F1UG0<&=7>"2_I<:*DP=?46I[8D4@<
MS?06V)FC3"U0I80!95/+?5V'Z'T%T )U<7=Z"\9@?.^M$? @_&=)+I@0)G1H
MR4QO$$Z,3L.E+3)<\T'P?1PO&IRY^ PE>=DH_CV<_Y5MW@W->DUV:Y'*:T\3
MGBK]RK/OS\OJ88\?.58__H,Z8PMZ_+X=M>;C6 ]RT8V+O9?$0N-!K7$;"LW7
MIG:&[_@>QI_;!6K>BZ.0 .>V<2Q9U'$'3:O;11I]-N=.*&--HP]@W\P?'2P0
MA84K6(0[X]\^(8O?L2AN,E&>]M"I^-G]IN@[[J8YOU2N7V$C_=6IF[[I6FU@
MRFO;+LQ"WPR2-=!=/R/TK2X/\E(P'0]#GAVF^RJT/8%BEQ:-..XL$K_6\6R'
M5QBWU:TPU&20601A*.U+UXXUX&J(A&K"J=>%Q-D'B1TAVR"%<IXD1/R>.PIE
M.&BH=U^YX"5GJV]C"I.AI$!M@CK.$;OWXT8!-=$O:3#HCK1?5!\:7XHO6F3[
MF-=^]Z"W.N?4(.^Z54V2_I&E06SH7M>+7?+I#'=1M;=G5:!Y,I2H1)")F5,H
M/L]LE.:=Q)1N<)-'D'Y_C(6K1ND?H@0<4\/,?T%5"PQ(XL5\%X@+ !S] S'^
MOY!6K*)'@4F""BSQ+'$*0HF"<C1USPT=B1/#=RQRHCW"JU-N_Y($SEK?7)C(
MP(' QY*E# JM?D?RA%.RQ+#X>;=QC>\[92$!U+VR8#WTWA-+):.?><:(XR7H
MZ@:U[>Q!EFY!%BJ_\2A?C%QK=HL)BRJ\NY[71^E<ZL"[&2NSL,L9A,[Y7K;Q
MGWF?HT>,^HRP<)-H/(_L:IPLO0)V5IO^J 6U4G YV?D/%TD0I@5!0B'$-D#_
M%$T R_>82#)!U&W/*\;\)OR]O6KIF=C'G>_ X.JQLGD]GC(]$QL7*/[L8&(X
MY6H>*V\CVO@Q(R/>P=2K%CHH,D5AK>"47L @AB9AIJBNSE2$R]OZ=N%"IIR^
MJ+;+'S7#QK(\AP/UN]%\!C>JKDZR-R04;.WN?CU=V&':R)ZCBB!IPX(V^*L%
MG/T!['$';:!!04^GU5:R(6R)^3KFQT\41.*RK!D+?EP_WY<IUUK1_B;MG?O9
MI)TSPG9J\&NX'5KZB8DP4"KJZMI95=F?\%:?R85+2;(X 1=AJ\T>_$./=5+]
MCK"FKHDVPHQ^SN[TM]I@$)+XOEL5KJ4,N0P?1.Y8C-"XM4/@ELU+L&QYD$R2
M[0G$*'_I;,< ?'*.+$D%QRK'5UY_;@-F%[:):&@J[PD84:$IIW"\*\UM1>BA
MML3$9!P_/5%'4008PV%BPJ&%,GE#1HD\XB?)?&="W:[5A&8C1%BZ'IG=SWZ2
M)H0/+G9J=FJS@\GE-\E?M/W+_0?\\R#9FNXE;*Y5XR,>665?)Z22[A[I_3;O
MD2SNW<MGMG1/:QU3(X[[<G\0Z29^X=\:5M4\6*OB[>6MT+))F*DBIM,$CK@R
MTT3+,P_QSE)K[@I<L#;N$H^5"@@UF!DOQQD4SL(__CD!RCEH;RAV>["U+Y7\
M)D[*YL?U-QUJ'[73C[;K7+BL[-P:'W1OVM(Q#<-GPD?QP!I@U%P<V!S6*6QP
M:A9&GE;T8BM\:A247Z_Q1"H_UKL</8]7*:)!_\!E?)IMYI!;GUJE$6#8HBA5
M[T3N9T=D9'P\R4/(H9/A:-A%!.$*R:;\/6@:'&JKHRM(FBG>V:7L6BJ213W1
M[]ZQLMDYO<NZYJ%ZN#C-\&@")MQ15HK&2^IA"C'X\6,; RE_T&JV:%)FTC=#
MVT:Z:%FC3$GCR;TFFNWC%$7YSR8NT)A8)"CG3=91N(EYV5_8KB- _FCM!Z>,
ME_#\\,+SI]QF%GR#(FN/%&53;"(2"[@[-2:Z[NB5)HM-$-.4B]B$08/Y(O6G
MI"("!7*WYUO_[9KGX9['?Q0V#Y5_Z^"K&9!&MJV\Y&M2SZ#L1*6QDEF72?R^
M)=Z",IK()OSBT&0I$U&?Z1Q"74$;K'1*POK]-/4*<E8H3O"!2,LZKZ;$%SBO
MMWK#ZG!T%.U]SMSUFAQ/(H?&D*!8>YM/.FX^H7JJ)6UC[L8"T#!+]HT:$Z^H
M(\J<S9DCOFLWKIP;T?2^9LG'A%^H;T",13'U.2+^^C9\:"@O>4NWU,*WIA&&
MMCY[ANMZTEK1*-24<TR#9UK=:KBE>V:W_UTW14-X<I?56'H-Q)>CBIP2MV)0
M[F3T\%@;Y_"^O."4#73NT37;E)$\LUA$NGC&M/ 8J1I0M2;,G2*'0?R36(7D
MIV5-WZD0KR-H*8]FWEI$EQ^RN<:H/N82I;Q?XH\U"@O0N/4^[5Y_O$[UIOL/
M :/ZD:"PT_Z<\+FPT:&KBW,$%LN(J GANBQ(]#+.H"+D"@_$IFM(*=E/TK%4
ME6N0E@6ZU>'3#Z$0J=D)#>VJ[>IY0>N95FQ=!G65V0AL]LE1<$4&8^;>J;'G
MM4 0W)?--GHLIP2R,G<#^MMY&Q.=W-T?\83C#O)J;O",EU3,+'W6*2<2BIN3
M9,FB8X4BL4*)>:\_894^(2Z+KJD>G$RS:.([S5R14("%HNRT:T8'M\M8=ZRH
MM5;C>9/SU_(*G&E0L\; 6-DN[9S#&L/VFC@47ZU=E ;/U6:T=NXP70AK;+=H
M@SKK[!DC"F.;'9K3(8(Q??656QV@!I OE!QXN)Q\]Q= WNB;N?OQ<K?Z]?!!
MT"?JIO339,>&W:7S)SG:M<_0WYA_E-S M!^\')M0>$H,$+T8I H$C15VN!I-
MA,5"X&[OWB4C2)Z]HX0[H:3XB70'>-,YTWF$GE\N^WEX7U[>OP6$7\"F_ZV/
MB[O5]?-JYRG<#.\%682/^F$'O;@JY8Z/4^VVK0]97R]>8=1$%.="\IRF'8Z3
M \G'182V=)FV3 'W$U^]W4[V,FH&/U9WPC)'EJU\]ZV/_%6K"ZOG#'TU9'$*
M'>6+Y%W$%P3S-0A,"?XTC1Y<A1Q=NA%3A"3,\4Z:_RA/01Q67OZQY_X97F.C
M>N)E]4M+4T-CCY&6Z"96N#P)#X7+\MI-0)52R\7L,4>W?(=)'?^@38/)J28Z
M(3B5TC^P^<.'Y?+9YL(SL\5BV[4I$.%LI5:1_;43R>+FJ'K59!ZUO5)<6KM^
MP8_>5!(%DI%[H=??8$<['YOREO>)[F&Z>G1%B-N*X$C!,MLBNQ;:H!UE:Q[-
M^GGJE*^G[U)8U4[X]%TZ'889^MN*?"S)I=JJ%3A/!VYTLEHF%NLLLT75/FC:
M)E$%S]U<?XPU7O^A= ?^"[CZAM-TWR-]B8[25O$B[O=C8VU=+U\BNGK[+&R9
MB[-Z;H7#M?&QI');KDZ<UW6"TK OF)9B]+-8U:*<:-1A !Z#QSW-\@/JD2FB
M:<(X@H>29^Q*Q8A.E_RL/M<@?-C7/P68%QB0DGD%2P<W[#5.KHXI4YM=S&E:
MY8PTU53/GBO74>7]O11EV07+"[Z59#WF7QQP.^2*F "&?ZX_WX77Y'G/4XOT
MGE"+?'\1EG+)974Q^'?4V<IPFU*_9<*9K&D2OV+0UI?)IRA7\XP\A-DOLM9L
MMHYW8<U$,$:O><#"RC[;K<Z1B.$,LP9!_9L,0'K.CEH4^?D0?N\EPY%@U':V
MP>B@<7JPU/GZZ=PW5J=Y/>F+AAFM):^PYM>B2N]*Z*9\KN\";.V)WD9\7TZ(
M%3VD^:G.!&_0-NH(I*-!'TEV1Q$!]!.+R=QBXKD-D>6I:#N[&AO>;'?<YFBS
MT./7/ U73='!0?A27_TADJ:"$JK-!/25<(";.RU%="L(TY0LM\ H\E7I(=U(
ML#D% 4N&;'J+(Y?G45A+ARL::O$IZRJ4O?;9=LI%$MX%YGTP8'&X#N"AI-:[
MYAE2W[8AS4:]HF"KN*ZHE)NEW\ 6V<ODGN8;]_U_@I1AY^<D("MDYU65Y.U2
M6Q^'L";9.XQ).KUN[Q2B&E*^M/M37 ZEK:0@4\9A'L-&ZL# E6Z35H/5<=U.
M75E>;VDUB%Z!%"1T4"?X+&V(/-PQR74; 5UO6,?,@W2^"#SXC8C079>3JL<-
M4DSHL@J?AQ9SV+EEE/\%&+Q.+4T;\C0]/< K"U5=2$3LHC,7I.V."W!>T=BF
MGI(GVD):+OIC\#77;+0($KQQ]*I-V8AJ[/*<<66\^@!)'977-I"!D/IJ7<Q]
M^XR"@US9\D88</MB\<O6GC_F$M(4JS#.G:S,.]G. <QE>@ 1'0NTD$*KY,7@
M(73XU.;XA>A!ASD^;,-T>\+^OICC??^.+%.LXC=^D9FX+#NSA%$,BJ4&;LW2
M0JY:+DYDJQP'G9ON_P0NK7B("&TMC!5>;]0V.\^/=G;COI[F,X&H@Z14HC]3
MS[<HT&26C,ZO+VY!IE7FL0)UZJS(97@/N$PACX 2:5">?DDCM'UI%'NS!/%)
M7=P$?G'%%I;R9OC6_1-^$FR.?#72E584\]GPD)9Y,=>H=F$[3K;(=R%+#AZA
MX<M;N[.=D7<#A1,?W34&T9$"27VB<'T3F[[S@4^;2>9-BY.CB/HB:1,5S4?!
M[X<"DCK['H['59(*7 F&Y=\K?V99D(7&5/Y,+*>]^YG(G-VFUZ:8LVBU'*S#
MND;"6L@YD=&QZ.'N-BMZIW,YYVR:WF$3F"J?<EZH3IB,]&.>_*A7QT2!MZ]+
MP>TN:2AIL\(T)#,2^M9@6%3(KN.]F!"1NK&X)?51FT5QH(QY+6= !=,Y)8)!
M=X-&C2.L9E"V;Z!>X2\@VH8$?Q9?,9/^+V!"O!Z%SN@:ERN3:]QQ,%J])0MF
MF3HP#;M)M>($;?IG-^#,/%L*+.Z4&:+6UL3P_(Y#_E$/B@,B!R9=*$>0)<K1
MURN;'U(>U[.1\%G_*O"X@&BV[S%.0>*B!CAM<7%! YH<'&B42* ]E>#G 7Y%
M !6^-C2'D2K%=R?C<Y3463S#GEI<5QF:4#)DA3+N&8$TA30>-Y*)@B!V24KX
M_?%L,..5L<:MF# [Y6L$S3JSI-&#TU5%!:\;^5Z^RZ9I1WV%1UVGI*Z>7K->
M."MKT+Y6,)^'DV.U&5DG@0)#77=34G*<J_^3# " @DN;!*ZM>O_H7J-S_+,<
M'KE"#E[3,P%$BFA-!J5_-N"@##MNP%LDP:^]EZM=*L9GP7]2;$ )#3Q3'X#1
MJ?QZA]1BX)GX\2;RZG4(TP#SIM*4?UJ/_4CKA,]EUR(?,T_NC>&*B_KZ9XA)
M5D;GW,P53CJ!1RH$63NKP S8F#YBANL\0Z^#GL9SN$_=#-298S-6L\)6)C6'
MS4@+EMK\_@Z-LCP;BU\]=P[ 3.QL4=#Q[LXM,#>;8:\)0:<N^R HUJ/TK9;6
M&F DG5!*3>CU_UHV!?S3LLGCW^WTS=V.WU+SKY?JO6H_F9ZH*9TVWZVA?\0,
M^^:X^KG-#-[VCK.,,!+?#2:O>36G9*$FK@%-?YG>".\+_%[SL$W:-0J3JRG9
MQ;6.M7Q]C ]5<D#VKR!PD!]4I8F$HU* IWD8ZC[CI!V'J 5.LMG+H>""!%.]
MLNY(.=@V"SV. ,*!YYE%"!$UD[ZA'-_2FMRV'99/!9&\SU=,I9J7YJ\JS]:>
MI4X1-W@A<8ONI7+)VX/\B8\D#5[.N8)F_) ?BL>%I9C5J7X-UY]TT/ELKZH)
M3)<ZI,O2QIX)@=[KZ!<3-+*?EB;^)*>8':<SB1$"G<E'SDI!&D=<G3\\F!(W
MZG/(H_W->9@3*YFDJM9:VBN4V S&*<_<RJ%TF_22UN=V[#X?V^>]JT.%H+10
MC<QBNY,44_VK*4UQ*S0,6A3,P>/T3PV68Y4+6KAXJNWT I:<4MC'+9\SNV(D
MNON=&WL [@F2KB:.$Q+2:!7T)=Q3.<9<B,9Y@0/P%RYC HN_36?%T11E(ZUW
MI$R[@G?D2X$><*?='?#W:.M$6NEU_Y*?&8,/L\D?74II3%M*G\ >#K\ICS+>
M6C?FM!S";=W(1TXVP4287.%QFRSF8QUUE)RQ4GW')Z.%1EOEZQ>,QQ4H9S^\
M+$SPY!-JRFS/PXZ > 44ZAT<@)Q.%0IZ2BNH+_>#R:@(PR6%)E3W]N[I@<1D
MY/'3G*JZ^!#WS"NXN2/S<D%%',TD@T^2!+_02*;3\7"-2NLQV-.)GI,,;@:,
M+#]U_(5G)^N^<CG:R6-):.EXSH+%/4JF>W].T6F=@_LG7F*V=QNQ;+4K%780
M]6I]Q"G$NOD?I6EHR[/B7,K>;4'1SC$L,K,&)>>]<8M3(%RBAX4&L%)<HLS(
M;M57[R'@SQ/3-GHWT2G;^<,_2DH/CI?]-]K=EY:= 94ZWB;WYJ_]M#D\ ]'?
MR S</==\5$L3S^)H4\QW>(P([K::-YHGNX7MQ!,#&LXT(I6J9\E]PTVKRNDR
M,ISW(N/<]!C_ M@8GG"GTDNOHHR_NM51E$IK@1#,3EN'::&-3?6."FK@%255
M&%8LT.9T6(5PP+IOEOU'1'VJBC_T0)RF,G/"7] 7=U^?0*X/J==0%MR"M>2"
MZLO[[2'3WWU>?ZM#UZ[95"#T1<EN^[:2!=\(BNN@HT/CPKF 2AX(E_,]E_+P
MWVI.'@BB8ESR*G?X@T,5 >\U/1P657ZJW )P2M-C* $ N!-18PRQ9S.*.[^&
M(T%P"1-0T/*0QA7W"/>HV+3 !2G_8Z14 4K:=QAC!")V^ H"Q]-C0-7EG7_W
M7T! 0$_/Z?-?@+Y_MG]NQRWLV<?<\OPG8/=3PRV&\ANZST_1&>*IR2/"_W]R
M%H$0K[HSW4_]QUT^1?EZJVFR-PVGV<KV:V930783,N<,8XU^%TUZQJ5T[K@F
MZM9O'-_B-NBVQ/<2)]5 5>O1*6\-#QP#;':M2_WN@F O?C2W<UO;$<)*-=O]
M)EH27G,C2H34''Y-/ 492 7.WA;SH3[4"6YEJ;C;Q)9(;2_PVP;OKG0.X?)Z
M,Z;'!VPD^W?!RU[K\#K=Y7*G&;BQ6)RT\GY*E1VEA5)H*V7@+(EZ,#JE8\"V
MY&Z,H!HJW>M>2'>_WQC_]= @JW1M%]F.TD*;A2,'56<5RU1#2P+,<1_--[SN
MLNY,QAO70@<KZ1DM2CU_YHH2[\@_9]/'/SUS3^C_^DD3<J#?,.&DE=M&1H.1
MC"XMZ_)3%C7WRF=>09IOKG6#D.APV[12Z#!6Z%=.@/K3.X<1]($++0%K2O7R
M?%3VRK-2=;F]!I=.ZD96H=_[8E<2T/ISBA]I%'E/_M"YN%%XWBH"Y/V7C*6"
MG/C8"P]L)P_,DSO.WNI&VXTN+D00=:LIG@*;OTL2@S84'1BJJH L6G"T%%>_
M6OL:T/Z;7/)T[?>B*+TM4>' >VR\X59X=WTSL"+J9Q^?K^+[#@4#.& JQ9E1
MPHLI6;A*VY/ID4^#(S!G(8W?"%?G;E HFM/]VJJ$Z'[JC\&*,HK%_-.:"1&=
MRVW,MO?07\LX77]D \\H>T8]HB*O<C-GC&7Z7@P/ X_.9?;^ F1O7=(IUZ9)
MX%I64%(6C64B5HV12E:XW*93KOXS@BQI!?T*%P].\2IHZ[O@1=W=[F)%R$T-
M0NQCLV_MC*K\QQ K!F?!JKLR_M4_;"<J/F5^Q5,4HT0.9T"K%U(-!M;UV8\2
M8]#+GU)+S7/&.V./4M.(&C)-Y4=<$_5#2$UU,$*4F,2 3N9<H,K9P3V_X%89
MAL*@+?KA^H]@4:-'YF;7H5\-)P86TS&?WSUU&$J=&_3PF&\^/2O2("JGH="C
MXQ35M:-L;A7[AU%=CQ>.5-%DM#W)?*2@VQ\5HUINCEMG/ ,FG/+PGLZV6+*S
MZ-CQVDI[>N.JEP&C^&C%]_=JA+I5M>0,].B%B7P6ED-3+B]VZWB["412G.2[
M>FO,+%?/33P:O5%^[5.=V*#2E*0DVCI /K2ZQ\+;+I.,<']?24%]':,J+ >L
MR37ZA7%T9FI04*J3EK7+T=,JJ5!-I645F$^Y#123^,4R\K14S:2G[)4)_IRC
MI-+//QW5#'2_)L..*Q]3C@;\C"DMLG%<#)MC%.?T\L0'7QG+MX=+J/:UU^I@
M)D/$W&BU25?X,6C_F8[D]?W^-^*'TK^ %!+I@%(],\+_W"\0#0EGAL6HE(XJ
MR,B6N_B&R-W JG#YA:6ZK['ZRM+V[@'AK7FT=QC*1OJCI%P*JU%$YJC>M#16
M@-R9%"3H"X8L'Q"C#?YYRK9KM>?.,7 1S#I<5WEF5N8.Z_[CMFB>TY:9J+VS
MQ=MC:!\49.-U'/Y3^V$%5LP9+2":/\B=I*-Q=KO&FO-L8Z1<57EM4#O@R<>0
M()/'W;!BB@1%8/#=@[2C]G2F(*%GLFM\/YNF!$')&OR>SV[+\WP:N##+H?43
M8D3(7N'29TI7#=K?*'3[R 5^>50K3.HR*:P=L.4<N10Q31[LK3$DR@FLP\#A
MU$GU%R1^&M1T2L'BC@5R-&1MUP8'/7)522%7<@/)_?2W23X$-FR475A,,U*]
MT70%#4&4D49#+FCQ>T4Q*8TGDY;.#=U%%D=1/"2;UGV_/"9$AC8JWE*F_=->
M2D?(I:L(YN>?WGKVIWF>+?Y51P?)](%1"+A*->+2G:U,'&-[:!]BUU9M#DR#
MX)=8]5^I3_&LTUJ.BLZ^OLL=JH\L=Q+G -'"\:HZ/'Y*D@1RG-<,*QU*_ F7
MTYO4>$A$L]Y=B:^C?.MRSZGY<_DK?! CZA;V^0$#OVZ$Z:1R\,M+K?[2TBV+
M$D$5J<6GC2J:1^D[KZ&8X-H/[X7-7;*O@Z<\D*&2KIW]U=\WN*HAP06V8Y4:
M&[XQ>^M[RYP?"W,5ANHEZ*KP-7"]3+,_CR6;X<:886JH<L8RNV[B)=\V)KWQ
MU*>D,K4_E5&/LE23#!9Z88&9KAY2<UQ7(N& .#/3RLMOHQ2X[BTB/CONR-W$
M?_S<L.WY"=@W])=7*ZJ7ESV7M&V7H8X#/[[A3T2_K]$7(M\,0R52U8^-G=YH
M$<;YJEX@(.^5.GG,V&PE#1W 89]S6Z!I(-V57E150!H8A)HG,\L)"HQD>'L>
M,S2$6\CU#>CVJQ=D"-([MZ>S7>RKE9\@EU6%=DTJN5G5( (>1BW":T0-%3>Q
M/U9=T>]<M%] _ E?F)>U=XQ0K143E1#B1 M)3TV0HN(D)ZJIV"QMTH5M,]R<
MJY8J*IW[IDD=2'\! *_P\R^K#8??_R=A%2<;[/*!R+WDUFY+]&QJ,N;7:\]@
MP!97R"^*/Q1[-4=W97\!"R,Q5OR?_LNK$F,%(2"5(Z6ERT=M6;"6MBT^RG;B
M,X8XI41CFP%YN=/*M$C>D6)D,4SJV2DY47VBZV,%JI#5*.7C6,"7H]&T<,N6
M_*,'=VUKZ5&O[)(%:Z+HN>+@JFE*QEE,NXH6&8$+;QTVN07K\%%Q!($%W961
M>1Y6>SO+7_"+";DGC<%^.?W!ZZ)&:EK*$TDU+L$G8[F;6VP\B63003R'U5JV
MCM3]!:Z.I<&9>P*G="WL-B6[,6:2&#-/AK14*59#%"U3S'$NTU\&Q,@AXDB*
M62D\D#LE^H%-Z-<M&RLEB;",7*(::,UP6;EP<<G[OIOYE)(,*U$>/J,I+7=D
M^J=T,A_U&OT938?JBH,M/9=-'R</L)/BE\5?.F8?2/V JD'YOC@%*IZIHKYG
MNQ_0"0S"HVKZ."5XB3_R)$LINJKYD+#'QMHG\;*L)RWXE3;;1X&*5;$PJ0 (
M4OZ/-^;S<J8Z5NEK<L60@U09X<9$T.">AV@%%X=I@!=_1R NH@I !0!_!B #
MB :2KXX>"/V?%G9$Q *';GW6F_#U%QB?5!:>*1?L%1F8QUA476D]7;'/4E:.
M(G92M-3JY4>)6O-FH59(< !5B7?2'$%)$/N=A>/+-3L.<!:XMG%-AFS4?N M
MQ)D*;6[$_.J$!TQ_1_8MI^*/WO?MA_ KBJBCO%FCK9._ )+%E3V(>LR3IN>M
M5IY#5>:2',AF03[(2,UF/]+[7+-SA&BIV)8FI?)EWP#<CM#@GGQ<86$>/ @\
M^.QV<>7*,JA#^!PB>*?E]L8J-]?Q]/#H45*3RE=6&F7X!]2_MT3]>\FSRJ/J
M6'N_H4@M:IJE([TEEEM)0*^&@[8BW4_BF)IX![N8XW#)/\(&)MI870(+W)!N
MOVNB:( U&\PV %5.CUXXEWW9PD(+E_5VUXGK!II@%36V0Q\T*NDVJ]/-LB(T
MV\^AVBP0Y@2$=&D$.I0/N#H:NA#N=5H@&+WWVAJ+$B$BDNQ=(2@R$+/LN[S8
MNT"KEOX3;P[O/!0_AE>Q+D1LSWAV  SPV<_]?'E=E(DWK,(>QBJ]EPCILI_W
M2L_0*K<'V356[G6 9AX(+&G3(UDOOKBF_Z#\+[+$L9SK7O]YS+5Y/3OT^+&)
MIX/SYO,&K#6H?D?S0E,4Q%73$Z^2:^EHL^UK2I!#]?ZO?(A@6AN?5RK7)?D[
M)2B:V?>06D-^JQ5Q,I E?KEFKO$S*FPI-ML"=%"C4UPC,$J6#LR8C+KR[7(2
MI:530*:2X1?!&%O>K..>C7+@D5=3S^B9[*VMLYZ8Z17VD*TYII84BF4-Q.?,
M-Q5IA 2#B9,DMN\O6K]O5K9=Q&ZF"']VJK<39&/SF)_\5NNMKBBO8?C9T#N_
MV'N'(=ZVPZ5QXX3;]0-)W6*Z^?-&M-,$^F9!:^IYFDJF7FLJE;]P$X,C>$]@
MK>ZTQ3;E7*>\JG&)0KZX3][C=$5[OY))QWGAC]!6'AVT]U!O;23KU )J-=AX
M;]]T+I3+K]O5NI?O3JR7T=BBYJF3E[P2A?/(V8\Z)' .7[,O2ERH21O .*KR
MUMV#>WBM,2YC;V&;2P,,./<6SW(9K[4_H9D_TI1+'&MD* "L2D+/V'=;<[(K
M4&X4OI7IOZP1$=D_)KZ5VDB,*#QZ;!GS.?;[&1SBKD]5(NUGY.Z7OU0@O&]5
M+I1>,!_>R7/KII SC(!-]-"8_Y,G<6;Z_C??5',1MVZ4M\/J>-P[IH<T3]R'
M9!.S:Q7;E9+UU1$FU!B.3XNDD*-H.494.<*?=W'_\=C#L^LT&:9X.>AE"-SE
M20+GY7O-8I$VL^-KR7=9W3*$AVG756:.>)IAS]E%H1752RJAE?H=%KW,Z)[J
MS8DRJ"#5IW?*M2._$;=(':PR(ZJ6VY75%)651^O"0B/-'(P[COEU/C-RQ<=;
M1RI?:,X/VP$WV\7O535159[CU"3'/2<C38/(#MIUBB&F4=SUH860%2;JN-=Q
M#E11+V&K,OL>*Z<X[UB_\^;IWUJ\T*JEA0;_UW5B!=7E,ODL9>$*KA&MPK!.
MCL[Z-IB&#/UYXCPORU5\-T?,:>\A[3+1$.\2T]G1R/''6$B#'8<QU&GBPE+O
MJ-0A:'.K5^X:\S(ATKI/@LH&IHBX9IZ>\!5:F)^"2)+NL?47\$>./V:RP4 _
ML80\KGM$GF0_%7]+J<9M.=D&:I.]FT[Y[0\=\@)CFML6:ZE+\2(U^+$VEV\>
M?#O]Q0(/>T/)Z9GL-@R'\IY<:57C/+QY\_>%0Z6;8#N2F)P:R8P7@>:X$NB*
M[7/*Z3%RH>8WSM?=KK^ 6DA"Z@^P_#X;TX&2;J5B9LI\98L**3#(#H*86GK0
M&;5,H?>$7-WTIM<8A_Q80_,GCA\$,M.8.9UPEJ(NP54@;.&61R\FI^WT^<"E
MHR9HVM4C9[(LOK=63ND615CWN+J0M#&ETX7K=(L\<'?"0?TG^/PUP.CF,/I@
M^%^91^MJ9H#V<?E-IN%<Y]+1#'H4'=<S&M024->UIXAEOBGYJA&<5%HN5[P8
M]9&4] 0S5%'1&"TTP$)2!UYG1:_F"^)?P) R]1#*7T!&8"XCX5O$][2WP(/I
M03XCED-!4&.G9+R#U\<Q2S@[V^-Q\SRJM%&A*&'BF7)H@Y(IJ$!3QO0G?++F
MG-Z]NAN;E)V/QVSUELYU,BL=6%1/IWD3?U!UOKGJYXDBGBNW<8[E:F-@Z%?_
M,/3-[QT>5AIQ_BDTD;WJCTV3W4FN(];:F[T6G@,:E@9^L4URIS9GYUO*-IG+
MTG* JK4^F*;9Y<CWV;/7P:%NDA>5!ZL_5JDV_D0.W*XO7WM&[YJ]PDH"KUG!
MISOXF;]O><@04;?#E;GO=)I[6>Q-%L99"R.3%B#R*23+0S*=RQ%.Y'FK&?[Y
MI'&9R1+A1E#]M8$7CH^52D3=KOXQRRZ?YI!D2O'%/>S:66R"B'3$.733CO,D
M:$WZCT[4?4:=CFPE,FS>9(@]=B(JL5=!&V?8P:T?%X5=*A4#$N?N?\F7'T">
M9:X=?>C[G()>E'=R+O9RL6U:Z-=<#/ RHY[Y>' VPCXQ.OW0K-P*NF;KGP,E
MKU%$T(I5F:.80W*.;V8;=C;^IZ;+C/=#D4AQHX*/4GF;KJ'7(_6OV=HO,I*,
M7,"\0%H*W*SHXF&(=UY:7J9,8/TA#N"=V0EYT=,>YM"'B;&+VI)%9A:S,1D-
M"G4FQFL/0"CY7LQ>$%8A9<1,X#76')7CBR3_DT:+;![H$KJ\<A!ZWGNW^ZF!
MXG#29R#@;76U+EOY_V.@(E8UO->1<$O7G[N8*?/*;]@.CIM(K.N5:.\6RWN-
M]L*OX$ZP0.X@.%^P/Z9"0OMA@*F!)Z5\79"O4'+.OTTX;_##H*Z'UN<K(J>,
MS<97^%)W"[?OD(4*C#*B<+^X9S#\T13Z,^.+_4/\$$]G?\35I/^T9!-.AD<\
M<$8K.6.)MH)3">P7XL$,2NS;G:\C=?'$31KND[),\E;X9K<5NGS5(:HE!QJ?
MM]CHL2.CH47D,-29@U1_F1V+Y,@R'_R]CCK 3GE6&FV%B.'"E 7P8VO2LQ4L
M5SWCF1-:M&2A@?Q.Q7Y#TTA(HA:--WYHB8_V6X#D*$VW8M ^6(U679$;@*M8
MSY$KE&RKE&+)LKY6M8(]-<].#QOT%8YK.27,L0>48R(*XV!+.I;I&5:^QZB7
M$G;+WENSEBN:#"4N$)?AM*7/_+9D13P[^A]",.7]"?<\P,QI?C4Z\6T$4N^"
M0N^HT/3\R ^&PHTSB1>;8$6@H@C)AB+TIT+Y;MI8K^\2)\*SPXHEW?'=L@T&
MK!(S'9/$=6JZG7-:R9X)_66F%E]1R-C1X#_VGF%S0GVM[,8L>]Y6<P)7UON=
MF,;E+]\"Y\[USPU635.7(;H'V4*#E>;)+^ZA][\_?.&R70',.Z))(VIJ<#)
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MOT#H*G?5E=3-3"N>PV(HK0&>>0WZA-YOPKWH_@QQ/72<I(=_ .(__^D>AG&
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MXRH,$B,_ @PY5E7P^@P=J%U<C7%E09<W(L^..0_XXOK9Q3G^\LGC2-Q\[R3
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MP9 3 B7.9V]_"L'KH8=+#<  >U2T#1%Y5$"0BC]V%Q9ORE=Q$@]XRM<A$O>
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M-NC+4?S[<7)%7FB-<G%1"@P?FD*(I9F"2MS&;_\D]FIF>>_<EH31"B.G4KW
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MKO_C>+?HU#\ WP'1H+ H]!\@_.@MQT*4EEU>@W0;D4%,T8)0#%#*NB8EY0\
M" M+R9[=/1\@!*$" <B6^:: YZ1 ,;9W= 6"=$OO[NGNK3/*G<@##KEX\#A"
MFOY;4HF.XF/KJ5K-LX7L"HE*VO4Y@MO5;PX*]]N_3'B08_$M@$EB6QS\DDNF
M2NKIS?:S"V$W\I;E9KFFK4'==EDBT35N4)=.>BL@(_:'#W I4CEA$@QUD]$6
MXO"DKGRIRTIA)._L<E65-BNQB]6+G(SJTL=\30ZGZJC/2;-/L]@"E!&"'I_
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MHTZ5FC3/0/!)XJ=,W$XE9S"W!E,GRH-)*D'#A[\X&A/$M0'!*-1=1Z2)HY%
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M99U+&O:V1OM?62H/7KR _DLP7@$U-<T) $!>1"W6#Q#=$_Q))<$J#L !4@(
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MC=ZNQ^E>8]X!*6T_DI&)6ELWB?APR(T&$^]"K>TW*FP)(($ZK\<>O>=9@T*
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M"5B<&Q*PHOQ#8[77.4P6TO1G7FV9\<0J3U"-8/(?@,@%2[=1V!WJ^(/Q(E9
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M\H+)0RZT>6DB2F8-R>[S^1I'336Y2F99\QS$&BUL$MCD&GGSGFY=>+T*9Q;
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MN@DX?K^&R<\XFKH1@UR+PQG[D5'+L$4@MZFH*5G&G/H4#KF70=X?G%0NB%*
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M+Y>DM&(AI?G?@IO_#.GH5!?3?H^W3CQF>\Q^9=)2=)%P&L#4]^,JBEZ75Y7
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M<.LG*/3G#G18.AL$B>*V,&9+Y[#[2"%X$+?T5GG\W_]),TEBHX6H??S?'VX
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MB4_U21?U%K&.WP5](^^:9V D;/VO:(H2SO3$W#R)'5$_X)3%23NHI&D1MR*
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M/9C/GA_9VIF-KY]Q]5[!I47M,4;Q)%$[?JQ[$QEOI8\$\]XX"6<U&VUW<-L
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M2U:H@%4-",5R-?$RO$DM&)Q/H%(".>I0U$!ITY_JF0#JR<MG?!LKX8E.O/M
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MJ-9H+ER>WYQ[9. "W@97O;D<Z&_0K'EZ7QQ3V!]UU "J73K9AO^HT[+?U2L
M+48O]!G.A5NZUK77K7<@O1VYB8$&W1]4MMTP(:KDQ$E:H?NG500N6"T25$XL
M<U[.'TX/Q:3LQY:KRY^$(O++PVN),ZJGU6:N<OZR4\\S5PY3P<S&QQ"C\S&2
MBLN1?%KW^<Z.K'ZKEM%%4>EWIU+@[(L\[\#4B)4D>5LWE!?^G!"UY]$^,A+-
MD:%5_UJJ(B%,ZLEXE*I@LKU@S+RWZ7U/A8U)H%?CT= 8POV$?BI9>M PU<JD
MTP$CWX=;WMF+(1N:)9K877-,0.A<Y])!3GXZU'5X-#DUE[MSW5DS."89]3E5
M6!W2%>GW:)WL,?!%:/2$;S7N=G\CX>@_96?3BPF/?KL<F#:W\M->KRXWPQI>
MI?18Q0KW>PFG!==$472&8:N*V'CA&'>2P6/)&S4GCN=A.E=7:?+P;M<F\=OR
M2"8BG>3>:YLE]/E9+GXB!)Y,>JGZ=D.VF8WFH32\V1EGLFXIU][AF%+SB]1F
M8W0[(LWA]L"'=^ROMV82NWXM\?E$?G+R0E'BOZVU8<2U),;L77"EN.);"[#H
M'R0JSKRI5A=\^23DOL92A5XZQO.Z0JZ\LI$_RD]8(X&Y]P<P[+VY9.QDHXN>
M+3G7Y?@?>?#OBGZIF*@/FYD23>"V>N[*>'W3$OY&178[AWR<V <5:[Y+LOXR
MB1'2ZGW5X<[X_2#R!5.G'\@5U-L4FO76K*@*F-1YC351TL[O8PS5^Y!+";B@
MPN%].D#8T )*U3K%4_=]@/J\)R;2X<Z!;,@P4&UEJ4ZJJ]B4^I]- I9:P0<R
M@,IH->D'84G,%0&5E8*74B[I%^K,8W8+=8&!N22M=ARKGRTZH[08=):M=T]F
M0S_[[BUU_3\3N:0YRG'QAN\.*&,N9RFE)<O&4>V*J%K()QS.456DP3!^GDHN
MKB\%C+/4ILJHT^'XV)Q<!$.NEY.*/WV'>(H%3"QG,)^L3@<>X4[?\[*%SG^>
M8G$LP&(>5$CLUWU_'!'*Q%_HGMW?D+-; Y2W:O_QMY>2ZHTI7RRL*78C%:>8
M2>4AY.][2F]"W^Q=_)$D[2>?02GYVRW**\*]^/\M[.7G;N^VJ/;^EYJ7M*;_
MQE#YU//Q&<#^#.#^#_LG5&VDTL([K*9C"8AWFIGF@XU.!??%^._BW@^VAWPS
M?,\ HUM][=>I6JN,$W&?1:MW1JN*4S0\ 79.R!ISN$6&* O"=:X) I.-4MU+
ML?;-84KPM[>%<@ _?DN.&0],3PE#YEY6+W:X.ASI5S'4.HV/,T=U6C@R5 DF
MS X6>##Y\KT80?J?A(S_*']!AJ]SQ1&"CTX?AHY._XWQS341T7W4I_O O^\8
M0Y1;F;\'^XC][?2;E&I/W.AP'JBVF &-#<PZK[WC"XDDIS#:UBC8RB[C;?UY
M:(TF?\I(-?PR!R1G9T6NCVZ<_1@6>JKZ?Q'VEE%Q1%V4:"=(T. >W#6XNTMP
MNG%W&I?&(2% <'=W:QJ7X,'=W9-@01J".[Q\;\W\>#/SS:L?=5?5K[JU]KGG
M['/OV><9<-M+A6PAB5::D6]659 T$=0KB9CD!WBK-,&_W,0W2$"HLE$+5.[C
MYF<23J:W92RFU?:P:ZA"62[ $REG3K'>7^32CC*C>4_Y89#5:@$'8]JD%.I>
M0@!6M[#'G4@<Q%"G'4DIMH<UL%1RL,K&TKV(922J2$C:D,!!4/S&E3PFBU!)
MFR0%H&+:1#0!)"%YCFU.N.33)FLCH.0V<^N_GM[+D;UZ(C<@51NVR8RNU?U%
M(IB4D9,=M,1"PR)490%-G^/^F"J5S1 [QYRBWY^:_!_E<LO/@'WFLJA.==X+
M.BYY=-$D3ED-"9#-GS</_L_3DA!%DB2FTCS9<.(M?6NSQ$'2=&^(&!)00S]2
MPNR-$%:S=\+6I_6GQR:_O/RFC&PI^T>"WZT>JUHGI@.2##NF54G:29QC[9)5
MTS)M/.&]2-2$R2D',7OM;F&N5:,)&YN)7@^;SDN_1Y&<NA399Q2BI)RMFMV5
M"<SO)2@S#"%."H=2P&*\D6EBU/4ON06U]+FI,& PJI-V]FP=2)9OAU7?:9RZ
M04_JCQ0"49[[;Z90=R)7[)S!^^W186K/9A4'(^;TRC%_559$PZ#Q;QLZT2;%
M3:"*.&(8/4D=J,;$XC<]^>Q^1BO0)YH6_\-PUTTJ_L([=*JDS)J/OQY&^9?6
M!.V7Z^R-Z1<F:[MQC,!GRR;[,#]9GS6T.:JD'Z[4N-QU.,<"4X[FBR!,]@[7
M:%X HDQ]^='#1TA8^!$9'TUZ2;VHLU8'P?6$PY_)VPOU)'$0'(Q455H")VQ8
M.ZK'@#' '-D#W98\( 8?H*4DLHY^.H%S#-1@+V3@FHU4;AXV.2=WN&Q5YL<*
MEXM]@S2#[$TN7C#B+*C+1+K2V]#")V9&IJ%"O59-Z;>N7: ..G6<'(B=[$LD
M7#)MI_((V7XGRP!""S\\H85118UKM'3UNNSE[N!%&&?QI3'2]O9;G8_<Y_\O
MZ*%:]OS#NG]8;8_.46%+0-O(2RGOT#5O&)V9HDPH;L/?Q>&SGB/=X)"PZP@=
M\^R<77W\N@:](BTSOQ)8-_O=(?P0^[/>L_VXA31WZ:O=>7DEFZ<WO@$UK]OC
M?=9M4:EY0J#J!W<DZ@@AW9Y*\6&I^E+-5)?J]LFRIN\/II:EJZ!5W>HI?5FN
M33WK4K;=1'P(R9@@DMK!LM%X27/N_F&SP\,+?<O<RIQ:*?SQK0XHOUU<\RBD
M\G=2_3C+C;0X4@(*51\:.R01$YL:3ZI2&4#[5K6E3]4I4&)2^.CH?6$YED8O
M[5O4>F%YO'TV14G;K.%*9C%(?TVC4*&6\==3>AB98VD44Y"-)%T22G$D+3:(
M?6TYNH3"WD@^2<+Y5T9R%DGKFX42@4[GLU61VL!3^6;TG/#>Q8=DJTWBL:-<
M<^> Z*61"=!/$FF%3I\F6OUWBKIO@Y1UJ,8*F*9GM;!_F9LFJJAK\[>4=>@C
M10L?>A'>HNJ],-H:6@XZ@>Q5,I+W=V2C%A('&M1)[QH!DQO@AY25+140NR&!
M9:O6W:(<3UE;S:Q56LX9D>, *(_+A@FXA&-9J?^A)(CTJ/3WI=8Q+&G>"N1B
M:-&+JM!FQ+^4=? 8.!/U)Q?<"HL8(]]L?T\0PVR3)+3U:9P<,6]462#J2?_H
M_*373!8]]QXR_S>]*$%#!'D^6&'H1@_=*1@9+:+I4V_(G8\<O@N3%$\_[H 5
MH)&";E:SL9&(,6W7<W^]MZ,+6LN#QG^C(=QND-283,PU4F17&*. G:NY(A!!
M$C/LT^4B5LWW5J [;--KZ]NR&C_/[?HZT&@QOJ%ZWD4IB-E_N9K"8*=\0=?X
MR\ADR@?_H4%OBFS$/#X1!=9JHU0!IA#TFW3C:BA#U% ^L"A?MR&,3C77F#M9
MZV;0S*YWE?>,=VX:[P9D*I4E*TM#X$1WIAG7M]L3F2?3M+O(KI-EUFZXKD&=
MU5W1ADG.6Y((NLH-%#(F]8[AC2FG;?8IFXT'"R>AZYV(K1?2>]'3C,-(-YO%
M%IN,APZDVY5"X7U=?JGIW]+95AUYAMSX]R5A:R/\R7[G_0(H:'UO0CTP0UM;
MEESFET[L3[4-TGEOH(2+H?,#B]=*)DB>?L?*C:0CM"DD5(?T[,N^:>)BH"XT
M @>]-H.MAIMY6Q77Y. A-T>!)+IU_]B/TD+6/:)NZDP^,=)Z1:S8LJAY'X.8
MFNC#)8R'P="E@QFE62])NTP!TJ#=+<S3P?F#1 ^.HU1_+WH\MNHLCCU3I1%6
MMAD]E=2%[)VROP6MA;[QF8X&^UM+0S6M+H3[>ZJQL*"^^J00T^4?++/U)OB>
M=G(.D>3 6*.2! 52Q6JB[="=9E:-1>WE:1=3\51^G.,68!G-$PZ\_+ZK@)N3
M:\3%"-W=5(M1/?.M%&5#6$9M6_8GI<OAFVKQLD:WDAXJ:I@$$SFPFQ/*9Y5-
M^(?@YP=R@@O)).=1&NVO13U,HLQCK6?6Y/"6?LN69%^+\=B2]&0K]H% @:@-
M]^IZ)2R9$AP"8*SD.4Z%--H-9EFYJ;:2=$M#*"LY2W-6D>0K(*,6(^*0>W+O
M)6'R2$1YN&CJ9*?X)@P>H*^]N&2(IV'P$ R](>QNTS !*R\Z7#;0,OSV2@6N
MIZ$GDD)Q8 6;3\GXOW=6AY77E(3AR;P82<A,-6T+W:T3;.M9L,:J>:F&:&L9
M,-C6)",*ONYW/QDQ$4=<PLQ;/6T-+K&Q.><88-($JL2!"H8$V;>?Q+PZ5(T#
M5=8SKV<6UQ:24@H+.#X--?N2"CN<TGQ10B=A[#QH[HDY\N*W2T<OE[DJ.^GY
M,<,NO*-KS!]VQ/X(%WCG^IGTI!_N08)I\BTTIB[SVY#\92VQ>$ DCNK;RK_I
M*X(W 0W@ZS/05V#E8LV:G?6&JGPC?6Y6K]VZ(MLD75Q?QZ<)ZRAJXN31:(K+
M[EH9BI9 *Q@$/N(Y:&@H/7%R!59,:/;,GJ'+I%<^F(L8.4DH0.;%VH7'V&$1
M\,)P].N.@7X2Q9"TE.9%YVLP1\J*Q]4!+TG?"<!HB624[N?AS*7S"9@#/M^@
M N/P-M7Z><3D!4#3VMN\1/5.J$C7K*ITQY&R=ZQ2X/7F&Z_VR<LH^C2)3X.'
MAF3ZJ=PXJ;3KL@8JS4<D-_:('LHWK@L#N=>:/"WC6M=?UH_1X[%F=D[?&#6Y
MU>:7H?%W-]Y-9<X_!#NWSV03V9_FA38>-@LM:^JW3O7%>6ZK'H$1!FAW"UF<
M264&!!S[>G!_[6;9NB:WM0'U>"VOBQC>?+BXZ&UO5LO;@K&09C_"@[;3IF%5
MHRZNS&/TJ?L:$R3[0)\DXD4:+)&QGWDCQX9R%(4&I\TG*\UE"W"JWW[KD!('
MX>.TJ@>-""N+.>E)&EU0W92LAF2B?-2[168(%N (]FWZ@5*!WJP#+!"P%2NV
ME;]*VF#>Y0>7:] I0 >D;(@,L]$1LWC#,7:3V$MH-P7\WNL01# \G]0& >M>
MDN%"+"AYQE#'PC8M3]S%QII501Z-+-I70"1.B3U1)#*EJC+.L@(].Z:/X**X
MD)"].8RB'90A0C?9M"Q0^WY\,:8XF^98R>[[^67J:G:1@H&EG4_6(IFH'?^[
M]=J 8:<HH- @H;8'5$"U9:L%$:'-E@=*[\%^E&[]V7C._33%=7#CDZC6"=D;
M6D/B&/2_&%DY8YLD+93L-4LR-2NC(%\^['Y>WE_U:M^AB']%M=D+&0O75 ]$
MV/:ZE-YX:0FO[/PU#,E::W98'%/W*EI921BU&@Q2-_";@/XB&F?[HNH3@B45
MT(=K!7&\V-[1UC;.,EF?,H5(1Y^(&\ N0A_WQQ968??\S?R=%X00IS40=KR3
MH]]UW^>_AXUL5'0N8#O(_;<'0R\K;^5F6MU]G;:J(7'S);$PE)]1: Y6F9L5
M*5\0OD%R;OPR(,+3AJKD?IY5?)$']QP\G3MO?66E]8_.BJYJ#++GX@1?G!2<
M<&)QJ0Y:8R_3%S],^]5"-B\#5I.LTKHJ+UO:#W*9S-.EI9VUA)(7JHDB#]/8
M$U29OGY/CH\PVT3P5SLX3'/7F5<\3!?,]T;L]+#5+N+/?C%F> 781,1>_ 65
MJQX=%X7+6TS,B76XMS^;9.! >2@>H[),%5R&3:B&38=\2M8<&D>Y,]DW>IR;
MDD?IO6)\^ S:[VBNGW[D5@LJ)EK>UGU:;+3\WX+Q#-#@*KZ8G%*#8V"N\^>B
M60<NM?WJ-*AHMEZ$7L004Z[W>^-NGR+%!$ HMBH59W5[D8Z&JIR:-"E?A]>?
M'S=L/:%V6'5(NXGM]!;A=)AT\XH*,1H#M6PUTC0\V#QB#O,;><+7.]PJM$@:
M*&CO@LYHZU$_*(I7TB>F"<X008!:L@K1%S*C%YT!_>UXG<K-!VV)^F@G\V/5
M%Y!HV8+5#SH6/UEU0C-AUCEU>B>8KP"L&NGA.N.GAF@J3^RWQ/MJ)KWT2]T-
M9-AJ2[<XX))ES5HRO0[KF]2T33W<3A/5XZB]DEPL:<0XW<146AN<ZS/"D9.L
MIK]/W46!*61D#2.TI4 O?M+F=6X]"86Q8>Z[DOX>G08VAZFC;Y.4HT3TF_?C
MEEZ4!Z,.)@WS<]R<(L9YH^7Z?[R?O>UC":WYI.=KV;ABX#'L6 M)L?*DQ/50
MX2P3N2RN,,^B'QK'/C"T)@X>]JI'4!PY&+QB"E[:;;R0CK6"'8ELJ>0NIM5&
MI)$H[%<-SQ\X*-_"UHI)1?GMY1T-X^:R^KJH]4\Y^D#I@Z#0E%FX KA'Z3>(
M*@VDF7T1#/[3/?&U9>SPMI6!>P$U7".]G6*B8*TY:*B\,]7ZK@2W<0&:XVBT
M+OB(H1&:@Y$^7S&FFMXF?QR9K!&:3*]4##7Y=;6&CKM:0R%DF=#OGESM;:>O
M8\-WNFBK;M!9: R2];J0Q[!DS\B;:)8R9W/MM1=-G&6;:ST**'VH'BOR@P0R
MRVHSUMMMZK$RD["[\RO^3QC=TQ&*0+",&$S=9AQ^N1.=BN^4)"XP!_V@?>S3
MP*I#>7[Y(10%8<:8*B]3+#'S.RNJ4!0+ZL*YF:BC2K*SM)SKK"^FW"#YP?@4
MIT'$XQR[6=X9-.5"S@X-=A3YZ'S-\5SO1)+44*=.9%1(W<)>KWXZWU0UCU3K
M?7,U\MUGY%>5SGJ6,>201OX(IYV!T\_F=RPZF0E9<5> ?=.U#R.I':RA6/YR
M=1&TJH)OG6E6_2C2ZJ3HO.Y5:Z(Q:>7I-XFG#IFHG!;@.QP.=G@Z3M#A+;RH
ML:JM;%HS:."RNG!)73ZN&IOY$7?3GZR7%C1EV6[U 2Y!DGUL+W^KNNVT0G.<
M37'-Z+)X9G!8%NM4[T6#;JS#Y[._US8'7?3&G G:3_Y(DUJYT\I*$3@W*H*\
M]]6!JWSO Z0SP('%E2S+H'GI\H6M ^W6NWDGVWW)PES^JA8_J1?Q>F&N.D*,
M]S)^Q'"V#I)E?##A*+/"U_*1&6K<G'1,7RZ]<%B-;7C1B)433;IZ_\-QFC05
MCM#J@_GCZ$KL%3!\(  7&ZZS>] :[8^"'[:Q@"9R"B8<,7--H<!,!AXBO=:3
MW>VLBDDO1Y7A6BH)C;TQZ"A-9:#[MEEDU4J V99VI7&+ 6:GFP--6I:Z*5#7
M_/LZVZU6(D5,X5(G'^U3BV*BHJ3HM-]0S<22X&T?N6=R4[,0II#\ON3)W%:V
M8<&27JD43- [=#5O,G+WDD8_"PF0;K)$]X>L>:=!:]8@NM2/R'Z9;U FR5M^
M$FH(-N0&&ZF>K,L1N:S8>8U?AR_B'O$-AEX[!( 96?C]#FU<%@3'))QW"83+
M&G:Y^@N_9EP8@UI2#,?&^_KF'=Q68!4B>1)W-;W%!8-%I\^[,9#ZNX&&IR8+
M"3JC:?6VFR>/*/$A\ 8D\$"H:OU=^MC4%";%/AIIUED=V@\Z/IOO(V&#X?><
M+\Z6F?&]4 CAP(E#"KI:YA_R4FF7BB=/OFW2&X/R!IOK:"ADF&ZQ0?31N>^4
M?<!L;3'*'N']E^(2C"/1(T%@W\3SZ8^AR1'PXH[JF#<INS7_ZD?VF:-ND'(D
MI+L&-LEN'/.PXJ!(%RD.N;J@3BA/*@]%_3U;%2-L$UBS'',>&SYE.Z-BFE:_
M0A+@Y)BN.[JM(GW20?4N?]Q^^4"'KF++!)31)+=9_<W>B^(1=J<-O3)400PU
M.:RS@VO9YX9C/E\0S+:/Z;(F=WP8#: ][[;&8MKW$I!7V+$[E]W^\%DV]A#F
MV&10*<ZVN!,&*DL[8([+K: -5F+M_:/BK*S$:*U).@&6O.G_XQZU9>U^(%??
MF4-QNJK9TD'NG.W$3I :4UOO!V*HU)IOJ'6OJT(>DC]G92R:^CEDR.MB8I?K
M-AF TW$JK%O9&MNP6E?AUS4P/KH57;>)7U?,W,PWA[O.TOU96<C?R.\05:Z8
M,+DR3_A#3%EO%FR@S F>*?W<U<JUTVX<'A[&[BG:8PJ O:\&I86:+EL8@U?.
M]2E0%]%Y09G1HQK*W?3TI^_&>U5BW=]+&7I;O(P_((V<*(BV%&?E/J)6&[J=
M8!* PO8JZ<"'2J29M.'>X?)>7B1U#LUZ+VHGIQ9S[93!3BH$9$5>)EO!'5[-
MVTZ?X)8SAB#F$_J?WKR\,-CN^)IA6B,CL9OF<8C<:,AG6;+L0R,BSDD1=W()
M$;(H7JC,\.%B,W0#5$K8;="R[=CT"D#WW=$AQ-U3*FM*[$G^ <Y4D/R:6QQC
MO_\SO;EQTF'KS)NBP[(JK;?>X*7KRKL%=XV %@57.1T,DK&ADYR=^"O$=L0M
MII.SU;RYTR@L$NO-L-_C4?9]#YY/[/]^9;7%.)V\3=B&[,@DZQ=TQU&E3?,*
M"0>Y!CNQ7I+7Q<B;01='8\!U4^!MGF%,[1#S\3TY)J1J:R?![69>1CG4\_10
M<'=>QN!Z,K3[8M%PG,NA&=93<TZ9E:I=\5BWM!3N;*WP][CEAE4Z;U (,_*L
M)/7C"8AYM[@J5B$63'C4($>?611?)2V1YBN2F\[?0\QPJ74=_T$6O'G><+.@
M +H@GW:ZPA<[L!T_R?C;WL]7,=[K2#SD[D)!KR$:LQCNCABSHSPF)(O-HV/P
M%+N G=\=)W08(+^L6EY>6]Y_TTXLN%NG3;#_A<-T9:Y>Z>2*KJ5Q#HK4T"!2
MY\I 3OO^>E-GRO2STS*8+S>>F:QYL]#Y9W=J<\(V+KL51:[\DG&FF3Q Z5"/
M4_%D[$W&\^=VLH/:>Y%40P*%Q4T/JL>Z6[!GLAY\MN:XMN++HNMT7"9&_+AY
MM]+W!.?!D6^+M 9&NTQ/)H5EY[9/'/G,>TD(2^4Z:^3Z-_#6G#"LJME*2IT4
MSV;X^)'\ED;7]Z^>#3:;HS@U@T4[;FGZO@Q;K )^%E\?) J21'0))2T]D[HV
MJ[/:W0NM7D8I9''+97[<<VU#CU27EY*: I%;!18MO=$#W:0CN_0D6I"4X/I,
MIZA%:7>EM#DRU6-!<EEQI9;46>6LP A-QJDO1Q;(8J$Y!J&:?[Q<+"V?J;9D
MAIT5;(03QXM#>JC3OBOFILDU3(/(N*Z%N:(&!QS,+9+D_GZEN-G,35L\EOMD
M_R]&7SMV,\C\N:$B'E<]UW1MCG+>!+']LDB3J)D6739HE40%+'Q9A=>$',61
M'J^EW<Z_MX]8KO++VP&NS+;WNX$-C+_D?K7HI3DJ4WSN0*!D>'%'K.3WY,%Y
MGRLWWNA[V>J\4H&:L@H]CY7/3G&-]GN.'K?@ "L8.\3<5*B+W+$JIO\R\""J
M15>D0 7KJVNA(@9IM58!H,G^_O9%^QKC)M]+77XM,ZPL-^M-TX \JC/IBFU<
M$$S<_ZY$&2RQ?K\/BQNY$H[A<3>\H/YZ))$5"5R20B5U[VP+K.G6*+NG9>>=
M-%3.K95P],#O'K97;%0XG(J,*2#>VE;_GC+KA3N*2(E.'R&0<%<X8?G7M'/6
M8)?O2._+9W$Y^EK>^A&Q+S$)ZL;[+#H6J^X<OK!&$3F3VSX.:@-;7:XFIBS,
MZU37"2#>Y>_8A?NW=.2M)@,WLLNXTXS7<%R(+"(=0V5SI.T/,VQ.T<10B_,1
M8D2 ,E7#\"/6AD3\MNBV$X972X?PS/6A[LIF",>WUG+,3%JU'IFKBEN*[0X!
M<KH+_7D'QPFEM*&&T(M[[^U*=L62H,?;L]%(L<?;;=_,78S&_V-V'#Q97L6W
M=5RJ?)P+T_S6I6F+'Z_E7&GF_)&:X2V+7!.4_R)&=D_ND5O<9M5:7Y@%]N%)
M,CL%I#CTR:W3;MK$1LZ7>25N+YCO/6TCE@V)=!V3 ;^XHKX>*^ GLH:"V6DE
M-VL#>X1)9S>&9A:)\#6V<,+A/@!#,S7JINNN$6%1OJ/PAOT5T&^;Q&Y?Y;7;
M?[A2\[#9,J+JA81X*O0$_VCJ$A58H_4>"O@**0N2.\96'\4D[,5QH4$I&<Q4
M8Z1^5]G$ZC8=8@BNY*O@_>L66+.IF&0_J/STU<)Q)8UG8\*A&NHN-9L^_Z5$
MCH.('5QB.A<<T61V929"2C8)^@Y)6 9[^S0L5AI;/5C$LGT:UY!(B/U4/!%V
M)NA4B6=W(6-W\:[-E\CTA/'AWI2HJ=O9DMJ\V/!Z/#KO+'0ED0S-U/C'H '-
MKY+]LG]FY3WS,<5A%5+9X[G&U]&L?$VM6S-$PG+H&S>F.-B>'1PI^C$0%OZ6
M(=VC?">1:]V)&@;_6!3H%2<!$MRKFQ66#QWJM3Q?;T[VZJM0+(/EZF+O9<%C
MX@HMYC:V))OYVBM/@LV4Z'ZLN<@K44?17ULGHJKM]A"M:9[47,X9JLCI0@*1
MOTSE\9<(+;L:5Y/^GJ_%^K0)\47A3VS?9V?-$770OJE"+<J?Y,BVLOJE'V#'
M\CX=Z0=FXSOYGG.)H.1A?FCJVHZ&'5OUYY;YW8].-VFGPV^.K$*:#5.AG7/#
ME <3U*8<'9/Z.H/5/TE)6/S\3<0?L_WUA#':(ZP6YQ?[C0\H-'G3G8;I$H81
M&U"I:^GF?.YBDOV0D^<#1G>/#>S8(S?6SZKXNJ=VGY<;C99O+M%DD#4(_9S[
M%F=<IVE"*C%)J\88^@89(B?@,I\)7#;?W)+-?>/HR3^X?P5X=YW\_VP=DM1
M^+<7_4+(_9'G5U*Z_-$VD8PJ:5T;9)=G\#6O[C'B?SNOYXY^E@7@.<JE"(6B
M21/W ?A)GT'S3MS+B\<U)PPV:+3E!H:8NT&]77QF/5L#;U9.KC/VLHBQ1T7K
M^TE#5,:.H@"/-Q.2KP!G*69U%E(*=R4?"M_",^>Z/#G962%>^>K<=!B55ZBB
M7-[FB;E1-=4 /I9%_'JWSQ<QC(*($FTFLDY3#(&Z(<9=HB8C$#)Y_# D]5>3
MWRU+"C2;7W_D3ZA53-X#Q;V>-]"T7HW5\"T*^?R7O(\>R\%<U%%MIK_I)7K@
M9[GV OQ;%V'LF^-=R.1(LNL7(DC%N8%59&)Y_CIAM<)!0/#BKGY?!8P"4A(C
M-1+Z5/]F0F4WFN%&<X;IO8[ZGV?^XE^AHL34R5+^VH1M0_T.HV^-LL:H"=G2
M,]#K#+EO9F25Q[[-*<[41@BS=WQ(;,V7-@Z7SPQ$^]$!THL\E,EXK#F_>VOC
MKGC"Q=A,#I%4&]UG0I'D;_PE)=#4_8L\K$7E<>O+Z?,,+.)=99?"#(89EJDD
MU]>S?)&H;91_!&%'W%UL^I^1-].^ AX"7P$]ZX^-D,O=X'OQ[)=4[U< 4.CQ
M:7R?\16 ;,3\"L@1:WP%=/A.CP=0O0*F @[^/5Q+/ R)WE.^J)>] DJ-7P&+
M[M3>\@.7!(;[75\9?J<703DK^:T,^?)S'&\?D1>^PJK@W..=8;8\V",&C:S!
MIQY:YR$E)3I:<7E\=V_H3?C6[M1Z?B'E*4G3MW4U<G$X+.UZ>5U?>ZRB!3(=
M))'D\!#^Z<?ODF,KU'RDHP7!RW9G9^IF^^50-'>OK!O94]2&L^63)*-/NNXY
MZ1?]K9 ^'[_Y2U\O/+=_[,&Y[D'&,%MJ:?%;MUKM)!W/7;EIA67TC<G@,H.C
M#4AI'EB(T=@&41343R9B5LA1WO0.9YE_$0%_SZ6?ZRXC=S)>2!IK*5A"L=0M
MH(73U2.YTH#PD!1S4XT71F]1UW[^QG.RCIOI7#)!9/XS:B>1F9+&S2+Z=7+F
M8Z18/9JZY/L1\L3& \?-_\U"K""'+X$+QF35'Q8$5,7"3LL-DVWK])?*WM<7
MDJ\RCWY/J:WE[N5#">U UD)47?V='S([_3X1SV_34VR4M-B3D)3P1A'?: E\
M<\,T,58#ULL&0@KK2;];71>'#^3%A*G(,"L5L[+9'9O7V/CCS+'U=?<-DB[-
MZA5F(?6 >D/;";R4*/#UI1L>$HDB(Q7,_+JUY]AT0]4ILYDGW*>N6Q)/G_V;
M^3M&]FN,%1:] K5+.:3$[))=/D0=R'<8TI;%[VX0X G$V22T:>\HX0A!@K.B
MTNGO9!IZS*1 XNSEM6+K[ M\<*<@LM5E\'XCSS-V=38Z=O\E'O=0\J=N-?3W
MUW9_5KJ*[FIAR]1$E$GN2H50%%3V"+ZG4_3;*E"D0D[#I#3J$U68_J[Z1R1Z
MR0EM3X;C0(_;]*V<^8BN-=$S-_B4Q@H0+"=579)#OA]=2O^G!K+74+<)U4:\
M#L*L1/)ESE@P:G4/U1Y,UM2P/,)N9FMGZ4&#GQ(T7U<^Z6]?D*G;DTHDSY[
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M4([&QR_6+'.5-P1+-QI+";JQ%)O+Y,-J;_88%4XNA9[:S_U#K#)3/(,2A@O
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M8O* ;LHW:9T1V+NDQL!V<=W*&4?Z%:G@^<C#T@,V.#>75WC_.S,4<<M1=6,
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M;MY87OOO"7$+<BBX;&4LD.7TVJ:8O]LFG%')2H\<1[3$%T&!_?ZVX(&V0'3
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M.YJ6?VF%O44N-N7%/;IQ2DM5[7E'W_ Y$Z3DG"2^X'WO459=N\/D;5SR.U9
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M+.G04&W8!]E=%[7LJ.7H4$*-[7RK6F 9,S>5KL!B2U=>Z&H[0%1"AE5I.S-
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MUVACRYTX-89@CIQ(E5H]P[M;N%?0FH*[WEOO2W'Z5YCZQII:EI$<@K(C/CH
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M$BYSFZ>0]#RU_9];"UMGG&^5[3+"A/G*1A&!5KXF767B^3S6+4]48)RAY&8
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MYG&3W,2ZMT*1.MTP*J%&G1Q4I+D\H$F]94*]":N-8LV0J;<&DPM\;E^P);,
MO&=>>IOD:A)(3_UPG*FG2)&:M59T@;+4RFXJ=H/WA;(:WE=<%RF%]SM9(L44
MBX7=$'/=(R[DZ%#B=">I<<X\VQHV\-C>,4^;,I9Z!N' \Y2U("IL_?5ZSDPN
M(>*[96I#SD./''=&CW/ G9L4_*$!/D 5B^)\]"T=%@ U*OT/(&?_SJ+\G\D
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MJE4#YWU($6\QMJ?=Z?<6Y]9 OFZ<3'TF*9#8R3$ KHF0_=9T+UQEA,1G[.#
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MGJ'$MJEG%<H;2WS#N!@I:YXP<>2%U1O *4O#^/5,IFK9L+*ZB.O6Z =*@PR
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M&;/E%/)7;N8X@LQJ5W)VC^MF]X1LF]1_D-0Y&IZS)R0G#I*NR7S(%WE"-^O
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M/!ZT2"&;)%TF!T(X!@T21:ANV^*9N>]M2_*HS%MN(:(\57!PN5ZI5CJG&&W
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MBG$72NQ/UHA:U%_E1BSWI"7)<\?724;5YTQD3:('TDYJ97&R<IYQ>/QSM]=
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M&E-!J,]*2^X'V!ZAI.%QMRFB(=J1P)3&-]S-C<.&[AMV4N!_%*#@?OOQ+;C
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MU^]45P-TGB7:%@U.R^9%2K\C>3*3BO+ZPV'A&44&,V2=IX_2ET1UO7>N>UV
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MMCH6O;/4C/FZW<;B]D,T.F;ID/@;G,,"03)WTT5$/3RWXBAL/&M/6N);_D-
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ME!507XE?J:6YPQ+/:L^L."R?Z8<@[(0X6J>Z)Z\MV*=T@5;^Q8?&16?POE,
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M$)WIPC><+.K?WN'@1%;36H+(:2FH,4GT/A'/44_NN4NLNI4C5U(H<H*JNMZ
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M] 1U2M"/AC1M<=G3=93K&X].9PN#UM[#]SJ*'!J>F:?K? <^'@+T'>K%$HM
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MT2+)SR<WE+Q]$$3XS?:ZD=%22_F*JGR4SY73OCU>D J-!KXBI<VMSP^*&/C
MJ7UQ4J-3C9IP -BL^MJNS0"K]H\&\Y89\90I HTF)IKV=A2I&^1]F8"RN@9_
M]U<C%SEIQ)RY_:(^;VD5Q I_6K(KM/%$2(2L1HJ[MU4_GJCZ**_/F+9[==JV
M0,_I%W4"W&EF<FBLS!K_7L>6M? A+F#1QZ4=B(106T+Z^V6WKG"2"0U,JJX&
M,3K?%<;?-7&NNO\,X#Y3;]?&(Q)SMXI3U.8P/ZD3NST879YY0H4XV&[9_L->
MEN[W9;J31%/_CWE\$",Y%EXS,#Z$TU[\YCAT&&>JZ?2)'8A#6:/]1?ZS+PGJ
MGA\E3L<(J$(3NP4IG*9VGF'\6,AE:W<LG<\ML%?$7:;:]CRL1C,N$@VY*>.^
M\WK*>Y'3O'JY18W!)$!8C8)!J@4/OJ45\"NY*GR"<=]8)4ID;Z:8L/&JT).M
M =3*Y.J?I(R-2Q\#$]=^2BC"<1O%JH^E;S;V\GP'<,?#E;1:-+6R5HFRBXM(
M["GKG]!,E)YBFL%S1BHC[03CJU,R\*<8.642)VV5I5H)^#JY+KU 33UUK[E7
M\J;D/1[9'X4X"Z'G*$V$*+9\WF_R:Z!(CP>SV5*U[9)6$*RO5-AXL+VK)<T\
M6FXM2X20PE!,\&R/SO]]?G&MLL/$2K.*V!_6Y<.X\)O4U$Z]0!8P!,>'A24.
M<K+DBD!NVH'X&6]2J-R!%DN]W&.J@YY4?TXU4EW_GL<<VE,QZ8HPH[71W8WF
MH7JRRSQF%>1=^:.O,CH9+=8R-1[!;KZ?!6H[ZPWNWGXH]ZXP_BLQE-*/S^YK
MU3K]<U,RVS9M,RT]<H<->($ZO7WPENQ3JC>-F0LZ>*;1>8M,AZ@"TUP@K'+=
M4L=!7RBX- E%S2&8M 1W<+YKF30T--N#^'$JM5=NB<T.2S5/DLOY2>0=B9UZ
M;9V9N%VQ4:ZYBPYGAX^(YB2<H^>VI[;Z8H3XA'8[#A/EH^58GD:XQ;5V@,!2
MG7?(N@NKT/\;FPD:[?JWE:-N+$!9%=5EX&V>ZUS+[MN)P9=&#J?+5;I40U/)
M;C-TO(3??O;G';TN(G7^]N@ 1GVK-PKEZJS +<RH4E_V)>^HFR6([_1W*2UQ
M+==!QX9<U"FXUH6JNPI/J!4-IG(6YU^(W[T9U,*0O+3&S8-/IWMJO>'-8A&8
MG++A7LTN[GPV<LX$AI[W+C- I?8](--G"K6 7G;_%F?C/$]#L_)=3E"1U4<>
M_%) T&?2F>048*/D-7VC=+$K;<) WHI; NGLJI6[],* DO0OUW=]Z<O_=P@5
M["WUN?*YO<=#7O%''_^_W=F2[5L[.V<CXG2G5ZL2&^__=SGOZ$-&AM*K@(+S
M6\E'^\PL-Y*/+E>;;8)^%I^<I3U[2)_+*)7+=';]+6Q&;I\A=[7Z^O#L>F/G
M?U"Q(#UZJAS7>()0V3$*QDR7@-E[K)LLHJR$B=F'/Y]HU5[,/C82<HMH[=P%
ML7Q[C=>^:?XME",WM./U1N2' @ #(9FQ+_WO;U]\K*1^A]5+_8KNIZCI6%&R
M]/KY\%%/-TTQOH%'(0.5-C!L-CE>YG'T> 9?[ ?5M$75MHU6S\DK1P4_(E 9
MC[<<$FMIF?2V!/U$FVPHP:?B"_GWUC3]*^?WOMW\HLNLA']>^%7!9$Q'I]Z%
MF;U)RGU4XSGYCD@,0"YVML,B]*(E+M,V 7Z1?#H0S"@[U T,WY.Q,9<]G7W;
M>J1BS3WX_U<AS;%LY4V_0ZW1V3Q9<2<@FK5-4.&0C>PT6G&()8O&R'?UO[?L
MZ:5/8.=+4D[NM-0.F!60<'LL[_)JX_-']>PZQ(5OM^/.YD+U(9>B@B^0L5KX
M@WT9K/#?4W]:R';T$L#=(\+ZLJ;P NEO]6S>=UR=6[F@14"1A5DMCN%'.6+,
M_0Q 0/^+_NKV,B2P,6:6X:*DD?0>C]/H'N_<*2GPUVC8/=Y)6>\_FAZ\QT,)
MOEHU9+AE:+O'FU.\QUO; /,!?.N\G;*S:^;KBA[NE!8F189 -:<\K;+*5V*T
MK@3\!=0>##XM_%G SZAX-&(9'Z.X0_\>Q/KLB^VGB2OQWR.IJOFKP'([$0K,
M8;JUO2]$YN%2W9I?^D _%T>H(*WJ2R4_,AD\[T2WF-,*6"6L]O%IP(\3>[6
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M\.J7^=8$5/P/U#$.!/S&S)DN7KI8)Y/H1T^UT'>?;B73TN7:S#P%1)*KD=?
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MO$\(/S2_!,=<A4W! [[0K3_?_>$2O<9Q"Z"I M<?W@+>^/@W3UA.A6Q.-<#
MUI>-)[(+/\]>6.GAE6W.,V-1KU?494N](-HVBPTV!,$!(5:;"6O3]5+[RC=L
M H^VH)CV;L=&&6'YFK?3NKS:[DP!.W42JP;[0SU4,?6ZSXIDJ'MYKK3 -:/C
M:DOF<E72&J%P,K>2)XSAPJF-;NN\3PR3F0YIG$A3L@_^KE?_3MM1?C2^2B2"
M%T+4SL.+MQO/DHU.BXJ5D2(UFI45V).2>Y7J'CQQ%CBB.@,EB]&!C<O5WZ&3
M:[ZR\FR\ >^322F0Y-&>^*3?YQG)+X:**K(RA:P<9LG^#.2A4O7>'W1I_\0:
M=%88U0[2XRZ!OC@&:5-^A*&8DH>BS5,40C""TB%'-CLJH#MVZRN3%L66&?T?
M*3NZ4-&#BUN [$9(!W;T:' I::9C.8_,$%>I<"33"5&+:"#25<E2?>'A0(U8
M+-9R3Y=31+5T]OC!398%-M$YE*0GLT^#:>@HN2ST7T+V6/A_I4AZH<P6 VGA
MT&1RGAR+'4K?'/3.!]_B/'%A3G/#DLES#VI@#HRB)A*].KDGA<N%EFL&5<D6
M7GA)QX]?^JQDR,53/!_6?WUB0].BO#VL K_NE!DW*6E>5Q18Z:I;9^>,)(;\
M0:KW(L3ZQ%\VO+JD%\*452&X'^776O'KN.N<%28\U;"Y&>FN)R3ZE-\"^!>7
MK3V6CH9;G^@3[!.6V1JWY\%^TNWOTHKJ-P*N3LDFK+(8-1YZ ,U&*P V#/3T
M^?Y\:V<N974X;+9N=9B:RQJ!^,C2VG2RZ\F(Z')G0HD#\)%$FO=7@_?TV:.5
MZS.='@,7!:L[CZ9VE 6OP&MM?WT"G5/?!FPJR5R^*XF#5KN)4"]Y9EC936=\
MR2Z\*K+K@:_'!;H6[Z7E=16)+5QXB*%EF#(#U1JM,2T*T:HMR!-$N43<.TLO
M"^\%L'V7K(:=B! ?-"2Y6?9;\YWZ/R+ =_ZJ!8O[I^SMABW[I=-+;'_"]Z!0
M(CY,R78#5'(O3Y+!=/JI5DIL:0J*GHDVN9RX:A 2<MY^V&K1'_"D&\(M8!0\
M?-[W_ ,2*G7Y)L;F$_+G PXK5+TG?D&I6_+5.O-F&D@/YTM8TBA<#P.UF:#G
MT[!4,LBDGV[?YQ_04E\4E"M(^*GAY]:M].(MDC%"SAI?XA\*,"%%CA !/619
M[!3*=.UF-)3T7IW=IB<<U0_R Z(?-U<W;8];7$AB(W*5/W,5Q787%0C$?NH;
M+J=>H[A0R-PG4U*TN[]W"]"$]X>RAVAM=#YTM.L1L.M!;8#C<A"$UI <-B\"
MK"-B0=6^Y &1A;Z[V WS90V)0W1*S_E=)Y(QB]_@M-\WUW="]>XM)619?R+_
MUC&IUY)>H[>57X7RH?M8[Y+T1?9MYS=TV$.>?26_CCO6D/U$ OCMBR?N#O,K
M6/@K;8=?]E1JJJ#E]%-T#[#[040TK=X(;S!CXCOZZ)NYG%"E7N>U1?$GM<UZ
MU5/)[KXR<JLJ&VV"RPP;LGON994-'D^\WO"5P;K83$<8H7QJ/U="0_4'_V.(
M":>?3TQ;8LQIMR7'5P"7<-\POA.7OZ -;X\[)M("!TS3Z@0_7/JPRHA>5W^6
MNIS947R9Q$X"+8@CI;ECS7F2DPTJB!)A?]/K3JA'EP0A\+]19TK4"=_GL1QU
M0KGVBK!CQ?Z/2$8'+^Z%7_Z%WQGEQ!=5&^<XI94PG$SKJD?_I+V]</S@*A;_
MZ& 'EJ^W.$^T^C+(NG7ACP2,CVQ-Z@JO;JTIY'8T$<7L/'#Z^J!+V"U )#CE
M.5RP9I*1T:[/8D'*GJEB!NE^[L@YF]UAV%5:4?2=2HS)\3!-8ZKDA]G>T?(G
MSD88M*"SL;V)B4XJ24?4>B%4C/*C(Z]>^K:9EL6E:X*<L[%*V<BK]1EB-/!<
M>^BD!2:%[Z0X)] HFGB,21,72RK>0!W@3!-T*%QD$Z+>(J @*U^%]IDE31 M
MLG@-R47WH5;XV5^M%M<,7VBUL 4;5]QLR^"83HV)T%3="X/^?@N&9XT:MP Z
M5S;41_>*'%F$RV U)>^.M]P;DLZ[;H]'[(XL?^!;E3Q7[?SM2F=W>Q2S>QIJ
M&M*+7G%V.S<_"S#HFM*V9R<Y,,8<W +<P7^Y]'LNR)3Y&AA/Q3JCD]T"N;MM
MC8?\.#Y8#?AAT//CE6!8H:_8L<^BWLQ.+.JC00Q(I]AM(X-C?TBF7;8>8;O4
M\8OBFH!8,(=)AX;J>9?9H$LGK'6&4EI21'?M[@K6PF61AE)\1O,68C.Z0YG/
M/DT'_HSJ*YI0SO=HCSVCVZLZP)@WPP(+H^Z=[D[I.0%?,/'0)DG1\O;F(X&%
MS[B%V7M#!:]LIG[GBW2?NW*<OZOZKD##C=\(YO0P1&Q#FP.GDF^XCC&[[(X"
M6=6:8K)0,=$!JMH!!I-75;B_F?$_E8'A*W^[C \^+&W X+OC'JQ^U7U:@CO5
MTQ5:\WP>AP3HMN.CX>&Y7LOB6\!#@V\++]!9/@S]J7/JI&+1]%%_^(O[0[W=
MR-R(F!;:\J?N_+/&TABG*8FW=Z=J%9L$95WOLY&$JTJ&LE\%S%T]/W\W*L?V
M$^;IN'&#:;\W2<!'A7*V-*)QJ#E/Z9JXJ=@J&\+"!8C$NH<4]DUK/VV-O>SC
M)E[YVSR(R'3=# .>_8W\4/WKTDD)5N^H=L%(\N\XQOB.A%S6%Y,2B_=6T_H#
M+&O*9*_,I6/FHG@CK056&/#['NF(F=V=QC.ZE5\ODV>]O+]U,09263A;Y*-
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MP$Q<8PE+L]RL"V0@7XU3@U8!%B'<9!!YO:MTEK"_:N>)V<$%<QIFN>_N]S"
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MO/#T&=U>69Z;^;[)IME;GEJ&_KN[3Z[!42[DC4HQ?WG3[''HVWQOYI^YS[<
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MM+[_LTX/GA(Y50'OD>QZ3ER1;][XK*:A9Q7H ]-SSR-,&P?Z0Z)CC%8B.$4
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M ;\MN-QKVL^7^ 9(#;N(4"QN:MB%8+*.I0+Q+&$=_*PRH^]4N:]@[1S>_+9
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M)5)X4N9K!Q<@)9+Z0V*:#O@V.W6?R2\"@*>/PQ^V\>,]Q%F[U(7=1M5T+;8
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MQ;2@UMW]:[RB$+T)IT'@^D1I'.>1"HUPES&WDTQM.-4 ;907S^/X:(;VY9>
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M]K)']N6YF0#+%Y0>FL[ONNO-<?LBQ:Z0=G(ACH ]"EG1/-^QV'V_OC:=.0%
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M)WPI*$DC;K+Y["4-&MYEX!F.HD7!B*$V+!MI<V_;!2_>:<C'4REYAL(:?5S
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M#%Q.R# EFC25QA$;'^5L/$IR+].@^@05OP.JW+T88D\ON$ZU:C#QF'X6SHI
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MDG7,_U66&?G)NI ADXZBI7G4F>1Y76YB%$-?]8@6Y5M[9X%GCE%,F$EIO*=
M) .^UC\"C-X#W! -LK%P9,@(I9QQ[O&MAXB&ICU\]K@[ .L." :')"W!P@&Q
MHV+@<&8B/JK&,%[,GU$_8N4#E$&>?OYO%_:F^9J /9>_KX952YKO3L1I"K/R
M.#DTWR<Z2(=N.BE]U&$RH"D7R8B<_^*V0#'5FTQ&L:PCCX[3C4@VP,1</:@(
M&L >A#P!1HRO?[0EL>8QLS#LBYD:(U0UCAK^U:[[#.5#4Z^CCF@8]T&6EE:9
M.:,'+M42_%OZBT5>>=UA_AU];\4"Q$R^O?07*G*OKEZPT^OOE&1\/110DNLE
M?L;0LQ:YXCFLO4UIJ@D0%IOP#,D^#,]M"AX5+E-HU]?_;0^\.DJ'#OZ'VU2&
MBX9"$R_,L;B(T.R L>Q]&=2@=)7+%DB9GSEC>S(TWM:2.?O-R)$6C9<?E:(4
MG$.G(W&FN]1ELZUH(1*/L-E\H$!CUAB=?Y0L;/<8#[6_3H>\#5?H^R#O!#S'
M&?5)OS98A*L'J07T2INM[3\!>@_O O_V<O;0_#<C4=KT=[._9#?C3X"\R7_5
M\:-"GM8 [<6#ZA-@D7KJ+Z(<_N\0#_I3>BSP!.BJC91^H&\;)SVHG)IJ^Y^Z
M9K0;YY:AWFNBTY(CRTF<YUQ0S4Z=AH@1WRCM+(W,7I%'!2UZVMFM%2-!_QCC
M497.+Q]2C2%"#-@9XKH#58,7AXC%A2#UC/.'!FL=]N8QH0\X8E^) KQJ]0E?
MD@$L=PI8ST'R"+#^>PO$1S(Y%06+)GH11(U[CHW#6'HQ!^>D]?\;_SD).YJV
MR\?>CP^//G"SS?L=]A3[V<_^]M2P#S7'4NWB7<(+(]R.G@8+M)7#XJ^=*0G6
M+*P*)R0,:V7JI;")0D&["=5R/%S<;/470-)=6_ZY6"WNI'+EBLYG51&Z,>;E
M-4GU+NN56\+<,J$P+Z43=USU+@QB2C]Y&>A=T>OZP,%LO>: L(CVAC_2+&IQ
MCEC5QB-(]FIW0R99R3+/T.!;& -),OFG=$;+X0']+10MYGMS4;2^>%EH6;6M
MX+LXSQ)JFC:D30LQYK"!&R@;Z=FTDCW&QY&?>#-@@.,DE#LL9_%] ,7*+%>@
M:("NP83.*.LJ^5Z+<%+.K)457.R6>JVWHEVAP6XF<\FM*<L(>_;#!LS D?DS
M*2J>(6775UADV'._A1[^!&!-T15)=F.4S*LUS?ZD.3D"(_,#FM9PM6.'F)P-
M/%ODX= ;Y<H-4AO%2YA_=^SKK!P#SQC?O$$A+I\ *C87QY(A:O."CBZC2RR(
M^7(BAS^0=R6#.KL(&CJR#S4J],*0BDF^$_O(M%1AN!Z-.ZO-/Z$&/V<7'!N.
MSJQ8 @))-5[ KJ$)OK!M$ -L6)OT;?-C8[O_R$%:P&^L#TFZSQC+<E_-IV-,
M"K'H7<T?JA>?M&@[Q=Y;'*N>P^5JJIVV%?W<AK[90JHFABE.5OD6YG+=?&-T
M%PJ7&YCITFLC1A8'8Y&#5QY+[=3& Z!N6P!_I7EA0FQ'[^\$7KXKN+WTWDB"
M-+?=BA6SG:]@W,RC<H4+#N,XQG&04176<E:(B]VVRTRZ%3?7K&ZZ)[ELSJL&
M=E06S@))E^"R<30,;DNFV;APIKN?^WJA6;R<[>P BAIN='V!KV6HV''H3"!P
M_.A<]NJM_YA_/FK^4,%.IT;S6&>;1U.T7J_"[UW*+.@((7W'6:*DA53!'!&(
M2HS=? Q:O]P8/L*2VLOO.JJ\,4<FJ9#[*&.&L&[HD*V;KV).!J;N?6H4>)$>
M!U>/=GH3D+<_%\'QI7MF[>QZXSKO-E:_:-LX4YW=KW3[71'I7VL#[;!4,UZ1
M/Q?I%<LF8X<->?XN&*RA\=@L2^E63X"T&-9$/K@&7^8?V]T#!LY_\/W,H6GQ
MPU7*#8=O)O%*M;[HBVN&(5H5B[[^J.CC&7"IHMZU00PN W?//>SJNB7";E:Z
ME:52=VB5M52#L]YA-L.T@TA2Q3WK$Y8F8M_6YCG?!2QV#DF$/HP?NL!H:\/W
MG(Z/'ZPEE?0"*" @E03,(M3P%JBD/)W;HU7]91)0[XR$9OJ.75E/,J<H6OP:
MB!-,F-TK^5TV;4:/69J><[!4SN6W,RO5=GK21;L=1ZS?V3;M)#3/U&?*:: N
MVXDDY#73)CH#<XA"X8&PL;1KPWNG-)UVTP$ZZUVB[_S!Y&3)2>2PD"CZ^(#V
MS-@4XPM?[__OKK@,"DXWCY#JCE#YOB[>;10:UUR FYH72$I>A-%I7&8%XL4O
MNVTE,![U?"LUA971A5<QEG4*'%ZDZ/E:A1-0Y_!5U?"U.6EE^:2&)-V>(_>Z
M?C.=K-,K55.$"ADV(5U<C#$P[M$/I]AV9-2UJN2D\B4NR3!S:A@%ECTFUBJ]
M  ?_"RA]0O"^N2WV[5;549731*?'XOVB\7%_B@.QV*%#2^GWU5<*.@/?0LU'
M,5Y!P#V&7+XB?EHSN_&6,E$OC.*>I3%[^,:+DB^MHV%6ZFZ%V(?]6A"P;]<,
M;R;*R==1?L3?FP@6M2D4;K=9JN)XF=D&1_B^]M*)UG_&5NI'$JP];DA2K6G1
M, &W?6<ONVCPB2,I6QCY]<<PX;=K_ZHW6N+JG;.>@2V\;\7]B\QE6PR:;3XL
MM=[>RQX[K1._PAJ_EM*T,5D R^ P:[O*#:=&H87W!Q^E1,_'<CA0O:*NK[Z.
M^Y&[5D3*Z=]L6*K5WMJ"B<%BPO>R#3L(.$6OHQ.%4>[:W1?0.7X"QZG_\8O<
M@>C"E8G8RXA=J,S^+DM@B)[4:W/]/39/R[W[N'^DQL]BV6F!NIE[+<IJ\6Q)
M3V2!CH)GP^6H;JT[-[_?"L2TU2^A9!XH_ [=P/Y]&5D#IRSO N6G2**L54<N
M9)-(<7O1)^[V7AZR@'D'2G3BM.;Z'PVR7"(=5D8WG8*=1EK[3! SY;%[_%7S
M]L;W'=0:";=)E>HA=//3!)X&Q=)-F,L$Z):@W5DSJ.>+"8(F77ID]%E?T3*5
M9LAB[JQ"1? LR2-EW8BS^$DA(J DSH=:O^^HI*OV9UGJ&YZ=$W%NCH87,S8H
MZP5GS)&H(GV/^Z$5R[K1#.519;$!<\KV2@9SM(X$PI.6U;@HS^?"5UP^+C7M
MBQSDW_[,KGI5V<NWO35^9MXSIJ%L.:P:.,$,0B6I!E?#PX4I OPL&R2&C*X_
M*VT[1Q8TIST;U:$6N^ZH#EFR4R9<^C!O5578+!YDH]LZ%(3T3M!K1=\J<JIC
M8@LX3*N1T?',^ GRD/&M<+3C%^O7$D:!JI,9P1Z.V(EW^%&0L#WI2*J[J?@W
M-)+=5HNSL#_^ZM*(60[UKO.3W^/'_T&$!"-,V&O].M+:YQ-??WXK&GE57>(O
MN_ Y1^2C8BCYRR+A"WP293GG 3!BQ;4,Y<O=%D'//FSERDLTH'D_00SC,GE/
M/0"$X:,RDW#;?_B5B,3[PA5SNJMJ-3?&(HQN"@WD)\9&VNM3J<OR#2;1>G87
M#,)HB=/!AXIDA'2,YI%VF46T!+F5XIW"-\ZH\Z;EL;88[A]-I]E<L<6AXA,S
MHP8SS#T\)DC*Z\S:24D8X/5($E-K88$ [\9 /6_1SOI%T/-?Y V]VVBX[?,+
M_J0;[IE+>0,4[,I'BEZ(\D8V>Y4K/'P!:JF<J1/U![V ])DS]0BIT8^-PT3"
MZ<U_\>9]Q(UJ*]^&&D6OM+<&+D()[2;J@+(O+#0<#;@:!CZ-"%O:E=S\N40^
MB/_W2&;Q(I'91C757$TK1#OQ7/JR^.%6[(8+S7:8L@0Y-LJ:C>'%(I,Z.5;D
M4V1C<PU_R*?O$[=HNCW@[H[4L\L[C%BZ2\1F[-D 28V7D+*8CRL9"- 6G[7N
MAP^^[ XOV5QJ9NT2"6J!^SW[#TN^VX&N$H&9H_F%E^L?Y=_3S3B>CK!PC38>
MZ]Y;\%A.;?*P;-RA=#803%(5R;;?5%U&O<DU86&DP'=]$+FO@Q95MB"1QR?
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M%CCBCX3QOAC<@=)@ 'LT36A_)DW)?2%.TE/LE=,1HZ9>55HGO_1#X20(XPG
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M1:KR@#C2S*T]'^,'LPCTRW*Z)YXTU>6YQ"">5)>.5/4ONP"7]0%OLTGI>B_
M>DBC:7[.]^BFQ7*^<?2:Y 8Y:CG:NNU@"-&RG+[O3P&7X-PO@F.(>F:G9=B=
M'?#*!+$,7Y[_B+[235SIN$3A\"OW-F#OPX)F40:<.BCWR"DGPUCO,"K^0&7P
M\CS/J^4)X.,?4LNK9KSJUP7#TF8"<FUIV;7R4>-+* TB:=6!?/-(+ZRZ$UQ4
MABT*Y!U7^=)SS8&APA;^9:,B5H*7#A?2^VR+\ULMXIOF!P-89;K^FVD2AEAY
M%V/$.0$WQ<-?*:HSJA'$W^EHW\S+)T"X5STA$B'5XSZ;>7FPF# EF9&S^@3X
MDQH(?]A/> +L_3DP[6F[V>Q>I6TFSHHK6&_R6LH-$UIW_S '>JUSR%]U%5)?
M/25DANFD6*?!CJ#;K;HY=Z$"L_D>?2%NC3G _C9 ^[5+X]KFVE>K?U4<6JK^
M_FK:B+0C_;AJR"I%!2>T@B1']0BV4T!D0QU$I*[F4^WR!/"W<D@5S+JBS'IE
M2A+1!XBQ^VHL4[_K<U"A8GZ[ S<S'7YWL_%CC!-2YW-\4L'O%SF/G^QPKVY,
M.>Q0__TMV\@#SLJG'%K;88SQ814LFTZ&)\!NNP%Q.723]"#D+#(D@AK>Q(-S
M_^_7H97MU=1FW'Y7!_A2:SFIN/X%W=:^L+D-N/I#;('IVIT"*<CWYOKRX6)[
MRA$>,//[A)KP-P;.C(?PU5K9-,<A#^%EL@Z;<C8PV)]OF$[_'*:)OQ=)Z;R2
M*^<4E%&+@^BWEGZN#4O@V:E%DV*9A2T;*"!^TU""K19GMR]I,Z12LN)']EEJ
M=9K,QJ-TO-QIS?J;IO3A&7]Z7,E)[B/VN +LJJ=Y*&JK[T<\JQ_Z%B#J-D?B
M%#'OW;(D/O]&BG$K;.S'OG'3P'!-?FAOGPB5V:SR_(.+<#;=U/DQU:!\?[\P
M77_.7 Y]IW86--#)GDW)N_%[X M3,#]&,"CO&'L0+G/E+F$GX+I-N+"(7I(R
M,E%'2#(WQU/Z=3Q)BIGQ#][;FZ0C'E,&6-\.98>WVL7/3K7YKEF48,,W80,_
M\1<.#5%CM"#\,^)&'%7/=[K'X<I&)1L6@TQ#0JF\*RGAY1"$1.V*>IC]+8._
MD8[\7F5Y8#-I<7J?3)]PSY@UB!"?GP^#("KS(#GS>H?[IU?5F@:'DR)C_GY>
M(H@O\]GS@V1H)CPA7IH[B+5^X_.-^/],5_Y?V4S,%G2(C KZ& DF"DHMWWL8
M\J<NI&N F*W]_C'7I]0P[2Z!T&7=3SDRR-A*$42-*\2*A>)^IF?16*N1?O-D
M3"R?A6$C$LFN,_4P8MV_*_;UH#2GO29"K3]6RDG6=N^#Q]S!A&QQ'_;O-?!4
MYN%!XZ#*C9A/%%RE>)/@P,GFFONG2N]NY;<4@]IJ34]G/-7WUD5'>$2V8!;"
MJOPFY=F75E 0R%66@.891EV7;:_@S.M.]C<^(9 %7AT2<:!7N9:5?TPVAM"Q
M--FA3/01)PH-\VT'^BQ<G/UW%BJ?X"\'.?9R;7YS%5FI=6657A7S&*S\"8!1
MDD/)J;SA';>/]Y,".2\:<VI$3CEU(,[SW^(=L5R+"0]^G%"(9V.)UV9&P2@2
MVC'R7Q!AYX@':U;-"/4>'0H7)F-#R"PQ%8B8=&YW!J)\'!CP!Q=';+7(XR__
M2J_2],#5K\;K_M.YVP$@N\/8F%-ON]*JM8Q:FA/<,-O+929T$Z6)6J6WEV3@
MJ=8JV>&R!<:B"CN_P??S#(2?_DI)U$<$B@:==I?"*))JNH7C@ X<[_2\]^LY
M>H3I):E'E1C.\W,E^6L'HQ*O1NXK#E-.>0JPY"%5?N9?.ZRMVW<JL!AM1?>Q
M1#(/9AFO=4[4='("EZX>@M2O@]2G3B:#I'*> (N/HJ/\.0X]?I_MC;S]38*^
MM*M$==<LJ:4>=TI2#!F6]$N M,NL*1C<>2AXR8 ,TKBR)KGL1AH:D1=I;3GN
M[8YR#L79GI1V1IO%6I,BLG=J6'3@R085V[>+NDSG\P802_ P2!'#$NB3&273
M&,;-D)B9Q^P3R@K7(/^C,NBGHC((WLUYLTNJ"=3.OS.G'O B@B1;#'.8ADO!
M:QK%Q+EZ8\4;6RPHG*6TA?+G1)#?P#B-7"*:].4WKI$72!-(/"Q\KFDYX4(6
M);$O*1KOIR<I<4&[O\.80G:93':PF@R]N7,7G3$K6-\Z]?KU6S8ZPZ5U_Q:^
M:%+HM.1Z$T? UNGPLZ'B_8 !)*QB\<7,MEK6B-T8+A9]F:#\:JH^0W*DBJ\<
M!O"/9*74Q&?KQB[L&4F&&L,E%(\E:N9#<XSF0_,J>L5DRJD<""V)[KGFDC%"
MS5W!N5;4^-T@W$L90&+B!--/RMBJ+4^:!1A?4('OP$BD^YJCQW4H2>?1PN:7
M^77:#L?8[Q[577'H2P)JS;7-)^(G.K"&5Q2A"P.JGNUQB[\CQT3XH@\Q4\[)
MAZV^P?E\HG<WJ,[\*'MF]-:/+_E,)S?2_,6^K_AV?GS14"?V6VSI,T?O4<WN
MDGYX*I#W54K$:F2''KF!>CI[85:);,%S#%TP$_XAABAY?#D-;!]D%06#9K&?
M7^QZCT2NG;24+1[4IKP!A-VV;GMUMS"7U@"R/@30#.KM9;CB5&,G$]5SA*?@
MK\:+_FI7#:'2&K>(JNE97/_[76HR<*J9AG#%B>,[CESEA-1&?VG6DB3_>'/:
MC.!Z@_(Z;E@JC!!=EY,9FO02TZ>;Y,+[HVWT+SM?!>PC=%8@X4PAMW]H*&M2
MYE$(]#^?E9E@<'Q]/7+R0EUD-<"Z?-3Y]=C[^X!PJG")G,!))CQ'^5PUXD<J
M9RS$32D\B\%HJYP,=BY4!TO0X,'+0:K/)BTA@]AR[HBR_RIA/MRO!='^\57)
M,^DLW^!Z\4).'$Q3T\T]_\:R16>E.Z^\.<U>T>=RJ-_%0=EQ7PH18L#$I<*6
MQG-*:WQDHB:5U'5P;&;=\_I,]T_G4L_F;21[K0E[C(ZSPW956XWGB%<+VD9Z
M_T!E9OPF6$7E"FF7>BX_9??68ZSHFJGDIYU,1'S9,^,$7N5=GR.V?<DG@,1%
MN9=THNG&;>D2FJ&)[95S,]K*5T.)G>'\4TI_AF-W1!USK6EY9*DNJL2"*0</
M]^UVL8:8H+8BC!)WS-CKO&71YT6_F8,'OH9MFG+-_!+[&9MM7DY+PY)JT[U+
MNVV_FEW;7K_6JL#A\TPRMI7*EE4>'*&<OE6W&D"J6VEC<8V^[ ]QNI0?YC)%
M^RQ0_LQ]2X;-Z,"F/RSSE&/7@7W:XC6@B04">06VI:U%B G_Y^)EU.]/(L8
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MBCK=/N==[#FD@A25-'1% 74*M4J&RR04)H2&<5*5=&=\E1N;H*KQ'V$V2 E
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MG3?<P<RU\7DK[$"_JW,V9G/=MS,D3&8J*5 S[=AFU(">?(+6@IAIGO&K>HI
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MXI>,M3LQ+E$"0%KH?+F7(6[R;F71P'8S3/ADQ5?':.<6<T9;?4MM^,G6:@D
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M:<W-K=\9XHH$.9_I'^4('_^HYNOB2?.$=:TIJA:N>4,(S6C%JWS+]2_4]RJ
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MSUKQ>+I,5.K&"E4-CB97X/RK9=!>=IJ?;Q!QHW="!ND,J)FD5?]C9*)QN#E
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M>UWG1;PR93#F\F6V,M\J],$J*<^]IPR%E !0.(QB$BE'JG#_":,44/  5>>
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M"@_T16)2NU,W'Y)V)&/ T8;YF/,Z9LBTA3(QPLF8LN9VK!&@42ZP5^(-/ $
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MZ)'DL'4?@<LP KT%HRN.N#=7":;8P<.1NS/'+50Z]"TBY9$+B%@'AUJK/%:
ME?F";PJS%7Z\+4EO(KPH.CV+*"Z]*^0E7K(;QSB^.$Y7ELIC_Q#I.?E4&9B?
M?RIL,C"4M;+J%Z31DX#&T#\TGS$-<84E9)@^4[VYK\>GB9X(&U80>E]'7Q(F
M8LZB?*/.PBC+LQ@3KZM%M!#*"PO 7 DZ;<FQS?/58_W?-(<S>.X2\_> 3:H)
MX?+TNR6L(D+?H+47TQ-O.LZQ].H28*B'M?^D<ZE!L"#:/L;6QV<SP5GF<A,X
MGN4_DG5$ B2.;^E#[+)EH&'YA%MU3XN&5(U325]0L[LQ:N8Q]9++MG1Y7S(T
MM]9[S)H38,SKBJQ;I8K";4CUFHXQ#KD4_<3$\M+VM-@'0V88/T6-^1H"06MP
M]2+$"4AANVF7>Q1&S#R<WJ;]&F(2Q[\I1(IH4;*@NP@WXA477C&P41C*];BT
MH^H_++HX.G*_PN<7Z;#P=]/ZHCQ+6TQSRGI%-4T%7[_M.6K_"F4T&9J?# N5
MH!Q<ED!=LP^K)>FJ=E_/X$1/ODY]_,H@_,^K"[[IC2'-6LXMQ-GB.;C=2M^6
M_T&IE;;4'M&BSC1EO0L:-,XE^&?-0D+,@.59P:P)_5KY?*F'_17=[Y_"O4H&
M.1B_\ /L);CJN@EK-8K'W"C:L^G=U4]C51KU,)^)Y$R-L K%Q_F>/+V/=O?U
MAQ9_X7)L.X203ZGE@9](->K#:\?N-.EL^0HYNTA8E2_5MIES^6S'HDS]4'+
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M@PW_;W*\N93D'J\,^S!OC>4ITT!L/E8-64"]!$;RX*X)2;G"Q]76PW]Q/(@
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MR7Y&TQXSL?8E0N9 R3^D 1.<56S+13)%["JMZ69L!N%\%Q66>B"-R52C/"-
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MU9YU7Z+M5?K1-X4";8RPGJVNO]J!/.5%]2W9WGR_*$!V(3F@?$-YK^W'>;F
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M]2^*<H/J"/-O"<L+-P9)$0MU$WN.M*CQ,*M_KF% R!E9I7-A]_H!BMWL'/+
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M+X$?IZX>GO4FOW5'(]J-NZF<[2.3%A=25PQZ:HN\6H:\1B<^$VJD6EM\U*D
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M3\=!)IKP=7)/6907R+:VVCXJTM;H/0LPPOP]D".J-8E>V)D$3'34[ZK!5:&
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M$&&%.>]*L/WWCO9??:N);&,>Q*(?7/?V/'328C,$OLAJ[KM]<#+]8AA!7XQ
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M6Z+88S(MC(3^*T";P2<MQSS -];<G(5U%SBI6-*,2Y9?I2+MBU$VXH"U99'
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M1NG_XI ;A$8/%+OIFRJT0DF(=.<J1/'G?*$"[K-F%> )#1C^=9(QRV595?8
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MRR"T&V7OW&NXT:1OU<I,($PI>[+%,?UZF/;%[*V^UPGDT2!)!FF8C%'3"OE
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MCY[XP_*K%J'O/T[JO,&?C]:B$W;F49;BKFA,S]?+,,,AZ[7/I&_\U*\*GW)
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MJ0OE:JN:M$UPI>JLN_DCDEC^JN1@4*AEW\$(OG_D2*H9I">WSS"M@#L2PBD
MA@647^;Y<@SSD^;L]PN?Q"#VK3>H$@V^D*LHK'<TH!J"0NM$LS15TX+Z5%C
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M>Q[5'IW5OJJ&H>-GGK#1C"RUI:;N.$>FM>-AL(AACQ0QTK_+(D27IJ23'Y!
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ML]MS0\WJV#_KK.NDV*9UG4]5,GAO:N>>_>2T;+=\I5O2"0(X+H6,F]IBH6C
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M]QE>])X/9/*W_T>L';,[\2]02P,$%     @ #H)O5'3E9Y^#Q   A\@  !(
M  !I;6<Q,#(Y.#0X.#A?.2YJ<&>TN@5L'4NS+KI,,<;,S,S,S$S+O,P0,S-3
M'#,S,S-CS,R,<9QE9G;,=_]'YS[M*SWI/.GJ]6AFU--2?:J:5O57\+G^^1N
M*B\M)PV @(" ZH/J P ^MP 2_YG]7XW_"/F_E0'QV0] @P.\0V!!0: !(-$@
MH- @/H<!Q  (  0T% 0$X/\9\#!?8.&@H!$@(/]9ET(%0$)" 2 !7R @8&"@
MH5$ T#!07R @80%P\&CH&)A8V&0(.!1L:KCDE&+7)LZ)C52\GL%XU.P<G%S\
M$N[>S2UM'0O_B"'\!P#R'Y1_P4! 0T+]!^F?55DT -1_Y@!HJ"]0,-#_H$-
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MZ[<M-T]G&*3W2IW?^\H/.<L-#"Y19]AE#3:*ZM4[*G%/D0YB5#?,';J,.[Z
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M8O/2MW<@7+Q;S;E+OMWX*,=^I4H'DZ7N/%#\0S*D[3 ?UX+8+.7WO=N6JZ5
M'I'O>4=&<<I!5? >X_91N]YB>-:XL(- JIGP2-5NM\?^CHV-$#VU]'J +='*
M=L^J7U&M:F8Q/ $+H(W?9#7(!V!Q2=+=8YP'WR8L1VR.N,);E(Z52MWM"GD
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MG9OY]@B[)M7[^\7C?%.^TV:X5R_6^@?H$T 4C8]C5)"MWA25L1/.30J*&44
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MOV^YVMJ2SFT#(5VGH:[@FUGX_R+CK*/B>/9M/R0! D&#NQ/<W=V"N[M;<+=
M<'=W=W=W=QE@<'=G<'@Y]]UW[_F=]T?76K-FS?3J_E;M_NS=585SI!-U;  O
M,-C35O9.CGNMQK3F4 0IQK;>B>OEP %-8C.$A3I>[Z+VC2V3<1M)(*]*YXA#
MF\WS$"NUQGY16_%)R[N.*N-[B]K(-:Y[.0F]6:A7^;*#<7DTV7YI3&E0>>;I
M"NWV?5>,69WKP>9YX12O^1&X*[C.1PN%#G^^=!7.?R<XQIH,%E(253O9NZR1
M"2<'@_C4A#XV+#_4E:;^<LY+1*:?Q H]?QJ:T;05D#,V*K=&@'9A3;>MJ4-
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M=U\RQG)$*>$OT.W8V=GLB(\N:*9H8E60HJD^@*@6DLN3W?]?4_[>]:K'93R
M-_^Y^L9&Y]L?;.>:'?Q453^N^;G#>GH$J!]  SP-)8D[M#W_&:,(A:)T!DPF
M=$:_U. Y+$$Z7C"^6-KQ;;^XD6 !P_<I[V6E,I5YJ-;&+Z(1YS7?<R1SZVJU
M/PWD^#DN/RSF&D!ERN=-*<<(M% T+)BO6E[_^V5--(,KVGH2-H/ZJK2H:Q3E
MUEYT5'#C,IL<L:2>YGYBJ"7@6N"G3T:F=I>H?@\3:SO]>K9:M3QJ@.A>L/C6
M77W__G=HOJ=9&K[CX%EEN70+>\MW.KQ0-*UF/^!-EZ6UP3D.$K@N8%^Q>.IC
MBXP(A$Z-T:*!3PK2S[Q#]Q M N/L"\)L5JU<._ZM&R]<>L!G^I:\W>7^AD]X
MOFU&%D$NN:\5Y]NWY5@]X5J1_"K-#&3V'CA+P^VD$GO^=+Z+=@S$-L:F^<:'
M39G7Z,I;)'5-:$RBYCB0-H^U7"9.^<UUJ+VN@*Z^'*G$V0C3#VAZNLC@BHTL
MZR7]XW?<OJT?LQ9>W_W(L*C9R.\"!8T2B-YL^"YH@D^Y=Z2:X<O7)%;$#G;#
MS=,C(*T(5#*<",( ]2?OL2LED;"[33>U0%-[@A-FENL\6&18:O=?]1#!X9 H
MWZ#*RO+:V)63Z'A>PQ>D[X)X[/>V.D4,.%K5^_'0BQ> C1GMO/[MZ+:[]4O@
M8D7UV(VER@R*KXOU"RZ%EI.SX.IF\ 7\BOOBOLI5,*Y"X"+\]VW1;YDJ(X?W
M%+KE"TA-QSK<2JM.QIW$M^[>BJ)C_F(%5'_V&E2KEL@#ZC>&,;@GKCG)@!,(
MZ*?Q^((BE[\;34R%<;#BH\F5C+=;QVZ;(VM6XX>5)R3"5YA0I7TJMW^E@+8^
M )>-&-0.2;R7*OI<NT6L;0("L' +8N5\S.KB2N7O<R\V+#P(<>/--%R]%\G\
M]Y>%:I=&#L\"5QZ7U;)UR>&=AGE0>;9%6^3W;W]4IL..C+J,J6/'C,_2X9@L
MZ_@R&>'J*QL;PW%I!N(/(%6J-'VV'[.=G9EY<QE6"!!H^B6%R?DL%'5+DEG3
MCF_*6VC"Z*2,8;97PHJXZ2ZOP.O?M7VQRF(W-1/26S7UD)RO)[,\MNE!FU9C
M2JM%&.5?&J8E2U6_Z:S*N-M(Z7AG4G6>R1GOMP6M*;)L6DK\F&N%>I',\J1R
M,&K3:#"">Y1MHKK6)%2-!3U@9#--CCYZPER9@2I CN-="*9"\K7-/K<_M_+;
M)S%&FK!P2[4X,=_1BZ@6&I'9QZOD8"V OT#@US,-%C\-IMN,V5$[M.P!N%?:
MJ1KZ0<=F>[[LL^"B!;=RG]6RLS77C4N%&-B),0+GTN>Z%9/H&GG==J+(8/M/
M.Q@O@#YC_9,J3-O1LJ%T!FU_-X2)9T-,)U-YP9-!=UPD-U('_MR_4B'O?5+#
M.\/_Q456@,?_,X+;!X!?\V[X?R>T_/=X 2;(Z5S">4"#2[UKS+KF?NJ6/$?L
M)@ E)D!C?"9YPJ>QZ/;0\][U8":\I)'^&\-H'<-1E%%RYJZ7\>;H_OOG5]X/
M0%#^A?@=WP=@Y'1Q\[\C@/^1IC+:A-"!JFX*U5.KO8C$TL]=SNCQQ9(\A-.D
MM"!!(JN[5,L5UH7YG;6KAAAUDWG#H2%'MCC>&(X?<;R(K0]@_.CZOT=WSUMC
M1G(C>2%^9B;&,,D@Y3C$G%DAA^N[,A_[=@@OSI.<9I;QA*5*T!=^&4O"DQNC
M'_5 PSG8MRA#-7B6:H5^Y'.C0&X+]N7[6+')J-@_(MCF]AZ[7R1(_,6_V$EL
MO0T3_+[CC:Z]XZ]9X#BYZ-3@JD>(<G?:BEV<5MY//AO.>X$^UJMI>8TT^E^%
M">XVH':>UN>CXRNT?_'X H35J^8K<]TTR@966/[V\M=BEZE;?(PD%TYH_!-#
M1HYVI1,&ZQ5-TW^.[_N4:3IOL^K3K9=5F-6L5C&O%*I3HA:[:+7E?=DKKJWX
M263;1^0F07R'1@/0B_@PFF9(_L)@\6"6)%GP7+!I4S>OLOEOU6O46AM7XQ;L
MH0]M$ZL*EW,3F2L@UMS9J\!71V"A-.MSSAZ+7:8,0%?^/ D.::G>Z(PXO<.Y
M?6X 6JX0Z9@15^PML7SMY"1FCZ]'$9RA>>-&$(4-0GZG5Z0Q>A#S**>BDBV9
M>AN+IK%BA305CMN[4^H5&,#V1:SA"KBJJ"(3*>^:E)6^:!4Q^54HJ2-I]RT9
MQA6IUK*N#RS.?8.-1U?(E?=S%0;)NX^@+5R;H7? CZT'LEHRW"N*JU6QGYDS
M/M?G2YH;D7"0;="&<BTMJ3(C ]RT@FS#HX+K"29BLI_#.E\9K/'-B'(2A:G9
M\32Q?Z<RD2*HW^!>R7_58T:G]1P6I0WI3Z$!8W9'7;2>W4DMXNZB=9*F0!5A
MH:8-*X=]@8H6:UC7Y+FCA&B?8_^(P0%L_2>Q3L"G#=L3 6?X6,3$$2>UL[HB
M,7J.%=04\0:81*R81&[S2?FPO6S,M-(OY5A#'P!6+&9ZN)LHN1>1@OUB;A1E
M^;U,H\1LQ$TE%)4JY?V.9GN%]</R"9>T]3;TL_+:V2QDT_S/4[J25NM 6C7)
M6E3AMK LI[Z:NK8Q"UAEPO;S/<@=A[0D/?COI0)G]!MVUAIIQHZ'U=*:2FBB
MYB>,I^K7NY4J-V:FA51KS"KF587*XY5EJ>BG^#P45K&<>PJQ:&FWB:$W4M:=
M]=XP]P+7K2/&#BG\*,G?6EA[<QMUAG^7?%_ESY#NSA'C3:+E"OFB\^[*)'R,
MV= C4^Z>+5<0$4(8ZD*-VK;W0]E)6CDMCWC("+I[I&,+HR^Q[X9SH&Y""6\]
M2SI"<JF.6S)O,%6G#FLE-5)[/Q#+<HET,9Y2 8/89.(LI.1$00#Y]CHNZ[S\
M R XI ,TISA2?%D_X6G2I9D$B#IYWI:\[--_M7'^B=LDB* 8E)D9,AF";(5@
M:. _M&249%7DNDD ?'/Z%Q^]0RM%_Y.0M!W&"Q@E65*':@>+;GXU^8YC6U2Y
M_"LIK<?>Y9Q^2WEZG-?5?D??\-_T9'<$[NPA-F&D%7DDU^!OL'R+H#],,%4)
MU_O>X(EG'01[K:;*=6G65Y[C)&7CS\8E&%0F#.%0L/^U6"8H]M'^KQ)V;VX^
M7S\]S]\_O/ET=W5*_'_;Z> /POP!;D1UD-%$9W)S"&J_2Q*+N,<%\@5\.5$/
MY%)?2&1;%1B2\&>2^1QGTX :61O2;%'5* 9EN&@ES*4=R/U[IN1W65K#/+*Z
MZA A=,3B_<H(C $*R==,$SSE^JI/-KU1\ 5?=6Y36"P>WMM:_I?!^>>QII_=
MYA5^G- ]GA"@\(=>FH&X9;M3;$Y_E;#Z^^AMBU;BI/MZJ<7J;VK;%+1;6)^N
MBJBNCE>M2I$:2?,XP(>2_966TV?LOVWUM.+*/W..140G>P_NW^O4J%+58C[.
MO0J+NR"'-]1LXV(_B?;I]M;3P+62)1RA[P4$RBY?%J UNL9R2QU411(>=^-H
MT<$S<)U%J9A/J C1TAY%;-*VR^Y*84"BVOI8 O0AAFZ-V4AR4RU50J$G=09-
MS%7FK3(5'&(T_WW!(T7JV#]WTB7ABE(+:?=V/9\#?/!R%HTTEE=5TAPM)ZRM
M$RFTGD\GT/1.1A^Y QLGMWZH-?@4!"6ZEVJUX3KTO8U(M]ZS,!E >FU'7'@1
M&%K,^*K70D3&[)MR&4-G&OY.1M/ZA)KZHXI:>D_1B=FIR=E]:!BN;*&7?+AA
M(--^*Z)0Q\IHDVA(1S@+<UE>S#8HMS L^QQ]-W04,;&Q_K]J+O P9(->L.F#
MWP3WO!6TF)AU_5R&WC43YPS+C4$P^G81>^\X:+5R^#) 2I<:\AY_4'::4&-@
MFEICAFU*GRZ_:?06_<K*P\?*]>\T7N6SY73DUEW&-W9?&M*S?+!&4KYNE,YT
M#N5$W"[N-B%M0==VWA1W(3]SC+YJU?28;,.7Z0+B&-*T0O5B=C?@4=N^/(YF
MX8,/LM>^;X^S,0R3</;WMJ$K+:M ST@L2O\5D=P86LX;GLQ]V3!PH-$,LMD#
M63<L73_^9R<N=!NKHW)QMEZHKNN;:KJBI))&T/["U@*C+G"K5I!9, .!2N>4
M?!\O;9P&C1!HYM \A_NKB4G9[+"LWGZ83"6]FC];7N[9P1?@3 5AHNHL( $)
MJE7^XJ?C3\VI AV_J-&"GY %\2((1>9D:3A"E3^KKZ-2_1N>5$B01=-+L!3)
MFZH?L]I[*8G75_VJZ+O:90OS$'E=:)/^*L]3]/-[=]4?2#)!. A")G\TOQ]!
M$/XU<+Q^8U\/EZ'5S"+%_D<21O]* DVZD<1.M#OIIO6NCM.\C&/3BTV3;U$+
M4-N,<\JWB#$ZR\NB)..1=3!<KWP=9WG4Z0,0 7X!R5GP1BYY-X*^QVO5WH/@
M^;-_-KUX=9UQ'C:$-0G$J^\,J>[Q^FRT CE7BD_O/P!1A=G_=%25[_/0(M&)
MK(W.W-42Q8Y<;"YU&\X'X*3%3_B$43Q^\FSB:)5]C<?J*+?.YDNHB HRI$1F
M/]"%SF&^1LH:XT.M2_$61J'_"7%GJJ1Q9WVD@J7%<[]!(5.<%M'/J5H)-JZ;
M='>.K..F..AE))%.H^'<<\<C[170/>M5P/J)[[G1EGC*UTBBZ#$PG9"M+&:M
MP!6=Q":R9XZ#A6 V9P4S.L82MY:)P);MF)$@3&(?693D[GAOLY_,:BQFU^?5
M)A=X3&9RLB!)599W?Q&8"-ABB@.0J "+34\$76"G)&G.IZDJSB1-#\L!ZMG[
M)%=<0#U#3[5:+]?R10VJ7V/:CD!75-8[7 ;LEX,WRQ=1+/Z+=D1ENM/Z?:D2
M>X?!6A8[[ KELQ)M0 *KM'6N^L4H!DWQP35<FK([.H=GD<V7%V)#(P.;5BQ,
MU4H.G_/,5BEN3YEB,J5D9/1*A:A*MZ0NU/C'U81>_TY!H]C$Q!9Q_*N$A-+3
MR "Q"02LY4=;L$8O-[RR\$5RXU[_0!G\QO7;Q?O6;(N:^+XJVNOJ,)YO",V)
MZO>MEIRZ\NQ\F6X%JGK-5TK*B083\?%VZ/W]$0::)0[G(S;J(ITF8%FZP3[-
MKX00CW79T6O\LPT:0[G@QVX$+3S,C3>C1"ZN]I$P5;;8(9W>'V*!<Y-P'@SB
MJ3) ?9#A8LE6M_%F<:P%S6SXKJ(C50*4MY#W*=@K,-,N!\O!/NQN)^<=N,Z:
MG:D10M JJ7N9:14OU1: WWPT<B"/H[0G2^/Q7>ZV-;>)2[%>&RD%Q<ZT!+7
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MZ?=) V*[V+><!^.K1WU[.T"AZMV3D_H>V)U@->$E&0B7W] H?..*N?.]P3T
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M,BYCD_W/.$N]<RI&O5/[')1L^TLLV!)'PMY8)/4^,&=^NN4JK.M+HQ&&!N;
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M(_$R%5?5:4M#>L^)_K7@:O!4ZHBTV@!Y1*U)Q834E()I)T+?(60=AP0E*Y.
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MUXZFW+GJ6(3HN(4>Q8^BRW1I6%>84*<>9F)\3T<I:XF/U*$7K2'ODZ,+R2?
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M=N<8>3>_92P.OIZF0S5N7X6N5A8U*>W(WO"\K<GVQ5^U\OY/ET])0-R=+ZA
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M_5FX8 QR1<3'_]VL)A]"WZVF%@@G+?+D'S0V>O<PO(RA;6N"-J7JF&:0QO)
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MMVXDKX)LK/\>E[L/<(/<+CHP!?=]+[R&"7Z7BM5NU>GGGWG7&K$%!HH9"GP
MQ!4_JX'#FD3+QGWVSD^'!/:9=&,#+%VTUYHJ3*<K?T:,W UDHN#"[+P*U(+8
M+;\)3[K31^>TGV>DUS']&1I;<^-R*1JNB)@-J[B6C!B/T(+Z;%;>E\@+]EZZ
M]BRJW6(2$\EUS11V]1')T>3<?0'F62_?\TKOBB&#PA?)#[3.G=OGSA$\L%M?
M@NIMCH#?T@S/QZ^W3F2O3X]'1_.>8JY)SRS@O/ZC4<DN#,K?A$$:1+C_\AJ0
M!S'H-JD2,P%M_&U[]=N2O;S?OE5C4.Q4W=2A#/5S\B$Y3X+X> PMLCP(N[7[
M4&(^I8C!C==*J%BJ&)CD728M!FMG.U@!S)X:*1:? [M+:IO!%$AY&BUIG![*
MQW^;G[/F64Y]/P#.7:$6]-]OZHO1"V=\&ZO.E,JV[>$L"N]^INAZ5U5B7LF'
M_1JHEIB7ACX<"I<IU2-(>*5[)U\+X"WFVM#TEAYB-I'M<J_[<I@=E+:Z7&XZ
M39%D*M3R8P'W7XH!IT:$>$*7ZE.\PW?]$M!!B)' ;[DJ/;E[/C")T[M,>_2]
MCGPV/'E3W_(<OSTOL#ZVA@3N&@XMHIG&ED)]S>RDXC[Z "B;1=4#(,]"-6*7
MR.]'@J$4@KN3^H'=)GF/+XO\?(\JKR)/6>39 Q0:CZQ9@<5_#&Z'J(U:+MCK
MX72^;NE;<BT<AI*H#*7HJR;0_BB^BQ?;E (VT4) ;>[+8\J!AWG()N&=T&-S
MIWW/.3TF4PMLYD:ZY4U77?IWM*J]]O+VQ,7Y+$QY$7:-93*R.()_H+)CF>N)
M&E9?W4JF8GE7;T]F;LD+O3 \V-U=!"L-,E^8IP5YNZ+'GRK%A=0GO6E1DL&_
M! &-3-)PZ'2^E]P.6.?Y CRK-\5K'4X6B2/U"4_OX?7O4G\SXXT\%QW,'3V'
M5@Y>FQ8%)KD_ )XN-T/^MM5=__>T VCC0:XJ\V6V#3-'\^]!3F5=D[[6NG?R
M6 0RT4X^6TW]WHLW^;_=9U;17NR4JSU%+HP3.)C0H;(1TZTF^*[F%O;,[6@V
M"..4&:_@]T M'F093<NG2W-7N\PX0Z2<N1GIQYLR/F'7U.]_4.Q9^_/PI)A8
M-,R&NH@00&^47L!=_4_H@F,E2E<N=KA1711Q;+GPZC?+H+PQ"K&;]^Z##T#0
M^P5E0/C./\)B<O08T!C7]23T[]V!-$\!G5U^.TK^W55/DYRQ+J"3G"Z?]_0G
M\^?7F[=_9$>,\@U$'_ST?/<6\&X2=#D':KF;JCVY><_;J>9M*O4/B F<O361
M?^Z%W@[KZ8R6G7WF,$JTIS"Y+RW$GV/1KS*E"KOBT[8+"$ CZ\8S+H3&I(RM
M=[3WA]C81M*LK7MOP:.BB3@*XCTZL82M+LQY.7;RB[QPY:<-.70VGL<F3@$K
MCO9VK2U25.*+^3>&N=:QM)KUT+;_G!/\LHYM!YZMTM -:I^@SL;UDX3'$?5#
M^C/LLI='I3LQPQ.+SP+G- ,LG".[*VSG+V4\R&P]MYVRWTR4:[19I6]=[%FY
MED=G0!:IY$%F32$-&V#K*C[O%?8U(9[$RK+6H981]1+A(4-.W'%E'"S/M^(C
MTD" 1B3+L64DRU,,V-62LM-(FGO[1KIH,-;ST(#RGFW*:FQ*;V4OH^S& R+_
MI P]LYT^%[@>2B1V\^4_&F;_.8W)'2@OEO?@H?HA;L_\,535>B7R-(#?[ECE
MFV 0:DG&A*/]4^=/36"YK?A)4?N+;K7!\AH;3+A0B.=K+R,/![:9R*"Y0]T@
M70K&2_TVBE)"CLG/!V8E;EP!<P+7E2QT3HW[X3*=RJK\QLJ$\##10$,17WE&
MDJ^3/V4)"'Q7T/+:KE*YKMR*4V$81?Z(^D3V?+^)H]O)7BN=)05='G!G]J[X
M#'=0S<(ET$)F[,X^ "LLY6W<+0%3ELBM?V35OAX^I\]7X7I MDD6*&NV<@%U
M]61LU':BE\48:L].22H;V$.:;ZN@C/K8BM)Y6D59?W["ZC%F5I?B1@.&"9 7
M1Z-\<;L8?;)%;W'.!\!7K5DM/497,#O/ =$I##>4-&TLE<.Y&/.OAH3@99+7
M'JO#?Z+*V/>=$H.E]L5H;GW%X38>=MN_=%'QHJK!GKN]3;1PVN'+.1D#R4J>
M5ER5H7UTDL?/R32M\B;Z=FVAA!A(9JRBAQHZ>/-TB=YATXI5IWZ/(L+9V5@=
M^<&HFHY$/,4F12=BU?_^+PD3*P7^%M"_U7*OU[G6%M3,F&X."VT+T^!$Q&@O
M;T)Z('Y.[NRC@#^6*G3F&&M,G&6_H$?H_="DG%+>T=OH:F+C(U)$ I_E![)X
MF%H"LWM4#7I861Z+Z:FIOYCRS'DQR9 J$T\:AS1T1W:7G4NJV?=TV^34^=PY
MVG)Y)C2[$F"9^<<WS7;I>+@*(G"1Y-"3Z*10G&%.&CJP\.5?EZ \F@4:1<P=
ML/A,6D-[YG[IX6M 58%^)&1/8R1'\-%!N[F^GA%,F,@H3)++Q[D 74/>@MZ#
M]D#$L__9@54@O-W&?IT%(2TF<]Z[]<!R-3%EDVJ\)]XP*W71<[3[=-"SH$O)
M5G7>U&?\II9]G>N6ZMJ4R]0F[U@)K^1S(RZ.:W?&O^8*HRM*MY 2,0ATDMB@
M'=.P0D@FLHG';B3WW*IS+L*CMT<VS/P9QQ(UD4;MGJFY'+04LTC^7='-22=;
MH1$827ZMP]&I>!_B,6^IHZG=W.]>+A*UW[[F(NS5GZ%2A?<.^B82Y/:^PWZ+
MH4?DSK/1_X/6X@N6@9S?1LG9=;!)!I9CVBI24$OW$.RRSK??RNL+BI3SCUD^
MD'7+N I:D5;\TKYKEFV!]*Q/<8'$W-Y;.0M7]#RIP 6+ ##[2K'.5H52#-WH
M,^&YS#(*?8YOX2HSM>OGP?I4WUWSY,%F@3C+:D6A#\"UQP>@G>+)YS.Y[)OH
MQE;ERLONT;\X3MHUH., Y3=[2-O\,M Y&3NQTZ!=.[YCPP#<10T^H;=PD(Y/
M/M&),#^AAKYL\4Y?T1,,0PRV\&V)]'1ZEFF[TAIR"H(9-M@Z/7[[F@**#GA4
MY\:!.<JL-\Y5P+3;_V65RRM_?)10LG2OZ<S9K-QI,ZM]K$.-XK=W3>AVTE$H
M^,D"]"V >)Q0BF35D%&0UWAGC.V,^E[R930@B7D;5=KX V#*]5J _:507L\Q
MZ,\B_%]/W/VU9V@3RH,J1#1N_4IC[:\:5F1?$K>!+@/Z?NY&H0Z-JZ(850%D
M2W+[EA=B*(J\UPPJ,PEID0E7R$X*@WH[P%H/G %H[GC V)2%VDWBNBAMW,84
M-:7ICD,W]J*CH0WX X!#+JBZ1(*2WC"8AUJ EOYNFW*+@JO55.UP[$\;]=.X
M5JNM$=>8.[,XREX9S72\9>]3M:*BS+<7_/([)=::"G+?N2&'!A1FV>[-/O\#
MV[W!&U(BTA1FZ:FUXCA=YXGFJ3T@90!E@V7F:@S5WWEM&09):36?<\XAN2=K
M5!*GWA+]<NRR[(5)C.$=\$(Z4K-^!_:D#:O*ME:T/$;F_SD$"6@+_L0+WJI:
M7%823VXG#HY$4[S6@A%N#"&Y?NW5X4U%FT(T>\\)8H(JC:(2U7UI^W9]*9HX
M&)AXC#7ZS!:U'E)+BJ^ZH:J]"_\ $<*6 ^1*)HYBU!#&%7]_@=:9H5XF!U5J
MO_Y7BV.78Q7?D,<JX60K9$Q@ZF[()>]FR.4# +1^][X4%XW8#915UD5LY6<I
M;UC?L\Y498XKB@C>=?Z98_1EUAOY*5"3I,:PQ>S^1UZJ&!5KR622?^T#[^H>
M"!"/'-I7<SPJ F\LL1E\&"<.I##\'K@C"?5UP+4W&EYTB1,6'^&<,$1"S!7I
MX4)'B&G/MP(>3UNUI*I\P55^WHXVF,&DC$ZYEC;AM^(FJ:,U0^Q#=H8+/DVN
MXT.J4=.&8]/8I=;NG31B]%21Q!1RZ"E8$ @ D.9@U(T'U'-:F9_64[1SOJ2*
M10*3RCT'YUI39'HR2^T/D^TF2@;O@T +I_@#C'G UT1/Q*#9WV;>IT2!$IFG
M-&(_@1ON.6ZP09HMDUTXCW%6W]N#1Z3)TM&1=G_O7O70YPILXCR2$?XP/O<M
MI?'Z5NQ#ZBI,CD!==RWX*KO/&^!_]1XD=I3W] %8?#?FF24:"AI[[SYY ]I6
M.(P5NCRR1]FR7@#WR7-*^$:%DDA8G807VNIP;+U&BSYGA2_U TQ7E+LQ31+,
MI'/J'S[-"O:*UDN(_08G&.>._KHK1S@YT_(M1G0";!F^!<^\I_P#CT*M]I<-
MA5K:DF*?36QYVQ#!W52)!VH=WZAUUVYJP?@"A40=!UJ[?2WD7@-JSZ0=PHPL
MY?X0,I I'V>,@JU/<H:H[M#UV1L00^&W")7G<>&?:O,Q#Y.Z>TK\372YW4-O
MFM;[<00KT1&8L[& 84"NH&CK714S7%VEAM+DH&W=ITJ=/_;DD\9B3M#NQQZI
M<F;15@[IF )?[6F*0*0^3#:U7;L2)=TB)2 2"4MC8<S\>"@:@/S7?.@ 5]TP
MF'/=2Y%CR7IR/$7,X@A (IYF/3_,AI86B\H2 \TS[#%(X6AMM5BR)]=CFI%_
M9DX9<&9=HJ^VO*4KP7G!,,V1\ EB0SH@39K83T0BVU%[U/5L[NBQ*C!6[H'6
M>ZS(X(2A/HI;%WI/*\7X%8.2ZP9"G>W'2"M!]EV;>7B7V1-Y(*#'K +W#:2]
MDXM>#<I[_0#<O.?*E&I2_='.):TM.,;FMS3DB)SEY/2FS_[Q5/!J5J)M>#DJ
M64]+(?8U$C81:3=<S$ZYOB0PC]*9I.9VD P&8Y]A )G^6[<,)8*Q-]!98F<Z
M5[,,6&UI5KIR;V(S$-#.X*1Y-7P0'W!RAV;7(ORG$O.3(EKR]%==QR@\4YG+
MP5#Y#!ECC0#*N6L)<L-].=CT6$BX_X'WSJ+#ZVL*F538LS2A</"A,#A%V_3>
M2HM6,U=.77R3G(<2NRA.(02L4@>&U#,EG<)_18+YKE)_H>5#%\5R%&GQ!SC2
M10TB.:MJ353:$1SP-1>$+':Y5"T/9;[>3_*N"D#&#%^SWREVWDEQIAX!\J\M
MLW?OUL'O%L%O=R/_&7Z81]<]QP6V]3"+:Y")^NHQK>UZ[00J0C:X8 =L5$*\
M-X'*-SF#7*SNE $W.;^2E X.-@-8JD2$R(=W9JE=( P;'D!L074,V'=KE;:Z
M/+N=<O:7BH[0?HQZ='$@N2PE1;\)?<4BDB=>>C*27!T+YG?\)7IMU&J"$*M
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MCV&31:!S;5E*?)B<1_(3"[ARL3&*UB8!5EB1@NZ[>YC" 0WOI3N3#C65[I]
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ME>ERWXLE:?6F^*=(X__?! !02P$"% ,4    "  .@F]4W^;J=NT4!0!//ST
M$0              @ $     86-E="TR,#(Q,3(S,2YH=&U02P$"% ,4
M"  .@F]4:8$%?+(@  "7G0$ $0              @ $<%04 86-E="TR,#(Q
M,3(S,2YX<V102P$"% ,4    "  .@F]4Q3WUB?86  !79@$ %0
M    @ ']-04 86-E="TR,#(Q,3(S,5]C86PN>&UL4$L! A0#%     @ #H)O
M5%/M-*-33P  YA<& !4              ( !)DT% &%C970M,C R,3$R,S%?
M9&5F+GAM;%!+ 0(4 Q0    (  Z";U3;6G;OQ!8! -^ #  5
M  "  :R<!0!A8V5T+3(P,C$Q,C,Q7VQA8BYX;6Q02P$"% ,4    "  .@F]4
M0S-1P"1X  ##F@D %0              @ &CLP8 86-E="TR,#(Q,3(S,5]P
M<F4N>&UL4$L! A0#%     @ #H)O5/3A014[P@  5L0* !
M ( !^BL' &%C970M97@Q,%\Q,2YH=&U02P$"% ,4    "  .@F]4V7Z8DC\<
M  !HP@  $               @ %C[@< 86-E="UE>#$P7S$T+FAT;5!+ 0(4
M Q0    (  Z";U2RKCW0"5\  )3X P 0              "  = *" !A8V5T
M+65X,3!?,34N:'1M4$L! A0#%     @ #H)O5(B2U)N,0   8B0" !
M         ( !!VH( &%C970M97@Q,%\Q-BYH=&U02P$"% ,4    "  .@F]4
MG9&CAM2)  #S:@0 $               @ '!J@@ 86-E="UE>#$P7S$W+FAT
M;5!+ 0(4 Q0    (  Z";U3^!^=2.PD  %9J   0              "  <,T
M"0!A8V5T+65X,3!?,3@N:'1M4$L! A0#%     @ #H)O5-..]C^E#@  ^&@
M !               ( !+#X) &%C970M97@Q,%\Q.2YH=&U02P$"% ,4
M"  .@F]4)/IF2*("   G#P  #P              @ '_3 D 86-E="UE>#(S
M7S$N:'1M4$L! A0#%     @ #H)O5&<3+6O1"   GTP   \
M ( !SD\) &%C970M97@S,5\Q+FAT;5!+ 0(4 Q0    (  Z";U3X[D_2S@@
M ))+   /              "  <Q8"0!A8V5T+65X,S%?,BYH=&U02P$"% ,4
M    "  .@F]4>I/43BH%   4)@  #P              @ ''80D 86-E="UE
M>#,R7S$N:'1M4$L! A0#%     @ #H)O5)DW**B=#   3R\   X
M     ( !'F<) &%C970M97@T7S,N:'1M4$L! A0#%     @ #H)O5+CZ9=3U
M:@  >ZH  !(              ( !YW,) &EM9S$P,CDX-#@X.%\P+FIP9U!+
M 0(4 Q0    (  Z";U0HC_I:VS<"  %' @ 2              "  0S?"0!I
M;6<Q,#(Y.#0X.#A?,2YJ<&=02P$"% ,4    "  .@F]4N)!(4L2% 0#/D@$
M$P              @ $7%PP :6UG,3 R.3@T.#@X7S$P+FIP9U!+ 0(4 Q0
M   (  Z";U3S.6B!OJ,  *RK   3              "  0R=#0!I;6<Q,#(Y
M.#0X.#A?,3$N:G!G4$L! A0#%     @ #H)O5.ET?.)K_@( $@$# !,
M         ( !^T . &EM9S$P,CDX-#@X.%\Q,BYJ<&=02P$"% ,4    "  .
M@F]4([@B@=+&  #>SP  $P              @ &7/Q$ :6UG,3 R.3@T.#@X
M7S$S+FIP9U!+ 0(4 Q0    (  Z";U2/(V7&#,D  *?3   3
M  "  9H&$@!I;6<Q,#(Y.#0X.#A?,30N:G!G4$L! A0#%     @ #H)O5$SI
M$G0VHP  !*H  !,              ( !U\\2 &EM9S$P,CDX-#@X.%\Q-2YJ
M<&=02P$"% ,4    "  .@F]4O&H!&ZJE  !GN@  $P              @ $^
M<Q, :6UG,3 R.3@T.#@X7S$V+FIP9U!+ 0(4 Q0    (  Z";U2A?!\E:OT
M (H* 0 3              "  1D9% !I;6<Q,#(Y.#0X.#A?,3<N:G!G4$L!
M A0#%     @ #H)O5-:K,'>(D   T)H  !(              ( !M!85 &EM
M9S$P,CDX-#@X.%\R+FIP9U!+ 0(4 Q0    (  Z";U2%1@6>%6@  "YN   2
M              "  6RG%0!I;6<Q,#(Y.#0X.#A?,RYJ<&=02P$"% ,4
M"  .@F]4LT$DI92. 0#!D@$ $@              @ &Q#Q8 :6UG,3 R.3@T
M.#@X7S0N:G!G4$L! A0#%     @ #H)O5!2*)QC<6@  -U\  !(
M     ( !=9X7 &EM9S$P,CDX-#@X.%\U+FIP9U!+ 0(4 Q0    (  Z";U1U
MWT%S<0P! %0I 0 2              "  8'Y%P!I;6<Q,#(Y.#0X.#A?-BYJ
M<&=02P$"% ,4    "  .@F]4*:Y(VB[C @ P]P( $@              @ $B
M!AD :6UG,3 R.3@T.#@X7S<N:G!G4$L! A0#%     @ #H)O5.)J,0@$50(
MD60" !(              ( !@.D; &EM9S$P,CDX-#@X.%\X+FIP9U!+ 0(4
M Q0    (  Z";U1TY6>?@\0  (?(   2              "  ;0^'@!I;6<Q
D,#(Y.#0X.#A?.2YJ<&=02P4&     "0 ) #T"   9P,?

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
